token,label
Web,O
-,O
Based,O
Interventions,O
Targeting,O
Cardiovascular,O
Risk,O
Factors,O
in,O
Middle,O
-,O
Aged,O
and,O
Older,O
People,O
:,O
A,O
Systematic,O
Review,O
and,O
Meta,O
-,O
Analysis,O
Background,O
Web,O
-,O
based,O
interventions,O
can,O
improve,O
single,O
cardiovascular,O
risk,O
factors,O
in,O
adult,O
populations,O
.,O
In,O
view,O
of,O
global,O
aging,O
and,O
the,O
associated,O
increasing,O
burden,O
of,O
cardiovascular,B-DS
disease,I-DS
",",O
older,O
people,O
form,O
an,O
important,O
target,O
population,O
as,O
well,O
.,O
Objective,O
In,O
this,O
systematic,O
review,O
and,O
meta,O
-,O
analysis,O
",",O
we,O
evaluated,O
whether,O
Web,O
-,O
based,O
interventions,O
for,O
cardiovascular,O
risk,O
factor,O
management,O
reduce,O
the,O
risk,O
of,O
cardiovascular,B-DS
disease,I-DS
in,O
older,O
people,O
.,O
Methods,O
Embase,O
",",O
Medline,O
",",O
Cochrane,O
and,O
CINAHL,O
were,O
systematically,O
searched,O
from,O
January,O
1995,O
to,O
November,O
2014,O
.,O
Search,O
terms,O
included,O
cardiovascular,O
risk,O
factors,O
and,O
diseases,O
(,O
specified,O
"),",O
Web,O
-,O
based,O
interventions,O
(,O
and,O
synonyms,O
),O
and,O
randomized,O
controlled,O
trial,O
.,O
Two,O
authors,O
independently,O
performed,O
study,O
selection,O
",",O
data,O
-,O
extraction,O
and,O
risk,O
of,O
bias,O
assessment,O
.,O
In,O
a,O
meta,O
-,O
analysis,O
",",O
outcomes,O
regarding,O
treatment,O
effects,O
on,O
cardiovascular,O
risk,O
factors,O
(,O
blood,O
pressure,O
",",O
glycated,O
hemoglobin,B-GP
A1c,O
(,O
HbA1C,O
"),",O
low,O
-,O
density,O
lipoprotein,O
(,O
LDL,O
),O
cholesterol,O
",",O
smoking,O
status,O
",",O
weight,O
and,O
physical,O
inactivity,O
),O
and,O
incident,O
cardiovascular,B-DS
disease,I-DS
were,O
pooled,O
with,O
random,O
effects,O
models,O
.,O
Results,O
A,O
total,O
of,O
57,O
studies,O
(,O
N,O
=,O
19,O
",",O
862,O
),O
fulfilled,O
eligibility,O
criteria,O
and,O
47,O
studies,O
contributed,O
to,O
the,O
meta,O
-,O
analysis,O
.,O
A,O
significant,O
reduction,O
in,O
systolic,O
blood,O
pressure,O
(,O
mean,O
difference,O
–,O
2,O
.,O
66,O
mmHg,O
",",O
95,O
%,O
CI,O
–,O
3,O
.,O
81,O
to,O
–,O
1,O
.,O
52,O
"),",O
diastolic,O
blood,O
pressure,O
(,O
mean,O
difference,O
–,O
1,O
.,O
26,O
mmHg,O
",",O
95,O
%,O
CI,O
–,O
1,O
.,O
92,O
to,O
–,O
0,O
.,O
60,O
"),",O
HbA1c,O
level,O
(,O
mean,O
difference,O
–,O
0,O
.,O
13,O
"%,",O
95,O
%,O
CI,O
–,O
0,O
.,O
22,O
to,O
–,O
0,O
.,O
05,O
"),",O
LDL,O
cholesterol,O
level,O
(,O
mean,O
difference,O
–,O
2,O
.,O
18,O
mg,O
/,O
dL,O
",",O
95,O
%,O
CI,O
–,O
3,O
.,O
96,O
to,O
–,O
0,O
.,O
41,O
"),",O
weight,O
(,O
mean,O
difference,O
–,O
1,O
.,O
34,O
kg,O
",",O
95,O
%,O
CI,O
–,O
1,O
.,O
91,O
to,O
–,O
0,O
.,O
77,O
"),",O
and,O
an,O
increase,O
of,O
physical,O
activity,O
(,O
standardized,O
mean,O
difference,O
0,O
.,O
25,O
",",O
95,O
%,O
CI,O
0,O
.,O
10,O
-,O
0,O
.,O
39,O
),O
in,O
the,O
Web,O
-,O
based,O
intervention,O
group,O
was,O
found,O
.,O
The,O
observed,O
effects,O
were,O
more,O
pronounced,O
in,O
studies,O
with,O
short,O
(<,O
12,O
months,O
),O
follow,O
-,O
up,O
and,O
studies,O
that,O
combined,O
the,O
Internet,O
application,O
with,O
human,B-OG
support,O
(,O
blended,O
care,O
).,O
No,O
difference,O
in,O
incident,O
cardiovascular,B-DS
disease,I-DS
was,O
found,O
between,O
groups,O
(,O
6,O
studies,O
).,O
Conclusions,O
Web,O
-,O
based,O
interventions,O
have,O
the,O
potential,O
to,O
improve,O
the,O
cardiovascular,O
risk,O
profile,O
of,O
older,O
people,O
",",O
but,O
the,O
effects,O
are,O
modest,O
and,O
decline,O
with,O
time,O
.,O
Currently,O
",",O
there,O
is,O
insufficient,O
evidence,O
for,O
an,O
effect,O
on,O
incident,O
cardiovascular,B-DS
disease,I-DS
.,O
A,O
focus,O
on,O
long,O
-,O
term,O
effects,O
",",O
clinical,O
endpoints,O
",",O
and,O
strategies,O
to,O
increase,O
sustainability,O
of,O
treatment,O
effects,O
is,O
recommended,O
for,O
future,O
studies,O
.,O
Introduction,O
The,O
field,O
of,O
eHealth,O
is,O
expanding,O
the,O
potential,O
of,O
contemporary,O
medicine,O
[,O
1,O
].,O
Global,O
aging,O
and,O
its,O
associated,O
burden,O
of,O
cardiovascular,B-DS
disease,I-DS
may,O
expand,O
the,O
scope,O
for,O
innovative,O
Internet,O
interventions,O
[,O
2,O
",",O
3,O
].,O
Current,O
cardiovascular,O
risk,O
management,O
programs,O
in,O
primary,O
care,O
will,O
become,O
too,O
expensive,O
and,O
",",O
although,O
they,O
are,O
highly,O
effective,O
in,O
research,O
settings,O
[,O
4,O
-,O
6,O
"],",O
their,O
effectiveness,O
is,O
markedly,O
lower,O
in,O
daily,O
life,O
[,O
7,O
].,O
This,O
evidence,O
-,O
practice,O
gap,O
has,O
several,O
causes,O
[,O
8,O
].,O
Adherence,O
to,O
life,O
-,O
long,O
lifestyle,O
and,O
medication,O
regimens,O
is,O
a,O
serious,O
challenge,O
",",O
illustrated,O
by,O
long,O
-,O
term,O
adherence,O
rates,O
in,O
chronic,B-DS
diseases,I-DS
that,O
average,O
as,O
low,O
as,O
50,O
%,O
[,O
9,O
",",O
10,O
].,O
Web,O
-,O
based,O
interventions,O
are,O
cheap,O
",",O
have,O
a,O
wide,O
reach,O
",",O
and,O
they,O
enable,O
self,O
-,O
management,O
[,O
11,O
].,O
This,O
renders,O
Web,O
-,O
based,O
interventions,O
potentially,O
powerful,O
and,O
scalable,O
tools,O
to,O
enhance,O
sustained,O
adherence,O
in,O
cardiovascular,O
risk,O
management,O
[,O
12,O
].,O
Older,O
people,O
form,O
an,O
important,O
target,O
population,O
because,O
cardiovascular,O
risk,O
reduction,O
appears,O
effective,O
until,O
old,O
age,O
[,O
13,O
-,O
16,O
].,O
In,O
2012,O
",",O
42,O
%,O
of,O
European,O
people,O
aged,O
between,O
55,O
and,O
74,O
years,O
used,O
the,O
Internet,O
and,O
this,O
number,O
is,O
increasing,O
[,O
17,O
].,O
Meta,O
-,O
analyses,O
showed,O
that,O
Web,O
-,O
based,O
interventions,O
targeting,O
single,O
cardiovascular,O
risk,O
factors,O
can,O
induce,O
improvements,O
in,O
adult,O
populations,O
[,O
18,O
-,O
21,O
].,O
However,O
",",O
optimal,O
cardiovascular,O
prevention,O
and,O
risk,O
management,O
practice,O
",",O
as,O
affirmed,O
by,O
the,O
European,O
Society,O
of,O
Cardiology,O
[,O
22,O
],O
and,O
the,O
American,O
Heart,O
Association,O
[,O
23,O
"],",O
requires,O
targeting,O
the,O
complete,O
cardiovascular,O
risk,O
profile,O
.,O
This,O
is,O
particularly,O
applicable,O
for,O
older,O
people,O
",",O
who,O
often,O
have,O
multiple,O
risk,O
factors,O
or,O
already,O
suffered,O
a,O
cardiovascular,O
event,O
.,O
A,O
comprehensive,O
approach,O
would,O
increase,O
the,O
value,O
of,O
Web,O
-,O
based,O
interventions,O
for,O
daily,O
practice,O
.,O
Currently,O
",",O
little,O
is,O
known,O
about,O
the,O
effectiveness,O
of,O
Web,O
-,O
based,O
interventions,O
in,O
older,O
people,O
.,O
In,O
this,O
systematic,O
review,O
and,O
meta,O
-,O
analysis,O
",",O
we,O
aim,O
to,O
answer,O
the,O
question,O
whether,O
Web,O
-,O
based,O
interventions,O
for,O
cardiovascular,O
risk,O
factor,O
management,O
reduce,O
cardiovascular,O
risk,O
and,O
disease,O
in,O
older,O
people,O
.,O
Methods,O
Search,O
Strategy,O
and,O
Selection,O
of,O
Eligible,O
Studies,O
We,O
performed,O
a,O
systematic,O
literature,O
search,O
for,O
randomized,O
controlled,O
trials,O
(,O
RCT,O
),O
on,O
Web,O
-,O
based,O
interventions,O
in,O
older,O
people,O
targeting,O
one,O
or,O
more,O
cardiovascular,O
risk,O
factors,O
and,O
/,O
or,O
disease,O
.,O
Methods,O
were,O
predefined,O
in,O
a,O
research,O
protocol,O
using,O
the,O
PRISMA,O
checklist,O
and,O
the,O
Systematic,O
Reviews,O
Guidelines,O
of,O
the,O
Center,O
of,O
Reviews,O
and,O
Dissemination,O
(,O
Multimedia,O
Appendix,O
1,O
).,O
We,O
defined,O
Web,O
-,O
based,O
interventions,O
as,O
Web,O
-,O
based,O
participant,O
-,O
centered,O
treatment,O
or,O
prevention,O
programs,O
delivered,O
via,O
the,O
Internet,O
and,O
interacting,O
with,O
the,O
participant,O
in,O
a,O
tailored,O
fashion,O
[,O
24,O
",",O
25,O
].,O
Internet,O
had,O
to,O
be,O
the,O
main,O
medium,O
through,O
which,O
the,O
intervention,O
was,O
delivered,O
",",O
but,O
other,O
media,O
(,O
phone,O
",",O
face,O
-,O
to,O
-,O
face,O
),O
could,O
be,O
included,O
too,O
.,O
We,O
excluded,O
the,O
following,O
eHealth,O
interventions,O
:,O
telemonitoring,O
",",O
telemedicine,O
",",O
and,O
mobile,O
phone,O
-,O
mediated,O
interventions,O
.,O
The,O
target,O
of,O
the,O
intervention,O
had,O
to,O
be,O
one,O
or,O
more,O
cardiovascular,O
risk,O
factors,O
and,O
/,O
or,O
cardiovascular,B-DS
disease,I-DS
.,O
Thus,O
",",O
we,O
included,O
interventions,O
for,O
both,O
primary,O
and,O
secondary,O
prevention,O
of,O
cardiovascular,B-DS
disease,I-DS
[,O
22,O
].,O
The,O
target,O
population,O
had,O
to,O
have,O
a,O
mean,O
age,O
of,O
50,O
years,O
or,O
older,O
and,O
could,O
have,O
a,O
mixed,O
level,O
of,O
cardiovascular,O
risk,O
(,O
one,O
or,O
more,O
cardiovascular,O
risk,O
factors,O
or,O
established,O
cardiovascular,B-DS
disease,I-DS
).,O
Main,O
outcomes,O
of,O
interest,O
were,O
incident,O
cardiovascular,B-DS
disease,I-DS
(,O
myocardial,B-DS
infarction,I-DS
",",O
angina,O
pectoris,O
",",O
heart,B-DS
failure,I-DS
",",O
stroke,B-DS
or,O
transient,B-DS
ischemic,I-DS
attack,I-DS
",",O
and,O
peripheral,B-DS
arterial,I-DS
disease,I-DS
"),",O
cardiovascular,O
mortality,O
and,O
overall,O
mortality,O
",",O
and,O
changes,O
in,O
cardiovascular,O
risk,O
factors,O
including,O
blood,O
pressure,O
(,O
BP,O
"),",O
glycated,O
hemoglobin,B-GP
A1c,O
(,O
HbA1c,O
"),",O
low,O
-,O
density,O
lipoprotein,O
(,O
LDL,O
),O
cholesterol,O
",",O
smoking,O
status,O
",",O
weight,O
",",O
level,O
of,O
physical,O
exercise,O
",",O
or,O
a,O
composite,O
cardiovascular,O
risk,O
score,O
.,O
We,O
performed,O
a,O
comprehensive,O
literature,O
search,O
in,O
the,O
EMBASE,O
",",O
Medline,O
",",O
CINAHL,O
",",O
and,O
Cochrane,O
databases,O
from,O
1995,O
onward,O
(,O
because,O
the,O
Internet,O
was,O
not,O
widely,O
available,O
before,O
then,O
).,O
Key,O
search,O
terms,O
were,O
cardiovascular,O
risk,O
factors,O
and,O
diseases,O
(,O
separate,O
diseases,O
and,O
risk,O
factors,O
specified,O
"),",O
terms,O
related,O
to,O
aspects,O
of,O
cardiovascular,O
risk,O
management,O
(,O
eg,O
",",O
diet,O
",",O
exercise,O
",",O
BP,O
control,O
"),",O
Web,O
-,O
based,O
interventions,O
(,O
including,O
all,O
definitions,O
and,O
synonyms,O
"),",O
and,O
RCT,O
/,O
review,O
/,O
meta,O
-,O
analysis,O
.,O
The,O
search,O
was,O
last,O
updated,O
on,O
November,O
3,O
",",O
2014,O
by,O
CRB,O
.,O
The,O
comprehensive,O
search,O
strategy,O
is,O
provided,O
in,O
Multimedia,O
Appendix,O
2,O
.,O
Studies,O
were,O
included,O
if,O
(,O
1,O
),O
they,O
were,O
on,O
Web,O
-,O
based,O
interventions,O
targeting,O
cardiovascular,O
risk,O
factors,O
and,O
/,O
or,O
disease,O
",",O
(,O
2,O
),O
study,O
design,O
was,O
a,O
RCT,O
",",O
(,O
3,O
),O
at,O
least,O
50,O
patients,O
were,O
included,O
",",O
(,O
4,O
),O
mean,O
age,O
was,O
at,O
least,O
50,O
years,O
",",O
(,O
5,O
),O
the,O
duration,O
of,O
the,O
intervention,O
was,O
4,O
or,O
more,O
weeks,O
and,O
follow,O
-,O
up,O
was,O
3,O
or,O
more,O
months,O
",",O
(,O
6,O
),O
at,O
least,O
one,O
of,O
the,O
outcomes,O
of,O
our,O
interest,O
was,O
reported,O
",",O
and,O
(,O
7,O
),O
language,O
was,O
English,O
.,O
Study,O
selection,O
was,O
performed,O
by,O
two,O
independent,O
researchers,O
(,O
CRB,O
and,O
BS,O
),O
by,O
means,O
of,O
screening,O
of,O
titles,O
and,O
abstracts,O
",",O
and,O
thereafter,O
reading,O
full,O
texts,O
on,O
the,O
basis,O
of,O
the,O
inclusion,O
criteria,O
.,O
If,O
two,O
publications,O
described,O
the,O
same,O
trial,O
",",O
the,O
paper,O
that,O
reported,O
the,O
primary,O
outcomes,O
of,O
the,O
trial,O
was,O
included,O
.,O
Disagreements,O
were,O
resolved,O
by,O
discussion,O
or,O
by,O
a,O
third,O
investigator,O
(,O
ER,O
).,O
We,O
assessed,O
reviews,O
and,O
meta,O
-,O
analyses,O
encountered,O
with,O
our,O
search,O
strategy,O
to,O
check,O
for,O
additional,O
relevant,O
articles,O
.,O
Data,O
Extraction,O
Two,O
reviewers,O
(,O
BS,O
and,O
CRB,O
),O
extracted,O
data,O
using,O
a,O
predefined,O
data,O
extraction,O
form,O
(,O
Multimedia,O
Appendix,O
3,O
),O
for,O
half,O
of,O
the,O
included,O
articles,O
and,O
checked,O
each,O
other,O
’,O
s,O
results,O
.,O
Extracted,O
information,O
included,O
study,O
characteristics,O
",",O
patient,O
baseline,O
characteristics,O
",",O
characteristics,O
of,O
the,O
intervention,O
and,O
control,O
conditions,O
",",O
and,O
available,O
data,O
on,O
clinical,O
and,O
intermediate,O
outcomes,O
.,O
For,O
BP,O
",",O
glucose,O
control,O
",",O
weight,O
",",O
lipids,O
",",O
and,O
physical,O
activity,O
level,O
",",O
we,O
extracted,O
all,O
baseline,O
and,O
follow,O
-,O
up,O
levels,O
",",O
change,O
scores,O
or,O
mean,O
differences,O
.,O
Corresponding,O
authors,O
were,O
contacted,O
if,O
needed,O
.,O
We,O
used,O
an,O
adapted,O
Cochrane,O
Risk,O
of,O
Bias,O
Tool,O
to,O
evaluate,O
randomization,O
procedures,O
",",O
representativeness,O
of,O
study,O
populations,O
",",O
blinding,O
of,O
outcome,O
assessors,O
(,O
blinding,O
of,O
participants,O
was,O
usually,O
not,O
possible,O
due,O
to,O
study,O
design,O
"),",O
completeness,O
of,O
outcome,O
data,O
",",O
and,O
completeness,O
of,O
reporting,O
.,O
Meta,O
-,O
Analysis,O
For,O
categorical,O
variables,O
",",O
we,O
calculated,O
odds,O
ratios,O
with,O
95,O
%,O
confidence,O
intervals,O
.,O
We,O
estimated,O
pooled,O
odds,O
ratios,O
with,O
Mantel,O
-,O
Haenszel,O
random,O
-,O
effects,O
models,O
.,O
For,O
continuous,O
outcomes,O
",",O
mean,O
differences,O
or,O
standardized,O
mean,O
differences,O
(,O
Hedges,O
’,O
g,O
effect,O
sizes,O
),O
with,O
95,O
%,O
confidence,O
intervals,O
were,O
calculated,O
.,O
We,O
estimated,O
pooled,O
effects,O
with,O
DerSimonian,O
and,O
Laird,O
random,O
-,O
effects,O
models,O
.,O
All,O
HbA1c,O
values,O
were,O
converted,O
to,O
percentages,O
.,O
All,O
LDL,O
cholesterol,O
values,O
were,O
converted,O
to,O
mg,O
/,O
dL,O
.,O
All,O
weight,O
values,O
were,O
converted,O
to,O
kg,O
.,O
For,O
level,O
of,O
physical,O
activity,O
",",O
which,O
was,O
assessed,O
with,O
various,O
instruments,O
",",O
we,O
calculated,O
standardized,O
mean,O
differences,O
and,O
95,O
%,O
confidence,O
intervals,O
.,O
If,O
mean,O
differences,O
or,O
standardized,O
mean,O
differences,O
were,O
reported,O
",",O
we,O
included,O
them,O
directly,O
in,O
the,O
pooled,O
analyses,O
.,O
If,O
not,O
",",O
we,O
calculated,O
change,O
scores,O
(,O
difference,O
between,O
baseline,O
and,O
follow,O
-,O
up,O
within,O
group,O
),O
or,O
values,O
assessed,O
at,O
follow,O
-,O
up,O
.,O
If,O
values,O
were,O
measured,O
at,O
multiple,O
time,O
points,O
",",O
we,O
used,O
the,O
values,O
recorded,O
at,O
the,O
last,O
follow,O
-,O
up,O
contact,O
.,O
For,O
studies,O
with,O
multiple,O
arms,O
",",O
we,O
included,O
only,O
one,O
intervention,O
arm,O
in,O
the,O
meta,O
-,O
analysis,O
in,O
order,O
not,O
to,O
create,O
“,O
unit,O
-,O
of,O
-,O
analysis,O
”,O
error,O
by,O
double,O
counting,O
the,O
control,O
group,O
.,O
Where,O
possible,O
",",O
we,O
selected,O
the,O
Internet,O
-,O
only,O
intervention,O
arm,O
.,O
No,O
data,O
were,O
imputed,O
.,O
We,O
estimated,O
pooled,O
effects,O
for,O
all,O
single,O
cardiovascular,O
risk,O
factors,O
.,O
To,O
address,O
the,O
overall,O
question,O
of,O
efficacy,O
of,O
Web,O
-,O
based,O
interventions,O
for,O
cardiovascular,O
risk,O
factor,O
management,O
",",O
we,O
evaluated,O
the,O
effect,O
on,O
cardiovascular,O
composite,O
scores,O
",",O
clinical,O
outcomes,O
(,O
cardiovascular,B-DS
morbidity,I-DS
and,O
mortality,O
"),",O
and,O
pooled,O
the,O
standardized,O
primary,O
outcomes,O
of,O
all,O
studies,O
.,O
We,O
used,O
the,O
primary,O
outcomes,O
as,O
defined,O
by,O
the,O
authors,O
of,O
the,O
studies,O
.,O
Funnel,O
plots,O
were,O
inspected,O
to,O
assess,O
for,O
potential,O
publication,O
bias,O
.,O
Statistical,O
heterogeneity,O
was,O
assessed,O
using,O
Q,O
and,O
I2,O
tests,O
.,O
We,O
explored,O
reasons,O
for,O
heterogeneity,O
by,O
jackknife,O
analysis,O
and,O
subgroup,O
analyses,O
.,O
We,O
assessed,O
the,O
following,O
factors,O
in,O
subgroup,O
analyses,O
:,O
study,O
duration,O
(,O
predefined,O
",",O
short,O
term,O
[<,O
12,O
months,O
],O
versus,O
long,O
term,O
[≥,O
12,O
months,O
"]),",O
type,O
of,O
cardiovascular,O
prevention,O
(,O
primary,O
versus,O
secondary,O
),O
[,O
22,O
"],",O
and,O
type,O
of,O
intervention,O
(,O
Internet,O
only,O
or,O
“,O
blended,O
”,O
[,O
Internet,O
application,O
combined,O
with,O
human,B-OG
support,O
]).,O
Subgroup,O
analyses,O
were,O
performed,O
on,O
the,O
studies,O
used,O
for,O
the,O
analysis,O
on,O
primary,O
outcomes,O
only,O
.,O
The,O
latter,O
subgroup,O
analysis,O
(,O
on,O
type,O
of,O
intervention,O
),O
consisted,O
of,O
two,O
separate,O
analyses,O
",",O
one,O
to,O
evaluate,O
the,O
Internet,O
-,O
only,O
interventions,O
versus,O
the,O
control,O
conditions,O
and,O
one,O
to,O
evaluate,O
the,O
blended,O
interventions,O
versus,O
control,O
conditions,O
.,O
In,O
case,O
a,O
study,O
tested,O
both,O
types,O
of,O
interventions,O
with,O
a,O
multiple,O
-,O
arm,O
design,O
",",O
the,O
appropriate,O
arm,O
was,O
included,O
for,O
each,O
analysis,O
.,O
In,O
addition,O
",",O
we,O
performed,O
a,O
mixed,O
effects,O
meta,O
-,O
regression,O
using,O
the,O
unrestricted,O
maximum,O
likelihood,O
method,O
to,O
explore,O
the,O
association,O
between,O
study,O
duration,O
and,O
effect,O
size,O
(,O
standardized,O
primary,O
outcome,O
).,O
Last,O
",",O
we,O
performed,O
sensitivity,O
analyses,O
for,O
the,O
different,O
domains,O
of,O
the,O
risk,O
-,O
of,O
-,O
bias,O
assessment,O
by,O
repeating,O
the,O
analysis,O
on,O
standardized,O
primary,O
outcomes,O
in,O
subgroups,O
of,O
studies,O
with,O
low,O
risk,O
of,O
bias,O
versus,O
studies,O
with,O
an,O
unclear,O
or,O
high,O
risk,O
of,O
bias,O
.,O
For,O
this,O
analysis,O
",",O
we,O
wanted,O
to,O
include,O
all,O
studies,O
that,O
contributed,O
to,O
one,O
of,O
the,O
meta,O
-,O
analyses,O
.,O
Therefore,O
",",O
we,O
complemented,O
the,O
sample,O
of,O
studies,O
with,O
defined,O
primary,O
outcomes,O
that,O
were,O
cardiovascular,O
risk,O
factors,O
of,O
interest,O
with,O
studies,O
that,O
had,O
not,O
defined,O
their,O
primary,O
outcome,O
.,O
If,O
there,O
was,O
no,O
defined,O
primary,O
outcome,O
",",O
we,O
used,O
the,O
cardiovascular,O
risk,O
factor,O
that,O
was,O
targeted,O
most,O
directly,O
in,O
the,O
intervention,O
studied,O
.,O
We,O
used,O
Review,O
Manager,O
5,O
.,O
2,O
to,O
draw,O
the,O
risk,O
-,O
of,O
-,O
bias,O
assessment,O
figure,O
and,O
to,O
calculate,O
standard,O
deviations,O
or,O
95,O
%,O
confidence,O
intervals,O
in,O
cases,O
where,O
only,O
standard,O
errors,O
were,O
available,O
in,O
the,O
original,O
data,O
.,O
We,O
used,O
Microsoft,O
Office,O
Excel,O
version,O
10,O
",",O
SPSS,O
version,O
20,O
",",O
and,O
Comprehensive,O
Meta,O
Analysis,O
version,O
2,O
.,O
2,O
.,O
064,O
for,O
the,O
statistical,O
analyses,O
.,O
Results,O
Study,O
Selection,O
The,O
search,O
yielded,O
5251,O
papers,O
after,O
removal,O
of,O
duplicates,O
.,O
We,O
did,O
not,O
identify,O
additional,O
studies,O
by,O
searching,O
reference,O
lists,O
.,O
After,O
screening,O
of,O
titles,O
and,O
abstracts,O
",",O
462,O
papers,O
remained,O
.,O
Review,O
of,O
these,O
full,O
texts,O
resulted,O
in,O
57,O
RCTs,O
(,O
corresponding,O
with,O
84,O
papers,O
),O
that,O
fulfilled,O
the,O
selection,O
criteria,O
and,O
were,O
included,O
in,O
the,O
systematic,O
review,O
.,O
We,O
contacted,O
16,O
authors,O
to,O
request,O
additional,O
data,O
:,O
nine,O
authors,O
responded,O
and,O
three,O
authors,O
complied,O
with,O
our,O
request,O
.,O
Out,O
of,O
this,O
final,O
selection,O
",",O
47,O
studies,O
could,O
be,O
included,O
in,O
the,O
meta,O
-,O
analysis,O
(,O
see,O
Figure,O
1,O
for,O
PRISMA,O
flowchart,O
).,O
Prisma,O
flowchart,O
illustrating,O
literature,O
search,O
.,O
Study,O
Characteristics,O
The,O
57,O
RCTs,O
included,O
19,O
",",O
862,O
individuals,O
(,O
Tables,O
1,O
-,O
5,O
).,O
Study,O
sample,O
size,O
ranged,O
from,O
61,O
to,O
2140,O
participants,O
.,O
Median,O
study,O
duration,O
was,O
9,O
months,O
(,O
interquartile,O
range,O
[,O
IQR,O
],O
6,O
",",O
range,O
3,O
-,O
60,O
months,O
).,O
The,O
mean,O
dropout,O
rate,O
was,O
15,O
%,O
(,O
range,O
0,O
%-,O
62,O
%).,O
The,O
mean,O
age,O
of,O
the,O
study,O
populations,O
ranged,O
from,O
50,O
to,O
71,O
years,O
.,O
In,O
only,O
7,O
studies,O
were,O
all,O
participants,O
older,O
than,O
50,O
years,O
of,O
age,O
.,O
All,O
participants,O
had,O
an,O
increased,O
risk,O
of,O
cardiovascular,B-DS
disease,I-DS
:,O
46,O
studies,O
conducted,O
primary,O
prevention,O
(,O
control,O
of,O
cardiovascular,O
risk,O
factors,O
or,O
diabetes,B-DS
),O
and,O
11,O
studies,O
conducted,O
secondary,O
prevention,O
.,O
In,O
41,O
studies,O
",",O
the,O
intervention,O
targeted,O
a,O
single,O
cardiovascular,O
risk,O
factor,O
;,O
in,O
16,O
studies,O
",",O
multiple,O
risk,O
factors,O
were,O
addressed,O
.,O
We,O
found,O
no,O
studies,O
on,O
interventions,O
for,O
smoking,O
cessation,O
meeting,O
our,O
inclusion,O
criteria,O
.,O
In,O
most,O
studies,O
",",O
the,O
primary,O
outcome,O
was,O
change,O
in,O
a,O
specific,O
cardiovascular,O
risk,O
factor,O
targeted,O
by,O
the,O
intervention,O
.,O
Sixteen,O
studies,O
reported,O
on,O
clinical,O
outcomes,O
including,O
new,O
cardiovascular,O
events,O
[,O
26,O
-,O
31,O
],O
and,O
mortality,O
rates,O
[,O
29,O
-,O
41,O
],O
as,O
a,O
part,O
of,O
adverse,O
event,O
monitoring,O
.,O
All,O
interventions,O
included,O
lifestyle,O
education,O
and,O
were,O
participant,O
-,O
centered,O
.,O
Forty,O
-,O
four,O
studies,O
stimulated,O
self,O
-,O
management,O
by,O
means,O
of,O
goal,O
setting,O
and,O
self,O
-,O
monitoring,O
.,O
Half,O
of,O
interventions,O
were,O
stand,O
-,O
alone,O
Internet,O
platforms,O
and,O
the,O
other,O
half,O
were,O
“,O
blended,O
”,O
(,O
ie,O
",",O
the,O
platforms,O
were,O
supported,O
by,O
a,O
nurse,O
or,O
another,O
health,O
care,O
professional,O
).,O
Intervention,O
usage,O
was,O
reported,O
by,O
22,O
studies,O
.,O
The,O
median,O
percentage,O
of,O
participants,O
logging,O
in,O
to,O
the,O
intervention,O
platform,O
was,O
72,O
%,O
(,O
range,O
33,O
%-,O
100,O
%).,O
Quality,O
Assessment,O
Methodological,O
quality,O
of,O
the,O
included,O
studies,O
varied,O
(,O
Multimedia,O
Appendix,O
4,O
).,O
Most,O
studies,O
adequately,O
described,O
the,O
randomization,O
and,O
allocation,O
concealment,O
procedures,O
.,O
Due,O
to,O
the,O
nature,O
of,O
the,O
interventions,O
",",O
none,O
of,O
the,O
studies,O
had,O
a,O
double,O
-,O
blind,O
design,O
.,O
In,O
20,O
studies,O
",",O
outcome,O
assessors,O
were,O
blinded,O
[,O
27,O
",",O
29,O
",",O
30,O
",",O
32,O
",",O
34,O
-,O
40,O
",",O
42,O
",",O
52,O
",",O
54,O
",",O
57,O
",",O
59,O
",",O
61,O
",",O
64,O
",",O
67,O
",",O
81,O
"],",O
in,O
19,O
studies,O
blinding,O
was,O
not,O
mentioned,O
or,O
unclear,O
[,O
28,O
",",O
31,O
",",O
33,O
",",O
41,O
",",O
43,O
",",O
44,O
",",O
46,O
",",O
48,O
",",O
53,O
",",O
56,O
",",O
60,O
",",O
63,O
",",O
65,O
",",O
69,O
",",O
71,O
",",O
74,O
",",O
76,O
",",O
77,O
",",O
80,O
"],",O
and,O
in,O
18,O
studies,O
outcome,O
assessors,O
were,O
not,O
blinded,O
[,O
26,O
",",O
45,O
",",O
47,O
",",O
49,O
-,O
51,O
",",O
55,O
",",O
58,O
",",O
62,O
",",O
66,O
",",O
68,O
",",O
70,O
",",O
72,O
",",O
73,O
",",O
75,O
",",O
78,O
",",O
79,O
",",O
82,O
].,O
Effect,O
of,O
Web,O
-,O
Based,O
Interventions,O
on,O
Single,O
Risk,O
Factors,O
Of,O
the,O
57,O
studies,O
included,O
in,O
the,O
systemic,O
review,O
",",O
47,O
studies,O
[,O
26,O
-,O
32,O
",",O
34,O
-,O
42,O
",",O
44,O
-,O
53,O
",",O
55,O
-,O
60,O
",",O
62,O
",",O
64,O
-,O
68,O
",",O
70,O
",",O
73,O
",",O
74,O
",",O
76,O
-,O
79,O
",",O
81,O
",",O
82,O
],O
provided,O
sufficient,O
information,O
to,O
be,O
included,O
in,O
the,O
meta,O
-,O
analysis,O
.,O
The,O
mean,O
age,O
of,O
the,O
study,O
populations,O
of,O
these,O
46,O
studies,O
had,O
the,O
same,O
range,O
as,O
the,O
complete,O
sample,O
of,O
57,O
studies,O
.,O
Systolic,O
and,O
Diastolic,O
Blood,O
Pressure,O
The,O
pooled,O
analysis,O
showed,O
a,O
significant,O
reduction,O
in,O
both,O
systolic,O
and,O
diastolic,O
BP,O
favoring,O
the,O
intervention,O
(,O
26,O
studies,O
;,O
n,O
=,O
7720,O
;,O
Figures,O
2,O
and,O
3,O
).,O
For,O
systolic,O
BP,O
",",O
the,O
weighted,O
mean,O
difference,O
was,O
–,O
2,O
.,O
66,O
mmHg,O
(,O
95,O
%,O
CI,O
–,O
3,O
.,O
81,O
to,O
–,O
1,O
.,O
52,O
;,O
I2,O
=,O
53,O
%).,O
For,O
diastolic,O
BP,O
",",O
the,O
weighted,O
mean,O
difference,O
was,O
–,O
1,O
.,O
26,O
mmHg,O
(,O
95,O
%,O
CI,O
–,O
1,O
.,O
92,O
to,O
–,O
0,O
.,O
60,O
;,O
I2,O
=,O
46,O
%).,O
Characteristics,O
of,O
the,O
studies,O
included,O
for,O
the,O
systematic,O
review,O
:,O
interventions,O
targeting,O
diabetes,B-DS
.,O
a,O
Study,O
Setting,O
and,O
study,O
length,O
Participants,O
Age,O
(,O
years,O
"),",O
mean,O
(,O
SD,O
),O
Sex,O
(%,O
female,O
),O
Intervention,O
Control,O
Primary,O
;,O
secondary,O
outcomes,O
Bond,O
2010,O
[,O
42,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
6,O
m,O
62,O
people,O
with,O
DM,B-DS
via,O
university,O
/,O
veteran,O
clinic,O
67,O
.,O
2,O
(,O
6,O
.,O
0,O
),O
45,O
Website,O
:,O
education,O
",",O
self,O
-,O
monitoring,O
(,O
glucose,O
",",O
exercise,O
",",O
weight,O
",",O
BP,O
",",O
medication,O
"),",O
forum,O
;,O
nurse,O
support,O
(,O
email,O
",",O
chat,O
),O
Standard,O
diabetes,B-DS
care,O
HbA1c,O
",",O
BP,O
",",O
weight,O
",",O
total,O
cholesterol,O
",",O
HDL,O
cholesterol,O
IDEATEL,O
2000,O
-,O
2010,O
[,O
34,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
60,O
m,O
1665,O
Medicare,O
recipients,O
with,O
DM,B-DS
70,O
.,O
9,O
(,O
6,O
.,O
7,O
),O
63,O
Online,O
home,O
telemedicine,O
unit,O
:,O
nurse,O
support,O
(,O
video,O
chat,O
"),",O
Web,O
portal,O
for,O
self,O
-,O
monitoring,O
(,O
glucose,O
",",O
BP,O
"),",O
education,O
Standard,O
diabetes,B-DS
care,O
HbA1c,O
",",O
systolic,O
BP,O
",",O
diastolic,O
BP,O
",",O
total,O
cholesterol,O
",",O
LDL,O
cholesterol,O
D,O
-,O
net,O
2001,O
[,O
43,O
],O
4,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
10,O
m,O
320,O
people,O
with,O
DM2,B-DS
",",O
Internet,O
",",O
from,O
16,O
GPs,O
59,O
(,O
9,O
.,O
2,O
),O
53,O
Website,O
:,O
(,O
1,O
),O
Self,O
-,O
management,O
(,O
glucose,O
"),",O
coach,O
support,O
;,O
(,O
2,O
),O
education,O
",",O
forum,O
;,O
(,O
3,O
),O
1,O
and,O
2,O
combinedb,O
(,O
4,O
),O
Information,O
on,O
medical,O
and,O
lifestyle,O
aspects,O
of,O
diabetes,B-DS
Not,O
defined,O
;,O
behavioral,O
",",O
biological,O
",",O
and,O
psychosocial,O
outcomes,O
My,O
path,O
2010,O
[,O
44,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
463,O
Medicare,O
recipients,O
with,O
DM2,B-DS
",",O
BMI,O
≥,O
25,O
kg,O
/,O
m2,O
or,O
≥,O
1,O
CV,O
risk,O
factor,O
",",O
Internet,O
58,O
.,O
4,O
(,O
9,O
.,O
2,O
),O
50,O
(,O
1,O
),O
Website,O
for,O
computer,O
-,O
assisted,O
self,O
-,O
management,O
(,O
CASM,O
):,O
goal,O
setting,O
",",O
monitoring,O
(,O
HbA1c,O
",",O
BP,O
",",O
cholesterol,O
"),",O
forum,O
",",O
education,O
;,O
b,O
",",O
c,O
(,O
2,O
),O
CASM,O
+,O
social,O
support,O
(,O
coach,O
",",O
group,O
sessions,O
),O
b,O
",",O
c,O
(,O
3,O
),O
Computer,O
-,O
based,O
health,O
risk,O
appraisal,O
",",O
no,O
key,O
features,O
of,O
CASM,O
Behavior,O
changes,O
in,O
diet,O
",",O
physical,O
activity,O
",",O
medication,O
adherence,O
My,O
care,O
team,O
2005,O
[,O
45,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
104,O
people,O
with,O
DM,B-DS
",",O
HbA1c,O
≥,O
9,O
.,O
0,O
%,O
via,O
veteran,O
clinic,O
63,O
.,O
5,O
(,O
7,O
.,O
0,O
),O
0,O
.,O
5,O
Website,O
:,O
self,O
-,O
management,O
(,O
glucose,O
",",O
BP,O
"),",O
education,O
",",O
reminders,O
(,O
phone,O
);,O
care,O
manager,O
support,O
DM,B-DS
self,O
-,O
management,O
training,O
",",O
usual,O
care,O
HbA1c,O
and,O
BP,O
at,O
3,O
",",O
6,O
",",O
9,O
",",O
and,O
12,O
m,O
Mobile,O
DM,B-DS
2011,O
[,O
32,O
],O
4,O
-,O
arm,O
cluster,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
26,O
physician,O
practices,O
with,O
163,O
people,O
with,O
DM,B-DS
and,O
HbA1c,O
≥,O
7,O
.,O
5,O
%,O
52,O
.,O
8,O
(,O
8,O
.,O
1,O
),O
50,O
(,O
2,O
),O
Self,O
-,O
management,O
via,O
website,O
+,O
mobile,O
phone,O
",",O
patient,O
informs,O
doctor,O
;,O
b,O
(,O
3,O
),O
2,O
+,O
doctor,O
access,O
to,O
data,O
;,O
(,O
4,O
),O
3,O
+,O
advice,O
from,O
doctorc,O
(,O
1,O
),O
Care,O
as,O
usual,O
Change,O
in,O
HbA1c,O
over,O
1,O
year,O
Avdal,O
2011,O
[,O
46,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Turkey,O
;,O
6,O
m,O
122,O
people,O
with,O
DM2,B-DS
",",O
Internet,O
from,O
clinic,O
51,O
(,O
7,O
.,O
3,O
),O
51,O
Website,O
:,O
review,O
risk,O
profile,O
",",O
messaging,O
to,O
researcher,O
",",O
daily,O
glucose,O
monitoring,O
Education,O
and,O
usual,O
care,O
HbA1c,O
",",O
attendance,O
rates,O
at,O
outpatient,O
clinic,O
Cho,O
2006,O
[,O
47,O
],O
2,O
-,O
arm,O
RCT,O
;,O
South,O
Korea,O
;,O
30,O
m,O
80,O
people,O
with,O
DM,B-DS
",",O
Internet,O
from,O
clinic,O
53,O
(,O
9,O
),O
39,O
Website,O
:,O
monitoring,O
(,O
glucose,O
",",O
medication,O
",",O
BP,O
",",O
weight,O
",",O
lifestyle,O
"),",O
nurse,O
feedback,O
",",O
medication,O
alterations,O
Conventional,O
note,O
-,O
keeping,O
record,O
system,O
HbA1c,O
and,O
HbA1c,O
fluctuation,O
index,O
Lorig,O
2010,O
[,O
48,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
6,O
m,O
761,O
people,O
with,O
DM2,B-DS
",",O
Internet,O
54,O
.,O
3,O
(,O
9,O
.,O
9,O
),O
73,O
Self,O
-,O
management,O
website,O
with,O
peer,O
support,O
:,O
lessons,O
",",O
action,O
plans,O
",",O
bulletin,O
board,O
",",O
messaging,O
Care,O
as,O
usual,O
HbA1C,O
level,O
at,O
6,O
and,O
18,O
months,O
Grant,O
2008,O
[,O
49,O
],O
2,O
-,O
arm,O
cluster,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
244,O
people,O
with,O
DM,B-DS
",",O
HbA1c,O
>,O
7,O
.,O
0,O
%,O
from,O
11,O
primary,O
clinics,O
56,O
.,O
1,O
(,O
11,O
.,O
6,O
),O
49,O
Online,O
personal,O
health,O
record,O
:,O
education,O
",",O
diabetes,B-DS
care,O
plan,O
",",O
agenda,O
",",O
messaging,O
",",O
prescription,O
refills,O
Access,O
to,O
general,O
website,O
Patient,O
Gateway,O
Changes,O
in,O
HbA1c,O
",",O
BP,O
",",O
and,O
LDL,O
cholesterol,O
McMahon,O
2012,O
[,O
50,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
151,O
people,O
with,O
DM,B-DS
",",O
HbA1c,O
>,O
8,O
.,O
5,O
%,O
from,O
veteran,O
health,O
services,O
60,O
.,O
2,O
(,O
10,O
.,O
8,O
),O
5,O
(,O
1,O
),O
Self,O
-,O
monitoring,O
via,O
phone,O
(,O
BP,O
",",O
glucose,O
);,O
(,O
2,O
),O
website,O
:,O
self,O
-,O
monitoring,O
(,O
BP,O
",",O
glucose,O
"),",O
education,O
",",O
support,O
by,O
care,O
managersb,O
",",O
c,O
(,O
3,O
),O
Website,O
with,O
links,O
to,O
other,O
DM,B-DS
websites,O
;,O
usual,O
care,O
Change,O
in,O
HbA1c,O
and,O
BP,O
over,O
time,O
Ralston,O
2009,O
[,O
51,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
83,O
people,O
with,O
DM2,B-DS
",",O
HbA1c,O
≥,O
7,O
.,O
0,O
%,O
and,O
Internet,O
from,O
clinic,O
:,O
65,O
%,O
with,O
2,O
CV,O
risk,O
factors,O
57,O
.,O
3,O
(—),O
52,O
Electronic,O
medical,O
record,O
:,O
self,O
-,O
monitoring,O
(,O
glucose,O
",",O
exercise,O
",",O
diet,O
",",O
medication,O
"),",O
support,O
by,O
care,O
manager,O
",",O
usual,O
care,O
visits,O
Usual,O
care,O
visits,O
Change,O
in,O
HbA1c,O
Kwon,O
2004,O
[,O
52,O
],O
2,O
-,O
arm,O
RCT,O
;,O
South,O
Korea,O
;,O
3,O
m,O
110,O
people,O
with,O
DM2,B-DS
",",O
Internet,O
from,O
clinic,O
:,O
27,O
%,O
hypertension,B-DS
54,O
.,O
1,O
(,O
9,O
.,O
1,O
),O
33,O
Website,O
:,O
self,O
-,O
monitoring,O
(,O
glucose,O
"),",O
reminders,O
",",O
professor,O
/,O
nurse,O
/,O
dietician,O
-,O
support,O
Monthly,O
visit,O
to,O
diabetes,B-DS
specialist,O
HbA1c,O
EMPOWER,O
-,O
D,O
2013,O
[,O
39,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
415,O
people,O
with,O
DM,B-DS
and,O
HbA1c,O
≥,O
7,O
.,O
5,O
%,O
from,O
clinic,O
53,O
.,O
7,O
(,O
10,O
.,O
2,O
),O
40,O
Online,O
health,O
record,O
:,O
risk,O
estimation,O
",",O
self,O
-,O
monitoring,O
(,O
glucose,O
",",O
diet,O
",",O
exercise,O
",",O
BP,O
"),",O
nurse,O
support,O
",",O
own,O
doctor,O
informed,O
Usual,O
care,O
HbA1c,O
at,O
12,O
m,O
REDEEM,O
2013,O
[,O
53,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
392,O
people,O
with,O
DM2,B-DS
",",O
Internet,O
from,O
community,O
centers,O
56,O
.,O
1,O
(,O
9,O
.,O
6,O
),O
54,O
(,O
1,O
),O
CASM,O
website,O
:,O
goal,O
setting,O
;,O
self,O
-,O
monitoring,O
(,O
HbA1c,O
",",O
BP,O
",",O
cholesterol,O
);,O
8,O
phone,O
calls,O
;,O
b,O
(,O
2,O
),O
Computer,O
-,O
assisted,O
self,O
-,O
management,O
+,O
problem,O
solving,O
treatment,O
(,O
CASP,O
):,O
CASM,O
+,O
8,O
sessions,O
problem,O
solving,O
Computer,O
health,O
risk,O
appraisal,O
",",O
education,O
",",O
same,O
phone,O
calls,O
as,O
intervention,O
Diabetes,B-DS
distress,O
;,O
HbA1c,O
",",O
physical,O
activity,O
",",O
medication,O
compliance,O
a,O
Abbreviations,O
:,O
BP,O
:,O
blood,O
pressure,O
;,O
CASM,O
:,O
computer,O
-,O
assisted,O
self,O
-,O
management,O
;,O
CASP,O
:,O
computer,O
-,O
assisted,O
self,O
-,O
management,O
+,O
problem,O
solving,O
treatment,O
;,O
CV,O
:,O
cardiovascular,O
;,O
DM,B-DS
:,O
diabetes,B-DS
mellitus,I-DS
;,O
DM2,B-DS
:,O
type,B-DS
2,I-DS
diabetes,I-DS
mellitus,I-DS
;,O
GP,O
:,O
general,O
practitioner,O
;,O
HbA1c,O
;,O
glycated,O
hemoglobin,B-GP
A1c,O
;,O
HDL,O
:,O
high,O
-,O
density,O
lipoprotein,O
;,O
LDL,O
:,O
low,O
-,O
density,O
lipoprotein,O
.,O
b,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
all,O
analyses,O
.,O
c,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
the,O
subgroup,O
analysis,O
on,O
blended,O
interventions,O
.,O
Effect,O
on,O
systolic,O
blood,O
pressure,O
(,O
26,O
studies,O
).,O
Characteristics,O
of,O
the,O
studies,O
included,O
for,O
the,O
systematic,O
review,O
:,O
interventions,O
targeting,O
blood,O
pressure,O
.,O
a,O
Study,O
Setting,O
and,O
study,O
length,O
Participants,O
Age,O
(,O
years,O
"),",O
mean,O
(,O
SD,O
),O
Sex,O
(%,O
female,O
),O
Intervention,O
Control,O
Primary,O
;,O
secondary,O
outcomes,O
e,O
-,O
BP,O
2008,O
[,O
29,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
778,O
people,O
with,O
Internet,O
",",O
hypertension,B-DS
",",O
from,O
GPs,O
:,O
61,O
.,O
1,O
%,O
obese,O
59,O
.,O
1,O
(,O
8,O
.,O
5,O
),O
52,O
(,O
1,O
),O
Website,O
:,O
BP,O
self,O
-,O
monitoring,O
;,O
b,O
(,O
2,O
),O
1,O
+,O
pharmacist,O
supportc,O
General,O
website,O
:,O
personal,O
medical,O
record,O
Change,O
in,O
diastolic,O
",",O
systolic,O
and,O
mean,O
BP,O
Nolan,O
2012,O
[,O
54,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Canada,O
;,O
4,O
m,O
387,O
people,O
with,O
hypertension,B-DS
via,O
website,O
:,O
41,O
%,O
obese,O
56,O
.,O
5,O
(,O
7,O
.,O
4,O
),O
59,O
BP,O
action,O
plan,O
website,O
:,O
assessing,O
motivational,O
readiness,O
",",O
advice,O
",",O
feedback,O
",",O
education,O
E,O
-,O
newsletters,O
Change,O
in,O
diastolic,O
and,O
systolic,O
BP,O
",",O
and,O
pulse,O
pressure,O
Bove,O
2013,O
[,O
55,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
6,O
m,O
241,O
people,O
with,O
elevated,O
BP,O
from,O
2,O
clinics,O
59,O
.,O
6,O
(,O
13,O
.,O
6,O
),O
65,O
Website,O
+,O
telephone,O
system,O
:,O
education,O
",",O
self,O
-,O
monitoring,O
(,O
BP,O
",",O
weight,O
",",O
exercise,O
"),",O
online,O
nurse,O
support,O
",",O
doctor,O
informed,O
Provision,O
of,O
data,O
from,O
initial,O
assessment,O
",",O
usual,O
care,O
Proportion,O
of,O
participants,O
with,O
controlled,O
BP,O
at,O
6,O
m,O
Madsen,O
2008,O
[,O
56,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Denmark,O
;,O
6,O
m,O
236,O
people,O
with,O
hypertension,B-DS
from,O
10,O
GPs,O
55,O
.,O
9,O
(,O
11,O
.,O
7,O
),O
50,O
Website,O
:,O
self,O
-,O
monitoring,O
(,O
BP,O
"),",O
feedback,O
from,O
own,O
doctor,O
by,O
email,O
Usual,O
care,O
Change,O
in,O
ambulatory,O
systolic,O
BP,O
-,O
at,O
6,O
m,O
Magid,O
2013,O
[,O
57,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
6,O
m,O
348,O
people,O
with,O
hypertension,B-DS
from,O
10,O
clinics,O
60,O
(,O
11,O
),O
40,O
Written,O
educational,O
material,O
",",O
website,O
:,O
self,O
-,O
monitoring,O
(,O
BP,O
"),",O
pharmacist,O
support,O
",",O
doctor,O
informed,O
",",O
reminders,O
Written,O
education,O
material,O
",",O
usual,O
care,O
Proportion,O
of,O
participants,O
with,O
controlled,O
BP,O
at,O
6,O
m,O
McKinstry,O
2013,O
[,O
38,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Scotland,O
;,O
6,O
m,O
401,O
people,O
with,O
hypertension,B-DS
from,O
20,O
GPs,O
60,O
.,O
7,O
(,O
11,O
.,O
2,O
),O
40,O
Telemonitoring,O
unit,O
+,O
website,O
:,O
self,O
-,O
monitoring,O
(,O
BP,O
"),",O
feedback,O
from,O
own,O
doctor,O
Usual,O
care,O
Mean,O
ambulatory,O
BP,O
at,O
6,O
m,O
Thiboutot,O
2013,O
[,O
58,O
],O
2,O
-,O
arm,O
cluster,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
500,O
patients,O
with,O
elevated,O
BP,O
from,O
54,O
GPs,O
60,O
.,O
5,O
(,O
11,O
.,O
9,O
),O
58,O
Website,O
:,O
self,O
-,O
monitoring,O
(,O
BP,O
",",O
medication,O
"),",O
feedback,O
",",O
reminders,O
Different,O
prevention,O
website,O
(,O
eg,O
",",O
breast,O
screening,O
),O
BP,O
control,O
at,O
12,O
m,O
a,O
Abbreviations,O
:,O
BP,O
:,O
blood,O
pressure,O
;,O
GP,O
:,O
general,O
practitioner,O
.,O
b,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
all,O
analyses,O
.,O
c,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
the,O
subgroup,O
analysis,O
on,O
blended,O
interventions,O
.,O
Characteristics,O
of,O
the,O
studies,O
included,O
for,O
the,O
systematic,O
review,O
:,O
interventions,O
targeting,O
weight,O
loss,O
and,O
weight,O
loss,O
maintenance,O
.,O
a,O
Study,O
Setting,O
and,O
study,O
length,O
Participants,O
Age,O
(,O
years,O
"),",O
mean,O
(,O
SD,O
),O
Sex,O
(%,O
female,O
),O
Intervention,O
Control,O
Primary,O
;,O
secondary,O
outcomes,O
Weight,O
loss,O
Appel,O
2011,O
[,O
35,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
24,O
m,O
415,O
people,O
with,O
obesity,B-DS
",",O
≥,O
1,O
CV,O
risk,O
factor,O
",",O
Internet,O
from,O
6,O
primary,O
clinics,O
54,O
(,O
10,O
.,O
2,O
),O
64,O
(,O
1,O
),O
Website,O
+,O
mobile,O
coach,O
support,O
:,O
education,O
",",O
self,O
-,O
monitoring,O
(,O
weight,O
",",O
diet,O
",",O
exercise,O
"),",O
reminders,O
",",O
doctor,O
informed,O
;,O
b,O
",",O
c,O
(,O
2,O
),O
1,O
+,O
in,O
-,O
person,O
support,O
1,O
(,O
or,O
2,O
),O
meetings,O
with,O
coach,O
;,O
brochure,O
with,O
websites,O
for,O
weight,O
loss,O
Change,O
in,O
weight,O
from,O
baseline,O
to,O
24,O
m,O
Bennett,O
2012,O
[,O
28,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
24,O
m,O
365,O
obese,O
people,O
with,O
hypertension,B-DS
from,O
3,O
clinics,O
54,O
.,O
6,O
(,O
10,O
.,O
9,O
),O
69,O
Website,O
/,O
interactive,O
voice,O
response,O
system,O
:,O
self,O
-,O
monitoring,O
weight,O
",",O
setting,O
",",O
coach,O
support,O
(,O
phone,O
"),",O
group,O
sessions,O
",",O
education,O
Self,O
-,O
help,O
booklet,O
Change,O
in,O
weight,O
at,O
24,O
m,O
Bennett,O
2010,O
[,O
59,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
3,O
m,O
101,O
obese,O
people,O
with,O
hypertension,B-DS
",",O
Internet,O
from,O
clinic,O
54,O
.,O
4,O
(,O
8,O
.,O
1,O
),O
48,O
Website,O
:,O
goal,O
setting,O
",",O
self,O
-,O
monitoring,O
",",O
behavioral,O
skills,O
education,O
",",O
forum,O
",",O
coach,O
support,O
(,O
online,O
",",O
phone,O
",",O
face,O
-,O
to,O
-,O
face,O
),O
Folder,O
on,O
healthy,O
weight,O
",",O
usual,O
care,O
Change,O
in,O
weight,O
at,O
12,O
weeks,O
Kraschnewsky,O
2011,O
[,O
60,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
3,O
m,O
100,O
overweight,O
people,O
",",O
Internet,O
via,O
flyers,O
/,O
Internet,O
50,O
.,O
3,O
(,O
10,O
.,O
9,O
),O
70,O
Website,O
:,O
target,O
body,O
weight,O
",",O
monitoring,O
",",O
behavioral,O
tips,O
",",O
videos,O
",",O
weight,O
loss,O
plan,O
",",O
tailored,O
feedback,O
",",O
reminders,O
Wait,O
list,O
",",O
people,O
got,O
access,O
to,O
website,O
after,O
12,O
weeks,O
Weight,O
loss,O
Webberd,O
2008,O
[,O
61,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
4,O
m,O
66,O
women,O
",",O
BMI,O
25,O
-,O
40,O
",",O
Internet,O
from,O
advertisements,O
50,O
.,O
0,O
(,O
9,O
.,O
9,O
),O
100,O
Website,O
:,O
weight,O
loss,O
tips,O
",",O
lessons,O
",",O
message,O
board,O
",",O
self,O
-,O
monitoring,O
(,O
weight,O
",",O
diet,O
"),",O
chat,O
sessions,O
All,O
features,O
of,O
intervention,O
except,O
for,O
online,O
chat,O
sessions,O
Not,O
defined,O
;,O
weight,O
",",O
BMI,O
",",O
diet,O
",",O
exercise,O
E,O
-,O
LITE,O
2013,O
[,O
36,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
15,O
m,O
241,O
people,O
with,O
a,O
BMI,O
≥,O
25,O
",",O
metabolic,B-DS
syndrome,I-DS
from,O
1,O
clinic,O
52,O
.,O
9,O
(,O
10,O
.,O
6,O
),O
47,O
(,O
1,O
),O
Website,O
+,O
12,O
lifestyle,O
classes,O
;,O
c,O
(,O
2,O
),O
website,O
:,O
self,O
-,O
monitoring,O
(,O
weight,O
",",O
exercise,O
"),",O
messaging,O
",",O
DVD,O
with,O
lifestyle,O
classesb,O
Usual,O
care,O
Change,O
in,O
BMI,O
from,O
baseline,O
to,O
15,O
m,O
POWER,O
2014,O
[,O
62,O
],O
4,O
-,O
arm,O
RCT,O
;,O
UK,O
;,O
12,O
m,O
179,O
people,O
with,O
BMI,O
≥,O
30,O
kg,O
/,O
m2,O
or,O
≥,O
28,O
kg,O
/,O
m2,O
+,O
CV,O
risk,O
factors,O
from,O
5,O
GPs,O
51,O
.,O
2,O
(,O
13,O
.,O
1,O
),O
66,O
(,O
1,O
),O
Website,O
:,O
12,O
self,O
-,O
management,O
sessions,O
monitoring,O
(,O
weight,O
"),",O
nurse,O
support,O
(,O
email,O
);,O
b,O
",",O
c,O
(,O
2,O
),O
1,O
+,O
3,O
nurse,O
contacts,O
;,O
(,O
3,O
),O
1,O
+,O
7,O
nurse,O
contacts,O
Usual,O
care,O
Weight,O
at,O
12,O
m,O
Weight,O
loss,O
maintenance,O
Stop,O
Regain,O
2008,O
[,O
41,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
18,O
m,O
314,O
people,O
with,O
10,O
%,O
weight,O
loss,O
in,O
2,O
years,O
",",O
via,O
advertisements,O
51,O
(,O
10,O
),O
81,O
(,O
1,O
),O
Website,O
:,O
self,O
-,O
monitoring,O
",",O
email,O
counseling,O
",",O
experts,O
chat,O
;,O
b,O
(,O
2,O
),O
face,O
-,O
to,O
-,O
face,O
:,O
self,O
-,O
monitoring,O
via,O
phone,O
",",O
weekly,O
group,O
sessions,O
(,O
3,O
),O
Newsletters,O
Weight,O
gain,O
at,O
18,O
m,O
WLM,O
2008,O
[,O
40,O
],O
2,O
-,O
phase,O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
30,O
m,O
1032,O
people,O
with,O
≥,O
4,O
kg,O
previous,O
weight,O
loss,O
",",O
hypertension,B-DS
",",O
Internet,O
via,O
university,O
/,O
medicare,O
55,O
.,O
6,O
(,O
8,O
.,O
7,O
),O
63,O
(,O
1,O
),O
Website,O
:,O
goal,O
setting,O
",",O
action,O
plans,O
",",O
self,O
-,O
monitoring,O
(,O
weight,O
",",O
PA,O
",",O
diet,O
"),",O
education,O
",",O
bulletin,O
board,O
",",O
reminders,O
",",O
support,O
(,O
email,O
/,O
phone,O
);,O
b,O
(,O
2,O
),O
personal,O
contact,O
(,O
phone,O
+,O
face,O
-,O
to,O
-,O
face,O
),O
Printed,O
lifestyle,O
guidelines,O
",",O
1,O
visit,O
with,O
coach,O
Change,O
in,O
weight,O
a,O
Abbreviations,O
:,O
BMI,O
:,O
body,O
mass,O
index,O
;,O
CV,O
:,O
cardiovascular,O
;,O
GP,O
:,O
general,O
practitioner,O
;,O
PA,O
:,O
physical,O
activity,O
.,O
b,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
all,O
analyses,O
.,O
c,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
the,O
subgroup,O
analysis,O
on,O
blended,O
interventions,O
.,O
d,O
Control,O
arm,O
consists,O
of,O
same,O
interactive,O
Internet,O
platform,O
as,O
intervention,O
arm,O
.,O
Characteristics,O
of,O
the,O
studies,O
included,O
for,O
the,O
systematic,O
review,O
:,O
interventions,O
targeting,O
physical,O
activity,O
and,O
cholesterol,O
.,O
a,O
Study,O
Setting,O
and,O
study,O
length,O
Participants,O
Age,O
(,O
years,O
"),",O
mean,O
(,O
SD,O
),O
Sex,O
(%,O
female,O
),O
Intervention,O
Control,O
Primary,O
;,O
secondary,O
outcomes,O
Physical,O
activity,O
Richardsonb,O
2010,O
[,O
63,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
4,O
m,O
324,O
patients,O
from,O
clinic,O
:,O
12,O
%,O
CHD,B-DS
",",O
20,O
%,O
DM2,B-DS
",",O
62,O
%,O
BMI,O
>,O
30,O
52,O
.,O
0,O
(,O
11,O
.,O
4,O
),O
65,O
Website,O
as,O
control,O
+,O
online,O
community,O
forum,O
Website,O
:,O
pedometer,O
",",O
tailored,O
feedback,O
Change,O
in,O
average,O
daily,O
step,O
count,O
",",O
patient,O
attrition,O
Reid,O
2011,O
[,O
30,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Canada,O
;,O
12,O
m,O
223,O
patients,O
with,O
a,O
recent,O
CHD,B-DS
event,O
",",O
Internet,O
via,O
2,O
cardiac,O
centers,O
56,O
.,O
4,O
(,O
9,O
.,O
0,O
),O
16,O
Website,O
:,O
tutorials,O
",",O
exercise,O
plans,O
",",O
self,O
-,O
monitoring,O
",",O
specialist,O
support,O
Usual,O
care,O
",",O
education,O
booklet,O
Mean,O
steps,O
per,O
day,O
Ferney,O
2009,O
[,O
64,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Australia,O
;,O
6,O
m,O
106,O
inactive,O
residents,O
:,O
58,O
%,O
overweight,O
52,O
.,O
0,O
(,O
4,O
.,O
6,O
),O
72,O
Website,O
:,O
behavioral,O
strategies,O
",",O
goal,O
setting,O
",",O
self,O
-,O
monitoring,O
",",O
advice,O
",",O
bulletin,O
board,O
",",O
news,O
Website,O
with,O
minimal,O
interactivity,O
Not,O
defined,O
;,O
physical,O
activity,O
",",O
website,O
use,O
Active,O
after,O
55,O
2013,O
[,O
65,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
3,O
m,O
405,O
sedentary,O
people,O
with,O
Internet,O
via,O
senior,O
centers,O
/,O
websites,O
60,O
.,O
3,O
(,O
4,O
.,O
9,O
),O
69,O
Website,O
:,O
education,O
",",O
goal,O
setting,O
",",O
exercise,O
planning,O
",",O
11,O
online,O
exercise,O
lessons,O
",",O
self,O
-,O
monitoring,O
",",O
reminders,O
No,O
access,O
to,O
the,O
intervention,O
Not,O
defined,O
;,O
physical,O
activity,O
",",O
BMI,O
HEART,O
2014,O
[,O
37,O
],O
2,O
-,O
arm,O
RCT,O
;,O
New,O
Zealand,O
;,O
6,O
m,O
171,O
people,O
with,O
stable,O
CHD,B-DS
",",O
Internet,O
from,O
2,O
hospitals,O
60,O
.,O
2,O
(,O
9,O
.,O
2,O
),O
19,O
Exercise,O
prescription,O
",",O
behavioral,O
strategies,O
",",O
Website,O
:,O
videos,O
",",O
self,O
-,O
monitoring,O
(,O
exercise,O
"),",O
education,O
",",O
reminders,O
Usual,O
care,O
Change,O
in,O
peak,O
oxygen,O
uptake,O
from,O
baseline,O
to,O
6,O
m,O
Philips,O
Direct,O
Life,O
2013,O
[,O
66,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Netherlands,O
;,O
3,O
m,O
235,O
inactive,O
people,O
with,O
Internet,O
through,O
local,O
media,O
64,O
.,O
8,O
(,O
2,O
.,O
9,O
),O
41,O
Website,O
:,O
goal,O
setting,O
",",O
self,O
-,O
monitoring,O
(,O
exercise,O
"),",O
e,O
-,O
coach,O
feedback,O
Waitlist,O
control,O
Change,O
in,O
physical,O
activity,O
Suboc,O
2014,O
[,O
67,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
3,O
m,O
114,O
sedentary,O
people,O
through,O
media,O
and,O
Internet,O
63,O
.,O
0,O
(,O
7,O
.,O
0,O
),O
34,O
(,O
1,O
),O
Pedometer,O
;,O
(,O
2,O
),O
website,O
+,O
pedometer,O
:,O
exercise,O
strategies,O
",",O
goal,O
setting,O
",",O
self,O
-,O
monitoring,O
(,O
exercise,O
),O
feedback,O
",",O
forumc,O
No,O
intervention,O
Endothelial,O
function,O
;,O
vascular,O
stiffness,O
",",O
step,O
count,O
",",O
exercise,O
Peels,O
2013,O
[,O
68,O
],O
5,O
-,O
arm,O
cluster,O
RCT,O
;,O
Netherlands,O
;,O
12,O
m,O
2140,O
people,O
from,O
6,O
municipal,O
regions,O
",",O
±,O
50,O
%,O
overweight,O
63,O
.,O
2,O
(,O
8,O
.,O
4,O
),O
51,O
(,O
1,O
),O
Printed,O
feedback,O
report,O
;,O
(,O
2,O
),O
1,O
+,O
local,O
exercise,O
tips,O
;,O
(,O
3,O
),O
Web,O
-,O
based,O
feedback,O
report,O
;,O
(,O
4,O
),O
3,O
+,O
local,O
exercise,O
tipsc,O
Waitlist,O
control,O
Physical,O
activity,O
Cholesterol,O
Blochb,O
2006,O
[,O
69,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
6,O
m,O
171,O
employees,O
with,O
increased,O
cholesterol,O
",",O
DM,B-DS
or,O
CHD,B-DS
54,O
.,O
8,O
(,O
9,O
.,O
4,O
),O
—,O
(,O
1,O
),O
Website,O
+,O
financial,O
reward,O
;,O
(,O
2,O
),O
website,O
+,O
4,O
classes,O
",",O
nurse,O
support,O
(,O
phone,O
),O
Website,O
",",O
10,O
-,O
year,O
CVD,B-DS
score,O
",",O
monitoring,O
",",O
goals,O
",",O
tailored,O
info,O
LDL,O
cholesterol,O
change,O
at,O
6,O
m,O
Live,O
well,O
2013,O
[,O
70,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
3,O
m,O
61,O
people,O
with,O
LDL,O
cholesterol,O
≥,O
3,O
.,O
37,O
mmol,O
/,O
L,O
",",O
Internet,O
from,O
primary,O
clinics,O
52,O
.,O
0,O
(,O
12,O
.,O
8,O
),O
75,O
Web,O
-,O
based,O
rate,O
-,O
your,O
-,O
plate,O
assessment,O
",",O
written,O
educational,O
material,O
",",O
Website,O
:,O
goal,O
setting,O
",",O
self,O
-,O
monitoring,O
",",O
reminders,O
Web,O
-,O
based,O
rate,O
-,O
your,O
-,O
plate,O
assessment,O
Not,O
defined,O
;,O
cholesterol,O
",",O
weight,O
",",O
Framingham,O
risk,O
score,O
a,O
Abbreviations,O
:,O
BMI,O
:,O
body,O
mass,O
index,O
;,O
CHD,B-DS
:,O
coronary,B-DS
heart,I-DS
disease,I-DS
;,O
CVD,B-DS
:,O
cardiovascular,B-DS
disease,I-DS
;,O
DM,B-DS
:,O
diabetes,B-DS
mellitus,I-DS
;,O
DM2,B-DS
:,O
type,B-DS
2,I-DS
diabetes,I-DS
mellitus,I-DS
;,O
LDL,O
:,O
low,O
-,O
density,O
lipoprotein,O
.,O
b,O
Control,O
arm,O
consists,O
of,O
same,O
interactive,O
Internet,O
platform,O
as,O
intervention,O
arm,O
.,O
c,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
all,O
analyses,O
.,O
Characteristics,O
of,O
the,O
studies,O
included,O
for,O
the,O
systematic,O
review,O
:,O
interventions,O
targeting,O
multiple,O
risk,O
factors,O
.,O
a,O
Study,O
Setting,O
and,O
study,O
length,O
Participants,O
Age,O
(,O
years,O
"),",O
mean,O
(,O
SD,O
),O
Sex,O
(%,O
female,O
),O
Intervention,O
Control,O
Primary,O
;,O
secondary,O
outcomes,O
Lindsay,O
2008,O
[,O
71,O
],O
2,O
-,O
arm,O
RCT,O
;,O
UK,O
;,O
6,O
m,O
108,O
heart,O
patients,O
living,O
in,O
deprived,O
areas,O
62,O
.,O
9,O
(,O
6,O
.,O
0,O
),O
33,O
eHealth,O
portal,O
:,O
glossary,O
",",O
education,O
",",O
local,O
community,O
links,O
",",O
discussion,O
forum,O
No,O
access,O
to,O
the,O
eHealth,O
portal,O
Not,O
defined,O
;,O
behavior,O
change,O
(,O
exercise,O
",",O
smoking,O
",",O
diet,O
),O
Heartcare,O
II,O
2010,O
[,O
72,O
],O
2,O
-,O
arm,O
cluster,O
RCT,O
;,O
USA,O
;,O
30,O
m,O
282,O
patients,O
with,O
chronic,B-DS
heart,I-DS
disease,I-DS
needing,O
nursing,O
care,O
64,O
.,O
0,O
(,O
12,O
.,O
7,O
),O
39,O
Personal,O
health,O
record,O
:,O
education,O
",",O
monitoring,O
",",O
communication,O
",",O
goal,O
setting,O
",",O
email,O
",",O
bulletin,O
board,O
Usual,O
care,O
as,O
the,O
home,O
care,O
agencies,O
use,O
to,O
provide,O
Satisfaction,O
with,O
nursing,O
care,O
Hughes,O
2011,O
[,O
73,O
],O
3,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
423,O
senior,O
university,O
employees,O
with,O
Internet,O
",",O
32,O
%,O
overweight,O
",",O
46,O
%,O
obese,O
51,O
.,O
0,O
(,O
7,O
.,O
0,O
),O
82,O
(,O
1,O
),O
Coach,O
for,O
Web,O
-,O
based,O
risk,O
assessment,O
",",O
lifestyle,O
plan,O
",",O
email,O
",",O
phone,O
or,O
in,O
-,O
person,O
contact,O
;,O
c,O
(,O
2,O
),O
website,O
:,O
risk,O
profile,O
assessment,O
",",O
advice,O
",",O
goal,O
setting,O
",",O
action,O
planningb,O
Printed,O
list,O
of,O
health,O
promotion,O
programs,O
Not,O
defined,O
;,O
diet,O
",",O
exercise,O
",",O
weight,O
Southard,O
2003,O
[,O
26,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
6,O
m,O
104,O
patients,O
with,O
CHD,B-DS
or,O
heart,B-DS
failure,I-DS
from,O
10,O
hospitals,O
",",O
200,O
GPs,O
",",O
adverts,O
62,O
.,O
3,O
(,O
10,O
.,O
6,O
),O
25,O
Website,O
+,O
nurse,O
:,O
education,O
",",O
self,O
-,O
monitoring,O
",",O
discussion,O
group,O
",",O
links,O
contact,O
(,O
email,O
",",O
phone,O
or,O
mail,O
"),",O
dietician,O
Usual,O
care,O
Not,O
defined,O
;,O
weight,O
",",O
exercise,O
",",O
BP,O
",",O
lipid,O
profile,O
",",O
new,O
CV,O
events,O
Winett,O
2007,O
[,O
74,O
],O
3,O
-,O
arm,O
cluster,O
RCT,O
;,O
USA,O
;,O
16,O
m,O
14,O
churches,O
with,O
1071,O
members,O
:,O
57,O
%,O
overweight,O
",",O
60,O
%,O
sedentary,O
51,O
.,O
4,O
(,O
15,O
.,O
7,O
),O
67,O
(,O
1,O
),O
Website,O
:,O
education,O
",",O
goal,O
setting,O
",",O
pedometer,O
;,O
b,O
(,O
2,O
),O
1,O
+,O
pulpit,O
supportc,O
Waitlist,O
condition,O
Nutrition,O
improvement,O
",",O
physical,O
activity,O
Vernooij,O
2012,O
[,O
27,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Netherlands,O
;,O
12,O
m,O
330,O
patients,O
with,O
CVD,B-DS
",",O
2,O
risk,O
factors,O
",",O
Internet,O
via,O
2,O
hospitals,O
59,O
.,O
9,O
(,O
8,O
.,O
4,O
),O
25,O
Website,O
:,O
risk,O
profile,O
",",O
self,O
-,O
monitoring,O
(,O
BP,O
",",O
cholesterol,O
"),",O
treatment,O
goal,O
",",O
nurse,O
support,O
",",O
news,O
",",O
medication,O
changes,O
Usual,O
care,O
by,O
specialist,O
or,O
GP,O
",",O
receiving,O
baseline,O
risk,O
profile,O
Relative,O
change,O
in,O
Framingham,O
heart,O
risk,O
score,O
after,O
1,O
year,O
Verheijden,O
2004,O
[,O
75,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Canada,O
;,O
8,O
m,O
146,O
people,O
with,O
increased,O
CV,O
risk,O
",",O
Internet,O
from,O
14,O
GPs,O
63,O
.,O
0,O
(,O
10,O
.,O
5,O
),O
45,O
Website,O
:,O
tailored,O
information,O
",",O
diet,O
tool,O
",",O
bulletin,O
board,O
Usual,O
care,O
Not,O
defined,O
;,O
BMI,O
",",O
BP,O
",",O
lipid,O
profile,O
Ross,O
2004,O
[,O
33,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
107,O
patients,O
with,O
heart,B-DS
failure,I-DS
",",O
Internet,O
via,O
clinic,O
56,O
.,O
0,O
(-),O
23,O
Online,O
medical,O
record,O
(,O
clinical,O
notes,O
",",O
laboratory,O
reports,O
",",O
test,O
results,O
"),",O
education,O
",",O
nurse,O
support,O
Usual,O
care,O
Change,O
in,O
self,O
-,O
efficacy,O
domain,O
Bove,O
2011,O
[,O
76,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
465,O
people,O
with,O
CVD,B-DS
risk,O
>,O
10,O
%,O
via,O
community,O
",",O
clinics,O
",",O
churches,O
61,O
.,O
0,O
(,O
10,O
.,O
0,O
),O
46,O
Online,O
telemedicine,O
system,O
:,O
laboratory,O
and,O
medication,O
review,O
",",O
self,O
-,O
monitoring,O
(,O
BP,O
",",O
weight,O
",",O
pedometer,O
"),",O
feedback,O
",",O
education,O
",",O
own,O
doctor,O
involved,O
4,O
-,O
months,O
meetings,O
with,O
nurse,O
:,O
review,O
data,O
from,O
logbooks,O
Reduction,O
in,O
Framingham,O
10,O
-,O
year,O
CVD,B-DS
risk,O
score,O
Keyserling,O
2014,O
[,O
31,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
12,O
m,O
385,O
people,O
with,O
CHD,B-DS
risk,O
score,O
≥,O
10,O
%,O
but,O
no,O
CVD,B-DS
from,O
5,O
GPs,O
62,O
.,O
0,O
(,O
7,O
.,O
8,O
),O
48,O
Website,O
:,O
CHD,B-DS
risk,O
calculator,O
",",O
advice,O
",",O
education,O
",",O
action,O
planning,O
",",O
goal,O
setting,O
.,O
Same,O
CHD,B-DS
risk,O
calculator,O
",",O
but,O
in,O
-,O
person,O
and,O
by,O
phone,O
Framingham,O
10,O
-,O
year,O
CHD,B-DS
risk,O
score,O
at,O
4,O
and,O
12,O
m,O
Zullig,O
2014,O
[,O
77,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
3,O
m,O
96,O
people,O
with,O
CVD,B-DS
or,O
DM,B-DS
from,O
primary,O
clinics,O
36,O
.,O
1,O
(,O
12,O
.,O
2,O
),O
67,O
CVD,B-DS
risk,O
assessment,O
",",O
website,O
:,O
6,O
modules,O
with,O
risk,O
assessments,O
",",O
goal,O
setting,O
",",O
education,O
Printed,O
information,O
on,O
CVD,B-DS
Not,O
defined,O
;,O
Framingham,O
10,O
-,O
year,O
CVD,B-DS
risk,O
score,O
",",O
BMI,O
",",O
smoking,O
status,O
",",O
systolic,O
BP,O
Activate,O
your,O
Heart,O
2014,O
[,O
78,O
],O
2,O
-,O
arm,O
RCT,O
;,O
UK,O
;,O
6,O
m,O
95,O
people,O
with,O
stable,B-DS
angina,I-DS
",",O
Internet,O
from,O
9,O
GPs,O
66,O
.,O
2,O
(,O
9,O
.,O
2,O
),O
25,O
Website,O
:,O
CVD,B-DS
risk,O
assessment,O
",",O
education,O
",",O
goal,O
setting,O
",",O
self,O
-,O
monitoring,O
",",O
email,O
/,O
chat,O
with,O
experts,O
Usual,O
care,O
with,O
GP,O
Change,O
in,O
step,O
count,O
at,O
6,O
weeks,O
and,O
6,O
m,O
e,O
-,O
Care,O
2014,O
[,O
79,O
],O
2,O
-,O
arm,O
RCT,O
USA,O
6m,O
101,O
people,O
with,O
BMI,O
>,O
26,O
",",O
elevated,O
BP,O
via,O
electronic,O
health,O
records,O
56,O
.,O
9,O
(,O
7,O
.,O
0,O
),O
42,O
Website,O
+,O
dietician,O
:,O
CVD,B-DS
risk,O
assessment,O
",",O
goal,O
setting,O
",",O
action,O
planning,O
",",O
self,O
-,O
monitoring,O
(,O
weight,O
",",O
BP,O
",",O
physical,O
activity,O
",",O
diet,O
),O
Usual,O
care,O
",",O
printed,O
report,O
for,O
patient,O
and,O
doctor,O
Change,O
in,O
systolic,O
BP,O
",",O
weight,O
and,O
10,O
-,O
year,O
CVD,B-DS
risk,O
score,O
Greene,O
2012,O
[,O
80,O
],O
2,O
-,O
arm,O
RCT,O
;,O
USA,O
;,O
6,O
m,O
513,O
employees,O
+,O
families,O
45,O
%,O
overweight,O
and,O
48,O
%,O
obese,O
60,O
%,O
older,O
than,O
50,O
years,O
79,O
Printed,O
lifestyle,O
guide,O
",",O
website,O
:,O
online,O
social,O
network,O
",",O
self,O
-,O
monitoring,O
(,O
weight,O
",",O
exercise,O
"),",O
goal,O
setting,O
",",O
feedback,O
Printed,O
lifestyle,O
guide,O
Not,O
defined,O
;,O
physical,O
activity,O
",",O
weight,O
",",O
lipid,O
profile,O
Holbrook,O
2009,O
[,O
81,O
],O
2,O
-,O
arm,O
cluster,O
RCT,O
;,O
Canada,O
;,O
12,O
m,O
46,O
GPs,O
with,O
511,O
people,O
with,O
DM,B-DS
",",O
≥,O
1,O
CV,O
risk,O
factor,O
60,O
.,O
7,O
(,O
12,O
.,O
5,O
),O
49,O
Personal,O
Web,O
-,O
based,O
profile,O
overview,O
for,O
DM,B-DS
/,O
CVRM,O
care,O
",",O
automated,O
telephone,O
reminders,O
",",O
summary,O
for,O
doctor,O
",",O
doctor,O
involved,O
Usual,O
care,O
Composite,O
score,O
for,O
process,O
of,O
care,O
Diabetes,B-DS
in,O
Check,O
2014,O
[,O
82,O
],O
2,O
-,O
arm,O
RCT,O
;,O
Australia,O
;,O
9,O
m,O
436,O
people,O
with,O
DM,B-DS
",",O
Internet,O
via,O
DM,B-DS
network,O
58,O
.,O
2,O
(,O
10,O
.,O
3,O
),O
48,O
Website,O
:,O
self,O
-,O
monitoring,O
(,O
exercise,O
),O
goal,O
setting,O
",",O
education,O
",",O
discussion,O
board,O
General,O
website,O
with,O
home,O
page,O
and,O
contacts,O
page,O
only,O
Not,O
defined,O
;,O
physical,O
activity,O
",",O
BMI,O
a,O
Abbreviations,O
:,O
BMI,O
:,O
body,O
mass,O
index,O
;,O
BP,O
:,O
blood,O
pressure,O
;,O
CHD,B-DS
:,O
coronary,B-DS
heart,I-DS
disease,I-DS
;,O
CV,O
:,O
cardiovascular,O
;,O
CVD,B-DS
:,O
cardiovascular,B-DS
disease,I-DS
;,O
CVRM,O
:,O
cardiovascular,O
risk,O
management,O
;,O
DM,B-DS
:,O
diabetes,B-DS
mellitus,I-DS
;,O
GP,O
:,O
general,O
practitioner,O
.,O
b,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
all,O
analyses,O
.,O
c,O
For,O
studies,O
with,O
more,O
than,O
2,O
arms,O
",",O
this,O
arm,O
was,O
used,O
for,O
the,O
subgroup,O
analysis,O
on,O
blended,O
interventions,O
.,O
Effect,O
on,O
diastolic,O
blood,O
pressure,O
(,O
26,O
studies,O
).,O
Glycated,O
Hemoglobin,B-GP
A1c,O
A,O
significant,O
reduction,O
in,O
HbA1c,O
level,O
favoring,O
the,O
intervention,O
among,O
patients,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
mellitus,I-DS
was,O
found,O
(,O
21,O
studies,O
;,O
n,O
=,O
6518,O
;,O
Figure,O
4,O
).,O
The,O
weighted,O
mean,O
difference,O
for,O
HbA1c,O
was,O
–,O
0,O
.,O
13,O
%,O
(,O
95,O
%,O
CI,O
–,O
0,O
.,O
22,O
to,O
–,O
0,O
.,O
05,O
;,O
I2,O
=,O
74,O
%).,O
The,O
jackknife,O
procedure,O
did,O
not,O
reveal,O
one,O
particular,O
study,O
responsible,O
for,O
high,O
heterogeneity,O
.,O
Effect,O
on,O
glycated,O
hemoglobin,B-GP
(,O
21,O
studies,O
).,O
Weight,O
Fifteen,O
studies,O
tested,O
interventions,O
for,O
weight,O
loss,O
and,O
two,O
studies,O
tested,O
interventions,O
for,O
maintenance,O
of,O
weight,O
loss,O
.,O
The,O
pooled,O
analysis,O
(,O
17,O
studies,O
;,O
n,O
=,O
3713,O
;,O
Figure,O
5,O
),O
showed,O
a,O
significant,O
reduction,O
in,O
weight,O
favoring,O
the,O
intervention,O
(,O
weighted,O
mean,O
difference,O
–,O
1,O
.,O
34,O
kg,O
",",O
95,O
%,O
CI,O
–,O
1,O
.,O
91,O
to,O
–,O
0,O
.,O
77,O
;,O
I2,O
=,O
61,O
%).,O
A,O
sensitivity,O
analysis,O
leaving,O
out,O
the,O
two,O
studies,O
on,O
weight,O
loss,O
maintenance,O
resulted,O
in,O
a,O
similar,O
effect,O
size,O
and,O
level,O
of,O
heterogeneity,O
.,O
The,O
jackknife,O
procedure,O
identified,O
three,O
studies,O
contributing,O
considerably,O
to,O
heterogeneity,O
[,O
35,O
",",O
42,O
",",O
59,O
].,O
Effect,O
on,O
weight,O
(,O
17,O
studies,O
).,O
Low,O
-,O
Density,O
Lipoprotein,O
Cholesterol,O
A,O
small,O
but,O
significant,O
reduction,O
in,O
LDL,O
cholesterol,O
favoring,O
the,O
intervention,O
was,O
found,O
(,O
17,O
studies,O
;,O
n,O
=,O
5035,O
;,O
Figure,O
6,O
;,O
weighted,O
mean,O
difference,O
–,O
2,O
.,O
18,O
mg,O
/,O
dL,O
",",O
95,O
%,O
CI,O
–,O
3,O
.,O
96,O
to,O
–,O
0,O
.,O
41,O
;,O
I2,O
=,O
44,O
%).,O
Effect,O
on,O
low,O
-,O
density,O
lipoprotein,O
cholesterol,O
(,O
17,O
studies,O
).,O
Physical,O
Activity,O
Fourteen,O
studies,O
(,O
n,O
=,O
4444,O
;,O
Figure,O
7,O
),O
reported,O
the,O
effect,O
on,O
physical,O
activity,O
.,O
Eight,O
studies,O
used,O
self,O
-,O
reported,O
physical,O
activity,O
levels,O
in,O
minutes,O
per,O
week,O
",",O
five,O
studies,O
used,O
daily,O
step,O
counts,O
obtained,O
from,O
pedometers,O
",",O
and,O
one,O
study,O
measured,O
physical,O
activity,O
with,O
accelerometers,O
.,O
Because,O
of,O
the,O
differences,O
in,O
measurement,O
instruments,O
",",O
we,O
calculated,O
standardized,O
mean,O
differences,O
.,O
A,O
small,O
significant,O
difference,O
in,O
increase,O
of,O
physical,O
activity,O
levels,O
was,O
found,O
in,O
favor,O
of,O
the,O
intervention,O
(,O
weighted,O
standardized,O
mean,O
difference,O
0,O
.,O
25,O
",",O
95,O
%,O
CI,O
0,O
.,O
10,O
-,O
0,O
.,O
39,O
;,O
I2,O
=,O
81,O
"%),",O
but,O
heterogeneity,O
was,O
high,O
.,O
The,O
jackknife,O
procedure,O
identified,O
one,O
study,O
[,O
65,O
],O
driving,O
a,O
substantial,O
part,O
of,O
heterogeneity,O
;,O
without,O
this,O
study,O
",",O
I2,O
was,O
68,O
%.,O
Effect,O
of,O
Web,O
-,O
Based,O
Interventions,O
on,O
Overall,O
Cardiovascular,O
Risk,O
Profile,O
",",O
Cardiovascular,B-DS
Morbidity,I-DS
",",O
and,O
Mortality,O
Cardiovascular,O
Composite,O
Scores,O
Nine,O
studies,O
(,O
n,O
=,O
2321,O
;,O
Figure,O
8,O
),O
reported,O
a,O
cardiovascular,O
composite,O
score,O
.,O
Five,O
studies,O
reported,O
the,O
Framingham,O
10,O
-,O
year,O
cardiovascular,B-DS
disease,I-DS
risk,O
score,O
",",O
three,O
studies,O
reported,O
the,O
Framingham,O
10,O
-,O
year,O
coronary,B-DS
heart,I-DS
disease,I-DS
risk,O
score,O
",",O
and,O
one,O
study,O
reported,O
a,O
clinical,O
composite,O
score,O
based,O
on,O
number,O
of,O
cardiovascular,O
risk,O
factors,O
on,O
target,O
(,O
BP,O
",",O
HbA1c,O
",",O
body,O
mass,O
index,O
",",O
LDL,O
cholesterol,O
",",O
physical,O
activity,O
",",O
albuminuria,O
",",O
foot,B-DS
ulcers,I-DS
",",O
and,O
smoking,O
).,O
Because,O
of,O
the,O
differences,O
between,O
the,O
composite,O
scores,O
",",O
we,O
calculated,O
standardized,O
mean,O
differences,O
.,O
A,O
small,O
significant,O
improvement,O
of,O
the,O
cardiovascular,O
composite,O
scores,O
was,O
found,O
(,O
weighted,O
standardized,O
mean,O
difference,O
–,O
0,O
.,O
10,O
",",O
95,O
%,O
CI,O
–,O
0,O
.,O
18,O
to,O
–,O
0,O
.,O
02,O
;,O
I2,O
=,O
0,O
%).,O
General,O
Effect,O
of,O
Web,O
-,O
Based,O
Interventions,O
on,O
Cardiovascular,O
Risk,O
Factors,O
Finally,O
",",O
we,O
pooled,O
the,O
primary,O
outcomes,O
of,O
the,O
37,O
studies,O
(,O
n,O
=,O
11,O
",",O
021,O
;,O
Figure,O
9,O
),O
that,O
defined,O
a,O
primary,O
outcome,O
(,O
systolic,O
BP,O
:,O
7,O
studies,O
;,O
HbA1c,O
:,O
13,O
studies,O
;,O
weight,O
:,O
8,O
studies,O
;,O
physical,O
activity,O
:,O
6,O
studies,O
;,O
cardiovascular,O
composite,O
score,O
:,O
3,O
studies,O
).,O
The,O
weighted,O
standardized,O
mean,O
difference,O
was,O
–,O
0,O
.,O
24,O
(,O
95,O
%,O
CI,O
–,O
0,O
.,O
31,O
to,O
–,O
0,O
.,O
16,O
;,O
I2,O
=,O
69,O
%),O
in,O
favor,O
of,O
the,O
intervention,O
.,O
The,O
jackknife,O
procedure,O
revealed,O
that,O
one,O
study,O
[,O
57,O
],O
somewhat,O
influenced,O
the,O
heterogeneity,O
;,O
without,O
this,O
study,O
",",O
heterogeneity,O
dropped,O
to,O
64,O
%.,O
The,O
funnel,O
plot,O
(,O
Multimedia,O
Appendix,O
5,O
),O
indicated,O
that,O
small,O
studies,O
reporting,O
large,O
effects,O
might,O
be,O
overrepresented,O
.,O
The,O
Egger,O
’,O
s,O
test,O
confirmed,O
that,O
the,O
funnel,O
plot,O
was,O
not,O
symmetrical,O
(,O
P,O
=.,O
01,O
).,O
Effect,O
on,O
physical,O
activity,O
(,O
14,O
studies,O
).,O
Effect,O
on,O
cardiovascular,O
composite,O
scores,O
(,O
9,O
studies,O
).,O
General,O
effect,O
on,O
primary,O
outcomes,O
(,O
37,O
studies,O
).,O
Cardiovascular,B-DS
Morbidity,I-DS
and,O
Total,O
Mortality,O
Six,O
studies,O
(,O
n,O
=,O
1904,O
;,O
1,O
short,O
-,O
term,O
and,O
5,O
long,O
-,O
term,O
studies,O
),O
reported,O
on,O
cardiovascular,O
event,O
rates,O
.,O
The,O
mean,O
length,O
of,O
the,O
studies,O
was,O
13,O
months,O
(,O
range,O
6,O
-,O
24,O
months,O
).,O
The,O
pooled,O
analysis,O
showed,O
no,O
difference,O
in,O
rate,O
between,O
groups,O
(,O
pooled,O
OR,O
0,O
.,O
75,O
",",O
95,O
%,O
CI,O
0,O
.,O
39,O
-,O
1,O
.,O
42,O
;,O
I2,O
=,O
27,O
%;,O
Figure,O
10,O
).,O
Total,O
mortality,O
rates,O
were,O
reported,O
in,O
13,O
studies,O
;,O
in,O
five,O
studies,O
",",O
no,O
deaths,O
occurred,O
and,O
in,O
the,O
other,O
eight,O
studies,O
",",O
there,O
were,O
no,O
differences,O
between,O
groups,O
.,O
Effect,O
on,O
cardiovascular,O
event,O
rates,O
(,O
6,O
studies,O
).,O
Association,O
between,O
study,O
duration,O
and,O
effect,O
size,O
(,O
Hedges,O
',O
g,O
).,O
One,O
outlier,O
study,O
(,O
Ideatel,O
),O
was,O
removed,O
from,O
analysis,O
.,O
Subgroup,O
Analyses,O
Results,O
are,O
summarized,O
in,O
Table,O
6,O
.,O
Within,O
the,O
analysis,O
of,O
pooled,O
primary,O
outcomes,O
",",O
the,O
intervention,O
effect,O
was,O
more,O
pronounced,O
in,O
the,O
short,O
-,O
term,O
studies,O
(,O
15,O
studies,O
;,O
n,O
=,O
2934,O
;,O
standardized,O
mean,O
difference,O
–,O
0,O
.,O
43,O
",",O
95,O
%,O
CI,O
–,O
0,O
.,O
57,O
to,O
–,O
0,O
.,O
29,O
;,O
I2,O
=,O
69,O
%),O
than,O
in,O
the,O
long,O
-,O
term,O
studies,O
(,O
22,O
studies,O
;,O
n,O
=,O
8087,O
;,O
standardized,O
mean,O
difference,O
–,O
0,O
.,O
12,O
",",O
95,O
%,O
CI,O
–,O
0,O
.,O
19,O
to,O
–,O
0,O
.,O
06,O
;,O
I2,O
=,O
41,O
%).,O
The,O
same,O
pattern,O
was,O
found,O
for,O
all,O
other,O
outcomes,O
except,O
for,O
LDL,O
cholesterol,O
(,O
Multimedia,O
Appendix,O
6,O
).,O
There,O
were,O
no,O
substantial,O
differences,O
in,O
effect,O
size,O
between,O
studies,O
on,O
primary,O
prevention,O
versus,O
secondary,O
prevention,O
.,O
To,O
further,O
explore,O
the,O
studies,O
targeting,O
primary,O
prevention,O
",",O
we,O
compared,O
studies,O
with,O
populations,O
of,O
relatively,O
low,O
age,O
(,O
not,O
all,O
participants,O
older,O
than,O
50,O
years,O
",",O
n,O
=,O
29,O
),O
with,O
studies,O
with,O
populations,O
of,O
older,O
age,O
(,O
all,O
participants,O
older,O
than,O
50,O
years,O
",",O
n,O
=,O
4,O
).,O
The,O
pooled,O
effect,O
size,O
was,O
larger,O
for,O
the,O
studies,O
with,O
older,O
participants,O
(,O
Hedges,O
’,O
g,O
=–,O
0,O
.,O
30,O
),O
than,O
for,O
the,O
studies,O
with,O
relatively,O
younger,O
participants,O
(,O
Hedges,O
’,O
g,O
=–,O
0,O
.,O
23,O
"),",O
but,O
the,O
confidence,O
intervals,O
overlapped,O
largely,O
.,O
We,O
repeated,O
the,O
analysis,O
of,O
pooled,O
primary,O
outcomes,O
on,O
the,O
sample,O
of,O
studies,O
testing,O
an,O
Internet,O
-,O
only,O
and,O
a,O
blended,O
intervention,O
.,O
The,O
intervention,O
effect,O
was,O
more,O
pronounced,O
in,O
the,O
sample,O
of,O
blended,O
studies,O
(,O
26,O
studies,O
;,O
n,O
=,O
7538,O
;,O
standardized,O
mean,O
difference,O
–,O
0,O
.,O
33,O
",",O
95,O
%,O
CI,O
–,O
0,O
.,O
43,O
to,O
–,O
0,O
.,O
22,O
;,O
I2,O
=,O
78,O
%),O
compared,O
to,O
the,O
sample,O
of,O
Internet,O
-,O
only,O
studies,O
(,O
14,O
studies,O
;,O
n,O
=,O
4280,O
;,O
standardized,O
mean,O
difference,O
–,O
0,O
.,O
15,O
",",O
95,O
%,O
CI,O
–,O
0,O
.,O
23,O
to,O
–,O
0,O
.,O
07,O
;,O
I2,O
=,O
40,O
%).,O
Subgroup,O
analyses,O
within,O
the,O
analysis,O
of,O
standardized,O
primary,O
outcomes,O
.,O
Subgroup,O
N,O
of,O
studies,O
Hedges,O
’,O
g,O
95,O
%,O
CI,O
I2,O
Duration,O
a,O
Short,O
(<,O
12,O
months,O
),O
15,O
–,O
0,O
.,O
43,O
–,O
0,O
.,O
57,O
",",O
–,O
0,O
.,O
29,O
69,O
%,O
Long,O
(≥,O
12,O
months,O
),O
22,O
–,O
0,O
.,O
12,O
–,O
0,O
.,O
19,O
",",O
–,O
0,O
.,O
06,O
41,O
%,O
Type,O
of,O
prevention,O
a,O
Primary,O
(,O
including,O
diabetes,B-DS
control,O
),O
33,O
–,O
0,O
.,O
25,O
–,O
0,O
.,O
32,O
",",O
–,O
0,O
.,O
17,O
72,O
%,O
Secondary,O
4,O
–,O
0,O
.,O
20,O
–,O
0,O
.,O
34,O
",",O
–,O
0,O
.,O
06,O
0,O
%,O
Primary,O
prevention,O
:,O
age,O
subgroups,O
b,O
Not,O
all,O
older,O
than,O
50,O
years,O
29,O
–,O
0,O
.,O
23,O
–,O
0,O
.,O
33,O
",",O
–,O
0,O
.,O
14,O
72,O
%,O
All,O
older,O
than,O
50,O
years,O
4,O
–,O
0,O
.,O
30,O
–,O
0,O
.,O
51,O
",",O
–,O
0,O
.,O
09,O
80,O
%,O
Internet,O
only,O
vs,O
controlc,O
14,O
–,O
0,O
.,O
15,O
–,O
0,O
.,O
23,O
",",O
–,O
0,O
.,O
07,O
40,O
%,O
Blended,O
vs,O
controld,O
26,O
–,O
0,O
.,O
33,O
–,O
0,O
.,O
43,O
",",O
–,O
0,O
.,O
22,O
79,O
%,O
a,O
Subgroup,O
analysis,O
performed,O
in,O
the,O
sample,O
of,O
studies,O
that,O
was,O
used,O
for,O
the,O
analysis,O
of,O
primary,O
outcomes,O
.,O
b,O
Subgroup,O
analysis,O
performed,O
on,O
the,O
sample,O
of,O
studies,O
that,O
targeted,O
primary,O
prevention,O
(,O
including,O
diabetes,B-DS
control,O
).,O
c,O
Subgroup,O
analysis,O
performed,O
on,O
the,O
sample,O
of,O
studies,O
that,O
evaluated,O
an,O
Internet,O
-,O
only,O
intervention,O
.,O
In,O
case,O
a,O
study,O
tested,O
multiple,O
arms,O
",",O
the,O
appropriate,O
arm,O
was,O
included,O
in,O
the,O
analysis,O
.,O
d,O
Subgroup,O
analysis,O
performed,O
on,O
the,O
sample,O
of,O
studies,O
that,O
evaluated,O
a,O
blended,O
intervention,O
.,O
In,O
case,O
a,O
study,O
tested,O
multiple,O
arms,O
",",O
the,O
appropriate,O
arm,O
was,O
included,O
in,O
the,O
analysis,O
.,O
Meta,O
-,O
Regression,O
Because,O
of,O
the,O
fairly,O
consistent,O
finding,O
that,O
treatment,O
effects,O
were,O
higher,O
in,O
short,O
-,O
term,O
studies,O
than,O
in,O
long,O
-,O
term,O
studies,O
",",O
we,O
performed,O
a,O
mixed,O
effects,O
meta,O
-,O
regression,O
to,O
explore,O
the,O
association,O
between,O
study,O
duration,O
and,O
effect,O
size,O
.,O
The,O
effect,O
size,O
seemed,O
to,O
become,O
smaller,O
in,O
studies,O
with,O
longer,O
follow,O
-,O
up,O
",",O
although,O
the,O
association,O
was,O
not,O
significant,O
(,O
Hedges,O
’,O
g,O
=–,O
0,O
.,O
321,O
+,O
0,O
.,O
006,O
*,O
months,O
;,O
P,O
=.,O
07,O
).,O
After,O
removal,O
of,O
one,O
outlier,O
study,O
[,O
34,O
],O
that,O
had,O
a,O
very,O
long,O
follow,O
-,O
up,O
(,O
5,O
years,O
"),",O
the,O
effect,O
size,O
significantly,O
decreased,O
over,O
time,O
in,O
studies,O
lasting,O
3,O
to,O
32,O
months,O
(,O
Hedges,O
’,O
g,O
=–,O
0,O
.,O
415,O
+,O
0,O
.,O
015,O
*,O
months,O
;,O
P,O
=.,O
008,O
;,O
Figure,O
.,O
11,O
).,O
Sensitivity,O
Analyses,O
for,O
the,O
Risk,O
-,O
of,O
-,O
Bias,O
Assessment,O
We,O
performed,O
sensitivity,O
analyses,O
for,O
each,O
of,O
the,O
six,O
domains,O
of,O
bias,O
assessed,O
with,O
the,O
adapted,O
Cochrane,O
Risk,O
of,O
Bias,O
Tool,O
by,O
comparing,O
the,O
standardized,O
primary,O
outcomes,O
of,O
the,O
studies,O
with,O
the,O
low,O
risk,O
and,O
unknown,O
/,O
high,O
risk,O
of,O
bias,O
(,O
Multimedia,O
Appendix,O
7,O
).,O
There,O
were,O
no,O
significant,O
differences,O
in,O
pooled,O
effect,O
sizes,O
in,O
any,O
of,O
the,O
domains,O
except,O
for,O
the,O
domain,O
random,O
sequence,O
generation,O
",",O
in,O
which,O
the,O
pooled,O
effect,O
was,O
significantly,O
larger,O
in,O
the,O
subgroup,O
of,O
studies,O
with,O
unknown,O
/,O
high,O
risk,O
of,O
bias,O
.,O
Discussion,O
In,O
this,O
systematic,O
review,O
and,O
meta,O
-,O
analysis,O
",",O
we,O
found,O
for,O
people,O
with,O
elevated,O
cardiovascular,O
risk,O
",",O
Web,O
-,O
based,O
interventions,O
lead,O
to,O
improvement,O
of,O
systolic,O
and,O
diastolic,O
BP,O
",",O
HbA1c,O
",",O
weight,O
",",O
LDL,O
cholesterol,O
",",O
physical,O
activity,O
levels,O
",",O
and,O
cardiovascular,O
risk,O
composite,O
scores,O
.,O
Only,O
seven,O
studies,O
included,O
participants,O
all,O
aged,O
50,O
years,O
or,O
older,O
.,O
Therefore,O
",",O
our,O
conclusions,O
apply,O
for,O
the,O
population,O
in,O
middle,O
age,O
and,O
beyond,O
.,O
Effects,O
were,O
more,O
pronounced,O
over,O
the,O
short,O
term,O
(,O
study,O
duration,O
<,O
12,O
months,O
),O
and,O
in,O
studies,O
that,O
tested,O
a,O
blended,O
intervention,O
(,O
combination,O
of,O
an,O
Internet,O
application,O
and,O
human,B-OG
support,O
).,O
We,O
found,O
no,O
evidence,O
for,O
an,O
effect,O
on,O
incident,O
cardiovascular,B-DS
disease,I-DS
.,O
Our,O
findings,O
on,O
single,O
cardiovascular,O
risk,O
factors,O
are,O
consistent,O
with,O
conclusions,O
of,O
other,O
meta,O
-,O
analyses,O
in,O
younger,O
adult,O
populations,O
[,O
19,O
-,O
21,O
].,O
We,O
found,O
a,O
significant,O
reduction,O
in,O
systolic,O
BP,O
of,O
2,O
.,O
66,O
mmHg,O
.,O
A,O
reduction,O
of,O
3,O
mmHg,O
in,O
systolic,O
BP,O
can,O
lead,O
to,O
an,O
8,O
%,O
reduction,O
in,O
annual,O
stroke,B-DS
mortality,O
rate,O
and,O
a,O
5,O
%,O
reduction,O
in,O
annual,O
coronary,B-DS
heart,I-DS
disease,I-DS
mortality,O
rate,O
[,O
83,O
].,O
We,O
found,O
a,O
reduction,O
of,O
LDL,O
cholesterol,O
of,O
2,O
.,O
18,O
mg,O
/,O
dL,O
(,O
converted,O
=,O
0,O
.,O
06,O
mmol,O
/,O
L,O
).,O
A,O
reduction,O
of,O
0,O
.,O
5,O
mmol,O
/,O
L,O
in,O
LDL,O
cholesterol,O
for,O
at,O
least,O
2,O
years,O
can,O
lead,O
to,O
a,O
reduction,O
in,O
coronary,B-DS
heart,I-DS
disease,I-DS
events,O
of,O
20,O
%,O
[,O
6,O
].,O
Theoretically,O
",",O
assuming,O
a,O
linear,O
relation,O
",",O
a,O
reduction,O
of,O
0,O
.,O
06,O
mmol,O
/,O
L,O
could,O
lead,O
to,O
a,O
2,O
.,O
4,O
%,O
reduction,O
of,O
coronary,B-DS
heart,I-DS
disease,I-DS
events,O
.,O
Thus,O
",",O
the,O
effects,O
on,O
Internet,O
interventions,O
on,O
BP,O
reduction,O
and,O
",",O
to,O
a,O
lesser,O
extent,O
",",O
LDL,O
cholesterol,O
reduction,O
",",O
can,O
be,O
clinically,O
relevant,O
at,O
the,O
population,O
level,O
if,O
reductions,O
are,O
maintained,O
.,O
In,O
addition,O
",",O
we,O
evaluated,O
the,O
effect,O
on,O
the,O
complete,O
cardiovascular,O
risk,O
profile,O
and,O
prevention,O
of,O
cardiovascular,B-DS
disease,I-DS
",",O
which,O
has,O
not,O
been,O
performed,O
before,O
.,O
One,O
other,O
systematic,O
review,O
without,O
meta,O
-,O
analysis,O
that,O
evaluated,O
Internet,O
interventions,O
for,O
lifestyle,O
change,O
in,O
older,O
people,O
reported,O
that,O
interventions,O
with,O
multiple,O
components,O
are,O
more,O
effective,O
than,O
interventions,O
with,O
a,O
single,O
component,O
[,O
84,O
].,O
We,O
found,O
that,O
the,O
beneficial,O
effects,O
of,O
Web,O
-,O
based,O
interventions,O
decline,O
over,O
time,O
and,O
effects,O
are,O
larger,O
when,O
interventions,O
are,O
combined,O
with,O
human,B-OG
support,O
.,O
Decreasing,O
adherence,O
over,O
time,O
was,O
reported,O
in,O
several,O
studies,O
included,O
in,O
our,O
meta,O
-,O
analysis,O
and,O
could,O
be,O
an,O
important,O
contributor,O
to,O
the,O
decreasing,O
effect,O
over,O
time,O
.,O
We,O
were,O
unable,O
to,O
formally,O
test,O
this,O
because,O
information,O
on,O
adherence,O
and,O
engagement,O
was,O
only,O
reported,O
by,O
22,O
studies,O
and,O
definitions,O
varied,O
widely,O
.,O
The,O
identified,O
effect,O
moderators,O
are,O
not,O
specific,O
to,O
Web,O
-,O
based,O
interventions,O
for,O
cardiovascular,O
risk,O
factors,O
[,O
85,O
",",O
86,O
].,O
Maintenance,O
of,O
behavioral,O
change,O
is,O
notoriously,O
complex,O
and,O
best,O
achieved,O
in,O
longer,O
studies,O
with,O
intensive,O
interventions,O
",",O
more,O
face,O
-,O
to,O
-,O
face,O
",",O
and,O
more,O
follow,O
-,O
up,O
contacts,O
.,O
However,O
",",O
such,O
interventions,O
lead,O
to,O
high,O
attrition,O
rates,O
",",O
probably,O
reflecting,O
selection,O
of,O
the,O
most,O
motivated,O
participants,O
[,O
87,O
].,O
A,O
careful,O
balance,O
should,O
be,O
sought,O
between,O
effectiveness,O
and,O
implementability,O
when,O
designing,O
cardiovascular,O
risk,O
management,O
interventions,O
",",O
whether,O
or,O
not,O
an,O
Internet,O
-,O
based,O
approach,O
is,O
used,O
.,O
Our,O
results,O
do,O
not,O
show,O
a,O
beneficial,O
effect,O
of,O
Web,O
-,O
based,O
interventions,O
on,O
incident,O
cardiovascular,B-DS
disease,I-DS
.,O
Although,O
the,O
declining,O
effect,O
over,O
time,O
could,O
play,O
a,O
role,O
",",O
more,O
likely,O
explanations,O
for,O
these,O
findings,O
are,O
the,O
limited,O
follow,O
-,O
up,O
time,O
of,O
the,O
studies,O
to,O
detect,O
these,O
outcomes,O
(,O
mean,O
length,O
of,O
the,O
studies,O
was,O
13,O
months,O
),O
and,O
the,O
fact,O
that,O
these,O
outcomes,O
were,O
not,O
the,O
primary,O
focus,O
of,O
these,O
studies,O
.,O
Because,O
of,O
the,O
latter,O
",",O
data,O
collection,O
may,O
not,O
have,O
been,O
systematic,O
and,O
adjudication,O
of,O
the,O
data,O
by,O
an,O
independent,O
committee,O
may,O
be,O
lacking,O
.,O
Therefore,O
",",O
we,O
cannot,O
draw,O
strong,O
conclusions,O
from,O
these,O
findings,O
.,O
The,O
results,O
of,O
this,O
study,O
should,O
be,O
interpreted,O
with,O
caution,O
because,O
of,O
several,O
limitations,O
.,O
The,O
methodological,O
quality,O
of,O
the,O
studies,O
was,O
fair,O
",",O
but,O
none,O
of,O
the,O
studies,O
was,O
double,O
blind,O
",",O
rendering,O
them,O
prone,O
to,O
performance,O
bias,O
.,O
Only,O
20,O
studies,O
had,O
a,O
blinded,O
outcome,O
assessment,O
",",O
so,O
detection,O
bias,O
may,O
also,O
be,O
present,O
.,O
Because,O
the,O
sensitivity,O
analyses,O
for,O
the,O
risk,O
-,O
of,O
-,O
bias,O
assessment,O
did,O
not,O
reveal,O
significant,O
differences,O
between,O
the,O
low,O
risk,O
and,O
unknown,O
/,O
high,O
risk,O
-,O
of,O
-,O
bias,O
subgroups,O
",",O
except,O
for,O
the,O
domain,O
of,O
random,O
sequence,O
generation,O
",",O
we,O
think,O
that,O
our,O
findings,O
have,O
not,O
been,O
largely,O
affected,O
by,O
these,O
potential,O
sources,O
of,O
bias,O
.,O
Another,O
limitation,O
is,O
the,O
substantial,O
heterogeneity,O
in,O
several,O
of,O
the,O
meta,O
-,O
analyses,O
that,O
is,O
",",O
in,O
part,O
",",O
explained,O
by,O
two,O
effect,O
modifiers,O
:,O
study,O
duration,O
and,O
intervention,O
type,O
.,O
Patient,O
groups,O
with,O
a,O
higher,O
burden,O
have,O
a,O
larger,O
window,O
of,O
opportunity,O
for,O
improvement,O
potentially,O
resulting,O
in,O
larger,O
intervention,O
effects,O
[,O
88,O
"],",O
which,O
could,O
also,O
have,O
contributed,O
to,O
heterogeneity,O
.,O
We,O
could,O
not,O
draw,O
firm,O
conclusions,O
on,O
the,O
difference,O
between,O
primary,O
and,O
secondary,O
prevention,O
",",O
because,O
only,O
four,O
studies,O
on,O
secondary,O
prevention,O
were,O
included,O
in,O
this,O
analysis,O
.,O
Last,O
",",O
there,O
is,O
a,O
potential,O
for,O
publication,O
bias,O
and,O
small,O
study,O
bias,O
.,O
Most,O
of,O
the,O
studies,O
with,O
small,O
sample,O
sizes,O
reported,O
large,O
effects,O
and,O
similar,O
studies,O
with,O
,O
findings,O
did,O
not,O
appear,O
in,O
the,O
funnel,O
plots,O
(,O
Multimedia,O
Appendix,O
5,O
).,O
Strengths,O
of,O
our,O
study,O
are,O
the,O
comprehensive,O
search,O
strategy,O
",",O
the,O
quantitative,O
meta,O
-,O
analysis,O
",",O
and,O
the,O
assessment,O
of,O
the,O
effect,O
of,O
Web,O
-,O
based,O
interventions,O
for,O
all,O
cardiovascular,O
risk,O
factors,O
using,O
both,O
intermediate,O
and,O
clinical,O
outcomes,O
.,O
Our,O
search,O
strategy,O
was,O
comprehensive,O
because,O
we,O
used,O
a,O
broad,O
definition,O
of,O
Web,O
-,O
based,O
interventions,O
and,O
only,O
excluded,O
telemedicine,O
and,O
mobile,O
phone,O
interventions,O
.,O
It,O
was,O
not,O
always,O
possible,O
to,O
set,O
Web,O
-,O
based,O
interventions,O
apart,O
from,O
telemedicine,O
and,O
mobile,O
phone,O
interventions,O
.,O
As,O
long,O
as,O
the,O
Web,O
-,O
based,O
program,O
was,O
the,O
main,O
component,O
of,O
the,O
intervention,O
",",O
we,O
judged,O
the,O
study,O
eligible,O
for,O
our,O
systematic,O
review,O
.,O
By,O
pooling,O
the,O
effect,O
sizes,O
on,O
all,O
different,O
cardiovascular,O
risk,O
factors,O
",",O
we,O
aimed,O
to,O
assess,O
the,O
overall,O
effect,O
of,O
an,O
Internet,O
-,O
based,O
approach,O
for,O
people,O
with,O
increased,O
risk,O
of,O
cardiovascular,B-DS
disease,I-DS
.,O
This,O
approach,O
provides,O
insight,O
into,O
the,O
overall,O
potential,O
of,O
Internet,O
-,O
based,O
interventions,O
in,O
this,O
field,O
.,O
Although,O
basic,O
computer,O
literacy,O
as,O
an,O
inclusion,O
criterion,O
probably,O
led,O
to,O
selection,O
of,O
participants,O
with,O
a,O
relatively,O
high,O
socioeconomic,O
status,O
",",O
several,O
studies,O
included,O
in,O
the,O
meta,O
-,O
analysis,O
focused,O
on,O
people,O
from,O
medically,O
underserved,O
areas,O
.,O
Therefore,O
",",O
the,O
external,O
validity,O
of,O
the,O
results,O
might,O
be,O
acceptable,O
and,O
may,O
be,O
generalizable,O
to,O
middle,O
-,O
aged,O
to,O
older,O
primary,O
care,O
populations,O
with,O
an,O
increased,O
risk,O
of,O
cardiovascular,B-DS
disease,I-DS
.,O
Our,O
results,O
show,O
that,O
Web,O
-,O
based,O
interventions,O
can,O
be,O
effective,O
in,O
improving,O
the,O
cardiovascular,O
risk,O
factor,O
profile,O
of,O
middle,O
-,O
aged,O
and,O
older,O
people,O
",",O
but,O
effects,O
are,O
modest,O
and,O
can,O
only,O
have,O
clinical,O
relevance,O
on,O
the,O
population,O
level,O
if,O
sustained,O
over,O
time,O
.,O
Considering,O
the,O
current,O
interest,O
and,O
focus,O
on,O
eHealth,O
by,O
policy,O
makers,O
",",O
funding,O
agencies,O
",",O
and,O
a,O
myriad,O
of,O
research,O
and,O
patient,O
organizations,O
[,O
89,O
",",O
90,O
"],",O
it,O
is,O
important,O
to,O
evaluate,O
the,O
actual,O
evidence,O
base,O
objectively,O
.,O
Unrealistic,O
expectations,O
of,O
the,O
effectiveness,O
of,O
Web,O
-,O
based,O
interventions,O
obscure,O
the,O
true,O
challenges,O
that,O
have,O
to,O
be,O
overcome,O
first,O
",",O
including,O
testing,O
interventions,O
that,O
were,O
designed,O
specifically,O
for,O
older,O
people,O
",",O
improving,O
methodological,O
robustness,O
of,O
studies,O
",",O
and,O
improving,O
sustainability,O
of,O
effects,O
.,O
On,O
the,O
macro,O
level,O
",",O
trials,O
can,O
assess,O
sustainability,O
by,O
prolonging,O
follow,O
-,O
up,O
",",O
recording,O
clinical,O
events,O
",",O
and,O
measuring,O
surrogate,O
cardiovascular,O
outcomes,O
(,O
eg,O
",",O
BP,O
",",O
cholesterol,O
levels,O
",",O
and,O
weight,O
),O
at,O
multiple,O
time,O
points,O
(,O
eg,O
",",O
at,O
6,O
",",O
12,O
",",O
24,O
",",O
and,O
36,O
months,O
).,O
On,O
the,O
micro,O
level,O
",",O
adherence,O
should,O
be,O
evaluated,O
by,O
studying,O
intervention,O
usage,O
through,O
time,O
with,O
standardized,O
evaluation,O
methods,O
.,O
Sustainability,O
is,O
of,O
particular,O
importance,O
because,O
long,O
-,O
term,O
effects,O
are,O
required,O
for,O
primary,O
and,O
secondary,O
prevention,O
to,O
truly,O
contribute,O
to,O
the,O
prevention,O
of,O
cardiovascular,B-DS
disease,I-DS
.,O
Web,O
-,O
based,O
interventions,O
combined,O
with,O
human,B-OG
support,O
are,O
more,O
promising,O
than,O
Internet,O
-,O
only,O
interventions,O
.,O
Authors,O
',O
Contributions,O
:,O
CRB,O
had,O
full,O
access,O
to,O
all,O
data,O
in,O
the,O
study,O
and,O
takes,O
responsibility,O
for,O
the,O
integrity,O
of,O
the,O
data,O
and,O
the,O
accuracy,O
of,O
the,O
data,O
analysis,O
.,O
ER,O
",",O
EMvC,O
",",O
WvG,O
",",O
CB,O
",",O
MK,O
",",O
SA,O
",",O
and,O
HS,O
conceived,O
the,O
study,O
.,O
CRB,O
",",O
BS,O
",",O
and,O
ER,O
wrote,O
the,O
study,O
protocol,O
and,O
analysis,O
plan,O
.,O
CRB,O
and,O
BS,O
collected,O
and,O
extracted,O
the,O
data,O
",",O
with,O
support,O
from,O
ER,O
and,O
EMvC,O
.,O
CRB,O
performed,O
the,O
statistical,O
analysis,O
",",O
supported,O
by,O
BS,O
",",O
ER,O
",",O
WB,O
",",O
and,O
WvG,O
.,O
CRB,O
and,O
ER,O
drafted,O
the,O
manuscript,O
and,O
all,O
authors,O
critically,O
revised,O
the,O
manuscript,O
for,O
important,O
intellectual,O
content,O
.,O
Conflicts,O
of,O
Interest,O
:,O
,O
declared,O
.,O
A,O
subunit,O
of,O
the,O
oligosaccharyltransferase,B-GP
complex,O
is,O
required,O
for,O
interspecific,O
gametophyte,O
recognition,O
in,O
Arabidopsis,B-OG
Present,O
address,O
:,O
Boyce,O
-,O
Thompson,O
Institute,O
for,O
Plant,B-OG
Research,O
",",O
533,O
Tower,O
Road,O
",",O
Ithaca,O
",",O
New,O
York,O
14853,O
",",O
USA,O
Present,O
address,O
:,O
Carnegie,O
Institution,O
for,O
Science,O
",",O
Department,O
of,O
Plant,B-OG
Biology,O
",",O
260,O
Panama,O
Street,O
",",O
Stanford,O
",",O
California,O
94305,O
",",O
USA,O
Species,O
-,O
specific,O
gamete,O
recognition,O
is,O
a,O
key,O
premise,O
to,O
ensure,O
reproductive,O
success,O
and,O
the,O
maintenance,O
of,O
species,O
boundaries,O
.,O
During,O
plant,B-OG
pollen,O
tube,O
(,O
PT,O
),O
reception,O
",",O
gametophyte,O
interactions,O
likely,O
allow,O
the,O
species,O
-,O
specific,O
recognition,O
of,O
signals,O
from,O
the,O
PT,O
(,O
male,O
gametophyte,O
),O
by,O
the,O
embryo,O
sac,O
(,O
female,O
gametophyte,O
"),",O
resulting,O
in,O
PT,O
rupture,O
",",O
sperm,O
release,O
",",O
and,O
double,O
fertilization,O
.,O
This,O
process,O
is,O
impaired,O
in,O
interspecific,O
crosses,O
between,O
Arabidopsis,B-OG
thaliana,I-OG
and,O
related,O
species,O
",",O
leading,O
to,O
PT,O
overgrowth,O
and,O
a,O
failure,O
to,O
deliver,O
the,O
sperm,O
cells,O
.,O
Here,O
we,O
show,O
that,O
ARTUMES,B-GP
(,O
ARU,B-GP
),O
specifically,O
regulates,O
the,O
recognition,O
of,O
interspecific,O
PTs,O
in,O
A,B-OG
.,I-OG
thaliana,I-OG
.,O
ARU,B-GP
",",O
identified,O
in,O
a,O
genome,O
-,O
wide,O
association,O
study,O
(,O
GWAS,O
"),",O
exclusively,O
influences,O
interspecific,O
—,O
but,O
not,O
intraspecific,O
—,O
gametophyte,O
interactions,O
.,O
ARU,B-GP
encodes,O
the,O
OST3,B-GP
/,O
6,O
subunit,O
of,O
the,O
oligosaccharyltransferase,B-GP
complex,O
conferring,O
protein,O
N,O
-,O
glycosylation,O
.,O
Our,O
results,O
suggest,O
that,O
glycosylation,O
patterns,O
of,O
cell,B-GP
surface,I-GP
proteins,I-GP
may,O
represent,O
an,O
important,O
mechanism,O
of,O
gametophyte,O
recognition,O
and,O
thus,O
speciation,O
.,O
Species,O
-,O
specific,O
gamete,O
recognition,O
is,O
needed,O
to,O
maintain,O
species,O
boundaries,O
.,O
Here,O
",",O
Müller,O
et,O
al,O
.,O
show,O
that,O
ARTUMES,B-GP
regulates,O
pollen,O
tube,O
recognition,O
between,O
different,O
Arabidopsis,B-OG
species,O
",",O
representing,O
the,O
first,O
gene,O
known,O
to,O
exclusively,O
influence,O
inter,O
-,O
but,O
not,O
intraspecific,O
gamete,O
interaction,O
in,O
plants,B-OG
.,O
Species,O
evolve,O
and,O
are,O
maintained,O
by,O
a,O
variety,O
of,O
hybridization,O
barriers,O
that,O
prevent,O
interspecific,O
gene,O
flow,O
and,O
thus,O
the,O
formation,O
of,O
potentially,O
unviable,O
or,O
sterile,O
hybrids1,O
.,O
To,O
date,O
",",O
the,O
molecular,O
basis,O
of,O
hybridization,O
barriers,O
is,O
still,O
poorly,O
understood,O
.,O
In,O
plants,B-OG
",",O
such,O
barriers,O
can,O
either,O
act,O
before,O
(,O
pre,O
-,O
pollination,O
barriers,O
),O
or,O
after,O
pollination,O
(,O
post,O
-,O
pollination,O
barriers,O
).,O
Pre,O
-,O
pollination,O
barriers,O
can,O
be,O
spatial,O
or,O
temporal,O
patterns,O
preventing,O
plants,B-OG
from,O
being,O
pollinated,O
by,O
pollen,O
from,O
a,O
different,O
species,O
",",O
whereas,O
post,O
-,O
pollination,O
barriers,O
come,O
into,O
play,O
only,O
after,O
an,O
interspecific,O
pollination,O
event,O
occurs,O
and,O
can,O
be,O
further,O
divided,O
into,O
pre,O
-,O
and,O
post,O
-,O
zygotic,O
barriers2,O
.,O
The,O
latter,O
usually,O
act,O
at,O
the,O
genomic,O
level,O
(,O
for,O
example,O
",",O
incompatibilities,O
leading,O
to,O
hybrid,O
lethality,O
or,O
sterility,O
"),",O
while,O
pre,O
-,O
zygotic,O
barriers,O
prevent,O
the,O
formation,O
of,O
a,O
zygote,O
and,O
usually,O
rely,O
on,O
direct,O
cell,O
–,O
cell,O
communication,O
between,O
the,O
male,O
and,O
female,O
tissues,O
.,O
Most,O
species,O
pairs,O
are,O
isolated,O
by,O
a,O
complex,O
interplay,O
of,O
different,O
types,O
of,O
isolation,O
barriers,O
.,O
Whereas,O
barriers,O
that,O
prevent,O
fertilization,O
(,O
both,O
pre,O
-,O
pollination,O
and,O
pre,O
-,O
zygotic,O
barriers,O
),O
often,O
represent,O
the,O
most,O
important,O
means,O
to,O
reduce,O
interspecific,O
gene,O
flow,O
",",O
post,O
-,O
zygotic,O
hybridization,O
barriers,O
appear,O
to,O
contribute,O
less,O
to,O
reproductive,O
isolation,O
in,O
many,O
species,O
pairs3,O
.,O
In,O
plants,B-OG
",",O
successful,O
fertilization,O
starts,O
with,O
the,O
deposition,O
of,O
intraspecific,O
(,O
same,O
-,O
species,O
),O
pollen,O
(,O
male,O
gametophyte,O
),O
onto,O
the,O
stigma,O
of,O
a,O
gynoecium,O
.,O
The,O
subsequent,O
steps,O
involve,O
extensive,O
communication,O
between,O
the,O
male,O
and,O
female,O
tissues,O
",",O
leading,O
to,O
pollen,O
adherence,O
",",O
hydration,O
",",O
and,O
the,O
germination,O
of,O
a,O
pollen,O
tube,O
(,O
PT,O
).,O
Within,O
its,O
cytoplasm,O
",",O
the,O
tip,O
-,O
growing,O
PT,O
transports,O
the,O
two,O
sperm,O
cells,O
through,O
the,O
transmitting,O
tract,O
of,O
the,O
pistil,O
to,O
the,O
embryo,O
sac,O
(,O
female,O
gametophyte,O
"),",O
which,O
is,O
deeply,O
embedded,O
in,O
the,O
ovule,O
",",O
the,O
precursor,O
of,O
seed,O
.,O
During,O
its,O
journey,O
",",O
the,O
PT,O
is,O
guided,O
towards,O
the,O
embryo,O
sacs,O
by,O
attractants,O
secreted,O
by,O
female,O
tissues4,O
.,O
On,O
arrival,O
at,O
the,O
embryo,O
sac,O
",",O
communication,O
between,O
the,O
PT,O
and,O
the,O
synergid,O
cells,O
of,O
the,O
female,O
gametophyte,O
is,O
initiated,O
(,O
Fig,O
.,O
1a,O
).,O
The,O
two,O
synergid,O
cells,O
are,O
located,O
at,O
the,O
micropylar,O
end,O
of,O
the,O
embryo,O
sac,O
and,O
possess,O
a,O
secretory,O
region,O
characterized,O
by,O
membrane,O
invaginations,O
and,O
thickened,O
cell,O
wall,O
structures5,O
.,O
This,O
so,O
-,O
called,O
filiform,O
apparatus,O
is,O
the,O
first,O
point,O
of,O
contact,O
between,O
the,O
male,O
and,O
female,O
gametophytes,O
",",O
which,O
communicate,O
in,O
preparation,O
for,O
penetration,O
of,O
the,O
receptive,O
synergid,O
cell,O
by,O
the,O
PT,O
",",O
PT,O
rupture,O
",",O
sperm,O
release,O
",",O
and,O
double,O
fertilization6,O
.,O
While,O
one,O
sperm,O
fuses,O
with,O
the,O
egg,O
cell,O
to,O
form,O
the,O
diploid,O
zygote,O
",",O
the,O
other,O
fertilizes,O
the,O
homo,O
-,O
diploid,O
central,O
cell,O
to,O
produce,O
the,O
triploid,O
endosperm,O
",",O
an,O
embryo,O
-,O
nourishing,O
tissue,O
.,O
The,O
communication,O
process,O
between,O
the,O
male,O
and,O
female,O
gametophytes,O
leading,O
to,O
PT,O
rupture,O
and,O
sperm,O
cell,O
discharge,O
is,O
known,O
as,O
PT,O
reception,O
",",O
and,O
its,O
success,O
or,O
failure,O
is,O
under,O
female,O
gametophytic,O
control6,O
.,O
However,O
",",O
if,O
a,O
pollen,O
grain,O
originating,O
from,O
a,O
different,O
species,O
(,O
interspecific,O
pollination,O
),O
is,O
placed,O
on,O
a,O
plant,B-OG
',O
s,O
stigma,O
",",O
all,O
the,O
communication,O
processes,O
described,O
above,O
have,O
the,O
potential,O
to,O
act,O
as,O
pre,O
-,O
zygotic,O
post,O
-,O
pollination,O
barriers,O
.,O
Several,O
studies,O
describe,O
a,O
species,O
-,O
preferential,O
behaviour,O
of,O
molecular,O
factors,O
involved,O
in,O
pollen,O
adherence,O
to,O
the,O
stigma,O
",",O
PT,O
growth,O
",",O
and,O
PT,O
guidance,O
towards,O
the,O
ovules47891011,O
.,O
In,O
interspecific,O
crosses,O
between,O
closely,O
related,O
Ericaceae,B-OG
or,O
Brassicaceae,B-OG
",",O
respectively,O
",",O
hybridization,O
barriers,O
act,O
at,O
the,O
stage,O
of,O
PT,O
reception1213,O
.,O
In,O
such,O
crosses,O
",",O
PTs,O
are,O
properly,O
targeted,O
to,O
the,O
female,O
gametophyte,O
but,O
",",O
upon,O
arrival,O
at,O
the,O
embryo,O
sacs,O
",",O
interspecific,O
PTs,O
are,O
not,O
recognized,O
and,O
fail,O
to,O
arrest,O
growth,O
and,O
discharge,O
their,O
sperm,O
.,O
Instead,O
",",O
they,O
continue,O
growing,O
inside,O
the,O
embryo,O
sacs,O
(,O
referred,O
to,O
as,O
PT,O
overgrowth,O
),O
and,O
cannot,O
effect,O
double,O
fertilization,O
.,O
Therefore,O
",",O
we,O
consider,O
PT,O
reception,O
to,O
be,O
an,O
integral,O
part,O
of,O
the,O
hybridization,O
barrier,O
in,O
these,O
species,O
.,O
Interspecific,O
PT,O
overgrowth,O
phenocopies,O
the,O
female,O
gametophytic,O
mutants,O
feronia,B-GP
/,O
sirène,B-GP
(,O
fer,B-GP
/,O
srn,B-GP
"),",O
lorelei,B-GP
(,O
lre,B-GP
"),",O
nortia,B-GP
(,O
nta,B-GP
"),",O
turan,B-GP
(,O
tun,B-GP
"),",O
evan,B-GP
(,O
evn,B-GP
"),",O
and,O
Zea,B-GP
mays,I-GP
embryo,I-GP
sac,I-GP
4,I-GP
(,O
ZmES4,B-GP
),O
RNAi,O
-,O
lines1314151617181920,O
",",O
which,O
are,O
defective,O
in,O
the,O
reception,O
of,O
intraspecific,O
PTs,O
.,O
In,O
addition,O
",",O
FER,B-GP
has,O
been,O
proposed,O
to,O
be,O
involved,O
in,O
interspecific,O
PT,O
recognition13,O
",",O
and,O
there,O
is,O
evidence,O
that,O
ZmES4,B-GP
is,O
sufficient,O
to,O
trigger,O
PT,O
growth,O
arrest,O
and,O
rupture,O
in,O
a,O
species,O
-,O
preferential,O
manner20,O
.,O
Despite,O
the,O
rapid,O
advance,O
in,O
our,O
understanding,O
of,O
the,O
molecular,O
basis,O
of,O
intraspecific,O
PT,O
reception21,O
",",O
the,O
genetic,O
basis,O
of,O
post,O
-,O
pollination,O
hybridization,O
barriers,O
remains,O
largely,O
unknown,O
.,O
All,O
molecular,O
factors,O
that,O
have,O
so,O
far,O
been,O
described,O
to,O
be,O
involved,O
in,O
pre,O
-,O
zygotic,O
species,O
-,O
discrimination,O
",",O
including,O
species,O
-,O
preferential,O
pollen,O
adherence,O
",",O
PT,O
guidance,O
",",O
growth,O
",",O
and,O
reception,O
",",O
act,O
primarily,O
during,O
intraspecific,O
pollination,O
and,O
have,O
additional,O
species,O
-,O
preferential,O
effects47891011,O
.,O
Here,O
",",O
we,O
report,O
the,O
identification,O
of,O
the,O
first,O
gene,O
required,O
exclusively,O
for,O
inter,O
-,O
but,O
not,O
for,O
intraspecific,O
pollination,O
",",O
thus,O
likely,O
representing,O
a,O
specific,O
component,O
for,O
the,O
establishment,O
of,O
a,O
hybridization,O
barrier,O
.,O
By,O
making,O
use,O
of,O
the,O
striking,O
natural,O
variation,O
of,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
in,O
interspecific,O
PT,O
reception,O
",",O
we,O
identified,O
ARTUMES,B-GP
(,O
ARU,B-GP
),O
as,O
an,O
indispensable,O
factor,O
for,O
the,O
recognition,O
of,O
interspecific,O
A,B-OG
.,I-OG
lyrata,I-OG
PTs,O
by,O
A,B-OG
.,I-OG
thaliana,I-OG
embryo,O
sacs,O
.,O
In,O
contrast,O
",",O
aru,B-GP
mutants,O
do,O
not,O
affect,O
gametophytic,O
communication,O
in,O
intraspecific,O
A,B-OG
.,I-OG
thaliana,I-OG
crosses,O
.,O
ARU,B-GP
encodes,O
the,O
OST3,B-GP
/,O
6,O
subunit,O
of,O
the,O
oligosaccharyltransferase,B-GP
complex,O
",",O
which,O
is,O
known,O
to,O
regulate,O
site,O
-,O
and,O
substrate,O
-,O
specific,O
N,O
-,O
glycosylation,O
of,O
proteins,O
in,O
yeast2223,B-OG
and,O
a,O
similar,O
substrate,O
specificity,O
has,O
been,O
reported,O
for,O
A,B-OG
.,I-OG
thaliana,I-OG
OST3,B-GP
/,O
6,O
(,O
ref,O
.,O
24,O
).,O
Thus,O
",",O
a,O
possible,O
mechanism,O
for,O
the,O
discrimination,O
of,O
inter,O
-,O
and,O
intraspecific,O
PTs,O
may,O
depend,O
on,O
the,O
species,O
-,O
specific,O
glycosylation,O
of,O
proteins,O
on,O
the,O
surface,O
of,O
the,O
synergid,O
cells,O
of,O
the,O
female,O
gametophyte,O
.,O
Results,O
PT,O
overgrowth,O
restricts,O
gene,O
flow,O
between,O
Arabidopsis,B-OG
species,O
Self,O
-,O
fertilizing,O
A,B-OG
.,I-OG
thaliana,I-OG
and,O
its,O
outcrossing,O
relative,O
A,B-OG
.,I-OG
lyrata,I-OG
are,O
separated,O
by,O
strong,O
pre,O
-,O
pollination,O
barriers,O
due,O
to,O
their,O
different,O
mating,O
systems1,O
.,O
In,O
addition,O
",",O
they,O
are,O
isolated,O
by,O
post,O
-,O
pollination,O
barriers,O
based,O
on,O
direct,O
male,O
–,O
female,O
interactions,O
.,O
Although,O
A,B-OG
.,I-OG
thaliana,I-OG
(,O
Col,O
-,O
0,O
),O
pollen,O
germination,O
is,O
inhibited,O
at,O
the,O
A,B-OG
.,I-OG
lyrata,I-OG
stigma,O
",",O
A,B-OG
.,I-OG
lyrata,I-OG
PTs,O
are,O
guided,O
towards,O
A,B-OG
.,I-OG
thaliana,I-OG
embryo,O
sacs,O
",",O
but,O
PT,O
reception,O
fails,O
(,O
Fig,O
.,O
1c,O
",",O
as,O
opposed,O
to,O
Fig,O
.,O
1b,O
showing,O
successful,O
PT,O
reception,O
",",O
Supplementary,O
Fig,O
.,O
1,O
).,O
Such,O
unilateral,O
incompatibility,O
is,O
similar,O
to,O
that,O
observed,O
in,O
other,O
crosses,O
between,O
self,O
-,O
compatible,O
and,O
self,O
-,O
incompatible,O
species25,O
.,O
We,O
also,O
observed,O
PT,O
overgrowth,O
in,O
interspecific,O
crosses,O
between,O
A,B-OG
.,I-OG
arenosa,I-OG
and,O
A,B-OG
.,I-OG
lyrata,I-OG
(,O
Supplementary,O
Fig,O
.,O
2,O
"),",O
between,O
which,O
natural,O
gene,O
flow,O
occurs26,O
.,O
This,O
finding,O
indicates,O
that,O
A,B-OG
.,I-OG
lyrata,I-OG
PT,O
overgrowth,O
in,O
A,B-OG
.,I-OG
thaliana,I-OG
ovules,O
does,O
not,O
only,O
occur,O
between,O
species,O
that,O
do,O
not,O
interbreed,O
in,O
nature,O
(,O
A,B-OG
.,I-OG
thaliana,I-OG
×,O
A,B-OG
.,I-OG
lyrata,I-OG
),O
but,O
also,O
between,O
species,O
that,O
are,O
only,O
partially,O
reproductively,O
isolated,O
and,O
do,O
interbreed,O
(,O
A,B-OG
.,I-OG
arenosa,I-OG
×,O
A,B-OG
.,I-OG
lyrata,I-OG
).,O
Natural,O
variation,O
in,O
interspecific,O
PT,O
reception,O
To,O
analyse,O
interspecific,O
hybridization,O
barriers,O
within,O
the,O
genus,O
Arabidopsis,B-OG
",",O
we,O
assessed,O
PT,O
overgrowth,O
in,O
86,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
that,O
were,O
pollinated,O
with,O
A,B-OG
.,I-OG
lyrata,I-OG
pollen,O
(,O
Supplementary,O
Table,O
1,O
).,O
PTs,O
were,O
visualized,O
by,O
staining,O
callose,O
in,O
PT,O
cell,O
walls,O
with,O
aniline,O
blue,O
.,O
We,O
scored,O
the,O
proportion,O
of,O
ovules,O
that,O
failed,O
to,O
recognize,O
interspecific,O
PTs,O
—,O
leading,O
to,O
PT,O
overgrowth,O
—,O
in,O
relation,O
to,O
the,O
total,O
number,O
of,O
ovules,O
that,O
attracted,O
a,O
PT,O
in,O
a,O
silique,O
(,O
overgrowth,O
per,O
silique,O
",",O
OG,O
/,O
S,O
).,O
We,O
found,O
a,O
striking,O
variation,O
in,O
the,O
ability,O
to,O
recognize,O
interspecific,O
PTs,O
between,O
different,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
",",O
with,O
OG,O
/,O
S,O
ranging,O
from,O
about,O
10,O
to,O
90,O
%,O
(,O
Fig,O
.,O
1d,O
",",O
broad,O
-,O
sense,O
heritability,O
H2,O
=,O
0,O
.,O
7,O
).,O
Examples,O
of,O
accessions,O
with,O
extreme,O
phenotypes,O
are,O
Lz,O
-,O
0,O
(,O
10,O
%,O
OG,O
/,O
S,O
",",O
n,O
=,O
12,O
siliques,O
),O
and,O
Kz,O
-,O
9,O
(,O
87,O
.,O
3,O
%,O
OG,O
/,O
S,O
",",O
n,O
=,O
10,O
;,O
Fig,O
.,O
1e,O
",",O
f,O
).,O
There,O
is,O
no,O
obvious,O
correlation,O
between,O
the,O
geographical,O
origin,O
of,O
the,O
accessions,O
and,O
their,O
phenotype,O
(,O
Supplementary,O
Fig,O
.,O
3,O
).,O
To,O
analyse,O
whether,O
the,O
variation,O
in,O
the,O
ability,O
to,O
recognize,O
interspecific,O
PTs,O
is,O
species,O
-,O
dependent,O
",",O
we,O
pollinated,O
a,O
subset,O
of,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
with,O
low,O
or,O
high,O
OG,O
/,O
S,O
in,O
crosses,O
with,O
A,B-OG
.,I-OG
lyrata,I-OG
(,O
Lz,O
-,O
0,O
",",O
Kas,O
-,O
1,O
",",O
Ga,O
-,O
0,O
",",O
Lp2,O
-,O
6,O
and,O
Col,O
-,O
0,O
",",O
Kz,O
-,O
1,O
",",O
Nd,O
-,O
1,O
",",O
respectively,O
),O
also,O
with,O
pollen,O
of,O
A,B-OG
.,I-OG
halleri,I-OG
and,O
A,B-OG
.,I-OG
arenosa,I-OG
.,O
Although,O
OG,O
/,O
S,O
in,O
the,O
accessions,O
pollinated,O
with,O
A,B-OG
.,I-OG
lyrata,I-OG
or,O
A,B-OG
.,I-OG
halleri,I-OG
pollen,O
was,O
highly,O
comparable,O
(,O
Fig,O
.,O
2a,O
",",O
b,O
"),",O
the,O
values,O
were,O
slightly,O
lower,O
for,O
all,O
accessions,O
when,O
pollinated,O
by,O
A,B-OG
.,I-OG
arenosa,I-OG
(,O
Fig,O
.,O
2c,O
"),",O
indicating,O
that,O
A,B-OG
.,I-OG
thaliana,I-OG
recognizes,O
A,B-OG
.,I-OG
arenosa,I-OG
PTs,O
better,O
than,O
those,O
of,O
A,B-OG
.,I-OG
lyrata,I-OG
or,O
A,B-OG
.,I-OG
halleri,I-OG
.,O
However,O
",",O
accessions,O
showing,O
very,O
low,O
or,O
high,O
OG,O
/,O
S,O
in,O
crosses,O
with,O
A,B-OG
.,I-OG
lyrata,I-OG
",",O
respectively,O
",",O
displayed,O
a,O
similar,O
phenotype,O
with,O
A,B-OG
.,I-OG
halleri,I-OG
and,O
A,B-OG
.,I-OG
arenosa,I-OG
as,O
pollen,O
donors,O
",",O
suggesting,O
a,O
common,O
molecular,O
PT,O
reception,O
mechanism,O
for,O
all,O
three,O
species,O
.,O
Thus,O
",",O
PT,O
overgrowth,O
is,O
a,O
hallmark,O
of,O
interspecific,O
crosses,O
with,O
close,O
Brassicaceae,B-OG
relatives,O
and,O
not,O
a,O
species,O
-,O
specific,O
feature,O
of,O
A,B-OG
.,I-OG
thaliana,I-OG
and,O
A,B-OG
.,I-OG
lyrata,I-OG
.,O
To,O
investigate,O
whether,O
intraspecific,O
PT,O
reception,O
was,O
affected,O
in,O
accessions,O
with,O
high,O
OG,O
/,O
S,O
(,O
Col,O
-,O
0,O
",",O
Kz,O
-,O
1,O
",",O
Kz,O
-,O
9,O
",",O
Nd,O
-,O
1,O
",",O
Fei,O
-,O
0,O
",",O
and,O
Sq,O
-,O
8,O
"),",O
we,O
crossed,O
them,O
with,O
A,B-OG
.,I-OG
thaliana,I-OG
pollen,O
(,O
from,O
both,O
low,O
and,O
high,O
OG,O
/,O
S,O
accessions,O
).,O
Intraspecific,O
PT,O
reception,O
was,O
normal,O
in,O
all,O
the,O
tested,O
accessions,O
(,O
Supplementary,O
Fig,O
.,O
3,O
"),",O
indicating,O
that,O
high,O
OG,O
/,O
S,O
frequencies,O
result,O
from,O
a,O
failure,O
in,O
the,O
recognition,O
of,O
interspecific,O
PTs,O
only,O
",",O
and,O
are,O
not,O
due,O
to,O
a,O
general,O
defect,O
in,O
PT,O
reception,O
.,O
ARTUMES,B-GP
regulates,O
inter,O
-,O
but,O
not,O
intraspecific,O
PT,O
reception,O
To,O
identify,O
loci,O
causing,O
the,O
variation,O
in,O
interspecific,O
PT,O
reception,O
in,O
A,B-OG
.,I-OG
thaliana,I-OG
",",O
we,O
used,O
publicly,O
available,O
single,O
-,O
nucleotide,O
polymorphism,O
(,O
SNP,O
),O
data,O
from,O
the,O
86,O
accessions,O
to,O
perform,O
a,O
genome,O
-,O
wide,O
association,O
study,O
(,O
GWAS,O
),O
27,O
.,O
To,O
date,O
",",O
most,O
GWAS,O
in,O
Arabidopsis,B-OG
have,O
identified,O
previously,O
known,O
candidate,O
genes,O
",",O
with,O
only,O
a,O
few,O
studies,O
identifying,O
novel,O
regulatory,O
genes,O
in,O
the,O
respective,O
pathways2829,O
.,O
Applying,O
the,O
GLM,O
function,O
implemented,O
in,O
TASSEL30,O
",",O
we,O
identified,O
a,O
region,O
on,O
chromosome,O
1,O
containing,O
8,O
of,O
the,O
top,O
20,O
SNPs,O
with,O
the,O
highest,O
correlation,O
to,O
the,O
OG,O
/,O
S,O
trait,O
(,O
Fig,O
.,O
3a,O
and,O
Supplementary,O
Table,O
2,O
).,O
This,O
28,O
-,O
kb,O
region,O
(,O
positions,O
22,O
",",O
814,O
",",O
316,O
to,O
22,O
",",O
842,O
",",O
689,O
),O
contains,O
six,O
genes,O
and,O
one,O
pseudogene,O
(,O
Fig,O
.,O
3b,O
).,O
Interestingly,O
",",O
calculation,O
with,O
mixed,O
linear,O
models,O
that,O
simultaneously,O
correct,O
for,O
population,O
structure,O
and,O
unequal,O
genetic,O
relatedness,O
between,O
individuals,O
masked,O
the,O
peak,O
",",O
whereas,O
it,O
could,O
be,O
detected,O
—,O
although,O
below,O
the,O
significance,O
threshold,O
—,O
using,O
a,O
step,O
-,O
wise,O
multi,O
-,O
locus,O
mixed,O
model,O
(,O
MLMM,O
),O
specifically,O
designed,O
for,O
mapping,O
complex,O
traits31,O
(,O
Supplementary,O
Fig,O
.,O
4,O
).,O
With,O
each,O
step,O
of,O
MLMM,O
",",O
new,O
peaks,O
appear,O
",",O
consistent,O
with,O
a,O
multigenic,O
basis,O
for,O
interspecific,O
PT,O
reception,O
.,O
To,O
narrow,O
down,O
the,O
28,O
-,O
kb,O
candidate,O
region,O
to,O
a,O
single,O
gene,O
",",O
we,O
analysed,O
OG,O
/,O
S,O
in,O
T,O
-,O
DNA,O
insertion,O
lines,O
of,O
three,O
synergid,O
-,O
expressed,O
genes32,O
in,O
this,O
region,O
because,O
the,O
synergids,O
control,O
PT,O
reception,O
(,O
At1g61780,B-GP
",",O
At1g61790,B-GP
and,O
At1g61810,B-GP
;,O
as,O
well,O
as,O
At1g61795,B-GP
",",O
for,O
which,O
no,O
expression,O
data,O
was,O
available,O
;,O
Supplementary,O
Fig,O
.,O
5,O
).,O
In,O
a,O
homozygous,O
T,O
-,O
DNA,O
insertion,O
allele,O
disrupting,O
the,O
coding,O
sequence,O
of,O
At1g61790,B-GP
(,O
Fig,O
.,O
4a,O
"),",O
an,O
average,O
of,O
84,O
.,O
3,O
%,O
(,O
n,O
=,O
18,O
siliques,O
),O
of,O
ovules,O
display,O
A,B-OG
.,I-OG
lyrata,I-OG
PT,O
overgrowth,O
",",O
significantly,O
more,O
than,O
in,O
the,O
Col,O
-,O
0,O
wild,O
-,O
type,O
control,O
(,O
58,O
.,O
7,O
%,O
OG,O
/,O
S,O
",",O
n,O
=,O
28,O
",",O
Student,O
',O
s,O
t,O
-,O
test,O
P,O
<,O
0,O
.,O
001,O
",",O
Fig,O
.,O
4b,O
",",O
d,O
",",O
e,O
).,O
We,O
named,O
the,O
At1g61790,B-GP
gene,O
",",O
which,O
has,O
previously,O
been,O
described,O
as,O
OST3,B-GP
/,O
6,O
based,O
on,O
homology24,O
",",O
ARTUMES,B-GP
(,O
ARU,B-GP
),O
after,O
the,O
Etruscan,O
goddess,O
of,O
night,O
",",O
nature,O
",",O
and,O
fertility33,O
.,O
The,O
T,O
-,O
DNA,O
allele,O
was,O
denoted,O
aru,B-GP
-,I-GP
1,I-GP
.,O
A,O
second,O
mutant,O
allele,O
",",O
aru,B-GP
-,I-GP
2,I-GP
",",O
carrying,O
an,O
EMS,O
-,O
induced,O
premature,O
stop,O
-,O
codon,O
after,O
aa,O
residue,O
129,O
(,O
ref,O
.,O
34,O
"),",O
also,O
showed,O
an,O
increase,O
in,O
interspecific,O
OG,O
/,O
S,O
(,O
96,O
.,O
1,O
"%,",O
n,O
=,O
20,O
",",O
Fig,O
.,O
4a,O
",",O
b,O
",",O
f,O
).,O
Likewise,O
",",O
aru,B-GP
-,I-GP
1,I-GP
mutants,O
pollinated,O
with,O
A,B-OG
.,I-OG
arenosa,I-OG
pollen,O
showed,O
significantly,O
more,O
ovules,O
with,O
PT,O
overgrowth,O
(,O
67,O
.,O
6,O
%,O
OG,O
/,O
S,O
",",O
n,O
=,O
8,O
),O
than,O
the,O
wild,O
type,O
(,O
34,O
.,O
9,O
%,O
OG,O
/,O
S,O
",",O
n,O
=,O
12,O
",",O
Student,O
',O
s,O
t,O
-,O
test,O
P,O
<,O
0,O
.,O
001,O
",",O
Supplementary,O
Fig,O
.,O
6,O
"),",O
suggesting,O
a,O
common,O
basis,O
for,O
interspecific,O
PT,O
recognition,O
.,O
In,O
contrast,O
",",O
aru,B-GP
mutant,O
ovules,O
have,O
no,O
problem,O
recognizing,O
and,O
receiving,O
intraspecific,O
PTs,O
from,O
A,B-OG
.,I-OG
thaliana,I-OG
(,O
Fig,O
.,O
4c,O
",",O
g,O
"),",O
indicating,O
that,O
the,O
PT,O
reception,O
pathway,O
is,O
fully,O
functional,O
within,O
the,O
species,O
.,O
To,O
confirm,O
that,O
ARU,B-GP
function,O
is,O
required,O
for,O
interspecific,O
PT,O
recognition,O
in,O
the,O
synergids,O
",",O
we,O
expressed,O
an,O
ARU,B-GP
-,O
GFP,B-GP
translational,O
fusion,O
protein,O
under,O
the,O
control,O
of,O
the,O
MYB98,B-GP
and,O
FERONIA,B-GP
promoters,O
(,O
pMYB98,O
::,O
ARU,B-GP
-,O
GFP,B-GP
and,O
pFER,O
::,O
ARU,B-GP
-,O
GFP,B-GP
),O
in,O
aru,B-GP
-,I-GP
1,I-GP
mutants,O
.,O
These,O
promoters,O
are,O
highly,O
active,O
in,O
synergids1335,O
",",O
and,O
in,O
ovules,O
the,O
strongest,O
ARU,B-GP
-,O
GFP,B-GP
signal,O
was,O
detected,O
in,O
these,O
cells,O
(,O
Fig,O
.,O
5a,O
and,O
Supplementary,O
Fig,O
.,O
7,O
).,O
ARU,B-GP
-,O
GFP,B-GP
localized,O
to,O
perinuclear,O
structures,O
resembling,O
the,O
ER,O
in,O
synergids,O
(,O
Fig,O
.,O
5a,O
",",O
inset,O
"),",O
and,O
co,O
-,O
localized,O
with,O
an,O
ER,O
-,O
marker,O
in,O
transiently,O
transformed,O
onion,O
epidermal,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
7,O
).,O
These,O
results,O
are,O
consistent,O
with,O
the,O
previously,O
reported,O
ER,O
-,O
localization,O
of,O
ARU,B-GP
-,O
GFP,B-GP
in,O
infiltrated,O
tobacco,B-OG
leaves24,O
.,O
Mutant,O
aru,B-GP
-,I-GP
1,I-GP
plants,B-OG
expressing,O
a,O
functional,O
copy,O
of,O
ARU,B-GP
-,O
GFP,B-GP
in,O
their,O
synergids,O
displayed,O
wild,O
-,O
type,O
-,O
like,O
PT,O
reception,O
in,O
interspecific,O
crosses,O
(,O
Fig,O
.,O
5b,O
and,O
Supplementary,O
Fig,O
.,O
7,O
"),",O
indicating,O
that,O
ARU,B-GP
expression,O
in,O
synergid,O
cells,O
is,O
sufficient,O
to,O
complement,O
the,O
aru,B-GP
mutant,O
phenotype,O
.,O
Consistent,O
with,O
this,O
",",O
the,O
ARU,B-GP
-,O
GFP,B-GP
translational,O
fusion,O
protein,O
driven,O
by,O
the,O
endogenous,O
promoter,O
(,O
pARU,O
::,O
ARU,B-GP
-,O
GFP,B-GP
),O
is,O
highly,O
expressed,O
in,O
wild,O
-,O
type,O
synergids,O
(,O
Supplementary,O
Fig,O
.,O
7,O
"),",O
suggesting,O
an,O
important,O
role,O
for,O
ARU,B-GP
in,O
these,O
cells,O
.,O
Functional,O
complementation,O
of,O
the,O
aru,B-GP
-,I-GP
1,I-GP
mutant,O
was,O
also,O
observed,O
when,O
ARU,B-GP
was,O
driven,O
by,O
the,O
endogenous,O
promoter,O
in,O
a,O
construct,O
also,O
containing,O
865,O
bp,O
downstream,O
sequence,O
(,O
pARU,O
::,O
ARU,B-GP
"),",O
although,O
there,O
was,O
more,O
line,O
-,O
to,O
-,O
line,O
variability,O
than,O
when,O
the,O
pMYB98,O
promoter,O
was,O
used,O
(,O
Supplementary,O
Fig,O
.,O
7,O
).,O
Since,O
ARU,B-GP
is,O
not,O
fused,O
to,O
a,O
fluorescent,O
tag,O
here,O
",",O
technical,O
difficulties,O
in,O
measuring,O
synergid,O
specific,O
expression,O
of,O
the,O
transgene,O
make,O
it,O
hard,O
to,O
explore,O
this,O
difference,O
experimentally,O
.,O
However,O
",",O
it,O
is,O
conceivable,O
that,O
additional,O
regulatory,O
sequences,O
",",O
up,O
-,O
or,O
downstream,O
of,O
the,O
ARU,B-GP
coding,O
sequence,O
that,O
are,O
present,O
in,O
the,O
pARU,O
::,O
ARU,B-GP
construct,O
but,O
not,O
in,O
pMYB98,O
::,O
ARU,B-GP
-,O
GFP,B-GP
or,O
pFER,O
::,O
ARU,B-GP
-,O
GFP,B-GP
",",O
contributed,O
to,O
the,O
observed,O
phenotypic,O
variability,O
.,O
SNPs,O
around,O
ARTUMES,B-GP
correlate,O
with,O
phenotypic,O
variation,O
We,O
assessed,O
the,O
correlation,O
of,O
amino,O
acid,O
differences,O
in,O
the,O
ARU,B-GP
coding,O
sequence,O
in,O
all,O
accessions,O
to,O
determine,O
whether,O
differences,O
in,O
the,O
protein,O
sequence,O
could,O
explain,O
the,O
phenotypic,O
variation,O
.,O
Within,O
this,O
population,O
",",O
we,O
detected,O
a,O
total,O
of,O
10,O
amino,O
acid,O
differences,O
",",O
four,O
of,O
which,O
are,O
significantly,O
correlated,O
to,O
variation,O
in,O
OG,O
/,O
S,O
(,O
Pearson,O
',O
s,O
correlation,O
coefficient,O
R,O
",",O
P,O
<,O
0,O
.,O
05,O
",",O
Supplementary,O
Data,O
1,O
).,O
However,O
",",O
differing,O
residues,O
had,O
similar,O
chemical,O
properties,O
",",O
implying,O
small,O
",",O
if,O
any,O
",",O
differences,O
in,O
protein,O
function,O
.,O
Alternatively,O
",",O
differential,O
expression,O
levels,O
could,O
cause,O
the,O
observed,O
phenotypic,O
variation,O
.,O
Therefore,O
",",O
we,O
examined,O
alignments,O
of,O
1,O
",",O
000,O
bp,O
up,O
-,O
and,O
downstream,O
sequence,O
of,O
ARU,B-GP
.,O
We,O
found,O
9,O
of,O
49,O
and,O
39,O
of,O
79,O
upstream,O
and,O
downstream,O
SNPs,O
",",O
respectively,O
",",O
to,O
be,O
correlated,O
with,O
phenotypic,O
variation,O
(,O
P,O
<,O
0,O
.,O
05,O
",",O
Supplementary,O
Data,O
1,O
"),",O
suggesting,O
that,O
phenotypic,O
variation,O
could,O
be,O
due,O
to,O
differences,O
in,O
gene,O
expression,O
.,O
To,O
investigate,O
this,O
further,O
",",O
we,O
used,O
RNA,O
extracts,O
from,O
pistils,O
and,O
ovules,O
collected,O
2,O
days,O
after,O
emasculation,O
from,O
selected,O
accessions,O
(,O
Lz,O
-,O
0,O
",",O
Kas,O
-,O
1,O
",",O
Ga,O
-,O
0,O
and,O
Col,O
-,O
0,O
",",O
Nd,O
-,O
1,O
",",O
Fei,O
-,O
0,O
",",O
Kz,O
-,O
1,O
",",O
Kz,O
-,O
9,O
),O
for,O
quantitative,O
real,O
-,O
time,O
PCR,O
and,O
digital,O
droplet,O
PCR,O
",",O
respectively36,O
.,O
We,O
found,O
ARU,B-GP
mRNA,O
levels,O
differed,O
between,O
accessions,O
(,O
Supplementary,O
Fig,O
.,O
8,O
"),",O
but,O
they,O
did,O
not,O
correlate,O
with,O
the,O
OG,O
/,O
S,O
phenotype,O
among,O
the,O
selected,O
set,O
of,O
accessions,O
.,O
Because,O
we,O
used,O
RNA,O
from,O
whole,O
pistils,O
and,O
ovules,O
",",O
we,O
cannot,O
exclude,O
the,O
possibility,O
that,O
ARU,B-GP
is,O
differentially,O
expressed,O
in,O
synergids,O
only,O
",",O
where,O
it,O
is,O
required,O
and,O
sufficient,O
for,O
interspecific,O
PT,O
reception,O
.,O
In,O
addition,O
",",O
post,O
-,O
transcriptional,O
regulation,O
of,O
gene,O
expression,O
could,O
play,O
a,O
role,O
in,O
mediating,O
ARU,B-GP
protein,O
levels,O
.,O
ARU,B-GP
has,O
a,O
410,O
bp,O
long,O
3,O
′-,O
UTR,O
(,O
3,O
′-,O
untranslated,O
region,O
),O
37,O
containing,O
17,O
SNPs,O
that,O
are,O
correlated,O
with,O
the,O
OG,O
/,O
S,O
phenotype,O
and,O
might,O
contribute,O
to,O
accession,O
-,O
specific,O
differences,O
in,O
ARU,B-GP
protein,O
levels,O
.,O
To,O
further,O
investigate,O
the,O
role,O
of,O
ARU,B-GP
in,O
different,O
accessions,O
",",O
we,O
transformed,O
high,O
OG,O
/,O
S,O
accessions,O
(,O
Fei,O
-,O
0,O
",",O
Kz,O
-,O
1,O
",",O
Kz,O
-,O
9,O
),O
with,O
pMYB98,O
::,O
ARU,B-GP
-,O
GFP,B-GP
to,O
ensure,O
strong,O
expression,O
in,O
synergid,O
cells,O
and,O
assessed,O
interspecific,O
PT,O
reception,O
in,O
these,O
lines,O
.,O
Of,O
several,O
independent,O
transformants,O
of,O
all,O
accessions,O
",",O
none,O
showed,O
a,O
significant,O
reduction,O
of,O
OG,O
/,O
S,O
(,O
Supplementary,O
Fig,O
.,O
8,O
"),",O
which,O
would,O
be,O
expected,O
if,O
low,O
expression,O
of,O
ARU,B-GP
alone,O
would,O
be,O
the,O
cause,O
of,O
impaired,O
interspecific,O
PT,O
reception,O
in,O
these,O
accessions,O
.,O
Similarly,O
",",O
the,O
ARU,B-GP
allele,O
(,O
including,O
1,O
",",O
492,O
bp,O
up,O
-,O
and,O
865,O
bp,O
downstream,O
sequence,O
),O
from,O
Ga,O
-,O
0,O
could,O
not,O
better,O
complement,O
the,O
aru,B-GP
mutant,O
—,O
which,O
is,O
in,O
the,O
Col,O
-,O
0,O
background,O
—,O
than,O
the,O
Col,O
-,O
0,O
allele,O
",",O
as,O
it,O
would,O
be,O
expected,O
if,O
differences,O
in,O
ARU,B-GP
alone,O
caused,O
the,O
phenotypic,O
difference,O
between,O
Ga,O
-,O
0,O
and,O
Col,O
-,O
0,O
(,O
Supplementary,O
Fig,O
.,O
7,O
).,O
Although,O
these,O
experiments,O
could,O
not,O
establish,O
a,O
mechanistic,O
link,O
between,O
variation,O
in,O
ARU,B-GP
and,O
variation,O
in,O
OG,O
/,O
S,O
",",O
they,O
are,O
not,O
inconsistent,O
with,O
the,O
hypothesis,O
that,O
ARU,B-GP
is,O
differentially,O
regulated,O
in,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
.,O
Because,O
ARU,B-GP
is,O
likely,O
only,O
one,O
of,O
several,O
factors,O
involved,O
in,O
interspecific,O
PT,O
reception,O
",",O
we,O
cannot,O
rule,O
out,O
that,O
crucial,O
epistatic,O
interactions,O
with,O
other,O
factors,O
were,O
missing,O
in,O
the,O
particular,O
accessions,O
we,O
tested,O
.,O
At,O
present,O
",",O
it,O
is,O
conceivable,O
that,O
population,O
structure,O
or,O
co,O
-,O
segregating,O
SNPs,O
",",O
which,O
do,O
not,O
directly,O
influence,O
ARU,B-GP
expression,O
or,O
protein,O
function,O
",",O
caused,O
the,O
GWAS,O
peak,O
on,O
chromosome,O
1,O
and,O
that,O
ARU,B-GP
itself,O
—,O
although,O
undoubtedly,O
involved,O
in,O
interspecific,O
PT,O
reception,O
—,O
is,O
not,O
responsible,O
for,O
the,O
observed,O
natural,O
variation,O
among,O
the,O
86,O
accessions,O
tested,O
.,O
We,O
consider,O
co,O
-,O
segregating,O
SNPs,O
a,O
highly,O
unlikely,O
explanation,O
",",O
however,O
",",O
because,O
mutations,O
disrupting,O
other,O
genes,O
in,O
the,O
region,O
identified,O
by,O
GWAS,O
did,O
not,O
show,O
a,O
phenotype,O
in,O
interspecific,O
crosses,O
with,O
A,B-OG
.,I-OG
lyrata,I-OG
pollen,O
.,O
Signatures,O
of,O
selection,O
at,O
the,O
ARTUMES,B-GP
locus,O
Genes,O
involved,O
in,O
reproductive,O
isolation,O
and,O
speciation,O
are,O
often,O
subject,O
to,O
selective,O
pressures,O
driving,O
rapid,O
divergence38,O
.,O
We,O
tested,O
ARU,B-GP
plus,O
1,O
",",O
000,O
bp,O
up,O
-,O
and,O
downstream,O
sequence,O
for,O
signatures,O
of,O
positive,O
selection,O
by,O
estimating,O
Tajima,O
',O
s,O
D39,O
for,O
a,O
set,O
of,O
96,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions40,O
",",O
including,O
all,O
accessions,O
used,O
in,O
this,O
study,O
.,O
A,O
negative,O
D,O
is,O
due,O
to,O
an,O
excess,O
of,O
low,O
frequency,O
polymorphisms,O
that,O
can,O
be,O
caused,O
by,O
positive,O
selection,O
on,O
the,O
locus,O
or,O
by,O
population,O
expansion,O
.,O
Tajima,O
',O
s,O
D,O
was,O
−,O
2,O
.,O
07,O
for,O
the,O
1,O
",",O
000,O
bp,O
upstream,O
of,O
the,O
translation,O
start,O
",",O
−,O
1,O
.,O
57,O
for,O
the,O
coding,O
sequence,O
and,O
−,O
1,O
.,O
58,O
for,O
the,O
1,O
",",O
000,O
bp,O
downstream,O
of,O
the,O
ARU,B-GP
stop,O
-,O
codon,O
.,O
All,O
values,O
significantly,O
deviate,O
from,O
the,O
neutral,O
model,O
(,O
P,O
<,O
0,O
.,O
05,O
"),",O
but,O
do,O
not,O
fall,O
into,O
the,O
5,O
%,O
tail,O
of,O
the,O
estimated,O
genomic,O
distribution,O
of,O
D,O
in,O
A,O
.,O
thaliana40,O
(,O
cut,O
-,O
off,O
value,O
:,O
−,O
2,O
.,O
08,O
).,O
Thus,O
",",O
although,O
the,O
1,O
",",O
000,O
bp,O
upstream,O
region,O
was,O
very,O
close,O
to,O
this,O
cut,O
-,O
off,O
",",O
the,O
observed,O
negative,O
values,O
might,O
be,O
influenced,O
by,O
demographic,O
factors,O
that,O
shaped,O
the,O
entire,O
genome,O
rather,O
than,O
selective,O
pressure,O
acting,O
on,O
the,O
ARU,B-GP
locus,O
.,O
In,O
addition,O
",",O
we,O
estimated,O
Fay,O
and,O
Wu,O
',O
s,O
H,O
",",O
another,O
test,O
statistic,O
to,O
detect,O
positive,O
selection41,O
",",O
which,O
is,O
not,O
as,O
sensitive,O
to,O
demographic,O
factors,O
as,O
Tajima,O
',O
s,O
D42,O
.,O
All,O
values,O
for,O
H,O
were,O
strongly,O
negative,O
(,O
upstream,O
region,O
:,O
−,O
20,O
.,O
20,O
",",O
coding,O
sequence,O
:,O
−,O
21,O
.,O
79,O
",",O
downstream,O
region,O
:,O
−,O
20,O
.,O
73,O
",",O
P,O
<,O
0,O
.,O
02,O
"),",O
and,O
fall,O
into,O
the,O
very,O
extreme,O
tails,O
of,O
both,O
an,O
empirical,O
and,O
a,O
simulated,O
distribution,O
of,O
H,O
calculated,O
with,O
12,O
accessions,O
",",O
which,O
represent,O
a,O
world,O
-,O
wide,O
distribution,O
and,O
are,O
a,O
subset,O
of,O
the,O
accessions,O
used,O
in,O
this,O
study42,O
.,O
Such,O
strongly,O
negative,O
values,O
for,O
H,O
indicate,O
that,O
positive,O
selection,O
may,O
indeed,O
have,O
acted,O
on,O
each,O
of,O
the,O
regions,O
of,O
the,O
ARU,B-GP
locus,O
.,O
The,O
fact,O
that,O
D,O
for,O
the,O
upstream,O
region,O
was,O
very,O
close,O
to,O
the,O
5,O
%,O
tail,O
and,O
the,O
strongly,O
negative,O
values,O
for,O
H,O
provide,O
evidence,O
for,O
possible,O
positive,O
selection,O
and,O
indicate,O
that,O
ARU,B-GP
may,O
have,O
undergone,O
a,O
recent,O
selective,O
sweep,O
.,O
This,O
is,O
consistent,O
with,O
the,O
lack,O
of,O
variation,O
in,O
ARU,B-GP
amino,O
acid,O
sequence,O
and,O
expression,O
level,O
but,O
is,O
difficult,O
",",O
although,O
not,O
impossible,O
",",O
to,O
reconcile,O
with,O
the,O
fact,O
that,O
we,O
identified,O
ARU,B-GP
in,O
a,O
GWAS,O
for,O
variation,O
in,O
the,O
OG,O
/,O
S,O
phenotype,O
.,O
As,O
pointed,O
out,O
above,O
",",O
this,O
may,O
be,O
due,O
to,O
epistatic,O
interactions,O
with,O
additional,O
factors,O
involved,O
in,O
this,O
complex,O
process,O
.,O
Nevertheless,O
",",O
as,O
in,O
animal,B-OG
speciation,O
genes,O
",",O
selective,O
pressures,O
appear,O
to,O
have,O
contributed,O
to,O
shaping,O
the,O
genetic,O
basis,O
that,O
underlies,O
interspecific,O
PT,O
reception,O
in,O
A,B-OG
.,I-OG
thaliana,I-OG
.,O
Interspecific,O
PT,O
reception,O
depends,O
on,O
protein,O
N,O
-,O
glycosylation,O
ARU,B-GP
encodes,O
the,O
OST3,B-GP
/,O
6,O
subunit,O
of,O
the,O
hetero,O
-,O
oligomeric,O
plant,B-OG
oligosaccharyltransferase,B-GP
complex,O
(,O
OST,B-GP
"),",O
which,O
catalyses,O
the,O
co,O
-,O
or,O
posttranslational,O
transfer,O
of,O
pre,O
-,O
assembled,O
carbohydrate,O
oligomers,O
(,O
Glc3Man9GlcNAc2,O
),O
to,O
asparagine,O
(,O
N,O
),O
residues,O
of,O
polypeptides43,O
.,O
N,O
-,O
glycosylation,O
affects,O
the,O
substrate,O
protein,O
',O
s,O
folding,O
",",O
targeting,O
",",O
and,O
/,O
or,O
processing,O
through,O
the,O
ER,O
.,O
Subsequently,O
",",O
the,O
N,O
-,O
linked,O
glycan,O
can,O
be,O
modified,O
in,O
the,O
Golgi,O
apparatus,O
in,O
a,O
cell,O
-,O
type,O
and,O
species,O
-,O
specific,O
manner,O
",",O
accounting,O
for,O
the,O
functionality,O
and,O
binding,O
specificity,O
of,O
the,O
glycoprotein43,O
.,O
The,O
yeast,B-OG
OST,B-GP
consists,O
of,O
eight,O
subunits,O
and,O
the,O
homologues,O
of,O
OST3,B-GP
/,O
6,O
",",O
Ost3p,O
and,O
Ost6p,O
",",O
differ,O
in,O
their,O
protein,O
substrate,O
and,O
site,O
-,O
specific,O
glycosylation,O
efficiency2223,O
.,O
In,O
plants,B-OG
",",O
OST3,B-GP
/,O
6,O
confers,O
similar,O
substrate,O
specificity,O
since,O
in,O
the,O
A,B-OG
.,I-OG
thaliana,I-OG
ost3,B-GP
/,O
6,O
(,O
aru,B-GP
),O
mutant,O
only,O
a,O
subset,O
of,O
glycoproteins,O
is,O
misglycosylated,O
and,O
therefore,O
non,O
-,O
functional24,O
.,O
Among,O
these,O
are,O
the,O
pathogen,B-GP
-,I-GP
associated,I-GP
molecular,I-GP
pattern,I-GP
(,I-GP
PAMP,I-GP
),I-GP
receptor,I-GP
kinase,I-GP
EF,B-GP
-,I-GP
TU,I-GP
RECEPTOR,I-GP
(,O
EFR,B-GP
"),",O
and,O
KORRIGAN1,B-GP
",",O
an,O
endo,B-GP
-,I-GP
β,I-GP
-,I-GP
1,I-GP
",",I-GP
4,I-GP
-,I-GP
glucanase,I-GP
involved,O
in,O
cellulose,O
biosynthesis,O
.,O
In,O
line,O
with,O
this,O
",",O
aru,B-GP
has,O
previously,O
been,O
identified,O
in,O
an,O
EMS,O
-,O
screen,O
for,O
cell,O
wall,O
mutants34,O
.,O
Some,O
of,O
the,O
known,O
members,O
in,O
the,O
PT,O
reception,O
pathway,O
",",O
FER,B-GP
and,O
NTA,B-GP
",",O
have,O
been,O
implicated,O
in,O
the,O
perception,O
of,O
cell,O
wall,O
perturbations,O
",",O
pathogen,O
resistance,O
",",O
and,O
innate,O
immunity174445,O
.,O
After,O
pollination,O
with,O
A,B-OG
.,I-OG
lyrata,I-OG
",",O
fer,B-GP
heterozygous,O
mutants,O
show,O
higher,O
OG,O
/,O
S,O
(,O
74,O
.,O
9,O
%),O
than,O
wild,O
-,O
type,O
segregants,O
(,O
61,O
.,O
2,O
"%,",O
P,O
<,O
0,O
.,O
01,O
",",O
Supplementary,O
Fig,O
.,O
9,O
"),",O
suggesting,O
that,O
inter,O
-,O
and,O
intraspecific,O
PT,O
reception,O
both,O
involve,O
the,O
FER,B-GP
pathway,O
.,O
Moreover,O
",",O
FER,B-GP
(,O
a,O
receptor,B-GP
-,I-GP
like,I-GP
kinase,I-GP
with,O
an,O
extracellular,O
malectin,B-GP
-,O
binding,O
domain,O
),O
and,O
LRE,B-GP
(,O
a,O
glycosylphosphatidylinositol,B-GP
-,I-GP
anchored,I-GP
protein,I-GP
),O
are,O
likely,O
to,O
be,O
glycosylated131646,O
and,O
could,O
be,O
substrates,O
of,O
ARU,B-GP
.,O
To,O
test,O
this,O
",",O
we,O
analysed,O
the,O
expression,O
and,O
localization,O
of,O
fluorescent,O
FER,B-GP
and,O
LRE,B-GP
fusion,O
proteins,O
in,O
aru,B-GP
ovules,O
.,O
We,O
included,O
NTA,B-GP
",",O
which,O
itself,O
does,O
not,O
contain,O
any,O
putative,O
glycosylation,O
sites,O
but,O
whose,O
subcellular,O
localization,O
depends,O
on,O
FER,B-GP
signalling17,O
.,O
All,O
fusion,O
proteins,O
displayed,O
a,O
wild,O
-,O
type,O
-,O
like,O
subcellular,O
localization,O
in,O
the,O
synergids,O
of,O
aru,B-GP
embryo,O
sacs,O
:,O
FER,B-GP
-,O
GFP,B-GP
and,O
LRE,B-GP
-,O
Citrine,B-GP
were,O
observed,O
at,O
the,O
micropylar,O
end,O
of,O
the,O
synergids,O
",",O
and,O
NTA,B-GP
-,O
GFP,B-GP
was,O
re,O
-,O
localized,O
there,O
upon,O
PT,O
arrival,O
(,O
Supplementary,O
Fig,O
.,O
10,O
).,O
These,O
results,O
indicate,O
that,O
",",O
in,O
the,O
absence,O
of,O
functional,O
ARU,B-GP
",",O
these,O
proteins,O
are,O
properly,O
targeted,O
to,O
their,O
subcellular,O
compartment,O
.,O
However,O
",",O
we,O
cannot,O
rule,O
out,O
that,O
the,O
extracellular,O
domain,O
of,O
FER,B-GP
is,O
un,O
-,O
or,O
misglycosylated,O
at,O
specific,O
glycosylation,O
sites,O
in,O
aru,B-GP
",",O
which,O
may,O
allow,O
the,O
protein,O
to,O
recognize,O
intra,O
-,O
but,O
not,O
interspecific,O
PTs,O
.,O
The,O
synergid,O
has,O
a,O
specialized,O
secretory,O
region,O
at,O
its,O
micropylar,O
end,O
",",O
the,O
filiform,O
apparatus,O
",",O
which,O
contains,O
a,O
large,O
amount,O
of,O
secreted,O
material,O
and,O
is,O
believed,O
to,O
be,O
the,O
site,O
of,O
PT,O
recognition6,O
.,O
It,O
is,O
possible,O
that,O
even,O
subtle,O
differences,O
in,O
ARU,B-GP
protein,O
levels,O
could,O
lead,O
to,O
the,O
misglycosylation,O
of,O
target,O
proteins,O
",",O
including,O
FER,B-GP
",",O
such,O
that,O
a,O
few,O
specific,O
glycosylation,O
sites,O
remain,O
unglycosylated,O
.,O
Given,O
the,O
high,O
secretory,O
activity,O
of,O
the,O
filiform,O
apparatus,O
",",O
such,O
small,O
changes,O
could,O
have,O
a,O
large,O
effect,O
on,O
PT,O
reception,O
.,O
Further,O
work,O
will,O
be,O
necessary,O
to,O
shed,O
more,O
light,O
on,O
the,O
target,O
proteins,O
of,O
ARU,B-GP
and,O
to,O
elucidate,O
the,O
role,O
of,O
specific,O
glycosylated,O
surface,B-GP
proteins,I-GP
in,O
PT,O
reception,O
.,O
Discussion,O
A,O
possible,O
interpretation,O
of,O
our,O
results,O
is,O
that,O
FER,B-GP
",",O
and,O
/,O
or,O
yet,O
unknown,O
synergid,O
(,O
co,O
-),O
receptors,O
",",O
bind,O
putative,O
ligands,O
from,O
intraspecific,O
PTs,O
both,O
via,O
specific,O
interactions,O
with,O
carbohydrates,O
on,O
the,O
receptor,O
protein,O
and,O
via,O
direct,O
protein,O
–,O
protein,O
interactions,O
",",O
a,O
mechanism,O
similar,O
to,O
the,O
proposed,O
‘,O
domain,O
-,O
specific,O
model,O
',O
in,O
mammalian,O
sperm,O
-,O
egg,O
binding47,O
(,O
Fig,O
.,O
6a,O
).,O
Ligands,O
from,O
interspecific,O
PTs,O
might,O
not,O
be,O
able,O
to,O
sufficiently,O
interact,O
via,O
protein,O
–,O
protein,O
contacts,O
alone,O
but,O
could,O
still,O
be,O
recognized,O
to,O
some,O
extent,O
via,O
the,O
carbohydrate,O
moieties,O
",",O
explaining,O
the,O
partial,O
A,B-OG
.,I-OG
lyrata,I-OG
PT,O
reception,O
success,O
in,O
Col,O
-,O
0,O
ovules,O
(,O
Fig,O
.,O
6b,O
).,O
It,O
is,O
conceivable,O
that,O
in,O
aru,B-GP
",",O
and,O
potentially,O
also,O
in,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
with,O
a,O
similar,O
phenotype,O
",",O
changes,O
in,O
the,O
glycosylation,O
status,O
of,O
the,O
receptor,O
could,O
completely,O
abolish,O
the,O
ability,O
to,O
recognize,O
and,O
receive,O
interspecific,O
PTs,O
(,O
Fig,O
.,O
6d,O
"),",O
while,O
ligands,O
from,O
A,B-OG
.,I-OG
thaliana,I-OG
PTs,O
are,O
still,O
efficiently,O
recognized,O
via,O
protein,O
–,O
protein,O
interactions,O
",",O
leading,O
to,O
normal,O
PT,O
reception,O
(,O
Fig,O
.,O
6c,O
).,O
The,O
crosstalk,O
between,O
gametophytes,O
constitutes,O
a,O
specific,O
form,O
of,O
cell,O
–,O
cell,O
communication,O
.,O
Cellular,O
interactions,O
are,O
often,O
mediated,O
by,O
specific,O
binding,O
of,O
an,O
extracellular,O
ligand,O
to,O
a,O
receptor,O
",",O
triggering,O
downstream,O
signalling,O
cascades,O
in,O
the,O
recipient,O
cell,O
.,O
Most,O
extracellular,O
ligands,O
and,O
receptors,O
are,O
heavily,O
glycosylated48,O
",",O
which,O
influences,O
their,O
binding,O
specificities,O
and,O
conformation,O
",",O
such,O
that,O
already,O
the,O
absence,O
of,O
a,O
single,O
glycosylation,O
motif,O
can,O
reduce,O
or,O
abolish,O
a,O
receptor,O
',O
s,O
function,O
and,O
ligand,O
-,O
binding,O
affinity4950,O
.,O
Our,O
results,O
suggest,O
that,O
both,O
protein,O
–,O
protein,O
interactions,O
and,O
recognition,O
mediated,O
by,O
carbohydrates,O
may,O
be,O
crucial,O
factors,O
to,O
ensure,O
species,O
-,O
specific,O
PT,O
reception,O
.,O
Thus,O
",",O
divergent,O
evolution,O
of,O
receptor,O
–,O
ligand,O
pairs,O
",",O
as,O
well,O
as,O
of,O
the,O
factors,O
controlling,O
their,O
glycosylation,O
status,O
",",O
could,O
establish,O
new,O
species,O
barriers,O
.,O
Deciphering,O
the,O
molecular,O
basis,O
of,O
speciation,O
in,O
plants,B-OG
might,O
enable,O
us,O
to,O
overcome,O
existing,O
hybridization,O
barriers,O
",",O
which,O
could,O
eventually,O
be,O
of,O
great,O
agronomic,O
importance,O
.,O
Methods,O
Plant,B-OG
material,O
and,O
growth,O
conditions,O
The,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
were,O
part,O
of,O
the,O
Nordborg,O
collection,O
for,O
GWAS2740,O
.,O
Amplified,O
seed,O
stocks,O
were,O
kindly,O
donated,O
by,O
Ortrun,O
Mittelsten,O
Scheid,O
(,O
Gregor,O
Mendel,O
Institute,O
",",O
Vienna,O
).,O
After,O
stratification,O
(,O
2,O
days,O
at,O
4,O
°,O
C,O
"),",O
the,O
seeds,O
were,O
allowed,O
to,O
germinate,O
for,O
6,O
days,O
on,O
MS,O
plates,O
(,O
22,O
°,O
C,O
",",O
16,O
h,O
light,O
",",O
MS,O
from,O
Carolina,O
Biological,O
Supply,O
).,O
Because,O
some,O
accessions,O
require,O
vernalization,O
",",O
all,O
the,O
seedlings,O
were,O
kept,O
in,O
a,O
vernalization,O
chamber,O
for,O
5,O
weeks,O
(,O
4,O
°,O
C,O
",",O
16,O
h,O
light,O
),O
on,O
MS,O
plates,O
before,O
they,O
were,O
transferred,O
to,O
the,O
soil,O
(,O
ED73,O
",",O
Universalerde,O
).,O
The,O
accessions,O
were,O
grouped,O
into,O
early,O
-,O
(,O
four,O
incomplete,O
blocks,O
A,O
",",O
B,O
",",O
C,O
and,O
D,O
"),",O
mid,O
"-,",O
and,O
late,O
flowering,B-OG
plants,I-OG
(,O
three,O
complete,O
blocks,O
A,O
",",O
B,O
",",O
C,O
each,O
),O
according,O
to,O
the,O
flowering,O
time27,O
",",O
and,O
were,O
grown,O
in,O
a,O
greenhouse,O
chamber,O
(,O
22,O
°,O
C,O
",",O
16,O
h,O
light,O
),O
in,O
an,O
incomplete,O
randomized,O
block,O
design,O
.,O
See,O
Supplementary,O
Table,O
1,O
for,O
the,O
assignment,O
of,O
accessions,O
to,O
the,O
blocks,O
.,O
A,O
.,O
lyrata13,O
",",O
A,B-OG
.,I-OG
halleri,I-OG
(,O
a,O
gift,O
from,O
Marcus,O
Koch,O
",",O
University,O
of,O
Heidelberg,O
"),",O
and,O
A,B-OG
.,I-OG
arenosa,I-OG
(,O
donated,O
by,O
Matthias,O
Helling,O
",",O
University,O
of,O
Zurich,O
),O
plants,B-OG
were,O
stratified,O
for,O
10,O
days,O
and,O
grown,O
in,O
the,O
same,O
greenhouse,O
chamber,O
.,O
Plants,B-OG
were,O
vernalized,O
to,O
induce,O
flowering,O
(,O
see,O
above,O
).,O
SALK,O
-,O
lines,O
were,O
obtained,O
from,O
NASC,O
:,O
SALK_067271,O
(,O
At1g61790,B-GP
",",O
aru,B-GP
-,I-GP
1,I-GP
"),",O
SALK_137883C,O
(,O
At1g61780,B-GP
"),",O
SALK_052207C,O
and,O
SALK_026074C,O
(,O
At1g61795,B-GP
"),",O
SALK_104077,O
(,O
At1g61810,B-GP
).,O
The,O
EMS,O
allele,O
aru,B-GP
-,I-GP
2,I-GP
(,O
ref,O
.,O
34,O
),O
was,O
a,O
gift,O
from,O
Peter,O
McCourt,O
(,O
University,O
of,O
Toronto,O
).,O
The,O
plants,B-OG
were,O
grown,O
as,O
described,O
before17,O
.,O
Crosses,O
and,O
aniline,O
blue,O
staining,O
Flowers,O
were,O
emasculated,O
and,O
the,O
pistils,O
were,O
pollinated,O
2,O
days,O
after,O
emasculation,O
(,O
dae,O
).,O
Siliques,O
were,O
collected,O
two,O
days,O
after,O
pollination,O
and,O
fixed,O
for,O
aniline,O
blue,O
staining,O
in,O
9,O
:,O
1,O
ethanol,O
:,O
acidic,O
acid,O
.,O
Aniline,O
blue,O
staining,O
was,O
performed,O
as,O
described,O
previously17,O
",",O
and,O
the,O
samples,O
were,O
analysed,O
with,O
a,O
Leica,O
DM6000B,O
microscope,O
(,O
Leica,O
Microsystems,O
).,O
For,O
GWAS,O
phenotyping,O
",",O
9,O
–,O
20,O
siliques,O
of,O
a,O
minimum,O
of,O
three,O
individuals,O
were,O
analysed,O
for,O
each,O
accession,O
(,O
Exceptions,O
:,O
Zdr,O
-,O
1,O
:,O
seven,O
siliques,O
",",O
Got,O
-,O
7,O
:,O
four,O
siliques,O
from,O
two,O
individuals,O
).,O
GWAS,O
analyses,O
Association,O
mapping,O
was,O
conducted,O
using,O
the,O
mean,O
values,O
of,O
the,O
proportions,O
of,O
ovules,O
with,O
PT,O
overgrowth,O
per,O
silique,O
(,O
OG,O
/,O
S,O
),O
as,O
phenotypes,O
.,O
An,O
A,B-OG
.,I-OG
thaliana,I-OG
250,O
K,O
Affymetrix,O
SNP,O
genotyping,O
data,O
set27,O
was,O
downloaded,O
from,O
https,O
://,O
cynin,O
.,O
gmi,O
.,O
oeaw,O
.,O
ac,O
.,O
at,O
/,O
home,O
/,O
resources,O
/,O
atpolydb,O
.,O
GWAS,O
analyses,O
were,O
performed,O
using,O
a,O
compressed,O
mixed,O
linear,O
model,O
",",O
using,O
population,O
parameters,O
previously,O
determined5152,O
",",O
and,O
a,O
kinship,O
matrix,O
to,O
account,O
for,O
family,O
relatedness,O
",",O
in,O
the,O
R,O
package,O
GAPIT53,O
.,O
The,O
mixed,O
linear,O
models,O
were,O
run,O
with,O
and,O
without,O
principal,O
components,O
as,O
fixed,O
effects,O
to,O
correct,O
for,O
population,O
structure,O
.,O
Multiple,O
testing,O
was,O
controlled,O
using,O
the,O
Bonferroni,O
correction,O
and,O
false,O
-,O
discovery,O
rate54,O
.,O
GWAS,O
analyses,O
were,O
also,O
run,O
using,O
a,O
general,O
linear,O
model,O
in,O
the,O
web,O
-,O
based,O
interface,O
TASSEL3,O
.,O
0,O
(,O
ref,O
.,O
30,O
),O
and,O
an,O
accelerated,O
mixed,O
model,O
with,O
Box,O
-,O
Cox,O
transformed,O
phenotypes,O
in,O
GWAPP55,O
.,O
MLMM,O
analysis,O
was,O
conducted,O
as,O
previously,O
described31,O
.,O
Constructs,O
for,O
stable,O
plant,B-OG
transformation,O
For,O
pMYB98,O
/,O
pFER,O
::,O
ARU,B-GP
-,O
GFP,B-GP
the,O
complete,O
coding,O
sequence,O
of,O
ARU,B-GP
without,O
the,O
stop,O
-,O
codon,O
was,O
amplified,O
using,O
gene,O
-,O
specific,O
primers,O
with,O
attB,O
-,O
sites,O
for,O
Gateway,O
cloning,O
:,O
5,O
′-,O
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGCGCTCAAATCAAAACTCGTC,O
-,O
3,O
′,O
and,O
5,O
′-,O
GGGGACCACTTTGTACAAGAAAGCTGGGTCACGCCAACTCGATGGCCAATACGGA,O
-,O
3,O
′.,O
We,O
introduced,O
the,O
PCR,O
-,O
fragment,O
into,O
pDONR207,O
",",O
and,O
subsequently,O
into,O
the,O
destination,O
vector,O
(,O
using,O
the,O
E,B-OG
.,I-OG
coli,I-OG
strain,I-OG
DH5,I-OG
-,I-OG
alpha,I-OG
F,I-OG
',I-OG
Iq,I-OG
from,O
New,O
England,O
Biolabs,O
).,O
The,O
destination,O
vector,O
was,O
a,O
modification,O
of,O
the,O
plant,B-OG
Gateway,O
vector,O
pMDC83,O
",",O
which,O
contains,O
the,O
2x35S,O
-,O
promotor,O
before,O
and,O
GFP,B-GP
after,O
the,O
Gateway,O
cassette56,O
.,O
For,O
our,O
purpose,O
",",O
we,O
exchanged,O
the,O
original,O
2x35S,O
-,O
promoter,O
with,O
the,O
promoters,O
of,O
FER13,O
and,O
MYB98,B-GP
(,O
ref,O
.,O
35,O
),O
to,O
express,O
ARU,B-GP
specifically,O
in,O
synergid,O
cells,O
.,O
The,O
MYB98,B-GP
promoter,O
was,O
amplified,O
from,O
Col,O
-,O
0,O
with,O
primers,O
5,O
′-,O
TTTAAGCTTATACACTCATTGTCCTTCG,O
-,O
3,O
′,O
and,O
5,O
′-,O
CCCTCTAGATGTTTTGGAAAGGAGAAAAAA,O
-,O
3,O
"′,",O
introducing,O
a,O
HindIII,B-GP
and,O
XbaI,B-GP
restriction,O
site,O
",",O
respectively,O
.,O
The,O
FER,B-GP
promoter,O
was,O
amplified,O
from,O
the,O
pFER,O
::,O
FER,B-GP
-,O
GFP,B-GP
construct13,O
using,O
specific,O
primers,O
5,O
′-,O
TTTGGTAAGCTTCGATTTAAGCGAG,O
-,O
3,O
′,O
and,O
5,O
′-,O
TTTTCTAGACGATCAAGAGCACTTCTCCGGG,O
-,O
3,O
"′,",O
which,O
introduce,O
HindIII,B-GP
and,O
XbaI,B-GP
restriction,O
sites,O
as,O
well,O
.,O
The,O
2x35S,O
-,O
promoter,O
was,O
cut,O
out,O
of,O
pMDC83,O
(,O
ref,O
.,O
56,O
),O
with,O
HindIII,B-GP
/,O
XbaI,B-GP
(,O
New,O
England,O
Biolabs,O
"),",O
and,O
the,O
PCR,O
fragments,O
were,O
introduced,O
into,O
the,O
dephosphorylated,O
vector,O
backbone,O
by,O
ligation,O
.,O
pDONR207,O
carrying,O
the,O
ARU,B-GP
coding,O
sequence,O
and,O
the,O
modified,O
destination,O
vector,O
were,O
combined,O
in,O
an,O
LR,O
reaction,O
.,O
The,O
resulting,O
vectors,O
",",O
pFER,O
::,O
ARU,B-GP
-,O
GFP,B-GP
and,O
pMYB98,O
::,O
ARU,B-GP
-,O
GFP,B-GP
were,O
transformed,O
into,O
Agrobacterium,B-OG
tumefaciens,I-OG
strain,I-OG
CV1310,I-OG
",",O
and,O
homozygous,O
aru,B-GP
-,I-GP
1,I-GP
plants,B-OG
were,O
transformed,O
by,O
the,O
floral,O
dip,O
method57,O
.,O
The,O
complementation,O
assays,O
were,O
conducted,O
in,O
the,O
T2,O
and,O
T3,O
generations,O
with,O
plants,B-OG
homozygous,O
for,O
the,O
complementation,O
construct,O
and,O
the,O
aru,B-GP
-,I-GP
1,I-GP
mutation,O
.,O
For,O
experiments,O
with,O
pMYB98,O
::,O
ARU,B-GP
-,O
GFP,B-GP
in,O
accessions,O
with,O
high,O
OG,O
/,O
S,O
",",O
the,O
construct,O
was,O
transformed,O
into,O
Fei,O
-,O
0,O
",",O
Kz,O
-,O
1,O
",",O
and,O
Kz,O
-,O
9,O
",",O
and,O
OG,O
/,O
S,O
was,O
assessed,O
in,O
heterozygous,O
plants,B-OG
(,O
T1,O
generation,O
).,O
For,O
the,O
constructs,O
with,O
ARU,B-GP
under,O
the,O
control,O
of,O
its,O
endogenous,O
promoter,O
",",O
the,O
ARU,B-GP
fragment,O
(,O
including,O
1,O
",",O
492,O
bp,O
of,O
upstream,O
",",O
ARU,B-GP
CDS,O
",",O
and,O
865,O
bp,O
of,O
downstream,O
sequence,O
),O
was,O
amplified,O
from,O
Col,O
-,O
0,O
and,O
Ga,O
-,O
0,O
genomic,O
DNA,O
using,O
primers,O
5,O
′-,O
TTTTACTAGTAGGCAATTCCATCAGTTGTT,O
-,O
3,O
′,O
and,O
5,O
′-,O
TTTTGGTACCGTTACTTCACTTTCTCGAGT,O
-,O
3,O
"′,",O
introducing,O
a,O
SpeI,B-GP
and,O
a,O
KpnI,B-GP
restriction,O
site,O
",",O
respectively,O
.,O
The,O
fragments,O
were,O
cloned,O
into,O
pMDC99,O
(,O
ref,O
.,O
56,O
),O
using,O
restriction,O
-,O
ligation,O
and,O
transformed,O
into,O
aru,B-GP
mutants,O
(,O
Col,O
-,O
0,O
background,O
).,O
pARU,O
::,O
ARU,B-GP
-,O
GFP,B-GP
was,O
cloned,O
by,O
amplification,O
of,O
a,O
part,O
of,O
ARU,B-GP
coupled,O
to,O
GFP,B-GP
-,O
tNOS,O
from,O
pFER,O
::,O
ARU,B-GP
-,O
GFP,B-GP
with,O
primers,O
5,O
′-,O
GCGTTAACGCTTTACCTCA,O
-,O
3,O
′,O
(,O
including,O
the,O
natural,O
HpaI,B-GP
site,O
in,O
ARU,B-GP
),O
and,O
5,O
′-,O
TTTGGATCCAGTAACATAGATGACACCGCG,O
-,O
3,O
′,O
(,O
introducing,O
a,O
BamHI,B-GP
site,O
after,O
tNOS,O
).,O
This,O
fragment,O
was,O
introduced,O
by,O
ligation,O
into,O
the,O
pMDC99,O
vector,O
carrying,O
the,O
genomic,O
fragment,O
of,O
ARU,B-GP
(,O
Col,O
-,O
0,O
).,O
By,O
cutting,O
this,O
vector,O
with,O
HpaI,B-GP
and,O
BamHI,B-GP
",",O
part,O
of,O
the,O
ARU,B-GP
coding,O
sequence,O
and,O
the,O
downstream,O
sequence,O
were,O
removed,O
and,O
replaced,O
with,O
the,O
respective,O
fragment,O
of,O
ARU,B-GP
coupled,O
to,O
GFP,B-GP
-,O
tNOS,O
",",O
resulting,O
in,O
pARU,O
(,O
1,O
",",O
492,O
bp,O
)::,O
ARU,B-GP
-,O
GFP,B-GP
",",O
which,O
was,O
transformed,O
into,O
Col,O
-,O
0,O
.,O
pLRE,O
::,O
LRE,B-GP
-,O
Citrine,B-GP
was,O
cloned,O
with,O
overlapping,O
PCR,O
fragments,O
that,O
were,O
assembled,O
using,O
the,O
Gibson,O
cloning,O
Master,O
Mix,O
from,O
New,O
England,O
Biolabs,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
recommendations,O
.,O
The,O
779,O
-,O
bp,O
long,O
promoter,O
sequence,O
with,O
the,O
predicted,O
signal,O
peptide,O
from,O
LRE16,O
was,O
amplified,O
with,O
primers,O
5,O
′-,O
GTGCTGCAAGGCGATTAAGTCCGTGTGCTCTGTCTGCATT,O
-,O
3,O
′,O
and,O
5,O
′-,O
CACAGCTCCACCTCCACCTCCAGGCCGGCCTATGGAACTTGAAGAGGAGAGAGA,O
-,O
3,O
"′,",O
introducing,O
an,O
overhang,O
complementary,O
to,O
the,O
vector,O
pMDC99,O
(,O
ref,O
.,O
56,O
).,O
Citrine,B-GP
was,O
amplified,O
from,O
the,O
transgenic,O
line,O
CS36962,O
(,O
ordered,O
from,O
Arabidopsis,B-OG
Biological,O
Resource,O
Center,O
",",O
ABRC,O
"),",O
using,O
gene,O
-,O
specific,O
primers,O
with,O
overhang,O
primers,O
for,O
the,O
signal,O
peptide,O
of,O
LRE,B-GP
and,O
overhang,O
primers,O
for,O
the,O
GPI,O
-,O
anchor,O
of,O
LRE,B-GP
:,O
5,O
′-,O
GGCCGGCCTGGAGGTGGAGGTGGAGCTGTGAGCAAGGGCGAGGAGCT,O
-,O
3,O
′,O
and,O
5,O
′-,O
GGCCCCAGCGGCCGCAGCAGCACCAGCAGGATCCTTGTACAGCTCGTCCA,O
-,O
3,O
′.,O
The,O
GPI,O
-,O
anchor,O
of,O
LRE,B-GP
was,O
amplified,O
with,O
overhang,O
primers,O
for,O
pMDC99,O
:,O
5,O
′-,O
TGCTGGTGCTGCTGCGGCCGCTGGGGCCTCGGGTATGTCTTTTTGTTGTC,O
-,O
3,O
′,O
and,O
5,O
′-,O
AGCTCCACCGCGGTGGCGGCCGCTCTAGAAGTCTCGCTTCTTCTTTTGT,O
-,O
3,O
′.,O
pMDC99,O
was,O
amplified,O
with,O
overhang,O
primers,O
for,O
the,O
LRE,B-GP
promoter,O
and,O
the,O
GPI,O
-,O
anchor,O
using,O
primers,O
:,O
5,O
′-,O
ACTTAATCGCCTTGCAGCAC,O
-,O
3,O
′,O
and,O
5,O
′-,O
TCTAGAGCGGCCGCCACCGCGG,O
-,O
3,O
′.,O
All,O
the,O
constructs,O
were,O
verified,O
by,O
sequencing,O
.,O
pFER,O
::,O
FER,B-GP
-,O
GFP,B-GP
and,O
pNTA,O
::,O
NTA,B-GP
-,O
GFP,B-GP
were,O
described,O
previously1317,O
.,O
ARU,B-GP
-,O
GFP,B-GP
subcellular,O
localization,O
We,O
used,O
the,O
pFER,O
::,O
ARU,B-GP
-,O
GFP,B-GP
construct,O
for,O
microprojectile,O
bombardment,O
of,O
onion,O
epidermal,O
cells,O
and,O
co,O
-,O
localized,O
it,O
with,O
the,O
ER,O
-,O
marker,O
pER,O
-,O
rk,O
(,O
mCherry,B-GP
),O
obtained,O
from,O
ABRC58,O
.,O
Biolistic,O
bombardment,O
of,O
onion,O
epidermis,O
was,O
performed,O
as,O
described17,O
.,O
For,O
visualizing,O
GFP,B-GP
expression,O
in,O
the,O
synergids,O
",",O
flowers,O
were,O
emasculated,O
and,O
pistils,O
were,O
dissected,O
2,O
dae,O
to,O
ensure,O
the,O
development,O
of,O
mature,O
",",O
unfertilized,O
embryo,O
sacs,O
.,O
The,O
tissue,O
was,O
mounted,O
on,O
slides,O
in,O
1,O
M,O
glycine,O
",",O
pH,O
9,O
.,O
6,O
.,O
Images,O
were,O
captured,O
on,O
Leica,O
Confocal,O
Microscopes,O
SP2,O
and,O
SP5,O
(,O
Leica,O
Microsystems,O
).,O
RNA,O
extraction,O
and,O
reverse,O
transcriptase,O
PCR,O
RNA,O
from,O
pistils,O
(,O
25,O
pistils,O
",",O
2,O
dae,O
"),",O
inflorescences,O
",",O
and,O
ovules,O
(,O
extracted,O
from,O
30,O
pistils,O
",",O
2,O
dae,O
),O
was,O
extracted,O
using,O
the,O
Trizol,O
reagent,O
(,O
Invitrogen,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
recommendations,O
.,O
Pistil,O
and,O
inflorescence,O
cDNA,O
was,O
reverse,O
transcribed,O
using,O
Oligo,O
-,O
dT,O
primers,O
and,O
Superscript,O
II,O
reverse,B-GP
transcriptase,I-GP
from,O
Invitrogen,O
.,O
Ovule,O
cDNA,O
was,O
amplified,O
using,O
the,O
Ovation,O
Pico,O
SL,O
WTA,O
system,O
V2,O
from,O
Nugen,O
.,O
Reverse,O
transcriptase,O
PCR,O
(,O
RT,O
–,O
PCR,O
),O
of,O
ARU,B-GP
was,O
done,O
using,O
primers,O
5,O
′-,O
CAATGTGCTTGTTCGAGTG,O
-,O
3,O
′,O
and,O
5,O
′-,O
ATCCAGTCTTCCAGTTATCCA,O
-,O
3,O
′.,O
For,O
quantitative,O
RT,O
and,O
digital,O
droplet,O
PCR,O
of,O
ARU,B-GP
in,O
A,B-OG
.,I-OG
thaliana,I-OG
accessions,O
",",O
the,O
primers,O
5,O
′-,O
GTTTGTTACCAATGTGCTTGTTCG,O
-,O
3,O
′,O
and,O
5,O
′-,O
TCCATATCCAGTCTTCCAGTTATCC,O
-,O
3,O
′,O
were,O
used,O
and,O
expression,O
levels,O
were,O
normalized,O
against,O
UBIQUITIN,B-GP
C,I-GP
(,O
UBC9,B-GP
",",O
primers,O
:,O
5,O
′-,O
ATGCTTGGAGTCCTGCTTGG,O
-,O
3,O
′,O
and,O
5,O
′-,O
TGCCATTGAATTGAACCCTCTC,O
-,O
3,O
′).,O
For,O
digital,O
droplet,O
PCR,O
on,O
ovule,O
cDNA,O
",",O
the,O
UBC9,B-GP
assay,O
was,O
performed,O
as,O
an,O
EvaGreen,O
assay,O
",",O
whereas,O
ARU,B-GP
transcripts,O
were,O
detected,O
using,O
a,O
gene,O
-,O
specific,O
probe,O
(,O
5,O
′-,O
FAM,O
-,O
TACTGCACAAAGGTTG,O
-,O
MGB,O
-,O
3,O
′).,O
The,O
samples,O
were,O
analysed,O
with,O
the,O
QX200,O
system,O
from,O
Bio,O
-,O
Rad,O
.,O
Population,O
genetic,O
analyses,O
and,O
statistical,O
tests,O
Determination,O
of,O
ARU,B-GP
gene,O
structure,O
and,O
UTRs,O
is,O
based,O
on,O
annotations,O
in,O
the,O
ARAMEMNON,O
database37,O
.,O
Sequences,O
of,O
ARU,B-GP
and,O
1,O
",",O
000,O
bp,O
up,O
-,O
and,O
downstream,O
flanking,O
regions,O
were,O
downloaded,O
from,O
http,O
://,O
signal,O
.,O
salk,O
.,O
edu,O
/,O
atg1001,O
/,O
3,O
.,O
0,O
/,O
gebrowser,O
.,O
php,O
.,O
For,O
accessions,O
for,O
which,O
no,O
sequences,O
or,O
only,O
sequences,O
with,O
missing,O
data,O
were,O
available,O
",",O
we,O
amplified,O
the,O
whole,O
region,O
from,O
genomic,O
DNA,O
using,O
primers,O
5,O
′-,O
TTTGCTATAGGCACATGTGT,O
-,O
3,O
′,O
and,O
5,O
′-,O
GACCCGAAATTGTCAAATGA,O
-,O
3,O
"′,",O
and,O
sequenced,O
the,O
resulting,O
PCR,O
products,O
of,O
Bay,O
-,O
0,O
",",O
Fab,O
-,O
2,O
",",O
Fab,O
-,O
4,O
",",O
Omo,O
-,O
2,O
-,O
3,O
",",O
Knox,O
-,O
10,O
",",O
Kz,O
-,O
1,O
",",O
LL,O
-,O
0,O
",",O
Lz,O
-,O
0,O
",",O
Mr,O
-,O
0,O
",",O
Mrk,O
-,O
0,O
",",O
Zdr,O
-,O
6,O
.,O
The,O
upstream,O
region,O
was,O
sequenced,O
additionally,O
from,O
Got,O
-,O
7,O
",",O
Pu2,O
-,O
23,O
",",O
and,O
Spr1,O
-,O
6,O
(,O
primer,O
5,O
′-,O
TTTGCTATAGGCACATGTGT,O
-,O
3,O
′,O
and,O
5,O
′-,O
CGGAGGTTAGGAATTTTGAGA,O
-,O
3,O
"′),",O
and,O
the,O
downstream,O
region,O
from,O
Got,O
-,O
7,O
",",O
Pu2,O
-,O
23,O
",",O
Kz,O
-,O
9,O
",",O
Mz,O
-,O
0,O
",",O
Pro,O
-,O
0,O
",",O
Van,O
-,O
0,O
",",O
and,O
Var2,O
-,O
1,O
(,O
primer,O
5,O
′-,O
CAATGTGCTTGTTCGAGTG,O
-,O
3,O
′,O
and,O
5,O
′-,O
GACCCGAAATTGTCAAATGA,O
-,O
3,O
′).,O
Tajima,O
',O
s,O
D,O
and,O
Fay,O
and,O
Wu,O
',O
s,O
H,O
were,O
calculated,O
separately,O
for,O
the,O
1,O
",",O
000,O
bp,O
up,O
-,O
and,O
downstream,O
as,O
well,O
as,O
the,O
coding,O
sequence,O
with,O
the,O
set,O
of,O
96,O
accessions40,O
using,O
DnaSP,O
5,O
.,O
10,O
(,O
ref,O
.,O
59,O
).,O
Several,O
accessions,O
that,O
had,O
big,O
indels,O
in,O
the,O
up,O
-,O
and,O
downstream,O
regions,O
were,O
left,O
out,O
from,O
the,O
analysis,O
(,O
Mr,O
-,O
0,O
",",O
Got,O
-,O
7,O
",",O
Pu2,O
-,O
23,O
",",O
and,O
Spr1,O
-,O
6,O
for,O
the,O
upstream,O
",",O
Var2,O
-,O
1,O
",",O
Nok,O
-,O
3,O
",",O
and,O
Got,O
-,O
7,O
for,O
the,O
downstream,O
region,O
).,O
A,B-OG
.,I-OG
lyrata,I-OG
was,O
used,O
as,O
outgroup,O
.,O
P,O
values,O
against,O
the,O
,O
model,O
were,O
obtained,O
by,O
running,O
10,O
",",O
000,O
coalescent,O
simulations,O
and,O
for,O
Tajima,O
',O
s,O
D,O
",",O
the,O
5,O
%,O
quantile,O
was,O
calculated,O
using,O
previously,O
published,O
estimates,O
for,O
D40,O
.,O
Additional,O
information,O
How,O
to,O
cite,O
this,O
article,O
:,O
Müller,O
",",O
L,O
.,O
M,O
.,O
et,O
al,O
.,O
A,O
subunit,O
of,O
the,O
oligosaccharyltransferase,B-GP
complex,O
is,O
required,O
for,O
interspecific,O
gametophyte,O
recognition,O
in,O
Arabidopsis,B-OG
.,O
Nat,O
.,O
Commun,O
.,O
7,O
:,O
10826,O
doi,O
:,O
10,O
.,O
1038,O
/,O
ncomms10826,O
(,O
2016,O
).,O
Supplementary,O
Material,O
Supplementary,O
Information,O
Supplementary,O
Figures,O
1,O
-,O
10,O
",",O
Supplementary,O
Tables,O
1,O
-,O
2,O
and,O
Supplementary,O
References,O
Supplementary,O
Data,O
1,O
Correlation,O
of,O
SNPs,O
(,O
1000,O
bp,O
downstream,O
region,O
),O
with,O
OG,O
/,O
S,O
phenotype,O
of,O
accessions,O
Author,O
contributions,O
U,O
.,O
G,O
.,O
initiated,O
and,O
supervised,O
the,O
project,O
.,O
L,O
.,O
M,O
.,O
M,O
.,O
and,O
U,O
.,O
G,O
.,O
conceived,O
the,O
experiments,O
and,O
wrote,O
the,O
manuscript,O
;,O
H,O
.,O
L,O
.,O
and,O
N,O
.,O
D,O
.,O
P,O
.,O
critically,O
read,O
and,O
commented,O
on,O
the,O
manuscript,O
;,O
L,O
.,O
M,O
.,O
M,O
".,",O
H,O
.,O
L,O
".,",O
N,O
.,O
D,O
.,O
P,O
".,",O
and,O
V,O
.,O
G,O
.,O
performed,O
the,O
experiments,O
.,O
All,O
the,O
authors,O
were,O
involved,O
in,O
data,O
analysis,O
and,O
interpretation,O
.,O
(,O
a,O
),O
Diagram,O
of,O
the,O
female,O
gametophyte,O
with,O
its,O
cell,O
types,O
.,O
The,O
synergids,O
with,O
their,O
membrane,O
-,O
rich,O
filiform,O
apparatus,O
are,O
crucial,O
for,O
communication,O
with,O
the,O
arriving,O
PT,O
.,O
(,O
b,O
),O
Ovule,O
with,O
normal,O
PT,O
reception,O
",",O
visualized,O
by,O
callose,O
staining,O
of,O
the,O
PT,O
cell,O
walls,O
with,O
Aniline,O
Blue,O
.,O
The,O
PT,O
stopped,O
its,O
growth,O
and,O
ruptured,O
.,O
Dashed,O
line,O
indicates,O
outline,O
of,O
the,O
ovule,O
.,O
(,O
c,O
),O
Ovule,O
with,O
PT,O
overgrowth,O
.,O
The,O
PT,O
continues,O
growing,O
inside,O
the,O
female,O
gametophyte,O
.,O
Dashed,O
line,O
indicates,O
outline,O
of,O
the,O
ovule,O
.,O
(,O
d,O
),O
Natural,O
variation,O
in,O
the,O
proportion,O
of,O
ovules,O
with,O
PT,O
overgrowth,O
per,O
silique,O
(,O
OG,O
/,O
S,O
),O
in,O
86,O
A,O
.,O
thaliana,O
accessions,O
that,O
were,O
pollinated,O
with,O
A,O
.,O
lyrata,O
pollen,O
.,O
OG,O
/,O
S,O
varies,O
between,O
10,O
%,O
and,O
more,O
than,O
90,O
"%,",O
depending,O
on,O
the,O
genotype,O
of,O
the,O
mother,O
.,O
(,O
e,O
),O
A,O
silique,O
of,O
Lz,O
-,O
0,O
pollinated,O
with,O
A,O
.,O
lyrata,O
pollen,O
.,O
Most,O
of,O
the,O
ovules,O
show,O
normal,O
PT,O
reception,O
.,O
Ovules,O
with,O
PT,O
overgrowth,O
are,O
marked,O
with,O
an,O
arrowhead,O
.,O
(,O
f,O
),O
A,O
silique,O
of,O
Kz,O
-,O
9,O
pollinated,O
with,O
A,O
.,O
lyrata,O
pollen,O
.,O
Most,O
of,O
the,O
ovules,O
display,O
PT,O
overgrowth,O
.,O
Asterisks,O
mark,O
ovules,O
with,O
normal,O
PT,O
reception,O
.,O
Per,O
accession,O
and,O
per,O
pollen,O
donor,O
",",O
5,O
–,O
10,O
siliques,O
were,O
analysed,O
.,O
Scale,O
bars,O
",",O
50,O
μm,O
(,O
b,O
and,O
c,O
"),",O
250,O
μm,O
(,O
e,O
and,O
f,O
).,O
(,O
a,O
),O
A,O
subset,O
of,O
A,O
.,O
thaliana,O
accessions,O
pollinated,O
with,O
A,O
.,O
lyrata,O
pollen,O
.,O
Per,O
accession,O
",",O
four,O
to,O
eight,O
siliques,O
were,O
analysed,O
.,O
Box,O
plots,O
are,O
ordered,O
by,O
the,O
mean,O
OG,O
/,O
S,O
value,O
and,O
colour,O
-,O
coded,O
to,O
facilitate,O
comparison,O
with,O
b,O
and,O
c,O
.,O
(,O
b,O
",",O
c,O
),O
The,O
same,O
subset,O
pollinated,O
with,O
pollen,O
from,O
A,O
.,O
halleri,O
(,O
b,O
),O
and,O
A,O
.,O
arenosa,O
(,O
c,O
).,O
The,O
accessions,O
show,O
comparable,O
OG,O
/,O
S,O
with,O
all,O
three,O
interspecific,O
pollen,O
donors,O
.,O
(,O
a,O
),O
Manhattan,O
plot,O
showing,O
a,O
peak,O
on,O
chromosome,O
1,O
(,O
grey,O
box,O
),O
with,O
its,O
highest,O
correlated,O
SNP,O
showing,O
significance,O
at,O
P,O
<,O
0,O
.,O
1,O
(,O
after,O
Bonferroni,O
correction,O
;,O
dotted,O
line,O
).,O
The,O
peak,O
corresponds,O
to,O
a,O
28,O
kb,O
region,O
spanning,O
position,O
22,O
",",O
842,O
",",O
689,O
–,O
22,O
",",O
814,O
",",O
316,O
(,O
magnified,O
in,O
the,O
second,O
panel,O
).,O
The,O
eight,O
SNPs,O
that,O
were,O
identified,O
to,O
be,O
among,O
the,O
20,O
most,O
highly,O
correlated,O
ones,O
in,O
the,O
GWAS,O
are,O
annotated,O
with,O
their,O
PERL,O
identifiers,O
.,O
(,O
b,O
),O
Genes,O
and,O
pseudogenes,O
(,O
grey,O
),O
in,O
the,O
28,O
kb,O
region,O
.,O
Genes,O
expressed,O
in,O
synergids,O
are,O
marked,O
in,O
red,O
",",O
genes,O
without,O
available,O
expression,O
data,O
are,O
in,O
orange32,O
.,O
(,O
a,O
),O
Genomic,O
region,O
of,O
ARTUMES,O
(,O
At1g61790,O
),O
with,O
the,O
two,O
mutant,O
alleles,O
aru,O
-,O
1,O
and,O
aru,O
-,O
2,O
",",O
and,O
the,O
surrounding,O
polymorphisms,O
identified,O
by,O
GWAS,O
.,O
(,O
b,O
),O
PT,O
overgrowth,O
of,O
Col,O
-,O
0,O
wild,O
-,O
type,O
(,O
n,O
=,O
28,O
siliques,O
),O
and,O
aru,O
mutant,O
plants,O
in,O
interspecific,O
crosses,O
.,O
Both,O
aru,O
mutant,O
alleles,O
show,O
significantly,O
higher,O
proportions,O
of,O
ovules,O
with,O
PT,O
overgrowth,O
per,O
silique,O
(,O
OG,O
/,O
S,O
",",O
Student,O
',O
s,O
t,O
-,O
test,O
***,O
P,O
<,O
0,O
.,O
001,O
;,O
n,O
=,O
18,O
and,O
20,O
siliques,O
",",O
respectively,O
).,O
(,O
c,O
),O
PT,O
overgrowth,O
of,O
aru,O
-,O
1,O
in,O
inter,O
-,O
and,O
intraspecific,O
crosses,O
.,O
The,O
mutant,O
is,O
impaired,O
in,O
interspecific,O
crosses,O
with,O
A,O
.,O
lyrata,O
pollen,O
(,O
n,O
=,O
9,O
siliques,O
"),",O
but,O
not,O
in,O
intraspecific,O
crosses,O
with,O
Col,O
-,O
0,O
(,O
n,O
=,O
6,O
),O
or,O
self,O
pollen,O
(,O
n,O
=,O
9,O
).,O
(,O
d,O
),O
A,O
silique,O
of,O
Col,O
-,O
0,O
pollinated,O
with,O
A,O
.,O
lyrata,O
pollen,O
.,O
Ovules,O
with,O
normal,O
PT,O
reception,O
(,O
marked,O
with,O
asterisks,O
),O
and,O
with,O
PT,O
overgrowth,O
are,O
visible,O
.,O
(,O
e,O
",",O
f,O
),O
aru,O
-,O
1,O
and,O
aru,O
-,O
2,O
siliques,O
pollinated,O
with,O
A,O
.,O
lyrata,O
pollen,O
.,O
Both,O
mutant,O
alleles,O
show,O
high,O
proportions,O
of,O
ovules,O
with,O
PT,O
overgrowth,O
in,O
interspecific,O
crosses,O
.,O
Ovules,O
with,O
normal,O
PT,O
reception,O
are,O
marked,O
with,O
asterisks,O
.,O
(,O
g,O
),O
A,O
silique,O
of,O
aru,O
-,O
1,O
pollinated,O
with,O
intraspecific,O
Col,O
-,O
0,O
pollen,O
.,O
All,O
ovules,O
display,O
normal,O
PT,O
reception,O
.,O
Scale,O
bars,O
",",O
250,O
μm,O
.,O
(,O
a,O
),O
An,O
ovule,O
expressing,O
pMYB98,O
::,O
ARU,O
-,O
GFP,O
in,O
the,O
synergids,O
.,O
Inset,O
:,O
ARU,O
-,O
GFP,O
localizes,O
to,O
perinuclear,O
structures,O
resembling,O
the,O
ER,O
.,O
(,O
b,O
),O
PT,O
overgrowth,O
in,O
interspecific,O
crosses,O
using,O
aru,O
-,O
1,O
(,O
n,O
=,O
22,O
siliques,O
"),",O
Col,O
-,O
0,O
(,O
n,O
=,O
28,O
"),",O
and,O
three,O
independent,O
transformant,O
lines,O
of,O
pMYB98,O
::,O
ARU,O
-,O
GFP,O
in,O
the,O
aru,O
-,O
1,O
background,O
as,O
mother,O
plants,O
and,O
A,O
.,O
lyrata,O
as,O
pollen,O
donor,O
.,O
All,O
the,O
three,O
transformant,O
lines,O
complement,O
the,O
mutant,O
phenotype,O
(,O
n,O
=,O
16,O
",",O
22,O
",",O
and,O
27,O
siliques,O
",",O
respectively,O
);,O
line,O
2,O
shows,O
even,O
lower,O
OG,O
/,O
S,O
than,O
the,O
wild,O
type,O
.,O
Significance,O
levels,O
in,O
comparison,O
with,O
Col,O
-,O
0,O
(,O
Student,O
',O
s,O
t,O
-,O
test,O
***,O
P,O
<,O
0,O
.,O
001,O
).,O
Scale,O
bar,O
",",O
50,O
μm,O
.,O
(,O
a,O
),O
In,O
wild,O
-,O
type,O
Col,O
-,O
0,O
synergid,O
cells,O
",",O
a,O
receptor,O
is,O
glycosylated,O
by,O
ARU,O
and,O
can,O
bind,O
putative,O
signals,O
from,O
the,O
A,O
.,O
thaliana,O
PT,O
with,O
its,O
carbohydrate,O
moieties,O
and,O
via,O
protein,O
–,O
protein,O
interactions,O
.,O
(,O
b,O
),O
A,O
.,O
lyrata,O
PT,O
signals,O
might,O
not,O
be,O
properly,O
recognized,O
by,O
protein,O
–,O
protein,O
contacts,O
but,O
partially,O
by,O
carbohydrate,O
interactions,O
",",O
thus,O
leading,O
to,O
PT,O
overgrowth,O
in,O
some,O
ovules,O
and,O
normal,O
PT,O
reception,O
in,O
others,O
.,O
(,O
c,O
),O
In,O
aru,O
mutants,O
",",O
the,O
synergid,O
receptor,O
is,O
un,O
-,O
or,O
misglycosylated,O
;,O
nevertheless,O
",",O
A,O
.,O
thaliana,O
PTs,O
can,O
be,O
efficiently,O
received,O
through,O
protein,O
–,O
protein,O
interactions,O
of,O
the,O
receptor,O
with,O
the,O
PT,O
signals,O
.,O
(,O
d,O
),O
In,O
aru,O
mutants,O
pollinated,O
with,O
A,O
.,O
lyrata,O
pollen,O
",",O
PT,O
reception,O
is,O
neither,O
possible,O
by,O
carbohydrate,O
",",O
nor,O
by,O
protein,O
–,O
protein,O
interactions,O
.,O
Therefore,O
",",O
almost,O
all,O
ovules,O
show,O
PT,O
overgrowth,O
.,O
Activation,O
of,O
mesenchymal,O
stem,O
cells,O
by,O
macrophages,O
promotes,O
tumor,B-DS
progression,O
through,O
immune,O
suppressive,O
effects,O
Cancer,B-DS
development,O
and,O
progression,O
is,O
linked,O
to,O
tumor,B-DS
-,O
associated,O
macrophages,O
(,O
TAMs,O
).,O
Distinct,O
TAMs,O
subsets,O
perform,O
either,O
protective,O
or,O
pathogenic,O
effects,O
in,O
cancer,B-DS
.,O
A,O
protective,O
role,O
in,O
carcinogenesis,O
has,O
been,O
described,O
for,O
M1,O
macrophages,O
",",O
which,O
activate,O
antitumor,O
mechanisms,O
.,O
By,O
comparison,O
",",O
TAMs,O
isolated,O
from,O
solid,O
and,O
metastatic,B-DS
tumors,I-DS
have,O
a,O
suppressive,O
M2,O
-,O
like,O
phenotype,O
",",O
which,O
could,O
support,O
multiple,O
aspects,O
of,O
tumor,B-DS
progression,O
.,O
Currently,O
",",O
it,O
has,O
not,O
been,O
clearly,O
understood,O
how,O
macrophages,O
in,O
tumor,B-DS
-,O
associated,O
stroma,O
could,O
be,O
hijacked,O
to,O
support,O
tumor,B-DS
growth,O
.,O
Mesenchymal,O
stem,O
cells,O
(,O
MSCs,O
),O
actively,O
interact,O
with,O
components,O
of,O
the,O
innate,O
immune,O
system,O
and,O
display,O
both,O
anti,O
-,O
inflammatory,O
and,O
pro,O
-,O
inflammatory,O
effects,O
.,O
Here,O
",",O
we,O
tested,O
whether,O
MSCs,O
could,O
favor,O
the,O
tumor,B-DS
to,O
escape,O
from,O
immunologic,O
surveillance,O
in,O
the,O
presence,O
of,O
M1,O
macrophages,O
.,O
We,O
found,O
that,O
MSCs,O
educated,O
by,O
M1,O
condition,O
medium,O
(,O
cMSCs,O
),O
possessed,O
a,O
greatly,O
enhanced,O
ability,O
in,O
promoting,O
tumor,B-DS
growth,O
in,O
vivo,O
.,O
Examination,O
of,O
cytokines,B-GP
/,O
chemokines,B-GP
showed,O
that,O
the,O
cMSCs,O
acquired,O
a,O
regulatory,O
profile,O
",",O
which,O
expressed,O
high,O
levels,O
of,O
iNOS,B-GP
and,O
MCP1,B-GP
.,O
Consistent,O
with,O
an,O
elevated,O
MCP1,B-GP
expression,O
in,O
cMSCs,O
",",O
the,O
tumor,B-DS
-,O
promoting,O
effect,O
of,O
the,O
cMSCs,O
depended,O
on,O
MCP1,B-GP
mediated,O
macrophage,O
recruitment,O
to,O
tumor,B-DS
sites,O
.,O
Furthermore,O
",",O
IL,B-GP
-,I-GP
6,I-GP
secreted,O
by,O
the,O
cMSCs,O
could,O
polarize,O
infiltrated,O
TAMs,O
into,O
M2,O
-,O
like,O
macrophages,O
.,O
Therefore,O
",",O
when,O
macrophages,O
changed,O
into,O
M1,O
pro,O
-,O
inflammation,O
type,O
in,O
tumor,B-DS
microenvironment,O
",",O
the,O
MSCs,O
would,O
act,O
as,O
poor,O
sensors,O
and,O
switchers,O
to,O
accelerate,O
tumor,B-DS
growth,O
.,O
INTRODUCTION,O
Cancers,B-DS
develop,O
in,O
complex,O
tumor,B-DS
microenvironments,O
",",O
which,O
include,O
cells,O
such,O
as,O
endothelial,O
cells,O
",",O
immune,O
cells,O
",",O
tumor,B-DS
-,O
associated,O
macrophages,O
(,O
TAMs,O
"),",O
and,O
mesenchymal,O
stem,O
cells,O
(,O
MSCs,O
),O
[,O
1,O
].,O
Non,O
-,O
cancerous,O
stromal,O
cells,O
have,O
different,O
capabilities,O
to,O
induce,O
both,O
tumor,B-DS
-,O
promoting,O
and,O
tumor,B-DS
-,O
antagonizing,O
effects,O
[,O
2,O
].,O
The,O
contradictory,O
phenomenon,O
brings,O
us,O
a,O
problem,O
how,O
the,O
tumor,B-DS
-,O
associated,O
stroma,O
at,O
the,O
primary,O
sites,O
is,O
hijacked,O
to,O
support,O
tumor,B-DS
growth,O
.,O
The,O
key,O
mechanisms,O
may,O
focus,O
on,O
the,O
role,O
of,O
macrophages,O
",",O
immune,O
suppressor,O
cells,O
",",O
MSCs,O
",",O
the,O
vasculature,O
and,O
various,O
other,O
components,O
of,O
a,O
tumor,B-DS
-,O
supportive,O
microenvironment,O
.,O
Macrophages,O
are,O
resident,O
phagocytic,O
cells,O
in,O
tissues,O
",",O
which,O
play,O
important,O
roles,O
in,O
steady,O
-,O
state,O
tissue,O
homoeostasis,O
by,O
removing,O
cellular,O
debris,O
and,O
apoptotic,O
cells,O
.,O
Although,O
macrophages,O
are,O
classically,O
regarded,O
as,O
key,O
effector,O
cells,O
during,O
immune,O
defense,O
",",O
numerous,O
studies,O
have,O
demonstrated,O
a,O
clear,O
role,O
for,O
TAMs,O
in,O
supporting,O
various,O
aspects,O
of,O
tumor,B-DS
development,O
[,O
3,O
].,O
An,O
explanation,O
for,O
the,O
disparate,O
roles,O
of,O
macrophages,O
during,O
normal,O
tissue,O
homeostasis,O
and,O
carcinogenesis,O
lies,O
in,O
their,O
phenotype,O
[,O
4,O
].,O
At,O
the,O
extremes,O
of,O
their,O
phenotypic,O
continuum,O
",",O
macrophages,O
range,O
from,O
an,O
M1,O
to,O
M2,O
polarization,O
status,O
:,O
classically,O
activated,O
M1,O
macrophages,O
have,O
an,O
anti,O
-,O
tumorigenic,O
role,O
;,O
on,O
the,O
other,O
hand,O
",",O
alternatively,O
activated,O
M2,O
macrophages,O
promote,O
anti,O
-,O
inflammatory,O
responses,O
and,O
have,O
pro,O
-,O
tumorigenic,O
functions,O
.,O
Currently,O
",",O
we,O
do,O
not,O
fully,O
understand,O
how,O
macrophages,O
initially,O
switch,O
from,O
being,O
anti,O
-,O
tumor,B-DS
to,O
pro,O
-,O
tumorigenic,O
at,O
the,O
onset,O
of,O
disease,O
[,O
5,O
].,O
MSCs,O
are,O
one,O
of,O
the,O
major,O
components,O
of,O
the,O
tumor,B-DS
stroma,O
and,O
there,O
is,O
a,O
close,O
interaction,O
between,O
MSCs,O
and,O
the,O
immune,O
system,O
[,O
6,O
–,O
9,O
].,O
MSCs,O
have,O
been,O
shown,O
to,O
interact,O
with,O
a,O
variety,O
of,O
adaptive,O
immune,O
cells,O
including,O
T,O
cells,O
",",O
B,O
cells,O
and,O
dendritic,O
cells,O
[,O
10,O
].,O
Recently,O
",",O
it,O
was,O
demonstrated,O
that,O
the,O
MSCs,O
actively,O
interacted,O
with,O
components,O
of,O
the,O
innate,O
immune,O
system,O
and,O
that,O
through,O
these,O
interactions,O
",",O
they,O
displayed,O
both,O
anti,O
-,O
inflammatory,O
and,O
pro,O
-,O
inflammatory,O
effects,O
[,O
11,O
",",O
12,O
].,O
Within,O
the,O
innate,O
immune,O
system,O
",",O
it,O
was,O
well,O
established,O
that,O
macrophages,O
were,O
key,O
players,O
in,O
initiating,O
and,O
controlling,O
inflammation,O
and,O
the,O
MSCs,O
could,O
influence,O
macrophage,O
functions,O
[,O
13,O
",",O
14,O
].,O
In,O
a,O
tumor,B-DS
microenvironment,O
",",O
the,O
MSCs,O
are,O
often,O
constantly,O
exposed,O
to,O
immune,O
cells,O
and,O
inflammatory,O
cytokines,B-GP
/,O
chemokines,B-GP
.,O
They,O
may,O
have,O
acquired,O
functions,O
that,O
are,O
distinct,O
from,O
those,O
of,O
normal,O
MSCs,O
[,O
15,O
].,O
The,O
unique,O
features,O
may,O
play,O
a,O
role,O
in,O
regulating,O
the,O
tumor,B-DS
microenvironment,O
and,O
ultimately,O
affecting,O
tumor,B-DS
progression,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
whether,O
the,O
MSCs,O
could,O
favor,O
a,O
tumor,B-DS
to,O
escape,O
from,O
immunologic,O
surveillance,O
in,O
an,O
environment,O
of,O
M1,O
macrophages,O
.,O
To,O
assess,O
the,O
possible,O
effects,O
of,O
M1,O
macrophages,O
on,O
the,O
MSCs,O
in,O
tumor,B-DS
growth,O
",",O
we,O
treated,O
MSCs,O
with,O
condition,O
medium,O
derived,O
from,O
M1,O
macrophages,O
(,O
cMSCs,O
"),",O
characterized,O
by,O
their,O
tumor,B-DS
-,O
promoting,O
activity,O
and,O
phenotype,O
",",O
and,O
studied,O
the,O
mechanism,O
of,O
the,O
cMSCs,O
in,O
affecting,O
tumor,B-DS
growth,O
in,O
comparison,O
to,O
normal,O
MSCs,O
.,O
We,O
found,O
that,O
M1,O
macrophages,O
could,O
activate,O
the,O
MSCs,O
to,O
adopt,O
a,O
regulatory,O
phenotype,O
",",O
and,O
the,O
cMSCs,O
promoted,O
tumor,B-DS
growth,O
by,O
iNOS,B-GP
and,O
MCP1,B-GP
.,O
Therefore,O
",",O
this,O
study,O
revealed,O
that,O
the,O
MSCs,O
sensed,O
and,O
controlled,O
inflammation,O
to,O
promote,O
tumor,B-DS
growth,O
in,O
a,O
pro,O
-,O
inflammatory,O
environment,O
.,O
RESULTS,O
cMSCs,O
had,O
more,O
potential,O
than,O
untreated,O
-,O
MSCs,O
to,O
promote,O
tumor,B-DS
growth,O
Macrophage,O
cell,O
-,O
line,O
RAW264,O
.,O
7,O
cell,O
exposure,O
to,O
IFN,B-GP
-,I-GP
γ,I-GP
and,O
LPS,O
drive,O
M1,O
polarization,O
with,O
potentiated,O
cytotoxic,O
and,O
antitumoral,O
properties,O
.,O
To,O
confirm,O
the,O
M1,O
macrophage,O
phenotype,O
",",O
the,O
expression,O
of,O
iNOS,B-GP
(,O
M1,O
macrophage,O
marker,O
),O
examined,O
by,O
a,O
FACS,O
analysis,O
clearly,O
increased,O
",",O
while,O
the,O
expression,O
of,O
CD11b,B-GP
(,O
macrophage,O
marker,O
),O
remained,O
unchanged,O
(,O
Figure,O
S1A,O
).,O
Macrophage,O
M1,O
polarization,O
was,O
also,O
assessed,O
at,O
the,O
mRNA,O
level,O
using,O
real,O
-,O
time,O
PCR,O
by,O
measuring,O
the,O
expression,O
of,O
several,O
classical,O
M1,O
markers,O
:,O
TNFα,B-GP
",",O
IL,B-GP
-,I-GP
1β,I-GP
",",O
and,O
iNOS,B-GP
.,O
An,O
increased,O
IL,B-GP
-,I-GP
1β,I-GP
and,O
iNOS,B-GP
expression,O
profile,O
was,O
obtained,O
by,O
incubation,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
and,O
LPS,O
.,O
We,O
also,O
checked,O
the,O
expression,O
at,O
the,O
mRNA,O
level,O
of,O
several,O
M2,O
markers,O
(,O
IL,B-GP
-,I-GP
10,I-GP
",",O
Arg,B-GP
-,I-GP
1,I-GP
and,O
FIZZ,B-GP
-,I-GP
1,I-GP
),O
in,O
M1,O
macrophages,O
",",O
but,O
in,O
our,O
conditions,O
",",O
we,O
observed,O
no,O
significant,O
expression,O
of,O
these,O
genes,O
.,O
In,O
addition,O
",",O
the,O
mRNA,O
abundance,O
of,O
signal,B-GP
regulatory,I-GP
protein,I-GP
-,I-GP
a,I-GP
(,O
SIRPα,B-GP
),O
was,O
significantly,O
reduced,O
(,O
Figure,O
S1A,O
).,O
SIRPα,B-GP
is,O
a,O
membrane,B-GP
receptor,I-GP
expressed,O
by,O
macrophages,O
.,O
The,O
interactions,O
of,O
CD47,B-GP
-,O
SIRPα,B-GP
form,O
a,O
barrier,O
for,O
antibody,O
-,O
mediated,O
tumor,B-DS
cell,O
destruction,O
[,O
16,O
].,O
In,O
order,O
to,O
study,O
the,O
effects,O
of,O
M1,O
macrophages,O
on,O
cancer,B-DS
cell,O
response,O
in,O
vivo,O
",",O
prior,O
to,O
implantation,O
of,O
M1,O
macrophages,O
",",O
breast,B-DS
cancer,I-DS
models,O
with,O
MDA,O
-,O
MB,O
-,O
231,O
-,O
FLUC,O
cells,O
were,O
set,O
up,O
.,O
Two,O
hours,O
after,O
M1,O
macrophages,O
had,O
been,O
injected,O
into,O
tumor,B-DS
sites,O
",",O
we,O
found,O
that,O
M1,O
macrophages,O
exhibited,O
radical,O
scavenging,O
potential,O
since,O
the,O
amount,O
of,O
tumor,B-DS
cells,O
remaining,O
was,O
10,O
%,O
compared,O
to,O
the,O
control,O
group,O
(,O
Figure,O
S1B,O
).,O
Therefore,O
",",O
incubation,O
of,O
macrophages,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
and,O
LPS,O
induces,O
their,O
polarization,O
into,O
M1,O
macrophages,O
",",O
and,O
M1,O
-,O
polarized,O
macrophages,O
have,O
strong,O
antitumor,O
activity,O
to,O
elicit,O
tumor,B-DS
disruption,O
.,O
To,O
investigate,O
the,O
characterization,O
of,O
the,O
cMSCs,O
",",O
MSCs,O
were,O
isolated,O
from,O
murine,B-OG
bone,O
marrow,O
.,O
The,O
morphology,O
of,O
the,O
mouse,B-OG
MSCs,O
displayed,O
a,O
homogenous,O
spindle,O
-,O
shaped,O
population,O
.,O
FACS,O
was,O
used,O
to,O
identify,O
the,O
surface,O
marker,O
expression,O
of,O
the,O
MSCs,O
.,O
High,O
expression,O
of,O
CD29,B-GP
",",O
CD73,B-GP
",",O
CD90,B-GP
and,O
CD105,B-GP
was,O
observed,O
",",O
but,O
CD34,B-GP
and,O
CD45,B-GP
were,O
down,O
-,O
regulated,O
(,O
data,O
not,O
shown,O
).,O
MSC,O
were,O
stimulated,O
by,O
the,O
medium,O
from,O
M1,O
macrophages,O
for,O
24,O
hours,O
to,O
achieve,O
the,O
cMSCs,O
.,O
To,O
determine,O
whether,O
the,O
cMSCs,O
could,O
promote,O
human,B-OG
tumor,B-DS
growth,O
",",O
we,O
injected,O
the,O
cMSCs,O
into,O
immune,O
deficient,O
mice,B-OG
with,O
human,B-OG
carcinoma,B-DS
cells,O
",",O
while,O
untreated,O
MSCs,O
were,O
used,O
as,O
controls,O
.,O
When,O
co,O
-,O
injected,O
with,O
MDA,O
-,O
MB,O
-,O
231,O
-,O
FLUC,O
breast,B-DS
cancer,I-DS
cells,O
",",O
the,O
cMSCs,O
but,O
not,O
the,O
untreated,O
MSC,O
remarkably,O
increased,O
the,O
tumor,B-DS
-,O
initiating,O
ability,O
and,O
tumor,B-DS
growth,O
(,O
Figure,O
1A,O
",",O
1D,O
).,O
We,O
also,O
tested,O
the,O
effect,O
of,O
the,O
cMSCs,O
on,O
hepatocellular,O
HCC,O
-,O
LM3,O
-,O
FLUC,O
tumor,B-DS
growth,O
in,O
vivo,O
.,O
Similar,O
to,O
the,O
breast,B-DS
cancer,I-DS
model,O
",",O
the,O
cMSCs,O
caused,O
a,O
tumor,B-DS
-,O
promoting,O
effect,O
in,O
the,O
hepatocellular,B-DS
carcinoma,I-DS
model,O
as,O
compared,O
to,O
the,O
untreated,O
control,O
MSCs,O
group,O
(,O
Figure,O
1B,O
",",O
1E,O
).,O
The,O
cMSCs,O
also,O
led,O
to,O
a,O
significant,O
tumor,B-DS
promotion,O
of,O
malignant,B-DS
glioblastoma,I-DS
U87MG,O
-,O
FLUC,O
cells,O
(,O
Figure,O
1C,O
",",O
1F,O
).,O
Furthermore,O
",",O
after,O
the,O
cMSCs,O
were,O
co,O
-,O
injected,O
with,O
murine,B-OG
4T1,O
-,O
FLUC,O
cells,O
into,O
a,O
fat,O
pad,O
of,O
normal,O
mice,B-OG
",",O
the,O
cMSCs,O
were,O
more,O
effective,O
than,O
the,O
control,O
MSCs,O
in,O
promoting,O
tumor,B-DS
growth,O
(,O
data,O
not,O
shown,O
).,O
Therefore,O
",",O
the,O
cMSCs,O
displayed,O
greater,O
potential,O
to,O
promote,O
tumor,B-DS
growth,O
in,O
comparison,O
to,O
the,O
untreated,O
MSCs,O
.,O
cMSCs,O
promoted,O
tumor,B-DS
growth,O
in,O
vivo,O
to,O
a,O
greater,O
extent,O
than,O
untreated,O
-,O
MSCs,O
(,O
A,O
–,O
C,O
),O
D,O
-,O
Luciferin,O
induced,O
bioluminescence,O
obtained,O
in,O
breast,O
(,O
A,O
"),",O
liver,O
(,O
B,O
"),",O
and,O
brain,O
(,O
C,O
),O
cancer,B-DS
mice,B-OG
co,O
-,O
injected,O
with,O
cMSCs,O
",",O
MSCs,O
or,O
PBS,O
.,O
cMSCs,O
-,O
treated,O
mice,B-OG
displayed,O
a,O
significant,O
increase,O
in,O
tumor,B-DS
growth,O
.,O
(,O
D,O
–,O
F,O
),O
Quantification,O
of,O
the,O
bioluminescent,O
signal,O
in,O
corresponding,O
breast,O
(,O
D,O
"),",O
liver,O
(,O
E,O
"),",O
and,O
brain,O
(,O
F,O
),O
tumors,B-DS
after,O
treatments,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
.,O
MSCs,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
05,O
vs,O
.,O
PBS,O
group,O
.,O
Stimulated,O
by,O
M1,O
medium,O
altering,O
the,O
cytokine,B-GP
/,O
chemokine,B-GP
expression,O
in,O
the,O
cMSCs,O
The,O
MSCs,O
affect,O
cancer,B-DS
progression,O
through,O
a,O
number,O
of,O
secreted,O
factors,O
triggering,O
activation,O
of,O
various,O
mechanisms,O
.,O
The,O
genetic,O
abnormalities,O
in,O
specific,O
genes,O
in,O
the,O
cMSCs,O
may,O
account,O
for,O
the,O
tumor,B-DS
-,O
promotion,O
activity,O
by,O
the,O
cMSCs,O
.,O
To,O
investigate,O
how,O
the,O
cMSCs,O
achieve,O
their,O
tumor,B-DS
-,O
promoting,O
effect,O
and,O
how,O
they,O
differ,O
from,O
untreated,O
MSCs,O
",",O
we,O
examined,O
the,O
gene,O
expression,O
profiling,O
of,O
the,O
cMSCs,O
.,O
Using,O
real,O
-,O
time,O
PCR,O
",",O
we,O
found,O
that,O
the,O
transcript,O
levels,O
of,O
iNOS,B-GP
",",O
MCP1,B-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
and,O
COX,B-GP
-,I-GP
2,I-GP
were,O
markedly,O
higher,O
in,O
the,O
cMSCs,O
than,O
in,O
untreated,O
MSCs,O
.,O
However,O
",",O
the,O
levels,O
of,O
CXCL9,B-GP
and,O
CXCL10,B-GP
were,O
lower,O
(,O
Figure,O
2A,O
).,O
A,O
previous,O
study,O
reported,O
a,O
new,O
MSCs,O
paradigm,O
by,O
specific,O
TLR,B-GP
-,O
priming,O
:,O
TLR4,B-GP
-,O
primed,O
MSC1,B-GP
and,O
TLR3,B-GP
-,O
primed,O
MSC2,B-GP
[,O
17,O
].,O
We,O
used,O
real,O
-,O
time,O
PCR,O
to,O
identify,O
additional,O
TLR,B-GP
genes,O
that,O
might,O
be,O
affected,O
",",O
and,O
found,O
that,O
TLR2,B-GP
",",O
TLR3,B-GP
",",O
and,O
TLR4,B-GP
were,O
induced,O
at,O
high,O
levels,O
in,O
the,O
cMSCs,O
compared,O
to,O
untreated,O
MSCs,O
.,O
Specifically,O
",",O
TLR3,B-GP
expression,O
was,O
increased,O
about,O
20,O
-,O
fold,O
after,O
M1,O
medium,O
treatment,O
(,O
Figure,O
2B,O
).,O
Furthermore,O
",",O
we,O
examined,O
the,O
chemotactic,O
potential,O
of,O
the,O
cMSCs,O
in,O
vitro,O
using,O
transwell,O
migration,O
assays,O
",",O
and,O
found,O
that,O
the,O
cMSCs,O
elicited,O
a,O
more,O
robust,O
migration,O
response,O
than,O
the,O
MSCs,O
(,O
Figure,O
2C,O
",",O
2D,O
).,O
Characterization,O
of,O
the,O
cMSCs,O
(,O
A,O
),O
The,O
effects,O
of,O
the,O
M1,O
-,O
conditioned,O
medium,O
on,O
the,O
activation,O
of,O
various,O
gene,O
expressions,O
in,O
the,O
MSCs,O
were,O
assessed,O
by,O
using,O
real,O
-,O
time,O
PCR,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
;,O
**,O
P,O
<,O
0,O
.,O
01,O
.,O
(,O
B,O
),O
The,O
expression,O
of,O
TLRs,B-GP
of,O
the,O
cMSCs,O
was,O
assessed,O
by,O
real,O
-,O
time,O
PCR,O
.,O
**,O
P,O
<,O
0,O
.,O
01,O
.,O
(,O
C,O
–,O
D,O
),O
The,O
migration,O
ability,O
of,O
the,O
cMSCs,O
was,O
evaluated,O
.,O
(,O
C,O
),O
Representative,O
images,O
of,O
the,O
MSCs,O
(,O
upper,O
),O
and,O
cMSCs,O
(,O
lower,O
),O
in,O
response,O
to,O
FBS,O
in,O
a,O
transwell,O
assay,O
.,O
Scale,O
bar,O
=,O
50,O
μm,O
.,O
(,O
D,O
),O
Average,O
number,O
of,O
migrated,O
cells,O
in,O
a,O
transwell,O
migration,O
assay,O
.,O
Results,O
are,O
mean,O
values,O
±,O
SEM,O
of,O
five,O
different,O
fields,O
from,O
four,O
independent,O
experiments,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
versus,O
MSCs,O
.,O
(,O
E,O
–,O
F,O
),O
Tumor,B-DS
-,O
associated,O
leukocytes,O
differ,O
among,O
the,O
cMSCs,O
and,O
MSCs,O
treated,O
groups,O
.,O
(,O
E,O
),O
Immunohistochemical,O
staining,O
for,O
CD45,B-GP
(,O
red,O
),O
and,O
DAPI,O
(,O
blue,O
),O
in,O
4T1,O
-,O
FLUC,O
breast,B-DS
tumors,I-DS
14,O
days,O
after,O
co,O
-,O
injection,O
.,O
Scale,O
bars,O
=,O
50,O
μm,O
.,O
(,O
F,O
),O
A,O
larger,O
number,O
of,O
CD45,B-GP
positive,O
bone,O
marrow,O
cells,O
were,O
stained,O
in,O
the,O
cMSCs,O
implantation,O
group,O
than,O
in,O
the,O
MSCs,O
and,O
the,O
PBS,O
injection,O
groups,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
.,O
MSCs,O
group,O
.,O
Abbreviations,O
:,O
HPF,O
",",O
high,O
-,O
power,O
field,O
.,O
Cancers,B-DS
develop,O
in,O
a,O
complex,O
tissue,O
environment,O
which,O
usually,O
contains,O
bone,O
marrow,O
derived,O
cells,O
.,O
We,O
employed,O
CD45,B-GP
+,O
to,O
identify,O
tumor,B-DS
-,O
associated,O
bone,O
marrow,O
cells,O
14,O
days,O
after,O
co,O
-,O
injection,O
with,O
4T1,O
-,O
FLUC,O
cells,O
and,O
cMSCs,O
or,O
untreated,O
MSCs,O
",",O
and,O
found,O
that,O
there,O
was,O
a,O
great,O
expansion,O
of,O
the,O
populations,O
of,O
CD45,B-GP
+,O
cells,O
in,O
tumors,B-DS
",",O
an,O
effect,O
that,O
was,O
dramatically,O
greater,O
with,O
the,O
cMSCs,O
than,O
untreated,O
MSCs,O
(,O
Figure,O
2E,O
",",O
2F,O
).,O
These,O
data,O
suggested,O
that,O
the,O
cMSCs,O
were,O
more,O
effective,O
than,O
the,O
untreated,O
MSCs,O
in,O
recruiting,O
CD45,B-GP
+,O
cells,O
to,O
tumor,B-DS
sites,O
.,O
In,O
view,O
of,O
the,O
immunosuppressive,O
ability,O
of,O
the,O
MSCs,O
",",O
we,O
examined,O
whether,O
cMSCs,O
have,O
immunosuppressive,O
function,O
.,O
The,O
splenocytes,O
were,O
activated,O
with,O
ConA,B-GP
followed,O
by,O
expansion,O
with,O
IL,B-GP
-,I-GP
2,I-GP
for,O
72,O
hours,O
.,O
We,O
co,O
-,O
cultured,O
the,O
activated,O
splenocytes,O
with,O
cMSCs,O
or,O
untreated,O
MSCs,O
.,O
The,O
results,O
showed,O
that,O
although,O
the,O
MSCs,O
could,O
not,O
inhibit,O
the,O
proliferation,O
of,O
splenocytes,O
",",O
the,O
inhibitory,O
effects,O
of,O
the,O
cMSCs,O
on,O
splenocytes,O
proliferation,O
were,O
significantly,O
increased,O
(,O
Figure,O
S2,O
).,O
cMSCs,O
exert,O
tumor,B-DS
promotion,O
of,O
the,O
required,O
iNOS,B-GP
High,O
concentrations,O
of,O
nitric,O
oxide,O
are,O
known,O
to,O
inhibit,O
immune,O
responses,O
to,O
promote,O
tumor,B-DS
growth,O
[,O
18,O
].,O
As,O
shown,O
above,O
",",O
iNOS,B-GP
mRNA,O
was,O
up,O
-,O
regulated,O
significantly,O
in,O
the,O
cMSCs,O
(,O
Figure,O
2A,O
).,O
To,O
investigate,O
the,O
role,O
of,O
nitric,O
oxide,O
",",O
its,O
production,O
was,O
shut,O
down,O
using,O
siRNA,O
to,O
inhibit,O
the,O
expression,O
of,O
iNOS,B-GP
.,O
RT,O
-,O
PCR,O
and,O
real,O
-,O
time,O
PCR,O
were,O
performed,O
to,O
assess,O
the,O
expression,O
of,O
iNOS,B-GP
in,O
cMSCs,O
to,O
further,O
confirm,O
the,O
transfection,O
efficiency,O
of,O
iNOS,B-GP
siRNA,O
.,O
iNOS,B-GP
expression,O
was,O
markedly,O
decreased,O
in,O
the,O
cMSCs,O
treated,O
by,O
iNOS,B-GP
siRNA,O
but,O
not,O
in,O
the,O
cMSCs,O
treated,O
by,O
control,O
-,O
siRNA,O
(,O
Figure,O
3A,O
"),",O
which,O
showed,O
more,O
than,O
an,O
80,O
%,O
inhibitory,O
efficiency,O
rate,O
(,O
Figure,O
3B,O
).,O
Moreover,O
",",O
in,O
mixed,O
co,O
-,O
cultures,O
of,O
splenocytes,O
and,O
cMSCs,O
pre,O
-,O
treated,O
with,O
iNOS,B-GP
siRNA,O
or,O
iNOS,B-GP
inhibitor,O
1400,O
W,O
",",O
splenocyte,O
proliferation,O
was,O
restored,O
to,O
a,O
normal,O
level,O
(,O
Figure,O
S2,O
).,O
The,O
results,O
strongly,O
suggested,O
that,O
nitric,O
oxide,O
produced,O
by,O
the,O
cMSCs,O
mediated,O
the,O
suppression,O
of,O
splenocytes,O
.,O
Furthermore,O
",",O
we,O
demonstrated,O
that,O
the,O
4T1,O
tumor,B-DS
-,O
promoting,O
ability,O
of,O
the,O
cMSCs,O
was,O
dependent,O
upon,O
the,O
expression,O
of,O
iNOS,B-GP
(,O
Figure,O
3C,O
–,O
3D,O
).,O
Therefore,O
",",O
these,O
data,O
supported,O
that,O
immunosuppression,O
mediated,O
by,O
the,O
cMSCs,O
via,O
nitric,O
oxide,O
play,O
an,O
important,O
role,O
in,O
favoring,O
tumor,B-DS
cells,O
growth,O
.,O
The,O
growth,O
of,O
the,O
tumor,B-DS
favored,O
by,O
the,O
cMSCs,O
in,O
vivo,O
can,O
be,O
inhibited,O
by,O
iNOS,B-GP
siRNA,O
To,O
determine,O
the,O
effect,O
of,O
iNOS,B-GP
in,O
the,O
cMSCs,O
",",O
the,O
cMSCs,O
were,O
transfected,O
with,O
iNOS,B-GP
siRNA,O
or,O
control,O
siRNA,O
.,O
Mice,B-OG
were,O
divided,O
into,O
the,O
si,O
-,O
iNOS,B-GP
/,O
cMSCs,O
group,O
and,O
si,O
-,O
control,O
/,O
cMSCs,O
group,O
.,O
(,O
A,O
),O
RT,O
-,O
PCR,O
showed,O
that,O
the,O
expression,O
of,O
iNOS,B-GP
was,O
decreased,O
in,O
the,O
cMSCs,O
in,O
which,O
transfections,O
of,O
iNOS,B-GP
siRNA,O
were,O
performed,O
with,O
a,O
Lipofectamine,O
.,O
(,O
B,O
),O
Real,O
-,O
time,O
PCR,O
showed,O
that,O
the,O
inhibitory,O
efficiency,O
was,O
more,O
than,O
80,O
%,O
compared,O
with,O
the,O
control,O
siRNA,O
in,O
the,O
cMSCs,O
.,O
(,O
C,O
),O
cMSCs,O
transfected,O
by,O
iNOS,B-GP
siRNA,O
did,O
not,O
support,O
4T1,O
-,O
FLUC,O
tumor,B-DS
cell,O
growth,O
.,O
(,O
D,O
),O
Quantification,O
of,O
the,O
bioluminescent,O
signal,O
(,O
C,O
),O
in,O
tumors,B-DS
after,O
treatments,O
.,O
MCP1,B-GP
-,O
mediated,O
macrophage,O
trafficking,O
is,O
critical,O
for,O
the,O
tumor,B-DS
-,O
promoting,O
effects,O
of,O
the,O
cMSCs,O
As,O
shown,O
above,O
",",O
the,O
cMSCs,O
were,O
more,O
effective,O
than,O
untreated,O
MSCs,O
in,O
recruiting,O
CD45,B-GP
+,O
cells,O
at,O
tumor,B-DS
sites,O
(,O
Figure,O
2E,O
"),",O
which,O
may,O
include,O
monocytes,O
/,O
macrophages,O
",",O
B,O
cells,O
and,O
T,O
cells,O
.,O
Monocytes,O
/,O
macrophages,O
are,O
essential,O
for,O
the,O
tumor,B-DS
-,O
promoting,O
effect,O
of,O
MSCs,O
isolated,O
from,O
tumor,B-DS
sites,O
[,O
14,O
].,O
To,O
determine,O
whether,O
monocytes,O
/,O
macrophages,O
mediated,O
the,O
tumor,B-DS
-,O
promoting,O
effect,O
of,O
the,O
cMSCs,O
",",O
we,O
depleted,O
systemic,O
monocytes,O
/,O
macrophages,O
with,O
clodronate,O
liposomes,O
(,O
Clo,O
-,O
Lip,O
),O
followed,O
by,O
injecting,O
mixtures,O
of,O
cMSCs,O
or,O
MSCs,O
with,O
4T1,O
tumor,B-DS
cells,O
into,O
mice,B-OG
14,O
days,O
after,O
transplantation,O
which,O
detected,O
the,O
tumor,B-DS
growth,O
by,O
BLI,O
.,O
We,O
found,O
that,O
depletion,O
of,O
monocytes,O
/,O
macrophages,O
in,O
our,O
system,O
had,O
an,O
effect,O
on,O
cMSCs,O
-,O
promoted,O
tumor,B-DS
growth,O
(,O
Figure,O
4A,O
"),",O
indicating,O
that,O
monocytes,O
/,O
macrophages,O
are,O
indispensable,O
for,O
tumor,B-DS
growth,O
enhancement,O
induced,O
by,O
the,O
cMSCs,O
.,O
Tumor,B-DS
-,O
promoting,O
effect,O
of,O
the,O
cMSCs,O
relied,O
on,O
the,O
MCP1,B-GP
to,O
recruit,O
TAMs,O
(,O
A,O
),O
Ablation,O
of,O
monocytes,O
/,O
macrophages,O
by,O
clodronate,O
liposomes,O
abolished,O
the,O
tumor,B-DS
-,O
promoting,O
activity,O
of,O
the,O
cMSCs,O
.,O
(,O
B,O
–,O
D,O
),O
cMSCs,O
were,O
transfected,O
with,O
MCP1,B-GP
siRNA,O
.,O
Impact,O
of,O
MCP1,B-GP
deficiency,O
on,O
cMSCs,O
tumor,B-DS
promoting,O
effects,O
was,O
detected,O
.,O
Animals,B-OG
were,O
divided,O
into,O
the,O
si,O
-,O
MCP1,B-GP
/,O
cMSCs,O
group,O
and,O
si,O
-,O
control,O
/,O
cMSCs,O
group,O
.,O
(,O
B,O
),O
Real,O
-,O
time,O
PCR,O
showed,O
that,O
the,O
expression,O
of,O
MCP1,B-GP
was,O
decreased,O
in,O
the,O
MSCs,O
in,O
which,O
transfections,O
of,O
MCP1,B-GP
siRNA,O
were,O
performed,O
with,O
a,O
Lipofectamine,O
.,O
(,O
C,O
),O
The,O
in,O
vivo,O
growth,O
of,O
the,O
tumor,B-DS
favored,O
by,O
the,O
cMSCs,O
could,O
be,O
inhibited,O
by,O
MCP1,B-GP
siRNA,O
.,O
4T1,O
-,O
FLUC,O
tumor,B-DS
cell,O
growth,O
was,O
detected,O
by,O
BLI,O
after,O
establishing,O
the,O
breast,B-DS
carcinoma,I-DS
model,O
.,O
(,O
D,O
),O
Representative,O
flow,O
cytometry,O
data,O
show,O
the,O
frequency,O
of,O
CD206,B-GP
macrophages,O
from,O
the,O
tumor,B-DS
and,O
peripheral,O
blood,O
of,O
4T1,O
bearing,O
control,O
mice,B-OG
.,O
MCP,B-GP
-,I-GP
1,I-GP
is,O
the,O
CCR2,B-GP
ligand,O
.,O
The,O
chemokine,B-GP
receptor,I-GP
CCR2,B-GP
is,O
known,O
to,O
be,O
expressed,O
on,O
monocytes,O
/,O
macrophages,O
.,O
Most,O
notably,O
",",O
MCP1,B-GP
",",O
the,O
major,O
chemokine,B-GP
for,O
macrophage,O
trafficking,O
",",O
was,O
expressed,O
at,O
a,O
high,O
level,O
by,O
the,O
cMSCs,O
",",O
but,O
not,O
by,O
the,O
untreated,O
MSCs,O
(,O
Figure,O
2A,O
"),",O
suggesting,O
that,O
cMSCs,O
-,O
produced,O
MCP1,B-GP
may,O
play,O
an,O
important,O
role,O
in,O
cMSCs,O
-,O
promoted,O
tumor,B-DS
growth,O
.,O
To,O
examine,O
this,O
possibility,O
",",O
we,O
performed,O
MCP1,B-GP
knock,O
down,O
in,O
the,O
cMSCs,O
using,O
siRNA,O
.,O
We,O
found,O
that,O
siRNA,O
targeting,O
MCP1,B-GP
was,O
capable,O
of,O
inhibiting,O
MCP1,B-GP
in,O
the,O
cMSCs,O
(,O
Figure,O
4B,O
).,O
To,O
establish,O
the,O
role,O
of,O
cMSCs,O
-,O
expressed,O
MCP1,B-GP
in,O
tumor,B-DS
growth,O
promotion,O
and,O
macrophage,O
infiltration,O
in,O
vivo,O
",",O
we,O
co,O
-,O
transplanted,O
MCP1,B-GP
siRNA,O
treated,O
cMSCs,O
and,O
4T1,O
-,O
FLUC,O
tumor,B-DS
cells,O
into,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
.,O
We,O
found,O
that,O
the,O
tumor,B-DS
promoting,O
activity,O
of,O
the,O
cMSCs,O
was,O
largely,O
MCP1,B-GP
dependent,O
since,O
it,O
was,O
significantly,O
blocked,O
by,O
adding,O
MCP1,B-GP
siRNA,O
(,O
Figure,O
4C,O
).,O
MCP1,B-GP
could,O
induce,O
emigration,O
of,O
macrophages,O
from,O
the,O
bone,O
marrow,O
to,O
the,O
periphery,O
.,O
Furthermore,O
",",O
the,O
infiltrated,O
CD206,B-GP
positive,O
macrophages,O
in,O
the,O
blood,O
and,O
tumor,B-DS
sites,O
in,O
mice,B-OG
who,O
were,O
administered,O
cMSCs,O
and,O
were,O
treated,O
by,O
MCP1,B-GP
siRNA,O
or,O
control,O
siRNA,O
were,O
examined,O
by,O
flow,O
cytometry,O
.,O
We,O
found,O
that,O
an,O
MCP1,B-GP
deficiency,O
led,O
to,O
a,O
significant,O
reduction,O
in,O
CD206,B-GP
positive,O
macrophages,O
in,O
both,O
tumor,B-DS
tissues,O
and,O
peripheral,O
blood,O
(,O
Figure,O
4D,O
"),",O
indicating,O
that,O
MCP1,B-GP
is,O
critical,O
for,O
trafficking,O
CD206,B-GP
+,O
macrophages,O
.,O
Altogether,O
",",O
these,O
data,O
demonstrate,O
that,O
the,O
cMSCs,O
probably,O
exert,O
their,O
tumor,B-DS
-,O
promoting,O
effect,O
by,O
recruiting,O
macrophages,O
to,O
tumor,B-DS
sites,O
through,O
the,O
production,O
of,O
MCP1,B-GP
.,O
cMSCs,O
convert,O
macrophages,O
into,O
M2,O
-,O
like,O
cells,O
to,O
promote,O
tumor,B-DS
growth,O
Macrophages,O
recruited,O
by,O
MCP1,B-GP
may,O
polarize,O
into,O
an,O
M1,O
or,O
M2,O
subset,O
in,O
a,O
tumor,B-DS
microenvironment,O
.,O
An,O
M2,O
polarized,O
population,O
promotes,O
tumor,B-DS
progression,O
.,O
To,O
examine,O
whether,O
the,O
cMSCs,O
remodel,O
the,O
phenotype,O
of,O
TAM,O
",",O
macrophages,O
and,O
cMSCs,O
were,O
co,O
-,O
incubated,O
in,O
a,O
transwell,O
for,O
24,O
hours,O
.,O
When,O
macrophages,O
were,O
further,O
examined,O
for,O
their,O
M1,O
/,O
M2,O
gene,O
expression,O
profile,O
by,O
real,O
-,O
time,O
PCR,O
",",O
we,O
found,O
that,O
macrophages,O
co,O
-,O
cultured,O
with,O
cMSCs,O
expressed,O
high,O
levels,O
of,O
FIZZ,B-GP
-,I-GP
1,I-GP
",",O
MCP1,B-GP
and,O
SIRPα,B-GP
(,O
Figure,O
5A,O
"),",O
comprising,O
an,O
M2,O
-,O
preferential,O
gene,O
signature,O
in,O
comparison,O
to,O
control,O
macrophages,O
.,O
Interestingly,O
",",O
these,O
cMSCs,O
-,O
educated,O
macrophages,O
differed,O
slightly,O
from,O
the,O
traditional,O
M2,O
type,O
",",O
since,O
they,O
expressed,O
a,O
low,O
level,O
of,O
Arg,B-GP
-,I-GP
1,I-GP
.,O
Meanwhile,O
",",O
FACS,O
analysis,O
showed,O
that,O
the,O
increase,O
in,O
the,O
frequency,O
of,O
CD206,B-GP
+,O
cells,O
caused,O
by,O
the,O
cMSCs,O
was,O
detected,O
(,O
Figure,O
5D,O
).,O
The,O
results,O
suggested,O
that,O
the,O
cMSCs,O
generated,O
macrophages,O
with,O
a,O
similar,O
M2,O
phenotype,O
.,O
Moreover,O
",",O
to,O
determine,O
whether,O
M2,O
-,O
like,O
macrophages,O
treated,O
by,O
cMSCs,O
stimulate,O
the,O
growth,O
of,O
mammary,B-DS
cancer,I-DS
cells,O
in,O
vivo,O
",",O
we,O
injected,O
4T1,O
-,O
FLUC,O
cells,O
into,O
the,O
mammary,O
fat,O
pads,O
of,O
mice,B-OG
either,O
alone,O
or,O
coupled,O
with,O
M2,O
-,O
like,O
macrophages,O
.,O
The,O
accumulation,O
of,O
4T1,O
-,O
FLUC,O
cancer,B-DS
cells,O
in,O
the,O
mammary,O
fat,O
pads,O
was,O
increased,O
significantly,O
and,O
observed,O
by,O
BLI,O
and,O
bioluminescence,O
tomography,O
(,O
BLT,O
),O
at,O
14,O
days,O
after,O
the,O
inoculation,O
as,O
compared,O
with,O
4T1,O
-,O
FLUC,O
cells,O
alone,O
(,O
Figure,O
5B,O
",",O
Movies,O
S1,O
and,O
S2,O
).,O
The,O
cMSCs,O
promoted,O
the,O
polarization,O
of,O
TAMs,O
into,O
M2,O
-,O
like,O
cells,O
through,O
IL,B-GP
-,I-GP
6,I-GP
(,O
A,O
),O
Real,O
-,O
time,O
PCR,O
showed,O
that,O
the,O
cMSCs,O
educated,O
macrophages,O
increased,O
the,O
expression,O
of,O
FIZZ,B-GP
-,I-GP
1,I-GP
",",O
MCP1,B-GP
and,O
SIRPα,B-GP
compared,O
to,O
untreated,O
macrophages,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
;,O
**,O
P,O
<,O
0,O
.,O
01,O
.,O
(,O
B,O
),O
The,O
growth,O
of,O
the,O
tumor,B-DS
was,O
favored,O
by,O
macrophages,O
stimulated,O
by,O
the,O
cMSCs,O
for,O
in,O
vivo,O
studies,O
.,O
(,O
C,O
–,O
D,O
),O
Blocking,O
IL,B-GP
-,I-GP
6,I-GP
inhibited,O
cMSCs,O
-,O
mediated,O
induction,O
of,O
M2,O
-,O
like,O
macrophages,O
.,O
(,O
C,O
),O
The,O
effects,O
of,O
IL,B-GP
-,I-GP
6,I-GP
and,O
COX,B-GP
-,I-GP
2,I-GP
antibody,O
on,O
the,O
activation,O
of,O
various,O
gene,O
expressions,O
in,O
the,O
cMSCs,O
were,O
assessed,O
by,O
using,O
real,O
-,O
time,O
PCR,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
.,O
(,O
D,O
),O
Characterization,O
of,O
the,O
cMSCs,O
educated,O
macrophages,O
treated,O
or,O
untreated,O
by,O
IL,B-GP
-,I-GP
6,I-GP
antibody,O
.,O
Previous,O
findings,O
showed,O
that,O
secretory,O
factors,O
play,O
an,O
essential,O
role,O
in,O
MSCs,O
induced,O
polarization,O
of,O
M2,O
macrophages,O
[,O
11,O
].,O
In,O
this,O
study,O
",",O
IL,B-GP
-,I-GP
6,I-GP
and,O
COX,B-GP
-,I-GP
2,I-GP
were,O
expressed,O
at,O
higher,O
levels,O
in,O
the,O
cMSCs,O
than,O
MSCs,O
",",O
thus,O
we,O
explored,O
whether,O
these,O
secretory,O
factors,O
contributed,O
to,O
the,O
polarization,O
of,O
TAM,O
toward,O
an,O
M2,O
-,O
like,O
phenotype,O
.,O
Hence,O
",",O
macrophages,O
were,O
co,O
-,O
cultured,O
with,O
cMSCs,O
in,O
transwells,O
in,O
the,O
presence,O
specific,O
neutralizing,O
antibodies,O
for,O
IL,B-GP
-,I-GP
6,I-GP
and,O
COX,B-GP
-,I-GP
2,I-GP
for,O
24,O
hours,O
",",O
and,O
M2,O
macrophage,O
characteristics,O
were,O
determined,O
by,O
real,O
-,O
time,O
PCR,O
and,O
flow,O
cytometry,O
.,O
We,O
showed,O
that,O
the,O
addition,O
of,O
neutralizing,O
antibodies,O
specific,O
for,O
IL,B-GP
-,I-GP
6,I-GP
significantly,O
decreased,O
the,O
mRNA,O
expression,O
of,O
FIZZ,B-GP
-,I-GP
1,I-GP
",",O
MCP1,B-GP
",",O
SIRPα,B-GP
",",O
and,O
reduced,O
the,O
percentage,O
of,O
CD206,B-GP
positive,O
cells,O
",",O
as,O
compared,O
with,O
the,O
co,O
-,O
culture,O
control,O
treated,O
with,O
nonspecific,O
antibodies,O
(,O
Figure,O
5C,O
",",O
5D,O
).,O
Therefore,O
",",O
these,O
results,O
suggested,O
that,O
IL,B-GP
-,I-GP
6,I-GP
contributed,O
to,O
the,O
induction,O
of,O
M2,O
-,O
like,O
macrophages,O
mediated,O
by,O
co,O
-,O
culturing,O
with,O
cMSCs,O
.,O
DISCUSSION,O
The,O
inflammatory,O
response,O
can,O
promote,O
carcinogenesis,O
;,O
one,O
of,O
the,O
major,O
challenges,O
in,O
understanding,O
the,O
connection,O
between,O
inflammation,O
and,O
cancer,B-DS
is,O
to,O
identify,O
the,O
triggering,O
events,O
that,O
lead,O
to,O
the,O
inflammatory,O
responses,O
which,O
can,O
promote,O
tumorigenesis,O
.,O
Our,O
findings,O
demonstrated,O
an,O
event,O
of,O
cancer,B-DS
development,O
induced,O
by,O
inflammation,O
:,O
when,O
the,O
microenvironment,O
became,O
M1,O
pro,O
-,O
inflammatory,O
",",O
the,O
MSCs,O
acquired,O
a,O
regulatory,O
phenotype,O
and,O
promoted,O
tumor,B-DS
growth,O
.,O
The,O
tumor,B-DS
-,O
promoting,O
abilities,O
required,O
iNOS,B-GP
and,O
TAMs,O
;,O
TAMs,O
were,O
recruited,O
by,O
MCP1,B-GP
and,O
further,O
polarized,O
into,O
an,O
M2,O
-,O
like,O
phenotype,O
to,O
affect,O
tumorigenesis,O
.,O
We,O
use,O
Figure,O
6,O
to,O
describe,O
this,O
effect,O
.,O
These,O
results,O
thus,O
establish,O
a,O
mechanistic,O
link,O
between,O
the,O
M1,O
macrophage,O
and,O
tumor,B-DS
cells,O
via,O
MSCs,O
.,O
Proposed,O
model,O
depicted,O
the,O
interaction,O
between,O
macrophages,O
and,O
the,O
MSCs,O
in,O
promoting,O
tumor,B-DS
growth,O
M1,O
macrophages,O
could,O
activate,O
the,O
MSCs,O
to,O
adopt,O
a,O
regulatory,O
phenotype,O
",",O
and,O
the,O
cMSCs,O
promoted,O
tumor,B-DS
growth,O
by,O
iNOS,B-GP
",",O
MCP1,B-GP
and,O
induced,O
macrophages,O
toward,O
M2,O
-,O
like,O
macrophages,O
.,O
The,O
tumor,B-DS
microenvironment,O
is,O
a,O
complex,O
cellular,O
",",O
molecular,O
network,O
.,O
In,O
this,O
network,O
",",O
one,O
kind,O
of,O
cell,O
may,O
be,O
subjected,O
to,O
influences,O
from,O
various,O
stimuli,O
.,O
In,O
our,O
experiments,O
",",O
the,O
cMSCs,O
could,O
become,O
a,O
potent,O
immune,O
-,O
regulatory,O
component,O
.,O
A,O
previous,O
study,O
found,O
that,O
the,O
concomitant,O
presence,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
and,O
IFN,B-GP
-,I-GP
γ,I-GP
could,O
induce,O
the,O
immunosuppressive,O
functions,O
of,O
the,O
MSCs,O
",",O
as,O
these,O
cytokine,O
combinations,O
provoke,O
the,O
expression,O
of,O
high,O
levels,O
of,O
CXCL9,B-GP
",",O
CXCL10,B-GP
and,O
iNOS,B-GP
[,O
18,O
].,O
In,O
our,O
experimental,O
setting,O
",",O
CXCL9,B-GP
and,O
CXCL10,B-GP
were,O
expressed,O
at,O
low,O
levels,O
in,O
the,O
cMSCs,O
.,O
These,O
differences,O
may,O
suggest,O
that,O
the,O
combination,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
and,O
IFN,B-GP
-,I-GP
γ,I-GP
could,O
not,O
completely,O
mimic,O
the,O
microenvironment,O
formed,O
by,O
M1,O
macrophages,O
.,O
The,O
key,O
factor,O
of,O
this,O
tumor,B-DS
promoting,O
pathway,O
is,O
the,O
MSCs,O
.,O
Recently,O
",",O
the,O
immune,O
modulatory,O
property,O
of,O
the,O
MSCs,O
has,O
been,O
extensively,O
studied,O
by,O
investigators,O
[,O
12,O
].,O
The,O
MSCs,O
influenced,O
both,O
adaptive,O
and,O
innate,O
immune,O
responses,O
.,O
The,O
ability,O
of,O
the,O
MSCs,O
to,O
control,O
an,O
inflammatory,O
environment,O
has,O
been,O
used,O
in,O
inflammatory,O
associated,O
disease,O
",",O
including,O
myocardial,B-DS
infarction,I-DS
[,O
19,O
"],",O
peritonitis,B-DS
[,O
20,O
"],",O
and,O
sepsis,B-DS
[,O
21,O
].,O
In,O
addition,O
to,O
polarization,O
of,O
macrophages,O
",",O
the,O
MSCs,O
could,O
also,O
polarize,O
into,O
two,O
distinctly,O
acting,O
phenotypes,O
following,O
specific,O
TLR,B-GP
-,O
activation,O
including,O
MSC1,B-GP
and,O
MSC2,B-GP
[,O
17,O
",",O
22,O
].,O
MSC1,B-GP
was,O
pro,O
-,O
inflammatory,O
",",O
and,O
MSC2,B-GP
showed,O
anti,O
-,O
inflammatory,O
properties,O
.,O
MSC1,B-GP
-,O
based,O
treatment,O
of,O
established,O
tumors,B-DS
in,O
an,O
immune,O
competent,O
model,O
attenuated,O
tumor,B-DS
growth,O
and,O
metastasis,O
in,O
contrast,O
to,O
MSC,O
-,O
or,O
MSC2,B-GP
-,O
treated,O
animals,B-OG
in,O
which,O
tumor,B-DS
growth,O
and,O
spread,O
was,O
increased,O
[,O
23,O
].,O
In,O
our,O
experiments,O
",",O
we,O
found,O
that,O
the,O
cMSCs,O
could,O
significantly,O
promote,O
tumor,B-DS
growth,O
",",O
recruit,O
CD45,B-GP
positive,O
bone,O
marrow,O
cells,O
in,O
vivo,O
",",O
and,O
had,O
immunosuppressive,O
potential,O
.,O
Meanwhile,O
",",O
Quantitative,O
PCR,O
showed,O
that,O
the,O
transcript,O
levels,O
of,O
iNOS,B-GP
and,O
TLR3,B-GP
were,O
markedly,O
higher,O
in,O
the,O
cMSCs,O
than,O
in,O
the,O
untreated,O
MSCs,O
.,O
Overall,O
",",O
these,O
results,O
may,O
suggest,O
that,O
the,O
cMSCs,O
had,O
a,O
regulatory,O
-,O
like,O
profile,O
similar,O
to,O
MSC2,B-GP
.,O
Previous,O
reports,O
indicated,O
that,O
the,O
MSCs,O
may,O
be,O
involved,O
in,O
cancer,B-DS
initiation,O
in,O
vivo,O
and,O
the,O
MSCs,O
may,O
spontaneously,O
transform,O
into,O
malignant,O
cells,O
in,O
vitro,O
[,O
24,O
].,O
It,O
is,O
clear,O
that,O
the,O
MSCs,O
secrete,O
a,O
number,O
of,O
paracrine,O
factors,O
that,O
may,O
influence,O
tumor,B-DS
growth,O
[,O
25,O
",",O
26,O
].,O
However,O
",",O
the,O
exact,O
mechanisms,O
of,O
MSCs,O
-,O
mediated,O
tumor,B-DS
growth,O
are,O
still,O
debated,O
",",O
especially,O
with,O
regards,O
to,O
immunosuppression,O
.,O
Previous,O
data,O
found,O
that,O
the,O
prevention,O
of,O
graft,B-DS
-,I-DS
versus,I-DS
-,I-DS
host,I-DS
disease,I-DS
by,O
the,O
MSCs,O
was,O
dependent,O
on,O
iNOS,B-GP
",",O
and,O
that,O
bone,O
marrow,O
-,O
derived,O
MSCs,O
could,O
exert,O
immunosuppressive,O
effects,O
by,O
iNOS,B-GP
to,O
favor,O
B16,O
melanoma,B-DS
cell,O
growth,O
[,O
18,O
].,O
In,O
our,O
experiments,O
",",O
cMSCs,O
-,O
mediated,O
immune,O
regulatory,O
effects,O
occurred,O
via,O
iNOS,B-GP
in,O
vitro,O
.,O
After,O
iNOS,B-GP
gene,O
knockdown,O
",",O
the,O
immune,O
suppression,O
and,O
tumor,B-DS
growth,O
enhancement,O
of,O
the,O
cMSCs,O
were,O
reduced,O
.,O
These,O
results,O
suggested,O
that,O
NO,O
-,O
mediated,O
immunosuppression,O
by,O
the,O
cMSCs,O
was,O
required,O
in,O
tumor,B-DS
progression,O
.,O
Additionally,O
",",O
macrophages,O
are,O
the,O
main,O
cells,O
in,O
the,O
tumor,B-DS
microenvironment,O
[,O
27,O
].,O
A,O
previous,O
study,O
showed,O
that,O
tumor,B-DS
-,O
educated,O
mesenchymal,O
stromal,O
cells,O
recruit,O
macrophages,O
via,O
CCR2,B-GP
[,O
15,O
].,O
In,O
our,O
experiments,O
",",O
we,O
found,O
that,O
the,O
cMSCs,O
could,O
recruit,O
macrophages,O
to,O
tumor,B-DS
sites,O
",",O
render,O
macrophages,O
into,O
M2,O
-,O
like,O
cells,O
",",O
and,O
consequently,O
enhance,O
tumor,B-DS
growth,O
.,O
Therefore,O
",",O
the,O
cMSCs,O
could,O
create,O
a,O
negative,O
-,O
feedback,O
loop,O
with,O
macrophages,O
in,O
the,O
tumor,B-DS
microenvironment,O
.,O
With,O
the,O
presence,O
of,O
pathogens,O
or,O
tissue,O
damage,O
",",O
the,O
negative,O
-,O
feedback,O
loop,O
may,O
be,O
initiated,O
by,O
tumor,B-DS
cells,O
following,O
accelerated,O
growth,O
.,O
In,O
the,O
tumor,B-DS
microenvironment,O
",",O
the,O
expression,O
of,O
various,O
immune,O
mediators,O
and,O
modulators,O
as,O
well,O
as,O
the,O
abundance,O
and,O
activation,O
state,O
of,O
different,O
cell,O
types,O
dictate,O
in,O
which,O
direction,O
the,O
balance,O
is,O
tipped,O
and,O
whether,O
tumor,B-DS
-,O
promoting,O
inflammation,O
or,O
antitumor,O
immunity,O
will,O
ensue,O
.,O
In,O
our,O
experiments,O
",",O
when,O
exposed,O
to,O
sufficient,O
levels,O
of,O
pro,O
-,O
inflammatory,O
cytokines,B-GP
in,O
the,O
M1,O
medium,O
",",O
the,O
MSCs,O
responded,O
to,O
adopting,O
an,O
immune,O
regulatory,O
phenotype,O
to,O
dampen,O
inflammation,O
and,O
promote,O
tumor,B-DS
growth,O
.,O
Our,O
research,O
may,O
inspire,O
a,O
subsequent,O
study,O
especially,O
in,O
how,O
inflammation,O
induces,O
tumor,B-DS
development,O
.,O
MATERIALS,O
AND,O
METHODS,O
Reagents,O
Recombinant,O
mouse,B-OG
TNFα,B-GP
",",O
interferon,B-GP
(,O
IFNγ,B-GP
"),",O
granulocyte,B-GP
macrophage,I-GP
-,I-GP
colony,I-GP
stimulating,I-GP
factor,I-GP
(,O
GM,B-GP
-,I-GP
CSF,I-GP
"),",O
M,B-GP
-,I-GP
CSF,I-GP
",",O
interleukin,B-GP
(,I-GP
IL,I-GP
)-,I-GP
4,I-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
10,I-GP
",",O
IL,B-GP
-,I-GP
12,I-GP
",",O
IL,B-GP
-,I-GP
2,I-GP
and,O
IL,B-GP
-,I-GP
15,I-GP
were,O
from,O
Pepro,O
Tech,O
(,O
London,O
",",O
UK,O
).,O
Lipopolysaccharide,O
(,O
LPS,O
),O
was,O
purchased,O
from,O
Sigma,O
.,O
Monoclonal,O
rat,B-OG
anti,O
-,O
mouse,B-OG
antibodies,O
against,O
CD29,B-GP
",",O
CD44,B-GP
",",O
CD45,B-GP
",",O
and,O
CD11b,B-GP
were,O
from,O
BD,O
Biosciences,O
;,O
and,O
rabbit,B-OG
anti,O
-,O
mouse,B-OG
inducible,O
nitric,B-GP
oxide,I-GP
synthase,I-GP
(,O
iNOS,B-GP
),O
and,O
CD206,B-GP
monoclonal,O
antibodies,O
were,O
from,O
Abcam,O
.,O
Alexa,O
Fluor,O
594,O
and,O
Alexa,O
Fluor,O
488,O
-,O
conjugated,O
secondary,O
antibodies,O
were,O
from,O
Invitrogen,O
.,O
Cell,O
culture,O
The,O
human,B-OG
breast,B-DS
carcinoma,I-DS
MDA,O
-,O
MB,O
-,O
231,O
-,O
FLUC,O
cells,O
",",O
human,B-OG
HCC,O
-,O
LM3,O
-,O
FLUC,O
hepatoma,B-DS
cells,O
",",O
human,B-OG
U87MG,O
-,O
FLUC,O
glioma,B-DS
cells,O
and,O
murine,B-OG
4T1,O
-,O
FLUC,O
breast,B-DS
cancer,I-DS
cells,O
were,O
stably,O
transfected,O
with,O
a,O
lentiviral,O
vector,O
containing,O
a,O
firefly,B-OG
luciferase,B-GP
reporter,O
gene,O
were,O
first,O
selected,O
in,O
vitro,O
",",O
and,O
then,O
injected,O
into,O
immune,O
-,O
deficient,O
or,O
normal,O
mice,B-OG
.,O
Murine,B-OG
macrophage,O
-,O
like,O
cells,O
RAW264,O
.,O
7,O
were,O
cultured,O
in,O
Dulbecco,O
',O
s,O
modified,O
Eagle,O
’,O
medium,O
(,O
Gibco,O
"),",O
M1,O
-,O
polarized,O
macrophages,O
were,O
prepared,O
by,O
stimulating,O
RAW264,O
.,O
7,O
macrophages,O
with,O
100,O
IU,O
/,O
ml,O
IFNγ,B-GP
plus,O
10,O
ng,O
/,O
ml,O
LPS,O
overnight,O
.,O
MSCs,O
were,O
collected,O
from,O
the,O
bone,O
marrow,O
of,O
the,O
tibia,O
and,O
femurs,O
of,O
mice,B-OG
aged,O
6,O
–,O
10,O
weeks,O
.,O
Animal,B-OG
model,O
Female,O
C57BL,B-OG
/,I-OG
6,I-OG
nude,I-OG
mice,I-OG
(,O
6,O
–,O
7,O
weeks,O
old,O
),O
were,O
purchased,O
from,O
the,O
Department,O
of,O
Experimental,O
Animals,B-OG
",",O
Peking,O
University,O
Health,O
Science,O
Center,O
.,O
Animal,B-OG
experiments,O
were,O
performed,O
according,O
to,O
the,O
guidelines,O
of,O
the,O
Institutional,O
Animal,B-OG
Care,O
and,O
Use,O
Committee,O
at,O
Peking,O
University,O
(,O
Permit,O
Number,O
:,O
2011,O
-,O
0039,O
).,O
Mice,B-OG
were,O
housed,O
in,O
a,O
specific,O
pathogen,O
-,O
free,O
colony,O
in,O
the,O
animal,B-OG
facility,O
",",O
and,O
100,O
μl,O
of,O
2,O
×,O
106,O
MDA,O
-,O
MB,O
-,O
231,O
-,O
FLUC,O
cells,O
",",O
or,O
100,O
μl,O
of,O
2,O
×,O
106,O
4T1,O
-,O
FLUC,O
cells,O
suspended,O
in,O
saline,O
were,O
injected,O
into,O
the,O
mammary,O
glands,O
of,O
mice,B-OG
to,O
establish,O
the,O
orthotopic,O
breast,B-DS
cancer,I-DS
model,O
respectively,O
.,O
The,O
orthotopic,O
liver,O
mouse,B-OG
models,O
were,O
established,O
by,O
injecting,O
100,O
μl,O
of,O
2,O
×,O
106,O
HCC,O
-,O
LM3,O
-,O
FLUC,O
cells,O
suspended,O
in,O
saline,O
into,O
the,O
liver,O
of,O
BALB,B-OG
/,I-OG
c,I-OG
nude,I-OG
mice,I-OG
.,O
For,O
orthotopic,O
brain,B-DS
tumor,I-DS
models,O
",",O
10,O
μl,O
of,O
2,O
×,O
105,O
U87MG,O
-,O
FLUC,O
cells,O
suspended,O
in,O
saline,O
were,O
implanted,O
manually,O
2,O
mm,O
anterior,O
and,O
2,O
mm,O
to,O
the,O
right,O
of,O
the,O
bregma,O
in,O
the,O
brains,O
of,O
mice,B-OG
.,O
After,O
the,O
injection,O
",",O
the,O
surface,O
was,O
cleaned,O
with,O
a,O
sterile,O
cotton,O
swab,O
",",O
and,O
the,O
burr,O
hole,O
was,O
filled,O
with,O
bone,O
wax,O
.,O
To,O
detect,O
the,O
effect,O
of,O
the,O
cMSCs,O
on,O
tumor,B-DS
growth,O
",",O
breast,O
",",O
liver,O
",",O
and,O
brain,B-DS
carcinoma,I-DS
cells,O
were,O
injected,O
either,O
alone,O
or,O
coupled,O
with,O
the,O
MSCs,O
into,O
nude,B-OG
mice,I-OG
.,O
The,O
MSCs,O
were,O
treated,O
with,O
M1,O
medium,O
or,O
left,O
untreated,O
.,O
Tumor,B-DS
cell,O
growth,O
was,O
evaluated,O
by,O
BLI,O
.,O
Mice,B-OG
were,O
divided,O
into,O
three,O
groups,O
(,O
n,O
=,O
6,O
per,O
group,O
):,O
the,O
MSCs,O
group,O
",",O
in,O
which,O
mice,B-OG
received,O
co,O
-,O
injection,O
of,O
1,O
×,O
106,O
MSCs,O
and,O
tumor,B-DS
cells,O
in,O
PBS,O
;,O
the,O
cMSCs,O
group,O
",",O
in,O
which,O
mice,B-OG
received,O
the,O
same,O
amount,O
of,O
M1,O
medium,O
-,O
treated,O
MSCs,O
and,O
cancer,B-DS
cells,O
;,O
and,O
the,O
control,O
(,O
PBS,O
),O
group,O
received,O
only,O
PBS,O
and,O
cancer,B-DS
cells,O
.,O
Mice,B-OG
were,O
matched,O
for,O
age,O
and,O
gender,O
in,O
each,O
experiment,O
.,O
To,O
determine,O
the,O
effect,O
of,O
iNOS,B-GP
in,O
the,O
cMSCs,O
",",O
4T1,O
-,O
FLUC,O
tumor,B-DS
cell,O
growth,O
was,O
detected,O
by,O
BLI,O
after,O
establishing,O
the,O
breast,B-DS
carcinoma,I-DS
model,O
.,O
Animals,B-OG
were,O
divided,O
into,O
two,O
groups,O
(,O
n,O
=,O
6,O
per,O
group,O
):,O
the,O
si,O
-,O
iNOS,B-GP
/,O
cMSCs,O
group,O
",",O
in,O
which,O
mice,B-OG
received,O
1,O
×,O
106,O
iNOS,B-GP
siRNA,O
treated,O
cMSCs,O
and,O
2,O
×,O
106,O
4T1,O
-,O
FLUC,O
cells,O
in,O
100,O
μl,O
of,O
PBS,O
;,O
and,O
the,O
control,O
(,O
si,O
-,O
control,O
/,O
cMSCs,O
),O
group,O
also,O
received,O
1,O
×,O
106,O
control,O
siRNA,O
treated,O
cMSCs,O
and,O
2,O
×,O
106,O
tumor,B-DS
cells,O
in,O
100,O
μl,O
of,O
PBS,O
.,O
Mice,B-OG
were,O
matched,O
for,O
age,O
and,O
gender,O
in,O
each,O
experiment,O
.,O
To,O
examine,O
the,O
effect,O
of,O
macrophages,O
on,O
tumor,B-DS
growth,O
in,O
vivo,O
",",O
mice,B-OG
were,O
injected,O
with,O
approximately,O
110,O
mg,O
/,O
kg,O
of,O
clodronate,O
liposomes,O
I,O
.,O
P,O
.,O
or,O
equal,O
volume,O
of,O
PBS,O
liposomes,O
.,O
Then,O
",",O
1,O
×,O
106,O
MSCs,O
or,O
cMSCs,O
were,O
co,O
-,O
injected,O
with,O
4T1,O
-,O
FLUC,O
cells,O
.,O
Tumor,B-DS
cell,O
growth,O
was,O
evaluated,O
by,O
BLI,O
on,O
day,O
14,O
.,O
To,O
determine,O
the,O
effect,O
of,O
MCP1,B-GP
on,O
cMSCs,O
",",O
cMSCs,O
were,O
transfected,O
with,O
MCP1,B-GP
siRNA,O
.,O
Animals,B-OG
were,O
divided,O
into,O
two,O
groups,O
(,O
n,O
=,O
6,O
per,O
group,O
):,O
the,O
si,O
-,O
MCP1,B-GP
/,O
cMSCs,O
group,O
",",O
in,O
which,O
mice,B-OG
received,O
1,O
×,O
106,O
MCP1,B-GP
siRNA,O
treated,O
cMSCs,O
and,O
2,O
×,O
106,O
4T1,O
-,O
FLUC,O
cells,O
in,O
100,O
μl,O
of,O
PBS,O
;,O
and,O
the,O
control,O
(,O
si,O
-,O
control,O
/,O
cMSCs,O
),O
group,O
also,O
received,O
1,O
×,O
106,O
control,O
siRNA,O
treated,O
cMSCs,O
and,O
2,O
×,O
106,O
tumor,B-DS
cells,O
in,O
100,O
μl,O
of,O
PBS,O
.,O
Mice,B-OG
were,O
matched,O
for,O
age,O
and,O
gender,O
in,O
each,O
experiment,O
.,O
To,O
examine,O
the,O
effect,O
of,O
the,O
cMSCs,O
educated,O
macrophages,O
on,O
tumor,B-DS
growth,O
",",O
cMSCs,O
educated,O
macrophages,O
were,O
co,O
-,O
injected,O
with,O
4T1,O
-,O
FLUC,O
cells,O
",",O
and,O
tumor,B-DS
cell,O
growth,O
was,O
evaluated,O
by,O
BLI,O
.,O
BLI,O
BLI,O
was,O
performed,O
using,O
the,O
Xenogen,O
IVIS,O
Lumina,O
II,O
system,O
(,O
Perkin,O
Elmer,O
",",O
Waltham,O
",",O
MA,O
",",O
USA,O
),O
as,O
detailed,O
previously,O
[,O
28,O
",",O
29,O
].,O
Real,O
-,O
time,O
PCR,O
Total,O
RNA,O
was,O
extracted,O
from,O
cell,O
pellets,O
using,O
Trizol,O
Reagent,O
(,O
Invitrogen,O
),O
and,O
treated,O
with,O
RNase,B-GP
-,O
free,O
DNase,B-GP
I,I-GP
(,O
Qiagen,O
",",O
USA,O
).,O
First,O
-,O
strand,O
cDNA,O
synthesis,O
was,O
performed,O
using,O
an,O
ABI,O
High,O
-,O
Capacity,O
cDNA,O
RT,O
kit,O
(,O
Applied,O
Biosystems,O
",",O
USA,O
).,O
Then,O
",",O
RT,O
-,O
PCR,O
and,O
Real,O
-,O
time,O
PCR,O
were,O
done,O
.,O
Primers,O
used,O
in,O
PCR,O
are,O
listed,O
in,O
Table,O
S1,O
",",O
including,O
interleukin,B-GP
-,I-GP
6,I-GP
(,O
IL,B-GP
-,I-GP
6,I-GP
"),",O
monocyte,B-GP
chemoattractant,I-GP
protein,I-GP
(,O
MCP1,B-GP
"),",O
Macrophage,B-GP
inflammatory,I-GP
protein,I-GP
-,I-GP
1β,I-GP
(,O
MIP,B-GP
-,I-GP
1β,I-GP
"),",O
tumor,B-GP
necrosis,I-GP
factor,I-GP
-,I-GP
α,I-GP
(,O
TNF,B-GP
-,I-GP
α,I-GP
"),",O
interleukin,B-GP
-,I-GP
19,I-GP
(,O
IL,B-GP
-,I-GP
19,I-GP
"),",O
matrix,B-GP
metalloproteinase,I-GP
-,I-GP
2,I-GP
(,O
MMP,B-GP
-,I-GP
2,I-GP
"),",O
arginase,B-GP
type,I-GP
1,I-GP
(,O
Arg,B-GP
-,I-GP
1,I-GP
"),",O
inflammatory,B-GP
zone,I-GP
1,I-GP
(,O
FIZZ,B-GP
-,I-GP
1,I-GP
"),",O
interleukin,B-GP
-,I-GP
10,I-GP
(,O
IL,B-GP
-,I-GP
10,I-GP
"),",O
CD47,B-GP
",",O
and,O
signal,B-GP
regulatory,I-GP
protein,I-GP
alpha,I-GP
(,O
SIRPα,B-GP
).,O
The,O
total,O
amount,O
of,O
mRNA,O
was,O
normalized,O
to,O
endogenous,O
GAPDH,B-GP
mRNA,O
.,O
Real,O
-,O
time,O
PCR,O
was,O
performed,O
in,O
triplicate,O
with,O
the,O
Fast,O
Start,O
Universal,O
SYBR,O
Green,O
Master,O
(,O
ROX,O
;,O
Roche,O
",",O
Mannheim,O
",",O
Germany,O
),O
and,O
the,O
iCycler,O
iQ52,O
.,O
0,O
Standard,O
Edition,O
Optical,O
System,O
(,O
Bio,O
-,O
Rad,O
",",O
Hercules,O
",",O
CA,O
",",O
USA,O
).,O
To,O
assess,O
the,O
gene,O
expression,O
of,O
the,O
cMSCs,O
",",O
the,O
MSCs,O
were,O
seeded,O
onto,O
12,O
-,O
well,O
plates,O
(,O
Corning,O
",",O
USA,O
),O
at,O
a,O
density,O
of,O
2,O
×,O
105,O
cells,O
/,O
well,O
and,O
incubated,O
overnight,O
.,O
The,O
medium,O
was,O
replaced,O
with,O
a,O
fresh,O
M1,O
medium,O
and,O
cultured,O
for,O
24,O
h,O
",",O
after,O
which,O
real,O
-,O
time,O
PCR,O
analysis,O
was,O
performed,O
.,O
All,O
experiments,O
were,O
performed,O
in,O
triplicate,O
.,O
To,O
examine,O
the,O
gene,O
expression,O
of,O
the,O
cMSCs,O
educated,O
macrophages,O
",",O
RAW264,O
.,O
7,O
macrophages,O
were,O
co,O
-,O
cultured,O
with,O
cMSCs,O
in,O
a,O
transwell,O
for,O
24,O
hours,O
.,O
The,O
upper,O
part,O
was,O
the,O
MSCs,O
",",O
and,O
the,O
lower,O
portion,O
included,O
macrophages,O
.,O
Then,O
",",O
real,O
-,O
time,O
PCR,O
analysis,O
was,O
performed,O
.,O
All,O
experiments,O
were,O
performed,O
in,O
triplicate,O
.,O
Immunohistochemistry,O
Tumors,B-DS
were,O
washed,O
thoroughly,O
in,O
PBS,O
and,O
embedded,O
in,O
the,O
optimal,O
cutting,O
temperature,O
medium,O
(,O
OCT,O
),O
(,O
Sakura,O
Finetek,O
",",O
Torrance,O
",",O
CA,O
",",O
USA,O
).,O
Cryosections,O
(,O
5,O
–,O
6,O
μm,O
),O
were,O
cut,O
and,O
stained,O
with,O
antibodies,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
protocol,O
.,O
To,O
quantify,O
tumor,B-DS
-,O
associated,O
bone,O
marrow,O
cell,O
recruitment,O
",",O
the,O
tumor,B-DS
sections,O
were,O
stained,O
with,O
rat,B-OG
anti,O
-,O
mouse,B-OG
CD45,B-GP
(,O
BD,O
Biosciences,O
Pharmingen,O
",",O
San,O
Diego,O
",",O
CA,O
"),",O
and,O
the,O
percentage,O
of,O
CD45,B-GP
-,O
positive,O
cells,O
was,O
determined,O
by,O
counting,O
the,O
number,O
of,O
cells,O
in,O
six,O
random,O
fields,O
(,O
400,O
×,O
magnification,O
),O
from,O
three,O
histology,O
sections,O
.,O
Counting,O
was,O
performed,O
by,O
two,O
“,O
blinded,O
”,O
independent,O
investigators,O
.,O
Alexa,O
Fluor,O
594,O
-,O
conjugated,O
donkey,B-OG
anti,O
-,O
rat,B-OG
secondary,O
antibody,O
(,O
BD,O
Biosciences,O
Pharmingen,O
",",O
San,O
Diego,O
",",O
CA,O
),O
was,O
applied,O
appropriately,O
.,O
DAPI,O
was,O
used,O
for,O
nuclear,O
counterstaining,O
.,O
Short,O
interfering,O
RNA,O
(,O
siRNA,O
),O
synthesis,O
and,O
transient,O
transfection,O
The,O
siRNA,O
sequences,O
of,O
iNOS,B-GP
(,O
Sense,O
:,O
5,O
′-,O
CAGCTGGGCTGTACAAACCdTdT,O
-,O
3,O
;,O
Antisense,O
:,O
5,O
′-,O
CATTGGAAGTGAAGCGTTTCGdTdT,O
-,O
3,O
′),O
and,O
MCP1,B-GP
(,O
Sense,O
:,O
5,O
′-,O
AAUUGAUUUAGCGUACACGdTdT,O
-,O
3,O
;,O
Antisense,O
:,O
5,O
′-,O
CGUGUACGCUAAAUCAAUUdTdT,O
-,O
3,O
′),O
were,O
designed,O
by,O
using,O
Oligoengine,O
software,O
and,O
confirmed,O
by,O
the,O
nucleotide,O
Basic,O
Local,O
Alignment,O
Search,O
Tool,O
(,O
BLAST,O
),O
searches,O
.,O
Transfections,O
were,O
performed,O
with,O
a,O
Lipofectamine,O
2000,O
kit,O
(,O
Invitrogen,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
Cells,O
(,O
1,O
–,O
3,O
×,O
106,O
),O
grown,O
to,O
a,O
confluency,O
of,O
50,O
–,O
60,O
%,O
in,O
10,O
cm,O
Petri,O
dishes,O
were,O
transfected,O
with,O
the,O
siRNA,O
sequence,O
",",O
and,O
then,O
the,O
cells,O
were,O
harvested,O
48,O
hours,O
after,O
transfection,O
.,O
Flow,O
cytometry,O
For,O
macrophage,O
surface,O
marker,O
analysis,O
",",O
macrophages,O
were,O
incubated,O
with,O
fluorescent,O
labeled,O
rat,B-OG
anti,O
-,O
mouse,B-OG
CD11b,B-GP
",",O
iNOS,B-GP
",",O
and,O
CD206,B-GP
antibodies,O
(,O
BD,O
Biosciences,O
Pharmingen,O
",",O
San,O
Diego,O
",",O
CA,O
).,O
To,O
measure,O
macrophage,O
infiltration,O
in,O
the,O
tumor,B-DS
sites,O
and,O
blood,O
",",O
the,O
tumor,B-DS
cells,O
and,O
peripheral,O
cells,O
were,O
stained,O
with,O
Alexa,O
Fluor,O
®,O
594,O
-,O
conjugated,O
rabbit,B-OG
anti,O
-,O
mouse,B-OG
CD206,B-GP
(,O
Abcam,O
",",O
Cambridge,O
",",O
MA,O
),O
and,O
FITC,O
-,O
labeled,O
anti,O
-,O
mouse,B-OG
F4,O
/,O
80,O
(,O
Abcam,O
",",O
Cambridge,O
",",O
MA,O
).,O
Statistical,O
analysis,O
All,O
data,O
were,O
expressed,O
as,O
the,O
mean,O
±,O
SEM,O
.,O
One,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
was,O
used,O
to,O
determine,O
the,O
intergroup,O
differences,O
.,O
Least,O
significant,O
difference,O
(,O
equal,O
variances,O
),O
and,O
Dunnett,O
',O
s,O
T3,O
(,O
non,O
-,O
equal,O
variances,O
),O
post,O
hoc,O
tests,O
were,O
used,O
for,O
testing,O
the,O
differences,O
between,O
groups,O
.,O
All,O
tests,O
were,O
two,O
-,O
tailed,O
",",O
and,O
differences,O
were,O
considered,O
statistically,O
significant,O
at,O
P,O
<,O
0,O
.,O
05,O
.,O
SUPPLEMENTARY,O
MATERIALS,O
FIGURES,O
AND,O
TABLE,O
CONFLICTS,O
OF,O
INTEREST,O
The,O
authors,O
declare,O
no,O
conflicts,O
of,O
interests,O
.,O
A,O
tandem,O
regression,O
-,O
outlier,O
analysis,O
of,O
a,O
ligand,O
cellular,O
system,O
for,O
key,O
structural,O
modifications,O
around,O
ligand,O
binding,O
Background,O
A,O
tandem,O
technique,O
of,O
hard,O
equipment,O
is,O
often,O
used,O
for,O
the,O
chemical,O
analysis,O
of,O
a,O
single,O
cell,O
to,O
first,O
isolate,O
and,O
then,O
detect,O
the,O
wanted,O
identities,O
.,O
The,O
first,O
part,O
is,O
the,O
separation,O
of,O
wanted,O
chemicals,O
from,O
the,O
bulk,O
of,O
a,O
cell,O
;,O
the,O
second,O
part,O
is,O
the,O
actual,O
detection,O
of,O
the,O
important,O
identities,O
.,O
To,O
identify,O
the,O
key,O
structural,O
modifications,O
around,O
ligand,O
binding,O
",",O
the,O
present,O
study,O
aims,O
to,O
develop,O
a,O
counterpart,O
of,O
tandem,O
technique,O
for,O
cheminformatics,O
.,O
A,O
statistical,O
regression,O
and,O
its,O
outliers,O
act,O
as,O
a,O
computational,O
technique,O
for,O
separation,O
.,O
Results,O
A,O
PPARγ,B-GP
(,O
peroxisome,B-GP
proliferator,I-GP
-,I-GP
activated,I-GP
receptor,I-GP
gamma,I-GP
),O
agonist,O
cellular,O
system,O
was,O
subjected,O
to,O
such,O
an,O
investigation,O
.,O
Results,O
show,O
that,O
this,O
tandem,O
regression,O
-,O
outlier,O
analysis,O
",",O
or,O
the,O
prioritization,O
of,O
the,O
context,O
equations,O
tagged,O
with,O
features,O
of,O
the,O
outliers,O
",",O
is,O
an,O
effective,O
regression,O
technique,O
of,O
cheminformatics,O
to,O
detect,O
key,O
structural,O
modifications,O
",",O
as,O
well,O
as,O
their,O
tendency,O
of,O
impact,O
to,O
ligand,O
binding,O
.,O
Conclusions,O
The,O
key,O
structural,O
modifications,O
around,O
ligand,O
binding,O
are,O
effectively,O
extracted,O
or,O
characterized,O
out,O
of,O
cellular,O
reactions,O
.,O
This,O
is,O
because,O
molecular,O
binding,O
is,O
the,O
paramount,O
factor,O
in,O
such,O
ligand,O
cellular,O
system,O
and,O
key,O
structural,O
modifications,O
around,O
ligand,O
binding,O
are,O
expected,O
to,O
create,O
outliers,O
.,O
Therefore,O
",",O
such,O
outliers,O
can,O
be,O
captured,O
by,O
this,O
tandem,O
regression,O
-,O
outlier,O
analysis,O
.,O
Background,O
In,O
any,O
chemical,O
analysis,O
of,O
a,O
single,O
cell,O
",",O
the,O
first,O
step,O
is,O
the,O
separation,O
of,O
wanted,O
chemicals,O
from,O
the,O
bulk,O
of,O
a,O
cell,O
.,O
This,O
is,O
due,O
to,O
the,O
fact,O
that,O
a,O
cellular,O
system,O
has,O
a,O
complex,O
",",O
heterogeneous,O
composition,O
.,O
Various,O
methods,O
[,O
1,O
],O
using,O
hard,O
equipment,O
have,O
been,O
developed,O
for,O
such,O
uses,O
.,O
After,O
a,O
single,O
cell,O
is,O
separated,O
from,O
the,O
other,O
cells,O
",",O
the,O
wanted,O
component,O
can,O
be,O
further,O
isolated,O
and,O
then,O
detected,O
through,O
what,O
is,O
called,O
a,O
tandem,O
technique,O
[,O
1,O
].,O
The,O
first,O
part,O
of,O
a,O
tandem,O
technique,O
",",O
as,O
mentioned,O
above,O
",",O
is,O
the,O
separation,O
of,O
wanted,O
chemicals,O
from,O
the,O
bulk,O
of,O
a,O
cell,O
;,O
the,O
second,O
part,O
is,O
the,O
detection,O
of,O
the,O
components,O
.,O
By,O
mimicking,O
such,O
a,O
tandem,O
technique,O
",",O
a,O
computational,O
counterpart,O
was,O
developed,O
herein,O
;,O
a,O
statistical,O
regression,O
and,O
its,O
outliers,O
(,O
influential,O
observations,O
[,O
2,O
]),O
act,O
as,O
a,O
computational,O
technique,O
for,O
separation,O
",",O
which,O
can,O
cause,O
the,O
important,O
identities,O
(,O
i,O
.,O
e,O
.,O
the,O
factors,O
causing,O
outliers,O
),O
to,O
be,O
isolated,O
from,O
the,O
bulk,O
of,O
a,O
cellular,O
system,O
.,O
As,O
a,O
pioneer,O
investigation,O
",",O
one,O
molecular,O
descriptor,O
and,O
one,O
class,O
of,O
descriptors,O
will,O
be,O
prepared,O
:,O
the,O
descriptor,O
resembles,O
the,O
filter,O
in,O
the,O
tandem,O
equipment,O
;,O
the,O
class,O
resembles,O
the,O
detector,O
.,O
In,O
a,O
ligand,O
-,O
dependent,O
receptor,O
-,O
mediated,O
cellular,O
system,O
(,O
or,O
ligand,O
cellular,O
system,O
"),",O
key,O
structural,O
modifications,O
surrounding,O
ligand,O
binding,O
are,O
expected,O
to,O
cause,O
outliers,O
.,O
For,O
example,O
",",O
hydrogen,O
bond,O
formation,O
",",O
or,O
deformation,O
",",O
can,O
cause,O
drastic,O
alterations,O
in,O
cellular,O
reaction,O
.,O
These,O
singular,O
situations,O
are,O
",",O
at,O
times,O
",",O
the,O
reasons,O
for,O
statistical,O
breakdown,O
points,O
in,O
many,O
analyses,O
that,O
are,O
otherwise,O
correct,O
(,O
i,O
.,O
e,O
.,O
resulting,O
in,O
the,O
outliers,O
of,O
a,O
statistical,O
regression,O
[,O
3,O
",",O
4,O
]).,O
At,O
the,O
same,O
time,O
",",O
such,O
outliers,O
can,O
have,O
the,O
most,O
prominent,O
and,O
often,O
most,O
informative,O
features,O
of,O
the,O
target,O
-,O
specific,O
activity,O
landscapes,O
[,O
5,O
].,O
Therefore,O
",",O
the,O
concept,O
that,O
after,O
this,O
tandem,O
regression,O
-,O
outlier,O
analysis,O
",",O
the,O
features,O
of,O
these,O
resulting,O
outliers,O
can,O
correspond,O
to,O
important,O
structural,O
modifications,O
around,O
molecular,O
binding,O
in,O
such,O
a,O
ligand,O
cellular,O
system,O
",",O
if,O
correct,O
",",O
would,O
be,O
very,O
useful,O
.,O
For,O
this,O
first,O
tandem,O
part,O
",",O
we,O
sought,O
the,O
most,O
representative,O
descriptor,O
for,O
the,O
bulk,O
system,O
of,O
a,O
cell,O
.,O
We,O
found,O
Jurs_RNCG,O
[,O
6,O
"],",O
after,O
observing,O
more,O
than,O
521,O
×,O
17,O
data,O
sets,O
of,O
PPARγ,B-GP
(,O
peroxisome,B-GP
proliferator,I-GP
-,I-GP
activated,I-GP
receptor,I-GP
gamma,I-GP
),O
agonists,O
[,O
7,O
-,O
21,O
].,O
The,O
methods,O
and,O
results,O
are,O
depicted,O
in,O
the,O
first,O
body,O
of,O
materials,O
",",O
methods,O
",",O
and,O
results,O
.,O
To,O
connect,O
this,O
to,O
the,O
second,O
tandem,O
part,O
",",O
the,O
descriptor,O
that,O
is,O
sought,O
in,O
the,O
first,O
part,O
has,O
functionality,O
",",O
which,O
yields,O
outlier,O
residues,O
for,O
the,O
second,O
part,O
.,O
Acting,O
as,O
an,O
assay,O
for,O
detection,O
in,O
the,O
second,O
tandem,O
part,O
",",O
for,O
which,O
the,O
electrotopological,O
state,O
(,O
ES,O
),O
class,O
of,O
descriptors,O
[,O
22,O
-,O
26,O
],O
is,O
used,O
.,O
All,O
possible,O
structural,O
modifications,O
in,O
a,O
given,O
collected,O
analog,O
set,O
are,O
pre,O
-,O
assigned,O
by,O
ES,O
descriptors,O
.,O
The,O
ES,O
descriptors,O
involve,O
atom,O
types,O
in,O
various,O
electro,O
-,O
topological,O
states,O
.,O
For,O
example,O
",",O
in,O
ES,O
terminology,O
",",O
an,O
ES_Count_ssO,O
of,O
a,O
molecular,O
structure,O
is,O
the,O
count,O
of,O
“,O
ssO,O
”,O
linkages,O
",",O
and,O
here,O
the,O
“,O
ssO,O
”,O
represents,O
a,O
bonding,O
oxygen,O
atom,O
(,O
O,O
),O
linked,O
via,O
two,O
single,O
bonds,O
(,O
ss,O
).,O
A,O
structural,O
modification,O
is,O
considered,O
a,O
fundamental,O
element,O
(,O
an,O
action,O
),O
for,O
the,O
reaction,O
of,O
such,O
a,O
ligand,O
cellular,O
system,O
.,O
In,O
actuality,O
",",O
any,O
structural,O
modification,O
of,O
such,O
an,O
analog,O
set,O
can,O
be,O
expressed,O
by,O
the,O
change,O
of,O
an,O
associated,O
ES,O
descriptor,O
.,O
The,O
details,O
and,O
results,O
of,O
the,O
second,O
part,O
are,O
also,O
depicted,O
in,O
the,O
second,O
body,O
of,O
materials,O
",",O
methods,O
and,O
results,O
.,O
This,O
tandem,O
regression,O
-,O
outlier,O
technique,O
is,O
",",O
therefore,O
",",O
in,O
mathematical,O
terms,O
",",O
carried,O
out,O
so,O
as,O
to,O
prioritize,O
the,O
context,O
equations,O
tagged,O
with,O
features,O
of,O
these,O
outliers,O
.,O
We,O
want,O
to,O
know,O
if,O
the,O
top,O
-,O
ranked,O
structural,O
modifications,O
correspond,O
to,O
the,O
key,O
interactions,O
around,O
molecular,O
binding,O
as,O
we,O
expected,O
them,O
to,O
.,O
This,O
expectation,O
was,O
based,O
on,O
the,O
fact,O
that,O
:,O
I,O
:,O
this,O
singular,O
situation,O
causes,O
outliers,O
in,O
a,O
regression,O
.,O
II,O
:,O
molecular,O
binding,O
is,O
the,O
paramount,O
factor,O
in,O
such,O
a,O
ligand,O
cellular,O
system,O
",",O
and,O
III,O
",",O
key,O
structural,O
modifications,O
around,O
ligand,O
binding,O
are,O
expected,O
to,O
create,O
singular,O
situations,O
",",O
i,O
.,O
e,O
.,O
cause,O
outliers,O
in,O
a,O
statistical,O
regression,O
.,O
In,O
the,O
end,O
",",O
after,O
this,O
tandem,O
regression,O
-,O
outlier,O
analysis,O
for,O
the,O
PPARγ,B-GP
agonist,O
cellular,O
system,O
",",O
a,O
top,O
ranked,O
ES,O
symbol,O
can,O
faithfully,O
correspond,O
to,O
key,O
interactions,O
around,O
molecular,O
binding,O
with,O
the,O
correct,O
order,O
of,O
potency,O
.,O
The,O
outcome,O
of,O
such,O
an,O
analysis,O
confirmed,O
the,O
two,O
main,O
underlying,O
and,O
mutually,O
-,O
dependent,O
speculations,O
;,O
one,O
being,O
that,O
",",O
in,O
the,O
second,O
tandem,O
part,O
",",O
the,O
top,O
ranked,O
ES,O
symbols,O
reflect,O
the,O
key,O
interactions,O
around,O
ligand,O
binding,O
",",O
and,O
the,O
other,O
that,O
",",O
in,O
the,O
first,O
tandem,O
part,O
",",O
the,O
designation,O
of,O
Jurs_RNCG,O
(,O
relative,O
negative,O
charge,O
),O
can,O
effectively,O
remove,O
the,O
general,O
effects,O
of,O
such,O
a,O
ligand,O
cellular,O
system,O
.,O
Methods,O
The,O
first,O
tandem,O
filter,O
:,O
in,O
order,O
to,O
seek,O
the,O
most,O
representative,O
descriptor,O
for,O
a,O
ligand,O
cellular,O
system,O
In,O
mathematics,O
",",O
the,O
dependent,O
variable,O
Y,O
is,O
the,O
ligand,O
-,O
dependent,O
receptor,O
-,O
mediated,O
cellular,O
reaction,O
.,O
The,O
context,O
equation,O
of,O
the,O
descriptor,O
selection,O
is,O
given,O
as,O
follows,O
:,O
(,O
1,O
),O
Y,O
=,O
β0,O
+,O
βchXch,O
where,O
Y,O
is,O
the,O
dependent,O
variable,O
that,O
stands,O
for,O
the,O
ligand,O
-,O
dependent,O
receptor,O
-,O
mediated,O
cellular,O
reaction,O
",",O
Xch,O
is,O
the,O
descriptor,O
to,O
be,O
chosen,O
",",O
and,O
β0,O
and,O
βch,O
are,O
the,O
regression,O
coefficients,O
after,O
the,O
least,O
squares,O
fit,O
.,O
Once,O
the,O
ligand,O
-,O
dependent,O
receptor,O
-,O
mediated,O
cellular,O
data,O
of,O
a,O
given,O
set,O
of,O
analogs,O
are,O
available,O
",",O
the,O
r2,O
correlation,O
fit,O
can,O
be,O
obtained,O
for,O
each,O
descriptor,O
.,O
Here,O
",",O
521,O
descriptors,O
of,O
eminent,O
classes,O
are,O
used,O
.,O
All,O
descriptors,O
in,O
the,O
working,O
equation,O
with,O
correlation,O
fits,O
are,O
prioritized,O
by,O
correlation,O
coefficient,O
.,O
All,O
calculations,O
of,O
descriptors,O
were,O
performed,O
using,O
the,O
Discovery,O
Studio,O
2,O
.,O
1,O
QSAR,O
module,O
[,O
27,O
].,O
The,O
regression,O
fits,O
were,O
conducted,O
for,O
each,O
descriptor,O
in,O
the,O
context,O
equation,O
and,O
Pearson,O
’,O
s,O
coefficients,O
were,O
performed,O
using,O
R,O
2,O
.,O
11,O
.,O
0,O
[,O
28,O
].,O
The,O
second,O
tandem,O
detector,O
:,O
to,O
prioritize,O
the,O
context,O
equations,O
tagged,O
with,O
all,O
possible,O
features,O
of,O
the,O
outliers,O
Following,O
the,O
designation,O
of,O
the,O
Jurs_RNCG,O
descriptor,O
",",O
a,O
three,O
-,O
variable,O
equation,O
is,O
used,O
for,O
the,O
prioritization,O
of,O
all,O
the,O
ES,O
descriptors,O
.,O
The,O
context,O
equation,O
using,O
Jurs_RNCG,O
",",O
tagged,O
with,O
all,O
possible,O
features,O
of,O
the,O
outliers,O
",",O
is,O
given,O
as,O
follows,O
:,O
(,O
2,O
),O
Y,O
=,O
β0,O
+,O
βJurs_RNCGJurs_RNCG,O
+,O
βESES,O
where,O
Y,O
is,O
the,O
dependent,O
variable,O
standing,O
for,O
the,O
ligand,O
-,O
dependent,O
receptor,O
-,O
mediated,O
cellular,O
reaction,O
",",O
Jurs_RNCG,O
is,O
the,O
calculated,O
Jurs,O
descriptor,O
",",O
ES,O
are,O
all,O
the,O
possible,O
ES,O
descriptors,O
;,O
and,O
all,O
βs,O
are,O
the,O
estimated,O
regression,O
coefficients,O
after,O
the,O
least,O
squares,O
fit,O
.,O
The,O
context,O
equations,O
tagged,O
with,O
all,O
possible,O
ES,O
descriptors,O
are,O
prioritized,O
by,O
correlation,O
coefficient,O
.,O
12,O
top,O
-,O
ranked,O
ES,O
descriptors,O
monitored,O
in,O
the,O
table,O
indicate,O
12,O
important,O
structural,O
modifications,O
in,O
a,O
given,O
analog,O
set,O
.,O
Materials,O
Three,O
data,O
sets,O
of,O
analogs,O
with,O
two,O
cores,O
To,O
demonstrate,O
the,O
ability,O
of,O
this,O
tandem,O
regression,O
-,O
outlier,O
analysis,O
to,O
remove,O
all,O
interference,O
from,O
any,O
general,O
effects,O
in,O
a,O
ligand,O
cellular,O
system,O
",",O
three,O
data,O
sets,O
of,O
the,O
ligand,O
-,O
dependent,O
receptor,O
-,O
mediated,O
data,O
are,O
used,O
here,O
.,O
The,O
first,O
data,O
set,O
is,O
a,O
collection,O
of,O
46,O
PPARγ,B-GP
agonists,O
with,O
the,O
thiazolidinedione,O
(,O
TZD,O
),O
core,O
.,O
The,O
second,O
data,O
set,O
is,O
composed,O
of,O
178,O
PPARγ,B-GP
agonists,O
with,O
a,O
carboxylic,O
acid,O
core,O
.,O
The,O
third,O
data,O
set,O
is,O
a,O
merger,O
of,O
the,O
first,O
and,O
second,O
data,O
set,O
(,O
i,O
.,O
e,O
".,",O
224,O
PPARγ,B-GP
agonists,O
mixed,O
with,O
both,O
TZD,O
and,O
carboxylic,O
acid,O
cores,O
).,O
The,O
two,O
main,O
cores,O
of,O
PPARγ,B-GP
agonists,O
and,O
their,O
merger,O
are,O
adopted,O
",",O
so,O
as,O
to,O
observe,O
the,O
variations,O
of,O
top,O
-,O
ranked,O
structural,O
modifications,O
.,O
All,O
EC50,O
(,O
50,O
%,O
efficacy,O
concentration,O
),O
data,O
were,O
extracted,O
from,O
the,O
literature,O
[,O
7,O
-,O
21,O
].,O
The,O
cellular,O
reaction,O
is,O
the,O
measurement,O
of,O
the,O
activation,O
of,O
PPARγ,B-GP
within,O
the,O
construct,O
of,O
the,O
cellular,O
transactivation,O
assays,O
.,O
Indeterminate,O
and,O
uncertain,O
EC50,O
values,O
were,O
excluded,O
.,O
A,O
negative,O
logarithm,O
of,O
the,O
EC50,O
values,O
of,O
PPARγ,B-GP
agonists,O
was,O
then,O
taken,O
.,O
The,O
original,O
publication,O
of,O
all,O
agonists,O
and,O
the,O
activity,O
quantities,O
are,O
listed,O
in,O
Additional,O
file,O
1,O
:,O
Tables,O
S1,O
and,O
S2,O
.,O
All,O
images,O
of,O
molecular,O
structures,O
were,O
created,O
by,O
using,O
Pybel,O
[,O
29,O
",",O
30,O
].,O
All,O
molecular,O
structures,O
were,O
energetically,O
geometry,O
-,O
optimized,O
using,O
molecular,O
mechanics,O
and,O
MMF97,O
calculations,O
",",O
which,O
were,O
implemented,O
using,O
the,O
ChemBio3D,O
software,O
of,O
the,O
ChemBioOffice,O
package,O
[,O
31,O
].,O
Results,O
Jurs_RNCG,O
as,O
most,O
representative,O
descriptor,O
In,O
the,O
mathematical,O
formulation,O
in,O
the,O
first,O
tandem,O
filter,O
",",O
we,O
used,O
a,O
large,O
number,O
data,O
set,O
",",O
or,O
178,O
collected,O
carboxylic,O
acid,O
PPARγ,B-GP
agonists,O
",",O
as,O
a,O
base,O
to,O
seek,O
the,O
most,O
representative,O
descriptor,O
.,O
More,O
details,O
about,O
PPARγ,B-GP
agonists,O
are,O
available,O
in,O
Material,O
Section,O
.,O
To,O
check,O
the,O
size,O
dependency,O
",",O
for,O
each,O
data,O
size,O
from,O
10,O
to,O
170,O
",",O
a,O
total,O
of,O
521,O
×,O
17,O
data,O
sets,O
were,O
taken,O
for,O
the,O
selection,O
of,O
the,O
descriptor,O
just,O
for,O
the,O
enough,O
randomness,O
.,O
Sample,O
agonists,O
of,O
each,O
size,O
were,O
picked,O
out,O
by,O
prioritizing,O
521,O
molecular,O
properties,O
.,O
The,O
dominant,O
descriptor,O
and,O
the,O
frequency,O
of,O
the,O
Jurs,O
type,O
descriptor,O
for,O
each,O
size,O
",",O
including,O
Jurs_RNCG,O
[,O
6,O
"],",O
is,O
listed,O
in,O
Table,O
1,O
.,O
For,O
example,O
",",O
in,O
the,O
data,O
size,O
of,O
170,O
agonists,O
",",O
the,O
dominant,O
descriptors,O
of,O
369,O
data,O
sets,O
among,O
a,O
total,O
of,O
521,O
sets,O
are,O
all,O
Jurs_RNCG,O
.,O
We,O
can,O
clearly,O
see,O
that,O
when,O
the,O
data,O
size,O
increases,O
",",O
the,O
Jurs_RNCG,O
is,O
more,O
frequently,O
dominant,O
or,O
near,O
dominant,O
(,O
rank,O
>,O
4,O
).,O
In,O
Jurs,O
terminology,O
",",O
RNCG,O
means,O
a,O
relative,O
negative,O
charge,O
[,O
6,O
].,O
Dominant,O
descriptors,O
for,O
each,O
data,O
size,O
and,O
the,O
frequency,O
of,O
Jurs_RNCG,O
(,O
Jurs,O
type,O
descriptors,O
),O
throughout,O
521,O
data,O
sets,O
are,O
summarized,O
here,O
Data,O
size,O
Dominant,O
descriptor,O
(,O
Near,O
dominant,O
),O
Frequency,O
of,O
Jurs,O
descriptors,O
(,O
Jurs_RNCG,O
/,O
Jurs,O
type,O
/,O
521,O
data,O
sets,O
),O
10,O
Molecular_PolarSASA,O
4,O
/,O
41,O
/,O
521,O
20,O
Molecular_FractionalPolarSASA,O
5,O
/,O
25,O
/,O
521,O
30,O
ES_Count_dOb,O
4,O
/,O
14,O
/,O
521,O
40,O
Num_RingBonds,O
10,O
/,O
14,O
/,O
521,O
50,O
SC_3_Pa,O
9,O
/,O
16,O
/,O
521,O
60,O
SC_3_Pa,O
9,O
/,O
12,O
/,O
521,O
70,O
ICa,O
18,O
/,O
31,O
/,O
521,O
80,O
ICa,O
18,O
/,O
33,O
/,O
521,O
90,O
Jurs_RNCG,O
21,O
/,O
31,O
/,O
521,O
100,O
ICa,O
(,O
Jurs_RNCG,O
),O
19,O
/,O
31,O
/,O
521,O
110,O
Jurs_RNCG,O
16,O
/,O
21,O
/,O
521,O
120,O
Num_AtomClasses,O
(,O
Jurs_RNCG,O
),O
21,O
/,O
23,O
/,O
521,O
130,O
ICa,O
(,O
Jurs_RNCG,O
),O
28,O
/,O
29,O
/,O
521,O
140,O
ICa,O
(,O
Jurs_RNCG,O
),O
39,O
/,O
306,O
/,O
521,O
150,O
Jurs_RNCG,O
39,O
/,O
39,O
/,O
521,O
160,O
ICa,O
(,O
Jurs_RNCG,O
),O
53,O
/,O
53,O
/,O
521,O
170,O
Jurs_RNCG,O
369,O
/,O
369,O
/,O
521,O
a,O
The,O
descriptors,O
SC_3_P,O
and,O
IC,O
are,O
calculated,O
based,O
on,O
graph,O
theory,O
.,O
b,O
The,O
descriptor,O
ES_Count_dO,O
is,O
a,O
fractional,O
descriptor,O
(,O
The,O
definition,O
of,O
a,O
fractional,O
descriptor,O
is,O
in,O
the,O
discussion,O
section,O
).,O
Agonists,O
of,O
each,O
data,O
set,O
are,O
selected,O
out,O
of,O
the,O
178,O
carboxylic,O
acid,O
PPARγ,B-GP
agonists,O
.,O
The,O
top,O
-,O
ranked,O
descriptor,O
of,O
each,O
set,O
was,O
selected,O
from,O
521,O
descriptors,O
of,O
eminent,O
classes,O
.,O
In,O
a,O
realistic,O
physical,O
-,O
chemical,O
representation,O
",",O
one,O
would,O
prefer,O
the,O
Jurs_RNCG,O
to,O
the,O
IC,O
(,O
Information,O
Content,O
),O
[,O
32,O
],O
as,O
the,O
most,O
representative,O
descriptor,O
for,O
all,O
general,O
effects,O
.,O
This,O
is,O
because,O
Jurs_RNCG,O
was,O
originally,O
designed,O
based,O
on,O
the,O
charge,O
-,O
related,O
nature,O
.,O
The,O
descriptor,O
IC,O
",",O
as,O
an,O
index,O
of,O
graph,O
theory,O
",",O
deals,O
with,O
the,O
topological,O
aspect,O
in,O
nature,O
.,O
Therefore,O
",",O
the,O
Jurs_RNCG,O
descriptor,O
here,O
is,O
thought,O
to,O
be,O
the,O
most,O
representative,O
single,O
descriptor,O
for,O
all,O
general,O
effects,O
in,O
the,O
PPARγ,B-GP
agonist,O
cellular,O
system,O
.,O
After,O
this,O
designation,O
",",O
to,O
our,O
surprise,O
",",O
the,O
Jurs_RNCG,O
is,O
further,O
shown,O
to,O
be,O
a,O
linear,O
combination,O
of,O
three,O
important,O
descriptors,O
:,O
LogD,O
(,O
partition,O
coefficient,O
"),",O
PSA,O
(,O
polar,O
surface,O
area,O
"),",O
and,O
shape,O
-,O
like,O
descriptors,O
in,O
a,O
subsequent,O
work,O
[,O
33,O
].,O
These,O
three,O
descriptors,O
happen,O
to,O
be,O
the,O
three,O
most,O
important,O
factors,O
of,O
investigation,O
in,O
medicinal,O
chemistry,O
over,O
the,O
past,O
50,O
years,O
[,O
34,O
].,O
Top,O
-,O
ranked,O
ES,O
descriptors,O
as,O
important,O
structural,O
modifications,O
around,O
ligand,O
binding,O
Table,O
2,O
lists,O
the,O
12,O
top,O
-,O
ranked,O
ES,O
descriptors,O
for,O
the,O
46,O
TZD,O
PPARγ,B-GP
agonists,O
after,O
the,O
conduct,O
of,O
prioritization,O
in,O
the,O
second,O
tandem,O
detector,O
.,O
Table,O
3,O
lists,O
the,O
12,O
top,O
-,O
ranked,O
ES,O
descriptors,O
for,O
the,O
178,O
carboxylic,O
acid,O
PPARγ,B-GP
agonists,O
.,O
Table,O
4,O
",",O
which,O
is,O
the,O
merger,O
of,O
the,O
two,O
former,O
sets,O
",",O
lists,O
the,O
12,O
top,O
-,O
ranked,O
ES,O
descriptors,O
for,O
the,O
224,O
PPARγ,B-GP
agonists,O
.,O
The,O
striking,O
feature,O
in,O
all,O
three,O
tables,O
is,O
that,O
the,O
ES,O
symbol,O
",",O
ssO,O
",",O
ranks,O
in,O
the,O
first,O
position,O
.,O
‘,O
s,O
’,O
indicates,O
a,O
single,O
bond,O
.,O
‘,O
ss,O
’,O
indicates,O
two,O
single,O
bonds,O
linked,O
in,O
structure,O
.,O
This,O
feature,O
reflects,O
a,O
key,O
interaction,O
between,O
potent,O
agonist,O
and,O
PPARγ,B-GP
receptors,I-GP
",",O
which,O
shows,O
concurrence,O
with,O
the,O
inference,O
of,O
the,O
X,O
-,O
ray,O
crystallography,O
depicted,O
in,O
the,O
next,O
section,O
.,O
The,O
top,O
-,O
ranked,O
ES,O
descriptors,O
of,O
46,O
TZD,O
PPARγ,B-GP
agonists,O
ES,O
descriptors,O
Rank,O
Sign,O
of,O
βES,O
Count_ssO,O
1,O
-,O
Sum_ssO,O
2,O
-,O
Sum_sssN,O
3,O
+,O
Count_sssN,O
4,O
+,O
Count_ssCH2,O
5,O
+,O
Sum_aaO,O
6,O
+,O
Count_aaO,O
7,O
+,O
Count_sCH3,O
8,O
-,O
Sum_aaN,O
9,O
+,O
Count_aaN,O
10,O
+,O
Count_dsCH,O
11,O
-,O
Sum_dsCH,O
12,O
-,O
The,O
top,O
-,O
ranked,O
ES,O
descriptors,O
of,O
178,O
carboxylic,O
acid,O
PPARγ,B-GP
agonists,O
ES,O
descriptors,O
Rank,O
Sign,O
of,O
βES,O
Sum_ssO,O
1,O
-,O
Count_ssO,O
2,O
-,O
Sum_aaO,O
3,O
+,O
Count_aaO,O
4,O
+,O
Count_aaaC,O
5,O
+,O
Sum_ssCH2,O
6,O
-,O
Count_aaaC,O
7,O
+,O
Count_ssCH2,O
8,O
-,O
Count_aaNH,O
9,O
+,O
Sum_aaNH,O
10,O
+,O
Count_ssssC,O
11,O
-,O
Sum_sssN,O
12,O
+,O
The,O
top,O
-,O
ranked,O
ES,O
descriptors,O
of,O
224,O
PPARγ,B-GP
agonists,O
with,O
both,O
TZD,O
and,O
carboxylic,O
acid,O
cores,O
ES,O
descriptors,O
Rank,O
Sign,O
of,O
βES,O
Count_ssO,O
1,O
-,O
Sum_ssO,O
2,O
-,O
Sum_aaO,O
3,O
+,O
Count_aaO,O
4,O
+,O
Sum_aaaC,O
5,O
+,O
Count_aaaC,O
6,O
+,O
Count_sssN,O
7,O
+,O
Sum_sssN,O
8,O
+,O
Count_aaNH,O
9,O
+,O
Sum_aaNH,O
10,O
+,O
Sum_aaN,O
11,O
+,O
Count_aaN,O
12,O
+,O
To,O
begin,O
with,O
",",O
in,O
Table,O
2,O
",",O
the,O
ES_Count_ssO,O
and,O
ES_Sum_ssO,O
rank,O
in,O
most,O
top,O
positions,O
with,O
a,O
negative,O
regression,O
coefficient,O
.,O
Basically,O
",",O
this,O
is,O
a,O
negative,O
structural,O
modification,O
with,O
respect,O
to,O
cellular,O
reaction,O
.,O
But,O
care,O
should,O
be,O
taken,O
here,O
:,O
this,O
does,O
not,O
mean,O
that,O
the,O
existence,O
of,O
ssO,O
moiety,O
in,O
the,O
structure,O
is,O
bad,O
.,O
On,O
the,O
contrary,O
",",O
the,O
existence,O
of,O
single,O
ssO,O
moiety,O
is,O
extremely,O
good,O
.,O
(,O
We,O
can,O
read,O
this,O
from,O
the,O
most,O
potent,O
leads,O
which,O
all,O
have,O
tyrosine,O
moiety,O
.),O
When,O
examining,O
the,O
original,O
data,O
",",O
each,O
collected,O
TZD,O
PPARγ,B-GP
agonist,O
has,O
at,O
least,O
one,O
ssO,O
moiety,O
in,O
the,O
structure,O
",",O
here,O
known,O
as,O
an,O
oxygen,O
atom,O
in,O
tyrosine,O
moiety,O
.,O
The,O
correct,O
interpretation,O
for,O
the,O
sign,O
of,O
such,O
a,O
symbol,O
here,O
therefore,O
is,O
that,O
the,O
introduction,O
of,O
more,O
than,O
one,O
ssO,O
moiety,O
importantly,O
decreases,O
cellular,O
reaction,O
.,O
Rosiglitazone,O
",",O
an,O
established,O
drug,O
that,O
is,O
one,O
of,O
the,O
collected,O
TZD,O
agonists,O
",",O
shows,O
this,O
corresponding,O
feature,O
with,O
the,O
ES,O
symbol,O
",",O
ssO,O
in,O
Figure,O
1,O
(,O
a,O
).,O
Molecular,O
structures,O
of,O
:,O
(,O
a,O
),O
Rosiglitzaone,O
with,O
tyrosine,O
moiety,O
(,O
ssO,O
"),",O
(,O
b,O
),O
Rosiglitzaone,O
with,O
tertiary,O
alkylamine,O
moiety,O
(,O
sssN,O
"),",O
(,O
c,O
),O
AD,O
-,O
7075,O
and,O
BRL48482,O
with,O
oxazole,O
moiety,O
(,O
aaO,O
"),",O
and,O
(,O
d,O
),O
Two,O
carboxylic,O
acid,O
agonists,O
with,O
Fmoc,O
-,O
like,O
moiety,O
(,O
aaaC,O
).,O
All,O
moiety,O
structures,O
are,O
colored,O
in,O
blue,O
and,O
the,O
atom,O
of,O
the,O
ES,O
symbol,O
is,O
colored,O
in,O
red,O
.,O
Next,O
",",O
the,O
ES,O
symbol,O
sssN,O
",",O
indicates,O
the,O
introduction,O
of,O
a,O
tertiary,O
amine,O
(,O
sssN,O
),O
moiety,O
",",O
which,O
is,O
a,O
positive,O
structural,O
modification,O
.,O
‘,O
sss,O
’,O
indicates,O
three,O
single,O
bonds,O
linked,O
in,O
structure,O
.,O
Nine,O
agonists,O
have,O
1,O
sssN,O
moiety,O
of,O
the,O
46,O
collected,O
agonists,O
.,O
The,O
corresponding,O
feature,O
of,O
the,O
ES,O
symbol,O
",",O
sssN,O
",",O
in,O
the,O
tertiary,O
amine,O
(,O
sssN,O
),O
moiety,O
",",O
is,O
shown,O
in,O
Figure,O
1,O
(,O
b,O
).,O
The,O
next,O
ES,O
symbol,O
in,O
Table,O
2,O
is,O
ssCH2,O
.,O
The,O
positive,O
regression,O
coefficient,O
indicates,O
that,O
the,O
elongation,O
of,O
a,O
ligand,O
structure,O
through,O
the,O
addition,O
of,O
carbon,O
moiety,O
(,O
ssCH2,O
),O
is,O
a,O
positive,O
structural,O
modification,O
.,O
This,O
topological,O
elongation,O
of,O
the,O
agonist,O
makes,O
a,O
large,O
impact,O
to,O
the,O
molecular,O
binding,O
.,O
However,O
",",O
we,O
notice,O
that,O
the,O
ssCH2,O
symbol,O
is,O
negative,O
in,O
Table,O
3,O
.,O
And,O
",",O
when,O
combining,O
two,O
data,O
sets,O
in,O
Table,O
4,O
",",O
the,O
topological,O
structural,O
modification,O
ssCH2,O
falls,O
out,O
of,O
the,O
monitor,O
table,O
.,O
Apparently,O
",",O
the,O
suitable,O
length,O
of,O
the,O
TZD,O
agonist,O
is,O
optimal,O
for,O
cellular,O
binding,O
.,O
The,O
ES,O
symbol,O
following,O
this,O
in,O
Table,O
2,O
is,O
aaO,O
.,O
‘,O
aa,O
’,O
indicates,O
oxygen,O
atom,O
in,O
an,O
aromatic,O
ring,O
.,O
Throughout,O
the,O
whole,O
46,O
TZD,O
agonists,O
there,O
are,O
only,O
two,O
agonists,O
:,O
AD,O
-,O
7075,O
and,O
BRL48482,O
",",O
in,O
Figure,O
1,O
(,O
c,O
"),",O
that,O
have,O
the,O
oxazole,O
moiety,O
.,O
We,O
notice,O
that,O
these,O
two,O
agonists,O
serve,O
as,O
very,O
good,O
examples,O
of,O
“,O
analog,O
outliers,O
"”,",O
which,O
bear,O
specific,O
feature,O
of,O
outliers,O
The,O
other,O
ES,O
symbols,O
",",O
aaO,O
",",O
aaN,O
and,O
aaCH,O
",",O
also,O
indicate,O
this,O
oxazole,O
moiety,O
.,O
The,O
5,O
-,O
methyl,O
-,O
oxazole,O
of,O
AD,O
-,O
7075,O
has,O
the,O
additional,O
symbols,O
aasC,O
and,O
sCH3,O
whereas,O
the,O
benzo,O
-,O
oxazole,O
of,O
BRL48482,O
has,O
the,O
additional,O
symbol,O
aaaC,O
.,O
Taken,O
together,O
",",O
the,O
significance,O
of,O
oxazole,O
moieties,O
are,O
faithfully,O
pointed,O
out,O
by,O
these,O
symbols,O
.,O
The,O
other,O
monitored,O
symbols,O
",",O
sCH3,O
and,O
dsCH,O
",",O
indicate,O
other,O
",",O
less,O
important,O
",",O
structural,O
modifications,O
.,O
Lastly,O
",",O
in,O
Table,O
3,O
and,O
Table,O
4,O
",",O
we,O
find,O
a,O
similar,O
picture,O
regarding,O
the,O
potency,O
order,O
of,O
structural,O
modifications,O
.,O
The,O
top,O
ES,O
symbol,O
",",O
ssO,O
",",O
represents,O
the,O
most,O
important,O
structural,O
modification,O
",",O
tyrosine,O
moiety,O
",",O
performed,O
on,O
the,O
middle,O
part,O
of,O
PPARγ,B-GP
agonist,O
.,O
The,O
rest,O
of,O
the,O
top,O
-,O
ranked,O
ES,O
symbols,O
represent,O
important,O
structural,O
modifications,O
done,O
to,O
the,O
tail,O
part,O
.,O
For,O
example,O
",",O
a,O
fmoc,O
-,O
like,O
moiety,O
(,O
fluorenylmethyloxycarbonyl,O
-,O
like,O
"),",O
other,O
than,O
oxazole,O
moiety,O
and,O
tertiary,O
amine,O
",",O
is,O
another,O
case,O
which,O
has,O
an,O
ES,O
symbol,O
of,O
significance,O
:,O
aaaC,O
.,O
Again,O
",",O
serving,O
as,O
analog,O
outliers,O
",",O
these,O
two,O
potent,O
agonists,O
[,O
18,O
],O
are,O
shown,O
in,O
Figure,O
1,O
(,O
d,O
).,O
There,O
is,O
one,O
more,O
observation,O
:,O
we,O
can,O
clearly,O
see,O
that,O
no,O
ES,O
symbol,O
regarding,O
TZD,O
moieties,O
",",O
dssC,O
",",O
dO,O
",",O
sssCH,O
",",O
ssNH,O
",",O
or,O
ssS,O
",",O
appears,O
in,O
Table,O
2,O
;,O
and,O
we,O
can,O
also,O
see,O
that,O
no,O
carboxylic,O
acid,O
symbols,O
",",O
such,O
as,O
dssC,O
",",O
dO,O
",",O
or,O
sOH,O
",",O
appear,O
in,O
Table,O
3,O
.,O
‘,O
d,O
’,O
indicates,O
double,O
bond,O
.,O
When,O
combining,O
the,O
two,O
data,O
sets,O
",",O
no,O
ES,O
symbols,O
regarding,O
TZD,O
or,O
carboxylic,O
acid,O
appear,O
in,O
Table,O
4,O
.,O
There,O
are,O
two,O
simple,O
interpretations,O
of,O
this,O
:,O
1,O
",",O
the,O
lack,O
of,O
modification,O
of,O
the,O
core,O
part,O
of,O
analogs,O
in,O
a,O
given,O
set,O
will,O
naturally,O
lead,O
to,O
no,O
ES,O
symbols,O
monitored,O
in,O
the,O
table,O
",",O
and,O
2,O
",",O
a,O
core,O
shift,O
in,O
the,O
combined,O
set,O
without,O
causing,O
a,O
large,O
difference,O
of,O
reaction,O
will,O
not,O
produce,O
related,O
ES,O
symbols,O
of,O
significance,O
.,O
Thus,O
",",O
in,O
conclusion,O
",",O
the,O
TZD,O
and,O
carboxylic,O
acid,O
are,O
known,O
as,O
the,O
necessary,O
parts,O
of,O
full,O
PPARγ,B-GP
agonists,O
without,O
synthetic,O
modifications,O
.,O
The,O
necessity,O
of,O
two,O
essential,O
cores,O
for,O
full,O
cellular,O
activity,O
can,O
be,O
immediately,O
inferred,O
when,O
comparing,O
the,O
inactive,O
compounds,O
at,O
initial,O
synthesis,O
.,O
The,O
top,O
-,O
ranked,O
ES,O
symbols,O
point,O
out,O
key,O
ligand,O
binding,O
interactions,O
As,O
mentioned,O
in,O
the,O
introduction,O
",",O
we,O
would,O
like,O
to,O
see,O
if,O
the,O
top,O
-,O
ranked,O
ES,O
descriptor,O
finds,O
its,O
corresponding,O
key,O
interactions,O
for,O
molecular,O
binding,O
.,O
In,O
this,O
section,O
we,O
examine,O
real,O
physical,O
pictures,O
.,O
First,O
",",O
in,O
Table,O
2,O
",",O
the,O
top,O
-,O
ranked,O
ES,O
symbols,O
are,O
ssO,O
and,O
sssN,O
.,O
We,O
can,O
go,O
to,O
the,O
crystallographic,O
image,O
of,O
the,O
rosiglitazone,O
-,O
PPARγ,B-GP
complex,O
(,O
PDB,O
code,O
:,O
2PRG,O
),O
[,O
35,O
].,O
Figure,O
2,O
shows,O
",",O
around,O
the,O
bound,O
structure,O
of,O
rosiglitazone,O
",",O
that,O
the,O
ES,O
symbol,O
ssO,O
can,O
detect,O
the,O
key,O
interaction,O
between,O
rosiglitazone,O
ether,O
oxygen,O
and,O
two,O
sulfurs,O
of,O
Cys285,O
(,O
3,O
.,O
79,O
Å,O
),O
and,O
Met364,O
(,O
4,O
.,O
70,O
Å,O
).,O
Another,O
important,O
ES,O
symbol,O
",",O
sssN,O
",",O
detects,O
the,O
key,O
interaction,O
between,O
rosiglitazone,O
tertiary,O
amine,O
nitrogen,O
and,O
Cys285,O
side,O
-,O
chain,O
sulfur,O
(,O
4,O
.,O
44,O
Å,O
"),",O
or,O
Leu340,O
backbone,O
oxygen,O
(,O
4,O
.,O
46,O
Å,O
).,O
We,O
noticed,O
that,O
all,O
the,O
measured,O
distances,O
are,O
between,O
relevant,O
heavy,O
atoms,O
because,O
hydrogen,O
is,O
transparent,O
in,O
X,O
-,O
ray,O
crystallography,O
.,O
Illustration,O
of,O
the,O
top,O
-,O
ranked,O
ES,O
symbols,O
",",O
ssO,O
and,O
sssN,O
.,O
Around,O
the,O
bound,O
structure,O
of,O
rosiglitazone,O
(,O
PDB,O
:,O
2PRG,O
"),",O
the,O
ES,O
symbol,O
ssO,O
can,O
detect,O
the,O
key,O
interaction,O
between,O
rosiglitazone,O
ether,O
oxygen,O
and,O
the,O
two,O
sulfurs,O
of,O
Cys285,O
(,O
3,O
.,O
79,O
Å,O
),O
and,O
Met364,O
(,O
4,O
.,O
70,O
Å,O
).,O
Another,O
important,O
ES,O
symbol,O
",",O
sssN,O
",",O
detects,O
the,O
key,O
interaction,O
between,O
rosiglitazone,O
trialkylamine,O
nitrogen,O
and,O
Cys285,O
side,O
-,O
chain,O
sulfur,O
(,O
4,O
.,O
44,O
Å,O
"),",O
or,O
Leu340,O
backbone,O
oxygen,O
(,O
4,O
.,O
46,O
Å,O
).,O
Notice,O
that,O
all,O
the,O
measured,O
distances,O
are,O
between,O
relevant,O
heavy,O
atoms,O
because,O
hydrogen,O
is,O
transparent,O
in,O
the,O
X,O
-,O
ray,O
crystallography,O
.,O
Second,O
",",O
in,O
Table,O
3,O
",",O
the,O
top,O
-,O
ranked,O
ES,O
symbols,O
are,O
ssO,O
and,O
aaO,O
.,O
We,O
then,O
look,O
at,O
the,O
crystallographic,O
image,O
of,O
the,O
1K74,O
ligand,O
-,O
PPARγ,B-GP
complex,O
(,O
PDB,O
code,O
:,O
1K47,O
),O
[,O
36,O
].,O
Figure,O
3,O
shows,O
that,O
",",O
around,O
the,O
bound,O
structure,O
of,O
the,O
1K47,O
ligand,O
",",O
a,O
important,O
ES,O
symbol,O
",",O
ssO,O
",",O
can,O
detect,O
the,O
key,O
interaction,O
between,O
1K74,O
ligand,O
ether,O
oxygen,O
and,O
Cys285,O
side,O
-,O
chain,O
sulfur,O
(,O
3,O
.,O
63,O
Å,O
),O
or,O
Met364,O
sulfur,O
(,O
4,O
.,O
87,O
Å,O
).,O
Another,O
important,O
ES,O
symbol,O
",",O
aaO,O
",",O
detects,O
the,O
key,O
interactions,O
between,O
1K74,O
ligand,O
oxazole,O
oxygen,O
and,O
Cys285,O
side,O
-,O
chain,O
sulfur,O
(,O
3,O
.,O
61,O
Å,O
).,O
Here,O
we,O
also,O
measured,O
the,O
distance,O
(,O
4,O
.,O
95,O
Å,O
),O
between,O
oxazole,O
nitrogen,O
(,O
aaN,O
),O
and,O
Leu340,O
backbone,O
oxygen,O
.,O
The,O
symbol,O
",",O
aaN,O
",",O
as,O
a,O
important,O
structural,O
modification,O
of,O
the,O
tail,O
part,O
",",O
is,O
indicated,O
in,O
Tables,O
2,O
and,O
4,O
.,O
More,O
ES,O
symbols,O
regarding,O
the,O
tail,O
part,O
modifications,O
of,O
PPARγ,B-GP
agonists,O
",",O
as,O
mentioned,O
above,O
",",O
can,O
also,O
detect,O
their,O
corresponding,O
key,O
interactions,O
in,O
other,O
crystallographic,O
images,O
of,O
potent,O
PPARγ,B-GP
agonists,O
.,O
Illustration,O
of,O
the,O
top,O
-,O
ranked,O
ES,O
symbols,O
ssO,O
",",O
aaO,O
",",O
and,O
aaN,O
.,O
Around,O
a,O
bound,O
structure,O
of,O
1K47,O
ligand,O
(,O
PDB,O
:,O
1k47,O
"),",O
the,O
important,O
ES,O
symbol,O
ssO,O
can,O
detect,O
the,O
key,O
interaction,O
between,O
1K74,O
ligand,O
ether,O
oxygen,O
and,O
Cys285,O
side,O
-,O
chain,O
sulfur,O
(,O
3,O
.,O
63,O
Å,O
),O
or,O
Met364,O
sulfur,O
(,O
4,O
.,O
87,O
Å,O
).,O
Another,O
key,O
ES,O
symbol,O
",",O
aaO,O
",",O
detects,O
the,O
key,O
interactions,O
between,O
1K74,O
ligand,O
oxazole,O
oxygen,O
and,O
Cys285,O
side,O
-,O
chain,O
sulfur,O
(,O
3,O
.,O
61,O
Å,O
).,O
Here,O
we,O
also,O
measured,O
the,O
distance,O
(,O
4,O
.,O
95,O
Å,O
),O
between,O
oxazole,O
nitrogen,O
(,O
aaN,O
),O
and,O
Leu340,O
backbone,O
oxygen,O
.,O
Taken,O
together,O
",",O
these,O
correspondences,O
clearly,O
point,O
out,O
that,O
the,O
top,O
-,O
ranked,O
ES,O
symbols,O
are,O
the,O
key,O
structural,O
modifications,O
surrounding,O
molecular,O
binding,O
.,O
Discussion,O
Jurs_RNCG,O
as,O
a,O
filter,O
The,O
descriptor,O
Jurs_RNCG,O
acts,O
as,O
a,O
filter,O
.,O
One,O
might,O
expect,O
to,O
see,O
some,O
outcomes,O
if,O
the,O
single,O
Jurs_RNCG,O
descriptor,O
is,O
not,O
included,O
",",O
i,O
.,O
e,O
.,O
there,O
is,O
no,O
first,O
filter,O
of,O
this,O
tandem,O
technique,O
.,O
Apparently,O
",",O
all,O
general,O
effects,O
will,O
contribute,O
to,O
the,O
top,O
-,O
ranked,O
ES,O
descriptor,O
.,O
In,O
Additional,O
file,O
1,O
:,O
Table,O
S3,O
",",O
for,O
example,O
",",O
the,O
top,O
-,O
ranked,O
ES,O
symbol,O
",",O
ssO,O
",",O
tyrosine,O
moiety,O
",",O
of,O
PPARγ,B-GP
agonists,O
",",O
falls,O
outside,O
the,O
monitor,O
table,O
.,O
In,O
other,O
words,O
",",O
we,O
need,O
a,O
descriptor,O
in,O
the,O
first,O
regression,O
that,O
can,O
effectively,O
remove,O
the,O
general,O
effect,O
of,O
a,O
ligand,O
cellular,O
system,O
.,O
As,O
mentioned,O
above,O
",",O
one,O
purpose,O
for,O
using,O
Jurs_RNCG,O
is,O
to,O
leave,O
outliers,O
for,O
the,O
second,O
part,O
.,O
Moreover,O
",",O
the,O
potency,O
orders,O
and,O
tendencies,O
(,O
signs,O
of,O
regression,O
coefficients,O
),O
of,O
structural,O
modifications,O
coincide,O
with,O
our,O
knowledge,O
about,O
the,O
structural,O
modifications,O
of,O
PPARγ,B-GP
agonists,O
.,O
So,O
the,O
top,O
-,O
ranked,O
structural,O
modifications,O
can,O
detect,O
their,O
corresponding,O
key,O
interactions,O
surrounding,O
molecular,O
binding,O
",",O
as,O
shown,O
in,O
the,O
X,O
-,O
ray,O
image,O
of,O
a,O
potent,O
agonist,O
-,O
PPARγ,B-GP
complex,O
.,O
The,O
outcomes,O
of,O
such,O
a,O
regression,O
-,O
outlier,O
analysis,O
also,O
tell,O
us,O
that,O
the,O
Jurs_RNCG,O
is,O
truly,O
an,O
adequate,O
filter,O
.,O
In,O
addition,O
",",O
and,O
exceeding,O
our,O
expectations,O
",",O
the,O
Jurs_RNCG,O
can,O
be,O
expressed,O
in,O
a,O
linear,O
combination,O
of,O
partition,O
coefficients,O
",",O
polar,O
surface,O
area,O
",",O
and,O
shape,O
-,O
like,O
descriptors,O
[,O
33,O
"],",O
which,O
further,O
reveals,O
three,O
essential,O
factors,O
for,O
drug,O
-,O
cell,O
interfaces,O
in,O
such,O
a,O
ligand,O
cellular,O
system,O
[,O
34,O
].,O
Three,O
types,O
of,O
dependency,O
in,O
the,O
top,O
-,O
ranked,O
ES,O
descriptors,O
For,O
a,O
closer,O
inspection,O
of,O
the,O
top,O
-,O
ranked,O
ES,O
descriptors,O
",",O
the,O
ES,O
symbols,O
from,O
Table,O
2,O
were,O
intentionally,O
combined,O
in,O
a,O
single,O
fitting,O
equation,O
.,O
Three,O
fitting,O
equations,O
are,O
listed,O
in,O
Table,O
5,O
.,O
First,O
",",O
in,O
Equation,O
1,O
of,O
Table,O
5,O
",",O
the,O
ES,O
symbol,O
Sum_ssO,O
",",O
has,O
a,O
positive,O
regression,O
coefficient,O
opposite,O
to,O
the,O
sign,O
presented,O
in,O
Table,O
2,O
.,O
In,O
Equation,O
2,O
",",O
the,O
symbol,O
Count_sssN,O
",",O
has,O
a,O
negative,O
regression,O
coefficient,O
opposite,O
to,O
the,O
sign,O
provided,O
in,O
Table,O
2,O
.,O
At,O
the,O
same,O
time,O
",",O
we,O
noticed,O
that,O
the,O
correlation,O
(,O
r,O
),O
between,O
Count_ssO,O
and,O
Sum_ssO,O
in,O
this,O
46,O
TZD,O
data,O
set,O
is,O
+,O
0,O
.,O
98,O
and,O
the,O
correlation,O
(,O
r,O
),O
between,O
Count_sssN,O
and,O
Sum_sssN,O
is,O
+,O
0,O
.,O
99,O
;,O
i,O
.,O
e,O
".,",O
they,O
have,O
extremely,O
significant,O
positive,O
correlations,O
.,O
In,O
the,O
interest,O
of,O
realistic,O
representation,O
",",O
it,O
is,O
impossible,O
that,O
an,O
identical,O
important,O
structural,O
modification,O
be,O
represented,O
by,O
two,O
highly,O
positive,O
-,O
correlated,O
descriptors,O
indicating,O
different,O
tendencies,O
.,O
However,O
",",O
the,O
fitting,O
regression,O
coefficient,O
resulting,O
in,O
the,O
different,O
signs,O
in,O
these,O
2,O
equations,O
is,O
obvious,O
.,O
Therefore,O
",",O
the,O
Count_ssO,O
and,O
Sum_ssO,O
(,O
or,O
",",O
the,O
Count_sssN,O
and,O
Sum_sssN,O
),O
have,O
a,O
dependency,O
of,O
description,O
on,O
identical,O
structural,O
modification,O
.,O
The,O
ES,O
symbols,O
monitored,O
in,O
the,O
Table2are,O
intentionally,O
combined,O
in,O
a,O
single,O
fitting,O
equation,O
#,O
Equation,O
1,O
Y,O
=,O
4,O
.,O
97,O
−,O
20,O
.,O
8Jurs,O
_,O
RNCG,O
−,O
2,O
.,O
81,O
Count,O
_,O
ssO,O
+,O
0,O
.,O
38,O
Sum,O
_,O
ssO,O
*,O
2,O
Y,O
=,O
3,O
.,O
41,O
−,O
4,O
.,O
50,O
Jurs_RNCG,O
−,O
3,O
.,O
09,O
Count_ssO,O
+,O
0,O
.,O
47,O
Sum_ssO,O
*,O
+,O
0,O
.,O
95,O
Sum_sssN,O
−,O
0,O
.,O
86,O
Count_ssN,O
*,O
3,O
Y,O
=,O
3,O
.,O
34,O
−,O
11,O
.,O
1,O
Jurs_RNCG,O
−,O
0,O
.,O
33,O
Count_ssO,O
+,O
0,O
.,O
31Count_sssN,O
+,O
0,O
.,O
47,O
Count_aaO,O
−,O
0,O
.,O
33,O
Count_sCH3,O
−,O
0,O
.,O
079,O
Count_aaN,O
*,O
*,O
The,O
coefficient,O
signs,O
of,O
these,O
ES,O
symbols,O
labeled,O
with,O
star,O
signs,O
(*),O
contradict,O
the,O
ones,O
presented,O
in,O
Table,O
2,O
.,O
Three,O
fitting,O
equations,O
with,O
signs,O
of,O
regression,O
coefficients,O
are,O
presented,O
.,O
Second,O
",",O
by,O
removing,O
the,O
modification,O
description,O
dependency,O
",",O
the,O
Count,O
and,O
Sum,O
values,O
of,O
the,O
same,O
ES,O
symbol,O
are,O
not,O
in,O
the,O
same,O
equation,O
.,O
In,O
Equation,O
3,O
of,O
Table,O
5,O
",",O
the,O
symbol,O
Count_aaN,O
has,O
a,O
negative,O
regression,O
coefficient,O
compared,O
to,O
the,O
sign,O
listed,O
in,O
Table,O
2,O
.,O
It,O
therefore,O
contradicts,O
the,O
observation,O
that,O
the,O
captured,O
symbols,O
",",O
aaO,O
",",O
aaaC,O
",",O
sssN,O
",",O
aaNH,O
",",O
and,O
aaN,O
",",O
represent,O
positive,O
structural,O
modifications,O
to,O
the,O
tail,O
part,O
of,O
PPARγ,B-GP
agonists,O
.,O
Obviously,O
",",O
in,O
this,O
equation,O
form,O
3,O
",",O
the,O
symbols,O
aaO,O
and,O
sssN,O
represent,O
the,O
identical,O
key,O
interaction,O
in,O
the,O
tail,O
part,O
of,O
PPARγ,B-GP
agonists,O
",",O
and,O
the,O
simultaneous,O
appearance,O
of,O
them,O
for,O
the,O
same,O
moiety,O
turned,O
the,O
regression,O
coefficient,O
of,O
the,O
additional,O
aaN,O
into,O
the,O
opposite,O
sign,O
.,O
Thus,O
",",O
one,O
can,O
say,O
here,O
that,O
the,O
ES,O
symbols,O
aaN,O
",",O
aaO,O
and,O
sssN,O
have,O
dependency,O
of,O
description,O
on,O
the,O
identical,O
moiety,O
.,O
Third,O
",",O
throughout,O
all,O
of,O
the,O
46,O
TZD,O
PPARγ,B-GP
agonists,O
",",O
when,O
examining,O
the,O
values,O
of,O
the,O
symbol,O
aaO,O
and,O
related,O
structural,O
moieties,O
",",O
we,O
found,O
that,O
no,O
structural,O
moiety,O
contains,O
this,O
aaO,O
feature,O
aside,O
for,O
oxazole,O
.,O
The,O
moiety,O
oxazole,O
exists,O
only,O
in,O
the,O
two,O
potent,O
agonists,O
AD,O
-,O
7057,O
and,O
BRL48482,O
[,O
10,O
].,O
The,O
value,O
of,O
ES_Count_aaO,O
is,O
1,O
for,O
these,O
2,O
agonists,O
whereas,O
the,O
value,O
is,O
0,O
for,O
the,O
rest,O
of,O
collected,O
PPARγ,B-GP
agonists,O
.,O
The,O
ES,O
symbols,O
of,O
oxazole,O
have,O
aaO,O
",",O
aaN,O
",",O
and,O
aaCH,O
.,O
Four,O
agonists,O
have,O
the,O
aaN,O
structural,O
moiety,O
of,O
these,O
46,O
collected,O
agonists,O
and,O
",",O
among,O
those,O
four,O
",",O
two,O
compounds,O
are,O
AD,O
-,O
7057,O
and,O
BRL48482,O
.,O
Moreover,O
",",O
all,O
agonists,O
have,O
the,O
aaCH,O
structural,O
moiety,O
",",O
but,O
the,O
symbol,O
aaCH,O
does,O
not,O
appear,O
in,O
Table,O
2,O
.,O
Clearly,O
",",O
the,O
symbols,O
aaO,O
",",O
aaN,O
and,O
aaCH,O
have,O
unequal,O
dependencies,O
of,O
description,O
in,O
these,O
data,O
samples,O
.,O
Especially,O
",",O
these,O
dependencies,O
of,O
descriptor,O
will,O
actually,O
cause,O
serious,O
consequence,O
to,O
all,O
QSARs,O
of,O
four,O
categories,O
(,O
classical,O
",",O
3,O
-,O
dimensional,O
",",O
decisional,O
and,O
orthogonal,O
),O
[,O
37,O
-,O
39,O
"],",O
their,O
existence,O
would,O
make,O
a,O
model,O
lose,O
its,O
interpretability,O
.,O
Put,O
together,O
",",O
the,O
three,O
types,O
of,O
dependencies,O
in,O
the,O
top,O
-,O
ranked,O
ES,O
symbols,O
actually,O
play,O
a,O
major,O
role,O
in,O
the,O
design,O
of,O
the,O
context,O
equation,O
.,O
That,O
is,O
",",O
two,O
ES,O
symbols,O
don,O
’,O
t,O
appear,O
simultaneously,O
in,O
a,O
context,O
equation,O
.,O
Obviously,O
",",O
if,O
one,O
forces,O
two,O
dependent,O
ES,O
descriptors,O
to,O
be,O
combined,O
in,O
a,O
single,O
equation,O
",",O
the,O
signs,O
in,O
the,O
regression,O
coefficients,O
of,O
key,O
structural,O
modifications,O
may,O
change,O
",",O
and,O
thus,O
fail,O
to,O
point,O
out,O
the,O
real,O
tendency,O
of,O
impact,O
to,O
ligand,O
binding,O
in,O
an,O
analog,O
set,O
.,O
If,O
one,O
mixes,O
two,O
ES,O
descriptors,O
in,O
a,O
single,O
equation,O
acting,O
as,O
a,O
detector,O
",",O
the,O
one,O
in,O
this,O
regression,O
-,O
outlier,O
analysis,O
will,O
lose,O
its,O
ability,O
to,O
correctly,O
detect,O
the,O
real,O
tendencies,O
of,O
key,O
structural,O
modifications,O
in,O
the,O
given,O
analog,O
sets,O
.,O
Conclusions,O
The,O
innovative,O
point,O
of,O
the,O
present,O
study,O
is,O
the,O
fact,O
that,O
we,O
used,O
a,O
statistical,O
regression,O
and,O
its,O
outlier,O
as,O
a,O
computational,O
technique,O
for,O
separation,O
.,O
This,O
technique,O
was,O
used,O
specifically,O
in,O
the,O
ligand,O
cellular,O
system,O
.,O
As,O
a,O
counterpart,O
to,O
the,O
hard,O
equipment,O
in,O
the,O
tandem,O
technique,O
",",O
the,O
prior,O
molecular,O
descriptor,O
resembles,O
a,O
filter,O
that,O
removes,O
the,O
influence,O
from,O
the,O
bulk,O
of,O
a,O
cell,O
and,O
the,O
latter,O
class,O
of,O
descriptors,O
is,O
an,O
array,O
of,O
detectors,O
that,O
can,O
identify,O
any,O
important,O
identities,O
.,O
In,O
the,O
case,O
of,O
the,O
PPARγ,B-GP
agonist,O
cellular,O
system,O
",",O
the,O
key,O
structural,O
modifications,O
surrounding,O
ligand,O
binding,O
were,O
successfully,O
detected,O
and,O
the,O
tendencies,O
of,O
impact,O
were,O
examined,O
.,O
In,O
the,O
end,O
",",O
after,O
the,O
tandem,O
regression,O
-,O
outlier,O
analysis,O
of,O
this,O
ligand,O
cellular,O
system,O
",",O
the,O
results,O
show,O
that,O
this,O
prioritization,O
of,O
the,O
context,O
equations,O
(,O
filter,O
),O
tagged,O
with,O
features,O
of,O
outliers,O
(,O
detector,O
),O
is,O
an,O
effective,O
computational,O
tool,O
for,O
cheminformatics,O
to,O
detect,O
possible,O
features,O
of,O
outliers,O
(,O
key,O
structural,O
modifications,O
"),",O
as,O
well,O
as,O
their,O
impact,O
tendencies,O
to,O
ligand,O
binding,O
.,O
Competing,O
interests,O
The,O
author,O
declares,O
that,O
he,O
has,O
no,O
competing,O
interests,O
.,O
Supplementary,O
Material,O
Additional,O
file,O
1,O
:,O
Table,O
S1,O
Lists,O
the,O
structures,O
of,O
the,O
TZD,O
PPARγ,B-GP
agonists,O
with,O
their,O
activities,O
.,O
All,O
images,O
of,O
molecular,O
structures,O
were,O
created,O
by,O
using,O
Pybel,O
[,O
29,O
",",O
30,O
].,O
Table,O
S2,O
lists,O
the,O
structures,O
of,O
the,O
Carboxylic,O
(,O
COOH,O
),O
PPARγ,B-GP
agonists,O
with,O
their,O
activities,O
.,O
All,O
images,O
of,O
molecular,O
structures,O
were,O
created,O
by,O
using,O
Pybel,O
[,O
29,O
",",O
30,O
].,O
Table,O
S3,O
lists,O
the,O
top,O
-,O
ranked,O
ES,O
descriptors,O
of,O
178,O
carboxylic,O
acid,O
PPARγ,B-GP
agonists,O
against,O
cellular,O
reactions,O
",",O
without,O
the,O
inclusion,O
of,O
Jurs_RNCG,O
.,O
Click,O
here,O
for,O
file,O
Protective,O
and,O
therapeutic,O
role,O
of,O
2,O
-,O
carba,O
-,O
cyclic,O
phosphatidic,O
acid,O
in,O
demyelinating,B-DS
disease,I-DS
Background,O
Multiple,B-DS
sclerosis,I-DS
is,O
a,O
neuroinflammatory,O
demyelinating,O
and,O
neurodegenerative,B-DS
disease,I-DS
of,O
the,O
central,O
nervous,O
system,O
characterized,O
by,O
recurrent,O
and,O
progressive,O
demyelination,B-DS
/,O
remyelination,O
cycles,O
",",O
neuroinflammation,O
",",O
oligodendrocyte,O
loss,O
",",O
demyelination,B-DS
",",O
and,O
axonal,O
degeneration,O
.,O
Cyclic,O
phosphatidic,O
acid,O
(,O
cPA,O
),O
is,O
a,O
natural,O
phospholipid,O
mediator,O
with,O
a,O
unique,O
cyclic,O
phosphate,O
ring,O
structure,O
at,O
the,O
sn,O
-,O
2,O
and,O
sn,O
-,O
3,O
positions,O
of,O
the,O
glycerol,O
backbone,O
.,O
We,O
reported,O
earlier,O
that,O
cPA,O
elicits,O
a,O
neurotrophin,B-GP
-,O
like,O
action,O
and,O
protects,O
hippocampal,O
neurons,O
from,O
ischemia,O
-,O
induced,O
delayed,O
neuronal,O
death,O
.,O
We,O
designed,O
",",O
chemically,O
synthesized,O
",",O
and,O
metabolically,O
stabilized,O
derivatives,O
of,O
cPA,O
:,O
2,O
-,O
carba,O
-,O
cPA,O
(,O
2ccPA,O
"),",O
a,O
synthesized,O
compound,O
in,O
which,O
one,O
of,O
the,O
phosphate,O
oxygen,O
molecules,O
is,O
replaced,O
with,O
a,O
methylene,O
group,O
at,O
the,O
sn,O
-,O
2,O
position,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
investigated,O
whether,O
2ccPA,O
exerts,O
protective,O
effects,O
in,O
oligodendrocytes,O
and,O
suppresses,O
pathology,O
in,O
the,O
two,O
most,O
common,O
mouse,B-OG
models,O
of,O
multiple,B-DS
sclerosis,I-DS
.,O
Methods,O
To,O
evaluate,O
whether,O
2ccPA,O
has,O
potential,O
beneficial,O
effects,O
on,O
the,O
pathology,O
of,O
multiple,B-DS
sclerosis,I-DS
",",O
we,O
investigated,O
the,O
effects,O
of,O
2ccPA,O
on,O
oligodendrocyte,O
cell,O
death,O
in,O
vitro,O
and,O
administrated,O
2ccPA,O
to,O
mouse,B-OG
models,O
of,O
experimental,B-DS
autoimmune,I-DS
encephalomyelitis,I-DS
(,O
EAE,B-DS
),O
and,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
.,O
Results,O
We,O
demonstrated,O
that,O
2ccPA,O
suppressed,O
the,O
CoCl2,O
-,O
induced,O
increase,O
in,O
the,O
Bax,B-GP
/,O
Bcl,B-GP
-,I-GP
2,I-GP
protein,O
expression,O
ratio,O
and,O
phosphorylation,O
levels,O
of,O
p38MAPK,B-GP
and,O
JNK,B-GP
protein,O
.,O
2ccPA,O
treatment,O
reduced,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
",",O
microglial,O
activation,O
",",O
NLRP3,B-GP
inflammasome,O
",",O
and,O
motor,O
dysfunction,O
.,O
Furthermore,O
",",O
2ccPA,O
treatment,O
reduced,O
autoreactive,O
T,O
cells,O
and,O
macrophages,O
",",O
spinal,B-DS
cord,I-DS
injury,I-DS
",",O
and,O
pathological,O
scores,O
in,O
EAE,B-DS
",",O
the,O
autoimmune,O
multiple,B-DS
sclerosis,I-DS
mouse,B-OG
model,O
.,O
Conclusions,O
We,O
demonstrated,O
that,O
2ccPA,O
protected,O
oligodendrocytes,O
via,O
suppression,O
of,O
the,O
mitochondrial,O
apoptosis,O
pathway,O
.,O
Also,O
",",O
we,O
found,O
beneficial,O
effects,O
of,O
2ccPA,O
in,O
the,O
multiperiod,O
of,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
and,O
the,O
pathology,O
of,O
EAE,B-DS
.,O
These,O
data,O
indicate,O
that,O
2ccPA,O
may,O
be,O
a,O
promising,O
compound,O
for,O
the,O
development,O
of,O
new,O
drugs,O
to,O
treat,O
demyelinating,B-DS
disease,I-DS
and,O
ameliorate,O
the,O
symptoms,O
of,O
multiple,B-DS
sclerosis,I-DS
.,O
Background,O
Multiple,B-DS
sclerosis,I-DS
is,O
an,O
inflammatory,O
demyelinating,O
and,O
neurodegenerative,B-DS
disease,I-DS
of,O
the,O
CNS,O
characterized,O
by,O
recurrent,O
and,O
progressive,O
demyelination,B-DS
/,O
remyelination,O
cycles,O
",",O
neuroinflammation,O
",",O
oligodendrocyte,O
loss,O
",",O
demyelination,B-DS
",",O
and,O
axonal,O
degeneration,O
[,O
1,O
–,O
3,O
].,O
In,O
multiple,B-DS
sclerosis,I-DS
",",O
oligodendrocytes,O
are,O
the,O
target,O
of,O
inflammatory,O
attacks,O
and,O
their,O
cell,O
death,O
mediated,O
by,O
activated,O
lymphocytes,O
",",O
macrophages,O
",",O
and,O
glial,O
activation,O
results,O
in,O
axonal,O
demyelination,B-DS
.,O
Since,O
myelin,O
-,O
forming,O
oligodendrocytes,O
provide,O
critical,O
support,O
to,O
the,O
neuronal,O
axon,O
",",O
demyelination,B-DS
results,O
in,O
diverse,O
neurological,O
symptoms,O
determined,O
by,O
the,O
functions,O
of,O
affected,O
neurons,O
.,O
Therefore,O
",",O
therapies,O
designed,O
to,O
protect,O
oligodendrocytes,O
and,O
myelin,O
during,O
neuroinflammation,O
are,O
important,O
strategies,O
to,O
halt,O
the,O
progression,O
of,O
multiple,B-DS
sclerosis,I-DS
.,O
The,O
most,O
commonly,O
studied,O
animal,B-OG
models,O
of,O
multiple,B-DS
sclerosis,I-DS
are,O
the,O
autoimmune,O
experimental,B-DS
autoimmune,I-DS
encephalomyelitis,I-DS
(,O
EAE,B-DS
),O
model,O
[,O
4,O
",",O
5,O
],O
and,O
the,O
cuprizone,O
(,O
bis,O
-,O
cyclohexanone,O
-,O
oxalyldihydrazone,O
",",O
CPZ,O
)-,O
induced,O
demyelination,B-DS
model,O
[,O
6,O
",",O
7,O
].,O
Extensive,O
research,O
regarding,O
the,O
detailed,O
mechanisms,O
underlying,O
immune,O
-,O
mediated,O
demyelination,B-DS
in,O
multiple,B-DS
sclerosis,I-DS
has,O
been,O
conducted,O
using,O
EAE,B-DS
model,O
mice,B-OG
[,O
4,O
",",O
5,O
].,O
Activated,O
autoreactive,O
T,O
cells,O
proliferate,O
and,O
release,O
cytokines,B-GP
",",O
which,O
disrupt,O
the,O
blood,O
-,O
brain,O
barrier,O
",",O
and,O
secrete,O
chemokines,B-GP
that,O
lead,O
to,O
the,O
recruitment,O
of,O
T,O
cells,O
",",O
B,O
cells,O
",",O
and,O
macrophages,O
.,O
Infiltrated,O
immune,O
cells,O
secrete,O
autoantibodies,O
against,O
the,O
myelin,O
sheath,O
",",O
ultimately,O
resulting,O
in,O
myelin,O
degeneration,O
[,O
8,O
].,O
The,O
cuprizone,O
model,O
is,O
characterized,O
by,O
the,O
apoptotic,O
death,O
of,O
mature,O
oligodendrocytes,O
[,O
7,O
],O
and,O
is,O
accompanied,O
by,O
neuroinflammation,O
and,O
motor,O
dysfunction,O
[,O
9,O
].,O
The,O
model,O
is,O
used,O
to,O
study,O
processes,O
of,O
demyelination,B-DS
and,O
remyelination,O
in,O
the,O
CNS,O
.,O
Primary,O
oligodendrocyte,O
apoptosis,O
in,O
connection,O
with,O
microglial,O
activation,O
are,O
the,O
major,O
histopathological,O
hallmarks,O
of,O
the,O
cuprizone,O
animal,B-OG
model,O
.,O
These,O
pathological,O
features,O
are,O
also,O
characteristics,O
of,O
lesion,O
formation,O
in,O
human,B-OG
multiple,B-DS
sclerosis,I-DS
[,O
10,O
].,O
Mitochondrial,O
dysfunction,O
is,O
also,O
an,O
important,O
component,O
of,O
human,B-OG
multiple,B-DS
sclerosis,I-DS
lesions,O
and,O
plays,O
a,O
key,O
role,O
in,O
the,O
loss,O
of,O
oligodendrocytes,O
and,O
axons,O
",",O
which,O
can,O
be,O
observed,O
in,O
both,O
the,O
EAE,B-DS
and,O
cuprizone,O
models,O
.,O
Cyclic,O
phosphatidic,O
acid,O
(,O
cPA,O
),O
is,O
a,O
natural,O
phospholipid,O
mediator,O
with,O
a,O
unique,O
cyclic,O
phosphate,O
ring,O
structure,O
at,O
the,O
sn,O
-,O
2,O
and,O
sn,O
-,O
3,O
positions,O
of,O
the,O
glycerol,O
backbone,O
.,O
cPA,O
elicits,O
a,O
neurotrophin,B-GP
-,O
like,O
action,O
[,O
11,O
],O
and,O
protects,O
neurons,O
from,O
mitochondrial,O
dysfunction,O
-,O
induced,O
apoptosis,O
[,O
12,O
],O
and,O
ischemia,O
-,O
induced,O
delayed,O
neuronal,O
death,O
[,O
13,O
].,O
We,O
have,O
also,O
reported,O
previously,O
that,O
cPA,O
suppresses,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
and,O
motor,O
dysfunction,O
[,O
14,O
].,O
We,O
designed,O
",",O
chemically,O
synthesized,O
",",O
and,O
metabolically,O
stabilized,O
derivatives,O
of,O
cPA,O
:,O
2,O
-,O
carba,O
-,O
cPA,O
(,O
2ccPA,O
"),",O
a,O
synthesized,O
compound,O
in,O
which,O
one,O
of,O
the,O
phosphate,O
oxygen,O
molecules,O
is,O
replaced,O
with,O
a,O
methylene,O
group,O
at,O
the,O
sn,O
-,O
2,O
position,O
;,O
this,O
showed,O
much,O
more,O
potent,O
biological,O
activity,O
than,O
natural,O
cPA,O
[,O
15,O
–,O
17,O
].,O
Our,O
preliminary,O
experiments,O
revealed,O
that,O
2ccPA,O
was,O
detected,O
in,O
the,O
mouse,B-OG
brain,O
following,O
intraperitoneal,O
administration,O
.,O
Based,O
on,O
this,O
finding,O
",",O
we,O
speculated,O
that,O
circulated,O
2ccPA,O
may,O
gain,O
access,O
to,O
the,O
brain,O
via,O
the,O
blood,O
-,O
brain,O
barrier,O
.,O
Currently,O
",",O
we,O
are,O
investigating,O
the,O
pharmacokinetics,O
of,O
2ccPA,O
in,O
a,O
separate,O
study,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
investigated,O
whether,O
2ccPA,O
exerts,O
protective,O
effects,O
in,O
oligodendrocytes,O
and,O
suppresses,O
pathology,O
in,O
EAE,B-DS
and,O
cuprizone,O
-,O
induced,O
mouse,B-OG
models,O
of,O
multiple,B-DS
sclerosis,I-DS
.,O
We,O
demonstrated,O
that,O
2ccPA,O
protected,O
oligodendrocytes,O
via,O
suppression,O
of,O
the,O
mitochondrial,O
apoptosis,O
pathway,O
",",O
suppressed,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
and,O
motor,O
dysfunction,O
",",O
and,O
attenuated,O
the,O
clinical,O
symptoms,O
of,O
EAE,B-DS
.,O
Methods,O
Pharmacologic,O
agents,O
2,O
-,O
Carba,O
-,O
cPA,O
(,O
2ccPA,O
),O
was,O
chemically,O
synthesized,O
as,O
previously,O
described,O
(,O
Fig,O
.,O
2a,O
),O
[,O
16,O
",",O
18,O
].,O
For,O
in,O
vivo,O
experiments,O
",",O
2ccPA,O
was,O
dissolved,O
in,O
saline,O
(,O
vehicle,O
).,O
For,O
in,O
vitro,O
experiments,O
",",O
2ccPA,O
was,O
dissolved,O
in,O
phosphatase,B-GP
-,O
buffered,O
saline,O
(,O
PBS,O
),O
containing,O
0,O
.,O
1,O
%,O
fatty,O
acid,O
-,O
free,O
bovine,O
serum,O
albumin,B-GP
(,O
BSA,O
),O
(,O
vehicle,O
).,O
Cell,O
culture,O
and,O
treatments,O
The,O
MO3,O
.,O
13,O
cell,O
line,O
(,O
CELLutions,O
Biosystems,O
",",O
Inc,O
.),O
is,O
an,O
immortalized,O
human,B-OG
-,O
human,B-OG
hybrid,O
line,O
that,O
expresses,O
the,O
phenotypic,O
characteristics,O
of,O
primary,O
oligodendrocyte,O
[,O
19,O
",",O
20,O
].,O
MO3,O
.,O
13,O
cells,O
were,O
cultured,O
in,O
Dulbecco,O
’,O
s,O
Modified,O
Eagle,O
Medium,O
(,O
DMEM,O
),O
(,O
Nacalai,O
Tesque,O
),O
supplemented,O
with,O
10,O
%,O
fetal,O
bovine,O
serum,O
(,O
FBS,O
",",O
Gibco,O
"),",O
penicillin,O
",",O
and,O
streptomycin,O
(,O
Gibco,O
),O
in,O
a,O
humidified,O
5,O
%,O
CO2,O
incubator,O
at,O
37,O
°,O
C,O
.,O
MO3,O
.,O
13,O
cells,O
attain,O
a,O
flattened,O
bipolar,O
morphology,O
with,O
elongated,O
processes,O
and,O
can,O
be,O
differentiated,O
into,O
an,O
oligodendrocyte,O
phenotype,O
.,O
To,O
induce,O
differentiation,O
",",O
MO3,O
.,O
13,O
cells,O
were,O
cultured,O
in,O
DMEM,O
without,O
FBS,O
for,O
5,O
days,O
.,O
Serum,O
-,O
starved,O
differentiated,O
MO3,O
.,O
13,O
cells,O
were,O
exposed,O
to,O
CoCl2,O
(,O
500,O
μm,O
),O
and,O
/,O
or,O
2ccPA,O
(,O
10,O
μm,O
),O
for,O
2,O
days,O
.,O
MTT,O
(,O
5,O
mg,O
/,O
ml,O
),O
was,O
added,O
to,O
each,O
well,O
",",O
followed,O
by,O
incubation,O
at,O
37,O
°,O
C,O
for,O
4,O
h,O
in,O
a,O
CO2,O
incubator,O
.,O
The,O
supernatants,O
were,O
carefully,O
removed,O
",",O
and,O
200,O
μl,O
of,O
isopropanol,O
was,O
added,O
to,O
each,O
well,O
.,O
The,O
optical,O
density,O
(,O
OD,O
),O
of,O
the,O
solution,O
was,O
measured,O
at,O
570,O
nm,O
using,O
a,O
microplate,O
reader,O
(,O
BIO,O
-,O
RAD,O
).,O
Western,O
blotting,O
analysis,O
MO3,O
.,O
13,O
cells,O
were,O
harvested,O
with,O
ice,O
-,O
cold,O
PBS,O
",",O
homogenized,O
in,O
ice,O
-,O
cold,O
RIPA,O
(,O
50,O
mM,O
Tris,O
-,O
HCl,O
pH,O
8,O
.,O
0,O
",",O
150,O
mM,O
NaCl,O
",",O
5,O
mM,O
ethylenediaminetetraacetic,O
acid,O
(,O
EDTA,O
"),",O
1,O
%,O
NP,O
-,O
40,O
",",O
0,O
.,O
1,O
%,O
SDS,O
",",O
0,O
.,O
5,O
%,O
deoxycholate,O
),O
containing,O
a,O
protease,B-GP
inhibitor,O
cocktail,O
(,O
Roche,O
),O
and,O
left,O
at,O
4,O
°,O
C,O
for,O
30,O
min,O
.,O
The,O
homogenates,O
were,O
centrifuged,O
at,O
×,O
20,O
",",O
000g,O
at,O
4,O
°,O
C,O
for,O
15,O
min,O
",",O
and,O
the,O
resulting,O
supernatants,O
were,O
collected,O
as,O
whole,O
-,O
cell,O
lysates,O
",",O
from,O
which,O
protein,O
concentrations,O
were,O
determined,O
using,O
a,O
protein,O
assay,O
kit,O
(,O
Thermo,O
Scientific,O
).,O
Proteins,O
were,O
separated,O
on,O
conventional,O
12,O
%,O
acrylamide,O
SDS,O
gels,O
and,O
transferred,O
to,O
nitrocellulose,O
membranes,O
.,O
After,O
blocking,O
with,O
5,O
%,O
skim,O
milk,O
(,O
MEGMILK,O
SNOW,O
BRAND,O
Co,O
.,O
Ltd,O
.),O
in,O
PBS,O
containing,O
0,O
.,O
05,O
%,O
Tween,O
20,O
(,O
PBS,O
-,O
T,O
"),",O
the,O
membranes,O
were,O
incubated,O
with,O
the,O
appropriate,O
primary,O
antibodies,O
(,O
anti,O
-,O
GAPDH,B-GP
(,O
Millipore,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
Bax,B-GP
(,O
cell,O
signaling,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
Bcl,B-GP
-,I-GP
2,I-GP
(,O
cell,O
signaling,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
phospho,O
-,O
JNK,B-GP
(,O
p,O
-,O
JNK,B-GP
",",O
Cell,O
Signaling,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
phospho,O
-,O
p38MAPK,B-GP
(,O
p,O
-,O
p38MAPK,B-GP
",",O
cell,O
signaling,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
myelin,B-GP
basic,I-GP
protein,I-GP
(,O
MBP,B-GP
",",O
Santa,O
cruz,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
oligodendrocyte,B-GP
transcription,I-GP
factor,I-GP
1,I-GP
(,O
Olig1,B-GP
",",O
Rockland,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
glial,B-GP
fibrillary,I-GP
acidic,I-GP
protein,I-GP
(,O
GFAP,B-GP
",",O
Epitomics,O
",",O
1,O
:,O
1000,O
"),",O
anti,O
-,O
glutamine,B-GP
synthetase,I-GP
(,O
GS,B-GP
",",O
Abcam,O
",",O
1,O
:,O
1000,O
)),O
overnight,O
",",O
followed,O
by,O
incubation,O
with,O
horseradish,B-OG
peroxidase,B-GP
-,O
conjugated,O
secondary,O
antibodies,O
for,O
2,O
h,O
at,O
room,O
temperature,O
.,O
After,O
washing,O
with,O
PBS,O
-,O
T,O
three,O
times,O
",",O
the,O
membranes,O
were,O
treated,O
with,O
reagent,O
for,O
exposure,O
(,O
Chemi,O
-,O
Lumi,O
One,O
Super,O
",",O
Nacalai,O
Tesque,O
;,O
ImmunoStar,O
LD,O
",",O
Wako,O
).,O
Images,O
of,O
the,O
membranes,O
were,O
captured,O
using,O
a,O
C,O
-,O
DiGit,O
Blot,O
Scanner,O
(,O
LI,O
-,O
COR,O
),O
and,O
subjected,O
to,O
ImageJ,O
1,O
.,O
46r,O
analysis,O
.,O
Animal,B-OG
procedures,O
Mice,B-OG
were,O
housed,O
in,O
appropriate,O
animal,B-OG
care,O
facilities,O
at,O
Saitama,O
Medical,O
University,O
(,O
Saitama,O
",",O
Japan,O
),O
and,O
handled,O
in,O
accordance,O
with,O
established,O
international,O
guidelines,O
.,O
Experimental,O
protocols,O
were,O
approved,O
by,O
the,O
Animal,B-OG
Research,O
Committee,O
of,O
Saitama,O
Medical,O
University,O
.,O
C57BL,B-OG
/,I-OG
6J,I-OG
mice,I-OG
(,O
Tokyo,O
Laboratory,O
Animals,B-OG
Science,O
),O
were,O
received,O
at,O
our,O
facility,O
at,O
10,O
weeks,O
of,O
age,O
.,O
Mice,B-OG
were,O
maintained,O
on,O
a,O
12,O
/,O
12,O
-,O
h,O
light,O
/,O
dark,O
cycle,O
.,O
For,O
histology,O
",",O
mice,B-OG
were,O
intracardially,O
perfused,O
with,O
4,O
%,O
paraformaldehyde,O
(,O
PFA,O
),O
in,O
PBS,O
.,O
The,O
brain,O
and,O
lumbar,O
spinal,O
cord,O
tissues,O
were,O
removed,O
and,O
post,O
-,O
fixed,O
overnight,O
in,O
4,O
%,O
PFA,O
in,O
PBS,O
",",O
following,O
which,O
they,O
were,O
cryoprotected,O
in,O
30,O
%,O
sucrose,O
solution,O
in,O
PBS,O
",",O
snap,O
frozen,O
",",O
and,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
further,O
use,O
.,O
Coronal,O
brain,O
sections,O
(,O
25,O
μm,O
),O
were,O
obtained,O
using,O
a,O
cryostat,O
(,O
CM1900,O
",",O
LEICA,O
),O
and,O
mounted,O
on,O
gelatin,O
-,O
coated,O
glass,O
slides,O
[,O
21,O
].,O
Induction,O
of,O
cuprizone,O
model,O
and,O
2ccPA,O
treatment,O
Male,O
C57BL,B-OG
/,I-OG
6J,I-OG
mice,I-OG
were,O
given,O
ad,O
libitum,O
access,O
to,O
a,O
powdered,O
diet,O
(,O
CLEA,O
Japan,O
),O
containing,O
0,O
.,O
2,O
%,O
bis,O
-,O
cyclohexanone,O
-,O
oxaldihydrazone,O
(,O
cuprizone,O
",",O
Merck,O
KGaA,O
).,O
Mice,B-OG
were,O
fed,O
the,O
cuprizone,O
diet,O
for,O
5,O
weeks,O
(,O
acute,O
peak,O
demyelination,B-DS
"),",O
6,O
weeks,O
(,O
spontaneous,O
remyelination,O
"),",O
and,O
10,O
weeks,O
(,O
chronic,O
demyelination,B-DS
).,O
In,O
the,O
present,O
study,O
",",O
2ccPA,O
was,O
chemically,O
synthesized,O
as,O
previously,O
described,O
(,O
Fig,O
.,O
2a,O
),O
[,O
17,O
"],",O
dissolved,O
in,O
saline,O
",",O
and,O
administered,O
at,O
a,O
dose,O
of,O
1,O
.,O
6,O
mg,O
/,O
kg,O
via,O
intraperitoneal,O
injection,O
once,O
daily,O
during,O
the,O
cuprizone,O
exposure,O
period,O
(,O
0,O
–,O
5,O
",",O
3,O
–,O
5,O
",",O
5,O
–,O
6,O
",",O
or,O
5,O
–,O
10,O
weeks,O
from,O
the,O
onset,O
of,O
exposure,O
).,O
The,O
protocol,O
for,O
2ccPA,O
administration,O
is,O
presented,O
in,O
Fig,O
.,O
1,O
.,O
Control,O
mice,B-OG
were,O
fed,O
a,O
cuprizone,O
-,O
free,O
diet,O
and,O
received,O
an,O
equal,O
dose,O
of,O
saline,O
via,O
intraperitoneal,O
injection,O
once,O
daily,O
during,O
each,O
experimental,O
period,O
.,O
Coronal,O
brain,O
sections,O
were,O
stained,O
for,O
myelin,O
using,O
Black,O
-,O
Gold,O
II,O
(,O
Histo,O
-,O
Chem,O
),O
as,O
previously,O
described,O
[,O
22,O
].,O
Briefly,O
",",O
sections,O
were,O
incubated,O
in,O
a,O
0,O
.,O
3,O
%,O
Black,O
-,O
Gold,O
II,O
solution,O
for,O
12,O
min,O
",",O
rinsed,O
in,O
distilled,O
water,O
",",O
fixed,O
in,O
1,O
%,O
sodium,O
thiosulfate,O
",",O
rinsed,O
in,O
tap,O
water,O
",",O
and,O
air,O
-,O
dried,O
.,O
Sections,O
were,O
coverslipped,O
using,O
Poly,O
-,O
Mount,O
(,O
Polysciences,O
Inc,O
).,O
Black,O
-,O
Gold,O
II,O
(,O
Histo,O
-,O
Chem,O
),O
stained,O
sections,O
were,O
selected,O
between,O
Bregma,O
−,O
0,O
.,O
22,O
and,O
−,O
0,O
.,O
58,O
mm,O
.,O
Sections,O
were,O
photographed,O
at,O
×,O
10,O
magnification,O
on,O
a,O
KEYENCE,O
BZ,O
-,O
X700,O
microscope,O
(,O
Keyence,O
Corporation,O
).,O
Images,O
were,O
captured,O
using,O
a,O
KEYENCE,O
BZ,O
-,O
X700,O
BZ,O
-,O
X,O
Analyzer,O
and,O
imported,O
into,O
ImageJ,O
1,O
.,O
46r,O
",",O
which,O
was,O
used,O
to,O
measure,O
the,O
mean,O
OD,O
within,O
the,O
middle,O
of,O
the,O
corpus,O
callosum,O
[,O
21,O
].,O
The,O
OD,O
of,O
the,O
tissue,O
-,O
free,O
area,O
was,O
used,O
as,O
a,O
background,O
",",O
and,O
blank,O
was,O
subtracted,O
from,O
the,O
ODs,O
for,O
tissue,O
.,O
The,O
resulting,O
ODs,O
for,O
myelin,O
in,O
each,O
mouse,B-OG
were,O
normalized,O
against,O
values,O
in,O
unchallenged,O
mice,B-OG
using,O
the,O
following,O
formula,O
:,O
myelin,O
score,O
(%),O
=,O
(,O
density,O
reading,O
/,O
unchallenged,O
density,O
average,O
),O
×,O
100,O
.,O
Fig,O
.,O
1Multiperiod,O
of,O
2ccPA,O
administration,O
protocol,O
.,O
For,O
protocol,O
A,O
",",O
2ccPA,O
was,O
administered,O
once,O
daily,O
via,O
intraperitoneal,O
injection,O
for,O
the,O
duration,O
of,O
the,O
5,O
-,O
week,O
period,O
of,O
cuprizone,O
exposure,O
(,O
0,O
–,O
5,O
weeks,O
:,O
acute,O
peak,O
demyelination,B-DS
).,O
For,O
protocol,O
B,O
",",O
2ccPA,O
was,O
administered,O
once,O
daily,O
via,O
intraperitoneal,O
injection,O
between,O
weeks,O
3,O
–,O
5,O
of,O
cuprizone,O
exposure,O
(,O
3,O
–,O
5,O
weeks,O
:,O
after,O
onset,O
of,O
demyelination,B-DS
).,O
For,O
protocol,O
C,O
",",O
2ccPA,O
was,O
administered,O
once,O
daily,O
via,O
intraperitoneal,O
injection,O
between,O
weeks,O
5,O
–,O
6,O
of,O
cuprizone,O
exposure,O
(,O
5,O
–,O
6,O
weeks,O
:,O
spontaneous,O
remyelination,O
).,O
For,O
protocol,O
D,O
",",O
2ccPA,O
was,O
administered,O
once,O
daily,O
via,O
intraperitoneal,O
injection,O
between,O
weeks,O
5,O
–,O
10,O
of,O
cuprizone,O
exposure,O
(,O
5,O
–,O
10,O
weeks,O
:,O
chronic,O
demyelination,B-DS
),O
Electron,O
microscopy,O
analysis,O
of,O
myelin,O
sheath,O
thickness,O
and,O
axon,O
diameter,O
in,O
the,O
cuprizone,O
model,O
Mice,B-OG
were,O
anesthetized,O
and,O
perfused,O
with,O
PBS,O
as,O
described,O
in,O
the,O
preceding,O
sections,O
",",O
following,O
which,O
they,O
were,O
fixed,O
using,O
4,O
%,O
PFA,O
and,O
2,O
.,O
5,O
%,O
glutaraldehyde,O
in,O
phosphate,O
buffer,O
and,O
re,O
-,O
fixed,O
overnight,O
at,O
4,O
°,O
C,O
.,O
The,O
fixed,O
brains,O
were,O
sliced,O
into,O
1,O
–,O
2,O
-,O
mm,O
sections,O
.,O
Sections,O
containing,O
the,O
corpus,O
callosum,O
area,O
were,O
divided,O
into,O
segments,O
of,O
2,O
–,O
3,O
mm,O
and,O
washed,O
in,O
0,O
.,O
1,O
M,O
sodium,O
cacodylate,O
buffer,O
.,O
After,O
washing,O
",",O
the,O
tissue,O
was,O
post,O
-,O
fixed,O
with,O
1,O
%,O
osmium,O
tetroxide,O
.,O
Sections,O
were,O
dehydrated,O
in,O
an,O
ascending,O
alcohol,O
series,O
and,O
embedded,O
in,O
epoxy,O
resin,O
.,O
Ultrathin,O
sections,O
of,O
the,O
corpus,O
callosum,O
were,O
prepared,O
using,O
a,O
Reichert,O
-,O
Nissei,O
ULTRACUT,O
-,O
N,O
ultramicrotome,O
(,O
Nissei,O
Sangyo,O
).,O
Ultrathin,O
sections,O
were,O
stained,O
with,O
lead,O
nitrate,O
and,O
3,O
%,O
uranyl,O
acetate,O
in,O
water,O
.,O
Digital,O
images,O
were,O
acquired,O
using,O
a,O
JEM,O
-,O
1400,O
Transmission,O
Electron,O
Microscope,O
(,O
JEOL,O
Ltd,O
.).,O
Ultrathin,O
sections,O
(,O
70,O
nm,O
),O
were,O
examined,O
with,O
a,O
transmission,O
electron,O
microscope,O
at,O
80,O
kV,O
[,O
23,O
].,O
The,O
number,O
of,O
myelinated,O
fibers,O
present,O
in,O
electron,O
microscope,O
pictures,O
was,O
counted,O
.,O
Using,O
ImageJ,O
1,O
.,O
46r,O
",",O
axonal,O
diameters,O
were,O
calculated,O
from,O
the,O
outer,O
perimeter,O
of,O
the,O
axon,O
divided,O
by,O
the,O
total,O
perimeter,O
of,O
the,O
axon,O
.,O
The,O
g,O
-,O
ratio,O
were,O
calculated,O
the,O
numerical,O
ratio,O
between,O
the,O
diameter,O
of,O
the,O
axon,O
proper,O
and,O
the,O
outer,O
diameter,O
of,O
the,O
myelinated,O
fibers,O
.,O
Pictures,O
were,O
randomly,O
chosen,O
for,O
each,O
mouse,B-OG
and,O
100,O
–,O
200,O
fibers,O
per,O
picture,O
were,O
calculated,O
.,O
The,O
data,O
are,O
shown,O
as,O
percent,O
of,O
myelinated,O
fibers,O
and,O
axonal,O
diameter,O
.,O
RNA,O
extraction,O
and,O
quantitative,O
real,O
-,O
time,O
PCR,O
Mice,B-OG
were,O
euthanized,O
",",O
and,O
tissue,O
from,O
the,O
corpus,O
callosum,O
was,O
collected,O
for,O
RNA,O
extraction,O
as,O
previously,O
reported,O
[,O
24,O
].,O
Briefly,O
",",O
gross,O
coronal,O
sections,O
were,O
obtained,O
between,O
approximately,O
Bregma,O
−,O
0,O
.,O
25,O
and,O
−,O
1,O
.,O
25,O
mm,O
.,O
Sagittal,O
cuts,O
were,O
made,O
through,O
the,O
cingulum,O
",",O
medial,O
to,O
each,O
lateral,O
ventricle,O
",",O
followed,O
by,O
cuts,O
above,O
and,O
below,O
the,O
corpus,O
callosum,O
to,O
remove,O
most,O
of,O
the,O
cortex,O
and,O
fornix,O
[,O
24,O
].,O
Corpus,O
callosum,O
tissue,O
samples,O
were,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
required,O
for,O
further,O
processing,O
.,O
Samples,O
of,O
fresh,O
frozen,O
corpus,O
callosum,O
were,O
processed,O
for,O
RNA,O
extraction,O
using,O
ISOGEN,O
(,O
Nippon,O
Gene,O
Co,O
.),O
following,O
the,O
manufacturer,O
’,O
s,O
instructions,O
.,O
Extracted,O
RNA,O
was,O
resuspended,O
in,O
RNase,B-GP
-,O
free,O
molecular,O
grade,O
water,O
(,O
Takara,O
Bio,O
Inc,O
.),O
and,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
required,O
for,O
analysis,O
.,O
For,O
qPCR,O
",",O
total,O
RNA,O
(,O
3,O
μg,O
),O
was,O
reverse,O
transcribed,O
using,O
a,O
PrimeScript,O
RT,O
reagent,O
kit,O
(,O
Takara,O
Bio,O
Inc,O
.).,O
qPCR,O
was,O
performed,O
using,O
the,O
7900,O
Sequence,O
Detection,O
System,O
(,O
Applied,O
Biosystems,O
"),",O
with,O
the,O
following,O
gene,O
-,O
specific,O
primers,O
:,O
phosphoglycerate,B-GP
kinase,I-GP
1,I-GP
(,O
PGK1,B-GP
",",O
forward,O
:,O
5,O
′-,O
ctgctgttccaagcatcaaa,O
-,O
3,O
′,O
reverse,O
:,O
5,O
′-,O
gcatcttttcccttcccttc,O
-,O
3,O
"′),",O
glial,B-GP
fibrillary,I-GP
acidic,I-GP
protein,I-GP
(,O
GFAP,B-GP
",",O
forward,O
:,O
5,O
′-,O
acgcttctccttgtctcgaa,O
-,O
3,O
′,O
reverse,O
:,O
5,O
′-,O
cggcgatagtcgttagcttc,O
-,O
3,O
"′),",O
ionized,B-GP
calcium,I-GP
binding,I-GP
adapter,I-GP
molecule,I-GP
1,I-GP
(,O
Iba1,B-GP
",",O
forward,O
:,O
5,O
′-,O
atgagccaaagcagggattt,O
-,O
3,O
′,O
reverse,O
:,O
5,O
′-,O
gaccagttggcctcttgtgt,O
-,O
3,O
"′),",O
NOD,B-GP
-,I-GP
like,I-GP
receptor,I-GP
family,I-GP
",",I-GP
pyrin,I-GP
domain,I-GP
containing,I-GP
3,I-GP
(,O
NLRP3,B-GP
",",O
forward,O
:,O
5,O
′-,O
ccttggaccaggttcagtgt,O
-,O
3,O
′,O
reverse,O
:,O
5,O
′-,O
aggagatgtcgaagcagcat,O
-,O
3,O
"′),",O
purinergic,B-GP
receptor,I-GP
P2X,I-GP
ligand,I-GP
-,I-GP
gated,I-GP
ion,I-GP
channel,I-GP
7,I-GP
(,O
P2X7R,B-GP
",",O
forward,O
:,O
5,O
′-,O
tgtgtgcattgacttgctca,O
-,O
3,O
′,O
reverse,O
:,O
5,O
′-,O
cttgcagacttttcccaagc,O
-,O
3,O
′),O
Interleukin,B-GP
-,I-GP
1,I-GP
beta,I-GP
(,O
IL,B-GP
-,I-GP
1β,I-GP
",",O
forward,O
:,O
5,O
′-,O
gaccttccaggatgaggaca,O
-,O
3,O
′,O
reverse,O
:,O
5,O
′-,O
aggccacaggtattttgtcg,O
-,O
3,O
′).,O
Q,O
-,O
PCR,O
conditions,O
were,O
95,O
°,O
C,O
for,O
30,O
s,O
",",O
followed,O
by,O
40,O
cycles,O
of,O
5,O
s,O
at,O
95,O
°,O
C,O
and,O
34,O
s,O
at,O
60,O
°,O
C,O
.,O
The,O
level,O
of,O
target,O
gene,O
expression,O
was,O
calculated,O
using,O
the,O
ΔΔCT,O
method,O
[,O
25,O
].,O
Data,O
were,O
analyzed,O
using,O
the,O
relative,O
quantification,O
technique,O
.,O
qPCR,O
results,O
were,O
normalized,O
to,O
the,O
expression,O
levels,O
of,O
PGK1,B-GP
",",O
as,O
previously,O
reported,O
[,O
21,O
].,O
Relative,O
changes,O
in,O
gene,O
expression,O
are,O
reported,O
as,O
a,O
percentage,O
of,O
the,O
level,O
of,O
expression,O
in,O
control,O
mice,B-OG
.,O
Rotarod,O
test,O
We,O
used,O
an,O
accelerating,O
rotarod,O
treadmill,O
for,O
mice,B-OG
(,O
Mouse,B-OG
Rotarod,O
",",O
UgoBasile,O
),O
to,O
evaluate,O
motor,O
balance,O
and,O
coordination,O
following,O
cuprizone,O
exposure,O
.,O
Mice,B-OG
exposed,O
to,O
cuprizone,O
for,O
5,O
weeks,O
(,O
2ccPA,O
administration,O
protocols,O
A,O
and,O
B,O
),O
were,O
tested,O
on,O
the,O
rotarod,O
at,O
28,O
rpm,O
",",O
while,O
those,O
exposed,O
to,O
cuprizone,O
for,O
10,O
weeks,O
(,O
2ccPA,O
administration,O
protocol,O
D,O
),O
were,O
tested,O
at,O
20,O
rpm,O
.,O
The,O
time,O
each,O
mouse,B-OG
stayed,O
on,O
the,O
rod,O
(,O
latency,O
time,O
),O
was,O
recorded,O
by,O
a,O
trip,O
switch,O
under,O
the,O
floor,O
of,O
each,O
rotating,O
drum,O
",",O
with,O
a,O
maximum,O
recording,O
time,O
of,O
300,O
s,O
.,O
The,O
number,O
of,O
falls,O
(,O
from,O
the,O
cylinder,O
),O
and,O
flips,O
(,O
when,O
the,O
animal,B-OG
clung,O
to,O
the,O
cylinder,O
),O
were,O
also,O
counted,O
.,O
Induction,O
of,O
EAE,B-DS
and,O
2ccPA,O
treatment,O
Female,O
C57BL,B-OG
/,I-OG
6J,I-OG
mice,I-OG
were,O
immunized,O
with,O
MOG35,O
−,O
55,O
/,O
CFA,O
emulsion,O
pertussis,B-DS
toxin,O
kits,O
(,O
EK,O
-,O
2110,O
",",O
Hooke,O
laboratories,O
),O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
instructions,O
[,O
26,O
",",O
27,O
].,O
Briefly,O
",",O
0,O
.,O
1,O
ml,O
MOG35,O
−,O
55,O
/,O
CFA,O
emulsion,O
was,O
injected,O
subcutaneously,O
into,O
both,O
flanks,O
of,O
each,O
mouse,B-OG
(,O
0,O
.,O
2,O
ml,O
/,O
animal,B-OG
",",O
200,O
μg,O
of,O
MOG35,O
−,O
55,O
peptide,O
in,O
each,O
0,O
.,O
2,O
ml,O
dose,O
).,O
Mice,B-OG
then,O
received,O
intraperitoneal,O
injections,O
of,O
pertussis,B-DS
toxin,O
(,O
0,O
.,O
1,O
ml,O
/,O
animal,B-OG
/,O
day,O
",",O
400,O
ng,O
pertussis,B-DS
toxin,O
in,O
each,O
0,O
.,O
1,O
ml,O
dose,O
),O
on,O
the,O
same,O
day,O
and,O
24,O
h,O
later,O
.,O
The,O
day,O
after,O
the,O
last,O
injection,O
of,O
MOG,B-GP
was,O
considered,O
day,O
1,O
.,O
Clinical,O
signs,O
were,O
scored,O
as,O
follows,O
:,O
0,O
",",O
no,O
clinical,O
sign,O
;,O
0,O
.,O
5,O
",",O
partial,O
tail,O
paralysis,O
;,O
1,O
.,O
0,O
",",O
complete,O
tail,O
paralysis,O
;,O
1,O
.,O
5,O
",",O
complete,O
tail,O
paralysis,O
and,O
discrete,O
hind,O
limb,O
weakness,O
;,O
2,O
.,O
0,O
",",O
complete,O
tail,O
paralysis,O
and,O
strong,O
hind,O
limb,O
weakness,O
;,O
2,O
.,O
5,O
",",O
unilateral,O
hind,O
limb,O
paralysis,O
;,O
3,O
",",O
complete,O
hind,O
limb,O
paralysis,O
;,O
3,O
.,O
5,O
",",O
hind,O
limb,O
paralysis,O
and,O
forelimb,O
weakness,O
;,O
4,O
.,O
0,O
",",O
complete,O
paralysis,O
(,O
tetraplegia,B-DS
"),",O
and,O
5,O
.,O
0,O
",",O
moribund,O
or,O
dead,O
[,O
26,O
",",O
27,O
].,O
In,O
each,O
mouse,B-OG
",",O
2ccPA,O
was,O
administered,O
at,O
a,O
dose,O
of,O
16,O
mg,O
/,O
kg,O
via,O
intraperitoneal,O
injection,O
once,O
daily,O
for,O
the,O
duration,O
of,O
the,O
EAE,B-DS
protocol,O
(,O
days,O
0,O
–,O
30,O
or,O
17,O
–,O
30,O
).,O
Sections,O
were,O
stained,O
H,O
&,O
E,O
.,O
Five,O
random,O
sections,O
from,O
each,O
mouse,B-OG
were,O
observed,O
to,O
evaluate,O
the,O
degree,O
of,O
inflammation,O
[,O
28,O
].,O
For,O
evaluation,O
of,O
inflammation,O
",",O
a,O
four,O
-,O
point,O
scale,O
was,O
graded,O
as,O
follows,O
:,O
0,O
",",O
no,O
sign,O
or,O
minimal,O
inflammation,O
;,O
1,O
",",O
inflammatory,O
cell,O
infiltrates,O
in,O
meninges,O
;,O
2,O
",",O
perivascular,O
inflammatory,O
cell,O
infiltrates,O
;,O
and,O
3,O
",",O
marked,O
infiltration,O
of,O
inflammatory,O
cells,O
into,O
the,O
parenchyma,O
.,O
The,O
histological,O
score,O
represented,O
the,O
mean,O
of,O
the,O
scores,O
of,O
all,O
sections,O
examined,O
[,O
28,O
].,O
Immunohistochemistry,O
Brain,O
sections,O
were,O
incubated,O
with,O
rabbit,B-OG
anti,O
-,O
Iba1,B-GP
antibody,O
(,O
Wako,O
",",O
1,O
:,O
250,O
"),",O
rabbit,B-OG
anti,O
-,O
CD4,B-GP
antibody,O
(,O
Bioss,O
",",O
1,O
:,O
250,O
"),",O
and,O
rat,B-OG
anti,O
-,O
F4,O
/,O
80,O
antibody,O
(,O
Bio,O
-,O
Rad,O
",",O
1,O
:,O
250,O
),O
at,O
4,O
°,O
C,O
overnight,O
",",O
followed,O
by,O
incubation,O
at,O
room,O
temperature,O
for,O
1,O
h,O
with,O
the,O
secondary,O
antibody,O
(,O
Cy3,O
-,O
conjugated,O
AffiniPure,O
goat,B-OG
anti,O
-,O
rabbit,B-OG
IgG,O
",",O
Jackson,O
ImmunoReseach,O
",",O
1,O
:,O
500,O
).,O
Sections,O
were,O
acquired,O
using,O
a,O
KEYENCE,O
BZ,O
-,O
X700,O
microscope,O
(,O
Keyence,O
Corporation,O
).,O
The,O
images,O
were,O
acquired,O
sequentially,O
using,O
the,O
561,O
nm,O
wavelength,O
of,O
a,O
light,O
-,O
emitting,O
diode,O
(,O
LED,O
),O
to,O
Cy3,O
.,O
All,O
images,O
were,O
acquired,O
using,O
a,O
UPLSAPO,O
×,O
40,O
numerical,O
aperture,O
0,O
.,O
95,O
dry,O
objective,O
lens,O
(,O
Olympus,O
).,O
The,O
fluorescence,O
intensity,O
was,O
measured,O
by,O
ImageJ,O
1,O
.,O
46r,O
.,O
Statistical,O
analysis,O
The,O
number,O
of,O
falls,O
and,O
flips,O
was,O
analyzed,O
using,O
a,O
nonparametric,O
Kruskal,O
-,O
Wallis,O
test,O
.,O
EAE,B-DS
score,O
was,O
analyzed,O
using,O
a,O
nonparametric,O
Mann,O
-,O
Whitney,O
U,O
test,O
.,O
The,O
protein,O
levels,O
of,O
oligodendrocyte,O
and,O
astrocyte,O
markers,O
were,O
analyzed,O
using,O
a,O
student,O
’,O
s,O
t,O
test,O
.,O
All,O
other,O
data,O
were,O
analyzed,O
by,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
followed,O
by,O
Newman,O
-,O
Keuls,O
post,O
hoc,O
test,O
.,O
All,O
data,O
were,O
analyzed,O
using,O
GraphPad,O
Prism,O
Ver,O
.,O
5,O
.,O
01,O
(,O
Graphpad,O
Software,O
Inc,O
.),O
and,O
expressed,O
as,O
the,O
mean,O
±,O
SEM,O
.,O
P,O
values,O
<,O
0,O
.,O
05,O
were,O
considered,O
statistically,O
significant,O
.,O
Results,O
2ccPA,O
protected,O
oligodendrocyte,O
cells,O
from,O
mitochondrial,O
apoptosis,O
We,O
undertook,O
in,O
vitro,O
investigations,O
using,O
the,O
MO3,O
.,O
13,O
oligodendrocyte,O
cell,O
line,O
",",O
an,O
immortalized,O
human,B-OG
-,O
human,B-OG
hybrid,O
cell,O
line,O
that,O
can,O
undergo,O
differentiation,O
into,O
an,O
oligodendrocyte,O
phenotype,O
.,O
In,O
the,O
present,O
study,O
",",O
undifferentiated,O
MO3,O
.,O
13,O
cells,O
with,O
few,O
processes,O
(,O
Fig,O
.,O
2b,O
),O
were,O
cultured,O
in,O
DMEM,O
without,O
FBS,O
for,O
5,O
days,O
to,O
induce,O
differentiation,O
.,O
Serum,O
-,O
starved,O
differentiated,O
MO3,O
.,O
13,O
cells,O
exhibited,O
increases,O
in,O
process,O
length,O
(,O
Fig,O
.,O
2c,O
).,O
Differentiated,O
cells,O
exhibited,O
expression,O
of,O
the,O
oligodendrocyte,O
markers,O
MBP,B-GP
and,O
Olig1,B-GP
(,O
Fig,O
.,O
2d,O
–,O
f,O
),O
and,O
decreased,O
expression,O
of,O
the,O
astrocyte,O
marker,O
GS,B-GP
(,O
Fig,O
.,O
2d,O
",",O
g,O
).,O
No,O
GFAP,B-GP
(,O
another,O
astrocytic,O
marker,O
),O
expression,O
was,O
detected,O
in,O
either,O
phenotype,O
(,O
Fig,O
.,O
2d,O
).,O
Differentiated,O
MO3,O
.,O
13,O
cells,O
were,O
then,O
used,O
for,O
subsequent,O
experiments,O
.,O
To,O
induce,O
mitochondrial,O
apoptosis,O
in,O
vitro,O
",",O
CoCl2,O
(,O
cobalt,O
chloride,O
"),",O
a,O
chemical,O
mitochondrial,O
apoptosis,O
-,O
inducing,O
agent,O
",",O
was,O
added,O
in,O
the,O
presence,O
or,O
absence,O
of,O
2ccPA,O
",",O
and,O
cell,O
viability,O
was,O
evaluated,O
using,O
MTT,O
.,O
Treatment,O
with,O
2ccPA,O
significantly,O
increased,O
cell,O
viability,O
in,O
the,O
presence,O
of,O
CoCl2,O
(,O
Fig,O
.,O
2h,O
).,O
The,O
Bcl,B-GP
-,I-GP
2,I-GP
family,O
is,O
an,O
important,O
regulator,O
of,O
mitochondrial,O
dysfunction,O
",",O
which,O
is,O
induced,O
via,O
apoptosis,O
pathways,O
.,O
Mitochondrial,O
dysfunction,O
induces,O
an,O
increase,O
in,O
the,O
expression,O
of,O
proapoptotic,O
proteins,O
",",O
such,O
as,O
Bax,B-GP
",",O
and,O
a,O
decrease,O
in,O
the,O
expression,O
of,O
antiapoptotic,O
proteins,O
",",O
such,O
as,O
Bcl,B-GP
-,I-GP
2,I-GP
.,O
Bax,B-GP
and,O
Bcl,B-GP
-,I-GP
2,I-GP
protein,O
levels,O
were,O
determined,O
by,O
Western,O
blot,O
analysis,O
(,O
Fig,O
.,O
2i,O
"),",O
and,O
the,O
Bax,B-GP
/,O
Bcl,B-GP
-,I-GP
2,I-GP
protein,O
expression,O
ratio,O
was,O
evaluated,O
(,O
Fig,O
.,O
2j,O
).,O
The,O
Bax,B-GP
/,O
Bcl,B-GP
-,I-GP
2,I-GP
ratio,O
increased,O
with,O
CoCl2,O
exposure,O
.,O
Treatment,O
with,O
2ccPA,O
suppressed,O
the,O
CoCl2,O
-,O
induced,O
increase,O
in,O
the,O
Bax,B-GP
/,O
Bcl,B-GP
-,I-GP
2,I-GP
ratio,O
",",O
which,O
suggested,O
that,O
2ccPA,O
protected,O
oligodendrocyte,O
cells,O
from,O
CoCl2,O
-,O
induced,O
mitochondrial,O
apoptosis,O
.,O
In,O
addition,O
",",O
we,O
observed,O
activation,O
of,O
p38MAPK,B-GP
and,O
JNK,B-GP
during,O
CoCl2,O
-,O
induced,O
apoptosis,O
[,O
29,O
",",O
30,O
].,O
CoCl2,O
increased,O
the,O
phosphorylation,O
levels,O
of,O
p38MAPK,B-GP
and,O
JNK,B-GP
protein,O
",",O
which,O
were,O
suppressed,O
by,O
2ccPA,O
treatment,O
(,O
Fig,O
.,O
2k,O
",",O
l,O
).,O
These,O
data,O
indicate,O
that,O
2ccPA,O
suppressed,O
the,O
CoCl2,O
-,O
induced,O
apoptosis,O
by,O
inhibiting,O
the,O
phosphorylation,O
of,O
p38MAPK,B-GP
and,O
JNK,B-GP
.,O
Fig,O
.,O
2Structure,O
and,O
effect,O
of,O
2ccPA,O
on,O
CoCl2,O
-,O
induced,O
apoptosis,O
.,O
Structure,O
of,O
2ccPA,O
18,O
:,O
1,O
.,O
2ccPA,O
is,O
the,O
compound,O
in,O
which,O
one,O
of,O
the,O
phosphate,O
oxygen,O
is,O
replaced,O
with,O
a,O
methylene,O
group,O
at,O
the,O
sn,O
-,O
2,O
position,O
(,O
a,O
).,O
Chemically,O
synthesized,O
cPA,O
derivative,O
",",O
2ccPA,O
",",O
used,O
for,O
the,O
present,O
experiments,O
.,O
Light,O
microscopic,O
undifferentiated,O
MO3,O
.,O
13,O
cells,O
(,O
b,O
),O
and,O
differentiated,O
MO3,O
.,O
13,O
cells,O
(,O
c,O
).,O
Scale,O
bar,O
=,O
100,O
μm,O
.,O
The,O
protein,O
levels,O
of,O
MBP,B-GP
",",O
Olig1,B-GP
",",O
GFAP,B-GP
",",O
GS,B-GP
",",O
and,O
GAPDH,B-GP
determined,O
by,O
Western,O
blot,O
analysis,O
(,O
d,O
).,O
Protein,O
levels,O
of,O
MBP,B-GP
(,O
e,O
"),",O
Olig1,B-GP
(,O
f,O
"),",O
and,O
GS,B-GP
(,O
g,O
).,O
Data,O
are,O
presented,O
as,O
the,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
6,O
.,O
Statistical,O
analysis,O
were,O
performed,O
using,O
a,O
student,O
’,O
s,O
t,O
test,O
.,O
(*,O
p,O
<,O
0,O
.,O
05,O
;,O
**,O
p,O
<,O
0,O
.,O
01,O
vs,O
.,O
control,O
).,O
MO3,O
.,O
13,O
cells,O
were,O
incubated,O
with,O
500,O
μm,O
CoCl2,O
in,O
the,O
presence,O
of,O
10,O
μm,O
2ccPA,O
.,O
Cell,O
viability,O
of,O
MO3,O
.,O
13,O
cells,O
were,O
evaluated,O
using,O
MTT,O
assay,O
(,O
h,O
).,O
The,O
protein,O
levels,O
of,O
Bax,B-GP
",",O
Bcl,B-GP
-,I-GP
2,I-GP
",",O
phosphorylated,O
-,O
p38MAPK,B-GP
(,O
p,O
-,O
p38MAPK,B-GP
"),",O
phosphorylated,O
-,O
JNK,B-GP
(,O
p,O
-,O
JNK,B-GP
"),",O
and,O
GAPDH,B-GP
were,O
determined,O
by,O
Western,O
blot,O
analysis,O
(,O
i,O
).,O
The,O
expression,O
of,O
Bax,B-GP
and,O
Bcl,B-GP
-,I-GP
2,I-GP
was,O
determined,O
using,O
a,O
densitometer,O
",",O
and,O
the,O
Bax,B-GP
/,O
Bcl,B-GP
-,I-GP
2,I-GP
ratio,O
was,O
calculated,O
(,O
j,O
).,O
Protein,O
levels,O
of,O
p,O
-,O
p38MAPK,B-GP
(,O
k,O
),O
and,O
p,O
-,O
JNK,B-GP
(,O
l,O
).,O
Data,O
are,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
6,O
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
hoc,O
Newman,O
-,O
Keuls,O
test,O
(***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
control,O
;,O
###,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
CoCl2,O
),O
2ccPA,O
suppressed,O
the,O
cuprizone,O
-,O
induced,O
acute,O
peak,O
demyelination,B-DS
To,O
investigate,O
the,O
effects,O
of,O
2ccPA,O
on,O
cuprizone,O
-,O
induced,O
acute,O
peak,O
demyelination,B-DS
",",O
we,O
fed,O
mice,B-OG
a,O
cuprizone,O
diet,O
and,O
administrated,O
2ccPA,O
for,O
5,O
weeks,O
(,O
Fig,O
.,O
1,O
",",O
protocol,O
A,O
).,O
Myelin,O
content,O
was,O
quantified,O
using,O
Black,O
-,O
Gold,O
II,O
staining,O
.,O
In,O
control,O
mice,B-OG
",",O
the,O
corpus,O
callosum,O
appeared,O
to,O
retain,O
sufficient,O
myelin,O
content,O
(,O
Fig,O
.,O
3a,O
).,O
Five,O
weeks,O
of,O
cuprizone,O
exposure,O
induced,O
acute,O
peak,O
demyelination,B-DS
in,O
the,O
corpus,O
callosum,O
(,O
Fig,O
.,O
3b,O
).,O
2ccPA,O
treatment,O
suppressed,O
the,O
acute,O
peak,O
demyelination,B-DS
almost,O
completely,O
(,O
Fig,O
.,O
3c,O
",",O
d,O
).,O
Electron,O
microscopy,O
was,O
then,O
used,O
to,O
obtain,O
data,O
for,O
quantitative,O
analysis,O
of,O
myelinated,O
axons,O
",",O
axonal,O
diameter,O
",",O
and,O
g,O
-,O
ratios,O
.,O
Control,O
mice,B-OG
exhibited,O
full,O
myelination,O
in,O
the,O
corpus,O
callosum,O
(,O
Fig,O
.,O
3e,O
).,O
In,O
contrast,O
",",O
mice,B-OG
exposed,O
to,O
cuprizone,O
for,O
5,O
weeks,O
exhibited,O
a,O
decrease,O
in,O
the,O
extent,O
of,O
myelination,O
and,O
residual,O
myelin,O
sheaths,O
(,O
Fig,O
.,O
3f,O
"),",O
while,O
treatment,O
with,O
2ccPA,O
attenuated,O
this,O
decrease,O
in,O
myelination,O
(,O
Fig,O
.,O
3g,O
).,O
In,O
addition,O
",",O
2ccPA,O
treatment,O
significantly,O
increased,O
the,O
number,O
of,O
myelinated,O
axons,O
(,O
Fig,O
.,O
3h,O
"),",O
reduced,O
axonal,O
diameter,O
(,O
Fig,O
.,O
3i,O
"),",O
and,O
lowered,O
g,O
-,O
ratios,O
(,O
Fig,O
.,O
3j,O
),O
in,O
comparison,O
to,O
values,O
obtained,O
for,O
cuprizone,O
-,O
treated,O
mice,B-OG
.,O
These,O
findings,O
indicate,O
that,O
treatment,O
with,O
2ccPA,O
suppresses,O
cuprizone,O
-,O
induced,O
axonal,O
damage,O
and,O
demyelination,B-DS
.,O
Fig,O
.,O
32ccPA,O
suppressed,O
the,O
cuprizone,O
-,O
induced,O
acute,O
peak,O
demyelination,B-DS
.,O
Representative,O
photomicrographs,O
of,O
coronal,O
brain,O
sections,O
at,O
the,O
level,O
of,O
the,O
fimbria,O
demonstrate,O
progressive,O
demyelination,B-DS
of,O
the,O
corpus,O
callosum,O
after,O
5,O
weeks,O
of,O
cuprizone,O
(,O
CPZ,O
),O
exposure,O
.,O
Black,O
-,O
Gold,O
II,O
staining,O
in,O
the,O
control,O
(,O
a,O
"),",O
CPZ,O
+,O
Ssaline,O
(,O
b,O
"),",O
and,O
CPZ,O
+,O
2ccPA,O
(,O
c,O
),O
groups,O
.,O
Myelin,O
densities,O
in,O
the,O
corpus,O
callosum,O
(,O
d,O
),O
were,O
compared,O
with,O
those,O
of,O
controls,O
and,O
expressed,O
as,O
a,O
percentage,O
of,O
the,O
control,O
value,O
using,O
the,O
ImageJ,O
analysis,O
program,O
.,O
Data,O
are,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
5,O
animals,B-OG
.,O
Scale,O
bars,O
=,O
500,O
mm,O
.,O
Electron,O
micrographs,O
demonstrate,O
an,O
acute,O
peak,O
demyelination,B-DS
of,O
the,O
corpus,O
callosum,O
after,O
5,O
weeks,O
of,O
CPZ,O
exposure,O
.,O
Electron,O
micrographs,O
of,O
control,O
(,O
e,O
"),",O
CPZ,O
+,O
Saline,O
(,O
f,O
"),",O
and,O
CPZ,O
+,O
2ccPA,O
(,O
g,O
),O
in,O
the,O
corpus,O
callosum,O
.,O
Myelinated,O
axons,O
(,O
h,O
"),",O
axonal,O
diameter,O
(,O
i,O
"),",O
and,O
g,O
-,O
ratio,O
(,O
j,O
).,O
Data,O
are,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
7,O
animals,B-OG
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
hoc,O
Newman,O
-,O
Keuls,O
test,O
(***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
control,O
;,O
###,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
CPZ,O
+,O
Saline,O
).,O
Scale,O
bar,O
=,O
5,O
μm,O
2ccPA,O
suppressed,O
the,O
neuroinflammation,O
We,O
evaluated,O
glial,O
activation,O
and,O
inflammasome,O
formation,O
to,O
investigate,O
the,O
effect,O
of,O
2ccPA,O
on,O
the,O
neuroinflammation,O
associated,O
with,O
demyelination,B-DS
.,O
Levels,O
of,O
gene,O
expression,O
for,O
the,O
microglial,O
marker,O
(,O
Iba1,B-GP
),O
and,O
astrocytic,O
marker,O
(,O
GFAP,B-GP
),O
were,O
evaluated,O
after,O
5,O
weeks,O
of,O
cuprizone,O
.,O
Cuprizone,O
exposure,O
increased,O
messenger,O
RNA,O
(,O
mRNA,O
),O
levels,O
of,O
Iba1,B-GP
and,O
GFAP,B-GP
.,O
2ccPA,O
treatment,O
suppressed,O
cuprizone,O
-,O
induced,O
increases,O
in,O
Iba1,B-GP
and,O
GFAP,B-GP
mRNA,O
expression,O
(,O
Fig,O
.,O
4a,O
",",O
b,O
).,O
Previous,O
studies,O
have,O
demonstrated,O
that,O
the,O
NLRP3,B-GP
inflammasome,O
plays,O
an,O
essential,O
role,O
in,O
neuroinflammatory,O
diseases,O
including,O
multiple,B-DS
sclerosis,I-DS
[,O
9,O
].,O
We,O
analyzed,O
the,O
gene,O
expression,O
levels,O
of,O
NLRP3,B-GP
inflammasome,O
-,O
related,O
genes,O
such,O
as,O
NLRP3,B-GP
",",O
P2X7R,B-GP
",",O
and,O
IL,B-GP
-,I-GP
1β,I-GP
.,O
NLRP3,B-GP
",",O
P2X7R,B-GP
",",O
and,O
IL,B-GP
-,I-GP
1β,I-GP
expression,O
levels,O
were,O
increased,O
by,O
cuprizone,O
exposure,O
and,O
were,O
suppressed,O
by,O
2ccPA,O
treatment,O
(,O
Fig,O
.,O
4c,O
–,O
e,O
).,O
Iba1,B-GP
-,O
positive,O
microglia,O
were,O
detected,O
by,O
immunofluorescence,O
analysis,O
in,O
the,O
corpus,O
callosum,O
(,O
Fig,O
.,O
4f,O
–,O
k,O
).,O
Microglia,O
were,O
seen,O
only,O
sporadically,O
in,O
the,O
corpus,O
callosum,O
of,O
the,O
control,O
mice,B-OG
(,O
Fig,O
.,O
4f,O
",",O
g,O
).,O
Mice,B-OG
exposed,O
to,O
cuprizone,O
exhibited,O
hypertrophic,O
microglia,O
with,O
enlarged,O
cell,O
bodies,O
(,O
Fig,O
.,O
4h,O
",",O
i,O
"),",O
which,O
were,O
suppressed,O
by,O
2ccPA,O
treatment,O
(,O
Fig,O
.,O
4j,O
",",O
k,O
).,O
The,O
cuprizone,O
-,O
induced,O
increases,O
in,O
microglia,O
in,O
the,O
corpus,O
callosum,O
were,O
reduced,O
by,O
2ccPA,O
treatment,O
(,O
Fig,O
.,O
4l,O
).,O
We,O
observed,O
no,O
significant,O
difference,O
in,O
levels,O
of,O
gene,O
expression,O
for,O
the,O
alternative,O
markers,O
of,O
microglial,O
activation,O
Arg1,B-GP
",",O
Fizz1,B-GP
",",O
and,O
Ym1,B-GP
among,O
corpus,O
callosum,O
tissue,O
samples,O
(,O
Control,O
",",O
CPZ,O
+,O
saline,O
",",O
CPZ,O
+,O
2ccPA,O
),O
(,O
data,O
not,O
shown,O
).,O
These,O
findings,O
indicate,O
that,O
treatment,O
with,O
2ccPA,O
effectively,O
suppressed,O
cuprizone,O
-,O
induced,O
NLRP3,B-GP
inflammasome,O
formation,O
and,O
microglial,O
activation,O
.,O
Fig,O
.,O
42ccPA,O
suppressed,O
the,O
neuroinflammation,O
.,O
The,O
mRNA,O
levels,O
of,O
Iba1,B-GP
(,O
a,O
"),",O
GFAP,B-GP
(,O
b,O
"),",O
NLRP3,B-GP
(,O
c,O
"),",O
P2X7R,B-GP
(,O
d,O
"),",O
and,O
IL,B-GP
-,I-GP
1β,I-GP
(,O
e,O
),O
relative,O
to,O
PGK1,B-GP
",",O
as,O
determined,O
by,O
qPCR,O
in,O
the,O
corpus,O
callosum,O
after,O
5,O
weeks,O
of,O
CPZ,O
exposure,O
.,O
Data,O
are,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
5,O
animals,B-OG
.,O
Immunostaining,O
with,O
anti,O
-,O
Iba1,B-GP
showed,O
microglial,O
activation,O
in,O
the,O
corpus,O
callosum,O
.,O
Control,O
(,O
f,O
",",O
g,O
"),",O
CPZ,O
+,O
saline,O
(,O
h,O
",",O
i,O
"),",O
and,O
CPZ,O
+,O
2ccPA,O
(,O
j,O
",",O
k,O
).,O
Number,O
of,O
microglia,O
in,O
the,O
corpus,O
callosum,O
(,O
l,O
).,O
Data,O
are,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
6,O
animals,B-OG
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
hoc,O
Newman,O
-,O
Keuls,O
test,O
(*,O
p,O
<,O
0,O
.,O
05,O
;,O
**,O
p,O
<,O
0,O
.,O
01,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
control,O
;,O
#,O
p,O
<,O
0,O
.,O
01,O
;,O
###,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
CPZ,O
+,O
saline,O
).,O
Scale,O
bar,O
500,O
-,O
μm,O
left,O
images,O
;,O
50,O
-,O
μm,O
right,O
images,O
Beneficial,O
effects,O
of,O
2ccPA,O
in,O
the,O
multiperiod,O
of,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
We,O
investigated,O
the,O
therapeutic,O
potential,O
of,O
2ccPA,O
in,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
.,O
In,O
three,O
experimental,O
settings,O
",",O
2ccPA,O
treatment,O
was,O
administrated,O
during,O
at,O
weeks,O
3,O
–,O
5,O
(,O
protocol,O
B,O
:,O
beginning,O
of,O
substantial,O
demyelination,B-DS
and,O
motor,O
dysfunction,O
"),",O
weeks,O
5,O
–,O
6,O
(,O
protocol,O
C,O
:,O
spontaneous,O
remyelination,O
"),",O
or,O
weeks,O
5,O
–,O
10,O
(,O
protocol,O
D,O
:,O
chronic,O
severe,O
demyelination,B-DS
),O
of,O
cuprizone,O
exposure,O
.,O
Treatment,O
with,O
2ccPA,O
(,O
protocol,O
B,O
),O
suppressed,O
acute,O
peak,O
demyelination,B-DS
after,O
the,O
onset,O
of,O
cuprizone,O
-,O
induced,O
neurological,O
symptoms,O
(,O
Fig,O
.,O
5a,O
–,O
d,O
).,O
It,O
is,O
well,O
known,O
that,O
spontaneous,O
remyelination,O
occurs,O
following,O
acute,O
demyelination,B-DS
in,O
the,O
corpus,O
callosum,O
of,O
cuprizone,O
model,O
mice,B-OG
.,O
At,O
6,O
weeks,O
of,O
cuprizone,O
exposure,O
",",O
we,O
observed,O
spontaneous,O
remyelination,O
in,O
cuprizone,O
mice,B-OG
(,O
Fig,O
.,O
5f,O
).,O
Treatment,O
with,O
2ccPA,O
during,O
the,O
final,O
week,O
(,O
protocol,O
C,O
),O
significantly,O
promoted,O
spontaneous,O
remyelination,O
(,O
Fig,O
.,O
5e,O
–,O
h,O
).,O
Prolonged,O
cuprizone,O
exposure,O
resulted,O
in,O
chronic,O
demyelination,B-DS
.,O
Treatment,O
with,O
2ccPA,O
(,O
5,O
–,O
10,O
weeks,O
),O
reduced,O
chronic,O
demyelination,B-DS
(,O
Fig,O
.,O
5i,O
–,O
l,O
).,O
These,O
results,O
demonstrate,O
that,O
2ccPA,O
exerts,O
beneficial,O
effects,O
in,O
the,O
multiperiod,O
of,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
.,O
Fig,O
.,O
5Effects,O
of,O
2ccPA,O
in,O
the,O
multiperiod,O
of,O
CPZ,O
-,O
induced,O
demyelination,B-DS
and,O
motor,O
dysfunction,O
.,O
Black,O
-,O
Gold,O
II,O
staining,O
of,O
control,O
(,O
a,O
",",O
e,O
",",O
and,O
i,O
"),",O
CPZ,O
+,O
saline,O
(,O
b,O
",",O
f,O
",",O
and,O
j,O
"),",O
CPZ,O
+,O
2ccPA,O
(,O
c,O
",",O
g,O
",",O
and,O
k,O
).,O
Myelin,O
densities,O
in,O
the,O
corpus,O
callosum,O
(,O
d,O
",",O
h,O
",",O
and,O
l,O
),O
were,O
compared,O
with,O
controls,O
and,O
expressed,O
as,O
a,O
percentage,O
of,O
control,O
value,O
using,O
the,O
ImageJ,O
analysis,O
program,O
.,O
Data,O
are,O
mean,O
±,O
SEM,O
".,",O
n,O
=,O
5,O
animals,B-OG
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
hoc,O
Newman,O
-,O
Keuls,O
test,O
(***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
control,O
;,O
##,O
p,O
<,O
0,O
.,O
01,O
;,O
###,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
CPZ,O
+,O
saline,O
).,O
Scale,O
bars,O
=,O
500,O
μm,O
.,O
Motor,O
performance,O
on,O
the,O
rotarod,O
.,O
Mice,B-OG
were,O
assessed,O
for,O
locomotion,O
time,O
during,O
a,O
period,O
of,O
300,O
s,O
(,O
m,O
",",O
o,O
",",O
and,O
q,O
).,O
Data,O
are,O
mean,O
±,O
SEM,O
".,",O
n,O
=,O
12,O
animals,B-OG
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
hoc,O
Newman,O
-,O
Keuls,O
test,O
(***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
control,O
;,O
###,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
CPZ,O
+,O
saline,O
).,O
Number,O
of,O
falls,O
and,O
flips,O
(,O
n,O
",",O
p,O
",",O
and,O
r,O
).,O
Data,O
are,O
mean,O
±,O
SEM,O
".,",O
n,O
=,O
12,O
animals,B-OG
(,O
0,O
–,O
5,O
weeks,O
group,O
"),",O
n,O
=,O
10,O
animals,B-OG
(,O
3,O
–,O
5,O
weeks,O
group,O
"),",O
and,O
n,O
=,O
15,O
animals,B-OG
(,O
5,O
–,O
10,O
weeks,O
group,O
).,O
Statistical,O
analysis,O
was,O
performed,O
using,O
non,O
-,O
parametric,O
Kruskal,O
-,O
Wallis,O
test,O
(*,O
p,O
<,O
0,O
.,O
05,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
control,O
;,O
#,O
p,O
<,O
0,O
.,O
05,O
;,O
###,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
CPZ,O
+,O
saline,O
),O
2ccPA,O
improved,O
cuprizone,O
-,O
induced,O
motor,O
dysfunction,O
To,O
investigate,O
the,O
effects,O
of,O
2ccPA,O
on,O
motor,O
dysfunction,O
caused,O
by,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
",",O
we,O
assessed,O
the,O
locomotor,O
coordination,O
and,O
balance,O
of,O
mice,B-OG
using,O
a,O
rotarod,O
apparatus,O
.,O
Mice,B-OG
exposed,O
to,O
cuprizone,O
(,O
0,O
–,O
5,O
and,O
5,O
–,O
10,O
weeks,O
),O
exhibited,O
significant,O
decreases,O
in,O
locomotion,O
time,O
as,O
well,O
as,O
significant,O
increases,O
in,O
the,O
number,O
of,O
falls,O
and,O
flips,O
.,O
Treatment,O
with,O
2ccPA,O
(,O
protocols,O
A,O
",",O
B,O
",",O
and,O
D,O
),O
significantly,O
restored,O
locomotion,O
time,O
remarkably,O
(,O
Fig,O
.,O
5m,O
",",O
o,O
",",O
and,O
q,O
),O
and,O
suppressed,O
the,O
number,O
of,O
falls,O
and,O
flips,O
(,O
Fig,O
.,O
5n,O
",",O
p,O
",",O
and,O
r,O
).,O
2ccPA,O
treatment,O
significantly,O
suppressed,O
the,O
cuprizone,O
-,O
induced,O
impairment,O
of,O
motor,O
performance,O
.,O
2ccPA,O
ameliorated,O
EAE,B-DS
pathology,O
We,O
assessed,O
the,O
potential,O
of,O
2ccPA,O
to,O
improve,O
the,O
disease,O
course,O
in,O
the,O
EAE,B-DS
model,O
mice,B-OG
.,O
Mice,B-OG
were,O
monitored,O
daily,O
for,O
clinical,O
symptoms,O
and,O
scored,O
in,O
accordance,O
with,O
established,O
criteria,O
[,O
31,O
].,O
Control,O
mice,B-OG
exhibited,O
no,O
obvious,O
symptoms,O
of,O
EAE,B-DS
disease,O
.,O
In,O
contrast,O
",",O
EAE,B-DS
mice,B-OG
developed,O
severe,O
EAE,B-DS
symptoms,O
",",O
although,O
treatment,O
with,O
2ccPA,O
significantly,O
reduced,O
clinical,O
EAE,B-DS
scores,O
.,O
Indeed,O
",",O
a,O
large,O
difference,O
in,O
disease,O
severity,O
between,O
the,O
control,O
and,O
treatment,O
groups,O
was,O
observed,O
throughout,O
the,O
observation,O
period,O
(,O
Fig,O
.,O
6a,O
).,O
Mean,O
clinical,O
EAE,B-DS
scores,O
were,O
significantly,O
lower,O
for,O
2ccPA,O
-,O
treated,O
mice,B-OG
than,O
EAE,B-DS
mice,B-OG
.,O
Although,O
EAE,B-DS
mice,B-OG
peaked,O
at,O
scores,O
of,O
3,O
–,O
4,O
following,O
immunization,O
",",O
2ccPA,O
-,O
treated,O
mice,B-OG
peaked,O
at,O
scores,O
of,O
1,O
following,O
immunization,O
.,O
We,O
then,O
examined,O
the,O
therapeutic,O
potential,O
of,O
2ccPA,O
in,O
mice,B-OG
already,O
exhibiting,O
EAE,B-DS
symptoms,O
.,O
2ccPA,O
successfully,O
attenuated,O
clinical,O
EAE,B-DS
symptoms,O
even,O
after,O
the,O
peak,O
stages,O
of,O
disease,O
(,O
Fig,O
.,O
6b,O
"),",O
suggesting,O
that,O
treatment,O
with,O
2ccPA,O
dramatically,O
suppresses,O
impairments,O
in,O
neurological,O
function,O
.,O
Inflammatory,O
infiltration,O
of,O
immune,O
cells,O
in,O
the,O
spinal,O
cord,O
is,O
a,O
well,O
-,O
documented,O
histological,O
feature,O
of,O
the,O
EAE,B-DS
model,O
.,O
Inflammatory,O
infiltration,O
of,O
immune,O
cells,O
in,O
the,O
spinal,O
cords,O
was,O
a,O
histological,O
feature,O
of,O
the,O
EAE,B-DS
model,O
.,O
The,O
spinal,O
cords,O
were,O
stained,O
with,O
H,O
&,O
E,O
to,O
assess,O
the,O
degree,O
of,O
inflammation,O
.,O
Inflammatory,O
cells,O
penetrated,O
the,O
pia,O
mater,O
and,O
infiltrated,O
the,O
perivascular,O
regions,O
and,O
parenchyma,O
.,O
Control,O
myelin,O
of,O
the,O
white,O
matter,O
was,O
highlighted,O
clearly,O
by,O
H,O
&,O
E,O
staining,O
(,O
Fig,O
.,O
6c,O
).,O
In,O
EAE,B-DS
mice,B-OG
",",O
we,O
found,O
mononuclear,O
infiltration,O
in,O
the,O
leptomeninges,O
and,O
scattered,O
throughout,O
the,O
white,O
matter,O
parenchyma,O
(,O
Fig,O
.,O
6d,O
).,O
We,O
observed,O
severe,O
inflammation,O
with,O
vacuolation,O
in,O
the,O
anterior,O
and,O
lateral,O
funiculi,O
of,O
the,O
spinal,O
cord,O
.,O
Treatment,O
with,O
2ccPA,O
reduced,O
infiltration,O
of,O
mononuclear,O
cells,O
(,O
Fig,O
.,O
6e,O
).,O
Treatment,O
with,O
2ccPA,O
suppressed,O
sustained,O
scores,O
for,O
inflammation,O
in,O
the,O
spinal,O
cord,O
(,O
Fig,O
.,O
6f,O
).,O
Fig,O
.,O
62ccPA,O
-,O
ameliorated,O
EAE,B-DS
pathological,O
condition,O
and,O
immunopathology,O
.,O
Mice,B-OG
treated,O
with,O
EAE,B-DS
+,O
saline,O
and,O
EAE,B-DS
+,O
2ccPA,O
were,O
immunized,O
with,O
the,O
MOG35,O
−,O
55,O
peptide,O
and,O
clinical,O
scores,O
were,O
assessed,O
daily,O
for,O
30,O
days,O
(,O
a,O
).,O
Treatment,O
with,O
2ccPA,O
after,O
the,O
peak,O
of,O
EAE,B-DS
symptoms,O
had,O
occurred,O
(,O
b,O
).,O
Data,O
are,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
5,O
animals,B-OG
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
two,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
hoc,O
Mann,O
-,O
Whitney,O
U,O
test,O
regarding,O
day,O
0,O
–,O
30,O
(,O
a,O
),O
or,O
day,O
17,O
–,O
30,O
(,O
b,O
"),",O
respectively,O
",",O
(**,O
p,O
<,O
0,O
.,O
01,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
EAE,B-DS
+,O
saline,O
).,O
H,O
&,O
E,O
staining,O
revealed,O
histological,O
features,O
of,O
MOG35,O
−,O
55,O
-,O
induced,O
EAE,B-DS
.,O
Control,O
(,O
c,O
"),",O
EAE,B-DS
+,O
saline,O
(,O
d,O
"),",O
EAE,B-DS
+,O
2ccPA,O
(,O
e,O
).,O
The,O
degrees,O
of,O
inflammation,O
(,O
f,O
).,O
Scale,O
bar,O
=,O
50,O
μm,O
.,O
Immunostaining,O
with,O
T,O
cell,O
and,O
macrophage,O
infiltration,O
in,O
the,O
spinal,O
cord,O
.,O
Fluorescence,O
for,O
CD4,B-GP
",",O
DAPI,O
",",O
and,O
marge,O
images,O
.,O
Control,O
(,O
g,O
"),",O
EAE,B-DS
+,O
saline,O
(,O
h,O
"),",O
EAE,B-DS
+,O
2ccPA,O
(,O
i,O
).,O
Number,O
of,O
infiltrating,O
T,O
cells,O
in,O
the,O
spinal,O
cord,O
(,O
m,O
).,O
Fluorescence,O
for,O
F4,O
/,O
80,O
",",O
DAPI,O
",",O
and,O
marge,O
images,O
.,O
Control,O
(,O
j,O
"),",O
EAE,B-DS
+,O
saline,O
(,O
k,O
"),",O
EAE,B-DS
+,O
2ccPA,O
(,O
l,O
).,O
Number,O
of,O
infiltrating,O
macrophages,O
in,O
the,O
spinal,O
cord,O
(,O
n,O
).,O
Data,O
are,O
mean,O
±,O
SEM,O
",",O
n,O
=,O
5,O
animals,B-OG
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
hoc,O
Newman,O
-,O
Keuls,O
test,O
(**,O
p,O
<,O
0,O
.,O
01,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
control,O
;,O
#,O
p,O
<,O
0,O
.,O
05,O
;,O
###,O
p,O
<,O
0,O
.,O
001,O
vs,O
.,O
EAE,B-DS
+,O
saline,O
).,O
Scale,O
bar,O
=,O
100,O
μm,O
2ccPA,O
suppressed,O
CD4,B-GP
-,O
or,O
F4,O
/,O
80,O
-,O
positive,O
T,O
cell,O
and,O
macrophage,O
infiltration,O
in,O
the,O
spinal,O
cord,O
Infiltration,O
of,O
immune,O
cells,O
(,O
T,O
cells,O
and,O
macrophages,O
),O
was,O
observed,O
in,O
mice,B-OG
exposed,O
to,O
EAE,B-DS
",",O
although,O
these,O
increases,O
were,O
suppressed,O
following,O
2ccPA,O
administration,O
.,O
Immunofluorescence,O
in,O
the,O
spinal,O
cord,O
was,O
evaluated,O
using,O
the,O
T,O
cell,O
marker,O
CD4,B-GP
and,O
macrophage,O
marker,O
F4,O
/,O
80,O
.,O
In,O
control,O
mice,B-OG
",",O
CD4,B-GP
-,O
and,O
F4,O
/,O
80,O
-,O
positive,O
cells,O
were,O
sporadically,O
distributed,O
in,O
the,O
spinal,O
cord,O
(,O
Fig,O
.,O
6g,O
",",O
j,O
"),",O
while,O
an,O
accumulation,O
of,O
infiltrative,O
cells,O
was,O
observed,O
in,O
meningeal,O
area,O
of,O
the,O
spinal,O
cord,O
in,O
mice,B-OG
exposed,O
to,O
EAE,B-DS
(,O
Fig,O
.,O
6h,O
",",O
k,O
).,O
Mice,B-OG
exposed,O
to,O
EAE,B-DS
exhibited,O
T,O
cell,O
and,O
macrophage,O
infiltration,O
",",O
although,O
such,O
infiltration,O
was,O
suppressed,O
by,O
2ccPA,O
treatment,O
(,O
Fig,O
.,O
6i,O
",",O
l,O
).,O
Therefore,O
",",O
treatment,O
with,O
2ccPA,O
effectively,O
suppressed,O
EAE,B-DS
-,O
induced,O
T,O
cell,O
and,O
macrophage,O
infiltration,O
in,O
the,O
spinal,O
cord,O
(,O
Fig,O
.,O
6m,O
",",O
n,O
).,O
Discussion,O
Multiple,B-DS
sclerosis,I-DS
is,O
a,O
heterogeneous,O
disease,O
in,O
clinical,O
presentation,O
",",O
in,O
terms,O
of,O
demyelinating,O
lesions,O
",",O
immunopathological,O
subtypes,O
",",O
response,O
to,O
therapy,O
",",O
and,O
genetic,O
associations,O
[,O
6,O
",",O
32,O
].,O
A,O
detailed,O
immunopathological,O
investigation,O
of,O
demyelinating,O
lesions,O
revealed,O
four,O
distinct,O
immunopathological,O
patterns,O
[,O
6,O
].,O
In,O
patterns,O
I,O
and,O
II,O
",",O
demyelination,B-DS
occurs,O
as,O
a,O
consequence,O
of,O
an,O
autoimmune,O
reaction,O
against,O
myelin,O
",",O
whereas,O
demyelination,B-DS
is,O
independent,O
of,O
immune,O
activation,O
and,O
is,O
caused,O
by,O
oligodendrocyte,O
primary,O
cell,O
loss,O
in,O
patterns,O
III,O
and,O
IV,O
.,O
Previous,O
studies,O
have,O
revealed,O
that,O
administration,O
of,O
EAE,B-DS
and,O
cuprizone,O
reproduces,O
the,O
pathology,O
observed,O
in,O
patterns,O
I,O
/,O
II,O
and,O
patterns,O
III,O
/,O
IV,O
",",O
respectively,O
[,O
33,O
].,O
These,O
animal,B-OG
models,O
accurately,O
represent,O
all,O
aspects,O
of,O
the,O
pathology,O
and,O
clinical,O
features,O
of,O
human,B-OG
multiple,B-DS
sclerosis,I-DS
[,O
34,O
].,O
The,O
findings,O
of,O
the,O
present,O
study,O
demonstrate,O
that,O
treatment,O
with,O
2ccPA,O
improved,O
cuprizone,O
-,O
induced,O
motor,O
dysfunction,O
and,O
pathological,O
EAE,B-DS
scores,O
",",O
suggesting,O
that,O
2ccPA,O
may,O
exert,O
beneficial,O
effects,O
in,O
all,O
subtypes,O
of,O
human,B-OG
multiple,B-DS
sclerosis,I-DS
.,O
Neuroinflammation,O
(,O
e,O
.,O
g,O
".,",O
lymphocyte,O
/,O
macrophage,O
infiltration,O
",",O
microglial,O
activation,O
",",O
enhanced,O
cytokine,B-GP
/,O
chemokine,B-GP
production,O
",",O
demyelination,B-DS
",",O
and,O
axonal,O
damage,O
[,O
35,O
–,O
37,O
]),O
is,O
a,O
key,O
component,O
of,O
the,O
pathological,O
progression,O
of,O
all,O
subtypes,O
of,O
multiple,B-DS
sclerosis,I-DS
and,O
in,O
both,O
the,O
EAE,B-DS
and,O
cuprizone,O
models,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
demonstrated,O
that,O
2ccPA,O
suppressed,O
neuroinflammation,O
in,O
the,O
EAE,B-DS
and,O
cuprizone,O
models,O
.,O
2ccPA,O
treatment,O
suppressed,O
the,O
infiltration,O
of,O
CD4,B-GP
-,O
positive,O
T,O
cells,O
and,O
F4,O
/,O
80,O
-,O
positive,O
macrophages,O
to,O
the,O
spinal,O
cord,O
in,O
EAE,B-DS
model,O
mice,B-OG
.,O
CD4,B-GP
-,O
positive,O
T,O
cells,O
secrete,O
proinflammatory,O
cytokines,B-GP
",",O
which,O
play,O
important,O
roles,O
in,O
the,O
neuroinflammatory,O
",",O
cascade,O
",",O
and,O
mediate,O
the,O
damage,O
to,O
the,O
myelin,O
sheath,O
",",O
demyelination,B-DS
",",O
and,O
eventually,O
damage,O
to,O
the,O
neuronal,O
axon,O
[,O
38,O
",",O
39,O
].,O
F4,O
/,O
80,O
-,O
positive,O
microglia,O
/,O
macrophages,O
produce,O
and,O
respond,O
to,O
a,O
wide,O
variety,O
of,O
cytokines,B-GP
",",O
impair,O
blood,O
-,O
brain,O
barrier,O
function,O
",",O
act,O
as,O
antigen,O
-,O
presenting,O
cells,O
within,O
the,O
CNS,O
",",O
mediate,O
phagocytic,O
events,O
",",O
and,O
damage,O
oligodendrocytes,O
[,O
40,O
",",O
41,O
].,O
Therefore,O
",",O
our,O
data,O
suggest,O
that,O
inhibition,O
of,O
T,O
cells,O
and,O
macrophage,O
infiltrates,O
into,O
CNS,O
by,O
2ccPA,O
treatment,O
should,O
be,O
associated,O
with,O
suppression,O
of,O
neuroinflammation,O
in,O
EAE,B-DS
.,O
Further,O
",",O
we,O
also,O
demonstrated,O
that,O
2ccPA,O
suppressed,O
cuprizone,O
-,O
induced,O
microglial,O
activation,O
and,O
NLRP3,B-GP
inflammasome,O
formation,O
.,O
Previous,O
studies,O
have,O
reported,O
that,O
demyelination,B-DS
occurs,O
in,O
parallel,O
with,O
microglial,O
activation,O
in,O
the,O
cuprizone,O
model,O
[,O
9,O
].,O
Activated,O
microglia,O
contribute,O
to,O
the,O
death,O
of,O
oligodendrocytes,O
by,O
secreting,O
proinflammatory,O
cytokines,B-GP
[,O
42,O
],O
and,O
to,O
axonal,O
damage,O
[,O
43,O
],O
by,O
stripping,O
synaptic,O
proteins,O
[,O
44,O
].,O
The,O
NLRP3,B-GP
inflammasome,O
signaling,O
pathway,O
is,O
involved,O
in,O
various,O
neuroinflammatory,O
diseases,O
",",O
including,O
multiple,B-DS
sclerosis,I-DS
and,O
the,O
EAE,B-DS
and,O
cuprizone,O
models,O
.,O
Activation,O
of,O
the,O
P2X7,B-GP
receptor,I-GP
",",O
principally,O
by,O
extracellular,O
ATP,O
",",O
induces,O
NLRP3,B-GP
inflammasome,O
activation,O
and,O
promotes,O
the,O
processing,O
and,O
release,O
of,O
IL,B-GP
-,I-GP
1β,I-GP
.,O
IL,B-GP
-,I-GP
1β,I-GP
is,O
a,O
pivotal,O
mediator,O
in,O
the,O
neuroinflammatory,O
response,O
[,O
9,O
],O
and,O
promotes,O
leukocyte,O
infiltration,O
by,O
inducing,O
the,O
expression,O
of,O
many,O
cytokines,B-GP
",",O
chemokines,B-GP
",",O
and,O
adhesion,O
molecules,O
.,O
A,O
recent,O
study,O
has,O
reported,O
that,O
microglia,O
express,O
the,O
NLRP3,B-GP
inflammasome,O
and,O
release,O
IL,B-GP
-,I-GP
1β,I-GP
[,O
45,O
"],",O
suggesting,O
that,O
the,O
microglial,O
NLRP3,B-GP
inflammasome,O
probably,O
promotes,O
CNS,O
inflammation,O
and,O
demyelination,B-DS
.,O
In,O
our,O
study,O
",",O
2ccPA,O
suppressed,O
cuprizone,O
-,O
induced,O
microglial,O
activation,O
and,O
NLRP3,B-GP
inflammasome,O
",",O
suggesting,O
that,O
2ccPA,O
suppressed,O
the,O
neuroinflammation,O
to,O
inhibit,O
the,O
microglial,O
NLRP3,B-GP
inflammasome,O
caused,O
by,O
excessive,O
microglial,O
activation,O
.,O
Microglia,O
are,O
known,O
to,O
develop,O
diverse,O
functional,O
phenotypes,O
of,O
proinflammatory,O
(,O
M1,O
),O
and,O
alternative,O
(,O
M2,O
),O
activation,O
[,O
46,O
",",O
47,O
].,O
Previous,O
findings,O
have,O
revealed,O
that,O
NLRP3,B-GP
promotes,O
microglial,O
M1,O
activation,O
and,O
that,O
the,O
NLRP3,B-GP
complex,O
is,O
contained,O
in,O
M1,O
microglia,O
[,O
48,O
].,O
In,O
the,O
present,O
study,O
",",O
2ccPA,O
treatment,O
suppressed,O
markers,O
of,O
the,O
NLRP3,B-GP
inflammasome,O
(,O
NLRP3,B-GP
",",O
P2X7,B-GP
",",O
and,O
IL,B-GP
-,I-GP
1b,I-GP
),O
but,O
not,O
of,O
M2,O
microglia,O
(,O
Arg1,B-GP
",",O
Fizz1,B-GP
",",O
and,O
Ym1,B-GP
"),",O
suggested,O
that,O
2ccPA,O
suppressed,O
the,O
microglial,O
M1,O
proinflammatory,O
activation,O
.,O
Taken,O
together,O
",",O
these,O
findings,O
suggest,O
that,O
2ccPA,O
improves,O
the,O
pathological,O
state,O
of,O
EAE,B-DS
and,O
cuprizone,O
model,O
mice,B-OG
by,O
mediating,O
the,O
attenuation,O
of,O
neuroinflammatory,O
conditions,O
(,O
i,O
.,O
e,O
".,",O
infiltration,O
of,O
immune,O
cells,O
and,O
microglial,O
NLRP3,B-GP
inflammasome,O
",",O
respectively,O
).,O
Under,O
neuroinflammatory,O
conditions,O
",",O
mitochondrial,O
apoptotic,O
cell,O
death,O
has,O
been,O
observed,O
following,O
damage,O
to,O
the,O
CNS,O
[,O
49,O
].,O
Mitochondrial,O
dysfunction,O
plays,O
a,O
crucial,O
role,O
in,O
the,O
loss,O
of,O
oligodendrocytes,O
and,O
neuronal,O
axons,O
in,O
multiple,B-DS
sclerosis,I-DS
[,O
50,O
],O
and,O
in,O
the,O
EAE,B-DS
and,O
cuprizone,O
models,O
.,O
The,O
mitochondria,O
-,O
mediated,O
apoptosis,O
pathway,O
is,O
largely,O
controlled,O
by,O
the,O
master,O
apoptosis,O
inducer,O
Bax,B-GP
and,O
the,O
apoptosis,O
suppressor,O
Bcl,B-GP
-,I-GP
2,I-GP
[,O
51,O
].,O
Phosphorylation,O
and,O
activation,O
of,O
JNK,B-GP
and,O
p38MAPK,B-GP
also,O
promote,O
mitochondrial,O
apoptotic,O
cell,O
death,O
[,O
52,O
",",O
53,O
].,O
In,O
this,O
study,O
",",O
we,O
showed,O
that,O
2ccPA,O
suppressed,O
CoCl2,O
-,O
induced,O
apoptosis,O
.,O
We,O
reported,O
previously,O
that,O
natural,O
cPA,O
suppressed,O
mitochondrial,O
apoptosis,O
of,O
neuronal,O
cells,O
in,O
vitro,O
and,O
delayed,O
neuronal,O
death,O
in,O
vivo,O
.,O
Therefore,O
",",O
our,O
results,O
suggest,O
that,O
the,O
protective,O
function,O
of,O
2ccPA,O
suppressed,O
the,O
mitochondrial,O
apoptosis,O
pathway,O
in,O
both,O
oligodendrocytes,O
and,O
neurons,O
",",O
which,O
is,O
likely,O
to,O
be,O
associated,O
with,O
protection,O
from,O
the,O
loss,O
of,O
oligodendrocytes,O
and,O
axons,O
in,O
demyelinative,O
conditions,O
.,O
Previously,O
",",O
we,O
reported,O
that,O
2ccPA,O
promotes,O
neurite,O
outgrowth,O
and,O
enhances,O
neuronal,O
survival,O
via,O
a,O
signaling,O
pathway,O
similar,O
to,O
that,O
of,O
NGF,B-GP
[,O
11,O
].,O
Therefore,O
",",O
it,O
is,O
possible,O
that,O
2ccPA,O
exerts,O
protective,O
effects,O
against,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
and,O
EAE,B-DS
pathology,O
via,O
NGF,B-GP
-,O
like,O
actions,O
.,O
Previous,O
studies,O
have,O
indicated,O
that,O
NGF,B-GP
exerts,O
a,O
dramatic,O
effect,O
on,O
neuron,O
and,O
oligodendrocyte,O
survival,O
and,O
stimulates,O
axonal,O
regeneration,O
/,O
remyelination,O
[,O
54,O
",",O
55,O
].,O
These,O
findings,O
are,O
in,O
accordance,O
with,O
the,O
protective,O
effects,O
against,O
CPZ,O
-,O
induced,O
demyelination,B-DS
observed,O
in,O
our,O
study,O
.,O
Additional,O
studies,O
have,O
indicated,O
that,O
NGF,B-GP
may,O
exert,O
protective,O
effects,O
in,O
EAE,B-DS
model,O
mice,B-OG
by,O
switching,O
the,O
immune,O
response,O
to,O
an,O
anti,O
-,O
inflammatory,O
status,O
[,O
56,O
",",O
57,O
].,O
Indeed,O
",",O
our,O
findings,O
indicate,O
that,O
a,O
similar,O
process,O
may,O
underlie,O
the,O
protective,O
effect,O
of,O
2ccPA,O
against,O
EAE,B-DS
.,O
Furthermore,O
",",O
NGF,B-GP
is,O
a,O
potent,O
anti,O
-,O
apoptotic,O
factor,O
that,O
regulates,O
levels,O
of,O
anti,O
-,O
apoptotic,O
Bcl,B-GP
-,I-GP
2,I-GP
protein,O
",",O
a,O
common,O
mechanism,O
by,O
which,O
2ccPA,O
protected,O
oligodendrocytes,O
from,O
CoCl2,O
-,O
induced,O
apoptosis,O
[,O
58,O
].,O
These,O
findings,O
suggest,O
that,O
multiple,O
effects,O
of,O
2ccPA,O
are,O
due,O
to,O
its,O
NGF,B-GP
-,O
like,O
actions,O
.,O
There,O
is,O
a,O
need,O
for,O
therapeutic,O
drug,O
treatment,O
of,O
progressive,B-DS
multiple,I-DS
sclerosis,I-DS
that,O
can,O
arrest,O
the,O
progression,O
of,O
demyelination,B-DS
.,O
Our,O
results,O
may,O
indicate,O
that,O
2ccPA,O
has,O
a,O
beneficial,O
effect,O
on,O
progressive,O
demyelination,B-DS
.,O
Treatment,O
with,O
2ccPA,O
suppressed,O
demyelination,B-DS
and,O
motor,O
dysfunction,O
even,O
after,O
the,O
onset,O
of,O
cuprizone,O
-,O
induced,O
pathology,O
(,O
protocol,O
B,O
and,O
D,O
).,O
Further,O
",",O
2ccPA,O
might,O
have,O
a,O
function,O
to,O
enhance,O
remyelination,O
(,O
protocol,O
C,O
).,O
In,O
summary,O
",",O
we,O
found,O
that,O
the,O
administration,O
of,O
2ccPA,O
reduced,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
",",O
microglial,O
activation,O
",",O
NLRP3,B-GP
inflammasome,O
",",O
and,O
motor,O
dysfunction,O
",",O
and,O
promoted,O
remyelination,O
.,O
Furthermore,O
",",O
we,O
found,O
that,O
2ccPA,O
reduced,O
autoreactive,O
T,O
cell,O
and,O
macrophage,O
",",O
spinal,B-DS
cord,I-DS
injury,I-DS
",",O
and,O
clinical,O
behavioral,O
dysfunction,O
in,O
the,O
autoimmune,O
multiple,B-DS
sclerosis,I-DS
model,O
of,O
EAE,B-DS
.,O
These,O
data,O
indicate,O
that,O
2ccPA,O
may,O
be,O
a,O
promising,O
seed,O
compound,O
for,O
the,O
development,O
of,O
new,O
drugs,O
to,O
treat,O
demyelinating,B-DS
disease,I-DS
and,O
ameliorate,O
the,O
symptoms,O
of,O
multiple,B-DS
sclerosis,I-DS
.,O
Conclusions,O
The,O
findings,O
of,O
the,O
present,O
study,O
demonstrate,O
that,O
2ccPA,O
protected,O
oligodendrocytes,O
via,O
suppression,O
of,O
the,O
mitochondrial,O
apoptosis,O
pathway,O
.,O
Beneficial,O
effects,O
of,O
2ccPA,O
were,O
observed,O
in,O
the,O
multiperiod,O
of,O
cuprizone,O
-,O
induced,O
demyelination,B-DS
and,O
EAE,B-DS
pathology,O
.,O
These,O
data,O
indicate,O
that,O
2ccPA,O
is,O
a,O
promising,O
candidate,O
for,O
the,O
development,O
of,O
new,O
drugs,O
for,O
the,O
treatment,O
of,O
demyelinating,O
conditions,O
such,O
as,O
multiple,B-DS
sclerosis,I-DS
.,O
Molecular,O
Cloning,O
",",O
Characterization,O
and,O
Expression,O
Analysis,O
of,O
Two,O
Members,O
of,O
the,O
Pht1,B-GP
Family,O
of,O
Phosphate,B-GP
Transporters,I-GP
in,O
Glycine,B-OG
max,I-OG
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
ZW,O
GX,O
JG,O
HX,O
.,O
Performed,O
the,O
experiments,O
:,O
ZW,O
RG,O
GH,O
.,O
Analyzed,O
the,O
data,O
:,O
ZW,O
JZ,O
.,O
Wrote,O
the,O
paper,O
:,O
ZW,O
HX,O
.,O
Background,O
Phosphorus,O
is,O
one,O
of,O
the,O
macronutrients,O
essential,O
for,O
plant,B-OG
growth,O
and,O
development,O
.,O
The,O
acquisition,O
and,O
translocation,O
of,O
phosphate,O
are,O
pivotal,O
processes,O
of,O
plant,B-OG
growth,O
.,O
In,O
a,O
large,O
number,O
of,O
plants,B-OG
",",O
phosphate,O
uptake,O
by,O
roots,O
and,O
translocation,O
within,O
the,O
plant,B-OG
are,O
presumed,O
to,O
occur,O
via,O
a,O
phosphate,O
/,O
proton,O
cotransport,O
mechanism,O
.,O
Principal,O
Findings,O
We,O
cloned,O
two,O
cDNAs,O
from,O
soybean,B-OG
(,O
Glycine,B-OG
max,I-OG
"),",O
GmPT1,B-GP
and,O
GmPT2,B-GP
",",O
which,O
show,O
homology,O
to,O
the,O
phosphate,B-GP
/,I-GP
proton,I-GP
cotransporter,I-GP
PHO84,B-GP
from,O
the,O
budding,O
yeast,B-OG
Saccharomyces,B-OG
cerevisiae,I-OG
.,O
The,O
amino,O
acid,O
sequence,O
of,O
the,O
products,O
predicted,O
from,O
GmPT1,B-GP
and,O
GmPT2,B-GP
share,O
61,O
%,O
and,O
63,O
%,O
identity,O
",",O
respectively,O
",",O
with,O
the,O
PHO84,B-GP
in,O
amino,O
acid,O
sequence,O
.,O
The,O
deduced,O
structure,O
of,O
the,O
encoded,O
proteins,O
revealed,O
12,O
membrane,O
-,O
spanning,O
domains,O
with,O
a,O
central,O
hydrophilic,O
region,O
.,O
The,O
molecular,O
mass,O
values,O
are,O
∼,O
58,O
.,O
7,O
kDa,O
for,O
GmPT1,B-GP
and,O
∼,O
58,O
.,O
6,O
kDa,O
for,O
GmPT2,B-GP
.,O
Transiently,O
expressed,O
GFP,B-GP
–,O
protein,O
fusions,O
provide,O
direct,O
evidence,O
that,O
the,O
two,O
Pi,B-GP
transporters,I-GP
are,O
located,O
in,O
the,O
plasma,O
membrane,O
.,O
Uptake,O
of,O
radioactive,O
orthophosphate,O
by,O
the,O
yeast,B-OG
mutant,O
MB192,O
showed,O
that,O
GmPT1,B-GP
and,O
GmPT2,B-GP
are,O
dependent,O
on,O
pH,O
and,O
uptake,O
is,O
reduced,O
by,O
the,O
addition,O
of,O
uncouplers,O
of,O
oxidative,O
phosphorylation,O
.,O
The,O
K,O
m,O
for,O
phosphate,O
uptake,O
by,O
GmPT1,B-GP
and,O
GmPT2,B-GP
is,O
6,O
.,O
65,O
mM,O
and,O
6,O
.,O
63,O
mM,O
",",O
respectively,O
.,O
A,O
quantitative,O
real,O
time,O
RT,O
-,O
PCR,O
assay,O
indicated,O
that,O
these,O
two,O
genes,O
are,O
expressed,O
in,O
the,O
roots,O
and,O
shoots,O
of,O
seedlings,O
whether,O
they,O
are,O
phosphate,O
-,O
deficient,O
or,O
not,O
.,O
Deficiency,O
of,O
phosphorus,O
caused,O
a,O
slight,O
change,O
of,O
the,O
expression,O
levels,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
.,O
Conclusions,O
The,O
results,O
of,O
our,O
experiments,O
show,O
that,O
the,O
two,O
phosphate,B-GP
transporters,I-GP
have,O
low,O
affinity,O
and,O
the,O
corresponding,O
genes,O
are,O
constitutively,O
expressed,O
.,O
Thereby,O
",",O
the,O
two,O
phosphate,B-GP
transporters,I-GP
can,O
perform,O
translocation,O
of,O
phosphate,O
within,O
the,O
plant,B-OG
.,O
Introduction,O
Phosphorus,O
is,O
one,O
of,O
the,O
most,O
important,O
macronutrients,O
required,O
for,O
plant,B-OG
growth,O
and,O
metabolism,O
",",O
and,O
is,O
the,O
key,O
component,O
of,O
nucleic,O
acids,O
",",O
phospholipids,O
and,O
energy,O
-,O
providing,O
ATP,O
as,O
well,O
as,O
several,O
enzymes,O
and,O
coenzymes,O
.,O
Phosphorus,O
is,O
involved,O
in,O
energy,O
metabolism,O
",",O
activation,O
of,O
metabolic,O
intermediates,O
",",O
carbon,O
assimilation,O
",",O
photosynthesis,O
",",O
respiration,O
",",O
signal,O
transduction,O
and,O
enzyme,O
regulation,O
[,O
1,O
"],",O
[,O
2,O
"],",O
[,O
3,O
].,O
In,O
soil,O
",",O
plants,B-OG
acquire,O
phosphorus,O
in,O
the,O
form,O
of,O
orthophosphate,O
(,O
Pi,O
),O
[,O
4,O
"],",O
[,O
5,O
"],",O
[,O
6,O
].,O
Phosphate,O
is,O
the,O
second,O
most,O
frequently,O
limiting,O
macronutrient,O
for,O
plant,B-OG
growth,O
mainly,O
because,O
it,O
exists,O
in,O
the,O
soil,O
in,O
complex,O
",",O
insoluble,O
",",O
inorganic,O
and,O
organic,O
forms,O
that,O
cannot,O
be,O
acquired,O
directly,O
by,O
the,O
plant,B-OG
[,O
4,O
"],",O
[,O
7,O
].,O
For,O
this,O
reason,O
",",O
the,O
concentration,O
of,O
Pi,O
in,O
soil,O
solution,O
can,O
be,O
as,O
high,O
as,O
10,O
µM,O
but,O
is,O
present,O
more,O
often,O
at,O
concentrations,O
as,O
low,O
as,O
1,O
µM,O
[,O
8,O
].,O
Plants,B-OG
respond,O
to,O
phosphate,O
deficiency,O
by,O
increasing,O
the,O
rate,O
of,O
Pi,O
uptake,O
by,O
roots,O
[,O
4,O
"],",O
and,O
upregulation,O
of,O
the,O
synthesis,O
of,O
a,O
carrier,O
system,O
is,O
believed,O
to,O
contribute,O
to,O
the,O
observed,O
increase,O
of,O
Pi,O
acquisition,O
[,O
9,O
].,O
There,O
are,O
two,O
Pi,O
transport,O
systems,O
required,O
by,O
plants,B-OG
to,O
facilitate,O
absorption,O
from,O
diverse,O
environments,O
and,O
enable,O
subsequent,O
transportation,O
to,O
all,O
of,O
the,O
cells,O
and,O
subcellular,O
compartments,O
within,O
the,O
plant,B-OG
.,O
Kinetic,O
characterization,O
of,O
the,O
Pi,O
uptake,O
system,O
of,O
whole,O
plants,B-OG
[,O
10,O
"],",O
[,O
11,O
],O
and,O
cultured,O
cells,O
[,O
12,O
],O
suggests,O
a,O
high,O
-,O
affinity,O
transport,O
operating,O
in,O
the,O
low,O
micromolar,O
range,O
and,O
a,O
low,O
-,O
affinity,O
system,O
operating,O
at,O
higher,O
concentrations,O
(,O
millimolar,O
range,O
),O
[,O
7,O
"],",O
[,O
13,O
"],",O
[,O
14,O
"],",O
[,O
15,O
"],",O
[,O
16,O
].,O
Because,O
the,O
concentration,O
of,O
Pi,O
in,O
soil,O
solution,O
seldom,O
exceeds,O
10,O
µM,O
[,O
8,O
"],",O
the,O
high,O
-,O
affinity,O
transport,O
is,O
assumed,O
to,O
be,O
the,O
predominant,O
system,O
responsible,O
for,O
Pi,O
uptake,O
.,O
Thus,O
",",O
a,O
number,O
of,O
Pi,B-GP
transporters,I-GP
might,O
function,O
primarily,O
in,O
Pi,O
uptake,O
at,O
the,O
soil,O
–,O
root,O
interface,O
",",O
whereas,O
the,O
others,O
might,O
participate,O
predominantly,O
in,O
translocation,O
within,O
the,O
plant,B-OG
and,O
/,O
or,O
transport,O
within,O
certain,O
tissues,O
or,O
cell,O
types,O
.,O
After,O
uptake,O
into,O
the,O
roots,O
",",O
Pi,O
is,O
mainly,O
translocated,O
symplastically,O
to,O
the,O
xylem,O
parenchyma,O
cells,O
",",O
and,O
secretion,O
into,O
the,O
xylem,O
for,O
long,O
-,O
distance,O
translocation,O
to,O
the,O
shoot,O
is,O
facilitated,O
by,O
another,O
type,O
of,O
transporter,B-GP
-,I-GP
like,I-GP
protein,I-GP
[,O
8,O
"],",O
[,O
17,O
].,O
In,O
plants,B-OG
that,O
are,O
not,O
Pi,O
-,O
deficient,O
",",O
most,O
of,O
the,O
Pi,O
uptake,O
by,O
the,O
roots,O
is,O
transported,O
in,O
the,O
xylem,O
to,O
growing,O
leaves,O
.,O
In,O
Pi,O
-,O
starved,O
plants,B-OG
",",O
however,O
",",O
the,O
limited,O
supply,O
of,O
Pi,O
from,O
roots,O
to,O
shoots,O
is,O
augmented,O
by,O
increased,O
mobilization,O
of,O
stored,O
Pi,O
in,O
older,O
leaves,O
and,O
retranslocation,O
to,O
both,O
younger,O
leaves,O
and,O
growing,O
roots,O
",",O
from,O
where,O
Pi,O
can,O
again,O
be,O
recycled,O
to,O
the,O
shoot,O
[,O
18,O
].,O
Consequently,O
",",O
the,O
uptake,O
and,O
allocation,O
of,O
Pi,O
in,O
plants,B-OG
requires,O
multiple,O
transport,O
systems,O
that,O
must,O
function,O
in,O
concert,O
to,O
maintain,O
homeostasis,O
throughout,O
growth,O
and,O
development,O
[,O
19,O
].,O
Remobilization,O
of,O
phosphate,O
stored,O
in,O
leaves,O
has,O
been,O
demonstrated,O
and,O
the,O
existence,O
of,O
a,O
Pi,B-GP
transporter,I-GP
that,O
facilitates,O
this,O
process,O
has,O
been,O
inferred,O
.,O
Rae,O
et,O
al,O
.,O
have,O
identified,O
several,O
genes,O
in,O
a,O
barley,B-OG
genomic,O
library,O
that,O
appear,O
to,O
be,O
members,O
of,O
the,O
Pht1,B-GP
gene,O
family,O
.,O
The,O
sequence,O
of,O
HORvu,B-OG
;,O
Pht1,B-GP
;,I-GP
6,I-GP
suggested,O
that,O
it,O
is,O
also,O
a,O
member,O
of,O
the,O
Pht1,B-GP
gene,O
family,O
.,O
The,O
estimated,O
K,O
m,O
of,O
HORvu,B-OG
;,O
Pht1,B-GP
;,I-GP
6,I-GP
is,O
38561,O
µM,O
",",O
which,O
is,O
characteristic,O
of,O
a,O
low,O
-,O
affinity,O
transporter,B-GP
.,O
HORvu,B-OG
;,O
Pht1,B-GP
;,I-GP
6,I-GP
is,O
expressed,O
in,O
the,O
above,O
-,O
ground,O
part,O
of,O
the,O
plant,B-OG
with,O
strongest,O
expression,O
in,O
old,O
leaves,O
and,O
flag,O
leaves,O
and,O
is,O
less,O
responsive,O
to,O
external,O
concentrations,O
of,O
Pi,O
",",O
indicating,O
that,O
Pht1,B-GP
;,I-GP
6,I-GP
is,O
unlikely,O
to,O
function,O
in,O
the,O
uptake,O
of,O
Pi,O
by,O
roots,O
from,O
soil,O
.,O
Both,O
of,O
these,O
organs,O
are,O
known,O
to,O
have,O
a,O
role,O
in,O
the,O
nutrition,O
of,O
developing,O
grains,O
.,O
The,O
expression,O
of,O
Pht1,B-GP
;,I-GP
6,I-GP
in,O
these,O
organs,O
suggested,O
that,O
it,O
might,O
also,O
play,O
a,O
role,O
in,O
the,O
remobilization,O
of,O
nutrients,O
during,O
grain,O
development,O
.,O
Furthermore,O
",",O
in,O
situ,O
hybridization,O
showed,O
that,O
Pht1,B-GP
;,I-GP
6,I-GP
is,O
expressed,O
in,O
the,O
phloem,O
of,O
vascular,O
bundles,O
in,O
leaves,O
and,O
ears,O
.,O
Taken,O
together,O
",",O
HORvu,B-OG
;,O
Pht1,B-GP
;,I-GP
6,I-GP
probably,O
functions,O
in,O
the,O
remobilization,O
of,O
stored,O
Pi,O
from,O
leaves,O
[,O
20,O
].,O
In,O
rice,B-OG
",",O
expression,O
of,O
OsPht1,B-GP
;,I-GP
2,I-GP
(,O
OsPT2,B-GP
),O
is,O
increased,O
significantly,O
in,O
response,O
to,O
Pi,O
deficiency,O
in,O
root,O
and,O
shoot,O
.,O
By,O
using,O
transgenic,O
rice,B-OG
plants,B-OG
expressing,O
the,O
GUS,B-GP
reporter,O
gene,O
",",O
OsPT2,B-GP
was,O
localized,O
exclusively,O
in,O
the,O
stele,O
of,O
primary,O
and,O
lateral,O
roots,O
.,O
The,O
knock,O
-,O
down,O
of,O
OsPT2,B-GP
by,O
RNA,O
interference,O
significantly,O
decreased,O
long,O
-,O
distance,O
transport,O
of,O
Pi,O
from,O
root,O
to,O
shoot,O
.,O
These,O
data,O
suggested,O
OsPT2,B-GP
functions,O
in,O
translocation,O
of,O
the,O
stored,O
Pi,O
in,O
the,O
plant,B-OG
[,O
21,O
].,O
In,O
conclusion,O
",",O
low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
have,O
a,O
wide,O
range,O
of,O
roles,O
in,O
Pi,O
uptake,O
and,O
translocation,O
within,O
the,O
plant,B-OG
and,O
are,O
required,O
to,O
facilitate,O
the,O
movement,O
of,O
phosphate,O
between,O
subcellular,O
compartments,O
and,O
organelles,O
.,O
However,O
",",O
most,O
studies,O
of,O
Pi,B-GP
transporters,I-GP
in,O
plants,B-OG
have,O
focused,O
on,O
the,O
roots,O
.,O
Soybean,B-OG
(,O
Glycine,B-OG
max,I-OG
L,O
.,O
Merr,O
.),O
is,O
one,O
of,O
the,O
most,O
economically,O
important,O
leguminous,O
seed,O
crops,O
that,O
provide,O
the,O
majority,O
of,O
plant,B-OG
proteins,O
",",O
and,O
more,O
than,O
a,O
quarter,O
of,O
the,O
world,O
',O
s,O
food,O
and,O
animal,B-OG
feed,O
[,O
22,O
"],",O
[,O
23,O
].,O
To,O
our,O
knowledge,O
",",O
there,O
is,O
no,O
report,O
of,O
soybean,B-OG
Pi,B-GP
transporters,I-GP
in,O
the,O
literature,O
.,O
Here,O
",",O
we,O
report,O
the,O
characterization,O
of,O
two,O
Pi,B-GP
transporters,I-GP
from,O
soybean,B-OG
.,O
The,O
two,O
genes,O
are,O
designated,O
GmPT1,B-GP
and,O
GmPT2,B-GP
according,O
to,O
the,O
rules,O
recommended,O
by,O
the,O
Commission,O
on,O
Plant,B-OG
Gene,O
Nomenclature,O
.,O
The,O
sequences,O
of,O
the,O
two,O
genes,O
share,O
great,O
similarity,O
with,O
that,O
of,O
the,O
plant,B-OG
proton,B-GP
–,I-GP
Pi,I-GP
cotransporter,I-GP
.,O
The,O
primary,O
functions,O
of,O
these,O
genes,O
appear,O
to,O
be,O
as,O
low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
within,O
the,O
plant,B-OG
.,O
Results,O
Cloning,O
and,O
Computational,O
Sequence,O
Analysis,O
We,O
identified,O
two,O
single,O
copy,O
Pi,B-GP
transporter,I-GP
genes,O
in,O
soybean,B-OG
located,O
on,O
chromosomes,O
Gm10,O
(,O
41,O
",",O
391,O
",",O
168,O
–,O
41,O
",",O
393,O
",",O
008,O
),O
and,O
Gm20,O
(,O
42,O
",",O
980,O
",",O
124,O
–,O
42,O
",",O
981,O
",",O
928,O
).,O
These,O
genes,O
are,O
designated,O
GmPT1,B-GP
(,O
accession,O
number,O
HQ392508,O
),O
and,O
GmPT2,B-GP
(,O
accession,O
number,O
HQ392509,O
"),",O
respectively,O
.,O
GmPT1,B-GP
is,O
1841,O
-,O
bp,O
long,O
(,O
Figure,O
1A,O
),O
and,O
contains,O
an,O
open,O
reading,O
frame,O
encoding,O
a,O
536,O
amino,O
acid,O
polypeptide,O
(,O
molecular,O
mass,O
58730,O
.,O
46,O
Da,O
).,O
GmPT2,B-GP
is,O
1802,O
bp,O
long,O
(,O
Figure,O
1A,O
),O
and,O
contains,O
an,O
open,O
reading,O
frame,O
encoding,O
a,O
536,O
amino,O
acid,O
polypeptide,O
(,O
molecular,O
mass,O
58627,O
.,O
29,O
Da,O
).,O
Interestingly,O
",",O
the,O
open,O
reading,O
frame,O
in,O
both,O
genes,O
spans,O
base,O
pairs,O
23,O
–,O
1633,O
.,O
These,O
genes,O
are,O
88,O
.,O
7,O
%,O
similar,O
in,O
nucleotide,O
sequence,O
and,O
97,O
.,O
9,O
%,O
similar,O
in,O
amino,O
acid,O
sequence,O
.,O
The,O
two,O
polypeptides,O
share,O
the,O
greatest,O
degree,O
of,O
similarity,O
with,O
the,O
characterized,O
Pi,B-GP
transporters,I-GP
from,O
mouse,B-OG
-,I-OG
ear,I-OG
cress,I-OG
(,O
Arabidopsis,B-OG
thaliana,I-OG
),O
[,O
14,O
"],",O
[,O
25,O
"],",O
tomato,B-OG
(,O
Lycopersicon,B-OG
esculentum,I-OG
L,I-OG
.),O
[,O
15,O
"],",O
potato,B-OG
(,O
Solanum,B-OG
tuberosum,I-OG
L,I-OG
.),O
[,O
26,O
],O
and,O
barrel,B-OG
clover,I-OG
(,O
Medicago,B-OG
truncatula,I-OG
),O
[,O
27,O
].,O
The,O
two,O
Pi,B-GP
transporters,I-GP
from,O
soybean,B-OG
have,O
a,O
very,O
high,O
degree,O
of,O
identity,O
with,O
fungal,O
Pi,B-GP
transporters,I-GP
from,O
the,O
mycorrhizal,O
fungus,B-OG
Glomus,B-OG
versiforme,I-OG
(,O
GvPT,B-GP
),O
and,O
the,O
budding,O
yeast,B-OG
Saccharomyces,B-OG
cerevisiae,I-OG
(,O
PHO84,B-GP
).,O
GmPT1,B-GP
shows,O
76,O
%,O
and,O
61,O
%,O
and,O
GmPT2,B-GP
shows,O
76,O
%,O
and,O
63,O
%,O
amino,O
acid,O
sequence,O
identity,O
with,O
GvPT,B-GP
(,O
accession,O
number,O
Q00908,O
),O
and,O
PHO84,B-GP
(,O
accession,O
number,O
P25297,O
"),",O
respectively,O
.,O
DNA,O
gel,O
analysis,O
of,O
two,O
soybean,B-OG
Pi,B-GP
transporters,I-GP
.,O
DNA,O
gel,O
-,O
blot,O
analysis,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
(,O
A,O
).,O
Lanes,O
2,O
and,O
3,O
contain,O
GmPT1,B-GP
and,O
GmPT2,B-GP
",",O
respectively,O
.,O
The,O
size,O
markers,O
are,O
shown,O
to,O
the,O
right,O
and,O
left,O
of,O
the,O
figure,O
.,O
The,O
expression,O
profile,O
of,O
the,O
two,O
proteins,O
in,O
different,O
parts,O
of,O
the,O
soybean,B-OG
seedling,O
(,O
B,O
).,O
Seven,O
days,O
old,O
soybean,B-OG
seedlings,O
were,O
used,O
to,O
examine,O
the,O
expression,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
with,O
cons15,O
as,O
the,O
control,O
.,O
Structure,O
of,O
the,O
Soybean,B-OG
Pi,B-GP
Transporters,I-GP
Hydropathy,O
plots,O
of,O
the,O
deduced,O
polypeptides,O
suggest,O
that,O
GmPT1,B-GP
and,O
GmPT2,B-GP
consist,O
of,O
12,O
membrane,O
-,O
spanning,O
regions,O
(,O
Figure,O
2,O
"),",O
a,O
feature,O
shared,O
by,O
other,O
Pi,B-GP
transporters,I-GP
",",O
irrespective,O
of,O
the,O
level,O
of,O
affinity,O
[,O
14,O
"],",O
[,O
15,O
"],",O
[,O
19,O
"],",O
[,O
20,O
"],",O
[,O
25,O
"],",O
[,O
26,O
"],",O
[,O
27,O
"],",O
[,O
28,O
"],",O
[,O
29,O
"],",O
[,O
30,O
"],",O
[,O
31,O
"],",O
[,O
32,O
"],",O
[,O
33,O
"],",O
[,O
34,O
"],",O
[,O
35,O
].,O
Computational,O
modeling,O
of,O
the,O
encoded,O
proteins,O
predicted,O
a,O
conserved,O
secondary,O
structure,O
containing,O
12,O
transmembrane,O
(,O
TM,O
),O
domains,O
with,O
a,O
large,O
hydrophilic,O
loop,O
between,O
TM6,O
and,O
TM7,O
(,O
Figure,O
2A,O
),O
and,O
the,O
hydrophilic,O
N,O
and,O
C,O
termini,O
located,O
in,O
the,O
cytoplasm,O
(,O
Figure,O
2B,O
).,O
The,O
amino,O
acid,O
sequences,O
are,O
similar,O
to,O
those,O
of,O
the,O
other,O
members,O
of,O
the,O
Pht1,B-GP
family,O
of,O
Pi,B-GP
transporters,I-GP
(,O
Figure,O
3,O
).,O
Several,O
amino,O
acid,O
domains,O
are,O
highly,O
conserved,O
between,O
these,O
two,O
Pi,B-GP
transporters,I-GP
and,O
include,O
sites,O
for,O
protein,B-GP
kinase,I-GP
C,I-GP
and,O
casein,B-GP
kinase,I-GP
II,I-GP
-,O
facilitated,O
phosphorylation,O
",",O
as,O
well,O
as,O
N,O
-,O
glycosylation,O
(,O
Figure,O
2B,O
).,O
The,O
existence,O
of,O
a,O
number,O
of,O
conserved,O
putative,O
phosphorylation,O
sites,O
present,O
within,O
the,O
Pht1,B-GP
family,O
suggested,O
that,O
regulation,O
of,O
the,O
transporters,B-GP
might,O
occur,O
at,O
the,O
post,O
-,O
translational,O
level,O
as,O
well,O
[,O
6,O
"],",O
[,O
9,O
].,O
Predicted,O
topology,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
.,O
Hydrophobicity,O
profiles,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
(,O
A,O
).,O
Hydropathy,O
values,O
for,O
a,O
window,O
of,O
14,O
residues,O
were,O
calculated,O
by,O
DNAMAN,O
version,O
6,O
.,O
0,O
.,O
3,O
.,O
93,O
using,O
algorithms,O
presented,O
by,O
Kyte,O
and,O
Doolittle,O
[,O
62,O
].,O
Hydrophobic,O
regions,O
correspond,O
to,O
positive,O
index,O
numbers,O
.,O
The,O
arabic,O
numerals,O
refer,O
to,O
putative,O
membrane,O
-,O
spanning,O
domains,O
.,O
A,O
topological,O
model,O
for,O
GmPT1,B-GP
and,O
GmPT2,B-GP
(,O
B,O
).,O
The,O
membrane,O
-,O
spanning,O
domains,O
of,O
GmPT1and,O
GmPT2,B-GP
were,O
predicted,O
by,O
HMMTOP,O
[,O
52,O
],O
and,O
their,O
numbering,O
is,O
indicated,O
by,O
arabic,O
numerals,O
1,O
–,O
12,O
.,O
The,O
model,O
was,O
drawn,O
with,O
the,O
aid,O
of,O
TOPO2,O
software,O
(,O
http,O
://,O
www,O
.,O
sacs,O
.,O
ucsf,O
.,O
edu,O
/,O
TOPO2,O
/).,O
Enlarged,O
symbols,O
indicate,O
sites,O
of,O
significant,O
structure,O
–,O
function,O
importance,O
:,O
red,O
",",O
N,O
-,O
glycosylation,O
;,O
green,O
",",O
protein,B-GP
kinase,I-GP
C,I-GP
phosphorylation,O
;,O
blue,O
",",O
casein,B-GP
kinase,I-GP
II,I-GP
phosphorylation,O
;,O
cyan,O
",",O
tyrosine,B-GP
kinase,I-GP
phosphorylation,O
;,O
purple,O
",",O
Amidation,O
;,O
and,O
magenta,O
",",O
N,O
-,O
myristoylation,O
.,O
Phylogenetic,O
relationship,O
between,O
GmPT1,B-GP
",",O
GmPT2,B-GP
and,O
other,O
plant,B-OG
and,O
fungal,O
Pi,B-GP
transporters,I-GP
.,O
Proteins,O
(,O
and,O
accession,O
numbers,O
):,O
PHO84,B-GP
(,O
P25297,O
),O
from,O
Saccharomyces,B-OG
cerevisiae,I-OG
;,O
GvPT,B-GP
(,O
Q00908,O
),O
from,O
Glomus,B-OG
versiforme,I-OG
;,O
GiPT,B-GP
(,O
AAL37552,O
),O
from,O
Glomus,B-OG
intraradices,I-OG
;,O
Pht1,B-GP
;,I-GP
1,I-GP
(,O
Y07682,O
"),",O
Pht1,B-GP
;,I-GP
2,I-GP
(,O
Y07681,O
),O
Pht1,B-GP
;,I-GP
3,I-GP
(,O
O48639,O
),O
and,O
Pht2,B-GP
;,I-GP
1,I-GP
(,O
CAC15560,O
),O
from,O
Arabidopsis,B-OG
thaliana,I-OG
;,O
StPT1,B-GP
(,O
Q43650,O
),O
and,O
StPT2,B-GP
(,O
Q41479,O
),O
from,O
Solanum,B-OG
tuberosum,I-OG
;,O
MtPT1,B-GP
(,O
O22301,O
),O
and,O
MtPT2,B-GP
(,O
O22302,O
),O
from,O
Medicago,B-OG
truncatula,I-OG
;,O
LePT1,B-GP
(,O
O24029,O
),O
and,O
LePT2,B-GP
(,O
O22549,O
),O
from,O
Lycopersicon,B-OG
esculentum,I-OG
;,O
LaPT1,B-GP
(,O
AAK01938,O
),O
and,O
LaPT2,B-GP
(,O
AAK38197,O
),O
from,O
Lupinus,B-OG
albus,I-OG
;,O
NtPT1,B-GP
(,O
AAF74025,O
),O
from,O
Nicotiana,B-OG
tabacum,I-OG
;,O
OsPT1,B-GP
(,O
AAN39042,O
),O
and,O
OsPT2,B-GP
(,O
AAN39043,O
),O
from,O
Oryza,B-OG
sativa,I-OG
;,O
and,O
GmPT1,B-GP
(,O
HQ392508,O
),O
and,O
GmPT2,B-GP
(,O
HQ392509,O
),O
from,O
Glycine,B-OG
max,I-OG
.,O
Subcellular,O
localization,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
The,O
TBpred,O
Prediction,O
Server,O
[,O
36,O
],O
(,O
http,O
://,O
www,O
.,O
imtech,O
.,O
res,O
.,O
in,O
/,O
raghava,O
/,O
tbpred,O
/),O
was,O
used,O
for,O
searches,O
that,O
yielded,O
unambiguous,O
results,O
with,O
positive,O
scores,O
for,O
the,O
integral,B-GP
membrane,I-GP
protein,I-GP
(,O
data,O
not,O
shown,O
).,O
To,O
verify,O
the,O
subcellular,O
locations,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
",",O
a,O
green,B-GP
fluorescent,I-GP
protein,I-GP
(,O
GFP,B-GP
)-,O
tagged,O
gene,O
was,O
fused,O
to,O
the,O
3,O
′,O
end,O
of,O
the,O
open,O
reading,O
frame,O
of,O
the,O
GmPT1,B-GP
or,O
GmPT2,B-GP
genes,O
.,O
The,O
chimeric,O
genes,O
were,O
placed,O
under,O
the,O
control,O
of,O
the,O
CaMV35S,O
promoter,O
and,O
the,O
constructs,O
were,O
transformed,O
into,O
onion,O
epidermal,O
cell,O
by,O
particle,O
bombarded,O
.,O
As,O
a,O
control,O
",",O
a,O
second,O
set,O
of,O
cells,O
was,O
bombarded,O
with,O
the,O
empty,O
vector,O
pBI,O
-,O
121,O
-,O
GFP,B-GP
.,O
The,O
cells,O
were,O
then,O
examined,O
by,O
confocal,O
laser,O
scanning,O
microscopy,O
to,O
determine,O
the,O
location,O
of,O
the,O
GmPT1,B-GP
/,O
GFP,B-GP
and,O
GmPT2,B-GP
/,O
GFP,B-GP
fusion,O
proteins,O
.,O
A,O
clear,O
GFP,B-GP
signal,O
was,O
observed,O
at,O
the,O
periphery,O
of,O
cells,O
bombarded,O
with,O
the,O
GmPT1,B-GP
/,O
GFP,B-GP
or,O
GmPT2,B-GP
/,O
GFP,B-GP
construction,O
(,O
Figure,O
4A,O
–,O
C,O
and,O
G,O
–,O
I,O
for,O
GmPT1,B-GP
and,O
GmPT2,B-GP
",",O
respectively,O
"),",O
whereas,O
the,O
signal,O
was,O
seen,O
throughout,O
cells,O
expressing,O
free,O
GFP,B-GP
(,O
Figure,O
4D,O
–,O
F,O
).,O
Localization,O
of,O
the,O
GmPT1,B-GP
/,O
GFP,B-GP
and,O
GmPT2,B-GP
/,O
GFP,B-GP
fusion,O
proteins,O
to,O
the,O
periphery,O
of,O
the,O
cells,O
indicated,O
that,O
the,O
two,O
proteins,O
are,O
targeted,O
to,O
the,O
plasma,O
membrane,O
.,O
This,O
is,O
consistent,O
with,O
the,O
results,O
of,O
earlier,O
biochemical,O
studies,O
and,O
together,O
these,O
data,O
suggest,O
that,O
the,O
GmPT1,B-GP
and,O
GmPT2,B-GP
proteins,O
are,O
located,O
in,O
the,O
plasma,O
membrane,O
.,O
Subcellular,O
localization,O
of,O
GmPT1,B-GP
/,O
GFP,B-GP
and,O
GmPT2,B-GP
/,O
GFP,B-GP
fusion,O
.,O
Images,O
showing,O
onion,O
epidermal,O
cells,O
expressing,O
GmPT1,B-GP
/,O
GFP,B-GP
(,O
A,O
–,O
C,O
"),",O
empty,O
vector,O
(,O
D,O
–,O
F,O
),O
and,O
GmPT2,B-GP
/,O
GFP,B-GP
(,O
G,O
–,O
I,O
),O
fusion,O
protein,O
examined,O
under,O
fluorescent,O
-,O
field,O
illumination,O
(,O
A,O
",",O
D,O
and,O
G,O
),O
to,O
examine,O
GFP,B-GP
fluorescence,O
;,O
under,O
bright,O
-,O
field,O
illumination,O
(,O
B,O
",",O
E,O
and,O
H,O
),O
and,O
by,O
confocal,O
microscopy,O
for,O
the,O
overlay,O
of,O
bright,O
and,O
fluorescent,O
illumination,O
(,O
C,O
",",O
F,O
and,O
I,O
).,O
The,O
scale,O
bars,O
represent,O
100,O
µM,O
.,O
Functional,O
and,O
Biochemical,O
Analysis,O
in,O
Yeast,B-OG
We,O
used,O
uptake,O
studies,O
with,O
inhibitors,O
to,O
confirm,O
the,O
pH,O
dependence,O
of,O
Pi,O
transport,O
(,O
Table,O
1,O
).,O
Pi,O
transport,O
activity,O
was,O
assessed,O
at,O
pH,O
values,O
in,O
the,O
range,O
4,O
–,O
7,O
.,O
Differences,O
were,O
detected,O
in,O
the,O
activity,O
profiles,O
but,O
the,O
uptake,O
rate,O
was,O
maximal,O
at,O
pH,O
4,O
and,O
increased,O
as,O
the,O
pH,O
was,O
reduced,O
from,O
7,O
to,O
4,O
in,O
each,O
case,O
(,O
Figure,O
5,O
).,O
To,O
investigate,O
this,O
influence,O
of,O
a,O
proton,O
motive,O
force,O
on,O
Pi,O
transport,O
activity,O
",",O
the,O
uncouplers,O
2,O
",",O
4,O
-,O
dinitrophenol,O
(,O
2,O
",",O
4,O
-,O
DNP,O
),O
and,O
carbonyl,O
cyanide,O
m,O
-,O
chlorophenylhydrazone,O
(,O
CCCP,O
"),",O
which,O
destroy,O
pH,O
gradients,O
across,O
membranes,O
",",O
were,O
applied,O
.,O
DNP,O
at,O
a,O
concentration,O
of,O
100,O
µM,O
reduced,O
the,O
Pi,O
uptake,O
rate,O
to,O
79,O
%,O
(,O
GmPT1,B-GP
),O
and,O
82,O
%,O
(,O
GmPT2,B-GP
),O
compared,O
with,O
100,O
%,O
uptake,O
in,O
the,O
inhibitor,O
-,O
free,O
control,O
.,O
The,O
rate,O
of,O
uptake,O
was,O
reduced,O
to,O
77,O
%,O
(,O
GmPT1,B-GP
),O
and,O
80,O
%,O
(,O
GmPT2,B-GP
),O
by,O
100,O
µM,O
CCCP,O
and,O
",",O
to,O
82,O
%,O
(,O
GmPT1,B-GP
),O
and,O
83,O
%,O
(,O
GmPT2,B-GP
),O
by,O
100,O
µM,O
Vanadate,O
",",O
an,O
inhibitor,O
of,O
P,B-GP
-,I-GP
type,I-GP
H,I-GP
+-,I-GP
ATPases,I-GP
.,O
The,O
transporter,B-GP
rate,O
was,O
decreased,O
significantly,O
compared,O
to,O
that,O
in,O
the,O
control,O
(,O
Table,O
1,O
).,O
These,O
results,O
confirmed,O
the,O
hypothesis,O
that,O
Pi,O
/,O
H,O
+,O
cotransport,O
via,O
GmPT1,B-GP
and,O
GmPT2,B-GP
depends,O
on,O
the,O
pH,O
gradient,O
across,O
the,O
cell,O
membrane,O
that,O
is,O
maintained,O
by,O
the,O
endogenous,O
plasma,O
membrane,O
H,B-GP
+-,I-GP
ATPases,I-GP
.,O
Moreover,O
",",O
competition,O
studies,O
showed,O
that,O
different,O
anions,O
did,O
not,O
reduce,O
the,O
Pi,O
uptake,O
rate,O
",",O
demonstrating,O
the,O
high,O
degree,O
of,O
specificity,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
for,O
Pi,O
.,O
Strains,O
carrying,O
the,O
GmPT1,B-GP
or,O
GmPT2,B-GP
cDNA,O
generally,O
uptake,O
Pi,O
at,O
rates,O
similar,O
to,O
those,O
of,O
the,O
vector,O
controls,O
at,O
millimolar,O
concentrations,O
of,O
Pi,O
(,O
Figure,O
5,O
).,O
Inorganic,O
phosphate,O
(,O
Pi,O
),O
uptake,O
as,O
a,O
function,O
of,O
external,O
pH,O
.,O
Pi,O
uptake,O
rates,O
for,O
yeast,B-OG
MB192,O
cells,O
expressing,O
the,O
indicated,O
GmPT1,B-GP
",",O
GmPT2,B-GP
or,O
carrying,O
the,O
control,O
vector,O
and,O
wild,O
type,O
yeast,B-OG
cell,O
were,O
determined,O
in,O
medium,O
at,O
the,O
indicated,O
pH,O
value,O
.,O
Values,O
shown,O
are,O
the,O
mean,O
±,O
SE,O
for,O
three,O
independent,O
experiments,O
.,O
Pharmacology,O
and,O
specificity,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
.,O
Inhibitor,O
32P,O
uptake,O
(%,O
of,O
the,O
control,O
),O
GmPT1Mean,O
±,O
SE,O
GmPT2Mean,O
±,O
SE,O
CCCP,O
(,O
10,O
µM,O
),O
93,O
±,O
0,O
.,O
04,O
96,O
±,O
0,O
.,O
06,O
CCCP,O
(,O
100,O
µM,O
),O
77,O
±,O
0,O
.,O
02,O
80,O
±,O
0,O
.,O
05,O
DNP,O
(,O
10,O
µM,O
),O
92,O
±,O
0,O
.,O
02,O
94,O
±,O
0,O
.,O
07,O
DNP,O
(,O
100,O
µM,O
),O
79,O
±,O
0,O
.,O
05,O
82,O
±,O
0,O
.,O
01,O
Vanadate,O
(,O
10,O
µM,O
),O
92,O
±,O
0,O
.,O
02,O
96,O
±,O
0,O
.,O
05,O
Vanadate,O
(,O
100,O
µM,O
),O
82,O
±,O
0,O
.,O
03,O
83,O
±,O
0,O
.,O
04,O
NH4Cl,O
(,O
5,O
mM,O
),O
78,O
±,O
0,O
.,O
08,O
76,O
±,O
0,O
.,O
05,O
KCl,O
(,O
5,O
mM,O
),O
75,O
±,O
0,O
.,O
03,O
72,O
±,O
0,O
.,O
07,O
NaAc,O
(,O
5,O
mM,O
),O
77,O
±,O
0,O
.,O
08,O
78,O
±,O
0,O
.,O
04,O
CCCP,O
",",O
carbonyl,O
cyanide,O
m,O
-,O
chlorophenylhydrazone,O
.,O
DNP,O
",",O
2,O
",",O
4,O
-,O
dinitrophenol,O
.,O
Inhibitors,O
were,O
added,O
to,O
yeast,B-OG
cells,O
30,O
s,O
before,O
addition,O
of,O
labeled,O
Pi,O
.,O
All,O
assays,O
were,O
done,O
at,O
pH,O
4,O
.,O
Values,O
for,O
each,O
treatment,O
were,O
derived,O
from,O
three,O
independent,O
measurements,O
.,O
Water,O
was,O
used,O
as,O
the,O
control,O
treatment,O
.,O
It,O
was,O
the,O
pioneering,O
work,O
of,O
Emmanuel,O
Epstein,O
that,O
demonstrated,O
ion,O
uptake,O
processes,O
across,O
the,O
plasma,O
membrane,O
follow,O
Michaelis,O
–,O
Menten,O
kinetics,O
[,O
37,O
"],",O
[,O
38,O
].,O
In,O
uptake,O
experiments,O
with,O
radioactive,O
Pi,O
",",O
the,O
rate,O
of,O
transport,O
was,O
linear,O
with,O
time,O
during,O
the,O
first,O
5,O
min,O
of,O
uptake,O
under,O
the,O
conditions,O
applied,O
[,O
30,O
"],",O
[,O
31,O
].,O
In,O
three,O
parallel,O
experiments,O
",",O
the,O
Lineweaver,O
–,O
Burk,O
diagram,O
",",O
calculated,O
using,O
reciprocal,O
uptake,O
velocities,O
at,O
5,O
min,O
after,O
addition,O
of,O
32Pi,O
",",O
indicated,O
that,O
Pi,O
uptake,O
facilitated,O
by,O
GmPT1and,O
GmPT2,B-GP
followed,O
Michaelis,O
–,O
Menten,O
kinetics,O
with,O
an,O
apparent,O
K,O
m,O
value,O
of,O
6,O
.,O
65,O
mM,O
and,O
6,O
.,O
63,O
mM,O
",",O
respectively,O
",",O
(,O
Figure,O
6A,O
and,O
B,O
).,O
Thus,O
",",O
GmPT1,B-GP
and,O
GmPT2,B-GP
are,O
low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
that,O
are,O
dependent,O
on,O
the,O
proton,O
gradient,O
across,O
the,O
plasma,O
membrane,O
.,O
Lineweaver,O
–,O
Burk,O
plots,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
.,O
Lineweaver,O
–,O
Burk,O
plot,O
of,O
Pi,O
uptake,O
of,O
strains,O
MB192,O
-,O
GmPT1,B-GP
and,O
MB192,O
-,O
GmPT2,B-GP
versus,O
external,O
Pi,O
concentrations,O
that,O
were,O
used,O
to,O
estimate,O
K,O
m,O
.,O
Expression,O
pattern,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
Root,O
",",O
stem,O
and,O
leaf,O
tissues,O
of,O
7,O
-,O
day,O
-,O
old,O
soybean,B-OG
seedlings,O
were,O
used,O
to,O
examine,O
the,O
expression,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
(,O
Figure,O
1B,O
).,O
Expression,O
of,O
the,O
two,O
Pi,B-GP
transporters,I-GP
was,O
enhanced,O
in,O
both,O
root,O
and,O
shoot,O
during,O
the,O
first,O
48,O
h,O
of,O
Pi,O
starvation,O
.,O
The,O
expression,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
in,O
seedling,O
tissues,O
was,O
increased,O
during,O
the,O
3,O
h,O
after,O
the,O
Pi,O
-,O
sufficient,O
treated,O
seedlings,O
were,O
transferred,O
to,O
a,O
Pi,O
-,O
deficient,O
solution,O
at,O
48,O
h,O
compared,O
to,O
the,O
expression,O
measured,O
in,O
Pi,O
-,O
sufficient,O
plants,B-OG
(,O
Figure,O
7A,O
",",O
C,O
and,O
E,O
for,O
GmPT1,B-GP
and,O
G,O
",",O
I,O
and,O
K,O
for,O
GmPT2,B-GP
).,O
The,O
transcript,O
levels,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
were,O
little,O
changed,O
in,O
plants,B-OG
that,O
were,O
grown,O
in,O
half,O
-,O
strength,O
nutrient,O
solution,O
for,O
7,O
days,O
and,O
then,O
transferred,O
to,O
a,O
Pi,O
-,O
sufficient,O
solution,O
.,O
A,O
decrease,O
in,O
the,O
transcript,O
abundance,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
in,O
the,O
leaf,O
",",O
stem,O
and,O
root,O
of,O
hydroponically,O
grown,O
soybean,B-OG
seedlings,O
was,O
apparent,O
within,O
3,O
h,O
of,O
Pi,O
deprivation,O
(,O
Figure,O
7,O
B,O
",",O
D,O
and,O
F,O
for,O
GmPT1,B-GP
and,O
H,O
",",O
J,O
and,O
L,O
for,O
GmPT2,B-GP
).,O
In,O
conclusion,O
",",O
the,O
expression,O
level,O
of,O
the,O
two,O
genes,O
was,O
not,O
altered,O
markedly,O
and,O
the,O
change,O
tendencies,O
were,O
complicated,O
irrespective,O
of,O
how,O
the,O
seedlings,O
were,O
treated,O
.,O
Therefore,O
",",O
the,O
GmPT1,B-GP
and,O
GmPT2,B-GP
soybean,B-OG
Pi,B-GP
transporters,I-GP
were,O
constitutively,O
expressed,O
.,O
Expression,O
levels,O
of,O
GmPT1,B-GP
(,O
A,O
–,O
F,O
),O
and,O
GmPT2,B-GP
(,O
G,O
–,O
L,O
),O
during,O
Pi,O
treatment,O
.,O
The,O
7,O
-,O
day,O
-,O
old,O
seedlings,O
were,O
grown,O
by,O
hydroponic,O
culture,O
with,O
0,O
.,O
5,O
×,O
Hoagland,O
solution,O
containing,O
5,O
µM,O
Pi,O
(,O
A,O
",",O
C,O
",",O
E,O
",",O
G,O
",",O
I,O
and,O
K,O
),O
or,O
1,O
mM,O
Pi,O
(,O
B,O
",",O
D,O
",",O
F,O
",",O
H,O
",",O
J,O
and,O
L,O
).,O
Seedling,O
tissues,O
were,O
harvested,O
at,O
0,O
",",O
1,O
.,O
0,O
",",O
3,O
.,O
0,O
",",O
12,O
.,O
0,O
",",O
24,O
.,O
0,O
and,O
48,O
.,O
0,O
h,O
after,O
treatment,O
(,O
on,O
the,O
dash,O
-,O
dot,O
line,O
at,O
the,O
left,O
).,O
After,O
treatment,O
for,O
48,O
h,O
",",O
the,O
deficient,O
/,O
sufficient,O
Pi,O
-,O
treated,O
seedlings,O
were,O
transferred,O
to,O
sufficient,O
/,O
deficient,O
Pi,O
in,O
Hoagland,O
solution,O
",",O
respectively,O
.,O
Seedling,O
tissues,O
were,O
sampled,O
at,O
0,O
",",O
1,O
.,O
0,O
and,O
3,O
.,O
0,O
h,O
after,O
changing,O
the,O
nutrient,O
solution,O
(,O
on,O
the,O
dash,O
-,O
dot,O
line,O
at,O
the,O
right,O
).,O
Leaf,O
",",O
A,O
and,O
B,O
",",O
G,O
and,O
H,O
;,O
stem,O
",",O
C,O
and,O
D,O
",",O
I,O
and,O
J,O
;,O
and,O
root,O
",",O
E,O
and,O
F,O
",",O
K,O
and,O
L,O
.,O
Discussion,O
GmPT1,B-GP
and,O
GmPT2,B-GP
are,O
members,O
of,O
the,O
Pht1,B-GP
family,O
Our,O
studies,O
provide,O
the,O
first,O
insights,O
into,O
the,O
molecular,O
nature,O
of,O
the,O
proteins,O
involved,O
in,O
phosphate,O
transport,O
in,O
the,O
soybean,B-OG
and,O
reveal,O
that,O
soybean,B-OG
has,O
phosphate,B-GP
transporters,I-GP
with,O
sequence,O
similarity,O
to,O
proton,B-GP
-,I-GP
coupled,I-GP
symporters,I-GP
from,O
a,O
large,O
number,O
of,O
plants,B-OG
and,O
fungi,B-OG
.,O
These,O
transporters,B-GP
belong,O
to,O
the,O
phosphate,B-GP
:,I-GP
H,I-GP
+,I-GP
symporter,I-GP
(,O
PHS,B-GP
),O
transporter,B-GP
family,O
of,O
the,O
major,O
facilitator,O
superfamily,O
[,O
39,O
].,O
Phylogenetically,O
",",O
the,O
Pi,B-GP
transporters,I-GP
in,O
plants,B-OG
and,O
fungi,B-OG
belong,O
to,O
a,O
closely,O
related,O
family,O
",",O
even,O
though,O
the,O
similarity,O
between,O
the,O
plant,B-OG
transporters,B-GP
is,O
significantly,O
higher,O
than,O
that,O
between,O
plants,B-OG
and,O
fungi,B-OG
transporters,B-GP
[,O
14,O
].,O
These,O
genes,O
have,O
been,O
grouped,O
into,O
the,O
Pht1,B-GP
family,O
of,O
proton,B-GP
–,I-GP
Pi,I-GP
cotransporters,I-GP
[,O
40,O
"],",O
which,O
are,O
energized,O
by,O
the,O
plasma,O
membrane,O
proton,B-GP
ATPase,I-GP
[,O
4,O
].,O
In,O
addition,O
",",O
at,O
least,O
one,O
phosphorylation,O
site,O
and,O
one,O
N,O
-,O
glycosylation,O
site,O
among,O
the,O
potential,O
protein,O
modification,O
sites,O
are,O
completely,O
conserved,O
in,O
all,O
plant,B-OG
transporters,B-GP
[,O
14,O
"],",O
[,O
15,O
"],",O
[,O
26,O
"],",O
[,O
33,O
].,O
GmPT1,B-GP
and,O
GmPT2,B-GP
are,O
low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
The,O
results,O
of,O
uptake,O
and,O
kinetic,O
studies,O
led,O
us,O
to,O
conclude,O
that,O
both,O
GmPT1,B-GP
and,O
GmPT2,B-GP
probably,O
have,O
a,O
low,O
affinity,O
for,O
Pi,O
at,O
millimolar,O
concentrations,O
",",O
similar,O
to,O
the,O
endogenous,O
yeast,B-OG
low,O
-,O
affinity,O
Pi,O
uptake,O
system,O
.,O
It,O
has,O
been,O
reported,O
that,O
Δpho87Δpho89Δpho90Δpho91,O
cells,O
in,O
a,O
wild,O
type,O
strain,O
do,O
not,O
show,O
any,O
significant,O
defect,O
in,O
Pi,O
uptake,O
under,O
high,O
-,O
Pi,O
conditions,O
;,O
meanwhile,O
",",O
the,O
loss,O
of,O
at,O
least,O
one,O
low,O
-,O
affinity,O
Pi,B-GP
transporter,I-GP
could,O
result,O
in,O
an,O
insufficient,O
Pi,O
uptake,O
similar,O
to,O
the,O
case,O
of,O
PHO84,B-GP
inactivation,O
under,O
Pi,O
-,O
limiting,O
conditions,O
[,O
41,O
].,O
These,O
results,O
revealed,O
that,O
the,O
inactivation,O
of,O
low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
does,O
not,O
result,O
in,O
a,O
substantial,O
defect,O
in,O
Pi,O
uptake,O
",",O
even,O
though,O
these,O
proteins,O
have,O
been,O
shown,O
to,O
play,O
a,O
role,O
in,O
Pi,O
uptake,O
.,O
The,O
high,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
are,O
inducible,O
in,O
plants,B-OG
and,O
fungi,B-OG
",",O
whereas,O
the,O
low,O
-,O
affinity,O
transporters,B-GP
are,O
expressed,O
constitutively,O
.,O
The,O
Pht2,B-GP
family,O
in,O
Arabidopsis,B-OG
is,O
considered,O
to,O
be,O
composed,O
of,O
low,O
-,O
affinity,O
proton,B-GP
/,I-GP
Pi,I-GP
symporters,I-GP
",",O
the,O
expression,O
of,O
which,O
is,O
high,O
in,O
shoots,O
and,O
is,O
not,O
altered,O
substantially,O
during,O
Pi,O
starvation,O
.,O
The,O
apparent,O
low,O
-,O
affinity,O
proton,B-GP
/,I-GP
Pi,I-GP
symporters,I-GP
that,O
are,O
highly,O
expressed,O
around,O
vascular,O
bundles,O
suggests,O
that,O
those,O
symporters,B-GP
play,O
a,O
role,O
in,O
loading,O
shoot,O
organs,O
with,O
Pi,O
[,O
40,O
].,O
The,O
profile,O
of,O
a,O
Pi,B-GP
transporter,I-GP
The,O
uptake,O
and,O
distribution,O
of,O
Pi,O
in,O
plants,B-OG
requires,O
multiple,O
Pi,O
transport,O
systems,O
that,O
must,O
function,O
in,O
concert,O
to,O
maintain,O
homeostasis,O
throughout,O
growth,O
and,O
development,O
.,O
Phosphate,O
uptake,O
in,O
plants,B-OG
is,O
an,O
energy,O
-,O
mediated,O
co,O
-,O
transport,O
process,O
driven,O
by,O
a,O
proton,O
gradient,O
generated,O
by,O
plasma,O
membrane,O
H,B-GP
+-,I-GP
ATPases,I-GP
[,O
6,O
"],",O
[,O
42,O
"],",O
[,O
43,O
"],",O
[,O
44,O
].,O
At,O
millimolar,O
concentrations,O
of,O
intracellular,O
Pi,O
",",O
Pi,O
uptake,O
is,O
accomplished,O
by,O
transport,O
of,O
the,O
anion,O
across,O
the,O
membrane,O
coupled,O
to,O
the,O
transport,O
of,O
protons,O
(,O
H,O
+-,O
symport,O
).,O
Therefore,O
",",O
the,O
driving,O
force,O
for,O
Pi,O
influx,O
is,O
the,O
proton,O
gradient,O
generated,O
by,O
the,O
H,B-GP
+-,I-GP
ATPases,I-GP
(,O
Figure,O
8,O
).,O
It,O
has,O
been,O
assumed,O
that,O
plant,B-OG
Pi,B-GP
transporters,I-GP
are,O
proton,B-GP
/,I-GP
Pi,I-GP
co,I-GP
-,I-GP
transporters,I-GP
with,O
a,O
stoichiometry,O
of,O
2,O
–,O
4,O
H,O
+/,O
Pi,O
[,O
2,O
].,O
By,O
complementation,O
of,O
a,O
knock,O
-,O
out,O
of,O
endogenous,O
high,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
of,O
various,O
yeast,B-OG
mutants,O
",",O
or,O
by,O
measuring,O
the,O
increase,O
of,O
Pi,O
uptake,O
in,O
transformed,O
plant,B-OG
cells,O
",",O
several,O
Pi,B-GP
transporters,I-GP
of,O
many,O
plant,B-OG
species,O
have,O
shown,O
common,O
properties,O
",",O
indicating,O
that,O
there,O
is,O
an,O
electrochemical,O
proton,O
gradient,O
across,O
the,O
plasma,O
membrane,O
[,O
6,O
"],",O
[,O
20,O
"],",O
[,O
26,O
"],",O
[,O
27,O
"],",O
[,O
30,O
"],",O
[,O
31,O
"],",O
[,O
45,O
].,O
The,O
Pi,B-GP
transporter,I-GP
mechanism,O
in,O
the,O
plant,B-OG
cell,O
.,O
A,O
membrane,O
-,O
integral,O
proton,B-GP
ATPase,I-GP
undirectionally,O
extrudes,O
protons,O
(,O
H,O
+),O
at,O
the,O
expense,O
of,O
ATP,O
.,O
The,O
proton,O
concentration,O
gradient,O
and,O
membrane,O
potential,O
generated,O
constitute,O
a,O
proton,O
electrochemical,O
potential,O
(,O
ΔμH,O
),O
across,O
the,O
membrane,O
.,O
Proton,O
movement,O
along,O
the,O
concentration,O
and,O
electrical,O
gradients,O
facilitates,O
Pi,O
movement,O
by,O
Pi,B-GP
transporters,I-GP
against,O
a,O
steep,O
concentration,O
gradient,O
.,O
Meanwhile,O
",",O
the,O
efflux,O
mechanism,O
helps,O
to,O
maintain,O
Pi,O
homeostasis,O
in,O
the,O
cells,O
.,O
The,O
transport,O
of,O
Pi,O
across,O
plant,B-OG
membranes,O
driven,O
by,O
the,O
proton,B-GP
/,I-GP
Pi,I-GP
co,I-GP
-,I-GP
transporter,I-GP
mechanism,O
is,O
pH,O
dependent,O
.,O
The,O
observed,O
increase,O
of,O
Pi,O
uptake,O
rates,O
in,O
response,O
to,O
decreasing,O
pH,O
is,O
consistent,O
with,O
the,O
operation,O
of,O
a,O
proton,B-GP
/,I-GP
Pi,I-GP
symporter,I-GP
.,O
Our,O
experiments,O
show,O
that,O
the,O
peak,O
of,O
Pi,O
uptake,O
is,O
at,O
pH,O
4,O
.,O
0,O
(,O
Figure,O
5,O
"),",O
which,O
reflects,O
the,O
fact,O
that,O
the,O
transport,O
mechanism,O
is,O
a,O
proton,O
/,O
Pi,O
symport,O
.,O
The,O
reduced,O
uptake,O
rate,O
(,O
Table,O
1,O
),O
in,O
the,O
presence,O
of,O
uncouplers,O
of,O
pH,O
gradients,O
across,O
membranes,O
",",O
such,O
as,O
DNP,O
and,O
CCCP,O
",",O
favors,O
the,O
latter,O
interpretation,O
.,O
This,O
view,O
is,O
supported,O
by,O
the,O
finding,O
that,O
addition,O
of,O
glucose,O
before,O
the,O
uptake,O
experiment,O
with,O
radioactive,O
Pi,O
enhances,O
the,O
uptake,O
capacity,O
of,O
transformants,O
.,O
This,O
effect,O
could,O
be,O
caused,O
by,O
an,O
enhanced,O
proton,O
extrusion,O
that,O
might,O
result,O
from,O
preincubation,O
with,O
glucose,O
.,O
We,O
have,O
demonstrated,O
the,O
Pi,O
transport,O
activity,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
",",O
which,O
are,O
low,O
-,O
affinity,O
transporters,B-GP
in,O
soybean,B-OG
",",O
are,O
dependent,O
on,O
the,O
electrochemical,O
gradient,O
of,O
protons,O
as,O
indicated,O
by,O
the,O
pH,O
dependence,O
and,O
the,O
pharmacological,O
assay,O
.,O
Transiently,O
expressed,O
GFP,B-GP
protein,O
fusions,O
provide,O
direct,O
evidence,O
that,O
the,O
two,O
Pi,B-GP
transporters,I-GP
are,O
located,O
in,O
the,O
plasma,O
membrane,O
(,O
Figure,O
4,O
).,O
The,O
results,O
suggested,O
also,O
that,O
the,O
encoded,O
proteins,O
function,O
in,O
the,O
plasma,O
membrane,O
.,O
Low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
play,O
important,O
roles,O
in,O
Pi,O
homeostasis,O
within,O
plants,B-OG
The,O
transport,O
of,O
Pi,O
across,O
membranes,O
is,O
a,O
pivotal,O
step,O
in,O
the,O
regulation,O
of,O
Pi,O
use,O
.,O
Plants,B-OG
require,O
multiple,O
Pi,O
transport,O
systems,O
to,O
facilitate,O
acquisition,O
of,O
Pi,O
from,O
diverse,O
environments,O
and,O
to,O
enable,O
its,O
subsequent,O
transport,O
to,O
all,O
of,O
the,O
cells,O
and,O
subcellular,O
compartments,O
of,O
the,O
plant,B-OG
[,O
8,O
].,O
The,O
low,O
concentration,O
of,O
Pi,O
commonly,O
found,O
in,O
the,O
soil,O
solution,O
[,O
8,O
],O
has,O
led,O
to,O
the,O
hypothesis,O
that,O
only,O
high,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
can,O
function,O
for,O
the,O
uptake,O
of,O
Pi,O
across,O
the,O
plasma,O
membrane,O
of,O
root,O
epidermal,O
cells,O
",",O
whereas,O
the,O
low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
could,O
be,O
responsible,O
for,O
transport,O
of,O
Pi,O
within,O
the,O
plant,B-OG
[,O
20,O
].,O
Initially,O
",",O
Pi,O
is,O
transported,O
into,O
root,O
epidermal,O
cells,O
and,O
subsequently,O
loaded,O
into,O
the,O
xylem,O
for,O
translocation,O
to,O
the,O
aerial,O
portions,O
of,O
the,O
plant,B-OG
.,O
Under,O
conditions,O
of,O
Pi,O
deficiency,O
",",O
Pi,O
can,O
be,O
retranslocated,O
from,O
shoot,O
tissues,O
to,O
the,O
roots,O
via,O
the,O
phloem,O
[,O
2,O
"],",O
[,O
4,O
"],",O
[,O
11,O
].,O
Two,O
A,B-OG
.,I-OG
thaliana,I-OG
mutants,O
exhibiting,O
altered,O
phosphate,O
accumulation,O
have,O
been,O
described,O
",",O
among,O
which,O
the,O
pho1,B-GP
mutant,O
is,O
deficient,O
in,O
the,O
translocation,O
of,O
Pi,O
from,O
the,O
roots,O
to,O
the,O
shoots,O
[,O
46,O
"],",O
whereas,O
a,O
mutation,O
at,O
the,O
pho2,B-GP
locus,O
resulted,O
in,O
excessive,O
accumulation,O
of,O
Pi,O
in,O
the,O
leaves,O
[,O
47,O
"],",O
[,O
48,O
].,O
OsPT2,B-GP
is,O
a,O
low,O
-,O
affinity,O
Pi,B-GP
transporter,I-GP
that,O
is,O
expressed,O
in,O
the,O
root,O
stele,O
and,O
leaf,O
phloem,O
and,O
xylem,O
.,O
On,O
the,O
basis,O
of,O
its,O
tissue,O
-,O
specific,O
expression,O
pattern,O
",",O
OsPT2,B-GP
is,O
assumed,O
to,O
function,O
in,O
translocation,O
of,O
stored,O
Pi,O
in,O
rice,B-OG
[,O
21,O
].,O
Over,O
-,O
expression,O
of,O
OsPT2,B-GP
(,O
PT2,B-GP
(,O
O,O
)),O
in,O
transgenic,O
plants,B-OG
resulted,O
in,O
accumulation,O
of,O
excess,O
shoot,O
Pi,O
and,O
growth,O
retardation,O
similar,O
to,O
that,O
of,O
rice,B-OG
pho2,B-GP
mutants,O
under,O
Pi,O
-,O
sufficient,O
conditions,O
.,O
There,O
is,O
no,O
significant,O
difference,O
in,O
the,O
concentration,O
of,O
Pi,O
in,O
either,O
shoot,O
or,O
root,O
between,O
wild,O
type,O
and,O
PT2,B-GP
(,O
O,O
),O
under,O
Pi,O
-,O
deficient,O
conditions,O
.,O
These,O
results,O
suggest,O
that,O
over,O
-,O
expression,O
of,O
OsPT2,B-GP
increases,O
Pi,O
uptake,O
and,O
translocation,O
of,O
Pi,O
from,O
root,O
to,O
shoot,O
",",O
resulting,O
in,O
the,O
accumulation,O
of,O
excess,O
Pi,O
in,O
shoots,O
under,O
abundant,O
Pi,O
conditions,O
[,O
49,O
].,O
Knock,O
-,O
down,O
of,O
OsPT2,B-GP
transgenic,O
line,O
r2,O
-,O
1,O
have,O
shown,O
that,O
the,O
concentration,O
of,O
Pi,O
in,O
the,O
shoot,O
is,O
much,O
lower,O
than,O
that,O
of,O
the,O
wild,O
type,O
[,O
21,O
];,O
therefore,O
",",O
OsPT2,B-GP
is,O
responsible,O
for,O
translocation,O
of,O
the,O
stored,O
Pi,O
in,O
the,O
plant,B-OG
.,O
When,O
the,O
supply,O
of,O
Pi,O
is,O
limited,O
",",O
plants,B-OG
grow,O
more,O
roots,O
",",O
increase,O
the,O
rate,O
of,O
Pi,O
uptake,O
by,O
roots,O
from,O
soil,O
solution,O
",",O
retranslocate,O
Pi,O
from,O
older,O
leaves,O
",",O
and,O
deplete,O
the,O
vacuolar,O
stores,O
of,O
Pi,O
.,O
There,O
is,O
also,O
significant,O
retranslocation,O
of,O
Pi,O
in,O
the,O
phloem,O
from,O
older,O
leaves,O
to,O
the,O
growing,O
shoot,O
and,O
from,O
the,O
shoot,O
to,O
the,O
root,O
.,O
In,O
Pi,O
-,O
deficient,O
plants,B-OG
",",O
the,O
restricted,O
supply,O
of,O
Pi,O
to,O
the,O
shoots,O
from,O
the,O
roots,O
via,O
the,O
xylem,O
is,O
supplemented,O
by,O
increased,O
mobilization,O
of,O
stored,O
P,O
in,O
the,O
older,O
leaves,O
and,O
retranslocation,O
to,O
both,O
the,O
younger,O
leaves,O
and,O
growing,O
roots,O
.,O
This,O
process,O
involves,O
both,O
the,O
depletion,O
of,O
Pi,O
stores,O
and,O
the,O
breakdown,O
of,O
organic,O
P,O
in,O
the,O
older,O
leaves,O
.,O
A,O
curious,O
feature,O
of,O
Pi,O
-,O
starved,O
plants,B-OG
is,O
that,O
approximately,O
one,O
-,O
half,O
of,O
the,O
Pi,O
translocated,O
from,O
the,O
shoot,O
to,O
the,O
root,O
in,O
the,O
phloem,O
is,O
then,O
transferred,O
to,O
the,O
xylem,O
and,O
recycled,O
back,O
to,O
the,O
shoot,O
[,O
4,O
].,O
Low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
in,O
the,O
Pht1,B-GP
family,O
are,O
now,O
thought,O
to,O
play,O
this,O
role,O
in,O
translocation,O
of,O
Pi,O
within,O
the,O
plant,B-OG
",",O
and,O
this,O
has,O
been,O
inferred,O
from,O
the,O
spatial,O
expression,O
of,O
these,O
genes,O
in,O
several,O
different,O
plant,B-OG
species,O
[,O
7,O
"],",O
[,O
30,O
"],",O
[,O
49,O
"],",O
[,O
50,O
].,O
In,O
conclusion,O
",",O
low,O
-,O
affinity,O
Pi,B-GP
transporters,I-GP
play,O
important,O
roles,O
in,O
Pi,O
homeostasis,O
within,O
plants,B-OG
.,O
Prospects,O
Under,O
conditions,O
of,O
Pi,O
starvation,O
",",O
soybean,B-OG
can,O
display,O
its,O
unique,O
strategies,O
to,O
improve,O
its,O
acquisition,O
and,O
remobilization,O
of,O
Pi,O
.,O
In,O
addition,O
",",O
the,O
physiological,O
and,O
molecular,O
processes,O
in,O
soybean,B-OG
under,O
conditions,O
of,O
Pi,O
deficiency,O
appear,O
more,O
complex,O
.,O
Therefore,O
",",O
a,O
global,O
survey,O
of,O
Pi,B-GP
transporter,I-GP
expression,O
in,O
response,O
to,O
Pi,O
starvation,O
is,O
necessary,O
to,O
understand,O
the,O
network,O
of,O
gene,O
expression,O
related,O
to,O
Pi,O
acquisition,O
",",O
translocation,O
",",O
recycling,O
and,O
signal,O
transduction,O
.,O
In,O
this,O
study,O
",",O
we,O
analyzed,O
the,O
temporal,O
and,O
spatial,O
expression,O
patterns,O
of,O
Pi,B-GP
transporters,I-GP
from,O
soybean,B-OG
seedlings,O
subjected,O
to,O
Pi,O
starvation,O
.,O
A,O
BLAST,O
search,O
of,O
the,O
soybean,B-OG
genome,O
",",O
combined,O
with,O
cDNA,O
cloning,O
",",O
showed,O
that,O
soybean,B-OG
possibly,O
contains,O
nine,O
Pi,B-GP
transporter,I-GP
genes,O
.,O
In,O
this,O
study,O
",",O
we,O
analyzed,O
the,O
expression,O
levels,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
",",O
but,O
there,O
could,O
be,O
other,O
Pi,B-GP
transporters,I-GP
in,O
soybean,B-OG
",",O
which,O
raises,O
the,O
question,O
of,O
whether,O
other,O
Pi,B-GP
transporters,I-GP
can,O
affect,O
Pi,O
acquisition,O
",",O
translocation,O
and,O
remobilization,O
and,O
what,O
is,O
the,O
relative,O
contribution,O
of,O
these,O
genes,O
to,O
overall,O
Pi,B-GP
transporter,I-GP
function,O
in,O
plants,B-OG
?,O
Multiple,O
Pi,B-GP
transporter,I-GP
genes,O
could,O
result,O
in,O
finer,O
control,O
over,O
protein,O
expression,O
;,O
if,O
so,O
",",O
how,O
does,O
each,O
of,O
these,O
genes,O
respond,O
to,O
deficiency,O
of,O
Pi,O
stress,O
?,O
Future,O
studies,O
of,O
the,O
expression,O
of,O
all,O
soybean,B-OG
Pi,B-GP
transporters,I-GP
in,O
response,O
to,O
different,O
concentrations,O
of,O
Pi,O
could,O
address,O
these,O
questions,O
",",O
providing,O
better,O
understanding,O
of,O
the,O
function,O
of,O
Pi,B-GP
transporter,I-GP
genes,O
in,O
soybean,B-OG
.,O
Materials,O
and,O
Methods,O
Plant,B-OG
material,O
and,O
growth,O
conditions,O
Surface,O
-,O
sterilized,O
soybean,B-OG
seeds,O
(,O
G,O
.,O
max,O
cv,O
.,O
gantai,O
),O
were,O
sown,O
in,O
sterile,O
",",O
acid,O
-,O
washed,O
quartz,O
sand,O
irrigated,O
with,O
0,O
.,O
5,O
×,O
Hoagland,O
solution,O
containing,O
5,O
µM,O
Pi,O
.,O
The,O
seedings,O
were,O
maintained,O
in,O
a,O
growth,O
chamber,O
with,O
70,O
%,O
relative,O
humidity,O
and,O
a,O
cycle,O
of,O
16,O
h,O
light,O
at,O
29,O
°,O
C,O
/,O
8,O
h,O
dark,O
at,O
23,O
°,O
C,O
.,O
After,O
7,O
days,O
",",O
fresh,O
roots,O
were,O
harvested,O
for,O
gene,O
cloning,O
.,O
At,O
the,O
same,O
time,O
",",O
whole,O
plants,B-OG
were,O
transferred,O
to,O
0,O
.,O
5,O
×,O
Hoagland,O
solution,O
for,O
a,O
Pi,O
-,O
deficiency,O
time,O
-,O
course,O
experiment,O
.,O
For,O
the,O
experiment,O
",",O
7,O
-,O
day,O
-,O
old,O
seedlings,O
were,O
grown,O
by,O
hydroponic,O
culture,O
with,O
0,O
.,O
5,O
×,O
Hoagland,O
solution,O
containing,O
5,O
µM,O
Pi,O
(,O
Pi,O
deficient,O
),O
or,O
1,O
mM,O
Pi,O
(,O
Pi,O
sufficient,O
"),",O
respectively,O
.,O
All,O
seedling,O
tissues,O
were,O
harvested,O
at,O
0,O
",",O
1,O
.,O
0,O
",",O
3,O
.,O
0,O
",",O
12,O
.,O
0,O
",",O
24,O
.,O
0,O
and,O
48,O
.,O
0,O
h,O
after,O
treatment,O
.,O
After,O
Pi,O
deficient,O
/,O
sufficient,O
treatment,O
for,O
48,O
h,O
",",O
the,O
seedlings,O
were,O
transferred,O
to,O
Hoagland,O
solution,O
with,O
sufficient,O
/,O
deficient,O
Pi,O
",",O
respectively,O
.,O
Seedling,O
tissues,O
were,O
sampled,O
at,O
0,O
",",O
1,O
.,O
0,O
",",O
and,O
3,O
.,O
0,O
h,O
after,O
transplanting,O
:,O
the,O
time,O
points,O
for,O
sampling,O
were,O
0,O
",",O
1,O
.,O
0,O
",",O
3,O
.,O
0,O
",",O
12,O
.,O
0,O
",",O
24,O
.,O
0,O
",",O
48,O
.,O
0,O
",",O
49,O
.,O
0,O
",",O
51,O
.,O
0,O
and,O
60,O
.,O
0,O
h,O
.,O
Gene,O
Cloning,O
Using,O
the,O
OsPT2,B-GP
nucleotide,O
sequence,O
(,O
accession,O
number,O
AF536962,O
),O
as,O
the,O
query,O
",",O
a,O
BALSTN,O
[,O
24,O
],O
search,O
was,O
done,O
on,O
the,O
web,O
page,O
of,O
the,O
phytozome,O
(,O
http,O
://,O
www,O
.,O
phytozome,O
.,O
net,O
/,O
search,O
.,O
php,O
?,O
show,O
=,O
blast,O
),O
to,O
identify,O
sequences,O
containing,O
OsPT2,B-GP
orthologs,O
in,O
the,O
soybean,B-OG
genomic,O
database,O
.,O
This,O
resulted,O
in,O
the,O
identification,O
of,O
two,O
cDNA,O
clones,O
designated,O
GmPT1,B-GP
and,O
GmPT2,B-GP
.,O
Two,O
pairs,O
of,O
primers,O
were,O
used,O
for,O
PCR,O
amplification,O
:,O
for,O
GmPT1,B-GP
forward,O
5,O
′-,O
CAGGTAGCTGAGTTAGTGAGTGA,O
-,O
3,O
′,O
reverse,O
5,O
′-,O
CACGTATGATTTAGACAACACTTC,O
-,O
3,O
′,O
for,O
GmPT2,B-GP
forward,O
5,O
′-,O
CAGGTAGCAGAGTTAGTGAGTAAT,O
-,O
3,O
′,O
reverse,O
5,O
′-,O
ACAAGAATGAAATACACACCC,O
-,O
3,O
′,O
Full,O
-,O
length,O
cDNA,O
was,O
amplified,O
from,O
the,O
root,O
cDNA,O
template,O
",",O
using,O
the,O
primers,O
at,O
the,O
end,O
of,O
the,O
cDNA,O
sequence,O
",",O
and,O
then,O
cloned,O
into,O
the,O
pMD,O
-,O
19,O
Simple,O
T,O
vector,O
(,O
Takara,O
),O
for,O
sequence,O
verification,O
.,O
Sequence,O
Analysis,O
Sequence,O
analysis,O
was,O
done,O
with,O
ANTHEPROT,O
[,O
51,O
"],",O
Lasergene,O
version,O
7,O
.,O
0,O
.,O
1,O
and,O
DNAMAN,O
version,O
6,O
.,O
0,O
.,O
3,O
.,O
93,O
software,O
.,O
Transmembrane,O
regions,O
and,O
subcellular,O
localization,O
were,O
predicted,O
by,O
HMMTOP,O
[,O
52,O
],O
(,O
http,O
://,O
www,O
.,O
enzim,O
.,O
hu,O
/,O
hmmtop,O
/,O
index,O
.,O
html,O
),O
and,O
the,O
TBpred,O
prediction,O
server,O
[,O
36,O
],O
(,O
http,O
://,O
www,O
.,O
imtech,O
.,O
res,O
.,O
in,O
/,O
raghava,O
/,O
tbpred,O
"/),",O
respectively,O
.,O
We,O
used,O
ScanProsite,O
to,O
scan,O
the,O
protein,O
sequences,O
for,O
the,O
occurrence,O
of,O
patterns,O
stored,O
in,O
the,O
PROSITE,O
database,O
[,O
53,O
].,O
The,O
ScanProsite,O
tools,O
are,O
available,O
on,O
the,O
ExPaSy,O
Molecular,O
Biology,O
of,O
Geneva,O
(,O
Switzerland,O
),O
website,O
(,O
http,O
://,O
expasy,O
.,O
org,O
/,O
tools,O
/,O
scanprosite,O
/).,O
Multiple,O
sequence,O
alignment,O
was,O
done,O
with,O
ClustalW,O
[,O
54,O
].,O
MEGA,O
4,O
[,O
55,O
],O
was,O
used,O
for,O
analysis,O
of,O
the,O
phylogenetic,O
relationships,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
and,O
other,O
Pi,B-GP
transporters,I-GP
.,O
The,O
evolutionary,O
history,O
was,O
inferred,O
using,O
the,O
neighbor,O
-,O
joining,O
method,O
.,O
The,O
bootstrap,O
consensus,O
tree,O
inferred,O
from,O
1000,O
replicates,O
was,O
taken,O
to,O
represent,O
the,O
evolutionary,O
history,O
of,O
the,O
taxa,O
analyzed,O
.,O
Branches,O
corresponding,O
to,O
partitions,O
reproduced,O
in,O
less,O
than,O
<,O
60,O
%,O
bootstrap,O
replicates,O
were,O
collapsed,O
.,O
The,O
percentage,O
of,O
replicate,O
trees,O
in,O
which,O
the,O
associated,O
taxa,O
clustered,O
together,O
in,O
the,O
bootstrap,O
test,O
(,O
1000,O
replicates,O
),O
are,O
shown,O
next,O
to,O
the,O
branches,O
(,O
next,O
to,O
the,O
branches,O
).,O
The,O
evolutionary,O
distances,O
were,O
computed,O
using,O
the,O
Poisson,O
correction,O
method,O
and,O
are,O
in,O
units,O
of,O
the,O
number,O
of,O
amino,O
acid,O
substitutions,O
per,O
site,O
.,O
All,O
positions,O
containing,O
gaps,O
and,O
missing,O
data,O
were,O
eliminated,O
from,O
the,O
dataset,O
(,O
complete,O
deletion,O
option,O
).,O
There,O
are,O
460,O
positions,O
in,O
the,O
final,O
dataset,O
.,O
Subcellular,O
Localization,O
GFP,B-GP
was,O
fused,O
to,O
the,O
3,O
′,O
ends,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
.,O
When,O
expressed,O
in,O
onion,O
epidermal,O
cells,O
",",O
these,O
gene,O
fusions,O
gave,O
rise,O
to,O
Pi,B-GP
transporter,I-GP
::,O
GFP,B-GP
fusion,O
proteins,O
.,O
A,O
PCR,O
-,O
generated,O
Xba,B-GP
I,I-GP
–,O
BamH,B-GP
I,I-GP
fragment,O
containing,O
the,O
open,O
reading,O
frame,O
of,O
GmPT1,B-GP
and,O
the,O
Xba,B-GP
I,I-GP
–,O
Xba,B-GP
I,I-GP
fragment,O
containing,O
the,O
open,O
reading,O
frame,O
of,O
GmPT2,B-GP
were,O
subcloned,O
in,O
-,O
frame,O
upstream,O
of,O
the,O
GFP,B-GP
gene,O
in,O
plasmid,O
pBI,O
-,O
121,O
-,O
GFP,B-GP
.,O
The,O
primers,O
were,O
:,O
for,O
GmPT1,B-GP
forward,O
5,O
′-,O
GCTCTAGAATGGCGGGAGGACAACTAG,O
-,O
3,O
′,O
reverse,O
5,O
′-,O
CGGGATCCAACTGGAACCGTCCTA,O
-,O
3,O
′,O
for,O
GmPT2,B-GP
forward,O
5,O
′-,O
GCT,O
CTAGAATGGCAGGAGGACAACTAG,O
-,O
3,O
′,O
reverse,O
5,O
′-,O
GCT,O
CTAGAAACTGGAACCGTCCTAGC,O
-,O
3,O
′,O
Expression,O
of,O
the,O
gene,O
fusions,O
was,O
controlled,O
by,O
the,O
CaMV35S,O
-,O
promoter,O
.,O
DNA,O
of,O
the,O
chimeric,O
genes,O
CaMV35S,O
-,O
GmPT1,B-GP
and,O
CaMV35S,O
-,O
GmPT2,B-GP
and,O
the,O
pBI,O
-,O
121,O
-,O
GFP,B-GP
empty,O
vector,O
were,O
introduced,O
into,O
onion,O
epidermal,O
cells,O
by,O
a,O
particle,O
bombardment,O
system,O
(,O
Biolistic,O
PDS,O
-,O
1000,O
/,O
He,O
System,O
;,O
BioRad,O
",",O
USA,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
Bombarded,O
samples,O
were,O
kept,O
in,O
the,O
dark,O
at,O
room,O
temperature,O
for,O
∼,O
24,O
h,O
and,O
then,O
examined,O
under,O
a,O
Leica,O
TCS,O
SP2,O
confocal,O
microscope,O
.,O
Yeast,B-OG
Manipulations,O
and,O
Pi,O
Uptake,O
Assays,O
The,O
open,O
reading,O
frames,O
of,O
GmPT1,B-GP
and,O
GmPT2,B-GP
were,O
separately,O
subcloned,O
into,O
yeast,B-OG
expression,O
vector,O
p112A1NE,O
[,O
56,O
],O
to,O
create,O
GmPT1,B-GP
/,O
p112A1NE,O
and,O
GmPT2,B-GP
/,O
p112A1NE,O
",",O
where,O
expression,O
of,O
GmPT1,B-GP
or,O
GmPT2,B-GP
gene,O
was,O
driven,O
by,O
the,O
alcohol,B-GP
dehydrogenase,I-GP
promoter,O
1,O
(,O
ADH1,B-GP
).,O
These,O
constructs,O
were,O
transformed,O
into,O
the,O
yeast,B-OG
mutant,O
MB192,O
(,O
MATa,O
pho3,B-GP
-,O
1,O
Δpho84,O
::,O
HIS3,B-GP
ade2,B-GP
leu2,B-GP
-,O
3,O
",",O
112,O
his3,B-GP
-,O
532,O
trp1,B-GP
-,O
289,O
ura3,B-GP
-,O
1,O
",",O
2,O
can1,B-GP
),O
[,O
28,O
],O
as,O
described,O
[,O
57,O
].,O
The,O
yeast,B-OG
cells,O
were,O
grown,O
until,O
the,O
logarithmic,O
phase,O
(,O
when,O
the,O
absorbance,O
at,O
600,O
nm,O
was,O
1,O
.,O
0,O
),O
on,O
YNB,O
liquid,O
medium,O
(,O
Difco,O
",",O
Chemie,O
Brunschwig,O
AG,O
",",O
Basel,O
",",O
Switzerland,O
"),",O
harvested,O
",",O
washed,O
three,O
times,O
with,O
Pi,O
-,O
free,O
medium,O
(,O
YNB,O
medium,O
containing,O
an,O
equimolar,O
concentration,O
of,O
potassium,O
chloride,O
instead,O
of,O
potassium,O
phosphate,O
"),",O
then,O
suspended,O
in,O
the,O
same,O
medium,O
and,O
incubated,O
at,O
30,O
°,O
C,O
for,O
10,O
min,O
.,O
Different,O
extracellular,O
pH,O
values,O
in,O
the,O
range,O
4,O
.,O
0,O
–,O
7,O
.,O
0,O
were,O
used,O
for,O
the,O
pH,O
-,O
dependent,O
Pi,O
uptake,O
experiments,O
.,O
Washed,O
and,O
Pi,O
-,O
starved,O
cells,O
were,O
suspended,O
and,O
activated,O
with,O
20,O
%,O
(,O
w,O
/,O
v,O
),O
glucose,O
to,O
guarantee,O
optimal,O
energization,O
of,O
the,O
plasma,O
membrane,O
to,O
5,O
%.,O
Then,O
1,O
ml,O
of,O
1,O
mM,O
32Pi,O
(,O
final,O
concentration,O
of,O
Pi,O
0,O
.,O
25,O
mM,O
),O
was,O
added,O
",",O
mixed,O
and,O
the,O
cells,O
were,O
incubated,O
with,O
shaking,O
at,O
30,O
°,O
C,O
for,O
5,O
min,O
.,O
Uptake,O
was,O
stopped,O
by,O
addition,O
of,O
4,O
ml,O
of,O
ice,O
-,O
cold,O
water,O
and,O
the,O
cells,O
were,O
harvested,O
immediately,O
on,O
glass,O
microfiber,O
filters,O
(,O
Whatman,O
®,O
GF,O
/,O
F,O
grade,O
),O
by,O
vacuum,O
filtration,O
.,O
The,O
filters,O
were,O
washed,O
twice,O
with,O
4,O
ml,O
of,O
ice,O
-,O
cold,O
water,O
then,O
transferred,O
to,O
scintillation,O
vials,O
and,O
radioactivity,O
was,O
measured,O
by,O
a,O
Beckman,O
LS,O
6500,O
Scintillation,O
Counter,O
.,O
Six,O
different,O
concentrations,O
of,O
Pi,O
(,O
2000,O
",",O
1000,O
",",O
500,O
",",O
250,O
",",O
100,O
and,O
50,O
µM,O
),O
were,O
used,O
to,O
derive,O
the,O
value,O
of,O
K,O
m,O
from,O
the,O
double,O
reciprocal,O
Lineweaver,O
–,O
Burk,O
plot,O
",",O
which,O
is,O
less,O
susceptible,O
to,O
skewing,O
as,O
a,O
consequence,O
of,O
the,O
multiple,O
kinetics,O
components,O
;,O
therefore,O
",",O
K,O
m,O
is,O
an,O
aggregate,O
value,O
reflecting,O
the,O
contribution,O
of,O
many,O
individual,O
kinetic,O
constants,O
[,O
58,O
].,O
For,O
inhibition,O
studies,O
",",O
the,O
reagents,O
given,O
in,O
Table,O
1,O
were,O
added,O
30,O
s,O
before,O
addition,O
of,O
the,O
labeled,O
Pi,O
.,O
Mes,O
(,O
2,O
-(,O
N,O
-,O
morpholino,O
),O
ethanesulfonic,O
acid,O
),O
buffer,O
at,O
a,O
final,O
concentration,O
of,O
25,O
mM,O
was,O
used,O
to,O
determine,O
transport,O
activity,O
at,O
different,O
pH,O
values,O
.,O
Quantitative,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
(,O
qRT,O
-,O
PCR,O
),O
RNA,O
was,O
extracted,O
from,O
root,O
and,O
shoot,O
samples,O
using,O
TRIzol,O
®,O
reagent,O
(,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
",",O
USA,O
).,O
RT,O
-,O
PCR,O
for,O
the,O
target,O
genes,O
",",O
GmPT1,B-GP
and,O
GmPT2,B-GP
and,O
cons7,O
(,O
accession,O
number,O
AW310136,O
),O
[,O
59,O
],O
using,O
gene,O
-,O
specific,O
primers,O
followed,O
the,O
protocol,O
as,O
described,O
[,O
60,O
].,O
PCR,O
was,O
done,O
in,O
triplicate,O
using,O
a,O
reaction,O
solution,O
containing,O
TaqMan,O
buffer,O
",",O
0,O
.,O
4,O
µM,O
forward,O
and,O
reverse,O
primers,O
and,O
0,O
.,O
3,O
µM,O
probe,O
was,O
done,O
with,O
the,O
ABI,O
7500,O
Fast,O
Real,O
-,O
Time,O
PCR,O
system,O
.,O
(,O
Applied,O
Biosystems,O
).,O
Expression,O
levels,O
were,O
normalized,O
according,O
to,O
cons7,O
and,O
fold,O
change,O
was,O
calculated,O
using,O
the,O
method,O
[,O
61,O
].,O
The,O
following,O
gene,O
-,O
specific,O
primers,O
and,O
probe,O
were,O
used,O
for,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
:,O
for,O
GmPT1,B-GP
5,O
′-,O
CTTATGCTTATGGTTCTGTGTTCC,O
-,O
3,O
"′,",O
5,O
′-,O
CAGACATAATTGTAGCTGATAGAGG,O
-,O
3,O
′,O
5,O
′-(,O
FAM,O
),O
CACCACCAATCCCAAAGTCAAGCCA,O
(,O
TAMRA,O
)-,O
3,O
′,O
for,O
GmPT2,B-GP
5,O
′-,O
GGCTTAACTCTTATGCTTATGGTTG,O
-,O
3,O
"′,",O
5,O
′-,O
CATGATTGTAGCTGATAGAGGGTAG,O
-,O
3,O
′,O
5,O
′-(,O
FAM,O
),O
CACCACCAATCCCAAAGCCAAGCCA,O
(,O
TAMRA,O
)-,O
3,O
′,O
for,O
cons7,O
5,O
′-,O
TATAAACCTGGAGGATGCACTAGC,O
-,O
3,O
′,O
5,O
′-,O
GTACATGGGAACCGTCATTCATC,O
-,O
3,O
′,O
5,O
′-(,O
FAM,O
),O
AACGGAAGCCTCAGAACCACACTTG,O
(,O
TAMRA,O
)-,O
3,O
′,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Responses,O
of,O
the,O
summer,O
Asian,O
-,O
Pacific,O
zonal,O
thermal,O
contrast,O
and,O
the,O
associated,O
evolution,O
of,O
atmospheric,O
circulation,O
to,O
transient,O
orbital,O
changes,O
during,O
the,O
Holocene,O
This,O
study,O
investigates,O
the,O
response,O
of,O
large,O
-,O
scale,O
atmospheric,O
circulation,O
over,O
the,O
Asian,O
-,O
Pacific,O
sector,O
and,O
precipitation,O
over,O
eastern,O
China,O
to,O
transient,O
orbital,O
changes,O
during,O
the,O
Holocene,O
summer,O
using,O
an,O
intermediate,O
-,O
complexity,O
climate,O
model,O
.,O
Corresponding,O
to,O
variations,O
in,O
the,O
incoming,O
solar,O
radiation,O
",",O
the,O
eddy,O
sea,O
level,O
pressure,O
(,O
SLP,O
),O
exhibited,O
an,O
out,O
-,O
of,O
-,O
phase,O
relationship,O
between,O
the,O
North,O
Pacific,O
and,O
the,O
Eurasian,O
landmass,O
that,O
was,O
similar,O
to,O
the,O
present,O
-,O
day,O
Asia,O
-,O
Pacific,O
Oscillation,O
(,O
APO,O
),O
pattern,O
and,O
was,O
defined,O
as,O
the,O
paleo,O
-,O
APO,O
.,O
Its,O
index,O
presented,O
an,O
increasing,O
trend,O
",",O
which,O
implies,O
the,O
enhancement,O
of,O
a,O
zonal,O
thermal,O
contrast,O
between,O
Asia,O
and,O
the,O
North,O
Pacific,O
.,O
Associated,O
with,O
the,O
strengthening,O
of,O
the,O
paleo,O
-,O
APO,O
was,O
the,O
westward,O
shift,O
in,O
North,O
Pacific,O
high,O
pressure,O
.,O
Accordingly,O
",",O
there,O
was,O
less,O
/,O
more,O
summer,O
precipitation,O
over,O
both,O
the,O
middle,O
reach,O
of,O
the,O
Yangtze,O
River,O
and,O
Southwest,O
China,O
/,O
over,O
North,O
China,O
.,O
The,O
high,O
-,O
resolution,O
stalagmite,O
δ18O,O
records,O
further,O
support,O
this,O
decrease,O
in,O
the,O
model,O
precipitation,O
.,O
Along,O
with,O
the,O
strengthening,O
of,O
paleo,O
-,O
APO,O
from,O
the,O
early,O
Holocene,O
to,O
the,O
present,O
",",O
the,O
eddy,O
SLP,O
anomalies,O
exhibited,O
a,O
decreasing,O
/,O
increasing,O
trend,O
over,O
the,O
Eurasian,O
landmass,O
/,O
the,O
North,O
Pacific,O
",",O
with,O
a,O
phase,O
change,O
of,O
approximately,O
4,O
.,O
5,O
ka,O
BP,O
",",O
and,O
they,O
both,O
moved,O
westward,O
.,O
Meanwhile,O
",",O
a,O
less,O
rainfall,O
belt,O
over,O
eastern,O
China,O
exhibited,O
northward,O
propagation,O
from,O
southern,O
China,O
.,O
The,O
East,O
Asian,O
summer,O
monsoon,O
(,O
EASM,O
),O
is,O
an,O
important,O
component,O
of,O
global,O
climate,O
systems,O
and,O
plays,O
significant,O
roles,O
in,O
global,O
energy,O
and,O
hydrological,O
cycles,O
.,O
Therefore,O
",",O
it,O
is,O
viewed,O
as,O
the,O
life,O
blood,O
providing,O
the,O
key,O
precipitation,O
for,O
agriculture1,O
.,O
However,O
",",O
some,O
extreme,O
variations,O
in,O
the,O
EASM,O
also,O
cause,O
harmful,O
drought,O
and,O
flooding,O
events2,O
.,O
In,O
particular,O
",",O
under,O
recent,O
global,O
warming,O
",",O
the,O
EASM,O
experienced,O
a,O
weakening,O
trend,O
",",O
with,O
severe,O
droughts,O
over,O
northern,O
China,O
and,O
disastrous,O
floods,O
over,O
the,O
Yangtze,O
River,O
valley3,O
.,O
Therefore,O
",",O
understanding,O
the,O
natural,O
variability,O
of,O
EASM,O
and,O
predicting,O
its,O
long,O
-,O
term,O
changes,O
in,O
a,O
warming,O
climate,O
are,O
helpful,O
for,O
disaster,O
mitigation,O
.,O
The,O
Holocene,O
is,O
another,O
significant,O
warming,O
period,O
that,O
occurred,O
since,O
the,O
last,O
glacial,O
period,O
.,O
Studies,O
of,O
EASM,O
during,O
the,O
Holocene,O
may,O
help,O
us,O
understand,O
the,O
mechanisms,O
responsible,O
for,O
the,O
natural,O
variability,O
of,O
EASM,O
under,O
a,O
warming,O
scenario,O
",",O
which,O
has,O
been,O
of,O
increasing,O
interest,O
during,O
the,O
past,O
decade456789101112,O
.,O
Some,O
studies,O
of,O
high,O
-,O
resolution,O
and,O
precisely,O
dated,O
contemporaneous,O
speleothem,O
δ18O,O
records,O
from,O
caves,O
have,O
indicated,O
a,O
long,O
-,O
term,O
downward,O
trend,O
of,O
the,O
EASM,O
precipitation,O
during,O
the,O
Holocene1314,O
.,O
This,O
trend,O
may,O
be,O
a,O
response,O
to,O
the,O
decreasing,O
solar,O
insolation,O
over,O
the,O
Northern,O
Hemisphere,O
(,O
NH,O
).,O
However,O
",",O
the,O
associated,O
mechanisms,O
remain,O
unknown,O
.,O
In,O
the,O
summer,O
",",O
a,O
remarkable,O
tropospheric,O
zonal,O
thermal,O
contrast,O
arises,O
between,O
the,O
warmer,O
Eurasian,O
continent,O
and,O
the,O
cooler,O
North,O
Pacific,O
or,O
Indian,O
Ocean,O
.,O
Some,O
in,O
-,O
depth,O
studies,O
have,O
explored,O
the,O
variations,O
in,O
the,O
thermal,O
contrast,O
and,O
their,O
links,O
with,O
EASM,O
and,O
precipitation,O
on,O
multiple,O
time,O
scales315161718,O
.,O
Recently,O
",",O
a,O
large,O
-,O
scale,O
summertime,O
teleconnection,O
pattern,O
of,O
the,O
tropospheric,O
temperature,O
over,O
the,O
extratropical,O
NH,O
",",O
with,O
opposite,O
anomalous,O
centers,O
between,O
Asia,O
and,O
the,O
North,O
Pacific,O
",",O
was,O
proposed,O
as,O
the,O
Asian,O
-,O
Pacific,O
Oscillation,O
(,O
APO,O
),O
19,O
.,O
A,O
higher,O
(,O
lower,O
),O
APO,O
index,O
often,O
represents,O
a,O
stronger,O
(,O
weaker,O
),O
thermal,O
contrast,O
between,O
the,O
Eurasian,O
continent,O
and,O
the,O
North,O
Pacific,O
Ocean,O
.,O
The,O
APO,O
index,O
also,O
sufficiently,O
represents,O
the,O
long,O
-,O
term,O
changes,O
in,O
the,O
EASM,O
rainfall,O
over,O
the,O
past,O
century20,O
and,O
millennium21222324,O
.,O
Climate,O
models,O
have,O
been,O
widely,O
used,O
to,O
improve,O
our,O
understanding,O
of,O
the,O
mechanisms,O
of,O
Holocene,O
climate,O
changes,O
.,O
In,O
particular,O
",",O
the,O
first,O
",",O
second,O
and,O
third,O
phases,O
of,O
the,O
Paleoclimate,O
Modeling,O
Inter,O
-,O
comparison,O
Project,O
(,O
PMIP1,O
",",O
PIMP2,O
",",O
and,O
PIMP3,O
),O
focused,O
on,O
the,O
Mid,O
-,O
Holocene,O
",",O
6,O
ka,O
before,O
the,O
present,O
(,O
ka,O
BP,O
).,O
Some,O
equilibrium,O
simulations,O
(,O
viz,O
".,",O
“,O
snapshot,O
”),O
were,O
applied,O
to,O
compare,O
the,O
characteristics,O
and,O
mechanisms,O
of,O
climate,O
change,O
over,O
China,O
between,O
the,O
Mid,O
-,O
Holocene,O
and,O
the,O
present,O
",",O
in,O
which,O
the,O
concentration,O
of,O
atmospheric,O
CO2,O
was,O
held,O
at,O
280,O
ppm252627282930,O
.,O
Zhou,O
and,O
Zhao31,O
examined,O
the,O
APO,O
variation,O
and,O
associated,O
summer,O
precipitation,O
anomalies,O
using,O
the,O
CCSM3,O
simulation,O
in,O
PIMP2,O
.,O
Their,O
results,O
presented,O
a,O
pattern,O
of,O
northwest,O
-,O
southeast,O
inclination,O
in,O
the,O
Mid,O
-,O
Holocene,O
",",O
which,O
mainly,O
results,O
from,O
the,O
incoming,O
solar,O
radiation,O
differences,O
caused,O
by,O
changes,O
in,O
the,O
orbital,O
parameters,O
.,O
Moreover,O
",",O
to,O
understand,O
climatic,O
evolutions,O
over,O
the,O
entire,O
Holocene,O
period,O
",",O
some,O
transient,O
simulations,O
under,O
the,O
forcing,O
of,O
orbital,O
changes,O
were,O
also,O
performed,O
with,O
different,O
complexity,O
climate,O
models,O
and,O
accelerated,O
schemes323334353637383940,O
.,O
Although,O
climate,O
simulations,O
for,O
the,O
Holocene,O
have,O
made,O
great,O
progress,O
",",O
a,O
number,O
of,O
questions,O
remain,O
unanswered,O
.,O
For,O
example,O
",",O
how,O
do,O
large,O
-,O
scale,O
circulations,O
respond,O
to,O
the,O
NH,O
decreasing,O
incoming,O
solar,O
radiation,O
during,O
the,O
Holocene,O
summer,O
?,O
Does,O
this,O
response,O
cause,O
a,O
significant,O
difference,O
between,O
land,O
and,O
ocean,O
?,O
If,O
so,O
",",O
how,O
do,O
they,O
affect,O
the,O
EASM,O
hydrological,O
climate,O
?,O
What,O
are,O
the,O
evolving,O
characteristics,O
of,O
atmospheric,O
circulation,O
in,O
the,O
Holocene,O
?,O
With,O
these,O
questions,O
in,O
mind,O
",",O
we,O
use,O
an,O
intermediate,O
-,O
complexity,O
climate,O
model,O
to,O
perform,O
a,O
transient,O
simulation,O
with,O
an,O
acceleration,O
factor,O
of,O
10,O
years,O
",",O
under,O
the,O
orbital,O
changes,O
during,O
the,O
past,O
10,O
ka,O
BP,O
",",O
and,O
investigate,O
an,O
APO,O
-,O
like,O
large,O
-,O
scale,O
teleconnection,O
over,O
the,O
Asian,O
-,O
Pacific,O
sector,O
and,O
the,O
associated,O
rainfall,O
anomalies,O
over,O
eastern,O
China,O
.,O
Meanwhile,O
",",O
some,O
simulated,O
results,O
are,O
compared,O
with,O
the,O
proxy,O
data,O
.,O
The,O
remainder,O
of,O
this,O
paper,O
is,O
organized,O
as,O
follows,O
.,O
The,O
UVic,O
Model,O
",",O
data,O
",",O
and,O
methods,O
are,O
introduced,O
in,O
the,O
next,O
section,O
.,O
In,O
the,O
result,O
section,O
",",O
the,O
responses,O
of,O
large,O
-,O
scale,O
circulations,O
to,O
orbital,O
changes,O
are,O
analyzed,O
and,O
compared,O
with,O
proxies,O
;,O
and,O
the,O
EASM,O
circulation,O
and,O
hydrological,O
climate,O
evolutions,O
associated,O
with,O
the,O
APO,O
-,O
like,O
large,O
-,O
scale,O
teleconnection,O
during,O
the,O
Holocene,O
are,O
investigated,O
.,O
A,O
summary,O
and,O
a,O
further,O
discussion,O
are,O
provided,O
in,O
the,O
last,O
section,O
.,O
Model,O
",",O
Experiment,O
",",O
Forcing,O
",",O
Data,O
and,O
Methods,O
Model,O
and,O
transient,O
experiment,O
The,O
UVic,O
Model,O
(,O
version,O
2,O
.,O
9,O
),O
developed,O
by,O
the,O
University,O
of,O
Victoria,O
",",O
Canada,O
couples,O
the,O
atmospheric,O
",",O
oceanic,O
",",O
sea,O
ice,O
",",O
and,O
land,O
surface,O
model,O
components,O
",",O
and,O
it,O
has,O
a,O
resolution,O
of,O
3,O
.,O
6,O
°,O
×,O
1,O
.,O
8,O
°,O
in,O
longitude,O
and,O
latitude,O
.,O
The,O
atmospheric,O
model,O
comprises,O
a,O
single,O
layer,O
(,O
that,O
is,O
",",O
a,O
vertically,O
integrated,O
energy,O
-,O
moisture,O
balance,O
model,O
).,O
The,O
ocean,O
component,O
comes,O
from,O
version,O
2,O
.,O
2,O
of,O
the,O
GFDL,O
Modular,O
Ocean,O
Model,O
",",O
with,O
19,O
-,O
vertical,O
levels,O
.,O
The,O
land,O
surface,O
model,O
employs,O
the,O
MOSES,O
(,O
Met,O
Office,O
Surface,O
Exchange,O
Scheme,O
),O
model,O
.,O
The,O
UVic,O
Model,O
is,O
often,O
used,O
as,O
a,O
tool,O
for,O
understanding,O
the,O
physical,O
process,O
and,O
feedback,O
in,O
the,O
climate,O
system,O
on,O
long,O
timescales,O
",",O
and,O
is,O
widely,O
used,O
in,O
paleoclimate,O
",",O
present,O
climate,O
",",O
and,O
future,O
climate,O
studies4142434445,O
.,O
This,O
model,O
could,O
reasonably,O
reproduce,O
temperature,O
",",O
precipitation,O
",",O
and,O
ocean,O
circulation,O
",",O
with,O
relatively,O
small,O
errors,O
",",O
even,O
compared,O
with,O
the,O
coupled,O
General,O
Circulation,O
Model,O
(,O
GCM,O
),O
42,O
.,O
However,O
",",O
the,O
internal,O
high,O
-,O
frequency,O
variations,O
of,O
almost,O
all,O
of,O
the,O
variables,O
on,O
interannual,O
and,O
interdecadal,O
timescales,O
in,O
the,O
UVic,O
Model,O
are,O
weaker,O
compared,O
with,O
those,O
of,O
the,O
complex,O
atmospheric,O
models46,O
.,O
Therefore,O
",",O
the,O
UVic,O
Model,O
is,O
mainly,O
used,O
to,O
investigate,O
the,O
climate,O
processes,O
and,O
feedback,O
on,O
long,O
timescales42,O
.,O
In,O
this,O
study,O
",",O
we,O
also,O
perform,O
five,O
experiments,O
with,O
different,O
initial,O
fields,O
to,O
test,O
the,O
uncertainty,O
of,O
the,O
model,O
results,O
.,O
An,O
ensemble,O
mean,O
of,O
variables,O
is,O
used,O
",",O
and,O
the,O
spreads,O
of,O
the,O
time,O
series,O
from,O
the,O
ensemble,O
mean,O
are,O
identified,O
.,O
Because,O
of,O
limited,O
computer,O
capabilities,O
",",O
simulations,O
with,O
acceleration,O
factors,O
between,O
10,O
and,O
100,O
have,O
been,O
applied,O
to,O
long,O
-,O
term,O
climate,O
studies,O
",",O
and,O
they,O
yield,O
similar,O
results47,O
.,O
In,O
the,O
present,O
study,O
",",O
following,O
Kutzbach,O
et,O
al,O
.,O
35,O
",",O
we,O
begin,O
with,O
orbital,O
parameters,O
at,O
10,O
ka,O
BP,O
",",O
and,O
they,O
are,O
advanced,O
by,O
10,O
years,O
at,O
the,O
end,O
of,O
each,O
model,O
year,O
(,O
that,O
is,O
",",O
with,O
an,O
acceleration,O
factor,O
of,O
10,O
).,O
The,O
UVic,O
model,O
is,O
spun,O
up,O
for,O
two,O
thousand,O
years,O
before,O
the,O
acceleration,O
and,O
is,O
then,O
integrated,O
for,O
1001,O
model,O
years,O
.,O
Sea,O
level,O
air,O
temperature,O
(,O
SLAT,O
"),",O
sea,O
level,O
pressure,O
(,O
SLP,O
"),",O
and,O
precipitation,O
are,O
used,O
to,O
analyze,O
the,O
climatic,O
variations,O
.,O
According,O
to,O
the,O
UVic,O
Model,O
",",O
we,O
calculate,O
SLP,O
from,O
the,O
output,O
of,O
SLAT,O
(,O
Ts,O
),O
as,O
follows42,O
:,O
where,O
R,O
is,O
the,O
gas,O
constant,O
of,O
dry,O
air,O
(,O
287,O
J,O
kg,O
−,O
1,O
K,O
−,O
1,O
);,O
ρ,O
is,O
the,O
air,O
density,O
;,O
and,O
ρ,O
=,O
a,O
+,O
bTs,O
.,O
This,O
relationship,O
between,O
ρ,O
and,O
Ts,O
has,O
been,O
demonstrated,O
as,O
reasonable,O
by,O
the,O
atmospheric,O
reanalysis,O
data,O
of,O
both,O
the,O
National,O
Centers,O
for,O
Environmental,O
Prediction,O
-,O
National,O
Centers,O
for,O
Atmospheric,O
Research,O
(,O
NCEP,O
-,O
NCAR,O
),O
and,O
the,O
European,O
Centre,O
for,O
Medium,O
-,O
range,O
Weather,O
Forecasts,O
(,O
ECMWF,O
),O
42,O
.,O
In,O
this,O
study,O
",",O
we,O
calculate,O
a,O
and,O
b,O
using,O
the,O
air,O
temperature,O
and,O
SLP,O
of,O
the,O
1981,O
–,O
2010,O
NCEP,O
-,O
NCAR,O
reanalysis,O
.,O
Transient,O
Orbital,O
Forcing,O
Due,O
to,O
the,O
precession,O
effect,O
",",O
the,O
incoming,O
solar,O
radiation,O
is,O
redistributed,O
over,O
months,O
of,O
a,O
year,O
during,O
the,O
past,O
10,O
ka,O
.,O
Figure,O
1a,O
shows,O
the,O
month,O
-,O
year,O
cross,O
section,O
of,O
the,O
transient,O
incoming,O
solar,O
radiation,O
along,O
30,O
°,O
N,O
that,O
is,O
used,O
in,O
this,O
study4849,O
.,O
The,O
incoming,O
solar,O
radiation,O
exhibits,O
a,O
decreasing,O
trend,O
in,O
the,O
warm,O
season,O
(,O
May,O
-,O
August,O
"),",O
with,O
a,O
maximum,O
variation,O
exceeding,O
32,O
.,O
5,O
W,O
·,O
m,O
−,O
2,O
",",O
an,O
increasing,O
trend,O
in,O
the,O
cold,O
season,O
(,O
October,O
-,O
March,O
"),",O
with,O
a,O
maximum,O
variation,O
exceeding,O
27,O
.,O
5,O
W,O
·,O
m,O
−,O
2,O
",",O
and,O
an,O
increase,O
(,O
decrease,O
),O
before,O
5,O
ka,O
and,O
a,O
subsequent,O
decrease,O
(,O
increase,O
),O
in,O
September,O
(,O
April,O
).,O
The,O
summer,O
incoming,O
solar,O
radiation,O
from,O
June,O
to,O
August,O
along,O
the,O
30,O
°,O
N,O
(,O
Fig,O
.,O
1b,O
),O
presents,O
an,O
obvious,O
declining,O
trend,O
",",O
ranging,O
from,O
491,O
to,O
462,O
W,O
·,O
m,O
−,O
2,O
during,O
the,O
Holocene,O
.,O
A,O
previous,O
study,O
indicated,O
that,O
the,O
application,O
of,O
different,O
calendars,O
in,O
the,O
paleoclimate,O
simulation,O
could,O
induce,O
artificial,O
phase,O
shifts,O
in,O
solar,O
insolation,O
forcing,O
and,O
climatic,O
responses50,O
.,O
Such,O
a,O
“,O
calendar,O
effect,O
”,O
in,O
each,O
month,O
due,O
to,O
the,O
precession,O
might,O
be,O
modified,O
by,O
the,O
fixed,O
angular,O
calendar,O
according,O
to,O
Chen,O
et,O
al,O
.,O
51,O
.,O
In,O
this,O
study,O
",",O
we,O
focus,O
on,O
the,O
variation,O
in,O
summer,O
(,O
June,O
",",O
July,O
and,O
August,O
",",O
JJA,O
),O
atmospheric,O
circulation,O
after,O
the,O
above,O
modification,O
.,O
Proxy,O
and,O
Reanalysis,O
Data,O
To,O
evaluate,O
the,O
simulated,O
SLAT,O
/,O
sea,O
surface,O
temperature,O
(,O
SST,O
),O
over,O
the,O
Eurasian,O
continent,O
/,O
the,O
North,O
Pacific,O
(,O
a,O
key,O
region,O
of,O
SLAT,O
/,O
SST,O
anomalies,O
associated,O
with,O
orbital,O
forcing,O
"),",O
we,O
employ,O
the,O
oxygen,O
isotope,O
record,O
from,O
the,O
Guliya,O
ice,O
cap,O
(,O
at,O
81,O
.,O
5,O
°,O
E,O
",",O
35,O
.,O
2,O
°,O
N,O
),O
of,O
western,O
China525354,O
and,O
the,O
reconstructed,O
northern,O
California,O
SST,O
(,O
at,O
124,O
.,O
9,O
°,O
W,O
",",O
41,O
.,O
7,O
°,O
N,O
),O
over,O
the,O
North,O
Pacific5556,O
",",O
which,O
have,O
the,O
ability,O
to,O
indicate,O
summer,O
conditions,O
.,O
Their,O
locations,O
are,O
shown,O
in,O
Fig,O
.,O
2b,O
.,O
The,O
Guliya,O
temperature,O
proxy,O
over,O
the,O
past,O
130,O
ka,O
",",O
drilled,O
from,O
the,O
Guliya,O
ice,O
cap,O
",",O
is,O
recorded,O
as,O
a,O
fluctuation,O
in,O
the,O
concentration,O
of,O
oxygen,O
18,O
(,O
δ18O,O
),O
(,O
hereinafter,O
Guliya,O
δ18O,O
record,O
),O
in,O
a,O
unit,O
of,O
Vienna,O
Pee,O
Dee,O
Belemnite,O
(,O
VPDB,O
).,O
The,O
monthly,O
concentration,O
of,O
δ18O,O
in,O
Guliya,O
is,O
shown,O
to,O
be,O
highly,O
related,O
to,O
the,O
local,O
monthly,O
surface,O
air,O
temperature57,O
.,O
Further,O
studies,O
disclosed,O
that,O
the,O
Guliya,O
δ18O,O
record,O
could,O
indicate,O
summer,O
temperatures,O
over,O
the,O
Tibetan,O
Plateau,O
during,O
the,O
past,O
130,O
ka4458,O
.,O
The,O
Northern,O
California,O
SST,O
was,O
reconstructed,O
from,O
the,O
alkenone,O
in,O
the,O
Ocean,O
Drilling,O
Program,O
(,O
ODP,O
),O
Site,O
1019,O
(,O
ODP,O
1019,O
"),",O
with,O
a,O
water,O
depth,O
of,O
980,O
m55,O
.,O
Generally,O
speaking,O
",",O
the,O
alkenone,O
SST,O
of,O
ODP,O
1019,O
represents,O
the,O
annual,O
mean,O
SST,O
.,O
Because,O
the,O
annual,O
mean,O
SST,O
over,O
the,O
region,O
110,O
°,O
W,O
–,O
120,O
°,O
W,O
",",O
35,O
°,O
N,O
–,O
45,O
°,O
N,O
in,O
the,O
present,O
-,O
day,O
climate,O
is,O
highly,O
related,O
to,O
the,O
local,O
June,O
–,O
July,O
SST,O
",",O
with,O
a,O
correlation,O
coefficient,O
of,O
0,O
.,O
82,O
during,O
1981,O
–,O
2010,O
(,O
exceeding,O
the,O
99,O
.,O
9,O
%,O
confidence,O
level,O
"),",O
the,O
annual,O
mean,O
SST,O
over,O
the,O
eastern,O
North,O
Pacific,O
might,O
be,O
used,O
to,O
indicate,O
the,O
equivalent,O
variation,O
in,O
the,O
local,O
June,O
-,O
July,O
averaged,O
SST,O
.,O
Moreover,O
",",O
the,O
annual,O
mean,O
SST,O
is,O
correlated,O
with,O
the,O
summer,O
North,O
Pacific,O
mean,O
SLP,O
over,O
the,O
region,O
120,O
°,O
W,O
–,O
180,O
"°,",O
15,O
–,O
60,O
°,O
N,O
",",O
with,O
a,O
correlation,O
coefficient,O
of,O
−,O
0,O
.,O
39,O
(,O
exceeding,O
the,O
95,O
%,O
confidence,O
level,O
).,O
This,O
correlation,O
is,O
higher,O
than,O
that,O
between,O
the,O
annual,O
mean,O
SST,O
and,O
the,O
winter,O
North,O
Pacific,O
SLP,O
(−,O
0,O
.,O
25,O
",",O
not,O
significant,O
at,O
the,O
95,O
%,O
confidence,O
level,O
"),",O
which,O
suggests,O
that,O
the,O
annual,O
mean,O
SST,O
over,O
the,O
eastern,O
North,O
Pacific,O
could,O
better,O
indicate,O
the,O
summer,O
North,O
Pacific,O
SLP,O
instead,O
of,O
the,O
winter,O
one,O
.,O
Therefore,O
",",O
we,O
employ,O
the,O
alkenone,O
SST,O
of,O
ODP,O
1019,O
to,O
indicate,O
the,O
summer,O
(,O
June,O
–,O
July,O
),O
SST,O
.,O
The,O
ODP,O
sites,O
1014,O
and,O
1016,O
",",O
adjacent,O
to,O
the,O
ODP,O
1019,O
",",O
could,O
indicate,O
the,O
variation,O
of,O
SLP,O
over,O
the,O
North,O
Pacific,O
and,O
their,O
reconstructed,O
SSTs,O
show,O
a,O
similar,O
low,O
-,O
frequency,O
SST,O
variation59,O
.,O
It,O
is,O
concluded,O
that,O
the,O
ODP,O
1019,O
SST,O
may,O
also,O
represent,O
the,O
variability,O
in,O
the,O
North,O
Pacific,O
high,O
pressure,O
like,O
the,O
ODP,O
sites,O
1014,O
and,O
1016,O
SST,O
.,O
Due,O
to,O
a,O
low,O
resolution,O
of,O
the,O
reconstructed,O
SSTs,O
in,O
the,O
ODP,O
sites,O
1014,O
and,O
1016,O
during,O
the,O
Holocene,O
",",O
we,O
use,O
the,O
reconstructed,O
northern,O
California,O
SST,O
in,O
the,O
ODP,O
1019,O
for,O
evaluating,O
the,O
simulated,O
SST,O
over,O
the,O
North,O
Pacific,O
.,O
Furthermore,O
",",O
we,O
also,O
use,O
the,O
reconstructed,O
July,O
temperatures,O
with,O
high,O
temporal,O
resolutions,O
over,O
the,O
middle,O
-,O
west,O
part,O
of,O
North,O
America60,O
and,O
Western,O
Europe,O
(,O
68,O
°,O
22,O
′,O
N,O
",",O
18,O
°,O
42,O
′,O
E,O
),O
61,O
(,O
shown,O
in,O
Fig,O
.,O
S1a,O
",",O
b,O
),O
to,O
further,O
examine,O
the,O
capability,O
of,O
the,O
model,O
.,O
To,O
evaluate,O
the,O
variation,O
in,O
the,O
model,O
summer,O
precipitation,O
over,O
eastern,O
China,O
",",O
five,O
high,O
-,O
resolution,O
speleothem,O
δ18O,O
records,O
at,O
Dongge,O
Cave,O
(,O
108,O
.,O
08,O
°,O
E,O
",",O
25,O
.,O
28,O
°,O
N,O
),O
61,O
",",O
Lianhua,O
Cave,O
(,O
109,O
.,O
53,O
°,O
E,O
",",O
29,O
.,O
48,O
°,O
N,O
),O
6,O
",",O
Sanbao,O
Cave,O
(,O
110,O
.,O
43,O
°,O
E,O
",",O
31,O
.,O
67,O
°,O
N,O
),O
7,O
",",O
Heshang,O
Cave,O
(,O
110,O
.,O
42,O
°,O
E,O
",",O
30,O
.,O
45,O
°,O
N,O
),O
9,O
",",O
and,O
Jiuxian,O
Cave,O
(,O
109,O
.,O
1,O
°,O
E,O
",",O
30,O
.,O
57,O
°,O
N,O
),O
5,O
",",O
released,O
on,O
a,O
website,O
from,O
the,O
World,O
Data,O
Center,O
for,O
Paleoclimatology,O
",",O
are,O
employed,O
to,O
compare,O
with,O
the,O
simulated,O
summer,O
precipitation,O
during,O
the,O
Holocene,O
.,O
These,O
records,O
were,O
derived,O
from,O
karst,O
caves,O
in,O
the,O
middle,O
reach,O
of,O
the,O
Yangtze,O
River,O
",",O
one,O
of,O
the,O
key,O
regions,O
of,O
EASM,O
where,O
the,O
Meiyu,O
rain,O
belt,O
appears,O
.,O
Previous,O
studies,O
have,O
argued,O
that,O
the,O
signal,O
of,O
the,O
oxygen,O
isotope,O
composition,O
(,O
δ18O,O
),O
in,O
speleothem,O
represents,O
precipitation,O
variations63646566,O
.,O
Caley,O
et,O
al,O
.,O
67,O
proposed,O
that,O
the,O
speleothem,O
δ18O,O
in,O
South,O
Asia,O
represents,O
a,O
change,O
in,O
hydrology,O
.,O
Their,O
results,O
suggested,O
that,O
the,O
calcite,O
δ18O,O
signal,O
of,O
South,O
Asian,O
speleothem,O
is,O
mainly,O
",",O
but,O
not,O
entirely,O
",",O
controlled,O
by,O
δ18O,O
in,O
precipitation,O
changes,O
.,O
Furthermore,O
",",O
δ18O,O
in,O
precipitation,O
over,O
South,O
Asia,O
is,O
correlated,O
to,O
the,O
northern,O
tropical,O
Indian,O
Ocean,O
which,O
is,O
one,O
of,O
the,O
important,O
moisture,O
sources,O
of,O
East,O
Asian,O
monsoon,O
precipitation,O
.,O
Moreover,O
",",O
the,O
East,O
Asian,O
speleothem,O
δ18O,O
may,O
relate,O
to,O
the,O
ratio,O
of,O
moisture,O
from,O
the,O
Bay,O
of,O
Bengal,O
(,O
BOB,O
),O
and,O
the,O
Northwest,O
Pacific68,O
.,O
In,O
a,O
modern,O
climate,O
",",O
precipitation,O
over,O
eastern,O
China,O
is,O
highly,O
correlated,O
with,O
moisture,O
over,O
the,O
BOB,O
and,O
the,O
Northwest,O
Pacific,O
;,O
that,O
is,O
",",O
a,O
change,O
of,O
δ18O,O
in,O
precipitation,O
is,O
the,O
most,O
important,O
factor,O
affecting,O
the,O
variation,O
of,O
the,O
speleothem,O
δ18O,O
records,O
in,O
eastern,O
China,O
.,O
Therefore,O
",",O
we,O
use,O
these,O
records,O
as,O
a,O
hydrologic,O
factor,O
and,O
compare,O
them,O
with,O
the,O
most,O
important,O
hydrological,O
factors,O
such,O
as,O
precipitation,O
.,O
Moreover,O
",",O
we,O
also,O
use,O
monthly,O
mean,O
air,O
temperature,O
and,O
SLP,O
of,O
the,O
NCEP,O
-,O
NCAR,O
reanalysis69,O
with,O
a,O
horizontal,O
resolution,O
of,O
2,O
.,O
5,O
°,O
and,O
the,O
monthly,O
Hadley,O
SST,O
with,O
1,O
°,O
in,O
both,O
longitude,O
and,O
latitude70,O
.,O
Statistical,O
Methods,O
Regression,O
and,O
correlation,O
analyses,O
are,O
used,O
to,O
investigate,O
the,O
relationship,O
between,O
two,O
variables,O
.,O
An,O
Empirical,O
Orthogonal,O
Function,O
(,O
EOF,O
),O
analysis,O
with,O
area,O
-,O
weighting,O
is,O
employed,O
to,O
examine,O
the,O
leading,O
mode,O
of,O
the,O
eddy,O
SLP,O
.,O
A,O
composite,O
analysis,O
between,O
the,O
higher,O
and,O
lower,O
indices,O
is,O
used,O
to,O
analyze,O
variations,O
in,O
a,O
variable,O
.,O
The,O
confidence,O
tests,O
in,O
this,O
study,O
are,O
all,O
based,O
on,O
a,O
Student,O
’,O
s,O
t,O
-,O
test,O
.,O
Results,O
Response,O
of,O
eddy,O
SLP,O
over,O
the,O
Asian,O
-,O
Pacific,O
sector,O
to,O
incoming,O
solar,O
insolation,O
Figure,O
2a,O
shows,O
the,O
regressed,O
model,O
summer,O
eddy,O
SLP,O
(),O
against,O
the,O
incoming,O
solar,O
radiation,O
along,O
30,O
°,O
N,O
",",O
in,O
which,O
the,O
is,O
defined,O
as,O
the,O
difference,O
of,O
SLP,O
from,O
the,O
global,O
zonal,O
mean,O
.,O
The,O
anomaly,O
pattern,O
associated,O
with,O
incoming,O
solar,O
radiation,O
presents,O
a,O
zonal,O
dipole,O
",",O
with,O
positive,O
anomalies,O
over,O
Europe,O
",",O
Asia,O
and,O
North,O
Africa,O
and,O
negative,O
anomalies,O
over,O
the,O
North,O
Pacific,O
Ocean,O
and,O
North,O
America,O
",",O
which,O
indicate,O
a,O
large,O
-,O
scale,O
out,O
-,O
of,O
-,O
phase,O
relationship,O
between,O
Eurasia,O
and,O
the,O
extratropical,O
North,O
Pacific,O
.,O
The,O
maximum,O
positive,O
center,O
is,O
8,O
Pa,O
/,O
W,O
·,O
m,O
−,O
2,O
",",O
larger,O
compared,O
with,O
the,O
absolute,O
value,O
of,O
the,O
negative,O
center,O
(−,O
5,O
Pa,O
/,O
W,O
·,O
m,O
−,O
2,O
).,O
This,O
result,O
indicates,O
that,O
when,O
the,O
over,O
the,O
East,O
Hemisphere,O
landmass,O
is,O
higher,O
(,O
lower,O
"),",O
it,O
is,O
lower,O
(,O
higher,O
),O
over,O
the,O
North,O
Pacific,O
Ocean,O
and,O
the,O
North,O
America,O
landmass,O
.,O
Furthermore,O
",",O
the,O
decrease,O
in,O
the,O
incoming,O
solar,O
radiation,O
is,O
associated,O
with,O
both,O
a,O
decrease,O
of,O
the,O
over,O
Eurasia,O
and,O
North,O
Africa,O
and,O
an,O
increase,O
over,O
the,O
North,O
Pacific,O
and,O
North,O
America,O
",",O
which,O
corresponds,O
to,O
a,O
strong,O
thermal,O
contrast,O
between,O
the,O
Eurasian,O
-,O
North,O
African,O
region,O
and,O
the,O
North,O
Pacific,O
-,O
North,O
American,O
region,O
.,O
In,O
fact,O
",",O
the,O
out,O
-,O
of,O
-,O
phase,O
relationship,O
presented,O
in,O
Fig,O
.,O
2a,O
is,O
also,O
a,O
major,O
feature,O
of,O
variability,O
.,O
The,O
EOF,O
analysis,O
on,O
the,O
summer,O
eddy,O
SLP,O
shows,O
that,O
the,O
leading,O
EOF,O
mode,O
(,O
Fig,O
.,O
2b,O
),O
of,O
the,O
eddy,O
SLP,O
",",O
accounting,O
for,O
98,O
.,O
2,O
%,O
of,O
the,O
total,O
variance,O
",",O
depicts,O
a,O
zonal,O
out,O
-,O
of,O
-,O
phase,O
structure,O
with,O
negative,O
anomalies,O
over,O
the,O
Eurasian,O
and,O
North,O
African,O
landmass,O
and,O
positive,O
anomalies,O
over,O
the,O
North,O
Pacific,O
",",O
similar,O
to,O
those,O
shown,O
in,O
Fig,O
.,O
2a,O
.,O
The,O
spatial,O
correlation,O
coefficient,O
between,O
the,O
regressed,O
field,O
(,O
in,O
Fig,O
.,O
2a,O
),O
and,O
the,O
leading,O
EOF,O
mode,O
(,O
Fig,O
.,O
2b,O
),O
is,O
0,O
.,O
99,O
(,O
significant,O
at,O
the,O
99,O
.,O
9,O
%,O
confidence,O
level,O
).,O
As,O
shown,O
in,O
Fig,O
.,O
2c,O
",",O
a,O
decreasing,O
trend,O
of,O
the,O
incoming,O
solar,O
radiation,O
is,O
corresponded,O
to,O
an,O
increasing,O
trend,O
in,O
the,O
PC1,O
.,O
This,O
result,O
indicates,O
that,O
the,O
summer,O
over,O
Eurasia,O
/,O
the,O
North,O
Pacific,O
and,O
North,O
America,O
decreases,O
/,O
increases,O
in,O
the,O
Holocene,O
",",O
which,O
may,O
lead,O
to,O
an,O
anomalous,O
zonal,O
contrast,O
of,O
the,O
between,O
the,O
Eurasian,O
landmass,O
and,O
the,O
North,O
Pacific,O
Ocean,O
.,O
Moreover,O
",",O
the,O
anomalous,O
pattern,O
of,O
the,O
during,O
the,O
Holocene,O
is,O
closely,O
associated,O
with,O
the,O
orbital,O
forcing,O
.,O
To,O
examine,O
the,O
reliability,O
of,O
the,O
simulation,O
",",O
referring,O
to,O
some,O
key,O
regions,O
of,O
the,O
anomalous,O
centers,O
in,O
Fig,O
.,O
2b,O
",",O
we,O
select,O
reconstructions,O
of,O
the,O
Guliya,O
record,O
and,O
the,O
northern,O
California,O
SST,O
at,O
the,O
ODP,O
1019,O
.,O
The,O
reconstructed,O
northern,O
California,O
SST,O
displays,O
a,O
low,O
frequent,O
variation,O
",",O
with,O
a,O
decreasing,O
trend,O
from,O
10,O
ka,O
to,O
6,O
.,O
4,O
ka,O
BP,O
and,O
an,O
increasing,O
trend,O
during,O
the,O
period,O
from,O
6,O
.,O
4,O
ka,O
BP,O
to,O
the,O
present,O
(,O
Fig,O
.,O
3a,O
).,O
A,O
high,O
frequent,O
variation,O
on,O
the,O
century,O
-,O
to,O
-,O
millennium,O
scales,O
is,O
superposed,O
over,O
this,O
low,O
frequent,O
variation,O
.,O
The,O
simulated,O
June,O
–,O
July,O
averaged,O
Northeast,O
Pacific,O
SST,O
also,O
indicates,O
a,O
decrease,O
during,O
the,O
epoch,O
10,O
–,O
5,O
ka,O
BP,O
and,O
then,O
an,O
increase,O
from,O
5,O
ka,O
BP,O
to,O
the,O
present,O
.,O
The,O
spread,O
of,O
the,O
ensemble,O
mean,O
June,O
–,O
July,O
Northeast,O
Pacific,O
SST,O
varies,O
within,O
small,O
fluctuation,O
",",O
approximately,O
from,O
0,O
.,O
05,O
in,O
the,O
early,O
Holocene,O
to,O
0,O
.,O
02,O
°,O
C,O
in,O
the,O
middle,O
and,O
late,O
Holocene,O
",",O
which,O
indicates,O
a,O
small,O
uncertainty,O
in,O
the,O
simulation,O
.,O
It,O
is,O
evident,O
that,O
the,O
simulated,O
and,O
reconstructed,O
SSTs,O
over,O
the,O
Northeast,O
Pacific,O
show,O
similar,O
lower,O
frequency,O
variations,O
during,O
the,O
Holocene,O
.,O
Figure,O
3b,O
displays,O
the,O
curves,O
of,O
the,O
simulated,O
summer,O
Guliya,O
SLAT,O
and,O
the,O
Guliya,O
δ18O,O
record,O
during,O
the,O
past,O
10,O
ka,O
.,O
The,O
Guliya,O
δ18O,O
record,O
",",O
indicating,O
a,O
summer,O
temperature,O
over,O
the,O
Tibetan,O
Plateau,O
",",O
presents,O
a,O
decrease,O
during,O
the,O
period,O
of,O
10,O
–,O
4,O
.,O
5,O
ka,O
BP,O
and,O
an,O
increase,O
from,O
4,O
.,O
5,O
ka,O
BP,O
to,O
the,O
present,O
.,O
The,O
simulated,O
summer,O
temperature,O
over,O
the,O
Guliya,O
region,O
also,O
shows,O
a,O
similar,O
lower,O
-,O
frequency,O
variation,O
",",O
with,O
a,O
decrease,O
during,O
10,O
–,O
4,O
.,O
5,O
ka,O
BP,O
and,O
an,O
increase,O
from,O
4,O
.,O
5,O
ka,O
BP,O
to,O
the,O
present,O
.,O
Uncertainties,O
in,O
the,O
ensemble,O
simulations,O
of,O
the,O
Guliya,O
temperature,O
show,O
little,O
spread,O
",",O
which,O
thereby,O
supports,O
a,O
more,O
stable,O
simulation,O
of,O
the,O
UVic,O
Model,O
.,O
Thus,O
",",O
the,O
simulated,O
Guliya,O
SLAT,O
reproduces,O
well,O
the,O
lower,O
-,O
frequency,O
variation,O
of,O
the,O
Guliya,O
δ18O,O
record,O
(,O
namely,O
",",O
the,O
summer,O
temperature,O
variation,O
over,O
the,O
Tibet,O
Plateau,O
).,O
Figure,O
S1,O
shows,O
the,O
simulated,O
and,O
reconstructed,O
July,O
temperatures,O
over,O
the,O
mid,O
-,O
western,O
part,O
of,O
the,O
United,O
States,O
and,O
Western,O
Europe,O
.,O
The,O
simulated,O
July,O
SLAT,O
over,O
the,O
mid,O
-,O
western,O
part,O
of,O
the,O
United,O
States,O
presents,O
a,O
declining,O
trend,O
during,O
the,O
Holocene,O
",",O
which,O
also,O
appears,O
in,O
the,O
reconstructed,O
time,O
series,O
(,O
Fig,O
.,O
S1a,O
).,O
Meanwhile,O
",",O
the,O
July,O
temperature,O
variation,O
over,O
the,O
mid,O
-,O
western,O
part,O
of,O
the,O
United,O
States,O
is,O
similar,O
to,O
that,O
of,O
the,O
North,O
Pacific,O
center,O
of,O
the,O
paleo,O
-,O
APO,O
pattern,O
.,O
Moreover,O
",",O
the,O
reconstructed,O
July,O
temperature,O
over,O
Western,O
Europe,O
also,O
supports,O
the,O
model,O
simulation,O
on,O
the,O
long,O
-,O
time,O
scales,O
(,O
Fig,O
.,O
S1b,O
).,O
The,O
consistency,O
suggests,O
the,O
reliability,O
of,O
the,O
simulated,O
results,O
over,O
Eurasia,O
and,O
the,O
North,O
Pacific,O
.,O
Previous,O
studies,O
have,O
shown,O
that,O
differences,O
in,O
SLP,O
between,O
Asia,O
and,O
the,O
North,O
Pacific,O
may,O
be,O
used,O
to,O
indicate,O
the,O
contrasts,O
in,O
surface,O
air,O
temperature,O
between,O
these,O
two,O
regions15161718,O
.,O
In,O
fact,O
",",O
the,O
anomalous,O
patterns,O
shown,O
in,O
both,O
Fig,O
.,O
2a,O
",",O
b,O
are,O
similar,O
to,O
the,O
eddy,O
SLP,O
anomalies,O
associated,O
with,O
APO,O
in,O
the,O
present,O
-,O
day,O
climate,O
(,O
during,O
1948,O
–,O
2014,O
"),",O
in,O
which,O
the,O
APO,O
is,O
a,O
leading,O
mode,O
of,O
the,O
tropospheric,O
eddy,O
temperature,O
and,O
its,O
index,O
is,O
defined,O
as,O
the,O
reference19,O
.,O
In,O
the,O
present,O
day,O
(,O
Fig,O
.,O
4,O
"),",O
negative,O
/,O
positive,O
anomalies,O
of,O
SLP,O
appear,O
over,O
North,O
Africa,O
and,O
Asia,O
/,O
the,O
North,O
Pacific,O
and,O
North,O
America,O
",",O
which,O
indicate,O
weaker,O
than,O
normal,O
Asian,O
landmass,O
low,O
pressure,O
and,O
stronger,O
than,O
normal,O
North,O
Pacific,O
high,O
pressure,O
.,O
Therefore,O
",",O
the,O
anomalous,O
pattern,O
of,O
SLP,O
in,O
the,O
UVic,O
Model,O
(,O
shown,O
in,O
Fig,O
.,O
2a,O
",",O
b,O
),O
is,O
called,O
the,O
paleo,O
-,O
APO,O
pattern,O
.,O
Referring,O
to,O
the,O
positions,O
of,O
positive,O
and,O
negative,O
SLP,O
anomalies,O
in,O
Fig,O
.,O
2a,O
",",O
b,O
",",O
we,O
define,O
the,O
paleo,O
-,O
APO,O
index,O
as,O
a,O
difference,O
in,O
the,O
simulated,O
normalized,O
between,O
the,O
North,O
Pacific,O
(,O
150,O
°,O
E,O
–,O
110,O
°,O
W,O
",",O
15,O
°–,O
60,O
°,O
N,O
),O
and,O
the,O
Eurasian,O
landmass,O
(,O
10,O
°–,O
110,O
°,O
E,O
",",O
15,O
°–,O
60,O
°,O
N,O
).,O
The,O
summer,O
paleo,O
-,O
APO,O
index,O
shows,O
an,O
increasing,O
trend,O
",",O
similar,O
to,O
the,O
variability,O
of,O
PC1,O
(,O
Fig,O
.,O
5a,O
).,O
This,O
result,O
suggests,O
that,O
the,O
paleo,O
-,O
APO,O
index,O
may,O
reasonably,O
indicate,O
a,O
variation,O
in,O
the,O
leading,O
mode,O
of,O
the,O
eddy,O
SLP,O
.,O
Meanwhile,O
",",O
the,O
summer,O
solar,O
radiation,O
insolation,O
along,O
30,O
°,O
N,O
(,O
Fig,O
.,O
1b,O
),O
changes,O
from,O
the,O
top,O
to,O
the,O
valley,O
.,O
Thus,O
",",O
when,O
the,O
NH,O
summer,O
incoming,O
solar,O
radiation,O
decreases,O
during,O
the,O
Holocene,O
",",O
the,O
surface,O
thermal,O
contrast,O
between,O
Eurasia,O
and,O
the,O
North,O
Pacific,O
increases,O
.,O
Figure,O
5b,O
shows,O
the,O
climatological,O
anomalies,O
of,O
the,O
over,O
Eurasia,O
and,O
the,O
North,O
Pacific,O
during,O
the,O
summer,O
.,O
The,O
Eurasian,O
varies,O
from,O
−,O
0,O
.,O
5,O
hPa,O
to,O
0,O
.,O
75,O
hPa,O
and,O
the,O
North,O
Pacific,O
changes,O
from,O
0,O
.,O
6,O
hPa,O
to,O
−,O
1,O
hPa,O
",",O
which,O
indicates,O
a,O
larger,O
varying,O
range,O
over,O
Eurasia,O
(,O
1,O
.,O
6,O
hPa,O
),O
than,O
over,O
the,O
North,O
Pacific,O
(,O
1,O
.,O
25,O
hPa,O
),O
and,O
also,O
suggests,O
a,O
larger,O
response,O
of,O
the,O
eddy,O
SLP,O
over,O
Eurasia,O
compared,O
with,O
that,O
over,O
the,O
North,O
Pacific,O
.,O
Meanwhile,O
",",O
the,O
shows,O
a,O
decreasing,O
trend,O
over,O
Eurasia,O
and,O
an,O
increasing,O
trend,O
over,O
the,O
North,O
Pacific,O
during,O
the,O
Holocene,O
",",O
which,O
also,O
leads,O
to,O
an,O
increased,O
trend,O
of,O
the,O
paleo,O
-,O
APO,O
index,O
during,O
the,O
Holocene,O
.,O
Compared,O
to,O
the,O
North,O
Pacific,O
",",O
therefore,O
",",O
the,O
land,O
response,O
to,O
the,O
orbital,O
forcing,O
possibly,O
plays,O
a,O
more,O
important,O
role,O
in,O
modulating,O
the,O
zonal,O
thermal,O
contrast,O
between,O
Eurasia,O
and,O
the,O
North,O
Pacific,O
.,O
Figure,O
6a,O
depicts,O
the,O
composite,O
summer,O
model,O
SLP,O
in,O
the,O
higher,O
and,O
lower,O
paleo,O
-,O
APO,O
indices,O
.,O
The,O
North,O
Pacific,O
high,O
pressure,O
has,O
the,O
central,O
values,O
of,O
1020,O
hPa,O
in,O
the,O
higher,O
and,O
lower,O
paleo,O
-,O
APO,O
years,O
",",O
but,O
exhibits,O
a,O
larger,O
domain,O
in,O
the,O
higher,O
paleo,O
-,O
APO,O
years,O
than,O
in,O
the,O
lower,O
paleo,O
-,O
APO,O
years,O
",",O
which,O
suggests,O
a,O
stronger,O
North,O
Pacific,O
high,O
pressure,O
in,O
the,O
higher,O
paleo,O
-,O
APO,O
phase,O
.,O
The,O
western,O
boundary,O
of,O
the,O
North,O
Pacific,O
high,O
pressure,O
in,O
the,O
higher,O
paleo,O
-,O
APO,O
phase,O
moves,O
westward,O
along,O
115,O
°,O
E,O
compared,O
with,O
the,O
lower,O
paleo,O
-,O
APO,O
phase,O
.,O
That,O
is,O
",",O
the,O
increasing,O
(,O
decreasing,O
),O
trend,O
of,O
the,O
over,O
the,O
North,O
Pacific,O
(,O
Eurasia,O
),O
implies,O
a,O
stronger,O
and,O
more,O
westward,O
high,O
pressure,O
over,O
the,O
North,O
Pacific,O
.,O
The,O
analyses,O
presented,O
here,O
show,O
that,O
the,O
response,O
of,O
the,O
eddy,O
SLP,O
to,O
orbital,O
forcing,O
displays,O
an,O
APO,O
-,O
like,O
pattern,O
",",O
with,O
positive,O
and,O
negative,O
anomalies,O
of,O
the,O
in,O
the,O
North,O
Pacific,O
and,O
Eurasia,O
",",O
respectively,O
.,O
Corresponding,O
to,O
the,O
NH,O
’,O
s,O
summer,O
reduced,O
incoming,O
solar,O
radiation,O
during,O
the,O
Holocene,O
",",O
the,O
paleo,O
-,O
APO,O
index,O
shows,O
an,O
increasing,O
trend,O
.,O
The,O
response,O
of,O
the,O
Eurasian,O
landmass,O
plays,O
a,O
more,O
important,O
role,O
due,O
to,O
a,O
(,O
an,O
),O
decreasing,O
(,O
increasing,O
),O
trend,O
of,O
the,O
over,O
Eurasia,O
(,O
the,O
North,O
Pacific,O
).,O
Meanwhile,O
",",O
the,O
increasing,O
trend,O
of,O
the,O
over,O
the,O
North,O
Pacific,O
indicates,O
a,O
stronger,O
and,O
more,O
westward,O
high,O
pressure,O
over,O
the,O
North,O
Pacific,O
.,O
Summer,O
hydrology,O
anomalies,O
over,O
eastern,O
China,O
associated,O
with,O
the,O
paleo,O
-,O
APO,O
at,O
the,O
precession,O
Many,O
studies,O
on,O
the,O
present,O
-,O
day,O
climate,O
have,O
shown,O
that,O
the,O
thermal,O
contrasts,O
between,O
the,O
East,O
Asian,O
landmass,O
and,O
its,O
adjacent,O
oceans,O
exerts,O
a,O
strong,O
influence,O
on,O
the,O
hydrological,O
climate,O
in,O
the,O
EASM,O
region,O
and,O
that,O
a,O
strong,O
and,O
westward,O
high,O
pressure,O
over,O
the,O
North,O
Pacific,O
could,O
strengthen,O
the,O
northward,O
transport,O
of,O
water,O
vapor,O
over,O
the,O
EASM,O
region,O
",",O
with,O
more,O
rainfall,O
over,O
North,O
China,O
and,O
less,O
rainfall,O
over,O
the,O
Yangtze,O
River,O
valleys315197172,O
.,O
When,O
the,O
paleo,O
-,O
APO,O
index,O
is,O
high,O
",",O
the,O
domain,O
(,O
central,O
intensity,O
),O
of,O
the,O
North,O
Pacific,O
high,O
pressure,O
is,O
larger,O
(,O
stronger,O
),O
compared,O
with,O
that,O
in,O
the,O
low,O
paleo,O
-,O
APO,O
index,O
",",O
and,O
the,O
western,O
part,O
of,O
the,O
North,O
Pacific,O
high,O
pressure,O
moves,O
westward,O
(,O
Fig,O
.,O
6a,O
).,O
This,O
variation,O
in,O
the,O
North,O
Pacific,O
high,O
pressure,O
favors,O
transport,O
of,O
water,O
moisture,O
toward,O
northern,O
China73,O
.,O
As,O
a,O
result,O
",",O
precipitation,O
is,O
often,O
less,O
over,O
the,O
Yangtze,O
River,O
.,O
At,O
the,O
precession,O
",",O
the,O
variability,O
of,O
thermal,O
contrasts,O
indicated,O
by,O
the,O
paleo,O
-,O
APO,O
index,O
is,O
also,O
associated,O
with,O
precipitation,O
over,O
eastern,O
China,O
.,O
Figure,O
6b,O
shows,O
the,O
summer,O
rainfall,O
anomalies,O
over,O
eastern,O
China,O
that,O
are,O
associated,O
with,O
the,O
paleo,O
-,O
APO,O
index,O
.,O
In,O
this,O
figure,O
",",O
the,O
rainfall,O
anomalies,O
present,O
a,O
meridional,O
“,O
positive,O
-,O
negative,O
-,O
positive,O
”,O
anomalous,O
pattern,O
",",O
with,O
negative,O
anomalies,O
along,O
the,O
Yangtze,O
River,O
and,O
over,O
Southwest,O
China,O
and,O
positive,O
rainfall,O
anomalies,O
over,O
North,O
China,O
.,O
This,O
anomalous,O
pattern,O
is,O
also,O
a,O
major,O
feature,O
of,O
the,O
leading,O
EOF,O
mode,O
of,O
summer,O
rainfall,O
over,O
eastern,O
China,O
during,O
the,O
Holocene,O
(,O
not,O
shown,O
).,O
Recent,O
studies,O
have,O
suggested,O
that,O
the,O
speleothem,O
δ18O,O
records,O
in,O
eastern,O
China,O
represent,O
the,O
changes,O
in,O
the,O
hydrological,O
climate,O
and,O
are,O
mainly,O
a,O
result,O
of,O
the,O
δ18O,O
changes,O
in,O
precipitation,O
.,O
Hence,O
",",O
we,O
compare,O
the,O
simulated,O
rainfall,O
with,O
five,O
speleothem,O
δ18O,O
records,O
over,O
Southwest,O
China,O
and,O
the,O
middle,O
valley,O
of,O
the,O
Yangtze,O
River,O
(,O
100,O
°–,O
112,O
°,O
E,O
",",O
22,O
°–,O
32,O
°,O
N,O
"),",O
one,O
key,O
region,O
of,O
the,O
EASM,O
precipitation,O
and,O
an,O
important,O
path,O
of,O
moisture,O
transport,O
from,O
the,O
Indian,O
Ocean,O
(,O
Fig,O
.,O
7,O
).,O
The,O
speleothem,O
δ18O,O
record,O
at,O
Dongge,O
Cave,O
(,O
Fig,O
.,O
7a,O
),O
has,O
generally,O
shown,O
a,O
decreasing,O
trend,O
before,O
a,O
slight,O
increase,O
trend,O
since,O
3,O
.,O
5,O
ka,O
BP,O
",",O
which,O
indicates,O
the,O
declining,O
precipitation,O
and,O
the,O
obvious,O
decadal,O
-,O
and,O
century,O
-,O
scale,O
fluctuations,O
.,O
Similarly,O
",",O
the,O
speleothem,O
δ18O,O
records,O
at,O
Lianhua,O
Cave,O
(,O
Fig,O
.,O
7b,O
"),",O
Sanbao,O
Cave,O
(,O
Fig,O
.,O
7c,O
"),",O
Heshang,O
Cave,O
(,O
Fig,O
.,O
7d,O
"),",O
and,O
Jiuxian,O
Cave,O
(,O
Fig,O
.,O
7e,O
),O
also,O
exhibit,O
a,O
downward,O
trend,O
during,O
the,O
Holocene,O
.,O
The,O
simulated,O
summer,O
precipitation,O
similarly,O
presents,O
a,O
decreasing,O
trend,O
before,O
4,O
ka,O
and,O
an,O
increasing,O
trend,O
afterwards,O
",",O
indicating,O
wetter,O
conditions,O
in,O
the,O
lower,O
paleo,O
-,O
APO,O
years,O
and,O
drier,O
conditions,O
in,O
the,O
higher,O
paleo,O
-,O
APO,O
years,O
",",O
similar,O
to,O
the,O
variation,O
in,O
the,O
speleothem,O
δ18O,O
records,O
.,O
This,O
result,O
further,O
supports,O
the,O
reliability,O
of,O
the,O
simulation,O
.,O
Atmospheric,O
circulation,O
anomalies,O
associated,O
with,O
the,O
paleo,O
-,O
APO,O
evolution,O
In,O
this,O
analysis,O
",",O
we,O
use,O
transient,O
simulation,O
to,O
examine,O
the,O
evolution,O
of,O
the,O
paleo,O
-,O
APO,O
and,O
associated,O
atmospheric,O
circulation,O
and,O
precipitation,O
.,O
It,O
is,O
seen,O
in,O
Fig,O
.,O
5a,O
that,O
the,O
paleo,O
-,O
APO,O
index,O
exhibits,O
an,O
increasing,O
trend,O
in,O
approximately,O
half,O
of,O
the,O
precession,O
period,O
.,O
According,O
to,O
the,O
paleo,O
-,O
APO,O
index,O
",",O
we,O
chose,O
9,O
.,O
0,O
",",O
6,O
.,O
5,O
",",O
4,O
.,O
8,O
",",O
2,O
.,O
5,O
",",O
and,O
0,O
ka,O
BP,O
to,O
analyze,O
the,O
evolution,O
of,O
atmospheric,O
circulation,O
.,O
Figure,O
8,O
shows,O
the,O
summer,O
eddy,O
SLP,O
anomalies,O
(,O
from,O
the,O
climatological,O
mean,O
),O
at,O
9,O
.,O
0,O
",",O
6,O
.,O
5,O
",",O
4,O
.,O
8,O
",",O
2,O
.,O
5,O
and,O
0,O
ka,O
BP,O
.,O
At,O
9,O
ka,O
BP,O
(,O
Fig,O
.,O
8a,O
"),",O
there,O
are,O
negative,O
SLP,O
anomalies,O
over,O
the,O
North,O
Pacific,O
",",O
with,O
a,O
maximum,O
negative,O
value,O
of,O
−,O
0,O
.,O
8,O
hPa,O
",",O
and,O
there,O
are,O
positive,O
SLP,O
anomalies,O
over,O
Eurasia,O
",",O
with,O
a,O
maximum,O
value,O
of,O
1,O
.,O
5,O
hPa,O
.,O
These,O
features,O
suggest,O
a,O
stronger,O
negative,O
phase,O
of,O
the,O
paleo,O
-,O
APO,O
.,O
At,O
6,O
.,O
5,O
ka,O
BP,O
(,O
Fig,O
.,O
8b,O
"),",O
the,O
eddy,O
SLP,O
anomalies,O
depict,O
a,O
similar,O
pattern,O
to,O
that,O
at,O
9,O
ka,O
BP,O
",",O
with,O
relatively,O
lower,O
SLP,O
anomalies,O
over,O
both,O
Eurasia,O
and,O
the,O
North,O
Pacific,O
",",O
indicating,O
a,O
moderate,O
negative,O
phase,O
of,O
the,O
paleo,O
-,O
APO,O
.,O
At,O
4,O
.,O
8,O
ka,O
BP,O
(,O
Fig,O
.,O
8c,O
"),",O
small,O
positive,O
eddy,O
anomalies,O
move,O
from,O
Eurasia,O
to,O
West,O
Europe,O
",",O
North,O
Africa,O
",",O
North,O
America,O
",",O
and,O
the,O
tropical,O
eastern,O
Pacific,O
",",O
whereas,O
the,O
other,O
regions,O
are,O
covered,O
by,O
small,O
negative,O
anomalies,O
.,O
This,O
distribution,O
of,O
the,O
eddy,O
SLP,O
anomalies,O
suggests,O
a,O
very,O
weak,O
paleo,O
-,O
APO,O
phase,O
at,O
4,O
.,O
8,O
ka,O
BP,O
.,O
The,O
eddy,O
SLP,O
anomalies,O
indicate,O
a,O
moderate,O
positive,O
phase,O
of,O
the,O
paleo,O
-,O
APO,O
at,O
2,O
.,O
5,O
ka,O
BP,O
(,O
Fig,O
.,O
8d,O
"),",O
which,O
is,O
opposite,O
to,O
the,O
value,O
at,O
6,O
.,O
5,O
ka,O
BP,O
.,O
At,O
the,O
present,O
day,O
(,O
Fig,O
.,O
8e,O
"),",O
the,O
paleo,O
-,O
APO,O
further,O
intensifies,O
",",O
with,O
larger,O
anomalies,O
over,O
the,O
North,O
Pacific,O
-,O
North,O
Atlantic,O
region,O
and,O
Eurasia,O
.,O
Thus,O
",",O
the,O
paleo,O
-,O
APO,O
changes,O
from,O
a,O
negative,O
phase,O
to,O
a,O
positive,O
one,O
during,O
the,O
Holocene,O
.,O
Figure,O
9,O
shows,O
the,O
evolution,O
of,O
the,O
eddy,O
SLP,O
anomalies,O
along,O
30,O
°,O
N,O
during,O
the,O
Holocene,O
.,O
There,O
is,O
an,O
anomalous,O
SLP,O
center,O
at,O
the,O
longitudes,O
30,O
°,O
W,O
–,O
120,O
°,O
E,O
during,O
10,O
–,O
5,O
.,O
5,O
ka,O
",",O
with,O
a,O
maximum,O
positive,O
value,O
of,O
1,O
hPa,O
along,O
50,O
°,O
E,O
at,O
9,O
ka,O
BP,O
.,O
As,O
time,O
goes,O
on,O
",",O
the,O
positive,O
anomalies,O
of,O
the,O
eddy,O
SLP,O
decrease,O
and,O
turn,O
to,O
the,O
negative,O
ones,O
after,O
5,O
.,O
5,O
ka,O
BP,O
.,O
The,O
strongest,O
negative,O
anomalies,O
appear,O
along,O
40,O
°,O
E,O
at,O
the,O
present,O
day,O
.,O
Over,O
the,O
North,O
African,O
and,O
Asian,O
landmasses,O
along,O
30,O
°,O
N,O
",",O
the,O
anomalous,O
SLP,O
center,O
moves,O
slightly,O
westward,O
during,O
the,O
Holocene,O
.,O
During,O
the,O
period,O
10,O
–,O
5,O
ka,O
",",O
negative,O
SLP,O
anomalies,O
appears,O
over,O
the,O
longitudes,O
120,O
°,O
E,O
–,O
30,O
°,O
W,O
",",O
with,O
a,O
center,O
of,O
−,O
0,O
.,O
6,O
hPa,O
along,O
140,O
°,O
W,O
–,O
180,O
°,O
and,O
a,O
relatively,O
weak,O
center,O
along,O
60,O
°,O
W,O
.,O
Similarly,O
",",O
the,O
negative,O
SLP,O
anomalies,O
decrease,O
",",O
turn,O
to,O
positive,O
values,O
",",O
and,O
reach,O
the,O
present,O
-,O
day,O
largest,O
values,O
.,O
The,O
negative,O
center,O
at,O
150,O
°,O
W,O
at,O
10,O
ka,O
BP,O
turns,O
to,O
a,O
positive,O
one,O
at,O
170,O
°,O
E,O
at,O
the,O
present,O
day,O
",",O
which,O
suggests,O
a,O
westward,O
shift,O
of,O
SLP,O
anomalies,O
over,O
the,O
North,O
Pacific,O
.,O
However,O
",",O
no,O
obvious,O
shift,O
in,O
SLP,O
anomalies,O
is,O
seen,O
over,O
the,O
North,O
Atlantic,O
during,O
the,O
Holocene,O
.,O
We,O
also,O
display,O
the,O
time,O
-,O
latitude,O
cross,O
section,O
of,O
summer,O
mean,O
precipitation,O
anomalies,O
(,O
from,O
the,O
climatological,O
mean,O
),O
over,O
eastern,O
China,O
along,O
110,O
°,O
E,O
(,O
Fig,O
.,O
10,O
).,O
At,O
10,O
ka,O
BP,O
",",O
there,O
is,O
a,O
meridional,O
dipole,O
pattern,O
of,O
rainfall,O
anomalies,O
",",O
with,O
positive,O
anomalies,O
south,O
of,O
36,O
°,O
N,O
and,O
negative,O
anomalies,O
at,O
higher,O
latitudes,O
.,O
Afterwards,O
",",O
the,O
positive,O
and,O
negative,O
anomalies,O
gradually,O
weaken,O
and,O
turn,O
to,O
negative,O
and,O
positive,O
values,O
",",O
respectively,O
",",O
in,O
which,O
negative,O
rainfall,O
anomalies,O
from,O
southern,O
China,O
show,O
a,O
northward,O
propagation,O
to,O
36,O
°,O
N,O
.,O
An,O
opposite,O
dipole,O
appears,O
between,O
5,O
.,O
5,O
ka,O
BP,O
and,O
2,O
.,O
5,O
ka,O
BP,O
.,O
After,O
that,O
",",O
a,O
triple,O
pattern,O
appears,O
over,O
eastern,O
China,O
",",O
with,O
positive,O
precipitation,O
anomalies,O
south,O
of,O
30,O
°,O
N,O
and,O
north,O
of,O
36,O
°,O
N,O
and,O
negative,O
precipitation,O
anomalies,O
near,O
the,O
Yangtze,O
River,O
.,O
These,O
results,O
indicate,O
that,O
when,O
the,O
paleo,O
-,O
APO,O
pattern,O
moves,O
from,O
a,O
negative,O
phase,O
to,O
a,O
positive,O
one,O
during,O
the,O
Holocene,O
",",O
the,O
rainfall,O
belt,O
exhibits,O
a,O
northward,O
propagation,O
from,O
southern,O
China,O
.,O
Summary,O
and,O
Discussion,O
We,O
employed,O
the,O
intermediate,O
-,O
complexity,O
UVic,O
Model,O
to,O
investigate,O
the,O
response,O
of,O
summer,O
large,O
-,O
scale,O
circulation,O
over,O
Eurasia,O
and,O
the,O
North,O
Pacific,O
and,O
the,O
associated,O
precipitation,O
anomalies,O
over,O
eastern,O
China,O
to,O
the,O
transient,O
orbit,O
forcing,O
during,O
the,O
Holocene,O
.,O
A,O
decrease,O
in,O
the,O
NH,O
summer,O
incoming,O
solar,O
radiation,O
is,O
corresponded,O
to,O
an,O
out,O
-,O
of,O
-,O
phase,O
relationship,O
of,O
the,O
summer,O
eddy,O
SLP,O
over,O
the,O
Asian,O
-,O
Pacific,O
region,O
",",O
with,O
positive,O
anomalies,O
over,O
the,O
Asia,O
-,O
Europe,O
-,O
African,O
continent,O
and,O
negative,O
anomalies,O
over,O
the,O
North,O
Pacific,O
and,O
North,O
America,O
",",O
which,O
reflect,O
the,O
leading,O
mode,O
of,O
the,O
eddy,O
SLP,O
during,O
the,O
Holocene,O
.,O
This,O
anomalous,O
pattern,O
is,O
similar,O
to,O
that,O
associated,O
with,O
the,O
present,O
-,O
day,O
APO,O
",",O
called,O
the,O
paleo,O
-,O
APO,O
.,O
The,O
paleo,O
-,O
APO,O
index,O
exhibits,O
an,O
upward,O
trend,O
during,O
the,O
Holocene,O
",",O
which,O
indicates,O
an,O
increase,O
in,O
the,O
zonal,O
thermal,O
contrast,O
between,O
the,O
North,O
Pacific,O
and,O
Eurasia,O
.,O
Such,O
a,O
trend,O
is,O
possibly,O
due,O
to,O
a,O
decrease,O
in,O
the,O
over,O
the,O
Eurasian,O
landmass,O
and,O
an,O
increase,O
in,O
the,O
over,O
the,O
North,O
Pacific,O
",",O
and,O
there,O
is,O
a,O
larger,O
varying,O
range,O
over,O
Eurasia,O
than,O
over,O
the,O
North,O
Pacific,O
.,O
This,O
result,O
suggests,O
that,O
the,O
response,O
of,O
atmospheric,O
circulation,O
over,O
the,O
Eurasian,O
landmass,O
to,O
orbital,O
forcing,O
is,O
larger,O
than,O
that,O
over,O
the,O
North,O
Pacific,O
",",O
possibly,O
playing,O
a,O
more,O
important,O
role,O
in,O
modulating,O
the,O
zonal,O
thermal,O
contrast,O
between,O
Eurasia,O
and,O
the,O
North,O
Pacific,O
.,O
A,O
higher,O
paleo,O
-,O
APO,O
index,O
during,O
the,O
Holocene,O
is,O
corresponded,O
to,O
a,O
stronger,O
high,O
-,O
pressure,O
system,O
over,O
the,O
North,O
Pacific,O
that,O
moves,O
more,O
westward,O
",",O
which,O
favors,O
the,O
northward,O
transport,O
of,O
water,O
vapor,O
toward,O
northern,O
China,O
.,O
Accordingly,O
",",O
there,O
is,O
more,O
precipitation,O
over,O
northern,O
China,O
and,O
less,O
rainfall,O
over,O
the,O
middle,O
and,O
lower,O
reaches,O
of,O
the,O
Yangtze,O
River,O
during,O
the,O
summer,O
.,O
This,O
decrease,O
in,O
the,O
simulated,O
precipitation,O
over,O
the,O
middle,O
and,O
lower,O
reaches,O
of,O
the,O
Yangtze,O
River,O
is,O
supported,O
by,O
the,O
local,O
speleothem,O
proxy,O
data,O
during,O
the,O
Holocene,O
.,O
The,O
paleo,O
-,O
APO,O
experiences,O
a,O
half,O
-,O
precession,O
cycle,O
during,O
the,O
Holocene,O
.,O
During,O
the,O
early,O
Holocene,O
",",O
the,O
paleo,O
-,O
APO,O
pattern,O
presents,O
a,O
negative,O
phase,O
with,O
positive,O
SLP,O
anomalies,O
over,O
the,O
Eurasian,O
landmass,O
and,O
negative,O
SLP,O
anomalies,O
over,O
the,O
North,O
Pacific,O
.,O
These,O
positive,O
(,O
negative,O
),O
anomalies,O
over,O
the,O
Eurasian,O
landmass,O
(,O
North,O
Pacific,O
and,O
North,O
Atlantic,O
),O
decrease,O
and,O
turn,O
into,O
negative,O
(,O
positive,O
),O
anomalies,O
",",O
which,O
indicate,O
a,O
change,O
in,O
the,O
paleo,O
-,O
APO,O
pattern,O
from,O
a,O
negative,O
phase,O
to,O
a,O
positive,O
one,O
.,O
The,O
negative,O
centers,O
over,O
the,O
North,O
Africa,O
-,O
Asian,O
region,O
and,O
the,O
North,O
Pacific,O
move,O
westward,O
.,O
Meanwhile,O
",",O
the,O
rainfall,O
belt,O
exhibits,O
a,O
northward,O
propagation,O
from,O
southern,O
China,O
",",O
and,O
a,O
meridional,O
dipole,O
pattern,O
of,O
rainfall,O
anomalies,O
during,O
the,O
early,O
Holocene,O
gradually,O
turns,O
into,O
the,O
present,O
-,O
day,O
triple,O
pattern,O
.,O
Zhou74,O
evaluated,O
the,O
performance,O
of,O
33,O
models,O
of,O
the,O
Coupled,O
Model,O
Intercomparison,O
Project,O
Phase,O
5,O
(,O
CMIP5,O
),O
in,O
simulating,O
the,O
summer,O
APO,O
",",O
and,O
projected,O
its,O
variation,O
under,O
warming,O
climate,O
scenarios,O
(,O
RCP4,O
.,O
5,O
and,O
RCP8,O
.,O
5,O
).,O
His,O
findings,O
suggested,O
that,O
the,O
intensity,O
of,O
APO,O
under,O
a,O
warming,O
climate,O
is,O
weaker,O
than,O
the,O
present,O
day,O
.,O
Similarly,O
",",O
with,O
the,O
reduced,O
trend,O
of,O
incoming,O
solar,O
radiation,O
in,O
the,O
Holocene,O
summer,O
",",O
the,O
paleo,O
-,O
APO,O
index,O
exhibits,O
an,O
increasing,O
trend,O
",",O
which,O
is,O
also,O
supported,O
by,O
Zhou,O
’,O
s,O
results,O
.,O
The,O
summer,O
precipitation,O
anomalies,O
over,O
eastern,O
China,O
associated,O
with,O
the,O
APO,O
were,O
investigated,O
using,O
the,O
reanalysis,O
and,O
gauge,O
data19,O
.,O
The,O
result,O
exhibits,O
more,O
rainfall,O
anomalies,O
over,O
northern,O
China,O
and,O
less,O
rainfall,O
over,O
the,O
Yangtze,O
River,O
.,O
This,O
relationship,O
between,O
APO,O
and,O
summer,O
precipitation,O
over,O
eastern,O
China,O
occurs,O
not,O
only,O
during,O
1900,O
–,O
200920,O
and,O
past,O
150,O
years71,O
but,O
also,O
throughout,O
the,O
past,O
millennium2122232475,O
.,O
Summer,O
rainfall,O
anomalies,O
associated,O
with,O
the,O
paleo,O
-,O
APO,O
during,O
the,O
Holocene,O
also,O
exhibit,O
a,O
similar,O
pattern,O
",",O
which,O
implies,O
that,O
this,O
relationship,O
between,O
APO,O
and,O
summer,O
rainfall,O
over,O
eastern,O
China,O
also,O
occurs,O
on,O
a,O
longer,O
precessional,O
scale,O
.,O
Furthermore,O
",",O
variations,O
in,O
the,O
paleo,O
-,O
APO,O
and,O
associated,O
rainfall,O
over,O
eastern,O
China,O
also,O
need,O
more,O
analyses,O
using,O
the,O
General,O
Circulation,O
Model,O
to,O
better,O
understand,O
the,O
underlying,O
mechanisms,O
and,O
processes,O
.,O
Ice,O
-,O
sheet,O
changes,O
are,O
often,O
considered,O
as,O
an,O
important,O
external,O
forcing,O
factor,O
of,O
climate,O
change,O
.,O
They,O
experienced,O
a,O
rapid,O
change,O
in,O
the,O
early,O
Holocene,O
(,O
Fig,O
.,O
S2a,O
).,O
At,O
that,O
time,O
",",O
the,O
ice,O
-,O
sheet,O
covered,O
the,O
northeast,O
portion,O
of,O
North,O
America,O
(,O
Fig,O
.,O
S2b,O
),O
and,O
exerted,O
a,O
strong,O
influence,O
on,O
climate,O
change,O
by,O
changing,O
the,O
surface,O
albedo,O
and,O
the,O
solar,O
insolation76,O
.,O
Some,O
studies,O
have,O
shown,O
that,O
temperature,O
anomalies,O
caused,O
by,O
ice,O
-,O
sheet,O
forcing,O
represent,O
planetary,O
-,O
scale,O
waves,O
in,O
the,O
extratropical,O
northern,O
hemispheric,O
in,O
winter,O
and,O
annual,O
mean,O
fields77,O
.,O
However,O
",",O
summer,O
temperature,O
anomalies,O
forced,O
by,O
ice,O
sheets,O
are,O
confined,O
in,O
the,O
northeastern,O
part,O
of,O
North,O
America,O
and,O
the,O
northern,O
part,O
of,O
the,O
North,O
Atlantic,O
",",O
which,O
implies,O
a,O
small,O
effect,O
of,O
the,O
ice,O
-,O
sheet,O
forcing,O
on,O
summer,O
temperature,O
over,O
the,O
extratropical,O
Asian,O
-,O
Pacific,O
sector77,O
.,O
In,O
this,O
study,O
",",O
we,O
further,O
examine,O
the,O
impacts,O
of,O
ice,O
-,O
sheets,O
in,O
the,O
early,O
Holocene,O
on,O
the,O
paleo,O
-,O
APO,O
pattern,O
and,O
its,O
variability,O
by,O
performing,O
a,O
simulation,O
under,O
both,O
orbital,O
and,O
ice,O
-,O
sheet,O
forcings,O
.,O
The,O
results,O
indicate,O
that,O
the,O
leading,O
mode,O
of,O
the,O
summer,O
eddy,O
SLP,O
under,O
both,O
orbital,O
and,O
ice,O
-,O
sheet,O
forcings,O
(,O
Fig,O
.,O
S3a,O
),O
are,O
very,O
similar,O
to,O
that,O
under,O
the,O
orbital,O
forcing,O
alone,O
except,O
that,O
the,O
positive,O
values,O
over,O
the,O
northern,O
part,O
of,O
the,O
North,O
Atlantic,O
become,O
larger,O
compared,O
to,O
the,O
ice,O
-,O
sheet,O
forcing,O
(,O
Fig,O
.,O
2b,O
).,O
The,O
PC,O
of,O
the,O
leading,O
mode,O
(,O
Fig,O
.,O
S3b,O
),O
generally,O
exhibits,O
an,O
increasing,O
trend,O
that,O
is,O
consistent,O
with,O
that,O
in,O
Fig,O
.,O
2c,O
",",O
although,O
with,O
a,O
weak,O
fluctuation,O
in,O
the,O
early,O
Holocene,O
.,O
Our,O
simulation,O
further,O
supports,O
that,O
ice,O
sheet,O
changes,O
in,O
the,O
early,O
Holocene,O
have,O
a,O
weak,O
influence,O
on,O
the,O
summer,O
extratropical,O
paleo,O
-,O
APO,O
pattern,O
.,O
Additional,O
Information,O
How,O
to,O
cite,O
this,O
article,O
:,O
Xiao,O
",",O
D,O
.,O
et,O
al,O
.,O
Responses,O
of,O
the,O
summer,O
Asian,O
-,O
Pacific,O
zonal,O
thermal,O
contrast,O
and,O
the,O
associated,O
evolution,O
of,O
atmospheric,O
circulation,O
to,O
transient,O
orbital,O
changes,O
during,O
the,O
Holocene,O
.,O
Sci,O
.,O
Rep,O
.,O
6,O
",",O
35816,O
;,O
doi,O
:,O
10,O
.,O
1038,O
/,O
srep35816,O
(,O
2016,O
).,O
Supplementary,O
Material,O
Supplementary,O
Information,O
Author,O
Contributions,O
D,O
.,O
X,O
.,O
performed,O
the,O
numerical,O
analysis,O
and,O
led,O
the,O
interpretation,O
of,O
the,O
results,O
and,O
writing,O
of,O
the,O
paper,O
.,O
P,O
.,O
Z,O
.,O
conceived,O
the,O
idea,O
and,O
designed,O
and,O
revised,O
the,O
paper,O
.,O
Y,O
.,O
W,O
.,O
and,O
X,O
.,O
Z,O
.,O
contributed,O
to,O
interpreting,O
the,O
results,O
.,O
(,O
a,O
),O
Annual,O
cycles,O
of,O
the,O
incoming,O
solar,O
radiation,O
anomaly,O
along,O
30,O
°,O
N,O
relative,O
to,O
the,O
climatological,O
mean,O
over,O
the,O
past,O
10,O
ka,O
and,O
(,O
b,O
),O
the,O
summer,O
incoming,O
solar,O
radiation,O
along,O
30,O
°,O
N,O
.,O
The,O
abscissa,O
is,O
time,O
before,O
the,O
present,O
(,O
1950,O
AD,O
"),",O
and,O
the,O
ordinate,O
in,O
(,O
a,O
),O
is,O
the,O
month,O
of,O
the,O
year,O
.,O
(,O
a,O
),O
Regressed,O
eddy,O
SLP,O
(,O
Unit,O
:,O
Pa,O
/,O
W,O
·,O
m,O
−,O
2,O
),O
on,O
the,O
JJA,O
incoming,O
solar,O
radiation,O
along,O
30,O
°,O
N,O
",",O
in,O
which,O
values,O
exceeding,O
the,O
95,O
%,O
confidence,O
level,O
are,O
plotted,O
.,O
(,O
b,O
),O
Leading,O
EOF,O
mode,O
of,O
the,O
eddy,O
SLP,O
",",O
in,O
which,O
the,O
green,O
circle,O
and,O
square,O
indicate,O
the,O
locations,O
of,O
the,O
Guliya,O
ice,O
core,O
and,O
the,O
ODP,O
1019,O
",",O
respectively,O
.,O
(,O
c,O
),O
The,O
PC1,O
and,O
JJA,O
incoming,O
solar,O
radiation,O
along,O
30,O
°,O
N,O
during,O
the,O
past,O
10,O
ka,O
BP,O
",",O
in,O
which,O
the,O
gray,O
shaded,O
area,O
represents,O
the,O
spread,O
of,O
the,O
ensemble,O
mean,O
PC1,O
.,O
These,O
figures,O
were,O
generated,O
by,O
the,O
Grid,O
Analysis,O
and,O
Display,O
System,O
(,O
GrADS,O
),O
Version,O
2,O
.,O
0,O
.,O
1,O
.,O
oga,O
.,O
1,O
Copyright,O
(,O
c,O
),O
1988,O
–,O
2011,O
by,O
Brian,O
Doty,O
and,O
the,O
Institute,O
for,O
Global,O
Environment,O
and,O
Society,O
(,O
IGES,O
),O
(,O
ftp,O
://,O
cola,O
.,O
gmu,O
.,O
edu,O
/,O
grads,O
/,O
2,O
.,O
0,O
/,O
old,O
/).,O
(,O
a,O
),O
Reconstructed,O
SST,O
(,O
unit,O
:,O
°,O
C,O
;,O
green,O
),O
at,O
the,O
ODP,O
1019,O
and,O
simulated,O
June,O
-,O
July,O
SST,O
(,O
unit,O
:,O
°,O
C,O
;,O
red,O
),O
over,O
the,O
northeastern,O
Pacific,O
(,O
110,O
°,O
W,O
–,O
120,O
°,O
W,O
",",O
35,O
°,O
N,O
–,O
45,O
°,O
N,O
"),",O
in,O
which,O
the,O
gray,O
shaded,O
area,O
represents,O
the,O
spread,O
from,O
the,O
model,O
ensemble,O
mean,O
.,O
(,O
b,O
),O
Same,O
as,O
(,O
a,O
),O
but,O
for,O
the,O
oxygen,O
isotope,O
record,O
in,O
the,O
Guliya,O
ice,O
core,O
(,O
unit,O
:,O
VPDB,O
;,O
green,O
),O
and,O
the,O
simulated,O
summer,O
SLAT,O
(,O
unit,O
:,O
°,O
C,O
;,O
red,O
),O
over,O
80,O
°,O
E,O
–,O
85,O
°,O
E,O
",",O
33,O
°,O
N,O
–,O
38,O
°,O
N,O
.,O
The,O
shaded,O
areas,O
are,O
significant,O
at,O
95,O
%,O
confidence,O
levels,O
and,O
the,O
green,O
contours,O
are,O
zero,O
.,O
This,O
figure,O
is,O
generated,O
by,O
the,O
Grid,O
Analysis,O
and,O
Display,O
System,O
(,O
GrADS,O
),O
Version,O
2,O
.,O
0,O
.,O
1,O
.,O
oga,O
.,O
1,O
Copyright,O
(,O
c,O
),O
1988,O
–,O
2011,O
by,O
Brian,O
Doty,O
and,O
the,O
Institute,O
for,O
Global,O
Environment,O
and,O
Society,O
(,O
IGES,O
),O
(,O
ftp,O
://,O
cola,O
.,O
gmu,O
.,O
edu,O
/,O
grads,O
/,O
2,O
.,O
0,O
/,O
old,O
/).,O
(,O
a,O
),O
The,O
paleo,O
-,O
APO,O
index,O
and,O
PC1,O
in,O
Fig,O
.,O
2b,O
and,O
(,O
b,O
),O
anomaly,O
from,O
climatological,O
mean,O
over,O
the,O
Eurasian,O
continent,O
and,O
the,O
North,O
Pacific,O
Ocean,O
over,O
the,O
past,O
10,O
ka,O
.,O
(,O
a,O
),O
Composite,O
SLP,O
filed,O
in,O
the,O
high,O
(,O
during,O
the,O
period,O
0,O
.,O
09,O
–,O
0,O
ka,O
BP,O
;,O
orange,O
),O
and,O
low,O
(,O
during,O
the,O
period,O
10,O
–,O
9,O
.,O
91,O
ka,O
BP,O
;,O
blue,O
),O
paleo,O
-,O
APO,O
index,O
years,O
",",O
in,O
which,O
the,O
contours,O
of,O
1018,O
hPa,O
are,O
thickened,O
to,O
denote,O
the,O
domain,O
of,O
the,O
North,O
Pacific,O
high,O
pressure,O
zone,O
.,O
(,O
b,O
),O
Regression,O
of,O
summer,O
precipitation,O
(,O
unit,O
:,O
mm,O
),O
over,O
eastern,O
China,O
on,O
the,O
paleo,O
-,O
APO,O
index,O
",",O
in,O
which,O
the,O
locations,O
of,O
stalagmite,O
proxy,O
data,O
at,O
the,O
Jiuxian,O
Cave,O
",",O
Sanbao,O
Cave,O
",",O
Heshang,O
Cave,O
Dongge,O
Cave,O
",",O
and,O
Lianhua,O
Cave,O
are,O
also,O
given,O
and,O
values,O
exceeding,O
significance,O
at,O
the,O
95,O
%,O
confidence,O
level,O
are,O
plotted,O
.,O
This,O
figure,O
is,O
generated,O
by,O
the,O
Grid,O
Analysis,O
and,O
Display,O
System,O
(,O
GrADS,O
),O
Version,O
2,O
.,O
0,O
.,O
1,O
.,O
oga,O
.,O
1,O
Copyright,O
(,O
c,O
),O
1988,O
–,O
2011,O
by,O
Brian,O
Doty,O
and,O
the,O
Institute,O
for,O
Global,O
Environment,O
and,O
Society,O
(,O
IGES,O
),O
(,O
ftp,O
://,O
cola,O
.,O
gmu,O
.,O
edu,O
/,O
grads,O
/,O
2,O
.,O
0,O
/,O
old,O
/).,O
(,O
a,O
),O
The,O
Dongge,O
Cave,O
δ18O,O
record,O
(,O
red,O
),O
and,O
the,O
simulated,O
July,O
precipitation,O
over,O
100,O
°,O
E,O
–,O
112,O
°,O
E,O
",",O
22,O
°,O
N,O
–,O
32,O
°,O
N,O
(,O
green,O
;,O
mm,O
"),",O
(,O
b,O
),O
the,O
Lianhua,O
Cave,O
δ18O,O
record,O
",",O
(,O
c,O
),O
the,O
Sanbao,O
Cave,O
δ18O,O
record,O
",",O
(,O
d,O
),O
the,O
Heshang,O
Cave,O
δ18O,O
record,O
",",O
and,O
(,O
e,O
),O
the,O
Jiuxian,O
Cave,O
δ18O,O
record,O
.,O
Anomalies,O
in,O
the,O
ensemble,O
mean,O
summer,O
eddy,O
SLP,O
(,O
unit,O
:,O
hPa,O
),O
from,O
the,O
climatological,O
mean,O
at,O
9,O
(,O
a,O
"),",O
6,O
.,O
5,O
(,O
b,O
"),",O
4,O
.,O
8,O
(,O
c,O
"),",O
2,O
.,O
5,O
(,O
d,O
"),",O
and,O
0,O
(,O
e,O
),O
ka,O
BP,O
.,O
This,O
figure,O
is,O
generated,O
by,O
the,O
Grid,O
Analysis,O
and,O
Display,O
System,O
(,O
GrADS,O
),O
Version,O
2,O
.,O
0,O
.,O
1,O
.,O
oga,O
.,O
1,O
Copyright,O
(,O
c,O
),O
1988,O
–,O
2011,O
by,O
Brian,O
Doty,O
and,O
the,O
Institute,O
for,O
Global,O
Environment,O
and,O
Society,O
(,O
IGES,O
),O
(,O
ftp,O
://,O
cola,O
.,O
gmu,O
.,O
edu,O
/,O
grads,O
/,O
2,O
.,O
0,O
/,O
old,O
/).,O
Assessment,O
of,O
the,O
circulating,O
cell,O
-,O
free,O
DNA,O
marker,O
association,O
with,O
diagnosis,O
and,O
prognostic,O
prediction,O
in,O
patients,O
with,O
lymphoma,B-DS
:,O
a,O
single,O
-,O
center,O
experience,O
Circulating,O
cell,O
-,O
free,O
DNA,O
(,O
ccfDNA,O
),O
has,O
been,O
shown,O
to,O
be,O
associated,O
with,O
the,O
clinical,O
characteristics,O
and,O
prognosis,O
of,O
cancer,B-DS
patients,O
.,O
Our,O
objective,O
was,O
to,O
assess,O
whether,O
the,O
concentration,O
and,O
integrity,O
index,O
of,O
ccfDNA,O
in,O
plasma,O
may,O
be,O
useful,O
for,O
diagnosing,O
and,O
monitoring,O
the,O
progression,O
of,O
patients,O
with,O
lymphoma,B-DS
.,O
We,O
included,O
plasma,O
samples,O
from,O
174,O
lymphoma,B-DS
patients,O
and,O
80,O
healthy,O
individuals,O
.,O
The,O
total,O
concentration,O
of,O
ccfDNA,O
was,O
determined,O
using,O
a,O
fluorometry,O
method,O
",",O
and,O
the,O
DNA,O
integrity,O
index,O
(,O
DII,O
"),",O
which,O
is,O
the,O
ratio,O
of,O
longer,O
to,O
shorter,O
DNA,O
fragments,O
",",O
for,O
the,O
APP,B-GP
gene,O
was,O
detected,O
using,O
real,O
-,O
time,O
quantitative,O
PCR,O
.,O
The,O
median,O
levels,O
of,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
in,O
patients,O
with,O
lymphoma,B-DS
were,O
significantly,O
higher,O
than,O
those,O
in,O
controls,O
(,O
both,O
P,O
<,O
0,O
.,O
0001,O
).,O
Increases,O
in,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
were,O
associated,O
with,O
advanced,O
stage,O
disease,O
",",O
elevated,O
lactate,B-GP
dehydrogenase,I-GP
levels,O
",",O
and,O
a,O
higher,O
prognosis,O
score,O
.,O
In,O
patients,O
with,O
diffuse,B-DS
large,I-DS
B,I-DS
cell,I-DS
lymphoma,I-DS
(,O
DLBCL,B-DS
"),",O
high,O
levels,O
of,O
ccfDNA,O
(,O
both,O
concentration,O
and,O
the,O
DII,O
),O
showed,O
an,O
inferior,O
2,O
-,O
year,O
progression,O
-,O
free,O
survival,O
(,O
PFS,O
),O
(,O
P,O
=,O
0,O
.,O
001,O
;,O
P,O
<,O
0,O
.,O
0001,O
",",O
respectively,O
).,O
Our,O
study,O
provides,O
quantitative,O
and,O
qualitative,O
evidence,O
in,O
favor,O
of,O
using,O
ccfDNA,O
analysis,O
in,O
lymphoma,B-DS
patients,O
for,O
diagnostic,O
and,O
prognostic,O
assessments,O
.,O
Introduction,O
Lymphoma,B-DS
",",O
which,O
is,O
a,O
common,O
cancer,B-DS
of,O
the,O
hematopoietic,O
system,O
",",O
represents,O
a,O
heterogeneous,O
collection,O
of,O
diseases,O
with,O
different,O
biological,O
characteristics,O
and,O
clinical,O
outcomes,O
.,O
In,O
China,O
",",O
more,O
than,O
80,O
",",O
000,O
new,O
cases,O
of,O
lymphoma,B-DS
and,O
an,O
estimated,O
52,O
",",O
000,O
deaths,O
attributed,O
to,O
lymphoma,B-DS
were,O
reported,O
in,O
2015,O
[,O
1,O
].,O
The,O
overall,O
survival,O
of,O
patients,O
with,O
lymphoma,B-DS
tends,O
to,O
be,O
poor,O
primarily,O
because,O
at,O
the,O
time,O
of,O
diagnosis,O
",",O
most,O
patients,O
are,O
already,O
in,O
the,O
late,O
stages,O
and,O
thus,O
lose,O
the,O
opportunity,O
for,O
timely,O
treatment,O
[,O
2,O
].,O
Therefore,O
",",O
there,O
is,O
an,O
urgent,O
need,O
for,O
a,O
noninvasive,O
tool,O
to,O
improve,O
the,O
diagnosis,O
and,O
prognostic,O
evaluation,O
of,O
lymphoma,B-DS
patients,O
.,O
Circulating,O
cell,O
-,O
free,O
DNA,O
(,O
ccfDNA,O
),O
are,O
DNA,O
fragments,O
circulating,O
within,O
the,O
bloodstream,O
and,O
can,O
be,O
obtained,O
by,O
a,O
simple,O
blood,O
collection,O
.,O
Mendel,O
and,O
Metais,O
first,O
reported,O
the,O
existence,O
of,O
ccfDNA,O
in,O
1948,O
[,O
3,O
"],",O
and,O
the,O
presence,O
of,O
ccfDNA,O
has,O
been,O
identified,O
in,O
inflammatory,B-DS
disease,I-DS
[,O
4,O
"],",O
autoimmune,B-DS
disease,I-DS
[,O
5,O
"],",O
trauma,O
[,O
6,O
"],",O
and,O
myocardial,B-DS
infarction,I-DS
[,O
7,O
].,O
Recently,O
",",O
quantifying,O
ccfDNA,O
levels,O
has,O
been,O
proposed,O
as,O
a,O
potential,O
biomarker,O
to,O
detect,O
malignant,B-DS
tumors,I-DS
.,O
A,O
study,O
by,O
Leon,O
et,O
al,O
.,O
[,O
8,O
],O
suggested,O
that,O
compared,O
with,O
that,O
of,O
healthy,O
individuals,O
",",O
the,O
concentration,O
of,O
ccfDNA,O
was,O
significantly,O
increased,O
in,O
cancer,B-DS
patients,O
;,O
furthermore,O
",",O
this,O
phenomenon,O
was,O
confirmed,O
by,O
other,O
studies,O
on,O
breast,B-DS
tumors,I-DS
[,O
9,O
"],",O
colorectal,B-DS
cancer,I-DS
[,O
10,O
"],",O
lung,B-DS
cancer,I-DS
[,O
11,O
"],",O
and,O
other,O
cancer,B-DS
types,O
[,O
12,O
].,O
The,O
ccfDNA,O
released,O
into,O
the,O
bloodstream,O
is,O
thought,O
to,O
originate,O
from,O
either,O
passive,O
release,O
from,O
apoptotic,O
and,O
necrotic,O
cells,O
or,O
active,O
secretion,O
from,O
nucleated,O
cells,O
such,O
as,O
lymphocytes,O
.,O
Unlike,O
uniformly,O
truncated,O
DNA,O
released,O
from,O
apoptotic,O
cells,O
",",O
ccfDNA,O
released,O
from,O
necrotic,O
tumor,B-DS
cells,O
varies,O
in,O
size,O
",",O
which,O
may,O
lead,O
to,O
elevated,O
levels,O
of,O
long,O
fragments,O
of,O
DNA,O
in,O
the,O
plasma,O
of,O
patients,O
with,O
malignant,O
diseases,O
[,O
13,O
].,O
Several,O
studies,O
have,O
demonstrated,O
that,O
compared,O
to,O
that,O
of,O
healthy,O
individuals,O
",",O
the,O
DNA,O
integrity,O
index,O
(,O
DII,O
"),",O
which,O
is,O
calculated,O
as,O
the,O
ratio,O
of,O
longer,O
to,O
shorter,O
DNA,O
fragments,O
",",O
was,O
increased,O
in,O
patients,O
with,O
cancers,B-DS
[,O
14,O
–,O
16,O
].,O
Although,O
the,O
presence,O
of,O
ccfDNA,O
has,O
been,O
widely,O
studied,O
in,O
malignant,B-DS
tumors,I-DS
",",O
there,O
are,O
only,O
few,O
reports,O
regarding,O
ccfDNA,O
in,O
lymphoproliferative,B-DS
diseases,I-DS
.,O
It,O
has,O
been,O
hypothesized,O
that,O
ccfDNA,O
may,O
be,O
a,O
good,O
candidate,O
for,O
diagnosis,O
and,O
prognosis,O
of,O
lymphoma,B-DS
because,O
some,O
studies,O
have,O
shown,O
that,O
the,O
concentration,O
of,O
ccfDNA,O
could,O
be,O
a,O
diagnostic,O
and,O
predictive,O
biomarker,O
in,O
lymphoma,B-DS
patients,O
[,O
17,O
",",O
18,O
];,O
however,O
",",O
to,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
there,O
are,O
no,O
studies,O
that,O
have,O
investigated,O
the,O
predictive,O
value,O
of,O
ccfDNA,O
integrity,O
.,O
Here,O
",",O
we,O
assessed,O
the,O
value,O
of,O
the,O
concentration,O
and,O
integrity,O
of,O
ccfDNA,O
in,O
diagnosing,O
lymphoma,B-DS
patients,O
and,O
analyzed,O
these,O
parameters,O
to,O
identify,O
associations,O
with,O
clinical,O
characteristics,O
and,O
prognosis,O
.,O
Materials,O
and,O
methods,O
Population,O
There,O
were,O
174,O
lymphoma,B-DS
patients,O
enrolled,O
in,O
this,O
study,O
.,O
Among,O
the,O
included,O
lymphoma,B-DS
cases,O
",",O
126,O
were,O
B,B-DS
cell,I-DS
non,I-DS
-,I-DS
Hodgkin,I-DS
lymphoma,I-DS
(,O
B,B-DS
-,I-DS
NHL,I-DS
"),",O
with,O
diffuse,B-DS
large,I-DS
B,I-DS
cell,I-DS
lymphoma,I-DS
(,O
DLBCL,B-DS
",",O
n,O
=,O
98,O
),O
as,O
the,O
most,O
common,O
subtype,O
.,O
There,O
were,O
18,O
",",O
9,O
",",O
and,O
21,O
patients,O
diagnosed,O
with,O
HL,B-DS
",",O
T,B-DS
cell,I-DS
non,I-DS
-,I-DS
HL,I-DS
(,O
T,B-DS
-,I-DS
NHL,I-DS
"),",O
and,O
extranodal,B-DS
NK,I-DS
/,I-DS
T,I-DS
cell,I-DS
lymphoma,I-DS
(,O
NK,B-DS
/,I-DS
TCL,I-DS
"),",O
respectively,O
.,O
The,O
diagnosis,O
of,O
all,O
patients,O
was,O
histologically,O
confirmed,O
.,O
Patient,O
samples,O
were,O
obtained,O
from,O
West,O
China,O
Hospital,O
of,O
Sichuan,O
University,O
between,O
September,O
2014,O
and,O
January,O
2016,O
.,O
Plasma,O
samples,O
were,O
collected,O
at,O
the,O
time,O
of,O
initial,O
diagnosis,O
.,O
The,O
median,O
follow,O
-,O
up,O
time,O
was,O
13,O
.,O
5,O
months,O
and,O
ranged,O
from,O
1,O
to,O
36,O
months,O
.,O
The,O
main,O
patient,O
characteristics,O
are,O
provided,O
in,O
Table,O
1,O
.,O
Table,O
1Main,O
characteristics,O
of,O
patients,O
included,O
in,O
the,O
studyTotalHLB,B-DS
-,I-DS
NHLT,I-DS
-,I-DS
NHLNK,I-DS
/,I-DS
TCLDLBCLOthers,I-DS
(,O
n,O
=,O
174,O
)(,O
n,O
=,O
18,O
)(,O
n,O
=,O
98,O
)(,O
n,O
=,O
28,O
)(,O
n,O
=,O
9,O
)(,O
n,O
=,O
21,O
),O
Gender,O
Male107106117613,O
Female678371138Age,O
(,O
range,O
"),",O
years,O
≤,O
60117156116718,O
>,O
60573371223Stage,O
I,O
–,O
IIA6924211114,O
IIB,O
–,O
IV10516561787B,O
-,O
symptoms,O
No916601429,O
Yes83123814712Bulky,O
disease,O
No153138426921,O
Yes21514200Lactate,O
dehydrogenase,O
Normal9694817814,O
Elevated789501117IPI,O
Low,O
(,O
0,O
or,O
1,O
),O
56,O
–,O
39836,O
Intermediate,O
low,O
(,O
2,O
),O
38,O
–,O
225110,O
Intermediate,O
high,O
(,O
3,O
),O
27,O
–,O
13815,O
High,O
(,O
4,O
or,O
5,O
),O
35,O
–,O
24740IPS,O
0,O
–,O
2,O
–,O
9,O
––––,O
≥,O
3,O
–,O
9,O
––––,O
Data,O
were,O
presented,O
as,O
n,O
HL,B-DS
",",O
Hodgkin,B-DS
’,I-DS
s,I-DS
lymphoma,I-DS
;,O
B,B-DS
-,I-DS
NHL,I-DS
",",O
B,B-DS
cell,I-DS
non,I-DS
-,I-DS
Hodgkin,I-DS
’,I-DS
s,I-DS
lymphoma,I-DS
;,O
DLBCL,B-DS
",",O
diffuse,B-DS
large,I-DS
B,I-DS
cell,I-DS
lymphoma,I-DS
;,O
Others,O
group,O
included,O
9,O
follicular,B-DS
lymphoma,I-DS
",",O
7,O
small,B-DS
cell,I-DS
lymphoma,I-DS
/,O
chronic,B-DS
lymphocytic,I-DS
leukemia,I-DS
",",O
6,O
marginal,B-DS
zone,I-DS
lymphoma,I-DS
",",O
5,O
mantle,B-DS
cell,I-DS
lymphoma,I-DS
and,O
1,O
Burkitt,B-DS
lymphoma,I-DS
;,O
T,B-DS
-,I-DS
NHL,I-DS
",",O
T,B-DS
cell,I-DS
non,I-DS
-,I-DS
Hodgkin,I-DS
’,I-DS
s,I-DS
lymphoma,I-DS
",",O
included,O
in,O
4,O
peripheral,B-DS
T,I-DS
cell,I-DS
lymphoma,I-DS
",",O
3,O
anaplastic,B-DS
large,I-DS
-,I-DS
cell,I-DS
lymphoma,I-DS
",",O
2,O
angioimmunoblastic,B-DS
T,I-DS
cell,I-DS
lymphoma,I-DS
;,O
NK,B-DS
/,I-DS
TCL,I-DS
",",O
extranodal,B-DS
NK,I-DS
/,I-DS
T,I-DS
cell,I-DS
lymphoma,I-DS
;,O
IPI,O
",",O
international,O
prognostic,O
index,O
;,O
IPS,O
",",O
international,O
prognostic,O
score,O
A,O
control,O
group,O
consisting,O
of,O
80,O
healthy,O
individuals,O
was,O
included,O
to,O
establish,O
the,O
normal,O
range,O
of,O
ccfDNA,O
levels,O
in,O
plasma,O
.,O
Informed,O
consent,O
was,O
obtained,O
from,O
patients,O
and,O
controls,O
according,O
to,O
the,O
institutional,O
guidelines,O
",",O
and,O
the,O
study,O
was,O
approved,O
by,O
the,O
Human,O
Research,O
Ethics,O
Committee,O
of,O
the,O
West,O
China,O
Hospital,O
of,O
Sichuan,O
University,O
.,O
Sample,O
collection,O
and,O
DNA,O
extraction,O
Peripheral,O
blood,O
samples,O
were,O
collected,O
into,O
tubes,O
containing,O
EDTA,O
and,O
centrifuged,O
(,O
2000,O
×,O
g,O
",",O
10,O
min,O
",",O
4,O
°,O
C,O
),O
within,O
4,O
h,O
of,O
collection,O
.,O
To,O
prevent,O
cellular,O
DNA,O
contamination,O
",",O
the,O
plasma,O
supernatants,O
were,O
carefully,O
removed,O
and,O
recentrifuged,O
(,O
16,O
",",O
000,O
×,O
g,O
;,O
10,O
min,O
at,O
4,O
°,O
C,O
).,O
The,O
prepared,O
plasma,O
samples,O
were,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
further,O
analysis,O
.,O
ccfDNA,O
was,O
extracted,O
using,O
the,O
MagMAX,O
™,O
Cell,O
-,O
Free,O
DNA,O
Isolation,O
Kit,O
(,O
Applied,O
Biosystems,O
",",O
Carlsbad,O
",",O
CA,O
",",O
USA,O
),O
following,O
the,O
manufacturer,O
’,O
s,O
instructions,O
.,O
The,O
isolated,O
ccfDNA,O
was,O
eluted,O
in,O
20,O
μl,O
of,O
the,O
provided,O
solution,O
and,O
stored,O
at,O
−,O
20,O
°,O
C,O
prior,O
to,O
quantitative,O
and,O
qualitative,O
analyses,O
.,O
Quantification,O
of,O
circulating,O
cell,O
-,O
free,O
DNA,O
Quantification,O
of,O
ccfDNA,O
was,O
performed,O
by,O
fluorometry,O
using,O
the,O
Qubit,O
®,O
dsDNA,O
HS,O
Assay,O
Kit,O
(,O
Molecular,O
Probes,O
",",O
Eugene,O
",",O
OR,O
",",O
USA,O
),O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
protocols,O
",",O
and,O
the,O
plates,O
were,O
read,O
in,O
a,O
Qubit,O
®,O
3,O
.,O
0,O
fluorometer,O
(,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
",",O
USA,O
).,O
The,O
ccfDNA,O
concentrations,O
were,O
determined,O
from,O
a,O
standard,O
curve,O
obtained,O
using,O
the,O
standard,O
stock,O
(,O
provided,O
by,O
the,O
manufacturer,O
).,O
Two,O
repeated,O
tests,O
were,O
performed,O
for,O
each,O
set,O
of,O
concentration,O
measurements,O
and,O
the,O
resulting,O
data,O
were,O
averaged,O
.,O
Real,O
-,O
time,O
quantitative,O
PCR,O
of,O
DNA,O
fragments,O
The,O
integrity,O
of,O
ccfDNA,O
in,O
plasma,O
was,O
determined,O
by,O
quantitative,O
real,O
-,O
time,O
PCR,O
.,O
The,O
quantitative,O
assay,O
was,O
based,O
on,O
amplification,O
of,O
the,O
APP,B-GP
gene,O
(,O
amyloid,B-GP
beta,I-GP
precursor,I-GP
protein,I-GP
",",O
chromosome,O
21q21,O
.,O
3,O
",",O
accession,O
NM_000484,O
);,O
the,O
lengths,O
of,O
the,O
two,O
amplicons,O
were,O
67,O
and,O
180,O
bp,O
and,O
were,O
obtained,O
using,O
two,O
primer,O
pairs,O
as,O
reported,O
previously,O
[,O
19,O
].,O
The,O
primer,O
set,O
for,O
APP67,O
amplified,O
both,O
shorter,O
(,O
truncated,O
by,O
apoptosis,O
),O
and,O
longer,O
DNA,O
fragments,O
(,O
truncated,O
by,O
nonapoptotic,O
means,O
"),",O
whereas,O
the,O
APP180,O
amplified,O
only,O
the,O
longer,O
DNA,O
fragments,O
.,O
Quantification,O
of,O
ccfDNA,O
fragments,O
was,O
performed,O
using,O
the,O
CFX96,O
Touch,O
™,O
Real,O
-,O
Time,O
instrument,O
(,O
Bio,O
-,O
Rad,O
",",O
Hercules,O
",",O
CA,O
",",O
USA,O
).,O
The,O
reaction,O
mixture,O
for,O
each,O
direct,O
quantitative,O
real,O
-,O
time,O
PCR,O
comprised,O
12,O
.,O
5,O
μl,O
of,O
SYBR,O
®,O
Premix,O
Ex,O
Taq,O
™,O
II,O
(,O
TaKaRa,O
",",O
Shiga,O
",",O
Japan,O
"),",O
1,O
μl,O
(,O
0,O
.,O
4,O
μM,O
),O
of,O
each,O
primer,O
",",O
and,O
2,O
μl,O
DNA,O
in,O
a,O
total,O
reaction,O
volume,O
of,O
20,O
μl,O
.,O
The,O
sequences,O
of,O
the,O
primers,O
are,O
as,O
follows,O
:,O
APP67,O
:,O
forward,O
",",O
5,O
′-,O
TCAGGTTGACGCCGCTGT,O
-,O
3,O
′,O
and,O
reverse,O
",",O
5,O
′-,O
TTCGTAGCCG,O
TTCTGCTGC,O
-,O
3,O
′;,O
and,O
APP180,O
:,O
forward,O
",",O
5,O
′-,O
TCAGGTTGACGCCGCTGT,O
-,O
3,O
′,O
and,O
reverse,O
",",O
5,O
′-,O
TCTATAAATGGACACCGATGGGTAGT,O
-,O
3,O
′.,O
The,O
real,O
-,O
time,O
PCR,O
protocol,O
included,O
an,O
initial,O
denaturation,O
step,O
at,O
95,O
°,O
C,O
for,O
30,O
s,O
followed,O
by,O
40,O
cycles,O
of,O
denaturation,O
at,O
95,O
°,O
C,O
for,O
5,O
s,O
and,O
annealing,O
at,O
64,O
°,O
C,O
for,O
30,O
s,O
.,O
A,O
melting,O
curve,O
analysis,O
was,O
conducted,O
to,O
confirm,O
PCR,O
product,O
specificity,O
",",O
and,O
the,O
DNA,O
copy,O
number,O
of,O
each,O
sample,O
was,O
determined,O
using,O
a,O
standard,O
curve,O
with,O
serial,O
dilutions,O
(,O
2,O
×,O
10,O
−,O
1,O
−,O
2,O
×,O
105,O
ng,O
/,O
ml,O
),O
of,O
human,B-OG
genomic,O
DNA,O
(,O
Promega,O
",",O
Madison,O
",",O
WI,O
",",O
USA,O
;,O
200,O
μg,O
/,O
ml,O
).,O
All,O
samples,O
were,O
analyzed,O
in,O
duplicate,O
",",O
and,O
a,O
negative,O
control,O
(,O
without,O
template,O
),O
was,O
included,O
in,O
each,O
plate,O
.,O
All,O
quantitative,O
real,O
-,O
time,O
PCR,O
assays,O
were,O
performed,O
in,O
a,O
blinded,O
fashion,O
without,O
knowledge,O
of,O
the,O
specimen,O
identity,O
.,O
Statistical,O
analysis,O
Comparison,O
of,O
the,O
relative,O
expression,O
levels,O
of,O
ccfDNA,O
(,O
including,O
concentration,O
and,O
the,O
DII,O
),O
between,O
patients,O
and,O
controls,O
was,O
performed,O
by,O
applying,O
the,O
nonparametric,O
Mann,O
-,O
Whitney,O
test,O
.,O
Analysis,O
of,O
receiver,O
operating,O
characteristics,O
(,O
ROC,O
),O
curves,O
and,O
binary,O
logistic,O
regression,O
were,O
performed,O
to,O
evaluate,O
the,O
diagnostic,O
performance,O
of,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
in,O
lymphoma,B-DS
.,O
The,O
relationship,O
between,O
the,O
levels,O
of,O
ccfDNA,O
and,O
the,O
clinicopathological,O
features,O
of,O
lymphoma,B-DS
patients,O
was,O
estimated,O
as,O
appropriate,O
per,O
variable,O
type,O
.,O
In,O
detail,O
",",O
differences,O
in,O
the,O
ccfDNA,O
levels,O
among,O
the,O
different,O
groups,O
of,O
categorical,O
parameters,O
were,O
analyzed,O
by,O
either,O
the,O
nonparametric,O
Mann,O
-,O
Whitney,O
test,O
for,O
binary,O
variables,O
or,O
the,O
respective,O
Kruskal,O
-,O
Wallis,O
test,O
for,O
the,O
parameters,O
consisting,O
of,O
several,O
independent,O
groups,O
.,O
The,O
Kaplan,O
-,O
Meier,O
survival,O
analysis,O
approach,O
and,O
Cox,O
proportional,O
hazard,O
regression,O
analysis,O
were,O
used,O
to,O
determine,O
progression,O
-,O
free,O
survival,O
(,O
PFS,O
).,O
PFS,O
was,O
defined,O
as,O
the,O
time,O
from,O
initial,O
diagnosis,O
until,O
disease,O
progression,O
/,O
relapse,O
or,O
death,O
from,O
any,O
cause,O
.,O
A,O
two,O
-,O
sided,O
P,O
<,O
0,O
.,O
05,O
indicated,O
statistical,O
significance,O
.,O
All,O
analyses,O
were,O
performed,O
using,O
SPSS,O
software,O
version,O
22,O
.,O
0,O
(,O
IBM,O
Corp,O
".,",O
Armonk,O
",",O
NY,O
),O
and,O
MedCalc,O
software,O
version,O
15,O
.,O
10,O
(,O
MedCalc,O
Software,O
",",O
Ostend,O
",",O
Belgium,O
).,O
Results,O
Concentration,O
of,O
circulating,O
cell,O
-,O
free,O
DNA,O
in,O
healthy,O
individuals,O
and,O
lymphoma,B-DS
patients,O
The,O
median,O
concentration,O
of,O
ccfDNA,O
in,O
the,O
80,O
healthy,O
individuals,O
tested,O
was,O
209,O
.,O
0,O
ng,O
/,O
ml,O
(,O
mean,O
222,O
.,O
5,O
ng,O
/,O
ml,O
",",O
range,O
100,O
.,O
0,O
–,O
456,O
.,O
0,O
ng,O
/,O
ml,O
);,O
however,O
",",O
in,O
patients,O
with,O
lymphoma,B-DS
(,O
n,O
=,O
174,O
"),",O
this,O
concentration,O
was,O
significantly,O
higher,O
(,O
median,O
686,O
.,O
0,O
ng,O
/,O
ml,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
with,O
greater,O
variability,O
among,O
the,O
patients,O
(,O
mean,O
1407,O
.,O
6,O
ng,O
/,O
ml,O
",",O
range,O
100,O
.,O
0,O
–,O
14,O
",",O
180,O
.,O
0,O
ng,O
/,O
ml,O
).,O
Elevated,O
ccfDNA,O
concentration,O
levels,O
were,O
observed,O
in,O
patients,O
with,O
HL,B-DS
(,O
n,O
=,O
18,O
",",O
median,O
681,O
.,O
0,O
ng,O
/,O
ml,O
",",O
mean,O
988,O
.,O
8,O
ng,O
/,O
ml,O
",",O
P,O
=,O
0,O
.,O
001,O
"),",O
DLBCL,B-DS
(,O
n,O
=,O
98,O
",",O
median,O
845,O
.,O
0,O
ng,O
/,O
ml,O
",",O
mean,O
1722,O
.,O
2,O
ng,O
/,O
ml,O
",",O
P,O
<,O
0,O
.,O
0001,O
"),",O
other,O
types,O
of,O
B,B-DS
-,I-DS
NHL,I-DS
(,O
n,O
=,O
28,O
",",O
median,O
332,O
.,O
0,O
ng,O
/,O
ml,O
",",O
mean,O
1096,O
.,O
3,O
ng,O
/,O
ml,O
",",O
P,O
<,O
0,O
.,O
0001,O
"),",O
T,B-DS
-,I-DS
NHL,I-DS
(,O
n,O
=,O
9,O
",",O
median,O
942,O
.,O
0,O
ng,O
/,O
ml,O
",",O
mean,O
1247,O
.,O
0,O
ng,O
/,O
ml,O
",",O
P,O
<,O
0,O
.,O
0001,O
"),",O
and,O
NK,B-DS
/,I-DS
TCL,I-DS
(,O
n,O
=,O
21,O
",",O
median,O
662,O
.,O
0,O
ng,O
/,O
ml,O
",",O
mean,O
782,O
.,O
7,O
ng,O
/,O
ml,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
(,O
Fig,O
.,O
1a,O
).,O
Fig,O
.,O
1Circulating,O
cell,O
-,O
free,O
DNA,O
levels,O
in,O
the,O
plasma,O
of,O
lymphoma,B-DS
patients,O
.,O
Box,O
plots,O
showed,O
circulating,O
cell,O
-,O
free,O
DNA,O
levels,O
of,O
a,O
concentrations,O
and,O
b,O
DII,O
in,O
healthy,O
controls,O
and,O
patients,O
with,O
lymphoma,B-DS
",",O
presented,O
as,O
median,O
value,O
(,O
black,O
line,O
"),",O
interquartile,O
range,O
(,O
box,O
"),",O
and,O
5th,O
and,O
95th,O
percentiles,O
(,O
whiskers,O
),O
To,O
assess,O
the,O
diagnostic,O
accuracy,O
of,O
the,O
ccfDNA,O
levels,O
in,O
lymphoma,B-DS
patients,O
",",O
an,O
ROC,O
curve,O
analysis,O
was,O
conducted,O
",",O
and,O
the,O
area,O
under,O
the,O
curve,O
(,O
AUC,O
),O
was,O
calculated,O
as,O
0,O
.,O
75,O
(,O
95,O
%,O
CI,O
0,O
.,O
66,O
–,O
0,O
.,O
84,O
",",O
P,O
=,O
0,O
.,O
001,O
),O
for,O
HL,B-DS
",",O
0,O
.,O
86,O
(,O
95,O
%,O
CI,O
0,O
.,O
80,O
–,O
0,O
.,O
90,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
for,O
DLBCL,B-DS
",",O
and,O
0,O
.,O
79,O
(,O
95,O
%,O
CI,O
0,O
.,O
70,O
–,O
0,O
.,O
87,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
for,O
NK,B-DS
/,I-DS
TCL,I-DS
",",O
suggesting,O
a,O
moderate,O
discriminatory,O
power,O
.,O
For,O
HL,B-DS
",",O
the,O
sensitivity,O
and,O
specificity,O
were,O
61,O
and,O
100,O
"%,",O
respectively,O
",",O
at,O
a,O
cut,O
-,O
off,O
of,O
456,O
.,O
0,O
ng,O
/,O
ml,O
;,O
for,O
DLBCL,B-DS
",",O
73,O
and,O
94,O
%,O
at,O
a,O
cut,O
-,O
off,O
of,O
340,O
.,O
0,O
ng,O
/,O
ml,O
",",O
and,O
for,O
NK,B-DS
/,I-DS
TCL,I-DS
",",O
71,O
and,O
96,O
%,O
at,O
a,O
cut,O
-,O
off,O
of,O
392,O
.,O
0,O
ng,O
/,O
ml,O
.,O
Based,O
on,O
these,O
results,O
",",O
elevated,O
levels,O
of,O
ccfDNA,O
were,O
associated,O
with,O
a,O
higher,O
risk,O
of,O
lymphoma,B-DS
.,O
When,O
analyzed,O
as,O
a,O
logistic,O
regression,O
model,O
",",O
a,O
10,O
.,O
0,O
ng,O
/,O
ml,O
increase,O
in,O
the,O
ccfDNA,O
concentration,O
increased,O
the,O
lymphoma,B-DS
risk,O
by,O
7,O
.,O
3,O
%,O
(,O
odds,O
ratio,O
1,O
.,O
073,O
;,O
95,O
%,O
CI,O
1,O
.,O
045,O
–,O
1,O
.,O
102,O
).,O
Integrity,O
of,O
circulating,O
cell,O
-,O
free,O
DNA,O
in,O
healthy,O
individuals,O
and,O
lymphoma,B-DS
patients,O
The,O
DII,O
was,O
calculated,O
as,O
the,O
ratio,O
of,O
the,O
quantitative,O
real,O
-,O
time,O
PCR,O
results,O
using,O
the,O
two,O
primer,O
sets,O
as,O
follows,O
:,O
QAPP180,O
/,O
QAPP67,O
.,O
Because,O
the,O
annealing,O
sites,O
of,O
APP67,O
are,O
contained,O
within,O
the,O
APP180,O
annealing,O
sites,O
",",O
the,O
DII,O
would,O
be,O
1,O
.,O
0,O
when,O
the,O
template,O
DNA,O
was,O
not,O
truncated,O
and,O
0,O
.,O
0,O
when,O
all,O
of,O
the,O
template,O
DNA,O
was,O
truncated,O
into,O
fragments,O
smaller,O
than,O
180,O
bp,O
.,O
The,O
median,O
DII,O
in,O
patients,O
with,O
lymphoma,B-DS
was,O
0,O
.,O
39,O
(,O
mean,O
0,O
.,O
42,O
",",O
range,O
0,O
.,O
11,O
–,O
0,O
.,O
97,O
"),",O
which,O
was,O
significantly,O
higher,O
than,O
that,O
of,O
the,O
normal,O
control,O
subjects,O
(,O
median,O
0,O
.,O
21,O
",",O
mean,O
0,O
.,O
22,O
",",O
range,O
0,O
.,O
07,O
–,O
0,O
.,O
49,O
;,O
P,O
<,O
0,O
.,O
0001,O
).,O
Elevated,O
DII,O
values,O
were,O
observed,O
in,O
patients,O
with,O
HL,B-DS
(,O
median,O
0,O
.,O
37,O
",",O
mean,O
0,O
.,O
40,O
",",O
P,O
<,O
0,O
.,O
0001,O
"),",O
DLBCL,B-DS
(,O
median,O
0,O
.,O
43,O
",",O
mean,O
0,O
.,O
46,O
",",O
P,O
<,O
0,O
.,O
0001,O
"),",O
other,O
types,O
of,O
B,B-DS
-,I-DS
NHL,I-DS
(,O
median,O
0,O
.,O
34,O
",",O
mean,O
0,O
.,O
35,O
",",O
P,O
=,O
0,O
.,O
002,O
"),",O
T,B-DS
-,I-DS
NHL,I-DS
(,O
median,O
0,O
.,O
42,O
",",O
mean,O
0,O
.,O
41,O
",",O
P,O
=,O
0,O
.,O
008,O
"),",O
and,O
NK,B-DS
/,I-DS
TCL,I-DS
(,O
median,O
0,O
.,O
33,O
",",O
mean,O
0,O
.,O
38,O
",",O
P,O
=,O
0,O
.,O
001,O
"),",O
respectively,O
(,O
Fig,O
.,O
1b,O
).,O
Using,O
the,O
ROC,O
analysis,O
",",O
the,O
AUC,O
of,O
the,O
ccfDNA,O
DII,O
was,O
0,O
.,O
83,O
(,O
95,O
%,O
CI,O
0,O
.,O
74,O
–,O
0,O
.,O
90,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
for,O
HL,B-DS
",",O
0,O
.,O
90,O
(,O
95,O
%,O
CI,O
0,O
.,O
83,O
–,O
0,O
.,O
93,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
for,O
DLBCL,B-DS
",",O
and,O
0,O
.,O
81,O
(,O
95,O
%,O
CI,O
0,O
.,O
72,O
–,O
0,O
.,O
88,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
for,O
NK,B-DS
/,I-DS
TCL,I-DS
.,O
Additionally,O
",",O
the,O
ROC,O
analysis,O
assessed,O
whether,O
a,O
combination,O
of,O
the,O
raw,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
could,O
improve,O
the,O
diagnostic,O
ability,O
compared,O
with,O
using,O
the,O
concentration,O
alone,O
.,O
The,O
results,O
showed,O
that,O
the,O
AUC,O
was,O
significantly,O
increased,O
after,O
the,O
addition,O
of,O
the,O
DII,O
to,O
the,O
ccfDNA,O
concentration,O
in,O
patients,O
with,O
DLBCL,B-DS
(,O
0,O
.,O
86,O
vs,O
.,O
0,O
.,O
91,O
;,O
Z,O
=,O
2,O
.,O
697,O
",",O
P,O
=,O
0,O
.,O
007,O
;,O
Fig,O
.,O
2,O
);,O
whereas,O
in,O
patients,O
with,O
either,O
HL,B-DS
or,O
NK,B-DS
/,I-DS
TCL,I-DS
",",O
there,O
was,O
only,O
a,O
trend,O
of,O
increased,O
AUC,O
observed,O
(,O
0,O
.,O
75,O
vs,O
.,O
0,O
.,O
84,O
;,O
Z,O
=,O
1,O
.,O
714,O
",",O
P,O
=,O
0,O
.,O
087,O
and,O
0,O
.,O
79,O
vs,O
.,O
0,O
.,O
88,O
;,O
Z,O
=,O
1,O
.,O
646,O
",",O
P,O
=,O
0,O
.,O
0997,O
",",O
respectively,O
).,O
Fig,O
.,O
2The,O
receiver,O
operating,O
characteristic,O
curves,O
of,O
the,O
circulating,O
cell,O
-,O
free,O
DNA,O
concentration,O
and,O
its,O
combination,O
with,O
DII,O
in,O
patients,O
with,O
DLBCL,B-DS
.,O
The,O
AUC,O
of,O
concentration,O
and,O
model,O
of,O
concentration,O
+,O
DII,O
was,O
0,O
.,O
86,O
(,O
95,O
%,O
CI,O
0,O
.,O
80,O
–,O
0,O
.,O
90,O
),O
and,O
0,O
.,O
91,O
(,O
95,O
%,O
CI,O
0,O
.,O
86,O
–,O
0,O
.,O
95,O
"),",O
respectively,O
(,O
Z,O
=,O
2,O
.,O
697,O
",",O
P,O
=,O
0,O
.,O
007,O
).,O
DII,O
",",O
DNA,O
integrity,O
index,O
;,O
AUC,O
",",O
area,O
under,O
the,O
curve,O
Correlation,O
of,O
circulating,O
cell,O
-,O
free,O
DNA,O
and,O
clinicopathological,O
features,O
in,O
lymphoma,B-DS
patients,O
To,O
assess,O
the,O
clinical,O
significance,O
of,O
ccfDNA,O
levels,O
",",O
we,O
analyzed,O
the,O
clinicopathological,O
correlations,O
in,O
the,O
total,O
lymphoma,B-DS
group,O
but,O
restricted,O
the,O
analysis,O
to,O
patients,O
with,O
DLBCL,B-DS
;,O
in,O
this,O
patient,O
subset,O
",",O
the,O
adverse,O
prognostic,O
factors,O
advanced,O
stage,O
disease,O
(,O
stage,O
IIB,O
–,O
IV,O
),O
and,O
elevated,O
LDH,B-GP
levels,O
were,O
associated,O
with,O
increased,O
ccfDNA,O
levels,O
and,O
DII,O
(,O
Table,O
2,O
).,O
In,O
patients,O
with,O
DLBCL,B-DS
",",O
the,O
presence,O
of,O
B,O
-,O
symptoms,O
was,O
also,O
correlated,O
with,O
increases,O
in,O
both,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
.,O
As,O
a,O
consequence,O
",",O
patients,O
with,O
an,O
adverse,O
prognostic,O
score,O
had,O
higher,O
levels,O
of,O
ccfDNA,O
",",O
which,O
was,O
significant,O
among,O
all,O
lymphoma,B-DS
patients,O
and,O
DLBCL,B-DS
patients,O
[,O
20,O
",",O
21,O
].,O
Otherwise,O
",",O
no,O
statistical,O
significance,O
was,O
observed,O
when,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
were,O
analyzed,O
with,O
regard,O
to,O
other,O
clinical,O
parameters,O
such,O
as,O
age,O
",",O
gender,O
",",O
and,O
bulky,O
disease,O
.,O
Table,O
2Plasma,O
circulating,O
cell,O
-,O
free,O
DNA,O
levels,O
and,O
clinicopathologic,O
features,O
in,O
lymphoma,B-DS
patientsAll,O
patientsDLBCLConcentrationDIIConcentrationDIIGender,O
Male660,O
.,O
0,O
(,O
290,O
.,O
0,O
–,O
1684,O
.,O
0,O
),O
0,O
.,O
38,O
(,O
0,O
.,O
29,O
–,O
0,O
.,O
54,O
),O
764,O
.,O
0,O
(,O
352,O
.,O
0,O
–,O
1868,O
.,O
5,O
),O
0,O
.,O
42,O
(,O
0,O
.,O
33,O
–,O
0,O
.,O
56,O
),O
Female702,O
.,O
0,O
(,O
284,O
.,O
0,O
–,O
2000,O
.,O
0,O
),O
0,O
.,O
42,O
(,O
0,O
.,O
33,O
–,O
0,O
.,O
53,O
),O
1118,O
.,O
0,O
(,O
295,O
.,O
0,O
–,O
3080,O
.,O
0,O
),O
0,O
.,O
48,O
(,O
0,O
.,O
35,O
–,O
0,O
.,O
59,O
),O
P,O
0,O
.,O
7690,O
.,O
2340,O
.,O
5070,O
.,O
558Age,O
(,O
range,O
"),",O
years,O
≤,O
60702,O
.,O
0,O
(,O
260,O
.,O
0,O
–,O
1868,O
.,O
5,O
),O
0,O
.,O
39,O
(,O
0,O
.,O
31,O
–,O
0,O
.,O
53,O
),O
802,O
.,O
0,O
(,O
287,O
.,O
0,O
–,O
2430,O
.,O
0,O
),O
0,O
.,O
47,O
(,O
0,O
.,O
33,O
–,O
0,O
.,O
56,O
),O
>,O
60656,O
.,O
0,O
(,O
355,O
.,O
0,O
–,O
1847,O
.,O
0,O
),O
0,O
.,O
41,O
(,O
0,O
.,O
30,O
–,O
0,O
.,O
55,O
),O
888,O
.,O
0,O
(,O
384,O
.,O
0,O
–,O
2220,O
.,O
0,O
),O
0,O
.,O
43,O
(,O
0,O
.,O
34,O
–,O
0,O
.,O
58,O
),O
P,O
0,O
.,O
4140,O
.,O
8560,O
.,O
6680,O
.,O
965Stage,O
I,O
–,O
IIA482,O
.,O
0,O
(,O
238,O
.,O
5,O
–,O
1081,O
.,O
0,O
),O
0,O
.,O
34,O
(,O
0,O
.,O
28,O
–,O
0,O
.,O
47,O
),O
488,O
.,O
0,O
(,O
262,O
.,O
8,O
–,O
1048,O
.,O
0,O
),O
0,O
.,O
35,O
(,O
0,O
.,O
29,O
–,O
0,O
.,O
48,O
),O
IIB,O
–,O
IV896,O
.,O
0,O
(,O
351,O
.,O
0,O
–,O
2330,O
.,O
0,O
),O
0,O
.,O
43,O
(,O
0,O
.,O
34,O
–,O
0,O
.,O
56,O
),O
1395,O
.,O
0,O
(,O
449,O
.,O
5,O
–,O
2720,O
.,O
0,O
),O
0,O
.,O
52,O
(,O
0,O
.,O
41,O
–,O
0,O
.,O
62,O
),O
P,O
0,O
.,O
003,O
0,O
.,O
0001,O
0,O
.,O
006,O
<,O
0,O
.,O
0001,O
B,O
-,O
symptoms,O
No496,O
.,O
0,O
(,O
267,O
.,O
0,O
–,O
1426,O
.,O
0,O
),O
0,O
.,O
39,O
(,O
0,O
.,O
29,O
–,O
0,O
.,O
52,O
),O
523,O
.,O
0,O
(,O
293,O
.,O
0,O
–,O
1672,O
.,O
8,O
),O
0,O
.,O
41,O
(,O
0,O
.,O
31,O
–,O
0,O
.,O
54,O
),O
Yes736,O
.,O
0,O
(,O
348,O
.,O
0,O
–,O
2240,O
.,O
0,O
),O
0,O
.,O
41,O
(,O
0,O
.,O
32,O
–,O
0,O
.,O
54,O
),O
1657,O
.,O
0,O
(,O
433,O
.,O
0,O
–,O
3520,O
.,O
0,O
),O
0,O
.,O
52,O
(,O
0,O
.,O
39,O
–,O
0,O
.,O
63,O
),O
P,O
0,O
.,O
1040,O
.,O
251,O
0,O
.,O
034,O
0,O
.,O
013,O
Bulky,O
disease,O
No662,O
.,O
0,O
(,O
287,O
.,O
0,O
–,O
1661,O
.,O
5,O
),O
0,O
.,O
39,O
(,O
0,O
.,O
30,O
–,O
0,O
.,O
53,O
),O
783,O
.,O
0,O
(,O
320,O
.,O
5,O
–,O
2330,O
.,O
0,O
),O
0,O
.,O
43,O
(,O
0,O
.,O
34,O
–,O
0,O
.,O
55,O
),O
Yes1011,O
.,O
0,O
(,O
269,O
.,O
0,O
–,O
2434,O
.,O
5,O
),O
0,O
.,O
42,O
(,O
0,O
.,O
31,O
–,O
0,O
.,O
59,O
),O
1148,O
.,O
0,O
(,O
334,O
.,O
5,O
–,O
2161,O
.,O
8,O
),O
0,O
.,O
45,O
(,O
0,O
.,O
35,O
–,O
0,O
.,O
61,O
),O
P,O
0,O
.,O
4310,O
.,O
4060,O
.,O
7410,O
.,O
737Lactate,O
dehydrogenase,O
Normal472,O
.,O
0,O
(,O
230,O
.,O
8,O
–,O
978,O
.,O
0,O
),O
0,O
.,O
37,O
(,O
0,O
.,O
29,O
–,O
0,O
.,O
49,O
),O
455,O
.,O
0,O
(,O
248,O
.,O
5,O
–,O
1114,O
.,O
0,O
),O
0,O
.,O
39,O
(,O
0,O
.,O
30,O
–,O
0,O
.,O
52,O
),O
Elevated1200,O
.,O
0,O
(,O
400,O
.,O
0,O
–,O
3020,O
.,O
0,O
),O
0,O
.,O
43,O
(,O
0,O
.,O
33,O
–,O
0,O
.,O
59,O
),O
1629,O
.,O
5,O
(,O
517,O
.,O
0,O
–,O
3520,O
.,O
0,O
),O
0,O
.,O
52,O
(,O
0,O
.,O
38,O
–,O
0,O
.,O
63,O
),O
P,O
<,O
0,O
.,O
0001,O
0,O
.,O
006,O
<,O
0,O
.,O
0001,O
0,O
.,O
003,O
Prognostic,O
score,O
Low,O
risk482,O
.,O
0,O
(,O
248,O
.,O
0,O
–,O
1024,O
.,O
0,O
),O
0,O
.,O
37,O
(,O
0,O
.,O
29,O
–,O
0,O
.,O
51,O
),O
522,O
.,O
0,O
(,O
267,O
.,O
5,O
–,O
1771,O
.,O
0,O
),O
0,O
.,O
41,O
(,O
0,O
.,O
30,O
–,O
0,O
.,O
52,O
),O
High,O
risk942,O
.,O
0,O
(,O
402,O
.,O
0,O
–,O
2600,O
.,O
0,O
),O
0,O
.,O
42,O
(,O
0,O
.,O
34,O
–,O
0,O
.,O
57,O
),O
1620,O
.,O
0,O
(,O
493,O
.,O
0,O
–,O
2870,O
.,O
0,O
),O
0,O
.,O
52,O
(,O
0,O
.,O
39,O
–,O
0,O
.,O
66,O
),O
P,O
0,O
.,O
001,O
0,O
.,O
01,O
0,O
.,O
002,O
0,O
.,O
005,O
Data,O
were,O
presented,O
as,O
median,O
(,O
IQR,O
25,O
–,O
75,O
);,O
IQR,O
",",O
interquartile,O
range,O
;,O
circulating,O
cell,O
-,O
free,O
DNA,O
analysis,O
included,O
in,O
concentration,O
and,O
DII,O
levels,O
;,O
DII,O
",",O
DNA,O
integrity,O
index,O
.,O
The,O
IPI,O
score,O
was,O
used,O
for,O
patients,O
with,O
non,B-DS
-,I-DS
Hodgkin,I-DS
’,I-DS
s,I-DS
lymphoma,I-DS
and,O
the,O
IPS,O
score,O
for,O
patients,O
with,O
Hodgkin,B-DS
’,I-DS
s,I-DS
lymphoma,I-DS
.,O
IPI,O
scores,O
0,O
and,O
1,O
were,O
considered,O
low,O
risk,O
",",O
2,O
and,O
3,O
as,O
high,O
risk,O
",",O
while,O
with,O
IPS,O
scores,O
0,O
–,O
2,O
were,O
considered,O
as,O
low,O
risk,O
and,O
3,O
as,O
high,O
risk,O
P,O
value,O
",",O
comparison,O
between,O
the,O
two,O
strata,O
of,O
each,O
individual,O
variable,O
.,O
P,O
values,O
below,O
0,O
.,O
05,O
were,O
shown,O
in,O
italics,O
Prognostic,O
significance,O
of,O
circulating,O
cell,O
-,O
free,O
DNA,O
in,O
diffuse,B-DS
large,I-DS
B,I-DS
cell,I-DS
lymphoma,I-DS
patients,O
The,O
role,O
of,O
the,O
ccfDNA,O
levels,O
at,O
the,O
time,O
of,O
diagnosis,O
as,O
a,O
prognostic,O
marker,O
was,O
analyzed,O
in,O
patients,O
with,O
DLBCL,B-DS
",",O
who,O
constituted,O
the,O
largest,O
diagnostic,O
entity,O
included,O
in,O
this,O
study,O
.,O
The,O
most,O
discriminatory,O
cut,O
-,O
offs,O
for,O
2,O
-,O
year,O
PFS,O
were,O
identified,O
by,O
ROC,O
.,O
The,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
were,O
analyzed,O
as,O
dichotomic,O
variables,O
using,O
1586,O
ng,O
/,O
ml,O
and,O
0,O
.,O
61,O
as,O
the,O
cut,O
-,O
off,O
points,O
",",O
respectively,O
.,O
As,O
shown,O
in,O
the,O
Kaplan,O
-,O
Meier,O
curves,O
for,O
the,O
different,O
levels,O
of,O
ccfDNA,O
concentration,O
",",O
patients,O
with,O
a,O
ccfDNA,O
concentration,O
>,O
1586,O
ng,O
/,O
ml,O
had,O
a,O
2,O
-,O
year,O
probability,O
of,O
PFS,O
of,O
only,O
44,O
%,O
(,O
95,O
%,O
CI,O
15,O
–,O
73,O
"%),",O
whereas,O
patients,O
with,O
a,O
ccfDNA,O
concentration,O
≤,O
1586,O
ng,O
/,O
ml,O
had,O
significantly,O
higher,O
probability,O
of,O
2,O
-,O
year,O
PFS,O
at,O
78,O
%,O
(,O
95,O
%,O
CI,O
55,O
–,O
99,O
%;,O
P,O
=,O
0,O
.,O
001,O
;,O
Fig,O
.,O
3a,O
).,O
The,O
prognostic,O
value,O
of,O
ccfDNA,O
fragmentation,O
on,O
PFS,O
was,O
also,O
evaluated,O
using,O
the,O
DII,O
.,O
Patients,O
showing,O
a,O
DII,O
>,O
0,O
.,O
61,O
had,O
a,O
59,O
%,O
probability,O
of,O
2,O
-,O
year,O
PFS,O
(,O
95,O
%,O
CI,O
38,O
–,O
79,O
"%),",O
which,O
was,O
significantly,O
shorter,O
than,O
that,O
in,O
patients,O
with,O
a,O
DII,O
≤,O
0,O
.,O
61,O
(,O
87,O
"%,",O
95,O
%,O
CI,O
69,O
–,O
100,O
"%,",O
P,O
<,O
0,O
.,O
0001,O
;,O
Fig,O
.,O
3b,O
).,O
Fig,O
.,O
3Survival,O
curves,O
of,O
DLBCL,B-DS
patients,O
stratified,O
by,O
circulating,O
cell,O
-,O
free,O
DNA,O
levels,O
.,O
Kaplan,O
-,O
Meier,O
survival,O
curve,O
and,O
log,O
-,O
rank,O
test,O
according,O
to,O
a,O
concentration,O
and,O
b,O
DII,O
determined,O
by,O
ccfDNA,O
analysis,O
were,O
using,O
the,O
cut,O
-,O
offs,O
identified,O
by,O
means,O
of,O
ROC,O
for,O
2,O
-,O
year,O
progression,O
-,O
free,O
survival,O
(,O
P,O
value,O
noted,O
in,O
the,O
figure,O
).,O
ccfDNA,O
",",O
circulating,O
cell,O
-,O
free,O
DNA,O
;,O
DII,O
",",O
DNA,O
integrity,O
index,O
;,O
ROC,O
",",O
receiver,O
operating,O
characteristic,O
Following,O
the,O
univariate,O
analysis,O
",",O
we,O
found,O
that,O
both,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
were,O
associated,O
with,O
PFS,O
;,O
moreover,O
",",O
advanced,O
stage,O
",",O
B,O
-,O
symptoms,O
",",O
and,O
elevated,O
LDH,B-GP
levels,O
were,O
significant,O
adverse,O
factors,O
(,O
Table,O
3,O
).,O
Thus,O
",",O
these,O
variables,O
were,O
assessed,O
in,O
a,O
multivariate,O
Cox,O
regression,O
model,O
",",O
which,O
showed,O
that,O
the,O
DII,O
appeared,O
to,O
be,O
a,O
statistically,O
independent,O
prognostic,O
factor,O
(,O
HR,O
=,O
3,O
.,O
04,O
",",O
95,O
%,O
CI,O
1,O
.,O
197,O
–,O
7,O
.,O
696,O
;,O
P,O
=,O
0,O
.,O
019,O
"),",O
whereas,O
the,O
ccfDNA,O
concentration,O
was,O
not,O
significant,O
in,O
this,O
multivariate,O
analysis,O
(,O
HR,O
=,O
1,O
.,O
45,O
",",O
95,O
%,O
CI,O
0,O
.,O
490,O
–,O
4,O
.,O
263,O
;,O
P,O
=,O
0,O
.,O
504,O
).,O
Table,O
3Univariable,O
Cox,O
regression,O
models,O
for,O
progression,O
-,O
free,O
survival,O
(,O
PFS,O
),O
in,O
diffuse,B-DS
large,I-DS
B,I-DS
cell,I-DS
lymphoma,I-DS
patientsHR,O
(,O
95,O
%,O
CI,O
),O
P,O
valueGender,O
(,O
male,O
),O
1,O
.,O
128,O
(,O
0,O
.,O
454,O
–,O
2,O
.,O
799,O
),O
0,O
.,O
796Age,O
(>,O
60,O
years,O
),O
1,O
.,O
196,O
(,O
0,O
.,O
495,O
–,O
2,O
.,O
886,O
),O
0,O
.,O
692Advanced,O
stage7,O
.,O
977,O
(,O
1,O
.,O
856,O
–,O
34,O
.,O
29,O
),O
0,O
.,O
005,O
B,O
-,O
symptoms6,O
.,O
639,O
(,O
2,O
.,O
404,O
–,O
18,O
.,O
33,O
),O
<,O
0,O
.,O
0001,O
Bulky,O
disease0,O
.,O
571,O
(,O
0,O
.,O
133,O
–,O
2,O
.,O
456,O
),O
0,O
.,O
452Elevated,O
LDH4,B-GP
.,O
545,O
(,O
1,O
.,O
522,O
–,O
13,O
.,O
57,O
),O
0,O
.,O
007,O
Elevated,O
ccfDNA,O
Concentration4,O
.,O
270,O
(,O
1,O
.,O
653,O
–,O
11,O
.,O
03,O
),O
0,O
.,O
003,O
DII5,O
.,O
165,O
(,O
2,O
.,O
187,O
–,O
12,O
.,O
19,O
),O
<,O
0,O
.,O
0001,O
Data,O
were,O
presented,O
as,O
HR,O
(,O
95,O
%,O
CI,O
);,O
HR,O
",",O
hazard,O
ratio,O
;,O
CI,O
",",O
confidence,O
interval,O
.,O
ccfDNA,O
",",O
circulating,O
cell,O
-,O
free,O
DNA,O
;,O
elevated,O
ccfDNA,O
was,O
included,O
in,O
both,O
concentration,O
and,O
DII,O
levels,O
P,O
values,O
below,O
0,O
.,O
05,O
were,O
shown,O
in,O
italics,O
Discussion,O
This,O
study,O
reveals,O
that,O
compared,O
to,O
healthy,O
individuals,O
",",O
patients,O
with,O
lymphoma,B-DS
frequently,O
have,O
higher,O
concentrations,O
and,O
longer,O
strands,O
of,O
ccfDNA,O
at,O
the,O
time,O
of,O
diagnosis,O
",",O
which,O
correlates,O
with,O
clinical,O
parameters,O
and,O
was,O
demonstrated,O
to,O
be,O
a,O
negative,O
predictor,O
of,O
DLBCL,B-DS
patients,O
’,O
outcome,O
.,O
Recently,O
",",O
studies,O
conducted,O
in,O
various,O
malignancies,O
have,O
shown,O
that,O
ccfDNA,O
levels,O
are,O
significantly,O
increased,O
in,O
cancer,B-DS
[,O
22,O
",",O
23,O
].,O
Our,O
work,O
revealed,O
that,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
levels,O
were,O
elevated,O
in,O
patients,O
with,O
lymphoma,B-DS
.,O
The,O
analysis,O
of,O
the,O
histological,O
subsets,O
revealed,O
that,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
levels,O
varied,O
according,O
to,O
the,O
lymphoma,B-DS
subtype,O
.,O
Unfortunately,O
",",O
the,O
B,B-DS
-,I-DS
NHL,I-DS
and,O
T,B-DS
-,I-DS
NHL,I-DS
cohorts,O
were,O
insufficient,O
to,O
perform,O
a,O
significant,O
histological,O
subtype,O
analysis,O
.,O
There,O
are,O
only,O
few,O
reports,O
that,O
studied,O
the,O
clinical,O
impact,O
of,O
ccfDNA,O
levels,O
on,O
lymphoma,B-DS
patients,O
and,O
were,O
mainly,O
oriented,O
to,O
analyze,O
the,O
correlation,O
between,O
an,O
increase,O
in,O
the,O
ccfDNA,O
concentration,O
with,O
disease,O
risk,O
and,O
adverse,O
clinical,O
performance,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
other,O
analytical,O
parameters,O
exhibited,O
by,O
ccfDNA,O
such,O
as,O
the,O
DII,O
have,O
not,O
been,O
studied,O
in,O
lymphoma,B-DS
patients,O
.,O
Here,O
",",O
we,O
confirmed,O
the,O
usefulness,O
of,O
detecting,O
the,O
quantity,O
and,O
quality,O
of,O
ccfDNA,O
as,O
a,O
diagnostic,O
tool,O
for,O
lymphoma,B-DS
.,O
Data,O
from,O
our,O
ROC,O
analysis,O
showed,O
that,O
the,O
AUC,O
of,O
the,O
concentration,O
to,O
distinguish,O
HL,B-DS
",",O
DLBCL,B-DS
",",O
and,O
NK,B-DS
/,I-DS
TCL,I-DS
patients,O
from,O
normal,O
controls,O
was,O
0,O
.,O
75,O
",",O
0,O
.,O
86,O
",",O
and,O
0,O
.,O
79,O
",",O
respectively,O
;,O
furthermore,O
",",O
the,O
AUC,O
of,O
the,O
DII,O
was,O
higher,O
than,O
that,O
of,O
the,O
concentration,O
(,O
0,O
.,O
83,O
",",O
0,O
.,O
90,O
",",O
and,O
0,O
.,O
81,O
for,O
HL,B-DS
",",O
DLBCL,B-DS
",",O
and,O
NK,B-DS
/,I-DS
TCL,I-DS
",",O
respectively,O
"),",O
indicating,O
that,O
the,O
ccfDNA,O
concentration,O
alone,O
appeared,O
to,O
be,O
insufficient,O
for,O
a,O
high,O
-,O
quality,O
diagnostic,O
performance,O
.,O
Hohaus,O
et,O
al,O
.,O
[,O
17,O
],O
conducted,O
a,O
diagnostic,O
analysis,O
of,O
the,O
ccfDNA,O
concentration,O
for,O
patients,O
with,O
HL,B-DS
and,O
DLBCL,B-DS
and,O
found,O
that,O
the,O
maximum,O
sensitivity,O
and,O
specificity,O
did,O
not,O
exceed,O
75,O
"%,",O
making,O
this,O
parameter,O
an,O
unlikely,O
candidate,O
for,O
lymphoma,B-DS
screening,O
.,O
Our,O
study,O
found,O
that,O
for,O
DLBCL,B-DS
patients,O
",",O
there,O
was,O
an,O
added,O
incremental,O
diagnostic,O
value,O
when,O
the,O
ccfDNA,O
concentration,O
was,O
combined,O
with,O
the,O
DII,O
.,O
Regarding,O
the,O
clinical,O
correlation,O
of,O
ccfDNA,O
levels,O
in,O
lymphoma,B-DS
patients,O
",",O
we,O
observed,O
an,O
association,O
between,O
the,O
ccfDNA,O
levels,O
and,O
a,O
number,O
of,O
clinical,O
parameters,O
that,O
indicate,O
a,O
worse,O
prognosis,O
such,O
as,O
advanced,O
stage,O
disease,O
",",O
the,O
presence,O
of,O
B,O
-,O
symptoms,O
",",O
elevated,O
LDH,B-GP
levels,O
",",O
and,O
high,O
IPI,O
score,O
;,O
these,O
correlations,O
suggest,O
that,O
both,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
might,O
reflect,O
actively,O
proliferating,O
disease,O
and,O
lymphoma,B-DS
burden,O
.,O
Nevertheless,O
",",O
a,O
literature,O
analysis,O
highlights,O
the,O
confusion,O
regarding,O
these,O
ccfDNA,O
parameters,O
with,O
tumor,B-DS
burden,O
and,O
predicting,O
a,O
therapeutic,O
response,O
.,O
Hohaus,O
et,O
al,O
.,O
[,O
17,O
],O
also,O
observed,O
significant,O
associations,O
between,O
the,O
ccfDNA,O
concentration,O
and,O
some,O
adverse,O
parameters,O
",",O
whereas,O
a,O
study,O
by,O
Jones,O
et,O
al,O
.,O
[,O
18,O
],O
found,O
that,O
the,O
ccfDNA,O
concentration,O
was,O
not,O
indicative,O
of,O
lymphoma,B-DS
burden,O
once,O
therapy,O
had,O
commenced,O
;,O
they,O
reported,O
that,O
only,O
lymphoma,B-DS
-,O
specific,O
DNA,O
such,O
as,O
Epstein,B-OG
-,I-OG
Barr,I-OG
virus,I-OG
DNA,O
could,O
be,O
used,O
to,O
monitor,O
the,O
disease,O
response,O
in,O
lymphoma,B-DS
patients,O
.,O
In,O
addition,O
",",O
both,O
the,O
ccfDNA,O
concentration,O
and,O
the,O
DII,O
were,O
not,O
significantly,O
different,O
between,O
germinal,O
center,O
B,O
cell,O
type,O
and,O
non,O
-,O
germinal,O
center,O
B,O
cell,O
type,O
DLBCL,B-DS
based,O
on,O
the,O
Hans,O
classification,O
system,O
(,O
data,O
not,O
shown,O
).,O
We,O
assessed,O
the,O
prognostic,O
significance,O
of,O
ccfDNA,O
levels,O
in,O
patients,O
with,O
DLBCL,B-DS
.,O
Our,O
data,O
showed,O
that,O
high,O
concentrations,O
of,O
ccfDNA,O
and,O
an,O
elevated,O
DII,O
were,O
strongly,O
correlated,O
with,O
poor,O
outcome,O
in,O
patients,O
with,O
DLBCL,B-DS
",",O
which,O
has,O
already,O
been,O
reported,O
[,O
17,O
].,O
However,O
",",O
our,O
study,O
data,O
revealed,O
that,O
the,O
ccfDNA,O
concentration,O
was,O
insufficient,O
as,O
an,O
independent,O
prognostic,O
factor,O
compared,O
to,O
other,O
existing,O
and,O
validated,O
adverse,O
factors,O
such,O
as,O
disease,O
stage,O
or,O
elevated,O
LDH,B-GP
levels,O
[,O
24,O
].,O
The,O
origin,O
of,O
ccfDNA,O
is,O
still,O
unclear,O
.,O
In,O
healthy,O
individuals,O
",",O
the,O
ccfDNA,O
concentration,O
is,O
low,O
",",O
which,O
is,O
ascribed,O
to,O
the,O
efficient,O
removal,O
of,O
most,O
nonliving,O
cells,O
from,O
circulation,O
by,O
phagocytes,O
.,O
Schwarzenbach,O
et,O
al,O
.,O
[,O
25,O
],O
proposed,O
that,O
ccfDNA,O
could,O
be,O
released,O
by,O
either,O
apoptosis,O
or,O
necrosis,O
and,O
found,O
that,O
the,O
predominant,O
fragment,O
length,O
of,O
ccfDNA,O
frequently,O
occurred,O
in,O
multiples,O
of,O
180,O
bp,O
",",O
which,O
is,O
typical,O
of,O
DNA,O
released,O
from,O
apoptotic,O
cells,O
.,O
However,O
",",O
the,O
presence,O
of,O
larger,O
fragments,O
such,O
as,O
those,O
found,O
in,O
cancer,B-DS
patients,O
suggested,O
that,O
ccfDNA,O
could,O
also,O
be,O
derived,O
from,O
necrotic,O
cells,O
.,O
Moreover,O
",",O
some,O
studies,O
have,O
attributed,O
a,O
notable,O
fraction,O
of,O
ccfDNA,O
to,O
active,O
release,O
from,O
lymphocytes,O
[,O
26,O
].,O
ccfDNA,O
is,O
not,O
specific,O
to,O
neoplastic,O
conditions,O
as,O
increased,O
levels,O
have,O
also,O
been,O
identified,O
in,O
inflammatory,O
and,O
autoimmune,B-DS
diseases,I-DS
.,O
An,O
association,O
between,O
a,O
high,O
concentration,O
of,O
ccfDNA,O
and,O
poor,O
prognosis,O
may,O
be,O
linked,O
to,O
tumor,B-DS
burden,O
[,O
27,O
];,O
however,O
",",O
changes,O
in,O
the,O
total,O
ccfDNA,O
concentration,O
may,O
reflect,O
not,O
only,O
changes,O
in,O
circulating,O
tumor,B-DS
DNA,O
(,O
ctDNA,O
),O
but,O
also,O
in,O
other,O
conditions,O
that,O
may,O
lead,O
to,O
an,O
increase,O
in,O
ccfDNA,O
",",O
including,O
infection,B-DS
or,O
chemotherapy,O
drug,O
-,O
induced,O
release,O
of,O
normal,O
ccfDNA,O
into,O
the,O
circulation,O
.,O
ctDNA,O
is,O
a,O
specific,O
ccfDNA,O
released,O
by,O
tumor,B-DS
cells,O
",",O
which,O
contains,O
genetic,O
and,O
epigenetic,O
alterations,O
concordant,O
with,O
those,O
of,O
the,O
primary,O
tumor,B-DS
.,O
This,O
may,O
explain,O
why,O
our,O
data,O
showed,O
the,O
levels,O
of,O
ccfDNA,O
in,O
HL,B-DS
patients,O
were,O
as,O
high,O
as,O
in,O
NHL,B-DS
patients,O
and,O
indicated,O
that,O
the,O
overall,O
concentration,O
of,O
ccfDNA,O
was,O
not,O
an,O
independent,O
significant,O
prognostic,O
factor,O
of,O
survival,O
to,O
some,O
extent,O
.,O
Actually,O
",",O
our,O
results,O
showed,O
the,O
limitations,O
of,O
analyzing,O
only,O
the,O
total,O
ccfDNA,O
levels,O
",",O
as,O
focusing,O
on,O
tumor,B-DS
-,O
specific,O
ccfDNA,O
might,O
serve,O
as,O
a,O
more,O
adequate,O
surrogate,O
biomarker,O
.,O
For,O
solid,B-DS
tumors,I-DS
",",O
many,O
studies,O
have,O
validated,O
that,O
genetic,O
alterations,O
detected,O
in,O
ctDNA,O
correspond,O
to,O
the,O
primary,O
tumor,B-DS
and,O
that,O
the,O
levels,O
of,O
ctDNA,O
could,O
assess,O
the,O
tumor,B-DS
response,O
and,O
even,O
provide,O
an,O
earlier,O
indication,O
of,O
disease,O
progression,O
[,O
28,O
–,O
30,O
].,O
Roschewski,O
et,O
al,O
.,O
[,O
31,O
],O
reported,O
that,O
monitoring,O
ctDNA,O
could,O
identify,O
patients,O
with,O
DLBCL,B-DS
who,O
are,O
at,O
risk,O
of,O
recurrence,O
before,O
the,O
manifestation,O
of,O
clinical,O
evidence,O
of,O
disease,O
",",O
and,O
interim,O
ctDNA,O
may,O
be,O
a,O
promising,O
biomarker,O
to,O
identify,O
patients,O
at,O
high,O
risk,O
of,O
treatment,O
failure,O
.,O
However,O
",",O
additional,O
studies,O
on,O
ctDNA,O
are,O
required,O
to,O
prove,O
its,O
value,O
in,O
clinical,O
practice,O
.,O
Thus,O
",",O
as,O
the,O
ccfDNA,O
levels,O
could,O
still,O
reflect,O
disease,O
progression,O
[,O
32,O
"],",O
they,O
remain,O
a,O
useful,O
biomarker,O
to,O
monitor,O
disease,O
status,O
",",O
especially,O
when,O
combined,O
with,O
other,O
parameters,O
such,O
as,O
the,O
DII,O
or,O
ctDNA,O
levels,O
.,O
In,O
this,O
study,O
",",O
it,O
should,O
be,O
noted,O
that,O
ccfDNA,O
extraction,O
was,O
performed,O
using,O
the,O
magnetic,O
bead,O
method,O
",",O
which,O
is,O
based,O
on,O
the,O
principle,O
of,O
nucleic,O
acid,O
adsorption,O
and,O
release,O
via,O
magnetic,O
beads,O
.,O
The,O
most,O
commonly,O
used,O
DNA,O
extraction,O
methods,O
include,O
the,O
phenol,O
-,O
chloroform,O
method,O
",",O
sodium,O
iodide,O
method,O
",",O
and,O
magnetic,O
bead,O
method,O
as,O
well,O
as,O
the,O
use,O
of,O
commercial,O
DNA,O
isolation,O
kits,O
[,O
33,O
].,O
Pan,O
et,O
al,O
.,O
[,O
34,O
],O
compared,O
the,O
phenol,O
-,O
chloroform,O
method,O
",",O
commercial,O
kits,O
",",O
and,O
magnetic,O
bead,O
method,O
in,O
the,O
detection,O
of,O
mycobacterium,B-OG
tuberculosis,I-OG
DNA,O
and,O
found,O
that,O
the,O
magnetic,O
bead,O
method,O
had,O
the,O
highest,O
DNA,O
extraction,O
efficiency,O
and,O
the,O
best,O
reproducibility,O
.,O
In,O
conclusion,O
",",O
our,O
study,O
demonstrated,O
that,O
the,O
quantification,O
and,O
integrity,O
analysis,O
of,O
ccfDNA,O
from,O
the,O
plasma,O
of,O
patients,O
with,O
lymphoma,B-DS
might,O
be,O
a,O
useful,O
noninvasive,O
technique,O
for,O
clinical,O
practice,O
.,O
In,O
patients,O
with,O
DLBCL,B-DS
",",O
high,O
levels,O
of,O
ccfDNA,O
and,O
an,O
elevated,O
integrity,O
index,O
were,O
associated,O
with,O
poor,O
prognosis,O
",",O
although,O
",",O
based,O
on,O
our,O
results,O
",",O
only,O
the,O
DII,O
was,O
an,O
independent,O
adverse,O
factor,O
for,O
PFS,O
.,O
These,O
results,O
suggest,O
that,O
additional,O
prospective,O
studies,O
with,O
larger,O
cohorts,O
and,O
a,O
longer,O
follow,O
-,O
up,O
should,O
be,O
initiated,O
to,O
assess,O
the,O
utility,O
of,O
ccfDNA,O
analysis,O
",",O
especially,O
using,O
tumor,B-DS
-,O
specific,O
ccfDNA,O
.,O
Navigating,O
the,O
journey,O
of,O
Aboriginal,O
childhood,O
disability,O
:,O
a,O
qualitative,O
study,O
of,O
carers,O
’,O
interface,O
with,O
services,O
Background,O
The,O
disadvantage,O
experienced,O
by,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
children,O
with,O
a,O
disability,O
is,O
well,O
recognized,O
.,O
The,O
long,O
term,O
consequences,O
of,O
failing,O
to,O
address,O
disability,O
on,O
health,O
",",O
education,O
and,O
employment,O
underlies,O
the,O
importance,O
of,O
early,O
intervention,O
.,O
Caregivers,O
experience,O
a,O
disproportionate,O
burden,O
and,O
have,O
challenges,O
accessing,O
services,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
describe,O
the,O
carer,O
journey,O
of,O
accessing,O
support,O
and,O
services,O
.,O
Methods,O
We,O
conducted,O
in,O
-,O
depth,O
semi,O
-,O
structured,O
interviews,O
with,O
nineteen,O
parents,O
and,O
carers,O
of,O
Aboriginal,O
children,O
aged,O
0,O
–,O
8,O
years,O
.,O
The,O
children,O
were,O
patients,O
at,O
a,O
child,O
developmental,O
clinic,O
at,O
a,O
metropolitan,O
area,O
Aboriginal,O
health,O
service,O
in,O
Eastern,O
Australia,O
.,O
Interpretive,O
phenomenological,O
analysis,O
was,O
applied,O
to,O
transcribed,O
verbatim,O
accounts,O
.,O
Results,O
Four,O
themes,O
were,O
developed,O
using,O
the,O
‘,O
journey,O
’,O
metaphor,O
to,O
describe,O
the,O
carer,O
pathway,O
of,O
accessing,O
support,O
and,O
services,O
at,O
the,O
community,O
",",O
service,O
and,O
policy,O
levels,O
.,O
Themes,O
included,O
1,O
),O
the,O
need,O
for,O
increased,O
signage,O
within,O
communities,O
via,O
community,O
education,O
",",O
information,O
and,O
awareness,O
",",O
2,O
),O
wrong,O
way,O
signs,O
",",O
roundabouts,O
and,O
roadblocks,O
encountered,O
when,O
accessing,O
services,O
",",O
3,O
),O
alternate,O
routes,O
can,O
facilitate,O
the,O
journey,O
",",O
and,O
4,O
),O
incompatibility,O
of,O
inflexible,O
bureaucratic,O
road,O
rules,O
and,O
lived,O
realities,O
.,O
Conclusions,O
The,O
challenges,O
of,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
are,O
indisputable,O
and,O
these,O
can,O
be,O
compounded,O
for,O
people,O
experiencing,O
socio,O
-,O
economic,O
disadvantage,O
and,O
marginalisation,O
.,O
Overcoming,O
challenges,O
to,O
service,O
access,O
faced,O
by,O
carers,O
of,O
Aboriginal,O
children,O
with,O
a,O
disability,O
will,O
require,O
investment,O
in,O
community,O
",",O
services,O
and,O
policy,O
to,O
tailor,O
culturally,O
appropriate,O
models,O
of,O
care,O
.,O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
doi,O
:,O
10,O
.,O
1186,O
/,O
s12913,O
-,O
016,O
-,O
1926,O
-,O
0,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Background,O
Disparity,O
in,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
childhood,O
disability,O
-,O
impact,O
on,O
outcomes,O
The,O
opportunity,O
for,O
health,O
",",O
social,O
development,O
",",O
education,O
and,O
wellbeing,O
in,O
people,O
with,O
disabilities,O
can,O
be,O
easily,O
blighted,O
by,O
adverse,O
social,O
and,O
environmental,O
forces,O
and,O
commonly,O
the,O
needs,O
of,O
individuals,O
can,O
be,O
invisible,O
[,O
1,O
].,O
In,O
Australia,O
",",O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
peoples,O
suffer,O
worse,O
health,O
and,O
more,O
disadvantage,O
than,O
other,O
Australians,O
",",O
the,O
effects,O
of,O
which,O
are,O
exacerbated,O
by,O
dispossession,O
",",O
disempowerment,O
and,O
racism,O
[,O
2,O
",",O
3,O
].,O
The,O
disparities,O
between,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
children,O
and,O
other,O
Australian,O
children,O
are,O
also,O
highlighted,O
in,O
experiences,O
of,O
disability,O
[,O
4,O
–,O
6,O
].,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
children,O
are,O
more,O
likely,O
to,O
experience,O
hearing,B-DS
loss,I-DS
[,O
7,O
–,O
9,O
"],",O
linked,O
to,O
higher,O
rates,O
of,O
middle,B-DS
ear,I-DS
disease,I-DS
such,O
as,O
otitis,B-DS
media,I-DS
[,O
4,O
"],",O
and,O
to,O
require,O
assistance,O
with,O
self,O
-,O
care,O
",",O
mobility,O
or,O
communication,O
than,O
other,O
children,O
[,O
10,O
].,O
Disparities,O
have,O
also,O
been,O
reported,O
in,O
the,O
prevalence,O
of,O
developmental,B-DS
delay,I-DS
[,O
11,O
].,O
The,O
high,O
prevalence,O
of,O
disability,O
can,O
have,O
life,O
-,O
long,O
negative,O
consequences,O
on,O
health,O
",",O
education,O
and,O
employment,O
outcomes,O
for,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
children,O
[,O
9,O
",",O
12,O
].,O
Evidence,O
links,O
low,O
educational,O
achievement,O
to,O
involvement,O
in,O
the,O
criminal,O
justice,O
system,O
[,O
13,O
].,O
On,O
average,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
youth,O
are,O
detained,O
within,O
the,O
juvenile,O
justice,O
system,O
at,O
24,O
times,O
the,O
rate,O
of,O
other,O
youth,O
[,O
6,O
],O
and,O
are,O
4,O
to,O
5,O
times,O
more,O
likely,O
to,O
have,O
an,O
intellectual,B-DS
disability,I-DS
than,O
the,O
general,O
population,O
[,O
14,O
].,O
Adolescents,O
coming,O
into,O
contact,O
with,O
the,O
juvenile,O
justice,O
system,O
are,O
more,O
likely,O
to,O
be,O
incarcerated,O
as,O
an,O
adult,O
[,O
15,O
].,O
The,O
World,O
Health,O
Organization,O
recognizes,O
the,O
importance,O
of,O
social,O
determinants,O
in,O
influencing,O
health,O
outcomes,O
",",O
and,O
the,O
Close,O
the,O
Gap,O
Campaign,O
is,O
an,O
important,O
focus,O
of,O
Australian,O
government,O
and,O
non,O
-,O
government,O
organisations,O
to,O
address,O
the,O
needs,O
of,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
people,O
.,O
Internationally,O
",",O
indigenous,O
children,O
with,O
a,O
disability,O
are,O
considered,O
‘,O
doubly,O
disadvantaged,O
’,O
[,O
16,O
",",O
17,O
].,O
A,O
recent,O
longitudinal,O
cohort,O
study,O
of,O
development,O
in,O
urban,O
Aboriginal,O
children,O
found,O
that,O
high,O
levels,O
of,O
socio,O
-,O
economic,O
disadvantage,O
are,O
a,O
predictor,O
for,O
developmental,O
progress,O
[,O
18,O
].,O
While,O
the,O
high,O
levels,O
of,O
socio,O
-,O
economic,O
disadvantage,O
increases,O
the,O
chance,O
of,O
having,O
a,O
disability,O
",",O
the,O
high,O
rates,O
of,O
disability,O
can,O
contribute,O
to,O
socio,O
-,O
economic,O
disadvantage,O
",",O
thus,O
reinforcing,O
a,O
life,O
-,O
long,O
cycle,O
[,O
6,O
].,O
Impact,O
of,O
service,O
access,O
barriers,O
on,O
early,O
intervention,O
Early,O
intervention,O
is,O
crucial,O
to,O
counteracting,O
the,O
negative,O
impact,O
of,O
disability,O
for,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
children,O
[,O
4,O
].,O
It,O
is,O
necessary,O
to,O
facilitate,O
timely,O
access,O
of,O
children,O
and,O
their,O
families,O
to,O
appropriate,O
health,O
services,O
",",O
social,O
support,O
services,O
and,O
treatment,O
.,O
This,O
involves,O
interacting,O
with,O
a,O
health,O
care,O
system,O
that,O
is,O
not,O
always,O
accommodating,O
of,O
unique,O
",",O
socio,O
-,O
cultural,O
needs,O
.,O
Involvement,O
of,O
sectors,O
other,O
than,O
health,O
",",O
such,O
as,O
education,O
and,O
social,O
services,O
",",O
is,O
also,O
required,O
for,O
effective,O
early,O
intervention,O
but,O
increases,O
the,O
complexity,O
of,O
engagement,O
[,O
18,O
–,O
20,O
].,O
Carers,O
report,O
a,O
number,O
of,O
barriers,O
to,O
accessing,O
early,O
intervention,O
and,O
support,O
services,O
[,O
21,O
].,O
Lack,O
of,O
awareness,O
of,O
appropriate,O
disability,O
services,O
",",O
frequent,O
absence,O
of,O
culturally,O
appropriate,O
support,O
",",O
insufficient,O
resources,O
to,O
provide,O
care,O
",",O
and,O
a,O
loss,O
of,O
social,O
-,O
capital,O
-,O
based,O
support,O
due,O
to,O
fractured,O
family,O
and,O
community,O
structures,O
have,O
been,O
reported,O
as,O
barriers,O
to,O
service,O
access,O
which,O
impedes,O
early,O
intervention,O
[,O
21,O
",",O
22,O
].,O
A,O
holistic,O
approach,O
to,O
service,O
access,O
Improving,O
service,O
access,O
is,O
important,O
to,O
addressing,O
health,O
disparities,O
[,O
23,O
].,O
Influencing,O
factors,O
exist,O
at,O
the,O
micro,O
",",O
meso,O
and,O
macro,O
levels,O
[,O
24,O
–,O
27,O
].,O
A,O
holistic,O
approach,O
is,O
required,O
when,O
addressing,O
service,O
access,O
issues,O
for,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
families,O
of,O
a,O
child,O
with,O
a,O
disability,O
[,O
25,O
",",O
28,O
].,O
Desirable,O
outcomes,O
are,O
unlikely,O
to,O
be,O
achieved,O
if,O
the,O
interdependency,O
of,O
influencing,O
factors,O
is,O
not,O
addressed,O
.,O
For,O
example,O
",",O
carers,O
play,O
a,O
central,O
role,O
as,O
navigators,O
of,O
their,O
child,O
’,O
s,O
care,O
[,O
29,O
"],",O
thus,O
",",O
exploring,O
the,O
experiences,O
of,O
carers,O
is,O
imperative,O
in,O
understanding,O
service,O
access,O
for,O
children,O
with,O
a,O
disability,O
.,O
Data,O
on,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
children,O
with,O
a,O
disability,O
are,O
limited,O
",",O
particularly,O
in,O
urban,O
populations,O
and,O
this,O
inhibits,O
adequate,O
service,O
planning,O
[,O
30,O
].,O
Although,O
over,O
half,O
of,O
the,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
population,O
live,O
in,O
urban,O
or,O
regional,O
areas,O
",",O
most,O
of,O
the,O
research,O
on,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
childhood,O
disability,O
is,O
on,O
rural,O
or,O
remote,O
populations,O
[,O
24,O
",",O
31,O
–,O
33,O
].,O
It,O
is,O
important,O
to,O
address,O
this,O
gap,O
in,O
knowledge,O
as,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
populations,O
can,O
be,O
less,O
visible,O
in,O
urban,O
areas,O
and,O
available,O
services,O
are,O
not,O
necessarily,O
appropriate,O
or,O
accessible,O
[,O
21,O
",",O
32,O
",",O
34,O
",",O
35,O
].,O
To,O
address,O
this,O
paucity,O
of,O
information,O
",",O
we,O
investigated,O
the,O
experiences,O
of,O
Aboriginal,O
carers,O
to,O
inform,O
service,O
planning,O
and,O
access,O
to,O
early,O
intervention,O
.,O
Methods,O
We,O
aimed,O
to,O
describe,O
the,O
carer,O
experience,O
of,O
accessing,O
support,O
and,O
services,O
and,O
investigate,O
the,O
barriers,O
and,O
facilitators,O
to,O
service,O
access,O
from,O
the,O
perspective,O
of,O
carers,O
.,O
We,O
used,O
a,O
socio,O
-,O
ecological,O
framework,O
to,O
situate,O
carers,O
’,O
experiences,O
at,O
the,O
macro,O
-,O
(,O
government,O
"),",O
exo,O
-,O
(,O
organizational,O
),O
and,O
meso,O
-,O
(,O
provider,O
/,O
community,O
),O
system,O
levels,O
in,O
recognition,O
of,O
the,O
interaction,O
and,O
inter,O
-,O
dependence,O
of,O
these,O
environmental,O
factors,O
.,O
The,O
carer,O
",",O
child,O
and,O
family,O
are,O
positioned,O
within,O
the,O
centre,O
",",O
or,O
the,O
individual,O
-,O
level,O
",",O
of,O
the,O
socio,O
-,O
ecological,O
framework,O
.,O
The,O
micro,O
-,O
level,O
(,O
individual,O
),O
experiences,O
included,O
caring,O
for,O
the,O
child,O
and,O
family,O
",",O
challenges,O
and,O
facilitators,O
to,O
this,O
caring,O
",",O
carer,O
health,O
and,O
wellbeing,O
and,O
associated,O
financial,O
expenses,O
and,O
non,O
-,O
economic,O
costs,O
(,O
manuscript,O
under,O
review,O
).,O
This,O
paper,O
reports,O
on,O
the,O
carers,O
’,O
interaction,O
with,O
systems,O
beyond,O
their,O
immediate,O
family,O
;,O
that,O
being,O
",",O
the,O
community,O
",",O
service,O
and,O
policy,O
levels,O
of,O
the,O
framework,O
in,O
pursuit,O
of,O
optimal,O
outcomes,O
for,O
their,O
child,O
with,O
a,O
disability,O
.,O
To,O
understand,O
carers,O
’,O
experiences,O
and,O
perspectives,O
of,O
seeking,O
and,O
obtaining,O
health,O
and,O
social,O
service,O
supports,O
for,O
their,O
children,O
",",O
we,O
used,O
a,O
phenomenological,O
approach,O
[,O
36,O
].,O
Context,O
",",O
participants,O
and,O
recruitment,O
Participants,O
were,O
parents,O
or,O
informal,O
primary,O
carers,O
(,O
hereafter,O
",",O
carers,O
),O
of,O
children,O
aged,O
0,O
–,O
8,O
years,O
who,O
were,O
patients,O
at,O
a,O
child,O
development,O
clinic,O
at,O
a,O
metropolitan,O
area,O
Aboriginal,O
health,O
service,O
.,O
The,O
clinic,O
caters,O
to,O
children,O
with,O
developmental,O
problems,O
aged,O
from,O
birth,O
to,O
16,O
years,O
and,O
deals,O
with,O
the,O
identification,O
and,O
management,O
of,O
conditions,O
such,O
as,O
attention,B-DS
deficit,I-DS
hyperactivity,I-DS
disorder,I-DS
",",O
behavioural,B-DS
problems,I-DS
and,O
developmental,B-DS
delays,I-DS
.,O
Clinic,O
staff,O
informed,O
potential,O
participants,O
about,O
the,O
study,O
and,O
supplied,O
information,O
sheets,O
and,O
flyers,O
to,O
interested,O
parties,O
.,O
The,O
term,O
disability,O
was,O
deliberately,O
kept,O
broad,O
to,O
include,O
a,O
range,O
of,O
disability,O
experiences,O
including,O
mild,O
",",O
moderate,O
and,O
severe,O
",",O
involving,O
physical,O
",",O
intellectual,O
or,O
developmental,O
issues,O
.,O
Recruitment,O
continued,O
until,O
no,O
new,O
issues,O
emerged,O
.,O
Data,O
collection,O
The,O
research,O
team,O
was,O
co,O
-,O
led,O
by,O
Aboriginal,O
and,O
non,O
-,O
Aboriginal,O
team,O
members,O
",",O
each,O
with,O
designated,O
tasks,O
and,O
expertise,O
",",O
who,O
frequently,O
met,O
to,O
discuss,O
research,O
processes,O
",",O
debrief,O
about,O
ongoing,O
data,O
collection,O
",",O
and,O
strategize,O
to,O
overcome,O
logistical,O
challenges,O
.,O
To,O
capture,O
the,O
range,O
of,O
experiences,O
and,O
perspectives,O
of,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
",",O
we,O
conducted,O
in,O
-,O
depth,O
semi,O
-,O
structured,O
interviews,O
at,O
two,O
time,O
-,O
points,O
with,O
each,O
participant,O
.,O
Initial,O
interviews,O
were,O
conducted,O
at,O
the,O
health,O
facility,O
in,O
private,O
clinic,O
rooms,O
with,O
one,O
of,O
two,O
researchers,O
trained,O
in,O
qualitative,O
methods,O
(,O
AA,O
&,O
BB,O
).,O
These,O
interviews,O
lasted,O
approximately,O
20,O
–,O
60,O
min,O
and,O
often,O
occurred,O
opportunistically,O
while,O
waiting,O
for,O
or,O
immediately,O
following,O
their,O
child,O
’,O
s,O
clinic,O
appointment,O
.,O
Children,O
sometimes,O
were,O
in,O
the,O
room,O
during,O
interviews,O
",",O
usually,O
playing,O
or,O
sleeping,O
",",O
because,O
no,O
other,O
supervision,O
was,O
available,O
.,O
Follow,O
-,O
up,O
interviews,O
were,O
conducted,O
with,O
participants,O
to,O
ascertain,O
and,O
document,O
activities,O
related,O
to,O
the,O
child,O
’,O
s,O
disability,O
",",O
services,O
sought,O
",",O
interactions,O
with,O
health,O
or,O
other,O
service,O
professionals,O
",",O
and,O
barriers,O
and,O
facilitators,O
to,O
support,O
since,O
the,O
first,O
interview,O
.,O
Follow,O
-,O
up,O
interviews,O
took,O
place,O
via,O
telephone,O
if,O
participants,O
were,O
unable,O
to,O
attend,O
the,O
service,O
in,O
person,O
.,O
All,O
follow,O
-,O
up,O
interviews,O
were,O
conducted,O
within,O
6,O
–,O
12,O
months,O
of,O
the,O
initial,O
interviews,O
according,O
to,O
the,O
preference,O
and,O
availability,O
of,O
participants,O
.,O
Participants,O
were,O
reimbursed,O
for,O
travel,O
and,O
child,O
care,O
expenses,O
incurred,O
as,O
a,O
result,O
of,O
participation,O
.,O
Data,O
collection,O
took,O
place,O
from,O
April,O
2013,O
to,O
June,O
2015,O
.,O
Interviewers,O
The,O
Aboriginal,O
leaders,O
and,O
cultural,O
mentors,O
of,O
the,O
project,O
were,O
unable,O
to,O
undertake,O
interviews,O
given,O
their,O
management,O
roles,O
at,O
the,O
health,O
facility,O
.,O
This,O
meant,O
that,O
the,O
non,O
-,O
Aboriginal,O
team,O
members,O
",",O
who,O
worked,O
in,O
another,O
area,O
of,O
the,O
health,O
service,O
one,O
or,O
more,O
days,O
each,O
week,O
",",O
were,O
designated,O
to,O
conduct,O
the,O
interviews,O
whenever,O
clinic,O
staff,O
telephoned,O
with,O
an,O
eligible,O
consenting,O
participant,O
.,O
One,O
of,O
these,O
interviewers,O
was,O
a,O
general,O
practitioner,O
(,O
GP,O
),O
at,O
the,O
health,O
service,O
and,O
a,O
university,O
academic,O
.,O
She,O
had,O
met,O
some,O
of,O
the,O
participants,O
previously,O
in,O
the,O
context,O
of,O
primary,O
care,O
consultations,O
",",O
however,O
she,O
was,O
not,O
involved,O
directly,O
in,O
the,O
child,O
’,O
s,O
healthcare,O
or,O
the,O
clinic,O
.,O
Prior,O
to,O
commencing,O
interviews,O
",",O
she,O
explained,O
the,O
research,O
role,O
to,O
participants,O
as,O
separate,O
to,O
her,O
GP,O
role,O
.,O
As,O
a,O
non,O
-,O
Aboriginal,O
woman,O
having,O
worked,O
part,O
-,O
time,O
for,O
over,O
twenty,O
years,O
at,O
the,O
health,O
service,O
where,O
this,O
research,O
was,O
conducted,O
",",O
this,O
interviewer,O
had,O
extensive,O
knowledge,O
and,O
experience,O
within,O
the,O
local,O
community,O
and,O
health,O
service,O
.,O
The,O
second,O
interviewer,O
",",O
also,O
a,O
non,O
-,O
Aboriginal,O
woman,O
",",O
had,O
qualifications,O
in,O
psychology,O
and,O
was,O
a,O
health,O
services,O
researcher,O
based,O
at,O
a,O
university,O
.,O
She,O
had,O
been,O
a,O
weekly,O
visiting,O
counsellor,O
at,O
the,O
health,O
service,O
for,O
8,O
years,O
.,O
Two,O
local,O
Aboriginal,O
elders,O
(,O
CC,O
&,O
DD,O
),O
co,O
-,O
led,O
this,O
project,O
and,O
acted,O
as,O
cultural,O
mentors,O
who,O
contributed,O
to,O
the,O
study,O
design,O
",",O
recruitment,O
and,O
analysis,O
.,O
At,O
each,O
stage,O
",",O
they,O
offered,O
perspectives,O
of,O
findings,O
conveyed,O
in,O
repeated,O
discussions,O
with,O
the,O
interviewers,O
.,O
Each,O
described,O
their,O
positioning,O
in,O
relation,O
to,O
this,O
research,O
and,O
described,O
their,O
conscious,O
biases,O
to,O
clarify,O
their,O
interpretations,O
.,O
Some,O
",",O
but,O
not,O
all,O
",",O
members,O
of,O
this,O
team,O
had,O
the,O
experience,O
of,O
parenting,O
or,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
.,O
The,O
interviewers,O
met,O
periodically,O
to,O
debrief,O
and,O
consider,O
interview,O
proceedings,O
.,O
Each,O
provided,O
important,O
insights,O
that,O
informed,O
the,O
others,O
’,O
interpretations,O
.,O
The,O
cultural,O
mentors,O
and,O
GP,O
interviewer,O
provided,O
service,O
and,O
community,O
context,O
from,O
Aboriginal,O
and,O
non,O
-,O
Aboriginal,O
perspectives,O
",",O
respectively,O
",",O
while,O
the,O
university,O
interviewer,O
offered,O
a,O
less,O
entrenched,O
experience,O
of,O
the,O
community,O
",",O
yet,O
with,O
an,O
appreciation,O
of,O
historical,O
and,O
social,O
context,O
.,O
The,O
semi,O
-,O
structured,O
interviews,O
attended,O
primarily,O
to,O
the,O
carer,O
’,O
s,O
own,O
narrative,O
.,O
Interview,O
topics,O
were,O
derived,O
from,O
a,O
literature,O
review,O
[,O
24,O
"],",O
experience,O
and,O
expertise,O
of,O
cultural,O
mentors,O
who,O
were,O
also,O
carers,O
",",O
and,O
the,O
social,O
determinants,O
of,O
health,O
and,O
social,O
capital,O
frameworks,O
[,O
2,O
",",O
17,O
",",O
37,O
],O
(,O
Additional,O
file,O
1,O
).,O
During,O
interviews,O
",",O
we,O
explored,O
participant,O
’,O
s,O
experiences,O
with,O
the,O
child,O
’,O
s,O
disability,O
",",O
their,O
meanings,O
and,O
interpretations,O
of,O
these,O
experiences,O
",",O
and,O
their,O
experiences,O
seeking,O
and,O
obtaining,O
support,O
and,O
services,O
.,O
Attention,O
was,O
paid,O
to,O
experiences,O
of,O
intake,O
and,O
triage,O
",",O
respite,O
use,O
and,O
need,O
",",O
allied,O
health,O
service,O
access,O
and,O
needs,O
and,O
preferences,O
for,O
information,O
",",O
services,O
and,O
support,O
.,O
Limited,O
demographic,O
and,O
health,O
-,O
related,O
information,O
was,O
collected,O
during,O
the,O
interviews,O
.,O
Upon,O
the,O
follow,O
-,O
up,O
interview,O
",",O
the,O
interviewer,O
summarised,O
thematic,O
content,O
of,O
the,O
previous,O
interview,O
with,O
participants,O
to,O
seek,O
confirmation,O
of,O
its,O
validity,O
[,O
38,O
].,O
Any,O
noted,O
discrepancies,O
were,O
discussed,O
",",O
clarified,O
and,O
resolved,O
to,O
the,O
satisfaction,O
of,O
the,O
participant,O
.,O
Data,O
analysis,O
and,O
trustworthiness,O
Analysis,O
began,O
with,O
development,O
of,O
a,O
contact,O
summary,O
sheet,O
with,O
key,O
demographic,O
information,O
and,O
emergent,O
issues,O
[,O
39,O
],O
for,O
each,O
interview,O
.,O
Interpretative,O
phenomenological,O
analysis,O
(,O
IPA,O
),O
was,O
used,O
to,O
analyse,O
carers,O
’,O
experiences,O
[,O
36,O
],O
as,O
this,O
approach,O
centres,O
on,O
individuals,O
ascribing,O
meaning,O
to,O
their,O
experiences,O
in,O
their,O
interactions,O
with,O
the,O
environment,O
.,O
IPA,O
is,O
a,O
set,O
of,O
systematic,O
processes,O
that,O
shift,O
from,O
phenomenological,O
to,O
interpretive,O
while,O
focusing,O
on,O
the,O
participant,O
’,O
s,O
perspective,O
and,O
understandings,O
in,O
different,O
contexts,O
[,O
36,O
].,O
It,O
is,O
an,O
iterative,O
",",O
inductive,O
and,O
flexible,O
approach,O
involving,O
close,O
reading,O
and,O
re,O
-,O
reading,O
of,O
transcripts,O
while,O
note,O
-,O
taking,O
in,O
margins,O
",",O
‘,O
bracketing,O
’,O
the,O
analyst,O
’,O
s,O
critical,O
perspective,O
",",O
recording,O
critical,O
and,O
interpretive,O
comments,O
in,O
a,O
reflexive,O
diary,O
;,O
re,O
-,O
reading,O
the,O
text,O
and,O
identifying,O
codes,O
and,O
themes,O
that,O
best,O
capture,O
the,O
essential,O
qualities,O
of,O
that,O
interview,O
while,O
also,O
looking,O
for,O
connections,O
between,O
themes,O
;,O
revisiting,O
earlier,O
transcripts,O
to,O
re,O
-,O
consider,O
data,O
;,O
clustering,O
themes,O
and,O
concepts,O
and,O
developing,O
an,O
overall,O
structure,O
using,O
excerpts,O
from,O
interviews,O
;,O
and,O
re,O
-,O
assessing,O
and,O
revising,O
new,O
themes,O
against,O
earlier,O
data,O
[,O
40,O
].,O
One,O
researcher,O
(,O
AA,O
),O
undertook,O
preliminary,O
analysis,O
wherein,O
transcripts,O
were,O
read,O
",",O
notes,O
added,O
to,O
the,O
document,O
",",O
and,O
a,O
coding,O
system,O
developed,O
to,O
elucidate,O
categories,O
.,O
To,O
facilitate,O
rigor,O
",",O
a,O
second,O
researcher,O
(,O
EE,O
),O
independently,O
coded,O
unmarked,O
transcripts,O
[,O
41,O
].,O
The,O
interviewers,O
had,O
frequent,O
informal,O
and,O
formal,O
discussions,O
regarding,O
code,O
development,O
and,O
emerging,O
findings,O
with,O
the,O
lead,O
cultural,O
mentor,O
(,O
CC,O
),O
who,O
provided,O
formative,O
insights,O
throughout,O
the,O
data,O
collection,O
and,O
preliminary,O
analysis,O
period,O
;,O
divergences,O
in,O
the,O
coding,O
scheme,O
were,O
discussed,O
until,O
consensus,O
was,O
reached,O
.,O
The,O
remaining,O
interviews,O
were,O
coded,O
according,O
to,O
the,O
developed,O
scheme,O
",",O
yet,O
emergent,O
categories,O
were,O
documented,O
and,O
considered,O
throughout,O
the,O
analysis,O
.,O
Categories,O
were,O
then,O
collapsed,O
into,O
themes,O
.,O
Preliminary,O
and,O
developed,O
themes,O
were,O
discussed,O
with,O
the,O
full,O
project,O
team,O
prior,O
to,O
cessation,O
of,O
analysis,O
and,O
this,O
was,O
followed,O
by,O
another,O
extensive,O
discussion,O
of,O
key,O
themes,O
with,O
the,O
lead,O
cultural,O
mentor,O
.,O
Transcript,O
excerpts,O
which,O
supported,O
each,O
theme,O
were,O
copied,O
into,O
a,O
Microsoft,O
Word,O
file,O
along,O
with,O
supporting,O
field,O
notes,O
.,O
All,O
supporting,O
evidence,O
was,O
then,O
considered,O
",",O
contextualised,O
and,O
written,O
into,O
an,O
account,O
illustrating,O
participants,O
’,O
experiences,O
and,O
perspectives,O
[,O
42,O
].,O
To,O
further,O
enhance,O
credibility,O
and,O
trustworthiness,O
",",O
stakeholder,O
checks,O
were,O
undertaken,O
[,O
41,O
"],",O
whereby,O
preliminary,O
analysis,O
of,O
findings,O
was,O
presented,O
to,O
clinic,O
staff,O
",",O
some,O
of,O
whom,O
were,O
also,O
carers,O
of,O
an,O
Aboriginal,O
child,O
with,O
a,O
disability,O
.,O
Additional,O
feedback,O
from,O
this,O
group,O
was,O
incorporated,O
into,O
theme,O
development,O
.,O
Ethical,O
considerations,O
Ethical,O
approval,O
was,O
granted,O
by,O
the,O
Aboriginal,O
Health,O
and,O
Medical,O
Research,O
Council,O
(,O
AH,O
&,O
MRC,O
),O
(,O
762,O
/,O
10,O
),O
and,O
University,O
of,O
Technology,O
Sydney,O
Human,O
Research,O
Ethics,O
Committee,O
(,O
UTS,O
HREC,O
2011,O
-,O
417R,O
).,O
The,O
study,O
adhered,O
to,O
key,O
principles,O
for,O
research,O
with,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
peoples,O
as,O
espoused,O
by,O
the,O
AH,O
&,O
MRC,O
.,O
Briefly,O
",",O
these,O
included,O
the,O
involvement,O
in,O
and,O
control,O
of,O
all,O
research,O
stages,O
by,O
the,O
Aboriginal,O
health,O
service,O
",",O
direct,O
consultation,O
with,O
members,O
of,O
the,O
community,O
affected,O
by,O
the,O
research,O
",",O
reimbursement,O
of,O
expenses,O
associated,O
with,O
participation,O
",",O
and,O
intended,O
outcomes,O
that,O
inform,O
the,O
design,O
and,O
delivery,O
of,O
needed,O
culturally,O
appropriate,O
services,O
for,O
children,O
and,O
their,O
families,O
and,O
are,O
aimed,O
at,O
increasing,O
the,O
community,O
’,O
s,O
knowledge,O
of,O
and,O
ways,O
to,O
access,O
support,O
and,O
services,O
[,O
43,O
].,O
Confidentiality,O
of,O
discussions,O
was,O
assured,O
and,O
participants,O
were,O
advised,O
that,O
their,O
care,O
or,O
status,O
at,O
the,O
health,O
service,O
would,O
be,O
influenced,O
neither,O
by,O
participation,O
nor,O
divulgence,O
.,O
Permission,O
to,O
audio,O
record,O
interviews,O
was,O
obtained,O
from,O
each,O
participant,O
.,O
Names,O
were,O
replaced,O
with,O
pseudonyms,O
and,O
identifying,O
information,O
was,O
removed,O
following,O
verbatim,O
transcription,O
of,O
recordings,O
.,O
Study,O
findings,O
are,O
reported,O
according,O
to,O
the,O
consolidated,O
criteria,O
for,O
reporting,O
qualitative,O
research,O
guidelines,O
[,O
44,O
].,O
Availability,O
of,O
data,O
and,O
materials,O
The,O
data,O
supporting,O
the,O
conclusions,O
of,O
this,O
article,O
are,O
included,O
within,O
the,O
article,O
in,O
the,O
form,O
of,O
interview,O
excerpts,O
.,O
Full,O
interview,O
transcripts,O
remain,O
the,O
property,O
of,O
the,O
participating,O
Aboriginal,O
Community,O
Controlled,O
Health,O
Organization,O
.,O
The,O
journey,O
metaphor,O
Pathways,O
and,O
journeys,O
have,O
increasingly,O
been,O
used,O
to,O
depict,O
experiences,O
of,O
health,O
conditions,O
and,O
service,O
use,O
as,O
these,O
terms,O
reflect,O
movement,O
or,O
progression,O
",",O
not,O
always,O
in,O
a,O
linear,O
direction,O
",",O
but,O
generally,O
resulting,O
in,O
an,O
accumulation,O
or,O
loss,O
of,O
knowledge,O
or,O
other,O
resources,O
over,O
time,O
[,O
45,O
].,O
We,O
often,O
refer,O
to,O
gaining,O
new,O
experience,O
or,O
skills,O
as,O
‘,O
going,O
on,O
a,O
journey,O
’.,O
This,O
metaphor,O
implies,O
that,O
there,O
is,O
a,O
process,O
",",O
a,O
starting,O
point,O
and,O
a,O
destination,O
on,O
which,O
people,O
travel,O
",",O
usually,O
figuratively,O
",",O
in,O
acquisition,O
of,O
information,O
or,O
resources,O
.,O
This,O
is,O
often,O
an,O
ongoing,O
process,O
that,O
involves,O
a,O
series,O
of,O
points,O
and,O
opportunities,O
for,O
learning,O
and,O
this,O
occurs,O
over,O
a,O
long,O
span,O
of,O
time,O
.,O
Some,O
continue,O
along,O
a,O
pre,O
-,O
determined,O
route,O
or,O
course,O
of,O
action,O
",",O
while,O
others,O
forge,O
a,O
path,O
as,O
a,O
result,O
of,O
circumstances,O
or,O
opportunity,O
.,O
The,O
term,O
‘,O
clinical,O
pathway,O
’,O
is,O
used,O
in,O
health,O
to,O
depict,O
standardised,O
",",O
evidence,O
-,O
based,O
multidisciplinary,O
management,O
plans,O
",",O
of,O
a,O
sequence,O
of,O
interventions,O
",",O
timeframes,O
",",O
milestones,O
and,O
expected,O
outcomes,O
for,O
a,O
patient,O
group,O
[,O
46,O
].,O
These,O
pathways,O
are,O
often,O
depicted,O
in,O
resources,O
to,O
map,O
the,O
patient,O
journey,O
",",O
to,O
foster,O
an,O
understanding,O
of,O
the,O
whole,O
pathway,O
(,O
including,O
environmental,O
influences,O
),O
and,O
its,O
distinct,O
components,O
",",O
including,O
specific,O
steps,O
or,O
critical,O
points,O
along,O
the,O
care,O
pathway,O
[,O
47,O
].,O
Pathways,O
to,O
service,O
delivery,O
have,O
likewise,O
been,O
depicted,O
as,O
roadmaps,O
.,O
Although,O
we,O
had,O
not,O
anticipated,O
",",O
originally,O
",",O
use,O
of,O
metaphor,O
to,O
help,O
us,O
understand,O
caregiving,O
or,O
care,O
-,O
seeking,O
behaviour,O
",",O
we,O
became,O
aware,O
of,O
the,O
symbols,O
",",O
words,O
and,O
metaphors,O
used,O
to,O
convey,O
interpretations,O
of,O
meaning,O
[,O
45,O
].,O
We,O
began,O
the,O
analysis,O
process,O
by,O
trying,O
to,O
describe,O
what,O
we,O
saw,O
in,O
experiences,O
.,O
Metaphors,O
arose,O
from,O
our,O
and,O
participants,O
’,O
descriptive,O
language,O
related,O
to,O
the,O
experiences,O
.,O
The,O
visual,O
representation,O
of,O
these,O
types,O
of,O
concepts,O
through,O
metaphors,O
aligns,O
with,O
the,O
narrative,O
approach,O
of,O
telling,O
stories,O
that,O
values,O
the,O
spoken,O
word,O
and,O
oral,O
history,O
tradition,O
in,O
Aboriginal,O
culture,O
and,O
is,O
considered,O
a,O
respectful,O
research,O
technique,O
[,O
48,O
].,O
Following,O
the,O
second,O
stakeholder,O
check,O
with,O
cultural,O
mentors,O
(,O
CC,O
&,O
DD,O
),O
this,O
depiction,O
was,O
deemed,O
a,O
culturally,O
congruent,O
representation,O
of,O
the,O
findings,O
.,O
We,O
link,O
the,O
findings,O
to,O
this,O
metaphor,O
in,O
an,O
effort,O
to,O
communicate,O
this,O
complex,O
phenomenon,O
.,O
Results,O
Participants,O
were,O
19,O
carers,O
of,O
Aboriginal,O
children,O
.,O
They,O
were,O
all,O
women,O
",",O
more,O
than,O
half,O
of,O
whom,O
(,O
n,O
=,O
10,O
),O
were,O
lone,O
carers,O
(,O
without,O
a,O
partner,O
or,O
spouse,O
"),",O
and,O
were,O
taking,O
care,O
of,O
60,O
children,O
at,O
home,O
",",O
half,O
of,O
whom,O
were,O
identified,O
as,O
having,O
a,O
disability,O
or,O
developmental,B-DS
delay,I-DS
.,O
The,O
majority,O
of,O
participants,O
were,O
the,O
mothers,O
of,O
the,O
children,O
(,O
n,O
=,O
16,O
"),",O
and,O
three,O
were,O
grandmothers,O
.,O
Factors,O
that,O
influenced,O
carer,O
journeys,O
to,O
access,O
support,O
and,O
services,O
reflected,O
their,O
interactions,O
with,O
community,O
",",O
service,O
and,O
policy,O
levels,O
.,O
Themes,O
depicting,O
these,O
journeys,O
included,O
:,O
need,O
for,O
increased,O
signage,O
via,O
community,O
education,O
",",O
information,O
and,O
awareness,O
;,O
wrong,O
way,O
signs,O
",",O
roundabouts,O
and,O
roadblocks,O
encountered,O
when,O
accessing,O
services,O
;,O
alternate,O
routes,O
can,O
facilitate,O
the,O
journey,O
;,O
and,O
the,O
incompatibility,O
of,O
inflexible,O
bureaucratic,O
road,O
rules,O
and,O
lived,O
realities,O
.,O
Need,O
for,O
‘,O
increased,O
signage,O
’,O
within,O
communities,O
via,O
community,O
education,O
",",O
information,O
and,O
awareness,O
The,O
community,O
",",O
defined,O
as,O
an,O
informal,O
network,O
of,O
extended,O
family,O
",",O
friends,O
and,O
other,O
carers,O
",",O
played,O
a,O
key,O
role,O
in,O
carers,O
’,O
accessing,O
support,O
and,O
services,O
.,O
Due,O
to,O
this,O
influence,O
",",O
carers,O
emphasised,O
the,O
need,O
for,O
investment,O
in,O
building,O
community,O
capacity,O
as,O
a,O
support,O
mechanism,O
through,O
increased,O
education,O
",",O
information,O
and,O
awareness,O
.,O
Carers,O
accessed,O
advice,O
and,O
recommendations,O
from,O
community,O
members,O
on,O
the,O
developmental,O
progress,O
of,O
children,O
and,O
available,O
services,O
.,O
Some,O
carers,O
experienced,O
tension,O
between,O
respecting,O
community,O
advice,O
while,O
knowing,O
something,O
is,O
wrong,O
with,O
their,O
child,O
.,O
Community,O
advice,O
in,O
this,O
context,O
is,O
inclusive,O
of,O
cultural,O
advice,O
as,O
identified,O
by,O
carers,O
.,O
Advice,O
by,O
community,O
members,O
that,O
there,O
was,O
nothing,O
wrong,O
with,O
a,O
child,O
contributed,O
to,O
delays,O
in,O
seeking,O
diagnoses,O
and,O
treatment,O
.,O
“,O
Yeah,O
",",O
you,O
let,O
things,O
slide,O
.,O
You,O
just,O
–,O
it,O
’,O
s,O
not,O
that,O
you,O
don,O
’,O
t,O
want,O
to,O
put,O
the,O
effort,O
into,O
it,O
and,O
go,O
and,O
sit,O
around,O
and,O
take,O
them,O
out,O
of,O
school,O
or,O
anything,O
like,O
that,O
",",O
it,O
’,O
s,O
just,O
you,O
’,O
ve,O
got,O
your,O
elder,O
saying,O
to,O
you,O
",",O
“,O
No,O
",",O
they,O
’,O
re,O
right,O
.,O
They,O
’,O
re,O
right,O
.,O
Don,O
’,O
t,O
worry,O
about,O
it,O
.,O
They,O
’,O
ll,O
pick,O
up,O
in,O
their,O
own,O
time,O
",”",O
and,O
sometimes,O
they,O
don,O
’,O
t,O
.”,O
(,O
Rita,O
),O
The,O
lack,O
of,O
community,O
education,O
",",O
information,O
and,O
awareness,O
around,O
disability,O
and,O
available,O
services,O
evidently,O
impeded,O
access,O
to,O
support,O
and,O
services,O
.,O
“,O
It,O
’,O
s,O
not,O
advertised,O
that,O
they,O
have,O
this,O
other,O
health,O
service,O
that,O
’,O
s,O
provided,O
for,O
black,O
kids,O
…,O
But,O
yeah,O
.,O
It,O
’,O
s,O
not,O
known,O
…,O
That,O
’,O
s,O
what,O
my,O
thing,O
is,O
…,O
But,O
how,O
many,O
other,O
people,O
are,O
missing,O
out,O
?”,O
(,O
Laura,O
),O
Carer,O
preferences,O
to,O
address,O
this,O
lack,O
of,O
clear,O
direction,O
and,O
mapping,O
were,O
access,O
to,O
a,O
local,O
database,O
of,O
preferred,O
providers,O
and,O
building,O
a,O
community,O
of,O
carers,O
through,O
support,O
groups,O
.,O
Carers,O
identified,O
that,O
they,O
would,O
prefer,O
to,O
have,O
the,O
database,O
and,O
support,O
groups,O
organised,O
and,O
hosted,O
through,O
the,O
local,O
Aboriginal,O
health,O
service,O
.,O
“,O
I,O
think,O
that,O
that,O
would,O
be,O
something,O
that,O
would,O
be,O
helpful,O
for,O
us,O
to,O
just,O
be,O
able,O
to,O
have,O
some,O
sort,O
of,O
connection,O
to,O
other,O
families,O
",",O
in,O
particular,O
Aboriginal,O
families,O
…,O
and,O
whether,O
the,O
[,O
Aboriginal,O
health,O
service,O
],O
can,O
",",O
sort,O
of,O
",",O
do,O
that,O
.”,O
(,O
Ainslee,O
),O
Wrong,O
way,O
signs,O
",",O
roundabouts,O
and,O
roadblocks,O
encountered,O
when,O
accessing,O
services,O
Carers,O
encountered,O
a,O
number,O
of,O
obstacles,O
when,O
attempting,O
to,O
access,O
and,O
interface,O
with,O
health,O
and,O
support,O
services,O
.,O
Many,O
carer,O
journeys,O
involved,O
referrals,O
to,O
and,O
interaction,O
with,O
multiple,O
service,O
providers,O
including,O
occupational,O
therapists,O
(,O
OT,O
"),",O
speech,O
therapists,O
",",O
physiotherapists,O
",",O
paediatricians,O
and,O
GPs,O
.,O
In,O
navigating,O
this,O
pathway,O
independently,O
",",O
there,O
were,O
accounts,O
of,O
providers,O
qualifying,O
the,O
extent,O
of,O
their,O
service,O
leading,O
to,O
inconsistent,O
service,O
access,O
.“,O
I,O
would,O
ring,O
a,O
private,O
speech,O
and,O
private,O
OT,O
",",O
and,O
stuff,O
and,O
a,O
lot,O
of,O
them,O
would,O
say,O
",",O
okay,O
",",O
but,O
we,O
don,O
’,O
t,O
deal,O
with,O
children,O
with,O
significant,O
disabilities,O
…,O
you,O
need,O
to,O
go,O
to,O
your,O
GP,O
",",O
and,O
it,O
would,O
be,O
like,O
[,O
laughs,O
],O
a,O
sort,O
of,O
a,O
catch,O
-,O
22,O
…,O
It,O
would,O
just,O
be,O
round,O
in,O
circles,O
…,O
it,O
just,O
really,O
wasn,O
’,O
t,O
helpful,O
at,O
all,O
.”,O
(,O
Ainslee,O
),O
Delays,O
to,O
assessment,O
and,O
treatment,O
caused,O
by,O
long,O
waitlists,O
were,O
a,O
significant,O
roadblock,O
encountered,O
by,O
carers,O
.,O
Long,O
waitlists,O
for,O
needed,O
procedures,O
could,O
lead,O
to,O
children,O
missing,O
school,O
",",O
lack,O
of,O
developmental,O
progress,O
and,O
stress,O
for,O
carers,O
.,O
“,O
And,O
I,O
said,O
",",O
I,O
understand,O
there,O
is,O
kids,O
that,O
are,O
a,O
lot,O
worse,O
than,O
[,O
child,O
].,O
I,O
do,O
understand,O
that,O
.,O
It,O
’,O
s,O
just,O
",",O
with,O
this,O
waiting,O
list,O
",",O
he,O
’,O
d,O
probably,O
be,O
able,O
to,O
speak,O
by,O
then,O
",",O
he,O
wouldn,O
’,O
t,O
even,O
need,O
it,O
…,O
And,O
then,O
I,O
got,O
upset,O
",",O
and,O
I,O
said,O
to,O
my,O
mum,O
",",O
it,O
’,O
s,O
like,O
no,O
-,O
one,O
’,O
s,O
out,O
there,O
that,O
wants,O
to,O
help,O
.”,O
(,O
Tabitha,O
),O
“,O
Waiting,O
and,O
waiting,O
for,O
appointments,O
",",O
you,O
know,O
",",O
like,O
",",O
nothing,O
gets,O
done,O
straight,O
away,O
…,O
it,O
’,O
s,O
just,O
such,O
a,O
long,O
process,O
…,O
I,O
am,O
no,O
closer,O
now,O
than,O
I,O
was,O
then,O
.,O
That,O
’,O
s,O
the,O
frustrating,O
part,O
about,O
it,O
.”,O
(,O
Nadia,O
),O
Only,O
one,O
carer,O
expressed,O
lack,O
of,O
concern,O
regarding,O
waitlists,O
stating,O
that,O
they,O
are,O
a,O
“,O
part,O
of,O
life,O
”,O
(,O
Rita,O
).,O
Contributing,O
to,O
this,O
acceptance,O
was,O
contextualizing,O
the,O
carers,O
’,O
own,O
situation,O
against,O
the,O
belief,O
that,O
there,O
is,O
always,O
someone,O
whose,O
need,O
is,O
greater,O
.,O
Lack,O
of,O
follow,O
-,O
up,O
led,O
to,O
children,O
falling,O
through,O
the,O
treatment,O
gap,O
due,O
to,O
missed,O
opportunities,O
for,O
timely,O
access,O
to,O
support,O
and,O
services,O
.,O
In,O
one,O
case,O
an,O
initial,O
needs,O
assessment,O
generated,O
a,O
list,O
of,O
required,O
therapeutic,O
interventions,O
for,O
one,O
child,O
but,O
no,O
follow,O
-,O
up,O
contact,O
was,O
made,O
to,O
link,O
the,O
carer,O
with,O
the,O
required,O
services,O
.,O
Despite,O
the,O
carer,O
following,O
-,O
up,O
there,O
had,O
been,O
no,O
additional,O
contact,O
made,O
with,O
her,O
or,O
consolidation,O
of,O
these,O
supports,O
.,O
Carers,O
identified,O
that,O
lack,O
of,O
follow,O
-,O
up,O
was,O
also,O
sometimes,O
due,O
to,O
clerical,O
errors,O
.“,O
We,O
went,O
and,O
had,O
the,O
very,O
first,O
assessment,O
where,O
[,O
government,O
service,O
],O
said,O
",",O
yeah,O
",",O
she,O
needs,O
OT,O
",",O
she,O
needs,O
speech,O
",",O
she,O
needs,O
physio,O
and,O
we,O
never,O
heard,O
from,O
them,O
again,O
.,O
It,O
was,O
",",O
sort,O
of,O
",",O
like,O
…,O
they,O
would,O
ring,O
us,O
and,O
–,O
and,O
",",O
um,O
",",O
say,O
that,O
",",O
you,O
know,O
",",O
we,O
’,O
re,O
still,O
",",O
sort,O
of,O
",",O
on,O
the,O
waiting,O
list,O
…,O
and,O
it,O
got,O
to,O
two,O
years,O
and,O
we,O
’,O
d,O
",",O
sort,O
of,O
",",O
had,O
nothing,O
…,O
I,O
spoke,O
to,O
them,O
and,O
they,O
",",O
sort,O
of,O
",",O
said,O
",",O
well,O
we,O
’,O
ll,O
find,O
out,O
what,O
’,O
s,O
happening,O
and,O
it,O
just,O
",",O
sort,O
of,O
",",O
never,O
eventuated,O
.”,O
(,O
Ainslee,O
),O
“,O
I,O
thought,O
I,O
signed,O
everything,O
and,O
I,O
thought,O
everything,O
got,O
faxed,O
through,O
.,O
Actually,O
",",O
everything,O
got,O
faxed,O
through,O
to,O
[,O
children,O
’,O
s,O
hospital,O
],O
and,O
they,O
",",O
um,O
",",O
lost,O
the,O
paper,O
and,O
then,O
it,O
had,O
to,O
be,O
re,O
-,O
faxed,O
through,O
.,O
So,O
",",O
yeah,O
and,O
I,O
had,O
to,O
re,O
-,O
sign,O
all,O
the,O
papers,O
.,O
Not,O
much,O
–,O
like,O
I,O
didn,O
’,O
t,O
know,O
much,O
about,O
that,O
then,O
because,O
I,O
thought,O
everything,O
was,O
going,O
ahead,O
",",O
going,O
through,O
",",O
thought,O
everything,O
was,O
fine,O
.”,O
(,O
Samantha,O
),O
Lack,O
of,O
assistance,O
from,O
service,O
providers,O
impeded,O
attempts,O
at,O
accessing,O
support,O
and,O
services,O
.,O
Carers,O
described,O
a,O
lack,O
of,O
assistance,O
in,O
seeking,O
funding,O
for,O
services,O
such,O
as,O
teachers,O
aids,O
as,O
well,O
as,O
in,O
managing,O
behavioural,B-DS
problems,I-DS
.,O
This,O
had,O
a,O
significant,O
impact,O
on,O
the,O
health,O
and,O
well,O
-,O
being,O
of,O
some,O
carers,O
.,O
“,O
He,O
was,O
more,O
or,O
less,O
going,O
to,O
be,O
a,O
forgotten,O
child,O
and,O
if,O
he,O
didn,O
’,O
t,O
keep,O
up,O
his,O
grades,O
they,O
weren,O
’,O
t,O
going,O
to,O
keep,O
him,O
back,O
but,O
they,O
weren,O
’,O
t,O
going,O
to,O
give,O
him,O
no,O
more,O
help,O
….,O
but,O
it,O
had,O
me,O
at,O
breaking,O
point,O
where,O
I,O
really,O
felt,O
like,O
I,O
was,O
having,O
a,O
nervous,B-DS
breakdown,I-DS
.,O
I,O
’,O
ve,O
been,O
in,O
tears,O
taking,O
him,O
to,O
school,O
",",O
bringing,O
him,O
home,O
.”,O
(,O
Rita,O
),O
Many,O
participants,O
did,O
not,O
have,O
access,O
to,O
private,O
transportation,O
.,O
Difficulty,O
attending,O
appointments,O
without,O
private,O
transport,O
was,O
a,O
prominent,O
roadblock,O
for,O
carers,O
.,O
The,O
majority,O
of,O
carers,O
had,O
no,O
private,O
means,O
of,O
transport,O
which,O
compounded,O
difficulties,O
associated,O
with,O
attending,O
multiple,O
appointments,O
at,O
multiple,O
services,O
.,O
Some,O
carers,O
described,O
having,O
to,O
begin,O
the,O
journey,O
hours,O
well,O
in,O
advance,O
of,O
appointments,O
if,O
referrals,O
were,O
made,O
to,O
geographically,O
distant,O
areas,O
.,O
Caring,O
for,O
more,O
than,O
one,O
child,O
with,O
a,O
disability,O
added,O
another,O
layer,O
of,O
complexity,O
for,O
carers,O
especially,O
if,O
the,O
children,O
attended,O
separate,O
schools,O
.,O
“,O
So,O
they,O
wanted,O
me,O
",",O
pick,O
her,O
up,O
and,O
then,O
bring,O
her,O
here,O
",",O
drop,O
her,O
off,O
.,O
I,O
said,O
",",O
no,O
",",O
no,O
",",O
no,O
",",O
no,O
",",O
it,O
’,O
s,O
too,O
complicated,O
for,O
me,O
.,O
Pick,O
up,O
the,O
boys,O
",",O
you,O
go,O
to,O
the,O
school,O
",",O
oh,O
no,O
",",O
we,O
can,O
’,O
t,O
do,O
that,O
.”,O
(,O
Helen,O
),O
The,O
extra,O
cost,O
of,O
using,O
taxis,O
caused,O
additional,O
stress,O
for,O
carers,O
.,O
Carers,O
who,O
used,O
public,O
transport,O
to,O
avoid,O
this,O
cost,O
experienced,O
difficulty,O
with,O
managing,O
children,O
",",O
especially,O
when,O
they,O
required,O
a,O
stroller,O
or,O
wheelchair,O
.,O
Addressing,O
these,O
roadblocks,O
was,O
particularly,O
important,O
in,O
facilitating,O
access,O
to,O
assessment,O
services,O
in,O
order,O
to,O
get,O
a,O
diagnosis,O
.,O
Without,O
a,O
diagnosis,O
it,O
was,O
difficult,O
for,O
carers,O
to,O
access,O
support,O
and,O
services,O
.“,O
The,O
school,O
actually,O
told,O
me,O
that,O
they,O
would,O
not,O
help,O
until,O
[,O
child,O
],O
did,O
have,O
an,O
MRI,O
to,O
see,O
if,O
there,O
was,O
something,O
wrong,O
because,O
I,O
’,O
ll,O
quote,O
the,O
words,O
of,O
the,O
principal,O
",",O
“,O
He,O
is,O
like,O
he,O
has,O
got,O
a,O
locked,O
door,O
and,O
we,O
cannot,O
find,O
the,O
key,O
to,O
open,O
it,O
.,O
Until,O
we,O
find,O
the,O
key,O
to,O
open,O
it,O
",",O
we,O
cannot,O
do,O
no,O
more,O
with,O
him,O
.,O
We,O
just,O
have,O
to,O
leave,O
that,O
door,O
locked,O
”.”,O
(,O
Rita,O
),O
For,O
some,O
carers,O
",",O
obtaining,O
a,O
diagnosis,O
to,O
access,O
support,O
and,O
services,O
was,O
influenced,O
by,O
whether,O
their,O
child,O
’,O
s,O
condition,O
was,O
acute,O
or,O
non,O
-,O
acute,O
.,O
Comparison,O
of,O
carer,O
journeys,O
suggest,O
that,O
children,O
with,O
more,O
acute,O
conditions,O
fit,O
better,O
into,O
the,O
streamlined,O
medical,O
model,O
of,O
care,O
compared,O
to,O
children,O
who,O
have,O
non,O
-,O
acute,O
conditions,O
which,O
are,O
not,O
as,O
severe,O
or,O
easy,O
to,O
diagnose,O
.,O
Alternate,O
routes,O
can,O
facilitate,O
the,O
journey,O
In,O
the,O
face,O
of,O
roadblocks,O
",",O
alternate,O
routes,O
in,O
the,O
form,O
of,O
models,O
of,O
care,O
that,O
differ,O
to,O
the,O
Western,O
bio,O
-,O
medical,O
approach,O
and,O
supportive,O
administrative,O
staff,O
and,O
organisation,O
procedures,O
enabled,O
carers,O
to,O
access,O
support,O
and,O
services,O
.,O
A,O
model,O
of,O
care,O
that,O
viewed,O
the,O
needs,O
of,O
the,O
child,O
and,O
carer,O
holistically,O
",",O
provided,O
a,O
one,O
-,O
stop,O
-,O
shop,O
and,O
implemented,O
a,O
centralised,O
team,O
-,O
based,O
approach,O
was,O
identified,O
as,O
important,O
by,O
a,O
number,O
of,O
carers,O
.,O
Many,O
carers,O
accessed,O
this,O
alternate,O
route,O
to,O
support,O
and,O
services,O
through,O
local,O
Aboriginal,O
Community,O
Controlled,O
Health,O
Organisations,O
(,O
ACCHOs,O
"),",O
yet,O
access,O
was,O
limited,O
.,O
Providing,O
support,O
and,O
services,O
through,O
a,O
holistic,O
lens,O
was,O
essential,O
for,O
carers,O
as,O
a,O
broad,O
range,O
of,O
personal,O
and,O
environmental,O
factors,O
influence,O
the,O
experience,O
of,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
and,O
the,O
ability,O
to,O
access,O
support,O
and,O
services,O
.,O
“,O
This,O
is,O
why,O
I,O
keep,O
coming,O
back,O
here,O
",",O
because,O
they,O
were,O
fantastic,O
.,O
Ah,O
",",O
um,O
",",O
not,O
only,O
do,O
they,O
help,O
with,O
[,O
child,O
"],",O
they,O
help,O
with,O
housing,O
",",O
they,O
help,O
with,O
me,O
with,O
my,O
ex,O
-,O
husband,O
",",O
you,O
know,O
what,O
I,O
mean,O
.,O
Um,O
",",O
they,O
help,O
me,O
with,O
getting,O
some,O
counselling,O
…”,O
(,O
Jocelyn,O
),O
The,O
convenience,O
of,O
a,O
one,O
-,O
stop,O
-,O
shop,O
and,O
centralised,O
team,O
-,O
based,O
approach,O
was,O
also,O
important,O
.,O
At,O
a,O
local,O
Aboriginal,O
health,O
service,O
convenience,O
was,O
ensured,O
by,O
holding,O
all,O
health,O
records,O
in,O
one,O
place,O
",",O
linking,O
appointments,O
with,O
different,O
internal,O
services,O
so,O
they,O
were,O
scheduled,O
in,O
close,O
succession,O
",",O
and,O
acting,O
as,O
a,O
conduit,O
to,O
external,O
services,O
when,O
required,O
.,O
Supportive,O
administrative,O
staff,O
and,O
organisation,O
procedures,O
facilitated,O
carer,O
access,O
to,O
support,O
and,O
services,O
.,O
Key,O
administrative,O
personnel,O
were,O
identified,O
as,O
important,O
to,O
facilitative,O
organisation,O
procedures,O
.,O
One,O
carer,O
reported,O
that,O
a,O
former,O
manager,O
used,O
to,O
make,O
sure,O
that,O
“,O
everyone,O
was,O
doing,O
what,O
they,O
were,O
supposed,O
to,O
be,O
doing,O
”,O
(,O
Helen,O
"),",O
however,O
when,O
the,O
staff,O
member,O
left,O
the,O
organisation,O
",",O
this,O
carer,O
had,O
difficulty,O
reaching,O
the,O
service,O
by,O
phone,O
.,O
The,O
positive,O
impacts,O
of,O
organisation,O
procedures,O
were,O
characterised,O
by,O
flexibility,O
with,O
payment,O
procedures,O
and,O
maintaining,O
confidentiality,O
.,O
“,O
Our,O
chemist,O
is,O
really,O
good,O
.,O
Like,O
",",O
you,O
know,O
",",O
if,O
you,O
’,O
re,O
short,O
of,O
cash,O
they,O
let,O
you,O
",",O
you,O
know,O
",",O
pay,O
it,O
next,O
time,O
.,O
I,O
mean,O
",",O
little,O
things,O
like,O
that,O
…,O
they,O
are,O
very,O
good,O
down,O
there,O
.,O
Very,O
confidential,O
…,O
They,O
don,O
’,O
t,O
yell,O
out,O
…,O
[,O
loud,O
voice,O
],O
“,O
Your,O
Ritalin,O
is,O
ready,O
.”,O
Or,O
",",O
“,O
Your,O
Concerta,O
’,O
s,O
ready,O
”.”,O
(,O
Laura,O
),O
Incompatibility,O
of,O
inflexible,O
bureaucratic,O
road,O
rules,O
and,O
lived,O
realities,O
Policies,O
guiding,O
government,O
agencies,O
and,O
funding,O
bodies,O
have,O
far,O
reaching,O
effects,O
on,O
carer,O
journeys,O
to,O
access,O
support,O
and,O
services,O
.,O
Many,O
carer,O
interactions,O
with,O
government,O
agencies,O
were,O
defined,O
by,O
barriers,O
generated,O
from,O
inflexible,O
rules,O
and,O
bureaucratic,O
processes,O
.,O
Carers,O
’,O
accounts,O
indicated,O
that,O
the,O
lived,O
reality,O
of,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
is,O
not,O
supported,O
or,O
acknowledged,O
by,O
current,O
policy,O
and,O
this,O
negatively,O
impacted,O
their,O
experiences,O
and,O
ability,O
to,O
care,O
for,O
their,O
child,O
.,O
Carers,O
described,O
incidents,O
where,O
agencies,O
were,O
unable,O
to,O
accommodate,O
their,O
specific,O
needs,O
due,O
to,O
inflexible,O
rules,O
.,O
Accessing,O
financial,O
assistance,O
from,O
Centrelink,O
to,O
assist,O
with,O
caregiving,O
related,O
responsibilities,O
was,O
particularly,O
difficult,O
due,O
to,O
rigid,O
eligibility,O
criteria,O
.,O
This,O
had,O
implications,O
for,O
carer,O
employment,O
and,O
support,O
payments,O
.,O
“…,O
the,O
Carer,O
’,O
s,O
Allowance,O
loan,O
was,O
supposed,O
to,O
be,O
coming,O
up,O
",",O
and,O
I,O
wanted,O
to,O
pay,O
the,O
rest,O
of,O
it,O
off,O
to,O
get,O
another,O
loan,O
for,O
[,O
children,O
’,O
s,O
hospital,O
"],",O
because,O
I,O
have,O
to,O
pay,O
for,O
an,O
overnight,O
stay,O
with,O
her,O
",",O
and,O
for,O
one,O
of,O
these,O
tests,O
I,O
have,O
to,O
pay,O
for,O
it,O
.,O
And,O
they,O
won,O
’,O
t,O
be,O
able,O
to,O
help,O
me,O
until,O
the,O
27,O
th,O
of,O
this,O
month,O
.,O
And,O
my,O
appointment,O
is,O
on,O
the,O
25,O
th,O
.”,O
(,O
Lesley,O
),O
The,O
Department,O
of,O
Housing,O
(,O
DoH,O
),O
was,O
another,O
government,O
agency,O
many,O
carers,O
interacted,O
with,O
which,O
was,O
also,O
defined,O
by,O
inflexible,O
rules,O
.,O
Carers,O
described,O
DoH,O
expectations,O
of,O
clients,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
as,O
inappropriate,O
.,O
The,O
strict,O
requirements,O
for,O
obtaining,O
housing,O
assistance,O
can,O
negatively,O
impact,O
carers,O
accessing,O
support,O
and,O
services,O
for,O
their,O
child,O
with,O
the,O
lack,O
of,O
assistance,O
perceived,O
as,O
dismissiveness,O
.“…,O
they,O
still,O
wanted,O
me,O
to,O
look,O
for,O
",",O
for,O
pretty,O
much,O
three,O
houses,O
a,O
day,O
",",O
um,O
",",O
um,O
and,O
I,O
’,O
ve,O
got,O
no,O
personal,O
transport,O
…,O
I,O
told,O
the,O
Department,O
of,O
Housing,O
",",O
you,O
know,O
",",O
“,O
You,O
are,O
expecting,O
me,O
to,O
drag,O
my,O
daughter,O
around,O
with,O
a,O
disability,O
to,O
look,O
for,O
houses,O
.”,O
They,O
wanted,O
–,O
they,O
said,O
they,O
wanted,O
me,O
to,O
go,O
out,O
to,O
[,O
suburb,O
1,O
],O
and,O
everything,O
.,O
Like,O
[,O
suburb,O
2,O
"],",O
and,O
then,O
I,O
said,O
",",O
“,O
Like,O
why,O
would,O
I,O
go,O
out,O
to,O
[,O
suburb,O
2,O
],O
when,O
my,O
family,O
is,O
in,O
[,O
suburb,O
3,O
]?”…,O
and,O
I,O
’,O
m,O
like,O
",",O
“,O
Yeah,O
",",O
but,O
I,O
can,O
’,O
t,O
live,O
in,O
[,O
suburb,O
2,O
],O
or,O
[,O
suburb,O
1,O
],O
or,O
anywhere,O
I,O
have,O
no,O
support,O
",”",O
and,O
they,O
were,O
like,O
",",O
“,O
Oh,O
well,O
",",O
it,O
doesn,O
’,O
t,O
matter,O
",",O
as,O
long,O
as,O
",",O
um,O
",",O
you,O
get,O
a,O
house,O
”.”,O
(,O
Samantha,O
),O
Bureaucratic,O
requirements,O
of,O
government,O
funding,O
mechanisms,O
and,O
support,O
services,O
reinforce,O
rigid,O
eligibility,O
criteria,O
that,O
mean,O
some,O
children,O
don,O
’,O
t,O
receive,O
the,O
support,O
they,O
require,O
.,O
The,O
rigid,O
eligibility,O
criteria,O
of,O
age,O
-,O
based,O
funding,O
structures,O
was,O
identified,O
as,O
an,O
issue,O
influencing,O
the,O
quality,O
of,O
specialists,O
that,O
children,O
with,O
a,O
disability,O
have,O
access,O
to,O
.,O
“,O
So,O
yep,O
",",O
it,O
doesn,O
’,O
t,O
help,O
a,O
lot,O
of,O
the,O
families,O
that,O
have,O
the,O
younger,O
kids,O
and,O
that,O
’,O
s,O
why,O
-,O
and,O
I,O
’,O
ve,O
always,O
said,O
that,O
that,O
’,O
s,O
why,O
they,O
don,O
’,O
t,O
get,O
seen,O
to,O
the,O
right,O
people,O
because,O
of,O
the,O
financial,O
cost,O
of,O
that,O
.”,O
(,O
Grace,O
),O
Rigid,O
eligibility,O
criteria,O
for,O
accessible,O
Aboriginal,O
education,O
officers,O
(,O
AEOs,O
"),",O
who,O
act,O
as,O
liaison,O
and,O
support,O
workers,O
within,O
schools,O
",",O
also,O
impacted,O
partnerships,O
between,O
schools,O
and,O
carers,O
.,O
One,O
school,O
did,O
not,O
have,O
the,O
required,O
percentage,O
of,O
Aboriginal,O
children,O
to,O
qualify,O
for,O
a,O
dedicated,O
AEO,O
.,O
For,O
this,O
carer,O
it,O
was,O
important,O
to,O
have,O
access,O
to,O
the,O
support,O
of,O
an,O
AEO,O
as,O
they,O
play,O
an,O
important,O
support,O
role,O
to,O
the,O
carer,O
getting,O
across,O
their,O
point,O
of,O
view,O
as,O
a,O
third,O
party,O
in,O
the,O
school,O
-,O
carer,O
partnership,O
.,O
“,O
So,O
",",O
yeah,O
",",O
it,O
’,O
s,O
not,O
feeling,O
like,O
you,O
’,O
re,O
ganged,O
up,O
on,O
",",O
kind,O
of,O
thing,O
.”,O
(,O
Rita,O
),O
Discussion,O
Carers,O
’,O
descriptions,O
of,O
their,O
attempts,O
to,O
access,O
support,O
for,O
their,O
child,O
with,O
a,O
disability,O
were,O
akin,O
to,O
a,O
journey,O
:,O
sometimes,O
they,O
did,O
not,O
know,O
where,O
to,O
go,O
(,O
as,O
a,O
result,O
of,O
poor,O
signage,O
"),",O
they,O
went,O
around,O
in,O
circles,O
",",O
in,O
the,O
wrong,O
direction,O
",",O
had,O
to,O
make,O
u,O
-,O
turns,O
and,O
encountered,O
roadblocks,O
and,O
traffic,O
.,O
For,O
many,O
who,O
set,O
out,O
on,O
a,O
journey,O
",",O
they,O
eventually,O
arrive,O
at,O
a,O
destination,O
",",O
but,O
these,O
carers,O
were,O
still,O
traveling,O
",",O
as,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
is,O
a,O
lifelong,O
voyage,O
.,O
Some,O
carers,O
received,O
directional,O
assistance,O
along,O
the,O
way,O
;,O
people,O
who,O
unlocked,O
gates,O
and,O
facilitated,O
access,O
to,O
needed,O
resources,O
.,O
For,O
instance,O
",",O
the,O
role,O
of,O
community,O
both,O
facilitated,O
and,O
obfuscated,O
carers,O
’,O
service,O
access,O
.,O
Community,O
influence,O
has,O
likewise,O
been,O
identified,O
in,O
culturally,O
and,O
linguistically,O
diverse,O
(,O
CALD,O
),O
carers,O
wherein,O
extended,O
family,O
and,O
community,O
members,O
sometimes,O
presented,O
a,O
barrier,O
to,O
access,O
by,O
denying,O
presence,O
of,O
a,O
disability,O
[,O
49,O
].,O
Another,O
Australian,O
study,O
of,O
CALD,O
carers,O
’,O
perceptions,O
of,O
preventive,O
health,O
care,O
for,O
their,O
children,O
found,O
that,O
social,O
influence,O
plays,O
a,O
key,O
role,O
in,O
identification,O
of,O
developmental,O
problems,O
and,O
the,O
need,O
to,O
access,O
services,O
[,O
50,O
].,O
In,O
their,O
review,O
of,O
vulnerable,O
groups,O
access,O
to,O
healthcare,O
",",O
Dixon,O
-,O
Woods,O
et,O
al,O
.,O
[,O
51,O
],O
found,O
that,O
people,O
from,O
socio,O
-,O
economically,O
disadvantaged,O
backgrounds,O
are,O
less,O
likely,O
to,O
present,O
for,O
services,O
due,O
to,O
the,O
normalization,O
of,O
poor,O
health,O
within,O
their,O
communities,O
and,O
a,O
fear,O
of,O
being,O
‘,O
blamed,O
’,O
by,O
health,O
care,O
professionals,O
[,O
51,O
].,O
Rather,O
than,O
not,O
recognizing,O
the,O
need,O
to,O
get,O
help,O
",",O
the,O
‘,O
wait,O
and,O
see,O
’,O
approach,O
advised,O
by,O
some,O
community,O
members,O
may,O
reflect,O
the,O
Aboriginal,O
world,O
view,O
of,O
health,O
[,O
52,O
],O
whereby,O
disability,O
is,O
‘,O
part,O
of,O
a,O
continuum,O
from,O
perfect,O
wellbeing,O
to,O
death,O
’,O
[,O
32,O
],O
compared,O
to,O
the,O
more,O
narrow,O
medical,O
definition,O
.,O
Gilroy,O
et,O
al,O
.,O
[,O
53,O
],O
assert,O
that,O
labeling,O
individuals,O
as,O
disabled,O
is,O
offensive,O
to,O
some,O
Aboriginal,O
communities,O
and,O
associated,O
with,O
past,O
government,O
policies,O
that,O
led,O
to,O
removal,O
of,O
children,O
from,O
families,O
[,O
53,O
].,O
It,O
is,O
also,O
suggested,O
that,O
in,O
some,O
Aboriginal,O
communities,O
support,O
and,O
care,O
for,O
a,O
person,O
with,O
a,O
disability,O
is,O
viewed,O
as,O
the,O
responsibility,O
of,O
family,O
and,O
kinship,O
networks,O
and,O
outside,O
help,O
viewed,O
as,O
questioning,O
family,O
competence,O
[,O
22,O
",",O
53,O
].,O
Despite,O
impacting,O
carer,O
access,O
to,O
services,O
",",O
the,O
resilience,O
and,O
strength,O
of,O
Aboriginal,O
communities,O
in,O
caring,O
for,O
each,O
other,O
represents,O
a,O
key,O
resource,O
that,O
requires,O
investment,O
.,O
Community,O
capacity,O
can,O
be,O
built,O
by,O
increasing,O
‘,O
signage,O
’,O
via,O
community,O
education,O
",",O
information,O
and,O
awareness,O
of,O
disability,O
and,O
services,O
.,O
The,O
multiple,O
roadblocks,O
described,O
throughout,O
carers,O
’,O
journeys,O
are,O
significant,O
barriers,O
to,O
accessing,O
services,O
and,O
support,O
.,O
The,O
impact,O
of,O
transport,O
is,O
a,O
particularly,O
important,O
consideration,O
and,O
is,O
reflected,O
in,O
other,O
studies,O
of,O
service,O
access,O
[,O
51,O
",",O
54,O
",",O
55,O
].,O
For,O
carers,O
",",O
services,O
that,O
provided,O
transport,O
to,O
and,O
from,O
appointments,O
were,O
invaluable,O
and,O
facilitated,O
service,O
access,O
.,O
Having,O
to,O
wait,O
months,O
to,O
access,O
services,O
and,O
confusion,O
caused,O
by,O
interaction,O
with,O
multiple,O
service,O
providers,O
has,O
also,O
been,O
found,O
in,O
an,O
Australian,O
study,O
of,O
the,O
experiences,O
of,O
CALD,O
carers,O
accessing,O
developmental,O
assessment,O
services,O
[,O
49,O
],O
suggesting,O
the,O
widespread,O
nature,O
of,O
these,O
barriers,O
.,O
Roadblocks,O
are,O
particularly,O
concerning,O
as,O
accessing,O
assessment,O
services,O
to,O
obtain,O
a,O
diagnosis,O
is,O
essential,O
in,O
being,O
able,O
to,O
access,O
support,O
and,O
services,O
[,O
54,O
].,O
Removing,O
those,O
barriers,O
may,O
help,O
patients,O
seek,O
and,O
access,O
the,O
medical,O
care,O
they,O
need,O
.,O
Dedicated,O
patient,O
navigators,O
may,O
be,O
a,O
solution,O
to,O
overcome,O
these,O
barriers,O
by,O
bridging,O
the,O
gap,O
between,O
carers,O
and,O
the,O
various,O
service,O
systems,O
involved,O
[,O
55,O
].,O
A,O
patient,O
navigator,O
is,O
akin,O
to,O
a,O
tour,O
guide,O
who,O
assists,O
patients,O
to,O
navigate,O
their,O
way,O
through,O
complex,O
systems,O
",",O
helping,O
to,O
remove,O
patient,O
-,O
level,O
barriers,O
to,O
reduce,O
delays,O
in,O
accessing,O
services,O
[,O
56,O
",",O
57,O
].,O
The,O
patient,O
navigator,O
model,O
can,O
be,O
a,O
key,O
‘,O
weapon,O
’,O
against,O
health,O
disparities,O
that,O
certain,O
groups,O
face,O
[,O
56,O
",",O
58,O
].,O
A,O
study,O
of,O
the,O
experiences,O
of,O
Aboriginal,O
patients,O
with,O
cancer,B-DS
accessing,O
diagnosis,O
and,O
treatment,O
found,O
that,O
a,O
patient,O
navigator,O
model,O
would,O
help,O
facilitate,O
mainstream,O
service,O
access,O
for,O
patients,O
[,O
59,O
].,O
Involving,O
Aboriginal,O
liaison,O
officers,O
in,O
these,O
roles,O
is,O
a,O
way,O
to,O
foster,O
cultural,O
security,O
[,O
60,O
].,O
Focus,O
groups,O
with,O
key,O
stakeholders,O
and,O
Aboriginal,O
carers,O
have,O
also,O
identified,O
that,O
patient,O
navigators,O
in,O
the,O
form,O
of,O
dedicated,O
disability,O
support,O
workers,O
within,O
Aboriginal,O
health,O
services,O
would,O
help,O
in,O
raising,O
awareness,O
of,O
available,O
support,O
and,O
services,O
for,O
families,O
[,O
21,O
].,O
While,O
a,O
patient,O
navigator,O
could,O
help,O
carers,O
to,O
by,O
-,O
pass,O
roadblocks,O
at,O
the,O
service,O
level,O
",",O
responsive,O
service,O
systems,O
are,O
critical,O
to,O
the,O
model,O
’,O
s,O
efficacy,O
.,O
Responsive,O
services,O
systems,O
that,O
are,O
informed,O
by,O
the,O
views,O
of,O
both,O
carers,O
and,O
the,O
workforces,O
responsible,O
for,O
service,O
delivery,O
",",O
especially,O
the,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
workforce,O
",",O
are,O
important,O
to,O
understanding,O
the,O
needs,O
of,O
carers,O
and,O
developing,O
responsive,O
strategies,O
to,O
address,O
them,O
[,O
61,O
].,O
Guiding,O
principles,O
for,O
responsive,O
service,O
systems,O
include,O
sharing,O
ownership,O
and,O
responsibility,O
for,O
change,O
",",O
responding,O
to,O
the,O
needs,O
of,O
families,O
in,O
the,O
context,O
of,O
where,O
they,O
live,O
",",O
as,O
well,O
as,O
the,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
workforce,O
",",O
working,O
together,O
from,O
the,O
micro,O
to,O
macro,O
levels,O
",",O
and,O
building,O
on,O
the,O
existing,O
strengths,O
of,O
families,O
and,O
relevant,O
workforces,O
[,O
61,O
].,O
The,O
use,O
of,O
alternate,O
routes,O
or,O
service,O
models,O
is,O
important,O
.,O
Future,O
planning,O
of,O
service,O
and,O
support,O
models,O
should,O
consider,O
the,O
elements,O
identified,O
by,O
carers,O
as,O
most,O
important,O
including,O
a,O
holistic,O
view,O
of,O
the,O
needs,O
of,O
the,O
child,O
and,O
carer,O
",",O
one,O
-,O
stop,O
-,O
shop,O
for,O
services,O
and,O
operationalizing,O
a,O
centralized,O
team,O
-,O
based,O
approach,O
.,O
These,O
elements,O
are,O
typically,O
embodied,O
in,O
the,O
model,O
of,O
care,O
provided,O
by,O
ACCHOs,O
and,O
argued,O
to,O
be,O
a,O
vital,O
part,O
of,O
improving,O
health,O
and,O
wellbeing,O
outcomes,O
for,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
peoples,O
[,O
62,O
].,O
The,O
incompatibility,O
between,O
inflexible,O
bureaucratic,O
policy,O
requirements,O
and,O
the,O
demands,O
and,O
challenges,O
of,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
was,O
a,O
significant,O
part,O
of,O
carer,O
journeys,O
.,O
Meeting,O
inflexible,O
requirements,O
for,O
eligibility,O
to,O
respite,O
services,O
and,O
funding,O
has,O
elsewhere,O
been,O
described,O
as,O
‘,O
jumping,O
through,O
hoops,O
’,O
[,O
54,O
].,O
Given,O
the,O
multiple,O
complex,O
needs,O
of,O
these,O
families,O
and,O
frequent,O
interaction,O
with,O
government,O
departments,O
",",O
Butler,O
et,O
al,O
.,O
[,O
55,O
],O
recommend,O
that,O
modification,O
of,O
inflexible,O
policy,O
requirements,O
is,O
essential,O
if,O
design,O
of,O
policies,O
and,O
programs,O
are,O
to,O
improve,O
service,O
access,O
for,O
parents,O
in,O
vulnerable,O
families,O
[,O
55,O
].,O
Limitations,O
Participants,O
were,O
purposefully,O
sampled,O
in,O
order,O
to,O
facilitate,O
in,O
-,O
depth,O
exploration,O
of,O
their,O
experiences,O
.,O
However,O
",",O
self,O
-,O
selection,O
bias,O
along,O
with,O
a,O
small,O
sample,O
size,O
means,O
that,O
these,O
findings,O
are,O
not,O
necessarily,O
generalizable,O
to,O
other,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
populations,O
or,O
to,O
indigenous,O
populations,O
globally,O
.,O
All,O
data,O
were,O
self,O
-,O
reported,O
reflecting,O
carers,O
’,O
individual,O
experiences,O
and,O
perspectives,O
.,O
Further,O
research,O
into,O
the,O
experiences,O
of,O
service,O
providers,O
would,O
help,O
contribute,O
to,O
a,O
more,O
comprehensive,O
picture,O
of,O
barriers,O
and,O
facilitators,O
to,O
service,O
access,O
.,O
Follow,O
-,O
up,O
interviews,O
were,O
conducted,O
within,O
a,O
12,O
month,O
period,O
despite,O
more,O
prolonged,O
service,O
access,O
journeys,O
.,O
All,O
participants,O
in,O
this,O
study,O
were,O
women,O
",",O
hence,O
the,O
perspectives,O
of,O
male,O
carers,O
is,O
needed,O
.,O
Conclusions,O
The,O
challenges,O
of,O
caring,O
for,O
a,O
child,O
with,O
a,O
disability,O
are,O
indisputable,O
.,O
The,O
socio,O
-,O
economic,O
challenges,O
and,O
marginalisation,O
experienced,O
by,O
many,O
Aboriginal,O
and,O
Torres,O
Strait,O
Islander,O
people,O
compound,O
these,O
challenges,O
.,O
Building,O
community,O
awareness,O
of,O
disability,O
services,O
and,O
support,O
",",O
increasing,O
access,O
to,O
alternate,O
routes,O
to,O
care,O
",",O
and,O
consideration,O
of,O
roadblocks,O
and,O
disadvantageous,O
road,O
rules,O
in,O
service,O
delivery,O
as,O
well,O
as,O
ways,O
of,O
overcoming,O
them,O
are,O
important,O
to,O
facilitating,O
service,O
access,O
.,O
Topic,O
guide,O
for,O
interview,O
with,O
parent,O
/,O
carer,O
.,O
(,O
DOCX,O
13,O
kb,O
),O
Implementation,O
of,O
Cognitive,O
Therapy,O
for,O
PTSD,B-DS
in,O
routine,O
clinical,O
care,O
:,O
Effectiveness,O
and,O
moderators,O
of,O
outcome,O
in,O
a,O
consecutive,O
sample,O
☆,O
Objective,O
Trauma,O
-,O
focused,O
psychological,O
treatments,O
are,O
recommended,O
as,O
first,O
-,O
line,O
treatments,O
for,O
Posttraumatic,B-DS
Stress,I-DS
Disorder,I-DS
(,O
PTSD,B-DS
"),",O
but,O
clinicians,O
may,O
be,O
concerned,O
that,O
the,O
good,O
outcomes,O
observed,O
in,O
randomized,O
controlled,O
trials,O
(,O
RCTs,O
),O
may,O
not,O
generalize,O
to,O
the,O
wide,O
range,O
of,O
traumas,O
and,O
presentations,O
seen,O
in,O
clinical,O
practice,O
.,O
This,O
study,O
investigated,O
whether,O
Cognitive,O
Therapy,O
for,O
PTSD,B-DS
(,O
CT,O
-,O
PTSD,B-DS
),O
can,O
be,O
effectively,O
implemented,O
into,O
a,O
UK,O
National,O
Health,O
Service,O
Outpatient,O
Clinic,O
serving,O
a,O
defined,O
ethnically,O
mixed,O
urban,O
catchment,O
area,O
.,O
Method,O
A,O
consecutive,O
sample,O
of,O
330,O
patients,O
with,O
PTSD,B-DS
(,O
age,O
17,O
–,O
83,O
),O
following,O
a,O
wide,O
range,O
of,O
traumas,O
were,O
treated,O
by,O
34,O
therapists,O
",",O
who,O
received,O
training,O
and,O
supervision,O
in,O
CT,O
-,O
PTSD,B-DS
.,O
Pre,O
and,O
post,O
treatment,O
data,O
(,O
PTSD,B-DS
symptoms,O
",",O
anxiety,B-DS
",",O
depression,B-DS
),O
were,O
collected,O
for,O
all,O
patients,O
",",O
including,O
dropouts,O
.,O
Hierarchical,O
linear,O
modeling,O
investigated,O
candidate,O
moderators,O
of,O
outcome,O
and,O
therapist,O
effects,O
.,O
Results,O
CT,O
-,O
PTSD,B-DS
was,O
well,O
tolerated,O
and,O
led,O
to,O
very,O
large,O
improvement,O
in,O
PTSD,B-DS
symptoms,O
",",O
depression,B-DS
and,O
anxiety,B-DS
.,O
The,O
majority,O
of,O
patients,O
showed,O
reliable,O
improvement,O
/,O
clinically,O
significant,O
change,O
:,O
intent,O
-,O
to,O
-,O
treat,O
:,O
78,O
.,O
8,O
%/,O
57,O
.,O
3,O
%;,O
completer,O
:,O
84,O
.,O
5,O
%/,O
65,O
.,O
1,O
%.,O
Dropouts,O
and,O
unreliable,O
attenders,O
had,O
worse,O
outcome,O
.,O
Statistically,O
reliable,O
symptom,O
exacerbation,O
with,O
treatment,O
was,O
observed,O
in,O
only,O
1,O
.,O
2,O
%,O
of,O
patients,O
.,O
Treatment,O
gains,O
were,O
maintained,O
during,O
follow,O
-,O
up,O
(,O
M,O
=,O
280,O
days,O
",",O
n,O
=,O
220,O
).,O
Few,O
of,O
the,O
selection,O
criteria,O
used,O
in,O
some,O
RCTs,O
",",O
demographic,O
",",O
diagnostic,O
and,O
trauma,O
characteristics,O
moderated,O
treatment,O
outcome,O
",",O
and,O
only,O
social,O
problems,O
and,O
needing,O
treatment,O
for,O
multiple,O
traumas,O
showed,O
unique,O
moderation,O
effects,O
.,O
There,O
were,O
no,O
random,O
effects,O
of,O
therapist,O
on,O
symptom,O
improvement,O
",",O
but,O
therapists,O
who,O
were,O
inexperienced,O
in,O
CT,O
-,O
PTSD,B-DS
had,O
more,O
dropouts,O
than,O
those,O
with,O
greater,O
experience,O
.,O
Conclusions,O
The,O
results,O
support,O
the,O
effectiveness,O
of,O
CT,O
-,O
PTSD,B-DS
and,O
suggest,O
that,O
trauma,O
-,O
focused,O
cognitive,O
behavior,O
therapy,O
can,O
be,O
successfully,O
implemented,O
in,O
routine,O
clinical,O
services,O
treating,O
patients,O
with,O
a,O
wide,O
range,O
of,O
traumas,O
.,O
Highlights,O
•,O
Cognitive,O
Therapy,O
for,O
PTSD,B-DS
can,O
be,O
effectively,O
implemented,O
in,O
routine,O
clinical,O
care,O
.•,O
The,O
intent,O
-,O
to,O
-,O
treat,O
analysis,O
showed,O
very,O
large,O
treatment,O
effects,O
.•,O
Patients,O
found,O
the,O
treatment,O
acceptable,O
",",O
and,O
the,O
majority,O
showed,O
clinically,O
significant,O
change,O
.•,O
Few,O
patient,O
characteristics,O
moderated,O
treatment,O
outcome,O
.•,O
Inexperienced,O
therapists,O
had,O
more,O
dropouts,O
.,O
A,O
substantial,O
number,O
of,O
randomized,O
controlled,O
trials,O
(,O
RCTs,O
),O
have,O
established,O
the,O
efficacy,O
of,O
trauma,O
-,O
focused,O
cognitive,O
behavioral,O
treatments,O
(,O
TF,O
-,O
CBT,O
),O
in,O
posttraumatic,B-DS
stress,I-DS
disorder,I-DS
(,O
PTSD,B-DS
),O
(,O
for,O
reviews,O
see,O
Australian,O
Centre,O
for,O
Posttraumatic,O
Mental,O
Health,O
",",O
2007,O
;,O
Bisson,O
et,O
al,O
".,",O
2007,O
;,O
Bradley,O
",",O
Greene,O
",",O
Russ,O
",",O
Dutra,O
",",O
&,O
Westen,O
",",O
2005,O
;,O
Kitchner,O
",",O
Roberts,O
",",O
Wilcox,O
",",O
&,O
Bisson,O
",",O
2012,O
;,O
Powers,O
",",O
Halpern,O
",",O
Ferenschak,O
",",O
Gillihan,O
",",O
&,O
Foa,O
",",O
2010,O
;,O
Stein,O
et,O
al,O
".,",O
2009,O
).,O
These,O
RCTs,O
have,O
shown,O
very,O
large,O
effect,O
sizes,O
in,O
treating,O
PTSD,B-DS
symptoms,O
and,O
associated,O
symptoms,O
of,O
depression,B-DS
and,O
anxiety,B-DS
for,O
a,O
range,O
of,O
TF,O
-,O
CBT,O
programs,O
.,O
There,O
is,O
as,O
yet,O
less,O
evidence,O
on,O
how,O
effective,O
such,O
treatment,O
programs,O
are,O
when,O
applied,O
in,O
routine,O
clinical,O
settings,O
.,O
Clinicians,O
are,O
often,O
concerned,O
that,O
that,O
the,O
good,O
outcomes,O
observed,O
in,O
RCTs,O
may,O
not,O
generalize,O
to,O
the,O
wide,O
range,O
of,O
traumas,O
and,O
presentations,O
seen,O
in,O
clinical,O
practice,O
.,O
Do,O
the,O
effects,O
of,O
TF,O
-,O
CBT,O
programs,O
generalize,O
to,O
routine,O
clinical,O
care,O
?,O
Several,O
factors,O
are,O
conceivable,O
that,O
could,O
potentially,O
limit,O
the,O
extent,O
to,O
which,O
the,O
treatment,O
effects,O
observed,O
in,O
RCTs,O
generalize,O
to,O
patients,O
seen,O
in,O
routine,O
clinical,O
practice,O
.,O
Although,O
most,O
RCTs,O
studied,O
clinically,O
pertinent,O
samples,O
with,O
moderate,O
to,O
severe,O
PTSD,B-DS
and,O
associated,O
comorbid,O
conditions,O
",",O
they,O
applied,O
certain,O
inclusion,O
and,O
exclusion,O
criteria,O
.,O
The,O
selection,O
may,O
influence,O
outcome,O
",",O
for,O
example,O
",",O
by,O
increasing,O
the,O
average,O
size,O
of,O
improvement,O
by,O
requiring,O
a,O
minimum,O
severity,O
or,O
by,O
excluding,O
difficult,O
-,O
to,O
-,O
treat,O
patients,O
.,O
One,O
of,O
these,O
potential,O
factors,O
is,O
that,O
many,O
RCTs,O
selected,O
patients,O
who,O
suffered,O
from,O
discrete,O
traumas,O
such,O
as,O
physical,O
or,O
sexual,B-DS
assault,I-DS
or,O
traffic,O
accidents,O
(,O
but,O
may,O
have,O
also,O
experienced,O
additional,O
other,O
traumas,O
",",O
e,O
.,O
g,O
".,",O
Bryant,O
",",O
Moulds,O
",",O
Guthrie,O
",",O
Dang,O
",",O
&,O
Nixon,O
",",O
2003,O
;,O
Ehlers,O
et,O
al,O
".,",O
2003,O
;,O
Foa,O
et,O
al,O
".,",O
2005,O
;,O
Resick,O
",",O
Nishith,O
",",O
Weaver,O
",",O
Astin,O
",",O
&,O
Feuer,O
",",O
2002,O
;,O
Schnurr,O
et,O
al,O
",",O
2007,O
"),",O
whereas,O
in,O
clinical,O
practice,O
patients,O
may,O
require,O
treatment,O
for,O
wider,O
range,O
of,O
traumas,O
including,O
prolonged,O
and,O
multiple,O
traumatic,O
events,O
.,O
It,O
remains,O
unclear,O
whether,O
the,O
exclusion,O
of,O
certain,O
demographic,O
groups,O
such,O
as,O
men,O
",",O
people,O
older,O
than,O
65,O
years,O
of,O
age,O
",",O
or,O
comorbid,O
conditions,O
such,O
as,O
borderline,B-DS
personality,I-DS
disorder,I-DS
influences,O
the,O
overall,O
treatment,O
effects,O
.,O
Second,O
",",O
there,O
have,O
been,O
concerns,O
about,O
a,O
possible,O
risk,O
of,O
symptom,O
exacerbation,O
with,O
exposure,O
to,O
trauma,O
memories,O
(,O
e,O
.,O
g,O
".,",O
Tarrier,O
et,O
al,O
".,",O
1999,O
).,O
Although,O
initial,O
reports,O
have,O
found,O
symptom,O
exacerbation,O
to,O
be,O
uncommon,O
in,O
RCT,O
samples,O
(,O
e,O
.,O
g,O
".,",O
Foa,O
",",O
Zoellner,O
",",O
Feeny,O
",",O
Hembree,O
",",O
&,O
Alvarez,O
-,O
Conrad,O
",",O
2002,O
;,O
Hackmann,O
",",O
Ehlers,O
",",O
Speckens,O
",",O
&,O
Clark,O
",",O
2004,O
"),",O
clinicians,O
may,O
be,O
concerned,O
that,O
this,O
problem,O
may,O
be,O
more,O
common,O
in,O
patients,O
seen,O
in,O
routine,O
clinical,O
care,O
.,O
A,O
third,O
concern,O
relates,O
to,O
treatment,O
dropouts,O
.,O
Many,O
of,O
the,O
earlier,O
RCTs,O
reported,O
completer,O
-,O
only,O
analyses,O
.,O
If,O
dropout,O
rates,O
are,O
substantial,O
",",O
completer,O
analyses,O
may,O
overestimate,O
the,O
efficacy,O
of,O
treatments,O
.,O
Some,O
RCTs,O
have,O
observed,O
high,O
dropout,O
rates,O
of,O
between,O
25,O
and,O
43,O
%,O
with,O
trauma,O
-,O
focused,O
PTSD,B-DS
treatments,O
in,O
RCTs,O
(,O
e,O
.,O
g,O
".,",O
Foa,O
et,O
al,O
".,",O
2005,O
;,O
Power,O
et,O
al,O
".,",O
2002,O
;,O
Resick,O
et,O
al,O
".,",O
2002,O
;,O
Schnurr,O
et,O
al,O
",",O
2007,O
"),",O
although,O
the,O
average,O
dropout,O
rate,O
may,O
not,O
be,O
higher,O
than,O
for,O
other,O
PTSD,B-DS
treatments,O
(,O
Hembree,O
et,O
al,O
".,",O
2003,O
).,O
Fourth,O
",",O
in,O
RCTs,O
treatment,O
is,O
usually,O
delivered,O
by,O
therapists,O
who,O
receive,O
specialized,O
training,O
and,O
supervision,O
in,O
TF,O
-,O
CBT,O
",",O
and,O
clinicians,O
with,O
less,O
training,O
and,O
supervision,O
may,O
find,O
it,O
difficult,O
to,O
replicate,O
their,O
results,O
.,O
Thus,O
",",O
there,O
is,O
a,O
need,O
to,O
empirically,O
investigate,O
how,O
well,O
the,O
excellent,O
outcomes,O
of,O
TF,O
-,O
CBT,O
observed,O
in,O
RCTs,O
can,O
be,O
replicated,O
in,O
routine,O
clinical,O
settings,O
where,O
patients,O
are,O
not,O
selected,O
for,O
RCT,O
suitability,O
and,O
treatment,O
is,O
delivered,O
by,O
therapists,O
with,O
a,O
range,O
of,O
prior,O
experience,O
with,O
TF,O
-,O
CBT,O
.,O
Preliminary,O
evidence,O
suggests,O
that,O
TF,O
-,O
CBT,O
programs,O
can,O
be,O
successfully,O
implemented,O
in,O
routine,O
clinical,O
services,O
(,O
for,O
reviews,O
see,O
Cohen,O
&,O
Mannarino,O
",",O
2008,O
;,O
Stewart,O
&,O
Chambless,O
",",O
2009,O
).,O
Foa,O
et,O
al,O
.',O
s,O
(,O
2005,O
),O
RCT,O
of,O
Prolonged,O
Exposure,O
for,O
sexual,B-DS
assault,I-DS
survivors,O
found,O
equivalent,O
outcomes,O
for,O
expert,O
therapists,O
and,O
newly,O
trained,O
therapists,O
working,O
in,O
a,O
community,O
center,O
.,O
Karlin,O
et,O
al,O
.,O
(,O
2010,O
),O
reported,O
that,O
veterans,O
treated,O
with,O
Prolonged,O
Exposure,O
or,O
Cognitive,O
Processing,O
Therapy,O
following,O
an,O
extensive,O
therapist,O
training,O
program,O
implemented,O
in,O
the,O
Veteran,O
Health,O
Administration,O
showed,O
a,O
30,O
%,O
decrease,O
in,O
PTSD,B-DS
symptoms,O
in,O
completer,O
analyses,O
(,O
see,O
also,O
Monson,O
et,O
al,O
".,",O
2006,O
;,O
Tuerk,O
et,O
al,O
".,",O
2011,O
).,O
Levitt,O
",",O
Malta,O
",",O
Martin,O
",",O
Davis,O
",",O
and,O
Cloitre,O
(,O
2007,O
),O
and,O
Brewin,O
et,O
al,O
.,O
(,O
2010,O
),O
reported,O
large,O
improvements,O
in,O
outreach,O
programs,O
for,O
survivors,O
of,O
9,O
/,O
11,O
and,O
the,O
London,O
bombings,O
who,O
suffered,O
from,O
PTSD,B-DS
.,O
Gillespie,O
",",O
Duffy,O
",",O
Hackmann,O
",",O
and,O
Clark,O
(,O
2002,O
),O
trained,O
therapists,O
from,O
a,O
range,O
of,O
professional,O
backgrounds,O
in,O
Cognitive,O
Therapy,O
for,O
PTSD,B-DS
",",O
a,O
version,O
of,O
TF,O
-,O
CBT,O
that,O
builds,O
on,O
Ehlers,O
and,O
Clark,O
',O
s,O
(,O
2000,O
),O
model,O
of,O
PTSD,B-DS
.,O
The,O
therapists,O
treated,O
an,O
unselected,O
group,O
of,O
patients,O
seeking,O
treatment,O
for,O
PTSD,B-DS
after,O
the,O
Omagh,O
bombing,O
in,O
Northern,O
Ireland,O
and,O
achieved,O
similarly,O
good,O
outcomes,O
as,O
those,O
observed,O
in,O
RCTs,O
.,O
Duffy,O
",",O
Gillespie,O
",",O
and,O
Clark,O
(,O
2007,O
),O
further,O
successfully,O
disseminated,O
this,O
treatment,O
to,O
an,O
unselected,O
group,O
of,O
patients,O
who,O
had,O
experienced,O
traumas,O
in,O
connection,O
with,O
the,O
civil,O
conflict,O
in,O
Northern,O
Ireland,O
",",O
the,O
majority,O
of,O
whom,O
had,O
experienced,O
multiple,O
traumatic,O
events,O
.,O
Whilst,O
these,O
initial,O
studies,O
evaluating,O
the,O
effectiveness,O
of,O
TF,O
-,O
CBT,O
for,O
PTSD,B-DS
are,O
promising,O
",",O
they,O
are,O
limited,O
in,O
number,O
",",O
and,O
further,O
studies,O
of,O
larger,O
samples,O
of,O
unselected,O
patients,O
with,O
PTSD,B-DS
following,O
the,O
wide,O
range,O
of,O
traumatic,O
events,O
seen,O
in,O
clinical,O
settings,O
are,O
needed,O
to,O
determine,O
the,O
effectiveness,O
of,O
TF,O
-,O
CBT,O
programs,O
.,O
The,O
present,O
study,O
describes,O
treatment,O
outcomes,O
of,O
consecutive,O
referrals,O
to,O
a,O
National,O
Health,O
Service,O
outpatient,O
clinic,O
treated,O
with,O
CT,O
-,O
PTSD,B-DS
.,O
The,O
clinic,O
was,O
newly,O
opened,O
in,O
April,O
2001,O
and,O
thus,O
provided,O
an,O
opportunity,O
to,O
train,O
new,O
therapists,O
in,O
delivering,O
this,O
treatment,O
",",O
and,O
to,O
study,O
treatment,O
effectiveness,O
",",O
moderators,O
of,O
treatment,O
outcome,O
and,O
possible,O
therapist,O
effects,O
in,O
a,O
consecutive,O
patient,O
sample,O
from,O
a,O
defined,O
catchment,O
area,O
.,O
Moderators,O
of,O
treatment,O
effectiveness,O
The,O
study,O
investigated,O
candidate,O
moderators,O
of,O
the,O
effectiveness,O
of,O
TF,O
-,O
CBT,O
in,O
routine,O
clinical,O
settings,O
.,O
We,O
were,O
interested,O
in,O
whether,O
selection,O
criteria,O
for,O
randomized,O
controlled,O
trials,O
actually,O
predict,O
treatment,O
response,O
",",O
and,O
whether,O
other,O
aspects,O
of,O
clinical,O
history,O
",",O
comorbidity,O
or,O
trauma,O
history,O
moderate,O
treatment,O
outcome,O
.,O
Kraemer,O
",",O
Wilson,O
",",O
Fairburn,O
",",O
and,O
Agras,O
(,O
2002,O
),O
distinguish,O
two,O
types,O
of,O
predictors,O
of,O
outcome,O
.,O
Nonspecific,O
predictors,O
of,O
outcome,O
influence,O
the,O
overall,O
severity,O
of,O
symptoms,O
",",O
but,O
do,O
not,O
influence,O
the,O
slope,O
of,O
treatment,O
-,O
induced,O
improvement,O
.,O
Some,O
TF,O
-,O
CBT,O
studies,O
have,O
correlated,O
candidate,O
predictors,O
with,O
symptom,O
severity,O
at,O
the,O
end,O
of,O
therapy,O
and,O
have,O
generally,O
found,O
that,O
patients,O
with,O
more,O
severe,O
symptoms,O
of,O
PTSD,B-DS
and,O
depression,B-DS
at,O
the,O
beginning,O
of,O
treatment,O
have,O
more,O
remaining,O
symptoms,O
at,O
the,O
end,O
of,O
treatment,O
(,O
e,O
.,O
g,O
".,",O
Blanchard,O
et,O
al,O
".,",O
2003,O
;,O
van,O
Emmerik,O
",",O
Kamphuis,O
",",O
Noordhof,O
",",O
&,O
Emmelkamp,O
",",O
2011,O
;,O
van,O
Minnen,O
",",O
Arntz,O
",",O
&,O
Keijsers,O
",",O
2002,O
;,O
Schulz,O
",",O
Resick,O
",",O
Huber,O
",",O
&,O
Griffin,O
",",O
2006,O
).,O
A,O
moderator,O
of,O
treatment,O
effectiveness,O
is,O
a,O
variable,O
that,O
influences,O
the,O
slope,O
of,O
improvement,O
(,O
Kraemer,O
et,O
al,O
".,",O
2002,O
).,O
Several,O
studies,O
of,O
TF,O
-,O
CBT,O
attempted,O
to,O
identify,O
moderators,O
of,O
treatment,O
response,O
in,O
RCTs,O
(,O
e,O
.,O
g,O
".,",O
Ehlers,O
",",O
Clark,O
",",O
Hackmann,O
",",O
McManus,O
",",O
&,O
Fennell,O
",",O
2005,O
;,O
Feeny,O
",",O
Zoellner,O
",",O
&,O
Foa,O
",",O
2002,O
;,O
Kubany,O
et,O
al,O
".,",O
2004,O
;,O
Rizvi,O
",",O
Vogt,O
",",O
&,O
Resick,O
",",O
2009,O
;,O
Tarrier,O
",",O
Sommerfield,O
",",O
Pilgrim,O
",",O
&,O
Faragher,O
",",O
2000,O
;,O
van,O
Emmerik,O
et,O
al,O
".,",O
2011,O
),O
and,O
routine,O
clinic,O
samples,O
(,O
e,O
.,O
g,O
".,",O
Gillespie,O
et,O
al,O
".,",O
2002,O
;,O
Richardson,O
",",O
Elhai,O
",",O
&,O
Sareen,O
",",O
2011,O
;,O
Rosenkranz,O
&,O
Muller,O
",",O
2011,O
;,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
).,O
The,O
results,O
were,O
often,O
inconsistent,O
and,O
few,O
moderators,O
have,O
been,O
identified,O
.,O
Variables,O
that,O
were,O
shown,O
in,O
some,O
studies,O
to,O
be,O
associated,O
with,O
less,O
favorable,O
treatment,O
response,O
included,O
•,O
demographic,O
variables,O
such,O
as,O
male,O
sex,O
(,O
Blain,O
",",O
Galovski,O
",",O
&,O
Robinson,O
",",O
2010,O
"),",O
younger,O
age,O
(,O
Rizvi,O
et,O
al,O
".,",O
2009,O
;,O
Taylor,O
",",O
Fedoroff,O
",",O
&,O
Koch,O
",",O
1999,O
"),",O
higher,O
level,O
of,O
education,O
(,O
Ehlers,O
et,O
al,O
".,",O
2005,O
),O
or,O
ethnic,O
minority,O
(,O
Walling,O
",",O
Suvak,O
",",O
Howard,O
",",O
Taft,O
",",O
&,O
Murphy,O
",",O
2012,O
);•,O
comorbidity,O
with,O
other,O
anxiety,B-DS
disorders,I-DS
or,O
high,O
symptoms,O
of,O
anxiety,B-DS
and,O
arousal,O
(,O
Rosenkranz,O
&,O
Muller,O
",",O
2011,O
;,O
Tarrier,O
et,O
al,O
".,",O
2000,O
;,O
but,O
see,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
;,O
Richardson,O
et,O
al,O
".,",O
2011,O
;,O
for,O
negative,O
findings,O
);,O
with,O
depression,B-DS
or,O
suicidal,O
ideation,O
(,O
Duffy,O
et,O
al,O
".,",O
2007,O
;,O
Tarrier,O
et,O
al,O
".,",O
2000,O
;,O
but,O
see,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
;,O
Richardson,O
et,O
al,O
".,",O
2011,O
;,O
for,O
negative,O
findings,O
);,O
substance,B-DS
abuse,I-DS
(,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
;,O
but,O
see,O
Richardson,O
et,O
al,O
".,",O
2011,O
;,O
for,O
negative,O
findings,O
);,O
personality,B-DS
disorders,I-DS
(,O
Clarke,O
",",O
Rizvi,O
",",O
&,O
Resick,O
",",O
2008,O
;,O
Feeny,O
et,O
al,O
".,",O
2002,O
);,O
use,O
of,O
psychotropic,O
medication,O
(,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
"),",O
and,O
permanent,O
physical,O
disability,O
resulting,O
from,O
the,O
trauma,O
(,O
Gillespie,O
et,O
al,O
".,",O
2002,O
;,O
but,O
see,O
Duffy,O
et,O
al,O
".,",O
2007,O
;,O
for,O
negative,O
findings,O
);•,O
trauma,O
characteristics,O
such,O
as,O
multiple,O
trauma,O
(,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
"),",O
childhood,O
trauma,O
(,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
;,O
but,O
also,O
see,O
Jaycox,O
",",O
Foa,O
",",O
&,O
Morral,O
",",O
1998,O
;,O
for,O
negative,O
findings,O
"),",O
interpersonal,O
trauma,O
committed,O
by,O
a,O
perpetrator,O
(,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
"),",O
longer,O
time,O
since,O
the,O
trauma,O
(,O
Duffy,O
et,O
al,O
".,",O
2007,O
;,O
but,O
see,O
Ehlers,O
et,O
al,O
".,",O
2005,O
;,O
Rizvi,O
et,O
al,O
".,",O
2009,O
;,O
for,O
negative,O
findings,O
).,O
Therapist,O
effects,O
In,O
a,O
meta,O
-,O
analysis,O
of,O
psychotherapy,O
outcome,O
studies,O
",",O
Crits,O
-,O
Christoph,O
et,O
al,O
.,O
(,O
1991,O
),O
found,O
that,O
on,O
average,O
8,O
.,O
6,O
%,O
of,O
the,O
variance,O
in,O
outcome,O
were,O
due,O
to,O
random,O
therapist,O
effects,O
.,O
Greater,O
therapist,O
effects,O
were,O
found,O
when,O
no,O
treatment,O
manual,O
was,O
used,O
and,O
therapists,O
were,O
inexperienced,O
.,O
More,O
recent,O
studies,O
are,O
consistent,O
with,O
this,O
pattern,O
of,O
results,O
.,O
Wampold,O
and,O
Brown,O
(,O
2005,O
),O
estimated,O
that,O
about,O
5,O
%,O
of,O
the,O
variation,O
in,O
outcome,O
of,O
6146,O
patients,O
with,O
different,O
diagnoses,O
treated,O
in,O
managed,O
care,O
was,O
due,O
to,O
therapists,O
.,O
Similarly,O
",",O
Lutz,O
",",O
Leon,O
",",O
Martinovich,O
",",O
Lyons,O
",",O
and,O
Stiles,O
(,O
2007,O
),O
investigated,O
outcomes,O
of,O
patients,O
in,O
managed,O
care,O
treated,O
by,O
therapists,O
of,O
different,O
professional,O
backgrounds,O
and,O
orientations,O
and,O
estimated,O
that,O
8,O
%,O
of,O
the,O
variance,O
in,O
outcome,O
could,O
be,O
attributed,O
to,O
therapists,O
.,O
Other,O
recent,O
studies,O
investigated,O
more,O
homogeneous,O
samples,O
of,O
clients,O
with,O
a,O
particular,O
disorder,O
who,O
were,O
treated,O
according,O
to,O
a,O
particular,O
protocol,O
and,O
found,O
no,O
significant,O
effects,O
of,O
therapist,O
on,O
outcome,O
(,O
e,O
.,O
g,O
".,",O
Cella,O
",",O
Stahl,O
",",O
Reme,O
",",O
&,O
Chalder,O
",",O
2011,O
;,O
Wilson,O
",",O
Wilfley,O
",",O
Agras,O
",",O
&,O
Bryson,O
",",O
2011,O
).,O
In,O
PTSD,B-DS
",",O
there,O
is,O
as,O
yet,O
little,O
data,O
on,O
therapist,O
effects,O
.,O
In,O
RCTs,O
",",O
Ehlers,O
et,O
al,O
.,O
(,O
2003,O
",",O
2005,O
",",O
see,O
Baldwin,O
et,O
al,O
".,",O
2011,O
),O
and,O
Kubany,O
et,O
al,O
.,O
(,O
2004,O
),O
found,O
no,O
therapist,O
effects,O
",",O
while,O
Duffy,O
et,O
al,O
.,O
(,O
2007,O
),O
reported,O
significantly,O
worse,O
outcome,O
for,O
one,O
therapist,O
who,O
was,O
inexperienced,O
in,O
delivering,O
the,O
treatment,O
protocol,O
.,O
Aims,O
of,O
the,O
study,O
This,O
study,O
had,O
the,O
following,O
aims,O
:(,O
1,O
),O
to,O
assess,O
the,O
effectiveness,O
of,O
CT,O
-,O
PTSD,B-DS
in,O
unselected,O
patients,O
referred,O
to,O
a,O
National,O
Health,O
Service,O
outpatient,O
clinic,O
",(",O
2,O
),O
to,O
assess,O
treatment,O
response,O
of,O
patients,O
who,O
do,O
not,O
complete,O
treatment,O
",(",O
3,O
),O
to,O
investigate,O
whether,O
candidate,O
diagnostic,O
variables,O
",",O
demographic,O
variables,O
and,O
aspects,O
of,O
trauma,O
history,O
moderate,O
treatment,O
response,O
",",O
and,O
(,O
4,O
),O
to,O
explore,O
therapist,O
effects,O
on,O
treatment,O
outcome,O
.,O
Method,O
Clinical,O
setting,O
and,O
patients,O
The,O
Centre,O
for,O
Anxiety,B-DS
Disorders,O
and,O
Trauma,O
",",O
Maudsley,O
Hospital,O
",",O
UK,O
",",O
is,O
an,O
outpatient,O
clinic,O
specializing,O
in,O
the,O
treatment,O
of,O
anxiety,B-DS
disorders,I-DS
in,O
adults,O
.,O
It,O
was,O
opened,O
in,O
April,O
2001,O
and,O
is,O
part,O
of,O
the,O
British,O
National,O
Health,O
Service,O
",",O
receiving,O
referrals,O
from,O
General,O
Practitioners,O
and,O
Community,O
Mental,O
Health,O
Teams,O
.,O
The,O
clinic,O
offers,O
assessment,O
and,O
treatment,O
for,O
survivors,O
of,O
trauma,O
in,O
adulthood,O
who,O
suffer,O
from,O
PTSD,B-DS
.,O
It,O
serves,O
a,O
population,O
of,O
about,O
867,O
",",O
000,O
people,O
living,O
in,O
the,O
South,O
London,O
Boroughs,O
of,O
Southwark,O
",",O
Lewisham,O
and,O
Lambeth,O
.,O
These,O
areas,O
have,O
substantially,O
higher,O
rates,O
of,O
social,O
deprivation,O
",",O
crime,O
",",O
and,O
a,O
greater,O
proportion,O
of,O
ethnic,O
minorities,O
than,O
the,O
UK,O
average,O
.,O
The,O
present,O
study,O
included,O
all,O
consecutive,O
patients,O
who,O
were,O
referred,O
for,O
assessment,O
for,O
possible,O
PTSD,B-DS
between,O
April,O
2001,O
and,O
August,O
2008,O
.,O
The,O
study,O
was,O
approved,O
by,O
the,O
local,O
research,O
ethics,O
committee,O
.,O
Fig,O
.,O
1,O
shows,O
that,O
577,O
patients,O
completed,O
the,O
assessment,O
",",O
and,O
408,O
were,O
suitable,O
for,O
trauma,O
-,O
focused,O
treatment,O
.,O
The,O
main,O
reasons,O
for,O
not,O
being,O
suitable,O
at,O
the,O
time,O
of,O
assessment,O
were,O
that,O
the,O
patient,O
did,O
not,O
have,O
PTSD,B-DS
(,O
n,O
=,O
42,O
"),",O
or,O
first,O
needed,O
treatment,O
for,O
another,O
primary,O
problem,O
such,O
as,O
alcohol,B-DS
dependence,I-DS
or,O
immediate,O
suicide,O
risk,O
(,O
n,O
=,O
73,O
).,O
The,O
main,O
reasons,O
for,O
not,O
being,O
offered,O
CT,O
-,O
PTSD,B-DS
despite,O
suitability,O
for,O
treatment,O
(,O
n,O
=,O
78,O
),O
were,O
that,O
the,O
patient,O
did,O
not,O
want,O
treatment,O
(,O
n,O
=,O
27,O
),O
or,O
participated,O
in,O
a,O
trial,O
where,O
they,O
received,O
another,O
psychological,O
treatment,O
(,O
n,O
=,O
21,O
).,O
A,O
total,O
of,O
330,O
patients,O
were,O
offered,O
a,O
course,O
of,O
CT,O
-,O
PTSD,B-DS
.,O
Data,O
for,O
initial,O
assessment,O
and,O
the,O
last,O
treatment,O
session,O
were,O
available,O
for,O
all,O
patients,O
",",O
including,O
dropouts,O
.,O
Two,O
thirds,O
(,O
n,O
=,O
220,O
),O
of,O
the,O
patients,O
provided,O
follow,O
-,O
up,O
data,O
.,O
Fifty,O
-,O
six,O
percent,O
(,O
n,O
=,O
185,O
),O
of,O
the,O
330,O
patients,O
in,O
the,O
intent,O
-,O
to,O
-,O
treat,O
sample,O
were,O
female,O
.,O
Their,O
ages,O
ranged,O
from,O
18,O
to,O
83,O
years,O
",",O
M,O
=,O
38,O
.,O
8,O
",",O
SD,O
=,O
11,O
.,O
5,O
.,O
A,O
large,O
proportion,O
(,O
43,O
.,O
7,O
%),O
of,O
the,O
patients,O
were,O
from,O
ethnic,O
minorities,O
",",O
and,O
either,O
unemployed,O
(,O
33,O
.,O
7,O
"%),",O
or,O
on,O
disability,O
/,O
retired,O
(,O
8,O
.,O
7,O
%),O
or,O
sick,O
leave,O
(,O
16,O
.,O
0,O
%),O
because,O
of,O
their,O
symptoms,O
.,O
The,O
majority,O
(,O
42,O
.,O
8,O
%),O
was,O
single,O
",",O
37,O
.,O
7,O
%,O
were,O
married,O
/,O
cohabitating,O
with,O
a,O
partner,O
",",O
and,O
19,O
.,O
5,O
%,O
were,O
divorced,O
/,O
widowed,O
.,O
The,O
majority,O
(,O
43,O
.,O
8,O
%),O
had,O
completed,O
mandatory,O
school,O
education,O
up,O
to,O
age,O
16,O
(,O
GCSE,O
or,O
equivalent,O
"),",O
18,O
%,O
had,O
not,O
completed,O
school,O
exams,O
",",O
15,O
%,O
had,O
taken,O
higher,O
school,O
exams,O
at,O
age,O
18,O
(,O
A,O
level,O
"),",O
and,O
23,O
.,O
2,O
%,O
had,O
attended,O
university,O
.,O
The,O
most,O
common,O
type,O
of,O
trauma,O
addressed,O
in,O
treatment,O
was,O
interpersonal,O
violence,O
(,O
including,O
physical,O
assault,O
",",O
sexual,B-DS
assault,I-DS
",",O
terrorist,O
attack,O
and,O
torture,O
",",O
56,O
.,O
7,O
%);,O
followed,O
by,O
accidents,O
or,O
disaster,O
(,O
22,O
.,O
4,O
"%),",O
traumatic,O
death,O
/,O
harm,O
to,O
others,O
(,O
9,O
.,O
5,O
"%),",O
and,O
other,O
traumas,O
(,O
11,O
.,O
2,O
%).,O
In,O
22,O
.,O
5,O
%,O
of,O
patients,O
",",O
the,O
trauma,O
had,O
involved,O
the,O
death,O
of,O
another,O
person,O
.,O
The,O
main,O
traumas,O
that,O
were,O
addressed,O
in,O
treatment,O
had,O
happened,O
between,O
3,O
and,O
360,O
months,O
ago,O
",",O
M,O
=,O
36,O
.,O
5,O
",",O
SD,O
=,O
56,O
.,O
9,O
.,O
Most,O
patients,O
(,O
82,O
.,O
0,O
%),O
had,O
been,O
injured,O
during,O
their,O
traumas,O
",",O
and,O
21,O
.,O
5,O
%,O
had,O
suffered,O
permanent,O
physical,O
disabilities,O
or,O
loss,O
of,O
function,O
due,O
to,O
the,O
trauma,O
.,O
A,O
third,O
of,O
the,O
patients,O
(,O
33,O
.,O
7,O
%),O
had,O
received,O
previous,O
treatment,O
for,O
their,O
PTSD,B-DS
",",O
and,O
9,O
.,O
1,O
%,O
had,O
had,O
a,O
previous,O
course,O
of,O
trauma,O
-,O
focused,O
CBT,O
.,O
The,O
majority,O
(,O
63,O
.,O
0,O
%),O
reported,O
a,O
history,O
of,O
further,O
traumas,O
",",O
and,O
17,O
.,O
8,O
%,O
reported,O
a,O
history,O
of,O
childhood,O
abuse,O
.,O
Comorbidity,O
with,O
other,O
disorders,O
was,O
common,O
;,O
75,O
.,O
8,O
%,O
met,O
diagnostic,O
criteria,O
for,O
at,O
least,O
one,O
current,O
comorbid,O
Axis,B-DS
1,I-DS
disorders,I-DS
",",O
and,O
29,O
.,O
1,O
%,O
met,O
criteria,O
for,O
Axis,B-DS
II,I-DS
disorders,I-DS
.,O
The,O
most,O
common,O
comorbid,O
Axis,O
1,O
conditions,O
were,O
mood,B-DS
disorders,I-DS
(,O
50,O
.,O
9,O
"%),",O
other,B-DS
anxiety,I-DS
disorders,I-DS
(,O
42,O
.,O
7,O
%),O
and,O
substance,B-DS
abuse,I-DS
(,O
22,O
.,O
1,O
%).,O
Nearly,O
half,O
(,O
48,O
.,O
5,O
%),O
reported,O
current,O
suicidal,O
ideation,O
",",O
and,O
14,O
.,O
2,O
%,O
reported,O
past,O
suicide,O
attempts,O
.,O
A,O
history,O
of,O
major,B-DS
depression,I-DS
was,O
common,O
(,O
69,O
.,O
7,O
"%),",O
and,O
a,O
significant,O
minority,O
(,O
18,O
.,O
8,O
%),O
reported,O
a,O
history,O
of,O
substance,B-DS
dependence,I-DS
.,O
The,O
mean,O
number,O
of,O
comorbid,O
disorders,O
was,O
2,O
.,O
2,O
",",O
SD,O
=,O
2,O
.,O
1,O
.,O
Patients,O
taking,O
psychotropic,O
medication,O
(,O
n,O
=,O
132,O
",",O
40,O
.,O
0,O
%),O
were,O
asked,O
to,O
remain,O
on,O
a,O
stable,O
dose,O
for,O
two,O
months,O
before,O
treatment,O
started,O
and,O
to,O
stay,O
on,O
the,O
same,O
dose,O
for,O
the,O
duration,O
of,O
treatment,O
",",O
and,O
the,O
majority,O
of,O
patients,O
reported,O
that,O
they,O
followed,O
this,O
advice,O
.,O
The,O
majority,O
(,O
54,O
.,O
5,O
%),O
of,O
these,O
patients,O
were,O
taking,O
SSRIs,O
",",O
16,O
.,O
3,O
%,O
tricyclic,O
antidepressants,O
",",O
4,O
.,O
9,O
%,O
benzodiazepines,O
",",O
6,O
.,O
5,O
%,O
hypnotics,O
.,O
and,O
17,O
.,O
9,O
%,O
other,O
medication,O
.,O
Patients,O
who,O
provided,O
follow,O
-,O
up,O
data,O
(,O
n,O
=,O
220,O
),O
were,O
comparable,O
to,O
those,O
who,O
did,O
not,O
(,O
n,O
=,O
110,O
),O
on,O
most,O
demographic,O
",",O
diagnostic,O
and,O
trauma,O
history,O
characteristics,O
",",O
but,O
had,O
higher,O
education,O
levels,O
",",O
χ2,O
(,O
3,O
",",O
n,O
=,O
306,O
),O
=,O
11,O
.,O
91,O
",",O
p,O
=,O
.,O
008,O
;,O
were,O
more,O
likely,O
to,O
be,O
employed,O
",",O
χ2,O
(,O
1,O
",",O
n,O
=,O
312,O
),O
=,O
4,O
.,O
91,O
",",O
p,O
=,O
.,O
027,O
",",O
and,O
less,O
likely,O
to,O
have,O
comorbid,O
mood,B-DS
disorders,I-DS
",",O
χ2,O
(,O
1,O
",",O
n,O
=,O
330,O
),O
=,O
14,O
.,O
77,O
",",O
p,O
<,O
.,O
001,O
",",O
current,O
substance,B-DS
abuse,I-DS
",",O
χ2,O
(,O
1,O
",",O
n,O
=,O
330,O
),O
=,O
5,O
.,O
62,O
",",O
p,O
<,O
.,O
018,O
",",O
or,O
personality,B-DS
disorders,I-DS
",",O
χ2,O
(,O
1,O
",",O
n,O
=,O
330,O
),O
=,O
4,O
.,O
99,O
",",O
p,O
=,O
.,O
025,O
.,O
Therapists,O
Therapists,O
included,O
both,O
qualified,O
clinicians,O
and,O
therapists,O
in,O
training,O
.,O
A,O
total,O
of,O
34,O
different,O
therapists,O
with,O
a,O
wide,O
range,O
of,O
prior,O
experience,O
in,O
CBT,O
treated,O
patients,O
during,O
the,O
study,O
period,O
.,O
This,O
included,O
clinical,O
psychologists,O
(,O
qualified,O
n,O
=,O
15,O
",",O
44,O
.,O
1,O
%;,O
trainees,O
=,O
11,O
",",O
32,O
.,O
3,O
"%),",O
nurse,O
therapists,O
(,O
n,O
=,O
3,O
",",O
8,O
.,O
8,O
%),O
and,O
psychiatrists,O
(,O
trainees,O
",",O
n,O
=,O
5,O
",",O
14,O
.,O
7,O
%).,O
Each,O
therapist,O
participated,O
in,O
a,O
two,O
-,O
day,O
workshop,O
in,O
CT,O
-,O
PTSD,B-DS
.,O
They,O
then,O
received,O
close,O
individual,O
supervision,O
in,O
treating,O
their,O
first,O
few,O
cases,O
and,O
had,O
the,O
opportunity,O
to,O
act,O
as,O
co,O
-,O
therapists,O
with,O
a,O
trained,O
therapist,O
for,O
at,O
least,O
one,O
case,O
.,O
Thereafter,O
",",O
cases,O
were,O
discussed,O
in,O
weekly,O
CT,O
-,O
PTSD,B-DS
focused,O
group,O
supervision,O
.,O
Data,O
for,O
all,O
patients,O
including,O
training,O
cases,O
were,O
included,O
in,O
the,O
data,O
analysis,O
.,O
Two,O
aspects,O
of,O
therapist,O
experience,O
were,O
coded,O
:,O
first,O
",",O
whether,O
the,O
therapist,O
was,O
a,O
trainee,O
or,O
a,O
staff,O
therapist,O
",",O
and,O
second,O
",",O
the,O
therapists,O
',O
experience,O
with,O
CT,O
-,O
PTSD,B-DS
(,O
experienced,O
was,O
defined,O
as,O
having,O
treated,O
more,O
than,O
12,O
patients,O
with,O
CT,O
-,O
PTSD,B-DS
).,O
Treatment,O
CT,O
-,O
PTSD,B-DS
is,O
based,O
on,O
Ehlers,O
and,O
Clark,O
',O
s,O
(,O
2000,O
),O
model,O
of,O
PTSD,B-DS
and,O
targets,O
three,O
factors,O
specified,O
in,O
this,O
model,O
.,O
It,O
is,O
suggested,O
that,O
people,O
with,O
PTSD,B-DS
perceive,O
a,O
serious,O
current,O
threat,O
which,O
has,O
two,O
sources,O
",",O
excessively,O
negative,O
appraisals,O
of,O
the,O
trauma,O
and,O
/,O
or,O
its,O
sequelae,O
and,O
characteristics,O
of,O
trauma,O
memories,O
that,O
lead,O
to,O
reexperiencing,O
symptoms,O
.,O
The,O
problem,O
is,O
maintained,O
by,O
cognitive,O
strategies,O
and,O
behaviors,O
(,O
such,O
as,O
thought,O
suppression,O
",",O
rumination,O
",",O
and,O
safety,O
-,O
seeking,O
behaviors,O
),O
that,O
are,O
intended,O
to,O
reduce,O
the,O
sense,O
of,O
current,O
threat,O
",",O
but,O
maintain,O
the,O
problem,O
by,O
preventing,O
change,O
in,O
the,O
appraisals,O
or,O
trauma,O
memory,O
",",O
and,O
/,O
or,O
by,O
increasing,O
symptoms,O
.,O
Details,O
of,O
the,O
treatment,O
procedures,O
are,O
found,O
in,O
Clark,O
and,O
Ehlers,O
(,O
2004,O
"),",O
Ehlers,O
et,O
al,O
.,O
(,O
2005,O
),O
and,O
Ehlers,O
et,O
al,O
.,O
(,O
2010,O
",",O
http,O
://,O
oxcadat,O
.,O
psy,O
.,O
ox,O
.,O
ac,O
.,O
uk,O
/,O
downloads,O
/,O
CT,O
-,O
PTSD,B-DS
%,O
20Treatment,O
%,O
20Procedures,O
.,O
pdf,O
/,O
view,O
).,O
Treatment,O
was,O
conducted,O
in,O
English,O
in,O
individual,O
treatment,O
sessions,O
.,O
Patients,O
received,O
a,O
mean,O
of,O
M,O
=,O
10,O
.,O
6,O
weekly,O
treatment,O
sessions,O
",",O
SD,O
=,O
5,O
.,O
0,O
",",O
and,O
M,O
=,O
2,O
.,O
0,O
monthly,O
booster,O
sessions,O
",",O
SD,O
=,O
3,O
.,O
0,O
",",O
similar,O
to,O
previous,O
trials,O
(,O
Ehlers,O
et,O
al,O
".,",O
2003,O
",",O
2005,O
).,O
Therapists,O
kept,O
detailed,O
notes,O
about,O
each,O
treatment,O
session,O
",",O
and,O
an,O
independent,O
rater,O
rated,O
the,O
extent,O
to,O
which,O
the,O
session,O
focused,O
on,O
the,O
PTSD,B-DS
treatment,O
model,O
",",O
on,O
a,O
scale,O
from,O
1,O
to,O
3,O
(,O
1,O
=,O
mainly,O
followed,O
trauma,O
-,O
focused,O
protocol,O
",",O
2,O
=,O
equal,O
focus,O
on,O
trauma,O
-,O
focused,O
protocol,O
and,O
other,O
problems,O
",",O
3,O
=,O
main,O
focus,O
on,O
other,O
problems,O
).,O
The,O
mean,O
rating,O
for,O
all,O
sessions,O
was,O
M,O
=,O
1,O
.,O
35,O
",",O
SD,O
=,O
0,O
.,O
39,O
",",O
and,O
for,O
90,O
.,O
1,O
%,O
of,O
the,O
patients,O
treatment,O
mainly,O
focused,O
on,O
the,O
PTSD,B-DS
treatment,O
protocol,O
(,O
mean,O
rating,O
of,O
below,O
2,O
).,O
The,O
most,O
common,O
other,O
problems,O
addressed,O
in,O
the,O
sessions,O
were,O
comorbid,O
disorders,O
",",O
and,O
other,O
stressors,O
such,O
as,O
social,O
problems,O
(,O
e,O
.,O
g,O
".,",O
financial,O
",",O
housing,O
",",O
legal,O
issues,O
),O
or,O
physical,O
health,O
problems,O
.,O
Measures,O
Self,O
-,O
reports,O
of,O
symptom,O
severity,O
were,O
taken,O
at,O
initial,O
assessment,O
",",O
at,O
the,O
first,O
and,O
last,O
treatment,O
session,O
",",O
and,O
at,O
follow,O
-,O
up,O
(,O
mean,O
280,O
days,O
).,O
Severity,O
of,O
PTSD,B-DS
symptoms,O
The,O
primary,O
outcome,O
measure,O
was,O
the,O
change,O
in,O
PTSD,B-DS
symptoms,O
.,O
Patients,O
completed,O
the,O
Posttraumatic,O
Diagnostic,O
Scale,O
(,O
PDS,O
",",O
Foa,O
",",O
Cashman,O
",",O
Jaycox,O
",",O
&,O
Perry,O
",",O
1997,O
).,O
The,O
PDS,O
asks,O
patients,O
to,O
rate,O
how,O
often,O
they,O
were,O
bothered,O
by,O
each,O
of,O
the,O
PTSD,B-DS
symptoms,O
specified,O
in,O
DSM,O
-,O
IV,O
ranging,O
from,O
0,O
=,O
never,O
to,O
3,O
=,O
5,O
times,O
per,O
week,O
or,O
more,O
/,O
almost,O
always,O
.,O
The,O
PDS,O
yields,O
a,O
sum,O
score,O
measuring,O
the,O
overall,O
severity,O
of,O
PTSD,B-DS
symptoms,O
.,O
Foa,O
et,O
al,O
.,O
(,O
1997,O
),O
showed,O
that,O
the,O
self,O
-,O
report,O
questionnaire,O
has,O
good,O
reliability,O
and,O
concurrent,O
validity,O
with,O
other,O
PTSD,B-DS
measures,O
.,O
Internal,O
consistency,O
in,O
this,O
sample,O
was,O
α,O
=,O
.,O
85,O
.,O
Depression,B-DS
and,O
anxiety,B-DS
Symptoms,O
of,O
anxiety,B-DS
and,O
depression,B-DS
were,O
secondary,O
outcome,O
measures,O
.,O
Patients,O
completed,O
the,O
Beck,O
Anxiety,B-DS
Inventory,O
(,O
BAI,O
",",O
Beck,O
&,O
Steer,O
",",O
1993a,O
),O
and,O
the,O
Beck,O
Depression,B-DS
Inventory,O
(,O
BDI,O
",",O
Beck,O
&,O
Steer,O
",",O
1993b,O
"),",O
standard,O
21,O
-,O
item,O
self,O
-,O
report,O
measures,O
with,O
high,O
reliability,O
and,O
validity,O
.,O
Internal,O
consistencies,O
in,O
this,O
sample,O
were,O
α,O
=,O
.,O
92,O
and,O
α,O
=,O
.,O
90,O
",",O
respectively,O
.,O
Candidate,O
moderators,O
At,O
initial,O
assessments,O
",",O
clinicians,O
conducted,O
the,O
Structured,O
Clinical,O
Interview,O
for,O
DSM,O
-,O
IV,O
(,O
SCID,O
),O
to,O
assess,O
Axis,O
I,O
(,O
First,O
",",O
Spitzer,O
",",O
Gibbon,O
",",O
&,O
Williams,O
",",O
1996,O
),O
and,O
II,O
diagnoses,O
(,O
First,O
",",O
Gibbon,O
",",O
Spitzer,O
",",O
&,O
Williams,O
",",O
1995,O
).,O
Interrater,O
-,O
reliability,O
for,O
PTSD,B-DS
(,O
determined,O
from,O
a,O
random,O
selection,O
of,O
37,O
audiotapes,O
of,O
the,O
interviews,O
),O
was,O
κ,O
=,O
0,O
.,O
95,O
.,O
Clinicians,O
also,O
determined,O
in,O
the,O
interview,O
what,O
the,O
patient,O
',O
s,O
main,O
problem,O
was,O
and,O
assessed,O
physical,O
consequences,O
of,O
the,O
trauma,O
(,O
disability,O
",",O
chronic,O
pain,O
),O
and,O
the,O
patients,O
',O
treatment,O
and,O
trauma,O
history,O
(,O
adapted,O
from,O
the,O
Clinician,O
Administered,O
PTSD,B-DS
Scale,O
",",O
Blake,O
et,O
al,O
".,",O
1995,O
).,O
Patients,O
provided,O
demographic,O
information,O
.,O
Four,O
groups,O
of,O
potential,O
moderators,O
were,O
extracted,O
on,O
the,O
basis,O
of,O
the,O
literature,O
reviewed,O
above,O
.,O
1,O
.,O
Selection,O
criteria,O
used,O
in,O
some,O
previous,O
RCTs,O
:,O
male,O
sex,O
;,O
age,O
;,O
patient,O
does,O
not,O
meet,O
full,O
DSM,O
-,O
IV,O
criteria,O
(,O
American,O
Psychiatric,O
Association,O
",",O
1994,O
),O
and,O
only,O
meets,O
ICD,O
-,O
10,O
(,O
World,O
Health,O
Organization,O
",",O
2010,O
),O
PTSD,B-DS
criteria,O
;,O
PTSD,B-DS
is,O
not,O
the,O
main,O
problem,O
(,O
i,O
.,O
e,O
".,",O
another,O
disorder,O
is,O
so,O
severe,O
that,O
it,O
needs,O
principal,O
concurrent,O
treatment,O
in,O
its,O
own,O
right,O
",",O
e,O
.,O
g,O
".,",O
very,O
severe,B-DS
depression,I-DS
or,O
agoraphobia,B-DS
);,O
borderline,B-DS
personality,I-DS
disorder,I-DS
;,O
current,O
substance,B-DS
abuse,I-DS
;,O
current,O
PTSD,B-DS
is,O
linked,O
to,O
multiple,O
traumas,O
;,O
history,O
of,O
childhood,O
abuse,O
;,O
no,O
memory,O
for,O
the,O
trauma,O
;,O
patient,O
had,O
a,O
previous,O
course,O
of,O
trauma,O
-,O
focused,O
CBT,O
for,O
PTSD,B-DS
.,O
2,O
.,O
Demographic,O
variables,O
:,O
ethnic,O
group,O
;,O
education,O
;,O
social,O
problems,O
(,O
defined,O
as,O
one,O
or,O
more,O
of,O
unemployment,O
",",O
financial,O
hardship,O
",",O
housing,O
problems,O
);,O
relationship,O
status,O
(,O
never,O
married,O
/,O
lived,O
with,O
partner,O
vs,O
.,O
married,O
",",O
cohabiting,O
",",O
widowed,O
or,O
divorced,O
);,O
ongoing,O
legal,O
proceedings,O
",",O
any,O
previous,O
treatment,O
for,O
PTSD,B-DS
.,O
3,O
.,O
Comorbidity,O
:,O
current,O
comorbid,O
anxiety,B-DS
disorder,I-DS
",",O
mood,B-DS
disorders,I-DS
",",O
other,O
axis,B-DS
1,I-DS
disorders,I-DS
",",O
personality,B-DS
disorder,I-DS
",",O
suicidal,O
ideation,O
",",O
taking,O
psychotropic,O
medication,O
;,O
physical,O
disability,O
resulting,O
from,O
trauma,O
",",O
chronic,O
pain,O
;,O
history,O
of,O
major,B-DS
depression,I-DS
",",O
substance,B-DS
dependence,I-DS
",",O
or,O
suicide,O
attempts,O
.,O
4,O
.,O
Aspects,O
of,O
trauma,O
history,O
:,O
Trauma,O
type,O
(,O
interpersonal,O
trauma,O
vs,O
other,O
);,O
trauma,O
involved,O
death,O
of,O
other,O
person,O
;,O
injured,O
in,O
trauma,O
;,O
months,O
since,O
main,O
trauma,O
;,O
history,O
of,O
other,O
traumas,O
;,O
total,O
number,O
of,O
traumas,O
experienced,O
.,O
Treatment,O
variables,O
Three,O
aspects,O
of,O
the,O
course,O
of,O
treatment,O
were,O
coded,O
from,O
the,O
session,O
notes,O
to,O
test,O
possible,O
effects,O
of,O
the,O
moderators,O
on,O
treatment,O
delivery,O
.,O
1,O
.,O
Dropout,O
:,O
This,O
was,O
defined,O
as,O
attending,O
less,O
than,O
8,O
sessions,O
",",O
unless,O
the,O
earlier,O
termination,O
was,O
determined,O
in,O
agreement,O
with,O
the,O
therapist,O
.,O
This,O
criterion,O
was,O
chosen,O
because,O
UK,O
treatment,O
guidelines,O
(,O
National,O
Institute,O
for,O
Health,O
and,O
Clinical,O
Excellence,O
",",O
2005,O
),O
recommend,O
8,O
sessions,O
as,O
an,O
adequate,O
trial,O
of,O
trauma,O
-,O
focused,O
treatments,O
for,O
PTSD,B-DS
on,O
the,O
basis,O
of,O
prior,O
research,O
.,O
2,O
.,O
Attendance,O
:,O
Therapists,O
indicated,O
in,O
the,O
session,O
notes,O
whether,O
or,O
not,O
the,O
patient,O
was,O
often,O
late,O
or,O
missed,O
appointments,O
without,O
notifying,O
the,O
therapist,O
.,O
3,O
.,O
Trauma,O
focus,O
:,O
the,O
degree,O
to,O
which,O
treatment,O
followed,O
the,O
trauma,O
-,O
focused,O
PTSD,B-DS
treatment,O
protocol,O
",",O
as,O
above,O
.,O
Data,O
analysis,O
Measures,O
of,O
treatment,O
response,O
The,O
main,O
outcome,O
variable,O
was,O
the,O
change,O
in,O
PDS,O
scores,O
with,O
treatment,O
.,O
Several,O
further,O
measures,O
of,O
treatment,O
response,O
were,O
calculated,O
for,O
comparability,O
with,O
previous,O
studies,O
.,O
Reliable,O
improvement,O
and,O
exacerbation,O
Reliable,O
change,O
thresholds,O
for,O
the,O
PDS,O
were,O
calculated,O
by,O
Foa,O
et,O
al,O
.,O
(,O
2002,O
),O
on,O
the,O
basis,O
of,O
the,O
retest,O
reliability,O
and,O
standard,O
deviation,O
of,O
the,O
scale,O
.,O
Reliable,O
improvement,O
and,O
exacerbation,O
are,O
decreases,O
/,O
increases,O
in,O
PDS,O
scores,O
of,O
greater,O
than,O
6,O
.,O
15,O
",",O
respectively,O
.,O
Clinically,O
significant,O
treatment,O
response,O
Clinical,O
significant,O
response,O
was,O
defined,O
as,O
in,O
Jacobson,O
and,O
Truax,O
(,O
1991,O
).,O
Patients,O
had,O
to,O
show,O
a,O
reliable,O
improvement,O
and,O
their,O
score,O
at,O
the,O
end,O
of,O
treatment,O
had,O
to,O
be,O
lower,O
than,O
the,O
halfway,O
point,O
between,O
2,O
SD,O
below,O
the,O
patients,O
',O
scores,O
at,O
the,O
beginning,O
of,O
treatment,O
",",O
and,O
2,O
SD,O
above,O
the,O
mean,O
of,O
a,O
sample,O
of,O
466,O
traumatized,O
people,O
without,O
PTSD,B-DS
from,O
the,O
same,O
catchment,O
area,O
(,O
M,O
=,O
7,O
.,O
22,O
",",O
SD,O
=,O
7,O
.,O
75,O
"),",O
i,O
.,O
e,O
".,",O
lower,O
than,O
19,O
.,O
775,O
.,O
This,O
criterion,O
is,O
similar,O
to,O
the,O
PDS,O
cut,O
-,O
offs,O
between,O
clinical,O
and,O
nonclinical,O
presentations,O
established,O
by,O
Ehring,O
",",O
Kleim,O
",",O
Clark,O
",",O
Foa,O
",",O
and,O
Ehlers,O
(,O
2007,O
),O
on,O
the,O
basis,O
of,O
agreement,O
with,O
structured,O
diagnostic,O
interviews,O
.,O
Effect,O
size,O
Treatment,O
effect,O
sizes,O
for,O
changes,O
in,O
symptom,O
scores,O
between,O
the,O
pre,O
treatment,O
assessment,O
and,O
final,O
treatment,O
session,O
were,O
calculated,O
using,O
Cohen,O
',O
s,O
d,O
statistic,O
(,O
Cohen,O
",",O
1988,O
).,O
As,O
other,O
studies,O
vary,O
in,O
whether,O
effect,O
sizes,O
are,O
reported,O
in,O
relation,O
to,O
pooled,O
pre,O
-,O
post,O
standard,O
deviations,O
",",O
or,O
pre,O
-,O
treatment,O
standard,O
deviations,O
",",O
we,O
report,O
both,O
for,O
comparison,O
.,O
Statistical,O
analysis,O
The,O
Statistical,O
Package,O
for,O
Social,O
Sciences,O
",",O
version,O
20,O
",",O
was,O
used,O
for,O
data,O
analysis,O
.,O
Hierarchical,O
linear,O
modeling,O
investigated,O
the,O
effect,O
of,O
candidate,O
moderators,O
and,O
therapist,O
effects,O
on,O
the,O
degree,O
of,O
improvement,O
in,O
the,O
PDS,O
with,O
treatment,O
",",O
following,O
guidelines,O
by,O
Heck,O
",",O
Thomas,O
",",O
and,O
Tabata,O
(,O
2010,O
).,O
This,O
analysis,O
uses,O
data,O
from,O
all,O
patients,O
.,O
All,O
variables,O
were,O
centered,O
for,O
this,O
analysis,O
(,O
Kraemer,O
et,O
al,O
".,",O
2002,O
).,O
At,O
Level,O
1,O
",",O
the,O
effects,O
of,O
repeated,O
observations,O
nested,O
within,O
patients,O
were,O
considered,O
.,O
Model,O
1,O
modeled,O
the,O
slope,O
of,O
improvement,O
in,O
PDS,O
scores,O
from,O
pre,O
treatment,O
to,O
post,O
treatment,O
to,O
follow,O
-,O
up,O
and,O
tested,O
random,O
slopes,O
and,O
intercepts,O
for,O
patients,O
.,O
Linear,O
and,O
quadratic,O
changes,O
in,O
PDS,O
scores,O
with,O
time,O
were,O
fitted,O
",",O
using,O
an,O
autoregressive,O
covariance,O
structure,O
at,O
Level,O
1,O
.,O
At,O
Level,O
2,O
",",O
patient,O
characteristics,O
that,O
may,O
influence,O
outcome,O
were,O
first,O
added,O
individually,O
(,O
because,O
of,O
some,O
missing,O
data,O
on,O
some,O
of,O
the,O
variables,O
),O
to,O
the,O
model,O
to,O
test,O
for,O
main,O
effects,O
on,O
PDS,O
scores,O
(,O
indicating,O
nonspecific,O
prediction,O
of,O
symptom,O
severity,O
",",O
Kraemer,O
et,O
al,O
".,",O
2002,O
),O
and,O
interactions,O
with,O
the,O
slope,O
of,O
improvement,O
(,O
moderator,O
effects,O
",",O
Kraemer,O
et,O
al,O
".,",O
2002,O
).,O
Next,O
",",O
variables,O
that,O
showed,O
significant,O
interactions,O
were,O
combined,O
into,O
an,O
overall,O
Model,O
2,O
to,O
determine,O
unique,O
moderators,O
of,O
slope,O
of,O
improvement,O
.,O
At,O
Level,O
3,O
(,O
therapist,O
effects,O
"),",O
random,O
slopes,O
and,O
intercepts,O
for,O
therapists,O
were,O
included,O
in,O
Model,O
3,O
.,O
In,O
Model,O
4,O
",",O
the,O
two,O
measures,O
of,O
therapist,O
experience,O
were,O
added,O
",",O
trainee,O
versus,O
staff,O
therapist,O
and,O
experienced,O
versus,O
inexperienced,O
in,O
delivering,O
CT,O
-,O
PTSD,B-DS
.,O
Results,O
Overall,O
effectiveness,O
of,O
treatment,O
There,O
was,O
no,O
significant,O
change,O
in,O
PTSD,B-DS
symptoms,O
during,O
the,O
wait,O
period,O
between,O
assessment,O
and,O
treatment,O
",",O
M,O
=,O
97,O
.,O
1,O
days,O
",",O
SD,O
=,O
77,O
.,O
0,O
",",O
PDS,O
scores,O
M,O
=,O
33,O
.,O
88,O
",",O
SD,O
=,O
8,O
.,O
67,O
to,O
M,O
=,O
33,O
.,O
15,O
",",O
SD,O
=,O
9,O
.,O
25,O
",",O
F,O
(,O
1,O
",",O
275,O
),O
=,O
2,O
.,O
71,O
",",O
p,O
=,O
.,O
101,O
",",O
d,O
=,O
0,O
.,O
08,O
.,O
Table,O
2,O
shows,O
the,O
PTSD,B-DS
symptom,O
scores,O
(,O
PDS,O
),O
at,O
initial,O
assessment,O
and,O
the,O
last,O
treatment,O
session,O
for,O
the,O
intent,O
-,O
to,O
-,O
treat,O
sample,O
of,O
330,O
patients,O
(,O
see,O
also,O
Fig,O
.,O
2,O
).,O
Patients,O
received,O
a,O
mean,O
of,O
12,O
.,O
57,O
sessions,O
(,O
SD,O
=,O
6,O
.,O
51,O
).,O
Patients,O
showed,O
very,O
large,O
improvement,O
in,O
PTSD,B-DS
symptom,O
severity,O
with,O
treatment,O
.,O
Two,O
hundred,O
sixty,O
patients,O
(,O
78,O
.,O
8,O
%),O
showed,O
a,O
reliable,O
improvement,O
(,O
Foa,O
et,O
al,O
".,",O
2002,O
).,O
The,O
mean,O
percent,O
change,O
in,O
PTSD,B-DS
symptoms,O
was,O
50,O
.,O
4,O
"%,",O
SD,O
=,O
40,O
.,O
38,O
.,O
The,O
majority,O
of,O
patients,O
(,O
n,O
=,O
189,O
",",O
57,O
.,O
3,O
%),O
showed,O
a,O
clinically,O
significant,O
change,O
.,O
Clinically,O
significant,O
change,O
was,O
associated,O
with,O
greater,O
trauma,O
focus,O
of,O
the,O
sessions,O
",",O
M,O
=,O
1,O
.,O
31,O
",",O
SD,O
=,O
0,O
.,O
37,O
versus,O
M,O
=,O
1,O
.,O
41,O
",",O
SD,O
=,O
0,O
.,O
42,O
",",O
F,O
(,O
1,O
",",O
322,O
),O
=,O
5,O
.,O
51,O
",",O
p,O
=,O
.,O
020,O
",",O
d,O
=,O
0,O
.,O
17,O
.,O
In,O
treatment,O
completers,O
",",O
PDS,O
scores,O
decreased,O
from,O
M,O
=,O
33,O
.,O
83,O
",",O
SD,O
=,O
8,O
.,O
67,O
to,O
M,O
=,O
15,O
.,O
18,O
",",O
SD,O
=,O
13,O
.,O
65,O
",",O
d,O
=,O
1,O
.,O
63,O
for,O
pooled,O
SD,O
and,O
d,O
=,O
2,O
.,O
15,O
for,O
pre,O
-,O
treatment,O
SD,O
",",O
and,O
the,O
mean,O
change,O
in,O
PDS,O
scores,O
was,O
57,O
.,O
95,O
"%,",O
SD,O
=,O
34,O
.,O
95,O
.,O
A,O
reliable,O
change,O
in,O
PDS,O
scores,O
was,O
observed,O
in,O
240,O
(,O
84,O
.,O
5,O
%),O
of,O
the,O
completers,O
",",O
and,O
a,O
clinically,O
significant,O
change,O
in,O
185,O
(,O
65,O
.,O
1,O
%).,O
Analysis,O
of,O
dropouts,O
and,O
attendance,O
The,O
overall,O
dropout,O
rate,O
was,O
13,O
.,O
9,O
"%,",O
46,O
of,O
330,O
patients,O
.,O
Of,O
these,O
",",O
6,O
patients,O
(,O
13,O
%),O
dropped,O
out,O
after,O
1,O
session,O
",",O
11,O
(,O
23,O
.,O
9,O
%),O
after,O
2,O
sessions,O
",",O
8,O
(,O
17,O
.,O
4,O
%),O
after,O
3,O
sessions,O
",",O
4,O
(,O
8,O
.,O
7,O
%),O
after,O
4,O
sessions,O
",",O
7,O
(,O
15,O
.,O
2,O
%),O
after,O
5,O
sessions,O
",",O
4,O
(,O
8,O
.,O
7,O
%),O
after,O
6,O
sessions,O
",",O
and,O
6,O
(,O
13,O
.,O
0,O
%),O
after,O
7,O
sessions,O
.,O
Patients,O
who,O
dropped,O
out,O
had,O
waited,O
longer,O
for,O
treatment,O
t,O
(,O
327,O
),O
=,O
4,O
.,O
89,O
",",O
p,O
=,O
.,O
005,O
.,O
Among,O
dropouts,O
",",O
only,O
8,O
.,O
7,O
%,O
(,O
4,O
/,O
46,O
),O
showed,O
a,O
clinically,O
significant,O
treatment,O
response,O
",",O
compared,O
to,O
66,O
.,O
9,O
%,O
(,O
190,O
/,O
94,O
),O
of,O
treatment,O
completers,O
",",O
χ2,O
(,O
1,O
",",O
n,O
=,O
330,O
),O
=,O
55,O
.,O
36,O
",",O
p,O
<,O
.,O
001,O
.,O
Twenty,O
-,O
one,O
percent,O
of,O
the,O
patients,O
(,O
n,O
=,O
71,O
),O
were,O
classified,O
as,O
unreliable,O
attenders,O
.,O
This,O
variable,O
was,O
independent,O
of,O
dropout,O
status,O
",",O
C,O
=,O
0,O
.,O
049,O
.,O
Unreliable,O
attenders,O
were,O
less,O
likely,O
to,O
show,O
clinically,O
significant,O
change,O
than,O
patients,O
who,O
attended,O
regularly,O
",",O
42,O
.,O
3,O
%,O
versus,O
63,O
.,O
3,O
"%,",O
χ2,O
(,O
1,O
",",O
n,O
=,O
330,O
),O
=,O
10,O
.,O
21,O
",",O
p,O
=,O
.,O
001,O
.,O
Symptom,O
exacerbation,O
Fourteen,O
patients,O
(,O
4,O
.,O
3,O
%),O
had,O
reliable,O
increases,O
on,O
the,O
PDS,O
between,O
initial,O
assessment,O
and,O
the,O
end,O
of,O
treatment,O
.,O
For,O
10,O
of,O
the,O
14,O
patients,O
(,O
71,O
.,O
4,O
"%),",O
the,O
reliable,O
increase,O
had,O
already,O
occurred,O
during,O
the,O
wait,O
period,O
between,O
the,O
initial,O
assessment,O
and,O
the,O
first,O
session,O
.,O
Thus,O
",",O
only,O
4,O
(,O
1,O
.,O
2,O
%),O
patients,O
showed,O
reliable,O
exacerbation,O
in,O
symptom,O
severity,O
during,O
treatment,O
.,O
Improvement,O
in,O
other,O
symptoms,O
Table,O
1,O
shows,O
the,O
changes,O
in,O
depressive,O
(,O
BDI,O
),O
and,O
anxiety,B-DS
(,O
BAI,O
),O
symptoms,O
with,O
treatment,O
.,O
Patients,O
showed,O
large,O
improvement,O
in,O
these,O
secondary,O
outcomes,O
.,O
Stability,O
of,O
treatment,O
effects,O
Two,O
thirds,O
of,O
the,O
patients,O
(,O
n,O
=,O
220,O
),O
provided,O
follow,O
-,O
up,O
data,O
.,O
The,O
mean,O
duration,O
of,O
the,O
follow,O
-,O
up,O
was,O
280,O
.,O
1,O
days,O
",",O
SD,O
=,O
177,O
.,O
7,O
.,O
There,O
were,O
no,O
significant,O
changes,O
in,O
symptom,O
scores,O
between,O
the,O
end,O
of,O
treatment,O
and,O
follow,O
-,O
up,O
",",O
PDS,O
:,O
F,O
(,O
1,O
",",O
217,O
),O
=,O
1,O
.,O
01,O
",",O
p,O
=,O
.,O
317,O
",",O
η2,O
=,O
0,O
.,O
005,O
;,O
BDI,O
:,O
F,O
(,O
1,O
",",O
211,O
),O
=,O
0,O
.,O
64,O
",",O
p,O
=,O
.,O
425,O
",",O
η2,O
=,O
0,O
.,O
003,O
;,O
BAI,O
",",O
time,O
effect,O
F,O
(,O
1,O
",",O
212,O
),O
=,O
0,O
.,O
28,O
",",O
p,O
=,O
.,O
595,O
",",O
η2,O
=,O
0,O
.,O
001,O
.,O
Moderators,O
of,O
treatment,O
response,O
To,O
reduce,O
the,O
number,O
of,O
potential,O
predictors,O
",",O
candidate,O
moderators,O
were,O
first,O
considered,O
individually,O
(,O
see,O
Table,O
2,O
).,O
Few,O
of,O
the,O
RCT,O
selection,O
criteria,O
",",O
comorbidity,O
",",O
trauma,O
and,O
demographic,O
characteristics,O
selected,O
from,O
the,O
literature,O
predicted,O
outcome,O
.,O
Significant,O
univariate,O
moderation,O
effects,O
were,O
found,O
for,O
8,O
predictors,O
:,O
PTSD,B-DS
is,O
not,O
the,O
main,O
problem,O
",",O
patient,O
needs,O
treatment,O
for,O
multiple,O
traumas,O
",",O
social,O
problems,O
",",O
relationship,O
status,O
",",O
comorbid,O
mood,B-DS
disorder,I-DS
",",O
history,O
of,O
suicide,O
attempts,O
",",O
history,O
of,O
substance,B-DS
dependence,I-DS
",",O
longer,O
time,O
since,O
the,O
main,O
trauma,O
were,O
associated,O
with,O
somewhat,O
less,O
improvement,O
.,O
Several,O
other,O
variables,O
predicted,O
a,O
greater,O
overall,O
severity,O
of,O
PTSD,B-DS
symptoms,O
",",O
but,O
not,O
the,O
slope,O
of,O
improvement,O
(,O
non,O
-,O
specific,O
predictors,O
).,O
These,O
included,O
meeting,O
DSM,O
-,O
IV,O
criteria,O
for,O
PTSD,B-DS
",",O
aspects,O
of,O
comorbidity,O
(,O
current,O
substance,B-DS
abuse,I-DS
",",O
suicidal,O
ideation,O
",",O
axis,B-DS
1,I-DS
disorder,I-DS
other,O
than,O
anxiety,B-DS
or,O
mood,B-DS
disorder,I-DS
",",O
comorbid,O
personality,B-DS
disorder,I-DS
",",O
chronic,O
pain,O
",",O
physical,O
disability,O
due,O
to,O
the,O
trauma,O
",",O
history,O
of,O
major,B-DS
depression,I-DS
"),",O
taking,O
psychotropic,O
medication,O
",",O
and,O
a,O
higher,O
level,O
of,O
education,O
.,O
Table,O
3,O
shows,O
the,O
results,O
of,O
the,O
hierarchical,O
modeling,O
analyses,O
for,O
four,O
models,O
of,O
increasing,O
complexity,O
",",O
which,O
are,O
shown,O
in,O
separate,O
columns,O
.,O
Overall,O
model,O
fits,O
and,O
random,O
effects,O
for,O
patients,O
and,O
therapists,O
are,O
shown,O
at,O
the,O
top,O
of,O
the,O
table,O
",",O
and,O
fixed,O
effects,O
for,O
candidate,O
moderators,O
and,O
therapist,O
variables,O
at,O
the,O
bottom,O
.,O
Model,O
1,O
(,O
Level,O
1,O
",",O
random,O
slopes,O
and,O
intercepts,O
for,O
patients,O
and,O
improvement,O
in,O
PDS,O
scores,O
from,O
pre,O
treatment,O
to,O
post,O
treatment,O
to,O
follow,O
-,O
up,O
and,O
),O
showed,O
highly,O
significant,O
linear,O
and,O
quadratic,O
changes,O
in,O
PDS,O
scores,O
across,O
assessment,O
points,O
",",O
indicating,O
a,O
steep,O
decrease,O
in,O
PTSD,B-DS
symptoms,O
with,O
treatment,O
",",O
which,O
flattened,O
out,O
during,O
follow,O
-,O
up,O
.,O
Random,O
slopes,O
and,O
intercepts,O
for,O
patients,O
were,O
also,O
highly,O
significant,O
.,O
Model,O
2,O
added,O
patient,O
characteristics,O
at,O
Level,O
2,O
;,O
analysis,O
was,O
restricted,O
to,O
the,O
8,O
candidate,O
moderators,O
that,O
showed,O
univariate,O
moderation,O
effects,O
.,O
In,O
the,O
multivariate,O
analysis,O
",",O
unique,O
moderation,O
effects,O
were,O
found,O
for,O
needing,O
treatment,O
for,O
multiple,O
traumas,O
and,O
social,O
problems,O
.,O
There,O
was,O
a,O
trend,O
for,O
relationship,O
status,O
.,O
Comorbid,O
mood,B-DS
disorders,I-DS
and,O
social,O
problems,O
were,O
nonspecific,O
predictors,O
",",O
i,O
.,O
e,O
".,",O
were,O
associated,O
with,O
higher,O
scores,O
both,O
at,O
the,O
beginning,O
and,O
end,O
of,O
treatment,O
.,O
All,O
other,O
effects,O
were,O
nonsignificant,O
.,O
Therapist,O
effects,O
In,O
Model,O
3,O
(,O
Table,O
3,O
),O
random,O
intercepts,O
and,O
slopes,O
were,O
added,O
for,O
therapists,O
.,O
There,O
were,O
no,O
significant,O
random,O
therapist,O
effects,O
",",O
and,O
the,O
results,O
for,O
patient,O
characteristics,O
were,O
identical,O
to,O
Model,O
2,O
.,O
Model,O
4,O
added,O
two,O
aspects,O
of,O
therapist,O
experience,O
(,O
staff,O
therapist,O
",",O
experience,O
with,O
CT,O
-,O
PTSD,B-DS
),O
to,O
the,O
prediction,O
.,O
There,O
was,O
a,O
trend,O
for,O
inexperienced,O
therapists,O
to,O
achieve,O
somewhat,O
less,O
good,O
outcome,O
.,O
Association,O
of,O
moderators,O
with,O
treatment,O
variables,O
Patients,O
who,O
needed,O
treatment,O
for,O
multiple,O
trauma,O
were,O
more,O
likely,O
to,O
attend,O
irregularly,O
than,O
those,O
who,O
were,O
treated,O
for,O
one,O
or,O
two,O
traumas,O
",",O
33,O
.,O
3,O
%,O
versus,O
19,O
.,O
6,O
"%,",O
χ2,O
(,O
1,O
",",O
n,O
=,O
330,O
),O
=,O
4,O
.,O
31,O
",",O
p,O
=,O
.,O
038,O
",",O
but,O
did,O
not,O
differ,O
in,O
dropout,O
rates,O
or,O
number,O
of,O
treatment,O
sessions,O
.,O
Their,O
treatment,O
was,O
less,O
trauma,O
-,O
focused,O
than,O
treatment,O
of,O
other,O
patients,O
",",O
M,O
=,O
1,O
.,O
46,O
(,O
SD,O
=,O
0,O
.,O
37,O
),O
versus,O
M,O
=,O
1,O
.,O
33,O
(,O
SD,O
=,O
0,O
.,O
40,O
"),",O
F,O
(,O
1,O
",",O
322,O
),O
=,O
4,O
.,O
28,O
",",O
p,O
=,O
.,O
039,O
",",O
η2,O
=,O
0,O
.,O
013,O
.,O
Patients,O
who,O
had,O
social,O
problems,O
were,O
more,O
likely,O
to,O
drop,O
out,O
of,O
treatment,O
",",O
18,O
.,O
5,O
%,O
versus,O
7,O
.,O
2,O
"%,",O
χ2,O
(,O
1,O
",",O
n,O
=,O
327,O
),O
=,O
8,O
.,O
54,O
",",O
p,O
=,O
.,O
003,O
.,O
Their,O
treatment,O
tended,O
to,O
be,O
less,O
trauma,O
-,O
focused,O
than,O
treatment,O
of,O
other,O
patients,O
",",O
M,O
=,O
1,O
.,O
39,O
(,O
SD,O
=,O
0,O
.,O
42,O
),O
versus,O
M,O
=,O
1,O
.,O
30,O
(,O
SD,O
=,O
0,O
.,O
36,O
"),",O
F,O
(,O
1,O
",",O
319,O
),O
=,O
3,O
.,O
432,O
",",O
p,O
=,O
.,O
065,O
",",O
η2,O
=,O
0,O
.,O
011,O
.,O
Associations,O
with,O
unreliable,O
attendance,O
(,O
p,O
.,O
=,O
0,O
.,O
105,O
),O
and,O
lower,O
number,O
of,O
sessions,O
(,O
p,O
=,O
.,O
094,O
),O
failed,O
to,O
reach,O
significance,O
.,O
Patients,O
were,O
more,O
likely,O
to,O
drop,O
out,O
if,O
the,O
therapist,O
was,O
inexperienced,O
in,O
delivering,O
CT,O
-,O
PTSD,B-DS
",",O
18,O
.,O
1,O
%,O
versus,O
10,O
.,O
3,O
"%,",O
χ2,O
(,O
1,O
",",O
n,O
=,O
330,O
),O
=,O
4,O
.,O
15,O
",",O
p,O
=,O
.,O
042,O
.,O
Discussion,O
The,O
study,O
supports,O
the,O
effectiveness,O
of,O
CT,O
for,O
PTSD,B-DS
in,O
routine,O
clinical,O
practice,O
.,O
It,O
shows,O
that,O
this,O
treatment,O
can,O
be,O
successfully,O
implemented,O
in,O
a,O
National,O
Health,O
Service,O
clinic,O
serving,O
an,O
ethnically,O
mixed,O
urban,O
catchment,O
area,O
",",O
with,O
therapists,O
who,O
ranged,O
in,O
previous,O
experience,O
in,O
CBT,O
and,O
in,O
treating,O
PTSD,B-DS
.,O
The,O
clinic,O
',O
s,O
catchment,O
area,O
was,O
clearly,O
defined,O
",",O
referral,O
was,O
by,O
local,O
family,O
doctors,O
and,O
community,O
mental,O
health,O
teams,O
",",O
and,O
a,O
consecutive,O
sample,O
was,O
assessed,O
",",O
supporting,O
the,O
representativeness,O
of,O
the,O
results,O
.,O
The,O
intent,O
-,O
to,O
-,O
treat,O
analysis,O
showed,O
very,O
large,O
effect,O
sizes,O
for,O
improvement,O
in,O
PTSD,B-DS
symptoms,O
with,O
treatment,O
.,O
The,O
effect,O
size,O
estimates,O
are,O
conservative,O
as,O
training,O
cases,O
were,O
included,O
in,O
the,O
analysis,O
.,O
The,O
mean,O
improvement,O
in,O
PTSD,B-DS
symptoms,O
was,O
large,O
",",O
50,O
.,O
3,O
%,O
for,O
the,O
intent,O
-,O
to,O
-,O
treat,O
sample,O
",",O
and,O
57,O
.,O
8,O
%,O
for,O
completers,O
",",O
and,O
the,O
majority,O
of,O
patients,O
showed,O
clinically,O
significant,O
change,O
",",O
57,O
.,O
3,O
%,O
and,O
65,O
.,O
1,O
%,O
respectively,O
.,O
Depression,B-DS
and,O
general,O
anxiety,B-DS
symptoms,O
also,O
showed,O
substantial,O
improvement,O
with,O
treatment,O
.,O
Treatment,O
was,O
well,O
tolerated,O
.,O
The,O
overall,O
dropout,O
rate,O
of,O
13,O
.,O
9,O
%,O
was,O
low,O
",",O
despite,O
the,O
fact,O
that,O
the,O
clinic,O
served,O
a,O
catchment,O
area,O
characterized,O
by,O
high,O
social,O
deprivation,O
and,O
high,O
mobility,O
and,O
that,O
some,O
of,O
the,O
therapists,O
were,O
inexperienced,O
in,O
delivering,O
the,O
treatment,O
.,O
It,O
is,O
below,O
that,O
observed,O
in,O
many,O
RCTs,O
(,O
e,O
.,O
g,O
".,",O
34,O
%,O
Resick,O
et,O
al,O
".,",O
2002,O
;,O
43,O
%,O
Power,O
et,O
al,O
".,",O
2002,O
;,O
34,O
%,O
Foa,O
et,O
al,O
".,",O
2005,O
;,O
38,O
%,O
Schnurr,O
et,O
al,O
",",O
2007,O
;,O
26,O
%,O
Galovski,O
",",O
Blain,O
",",O
Mott,O
",",O
Elwood,O
",",O
&,O
Houle,O
",",O
2012,O
),O
and,O
effectiveness,O
studies,O
of,O
trauma,O
-,O
focused,O
PTSD,B-DS
treatments,O
(,O
e,O
.,O
g,O
".,",O
36,O
%,O
Levitt,O
et,O
al,O
".,",O
2007,O
;,O
24,O
%,O
and,O
32,O
%;,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
).,O
Although,O
limited,O
conclusions,O
can,O
be,O
drawn,O
from,O
comparing,O
dropout,O
rates,O
in,O
different,O
samples,O
across,O
countries,O
with,O
different,O
health,O
systems,O
",",O
it,O
appears,O
safe,O
to,O
conclude,O
that,O
the,O
low,O
dropout,O
rates,O
support,O
the,O
acceptability,O
of,O
CT,O
-,O
PTSD,B-DS
to,O
patients,O
.,O
This,O
study,O
further,O
found,O
that,O
patients,O
who,O
dropped,O
out,O
and,O
those,O
who,O
attended,O
irregularly,O
had,O
poorer,O
outcomes,O
",",O
so,O
that,O
limiting,O
dropout,O
rates,O
is,O
likely,O
to,O
improve,O
the,O
overall,O
effectiveness,O
of,O
interventions,O
.,O
Consistent,O
with,O
previous,O
studies,O
(,O
Foa,O
et,O
al,O
".,",O
2002,O
;,O
Hackmann,O
et,O
al,O
".,",O
2004,O
"),",O
symptom,O
exacerbations,O
were,O
only,O
found,O
in,O
a,O
small,O
minority,O
of,O
patients,O
.,O
Interestingly,O
",",O
the,O
results,O
indicated,O
that,O
the,O
exacerbation,O
mainly,O
occurred,O
between,O
assessment,O
and,O
the,O
start,O
of,O
treatment,O
.,O
This,O
result,O
is,O
similar,O
to,O
Duffy,O
et,O
al,O
.,O
(,O
2007,O
),O
who,O
found,O
that,O
deterioration,O
was,O
more,O
common,O
in,O
the,O
wait,O
period,O
than,O
during,O
therapy,O
.,O
For,O
the,O
majority,O
of,O
patients,O
",",O
such,O
symptom,O
exacerbations,O
may,O
thus,O
reflect,O
the,O
influence,O
of,O
other,O
factors,O
such,O
as,O
new,O
trauma,O
or,O
additional,O
stressors,O
rather,O
than,O
negative,O
effects,O
of,O
treatment,O
per,O
se,O
.,O
This,O
raises,O
the,O
question,O
of,O
what,O
effect,O
waiting,O
for,O
treatment,O
may,O
have,O
on,O
the,O
probability,O
of,O
engagement,O
with,O
treatment,O
.,O
The,O
average,O
waiting,O
time,O
of,O
about,O
3,O
months,O
was,O
relatively,O
short,O
for,O
psychological,O
services,O
in,O
the,O
UK,O
National,O
Health,O
Service,O
at,O
the,O
time,O
of,O
the,O
study,O
.,O
Overall,O
",",O
symptom,O
scores,O
were,O
stable,O
over,O
the,O
waiting,O
period,O
.,O
Some,O
patients,O
waited,O
longer,O
",",O
partly,O
due,O
to,O
the,O
availability,O
of,O
therapists,O
and,O
partly,O
due,O
to,O
patient,O
-,O
determined,O
factors,O
such,O
as,O
scheduled,O
surgery,O
/,O
physical,O
rehabilitation,O
",",O
work,O
schedules,O
",",O
travel,O
or,O
childbirth,O
.,O
It,O
is,O
unlikely,O
that,O
the,O
wait,O
for,O
treatment,O
contributed,O
to,O
the,O
relatively,O
low,O
dropout,O
rates,O
observed,O
in,O
this,O
study,O
as,O
patients,O
who,O
dropped,O
out,O
had,O
waited,O
longer,O
than,O
completers,O
.,O
This,O
suggests,O
that,O
it,O
is,O
desirable,O
to,O
reduce,O
waiting,O
times,O
to,O
help,O
reduce,O
the,O
risk,O
of,O
symptom,O
deterioration,O
and,O
dropouts,O
.,O
Effect,O
sizes,O
in,O
the,O
present,O
study,O
were,O
comparable,O
to,O
those,O
obtained,O
by,O
Duffy,O
et,O
al,O
.,O
(,O
2007,O
),O
with,O
the,O
same,O
treatment,O
in,O
an,O
unselected,O
sample,O
of,O
patients,O
with,O
very,O
chronic,O
PTSD,B-DS
.,O
The,O
intent,O
-,O
to,O
-,O
treat,O
effect,O
sizes,O
were,O
somewhat,O
smaller,O
than,O
those,O
observed,O
in,O
some,O
previous,O
RCTs,O
of,O
CT,O
-,O
PTSD,B-DS
(,O
Ehlers,O
et,O
al,O
".,",O
2003,O
",",O
2005,O
"),",O
but,O
similar,O
to,O
or,O
larger,O
than,O
those,O
observed,O
in,O
intent,O
-,O
to,O
-,O
treat,O
analyses,O
in,O
other,O
RCTs,O
of,O
trauma,O
-,O
focused,O
cognitive,O
behavior,O
therapy,O
(,O
Bryant,O
et,O
al,O
".,",O
2003,O
;,O
Resick,O
et,O
al,O
".,",O
2002,O
;,O
Schnurr,O
et,O
al,O
",",O
2007,O
).,O
Given,O
that,O
the,O
study,O
reports,O
on,O
a,O
consecutive,O
intent,O
-,O
to,O
-,O
treat,O
sample,O
with,O
a,O
wide,O
range,O
of,O
traumas,O
from,O
an,O
ethnically,O
diverse,O
and,O
socially,O
deprived,O
catchment,O
area,O
",",O
and,O
patients,O
were,O
treated,O
by,O
both,O
trainees,O
and,O
experienced,O
clinicians,O
",",O
the,O
outcomes,O
can,O
be,O
considered,O
as,O
encouraging,O
.,O
The,O
moderator,O
analysis,O
showed,O
that,O
many,O
of,O
the,O
criteria,O
that,O
have,O
sometimes,O
been,O
used,O
to,O
exclude,O
patients,O
from,O
RCTs,O
were,O
not,O
related,O
to,O
poorer,O
outcome,O
.,O
The,O
only,O
exceptions,O
were,O
that,O
patients,O
who,O
needed,O
treatment,O
for,O
multiple,O
traumas,O
and,O
those,O
for,O
whom,O
PTSD,B-DS
was,O
not,O
the,O
main,O
clinical,O
problem,O
showed,O
somewhat,O
less,O
improvement,O
.,O
Overall,O
the,O
results,O
suggest,O
that,O
the,O
treatment,O
is,O
effective,O
in,O
patients,O
who,O
do,O
not,O
meet,O
all,O
inclusion,O
criteria,O
for,O
RCTs,O
and,O
should,O
not,O
be,O
withheld,O
from,O
these,O
patients,O
(,O
see,O
also,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
).,O
Like,O
other,O
studies,O
of,O
TF,O
-,O
CBT,O
programs,O
(,O
e,O
.,O
g,O
".,",O
Richardson,O
et,O
al,O
".,",O
2011,O
;,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
"),",O
this,O
study,O
found,O
few,O
other,O
moderators,O
of,O
treatment,O
response,O
",",O
further,O
indicating,O
that,O
CT,O
-,O
PTSD,B-DS
is,O
effective,O
in,O
a,O
wide,O
range,O
of,O
patients,O
.,O
Most,O
demographic,O
variables,O
such,O
as,O
sex,O
",",O
age,O
",",O
ethnic,O
group,O
or,O
education,O
level,O
were,O
unrelated,O
to,O
treatment,O
response,O
.,O
This,O
is,O
consistent,O
with,O
the,O
results,O
of,O
several,O
other,O
studies,O
(,O
e,O
.,O
g,O
".,",O
Richardson,O
et,O
al,O
"..,",O
2011,O
;,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
"),",O
although,O
some,O
studies,O
reported,O
poorer,O
outcome,O
or,O
larger,O
drop,O
-,O
out,O
rates,O
for,O
men,O
(,O
Blain,O
et,O
al,O
".,",O
2010,O
).,O
It,O
remains,O
to,O
be,O
tested,O
whether,O
the,O
differences,O
in,O
results,O
are,O
due,O
to,O
sample,O
differences,O
or,O
differences,O
in,O
procedures,O
.,O
With,O
the,O
exception,O
of,O
mood,B-DS
disorders,I-DS
",",O
current,O
comorbidity,O
did,O
not,O
moderate,O
outcome,O
",",O
but,O
acted,O
as,O
a,O
nonspecific,O
predictor,O
of,O
outcome,O
only,O
.,O
High,O
levels,O
of,O
depression,B-DS
were,O
also,O
associated,O
with,O
less,O
favorable,O
outcome,O
in,O
Duffy,O
et,O
al,O
.,O
(,O
2007,O
),O
and,O
Tarrier,O
et,O
al,O
.,O
(,O
2000,O
"),",O
but,O
not,O
in,O
other,O
studies,O
of,O
TF,O
-,O
CBT,O
(,O
Ehlers,O
et,O
al,O
".,",O
2005,O
;,O
Richardson,O
et,O
al,O
".,",O
2011,O
;,O
van,O
Minnen,O
et,O
al,O
".,",O
2002,O
).,O
One,O
possible,O
explanation,O
for,O
the,O
discrepant,O
results,O
may,O
be,O
the,O
range,O
of,O
depression,B-DS
severity,O
included,O
in,O
the,O
studies,O
.,O
The,O
studies,O
that,O
reported,O
negative,O
findings,O
had,O
lower,O
mean,O
depression,B-DS
scores,O
than,O
those,O
finding,O
an,O
effect,O
of,O
depression,B-DS
.,O
Comorbid,O
depression,B-DS
may,O
only,O
hamper,O
progress,O
in,O
therapy,O
if,O
it,O
is,O
so,O
severe,O
that,O
it,O
affects,O
daily,O
activity,O
levels,O
and,O
motivation,O
to,O
engage,O
in,O
the,O
therapy,O
assignments,O
.,O
The,O
lack,O
of,O
a,O
moderating,O
effect,O
of,O
comorbid,O
personality,B-DS
disorders,I-DS
including,O
borderline,B-DS
personality,I-DS
disorder,I-DS
is,O
noteworthy,O
and,O
consistent,O
with,O
other,O
studies,O
(,O
Clarke,O
et,O
al,O
".,",O
2008,O
;,O
Feeny,O
et,O
al,O
".,",O
2002,O
).,O
Longer,O
time,O
since,O
the,O
trauma,O
",",O
a,O
history,O
of,O
suicide,O
attempts,O
or,O
substance,B-DS
dependence,I-DS
",",O
social,O
problems,O
",",O
and,O
relationship,O
status,O
(,O
never,O
having,O
been,O
married,O
or,O
lived,O
with,O
a,O
partner,O
),O
were,O
associated,O
with,O
a,O
somewhat,O
less,O
favorable,O
treatment,O
response,O
.,O
The,O
effect,O
of,O
past,O
suicide,O
attempts,O
replicates,O
Tarrier,O
et,O
al,O
.',O
s,O
(,O
2000,O
),O
findings,O
.,O
These,O
characteristics,O
",",O
and,O
possibly,O
very,O
high,O
levels,O
of,O
depression,B-DS
",",O
may,O
characterize,O
a,O
group,O
of,O
patients,O
with,O
high,O
levels,O
of,O
demoralization,O
and,O
hopelessness,O
",",O
who,O
may,O
not,O
have,O
been,O
fully,O
engaged,O
in,O
treatment,O
by,O
their,O
therapists,O
.,O
Time,O
since,O
the,O
trauma,O
has,O
shown,O
an,O
inconsistent,O
pattern,O
of,O
associations,O
with,O
outcome,O
.,O
RCTs,O
have,O
generally,O
not,O
found,O
an,O
effect,O
(,O
e,O
.,O
g,O
".,",O
Ehlers,O
et,O
al,O
".,",O
2005,O
;,O
Resick,O
et,O
al,O
".,",O
2002,O
"),",O
although,O
Schnurr,O
et,O
al,O
(,O
2007,O
),O
concluded,O
that,O
the,O
modest,O
treatment,O
gains,O
observed,O
in,O
their,O
study,O
may,O
be,O
related,O
to,O
the,O
extreme,O
chronicity,O
of,O
their,O
sample,O
(,O
M,O
=,O
23,O
years,O
).,O
Like,O
the,O
current,O
study,O
",",O
Duffy,O
et,O
al,O
.,O
(,O
2007,O
),O
also,O
found,O
that,O
longer,O
duration,O
since,O
the,O
trauma,O
was,O
associated,O
with,O
less,O
favorable,O
outcome,O
.,O
The,O
differences,O
in,O
results,O
may,O
also,O
be,O
linked,O
to,O
the,O
wide,O
range,O
of,O
traumas,O
included,O
in,O
the,O
latter,O
samples,O
(,O
for,O
example,O
",",O
the,O
inclusion,O
of,O
traumatic,O
death,O
of,O
significant,O
others,O
"),",O
or,O
the,O
long,O
-,O
term,O
effects,O
of,O
the,O
trauma,O
and,O
/,O
or,O
PTSD,B-DS
symptoms,O
on,O
important,O
life,O
areas,O
such,O
as,O
employment,O
",",O
significant,O
relationships,O
or,O
other,O
resources,O
(,O
Hobfoll,O
",",O
2002,O
).,O
The,O
present,O
sample,O
",",O
like,O
Duffy,O
et,O
al,O
.',O
s,O
(,O
2007,O
),O
included,O
a,O
high,O
percentage,O
of,O
patients,O
with,O
long,O
-,O
term,O
loss,O
of,O
resources,O
and,O
significant,O
relationships,O
.,O
Social,O
problems,O
and,O
social,O
isolation,O
may,O
make,O
it,O
harder,O
to,O
overcome,O
PTSD,B-DS
and,O
may,O
also,O
create,O
additional,O
ongoing,O
stress,O
(,O
see,O
also,O
Galovski,O
et,O
al,O
".,",O
2012,O
).,O
The,O
result,O
that,O
patients,O
who,O
had,O
never,O
lived,O
with,O
a,O
partner,O
had,O
somewhat,O
worse,O
outcome,O
may,O
also,O
point,O
to,O
a,O
role,O
of,O
poor,O
social,O
support,O
and,O
interpersonal,O
skills,O
in,O
the,O
recovery,O
from,O
PTSD,B-DS
(,O
see,O
also,O
Cloitre,O
",",O
Koenen,O
",",O
Cohen,O
",",O
&,O
Han,O
",",O
2002,O
).,O
When,O
the,O
significant,O
moderators,O
were,O
considered,O
together,O
in,O
a,O
multivariate,O
analysis,O
",",O
only,O
social,O
problems,O
and,O
needing,O
treatment,O
for,O
multiple,O
traumas,O
emerged,O
as,O
unique,O
moderators,O
of,O
outcome,O
.,O
The,O
associations,O
of,O
these,O
moderators,O
with,O
treatment,O
characteristics,O
suggest,O
a,O
dose,O
–,O
response,O
effect,O
.,O
Treatment,O
was,O
less,O
trauma,O
-,O
focused,O
for,O
these,O
patients,O
and,O
significant,O
time,O
in,O
the,O
sessions,O
was,O
used,O
to,O
address,O
other,O
important,O
problems,O
such,O
as,O
comorbid,O
disorders,O
or,O
social,O
problems,O
such,O
as,O
problems,O
with,O
state,O
benefits,O
or,O
social,O
housing,O
",",O
with,O
a,O
similar,O
overall,O
treatment,O
duration,O
of,O
between,O
12,O
and,O
13,O
sessions,O
.,O
Patients,O
with,O
multiple,O
trauma,O
were,O
less,O
reliable,O
in,O
attending,O
sessions,O
than,O
other,O
patients,O
",",O
and,O
those,O
with,O
social,O
problems,O
were,O
more,O
likely,O
to,O
drop,O
out,O
.,O
This,O
may,O
have,O
led,O
to,O
a,O
less,O
than,O
optimal,O
dose,O
of,O
treatment,O
for,O
each,O
of,O
the,O
patients,O
',O
traumas,O
",",O
and,O
more,O
treatment,O
sessions,O
may,O
be,O
necessary,O
to,O
further,O
improve,O
outcome,O
(,O
see,O
also,O
National,O
Institute,O
for,O
Health,O
and,O
Clinical,O
Excellence,O
",",O
2005,O
).,O
For,O
example,O
",",O
Galovski,O
et,O
al,O
.,O
(,O
2012,O
),O
found,O
significant,O
further,O
treatment,O
gains,O
with,O
cognitive,O
processing,O
therapy,O
for,O
patients,O
who,O
had,O
not,O
fully,O
responded,O
by,O
session,O
12,O
.,O
Therapists,O
may,O
need,O
to,O
pay,O
special,O
attention,O
to,O
engaging,O
these,O
patients,O
in,O
treatment,O
.,O
These,O
patients,O
may,O
also,O
benefit,O
from,O
ancillary,O
case,O
management,O
services,O
.,O
When,O
therapists,O
were,O
included,O
as,O
a,O
random,O
factor,O
in,O
the,O
hierarchical,O
linear,O
model,O
",",O
no,O
significant,O
effects,O
on,O
treatment,O
outcome,O
were,O
observed,O
.,O
This,O
result,O
is,O
consistent,O
with,O
those,O
of,O
other,O
studies,O
of,O
patients,O
with,O
a,O
particular,O
disorder,O
who,O
were,O
treated,O
with,O
a,O
defined,O
treatment,O
protocol,O
(,O
Baldwin,O
et,O
al,O
".,",O
2011,O
;,O
Cella,O
et,O
al,O
".,",O
2011,O
;,O
Kubany,O
et,O
al,O
".,",O
2004,O
;,O
Wilson,O
et,O
al,O
".,",O
2011,O
"),",O
and,O
with,O
Crits,O
-,O
Christoph,O
et,O
al,O
.',O
s,O
(,O
1991,O
),O
conclusion,O
that,O
the,O
use,O
of,O
a,O
treatment,O
manual,O
reduces,O
therapist,O
effects,O
.,O
Studies,O
of,O
mixed,O
patient,O
samples,O
treated,O
by,O
therapists,O
of,O
different,O
theoretical,O
orientation,O
have,O
tended,O
to,O
show,O
larger,O
random,O
effects,O
of,O
therapists,O
",",O
in,O
the,O
range,O
of,O
5,O
–,O
8,O
%,O
of,O
the,O
variance,O
in,O
outcome,O
(,O
Lutz,O
et,O
al,O
".,",O
2007,O
;,O
Wampold,O
&,O
Brown,O
",",O
2005,O
).,O
These,O
results,O
do,O
not,O
necessarily,O
contradict,O
each,O
other,O
as,O
smaller,O
variation,O
in,O
treatment,O
procedures,O
may,O
restrict,O
the,O
variance,O
due,O
to,O
individual,O
therapists,O
.,O
In,O
this,O
study,O
",",O
therapist,O
experience,O
with,O
the,O
specific,O
treatment,O
protocol,O
showed,O
a,O
trend,O
for,O
an,O
association,O
with,O
somewhat,O
better,O
outcome,O
",",O
and,O
inexperienced,O
therapists,O
had,O
more,O
dropouts,O
.,O
This,O
result,O
is,O
similar,O
to,O
Duffy,O
et,O
al,O
.,O
(,O
2007,O
),O
who,O
found,O
that,O
one,O
reason,O
for,O
dropouts,O
was,O
that,O
some,O
inexperienced,O
therapists,O
pushed,O
patients,O
into,O
reliving,O
their,O
trauma,O
without,O
adequately,O
addressing,O
their,O
concerns,O
first,O
.,O
Training,O
programs,O
and,O
supervision,O
for,O
novice,O
therapists,O
need,O
attention,O
on,O
how,O
to,O
effectively,O
engage,O
patients,O
with,O
trauma,O
memory,O
work,O
.,O
The,O
study,O
had,O
several,O
limitations,O
.,O
First,O
",",O
the,O
study,O
did,O
not,O
have,O
an,O
untreated,O
control,O
group,O
and,O
the,O
results,O
therefore,O
cannot,O
be,O
unambiguously,O
interpreted,O
as,O
therapy,O
effects,O
.,O
However,O
",",O
several,O
factors,O
suggest,O
that,O
it,O
is,O
unlikely,O
that,O
the,O
symptom,O
changes,O
represented,O
natural,O
recovery,O
.,O
Patients,O
were,O
referred,O
to,O
the,O
clinic,O
as,O
they,O
were,O
judged,O
by,O
health,O
professionals,O
to,O
need,O
professional,O
help,O
",",O
they,O
had,O
chronic,O
",",O
moderate,O
to,O
severe,O
PTSD,B-DS
with,O
a,O
mean,O
duration,O
of,O
3,O
years,O
",",O
high,O
comorbidity,O
",",O
and,O
did,O
not,O
improve,O
during,O
the,O
wait,O
period,O
before,O
treatment,O
started,O
.,O
Second,O
",",O
the,O
clinic,O
focuses,O
on,O
PTSD,B-DS
following,O
trauma,O
in,O
adulthood,O
and,O
it,O
remains,O
unclear,O
whether,O
the,O
results,O
generalize,O
to,O
patients,O
whose,O
main,O
traumas,O
were,O
in,O
childhood,O
.,O
However,O
",",O
a,O
history,O
of,O
childhood,O
abuse,O
was,O
not,O
predictive,O
of,O
poor,O
outcome,O
in,O
this,O
sample,O
(,O
see,O
also,O
Ford,O
&,O
Kidd,O
",",O
1998,O
).,O
Third,O
",",O
although,O
data,O
for,O
the,O
intent,O
-,O
to,O
-,O
treat,O
analysis,O
of,O
treatment,O
effects,O
were,O
complete,O
",",O
the,O
sample,O
size,O
was,O
reduced,O
at,O
follow,O
-,O
up,O
and,O
it,O
remains,O
unclear,O
whether,O
loss,O
to,O
follow,O
-,O
up,O
was,O
random,O
.,O
Fourth,O
",",O
we,O
did,O
not,O
have,O
the,O
resources,O
to,O
obtain,O
fidelity,O
or,O
therapist,O
competency,O
ratings,O
from,O
recordings,O
of,O
the,O
therapy,O
sessions,O
.,O
This,O
may,O
have,O
introduced,O
error,O
variance,O
.,O
However,O
",",O
the,O
close,O
supervision,O
of,O
all,O
cases,O
ensured,O
that,O
therapists,O
followed,O
the,O
protocol,O
.,O
The,O
analysis,O
of,O
session,O
notes,O
confirmed,O
that,O
treatment,O
sessions,O
mainly,O
focused,O
on,O
the,O
PTSD,B-DS
treatment,O
protocol,O
.,O
Fifth,O
",",O
some,O
of,O
the,O
577,O
patients,O
who,O
were,O
referred,O
to,O
the,O
clinic,O
for,O
an,O
assessment,O
were,O
not,O
suitable,O
for,O
PTSD,B-DS
treatment,O
at,O
the,O
time,O
and,O
were,O
treated,O
elsewhere,O
.,O
The,O
most,O
common,O
reasons,O
were,O
not,O
having,O
PTSD,B-DS
(,O
n,O
=,O
42,O
),O
and,O
needing,O
treatment,O
for,O
another,O
problem,O
such,O
as,O
substance,B-DS
dependence,I-DS
or,O
immediate,O
suicide,O
risk,O
first,O
(,O
n,O
=,O
73,O
).,O
This,O
pattern,O
is,O
to,O
be,O
expected,O
as,O
General,O
Practitioners,O
in,O
the,O
UK,O
National,O
Health,O
Service,O
have,O
very,O
limited,O
time,O
for,O
each,O
consultation,O
and,O
may,O
ask,O
for,O
specialist,O
assessment,O
to,O
determine,O
the,O
best,O
care,O
pathway,O
for,O
their,O
patients,O
.,O
Nevertheless,O
",",O
this,O
pattern,O
highlights,O
the,O
fact,O
that,O
not,O
only,O
RCTs,O
",",O
but,O
also,O
routine,O
clinical,O
services,O
have,O
intake,O
criteria,O
and,O
need,O
to,O
exclude,O
some,O
patients,O
",",O
and,O
that,O
some,O
of,O
the,O
reasons,O
for,O
why,O
a,O
trauma,O
-,O
focused,O
treatment,O
is,O
not,O
offered,O
may,O
overlap,O
.,O
Sixth,O
",",O
the,O
sample,O
size,O
was,O
modest,O
for,O
the,O
investigation,O
of,O
therapist,O
effects,O
and,O
larger,O
samples,O
may,O
be,O
more,O
sensitive,O
in,O
detecting,O
therapist,O
variables,O
that,O
are,O
associated,O
with,O
good,O
outcome,O
.,O
In,O
conclusion,O
",",O
the,O
results,O
support,O
the,O
effectiveness,O
of,O
CT,O
-,O
PTSD,B-DS
in,O
a,O
wide,O
range,O
of,O
traumas,O
and,O
suggest,O
that,O
CT,O
-,O
PTSD,B-DS
can,O
be,O
successfully,O
implemented,O
in,O
the,O
routine,O
care,O
of,O
patients,O
with,O
PTSD,B-DS
.,O
Patients,O
who,O
need,O
treatment,O
for,O
multiple,O
traumas,O
",",O
severe,O
comorbid,O
disorders,O
or,O
social,O
problems,O
may,O
benefit,O
from,O
extending,O
the,O
duration,O
of,O
treatment,O
.,O
Training,O
new,O
therapists,O
in,O
CT,O
-,O
PTSD,B-DS
or,O
other,O
TF,O
-,O
CBT,O
protocols,O
may,O
benefit,O
from,O
special,O
attention,O
to,O
engaging,O
patients,O
with,O
treatment,O
to,O
avoid,O
dropouts,O
.,O
This,O
is,O
an,O
open,O
-,O
access,O
article,O
distributed,O
under,O
the,O
terms,O
of,O
the,O
Creative,O
Commons,O
Attribution,O
License,O
",",O
which,O
permits,O
unrestricted,O
use,O
",",O
distribution,O
",",O
and,O
reproduction,O
in,O
any,O
medium,O
",",O
provided,O
the,O
original,O
author,O
and,O
source,O
are,O
credited,O
.,O
Patient,O
flow,O
.,O
Intent,O
-,O
to,O
-,O
treat,O
outcome,O
for,O
patients,O
who,O
were,O
offered,O
treatment,O
(,O
n,O
=,O
330,O
).,O
PDS,O
=,O
Posttraumatic,O
Diagnostic,O
Scale,O
(,O
n,O
=,O
330,O
);,O
BDI,O
=,O
Beck,O
Depression,B-DS
Inventory,O
(,O
n,O
=,O
320,O
);,O
BAI,O
=,O
Beck,O
Anxiety,B-DS
Inventory,O
(,O
n,O
=,O
321,O
).,O
Intent,O
-,O
to,O
-,O
treat,O
treatment,O
outcome,O
for,O
all,O
consecutive,O
patients,O
who,O
were,O
offered,O
treatment,O
including,O
drop,O
-,O
outs,O
.,O
Outcome,O
measure,O
and,O
assessment,O
point,O
All,O
patients,O
(,O
N,O
=,O
330,O
),O
M,O
SD,O
PDS,O
pre,O
treatment,O
33,O
.,O
98,O
8,O
.,O
77,O
End,O
of,O
treatment,O
17,O
.,O
46,O
14,O
.,O
37,O
ES,O
(,O
pre,O
–,O
end,O
",",O
pooled,O
SD,O
),O
d,O
=,O
1,O
.,O
39,O
ES,O
(,O
pre,O
–,O
end,O
",",O
pre,O
SD,O
),O
d,O
=,O
1,O
.,O
88,O
BDI,O
pre,O
treatment,O
27,O
.,O
33,O
11,O
.,O
75,O
End,O
of,O
treatment,O
15,O
.,O
87,O
13,O
.,O
42,O
ES,O
(,O
pre,O
–,O
end,O
",",O
pooled,O
SD,O
),O
d,O
=,O
0,O
.,O
91,O
ES,O
(,O
pre,O
–,O
end,O
",",O
pre,O
SD,O
),O
d,O
=,O
0,O
.,O
98,O
BAI,O
pre,O
treatment,O
28,O
.,O
39,O
13,O
.,O
62,O
End,O
of,O
treatment,O
14,O
.,O
52,O
14,O
.,O
92,O
ES,O
(,O
pre,O
–,O
end,O
",",O
pooled,O
SD,O
),O
d,O
=,O
0,O
.,O
97,O
ES,O
(,O
pre,O
–,O
end,O
",",O
pre,O
SD,O
),O
d,O
=,O
1,O
.,O
02,O
Overview,O
of,O
individual,O
candidate,O
predictors,O
of,O
outcome,O
and,O
fixed,O
effects,O
estimates,O
from,O
hierarchical,O
linear,O
modeling,O
(,O
in,O
points,O
on,O
centered,O
PDS,O
scale,O
).,O
Predictor,O
Type,O
of,O
effect,O
Size,O
of,O
effect,O
(,O
fixed,O
effect,O
estimate,O
and,O
standard,O
error,O
),O
Exclusion,O
criteria,O
used,O
in,O
some,O
RCTs,O
Male,O
sex,O
Not,O
a,O
predictor,O
Age,O
Not,O
a,O
predictor,O
Does,O
not,O
meet,O
full,O
DSM,O
-,O
IV,O
criteria,O
Nonspecific,O
predictor,O
−,O
10,O
.,O
35,O
(,O
1,O
.,O
68,O
)***,O
PTSD,B-DS
not,O
main,O
problem,O
Moderator,O
3,O
.,O
31,O
(,O
1,O
.,O
21,O
)**,O
Current,O
substance,B-DS
abuse,I-DS
Nonspecific,O
predictor,O
2,O
.,O
50,O
(,O
1,O
.,O
26,O
)*,O
Borderline,B-DS
personality,I-DS
disorder,I-DS
Not,O
a,O
predictor,O
Needs,O
treatment,O
for,O
multiple,O
traumas,O
Moderator,O
4,O
.,O
01,O
(,O
1,O
.,O
30,O
)**,O
History,O
of,O
childhood,O
abuse,O
Not,O
a,O
predictor,O
No,O
memory,O
of,O
trauma,O
Not,O
a,O
predictor,O
Previous,O
CBT,O
for,O
PTSD,B-DS
Not,O
a,O
predictor,O
Demographics,O
Ethnic,O
minority,O
Not,O
a,O
predictor,O
Lower,O
level,O
of,O
education,O
Nonspecific,O
predictor,O
−,O
2,O
.,O
78,O
(,O
1,O
.,O
03,O
),O
Social,O
problems,O
Moderator,O
andNonspecific,O
predictor,O
5,O
.,O
23,O
(,O
1,O
.,O
02,O
)***,O
3,O
.,O
76,O
(,O
0,O
.,O
89,O
)***,O
No,O
relationship,O
(,O
never,O
married,O
or,O
living,O
with,O
partner,O
),O
Moderator,O
2,O
.,O
46,O
(,O
0,O
.,O
93,O
)**,O
Ongoing,O
legal,O
proceedings,O
Not,O
a,O
predictor,O
Any,O
previous,O
treatment,O
for,O
PTSD,B-DS
Not,O
a,O
predictor,O
Comorbidity,O
Current,O
comorbid,O
anxiety,B-DS
disorder,O
Not,O
a,O
predictor,O
Current,O
mood,B-DS
disorder,I-DS
Moderator,O
andNonspecific,O
predictor,O
1,O
.,O
95,O
(,O
0,O
.,O
92,O
)*,O
7,O
.,O
00,O
(,O
0,O
.,O
97,O
)***,O
Current,O
other,O
axis,B-DS
1,I-DS
disorder,I-DS
Nonspecific,O
predictor,O
4,O
.,O
73,O
(,O
1,O
.,O
78,O
)**,O
Any,O
personality,B-DS
disorder,I-DS
Nonspecific,O
predictor,O
2,O
.,O
57,O
(,O
1,O
.,O
15,O
)*,O
Current,O
suicidal,O
ideation,O
Nonspecific,O
predictor,O
5,O
.,O
92,O
(,O
0,O
.,O
99,O
)***,O
Taking,O
psychotropic,O
medication,O
Nonspecific,O
predictor,O
5,O
.,O
87,O
(,O
1,O
.,O
08,O
)***,O
Chronic,O
pain,O
Nonspecific,O
predictor,O
3,O
.,O
08,O
(,O
1,O
.,O
14,O
)**,O
Physical,O
disability,O
due,O
to,O
trauma,O
Nonspecific,O
predictor,O
2,O
.,O
54,O
(,O
1,O
.,O
27,O
)*,O
History,O
of,O
major,B-DS
depression,I-DS
Nonspecific,O
predictor,O
5,O
.,O
39,O
(,O
1,O
.,O
10,O
)***,O
History,O
of,O
substance,B-DS
dependence,I-DS
Moderator,O
andNonspecific,O
predictor,O
3,O
.,O
34,O
(,O
1,O
.,O
19,O
)**,O
3,O
.,O
48,O
(,O
1,O
.,O
33,O
)**,O
Past,O
suicide,O
attempts,O
Moderator,O
andNonspecific,O
predictor,O
2,O
.,O
96,O
(,O
1,O
.,O
30,O
)*,O
3,O
.,O
34,O
(,O
1,O
.,O
50,O
)*,O
Trauma,O
History,O
Main,O
trauma,O
interpersonal,O
Not,O
a,O
predictor,O
Someone,O
died,O
in,O
main,O
trauma,O
Not,O
a,O
predictor,O
Injured,O
in,O
trauma,O
Not,O
a,O
predictor,O
Months,O
since,O
main,O
trauma,O
Moderator,O
1,O
.,O
06,O
(,O
0,O
.,O
46,O
)*,O
History,O
of,O
other,O
traumas,O
Not,O
a,O
predictor,O
Number,O
of,O
traumas,O
Not,O
a,O
predictor,O
History,O
of,O
child,O
abuse,O
Not,O
a,O
predictor,O
Injured,O
in,O
trauma,O
Not,O
a,O
predictor,O
Hierarchical,O
linear,O
modeling,O
:,O
Estimates,O
of,O
random,O
effects,O
(,O
patient,O
",",O
therapist,O
),O
and,O
fixed,O
effects,O
(,O
time,O
",",O
patient,O
characteristics,O
",",O
therapist,O
experience,O
),O
on,O
improvement,O
in,O
PTSD,B-DS
symptoms,O
with,O
therapy,O
.,O
Model,O
1,O
slope,O
of,O
improvement,O
and,O
random,O
patient,O
effects,O
Model,O
2,O
including,O
patient,O
characteristics,O
Model,O
3,O
including,O
random,O
therapist,O
effects,O
Model,O
4,O
including,O
therapist,O
experience,O
Overall,O
fit,O
:,O
AIC,O
6608,O
.,O
21,O
5967,O
.,O
25,O
5967,O
.,O
19,O
5951,O
.,O
56,O
Variance,O
-,O
covariance,O
estimates,O
for,O
random,O
parameters,O
Level,O
1,O
:,O
patient,O
Patient,O
random,O
intercept,O
66,O
.,O
46,O
(,O
12,O
.,O
16,O
)***,O
41,O
.,O
09,O
(,O
10,O
.,O
44,O
)***,O
37,O
.,O
41,O
(,O
11,O
.,O
22,O
)***,O
35,O
.,O
39,O
(,O
11,O
.,O
85,O
)**,O
Patient,O
random,O
slope,O
40,O
.,O
71,O
(,O
6,O
.,O
87,O
)***,O
29,O
.,O
66,O
(,O
5,O
.,O
49,O
)***,O
28,O
.,O
11,O
(,O
5,O
.,O
49,O
)***,O
27,O
.,O
11,O
(,O
5,O
.,O
46,O
)***,O
Level,O
2,O
:,O
therapist,O
Therapist,O
random,O
intercept,O
1,O
.,O
88,O
(,O
1,O
.,O
84,O
),O
1,O
.,O
69,O
(,O
1,O
.,O
78,O
),O
Therapist,O
random,O
slope,O
0,O
.,O
79,O
(,O
1,O
.,O
29,O
),O
1,O
.,O
02,O
(,O
1,O
.,O
35,O
),O
Fixed,O
effect,O
estimates,O
Level,O
1,O
:,O
time,O
effects,O
Intercept,O
11,O
.,O
00,O
(,O
0,O
.,O
55,O
)***,O
18,O
.,O
90,O
(,O
2,O
.,O
23,O
)***,O
18,O
.,O
89,O
(,O
2,O
.,O
26,O
)***,O
18,O
.,O
50,O
(,O
2,O
.,O
30,O
)***,O
Linear,O
time,O
effect,O
−,O
24,O
.,O
88,O
(,O
1,O
.,O
01,O
)***,O
−,O
18,O
.,O
33,O
(,O
2,O
.,O
29,O
)***,O
−,O
18,O
.,O
63,O
(,O
2,O
.,O
30,O
)***,O
−,O
19,O
.,O
23,O
(,O
2,O
.,O
34,O
)***,O
Quadratic,O
time,O
effect,O
8,O
.,O
42,O
(,O
0,O
.,O
50,O
)***,O
8,O
.,O
38,O
(,O
0,O
.,O
52,O
)***,O
8,O
.,O
35,O
(,O
0,O
.,O
52,O
)***,O
8,O
.,O
36,O
(,O
0,O
.,O
52,O
)***,O
Level,O
2,O
:,O
patient,O
characteristics,O
PTSD,B-DS
not,O
main,O
problem,O
-,O
Nonspecific,O
predictor,O
2,O
.,O
43,O
(,O
1,O
.,O
37,O
)(*),O
2,O
.,O
28,O
(,O
1,O
.,O
38,O
),O
2,O
.,O
11,O
(,O
1,O
.,O
40,O
),O
-,O
Moderator,O
effect,O
0,O
.,O
71,O
(,O
1,O
.,O
33,O
),O
0,O
.,O
79,O
(,O
1,O
.,O
33,O
),O
0,O
.,O
44,O
(,O
1,O
.,O
35,O
),O
Multiple,O
traumas,O
need,O
treatment,O
-,O
Nonspecific,O
predictor,O
1,O
.,O
99,O
(,O
1,O
.,O
50,O
),O
1,O
.,O
79,O
(,O
1,O
.,O
49,O
),O
1,O
.,O
69,O
(,O
1,O
.,O
51,O
),O
-,O
Moderator,O
effect,O
3,O
.,O
81,O
(,O
1,O
.,O
38,O
)**,O
3,O
.,O
66,O
(,O
1,O
.,O
39,O
)**,O
3,O
.,O
25,O
(,O
1,O
.,O
40,O
)*,O
Social,O
problems,O
-,O
Nonspecific,O
predictor,O
3,O
.,O
26,O
(,O
1,O
.,O
04,O
)**,O
3,O
.,O
05,O
(,O
1,O
.,O
04,O
)**,O
3,O
.,O
17,O
(,O
1,O
.,O
05,O
)**,O
-,O
Moderator,O
effect,O
2,O
.,O
89,O
(,O
0,O
.,O
94,O
)**,O
2,O
.,O
79,O
(,O
0,O
.,O
94,O
)**,O
2,O
.,O
99,O
(,O
0,O
.,O
96,O
)**,O
No,O
relationship,O
-,O
Nonspecific,O
predictor,O
0,O
.,O
14,O
(,O
1,O
.,O
00,O
),O
0,O
.,O
08,O
(,O
1,O
.,O
00,O
),O
0,O
.,O
02,O
(,O
1,O
.,O
00,O
),O
-,O
Moderator,O
effect,O
1,O
.,O
68,O
(,O
0,O
.,O
92,O
)(*),O
1,O
.,O
70,O
(,O
0,O
.,O
92,O
)(*),O
1,O
.,O
55,O
(,O
0,O
.,O
93,O
)(*),O
Comorbid,O
mood,O
disorder,O
-,O
Nonspecific,O
predictor,O
5,O
.,O
85,O
(,O
1,O
.,O
02,O
)***,O
5,O
.,O
79,O
(,O
1,O
.,O
01,O
)***,O
5,O
.,O
79,O
(,O
1,O
.,O
02,O
)***,O
-,O
Moderator,O
effect,O
0,O
.,O
22,O
(,O
0,O
.,O
94,O
),O
0,O
.,O
17,O
(,O
0,O
.,O
94,O
),O
0,O
.,O
22,O
(,O
0,O
.,O
94,O
),O
Suicide,O
attempts,O
-,O
Nonspecific,O
predictor,O
0,O
.,O
87,O
(,O
1,O
.,O
46,O
),O
0,O
.,O
95,O
(,O
1,O
.,O
47,O
),O
0,O
.,O
95,O
(,O
1,O
.,O
48,O
),O
-,O
Moderator,O
effect,O
1,O
.,O
31,O
(,O
1,O
.,O
35,O
),O
1,O
.,O
33,O
(,O
1,O
.,O
36,O
),O
1,O
.,O
37,O
(,O
1,O
.,O
36,O
),O
History,O
of,O
substance,O
dependence,O
-,O
Nonspecific,O
predictor,O
2,O
.,O
26,O
(,O
1,O
.,O
32,O
)(*),O
2,O
.,O
39,O
(,O
1,O
.,O
32,O
)(*),O
2,O
.,O
37,O
(,O
1,O
.,O
32,O
),O
(*),O
-,O
Moderator,O
effect,O
1,O
.,O
76,O
(,O
1,O
.,O
24,O
),O
1,O
.,O
77,O
(,O
1,O
.,O
24,O
),O
1,O
.,O
84,O
(,O
1,O
.,O
24,O
),O
Months,O
since,O
trauma,O
-,O
Nonspecific,O
predictor,O
−,O
0,O
.,O
59,O
(,O
0,O
.,O
50,O
),O
−,O
0,O
.,O
64,O
(,O
0,O
.,O
50,O
),O
−,O
0,O
.,O
60,O
(,O
0,O
.,O
50,O
),O
-,O
Moderator,O
effect,O
0,O
.,O
59,O
(,O
0,O
.,O
46,O
),O
0,O
.,O
59,O
(,O
0,O
.,O
46,O
),O
0,O
.,O
66,O
(,O
0,O
.,O
47,O
),O
Level,O
3,O
:,O
therapist,O
effects,O
Staff,O
therapist,O
-,O
Nonspecific,O
predictor,O
0,O
.,O
69,O
(,O
1,O
.,O
49,O
),O
-,O
Moderator,O
effect,O
2,O
.,O
05,O
(,O
1,O
.,O
37,O
),O
Experienced,O
in,O
CT,O
-,O
PTSD,O
-,O
Nonspecific,O
predictor,O
−,O
1,O
.,O
19,O
(,O
1,O
.,O
24,O
),O
-,O
Moderator,O
effect,O
−,O
2,O
.,O
23,O
(,O
1,O
.,O
15,O
),O
(*),O
The,O
CULTEX,O
RFS,O
:,O
A,O
Comprehensive,O
Technical,O
Approach,O
for,O
the,O
In,O
Vitro,O
Exposure,O
of,O
Airway,O
Epithelial,O
Cells,O
to,O
the,O
Particulate,O
Matter,O
at,O
the,O
Air,O
-,O
Liquid,O
Interface,O
Academic,O
Editor,O
:,O
Abderrahim,O
Nemmar,O
The,O
EU,O
Regulation,O
on,O
Registration,O
",",O
Evaluation,O
",",O
Authorization,O
and,O
Restriction,O
of,O
Chemicals,O
(,O
REACH,O
),O
demands,O
the,O
implementation,O
of,O
alternative,O
methods,O
for,O
analyzing,O
the,O
hazardous,O
effects,O
of,O
chemicals,O
including,O
particulate,O
formulations,O
.,O
In,O
the,O
field,O
of,O
inhalation,O
toxicology,O
",",O
a,O
variety,O
of,O
in,O
vitro,O
models,O
have,O
been,O
developed,O
for,O
such,O
studies,O
.,O
To,O
simulate,O
the,O
in,O
vivo,O
situation,O
",",O
an,O
adequate,O
exposure,O
device,O
is,O
necessary,O
for,O
the,O
direct,O
exposure,O
of,O
cultivated,O
lung,O
cells,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
(,O
ALI,O
).,O
The,O
CULTEX,O
RFS,O
fulfills,O
these,O
requirements,O
and,O
has,O
been,O
optimized,O
for,O
the,O
exposure,O
of,O
cells,O
to,O
atomized,O
suspensions,O
",",O
gases,O
",",O
and,O
volatile,O
compounds,O
as,O
well,O
as,O
micro,O
-,O
and,O
nanosized,O
particles,O
.,O
This,O
study,O
provides,O
information,O
on,O
the,O
construction,O
and,O
functional,O
aspects,O
of,O
the,O
exposure,O
device,O
.,O
By,O
using,O
the,O
Computational,O
Fluid,O
Dynamics,O
(,O
CFD,O
),O
analysis,O
",",O
the,O
technical,O
design,O
was,O
optimized,O
to,O
realize,O
a,O
stable,O
",",O
reproducible,O
",",O
and,O
homogeneous,O
deposition,O
of,O
particles,O
.,O
The,O
efficiency,O
of,O
the,O
exposure,O
procedure,O
is,O
demonstrated,O
by,O
exposing,O
A549,O
cells,O
dose,O
dependently,O
to,O
lactose,O
monohydrate,O
",",O
copper,O
(,O
II,O
),O
sulfate,O
",",O
copper,O
(,O
II,O
),O
oxide,O
",",O
and,O
micro,O
-,O
and,O
nanoparticles,O
.,O
All,O
copper,O
compounds,O
induced,O
cytotoxic,O
effects,O
",",O
most,O
pronounced,O
for,O
soluble,O
copper,O
(,O
II,O
),O
sulfate,O
.,O
Micro,O
-,O
and,O
nanosized,O
copper,O
(,O
II,O
),O
oxide,O
also,O
showed,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
the,O
cell,O
viability,O
",",O
whereby,O
the,O
nanosized,O
particles,O
decreased,O
the,O
metabolic,O
activity,O
of,O
the,O
cells,O
more,O
severely,O
.,O
1,O
.,O
Introduction,O
Provoked,O
by,O
public,O
pressure,O
and,O
triggered,O
by,O
an,O
increasing,O
number,O
of,O
lethal,O
lung,B-DS
diseases,I-DS
over,O
the,O
last,O
few,O
decades,O
[,O
1,O
",",O
2,O
"],",O
more,O
and,O
more,O
studies,O
in,O
the,O
field,O
of,O
inhalation,O
toxicology,O
now,O
concentrate,O
on,O
the,O
understanding,O
of,O
particle,O
-,O
lung,O
interactions,O
.,O
Investigations,O
of,O
the,O
toxicological,O
effects,O
of,O
inhalable,O
substances,O
on,O
the,O
respiratory,O
tract,O
mainly,O
focus,O
on,O
results,O
from,O
animal,B-OG
experiments,O
based,O
on,O
the,O
OECD,O
guideline,O
403,O
on,O
acute,O
inhalation,O
toxicology,O
.,O
So,O
far,O
",",O
only,O
a,O
few,O
in,O
vitro,O
alternatives,O
to,O
animal,B-OG
inhalation,O
tests,O
for,O
toxicology,O
have,O
been,O
described,O
[,O
3,O
",",O
4,O
].,O
However,O
",",O
none,O
of,O
them,O
is,O
validated,O
or,O
officially,O
accepted,O
by,O
the,O
authorities,O
.,O
Recent,O
changes,O
in,O
the,O
EU,O
chemical,O
policy,O
",",O
namely,O
",",O
the,O
new,O
Registration,O
",",O
Evaluation,O
",",O
Authorization,O
and,O
Restriction,O
of,O
Chemicals,O
directive,O
(,O
REACH,O
;,O
EC,O
no,O
.,O
1907,O
/,O
2006,O
"),",O
and,O
complaints,O
about,O
the,O
immense,O
number,O
of,O
animals,B-OG
needed,O
to,O
fulfill,O
the,O
requirements,O
of,O
REACH,O
[,O
6,O
],O
demand,O
the,O
development,O
and,O
implementation,O
of,O
novel,O
in,O
vitro,O
technologies,O
—,O
also,O
in,O
the,O
field,O
of,O
inhalation,O
toxicology,O
.,O
In,O
order,O
to,O
evaluate,O
the,O
effects,O
of,O
relevant,O
particulate,O
substances,O
",",O
only,O
classic,O
methodological,O
approaches,O
are,O
available,O
using,O
either,O
suspended,O
or,O
dissolved,O
particles,O
under,O
submerged,O
conditions,O
in,O
cell,O
culture,O
experiments,O
[,O
4,O
",",O
7,O
].,O
The,O
main,O
concerns,O
about,O
these,O
test,O
methods,O
are,O
(,O
1,O
),O
the,O
unrealistic,O
behavior,O
of,O
suspended,O
particles,O
and,O
(,O
2,O
),O
culture,O
and,O
exposure,O
conditions,O
which,O
do,O
not,O
reflect,O
the,O
situation,O
in,O
the,O
lung,O
.,O
The,O
fact,O
of,O
losing,O
nanosized,O
particles,O
by,O
agglomeration,O
or,O
the,O
uncontrollable,O
behavior,O
of,O
nanosized,O
particles,O
in,O
suspensions,O
may,O
lead,O
to,O
uncertainties,O
in,O
the,O
results,O
[,O
8,O
].,O
Another,O
major,O
point,O
of,O
the,O
discussion,O
is,O
the,O
transferability,O
of,O
data,O
from,O
animal,B-OG
experiments,O
to,O
the,O
human,B-OG
organism,O
due,O
to,O
species,O
-,O
specific,O
reactions,O
and,O
the,O
generation,O
of,O
false,O
positive,O
or,O
negative,O
results,O
[,O
9,O
].,O
One,O
of,O
the,O
“,O
first,O
”,O
approaches,O
for,O
direct,O
cell,O
exposure,O
came,O
from,O
Tarkington,O
et,O
al,O
.,O
[,O
10,O
],O
who,O
conducted,O
the,O
atmosphere,O
via,O
a,O
vertical,O
stream,O
directly,O
over,O
the,O
cultivated,O
test,O
organisms,O
.,O
The,O
system,O
is,O
also,O
based,O
on,O
a,O
biphasic,O
cell,O
culture,O
exposed,O
at,O
an,O
air,O
-,O
liquid,O
interface,O
[,O
11,O
].,O
The,O
basic,O
idea,O
is,O
to,O
mimic,O
the,O
inhalation,O
cycle,O
in,O
vitro,O
by,O
taking,O
into,O
consideration,O
the,O
most,O
important,O
biological,O
and,O
technical,O
aspects,O
.,O
The,O
selection,O
of,O
an,O
appropriate,O
cell,O
model,O
and,O
its,O
cultivation,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
are,O
the,O
basic,O
prerequisites,O
for,O
such,O
a,O
system,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
technical,O
implementation,O
should,O
guarantee,O
the,O
direct,O
contact,O
of,O
the,O
test,O
substances,O
with,O
the,O
cells,O
",",O
as,O
well,O
as,O
the,O
homogeneous,O
exposure,O
of,O
the,O
entire,O
cell,O
layer,O
without,O
interfering,O
with,O
the,O
cell,O
viability,O
.,O
These,O
theoretical,O
concepts,O
led,O
to,O
the,O
development,O
of,O
the,O
CULTEX,O
exposure,O
module,O
in,O
1999,O
by,O
Aufderheide,O
and,O
Mohr,O
[,O
12,O
],O
for,O
the,O
exposure,O
of,O
cultivated,O
cells,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
.,O
The,O
test,O
aerosol,O
is,O
conducted,O
directly,O
over,O
the,O
cells,O
through,O
specially,O
designed,O
inlet,O
nozzles,O
.,O
This,O
setup,O
guarantees,O
a,O
close,O
contact,O
between,O
the,O
test,O
aerosol,O
and,O
the,O
cells,O
without,O
any,O
interference,O
of,O
the,O
cell,O
culture,O
media,O
.,O
The,O
first,O
CULTEX,O
exposure,O
devices,O
were,O
used,O
for,O
the,O
exposure,O
to,O
complex,O
mixtures,O
like,O
cigarette,O
smoke,O
and,O
gases,O
",",O
or,O
in,O
a,O
modified,O
version,O
to,O
analyze,O
the,O
mutagenic,O
potency,O
of,O
airborne,O
materials,O
in,O
the,O
AMES,O
assay,O
[,O
13,O
].,O
Nowadays,O
",",O
a,O
large,O
number,O
of,O
other,O
air,O
-,O
liquid,O
interface,O
exposure,O
systems,O
are,O
available,O
",",O
ranging,O
from,O
the,O
exposure,O
of,O
two,O
-,O
cell,O
culture,O
plates,O
(,O
6,O
-,O
well,O
"),",O
like,O
the,O
ALICE,O
exposure,O
device,O
[,O
14,O
],O
or,O
a,O
flow,O
-,O
through,O
system,O
[,O
15,O
],O
to,O
a,O
radial,O
multiwell,O
module,O
[,O
16,O
].,O
All,O
of,O
these,O
modules,O
have,O
certain,O
advantages,O
and,O
disadvantages,O
and,O
may,O
therefore,O
only,O
be,O
used,O
for,O
a,O
limited,O
test,O
assembly,O
.,O
The,O
results,O
obtained,O
from,O
exposure,O
studies,O
with,O
the,O
CULTEX,O
RFS,O
module,O
have,O
shown,O
that,O
the,O
interactions,O
between,O
cells,O
and,O
particles,O
are,O
closely,O
linked,O
to,O
the,O
physical,O
and,O
chemical,O
properties,O
of,O
these,O
compounds,O
and,O
have,O
advanced,O
the,O
redesign,O
of,O
the,O
handmade,O
CULTEX,O
glass,O
modules,O
.,O
The,O
CULTEX,O
Radial,O
Flow,O
System,O
(,O
RFS,O
),O
presented,O
here,O
overcomes,O
the,O
limitations,O
of,O
its,O
predecessor,O
model,O
and,O
includes,O
all,O
features,O
that,O
are,O
required,O
to,O
realize,O
the,O
exposure,O
of,O
cultivated,O
cells,O
to,O
airborne,O
particles,O
under,O
realistic,O
conditions,O
.,O
2,O
.,O
Material,O
and,O
Methods,O
2,O
.,O
1,O
.,O
Technical,O
Description,O
The,O
CULTEX,O
RFS,O
module,O
was,O
designed,O
for,O
exposing,O
adherent,O
growing,O
cells,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
and,O
is,O
a,O
precision,O
instrument,O
",",O
characterized,O
by,O
a,O
modular,O
construction,O
(,O
Figure,O
1,O
).,O
The,O
basic,O
CULTEX,O
RFS,O
consists,O
of,O
the,O
following,O
parts,O
:,O
(,O
1,O
),O
the,O
inlet,O
adapter,O
which,O
connects,O
the,O
aerosol,O
generation,O
and,O
aerosol,O
guiding,O
module,O
(,O
Figure,O
1,O
"),",O
(,O
2,O
),O
the,O
aerosol,O
guiding,O
module,O
to,O
conduct,O
and,O
distribute,O
the,O
particles,O
to,O
be,O
deposited,O
on,O
the,O
cell,O
culture,O
inserts,O
in,O
the,O
sampling,O
module,O
(,O
Figures,O
2,O
(,O
a,O
),O
and,O
2,O
(,O
b,O
")),",O
and,O
(,O
3,O
),O
the,O
sampling,O
and,O
socket,O
module,O
with,O
three,O
exposure,O
chambers,O
where,O
the,O
cell,O
culture,O
inserts,O
or,O
Petri,O
dishes,O
are,O
located,O
(,O
Figures,O
1,O
and,O
2,O
(,O
c,O
)).,O
The,O
aerosol,O
guiding,O
module,O
as,O
well,O
as,O
the,O
sampling,O
module,O
can,O
be,O
heated,O
to,O
the,O
appropriate,O
temperature,O
(,O
e,O
.,O
g,O
".,",O
37,O
°,O
C,O
),O
by,O
the,O
connection,O
to,O
an,O
external,O
water,O
bath,O
.,O
The,O
socket,O
module,O
(,O
4,O
),O
guides,O
the,O
sampling,O
module,O
on,O
the,O
slide,O
rails,O
of,O
the,O
locking,O
device,O
(,O
5,O
),O
and,O
serves,O
as,O
a,O
spacer,O
for,O
integrating,O
additional,O
functions,O
",",O
like,O
a,O
control,O
unit,O
for,O
electrostatic,O
precipitation,O
.,O
In,O
addition,O
to,O
the,O
above,O
-,O
mentioned,O
modular,O
components,O
",",O
the,O
system,O
can,O
also,O
be,O
equipped,O
with,O
special,O
adapters,O
to,O
enable,O
the,O
use,O
of,O
commercial,O
inserts,O
from,O
different,O
suppliers,O
and,O
of,O
different,O
sizes,O
or,O
for,O
Petri,O
dishes,O
.,O
The,O
aerosol,O
emission,O
ducts,O
are,O
adapted,O
correspondingly,O
.,O
To,O
increase,O
the,O
particle,O
deposition,O
efficiency,O
",",O
notably,O
for,O
nanosized,O
particles,O
",",O
the,O
electrical,O
deposition,O
device,O
(,O
Cultex,O
EDD,O
),O
can,O
further,O
be,O
integrated,O
into,O
the,O
technical,O
setup,O
(,O
Figure,O
3,O
).,O
2,O
.,O
2,O
.,O
Test,O
Materials,O
Dry,O
powder,O
atmospheres,O
were,O
prepared,O
from,O
the,O
substances,O
listed,O
in,O
Tables,O
1,O
and,O
2,O
and,O
used,O
for,O
the,O
exposure,O
studies,O
.,O
The,O
substances,O
were,O
pressed,O
into,O
powder,O
cakes,O
by,O
the,O
CULTEX,O
HyP,O
-,O
Hydraulic,O
Press,O
(,O
Cultex,O
Laboratories,O
GmbH,O
",",O
Germany,O
"),",O
which,O
allows,O
electronically,O
controlled,O
compression,O
of,O
a,O
high,O
variety,O
of,O
powders,O
by,O
a,O
pneumo,O
-,O
hydraulic,O
cylinder,O
.,O
2,O
.,O
3,O
.,O
Aerosol,O
Generation,O
The,O
aerosol,O
was,O
generated,O
from,O
the,O
prepared,O
powder,O
cakes,O
with,O
the,O
CULTEX,O
DG,O
(,O
Dust,O
Generator,O
),O
(,O
Cultex,O
Laboratories,O
GmbH,O
),O
according,O
to,O
Wright,O
[,O
5,O
],O
(,O
Figure,O
4,O
).,O
The,O
fully,O
computerized,O
generator,O
is,O
able,O
to,O
provide,O
uniform,O
airborne,O
concentrations,O
of,O
dust,O
over,O
a,O
long,O
period,O
of,O
time,O
.,O
The,O
highly,O
compressed,O
substances,O
are,O
scraped,O
off,O
by,O
a,O
rotating,O
scraper,O
under,O
standardized,O
controlled,O
conditions,O
(,O
feed,O
rate,O
0,O
.,O
24,O
to,O
20,O
mm,O
/,O
h,O
",",O
rotation,O
1,O
to,O
800,O
revs,O
/,O
h,O
).,O
The,O
total,O
exposure,O
time,O
is,O
varied,O
from,O
15,O
",",O
30,O
",",O
to,O
60,O
minutes,O
to,O
generate,O
different,O
particle,O
concentrations,O
on,O
the,O
cell,O
culture,O
membranes,O
without,O
changing,O
the,O
aerosol,O
generation,O
or,O
any,O
other,O
physical,O
or,O
chemical,O
parameter,O
.,O
The,O
generated,O
particles,O
were,O
transported,O
to,O
the,O
integrated,O
elutriator,O
by,O
a,O
constant,O
air,O
stream,O
(,O
8,O
L,O
/,O
min,O
).,O
The,O
elutriator,O
retains,O
undesired,O
large,O
particles,O
(>,O
approx,O
.,O
8,O
μm,O
),O
and,O
serves,O
as,O
a,O
reservoir,O
for,O
a,O
uniform,O
aerosol,O
which,O
is,O
finally,O
drawn,O
through,O
the,O
CULTEX,O
RFS,O
.,O
The,O
complete,O
experimental,O
setup,O
is,O
shown,O
in,O
Figure,O
5,O
consisting,O
of,O
the,O
particle,O
generation,O
unit,O
",",O
two,O
CULTEX,O
RFS,O
devices,O
",",O
and,O
two,O
pumps,O
for,O
the,O
medium,O
supply,O
.,O
The,O
cells,O
are,O
exposed,O
to,O
the,O
test,O
aerosol,O
and,O
clean,O
air,O
(,O
process,O
control,O
),O
in,O
parallel,O
",",O
in,O
order,O
to,O
preclude,O
process,O
-,O
related,O
reactions,O
which,O
might,O
interfere,O
with,O
the,O
substance,O
-,O
specific,O
effects,O
.,O
2,O
.,O
4,O
.,O
CFD,O
Analysis,O
The,O
aerosol,O
flow,O
within,O
the,O
experimental,O
setup,O
was,O
simulated,O
and,O
optimized,O
by,O
means,O
of,O
Computational,O
Fluid,O
Dynamics,O
(,O
CFD,O
),O
software,O
(,O
ANSYS,O
CFX,O
",",O
ANSYS,O
Incorporated,O
).,O
2,O
.,O
5,O
.,O
Particle,O
Number,O
and,O
Mass,O
Distribution,O
The,O
determination,O
of,O
the,O
particle,O
number,O
and,O
mass,O
distribution,O
was,O
conducted,O
with,O
an,O
Aerodynamic,O
Particle,O
Sizer,O
APS,O
(,O
3321,O
/,O
TSI,O
Incorporated,O
),O
in,O
the,O
size,O
range,O
of,O
0,O
.,O
5,O
to,O
20,O
μm,O
.,O
By,O
accelerating,O
particles,O
through,O
a,O
nozzle,O
and,O
optical,O
time,O
-,O
of,O
-,O
flight,O
measurement,O
of,O
the,O
particles,O
",",O
they,O
are,O
classified,O
into,O
51,O
logarithmic,O
size,O
ranges,O
between,O
0,O
.,O
523,O
and,O
20,O
μm,O
.,O
2,O
.,O
6,O
.,O
Particle,O
Deposition,O
The,O
deposition,O
of,O
the,O
particles,O
was,O
analyzed,O
by,O
gravimetric,O
methods,O
",",O
using,O
the,O
precision,O
balance,O
(,O
SE2,O
-,O
F,O
filter,O
ultra,O
-,O
microbalance,O
",",O
Sartorius,O
).,O
In,O
preliminary,O
tests,O
",",O
the,O
particle,O
mass,O
concentration,O
within,O
the,O
exposure,O
system,O
was,O
analyzed,O
at,O
three,O
sampling,O
points,O
(,O
sampling,O
point,O
1,O
:,O
200,O
seconds,O
",",O
sampling,O
point,O
2,O
+,O
3,O
:,O
60,O
minutes,O
),O
to,O
determine,O
appropriate,O
exposure,O
times,O
for,O
the,O
corresponding,O
test,O
particles,O
(,O
Figure,O
6,O
),O
and,O
to,O
check,O
for,O
uniform,O
particle,O
distribution,O
.,O
The,O
first,O
sampling,O
point,O
was,O
located,O
directly,O
after,O
the,O
elutriator,O
",",O
the,O
second,O
at,O
the,O
outlet,O
port,O
of,O
the,O
aerosol,O
emission,O
duct,O
to,O
estimate,O
the,O
particle,O
mass,O
entering,O
the,O
exposure,O
chamber,O
",",O
and,O
the,O
third,O
at,O
the,O
insert,O
membrane,O
surface,O
to,O
measure,O
the,O
particle,O
mass,O
deposited,O
on,O
the,O
cultivated,O
cells,O
.,O
The,O
particle,O
mass,O
was,O
determined,O
by,O
collecting,O
the,O
particles,O
on,O
filter,O
pads,O
(,O
glass,O
fiber,O
filter,O
/,O
GF,O
-,O
A,O
/,O
Macherey,O
-,O
Nagel,O
"),",O
which,O
were,O
weighed,O
before,O
and,O
after,O
the,O
exposure,O
over,O
a,O
constant,O
period,O
(,O
15,O
minutes,O
).,O
This,O
approach,O
allows,O
the,O
analysis,O
of,O
the,O
deposition,O
efficiency,O
of,O
each,O
test,O
atmosphere,O
within,O
the,O
exposure,O
module,O
.,O
Under,O
these,O
experimental,O
conditions,O
",",O
the,O
deposited,O
particle,O
numbers,O
on,O
the,O
cell,O
cultures,O
can,O
only,O
be,O
calculated,O
by,O
taking,O
into,O
consideration,O
the,O
measurements,O
of,O
the,O
Aerodynamic,O
Particle,O
Sizer,O
APS,O
(,O
3321,O
/,O
TSI,O
Incorporated,O
),O
and,O
the,O
system,O
-,O
specific,O
deposition,O
capacities,O
(,O
Aufderheide,O
et,O
al,O
.,O
[,O
17,O
"],",O
Supplementary,O
Material,O
).,O
2,O
.,O
7,O
.,O
Cell,O
Cultivation,O
and,O
Exposure,O
For,O
particle,O
exposure,O
experiments,O
",",O
the,O
human,B-OG
lung,B-DS
adenocarcinoma,I-DS
epithelial,O
cell,O
line,O
A549,O
(,O
ATCC,O
number,O
:,O
CCL,O
-,O
185,O
),O
was,O
used,O
[,O
18,O
",",O
19,O
].,O
The,O
cells,O
were,O
grown,O
in,O
Dulbecco,O
',O
s,O
MEM,O
(,O
Biochrom,O
FG,O
0145,O
",",O
Germany,O
),O
supplemented,O
with,O
10,O
%,O
fetal,O
calf,O
serum,O
and,O
gentamicin,O
(,O
5,O
μg,O
/,O
mL,O
).,O
A549,O
cells,O
were,O
seeded,O
onto,O
microporous,O
membranes,O
(,O
growth,O
area,O
:,O
4,O
.,O
2,O
cm²,O
),O
of,O
cell,O
culture,O
inserts,O
(,O
0,O
.,O
4,O
μm,O
pore,O
size,O
",",O
BD,O
Biosciences,O
),O
with,O
a,O
density,O
of,O
1,O
∗,O
105,O
cells,O
/,O
cm2,O
and,O
cultivated,O
submerged,O
in,O
a,O
cell,O
culture,O
medium,O
.,O
After,O
24,O
hours,O
",",O
the,O
apical,O
medium,O
was,O
removed,O
from,O
the,O
confluent,O
cell,O
layers,O
and,O
the,O
direct,O
exposure,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
with,O
the,O
CULTEX,O
RFS,O
was,O
started,O
.,O
The,O
cells,O
were,O
exposed,O
either,O
to,O
the,O
test,O
substances,O
(,O
deposition,O
rate,O
:,O
25,O
μg,O
/,O
cm²,O
/,O
15,O
min,O
),O
or,O
clean,O
air,O
(,O
process,O
control,O
),O
for,O
15,O
",",O
30,O
",",O
and,O
60,O
minutes,O
.,O
The,O
incubator,O
control,O
cultures,O
were,O
cultivated,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
in,O
the,O
incubator,O
during,O
the,O
exposure,O
period,O
.,O
2,O
.,O
8,O
.,O
WST,O
Assay,O
The,O
aim,O
of,O
our,O
study,O
was,O
the,O
characterization,O
of,O
the,O
exposure,O
device,O
",",O
limited,O
to,O
the,O
functional,O
description,O
of,O
the,O
system,O
.,O
Accordingly,O
",",O
we,O
used,O
only,O
one,O
biological,O
endpoint,O
",",O
the,O
metabolic,O
activity,O
of,O
the,O
cells,O
",",O
to,O
demonstrate,O
dose,O
-,O
dependent,O
cytotoxic,O
reactions,O
",",O
not,O
investigating,O
further,O
into,O
the,O
mechanisms,O
behind,O
these,O
effects,O
.,O
After,O
a,O
postincubation,O
time,O
of,O
24,O
hours,O
(,O
air,O
-,O
liquid,O
interface,O
;,O
37,O
°,O
C,O
/,O
5,O
%,O
CO2,O
"),",O
the,O
particle,O
-,O
exposed,O
cells,O
and,O
the,O
control,O
cultures,O
(,O
incubator,O
control,O
:,O
unexposed,O
cells,O
",",O
process,O
control,O
:,O
clean,O
air,O
-,O
exposed,O
cells,O
),O
were,O
analyzed,O
for,O
cell,O
viability,O
by,O
using,O
the,O
WST,O
-,O
1,O
assay,O
for,O
the,O
mitochondrial,O
activity,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
(,O
Roche,O
Diagnostics,O
",",O
Germany,O
).,O
The,O
data,O
of,O
the,O
exposed,O
cells,O
were,O
normalized,O
to,O
the,O
values,O
of,O
the,O
clean,O
air,O
control,O
.,O
The,O
incubator,O
controls,O
were,O
not,O
considered,O
",",O
because,O
they,O
did,O
not,O
show,O
significant,O
differences,O
to,O
the,O
clean,O
air,O
controls,O
.,O
2,O
.,O
9,O
.,O
Statistical,O
Analysis,O
The,O
results,O
of,O
three,O
independent,O
tests,O
with,O
three,O
samples,O
each,O
is,O
expressed,O
as,O
mean,O
±,O
SD,O
.,O
A,O
Student,O
',O
s,O
t,O
-,O
test,O
was,O
performed,O
to,O
analyze,O
whether,O
the,O
differences,O
between,O
the,O
mean,O
values,O
of,O
the,O
three,O
exposure,O
times,O
are,O
significant,O
[,O
20,O
].,O
3,O
.,O
Results,O
3,O
.,O
1,O
.,O
Deposition,O
Efficiency,O
The,O
CULTEX,O
RFS,O
was,O
designed,O
for,O
exposing,O
adherent,O
cells,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
to,O
airborne,O
materials,O
like,O
gases,O
",",O
complex,O
mixtures,O
",",O
and,O
particles,O
.,O
When,O
dealing,O
with,O
particulate,O
matter,O
especially,O
",",O
questions,O
arise,O
concerning,O
the,O
deposition,O
efficiency,O
of,O
such,O
an,O
exposure,O
device,O
.,O
The,O
basic,O
and,O
theoretical,O
considerations,O
forming,O
the,O
basis,O
of,O
the,O
efficiency,O
of,O
the,O
system,O
are,O
already,O
described,O
by,O
Aufderheide,O
et,O
al,O
.,O
([,O
17,O
"],",O
Electronic,O
Supplementary,O
Material,O
).,O
3,O
.,O
2,O
.,O
CFD,O
Analysis,O
—,O
Flow,O
Conditions,O
within,O
the,O
System,O
When,O
developing,O
the,O
CULTEX,O
RFS,O
and,O
its,O
peripheral,O
devices,O
",",O
a,O
key,O
to,O
achieve,O
uniform,O
particle,O
deposition,O
on,O
the,O
cell,O
cultures,O
was,O
the,O
simulation,O
and,O
optimization,O
of,O
the,O
particle,O
flow,O
within,O
the,O
system,O
by,O
means,O
of,O
CFD,O
analysis,O
(,O
Figures,O
7,O
to,O
9,O
).,O
Figure,O
7,O
shows,O
a,O
cross,O
-,O
section,O
through,O
the,O
elutriator,O
(,O
a,O
),O
and,O
a,O
streamline,O
velocity,O
plot,O
(,O
b,O
),O
of,O
the,O
CFD,O
analysis,O
.,O
The,O
basic,O
principle,O
of,O
an,O
elutriator,O
consists,O
of,O
separating,O
small,O
(,O
light,O
),O
from,O
large,O
(,O
heavy,O
),O
particles,O
in,O
a,O
vertically,O
upward,O
directed,O
stream,O
.,O
The,O
elutriator,O
features,O
an,O
additional,O
outlet,O
at,O
the,O
bottom,O
for,O
discharging,O
excess,O
aerosol,O
",",O
as,O
aerosol,O
generation,O
may,O
require,O
higher,O
flow,O
rates,O
(,O
e,O
.,O
g,O
".,",O
8,O
L,O
/,O
min,O
),O
than,O
those,O
for,O
the,O
CULTEX,O
RFS,O
exposure,O
module,O
(,O
e,O
.,O
g,O
".,",O
1,O
.,O
6,O
L,O
/,O
min,O
).,O
The,O
streamline,O
plot,O
shows,O
a,O
curl,O
in,O
the,O
lower,O
zone,O
of,O
the,O
device,O
but,O
a,O
uniform,O
upstream,O
above,O
",",O
which,O
is,O
essential,O
for,O
a,O
reliable,O
particle,O
separation,O
.,O
The,O
results,O
are,O
based,O
on,O
flow,O
rates,O
of,O
8,O
.,O
0,O
L,O
/,O
min,O
at,O
the,O
inlet,O
",",O
1,O
.,O
09,O
L,O
/,O
min,O
at,O
the,O
outlet,O
",",O
and,O
6,O
.,O
91,O
L,O
/,O
min,O
at,O
the,O
aerosol,O
excess,O
outlet,O
.,O
Further,O
calculations,O
with,O
the,O
same,O
flow,O
rate,O
at,O
the,O
inlet,O
but,O
1,O
.,O
59,O
L,O
/,O
min,O
at,O
the,O
aerosol,O
outlet,O
showed,O
no,O
substantial,O
differences,O
.,O
Figure,O
8,O
shows,O
particle,O
trajectory,O
simulations,O
with,O
particle,O
sizes,O
of,O
2,O
μm,O
(,O
a,O
),O
and,O
10,O
μm,O
(,O
b,O
).,O
While,O
small,O
particles,O
are,O
transported,O
upwards,O
to,O
the,O
aerosol,O
outlet,O
and,O
the,O
Cultex,O
RFS,O
module,O
",",O
large,O
particles,O
remain,O
in,O
the,O
elutriator,O
.,O
The,O
major,O
portion,O
of,O
the,O
particles,O
is,O
carried,O
to,O
the,O
excess,O
outlet,O
",",O
as,O
a,O
flow,O
rate,O
of,O
only,O
1,O
.,O
09,O
L,O
/,O
min,O
from,O
totally,O
8,O
L,O
/,O
min,O
was,O
conducted,O
to,O
the,O
module,O
in,O
this,O
simulation,O
.,O
When,O
testing,O
prototypes,O
of,O
the,O
Cultex,O
RFS,O
module,O
",",O
the,O
distribution,O
patterns,O
between,O
the,O
three,O
deposition,O
chambers,O
and,O
within,O
the,O
individual,O
chambers,O
showed,O
considerable,O
differences,O
.,O
CFD,O
calculations,O
of,O
the,O
gas,O
flow,O
lines,O
and,O
particle,O
trajectories,O
resulted,O
in,O
the,O
following,O
essential,O
findings,O
.,O
Figure,O
9,O
(,O
a,O
),O
shows,O
the,O
aerosol,O
flow,O
channels,O
within,O
the,O
Cultex,O
RFS,O
module,O
including,O
a,O
curved,O
aerosol,O
feeding,O
tube,O
with,O
6,O
mm,O
diameter,O
and,O
200,O
mm,O
length,O
.,O
The,O
flow,O
lines,O
represent,O
an,O
aerosol,O
flow,O
of,O
1590,O
mL,O
/,O
min,O
in,O
the,O
feeding,O
tube,O
",",O
which,O
is,O
divided,O
into,O
three,O
minor,O
flows,O
of,O
30,O
mL,O
/,O
min,O
leading,O
to,O
the,O
deposition,O
chambers,O
and,O
an,O
excess,O
flow,O
of,O
1500,O
mL,O
/,O
min,O
.,O
Backtracking,O
a,O
defined,O
number,O
of,O
particles,O
from,O
the,O
deposition,O
chamber,O
to,O
the,O
beginning,O
of,O
the,O
curved,O
aerosol,O
feeding,O
tube,O
(,O
which,O
is,O
equal,O
to,O
the,O
elutriator,O
outlet,O
),O
showed,O
that,O
these,O
particles,O
originate,O
from,O
specific,O
locations,O
in,O
the,O
tube,O
profile,O
(,O
Figure,O
9,O
(,O
b,O
)).,O
Further,O
calculations,O
showed,O
that,O
the,O
specific,O
locations,O
are,O
sensitive,O
to,O
changes,O
in,O
tube,O
bending,O
radius,O
",",O
tube,O
length,O
",",O
or,O
flow,O
rate,O
.,O
As,O
the,O
particle,O
concentration,O
and,O
particle,O
size,O
distribution,O
at,O
the,O
beginning,O
of,O
the,O
feeding,O
tube,O
is,O
usually,O
nonuniform,O
across,O
the,O
tube,O
profile,O
",",O
the,O
distribution,O
pattern,O
in,O
the,O
deposition,O
chambers,O
are,O
consequently,O
also,O
nonuniform,O
.,O
An,O
optimal,O
solution,O
to,O
completely,O
avoid,O
these,O
undesired,O
effects,O
was,O
the,O
integration,O
of,O
a,O
jet,O
nozzle,O
into,O
the,O
inlet,O
adapter,O
of,O
the,O
Cultex,O
RFS,O
module,O
.,O
Figure,O
10,O
(,O
a,O
),O
shows,O
the,O
deposition,O
of,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
on,O
insert,O
membranes,O
without,O
using,O
a,O
jet,O
nozzle,O
.,O
The,O
integration,O
of,O
a,O
jet,O
nozzle,O
into,O
the,O
inlet,O
adapter,O
(,O
Figure,O
10,O
(,O
b,O
)),O
resulted,O
in,O
a,O
homogenous,O
distribution,O
of,O
the,O
particles,O
on,O
the,O
insert,O
membranes,O
(,O
Figure,O
10,O
(,O
c,O
"),",O
Table,O
3,O
).,O
3,O
.,O
3,O
.,O
Dose,O
-,O
Response,O
Relationship,O
After,O
optimizing,O
the,O
deposition,O
characteristics,O
within,O
the,O
CULTEX,O
RFS,O
module,O
",",O
A549,O
cells,O
were,O
exposed,O
to,O
lactose,O
monohydrate,O
(,O
process,O
control,O
"),",O
copper,O
(,O
II,O
),O
sulfate,O
(,O
soluble,O
substance,O
"),",O
copper,O
(,O
II,O
),O
oxide,O
micro,O
as,O
well,O
as,O
copper,O
(,O
II,O
),O
oxide,O
nanoparticles,O
(,O
insoluble,O
),O
for,O
15,O
",",O
30,O
",",O
and,O
60,O
minutes,O
.,O
The,O
particle,O
generation,O
was,O
adjusted,O
for,O
each,O
substance,O
to,O
result,O
in,O
a,O
particle,O
deposition,O
of,O
25,O
μg,O
/,O
cm²,O
(,O
low,O
dose,O
),O
during,O
an,O
exposure,O
time,O
of,O
15,O
minutes,O
.,O
The,O
concentration,O
(,O
low,O
effect,O
level,O
",",O
LOEL,O
),O
is,O
based,O
on,O
an,O
interdisciplinary,O
European,O
project,O
in,O
which,O
the,O
cytotoxic,O
potency,O
of,O
a,O
variety,O
of,O
particles,O
was,O
analyzed,O
with,O
different,O
cell,O
types,O
under,O
submersed,O
culture,O
conditions,O
[,O
21,O
].,O
The,O
conditions,O
for,O
the,O
particle,O
generation,O
had,O
to,O
be,O
adjusted,O
in,O
preliminary,O
experiments,O
due,O
to,O
substance,O
-,O
specific,O
variations,O
.,O
24,O
hours,O
after,O
exposure,O
",",O
the,O
cell,O
viability,O
was,O
measured,O
.,O
The,O
values,O
obtained,O
for,O
the,O
particle,O
-,O
exposed,O
cultures,O
were,O
normalized,O
to,O
the,O
clean,O
air,O
-,O
exposed,O
cells,O
.,O
The,O
results,O
are,O
shown,O
in,O
Figures,O
11,O
",",O
12,O
",",O
13,O
",",O
14,O
",",O
15,O
",",O
16,O
",",O
17,O
",",O
and,O
18,O
.,O
Generally,O
the,O
clean,O
air,O
-,O
exposed,O
cells,O
(,O
process,O
control,O
),O
showed,O
no,O
significant,O
reduction,O
in,O
the,O
cell,O
viability,O
in,O
comparison,O
with,O
the,O
incubator,O
control,O
.,O
Accordingly,O
",",O
the,O
exposure,O
process,O
itself,O
had,O
no,O
influence,O
on,O
the,O
metabolic,O
activity,O
of,O
the,O
cells,O
.,O
The,O
exposure,O
of,O
the,O
cell,O
cultures,O
to,O
the,O
test,O
compounds,O
showed,O
",",O
dependent,O
on,O
the,O
chemical,O
and,O
physical,O
properties,O
of,O
the,O
particulate,O
atmosphere,O
",",O
considerable,O
differences,O
in,O
the,O
cytotoxic,O
response,O
among,O
the,O
three,O
exposure,O
times,O
.,O
The,O
comparison,O
of,O
the,O
15,O
",",O
30,O
",",O
and,O
60,O
minutes,O
exposures,O
in,O
a,O
Student,O
',O
s,O
t,O
-,O
test,O
demonstrates,O
significant,O
differences,O
with,O
a,O
5,O
%,O
error,O
probability,O
.,O
No,O
significant,O
differences,O
could,O
be,O
obtained,O
for,O
lactose,O
monohydrate,O
(,O
30,O
minutes,O
compared,O
to,O
15,O
minutes,O
),O
and,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
-,O
sized,O
(,O
60,O
minutes,O
compared,O
to,O
30,O
minutes,O
),O
due,O
to,O
the,O
low,O
number,O
of,O
tests,O
.,O
The,O
exposure,O
of,O
A549,O
cells,O
to,O
lactose,O
monohydrate,O
(,O
negative,O
substance,O
),O
led,O
to,O
a,O
slight,O
decrease,O
in,O
the,O
cell,O
viability,O
of,O
the,O
cells,O
after,O
15,O
minutes,O
(,O
94,O
%,O
of,O
the,O
clean,O
air,O
control,O
).,O
By,O
increasing,O
the,O
exposure,O
time,O
to,O
60,O
minutes,O
",",O
the,O
metabolic,O
activity,O
of,O
the,O
cells,O
was,O
reduced,O
by,O
30,O
%,O
in,O
comparison,O
to,O
the,O
clean,O
air,O
control,O
.,O
At,O
that,O
point,O
",",O
the,O
cultures,O
were,O
covered,O
by,O
a,O
dense,O
layer,O
of,O
the,O
particulate,O
matter,O
thus,O
pointing,O
to,O
an,O
overload,O
effect,O
.,O
The,O
particle,O
number,O
(,O
black,O
line,O
),O
and,O
mass,O
distribution,O
(,O
red,O
line,O
),O
of,O
the,O
lactose,O
monohydrate,O
aerosol,O
dependent,O
on,O
particle,O
size,O
are,O
shown,O
in,O
Figure,O
12,O
.,O
The,O
units,O
number,O
",",O
respectively,O
",",O
mass,O
per,O
μm,O
∗,O
cm3,O
may,O
be,O
unfamiliar,O
at,O
first,O
glance,O
.,O
As,O
the,O
curves,O
are,O
based,O
on,O
particle,O
counts,O
",",O
classified,O
to,O
51,O
particle,O
size,O
intervals,O
",",O
the,O
counts,O
have,O
to,O
be,O
divided,O
not,O
only,O
through,O
the,O
volume,O
but,O
also,O
through,O
the,O
interval,O
width,O
to,O
get,O
the,O
required,O
values,O
for,O
particle,O
distribution,O
curves,O
.,O
The,O
particle,O
number,O
distribution,O
curve,O
exhibits,O
its,O
peak,O
value,O
at,O
a,O
particle,O
size,O
of,O
0,O
.,O
7,O
μm,O
while,O
the,O
particle,O
mass,O
distribution,O
curve,O
shows,O
its,O
peak,O
value,O
at,O
a,O
particle,O
size,O
of,O
4,O
.,O
2,O
μm,O
due,O
to,O
the,O
greater,O
mass,O
of,O
larger,O
particles,O
.,O
The,O
exposure,O
of,O
the,O
cell,O
populations,O
to,O
copper,O
(,O
II,O
),O
sulfate,O
led,O
to,O
a,O
pronounced,O
decrease,O
in,O
the,O
cell,O
viability,O
after,O
15,O
minutes,O
19,O
%,O
of,O
the,O
clean,O
air,O
control,O
.,O
By,O
increasing,O
the,O
time,O
to,O
60,O
minutes,O
",",O
the,O
metabolic,O
activity,O
was,O
reduced,O
by,O
more,O
than,O
91,O
%,O
compared,O
to,O
the,O
clean,O
air,O
control,O
.,O
The,O
peak,O
for,O
the,O
particle,O
number,O
distribution,O
was,O
at,O
0,O
.,O
9,O
μm,O
and,O
the,O
peak,O
for,O
the,O
particle,O
mass,O
distribution,O
was,O
at,O
3,O
.,O
8,O
μm,O
(,O
Figure,O
14,O
).,O
Both,O
particle,O
number,O
and,O
particle,O
mass,O
were,O
about,O
five,O
times,O
higher,O
than,O
for,O
lactose,O
monohydrate,O
.,O
The,O
results,O
after,O
the,O
exposure,O
of,O
A549,O
cells,O
to,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
also,O
indicated,O
a,O
dose,O
-,O
dependent,O
decrease,O
of,O
the,O
metabolic,O
activity,O
over,O
the,O
exposure,O
time,O
(,O
Figure,O
15,O
).,O
The,O
decrease,O
of,O
cell,O
viability,O
after,O
60,O
minutes,O
exposure,O
(,O
61,O
%,O
reduction,O
in,O
comparison,O
to,O
the,O
synthetic,O
air,O
control,O
),O
is,O
significantly,O
higher,O
than,O
for,O
lactose,O
monohydrate,O
but,O
not,O
as,O
clear,O
as,O
for,O
copper,O
(,O
II,O
),O
sulfate,O
.,O
In,O
comparison,O
with,O
copper,O
(,O
II,O
),O
sulfate,O
",",O
the,O
particle,O
number,O
distribution,O
of,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
also,O
showed,O
a,O
peak,O
at,O
0,O
.,O
9,O
μm,O
",",O
but,O
with,O
a,O
more,O
than,O
four,O
times,O
lower,O
number,O
of,O
particles,O
(,O
Figure,O
16,O
).,O
The,O
values,O
for,O
the,O
particle,O
mass,O
distribution,O
were,O
about,O
25,O
%,O
lower,O
compared,O
to,O
copper,O
(,O
II,O
),O
sulfate,O
",",O
indicating,O
that,O
the,O
substances,O
mostly,O
differ,O
in,O
their,O
content,O
of,O
small,O
particles,O
.,O
The,O
cell,O
viability,O
of,O
the,O
A549,O
cells,O
was,O
significantly,O
reduced,O
after,O
the,O
exposure,O
to,O
copper,O
(,O
II,O
),O
oxide,O
nanoparticles,O
.,O
After,O
15,O
minutes,O
",",O
the,O
metabolic,O
activity,O
was,O
reduced,O
to,O
less,O
than,O
50,O
%,O
compared,O
to,O
the,O
clean,O
air,O
and,O
incubator,O
control,O
.,O
A,O
particle,O
mass,O
of,O
100,O
μg,O
/,O
cm2,O
(,O
60,O
minutes,O
),O
led,O
to,O
a,O
reduction,O
in,O
the,O
metabolic,O
activity,O
of,O
85,O
"%,",O
indicating,O
a,O
higher,O
cytotoxic,O
effect,O
by,O
the,O
nanopowder,O
compared,O
to,O
the,O
micro,O
.,O
Copper,O
(,O
II,O
),O
oxide,O
nano,O
does,O
not,O
differ,O
strongly,O
from,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
in,O
numbers,O
of,O
sub,O
-,O
μm,O
particles,O
.,O
The,O
nanopowder,O
exhibits,O
much,O
lower,O
mass,O
distribution,O
values,O
",",O
however,O
",",O
due,O
to,O
few,O
particles,O
in,O
the,O
size,O
range,O
over,O
1,O
μm,O
.,O
4,O
.,O
Discussion,O
Due,O
to,O
changes,O
in,O
the,O
EU,O
regulations,O
concerning,O
the,O
approval,O
of,O
chemical,O
substances,O
(,O
Regulation,O
(,O
EU,O
),O
no,O
.,O
1907,O
/,O
2006,O
),O
and,O
the,O
ongoing,O
demand,O
for,O
alternative,O
methods,O
",",O
new,O
cell,O
systems,O
and,O
exposure,O
techniques,O
were,O
developed,O
and,O
characterized,O
",",O
also,O
in,O
the,O
field,O
of,O
inhalation,O
toxicology,O
.,O
The,O
latter,O
should,O
meet,O
special,O
requirements,O
with,O
regard,O
to,O
the,O
cell,O
type,O
and,O
the,O
type,O
of,O
exposure,O
.,O
The,O
biological,O
test,O
systems,O
include,O
bronchial,O
(,O
Calu,O
-,O
3,O
",",O
16HBE14o,O
"-,",O
BEAS,O
-,O
2B,O
),O
and,O
alveolar,O
epithelial,O
(,O
A549,O
),O
cell,O
lines,O
",",O
mostly,O
from,O
tumors,B-DS
as,O
well,O
as,O
human,B-OG
primary,O
cells,O
isolated,O
from,O
different,O
regions,O
of,O
the,O
respiratory,O
tract,O
[,O
22,O
–,O
25,O
].,O
At,O
the,O
moment,O
primary,O
cell,O
cultures,O
are,O
mostly,O
studied,O
under,O
mechanistic,O
aspects,O
(,O
differentiation,O
",",O
cellular,O
interactions,O
),O
[,O
26,O
],O
and,O
are,O
not,O
used,O
routinely,O
for,O
screening,O
methods,O
to,O
address,O
acute,O
toxicity,O
.,O
Therefore,O
",",O
the,O
studies,O
are,O
mostly,O
performed,O
with,O
cell,O
lines,O
like,O
the,O
alveolar,O
epithelial,O
cell,O
line,O
A549,O
",",O
which,O
allows,O
the,O
generation,O
of,O
stable,O
cultures,O
(,O
undifferentiated,O
).,O
The,O
advantage,O
of,O
these,O
cultures,O
is,O
the,O
delivery,O
of,O
stable,O
",",O
reproducible,O
",",O
and,O
significant,O
data,O
for,O
the,O
calculation,O
of,O
dose,O
-,O
response,O
curves,O
as,O
well,O
as,O
the,O
definition,O
of,O
key,O
values,O
(,O
effective,O
dose,O
:,O
EC50,O
).,O
The,O
exposure,O
of,O
cultivated,O
cells,O
from,O
the,O
respiratory,O
tract,O
for,O
studying,O
the,O
effects,O
of,O
airborne,O
substances,O
represents,O
a,O
challenge,O
with,O
regard,O
to,O
the,O
experimental,O
design,O
.,O
The,O
exposure,O
of,O
cells,O
under,O
conventional,O
submerged,O
conditions,O
",",O
mostly,O
with,O
soluble,O
test,O
substances,O
",",O
shows,O
a,O
variety,O
of,O
shortcomings,O
like,O
the,O
interference,O
of,O
the,O
test,O
atmosphere,O
with,O
medium,O
components,O
",",O
unrealistic,O
exposure,O
conditions,O
including,O
uncertain,O
effective,O
doses,O
for,O
gases,O
and,O
particles,O
.,O
Therefore,O
",",O
several,O
approaches,O
have,O
been,O
made,O
for,O
the,O
development,O
of,O
exposure,O
systems,O
(,O
Table,O
4,O
),O
at,O
the,O
air,O
-,O
liquid,O
interface,O
[,O
3,O
",",O
12,O
",",O
14,O
",",O
17,O
",",O
27,O
–,O
35,O
].,O
Under,O
such,O
conditions,O
",",O
the,O
cells,O
are,O
in,O
direct,O
contact,O
with,O
the,O
test,O
aerosol,O
",",O
which,O
is,O
conducted,O
through,O
the,O
exposure,O
device,O
to,O
the,O
cells,O
.,O
The,O
exposure,O
systems,O
have,O
to,O
fulfill,O
cell,O
-,O
specific,O
requirements,O
",",O
meaning,O
the,O
maintenance,O
of,O
the,O
cell,O
cultures,O
during,O
the,O
exposure,O
process,O
by,O
medium,O
supply,O
and,O
the,O
establishment,O
of,O
a,O
cell,O
-,O
specific,O
environment,O
(,O
pH,O
value,O
",",O
37,O
°,O
C,O
).,O
All,O
described,O
systems,O
have,O
taken,O
into,O
consideration,O
those,O
basic,O
requirements,O
.,O
The,O
inserts,O
are,O
located,O
in,O
medium,O
-,O
containing,O
chambers,O
",",O
connected,O
with,O
a,O
medium,O
supply,O
for,O
intermittent,O
or,O
continuous,O
medium,O
exchange,O
.,O
In,O
the,O
system,O
described,O
by,O
Adamson,O
et,O
al,O
.,O
[,O
36,O
"],",O
4,O
culture,O
vessels,O
are,O
placed,O
together,O
in,O
a,O
chamber,O
filled,O
up,O
with,O
medium,O
to,O
the,O
bottom,O
of,O
the,O
cell,O
culture,O
inserts,O
.,O
In,O
the,O
CULTEX,O
RFS,O
",",O
and,O
also,O
the,O
CULTEX,O
glass,O
modules,O
[,O
27,O
",",O
28,O
"],",O
the,O
inserts,O
are,O
housed,O
separately,O
and,O
are,O
supplied,O
individually,O
with,O
nutrients,O
",",O
as,O
independent,O
exposure,O
chambers,O
within,O
one,O
module,O
.,O
The,O
medium,O
level,O
is,O
adjusted,O
via,O
an,O
overflow,O
tube,O
to,O
establish,O
comparable,O
conditions,O
in,O
all,O
three,O
chambers,O
.,O
The,O
basic,O
principle,O
of,O
cellular,O
exposure,O
to,O
airborne,O
materials,O
is,O
based,O
on,O
the,O
treatment,O
of,O
the,O
cultivated,O
cells,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
(,O
ALI,O
).,O
The,O
experimental,O
setup,O
to,O
realize,O
a,O
direct,O
contact,O
between,O
the,O
cells,O
and,O
the,O
test,O
atmosphere,O
differs,O
considerably,O
in,O
the,O
different,O
systems,O
",",O
which,O
are,O
listed,O
in,O
Table,O
4,O
.,O
A,O
limited,O
number,O
of,O
devices,O
favor,O
the,O
exposure,O
of,O
the,O
cultures,O
to,O
an,O
aerosol,O
passing,O
through,O
a,O
box,O
or,O
exposure,O
chamber,O
[,O
35,O
",",O
36,O
"],",O
but,O
most,O
of,O
the,O
exposure,O
systems,O
prefer,O
a,O
stream,O
directed,O
towards,O
the,O
cell,O
culture,O
to,O
realize,O
a,O
close,O
contact,O
between,O
the,O
test,O
atmosphere,O
and,O
the,O
cell,O
surface,O
for,O
depositing,O
particles,O
.,O
Gaseous,O
compounds,O
can,O
be,O
studied,O
in,O
all,O
systems,O
due,O
to,O
the,O
homogeneous,O
distribution,O
of,O
their,O
test,O
atmosphere,O
",",O
whereas,O
the,O
exposure,O
of,O
particulate,O
materials,O
is,O
based,O
mostly,O
on,O
a,O
directed,O
aerosol,O
flow,O
.,O
A,O
comparative,O
study,O
of,O
the,O
different,O
test,O
systems,O
is,O
limited,O
due,O
to,O
the,O
limited,O
availability,O
of,O
the,O
modules,O
and,O
the,O
absence,O
of,O
information,O
.,O
The,O
CULTEX,O
glass,O
modules,O
as,O
well,O
as,O
the,O
RFS,O
are,O
designed,O
to,O
establish,O
an,O
incoming,O
flow,O
which,O
is,O
directed,O
immediately,O
via,O
emission,O
ducts,O
to,O
the,O
surface,O
of,O
the,O
cells,O
to,O
guarantee,O
a,O
close,O
contact,O
with,O
the,O
test,O
atmosphere,O
",",O
both,O
qualitatively,O
and,O
quantitatively,O
.,O
In,O
comparison,O
with,O
the,O
glass,O
modules,O
",",O
the,O
aerosol,O
guiding,O
module,O
of,O
the,O
RFS,O
has,O
been,O
optimized,O
concerning,O
the,O
uniform,O
distribution,O
of,O
the,O
incoming,O
test,O
atmosphere,O
to,O
the,O
three,O
exposure,O
chambers,O
",",O
thus,O
stabilizing,O
the,O
whole,O
exposure,O
process,O
.,O
In,O
the,O
glass,O
modules,O
",",O
the,O
aerosol,O
is,O
guided,O
linearly,O
above,O
the,O
module,O
and,O
the,O
sampling,O
points,O
for,O
the,O
test,O
atmosphere,O
are,O
arranged,O
in,O
succession,O
.,O
In,O
the,O
case,O
of,O
gaseous,O
compounds,O
",",O
the,O
homogeneous,O
distribution,O
of,O
the,O
atmosphere,O
is,O
not,O
limited,O
",",O
but,O
airborne,O
particles,O
belong,O
to,O
another,O
category,O
",",O
especially,O
with,O
regard,O
to,O
their,O
aerosol,O
physical,O
properties,O
.,O
A,O
linear,O
flow,O
path,O
above,O
the,O
glass,O
module,O
leads,O
to,O
a,O
concentration,O
gradient,O
",",O
which,O
may,O
result,O
",",O
due,O
to,O
the,O
sequentially,O
arranged,O
sampling,O
points,O
",",O
at,O
different,O
exposure,O
levels,O
.,O
In,O
contrast,O
",",O
the,O
CULTEX,O
RFS,O
module,O
is,O
characterized,O
by,O
a,O
central,O
inlet,O
for,O
the,O
test,O
atmosphere,O
into,O
the,O
exposure,O
device,O
",",O
wherefrom,O
the,O
aerosol,O
is,O
distributed,O
into,O
the,O
chambers,O
and,O
the,O
particles,O
deposited,O
on,O
the,O
cell,O
cultures,O
.,O
The,O
resulting,O
data,O
are,O
characterized,O
by,O
a,O
small,O
standard,O
deviation,O
within,O
a,O
test,O
or,O
for,O
multiple,O
experiments,O
.,O
Another,O
relevant,O
advantage,O
of,O
the,O
new,O
system,O
is,O
the,O
adjustment,O
of,O
the,O
medium,O
level,O
",",O
which,O
ensures,O
a,O
comparable,O
microenvironment,O
for,O
all,O
cultures,O
.,O
The,O
level,O
in,O
the,O
Cultex,O
RFS,O
is,O
controlled,O
by,O
special,O
overflow,O
tubes,O
to,O
stabilize,O
the,O
sensitive,O
microclimate,O
around,O
the,O
cells,O
.,O
An,O
autonomous,O
medium,O
supply,O
for,O
each,O
cell,O
culture,O
insert,O
offers,O
the,O
opportunity,O
to,O
test,O
different,O
medium,O
additives,O
without,O
interaction,O
between,O
the,O
three,O
test,O
chambers,O
.,O
The,O
new,O
modular,O
design,O
of,O
the,O
Cultex,O
RFS,O
guarantees,O
a,O
high,O
flexibility,O
in,O
working,O
with,O
different,O
types,O
of,O
cell,O
culture,O
inserts,O
or,O
even,O
Petri,O
dishes,O
(,O
for,O
the,O
AMES,O
assay,O
),O
by,O
using,O
special,O
adapters,O
.,O
The,O
efficiency,O
of,O
the,O
exposure,O
process,O
depends,O
on,O
the,O
deposition,O
efficiency,O
and,O
represents,O
",",O
especially,O
in,O
the,O
case,O
of,O
fine,O
and,O
ultrafine,O
particles,O
(,O
nano,O
particles,O
"),",O
one,O
of,O
the,O
main,O
challenges,O
[,O
17,O
].,O
The,O
deposition,O
efficiency,O
of,O
the,O
particles,O
in,O
most,O
air,O
-,O
liquid,O
interface,O
systems,O
is,O
based,O
on,O
sedimentation,O
and,O
diffusion,O
.,O
Accordingly,O
",",O
a,O
characterization,O
of,O
the,O
test,O
aerosol,O
with,O
regard,O
to,O
the,O
particle,O
number,O
and,O
particle,O
mass,O
dependent,O
on,O
the,O
particle,O
size,O
is,O
one,O
of,O
the,O
main,O
requirements,O
to,O
judge,O
the,O
biological,O
activity,O
of,O
the,O
airborne,O
material,O
.,O
Due,O
to,O
changes,O
within,O
the,O
aerosol,O
during,O
the,O
generation,O
process,O
and,O
due,O
to,O
particle,O
-,O
particle,O
interactions,O
",",O
the,O
primary,O
particle,O
size,O
should,O
only,O
be,O
used,O
as,O
a,O
basic,O
indication,O
.,O
In,O
this,O
context,O
",",O
particle,O
loss,O
within,O
the,O
system,O
and,O
agglomeration,O
of,O
the,O
particles,O
has,O
to,O
be,O
taken,O
into,O
account,O
.,O
In,O
the,O
literature,O
",",O
the,O
deposition,O
efficiency,O
rate,O
of,O
in,O
vitro,O
exposure,O
devices,O
is,O
described,O
inconsistently,O
.,O
Theoretical,O
considerations,O
and,O
experimental,O
exposure,O
data,O
with,O
ultrafine,O
carbonaceous,O
model,O
particles,O
with,O
a,O
CMD,O
of,O
95,O
nm,O
resulted,O
in,O
an,O
efficiency,O
of,O
2,O
%,O
[,O
37,O
].,O
The,O
combination,O
of,O
such,O
air,O
-,O
liquid,O
interface,O
exposure,O
systems,O
with,O
an,O
electrical,O
charger,O
and,O
precipitator,O
could,O
improve,O
particle,O
deposition,O
.,O
Experimental,O
data,O
from,O
Savi,O
et,O
al,O
.,O
[,O
16,O
],O
showed,O
that,O
the,O
deposition,O
efficiency,O
can,O
be,O
increased,O
to,O
30,O
%,O
with,O
this,O
type,O
of,O
setup,O
without,O
causing,O
a,O
cytotoxic,O
effect,O
on,O
the,O
exposed,O
cells,O
.,O
First,O
results,O
obtained,O
with,O
the,O
Cultex,O
RFS,O
in,O
combination,O
with,O
an,O
electrical,O
deposition,O
device,O
(,O
Cultex,O
EDD,O
),O
indicated,O
that,O
the,O
efficiency,O
for,O
particles,O
which,O
are,O
not,O
deposited,O
by,O
sedimentation,O
or,O
diffusion,O
can,O
be,O
increased,O
up,O
to,O
95,O
%,O
(,O
data,O
not,O
shown,O
).,O
The,O
outstanding,O
importance,O
of,O
particle,O
size,O
and,O
mass,O
for,O
the,O
deposition,O
efficiency,O
highlights,O
the,O
importance,O
of,O
a,O
controlled,O
and,O
stable,O
generation,O
of,O
particulate,O
atmospheres,O
as,O
well,O
as,O
the,O
behavior,O
of,O
such,O
particles,O
in,O
an,O
exposure,O
device,O
.,O
To,O
obtain,O
more,O
insights,O
into,O
the,O
flow,O
conditions,O
within,O
our,O
Cultex,O
RFS,O
module,O
",",O
CFD,O
analysis,O
was,O
conducted,O
by,O
taking,O
into,O
consideration,O
all,O
components,O
of,O
the,O
experimental,O
setup,O
.,O
CFD,O
simulations,O
included,O
the,O
particle,O
distribution,O
in,O
the,O
tubing,O
system,O
(,O
connection,O
between,O
the,O
elutriator,O
and,O
the,O
exposure,O
module,O
),O
and,O
the,O
exposure,O
module,O
itself,O
.,O
Here,O
",",O
we,O
found,O
that,O
inhomogeneous,O
particle,O
distributions,O
propagate,O
over,O
long,O
distances,O
due,O
to,O
laminar,O
flow,O
conditions,O
.,O
The,O
integration,O
of,O
a,O
jet,O
nozzle,O
into,O
the,O
inlet,O
adapter,O
enabled,O
a,O
homogeneous,O
particle,O
distribution,O
and,O
deposition,O
on,O
the,O
insert,O
membranes,O
as,O
shown,O
in,O
Figure,O
10,O
at,O
the,O
example,O
of,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
.,O
The,O
CFD,O
analysis,O
provides,O
a,O
good,O
method,O
to,O
simulate,O
the,O
trajectories,O
of,O
the,O
particles,O
from,O
generation,O
to,O
deposition,O
.,O
The,O
consideration,O
of,O
different,O
experimental,O
conditions,O
like,O
the,O
air,O
flow,O
rate,O
or,O
dimensions,O
of,O
the,O
connecting,O
tubes,O
allows,O
the,O
selection,O
of,O
the,O
appropriate,O
experimental,O
design,O
to,O
enhance,O
the,O
efficiency,O
of,O
the,O
exposure,O
system,O
.,O
Besides,O
the,O
experimental,O
setup,O
",",O
the,O
chemical,O
and,O
physical,O
properties,O
of,O
the,O
particles,O
highly,O
influence,O
their,O
deposition,O
efficiency,O
.,O
To,O
compare,O
the,O
biological,O
activity,O
of,O
the,O
different,O
copper,O
compounds,O
",",O
the,O
particle,O
mass,O
concentration,O
per,O
area,O
was,O
adjusted,O
for,O
each,O
substance,O
to,O
establish,O
a,O
comparable,O
particle,O
mass,O
deposition,O
(,O
deposition,O
rate,O
:,O
25,O
μg,O
/,O
cm²,O
/,O
15,O
min,O
).,O
A549,O
cells,O
were,O
exposed,O
for,O
15,O
",",O
30,O
",",O
and,O
60,O
minutes,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
to,O
the,O
different,O
test,O
atmospheres,O
and,O
the,O
metabolic,O
activity,O
of,O
the,O
cells,O
was,O
analyzed,O
as,O
an,O
estimate,O
for,O
cytotoxicity,O
.,O
In,O
comparison,O
to,O
the,O
incubator,O
control,O
",",O
the,O
cells,O
that,O
were,O
exposed,O
to,O
clean,O
air,O
showed,O
no,O
reduction,O
in,O
the,O
cell,O
viability,O
",",O
indicating,O
that,O
the,O
exposure,O
procedure,O
itself,O
had,O
no,O
effect,O
on,O
this,O
analyzed,O
endpoint,O
.,O
As,O
a,O
negative,O
substance,O
control,O
we,O
used,O
lactose,O
",",O
which,O
induced,O
no,O
considerable,O
cell,O
damage,O
(,O
13,O
%,O
after,O
an,O
exposure,O
time,O
of,O
30,O
minutes,O
).,O
At,O
the,O
end,O
of,O
the,O
exposure,O
period,O
",",O
the,O
cultures,O
were,O
covered,O
by,O
a,O
dense,O
particle,O
layer,O
and,O
a,O
further,O
reduction,O
in,O
cell,O
viability,O
(,O
37,O
%,O
of,O
the,O
clean,O
air,O
control,O
),O
was,O
measured,O
probably,O
due,O
to,O
an,O
overload,O
effect,O
.,O
In,O
comparison,O
with,O
lactose,O
monohydrate,O
",",O
all,O
copper,O
compounds,O
induced,O
significant,O
dose,O
-,O
related,O
effects,O
.,O
The,O
cytotoxic,O
signal,O
correlated,O
strongly,O
with,O
the,O
chemical,O
and,O
physical,O
properties,O
of,O
the,O
test,O
compound,O
.,O
Copper,O
(,O
II,O
),O
sulfate,O
",",O
as,O
soluble,O
compound,O
",",O
induced,O
a,O
pronounced,O
cytotoxic,O
effect,O
already,O
after,O
an,O
exposure,O
time,O
of,O
15,O
minutes,O
(,O
reduction,O
of,O
cell,O
viability,O
of,O
80,O
%).,O
Comparable,O
effects,O
could,O
also,O
be,O
observed,O
for,O
the,O
insoluble,O
copper,O
(,O
II,O
),O
oxide,O
compounds,O
",",O
but,O
to,O
a,O
lesser,O
extent,O
.,O
As,O
described,O
by,O
Karlsson,O
and,O
coworkers,O
[,O
38,O
"],",O
the,O
exposure,O
of,O
the,O
cells,O
to,O
both,O
substances,O
resulted,O
in,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
the,O
cell,O
viability,O
by,O
increasing,O
the,O
particle,O
concentration,O
",",O
whereby,O
the,O
copper,O
(,O
II,O
),O
oxide,O
nanomaterial,O
appeared,O
to,O
be,O
more,O
harmful,O
to,O
the,O
cells,O
than,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
",",O
based,O
on,O
the,O
exposed,O
particle,O
mass,O
.,O
In,O
the,O
literature,O
",",O
nanoparticles,O
are,O
repeatedly,O
described,O
to,O
be,O
more,O
potent,O
in,O
causing,O
a,O
cellular,O
damage,O
than,O
microparticles,O
[,O
38,O
–,O
40,O
"],",O
but,O
there,O
is,O
also,O
evidence,O
that,O
there,O
is,O
no,O
difference,O
in,O
their,O
biological,O
activity,O
[,O
41,O
–,O
43,O
].,O
In,O
agreement,O
with,O
the,O
above,O
-,O
mentioned,O
studies,O
",",O
our,O
direct,O
exposure,O
studies,O
with,O
nanosized,O
copper,O
(,O
II,O
),O
oxide,O
exhibited,O
a,O
stronger,O
cytotoxicity,O
than,O
the,O
micro,O
-,O
sized,O
particles,O
.,O
Most,O
of,O
the,O
studies,O
on,O
micro,O
-,O
or,O
nanosized,O
particles,O
have,O
been,O
conducted,O
under,O
submersed,O
conditions,O
.,O
Ahamed,O
and,O
coworkers,O
also,O
used,O
A549,O
cells,O
",",O
which,O
were,O
treated,O
with,O
CuO,O
nanoparticles,O
(,O
NP,O
),O
suspended,O
in,O
medium,O
(,O
0,O
",",O
10,O
",",O
25,O
",",O
and,O
50,O
μg,O
/,O
mL,O
for,O
24,O
hours,O
),O
[,O
44,O
].,O
CuO,O
NPs,O
significantly,O
decreased,O
cell,O
viability,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
The,O
highest,O
concentration,O
(,O
50,O
μg,O
/,O
mL,O
),O
induced,O
a,O
reduction,O
in,O
viability,O
of,O
52,O
"%,",O
whereas,O
the,O
directly,O
exposed,O
A549,O
cells,O
showed,O
a,O
decrease,O
of,O
more,O
than,O
75,O
"%,",O
pointing,O
to,O
a,O
more,O
efficient,O
contact,O
and,O
interaction,O
between,O
deposited,O
particles,O
and,O
the,O
lung,O
cells,O
.,O
Investigations,O
of,O
Karlsson,O
et,O
al,O
.,O
support,O
this,O
assessment,O
[,O
38,O
",",O
45,O
].,O
Concerning,O
the,O
number,O
of,O
particles,O
per,O
cm2,O
for,O
each,O
substance,O
",",O
A549,O
cells,O
were,O
exposed,O
in,O
the,O
case,O
of,O
copper,O
(,O
II,O
),O
oxide,O
nano,O
to,O
more,O
particles,O
in,O
comparison,O
to,O
copper,O
(,O
II,O
),O
oxide,O
micro,O
.,O
Accordingly,O
",",O
the,O
higher,O
cytotoxicity,O
may,O
also,O
be,O
a,O
result,O
of,O
the,O
higher,O
number,O
of,O
smaller,O
particles,O
coming,O
into,O
contact,O
with,O
the,O
surface,O
of,O
the,O
cells,O
.,O
In,O
summary,O
",",O
our,O
results,O
show,O
that,O
an,O
efficient,O
and,O
stable,O
cell,O
exposure,O
system,O
like,O
the,O
Cultex,O
RFS,O
module,O
allows,O
a,O
reproducible,O
analysis,O
of,O
dose,O
-,O
dependent,O
reactions,O
to,O
airborne,O
materials,O
.,O
The,O
cell,O
cultures,O
can,O
be,O
exposed,O
to,O
the,O
generated,O
particulate,O
atmospheres,O
",",O
characterized,O
with,O
regard,O
to,O
particle,O
size,O
and,O
mass,O
distribution,O
",",O
under,O
controlled,O
conditions,O
thus,O
favoring,O
the,O
generation,O
of,O
valid,O
data,O
for,O
the,O
calculation,O
of,O
key,O
values,O
(,O
effective,O
dose,O
).,O
These,O
data,O
can,O
be,O
compared,O
with,O
animal,B-OG
or,O
clinical,O
data,O
and,O
offer,O
the,O
possibility,O
to,O
verify,O
the,O
relevance,O
and,O
meaningfulness,O
of,O
these,O
in,O
vitro,O
studies,O
.,O
Overview,O
image,O
of,O
the,O
modular,O
CULTEX,O
RFS,O
exposure,O
system,O
.,O
The,O
device,O
is,O
composed,O
of,O
the,O
following,O
components,O
:,O
(,O
1,O
),O
inlet,O
adapter,O
",",O
(,O
2,O
),O
aerosol,O
guiding,O
module,O
",",O
(,O
3,O
),O
sampling,O
module,O
and,O
socket,O
module,O
",",O
and,O
(,O
4,O
),O
locking,O
module,O
with,O
a,O
hand,O
wheel,O
.,O
Aerosol,O
guiding,O
module,O
of,O
the,O
CULTEX,O
RFS,O
:,O
(,O
a,O
),O
top,O
view,O
",",O
(,O
b,O
),O
bottom,O
view,O
",",O
and,O
(,O
c,O
),O
sampling,O
module,O
.,O
The,O
CULTEX,O
RFS,O
exposure,O
device,O
extended,O
with,O
an,O
electrical,O
deposition,O
device,O
(,O
Cultex,O
EDD,O
),O
for,O
the,O
increased,O
particle,O
deposition,O
efficiency,O
.,O
The,O
CULTEX,O
DG,O
(,O
Dust,O
Generator,O
),O
(,O
Cultex,O
Laboratories,O
GmbH,O
",",O
Germany,O
),O
enables,O
the,O
generation,O
of,O
aerosols,O
from,O
a,O
powder,O
cake,O
according,O
to,O
Wright,O
[,O
5,O
].,O
Experimental,O
setup,O
for,O
exposing,O
cultivated,O
cells,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
to,O
particles,O
.,O
The,O
components,O
of,O
the,O
exposure,O
station,O
are,O
the,O
particle,O
generator,O
according,O
to,O
Wright,O
",",O
the,O
elutriator,O
",",O
two,O
CULTEX,O
RFS,O
devices,O
for,O
exposure,O
to,O
particles,O
and,O
clean,O
air,O
and,O
medium,O
pumps,O
for,O
the,O
automatic,O
nutrient,O
supply,O
.,O
Schematic,O
overview,O
of,O
the,O
CULTEX,O
system,O
for,O
exposing,O
cultivated,O
cells,O
to,O
particles,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
.,O
Components,O
of,O
the,O
exposure,O
station,O
:,O
(,O
a,O
),O
particle,O
generator,O
according,O
to,O
Wright,O
(,O
CULTEX,O
Dust,O
Generator,O
);,O
(,O
b,O
),O
elutriator,O
:,O
glass,O
tube,O
with,O
vertical,O
upward,O
flow,O
",",O
where,O
large,O
particles,O
are,O
removed,O
from,O
the,O
aerosol,O
due,O
to,O
sedimentation,O
;,O
(,O
c,O
),O
CULTEX,O
RFS,O
modules,O
for,O
exposure,O
to,O
particles,O
and,O
synthetic,O
air,O
.,O
The,O
sampling,O
points,O
(,O
1,O
–,O
3,O
),O
for,O
the,O
test,O
aerosols,O
in,O
the,O
overall,O
stream,O
are,O
marked,O
.,O
Sectional,O
view,O
of,O
the,O
elutriator,O
(,O
a,O
),O
and,O
streamline,O
plot,O
calculated,O
by,O
CFD,O
Analysis,O
(,O
b,O
).,O
Particle,O
track,O
simulation,O
for,O
2,O
μm,O
(,O
a,O
),O
and,O
10,O
μm,O
(,O
b,O
),O
particles,O
.,O
8,O
L,O
/,O
min,O
inlet,O
flow,O
rate,O
(,O
1,O
),O
and,O
1,O
.,O
09,O
L,O
/,O
min,O
outlet,O
low,O
rate,O
(,O
2,O
).,O
(,O
a,O
),O
Backtracking,O
of,O
flow,O
lines,O
from,O
deposition,O
chambers,O
and,O
excess,O
outlet,O
to,O
the,O
beginning,O
of,O
the,O
aerosol,O
feeding,O
tube,O
.,O
(,O
b,O
),O
Flow,O
lines,O
running,O
to,O
the,O
deposition,O
chambers,O
start,O
at,O
specific,O
locations,O
at,O
the,O
beginning,O
of,O
the,O
feeding,O
tube,O
.,O
(,O
a,O
),O
Unequal,O
deposition,O
of,O
copper,O
(,O
II,O
),O
oxide,O
microparticles,O
on,O
filter,O
membranes,O
after,O
a,O
60,O
min,O
exposure,O
.,O
(,O
b,O
),O
Inlet,O
-,O
adapter,O
with,O
an,O
integrated,O
jet,O
nozzle,O
to,O
avoid,O
unequal,O
particle,O
deposition,O
within,O
the,O
CULTEX,O
RFS,O
module,O
.,O
(,O
c,O
),O
Uniform,O
deposition,O
of,O
copper,O
(,O
II,O
),O
oxide,O
on,O
filter,O
membranes,O
after,O
a,O
60,O
min,O
exposure,O
with,O
a,O
jet,O
nozzle,O
.,O
Relative,O
cell,O
viability,O
of,O
A549,O
cells,O
after,O
exposure,O
to,O
lactose,O
monohydrate,O
particles,O
normalized,O
to,O
the,O
clean,O
air,O
control,O
dependent,O
on,O
time,O
(,O
15,O
",",O
30,O
",",O
and,O
60,O
min,O
).,O
Particle,O
number,O
(,O
black,O
line,O
),O
and,O
particle,O
mass,O
distribution,O
(,O
red,O
line,O
),O
of,O
the,O
generated,O
lactose,O
monohydrate,O
aerosol,O
entering,O
the,O
exposure,O
module,O
.,O
The,O
analysis,O
was,O
performed,O
with,O
an,O
Aerodynamic,O
Particle,O
Sizer,O
(,O
TSI,O
Inc,O
.).,O
Relative,O
cell,O
viability,O
of,O
A549,O
cells,O
after,O
exposure,O
to,O
copper,O
(,O
II,O
),O
sulfate,O
particles,O
normalized,O
to,O
the,O
clean,O
air,O
control,O
dependent,O
on,O
time,O
(,O
15,O
",",O
30,O
",",O
and,O
60,O
min,O
).,O
Particle,O
number,O
(,O
black,O
line,O
),O
and,O
particle,O
mass,O
distribution,O
(,O
red,O
line,O
),O
of,O
the,O
generated,O
copper,O
(,O
II,O
),O
sulfate,O
aerosol,O
entering,O
the,O
exposure,O
module,O
.,O
The,O
analysis,O
was,O
performed,O
with,O
an,O
Aerodynamic,O
Particle,O
Sizer,O
(,O
TSI,O
Inc,O
.).,O
Relative,O
cell,O
viability,O
of,O
A549,O
cells,O
after,O
exposure,O
to,O
copper,O
(,O
II,O
),O
oxide,O
microparticles,O
normalized,O
to,O
the,O
clean,O
air,O
control,O
dependent,O
on,O
time,O
(,O
15,O
",",O
30,O
",",O
and,O
60,O
min,O
).,O
Particle,O
number,O
(,O
black,O
line,O
),O
and,O
particle,O
mass,O
distribution,O
(,O
red,O
line,O
),O
of,O
the,O
generated,O
copper,O
(,O
II,O
),O
oxide,O
microaerosol,O
entering,O
the,O
exposure,O
module,O
.,O
The,O
analysis,O
was,O
performed,O
with,O
an,O
Aerodynamic,O
Particle,O
Sizer,O
(,O
TSI,O
Inc,O
.).,O
Relative,O
cell,O
viability,O
of,O
A549,O
cells,O
after,O
exposure,O
to,O
copper,O
(,O
II,O
),O
oxide,O
nanoparticles,O
normalized,O
to,O
the,O
clean,O
air,O
control,O
dependent,O
on,O
time,O
(,O
15,O
",",O
30,O
",",O
and,O
60,O
min,O
).,O
Particle,O
number,O
(,O
black,O
line,O
),O
and,O
particle,O
mass,O
distribution,O
(,O
red,O
line,O
),O
of,O
the,O
generated,O
copper,O
(,O
II,O
),O
oxide,O
nano,O
aerosol,O
entering,O
the,O
exposure,O
module,O
.,O
The,O
analysis,O
was,O
performed,O
with,O
an,O
Aerodynamic,O
Particle,O
Sizer,O
(,O
TSI,O
Inc,O
.).,O
Substances,O
used,O
for,O
the,O
generation,O
of,O
dry,O
powder,O
atmospheres,O
.,O
Substance,O
Producer,O
/,O
catalogue,O
number,O
Primary,O
particle,O
size,O
Lactose,O
monohydrat,O
Fluka,O
/,O
61341,O
Not,O
available,O
Copper,O
(,O
II,O
),O
oxide,O
nano,O
Ionic,O
Liquids,O
Technologies,O
GmbH,O
/,O
NO,O
-,O
0031,O
-,O
HP,O
40,O
–,O
80,O
nm,O
Copper,O
(,O
II,O
),O
oxide,O
mikro,O
Sigma,O
Aldrich,O
/,O
20844,O
-,O
1,O
5,O
μm,O
Copper,O
(,O
II,O
),O
sulfat,O
Sigma,O
Aldrich,O
/,O
12852,O
Not,O
available,O
Conditions,O
for,O
the,O
generation,O
of,O
powder,O
cakes,O
and,O
particulate,O
atmospheres,O
.,O
Substance,O
Powder,O
cake,O
generation,O
Particle,O
generation,O
Pressure,O
(,O
bar,O
),O
Scraper,O
(,O
rev,O
/,O
h,O
),O
Feed,O
rate,O
(,O
mm,O
/,O
h,O
),O
Lactose,O
monohydrat,O
110,O
800,O
10,O
.,O
0,O
Copper,O
(,O
II,O
),O
oxide,O
nano,O
82,O
800,O
2,O
.,O
5,O
Copper,O
(,O
II,O
),O
oxide,O
micro,O
82,O
800,O
2,O
.,O
0,O
Copper,O
(,O
II,O
),O
sulfate,O
82,O
800,O
4,O
.,O
5,O
Deposition,O
of,O
copper,O
(,O
II,O
),O
oxide,O
microparticles,O
on,O
filter,O
membranes,O
after,O
an,O
exposure,O
time,O
of,O
60,O
minutes,O
with,O
a,O
jet,O
nozzle,O
in,O
the,O
inlet,O
adapter,O
.,O
60,O
minutes,O
exposure,O
of,O
copper,O
(,O
II,O
),O
oxide,O
Chamber,O
1,O
Chamber,O
2,O
Chamber,O
3,O
Weight,O
gain,O
of,O
filter,O
paper,O
(,O
μg,O
),O
530,O
529,O
549,O
Weight,O
gain,O
of,O
filter,O
paper,O
(,O
μg,O
),O
529,O
537,O
521,O
Weight,O
gain,O
of,O
filter,O
paper,O
(,O
μg,O
),O
548,O
553,O
548,O
Exposure,O
systems,O
for,O
exposing,O
cultivated,O
cells,O
at,O
the,O
air,O
-,O
liquid,O
interface,O
.,O
Exposure,O
system,O
Electrostatic,O
precipitation,O
Cell,O
type,O
Test,O
atmosphere,O
Literature,O
Cultex,O
CG,O
No,O
LK004HFBE,O
-,O
21CHO,O
-,O
K1A549BEAS,O
-,O
2B,O
Cigarette,O
smokeDiesel,O
exhaust,O
Ozone,O
and,O
nitrogene,O
dioxidePhosgeneVolatile,O
organic,O
compoundsPharmaceuticalsTrichloramineFly,O
ashParticles,O
Aufderheide,O
and,O
Mohr,O
1999,O
[,O
12,O
],O
Ritter,O
et,O
al,O
.,O
2001,O
[,O
46,O
],O
Knebel,O
et,O
al,O
.,O
2002,O
[,O
47,O
],O
Diabaté,O
et,O
al,O
.,O
2008,O
[,O
48,O
],O
Pariselli,O
et,O
al,O
.,O
2009,O
[,O
49,O
],O
Deschl,O
et,O
al,O
.,O
2011,O
[,O
50,O
],O
Schmalz,O
et,O
al,O
.,O
2011,O
[,O
51,O
],O
Wijte,O
et,O
al,O
.,O
2011,O
[,O
52,O
],O
Nara,O
et,O
al,O
.,O
[,O
53,O
],O
Elihn,O
et,O
al,O
.,O
2012,O
[,O
54,O
],O
Cultex,O
RFS,O
Yes,O
A54916HBE14o,O
-,O
Cigarette,O
smoke,O
Aufderheide,O
et,O
al,O
.,O
2011,O
[,O
17,O
],O
ALICE,O
No,O
A549,O
Carbon,O
black,O
nanoparticlesZinc,O
oxide,O
nanoparticlesGold,O
nanoparticles,O
Lenz,O
et,O
al,O
.,O
2009,O
[,O
14,O
],O
NACIVT,O
Yes,O
BEAS,O
-,O
2BPorcine,O
lung,O
macrophages,O
Secondary,O
organic,O
aerosolsPolystyrene,O
particles,O
Gaschen,O
et,O
al,O
.,O
2010,O
[,O
55,O
],O
Savi,O
et,O
al,O
.,O
2008,O
[,O
16,O
],O
Vitrocell,O
No,O
A549,O
Laser,O
printer,O
emissionsVolatile,O
organic,O
compoundsCarbon,O
nanotubes,O
Tang,O
et,O
al,O
.,O
2012,O
[,O
56,O
],O
Frohlich,O
et,O
al,O
.,O
2012,O
[,O
57,O
],O
Anderson,O
et,O
al,O
.,O
2010,O
[,O
58,O
],O
Gminski,O
et,O
al,O
.,O
2011,O
[,O
59,O
],O
BAT,O
No,O
NCI,O
-,O
H292,O
Cigarette,O
smoke,O
Phillips,O
et,O
al,O
.,O
2005,O
[,O
35,O
],O
EAVES,O
Yes,O
A549,O
Polystyrene,O
particlesDiesel,O
exhaustCoarse,O
ambient,O
particles,O
de,O
Bruijne,O
et,O
al,O
.,O
2009,O
[,O
15,O
],O
Volckens,O
et,O
al,O
.,O
2009,O
[,O
60,O
],O
Complex,O
Admixture,O
Preceded,O
and,O
Followed,O
the,O
Extinction,O
of,O
Wisent,B-OG
in,O
the,O
Wild,O
Retracing,O
complex,O
population,O
processes,O
that,O
precede,O
extreme,O
bottlenecks,O
may,O
be,O
impossible,O
using,O
data,O
from,O
living,O
individuals,O
.,O
The,O
wisent,B-OG
(,O
Bison,B-OG
bonasus,I-OG
"),",O
Europe,O
’,O
s,O
largest,O
terrestrial,O
mammal,B-OG
",",O
exemplifies,O
such,O
a,O
population,O
history,O
",",O
having,O
gone,O
extinct,O
in,O
the,O
wild,O
but,O
subsequently,O
restored,O
by,O
captive,O
breeding,O
efforts,O
.,O
Using,O
low,O
coverage,O
genomic,O
data,O
from,O
modern,O
and,O
historical,O
individuals,O
",",O
we,O
investigate,O
population,O
processes,O
occurring,O
before,O
and,O
after,O
this,O
extinction,O
.,O
Analysis,O
of,O
aligned,O
genomes,O
supports,O
the,O
division,O
of,O
wisent,B-OG
into,O
two,O
previously,O
recognized,O
subspecies,O
",",O
but,O
almost,O
half,O
of,O
the,O
genomic,O
alignment,O
contradicts,O
this,O
population,O
history,O
as,O
a,O
result,O
of,O
incomplete,O
lineage,O
sorting,O
and,O
admixture,O
.,O
Admixture,O
between,O
subspecies,O
populations,O
occurred,O
prior,O
to,O
extinction,O
and,O
subsequently,O
during,O
the,O
captive,O
breeding,O
program,O
.,O
Admixture,O
with,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
is,O
also,O
widespread,O
but,O
results,O
from,O
ancient,O
events,O
rather,O
than,O
recent,O
hybridization,O
with,O
domestics,O
.,O
Our,O
study,O
demonstrates,O
the,O
huge,O
potential,O
of,O
historical,O
genomes,O
for,O
both,O
studying,O
evolutionary,O
histories,O
and,O
for,O
guiding,O
conservation,O
strategies,O
.,O
Introduction,O
The,O
last,O
known,O
wild,O
wisent,B-OG
",",O
or,O
European,B-OG
bison,I-OG
(,O
Bison,B-OG
bonasus,I-OG
"),",O
was,O
shot,O
and,O
killed,O
in,O
1927,O
",",O
marking,O
the,O
extinction,O
of,O
this,O
species,O
in,O
the,O
wild,O
(,O
Pucek,O
1991,O
).,O
As,O
a,O
result,O
of,O
an,O
intensive,O
captive,O
breeding,O
program,O
and,O
a,O
series,O
of,O
re,O
-,O
establishments,O
",",O
today,O
the,O
species,O
again,O
occupies,O
part,O
of,O
its,O
former,O
range,O
in,O
Central,O
and,O
Eastern,O
Europe,O
.,O
The,O
total,O
population,O
of,O
free,O
-,O
ranging,O
wisent,B-OG
now,O
stands,O
at,O
over,O
5,O
",",O
000,O
individuals,O
(,O
Raczyński,O
2014,O
"),",O
and,O
the,O
International,O
Union,O
for,O
Conservation,O
of,O
Nature,O
has,O
downgraded,O
the,O
conservation,O
status,O
of,O
wisent,B-OG
to,O
threatened,O
(,O
Olech,O
2008,O
).,O
In,O
historical,O
times,O
",",O
wisent,B-OG
ranged,O
extensively,O
across,O
semi,O
-,O
open,O
habitats,O
and,O
broadleaved,O
",",O
mixed,O
and,O
coniferous,O
forests,O
in,O
Western,O
Europe,O
",",O
from,O
what,O
is,O
today,O
France,O
in,O
the,O
west,O
to,O
the,O
Volga,O
River,O
and,O
the,O
Caucasus,O
in,O
the,O
east,O
",",O
with,O
the,O
northernmost,O
range,O
limits,O
around,O
60,O
°,O
north,O
(,O
fig,O
.,O
1,O
;,O
Kuemmerle,O
et,O
al,O
.,O
2011,O
;,O
Kerley,O
et,O
al,O
.,O
2012,O
;,O
Bocherens,O
et,O
al,O
.,O
2015,O
).,O
However,O
",",O
ongoing,O
habitat,O
fragmentation,O
and,O
overhunting,O
eradicated,O
most,O
populations,O
.,O
By,O
the,O
end,O
of,O
the,O
19th,O
century,O
",",O
there,O
were,O
only,O
two,O
populations,O
of,O
wisent,B-OG
left,O
in,O
the,O
wild,O
that,O
were,O
assigned,O
to,O
separate,O
subspecies,O
:,O
in,O
Białowieża,O
Forest,O
(,O
Lowland,B-OG
wisent,I-OG
",",O
B,B-OG
.,I-OG
b,I-OG
.,I-OG
bonasus,I-OG
),O
and,O
in,O
the,O
western,O
Caucasus,O
Mountains,O
(,O
Caucasian,B-OG
wisent,I-OG
",",O
B,B-OG
.,I-OG
b,I-OG
.,I-OG
caucasicus,I-OG
).,O
Finally,O
",",O
even,O
these,O
populations,O
collapsed,O
;,O
the,O
last,O
wild,O
Lowland,B-OG
wisent,I-OG
was,O
shot,O
in,O
Poland,O
in,O
1919,O
followed,O
by,O
the,O
last,O
Caucasian,O
animal,B-OG
in,O
1927,O
(,O
Pucek,O
1991,O
).,O
Fig,O
.,O
1Map,O
of,O
Western,O
Europe,O
showing,O
the,O
putative,O
historical,O
range,O
of,O
Lowland,B-OG
wisent,I-OG
(,O
shaded,O
green,O
),O
and,O
Caucasian,B-OG
wisent,I-OG
(,O
shaded,O
grey,O
),O
based,O
on,O
bone,O
remains,O
and,O
written,O
records,O
(,O
according,O
to,O
Benecke,O
2005,O
;,O
Kuemmerle,O
et,O
al,O
.,O
2011,O
;,O
Tokarska,O
et,O
al,O
.,O
2011,O
;,O
Bocherens,O
et,O
al,O
.,O
2015,O
),O
and,O
sample,O
locations,O
.,O
Black,O
circles,O
indicate,O
contemporary,O
free,O
-,O
ranging,O
modern,O
L,O
line,O
herds,O
and,O
white,O
circles,O
indicate,O
modern,O
LC,O
line,O
herds,O
.,O
Purple,O
and,O
peach,O
circles,O
denote,O
the,O
locations,O
of,O
investigated,O
modern,O
L,O
(,O
MdL1,O
",",O
MdL2,O
),O
and,O
LC,O
(,O
MdLC,O
),O
line,O
wisent,B-OG
",",O
respectively,O
",",O
orange,O
squares,O
show,O
the,O
location,O
of,O
the,O
Holocene,O
Lowland,B-OG
wisent,I-OG
(,O
Bb1,O
–,O
3,O
),O
and,O
blue,O
and,O
yellow,O
triangles,O
indicate,O
historical,O
founding,O
wisent,B-OG
from,O
the,O
Pszczyna,O
population,O
(,O
PLANTA,O
and,O
PLATEN,O
),O
and,O
the,O
extinct,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc1,O
–,O
3,O
"),",O
respectively,O
.,O
In,O
1924,O
",",O
the,O
captive,O
population,O
consisted,O
of,O
only,O
54,O
individuals,O
(,O
29,O
males,O
and,O
25,O
females,O
).,O
However,O
",",O
the,O
actual,O
founding,O
captive,O
population,O
of,O
wisent,B-OG
was,O
considerably,O
smaller,O
",",O
and,O
is,O
thought,O
to,O
comprise,O
of,O
just,O
12,O
individuals,O
(,O
Slatis,O
1960,O
).,O
All,O
but,O
one,O
of,O
these,O
12,O
founders,O
were,O
Lowland,B-OG
wisent,I-OG
",",O
almost,O
half,O
of,O
which,O
came,O
from,O
a,O
population,O
established,O
in,O
1865,O
in,O
Pless,O
(,O
now,O
Pszczyna,O
",",O
Poland,O
).,O
The,O
remaining,O
founder,O
was,O
a,O
Caucasian,B-OG
wisent,I-OG
bull,I-OG
named,O
M100,O
KAUKASUS,O
that,O
represented,O
the,O
last,O
surviving,O
pure,O
Caucasian,B-OG
wisent,I-OG
in,O
captivity,O
.,O
The,O
modern,O
herds,O
that,O
are,O
derived,O
from,O
this,O
founding,O
population,O
are,O
managed,O
as,O
two,O
separate,O
genetic,O
lines,O
.,O
The,O
Lowland,O
line,O
(,O
L,O
),O
derives,O
from,O
seven,O
Lowland,O
founders,O
(,O
4,O
males,O
and,O
3,O
females,O
"),",O
and,O
is,O
thus,O
considered,O
to,O
represent,O
a,O
pure,O
Lowland,B-OG
wisent,I-OG
lineage,O
.,O
The,O
Lowland,O
-,O
Caucasian,O
(,O
LC,O
),O
line,O
originates,O
from,O
all,O
12,O
founders,O
(,O
5,O
males,O
",",O
7,O
females,O
"),",O
which,O
included,O
the,O
last,O
remaining,O
Caucasian,B-OG
wisent,I-OG
bull,I-OG
(,O
Slatis,O
1960,O
).,O
Descendants,O
of,O
the,O
LC,O
line,O
thus,O
represent,O
a,O
mixture,O
of,O
Lowland,O
and,O
Caucasian,B-OG
wisent,I-OG
ancestry,O
.,O
Although,O
the,O
wisent,B-OG
restitution,O
undoubtedly,O
represents,O
a,O
tremendous,O
conservation,O
success,O
",",O
several,O
factors,O
may,O
limit,O
the,O
long,O
-,O
term,O
viability,O
of,O
the,O
species,O
",",O
many,O
of,O
which,O
are,O
applicable,O
to,O
ex,O
-,O
situ,O
conservation,O
strategies,O
in,O
general,O
.,O
A,O
factor,O
that,O
has,O
received,O
particular,O
attention,O
is,O
that,O
of,O
reduced,O
genetic,O
variability,O
",",O
which,O
may,O
be,O
correlated,O
with,O
a,O
lowered,O
resistance,O
to,O
disease,O
and,O
parasites,O
in,O
wisent,B-OG
(,O
Karbowiak,O
et,O
al,O
.,O
2014a,O
",",O
b,O
;,O
Majewska,O
et,O
al,O
.,O
2014,O
;,O
Panasiewicz,O
et,O
al,O
.,O
2015,O
"),",O
and,O
also,O
seriously,O
impacts,O
conservation,O
programs,O
for,O
other,O
threatened,O
species,O
(,O
Altizer,O
et,O
al,O
.,O
2007,O
).,O
Although,O
genetic,O
variability,O
among,O
living,O
wisent,B-OG
herds,O
has,O
been,O
widely,O
investigated,O
using,O
a,O
variety,O
of,O
genetic,O
markers,O
(,O
Gralak,O
et,O
al,O
.,O
2004,O
;,O
Luenser,O
et,O
al,O
.,O
2005,O
;,O
Radwan,O
et,O
al,O
.,O
2007,O
;,O
Wójcik,O
et,O
al,O
.,O
2009,O
;,O
Babik,O
et,O
al,O
.,O
2012,O
;,O
Tokarska,O
",",O
Kawałko,O
",",O
et,O
al,O
.,O
2009,O
;,O
Tokarska,O
",",O
Marshall,O
",",O
et,O
al,O
.,O
2009,O
;,O
Tokarska,O
et,O
al,O
.,O
2015,O
"),",O
studies,O
at,O
the,O
level,O
of,O
the,O
complete,O
genome,O
have,O
been,O
far,O
less,O
frequent,O
.,O
A,O
recent,O
study,O
(,O
Gautier,O
et,O
al,O
.,O
2016,O
),O
presented,O
moderate,O
-,O
coverage,O
(∼,O
10,O
×),O
genomic,O
data,O
from,O
two,O
modern,O
L,O
line,O
wisent,B-OG
.,O
They,O
found,O
levels,O
of,O
heterozygosity,O
in,O
these,O
individuals,O
to,O
be,O
similar,O
to,O
that,O
found,O
in,O
modern,O
domestic,B-OG
cow,I-OG
breeds,O
.,O
However,O
",",O
levels,O
of,O
genetic,O
variability,O
occurring,O
prior,O
to,O
extinction,O
of,O
wisent,B-OG
in,O
the,O
wild,O
",",O
and,O
any,O
potential,O
loss,O
of,O
genetic,O
variability,O
following,O
the,O
establishment,O
of,O
the,O
captive,O
breeding,O
population,O
",",O
remains,O
unquantified,O
.,O
A,O
second,O
threat,O
for,O
wisent,B-OG
is,O
potential,O
hybridization,O
with,O
domestic,B-OG
cattle,I-OG
(,O
Bos,B-OG
taurus,I-OG
).,O
Although,O
F1,O
hybrid,O
bulls,B-OG
are,O
sterile,O
",",O
hybrid,O
female,O
offspring,O
are,O
not,O
(,O
Basrur,O
1968,O
"),",O
and,O
would,O
therefore,O
have,O
the,O
potential,O
to,O
reintegrate,O
back,O
into,O
the,O
wild,O
population,O
.,O
The,O
bison,B-OG
lineage,O
(,O
including,O
wisent,B-OG
",",O
American,B-OG
bison,I-OG
and,O
the,O
extinct,O
steppe,B-OG
bison,I-OG
),O
is,O
thought,O
to,O
have,O
diverged,O
from,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
around,O
0,O
.,O
85,O
–,O
1,O
.,O
7,O
YBP,O
",",O
and,O
likely,O
included,O
an,O
extended,O
period,O
of,O
geneflow,O
(,O
Gautier,O
et,O
al,O
.,O
2016,O
).,O
Analysis,O
of,O
genomic,O
data,O
from,O
modern,O
wisent,B-OG
has,O
suggested,O
",",O
in,O
addition,O
",",O
more,O
recent,O
admixture,O
between,O
wisent,B-OG
and,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
(,O
Gautier,O
et,O
al,O
.,O
2016,O
).,O
However,O
",",O
the,O
timing,O
of,O
admixture,O
",",O
in,O
particular,O
whether,O
it,O
preceded,O
or,O
followed,O
the,O
establishment,O
of,O
the,O
captive,O
breeding,O
program,O
",",O
remains,O
uncertain,O
.,O
Such,O
information,O
is,O
critical,O
to,O
assess,O
the,O
magnitude,O
of,O
the,O
threat,O
that,O
domestic,B-OG
cattle,I-OG
admixture,O
represents,O
to,O
the,O
long,O
term,O
viability,O
and,O
integrity,O
of,O
living,O
wisent,B-OG
populations,O
.,O
Here,O
we,O
present,O
low,O
-,O
coverage,O
whole,O
genome,O
sequencing,O
data,O
from,O
modern,O
and,O
historical,O
wisent,B-OG
",",O
including,O
representatives,O
from,O
both,O
modern,O
genetic,O
lines,O
",",O
from,O
the,O
original,O
founding,O
population,O
",",O
and,O
from,O
the,O
extinct,O
Caucasian,B-OG
wisent,I-OG
subspecies,O
.,O
Using,O
these,O
data,O
",",O
we,O
are,O
able,O
to,O
track,O
changes,O
in,O
genetic,O
variability,O
through,O
the,O
wisent,B-OG
extinction,O
and,O
their,O
subsequent,O
restitution,O
.,O
Furthermore,O
",",O
by,O
inclusion,O
of,O
historical,O
individuals,O
",",O
we,O
not,O
only,O
detect,O
admixture,O
between,O
wisent,B-OG
subspecies,O
and,O
between,O
wisent,B-OG
and,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
",",O
but,O
also,O
place,O
these,O
events,O
along,O
an,O
absolute,O
timescale,O
of,O
pre,O
-,O
or,O
post,O
-,O
extinction,O
age,O
.,O
Our,O
results,O
demonstrate,O
the,O
huge,O
potential,O
of,O
genomic,O
approaches,O
",",O
in,O
particular,O
applied,O
to,O
historical,O
samples,O
",",O
for,O
studying,O
evolutionary,O
histories,O
and,O
also,O
for,O
the,O
conservation,O
management,O
of,O
endangered,O
species,O
.,O
Results,O
Sequencing,O
of,O
Wisent,B-OG
Genomes,O
We,O
conducted,O
shotgun,O
sequencing,O
of,O
wisent,B-OG
genomes,O
using,O
Illumina,O
technology,O
and,O
mapped,O
the,O
resulting,O
sequence,O
reads,O
to,O
the,O
reference,O
genome,O
assembly,O
of,O
the,O
Asian,B-OG
water,I-OG
buffalo,I-OG
",",O
Bubalus,B-OG
bubalis,I-OG
(,O
GenBank,O
accession,O
no,O
.,O
GCA_000471725,O
.,O
1,O
"),",O
which,O
represents,O
an,O
outgroup,O
to,O
the,O
wisent,B-OG
/,O
Bos,B-OG
cattle,B-OG
lineage,O
(,O
supplementary,O
fig,O
.,O
S1,O
",",O
supplementary,O
material,O
online,O
;,O
Hassanin,O
et,O
al,O
.,O
2012,O
",",O
2013,O
).,O
Although,O
the,O
reference,O
genome,O
assembly,O
of,O
Bos,B-OG
taurus,I-OG
would,O
provide,O
a,O
more,O
complete,O
assembly,O
and,O
evolutionarily,O
less,O
-,O
diverged,O
reference,O
for,O
mapping,O
",",O
we,O
did,O
not,O
use,O
this,O
reference,O
at,O
it,O
may,O
have,O
led,O
to,O
biased,O
estimates,O
of,O
admixture,O
between,O
wisent,B-OG
and,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
",",O
in,O
particular,O
at,O
lower,O
levels,O
of,O
genomic,O
coverage,O
.,O
In,O
total,O
",",O
we,O
sequenced,O
seven,O
individuals,O
that,O
we,O
divide,O
into,O
three,O
categories,O
.,O
Detailed,O
sample,O
information,O
",",O
including,O
provenance,O
",",O
is,O
provided,O
in,O
table,O
1,O
and,O
sample,O
localities,O
are,O
shown,O
in,O
fig,O
.,O
1,O
.,O
Table,O
1Basic,O
Information,O
about,O
Sampled,O
Individuals,O
.,O
Sample,O
CodeSample,O
NameTaxonGroupSample,O
LocationSample,O
OriginTissue,O
TypeYear,O
of,O
Death,O
*/,O
Radiocarbon,O
AgeWater,B-OG
Buffalo,I-OG
nDNA,O
Mapping,O
Coverage,O
/,O
mtDNA,O
CoverageMdL1Z3Bison,O
bonasusModern,O
Lowland,O
line,O
(,O
L,O
),O
Białowieża,O
Forest,O
",",O
Polish,O
part,O
",",O
PolandKidney20061,O
.,O
59,O
(,O
n,O
),O
MdL2868Białowieża,O
Forest,O
",",O
Belarusian,O
part,O
",",O
BelarusMuscles20091,O
.,O
63,O
(,O
n,O
),O
MdLCDyModern,O
Lowland,O
-,O
Caucasian,O
line,O
(,O
LC,O
),O
Dydiowa,O
",",O
Bieszczady,O
Mountains,O
",",O
PolandMuscles20121,O
.,O
49,O
(,O
n,O
),O
PLANTAF42,O
PLANTABison,O
b,O
.,O
bonasusFoundersPszczyna,O
",",O
PolandUpper,O
Silesian,O
Museum,O
",",O
Bytom,O
",",O
PolandHorns19311,O
.,O
50,O
(,O
n,O
),O
PLATENM158,O
PLATEN19331,O
.,O
39,O
(,O
n,O
),O
Cc18853Bison,B-OG
b,I-OG
.,I-OG
caucasicusCaucasian,I-OG
wisentKuban,O
Oblast,O
",",O
RussiaZoological,O
Institute,O
RAS,O
",",O
Sankt,O
Petersburg,O
",",O
RussiaSkull,O
bones1911,O
*,O
1,O
.,O
07,O
(,O
n,O
),O
Cc222533North,O
Ossetia,O
-,O
Alania,O
",",O
RussiaState,O
Darwin,O
Museum,O
",",O
Moscow,O
",",O
Russia1949,O
*,O
0,O
.,O
92,O
(,O
n,O
),O
Cc3AF005Holocene,O
Caucasian,O
wisentSevan,O
Lake,O
region,O
",",O
ArmeniaHorn,O
core14C,O
:,O
4972,O
±,O
2958,O
.,O
10,O
(,O
mt,O
),O
OxA,O
-,O
319355724,O
–,O
5657Bb1BS587Bison,O
b,O
.,O
bonasusHolocene,O
Lowland,B-OG
wisentStyria,I-OG
",",O
AustriaVMNH,O
H,O
-,O
1981,O
-,O
28,O
-,O
6Tibia14C,O
:,O
1480,O
±,O
70115,O
.,O
56,O
(,O
mt,O
),O
VERA,O
01451511,O
–,O
1302Bb2BS589VMNH,O
H,O
-,O
1977,O
-,O
49,O
-,O
1Femur14C,O
:,O
1980,O
±,O
45165,O
.,O
75,O
(,O
mt,O
),O
VERA,O
01421987,O
–,O
1886Bb3BS607Upper,O
Austria,O
",",O
AustriaVMNH,O
H,O
-,O
1979,O
-,O
48,O
-,O
1Femur14C,O
:,O
1370,O
±,O
5014,O
.,O
10,O
(,O
mt,O
),O
VERA,O
01431338,O
-,O
1265Note,O
.—,O
The,O
last,O
column,O
is,O
the,O
average,O
coverage,O
for,O
each,O
sample,O
after,O
mapping,O
it,O
to,O
either,O
the,O
water,B-OG
buffalo,I-OG
(,O
Bubalus,B-OG
bubalis,I-OG
),O
nuclear,O
reference,O
genome,O
(,O
GenBank,O
accession,O
no,O
.,O
GCA_000471725,O
.,O
1,O
),O
or,O
the,O
American,B-OG
bison,I-OG
(,O
Bison,B-OG
bison,I-OG
),O
mitochondrial,O
reference,O
genome,O
(,O
GenBank,O
accession,O
no,O
.,O
NC_012346,O
.,O
1,O
).*,O
For,O
Caucasian,O
individuals,O
(,O
Cc1,O
",",O
Cc2,O
),O
year,O
of,O
collecting,O
the,O
sample,O
is,O
given,O
.,O
VNHM,O
",",O
Vienna,O
Museum,O
of,O
Natural,O
History,O
.,O
n,O
;,O
nuclear,O
",",O
mt,O
;,O
mitochondrial,O
.,O
Radiocarbon,O
dates,O
include,O
the,O
14C,O
age,O
(,O
years,O
before,O
present,O
;,O
yr,O
BP,O
"),",O
14C,O
accession,O
(,O
where,O
known,O
"),",O
and,O
calibrated,O
age,O
BP,O
(,O
1σ,O
).,O
Calibrated,O
dates,O
follow,O
the,O
IntCal13,O
calibration,O
curve,O
.,O
Modern,O
wisent,B-OG
—,O
three,O
modern,O
individuals,O
representing,O
both,O
genetic,O
lines,O
.,O
These,O
comprise,O
two,O
individuals,O
from,O
the,O
L,O
line,O
(,O
MdL1,O
",",O
mean,O
read,O
depth,O
1,O
.,O
59,O
×;,O
and,O
MdL2,O
",",O
mean,O
read,O
depth,O
1,O
.,O
63,O
×;,O
from,O
the,O
Polish,O
and,O
Belarusian,O
parts,O
of,O
the,O
Białowieża,O
Forest,O
",",O
respectively,O
),O
and,O
one,O
individual,O
from,O
the,O
LC,O
line,O
(,O
MdLC,O
",",O
from,O
Dydiowa,O
in,O
the,O
Bieszczady,O
Mountains,O
",",O
mean,O
read,O
depth,O
1,O
.,O
49,O
×).,O
Founding,O
wisent,B-OG
—,O
two,O
individuals,O
assignable,O
to,O
the,O
Lowland,B-OG
wisent,I-OG
subspecies,O
B,B-OG
.,I-OG
b,I-OG
.,I-OG
bonasus,I-OG
from,O
the,O
initial,O
breeding,O
population,O
originating,O
from,O
Pszczyna,O
",",O
both,O
of,O
which,O
contributed,O
to,O
the,O
establishment,O
of,O
both,O
the,O
L,O
and,O
the,O
LC,O
genetic,O
lines,O
:,O
foundress,O
F42,O
PLANTA,O
(,O
1904,O
–,O
1931,O
",",O
mean,O
read,O
depth,O
1,O
.,O
82,O
×),O
and,O
her,O
male,O
offspring,O
",",O
M158,O
PLATEN,O
(,O
1926,O
–,O
1933,O
",",O
mean,O
read,O
depth,O
1,O
.,O
36,O
"×),",O
who,O
was,O
fathered,O
by,O
another,O
founder,O
M45,O
PLEBEJER,O
(,O
1917,O
–,O
1937,O
).,O
Caucasian,B-OG
wisent,I-OG
—,O
two,O
individuals,O
from,O
the,O
early,O
1900,O
',O
s,O
representing,O
the,O
now,O
extinct,O
Caucasian,B-OG
wisent,I-OG
subspecies,O
B,B-OG
.,I-OG
b,I-OG
.,I-OG
caucasicus,I-OG
(,O
Cc1,O
",",O
from,O
Kuban,O
Oblast,O
",",O
mean,O
read,O
depth,O
1,O
.,O
17,O
×;,O
and,O
Cc2,O
",",O
from,O
North,O
Ossetia,O
-,O
Alania,O
",",O
mean,O
read,O
depth,O
0,O
.,O
92,O
×).,O
For,O
each,O
individual,O
",",O
we,O
collapsed,O
mapped,O
reads,O
into,O
a,O
single,O
pseudo,O
-,O
haploid,O
genome,O
sequence,O
by,O
randomly,O
selecting,O
a,O
single,O
high,O
quality,O
nucleotide,O
from,O
the,O
read,O
stack,O
at,O
each,O
position,O
of,O
the,O
reference,O
genome,O
",",O
following,O
the,O
procedure,O
described,O
by,O
Cahill,O
et,O
al,O
.,O
(,O
2013,O
",",O
2015,O
).,O
This,O
procedure,O
disregards,O
heterozygous,O
positions,O
",",O
where,O
only,O
one,O
allele,O
will,O
be,O
sampled,O
",",O
but,O
should,O
not,O
introduce,O
any,O
biases,O
in,O
allele,O
sampling,O
.,O
Ancient,O
DNA,O
fragments,O
frequently,O
contain,O
miscoding,O
lesions,O
resulting,O
from,O
postmortem,O
DNA,O
degradation,O
",",O
the,O
most,O
common,O
of,O
which,O
involves,O
the,O
deamination,O
of,O
cytosine,O
to,O
uracil,O
",",O
which,O
causes,O
C,O
to,O
T,O
substitutions,O
in,O
the,O
resulting,O
data,O
(,O
Dabney,O
",",O
Meyer,O
",",O
et,O
al,O
.,O
2013,O
).,O
This,O
pattern,O
is,O
present,O
at,O
varying,O
levels,O
in,O
sequence,O
data,O
from,O
our,O
historical,O
samples,O
(,O
supplementary,O
fig,O
.,O
S2,O
–,O
S5,O
",",O
Supplementary,O
Material,O
online,O
"),",O
and,O
so,O
we,O
restricted,O
all,O
subsequent,O
analyses,O
to,O
transversion,O
sites,O
only,O
to,O
avoid,O
any,O
confounding,O
effects,O
of,O
DNA,O
damage,O
.,O
Genomic,O
Divergence,O
We,O
investigated,O
patterns,O
of,O
nuclear,O
genomic,O
divergence,O
among,O
wisent,B-OG
by,O
conducting,O
pairwise,O
comparisons,O
of,O
the,O
number,O
of,O
transversion,O
differences,O
occurring,O
along,O
a,O
sliding,O
window,O
of,O
1,O
Mb,O
",",O
producing,O
a,O
distribution,O
of,O
genomic,O
divergence,O
for,O
each,O
wisent,B-OG
pair,O
.,O
The,O
resulting,O
probability,O
densities,O
showed,O
that,O
nuclear,O
genomic,O
divergence,O
is,O
broadly,O
similar,O
among,O
all,O
modern,O
and,O
founding,O
wisent,B-OG
(,O
fig,O
.,O
2A,O
).,O
The,O
two,O
founding,O
individuals,O
",",O
PLANTA,O
and,O
PLATEN,O
",",O
are,O
somewhat,O
less,O
diverged,O
from,O
one,O
another,O
than,O
either,O
is,O
from,O
all,O
modern,O
wisent,B-OG
(,O
fig,O
.,O
2A,O
"),",O
reflecting,O
their,O
mother,O
-,O
son,O
relationship,O
.,O
Slightly,O
increased,O
divergence,O
is,O
observed,O
between,O
the,O
modern,O
LC,O
line,O
individual,O
(,O
MdLC,O
),O
and,O
all,O
modern,O
and,O
founding,O
wisent,B-OG
(,O
fig,O
.,O
2A,O
"),",O
which,O
may,O
reflect,O
the,O
increased,O
component,O
of,O
Caucasian,B-OG
wisent,I-OG
ancestry,O
in,O
this,O
individual,O
resulting,O
from,O
the,O
captive,O
breeding,O
program,O
.,O
Fig,O
.,O
2Pairwise,O
genomic,O
divergence,O
among,O
wisent,B-OG
.,O
A,O
",",O
B,O
",",O
C,O
",",O
show,O
probability,O
densities,O
for,O
pairwise,O
transversion,O
divergence,O
(,O
x,O
axes,O
),O
along,O
a,O
sliding,O
window,O
of,O
1,O
Mb,O
.,O
Individual,O
plots,O
show,O
all,O
pairwise,O
comparisons,O
among,O
modern,O
and,O
founding,O
individuals,O
(,O
A,O
);,O
comparisons,O
of,O
modern,O
and,O
founding,O
individuals,O
and,O
Caucasian,B-OG
wisent,I-OG
Cc1,O
(,O
B,O
);,O
and,O
comparisons,O
of,O
Caucasian,B-OG
wisent,I-OG
Cc2,O
and,O
all,O
other,O
individuals,O
(,O
C,O
).,O
Specific,O
comparisons,O
discussed,O
in,O
the,O
text,O
are,O
identified,O
by,O
colors,O
",",O
according,O
to,O
the,O
key,O
at,O
the,O
top,O
right,O
of,O
each,O
plot,O
.,O
Schematic,O
neighbor,O
-,O
joining,O
phylogeny,O
based,O
on,O
whole,O
genome,O
distances,O
(,O
D,O
).,O
Genomic,O
divergence,O
between,O
Caucasian,O
and,O
both,O
modern,O
and,O
founding,O
wisent,B-OG
greatly,O
exceeds,O
that,O
occurring,O
between,O
the,O
latter,O
two,O
groups,O
(,O
fig,O
.,O
2A,O
–,O
C,O
).,O
Substantial,O
divergence,O
is,O
also,O
found,O
between,O
the,O
two,O
Caucasian,B-OG
wisent,I-OG
individuals,O
.,O
One,O
of,O
these,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc1,O
),O
was,O
found,O
to,O
be,O
less,O
diverged,O
from,O
modern,O
and,O
founding,O
wisent,B-OG
than,O
other,O
Caucasian,B-OG
wisent,I-OG
individual,O
(,O
Cc2,O
"),",O
suggesting,O
the,O
presence,O
of,O
not,O
only,O
substantial,O
genetic,O
diversity,O
but,O
also,O
substantial,O
population,O
structure,O
in,O
the,O
extinct,O
Caucasian,B-OG
wisent,I-OG
subspecies,O
.,O
We,O
also,O
investigated,O
mitochondrial,O
genome,O
variability,O
among,O
all,O
individuals,O
subjected,O
to,O
nuclear,O
genome,O
sequencing,O
",",O
in,O
addition,O
to,O
seven,O
other,O
modern,O
wisent,B-OG
(,O
supplementary,O
table,O
S1,O
",",O
Supplementary,O
Material,O
online,O
).,O
Sequence,O
analysis,O
revealed,O
that,O
all,O
investigated,O
modern,O
wisent,B-OG
",",O
both,O
founding,O
wisent,B-OG
",",O
and,O
a,O
single,O
historical,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc1,O
"),",O
share,O
a,O
single,O
haplotype,O
.,O
The,O
haplotype,O
occurring,O
in,O
the,O
second,O
historical,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc2,O
),O
differed,O
from,O
this,O
widely,O
shared,O
haplotype,O
by,O
a,O
single,O
transition,O
site,O
.,O
These,O
results,O
hint,O
at,O
a,O
major,O
loss,O
of,O
mitochondrial,O
haplotype,O
diversity,O
prior,O
to,O
the,O
extinction,O
of,O
wisent,B-OG
in,O
the,O
wild,O
.,O
This,O
inference,O
is,O
supported,O
by,O
additional,O
haplotypes,O
that,O
we,O
recovered,O
from,O
three,O
ancient,O
late,O
Holocene,O
Lowland,B-OG
wisent,I-OG
from,O
Austria,O
(,O
the,O
range,O
of,O
calibrated,O
age,O
is,O
from,O
ca,O
.,O
1,O
.,O
3,O
kyr,O
to,O
1,O
.,O
9,O
kyr,O
),O
and,O
one,O
ancient,O
middle,O
Holocene,O
Caucasian,B-OG
wisent,I-OG
from,O
Armenia,O
(,O
ca,O
.,O
5,O
.,O
7,O
kyr,O
).,O
All,O
these,O
ancient,O
haplotypes,O
are,O
substantially,O
divergent,O
from,O
those,O
found,O
in,O
modern,O
and,O
historical,O
wisent,B-OG
",",O
suggesting,O
a,O
substantial,O
loss,O
of,O
haplotype,O
diversity,O
",",O
potentially,O
within,O
the,O
last,O
∼,O
1,O
",",O
300,O
years,O
.,O
Neighbor,O
-,O
joining,O
phylogenetic,O
analysis,O
of,O
total,O
nuclear,O
genomic,O
divergence,O
supports,O
paraphyly,O
of,O
Caucasian,B-OG
wisent,I-OG
(,O
fig,O
.,O
2D,O
"),",O
as,O
does,O
analysis,O
of,O
mitochondrial,O
haplotypes,O
(,O
supplementary,O
fig,O
.,O
S1,O
",",O
Supplementary,O
Material,O
online,O
).,O
We,O
further,O
investigated,O
the,O
population,O
history,O
of,O
wisent,B-OG
by,O
dividing,O
aligned,O
nuclear,O
genome,O
sequences,O
into,O
non,O
-,O
overlapping,O
1,O
Mb,O
blocks,O
and,O
subjecting,O
each,O
block,O
to,O
maximum,O
-,O
likelihood,O
phylogenetic,O
analysis,O
.,O
For,O
this,O
analysis,O
",",O
we,O
included,O
both,O
Caucasian,B-OG
wisent,I-OG
and,O
both,O
modern,O
L,O
line,O
wisent,B-OG
as,O
representatives,O
of,O
the,O
Lowland,B-OG
wisent,I-OG
subspecies,O
",",O
with,O
water,B-OG
buffalo,I-OG
as,O
outgroup,O
.,O
Founding,O
wisent,B-OG
and,O
the,O
modern,O
LC,O
line,O
wisent,B-OG
were,O
not,O
included,O
to,O
avoid,O
any,O
confounding,O
effects,O
of,O
direct,O
ancestor,O
-,O
descendent,O
relationships,O
and,O
documented,O
Caucasian,B-OG
wisent,I-OG
introgression,O
(,O
Slatis,O
1960,O
),O
on,O
phylogenetic,O
interpretation,O
",",O
respectively,O
.,O
We,O
found,O
that,O
57,O
%,O
of,O
the,O
investigated,O
genomic,O
blocks,O
support,O
reciprocal,O
monophyly,O
of,O
Caucasian,O
and,O
Lowland,B-OG
wisent,I-OG
(,O
fig,O
.,O
3,O
).,O
We,O
therefore,O
conclude,O
that,O
this,O
most,O
likely,O
represents,O
the,O
true,O
population,O
history,O
.,O
All,O
alternative,O
topologies,O
occur,O
",",O
individually,O
",",O
at,O
a,O
much,O
lower,O
frequency,O
.,O
Nevertheless,O
",",O
almost,O
half,O
of,O
the,O
genome,O
sequence,O
alignment,O
of,O
these,O
individuals,O
contradicts,O
the,O
true,O
population,O
history,O
.,O
Fig,O
.,O
3Population,O
history,O
of,O
Lowland,O
and,O
Caucasian,B-OG
wisent,I-OG
",",O
estimated,O
using,O
two,O
representatives,O
of,O
each,O
.,O
The,O
pie,O
chart,O
shows,O
the,O
percentage,O
of,O
1,O
Mb,O
genomic,O
blocks,O
supporting,O
each,O
alternatively,O
rooted,O
tree,O
topology,O
.,O
This,O
indicates,O
fraction,O
of,O
genome,O
blocks,O
returning,O
both,O
wisent,B-OG
subspecies,O
as,O
reciprocally,O
monophyletic,O
.,O
Dark,O
and,O
light,O
blue,O
colors,O
show,O
the,O
next,O
most,O
frequently,O
encountered,O
topologies,O
in,O
which,O
Caucasian,B-OG
wisent,I-OG
are,O
paraphyletic,O
(,O
dark,O
blue,O
:,O
Cc2,O
most,O
divergent,O
",",O
and,O
light,O
blue,O
:,O
Cc1,O
most,O
divergent,O
",",O
the,O
first,O
of,O
which,O
is,O
compatible,O
with,O
estimates,O
pairwise,O
genomic,O
divergence,O
;,O
see,O
fig,O
2D,O
).,O
In,O
order,O
to,O
interpret,O
wisent,B-OG
genomic,O
divergence,O
in,O
the,O
context,O
of,O
total,O
species,O
genetic,O
diversity,O
",",O
we,O
obtained,O
data,O
from,O
the,O
NCBI,O
Short,O
Read,O
Archive,O
for,O
seven,O
domestic,B-OG
cattle,I-OG
and,O
seven,O
yak,B-OG
(,O
Bos,B-OG
grunniens,I-OG
;,O
supplementary,O
table,O
S4,O
",",O
Supplementary,O
Material,O
online,O
),O
and,O
subjected,O
them,O
to,O
the,O
same,O
analysis,O
pipeline,O
.,O
Genomic,O
divergence,O
among,O
modern,O
wisent,B-OG
was,O
found,O
to,O
be,O
similar,O
to,O
that,O
found,O
among,O
domestic,B-OG
cattle,I-OG
",",O
and,O
exceeded,O
that,O
found,O
among,O
yak,B-OG
(,O
fig,O
.,O
4,O
).,O
We,O
conducted,O
equivalent,O
comparisons,O
for,O
modern,O
wisent,B-OG
and,O
these,O
other,O
bovid,O
species,O
but,O
with,O
the,O
inclusion,O
of,O
transition,O
as,O
well,O
as,O
transversion,O
sites,O
.,O
Interestingly,O
",",O
the,O
distribution,O
of,O
genomic,O
divergence,O
for,O
pairs,O
of,O
wisent,B-OG
was,O
bimodal,O
in,O
all,O
cases,O
(,O
fig,O
.,O
4,O
"),",O
but,O
the,O
relative,O
levels,O
of,O
genomic,O
divergence,O
between,O
species,O
were,O
similar,O
to,O
that,O
measured,O
using,O
only,O
transversion,O
sites,O
.,O
Fig,O
.,O
4Comparison,O
of,O
pairwise,O
genomic,O
divergence,O
within,O
three,O
bovid,O
species,O
:,O
wisent,B-OG
(,O
Bison,B-OG
bonasus,I-OG
"),",O
domestic,B-OG
cattle,I-OG
(,O
Bos,B-OG
taurus,I-OG
"),",O
and,O
yak,B-OG
(,O
Bos,B-OG
grunniens,I-OG
).,O
Probability,O
densities,O
were,O
calculated,O
along,O
a,O
sliding,O
window,O
of,O
1,O
Mb,O
from,O
transversions,O
only,O
(,O
A,O
"),",O
and,O
from,O
transitions,O
and,O
transversions,O
(,O
B,O
).,O
For,O
wisent,B-OG
",",O
only,O
modern,O
samples,O
included,O
.,O
Wisent,B-OG
Geneflow,O
and,O
Admixture,O
We,O
investigated,O
patterns,O
of,O
admixture,O
among,O
wisent,B-OG
using,O
the,O
D,O
statistic,O
test,O
for,O
admixture,O
(,O
Green,O
et,O
al,O
.,O
2010,O
).,O
This,O
test,O
identifies,O
any,O
imbalance,O
in,O
the,O
number,O
of,O
derived,O
alleles,O
that,O
either,O
of,O
two,O
closely,O
related,O
individuals,O
share,O
with,O
a,O
candidate,O
introgressor,O
.,O
A,O
significant,O
excess,O
of,O
derived,O
alleles,O
shared,O
between,O
one,O
individual,O
and,O
the,O
introgressor,O
provides,O
evidence,O
of,O
admixture,O
between,O
them,O
(,O
Durand,O
et,O
al,O
.,O
2011,O
).,O
For,O
all,O
D,O
statistic,O
tests,O
",",O
we,O
used,O
water,B-OG
buffalo,I-OG
(,O
Bubalus,B-OG
bubalis,I-OG
),O
as,O
outgroup,O
for,O
allele,O
polarization,O
.,O
We,O
first,O
investigated,O
patterns,O
of,O
derived,O
allele,O
sharing,O
among,O
modern,O
wisent,B-OG
",",O
and,O
found,O
no,O
statistically,O
significant,O
signal,O
of,O
admixture,O
between,O
the,O
modern,O
LC,O
line,O
individual,O
and,O
either,O
modern,O
L,O
line,O
individual,O
(,O
supplementary,O
table,O
S5,O
",",O
Supplementary,O
Material,O
online,O
).,O
Between,O
modern,O
and,O
founding,O
wisent,B-OG
",",O
we,O
found,O
that,O
modern,O
L,O
line,O
wisent,B-OG
share,O
a,O
significantly,O
greater,O
number,O
of,O
derived,O
alleles,O
with,O
founding,O
wisent,B-OG
than,O
the,O
modern,O
LC,O
line,O
individual,O
does,O
(,O
fig,O
.,O
5A,O
"),",O
indicating,O
a,O
greater,O
contribution,O
of,O
the,O
two,O
founding,O
wisent,B-OG
investigated,O
here,O
to,O
the,O
L,O
line,O
",",O
relative,O
to,O
the,O
LC,O
line,O
",",O
which,O
is,O
consistent,O
with,O
pedigrees,O
(,O
Slatis,O
1960,O
).,O
Fig,O
.,O
5Results,O
of,O
D,O
statistical,O
analysis,O
.,O
Red,O
and,O
grey,O
points,O
show,O
significant,O
and,O
nonsignificant,O
D,O
values,O
(,O
x,O
axis,O
"),",O
respectively,O
",",O
and,O
show,O
:,O
the,O
genetic,O
contribution,O
of,O
the,O
founders,O
(,O
F,O
),O
to,O
the,O
modern,O
individuals,O
(,O
A,O
);,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc,O
),O
admixture,O
with,O
modern,O
L,O
and,O
LC,O
herds,O
(,O
MdL,O
and,O
MdLC,O
),O
and,O
one,O
founder,O
",",O
PLANTA,O
",",O
relative,O
to,O
the,O
least,O
Caucasian,O
admixed,O
wisent,B-OG
",",O
founder,O
PLATEN,O
(,O
B,O
);,O
Caucasian,B-OG
wisent,I-OG
admixture,O
among,O
modern,O
wisent,B-OG
(,O
C,O
);,O
apparent,O
cattle,B-OG
(,O
DC,O
),O
admixture,O
with,O
all,O
investigated,O
wisent,B-OG
(,O
W,O
),O
relative,O
to,O
aurochs,B-OG
(,O
Aur,O
),O
(,O
D,O
);,O
variance,O
in,O
cattle,B-OG
/,O
aurochs,B-OG
admixture,O
among,O
wisent,B-OG
(,O
W,O
),O
compared,O
to,O
PLATEN,O
(,O
E,O
).,O
Detailed,O
D,O
statistic,O
results,O
are,O
provided,O
in,O
supplementary,O
table,O
S5,O
",",O
Supplementary,O
Material,O
online,O
.,O
We,O
then,O
investigated,O
admixture,O
involving,O
Caucasian,B-OG
wisent,I-OG
.,O
We,O
found,O
a,O
significant,O
excess,O
of,O
derived,O
allele,O
sharing,O
between,O
one,O
founding,O
wisent,B-OG
",",O
PLANTA,O
",",O
and,O
one,O
Caucasian,B-OG
wisent,I-OG
",",O
Cc2,O
",",O
relative,O
to,O
the,O
other,O
founding,O
wisent,B-OG
",",O
her,O
son,O
PLATEN,O
(,O
fig,O
.,O
5B,O
).,O
This,O
indicates,O
that,O
a,O
proportion,O
of,O
the,O
genome,O
of,O
PLANTA,O
can,O
be,O
attributed,O
to,O
admixture,O
with,O
Caucasian,B-OG
wisent,I-OG
.,O
Furthermore,O
",",O
we,O
can,O
deduce,O
that,O
PLEBEJER,O
",",O
the,O
father,O
of,O
PLATEN,O
",",O
must,O
have,O
possessed,O
a,O
lower,O
level,O
of,O
Caucasian,B-OG
wisent,I-OG
admixture,O
than,O
PLANTA,O
",",O
and,O
that,O
PLATEN,O
himself,O
was,O
likely,O
admixed,O
to,O
some,O
degree,O
through,O
inheritance,O
from,O
PLANTA,O
.,O
The,O
detection,O
of,O
admixture,O
involving,O
one,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc2,O
),O
but,O
not,O
the,O
other,O
(,O
Cc1,O
),O
further,O
supports,O
the,O
existence,O
of,O
genetic,O
structure,O
in,O
Caucasian,B-OG
wisent,I-OG
inferred,O
from,O
estimates,O
of,O
genomic,O
divergence,O
(,O
fig,O
.,O
2B,O
and,O
C,O
).,O
Next,O
",",O
we,O
investigated,O
evidence,O
of,O
Caucasian,B-OG
wisent,I-OG
admixture,O
among,O
modern,O
wisent,B-OG
.,O
Consistent,O
with,O
expectations,O
",",O
we,O
found,O
that,O
the,O
modern,O
LC,O
line,O
individual,O
(,O
MdLC,O
),O
shares,O
an,O
excess,O
of,O
derived,O
alleles,O
with,O
one,O
of,O
the,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc1,O
),O
relative,O
to,O
modern,O
L,O
line,O
individuals,O
(,O
fig,O
.,O
5C,O
).,O
We,O
did,O
not,O
",",O
however,O
",",O
detect,O
such,O
an,O
excess,O
between,O
the,O
modern,O
LC,O
line,O
individual,O
and,O
the,O
second,O
Caucasian,B-OG
wisent,I-OG
(,O
Cc2,O
"),",O
relative,O
to,O
the,O
modern,O
L,O
line,O
individuals,O
.,O
We,O
can,O
therefore,O
infer,O
that,O
the,O
last,O
surviving,O
Caucasian,B-OG
wisent,I-OG
",",O
KAUKASUS,O
",",O
whose,O
living,O
descendants,O
comprise,O
the,O
modern,O
LC,O
line,O
",",O
was,O
more,O
closely,O
related,O
to,O
Caucasian,B-OG
wisent,I-OG
individual,O
Cc1,O
that,O
to,O
individual,O
Cc2,O
.,O
We,O
further,O
investigated,O
Caucasian,O
ancestry,O
in,O
the,O
genome,O
of,O
the,O
modern,O
LC,O
line,O
individual,O
by,O
performing,O
phylogenetic,O
analysis,O
of,O
non,O
-,O
overlapping,O
1,O
Mb,O
genomic,O
blocks,O
.,O
The,O
fragmented,O
water,B-OG
buffalo,I-OG
reference,O
genome,O
assembly,O
precludes,O
examination,O
of,O
the,O
variance,O
in,O
ancestry,O
along,O
entire,O
chromosomes,O
.,O
To,O
achieve,O
this,O
",",O
we,O
instead,O
mapped,O
reads,O
to,O
the,O
reference,O
genome,O
of,O
the,O
domesticated,O
zebu,B-OG
cattle,I-OG
",",O
Bos,B-OG
indicus,I-OG
",",O
which,O
was,O
itself,O
generated,O
by,O
mapping,O
short,O
read,O
data,O
to,O
the,O
chromosome,O
-,O
level,O
assembly,O
of,O
B,B-OG
.,I-OG
taurus,I-OG
(,O
Canavez,O
et,O
al,O
.,O
2012,O
).,O
Any,O
potential,O
biases,O
introduced,O
by,O
using,O
a,O
cattle,B-OG
reference,O
are,O
mitigated,O
by,O
selecting,O
this,O
cattle,B-OG
breed,O
originating,O
from,O
a,O
domestication,O
center,O
on,O
the,O
Indian,O
subcontinent,O
(,O
Loftus,O
et,O
al,O
.,O
1994,O
"),",O
which,O
is,O
geographically,O
distant,O
from,O
the,O
historical,O
distribution,O
of,O
wisent,B-OG
.,O
Analysis,O
of,O
aligned,O
1,O
Mb,O
genomic,O
blocks,O
involved,O
the,O
modern,O
LC,O
line,O
wisent,B-OG
(,O
MdLC,O
"),",O
the,O
founding,O
wisent,B-OG
(,O
PLATEN,O
),O
that,O
was,O
found,O
to,O
be,O
least,O
admixed,O
with,O
Caucasian,B-OG
wisent,I-OG
",",O
Caucasian,B-OG
wisent,I-OG
(,O
Cc1,O
),O
and,O
domestic,B-OG
cattle,I-OG
",",O
with,O
water,B-OG
buffalo,I-OG
as,O
outgroup,O
.,O
Of,O
the,O
investigated,O
genomic,O
blocks,O
",",O
we,O
find,O
that,O
22,O
%,O
return,O
the,O
modern,O
LC,O
line,O
and,O
Caucasian,B-OG
wisent,I-OG
as,O
monophyletic,O
(,O
fig,O
.,O
6,O
"),",O
and,O
may,O
therefore,O
represent,O
introgressed,O
segments,O
of,O
Caucasian,B-OG
wisent,I-OG
ancestry,O
in,O
this,O
modern,O
LC,O
line,O
individual,O
.,O
Around,O
8,O
%,O
of,O
these,O
blocks,O
are,O
likely,O
to,O
result,O
from,O
incomplete,O
lineage,O
sorting,O
",",O
based,O
on,O
the,O
frequency,O
of,O
occurrence,O
of,O
the,O
opposing,O
topology,O
(,O
fig,O
.,O
6,O
"),",O
producing,O
an,O
overall,O
estimate,O
of,O
14,O
%,O
of,O
the,O
genome,O
of,O
the,O
modern,O
LC,O
individual,O
that,O
results,O
from,O
Caucasian,B-OG
wisent,I-OG
admixture,O
",",O
most,O
likely,O
inherited,O
from,O
the,O
bull,O
KAUKASUS,O
.,O
In,O
addition,O
to,O
providing,O
an,O
estimate,O
of,O
admixture,O
proportions,O
",",O
our,O
method,O
is,O
also,O
able,O
to,O
accurately,O
map,O
admixed,O
segments,O
of,O
the,O
genome,O
(,O
fig,O
.,O
6A,O
).,O
Many,O
of,O
these,O
segments,O
span,O
multiple,O
megabase,O
blocks,O
.,O
For,O
example,O
",",O
a,O
contiguous,O
22,O
Mb,O
admixed,O
block,O
is,O
observed,O
on,O
chromosome,O
4,O
",",O
which,O
may,O
span,O
as,O
much,O
as,O
33,O
Mb,O
under,O
the,O
assumption,O
that,O
intervening,O
blocks,O
with,O
missing,O
data,O
are,O
linked,O
to,O
adjacent,O
ones,O
.,O
Relative,O
admixture,O
proportions,O
also,O
vary,O
among,O
chromosomes,O
in,O
this,O
individual,O
.,O
For,O
example,O
",",O
chromosome,O
27,O
almost,O
entirely,O
lacks,O
Caucasian,B-OG
wisent,I-OG
ancestry,O
whereas,O
around,O
50,O
%,O
of,O
chromosomes,O
4,O
and,O
15,O
are,O
likely,O
derived,O
from,O
admixture,O
.,O
Fig,O
.,O
6Genomic,O
admixture,O
map,O
(,O
A,O
),O
of,O
Caucasian,B-OG
wisent,I-OG
ancestry,O
in,O
the,O
modern,O
LC,O
line,O
individual,O
(,O
MdLC,O
).,O
Colored,O
blocks,O
indicate,O
1,O
Mb,O
genomic,O
blocks,O
returning,O
alternative,O
tree,O
topologies,O
",",O
blue,O
blocks,O
are,O
compatible,O
with,O
the,O
species,O
tree,O
;,O
yellow,O
blocks,O
return,O
the,O
monophly,O
of,O
the,O
modern,O
LC,O
line,O
and,O
Caucasian,B-OG
wisent,I-OG
",",O
and,O
likely,O
result,O
from,O
admixture,O
and,O
to,O
a,O
lesser,O
extent,O
incomplete,O
lineage,O
sorting,O
;,O
red,O
blocks,O
return,O
the,O
monophyly,O
of,O
PLATEN,O
and,O
Caucasian,B-OG
wisent,I-OG
and,O
likely,O
result,O
from,O
incomplete,O
lineage,O
sorting,O
.,O
“,O
X,O
”,O
shows,O
blocks,O
with,O
missing,O
data,O
.,O
The,O
pie,O
chart,O
(,O
B,O
),O
shows,O
the,O
percentage,O
of,O
1,O
Mb,O
genomic,O
supporting,O
each,O
tree,O
topology,O
identified,O
by,O
colors,O
",",O
according,O
to,O
the,O
key,O
presented,O
above,O
.,O
Finally,O
",",O
we,O
investigated,O
evidence,O
of,O
Caucasian,B-OG
wisent,I-OG
ancestry,O
in,O
the,O
modern,O
L,O
line,O
.,O
We,O
found,O
that,O
both,O
modern,O
L,O
line,O
wisent,B-OG
share,O
a,O
significant,O
excess,O
of,O
derived,O
alleles,O
with,O
Caucasian,B-OG
wisent,I-OG
(,O
fig,O
.,O
5B,O
"),",O
relative,O
to,O
founding,O
wisent,B-OG
.,O
Thus,O
",",O
modern,O
L,O
line,O
individuals,O
appear,O
more,O
admixed,O
with,O
Caucasian,B-OG
wisent,I-OG
than,O
the,O
two,O
founding,O
wisent,B-OG
investigated,O
here,O
.,O
This,O
admixture,O
signal,O
could,O
result,O
from,O
either,O
variable,O
admixture,O
proportions,O
among,O
founding,O
individuals,O
",",O
or,O
recent,O
geneflow,O
between,O
the,O
L,O
and,O
LC,O
lines,O
",",O
although,O
D,O
statistic,O
comparison,O
of,O
modern,O
individuals,O
failed,O
to,O
detect,O
the,O
latter,O
(,O
see,O
above,O
).,O
We,O
further,O
investigated,O
these,O
alternative,O
hypotheses,O
by,O
comparing,O
the,O
sizes,O
of,O
putatively,O
admixed,O
genomic,O
blocks,O
.,O
Recent,O
geneflow,O
results,O
in,O
large,O
contiguous,O
genomic,O
blocks,O
derived,O
from,O
admixture,O
in,O
the,O
genomes,O
of,O
the,O
recipient,O
population,O
",",O
which,O
are,O
broken,O
up,O
over,O
time,O
as,O
a,O
result,O
of,O
recombination,O
.,O
Pedigree,O
information,O
provides,O
an,O
approximate,O
date,O
for,O
geneflow,O
from,O
Caucasian,B-OG
wisent,I-OG
into,O
the,O
modern,O
LC,O
line,O
around,O
90,O
years,O
ago,O
(,O
15,O
–,O
22,O
generations,O
"),",O
the,O
result,O
of,O
which,O
are,O
many,O
intact,O
multi,O
-,O
megabase,O
genomic,O
blocks,O
derived,O
from,O
Caucasian,B-OG
wisent,I-OG
in,O
the,O
modern,O
LC,O
line,O
individual,O
(,O
fig,O
.,O
6,O
).,O
We,O
compared,O
the,O
sizes,O
of,O
these,O
blocks,O
with,O
those,O
of,O
putative,O
Caucasian,B-OG
wisent,I-OG
ancestry,O
in,O
a,O
modern,O
L,O
line,O
individual,O
",",O
and,O
found,O
the,O
abundance,O
of,O
large,O
blocks,O
to,O
be,O
considerably,O
lower,O
in,O
the,O
latter,O
(,O
fig,O
.,O
7,O
).,O
This,O
rejects,O
recent,O
admixture,O
and,O
instead,O
supports,O
variable,O
admixture,O
proportions,O
among,O
the,O
founding,O
herd,O
in,O
explaining,O
the,O
observed,O
signal,O
of,O
Caucasian,B-OG
wisent,I-OG
admixture,O
in,O
this,O
modern,O
L,O
line,O
individual,O
.,O
Fig,O
.,O
7Variation,O
in,O
the,O
sizes,O
of,O
genomic,O
blocks,O
in,O
modern,O
L,O
(,O
blue,O
),O
and,O
LC,O
(,O
red,O
),O
likely,O
resulting,O
from,O
Caucasian,B-OG
wisent,I-OG
admixture,O
.,O
Plots,O
show,O
cumulative,O
probability,O
densities,O
calculated,O
at,O
a,O
scale,O
of,O
1,O
Mb,O
.,O
Genomic,O
blocks,O
in,O
the,O
LC,O
line,O
wisent,B-OG
(,O
red,O
),O
result,O
from,O
admixture,O
occurring,O
around,O
90,O
years,O
ago,O
;,O
the,O
lower,O
abundance,O
of,O
larger,O
admixed,O
blocks,O
in,O
the,O
modern,O
L,O
line,O
wisent,B-OG
support,O
that,O
this,O
admixture,O
event,O
preceded,O
the,O
former,O
.,O
The,O
plots,O
have,O
been,O
truncated,O
to,O
aid,O
visualization,O
",",O
and,O
single,O
blocks,O
of,O
18,O
and,O
22,O
Mb,O
in,O
the,O
LC,O
line,O
individual,O
are,O
not,O
shown,O
.,O
The,O
largest,O
block,O
size,O
detected,O
in,O
the,O
modern,O
L,O
line,O
individual,O
was,O
8,O
Mb,O
.,O
Admixture,O
with,O
the,O
Bos,B-OG
Cattle,B-OG
Lineage,O
We,O
investigated,O
potential,O
admixture,O
between,O
wisent,B-OG
and,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
using,O
pseudo,O
-,O
haploid,O
sequences,O
generated,O
from,O
short,O
read,O
data,O
of,O
two,O
domestic,O
Holstein,O
cows,B-OG
and,O
an,O
ancient,O
aurochs,B-OG
(,O
Bos,B-OG
primigenius,I-OG
;,O
Park,O
et,O
al,O
.,O
2015,O
"),",O
the,O
extinct,O
species,O
from,O
which,O
cattle,B-OG
were,O
domesticated,O
and,O
that,O
lived,O
sympatrically,O
with,O
wisent,B-OG
up,O
until,O
its,O
extinction,O
around,O
400,O
years,O
ago,O
(,O
van,O
Vuure,O
2005,O
).,O
First,O
",",O
we,O
looked,O
for,O
significant,O
differences,O
in,O
derived,O
allele,O
sharing,O
between,O
cattle,B-OG
and,O
wisent,B-OG
",",O
relative,O
to,O
the,O
aurochs,B-OG
.,O
We,O
found,O
that,O
all,O
investigated,O
wisent,B-OG
share,O
a,O
significant,O
excess,O
of,O
derived,O
alleles,O
with,O
cattle,B-OG
relative,O
to,O
aurochs,B-OG
(,O
fig,O
.,O
5D,O
).,O
This,O
suggests,O
either,O
admixture,O
between,O
wisent,B-OG
and,O
domestic,B-OG
cattle,I-OG
",",O
or,O
alternatively,O
",",O
admixture,O
with,O
aurochs,B-OG
",",O
if,O
aurochs,B-OG
populations,O
were,O
highly,O
structured,O
and,O
the,O
admixing,O
individuals,O
were,O
from,O
a,O
population,O
more,O
closely,O
related,O
to,O
domestic,B-OG
cattle,I-OG
than,O
the,O
British,O
aurochs,B-OG
used,O
in,O
this,O
analysis,O
.,O
We,O
also,O
compared,O
derived,O
allele,O
sharing,O
with,O
cattle,B-OG
among,O
the,O
individual,O
wisent,B-OG
.,O
We,O
found,O
that,O
all,O
modern,O
wisent,B-OG
investigated,O
here,O
share,O
a,O
significant,O
excess,O
of,O
derived,O
alleles,O
with,O
cattle,B-OG
relative,O
to,O
any,O
founding,O
or,O
Caucasian,B-OG
wisent,I-OG
(,O
fig,O
.,O
5E,O
).,O
Variable,O
admixture,O
was,O
also,O
observed,O
among,O
founding,O
wisent,B-OG
.,O
Specifically,O
",",O
PLANTA,O
shares,O
more,O
derived,O
alleles,O
with,O
domestic,B-OG
cattle,I-OG
than,O
either,O
Caucasian,B-OG
wisent,I-OG
or,O
PLATEN,O
do,O
.,O
Since,O
D,O
statistic,O
is,O
a,O
relative,O
test,O
",",O
and,O
PLATEN,O
is,O
the,O
offspring,O
of,O
admixed,O
founder,O
PLANTA,O
",",O
it,O
is,O
reasonable,O
to,O
infer,O
that,O
PLATEN,O
is,O
also,O
admixed,O
to,O
some,O
extent,O
",",O
however,O
.,O
Finally,O
",",O
using,O
the,O
f,O
^,O
statistic,O
(,O
Durand,O
et,O
al,O
.,O
2011,O
"),",O
we,O
estimated,O
a,O
fraction,O
of,O
2,O
.,O
4,O
–,O
3,O
.,O
2,O
%,O
of,O
the,O
genomes,O
of,O
the,O
modern,O
wisent,B-OG
that,O
could,O
be,O
attributed,O
to,O
admixture,O
with,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
",",O
above,O
that,O
occurring,O
in,O
the,O
founding,O
wisent,B-OG
(,O
supplementary,O
table,O
S6,O
",",O
Supplementary,O
Material,O
online,O
).,O
This,O
increased,O
admixture,O
signal,O
observed,O
in,O
all,O
modern,O
wisent,B-OG
relative,O
to,O
founding,O
wisent,B-OG
could,O
result,O
from,O
either,O
variable,O
admixture,O
proportions,O
among,O
the,O
founding,O
herd,O
from,O
which,O
all,O
modern,O
wisent,B-OG
are,O
derived,O
",",O
or,O
alternatively,O
",",O
from,O
recent,O
admixture,O
with,O
modern,O
cattle,B-OG
.,O
However,O
",",O
the,O
fact,O
that,O
we,O
do,O
not,O
find,O
evidence,O
of,O
any,O
complete,O
genomic,O
1,O
Mb,O
blocks,O
resulting,O
from,O
cattle,B-OG
admixture,O
in,O
the,O
modern,O
LC,O
line,O
individual,O
(,O
fig,O
.,O
6A,O
),O
argues,O
strongly,O
against,O
recent,O
cattle,B-OG
admixture,O
",",O
and,O
instead,O
supports,O
variable,O
admixture,O
among,O
the,O
founding,O
herd,O
in,O
explaining,O
the,O
excess,O
of,O
derived,O
alleles,O
shared,O
among,O
domestic,B-OG
cattle,I-OG
and,O
modern,O
wisent,B-OG
.,O
Discussion,O
Retracing,O
complex,O
population,O
histories,O
can,O
be,O
challenging,O
.,O
In,O
particular,O
",",O
admixture,O
involving,O
populations,O
or,O
species,O
that,O
are,O
now,O
extinct,O
may,O
be,O
impossible,O
based,O
solely,O
on,O
data,O
from,O
living,O
individuals,O
(,O
Hofreiter,O
et,O
al,O
.,O
2015,O
).,O
Through,O
the,O
use,O
of,O
low,O
-,O
coverage,O
genomic,O
data,O
from,O
modern,O
and,O
historical,O
wisent,B-OG
",",O
including,O
from,O
the,O
now,O
extinct,O
Caucasian,B-OG
wisent,I-OG
subspecies,O
",",O
we,O
have,O
revealed,O
the,O
complexity,O
of,O
wisent,B-OG
evolution,O
.,O
This,O
complex,O
history,O
involved,O
not,O
only,O
admixture,O
resulting,O
directly,O
from,O
the,O
captive,O
breeding,O
program,O
",",O
but,O
also,O
older,O
processes,O
occurring,O
prior,O
to,O
their,O
extinction,O
in,O
the,O
wild,O
",",O
which,O
included,O
admixture,O
with,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
(,O
fig,O
.,O
8,O
).,O
Fig,O
.,O
8Schematic,O
diagram,O
showing,O
inferred,O
admixture,O
among,O
wisent,B-OG
",",O
and,O
among,O
wisent,B-OG
and,O
the,O
cattle,B-OG
/,O
aurochs,B-OG
lineage,O
.,O
Arrows,O
indicate,O
the,O
direction,O
of,O
the,O
geneflow,O
.,O
Black,O
lines,O
indicate,O
admixture,O
between,O
wisent,B-OG
and,O
cattle,B-OG
/,O
aurochs,B-OG
",",O
yellow,O
lines,O
/,O
arrow,O
—,O
between,O
Caucasian,O
and,O
founding,O
or,O
modern,O
wisent,B-OG
respectively,O
",",O
and,O
the,O
blue,O
arrow,O
—,O
from,O
founders,O
to,O
modern,O
wisent,B-OG
.,O
Wisent,B-OG
Evolution,O
and,O
Admixture,O
The,O
accepted,O
view,O
of,O
wisent,B-OG
evolution,O
is,O
of,O
two,O
distinct,O
subspecies,O
",",O
Lowland,B-OG
wisent,I-OG
and,O
Caucasian,B-OG
wisent,I-OG
",",O
that,O
both,O
underwent,O
dramatic,O
population,O
declines,O
",",O
with,O
the,O
last,O
few,O
surviving,O
individuals,O
serving,O
as,O
founders,O
of,O
the,O
modern,O
L,O
(,O
Lowland,O
only,O
),O
and,O
LC,O
(,O
Lowland,O
and,O
Caucasian,O
),O
lines,O
(,O
Pucek,O
et,O
al,O
.,O
2004,O
).,O
Our,O
results,O
show,O
that,O
this,O
model,O
is,O
an,O
oversimplification,O
.,O
We,O
find,O
evidence,O
of,O
at,O
least,O
two,O
highly,O
differentiated,O
populations,O
within,O
Caucasian,B-OG
wisent,I-OG
",",O
with,O
one,O
of,O
these,O
showing,O
greater,O
pairwise,O
similarities,O
with,O
Lowland,B-OG
wisent,I-OG
than,O
with,O
the,O
second,O
Caucasian,O
population,O
",",O
at,O
the,O
level,O
of,O
the,O
complete,O
genome,O
(,O
fig,O
.,O
2,O
).,O
However,O
",",O
analysis,O
of,O
aligned,O
nuclear,O
genomic,O
blocks,O
from,O
four,O
individuals,O
returns,O
Caucasian,O
and,O
Lowland,B-OG
wisent,I-OG
as,O
reciprocally,O
monophyletic,O
across,O
slightly,O
more,O
than,O
half,O
of,O
the,O
genomic,O
alignment,O
(,O
fig,O
.,O
3,O
"),",O
providing,O
support,O
that,O
this,O
topology,O
reflects,O
the,O
true,O
history,O
of,O
population,O
divergence,O
.,O
Thus,O
",",O
among,O
any,O
two,O
Caucasian,B-OG
wisent,I-OG
and,O
any,O
two,O
modern,O
(,O
or,O
founding,O
Lowland,O
),O
wisent,B-OG
",",O
we,O
may,O
expect,O
that,O
any,O
single,O
locus,O
has,O
only,O
around,O
50,O
%,O
probability,O
of,O
reflecting,O
the,O
true,O
history,O
of,O
population,O
divergence,O
.,O
Moreover,O
",",O
increased,O
sampling,O
of,O
individuals,O
is,O
likely,O
to,O
further,O
reduce,O
this,O
proportion,O
",",O
potentially,O
to,O
such,O
an,O
extent,O
that,O
",",O
at,O
a,O
given,O
sampling,O
level,O
",",O
the,O
true,O
evolutionary,O
history,O
cannot,O
be,O
untangled,O
from,O
the,O
effects,O
of,O
random,O
drift,O
and,O
more,O
recent,O
admixture,O
.,O
This,O
result,O
reinforces,O
the,O
notion,O
that,O
phylogeny,O
-,O
based,O
interpretation,O
may,O
be,O
inappropriate,O
at,O
the,O
level,O
of,O
the,O
complete,O
genome,O
",",O
and,O
that,O
alternative,O
",",O
more,O
flexible,O
models,O
will,O
be,O
required,O
to,O
keep,O
pace,O
with,O
our,O
ability,O
to,O
generate,O
such,O
data,O
(,O
Hofreiter,O
et,O
al,O
.,O
2015,O
).,O
A,O
further,O
implied,O
assumption,O
of,O
the,O
traditional,O
view,O
of,O
wisent,B-OG
evolution,O
is,O
that,O
",",O
with,O
the,O
exception,O
of,O
the,O
Caucasian,B-OG
bull,I-OG
KAUKASUS,O
",",O
all,O
founding,O
wisent,B-OG
represented,O
“,O
pure,O
”,O
Lowland,B-OG
wisent,I-OG
(,O
Pucek,O
et,O
al,O
.,O
2004,O
;,O
Tokarska,O
et,O
al,O
.,O
2015,O
).,O
On,O
this,O
basis,O
",",O
the,O
modern,O
L,O
line,O
that,O
is,O
derived,O
only,O
from,O
the,O
latter,O
can,O
also,O
be,O
considered,O
as,O
pure,O
Lowland,B-OG
wisent,I-OG
",",O
referable,O
to,O
the,O
subspecies,O
B,B-OG
.,I-OG
b,I-OG
.,I-OG
bonasus,I-OG
.,O
Our,O
results,O
also,O
demonstrate,O
that,O
the,O
notion,O
of,O
wisent,B-OG
subspecies,O
purity,O
is,O
flawed,O
in,O
the,O
sense,O
that,O
founding,O
Lowland,O
individuals,O
were,O
in,O
fact,O
admixed,O
with,O
Caucasian,B-OG
wisent,I-OG
to,O
varying,O
degrees,O
.,O
We,O
demonstrate,O
this,O
",",O
both,O
directly,O
for,O
the,O
founder,O
PLANTA,O
in,O
comparison,O
to,O
another,O
founder,O
",",O
her,O
son,O
PLATEN,O
",",O
and,O
also,O
indirectly,O
",",O
by,O
the,O
elevated,O
signal,O
of,O
Caucasian,B-OG
wisent,I-OG
admixture,O
in,O
modern,O
L,O
line,O
wisent,B-OG
",",O
relative,O
to,O
these,O
founders,O
",",O
most,O
likely,O
a,O
result,O
of,O
inheritance,O
from,O
other,O
founding,O
individuals,O
not,O
included,O
in,O
this,O
analysis,O
(,O
fig,O
.,O
7,O
).,O
The,O
notion,O
of,O
subspecies,O
purity,O
therefore,O
disregards,O
the,O
fact,O
that,O
admixture,O
between,O
Caucasian,O
and,O
Lowland,B-OG
wisent,I-OG
almost,O
certainly,O
occurred,O
prior,O
to,O
the,O
extinction,O
of,O
wisent,B-OG
in,O
the,O
wild,O
",",O
and,O
such,O
admixture,O
could,O
therefore,O
be,O
regarded,O
as,O
part,O
of,O
the,O
normal,O
population,O
processes,O
and,O
dynamics,O
of,O
this,O
species,O
.,O
The,O
notion,O
of,O
subspecies,O
purity,O
has,O
driven,O
efforts,O
to,O
ensure,O
that,O
free,O
-,O
living,O
L,O
and,O
LC,O
herds,O
do,O
not,O
come,O
into,O
contact,O
(,O
Pucek,O
et,O
al,O
.,O
2004,O
"),",O
and,O
also,O
motivated,O
genetic,O
investigations,O
of,O
living,O
populations,O
that,O
may,O
have,O
been,O
recipients,O
of,O
geneflow,O
from,O
the,O
opposing,O
genetic,O
line,O
(,O
Tokarska,O
et,O
al,O
.,O
2015,O
).,O
The,O
latter,O
study,O
investigated,O
the,O
modern,O
L,O
line,O
population,O
that,O
currently,O
inhabits,O
the,O
eastern,O
",",O
Belarusian,O
part,O
of,O
the,O
Białowieża,O
Forest,O
.,O
Some,O
individuals,O
were,O
found,O
to,O
possess,O
a,O
microsatellite,O
allele,O
that,O
was,O
common,O
among,O
Caucasian,B-OG
wisent,I-OG
but,O
absent,O
in,O
all,O
studied,O
Lowland,B-OG
wisent,I-OG
",",O
which,O
these,O
authors,O
interpreted,O
as,O
evidence,O
of,O
recent,O
admixture,O
with,O
the,O
modern,O
LC,O
line,O
.,O
Although,O
the,O
individual,O
from,O
this,O
population,O
(,O
modern,O
L,O
line,O
",",O
MdL2,O
),O
that,O
we,O
sequenced,O
does,O
not,O
possess,O
this,O
putative,O
Caucasian,B-OG
wisent,I-OG
allele,O
",",O
we,O
nevertheless,O
detected,O
evidence,O
of,O
Caucasian,B-OG
wisent,I-OG
admixture,O
above,O
that,O
occurring,O
in,O
founding,O
wisent,B-OG
for,O
this,O
individual,O
(,O
fig,O
.,O
5,O
).,O
However,O
",",O
the,O
small,O
size,O
of,O
admixed,O
blocks,O
",",O
in,O
addition,O
to,O
non,O
-,O
significant,O
D,O
comparisons,O
of,O
modern,O
lines,O
",",O
supports,O
variable,O
Caucasian,B-OG
wisent,I-OG
admixture,O
among,O
founding,O
wisent,B-OG
in,O
explaining,O
this,O
result,O
",",O
which,O
may,O
also,O
account,O
for,O
the,O
occurrence,O
of,O
putative,O
Caucasian,B-OG
wisent,I-OG
alleles,O
in,O
other,O
individuals,O
from,O
this,O
population,O
.,O
Future,O
studies,O
of,O
such,O
individuals,O
using,O
the,O
methodology,O
applied,O
here,O
would,O
provide,O
a,O
robust,O
test,O
of,O
these,O
alternative,O
hypotheses,O
.,O
Wisent,B-OG
Conservation,O
and,O
De,O
-,O
Extinction,O
The,O
issue,O
of,O
low,O
genetic,O
variability,O
among,O
living,O
wisent,B-OG
is,O
considered,O
as,O
cause,O
for,O
concern,O
",",O
and,O
has,O
been,O
inferred,O
by,O
several,O
population,O
-,O
level,O
studies,O
using,O
various,O
molecular,O
and,O
biochemical,O
markers,O
",",O
such,O
as,O
blood,O
-,O
group,O
systems,O
and,O
blood,O
serum,O
proteins,O
(,O
Sipko,O
et,O
al,O
.,O
1995,O
;,O
Gębczyński,O
and,O
Tomaszewska,O
-,O
Guszkiewicz,O
1987,O
;,O
Hartl,O
and,O
Pucek,O
1994,O
;,O
Sipko,O
et,O
al,O
.,O
1997,O
"),",O
mtDNA,O
(,O
this,O
study,O
;,O
Tiedemann,O
et,O
al,O
.,O
1998,O
;,O
Burzyńska,O
et,O
al,O
.,O
1999,O
;,O
Wójcik,O
et,O
al,O
.,O
2009,O
;,O
Hassanin,O
et,O
al,O
.,O
2012,O
"),",O
nuclear,O
gene,O
sequences,O
(,O
Burzyńska,O
and,O
Topczewski,O
1995,O
;,O
Radwan,O
et,O
al,O
.,O
2007,O
;,O
Babik,O
et,O
al,O
.,O
2012,O
;,O
Hassanin,O
et,O
al,O
.,O
2013,O
"),",O
microsatellites,O
(,O
Gralak,O
et,O
al,O
.,O
2004,O
;,O
Luenser,O
et,O
al,O
.,O
2005,O
;,O
Tokarska,O
",",O
Kawałko,O
",",O
et,O
al,O
.,O
2009,O
;,O
Tokarska,O
",",O
Marshall,O
",",O
et,O
al,O
.,O
2009,O
),O
and,O
SNPs,O
(,O
Tokarska,O
",",O
Marshall,O
",",O
et,O
al,O
.,O
2009,O
",",O
Tokarska,O
et,O
al,O
.,O
2015,O
).,O
In,O
apparent,O
contrast,O
to,O
these,O
results,O
",",O
whole,O
-,O
genome,O
heterozygosity,O
in,O
modern,O
wisent,B-OG
has,O
been,O
shown,O
to,O
be,O
similar,O
to,O
that,O
found,O
within,O
domestic,B-OG
cow,I-OG
breeds,O
(,O
Gautier,O
et,O
al,O
.,O
2016,O
).,O
Our,O
results,O
further,O
support,O
this,O
finding,O
using,O
measures,O
of,O
pairwise,O
genomic,O
divergences,O
among,O
modern,O
and,O
founding,O
wisent,B-OG
",",O
which,O
are,O
approximately,O
equal,O
to,O
or,O
greater,O
than,O
that,O
found,O
between,O
pairs,O
of,O
cattle,B-OG
or,O
yak,B-OG
",",O
respectively,O
.,O
However,O
",",O
the,O
bimodal,O
distributions,O
observed,O
for,O
pairwise,O
comparisons,O
based,O
on,O
transitions,O
and,O
transversions,O
for,O
modern,O
wisent,B-OG
suggests,O
that,O
",",O
among,O
any,O
pair,O
of,O
modern,O
wisent,B-OG
",",O
large,O
chromosomal,O
blocks,O
will,O
show,O
high,O
genetic,O
similarity,O
",",O
which,O
is,O
indicative,O
of,O
inbreeding,O
",",O
and,O
has,O
been,O
shown,O
previously,O
using,O
SNP,O
array,O
data,O
(,O
Pertoldi,O
et,O
al,O
.,O
2009,O
).,O
Overall,O
",",O
the,O
wisent,B-OG
captive,O
breeding,O
program,O
",",O
based,O
on,O
a,O
founding,O
herd,O
of,O
just,O
12,O
individuals,O
",",O
appears,O
to,O
have,O
succeeded,O
in,O
retaining,O
reasonable,O
levels,O
of,O
genetic,O
variability,O
in,O
modern,O
populations,O
.,O
Nevertheless,O
",",O
the,O
extinction,O
of,O
wisent,B-OG
in,O
the,O
wild,O
was,O
clearly,O
accompanied,O
by,O
a,O
major,O
loss,O
of,O
total,O
genetic,O
diversity,O
.,O
Divergent,O
mitochondrial,O
haplotypes,O
detected,O
in,O
ancient,O
wisent,B-OG
appear,O
to,O
have,O
been,O
entirely,O
lost,O
from,O
modern,O
populations,O
",",O
which,O
our,O
results,O
suggest,O
may,O
possess,O
only,O
a,O
single,O
haplotype,O
.,O
Moreover,O
",",O
substantial,O
pairwise,O
nuclear,O
genomic,O
divergences,O
detected,O
between,O
modern,O
and,O
historical,O
Caucasian,B-OG
wisent,I-OG
indicate,O
a,O
huge,O
loss,O
of,O
diversity,O
following,O
the,O
extinction,O
of,O
the,O
latter,O
population,O
.,O
A,O
fraction,O
of,O
the,O
genepool,O
of,O
extinct,O
Caucasian,B-OG
wisent,I-OG
survives,O
in,O
the,O
genomes,O
of,O
modern,O
individuals,O
.,O
Our,O
results,O
provide,O
not,O
only,O
a,O
direct,O
measure,O
of,O
this,O
admixture,O
in,O
a,O
modern,O
LC,O
line,O
individual,O
",",O
but,O
also,O
allow,O
us,O
to,O
map,O
with,O
relative,O
accuracy,O
chromosomal,O
segments,O
that,O
are,O
inherited,O
from,O
Caucasian,B-OG
wisent,I-OG
.,O
Although,O
sometimes,O
controversial,O
",",O
the,O
concept,O
of,O
de,O
-,O
extinction,O
has,O
generated,O
considerable,O
interest,O
(,O
Sherkow,O
and,O
Greely,O
2013,O
"),",O
and,O
attempts,O
are,O
currently,O
underway,O
to,O
generate,O
animals,B-OG
that,O
",",O
at,O
least,O
superficially,O
",",O
resemble,O
the,O
quagga,B-OG
(,O
Equus,B-OG
quagga,I-OG
;,O
Heywood,O
2013,O
"),",O
an,O
extinct,O
subspecies,O
of,O
plains,B-OG
zebra,I-OG
",",O
and,O
also,O
the,O
aurochs,B-OG
(,O
van,O
Vuure,O
2005,O
"),",O
by,O
careful,O
selective,O
breeding,O
of,O
their,O
living,O
relatives,O
.,O
In,O
both,O
of,O
these,O
cases,O
",",O
selective,O
breeding,O
and,O
the,O
ultimate,O
success,O
of,O
the,O
project,O
are,O
based,O
solely,O
on,O
morphological,O
criteria,O
.,O
Our,O
study,O
demonstrates,O
that,O
",",O
at,O
least,O
in,O
principle,O
",",O
by,O
generating,O
chromosomal,O
admixture,O
maps,O
for,O
multiple,O
living,O
representatives,O
of,O
the,O
LC,O
line,O
",",O
it,O
would,O
be,O
possible,O
to,O
selectively,O
breed,O
an,O
animal,B-OG
that,O
is,O
",",O
at,O
the,O
genomic,O
level,O
",",O
highly,O
similar,O
to,O
a,O
Caucasian,B-OG
wisent,I-OG
.,O
Admixture,O
with,O
the,O
Bos,B-OG
Cattle,B-OG
Lineage,O
Hybridization,O
of,O
wild,O
species,O
with,O
their,O
domesticated,O
close,O
relatives,O
is,O
a,O
subject,O
of,O
considerable,O
discussion,O
and,O
concern,O
for,O
conservation,O
management,O
(,O
Ellstrand,O
et,O
al,O
.,O
2010,O
).,O
Previous,O
studies,O
have,O
found,O
evidence,O
of,O
admixture,O
with,O
the,O
Bos,B-OG
cattle,B-OG
lineage,O
in,O
modern,O
L,O
line,O
wisent,B-OG
(,O
Gautier,O
et,O
al,O
.,O
2016,O
).,O
We,O
extend,O
this,O
result,O
by,O
demonstrating,O
that,O
such,O
admixture,O
is,O
widespread,O
across,O
wisent,B-OG
",",O
including,O
both,O
modern,O
genetic,O
lines,O
",",O
representatives,O
of,O
the,O
original,O
founding,O
herd,O
",",O
and,O
also,O
extinct,O
Caucasian,B-OG
wisent,I-OG
.,O
This,O
admixture,O
post,O
-,O
dates,O
the,O
common,O
ancestor,O
of,O
English,O
aurochs,B-OG
and,O
taurine,B-OG
cattle,I-OG
",",O
and,O
involved,O
a,O
representative,O
of,O
the,O
latter,O
lineage,O
.,O
However,O
",",O
the,O
precise,O
identity,O
of,O
the,O
introgressor,O
—,O
aurochs,B-OG
or,O
domestic,B-OG
cattle,I-OG
—,O
is,O
less,O
certain,O
",",O
given,O
the,O
lack,O
of,O
knowledge,O
of,O
population,O
structure,O
in,O
aurochs,B-OG
.,O
Testing,O
these,O
two,O
alternatives,O
would,O
require,O
data,O
from,O
additional,O
aurochs,B-OG
populations,O
from,O
within,O
the,O
core,O
distribution,O
of,O
wisent,B-OG
",",O
and,O
would,O
be,O
a,O
valuable,O
direction,O
for,O
future,O
research,O
.,O
The,O
timing,O
of,O
admixture,O
also,O
has,O
implications,O
for,O
conservation,O
management,O
.,O
Specifically,O
",",O
the,O
removal,O
of,O
individuals,O
resulting,O
from,O
very,O
recent,O
hybridization,O
may,O
be,O
deemed,O
appropriate,O
(,O
Halbert,O
and,O
Derr,O
2007,O
).,O
The,O
small,O
size,O
of,O
cattle,B-OG
admixed,O
blocks,O
in,O
modern,O
wisent,B-OG
(,O
at,O
least,O
undetectable,O
at,O
a,O
1,O
Mb,O
scale,O
),O
clearly,O
rejects,O
very,O
recent,O
cattle,B-OG
admixture,O
for,O
the,O
individuals,O
investigated,O
here,O
.,O
Instead,O
",",O
admixture,O
must,O
have,O
occurred,O
prior,O
to,O
the,O
establishment,O
of,O
the,O
captive,O
breeding,O
program,O
",",O
and,O
the,O
admixture,O
signal,O
detected,O
in,O
modern,O
wisent,B-OG
results,O
from,O
inheritance,O
from,O
the,O
founders,O
that,O
were,O
admixed,O
with,O
cattle,B-OG
to,O
varying,O
degrees,O
.,O
Thus,O
",",O
based,O
on,O
the,O
current,O
evidence,O
",",O
cattle,B-OG
introgression,O
appears,O
of,O
low,O
concern,O
for,O
wisent,B-OG
conservation,O
for,O
the,O
following,O
reasons,O
:,O
(,O
1,O
),O
admixture,O
does,O
not,O
appear,O
to,O
have,O
occurred,O
since,O
the,O
establishment,O
of,O
the,O
captive,O
breeding,O
program,O
",",O
although,O
screening,O
of,O
additional,O
individuals,O
may,O
be,O
desirable,O
to,O
further,O
support,O
this,O
generalization,O
;,O
(,O
2,O
),O
the,O
number,O
of,O
intervening,O
generations,O
separating,O
living,O
wisent,B-OG
from,O
the,O
F1,O
hybrids,O
is,O
likely,O
sufficient,O
that,O
all,O
living,O
wisent,B-OG
are,O
admixed,O
to,O
some,O
extent,O
(,O
Chang,O
1999,O
);,O
and,O
(,O
3,O
),O
our,O
results,O
may,O
in,O
fact,O
reflect,O
admixture,O
with,O
aurochs,B-OG
",",O
rather,O
than,O
domestic,B-OG
cattle,I-OG
",",O
although,O
this,O
hypothesis,O
requires,O
further,O
investigation,O
.,O
An,O
Exemplar,O
for,O
the,O
Study,O
of,O
Admixture,O
The,O
ability,O
to,O
detect,O
admixture,O
is,O
of,O
key,O
importance,O
for,O
both,O
evolutionary,O
and,O
applied,O
conservation,O
studies,O
.,O
However,O
",",O
interpretation,O
of,O
a,O
significant,O
signal,O
of,O
admixture,O
",",O
in,O
terms,O
of,O
both,O
evolutionary,O
inference,O
and,O
the,O
formulation,O
of,O
management,O
strategies,O
",",O
may,O
require,O
information,O
its,O
timing,O
.,O
Using,O
seven,O
low,O
-,O
coverage,O
wisent,B-OG
genomes,O
from,O
both,O
modern,O
and,O
historical,O
wisent,B-OG
we,O
have,O
revealed,O
multiple,O
instances,O
of,O
admixture,O
",",O
but,O
moreover,O
",",O
because,O
the,O
approximate,O
age,O
of,O
introgression,O
of,O
Caucasian,B-OG
wisent,I-OG
into,O
the,O
modern,O
LC,O
line,O
is,O
known,O
",",O
through,O
comparisons,O
of,O
the,O
sizes,O
of,O
likely,O
admixed,O
genomic,O
segments,O
we,O
have,O
inferred,O
the,O
relative,O
ages,O
of,O
other,O
admixture,O
events,O
.,O
This,O
unique,O
historical,O
information,O
",",O
coupled,O
with,O
the,O
ability,O
to,O
recover,O
genomic,O
data,O
from,O
historical,O
samples,O
",",O
establish,O
wisent,B-OG
as,O
an,O
exemplary,O
taxon,O
for,O
the,O
study,O
of,O
admixture,O
in,O
wild,O
populations,O
.,O
As,O
new,O
analytical,O
methods,O
for,O
studying,O
admixture,O
are,O
developed,O
",",O
wisent,B-OG
can,O
serve,O
as,O
a,O
valuable,O
empirical,O
test,O
of,O
both,O
their,O
performance,O
and,O
utility,O
.,O
Materials,O
and,O
Methods,O
Complete,O
details,O
of,O
all,O
samples,O
and,O
specimens,O
used,O
in,O
this,O
study,O
are,O
shown,O
in,O
table,O
1,O
.,O
Laboratory,O
Methods,O
",",O
Modern,O
Samples,O
DNA,O
was,O
extracted,O
from,O
tissue,O
samples,O
of,O
three,O
modern,O
wisent,B-OG
using,O
either,O
a,O
DNeasy,O
Blood,O
and,O
Tissue,O
Kit,O
(,O
Qiagen,O
),O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
instructions,O
(,O
sample,O
MdL1,O
),O
or,O
by,O
phenol,O
/,O
chloroform,O
extraction,O
(,O
Sambrook,O
and,O
Russell,O
2001,O
).,O
We,O
mechanically,O
sheared,O
the,O
DNA,O
of,O
the,O
modern,O
samples,O
using,O
a,O
Covaris,O
S220,O
sonicator,O
to,O
an,O
average,O
fragment,O
length,O
of,O
500,O
bp,O
and,O
prepared,O
indexed,O
Illumina,O
libraries,O
from,O
500,O
ng,O
of,O
each,O
modern,O
DNA,O
extract,O
using,O
a,O
published,O
double,O
-,O
stranded,O
protocol,O
(,O
Meyer,O
and,O
Kircher,O
2010,O
),O
with,O
modifications,O
(,O
Fortes,O
and,O
Paijmans,O
2015,O
).,O
Library,O
molecules,O
from,O
450,O
bp,O
to,O
1000,O
bp,O
were,O
then,O
selected,O
using,O
a,O
Pippin,O
Prep,O
Instrument,O
(,O
Sage,O
Science,O
).,O
Laboratory,O
Methods,O
",",O
Historical,O
Samples,O
DNA,O
extraction,O
from,O
four,O
museum,O
specimens,O
as,O
well,O
as,O
sequencing,O
library,O
preparation,O
steps,O
preceding,O
amplification,O
were,O
performed,O
in,O
a,O
dedicated,O
ancient,O
DNA,O
laboratory,O
(,O
Evolutionary,O
Adaptive,O
Genomics,O
Group,O
",",O
Potsdam,O
University,O
",",O
Germany,O
).,O
DNA,O
extracts,O
were,O
prepared,O
from,O
horn,O
and,O
bone,O
powder,O
obtained,O
by,O
grinding,O
in,O
a,O
mixer,O
mill,O
(,O
MM,O
400,O
",",O
RETSCH,O
).,O
DNA,O
extraction,O
followed,O
the,O
protocol,O
of,O
Dabney,O
",",O
Knapp,O
",",O
et,O
al,O
.,O
(,O
2013,O
"),",O
except,O
for,O
horn,O
samples,O
where,O
we,O
used,O
a,O
different,O
digestion,O
buffer,O
containing,O
10mM,O
Tris,O
buffer,O
(,O
pH,O
8,O
.,O
0,O
"),",O
10,O
mM,O
NaCl,O
",",O
5,O
mM,O
CaCl2,O
",",O
2,O
.,O
5,O
mM,O
EDTA,O
(,O
pH,O
8,O
.,O
0,O
"),",O
2,O
%,O
SDS,O
(,O
Shapiro,O
and,O
Hofreiter,O
2012,O
).,O
The,O
museum,O
samples,O
were,O
already,O
fragmented,O
due,O
to,O
degradation,O
",",O
so,O
were,O
not,O
sonicated,O
.,O
We,O
used,O
25,O
µl,O
of,O
each,O
DNA,O
extract,O
to,O
construct,O
single,O
-,O
stranded,O
indexed,O
Illumina,O
libraries,O
according,O
to,O
the,O
protocol,O
of,O
Gansauge,O
and,O
Meyer,O
(,O
2013,O
).,O
Sequencing,O
Final,O
library,O
concentrations,O
and,O
the,O
distribution,O
of,O
insert,O
sizes,O
were,O
determined,O
using,O
a,O
2200,O
TapeStation,O
(,O
Agilent,O
Technologies,O
),O
and,O
Qubit,O
HS,O
-,O
assay,O
(,O
Thermo,O
Fisher,O
Scientific,O
"),",O
respectively,O
.,O
Each,O
library,O
was,O
then,O
sequenced,O
using,O
an,O
Illumina,O
NextSeq,O
500,O
instrument,O
.,O
For,O
modern,O
libraries,O
we,O
used,O
a,O
High,O
Output,O
Kit,O
(,O
75,O
bp,O
paired,O
-,O
end,O
sequencing,O
"),",O
for,O
libraries,O
obtained,O
from,O
historical,O
horn,O
samples,O
we,O
used,O
High,O
Output,O
Kits,O
(,O
75,O
bp,O
single,O
-,O
end,O
and,O
150,O
bp,O
paired,O
-,O
end,O
),O
and,O
each,O
library,O
built,O
from,O
historical,O
bone,O
samples,O
was,O
sequenced,O
separately,O
with,O
High,O
Output,O
Kits,O
(,O
75,O
bp,O
single,O
-,O
end,O
and,O
paired,O
-,O
end,O
).,O
Full,O
details,O
of,O
sequencing,O
results,O
are,O
provided,O
in,O
supplementary,O
tables,O
S2,O
and,O
S3,O
",",O
Supplementary,O
Material,O
online,O
.,O
Whole,O
genome,O
shotgun,O
sequencing,O
data,O
produced,O
for,O
this,O
study,O
are,O
available,O
in,O
the,O
NCBI,O
Short,O
Read,O
Archive,O
as,O
SAMN05950802,O
–,O
SAMN05950808,O
.,O
Data,O
Processing,O
",",O
Mapping,O
and,O
Pseudo,O
-,O
Haploidization,O
For,O
paired,O
-,O
end,O
data,O
",",O
we,O
trimmed,O
adapter,O
sequences,O
and,O
merged,O
overlapping,O
read,O
pairs,O
using,O
SeqPrep,O
(,O
https,O
://,O
github,O
.,O
com,O
/,O
jstjohn,O
/,O
SeqPrep,O
"),",O
requiring,O
a,O
minimum,O
read,O
length,O
of,O
30,O
bp,O
(-,O
L,O
30,O
"),",O
minimum,O
overlap,O
of,O
15,O
bp,O
(-,O
o,O
15,O
"),",O
and,O
a,O
minimum,O
merge,O
quality,O
of,O
13,O
(-,O
q,O
13,O
).,O
Adapters,O
occurring,O
at,O
the,O
3,O
′,O
ends,O
of,O
single,O
-,O
end,O
reads,O
were,O
trimmed,O
using,O
cutadapt,O
(,O
Martin,O
2011,O
"),",O
also,O
requiring,O
a,O
minimum,O
length,O
of,O
reads,O
of,O
30,O
(-,O
m,O
30,O
).,O
We,O
then,O
mapped,O
the,O
resulting,O
data,O
to,O
the,O
zebu,B-OG
(,O
Bos,B-OG
indicus,I-OG
;,O
GenBank,O
accession,O
no,O
.,O
GCA_000247795,O
.,O
2,O
),O
and,O
water,B-OG
buffalo,I-OG
(,O
Bubalus,B-OG
bubalis,I-OG
;,O
GenBank,O
accession,O
no,O
.,O
GCA_000471725,O
.,O
1,O
),O
nuclear,O
genomes,O
and,O
wisent,B-OG
mitochondrial,O
genome,O
(,O
GenBank,O
accession,O
no,O
.,O
KY055664,O
),O
using,O
BWA,O
aln,O
version,O
0,O
.,O
7,O
.,O
8,O
(,O
Li,O
and,O
Durbin,O
2009,O
),O
with,O
default,O
0,O
.,O
04,O
mismatch,O
value,O
.,O
We,O
removed,O
duplicate,O
reads,O
likely,O
resulting,O
from,O
PCR,O
amplification,O
using,O
samtools,O
rmdup,O
(,O
Li,O
et,O
al,O
.,O
2009,O
).,O
Detailed,O
descriptions,O
of,O
the,O
mapping,O
results,O
are,O
provided,O
in,O
supplementary,O
tables,O
S2,O
and,O
S3,O
",",O
Supplementary,O
Material,O
online,O
.,O
We,O
then,O
generated,O
pseudo,O
-,O
haploid,O
sequences,O
as,O
described,O
by,O
Cahill,O
et,O
al,O
.,O
(,O
2015,O
),O
and,O
used,O
these,O
for,O
further,O
analysis,O
.,O
Pairwise,O
Genomic,O
Divergence,O
Pairwise,O
genomic,O
divergence,O
was,O
calculated,O
by,O
dividing,O
genomic,O
alignments,O
into,O
non,O
-,O
overlapping,O
1,O
Mb,O
blocks,O
and,O
calculating,O
the,O
proportion,O
of,O
transversions,O
",",O
or,O
transitions,O
plus,O
transversions,O
(,O
comparisons,O
of,O
modern,O
individuals,O
only,O
"),",O
for,O
each,O
pair,O
of,O
individuals,O
",",O
accounting,O
for,O
the,O
presence,O
of,O
missing,O
data,O
.,O
Blocks,O
with,O
>,O
75,O
%,O
missing,O
data,O
were,O
disregarded,O
.,O
Probability,O
densities,O
were,O
generated,O
by,O
kernel,O
density,O
estimation,O
in,O
R,O
(,O
R,O
Core,O
Team,O
2014,O
),O
using,O
default,O
parameters,O
.,O
Full,O
details,O
of,O
comparative,O
data,O
generated,O
for,O
domestic,B-OG
cattle,I-OG
and,O
yak,B-OG
(,O
data,O
from,O
the,O
NCBI,O
Short,O
Read,O
Archive,O
),O
are,O
provided,O
in,O
supplementary,O
table,O
S4,O
",",O
Supplementary,O
Material,O
online,O
.,O
Mitochondrial,O
Genome,O
Analysis,O
In,O
addition,O
to,O
the,O
mitochondrial,O
genomes,O
generated,O
from,O
the,O
three,O
modern,O
and,O
four,O
historical,O
specimens,O
",",O
we,O
obtained,O
mitogenomes,O
from,O
seven,O
other,O
modern,O
wisent,B-OG
with,O
Sanger,O
technology,O
and,O
from,O
four,O
ancient,O
Holocene,O
wisent,B-OG
individuals,O
using,O
hybridisation,O
capture,O
(,O
supplementary,O
table,O
S1,O
",",O
Supplementary,O
Material,O
online,O
).,O
These,O
ancient,O
samples,O
were,O
radiocarbon,O
dated,O
at,O
either,O
the,O
Oxford,O
University,O
Radiocarbon,O
Accelerator,O
Unit,O
(,O
Oxford,O
",",O
UK,O
),O
using,O
ultrafiltered,O
collagen,O
and,O
accelerator,O
mass,O
spectrometry,O
(,O
Ramsey,O
",",O
Gigham,O
",",O
et,O
al,O
.,O
2004,O
;,O
Ramsey,O
",",O
Higham,O
",",O
et,O
al,O
.,O
2004,O
),O
or,O
the,O
VERA,O
-,O
Laboratorium,O
Institut,O
für,O
Isotopenforschung,O
und,O
Kernphysik,O
(,O
Vienna,O
",",O
Austria,O
).,O
We,O
calibrated,O
radiocarbon,O
dates,O
using,O
the,O
IntCal13,O
calibration,O
curve,O
(,O
Reimer,O
et,O
al,O
.,O
2013,O
),O
in,O
OxCal,O
v4,O
.,O
2,O
(,O
https,O
://,O
c14,O
.,O
arch,O
.,O
ox,O
.,O
ac,O
.,O
uk,O
/,O
oxcal,O
/,O
OxCal,O
.,O
html,O
).,O
DNA,O
was,O
extracted,O
from,O
the,O
Holocene,O
B,B-OG
.,I-OG
b,I-OG
.,I-OG
bonasus,I-OG
samples,O
(,O
Bb1,O
-,O
Bb3,O
),O
at,O
the,O
Henry,O
Wellcome,O
Ancient,O
Biomolecules,O
Centre,O
(,O
Oxford,O
University,O
",",O
UK,O
"),",O
following,O
Shapiro,O
et,O
al,O
.,O
(,O
2004,O
).,O
We,O
extracted,O
the,O
Holocene,O
B,B-OG
.,I-OG
b,I-OG
.,I-OG
caucasicus,I-OG
sample,O
(,O
Cc3,O
),O
in,O
the,O
specialist,O
Paleogenomics,O
facility,O
at,O
UC,O
Santa,O
Cruz,O
",",O
following,O
Rohland,O
et,O
al,O
.,O
(,O
2010,O
).,O
DNA,O
library,O
construction,O
",",O
mitochondrial,O
target,O
enrichment,O
",",O
sequencing,O
",",O
and,O
sequence,O
data,O
processing,O
protocols,O
for,O
the,O
four,O
Holocene,O
samples,O
followed,O
approach,O
four,O
in,O
Heintzman,O
et,O
al,O
.,O
(,O
2016,O
"),",O
except,O
that,O
the,O
whole,O
mitochondrial,O
genome,O
consensus,O
sequence,O
was,O
retained,O
.,O
The,O
mean,O
read,O
depth,O
of,O
these,O
Holocene,O
consensus,O
sequences,O
ranged,O
from,O
14,O
.,O
1,O
to,O
165,O
.,O
7,O
×.,O
The,O
consensus,O
sequences,O
for,O
the,O
four,O
Holocene,O
and,O
one,O
historic,O
Caucasian,B-OG
wisent,I-OG
have,O
been,O
deposited,O
in,O
GenBank,O
with,O
accession,O
numbers,O
KX553930,O
–,O
KX553934,O
.,O
The,O
mitogenomic,O
sequence,O
from,O
the,O
remaining,O
modern,O
and,O
historic,O
samples,O
has,O
been,O
submitted,O
to,O
GenBank,O
with,O
accession,O
number,O
KY055664,O
(,O
supplementary,O
table,O
S1,O
",",O
Supplementary,O
Material,O
online,O
).,O
We,O
assessed,O
phylogenetic,O
relationships,O
among,O
wisent,B-OG
mitochondrial,O
haplotypes,O
",",O
as,O
well,O
as,O
their,O
placement,O
within,O
the,O
wider,O
bovine,O
(,O
tribe,O
Bovini,O
),O
tree,O
.,O
Wisent,B-OG
sequences,O
were,O
aligned,O
with,O
those,O
of,O
12,O
other,O
bovin,O
taxa,O
",",O
including,O
the,O
extinct,O
steppe,B-OG
bison,I-OG
(,O
Bison,B-OG
priscus,I-OG
),O
and,O
aurochs,B-OG
(,O
Bos,B-OG
primigenius,I-OG
),O
(,O
supplementary,O
table,O
S1,O
",",O
Supplementary,O
Material,O
online,O
).,O
We,O
excluded,O
two,O
previously,O
published,O
wisent,B-OG
mitochondrial,O
genomes,O
from,O
the,O
phylogenetic,O
analysis,O
(,O
GenBank,O
accessions,O
:,O
HQ223450,O
",",O
HM045017,O
/,O
NC_014044,O
"),",O
as,O
these,O
sequences,O
were,O
considered,O
problematic,O
.,O
Specifically,O
",",O
HQ223450,O
has,O
multiple,O
insertions,O
totaling,O
9,O
bp,O
in,O
the,O
ND4,B-GP
coding,O
region,O
",",O
and,O
HM045017,O
/,O
NC_014044,O
has,O
multiple,O
indels,O
and,O
point,O
mutations,O
concentrated,O
in,O
the,O
large,O
rRNA,O
and,O
ND3,B-GP
coding,O
regions,O
.,O
Sequence,O
alignment,O
",",O
partitioning,O
",",O
model,O
testing,O
",",O
and,O
phylogenetic,O
and,O
associated,O
statistical,O
support,O
methods,O
followed,O
the,O
ordinal,O
-,O
level,O
analyses,O
of,O
Heintzman,O
et,O
al,O
.,O
(,O
2015,O
"),",O
except,O
that,O
we,O
used,O
the,O
B,B-OG
.,I-OG
bison,I-OG
reference,O
mitochondrial,O
genome,O
(,O
NC_012346,O
),O
for,O
partitioning,O
.,O
We,O
selected,O
the,O
following,O
models,O
of,O
molecular,O
evolution,O
for,O
the,O
six,O
partitions,O
:,O
GTR,O
+,O
I,O
+,O
G,O
(,O
CP1,O
",",O
3803,O
bp,O
;,O
rRNAs,O
",",O
2541,O
bp,O
"),",O
GTR,O
+,O
G,O
(,O
CP3,O
",",O
3803,O
bp,O
"),",O
HKY,O
+,O
I,O
+,O
G,O
(,O
CP2,O
",",O
3803,O
bp,O
;,O
tRNAs,O
",",O
1526,O
bp,O
;,O
control,O
region,O
",",O
927,O
bp,O
).,O
We,O
used,O
the,O
saola,B-OG
(,O
Pseudoryx,B-OG
nghetinhensis,I-OG
;,O
supplementary,O
table,O
S1,O
",",O
Supplementary,O
Material,O
online,O
),O
as,O
outgroup,O
in,O
both,O
the,O
maximum,O
likelihood,O
and,O
Bayesian,O
analyses,O
",",O
following,O
Bibi,O
(,O
2013,O
).,O
D,O
Statistic,O
Tests,O
The,O
D,O
statistic,O
involves,O
four,O
genomes,O
:,O
a,O
genome,O
from,O
each,O
of,O
two,O
sister,O
populations,O
(,O
P1,O
and,O
P2,O
"),",O
a,O
genome,O
from,O
a,O
third,O
population,O
as,O
the,O
potential,O
source,O
of,O
introgression,O
(,O
P3,O
"),",O
and,O
an,O
outgroup,O
genome,O
(,O
O,O
),O
to,O
identify,O
the,O
ancestral,O
state,O
(,O
identified,O
as,O
the,O
A,O
allele,O
).,O
We,O
identified,O
variable,O
positions,O
at,O
which,O
P3,O
possessed,O
the,O
derived,O
allele,O
(,O
B,O
),O
and,O
presence,O
of,O
the,O
derived,O
allele,O
is,O
variable,O
among,O
P1,O
and,O
P2,O
",",O
leading,O
to,O
two,O
possible,O
patterns,O
:,O
either,O
ABBA,O
or,O
BABA,O
.,O
Under,O
the,O
scenario,O
of,O
incomplete,O
lineage,O
sorting,O
without,O
geneflow,O
these,O
patterns,O
should,O
occur,O
with,O
equal,O
frequency,O
and,O
the,O
expected,O
D,O
value,O
will,O
be,O
zero,O
.,O
An,O
excess,O
of,O
ABBA,O
or,O
BABA,O
patterns,O
is,O
interpreted,O
as,O
evidence,O
of,O
admixture,O
.,O
However,O
",",O
it,O
might,O
also,O
arise,O
from,O
nonrandom,O
mating,O
in,O
the,O
ancestral,O
population,O
due,O
to,O
population,O
structure,O
(,O
Eriksson,O
and,O
Manica,O
2012,O
).,O
To,O
determine,O
the,O
ancestral,O
state,O
we,O
used,O
the,O
water,B-OG
buffalo,I-OG
genome,O
.,O
In,O
all,O
tests,O
involving,O
data,O
mapped,O
to,O
the,O
zebu,B-OG
genome,O
",",O
we,O
took,O
into,O
consideration,O
the,O
autosomes,O
only,O
.,O
We,O
performed,O
a,O
total,O
of,O
105,O
comparisons,O
considering,O
all,O
possible,O
combinations,O
of,O
wisent,B-OG
",",O
all,O
wisent,B-OG
with,O
either,O
domestic,B-OG
cattle,I-OG
or,O
aurochs,B-OG
as,O
candidate,O
admixer,O
",",O
and,O
domestic,B-OG
cattle,I-OG
and,O
aurochs,B-OG
with,O
all,O
wisent,B-OG
as,O
candidate,O
admixer,O
.,O
These,O
results,O
are,O
reported,O
in,O
supplementary,O
table,O
S4,O
",",O
Supplementary,O
Material,O
online,O
.,O
f,O
^,O
test,O
(,O
Green,O
et,O
al,O
.,O
2010,O
;,O
Durand,O
et,O
al,O
.,O
2011,O
),O
was,O
used,O
to,O
estimate,O
the,O
proportion,O
of,O
the,O
genome,O
derived,O
from,O
admixture,O
.,O
This,O
test,O
requires,O
two,O
individuals,O
of,O
the,O
candidate,O
introgressor,O
species,O
that,O
are,O
not,O
themselves,O
admixed,O
.,O
For,O
our,O
datasets,O
this,O
was,O
possible,O
only,O
for,O
admixture,O
involving,O
the,O
cattle,B-OG
/,O
aurochs,B-OG
lineage,O
.,O
For,O
both,O
D,O
statistic,O
and,O
f,O
^,O
test,O
",",O
significance,O
was,O
assessed,O
using,O
a,O
weighted,O
block,O
jackknife,O
using,O
1,O
Mb,O
blocks,O
(,O
Green,O
et,O
al,O
.,O
2010,O
;,O
Durand,O
et,O
al,O
.,O
2011,O
).,O
The,O
weighted,O
block,O
jackknife,O
tests,O
if,O
admixture,O
signals,O
are,O
uniform,O
across,O
the,O
whole,O
genome,O
and,O
therefore,O
reflect,O
the,O
same,O
population,O
history,O
.,O
By,O
removing,O
one,O
at,O
a,O
time,O
blocks,O
of,O
adjacent,O
sites,O
(,O
larger,O
than,O
the,O
extent,O
of,O
linkage,O
disequilibrium,O
),O
and,O
computing,O
the,O
variance,O
of,O
the,O
D,O
statistic,O
or,O
f,O
^,O
values,O
over,O
the,O
entire,O
genome,O
M,O
times,O
leaving,O
each,O
block,O
of,O
the,O
genome,O
in,O
turn,O
",",O
and,O
then,O
multiplying,O
by,O
M,O
and,O
taking,O
the,O
square,O
root,O
we,O
generated,O
the,O
standard,O
error,O
.,O
The,O
number,O
of,O
standard,O
errors,O
by,O
which,O
D,O
or,O
f,O
^,O
differs,O
from,O
zero,O
is,O
the,O
Z,O
score,O
.,O
The,O
results,O
with,O
Z,O
scores,O
greater,O
than,O
3,O
in,O
absolute,O
value,O
were,O
qualified,O
as,O
statistically,O
significant,O
(,O
Green,O
et,O
al,O
.,O
2010,O
).,O
Nuclear,O
Genome,O
Phylogenetic,O
Tests,O
The,O
aligned,O
pseudohaploid,O
sequences,O
",",O
generated,O
by,O
mapping,O
reads,O
to,O
the,O
Bos,B-OG
indicus,I-OG
reference,O
",",O
were,O
divided,O
into,O
non,O
-,O
overlapping,O
blocks,O
of,O
1,O
Mb,O
.,O
If,O
each,O
of,O
the,O
five,O
taxa,O
contained,O
no,O
more,O
than,O
50,O
%,O
gaps,O
within,O
a,O
window,O
",",O
the,O
sequence,O
data,O
were,O
recoded,O
into,O
binary,O
characters,O
to,O
only,O
score,O
transversions,O
(,O
Rs,O
:,O
0,O
",",O
Ys,O
:,O
1,O
"),",O
otherwise,O
the,O
window,O
was,O
recorded,O
as,O
having,O
insufficient,O
data,O
.,O
A,O
Maximum,O
Likelihood,O
phylogeny,O
under,O
the,O
BINGAMMA,O
model,O
and,O
with,O
the,O
water,B-OG
buffalo,I-OG
as,O
outgroup,O
was,O
then,O
computed,O
for,O
each,O
alignment,O
with,O
sufficient,O
data,O
using,O
RaxML,O
(,O
Stamatakis,O
2014,O
).,O
The,O
topology,O
of,O
each,O
phylogeny,O
was,O
evaluated,O
using,O
a,O
custom,O
Perl,O
script,O
that,O
made,O
use,O
of,O
the,O
ETE3,O
software,O
(,O
Huerta,O
-,O
Cepas,O
et,O
al,O
.,O
2016,O
).,O
The,O
lengths,O
of,O
admixed,O
genomic,O
regions,O
were,O
estimated,O
by,O
counting,O
the,O
number,O
of,O
consecutive,O
1,O
Mb,O
blocks,O
returning,O
the,O
respective,O
tree,O
topology,O
.,O
Due,O
to,O
the,O
presence,O
of,O
blocks,O
with,O
insufficient,O
data,O
",",O
these,O
measurements,O
are,O
likely,O
to,O
be,O
underestimates,O
.,O
Evaluation,O
of,O
the,O
lengths,O
of,O
genomic,O
regions,O
was,O
conducted,O
using,O
the,O
empirical,O
cumulative,O
distribution,O
function,O
in,O
R,O
",",O
with,O
default,O
parameters,O
.,O
Supplementary,O
Material,O
Supplementary,O
data,O
are,O
available,O
at,O
Molecular,O
Biology,O
and,O
Evolution,O
online,O
.,O
Author,O
Contributions,O
K,O
.,O
W,O
".,",O
J,O
.,O
M,O
.,O
S,O
".,",O
A,O
.,O
B,O
".,",O
and,O
M,O
.,O
H,O
.,O
conceived,O
the,O
study,O
;,O
A,O
.,O
B,O
".,",O
K,O
.,O
W,O
".,",O
J,O
.,O
L,O
.,O
A,O
.,O
P,O
".,",O
and,O
P,O
.,O
D,O
.,O
H,O
.,O
designed,O
laboratory,O
experiments,O
;,O
K,O
.,O
W,O
".,",O
U,O
.,O
T,O
".,",O
G,O
.,O
X,O
".,",O
P,O
.,O
D,O
.,O
H,O
".,",O
and,O
B,O
.,O
S,O
.,O
performed,O
lab,O
work,O
;,O
K,O
.,O
W,O
".,",O
S,O
.,O
H,O
".,",O
A,O
.,O
B,O
".,",O
J,O
.,O
A,O
.,O
C,O
".,",O
J,O
.,O
L,O
.,O
A,O
.,O
P,O
".,",O
and,O
P,O
.,O
D,O
.,O
H,O
.,O
coordinated,O
data,O
analysis,O
;,O
K,O
.,O
W,O
".,",O
S,O
.,O
H,O
".,",O
A,O
.,O
B,O
".,",O
and,O
P,O
.,O
D,O
.,O
H,O
.,O
performed,O
data,O
analysis,O
;,O
K,O
.,O
W,O
".,",O
A,O
.,O
B,O
".,",O
and,O
M,O
.,O
H,O
.,O
coordinated,O
writing,O
of,O
the,O
manuscript,O
;,O
K,O
.,O
W,O
".,",O
J,O
.,O
M,O
.,O
S,O
".,",O
and,O
M,O
.,O
H,O
.,O
obtained,O
funding,O
;,O
G,O
.,O
B,O
".,",O
A,O
.,O
N,O
.,O
B,O
".,",O
J,O
.,O
J,O
.,O
C,O
".,",O
R,O
.,O
D,O
".,",O
N,O
.,O
M,O
".,",O
H,O
.,O
O,O
".,",O
M,O
.,O
T,O
".,",O
S,O
.,O
T,O
.,O
T,O
".,",O
J,O
.,O
M,O
.,O
W,O
".,",O
and,O
W,O
.,O
Ż,O
.,O
provided,O
samples,O
.,O
All,O
authors,O
read,O
",",O
gave,O
comments,O
and,O
helped,O
revise,O
the,O
final,O
version,O
of,O
the,O
manuscript,O
.,O
Supplementary,O
Material,O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Associate,O
editor,O
:,O
Rasmus,O
Nielsen,O
Human,B-OG
β,B-GP
-,I-GP
Defensin,I-GP
3,I-GP
Reduces,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
Induced,O
Inflammation,O
and,O
Monocyte,O
Adhesion,O
in,O
Human,B-OG
Umbilical,O
Vein,O
Endothelial,O
Cells,O
Academic,O
Editor,O
:,O
Ulrich,O
Eisel,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
the,O
role,O
of,O
human,B-OG
β,B-GP
-,I-GP
defensin,I-GP
3,I-GP
(,O
hBD3,B-GP
),O
in,O
the,O
initiation,O
stage,O
of,O
atherosclerosis,B-DS
with,O
human,B-OG
umbilical,O
vein,O
endothelial,O
cells,O
(,O
HUVECs,O
),O
triggered,O
by,O
tumor,B-GP
necrosis,I-GP
factor,I-GP
-,O
(,B-GP
TNF,I-GP
-),I-GP
α,I-GP
.,O
The,O
effects,O
of,O
hBD3,B-GP
on,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
endothelial,O
injury,O
and,O
inflammatory,O
response,O
were,O
evaluated,O
.,O
Our,O
data,O
revealed,O
that,O
first,O
",",O
hBD3,B-GP
reduced,O
the,O
production,O
of,O
interleukin,B-GP
-,I-GP
6,I-GP
(,O
IL,B-GP
-,I-GP
6,I-GP
"),",O
IL,B-GP
-,I-GP
8,I-GP
",",O
monocyte,B-GP
chemoattractant,I-GP
protein,I-GP
-,I-GP
1,I-GP
(,O
MCP,B-GP
-,I-GP
1,I-GP
"),",O
and,O
macrophage,B-GP
migration,I-GP
inhibitory,I-GP
factor,I-GP
(,O
MIF,B-GP
),O
in,O
HUVECs,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
In,O
addition,O
",",O
hBD3,B-GP
significantly,O
prevented,O
intracellular,O
reactive,O
oxygen,O
species,O
(,O
ROS,O
),O
production,O
by,O
HUVECs,O
.,O
Second,O
",",O
western,O
blot,O
analysis,O
demonstrated,O
that,O
hBD3,B-GP
dose,O
-,O
dependently,O
suppressed,O
the,O
protein,O
levels,O
of,O
intracellular,B-GP
adhesion,I-GP
molecule,I-GP
-,I-GP
1,I-GP
(,O
ICAM,B-GP
-,I-GP
1,I-GP
),O
and,O
vascular,B-GP
cell,I-GP
adhesion,I-GP
molecule,I-GP
-,I-GP
1,I-GP
(,O
VCAM,B-GP
-,I-GP
1,I-GP
),O
in,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
HUVECs,O
.,O
As,O
a,O
result,O
",",O
hBD3,B-GP
inhibited,O
monocyte,O
adhesion,O
to,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
treated,O
endothelial,O
cells,O
.,O
Additionally,O
",",O
hBD3,B-GP
suppressed,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
F,B-GP
-,I-GP
actin,I-GP
reorganization,O
in,O
HUVECs,O
.,O
Third,O
",",O
hBD3,B-GP
markedly,O
inhibited,O
NF,B-GP
-,I-GP
κB,I-GP
activation,O
by,O
decreasing,O
the,O
phosphorylation,O
of,O
IKK,B-GP
-,I-GP
α,I-GP
/,O
β,O
",",O
IκB,B-GP
",",O
and,O
p65,B-GP
subunit,O
within,O
30,O
min,O
.,O
Moreover,O
",",O
the,O
phosphorylation,O
of,O
p38,B-GP
and,O
c,B-GP
-,I-GP
Jun,I-GP
N,I-GP
-,I-GP
terminal,I-GP
protein,I-GP
kinase,I-GP
(,O
JNK,B-GP
),O
in,O
the,O
mitogen,B-GP
-,I-GP
activated,I-GP
protein,I-GP
kinase,I-GP
(,O
MAPK,B-GP
),O
pathway,O
were,O
also,O
inhibited,O
by,O
hBD3,B-GP
in,O
HUVECs,O
.,O
In,O
conclusion,O
",",O
hBD3,B-GP
exerts,O
anti,O
-,O
inflammatory,O
and,O
antioxidative,O
effects,O
in,O
endothelial,O
cells,O
in,O
response,O
to,O
TNF,B-GP
-,I-GP
α,I-GP
by,O
inhibiting,O
NF,B-GP
-,I-GP
κB,I-GP
and,O
MAPK,B-GP
signaling,O
.,O
1,O
.,O
Introduction,O
Atherosclerosis,B-DS
is,O
a,O
vascular,B-DS
inflammatory,I-DS
disease,I-DS
characterized,O
by,O
the,O
accumulation,O
of,O
lipids,O
and,O
immune,O
cells,O
on,O
the,O
inner,O
face,O
of,O
the,O
arterial,O
wall,O
.,O
Inflammatory,O
stimulation,O
",",O
even,O
low,O
level,O
endotoxemia,B-DS
",",O
can,O
aggravate,O
the,O
progression,O
of,O
this,O
disease,O
[,O
1,O
].,O
A,O
monolayer,O
of,O
endothelial,O
cells,O
",",O
which,O
directly,O
contacts,O
the,O
flowing,O
blood,O
",",O
is,O
easily,O
attacked,O
by,O
various,O
stimulating,O
factors,O
.,O
Endothelial,O
cell,O
dysfunction,O
triggered,O
by,O
such,O
stimulations,O
is,O
believed,O
to,O
be,O
the,O
initiation,O
step,O
and,O
key,O
contributor,O
in,O
the,O
pathogenesis,O
of,O
atherosclerosis,B-DS
[,O
2,O
].,O
Endothelial,O
cells,O
at,O
sites,O
of,O
inflammation,O
are,O
not,O
only,O
participants,O
but,O
also,O
regulators,O
of,O
inflammation,O
[,O
3,O
",",O
4,O
].,O
During,O
inflammation,O
",",O
a,O
large,O
amount,O
of,O
inflammatory,O
mediators,O
are,O
produced,O
by,O
immune,O
cells,O
",",O
such,O
as,O
macrophages,O
",",O
and,O
endothelial,O
cells,O
are,O
the,O
main,O
targets,O
.,O
Then,O
",",O
the,O
activated,O
endothelial,O
cells,O
secrete,O
a,O
broad,O
spectrum,O
of,O
cytokines,B-GP
and,O
chemokines,B-GP
",",O
recruiting,O
monocytes,O
.,O
Enhanced,O
migration,O
and,O
adhesion,O
of,O
monocytes,O
to,O
the,O
endothelium,O
are,O
suggested,O
to,O
play,O
a,O
crucial,O
role,O
in,O
atherosclerosis,B-DS
.,O
In,O
addition,O
",",O
the,O
expression,O
of,O
adhesion,B-GP
molecules,I-GP
required,O
for,O
the,O
firm,O
binding,O
of,O
monocytes,O
is,O
also,O
upregulated,O
on,O
endothelial,O
cell,O
surfaces,O
[,O
5,O
].,O
In,O
our,O
previous,O
study,O
",",O
the,O
results,O
demonstrated,O
that,O
chronic,O
exposure,O
to,O
the,O
endotoxin,O
of,O
Porphyromonas,B-OG
gingivalis,I-OG
can,O
aggravate,O
atherosclerotic,B-DS
lesions,I-DS
in,O
ApoE,B-GP
-,O
deficient,O
mice,B-OG
[,O
6,O
].,O
Indeed,O
",",O
compelling,O
evidence,O
has,O
demonstrated,O
the,O
proatherogenic,O
role,O
of,O
inflammatory,B-GP
cytokines,I-GP
in,O
the,O
pathogenesis,O
of,O
atherosclerosis,B-DS
.,O
Elevated,O
levels,O
of,O
several,O
inflammatory,O
markers,O
in,O
the,O
circulation,O
are,O
risk,O
factors,O
for,O
atherosclerotic,O
events,O
[,O
7,O
].,O
Tumor,B-GP
necrosis,I-GP
factor,I-GP
-,I-GP
α,I-GP
(,O
TNF,B-GP
-,I-GP
α,I-GP
"),",O
one,O
of,O
the,O
most,O
potent,O
inflammatory,B-GP
cytokines,I-GP
",",O
is,O
closely,O
associated,O
with,O
atherosclerosis,B-DS
.,O
It,O
is,O
mainly,O
produced,O
by,O
activated,O
macrophages,O
.,O
It,O
is,O
a,O
pleiotropic,O
cytokine,B-GP
mediating,O
inflammation,O
",",O
immunity,O
",",O
and,O
apoptosis,O
.,O
For,O
vascular,O
endothelial,O
cells,O
",",O
exposure,O
to,O
TNF,B-GP
-,I-GP
α,I-GP
triggers,O
several,O
signaling,O
cascades,O
in,O
human,B-OG
umbilical,O
vein,O
endothelial,O
cells,O
(,O
HUVECs,O
"),",O
especially,O
the,O
nuclear,B-GP
factor,I-GP
κB,I-GP
(,O
NF,B-GP
-,I-GP
κB,I-GP
"),",O
c,B-GP
-,I-GP
Jun,I-GP
N,I-GP
-,I-GP
terminal,I-GP
kinase,I-GP
(,O
JNK,B-GP
"),",O
and,O
p38,B-GP
mitogen,I-GP
-,I-GP
activated,I-GP
protein,I-GP
kinase,I-GP
pathways,O
",",O
leading,O
to,O
the,O
production,O
of,O
inflammatory,B-GP
cytokines,I-GP
[,O
8,O
].,O
In,O
addition,O
",",O
TNF,B-GP
-,I-GP
α,I-GP
can,O
reorganize,O
the,O
F,B-GP
-,I-GP
actin,I-GP
cytoskeleton,O
of,O
endothelial,O
cells,O
",",O
leading,O
to,O
the,O
formation,O
of,O
stress,O
fibers,O
[,O
9,O
].,O
TNF,B-GP
-,I-GP
α,I-GP
can,O
also,O
modulate,O
EC,O
permeability,O
by,O
enlarging,O
intercellular,O
gaps,O
",",O
promoting,O
vascular,O
leakage,O
at,O
sites,O
of,O
inflammation,O
[,O
10,O
].,O
TNF,B-GP
-,I-GP
α,I-GP
stimulation,O
is,O
also,O
associated,O
with,O
increased,O
intracellular,O
levels,O
of,O
reactive,O
oxygen,O
species,O
(,O
ROS,O
),O
formation,O
",",O
enhancing,O
monocyte,O
recruitment,O
and,O
adhesion,O
to,O
the,O
vascular,O
endothelium,O
.,O
This,O
process,O
is,O
mediated,O
mainly,O
by,O
elevated,O
cell,B-GP
adhesion,I-GP
molecules,I-GP
such,O
as,O
intercellular,B-GP
adhesion,I-GP
molecule,I-GP
-,I-GP
1,I-GP
(,O
ICAM,B-GP
-,I-GP
1,I-GP
"),",O
vascular,B-GP
cell,I-GP
adhesion,I-GP
molecule,I-GP
-,I-GP
1,I-GP
(,O
VCAM,B-GP
-,I-GP
1,I-GP
"),",O
and,O
endothelial,B-GP
cell,I-GP
selectin,I-GP
(,O
E,B-GP
-,I-GP
selectin,I-GP
).,O
Defensins,B-GP
are,O
naturally,O
occurring,O
peptides,O
with,O
a,O
wide,O
range,O
of,O
antimicrobial,O
",",O
antiviral,O
",",O
and,O
immunomodulatory,O
properties,O
.,O
They,O
are,O
cationic,O
",",O
cysteine,O
-,O
rich,O
",",O
β,O
-,O
sheet,O
",",O
and,O
tridisulfide,O
peptides,O
.,O
In,O
humans,B-OG
",",O
defensins,B-GP
are,O
classified,O
into,O
two,O
categories,O
",",O
α,O
-,O
and,O
β,B-GP
-,I-GP
defensins,I-GP
.,O
β,B-GP
-,I-GP
defensins,I-GP
are,O
mainly,O
produced,O
by,O
the,O
mucosa,O
and,O
epithelial,O
cells,O
.,O
Intraocular,O
tissues,O
and,O
the,O
human,B-OG
endometrium,O
are,O
also,O
reported,O
to,O
express,O
β,B-GP
-,I-GP
defensins,I-GP
[,O
11,O
].,O
Several,O
studies,O
have,O
documented,O
the,O
participation,O
of,O
antimicrobial,B-GP
peptides,I-GP
in,O
endothelial,O
immune,O
defense,O
[,O
12,O
",",O
13,O
].,O
In,O
addition,O
",",O
β,B-GP
-,I-GP
defensins,I-GP
are,O
beneficial,O
for,O
wound,O
healing,O
of,O
endothelial,O
cells,O
[,O
14,O
].,O
Human,B-OG
β,B-GP
-,I-GP
defensin,I-GP
3,I-GP
(,O
hBD3,B-GP
),O
is,O
a,O
member,O
of,O
the,O
β,B-GP
-,I-GP
defensin,I-GP
family,O
.,O
In,O
addition,O
to,O
epithelial,O
cells,O
",",O
hBD3,B-GP
is,O
also,O
expressed,O
in,O
endothelial,O
cells,O
.,O
The,O
gene,O
and,O
protein,O
expression,O
of,O
hBD3,B-GP
are,O
induced,O
in,O
human,B-OG
umbilical,O
vein,O
endothelial,O
cells,O
simulated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
[,O
15,O
].,O
The,O
upregulation,O
of,O
hBD3,B-GP
by,O
TNF,B-GP
-,I-GP
α,I-GP
in,O
HUVECs,O
illustrates,O
the,O
important,O
role,O
that,O
defensins,B-GP
play,O
in,O
host,O
immune,O
defense,O
against,O
inflammation,O
.,O
In,O
our,O
previous,O
study,O
",",O
we,O
demonstrated,O
that,O
hBD3,B-GP
strongly,O
inhibited,O
the,O
progression,O
of,O
early,O
-,O
stage,O
atherosclerotic,B-DS
lesions,I-DS
and,O
inflammation,O
levels,O
in,O
RAW,O
264,O
.,O
7,O
cells,O
and,O
human,B-OG
THP,O
-,O
1,O
-,O
derived,O
macrophages,O
[,O
16,O
",",O
17,O
].,O
However,O
",",O
the,O
cell,O
types,O
targeted,O
by,O
hBD3,B-GP
might,O
not,O
be,O
restricted,O
to,O
macrophages,O
.,O
Vascular,O
endothelial,O
cells,O
and,O
monocytes,O
/,O
macrophages,O
are,O
both,O
atherogenic,O
and,O
critical,O
components,O
in,O
the,O
process,O
of,O
atherogenesis,O
[,O
18,O
].,O
The,O
interaction,O
between,O
macrophages,O
and,O
endothelial,O
cells,O
is,O
very,O
crucial,O
in,O
atherosclerosis,B-DS
.,O
In,O
normal,O
conditions,O
",",O
resting,O
endothelial,O
cells,O
form,O
an,O
integrated,O
barrier,O
at,O
the,O
blood,O
-,O
tissue,O
interface,O
.,O
Upon,O
inflammatory,O
stimulation,O
",",O
quiescent,O
endothelial,O
cells,O
may,O
transform,O
into,O
a,O
proatherogenic,O
phenotype,O
",",O
inducing,O
the,O
infiltration,O
of,O
monocytes,O
[,O
19,O
].,O
The,O
recruited,O
monocytes,O
then,O
differentiate,O
into,O
macrophages,O
",",O
contributing,O
to,O
a,O
vicious,O
cycle,O
promoting,O
endothelial,B-DS
dysfunction,I-DS
[,O
20,O
].,O
As,O
the,O
endothelium,O
has,O
already,O
been,O
a,O
therapeutic,O
target,O
",",O
hBD3,B-GP
might,O
also,O
manifest,O
its,O
protective,O
effects,O
by,O
interacting,O
with,O
vessel,O
endothelial,O
cells,O
.,O
The,O
effects,O
of,O
hBD3,B-GP
on,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
endothelial,O
cell,O
activation,O
remain,O
unknown,O
.,O
Thus,O
",",O
the,O
present,O
study,O
was,O
designed,O
to,O
focus,O
on,O
the,O
effects,O
of,O
hBD3,B-GP
on,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
stimulated,O
endothelial,O
cell,O
dysfunction,O
",",O
including,O
the,O
enhanced,O
production,O
of,O
inflammatory,O
mediators,O
",",O
monocyte,O
adhesion,O
",",O
and,O
the,O
expression,O
of,O
cell,B-GP
adhesion,I-GP
molecules,I-GP
",",O
all,O
of,O
which,O
are,O
early,O
events,O
in,O
the,O
pathogenesis,O
of,O
atherosclerosis,B-DS
.,O
2,O
.,O
Materials,O
and,O
Methods,O
2,O
.,O
1,O
.,O
Cell,O
Culture,O
and,O
Reagents,O
Human,B-OG
primary,O
umbilical,O
vein,O
endothelial,O
cells,O
(,O
HUVECs,O
),O
(,O
ScienCell,O
Research,O
Laboratories,O
",",O
San,O
Diego,O
",",O
CA,O
),O
were,O
maintained,O
in,O
endothelial,O
cell,O
medium,O
(,O
ECM,O
),O
(,O
ScienCell,O
Research,O
Laboratories,O
),O
supplemented,O
with,O
5,O
%,O
FBS,O
",",O
1,O
%,O
penicillin,O
/,O
streptomycin,O
",",O
and,O
1,O
%,O
endothelial,O
cell,O
growth,O
supplement,O
(,O
ECGS,O
).,O
For,O
the,O
present,O
study,O
",",O
cells,O
at,O
passages,O
3,O
–,O
6,O
were,O
seeded,O
and,O
grown,O
until,O
confluence,O
.,O
Recombinant,O
human,B-OG
TNF,B-GP
-,I-GP
α,I-GP
and,O
hBD3,B-GP
were,O
obtained,O
from,O
PeproTech,O
(,O
Rocky,O
Hill,O
",",O
NJ,O
",",O
USA,O
).,O
Anti,O
-,O
ICAM,B-GP
-,I-GP
1,I-GP
and,O
anti,O
-,O
VCAM,B-GP
-,I-GP
1,I-GP
antibodies,B-GP
were,O
obtained,O
from,O
Santa,O
Cruz,O
Biotechnology,O
(,O
Santa,O
Cruz,O
",",O
CA,O
",",O
USA,O
).,O
Antiphosphorylated,O
and,O
total,O
IκBα,B-GP
",",O
p65,B-GP
",",O
p38,B-GP
",",O
ERK,B-GP
",",O
and,O
JNK,B-GP
antibodies,B-GP
were,O
purchased,O
from,O
Cell,O
Signaling,O
Technology,O
(,O
Beverly,O
",",O
MA,O
).,O
2,O
.,O
2,O
.,O
Cell,O
Viability,O
Assay,O
The,O
cell,O
viability,O
of,O
HUVECs,O
was,O
determined,O
using,O
a,O
CCK8,O
assay,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
HUVECs,O
(,O
5000,O
cells,O
/,O
well,O
),O
were,O
prepared,O
in,O
96,O
-,O
well,O
plates,O
and,O
incubated,O
overnight,O
before,O
treatment,O
with,O
various,O
concentrations,O
of,O
hBD3,B-GP
(,O
20,O
",",O
10,O
",",O
5,O
",",O
2,O
.,O
5,O
",",O
or,O
1,O
.,O
25,O
μg,O
/,O
mL,O
),O
and,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
40,O
ng,O
/,O
mL,O
),O
for,O
24,O
h,O
.,O
Subsequently,O
",",O
10,O
μL,O
of,O
CCK8,O
solution,O
(,O
Dojindo,O
Laboratories,O
",",O
Kumamoto,O
",",O
Japan,O
),O
was,O
added,O
to,O
each,O
well,O
",",O
and,O
the,O
cells,O
were,O
incubated,O
for,O
an,O
additional,O
3,O
h,O
.,O
The,O
optical,O
density,O
of,O
each,O
well,O
was,O
evaluated,O
at,O
a,O
wavelength,O
of,O
450,O
nm,O
on,O
a,O
microplate,O
spectrophotometer,O
.,O
2,O
.,O
3,O
.,O
Enzyme,O
-,O
Linked,O
Immunosorbent,O
Assay,O
(,O
ELISA,O
),O
HUVECs,O
were,O
seeded,O
and,O
cultured,O
in,O
a,O
96,O
-,O
well,O
plate,O
until,O
confluent,O
.,O
The,O
control,O
group,O
was,O
treated,O
with,O
ECM,O
and,O
the,O
other,O
seven,O
groups,O
were,O
treated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
40,O
ng,O
/,O
mL,O
),O
in,O
the,O
presence,O
of,O
various,O
concentrations,O
of,O
hBD3,B-GP
for,O
24,O
h,O
.,O
Then,O
the,O
cell,O
supernatants,O
were,O
collected,O
by,O
centrifugation,O
.,O
The,O
assay,O
was,O
performed,O
with,O
specific,O
ELISA,O
kits,O
(,O
R,O
&,O
D,O
Systems,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
recommendations,O
.,O
2,O
.,O
4,O
.,O
Monocyte,O
Adhesion,O
Assay,O
Confluent,O
HUVECs,O
were,O
stimulated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
40,O
ng,O
/,O
mL,O
),O
in,O
the,O
presence,O
or,O
absence,O
of,O
hBD3,B-GP
for,O
24,O
h,O
.,O
After,O
that,O
",",O
the,O
cells,O
were,O
washed,O
with,O
RPMI,O
-,O
1640,O
medium,O
before,O
being,O
cocultured,O
with,O
THP,O
-,O
1,O
cells,O
.,O
THP,O
-,O
1,O
cells,O
were,O
prelabeled,O
with,O
2,O
μM,O
calcein,O
-,O
AM,O
(,O
Dojindo,O
Laboratories,O
),O
in,O
RPMI,O
-,O
1640,O
medium,O
for,O
20,O
min,O
in,O
the,O
cell,O
incubator,O
before,O
being,O
added,O
to,O
each,O
well,O
of,O
HUVECs,O
and,O
further,O
incubated,O
for,O
30,O
min,O
.,O
After,O
coincubation,O
",",O
each,O
well,O
was,O
washed,O
gently,O
and,O
thoroughly,O
with,O
RPMI,O
-,O
1640,O
medium,O
supplemented,O
with,O
1,O
%,O
FBS,O
to,O
remove,O
the,O
nonadherent,O
THP,O
-,O
1,O
cells,O
.,O
The,O
attached,O
THP,O
-,O
1,O
cells,O
were,O
examined,O
under,O
a,O
microscope,O
(,O
Olympus,O
Corporation,O
",",O
Tokyo,O
",",O
Japan,O
),O
and,O
fluorescence,O
microplate,O
reader,O
at,O
excitation,O
and,O
emission,O
wavelengths,O
of,O
490,O
nm,O
and,O
515,O
nm,O
.,O
2,O
.,O
5,O
.,O
Western,O
Blot,O
Analysis,O
The,O
cells,O
were,O
lysed,O
in,O
RIPA,O
buffer,O
supplemented,O
with,O
protease,B-GP
inhibitors,O
for,O
30,O
min,O
",",O
and,O
the,O
whole,O
cell,O
lysates,O
were,O
separated,O
by,O
electrophoresis,O
in,O
sodium,O
dodecyl,O
sulfate,O
polyacrylamide,O
gels,O
(,O
SDS,O
-,O
PAGE,O
),O
and,O
then,O
transferred,O
to,O
PVDF,O
membranes,O
(,O
Millipore,O
",",O
Bedford,O
",",O
MA,O
",",O
USA,O
).,O
The,O
membranes,O
were,O
blocked,O
with,O
5,O
%,O
BSA,B-GP
at,O
room,O
temperature,O
for,O
2,O
h,O
before,O
incubation,O
overnight,O
with,O
primary,O
antibodies,B-GP
against,O
the,O
target,O
protein,O
.,O
Blots,O
were,O
washed,O
with,O
Tris,O
-,O
buffered,O
saline,O
containing,O
0,O
.,O
1,O
%,O
Tween,O
20,O
three,O
times,O
and,O
then,O
incubated,O
for,O
2,O
h,O
with,O
anti,O
-,O
rabbit,B-OG
secondary,O
antibody,B-GP
at,O
room,O
temperature,O
.,O
The,O
bands,O
were,O
detected,O
using,O
chemiluminescence,O
detection,O
agents,O
.,O
Images,O
were,O
captured,O
with,O
an,O
ImageQuant,O
LAS,O
4000,O
digital,O
imaging,O
system,O
(,O
GE,O
Healthcare,O
",",O
Piscataway,O
",",O
NJ,O
).,O
2,O
.,O
6,O
.,O
Immunofluorescence,O
Analysis,O
HUVECs,O
were,O
seeded,O
onto,O
sterile,O
glass,O
coverslips,O
in,O
a,O
12,O
-,O
well,O
cell,O
culture,O
plate,O
.,O
After,O
incubation,O
overnight,O
",",O
the,O
cells,O
were,O
treated,O
with,O
the,O
indicated,O
concentrations,O
of,O
hBD3,B-GP
under,O
TNF,B-GP
-,I-GP
α,I-GP
stimulation,O
for,O
the,O
indicated,O
time,O
.,O
Subsequently,O
",",O
the,O
cells,O
were,O
washed,O
and,O
fixed,O
in,O
4,O
%,O
paraformaldehyde,O
for,O
20,O
min,O
at,O
room,O
temperature,O
and,O
then,O
treated,O
with,O
0,O
.,O
3,O
%,O
Triton,O
X,O
-,O
100,O
for,O
15,O
min,O
.,O
After,O
that,O
",",O
the,O
cells,O
were,O
blocked,O
with,O
3,O
%,O
BSA,B-GP
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
Then,O
",",O
the,O
cells,O
were,O
further,O
incubated,O
with,O
the,O
indicated,O
rabbit,B-OG
primary,O
antibody,B-GP
at,O
4,O
°,O
C,O
overnight,O
",",O
followed,O
by,O
incubation,O
with,O
a,O
goat,B-OG
anti,O
-,O
rabbit,B-OG
secondary,O
antibody,B-GP
conjugated,O
to,O
Alexa,O
Fluor,O
488,O
(,O
for,O
NF,B-GP
-,I-GP
κB,I-GP
p65,B-GP
),O
(,O
1,O
:,O
1000,O
",",O
Abcam,O
),O
or,O
Alexa,O
Fluor,O
594,O
(,O
for,O
ICAM,B-GP
-,I-GP
1,I-GP
),O
(,O
1,O
:,O
1000,O
",",O
Abcam,O
),O
for,O
2,O
h,O
at,O
room,O
temperature,O
.,O
The,O
slides,O
were,O
then,O
mounted,O
with,O
one,O
drop,O
of,O
mounting,O
medium,O
that,O
contained,O
DAPI,O
.,O
NF,B-GP
-,I-GP
κB,I-GP
p65,B-GP
and,O
ICAM,B-GP
-,I-GP
1,I-GP
were,O
imaged,O
using,O
a,O
confocal,O
microscope,O
.,O
ICAM,B-GP
-,I-GP
1,I-GP
was,O
visualized,O
as,O
red,O
and,O
NF,B-GP
-,I-GP
κB,I-GP
p65,B-GP
was,O
visualized,O
as,O
green,O
",",O
with,O
nuclei,O
as,O
blue,O
.,O
2,O
.,O
7,O
.,O
Measurement,O
of,O
Intracellular,O
Reactive,O
Oxygen,O
Species,O
Intracellular,O
ROS,O
formation,O
was,O
determined,O
with,O
DCFH,O
-,O
DA,O
(,O
KeyGEN,O
",",O
Jiangsu,O
",",O
China,O
).,O
HUVECs,O
were,O
seeded,O
in,O
black,O
96,O
-,O
well,O
plates,O
.,O
Subsequently,O
",",O
the,O
cells,O
were,O
treated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
with,O
or,O
without,O
indicated,O
concentrations,O
of,O
hBD3,B-GP
for,O
2,O
h,O
.,O
The,O
cells,O
were,O
then,O
washed,O
with,O
PBS,O
and,O
incubated,O
with,O
20,O
μM,O
DCFH,O
-,O
DA,O
for,O
30,O
min,O
at,O
37,O
°,O
C,O
in,O
the,O
dark,O
.,O
The,O
fluorescence,O
level,O
was,O
determined,O
using,O
a,O
fluorescence,O
microplate,O
reader,O
at,O
an,O
excitation,O
wavelength,O
of,O
485,O
nm,O
and,O
an,O
emission,O
wavelength,O
of,O
530,O
nm,O
.,O
2,O
.,O
8,O
.,O
F,B-GP
-,I-GP
Actin,I-GP
Staining,O
Human,B-OG
umbilical,O
vein,O
endothelial,O
cells,O
were,O
cultured,O
and,O
treated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
as,O
indicated,O
.,O
Then,O
",",O
the,O
cells,O
were,O
fixed,O
with,O
4,O
%,O
paraformaldehyde,O
at,O
room,O
temperature,O
for,O
20,O
min,O
.,O
After,O
that,O
",",O
the,O
actin,B-GP
cytoskeleton,O
was,O
stained,O
with,O
DyLight,O
488,O
-,O
phalloidin,O
",",O
and,O
the,O
nuclei,O
were,O
stained,O
with,O
DAPI,O
.,O
Stained,O
HUVECs,O
were,O
visualized,O
using,O
a,O
confocal,O
microscope,O
(,O
Olympus,O
FV,O
10i,O
).,O
2,O
.,O
9,O
.,O
Statistical,O
Analysis,O
Data,O
are,O
expressed,O
as,O
the,O
means,O
±,O
SD,O
.,O
Comparison,O
between,O
different,O
treatments,O
was,O
performed,O
using,O
GraphPad,O
PRISM,O
software,O
version,O
6,O
.,O
0,O
using,O
one,O
-,O
way,O
ANOVA,O
with,O
Tukey,O
',O
s,O
post,O
hoc,O
test,O
.,O
Statistical,O
significance,O
was,O
set,O
at,O
p,O
values,O
<,O
0,O
.,O
05,O
.,O
3,O
.,O
Results,O
3,O
.,O
1,O
.,O
Effects,O
of,O
hBD3,B-GP
on,O
the,O
Viability,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
Induced,O
Endothelial,O
Cells,O
Numerous,O
studies,O
have,O
demonstrated,O
that,O
TNF,B-GP
-,I-GP
α,I-GP
treatment,O
can,O
impair,O
endothelial,O
cell,O
viability,O
and,O
induce,O
apoptosis,O
.,O
First,O
",",O
we,O
evaluated,O
the,O
cytotoxic,O
effects,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
on,O
HUVECs,O
using,O
a,O
CCK8,O
assay,O
.,O
All,O
data,O
are,O
expressed,O
as,O
the,O
survival,O
percentage,O
of,O
each,O
group,O
relative,O
to,O
the,O
control,O
group,O
",",O
which,O
is,O
defined,O
as,O
100,O
%.,O
As,O
shown,O
in,O
Figure,O
1,O
",",O
compared,O
with,O
the,O
control,O
group,O
",",O
TNF,B-GP
-,I-GP
α,I-GP
at,O
a,O
concentration,O
of,O
40,O
ng,O
/,O
mL,O
could,O
markedly,O
suppress,O
the,O
proliferation,O
of,O
HUVECs,O
by,O
nearly,O
50,O
%.,O
In,O
addition,O
",",O
treatment,O
with,O
hBD3,B-GP
at,O
5,O
μg,O
/,O
mL,O
and,O
10,O
μg,O
/,O
mL,O
markedly,O
recovered,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
impaired,O
cell,O
viability,O
to,O
about,O
79,O
.,O
1,O
%,O
and,O
101,O
.,O
7,O
"%,",O
respectively,O
.,O
The,O
results,O
also,O
suggested,O
that,O
hBD3,B-GP
does,O
not,O
influence,O
the,O
viability,O
of,O
HUVECs,O
.,O
3,O
.,O
2,O
.,O
Effects,O
of,O
hBD3,B-GP
on,O
the,O
Production,O
of,O
Proinflammatory,O
Mediators,O
by,O
Endothelial,O
Cells,O
Stimulated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
Next,O
",",O
we,O
examined,O
the,O
effects,O
of,O
hBD3,B-GP
on,O
endothelial,O
cell,O
activation,O
stimulated,O
by,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
Endothelial,O
cells,O
stimulated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
produce,O
proinflammatory,O
mediators,O
",",O
including,O
interleukin,B-GP
-,I-GP
(,I-GP
IL,I-GP
-),I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
8,I-GP
",",O
and,O
monocyte,B-GP
chemoattractant,I-GP
protein,I-GP
-,I-GP
1,I-GP
(,O
MCP,B-GP
-,I-GP
1,I-GP
"),",O
which,O
cause,O
more,O
monocytes,O
to,O
be,O
recruited,O
.,O
These,O
proinflammatory,O
mediators,O
are,O
reported,O
to,O
aggravate,O
endothelial,B-DS
dysfunction,I-DS
.,O
As,O
shown,O
in,O
Figure,O
2,O
(,O
a,O
"),",O
when,O
the,O
cells,O
were,O
treated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
for,O
24,O
h,O
",",O
IL,B-GP
-,I-GP
8,I-GP
production,O
in,O
the,O
supernatant,O
was,O
significantly,O
elevated,O
;,O
however,O
",",O
with,O
hBD3,B-GP
intervention,O
",",O
IL,B-GP
-,I-GP
8,I-GP
level,O
was,O
markedly,O
and,O
dose,O
-,O
dependently,O
inhibited,O
.,O
The,O
same,O
trend,O
of,O
IL,B-GP
-,I-GP
6,I-GP
and,O
MCP,B-GP
-,I-GP
1,I-GP
was,O
also,O
observed,O
in,O
Figures,O
2,O
(,O
b,O
),O
and,O
2,O
(,O
c,O
).,O
Macrophage,B-GP
migration,I-GP
inhibitory,I-GP
factor,I-GP
(,O
MIF,B-GP
),O
is,O
a,O
key,O
factor,O
mediating,O
the,O
interactions,O
between,O
macrophages,O
and,O
endothelial,O
cells,O
[,O
21,O
].,O
It,O
is,O
considered,O
to,O
interact,O
with,O
other,O
proinflammatory,B-GP
cytokines,I-GP
during,O
inflammation,O
.,O
There,O
is,O
evidence,O
showing,O
it,O
is,O
a,O
potent,O
activator,O
of,O
macrophages,O
released,O
by,O
activated,O
endothelial,O
cells,O
.,O
The,O
release,O
of,O
MIF,B-GP
by,O
HUVECs,O
was,O
markedly,O
inhibited,O
in,O
response,O
to,O
hBD3,B-GP
treatment,O
(,O
Figure,O
2,O
(,O
d,O
)).,O
3,O
.,O
3,O
.,O
Effects,O
of,O
hBD3,B-GP
on,O
the,O
Expression,O
of,O
Adhesion,B-GP
Molecules,I-GP
by,O
HUVECs,O
Accumulated,O
evidence,O
supports,O
a,O
role,O
for,O
adhesion,B-GP
molecules,I-GP
in,O
the,O
progression,O
of,O
atherosclerosis,B-DS
.,O
ICAM,B-GP
-,I-GP
1,I-GP
and,O
VCAM,B-GP
-,I-GP
1,I-GP
are,O
constitutively,O
expressed,O
on,O
the,O
surface,O
of,O
HUVECs,O
",",O
and,O
E,B-GP
-,I-GP
selectin,I-GP
is,O
only,O
expressed,O
on,O
the,O
activated,O
endothelium,O
[,O
22,O
].,O
The,O
interaction,O
of,O
E,B-GP
-,I-GP
selectin,I-GP
and,O
leukocytes,O
mediates,O
the,O
rolling,O
of,O
leukocytes,O
on,O
the,O
activated,O
endothelium,O
",",O
which,O
is,O
the,O
first,O
event,O
in,O
firm,O
adhesion,O
.,O
TNF,B-GP
-,I-GP
α,I-GP
is,O
known,O
to,O
transiently,O
upregulate,O
the,O
expression,O
of,O
adhesion,B-GP
molecules,I-GP
",",O
such,O
as,O
ICAM,B-GP
-,I-GP
1,I-GP
and,O
VCAM,B-GP
-,I-GP
1,I-GP
",",O
in,O
HUVECs,O
[,O
23,O
].,O
We,O
then,O
evaluated,O
the,O
effects,O
of,O
hBD3,B-GP
on,O
the,O
expression,O
of,O
adhesion,B-GP
molecules,I-GP
induced,O
by,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
As,O
demonstrated,O
in,O
Figure,O
3,O
(,O
a,O
"),",O
treatment,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
40,O
ng,O
/,O
mL,O
),O
significantly,O
enhanced,O
the,O
expression,O
level,O
of,O
ICAM,B-GP
-,I-GP
1,I-GP
(,O
24,O
h,O
"),",O
VCAM,B-GP
-,I-GP
1,I-GP
(,O
24,O
h,O
"),",O
and,O
E,B-GP
-,I-GP
selectin,I-GP
(,O
4,O
h,O
).,O
In,O
addition,O
",",O
hBD3,B-GP
treatment,O
dose,O
-,O
dependently,O
prevented,O
the,O
upregulation,O
of,O
ICAM,B-GP
-,I-GP
1,I-GP
",",O
VCAM,B-GP
-,I-GP
1,I-GP
",",O
and,O
E,B-GP
-,I-GP
selectin,I-GP
levels,O
by,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
The,O
immunofluorescence,O
staining,O
assay,O
also,O
validated,O
the,O
inhibitory,O
effects,O
of,O
hBD3,B-GP
(,O
15,O
μg,O
/,O
mL,O
),O
on,O
ICAM,B-GP
-,I-GP
1,I-GP
expression,O
levels,O
triggered,O
by,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
Figure,O
3,O
(,O
b,O
)).,O
3,O
.,O
4,O
.,O
Effects,O
of,O
hBD3,B-GP
on,O
Monocyte,O
Adhesion,O
to,O
Endothelial,O
Cells,O
During,O
the,O
initiation,O
of,O
atherosclerosis,B-DS
",",O
endothelial,O
cells,O
are,O
activated,O
and,O
upregulate,O
adhesion,B-GP
molecules,I-GP
and,O
chemokine,B-GP
and,O
cytokine,B-GP
secretion,O
",",O
which,O
is,O
beneficial,O
for,O
monocyte,O
recruitment,O
.,O
Due,O
to,O
the,O
significant,O
decrease,O
in,O
cell,O
surface,O
adhesion,B-GP
molecules,I-GP
and,O
proinflammatory,O
mediators,O
in,O
hBD3,B-GP
-,O
treated,O
HUVECs,O
",",O
we,O
investigated,O
whether,O
hBD3,B-GP
could,O
affect,O
the,O
attachment,O
of,O
immune,O
cells,O
to,O
endothelial,O
cells,O
.,O
To,O
evaluate,O
the,O
effects,O
of,O
hBD3,B-GP
on,O
THP,O
-,O
1,O
monocyte,O
adhesion,O
to,O
HUVECs,O
in,O
a,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
stimulated,O
proinflammatory,O
environment,O
",",O
HUVECs,O
were,O
seeded,O
and,O
cultured,O
to,O
about,O
90,O
%,O
confluence,O
and,O
then,O
stimulated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
40,O
ng,O
/,O
mL,O
),O
in,O
the,O
presence,O
or,O
absence,O
of,O
hBD3,B-GP
(,O
15,O
μg,O
/,O
mL,O
),O
for,O
24,O
h,O
.,O
Subsequently,O
",",O
HUVECs,O
were,O
cocultured,O
with,O
prelabeled,O
THP,O
-,O
1,O
cells,O
for,O
30,O
min,O
.,O
After,O
removal,O
of,O
nonadherent,O
THP,O
-,O
1,O
cells,O
by,O
gentle,O
washing,O
",",O
images,O
were,O
captured,O
under,O
a,O
fluorescence,O
microscope,O
.,O
As,O
shown,O
in,O
Figures,O
4,O
(,O
a,O
),O
and,O
4,O
(,O
b,O
"),",O
we,O
observed,O
that,O
",",O
compared,O
with,O
the,O
control,O
group,O
",",O
TNF,B-GP
-,I-GP
α,I-GP
treatment,O
resulted,O
in,O
a,O
4,O
-,O
fold,O
increase,O
(,O
p,O
<,O
0,O
.,O
001,O
),O
in,O
THP,O
-,O
1,O
attachment,O
to,O
HUVECs,O
.,O
However,O
",",O
hBD3,B-GP
intervention,O
significantly,O
decreased,O
THP,O
-,O
1,O
adhesion,O
to,O
HUVECs,O
(,O
p,O
<,O
0,O
.,O
01,O
).,O
3,O
.,O
5,O
.,O
hBD3,B-GP
Suppressed,O
Activation,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
and,O
MAPK,B-GP
Pathways,O
in,O
HUVECs,O
NF,B-GP
-,I-GP
κB,I-GP
is,O
considered,O
as,O
an,O
important,O
regulator,O
of,O
the,O
proinflammatory,O
process,O
and,O
monocyte,O
adhesion,O
.,O
To,O
identify,O
the,O
probable,O
molecular,O
mechanism,O
responsible,O
for,O
hBD3,B-GP
involvement,O
in,O
the,O
modulation,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
treated,O
HUVECs,O
",",O
we,O
first,O
evaluated,O
the,O
classical,O
NF,B-GP
-,I-GP
κB,I-GP
signaling,O
pathway,O
.,O
Here,O
",",O
we,O
show,O
that,O
hBD3,B-GP
strongly,O
inhibits,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
stimulated,O
HUVECs,O
via,O
two,O
distinct,O
signaling,O
pathways,O
",",O
an,O
NF,B-GP
-,I-GP
κB,I-GP
-,O
dependent,O
pathway,O
and,O
the,O
MAPK,B-GP
pathway,O
.,O
We,O
examined,O
key,O
factors,O
in,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
with,O
western,O
blot,O
.,O
Activation,O
of,O
NF,B-GP
-,I-GP
κB,I-GP
required,O
the,O
phosphorylation,O
and,O
degradation,O
of,O
IκB,B-GP
.,O
As,O
shown,O
in,O
Figure,O
5,O
(,O
a,O
"),",O
degradation,O
and,O
phosphorylation,O
of,O
IκB,B-GP
were,O
significantly,O
suppressed,O
by,O
the,O
addition,O
of,O
hBD3,B-GP
.,O
The,O
effective,O
role,O
of,O
hBD3,B-GP
to,O
prevent,O
phosphorylation,O
of,O
p65,B-GP
subunit,O
was,O
also,O
observed,O
.,O
In,O
addition,O
",",O
phosphorylated,O
IKKα,B-GP
",",O
which,O
is,O
the,O
upstream,O
modulator,O
in,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
",",O
was,O
also,O
inhibited,O
by,O
hBD3,B-GP
.,O
To,O
validate,O
this,O
result,O
",",O
immunofluorescence,O
staining,O
was,O
used,O
to,O
determine,O
NF,B-GP
-,I-GP
κB,I-GP
nuclear,O
translocation,O
.,O
As,O
shown,O
in,O
Figure,O
5,O
(,O
b,O
"),",O
NF,B-GP
-,I-GP
κB,I-GP
p65,B-GP
was,O
predominantly,O
located,O
within,O
the,O
cytoplasm,O
in,O
unstimulated,O
cells,O
.,O
With,O
TNF,B-GP
-,I-GP
α,I-GP
treatment,O
",",O
p65,B-GP
translocated,O
to,O
the,O
nucleus,O
within,O
30,O
min,O
.,O
However,O
",",O
treatment,O
with,O
hBD3,B-GP
at,O
15,O
μg,O
/,O
mL,O
led,O
to,O
retention,O
of,O
the,O
p65,B-GP
subunit,O
in,O
the,O
cytoplasm,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
stimulated,O
cells,O
.,O
We,O
then,O
investigated,O
the,O
role,O
of,O
the,O
MAPK,B-GP
pathway,O
in,O
this,O
process,O
.,O
The,O
key,O
components,O
of,O
the,O
MAPK,B-GP
pathway,O
",",O
p38,B-GP
",",O
ERK,B-GP
",",O
and,O
JNK,B-GP
were,O
evaluated,O
with,O
a,O
western,O
blot,O
.,O
As,O
shown,O
in,O
Figure,O
5,O
(,O
c,O
"),",O
treatment,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
resulted,O
in,O
a,O
significant,O
increase,O
of,O
phosphorylation,O
in,O
the,O
MAPK,B-GP
pathway,O
.,O
The,O
phosphorylation,O
of,O
p38,B-GP
and,O
JNK,B-GP
was,O
significantly,O
and,O
concentration,O
-,O
dependently,O
suppressed,O
by,O
hBD3,B-GP
at,O
30,O
min,O
",",O
while,O
the,O
phosphorylation,O
of,O
ERK,B-GP
was,O
not,O
altered,O
.,O
The,O
cell,O
lysates,O
obtained,O
at,O
45,O
min,O
also,O
validated,O
this,O
result,O
.,O
3,O
.,O
6,O
.,O
Effects,O
of,O
hBD3,B-GP
on,O
the,O
Activation,O
of,O
Caspases,B-GP
and,O
Bcl,B-GP
-,I-GP
2,I-GP
Expression,O
in,O
HUVECs,O
TNF,B-GP
-,I-GP
α,I-GP
has,O
been,O
reported,O
to,O
stimulate,O
apoptosis,O
in,O
HUVECs,O
.,O
In,O
addition,O
",",O
the,O
cleavage,O
of,O
caspase,B-GP
-,I-GP
3,I-GP
is,O
a,O
key,O
step,O
in,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
cell,O
death,O
.,O
Before,O
activation,O
",",O
caspase,B-GP
-,I-GP
3,I-GP
exists,O
as,O
an,O
inactive,O
form,O
.,O
After,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
treatment,O
",",O
caspase,B-GP
-,I-GP
3,I-GP
was,O
cleaved,O
to,O
the,O
active,O
form,O
.,O
The,O
activation,O
of,O
caspases,B-GP
is,O
considered,O
one,O
mechanism,O
of,O
apoptosis,O
.,O
Therefore,O
",",O
we,O
investigated,O
the,O
effects,O
of,O
hBD3,B-GP
on,O
the,O
activation,O
of,O
caspases,B-GP
.,O
HUVECs,O
were,O
treated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
40,O
ng,O
/,O
mL,O
),O
for,O
6,O
h,O
.,O
The,O
expression,O
levels,O
of,O
caspase,B-GP
-,I-GP
3,I-GP
were,O
examined,O
with,O
western,O
blot,O
.,O
Western,O
blot,O
analysis,O
revealed,O
that,O
the,O
expression,O
levels,O
of,O
cleaved,O
caspase,B-GP
-,I-GP
3,I-GP
significantly,O
increased,O
following,O
TNF,B-GP
-,I-GP
α,I-GP
treatment,O
",",O
while,O
hBD3,B-GP
markedly,O
suppressed,O
this,O
phenomenon,O
.,O
Meanwhile,O
",",O
we,O
examined,O
the,O
expression,O
level,O
of,O
Bcl,B-GP
-,I-GP
2,I-GP
.,O
As,O
shown,O
in,O
Figure,O
6,O
",",O
there,O
was,O
a,O
clear,O
decrease,O
in,O
the,O
expression,O
of,O
Bcl,B-GP
-,I-GP
2,I-GP
after,O
treatment,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
These,O
results,O
suggested,O
that,O
hBD3,B-GP
inhibited,O
the,O
apoptosis,O
of,O
HUVECs,O
stimulated,O
by,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
3,O
.,O
7,O
.,O
hBD3,B-GP
Suppressed,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
Induced,O
ROS,O
Formation,O
in,O
HUVECs,O
It,O
has,O
been,O
suggested,O
that,O
the,O
enhanced,O
production,O
of,O
intracellular,O
ROS,O
can,O
lead,O
to,O
cell,O
apoptosis,O
.,O
To,O
measure,O
the,O
potential,O
modulation,O
of,O
apoptosis,O
and,O
oxidative,O
stress,O
by,O
hBD3,B-GP
",",O
the,O
production,O
of,O
ROS,O
was,O
evaluated,O
for,O
fluorescence,O
intensity,O
in,O
HUVECs,O
.,O
As,O
revealed,O
in,O
Figure,O
7,O
(,O
a,O
"),",O
HUVECs,O
stimulated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
produced,O
an,O
intracellular,O
burst,O
of,O
ROS,O
(,O
about,O
3,O
.,O
9,O
-,O
fold,O
change,O
).,O
The,O
intracellular,O
ROS,O
production,O
in,O
HUVECs,O
was,O
significantly,O
suppressed,O
when,O
treated,O
with,O
hBD3,B-GP
.,O
However,O
",",O
the,O
basal,O
level,O
of,O
ROS,O
was,O
not,O
altered,O
by,O
treatment,O
with,O
hBD3,B-GP
alone,O
.,O
3,O
.,O
8,O
.,O
hBD3,B-GP
Repressed,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
Induced,O
F,B-GP
-,I-GP
Actin,I-GP
Reorganization,O
in,O
HUVECs,O
TNF,B-GP
-,I-GP
α,I-GP
is,O
reported,O
to,O
have,O
the,O
ability,O
to,O
alter,O
the,O
permeability,O
and,O
morphology,O
of,O
endothelial,O
cells,O
.,O
To,O
investigate,O
the,O
role,O
of,O
hBD3,B-GP
in,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
endothelial,O
function,O
",",O
HUVECs,O
were,O
treated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
(,O
40,O
ng,O
/,O
mL,O
),O
in,O
the,O
presence,O
or,O
absence,O
of,O
hBD3,B-GP
(,O
15,O
μg,O
/,O
mL,O
),O
for,O
24,O
h,O
.,O
Then,O
",",O
the,O
cells,O
were,O
fixed,O
and,O
stained,O
with,O
phalloidin,O
.,O
As,O
shown,O
in,O
Figure,O
8,O
",",O
stimulating,O
HUVECs,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
resulted,O
in,O
a,O
significant,O
increase,O
in,O
the,O
formation,O
of,O
actin,B-GP
stress,O
fibers,O
.,O
In,O
addition,O
",",O
hBD3,B-GP
treatment,O
markedly,O
reduced,O
this,O
alteration,O
in,O
HUVECs,O
.,O
4,O
.,O
Discussion,O
Atherosclerosis,B-DS
is,O
defined,O
as,O
a,O
chronic,O
inflammatory,O
-,O
fibroproliferative,O
response,O
of,O
the,O
vascular,O
wall,O
to,O
various,O
forms,O
of,O
inflammatory,O
stimuli,O
.,O
Disruption,O
of,O
the,O
endothelial,O
cell,O
barrier,O
induced,O
by,O
proinflammatory,B-GP
cytokines,I-GP
",",O
such,O
as,O
TNF,B-GP
-,I-GP
α,I-GP
",",O
is,O
the,O
initiating,O
step,O
of,O
this,O
disease,O
.,O
Endothelial,O
cells,O
maintain,O
vascular,O
homeostasis,O
via,O
the,O
secretion,O
of,O
several,O
vasoactive,O
factors,O
",",O
and,O
impairment,O
of,O
barrier,O
integrity,O
leads,O
to,O
the,O
development,O
of,O
vascular,B-DS
inflammatory,I-DS
diseases,I-DS
",",O
such,O
as,O
atherosclerosis,B-DS
.,O
As,O
a,O
monolayer,O
in,O
direct,O
contact,O
with,O
the,O
bloodstream,O
",",O
the,O
vascular,O
endothelium,O
is,O
the,O
principal,O
physiological,O
target,O
of,O
the,O
proinflammatory,O
actions,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
and,O
IL,B-GP
-,I-GP
1,I-GP
.,O
Extensive,O
evidence,O
has,O
suggested,O
that,O
the,O
endothelium,O
is,O
not,O
simply,O
the,O
inner,O
cellular,O
lining,O
of,O
blood,O
vessels,O
[,O
24,O
].,O
Beyond,O
being,O
passively,O
targeted,O
",",O
endothelial,O
cells,O
are,O
believed,O
to,O
be,O
profoundly,O
involved,O
in,O
this,O
inflammatory,O
process,O
",",O
especially,O
in,O
the,O
regulation,O
of,O
effector,O
cells,O
",",O
such,O
as,O
monocytes,O
and,O
lymphocytes,O
.,O
Therefore,O
",",O
the,O
endothelium,O
may,O
act,O
as,O
a,O
therapeutic,O
target,O
due,O
to,O
its,O
critical,O
role,O
in,O
the,O
inflammatory,O
process,O
[,O
25,O
].,O
Macrophage,B-GP
migration,I-GP
inhibitory,I-GP
factor,I-GP
(,O
MIF,B-GP
),O
is,O
one,O
of,O
the,O
most,O
important,O
cytokines,B-GP
produced,O
by,O
endothelial,O
cells,O
to,O
control,O
the,O
accumulation,O
of,O
effector,O
cells,O
[,O
26,O
].,O
It,O
is,O
recognized,O
as,O
an,O
effective,O
activator,O
of,O
macrophages,O
",",O
participating,O
in,O
the,O
process,O
of,O
recruitment,O
and,O
the,O
accumulation,O
of,O
macrophages,O
at,O
local,O
inflammatory,O
sites,O
.,O
As,O
monocyte,O
adhesion,O
to,O
the,O
endothelium,O
is,O
a,O
crucial,O
step,O
in,O
the,O
early,O
stages,O
of,O
atherosclerosis,B-DS
",",O
MIF,B-GP
is,O
considered,O
to,O
be,O
involved,O
in,O
the,O
pathogenesis,O
of,O
atherosclerosis,B-DS
and,O
is,O
closely,O
related,O
to,O
plaque,O
stability,O
[,O
27,O
].,O
Elevated,O
MIF,B-GP
expression,O
was,O
observed,O
in,O
response,O
to,O
some,O
immunostimulants,O
in,O
HUVECs,O
[,O
28,O
].,O
In,O
our,O
experiment,O
",",O
the,O
production,O
of,O
MIF,B-GP
was,O
markedly,O
increased,O
under,O
TNF,B-GP
-,I-GP
α,I-GP
stimulation,O
in,O
HUVECs,O
",",O
while,O
treatment,O
with,O
hBD3,B-GP
dose,O
-,O
dependently,O
reduced,O
MIF,B-GP
expression,O
.,O
This,O
result,O
was,O
also,O
confirmed,O
by,O
the,O
effect,O
of,O
hBD3,B-GP
in,O
inhibiting,O
the,O
adhesion,O
of,O
monocytes,O
to,O
endothelial,O
cells,O
.,O
A,O
prominent,O
feature,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
endothelial,O
cell,O
injury,O
is,O
the,O
excess,O
generation,O
of,O
intracellular,O
ROS,O
.,O
Moderate,O
levels,O
of,O
ROS,O
have,O
been,O
reported,O
to,O
participate,O
in,O
the,O
physiological,O
functions,O
of,O
cells,O
",",O
while,O
the,O
overproduction,O
of,O
intracellular,O
ROS,O
is,O
closely,O
associated,O
with,O
the,O
progression,O
of,O
atherosclerosis,B-DS
[,O
29,O
",",O
30,O
].,O
Oxidative,O
stress,O
activates,O
endothelial,O
cells,O
",",O
causing,O
cell,O
injury,O
",",O
apoptosis,O
",",O
and,O
enhanced,O
monocyte,O
adhesion,O
.,O
In,O
the,O
present,O
study,O
",",O
treatment,O
with,O
hBD3,B-GP
attenuated,O
ROS,O
production,O
in,O
HUVECs,O
stimulated,O
with,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
The,O
binding,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
to,O
cell,B-GP
surface,I-GP
receptors,I-GP
triggers,O
multiple,O
signaling,O
events,O
",",O
including,O
NF,B-GP
-,I-GP
κB,I-GP
and,O
MAPK,B-GP
pathway,O
.,O
NF,B-GP
-,I-GP
κB,I-GP
has,O
been,O
demonstrated,O
to,O
be,O
a,O
key,O
transcription,B-GP
factor,I-GP
in,O
this,O
signaling,O
pathway,O
.,O
Activation,O
of,O
NF,B-GP
-,I-GP
κB,I-GP
is,O
closely,O
associated,O
with,O
the,O
initiation,O
and,O
progression,O
of,O
atherosclerosis,B-DS
.,O
In,O
resting,O
cells,O
",",O
NF,B-GP
-,I-GP
κB,I-GP
is,O
maintained,O
in,O
an,O
inactive,O
form,O
within,O
the,O
cytoplasm,O
by,O
the,O
inhibitor,B-GP
of,I-GP
κB,I-GP
(,O
IκB,B-GP
),O
family,O
but,O
enters,O
the,O
nucleus,O
in,O
response,O
to,O
external,O
stimuli,O
",",O
such,O
as,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
IκB,B-GP
kinase,I-GP
-,O
(,O
IKK,B-GP
-),O
dependent,O
phosphorylation,O
and,O
the,O
subsequent,O
ubiquitination,O
and,O
degradation,O
of,O
IκB,B-GP
make,O
NF,B-GP
-,I-GP
κB,I-GP
free,O
to,O
translocate,O
to,O
the,O
nucleus,O
and,O
induce,O
downstream,O
transcription,O
[,O
31,O
].,O
NF,B-GP
-,I-GP
κB,I-GP
has,O
been,O
identified,O
as,O
an,O
important,O
target,O
in,O
the,O
treatment,O
of,O
atherosclerosis,B-DS
.,O
Our,O
data,O
revealed,O
that,O
hBD3,B-GP
markedly,O
reduced,O
the,O
phosphorylation,O
of,O
IκB,B-GP
.,O
Additionally,O
",",O
the,O
p65,B-GP
subunit,O
of,O
NF,B-GP
-,I-GP
κB,I-GP
is,O
constitutively,O
phosphorylated,O
at,O
a,O
low,O
level,O
in,O
unstimulated,O
conditions,O
",",O
and,O
treatment,O
with,O
inflammatory,O
triggers,O
",",O
LPS,O
and,O
TNF,B-GP
-,I-GP
α,I-GP
",",O
for,O
example,O
",",O
results,O
in,O
further,O
phosphorylation,O
.,O
The,O
total,O
level,O
of,O
phosphorylation,O
of,O
p65,B-GP
was,O
also,O
suppressed,O
by,O
the,O
addition,O
of,O
hBD3,B-GP
.,O
We,O
also,O
investigated,O
the,O
phosphorylation,O
of,O
IKK,B-GP
-,I-GP
α,I-GP
/,O
β,O
",",O
which,O
is,O
an,O
upstream,O
signaling,O
molecule,O
of,O
NF,B-GP
-,I-GP
κB,I-GP
.,O
The,O
results,O
demonstrated,O
that,O
hBD3,B-GP
inhibited,O
IKK,B-GP
-,I-GP
α,I-GP
/,O
β,O
phosphorylation,O
30,O
min,O
after,O
TNF,B-GP
-,I-GP
α,I-GP
stimulation,O
.,O
In,O
addition,O
",",O
the,O
inhibition,O
of,O
ROS,O
generation,O
also,O
contributes,O
to,O
the,O
decrease,O
in,O
NF,B-GP
-,I-GP
κB,I-GP
activation,O
",",O
as,O
NF,B-GP
-,I-GP
κB,I-GP
activation,O
by,O
ROS,O
through,O
the,O
IKK,B-GP
pathway,O
has,O
been,O
suggested,O
[,O
32,O
].,O
The,O
downregulation,O
of,O
cell,B-GP
adhesion,I-GP
molecules,I-GP
in,O
HUVECs,O
by,O
hBD3,B-GP
might,O
be,O
mediated,O
through,O
inhibition,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
",",O
as,O
the,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
mediated,O
increase,O
in,O
ICAM,B-GP
-,I-GP
1,I-GP
and,O
VCAM,B-GP
-,I-GP
1,I-GP
expression,O
is,O
mediated,O
through,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
",",O
not,O
the,O
MAPK,B-GP
pathway,O
[,O
33,O
].,O
Ample,O
evidence,O
has,O
documented,O
intensive,O
crosstalk,O
between,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
and,O
MAPK,B-GP
signaling,O
pathways,O
.,O
The,O
MAPK,B-GP
pathway,O
is,O
required,O
for,O
NF,B-GP
-,I-GP
κB,I-GP
activation,O
in,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
mediated,O
inflammation,O
[,O
34,O
].,O
In,O
addition,O
",",O
the,O
JNK,B-GP
pathway,O
was,O
suggested,O
to,O
promote,O
cell,O
apoptosis,O
[,O
35,O
].,O
hBD3,B-GP
was,O
reported,O
to,O
rapidly,O
enter,O
the,O
cells,O
and,O
impact,O
TLR,B-GP
signaling,O
pathway,O
associated,O
with,O
MyD88,B-GP
and,O
TRIF,B-GP
[,O
36,O
].,O
In,O
this,O
case,O
",",O
there,O
is,O
also,O
possibility,O
that,O
hBD3,B-GP
inhibits,O
TNF,B-GP
signaling,O
via,O
interaction,O
with,O
the,O
upstream,O
molecules,O
in,O
the,O
signaling,O
pathway,O
.,O
Further,O
research,O
needs,O
to,O
be,O
done,O
to,O
elucidate,O
this,O
problem,O
.,O
Human,B-OG
β,B-GP
-,I-GP
defensin,I-GP
3,I-GP
is,O
a,O
multifunctional,O
effector,O
molecule,O
involved,O
in,O
a,O
startling,O
range,O
of,O
cellular,O
processes,O
.,O
First,O
",",O
as,O
an,O
antimicrobial,O
peptide,O
",",O
hBD3,B-GP
exhibits,O
broad,O
antimicrobial,O
activity,O
against,O
Gram,O
-,O
positive,O
and,O
Gram,O
-,O
negative,O
bacteria,B-OG
",",O
fungi,B-OG
",",O
and,O
viruses,B-OG
[,O
37,O
].,O
Second,O
",",O
it,O
was,O
demonstrated,O
to,O
have,O
immunomodulatory,O
effects,O
due,O
to,O
its,O
biphasic,O
effect,O
in,O
the,O
host,O
immune,O
response,O
.,O
It,O
can,O
be,O
either,O
proinflammatory,O
or,O
anti,O
-,O
inflammatory,O
",",O
depending,O
on,O
the,O
circumstances,O
[,O
38,O
",",O
39,O
].,O
In,O
addition,O
",",O
the,O
beneficial,O
effects,O
of,O
hBD3,B-GP
on,O
wound,O
healing,O
were,O
also,O
reported,O
[,O
40,O
].,O
We,O
previously,O
demonstrated,O
that,O
hBD3,B-GP
significantly,O
inhibited,O
the,O
progression,O
of,O
early,O
-,O
stage,O
atherosclerotic,B-DS
lesions,I-DS
",",O
and,O
this,O
effect,O
was,O
correlated,O
with,O
downregulation,O
of,O
macrophage,O
inflammation,O
.,O
To,O
date,O
",",O
there,O
is,O
no,O
study,O
focusing,O
on,O
the,O
effects,O
of,O
hBD3,B-GP
on,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
endothelial,O
inflammation,O
.,O
In,O
the,O
present,O
study,O
",",O
our,O
data,O
extend,O
the,O
protective,O
effects,O
of,O
hBD3,B-GP
to,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
endothelial,O
cell,O
injury,O
.,O
Owing,O
to,O
their,O
strong,O
antimicrobial,O
activity,O
",",O
low,O
molecular,O
weight,O
",",O
and,O
immunogenicity,O
",",O
several,O
researchers,O
and,O
studies,O
are,O
focusing,O
on,O
the,O
clinical,O
use,O
of,O
antimicrobial,B-GP
peptides,I-GP
as,O
a,O
new,O
class,O
of,O
antibiotics,O
[,O
41,O
"],",O
and,O
some,O
of,O
them,O
are,O
already,O
in,O
the,O
clinical,O
development,O
stage,O
[,O
42,O
].,O
However,O
",",O
β,B-GP
-,I-GP
defensins,I-GP
had,O
limited,O
success,O
in,O
clinical,O
application,O
.,O
The,O
reasons,O
include,O
the,O
high,O
synthesis,O
cost,O
and,O
short,O
half,O
-,O
lives,O
in,O
blood,O
.,O
Cationic,O
peptides,O
are,O
not,O
stable,O
in,O
the,O
serum,O
due,O
to,O
high,O
susceptibility,O
to,O
enzymatic,O
degradation,O
.,O
hBD3,B-GP
was,O
observed,O
to,O
be,O
completely,O
digested,O
in,O
contact,O
with,O
simulated,O
gastric,O
fluid,O
[,O
43,O
].,O
One,O
solution,O
to,O
the,O
limitations,O
is,O
gene,O
delivery,O
of,O
hBD3,B-GP
.,O
Another,O
way,O
is,O
to,O
develop,O
a,O
structurally,O
modified,O
peptide,O
of,O
hBD3,B-GP
with,O
certain,O
biological,O
activity,O
.,O
Notable,O
examples,O
include,O
a,O
C,O
-,O
terminus,O
peptide,O
and,O
a,O
linear,O
hBD3,B-GP
peptide,O
with,O
anti,O
-,O
inflammatory,O
and,O
antifungal,O
activities,O
[,O
44,O
–,O
46,O
].,O
This,O
may,O
provide,O
new,O
therapeutic,O
approaches,O
to,O
harness,O
the,O
pharmaceutical,O
potential,O
of,O
hBD3,B-GP
.,O
However,O
",",O
the,O
endothelial,O
cells,O
we,O
used,O
in,O
this,O
study,O
were,O
obtained,O
from,O
the,O
human,B-OG
umbilical,O
vein,O
",",O
not,O
aortas,O
",",O
which,O
are,O
the,O
main,O
location,O
forming,O
atherosclerotic,O
plaques,O
.,O
The,O
difference,O
in,O
physiology,O
and,O
shear,O
stress,O
between,O
veins,O
and,O
arteries,O
might,O
contribute,O
to,O
heterogeneity,O
between,O
ECs,O
in,O
veins,O
and,O
aortas,O
[,O
47,O
–,O
49,O
].,O
In,O
addition,O
",",O
some,O
differences,O
in,O
the,O
immune,O
response,O
to,O
proinflammatory,B-GP
cytokines,I-GP
",",O
such,O
as,O
TNF,B-GP
-,I-GP
α,I-GP
",",O
might,O
exist,O
.,O
Further,O
confirmation,O
in,O
animal,O
models,O
should,O
be,O
performed,O
to,O
uncover,O
the,O
underlying,O
molecular,O
mechanisms,O
.,O
In,O
addition,O
",",O
cell,O
density,O
was,O
identified,O
to,O
have,O
an,O
impact,O
on,O
the,O
immune,O
response,O
of,O
HUVECs,O
[,O
50,O
].,O
5,O
.,O
Conclusion,O
In,O
summary,O
",",O
the,O
results,O
of,O
this,O
study,O
demonstrate,O
that,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
induced,O
endothelial,O
cell,O
activation,O
can,O
be,O
reversed,O
by,O
treatment,O
with,O
hBD3,B-GP
.,O
Furthermore,O
",",O
the,O
anti,O
-,O
inflammatory,O
effects,O
of,O
hBD3,B-GP
in,O
TNF,B-GP
-,I-GP
α,I-GP
-,O
treated,O
HUVECs,O
seem,O
to,O
be,O
closely,O
related,O
to,O
downregulation,O
of,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
and,O
MAPK,B-GP
pathway,O
.,O
Effects,O
of,O
hBD3,O
on,O
TNF,O
-,O
α,O
-,O
induced,O
cell,O
death,O
.,O
HUVECs,O
were,O
treated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
and,O
various,O
concentrations,O
of,O
hBD3,O
for,O
24,O
h,O
.,O
The,O
cell,O
viability,O
of,O
HUVECs,O
was,O
determined,O
with,O
a,O
CCK8,O
assay,O
according,O
to,O
the,O
instructions,O
of,O
manufacturers,O
.,O
Data,O
are,O
presented,O
as,O
the,O
survival,O
rate,O
compared,O
to,O
the,O
control,O
group,O
",",O
which,O
is,O
defined,O
as,O
100,O
%.,O
Values,O
represent,O
the,O
means,O
±,O
SD,O
(,O
n,O
=,O
6,O
).,O
###,O
p,O
<,O
0,O
.,O
001,O
compared,O
with,O
the,O
control,O
group,O
.,O
∗∗,O
p,O
<,O
0,O
.,O
01,O
",",O
∗∗∗,O
p,O
<,O
0,O
.,O
001,O
compared,O
with,O
TNF,O
-,O
α,O
group,O
.,O
Effects,O
of,O
hBD3,O
on,O
IL,O
-,O
8,O
",",O
IL,O
-,O
6,O
",",O
MCP,O
-,O
1,O
",",O
and,O
MIF,O
production,O
in,O
TNF,O
-,O
α,O
-,O
stimulated,O
HUVECs,O
.,O
Cells,O
were,O
incubated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
with,O
or,O
without,O
various,O
concentrations,O
of,O
hBD3,O
for,O
24,O
h,O
.,O
Then,O
",",O
the,O
culture,O
supernatants,O
were,O
collected,O
by,O
centrifugation,O
and,O
analyzed,O
by,O
ELISA,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
Data,O
are,O
expressed,O
as,O
the,O
mean,O
±,O
SD,O
(,O
n,O
=,O
6,O
).,O
###,O
p,O
<,O
0,O
.,O
001,O
compared,O
with,O
the,O
control,O
group,O
.,O
∗,O
p,O
<,O
0,O
.,O
05,O
",",O
∗∗,O
p,O
<,O
0,O
.,O
01,O
",",O
and,O
∗∗∗,O
p,O
<,O
0,O
.,O
001,O
compared,O
with,O
TNF,O
-,O
α,O
group,O
.,O
The,O
effects,O
of,O
hBD3,O
on,O
the,O
expression,O
of,O
adhesion,O
molecules,O
in,O
TNF,O
-,O
α,O
-,O
activated,O
HUVECs,O
.,O
(,O
a,O
),O
HUVECs,O
were,O
incubated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
with,O
or,O
without,O
the,O
indicated,O
concentrations,O
of,O
hBD3,O
for,O
24,O
h,O
(,O
ICAM,O
-,O
1,O
and,O
VCAM,O
-,O
1,O
analysis,O
),O
or,O
4,O
h,O
(,O
E,O
-,O
selectin,O
analysis,O
).,O
Whole,O
cell,O
lysates,O
were,O
extracted,O
and,O
analyzed,O
by,O
western,O
blot,O
using,O
antibodies,O
specific,O
to,O
VCAM,O
-,O
1,O
",",O
ICAM,O
-,O
1,O
",",O
and,O
E,O
-,O
selectin,O
.,O
(,O
b,O
),O
Immunofluorescence,O
analysis,O
for,O
ICAM,O
-,O
1,O
expression,O
was,O
conducted,O
as,O
mentioned,O
above,O
",",O
and,O
images,O
were,O
obtained,O
using,O
a,O
fluorescence,O
microscope,O
(,O
original,O
magnification,O
:,O
400x,O
",",O
scale,O
bar,O
50,O
μm,O
).,O
Effects,O
of,O
hBD3,O
on,O
TNF,O
-,O
α,O
-,O
induced,O
adhesion,O
to,O
THP,O
-,O
1,O
cells,O
in,O
HUVECs,O
.,O
HUVECs,O
were,O
stimulated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
and,O
the,O
indicated,O
concentrations,O
of,O
hBD3,O
for,O
24,O
h,O
.,O
After,O
stimulation,O
",",O
HUVECs,O
were,O
cocultured,O
with,O
calcein,O
-,O
AM,O
-,O
labeled,O
THP,O
-,O
1,O
cells,O
for,O
30,O
min,O
.,O
(,O
a,O
),O
Images,O
were,O
captured,O
using,O
a,O
fluorescence,O
microscope,O
(,O
original,O
magnification,O
:,O
100x,O
).,O
(,O
b,O
),O
Adherent,O
cells,O
were,O
measured,O
using,O
a,O
microplate,O
reader,O
at,O
excitation,O
and,O
emission,O
wavelengths,O
of,O
490,O
nm,O
and,O
515,O
nm,O
",",O
respectively,O
.,O
The,O
results,O
were,O
expressed,O
as,O
the,O
mean,O
±,O
SD,O
",",O
n,O
=,O
3,O
.,O
###,O
p,O
<,O
0,O
.,O
001,O
compared,O
with,O
the,O
control,O
group,O
.,O
∗∗,O
p,O
<,O
0,O
.,O
01,O
compared,O
with,O
TNF,O
-,O
α,O
group,O
.,O
Effects,O
of,O
hBD3,O
on,O
TNF,O
-,O
α,O
-,O
induced,O
NF,O
-,O
κB,O
and,O
MAPK,O
activation,O
in,O
HUVECs,O
.,O
(,O
a,O
),O
HUVECs,O
were,O
incubated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
with,O
or,O
without,O
the,O
indicated,O
concentrations,O
of,O
hBD3,O
for,O
30,O
min,O
.,O
Whole,O
cell,O
lysates,O
were,O
centrifuged,O
and,O
analyzed,O
with,O
western,O
blot,O
using,O
specific,O
antibodies,O
.,O
(,O
b,O
),O
Immunofluorescence,O
analysis,O
for,O
NF,O
-,O
κB,O
p65,O
localization,O
was,O
conducted,O
as,O
mentioned,O
above,O
",",O
and,O
images,O
were,O
captured,O
using,O
a,O
confocal,O
laser,O
scanning,O
microscope,O
system,O
(,O
Nikon,O
A1,O
",",O
Japan,O
),O
(,O
original,O
magnification,O
:,O
400x,O
",",O
scale,O
bar,O
50,O
μm,O
).,O
(,O
c,O
),O
HUVECs,O
were,O
incubated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
with,O
or,O
without,O
the,O
indicated,O
concentrations,O
of,O
hBD3,O
for,O
30,O
min,O
and,O
45,O
min,O
.,O
Whole,O
cell,O
lysates,O
were,O
centrifuged,O
and,O
analyzed,O
with,O
western,O
blot,O
using,O
specific,O
antibodies,O
.,O
hBD3,O
inhibits,O
HUVEC,O
apoptosis,O
stimulated,O
by,O
TNF,O
-,O
α,O
.,O
After,O
incubation,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
and,O
different,O
concentrations,O
of,O
hBD3,O
for,O
6,O
h,O
",",O
the,O
protein,O
levels,O
of,O
cleaved,O
caspase,O
-,O
3,O
and,O
β,O
-,O
actin,O
in,O
HUVECs,O
were,O
detected,O
with,O
an,O
immunoblot,O
assay,O
.,O
Inhibitory,O
effects,O
of,O
hBD3,O
on,O
TNF,O
-,O
α,O
-,O
induced,O
ROS,O
formation,O
in,O
HUVECs,O
.,O
HUVECs,O
were,O
incubated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
and,O
hBD3,O
(,O
15,O
μg,O
/,O
mL,O
),O
for,O
2,O
h,O
.,O
Intracellular,O
ROS,O
accumulation,O
was,O
determined,O
by,O
observation,O
under,O
a,O
fluorescence,O
microscope,O
(,O
a,O
),O
or,O
fluorescence,O
measurement,O
with,O
a,O
microplate,O
reader,O
(,O
b,O
),O
after,O
incubation,O
with,O
the,O
ROS,O
detector,O
DCFH,O
-,O
DA,O
for,O
30,O
min,O
(,O
original,O
magnification,O
:,O
400x,O
).,O
Values,O
represent,O
the,O
mean,O
±,O
SD,O
.,O
###,O
p,O
<,O
0,O
.,O
001,O
compared,O
with,O
the,O
control,O
group,O
;,O
∗∗∗,O
p,O
<,O
0,O
.,O
001,O
compared,O
with,O
TNF,O
-,O
α,O
alone,O
.,O
Effects,O
of,O
hBD3,O
on,O
TNF,O
-,O
α,O
-,O
induced,O
F,O
-,O
actin,O
rearrangement,O
.,O
HUVECs,O
were,O
incubated,O
with,O
TNF,O
-,O
α,O
(,O
40,O
ng,O
/,O
mL,O
),O
with,O
or,O
without,O
hBD3,O
(,O
15,O
μg,O
/,O
mL,O
),O
for,O
24,O
h,O
.,O
After,O
that,O
",",O
cells,O
were,O
washed,O
with,O
PBS,O
.,O
F,O
-,O
actin,O
was,O
stained,O
with,O
DyLight,O
488,O
-,O
phalloidin,O
for,O
15,O
min,O
in,O
the,O
dark,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
Images,O
were,O
obtained,O
using,O
a,O
confocal,O
microscope,O
(,O
Olympus,O
FV10i,O
),O
(,O
original,O
magnification,O
:,O
600x,O
",",O
scale,O
bar,O
50,O
μm,O
).,O
The,O
humanistic,O
",",O
economic,O
and,O
societal,O
burden,O
of,O
Herpes,B-DS
Zoster,I-DS
in,O
Europe,O
:,O
a,O
critical,O
review,O
Background,O
Herpes,B-DS
zoster,I-DS
(,O
HZ,B-DS
),O
or,O
“,O
shingles,B-DS
”,O
is,O
common,O
in,O
persons,O
aged,O
50,O
years,O
or,O
over,O
.,O
HZ,B-DS
is,O
characterised,O
by,O
a,O
painful,O
dermatological,O
rash,O
which,O
typically,O
resolves,O
in,O
approximately,O
one,O
month,O
.,O
Persistent,O
pain,O
for,O
months,O
or,O
years,O
after,O
rash,O
onset,O
",",O
however,O
",",O
is,O
a,O
common,O
complication,O
of,O
HZ,B-DS
;,O
referred,O
to,O
as,O
post,B-DS
-,I-DS
herpetic,I-DS
neuralgia,I-DS
(,O
PHN,B-DS
).,O
Both,O
HZ,B-DS
and,O
PHN,B-DS
have,O
a,O
significant,O
impact,O
on,O
patients,O
’,O
lives,O
",",O
with,O
considerable,O
implications,O
for,O
healthcare,O
systems,O
and,O
wider,O
society,O
.,O
The,O
aim,O
of,O
the,O
present,O
review,O
is,O
to,O
provide,O
comprehensive,O
documentation,O
and,O
critical,O
appraisal,O
of,O
published,O
data,O
concerning,O
the,O
humanistic,O
",",O
economic,O
and,O
societal,O
burden,O
of,O
HZ,B-DS
in,O
Europe,O
.,O
Methods,O
Systematic,O
literature,O
searches,O
were,O
conducted,O
in,O
Medline,O
",",O
EMBASE,O
",",O
PsycINFO,O
",",O
EconLit,O
",",O
HEED,O
and,O
CRD,O
databases,O
.,O
Searches,O
were,O
conducted,O
in,O
July,O
2014,O
and,O
restricted,O
to,O
articles,O
published,O
in,O
the,O
past,O
20,O
years,O
.,O
Articles,O
were,O
selected,O
for,O
full,O
review,O
by,O
two,O
independent,O
researchers,O
in,O
accordance,O
with,O
predefined,O
eligibility,O
criteria,O
.,O
Results,O
From,O
a,O
review,O
of,O
1619,O
abstracts,O
",",O
53,O
eligible,O
articles,O
",",O
were,O
identified,O
which,O
reported,O
data,O
concerning,O
healthcare,O
resource,O
use,O
(,O
n,O
=,O
38,O
"),",O
direct,O
costs,O
(,O
n,O
=,O
20,O
"),",O
indirect,O
costs,O
(,O
n,O
=,O
16,O
"),",O
total,O
costs,O
(,O
n,O
=,O
10,O
),O
and,O
impact,O
on,O
health,O
-,O
related,O
quality,O
of,O
life,O
(,O
HRQoL,O
),O
(,O
n,O
=,O
21,O
).,O
Findings,O
highlight,O
that,O
PHN,B-DS
is,O
associated,O
with,O
greater,O
impairments,O
in,O
HRQoL,O
and,O
higher,O
costs,O
of,O
management,O
than,O
HZ,B-DS
.,O
For,O
both,O
HZ,B-DS
and,O
PHN,B-DS
",",O
pain,O
severity,O
is,O
a,O
significant,O
predictor,O
of,O
impact,O
on,O
individuals,O
",",O
healthcare,O
systems,O
and,O
society,O
.,O
While,O
the,O
incidence,O
of,O
HZ,B-DS
and,O
PHN,B-DS
increase,O
with,O
age,O
",",O
age,O
does,O
not,O
appear,O
to,O
be,O
a,O
key,O
driver,O
of,O
overall,O
costs,O
for,O
HZ,B-DS
and,O
PHN,B-DS
.,O
Specifically,O
",",O
while,O
direct,O
costs,O
(,O
e,O
.,O
g,O
.,O
GP,O
",",O
specialists,O
",",O
medications,O
",",O
hospitalisations,O
),O
tend,O
to,O
be,O
higher,O
for,O
older,O
patients,O
",",O
indirect,O
costs,O
(,O
e,O
.,O
g,O
.,O
work,O
time,O
missed,O
),O
are,O
higher,O
for,O
younger,O
patients,O
.,O
Conclusions,O
Available,O
evidence,O
highlights,O
that,O
HZ,B-DS
and,O
PHN,B-DS
result,O
in,O
significant,O
humanistic,O
and,O
economic,O
burden,O
for,O
patients,O
",",O
healthcare,O
systems,O
and,O
wider,O
societies,O
.,O
A,O
tendency,O
to,O
focus,O
upon,O
healthcare,O
resource,O
use,O
and,O
the,O
direct,O
costs,O
of,O
management,O
at,O
the,O
expense,O
of,O
other,O
impacts,O
(,O
e,O
.,O
g,O
.,O
informal,O
caregivers,O
and,O
formal,O
social,O
care,O
),O
may,O
result,O
in,O
an,O
underestimation,O
of,O
the,O
true,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
.,O
Background,O
Herpes,B-DS
zoster,I-DS
(,O
HZ,B-DS
"),",O
also,O
known,O
as,O
shingles,B-DS
",",O
is,O
caused,O
by,O
the,O
reactivation,O
of,O
the,O
varicella,B-OG
zoster,I-OG
virus,I-OG
(,O
VZV,B-OG
).,O
Primary,O
infection,B-DS
with,O
VZV,B-OG
usually,O
occurs,O
during,O
childhood,O
",",O
manifesting,O
as,O
chickenpox,B-DS
",",O
after,O
which,O
the,O
virus,O
lies,O
dormant,O
[,O
1,O
].,O
The,O
great,O
majority,O
(,O
95,O
%),O
[,O
2,O
],O
of,O
the,O
population,O
hosts,O
VZV,B-OG
and,O
approximately,O
one,O
in,O
four,O
persons,O
will,O
develop,O
HZ,B-DS
in,O
their,O
lifetime,O
through,O
reactivation,O
",",O
leading,O
to,O
an,O
estimated,O
1,O
.,O
7,O
million,O
episodes,O
in,O
Europe,O
annually,O
[,O
3,O
].,O
VZV,B-OG
reactivation,O
is,O
primarily,O
related,O
to,O
an,O
age,O
-,O
related,O
decline,O
in,O
VZV,B-OG
-,O
specific,O
immunity,O
;,O
it,O
is,O
well,O
documented,O
that,O
the,O
incidence,O
of,O
HZ,B-DS
increases,O
with,O
age,O
",",O
with,O
the,O
majority,O
of,O
cases,O
occurring,O
in,O
patients,O
over,O
50,O
years,O
of,O
age,O
[,O
4,O
].,O
HZ,B-DS
is,O
characterized,O
by,O
a,O
painful,O
dermatomal,O
rash,O
",",O
which,O
most,O
commonly,O
presents,O
on,O
the,O
trunk,O
and,O
lumbar,O
regions,O
.,O
HZ,B-DS
",",O
however,O
",",O
may,O
present,O
along,O
any,O
nerve,O
including,O
the,O
ophthalmic,O
division,O
of,O
the,O
trigeminal,O
nerve,O
where,O
it,O
can,O
affect,O
the,O
eye,O
.,O
Herpes,B-DS
Zoster,I-DS
Ophthalmicus,I-DS
(,O
HZO,B-DS
),O
occurs,O
in,O
10,O
-,O
20,O
%,O
of,O
all,O
HZ,B-DS
cases,O
and,O
in,O
some,O
cases,O
can,O
lead,O
to,O
ocular,O
complications,O
[,O
5,O
].,O
The,O
dermatological,O
rash,O
and,O
pain,O
associated,O
with,O
HZ,B-DS
typically,O
resolves,O
within,O
one,O
month,O
of,O
presentation,O
[,O
4,O
];,O
however,O
",",O
long,O
-,O
term,O
complications,O
can,O
arise,O
.,O
Post,B-DS
-,I-DS
herpetic,I-DS
neuralgia,I-DS
(,O
PHN,B-DS
),O
is,O
the,O
most,O
common,O
and,O
debilitating,O
complication,O
of,O
HZ,B-DS
",",O
occurring,O
in,O
approximately,O
10,O
-,O
20,O
%,O
of,O
all,O
sufferers,O
[,O
6,O
-,O
8,O
],O
and,O
as,O
many,O
as,O
50,O
%,O
of,O
those,O
aged,O
85,O
years,O
and,O
over,O
[,O
9,O
].,O
PHN,B-DS
is,O
a,O
neuropathic,B-DS
syndrome,I-DS
manifesting,O
as,O
on,O
-,O
going,O
pain,O
along,O
the,O
nerves,O
in,O
the,O
area,O
of,O
the,O
prior,O
HZ,B-DS
rash,O
and,O
typically,O
involves,O
one,O
or,O
more,O
of,O
the,O
following,O
:,O
spontaneous,O
aching,O
or,O
burning,O
;,O
paroxysmal,O
shooting,O
pains,O
;,O
allodynia,O
",",O
and,O
hyperalgesia,O
[,O
9,O
",",O
10,O
].,O
There,O
is,O
no,O
consensus,O
regarding,O
the,O
definition,O
of,O
PHN,B-DS
;,O
however,O
",",O
PHN,B-DS
is,O
often,O
defined,O
as,O
pain,O
persisting,O
for,O
90,O
days,O
from,O
HZ,B-DS
rash,O
onset,O
[,O
4,O
",",O
6,O
",",O
10,O
",",O
11,O
].,O
While,O
HZ,B-DS
is,O
an,O
acute,O
experience,O
that,O
typically,O
resolves,O
within,O
one,O
month,O
",",O
in,O
the,O
majority,O
of,O
sufferers,O
",",O
PHN,B-DS
persists,O
for,O
at,O
least,O
6,O
months,O
with,O
some,O
patients,O
experiencing,O
PHN,B-DS
for,O
years,O
[,O
12,O
-,O
15,O
].,O
As,O
expected,O
given,O
the,O
relationship,O
to,O
HZ,B-DS
",",O
the,O
incidence,O
of,O
PHN,B-DS
increases,O
markedly,O
with,O
age,O
[,O
16,O
-,O
18,O
].,O
The,O
incidence,O
of,O
PHN,B-DS
is,O
also,O
linked,O
to,O
the,O
severity,O
of,O
pain,O
experienced,O
during,O
the,O
prior,O
HZ,B-DS
episode,O
(,O
among,O
other,O
predictors,O
such,O
as,O
the,O
severity,O
of,O
the,O
dermatomal,O
rash,O
and,O
prodromal,O
symptoms,O
),O
[,O
19,O
"],",O
with,O
those,O
patients,O
experiencing,O
the,O
highest,O
levels,O
of,O
pain,O
during,O
HZ,B-DS
presentation,O
being,O
most,O
at,O
risk,O
of,O
developing,O
PHN,B-DS
[,O
20,O
].,O
As,O
conditions,O
primarily,O
affecting,O
older,O
persons,O
",",O
many,O
patients,O
with,O
HZ,B-DS
and,O
PHN,B-DS
may,O
already,O
experience,O
significant,O
deficits,O
in,O
health,O
status,O
.,O
Findings,O
from,O
a,O
number,O
of,O
articles,O
indicate,O
that,O
the,O
pain,O
and,O
resulting,O
discomfort,O
associated,O
with,O
HZ,B-DS
and,O
PHN,B-DS
can,O
have,O
a,O
substantial,O
negative,O
and,O
widespread,O
impact,O
on,O
patients,O
’,O
health,O
-,O
related,O
quality,O
of,O
life,O
(,O
HRQoL,O
),O
and,O
patients,O
’,O
ability,O
to,O
engage,O
in,O
activities,O
of,O
daily,O
living,O
[,O
7,O
",",O
20,O
-,O
25,O
].,O
In,O
addition,O
to,O
the,O
burden,O
encountered,O
by,O
the,O
individual,O
with,O
HZ,B-DS
",",O
the,O
condition,O
is,O
also,O
associated,O
with,O
considerable,O
economic,O
burden,O
.,O
For,O
example,O
",",O
considerable,O
costs,O
to,O
healthcare,O
systems,O
[,O
26,O
-,O
31,O
],O
arise,O
from,O
the,O
care,O
provision,O
for,O
HZ,B-DS
and,O
PHN,B-DS
patients,O
",",O
including,O
visits,O
to,O
primary,O
care,O
(,O
general,O
practitioner,O
),O
and,O
outpatient,O
secondary,O
/,O
tertiary,O
care,O
(,O
specialist,O
pain,O
clinics,O
and,O
ophthalmologists,O
"),",O
inpatient,O
visits,O
(,O
hospitalisations,O
),O
and,O
prescription,O
costs,O
.,O
Furthermore,O
",",O
HZ,B-DS
and,O
PHN,B-DS
are,O
also,O
associated,O
with,O
significant,O
indirect,O
costs,O
",",O
primarily,O
in,O
terms,O
of,O
loss,O
of,O
productivity,O
for,O
younger,O
patients,O
[,O
7,O
",",O
21,O
",",O
23,O
",",O
24,O
",",O
28,O
",",O
32,O
].,O
Finally,O
",",O
as,O
conditions,O
occurring,O
in,O
retired,O
and,O
older,O
patients,O
",",O
HZ,B-DS
and,O
PHN,B-DS
can,O
also,O
have,O
significant,O
consequences,O
for,O
the,O
caregivers,O
of,O
patients,O
including,O
partners,O
",",O
relatives,O
",",O
and,O
friends,O
of,O
people,O
with,O
the,O
conditions,O
[,O
7,O
].,O
Such,O
details,O
",",O
however,O
",",O
may,O
often,O
go,O
unreported,O
and,O
are,O
not,O
often,O
communicated,O
in,O
the,O
research,O
literature,O
.,O
Evidence,O
for,O
the,O
efficacy,O
of,O
a,O
VZV,B-OG
vaccine,O
in,O
the,O
prevention,O
of,O
HZ,B-DS
and,O
PHN,B-DS
episodes,O
and,O
attenuation,O
of,O
the,O
severity,O
of,O
HZ,B-DS
and,O
PHN,B-DS
episodes,O
and,O
associated,O
impact,O
has,O
been,O
documented,O
in,O
recent,O
years,O
[,O
11,O
",",O
33,O
].,O
In,O
order,O
to,O
understand,O
the,O
value,O
of,O
preventative,O
strategies,O
",",O
a,O
complete,O
understanding,O
of,O
the,O
impact,O
of,O
HZ,B-DS
and,O
PHN,B-DS
is,O
required,O
.,O
While,O
a,O
significant,O
body,O
of,O
literature,O
has,O
sought,O
to,O
determine,O
the,O
impact,O
of,O
HZ,B-DS
and,O
PHN,B-DS
on,O
patients,O
",",O
healthcare,O
systems,O
and,O
wider,O
society,O
within,O
EU,O
countries,O
",",O
to,O
date,O
",",O
no,O
comprehensive,O
review,O
of,O
these,O
studies,O
has,O
been,O
conducted,O
.,O
The,O
aim,O
of,O
this,O
review,O
",",O
therefore,O
",",O
is,O
to,O
provide,O
a,O
comprehensive,O
and,O
holistic,O
overview,O
of,O
the,O
humanistic,O
",",O
economic,O
and,O
societal,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
in,O
Europe,O
as,O
reported,O
within,O
the,O
published,O
peer,O
-,O
reviewed,O
literature,O
.,O
Methods,O
Published,O
peer,O
-,O
reviewed,O
articles,O
were,O
identified,O
via,O
systematic,O
searches,O
conducted,O
in,O
the,O
following,O
biomedical,O
and,O
economic,O
databases,O
:,O
EMBASE,O
",",O
Medline,O
",",O
PsycINFO,O
",",O
EconLit,O
",",O
Health,O
Economic,O
Evaluations,O
Database,O
(,O
HEED,O
),O
and,O
the,O
Centre,O
for,O
Reviews,O
and,O
Dissemination,O
databases,O
at,O
the,O
University,O
of,O
York,O
.,O
Searches,O
and,O
reviews,O
were,O
conducted,O
in,O
accordance,O
with,O
the,O
Cochrane,O
systematic,O
review,O
guidelines,O
[,O
34,O
].,O
A,O
range,O
of,O
disease,O
-,O
related,O
",",O
economic,O
",",O
societal,O
and,O
HRQoL,O
-,O
related,O
keywords,O
was,O
utilized,O
to,O
capture,O
the,O
humanistic,O
",",O
economic,O
and,O
societal,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
(,O
see,O
Table,O
1,O
).,O
Searches,O
were,O
conducted,O
in,O
July,O
2014,O
and,O
were,O
restricted,O
to,O
articles,O
published,O
in,O
the,O
last,O
20,O
years,O
.,O
Although,O
data,O
relating,O
to,O
the,O
EU,O
was,O
the,O
primary,O
focus,O
of,O
this,O
review,O
",",O
no,O
limits,O
regarding,O
study,O
country,O
or,O
article,O
language,O
were,O
implemented,O
during,O
the,O
search,O
stage,O
(,O
so,O
to,O
not,O
exclude,O
potentially,O
relevant,O
articles,O
).,O
Instead,O
",",O
articles,O
focused,O
on,O
the,O
EU,O
were,O
prioritized,O
as,O
part,O
of,O
the,O
article,O
selection,O
process,O
.,O
Table,O
1Search,O
terms,O
Databases,O
searched,O
Disease,O
search,O
terms,O
Economic,O
",",O
humanistic,O
and,O
societal,O
burden,O
search,O
terms,O
•,O
Medline,O
“,O
Herpes,B-DS
Zoster,I-DS
”,O
OR,O
“,O
Shingles,B-DS
”,O
OR,O
“,O
Post,B-DS
-,I-DS
herpetic,I-DS
Neuralgia,I-DS
”,O
OR,O
“,O
Post,B-DS
herpetic,I-DS
Neuralgia,I-DS
”,O
OR,O
“,O
Postherpetic,B-DS
Neuralgia,I-DS
”,O
OR,O
“,O
PHN,B-DS
”“,O
Burden,O
”,O
OR,O
“,O
Humanistic,O
”,O
OR,O
“,O
quality,O
of,O
life,O
”,O
OR,O
“,O
QOL,O
”,O
OR,O
“,O
HRQOL,O
”,O
OR,O
“,O
cost,O
”,O
OR,O
“,O
economic,O
”,O
OR,O
“,O
resource,O
”,O
OR,O
“,O
society,O
”,O
OR,O
“,O
societal,O
”,O
OR,O
“,O
family,O
”,O
OR,O
“,O
relatives,O
”,O
OR,O
“,O
Caregiver,O
”,O
OR,O
“,O
care,O
$”,O
OR,O
“,O
activities,O
of,O
daily,O
living,O
”,O
OR,O
“,O
ADLS,O
”,O
OR,O
“,O
daily,O
activities,O
”,O
OR,O
“,O
cost,O
of,O
illness,O
”,O
OR,O
“,O
autonomy,O
”,O
OR,O
“,O
hospitalisation,O
”,O
OR,O
“,O
hospitalization,O
”,O
•,O
Embase,O
•,O
PscyINFO,O
•,O
EconLit,O
.,O
•,O
Health,O
Economic,O
Evaluations,O
Database,O
(,O
HEED,O
),O
•,O
Centre,O
for,O
Reviews,O
and,O
Dissemination,O
databases,O
:,O
-,O
Database,O
of,O
Abstracts,O
of,O
Reviews,O
of,O
Effects,O
(,O
DARE,O
"),",O
-,O
Health,O
Technology,O
Assessment,O
(,O
HTA,O
),O
-,O
NHS,O
Economic,O
Evaluation,O
Database,O
(,O
NHS,O
EED,O
),O
In,O
accordance,O
with,O
Cochrane,O
review,O
guidelines,O
[,O
35,O
"],",O
all,O
abstracts,O
were,O
reviewed,O
by,O
two,O
researchers,O
independently,O
according,O
to,O
formal,O
inclusion,O
/,O
exclusion,O
criteria,O
(,O
Table,O
2,O
).,O
For,O
inclusion,O
in,O
the,O
review,O
",",O
abstracts,O
were,O
required,O
present,O
information,O
specific,O
to,O
adult,O
patients,O
in,O
the,O
EU,O
and,O
to,O
contain,O
information,O
pertaining,O
to,O
the,O
key,O
search,O
terms,O
(,O
see,O
Table,O
1,O
).,O
In,O
instances,O
were,O
aforementioned,O
details,O
were,O
not,O
clear,O
from,O
the,O
abstract,O
",",O
full,O
text,O
articles,O
were,O
obtained,O
to,O
confirm,O
whether,O
the,O
article,O
should,O
be,O
included,O
/,O
excluded,O
.,O
Real,O
world,O
data,O
",",O
observational,O
studies,O
",",O
effectiveness,O
studies,O
",",O
qualitative,O
studies,O
",",O
economic,O
evaluations,O
and,O
cost,O
studies,O
were,O
all,O
considered,O
relevant,O
for,O
review,O
.,O
The,O
final,O
list,O
of,O
abstracts,O
and,O
articles,O
for,O
full,O
in,O
-,O
depth,O
review,O
was,O
agreed,O
following,O
consensus,O
between,O
the,O
authors,O
.,O
Table,O
2,O
Study,O
Inclusion,O
/,O
exclusion,O
criteria,O
Inclusion,O
criteria,O
Exclusion,O
criteria,O
Country,O
setting,O
Present,O
data,O
from,O
a,O
country,O
in,O
the,O
EU,O
or,O
EU,O
in,O
general,O
Only,O
present,O
data,O
from,O
a,O
non,O
-,O
EU,O
country,O
.,O
No,O
data,O
specific,O
to,O
the,O
EU,O
.,O
Population,O
Adults,O
with,O
HZ,B-DS
or,O
PHN,B-DS
Children,O
Focus,O
mainly,O
on,O
chicken,O
pox,O
Immunodepressed,O
patients,O
only,O
(,O
e,O
.,O
g,O
.,O
HIV,B-OG
patients,O
),O
Studies,O
that,O
contain,O
information,O
on,O
key,O
search,O
terms,O
(,O
inc,O
.,O
QoL,O
",",O
burden,O
",",O
productivity,O
),O
Studies,O
that,O
do,O
NOT,O
contain,O
information,O
on,O
key,O
search,O
terms,O
Study,O
design,O
Real,O
world,O
data,O
",",O
observational,O
studies,O
",",O
effectiveness,O
",",O
qualitative,O
research,O
and,O
cost,O
studies,O
Clinical,O
trials,O
of,O
efficacy,O
and,O
safety,O
of,O
treatments,O
presenting,O
QoL,O
data,O
as,O
secondary,O
endpoint,O
only,O
Clinical,O
trials,O
of,O
Zostavax,O
Focus,O
mainly,O
on,O
epidemiological,O
evidence,O
(,O
e,O
.,O
g,O
.,O
incidence,O
",",O
prevalence,O
etc,O
.),O
Publication,O
type,O
For,O
conference,O
abstracts,O
",",O
exclusion,O
if,O
manuscript,O
corresponding,O
to,O
this,O
abstract,O
and,O
presenting,O
equivalent,O
information,O
is,O
already,O
published,O
Data,O
extraction,O
tables,O
were,O
developed,O
to,O
accurately,O
record,O
information,O
from,O
the,O
articles,O
chosen,O
for,O
review,O
.,O
Of,O
importance,O
was,O
information,O
related,O
to,O
the,O
study,O
aims,O
",",O
design,O
and,O
outcomes,O
of,O
interest,O
",",O
sample,O
characteristics,O
",",O
country,O
of,O
study,O
",",O
resource,O
use,O
data,O
",",O
cost,O
data,O
(,O
direct,O
and,O
indirect,O
),O
and,O
any,O
patient,O
-,O
reported,O
impacts,O
of,O
HZ,B-DS
and,O
PHN,B-DS
.,O
All,O
referenced,O
costs,O
are,O
provided,O
in,O
Euros,O
and,O
have,O
been,O
adjusted,O
to,O
the,O
same,O
price,O
year,O
(,O
2015,O
),O
based,O
on,O
annual,O
average,O
rate,O
of,O
change,O
(%),O
in,O
the,O
Harmonised,O
Index,O
of,O
Consumer,O
Prices,O
[,O
36,O
].,O
Results,O
Search,O
results,O
Figure,O
1,O
provides,O
an,O
overview,O
of,O
the,O
article,O
selection,O
process,O
.,O
A,O
total,O
of,O
1619,O
titles,O
and,O
abstracts,O
were,O
reviewed,O
against,O
the,O
inclusion,O
/,O
exclusion,O
criteria,O
",",O
resulting,O
in,O
78,O
EU,O
based,O
articles,O
for,O
full,O
text,O
review,O
.,O
A,O
further,O
25,O
articles,O
were,O
excluded,O
following,O
full,O
text,O
review,O
",",O
leaving,O
a,O
total,O
of,O
53,O
studies,O
to,O
be,O
included,O
in,O
this,O
review,O
.,O
Figure,O
1,O
Overview,O
of,O
study,O
selection,O
for,O
review,O
.,O
Overview,O
of,O
selected,O
articles,O
A,O
summary,O
of,O
the,O
53,O
articles,O
selected,O
for,O
inclusion,O
in,O
the,O
review,O
(,O
including,O
study,O
countries,O
",",O
population,O
",",O
data,O
presented,O
),O
is,O
provided,O
in,O
Table,O
3,O
.,O
Table,O
3,O
Overview,O
of,O
included,O
studies,O
Author,O
and,O
year,O
Country,O
perspective,O
Population,O
Healthcare,O
utilisation,O
Economic,O
data,O
HRQoL,O
HZ,B-DS
HZ,B-DS
and,O
PHN,B-DS
PHN1,O
PHN3,O
PHN,B-DS
Other,O
/,O
Undefined,O
Direct,O
costs,O
Indirect,O
costs,O
Total,O
costs,O
Annemans,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
26,O
],O
Belgium,O
✓,O
X,O
✓✓,O
X,O
✓✓✓✓,O
XBayas,O
et,O
al,O
.,O
(,O
2011,O
),O
[,O
37,O
],O
Spain,O
CataloniaX,O
✓,O
XXX,O
✓✓,O
XXXBerrut,O
",",O
G,O
.,O
and,O
C,O
.,O
Baptiste,O
(,O
2013,O
),O
[,O
38,O
],O
France,O
✓,O
XXXX,O
✓,O
XXXXBlein,O
",",O
C,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
39,O
],O
France,O
✓,O
XXXX,O
✓,O
XXXXBilcke,O
et,O
al,O
.,O
(,O
2012,O
),O
[,O
40,O
],O
BelgiumX,O
✓,O
X,O
✓,O
X,O
✓✓✓,O
XXBouhassira,O
et,O
al,O
.,O
(,O
2012,O
),O
[,O
15,O
],O
France,O
✓✓,O
X,O
✓,O
XXXXX,O
✓,O
Bresse,O
",",O
X,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
41,O
],O
France,O
✓,O
XX,O
✓,O
X,O
✓,O
XXXXBricout,O
",",O
H,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
42,O
],O
Italy,O
✓,O
XXXXXX,O
✓,O
X,O
✓,O
Bricout,O
",",O
H,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
42,O
],O
Italy,O
✓,O
XX,O
✓,O
X,O
✓,O
XXX,O
✓,O
Brisson,O
et,O
al,O
.,O
(,O
2003,O
),O
[,O
43,O
],O
England,O
&,O
WalesX,O
✓,O
XX,O
✓✓✓✓✓,O
XCastro,O
-,O
Lopes,O
",",O
J,O
.,O
M,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
44,O
],O
PortugalXXXX,O
✓✓,O
XXX,O
✓,O
Cebrian,O
-,O
Cuenca,O
et,O
al,O
.,O
(,O
2011,O
),O
[,O
27,O
],O
Spain,O
",",O
Valencia,O
✓,O
X,O
✓✓,O
X,O
✓✓✓✓,O
XChidiac,O
et,O
al,O
.,O
(,O
2001,O
),O
[,O
21,O
],O
France,O
✓✓,O
XX,O
✓✓,O
XXX,O
✓,O
De,O
Juanes,O
et,O
al,O
.,O
(,O
2011,O
),O
[,O
45,O
],O
Spain,O
MadridX,O
✓,O
XX,O
✓✓✓,O
XXXDi,O
Legami,O
et,O
al,O
.,O
(,O
2007,O
),O
[,O
46,O
],O
Italy,O
–,O
Piemonte,O
✓,O
XXX,O
✓✓✓,O
XXXEdmunds,O
et,O
al,O
.,O
(,O
2001,O
),O
[,O
47,O
],O
England,O
and,O
WalesX,O
✓✓,O
XX,O
✓✓,O
XXXFranco,O
",",O
E,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
48,O
],O
Italy,O
✓,O
XX,O
✓,O
X,O
✓,O
XXX,O
✓,O
Garcia,O
-,O
Doval,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
49,O
],O
Spain,O
✓,O
XXX,O
✓✓,O
XXXXGater,O
",",O
A,O
".,",O
et,O
al,O
.,O
(,O
2014,O
),O
[,O
50,O
],O
UK,O
✓,O
XXXX,O
✓,O
XXX,O
✓,O
Gauthier,O
et,O
al,O
.,O
(,O
2009,O
),O
[,O
28,O
],O
UK,O
✓,O
X,O
✓✓,O
X,O
✓✓,O
XX,O
✓,O
Gialloreti,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
29,O
],O
Italy,O
✓,O
X,O
✓✓,O
X,O
✓✓✓✓,O
XGil,O
et,O
al,O
.,O
(,O
2004,O
),O
[,O
51,O
],O
Spain,O
✓,O
XXXX,O
✓✓,O
XXXGil,O
et,O
al,O
.,O
(,O
2009,O
),O
[,O
52,O
],O
Spain,O
✓,O
XXXX,O
✓✓,O
XXXGil,O
-,O
Prieto,O
et,O
al,O
.,O
(,O
2011,O
),O
[,O
53,O
],O
Spain,O
✓,O
XXXX,O
✓✓,O
XXXGil,O
-,O
Prieto,O
",",O
R,O
".,",O
et,O
al,O
.,O
(,O
2014,O
),O
[,O
54,O
],O
Spain,O
✓,O
XXXX,O
✓,O
XXXXGonzalez,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
55,O
],O
France,O
✓,O
XXXX,O
✓,O
XXXXLionis,O
et,O
al,O
.,O
(,O
2011,O
),O
[,O
56,O
],O
Greece,O
✓,O
X,O
✓,O
XXXXXX,O
✓,O
Loncar,O
",",O
Z,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
57,O
],O
Croatia,O
✓,O
XXXX,O
✓,O
XXX,O
✓,O
Lukas,O
et,O
al,O
.,O
(,O
2012,O
),O
[,O
58,O
],O
Germany,O
",",O
Spain,O
",",O
Portugal,O
",",O
the,O
Netherlands,O
",",O
Belgium,O
",",O
Sweden,O
and,O
Switzerland,O
✓✓,O
X,O
✓,O
XXX,O
✓,O
X,O
✓,O
Mesquita,O
",",O
M,O
.,O
and,O
F,O
.,O
Froes,O
(,O
2013,O
),O
[,O
59,O
],O
Portugal,O
✓,O
XXXX,O
✓,O
XXXXMick,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
30,O
],O
FranceX,O
✓,O
X,O
✓,O
X,O
✓✓✓✓,O
XMoore,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
60,O
],O
UKX,O
✓✓✓,O
XXX,O
✓,O
XXMorant,O
-,O
Talamante,O
",",O
N,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
61,O
],O
Spain,O
✓,O
XXXX,O
✓,O
XXXXMordarski,O
et,O
al,O
.,O
(,O
2009,O
),O
[,O
62,O
],O
PolandXXXX,O
✓,O
XXXX,O
✓,O
Nilsson,O
",",O
J,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
63,O
],O
SwedenX,O
✓,O
XXXXX,O
✓✓,O
XPierik,O
et,O
al,O
.,O
(,O
2012,O
),O
[,O
64,O
],O
Holland,O
/,O
the,O
Netherlands,O
✓,O
XXXX,O
✓,O
XXXXRabaud,O
",",O
C,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
65,O
],O
France,O
✓,O
X,O
✓✓,O
X,O
✓,O
XXX,O
✓,O
Rehm,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
66,O
],O
14,O
European,O
countries,O
(,O
countries,O
not,O
specified,O
),O
XX,O
✓,O
XXXXXX,O
✓,O
Schiffner,O
-,O
Rohe,O
et,O
al,O
.,O
(,O
2011,O
),O
[,O
67,O
],O
Germany,O
✓,O
X,O
✓,O
XX,O
✓✓,O
X,O
✓,O
XScott,O
et,O
al,O
.,O
(,O
2003,O
),O
[,O
68,O
],O
UK,O
✓,O
XX,O
✓,O
XXXXX,O
✓,O
Scott,O
et,O
al,O
.,O
(,O
2006,O
),O
[,O
7,O
],O
UKX,O
✓,O
X,O
✓,O
XXX,O
✓✓✓,O
Serpell,O
",",O
M,O
".,",O
et,O
al,O
.,O
(,O
2014,O
),O
[,O
14,O
],O
UKXXX,O
✓,O
X,O
✓,O
XXX,O
✓,O
Sicras,O
-,O
Mainar,O
et,O
al,O
.,O
(,O
2012,O
),O
[,O
69,O
],O
Spain,O
✓✓,O
XX,O
✓✓✓✓✓,O
XSouliotis,O
",",O
K,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
70,O
],O
GreeceX,O
✓,O
XXXX,O
✓✓,O
XXStudahl,O
",",O
M,O
".,",O
et,O
al,O
.,O
(,O
2013,O
),O
[,O
71,O
],O
Sweden,O
✓,O
XXXX,O
✓,O
XXXXSzucs,O
(,O
2011,O
),O
[,O
72,O
],O
Switzerland,O
✓,O
XX,O
✓✓,O
X,O
✓✓✓,O
XUltsch,O
et,O
al,O
.,O
(,O
2011,O
),O
[,O
73,O
],O
Germany,O
✓,O
XX,O
✓,O
X,O
✓,O
XXXXUltsch,O
et,O
al,O
.,O
(,O
2012,O
),O
[,O
31,O
],O
Germany,O
✓,O
XX,O
✓,O
X,O
✓✓✓✓,O
XVan,O
Hoek,O
et,O
al,O
.,O
(,O
2009,O
),O
[,O
74,O
],O
England,O
and,O
Wales,O
✓,O
XX,O
✓,O
X,O
✓✓,O
XXXVan,O
Seventer,O
et,O
al,O
.,O
(,O
2006,O
),O
[,O
25,O
],O
France,O
",",O
Germany,O
",",O
Italy,O
",",O
Netherlands,O
",",O
Spain,O
",",O
UKXXX,O
✓,O
X,O
✓,O
XXX,O
✓,O
Volpi,O
et,O
al,O
.,O
(,O
2007,O
),O
[,O
75,O
],O
Italy,O
✓,O
XXXXXXXX,O
✓,O
Volpi,O
et,O
al,O
.,O
(,O
2008,O
),O
[,O
76,O
],O
Italy,O
✓✓,O
X,O
✓✓,O
XXXX,O
✓,O
Weinke,O
et,O
al,O
.,O
(,O
2010,O
),O
[,O
77,O
],O
Germany,O
✓,O
XX,O
✓,O
XXX,O
✓,O
X,O
✓✓,O
and,O
x,O
indicate,O
the,O
presence,O
/,O
absence,O
of,O
evidence,O
",",O
respectively,O
.,O
The,O
references,O
selected,O
for,O
review,O
presented,O
data,O
from,O
14,O
European,O
countries,O
with,O
the,O
majority,O
(,O
n,O
=,O
39,O
",",O
73,O
.,O
6,O
%),O
of,O
articles,O
providing,O
data,O
from,O
the,O
‘,O
Big,O
5,O
’,O
EU,O
countries,O
(,O
UK,O
;,O
Spain,O
;,O
France,O
;,O
Germany,O
&,O
Italy,O
).,O
Of,O
the,O
included,O
references,O
",",O
39,O
reported,O
data,O
specifically,O
attributed,O
to,O
HZ,B-DS
patients,O
and,O
35,O
reported,O
data,O
specifically,O
attributed,O
to,O
PHN,B-DS
patients,O
.,O
Data,O
attributed,O
to,O
a,O
combined,O
HZ,B-DS
and,O
PHN,B-DS
population,O
was,O
included,O
in,O
15,O
references,O
.,O
The,O
references,O
eligible,O
for,O
inclusion,O
in,O
the,O
study,O
were,O
all,O
published,O
between,O
2000,O
and,O
2014,O
.,O
Data,O
presented,O
in,O
reviewed,O
references,O
was,O
categorized,O
as,O
follows,O
:,O
1,O
),O
Healthcare,O
utilisation,O
in,O
terms,O
of,O
rates,O
of,O
medical,O
visits,O
",",O
hospitalisations,O
and,O
medication,O
prescribed,O
",",O
2,O
),O
Direct,O
costs,O
corresponding,O
to,O
the,O
management,O
of,O
HZ,B-DS
/,O
PHN,B-DS
",",O
3,O
),O
Indirect,O
costs,O
",",O
4,O
),O
Total,O
costs,O
and,O
5,O
),O
Health,O
related,O
quality,O
of,O
life,O
and,O
humanistic,O
burden,O
.,O
Of,O
note,O
",",O
some,O
references,O
contained,O
data,O
pertaining,O
to,O
multiple,O
categories,O
.,O
Healthcare,O
utilisation,O
Information,O
regarding,O
healthcare,O
resource,O
was,O
included,O
in,O
38,O
of,O
the,O
identified,O
references,O
(,O
as,O
summarized,O
in,O
Table,O
3,O
).,O
Data,O
indicated,O
that,O
HZ,B-DS
and,O
PHN,B-DS
are,O
associated,O
with,O
considerable,O
healthcare,O
utilisation,O
",",O
with,O
increased,O
resource,O
use,O
associated,O
with,O
increasing,O
age,O
and,O
the,O
presence,O
of,O
PHN,B-DS
.,O
Data,O
concerning,O
healthcare,O
utilisation,O
was,O
presented,O
in,O
terms,O
of,O
rates,O
of,O
medical,O
visits,O
(,O
including,O
GP,O
and,O
specialist,O
visits,O
"),",O
hospitalisations,O
(,O
including,O
duration,O
of,O
stay,O
"),",O
use,O
of,O
medications,O
and,O
additional,O
diagnostic,O
/,O
laboratory,O
procedures,O
.,O
Medical,O
visits,O
The,O
majority,O
of,O
patients,O
presenting,O
with,O
HZ,B-DS
will,O
consult,O
their,O
GP,O
at,O
least,O
once,O
[,O
43,O
",",O
50,O
].,O
Reflecting,O
the,O
chronic,O
nature,O
of,O
PHN,B-DS
",",O
higher,O
rates,O
of,O
medical,O
visits,O
(,O
GP,O
and,O
specialist,O
visits,O
),O
have,O
been,O
reported,O
in,O
PHN,B-DS
patients,O
compared,O
to,O
HZ,B-DS
patients,O
[,O
14,O
",",O
21,O
",",O
27,O
",",O
29,O
",",O
50,O
].,O
For,O
example,O
",",O
reports,O
from,O
a,O
study,O
in,O
Italy,O
indicated,O
that,O
patients,O
over,O
the,O
age,O
of,O
50,O
with,O
HZ,B-DS
made,O
approximately,O
1,O
.,O
9,O
visits,O
to,O
their,O
GP,O
.,O
By,O
contrast,O
",",O
the,O
reported,O
number,O
of,O
visits,O
among,O
patients,O
with,O
PHN,B-DS
was,O
11,O
.,O
9,O
and,O
12,O
.,O
0,O
(,O
PHN,B-DS
-,O
1,O
month,O
and,O
PHN,B-DS
3,O
-,O
months,O
definitions,O
",",O
respectively,O
),O
[,O
29,O
].,O
The,O
proportion,O
of,O
patients,O
referred,O
to,O
specialists,O
(,O
74,O
%,O
PHN,B-DS
versus,O
18,O
%,O
HZ,B-DS
),O
and,O
the,O
number,O
of,O
specialist,O
visits,O
per,O
case,O
(,O
3,O
.,O
5,O
and,O
3,O
.,O
9,O
for,O
PHN,B-DS
-,O
1,O
month,O
and,O
PHN,B-DS
3,O
-,O
months,O
vs,O
0,O
.,O
2,O
for,O
HZ,B-DS
),O
were,O
also,O
higher,O
for,O
PHN,B-DS
patients,O
compared,O
to,O
HZ,B-DS
patients,O
.,O
More,O
frequent,O
specialist,O
visits,O
have,O
also,O
been,O
reported,O
among,O
patients,O
with,O
HZO,B-DS
compared,O
to,O
those,O
with,O
HZ,B-DS
[,O
21,O
].,O
The,O
average,O
annual,O
incidence,O
of,O
herpes,B-DS
zoster,I-DS
GP,O
-,O
consultations,O
has,O
been,O
reported,O
to,O
increase,O
with,O
age,O
from,O
32,O
.,O
8,O
/,O
10,O
",",O
000,O
among,O
those,O
aged,O
<,O
60,O
years,O
",",O
to,O
93,O
.,O
1,O
and,O
113,O
.,O
2,O
/,O
10,O
",",O
000,O
among,O
those,O
aged,O
60,O
–,O
64,O
years,O
and,O
≥,O
65,O
years,O
respectively,O
[,O
64,O
].,O
Similarly,O
",",O
the,O
average,O
number,O
of,O
specialist,O
visits,O
was,O
also,O
higher,O
in,O
patients,O
over,O
the,O
age,O
of,O
50,O
compared,O
to,O
those,O
over,O
the,O
age,O
of,O
14,O
[,O
27,O
].,O
Hospitalisations,O
The,O
rates,O
of,O
hospitalisations,O
due,O
to,O
HZ,B-DS
and,O
/,O
or,O
PHN,B-DS
reported,O
in,O
the,O
literature,O
(,O
generally,O
derived,O
from,O
national,O
or,O
insurance,O
databases,O
of,O
hospital,O
admissions,O
),O
suggest,O
that,O
increased,O
rates,O
of,O
hospitalisation,O
are,O
also,O
associated,O
with,O
increasing,O
age,O
[,O
55,O
",",O
71,O
].,O
More,O
frequent,O
hospitalisations,O
have,O
also,O
been,O
observed,O
among,O
patients,O
with,O
PHN,B-DS
when,O
compared,O
to,O
patients,O
with,O
HZ,B-DS
across,O
studies,O
in,O
Italy,O
[,O
29,O
"],",O
Belgium,O
[,O
40,O
"],",O
France,O
[,O
55,O
"],",O
Germany,O
[,O
73,O
"],",O
Spain,O
[,O
37,O
",",O
45,O
",",O
49,O
",",O
51,O
",",O
52,O
",",O
61,O
].,O
and,O
Portugal,O
[,O
59,O
].,O
There,O
are,O
also,O
reports,O
of,O
a,O
greater,O
rate,O
of,O
hospitalisations,O
among,O
female,O
HZ,B-DS
patients,O
compared,O
to,O
male,O
HZ,B-DS
patients,O
at,O
across,O
all,O
age,O
groups,O
[,O
71,O
].,O
The,O
average,O
length,O
of,O
inpatient,O
stay,O
for,O
PHN,B-DS
(,O
10,O
.,O
2,O
±,O
8,O
.,O
6,O
days,O
),O
has,O
been,O
reported,O
to,O
be,O
higher,O
than,O
those,O
associated,O
with,O
HZ,B-DS
(,O
7,O
.,O
8,O
±,O
5,O
.,O
4,O
days,O
),O
[,O
29,O
].,O
The,O
average,O
duration,O
of,O
stay,O
in,O
hospital,O
among,O
HZ,B-DS
patients,O
also,O
appears,O
to,O
be,O
influenced,O
by,O
age,O
[,O
47,O
",",O
74,O
].,O
For,O
example,O
",",O
analysis,O
of,O
Hospital,O
Episode,O
Statistics,O
(,O
2002,O
–,O
2005,O
),O
from,O
England,O
indicates,O
the,O
average,O
length,O
of,O
stay,O
among,O
HZ,B-DS
/,O
PHN,B-DS
patients,O
aged,O
60,O
–,O
64,O
is,O
9,O
.,O
3,O
days,O
whereas,O
those,O
aged,O
85,O
–,O
90,O
is,O
22,O
.,O
3,O
days,O
[,O
74,O
].,O
Comparisons,O
between,O
HZ,B-DS
and,O
HZO,B-DS
patients,O
over,O
50,O
years,O
of,O
age,O
also,O
indicate,O
longer,O
hospital,O
stays,O
in,O
patients,O
with,O
HZO,B-DS
(,O
9,O
.,O
8,O
vs,O
7,O
.,O
8,O
days,O
),O
[,O
38,O
].,O
Medication,O
use,O
It,O
is,O
reported,O
that,O
up,O
to,O
100,O
%,O
of,O
PHN,B-DS
patients,O
and,O
83,O
.,O
2,O
%,O
of,O
patients,O
with,O
HZ,B-DS
receive,O
medication,O
for,O
their,O
condition,O
across,O
all,O
ages,O
[,O
31,O
].,O
Polypharmacy,O
is,O
common,O
among,O
HZ,B-DS
patients,O
with,O
HZ,B-DS
patients,O
reported,O
to,O
be,O
taking,O
at,O
least,O
4,O
different,O
medications,O
on,O
average,O
and,O
PHN,B-DS
patients,O
reported,O
to,O
be,O
taking,O
5,O
medications,O
[,O
50,O
].,O
This,O
could,O
potentially,O
have,O
wider,O
implications,O
as,O
polypharmacy,O
is,O
known,O
to,O
be,O
a,O
major,O
cause,O
of,O
drug,O
interactions,O
and,O
issues,O
with,O
treatment,O
adherence,O
and,O
safety,O
[,O
78,O
].,O
The,O
types,O
of,O
medication,O
used,O
has,O
been,O
reported,O
to,O
vary,O
depending,O
on,O
the,O
population,O
being,O
considered,O
(,O
HZ,B-DS
or,O
PHN,B-DS
),O
[,O
14,O
",",O
21,O
",",O
29,O
",",O
50,O
].,O
Indeed,O
",",O
current,O
treatment,O
of,O
HZ,B-DS
aims,O
to,O
relieve,O
pain,O
",",O
to,O
limit,O
the,O
spread,O
and,O
duration,O
of,O
the,O
dermatomal,O
lesions,O
and,O
(,O
when,O
started,O
within,O
72,O
hours,O
of,O
rash,O
onset,O
),O
to,O
prevent,O
or,O
alleviate,O
complications,O
associated,O
with,O
HZ,B-DS
.,O
By,O
contrast,O
",",O
for,O
PHN,B-DS
",",O
the,O
focus,O
of,O
medications,O
is,O
to,O
alleviate,O
pain,O
[,O
79,O
",",O
80,O
].,O
The,O
amount,O
of,O
available,O
information,O
regarding,O
medication,O
use,O
in,O
EU,O
countries,O
was,O
somewhat,O
limited,O
;,O
however,O
available,O
evidence,O
from,O
the,O
literature,O
suggests,O
that,O
",",O
despite,O
the,O
availability,O
of,O
European,O
Guidelines,O
for,O
the,O
management,O
of,O
HZ,B-DS
[,O
80,O
",",O
81,O
"],",O
medication,O
prescribing,O
practices,O
(,O
for,O
the,O
treatment,O
of,O
PHN,B-DS
in,O
particular,O
),O
are,O
not,O
consistent,O
across,O
countries,O
[,O
14,O
",",O
21,O
",",O
25,O
",",O
29,O
",",O
44,O
",",O
50,O
].,O
An,O
observational,O
study,O
of,O
PHN,B-DS
patients,O
over,O
the,O
age,O
of,O
50,O
conducted,O
in,O
France,O
",",O
Germany,O
",",O
Italy,O
",",O
Netherlands,O
",",O
Spain,O
and,O
the,O
UK,O
(,O
n,O
=,O
84,O
"),",O
for,O
example,O
",",O
reported,O
that,O
neuropathic,O
pain,O
medications,O
(,O
89,O
"%),",O
analgesics,O
(,O
64,O
%),O
and,O
anticonvulsants,O
(,O
52,O
%),O
were,O
most,O
commonly,O
prescribed,O
for,O
the,O
treatment,O
of,O
PHN,B-DS
[,O
25,O
].,O
However,O
",",O
a,O
study,O
conducted,O
in,O
the,O
UK,O
reported,O
that,O
antidepressants,O
were,O
most,O
commonly,O
prescribed,O
for,O
PHN,B-DS
followed,O
by,O
level,O
1,O
and,O
2,O
analgesics,O
(,O
59,O
.,O
2,O
"%,",O
55,O
.,O
3,O
%,O
and,O
50,O
%,O
respectively,O
),O
[,O
14,O
].,O
Similarly,O
",",O
studies,O
in,O
Italy,O
and,O
Portugal,O
have,O
reported,O
that,O
anticonvulsants,O
to,O
be,O
the,O
most,O
commonly,O
prescribed,O
treatment,O
for,O
PHN,B-DS
",",O
followed,O
by,O
opioid,O
analgesics,O
[,O
29,O
",",O
44,O
].,O
Where,O
reported,O
",",O
medication,O
usage,O
for,O
the,O
treatment,O
of,O
HZ,B-DS
was,O
consistent,O
across,O
studies,O
;,O
with,O
antivirals,O
(,O
typically,O
taken,O
for,O
7,O
days,O
),O
the,O
most,O
commonly,O
prescribed,O
treatment,O
[,O
14,O
",",O
21,O
",",O
29,O
",",O
42,O
",",O
50,O
",",O
71,O
].,O
Of,O
note,O
",",O
despite,O
the,O
widespread,O
use,O
of,O
pharmacological,O
therapies,O
for,O
the,O
management,O
of,O
HZ,B-DS
and,O
PHN,B-DS
",",O
reports,O
from,O
patients,O
indicate,O
dissatisfaction,O
with,O
treatments,O
",",O
particularly,O
in,O
regards,O
to,O
perceived,O
efficacy,O
[,O
14,O
",",O
50,O
].,O
Diagnostic,O
/,O
laboratory,O
procedures,O
Details,O
of,O
additional,O
investigations,O
among,O
patients,O
with,O
HZ,B-DS
and,O
PHN,B-DS
were,O
reported,O
from,O
studies,O
in,O
France,O
",",O
Italy,O
",",O
Spain,O
and,O
the,O
UK,O
[,O
14,O
",",O
21,O
",",O
27,O
",",O
29,O
",",O
50,O
].,O
Additional,O
investigations,O
reported,O
included,O
blood,O
and,O
urine,O
tests,O
",",O
assessments,O
of,O
inflammation,O
(,O
e,O
.,O
g,O
.,O
erythrocyte,O
sedimentation,O
rate,O
",",O
C,B-GP
-,I-GP
reactive,I-GP
protein,I-GP
level,O
"),",O
ophthalmological,O
/,O
ontological,O
examinations,O
",",O
radiology,O
",",O
X,O
-,O
ray,O
",",O
electrocardiograms,O
and,O
ultrasound,O
.,O
Further,O
diagnostic,O
or,O
laboratory,O
examinations,O
were,O
reported,O
in,O
28,O
.,O
0,O
%,O
of,O
incident,O
cases,O
of,O
HZ,B-DS
among,O
an,O
Italian,O
sample,O
of,O
immunocompetent,O
individuals,O
",",O
with,O
the,O
mean,O
number,O
of,O
procedures,O
and,O
examinations,O
reported,O
to,O
be,O
2,O
.,O
6,O
per,O
case,O
[,O
29,O
].,O
By,O
comparison,O
",",O
rates,O
of,O
additional,O
investigations,O
reported,O
in,O
France,O
",",O
Spain,O
and,O
the,O
UK,O
were,O
lower,O
[,O
14,O
",",O
21,O
",",O
27,O
",",O
50,O
"],",O
with,O
evidence,O
suggesting,O
that,O
rates,O
of,O
additional,O
investigations,O
were,O
higher,O
in,O
those,O
with,O
PHN,B-DS
(,O
10,O
–,O
12,O
.,O
5,O
%,O
compared,O
to,O
HZ,B-DS
(,O
4,O
.,O
4,O
-,O
9,O
%),O
[,O
14,O
",",O
21,O
",",O
50,O
].,O
Additional,O
investigations,O
are,O
also,O
more,O
likely,O
among,O
those,O
patients,O
with,O
HZO,B-DS
compared,O
to,O
HZ,B-DS
[,O
21,O
].,O
Direct,O
costs,O
of,O
management,O
Direct,O
costs,O
of,O
the,O
management,O
of,O
HZ,B-DS
and,O
PHN,B-DS
patients,O
were,O
reported,O
in,O
20,O
studies,O
.,O
The,O
reviewed,O
articles,O
presented,O
data,O
from,O
Spain,O
[,O
27,O
",",O
37,O
",",O
45,O
",",O
51,O
-,O
53,O
",",O
69,O
"],",O
the,O
UK,O
[,O
7,O
",",O
28,O
",",O
43,O
",",O
47,O
",",O
74,O
"],",O
France,O
[,O
30,O
"],",O
Italy,O
[,O
29,O
",",O
46,O
"],",O
Germany,O
[,O
31,O
",",O
67,O
"],",O
Belgium,O
[,O
26,O
",",O
40,O
"],",O
Greece,O
[,O
70,O
],O
and,O
Switzerland,O
[,O
72,O
].,O
Outpatient,O
costs,O
(,O
including,O
medical,O
visits,O
",",O
diagnostic,O
tests,O
and,O
medications,O
"),",O
hospitalization,O
and,O
inpatient,O
costs,O
were,O
identified,O
in,O
the,O
literature,O
as,O
key,O
contributors,O
to,O
the,O
overall,O
cost,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
.,O
Outpatient,O
costs,O
Studies,O
in,O
Belgium,O
[,O
26,O
"],",O
Germany,O
[,O
31,O
",",O
67,O
"],",O
Italy,O
[,O
29,O
],O
and,O
the,O
UK,O
[,O
28,O
],O
have,O
consistently,O
reported,O
higher,O
outpatient,O
management,O
costs,O
(,O
including,O
medical,O
visits,O
",",O
diagnostic,O
tests,O
and,O
medications,O
),O
among,O
patients,O
who,O
go,O
on,O
to,O
develop,O
PHN,B-DS
.,O
For,O
example,O
",",O
mean,O
direct,O
costs,O
of,O
outpatient,O
management,O
have,O
been,O
reported,O
as,O
€,O
107,O
.,O
98,O
per,O
HZ,B-DS
episode,O
and,O
€,O
406,O
.,O
04,O
and,O
€,O
485,O
.,O
51,O
per,O
PHN,B-DS
episode,O
(,O
1,O
-,O
and,O
3,O
-,O
month,O
definition,O
respectively,O
),O
[,O
28,O
],O
a,O
.,O
In,O
addition,O
",",O
costs,O
for,O
outpatient,O
management,O
of,O
HZ,B-DS
and,O
PHN,B-DS
have,O
been,O
reported,O
to,O
increase,O
markedly,O
with,O
pain,O
severity,O
[,O
26,O
",",O
28,O
].,O
For,O
example,O
",",O
outpatient,O
costs,O
among,O
HZ,B-DS
patients,O
ranging,O
from,O
€,O
85,O
.,O
89,O
(,O
no,O
pain,O
),O
to,O
€,O
178,O
.,O
32,O
(,O
severe,O
pain,O
),O
per,O
case,O
have,O
been,O
reported,O
in,O
the,O
UK,O
.,O
Reported,O
differences,O
are,O
more,O
pronounced,O
among,O
PHN,B-DS
patients,O
with,O
costs,O
per,O
case,O
ranging,O
from,O
€,O
237,O
.,O
90,O
/,O
284,O
.,O
80,O
(,O
PHN1,O
/,O
PHN3,O
),O
among,O
patients,O
with,O
mild,O
pain,O
to,O
€,O
741,O
.,O
91,O
/,O
878,O
.,O
88,O
(,O
PHN1,O
/,O
PHN3,O
),O
among,O
patients,O
with,O
severe,O
pain,O
[,O
28,O
],O
a,O
.,O
Key,O
differences,O
in,O
the,O
attribution,O
of,O
outpatient,O
costs,O
for,O
HZ,B-DS
and,O
PHN,B-DS
have,O
been,O
reported,O
for,O
Italy,O
;,O
for,O
patients,O
that,O
did,O
not,O
develop,O
PHN,B-DS
",",O
the,O
majority,O
of,O
the,O
cost,O
of,O
management,O
has,O
been,O
reported,O
to,O
be,O
due,O
to,O
the,O
cost,O
of,O
medication,O
(,O
83,O
%),O
whereas,O
for,O
patients,O
that,O
develop,O
PHN,B-DS
a,O
greater,O
proportion,O
of,O
cost,O
was,O
attributed,O
to,O
diagnostic,O
and,O
investigative,O
procedures,O
[,O
29,O
].,O
Other,O
studies,O
",",O
however,O
",",O
indicate,O
costs,O
of,O
diagnostic,O
procedures,O
to,O
be,O
the,O
smallest,O
contributor,O
to,O
outpatient,O
costs,O
among,O
patients,O
with,O
HZ,B-DS
and,O
PHN,B-DS
(,O
PHN,B-DS
-,O
1,O
and,O
PHN,B-DS
-,O
3,O
),O
[,O
27,O
].,O
While,O
the,O
average,O
cost,O
of,O
outpatient,O
management,O
per,O
case,O
is,O
higher,O
for,O
patients,O
with,O
PHN,B-DS
than,O
for,O
patients,O
with,O
HZ,B-DS
",",O
when,O
considering,O
overall,O
burden,O
of,O
disease,O
at,O
a,O
country,O
level,O
",",O
the,O
overall,O
cost,O
of,O
disease,O
is,O
higher,O
for,O
HZ,B-DS
.,O
This,O
is,O
primarily,O
a,O
result,O
of,O
the,O
higher,O
incidence,O
rates,O
of,O
HZ,B-DS
.,O
These,O
differences,O
were,O
highlighted,O
by,O
one,O
study,O
which,O
investigated,O
the,O
annual,O
cost,O
of,O
HZ,B-DS
and,O
PHN,B-DS
to,O
healthcare,O
providers,O
located,O
in,O
England,O
and,O
Wales,O
[,O
47,O
].,O
Based,O
on,O
an,O
estimated,O
260,O
",",O
995,O
episodes,O
of,O
HZ,B-DS
occurring,O
annually,O
",",O
with,O
14,O
%,O
of,O
cases,O
developing,O
PHN,B-DS
",",O
an,O
estimated,O
€,O
76,O
.,O
39,O
milliona,O
is,O
spent,O
on,O
the,O
management,O
of,O
HZ,B-DS
(,O
including,O
PHN,B-DS
).,O
Of,O
this,O
",",O
€,O
52,O
.,O
32,O
million,O
was,O
attributable,O
to,O
HZ,B-DS
(€,O
22,O
.,O
47,O
m,O
due,O
to,O
hospitalisation,O
",",O
€,O
19,O
.,O
26,O
m,O
due,O
to,O
prescription,O
medications,O
and,O
€,O
9,O
.,O
63,O
m,O
due,O
to,O
GP,O
consultations,O
),O
and,O
€,O
24,O
.,O
07,O
million,O
to,O
PHN1,O
(,O
cost,O
breakdown,O
not,O
provided,O
).,O
Similar,O
findings,O
are,O
reported,O
in,O
Germany,O
where,O
statutory,O
health,O
insurance,O
bills,O
have,O
been,O
estimated,O
at,O
€,O
115,O
.,O
5,O
m,O
;,O
€,O
93,O
.,O
5,O
m,O
attributed,O
to,O
HZ,B-DS
treatment,O
and,O
€,O
22,O
m,O
attributed,O
to,O
treatment,O
of,O
PHN,B-DS
[,O
31,O
].,O
Hospitalisation,O
and,O
inpatient,O
costs,O
Hospitalisation,O
costs,O
contribute,O
significantly,O
to,O
the,O
overall,O
direct,O
cost,O
of,O
managing,O
HZ,B-DS
and,O
PHN,B-DS
.,O
Rates,O
of,O
hospitalisation,O
and,O
duration,O
of,O
stay,O
were,O
found,O
to,O
be,O
higher,O
for,O
PHN,B-DS
than,O
for,O
HZ,B-DS
",",O
and,O
to,O
increase,O
with,O
increasing,O
age,O
",",O
translating,O
into,O
higher,O
inpatient,O
costs,O
for,O
patients,O
that,O
develop,O
PHN,B-DS
(,O
Table,O
4,O
),O
[,O
18,O
",",O
24,O
",",O
33,O
",",O
70,O
].,O
Note,O
that,O
data,O
on,O
hospitalisations,O
and,O
inpatient,O
costs,O
was,O
primarily,O
extracted,O
from,O
a,O
range,O
of,O
national,O
and,O
insurance,O
databases,O
in,O
each,O
country,O
.,O
No,O
studies,O
identified,O
provided,O
a,O
breakdown,O
of,O
the,O
cost,O
elements,O
that,O
are,O
included,O
in,O
a,O
‘,O
hospital,O
stay,O
’.,O
Table,O
4,O
Mean,O
cost,O
per,O
hospitalised,O
case,O
of,O
HZ,B-DS
/,O
PHN,B-DS
",",O
by,O
country,O
Country,O
HZ,B-DS
/,O
PHN,B-DS
HZ,B-DS
(,O
without,O
PHN,B-DS
),O
PHN,B-DS
Belgium,O
[,O
40,O
]-€,O
5,O
",",O
982,O
(€,O
798,O
-,O
31,O
",",O
689,O
)-(,O
all,O
ages,O
),O
France,O
[,O
41,O
]-€,O
2,O
",",O
774,O
.,O
28,O
(,O
50,O
+,O
years,O
)€,O
3,O
",",O
731,O
.,O
09,O
(,O
50,O
+,O
years,O
),O
Germany,O
[,O
31,O
]-€,O
4,O
",",O
189,O
.,O
74,O
(,O
50,O
+,O
years,O
)€,O
4,O
",",O
279,O
.,O
68,O
(,O
50,O
+,O
years,O
)€,O
3,O
",",O
282,O
.,O
64,O
(,O
all,O
ages,O
)€,O
4,O
",",O
112,O
.,O
03,O
(,O
all,O
ages,O
),O
Italy,O
[,O
29,O
]-€,O
3,O
",",O
188,O
.,O
16,O
±,O
€,O
1,O
",",O
614,O
.,O
99,O
(,O
50,O
+,O
years,O
)€,O
3,O
",",O
451,O
.,O
38,O
±,O
€,O
3,O
",",O
248,O
.,O
43,O
(,O
50,O
+,O
years,O
),O
Spain,O
[,O
37,O
",",O
45,O
",",O
52,O
",",O
53,O
]€,O
3,O
",",O
366,O
.,O
4,O
-,O
4,O
",",O
505,O
.,O
6,O
€,O
5,O
",",O
019,O
.,O
84,O
(,O
aged,O
40,O
–,O
49,O
)€,O
5,O
",",O
108,O
.,O
04,O
(,O
aged,O
50,O
–,O
59,O
)(,O
all,O
ages,O
)€,O
4,O
",",O
495,O
.,O
68,O
–,O
5,O
",",O
139,O
.,O
54,O
(,O
aged,O
50,O
–,O
59,O
)€,O
4,O
",",O
732,O
.,O
56,O
(,O
aged,O
60,O
–,O
69,O
)€,O
4,O
",",O
210,O
.,O
92,O
–,O
4,O
",",O
782,O
.,O
96,O
(,O
aged,O
60,O
–,O
69,O
)€,O
4,O
",",O
478,O
.,O
04,O
(,O
70,O
+)€,O
4,O
",",O
062,O
.,O
24,O
–,O
4,O
",",O
556,O
.,O
16,O
(,O
aged,O
70,O
+),O
Indirect,O
costs,O
Indirect,O
costs,O
considered,O
in,O
the,O
EU,O
literature,O
were,O
mainly,O
related,O
to,O
costs,O
associated,O
with,O
sick,O
leave,O
(,O
absenteeism,O
).,O
Seventeen,O
articles,O
reported,O
data,O
on,O
sick,O
leave,O
due,O
to,O
HZ,B-DS
and,O
PHN,B-DS
and,O
the,O
costs,O
that,O
this,O
incurs,O
[,O
7,O
",",O
26,O
",",O
27,O
",",O
29,O
-,O
31,O
",",O
40,O
",",O
42,O
",",O
58,O
",",O
60,O
",",O
63,O
",",O
69,O
",",O
70,O
",",O
72,O
",",O
73,O
",",O
77,O
",",O
82,O
].,O
Absenteeism,O
due,O
to,O
HZ,B-DS
and,O
PHN,B-DS
is,O
a,O
significant,O
cost,O
driver,O
",",O
with,O
increased,O
costs,O
found,O
to,O
be,O
associated,O
with,O
the,O
presence,O
of,O
PHN,B-DS
[,O
29,O
",",O
31,O
",",O
72,O
],O
and,O
increased,O
levels,O
of,O
pain,O
experienced,O
[,O
26,O
",",O
72,O
].,O
Up,O
to,O
65,O
%,O
of,O
employed,O
patients,O
report,O
work,O
absence,O
due,O
to,O
their,O
disease,O
[,O
77,O
].,O
Costs,O
associated,O
with,O
absenteeism,O
varied,O
across,O
EU,O
countries,O
.,O
In,O
France,O
",",O
these,O
costs,O
accounted,O
for,O
up,O
to,O
30,O
%,O
of,O
the,O
costs,O
of,O
management,O
of,O
HZ,B-DS
from,O
the,O
societal,O
perspective,O
and,O
up,O
to,O
10,O
%,O
of,O
the,O
costs,O
of,O
management,O
for,O
PHN,B-DS
in,O
patients,O
aged,O
50,O
years,O
and,O
over,O
[,O
30,O
].,O
In,O
Germany,O
",",O
the,O
mean,O
annual,O
cost,O
of,O
sick,O
leave,O
due,O
to,O
HZ,B-DS
was,O
€,O
1,O
",",O
504,O
per,O
patient,O
(,O
increasing,O
to,O
€,O
1,O
",",O
826,O
for,O
patients,O
over,O
the,O
age,O
of,O
50,O
"),",O
with,O
patients,O
missing,O
an,O
average,O
of,O
12,O
.,O
5,O
days,O
from,O
work,O
.,O
The,O
costs,O
associated,O
with,O
PHN,B-DS
were,O
found,O
to,O
be,O
higher,O
at,O
€,O
7,O
",",O
183,O
(€,O
7,O
.,O
590,O
for,O
patients,O
over,O
50,O
),O
with,O
patients,O
missing,O
an,O
average,O
of,O
2,O
months,O
from,O
work,O
[,O
31,O
].,O
The,O
average,O
costs,O
associated,O
with,O
absenteeism,O
were,O
found,O
to,O
be,O
lower,O
in,O
Italy,O
and,O
Switzerland,O
than,O
those,O
reported,O
for,O
Germany,O
[,O
29,O
",",O
72,O
].,O
Average,O
costs,O
for,O
patients,O
over,O
the,O
age,O
of,O
50,O
in,O
Italy,O
were,O
€,O
684,O
per,O
case,O
of,O
HZ,B-DS
and,O
€,O
978,O
per,O
case,O
of,O
PHN,B-DS
[,O
29,O
].,O
In,O
Switzerland,O
",",O
reported,O
costs,O
of,O
sick,O
leave,O
per,O
case,O
for,O
patients,O
with,O
varying,O
levels,O
of,O
pain,O
were,O
as,O
follows,O
:,O
mild,O
pain,O
(,O
HZ,B-DS
€,O
335,O
;,O
PHN,B-DS
381,O
"),",O
moderate,O
pain,O
(,O
HZ,B-DS
€,O
421,O
;,O
PHN,B-DS
€,O
1,O
",",O
018,O
"),",O
severe,O
pain,O
(,O
HZ,B-DS
€,O
1,O
",",O
837,O
;,O
PHN,B-DS
€,O
2,O
",",O
443,O
),O
b,O
[,O
72,O
].,O
In,O
Spain,O
",",O
the,O
findings,O
from,O
an,O
observational,O
study,O
[,O
27,O
],O
of,O
130,O
HZ,B-DS
patients,O
aged,O
19,O
–,O
45,O
(,O
median,O
age,O
of,O
63,O
.,O
5,O
yrs,O
),O
who,O
were,O
observed,O
for,O
1,O
year,O
suggest,O
that,O
an,O
average,O
of,O
4,O
.,O
3,O
hours,O
of,O
work,O
were,O
missed,O
per,O
patient,O
at,O
a,O
cost,O
of,O
€,O
52,O
.,O
98,O
.,O
This,O
study,O
also,O
found,O
that,O
a,O
total,O
of,O
6,O
work,O
hours,O
were,O
lost,O
by,O
carers,O
across,O
the,O
study,O
sample,O
of,O
130,O
",",O
resulting,O
in,O
a,O
total,O
loss,O
of,O
€,O
86,O
.,O
31,O
.,O
The,O
cost,O
and,O
time,O
implications,O
of,O
time,O
taken,O
off,O
work,O
by,O
carers,O
were,O
also,O
considered,O
in,O
two,O
further,O
studies,O
that,O
were,O
conducted,O
in,O
Belgium,O
and,O
the,O
UK,O
respectively,O
.,O
The,O
study,O
conducted,O
in,O
Belgium,O
found,O
that,O
14,O
/,O
184,O
patients,O
reported,O
that,O
someone,O
else,O
could,O
not,O
go,O
to,O
work,O
due,O
to,O
their,O
illness,O
for,O
between,O
0,O
.,O
5,O
-,O
10days,O
",",O
resulting,O
in,O
an,O
average,O
loss,O
of,O
€,O
52,O
per,O
case,O
due,O
to,O
carer,O
absenteeism,O
[,O
40,O
].,O
For,O
the,O
study,O
conducted,O
in,O
the,O
UK,O
",",O
among,O
70,O
HZ,B-DS
patients,O
",",O
a,O
total,O
of,O
52,O
work,O
days,O
were,O
lost,O
by,O
their,O
carers,O
[,O
7,O
].,O
However,O
as,O
the,O
majority,O
of,O
the,O
reviewed,O
studies,O
usually,O
do,O
not,O
report,O
the,O
cost,O
burden,O
associated,O
with,O
time,O
lost,O
by,O
carers,O
this,O
cost,O
is,O
likely,O
to,O
be,O
underestimated,O
.,O
Total,O
costs,O
of,O
management,O
A,O
total,O
of,O
10,O
studies,O
reported,O
the,O
total,O
cost,O
per,O
case,O
of,O
HZ,B-DS
and,O
/,O
or,O
PHN,B-DS
in,O
EU,O
countries,O
",",O
taking,O
into,O
account,O
both,O
direct,O
costs,O
(,O
including,O
medical,O
visits,O
",",O
medications,O
and,O
hospitalisations,O
),O
and,O
indirect,O
costs,O
(,O
including,O
time,O
missed,O
from,O
work,O
).,O
Table,O
5,O
presents,O
the,O
average,O
cost,O
per,O
case,O
in,O
each,O
country,O
based,O
on,O
the,O
data,O
that,O
was,O
detailed,O
in,O
the,O
reviewed,O
literature,O
.,O
Overall,O
",",O
higher,O
costs,O
were,O
consistently,O
associated,O
with,O
the,O
presence,O
of,O
PHN,B-DS
and,O
increased,O
levels,O
of,O
pain,O
.,O
Of,O
note,O
",",O
whilst,O
HZ,B-DS
and,O
PHN,B-DS
are,O
associated,O
with,O
higher,O
costs,O
to,O
healthcare,O
providers,O
in,O
elderly,O
populations,O
",",O
costs,O
to,O
society,O
in,O
terms,O
of,O
time,O
missed,O
for,O
work,O
tends,O
to,O
be,O
lower,O
",",O
so,O
the,O
total,O
costs,O
overall,O
are,O
similar,O
across,O
age,O
groups,O
[,O
60,O
].,O
Table,O
5,O
Mean,O
total,O
cost,O
of,O
management,O
per,O
HZ,B-DS
or,O
PHN,B-DS
case,O
Country,O
Population,O
age,O
Cost,O
per,O
case,O
HZ,B-DS
PHN1,O
*,O
PHN3,O
^,O
Belgium,O
[,O
26,O
],O
Aged,O
≥,O
50,O
€,O
118,O
(,O
no,O
pain,O
)€,O
156,O
.,O
94,O
(,O
mild,O
pain,O
)€,O
329,O
.,O
22,O
(,O
mild,O
pain,O
)€,O
1,O
",",O
150,O
.,O
50,O
(,O
severe,O
pain,O
)€,O
1,O
",",O
085,O
.,O
60,O
(,O
severe,O
pain,O
)€,O
2,O
",",O
037,O
.,O
86,O
(,O
severe,O
pain,O
),O
France,O
[,O
30,O
],O
Aged,O
≥,O
50,O
€,O
419,O
.,O
87,O
(,O
271,O
–,O
586,O
)€,O
672,O
.,O
76,O
(,O
451,O
–,O
968,O
)-,O
Germany,O
[,O
31,O
],O
Aged,O
≥,O
50,O
€,O
388,O
.,O
30,O
(,O
354,O
–,O
425,O
)-€,O
1,O
",",O
427,O
.,O
80,O
(,O
1,O
",",O
002,O
-,O
1,O
",",O
917,O
),O
Germany,O
[,O
67,O
],O
Aged,O
≥,O
50,O
€,O
729,O
.,O
57,O
€,O
2,O
",",O
167,O
.,O
89Italy,O
[,O
29,O
],O
Aged,O
≥,O
50,O
€,O
888,O
.,O
06,O
-€,O
1,O
",",O
66,O
.,O
65Spain,O
[,O
27,O
],O
Aged,O
>,O
14,O
Overall,O
:,O
€,O
446,O
.,O
04,O
(,O
SD,O
508,O
.,O
58,O
)€,O
647,O
.,O
82,O
(,O
SD,O
684,O
.,O
4,O
)€,O
968,O
.,O
78,O
(,O
SD,O
803,O
.,O
58,O
),O
50,O
-,O
59,O
:,O
€,O
282,O
.,O
06,O
(,O
SD,O
273,O
.,O
15,O
),O
60,O
-,O
69,O
:€,O
510,O
.,O
52,O
(,O
SD,O
512,O
.,O
73,O
),O
>,O
70,O
:,O
€,O
422,O
.,O
91,O
(,O
SD,O
388,O
.,O
66,O
),O
Spain,O
[,O
69,O
],O
Aged,O
>,O
30,O
€,O
460,O
.,O
95,O
€,O
1,O
",",O
956,O
.,O
15,O
-,O
Sweden,O
[,O
63,O
],O
All,O
ages,O
€,O
902,O
.,O
88,O
(,O
HZ,B-DS
and,O
PHN,B-DS
),O
Switzerland,O
[,O
72,O
],O
Aged,O
≥,O
50,O
€,O
394,O
.,O
46,O
(,O
no,O
pain,O
)-€,O
381,O
.,O
15,O
(,O
no,O
pain,O
)€,O
1,O
",",O
835,O
.,O
57,O
(,O
severe,O
pain,O
)€,O
2,O
",",O
442,O
.,O
99,O
(,O
severe,O
pain,O
),O
UK,O
[,O
7,O
],O
Not,O
specified,O
€,O
793,O
.,O
60,O
(,O
31,O
–,O
6,O
",",O
394,O
)--(,O
all,O
ages,O
),O
Aged,O
+,O
65,O
:,O
€,O
788,O
.,O
48,O
*,O
PHN,B-DS
defined,O
as,O
pain,O
persisting,O
for,O
one,O
month,O
following,O
resolution,O
of,O
HZ,B-DS
rash,O
.^,O
PHN,B-DS
defined,O
as,O
pain,O
persisting,O
for,O
three,O
months,O
following,O
resolution,O
of,O
HZ,B-DS
rash,O
.,O
The,O
total,O
annual,O
cost,O
(,O
direct,O
and,O
indirect,O
costs,O
),O
of,O
HZ,B-DS
and,O
PHN,B-DS
on,O
a,O
country,O
level,O
basis,O
was,O
only,O
available,O
for,O
the,O
UK,O
[,O
43,O
"],",O
France,O
[,O
30,O
"],",O
Germany,O
[,O
31,O
"],",O
Italy,O
[,O
29,O
],O
and,O
Sweden,O
[,O
63,O
].,O
Two,O
studies,O
presented,O
data,O
separately,O
for,O
the,O
cost,O
of,O
HZ,B-DS
and,O
PHN,B-DS
and,O
patients,O
over,O
the,O
age,O
of,O
50,O
[,O
29,O
",",O
31,O
].,O
Further,O
details,O
are,O
provided,O
in,O
Figure,O
2,O
.,O
Figure,O
2,O
Estimated,O
total,O
cost,O
burden,O
associated,O
with,O
HZ,B-DS
and,O
PHN,B-DS
considering,O
outpatient,O
",",O
hospitalisation,O
and,O
indirect,O
costs,O
.,O
Humanistic,O
burden,O
and,O
impact,O
on,O
quality,O
of,O
life,O
A,O
total,O
of,O
21,O
EU,O
studies,O
[,O
7,O
",",O
14,O
",",O
15,O
",",O
21,O
",",O
25,O
",",O
28,O
",",O
42,O
",",O
44,O
",",O
48,O
",",O
50,O
",",O
56,O
-,O
58,O
",",O
62,O
",",O
65,O
",",O
66,O
",",O
68,O
",",O
75,O
-,O
77,O
],O
reported,O
data,O
on,O
the,O
humanistic,O
burden,O
associated,O
with,O
HZ,B-DS
and,O
PHN,B-DS
",",O
with,O
the,O
significant,O
negative,O
impact,O
of,O
HZ,B-DS
and,O
PHN,B-DS
on,O
patients,O
’,O
HRQOL,O
consistently,O
reported,O
.,O
Of,O
note,O
",",O
pain,O
experienced,O
due,O
to,O
the,O
disease,O
was,O
found,O
to,O
interfere,O
with,O
many,O
aspects,O
of,O
patient,O
’,O
s,O
daily,O
life,O
.,O
Greater,O
interference,O
was,O
associated,O
with,O
increased,O
levels,O
of,O
pain,O
[,O
25,O
",",O
83,O
],O
and,O
the,O
presence,O
of,O
PHN,B-DS
was,O
associated,O
with,O
a,O
greater,O
impact,O
on,O
most,O
domains,O
of,O
HRQoL,O
[,O
14,O
",",O
50,O
",",O
58,O
",",O
77,O
].,O
Patients,O
also,O
reported,O
consequences,O
for,O
their,O
family,O
and,O
social,O
circle,O
when,O
suffering,O
from,O
HZ,B-DS
or,O
PHN,B-DS
[,O
58,O
",",O
77,O
",",O
84,O
].,O
Pain,O
and,O
interference,O
with,O
daily,O
activities,O
Reports,O
within,O
the,O
reviewed,O
literature,O
indicate,O
that,O
patients,O
with,O
HZ,B-DS
and,O
PHN,B-DS
experience,O
moderate,O
-,O
severe,O
pain,O
.,O
Ratings,O
of,O
average,O
and,O
worst,O
pain,O
reported,O
in,O
the,O
literature,O
are,O
higher,O
among,O
PHN,B-DS
patients,O
compared,O
to,O
HZ,B-DS
patients,O
[,O
14,O
",",O
41,O
",",O
50,O
",",O
58,O
",",O
77,O
].,O
A,O
number,O
of,O
the,O
reviewed,O
articles,O
provided,O
data,O
from,O
the,O
Zoster,O
Brief,O
Pain,O
Inventory,O
(,O
ZBPI,O
),O
and,O
the,O
Modified,O
Brief,O
Pain,O
Short,O
Form,O
(,O
mBPI,O
-,O
SF,O
),O
c,O
–,O
derivative,O
measures,O
of,O
the,O
Brief,O
Pain,O
Inventory,O
(,O
BPI,O
),O
which,O
require,O
patients,O
to,O
rate,O
the,O
level,O
of,O
interference,O
they,O
experience,O
on,O
a,O
scale,O
of,O
0,O
–,O
10,O
(‘,O
does,O
not,O
interfere,O
’,O
–,O
‘,O
completely,O
interferes,O
"’),",O
across,O
seven,O
health,O
status,O
domain,O
;,O
general,O
activity,O
",",O
mood,O
",",O
walking,O
ability,O
",",O
normal,O
work,O
",",O
social,O
relations,O
",",O
sleep,O
and,O
enjoyment,O
of,O
life,O
.,O
Table,O
6,O
presents,O
the,O
mean,O
scores,O
for,O
patients,O
with,O
HZ,B-DS
and,O
PHN,B-DS
from,O
five,O
studies,O
.,O
In,O
general,O
",",O
reports,O
of,O
pain,O
interference,O
on,O
all,O
seven,O
health,O
status,O
domains,O
were,O
greater,O
among,O
patients,O
experiencing,O
PHN,B-DS
compared,O
to,O
patients,O
with,O
HZ,B-DS
[,O
14,O
",",O
50,O
",",O
58,O
",",O
77,O
].,O
HZ,B-DS
and,O
PHN,B-DS
patients,O
reported,O
sleep,O
to,O
be,O
the,O
aspect,O
of,O
their,O
daily,O
lives,O
most,O
affected,O
by,O
pain,O
(,O
4,O
.,O
5,O
-,O
4,O
.,O
9,O
and,O
6,O
.,O
3,O
-,O
6,O
.,O
5,O
mean,O
scores,O
respectively,O
"),",O
while,O
walking,O
ability,O
was,O
the,O
least,O
affected,O
in,O
HZ,B-DS
patients,O
(,O
1,O
.,O
7,O
-,O
4,O
.,O
0,O
mean,O
score,O
),O
and,O
enjoyment,O
of,O
life,O
was,O
least,O
affected,O
in,O
PHN,B-DS
patients,O
(,O
3,O
.,O
8,O
-,O
5,O
.,O
2,O
mean,O
score,O
),O
[,O
14,O
",",O
15,O
",",O
50,O
",",O
58,O
",",O
77,O
].,O
Increased,O
levels,O
of,O
pain,O
are,O
reported,O
to,O
be,O
associated,O
with,O
increased,O
levels,O
of,O
interference,O
[,O
25,O
",",O
83,O
].,O
Levels,O
of,O
pain,O
interference,O
",",O
however,O
",",O
do,O
not,O
appear,O
to,O
be,O
associated,O
with,O
age,O
.,O
Lukas,O
et,O
al,O
.,O
[,O
58,O
],O
presented,O
pain,O
interference,O
data,O
separately,O
for,O
six,O
European,O
countries,O
included,O
in,O
the,O
study,O
.,O
While,O
differences,O
in,O
the,O
level,O
of,O
interference,O
observed,O
varied,O
from,O
country,O
to,O
country,O
",",O
the,O
domains,O
of,O
health,O
status,O
most,O
affected,O
was,O
largely,O
consistent,O
.,O
Table,O
6,O
Level,O
of,O
pain,O
interference,O
across,O
seven,O
health,O
state,O
domains,O
as,O
assessed,O
by,O
the,O
ZBPI,O
(,O
or,O
similar,O
instrument,O
),O
Health,O
state,O
domains,O
HZ,B-DS
(,O
mean,O
scores,O
),O
PHN,B-DS
(,O
mean,O
scores,O
),O
General,O
activity,O
3,O
.,O
8,O
-,O
4,O
.,O
43,O
.,O
1,O
-,O
5,O
.,O
7,O
Mood,O
3,O
.,O
4,O
-,O
4,O
.,O
53,O
.,O
4,O
-,O
5,O
.,O
9,O
Walking,O
ability,O
1,O
.,O
7,O
-,O
4,O
.,O
01,O
.,O
7,O
-,O
5,O
.,O
8,O
Normal,O
work,O
3,O
.,O
3,O
-,O
4,O
.,O
42,O
.,O
9,O
-,O
6,O
.,O
1,O
Social,O
relations,O
2,O
.,O
1,O
-,O
3,O
.,O
52,O
.,O
1,O
-,O
5,O
.,O
4,O
Sleep,O
4,O
.,O
5,O
-,O
4,O
.,O
96,O
.,O
3,O
-,O
6,O
.,O
5,O
Enjoyment,O
of,O
life,O
3,O
.,O
6,O
-,O
4,O
.,O
03,O
.,O
8,O
-,O
5,O
.,O
2Data,O
from,O
Bouhassira,O
2012,O
[,O
15,O
"],",O
Gater,O
2014,O
[,O
50,O
"],",O
Lukas,O
2012,O
[,O
58,O
"],",O
Serpell,O
2014,O
[,O
14,O
"],",O
Weinke,O
2010,O
[,O
77,O
].,O
Impact,O
on,O
general,O
health,O
-,O
related,O
quality,O
of,O
life,O
A,O
number,O
of,O
studies,O
have,O
included,O
generic,O
HRQoL,O
measures,O
such,O
as,O
the,O
SF,O
-,O
12,O
[,O
15,O
",",O
83,O
"],",O
SF,O
-,O
36,O
[,O
14,O
",",O
21,O
",",O
50,O
"],",O
EQ,O
-,O
5D,O
[,O
7,O
",",O
14,O
",",O
25,O
",",O
50,O
],O
and,O
Short,O
Italian,O
Questionnaire,O
(,O
SIQ,O
),O
[,O
75,O
",",O
76,O
],O
to,O
assess,O
HRQoL,O
in,O
HZ,B-DS
and,O
PHN,B-DS
patients,O
.,O
Generally,O
",",O
HRQoL,O
has,O
found,O
to,O
be,O
inversely,O
associated,O
with,O
levels,O
of,O
reported,O
pain,O
[,O
14,O
",",O
25,O
",",O
50,O
",",O
83,O
],O
and,O
the,O
poorest,O
HRQoL,O
has,O
been,O
observed,O
for,O
patients,O
with,O
PHN,B-DS
[,O
14,O
",",O
21,O
",",O
50,O
].,O
Consideration,O
of,O
HRQoL,O
scores,O
from,O
normative,O
populations,O
indicates,O
an,O
inverse,O
relationship,O
between,O
age,O
and,O
HRQoL,O
.,O
As,O
a,O
condition,O
mainly,O
inflicting,O
the,O
elderly,O
",",O
therefore,O
",",O
HRQoL,O
is,O
already,O
considerably,O
compromised,O
in,O
HZ,B-DS
and,O
PHN,B-DS
patients,O
.,O
Nonetheless,O
",",O
recent,O
research,O
indicates,O
that,O
both,O
HZ,B-DS
and,O
PHN,B-DS
patients,O
demonstrate,O
statistically,O
significant,O
and,O
clinically,O
relevant,O
deficits,O
in,O
HRQoL,O
when,O
scores,O
for,O
validated,O
measures,O
of,O
HRQoL,O
(,O
e,O
.,O
g,O
.,O
SF,O
-,O
36,O
and,O
EQ,O
-,O
5D,O
),O
among,O
these,O
populations,O
are,O
compared,O
to,O
those,O
from,O
aged,O
-,O
matched,O
normative,O
samples,O
(,O
Figures,O
3,O
and,O
4,O
),O
[,O
14,O
",",O
50,O
].,O
Figure,O
3,O
Comparison,O
of,O
SF,O
-,O
36,O
domain,O
and,O
component,O
scores,O
for,O
HZ,B-DS
patients,O
compared,O
to,O
age,O
-,O
matched,O
norms,O
[,O
50,O
].,O
No,O
*,O
s,O
p,O
≥,O
0,O
.,O
05,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
;,O
**,O
p,O
>,O
0,O
.,O
01,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
†,O
=,O
clinically,O
meaningful,O
PF,O
=,O
Physical,O
functioning,O
",",O
R,O
-,O
P,O
=,O
Role,O
-,O
physical,O
",",O
BP,O
=,O
Bodily,O
pain,O
",",O
GH,O
=,O
General,O
health,O
",",O
V,O
=,O
Vitality,O
",",O
SF,O
=,O
Social,O
functioning,O
",",O
R,O
-,O
E,O
=,O
Role,O
-,O
emotional,O
",",O
MH,O
=,O
Mental,O
health,O
",",O
PCS,O
=,O
Physical,O
component,O
summary,O
",",O
MCS,O
=,O
Mental,O
component,O
summary,O
.,O
Note,O
:,O
Data,O
collected,O
on,O
initial,O
presentation,O
of,O
HZ,B-DS
to,O
healthcare,O
professional,O
and,O
then,O
again,O
7,O
-,O
14,O
days,O
later,O
(,O
follow,O
-,O
up,O
).,O
Figure,O
4,O
Comparison,O
of,O
SF,O
-,O
36,O
domain,O
and,O
component,O
scores,O
for,O
PHN,B-DS
patients,O
compared,O
to,O
age,O
-,O
matched,O
norms,O
[,O
14,O
].,O
No,O
*,O
s,O
p,O
≥,O
0,O
.,O
05,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
;,O
**,O
p,O
<,O
0,O
.,O
01,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
†,O
=,O
clinically,O
meaningful,O
PF,O
=,O
Physical,O
functioning,O
",",O
R,O
-,O
P,O
=,O
Role,O
-,O
physical,O
",",O
BP,O
=,O
Bodily,O
pain,O
",",O
GH,O
=,O
General,O
health,O
",",O
V,O
=,O
Vitality,O
",",O
SF,O
=,O
Social,O
functioning,O
",",O
R,O
-,O
E,O
=,O
Role,O
-,O
emotional,O
",",O
MH,O
=,O
Mental,O
health,O
",",O
PCS,O
=,O
Physical,O
component,O
summary,O
",",O
MCS,O
=,O
Mental,O
component,O
summary,O
.,O
Impact,O
on,O
mood,O
and,O
mental,O
well,O
-,O
being,O
Data,O
presented,O
across,O
studies,O
demonstrates,O
that,O
patients,O
experience,O
a,O
negative,O
impact,O
on,O
their,O
mood,O
and,O
mental,O
well,O
-,O
being,O
",",O
with,O
patients,O
reporting,O
stress,O
",",O
anxiety,B-DS
and,O
depressive,O
symptoms,O
[,O
14,O
",",O
15,O
",",O
50,O
",",O
56,O
",",O
58,O
",",O
76,O
",",O
77,O
].,O
Across,O
studies,O
",",O
a,O
range,O
of,O
instruments,O
have,O
been,O
used,O
to,O
assess,O
the,O
impact,O
of,O
HZ,B-DS
and,O
PHN,B-DS
on,O
mood,O
",",O
including,O
the,O
Hospital,O
Anxiety,B-DS
and,O
Depression,B-DS
scale,O
(,O
HADS,O
),O
[,O
7,O
",",O
15,O
"],",O
10,O
",",O
47,O
Short,O
Italian,O
Questionnaire,O
(,O
SIQ,O
),O
[,O
75,O
",",O
76,O
"],",O
the,O
Short,O
Anxiety,B-DS
Screening,O
Test,O
(,O
SAST,O
),O
[,O
56,O
],O
and,O
bespoke,O
questions,O
[,O
58,O
",",O
77,O
].,O
Up,O
to,O
29,O
%,O
of,O
patients,O
with,O
HZ,B-DS
reported,O
feelings,O
of,O
moderate,O
anxiety,B-DS
or,O
depression,B-DS
",",O
rising,O
to,O
43,O
%,O
in,O
patients,O
with,O
PHN,B-DS
.,O
Further,O
",",O
a,O
larger,O
percentage,O
of,O
PHN,B-DS
patients,O
reported,O
extreme,O
anxiety,B-DS
or,O
depression,B-DS
(,O
11,O
%,O
vs,O
.,O
5,O
%),O
[,O
58,O
",",O
77,O
"],",O
evidencing,O
that,O
mood,O
and,O
mental,O
well,O
-,O
being,O
issues,O
are,O
greater,O
for,O
PHN,B-DS
patients,O
.,O
The,O
majority,O
of,O
patients,O
reported,O
experiencing,O
stress,O
some,O
of,O
the,O
time,O
(,O
up,O
to,O
78,O
%,O
for,O
HZ,B-DS
and,O
91,O
%,O
for,O
PHN,B-DS
),O
or,O
most,O
of,O
the,O
time,O
(,O
up,O
to,O
19,O
%,O
HZ,B-DS
and,O
41,O
%,O
PHN,B-DS
),O
[,O
58,O
",",O
77,O
].,O
Impact,O
on,O
family,O
and,O
social,O
relations,O
Up,O
to,O
50,O
%,O
of,O
patients,O
with,O
HZ,B-DS
and,O
81,O
%,O
of,O
patients,O
with,O
PHN,B-DS
reported,O
consequences,O
for,O
their,O
family,O
members,O
and,O
social,O
circle,O
[,O
58,O
",",O
77,O
].,O
Despite,O
the,O
high,O
proportion,O
of,O
patients,O
reporting,O
impacts,O
on,O
their,O
social,O
and,O
family,O
lives,O
",",O
only,O
three,O
studies,O
assessed,O
this,O
issue,O
beyond,O
comparing,O
scores,O
on,O
social,O
dimensions,O
of,O
instruments,O
such,O
as,O
the,O
ZBPI,O
or,O
SF,O
-,O
36,O
[,O
58,O
",",O
77,O
",",O
84,O
].,O
In,O
one,O
study,O
in,O
particular,O
",",O
one,O
fifth,O
of,O
the,O
respondents,O
felt,O
isolated,O
from,O
their,O
family,O
and,O
friends,O
while,O
suffering,O
from,O
HZ,B-DS
or,O
PHN,B-DS
",",O
with,O
19,O
%,O
and,O
27,O
%,O
of,O
patients,O
respectively,O
reporting,O
reduced,O
communication,O
during,O
their,O
illness,O
[,O
58,O
].,O
Of,O
note,O
",",O
impacts,O
were,O
not,O
limited,O
to,O
the,O
patient,O
themselves,O
",",O
with,O
findings,O
from,O
a,O
qualitative,O
focus,O
group,O
of,O
patient,O
’,O
s,O
relatives,O
demonstrating,O
that,O
relatives,O
were,O
worried,O
and,O
stressed,O
by,O
the,O
impact,O
of,O
HZ,B-DS
on,O
the,O
patients,O
[,O
84,O
].,O
Discussion,O
The,O
aim,O
of,O
this,O
article,O
was,O
to,O
provide,O
a,O
holistic,O
overview,O
of,O
the,O
published,O
literature,O
concerning,O
the,O
humanistic,O
",",O
economic,O
and,O
societal,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
in,O
Europe,O
.,O
The,O
reviewed,O
evidence,O
highlights,O
the,O
significant,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
for,O
patients,O
",",O
healthcare,O
systems,O
and,O
wider,O
society,O
.,O
A,O
number,O
of,O
key,O
findings,O
are,O
noted,O
.,O
Firstly,O
",",O
the,O
direct,O
costs,O
of,O
managing,O
HZ,B-DS
represent,O
a,O
significant,O
proportion,O
of,O
the,O
total,O
costs,O
associated,O
with,O
the,O
disease,O
",",O
with,O
higher,O
costs,O
associated,O
with,O
the,O
presence,O
of,O
PHN,B-DS
and,O
with,O
greater,O
pain,O
severity,O
.,O
Secondly,O
",",O
absenteeism,O
was,O
identified,O
as,O
a,O
significant,O
cost,O
driver,O
(,O
albeit,O
in,O
a,O
small,O
number,O
of,O
studies,O
"),",O
with,O
up,O
to,O
65,O
%,O
of,O
employed,O
patients,O
reporting,O
work,O
absence,O
due,O
to,O
their,O
disease,O
.,O
Lastly,O
",",O
research,O
suggests,O
that,O
age,O
",",O
pain,O
severity,O
and,O
the,O
presence,O
of,O
PHN,B-DS
are,O
the,O
key,O
drivers,O
of,O
burden,O
to,O
patients,O
",",O
healthcare,O
systems,O
and,O
society,O
.,O
In,O
Europe,O
the,O
percentage,O
of,O
people,O
aged,O
65,O
years,O
or,O
over,O
is,O
projected,O
to,O
increase,O
from,O
17,O
.,O
1,O
%,O
(,O
84,O
.,O
6million,O
),O
in,O
2008,O
to,O
30,O
.,O
0,O
%,O
(,O
151,O
.,O
5,O
million,O
),O
in,O
2060,O
[,O
85,O
].,O
This,O
demographic,O
shift,O
is,O
likely,O
to,O
have,O
a,O
profound,O
influence,O
on,O
the,O
incidence,O
of,O
HZ,B-DS
and,O
PHN,B-DS
and,O
may,O
contribute,O
to,O
increased,O
concern,O
among,O
European,O
healthcare,O
authorities,O
;,O
particularly,O
if,O
economic,O
crisis,O
and,O
healthcare,O
budget,O
constrains,O
persist,O
in,O
the,O
long,O
term,O
.,O
Findings,O
from,O
this,O
review,O
indicate,O
that,O
the,O
direct,O
costs,O
of,O
HZ,B-DS
and,O
PHN,B-DS
management,O
are,O
greater,O
for,O
older,O
patients,O
.,O
In,O
addition,O
",",O
older,O
adults,O
typically,O
have,O
lower,O
HRQoL,O
than,O
younger,O
adults,O
(,O
deficits,O
which,O
are,O
more,O
pronounced,O
with,O
the,O
presence,O
of,O
HZ,B-DS
and,O
PHN,B-DS
),O
and,O
may,O
be,O
less,O
able,O
to,O
complete,O
activities,O
of,O
daily,O
living,O
and,O
self,O
-,O
care,O
unassisted,O
.,O
The,O
potential,O
implications,O
of,O
an,O
aging,O
population,O
to,O
wider,O
society,O
",",O
therefore,O
",",O
are,O
wide,O
reaching,O
.,O
Limitations,O
of,O
the,O
current,O
literature,O
and,O
potential,O
gaps,O
that,O
provide,O
opportunities,O
for,O
future,O
research,O
A,O
number,O
of,O
limitations,O
concerning,O
the,O
currently,O
available,O
body,O
of,O
evidence,O
were,O
identified,O
.,O
Inconsistencies,O
in,O
data,O
There,O
is,O
currently,O
no,O
consensus,O
regarding,O
the,O
definition,O
of,O
PHN,B-DS
and,O
a,O
lack,O
of,O
consistency,O
in,O
the,O
definition,O
of,O
PHN,B-DS
employed,O
in,O
studies,O
was,O
evident,O
throughout,O
the,O
review,O
.,O
This,O
presents,O
a,O
number,O
of,O
challenges,O
when,O
attempting,O
to,O
accurately,O
understand,O
the,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
.,O
For,O
example,O
",",O
it,O
has,O
been,O
demonstrated,O
that,O
the,O
prevalence,O
of,O
PHN,B-DS
varies,O
dramatically,O
depending,O
on,O
the,O
point,O
at,O
which,O
HZ,B-DS
-,O
related,O
pain,O
becomes,O
classified,O
as,O
PHN,B-DS
(,O
PHN1,O
or,O
PHN3,O
),O
[,O
86,O
].,O
Accurately,O
attributing,O
costs,O
to,O
HZ,B-DS
and,O
PHN,B-DS
and,O
determining,O
the,O
overall,O
cost,O
burden,O
of,O
the,O
conditions,O
",",O
therefore,O
",",O
is,O
difficult,O
.,O
Similarly,O
",",O
cost,O
per,O
case,O
may,O
vary,O
dramatically,O
depending,O
on,O
the,O
definition,O
employed,O
.,O
For,O
this,O
reason,O
",",O
PHN,B-DS
definitions,O
employed,O
in,O
the,O
referenced,O
studies,O
have,O
been,O
highlighted,O
throughout,O
this,O
review,O
and,O
should,O
be,O
considered,O
when,O
interpreting,O
the,O
findings,O
from,O
individual,O
studies,O
.,O
Furthermore,O
",",O
there,O
is,O
a,O
lack,O
of,O
consistency,O
in,O
the,O
use,O
of,O
International,O
Classification,O
of,O
Diseases,O
(,O
ICD,O
),O
codes,O
used,O
to,O
identify,O
PHN,B-DS
patients,O
in,O
clinical,O
practice,O
.,O
As,O
a,O
result,O
",",O
there,O
may,O
be,O
a,O
significant,O
proportion,O
of,O
PHN,B-DS
patients,O
who,O
have,O
not,O
been,O
considered,O
in,O
these,O
studies,O
;,O
consequently,O
decreasing,O
confidence,O
in,O
the,O
accuracy,O
of,O
estimates,O
regarding,O
the,O
burden,O
of,O
PHN,B-DS
.,O
A,O
lack,O
of,O
consistency,O
in,O
the,O
ways,O
in,O
which,O
data,O
had,O
been,O
collected,O
provides,O
further,O
difficulties,O
in,O
interpreting,O
and,O
comparing,O
the,O
available,O
data,O
across,O
studies,O
",",O
with,O
databases,O
",",O
patient,O
records,O
and,O
patient,O
surveys,O
all,O
utilized,O
.,O
For,O
example,O
",",O
rates,O
of,O
resource,O
use,O
were,O
derived,O
from,O
a,O
range,O
of,O
sources,O
including,O
:,O
analysis,O
of,O
patient,O
records,O
or,O
an,O
observed,O
sample,O
",",O
patient,O
responses,O
to,O
surveys,O
and,O
national,O
and,O
insurance,O
databases,O
",",O
with,O
each,O
of,O
these,O
methods,O
having,O
their,O
own,O
limitations,O
.,O
The,O
use,O
of,O
databases,O
is,O
a,O
valuable,O
way,O
of,O
gathering,O
data,O
at,O
a,O
national,O
level,O
",",O
however,O
it,O
assumes,O
information,O
is,O
recorded,O
consistently,O
and,O
accurately,O
across,O
databases,O
and,O
that,O
the,O
database,O
has,O
adequate,O
and,O
representative,O
population,O
coverage,O
.,O
Analysis,O
of,O
patient,O
records,O
assumes,O
information,O
is,O
accurately,O
recorded,O
by,O
GPs,O
",",O
who,O
have,O
a,O
myriad,O
of,O
demands,O
on,O
their,O
time,O
",",O
and,O
analysis,O
of,O
patient,O
’,O
s,O
responses,O
assumes,O
accuracy,O
in,O
their,O
recall,O
.,O
Of,O
note,O
",",O
the,O
incidence,O
of,O
hospitalisations,O
were,O
largely,O
based,O
on,O
rates,O
derived,O
from,O
databases,O
in,O
different,O
countries,O
",",O
or,O
rates,O
recorded,O
in,O
observed,O
samples,O
",",O
thus,O
inaccuracies,O
may,O
occur,O
when,O
these,O
data,O
are,O
extrapolated,O
to,O
the,O
country,O
population,O
.,O
Variation,O
in,O
reports,O
of,O
healthcare,O
resource,O
use,O
",",O
indirect,O
costs,O
and,O
humanistic,O
burden,O
are,O
also,O
likely,O
to,O
have,O
resulted,O
from,O
inconsistency,O
in,O
the,O
time,O
frame,O
that,O
different,O
studies,O
considered,O
relevant,O
.,O
With,O
respect,O
to,O
the,O
literature,O
on,O
economic,O
burden,O
",",O
it,O
is,O
understood,O
that,O
costs,O
are,O
likely,O
to,O
vary,O
between,O
countries,O
in,O
terms,O
of,O
the,O
cost,O
of,O
medical,O
resources,O
",",O
medical,O
visits,O
and,O
prescribed,O
medications,O
.,O
Currently,O
these,O
differences,O
are,O
not,O
reflected,O
in,O
the,O
published,O
literature,O
and,O
in,O
some,O
cases,O
",",O
the,O
cost,O
of,O
treating,O
a,O
case,O
of,O
HZ,B-DS
or,O
PHN,B-DS
were,O
calculated,O
inconsistently,O
",",O
with,O
some,O
studies,O
presenting,O
the,O
cost,O
per,O
treated,O
case,O
while,O
others,O
presented,O
the,O
average,O
across,O
all,O
patients,O
.,O
As,O
such,O
there,O
was,O
a,O
wide,O
variation,O
between,O
studies,O
.,O
Only,O
one,O
study,O
provided,O
costs,O
(,O
per,O
treated,O
case,O
),O
for,O
the,O
different,O
types,O
of,O
medications,O
used,O
to,O
treat,O
HZ,B-DS
or,O
PHN,B-DS
[,O
46,O
].,O
Similarly,O
",",O
no,O
studies,O
provided,O
breakdown,O
or,O
clarification,O
of,O
cost,O
elements,O
included,O
in,O
a,O
‘,O
hospital,O
stay,O
’.,O
Great,O
caution,O
",",O
therefore,O
",",O
should,O
be,O
taken,O
in,O
comparing,O
and,O
interpreting,O
the,O
available,O
data,O
.,O
Furthermore,O
this,O
highlights,O
an,O
unmet,O
need,O
for,O
data,O
that,O
clearly,O
distinguishes,O
between,O
HZ,B-DS
and,O
PHN,B-DS
and,O
also,O
for,O
‘,O
per,O
treated,O
case,O
’,O
data,O
for,O
a,O
wide,O
range,O
of,O
EU,O
countries,O
.,O
A,O
further,O
notable,O
limitation,O
was,O
that,O
data,O
were,O
not,O
available,O
for,O
all,O
EU,O
countries,O
.,O
Despite,O
comprehensive,O
database,O
searches,O
",",O
in,O
which,O
no,O
restrictions,O
on,O
country,O
of,O
interest,O
or,O
language,O
of,O
publication,O
were,O
implemented,O
",",O
cost,O
burden,O
data,O
for,O
the,O
majority,O
of,O
Eastern,O
European,O
countries,O
was,O
not,O
identified,O
.,O
The,O
majority,O
of,O
studies,O
",",O
instead,O
",",O
focus,O
primarily,O
on,O
the,O
UK,O
",",O
Spain,O
",",O
France,O
",",O
Italy,O
",",O
Belgium,O
and,O
Germany,O
.,O
Gaps,O
in,O
evidence,O
A,O
number,O
of,O
evidence,O
gaps,O
were,O
identified,O
",",O
some,O
of,O
which,O
provide,O
opportunities,O
for,O
future,O
research,O
.,O
A,O
key,O
gap,O
identified,O
in,O
the,O
available,O
evidence,O
pool,O
relates,O
to,O
how,O
indirect,O
costs,O
are,O
assessed,O
.,O
While,O
a,O
number,O
of,O
EU,O
studies,O
presented,O
data,O
on,O
the,O
time,O
missed,O
from,O
work,O
and,O
associated,O
costs,O
",",O
data,O
on,O
productivity,O
while,O
at,O
work,O
and,O
associated,O
costs,O
is,O
lacking,O
.,O
Studies,O
in,O
the,O
US,O
and,O
Canada,O
",",O
however,O
",",O
report,O
that,O
presenteeism,O
could,O
account,O
for,O
up,O
to,O
75,O
%,O
of,O
the,O
cost,O
burden,O
associated,O
with,O
work,O
loss,O
[,O
87,O
],O
and,O
that,O
an,O
average,O
of,O
46,O
hours,O
were,O
lost,O
(,O
per,O
employed,O
patient,O
),O
due,O
to,O
presenteeism,O
[,O
88,O
].,O
In,O
Europe,O
",",O
decisions,O
regarding,O
access,O
and,O
reimbursement,O
of,O
medical,O
interventions,O
are,O
predominately,O
driven,O
by,O
considerations,O
of,O
cost,O
-,O
effectiveness,O
.,O
Consideration,O
of,O
the,O
impact,O
of,O
conditions,O
as,O
reported,O
by,O
patients,O
themselves,O
",",O
however,O
",",O
provides,O
important,O
information,O
regarding,O
unmet,O
need,O
and,O
the,O
efficacy,O
of,O
medical,O
interventions,O
.,O
A,O
number,O
of,O
studies,O
assessing,O
aspects,O
of,O
humanistic,O
burden,O
associated,O
with,O
HZ,B-DS
and,O
PHN,B-DS
were,O
identified,O
.,O
However,O
",",O
there,O
are,O
number,O
of,O
notable,O
limitations,O
.,O
Firstly,O
",",O
the,O
impact,O
of,O
HZ,B-DS
and,O
PHN,B-DS
was,O
generally,O
assessed,O
using,O
disease,O
specific,O
questionnaires,O
(,O
such,O
as,O
the,O
ZBPI,O
),O
or,O
‘,O
bespoke,O
’,O
questions,O
which,O
have,O
not,O
been,O
tested,O
or,O
validated,O
.,O
There,O
was,O
only,O
limited,O
use,O
of,O
generic,O
HRQoL,O
instruments,O
in,O
the,O
EU,O
studies,O
conducted,O
to,O
date,O
.,O
However,O
",",O
data,O
from,O
such,O
instruments,O
are,O
valuable,O
for,O
quantifying,O
burden,O
with,O
reference,O
to,O
the,O
normative,O
population,O
and,O
patients,O
with,O
other,O
diseases,O
–,O
data,O
that,O
is,O
important,O
for,O
contextualizing,O
the,O
relative,O
burden,O
associated,O
with,O
HZ,B-DS
and,O
PHN,B-DS
.,O
The,O
available,O
evidence,O
does,O
not,O
typically,O
look,O
beyond,O
the,O
pain,O
which,O
accompanies,O
or,O
persists,O
beyond,O
the,O
rash,O
and,O
the,O
omission,O
of,O
other,O
factors,O
that,O
can,O
impact,O
on,O
patients,O
’,O
quality,O
of,O
life,O
(,O
e,O
.,O
g,O
.,O
fatigue,O
",",O
stomach,O
upsets,O
",",O
allodynia,O
",",O
and,O
numbness,O
).,O
This,O
should,O
be,O
addressed,O
",",O
preferably,O
through,O
a,O
combination,O
of,O
quantitative,O
and,O
qualitative,O
research,O
",",O
the,O
latter,O
of,O
which,O
was,O
notably,O
lacking,O
in,O
the,O
literature,O
.,O
Finally,O
",",O
the,O
lack,O
of,O
literature,O
relating,O
to,O
the,O
wider,O
societal,O
burden,O
potentially,O
caused,O
by,O
HZ,B-DS
and,O
PHN,B-DS
(,O
particularly,O
with,O
respect,O
to,O
the,O
impact,O
on,O
caregivers,O
and,O
the,O
broader,O
implications,O
of,O
HZ,B-DS
and,O
PHN,B-DS
on,O
provision,O
of,O
formal,O
and,O
informal,O
social,O
care,O
),O
may,O
be,O
considered,O
a,O
critical,O
gap,O
.,O
To,O
date,O
burden,O
among,O
informal,O
caregivers,O
has,O
rarely,O
been,O
considered,O
",",O
and,O
only,O
in,O
terms,O
of,O
time,O
lost,O
from,O
work,O
.,O
Significantly,O
",",O
this,O
omits,O
the,O
potential,O
impacts,O
of,O
providing,O
informal,O
care,O
to,O
patients,O
that,O
may,O
not,O
have,O
resulted,O
in,O
time,O
lost,O
from,O
work,O
(,O
e,O
.,O
g,O
.,O
negative,O
impact,O
on,O
the,O
health,O
and,O
well,O
-,O
being,O
of,O
caregivers,O
).,O
Furthermore,O
",",O
consideration,O
of,O
healthcare,O
resource,O
use,O
and,O
the,O
economic,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
has,O
typically,O
focussed,O
on,O
impacts,O
within,O
the,O
healthcare,O
system,O
;,O
the,O
broader,O
implications,O
of,O
HZ,B-DS
and,O
PHN,B-DS
are,O
rarely,O
appreciated,O
.,O
For,O
example,O
",",O
the,O
functional,O
deficits,O
observed,O
among,O
HZ,B-DS
and,O
PHN,B-DS
patients,O
that,O
may,O
lead,O
to,O
a,O
loss,O
of,O
autonomy,O
and,O
increased,O
reliance,O
on,O
formal,O
paid,O
care,O
have,O
not,O
been,O
estimated,O
.,O
Beyond,O
some,O
evidence,O
of,O
direct,O
and,O
indirect,O
costs,O
related,O
to,O
the,O
disease,O
",",O
the,O
potential,O
impact,O
of,O
HZ,B-DS
and,O
PHN,B-DS
on,O
the,O
social,O
care,O
system,O
remains,O
unknown,O
.,O
Conclusions,O
This,O
literature,O
review,O
highlights,O
the,O
burden,O
faced,O
by,O
patients,O
",",O
healthcare,O
systems,O
and,O
society,O
due,O
to,O
HZ,B-DS
and,O
PHN,B-DS
in,O
Europe,O
.,O
While,O
the,O
incidence,O
of,O
HZ,B-DS
and,O
PHN,B-DS
increases,O
with,O
age,O
",",O
the,O
total,O
cost,O
per,O
case,O
of,O
HZ,B-DS
and,O
PHN,B-DS
management,O
is,O
not,O
necessarily,O
age,O
-,O
dependent,O
.,O
Pain,O
severity,O
was,O
associated,O
with,O
increased,O
costs,O
for,O
both,O
HZ,B-DS
and,O
PHN,B-DS
",",O
and,O
",",O
as,O
a,O
chronic,O
condition,O
",",O
costs,O
were,O
higher,O
for,O
patients,O
experiencing,O
PHN,B-DS
.,O
No,O
study,O
fully,O
addressed,O
the,O
humanistic,O
and,O
economic,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
to,O
patients,O
",",O
their,O
families,O
and,O
society,O
as,O
a,O
whole,O
.,O
Based,O
on,O
the,O
reviewed,O
evidence,O
and,O
an,O
assessment,O
of,O
the,O
gaps,O
in,O
the,O
evidence,O
base,O
",",O
it,O
is,O
likely,O
that,O
the,O
true,O
burden,O
of,O
HZ,B-DS
and,O
PHN,B-DS
is,O
underestimated,O
in,O
the,O
Europe,O
.,O
Further,O
research,O
is,O
required,O
to,O
build,O
a,O
holistic,O
understanding,O
of,O
the,O
impact,O
of,O
HZ,B-DS
and,O
PHN,B-DS
to,O
patients,O
",",O
healthcare,O
systems,O
and,O
society,O
.,O
Endnotes,O
a,O
*,O
Costs,O
originally,O
reported,O
in,O
2006,O
GBP,O
sterling,O
"(£),",O
converted,O
to,O
euros,O
(€),O
using,O
the,O
following,O
conversion,O
rate,O
£,O
1,O
=,O
€,O
1,O
.,O
18,O
.,O
b,O
*,O
Costs,O
originally,O
reported,O
in,O
2006,O
Swiss,O
francs,O
(,O
CHF,O
"),",O
converted,O
to,O
euros,O
(€),O
using,O
the,O
following,O
conversion,O
rate,O
1CHF,O
=,O
€,O
0,O
.,O
81,O
.,O
cAlthough,O
2,O
studies,O
do,O
not,O
report,O
a,O
specific,O
instrument,O
",",O
items,O
reported,O
appear,O
to,O
be,O
derived,O
from,O
the,O
ZBPI,O
(,O
38,O
",",O
55,O
).,O
Competing,O
interests,O
AG,O
and,O
RM,O
are,O
/,O
were,O
employees,O
of,O
Adelphi,O
Values,O
",",O
a,O
health,O
outcomes,O
agency,O
commissioned,O
by,O
Sanofi,O
Pasteur,O
MSD,O
",",O
to,O
conduct,O
",",O
analyse,O
and,O
communicate,O
findings,O
from,O
this,O
research,O
on,O
their,O
behalf,O
.,O
MU,O
and,O
EP,O
are,O
employees,O
of,O
Sanofi,O
Pasteur,O
MSD,O
",",O
a,O
provider,O
of,O
a,O
herpes,B-DS
zoster,I-DS
vaccine,O
approved,O
in,O
the,O
European,O
Union,O
.,O
The,O
authors,O
have,O
no,O
other,O
competing,O
interests,O
to,O
declare,O
.,O
Authors,O
’,O
contributions,O
AG,O
and,O
EP,O
designed,O
the,O
study,O
.,O
RA,O
and,O
AG,O
conducted,O
the,O
literature,O
searches,O
",",O
determined,O
eligibility,O
of,O
studies,O
for,O
inclusion,O
in,O
the,O
review,O
and,O
were,O
responsible,O
for,O
primary,O
data,O
extraction,O
and,O
analysis,O
.,O
EP,O
and,O
MU,O
contributed,O
to,O
the,O
analysis,O
.,O
AG,O
",",O
EP,O
and,O
MU,O
drafted,O
the,O
manuscript,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Fructooligosacharides,O
Reduce,O
Pseudomonas,B-OG
aeruginosa,I-OG
PAO1,I-OG
Pathogenicity,O
through,O
Distinct,O
Mechanisms,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
MG,O
OMA,O
DA,O
.,O
Performed,O
the,O
experiments,O
:,O
OMA,O
FSM,O
TK,O
DA,O
.,O
Analyzed,O
the,O
data,O
:,O
DA,O
OMA,O
TK,O
FSM,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
CM,O
RP,O
DP,O
DA,O
.,O
Wrote,O
the,O
paper,O
:,O
FSM,O
OMA,O
TK,O
DA,O
.,O
Pseudomonas,B-OG
aeruginosa,I-OG
is,O
ubiquitously,O
present,O
in,O
the,O
environment,O
and,O
acts,O
as,O
an,O
opportunistic,O
pathogen,O
on,O
humans,B-OG
",",O
animals,B-OG
and,O
plants,B-OG
.,O
We,O
report,O
here,O
the,O
effects,O
of,O
the,O
prebiotic,O
polysaccharide,O
inulin,O
and,O
its,O
hydrolysed,O
form,O
FOS,O
on,O
this,O
bacterium,B-OG
.,O
FOS,O
was,O
found,O
to,O
inhibit,O
bacterial,O
growth,O
of,O
strain,O
PAO1,B-OG
",",O
while,O
inulin,O
did,O
not,O
affect,O
growth,O
rate,O
or,O
yield,O
in,O
a,O
significant,O
manner,O
.,O
Inulin,O
stimulated,O
biofilm,O
formation,O
",",O
whereas,O
a,O
dramatic,O
reduction,O
of,O
the,O
biofilm,O
formation,O
was,O
observed,O
in,O
the,O
presence,O
of,O
FOS,O
.,O
Similar,O
opposing,O
effects,O
were,O
observed,O
for,O
bacterial,O
motility,O
",",O
where,O
FOS,O
inhibited,O
the,O
swarming,O
and,O
twitching,O
behaviour,O
whereas,O
inulin,O
caused,O
its,O
stimulation,O
.,O
In,O
co,O
-,O
cultures,O
with,O
eukaryotic,O
cells,O
(,O
macrophages,O
),O
FOS,O
and,O
",",O
to,O
a,O
lesser,O
extent,O
",",O
inulin,O
reduced,O
the,O
secretion,O
of,O
the,O
inflammatory,B-GP
cytokines,I-GP
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
10,I-GP
and,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
Western,O
blot,O
experiments,O
indicated,O
that,O
the,O
effects,O
mediated,O
by,O
FOS,O
in,O
macrophages,O
are,O
associated,O
with,O
a,O
decreased,O
activation,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
.,O
Since,O
FOS,O
and,O
inulin,O
stimulate,O
pathway,O
activation,O
in,O
the,O
absence,O
of,O
bacteria,B-OG
",",O
the,O
FOS,O
mediated,O
effect,O
is,O
likely,O
to,O
be,O
of,O
indirect,O
nature,O
",",O
such,O
as,O
via,O
a,O
reduction,O
of,O
bacterial,O
virulence,O
.,O
Further,O
",",O
this,O
modulatory,O
effect,O
is,O
observed,O
also,O
with,O
the,O
highly,O
virulent,O
ptxS,B-GP
mutated,O
strain,O
.,O
Co,O
-,O
culture,O
experiments,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
with,O
IEC18,O
eukaryotic,O
cells,O
showed,O
that,O
FOS,O
reduces,O
the,O
concentration,O
of,O
the,O
major,O
virulence,O
factor,O
",",O
exotoxin,B-GP
A,I-GP
",",O
suggesting,O
that,O
this,O
is,O
a,O
possible,O
mechanism,O
for,O
the,O
reduction,O
of,O
pathogenicity,O
.,O
The,O
potential,O
of,O
these,O
compounds,O
as,O
components,O
of,O
antibacterial,O
and,O
anti,O
-,O
inflammatory,O
cocktails,O
is,O
discussed,O
.,O
Introduction,O
Strains,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
are,O
ubiquitously,O
present,O
in,O
the,O
environment,O
[,O
1,O
"],",O
which,O
is,O
due,O
to,O
their,O
capacity,O
to,O
colonize,O
different,O
ecological,O
niches,O
[,O
2,O
"],",O
[,O
3,O
],O
and,O
metabolic,O
versatility,O
[,O
4,O
].,O
P,B-OG
.,I-OG
aeruginosa,I-OG
is,O
an,O
opportunistic,O
pathogen,O
able,O
to,O
infect,O
different,O
animals,B-OG
and,O
plants,B-OG
[,O
5,O
"],",O
[,O
6,O
"],",O
being,O
a,O
frequent,O
cause,O
of,O
hospital,B-DS
-,I-DS
acquired,I-DS
infections,I-DS
including,O
ventilator,B-DS
associated,I-DS
pneumonia,I-DS
[,O
7,O
],O
and,O
catheter,B-DS
infections,I-DS
in,O
immuno,O
-,O
compromised,O
patients,O
.,O
P,B-DS
.,I-DS
aeruginosa,I-DS
lung,I-DS
infections,I-DS
are,O
the,O
main,O
cause,O
of,O
morbidity,O
and,O
mortality,O
in,O
cystic,B-DS
fibrosis,I-DS
(,O
CF,B-DS
),O
patients,O
[,O
8,O
].,O
The,O
bacterium,B-OG
is,O
highly,O
resistant,O
to,O
antibiotic,O
treatment,O
and,O
difficult,O
to,O
eradicate,O
once,O
established,O
in,O
the,O
host,O
[,O
9,O
].,O
One,O
of,O
the,O
important,O
antibiotic,O
resistance,O
mechanisms,O
is,O
the,O
formation,O
of,O
biofilms,O
[,O
10,O
"],",O
hence,O
a,O
great,O
deal,O
of,O
attention,O
has,O
been,O
given,O
to,O
the,O
study,O
of,O
the,O
molecular,O
mechanisms,O
involved,O
in,O
its,O
generation,O
",",O
maturation,O
and,O
dispersal,O
[,O
11,O
"],",O
[,O
12,O
].,O
It,O
has,O
been,O
shown,O
that,O
flagella,O
and,O
type,O
IV,O
pili,O
-,O
mediated,O
motility,O
are,O
required,O
for,O
efficient,O
biofilm,O
formation,O
[,O
13,O
]–[,O
15,O
].,O
Bacteria,B-OG
use,O
different,O
secretion,O
systems,O
to,O
inject,O
virulence,O
factors,O
into,O
the,O
cytoplasm,O
of,O
eukaryotic,O
cells,O
",",O
leading,O
to,O
bacterial,O
replication,O
within,O
macrophages,O
and,O
",",O
consequently,O
",",O
evasion,O
from,O
the,O
immune,O
system,O
[,O
16,O
].,O
In,O
Gram,B-OG
-,I-OG
negative,I-OG
bacteria,I-OG
several,O
secretion,O
systems,O
have,O
been,O
characterized,O
",",O
referred,O
to,O
as,O
type,O
I,O
to,O
type,O
VI,O
systems,O
[,O
17,O
"],",O
[,O
18,O
].,O
The,O
type,O
II,O
(,O
T2SS,O
),O
and,O
type,O
III,O
secretion,O
system,O
(,O
T3SS,O
),O
secrete,O
the,O
majority,O
of,O
known,O
toxins,O
[,O
19,O
].,O
They,O
differ,O
in,O
their,O
molecular,O
mechanisms,O
and,O
operate,O
on,O
several,O
substrates,O
.,O
The,O
secretion,O
system,O
type,O
I,O
is,O
an,O
ABC,B-GP
transporter,I-GP
composed,O
of,O
an,O
ABC,B-GP
protein,I-GP
",",O
a,O
membrane,B-GP
fusion,I-GP
protein,I-GP
and,O
an,O
outer,B-GP
membrane,I-GP
protein,I-GP
.,O
This,O
system,O
transports,O
various,O
molecules,O
of,O
diverse,O
nature,O
such,O
as,O
ions,O
",",O
drugs,O
",",O
and,O
proteins,O
[,O
20,O
].,O
Similarly,O
",",O
type,O
II,O
and,O
V,O
secretion,O
systems,O
generally,O
transport,O
proteins,O
to,O
the,O
surface,O
of,O
the,O
host,O
cell,O
and,O
are,O
involved,O
in,O
the,O
extracellular,O
release,O
of,O
various,O
toxins,O
and,O
hydrolytic,O
enzymes,O
such,O
as,O
exotoxin,B-GP
A,I-GP
",",O
Las,B-GP
A,I-GP
",",O
Las,B-GP
B,I-GP
",",O
protease,B-GP
and,O
elastase,B-GP
[,O
21,O
"],",O
[,O
22,O
].,O
In,O
contrast,O
",",O
the,O
type,O
III,O
secretion,O
system,O
(,O
T3SS,O
),O
injects,O
proteins,O
",",O
small,O
molecular,O
weight,O
compounds,O
and,O
hydrolytic,O
enzymes,O
into,O
the,O
cytosol,O
of,O
eukaryotic,O
cells,O
[,O
23,O
"],",O
which,O
corresponds,O
to,O
a,O
potent,O
virulence,O
mechanism,O
shared,O
by,O
many,O
pathogenic,O
Gram,B-OG
-,I-OG
negative,I-OG
bacteria,I-OG
.,O
This,O
protein,O
injection,O
in,O
turn,O
triggers,O
a,O
cytoskeletal,O
reorganization,O
of,O
the,O
host,O
cell,O
as,O
shown,O
by,O
the,O
inhibition,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
internalization,O
upon,O
incubation,O
with,O
cytochalasin,O
D,O
[,O
24,O
"],",O
which,O
destroys,O
microfilaments,O
",",O
thereby,O
preventing,O
further,O
uptake,O
of,O
bacteria,B-OG
[,O
16,O
"],",O
[,O
23,O
"],",O
[,O
25,O
].,O
A,O
significant,O
number,O
of,O
natural,O
compounds,O
have,O
been,O
found,O
to,O
inhibit,O
bacterial,O
growth,O
",",O
although,O
their,O
mechanism,O
of,O
action,O
remains,O
unclear,O
in,O
most,O
cases,O
[,O
26,O
"],",O
[,O
27,O
].,O
Here,O
we,O
report,O
a,O
study,O
on,O
the,O
activity,O
of,O
the,O
fructo,O
-,O
oligosaccharides,O
(,O
FOS,O
),O
and,O
inulin,O
on,O
P,B-OG
.,I-OG
aeruginosa,I-OG
proliferation,O
.,O
Inulin,O
is,O
a,O
linear,O
polymer,O
formed,O
by,O
20,O
to,O
over,O
60,O
β,O
-,O
2,O
",",O
1,O
-,O
linked,O
fructose,O
monomers,O
with,O
a,O
terminal,O
glucose,O
residue,O
",",O
whereas,O
FOS,O
are,O
short,O
-,O
chain,O
oligosaccharides,O
with,O
the,O
same,O
structure,O
but,O
a,O
maximal,O
chain,O
length,O
of,O
2,O
to,O
20,O
monomeric,O
units,O
which,O
are,O
generated,O
by,O
hydrolysis,O
of,O
inulin,O
[,O
28,O
].,O
Inulin,O
is,O
found,O
in,O
different,O
nutrients,O
such,O
as,O
wheat,B-OG
",",O
onion,B-OG
",",O
garlic,B-OG
and,O
banana,B-OG
[,O
29,O
].,O
Inulin,O
and,O
FOS,O
are,O
considered,O
prebiotics,O
",",O
based,O
on,O
the,O
observation,O
that,O
they,O
promote,O
the,O
growth,O
of,O
certain,O
beneficial,O
gut,O
bacteria,B-OG
such,O
as,O
bifidobacteria,B-OG
[,O
30,O
"],",O
[,O
31,O
"],",O
but,O
they,O
have,O
been,O
also,O
found,O
to,O
inhibit,O
the,O
growth,O
of,O
pathogenic,O
bacteria,B-OG
such,O
as,O
Salmonella,B-OG
typhimurium,I-OG
[,O
32,O
"],",O
S,O
.,O
enteritidis,O
[,O
33,O
],O
Listeria,B-OG
monocytogenes,I-OG
or,O
the,O
fungus,B-OG
Candida,B-OG
albicans,I-OG
[,O
34,O
].,O
In,O
addition,O
inulin,O
and,O
FOS,O
have,O
been,O
found,O
to,O
have,O
a,O
beneficial,O
impact,O
on,O
human,B-OG
health,O
",",O
including,O
the,O
stimulation,O
of,O
calcium,O
",",O
iron,O
and,O
zinc,O
absorption,O
[,O
35,O
],O
and,O
the,O
modulation,O
of,O
local,O
and,O
systemic,O
immune,O
responses,O
[,O
36,O
].,O
Here,O
we,O
show,O
that,O
the,O
addition,O
of,O
FOS,O
to,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
cultures,O
decreases,O
growth,O
and,O
biofilm,O
formation,O
.,O
This,O
effect,O
appears,O
to,O
be,O
specific,O
for,O
FOS,O
since,O
it,O
was,O
not,O
observed,O
following,O
inulin,O
treatment,O
.,O
In,O
addition,O
",",O
FOS,O
reduces,O
the,O
cytokine,B-GP
response,O
of,O
rat,B-OG
primary,O
monocytes,O
to,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infection,I-DS
",",O
an,O
effect,O
considered,O
indirect,O
since,O
this,O
oligosaccharide,O
was,O
found,O
to,O
activate,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
.,O
Attenuated,O
responses,O
are,O
observed,O
also,O
with,O
the,O
virulent,O
ptxS,B-GP
mutant,O
strain,O
.,O
Exotoxin,B-GP
A,I-GP
production,O
is,O
lowered,O
by,O
FOS,O
treatment,O
",",O
suggesting,O
that,O
FOS,O
may,O
interfere,O
with,O
exotoxin,O
synthesis,O
and,O
/,O
or,O
secretion,O
.,O
Taken,O
together,O
",",O
our,O
data,O
suggest,O
that,O
FOS,O
may,O
be,O
a,O
useful,O
component,O
of,O
drug,O
cocktails,O
for,O
the,O
treatment,O
of,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infections,I-DS
.,O
Results,O
Differential,O
effect,O
of,O
FOS,O
and,O
inulin,O
on,O
the,O
growth,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
As,O
stated,O
in,O
the,O
introduction,O
",",O
a,O
number,O
of,O
natural,O
compounds,O
can,O
either,O
promote,O
or,O
slow,O
down,O
the,O
growth,O
of,O
microorganisms,O
.,O
To,O
assess,O
the,O
effect,O
of,O
inulin,O
and,O
FOS,O
on,O
P,B-OG
.,I-OG
aeruginosa,I-OG
",",O
growth,O
curves,O
were,O
recorded,O
in,O
minimal,O
medium,O
M9,O
supplemented,O
with,O
citrate,O
.,O
Under,O
these,O
conditions,O
only,O
minor,O
changes,O
in,O
the,O
bacterial,O
growth,O
rate,O
and,O
yield,O
were,O
observed,O
in,O
the,O
presence,O
of,O
5,O
–,O
20,O
mg,O
/,O
ml,O
inulin,O
.,O
Namely,O
",",O
5,O
and,O
15,O
mg,O
/,O
ml,O
of,O
inulin,O
resulted,O
in,O
a,O
slight,O
to,O
moderate,O
stimulation,O
of,O
growth,O
",",O
whereas,O
at,O
the,O
concentration,O
of,O
20,O
mg,O
/,O
ml,O
a,O
slight,O
reduction,O
was,O
noted,O
(,O
Fig,O
.,O
1A,O
).,O
Effect,O
of,O
inulin,O
and,O
FOS,O
on,O
the,O
growth,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
.,O
Growth,O
curves,O
in,O
minimal,O
medium,O
M9,O
supplemented,O
with,O
50,O
(,O
A,O
),O
and,O
FOS,O
(,O
B,O
),O
are,O
shown,O
.,O
As,O
a,O
control,O
",",O
growth,O
in,O
the,O
minimal,O
medium,O
M9,O
supplemented,O
with,O
20,O
mg,O
/,O
ml,O
of,O
goat,B-OG
milk,O
oligosaccharides,O
(,O
OS,O
),O
is,O
shown,O
.,O
Growth,O
curves,O
were,O
recorded,O
at,O
37,O
°,O
C,O
for,O
24,O
hours,O
.,O
Representative,O
data,O
from,O
one,O
of,O
three,O
independent,O
experiments,O
with,O
similar,O
results,O
are,O
shown,O
.,O
Similarly,O
",",O
in,O
the,O
presence,O
of,O
5,O
–,O
15,O
mg,O
/,O
ml,O
of,O
FOS,O
a,O
minor,O
stimulation,O
of,O
bacterial,O
growth,O
was,O
noted,O
(,O
Fig,O
.,O
1B,O
);,O
however,O
",",O
at,O
the,O
concentration,O
of,O
20,O
mg,O
/,O
ml,O
a,O
marked,O
inhibition,O
was,O
observed,O
(,O
Fig,O
.,O
1B,O
).,O
Since,O
inulin,O
and,O
FOS,O
differ,O
only,O
in,O
the,O
carbohydrate,O
chain,O
length,O
",",O
this,O
parameter,O
appears,O
to,O
be,O
central,O
for,O
antibacterial,O
activity,O
.,O
In,O
comparison,O
",",O
a,O
growth,O
curve,O
was,O
recorded,O
in,O
the,O
presence,O
of,O
20,O
mg,O
/,O
ml,O
of,O
control,O
goat,B-OG
milk,O
oligosaccharides,O
(,O
OS,O
"),",O
showing,O
promotion,O
of,O
bacterial,O
growth,O
at,O
the,O
same,O
concentration,O
at,O
which,O
FOS,O
inhibits,O
growth,O
.,O
In,O
fact,O
",",O
both,O
FOS,O
and,O
inulin,O
(,O
at,O
15,O
–,O
20,O
mg,O
/,O
ml,O
),O
are,O
able,O
to,O
support,O
bacterial,O
growth,O
when,O
M9,O
minimal,O
medium,O
is,O
used,O
(,O
data,O
not,O
shown,O
).,O
Reduction,O
of,O
biofilm,O
formation,O
in,O
the,O
presence,O
of,O
FOS,O
To,O
assess,O
the,O
influence,O
of,O
FOS,O
and,O
inulin,O
on,O
biofilm,O
formation,O
",",O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
was,O
cultured,O
in,O
24,O
-,O
well,O
plates,O
in,O
the,O
absence,O
or,O
presence,O
of,O
different,O
concentrations,O
of,O
both,O
compounds,O
for,O
6,O
hours,O
(,O
Fig,O
.,O
2A,O
"),",O
followed,O
by,O
a,O
quantification,O
of,O
biofilm,O
formation,O
.,O
Fig,O
.,O
2,O
B,O
and,O
Fig,O
.,O
S1,O
show,O
the,O
relative,O
amount,O
of,O
biofilm,O
formation,O
as,O
a,O
function,O
of,O
the,O
inulin,O
/,O
FOS,O
concentration,O
(,O
logarithmic,O
scale,O
).,O
It,O
became,O
apparent,O
that,O
both,O
compounds,O
have,O
opposite,O
effects,O
;,O
whereas,O
inulin,O
stimulated,O
biofilm,O
formation,O
",",O
FOS,O
had,O
a,O
concentration,O
dependent,O
inhibitory,O
effect,O
.,O
Fitting,O
of,O
data,O
(,O
Fig,O
.,O
2B,O
),O
resulted,O
in,O
an,O
EC50,O
value,O
of,O
2,O
.,O
1,O
mg,O
/,O
ml,O
for,O
FOS,O
(,O
inhibition,O
),O
and,O
5,O
.,O
8,O
mg,O
/,O
ml,O
for,O
inulin,O
(,O
stimulation,O
).,O
Biofilm,O
formation,O
was,O
almost,O
completely,O
inhibited,O
at,O
a,O
FOS,O
concentration,O
of,O
4,O
–,O
8,O
mg,O
/,O
ml,O
",",O
which,O
is,O
in,O
sharp,O
contrast,O
with,O
inulin,O
that,O
produced,O
a,O
∼,O
10,O
-,O
fold,O
enhancement,O
at,O
concentrations,O
up,O
to,O
approximately,O
10,O
mg,O
/,O
ml,O
.,O
Formation,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
biofilm,O
.,O
A,O
),O
Biofilm,O
formation,O
in,O
the,O
absence,O
and,O
presence,O
of,O
different,O
concentrations,O
of,O
FOS,O
and,O
inulin,O
in,O
24,O
-,O
well,O
plates,O
.,O
Biofilm,O
formation,O
was,O
monitored,O
in,O
M9,O
minimal,O
medium,O
supplemented,O
with,O
0,O
.,O
2,O
%,O
(,O
w,O
/,O
v,O
),O
glucose,O
and,O
casamino,O
acids,O
and,O
quantified,O
after,O
6,O
h,O
.,O
B,O
),O
The,O
relative,O
amounts,O
of,O
biofilm,O
formation,O
in,O
the,O
experiments,O
shown,O
in,O
Fig,O
.,O
2A,O
are,O
plotted,O
against,O
the,O
logarithm,O
of,O
inulin,O
/,O
FOS,O
concentration,O
.,O
Data,O
were,O
fitted,O
with,O
the,O
sigmoidal,O
model,O
of,O
the,O
ORIGIN,O
software,O
package,O
to,O
determine,O
EC50,O
values,O
.,O
Data,O
are,O
the,O
average,O
of,O
three,O
independent,O
assays,O
.,O
C,O
),O
Microscopic,O
inspection,O
of,O
biofilm,O
formation,O
in,O
the,O
absence,O
and,O
in,O
the,O
presence,O
of,O
20,O
mg,O
/,O
ml,O
inulin,O
or,O
FOS,O
at,O
2,O
",",O
4,O
and,O
6,O
hours,O
.,O
Subsequently,O
",",O
biofilms,O
formed,O
in,O
the,O
presence,O
or,O
absence,O
of,O
both,O
compounds,O
(,O
at,O
20,O
mg,O
/,O
ml,O
),O
were,O
observed,O
under,O
the,O
microscope,O
(,O
Fig,O
.,O
2C,O
).,O
To,O
this,O
end,O
bacteria,B-OG
were,O
grown,O
in,O
M9,O
minimal,O
medium,O
supplemented,O
with,O
0,O
.,O
2,O
%,O
(,O
w,O
/,O
v,O
),O
glucose,O
",",O
0,O
.,O
4,O
%,O
(,O
wt,O
/,O
v,O
),O
casamino,O
acids,O
and,O
with,O
inulin,O
or,O
FOS,O
.,O
In,O
control,O
conditions,O
clear,O
biofilm,O
formation,O
was,O
observed,O
after,O
4,O
and,O
6,O
hours,O
of,O
culture,O
",",O
as,O
expected,O
(,O
Fig,O
.,O
2C,O
).,O
Similar,O
results,O
were,O
obtained,O
with,O
20,O
mg,O
/,O
ml,O
of,O
inulin,O
",",O
but,O
the,O
biofilm,O
was,O
more,O
prominent,O
after,O
6,O
h,O
as,O
compared,O
to,O
the,O
control,O
sample,O
.,O
In,O
contrast,O
",",O
while,O
biofilm,O
formation,O
in,O
the,O
presence,O
of,O
FOS,O
was,O
comparable,O
to,O
that,O
in,O
control,O
conditions,O
after,O
4,O
hours,O
",",O
it,O
was,O
virtually,O
absent,O
at,O
6,O
h,O
(,O
Fig,O
.,O
2C,O
).,O
FOS,O
and,O
inulin,O
have,O
opposite,O
effects,O
on,O
bacterial,O
motility,O
P,B-OG
.,I-OG
aeruginosa,I-OG
has,O
been,O
shown,O
to,O
exhibit,O
three,O
different,O
types,O
of,O
motility,O
",",O
namely,O
swimming,O
",",O
swarming,O
and,O
twitching,O
[,O
37,O
"],",O
[,O
38,O
].,O
Twitching,O
motility,O
across,O
solid,O
surfaces,O
[,O
39,O
],O
has,O
been,O
found,O
to,O
be,O
required,O
for,O
biofilm,O
development,O
[,O
13,O
"],",O
[,O
40,O
"],",O
as,O
well,O
as,O
for,O
a,O
persistent,O
colonization,O
of,O
lungs,O
",",O
and,O
it,O
is,O
associated,O
with,O
virulence,O
in,O
corneal,B-DS
infection,I-DS
models,O
[,O
39,O
"],",O
[,O
41,O
].,O
We,O
have,O
studied,O
the,O
effect,O
of,O
inulin,O
and,O
FOS,O
at,O
5,O
mg,O
/,O
ml,O
on,O
P,B-OG
.,I-OG
aeruginosa,I-OG
bacterial,O
motility,O
on,O
agar,O
plates,O
and,O
in,O
bacterial,O
suspension,O
(,O
Fig,O
.,O
3,O
).,O
Neither,O
FOS,O
nor,O
inulin,O
affected,O
swimming,O
behaviour,O
(,O
Fig,O
.,O
3A,O
).,O
Interestingly,O
",",O
FOS,O
inhibited,O
both,O
swarming,O
and,O
twitching,O
motility,O
",",O
whereas,O
inulin,O
treatment,O
resulted,O
in,O
the,O
opposite,O
effect,O
",",O
i,O
.,O
e,O
.,O
stimulation,O
(,O
Fig,O
.,O
3B,O
and,O
C,O
).,O
Effects,O
of,O
FOS,O
and,O
inulin,O
on,O
the,O
motility,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
.,O
Motility,O
assays,O
were,O
carried,O
out,O
as,O
described,O
in,O
materials,O
and,O
methods,O
.,O
Inulin,O
or,O
FOS,O
at,O
5,O
mg,O
/,O
ml,O
was,O
present,O
in,O
the,O
agar,O
plates,O
and,O
in,O
the,O
bacterial,O
suspensions,O
.,O
A,O
),O
Swimming,O
assays,O
.,O
B,O
),O
Swarming,O
assays,O
and,O
C,O
),O
Twitching,O
assays,O
.,O
Average,O
values,O
of,O
the,O
distances,O
of,O
bacterial,O
migration,O
are,O
shown,O
.,O
Data,O
are,O
the,O
average,O
of,O
three,O
independent,O
assays,O
.,O
Values,O
are,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
".,",O
n,O
=,O
6,O
;,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
without,O
effectors,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
Inulin,O
and,O
FOS,O
reduce,O
cytokine,B-GP
secretion,O
in,O
P,B-OG
.,I-OG
aeruginosa,I-OG
infected,O
macrophages,O
Tissue,B-DS
injury,I-DS
or,O
infection,B-DS
results,O
in,O
the,O
recruitment,O
and,O
activation,O
of,O
host,O
immune,O
cells,O
.,O
Macrophages,O
are,O
the,O
first,O
immune,O
cells,O
likely,O
to,O
encounter,O
P,B-OG
.,I-OG
aeruginosa,I-OG
.,O
The,O
activation,O
of,O
macrophages,O
is,O
based,O
largely,O
on,O
the,O
recognition,O
of,O
pathogens,O
by,O
molecular,O
pattern,O
receptors,O
",",O
including,O
Toll,B-GP
-,I-GP
like,I-GP
receptors,I-GP
(,O
TLRs,B-GP
"),",O
such,O
as,O
TLR4,B-GP
[,O
16,O
"],",O
[,O
42,O
].,O
Macrophages,O
can,O
internalize,O
and,O
kill,O
bacterial,O
pathogens,O
;,O
however,O
",",O
during,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infections,I-DS
their,O
role,O
in,O
pathogen,O
sensing,O
is,O
of,O
primary,O
importance,O
[,O
43,O
].,O
This,O
in,O
turn,O
causes,O
significant,O
changes,O
in,O
gene,O
expression,O
and,O
the,O
secretion,O
of,O
proinflammatory,B-GP
cytokines,I-GP
IL,B-GP
-,I-GP
6,I-GP
and,O
TNF,B-GP
-,I-GP
α,I-GP
that,O
recruit,O
inflammatory,O
cells,O
in,O
response,O
to,O
bacterial,O
virulence,O
factors,O
",",O
while,O
IL,B-GP
-,I-GP
10,I-GP
tends,O
to,O
mitigate,O
this,O
response,O
[,O
44,O
]–[,O
47,O
].,O
These,O
are,O
among,O
the,O
main,O
signalling,O
mediators,O
released,O
by,O
monocyte,O
/,O
macrophages,O
.,O
Initial,O
experiments,O
were,O
carried,O
out,O
to,O
establish,O
the,O
experimental,O
conditions,O
for,O
the,O
assessment,O
of,O
the,O
effect,O
of,O
FOS,O
and,O
inulin,O
on,O
cytokine,B-GP
secretion,O
(,O
Fig,O
.,O
S2,O
).,O
Macrophages,O
were,O
incubated,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
and,O
interleukin,B-GP
6,I-GP
secretion,O
was,O
measured,O
at,O
different,O
time,O
intervals,O
(,O
Fig,O
.,O
S2,O
).,O
Maximal,O
secretion,O
was,O
observed,O
after,O
4,O
hours,O
of,O
incubation,O
.,O
Therefore,O
",",O
these,O
experimental,O
conditions,O
were,O
used,O
to,O
quantify,O
the,O
effect,O
of,O
FOS,O
/,O
inulin,O
on,O
the,O
secretion,O
of,O
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
10,I-GP
and,O
TNF,B-GP
-,I-GP
α,I-GP
.,O
In,O
the,O
absence,O
of,O
bacteria,B-OG
(,O
Fig,O
.,O
4,O
",",O
column,O
–,O
PAO1,B-OG
"),",O
inulin,O
and,O
FOS,O
had,O
no,O
significant,O
effect,O
on,O
cytokine,B-GP
secretion,O
",",O
although,O
a,O
slight,O
increase,O
was,O
noted,O
.,O
PAO,B-DS
-,I-DS
1,I-DS
infection,I-DS
caused,O
the,O
expected,O
significant,O
increase,O
in,O
cytokine,B-GP
secretion,O
.,O
This,O
response,O
was,O
markedly,O
attenuated,O
for,O
the,O
three,O
cytokines,B-GP
in,O
the,O
presence,O
of,O
FOS,O
",",O
while,O
inulin,O
caused,O
exclusively,O
a,O
reduction,O
in,O
IL,B-GP
-,I-GP
6,I-GP
levels,O
(,O
Fig,O
.,O
4,O
).,O
These,O
data,O
therefore,O
show,O
that,O
the,O
presence,O
of,O
inulin,O
and,O
particularly,O
FOS,O
reduced,O
the,O
inflammatory,O
response,O
of,O
macrophages,O
to,O
bacterial,B-DS
infection,I-DS
.,O
Since,O
FOS,O
/,O
inulin,O
did,O
not,O
reduce,O
the,O
cytokine,B-GP
release,O
in,O
the,O
absence,O
of,O
bacteria,B-OG
",",O
our,O
results,O
suggest,O
that,O
the,O
inhibitory,O
effect,O
of,O
FOS,O
is,O
probably,O
due,O
to,O
a,O
direct,O
interaction,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
.,O
Effect,O
of,O
inulin,O
and,O
FOS,O
on,O
inflammatory,O
response,O
of,O
macrophages,O
against,O
P,B-OG
.,I-OG
aeruginosa,I-OG
(,O
WT,O
).,O
Macrophages,O
were,O
incubated,O
with,O
WT,O
P,B-OG
.,I-OG
aeruginosa,I-OG
cells,O
(,O
ratio,O
1,O
/,O
5,O
),O
for,O
4,O
hours,O
in,O
either,O
the,O
absence,O
or,O
the,O
presence,O
of,O
5,O
mg,O
/,O
ml,O
FOS,O
and,O
inulin,O
prior,O
to,O
the,O
determination,O
of,O
IL,B-GP
-,I-GP
6,I-GP
(,O
A,O
"),",O
IL,B-GP
-,I-GP
10,I-GP
(,O
B,O
),O
and,O
TNF,B-GP
-,I-GP
α,I-GP
secretion,O
(,O
C,O
).,O
Values,O
are,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
".,",O
n,O
=,O
6,O
–,O
8,O
;,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
macrophage,O
without,O
bacteria,B-OG
and,O
&,O
P,O
<,O
0,O
.,O
05,O
vs,O
WT,O
in,O
the,O
absence,O
of,O
inulin,O
or,O
FOS,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
Activation,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
signal,O
transduction,O
pathway,O
is,O
downregulated,O
by,O
FOS,O
The,O
mitogen,B-GP
-,I-GP
activated,I-GP
protein,I-GP
kinase,I-GP
(,O
MAPK,B-GP
),O
and,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
signalling,O
pathways,O
are,O
implicated,O
in,O
the,O
production,O
of,O
TNF,B-GP
-,I-GP
α,I-GP
and,O
IL,B-GP
-,I-GP
6,I-GP
in,O
macrophages,O
[,O
48,O
].,O
In,O
addition,O
",",O
it,O
has,O
been,O
reported,O
that,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infection,I-DS
is,O
associated,O
to,O
stimulation,O
of,O
TLR4,B-GP
receptors,O
",",O
leading,O
to,O
an,O
activation,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
[,O
49,O
].,O
To,O
assess,O
the,O
impact,O
of,O
inulin,O
and,O
FOS,O
on,O
the,O
inflammatory,O
response,O
",",O
the,O
role,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
and,O
MAPK,B-GP
signalling,O
pathways,O
in,O
the,O
FOS,O
-,O
mediated,O
modulation,O
of,O
macrophages,O
was,O
assessed,O
.,O
One,O
of,O
the,O
ways,O
to,O
activate,O
NF,B-GP
-,I-GP
κB,I-GP
by,O
extracellular,O
stimuli,O
involves,O
the,O
rapid,O
degradation,O
of,O
IκB,B-GP
-,I-GP
α,I-GP
as,O
a,O
consequence,O
of,O
IκB,B-GP
-,I-GP
α,I-GP
phosphorylation,O
at,O
Ser32,O
by,O
IκB,B-GP
kinase,I-GP
",",O
which,O
corresponds,O
to,O
IKK,B-GP
in,O
the,O
so,O
-,O
called,O
canonical,O
pathway,O
.,O
We,O
studied,O
the,O
effect,O
of,O
inulin,O
and,O
FOS,O
on,O
the,O
activation,O
(,O
phosphorylation,O
),O
of,O
IκB,B-GP
-,I-GP
α,I-GP
and,O
MAPK,B-GP
",",O
ERK,B-GP
",",O
JNK,B-GP
and,O
p38,B-GP
by,O
Western,O
blot,O
analysis,O
in,O
macrophages,O
infected,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
.,O
As,O
shown,O
in,O
Fig,O
.,O
5A,O
",",O
neither,O
FOS,O
nor,O
inulin,O
affected,O
the,O
phosphospecific,O
signal,O
of,O
the,O
three,O
MAPK,B-GP
",",O
suggesting,O
that,O
they,O
are,O
not,O
involved,O
in,O
the,O
observed,O
changes,O
.,O
In,O
contrast,O
",",O
FOS,O
but,O
not,O
inulin,O
reduced,O
IκB,B-GP
-,I-GP
α,I-GP
phosphorylation,O
",",O
pointing,O
to,O
a,O
modulation,O
of,O
the,O
NFκ,O
-,O
B,O
canonical,O
pathway,O
.,O
FOS,O
but,O
not,O
inulin,O
reduces,O
the,O
amount,O
of,O
phosphorylated,O
IkB,B-GP
-,I-GP
α,I-GP
.,O
A,O
),O
Macrophages,O
were,O
infected,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
in,O
the,O
absence,O
or,O
presence,O
of,O
either,O
5,O
mg,O
/,O
ml,O
FOS,O
or,O
inulin,O
.,O
After,O
4,O
h,O
growth,O
Western,O
blots,O
were,O
performed,O
using,O
cell,O
extracts,O
and,O
the,O
corresponding,O
antibodies,O
against,O
ERK,B-GP
(,O
Extracellular,B-GP
Regulated,I-GP
Kinase,I-GP
"),",O
p,O
-,O
ERK,B-GP
(,O
the,O
phosphorylated,O
form,O
of,O
Extracellular,B-GP
Regulated,I-GP
Kinase,I-GP
"),",O
p,O
-,O
P38,B-GP
(,O
activated,O
and,O
phosphorylated,O
form,O
of,O
P38,B-GP
mitogen,I-GP
-,I-GP
activated,I-GP
protein,I-GP
kinases,I-GP
"),",O
p,O
-,O
JNK,B-GP
(,O
Jun,B-GP
N,I-GP
-,I-GP
terminal,I-GP
kinases,I-GP
),O
and,O
after,O
1,O
h,O
for,O
p,O
-,O
IκB,B-GP
-,I-GP
α,I-GP
(,O
activated,O
form,O
in,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
canonical,O
pathway,O
).,O
As,O
control,O
",",O
actin,B-GP
was,O
quantified,O
in,O
all,O
samples,O
using,O
an,O
anti,O
-,O
α,B-GP
-,I-GP
actin,I-GP
antibody,O
.,O
Duplicate,O
samples,O
in,O
the,O
absence,O
of,O
added,O
effectors,O
and,O
triplicate,O
samples,O
in,O
the,O
presence,O
of,O
FOS,O
and,O
inulin,O
are,O
shown,O
.,O
B,O
),O
NF,B-GP
-,I-GP
κB,I-GP
activation,O
was,O
determined,O
by,O
measuring,O
the,O
nuclear,O
translocation,O
of,O
the,O
p65,B-GP
component,O
",",O
expressed,O
as,O
the,O
OD450,O
nm,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
macrophage,O
without,O
bacteria,B-OG
and,O
&,O
P,O
<,O
0,O
.,O
05,O
vs,O
WT,O
in,O
the,O
absence,O
of,O
inulin,O
or,O
FOS,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
Moreover,O
",",O
the,O
activation,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
transcription,O
factor,O
is,O
associated,O
with,O
the,O
nuclear,O
translocation,O
of,O
the,O
p65,B-GP
component,O
of,O
the,O
complex,O
.,O
To,O
confirm,O
the,O
effect,O
of,O
inulin,O
or,O
FOS,O
on,O
nuclear,O
NF,B-GP
-,I-GP
κB,I-GP
/,O
p65,B-GP
translocation,O
",",O
p65,B-GP
was,O
quantified,O
by,O
ELISA,O
in,O
cell,O
nuclei,O
following,O
1,O
h,O
activation,O
.,O
In,O
contrast,O
to,O
inulin,O
",",O
FOS,O
(,O
5,O
mg,O
/,O
ml,O
),O
effectively,O
reduced,O
NF,B-GP
-,I-GP
κB,I-GP
/,O
p65,B-GP
translocation,O
(,O
Fig,O
.,O
5B,O
).,O
Therefore,O
",",O
the,O
effect,O
of,O
FOS,O
is,O
associated,O
with,O
a,O
minor,O
activation,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
signalling,O
pathway,O
.,O
The,O
effect,O
of,O
FOS,O
is,O
observed,O
in,O
P,B-OG
.,I-OG
aeruginosa,I-OG
mutant,O
strains,O
with,O
different,O
degrees,O
of,O
virulence,O
Since,O
the,O
FOS,O
-,O
mediated,O
inhibition,O
of,O
bacterial,O
growth,O
and,O
biofilm,O
formation,O
may,O
reduce,O
virulence,O
",",O
we,O
hypothesized,O
that,O
the,O
response,O
of,O
eukaryotic,O
cells,O
to,O
infection,B-DS
may,O
be,O
modulated,O
by,O
the,O
presence,O
of,O
this,O
oligosaccharide,O
.,O
Subsequent,O
experiments,O
were,O
aimed,O
at,O
assessing,O
the,O
effect,O
of,O
FOS,O
and,O
inulin,O
in,O
two,O
strains,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
showing,O
different,O
levels,O
of,O
virulence,O
compared,O
as,O
compared,O
to,O
wild,O
type,O
strain,O
.,O
We,O
used,O
mutants,O
deficient,O
in,O
PtxS,B-GP
and,O
PtxR,B-GP
",",O
two,O
transcriptional,B-GP
regulators,I-GP
that,O
control,O
the,O
expression,O
of,O
the,O
toxA,B-GP
gene,O
",",O
encoding,O
the,O
exotoxin,B-GP
A,I-GP
virulence,O
factor,O
[,O
50,O
].,O
Both,O
",",O
PtxR,B-GP
and,O
PtxS,B-GP
play,O
a,O
role,O
in,O
regulating,O
the,O
activity,O
from,O
the,O
PtoxA,O
promoter,O
[,O
51,O
].,O
Mutation,O
of,O
ptxS,B-GP
increases,O
toxA,B-GP
expression,O
by,O
a,O
factor,O
of,O
∼,O
4,O
",",O
whereas,O
deletion,O
of,O
ptxR,B-GP
causes,O
a,O
∼,O
2,O
-,O
fold,O
reduction,O
[,O
51,O
].,O
The,O
increase,O
in,O
toxicity,O
of,O
the,O
ptxS,B-GP
mutant,O
(,O
Fig,O
.,O
6A,O
),O
is,O
reflected,O
in,O
the,O
colour,O
of,O
bacterial,O
cultures,O
due,O
to,O
the,O
increased,O
production,O
of,O
the,O
bright,O
blue,O
-,O
green,O
siderophore,O
pyocyanin,O
",",O
an,O
important,O
virulence,O
factor,O
of,O
fluorescent,B-OG
Pseudomonads,I-OG
[,O
52,O
]–[,O
54,O
].,O
In,O
contrast,O
the,O
colour,O
of,O
the,O
ptxR,B-GP
mutant,O
is,O
similar,O
to,O
that,O
of,O
the,O
wild,O
type,O
strain,O
.,O
Further,O
",",O
anti,O
-,O
exotoxin,B-GP
A,I-GP
western,O
blot,O
showed,O
that,O
ptxS,B-GP
mutant,O
produces,O
significantly,O
more,O
exotoxin,B-GP
A,I-GP
than,O
the,O
ptxR,B-GP
mutant,O
(,O
Fig,O
.,O
6B,O
).,O
Subsequently,O
",",O
the,O
cytotoxic,O
activity,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
on,O
macrophages,O
was,O
analysed,O
4,O
hours,O
after,O
infection,B-DS
",",O
using,O
the,O
Cytotox,O
96,O
®,O
non,O
-,O
radioactive,O
cytotoxicity,O
assay,O
kit,O
.,O
As,O
expected,O
",",O
cytotoxicity,O
was,O
highest,O
for,O
the,O
ptxS,B-GP
mutant,O
(,O
Fig,O
.,O
6C,O
),O
where,O
approximately,O
25,O
%,O
of,O
cells,O
died,O
",",O
followed,O
by,O
the,O
wild,O
type,O
strain,O
(,O
10,O
%,O
of,O
cell,O
death,O
),O
and,O
the,O
ptxR,B-GP
mutant,O
for,O
which,O
no,O
toxicity,O
was,O
detected,O
(,O
Figure,O
6C,O
).,O
The,O
lactase,B-GP
dehydrogenase,I-GP
(,O
LDH,B-GP
),O
is,O
a,O
marker,O
for,O
cytotoxicity,O
.,O
We,O
have,O
determined,O
the,O
LDH,B-GP
levels,O
of,O
0,O
.,O
1,O
–,O
0,O
.,O
2,O
mU,O
/,O
µl,O
in,O
the,O
absence,O
of,O
bacteria,B-OG
but,O
in,O
the,O
presence,O
of,O
FOS,O
or,O
inulin,O
(,O
data,O
not,O
shown,O
).,O
Both,O
compounds,O
did,O
not,O
induce,O
any,O
significant,O
changes,O
in,O
the,O
LDH,B-GP
levels,O
",",O
indicating,O
that,O
they,O
are,O
not,O
cytotoxic,O
to,O
macrophages,O
under,O
the,O
conditions,O
used,O
(,O
data,O
not,O
shown,O
).,O
Effect,O
of,O
wild,O
type,O
and,O
mutant,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
on,O
macrophages,O
.,O
A,O
),O
Cultures,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
and,O
its,O
mutants,O
deficient,O
in,O
ptxS,B-GP
and,O
ptxR,B-GP
were,O
grown,O
in,O
M9,O
Minimum,O
medium,O
supplemented,O
with,O
50,O
mM,O
citrate,O
for,O
24,O
hours,O
.,O
The,O
blue,O
-,O
green,O
colour,O
is,O
indicative,O
of,O
an,O
increased,O
pyocyanin,O
secretion,O
.,O
B,O
),O
Western,O
blot,O
determination,O
of,O
exotoxin,B-GP
A,I-GP
concentration,O
secreted,O
by,O
P,B-OG
.,I-OG
aeruginosa,I-OG
WT,O
and,O
its,O
isogenic,O
mutants,O
ptxS,B-GP
and,O
ptxR,B-GP
.,O
C,O
),O
The,O
macrophage,O
mortality,O
induced,O
by,O
WT,O
P,B-OG
.,I-OG
aeruginosa,I-OG
and,O
its,O
ptxS,B-GP
and,O
ptxR,B-GP
mutants,O
was,O
measured,O
by,O
the,O
total,O
release,O
of,O
cytoplasmic,O
lactate,B-GP
dehydrogenase,I-GP
(,O
LDH,B-GP
).,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
macrophage,O
without,O
bacteria,B-OG
and,O
&,O
P,O
<,O
0,O
.,O
05,O
vs,O
macrophage,O
with,O
WT,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
As,O
expected,O
",",O
the,O
cytokine,B-GP
secretory,O
response,O
followed,O
the,O
same,O
pattern,O
",",O
being,O
higher,O
with,O
the,O
ptxS,B-GP
mutant,O
",",O
followed,O
by,O
the,O
wild,O
type,O
and,O
lower,O
for,O
the,O
ptxR,B-GP
mutant,O
(,O
Fig,O
.,O
7,O
),O
(,O
Data,O
from,O
Fig,O
.,O
4,O
are,O
included,O
for,O
comparison,O
),O
[,O
51,O
].,O
For,O
all,O
three,O
bacterial,O
strains,O
analysed,O
",",O
FOS,O
caused,O
a,O
very,O
pronounced,O
reduction,O
(,O
Fig,O
.,O
7,O
"),",O
while,O
inulin,O
caused,O
a,O
more,O
moderate,O
reduction,O
.,O
Interestingly,O
",",O
the,O
FOS,O
/,O
inulin,O
mediated,O
reduction,O
was,O
more,O
pronounced,O
in,O
the,O
ptxS,B-GP
mutant,O
than,O
in,O
WT,O
strain,O
",",O
suggesting,O
that,O
virulent,O
strains,O
may,O
be,O
more,O
sensitive,O
to,O
the,O
effect,O
of,O
fructose,O
oligosaccharides,O
.,O
Effect,O
of,O
inulin,O
and,O
FOS,O
on,O
inflammatory,O
response,O
of,O
macrophages,O
against,O
WT,O
P,B-OG
.,I-OG
aeruginosa,I-OG
and,O
its,O
isogenic,O
mutants,O
ptxS,B-GP
and,O
ptxR,B-GP
.,O
Macrophages,O
were,O
incubated,O
with,O
WT,O
and,O
mutant,O
P,B-OG
.,I-OG
aeruginosa,I-OG
cells,O
(,O
ratio,O
1,O
/,O
5,O
),O
for,O
4,O
hours,O
in,O
either,O
the,O
absence,O
or,O
the,O
presence,O
of,O
5,O
mg,O
/,O
ml,O
FOS,O
and,O
inulin,O
prior,O
to,O
the,O
determination,O
of,O
IL,B-GP
-,I-GP
6,I-GP
(,O
A,O
"),",O
IL,B-GP
-,I-GP
10,I-GP
(,O
B,O
),O
and,O
TNF,B-GP
-,I-GP
α,I-GP
secretion,O
(,O
C,O
).,O
Values,O
are,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
".,",O
n,O
=,O
6,O
–,O
8,O
;,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
WT,O
in,O
the,O
absence,O
of,O
inulin,O
or,O
FOS,O
;,O
&,O
P,O
<,O
0,O
.,O
05,O
vs,O
ptxS,B-GP
mutant,O
without,O
effectors,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
P,B-OG
.,I-OG
aeruginosa,I-OG
employs,O
a,O
number,O
of,O
systems,O
to,O
secrete,O
proteins,O
which,O
play,O
different,O
roles,O
during,O
infection,B-DS
.,O
To,O
analyse,O
the,O
role,O
of,O
FOS,O
or,O
inulin,O
on,O
P,B-OG
.,I-OG
aeruginosa,I-OG
virulence,O
",",O
exotoxin,B-GP
A,I-GP
was,O
quantified,O
in,O
supernatants,O
of,O
bacterial,O
co,O
-,O
cultures,O
with,O
eukaryotic,O
cells,O
as,O
well,O
as,O
within,O
eukaryotic,O
cells,O
.,O
To,O
achieve,O
a,O
good,O
separation,O
of,O
eukaryotic,O
cells,O
from,O
bacteria,B-OG
",",O
we,O
used,O
the,O
rat,B-OG
small,O
intestinal,O
cell,O
line,O
IEC18,O
that,O
grows,O
on,O
surfaces,O
and,O
exhibits,O
inflammatory,O
responses,O
[,O
55,O
"],",O
[,O
56,O
].,O
Bacteria,B-OG
are,O
removed,O
by,O
a,O
washing,O
step,O
with,O
fresh,O
PBS,O
solution,O
",",O
leaving,O
an,O
intact,O
IEC18,O
cell,O
monolayer,O
containing,O
infecting,O
Pseudomonas,B-OG
.,O
Anti,O
-,O
exotoxin,B-GP
A,I-GP
western,O
blot,O
analysis,O
showed,O
that,O
the,O
addition,O
of,O
FOS,O
and,O
inulin,O
to,O
eukaryotic,O
cells,O
did,O
not,O
alter,O
exotoxin,B-GP
A,I-GP
levels,O
present,O
in,O
the,O
culture,O
medium,O
(,O
data,O
not,O
shown,O
).,O
In,O
contrast,O
",",O
FOS,O
was,O
found,O
to,O
reduce,O
intracellular,O
exotoxin,B-GP
A,I-GP
levels,O
in,O
IEC18,O
cells,O
co,O
-,O
cultured,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
",",O
whereas,O
no,O
significant,O
change,O
was,O
observed,O
in,O
the,O
presence,O
of,O
inulin,O
(,O
Fig,O
.,O
8A,O
and,O
B,O
).,O
These,O
data,O
suggest,O
that,O
the,O
type,O
II,O
-,O
dependent,O
exotoxin,B-GP
A,I-GP
secretion,O
from,O
P,B-OG
.,I-OG
aeruginosa,I-OG
to,O
the,O
cell,O
cytosol,O
is,O
inhibited,O
by,O
FOS,O
",",O
presumably,O
limiting,O
its,O
virulence,O
.,O
Because,O
we,O
cannot,O
rule,O
out,O
the,O
presence,O
of,O
extracellular,O
",",O
cell,O
adherent,O
bacteria,B-OG
in,O
the,O
sample,O
",",O
it,O
may,O
be,O
possible,O
that,O
FOS,O
also,O
downregulates,O
exotoxin,B-GP
A,I-GP
in,O
extracellular,O
Pseudomonas,B-OG
.,O
FOS,O
reduces,O
exotoxin,B-GP
A,I-GP
expression,O
.,O
A,O
),O
Western,O
blot,O
determination,O
of,O
the,O
cellular,O
concentration,O
of,O
exotoxin,B-GP
A,I-GP
in,O
IEC18,O
cells,O
following,O
co,O
-,O
culture,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
in,O
the,O
presence,O
and,O
absence,O
of,O
FOS,O
and,O
inulin,O
.,O
B,O
),O
Densitometric,O
analysis,O
of,O
above,O
data,O
.,O
Exotoxin,B-GP
A,I-GP
densities,O
were,O
corrected,O
with,O
those,O
obtained,O
for,O
α,B-GP
-,I-GP
actin,I-GP
.,O
Values,O
are,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
".,",O
n,O
=,O
3,O
;,O
&,O
P,O
<,O
0,O
.,O
05,O
vs,O
macrophage,O
/,O
WT,O
without,O
inulin,O
or,O
FOS,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
Discussion,O
Prebiotics,O
are,O
defined,O
as,O
compounds,O
that,O
have,O
beneficial,O
effects,O
on,O
humans,B-OG
by,O
altering,O
the,O
intestinal,O
microbiota,O
in,O
a,O
manner,O
that,O
is,O
beneficial,O
to,O
health,O
.,O
The,O
mechanism,O
of,O
their,O
action,O
is,O
not,O
clear,O
",",O
but,O
it,O
is,O
thought,O
to,O
involve,O
preferential,O
utilization,O
of,O
oligosaccharides,O
by,O
host,O
-,O
friendly,O
bacterial,O
species,O
such,O
as,O
bifidobacteria,B-OG
or,O
lactobacilli,B-OG
",",O
indicating,O
that,O
prebiotic,O
substances,O
might,O
have,O
the,O
capacity,O
to,O
protect,O
against,O
infections,O
and,O
reduce,O
the,O
presence,O
of,O
clinically,O
relevant,O
pathogens,O
in,O
the,O
faecal,O
flora,O
[,O
57,O
"],",O
[,O
58,O
].,O
Another,O
proposed,O
mechanism,O
involves,O
enhanced,O
bacteriocin,B-GP
secretion,O
by,O
lactobacilli,B-OG
[,O
59,O
"],",O
which,O
in,O
turn,O
facilitates,O
the,O
incorporation,O
of,O
bacteria,B-OG
into,O
a,O
niche,O
and,O
inhibits,O
the,O
invasion,O
of,O
competing,O
strains,O
or,O
pathogens,O
",",O
leading,O
ultimately,O
to,O
a,O
modulation,O
of,O
the,O
microbiota,O
and,O
of,O
the,O
host,O
immune,O
system,O
.,O
Therefore,O
",",O
the,O
inhibition,O
of,O
pathogens,O
by,O
prebiotics,O
is,O
thought,O
to,O
be,O
largely,O
due,O
to,O
indirect,O
effects,O
[,O
60,O
].,O
However,O
",",O
antimicrobial,O
properties,O
have,O
been,O
described,O
for,O
a,O
number,O
of,O
oligosaccharides,O
[,O
61,O
].,O
To,O
our,O
knowledge,O
this,O
is,O
the,O
first,O
report,O
showing,O
that,O
FOS,O
",",O
one,O
of,O
the,O
most,O
studied,O
and,O
used,O
prebiotics,O
",",O
has,O
specific,O
effects,O
on,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
.,O
We,O
were,O
able,O
to,O
show,O
that,O
FOS,O
(,O
1,O
),O
inhibits,O
P,B-OG
.,I-OG
aeruginosa,I-OG
growth,O
",",O
biofilm,O
formation,O
and,O
motility,O
;,O
(,O
2,O
),O
limits,O
the,O
P,B-OG
.,I-OG
aeruginosa,I-OG
evoked,O
NF,B-GP
-,I-GP
κB,I-GP
dependent,O
cytokine,B-GP
secretion,O
in,O
macrophages,O
;,O
and,O
(,O
3,O
),O
decreases,O
exotoxin,B-GP
A,I-GP
levels,O
in,O
P,B-OG
.,I-OG
aeruginosa,I-OG
infected,O
IEC18,O
cells,O
.,O
These,O
effects,O
have,O
also,O
been,O
observed,O
for,O
inulin,O
",",O
but,O
in,O
general,O
the,O
magnitude,O
of,O
the,O
changes,O
induced,O
by,O
FOS,O
was,O
superior,O
to,O
that,O
of,O
inulin,O
.,O
This,O
indicates,O
that,O
the,O
length,O
of,O
the,O
oligosaccharide,O
chains,O
is,O
an,O
essential,O
determinant,O
for,O
the,O
magnitude,O
of,O
the,O
biological,O
activities,O
observed,O
.,O
This,O
is,O
exemplified,O
by,O
growth,O
inhibition,O
:,O
both,O
FOS,O
and,O
inulin,O
can,O
be,O
used,O
as,O
carbon,O
and,O
energy,O
source,O
by,O
P,B-OG
.,I-OG
aeruginosa,I-OG
and,O
it,O
is,O
therefore,O
not,O
surprising,O
to,O
see,O
a,O
growth,O
stimulation,O
in,O
the,O
presence,O
of,O
up,O
to,O
10,O
mg,O
/,O
ml,O
of,O
both,O
compounds,O
(,O
Fig,O
.,O
1,O
and,O
data,O
not,O
shown,O
).,O
However,O
",",O
at,O
a,O
concentration,O
of,O
20,O
mg,O
/,O
ml,O
inulin,O
had,O
a,O
very,O
modest,O
effect,O
on,O
growth,O
which,O
contrasts,O
with,O
FOS,O
that,O
caused,O
a,O
very,O
significant,O
growth,O
inhibition,O
.,O
These,O
results,O
are,O
consistent,O
with,O
a,O
biphasic,O
response,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
to,O
FOS,O
/,O
inulin,O
:,O
growth,O
is,O
stimulated,O
at,O
low,O
concentrations,O
of,O
inulin,O
and,O
then,O
inhibited,O
to,O
a,O
certain,O
extent,O
;,O
the,O
same,O
response,O
is,O
observed,O
with,O
FOS,O
",",O
but,O
growth,O
inhibition,O
is,O
clearly,O
more,O
pronounced,O
.,O
The,O
control,O
goat,B-OG
milk,O
oligosaccharides,O
did,O
not,O
produce,O
any,O
inhibition,O
at,O
similar,O
concentrations,O
",",O
underlining,O
the,O
specificity,O
of,O
action,O
of,O
FOS,O
.,O
The,O
variety,O
of,O
cellular,O
processes,O
modulated,O
by,O
FOS,O
was,O
a,O
surprising,O
finding,O
and,O
it,O
is,O
tempting,O
to,O
speculate,O
that,O
glycoside,B-GP
receptors,I-GP
may,O
be,O
involved,O
in,O
the,O
recognition,O
of,O
FOS,O
and,O
that,O
these,O
receptors,O
signal,O
via,O
different,O
cascades,O
modulating,O
different,O
cellular,O
processes,O
.,O
Such,O
a,O
mechanism,O
would,O
be,O
comparable,O
to,O
that,O
for,O
the,O
sensing,O
of,O
other,O
antimicrobial,O
glycosides,O
[,O
62,O
].,O
Otherwise,O
",",O
biofilm,O
formation,O
is,O
a,O
major,O
mechanism,O
that,O
confers,O
bacterial,O
resistance,O
and,O
biofilm,O
induced,O
antibiotics,O
tolerance,O
is,O
of,O
major,O
clinical,O
importance,O
[,O
63,O
].,O
Currently,O
significant,O
research,O
efforts,O
are,O
being,O
made,O
to,O
identify,O
compounds,O
that,O
interfere,O
with,O
biofilm,O
formation,O
",",O
maturation,O
and,O
dispersion,O
and,O
to,O
explore,O
their,O
effect,O
in,O
infection,B-DS
models,O
[,O
64,O
].,O
Here,O
we,O
show,O
that,O
FOS,O
and,O
inulin,O
have,O
opposite,O
effects,O
on,O
biofilm,O
formation,O
.,O
While,O
inulin,O
caused,O
a,O
stimulation,O
",",O
a,O
dramatic,O
reduction,O
was,O
observed,O
in,O
the,O
presence,O
of,O
FOS,O
(,O
Fig,O
.,O
2,O
and,O
Fig,O
.,O
S1,O
).,O
Interestingly,O
",",O
FOS,O
did,O
not,O
appear,O
to,O
affect,O
the,O
early,O
stages,O
of,O
biofilm,O
formation,O
since,O
no,O
significant,O
changes,O
were,O
observed,O
after,O
4,O
hours,O
growth,O
(,O
Fig,O
.,O
2C,O
).,O
In,O
turn,O
",",O
a,O
dramatic,O
reduction,O
was,O
seen,O
after,O
6,O
hours,O
(,O
Fig,O
.,O
2C,O
"),",O
suggesting,O
that,O
FOS,O
interferes,O
with,O
later,O
stages,O
of,O
biofilm,O
formation,O
or,O
triggers,O
its,O
dispersal,O
.,O
Further,O
experiments,O
to,O
elucidate,O
this,O
point,O
are,O
underway,O
.,O
We,O
hypothesized,O
that,O
these,O
effects,O
may,O
alter,O
P,B-OG
.,I-OG
aeruginosa,I-OG
virulence,O
.,O
In,O
order,O
to,O
test,O
this,O
hypothesis,O
",",O
we,O
infected,O
rat,B-OG
primary,O
monocyte,O
cultures,O
with,O
PAO1,B-OG
and,O
measured,O
cytokine,B-GP
release,O
in,O
the,O
presence,O
and,O
absence,O
of,O
oligosaccharides,O
.,O
Monocytes,O
display,O
an,O
enhanced,O
release,O
of,O
cytokines,B-GP
in,O
response,O
to,O
infection,B-DS
",",O
which,O
was,O
shown,O
to,O
be,O
chiefly,O
dependent,O
on,O
NF,B-GP
-,I-GP
κB,I-GP
activation,O
and,O
p65,B-GP
nuclear,O
translocation,O
.,O
These,O
are,O
early,O
changes,O
associated,O
with,O
modest,O
cytotoxicity,O
due,O
to,O
the,O
short,O
incubation,O
time,O
.,O
Remarkably,O
",",O
treatment,O
with,O
FOS,O
attenuated,O
significantly,O
all,O
the,O
steps,O
of,O
this,O
response,O
",",O
i,O
.,O
e,O
.,O
secretion,O
of,O
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
10,I-GP
and,O
TNF,B-GP
-,I-GP
α,I-GP
",",O
IκB,B-GP
-,I-GP
α,I-GP
phosphorylation,O
and,O
p65,B-GP
nuclear,O
translocation,O
(,O
Figs,O
.,O
4,O
and,O
5,O
).,O
Inulin,O
in,O
contrast,O
had,O
a,O
significantly,O
more,O
moderate,O
effect,O
.,O
In,O
the,O
absence,O
of,O
bacteria,B-OG
neither,O
FOS,O
nor,O
inulin,O
caused,O
an,O
effect,O
on,O
cytokine,B-GP
secretion,O
and,O
their,O
long,O
-,O
term,O
effect,O
on,O
macrophages,O
(,O
and,O
intestinal,O
epithelial,O
cells,O
),O
is,O
an,O
activation,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
pathway,O
[,O
65,O
],O
and,O
thus,O
contrary,O
to,O
the,O
oligosaccharide,O
reduction,O
of,O
pathway,O
activity,O
.,O
Thus,O
it,O
follows,O
that,O
the,O
inhibited,O
NF,B-GP
-,I-GP
κB,I-GP
response,O
in,O
this,O
case,O
is,O
likely,O
to,O
be,O
of,O
indirect,O
nature,O
",",O
i,O
.,O
e,O
.,O
borne,O
out,O
of,O
a,O
reduced,O
stimulation,O
by,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infection,I-DS
",",O
confirming,O
our,O
hypothesis,O
.,O
This,O
may,O
also,O
explain,O
why,O
inulin,O
failed,O
to,O
inhibit,O
IκB,B-GP
-,I-GP
α,I-GP
phosphorylation,O
",",O
since,O
it,O
is,O
also,O
capable,O
of,O
activating,O
this,O
signalling,O
pathway,O
;,O
however,O
",",O
it,O
is,O
unclear,O
why,O
inulin,O
decreases,O
IL,B-GP
-,I-GP
6,I-GP
and,O
IL,B-GP
-,I-GP
10,I-GP
secretion,O
.,O
Our,O
data,O
suggest,O
that,O
MAPK,B-GP
is,O
not,O
involved,O
in,O
this,O
process,O
.,O
We,O
then,O
investigated,O
potential,O
links,O
between,O
FOS,O
and,O
other,O
determinants,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
virulence,O
",",O
such,O
as,O
the,O
PtxS,B-GP
and,O
PtxR,B-GP
regulators,O
that,O
modulate,O
exotoxin,B-GP
A,I-GP
expression,O
(,O
Fig,O
.,O
6B,O
).,O
Mutation,O
of,O
the,O
corresponding,O
genes,O
showed,O
the,O
expected,O
alterations,O
in,O
cytokine,B-GP
release,O
and,O
cytotoxicity,O
in,O
infected,O
monocytes,O
",",O
respectively,O
",",O
confirming,O
previous,O
observations,O
[,O
51,O
].,O
These,O
changes,O
correlated,O
with,O
toxA,B-GP
expression,O
",",O
since,O
the,O
highest,O
cytokine,B-GP
secretion,O
/,O
toxA,B-GP
transcription,O
was,O
observed,O
in,O
the,O
ptxS,B-GP
mutant,O
",",O
followed,O
by,O
the,O
WT,O
strain,O
and,O
the,O
ptxR,B-GP
mutant,O
[,O
51,O
].,O
It,O
is,O
therefore,O
likely,O
that,O
exotoxin,B-GP
A,I-GP
plays,O
a,O
role,O
in,O
stimulating,O
cytokine,B-GP
secretion,O
in,O
the,O
host,O
cell,O
.,O
The,O
main,O
finding,O
of,O
this,O
series,O
of,O
experiments,O
is,O
that,O
FOS,O
exerts,O
its,O
modulatory,O
effects,O
also,O
on,O
the,O
more,O
virulent,O
ptxS,B-GP
mutant,O
.,O
Of,O
note,O
",",O
the,O
effect,O
of,O
inulin,O
was,O
somewhat,O
increased,O
compared,O
to,O
that,O
on,O
the,O
wild,O
type,O
",",O
although,O
always,O
lower,O
than,O
that,O
of,O
FOS,O
.,O
Our,O
results,O
therefore,O
suggest,O
that,O
FOS,O
effectively,O
reduces,O
the,O
virulence,O
of,O
3,O
different,O
strains,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
.,O
Modulation,O
of,O
exotoxin,B-GP
A,I-GP
expression,O
or,O
transport,O
can,O
probably,O
be,O
associated,O
with,O
this,O
effect,O
.,O
P,B-OG
.,I-OG
aeruginosa,I-OG
is,O
an,O
opportunistic,O
pathogen,O
and,O
can,O
infect,O
immunocompromised,O
individuals,O
at,O
different,O
sites,O
such,O
as,O
the,O
respiratory,O
tract,O
",",O
intestine,O
",",O
skin,O
",",O
urinary,O
tract,O
",",O
and,O
wounds,O
.,O
The,O
severity,O
of,O
the,O
opportunistic,B-DS
infection,I-DS
depends,O
to,O
a,O
great,O
extent,O
on,O
the,O
virulence,O
factors,O
expressed,O
by,O
the,O
bacterium,B-OG
",",O
which,O
in,O
turn,O
influence,O
cytotoxicity,O
and,O
antibiotic,O
resistance,O
.,O
As,O
a,O
result,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infections,I-DS
are,O
notoriously,O
difficult,O
to,O
treat,O
.,O
Several,O
classes,O
of,O
antibiotics,O
including,O
cephalosporins,O
",",O
penicillins,O
",",O
carbapenems,O
",",O
quinolones,O
and,O
aminoglycosides,O
are,O
currently,O
been,O
used,O
to,O
combat,O
P,B-OG
.,I-OG
aeruginosa,I-OG
clinically,O
",",O
but,O
specific,O
sensitivity,O
testing,O
is,O
mandatory,O
[,O
66,O
].,O
Our,O
data,O
suggest,O
that,O
FOS,O
may,O
be,O
a,O
useful,O
component,O
of,O
a,O
drug,O
cocktail,O
to,O
combat,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infection,I-DS
.,O
Alternatively,O
",",O
it,O
appears,O
also,O
plausible,O
to,O
use,O
FOS,O
in,O
a,O
prophylactic,O
context,O
to,O
prevent,O
gastrointestinal,B-DS
infections,I-DS
.,O
Oral,O
FOS,O
supplements,O
are,O
currently,O
been,O
used,O
to,O
prevent,O
gastrointestinal,B-DS
infections,I-DS
[,O
67,O
"],",O
which,O
implies,O
that,O
the,O
oral,O
route,O
may,O
be,O
also,O
valid,O
to,O
administer,O
FOS,O
to,O
fight,O
Pseudomonas,B-OG
infection,B-DS
.,O
However,O
",",O
any,O
clinical,O
application,O
will,O
require,O
an,O
extensive,O
study,O
of,O
the,O
potential,O
effects,O
of,O
FOS,O
on,O
the,O
human,B-OG
body,O
which,O
are,O
issues,O
that,O
are,O
to,O
be,O
addressed,O
in,O
the,O
future,O
.,O
Materials,O
and,O
Methods,O
Animals,B-OG
Wistar,B-OG
rats,I-OG
(,O
200,O
–,O
250,O
g,O
),O
obtained,O
from,O
the,O
Animal,O
Service,O
Laboratory,O
of,O
the,O
University,O
of,O
Granada,O
(,O
Spain,O
),O
were,O
used,O
",",O
housed,O
in,O
macrolon,O
cages,O
",",O
and,O
maintained,O
in,O
air,O
-,O
conditioned,O
animal,O
quarters,O
with,O
a,O
12,O
-,O
h,O
light,O
-,O
dark,O
cycle,O
.,O
Rats,B-OG
were,O
given,O
free,O
access,O
to,O
tap,O
water,O
and,O
food,O
.,O
This,O
study,O
was,O
carried,O
out,O
in,O
accordance,O
with,O
the,O
Directive,O
for,O
the,O
Protection,O
of,O
Vertebrate,O
Animals,B-OG
used,O
for,O
Experimental,O
and,O
other,O
Scientific,O
Purposes,O
of,O
the,O
European,O
Union,O
(,O
86,O
/,O
609,O
/,O
EEC,O
),O
and,O
the,O
animal,O
protocol,O
used,O
has,O
been,O
approved,O
by,O
the,O
ethics,O
committee,O
of,O
the,O
Granada,O
University,O
.,O
Bacterial,O
strains,O
used,O
in,O
this,O
study,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
and,O
its,O
mutants,O
deficient,O
in,O
ptxS,B-GP
and,O
ptxR,B-GP
obtained,O
through,O
insertion,O
of,O
streptomycin,O
and,O
tetracycline,O
cassettes,O
",",O
respectively,O
[,O
51,O
"],",O
were,O
grown,O
in,O
LB,O
medium,O
or,O
M9,O
minimal,O
medium,O
(,O
Na2HPO4,O
:,O
6,O
g,O
/,O
l,O
;,O
KH2PO4,O
:,O
3,O
g,O
/,O
l,O
;,O
NaCl,O
:,O
0,O
.,O
5,O
g,O
/,O
l,O
;,O
NH4Cl,O
:,O
1,O
g,O
/,O
l,O
",",O
1,O
mM,O
MgSO4,O
",",O
0,O
.,O
3,O
mM,O
CaCl2,O
and,O
0,O
.,O
2,O
ml,O
/,O
l,O
of,O
1,O
%,O
ferric,O
ammonium,O
citrate,O
),O
[,O
68,O
].,O
When,O
required,O
",",O
antibiotics,O
were,O
added,O
to,O
the,O
culture,O
medium,O
to,O
reach,O
a,O
final,O
concentration,O
of,O
50,O
µg,O
/,O
ml,O
ampicillin,O
",",O
50,O
µg,O
/,O
ml,O
streptomycin,O
and,O
30,O
µg,O
/,O
ml,O
tetracycline,O
.,O
Chemicals,O
Inulin,O
and,O
FOS,O
were,O
provided,O
by,O
BENEO,O
-,O
Orafti,O
(,O
Tienen,O
",",O
Belgium,O
).,O
FOS,O
and,O
inulin,O
were,O
kindly,O
provided,O
by,O
BENEO,O
Orafti,O
®,O
(,O
Tienen,O
",",O
Belgium,O
).,O
Orafti,O
®,O
GR,O
(,O
inulin,O
),O
is,O
a,O
food,O
ingredient,O
consisting,O
mainly,O
of,O
chicory,B-OG
root,O
inulin,O
",",O
a,O
mixture,O
of,O
oligo,O
-,O
and,O
polysaccharides,O
which,O
are,O
composed,O
of,O
fructose,O
units,O
linked,O
together,O
by,O
β,O
(,O
2,O
-,O
1,O
),O
linkages,O
.,O
Almost,O
every,O
molecule,O
is,O
terminated,O
by,O
a,O
glucose,O
unit,O
.,O
The,O
total,O
number,O
of,O
fructose,O
or,O
glucose,O
units,O
(,O
=,O
Degree,O
of,O
Polymerization,O
or,O
DP,O
),O
of,O
chicory,B-OG
inulin,O
ranges,O
mainly,O
between,O
2,O
and,O
60,O
.,O
Orafti,O
®,O
P95,O
oligofructose,O
(,O
FOS,O
),O
is,O
produced,O
by,O
the,O
partial,O
enzymatic,O
hydrolysis,O
of,O
chicory,B-OG
-,O
derived,O
inulin,O
",",O
consisting,O
mainly,O
of,O
molecules,O
with,O
DP,O
between,O
2,O
and,O
8,O
.,O
Solutions,O
were,O
made,O
at,O
200,O
g,O
/,O
l,O
in,O
M9,O
minimal,O
medium,O
and,O
",",O
in,O
the,O
case,O
of,O
eukaryotic,O
cell,O
cultures,O
",",O
in,O
Dulbecco,O
',O
s,O
Modified,O
Eagle,O
Medium,O
(,O
DMEM,O
),O
containing,O
fetal,O
bovine,O
serum,O
(,O
10,O
"%),",O
2,O
mM,O
L,O
-,O
glutamine,O
",",O
and,O
2,O
.,O
5,O
mg,O
/,O
mL,O
amphotericin,O
B,O
",",O
all,O
provided,O
by,O
Sigma,O
.,O
Solutions,O
were,O
filtered,O
using,O
0,O
.,O
22,O
µm,O
cut,O
-,O
off,O
filters,O
and,O
aliquots,O
were,O
stored,O
at,O
−,O
20,O
°,O
C,O
.,O
The,O
goat,B-OG
milk,O
oligosaccharides,O
(,O
OS,O
),O
were,O
obtained,O
according,O
to,O
the,O
method,O
described,O
in,O
[,O
69,O
].,O
A,O
product,O
containing,O
>,O
80,O
%,O
of,O
the,O
original,O
oligosaccharide,O
content,O
",",O
only,O
5,O
%,O
(,O
w,O
/,O
w,O
),O
of,O
lactose,O
and,O
virtually,O
salt,O
free,O
",",O
was,O
obtained,O
and,O
used,O
to,O
carry,O
out,O
all,O
the,O
experiments,O
.,O
Effects,O
of,O
inulin,O
and,O
FOS,O
on,O
P,B-OG
.,I-OG
aeruginosa,I-OG
growth,O
Individual,O
colonies,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
were,O
picked,O
from,O
the,O
surface,O
of,O
freshly,O
grown,O
LB,O
plates,O
and,O
grown,O
overnight,O
in,O
M9,O
minimum,O
medium,O
(,O
supplemented,O
with,O
5,O
mM,O
of,O
citrate,O
),O
at,O
37,O
°,O
C,O
.,O
The,O
overnight,O
culture,O
was,O
diluted,O
with,O
fresh,O
M9,O
minimum,O
medium,O
to,O
an,O
OD660,O
nm,O
of,O
0,O
.,O
05,O
and,O
96,O
well,O
flat,O
-,O
bottomed,O
polystyrene,O
microtiter,O
plates,O
were,O
filled,O
with,O
180,O
µl,O
of,O
this,O
cellular,O
suspension,O
.,O
Then,O
",",O
20,O
µl,O
of,O
either,O
inulin,O
or,O
FOS,O
were,O
added,O
to,O
reach,O
final,O
concentrations,O
of,O
5,O
",",O
15,O
and,O
20,O
mg,O
/,O
ml,O
.,O
Plates,O
were,O
incubated,O
at,O
37,O
°,O
C,O
under,O
continuous,O
agitation,O
in,O
a,O
Bioscreen,O
C,O
MBR,O
analyser,O
FP,O
-,O
1100,O
-,O
C,O
(,O
OY,O
Growth,O
Curves,O
Ab,O
Ltd,O
".,",O
Raisio,O
",",O
Finland,O
).,O
The,O
turbidity,O
was,O
measured,O
using,O
a,O
wideband,O
filter,O
at,O
420,O
–,O
660,O
nm,O
every,O
60,O
minutes,O
over,O
a,O
24,O
h,O
period,O
.,O
The,O
measurements,O
at,O
580,O
nm,O
were,O
used,O
to,O
generate,O
growth,O
curves,O
.,O
Some,O
cultures,O
were,O
carried,O
out,O
with,O
the,O
same,O
medium,O
without,O
citrate,O
.,O
Semiquantitative,O
determination,O
of,O
biofilm,O
formation,O
Semiquantitative,O
determination,O
of,O
biofilm,O
formation,O
was,O
performed,O
as,O
described,O
[,O
70,O
].,O
Experiments,O
were,O
conducted,O
in,O
24,O
well,O
flat,O
-,O
bottomed,O
polystyrene,O
microtiter,O
plates,O
in,O
M9,O
minimal,O
medium,O
supplemented,O
with,O
0,O
.,O
2,O
%,O
(,O
w,O
/,O
v,O
),O
of,O
glucose,O
and,O
0,O
.,O
4,O
%,O
(,O
w,O
/,O
v,O
),O
casamino,O
acids,O
in,O
the,O
absence,O
and,O
in,O
the,O
presence,O
of,O
different,O
concentrations,O
(,O
up,O
to,O
20,O
mg,O
/,O
ml,O
),O
of,O
inulin,O
or,O
FOS,O
.,O
Biofilm,O
formation,O
was,O
quantified,O
after,O
6,O
h,O
by,O
staining,O
with,O
crystal,O
violet,O
following,O
the,O
method,O
described,O
in,O
[,O
71,O
].,O
The,O
structure,O
of,O
biofilms,O
was,O
observed,O
under,O
contrast,O
-,O
phase,O
microscopy,O
using,O
a,O
Zeiss,O
Axioscope,O
fluorescence,O
microscope,O
coupled,O
to,O
a,O
Nikon,O
DSS,O
-,O
Mc,O
CCD,O
camera,O
and,O
a,O
100,O
-,O
fold,O
magnifier,O
.,O
Data,O
reported,O
are,O
means,O
from,O
two,O
independent,O
experiments,O
each,O
conducted,O
in,O
quadruplet,O
repeats,O
.,O
Motility,O
assays,O
Assays,O
were,O
carried,O
out,O
to,O
determine,O
the,O
effect,O
of,O
inulin,O
and,O
FOS,O
(,O
each,O
at,O
a,O
concentration,O
of,O
5,O
mg,O
/,O
ml,O
),O
on,O
swimming,O
",",O
twitching,O
and,O
swarming,O
.,O
In,O
all,O
assays,O
these,O
compounds,O
were,O
added,O
at,O
identical,O
concentrations,O
to,O
the,O
bacterial,O
suspension,O
in,O
the,O
plates,O
.,O
For,O
swimming,O
assays,O
bacteria,B-OG
were,O
placed,O
with,O
the,O
help,O
of,O
a,O
sterile,O
tooth,O
-,O
pick,O
at,O
the,O
centre,O
of,O
plates,O
containing,O
a,O
5,O
mm,O
layer,O
of,O
LB,O
medium,O
with,O
0,O
.,O
3,O
%,O
(,O
w,O
/,O
v,O
),O
Bacto,O
agar,O
",",O
0,O
.,O
2,O
%,O
casamino,O
acids,O
(,O
w,O
/,O
v,O
),O
and,O
30,O
mM,O
glucose,O
.,O
Plates,O
were,O
incubated,O
at,O
37,O
°,O
C,O
for,O
24,O
h,O
and,O
the,O
radial,O
diffusion,O
of,O
bacteria,B-OG
",",O
due,O
to,O
swimming,O
",",O
was,O
measured,O
.,O
To,O
monitor,O
twitching,O
motility,O
bacteria,B-OG
were,O
placed,O
with,O
a,O
toothpick,O
into,O
a,O
2,O
mm,O
thick,O
layer,O
containing,O
1,O
.,O
5,O
%,O
(,O
w,O
/,O
v,O
),O
Bacto,O
agar,O
",",O
0,O
.,O
2,O
%,O
(,O
w,O
/,O
v,O
),O
casamino,O
acids,O
and,O
30,O
mM,O
glucose,O
.,O
After,O
incubation,O
for,O
24,O
h,O
at,O
37,O
°,O
C,O
",",O
the,O
expansion,O
of,O
bacteria,B-OG
on,O
the,O
plate,O
was,O
observed,O
.,O
For,O
swarming,O
assays,O
5,O
µl,O
of,O
an,O
overnight,O
culture,O
of,O
bacteria,B-OG
were,O
placed,O
into,O
the,O
centre,O
of,O
swarm,O
plates,O
",",O
which,O
are,O
made,O
of,O
0,O
.,O
5,O
%,O
(,O
w,O
/,O
v,O
),O
Bacto,O
agar,O
supplement,O
with,O
0,O
.,O
2,O
%,O
(,O
w,O
/,O
v,O
),O
casamino,O
acids,O
and,O
30,O
mM,O
glucose,O
.,O
Plates,O
were,O
incubated,O
at,O
37,O
°,O
C,O
for,O
24,O
h,O
",",O
followed,O
by,O
an,O
inspection,O
of,O
the,O
bacterial,O
surface,O
movement,O
[,O
72,O
].,O
All,O
the,O
motility,O
assays,O
were,O
performed,O
in,O
triplicates,O
.,O
Macrophage,O
cell,O
isolation,O
by,O
magnetic,O
activated,O
cell,O
sorting,O
Female,O
Wistar,B-OG
rats,I-OG
were,O
sacrificed,O
by,O
cervical,O
dislocation,O
and,O
the,O
spleen,O
was,O
extracted,O
aseptically,O
.,O
Cell,O
suspensions,O
were,O
obtained,O
by,O
disrupting,O
the,O
tissues,O
between,O
dissecting,O
forceps,O
in,O
medium,O
.,O
After,O
centrifugation,O
(,O
1500,O
×,O
rpm,O
/,O
5,O
min,O
"),",O
cells,O
were,O
cleared,O
of,O
erythrocytes,O
by,O
resuspension,O
in,O
hypotonic,O
lysis,O
buffer,O
(,O
15,O
mM,O
NH4Cl,O
",",O
10,O
mM,O
KHCO3,O
",",O
0,O
.,O
1,O
mM,O
Na2EDTA,O
",",O
pH,O
7,O
.,O
3,O
),O
for,O
30,O
min,O
on,O
ice,O
.,O
Mononuclear,O
cells,O
were,O
washed,O
and,O
resuspended,O
in,O
MACs,O
buffer,O
(,O
PBS,O
containing,O
0,O
.,O
5,O
%,O
(,O
w,O
/,O
v,O
),O
BSA,O
",",O
2,O
mM,O
EDTA,O
",",O
pH,O
7,O
.,O
2,O
).,O
To,O
obtain,O
a,O
monocellular,O
suspension,O
",",O
cells,O
were,O
passed,O
through,O
70,O
µm,O
nylon,O
mesh,O
prior,O
to,O
magnetic,O
labelling,O
and,O
subsequently,O
isolated,O
by,O
negative,O
selection,O
.,O
To,O
remove,O
lymphocytes,O
",",O
CD161,B-GP
.,O
1,O
-,O
biotin,O
(,O
1,O
∶,O
200,O
"),",O
CD45RA,B-GP
-,O
PE,B-GP
(,O
1,O
∶,O
200,O
),O
and,O
CD3,B-GP
(,O
1,O
∶,O
150,O
),O
(,O
Biosciences,O
"),",O
were,O
added,O
and,O
incubated,O
at,O
4,O
°,O
C,O
for,O
30,O
min,O
.,O
Cells,O
were,O
washed,O
and,O
sedimented,O
by,O
centrifugation,O
at,O
1500,O
×,O
rpm,O
for,O
5,O
min,O
.,O
After,O
resuspension,O
in,O
MACs,O
buffer,O
",",O
25,O
µl,O
of,O
each,O
antibiotin,O
Microbeads,O
and,O
anti,O
-,O
PE,B-GP
-,O
microbeads,O
(,O
Miltenyi,O
Biotec,O
"),",O
were,O
added,O
and,O
the,O
resulting,O
suspension,O
incubated,O
at,O
4,O
°,O
C,O
during,O
30,O
min,O
.,O
Cells,O
were,O
washed,O
",",O
centrifuged,O
and,O
dissolved,O
in,O
DMEM,O
medium,O
(,O
Dulbecco,O
',O
s,O
Modified,O
Eagle,O
Medium,O
).,O
CD161,B-GP
.,O
1,O
"+,",O
CD45RA,B-GP
+,O
and,O
CD3,B-GP
+,O
cells,O
were,O
discarded,O
using,O
an,O
LD,O
column,O
(,O
Miltenyi,O
Biotec,O
).,O
Macrophages,O
in,O
the,O
flow,O
-,O
through,O
were,O
centrifuged,O
at,O
1500,O
×,O
rpm,O
for,O
5,O
min,O
and,O
resuspended,O
in,O
Dulbecco,O
',O
s,O
Modified,O
Eagle,O
Medium,O
(,O
DMEM,O
Sigma,O
®),O
supplemented,O
with,O
10,O
%,O
FBS,O
(,O
sigma,O
"),",O
2,O
.,O
5,O
mg,O
/,O
L,O
amphotericin,O
B,O
and,O
2,O
mM,O
L,O
-,O
glutamine,O
.,O
Measurement,O
of,O
inulin,O
-,O
and,O
FOS,O
-,O
induced,O
changes,O
in,O
cytokine,B-GP
secretion,O
from,O
macrophages,O
following,O
infection,B-DS
by,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
For,O
the,O
determination,O
of,O
cytokine,B-GP
levels,O
the,O
macrophage,O
suspensions,O
(,O
106,O
cells,O
/,O
ml,O
DMEM,O
medium,O
),O
were,O
co,O
-,O
cultured,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
and,O
incubated,O
with,O
5,O
mg,O
/,O
ml,O
FOS,O
or,O
inulin,O
for,O
4,O
hours,O
.,O
Following,O
centrifugation,O
at,O
4,O
°,O
C,O
and,O
10,O
.,O
000,O
×,O
rpm,O
for,O
5,O
min,O
",",O
the,O
resulting,O
supernatants,O
were,O
frozen,O
at,O
−,O
80,O
°,O
C,O
.,O
Aliquots,O
were,O
thawed,O
and,O
cytokine,B-GP
levels,O
determined,O
using,O
ELISA,O
-,O
based,O
kits,O
(,O
BD,O
Biosciences,O
",",O
Erembodegem,O
",",O
Belgium,O
),O
following,O
the,O
protocol,O
provided,O
by,O
the,O
manufacturer,O
.,O
In,O
addition,O
",",O
macrophage,O
cells,O
were,O
used,O
for,O
the,O
quantification,O
of,O
phosphorylated,O
IκB,B-GP
-,I-GP
α,I-GP
and,O
MAP,B-GP
kinases,I-GP
by,O
Western,O
blot,O
determination,O
as,O
described,O
below,O
.,O
Western,O
blot,O
For,O
the,O
detection,O
of,O
ERK,B-GP
",",O
p,O
-,O
ERK,B-GP
",",O
p,O
-,O
P38,B-GP
",",O
p,O
-,O
JNK,B-GP
and,O
phosphorylated,O
IκB,O
-,O
P,O
",",O
cells,O
were,O
homogenized,O
in,O
lysis,O
buffer,O
(,O
PBS,O
containing,O
0,O
.,O
1,O
%,O
(,O
w,O
/,O
v,O
),O
SDS,O
",",O
0,O
.,O
1,O
%,O
(,O
w,O
/,O
v,O
),O
sodium,O
deoxycholate,O
",",O
1,O
%,O
(,O
v,O
/,O
v,O
),O
Triton,O
X,O
-,O
100,O
),O
with,O
protease,B-GP
inhibitor,O
cocktail,O
(,O
Sigma,O
),O
1,O
∶,O
100,O
(,O
v,O
/,O
v,O
).,O
Subsequently,O
",",O
homogenates,O
were,O
sonicated,O
and,O
centrifuged,O
7000,O
×,O
g,O
for,O
5,O
min,O
at,O
4,O
°,O
C,O
.,O
Protein,O
concentrations,O
were,O
determined,O
using,O
the,O
Bicinchoninic,O
acid,O
assay,O
[,O
73,O
].,O
Samples,O
were,O
boiled,O
in,O
5,O
×,O
Laemmli,O
buffer,O
(,O
220,O
mM,O
Tris,O
",",O
312,O
µM,O
SDS,O
",",O
50,O
%,O
(,O
v,O
/,O
v,O
),O
glycerol,O
",",O
1,O
%,O
(,O
v,O
/,O
v,O
),O
2,O
-,O
mercaptoethanol,O
",",O
22,O
.,O
5,O
mM,O
EDTA,O
",",O
pH,O
6,O
.,O
8,O
",",O
containing,O
traces,O
of,O
bromphenol,O
blue,O
),O
for,O
5,O
min,O
",",O
separated,O
by,O
SDS,O
-,O
PAGE,O
",",O
electroblotted,O
to,O
PVDF,O
membranes,O
(,O
Millipore,O
",",O
Madrid,O
",",O
Spain,O
"),",O
and,O
exposed,O
to,O
the,O
primary,O
antibodies,O
against,O
ERK,B-GP
",",O
p,O
-,O
ERK,B-GP
(,O
both,O
from,O
Sigma,O
"),",O
p,O
-,O
P38,B-GP
",",O
p,O
-,O
JNK,B-GP
and,O
phosphorylated,O
IkB,B-GP
-,O
P,O
",",O
respectively,O
(,O
all,O
three,O
from,O
Cell,O
signalling,O
",",O
Danvers,O
",",O
MA,O
).,O
Prior,O
to,O
exposure,O
to,O
the,O
secondary,O
IgG,B-GP
Peroxidase,B-GP
antibody,O
(,O
anti,O
-,O
mouse,B-OG
IgG,B-GP
for,O
ERK,B-GP
and,O
p,O
-,O
ERK,B-GP
",",O
anti,O
-,O
rabit,O
IgG,B-GP
for,O
p,O
-,O
P38,B-GP
",",O
p,O
-,O
JNK,B-GP
and,O
p,O
-,O
IkB,B-GP
",",O
(,O
Sigma,O
),O
the,O
bands,O
were,O
visualized,O
by,O
enhanced,O
chemiluminescence,O
(,O
PerkinElmer,O
",",O
Waltham,O
",",O
MA,O
),O
and,O
quantified,O
with,O
the,O
NIH,O
software,O
(,O
Scion,O
Image,O
).,O
Determination,O
of,O
the,O
NF,B-GP
-,I-GP
κB,I-GP
p65,B-GP
subunit,O
in,O
macrophages,O
nuclear,O
extracts,O
Macrophages,O
were,O
co,O
-,O
cultured,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
with,O
a,O
1,O
∶,O
5,O
ratio,O
and,O
incubated,O
with,O
FOS,O
(,O
5,O
mg,O
/,O
ml,O
),O
or,O
inulin,O
(,O
5,O
mg,O
/,O
ml,O
).,O
After,O
1,O
h,O
",",O
nuclear,O
extracts,O
were,O
obtained,O
using,O
a,O
nuclear,O
extract,O
kit,O
(,O
Active,O
Motif,O
",",O
Belgium,O
),O
and,O
NF,B-GP
-,I-GP
κB,I-GP
activation,O
was,O
determined,O
by,O
quantifying,O
the,O
p65,B-GP
component,O
using,O
a,O
TransAM,O
kit,O
following,O
the,O
protocols,O
recommended,O
by,O
the,O
manufacturers,O
(,O
Active,O
Motif,O
",",O
Belgium,O
).,O
Cytotoxicity,O
Assays,O
Measurement,O
of,O
P,B-OG
.,I-OG
aeruginosa,I-OG
induced,O
cytotoxicity,O
in,O
macrophages,O
:,O
Macrophages,O
were,O
incubated,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
with,O
a,O
ratio,O
of,O
1,O
∶,O
5,O
for,O
4,O
hours,O
and,O
the,O
percentage,O
of,O
cytotoxicity,O
was,O
determinate,O
using,O
cytotox,O
96,O
non,O
-,O
radioactive,O
cytotoxicity,O
assay,O
kit,O
following,O
the,O
protocols,O
recommended,O
by,O
the,O
manufacturers,O
(,O
Promega,O
),O
which,O
evaluates,O
cytotoxicity,O
by,O
assessing,O
the,O
total,O
release,O
of,O
cytoplasmic,O
lactate,B-GP
dehydrogenase,I-GP
(,O
LDH,B-GP
"),",O
by,O
the,O
calorimetric,O
detection,O
",",O
into,O
culture,O
medium,O
as,O
a,O
consequence,O
of,O
damaged,O
cell,O
membranes,O
[,O
74,O
].,O
Determination,O
of,O
exotoxin,B-GP
A,I-GP
concentration,O
in,O
rat,B-OG
IEC18,O
cells,O
infected,O
by,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,I-OG
IEC18,O
cells,O
were,O
cultured,O
in,O
6,O
well,O
plates,O
.,O
At,O
confluence,O
IEC18,O
cells,O
were,O
infected,O
with,O
P,B-OG
.,I-OG
aeruginosa,I-OG
at,O
a,O
ratio,O
of,O
5,O
bacterial,O
cells,O
per,O
eukaryotic,O
cell,O
in,O
the,O
absence,O
and,O
in,O
the,O
presence,O
of,O
5,O
mg,O
/,O
ml,O
FOS,O
or,O
inulin,O
.,O
Plates,O
containing,O
cells,O
were,O
washed,O
3,O
times,O
with,O
PBS,O
and,O
incubated,O
with,O
gentamicin,O
at,O
100,O
µg,O
/,O
ml,O
for,O
1,O
h,O
to,O
eliminate,O
bacteria,B-OG
.,O
Subsequently,O
",",O
plates,O
were,O
washed,O
3,O
times,O
with,O
PBS,O
prior,O
to,O
cell,O
collection,O
using,O
RIPA,O
buffer,O
[,O
25,O
mM,O
Tris,O
–,O
HCl,O
",",O
pH,O
7,O
.,O
2,O
",",O
150,O
mM,O
NaCl,O
",",O
0,O
.,O
1,O
%,O
sodium,O
deoxycholate,O
and,O
0,O
.,O
1,O
%,O
sodium,O
dodecyl,O
sulfate,O
(,O
SDS,O
)],O
containing,O
a,O
protease,B-GP
inhibitor,O
cocktail,O
(,O
Sigma,O
).,O
Proteins,O
were,O
extracted,O
for,O
Western,O
blot,O
analysis,O
",",O
as,O
described,O
above,O
.,O
Western,O
blot,O
were,O
carried,O
out,O
as,O
outlined,O
above,O
using,O
the,O
Exotoxin,B-GP
A,I-GP
antibody,O
(,O
Sigma,O
),O
at,O
a,O
1,O
∶,O
2,O
.,O
000,O
dilution,O
.,O
Following,O
overnight,O
incubation,O
with,O
the,O
primary,O
antibody,O
the,O
membrane,O
was,O
incubated,O
with,O
the,O
secondary,O
IgG,B-GP
Peroxidase,B-GP
anti,O
-,O
rabbit,B-OG
antibody,O
(,O
Sigma,O
),O
at,O
a,O
1,O
∶,O
3,O
.,O
000,O
dilution,O
for,O
two,O
hours,O
.,O
The,O
bands,O
were,O
detected,O
by,O
enhanced,O
chemiluminescence,O
(,O
PerkinElmer,O
",",O
Waltham,O
",",O
MA,O
),O
and,O
quantified,O
with,O
NIH,O
software,O
(,O
Scion,O
Image,O
).,O
Statistical,O
analysis,O
All,O
results,O
are,O
expressed,O
as,O
means,O
with,O
the,O
corresponding,O
standard,O
deviations,O
.,O
Differences,O
among,O
means,O
were,O
analysed,O
for,O
statistical,O
significance,O
by,O
a,O
one,O
-,O
way,O
ANOVA,O
analysis,O
and,O
a,O
posteriori,O
least,O
significance,O
test,O
.,O
All,O
analyses,O
were,O
carried,O
out,O
using,O
the,O
SigmaStat,O
2,O
.,O
03,O
program,O
(,O
Jandel,O
Corporation,O
",",O
San,O
Rafael,O
",",O
CA,O
).,O
Concentration,O
-,O
response,O
curves,O
were,O
fitted,O
to,O
a,O
logarithmic,O
curve,O
when,O
possible,O
with,O
Origin,O
7,O
.,O
0,O
(,O
OriginLab,O
Corporation,O
",",O
Northampton,O
",",O
MA,O
).,O
Differences,O
were,O
considered,O
significant,O
at,O
P,O
<,O
0,O
.,O
05,O
.,O
Supporting,O
Information,O
The,O
OD,O
at,O
560,O
nm,O
of,O
crystal,O
violet,O
(,O
CV,O
),O
stained,O
and,O
resuspended,O
bacteria,B-OG
from,O
biofilm,O
are,O
given,O
.,O
Shown,O
are,O
means,O
and,O
standard,O
deviations,O
with,O
n,O
=,O
3,O
–,O
6,O
;,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
WT,O
in,O
the,O
absence,O
of,O
inulin,O
or,O
FOS,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
The,O
densitometric,O
analysis,O
of,O
experiments,O
is,O
shown,O
in,O
Fig,O
.,O
2A,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Measurement,O
of,O
interleukin,O
-,O
6,O
secretion,O
of,O
macrophages,O
in,O
the,O
presence,O
of,O
WT,O
P,B-OG
.,I-OG
aeruginosa,I-OG
PAO1,B-OG
and,O
its,O
ptxS,B-GP
and,O
ptxR,B-GP
mutants,O
.,O
The,O
macrophage,O
/,O
bacteria,B-OG
ratio,O
was,O
of,O
1,O
∶,O
5,O
.,O
Experimental,O
conditions,O
involving,O
incubation,O
for,O
4,O
hours,O
were,O
subsequently,O
used,O
to,O
assess,O
the,O
effect,O
of,O
FOS,O
and,O
inulin,O
on,O
interleukin,O
secretion,O
as,O
reported,O
in,O
Fig,O
.,O
4,O
and,O
7,O
.,O
Values,O
are,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
".,",O
n,O
=,O
3,O
;,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
macrophage,O
without,O
bacteria,B-OG
and,O
&,O
P,O
<,O
0,O
.,O
05,O
vs,O
macrophage,O
with,O
WT,O
(,O
ANOVA,O
followed,O
by,O
least,O
significance,O
tests,O
).,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
The,O
Csr,B-GP
System,O
Regulates,O
Escherichia,B-OG
coli,I-OG
Fitness,O
by,O
Controlling,O
Glycogen,O
Accumulation,O
and,O
Energy,O
Levels,O
B,O
.,O
E,O
.,O
and,O
M,O
.,O
C,O
.-,O
B,O
.,O
contributed,O
equally,O
to,O
this,O
work,O
.,O
ABSTRACT,O
In,O
the,O
bacterium,B-OG
Escherichia,B-OG
coli,I-OG
",",O
the,O
posttranscriptional,O
regulatory,O
system,O
Csr,B-GP
was,O
postulated,O
to,O
influence,O
the,O
transition,O
from,O
glycolysis,O
to,O
gluconeogenesis,O
.,O
Here,O
",",O
we,O
explored,O
the,O
role,O
of,O
the,O
Csr,B-GP
system,O
in,O
the,O
glucose,O
-,O
acetate,O
transition,O
as,O
a,O
model,O
of,O
the,O
glycolysis,O
-,O
to,O
-,O
gluconeogenesis,O
switch,O
.,O
Mutations,O
in,O
the,O
Csr,B-GP
system,O
influence,O
the,O
reorganization,O
of,O
gene,O
expression,O
after,O
glucose,O
exhaustion,O
and,O
disturb,O
the,O
timing,O
of,O
acetate,O
reconsumption,O
after,O
glucose,O
exhaustion,O
.,O
Analysis,O
of,O
metabolite,O
concentrations,O
during,O
the,O
transition,O
revealed,O
that,O
the,O
Csr,B-GP
system,O
has,O
a,O
major,O
effect,O
on,O
the,O
energy,O
levels,O
of,O
the,O
cells,O
after,O
glucose,O
exhaustion,O
.,O
This,O
influence,O
was,O
demonstrated,O
to,O
result,O
directly,O
from,O
the,O
effect,O
of,O
the,O
Csr,B-GP
system,O
on,O
glycogen,O
accumulation,O
.,O
Mutation,O
in,O
glycogen,O
metabolism,O
was,O
also,O
demonstrated,O
to,O
hinder,O
metabolic,O
adaptation,O
after,O
glucose,O
exhaustion,O
because,O
of,O
insufficient,O
energy,O
.,O
This,O
work,O
explains,O
how,O
the,O
Csr,B-GP
system,O
influences,O
E,B-OG
.,I-OG
coli,I-OG
fitness,O
during,O
the,O
glycolysis,O
-,O
gluconeogenesis,O
switch,O
and,O
demonstrates,O
the,O
role,O
of,O
glycogen,O
in,O
maintenance,O
of,O
the,O
energy,O
charge,O
during,O
metabolic,O
adaptation,O
.,O
IMPORTANCE,O
Glycogen,O
is,O
a,O
polysaccharide,O
and,O
the,O
main,O
storage,O
form,O
of,O
glucose,O
from,O
bacteria,B-OG
such,O
as,O
Escherichia,B-OG
coli,I-OG
to,O
yeasts,B-OG
and,O
mammals,B-OG
.,O
Although,O
its,O
function,O
as,O
a,O
sugar,O
reserve,O
in,O
mammals,B-OG
is,O
well,O
documented,O
",",O
the,O
role,O
of,O
glycogen,O
in,O
bacteria,B-OG
is,O
not,O
as,O
clear,O
.,O
By,O
studying,O
the,O
role,O
of,O
posttranscriptional,O
regulation,O
during,O
metabolic,O
adaptation,O
",",O
for,O
the,O
first,O
time,O
",",O
we,O
demonstrate,O
the,O
role,O
of,O
sugar,O
reserve,O
played,O
by,O
glycogen,O
in,O
E,B-OG
.,I-OG
coli,I-OG
.,O
Indeed,O
",",O
glycogen,O
not,O
only,O
makes,O
it,O
possible,O
to,O
maintain,O
sufficient,O
energy,O
during,O
metabolic,O
transitions,O
but,O
is,O
also,O
the,O
key,O
component,O
in,O
the,O
capacity,O
of,O
cells,O
to,O
resume,O
growth,O
.,O
Since,O
the,O
essential,O
posttranscriptional,O
regulatory,O
system,O
Csr,B-GP
is,O
a,O
major,O
regulator,O
of,O
glycogen,O
accumulation,O
",",O
this,O
work,O
also,O
sheds,O
light,O
on,O
the,O
central,O
role,O
of,O
posttranscriptional,O
regulation,O
in,O
metabolic,O
adaptation,O
.,O
INTRODUCTION,O
Metabolic,O
adaptation,O
describes,O
the,O
capacity,O
to,O
switch,O
from,O
one,O
substrate,O
to,O
another,O
.,O
This,O
mechanism,O
is,O
essential,O
for,O
the,O
fitness,O
and,O
survival,O
of,O
microorganisms,O
(,O
1,O
",",O
2,O
).,O
In,O
the,O
model,O
bacterium,B-OG
Escherichia,B-OG
coli,I-OG
",",O
metabolic,O
adaptation,O
influences,O
the,O
productivity,O
of,O
bioprocesses,O
and,O
also,O
its,O
persistence,O
in,O
the,O
gut,O
",",O
with,O
major,O
consequences,O
for,O
human,B-OG
health,O
.,O
The,O
persistence,O
of,O
commensal,O
E,B-OG
.,I-OG
coli,I-OG
strains,O
has,O
already,O
been,O
shown,O
to,O
provide,O
a,O
barrier,O
to,O
infection,B-DS
in,O
the,O
intestine,O
(,O
3,O
",",O
4,O
).,O
E,B-OG
.,I-OG
coli,I-OG
first,O
consumes,O
sugars,O
and,O
sugar,O
derivatives,O
through,O
glycolytic,O
pathways,O
.,O
In,O
the,O
absence,O
of,O
such,O
substrates,O
",",O
it,O
uses,O
less,O
favorable,O
molecules,O
such,O
as,O
acetate,O
",",O
succinate,O
",",O
or,O
formate,O
by,O
activating,O
the,O
gluconeogenic,O
pathway,O
(,O
1,O
",",O
5,O
).,O
The,O
mechanisms,O
involved,O
in,O
pathogen,O
exclusion,O
in,O
natural,O
ecosystems,O
are,O
complex,O
but,O
notably,O
involve,O
competitive,O
metabolic,O
interactions,O
with,O
available,O
nutriments,O
(,O
4,O
",",O
6,O
",",O
7,O
).,O
Since,O
the,O
availability,O
of,O
carbon,O
substrates,O
in,O
the,O
gut,O
is,O
constantly,O
changing,O
",",O
metabolic,O
adaptation,O
and,O
the,O
capacity,O
to,O
switch,O
from,O
glycolysis,O
to,O
gluconeogenesis,O
are,O
essential,O
for,O
colonization,O
and,O
persistence,O
of,O
E,B-OG
.,I-OG
coli,I-OG
and,O
hence,O
for,O
health,O
(,O
8,O
).,O
Although,O
the,O
metabolic,O
organization,O
of,O
E,B-OG
.,I-OG
coli,I-OG
is,O
well,O
described,O
",",O
metabolic,O
adaptation,O
is,O
still,O
not,O
fully,O
understood,O
(,O
9,O
–,O
11,O
).,O
In,O
central,O
carbon,O
metabolism,O
(,O
CCM,O
"),",O
the,O
accumulation,O
of,O
several,O
layers,O
of,O
regulatory,O
mechanisms,O
(,O
transcriptional,O
",",O
posttranscriptional,O
",",O
translational,O
",",O
and,O
posttranslational,O
regulatory,O
mechanisms,O
),O
results,O
in,O
a,O
complex,O
and,O
entangled,O
control,O
of,O
carbon,O
fluxes,O
.,O
At,O
the,O
posttranscriptional,O
level,O
(,O
i,O
.,O
e,O
".,",O
control,O
of,O
the,O
stability,O
and,O
translation,O
of,O
mRNA,O
"),",O
the,O
main,O
controller,O
of,O
CCM,O
reported,O
so,O
far,O
is,O
the,O
carbon,B-GP
storage,I-GP
regulator,I-GP
(,O
Csr,B-GP
),O
system,O
(,O
12,O
–,O
16,O
).,O
This,O
posttranscriptional,O
controller,O
is,O
highly,O
pleiotropic,O
(,O
17,O
",",O
18,O
),O
and,O
is,O
involved,O
in,O
the,O
regulation,O
of,O
most,O
adaptive,O
phenomena,O
",",O
including,O
virulence,O
(,O
19,O
"),",O
motility,O
(,O
20,O
",",O
21,O
"),",O
stringent,O
response,O
(,O
12,O
"),",O
and,O
glycogen,O
synthesis,O
(,O
14,O
",",O
22,O
).,O
Its,O
main,O
component,O
is,O
the,O
conditionally,O
essential,O
protein,O
CsrA,B-GP
",",O
which,O
is,O
able,O
to,O
bind,O
to,O
target,O
mRNAs,O
",",O
leading,O
to,O
either,O
their,O
degradation,O
or,O
their,O
stabilization,O
.,O
CsrA,B-GP
activity,O
is,O
controlled,O
through,O
sequestration,O
by,O
CsrB,B-GP
and,O
CsrC,B-GP
",",O
two,O
noncoding,O
RNAs,O
(,O
ncRNAs,O
),O
(,O
23,O
–,O
25,O
).,O
Both,O
of,O
these,O
ncRNAs,O
are,O
targeted,O
by,O
the,O
protein,O
CsrD,B-GP
",",O
which,O
triggers,O
their,O
RNase,B-GP
E,I-GP
-,O
dependent,O
degradation,O
(,O
26,O
"),",O
through,O
a,O
molecular,O
mechanism,O
based,O
on,O
CsrD,B-GP
and,O
CsrA,B-GP
antagonism,O
(,O
27,O
).,O
Transcription,O
of,O
CsrB,B-GP
and,O
CsrC,B-GP
is,O
activated,O
by,O
the,O
BarA,B-GP
/,O
UvrY,B-GP
two,O
-,O
component,O
system,O
(,O
23,O
",",O
25,O
",",O
28,O
),O
and,O
is,O
repressed,O
by,O
cAMP,O
-,O
CRP,B-GP
(,O
29,O
).,O
The,O
Csr,B-GP
system,O
is,O
said,O
to,O
positively,O
regulate,O
glycolysis,O
while,O
inhibiting,O
gluconeogenesis,O
(,O
14,O
–,O
16,O
",",O
30,O
).,O
It,O
is,O
hypothesized,O
to,O
be,O
involved,O
in,O
the,O
switch,O
between,O
the,O
two,O
metabolisms,O
since,O
the,O
BarA,B-GP
/,O
UvrY,B-GP
two,O
-,O
component,O
system,O
is,O
needed,O
for,O
the,O
efficient,O
transition,O
from,O
glycolytic,O
to,O
gluconeogenic,O
metabolism,O
(,O
2,O
).,O
The,O
recently,O
discovered,O
circuitry,O
linking,O
catabolite,O
repression,O
and,O
Csr,B-GP
regulatory,O
systems,O
(,O
29,O
),O
also,O
suggests,O
the,O
involvement,O
of,O
CsrA,B-GP
in,O
the,O
transition,O
",",O
since,O
the,O
switch,O
to,O
gluconeogenic,O
substrate,O
consumption,O
requires,O
the,O
alleviation,O
of,O
catabolite,O
repression,O
.,O
Here,O
",",O
we,O
investigated,O
the,O
putative,O
role,O
of,O
the,O
Csr,B-GP
system,O
in,O
the,O
metabolic,O
adaptation,O
from,O
glycolysis,O
to,O
gluconeogenesis,O
.,O
Gene,O
expression,O
and,O
metabolite,O
pool,O
analyses,O
were,O
performed,O
with,O
Csr,B-GP
system,O
mutant,O
strains,O
throughout,O
the,O
glucose,O
-,O
acetate,O
transition,O
",",O
which,O
was,O
considered,O
a,O
model,O
of,O
metabolic,O
adaptation,O
(,O
9,O
",",O
10,O
",",O
31,O
).,O
We,O
demonstrate,O
the,O
important,O
role,O
of,O
the,O
Csr,B-GP
system,O
during,O
this,O
metabolic,O
transition,O
through,O
its,O
control,O
of,O
glycogen,O
accumulation,O
and,O
cell,O
energy,O
homeostasis,O
.,O
(,O
Parts,O
of,O
this,O
work,O
were,O
conducted,O
as,O
M,O
.,O
M,O
.’,O
s,O
thesis,O
project,O
.),O
RESULTS,O
The,O
Csr,B-GP
system,O
influences,O
the,O
dynamics,O
of,O
acetate,O
reconsumption,O
after,O
glucose,O
exhaustion,O
.,O
The,O
glucose,O
-,O
acetate,O
transition,O
is,O
a,O
model,O
of,O
adaptation,O
from,O
glycolytic,O
to,O
gluconeogenic,O
metabolism,O
(,O
9,O
",",O
10,O
",",O
31,O
).,O
Briefly,O
",",O
this,O
transition,O
consists,O
of,O
E,B-OG
.,I-OG
coli,I-OG
cells,O
growing,O
exponentially,O
on,O
a,O
glucose,O
minimal,O
medium,O
and,O
excreting,O
acetate,O
into,O
the,O
medium,O
as,O
a,O
metabolic,O
overflow,O
product,O
.,O
When,O
the,O
cells,O
run,O
out,O
of,O
glucose,O
",",O
the,O
CCM,O
is,O
reorganized,O
",",O
thereby,O
enabling,O
the,O
cell,O
to,O
consume,O
the,O
acetate,O
.,O
The,O
behaviors,O
of,O
three,O
strains,O
with,O
modified,O
CsrA,B-GP
activities,O
(,O
csrA51,B-GP
",",O
ΔcsrBC,O
",",O
and,O
ΔcsrD,O
mutant,O
strains,O
),O
were,O
investigated,O
.,O
Deletions,O
of,O
CsrB,B-GP
and,O
",",O
to,O
a,O
lesser,O
extent,O
",",O
of,O
CsrC,B-GP
ncRNAs,O
are,O
known,O
to,O
increase,O
CsrA,B-GP
activity,O
by,O
preventing,O
its,O
sequestration,O
(,O
24,O
",",O
25,O
).,O
Deletion,O
of,O
csrD,B-GP
triggers,O
an,O
increase,O
in,O
CsrB,B-GP
and,O
CsrC,B-GP
ncRNA,O
concentrations,O
",",O
which,O
promotes,O
the,O
sequestration,O
of,O
CsrA,B-GP
and,O
reduces,O
its,O
activity,O
(,O
26,O
).,O
In,O
the,O
csrA51,B-GP
mutant,O
strain,O
",",O
the,O
deletion,O
of,O
the,O
last,O
11,O
amino,O
acids,O
of,O
CsrA,B-GP
has,O
been,O
reported,O
to,O
dramatically,O
reduce,O
its,O
activity,O
while,O
maintaining,O
strain,O
viability,O
.,O
This,O
construction,O
has,O
been,O
widely,O
used,O
as,O
the,O
gold,O
standard,O
to,O
explore,O
the,O
function,O
of,O
CsrA,B-GP
(,O
17,O
",",O
32,O
",",O
33,O
).,O
To,O
investigate,O
the,O
glucose,O
-,O
acetate,O
transition,O
",",O
the,O
three,O
mutants,O
and,O
their,O
wild,O
-,O
type,O
(,O
WT,O
),O
isogenic,O
control,O
were,O
grown,O
dynamically,O
in,O
controlled,O
bioreactors,O
in,O
M9,O
minimal,O
medium,O
supplemented,O
with,O
0,O
.,O
27,O
%,O
glucose,O
(,O
9,O
).,O
The,O
biomass,O
and,O
extracellular,O
glucose,O
and,O
acetate,O
concentrations,O
were,O
measured,O
at,O
30,O
-,O
min,O
intervals,O
(,O
Fig,O
.,O
1,O
).,O
The,O
growth,O
of,O
all,O
four,O
strains,O
was,O
exponential,O
during,O
glucose,O
consumption,O
(,O
Fig,O
.,O
1A,O
).,O
As,O
expected,O
from,O
previous,O
work,O
(,O
16,O
"),",O
the,O
csrA51,B-GP
mutant,O
’,O
s,O
growth,O
rate,O
on,O
glucose,O
was,O
lower,O
than,O
that,O
of,O
the,O
WT,O
(,O
Fig,O
.,O
1A,O
).,O
No,O
significant,O
differences,O
were,O
observed,O
between,O
the,O
WT,O
and,O
the,O
ΔcsrBC,O
and,O
ΔcsrD,O
mutant,O
strains,O
during,O
the,O
growth,O
phase,O
on,O
glucose,O
(,O
Fig,O
.,O
1A,O
).,O
This,O
was,O
corroborated,O
by,O
the,O
similar,O
glucose,O
consumption,O
profiles,O
of,O
the,O
strains,O
(,O
Fig,O
.,O
1B,O
).,O
The,O
csrA51,B-GP
mutant,O
strain,O
produced,O
a,O
very,O
low,O
level,O
of,O
acetate,O
during,O
growth,O
on,O
glucose,O
in,O
comparison,O
with,O
the,O
three,O
other,O
strains,O
",",O
whose,O
production,O
rates,O
and,O
final,O
levels,O
of,O
acetate,O
were,O
similar,O
(,O
Fig,O
.,O
1C,O
).,O
The,O
small,O
amount,O
of,O
acetate,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
was,O
completely,O
consumed,O
in,O
the,O
minutes,O
following,O
glucose,O
exhaustion,O
.,O
The,O
other,O
three,O
strains,O
also,O
consumed,O
the,O
acetate,O
produced,O
after,O
glucose,O
exhaustion,O
but,O
with,O
different,O
timings,O
",",O
resulting,O
in,O
the,O
ΔcsrD,O
mutant,O
strain,O
consuming,O
its,O
acetate,O
first,O
",",O
followed,O
by,O
the,O
WT,O
and,O
then,O
the,O
ΔcsrBC,O
mutant,O
strain,O
(,O
Fig,O
.,O
1C,O
).,O
Accordingly,O
",",O
during,O
the,O
acetate,O
consumption,O
phase,O
",",O
higher,O
rates,O
of,O
acetate,O
consumption,O
were,O
observed,O
in,O
the,O
ΔcsrD,O
mutant,O
strain,O
",",O
followed,O
by,O
the,O
WT,O
and,O
then,O
the,O
ΔcsrBC,O
mutant,O
strain,O
(,O
Fig,O
.,O
1D,O
).,O
To,O
illustrate,O
",",O
at,O
1,O
h,O
after,O
glucose,O
exhaustion,O
",",O
these,O
rates,O
were,O
",",O
respectively,O
",",O
−,O
1,O
.,O
50,O
±,O
0,O
.,O
26,O
",",O
−,O
0,O
.,O
82,O
±,O
0,O
.,O
32,O
",",O
and,O
−,O
0,O
.,O
58,O
±,O
0,O
.,O
12,O
mM,O
⋅,O
g,O
of,O
dry,O
weight,O
(,O
gDW,O
)−,O
1,O
⋅,O
h,O
−,O
1,O
in,O
the,O
ΔcsrD,O
mutant,O
",",O
WT,O
",",O
and,O
ΔcsrBC,O
mutant,O
strains,O
.,O
We,O
detected,O
no,O
difference,O
in,O
biomass,O
content,O
that,O
could,O
be,O
related,O
to,O
the,O
differences,O
in,O
the,O
timing,O
of,O
acetate,O
consumption,O
(,O
Fig,O
.,O
1A,O
).,O
Behavior,O
of,O
Csr,B-GP
system,O
mutants,O
during,O
the,O
glucose,O
-,O
acetate,O
transition,O
.,O
Cultures,O
were,O
monitored,O
from,O
6,O
h,O
before,O
to,O
4,O
h,O
after,O
glucose,O
exhaustion,O
",",O
which,O
was,O
set,O
as,O
time,O
zero,O
.,O
All,O
data,O
concerning,O
the,O
replicates,O
are,O
displayed,O
as,O
dots,O
",",O
and,O
the,O
fitted,O
average,O
value,O
of,O
each,O
strain,O
is,O
displayed,O
as,O
a,O
line,O
.,O
Shaded,O
areas,O
represent,O
±,O
1,O
standard,O
deviation,O
.,O
WT,O
",",O
black,O
circles,O
;,O
csrBC,O
mutant,O
",",O
green,O
squares,O
;,O
csrD,B-GP
mutant,O
",",O
orange,O
triangles,O
;,O
csrA51,B-GP
mutant,O
",",O
red,O
diamonds,O
.,O
(,O
A,O
),O
Changes,O
in,O
the,O
biomass,O
concentration,O
(,O
gDW,O
⋅,O
liter,O
−,O
1,O
),O
and,O
growth,O
rate,O
μ,O
(,O
h,O
−,O
1,O
).,O
(,O
B,O
),O
Extracellular,O
glucose,O
concentration,O
(,O
mM,O
),O
and,O
specific,O
glucose,O
production,O
rates,O
(,O
mM,O
⋅,O
h,O
−,O
1,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
).,O
(,O
C,O
),O
Extracellular,O
acetate,O
concentration,O
(,O
mM,O
),O
and,O
specific,O
acetate,O
production,O
rates,O
(,O
mM,O
⋅,O
h,O
−,O
1,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
).,O
(,O
D,O
),O
Glycogen,O
concentration,O
(,O
ggluc,O
⋅,O
gDW,O
−,O
1,O
),O
and,O
specific,O
glycogen,O
production,O
rates,O
(,O
ggluc,O
⋅,O
h,O
−,O
1,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
).,O
Since,O
the,O
csrA51,B-GP
mutant,O
strain,O
is,O
reported,O
to,O
overaccumulate,O
glycogen,O
(,O
14,O
",",O
16,O
",",O
22,O
"),",O
we,O
assessed,O
the,O
concentration,O
of,O
this,O
storage,O
polysaccharide,O
in,O
the,O
cell,O
during,O
the,O
glucose,O
-,O
acetate,O
transition,O
(,O
Fig,O
.,O
1D,O
).,O
As,O
expected,O
(,O
22,O
"),",O
the,O
csrA51,B-GP
mutant,O
strain,O
accumulated,O
up,O
to,O
0,O
.,O
28,O
g,O
of,O
glucose,O
(,O
ggluc,O
),O
⋅,O
gDW,O
of,O
glycogen,O
−,O
1,O
",",O
representing,O
about,O
30,O
%,O
of,O
the,O
biomass,O
dry,O
weight,O
.,O
Glycogen,O
also,O
accumulated,O
in,O
the,O
ΔcsrD,O
mutant,O
cells,O
but,O
to,O
a,O
lesser,O
extent,O
(,O
maximum,O
of,O
0,O
.,O
07,O
ggluc,O
⋅,O
gDW,O
−,O
1,O
",",O
representing,O
7,O
%,O
of,O
the,O
cell,O
dry,O
weight,O
),O
and,O
even,O
less,O
in,O
the,O
WT,O
(,O
4,O
%,O
of,O
the,O
cell,O
dry,O
weight,O
).,O
In,O
contrast,O
",",O
the,O
ΔcsrBC,O
mutant,O
cells,O
stored,O
a,O
very,O
small,O
quantity,O
of,O
glycogen,O
(,O
maximum,O
of,O
0,O
.,O
01,O
ggluc,O
⋅,O
gDW,O
−,O
1,O
",",O
representing,O
about,O
1,O
%,O
of,O
the,O
biomass,O
).,O
The,O
glycogen,O
content,O
in,O
the,O
four,O
strains,O
remained,O
mostly,O
stable,O
during,O
the,O
exponential,O
phase,O
of,O
growth,O
on,O
glucose,O
(,O
concentrations,O
and,O
rates,O
remained,O
constant,O
"),",O
and,O
all,O
four,O
strains,O
used,O
glycogen,O
after,O
glucose,O
exhaustion,O
.,O
Overall,O
",",O
glycogen,O
production,O
and,O
consumption,O
rates,O
were,O
high,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
(,O
respectively,O
",",O
0,O
.,O
078,O
±,O
0,O
.,O
014,O
and,O
−,O
0,O
.,O
057,O
±,O
0,O
.,O
014,O
gglc,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
1,O
h,O
before,O
and,O
1,O
h,O
after,O
glucose,O
exhaustion,O
"),",O
medium,O
in,O
the,O
ΔcsrD,O
mutant,O
(,O
0,O
.,O
035,O
±,O
0,O
.,O
004,O
and,O
−,O
0,O
.,O
018,O
±,O
0,O
.,O
001,O
gglc,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
"),",O
and,O
low,O
in,O
the,O
ΔcsrBC,O
mutant,O
(,O
0,O
.,O
003,O
±,O
0,O
.,O
001,O
and,O
−,O
0,O
.,O
002,O
±,O
0,O
.,O
001,O
gglc,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
),O
compared,O
to,O
those,O
of,O
the,O
WT,O
(,O
0,O
.,O
028,O
±,O
0,O
.,O
001,O
and,O
−,O
0,O
.,O
012,O
±,O
0,O
.,O
007,O
gglc,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
).,O
To,O
conclude,O
",",O
the,O
investigated,O
strains,O
showed,O
a,O
range,O
of,O
phenotypes,O
according,O
to,O
their,O
CsrA,B-GP
activity,O
.,O
The,O
csrA51,B-GP
mutant,O
was,O
the,O
most,O
affected,O
strain,O
",",O
with,O
high,O
glycogen,O
and,O
low,O
acetate,O
contents,O
and,O
a,O
reduced,O
growth,O
rate,O
.,O
The,O
ΔcsrD,O
mutant,O
also,O
had,O
a,O
higher,O
glycogen,O
content,O
than,O
the,O
WT,O
and,O
accelerated,O
acetate,O
consumption,O
.,O
The,O
ΔcsrBC,O
mutant,O
displayed,O
the,O
reverse,O
phenotypes,O
(,O
low,O
to,O
no,O
glycogen,O
content,O
and,O
delayed,O
acetate,O
consumption,O
).,O
In,O
addition,O
to,O
its,O
effect,O
on,O
growth,O
rates,O
and,O
glycogen,O
accumulation,O
",",O
the,O
Csr,B-GP
system,O
is,O
involved,O
in,O
the,O
dynamics,O
of,O
the,O
glycolysis,O
-,O
gluconeogenesis,O
transition,O
",",O
notably,O
through,O
its,O
impact,O
on,O
acetate,O
consumption,O
after,O
glucose,O
exhaustion,O
.,O
CCM,O
gene,O
expression,O
is,O
differently,O
influenced,O
by,O
the,O
Csr,B-GP
system,O
before,O
and,O
after,O
glucose,O
exhaustion,O
.,O
We,O
assumed,O
that,O
the,O
differences,O
in,O
acetate,O
consumption,O
between,O
the,O
strains,O
could,O
result,O
from,O
differential,O
gene,O
expression,O
in,O
the,O
CCM,O
after,O
glucose,O
exhaustion,O
.,O
This,O
was,O
assessed,O
by,O
performing,O
quantitative,O
reverse,O
transcription,O
(,O
RT,O
)-,O
PCR,O
analysis,O
of,O
14,O
key,O
CCM,O
genes,O
(,O
34,O
),O
during,O
the,O
metabolic,O
transition,O
from,O
3,O
h,O
preceding,O
to,O
2,O
h,O
after,O
glucose,O
exhaustion,O
(,O
Fig,O
.,O
2,O
).,O
During,O
the,O
glucose,O
consumption,O
phase,O
",",O
massive,O
differences,O
in,O
gene,O
expression,O
were,O
observed,O
between,O
the,O
mutant,O
strains,O
and,O
the,O
WT,O
",",O
especially,O
the,O
csrA51,B-GP
mutant,O
strain,O
(,O
as,O
previously,O
described,O
by,O
Morin,O
et,O
al,O
.,O
[,O
16,O
]).,O
In,O
contrast,O
",",O
the,O
differences,O
between,O
the,O
strains,O
were,O
globally,O
reduced,O
after,O
glucose,O
exhaustion,O
",",O
except,O
for,O
the,O
genes,O
involved,O
in,O
acetate,O
and,O
glycogen,O
metabolism,O
(,O
Fig,O
.,O
2,O
).,O
For,O
acetate,O
metabolism,O
(,O
ACS,B-GP
",",O
ack,B-GP
",",O
and,O
pta,B-GP
"),",O
higher,O
expression,O
was,O
noticed,O
in,O
the,O
csrA51,B-GP
and,O
ΔcsrD,O
mutant,O
strains,O
than,O
in,O
the,O
WT,O
",",O
which,O
could,O
be,O
consistent,O
with,O
their,O
improved,O
acetate,O
consumption,O
rates,O
.,O
The,O
expression,O
of,O
glycogen,O
-,O
related,O
genes,O
(,O
pgm,B-GP
and,O
glgC,B-GP
),O
was,O
increased,O
",",O
but,O
only,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
.,O
We,O
thus,O
conclude,O
that,O
the,O
Csr,B-GP
system,O
controls,O
different,O
sets,O
of,O
genes,O
before,O
and,O
after,O
glucose,O
exhaustion,O
",",O
the,O
later,O
set,O
being,O
devoted,O
to,O
the,O
use,O
of,O
the,O
remaining,O
carbon,O
sources,O
(,O
acetate,O
and,O
glycogen,O
).,O
Expression,O
of,O
key,O
metabolic,O
genes,O
during,O
the,O
glucose,O
-,O
acetate,O
transition,O
of,O
Csr,B-GP
system,O
mutants,O
.,O
Gene,O
expression,O
(,O
relative,O
to,O
the,O
idnT,B-GP
RNA,O
reference,O
),O
was,O
investigated,O
from,O
3,O
h,O
before,O
to,O
2,O
h,O
after,O
glucose,O
exhaustion,O
.,O
WT,O
",",O
black,O
circles,O
;,O
csrBC,O
mutant,O
",",O
green,O
squares,O
;,O
csrD,B-GP
mutant,O
",",O
orange,O
triangles,O
;,O
csrA51,B-GP
mutant,O
",",O
red,O
diamonds,O
.,O
ptsG,B-GP
",",O
glucose,B-GP
phosphotransferase,I-GP
system,I-GP
permease,I-GP
PtsG,I-GP
subunit,I-GP
(,O
European,O
Bioinformatics,O
Institute,O
European,O
Nucleotide,O
Archive,O
accession,O
no,O
.,O
EG10787,O
);,O
pgm,B-GP
",",O
phosphoglucomutase,B-GP
(,O
accession,O
no,O
.,O
EG12144,O
);,O
glgC,B-GP
",",O
glucose,B-GP
-,I-GP
1,I-GP
-,I-GP
phosphate,I-GP
adenylyltransferase,I-GP
(,O
accession,O
no,O
.,O
EG10379,O
);,O
zwf,B-GP
",",O
glucose,B-GP
6,I-GP
-,I-GP
phosphate,I-GP
-,I-GP
1,I-GP
-,I-GP
dehydrogenase,I-GP
(,O
accession,O
no,O
.,O
EG11221,O
);,O
pgi,B-GP
",",O
phosphoglucose,B-GP
isomerase,I-GP
(,O
accession,O
no,O
.,O
EG10702,O
);,O
pfkA,B-GP
",",O
phosphofructokinase,B-GP
(,O
accession,O
no,O
.,O
EG10699,O
);,O
eno,B-GP
",",O
enolase,B-GP
(,O
accession,O
no,O
.,O
EG10258,O
);,O
icd,B-GP
",",O
isocitrate,B-GP
dehydrogenase,I-GP
(,O
accession,O
no,O
.,O
EG10489,O
);,O
pck,B-GP
",",O
phosphoenolpyruvate,B-GP
carboxykinase,I-GP
(,O
accession,O
no,O
.,O
EG10688,O
);,O
pta,B-GP
",",O
phosphate,B-GP
acetyltransferase,I-GP
(,O
accession,O
no,O
.,O
EG20173,O
);,O
ack,B-GP
",",O
acetate,B-GP
kinase,I-GP
(,O
accession,O
no,O
.,O
EG10027,O
);,O
ACS,B-GP
",",O
acetyl,B-GP
coenzyme,I-GP
A,I-GP
synthetase,I-GP
(,O
accession,O
no,O
.,O
EG11448,O
);,O
pck,B-GP
",",O
phosphoenolpyruvate,B-GP
carboxykinase,I-GP
(,O
accession,O
no,O
.,O
EG10688,O
);,O
fbp,B-GP
",",O
fructose,B-GP
1,I-GP
",",I-GP
6,I-GP
-,I-GP
bisphosphatase,I-GP
(,O
accession,O
no,O
.,O
EG10283,O
).,O
The,O
values,O
are,O
averages,O
of,O
three,O
replicates,O
with,O
error,O
bars,O
representing,O
standard,O
deviations,O
.,O
PPP,O
",",O
pentose,O
phosphate,O
pathway,O
;,O
TCA,O
",",O
tricarboxylic,O
acid,O
cycle,O
.,O
Analysis,O
of,O
the,O
metabolite,O
pools,O
revealed,O
different,O
energy,O
status,O
in,O
the,O
Csr,B-GP
system,O
mutant,O
strains,O
after,O
glucose,O
exhaustion,O
.,O
We,O
then,O
measured,O
key,O
metabolite,O
pools,O
in,O
the,O
CCM,O
over,O
time,O
in,O
the,O
four,O
strains,O
by,O
using,O
liquid,O
chromatography,O
-,O
tandem,O
mass,O
spectrometry,O
(,O
LC,O
-,O
MS,O
/,O
MS,O
),O
(,O
Fig,O
.,O
3,O
).,O
The,O
profiles,O
of,O
the,O
metabolites,O
assessed,O
over,O
time,O
were,O
mostly,O
similar,O
in,O
the,O
four,O
strains,O
",",O
with,O
a,O
drop,O
in,O
concentrations,O
after,O
glucose,O
exhaustion,O
",",O
except,O
for,O
the,O
alarmone,O
cAMP,O
and,O
for,O
phosphoenolpyruvate,O
",",O
as,O
previously,O
described,O
in,O
the,O
WT,O
strain,O
(,O
9,O
).,O
Before,O
glucose,O
exhaustion,O
",",O
the,O
ΔcsrBC,O
mutant,O
strain,O
had,O
higher,O
concentrations,O
of,O
fructose,O
1,O
",",O
6,O
-,O
bisphosphate,O
(,O
FBP,O
),O
and,O
malate,O
",",O
whereas,O
the,O
ΔcsrD,O
pools,O
were,O
mostly,O
comparable,O
to,O
those,O
of,O
the,O
WT,O
(,O
Fig,O
.,O
3A,O
).,O
As,O
expected,O
(,O
16,O
"),",O
the,O
csrA51,B-GP
mutant,O
strain,O
displayed,O
larger,O
metabolite,O
pools,O
in,O
the,O
upper,O
part,O
of,O
the,O
glycolysis,O
process,O
(,O
glucose,O
-,O
6,O
-,O
phosphate,O
[,O
G6P,O
"],",O
fructose,O
-,O
6,O
-,O
phosphate,O
[,O
F6P,O
]),O
than,O
the,O
WT,O
.,O
These,O
pools,O
decreased,O
after,O
glucose,O
exhaustion,O
but,O
",",O
unexpectedly,O
",",O
were,O
maintained,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
at,O
levels,O
equivalent,O
to,O
those,O
measured,O
in,O
the,O
WT,O
strain,O
during,O
the,O
glucose,O
consumption,O
phase,O
(,O
Fig,O
.,O
3A,O
).,O
Likewise,O
",",O
the,O
nucleotide,O
triphosphate,O
pools,O
remained,O
high,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
even,O
after,O
glucose,O
exhaustion,O
.,O
Concentrations,O
of,O
key,O
central,O
carbon,O
metabolites,O
during,O
the,O
glucose,O
-,O
acetate,O
transition,O
of,O
Csr,B-GP
system,O
mutants,O
.,O
(,O
A,O
),O
Metabolite,O
concentrations,O
were,O
investigated,O
from,O
3,O
h,O
before,O
to,O
2,O
h,O
after,O
glucose,O
exhaustion,O
.,O
WT,O
",",O
black,O
circles,O
;,O
csrBC,O
mutant,O
",",O
green,O
squares,O
;,O
csrD,B-GP
mutant,O
",",O
orange,O
triangles,O
;,O
csrA51,B-GP
mutant,O
",",O
red,O
diamonds,O
.,O
PEP,O
",",O
phosphoenolpyruvate,O
.,O
(,O
B,O
),O
The,O
AECs,O
of,O
the,O
same,O
four,O
strains,O
during,O
glucose,O
consumption,O
(,O
plain,O
bars,O
),O
and,O
1,O
.,O
5,O
h,O
after,O
glucose,O
exhaustion,O
(,O
striped,O
bars,O
),O
are,O
shown,O
.,O
A,O
significant,O
difference,O
between,O
a,O
mutant,O
and,O
the,O
WT,O
is,O
represented,O
by,O
an,O
asterisk,O
(,O
P,O
<,O
0,O
.,O
05,O
[,O
t,O
test,O
]).,O
The,O
values,O
in,O
both,O
panels,O
are,O
averages,O
of,O
three,O
independent,O
biological,O
replicates,O
with,O
error,O
bars,O
representing,O
standard,O
deviations,O
.,O
These,O
results,O
suggested,O
that,O
the,O
energy,O
level,O
after,O
glucose,O
exhaustion,O
differs,O
between,O
strains,O
.,O
We,O
therefore,O
investigated,O
the,O
energy,O
status,O
of,O
the,O
cells,O
by,O
calculating,O
the,O
adenylate,O
energy,O
charge,O
(,O
AEC,O
),O
as,O
an,O
index,O
of,O
the,O
bacterium,B-OG
metabolic,O
state,O
(,O
35,O
).,O
The,O
AEC,O
on,O
glucose,O
was,O
between,O
0,O
.,O
87,O
and,O
0,O
.,O
91,O
in,O
all,O
of,O
the,O
strains,O
during,O
the,O
glucose,O
consumption,O
phase,O
(,O
Fig,O
.,O
3B,O
).,O
Such,O
values,O
are,O
expected,O
in,O
exponentially,O
growing,O
cells,O
(,O
35,O
).,O
At,O
90,O
min,O
after,O
glucose,O
exhaustion,O
",",O
the,O
AEC,O
had,O
decreased,O
in,O
all,O
of,O
the,O
strains,O
.,O
However,O
",",O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
",",O
the,O
AEC,O
remained,O
significantly,O
higher,O
than,O
in,O
the,O
WT,O
",",O
and,O
the,O
ΔcsrBC,O
mutant,O
AEC,O
collapsed,O
to,O
0,O
.,O
50,O
",",O
a,O
value,O
previously,O
linked,O
to,O
dying,O
cells,O
(,O
35,O
).,O
In,O
conclusion,O
",",O
the,O
csrA51,B-GP
mutant,O
strain,O
maintained,O
high,O
energy,O
levels,O
after,O
glucose,O
exhaustion,O
",",O
whereas,O
there,O
was,O
a,O
dramatic,O
drop,O
in,O
the,O
energy,O
status,O
of,O
the,O
ΔcsrBC,O
mutant,O
strain,O
.,O
We,O
thus,O
hypothesize,O
that,O
the,O
energy,O
levels,O
in,O
the,O
Csr,B-GP
system,O
mutant,O
strains,O
could,O
be,O
linked,O
to,O
the,O
observed,O
differences,O
in,O
the,O
kinetics,O
of,O
acetate,O
consumption,O
.,O
Both,O
glycogen,O
and,O
acetate,O
influence,O
the,O
energy,O
status,O
after,O
glucose,O
exhaustion,O
.,O
We,O
analyzed,O
the,O
relationship,O
between,O
energy,O
fluxes,O
and,O
acetate,O
consumption,O
rates,O
by,O
investigating,O
the,O
distribution,O
of,O
the,O
energy,O
fluxes,O
after,O
glucose,O
exhaustion,O
in,O
the,O
different,O
strains,O
.,O
During,O
the,O
acetate,O
consumption,O
phase,O
",",O
glycogen,O
is,O
also,O
consumed,O
as,O
an,O
intracellular,O
storage,O
sugar,O
and,O
is,O
thus,O
also,O
likely,O
to,O
be,O
involved,O
in,O
the,O
balance,O
between,O
energy,O
fluxes,O
.,O
To,O
examine,O
the,O
influence,O
of,O
glycogen,O
and,O
acetate,O
flux,O
on,O
the,O
growth,O
rate,O
and,O
ATP,O
flux,O
",",O
we,O
used,O
a,O
previously,O
developed,O
constraint,O
-,O
based,O
model,O
of,O
E,B-OG
.,I-OG
coli,I-OG
(,O
16,O
",",O
36,O
).,O
These,O
parameters,O
were,O
analyzed,O
in,O
the,O
ranges,O
of,O
acetate,O
and,O
glycogen,O
consumption,O
rates,O
we,O
monitored,O
after,O
glucose,O
exhaustion,O
(,O
Fig,O
.,O
1,O
;,O
see,O
Materials,O
and,O
Methods,O
for,O
details,O
of,O
the,O
procedure,O
).,O
We,O
compared,O
the,O
ATP,O
fluxes,O
predicted,O
by,O
the,O
model,O
with,O
cell,O
maintenance,O
that,O
we,O
estimated,O
at,O
2,O
.,O
9,O
mmol,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
from,O
experimental,O
data,O
obtained,O
with,O
the,O
WT,O
strain,O
(,O
32,O
),O
and,O
considered,O
to,O
be,O
the,O
same,O
in,O
all,O
four,O
strains,O
.,O
The,O
results,O
of,O
analysis,O
of,O
the,O
flux,O
balance,O
are,O
shown,O
in,O
Fig,O
.,O
4,O
.,O
Acetate,O
and,O
glycogen,O
uptake,O
rates,O
were,O
insufficient,O
to,O
detect,O
growth,O
(,O
µ,O
<,O
0,O
.,O
05,O
h,O
−,O
1,O
),O
in,O
any,O
of,O
the,O
four,O
strains,O
(,O
Fig,O
.,O
4A,O
"),",O
since,O
ATP,O
production,O
barely,O
covered,O
the,O
maintenance,O
costs,O
(,O
Fig,O
.,O
4B,O
).,O
At,O
2,O
.,O
5,O
h,O
after,O
glucose,O
exhaustion,O
",",O
the,O
WT,O
and,O
ΔcsrBC,O
mutant,O
strains,O
produced,O
ATP,O
from,O
acetate,O
in,O
the,O
absence,O
of,O
glycogen,O
(,O
the,O
ATP,O
fluxes,O
produced,O
ranged,O
between,O
5,O
and,O
12,O
mmol,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
"),",O
while,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
",",O
ATP,O
was,O
produced,O
from,O
glycogen,O
in,O
the,O
absence,O
of,O
acetate,O
.,O
Although,O
the,O
ΔcsrD,O
mutant,O
strain,O
displayed,O
the,O
greatest,O
ATP,O
flux,O
from,O
a,O
mixture,O
of,O
glycogen,O
and,O
acetate,O
90,O
min,O
after,O
glucose,O
exhaustion,O
(,O
Fig,O
.,O
4A,O
"),",O
growth,O
was,O
only,O
barely,O
detectable,O
and,O
stopped,O
1,O
h,O
later,O
when,O
both,O
acetate,O
and,O
glycogen,O
were,O
depleted,O
(,O
Fig,O
.,O
1,O
and,O
4,O
).,O
We,O
thus,O
conclude,O
that,O
both,O
acetate,O
and,O
glycogen,O
can,O
be,O
used,O
to,O
maintain,O
the,O
energy,O
status,O
of,O
the,O
cells,O
after,O
glucose,O
exhaustion,O
but,O
that,O
their,O
consumption,O
rates,O
are,O
too,O
low,O
to,O
ensure,O
observable,O
growth,O
.,O
Even,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
",",O
which,O
has,O
the,O
highest,O
energy,O
level,O
AEC,O
and,O
glycogen,O
content,O
(,O
up,O
to,O
30,O
%,O
of,O
the,O
biomass,O
"),",O
the,O
ATP,O
produced,O
is,O
only,O
sufficient,O
to,O
ensure,O
maintenance,O
",",O
i,O
.,O
e,O
".,",O
to,O
allow,O
the,O
strain,O
to,O
survive,O
but,O
not,O
to,O
grow,O
efficiently,O
.,O
Metabolic,O
capacities,O
of,O
the,O
WT,O
and,O
Csr,B-GP
system,O
mutant,O
strains,O
during,O
growth,O
on,O
glycogen,O
and,O
acetate,O
.,O
Flux,O
balance,O
analysis,O
of,O
the,O
four,O
strains,O
was,O
performed,O
with,O
glycogen,O
and,O
acetate,O
as,O
carbon,O
sources,O
by,O
using,O
two,O
different,O
objective,O
functions,O
",",O
biomass,O
and,O
ATP,O
production,O
(,O
see,O
Materials,O
and,O
Methods,O
for,O
details,O
).,O
(,O
A,O
),O
Maximum,O
predicted,O
growth,O
rates,O
(,O
μ,O
),O
for,O
various,O
pairs,O
of,O
glycogen,O
and,O
acetate,O
uptake,O
rates,O
(,O
qs,O
).,O
(,O
B,O
),O
Maximum,O
flux,O
of,O
ATP,O
predicted,O
by,O
the,O
model,O
.,O
Bars,O
to,O
the,O
right,O
of,O
each,O
plot,O
indicate,O
the,O
color,O
code,O
used,O
for,O
the,O
growth,O
rate,O
(,O
A,O
),O
and,O
ATP,O
flux,O
(,O
B,O
),O
values,O
.,O
The,O
four,O
strains,O
",",O
the,O
WT,O
(,O
gray,O
circles,O
"),",O
the,O
csrBC,O
mutant,O
(,O
green,O
squares,O
"),",O
the,O
csrD,B-GP
mutant,O
(,O
orange,O
triangles,O
"),",O
and,O
the,O
csrA51,B-GP
mutant,O
(,O
red,O
diamonds,O
"),",O
were,O
assessed,O
at,O
two,O
different,O
times,O
90,O
min,O
(*),O
and,O
150,O
min,O
(**).,O
The,O
values,O
are,O
averages,O
of,O
three,O
replicates,O
with,O
error,O
bars,O
representing,O
standard,O
deviations,O
.,O
Suppression,O
of,O
glycogen,O
synthesis,O
hinders,O
the,O
capacity,O
of,O
the,O
csrA51,B-GP
mutant,O
strain,O
to,O
maintain,O
high,O
energy,O
levels,O
after,O
glucose,O
exhaustion,O
.,O
As,O
shown,O
above,O
",",O
both,O
acetate,O
and,O
glycogen,O
can,O
be,O
used,O
to,O
maintain,O
the,O
energy,O
status,O
after,O
glucose,O
exhaustion,O
but,O
the,O
corresponding,O
ATP,O
fluxes,O
did,O
not,O
enable,O
us,O
to,O
distinguish,O
differences,O
in,O
the,O
energy,O
level,O
AEC,O
and,O
fitness,O
related,O
to,O
acetate,O
consumption,O
in,O
the,O
different,O
strains,O
.,O
Only,O
glycogen,O
levels,O
appeared,O
to,O
accompany,O
the,O
high,O
energy,O
level,O
of,O
the,O
csrA51,B-GP
mutant,O
strain,O
and,O
the,O
low,O
energy,O
level,O
of,O
the,O
ΔcsrBC,O
mutant,O
(,O
Fig,O
.,O
1D,O
and,O
3B,O
).,O
We,O
therefore,O
hypothesized,O
that,O
the,O
impact,O
of,O
Csr,B-GP
on,O
the,O
energy,O
status,O
can,O
only,O
be,O
mediated,O
by,O
the,O
impact,O
of,O
CsrA,B-GP
on,O
glycogen,O
accumulation,O
.,O
To,O
confirm,O
this,O
hypothesis,O
",",O
we,O
prevented,O
glycogen,O
synthesis,O
in,O
the,O
WT,O
and,O
csrA51,B-GP
mutant,O
strains,O
by,O
deleting,O
the,O
glgC,B-GP
gene,O
.,O
The,O
same,O
pools,O
of,O
metabolites,O
as,O
those,O
shown,O
in,O
Fig,O
.,O
3,O
were,O
then,O
assessed,O
during,O
the,O
glucose,O
-,O
acetate,O
transition,O
in,O
the,O
WT,O
and,O
ΔglgC,O
",",O
csrA51,B-GP
",",O
and,O
csrA51,B-GP
ΔglgC,O
mutant,O
strains,O
(,O
Fig,O
.,O
5A,O
).,O
Some,O
of,O
the,O
WT,O
and,O
csrA51,B-GP
mutant,O
metabolite,O
pools,O
",",O
e,O
.,O
g,O
".,",O
FBP,O
",",O
differed,O
quantitatively,O
from,O
those,O
shown,O
in,O
Fig,O
.,O
3A,O
",",O
very,O
likely,O
because,O
these,O
cultures,O
were,O
performed,O
in,O
Erlenmeyer,O
flasks,O
instead,O
of,O
in,O
reactors,O
with,O
regulated,O
pH,O
and,O
monitored,O
oxygenation,O
.,O
However,O
",",O
the,O
trends,O
were,O
similar,O
under,O
both,O
conditions,O
.,O
Remarkably,O
",",O
the,O
deletion,O
of,O
glgC,B-GP
prevented,O
the,O
maintenance,O
of,O
elevated,O
G6P,O
",",O
F6P,O
",",O
and,O
nucleotide,O
triphosphate,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
.,O
Prevention,O
of,O
glycogen,O
synthesis,O
did,O
not,O
affect,O
the,O
AEC,O
before,O
glucose,O
exhaustion,O
(,O
Fig,O
.,O
5B,O
).,O
After,O
glucose,O
exhaustion,O
",",O
the,O
AEC,O
of,O
the,O
two,O
strains,O
unable,O
to,O
store,O
glycogen,O
dropped,O
drastically,O
in,O
comparison,O
to,O
that,O
of,O
the,O
WT,O
and,O
csrA51,B-GP
mutant,O
strains,O
.,O
We,O
therefore,O
conclude,O
that,O
the,O
maintenance,O
of,O
the,O
energy,O
status,O
after,O
glucose,O
exhaustion,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
results,O
from,O
its,O
high,O
glycogen,O
content,O
.,O
Concentrations,O
of,O
key,O
central,O
carbon,O
metabolites,O
throughout,O
the,O
glucose,O
-,O
acetate,O
transition,O
of,O
Csr,B-GP
system,O
and,O
/,O
or,O
glycogen,O
-,O
deficient,O
mutants,O
.,O
(,O
A,O
),O
Metabolite,O
concentrations,O
were,O
investigated,O
from,O
3,O
h,O
before,O
to,O
2,O
h,O
after,O
glucose,O
exhaustion,O
.,O
WT,O
",",O
black,O
circles,O
;,O
ΔglgC,O
mutant,O
",",O
gray,O
squares,O
;,O
csrA51,B-GP
mutant,O
",",O
red,O
diamonds,O
;,O
csrA51,B-GP
ΔglgC,O
mutant,O
",",O
brown,O
triangles,O
.,O
PEP,O
",",O
phosphoenolpyruvate,O
.,O
(,O
B,O
),O
The,O
AECs,O
of,O
the,O
same,O
four,O
strains,O
during,O
glucose,O
consumption,O
(,O
plain,O
bars,O
),O
and,O
90,O
min,O
after,O
glucose,O
exhaustion,O
(,O
striped,O
bars,O
),O
are,O
shown,O
.,O
A,O
significant,O
difference,O
between,O
a,O
mutant,O
and,O
the,O
WT,O
is,O
represented,O
by,O
an,O
asterisk,O
(,O
P,O
<,O
0,O
.,O
05,O
[,O
t,O
test,O
]).,O
The,O
values,O
are,O
averages,O
of,O
three,O
independent,O
biological,O
replicates,O
with,O
error,O
bars,O
representing,O
standard,O
deviations,O
.,O
The,O
Csr,B-GP
system,O
affects,O
cellular,O
fitness,O
through,O
its,O
control,O
of,O
glycogen,O
synthesis,O
.,O
Taken,O
together,O
",",O
our,O
results,O
suggest,O
that,O
the,O
Csr,B-GP
system,O
influences,O
the,O
energy,O
status,O
through,O
the,O
control,O
of,O
glycogen,O
synthesis,O
.,O
This,O
affects,O
the,O
ability,O
of,O
the,O
strain,O
to,O
switch,O
to,O
acetate,O
metabolism,O
after,O
glucose,O
exhaustion,O
.,O
To,O
demonstrate,O
this,O
scenario,O
",",O
we,O
investigated,O
the,O
dynamics,O
of,O
the,O
metabolic,O
adaptation,O
of,O
the,O
cells,O
when,O
switched,O
to,O
fresh,O
medium,O
containing,O
acetate,O
as,O
the,O
sole,O
carbon,O
source,O
.,O
The,O
capacity,O
of,O
Csr,B-GP
and,O
/,O
or,O
glycogen,O
mutant,O
cells,O
to,O
resume,O
growth,O
on,O
fresh,O
acetate,O
minimum,O
medium,O
was,O
assessed,O
before,O
and,O
after,O
glucose,O
exhaustion,O
.,O
The,O
times,O
required,O
to,O
recover,O
full,O
growth,O
on,O
acetate,O
were,O
determined,O
(,O
Fig,O
.,O
6,O
).,O
As,O
previously,O
demonstrated,O
(,O
31,O
"),",O
the,O
WT,O
strain,O
required,O
38,O
min,O
to,O
switch,O
from,O
glucose,O
-,O
to,O
acetate,O
-,O
based,O
growth,O
.,O
This,O
delay,O
was,O
reduced,O
to,O
21,O
min,O
when,O
the,O
cells,O
were,O
sampled,O
1,O
h,O
after,O
glucose,O
exhaustion,O
",",O
likely,O
because,O
of,O
the,O
induced,O
expression,O
of,O
gluconeogenic,B-GP
enzymes,I-GP
.,O
The,O
delays,O
were,O
similar,O
in,O
the,O
ΔcsrD,O
mutant,O
strain,O
.,O
In,O
the,O
csrA51,B-GP
mutant,O
strain,O
",",O
the,O
delays,O
increased,O
by,O
40,O
to,O
50,O
%,O
but,O
the,O
same,O
relative,O
decrease,O
was,O
observed,O
after,O
glucose,O
exhaustion,O
.,O
The,O
long,O
delays,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
could,O
be,O
explained,O
by,O
the,O
difficulty,O
in,O
setting,O
up,O
acetate,O
consumption,O
in,O
the,O
presence,O
of,O
highly,O
abundant,O
glycogen,O
",",O
which,O
could,O
be,O
a,O
more,O
favorable,O
substrate,O
.,O
The,O
delay,O
in,O
the,O
ΔcsrBC,O
mutant,O
strain,O
growing,O
on,O
glucose,O
was,O
similar,O
to,O
that,O
in,O
the,O
WT,O
strain,O
.,O
In,O
contrast,O
",",O
the,O
delay,O
in,O
the,O
ΔcsrBC,O
mutant,O
strain,O
was,O
not,O
reduced,O
after,O
glucose,O
exhaustion,O
.,O
This,O
property,O
was,O
also,O
observed,O
in,O
the,O
ΔglgC,O
and,O
csrA51,B-GP
ΔglgC,O
mutant,O
strains,O
.,O
The,O
increase,O
in,O
the,O
delays,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
switched,O
to,O
acetate,O
was,O
also,O
suppressed,O
in,O
the,O
csrA51,B-GP
ΔglgC,O
mutant,O
strain,O
.,O
Since,O
the,O
glycogen,O
level,O
in,O
the,O
csrBC,O
mutant,O
strain,O
was,O
zero,O
after,O
glucose,O
exhaustion,O
(,O
Fig,O
.,O
1D,O
"),",O
we,O
conclude,O
that,O
glycogen,O
is,O
necessary,O
to,O
start,O
acetate,O
uptake,O
1,O
h,O
after,O
glucose,O
exhaustion,O
.,O
Therefore,O
",",O
the,O
Csr,B-GP
system,O
affects,O
the,O
establishment,O
of,O
metabolic,O
adaptation,O
after,O
glucose,O
exhaustion,O
through,O
its,O
control,O
of,O
glycogen,O
synthesis,O
.,O
Delay,O
before,O
the,O
full,O
growth,O
rate,O
was,O
reached,O
on,O
acetate,O
.,O
For,O
each,O
strain,O
",",O
cells,O
from,O
a,O
mother,O
culture,O
on,O
M9,O
-,O
glucose,O
were,O
transferred,O
to,O
M9,O
-,O
acetate,O
and,O
the,O
time,O
lag,O
until,O
full,O
growth,O
on,O
the,O
new,O
substrate,O
was,O
measured,O
.,O
Cells,O
were,O
sampled,O
either,O
60,O
min,O
before,O
(,O
plain,O
bars,O
),O
or,O
60,O
min,O
after,O
(,O
striped,O
bars,O
),O
glucose,O
exhaustion,O
.,O
The,O
data,O
are,O
averages,O
of,O
three,O
or,O
more,O
independent,O
biological,O
replicates,O
with,O
error,O
bars,O
representing,O
standard,O
deviations,O
.,O
A,O
significant,O
difference,O
between,O
a,O
mutant,O
and,O
the,O
WT,O
is,O
represented,O
by,O
an,O
asterisk,O
(,O
P,O
<,O
0,O
.,O
05,O
[,O
t,O
test,O
]).,O
DISCUSSION,O
The,O
Csr,B-GP
system,O
was,O
recently,O
demonstrated,O
to,O
be,O
a,O
major,O
controller,O
of,O
upper,O
glycolysis,O
fluxes,O
(,O
16,O
"),",O
but,O
its,O
involvement,O
in,O
metabolic,O
adaptation,O
is,O
less,O
clear,O
in,O
the,O
literature,O
.,O
CsrA,B-GP
is,O
known,O
to,O
positively,O
regulate,O
glycolytic,O
genes,O
and,O
negatively,O
regulate,O
gluconeogenic,O
genes,O
(,O
15,O
",",O
16,O
).,O
A,O
study,O
of,O
the,O
BarA,B-GP
/,O
UvrY,B-GP
two,O
-,O
component,O
system,O
during,O
the,O
metabolic,O
switch,O
suggested,O
that,O
the,O
Csr,B-GP
system,O
is,O
crucial,O
for,O
efficient,O
adaptation,O
between,O
different,O
metabolic,O
pathways,O
(,O
2,O
).,O
Here,O
",",O
we,O
showed,O
that,O
gene,O
expression,O
in,O
the,O
CCM,O
(,O
glycolysis,O
",",O
gluconeogenesis,O
",",O
the,O
pentose,O
phosphate,O
pathway,O
",",O
and,O
the,O
tricarboxylic,O
acid,O
cycle,O
),O
did,O
not,O
present,O
strong,O
discrepancies,O
between,O
the,O
Csr,B-GP
system,O
mutants,O
during,O
the,O
acetate,O
consumption,O
phase,O
",",O
in,O
deep,O
contrast,O
to,O
the,O
situation,O
during,O
glucose,O
consumption,O
.,O
It,O
will,O
be,O
awkward,O
to,O
totally,O
rule,O
out,O
any,O
control,O
of,O
these,O
genes,O
by,O
CsrA,B-GP
",",O
since,O
regulation,O
could,O
be,O
at,O
the,O
posttranscriptional,O
level,O
.,O
The,O
control,O
by,O
CsrA,B-GP
could,O
also,O
be,O
counterbalanced,O
by,O
its,O
higher,O
sequestration,O
by,O
CsrB,B-GP
",",O
since,O
the,O
latter,O
level,O
has,O
been,O
reported,O
to,O
increase,O
during,O
the,O
transition,O
(,O
23,O
",",O
37,O
).,O
Most,O
importantly,O
",",O
CsrA,B-GP
was,O
demonstrated,O
to,O
control,O
the,O
expression,O
of,O
genes,O
encoding,O
functions,O
in,O
acetate,O
and,O
glycogen,O
metabolism,O
after,O
glucose,O
exhaustion,O
.,O
This,O
gene,O
expression,O
profiling,O
",",O
combined,O
with,O
acetate,O
measurements,O
and,O
switch,O
experiments,O
",",O
demonstrated,O
that,O
CsrA,B-GP
influences,O
the,O
timing,O
of,O
acetate,O
and,O
glycogen,O
utilization,O
after,O
glucose,O
exhaustion,O
.,O
We,O
proved,O
that,O
glycogen,O
allows,O
the,O
maintenance,O
of,O
a,O
minimal,O
cellular,O
energy,O
level,O
after,O
glucose,O
exhaustion,O
.,O
The,O
energy,O
related,O
to,O
glycogen,O
and,O
/,O
or,O
acetate,O
catabolism,O
provided,O
the,O
energy,O
required,O
for,O
maintenance,O
but,O
was,O
not,O
sufficient,O
to,O
sustain,O
growth,O
on,O
glycogen,O
alone,O
.,O
We,O
also,O
showed,O
that,O
glycogen,O
accumulation,O
increased,O
cell,O
fitness,O
by,O
allowing,O
a,O
rapid,O
restart,O
on,O
acetate,O
.,O
In,O
the,O
csrA51,B-GP
mutant,O
strain,O
",",O
the,O
overaccumulation,O
of,O
glycogen,O
was,O
also,O
accompanied,O
by,O
levels,O
of,O
G6P,O
and,O
F6P,O
and,O
energy,O
status,O
after,O
glucose,O
exhaustion,O
matching,O
those,O
of,O
the,O
WT,O
during,O
growth,O
on,O
glucose,O
.,O
Conversely,O
",",O
a,O
ΔcsrBC,O
mutant,O
strain,O
that,O
accumulates,O
a,O
very,O
low,O
level,O
of,O
glycogen,O
presents,O
phenotypes,O
similar,O
to,O
those,O
of,O
a,O
ΔglgC,O
mutant,O
strain,O
after,O
glucose,O
exhaustion,O
",",O
with,O
a,O
low,O
energy,O
status,O
and,O
a,O
weaker,O
adaptive,O
capacity,O
to,O
use,O
acetate,O
.,O
From,O
our,O
work,O
",",O
it,O
is,O
now,O
clear,O
that,O
CsrA,B-GP
regulates,O
the,O
metabolic,O
transition,O
from,O
glycolysis,O
to,O
gluconeogenesis,O
in,O
E,B-OG
.,I-OG
coli,I-OG
.,O
Most,O
of,O
the,O
elements,O
presented,O
here,O
strengthen,O
the,O
hypothesis,O
that,O
the,O
transition,O
control,O
by,O
the,O
Csr,B-GP
system,O
is,O
exerted,O
through,O
the,O
regulation,O
of,O
glycogen,O
synthesis,O
and,O
its,O
utilization,O
.,O
The,O
only,O
clue,O
we,O
observed,O
concerning,O
a,O
glycogen,O
-,O
independent,O
effect,O
of,O
CsrA,B-GP
during,O
the,O
transition,O
is,O
in,O
the,O
production,O
of,O
cAMP,O
",",O
an,O
alarmone,O
that,O
has,O
an,O
important,O
function,O
in,O
the,O
catabolite,O
repression,O
process,O
(,O
38,O
).,O
Indeed,O
",",O
a,O
csrA51,B-GP
mutant,O
strain,O
induced,O
cAMP,O
production,O
after,O
glucose,O
exhaustion,O
",",O
but,O
the,O
levels,O
were,O
about,O
five,O
times,O
lower,O
than,O
in,O
the,O
WT,O
(,O
Fig,O
.,O
5A,O
).,O
This,O
could,O
result,O
from,O
the,O
greater,O
availability,O
of,O
G6P,O
",",O
since,O
this,O
substrate,O
indirectly,O
controls,O
adenylate,B-GP
cyclase,I-GP
activity,O
(,O
39,O
).,O
However,O
",",O
the,O
csrA51,B-GP
ΔglgC,O
mutant,O
strain,O
presents,O
the,O
same,O
phenotype,O
",",O
proving,O
that,O
this,O
lower,O
cAMP,O
level,O
does,O
not,O
result,O
from,O
the,O
greater,O
glycogen,O
content,O
and,O
is,O
therefore,O
directly,O
linked,O
to,O
CsrA,B-GP
activity,O
.,O
CsrA,B-GP
could,O
thus,O
affect,O
important,O
metabolic,O
adaption,O
processes,O
",",O
such,O
as,O
catabolite,O
repression,O
",",O
independently,O
of,O
glycogen,O
content,O
.,O
This,O
reinforces,O
the,O
very,O
recently,O
discovered,O
link,O
between,O
Csr,B-GP
and,O
catabolite,O
repression,O
regulatory,O
systems,O
(,O
29,O
).,O
This,O
new,O
regulation,O
was,O
shown,O
to,O
be,O
related,O
to,O
the,O
control,O
of,O
the,O
expression,O
of,O
the,O
CsrB,B-GP
and,O
CsrC,B-GP
ncRNAs,O
via,O
the,O
main,O
catabolic,O
repression,O
actors,O
EIIAGluc,B-GP
and,O
cAMP,O
-,O
CRP,B-GP
.,O
There,O
could,O
be,O
another,O
clue,O
to,O
glycogen,O
-,O
independent,O
control,O
;,O
i,O
.,O
e,O
".,",O
if,O
glycogen,O
exhaustion,O
hinders,O
metabolic,O
adaptation,O
",",O
glycogen,O
overaccumulation,O
(,O
as,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
),O
should,O
favor,O
it,O
.,O
However,O
",",O
the,O
delay,O
before,O
the,O
beginning,O
of,O
acetate,O
anabolism,O
was,O
longer,O
in,O
the,O
csrA51,B-GP
mutant,O
strain,O
.,O
This,O
phenotype,O
is,O
very,O
likely,O
explained,O
by,O
the,O
fact,O
that,O
glycolysis,O
is,O
still,O
supplied,O
in,O
G6P,O
by,O
glycogen,O
after,O
glucose,O
exhaustion,O
in,O
the,O
csrA51,B-GP
mutant,O
and,O
this,O
could,O
impair,O
/,O
prevent,O
the,O
establishment,O
of,O
gluconeogenic,O
metabolism,O
.,O
Therefore,O
",",O
here,O
again,O
",",O
this,O
phenotype,O
is,O
linked,O
to,O
glycogen,O
accumulation,O
.,O
We,O
consequently,O
conclude,O
that,O
CsrA,B-GP
control,O
of,O
metabolic,O
adaptation,O
is,O
mediated,O
mainly,O
through,O
glycogen,O
accumulation,O
.,O
Given,O
its,O
structural,O
characteristics,O
and,O
its,O
metabolic,O
regulation,O
",",O
glycogen,O
was,O
hypothesized,O
to,O
be,O
a,O
storage,O
compound,O
providing,O
both,O
carbon,O
and,O
energy,O
for,O
microorganisms,O
(,O
40,O
).,O
However,O
",",O
no,O
demonstration,O
of,O
this,O
function,O
was,O
previously,O
reported,O
in,O
the,O
literature,O
(,O
41,O
–,O
43,O
).,O
Here,O
",",O
using,O
a,O
metabolomics,O
approach,O
",",O
we,O
proved,O
for,O
the,O
first,O
time,O
that,O
glycogen,O
is,O
essential,O
to,O
maintain,O
the,O
cell,O
energy,O
level,O
after,O
glucose,O
exhaustion,O
.,O
This,O
is,O
especially,O
important,O
since,O
it,O
was,O
postulated,O
that,O
to,O
classify,O
glycogen,O
as,O
an,O
energy,O
storage,O
compound,O
",",O
its,O
use,O
as,O
a,O
supply,O
for,O
energy,O
maintenance,O
had,O
to,O
be,O
demonstrated,O
(,O
40,O
).,O
With,O
this,O
work,O
",",O
this,O
is,O
now,O
the,O
case,O
.,O
Glycogen,O
metabolism,O
was,O
also,O
linked,O
to,O
environmental,O
survival,O
(,O
43,O
).,O
It,O
was,O
recently,O
hypothesized,O
and,O
backed,O
up,O
by,O
modeling,O
that,O
glycogen,O
is,O
an,O
energy,O
supply,O
for,O
immediate,O
use,O
in,O
the,O
following,O
growth,O
phase,O
of,O
E,B-OG
.,I-OG
coli,I-OG
(,O
42,O
).,O
Here,O
again,O
",",O
we,O
experimentally,O
demonstrated,O
the,O
validity,O
of,O
these,O
in,O
silico,O
-,O
based,O
conclusions,O
by,O
showing,O
that,O
metabolic,O
adaptation,O
of,O
cells,O
depends,O
on,O
glycogen,O
content,O
.,O
Thus,O
",",O
this,O
work,O
also,O
provides,O
significant,O
clues,O
to,O
the,O
function,O
of,O
glycogen,O
in,O
E,B-OG
.,I-OG
coli,I-OG
.,O
To,O
conclude,O
",",O
this,O
work,O
is,O
of,O
particular,O
importance,O
in,O
understanding,O
(,O
i,O
),O
the,O
function,O
of,O
CsrA,B-GP
-,O
mediated,O
posttranscriptional,O
control,O
",",O
(,O
ii,O
),O
the,O
role,O
of,O
glycogen,O
in,O
bacteria,B-OG
",",O
and,O
(,O
iii,O
),O
the,O
mechanisms,O
behind,O
metabolic,O
adaptation,O
and,O
fitness,O
.,O
This,O
knowledge,O
is,O
crucial,O
not,O
only,O
for,O
control,O
of,O
the,O
ability,O
of,O
E,B-OG
.,I-OG
coli,I-OG
to,O
efficiently,O
colonize,O
the,O
gut,O
or,O
other,O
microbial,O
communities,O
and,O
environments,O
but,O
also,O
for,O
the,O
optimization,O
of,O
biotechnological,O
processes,O
in,O
which,O
the,O
metabolic,O
flexibility,O
of,O
E,B-OG
.,I-OG
coli,I-OG
is,O
extensively,O
exploited,O
for,O
the,O
use,O
of,O
a,O
broad,O
range,O
of,O
substrates,O
.,O
MATERIALS,O
AND,O
METHODS,O
Strains,O
.,O
All,O
of,O
the,O
strains,O
used,O
in,O
this,O
study,O
came,O
from,O
E,B-OG
.,I-OG
coli,I-OG
K,I-OG
-,I-OG
12,I-OG
MG1655,I-OG
(,O
WT,O
).,O
The,O
csrA51,B-GP
mutant,O
strain,O
was,O
built,O
by,O
deleting,O
the,O
last,O
11,O
amino,O
acids,O
of,O
the,O
CsrA,B-GP
protein,O
by,O
λ,O
Red,O
system,O
recombination,O
(,O
17,O
",",O
32,O
).,O
The,O
csrD,B-GP
mutant,O
strain,O
was,O
constructed,O
by,O
completely,O
deleting,O
the,O
csrD,B-GP
gene,O
by,O
λ,O
Red,O
system,O
recombination,O
(,O
17,O
).,O
Likewise,O
",",O
the,O
csrBC,O
mutant,O
strain,O
was,O
constructed,O
by,O
completely,O
deleting,O
the,O
CsrB,B-GP
and,O
CsrC,B-GP
ncRNAs,O
by,O
λ,O
Red,O
system,O
recombination,O
.,O
The,O
ΔglgC,O
and,O
csrA51,B-GP
ΔglgC,O
mutants,O
were,O
obtained,O
from,O
the,O
JW3393,O
strain,O
(,O
Keio,O
collection,O
[,O
44,O
]),O
by,O
moving,O
the,O
mutation,O
(,O
ΔglgC,O
::,O
Kan,O
),O
to,O
the,O
WT,O
or,O
the,O
background,O
of,O
the,O
csrA51,B-GP
mutant,O
strain,O
by,O
bacteriophage,B-OG
P1,I-OG
-,O
mediated,O
transduction,O
.,O
Growth,O
conditions,O
.,O
Bioreactor,O
cultures,O
were,O
performed,O
with,O
a,O
volume,O
of,O
500,O
ml,O
of,O
M9,O
medium,O
complemented,O
with,O
2,O
.,O
7,O
g,O
⋅,O
liter,O
−,O
1,O
glucose,O
with,O
pH,O
and,O
oxygenation,O
controls,O
(,O
16,O
).,O
Three,O
biological,O
replicates,O
were,O
produced,O
per,O
strain,O
(,O
two,O
for,O
the,O
csrA51,B-GP
mutant,O
strain,O
).,O
The,O
optical,O
density,O
at,O
600,O
nm,O
(,O
OD600,O
),O
of,O
extra,O
-,O
and,O
intracellular,O
samples,O
was,O
measured,O
at,O
30,O
-,O
min,O
intervals,O
throughout,O
the,O
culture,O
period,O
.,O
Flask,O
cultures,O
were,O
performed,O
with,O
200,O
-,O
ml,O
baffled,O
Erlenmeyer,O
flasks,O
with,O
a,O
total,O
volume,O
of,O
50,O
ml,O
of,O
M9,O
medium,O
supplemented,O
with,O
2,O
.,O
7,O
g,O
⋅,O
liter,O
−,O
1,O
glucose,O
.,O
All,O
of,O
the,O
cultures,O
were,O
performed,O
at,O
37,O
°,O
C,O
.,O
Extracellular,O
and,O
intracellular,O
metabolites,O
.,O
The,O
extracellular,O
metabolites,O
were,O
identified,O
and,O
quantified,O
by,O
H,O
+,O
high,O
-,O
performance,O
liquid,O
chromatography,O
(,O
HPLC,O
),O
(,O
Agilent,O
Technologies,O
1200,O
Series,O
HPLC,O
and,O
an,O
Aminex,O
HPX,O
-,O
87h,O
column,O
to,O
separate,O
acid,O
and,O
sugar,O
).,O
The,O
analysis,O
was,O
carried,O
out,O
at,O
48,O
°,O
C,O
with,O
5,O
mM,O
H2SO4,O
as,O
the,O
eluent,O
.,O
Intracellular,O
metabolites,O
were,O
sampled,O
at,O
four,O
different,O
times,O
during,O
culture,O
by,O
the,O
differential,O
method,O
(,O
45,O
).,O
The,O
metabolic,O
intracellular,O
content,O
was,O
assessed,O
by,O
LC,O
-,O
MS,O
/,O
MS,O
as,O
previously,O
described,O
(,O
16,O
).,O
The,O
AEC,O
was,O
quantified,O
as,O
previously,O
described,O
(,O
35,O
).,O
Specific,O
growth,O
rates,O
and,O
consumption,O
and,O
production,O
rates,O
were,O
determined,O
as,O
previously,O
described,O
(,O
46,O
).,O
RT,O
-,O
PCR,O
analysis,O
.,O
Gene,O
expression,O
levels,O
were,O
analyzed,O
by,O
quantitative,O
PCR,O
(,O
EvaGreen,O
;,O
Biotium,O
",",O
CA,O
),O
on,O
a,O
Biomark,O
96,O
.,O
96,O
Dynamic,O
Array,O
(,O
Fluidigm,O
",",O
CA,O
),O
as,O
previously,O
described,O
(,O
16,O
).,O
Briefly,O
",",O
the,O
equivalent,O
of,O
5,O
mg,O
of,O
cell,O
dry,O
weight,O
was,O
harvested,O
and,O
directly,O
flash,O
frozen,O
in,O
liquid,O
nitrogen,O
at,O
the,O
same,O
time,O
as,O
the,O
intracellular,O
metabolites,O
.,O
RNA,O
extraction,O
and,O
RT,O
were,O
performed,O
as,O
previously,O
described,O
(,O
32,O
).,O
The,O
transcripts,O
levels,O
were,O
normalized,O
to,O
the,O
idnT,B-GP
reference,O
gene,O
used,O
as,O
a,O
constitutive,O
reference,O
(,O
47,O
).,O
Quantification,O
of,O
intracellular,O
glycogen,O
.,O
Intracellular,O
glycogen,O
was,O
quantified,O
as,O
previously,O
described,O
(,O
48,O
).,O
Briefly,O
",",O
cells,O
were,O
lysed,O
and,O
glycogen,O
was,O
hydrolyzed,O
into,O
glucose,O
subunits,O
by,O
an,O
amyloglucosidase,B-GP
.,O
The,O
glucose,O
subunits,O
were,O
then,O
quantified,O
with,O
the,O
Glucose,O
(,O
GO,O
),O
Assay,O
kit,O
(,O
Sigma,O
-,O
Aldrich,O
",",O
France,O
).,O
Flux,O
balance,O
analysis,O
.,O
The,O
genome,O
scale,O
model,O
and,O
constraints,O
used,O
in,O
this,O
study,O
were,O
previously,O
described,O
(,O
16,O
"),",O
except,O
for,O
the,O
lower,O
boundary,O
of,O
the,O
non,O
-,O
growth,O
-,O
associated,O
maintenance,O
flux,O
",",O
which,O
was,O
set,O
to,O
2,O
.,O
9,O
mmol,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
.,O
The,O
model,O
is,O
a,O
slightly,O
modified,O
version,O
of,O
the,O
genome,O
scale,O
reconstruction,O
iAF1260,O
-,O
flux2,O
(,O
36,O
).,O
Flux,O
balance,O
analyses,O
were,O
performed,O
with,O
the,O
COBRAv2,O
toolbox,O
with,O
GLPK,O
as,O
the,O
linear,O
programming,O
solver,O
(,O
49,O
).,O
The,O
glucose,O
uptake,O
rate,O
was,O
set,O
to,O
zero,O
",",O
while,O
the,O
oxygen,O
uptake,O
rate,O
was,O
set,O
to,O
a,O
limiting,O
value,O
of,O
−,O
15,O
mmol,O
⋅,O
gDW,O
−,O
1,O
⋅,O
h,O
−,O
1,O
to,O
allow,O
growth,O
on,O
acetate,O
.,O
The,O
acetate,O
and,O
glycogen,O
uptake,O
rates,O
were,O
varied,O
within,O
the,O
range,O
of,O
values,O
monitored,O
after,O
glucose,O
exhaustion,O
(,O
see,O
Fig,O
.,O
1,O
"),",O
and,O
for,O
each,O
pair,O
of,O
uptake,O
rates,O
",",O
either,O
the,O
biomass,O
or,O
the,O
ATP,O
flux,O
was,O
optimized,O
(,O
with,O
the,O
lower,O
boundary,O
of,O
the,O
maintenance,O
flux,O
set,O
to,O
zero,O
in,O
the,O
latter,O
case,O
).,O
Switch,O
experiments,O
.,O
To,O
investigate,O
the,O
timing,O
of,O
phenotypic,O
adaptation,O
",",O
cell,O
samples,O
were,O
collected,O
from,O
a,O
“,O
mother,O
”,O
culture,O
60,O
min,O
before,O
and,O
60,O
min,O
after,O
glucose,O
exhaustion,O
as,O
previously,O
described,O
(,O
31,O
).,O
Briefly,O
",",O
cell,O
samples,O
were,O
rapidly,O
filtered,O
",",O
rinsed,O
",",O
and,O
used,O
to,O
inoculate,O
250,O
-,O
ml,O
Erlenmeyer,O
flasks,O
filled,O
with,O
30,O
ml,O
of,O
acetate,O
medium,O
.,O
Growth,O
of,O
the,O
“,O
daughter,O
”,O
cultures,O
was,O
monitored,O
by,O
measuring,O
the,O
OD600,O
by,O
spectrophotometry,O
at,O
0,O
",",O
15,O
",",O
80,O
",",O
and,O
120,O
min,O
after,O
inoculation,O
.,O
We,O
made,O
sure,O
that,O
the,O
cells,O
from,O
the,O
daughter,O
cultures,O
reached,O
the,O
maximal,O
growth,O
rate,O
(,O
μmax,O
),O
by,O
measuring,O
the,O
growth,O
rate,O
between,O
80,O
and,O
120,O
min,O
.,O
The,O
lag,O
time,O
was,O
calculated,O
as,O
previously,O
described,O
(,O
31,O
).,O
Citation,O
Morin,O
M,O
",",O
Ropers,O
D,O
",",O
Cinquemani,O
E,O
",",O
Portais,O
J,O
",",O
Enjalbert,O
B,O
",",O
Cocaign,O
-,O
Bousquet,O
M,O
.,O
2017,O
.,O
The,O
Csr,B-GP
system,O
regulates,O
Escherichia,B-OG
coli,I-OG
fitness,O
by,O
controlling,O
glycogen,O
accumulation,O
and,O
energy,O
levels,O
.,O
mBio,O
8,O
:,O
e01628,O
-,O
17,O
.,O
https,O
://,O
doi,O
.,O
org,O
/,O
10,O
.,O
1128,O
/,O
mBio,O
.,O
01628,O
-,O
17,O
.,O
Identification,O
of,O
gene,O
expression,O
patterns,O
crucially,O
involved,O
in,O
experimental,B-DS
autoimmune,I-DS
encephalomyelitis,I-DS
and,O
multiple,B-DS
sclerosis,I-DS
ABSTRACT,O
After,O
encounter,O
with,O
a,O
central,O
nervous,O
system,O
(,O
CNS,O
)-,O
derived,O
autoantigen,O
",",O
lymphocytes,O
leave,O
the,O
lymph,O
nodes,O
and,O
enter,O
the,O
CNS,O
.,O
This,O
event,O
leads,O
only,O
rarely,O
to,O
subsequent,O
tissue,O
damage,O
.,O
Genes,O
relevant,O
to,O
CNS,O
pathology,O
after,O
cell,O
infiltration,O
are,O
largely,O
undefined,O
.,O
Myelin,B-GP
-,I-GP
oligodendrocyte,I-GP
-,I-GP
glycoprotein,I-GP
(,O
MOG,B-GP
)-,O
induced,O
experimental,B-DS
autoimmune,I-DS
encephalomyelitis,I-DS
(,O
EAE,B-DS
),O
is,O
an,O
animal,B-OG
model,O
of,O
multiple,B-DS
sclerosis,I-DS
(,O
MS,B-DS
"),",O
a,O
chronic,B-DS
autoimmune,I-DS
disease,I-DS
of,O
the,O
CNS,O
that,O
results,O
in,O
disability,O
.,O
To,O
assess,O
genes,O
that,O
are,O
involved,O
in,O
encephalitogenicity,O
and,O
subsequent,O
tissue,O
damage,O
mediated,O
by,O
CNS,O
-,O
infiltrating,O
cells,O
",",O
we,O
performed,O
a,O
DNA,O
microarray,O
analysis,O
from,O
cells,O
derived,O
from,O
lymph,O
nodes,O
and,O
eluted,O
from,O
CNS,O
in,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
MOG,B-GP
91,O
-,O
108,O
.,O
The,O
data,O
was,O
compared,O
to,O
immunizations,O
with,O
adjuvant,O
alone,O
or,O
naive,O
rats,B-OG
and,O
to,O
immunizations,O
with,O
the,O
immunogenic,O
but,O
not,O
encephalitogenic,O
MOG,B-GP
73,O
-,O
90,O
peptide,O
.,O
Here,O
",",O
we,O
show,O
involvement,O
of,O
Cd38,B-GP
",",O
Cxcr4,B-GP
and,O
Akt,B-GP
and,O
confirm,O
these,O
findings,O
by,O
the,O
use,O
of,O
Cd38,B-GP
-,O
knockout,O
(,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
),O
mice,B-OG
",",O
S1P,B-GP
-,I-GP
receptor,I-GP
modulation,O
during,O
EAE,B-DS
and,O
quantitative,O
expression,O
analysis,O
in,O
individuals,O
with,O
MS,B-DS
.,O
The,O
hereby,O
-,O
defined,O
underlying,O
pathways,O
indicate,O
cellular,O
activation,O
and,O
migration,O
pathways,O
mediated,O
by,O
G,B-GP
-,I-GP
protein,I-GP
-,I-GP
coupled,I-GP
receptors,I-GP
as,O
crucial,O
events,O
in,O
CNS,O
tissue,O
damage,O
.,O
These,O
pathways,O
can,O
be,O
further,O
explored,O
for,O
novel,O
therapeutic,O
interventions,O
.,O
Summary,O
:,O
To,O
define,O
disease,O
-,O
inducing,O
immune,O
responses,O
",",O
unbiased,O
gene,O
expression,O
in,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
autoantigen,O
-,O
derived,O
encephalitogenic,O
and,O
non,O
-,O
encephalitogenic,O
peptides,O
was,O
investigated,O
in,O
MOG,B-GP
-,O
EAE,B-DS
.,O
CXCR4,B-GP
",",O
CXCL12,B-GP
",",O
AKT,B-GP
and,O
CD38,B-GP
control,O
CNS,O
inflammation,O
.,O
INTRODUCTION,O
Multiple,B-DS
sclerosis,I-DS
(,O
MS,B-DS
),O
is,O
a,O
disease,O
of,O
the,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
that,O
leads,O
to,O
chronic,O
inflammation,O
",",O
demyelination,O
",",O
and,O
axonal,O
and,O
neuronal,O
loss,O
",",O
resulting,O
in,O
disability,O
(,O
Noseworthy,O
et,O
al,O
".,",O
2000,O
;,O
Weissert,O
",",O
2013,O
).,O
Myelin,B-GP
-,I-GP
oligodendrocyte,I-GP
-,I-GP
glycoprotein,I-GP
(,O
MOG,B-GP
)-,O
induced,O
experimental,B-DS
autoimmune,I-DS
encephalomyelitis,I-DS
(,O
EAE,B-DS
),O
in,O
rats,B-OG
reproduces,O
major,O
aspects,O
of,O
the,O
human,B-OG
pathology,O
(,O
Weissert,O
et,O
al,O
".,",O
1998b,O
;,O
Storch,O
et,O
al,O
".,",O
1998,O
;,O
Kornek,O
et,O
al,O
".,",O
2000,O
;,O
Weissert,O
",",O
2016,O
).,O
MOG,B-GP
is,O
expressed,O
on,O
the,O
outer,O
surface,O
of,O
the,O
myelin,O
sheath,O
.,O
In,O
contrast,O
to,O
merely,O
T,O
-,O
cell,O
-,O
mediated,O
animal,B-OG
models,O
",",O
the,O
pathogenesis,O
of,O
MOG,B-GP
-,O
induced,O
EAE,B-DS
in,O
the,O
rat,B-OG
involves,O
the,O
combined,O
action,O
of,O
T,O
and,O
B,O
cells,O
",",O
antibodies,B-GP
and,O
macrophages,O
",",O
mimicking,O
type,O
II,O
lesions,O
in,O
MS,B-DS
(,O
Genain,O
et,O
al,O
".,",O
1995,O
;,O
Mathey,O
et,O
al,O
".,",O
2004,O
;,O
Lucchinetti,O
et,O
al,O
".,",O
2000,O
).,O
Encephalitogenic,O
peptides,O
presented,O
on,O
MHC,B-GP
class,I-GP
II,I-GP
molecules,O
to,O
T,O
cells,O
lead,O
to,O
a,O
program,O
that,O
forces,O
lymphocytes,O
to,O
be,O
activated,O
and,O
migrate,O
towards,O
the,O
CNS,O
(,O
Riedhammer,O
and,O
Weissert,O
",",O
2015,O
).,O
Adjuvant,O
contributes,O
by,O
affecting,O
multiple,O
signaling,O
pathways,O
in,O
lymphocytes,O
as,O
well,O
as,O
in,O
organ,O
-,O
resident,O
cells,O
like,O
in,O
the,O
CNS,O
.,O
We,O
have,O
previously,O
demonstrated,O
that,O
MOG,B-GP
91,O
-,O
108,O
is,O
the,O
major,O
determinant,O
to,O
trigger,O
disease,O
in,O
rats,B-OG
expressing,O
RT1av1,O
or,O
RT1n,O
haplotypes,O
(,O
Weissert,O
et,O
al,O
".,",O
2001,O
).,O
Interestingly,O
",",O
the,O
capacity,O
of,O
MOG,B-GP
91,O
-,O
108,O
to,O
induce,O
EAE,B-DS
was,O
dissociated,O
in,O
regard,O
to,O
Th1,O
or,O
Th2,O
cytokine,B-GP
expression,O
in,O
lymphoid,O
tissue,O
compared,O
to,O
the,O
CNS,O
.,O
Moreover,O
",",O
different,O
MOG,B-GP
1,O
-,O
125,O
-,O
derived,O
peptides,O
",",O
such,O
as,O
MOG,B-GP
73,O
-,O
90,O
",",O
were,O
immunogenic,O
",",O
showing,O
strong,O
Th1,O
responses,O
",",O
but,O
were,O
not,O
encephalitogenic,O
.,O
The,O
induction,O
of,O
active,O
EAE,B-DS
in,O
LEW,O
MHC,B-GP
congenic,O
rat,B-OG
strains,O
and,O
Dark,O
Agouti,O
(,O
DA,O
),O
(,O
RT1av1,O
),O
rats,B-OG
does,O
not,O
require,O
the,O
application,O
of,O
pertussis,B-GP
toxin,I-GP
like,O
in,O
mice,B-OG
.,O
This,O
is,O
an,O
advantage,O
because,O
the,O
exact,O
role,O
of,O
pertussis,B-GP
toxin,I-GP
in,O
EAE,B-DS
induction,O
is,O
not,O
clear,O
so,O
far,O
.,O
Pertussis,B-GP
toxin,I-GP
inhibits,O
Gi,B-GP
proteins,I-GP
and,O
thereby,O
influences,O
multiple,O
cellular,O
processes,O
and,O
pathways,O
(,O
Dumas,O
et,O
al,O
".,",O
2014,O
).,O
Active,O
EAE,B-DS
in,O
susceptible,O
rat,B-OG
strains,O
is,O
induced,O
by,O
immunization,O
with,O
an,O
encephalitogenic,O
peptide,O
mixed,O
with,O
mineral,O
oil,O
[,O
incomplete,O
Freund,O
',O
s,O
adjuvant,O
(,O
IFA,O
)],O
with,O
the,O
addition,O
of,O
heat,O
-,O
inactivated,O
mycobacterium,B-OG
tuberculosis,I-OG
(,O
MT,B-OG
),O
as,O
adjuvant,O
[,O
complete,O
Freund,O
',O
s,O
adjuvant,O
(,O
CFA,O
)].,O
MT,B-OG
leads,O
by,O
binding,O
and,O
signaling,O
through,O
Toll,B-GP
-,I-GP
like,I-GP
receptors,I-GP
(,O
TLRs,B-GP
),O
to,O
an,O
activation,O
program,O
in,O
a,O
number,O
of,O
cell,O
types,O
and,O
is,O
also,O
a,O
systemic,O
‘,O
danger,O
signal,O
’,O
(,O
Mills,O
",",O
2011,O
).,O
In,O
regard,O
to,O
susceptibility,O
to,O
EAE,B-DS
and,O
MS,B-DS
",",O
gene,O
expression,O
profiling,O
studies,O
have,O
been,O
performed,O
to,O
elucidate,O
genes,O
that,O
are,O
involved,O
in,O
disease,O
pathogenesis,O
.,O
A,O
number,O
of,O
interesting,O
genes,O
were,O
described,O
",",O
such,O
as,O
osteopontin,B-GP
(,O
Hur,O
et,O
al,O
".,",O
2007,O
).,O
In,O
no,O
study,O
was,O
a,O
systematic,O
comparison,O
of,O
gene,O
expression,O
profiles,O
performed,O
in,O
EAE,B-DS
in,O
which,O
the,O
influence,O
of,O
adjuvant,O
and,O
antigen,O
was,O
systematically,O
compared,O
on,O
the,O
expression,O
profile,O
of,O
lymph,O
node,O
(,O
LN,O
)-,O
derived,O
cells,O
or,O
cells,O
eluted,O
from,O
CNS,O
of,O
diseased,O
animals,B-OG
.,O
In,O
the,O
present,O
study,O
",",O
we,O
systematically,O
compared,O
the,O
gene,O
expression,O
profiles,O
of,O
cells,O
from,O
draining,O
LNs,O
and,O
CNS,O
-,O
infiltrating,O
cells,O
that,O
were,O
eluted,O
in,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
MOG,B-GP
91,O
-,O
108,O
in,O
CFA,O
",",O
CFA,O
alone,O
and,O
in,O
naive,O
rats,B-OG
.,O
Moreover,O
",",O
we,O
compared,O
the,O
gene,O
expression,O
profile,O
of,O
rats,B-OG
immunized,O
with,O
the,O
encephalitogenic,O
MOG,B-GP
peptide,O
91,O
-,O
108,O
with,O
rats,B-OG
immunized,O
with,O
the,O
non,O
-,O
encephalitogenic,O
MOG,B-GP
peptide,O
73,O
-,O
90,O
.,O
We,O
found,O
differentially,O
expressed,O
genes,O
that,O
are,O
of,O
major,O
importance,O
for,O
encephalitogenicity,O
.,O
The,O
influence,O
of,O
these,O
genes,O
was,O
subsequently,O
verified,O
by,O
different,O
means,O
.,O
RESULTS,O
Gene,O
expression,O
after,O
immunization,O
with,O
encephalitogenic,O
and,O
non,O
-,O
encephalitogenic,O
peptides,O
One,O
of,O
the,O
important,O
issues,O
in,O
MS,B-DS
and,O
other,O
inflammatory,B-DS
diseases,I-DS
of,O
the,O
CNS,O
is,O
understanding,O
the,O
requisites,O
of,O
autoantigenic,O
peptides,O
to,O
induce,O
CNS,O
inflammation,O
(,O
Riedhammer,O
and,O
Weissert,O
",",O
2015,O
).,O
Beside,O
presentation,O
of,O
autoantigen,O
-,O
derived,O
peptides,O
on,O
MHC,B-GP
molecules,O
and,O
the,O
availability,O
of,O
reactive,O
T,O
-,O
cell,O
and,O
B,O
-,O
cell,O
repertoires,O
as,O
well,O
as,O
the,O
presence,O
of,O
the,O
target,O
antigen,O
in,O
the,O
CNS,O
",",O
pathways,O
of,O
cellular,O
activation,O
exist,O
that,O
allow,O
disease,O
development,O
.,O
These,O
pathways,O
are,O
presently,O
only,O
partly,O
elucidated,O
.,O
We,O
used,O
MOG,B-GP
-,O
induced,O
EAE,B-DS
in,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
as,O
a,O
model,O
system,O
for,O
CNS,O
inflammation,O
.,O
In,O
this,O
EAE,B-DS
model,O
",",O
the,O
determinant,O
MOG,B-GP
91,O
-,O
108,O
is,O
immunogenic,O
and,O
encephalitogenic,O
.,O
In,O
contrast,O
",",O
the,O
determinant,O
MOG,B-GP
73,O
-,O
90,O
is,O
immunogenic,O
but,O
not,O
encephalitogenic,O
.,O
We,O
assessed,O
the,O
gene,O
expression,O
profiles,O
by,O
gene,O
arrays,O
of,O
lymphocytes,O
from,O
draining,O
LNs,O
and,O
from,O
lymphocytes,O
eluted,O
from,O
the,O
CNS,O
.,O
To,O
focus,O
on,O
genes,O
that,O
are,O
truly,O
relevant,O
to,O
encephalitogenicity,O
and,O
not,O
simply,O
involved,O
in,O
general,O
inflammatory,O
responses,O
",",O
we,O
compared,O
gene,O
arrays,O
of,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
the,O
encephalitogenic,O
MOG,B-GP
stretch,O
MOG,B-GP
91,O
-,O
108,O
to,O
naive,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
and,O
rats,B-OG
immunized,O
with,O
the,O
adjuvant,O
CFA,O
alone,O
as,O
well,O
as,O
rats,B-OG
immunized,O
with,O
the,O
non,O
-,O
encephalitogenic,O
MOG,B-GP
73,O
-,O
90,O
determinant,O
.,O
We,O
analyzed,O
ten,O
comparisons,O
for,O
each,O
of,O
the,O
naive,O
and,O
CFA,O
groups,O
versus,O
MOG,B-GP
91,O
-,O
108,O
and,O
five,O
comparisons,O
for,O
MOG,B-GP
73,O
-,O
90,O
versus,O
MOG,B-GP
91,O
-,O
108,O
.,O
The,O
number,O
of,O
comparisons,O
in,O
which,O
a,O
given,O
gene,O
had,O
a,O
signal,O
log,O
ratio,O
(,O
SLR,O
),O
of,O
above,O
1,O
was,O
counted,O
.,O
In,O
Table,O
1,O
",",O
we,O
show,O
genes,O
that,O
are,O
upregulated,O
in,O
at,O
least,O
half,O
of,O
the,O
comparisons,O
(=,O
50,O
%).,O
Besides,O
Cxcr4,B-GP
and,O
Cd38,B-GP
",",O
which,O
were,O
subsequently,O
analyzed,O
in,O
greater,O
detail,O
",",O
many,O
genes,O
with,O
a,O
known,O
function,O
in,O
EAE,B-DS
and,O
MS,B-DS
pathology,O
were,O
found,O
to,O
have,O
an,O
increased,O
expression,O
in,O
MOG,B-GP
91,O
-,O
108,O
-,O
immunized,O
rats,B-OG
as,O
compared,O
to,O
controls,O
.,O
This,O
validates,O
our,O
gene,O
list,O
and,O
supports,O
the,O
relevance,O
of,O
the,O
genes,O
not,O
previously,O
described,O
in,O
EAE,B-DS
.,O
In,O
Table,O
S1,O
",",O
genes,O
with,O
decreased,O
expression,O
in,O
EAE,B-DS
are,O
listed,O
.,O
In,O
this,O
analysis,O
",",O
the,O
variability,O
between,O
gene,O
arrays,O
was,O
much,O
higher,O
and,O
fewer,O
genes,O
were,O
found,O
to,O
be,O
regulated,O
with,O
a,O
clear,O
pattern,O
according,O
to,O
our,O
criteria,O
.,O
Table,O
1,O
.,O
Genes,O
with,O
increased,O
expression,O
in,O
lymph,O
-,O
node,O
cells,O
of,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
Comparisons,O
of,O
microarrays,O
of,O
CNS,O
-,O
infiltrating,O
lymphocytes,O
derived,O
from,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
after,O
immunization,O
with,O
MOG,B-GP
91,O
-,O
108,O
",",O
MOG,B-GP
73,O
-,O
90,O
and,O
CFA,O
alone,O
resulted,O
in,O
many,O
more,O
genes,O
being,O
differentially,O
expressed,O
as,O
compared,O
to,O
the,O
analysis,O
of,O
LN,O
cells,O
(,O
Tables,O
S2,O
and,O
S3,O
).,O
This,O
could,O
mirror,O
the,O
influx,O
of,O
different,O
cell,O
populations,O
into,O
the,O
CNS,O
during,O
an,O
inflammatory,O
attack,O
.,O
Similar,O
to,O
the,O
analysis,O
of,O
LN,O
cells,O
",",O
we,O
found,O
that,O
Cd38,B-GP
and,O
Cxcr4,B-GP
mRNA,O
was,O
strongly,O
increased,O
in,O
CNS,O
-,O
infiltrating,O
cells,O
.,O
Subsequently,O
",",O
we,O
analyzed,O
purified,O
CD4,B-GP
+,O
cells,O
from,O
LNs,O
and,O
CNS,O
of,O
MOG,B-GP
91,O
-,O
108,O
-,O
and,O
MOG,B-GP
73,O
-,O
90,O
-,O
immunized,O
rats,B-OG
.,O
To,O
some,O
extent,O
",",O
similar,O
gene,O
expression,O
profiles,O
were,O
found,O
in,O
the,O
purified,O
CD4,B-GP
+,O
cell,O
population,O
compared,O
to,O
non,O
-,O
separated,O
LN,O
cells,O
(,O
Table,O
1,O
",",O
Tables,O
S4,O
and,O
S5,O
).,O
Owing,O
to,O
their,O
strong,O
expression,O
in,O
MOG,B-GP
91,O
-,O
108,O
-,O
immunized,O
rats,B-OG
compared,O
to,O
naive,O
",",O
CFA,O
-,O
immunized,O
and,O
MOG,B-GP
73,O
-,O
90,O
-,O
immunized,O
rats,B-OG
",",O
we,O
chose,O
Cxcr4,B-GP
and,O
Cd38,B-GP
for,O
further,O
analysis,O
.,O
Cxcr4,B-GP
and,O
Cd38,B-GP
in,O
EAE,B-DS
in,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
Confirming,O
our,O
microarray,O
results,O
by,O
quantitative,O
PCR,O
",",O
we,O
found,O
a,O
significant,O
upregulation,O
of,O
Cxcr4,B-GP
expression,O
in,O
LN,O
cells,O
of,O
MOG,B-GP
91,O
-,O
108,O
-,O
immunized,O
rats,B-OG
(,O
n,O
=,O
8,O
),O
as,O
compared,O
to,O
CFA,O
-,O
immunized,O
(,O
n,O
=,O
8,O
",",O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
and,O
naive,O
(,O
n,O
=,O
6,O
",",O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
0001,O
),O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
(,O
Fig,O
.,O
1A,O
).,O
Also,O
",",O
an,O
increased,O
expression,O
of,O
Cd38,B-GP
was,O
measured,O
[,O
MOG,B-GP
91,O
-,O
108,O
-,O
immunized,O
rats,B-OG
(,O
n,O
=,O
8,O
),O
as,O
compared,O
to,O
CFA,O
-,O
immunized,O
(,O
n,O
=,O
8,O
",",O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
and,O
naive,O
(,O
n,O
=,O
6,O
",",O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
].,O
Fig,O
.,O
1,O
.,O
Cxcr4,B-GP
and,O
Cd38,B-GP
expression,O
in,O
lymph,O
node,O
cells,O
and,O
CNS,O
.,O
(,O
A,O
),O
Quantitative,O
SYBR,O
green,O
real,O
-,O
time,O
PCR,O
was,O
performed,O
for,O
Cxcr4,B-GP
and,O
Cd38,B-GP
in,O
lymph,O
node,O
(,O
LN,O
),O
cells,O
from,O
naive,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
(,O
black,O
bars,O
",",O
n,O
=,O
6,O
"),",O
or,O
those,O
immunized,O
with,O
CFA,O
(,O
gray,O
bars,O
",",O
n,O
=,O
8,O
),O
or,O
MOG,B-GP
91,O
-,O
108,O
in,O
CFA,O
(,O
white,O
bars,O
",",O
n,O
=,O
8,O
"),",O
on,O
day,O
12,O
p,O
.,O
i,O
.,O
Increased,O
Cxcr4,B-GP
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
0001,O
),O
and,O
Cd38,B-GP
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
),O
expression,O
was,O
found,O
in,O
MOG,B-GP
91,O
-,O
108,O
in,O
CFA,O
-,O
immunized,O
rats,B-OG
compared,O
to,O
naive,O
and,O
CFA,O
-,O
alone,O
-,O
immunized,O
rats,B-OG
.,O
(,O
B,O
),O
Quantitative,O
expression,O
of,O
Cxcr4,B-GP
in,O
cells,O
eluted,O
from,O
the,O
CNS,O
of,O
CFA,O
(,O
white,O
bars,O
",",O
n,O
=,O
6,O
")-,",O
MOG,B-GP
73,O
-,O
90,O
in,O
CFA,O
(,O
gray,O
bars,O
",",O
n,O
=,O
6,O
)-,O
and,O
MOG,B-GP
91,O
-,O
108,O
in,O
CFA,O
(,O
n,O
=,O
6,O
)-,O
immunized,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
.,O
Cxcr4,B-GP
was,O
upregulated,O
in,O
MOG,B-GP
91,O
-,O
108,O
in,O
CFA,O
-,O
immunized,O
rats,B-OG
compared,O
to,O
the,O
other,O
groups,O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
001,O
),O
on,O
day,O
12,O
p,O
.,O
i,O
.,O
(,O
C,O
),O
Quantitative,O
expression,O
of,O
Cd38,B-GP
of,O
lymphocytes,O
eluted,O
from,O
the,O
CNS,O
of,O
CFA,O
(,O
white,O
bars,O
",",O
n,O
=,O
6,O
")-,",O
MOG,B-GP
73,O
-,O
90,O
in,O
CFA,O
(,O
gray,O
bars,O
",",O
n,O
=,O
6,O
)-,O
and,O
MOG,B-GP
91,O
-,O
108,O
in,O
CFA,O
(,O
n,O
=,O
6,O
)-,O
immunized,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
on,O
day,O
12,O
p,O
.,O
i,O
.,O
Cd38,B-GP
was,O
upregulated,O
in,O
MOG,B-GP
91,O
-,O
108,O
in,O
CFA,O
-,O
immunized,O
rats,B-OG
compared,O
to,O
the,O
other,O
groups,O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
001,O
).,O
Results,O
are,O
expressed,O
as,O
2,O
−,O
ΔΔ,O
CT,O
values,O
.,O
Numbers,O
are,O
mean,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
In,O
cells,O
eluted,O
from,O
the,O
CNS,O
",",O
we,O
found,O
upregulation,O
of,O
Cxcr4,B-GP
(,O
Fig,O
.,O
1B,O
),O
and,O
Cd38,B-GP
(,O
Fig,O
.,O
1C,O
),O
in,O
MOG,B-GP
91,O
-,O
108,O
-,O
immunized,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
(,O
n,O
=,O
6,O
),O
compared,O
to,O
rats,B-OG
immunized,O
with,O
MOG,B-GP
73,O
-,O
90,O
(,O
n,O
=,O
6,O
",",O
ANOVA,O
",",O
Cxcr4,B-GP
and,O
Cd38,B-GP
each,O
P,O
<,O
0,O
.,O
001,O
),O
or,O
CFA,O
alone,O
(,O
n,O
=,O
6,O
",",O
ANOVA,O
",",O
Cxcr4,B-GP
and,O
Cd38,B-GP
each,O
P,O
<,O
0,O
.,O
001,O
).,O
Cxcr4,B-GP
and,O
Cxcl12,B-GP
expression,O
in,O
spinal,O
cord,O
of,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
Next,O
",",O
we,O
assessed,O
the,O
mRNA,O
expression,O
of,O
Cxcr4,B-GP
(,O
Fig,O
.,O
2A,O
),O
and,O
its,O
ligand,O
Cxcl12,B-GP
(,O
Fig,O
.,O
2B,O
),O
in,O
spinal,O
cord,O
of,O
either,O
naive,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
or,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
IFA,O
or,O
CFA,O
alone,O
or,O
MOG,B-GP
1,O
-,O
125,O
in,O
IFA,O
or,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
(,O
each,O
n,O
=,O
4,O
).,O
Upregulation,O
of,O
both,O
Cxcl12,B-GP
and,O
Cxcr4,B-GP
mRNA,O
expression,O
was,O
observed,O
in,O
CFA,O
-,O
and,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
-,O
immunized,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
in,O
spinal,O
cord,O
compared,O
to,O
naive,O
rats,B-OG
",",O
IFA,O
-,O
injected,O
or,O
MOG,B-GP
1,O
-,O
125,O
in,O
IFA,O
-,O
immunized,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
001,O
).,O
Increased,O
Cxcl12,B-GP
and,O
Cxcr4,B-GP
mRNA,O
expression,O
was,O
observed,O
in,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
-,O
compared,O
to,O
CFA,O
-,O
immunized,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
01,O
).,O
Fig,O
.,O
2,O
.,O
Cxr4,B-GP
and,O
Cxcl12,B-GP
expression,O
in,O
spinal,O
cord,O
of,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
.,O
Quantitative,O
SYBR,O
green,O
real,O
-,O
time,O
PCR,O
was,O
performed,O
for,O
Cxcr4,B-GP
(,O
A,O
),O
and,O
Cxcl12,B-GP
(,O
B,O
),O
from,O
PBS,O
-,O
perfused,O
spinal,O
cord,O
tissue,O
of,O
naive,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
(,O
n,O
=,O
4,O
"),",O
rats,B-OG
immunized,O
with,O
IFA,O
(,O
n,O
=,O
4,O
),O
or,O
CFA,O
alone,O
(,O
n,O
=,O
4,O
),O
and,O
DA,O
rats,B-OG
immunized,O
with,O
MOG,B-GP
1,O
-,O
125,O
in,O
IFA,O
(,O
n,O
=,O
4,O
),O
or,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
(,O
n,O
=,O
4,O
),O
on,O
day,O
12,O
p,O
.,O
i,O
.,O
Increased,O
Cxcr4,B-GP
and,O
Cxcl12,B-GP
expression,O
was,O
observed,O
in,O
spinal,O
cord,O
of,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
CFA,O
and,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
001,O
).,O
There,O
was,O
an,O
upregulation,O
of,O
Cxcr4,B-GP
and,O
Cxcl12,B-GP
mRNA,O
in,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
compared,O
to,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
immunized,O
with,O
CFA,O
alone,O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
01,O
).,O
Quantitative,O
PCR,O
results,O
are,O
expressed,O
as,O
2,O
−,O
ΔΔCT,O
values,O
.,O
Numbers,O
are,O
mean,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
Cxcr4,B-GP
and,O
CXCL12,B-GP
in,O
individuals,O
with,O
MS,B-DS
Upregulation,O
of,O
CXCR4,B-GP
mRNA,O
was,O
also,O
observed,O
in,O
white,O
blood,O
cells,O
of,O
individuals,O
with,O
MS,B-DS
with,O
a,O
relapsing,O
-,O
remitting,O
disease,O
course,O
(,O
RRMS,O
;,O
n,O
=,O
32,O
),O
and,O
a,O
secondary,O
chronic,B-DS
progressive,I-DS
disease,I-DS
course,O
(,O
SPMS,O
;,O
n,O
=,O
22,O
"),",O
and,O
compared,O
to,O
controls,O
(,O
n,O
=,O
25,O
",",O
ANOVA,O
",",O
RRMS,O
and,O
SPMS,O
each,O
P,O
<,O
0,O
.,O
05,O
),O
(,O
Fig,O
.,O
3A,O
",",O
Tables,O
S6,O
and,O
S7,O
).,O
Also,O
",",O
we,O
detected,O
increased,O
protein,O
CXCL12,B-GP
serum,O
levels,O
in,O
both,O
individuals,O
with,O
RRMS,O
(,O
n,O
=,O
24,O
),O
and,O
SPMS,O
(,O
n,O
=,O
28,O
),O
compared,O
to,O
controls,O
(,O
n,O
=,O
21,O
",",O
ANOVA,O
",",O
RRMS,O
and,O
SPMS,O
each,O
P,O
<,O
0,O
.,O
05,O
),O
(,O
Fig,O
.,O
3B,O
",",O
Tables,O
S6,O
and,O
S7,O
).,O
Fig,O
.,O
3,O
.,O
Cxcr4,B-GP
expression,O
in,O
white,O
blood,O
cells,O
and,O
CXCL12,B-GP
protein,O
in,O
serum,O
of,O
individuals,O
with,O
MS,B-DS
.,O
(,O
A,O
),O
Cxcr4,B-GP
mRNA,O
was,O
quantified,O
by,O
real,O
-,O
time,O
PCR,O
from,O
white,O
blood,O
cells,O
of,O
individuals,O
with,O
relapsing,B-DS
-,I-DS
remitting,I-DS
MS,I-DS
(,O
RR,B-DS
-,I-DS
MS,I-DS
;,O
gray,O
bars,O
",",O
n,O
=,O
32,O
"),",O
secondary,B-DS
chronic,I-DS
-,I-DS
progressive,I-DS
MS,I-DS
(,O
SP,B-DS
-,I-DS
MS,I-DS
;,O
black,O
bars,O
",",O
n,O
=,O
22,O
),O
and,O
controls,O
(,O
white,O
bars,O
",",O
n,O
=,O
25,O
).,O
Upregulation,O
of,O
Cxcr4,B-GP
in,O
both,O
patient,O
groups,O
compared,O
to,O
controls,O
was,O
observed,O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
).,O
(,O
B,O
),O
CXCL12,B-GP
serum,O
levels,O
were,O
assessed,O
by,O
ELISA,O
in,O
individuals,O
with,O
RR,B-DS
-,I-DS
MS,I-DS
(,O
gray,O
bars,O
",",O
n,O
=,O
24,O
"),",O
SP,B-DS
-,I-DS
MS,I-DS
(,O
black,O
bars,O
",",O
n,O
=,O
28,O
),O
and,O
controls,O
(,O
white,O
bars,O
",",O
n,O
=,O
21,O
).,O
Increased,O
serum,O
levels,O
of,O
CXCL12,B-GP
were,O
measured,O
in,O
both,O
MS,B-DS
groups,O
compared,O
to,O
controls,O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
).,O
Quantitative,O
PCR,O
results,O
are,O
expressed,O
as,O
2,O
−,O
ΔΔCT,O
values,O
.,O
Numbers,O
are,O
mean,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
EAE,B-DS
in,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
Cd38,B-GP
was,O
strongly,O
upregulated,O
in,O
encephalitogenic,O
LN,O
cells,O
.,O
To,O
functionally,O
validate,O
our,O
data,O
and,O
to,O
elucidate,O
the,O
role,O
of,O
CD38,B-GP
in,O
EAE,B-DS
",",O
we,O
induced,O
disease,O
with,O
the,O
extracellular,O
domain,O
of,O
MOG,B-GP
(,O
MOG,B-GP
1,O
-,O
125,O
),O
in,O
Cd38,B-GP
-,O
knockout,O
(,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
),O
mice,B-OG
and,O
appropriate,O
controls,O
.,O
We,O
found,O
reduced,O
disease,O
severity,O
in,O
MOG,B-GP
1,O
-,O
125,O
-,O
immunized,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
(,O
n,O
=,O
22,O
),O
compared,O
to,O
wild,O
-,O
type,O
control,O
mice,B-OG
(,O
n,O
=,O
21,O
",",O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
P,O
<,O
0,O
.,O
01,O
),O
(,O
Fig,O
.,O
4A,O
).,O
Next,O
",",O
we,O
determined,O
the,O
height,O
of,O
the,O
antibody,B-GP
response,O
to,O
MOG,B-GP
1,O
-,O
125,O
.,O
Reduced,O
anti,O
-,O
MOG,B-GP
IgG,B-GP
autoantibody,B-GP
responses,O
in,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
(,O
n,O
=,O
4,O
),O
compared,O
to,O
wild,O
-,O
type,O
control,O
mice,B-OG
(,O
n,O
=,O
4,O
",",O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
after,O
immunization,O
with,O
MOG,B-GP
1,O
-,O
125,O
were,O
seen,O
(,O
Fig,O
.,O
4B,O
),O
on,O
day,O
12,O
post,O
-,O
immunization,O
(,O
p,O
.,O
i,O
.).,O
Furthermore,O
",",O
also,O
T,O
-,O
cell,O
responses,O
upon,O
restimulation,O
with,O
MOG,B-GP
1,O
-,O
125,O
were,O
reduced,O
in,O
the,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
(,O
n,O
=,O
4,O
),O
on,O
day,O
12,O
p,O
.,O
i,O
.,O
compared,O
to,O
control,O
mice,B-OG
(,O
n,O
=,O
4,O
",",O
t,O
-,O
test,O
for,O
stimulation,O
with,O
50,O
µg,O
/,O
ml,O
MOG,B-GP
1,O
-,O
125,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
as,O
measured,O
in,O
a,O
proliferation,O
assay,O
",",O
indicating,O
in,O
addition,O
a,O
T,O
-,O
cell,O
priming,O
or,O
expansion,O
defect,O
in,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
(,O
Fig,O
.,O
4C,O
).,O
Fig,O
.,O
4,O
.,O
EAE,B-DS
in,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
.,O
(,O
A,O
),O
EAE,B-DS
was,O
induced,O
in,O
female,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
(,O
white,O
triangles,O
),O
and,O
C57BL,O
/,O
6J,O
000664,O
controls,O
(,O
black,O
triangles,O
),O
with,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
.,O
On,O
days,O
0,O
and,O
2,O
p,O
.,O
i,O
".,",O
mice,B-OG
received,O
an,O
intravenous,O
injection,O
of,O
150,O
ng,O
pertussis,B-GP
toxin,I-GP
.,O
EAE,B-DS
was,O
scored,O
as,O
follows,O
:,O
0,O
",",O
no,O
disease,O
;,O
1,O
",",O
tail,O
paralysis,O
;,O
2,O
",",O
paraparesis,O
;,O
3,O
",",O
paraplegia,B-DS
;,O
4,O
",",O
tetraparalysis,O
;,O
5,O
",",O
moribund,O
or,O
dead,O
.,O
Immunization,O
with,O
the,O
extracellular,O
domain,O
of,O
MOG,B-GP
1,O
-,O
125,O
resulted,O
in,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
(,O
n,O
=,O
22,O
),O
with,O
lower,O
disease,O
severity,O
compared,O
to,O
C57BL,B-OG
/,I-OG
6J,I-OG
000664,I-OG
mice,I-OG
(,O
n,O
=,O
21,O
),O
(,O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
",",O
P,O
=,O
0,O
.,O
01,O
).,O
(,O
B,O
),O
Antibodies,B-GP
against,O
MOG,B-GP
1,O
-,O
125,O
were,O
measured,O
by,O
ELISA,O
as,O
described,O
(,O
Weissert,O
et,O
al,O
".,",O
2001,O
).,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
(,O
white,O
bars,O
",",O
n,O
=,O
4,O
),O
had,O
reduced,O
IgG,B-GP
and,O
IgG1,B-GP
antibodies,B-GP
compared,O
to,O
C57BL,O
/,O
6J,O
000664,O
mice,B-OG
(,O
black,O
bars,O
",",O
n,O
=,O
4,O
),O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
),O
on,O
day,O
12,O
p,O
.,O
i,O
.,O
(,O
C,O
),O
T,O
-,O
cell,O
responses,O
upon,O
restimulation,O
against,O
MOG,B-GP
1,O
-,O
125,O
from,O
draining,O
lymph,O
nodes,O
(,O
LNs,O
),O
on,O
day,O
12,O
p,O
.,O
i,O
.,O
were,O
reduced,O
in,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
(,O
white,O
triangles,O
",",O
n,O
=,O
4,O
),O
compared,O
to,O
C57BL,O
/,O
6J,O
000664,O
(,O
black,O
triangles,O
",",O
n,O
=,O
4,O
),O
mice,B-OG
(,O
t,O
-,O
test,O
for,O
stimulation,O
with,O
50,O
µg,O
/,O
ml,O
MOG,B-GP
1,O
-,O
125,O
",",O
*,O
P,O
=,O
0,O
.,O
05,O
).,O
Numbers,O
are,O
mean,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
Targeting,O
cellular,O
migration,O
by,O
FTY720,O
We,O
found,O
an,O
upregulation,O
of,O
Akt,B-GP
in,O
our,O
differential,O
gene,O
expression,O
studies,O
(,O
Table,O
1,O
).,O
FTY720,O
is,O
an,O
S1P,B-GP
-,I-GP
receptor,I-GP
modulator,O
known,O
to,O
influence,O
T,O
-,O
cell,O
trafficking,O
by,O
an,O
Akt,B-GP
-,O
dependent,O
mechanism,O
",",O
as,O
does,O
CXCR4,B-GP
(,O
Mandala,O
et,O
al,O
".,",O
2002,O
;,O
Cyster,O
",",O
2005,O
;,O
Lee,O
et,O
al,O
".,",O
2001,O
;,O
Brinkmann,O
et,O
al,O
".,",O
2002,O
;,O
Matloubian,O
et,O
al,O
".,",O
2004,O
).,O
We,O
evaluated,O
inhibition,O
of,O
Akt,B-GP
-,O
dependent,O
cell,O
trafficking,O
in,O
MOG,B-GP
91,O
-,O
108,O
-,O
immunized,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
.,O
Disease,O
was,O
completely,O
inhibited,O
in,O
rats,B-OG
treated,O
from,O
day,O
0,O
p,O
.,O
i,O
.,O
with,O
FTY720,O
(,O
n,O
=,O
10,O
),O
as,O
compared,O
to,O
the,O
vehicle,O
-,O
treated,O
controls,O
(,O
n,O
=,O
10,O
",",O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
P,O
<,O
0,O
.,O
0001,O
),O
(,O
Fig,O
.,O
5A,O
).,O
Next,O
",",O
we,O
tested,O
the,O
efficacy,O
of,O
FTY720,O
to,O
treat,O
established,O
relapsing,O
-,O
remitting,O
MOG,B-GP
1,O
-,O
125,O
-,O
induced,O
EAE,B-DS
in,O
the,O
DA,O
(,O
RT1av1,O
),O
rat,B-OG
.,O
FTY720,O
treatment,O
was,O
started,O
on,O
day,O
21,O
p,O
.,O
i,O
".,",O
after,O
the,O
first,O
bout,O
of,O
disease,O
(,O
n,O
=,O
8,O
"),",O
and,O
showed,O
a,O
significant,O
effect,O
on,O
the,O
disease,O
course,O
as,O
compared,O
to,O
vehicle,O
treatment,O
(,O
n,O
=,O
8,O
",",O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
day,O
21,O
-,O
44,O
p,O
.,O
i,O
".,",O
P,O
<,O
0,O
.,O
01,O
),O
(,O
Fig,O
.,O
5B,O
).,O
To,O
further,O
examine,O
the,O
beneficial,O
effect,O
of,O
FTY720,O
treatment,O
on,O
EAE,B-DS
",",O
we,O
boosted,O
the,O
rats,B-OG
with,O
MOG,B-GP
1,O
-,O
125,O
on,O
day,O
44,O
after,O
the,O
first,O
immunization,O
.,O
Although,O
a,O
relapse,O
was,O
induced,O
in,O
both,O
groups,O
",",O
the,O
DA,O
rats,B-OG
under,O
FTY720,O
treatment,O
had,O
a,O
better,O
clinical,O
outcome,O
compared,O
to,O
the,O
vehicle,O
-,O
treated,O
animals,B-OG
(,O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
day,O
45,O
-,O
56,O
p,O
.,O
i,O
".,",O
P,O
<,O
0,O
.,O
0001,O
).,O
On,O
day,O
14,O
p,O
.,O
i,O
".,",O
FTY720,O
treatment,O
led,O
to,O
an,O
increase,O
of,O
the,O
relative,O
size,O
of,O
the,O
CD4,B-GP
T,O
-,O
cell,O
compartment,O
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
01,O
),O
in,O
the,O
treated,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
(,O
n,O
=,O
10,O
),O
compared,O
to,O
controls,O
(,O
n,O
=,O
9,O
),O
concurrent,O
with,O
a,O
decrease,O
in,O
the,O
CD8,B-GP
T,O
-,O
cell,O
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
01,O
),O
and,O
the,O
B,O
-,O
cell,O
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
01,O
),O
compartment,O
(,O
Fig,O
.,O
5C,O
;,O
Fig,O
.,O
S1,O
).,O
FTY720,O
treatment,O
(,O
n,O
=,O
9,O
),O
compared,O
to,O
controls,O
(,O
n,O
=,O
9,O
),O
led,O
to,O
the,O
downregulation,O
of,O
mRNA,O
expression,O
of,O
its,O
receptor,O
",",O
S1p1,B-GP
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
0001,O
"),",O
and,O
of,O
Akt2,B-GP
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
0001,O
"),",O
one,O
of,O
the,O
genes,O
involved,O
in,O
the,O
intracellular,O
signaling,O
cascade,O
connected,O
to,O
S1P1,B-GP
and,O
CXCR4,B-GP
",",O
on,O
day,O
14,O
p,O
.,O
i,O
.,O
Treatment,O
also,O
had,O
a,O
negative,O
effect,O
on,O
the,O
expression,O
levels,O
of,O
Cd38,B-GP
(,O
ANOVA,O
",",O
P,O
<,O
0,O
.,O
0001,O
).,O
In,O
contrast,O
",",O
the,O
expression,O
of,O
Cxcr4,B-GP
was,O
not,O
altered,O
(,O
ANOVA,O
",",O
not,O
significant,O
),O
(,O
Fig,O
.,O
5D,O
).,O
Fig,O
.,O
5,O
.,O
Influence,O
of,O
FTY720,O
in,O
EAE,B-DS
.,O
(,O
A,O
),O
Female,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
were,O
immunized,O
with,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
.,O
EAE,B-DS
was,O
scored,O
as,O
follows,O
:,O
0,O
",",O
no,O
disease,O
;,O
1,O
",",O
tail,O
paralysis,O
;,O
2,O
",",O
paraparesis,O
;,O
3,O
",",O
paraplegia,B-DS
;,O
4,O
",",O
tetraparalysis,O
;,O
5,O
",",O
moribund,O
or,O
dead,O
.,O
FTY720,O
completely,O
inhibited,O
EAE,B-DS
in,O
rats,B-OG
treated,O
orally,O
with,O
0,O
.,O
4,O
mg,O
/,O
kg,O
body,O
weight,O
from,O
day,O
0,O
p,O
.,O
i,O
.,O
daily,O
(,O
white,O
triangles,O
",",O
n,O
=,O
10,O
),O
as,O
compared,O
to,O
vehicle,O
(,O
PBS,O
)-,O
treated,O
controls,O
(,O
black,O
triangles,O
",",O
n,O
=,O
10,O
),O
(,O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
",",O
P,O
<,O
0,O
.,O
0001,O
).,O
(,O
B,O
),O
Female,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
treated,O
orally,O
with,O
0,O
.,O
4,O
mg,O
/,O
kg,O
body,O
weight,O
FTY720,O
daily,O
starting,O
on,O
day,O
21,O
p,O
.,O
i,O
.,O
after,O
a,O
first,O
bout,O
of,O
disease,O
(,O
white,O
triangles,O
",",O
n,O
=,O
8,O
),O
showed,O
a,O
reduced,O
disease,O
course,O
compared,O
to,O
vehicle,O
(,O
PBS,O
)-,O
treated,O
controls,O
(,O
black,O
triangles,O
",",O
n,O
=,O
8,O
),O
(,O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
day,O
21,O
-,O
44,O
p,O
.,O
i,O
".,",O
P,O
=,O
0,O
.,O
01,O
).,O
On,O
day,O
44,O
p,O
.,O
i,O
".,",O
rats,B-OG
were,O
boosted,O
with,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
.,O
Both,O
groups,O
relapsed,O
but,O
with,O
a,O
better,O
outcome,O
for,O
the,O
FTY720,O
-,O
treated,O
group,O
(,O
t,O
-,O
test,O
",",O
cumulative,O
disease,O
score,O
day,O
45,O
-,O
56,O
p,O
.,O
i,O
".,",O
P,O
<,O
0,O
.,O
0001,O
).,O
(,O
C,O
),O
FACS,O
analysis,O
of,O
cells,O
from,O
draining,O
lymph,O
nodes,O
(,O
LNs,O
),O
demonstrated,O
an,O
increase,O
in,O
relative,O
size,O
of,O
the,O
CD4,B-GP
T,O
-,O
cell,O
compartment,O
and,O
a,O
decrease,O
in,O
the,O
size,O
of,O
the,O
CD8,B-GP
and,O
B,O
-,O
cell,O
compartment,O
in,O
FTY720,O
-,O
treated,O
(,O
white,O
bars,O
",",O
n,O
=,O
10,O
),O
rats,B-OG
compared,O
to,O
controls,O
(,O
black,O
bars,O
",",O
n,O
=,O
9,O
),O
(,O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
01,O
),O
on,O
day,O
14,O
p,O
.,O
i,O
.,O
(,O
D,O
),O
Expression,O
of,O
S1p1,B-GP
(,O
Edg1,B-GP
"),",O
Akt2,B-GP
",",O
Cxcr4,B-GP
and,O
Cd38,B-GP
was,O
assessed,O
in,O
FTY720,O
-,O
treated,O
rats,B-OG
(,O
white,O
bars,O
",",O
n,O
=,O
9,O
),O
compared,O
to,O
vehicle,O
-,O
treated,O
controls,O
(,O
black,O
bars,O
",",O
n,O
=,O
9,O
),O
by,O
quantitative,O
PCR,O
.,O
FTY720,O
treatment,O
led,O
to,O
downregulation,O
of,O
S1p1,B-GP
and,O
Akt2,B-GP
as,O
well,O
as,O
Cd38,B-GP
",",O
but,O
not,O
of,O
Cxcr4,B-GP
(,O
ANOVA,O
for,O
all,O
except,O
Cxcr4,B-GP
",",O
*,O
P,O
<,O
0,O
.,O
0001,O
),O
on,O
day,O
14,O
p,O
.,O
i,O
.,O
from,O
cells,O
derived,O
from,O
LNs,O
.,O
Results,O
are,O
expressed,O
as,O
2,O
−,O
ΔΔCT,O
values,O
.,O
Numbers,O
are,O
mean,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
DISCUSSION,O
In,O
this,O
study,O
we,O
identified,O
gene,O
networks,O
that,O
are,O
crucially,O
involved,O
not,O
only,O
in,O
raising,O
an,O
autoantigen,O
-,O
specific,O
immune,O
response,O
but,O
also,O
in,O
constituting,O
encephalitogenicity,O
.,O
We,O
analyzed,O
the,O
expression,O
and,O
functional,O
relevance,O
of,O
genes,O
and,O
their,O
products,O
expressed,O
on,O
lymphocytes,O
after,O
immunization,O
with,O
the,O
encephalitogenic,O
MOG,B-GP
91,O
-,O
108,O
peptide,O
in,O
adjuvant,O
",",O
the,O
non,O
-,O
encephalitogenic,O
MOG,B-GP
73,O
-,O
90,O
peptide,O
in,O
adjuvant,O
",",O
adjuvant,O
alone,O
or,O
naive,O
rats,B-OG
.,O
Most,O
interestingly,O
",",O
in,O
the,O
comparison,O
of,O
MOG,B-GP
91,O
-,O
108,O
in,O
adjuvant,O
to,O
MOG,B-GP
73,O
-,O
90,O
in,O
adjuvant,O
immunized,O
rats,B-OG
",",O
compared,O
to,O
the,O
other,O
analyses,O
",",O
only,O
a,O
small,O
number,O
of,O
genes,O
were,O
differentially,O
expressed,O
.,O
These,O
genes,O
seem,O
to,O
be,O
of,O
major,O
importance,O
because,O
they,O
are,O
genes,O
involved,O
in,O
the,O
encephalitogenic,O
response,O
leading,O
to,O
disease,O
manifestation,O
.,O
From,O
the,O
overall,O
expression,O
data,O
",",O
we,O
selected,O
three,O
genes,O
that,O
were,O
upregulated,O
in,O
many,O
comparisons,O
:,O
Cxcr4,B-GP
",",O
Cd38,B-GP
and,O
Akt,B-GP
.,O
We,O
performed,O
functional,O
studies,O
regarding,O
these,O
genes,O
in,O
EAE,B-DS
and,O
analyzed,O
tissue,O
samples,O
from,O
individuals,O
with,O
MS,B-DS
.,O
CXCR4,B-GP
(,O
CD184,B-GP
),O
is,O
a,O
seven,B-GP
-,I-GP
transmembrane,I-GP
G,I-GP
-,I-GP
coupled,I-GP
receptor,I-GP
expressed,O
by,O
a,O
number,O
of,O
tissues,O
",",O
including,O
cells,O
of,O
the,O
immune,O
system,O
(,O
Campbell,O
et,O
al,O
".,",O
2003,O
).,O
Cxcr4,B-GP
-,O
knockout,O
mice,B-OG
die,O
in,O
utero,O
or,O
perinatally,O
and,O
do,O
not,O
only,O
have,O
defects,O
in,O
the,O
hematopoietic,O
system,O
(,O
impairment,O
of,O
myeloid,O
and,O
B,O
-,O
cell,O
generation,O
",",O
reduced,O
proliferation,O
of,O
triple,O
-,O
negative,O
and,O
double,O
-,O
positive,O
lymphocytes,O
"),",O
but,O
also,O
in,O
the,O
circulatory,O
system,O
and,O
in,O
the,O
CNS,O
(,O
Zou,O
et,O
al,O
".,",O
1998,O
;,O
Tachibana,O
et,O
al,O
".,",O
1998,O
).,O
Overexpression,O
of,O
CXCR4,B-GP
on,O
T,O
cells,O
induces,O
their,O
accumulation,O
in,O
the,O
bone,O
marrow,O
and,O
reduction,O
of,O
these,O
cells,O
in,O
the,O
peripheral,O
blood,O
.,O
CXCR4,B-GP
signaling,O
leads,O
to,O
a,O
prolonged,O
protein,B-GP
kinase,I-GP
B,I-GP
(,O
AKT,B-GP
),O
and,O
extracellular,B-GP
signal,I-GP
-,I-GP
regulated,I-GP
kinase,I-GP
2,I-GP
activation,O
in,O
T,O
cells,O
.,O
AKT,B-GP
activation,O
promotes,O
cell,O
survival,O
and,O
can,O
act,O
as,O
a,O
co,O
-,O
stimulation,O
for,O
T,O
-,O
cell,O
activation,O
(,O
Tilton,O
et,O
al,O
".,",O
2000,O
).,O
CXCR4,B-GP
has,O
only,O
one,O
known,O
cognate,O
ligand,O
",",O
which,O
is,O
CXCL12,B-GP
.,O
CXCL12,B-GP
is,O
constitutively,O
produced,O
by,O
stromal,O
and,O
endothelial,O
cells,O
.,O
CXCL12,B-GP
activates,O
numerous,O
signaling,O
pathways,O
",",O
such,O
as,O
receptor,O
-,O
associated,O
trimeric,O
G,B-GP
proteins,I-GP
",",O
phospholipase,B-GP
Cγ,I-GP
",",O
PI3K,B-GP
and,O
small,B-GP
G,I-GP
proteins,I-GP
(,O
Pawig,O
et,O
al,O
".,",O
2015,O
).,O
Signaling,O
through,O
these,O
receptors,O
leads,O
to,O
an,O
increase,O
in,O
the,O
intracellular,O
calcium,O
concentration,O
",",O
cytoskeleton,O
reorganization,O
and,O
cellular,O
migration,O
.,O
Several,O
modulating,O
factors,O
such,O
as,O
phosphatases,B-GP
",",O
regulator,B-GP
of,I-GP
G,I-GP
-,I-GP
protein,I-GP
signaling,I-GP
",",O
adaptor,B-GP
proteins,I-GP
and,O
ubiquitin,B-GP
may,O
affect,O
signaling,O
and,O
/,O
or,O
chemotactic,O
response,O
of,O
CXCR4,B-GP
to,O
its,O
ligand,O
(,O
CXCL12,B-GP
).,O
An,O
important,O
function,O
of,O
CXCR4,B-GP
/,O
CXCL12,B-GP
is,O
the,O
regulation,O
of,O
bone,O
-,O
marrow,O
homeostasis,O
and,O
lymphocyte,O
trafficking,O
.,O
Chemotaxis,O
and,O
integrin,B-GP
-,O
mediated,O
adhesion,O
are,O
the,O
main,O
cellular,O
responses,O
to,O
CXCL12,B-GP
.,O
Cxcl12,B-GP
-,O
knockout,O
mice,B-OG
display,O
the,O
same,O
phenotype,O
as,O
Cxcr4,B-GP
-,O
knockout,O
mice,B-OG
(,O
Nagasawa,O
et,O
al,O
".,",O
1996,O
).,O
In,O
autoimmunity,O
there,O
are,O
indications,O
that,O
the,O
interaction,O
of,O
CXCR4,B-GP
and,O
CXCL12,B-GP
could,O
be,O
important,O
.,O
CXCL12,B-GP
recruits,O
B,O
cells,O
to,O
inflamed,O
glomeruli,O
",",O
in,O
which,O
these,O
cells,O
can,O
produce,O
autoantibodies,B-GP
(,O
Balabanian,O
et,O
al,O
".,",O
2003,O
).,O
Also,O
",",O
in,O
rheumatoid,B-DS
arthritis,I-DS
",",O
CXCR4,B-GP
and,O
CXCL12,B-GP
have,O
been,O
proposed,O
to,O
be,O
important,O
in,O
the,O
disease,O
precipitation,O
(,O
Zhang,O
et,O
al,O
".,",O
2005,O
).,O
A,O
role,O
of,O
CXCR4,B-GP
and,O
CXCL12,B-GP
in,O
EAE,B-DS
(,O
Meiron,O
et,O
al,O
".,",O
2008,O
;,O
Kohler,O
et,O
al,O
".,",O
2008,O
;,O
McCandless,O
et,O
al,O
".,",O
2006,O
),O
as,O
well,O
as,O
in,O
MS,B-DS
(,O
Azin,O
et,O
al,O
".,",O
2012,O
;,O
Krumbholz,O
et,O
al,O
".,",O
2006,O
),O
has,O
been,O
described,O
.,O
Our,O
data,O
indicate,O
that,O
",",O
also,O
in,O
MOG,B-GP
-,O
induced,O
EAE,B-DS
and,O
possibly,O
in,O
MS,B-DS
",",O
the,O
interaction,O
of,O
CXCR4,B-GP
and,O
CXCL12,B-GP
is,O
of,O
paramount,O
importance,O
for,O
disease,O
development,O
.,O
We,O
found,O
specific,O
upregulation,O
of,O
Cxcr4,B-GP
on,O
cells,O
derived,O
from,O
LNs,O
and,O
eluted,O
from,O
the,O
CNS,O
of,O
rats,B-OG
immunized,O
with,O
encephalitogenic,O
MOG,B-GP
91,O
-,O
108,O
peptide,O
in,O
comparison,O
to,O
controls,O
.,O
In,O
addition,O
",",O
we,O
measured,O
upregulation,O
of,O
Cxcl12,B-GP
and,O
Cxcr4,B-GP
in,O
spinal,O
cords,O
in,O
EAE,B-DS
rats,B-OG
compared,O
to,O
controls,O
.,O
CXCL12,B-GP
is,O
upregulated,O
in,O
the,O
CNS,O
of,O
individuals,O
with,O
MS,B-DS
(,O
Krumbholz,O
et,O
al,O
".,",O
2006,O
and,O
our,O
own,O
unpublished,O
observations,O
).,O
Together,O
",",O
the,O
presented,O
data,O
would,O
argue,O
for,O
a,O
scenario,O
in,O
which,O
LN,O
-,O
derived,O
cells,O
are,O
",",O
in,O
the,O
context,O
of,O
an,O
encounter,O
with,O
an,O
encephalitogenic,O
antigen,O
",",O
activated,O
and,O
migrate,O
towards,O
CXCL12,B-GP
in,O
the,O
CNS,O
.,O
This,O
is,O
further,O
underscored,O
by,O
the,O
fact,O
that,O
nitric,O
oxide,O
enhances,O
lipopolysaccharide,O
(,O
LPS,O
)-,O
induced,O
expression,O
of,O
CXCR4,B-GP
and,O
migration,O
towards,O
CXCL12,B-GP
(,O
Giordano,O
et,O
al,O
".,",O
2006,O
).,O
CD38,B-GP
is,O
a,O
membrane,B-GP
-,I-GP
associated,I-GP
type,I-GP
II,I-GP
glycoprotein,I-GP
that,O
acts,O
both,O
as,O
a,O
receptor,O
and,O
enzyme,O
(,O
Cockayne,O
et,O
al,O
".,",O
1998,O
;,O
Kato,O
et,O
al,O
".,",O
1999,O
;,O
Salmi,O
and,O
Jalkanen,O
",",O
2005,O
).,O
As,O
an,O
enzyme,O
it,O
catalyzes,O
NAD,O
+,O
into,O
cyclic,O
ADP,O
-,O
ribose,O
and,O
further,O
into,O
ADP,O
-,O
ribose,O
.,O
It,O
also,O
regulates,O
Ca2,O
+,O
levels,O
from,O
ryanodine,B-GP
receptor,I-GP
stores,O
.,O
CD38,B-GP
is,O
expressed,O
on,O
a,O
variety,O
of,O
myeloid,O
and,O
lymphoid,O
cells,O
.,O
CD38,B-GP
ligation,O
in,O
B,O
cells,O
leads,O
to,O
tyrosine,O
phosphorylation,O
of,O
several,O
intracellular,O
proteins,O
such,O
as,O
Syk,B-GP
",",O
p85,B-GP
of,O
phophatidylinositol,B-GP
-,I-GP
3,I-GP
kinase,I-GP
and,O
phospholipase,B-GP
C,I-GP
-,I-GP
γ,I-GP
(,O
Silvennoinen,O
et,O
al,O
".,",O
1996,O
).,O
CD38,B-GP
ligation,O
in,O
T,O
cells,O
results,O
in,O
phosphorylation,O
of,O
the,O
Raf,B-GP
-,I-GP
1,I-GP
/,O
MAP,B-GP
kinase,I-GP
and,O
CD3,B-GP
-,I-GP
ζ,I-GP
/,O
ZAP,B-GP
-,I-GP
70,I-GP
signaling,O
pathway,O
(,O
Zubiaur,O
et,O
al,O
".,",O
1997,O
).,O
Furthermore,O
",",O
it,O
is,O
involved,O
in,O
dendritic,O
cell,O
migration,O
and,O
adhesion,O
between,O
lymphocytes,O
and,O
endothelial,O
cells,O
(,O
Partida,O
-,O
Sanchez,O
et,O
al,O
".,",O
2004,O
).,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
show,O
a,O
slight,O
reduction,O
of,O
antibody,B-GP
titers,O
to,O
T,O
-,O
cell,O
-,O
dependent,O
antigens,O
(,O
Cockayne,O
et,O
al,O
".,",O
1998,O
).,O
Additionally,O
",",O
these,O
mice,B-OG
had,O
increased,O
susceptibility,O
to,O
bacterial,B-DS
infections,I-DS
",",O
which,O
is,O
thought,O
to,O
be,O
caused,O
by,O
a,O
defective,O
chemotactic,O
response,O
of,O
neutrophils,O
towards,O
bacteria,O
",",O
underscoring,O
a,O
role,O
in,O
innate,O
immunity,O
as,O
well,O
(,O
Partida,O
-,O
Sanchez,O
et,O
al,O
".,",O
2001,O
).,O
We,O
induced,O
EAE,B-DS
in,O
Cd38,B-GP
-,O
knockout,O
mice,B-OG
(,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
),O
and,O
controls,O
.,O
Cd38,B-GP
-,O
knockout,O
mice,B-OG
had,O
a,O
reduced,O
disease,O
severity,O
and,O
lower,O
autoantibody,B-GP
and,O
T,O
-,O
cell,O
responses,O
as,O
compared,O
to,O
the,O
controls,O
.,O
These,O
findings,O
show,O
the,O
importance,O
of,O
CD38,B-GP
in,O
EAE,B-DS
and,O
possibly,O
MS,B-DS
.,O
This,O
work,O
forms,O
the,O
basis,O
for,O
further,O
analysis,O
of,O
the,O
involved,O
cellular,O
compartments,O
and,O
regulation,O
of,O
human,B-OG
disease,O
(,O
Mayo,O
et,O
al,O
".,",O
2008,O
;,O
Lischke,O
et,O
al,O
".,",O
2013,O
).,O
FTY720,O
is,O
a,O
potent,O
drug,O
that,O
affects,O
lymphocyte,O
trafficking,O
and,O
homing,O
.,O
Our,O
studies,O
and,O
studies,O
by,O
others,O
(,O
Brinkmann,O
et,O
al,O
".,",O
2002,O
;,O
Balatoni,O
et,O
al,O
".,",O
2007,O
),O
showed,O
a,O
strong,O
beneficial,O
effect,O
of,O
FTY720,O
on,O
EAE,B-DS
under,O
various,O
experimental,O
settings,O
.,O
The,O
drug,O
was,O
approved,O
for,O
treatment,O
of,O
MS,B-DS
(,O
Kappos,O
et,O
al,O
".,",O
2010,O
).,O
We,O
demonstrate,O
that,O
treatment,O
of,O
MOG,B-GP
-,O
induced,O
EAE,B-DS
with,O
FTY720,O
impacts,O
the,O
gene,O
expression,O
of,O
the,O
genes,O
that,O
are,O
involved,O
in,O
encephalitogenic,O
immune,O
responses,O
.,O
This,O
further,O
validates,O
our,O
approach,O
.,O
We,O
measured,O
changes,O
in,O
expression,O
of,O
S1P1,B-GP
",",O
Akt2,B-GP
and,O
Cd38,B-GP
.,O
Interestingly,O
",",O
no,O
changes,O
in,O
expression,O
of,O
Cxcr4,B-GP
was,O
observed,O
.,O
The,O
reason,O
for,O
this,O
is,O
not,O
fully,O
understood,O
and,O
deserves,O
further,O
investigations,O
.,O
In,O
conclusion,O
",",O
in,O
this,O
study,O
we,O
have,O
identified,O
genes,O
that,O
are,O
involved,O
not,O
only,O
in,O
raising,O
autoantigen,O
-,O
specific,O
immune,O
responses,O
but,O
which,O
constitute,O
encephalitogenicity,O
.,O
The,O
immunization,O
with,O
encephalitogenic,O
peptides,O
induces,O
a,O
network,O
of,O
genes,O
involved,O
in,O
activation,O
and,O
migration,O
of,O
lymphocytes,O
.,O
Based,O
on,O
this,O
platform,O
",",O
we,O
have,O
established,O
the,O
paramount,O
importance,O
of,O
G,B-GP
-,I-GP
coupled,I-GP
proteins,I-GP
in,O
encephalitogenicity,O
of,O
adaptive,O
immune,O
responses,O
.,O
We,O
speculate,O
that,O
similar,O
involvement,O
might,O
operate,O
also,O
in,O
other,O
autoimmune,B-DS
diseases,I-DS
and,O
possibly,O
in,O
transplant,O
rejection,O
",",O
thereby,O
establishing,O
common,O
mechanisms,O
.,O
These,O
pathways,O
might,O
be,O
valuable,O
targets,O
of,O
therapeutic,O
approaches,O
as,O
we,O
have,O
shown,O
attenuation,O
of,O
EAE,B-DS
after,O
treatment,O
with,O
FTY720,O
or,O
reduced,O
EAE,B-DS
severity,O
in,O
CD38,B-GP
-,O
deficient,O
mice,B-OG
.,O
These,O
findings,O
not,O
only,O
validate,O
our,O
gene,O
expression,O
data,O
",",O
but,O
also,O
underscore,O
the,O
importance,O
of,O
the,O
rat,B-OG
EAE,B-DS
model,O
in,O
translational,O
medicine,O
.,O
MATERIALS,O
AND,O
METHODS,O
Animals,B-OG
and,O
EAE,B-DS
induction,O
Female,O
rats,B-OG
or,O
mice,B-OG
",",O
10,O
-,O
14,O
weeks,O
of,O
age,O
",",O
were,O
used,O
in,O
all,O
experiments,O
.,O
LEW,O
.,O
1AV1,O
(,O
RT1av1,O
),O
rats,B-OG
were,O
obtained,O
from,O
Hans,O
Hedrich,O
(,O
Central,O
Animal,B-OG
Laboratory,O
",",O
Hannover,O
Medical,O
School,O
",",O
Hannover,O
",",O
Germany,O
),O
and,O
DA,O
(,O
RT1av1,O
),O
rats,B-OG
were,O
obtained,O
from,O
Harlan,O
Winkelmann,O
(,O
Borchen,O
",",O
Germany,O
).,O
Female,O
B6,O
.,O
129P2,O
-,O
Cd38tm1Lnd,O
/,O
J,O
mice,B-OG
and,O
the,O
appropriate,O
controls,O
(,O
C57BL,O
/,O
6J,O
000664,O
),O
were,O
purchased,O
from,O
the,O
Jackson,O
Laboratory,O
(,O
Bar,O
Harbor,O
",",O
USA,O
).,O
Animals,B-OG
were,O
bred,O
and,O
kept,O
under,O
specific,O
pathogen,O
-,O
free,O
conditions,O
.,O
Animals,B-OG
were,O
injected,O
intradermally,O
at,O
the,O
base,O
of,O
the,O
tail,O
(,O
rats,B-OG
),O
or,O
both,O
flanks,O
(,O
mice,B-OG
),O
with,O
100,O
µg,O
of,O
MOG,B-GP
91,O
-,O
108,O
(,O
rats,B-OG
),O
or,O
50,O
µg,O
of,O
rat,B-OG
recombinant,O
MOG,B-GP
1,O
-,O
125,O
(,O
rats,B-OG
),O
or,O
100,O
µg,O
MOG,B-GP
35,O
-,O
55,O
(,O
mice,B-OG
),O
or,O
20,O
µg,O
rat,B-OG
recombinant,O
MOG,B-GP
1,O
-,O
125,O
(,O
mice,B-OG
).,O
The,O
antigens,O
in,O
a,O
total,O
volume,O
of,O
100,O
µl,O
were,O
mixed,O
with,O
100,O
µl,O
of,O
CFA,O
(,O
1,O
:,O
1,O
).,O
A,O
total,O
of,O
100,O
µl,O
of,O
CFA,O
consisted,O
of,O
IFA,O
(,O
Sigma,O
-,O
Aldrich,O
",",O
St,O
Louis,O
",",O
MO,O
),O
and,O
500,O
µg,O
for,O
rats,B-OG
or,O
400,O
µg,O
for,O
mice,B-OG
of,O
heat,O
-,O
inactivated,O
Mycobacterium,B-OG
tuberculosis,I-OG
(,O
strain,O
H37,O
RA,O
;,O
Difco,O
Laboratories,O
",",O
Detroit,O
",",O
MI,O
),O
(,O
Weissert,O
",",O
2016,O
).,O
Mice,B-OG
additionally,O
received,O
100,O
ng,O
of,O
pertussis,B-GP
toxin,I-GP
(,O
Calbiochem,O
",",O
Darmstadt,O
",",O
Germany,O
),O
on,O
day,O
0,O
and,O
2,O
intravenously,O
.,O
Some,O
groups,O
of,O
rats,B-OG
were,O
also,O
injected,O
with,O
100,O
µl,O
IFA,O
mixed,O
with,O
100,O
µl,O
MOG,B-GP
1,O
-,O
125,O
in,O
PBS,O
(,O
50,O
µg,O
),O
without,O
the,O
addition,O
of,O
Mycobacterium,B-OG
tuberculosis,I-OG
or,O
with,O
IFA,O
or,O
CFA,O
alone,O
.,O
The,O
clinical,O
scoring,O
was,O
as,O
follows,O
:,O
0,O
=,O
no,O
illness,O
;,O
1,O
=,O
tail,O
weakness,O
or,O
paralysis,O
;,O
2,O
=,O
hind,O
-,O
leg,O
paraparesis,O
or,O
hemiparesis,O
;,O
3,O
=,O
hind,O
-,O
leg,O
paralysis,O
or,O
hemiparalysis,O
;,O
4,O
=,O
tetraparesis,O
or,O
moribund,O
.,O
All,O
experiments,O
were,O
approved,O
by,O
the,O
regional,O
board,O
in,O
Tübingen,O
",",O
Germany,O
.,O
Human,B-OG
samples,O
Blood,O
samples,O
were,O
obtained,O
after,O
consent,O
from,O
individuals,O
with,O
MS,B-DS
and,O
controls,O
.,O
The,O
characteristics,O
of,O
the,O
MS,B-DS
individuals,O
and,O
controls,O
are,O
indicated,O
in,O
Tables,O
S6,O
and,O
S7,O
.,O
The,O
research,O
was,O
approved,O
by,O
the,O
Ethics,O
Committee,O
of,O
the,O
University,O
of,O
Tübingen,O
in,O
Germany,O
(,O
Permission,O
125,O
/,O
2001,O
).,O
Isolation,O
of,O
CNS,O
-,O
infiltrating,O
cells,O
Infiltrating,O
cells,O
from,O
the,O
CNS,O
were,O
prepared,O
as,O
described,O
before,O
(,O
Weissert,O
et,O
al,O
".,",O
1998a,O
",",O
2001,O
).,O
In,O
brief,O
",",O
rats,B-OG
were,O
perfused,O
with,O
cold,O
PBS,O
",",O
and,O
brains,O
and,O
spinal,O
cords,O
were,O
dissected,O
out,O
on,O
day,O
12,O
p,O
.,O
i,O
.,O
Subsequently,O
",",O
brains,O
and,O
spinal,O
cords,O
were,O
homogenized,O
in,O
10,O
ml,O
50,O
%,O
Percoll,O
/,O
0,O
.,O
1,O
%,O
BSA,B-GP
/,O
1,O
%,O
glucose,O
(,O
Amersham,O
Pharmacia,O
Biotech,O
),O
containing,O
500,O
U,O
DNase,B-GP
type,I-GP
I,I-GP
(,O
Life,O
Technologies,O
).,O
Ten,O
ml,O
of,O
50,O
%,O
Percoll,O
was,O
added,O
to,O
each,O
sample,O
after,O
homogenization,O
.,O
A,O
discontinuous,O
Percoll,O
gradient,O
was,O
obtained,O
by,O
adding,O
7,O
ml,O
of,O
63,O
%,O
Percoll,O
below,O
and,O
20,O
ml,O
of,O
30,O
%,O
Percoll,O
above,O
the,O
sample,O
.,O
Samples,O
were,O
centrifuged,O
for,O
40,O
min,O
at,O
1000,O
g,O
at,O
4,O
°,O
C,O
.,O
Lymphocytes,O
were,O
collected,O
from,O
the,O
63,O
/,O
50,O
%,O
Percoll,O
interface,O
.,O
The,O
cells,O
were,O
subsequently,O
washed,O
twice,O
in,O
15,O
-,O
25,O
ml,O
PBS,O
with,O
centrifugation,O
at,O
600,O
g,O
for,O
15,O
min,O
at,O
4,O
°,O
C,O
.,O
Isolation,O
of,O
mononuclear,O
cells,O
from,O
lymph,O
nodes,O
and,O
spleens,O
Draining,O
inguinal,O
LNs,O
and,O
spleens,O
were,O
dissected,O
out,O
under,O
deep,O
anesthesia,O
.,O
LNs,O
were,O
disrupted,O
and,O
mononuclear,O
cells,O
(,O
MNCs,O
),O
washed,O
twice,O
in,O
Dulbecco,O
',O
s,O
modified,O
Eagle,O
',O
s,O
medium,O
(,O
DMEM,O
;,O
Life,O
Technologies,O
",",O
Paisley,O
",",O
UK,O
"),",O
resuspended,O
in,O
complete,O
medium,O
(,O
CM,O
),O
containing,O
DMEM,O
supplemented,O
with,O
5,O
%,O
fetal,O
calf,O
serum,O
(,O
PAA,O
Laboratories,O
Linz,O
",",O
Austria,O
"),",O
1,O
%,O
penicillin,O
/,O
streptomycin,O
(,O
Life,O
Technologies,O
"),",O
1,O
%,O
glutamine,O
(,O
Life,O
Technologies,O
),O
and,O
50,O
µM,O
2,O
-,O
mercaptoethanol,O
(,O
Life,O
Technologies,O
"),",O
and,O
flushed,O
through,O
a,O
70,O
-,O
µm,O
plastic,O
strainer,O
(,O
Falcon,O
;,O
BD,O
Biosciences,O
",",O
Franklin,O
Lakes,O
",",O
NJ,O
).,O
MNCs,O
from,O
spleen,O
were,O
prepared,O
in,O
the,O
same,O
way,O
as,O
from,O
LNs,O
with,O
the,O
difference,O
that,O
red,O
blood,O
cells,O
were,O
lysed,O
with,O
lysis,O
buffer,O
consisting,O
of,O
0,O
.,O
15,O
M,O
NH4Cl,O
",",O
10,O
mM,O
KHCO3,O
and,O
0,O
.,O
1,O
mM,O
Na2,O
EDTA,O
adjusted,O
to,O
pH,O
7,O
.,O
4,O
.,O
CD4,B-GP
+,O
cells,O
were,O
isolated,O
by,O
anti,O
-,O
rat,B-OG
CD4,B-GP
microbeads,O
using,O
MACS,O
technology,O
(,O
Miltenyi,O
Biotech,O
",",O
Bergisch,O
Gladbach,O
",",O
Germany,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instruction,O
.,O
CD4,B-GP
+,O
cell,O
purification,O
CD4,B-GP
+,O
cells,O
from,O
the,O
LNs,O
were,O
purified,O
by,O
MACS,O
(,O
Miltenyi,O
Biotech,O
",",O
Bergisch,O
Gladbach,O
",",O
Germany,O
),O
and,O
subsequently,O
analyzed,O
by,O
Affymetrix,O
gene,O
array,O
for,O
differential,O
gene,O
expression,O
.,O
Spinal,O
cord,O
tissue,O
From,O
PBS,O
-,O
perfused,O
naive,O
rats,B-OG
or,O
in,O
DA,O
rats,B-OG
immunized,O
with,O
either,O
IFA,O
",",O
CFA,O
",",O
MOG,B-GP
1,O
-,O
125,O
in,O
IFA,O
or,O
MOG,B-GP
1,O
-,O
125,O
in,O
CFA,O
",",O
spinal,O
cord,O
tissue,O
was,O
dissected,O
and,O
homogenized,O
and,O
subsequently,O
assessed,O
for,O
mRNA,O
expression,O
.,O
RNA,O
preparation,O
Total,O
RNA,O
of,O
brain,O
-,O
infiltrating,O
leukocytes,O
or,O
lymphocytes,O
or,O
spinal,O
cord,O
tissue,O
was,O
isolated,O
by,O
using,O
an,O
RNeasy,O
kit,O
(,O
Qiagen,O
",",O
Hilden,O
",",O
Germany,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
The,O
RNA,O
quality,O
was,O
analyzed,O
with,O
a,O
Bioanalyser,O
2100,O
(,O
Agilent,O
",",O
Palo,O
Alto,O
",",O
CA,O
).,O
Microarrays,O
Affymetrix,O
microarrays,O
of,O
the,O
type,O
RG,O
U34,O
A,O
(,O
Affymetrix,O
Inc,O
".,",O
Santa,O
Clara,O
",",O
CA,O
),O
representing,O
approximately,O
7000,O
full,O
-,O
length,O
genes,O
and,O
1000,O
expressed,O
sequence,O
tag,O
(,O
EST,O
),O
clusters,O
were,O
used,O
.,O
For,O
the,O
purified,O
CD4,B-GP
+,O
cells,O
",",O
the,O
rat,B-OG
expression,O
set,O
230A,O
(,O
Affymetrix,O
),O
containing,O
about,O
30,O
",",O
000,O
features,O
was,O
used,O
.,O
For,O
each,O
array,O
",",O
samples,O
from,O
at,O
least,O
three,O
rats,B-OG
were,O
pooled,O
.,O
Biotin,O
-,O
labeled,O
cRNA,O
was,O
prepared,O
and,O
hybridized,O
to,O
the,O
arrays,O
.,O
In,O
brief,O
",",O
double,O
-,O
stranded,O
cDNA,O
was,O
synthesized,O
from,O
whole,O
RNA,O
using,O
a,O
superscript,O
choice,O
kit,O
(,O
Invitrogen,O
),O
with,O
a,O
T7,B-OG
-(,O
dT,O
),O
24,O
primer,O
(,O
Metabion,O
),O
and,O
in,O
vitro,O
transcribed,O
into,O
biotin,O
-,O
labeled,O
cRNA,O
.,O
After,O
hybridization,O
",",O
gene,O
arrays,O
were,O
washed,O
and,O
stained,O
by,O
a,O
fluidics,O
station,O
(,O
Affymetrix,O
),O
and,O
scanned,O
by,O
a,O
confocal,O
laser,O
scanning,O
microscope,O
(,O
Agilent,O
).,O
The,O
data,O
were,O
analyzed,O
using,O
the,O
microarray,O
suite,O
software,O
",",O
micro,O
DB,O
",",O
and,O
data,O
-,O
mining,O
tool,O
(,O
Affymetrix,O
).,O
Only,O
genes,O
and,O
ESTs,O
that,O
were,O
‘,O
present,O
’,O
and,O
gave,O
a,O
difference,O
call,O
of,O
either,O
‘,O
increase,O
’,O
or,O
‘,O
decrease,O
’,O
according,O
to,O
the,O
Affymetrix,O
software,O
were,O
included,O
in,O
further,O
analysis,O
.,O
The,O
extent,O
of,O
differential,O
expression,O
is,O
expressed,O
as,O
an,O
SLR,O
.,O
For,O
the,O
tables,O
",",O
the,O
cut,O
-,O
off,O
was,O
set,O
to,O
an,O
SLR,O
of,O
1,O
signifying,O
a,O
twofold,O
change,O
in,O
expression,O
.,O
Doubles,O
",",O
ESTs,O
and,O
sequences,O
not,O
corresponding,O
to,O
a,O
gene,O
were,O
not,O
included,O
in,O
the,O
tables,O
.,O
Real,O
-,O
time,O
PCR,O
To,O
avoid,O
amplification,O
/,O
detection,O
of,O
contaminating,O
genomic,O
DNA,O
",",O
extracted,O
RNA,O
was,O
treated,O
with,O
RNase,B-GP
free,O
DNase,B-GP
(,O
Promega,O
",",O
Madison,O
",",O
WI,O
).,O
Subsequently,O
",",O
cDNA,O
was,O
synthesized,O
by,O
reverse,O
transcription,O
with,O
Moloney,B-OG
murine,I-OG
leukemia,I-OG
virus,I-OG
reverse,B-GP
transcriptase,I-GP
and,O
random,O
pdN6,O
primers,O
in,O
the,O
presence,O
of,O
RNase,B-GP
inhibitor,O
(,O
Promega,O
).,O
Amplification,O
was,O
performed,O
on,O
an,O
Applied,O
Biosystems,O
Prism,O
7000,O
Sequence,O
Detection,O
System,O
(,O
Applied,O
Biosystems,O
",",O
Foster,O
City,O
",",O
CA,O
),O
using,O
a,O
SYBR,O
green,O
protocol,O
.,O
Results,O
were,O
expressed,O
as,O
2,O
−,O
ΔΔCT,O
values,O
.,O
The,O
primer,O
sequences,O
5,O
′,O
to,O
3,O
′,O
were,O
as,O
follows,O
:,O
Rat,B-OG
primers,O
forward,O
:,O
GGTTGTCTCCTGTGACTTCAA,O
reverse,O
:,O
CATACCAGGAAATGAGCTTCAC,O
forward,O
:,O
TAGCCGCAGCAAATCAGAC,O
reverse,O
:,O
GCAGCAGTGGAGAAAGAGAGA,O
forward,O
:,O
GATGGTGGTGTTCCAGTTCC,O
reverse,O
:,O
CAGCTTGGAGATGATGATGC,O
forward,O
:,O
CGATTCTTTGAGAGCCATGT,O
reverse,O
:,O
AGGGCACAGTTTGGAGTGTT,O
forward,O
:,O
AGGACACACTGCTGGGCTAT,O
reverse,O
:,O
CAGGGTTGTTGGGACAATTT,O
forward,O
:,O
GAAGACTGAGAGGCCACGAC,O
reverse,O
:,O
GGGAGCCACACTTGTAATCC,O
Human,B-OG
primers,O
forward,O
:,O
CGGCTACCACATCCAAGGAA,O
reverse,O
:,O
GCTGGAATTACCGCGGCT,O
forward,O
:,O
CATCAGTCTGGACCGCTACC,O
reverse,O
:,O
GGATCCAGACGCCAACATAG,O
.,O
FACS,O
FITC,O
-,O
conjugated,O
monoclonal,O
antibody,B-GP
(,O
mAb,O
),O
against,O
CD45RA,B-GP
(,O
OX,O
-,O
33,O
),O
and,O
TCRAB,B-GP
(,O
R73,O
),O
and,O
phycoerythrin,B-GP
(,O
PE,B-GP
)-,O
conjugated,O
mAb,O
against,O
CD4,B-GP
(,O
OX,O
-,O
35,O
),O
and,O
MHC,B-GP
II,I-GP
(,O
OX,O
-,O
6,O
),O
and,O
appropriate,O
isotype,O
controls,O
were,O
purchased,O
from,O
Becton,O
Dickinson,O
(,O
Heidelberg,O
",",O
Germany,O
).,O
Flow,O
cytometry,O
was,O
performed,O
on,O
a,O
FACScalibur,O
running,O
with,O
Cellquest,O
software,O
(,O
Becton,O
Dickinson,O
).,O
Cells,O
were,O
gated,O
on,O
the,O
lymphocyte,O
population,O
in,O
the,O
forward,O
scatter,O
(,O
FSC,O
)-,O
side,O
scatter,O
(,O
SSC,O
),O
dot,O
plot,O
.,O
For,O
data,O
analysis,O
",",O
Flowing,O
Software,O
2,O
.,O
5,O
.,O
1,O
(,O
Turku,O
Center,O
for,O
Biotechnology,O
",",O
Finland,O
),O
was,O
used,O
.,O
ELISA,O
Serum,O
taken,O
at,O
the,O
time,O
point,O
of,O
euthanasia,O
was,O
subject,O
to,O
an,O
anti,O
-,O
MOG,B-GP
autoantibody,B-GP
ELISA,O
.,O
ELISA,O
plates,O
(,O
96,O
-,O
well,O
;,O
Nunc,O
",",O
Roskilde,O
",",O
Denmark,O
),O
were,O
coated,O
with,O
2,O
.,O
5,O
µg,O
/,O
ml,O
(,O
100,O
µl,O
/,O
well,O
),O
MOG,B-GP
1,O
-,O
125,O
overnight,O
at,O
4,O
°,O
C,O
.,O
Plates,O
were,O
washed,O
with,O
PBS,O
/,O
0,O
.,O
05,O
%,O
Tween,O
20,O
and,O
blocked,O
with,O
milk,O
powder,O
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
After,O
washing,O
",",O
diluted,O
serum,O
samples,O
were,O
added,O
and,O
plates,O
were,O
incubated,O
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
Then,O
",",O
plates,O
were,O
washed,O
and,O
rabbit,B-OG
anti,O
-,O
mouse,B-OG
antiserum,O
(,O
IgG,B-GP
",",O
IgG1,B-GP
",",O
IgG2a,B-GP
",",O
IgG2b,B-GP
",",O
IgG3,B-GP
",",O
IgM,B-GP
;,O
Nordic,O
",",O
Tilburg,O
",",O
The,O
Netherlands,O
),O
was,O
added,O
and,O
incubated,O
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
Plates,O
were,O
washed,O
prior,O
to,O
the,O
addition,O
of,O
peroxidase,B-GP
-,O
conjugated,O
goat,B-OG
anti,O
-,O
rabbit,B-OG
antiserum,O
(,O
Nordic,O
),O
diluted,O
in,O
PBS,O
/,O
0,O
.,O
05,O
%,O
Tween,O
20,O
.,O
After,O
30,O
min,O
incubation,O
",",O
plates,O
were,O
washed,O
and,O
bound,O
antibodies,B-GP
were,O
visualized,O
by,O
addition,O
of,O
2,O
",",O
2,O
′,O
azino,O
-,O
bis,O
(,O
3,O
-,O
ethylbenzothiazoline,O
-,O
6,O
-,O
sulphonic,O
acid,O
),O
(,O
ABTS,O
),O
(,O
Roche,O
Diagnostics,O
",",O
Mannheim,O
",",O
Germany,O
).,O
After,O
15,O
min,O
of,O
incubation,O
",",O
optical,O
density,O
was,O
read,O
at,O
405,O
nm,O
.,O
ELISA,O
with,O
human,B-OG
serum,O
was,O
performed,O
according,O
to,O
the,O
instructions,O
of,O
the,O
manufacturer,O
[,O
Quantikine,O
human,B-OG
SDF1alpha,B-GP
Immunoassay,O
(,O
R,O
&,O
D,O
Systems,O
",",O
Minneapolis,O
",",O
MN,O
)].,O
Proliferation,O
assay,O
Cells,O
from,O
draining,O
LNs,O
were,O
prepared,O
as,O
described,O
above,O
and,O
cultured,O
in,O
the,O
presence,O
of,O
rrMOG,B-GP
in,O
96,O
-,O
well,O
plates,O
as,O
described,O
by,O
Weissert,O
et,O
al,O
.,O
(,O
1998b,O
).,O
Cells,O
were,O
cultured,O
for,O
48,O
h,O
and,O
pulsed,O
with,O
1,O
µCi,O
[,O
3H,O
],O
thymidine,O
for,O
the,O
last,O
18,O
h,O
.,O
The,O
incorporation,O
of,O
[,O
3H,O
],O
thymidine,O
was,O
measured,O
using,O
a,O
beta,O
-,O
scintillation,O
counter,O
.,O
FTY720,O
treatment,O
Rats,B-OG
were,O
treated,O
with,O
FTY720,O
(,O
generous,O
gift,O
of,O
Novartis,O
AG,O
",",O
Switzerland,O
),O
and,O
received,O
a,O
daily,O
dose,O
of,O
0,O
.,O
4,O
mg,O
/,O
kg,O
body,O
weight,O
in,O
sterile,O
water,O
by,O
oral,O
gavage,O
as,O
described,O
(,O
Balatoni,O
et,O
al,O
".,",O
2007,O
).,O
This,O
article,O
is,O
part,O
of,O
a,O
special,O
subject,O
collection,O
‘,O
Spotlight,O
on,O
Rat,B-OG
:,O
Translational,O
Impact,O
"’,",O
guest,O
edited,O
by,O
Tim,O
Aitman,O
and,O
Aron,O
Geurts,O
.,O
See,O
related,O
articles,O
in,O
this,O
collection,O
at,O
http,O
://,O
dmm,O
.,O
biologists,O
.,O
org,O
/,O
collection,O
/,O
rat,B-OG
-,O
disease,O
-,O
model,O
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
no,O
competing,O
or,O
financial,O
interests,O
.,O
Author,O
contributions,O
M,O
.,O
M,O
.,O
H,O
.,O
performed,O
the,O
gene,O
arrays,O
",",O
data,O
analysis,O
",",O
target,O
validation,O
in,O
rats,B-OG
and,O
revised,O
the,O
paper,O
.,O
S,O
.,O
B,O
.,O
performed,O
the,O
gene,O
arrays,O
",",O
data,O
analysis,O
and,O
the,O
target,O
validation,O
.,O
B,O
.,O
G,O
.,O
did,O
the,O
work,O
on,O
CD38,B-GP
in,O
mice,B-OG
.,O
K,O
.,O
M,O
.,O
S,O
.,O
performed,O
target,O
validation,O
studies,O
in,O
rats,B-OG
and,O
analyzed,O
the,O
data,O
.,O
A,O
.,O
B,O
.,O
performed,O
studies,O
in,O
individuals,O
with,O
MS,B-DS
and,O
controls,O
.,O
R,O
.,O
W,O
.,O
designed,O
the,O
study,O
",",O
raised,O
the,O
funding,O
",",O
performed,O
the,O
data,O
analysis,O
",",O
and,O
wrote,O
and,O
revised,O
the,O
paper,O
.,O
Funding,O
This,O
study,O
was,O
supported,O
by,O
grants,O
from,O
the,O
Interdisciplinary,O
Centre,O
for,O
Clinical,O
Research,O
(,O
Bundesministerium,O
für,O
Bildung,O
und,O
Forschung,O
),O
(,O
Fö,O
.,O
01KS9602,O
"),",O
and,O
German,O
Research,O
Foundation,O
(,O
Deutsche,O
Forschungsgemeinschaft,O
),O
to,O
R,O
.,O
W,O
.,O
(,O
DFG,O
We,O
1947,O
).,O
Supplementary,O
information,O
Supplementary,O
information,O
available,O
online,O
at,O
http,O
://,O
dmm,O
.,O
biologists,O
.,O
org,O
/,O
lookup,O
/,O
doi,O
/,O
10,O
.,O
1242,O
/,O
dmm,O
.,O
025536,O
.,O
supplemental,O
Constitutive,O
Neutrophil,O
Apoptosis,O
:,O
Regulation,O
by,O
Cell,O
Concentration,O
via,O
S100,B-GP
A8,I-GP
/,O
9,O
and,O
the,O
MEK,B-GP
–,O
ERK,B-GP
Pathway,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
MA,O
DM,O
.,O
Performed,O
the,O
experiments,O
:,O
MA,O
AK,O
UT,O
SB,O
AG,O
IV,O
DM,O
.,O
Analyzed,O
the,O
data,O
:,O
MA,O
AK,O
UT,O
SB,O
AG,O
IV,O
DM,O
.,O
Wrote,O
the,O
paper,O
:,O
MA,O
DM,O
.,O
Programmed,O
cell,O
death,O
(,O
PCD,O
),O
is,O
a,O
fundamental,O
mechanism,O
in,O
tissue,O
and,O
cell,O
homeostasis,O
.,O
It,O
was,O
long,O
suggested,O
that,O
apoptosis,O
regulates,O
the,O
cell,O
number,O
in,O
diverse,O
cell,O
populations,O
;,O
however,O
no,O
clear,O
mechanism,O
was,O
shown,O
.,O
Neutrophils,O
are,O
the,O
short,O
-,O
lived,O
",",O
first,O
-,O
line,O
defense,O
of,O
innate,O
immunity,O
",",O
with,O
an,O
estimated,O
t,O
=,O
1,O
/,O
2,O
of,O
8,O
hours,O
and,O
a,O
high,O
turnover,O
rate,O
.,O
Here,O
we,O
first,O
show,O
that,O
spontaneous,O
neutrophil,O
constitutive,O
PCD,O
is,O
regulated,O
by,O
cell,O
concentrations,O
.,O
Using,O
a,O
proteomic,O
approach,O
",",O
we,O
identified,O
the,O
S100,B-GP
A8,I-GP
/,O
9,O
complex,O
",",O
which,O
constitutes,O
roughly,O
40,O
%,O
of,O
cytosolic,O
protein,O
in,O
neutrophils,O
",",O
as,O
mediating,O
this,O
effect,O
.,O
We,O
further,O
demonstrate,O
that,O
it,O
regulates,O
cell,O
survival,O
via,O
a,O
signaling,O
mechanism,O
involving,O
MEK,B-GP
-,O
ERK,B-GP
via,O
TLR4,B-GP
and,O
CD11B,B-GP
/,O
CD18,B-GP
.,O
This,O
mechanism,O
is,O
suggested,O
to,O
have,O
a,O
fine,O
-,O
tuning,O
role,O
in,O
regulating,O
the,O
neutrophil,O
number,O
in,O
bone,O
marrow,O
",",O
peripheral,O
blood,O
",",O
and,O
inflammatory,O
sites,O
.,O
Introduction,O
Programmed,O
cell,O
death,O
(,O
PCD,O
),O
is,O
a,O
fundamental,O
mechanism,O
in,O
tissue,O
and,O
cell,O
homeostasis,O
",",O
long,O
thought,O
to,O
regulate,O
cell,O
number,O
in,O
diverse,O
populations,O
.,O
In,O
developmental,O
biology,O
",",O
PCD,O
provides,O
an,O
efficient,O
mechanism,O
for,O
eliminating,O
unwanted,O
cells,O
",",O
as,O
shown,O
in,O
studies,O
with,O
the,O
nematode,B-OG
Caenorhabditis,B-OG
elegans,I-OG
[,O
1,O
].,O
Of,O
the,O
1090,O
somatic,O
cells,O
formed,O
during,O
the,O
development,O
of,O
an,O
adult,O
hermaphrodite,B-OG
",",O
exactly,O
131,O
die,O
",",O
demonstrating,O
the,O
morphological,O
features,O
of,O
apoptosis,O
.,O
In,O
the,O
mammalian,O
immune,O
system,O
",",O
clonal,O
triggering,O
results,O
in,O
lymphocyte,O
proliferation,O
followed,O
by,O
activation,O
-,O
induced,O
cell,O
death,O
that,O
ensures,O
T,O
cells,O
will,O
return,O
to,O
their,O
original,O
concentration,O
",",O
adding,O
only,O
a,O
negligible,O
number,O
of,O
memory,O
cells,O
[,O
2,O
].,O
Few,O
studies,O
in,O
the,O
human,B-OG
immune,O
system,O
have,O
questioned,O
the,O
mechanism,O
of,O
constitutive,O
leukocyte,O
blood,O
concentration,O
regulation,O
via,O
PCD,O
.,O
In,O
humans,B-OG
",",O
neutrophils,O
are,O
the,O
short,O
-,O
lived,O
",",O
first,O
-,O
line,O
defense,O
of,O
innate,O
immunity,O
",",O
with,O
estimated,O
t,O
=,O
1,O
/,O
2,O
of,O
8,O
hours,O
and,O
a,O
high,O
turnover,O
rate,O
[,O
3,O
].,O
These,O
cells,O
",",O
which,O
represent,O
50,O
–,O
60,O
%,O
of,O
the,O
circulating,O
leukocytes,O
in,O
normal,O
conditions,O
",",O
are,O
considered,O
terminally,O
differentiated,O
cells,O
.,O
They,O
are,O
rapidly,O
recruited,O
and,O
accumulate,O
in,O
the,O
early,O
phase,O
of,O
inflammation,O
.,O
Under,O
normal,O
physiological,O
conditions,O
",",O
absent,O
triggers,O
initiating,O
neutrophil,O
exit,O
from,O
the,O
blood,O
pool,O
into,O
tissues,O
",",O
human,B-OG
blood,O
neutrophil,O
counts,O
are,O
determined,O
by,O
the,O
balance,O
between,O
neutrophil,O
hematopoiesis,O
",",O
neutrophil,O
mobilization,O
from,O
the,O
bone,O
marrow,O
",",O
the,O
marginal,O
pool,O
",",O
spontaneous,O
constitutive,O
PCD,O
",",O
and,O
phagocytosis,O
of,O
apoptotic,O
neutrophils,O
.,O
Human,B-OG
neutrophils,O
are,O
generated,O
in,O
bone,O
marrow,O
",",O
mainly,O
under,O
the,O
control,O
of,O
G,B-GP
-,I-GP
CSF,I-GP
and,O
additional,O
cytokines,B-GP
and,O
growth,O
factors,O
",",O
including,O
M,B-GP
-,I-GP
CSF,I-GP
",",O
GM,B-GP
-,I-GP
CSF,I-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
3,I-GP
(,O
reviewed,O
by,O
Metcalf,O
[,O
4,O
"]),",O
and,O
possibly,O
IL,B-GP
-,I-GP
17,I-GP
and,O
IL,B-GP
-,I-GP
23,I-GP
[,O
5,O
"],",O
as,O
well,O
as,O
IL,B-GP
-,I-GP
22,I-GP
.,O
Martin,O
et,O
al,O
".,",O
and,O
others,O
",",O
suggested,O
that,O
neutrophils,O
are,O
retained,O
in,O
the,O
bone,O
marrow,O
through,O
interaction,O
of,O
CXCL12,B-GP
(,O
stromal,B-GP
derived,I-GP
factor,I-GP
1,I-GP
",",O
or,O
SDF,B-GP
-,I-GP
1,I-GP
),O
with,O
its,O
receptor,O
CXCR4,B-GP
[,O
6,O
]–[,O
7,O
].,O
In,O
the,O
blood,O
pool,O
",",O
neutrophils,O
circulate,O
until,O
they,O
are,O
marginated,O
or,O
develop,O
morphological,O
changes,O
due,O
to,O
PCD,O
",",O
and,O
are,O
cleared,O
by,O
Kupfer,O
cells,O
in,O
the,O
liver,O
[,O
8,O
],O
or,O
by,O
bone,O
marrow,O
macrophages,O
[,O
9,O
].,O
Various,O
cytokines,B-GP
regulate,O
blood,O
neutrophil,O
counts,O
.,O
Catecholamines,O
mobilize,O
the,O
marginal,O
pool,O
[,O
10,O
"],",O
while,O
G,B-GP
-,I-GP
CSF,I-GP
",",O
IL,B-GP
-,I-GP
17,I-GP
",",O
and,O
IL,B-GP
-,I-GP
23,I-GP
[,O
5,O
],O
may,O
modify,O
counts,O
via,O
bone,O
marrow,O
.,O
Yet,O
",",O
the,O
major,O
regulator,O
of,O
blood,O
neutrophil,O
counts,O
and,O
neutrophils,O
at,O
inflammatory,O
sites,O
is,O
PCD,O
",",O
which,O
allows,O
only,O
a,O
short,O
neutrophil,O
life,O
span,O
",",O
modulated,O
according,O
to,O
specific,O
needs,O
",",O
such,O
as,O
inflammation,O
.,O
Molecular,O
events,O
leading,O
to,O
this,O
short,O
neutrophil,O
lifespan,O
are,O
better,O
understood,O
now,O
.,O
An,O
important,O
regulator,O
of,O
neutrophil,O
apoptosis,O
seems,O
to,O
be,O
the,O
Bcl,B-GP
-,I-GP
2,I-GP
protein,O
family,O
",",O
and,O
a,O
major,O
event,O
in,O
spontaneous,O
neutrophil,O
PCD,O
appears,O
related,O
to,O
loss,O
of,O
anti,O
-,O
apoptotic,O
proteins,O
.,O
Bcl,B-GP
-,I-GP
2,I-GP
is,O
lost,O
during,O
neutrophil,O
differentiation,O
",",O
and,O
not,O
expressed,O
by,O
peripheral,O
blood,O
neutrophils,O
[,O
11,O
]–[,O
14,O
].,O
Bcl,B-GP
-,I-GP
xl,I-GP
is,O
also,O
expressed,O
by,O
neutrophils,O
",",O
and,O
expression,O
decreases,O
upon,O
TNFα,B-GP
-,O
mediated,O
apoptosis,O
[,O
14,O
].,O
Mcl1,B-GP
declines,O
as,O
neutrophils,O
undergo,O
spontaneous,O
apoptosis,O
",",O
and,O
is,O
upregulated,O
when,O
cells,O
are,O
exposed,O
to,O
survival,O
factors,O
such,O
as,O
GMCSF,B-GP
",",O
butyrate,O
",",O
ILβ,B-GP
",",O
and,O
LPS,O
[,O
12,O
].,O
A1,B-GP
",",O
expressed,O
in,O
neutrophils,O
at,O
the,O
mRNA,O
level,O
[,O
13,O
"],",O
[,O
15,O
"],",O
is,O
also,O
upregulated,O
by,O
survival,O
factors,O
GCSF,B-GP
and,O
LPS,O
[,O
15,O
].,O
Furthermore,O
",",O
neutrophils,O
do,O
not,O
express,O
survivin,B-GP
",",O
an,O
inhibitor,B-GP
-,I-GP
of,I-GP
-,I-GP
apoptosis,I-GP
protein,I-GP
(,O
IAP,B-GP
"),",O
unless,O
expression,O
is,O
induced,O
by,O
GCSF,B-GP
and,O
GMCSF,B-GP
or,O
in,O
inflammatory,O
conditions,O
[,O
16,O
].,O
In,O
contrast,O
",",O
pro,O
-,O
apoptotic,O
proteins,O
Bax,B-GP
",",O
Bak,B-GP
",",O
and,O
Bad,B-GP
are,O
constitutively,O
expressed,O
[,O
13,O
"],",O
[,O
14,O
"],",O
[,O
17,O
].,O
The,O
extrinsic,O
pathway,O
may,O
also,O
be,O
involved,O
.,O
Neutrophils,O
constitutively,O
express,O
Fas,B-GP
and,O
Fas,B-GP
ligand,I-GP
",",O
although,O
the,O
importance,O
of,O
Fas,B-GP
-,O
induced,O
death,O
remains,O
controversial,O
[,O
11,O
"],",O
[,O
18,O
]–[,O
20,O
].,O
In,O
addition,O
",",O
neutrophil,O
life,O
expectancy,O
can,O
be,O
modulated,O
by,O
various,O
mediators,O
(,O
G,B-GP
-,I-GP
CSF,I-GP
",",O
GM,B-GP
-,I-GP
CSF,I-GP
",",O
IL1β,B-GP
",",O
IFN,B-GP
-,I-GP
gamma,I-GP
",",O
and,O
LPS,O
[,O
21,O
]–[,O
25,O
]),O
or,O
functional,O
events,O
such,O
as,O
transmigration,O
across,O
the,O
endothelium,O
[,O
26,O
].,O
Despite,O
our,O
growing,O
understanding,O
of,O
molecular,O
control,O
of,O
neutrophil,O
PCD,O
",",O
it,O
remains,O
unclear,O
how,O
specific,O
neutrophil,O
blood,O
concentration,O
is,O
maintained,O
.,O
We,O
hypothesized,O
that,O
cell,O
concentration,O
might,O
serve,O
as,O
a,O
neutrophil,O
count,O
regulator,O
via,O
a,O
feedback,O
mechanism,O
affecting,O
PCD,O
.,O
We,O
examined,O
the,O
in,O
vitro,O
effect,O
of,O
cell,O
number,O
on,O
spontaneous,O
neutrophil,O
PCD,O
",",O
and,O
demonstrated,O
that,O
neutrophil,O
PCD,O
is,O
strongly,O
influenced,O
by,O
cell,O
concentration,O
.,O
We,O
hypothesized,O
that,O
secreted,O
molecules,O
mediate,O
this,O
effect,O
",",O
and,O
used,O
a,O
proteomic,O
approach,O
",",O
which,O
showed,O
that,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
is,O
regulated,O
by,O
cell,O
concentration,O
through,O
molecules,O
released,O
during,O
neutrophil,O
PCD,O
.,O
We,O
further,O
show,O
that,O
the,O
S100,B-GP
A8,I-GP
/,O
9,O
complex,O
is,O
a,O
primary,O
regulatory,O
molecule,O
regulating,O
cell,O
survival,O
via,O
CD11b,B-GP
/,O
CD18,B-GP
and,O
TLR4,B-GP
",",O
and,O
through,O
a,O
signaling,O
mechanism,O
involving,O
MEK,B-GP
-,O
ERK,B-GP
.,O
Materials,O
and,O
Methods,O
Materials,O
Cell,O
culture,O
medium,O
consisted,O
of,O
RPMI,O
1640,O
(,O
Invitrogen,O
-,O
Gibco,O
",",O
NY,O
),O
supplemented,O
with,O
1,O
%,O
L,O
-,O
glutamine,O
and,O
1,O
%,O
penicillin,O
/,O
streptomycin,O
(,O
Biological,O
Industries,O
",",O
Kibbutz,O
Beit,O
-,O
Haemek,O
",",O
Israel,O
).,O
The,O
APOPTEST,O
-,O
FITC,O
Kit,O
containing,O
Annexin,B-GP
V,I-GP
-,O
FITC,O
was,O
obtained,O
from,O
Nexins,O
Research,O
B,O
.,O
V,O
.,O
(,O
Hoeven,O
",",O
The,O
Netherlands,O
),O
or,O
from,O
MBL,O
International,O
(,O
Cambridge,O
",",O
MA,O
).,O
Propidium,O
iodide,O
(,O
PI,O
),O
was,O
from,O
Molecular,O
Probes,O
(,O
Eugene,O
",",O
OR,O
).,O
Recombinant,O
proteins,O
S100A8,B-GP
and,O
S100A9,B-GP
",",O
and,O
blocking,O
antibodies,B-GP
were,O
generously,O
supplied,O
by,O
Dr,O
.,O
Philippe,O
A,O
.,O
Tessier,O
.,O
(,O
Laval,O
University,O
",",O
Quebec,O
",",O
Canada,O
).,O
The,O
pan,O
-,O
caspase,B-GP
inhibitor,O
zVAD,O
-,O
fmk,O
was,O
purchased,O
from,O
R,O
&,O
D,O
systems,O
(,O
Minneapolis,O
",",O
MN,O
).,O
Mouse,B-OG
anti,O
-,O
human,B-OG
CD36,B-GP
-,O
PE,B-GP
",",O
mouse,B-OG
anti,O
-,O
human,B-OG
CD11b,B-GP
-,O
PE,B-GP
",",O
and,O
isotype,O
control,O
IgG1,B-GP
-,O
PE,B-GP
were,O
obtained,O
from,O
Serotec,O
(,O
Oxford,O
",",O
UK,O
"),",O
and,O
isotype,O
control,O
mouse,B-OG
IgM,B-GP
-,O
PE,B-GP
from,O
Dako,O
(,O
Glostrup,O
",",O
Denmark,O
).,O
DiOC6,O
(,O
3,O
),O
(,O
3,O
",",O
3,O
-,O
dihexyloxacarbocyanine,O
iodide,O
),O
was,O
purchased,O
from,O
Sigma,O
-,O
Aldrich,O
(,O
St,O
.,O
Louis,O
",",O
MO,O
).,O
MEK,B-GP
inhibitor,O
PD98059,O
was,O
purchased,O
from,O
Cell,O
Signaling,O
(,O
Danvers,O
",",O
MA,O
).,O
Antibody,B-GP
against,O
the,O
complex,O
S100A8,B-GP
/,O
9,O
for,O
flow,O
cytometry,O
analysis,O
was,O
purchased,O
from,O
Abcam,O
(,O
Cambridge,O
",",O
MA,O
).,O
For,O
blocking,O
assays,O
",",O
rabbit,B-OG
polyclonal,O
anti,O
-,O
S100A9,B-GP
and,O
anti,O
-,O
S100A8,B-GP
were,O
generously,O
supplied,O
by,O
Dr,O
Philippe,O
A,O
.,O
Tessier,O
",",O
and,O
blocking,O
antibody,B-GP
against,O
CD11b,B-GP
(,O
BioLegend,O
",",O
San,O
Diego,O
",",O
CA,O
),O
was,O
used,O
at,O
different,O
dilutions,O
as,O
indicated,O
.,O
Rabbit,B-OG
serum,O
was,O
obtained,O
from,O
Jackson,O
Laboratories,O
(,O
Jackson,O
ImmunoResearch,O
",",O
West,O
Grove,O
",",O
PA,O
).,O
Cell,O
isolation,O
and,O
culturing,O
Blood,O
neutrophils,O
were,O
isolated,O
from,O
fresh,O
buffy,O
coats,O
obtained,O
from,O
healthy,O
donors,O
.,O
RBCs,O
were,O
sedimented,O
by,O
adding,O
6,O
%,O
hetastarch,O
in,O
0,O
.,O
9,O
%,O
NaCl,O
solution,O
(,O
Stem,O
Cell,O
Technologies,O
",",O
Vancouver,O
",",O
Canada,O
),O
and,O
kept,O
at,O
25,O
°,O
C,O
for,O
up,O
to,O
45,O
min,O
.,O
The,O
leukocyte,O
-,O
rich,O
upper,O
layer,O
of,O
the,O
suspension,O
was,O
then,O
collected,O
and,O
centrifuged,O
on,O
a,O
density,O
gradient,O
with,O
Ficoll,O
-,O
Paque,O
(,O
Amersham,O
Biosciences,O
",",O
Uppsala,O
",",O
Sweden,O
).,O
Residual,O
erythrocytes,O
were,O
removed,O
by,O
hypotonic,O
lysis,O
.,O
Neutrophils,O
were,O
maintained,O
in,O
suspension,O
",",O
at,O
different,O
concentrations,O
as,O
indicated,O
",",O
in,O
RPMI,O
1640,O
medium,O
",",O
1,O
%,O
L,O
-,O
glutamine,O
",",O
and,O
1,O
%,O
penicillin,O
/,O
streptomycin,O
",",O
in,O
24,O
-,O
well,O
plates,O
at,O
37,O
°,O
C,O
",",O
in,O
a,O
humidified,O
incubator,O
containing,O
5,O
%,O
CO2,O
.,O
Cells,O
were,O
>,O
95,O
%,O
neutrophils,O
as,O
determined,O
by,O
morphological,O
analysis,O
and,O
>,O
99,O
%,O
viable,O
as,O
determined,O
by,O
Trypan,O
blue,O
dye,O
exclusion,O
Apoptosis,O
assessment,O
Apoptosis,O
assessment,O
was,O
performed,O
as,O
previously,O
described,O
[,O
27,O
],O
(,O
For,O
detailed,O
method,O
see,O
–,O
Methods,O
S1,O
).,O
Supernatant,O
transfer,O
Neutrophils,O
were,O
suspended,O
at,O
concentrations,O
of,O
either,O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
or,O
16,O
×,O
106,O
/,O
ml,O
",",O
for,O
different,O
times,O
as,O
indicated,O
",",O
at,O
37,O
°,O
C,O
/,O
5,O
%,O
CO2,O
.,O
After,O
culturing,O
",",O
the,O
supernatants,O
of,O
the,O
high,O
concentration,O
were,O
collected,O
and,O
added,O
to,O
fresh,O
neutrophils,O
from,O
the,O
same,O
donor,O
at,O
concentration,O
of,O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
and,O
vice,O
versa,O
.,O
The,O
neutrophils,O
were,O
then,O
allowed,O
to,O
undergo,O
constitutive,O
spontaneous,O
PCD,O
and,O
apoptosis,O
was,O
detected,O
as,O
described,O
.,O
Transmission,O
electron,O
microscopy,O
Cells,O
were,O
fixed,O
in,O
2,O
%,O
glutaraldedyde,O
in,O
cacodylate,O
buffer,O
(,O
0,O
.,O
1M,O
",",O
PH,O
7,O
.,O
2,O
–,O
7,O
.,O
4,O
),O
and,O
washed,O
three,O
times,O
in,O
the,O
same,O
buffer,O
.,O
Cells,O
were,O
then,O
postfixed,O
in,O
1,O
%,O
OSO4,O
for,O
1,O
h,O
at,O
room,O
temperature,O
",",O
washed,O
in,O
cacodylate,O
buffer,O
",",O
dedydrated,O
in,O
gradient,O
series,O
of,O
ethanol,O
(,O
25,O
"%,",O
50,O
"%,",O
75,O
"%,",O
95,O
"%,",O
100,O
%×,O
2,O
"),",O
treated,O
with,O
propylene,O
-,O
oxide,O
for,O
20,O
min,O
(,O
2,O
changes,O
"),",O
and,O
embedded,O
in,O
Araldite,O
Resin,O
.,O
Thin,O
sections,O
were,O
prepared,O
with,O
an,O
ultramicrotom,O
and,O
examined,O
at,O
an,O
accelerated,O
voltage,O
of,O
100KW,O
by,O
transmission,O
electron,O
microscope,O
(,O
CM12,O
",",O
Philips,O
",",O
Eindhoeven,O
",",O
The,O
Netherlands,O
).,O
Proteomic,O
(,O
SDS,O
-,O
PAGE,O
and,O
MS,O
),O
and,O
Western,O
blotting,O
Proteomic,O
(,O
SDS,O
-,O
PAGE,O
and,O
MS,O
),O
and,O
Western,O
blotting,O
were,O
performed,O
as,O
previously,O
described,O
[,O
28,O
],O
(,O
For,O
detailed,O
method,O
see,O
–,O
Methods,O
S1,O
).,O
Transfection,O
The,O
two,O
cell,O
lines,O
",",O
Chinese,B-OG
hamster,I-OG
ovary,O
(,O
CHO,O
"),",O
and,O
CHO,O
stably,O
transfected,O
with,O
complement,B-GP
receptor,I-GP
CR3,B-GP
",",O
were,O
kindly,O
provided,O
by,O
Drs,O
.,O
R,O
.,O
R,O
.,O
Ingalls,O
and,O
D,O
.,O
T,O
.,O
Golenbock,O
",",O
Boston,O
Medical,O
Center,O
",",O
Boston,O
",",O
MA,O
.,O
Leukocyte,B-DS
adhesion,I-DS
deficiency,I-DS
patients,O
and,O
controls,O
LAD,B-DS
patients,O
signed,O
an,O
informed,O
consent,O
approved,O
by,O
the,O
Ethics,O
Committee,O
of,O
Hadassah,O
-,O
Hebrew,O
University,O
Medical,O
Center,O
.,O
Controls,O
consisted,O
of,O
age,O
-,O
and,O
gender,O
-,O
matched,O
healthy,O
donors,O
",",O
who,O
signed,O
an,O
informed,O
consent,O
.,O
Blood,O
(,O
10,O
ml,O
),O
from,O
healthy,O
donors,O
and,O
heparinized,O
blood,O
(,O
10,O
ml,O
),O
from,O
patients,O
was,O
drawn,O
and,O
evaluated,O
on,O
the,O
same,O
day,O
.,O
Detection,O
of,O
intracellular,O
phosphorylated,O
ERK,B-GP
by,O
flow,O
cytometry,O
For,O
the,O
assessment,O
of,O
phosphorylation,O
of,O
the,O
ERK,B-GP
",",O
freshly,O
isolated,O
neutrophils,O
were,O
treated,O
as,O
indicated,O
and,O
prepared,O
for,O
intracellular,O
staining,O
.,O
Cells,O
were,O
washed,O
with,O
PBS,O
",",O
fixed,O
with,O
2,O
%,O
formaldehyde,O
for,O
10,O
min,O
at,O
37,O
°,O
C,O
",",O
and,O
permeabilized,O
with,O
90,O
%,O
methanol,O
for,O
30,O
min,O
on,O
ice,O
.,O
Cells,O
then,O
were,O
rinsed,O
and,O
incubated,O
for,O
10,O
min,O
at,O
RT,O
in,O
PBS,O
containing,O
0,O
.,O
5,O
%,O
BSA,B-GP
(,O
for,O
blocking,O
"),",O
and,O
stained,O
with,O
either,O
mouse,B-OG
anti,O
-,O
human,B-OG
phospho,O
-,O
p44,B-GP
/,O
42,O
MAPK,B-GP
alexa,O
fluor,O
488,O
(,O
Cell,O
Signaling,O
Technology,O
),O
or,O
isotype,O
control,O
mouse,B-OG
IgG1,B-GP
alexa,O
fluor,O
488,O
(,O
BioLegend,O
).,O
Statistical,O
analysis,O
The,O
Student,O
',O
s,O
t,O
test,O
and,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
were,O
used,O
to,O
compare,O
mean,O
data,O
.,O
The,O
Kolmogorov,O
-,O
Smirnov,O
test,O
was,O
used,O
to,O
analyze,O
flow,O
cytometry,O
results,O
.,O
Differences,O
were,O
considered,O
statistically,O
significant,O
for,O
p,O
<,O
0,O
.,O
05,O
.,O
Results,O
The,O
effect,O
of,O
cell,O
concentration,O
on,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
We,O
assumed,O
constitutive,O
spontaneous,O
PCD,O
requires,O
one,O
or,O
more,O
autoregulatory,O
negative,O
feedback,O
mechanisms,O
exerted,O
by,O
dying,O
neutrophils,O
that,O
affect,O
survival,O
rates,O
of,O
the,O
remaining,O
cells,O
(,O
Fig,O
.,O
1,O
).,O
Without,O
this,O
effect,O
",",O
one,O
might,O
assume,O
that,O
PCD,O
increases,O
at,O
higher,O
concentrations,O
due,O
to,O
competition,O
for,O
nutrition,O
and,O
other,O
ingredients,O
.,O
We,O
designed,O
an,O
experiment,O
to,O
examine,O
the,O
effect,O
of,O
various,O
cell,O
concentrations,O
in,O
the,O
physiological,O
range,O
(,O
peripheral,O
blood,O
neutrophil,O
concentration,O
∼,O
2,O
−,O
6,O
×,O
106,O
/,O
ml,O
),O
on,O
the,O
constitutive,O
spontaneous,O
PCD,O
rate,O
.,O
A,O
higher,O
apoptotic,O
cell,O
concentration,O
had,O
a,O
protective,O
anti,O
-,O
apoptotic,O
effect,O
",",O
and,O
the,O
rate,O
of,O
neutrophil,O
PCD,O
was,O
inversely,O
proportional,O
to,O
cell,O
concentration,O
",",O
indicating,O
an,O
anti,O
-,O
apoptotic,O
effect,O
(,O
Fig,O
.,O
2A,O
).,O
Whereas,O
following,O
12h,O
of,O
spontaneous,O
constitutive,O
PCD,O
only,O
5,O
%,O
of,O
cells,O
were,O
still,O
alive,O
at,O
a,O
concentration,O
of,O
0,O
.,O
5,O
×,O
106,O
neutrophils,O
/,O
ml,O
",",O
in,O
conditions,O
of,O
32,O
fold,O
concentration,O
",",O
at,O
16,O
×,O
106,O
neutrophils,O
/,O
ml,O
",",O
more,O
than,O
40,O
%,O
of,O
the,O
cells,O
were,O
still,O
alive,O
",",O
as,O
shown,O
by,O
Annexin,B-GP
V,I-GP
and,O
PI,O
negative,O
staining,O
(,O
Fig,O
.,O
2B,O
),O
and,O
verified,O
by,O
mitochondrial,O
potential,O
loss,O
studies,O
(,O
not,O
shown,O
"),",O
both,O
methods,O
of,O
apoptosis,O
detection,O
indicated,O
early,O
apoptosis,O
state,O
.,O
This,O
phenomenon,O
was,O
further,O
emphasized,O
using,O
cell,O
count,O
.,O
There,O
was,O
loss,O
of,O
over,O
50,O
%,O
of,O
cells,O
through,O
constitutive,O
spontaneous,O
PCD,O
at,O
concentrations,O
of,O
­­­­,O
0,O
.,O
5x106,O
/,O
ml,O
for,O
12h,O
(,O
Fig,O
.,O
2C,O
"),",O
and,O
this,O
loss,O
decreased,O
in,O
proportion,O
to,O
increasing,O
cell,O
concentrations,O
up,O
to,O
16x106,O
/,O
ml,O
.,O
At,O
concentrations,O
above,O
16x106,O
/,O
ml,O
",",O
there,O
was,O
a,O
decline,O
in,O
cell,O
number,O
and,O
a,O
prodeath,O
effect,O
",",O
probably,O
as,O
a,O
result,O
of,O
competition,O
for,O
nutrition,O
and,O
other,O
ingredients,O
.,O
Constitutive,O
spontaneous,O
neutrophil,O
PCD,O
.,O
A,O
.,O
Kinetics,O
of,O
spontaneous,O
constitutive,O
neutrophil,O
PCD,O
.,O
Neutrophils,O
were,O
isolated,O
and,O
allowed,O
to,O
undergo,O
spontaneous,O
constitutive,O
PCD,O
at,O
a,O
concentration,O
of,O
1,O
×,O
106,O
/,O
ml,O
.,O
Samples,O
were,O
obtained,O
at,O
the,O
indicated,O
intervals,O
",",O
and,O
the,O
apoptosis,O
rate,O
was,O
measured,O
using,O
Annexin,B-GP
V,I-GP
-,O
FITC,O
and,O
PI,O
staining,O
.,O
B,O
.,O
Transmission,O
electron,O
microscopy,O
(,O
TEM,O
),O
of,O
spontaneous,O
constitutive,O
neutrophil,O
PCD,O
.,O
Morphology,O
of,O
viable,O
or,O
early,O
apoptotic,O
(,O
white,O
arrow,O
),O
and,O
apoptotic,O
(,O
black,O
arrows,O
),O
neutrophils,O
is,O
shown,O
.,O
Apoptotic,O
cells,O
show,O
the,O
typical,O
morphology,O
of,O
condensed,O
cytoplasm,O
and,O
chromatin,O
.,O
Cells,O
were,O
prepared,O
for,O
TEM,O
as,O
described,O
in,O
Materials,O
and,O
methods,O
.,O
C,O
.,O
Inhibition,O
of,O
spontaneous,O
constitutive,O
neutrophil,O
PCD,O
by,O
pan,O
-,O
caspase,B-GP
inhibitor,O
zVAD,O
-,O
fmk,O
.,O
Sample,O
dot,O
plots,O
of,O
AnnexinV,B-GP
-,O
PI,O
staining,O
of,O
neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
for,O
14,O
h,O
at,O
a,O
concentration,O
of,O
1,O
×,O
106,O
/,O
ml,O
",",O
in,O
the,O
presence,O
or,O
absence,O
of,O
20,O
µM,O
Zvad,O
-,O
fmk,O
.,O
Pan,O
-,O
caspase,B-GP
inhibition,O
rescued,O
cells,O
from,O
apoptotic,O
death,O
and,O
viable,O
cells,O
are,O
increased,O
from,O
19,O
to,O
49,O
%,O
(,O
p,O
<,O
0,O
.,O
001,O
).,O
Data,O
are,O
representative,O
of,O
3,O
or,O
more,O
experiments,O
.,O
Spontaneous,O
constitutive,O
neutrophil,O
PCD,O
is,O
cell,O
concentration,O
-,O
dependent,O
.,O
A,O
.,O
Neutrophils,O
underwent,O
spontaneous,O
constitutive,O
PCD,O
for,O
12,O
h,O
at,O
cell,O
concentrations,O
ranging,O
from,O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
up,O
to,O
50,O
×,O
106,O
/,O
ml,O
.,O
(,O
The,O
physiological,O
blood,O
concentration,O
is,O
2,O
−,O
6,O
×,O
106,O
/,O
ml,O
.),O
Apoptosis,O
was,O
assessed,O
by,O
AnnexinV,B-GP
-,O
FITC,O
and,O
PI,O
staining,O
",",O
as,O
described,O
in,O
Materials,O
and,O
methods,O
.,O
Data,O
represents,O
the,O
mean,O
±,O
SD,O
of,O
3,O
experiments,O
.,O
B,O
.,O
Sample,O
dot,O
plots,O
of,O
AnnexinV,B-GP
-,O
PI,O
staining,O
of,O
neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
for,O
12,O
h,O
in,O
(,O
a,O
),O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
",",O
and,O
(,O
b,O
),O
16,O
×,O
106,O
/,O
ml,O
.,O
The,O
percentage,O
of,O
viable,O
",",O
early,O
(,O
AnnexinV,B-GP
+/,O
PI,O
−),O
and,O
late,O
(,O
AnnexinV,B-GP
+/,O
PI,O
+),O
apoptotic,O
cells,O
is,O
indicated,O
within,O
the,O
respective,O
quadrants,O
.,O
C,O
.,O
Survival,O
of,O
neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
",",O
based,O
on,O
cell,O
counts,O
.,O
Data,O
presented,O
is,O
the,O
mean,O
±,O
SD,O
of,O
3,O
experiments,O
.,O
Thus,O
",",O
at,O
physiological,O
concentrations,O
of,O
neutrophils,O
",",O
there,O
was,O
an,O
anti,O
-,O
apoptotic,O
effect,O
at,O
higher,O
neutrophil,O
concentrations,O
.,O
We,O
termed,O
this,O
a,O
“,O
community,O
effect,O
”,O
―,O
neutrophils,O
are,O
encouraged,O
to,O
live,O
longer,O
as,O
their,O
community,O
is,O
enlarged,O
.,O
Factors,O
mediating,O
the,O
community,O
effect,O
are,O
present,O
in,O
the,O
supernatant,O
In,O
order,O
to,O
determine,O
whether,O
the,O
factor,O
(,O
s,O
),O
responsible,O
for,O
the,O
community,O
anti,O
-,O
apoptotic,O
effect,O
are,O
found,O
in,O
the,O
supernatant,O
",",O
we,O
exchanged,O
media,O
obtained,O
from,O
low,O
-,O
and,O
high,O
concentrations,O
of,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
.,O
The,O
supernatants,O
from,O
high,O
concentrations,O
were,O
collected,O
and,O
used,O
as,O
media,O
for,O
low,O
-,O
concentration,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
of,O
the,O
same,O
donor,O
",",O
and,O
the,O
supernatants,O
of,O
low,O
concentrations,O
were,O
used,O
as,O
media,O
for,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
at,O
high,O
cell,O
concentration,O
.,O
Media,O
based,O
on,O
high,O
-,O
concentration,O
PCD,O
donors,O
(,O
16,O
×,O
106,O
cells,O
/,O
ml,O
),O
rescued,O
cells,O
undergoing,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
at,O
low,O
concentration,O
(,O
0,O
.,O
5,O
×,O
106,O
cells,O
/,O
ml,O
),O
from,O
apoptosis,O
",",O
as,O
compared,O
with,O
normal,O
medium,O
(,O
Fig,O
.,O
3A,O
).,O
High,O
-,O
concentration,O
medium,O
increased,O
the,O
rate,O
of,O
viable,O
cells,O
from,O
9,O
%,O
(,O
upper,O
left,O
panel,O
",",O
Fig,O
.,O
3B,O
),O
to,O
31,O
%,O
(,O
upper,O
right,O
panel,O
",",O
Fig,O
.,O
3B,O
).,O
In,O
the,O
opposite,O
experiment,O
",",O
low,O
-,O
concentration,O
media,O
had,O
no,O
effect,O
on,O
survival,O
in,O
high,O
cell,O
concentration,O
samples,O
(,O
left,O
and,O
right,O
lower,O
panels,O
",",O
Fig,O
.,O
3B,O
).,O
All,O
these,O
experiments,O
were,O
based,O
on,O
at,O
least,O
three,O
experiments,O
each,O
and,O
results,O
with,O
Annexin,B-GP
V,I-GP
were,O
verified,O
using,O
mitochondrial,O
potential,O
loss,O
studies,O
.,O
Identification,O
of,O
candidate,O
molecules,O
that,O
induce,O
the,O
community,O
effect,O
.,O
A,O
.,O
Supernatant,O
of,O
cells,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
at,O
high,O
concentrations,O
has,O
rescued,O
cells,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
from,O
apoptosis,O
at,O
low,O
concentrations,O
",",O
and,O
improved,O
their,O
survival,O
(,O
p,O
<,O
0,O
.,O
001,O
).,O
Data,O
is,O
representative,O
of,O
3,O
experiments,O
.,O
B,O
.,O
Representative,O
dot,O
plot,O
of,O
supernatant,O
transfer,O
assay,O
.,O
Apoptosis,O
was,O
assessed,O
by,O
AnnexinV,B-GP
and,O
PI,O
staining,O
of,O
neutrophils,O
after,O
12,O
h,O
of,O
spontaneous,O
constitutive,O
PCD,O
.,O
The,O
transfer,O
assay,O
was,O
performed,O
as,O
follows,O
:,O
neutrophils,O
underwent,O
spontaneous,O
constitutive,O
PCD,O
at,O
low,O
(,O
a,O
",",O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
),O
or,O
high,O
(,O
c,O
",",O
16,O
×,O
106,O
/,O
ml,O
),O
concentration,O
for,O
12,O
h,O
.,O
The,O
supernatant,O
of,O
the,O
cells,O
incubated,O
at,O
high,O
concentrations,O
was,O
collected,O
and,O
used,O
as,O
media,O
for,O
neutrophils,O
undergoing,O
constitutive,O
spontaneous,O
PCD,O
at,O
low,O
concentrations,O
(,O
b,O
"),",O
and,O
the,O
supernatant,O
of,O
the,O
cells,O
incubated,O
at,O
low,O
concentrations,O
was,O
collected,O
and,O
used,O
for,O
neutrophils,O
undergoing,O
constitutive,O
spontaneous,O
PCD,O
at,O
high,O
concentrations,O
(,O
d,O
).,O
C,O
.,O
SDS,O
-,O
PAGE,O
of,O
differentially,O
displayed,O
proteins,O
from,O
high,O
-,O
and,O
low,O
-,O
concentration,O
spontaneous,O
constitutive,O
PCD,O
.,O
The,O
supernatants,O
of,O
cells,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
at,O
high,O
-,O
and,O
low,O
concentrations,O
were,O
collected,O
",",O
and,O
the,O
proteins,O
were,O
purified,O
as,O
described,O
in,O
Materials,O
and,O
methods,O
.,O
Protein,O
samples,O
were,O
electrophorized,O
and,O
stained,O
with,O
Coomassie,O
",",O
as,O
shown,O
.,O
Two,O
proteins,O
",",O
∼,O
14,O
KD,O
and,O
∼,O
10,O
KD,O
",",O
were,O
identified,O
in,O
the,O
supernatant,O
of,O
cells,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
at,O
high,O
concentrations,O
(,O
16,O
×,O
106,O
/,O
ml,O
).,O
These,O
results,O
suggest,O
that,O
in,O
the,O
presence,O
of,O
high,O
neutrophil,O
concentrations,O
",",O
anti,O
-,O
apoptotic,O
factor,O
(,O
s,O
),O
are,O
secreted,O
and,O
provide,O
a,O
survival,O
signal,O
to,O
the,O
viable,O
neutrophil,O
community,O
.,O
Proteomic,O
analysis,O
of,O
the,O
supernatants,O
and,O
identification,O
of,O
S100A8,B-GP
and,O
S100A9,B-GP
as,O
candidate,O
molecules,O
for,O
mediation,O
of,O
the,O
community,O
anti,O
-,O
apoptotic,O
signal,O
We,O
used,O
a,O
differentially,O
displayed,O
proteomic,O
approach,O
",",O
as,O
we,O
have,O
previously,O
described,O
[,O
28,O
"],",O
to,O
search,O
for,O
secreted,O
factor,O
(,O
s,O
),O
in,O
the,O
supernatant,O
that,O
may,O
be,O
responsible,O
for,O
the,O
“,O
community,O
effect,O
”,O
on,O
neutrophil,O
survival,O
.,O
The,O
secreted,O
proteomes,O
of,O
neutrophils,O
undergoing,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
at,O
high,O
concentrations,O
(,O
16,O
×,O
106,O
/,O
ml,O
),O
and,O
low,O
concentrations,O
(,O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
),O
were,O
collected,O
and,O
compared,O
by,O
SDS,O
-,O
PAGE,O
and,O
Coomassie,O
staining,O
.,O
Differentially,O
expressed,O
proteins,O
were,O
further,O
analyzed,O
by,O
mass,O
spectrometry,O
(,O
MS,O
).,O
Expression,O
of,O
two,O
proteins,O
",",O
∼,O
10,O
KD,O
and,O
∼,O
14KD,O
",",O
represented,O
the,O
primary,O
difference,O
between,O
the,O
supernatants,O
(,O
Fig,O
.,O
3C,O
).,O
Both,O
were,O
expressed,O
at,O
significantly,O
greater,O
levels,O
in,O
supernatant,O
of,O
cells,O
cultured,O
at,O
high,O
neutrophil,O
concentrations,O
",",O
versus,O
supernatant,O
of,O
cells,O
cultured,O
at,O
low,O
concentrations,O
",",O
despite,O
protein,O
normalization,O
according,O
to,O
cell,O
number,O
and,O
equal,O
protein,O
loading,O
in,O
the,O
gel,O
.,O
Proteins,O
were,O
further,O
identified,O
by,O
MS,O
as,O
S100A8,B-GP
and,O
S100A9,B-GP
",",O
as,O
the,O
best,O
candidates,O
for,O
the,O
community,O
effect,O
(,O
Table,O
1,O
).,O
The,O
experimental,O
approach,O
was,O
designed,O
to,O
use,O
2D,O
gel,O
;,O
however,O
",",O
1D,O
gel,O
identified,O
with,O
high,O
certainty,O
two,O
candidate,O
proteins,O
that,O
were,O
chosen,O
for,O
further,O
functional,O
studies,O
.,O
Table,O
1,O
.,O
Proteins,O
identified,O
by,O
mass,O
spectrometry,O
.,O
Peptide,O
sequence,O
Protein,O
score,O
(,O
Mowse,O
),O
Identified,O
protein,O
Remarks,O
MTCKMSQLER,O
NIETIINTFH,O
QYSVKLGHPD,O
TLNQGEFKEL,O
VRKDLQNFLK,O
KENKNEKVIE,O
HIMEDLDTNA,O
DKQLSFEEFI,O
MLMARLTWAS,O
HEKMHEGDEG,O
PGHHHKPGLG,O
EGTP,O
330,O
S100A9,B-GP
Reported,O
role,O
in,O
inflammation,O
MLTELEKALN,O
SIIDVYHKYS,O
LIKGNFHAVY,O
RDDLKKLLET,O
ECPQYIRKKG,O
ADVWFKELDI,O
NTDGAVNFQE,O
FLILVIKMAW,O
QPTKKAMKKA,O
TKSS,O
458,O
S100A8,B-GP
Reported,O
role,O
in,O
inflammation,O
MVHLTPEEKS,O
AVTALWGKVN,O
VDEVGGEALG,O
RLLVVYPWTQ,O
RFFESFGDLS,O
TPDAVMGNPK,O
VKAHGKKVLG,O
AFSDGLAHLD,O
NLKGTFATLS,O
ELHCDKLHVD,O
PENFRLLGNV,O
LVCVLAHHFG,O
KKFTPPVQAA,O
YQKVVAGVAN,O
ALAHKYH,O
207,O
beta,B-GP
globin,I-GP
chain,O
variant,O
Beta,B-GP
globin,I-GP
chain,O
VLSPADKTNV,O
KAAWGKVGAH,O
AGEYGAEALE,O
RMFLSFPTTK,O
TYFPHFDLSH,O
GSAQVKGHGK,O
KVADALTNAV,O
AHVDDMPNAL,O
SALSDLHAHK,O
LRVDPWNFKL,O
LSHCLLVTLA,O
AHLPAEFTPA,O
VHASLDKFLA,O
SVSTVLTSKY,O
R,O
94,O
Chain,O
C,O
",",O
T,O
State,O
Human,B-OG
Hemoglobin,B-GP
[,O
alpha,O
V96w,O
],O
Hemoglobin,B-GP
chain,O
RRPDFCLEPP,O
YTGPCKARII,O
RYFYNAKAGL,O
CQTFVYGGCR,O
AKRNNFKSAE,O
DCMRTCGGA,O
113,O
Aprotinin,B-GP
Protease,B-GP
inhibitor,O
(,O
synthetic,O
),O
Analysis,O
of,O
proteins,O
identified,O
by,O
mass,O
spectrometry,O
.,O
Sequences,O
corresponding,O
to,O
the,O
identified,O
peptides,O
are,O
bolded,O
.,O
Score,O
was,O
based,O
on,O
molecular,O
weight,O
search,O
(,O
MOWSE,O
),O
peptide,O
-,O
mass,O
database,O
.,O
The,O
results,O
identified,O
S100A8,B-GP
and,O
S100A9,B-GP
as,O
candidate,O
proteins,O
.,O
Functional,O
studies,O
suggest,O
that,O
S100A8,B-GP
-,O
9,O
mediates,O
the,O
community,O
effect,O
We,O
sought,O
to,O
verify,O
S100A8,B-GP
and,O
A9,B-GP
mediation,O
of,O
the,O
community,O
anti,O
-,O
apoptotic,O
effect,O
using,O
recombinant,O
human,B-OG
S100A8,B-GP
and,O
A9,B-GP
(,O
kindly,O
provided,O
by,O
Philippe,O
A,O
.,O
Tessier,O
",",O
Laval,O
University,O
",",O
Quebec,O
",",O
Canada,O
),O
added,O
to,O
neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
.,O
Increased,O
S100A9,B-GP
and,O
S100A8,B-GP
/,O
9,O
levels,O
had,O
a,O
dramatic,O
rescue,O
effect,O
on,O
the,O
number,O
of,O
neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
at,O
low,O
cell,O
concentrations,O
(*,O
p,O
<,O
0,O
.,O
05,O
"),",O
paralleling,O
the,O
rescue,O
effect,O
of,O
the,O
high,O
cell,O
concentration,O
supernatant,O
(,O
Fig,O
.,O
4A,O
).,O
Survival,O
increased,O
by,O
more,O
than,O
150,O
%±,O
35,O
%,O
in,O
the,O
presence,O
of,O
5,O
µg,O
/,O
ml,O
of,O
S100A8,B-GP
/,O
9,O
",",O
as,O
measured,O
by,O
Annexin,B-GP
V,I-GP
and,O
PI,O
(**,O
p,O
<,O
0,O
.,O
02,O
).,O
The,O
survival,O
effect,O
of,O
S100A9,B-GP
and,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
was,O
more,O
prominent,O
compared,O
to,O
S100A9,B-GP
alone,O
.,O
Only,O
S100A9,B-GP
had,O
an,O
effect,O
already,O
at,O
a,O
concentration,O
of,O
1,O
µg,O
/,O
ml,O
.,O
Nonetheless,O
",",O
S100A8,B-GP
in,O
higher,O
concentrations,O
of,O
2,O
and,O
5,O
µg,O
/,O
ml,O
also,O
had,O
a,O
significant,O
rescue,O
effect,O
(,O
Fig,O
.,O
4A,O
).,O
To,O
further,O
verify,O
the,O
anti,O
-,O
apoptotic,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
",",O
we,O
measured,O
mitochondrial,O
transmemebrane,O
potential,O
as,O
an,O
additional,O
early,O
PCD,O
evaluation,O
",",O
demonstrating,O
a,O
perfect,O
correlation,O
to,O
the,O
Annexin,B-GP
V,I-GP
-,O
PI,O
measurements,O
(,O
Fig,O
.,O
4B,O
).,O
Effect,O
of,O
S100A9,B-GP
and,O
S100A8,B-GP
on,O
neutrophil,O
apoptosis,O
.,O
A,O
.,O
S100A9,B-GP
and,O
S100A8,B-GP
add,O
-,O
in,O
experiments,O
.,O
Varying,O
concentrations,O
of,O
S100A9,B-GP
",",O
S100A8,B-GP
",",O
and,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
were,O
added,O
to,O
supernatants,O
of,O
neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
at,O
a,O
concentration,O
of,O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
.,O
After,O
10,O
hours,O
apoptosis,O
was,O
evaluated,O
using,O
Annexin,B-GP
V,I-GP
-,O
PI,O
and,O
mitochondrial,O
staining,O
.,O
Data,O
is,O
presented,O
as,O
mean,O
±,O
SD,O
of,O
Annexin,B-GP
V,I-GP
-,O
PI,O
staining,O
(*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
02,O
).,O
B,O
.,O
S100A9,B-GP
and,O
S100A8,B-GP
add,O
-,O
in,O
experiments,O
.,O
A,O
representative,O
sample,O
of,O
Annexin,B-GP
V,I-GP
-,O
PI,O
and,O
mitochondrial,O
staining,O
.,O
Neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
without,O
(,O
a,O
and,O
c,O
),O
or,O
with,O
(,O
b,O
and,O
d,O
),O
the,O
addition,O
of,O
2,O
µg,O
/,O
ml,O
S100A8,B-GP
/,O
9,O
.,O
Cells,O
were,O
stained,O
either,O
with,O
Annexin,B-GP
V,I-GP
-,O
FITC,O
(,O
a,O
and,O
b,O
),O
or,O
with,O
DiOC6,O
(,O
c,O
and,O
d,O
"),",O
as,O
well,O
as,O
PI,O
(,O
a,O
",",O
b,O
",",O
c,O
",",O
d,O
),O
and,O
assessed,O
by,O
flow,O
cytometry,O
.,O
Dot,O
plots,O
are,O
representative,O
of,O
6,O
experiments,O
.,O
C,O
.,O
The,O
effect,O
of,O
anti,O
-,O
S100A8,B-GP
and,O
A9,B-GP
on,O
add,O
-,O
in,O
experiments,O
.,O
Neutrophils,O
undergoing,O
spontaneous,O
constitutive,O
PCD,O
at,O
a,O
concentration,O
of,O
0,O
.,O
5,O
×,O
106,O
/,O
ml,O
for,O
12h,O
",",O
with,O
rabbit,B-OG
polyclonal,O
antibody,B-GP
dilutions,O
of,O
1,O
∶,O
100,O
",",O
1,O
∶,O
1000,O
",",O
and,O
1,O
∶,O
10,O
",",O
000,O
against,O
S100A9,B-GP
and,O
S100A8,B-GP
",",O
were,O
then,O
treated,O
with,O
2,O
µg,O
/,O
ml,O
S100A8,B-GP
/,O
9,O
complex,O
.,O
Rabbit,B-OG
serum,O
at,O
the,O
same,O
dilutions,O
of,O
1,O
∶,O
100,O
",",O
1,O
∶,O
1000,O
",",O
and,O
1,O
∶,O
10,O
",",O
000,O
was,O
used,O
as,O
a,O
control,O
.,O
Apoptosis,O
was,O
assessed,O
using,O
Annexin,B-GP
V,I-GP
-,O
FITC,O
and,O
PI,O
staining,O
.,O
Percentages,O
of,O
viable,O
",",O
early,O
"-,",O
and,O
late,O
apoptotic,O
cells,O
are,O
indicated,O
within,O
the,O
respective,O
quadrants,O
.,O
Dot,O
plots,O
are,O
representative,O
of,O
6,O
experiments,O
.,O
We,O
sought,O
to,O
verify,O
whether,O
S100A9,B-GP
and,O
S100A8,B-GP
/,O
9,O
effects,O
are,O
blocked,O
with,O
specific,O
antibodies,B-GP
",",O
using,O
rabbit,B-OG
polyclonal,O
antibodies,B-GP
raised,O
against,O
human,B-OG
S100A8,B-GP
or,O
S100A9,B-GP
.,O
Antisera,O
were,O
used,O
at,O
a,O
range,O
of,O
dilutions,O
between,O
1,O
/,O
10,O
and,O
1,O
/,O
10,O
",",O
000,O
",",O
as,O
indicated,O
.,O
Adding,O
the,O
antibodies,B-GP
reduced,O
neutrophil,O
survival,O
by,O
30,O
−,O
40,O
%,O
in,O
various,O
dilutions,O
(,O
Fig,O
.,O
4C,O
"),",O
compared,O
to,O
control,O
antibodies,B-GP
",",O
and,O
induced,O
accelerated,O
PCD,O
similar,O
to,O
that,O
seen,O
in,O
spontaneous,O
constitutive,O
PCD,O
in,O
low,O
cell,O
concentration,O
supernatants,O
.,O
Mitochondrial,O
transmemebrane,O
potential,O
as,O
an,O
additional,O
early,O
PCD,O
evaluation,O
",",O
demonstrated,O
a,O
perfect,O
correlation,O
to,O
the,O
Annexin,B-GP
V,I-GP
-,O
PI,O
measurements,O
.,O
This,O
further,O
supports,O
a,O
role,O
for,O
S100A8,B-GP
/,O
9,O
as,O
the,O
main,O
factor,O
triggering,O
the,O
community,O
anti,O
-,O
apoptotic,O
effect,O
.,O
S100A8,B-GP
/,O
9,O
does,O
not,O
mediate,O
the,O
community,O
effect,O
via,O
McL1,B-GP
",",O
A1,B-GP
",",O
the,O
bcl,B-GP
-,I-GP
2,I-GP
protein,O
family,O
",",O
or,O
survivin,B-GP
We,O
examined,O
the,O
expression,O
of,O
different,O
members,O
of,O
the,O
PCD,O
intrinsic,O
pathway,O
",",O
focusing,O
on,O
those,O
known,O
to,O
be,O
important,O
in,O
neutrophil,O
PCD,O
.,O
McL1,B-GP
",",O
an,O
anti,O
-,O
apoptotic,O
member,O
",",O
was,O
expressed,O
by,O
freshly,O
isolated,O
neutrophils,O
(,O
see,O
Figure,O
S3,O
"),",O
and,O
expression,O
was,O
still,O
detected,O
during,O
spontaneous,O
constitutive,O
apoptosis,O
.,O
Adding,O
S100A8,B-GP
/,O
9,O
did,O
not,O
change,O
McL1,B-GP
expression,O
.,O
A1,B-GP
protein,O
has,O
also,O
been,O
found,O
to,O
be,O
expressed,O
in,O
neutrophils,O
[,O
13,O
"],",O
[,O
15,O
].,O
We,O
found,O
that,O
A1,B-GP
was,O
expressed,O
by,O
freshly,O
isolated,O
neutrophils,O
",",O
with,O
expression,O
dramatically,O
decreased,O
during,O
constitutive,O
spontaneous,O
PCD,O
(,O
see,O
Figure,O
S3,O
).,O
Adding,O
S100A8,B-GP
/,O
9,O
did,O
not,O
prevent,O
decreased,O
A1,B-GP
expression,O
.,O
Bclxl,B-GP
was,O
found,O
to,O
be,O
expressed,O
by,O
freshly,O
isolated,O
neutrophils,O
.,O
Expression,O
was,O
neither,O
decreased,O
by,O
constitutive,O
spontaneous,O
PCD,O
",",O
nor,O
increased,O
by,O
adding,O
S100A8,B-GP
/,O
9,O
.,O
We,O
also,O
examined,O
the,O
expression,O
of,O
Bcl2,B-GP
and,O
survivin,B-GP
proteins,O
.,O
These,O
two,O
proteins,O
were,O
not,O
expressed,O
by,O
freshly,O
isolated,O
neutrophils,O
or,O
during,O
induction,O
of,O
constitutive,O
spontaneous,O
PCD,O
",",O
which,O
is,O
consistent,O
with,O
observations,O
that,O
peripheral,O
blood,O
neutrophils,O
don,O
',O
t,O
express,O
these,O
two,O
proteins,O
[,O
11,O
−,O
14,O
"],",O
.,O
In,O
conclusion,O
",",O
we,O
could,O
not,O
identify,O
an,O
anti,O
-,O
apoptotic,O
mechanism,O
in,O
the,O
main,O
intrinsic,O
pathway,O
players,O
of,O
neutrophil,O
PCD,O
.,O
The,O
survival,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
involves,O
the,O
MEK,B-GP
-,O
ERK,B-GP
signaling,O
pathway,O
",",O
and,O
is,O
partially,O
mediated,O
through,O
TLR4,B-GP
and,O
the,O
integrin,B-GP
CD11b,B-GP
/,O
CD18,B-GP
S100A8,B-GP
and,O
A9,B-GP
specific,O
receptors,O
have,O
not,O
yet,O
been,O
identified,O
.,O
However,O
",",O
Vogl,O
et,O
al,O
demonstrated,O
that,O
S100A8,B-GP
specifically,O
interacts,O
with,O
the,O
TLR4,B-GP
-,O
MD2,B-GP
complex,O
[,O
29,O
"],",O
and,O
Newton,O
RA,O
et,O
al,O
suggested,O
that,O
a,O
pertusis,B-GP
toxin,I-GP
-,O
sensitive,O
G,B-GP
-,I-GP
coupled,I-GP
protein,I-GP
receptor,I-GP
could,O
be,O
the,O
S100A9,B-GP
receptor,I-GP
[,O
30,O
].,O
S100A8,B-GP
and,O
A9,B-GP
have,O
been,O
shown,O
to,O
exert,O
their,O
effects,O
via,O
CD36,B-GP
and,O
CD11b,B-GP
/,O
CD18,B-GP
(,O
Mac,B-GP
-,I-GP
1,I-GP
),O
[,O
30,O
−,O
32,O
].,O
CD11b,B-GP
/,O
CD18,B-GP
is,O
well,O
expressed,O
in,O
freshly,O
isolated,O
neutrophils,O
",",O
but,O
CD36,B-GP
is,O
not,O
(,O
Fig,O
.,O
5A,O
",",O
upper,O
panel,O
).,O
Furthermore,O
",",O
CD11b,B-GP
/,O
CD18,B-GP
was,O
suggested,O
as,O
a,O
pro,O
-,O
apoptotic,O
integrin,B-GP
[,O
33,O
"],",O
[,O
34,O
].,O
The,O
survival,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
is,O
mediated,O
through,O
CD11b,B-GP
/,O
CD18,B-GP
and,O
TLR4,B-GP
.,O
A,O
.,O
Expression,O
of,O
CD11b,B-GP
on,O
neutrophils,O
.,O
Upper,O
panel,O
.,O
Freshly,O
isolated,O
neutrophils,O
express,O
CD11b,B-GP
/,O
CD18,B-GP
(,O
isotype,O
control,O
is,O
shown,O
as,O
filled,O
histogram,O
and,O
anti,O
-,O
CD11b,B-GP
/,O
CD18,B-GP
-,O
PE,B-GP
in,O
dotted,O
line,O
",",O
middle,O
),O
but,O
not,O
CD36,B-GP
(,O
left,O
).,O
Following,O
12,O
h,O
of,O
spontaneous,O
PCD,O
(,O
gray,O
line,O
",",O
middle,O
),O
there,O
was,O
a,O
marked,O
decrease,O
in,O
the,O
expression,O
of,O
CD11b,B-GP
/,O
CD18,B-GP
in,O
comparison,O
to,O
freshly,O
isolated,O
neutrophils,O
.,O
Addition,O
of,O
S100A8,B-GP
/,O
9,O
resulted,O
in,O
two,O
different,O
cell,O
populations,O
:,O
high,O
and,O
low,O
-,O
CD11b,B-GP
/,O
CD18,B-GP
(,O
black,O
line,O
",",O
right,O
).,O
Lower,O
panel,O
.,O
Left,O
.,O
Correlation,O
between,O
CD11b,B-GP
and,O
phosphatidylserine,O
expression,O
demonstrates,O
that,O
when,O
neutrophils,O
become,O
apoptotic,O
they,O
downregulate,O
CD11b,B-GP
expression,O
.,O
Right,O
.,O
S100A8,B-GP
/,O
9,O
upregulates,O
CD11b,B-GP
expression,O
.,O
B,O
.,O
S100A8,B-GP
/,O
9,O
dramatically,O
increases,O
CD11b,B-GP
on,O
viable,O
cells,O
.,O
Viable,O
cells,O
(,O
R1,O
",",O
black,O
line,O
),O
increase,O
CD11b,B-GP
expression,O
from,O
a,O
mean,O
fluorescence,O
of,O
552,O
to,O
1094,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
Apoptotic,O
cells,O
(,O
R2,O
",",O
gray,O
line,O
),O
still,O
maintain,O
some,O
of,O
this,O
effect,O
and,O
show,O
a,O
mean,O
fluorescence,O
of,O
473,O
",",O
compared,O
to,O
362,O
in,O
the,O
absence,O
of,O
S100A8,B-GP
/,O
9,O
.,O
Filled,O
histograms,O
represent,O
isotype,O
control,O
.,O
Neutrophils,O
were,O
harvested,O
after,O
12,O
h,O
spontaneous,O
constitutive,O
PCD,O
",",O
with,O
or,O
without,O
treatment,O
with,O
2,O
µg,O
/,O
ml,O
S100A8,B-GP
/,O
9,O
.,O
Histograms,O
are,O
representative,O
of,O
at,O
least,O
3,O
different,O
experiments,O
.,O
C,O
.,O
The,O
survival,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
in,O
the,O
presence,O
of,O
anti,O
-,O
CD11b,B-GP
/,O
CD18,B-GP
.,O
Upper,O
panel,O
.,O
Right,O
.,O
Neutrophils,O
were,O
incubated,O
for,O
12,O
h,O
and,O
treated,O
with,O
either,O
anti,O
-,O
CD11b,B-GP
or,O
the,O
isotype,O
control,O
IgG1,B-GP
before,O
addition,O
of,O
S100A8,B-GP
/,O
9,O
complex,O
.,O
Integrin,B-GP
inhibition,O
reduced,O
the,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
by,O
40,O
−,O
100,O
%,O
in,O
comparison,O
with,O
the,O
isotype,O
control,O
(,O
p,O
<,O
0,O
.,O
001,O
).,O
The,O
average,O
of,O
6,O
experiments,O
is,O
presented,O
.,O
Lower,O
panel,O
.,O
A,O
representative,O
dot,O
plot,O
is,O
shown,O
.,O
Upper,O
panel,O
.,O
Left,O
.,O
S100A8,B-GP
/,O
9,O
binds,O
to,O
CD11b,B-GP
/,O
CD18,B-GP
.,O
CHO,O
cells,O
transfected,O
with,O
CR3,B-GP
(,O
black,O
),O
or,O
vector,O
(,O
gray,O
),O
were,O
evaluated,O
for,O
S100A8,B-GP
/,O
9,O
binding,O
.,O
CR3,B-GP
-,O
ransfected,O
cells,O
bound,O
at,O
rates,O
almost,O
twofold,O
higher,O
than,O
CHO,O
control,O
cells,O
(,O
median,O
fluorescence,O
13,O
.,O
3,O
vs,O
.,O
6,O
.,O
6,O
",",O
p,O
<,O
0,O
.,O
001,O
).,O
The,O
filled,O
curve,O
represents,O
isotype,O
control,O
;,O
the,O
histogram,O
is,O
representative,O
of,O
3,O
experiments,O
.,O
D,O
.,O
S100A8,B-GP
/,O
9,O
effect,O
on,O
neutrophils,O
from,O
a,O
CD11b,B-GP
/,O
CD18,B-GP
-,O
deficient,O
patient,O
.,O
Neutrophil,O
expression,O
of,O
CD11b,B-GP
from,O
a,O
healthy,O
control,O
and,O
a,O
patient,O
with,O
leukocyte,B-DS
adhesion,I-DS
deficiency,I-DS
is,O
shown,O
in,O
the,O
upper,O
panel,O
.,O
Spontaneous,O
constitutive,O
apoptosis,O
is,O
shown,O
in,O
the,O
lower,O
panel,O
",",O
together,O
with,O
the,O
S100A8,B-GP
/,O
9,O
effect,O
.,O
Neutrophils,O
were,O
isolated,O
from,O
a,O
CD11b,B-GP
-,O
deficient,O
patient,O
and,O
a,O
healthy,O
control,O
",",O
as,O
described,O
in,O
Materials,O
and,O
methods,O
",",O
incubated,O
at,O
a,O
concentration,O
of,O
1,O
×,O
106,O
/,O
ml,O
and,O
allowed,O
to,O
undergo,O
spontaneous,O
constitutive,O
PCD,O
for,O
10,O
h,O
",",O
with,O
or,O
without,O
addition,O
of,O
S100A8,B-GP
/,O
9,O
.,O
Apoptosis,O
was,O
assessed,O
by,O
Annexin,B-GP
V,I-GP
-,O
PI,O
staining,O
.,O
E,O
.,O
The,O
survival,O
effect,O
induced,O
by,O
the,O
complex,O
S100A8,B-GP
/,O
9,O
in,O
the,O
presence,O
of,O
pertussis,B-GP
toxin,I-GP
.,O
Bordetella,B-OG
pertussis,I-OG
toxin,O
at,O
100,O
and,O
500,O
ng,O
/,O
ml,O
were,O
added,O
to,O
neutrophils,O
45,O
min,O
before,O
adding,O
S100A8,B-GP
/,O
9,O
.,O
Neutrophils,O
then,O
were,O
allowed,O
to,O
undergo,O
constitutive,O
spontaneous,O
PCD,O
that,O
was,O
assessed,O
using,O
AnnexinV,B-GP
-,O
FITC,O
and,O
PI,O
staining,O
after,O
12,O
h,O
.,O
The,O
dot,O
plots,O
are,O
representative,O
of,O
3,O
experiments,O
.,O
F,O
.,O
The,O
survival,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
in,O
the,O
presence,O
of,O
anti,O
-,O
TLR4,B-GP
.,O
Neutrophils,O
were,O
incubated,O
for,O
10,O
h,O
and,O
treated,O
with,O
either,O
anti,O
-,O
TLR4,B-GP
or,O
the,O
isotype,O
control,O
IgG2a,B-GP
",",O
as,O
described,O
in,O
Materials,O
and,O
methods,O
.,O
Inhibition,O
of,O
TLR4,B-GP
abrogated,O
the,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
by,O
30,O
−,O
60,O
%,O
(,O
p,O
<,O
0,O
.,O
001,O
),O
in,O
comparison,O
with,O
the,O
isotype,O
control,O
",",O
as,O
seen,O
in,O
upper,O
panel,O
.,O
The,O
upper,O
panel,O
is,O
presented,O
as,O
percentage,O
of,O
control,O
.,O
The,O
experiment,O
is,O
a,O
summary,O
of,O
four,O
experiments,O
(,O
upper,O
panel,O
),O
with,O
representative,O
Plots,O
in,O
the,O
lower,O
panel,O
.,O
Following,O
spontaneous,O
constitutive,O
PCD,O
",",O
we,O
detected,O
a,O
homogeneous,O
decrease,O
in,O
neutrophil,O
expression,O
of,O
CD11b,B-GP
/,O
CD18,B-GP
.,O
Gating,O
apoptotic,O
(,O
Annexin,B-GP
V,I-GP
-,O
positive,O
),O
versus,O
nonapoptotic,O
(,O
Annexin,B-GP
V,I-GP
-,O
negative,O
),O
cells,O
(,O
Fig,O
.,O
5B,O
),O
revealed,O
higher,O
CD11b,B-GP
/,O
CD18,B-GP
expression,O
on,O
viable,O
-,O
versus,O
apoptotic,O
neutrophils,O
(,O
Fig,O
.,O
5A,O
−,O
B,O
).,O
Furthermore,O
",",O
adding,O
S100A8,B-GP
/,O
9,O
dramatically,O
upregulated,O
CD11b,B-GP
/,O
CD18,B-GP
",",O
establishing,O
a,O
new,O
subpopulation,O
with,O
very,O
high,O
expression,O
on,O
viable,O
cells,O
(,O
Fig,O
.,O
5A,O
−,O
B,O
).,O
We,O
then,O
blocked,O
CD11b,B-GP
/,O
CD18,B-GP
prior,O
to,O
addition,O
of,O
S100A8,B-GP
/,O
9,O
.,O
CD11b,B-GP
inhibition,O
during,O
constitutive,O
spontaneous,O
neutrophil,O
PCD,O
decreased,O
cell,O
survival,O
by,O
20,O
"%,",O
and,O
in,O
the,O
presence,O
of,O
S100A8,B-GP
/,O
9,O
",",O
CD11b,B-GP
inhibition,O
cut,O
the,O
survival,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
by,O
50,O
−,O
75,O
%,O
(,O
Fig,O
.,O
5C,O
"),",O
suggesting,O
that,O
S100A8,B-GP
/,O
9,O
may,O
exert,O
its,O
survival,O
effect,O
",",O
at,O
least,O
in,O
part,O
",",O
by,O
either,O
binding,O
or,O
expressing,O
CD11b,B-GP
",",O
a,O
known,O
receptor,O
involved,O
in,O
neutrophil,O
apoptosis,O
.,O
For,O
further,O
assessments,O
",",O
we,O
used,O
a,O
CHO,O
cell,O
line,O
transfected,O
with,O
CD11b,B-GP
/,O
CD18,B-GP
.,O
Transfected,O
CHO,O
cells,O
increased,O
binding,O
of,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
by,O
almost,O
twofold,O
in,O
comparison,O
with,O
control,O
CHO,O
cells,O
(,O
Fig,O
.,O
5C,O
",",O
upper,O
right,O
).,O
However,O
",",O
when,O
we,O
examined,O
the,O
effect,O
of,O
recombinant,O
S100A8,B-GP
/,O
9,O
on,O
CD11b,B-GP
/,O
CD18,B-GP
-,O
deficient,O
neutrophils,O
from,O
a,O
leukocyte,B-DS
adhesion,I-DS
deficiency,I-DS
(,O
LAD,B-DS
),O
patient,O
",",O
results,O
were,O
less,O
clear,O
.,O
As,O
expected,O
",",O
CD11b,B-GP
-,O
deficient,O
neutrophils,O
showed,O
delayed,O
PCD,O
in,O
comparison,O
with,O
neutrophils,O
from,O
healthy,O
donors,O
(,O
Fig,O
.,O
5D,O
"),",O
however,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
kept,O
its,O
protective,O
anti,O
-,O
apoptotic,O
effect,O
on,O
CD11b,B-GP
-,O
deficient,O
neutrophils,O
",",O
and,O
survival,O
was,O
increased,O
by,O
50,O
−,O
90,O
%.,O
This,O
supports,O
the,O
hypothesis,O
that,O
these,O
proteins,O
exert,O
their,O
survival,O
effect,O
only,O
partially,O
by,O
CD11b,B-GP
/,O
CD18,B-GP
",",O
and,O
other,O
receptors,O
are,O
involved,O
.,O
To,O
evaluate,O
the,O
role,O
of,O
one,O
alternative,O
candidate,O
",",O
we,O
examined,O
a,O
G,B-GP
-,I-GP
coupled,I-GP
protein,I-GP
receptor,I-GP
.,O
Pertusis,B-GP
toxin,I-GP
",",O
which,O
abrogates,O
G,B-GP
-,I-GP
coupled,I-GP
protein,I-GP
receptor,I-GP
function,O
",",O
did,O
not,O
influence,O
the,O
survival,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
(,O
Fig,O
.,O
5E,O
).,O
An,O
additional,O
possible,O
receptor,O
is,O
Toll,B-GP
-,I-GP
like,I-GP
receptor,I-GP
4,I-GP
[,O
29,O
].,O
Inhibiting,O
TLR4,B-GP
abrogated,O
the,O
survival,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
by,O
25,O
−,O
60,O
%,O
(,O
Fig,O
.,O
5F,O
"),",O
suggesting,O
that,O
both,O
CD11b,B-GP
/,O
CD18,B-GP
and,O
TLR4,B-GP
may,O
be,O
involved,O
in,O
the,O
pathway,O
enabling,O
these,O
proteins,O
to,O
affect,O
neutrophil,O
PCD,O
.,O
Extracellular,B-GP
signal,I-GP
-,I-GP
regulated,I-GP
kinase,I-GP
(,O
ERK,B-GP
"),",O
one,O
of,O
the,O
mitogen,B-GP
-,I-GP
activated,I-GP
protein,I-GP
kinases,I-GP
(,O
MAPK,B-GP
"),",O
is,O
involved,O
in,O
integrin,B-GP
signaling,O
and,O
Toll,B-GP
-,I-GP
like,I-GP
receptors,I-GP
in,O
general,O
.,O
It,O
appears,O
to,O
mediate,O
signals,O
promoting,O
cell,O
proliferation,O
",",O
differentiation,O
",",O
and,O
survival,O
",",O
as,O
reviewed,O
by,O
Roux,O
",",O
et,O
al,O
[,O
35,O
].,O
We,O
assessed,O
the,O
role,O
of,O
ERK,B-GP
in,O
the,O
neutrophil,O
S100A8,B-GP
/,O
9,O
survival,O
effect,O
using,O
intracellular,O
staining,O
of,O
phosphorylated,O
ERK,B-GP
.,O
Neutrophils,O
exposed,O
to,O
S100A8,B-GP
/,O
9,O
for,O
10,O
min,O
showed,O
more,O
than,O
a,O
threefold,O
increase,O
in,O
phosphorylation,O
of,O
the,O
ERK,B-GP
kinase,O
(,O
Fig,O
.,O
6A,O
).,O
This,O
activation,O
continues,O
to,O
a,O
lesser,O
extent,O
following,O
30,O
and,O
60,O
min,O
exposure,O
.,O
Furthermore,O
",",O
the,O
inhibitor,O
PD98059,O
(,O
MEK,B-GP
inhibitor,O
),O
reduced,O
ERK,B-GP
phosphorylation,O
by,O
more,O
than,O
50,O
%,O
(,O
Fig,O
.,O
6B,O
),O
and,O
abolished,O
the,O
S100A8,B-GP
/,O
9,O
survival,O
effect,O
by,O
50,O
−,O
100,O
%,O
at,O
various,O
concentrations,O
(,O
Fig,O
.,O
6C,O
"),",O
suggesting,O
that,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
survival,O
effect,O
involves,O
the,O
MEK,B-GP
-,O
ERK,B-GP
signaling,O
pathway,O
.,O
Effects,O
of,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
are,O
mediated,O
through,O
the,O
MAPK,B-GP
-,O
ERK,B-GP
pathway,O
.,O
A,O
.,O
Phosphorylation,O
of,O
MAPK,B-GP
following,O
exposure,O
to,O
S100A8,B-GP
/,O
9,O
.,O
Freshly,O
isolated,O
neutrophils,O
with,O
or,O
without,O
treatment,O
with,O
2,O
µg,O
/,O
ml,O
S100A8,B-GP
/,O
9,O
for,O
various,O
times,O
as,O
indicated,O
",",O
and,O
then,O
prepared,O
for,O
intracellular,O
staining,O
with,O
mouse,B-OG
anti,O
-,O
human,B-OG
phospho,O
-,O
p44,B-GP
/,O
42,O
MAPK,B-GP
alexa,O
fluor,O
488,O
(,O
gray,O
),O
or,O
isotype,O
control,O
(,O
black,O
"),",O
as,O
described,O
in,O
Materials,O
and,O
methods,O
.,O
In,O
the,O
presence,O
of,O
S100A8,B-GP
/,O
9,O
",",O
phosphorylation,O
was,O
increased,O
by,O
3,O
.,O
22,O
-,O
fold,O
after,O
10,O
min,O
(,O
p,O
<,O
0,O
.,O
001,O
"),",O
1,O
.,O
5,O
-,O
fold,O
after,O
30,O
min,O
(,O
p,O
<,O
0,O
.,O
001,O
"),",O
and,O
decayed,O
at,O
60,O
min,O
(,O
p,O
<,O
0,O
.,O
001,O
).,O
Histograms,O
are,O
representative,O
of,O
3,O
independent,O
experiments,O
.,O
B,O
.,O
Reduced,O
phosphorylation,O
of,O
MAPK,B-GP
following,O
exposure,O
to,O
S100A8,B-GP
/,O
9,O
in,O
the,O
presence,O
of,O
PD98059,O
",",O
a,O
MAPK,B-GP
phosphorylation,O
inhibitor,O
.,O
Freshly,O
isolated,O
neutrophils,O
were,O
treated,O
with,O
the,O
inhibitor,O
PD98059,O
or,O
with,O
DMSO,O
as,O
a,O
control,O
for,O
30,O
min,O
",",O
and,O
then,O
treated,O
with,O
2,O
µg,O
/,O
ml,O
S100A8,B-GP
/,O
9,O
.,O
Cells,O
were,O
then,O
harvested,O
and,O
prepared,O
for,O
intracellular,O
staining,O
of,O
phospho,O
-,O
p44,B-GP
/,O
42,O
MAPK,B-GP
(,O
gray,O
),O
or,O
isotype,O
control,O
(,O
black,O
"),",O
as,O
described,O
in,O
Materials,O
and,O
methods,O
.,O
Treatment,O
with,O
PD98059,O
inhibitor,O
reduced,O
phosphorylation,O
caused,O
by,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
(,O
p,O
<,O
0,O
.,O
001,O
).,O
Histograms,O
are,O
representative,O
of,O
3,O
experiments,O
.,O
C,O
.,O
Effect,O
of,O
the,O
S100A8,B-GP
/,O
9,O
complex,O
in,O
the,O
presence,O
of,O
MAPK,B-GP
-,O
ERK,B-GP
inhibitor,O
.,O
The,O
effect,O
of,O
S100A8,B-GP
/,O
9,O
was,O
assessed,O
in,O
the,O
presence,O
of,O
PD98059,O
.,O
Freshly,O
isolated,O
neutrophils,O
were,O
treated,O
with,O
varying,O
combinations,O
and,O
concentrations,O
of,O
DMSO,O
(,O
white,O
bars,O
"),",O
S100A8,B-GP
/,O
9,O
complex,O
(,O
gray,O
bars,O
"),",O
or,O
S100A8,B-GP
/,O
9,O
complex,O
with,O
PD98059,O
(,O
black,O
bars,O
"),",O
as,O
indicated,O
",",O
for,O
30,O
min,O
before,O
adding,O
S100A8,B-GP
/,O
9,O
.,O
Neutrophils,O
were,O
allowed,O
to,O
undergo,O
constitutive,O
spontaneous,O
PCD,O
.,O
Results,O
represent,O
the,O
percentage,O
of,O
viable,O
cells,O
according,O
to,O
Annexin,B-GP
V,I-GP
-,O
FITC,O
and,O
PI,O
staining,O
.,O
Data,O
is,O
representative,O
of,O
3,O
experiments,O
(,O
p,O
<,O
0,O
.,O
001,O
).,O
Apoptotic,O
neutrophils,O
are,O
not,O
activated,O
neutrophils,O
As,O
S100A8,B-GP
/,O
9,O
was,O
mainly,O
reported,O
thus,O
far,O
to,O
be,O
released,O
during,O
inflammation,O
(,O
see,O
discussion,O
"),",O
it,O
may,O
be,O
attributed,O
to,O
release,O
due,O
to,O
neutrophil,O
activation,O
.,O
We,O
wanted,O
to,O
further,O
verify,O
that,O
apoptotic,O
neutrophils,O
are,O
not,O
activated,O
due,O
to,O
extraction,O
method,O
or,O
in,O
vitro,O
effect,O
.,O
Therefore,O
we,O
analyzed,O
three,O
surface,O
molecules,O
that,O
are,O
upregulated,O
upon,O
neutrophil,O
activation,O
and,O
downregulated,O
upon,O
neutrophil,O
PCD,O
.,O
In,O
figures,O
S1,O
and,O
S2,O
",",O
CD16,B-GP
and,O
CD62L,B-GP
",",O
both,O
markers,O
of,O
neutrophil,O
activation,O
showed,O
clear,O
down,O
regulation,O
in,O
the,O
examined,O
neutrophils,O
",",O
in,O
correlation,O
to,O
apoptotic,O
state,O
[,O
36,O
].,O
In,O
addition,O
CD11b,B-GP
",",O
is,O
a,O
third,O
molecule,O
",",O
that,O
is,O
upregulated,O
upon,O
activation,O
was,O
downregulated,O
in,O
apoptotic,O
neutrophils,O
releasing,O
S100A8,B-GP
and,O
S100A9,B-GP
(,O
see,O
Figure,O
5,O
).,O
Taken,O
together,O
",",O
S100,B-GP
A8,I-GP
and,O
S100A9,B-GP
were,O
released,O
in,O
the,O
context,O
of,O
apoptotic,O
neutrophil,O
death,O
in,O
non,O
activated,O
neutrophils,O
.,O
Discussion,O
Neutrophils,O
are,O
responsible,O
for,O
the,O
body,O
',O
s,O
rapid,O
and,O
effective,O
response,O
to,O
infection,B-DS
or,O
injury,O
[,O
37,O
].,O
Efficient,O
function,O
necessitates,O
an,O
optimal,O
balance,O
between,O
a,O
sufficient,O
number,O
of,O
blood,O
neutrophils,O
",",O
response,O
to,O
stimuli,O
",",O
and,O
transmigration,O
properties,O
",",O
on,O
one,O
hand,O
",",O
against,O
regulation,O
of,O
the,O
termination,O
of,O
a,O
neutrophil,O
-,O
mediated,O
inflammatory,O
response,O
on,O
the,O
other,O
.,O
Thus,O
",",O
control,O
of,O
neutrophil,O
turnover,O
in,O
the,O
bone,O
marrow,O
and,O
circulation,O
",",O
and,O
at,O
inflammatory,O
sites,O
",",O
is,O
key,O
to,O
both,O
homeostasis,O
and,O
inflammation,O
.,O
PCD,O
plays,O
a,O
critical,O
role,O
in,O
neutrophil,O
homeostasis,O
for,O
an,O
optimal,O
functioning,O
in,O
the,O
human,B-OG
body,O
.,O
Polymorphonuclears,O
comprise,O
approximately,O
75,O
%,O
of,O
all,O
nucleated,O
cells,O
in,O
the,O
hematopoietic,O
compartment,O
of,O
the,O
newborn,O
marrow,O
",",O
with,O
the,O
majority,O
being,O
neutrophils,O
.,O
Already,O
in,O
the,O
bone,O
marrow,O
",",O
large,O
-,O
scale,O
neutrophil,O
death,O
and,O
removal,O
of,O
neutrophils,O
by,O
phagocytes,O
are,O
seen,O
[,O
38,O
].,O
Yet,O
",",O
the,O
major,O
regulator,O
of,O
blood,O
neutrophil,O
counts,O
",",O
as,O
well,O
as,O
neutrophil,O
counts,O
at,O
inflammatory,O
sites,O
",",O
is,O
PCD,O
",",O
which,O
allows,O
only,O
a,O
short,O
life,O
span,O
",",O
with,O
modulation,O
according,O
to,O
needs,O
such,O
as,O
inflammation,O
.,O
Here,O
we,O
show,O
that,O
the,O
S100,B-GP
A8,I-GP
/,O
9,O
complex,O
regulates,O
neutrophil,O
number,O
and,O
PCD,O
in,O
response,O
to,O
neutrophil,O
concentration,O
",",O
by,O
an,O
anti,O
-,O
apoptotic,O
effect,O
.,O
S100A9,B-GP
(,O
MRP14,B-GP
),O
and,O
S100A8,B-GP
(,O
MRP8,B-GP
),O
constitute,O
roughly,O
40,O
%,O
of,O
the,O
cytosolic,O
protein,O
in,O
neutrophils,O
;,O
their,O
pure,O
abundance,O
implies,O
an,O
important,O
role,O
in,O
neutrophil,O
functions,O
.,O
However,O
",",O
our,O
understanding,O
of,O
the,O
mechanisms,O
implicating,O
both,O
molecules,O
in,O
neutrophil,O
/,O
monocyte,O
physiology,O
remains,O
incomplete,O
",",O
as,O
reviewed,O
by,O
Nacken,O
",",O
et,O
al,O
[,O
39,O
].,O
S100A9,B-GP
and,O
S100A8,B-GP
readily,O
form,O
hetero,O
-,O
and,O
homodimeric,O
",",O
trimeric,O
",",O
and,O
tetrameric,O
complexes,O
",",O
but,O
apparently,O
also,O
exert,O
specific,O
functions,O
as,O
monomers,O
.,O
It,O
has,O
been,O
suggested,O
that,O
S100A9,B-GP
plays,O
a,O
prominent,O
role,O
in,O
leukocyte,O
trafficking,O
and,O
arachidonic,O
acid,O
metabolism,O
",",O
and,O
elevated,O
S100A9,B-GP
and,O
S100A8,B-GP
levels,O
are,O
found,O
in,O
body,O
fluids,O
of,O
inflamed,O
tissues,O
.,O
When,O
neutrophils,O
undergo,O
PCD,O
",",O
they,O
release,O
S100A8,B-GP
/,O
9,O
",",O
which,O
partially,O
protects,O
surrounding,O
neutrophils,O
from,O
PCD,O
",",O
a,O
mechanism,O
that,O
may,O
be,O
of,O
crucial,O
importance,O
in,O
fine,O
-,O
tuning,O
neutrophil,O
concentrations,O
in,O
the,O
bone,O
marrow,O
and,O
blood,O
",",O
and,O
in,O
inflammatory,O
sites,O
.,O
This,O
finding,O
is,O
supported,O
by,O
the,O
decrease,O
in,O
bone,O
marrow,O
neutrophils,O
in,O
S100A9,B-GP
-,O
deficient,O
mice,B-OG
[,O
40,O
"],",O
and,O
the,O
accumulation,O
of,O
S100A8,B-GP
/,O
9,O
at,O
inflammatory,O
sites,O
",",O
where,O
prolonged,O
survival,O
of,O
neutrophils,O
is,O
usually,O
needed,O
for,O
chemotaxis,O
and,O
neutrophil,O
adhesion,O
[,O
32,O
].,O
As,O
shown,O
in,O
figure,O
5A,O
and,O
supplemental,O
figures,O
1,O
and,O
2,O
",",O
apoptotic,O
neutrophils,O
were,O
not,O
activated,O
and,O
their,O
S100,B-GP
A8,I-GP
and,O
S100,O
A9,B-GP
release,O
was,O
associated,O
with,O
PCD,O
and,O
not,O
inflammation,O
or,O
activation,O
.,O
S100A8,B-GP
deficiency,O
is,O
lethal,O
[,O
41,O
"],",O
thus,O
further,O
research,O
to,O
gain,O
understanding,O
of,O
the,O
role,O
of,O
S100A8,B-GP
/,O
9,O
is,O
partially,O
limited,O
to,O
animal,O
models,O
.,O
By,O
prolonging,O
neutrophil,O
life,O
",",O
S100A8,B-GP
/,O
9,O
accumulation,O
could,O
be,O
also,O
a,O
contributing,O
mechanism,O
to,O
autoimmune,O
conditions,O
and,O
the,O
development,O
of,O
chronic,O
inflammation,O
or,O
acute,O
sterile,O
danger,O
-,O
related,O
inflammation,O
.,O
In,O
conditions,O
such,O
as,O
gout,B-DS
",",O
monosodium,O
urate,O
monohydrate,O
crystals,O
induce,O
the,O
release,O
of,O
S100A8,B-GP
/,O
A9,B-GP
from,O
neutrophils,O
[,O
42,O
],O
and,O
allow,O
inflammatory,O
attack,O
by,O
prolonging,O
neutrophil,O
life,O
.,O
High,O
S100A8,B-GP
/,O
9,O
levels,O
were,O
found,O
in,O
chronically,O
inflamed,O
joints,O
of,O
patients,O
with,O
rheumatoid,B-DS
arthritis,I-DS
[,O
43,O
].,O
Our,O
study,O
also,O
proposes,O
an,O
additional,O
possible,O
mechanism,O
for,O
neutropenia,B-DS
following,O
chemotherapy,O
",",O
suggesting,O
that,O
low,O
neutrophil,O
concentration,O
may,O
be,O
further,O
aggravated,O
due,O
to,O
accelerated,O
PCD,O
",",O
induced,O
at,O
low,O
neutrophil,O
concentrations,O
.,O
This,O
hypothesis,O
needs,O
further,O
investigation,O
.,O
We,O
were,O
also,O
able,O
to,O
gain,O
a,O
better,O
understanding,O
of,O
the,O
mechanism,O
enabling,O
S100A8,B-GP
/,O
9,O
function,O
.,O
S100A8,B-GP
/,O
9,O
clearly,O
upregulates,O
and,O
binds,O
to,O
CD11b,B-GP
",",O
previously,O
shown,O
to,O
be,O
a,O
major,O
regulator,O
of,O
neutrophil,O
PCD,O
[,O
44,O
"],",O
with,O
possible,O
anti,O
-,O
or,O
pro,O
-,O
apoptotic,O
effect,O
.,O
However,O
",",O
as,O
shown,O
here,O
",",O
this,O
effect,O
was,O
retained,O
in,O
CD11b,B-GP
-,O
deficient,O
neutrophils,O
",",O
indicating,O
additional,O
mechanisms,O
such,O
as,O
TLR4,B-GP
.,O
Indeed,O
",",O
blocking,O
TLR4,B-GP
partially,O
abrogated,O
the,O
S100A8,B-GP
/,O
9,O
survival,O
effect,O
",",O
suggesting,O
that,O
S100A8,B-GP
/,O
9,O
is,O
an,O
endogenous,O
TLR4,B-GP
ligand,O
mediating,O
survival,O
.,O
It,O
has,O
been,O
shown,O
that,O
the,O
TLR4,B-GP
agonist,O
LPS,O
and,O
others,O
inhibit,O
neutrophil,O
apoptosis,O
[,O
12,O
"],",O
[,O
45,O
].,O
Here,O
we,O
show,O
for,O
the,O
first,O
time,O
an,O
endogenous,O
ligand,O
that,O
inhibits,O
neutrophil,O
apoptosis,O
.,O
Our,O
results,O
also,O
show,O
a,O
role,O
for,O
the,O
MEK,B-GP
/,O
ERK,B-GP
pathway,O
following,O
activation,O
by,O
S100A8,B-GP
/,O
9,O
.,O
This,O
pathway,O
has,O
been,O
well,O
documented,O
to,O
mediate,O
signaling,O
of,O
both,O
integrins,B-GP
and,O
Toll,B-GP
-,I-GP
like,I-GP
receptors,I-GP
",",O
supporting,O
a,O
role,O
for,O
CD11b,B-GP
",",O
TLR4,B-GP
",",O
and,O
possibly,O
additional,O
receptors,O
.,O
This,O
mechanism,O
has,O
been,O
shown,O
in,O
the,O
past,O
to,O
be,O
anti,O
-,O
apoptotic,O
in,O
neutrophils,O
via,O
both,O
intrinsic,O
[,O
46,O
],O
and,O
extrinsic,O
[,O
47,O
],O
PCD,O
pathways,O
.,O
The,O
correlation,O
between,O
beta2,B-GP
-,I-GP
integrin,I-GP
and,O
TLR4,B-GP
has,O
been,O
suggested,O
.,O
These,O
two,O
receptors,O
may,O
cooperate,O
to,O
produce,O
signals,O
that,O
are,O
transmitted,O
into,O
the,O
cell,O
.,O
Also,O
",",O
TLR4,B-GP
has,O
been,O
suggested,O
to,O
be,O
an,O
“,O
inside,O
-,O
out,O
”,O
regulator,O
of,O
the,O
beta2,B-GP
-,I-GP
integrins,I-GP
[,O
48,O
"],",O
and,O
even,O
a,O
direct,O
TLR4,B-GP
-,O
beta2,B-GP
integrin,I-GP
interaction,O
has,O
been,O
suggested,O
[,O
49,O
].,O
Other,O
possible,O
functional,O
proteins,O
that,O
could,O
have,O
a,O
“,O
community,O
effect,O
”,O
may,O
be,O
found,O
in,O
the,O
secreted,O
proteome,O
of,O
apoptotic,O
cells,O
.,O
An,O
experimental,O
approach,O
using,O
2D,O
gel,O
may,O
discover,O
additional,O
candidate,O
proteins,O
and,O
functional,O
studies,O
may,O
establish,O
their,O
potential,O
role,O
in,O
PCD,O
.,O
In,O
summary,O
",",O
the,O
physiological,O
role,O
of,O
S100A8,B-GP
/,O
9,O
",",O
the,O
most,O
abundant,O
cytosol,O
protein,O
in,O
neutrophils,O
",",O
was,O
not,O
previously,O
understood,O
.,O
We,O
propose,O
that,O
at,O
physiological,O
protein,O
[,O
50,O
],O
and,O
cell,O
concentrations,O
",",O
its,O
main,O
function,O
is,O
in,O
modulating,O
neutrophil,O
PCD,O
",",O
and,O
that,O
cell,O
concentration,O
is,O
regulated,O
by,O
an,O
autocrine,O
and,O
paracrine,O
mechanism,O
via,O
S100A8,B-GP
/,O
9,O
.,O
Finally,O
",",O
a,O
biological,O
“,O
proof,O
”,O
is,O
presented,O
here,O
",",O
suggesting,O
that,O
nature,O
encourages,O
“,O
community,O
life,O
”,O
at,O
the,O
level,O
of,O
neutrophil,O
survival,O
",",O
which,O
could,O
be,O
seen,O
as,O
a,O
cellular,O
illustration,O
for,O
human,B-OG
life,O
.,O
Supporting,O
Information,O
Apoptotic,O
neutrophils,O
downregulate,O
CD16,B-GP
.,O
The,O
expression,O
of,O
CD16,B-GP
(,O
Fc,B-GP
gamma,I-GP
RIII,I-GP
),O
on,O
neutrophils,O
.,O
Freshly,O
isolated,O
neutrophils,O
CD16,B-GP
expession,O
at,O
time,O
0,O
(,O
black,O
line,O
",",O
median,O
fluorescence,O
of,O
382,O
),O
and,O
following,O
12,O
h,O
of,O
spontaneous,O
PCD,O
(,O
gray,O
line,O
",",O
median,O
fluorescence,O
of,O
35,O
).,O
Isotype,O
control,O
is,O
shown,O
as,O
filled,O
histogram,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Apoptotic,O
neutrophils,O
downregulate,O
CD62L,B-GP
.,O
The,O
expression,O
of,O
CD62L,B-GP
(,O
L,B-GP
-,I-GP
selectin,I-GP
),O
on,O
neutrophils,O
.,O
Freshly,O
isolated,O
neutrophils,O
CD62L,B-GP
expession,O
at,O
time,O
0,O
(,O
black,O
line,O
",",O
median,O
fluorescence,O
of,O
791,O
),O
and,O
following,O
12,O
h,O
of,O
spontaneous,O
PCD,O
(,O
gray,O
line,O
",",O
median,O
fluorescence,O
of,O
27,O
).,O
Isotype,O
control,O
is,O
shown,O
as,O
filled,O
histogram,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Apoptosis,O
-,O
related,O
proteins,O
during,O
spontaneous,O
constitutive,O
PCD,O
in,O
the,O
presence,O
of,O
S100A8,B-GP
/,O
9,O
.,O
SDS,O
-,O
PAGE,O
of,O
McL1,B-GP
",",O
Bcl,B-GP
-,I-GP
xl,I-GP
",",O
A1,B-GP
",",O
Bcl2,B-GP
",",O
and,O
survivin,B-GP
in,O
spontaneous,O
constitutive,O
apoptosis,O
",",O
with,O
and,O
without,O
addition,O
of,O
S100A8,B-GP
/,O
9,O
.,O
McL1,B-GP
(,O
39,O
KD,O
),O
and,O
Bcl,B-GP
-,I-GP
xl,I-GP
(,O
26,O
KD,O
),O
were,O
detected,O
in,O
all,O
conditions,O
.,O
A1,B-GP
(,O
20KD,O
),O
was,O
detected,O
from,O
freshly,O
isolated,O
neutrophils,O
but,O
expression,O
was,O
downregulated,O
significantly,O
by,O
spontaneous,O
constitutive,O
apoptosis,O
.,O
Addition,O
of,O
S100A8,B-GP
/,O
9,O
did,O
not,O
rescue,O
protein,O
expression,O
.,O
Bcl2,B-GP
(,O
25KD,O
),O
and,O
survivin,B-GP
(,O
19KD,O
),O
were,O
not,O
detected,O
under,O
any,O
experimental,O
conditions,O
.,O
The,O
lysates,O
of,O
40,O
×,O
106,O
neutrophils,O
under,O
different,O
conditions,O
",",O
including,O
freshly,O
isolated,O
",",O
after,O
8,O
–,O
10,O
h,O
of,O
spontaneous,O
constitutive,O
PCD,O
",",O
or,O
after,O
8,O
–,O
10,O
h,O
of,O
spontaneous,O
constitutive,O
PCD,O
with,O
addition,O
of,O
S100A8,B-GP
/,O
9,O
",",O
were,O
loaded,O
and,O
separated,O
by,O
SDS,O
-,O
PAGE,O
",",O
as,O
described,O
in,O
Experimental,O
Procedures,O
.,O
Proteins,O
were,O
transferred,O
to,O
the,O
PVDF,O
membrane,O
and,O
exposed,O
to,O
the,O
appropriate,O
primary,O
antibody,B-GP
according,O
to,O
manufacturers,O
',O
instructions,O
",",O
and,O
then,O
to,O
secondary,O
antibody,B-GP
conjugated,O
with,O
HRP,B-GP
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Additional,O
details,O
of,O
methods,O
used,O
in,O
proteomics,O
and,O
programmed,O
cell,O
death,O
evaluation,O
.,O
(,O
DOC,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Antidepressant,O
-,O
Like,O
Effects,O
of,O
Fractions,O
Prepared,O
from,O
Danzhi,O
-,O
Xiaoyao,O
-,O
San,O
Decoction,O
in,O
Rats,B-OG
with,O
Chronic,O
Unpredictable,O
Mild,O
Stress,O
:,O
Effects,O
on,O
Hypothalamic,O
-,O
Pituitary,O
-,O
Adrenal,O
Axis,O
",",O
Arginine,B-GP
Vasopressin,I-GP
",",O
and,O
Neurotransmitters,O
Academic,O
Editor,O
:,O
Maria,O
Camilla,O
Bergonzi,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
antidepressant,O
-,O
like,O
effects,O
of,O
two,O
fractions,O
",",O
including,O
petroleum,O
ether,O
soluble,O
fraction,O
(,O
Fraction,O
A,O
",",O
FA,O
),O
and,O
water,O
-,O
EtOH,O
soluble,O
fraction,O
(,O
Fraction,O
B,O
",",O
FB,O
),O
prepared,O
from,O
the,O
Danzhi,O
-,O
xiaoyao,O
-,O
san,O
(,O
DZXYS,O
),O
by,O
using,O
chronic,O
unpredictable,O
mild,O
stress,O
-,O
induced,O
depressive,O
rat,B-OG
model,O
.,O
The,O
results,O
indicated,O
that,O
DZXYS,O
could,O
ameliorate,O
the,O
depression,B-DS
-,O
like,O
behavior,O
in,O
chronic,O
stress,O
model,O
of,O
rats,B-OG
.,O
The,O
inhibition,O
of,O
hyperactivity,O
of,O
HPA,O
axis,O
and,O
the,O
modulation,O
of,O
monoamine,O
and,O
amino,O
acid,O
neurotransmitters,O
in,O
the,O
hippocampus,O
may,O
be,O
the,O
important,O
mechanisms,O
underlying,O
the,O
action,O
of,O
DZXYS,O
antidepressant,O
-,O
like,O
effect,O
in,O
chronically,O
stressed,O
rats,B-OG
.,O
1,O
.,O
Introduction,O
Depression,B-DS
is,O
the,O
commonest,O
psychiatric,B-DS
disorder,I-DS
with,O
such,O
main,O
clinical,O
features,O
as,O
significant,O
and,O
lasting,O
depression,B-DS
",",O
mental,O
retardation,O
",",O
cognitive,O
impairment,O
",",O
and,O
depression,B-DS
and,O
somatic,O
symptoms,O
.,O
Furthermore,O
",",O
depression,B-DS
is,O
a,O
risk,O
factor,O
for,O
the,O
onset,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
mellitus,I-DS
",",O
hypertension,B-DS
",",O
coronary,B-DS
heart,I-DS
disease,I-DS
",",O
cancer,B-DS
",",O
and,O
so,O
on,O
[,O
1,O
"],",O
which,O
is,O
projected,O
to,O
become,O
the,O
second,O
biggest,O
contributor,O
to,O
the,O
global,O
burden,O
of,O
disease,O
and,O
disability,O
by,O
2020,O
according,O
to,O
WHO,O
',O
s,O
prediction,O
.,O
Monoamine,B-DS
neurotransmitters,I-DS
disorder,I-DS
and,O
hypothalamic,O
-,O
pituitary,O
-,O
adrenal,O
(,O
HPA,O
),O
axis,O
hyperactivity,O
",",O
widely,O
recognized,O
",",O
are,O
the,O
two,O
important,O
mechanisms,O
of,O
the,O
occurrence,O
of,O
depression,B-DS
.,O
At,O
present,O
",",O
based,O
on,O
the,O
hypothesis,O
of,O
monoamine,O
neurotransmitters,O
function,O
deficiency,O
",",O
antidepression,O
drugs,O
",",O
such,O
as,O
the,O
tricyclic,O
antidepressants,O
(,O
TCAs,O
"),",O
the,O
selective,O
serotonin,O
reuptake,O
inhibitors,O
(,O
SSRIs,O
"),",O
the,O
selective,O
norepinephrine,O
reuptake,O
inhibitors,O
(,O
SNRIs,O
"),",O
the,O
selective,O
norepinephrine,O
-,O
dopamine,O
reuptake,O
inhibitors,O
",",O
and,O
the,O
monoamine,B-GP
oxidase,I-GP
inhibitors,O
(,O
MAOIs,O
"),",O
have,O
been,O
developed,O
",",O
which,O
are,O
mainly,O
by,O
inhibiting,O
the,O
transporter,O
function,O
of,O
5,O
-,O
hydroxytryptamine,O
(,O
5,O
-,O
HT,O
"),",O
dopamine,O
(,O
DA,O
"),",O
and,O
norepinephrine,O
(,O
NE,O
),O
to,O
block,O
the,O
reuptake,O
of,O
monoamine,O
neurotransmitters,O
to,O
increase,O
the,O
concentration,O
of,O
those,O
neurotransmitters,O
mentioned,O
above,O
in,O
synaptic,O
cleft,O
to,O
improve,O
the,O
symptoms,O
of,O
depression,B-DS
.,O
But,O
now,O
",",O
the,O
efficacy,O
of,O
those,O
drugs,O
has,O
been,O
faced,O
with,O
serious,O
challenges,O
[,O
2,O
].,O
It,O
is,O
noted,O
that,O
inhibition,O
of,O
HPA,O
axis,O
activity,O
is,O
a,O
very,O
effective,O
antidepressant,O
treatment,O
",",O
but,O
so,O
far,O
new,O
antidepression,O
drugs,O
taking,O
the,O
HPA,O
axis,O
as,O
the,O
target,O
have,O
not,O
been,O
successfully,O
tested,O
by,O
the,O
clinical,O
trials,O
[,O
3,O
].,O
Therefore,O
",",O
the,O
need,O
for,O
more,O
effective,O
and,O
safer,O
antidepression,O
drugs,O
continues,O
to,O
command,O
attention,O
in,O
neuropsychopharmacology,O
within,O
the,O
psychotherapeutic,O
community,O
.,O
Nowadays,O
",",O
traditional,O
Chinese,O
medicine,O
(,O
TCM,O
),O
has,O
offered,O
prospective,O
alternative,O
therapy,O
for,O
the,O
treatment,O
of,O
depression,B-DS
.,O
The,O
records,O
of,O
treating,O
mental,B-DS
disorders,I-DS
could,O
be,O
found,O
in,O
ancient,O
medicinal,O
books,O
",",O
and,O
herbal,O
decoction,O
Danzhi,O
-,O
xiaoyao,O
-,O
san,O
(,O
DZXYS,O
"),",O
also,O
called,O
Jiawei,O
-,O
xiaoyao,O
-,O
san,O
",",O
is,O
one,O
of,O
the,O
most,O
popular,O
classical,O
ones,O
.,O
The,O
first,O
description,O
of,O
DZXYS,O
is,O
recorded,O
in,O
Jiaozhu,O
Furen,O
Liangfang,O
“,O
Edited,O
and,O
Commented,O
Effective,O
Formulae,O
for,O
Woman,O
”,O
written,O
by,O
Xue,O
Yi,O
(,O
1487,O
–,O
1559,O
),O
in,O
Ming,O
Dynasty,O
.,O
This,O
herbal,O
formula,O
is,O
composed,O
of,O
the,O
following,O
herbs,O
:,O
Radix,O
Bupleuri,O
",",O
Paeoniae,B-OG
Radix,O
Alba,O
",",O
Angelica,B-OG
sinensis,I-OG
",",O
bighead,O
atractylodes,B-OG
rhizome,O
",",O
Poria,B-OG
cocos,I-OG
",",O
bark,O
of,O
tree,B-OG
peony,I-OG
root,O
",",O
Fructus,O
Gardeniae,B-OG
",",O
Mentha,B-OG
haplocalyx,I-OG
",",O
and,O
Licorice,B-OG
.,O
It,O
is,O
well,O
known,O
that,O
DZXYS,O
decoction,O
plays,O
an,O
important,O
role,O
in,O
the,O
clinical,O
therapy,O
of,O
depression,B-DS
-,I-DS
related,I-DS
disorders,I-DS
in,O
China,O
[,O
4,O
",",O
5,O
].,O
In,O
Chinese,O
medicinal,O
theory,O
",",O
DZXYS,O
decoction,O
exhibits,O
therapeutic,O
effects,O
by,O
releasing,O
constraint,O
and,O
encouraging,O
the,O
free,O
-,O
flow,O
of,O
liver,O
qi,O
",",O
clearing,O
liver,O
heat,O
",",O
nourishing,O
blood,O
",",O
and,O
invigorating,O
spleen,O
.,O
Although,O
this,O
decoction,O
has,O
been,O
used,O
frequently,O
",",O
thus,O
far,O
",",O
it,O
remains,O
unclear,O
as,O
to,O
which,O
active,O
fraction,O
of,O
the,O
DZXYS,O
is,O
responsible,O
for,O
the,O
antidepressant,O
effect,O
and,O
its,O
possible,O
regulatory,O
mechanism,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
antidepressant,O
-,O
like,O
effects,O
of,O
two,O
fractions,O
",",O
including,O
petroleum,O
ether,O
soluble,O
fraction,O
(,O
Fraction,O
A,O
",",O
FA,O
),O
and,O
water,O
-,O
EtOH,O
soluble,O
fraction,O
(,O
Fraction,O
B,O
",",O
FB,O
),O
prepared,O
from,O
the,O
DZXYS,O
by,O
using,O
chronic,O
unpredictable,O
mild,O
stress,O
-,O
(,O
CUMS,O
-),O
induced,O
depressive,O
rat,B-OG
model,O
.,O
The,O
underlying,O
mechanism,O
of,O
antidepression,O
was,O
mainly,O
explored,O
by,O
measuring,O
the,O
function,O
of,O
HPA,O
axis,O
and,O
the,O
contents,O
of,O
monoamine,O
and,O
amino,O
acid,O
neurotransmitters,O
in,O
hippocampus,O
.,O
In,O
addition,O
",",O
as,O
a,O
neuropeptide,O
",",O
the,O
arginine,B-GP
vasopressin,I-GP
(,O
AVP,B-GP
),O
contents,O
in,O
plasma,O
and,O
hypothalamus,O
were,O
detected,O
in,O
the,O
study,O
in,O
order,O
to,O
further,O
explore,O
the,O
antidepressant,O
mechanisms,O
of,O
DZXYS,O
in,O
modulating,O
HPA,O
axis,O
.,O
2,O
.,O
Materials,O
and,O
Methods,O
2,O
.,O
1,O
.,O
Plant,B-OG
Materials,O
Medical,O
plants,B-OG
(,O
dried,O
crude,O
herbs,O
),O
used,O
for,O
preparation,O
of,O
DZXYS,O
were,O
purchased,O
from,O
Medicinal,O
Materials,O
Company,O
of,O
Guangzhou,O
",",O
Guangzhou,O
",",O
China,O
",",O
and,O
authenticated,O
by,O
Professor,O
Ming,O
-,O
Ping,O
Liu,O
",",O
Chinese,O
Materia,O
Medica,O
College,O
",",O
Guangzhou,O
University,O
of,O
Chinese,O
Medicine,O
.,O
DZXYS,O
consists,O
of,O
nine,O
dried,O
crude,O
herbs,O
listed,O
in,O
Table,O
1,O
.,O
The,O
ratio,O
of,O
Radix,O
Bupleuri,O
",",O
Paeoniae,B-OG
Radix,O
Alba,O
",",O
Angelica,B-OG
sinensis,I-OG
",",O
bighead,O
atractylodes,B-OG
rhizome,O
",",O
Poria,B-OG
cocos,I-OG
",",O
bark,O
of,O
tree,B-OG
peony,I-OG
root,O
",",O
Fructus,O
Gardeniae,B-OG
",",O
Mentha,B-OG
haplocalyx,I-OG
",",O
and,O
Licorice,B-OG
is,O
2,O
:,O
2,O
:,O
2,O
:,O
2,O
:,O
2,O
:,O
2,O
:,O
2,O
:,O
1,O
:,O
1,O
.,O
The,O
voucher,O
specimens,O
were,O
conserved,O
at,O
the,O
herbal,O
herbarium,O
of,O
Chinese,O
Materia,O
Medica,O
College,O
",",O
Guangzhou,O
University,O
of,O
Chinese,O
Medicine,O
",",O
Guangzhou,O
",",O
China,O
.,O
The,O
voucher,O
specimens,O
of,O
the,O
herbal,O
materials,O
were,O
deposited,O
for,O
possible,O
future,O
comparison,O
.,O
2,O
.,O
2,O
.,O
Preparation,O
of,O
Fractions,O
from,O
DZXYS,O
The,O
crude,O
powdered,O
mixture,O
of,O
DZXYS,O
",",O
5000,O
g,O
",",O
according,O
to,O
the,O
prescription,O
proportion,O
",",O
was,O
added,O
with,O
petroleum,O
ether,O
(,O
bp,O
60,O
–,O
90,O
°,O
C,O
),O
and,O
then,O
water,O
-,O
bath,O
-,O
heated,O
and,O
refluxed,O
for,O
4,O
times,O
(,O
2,O
h,O
",",O
1,O
.,O
5,O
h,O
",",O
1,O
.,O
5,O
h,O
",",O
and,O
1,O
.,O
5,O
h,O
);,O
the,O
petroleum,O
-,O
soluble,O
fraction,O
(,O
Fraction,O
A,O
",",O
FA,O
",",O
yield,O
:,O
1,O
.,O
24,O
%),O
and,O
precipitate,O
were,O
obtained,O
.,O
The,O
precipitate,O
was,O
extracted,O
for,O
3,O
times,O
(,O
2,O
h,O
",",O
1,O
.,O
5,O
h,O
",",O
and,O
1,O
.,O
5,O
h,O
),O
with,O
boiling,O
water,O
",",O
and,O
then,O
the,O
combined,O
water,O
extracts,O
were,O
filtered,O
and,O
concentrated,O
to,O
2500,O
mL,O
solution,O
which,O
was,O
concentrated,O
under,O
reduced,O
pressure,O
and,O
fractionated,O
by,O
the,O
addition,O
of,O
1710,O
mL,O
of,O
95,O
%,O
ethyl,O
alcohol,O
(,O
EtOH,O
),O
to,O
give,O
a,O
water,O
-,O
EtOH,O
soluble,O
supernatant,O
fraction,O
(,O
Fraction,O
B,O
",",O
FB,O
",",O
the,O
yield,O
:,O
25,O
.,O
9,O
%).,O
FA,O
and,O
FB,O
were,O
lyophilized,O
into,O
dry,O
powders,O
.,O
In,O
this,O
paper,O
",",O
the,O
doses,O
of,O
FA,O
and,O
FB,O
were,O
expressed,O
in,O
terms,O
of,O
dried,O
weight,O
of,O
herbal,O
material,O
used,O
for,O
extraction,O
per,O
unit,O
body,O
weight,O
of,O
experimental,O
rats,B-OG
(,O
g,O
/,O
kg,O
).,O
2,O
.,O
3,O
.,O
Drugs,O
",",O
Reagents,O
",",O
and,O
Chemicals,O
Imipramine,O
hydrochloride,O
(,O
IMI,O
),O
was,O
purchased,O
from,O
Sigma,O
(,O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
).,O
The,O
assay,O
kits,O
of,O
corticosterone,O
(,O
CORT,O
"),",O
corticotrophin,B-GP
-,I-GP
releasing,I-GP
hormone,I-GP
(,O
CRH,B-GP
"),",O
adrenocorticotropin,B-GP
(,O
ACTH,B-GP
"),",O
and,O
arginine,B-GP
vasopressin,I-GP
(,O
AVP,B-GP
),O
were,O
purchased,O
from,O
Nanjing,O
Jiancheng,O
Institute,O
of,O
Biotechnology,O
",",O
Nanjing,O
",",O
China,O
.,O
The,O
standard,O
5,O
-,O
hydroxytryptamine,O
(,O
5,O
-,O
HT,O
"),",O
dopamine,O
(,O
DA,O
"),",O
and,O
norepinephrine,O
(,O
NE,O
),O
were,O
purchased,O
from,O
Sigma,O
(,O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
).,O
Disodium,O
ethylenediaminetetraacetate,O
(,O
EDTA,O
),O
and,O
the,O
standard,O
amino,O
acids,O
including,O
glutamic,O
acid,O
(,O
Glu,O
"),",O
aspartic,O
acid,O
(,O
Asp,O
"),",O
γ,O
-,O
aminobutyric,O
acid,O
(,O
GABA,O
"),",O
and,O
taurine,O
(,O
Tau,O
),O
were,O
obtained,O
from,O
Sigma,O
(,O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
).,O
All,O
other,O
reagents,O
used,O
were,O
of,O
analytical,O
grade,O
.,O
2,O
.,O
4,O
.,O
Experimental,O
Animals,B-OG
Male,O
Wistar,B-OG
rats,I-OG
weighing,O
180,O
–,O
220,O
g,O
were,O
purchased,O
from,O
the,O
Laboratory,O
Animal,O
Center,O
of,O
Nanfang,O
Medical,O
University,O
",",O
Guangzhou,O
",",O
China,O
.,O
Animals,B-OG
were,O
allowed,O
1,O
week,O
to,O
adapt,O
to,O
the,O
surroundings,O
before,O
beginning,O
any,O
experimentation,O
.,O
Animals,B-OG
were,O
maintained,O
on,O
a,O
12,O
h,O
light,O
/,O
dark,O
cycle,O
under,O
controlled,O
temperature,O
of,O
22,O
±,O
2,O
°,O
C,O
and,O
had,O
free,O
access,O
to,O
food,O
and,O
water,O
.,O
All,O
animals,B-OG
handling,O
procedures,O
were,O
performed,O
in,O
strict,O
accordance,O
with,O
the,O
China,O
legislation,O
on,O
the,O
use,O
and,O
care,O
of,O
laboratory,O
animals,B-OG
and,O
were,O
approved,O
by,O
the,O
Animal,O
Experimentation,O
Ethics,O
Committee,O
of,O
the,O
Guangzhou,O
University,O
of,O
Chinese,O
Medicine,O
.,O
All,O
efforts,O
were,O
made,O
to,O
minimize,O
the,O
number,O
and,O
suffering,O
of,O
animals,B-OG
needed,O
to,O
produce,O
reliable,O
data,O
.,O
2,O
.,O
5,O
.,O
Chronic,O
Unpredictable,O
Mild,O
Stress,O
(,O
CUMS,O
),O
The,O
stress,O
procedure,O
performed,O
here,O
mainly,O
referred,O
to,O
Willner,O
[,O
6,O
],O
with,O
some,O
modifications,O
.,O
Briefly,O
",",O
the,O
CUMS,O
protocol,O
consisted,O
of,O
the,O
sequential,O
application,O
of,O
a,O
variety,O
of,O
unpredictable,O
mild,O
stressors,O
:,O
(,O
1,O
),O
food,O
deprivation,O
for,O
24,O
hours,O
",",O
(,O
2,O
),O
water,O
deprivation,O
for,O
24,O
hours,O
",",O
(,O
3,O
),O
exposure,O
to,O
an,O
empty,O
bottle,O
for,O
1,O
hour,O
",",O
(,O
4,O
),O
cage,O
tilt,O
(,O
45,O
°),O
for,O
7,O
hours,O
",",O
(,O
5,O
),O
overnight,O
illumination,O
",",O
(,O
6,O
),O
soiled,O
cage,O
(,O
200,O
mL,O
water,O
in,O
100,O
g,O
sawdust,O
bedding,O
),O
for,O
24,O
hours,O
",",O
(,O
7,O
),O
forced,O
swimming,O
at,O
8,O
°,O
C,O
for,O
6,O
minutes,O
",",O
(,O
8,O
),O
physical,O
restraint,O
for,O
2,O
hours,O
",",O
and,O
(,O
9,O
),O
exposure,O
to,O
a,O
foreign,O
object,O
(,O
e,O
.,O
g,O
".,",O
a,O
piece,O
of,O
plastic,O
),O
for,O
24,O
hours,O
.,O
These,O
stressors,O
were,O
randomly,O
scheduled,O
over,O
a,O
one,O
-,O
week,O
period,O
and,O
repeated,O
throughout,O
the,O
4,O
weeks,O
of,O
experiment,O
(,O
Figure,O
1,O
).,O
Nonstressed,O
animals,B-OG
were,O
left,O
undisturbed,O
in,O
their,O
home,O
cages,O
except,O
during,O
housekeeping,O
procedures,O
such,O
as,O
cage,O
cleaning,O
.,O
2,O
.,O
6,O
.,O
Treatment,O
of,O
Animals,B-OG
In,O
experiments,O
",",O
animals,B-OG
were,O
randomized,O
into,O
seven,O
groups,O
of,O
ten,O
individuals,O
.,O
The,O
control,O
animals,B-OG
were,O
unstressed,O
and,O
intragastrically,O
given,O
daily,O
2,O
mL,O
distilled,O
water,O
.,O
For,O
another,O
six,O
groups,O
",",O
the,O
animals,B-OG
were,O
treated,O
simultaneously,O
with,O
CUMS,O
.,O
The,O
drugs,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
/,O
day,O
",",O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
and,O
IMI,O
at,O
20,O
mg,O
/,O
kg,O
/,O
day,O
",",O
suspended,O
in,O
distilled,O
water,O
),O
were,O
intragastrically,O
given,O
daily,O
1,O
h,O
before,O
the,O
stress,O
exposure,O
for,O
the,O
entire,O
4,O
weeks,O
.,O
Following,O
each,O
stress,O
session,O
",",O
animals,B-OG
were,O
returned,O
to,O
their,O
home,O
cages,O
and,O
were,O
able,O
to,O
access,O
food,O
and,O
water,O
freely,O
for,O
the,O
remainder,O
of,O
the,O
day,O
.,O
2,O
.,O
7,O
.,O
Rat,B-OG
Sucrose,O
Preference,O
Test,O
Sucrose,O
preference,O
test,O
was,O
carried,O
out,O
at,O
the,O
end,O
of,O
4,O
-,O
week,O
CUMS,O
exposure,O
.,O
The,O
test,O
was,O
performed,O
as,O
described,O
previously,O
[,O
7,O
],O
with,O
minor,O
modifications,O
.,O
Briefly,O
",",O
after,O
one,O
week,O
of,O
the,O
single,O
cage,O
feeding,O
adaptation,O
",",O
the,O
rats,B-OG
received,O
a,O
week,O
of,O
double,O
bottle,O
training,O
.,O
One,O
bottle,O
was,O
1,O
%,O
sucrose,O
solution,O
(,O
w,O
/,O
v,O
),O
100,O
mL,O
(,O
in,O
the,O
cage,O
on,O
the,O
left,O
"),",O
another,O
was,O
pure,O
water,O
100,O
mL,O
(,O
in,O
the,O
cage,O
on,O
the,O
right,O
"),",O
and,O
two,O
bottles,O
were,O
fixed,O
.,O
Sucrose,O
solution,O
and,O
pure,O
water,O
were,O
added,O
every,O
morning,O
.,O
After,O
one,O
-,O
week,O
training,O
",",O
the,O
rats,B-OG
were,O
deprived,O
of,O
water,O
and,O
food,O
for,O
24,O
hours,O
",",O
and,O
then,O
1,O
h,O
sucrose,O
solution,O
consumption,O
experiments,O
were,O
conducted,O
to,O
measure,O
the,O
basis,O
of,O
sucrose,O
preference,O
at,O
9,O
:,O
00,O
am,O
in,O
which,O
rats,B-OG
were,O
housed,O
in,O
individual,O
cages,O
and,O
were,O
free,O
to,O
access,O
two,O
bottles,O
.,O
After,O
4,O
weeks,O
of,O
experiment,O
",",O
the,O
sucrose,O
preference,O
was,O
conducted,O
again,O
by,O
the,O
method,O
described,O
above,O
.,O
The,O
sucrose,O
preference,O
was,O
calculated,O
by,O
the,O
following,O
formula,O
:,O
sucrose,O
preference,O
(%),O
=,O
sucrose,O
consumption,O
/,O
total,O
liquid,O
consumption,O
×,O
100,O
%,O
[,O
8,O
].,O
2,O
.,O
8,O
.,O
Forced,O
Swimming,O
Test,O
(,O
FST,O
),O
The,O
forced,O
swimming,O
test,O
was,O
performed,O
according,O
to,O
the,O
method,O
of,O
Porsolt,O
[,O
9,O
],O
with,O
modifications,O
.,O
Briefly,O
",",O
rats,B-OG
were,O
forced,O
to,O
swim,O
in,O
a,O
transparent,O
glass,O
vessel,O
(,O
25,O
cm,O
in,O
height,O
and,O
14,O
cm,O
in,O
diameter,O
),O
filled,O
with,O
15,O
cm,O
of,O
water,O
at,O
24,O
±,O
1,O
°,O
C,O
.,O
The,O
total,O
duration,O
of,O
immobility,O
(,O
seconds,O
),O
was,O
measured,O
during,O
the,O
last,O
4,O
minutes,O
of,O
a,O
single,O
6,O
-,O
minute,O
test,O
session,O
[,O
10,O
].,O
Rats,B-OG
were,O
considered,O
immobile,O
when,O
they,O
ceased,O
struggling,O
and,O
remained,O
floating,O
motionless,O
in,O
the,O
water,O
except,O
the,O
movements,O
necessary,O
to,O
keep,O
their,O
heads,O
above,O
the,O
water,O
.,O
Decrease,O
in,O
the,O
duration,O
of,O
immobility,O
during,O
the,O
FST,O
was,O
taken,O
as,O
a,O
measure,O
of,O
antidepressant,O
activity,O
.,O
2,O
.,O
9,O
.,O
Tail,O
Suspension,O
Test,O
(,O
TST,O
),O
The,O
duration,O
of,O
immobility,O
time,O
induced,O
by,O
tail,O
suspension,O
was,O
measured,O
according,O
to,O
the,O
method,O
of,O
Steru,O
[,O
11,O
].,O
Rats,B-OG
both,O
acoustically,O
and,O
visually,O
isolated,O
were,O
suspended,O
above,O
the,O
floor,O
by,O
adhesive,O
tape,O
placed,O
approximately,O
1,O
cm,O
from,O
the,O
tip,O
of,O
the,O
tail,O
.,O
The,O
remaining,O
immobile,O
time,O
of,O
TST,O
was,O
quantified,O
for,O
6,O
min,O
.,O
Rats,B-OG
were,O
considered,O
immobile,O
only,O
when,O
they,O
hung,O
passively,O
and,O
completely,O
motionless,O
.,O
2,O
.,O
10,O
.,O
Open,O
-,O
Field,O
Test,O
(,O
OFT,O
),O
The,O
OFT,O
was,O
based,O
on,O
the,O
method,O
of,O
Archer,O
[,O
12,O
].,O
The,O
OFT,O
apparatus,O
consisted,O
of,O
a,O
clear,O
acrylic,O
box,O
(,O
100,O
cm,O
×,O
100,O
cm,O
×,O
50,O
cm,O
),O
with,O
a,O
lid,O
.,O
The,O
floor,O
was,O
divided,O
by,O
drawn,O
lines,O
into,O
36,O
areas,O
of,O
about,O
25,O
sq,O
.,O
cm,O
.,O
The,O
test,O
was,O
performed,O
in,O
a,O
light,O
-,O
and,O
sound,O
-,O
attenuated,O
shield,O
box,O
with,O
a,O
dim,O
light,O
.,O
The,O
locomotor,O
activity,O
counts,O
and,O
the,O
rearing,O
counts,O
were,O
recorded,O
for,O
5,O
min,O
.,O
All,O
test,O
sessions,O
were,O
recorded,O
by,O
a,O
video,O
camera,O
.,O
Between,O
subjects,O
",",O
the,O
box,O
was,O
thoroughly,O
cleaned,O
with,O
cotton,O
and,O
95,O
%,O
ethanol,O
.,O
2,O
.,O
11,O
.,O
CORT,O
",",O
CRH,B-GP
",",O
ACTH,B-GP
",",O
and,O
AVP,B-GP
Contents,O
in,O
Plasma,O
Assays,O
After,O
the,O
end,O
of,O
the,O
experimental,O
period,O
",",O
all,O
rats,B-OG
were,O
sacrificed,O
by,O
decapitation,O
between,O
10,O
:,O
00,O
and,O
11,O
:,O
00,O
am,O
in,O
the,O
laboratory,O
.,O
After,O
decapitation,O
",",O
the,O
blood,O
samples,O
were,O
collected,O
into,O
heparinized,O
Eppendorf,O
tubes,O
and,O
immediately,O
centrifuged,O
for,O
1,O
min,O
(,O
10,O
",",O
000,O
rpm,O
),O
at,O
4,O
°,O
C,O
to,O
separate,O
plasma,O
",",O
which,O
was,O
then,O
frozen,O
at,O
−,O
20,O
°,O
C,O
until,O
subsequent,O
assays,O
.,O
CORT,O
",",O
CRH,B-GP
",",O
ACTH,B-GP
",",O
and,O
AVP,B-GP
contents,O
in,O
plasma,O
were,O
determined,O
by,O
using,O
competitive,O
radioimmunoassay,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instruction,O
.,O
2,O
.,O
12,O
.,O
CRH,B-GP
",",O
ACTH,B-GP
",",O
and,O
AVP,B-GP
Contents,O
in,O
Hypothalamus,O
Assays,O
After,O
decapitation,O
",",O
the,O
brains,O
were,O
rapidly,O
removed,O
and,O
immersed,O
into,O
the,O
boiling,O
saline,O
for,O
5,O
min,O
.,O
Hypothalamus,O
was,O
dissected,O
according,O
to,O
the,O
method,O
described,O
by,O
Yan,O
et,O
al,O
.,O
[,O
13,O
"],",O
weighed,O
",",O
and,O
then,O
homogenized,O
in,O
0,O
.,O
2,O
mL,O
of,O
1,O
M,O
acetic,O
acid,O
solution,O
.,O
After,O
incubation,O
for,O
100,O
minutes,O
at,O
room,O
temperature,O
",",O
homogenate,O
solution,O
was,O
mixed,O
with,O
0,O
.,O
2,O
mL,O
of,O
1,O
M,O
NaOH,O
solution,O
and,O
centrifuged,O
for,O
20,O
min,O
(,O
3500,O
rpm,O
),O
at,O
4,O
°,O
C,O
.,O
The,O
supernatants,O
were,O
collected,O
and,O
stored,O
at,O
−,O
40,O
°,O
C,O
.,O
Radioimmunoassay,O
was,O
performed,O
to,O
measure,O
CRH,B-GP
",",O
ACTH,B-GP
",",O
and,O
AVP,B-GP
in,O
hypothalamus,O
following,O
the,O
manufacturer,O
',O
s,O
instruction,O
.,O
2,O
.,O
13,O
.,O
Monoamine,O
and,O
Amino,O
Acid,O
Neurotransmitters,O
Contents,O
in,O
Hippocampus,O
Determination,O
After,O
the,O
end,O
of,O
the,O
experimental,O
period,O
",",O
all,O
rats,B-OG
were,O
sacrificed,O
by,O
decapitation,O
between,O
10,O
:,O
00,O
and,O
11,O
:,O
00,O
am,O
in,O
the,O
laboratory,O
.,O
After,O
decapitation,O
",",O
the,O
whole,O
rat,B-OG
brains,O
were,O
rapidly,O
removed,O
and,O
the,O
hippocampus,O
was,O
carefully,O
dissected,O
according,O
to,O
the,O
method,O
described,O
previously,O
[,O
14,O
].,O
The,O
contents,O
of,O
5,O
-,O
HT,O
",",O
5,O
-,O
hydroxyindoleacetic,O
acid,O
(,O
5,O
-,O
HIAA,O
"),",O
DA,O
",",O
and,O
NE,O
in,O
hippocampus,O
were,O
determined,O
by,O
using,O
an,O
electrochemical,O
high,O
-,O
performance,O
liquid,O
chromatography,O
system,O
(,O
EC,O
-,O
HPLC,O
).,O
Tissues,O
were,O
placed,O
in,O
0,O
.,O
1,O
N,O
perchloric,O
acid,O
(,O
including,O
0,O
.,O
1,O
%,O
aminothiopropionic,O
acid,O
"),",O
then,O
sonicated,O
",",O
and,O
centrifuged,O
twice,O
for,O
20,O
min,O
at,O
10,O
",",O
000,O
rpm,O
.,O
The,O
supernatants,O
were,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
being,O
analyzed,O
for,O
the,O
contents,O
of,O
DA,O
",",O
5,O
-,O
HT,O
",",O
and,O
NE,O
.,O
The,O
pellets,O
were,O
digested,O
in,O
1,O
mL,O
of,O
0,O
.,O
5,O
N,O
NaOH,O
for,O
measurements,O
of,O
protein,O
concentration,O
using,O
Bio,O
-,O
Rad,O
assay,O
reagents,O
.,O
For,O
EC,O
-,O
HPLC,O
analysis,O
",",O
samples,O
were,O
loaded,O
onto,O
a,O
Waters,O
7125,O
plus,O
autosampler,O
(,O
Waters,O
",",O
Milford,O
",",O
USA,O
),O
and,O
the,O
mobile,O
phase,O
was,O
delivered,O
at,O
a,O
constant,O
rate,O
of,O
1,O
mL,O
/,O
min,O
by,O
a,O
Waters,O
Model,O
515,O
pump,O
(,O
Waters,O
",",O
Milford,O
",",O
USA,O
),O
through,O
a,O
C18,O
",",O
5,O
mm,O
",",O
250,O
mm,O
×,O
4,O
.,O
6,O
mm,O
analytical,O
column,O
(,O
HiQsil,O
",",O
Japan,O
),O
placed,O
in,O
a,O
column,O
heater,O
(,O
35,O
°,O
C,O
).,O
The,O
LC,O
amperometric,O
potential,O
was,O
set,O
to,O
0,O
.,O
75,O
V,O
with,O
reference,O
to,O
an,O
Ag,O
-,O
AgCl,O
reference,O
electrode,O
and,O
the,O
sensitivity,O
of,O
the,O
detector,O
was,O
modified,O
according,O
to,O
the,O
content,O
of,O
amines,O
in,O
the,O
sample,O
.,O
The,O
mobile,O
phase,O
consisted,O
of,O
0,O
.,O
1,O
M,O
monosodium,O
phosphate,O
",",O
0,O
.,O
15,O
mM,O
EDTA,O
",",O
2,O
mM,O
NaCl,O
",",O
1,O
.,O
4,O
mM,O
octyl,O
sodium,O
sulfate,O
",",O
and,O
12,O
%,O
methanol,O
.,O
The,O
signal,O
from,O
the,O
detector,O
was,O
recorded,O
and,O
the,O
data,O
was,O
analyzed,O
using,O
a,O
N2000,O
Workstation,O
(,O
Institute,O
of,O
Intelligent,O
Information,O
Engineering,O
",",O
Zhejiang,O
University,O
",",O
Zhejiang,O
",",O
China,O
).,O
The,O
monoamine,O
neurotransmitter,O
contents,O
were,O
expressed,O
as,O
ng,O
/,O
g,O
weight,O
of,O
tissue,O
.,O
Amino,O
acids,O
in,O
hippocampus,O
were,O
determined,O
by,O
OPA,O
precolumn,O
derivatization,O
and,O
RP,O
-,O
HPLC,O
with,O
a,O
high,O
-,O
performance,O
liquid,O
chromatography,O
system,O
(,O
Hewlett,O
-,O
Packed,O
1100,O
series,O
",",O
USA,O
).,O
The,O
derivatization,O
procedure,O
was,O
accomplished,O
by,O
an,O
online,O
autoinjector,O
.,O
The,O
derivatives,O
were,O
separated,O
on,O
a,O
Hypersil,O
ODS,O
and,O
the,O
signals,O
were,O
detected,O
with,O
a,O
programmable,O
fluorospectrophotometer,O
detector,O
.,O
Mobile,O
phase,O
A,O
was,O
10,O
mmol,O
/,O
L,O
",",O
PH,O
7,O
.,O
2,O
sodium,O
phosphate,O
buffer,O
(,O
PB,O
),O
containing,O
0,O
.,O
5,O
%,O
(,O
φ,O
),O
tetrahydrofuran,O
",",O
and,O
B,O
was,O
PB,O
-,O
methanol,O
-,O
acetonitrile,O
(,O
50,O
:,O
35,O
:,O
15,O
by,O
volume,O
).,O
The,O
elution,O
program,O
was,O
100,O
%,O
A,O
with,O
0,O
%,O
B,O
at,O
the,O
start,O
(,O
0,O
min,O
),O
and,O
0,O
%,O
A,O
with,O
100,O
%,O
B,O
at,O
the,O
end,O
(,O
25,O
min,O
),O
of,O
the,O
program,O
.,O
OPA,O
-,O
reactive,O
compounds,O
were,O
detected,O
at,O
excitation,O
wavelength,O
of,O
340,O
nm,O
and,O
emission,O
wavelength,O
of,O
450,O
nm,O
",",O
and,O
chromatograms,O
were,O
analyzed,O
.,O
2,O
.,O
14,O
.,O
Statistical,O
Analysis,O
The,O
data,O
were,O
expressed,O
as,O
mean,O
±,O
standard,O
deviation,O
(,O
SD,O
).,O
The,O
significance,O
of,O
the,O
difference,O
was,O
statistically,O
evaluated,O
using,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
as,O
well,O
as,O
the,O
least,O
significant,O
difference,O
test,O
.,O
P,O
<,O
0,O
.,O
05,O
was,O
considered,O
statistically,O
significant,O
.,O
3,O
.,O
Results,O
3,O
.,O
1,O
.,O
Sucrose,O
Preference,O
Test,O
in,O
Each,O
Group,O
As,O
shown,O
in,O
Figure,O
2,O
",",O
compared,O
with,O
the,O
control,O
group,O
",",O
CUMS,O
decreased,O
the,O
sucrose,O
preference,O
in,O
rats,B-OG
significantly,O
(,O
P,O
<,O
0,O
.,O
01,O
).,O
Compared,O
with,O
the,O
CUMS,O
group,O
",",O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
significantly,O
increased,O
the,O
sucrose,O
preference,O
(,O
P,O
<,O
0,O
.,O
01,O
",",O
Figure,O
2,O
).,O
3,O
.,O
2,O
.,O
Forced,O
Swimming,O
Test,O
(,O
FST,O
),O
in,O
Each,O
Group,O
In,O
FST,O
",",O
compared,O
with,O
the,O
control,O
group,O
",",O
the,O
duration,O
of,O
immobility,O
in,O
rats,B-OG
with,O
CUMS,O
increased,O
significantly,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
Compared,O
with,O
the,O
CUMS,O
group,O
",",O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
duration,O
of,O
immobility,O
(,O
P,O
<,O
0,O
.,O
05,O
",",O
Figure,O
3,O
).,O
3,O
.,O
3,O
.,O
Tail,O
Suspension,O
Test,O
(,O
TST,O
),O
in,O
Each,O
Group,O
In,O
TST,O
",",O
compared,O
with,O
the,O
control,O
group,O
",",O
the,O
duration,O
of,O
immobility,O
in,O
rats,B-OG
with,O
CUMS,O
increased,O
significantly,O
(,O
P,O
<,O
0,O
.,O
01,O
).,O
Compared,O
with,O
the,O
CUMS,O
group,O
",",O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
duration,O
of,O
immobility,O
(,O
P,O
<,O
0,O
.,O
05,O
",",O
Figure,O
4,O
).,O
3,O
.,O
4,O
.,O
Open,O
-,O
Field,O
Test,O
(,O
OFT,O
),O
in,O
Each,O
Group,O
In,O
the,O
OFT,O
",",O
compared,O
with,O
the,O
control,O
group,O
",",O
both,O
the,O
locomotor,O
activity,O
and,O
the,O
rearing,O
counts,O
for,O
5,O
min,O
were,O
lower,O
in,O
the,O
rats,B-OG
with,O
CUMS,O
(,O
P,O
<,O
0,O
.,O
01,O
).,O
The,O
results,O
showed,O
that,O
the,O
rats,B-OG
with,O
CUMS,O
appeared,O
to,O
have,O
depressant,O
-,O
like,O
behavioral,O
changes,O
.,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
significantly,O
increased,O
the,O
locomotor,O
activity,O
and,O
the,O
rearing,O
counts,O
(,O
P,O
<,O
0,O
.,O
05,O
or,O
P,O
<,O
0,O
.,O
01,O
",",O
Figure,O
5,O
).,O
3,O
.,O
5,O
.,O
CORT,O
",",O
CRH,B-GP
",",O
and,O
ACTH,B-GP
Contents,O
in,O
Plasma,O
and,O
Hypothalamus,O
in,O
Each,O
Group,O
As,O
shown,O
in,O
Table,O
2,O
",",O
CUMS,O
significantly,O
increased,O
the,O
contents,O
of,O
CORT,O
",",O
CRH,B-GP
",",O
and,O
ACTH,B-GP
in,O
plasma,O
in,O
rats,B-OG
(,O
P,O
<,O
0,O
.,O
05,O
).,O
Compared,O
with,O
the,O
control,O
group,O
",",O
the,O
contents,O
of,O
CRH,B-GP
and,O
ACTH,B-GP
in,O
hypothalamus,O
in,O
rats,B-OG
with,O
CUMS,O
were,O
also,O
higher,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
Compared,O
with,O
the,O
CUMS,O
group,O
",",O
FA,O
at,O
0,O
.,O
172,O
g,O
/,O
kg,O
",",O
FB,O
at,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
CORT,O
",",O
CRH,B-GP
",",O
and,O
ACTH,B-GP
contents,O
in,O
plasma,O
and,O
hypothalamus,O
(,O
P,O
<,O
0,O
.,O
05,O
or,O
P,O
<,O
0,O
.,O
01,O
).,O
3,O
.,O
6,O
.,O
AVP,B-GP
Contents,O
in,O
Plasma,O
and,O
Hypothalamus,O
in,O
Each,O
Group,O
As,O
shown,O
in,O
Table,O
3,O
",",O
CUMS,O
significantly,O
increased,O
the,O
AVP,B-GP
contents,O
both,O
in,O
hypothalamus,O
and,O
in,O
plasma,O
(,O
P,O
<,O
0,O
.,O
01,O
).,O
The,O
AVP,B-GP
contents,O
could,O
be,O
significantly,O
decreased,O
in,O
both,O
hypothalamus,O
and,O
plasma,O
by,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
(,O
P,O
<,O
0,O
.,O
05,O
or,O
P,O
<,O
0,O
.,O
01,O
).,O
3,O
.,O
7,O
.,O
Monoamine,O
Neurotransmitters,O
Contents,O
in,O
Hippocampus,O
in,O
Each,O
Group,O
As,O
shown,O
in,O
Table,O
4,O
and,O
Figures,O
6,O
and,O
7,O
",",O
compared,O
with,O
the,O
control,O
group,O
",",O
CUMS,O
markedly,O
decreased,O
the,O
contents,O
of,O
5,O
-,O
HT,O
and,O
DA,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
and,O
increased,O
the,O
NE,O
content,O
in,O
hippocampus,O
(,O
P,O
<,O
0,O
.,O
01,O
).,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
),O
and,O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
),O
significantly,O
increased,O
the,O
contents,O
of,O
5,O
-,O
HT,O
and,O
DA,O
and,O
decreased,O
the,O
content,O
of,O
NE,O
in,O
hippocampus,O
(,O
P,O
<,O
0,O
.,O
05,O
or,O
P,O
<,O
0,O
.,O
01,O
).,O
As,O
a,O
positive,O
control,O
",",O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
could,O
increase,O
the,O
5,O
-,O
HT,O
content,O
and,O
decrease,O
the,O
NE,O
content,O
in,O
hippocampus,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
but,O
had,O
no,O
effect,O
on,O
DA,O
.,O
As,O
a,O
metabolite,O
of,O
serotonin,O
",",O
the,O
ratio,O
of,O
5,O
-,O
HIAA,O
/,O
5,O
-,O
HT,O
could,O
be,O
used,O
as,O
an,O
index,O
for,O
the,O
turnover,O
of,O
5,O
-,O
HT,O
[,O
15,O
",",O
16,O
].,O
Here,O
",",O
the,O
ratio,O
of,O
5,O
-,O
HIAA,O
/,O
5,O
-,O
HT,O
was,O
calculated,O
.,O
The,O
amount,O
of,O
5,O
-,O
HIAA,O
was,O
not,O
altered,O
in,O
hippocampus,O
of,O
rat,B-OG
with,O
CUMS,O
(,O
Table,O
4,O
).,O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
),O
as,O
well,O
as,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
significantly,O
elevated,O
the,O
amount,O
of,O
5,O
-,O
HIAA,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
The,O
ratio,O
of,O
5,O
-,O
HIAA,O
/,O
5,O
-,O
HT,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
was,O
significantly,O
increased,O
by,O
CUMS,O
",",O
which,O
could,O
be,O
reversed,O
by,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
).,O
3,O
.,O
8,O
.,O
Amino,O
Acid,O
Neurotransmitters,O
Contents,O
in,O
Hippocampus,O
in,O
Each,O
Group,O
Compared,O
with,O
the,O
control,O
group,O
",",O
the,O
contents,O
of,O
Glu,O
and,O
Asp,O
in,O
hippocampus,O
were,O
significantly,O
higher,O
(,O
P,O
<,O
0,O
.,O
01,O
"),",O
while,O
the,O
GABA,O
and,O
Tau,O
contents,O
were,O
significantly,O
lower,O
(,O
P,O
<,O
0,O
.,O
05,O
or,O
P,O
<,O
0,O
.,O
01,O
).,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
contents,O
of,O
Glu,O
and,O
Asp,O
in,O
the,O
hippocampus,O
(,O
P,O
<,O
0,O
.,O
05,O
or,O
P,O
<,O
0,O
.,O
01,O
",",O
Figure,O
8,O
),O
but,O
had,O
no,O
effects,O
on,O
GABA,O
and,O
Tau,O
.,O
4,O
.,O
Discussion,O
Traditional,O
Chinese,O
medicine,O
has,O
offered,O
a,O
possible,O
therapy,O
for,O
the,O
treatment,O
of,O
depression,B-DS
.,O
DZXYS,O
",",O
an,O
ancient,O
Chinese,O
herbal,O
decoction,O
",",O
has,O
been,O
used,O
in,O
Chinese,O
medicinal,O
herbal,O
mixture,O
for,O
antidepression,O
.,O
However,O
",",O
its,O
action,O
mechanism,O
has,O
not,O
been,O
revealed,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
provided,O
different,O
lines,O
of,O
evidence,O
to,O
support,O
the,O
antidepression,O
role,O
of,O
DZXYS,O
in,O
CUMS,O
rat,B-OG
model,O
system,O
.,O
The,O
pathogenesis,O
of,O
depression,B-DS
model,O
established,O
by,O
using,O
stress,O
factors,O
is,O
more,O
consistent,O
with,O
that,O
of,O
depression,B-DS
in,O
human,B-OG
beings,O
.,O
The,O
symptoms,O
such,O
as,O
reduced,O
activity,O
",",O
decreased,O
exploratory,O
behavior,O
",",O
and,O
reduced,O
sucrose,O
preference,O
appear,O
in,O
stressed,O
animals,B-OG
",",O
which,O
are,O
similar,O
to,O
the,O
changes,O
of,O
behavior,O
and,O
the,O
loss,O
of,O
interest,O
or,O
pleasure,O
in,O
the,O
clinical,O
diagnosis,O
of,O
depression,B-DS
[,O
17,O
].,O
The,O
CUMS,O
model,O
of,O
depression,B-DS
is,O
accepted,O
as,O
a,O
valuable,O
method,O
for,O
evaluating,O
antidepressant,O
effects,O
in,O
animals,B-OG
.,O
In,O
the,O
present,O
study,O
",",O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
),O
and,O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
),O
prepared,O
from,O
DZXYS,O
exhibited,O
a,O
significant,O
increase,O
of,O
sucrose,O
preference,O
in,O
the,O
rats,B-OG
with,O
CUMS,O
.,O
The,O
FST,O
",",O
TST,O
",",O
and,O
OFT,O
are,O
the,O
most,O
widely,O
used,O
as,O
behavioral,O
tools,O
for,O
assessing,O
antidepressant,O
activity,O
[,O
18,O
",",O
19,O
].,O
Characteristic,O
of,O
rat,B-OG
behaviors,O
scored,O
in,O
both,O
tests,O
is,O
termed,O
immobility,O
",",O
which,O
reflects,O
behavioral,O
despair,O
as,O
seen,O
in,O
human,B-OG
depression,B-DS
.,O
The,O
duration,O
of,O
immobility,O
time,O
in,O
rats,B-OG
that,O
are,O
trapped,O
and,O
forced,O
to,O
swim,O
is,O
closely,O
related,O
to,O
helplessness,O
[,O
20,O
].,O
It,O
was,O
observed,O
from,O
our,O
results,O
that,O
there,O
was,O
significant,O
prolongation,O
of,O
immobility,O
time,O
in,O
these,O
groups,O
after,O
modeling,O
.,O
The,O
two,O
fractions,O
at,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
respectively,O
",",O
could,O
significantly,O
decrease,O
the,O
duration,O
of,O
immobility,O
both,O
in,O
FST,O
and,O
in,O
TST,O
and,O
significantly,O
increase,O
the,O
locomotor,O
activity,O
in,O
OFT,O
.,O
These,O
results,O
may,O
further,O
confirm,O
that,O
the,O
DZXYS,O
has,O
an,O
antidepressant,O
activity,O
.,O
The,O
nervous,O
system,O
and,O
the,O
endocrine,O
system,O
are,O
closely,O
related,O
",",O
which,O
constitute,O
a,O
complete,O
network,O
to,O
maintain,O
homeostasis,O
.,O
HPA,O
axis,O
activation,O
and,O
the,O
resulting,O
increase,O
in,O
glucocorticoid,O
(,O
GC,O
),O
secretion,O
are,O
the,O
two,O
most,O
important,O
features,O
of,O
the,O
stress,O
response,O
.,O
When,O
in,O
stress,O
state,O
",",O
the,O
hypothalamus,O
releases,O
CRH,B-GP
and,O
AVP,B-GP
in,O
response,O
to,O
a,O
stressor,O
",",O
which,O
in,O
turn,O
activate,O
the,O
secretion,O
of,O
ACTH,B-GP
from,O
the,O
pituitary,O
",",O
which,O
finally,O
stimulates,O
the,O
secretion,O
of,O
cortisol,O
(,O
in,O
humans,B-OG
),O
or,O
CORT,O
(,O
in,O
rodents,B-OG
),O
from,O
the,O
adrenal,O
cortex,O
[,O
21,O
].,O
From,O
the,O
actual,O
situation,O
of,O
human,B-OG
depression,B-DS
",",O
stressful,O
life,O
events,O
play,O
an,O
important,O
role,O
in,O
depression,B-DS
.,O
Stressor,O
or,O
stressful,O
environment,O
usually,O
precedes,O
depressive,O
symptoms,O
",",O
which,O
leads,O
to,O
neurobiochemical,O
changes,O
associated,O
with,O
depression,B-DS
[,O
17,O
].,O
Since,O
the,O
1970s,O
",",O
people,O
have,O
found,O
that,O
the,O
HPA,O
axis,O
is,O
involved,O
in,O
the,O
pathological,O
mechanism,O
of,O
depression,B-DS
.,O
Many,O
studies,O
suggested,O
that,O
HPA,O
axis,O
activation,O
results,O
in,O
some,O
of,O
the,O
symptoms,O
and,O
signs,O
in,O
depression,B-DS
[,O
22,O
].,O
Moreover,O
",",O
it,O
has,O
been,O
found,O
that,O
the,O
damage,O
of,O
HPA,O
axis,O
is,O
more,O
severe,O
in,O
patients,O
with,O
refractory,B-DS
depression,I-DS
[,O
23,O
].,O
Hyperactivity,O
of,O
HPA,O
axis,O
often,O
occurs,O
in,O
both,O
depressed,O
patients,O
and,O
animal,B-OG
models,O
",",O
which,O
is,O
mainly,O
presented,O
as,O
hypersecreted,O
CRH,B-GP
and,O
higher,O
contents,O
of,O
ACTH,B-GP
and,O
GC,O
[,O
24,O
",",O
25,O
].,O
Combined,O
with,O
receptors,O
in,O
multiple,O
target,O
tissues,O
(,O
including,O
HPA,O
axis,O
"),",O
GC,O
could,O
exert,O
physiological,O
effects,O
.,O
When,O
in,O
state,O
of,O
stress,O
",",O
GC,O
is,O
hypersecreted,O
and,O
then,O
combined,O
with,O
glucocorticoid,B-GP
receptor,I-GP
(,O
GR,B-GP
"),",O
thereby,O
inhibiting,O
the,O
hypothalamus,O
to,O
secrete,O
CRF,B-GP
and,O
AVP,B-GP
by,O
negative,O
feedback,O
to,O
restore,O
the,O
hyperactivated,O
HPA,O
axis,O
to,O
the,O
basal,O
level,O
.,O
However,O
",",O
chronic,O
stress,O
could,O
result,O
in,O
the,O
state,O
of,O
persistent,O
hyperactivity,O
of,O
the,O
HPA,O
axis,O
;,O
excessive,O
GC,O
constantly,O
stimulates,O
GR,B-GP
",",O
which,O
leads,O
to,O
the,O
injury,O
of,O
hippocampal,O
neurons,O
and,O
the,O
dysfunction,O
of,O
emotion,O
regulation,O
center,O
",",O
and,O
then,O
induces,O
depression,B-DS
[,O
26,O
].,O
As,O
observed,O
in,O
our,O
experiment,O
",",O
the,O
CUMS,O
could,O
significantly,O
increase,O
the,O
contents,O
of,O
CORT,O
",",O
CRH,B-GP
",",O
and,O
ACTH,B-GP
in,O
both,O
plasma,O
and,O
hypothalamus,O
in,O
rats,B-OG
",",O
accompanied,O
by,O
the,O
depressive,O
-,O
like,O
behavioral,O
alterations,O
;,O
thus,O
",",O
we,O
confirmed,O
that,O
HPA,O
axis,O
hyperactivity,O
is,O
related,O
to,O
the,O
pathogenesis,O
of,O
depression,B-DS
.,O
Results,O
from,O
the,O
present,O
study,O
demonstrated,O
that,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
),O
and,O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
),O
prepared,O
from,O
DZXYS,O
could,O
significantly,O
decrease,O
the,O
CORT,O
",",O
CRH,B-GP
",",O
and,O
ACTH,B-GP
contents,O
in,O
plasma,O
and,O
hypothalamus,O
",",O
which,O
suggested,O
that,O
antidepressant,O
effects,O
exerted,O
by,O
DZXYS,O
were,O
partly,O
due,O
to,O
inhibiting,O
the,O
hyperactivity,O
of,O
the,O
HPA,O
axis,O
.,O
Some,O
previous,O
studies,O
have,O
shown,O
that,O
there,O
are,O
significant,O
increases,O
of,O
AVP,B-GP
neurons,O
expression,O
and,O
AVP,B-GP
level,O
in,O
the,O
paraventricular,O
nucleus,O
",",O
AVP,B-GP
reactivity,O
in,O
the,O
pituitary,O
",",O
and,O
AVP,B-GP
mRNA,O
expression,O
in,O
the,O
supraoptic,O
nucleus,O
in,O
depressed,O
patients,O
[,O
27,O
",",O
28,O
"],",O
which,O
also,O
suggests,O
that,O
AVP,B-GP
changes,O
in,O
the,O
paraventricular,O
nucleus,O
and,O
supraoptic,O
nucleus,O
may,O
be,O
the,O
basis,O
for,O
the,O
onset,O
of,O
depression,B-DS
.,O
In,O
addition,O
",",O
AVP,B-GP
level,O
in,O
the,O
plasma,O
in,O
depressed,O
patients,O
is,O
higher,O
than,O
that,O
in,O
the,O
healthy,O
control,O
group,O
",",O
which,O
is,O
related,O
to,O
the,O
severity,O
of,O
the,O
disease,O
[,O
29,O
].,O
AVP,B-GP
",",O
a,O
nonapeptide,O
synthesized,O
in,O
hypothalamic,O
nuclei,O
",",O
is,O
critical,O
for,O
the,O
regulation,O
of,O
the,O
activity,O
of,O
the,O
HPA,O
axis,O
representing,O
a,O
major,O
component,O
of,O
the,O
stress,O
response,O
.,O
CRH,B-GP
and,O
AVP,B-GP
act,O
synergistically,O
in,O
bringing,O
about,O
ACTH,B-GP
release,O
from,O
the,O
corticotropes,O
of,O
the,O
anterior,O
pituitary,O
",",O
which,O
in,O
turn,O
stimulates,O
cortisol,O
output,O
from,O
the,O
adrenal,O
cortex,O
.,O
AVP,B-GP
is,O
involved,O
in,O
the,O
pathogenesis,O
of,O
depression,B-DS
by,O
regulating,O
the,O
HPA,O
axis,O
function,O
[,O
30,O
].,O
In,O
order,O
to,O
further,O
explore,O
the,O
effect,O
of,O
DZXYS,O
on,O
HPA,O
axis,O
",",O
the,O
levels,O
of,O
AVP,B-GP
in,O
plasma,O
and,O
hypothalamus,O
were,O
measured,O
in,O
the,O
present,O
study,O
.,O
Our,O
results,O
showed,O
that,O
",",O
in,O
rats,B-OG
with,O
CUMS,O
",",O
AVP,B-GP
levels,O
significantly,O
increased,O
in,O
plasma,O
and,O
hypothalamus,O
",",O
which,O
could,O
be,O
significantly,O
reversed,O
by,O
the,O
treatment,O
of,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
"),",O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
and,O
IMI,O
(,O
20,O
mg,O
/,O
kg,O
).,O
Combined,O
with,O
the,O
results,O
of,O
HPA,O
axis,O
determination,O
in,O
our,O
study,O
",",O
it,O
suggested,O
that,O
DZXYS,O
could,O
regulate,O
the,O
HPA,O
axis,O
by,O
acting,O
on,O
the,O
AVP,B-GP
to,O
exert,O
antidepressant,O
effect,O
.,O
As,O
a,O
significant,O
contribution,O
to,O
depression,B-DS
",",O
“,O
monoamine,O
hypothesis,O
”,O
has,O
been,O
proposed,O
in,O
the,O
20th,O
century,O
",",O
thereby,O
setting,O
up,O
the,O
foundation,O
for,O
today,O
',O
s,O
antidepressant,O
treatment,O
.,O
Monoamine,O
neurotransmitters,O
",",O
such,O
as,O
5,O
-,O
HT,O
",",O
DA,O
",",O
and,O
NE,O
",",O
are,O
the,O
important,O
bioactive,O
substances,O
in,O
central,O
nervous,O
system,O
which,O
participate,O
in,O
many,O
physiological,O
activities,O
of,O
the,O
body,O
",",O
including,O
emotion,O
",",O
learning,O
",",O
and,O
memory,O
.,O
NE,O
plays,O
an,O
important,O
role,O
in,O
maintaining,O
arousal,O
and,O
is,O
involved,O
in,O
the,O
brain,O
reward,O
system,O
and,O
learning,O
and,O
memory,O
function,O
.,O
The,O
concentration,O
of,O
NE,O
in,O
the,O
hypothalamus,O
is,O
significantly,O
decreased,O
",",O
which,O
suggests,O
that,O
the,O
dysfunction,O
of,O
central,O
NE,O
is,O
related,O
to,O
depression,B-DS
[,O
31,O
].,O
Dysfunction,O
of,O
5,O
-,O
HT,O
is,O
related,O
to,O
depressed,O
mood,O
",",O
anxiety,B-DS
",",O
inhibition,O
of,O
movement,O
",",O
loss,O
of,O
appetite,O
",",O
sleep,B-DS
disorders,I-DS
",",O
circadian,B-DS
rhythm,I-DS
disorders,I-DS
",",O
and,O
so,O
on,O
in,O
depression,B-DS
[,O
32,O
].,O
Dopamine,O
(,O
DA,O
),O
is,O
involved,O
in,O
the,O
regulation,O
of,O
motivation,O
",",O
volition,O
",",O
interest,O
/,O
pleasure,O
",",O
and,O
attention,O
/,O
concentration,O
",",O
all,O
of,O
which,O
are,O
likely,O
to,O
be,O
impaired,O
in,O
depressed,O
patients,O
.,O
Several,O
previous,O
reports,O
have,O
suggested,O
that,O
depression,B-DS
may,O
often,O
be,O
accompanied,O
by,O
a,O
relative,O
hypodopaminergic,O
state,O
[,O
33,O
].,O
According,O
to,O
the,O
“,O
monoamine,O
hypothesis,O
",”",O
the,O
decreased,O
releasing,O
and,O
lower,O
contents,O
in,O
the,O
synapse,O
of,O
5,O
-,O
HT,O
",",O
DA,O
",",O
or,O
NE,O
in,O
central,O
nervous,O
system,O
are,O
involved,O
in,O
pathogenesis,O
of,O
depression,B-DS
.,O
Thus,O
",",O
it,O
is,O
well,O
known,O
that,O
many,O
antidepressant,O
drugs,O
currently,O
in,O
use,O
exert,O
effects,O
by,O
regulating,O
the,O
reuptake,O
and,O
metabolic,O
balance,O
of,O
monoamine,O
neurotransmitters,O
[,O
34,O
].,O
Our,O
experimental,O
results,O
showed,O
that,O
the,O
5,O
-,O
HT,O
and,O
DA,O
contents,O
significantly,O
decreased,O
",",O
while,O
the,O
NE,O
content,O
and,O
the,O
ratio,O
of,O
5,O
-,O
HIAA,O
/,O
5,O
-,O
HT,O
significantly,O
increased,O
in,O
hippocampus,O
in,O
rats,B-OG
",",O
accompanied,O
by,O
the,O
depressive,O
-,O
like,O
behavioral,O
alterations,O
",",O
which,O
confirm,O
that,O
the,O
dysfunction,O
of,O
monoamine,O
neurotransmitters,O
plays,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
depression,B-DS
.,O
Amino,O
acid,O
neurotransmitters,O
can,O
be,O
divided,O
into,O
two,O
types,O
of,O
excitatory,O
amino,O
acid,O
and,O
inhibitory,O
amino,O
acid,O
;,O
the,O
former,O
includes,O
Glu,O
and,O
Asp,O
",",O
while,O
GABA,O
and,O
Tau,O
belong,O
to,O
the,O
latter,O
.,O
Some,O
of,O
the,O
studies,O
",",O
whether,O
in,O
rodent,O
models,O
of,O
depression,B-DS
or,O
in,O
depressed,O
patients,O
",",O
indicate,O
that,O
the,O
increase,O
of,O
the,O
Glu,O
concentration,O
is,O
closely,O
related,O
to,O
depression,B-DS
[,O
35,O
].,O
As,O
an,O
important,O
inhibitory,O
neurotransmitter,O
in,O
the,O
brain,O
",",O
GABA,O
decreases,O
significantly,O
in,O
the,O
patients,O
of,O
depression,B-DS
[,O
36,O
].,O
Therefore,O
",",O
the,O
change,O
of,O
the,O
ratio,O
of,O
excitatory,O
/,O
inhibitory,O
amino,O
acid,O
in,O
the,O
brain,O
has,O
an,O
important,O
influence,O
on,O
the,O
incidence,O
of,O
depression,B-DS
[,O
37,O
].,O
In,O
the,O
present,O
study,O
",",O
we,O
found,O
that,O
the,O
contents,O
of,O
Glu,O
and,O
Asp,O
significantly,O
increased,O
",",O
while,O
the,O
GABA,O
and,O
Tau,O
contents,O
decreased,O
in,O
hippocampus,O
in,O
depressed,O
rats,B-OG
;,O
it,O
is,O
suggested,O
that,O
CUMS,O
could,O
lead,O
to,O
the,O
imbalance,O
of,O
excitatory,O
/,O
inhibitory,O
amino,O
acids,O
in,O
the,O
brain,O
",",O
which,O
may,O
account,O
for,O
the,O
mechanism,O
underlying,O
the,O
behavioral,O
changes,O
in,O
rats,B-OG
.,O
In,O
the,O
rat,B-OG
and,O
other,O
mammalian,O
species,O
",",O
including,O
human,B-OG
beings,O
",",O
HPA,O
axis,O
and,O
neurotransmitters,O
system,O
are,O
closely,O
interacted,O
in,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
(,O
particularly,O
in,O
hippocampus,O
),O
and,O
greatly,O
involved,O
in,O
stress,B-DS
related,I-DS
disorder,I-DS
[,O
38,O
",",O
39,O
].,O
Under,O
the,O
chronic,O
stress,O
",",O
as,O
high,O
concentration,O
of,O
GC,O
could,O
induce,O
the,O
liver,O
to,O
produce,O
tryptophan,B-GP
pyrrole,I-GP
enzyme,I-GP
",",O
it,O
could,O
degrade,O
the,O
tryptophan,O
in,O
the,O
blood,O
.,O
Tryptophan,O
is,O
the,O
precursor,O
of,O
5,O
-,O
HT,O
and,O
its,O
reduction,O
could,O
lead,O
to,O
synthesis,O
of,O
5,O
-,O
HT,O
and,O
so,O
lead,O
to,O
5,O
-,O
HT,O
content,O
decrease,O
in,O
the,O
brain,O
",",O
thus,O
causing,O
depressive,O
symptoms,O
[,O
40,O
].,O
In,O
a,O
stress,O
state,O
",",O
HPA,O
axis,O
function,O
becomes,O
hyperactive,O
and,O
5,O
-,O
HT,O
synthesis,O
significantly,O
decreases,O
as,O
a,O
result,O
of,O
insufficient,O
tryptophan,O
transported,O
into,O
the,O
CNS,O
[,O
41,O
].,O
Moreover,O
",",O
high,O
concentration,O
of,O
GC,O
can,O
make,O
5,B-GP
-,I-GP
HT,I-GP
transporter,I-GP
(,O
5,B-GP
-,I-GP
HTT,I-GP
),O
expression,O
increase,O
in,O
hippocampus,O
",",O
amygdala,O
",",O
dorsal,O
raphe,O
nucleus,O
",",O
and,O
other,O
brain,O
areas,O
by,O
GR,B-GP
dependent,O
manner,O
.,O
The,O
increased,O
5,B-GP
-,I-GP
HTT,I-GP
will,O
increase,O
the,O
reuptake,O
of,O
5,O
-,O
HT,O
in,O
synaptic,O
cleft,O
",",O
which,O
aggravates,O
the,O
decrease,O
of,O
5,O
-,O
HT,O
concentration,O
and,O
the,O
severity,O
of,O
the,O
symptoms,O
in,O
depressed,O
patients,O
[,O
42,O
].,O
Stress,O
can,O
affect,O
the,O
excitability,O
of,O
neurons,O
of,O
locus,O
coeruleus,O
(,O
LC,O
"),",O
raphe,O
nucleus,O
",",O
and,O
substantia,O
nigra,O
by,O
HPA,O
axis,O
and,O
5,O
-,O
HT,O
and,O
NE,O
/,O
DA,O
play,O
an,O
important,O
role,O
in,O
the,O
change,O
of,O
emotion,O
and,O
mood,O
[,O
43,O
].,O
In,O
the,O
study,O
of,O
social,O
stress,O
in,O
mice,B-OG
",",O
by,O
using,O
the,O
intracellular,O
recording,O
technique,O
in,O
vitro,O
",",O
it,O
is,O
found,O
that,O
CRH,B-GP
can,O
directly,O
activate,O
noradrenergic,O
neurons,O
of,O
the,O
LC,O
",",O
thus,O
resulting,O
in,O
the,O
increase,O
of,O
NE,O
in,O
the,O
brain,O
[,O
44,O
].,O
In,O
addition,O
",",O
some,O
of,O
the,O
studies,O
indicate,O
that,O
5,O
-,O
HT,O
",",O
DA,O
",",O
and,O
NE,O
can,O
stimulate,O
the,O
hypothalamus,O
to,O
secret,O
CRH,B-GP
",",O
which,O
suggest,O
that,O
a,O
positive,O
feedback,O
neural,O
circuit,O
exists,O
between,O
hypothalamic,O
neurons,O
and,O
neurons,O
secreting,O
5,O
-,O
HT,O
",",O
DA,O
",",O
and,O
NE,O
[,O
45,O
].,O
In,O
chronic,O
stress,O
",",O
high,O
GC,O
concentration,O
may,O
increase,O
the,O
releasing,O
of,O
excitatory,O
amino,O
acid,O
from,O
the,O
synaptic,O
vesicle,O
of,O
the,O
glutamatergic,O
nerve,O
endings,O
and,O
inhibit,O
its,O
reuptake,O
at,O
the,O
same,O
time,O
",",O
which,O
causes,O
the,O
persistent,O
increase,O
of,O
excitatory,O
amino,O
acid,O
[,O
46,O
].,O
The,O
accumulation,O
of,O
Glu,O
can,O
cause,O
hippocampal,O
toxicity,O
",",O
and,O
the,O
high,O
level,O
of,O
extracellular,O
Glu,O
may,O
in,O
turn,O
make,O
the,O
HPA,O
axis,O
more,O
hyperactive,O
to,O
secrete,O
more,O
GC,O
[,O
47,O
].,O
Glu,O
directly,O
injected,O
into,O
paraventricular,O
nucleus,O
(,O
PVN,O
),O
in,O
hypothalamus,O
could,O
accelerate,O
the,O
release,O
of,O
ACTH,B-GP
[,O
48,O
].,O
GABA,O
could,O
inhibit,O
the,O
releasing,O
of,O
ACTH,B-GP
",",O
CORT,O
",",O
and,O
CRH,B-GP
in,O
hypothalamus,O
and,O
reregulate,O
the,O
hyperactivity,O
of,O
HPA,O
axis,O
;,O
Tau,O
",",O
as,O
an,O
inhibitory,O
amino,O
acid,O
",",O
has,O
the,O
synergistic,O
action,O
with,O
GABA,O
to,O
exert,O
the,O
effect,O
on,O
inhibiting,O
the,O
activation,O
of,O
HPA,O
axis,O
[,O
49,O
",",O
50,O
].,O
Our,O
data,O
indicated,O
that,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
),O
and,O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
),O
significantly,O
increased,O
the,O
5,O
-,O
HT,O
and,O
DA,O
contents,O
and,O
decreased,O
the,O
NE,O
content,O
in,O
the,O
hippocampus,O
;,O
meanwhile,O
",",O
the,O
ratio,O
of,O
5,O
-,O
HIAA,O
/,O
5,O
-,O
HT,O
in,O
rats,B-OG
with,O
CUMS,O
could,O
be,O
reversed,O
by,O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
),O
and,O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
"),",O
which,O
may,O
account,O
for,O
primary,O
monoamine,O
neurotransmitters,O
regulating,O
mechanism,O
underlying,O
DZXYS,O
antidepressant,O
effects,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
found,O
that,O
although,O
having,O
no,O
effects,O
on,O
GABA,O
and,O
Tau,O
",",O
FA,O
(,O
0,O
.,O
172,O
g,O
/,O
kg,O
),O
and,O
FB,O
(,O
3,O
.,O
608,O
g,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
contents,O
of,O
Glu,O
and,O
Asp,O
in,O
hippocampus,O
",",O
which,O
suggested,O
that,O
DZXYS,O
could,O
reduce,O
the,O
excitatory,O
toxicity,O
caused,O
by,O
the,O
accumulation,O
of,O
Glu,O
and,O
Asp,O
in,O
hippocampus,O
in,O
depressed,O
rats,B-OG
",",O
partly,O
regulating,O
the,O
imbalance,O
of,O
the,O
ratio,O
of,O
excitatory,O
/,O
inhibitory,O
amino,O
acid,O
that,O
may,O
be,O
involved,O
in,O
its,O
antidepressant,O
effects,O
.,O
There,O
is,O
a,O
close,O
relationship,O
between,O
HAP,O
and,O
neurotransmitters,O
in,O
regulating,O
emotion,O
and,O
behavior,O
in,O
depression,B-DS
[,O
51,O
].,O
As,O
observed,O
in,O
our,O
experiment,O
",",O
it,O
could,O
be,O
speculated,O
that,O
the,O
amelioration,O
produced,O
by,O
DZXYS,O
on,O
the,O
neurotransmitter,O
system,O
may,O
be,O
associated,O
with,O
its,O
effect,O
on,O
HPA,O
axis,O
.,O
However,O
",",O
the,O
cellular,O
and,O
molecular,O
biological,O
mechanism,O
of,O
exerting,O
regulating,O
effect,O
of,O
DZXYS,O
between,O
the,O
HPA,O
axis,O
and,O
neurotransmitters,O
remains,O
to,O
be,O
further,O
studied,O
in,O
the,O
future,O
.,O
In,O
conclusion,O
",",O
in,O
the,O
present,O
study,O
",",O
the,O
antidepressant,O
effects,O
of,O
two,O
fractions,O
(,O
petroleum,O
ether,O
soluble,O
fraction,O
",",O
FA,O
",",O
and,O
water,O
-,O
EtOH,O
soluble,O
fraction,O
",",O
FB,O
),O
prepared,O
from,O
DZXYS,O
were,O
observed,O
.,O
The,O
results,O
demonstrated,O
that,O
DZXYS,O
could,O
ameliorate,O
the,O
depression,B-DS
-,O
like,O
behavior,O
in,O
chronic,O
stress,O
model,O
of,O
rats,B-OG
.,O
The,O
mechanisms,O
of,O
action,O
of,O
DZXYS,O
might,O
be,O
accounted,O
for,O
by,O
inhibiting,O
hyperactivity,O
of,O
HPA,O
axis,O
and,O
modulating,O
monoamine,O
and,O
amino,O
acid,O
neurotransmitters,O
in,O
the,O
hippocampus,O
.,O
Thus,O
",",O
we,O
confirmed,O
that,O
DZXYS,O
has,O
the,O
potential,O
to,O
be,O
a,O
beneficial,O
remedy,O
for,O
the,O
treatment,O
of,O
depression,B-DS
.,O
Because,O
of,O
multiple,O
using,O
of,O
plants,B-OG
in,O
a,O
traditional,O
herbal,O
medicine,O
and,O
the,O
complexity,O
of,O
the,O
pathological,O
mechanism,O
of,O
depression,B-DS
",",O
it,O
is,O
undoubted,O
that,O
there,O
exist,O
more,O
other,O
active,O
fractions,O
from,O
DZXYS,O
and,O
further,O
regulatory,O
mechanisms,O
of,O
DZXYS,O
in,O
antidepression,O
.,O
These,O
works,O
are,O
currently,O
being,O
conducted,O
in,O
our,O
laboratory,O
.,O
Schedule,O
of,O
chronic,O
unpredictable,O
mild,O
stress,O
(,O
CUMS,O
),O
procedure,O
.,O
The,O
CUMS,O
protocol,O
consisted,O
of,O
the,O
sequential,O
application,O
of,O
a,O
variety,O
of,O
unpredictable,O
mild,O
stressors,O
.,O
These,O
stressors,O
were,O
randomly,O
scheduled,O
over,O
a,O
one,O
-,O
week,O
period,O
from,O
day,O
1,O
to,O
day,O
7,O
and,O
repeated,O
for,O
4,O
weeks,O
during,O
the,O
entire,O
experiment,O
.,O
The,O
effect,O
of,O
DZXYS,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
intragastrically,O
),O
on,O
the,O
sucrose,O
consumption,O
in,O
rats,B-OG
with,O
chronic,O
unpredictable,O
mild,O
stress,O
.,O
IMI,O
at,O
daily,O
dosage,O
of,O
20,O
mg,O
/,O
kg,O
was,O
set,O
as,O
a,O
positive,O
control,O
.,O
Each,O
column,O
represents,O
mean,O
±,O
SD,O
",",O
n,O
=,O
10,O
.,O
∗,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
control,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
CUMS,O
group,O
.,O
The,O
effect,O
of,O
DZXYS,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
intragastrically,O
),O
on,O
the,O
duration,O
of,O
immobility,O
in,O
FST,O
in,O
rats,B-OG
with,O
chronic,O
unpredictable,O
mild,O
stress,O
.,O
IMI,O
at,O
daily,O
dosage,O
of,O
20,O
mg,O
/,O
kg,O
was,O
set,O
as,O
a,O
positive,O
control,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
SD,O
",",O
n,O
=,O
10,O
.,O
∗,O
P,O
<,O
0,O
.,O
05,O
as,O
compared,O
with,O
control,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
05,O
as,O
compared,O
with,O
CUMS,O
group,O
.,O
The,O
effect,O
of,O
DZXYS,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
intragastrically,O
),O
on,O
the,O
duration,O
of,O
immobility,O
in,O
TST,O
in,O
rats,B-OG
with,O
chronic,O
unpredictable,O
mild,O
stress,O
.,O
IMI,O
at,O
daily,O
dosage,O
of,O
20,O
mg,O
/,O
kg,O
was,O
set,O
as,O
a,O
positive,O
control,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
SD,O
",",O
n,O
=,O
10,O
.,O
∗,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
control,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
05,O
as,O
compared,O
with,O
CUMS,O
group,O
.,O
The,O
effect,O
of,O
DZXYS,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
intragastrically,O
),O
on,O
the,O
duration,O
of,O
immobility,O
in,O
OFT,O
in,O
rats,B-OG
with,O
chronic,O
unpredictable,O
mild,O
stress,O
.,O
IMI,O
at,O
daily,O
dosage,O
of,O
20,O
mg,O
/,O
kg,O
was,O
set,O
as,O
a,O
positive,O
control,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
SD,O
",",O
n,O
=,O
10,O
.,O
∗,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
control,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
05,O
and,O
##,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
CUMS,O
group,O
.,O
The,O
effect,O
of,O
DZXYS,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
intragastrically,O
),O
on,O
the,O
contents,O
of,O
DA,O
in,O
hippocampus,O
in,O
rats,B-OG
with,O
chronic,O
unpredictable,O
mild,O
stress,O
.,O
IMI,O
at,O
daily,O
dosage,O
of,O
20,O
mg,O
/,O
kg,O
was,O
set,O
as,O
a,O
positive,O
control,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
SD,O
",",O
n,O
=,O
10,O
.,O
∗,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
control,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
05,O
and,O
##,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
CUMS,O
group,O
.,O
The,O
effect,O
of,O
DZXYS,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
intragastrically,O
),O
on,O
the,O
contents,O
of,O
NE,O
in,O
hippocampus,O
in,O
rats,B-OG
with,O
chronic,O
unpredictable,O
mild,O
stress,O
.,O
IMI,O
at,O
daily,O
dosage,O
of,O
20,O
mg,O
/,O
kg,O
was,O
set,O
as,O
a,O
positive,O
control,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
SD,O
",",O
n,O
=,O
10,O
.,O
∗,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
control,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
CUMS,O
group,O
.,O
The,O
effect,O
of,O
DZXYS,O
(,O
FA,O
at,O
0,O
.,O
086,O
and,O
0,O
.,O
172,O
g,O
/,O
kg,O
and,O
FB,O
at,O
1,O
.,O
804,O
and,O
3,O
.,O
608,O
g,O
/,O
kg,O
",",O
intragastrically,O
),O
on,O
the,O
contents,O
of,O
Glu,O
",",O
Asp,O
",",O
GABA,O
",",O
and,O
Tau,O
in,O
hippocampus,O
in,O
rats,B-OG
with,O
chronic,O
unpredictable,O
mild,O
stress,O
.,O
IMI,O
at,O
daily,O
dosage,O
of,O
20,O
mg,O
/,O
kg,O
was,O
set,O
as,O
a,O
positive,O
control,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
SD,O
",",O
n,O
=,O
10,O
.,O
∗,O
P,O
<,O
0,O
.,O
05,O
and,O
∗∗,O
P,O
<,O
0,O
.,O
01,O
as,O
compared,O
with,O
control,O
group,O
;,O
#,O
P,O
<,O
0,O
.,O
05,O
and,O
##,O
P,O
<,O
0,O
.,O
01,O
",",O
as,O
compared,O
with,O
CUMS,O
group,O
.,O
Different,O
components,O
in,O
the,O
formula,O
of,O
DZXYS,O
.,O
Pharmaceutical,O
name,O
Family,O
name,O
Plant,B-OG
part,O
Chinese,O
name,O
Radix,O
Bupleuri,O
Umbelliferae,B-OG
Root,O
Chai,O
hu,O
Paeoniae,B-OG
Radix,O
Alba,O
Ranunculaceae,B-OG
Root,O
Bai,O
shao,O
Angelica,B-OG
sinensis,I-OG
Umbelliferae,B-OG
Root,O
Dang,O
gui,O
Bighead,O
atractylodes,B-OG
rhizome,O
Compositae,O
Rhizoma,O
Bai,O
zhu,O
Poria,B-OG
cocos,I-OG
Polyporaceae,O
Sclerotium,O
Fu,O
ling,O
Bark,O
of,O
tree,B-OG
peony,I-OG
root,O
Ranunculaceae,B-OG
Root,O
-,O
bark,O
Mu,O
dan,O
pi,O
Fructus,O
Gardeniae,B-OG
Rubiaceae,O
Fruit,O
Zhi,O
zi,O
Mentha,B-OG
haplocalyx,I-OG
Lamiaceae,O
Leaf,O
Bo,O
he,O
Licorice,B-OG
Leguminosae,O
Root,O
Gan,O
cao,O
The,O
contents,O
of,O
CORT,O
",",O
CRH,B-GP
",",O
and,O
ACTH,B-GP
in,O
plasma,O
and,O
hypothalamus,O
in,O
each,O
group,O
.,O
Group,O
Dose,O
CORT,O
CRH,B-GP
ACTH,B-GP
Plasma,O
(,O
ng,O
/,O
mL,O
),O
Plasma,O
(,O
ng,O
/,O
mL,O
),O
Hypothalamus,O
(,O
ng,O
/,O
g,O
),O
Plasma,O
(,O
ng,O
/,O
mL,O
),O
Hypothalamus,O
(,O
ng,O
/,O
g,O
),O
Control,O
—,O
12,O
.,O
60,O
±,O
6,O
.,O
88,O
3,O
.,O
31,O
±,O
0,O
.,O
64,O
20,O
.,O
65,O
±,O
12,O
.,O
52,O
42,O
.,O
11,O
±,O
19,O
.,O
55,O
19,O
.,O
65,O
±,O
8,O
.,O
97,O
CUMS,O
—,O
22,O
.,O
69,O
±,O
13,O
.,O
49,O
∗,O
7,O
.,O
38,O
±,O
1,O
.,O
78,O
∗,O
36,O
.,O
74,O
±,O
8,O
.,O
73,O
∗,O
51,O
.,O
44,O
±,O
25,O
.,O
80,O
∗,O
22,O
.,O
79,O
±,O
7,O
.,O
33,O
∗,O
FA,O
(,O
g,O
/,O
kg,O
),O
0,O
.,O
086,O
22,O
.,O
32,O
±,O
13,O
.,O
31,O
7,O
.,O
37,O
±,O
1,O
.,O
63,O
35,O
.,O
35,O
±,O
8,O
.,O
02,O
50,O
.,O
56,O
±,O
24,O
.,O
71,O
22,O
.,O
42,O
±,O
7,O
.,O
32,O
0,O
.,O
172,O
14,O
.,O
74,O
±,O
10,O
.,O
30,O
##,O
5,O
.,O
33,O
±,O
0,O
.,O
79,O
#,O
23,O
.,O
02,O
±,O
12,O
.,O
8,O
##,O
46,O
.,O
83,O
±,O
23,O
.,O
32,O
##,O
20,O
.,O
83,O
±,O
6,O
.,O
92,O
#,O
FB,O
(,O
g,O
/,O
kg,O
),O
1,O
.,O
804,O
20,O
.,O
00,O
±,O
6,O
.,O
71,O
7,O
.,O
25,O
±,O
1,O
.,O
77,O
33,O
.,O
36,O
±,O
10,O
.,O
57,O
51,O
.,O
32,O
±,O
10,O
.,O
28,O
22,O
.,O
26,O
±,O
9,O
.,O
20,O
3,O
.,O
608,O
10,O
.,O
91,O
±,O
3,O
.,O
30,O
##,O
3,O
.,O
95,O
±,O
0,O
.,O
12,O
##,O
16,O
.,O
04,O
±,O
9,O
.,O
34,O
##,O
44,O
.,O
47,O
±,O
20,O
.,O
31,O
#,O
20,O
.,O
59,O
±,O
6,O
.,O
88,O
#,O
IMI,O
(,O
mg,O
/,O
kg,O
),O
20,O
10,O
.,O
23,O
±,O
3,O
.,O
21,O
##,O
3,O
.,O
67,O
±,O
0,O
.,O
13,O
##,O
15,O
.,O
44,O
±,O
9,O
.,O
02,O
##,O
42,O
.,O
26,O
±,O
20,O
.,O
01,O
##,O
19,O
.,O
13,O
±,O
6,O
.,O
76,O
##,O
The,O
AVP,O
contents,O
in,O
plasma,O
and,O
hypothalamus,O
in,O
each,O
group,O
.,O
Group,O
Dose,O
AVP,O
Plasma,O
(,O
pg,O
/,O
mL,O
),O
Hypothalamus,O
(,O
pg,O
/,O
mg,O
),O
Control,O
—,O
14,O
.,O
70,O
±,O
4,O
.,O
80,O
58,O
.,O
50,O
±,O
17,O
.,O
80,O
CUMS,O
—,O
25,O
.,O
20,O
±,O
7,O
.,O
30,O
∗,O
309,O
.,O
20,O
±,O
70,O
.,O
41,O
∗,O
FA,O
(,O
g,O
/,O
kg,O
),O
0,O
.,O
086,O
24,O
.,O
23,O
±,O
7,O
.,O
12,O
306,O
.,O
20,O
±,O
70,O
.,O
33,O
0,O
.,O
172,O
12,O
.,O
60,O
±,O
3,O
.,O
20,O
#,O
267,O
.,O
40,O
±,O
58,O
.,O
60,O
#,O
FB,O
(,O
g,O
/,O
kg,O
),O
1,O
.,O
804,O
23,O
.,O
74,O
±,O
7,O
.,O
10,O
301,O
.,O
60,O
±,O
70,O
.,O
70,O
3,O
.,O
608,O
12,O
.,O
30,O
±,O
3,O
.,O
40,O
##,O
173,O
.,O
20,O
±,O
20,O
.,O
90,O
##,O
IMI,O
(,O
mg,O
/,O
kg,O
),O
20,O
11,O
.,O
21,O
±,O
3,O
.,O
12,O
##,O
168,O
.,O
53,O
±,O
20,O
.,O
11,O
##,O
The,O
contents,O
of,O
5,O
-,O
HT,O
",",O
5,O
-,O
HIAA,O
",",O
and,O
5,O
-,O
HIAA,O
/,O
5,O
-,O
HT,O
ratio,O
in,O
hippocampus,O
in,O
each,O
group,O
.,O
Group,O
Dose,O
5,O
-,O
HT,O
(,O
ng,O
/,O
g,O
wet,O
tissue,O
),O
5,O
-,O
HIAA,O
(,O
ng,O
/,O
g,O
wet,O
tissue,O
),O
5,O
-,O
HIAA,O
/,O
5,O
-,O
HT,O
Control,O
—,O
428,O
.,O
3,O
±,O
171,O
.,O
2,O
376,O
.,O
3,O
±,O
210,O
.,O
3,O
1,O
.,O
04,O
±,O
0,O
.,O
41,O
CUMS,O
—,O
213,O
.,O
7,O
±,O
142,O
.,O
4,O
∗∗,O
387,O
.,O
6,O
±,O
146,O
.,O
6,O
1,O
.,O
62,O
±,O
0,O
.,O
82,O
∗,O
FA,O
(,O
g,O
/,O
kg,O
),O
0,O
.,O
086,O
262,O
.,O
5,O
±,O
145,O
.,O
8,O
370,O
.,O
6,O
±,O
107,O
.,O
8,O
1,O
.,O
58,O
±,O
0,O
.,O
83,O
0,O
.,O
172,O
447,O
.,O
8,O
±,O
236,O
.,O
7,O
#,O
436,O
.,O
8,O
±,O
311,O
.,O
2,O
1,O
.,O
02,O
±,O
0,O
.,O
46,O
#,O
FB,O
(,O
g,O
/,O
kg,O
),O
1,O
.,O
804,O
301,O
.,O
2,O
±,O
146,O
.,O
5,O
378,O
.,O
7,O
±,O
118,O
.,O
1,O
1,O
.,O
57,O
±,O
0,O
.,O
79,O
3,O
.,O
608,O
468,O
.,O
2,O
±,O
139,O
.,O
3,O
##,O
487,O
.,O
2,O
±,O
83,O
.,O
2,O
#,O
0,O
.,O
97,O
±,O
0,O
.,O
56,O
#,O
IMI,O
(,O
mg,O
/,O
kg,O
),O
20,O
479,O
.,O
5,O
±,O
148,O
.,O
7,O
##,O
509,O
.,O
3,O
±,O
84,O
.,O
7,O
#,O
1,O
.,O
01,O
±,O
0,O
.,O
33,O
#,O
Histone,B-GP
hypo,O
-,O
acetylation,O
of,O
Sox9,B-GP
mediates,O
nicotine,O
-,O
induced,O
weak,O
cartilage,O
repair,O
by,O
suppressing,O
BMSC,O
chondrogenic,O
differentiation,O
Background,O
Nicotine,O
has,O
negative,O
effects,O
on,O
tissue,O
repair,O
",",O
little,O
research,O
concerns,O
its,O
effect,O
on,O
the,O
cartilage,O
repair,O
of,O
tissue,O
engineering,O
stem,O
cells,O
.,O
The,O
present,O
study,O
aimed,O
to,O
investigate,O
the,O
effects,O
of,O
nicotine,O
on,O
the,O
bone,O
marrow,O
-,O
derived,O
mesenchymal,O
stem,O
cells,O
’,O
(,O
BMSCs,O
),O
chondrogenic,O
repair,O
function,O
of,O
cartilage,O
defects,O
and,O
explored,O
the,O
molecular,O
mechanism,O
.,O
Methods,O
A,O
cartilage,O
defect,O
model,O
of,O
rat,B-OG
was,O
repaired,O
by,O
BMSC,O
transplantation,O
",",O
and,O
treated,O
with,O
nicotine,O
or,O
saline,O
at,O
2,O
.,O
0,O
mg,O
/,O
kg,O
/,O
d,O
in,O
12,O
weeks,O
.,O
Nicotine,O
’,O
s,O
effect,O
on,O
chondrogenic,O
differentiation,O
was,O
studied,O
by,O
exposing,O
BMSCs,O
to,O
nicotine,O
at,O
0,O
.,O
1,O
",",O
1,O
",",O
10,O
",",O
and,O
100,O
μM,O
",",O
and,O
methyllycaconitine,O
(,O
MLA,O
"),",O
which,O
is,O
a,O
selective,O
α7,B-GP
-,I-GP
nicotinic,I-GP
acetylcholine,I-GP
receptor,I-GP
(,O
nAChR,B-GP
),O
inhibitor,O
and,O
si,O
-,O
RNA,O
of,O
nuclear,B-GP
factor,I-GP
of,I-GP
activated,I-GP
T,I-GP
cells,I-GP
2,I-GP
(,O
NFATc2,B-GP
"),",O
were,O
used,O
to,O
verify,O
the,O
molecular,O
mechanism,O
of,O
nicotine,O
’,O
s,O
effect,O
.,O
Results,O
Data,O
showed,O
that,O
nicotine,O
inhibited,O
cartilage,O
repair,O
function,O
by,O
suppressing,O
SRY,B-GP
-,I-GP
type,I-GP
high,I-GP
-,I-GP
mobility,I-GP
group,I-GP
box,I-GP
9,I-GP
(,O
Sox9,B-GP
),O
in,O
regenerated,O
tissues,O
.,O
Further,O
in,O
vitro,O
study,O
demonstrated,O
that,O
nicotine,O
enhanced,O
intracellular,O
Ca2,O
+,O
and,O
activity,O
of,O
calcineurin,B-GP
(,O
CaN,B-GP
),O
through,O
α7,B-GP
-,I-GP
nAChR,I-GP
",",O
increased,O
the,O
nucleic,O
expressions,O
of,O
NFATc2,B-GP
and,O
the,O
bindings,O
to,O
SOX9,B-GP
promoter,O
",",O
and,O
thus,O
reduced,O
the,O
acetylation,O
of,O
H3K9,O
and,O
H3K14,O
in,O
SOX9,B-GP
promoter,O
.,O
Conclusions,O
Findings,O
from,O
this,O
study,O
demonstrated,O
that,O
nicotine,O
suppressed,O
the,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
in,O
vivo,O
and,O
in,O
vitro,O
",",O
which,O
offers,O
insight,O
into,O
the,O
risk,O
assessment,O
of,O
cartilage,O
defect,O
repair,O
in,O
a,O
nicotine,O
exposure,O
population,O
and,O
its,O
therapeutic,O
target,O
.,O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
10,O
.,O
1186,O
/,O
s13287,O
-,O
018,O
-,O
0853,O
-,O
x,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Background,O
Articular,O
cartilage,O
is,O
composed,O
of,O
chondrocytes,O
and,O
extracellular,O
matrix,O
",",O
which,O
primarily,O
consists,O
of,O
collagen,B-GP
II,I-GP
and,O
proteoglycans,B-GP
[,O
1,O
].,O
It,O
covers,O
the,O
metaphysis,O
of,O
long,O
bones,O
and,O
provides,O
shock,O
absorption,O
and,O
lubrication,O
to,O
diarthrodial,O
joints,O
.,O
Cartilage,O
tissue,O
has,O
poor,O
self,O
-,O
healing,O
capacity,O
because,O
it,O
is,O
avascular,O
and,O
thus,O
has,O
inadequate,O
access,O
to,O
progenitor,O
cells,O
from,O
blood,O
and,O
bone,O
marrow,O
(,O
BM,O
"),",O
which,O
facilitate,O
regeneration,O
[,O
2,O
].,O
The,O
articular,O
cartilage,O
defect,O
is,O
accompanied,O
by,O
pain,O
and,O
loss,O
of,O
function,O
",",O
and,O
progressive,O
breakdown,O
leads,O
to,O
degenerative,B-DS
disorders,I-DS
",",O
such,O
as,O
osteoarthritis,B-DS
",",O
which,O
can,O
seriously,O
affect,O
a,O
patient,O
’,O
s,O
life,O
and,O
work,O
.,O
Epidemiological,O
studies,O
had,O
indicated,O
that,O
cartilage,O
defects,O
were,O
found,O
in,O
60,O
%,O
of,O
patients,O
who,O
undergone,O
arthroscopic,O
surgery,O
and,O
that,O
the,O
main,O
population,O
included,O
young,O
adults,O
[,O
3,O
].,O
Therefore,O
",",O
the,O
optional,O
repair,O
and,O
regeneration,O
of,O
cartilage,O
defect,O
is,O
an,O
important,O
issue,O
in,O
medical,O
research,O
.,O
Mesenchymal,O
stem,O
cells,O
(,O
MSCs,O
),O
can,O
be,O
isolated,O
from,O
various,O
tissues,O
and,O
can,O
differentiate,O
into,O
chondrogenic,O
lineage,O
cells,O
in,O
vitro,O
and,O
in,O
vivo,O
[,O
4,O
",",O
5,O
].,O
In,O
2002,O
",",O
Wakitani,O
et,O
al,O
.,O
[,O
6,O
],O
applied,O
bone,O
marrow,O
mesenchymal,O
stem,O
cell,O
(,O
BMSC,O
),O
transplantations,O
to,O
repair,O
human,B-OG
articular,O
cartilage,O
defects,O
in,O
osteoarthritic,O
knee,O
joints,O
and,O
observed,O
that,O
the,O
cartilage,O
defects,O
were,O
partially,O
covered,O
with,O
hyaline,O
cartilage,O
-,O
like,O
tissue,O
",",O
which,O
highlighted,O
the,O
availability,O
of,O
autologous,O
culture,O
-,O
expanded,O
BMSC,O
transplantation,O
for,O
the,O
repair,O
of,O
articular,O
cartilage,O
defects,O
in,O
humans,B-OG
.,O
Since,O
then,O
",",O
numerous,O
studies,O
on,O
using,O
BMSCs,O
to,O
repair,O
cartilage,O
lesions,O
",",O
from,O
preclinical,O
findings,O
to,O
clinical,O
application,O
",",O
have,O
been,O
performed,O
as,O
BMSCs,O
can,O
be,O
easily,O
obtained,O
and,O
used,O
[,O
7,O
].,O
The,O
transplantation,O
of,O
BMSCs,O
has,O
become,O
one,O
of,O
the,O
main,O
methods,O
for,O
treating,O
cartilage,O
defects,O
[,O
8,O
–,O
10,O
].,O
However,O
",",O
the,O
majority,O
focused,O
on,O
how,O
to,O
optimize,O
the,O
microenvironment,O
or,O
improve,O
the,O
efficiency,O
of,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
",",O
and,O
there,O
was,O
no,O
concern,O
about,O
adverse,O
factors,O
in,O
the,O
differentiation,O
process,O
.,O
As,O
a,O
key,O
component,O
of,O
smoking,O
",",O
nicotine,O
has,O
negative,O
effects,O
on,O
tissue,O
repair,O
and,O
healing,O
[,O
11,O
",",O
12,O
].,O
An,O
epidemiological,O
study,O
had,O
demonstrated,O
that,O
nicotine,O
abuse,O
was,O
a,O
high,O
-,O
risk,O
factor,O
that,O
influences,O
the,O
clinical,O
outcome,O
of,O
cartilage,O
defects,O
repair,O
of,O
the,O
knee,O
[,O
13,O
].,O
Our,O
previous,O
study,O
indicated,O
that,O
prenatal,O
nicotine,O
exposure,O
induced,O
fetal,O
articular,O
dyschondroplasia,B-DS
[,O
14,O
].,O
The,O
epiphyseal,O
cartilage,O
development,O
is,O
a,O
process,O
of,O
proliferation,O
and,O
differentiation,O
of,O
MSCs,O
[,O
15,O
"],",O
in,O
which,O
nicotine,O
can,O
interfere,O
with,O
the,O
chondrogenic,O
differentiation,O
of,O
MSCs,O
in,O
vivo,O
.,O
The,O
process,O
of,O
repairing,O
cartilage,O
defects,O
is,O
also,O
a,O
process,O
of,O
chondrogenic,O
differentiation,O
of,O
stem,O
cells,O
[,O
16,O
];,O
therefore,O
",",O
nicotine,O
may,O
have,O
an,O
adverse,O
effect,O
on,O
the,O
chondrogenic,O
repair,O
of,O
BMSCs,O
in,O
cartilage,O
defects,O
.,O
Our,O
previous,O
work,O
has,O
demonstrated,O
that,O
nicotine,O
could,O
suppress,O
the,O
chondrogenic,O
differentiation,O
potential,O
of,O
BMSCs,O
and,O
result,O
in,O
poorly,O
differentiated,O
cartilage,O
[,O
17,O
].,O
However,O
",",O
the,O
mechanism,O
is,O
still,O
unclear,O
.,O
SRY,B-GP
-,I-GP
type,I-GP
high,I-GP
mobility,I-GP
group,I-GP
box,I-GP
9,I-GP
(,O
Sox9,B-GP
),O
is,O
a,O
key,O
regulator,O
and,O
controls,O
the,O
expression,O
of,O
the,O
α1,B-GP
chain,I-GP
of,I-GP
type,I-GP
II,I-GP
collagen,I-GP
(,O
Col2A1,B-GP
),O
gene,O
in,O
the,O
initiation,O
stage,O
of,O
MSC,O
chondrogenic,O
differentiation,O
[,O
18,O
].,O
During,O
primary,O
chondrogenesis,O
",",O
which,O
is,O
activated,O
by,O
transforming,B-GP
growth,I-GP
factor,I-GP
beta,I-GP
(,O
TGF,B-GP
-,I-GP
β,I-GP
"),",O
Sox9,B-GP
binds,O
to,O
essential,O
sequences,O
in,O
the,O
Col2A1,B-GP
gene,O
enhancers,O
and,O
initiates,O
its,O
expression,O
[,O
19,O
].,O
The,O
functional,O
modulation,O
of,O
Sox9,B-GP
is,O
a,O
critical,O
step,O
for,O
the,O
initiation,O
of,O
chondrogenesis,O
and,O
is,O
mainly,O
regulated,O
by,O
histone,B-GP
acetylation,O
[,O
20,O
].,O
The,O
nuclear,B-GP
factor,I-GP
of,I-GP
activated,I-GP
T,I-GP
cells,I-GP
(,O
NFAT,B-GP
),O
transcription,B-GP
factor,I-GP
NFATp,B-GP
(,O
NFATc2,B-GP
),O
is,O
a,O
repressor,O
of,O
chondrogenesis,O
[,O
21,O
],O
and,O
can,O
interact,O
with,O
histone,B-GP
deacetylase,I-GP
(,O
HDAC,B-GP
),O
proteins,O
to,O
induce,O
gene,O
silencing,O
[,O
22,O
].,O
Calcineurin,B-GP
(,O
CaN,B-GP
"),",O
an,O
upstream,O
molecule,O
of,O
NFATc2,B-GP
",",O
is,O
induced,O
by,O
increased,O
Ca2,O
+,O
and,O
can,O
translocate,O
the,O
dephosphorylated,O
NFATc2,B-GP
into,O
the,O
nucleus,O
[,O
23,O
].,O
The,O
stimulus,O
of,O
nicotine,O
can,O
increase,O
the,O
intracellular,O
Ca2,O
+,O
of,O
MSCs,O
through,O
nicotinic,B-GP
acetylcholine,I-GP
receptor,I-GP
(,O
nAChR,B-GP
),O
[,O
24,O
].,O
Therefore,O
",",O
we,O
hypothesized,O
that,O
nicotine,O
could,O
decrease,O
Sox9,B-GP
’,O
s,O
promoter,O
histone,B-GP
acetylation,O
and,O
inhibit,O
its,O
expression,O
through,O
HDAC,B-GP
recruitment,O
by,O
the,O
activated,O
nAChR,B-GP
/,O
Ca2,O
+/,O
calcineurin,B-GP
/,O
NFAT,B-GP
pathway,O
in,O
BMSCs,O
.,O
In,O
this,O
study,O
",",O
we,O
confirmed,O
that,O
nicotine,O
interfered,O
with,O
BMSC,O
transplantation,O
repair,O
of,O
cartilage,O
defects,O
by,O
inhibiting,O
Sox9,B-GP
expression,O
in,O
vivo,O
and,O
that,O
nicotine,O
-,O
induced,O
Sox9,B-GP
gene,O
suppression,O
via,O
nAChRs,B-GP
is,O
mediated,O
directly,O
by,O
decreasing,O
the,O
histone,B-GP
acetylation,O
of,O
the,O
Sox9,B-GP
promoter,O
.,O
Methods,O
Animal,B-OG
studies,O
Animal,B-OG
experiments,O
in,O
this,O
study,O
were,O
approved,O
by,O
the,O
Committee,O
on,O
the,O
Ethics,O
of,O
Animal,B-OG
Experiments,O
of,O
the,O
Wuhan,O
University,O
School,O
of,O
Medicine,O
(,O
No,O
.,O
14016,O
).,O
The,O
animal,B-OG
experimental,O
procedures,O
were,O
performed,O
in,O
accordance,O
with,O
the,O
Guidelines,O
for,O
the,O
Care,O
and,O
Use,O
of,O
Laboratory,O
Animals,B-OG
(,O
eighth,O
edition,O
),O
from,O
the,O
National,O
Research,O
Council,O
of,O
the,O
United,O
States,O
National,O
Academies,O
",",O
and,O
performed,O
in,O
the,O
Center,O
for,O
Animal,B-OG
Experiment,O
of,O
Wuhan,O
University,O
(,O
Wuhan,O
",",O
China,O
"),",O
which,O
was,O
accredited,O
by,O
the,O
Association,O
for,O
Assessment,O
and,O
Accreditation,O
of,O
Laboratory,O
Animal,B-OG
Care,O
International,O
(,O
AAALAC,O
International,O
).,O
Female,O
(,O
weighing,O
180,O
–,O
220,O
g,O
),O
and,O
male,O
(,O
weighing,O
260,O
–,O
300,O
g,O
),O
Wistar,B-OG
rats,I-OG
at,O
12,O
weeks,O
old,O
were,O
obtained,O
from,O
the,O
Experimental,O
Center,O
of,O
the,O
Medical,O
Scientific,O
Academy,O
of,O
Hubei,O
(,O
no,O
.,O
2008,O
–,O
0005,O
).,O
Rats,B-OG
were,O
housed,O
in,O
metal,O
cages,O
with,O
wire,O
-,O
mesh,O
floors,O
in,O
an,O
air,O
-,O
conditioned,O
room,O
under,O
standard,O
conditions,O
(,O
room,O
temperature,O
:,O
18,O
–,O
22,O
°,O
C,O
;,O
humidity,O
:,O
40,O
–,O
60,O
%;,O
light,O
cycle,O
:,O
12,O
h,O
light,O
-,O
dark,O
cycle,O
;,O
10,O
–,O
15,O
air,O
changes,O
per,O
hour,O
),O
and,O
allowed,O
free,O
access,O
to,O
rat,B-OG
chow,O
and,O
tap,O
water,O
.,O
Rats,B-OG
were,O
randomly,O
distributed,O
into,O
control,O
(,O
BMSCs,O
),O
and,O
experimental,O
(,O
BMSCs,O
+,O
nicotine,O
),O
groups,O
(,O
n,O
=,O
8,O
for,O
each,O
group,O
).,O
The,O
cartilage,O
defect,O
model,O
in,O
the,O
two,O
groups,O
followed,O
the,O
method,O
described,O
by,O
Chung,O
et,O
al,O
.,O
[,O
25,O
].,O
In,O
brief,O
",",O
anesthesia,O
was,O
performed,O
with,O
an,O
intraperitoneal,O
injection,O
of,O
3,O
.,O
5,O
ml,O
/,O
kg,O
of,O
10,O
%,O
chloral,O
hydrate,O
.,O
In,O
each,O
case,O
",",O
after,O
cleaning,O
with,O
10,O
%,O
betadine,O
solution,O
",",O
right,O
knee,O
joints,O
of,O
each,O
rat,B-OG
were,O
sterilely,O
draped,O
and,O
opened,O
using,O
an,O
anteromedial,O
approach,O
.,O
The,O
patellae,O
were,O
laterally,O
dislocated,O
",",O
and,O
full,O
-,O
thickness,O
articular,O
cartilage,O
defects,O
(,O
2,O
mm,O
in,O
diameter,O
),O
were,O
created,O
in,O
trochlear,O
grooves,O
by,O
carefully,O
drilling,O
in,O
a,O
vertical,O
direction,O
using,O
a,O
2,O
-,O
mm,O
drill,O
.,O
Drilling,O
was,O
performed,O
in,O
3,O
mm,O
deep,O
through,O
subchondral,O
bone,O
.,O
After,O
removing,O
cartilage,O
and,O
bone,O
debris,O
",",O
boundaries,O
around,O
the,O
drill,O
were,O
trimmed,O
using,O
a,O
surgical,O
knife,O
and,O
washed,O
out,O
.,O
The,O
mixture,O
containing,O
BMSCs,O
(,O
2,O
×,O
106,O
cells,O
/,O
ml,O
),O
and,O
1,O
.,O
25,O
%,O
alginate,O
in,O
0,O
.,O
15,O
M,O
saline,O
[,O
26,O
],O
was,O
then,O
transplanted,O
into,O
the,O
full,O
-,O
thickness,O
defect,O
in,O
the,O
right,O
knee,O
.,O
Following,O
implantation,O
",",O
patellar,O
retinaculum,O
and,O
overlying,O
soft,O
tissues,O
were,O
closed,O
in,O
layers,O
.,O
Rats,B-OG
were,O
allowed,O
to,O
move,O
knee,O
joints,O
freely,O
in,O
their,O
cages,O
without,O
restriction,O
.,O
An,O
intraperitoneal,O
injection,O
of,O
4,O
×,O
105,O
U,O
of,O
penicillin,O
(,O
Harbin,O
Pharmaceutical,O
Group,O
",",O
Shanghai,O
",",O
China,O
),O
was,O
administered,O
immediately,O
after,O
implantation,O
and,O
once,O
daily,O
for,O
1,O
week,O
.,O
Clinical,O
signs,O
were,O
observed,O
daily,O
during,O
the,O
study,O
period,O
.,O
Animals,B-OG
were,O
sacrificed,O
at,O
12,O
weeks,O
post,O
-,O
implantation,O
to,O
assess,O
cartilage,O
repair,O
statuses,O
.,O
The,O
experimental,O
group,O
was,O
injected,O
with,O
nicotine,O
(,O
Sigma,O
-,O
Aldrich,O
",",O
St,O
Louis,O
",",O
MO,O
",",O
USA,O
),O
at,O
1,O
.,O
0,O
mg,O
/,O
kg,O
twice,O
per,O
day,O
(,O
2,O
.,O
0,O
mg,O
/,O
kg,O
/,O
d,O
).,O
As,O
a,O
preliminary,O
study,O
",",O
defects,O
of,O
the,O
same,O
size,O
(,O
2,O
mm,O
diameter,O
and,O
3,O
mm,O
deep,O
),O
were,O
created,O
",",O
and,O
the,O
cartilage,O
repair,O
with,O
no,O
treatment,O
or,O
alginate,O
only,O
was,O
observed,O
.,O
At,O
12,O
weeks,O
post,O
-,O
transplantation,O
",",O
the,O
defects,O
showed,O
very,O
poor,O
cartilage,O
repair,O
(,O
Additional,O
file,O
1,O
"),",O
whose,O
surface,O
was,O
concave,O
",",O
irregular,O
or,O
sometimes,O
empty,O
in,O
the,O
middle,O
and,O
few,O
regenerated,O
tissues,O
could,O
be,O
seen,O
at,O
peripheral,O
regions,O
",",O
meaning,O
that,O
this,O
size,O
of,O
articular,O
cartilage,O
defect,O
in,O
a,O
rat,B-OG
joint,O
is,O
a,O
critical,O
-,O
size,O
defect,O
that,O
cannot,O
heal,O
by,O
itself,O
.,O
Therefore,O
",",O
a,O
defect,O
only,O
without,O
BMSC,O
transplantation,O
(,O
no,O
treatment,O
or,O
alginate,O
only,O
),O
was,O
not,O
included,O
in,O
the,O
present,O
study,O
.,O
Gross,O
and,O
histological,O
evaluations,O
Rats,B-OG
were,O
sacrificed,O
by,O
cervical,O
dislocation,O
with,O
an,O
intraperitoneal,O
injection,O
of,O
3,O
.,O
5,O
ml,O
/,O
kg,O
of,O
10,O
%,O
chloral,O
hydrate,O
.,O
The,O
entire,O
right,O
knee,O
was,O
dissected,O
",",O
and,O
a,O
distal,O
part,O
of,O
the,O
femur,O
was,O
then,O
extirpated,O
.,O
The,O
samples,O
from,O
each,O
group,O
were,O
examined,O
and,O
photographed,O
to,O
evaluate,O
the,O
degree,O
of,O
defect,O
repair,O
(,O
0,O
–,O
4,O
"),",O
integration,O
to,O
border,O
zone,O
(,O
0,O
–,O
4,O
"),",O
and,O
macroscopic,O
appearance,O
(,O
0,O
–,O
4,O
),O
according,O
to,O
the,O
International,O
Cartilage,O
Repair,O
Society,O
(,O
ICRS,O
),O
macroscopic,O
assessment,O
scale,O
for,O
cartilage,O
repair,O
[,O
27,O
].,O
After,O
gross,O
examination,O
",",O
samples,O
were,O
fixed,O
in,O
4,O
%,O
paraformaldehyde,O
",",O
decalcified,O
in,O
20,O
%,O
ethylenediaminetetraacetic,O
acid,O
(,O
EDTA,O
),O
(,O
pH,O
7,O
.,O
4,O
),O
for,O
21,O
d,O
",",O
and,O
embedded,O
in,O
paraffin,O
.,O
Serial,O
5,O
-,O
mm,O
thick,O
sections,O
were,O
cut,O
in,O
a,O
horizontal,O
plane,O
across,O
the,O
joint,O
.,O
Two,O
sections,O
within,O
every,O
consecutive,O
ten,O
sections,O
were,O
stained,O
with,O
Safranin,O
-,O
O,O
/,O
Fast,O
green,O
(,O
Sigma,O
-,O
Aldrich,O
),O
and,O
the,O
one,O
with,O
better,O
morphology,O
was,O
used,O
for,O
quantification,O
.,O
The,O
cartilage,O
repair,O
was,O
scored,O
by,O
two,O
blinded,O
authors,O
(,O
K,O
.,O
T,O
.,O
and,O
Y,O
.,O
D,O
.),O
using,O
a,O
method,O
described,O
by,O
Wakitani,O
[,O
28,O
].,O
In,O
brief,O
",",O
each,O
section,O
was,O
assigned,O
a,O
score,O
",",O
which,O
was,O
the,O
sum,O
of,O
cell,O
morphology,O
(,O
0,O
–,O
4,O
"),",O
matrix,O
-,O
staining,O
(,O
0,O
–,O
3,O
"),",O
surface,O
regularity,O
(,O
0,O
–,O
3,O
"),",O
thickness,O
of,O
cartilage,O
(,O
0,O
–,O
3,O
"),",O
and,O
integration,O
of,O
donor,O
with,O
host,O
(,O
0,O
–,O
3,O
).,O
The,O
expression,O
of,O
Col2A1,B-GP
and,O
Sox9,B-GP
in,O
the,O
regenerated,O
tissue,O
was,O
analyzed,O
by,O
immunohistological,O
staining,O
.,O
After,O
antigen,O
retrieval,O
by,O
boiling,O
the,O
samples,O
in,O
sodium,O
citrate,O
buffer,O
",",O
the,O
sections,O
were,O
blocked,O
in,O
serum,O
for,O
30,O
min,O
",",O
followed,O
by,O
incubation,O
with,O
the,O
primary,O
antibody,O
in,O
a,O
humidified,O
chamber,O
at,O
4,O
°,O
C,O
overnight,O
.,O
A,O
biotinylated,O
secondary,O
antibody,O
was,O
added,O
for,O
30,O
min,O
on,O
day,O
2,O
",",O
followed,O
by,O
an,O
avidin,B-GP
-,O
biotinylated,O
horseradish,B-OG
peroxidase,B-GP
complex,O
",",O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
directions,O
.,O
Finally,O
",",O
the,O
peroxidase,B-GP
activity,O
was,O
revealed,O
by,O
immersion,O
in,O
DAB,O
substrate,O
.,O
The,O
following,O
primary,O
antibodies,O
were,O
used,O
:,O
rabbit,B-OG
anti,O
-,O
Sox9,B-GP
",",O
and,O
rabbit,B-OG
anti,O
-,O
Col2A1,B-GP
(,O
both,O
from,O
Santa,O
Cruz,O
Biotechnology,O
",",O
Dallas,O
",",O
TX,O
",",O
USA,O
).,O
To,O
characterize,O
the,O
changes,O
in,O
immunostaining,O
",",O
the,O
mean,O
optical,O
densities,O
(,O
MODs,O
),O
were,O
obtained,O
from,O
ten,O
areas,O
of,O
regenerated,O
tissue,O
from,O
five,O
separate,O
samples,O
.,O
Culture,O
of,O
BMSCs,O
and,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
The,O
isolation,O
and,O
culture,O
of,O
rat,B-OG
BMSCs,O
from,O
the,O
tibias,O
and,O
femurs,O
of,O
4,O
-,O
week,O
-,O
old,O
Wistar,B-OG
rats,I-OG
were,O
performed,O
as,O
described,O
previously,O
[,O
17,O
].,O
Briefly,O
",",O
the,O
rats,B-OG
were,O
sacrificed,O
by,O
cervical,O
dislocation,O
after,O
anesthesia,O
(,O
intraperitoneal,O
injection,O
of,O
10,O
%,O
chloral,O
hydrate,O
),O
and,O
sterilized,O
using,O
75,O
%,O
ethanol,O
for,O
10,O
min,O
before,O
surgery,O
.,O
After,O
dissecting,O
the,O
metaphyseal,O
ends,O
of,O
the,O
bones,O
under,O
sterile,O
conditions,O
",",O
the,O
bone,O
marrow,O
cells,O
were,O
flushed,O
out,O
using,O
Dulbecco,O
’,O
s,O
modified,O
Eagle,O
’,O
s,O
medium,O
(,O
DMEM,O
)/,O
F12,O
medium,O
supplemented,O
with,O
10,O
%,O
fetal,O
bovine,O
serum,O
(,O
Gibco,O
",",O
Carlsbad,O
",",O
CA,O
",",O
USA,O
"),",O
50,O
mg,O
/,O
ml,O
of,O
L,O
-,O
ascorbic,O
acid,O
(,O
Sigma,O
-,O
Aldrich,O
"),",O
1,O
%,O
glutamine,O
(,O
Sigma,O
-,O
Aldrich,O
"),",O
100,O
mg,O
/,O
ml,O
of,O
streptomycin,O
and,O
penicillin,O
(,O
Sigma,O
-,O
Aldrich,O
"),",O
and,O
centrifuged,O
at,O
1000,O
rpm,O
for,O
5,O
min,O
.,O
The,O
cells,O
were,O
resuspended,O
and,O
expanded,O
in,O
T,O
-,O
25,O
flasks,O
(,O
Cyagen,O
Biosciences,O
",",O
Santa,O
Clara,O
",",O
CA,O
",",O
USA,O
),O
with,O
DMEM,O
/,O
F12,O
medium,O
and,O
incubated,O
at,O
37,O
°,O
C,O
under,O
conditions,O
of,O
5,O
%,O
CO2,O
.,O
The,O
medium,O
was,O
changed,O
every,O
3,O
days,O
.,O
Upon,O
reaching,O
70,O
%–,O
80,O
%,O
confluence,O
",",O
adherent,O
cells,O
were,O
trypsinized,O
",",O
harvested,O
",",O
and,O
expanded,O
.,O
Cells,O
that,O
had,O
undergone,O
three,O
passages,O
were,O
used,O
in,O
subsequent,O
experiments,O
.,O
Chondrogenic,O
differentiation,O
of,O
BMSCs,O
was,O
performed,O
following,O
the,O
method,O
described,O
in,O
our,O
previous,O
work,O
[,O
17,O
].,O
Monolayer,O
culture,O
cells,O
in,O
T,O
-,O
25,O
flasks,O
were,O
trypsinized,O
",",O
washed,O
",",O
and,O
centrifuged,O
.,O
The,O
isolated,O
BMSCs,O
were,O
suspended,O
at,O
a,O
concentration,O
of,O
6,O
×,O
106,O
cells,O
/,O
ml,O
in,O
a,O
1,O
.,O
25,O
%,O
alginate,O
(,O
Sigma,O
-,O
Aldrich,O
),O
in,O
0,O
.,O
15,O
M,O
NaCl,O
",",O
and,O
then,O
the,O
cell,O
suspension,O
was,O
slowly,O
dropped,O
into,O
a,O
102,O
mM,O
CaCl2,O
solution,O
.,O
The,O
beads,O
were,O
cultured,O
in,O
six,O
-,O
well,O
plates,O
under,O
conditions,O
of,O
5,O
%,O
O2,O
with,O
DMEM,O
/,O
F12,O
medium,O
containing,O
1,O
%,O
insulin,B-GP
",",O
transferrin,B-GP
and,O
selenous,O
(,O
ITS,O
),O
(,O
Sigma,O
-,O
Aldrich,O
"),",O
100,O
nM,O
dexamethasone,O
(,O
Sigma,O
-,O
Aldrich,O
),O
and,O
10,O
ng,O
/,O
ml,O
transforming,B-GP
growth,I-GP
factor,I-GP
-,I-GP
β1,I-GP
(,O
TGF,B-GP
-,I-GP
β1,I-GP
),O
(,O
PeproTech,O
Rocky,O
Hill,O
",",O
NJ,O
",",O
USA,O
).,O
During,O
the,O
period,O
of,O
chondrogenic,O
differentiation,O
",",O
the,O
culture,O
medium,O
with,O
or,O
without,O
nicotine,O
at,O
concentrations,O
of,O
0,O
.,O
1,O
",",O
1,O
",",O
10,O
",",O
and,O
100μM,O
was,O
replaced,O
every,O
other,O
day,O
.,O
The,O
BMSCs,O
treated,O
with,O
nicotine,O
for,O
24,O
h,O
were,O
used,O
in,O
the,O
experiments,O
for,O
molecular,O
mechanism,O
detection,O
.,O
RNA,O
interference,O
siRNAs,O
for,O
NFATc2,B-GP
(,O
L,O
-,O
011778,O
),O
were,O
purchased,O
from,O
Gene,O
Pharma,O
(,O
Shanghai,O
Gene,O
Pharma,O
Co,O
.).,O
The,O
scramble,O
-,O
sense,O
siRNA,O
targeted,O
the,O
sequence,O
5,O
’-,O
GGAAGCUACAGUGGAUAAATT,O
-,O
3,O
"′,",O
and,O
the,O
scramble,O
antisense,O
siRNA,O
targeted,O
the,O
sequence,O
5,O
’-,O
UUUAUCCACUGUAGCUUCCTT,O
-,O
3,O
′.,O
In,O
brief,O
",",O
passage,O
3,O
BMSCs,O
were,O
plated,O
to,O
obtain,O
70,O
–,O
80,O
%,O
confluence,O
in,O
six,O
-,O
well,O
plates,O
and,O
transfected,O
with,O
si,O
-,O
NFATc2,B-GP
using,O
Lipofectamine,O
2000,O
(,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
",",O
USA,O
"),",O
negative,O
control,O
siRNA,O
or,O
Lipofectamine,O
2000,O
only,O
.,O
After,O
6,O
h,O
of,O
transfection,O
",",O
fresh,O
medium,O
was,O
exchanged,O
.,O
The,O
expression,O
of,O
NFATc2,B-GP
was,O
detected,O
using,O
RT,O
-,O
qPCR,O
and,O
Western,O
blotting,O
.,O
Calcium,O
imaging,O
and,O
phosphatase,B-GP
activity,O
of,O
calcineurin,B-GP
P3,O
BMSC,O
cultures,O
in,O
35,O
mm,O
glass,O
-,O
bottomed,O
plates,O
were,O
prepared,O
.,O
The,O
cells,O
were,O
washed,O
using,O
Hank,O
’,O
s,O
solution,O
three,O
times,O
and,O
incubated,O
in,O
dye,O
loading,O
solution,O
containing,O
1μM,O
Fluo,O
-,O
3,O
AM,O
(,O
DoJinDo,O
",",O
Shanghai,O
",",O
China,O
),O
at,O
37,O
°,O
C,O
for,O
30,O
min,O
and,O
then,O
at,O
room,O
temperature,O
for,O
an,O
additional,O
30,O
min,O
.,O
Before,O
nicotine,O
stimulation,O
",",O
PBS,O
buffer,O
was,O
used,O
to,O
wash,O
the,O
cells,O
three,O
times,O
.,O
The,O
fluorescence,O
was,O
measured,O
after,O
the,O
addition,O
of,O
0,O
.,O
1,O
",",O
1,O
",",O
10,O
",",O
and,O
100,O
μM,O
nicotine,O
.,O
Measurements,O
were,O
performed,O
in,O
a,O
laser,O
scanning,O
confocal,O
microscope,O
(,O
Carl,O
Zeiss,O
",",O
Oberkochen,O
",",O
Germany,O
),O
by,O
collecting,O
data,O
points,O
every,O
5,O
s,O
over,O
20,O
min,O
using,O
LCS,O
Lite,O
confocal,O
software,O
.,O
The,O
phosphatase,B-GP
activity,O
of,O
calcineurin,B-GP
was,O
measured,O
using,O
a,O
calcineurin,B-GP
assay,O
kit,O
(,O
A068,O
",",O
Nanjing,O
Jiancheng,O
Bioengineering,O
Institute,O
",",O
Nanjing,O
",",O
China,O
).,O
In,O
short,O
",",O
the,O
protein,O
of,O
BMSCs,O
was,O
extracted,O
and,O
quantified,O
",",O
the,O
enzymatic,O
reaction,O
was,O
initiated,O
using,O
calmodulin,B-GP
and,O
p,O
-,O
nitrophenyl,O
phosphate,O
(,O
PNPP,O
),O
as,O
a,O
substrate,O
",",O
and,O
then,O
the,O
inorganic,O
phosphorus,O
content,O
was,O
measured,O
.,O
The,O
enzyme,O
activity,O
unit,O
of,O
calcineurin,B-GP
was,O
defined,O
as,O
the,O
amount,O
of,O
1,O
M,O
inorganic,O
phosphorus,O
produced,O
by,O
decomposing,O
1,O
mg,O
calcineurin,B-GP
from,O
the,O
substrate,O
PNPP,O
per,O
hour,O
",",O
and,O
the,O
results,O
were,O
expressed,O
as,O
U,O
/,O
mg,O
protein,O
.,O
Reverse,O
transcription,O
and,O
real,O
-,O
time,O
quantitative,O
PCR,O
(,O
qRT,O
-,O
PCR,O
),O
Total,O
RNA,O
from,O
regenerated,O
tissues,O
and,O
BMSCs,O
was,O
extracted,O
using,O
the,O
Trizol,O
(,O
Invitrogen,O
),O
reagent,O
following,O
the,O
manufacturer,O
’,O
s,O
protocol,O
.,O
The,O
RNA,O
was,O
reverse,O
transcribed,O
using,O
a,O
first,O
-,O
strand,O
cDNA,O
synthesis,O
kit,O
.,O
The,O
cDNA,O
was,O
amplified,O
using,O
a,O
one,O
-,O
step,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
-,O
PCR,O
),O
reaction,O
.,O
The,O
PCR,O
products,O
of,O
all,O
of,O
the,O
subtypes,O
of,O
nAChR,B-GP
were,O
separated,O
by,O
electrophoresis,O
on,O
2,O
%,O
agarose,O
gels,O
.,O
The,O
relative,O
mRNA,O
expression,O
levels,O
of,O
the,O
Sox9,B-GP
and,O
Col2A1,B-GP
were,O
normalized,O
to,O
the,O
level,O
of,O
glyceraldehyde,B-GP
3,I-GP
-,I-GP
phosphate,I-GP
dehydrogenase,I-GP
(,O
GAPDH,B-GP
).,O
The,O
rat,B-OG
primer,O
sequences,O
and,O
annealing,O
temperatures,O
used,O
are,O
shown,O
in,O
Table,O
1,O
.,O
Table,O
1Primer,O
used,O
for,O
qPCRGeneForward,O
PrimerReverse,O
PrimerAnnealGAPDHGCAAGTTCAACGGCACAGGCCAGTAGACTCCACGACA60,B-GP
°,O
CCol2A1GAGTGGAAGAGCGGAGACTACTGCTCCATGTTGCAGAAGACTTTCA60,O
°,O
CSox9CCAGCAAGAACAAGCCACACCTTGCCCAGAGTCTTGCTGA60,O
°,O
Cα3,B-GP
-,I-GP
nAChRGGTGGATGACAAGACCAAAGCAGGGCAGGTAGAAGACAAGCA60,I-GP
°,O
Cα4,B-GP
-,I-GP
nAChRCACGGTCTTCGTGCTCAATGTCCTTGGTTGCAGATGTCACTC62,I-GP
°,O
Cα5,B-GP
-,I-GP
nAChRGCTGCGCTGCTCTTGATGGTCGTATGTCCACGAGCCGAAT60,I-GP
°,O
Cα7,O
-,O
nAChRACAATACTTCGCCAGCACCAGGCATTTTGCCACCATCAGG60,O
°,O
Cβ2,B-GP
-,I-GP
nAChRGGAGTGGGAAGATTACCGCCTCAAGTCGTCGTGGTTCTCGTTGCG60,I-GP
°,O
Cβ4,B-GP
-,I-GP
nAChRGATTCTCCCAAGTCAGAACCTTTAAGCTGGAGATTTGATGTGGTTA60,I-GP
°,O
CAbbreviations,O
:,O
PCR,O
polymerase,O
chain,O
reaction,O
",",O
GAPDH,B-GP
glyceraldehyde,B-GP
phosphate,I-GP
dehydrogenase,I-GP
",",O
Col2A1,B-GP
α1,B-GP
chain,I-GP
of,I-GP
type,I-GP
II,I-GP
collagen,I-GP
gene,O
",",O
Sox9,B-GP
SRY,B-GP
-,I-GP
type,I-GP
high,I-GP
mobility,I-GP
group,I-GP
box9,I-GP
",",O
nAChR,B-GP
nicotinic,B-GP
acetylcholine,I-GP
receptor,I-GP
Western,O
blotting,O
To,O
obtain,O
total,O
protein,O
",",O
the,O
cells,O
were,O
harvested,O
and,O
dissolved,O
in,O
RIPA,O
(,O
Beyotime,O
",",O
Nanjing,O
",",O
China,O
),O
buffer,O
.,O
The,O
protein,O
concentrations,O
were,O
determined,O
by,O
a,O
BCA,O
protein,O
assay,O
kit,O
.,O
Equal,O
amounts,O
of,O
protein,O
lysates,O
(,O
40,O
mg,O
/,O
lane,O
),O
were,O
loaded,O
and,O
resolved,O
on,O
10,O
%,O
sodium,O
-,O
dodecyl,O
sulfate,O
-,O
polyacrylamide,O
gel,O
electrophoresis,O
(,O
SDS,O
-,O
PAGE,O
),O
(,O
Sigma,O
-,O
Aldrich,O
),O
and,O
then,O
were,O
transferred,O
onto,O
nitrocellulose,O
filters,O
and,O
probed,O
with,O
rabbit,B-OG
anti,O
-,O
Col2A1,B-GP
",",O
Sox9,B-GP
",",O
β,B-GP
-,I-GP
actin,I-GP
",",O
histone,B-GP
3,I-GP
",",O
NFATc2,B-GP
(,O
1,O
:,O
900,O
),O
(,O
all,O
from,O
Santa,O
Cruz,O
Biotechnology,O
"),",O
and,O
p,O
-,O
NFATc2,B-GP
(,O
1,O
:,O
500,O
),O
(,O
Abcam,O
",",O
Cambridge,O
",",O
MA,O
",",O
USA,O
),O
antibodies,O
at,O
4,O
°,O
C,O
overnight,O
.,O
After,O
incubation,O
with,O
a,O
horseradish,B-OG
peroxidase,B-GP
-,O
conjugated,O
secondary,O
antibody,O
(,O
Santa,O
Cruz,O
Biotechnology,O
"),",O
the,O
blots,O
were,O
developed,O
by,O
enhanced,O
chemiluminescence,O
following,O
the,O
manufacturer,O
’,O
s,O
protocol,O
and,O
were,O
visualized,O
by,O
exposure,O
to,O
a,O
Fusion,O
FX,O
system,O
(,O
VilberLourmat,O
",",O
Marne,O
-,O
la,O
-,O
Vallee,O
",",O
France,O
).,O
The,O
protein,O
amounts,O
in,O
electrophoresis,O
gels,O
were,O
analyzed,O
with,O
the,O
Quantity,O
One,O
4,O
.,O
6,O
analysis,O
software,O
(,O
Bio,O
-,O
Rad,O
Laboratories,O
",",O
Hercules,O
",",O
CA,O
",",O
USA,O
).,O
All,O
solutions,O
in,O
this,O
procedure,O
contained,O
a,O
mixture,O
of,O
protease,B-GP
and,O
phosphatase,B-GP
inhibitors,O
.,O
Chromatin,O
immunoprecipitation,O
assay,O
Chromatin,O
immunoprecipitation,O
(,O
ChIP,O
),O
assays,O
were,O
performed,O
as,O
previously,O
described,O
[,O
29,O
].,O
In,O
brief,O
",",O
6,O
×,O
106,O
cells,O
were,O
fixed,O
with,O
1,O
%,O
formaldehyde,O
and,O
quenched,O
by,O
glycine,O
.,O
The,O
cells,O
were,O
washed,O
three,O
times,O
with,O
PBS,O
and,O
then,O
harvested,O
in,O
ChIP,O
lysis,O
buffer,O
(,O
50,O
mMTris,O
-,O
HCl,O
",",O
pH,O
8,O
.,O
0,O
",",O
1,O
%,O
SDS,O
and,O
5,O
mM,O
EDTA,O
",",O
all,O
from,O
Sigma,O
-,O
Aldrich,O
).,O
DNA,O
was,O
sonicated,O
to,O
400,O
–,O
600,O
bp,O
before,O
extensive,O
centrifugation,O
.,O
Four,O
volumes,O
of,O
ChIP,O
dilution,O
buffer,O
(,O
20,O
mM,O
Tris,O
-,O
HCl,O
pH,O
8,O
.,O
0,O
",",O
150,O
mM,O
NaCl,O
",",O
2,O
mM,O
EDTA,O
and,O
1,O
%,O
Triton,O
X,O
-,O
100,O
",",O
all,O
from,O
Sigma,O
-,O
Aldrich,O
),O
were,O
added,O
to,O
the,O
supernatant,O
.,O
The,O
resulting,O
lysate,O
was,O
then,O
incubated,O
with,O
protein,B-GP
G,I-GP
beads,O
(,O
GE,O
Healthcare,O
",",O
Chicago,O
",",O
IL,O
",",O
USA,O
),O
and,O
H3K9,O
(,O
Abcam,O
"),",O
H3K14,O
(,O
Abcam,O
),O
antibodies,O
at,O
4,O
°,O
C,O
overnight,O
.,O
The,O
beads,O
were,O
washed,O
five,O
times,O
and,O
DNA,O
was,O
eluted,O
in,O
ChIP,O
elution,O
buffer,O
(,O
0,O
.,O
1,O
M,O
NaHCO3,O
",",O
1,O
%,O
SDS,O
and,O
30,O
μg,O
/,O
ml,O
proteinase,B-GP
K,I-GP
",",O
all,O
from,O
Sigma,O
-,O
Aldrich,O
).,O
The,O
elution,O
was,O
incubated,O
at,O
65,O
°,O
C,O
overnight,O
and,O
DNA,O
was,O
extracted,O
with,O
a,O
DNA,O
purification,O
kit,O
(,O
Tiangen,O
Biotech,O
",",O
Beijing,O
",",O
China,O
).,O
The,O
purified,O
DNA,O
was,O
assayed,O
by,O
quantitative,O
PCR,O
assays,O
were,O
repeated,O
at,O
least,O
three,O
times,O
.,O
Data,O
were,O
expressed,O
as,O
a,O
percentage,O
of,O
input,O
DNA,O
.,O
The,O
primer,O
information,O
is,O
in,O
Table,O
2,O
.,O
Table,O
2Primer,O
used,O
for,O
ChIPTranscriptSense,O
primerAntisense,O
primerProductAnneaSox9,O
(,O
327,O
~,O
429,O
),O
GCTCGGAACTGTCTGGAAACGAAACCAGGGCTACTTGCAC103,O
bp60,O
°,O
CCol2A1,O
(,O
413,O
~,O
546,O
),O
GCACCTAGGCGATCTGGTTAGAGCTGCTGGCTGACTCTTT134,O
bp60,O
°,O
CAbbreviations,O
:,O
ChiP,O
chromatin,O
immunoprecipitation,O
",",O
Col2A1,B-GP
α1,B-GP
chain,I-GP
of,I-GP
type,I-GP
II,I-GP
collagen,I-GP
gene,O
",",O
Sox9,B-GP
SRY,O
-,O
type,O
high,O
mobility,O
group,O
box,O
9,O
Immunoprecipitation,O
Immunoprecipitation,O
was,O
performed,O
following,O
the,O
method,O
described,O
in,O
a,O
previous,O
study,O
[,O
30,O
].,O
Cell,O
lysates,O
from,O
BMSCs,O
were,O
prepared,O
in,O
NP40,O
lysis,O
buffer,O
(,O
50,O
mM,O
Tris,O
-,O
HCl,O
pH,O
7,O
.,O
4,O
",",O
150,O
mM,O
NaCl,O
",",O
0,O
.,O
5,O
%,O
NP40,O
",",O
all,O
from,O
Sigma,O
),O
or,O
high,O
-,O
salt,O
lysis,O
buffer,O
(,O
20,O
mM,O
HEPES,O
pH,O
7,O
.,O
4,O
",",O
10,O
%,O
glycerol,O
",",O
0,O
.,O
35,O
M,O
NaCl,O
",",O
1,O
mM,O
MgCl2,O
",",O
0,O
.,O
5,O
%,O
Triton,O
X,O
-,O
100,O
",",O
1,O
mM,O
DTT,O
",",O
all,O
from,O
Sigma,O
-,O
Aldrich,O
),O
with,O
proteinase,B-GP
inhibitors,O
.,O
The,O
supernatant,O
was,O
then,O
incubated,O
with,O
protein,B-GP
G,I-GP
beads,O
(,O
GE,O
Healthcare,O
),O
and,O
the,O
NFATc2,B-GP
antibody,O
(,O
Santa,O
Cruz,O
Biotechnology,O
),O
at,O
4,O
°,O
C,O
for,O
4,O
h,O
.,O
Beads,O
conjugated,O
with,O
the,O
lysates,O
and,O
antibodies,O
were,O
collected,O
by,O
centrifugation,O
and,O
washed,O
three,O
times,O
with,O
lysis,O
buffer,O
.,O
The,O
final,O
amount,O
of,O
wash,O
buffer,O
was,O
aspirated,O
and,O
SDS,O
loading,O
buffer,O
was,O
added,O
to,O
the,O
beads,O
.,O
The,O
prepared,O
proteins,O
were,O
resolved,O
using,O
10,O
%,O
SDS,O
-,O
PAGE,O
and,O
then,O
transferred,O
to,O
nitrocellulose,O
membranes,O
.,O
Finally,O
",",O
the,O
membranes,O
were,O
incubated,O
with,O
antibodies,O
against,O
HDAC1,B-GP
(,O
Santa,O
Cruz,O
Biotechnology,O
),O
for,O
12,O
h,O
.,O
Chemiluminescence,O
was,O
detected,O
using,O
the,O
abovementioned,O
ECL,O
system,O
.,O
Statistical,O
analysis,O
SPSS,O
17,O
(,O
SPSS,O
Science,O
",",O
Chicago,O
",",O
IL,O
",",O
USA,O
),O
was,O
used,O
for,O
data,O
analysis,O
.,O
Quantitative,O
data,O
were,O
expressed,O
as,O
the,O
means,O
±,O
SEM,O
.,O
Data,O
of,O
two,O
groups,O
were,O
evaluated,O
with,O
independent,O
sample,O
Student,O
’,O
s,O
t,O
tests,O
",",O
and,O
the,O
comparisons,O
among,O
more,O
than,O
two,O
groups,O
were,O
performed,O
using,O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
Dunnett,O
’,O
s,O
post,O
hoc,O
Student,O
’,O
s,O
t,O
tests,O
.,O
The,O
macroscopic,O
and,O
histological,O
score,O
was,O
evaluated,O
using,O
the,O
Mann,O
–,O
Whitney,O
U,O
test,O
.,O
Statistical,O
significance,O
was,O
defined,O
as,O
P,O
<,O
0,O
.,O
05,O
.,O
Results,O
Nicotine,O
had,O
an,O
adverse,O
effect,O
on,O
chondrogenic,O
repair,O
of,O
BMSCs,O
in,O
cartilage,O
defect,O
To,O
evaluate,O
the,O
impact,O
of,O
nicotine,O
on,O
cartilage,O
defect,O
repair,O
",",O
we,O
used,O
a,O
femoral,O
trochlear,O
cartilage,O
defect,O
rat,B-OG
model,O
",",O
which,O
was,O
repaired,O
by,O
BMSC,O
transplantation,O
.,O
Nicotine,O
was,O
injected,O
at,O
1,O
.,O
0,O
mg,O
/,O
kg,O
twice,O
per,O
day,O
(,O
2,O
.,O
0,O
mg,O
/,O
kg,O
/,O
d,O
).,O
The,O
effect,O
of,O
nicotine,O
on,O
cartilage,O
repair,O
was,O
analyzed,O
.,O
At,O
12,O
weeks,O
post,O
-,O
transplantation,O
",",O
no,O
abnormal,O
findings,O
suggested,O
rejection,O
or,O
infection,B-DS
",",O
such,O
as,O
severe,O
inflammation,O
or,O
extensive,O
fibrosis,O
",",O
and,O
no,O
synovial,O
edema,O
was,O
observed,O
in,O
either,O
group,O
.,O
In,O
the,O
control,O
group,O
",",O
the,O
defects,O
were,O
covered,O
with,O
smooth,O
regenerated,O
tissues,O
with,O
surrounding,O
cartilage,O
",",O
and,O
the,O
tissues,O
were,O
well,O
integrated,O
with,O
the,O
surrounding,O
cartilage,O
although,O
there,O
remained,O
part,O
of,O
a,O
depressed,O
tissue,O
with,O
a,O
demarcating,O
border,O
<,O
1,O
mm,O
(,O
Fig,O
.,O
1a,O
).,O
Safranin,O
O,O
staining,O
showed,O
that,O
the,O
cartilage,O
defect,O
was,O
filled,O
to,O
the,O
full,O
depth,O
and,O
smooth,O
regenerated,O
tissues,O
with,O
good,O
column,O
alignment,O
",",O
which,O
were,O
well,O
integrated,O
with,O
both,O
edges,O
of,O
normal,O
cartilage,O
",",O
and,O
the,O
graft,O
had,O
a,O
normal,O
matrix,O
-,O
staining,O
compared,O
with,O
adjacent,O
cartilage,O
.,O
The,O
cell,O
morphology,O
was,O
similar,O
to,O
the,O
native,O
cartilage,O
",",O
which,O
was,O
round,O
or,O
ovoid,O
shaped,O
in,O
neat,O
rows,O
and,O
obvious,O
lacuna,O
(,O
Fig,O
.,O
1d,O
).,O
In,O
the,O
experimental,O
group,O
",",O
part,O
of,O
the,O
regenerated,O
tissues,O
had,O
a,O
fibrillated,O
surface,O
",",O
most,O
parts,O
of,O
the,O
defects,O
were,O
filled,O
with,O
regenerated,O
tissues,O
level,O
with,O
the,O
surrounding,O
cartilage,O
",",O
little,O
was,O
clearly,O
distinguishable,O
from,O
the,O
normal,O
cartilage,O
",",O
and,O
part,O
of,O
the,O
graft,O
had,O
a,O
fibrillated,O
surface,O
(,O
Fig,O
.,O
1b,O
).,O
The,O
marked,O
reduced,O
safranin,O
-,O
O,O
staining,O
was,O
exhibited,O
in,O
regenerated,O
tissues,O
",",O
which,O
fully,O
covered,O
the,O
defect,O
.,O
The,O
cell,O
morphology,O
was,O
almost,O
the,O
same,O
as,O
fibrocartilage,O
",",O
which,O
showed,O
an,O
irregular,O
arrangement,O
and,O
no,O
lacuna,O
(,O
Fig,O
.,O
1e,O
).,O
The,O
macroscopic,O
scores,O
of,O
the,O
control,O
group,O
were,O
much,O
higher,O
than,O
those,O
of,O
the,O
experimental,O
group,O
(,O
Fig,O
.,O
1c,O
"),",O
and,O
the,O
microscopic,O
scores,O
in,O
the,O
control,O
group,O
were,O
much,O
lower,O
than,O
the,O
experimental,O
group,O
(,O
Fig,O
.,O
1f,O
).,O
The,O
result,O
suggested,O
that,O
the,O
transplantation,O
of,O
BMSCs,O
with,O
alginate,O
could,O
effectively,O
repair,O
the,O
cartilage,O
defect,O
as,O
the,O
regenerated,O
tissue,O
was,O
almost,O
the,O
same,O
as,O
hyaline,O
cartilage,O
.,O
Nicotine,O
had,O
an,O
obvious,O
adverse,O
effect,O
on,O
cell,O
morphology,O
of,O
the,O
regenerated,O
tissue,O
and,O
synthesis,O
of,O
cartilage,O
matrix,O
.,O
Fig,O
.,O
1Effects,O
of,O
nicotine,O
on,O
the,O
repair,O
of,O
the,O
cartilage,O
defect,O
with,O
BMSCs,O
transplantation,O
in,O
a,O
rat,B-OG
model,O
after,O
12,O
weeks,O
.,O
a,O
and,O
b,O
Macroscopic,O
observation,O
of,O
cartilage,O
repair,O
(×,O
100,O
).,O
c,O
Macroscopic,O
scores,O
of,O
cartilage,O
repair,O
.,O
d,O
and,O
e,O
Safranin,O
-,O
O,O
and,O
fast,O
green,O
staining,O
of,O
cartilage,O
repair,O
(×,O
100,O
).,O
f,O
Histological,O
scores,O
of,O
cartilage,O
repair,O
.,O
Data,O
represent,O
mean,O
±,O
SD,O
(,O
n,O
=,O
8,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
.,O
Scale,O
bar,O
=,O
200,O
μm,O
.,O
BMSCs,O
bone,O
marrow,O
mesenchymal,O
stem,O
cells,O
.,O
Nicotine,O
inhibited,O
cartilage,O
repair,O
by,O
suppressing,O
Sox9,B-GP
expression,O
To,O
explore,O
the,O
mechanism,O
of,O
nicotine,O
’,O
s,O
suppression,O
on,O
the,O
chondrogenic,O
cartilage,O
repair,O
of,O
the,O
cartilage,O
defect,O
",",O
we,O
measured,O
the,O
expression,O
of,O
matrix,O
and,O
Sox9,B-GP
in,O
the,O
regenerated,O
tissues,O
.,O
Immunohistochemical,O
staining,O
of,O
sections,O
with,O
Col2A1,B-GP
and,O
Sox9,B-GP
antibodies,O
showed,O
the,O
proteins,O
in,O
the,O
regenerated,O
tissue,O
stained,O
positive,O
.,O
The,O
staining,O
of,O
Col2A1,B-GP
was,O
stronger,O
in,O
the,O
control,O
group,O
than,O
the,O
experimental,O
group,O
(,O
Fig,O
.,O
2a,O
and,O
b,O
"),",O
similar,O
to,O
Sox9,B-GP
(,O
Fig,O
.,O
2d,O
and,O
e,O
).,O
The,O
mean,O
optical,O
densities,O
of,O
Col2A1,B-GP
and,O
Sox9,B-GP
were,O
reduced,O
in,O
the,O
experimental,O
group,O
(,O
Fig,O
.,O
2c,O
and,O
f,O
).,O
RNA,O
was,O
extracted,O
from,O
the,O
regenerated,O
tissues,O
of,O
both,O
groups,O
",",O
and,O
the,O
mRNA,O
expression,O
of,O
aggrecan,B-GP
",",O
Col2A1,B-GP
",",O
and,O
Sox9,B-GP
in,O
the,O
experimental,O
group,O
were,O
decreased,O
(,O
Fig,O
.,O
2g,O
"),",O
which,O
was,O
consistent,O
with,O
protein,O
expression,O
by,O
immunostaining,O
.,O
These,O
findings,O
demonstrated,O
that,O
nicotine,O
inhibited,O
the,O
expression,O
of,O
Col2A1,B-GP
and,O
Sox9,B-GP
in,O
regenerated,O
tissue,O
.,O
As,O
Sox9,B-GP
is,O
the,O
upstream,O
cellular,O
signal,O
of,O
Col2A1,B-GP
",",O
we,O
concluded,O
that,O
nicotine,O
decreased,O
the,O
expression,O
of,O
Col2A1,B-GP
by,O
suppressing,O
Sox9,B-GP
and,O
then,O
negatively,O
influenced,O
the,O
cartilage,O
defect,O
repair,O
.,O
Fig,O
.,O
2Effects,O
of,O
nicotine,O
on,O
the,O
regenerated,O
tissue,O
of,O
cartilage,O
defect,O
with,O
BMSCs,O
transplantation,O
in,O
a,O
rat,B-OG
model,O
after,O
12,O
weeks,O
.,O
a,O
and,O
b,O
Immunohistological,O
staining,O
of,O
Col2A1,B-GP
in,O
regenerated,O
tissue,O
(×,O
100,O
).,O
c,O
Quantification,O
of,O
the,O
MOD,O
of,O
Col2A1,B-GP
.,O
d,O
and,O
e,O
Immunohistological,O
staining,O
of,O
Sox9,B-GP
in,O
regenerated,O
tissue,O
(×,O
100,O
).,O
f,O
Quantification,O
of,O
the,O
MOD,O
of,O
Sox9,B-GP
.,O
g,O
mRNA,O
expression,O
of,O
Col2A,B-GP
",",O
aggrecan,B-GP
and,O
Sox9,B-GP
in,O
regenerated,O
tissue,O
.,O
Data,O
represent,O
mean,O
±,O
SD,O
(,O
n,O
=,O
8,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
.,O
Scale,O
bar,O
=,O
200,O
μm,O
.,O
BMSCs,O
bone,O
marrow,O
mesenchymal,O
stem,O
cells,O
",",O
Col2A1,B-GP
α1,B-GP
chain,I-GP
of,I-GP
type,I-GP
II,I-GP
collagen,I-GP
",",O
MOD,O
mean,O
optical,O
density,O
",",O
Sox9,B-GP
SRY,B-GP
-,I-GP
type,I-GP
high,I-GP
-,I-GP
mobility,I-GP
group,I-GP
box,I-GP
9,I-GP
Nicotine,O
increased,O
the,O
intracellular,O
Ca2,O
+,O
and,O
phosphatase,B-GP
activity,O
of,O
calcineurin,B-GP
through,O
α7,B-GP
-,I-GP
nAChR,I-GP
To,O
investigate,O
the,O
mechanism,O
of,O
nicotine,O
’,O
s,O
suppression,O
on,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
",",O
0,O
.,O
1,O
to,O
100μM,O
nicotine,O
treatment,O
was,O
used,O
in,O
BMSCs,O
.,O
The,O
intracellular,O
signals,O
were,O
tested,O
to,O
verify,O
whether,O
the,O
Ca2,O
+/,O
CaN,B-GP
/,O
NFAT,B-GP
pathway,O
mediated,O
the,O
inhibitory,O
effect,O
of,O
nicotine,O
.,O
We,O
performed,O
a,O
calcium,O
imaging,O
assay,O
for,O
P3,O
BMSCs,O
.,O
The,O
results,O
showed,O
that,O
the,O
fluorescence,O
intensity,O
of,O
BMSCs,O
increased,O
5,O
–,O
10,O
min,O
after,O
administering,O
nicotine,O
and,O
that,O
the,O
slope,O
of,O
the,O
fluorescence,O
intensity,O
curve,O
was,O
different,O
",",O
which,O
grew,O
gradually,O
with,O
increasing,O
nicotine,O
exposure,O
.,O
Nicotine,O
elicited,O
an,O
increase,O
of,O
intracellular,O
calcium,O
in,O
a,O
concentration,O
-,O
dependent,O
manner,O
(,O
Fig,O
.,O
3a,O
).,O
The,O
onset,O
time,O
of,O
nicotine,O
in,O
our,O
research,O
was,O
5,O
–,O
10,O
min,O
due,O
to,O
the,O
process,O
of,O
nicotine,O
’,O
s,O
diffusion,O
into,O
BMSCs,O
.,O
Thus,O
",",O
we,O
measured,O
the,O
phosphatase,B-GP
activity,O
of,O
calcineurin,B-GP
in,O
0,O
.,O
5,O
h,O
after,O
nicotine,O
stimulus,O
and,O
found,O
that,O
the,O
enzyme,O
activity,O
of,O
calcineurin,B-GP
was,O
also,O
increased,O
in,O
a,O
concentration,O
-,O
dependent,O
manner,O
(,O
Fig,O
.,O
3b,O
).,O
Fig,O
.,O
3Effects,O
of,O
nicotine,O
on,O
intracellular,O
Ca2,O
+,O
concentration,O
and,O
phosphatase,B-GP
activity,O
of,O
calcineurin,B-GP
in,O
BMSCs,O
.,O
Assay,O
was,O
performed,O
immediately,O
(,O
a,O
and,O
d,O
),O
and,O
30,O
mins,O
(,O
b,O
),O
after,O
nicotine,O
stimulus,O
of,O
in,O
-,O
vitro,O
culture,O
.,O
a,O
Change,O
of,O
fluorescence,O
intensity,O
of,O
Ca2,O
+,O
after,O
the,O
stimulus,O
of,O
nicotine,O
at,O
different,O
concentrations,O
.,O
b,O
Change,O
of,O
fluorescence,O
intensity,O
of,O
calcineurin,B-GP
phosphatase,B-GP
activity,O
of,O
CaN,B-GP
calcineurin,B-GP
after,O
the,O
stimulus,O
of,O
nicotine,O
at,O
different,O
concentrations,O
.,O
c,O
Expression,O
of,O
the,O
subtypes,O
of,O
nAChR,B-GP
in,O
BMSCs,O
.,O
d,O
Effects,O
of,O
MLA,O
on,O
nicotine,O
’,O
s,O
augmentation,O
of,O
intracellular,O
Ca2,O
+,O
concentration,O
in,O
BMSCs,O
.,O
Data,O
represent,O
mean,O
±,O
SEM,O
(,O
n,O
=,O
3,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
.,O
Scale,O
bar,O
=,O
100,O
μm,O
.,O
BMSCs,O
bone,O
marrow,O
mesenchymal,O
stem,O
cells,O
",",O
CaN,B-GP
calcineurin,B-GP
",",O
MLA,O
methyllycaconitine,O
",",O
nAChR,B-GP
nicotinic,B-GP
acetylcholine,I-GP
receptor,I-GP
",",O
Because,O
nAChR,B-GP
in,O
MSCs,O
has,O
a,O
large,O
Ca2,O
+,O
permeability,O
and,O
induces,O
elevated,O
intracellular,O
free,O
calcium,O
by,O
releasing,O
intracellular,O
calcium,O
stores,O
",",O
we,O
verified,O
whether,O
nicotine,O
exerted,O
its,O
effect,O
through,O
nAChR,B-GP
in,O
BMSCs,O
.,O
Total,O
RNA,O
and,O
proteins,O
were,O
extracted,O
from,O
BMSCs,O
",",O
and,O
an,O
examination,O
by,O
RT,O
-,O
PCR,O
and,O
Western,O
blotting,O
showed,O
that,O
α7,B-GP
-,I-GP
nAchR,I-GP
was,O
expressed,O
in,O
BMSCs,O
(,O
Fig,O
.,O
3c,O
).,O
We,O
found,O
that,O
10μM,O
methyllycaconitine,O
(,O
MLA,O
"),",O
the,O
specific,O
antagonist,O
of,O
α7,B-GP
-,I-GP
nAChR,I-GP
",",O
conversely,O
eliminated,O
the,O
nicotine,O
-,O
induced,O
calcium,O
influx,O
(,O
Fig,O
.,O
3d,O
"),",O
implying,O
that,O
the,O
effect,O
of,O
nicotine,O
on,O
BMSCs,O
was,O
fulfilled,O
through,O
α7,B-GP
-,I-GP
nAChR,I-GP
.,O
Nicotine,O
suppressed,O
Sox9,B-GP
by,O
activating,O
the,O
Ca2,O
+/,O
calcineurin,B-GP
/,O
NFATc2,B-GP
signaling,O
pathway,O
through,O
α7,B-GP
-,I-GP
nAChR,I-GP
Nicotine,O
exposure,O
increased,O
the,O
concentration,O
of,O
Ca2,O
+,O
and,O
calcineurin,B-GP
phosphatase,B-GP
activity,O
increased,O
over,O
a,O
short,O
period,O
.,O
To,O
detect,O
the,O
molecular,O
mechanism,O
of,O
nicotine,O
’,O
s,O
negative,O
effect,O
",",O
BMSCs,O
were,O
treated,O
with,O
nicotine,O
at,O
different,O
times,O
to,O
detect,O
the,O
expression,O
change,O
of,O
Sox9,B-GP
.,O
The,O
results,O
showed,O
that,O
the,O
mRNA,O
expression,O
of,O
Sox9,B-GP
decreased,O
in,O
24,O
h,O
after,O
nicotine,O
exposure,O
(,O
Fig,O
.,O
4a,O
-,O
c,O
"),",O
and,O
the,O
protein,O
expression,O
of,O
Sox9,B-GP
also,O
declined,O
(,O
Fig,O
.,O
4d,O
and,O
e,O
).,O
The,O
NFAT,B-GP
protein,O
has,O
calcineurin,B-GP
binding,O
sites,O
in,O
the,O
regulatory,O
domain,O
and,O
is,O
regulated,O
by,O
Ca2,B-GP
+,I-GP
and,I-GP
calmodulin,I-GP
-,I-GP
dependent,I-GP
serine,I-GP
phosphatase,I-GP
calcineurin,B-GP
[,O
22,O
];,O
therefore,O
",",O
we,O
extracted,O
the,O
total,O
protein,O
",",O
cytoplasmic,O
proteins,O
and,O
nucleoproteins,B-GP
and,O
found,O
that,O
although,O
no,O
significant,O
changes,O
were,O
observed,O
in,O
the,O
expression,O
of,O
NFATc2,B-GP
of,O
whole,O
cells,O
(,O
Fig,O
.,O
4f,O
and,O
g,O
"),",O
the,O
expression,O
of,O
nucleic,O
NFATc2,B-GP
protein,O
was,O
elevated,O
(,O
Fig,O
.,O
4h,O
and,O
i,O
),O
and,O
the,O
cytoplasm,O
phosphorylated,O
NFATc2,B-GP
was,O
reduced,O
by,O
nicotine,O
(,O
Fig,O
.,O
4j,O
and,O
k,O
"),",O
indicating,O
that,O
NFATc2,B-GP
was,O
rapidly,O
dephosphorylated,O
and,O
localized,O
to,O
the,O
nucleus,O
following,O
nicotine,O
treatment,O
and,O
that,O
the,O
dephosphorylated,O
NFATc2,B-GP
remains,O
in,O
the,O
nucleus,O
in,O
the,O
continued,O
presence,O
of,O
nicotine,O
.,O
To,O
further,O
verify,O
the,O
molecular,O
mechanism,O
of,O
nicotine,O
’,O
s,O
suppression,O
of,O
Sox9,B-GP
",",O
we,O
performed,O
RNAi,O
-,O
mediated,O
stable,O
knockdown,O
of,O
NFATc2,B-GP
expression,O
in,O
cultured,O
BMSCs,O
.,O
NFATc2,B-GP
expression,O
was,O
significantly,O
suppressed,O
at,O
both,O
the,O
mRNA,O
and,O
protein,O
levels,O
(,O
Fig,O
.,O
4l,O
and,O
m,O
).,O
The,O
results,O
showed,O
that,O
the,O
expression,O
of,O
Sox9,B-GP
had,O
no,O
change,O
when,O
10,O
μM,O
MLA,O
and,O
Si,O
-,O
NFATc2,B-GP
were,O
given,O
0,O
.,O
5,O
h,O
before,O
the,O
nicotine,O
exposure,O
(,O
Fig,O
.,O
4n,O
and,O
o,O
"),",O
implying,O
that,O
interventions,O
aimed,O
at,O
α7,B-GP
-,I-GP
nAChR,I-GP
and,O
NFATc2,B-GP
could,O
reverse,O
nicotine,O
’,O
s,O
suppressive,O
effect,O
on,O
the,O
expression,O
of,O
Sox9,B-GP
.,O
Therefore,O
",",O
nicotine,O
suppressed,O
Sox9,B-GP
by,O
activating,O
the,O
Ca2,O
+/,O
calcineurin,B-GP
/,O
NFATc2,B-GP
signaling,O
pathway,O
through,O
α7,B-GP
-,I-GP
nAChR,I-GP
.,O
Fig,O
.,O
4Effects,O
of,O
nicotine,O
on,O
Sox9,B-GP
and,O
NFATc2,B-GP
expression,O
in,O
BMSCs,O
.,O
Assay,O
was,O
performed,O
after,O
24,O
h,O
of,O
in,O
vitro,O
culture,O
.,O
a,O
mRNA,O
expression,O
of,O
Sox9,B-GP
in,O
BMSCs,O
with,O
stimulus,O
of,O
nicotine,O
for,O
8,O
h,O
.,O
b,O
mRNA,O
expression,O
of,O
Sox9,B-GP
in,O
BMSCs,O
with,O
stimulus,O
of,O
nicotine,O
for,O
16,O
h,O
.,O
c,O
mRNA,O
expression,O
of,O
Sox9,B-GP
in,O
BMSCs,O
with,O
stimulus,O
of,O
nicotine,O
for,O
24,O
h,O
.,O
d,O
and,O
e,O
Protein,O
expression,O
of,O
Sox9,B-GP
in,O
BMSCs,O
with,O
stimulus,O
of,O
nicotine,O
for,O
24,O
h,O
.,O
f,O
and,O
g,O
Expression,O
of,O
NFATc2,B-GP
in,O
nucleoproteins,B-GP
with,O
stimulus,O
of,O
nicotine,O
for,O
24,O
h,O
.,O
h,O
and,O
i,O
Expression,O
of,O
phosphorylated,O
NFATc2,B-GP
in,O
the,O
cytoplasm,O
with,O
stimulus,O
of,O
nicotine,O
for,O
24,O
h,O
.,O
j,O
and,O
k,O
Expression,O
of,O
NFATc2,B-GP
in,O
total,O
protein,O
with,O
stimulus,O
of,O
nicotine,O
for,O
24,O
h,O
.,O
l,O
and,O
m,O
Effect,O
of,O
Si,O
-,O
NFATc2,B-GP
in,O
BMSCs,O
.,O
n,O
and,O
o,O
Effects,O
of,O
MLA,O
and,O
Si,O
-,O
NFATc2,B-GP
on,O
nicotine,O
’,O
s,O
suppression,O
of,O
Sox9,B-GP
in,O
BMSCs,O
.,O
Data,O
represent,O
mean,O
±,O
SEM,O
(,O
n,O
=,O
3,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
.,O
BMSCs,O
bone,O
marrow,O
mesenchymal,O
stem,O
cells,O
",",O
Col2A1,B-GP
α1,B-GP
chain,I-GP
of,I-GP
type,I-GP
II,I-GP
collagen,I-GP
",",O
MLA,O
methyllycaconitine,O
",",O
NFATc2,B-GP
nuclear,B-GP
factor,I-GP
of,I-GP
activated,I-GP
T,I-GP
cell,I-GP
2,I-GP
",",O
Sox9,B-GP
SRY,B-GP
-,I-GP
type,I-GP
high,I-GP
-,I-GP
mobility,I-GP
group,I-GP
box,I-GP
9,I-GP
Nicotine,O
decreased,O
the,O
histone,B-GP
acetylation,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
in,O
BMSCs,O
Nicotine,O
exposure,O
resulted,O
in,O
the,O
dephosphorylation,O
and,O
increased,O
the,O
nucleic,O
translocation,O
of,O
NFATc2,B-GP
",",O
and,O
then,O
NFATc2,B-GP
could,O
bind,O
to,O
a,O
site,O
downstream,O
of,O
the,O
transcriptional,O
start,O
site,O
of,O
the,O
target,O
gene,O
and,O
play,O
a,O
role,O
in,O
the,O
downregulation,O
of,O
gene,O
expression,O
[,O
23,O
].,O
Given,O
the,O
finding,O
that,O
nicotine,O
exposure,O
resulted,O
in,O
a,O
significant,O
decrease,O
of,O
Sox9,B-GP
expression,O
",",O
our,O
investigation,O
further,O
focused,O
on,O
the,O
histone,B-GP
acetylation,O
of,O
the,O
Sox9,B-GP
promoter,O
.,O
The,O
result,O
of,O
ChIP,O
analysis,O
indicated,O
that,O
the,O
binding,O
of,O
NFATc2,B-GP
and,O
HDAC1,B-GP
on,O
the,O
Sox9,B-GP
promoter,O
was,O
increased,O
(,O
Fig,O
.,O
5c,O
and,O
d,O
),O
and,O
that,O
H3K9ac,O
and,O
H3K14ac,O
levels,O
on,O
the,O
Sox9,B-GP
promoter,O
were,O
reduced,O
(,O
Fig,O
.,O
5a,O
and,O
b,O
),O
while,O
a,O
decreased,O
binding,O
of,O
Sox9,B-GP
on,O
Col2A1,B-GP
was,O
also,O
observed,O
(,O
Fig,O
.,O
5e,O
).,O
The,O
above,O
changes,O
induced,O
by,O
nicotine,O
were,O
characterized,O
in,O
a,O
concentration,O
-,O
dependent,O
manner,O
.,O
Moreover,O
",",O
when,O
treatment,O
of,O
10,O
μM,O
MLA,O
or,O
si,O
-,O
NFATc2,B-GP
was,O
performed,O
before,O
nicotine,O
exposure,O
",",O
the,O
levels,O
of,O
H3K9ac,O
and,O
H3K14ac,O
were,O
rescued,O
to,O
the,O
level,O
of,O
untreated,O
control,O
(,O
Fig,O
.,O
5f,O
and,O
g,O
"),",O
and,O
the,O
induced,O
binding,O
of,O
Sox9,B-GP
on,O
Col2A1,B-GP
was,O
also,O
reversed,O
(,O
Fig,O
.,O
5h,O
).,O
Therefore,O
",",O
nicotine,O
treatment,O
resulted,O
in,O
dephosphorylation,O
and,O
increased,O
nucleic,O
translocation,O
of,O
NFATc2,B-GP
.,O
Then,O
",",O
NFATc2,B-GP
and,O
HDAC1,B-GP
bound,O
on,O
the,O
Sox9,B-GP
promoter,O
reduced,O
the,O
levels,O
of,O
H3K9ac,O
and,O
H3K14ac,O
on,O
the,O
Sox9,B-GP
promoter,O
and,O
decreased,O
Sox9,B-GP
expression,O
.,O
Reduced,O
binding,O
of,O
Sox9,B-GP
with,O
Col2A1,B-GP
further,O
decreased,O
Col2A1,B-GP
expression,O
.,O
Fig,O
.,O
5Effects,O
of,O
nicotine,O
on,O
histone,B-GP
acetylation,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
in,O
BMSCs,O
.,O
Assay,O
were,O
performed,O
after,O
24,O
h,O
of,O
in,O
vitro,O
culture,O
.,O
a,O
Change,O
of,O
H3K9,O
acetylation,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
.,O
b,O
Change,O
of,O
H3K14,O
acetylation,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
.,O
c,O
Change,O
of,O
NFATc2,B-GP
binding,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
.,O
d,O
Change,O
of,O
1,O
binding,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
.,O
e,O
Change,O
of,O
Sox9,B-GP
binding,O
on,O
the,O
enhancer,O
of,O
Col2A1,B-GP
.,O
f,O
Effects,O
of,O
methyllycaconitine,O
(,O
MLA,O
),O
and,O
Si,O
-,O
NFATc2,B-GP
on,O
nicotine,O
’,O
s,O
suppression,O
of,O
H3K9,O
acetylation,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
.,O
g,O
Effects,O
of,O
MLA,O
and,O
Si,O
-,O
NFATc2,B-GP
on,O
nicotine,O
’,O
s,O
suppression,O
of,O
H3K14,O
acetylation,O
on,O
the,O
promoter,O
of,O
Sox9,B-GP
.,O
h,O
Effects,O
of,O
MLA,O
and,O
Si,O
-,O
NFATc2,B-GP
on,O
nicotine,O
’,O
s,O
suppression,O
of,O
Sox9,B-GP
binding,O
on,O
the,O
enhancer,O
of,O
Col2A1,B-GP
.,O
Data,O
represent,O
mean,O
±,O
SEM,O
(,O
n,O
=,O
3,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
.,O
BMSCs,O
bone,O
marrow,O
mesenchymal,O
stem,O
cells,O
",",O
Col2A1,B-GP
α1,B-GP
chain,I-GP
of,I-GP
type,I-GP
II,I-GP
collagen,I-GP
",",O
HDAC1,B-GP
histone,B-GP
deacetylase1,I-GP
",",O
MLA,O
methyllycaconitine,O
",",O
NFATc2,B-GP
nuclear,B-GP
factor,I-GP
of,I-GP
activated,I-GP
T,I-GP
cell,I-GP
2,I-GP
",",O
Sox9,B-GP
SRY,B-GP
-,I-GP
type,I-GP
high,I-GP
-,I-GP
mobility,I-GP
group,I-GP
box,I-GP
9,I-GP
Nicotine,O
increased,O
the,O
interaction,O
of,O
NFATc2,B-GP
and,O
HDAC1,B-GP
HDACs,B-GP
participate,O
in,O
decreasing,O
the,O
histone,B-GP
acetylation,O
level,O
of,O
gene,O
promoters,O
.,O
The,O
transcriptional,O
activity,O
of,O
NFAT,B-GP
proteins,O
can,O
regulate,O
gene,O
expression,O
negatively,O
depending,O
on,O
which,O
binding,O
partners,O
are,O
involved,O
.,O
Nicotine,O
exposure,O
resulted,O
in,O
the,O
binding,O
of,O
NFATc2,B-GP
to,O
Sox9,B-GP
and,O
decreasing,O
H3K9ac,O
and,O
H3K14ac,O
levels,O
in,O
the,O
Sox9,B-GP
promoter,O
.,O
To,O
investigate,O
the,O
molecular,O
mechanism,O
of,O
the,O
nicotine,O
-,O
induced,O
decreased,O
level,O
of,O
H3K9ac,O
and,O
H3K14ac,O
in,O
the,O
Sox9,B-GP
promoter,O
",",O
we,O
used,O
immunoprecipitation,O
to,O
measure,O
the,O
interaction,O
of,O
NFATc2,B-GP
and,O
HDAC,B-GP
.,O
The,O
result,O
showed,O
that,O
the,O
interaction,O
of,O
NFATc2,B-GP
with,O
HDAC1,B-GP
was,O
enhanced,O
in,O
a,O
concentration,O
-,O
dependent,O
manner,O
after,O
nicotine,O
exposure,O
(,O
Fig,O
.,O
6a,O
"),",O
and,O
no,O
significant,O
change,O
of,O
interaction,O
was,O
observed,O
when,O
Si,O
-,O
NFATc2,B-GP
and,O
MLA,O
were,O
used,O
before,O
nicotine,O
treatment,O
(,O
Fig,O
.,O
6b,O
).,O
These,O
results,O
implied,O
that,O
NFATc2,B-GP
could,O
bind,O
to,O
the,O
Sox9,B-GP
promoter,O
and,O
recruit,O
HDAC1,B-GP
",",O
which,O
also,O
binds,O
to,O
the,O
Sox9,B-GP
promoter,O
to,O
form,O
the,O
complex,O
",",O
and,O
the,O
latter,O
could,O
reduce,O
H3K9ac,O
and,O
H3K14ac,O
levels,O
in,O
the,O
Sox9,B-GP
promoter,O
and,O
decrease,O
the,O
expression,O
of,O
Sox9,B-GP
.,O
Fig,O
.,O
6Effects,O
of,O
nicotine,O
on,O
interaction,O
of,O
NFATc2,B-GP
and,O
HDAC1,B-GP
in,O
BMSCs,O
.,O
Assay,O
was,O
performed,O
after,O
24,O
h,O
of,O
in,O
vitro,O
culture,O
.,O
a,O
Interaction,O
of,O
NFATc2,B-GP
and,O
HDAC1,B-GP
under,O
stimulus,O
of,O
nicotine,O
with,O
different,O
concentrations,O
.,O
b,O
Effects,O
of,O
MLA,O
and,O
Si,O
-,O
NFATc2,B-GP
on,O
the,O
interaction,O
of,O
NFATc2,B-GP
and,O
HDAC1,B-GP
induced,O
by,O
nicotine,O
.,O
IgG,B-GP
is,O
a,O
negative,O
control,O
.,O
Input,O
is,O
a,O
positive,O
control,O
.,O
NFATc2,B-GP
is,O
the,O
precipitated,O
protein,O
.,O
HDAC1,B-GP
is,O
the,O
protein,O
of,O
interest,O
.,O
BMSCs,O
bone,O
marrow,O
mesenchymal,O
stem,O
cells,O
",",O
HDAC1,B-GP
histone,B-GP
deacetylase1,I-GP
",",O
MLA,O
methyllycaconitine,O
",",O
NFATc2,B-GP
nuclear,B-GP
factor,I-GP
of,I-GP
activated,I-GP
T,I-GP
cell,I-GP
2,I-GP
Discussion,O
In,O
the,O
present,O
study,O
",",O
we,O
first,O
verified,O
the,O
adverse,O
effect,O
of,O
nicotine,O
on,O
the,O
chondrogenic,O
repair,O
function,O
of,O
BMSCs,O
in,O
rat,B-OG
articular,O
cartilage,O
defects,O
and,O
proposed,O
that,O
Sox9,B-GP
plays,O
a,O
key,O
role,O
in,O
this,O
process,O
.,O
Based,O
on,O
our,O
previous,O
study,O
",",O
we,O
further,O
confirmed,O
nicotine,O
’,O
s,O
suppression,O
of,O
Col2A1,B-GP
expression,O
and,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
",",O
the,O
mechanism,O
of,O
which,O
may,O
involve,O
decreasing,O
the,O
histone,B-GP
acetylation,O
of,O
the,O
Sox9,B-GP
promoter,O
region,O
through,O
activation,O
of,O
Ca2,O
+/,O
CaN,B-GP
/,O
NFAT,B-GP
signaling,O
.,O
The,O
altered,O
gene,O
expression,O
and,O
promoter,O
acetylation,O
patterns,O
could,O
be,O
blocked,O
by,O
antagonism,O
of,O
α7,B-GP
-,I-GP
nAChR,I-GP
",",O
indicating,O
that,O
the,O
direct,O
effect,O
of,O
nicotine,O
is,O
mediated,O
by,O
α7,B-GP
-,I-GP
nAChR,I-GP
.,O
Therefore,O
",",O
nicotine,O
could,O
interfere,O
with,O
cartilage,O
repair,O
through,O
suppressing,O
Sox9,B-GP
expression,O
in,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
.,O
Nicotine,O
is,O
a,O
high,O
-,O
risk,O
factor,O
for,O
many,O
diseases,O
and,O
has,O
negative,O
effects,O
on,O
soft,O
and,O
bony,O
tissue,O
healing,O
[,O
11,O
",",O
12,O
"],",O
which,O
can,O
also,O
influence,O
the,O
repair,O
of,O
cartilage,O
defects,O
and,O
suppress,O
the,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
[,O
13,O
",",O
17,O
].,O
However,O
",",O
the,O
mechanism,O
of,O
nicotine,O
’,O
s,O
adverse,O
effect,O
is,O
still,O
unclear,O
.,O
Previous,O
researches,O
had,O
clarified,O
the,O
chondrogenic,O
potential,O
of,O
MSCs,O
involved,O
in,O
cartilage,O
regeneration,O
[,O
28,O
",",O
31,O
].,O
Similarly,O
",",O
the,O
regenerated,O
tissue,O
in,O
our,O
study,O
could,O
have,O
been,O
differentiated,O
from,O
BMSCs,O
.,O
In,O
addition,O
to,O
their,O
differentiation,O
potential,O
",",O
the,O
paracrine,O
action,O
of,O
MSCs,O
was,O
also,O
believed,O
to,O
contribute,O
to,O
their,O
therapeutic,O
effects,O
[,O
32,O
",",O
33,O
"],",O
unknown,O
factors,O
secreted,O
from,O
BMSCs,O
may,O
stimulate,O
chondrogenic,O
differentiation,O
in,O
the,O
repair,O
process,O
.,O
Thus,O
",",O
we,O
believed,O
the,O
mechanism,O
of,O
cartilage,O
repair,O
in,O
defect,O
was,O
associated,O
with,O
chondrogenic,O
differentiation,O
and,O
the,O
secretive,O
action,O
of,O
BMSCs,O
.,O
Sox9,B-GP
is,O
a,O
key,O
transcriptional,O
factor,O
and,O
plays,O
an,O
important,O
role,O
in,O
the,O
process,O
of,O
chondrocyte,O
differentiation,O
and,O
cartilage,O
formation,O
[,O
18,O
].,O
In,O
the,O
initial,O
stage,O
of,O
chondrogenesis,O
",",O
mesenchymal,O
stem,O
cells,O
condense,O
and,O
then,O
differentiate,O
into,O
chondrocytes,O
.,O
Sox9,B-GP
can,O
bind,O
to,O
essential,O
sequences,O
in,O
the,O
Col2A1,B-GP
gene,O
at,O
chondrocyte,O
-,O
specific,O
enhancers,O
and,O
activate,O
its,O
expression,O
",",O
and,O
Sox9,B-GP
has,O
been,O
identified,O
as,O
a,O
regulator,O
of,O
the,O
chondrocyte,O
lineage,O
[,O
34,O
].,O
Research,O
had,O
shown,O
that,O
the,O
inactivation,O
of,O
Sox9,B-GP
in,O
limb,O
buds,O
before,O
mesenchymal,O
condensation,O
resulted,O
in,O
a,O
complete,O
absence,O
of,O
cartilage,O
.,O
A,O
delayed,O
development,O
of,O
cartilage,O
can,O
also,O
be,O
induced,O
when,O
the,O
Sox9,B-GP
gene,O
is,O
inactivated,O
after,O
chondrogenic,O
mesenchymal,O
condensation,O
[,O
35,O
].,O
Thus,O
",",O
Sox9,B-GP
is,O
essential,O
in,O
the,O
condensed,O
stage,O
of,O
MSCs,O
and,O
subsequent,O
differentiation,O
in,O
the,O
process,O
of,O
cartilage,O
formation,O
[,O
15,O
].,O
In,O
addition,O
",",O
Sox9,B-GP
also,O
plays,O
an,O
essential,O
role,O
in,O
the,O
physiological,O
control,O
of,O
cartilaginous,O
tissues,O
[,O
36,O
].,O
BMSCs,O
with,O
Sox9,B-GP
gene,O
transfer,O
by,O
adenovirus,B-OG
could,O
promote,O
cartilage,O
defect,O
repair,O
[,O
37,O
].,O
Therefore,O
",",O
Sox9,B-GP
also,O
play,O
an,O
important,O
role,O
in,O
cartilage,O
repair,O
using,O
BMSCs,O
.,O
Our,O
results,O
found,O
that,O
nicotine,O
reduced,O
Sox9,B-GP
expression,O
in,O
the,O
regenerated,O
tissue,O
in,O
the,O
cartilage,O
defect,O
area,O
",",O
which,O
demonstrated,O
that,O
nicotine,O
has,O
an,O
adverse,O
effect,O
on,O
cartilage,O
repair,O
through,O
the,O
suppression,O
of,O
Sox9,B-GP
in,O
regenerated,O
tissue,O
.,O
Histone,B-GP
acetyltransferases,I-GP
(,O
HATs,B-GP
),O
and,O
HDACs,B-GP
are,O
two,O
classes,O
of,O
histone,B-GP
acetylation,O
enzymes,O
",",O
which,O
determine,O
the,O
acetylation,O
status,O
of,O
histones,B-GP
of,O
genes,O
.,O
The,O
activated,O
balance,O
of,O
HATs,B-GP
and,O
HDACs,B-GP
affects,O
the,O
regulation,O
of,O
gene,O
expression,O
[,O
38,O
].,O
The,O
reduction,O
of,O
acetylation,O
in,O
the,O
transcriptional,O
regulatory,O
regions,O
often,O
leads,O
to,O
the,O
inhibition,O
of,O
gene,O
expression,O
[,O
39,O
].,O
The,O
Sox9,B-GP
-,O
based,O
transcriptional,O
complex,O
",",O
including,O
CBP,B-GP
/,O
p300,B-GP
",",O
which,O
has,O
an,O
intrinsic,O
HATs,B-GP
activity,O
",",O
plays,O
an,O
important,O
role,O
in,O
the,O
initiation,O
of,O
chondrogenic,O
differentiation,O
of,O
MSCs,O
[,O
19,O
].,O
Thus,O
",",O
the,O
expression,O
of,O
Sox9,B-GP
itself,O
is,O
mainly,O
regulated,O
by,O
histone,B-GP
acetylation,O
[,O
20,O
].,O
Histone,B-GP
acetylation,O
is,O
concentrated,O
mainly,O
on,O
histone,B-GP
3,I-GP
and,O
histone,B-GP
4,I-GP
[,O
40,O
"],",O
and,O
H3K9,O
and,O
H3K14,O
acetylation,O
often,O
co,O
-,O
occur,O
at,O
many,O
gene,O
regulatory,O
elements,O
and,O
adjust,O
the,O
gene,O
expression,O
in,O
stem,O
cells,O
[,O
41,O
].,O
Based,O
on,O
these,O
data,O
",",O
we,O
focused,O
on,O
nicotine,O
’,O
s,O
regulation,O
of,O
H3K9,O
and,O
H3K14,O
acetylation,O
of,O
Sox9,B-GP
during,O
the,O
process,O
of,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
.,O
We,O
observed,O
that,O
nicotine,O
could,O
reduce,O
the,O
expression,O
of,O
Sox9,B-GP
through,O
decreasing,O
H3K9,O
and,O
H3K14,O
acetylation,O
of,O
the,O
Sox9,B-GP
promoter,O
region,O
and,O
finally,O
suppress,O
the,O
chondrogenic,O
differentiation,O
potential,O
of,O
BMSCs,O
.,O
Our,O
in,O
vitro,O
data,O
are,O
consistent,O
with,O
the,O
in,O
vivo,O
results,O
where,O
nicotine,O
directly,O
decreased,O
the,O
expression,O
of,O
Sox9,B-GP
through,O
α7,B-GP
-,I-GP
nAChR,I-GP
by,O
suppressing,O
the,O
histone,B-GP
acetylation,O
of,O
the,O
Sox9,B-GP
promoter,O
during,O
the,O
process,O
of,O
BMSCs,O
chondrogenic,O
differentiation,O
.,O
NFAT,B-GP
is,O
a,O
family,O
of,O
transcription,B-GP
factors,I-GP
critical,O
in,O
regulating,O
early,O
gene,O
transcription,O
in,O
response,O
to,O
T,B-GP
cell,I-GP
receptor,I-GP
-,O
mediated,O
signals,O
in,O
lymphocytes,O
[,O
42,O
].,O
NFATc2,B-GP
is,O
a,O
repressor,O
of,O
chondrogenesis,O
[,O
21,O
],O
and,O
can,O
induce,O
gene,O
silencing,O
through,O
interaction,O
with,O
HDAC,B-GP
[,O
22,O
].,O
Our,O
study,O
demonstrated,O
that,O
NFATc2,B-GP
could,O
bind,O
with,O
Sox9,B-GP
and,O
recruit,O
HDAC1,B-GP
to,O
decrease,O
the,O
histone,B-GP
acetylation,O
of,O
theSox9,O
promoter,O
.,O
Calcineurin,B-GP
(,O
also,O
called,O
protein,B-GP
phosphatase,I-GP
2B,I-GP
"),",O
the,O
only,O
serine,B-GP
/,I-GP
threonine,I-GP
protein,I-GP
phosphatase,I-GP
under,O
the,O
control,O
of,O
Ca2,O
+/,O
calmodulin,B-GP
",",O
plays,O
a,O
critical,O
role,O
in,O
the,O
coupling,O
of,O
Ca2,O
+,O
signals,O
to,O
cellular,O
responses,O
[,O
43,O
].,O
Ca2,O
+,O
is,O
the,O
upstream,O
signaling,O
molecule,O
of,O
calcineurin,B-GP
",",O
and,O
the,O
increased,O
Ca2,O
+,O
can,O
activate,O
the,O
enzyme,O
activity,O
of,O
calcineurin,B-GP
.,O
The,O
complex,O
regulation,O
of,O
calcineurin,B-GP
can,O
dephosphorylate,O
phosphorylated,O
serine,O
/,O
threonine,O
proteins,O
and,O
initiate,O
multiple,O
pathways,O
.,O
NFATc2,B-GP
is,O
the,O
downstream,O
signal,O
of,O
calcineurin,B-GP
[,O
44,O
"],",O
and,O
the,O
response,O
to,O
an,O
increase,O
of,O
intracellular,O
Ca2,O
+,O
is,O
dependent,O
upon,O
the,O
dephosphorylation,O
of,O
NFATc2,B-GP
by,O
calcineurin,B-GP
.,O
The,O
activated,O
calcineurin,B-GP
controls,O
the,O
translocation,O
of,O
NFAT,B-GP
proteins,O
from,O
the,O
cytoplasm,O
to,O
the,O
nucleus,O
and,O
regulates,O
the,O
expression,O
of,O
target,O
genes,O
[,O
23,O
].,O
Neuronal,O
nAchR,B-GP
is,O
usually,O
in,O
excitable,O
cells,O
of,O
the,O
central,O
nervous,O
system,O
and,O
controls,O
the,O
influx,O
and,O
efflux,O
of,O
Na,O
"+,",O
K,O
"+,",O
and,O
Ca2,O
+,O
[,O
45,O
].,O
Recent,O
studies,O
found,O
that,O
nAchR,B-GP
was,O
also,O
in,O
non,O
-,O
excitable,O
cells,O
outside,O
the,O
nervous,O
system,O
[,O
24,O
",",O
46,O
"],",O
providing,O
physiologic,O
functions,O
in,O
these,O
cells,O
[,O
47,O
"],",O
in,O
which,O
Ca2,O
+,O
plays,O
an,O
important,O
role,O
in,O
a,O
signaling,O
cascade,O
activated,O
by,O
nAchR,B-GP
.,O
Stimulation,O
of,O
MSCs,O
with,O
nicotine,O
induced,O
increases,O
of,O
intracellular,O
Ca2,O
+,O
concentration,O
and,O
initiated,O
the,O
downstream,O
pathway,O
of,O
cascade,O
activation,O
while,O
MLA,O
",",O
which,O
is,O
the,O
specific,O
antagonist,O
of,O
α7,B-GP
-,I-GP
nAChR,I-GP
",",O
could,O
inhibit,O
the,O
calcium,O
influx,O
[,O
48,O
].,O
In,O
the,O
present,O
study,O
",",O
we,O
found,O
that,O
α7,B-GP
-,I-GP
nAChR,I-GP
was,O
presented,O
in,O
BMSCs,O
and,O
a,O
nicotine,O
stimulus,O
could,O
increase,O
intracellular,O
Ca2,O
+,O
and,O
the,O
enzyme,O
activity,O
of,O
calcineurin,B-GP
of,O
BMSCs,O
.,O
The,O
expression,O
of,O
dephosphorylated,O
NFATc2,B-GP
in,O
the,O
cytoplasm,O
decreased,O
and,O
NFATc2,B-GP
in,O
the,O
nucleus,O
increased,O
.,O
Therefore,O
",",O
nicotine,O
could,O
activate,O
Ca2,O
+/,O
Calcineurin,B-GP
/,O
NFAT,B-GP
signaling,O
in,O
BMSCs,O
throughα7,O
-,O
nAChR,B-GP
",",O
resulting,O
in,O
recruitment,O
of,O
HDAC1,B-GP
",",O
which,O
decreased,O
histone,B-GP
acetylation,O
of,O
the,O
Sox9,B-GP
promoter,O
region,O
and,O
finally,O
inhibited,O
BMSC,O
chondrogenic,O
differentiation,O
.,O
The,O
dose,O
of,O
nicotine,O
exposure,O
in,O
our,O
study,O
is,O
2,O
mg,O
/,O
kg,O
/,O
d,O
",",O
which,O
is,O
consistent,O
with,O
previous,O
animal,B-OG
studies,O
[,O
49,O
",",O
50,O
].,O
According,O
to,O
a,O
previous,O
investigation,O
",",O
an,O
average,O
tobacco,O
rod,O
contains,O
10,O
–,O
14,O
mg,O
of,O
nicotine,O
",",O
and,O
on,O
average,O
",",O
approximately,O
1,O
.,O
5,O
mg,O
of,O
nicotine,O
is,O
absorbed,O
systemically,O
during,O
smoking,O
[,O
51,O
].,O
Based,O
on,O
the,O
dose,O
–,O
conversion,O
correlation,O
between,O
humans,B-OG
and,O
rats,B-OG
(,O
human,B-OG
:,O
rats,B-OG
=,O
1,O
:,O
6,O
.,O
17,O
),O
[,O
52,O
"],",O
the,O
dose,O
of,O
nicotine,O
exposure,O
in,O
the,O
present,O
study,O
is,O
equivalent,O
to,O
the,O
nicotine,O
exposure,O
in,O
an,O
adult,O
weighing,O
approximately,O
70,O
kg,O
smoking,O
2,O
.,O
3,O
cigarettes,O
per,O
day,O
(,O
calculated,O
as,O
follows,O
:,O
2,O
mg,O
/,O
kg,O
/,O
d,O
÷,O
6,O
.,O
17,O
×,O
70,O
kg,O
÷,O
10,O
mg,O
/,O
cigarette,O
=,O
2,O
.,O
3,O
cigarettes,O
/,O
d,O
).,O
The,O
definition,O
of,O
nicotine,B-DS
dependence,I-DS
is,O
the,O
equivalent,O
of,O
more,O
than,O
ten,O
cigarettes,O
per,O
day,O
",",O
and,O
each,O
cigarette,O
contains,O
at,O
least,O
0,O
.,O
5,O
mg,O
nicotine,O
[,O
53,O
].,O
The,O
dose,O
of,O
nicotine,O
in,O
our,O
study,O
was,O
lower,O
than,O
the,O
actual,O
exposure,O
of,O
nicotine,B-DS
dependence,I-DS
in,O
daily,O
life,O
.,O
The,O
present,O
results,O
showed,O
the,O
obvious,O
impact,O
of,O
nicotine,O
on,O
cartilage,O
repair,O
.,O
Thus,O
nicotine,O
’,O
s,O
adverse,O
effect,O
with,O
nicotine,B-DS
dependence,I-DS
would,O
be,O
more,O
serious,O
.,O
The,O
concentration,O
of,O
nicotine,O
(,O
0,O
.,O
01,O
–,O
10,O
μM,O
),O
used,O
in,O
our,O
chondrogenic,O
differentiation,O
model,O
is,O
consistent,O
with,O
those,O
often,O
used,O
in,O
pluripotent,O
stem,O
cell,O
studies,O
[,O
54,O
",",O
55,O
].,O
The,O
blood,O
concentrations,O
of,O
nicotine,O
during,O
daily,O
smoking,O
are,O
0,O
.,O
06,O
μM,O
to,O
0,O
.,O
23,O
μM,O
[,O
56,O
"],",O
the,O
initial,O
concentration,O
of,O
nicotine,O
in,O
our,O
study,O
was,O
0,O
.,O
1,O
μM,O
",",O
which,O
was,O
within,O
the,O
range,O
of,O
a,O
daily,O
smoker,O
’,O
s,O
nicotinic,O
blood,O
concentration,O
and,O
could,O
suppress,O
the,O
chondrogenic,O
differentiation,O
of,O
BMSCs,O
.,O
Based,O
on,O
the,O
principle,O
of,O
toxicology,O
",",O
we,O
set,O
a,O
concentration,O
gradient,O
from,O
0,O
.,O
1,O
to,O
100,O
μM,O
.,O
The,O
result,O
showed,O
that,O
nicotinic,O
suppression,O
on,O
BMSC,O
chondrogenic,O
differentiation,O
has,O
concentration,O
-,O
dependent,O
characteristics,O
.,O
Although,O
the,O
largest,O
nicotine,O
exposure,O
used,O
in,O
the,O
present,O
study,O
was,O
100,O
μM,O
",",O
which,O
was,O
significantly,O
higher,O
than,O
the,O
plasma,O
nicotine,O
level,O
of,O
nicotine,B-DS
dependence,I-DS
",",O
the,O
result,O
was,O
the,O
most,O
obvious,O
and,O
the,O
reversing,O
experiment,O
verified,O
the,O
key,O
point,O
of,O
the,O
molecular,O
mechanism,O
in,O
this,O
concentration,O
",",O
which,O
is,O
also,O
helpful,O
in,O
clarifying,O
the,O
molecular,O
mechanism,O
.,O
Conclusions,O
In,O
this,O
study,O
",",O
we,O
showed,O
that,O
nicotine,O
at,O
a,O
dose,O
under,O
the,O
actual,O
exposure,O
of,O
nicotine,B-DS
dependence,I-DS
in,O
daily,O
life,O
had,O
an,O
adverse,O
effect,O
on,O
the,O
chondrogenic,O
repair,O
of,O
BMSCs,O
in,O
cartilage,O
defects,O
and,O
that,O
nicotine,O
suppressed,O
BMSC,O
chondrogenic,O
differentiation,O
via,O
the,O
activation,O
Ca2,O
+/,O
Calcineurin,B-GP
/,O
NFATc2,B-GP
signaling,O
",",O
which,O
decreased,O
the,O
histone,B-GP
acetylation,O
of,O
the,O
Sox9,B-GP
promoter,O
region,O
.,O
The,O
current,O
study,O
offers,O
insight,O
into,O
the,O
risk,O
assessment,O
of,O
cartilage,O
defect,O
repair,O
in,O
a,O
nicotine,O
exposure,O
population,O
",",O
advising,O
individuals,O
to,O
avoid,O
the,O
negative,O
impact,O
of,O
nicotine,O
on,O
BMSC,O
cartilage,O
repair,O
to,O
achieve,O
high,O
-,O
quality,O
repair,O
of,O
cartilage,O
tissue,O
.,O
Additional,O
file,O
Additional,O
file,O
1,O
:,O
Macroscopic,O
observation,O
of,O
cartilage,O
defect,O
with,O
no,O
treatment,O
and,O
alginate,O
transplantation,O
in,O
a,O
rat,B-OG
model,O
after,O
12,O
weeks,O
.,O
a,O
Cartilage,O
defect,O
with,O
no,O
treatment,O
.,O
b,O
Cartilage,O
defect,O
with,O
alginate,O
only,O
.,O
(,O
DOCX,O
413,O
kb,O
),O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
10,O
.,O
1186,O
/,O
s13287,O
-,O
018,O
-,O
0853,O
-,O
x,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Identification,O
and,O
application,O
of,O
keto,B-GP
acids,I-GP
transporters,I-GP
in,O
Yarrowia,B-OG
lipolytica,I-OG
Production,O
of,O
organic,O
acids,O
by,O
microorganisms,B-OG
is,O
of,O
great,O
importance,O
for,O
obtaining,O
building,O
-,O
block,O
chemicals,O
from,O
sustainable,O
biomass,O
.,O
Extracellular,O
accumulation,O
of,O
organic,O
acids,O
involved,O
a,O
series,O
of,O
transporters,B-GP
",",O
which,O
play,O
important,O
roles,O
in,O
the,O
accumulation,O
of,O
specific,O
organic,O
acid,O
while,O
lack,O
of,O
systematic,O
demonstration,O
in,O
eukaryotic,O
microorganisms,B-OG
.,O
To,O
circumvent,O
accumulation,O
of,O
by,O
-,O
product,O
",",O
efforts,O
have,O
being,O
orchestrated,O
to,O
carboxylate,O
transport,O
mechanism,O
for,O
potential,O
clue,O
in,O
Yarrowia,B-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
.,O
Six,O
endogenous,O
putative,O
transporter,B-GP
genes,O
",",O
YALI0B19470g,B-GP
",",O
YALI0C15488g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
YALI0D20108g,B-GP
and,O
YALI0E32901g,B-GP
",",O
were,O
identified,O
.,O
Transport,O
characteristics,O
and,O
substrate,O
specificities,O
were,O
further,O
investigated,O
using,O
a,O
carboxylate,O
-,O
transport,O
-,O
deficient,O
Saccharomyces,B-OG
cerevisiae,I-OG
strain,O
.,O
These,O
transporters,B-GP
were,O
expressed,O
in,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
to,O
assess,O
their,O
roles,O
in,O
regulating,O
extracellular,O
keto,O
acids,O
accumulation,O
.,O
In,O
a,O
Y,B-OG
.,I-OG
lipolytica,I-OG
T1,O
line,O
over,O
expressing,O
YALI0B19470g,B-GP
",",O
α,O
-,O
ketoglutarate,O
accumulated,O
to,O
46,O
.,O
7,O
g,O
·,O
L,O
−,O
1,O
",",O
whereas,O
the,O
concentration,O
of,O
pyruvate,O
decreased,O
to,O
12,O
.,O
3,O
g,O
·,O
L,O
−,O
1,O
.,O
Systematic,O
identification,O
of,O
these,O
keto,B-GP
acids,I-GP
transporters,I-GP
would,O
provide,O
clues,O
to,O
further,O
improve,O
the,O
accumulation,O
of,O
specific,O
organic,O
acids,O
with,O
higher,O
efficiency,O
in,O
eukaryotic,O
microorganisms,B-OG
.,O
Light,O
have,O
been,O
shed,O
on,O
economic,O
feasibility,O
of,O
production,O
of,O
organic,O
acids,O
by,O
microorganisms,B-OG
",",O
expecially,O
considering,O
the,O
finiteness,O
of,O
fossil,O
raw,O
materials1,O
.,O
Although,O
organic,O
acids,O
occupy,O
a,O
key,O
position,O
among,O
the,O
building,O
-,O
block,O
chemicals,O
",",O
economic,O
production,O
by,O
microorganisms,B-OG
is,O
still,O
a,O
big,O
chagllenge,O
to,O
replace,O
petroleum,O
-,O
derived,O
commodity,O
chemicals2,O
.,O
In,O
particular,O
",",O
bio,O
-,O
based,O
production,O
of,O
organic,O
acids,O
is,O
unharnessed,O
by,O
low,O
titres,O
",",O
low,O
yield,O
and,O
accumution,O
of,O
by,O
-,O
products345,O
.,O
The,O
metabolism,O
and,O
accumulation,O
of,O
α,O
-,O
ketoglutaric,O
acid,O
(,O
α,O
-,O
KG,O
),O
are,O
subjected,O
to,O
a,O
higher,O
level,O
of,O
regulation,O
than,O
other,O
organic,O
acids,O
involved,O
in,O
central,O
carbon,O
metabolism6,O
",",O
as,O
α,O
-,O
KG,O
occupies,O
a,O
key,O
position,O
in,O
both,O
carbon,O
central,O
metabolism7,O
and,O
the,O
regulation,O
of,O
the,O
carbon,O
–,O
nitrogen,O
balance8,O
.,O
Metabolic,O
strategies,O
concerning,O
the,O
following,O
have,O
been,O
investigated,O
for,O
α,O
-,O
KG,O
production,O
:,O
regulation,O
of,O
key,O
enzymes,O
",",O
including,O
pyruvate,B-GP
dehydrogenase,I-GP
complex9,I-GP
",",O
pyruvate,B-GP
carboxylase10,I-GP
",",O
fumarase3,O
",",O
aconitase11,B-GP
",",O
isocitrate,B-GP
lyase12,I-GP
",",O
isocitrate,B-GP
dehydrogenase13,I-GP
and,O
components,O
of,O
the,O
α,B-GP
-,I-GP
ketoglutarate,I-GP
dehydrogenase,I-GP
complex14,O
;,O
and,O
co,O
-,O
factor,O
engineering,O
of,O
acetyl,O
-,O
CoA,O
biosynthesis,O
and,O
regeneration15,O
.,O
Extracellular,O
accumulation,O
of,O
non,O
-,O
target,O
carboxylates,O
is,O
a,O
common,O
problem,O
for,O
the,O
production,O
of,O
carboxylates1617,O
.,O
Manipulation,O
of,O
transporters,B-GP
has,O
been,O
an,O
efficient,O
tool,O
to,O
improve,O
the,O
productivity,O
for,O
target,O
carboxylates5,O
.,O
A,O
successful,O
metabolic,O
engineering,O
approach,O
for,O
the,O
over,O
-,O
synthesis,O
of,O
organic,O
acids,O
also,O
requires,O
incorporation,O
of,O
an,O
appropriate,O
exporter,O
to,O
increase,O
productivity18,O
.,O
A,O
comparative,O
study,O
revealed,O
that,O
the,O
highest,O
malate,O
yield,O
was,O
obtained,O
once,O
the,O
malate,B-GP
transporter,I-GP
was,O
recruited,O
in,O
the,O
mutants19,O
.,O
Lactate,O
production,O
in,O
S,B-OG
.,I-OG
cerevisiae,I-OG
could,O
be,O
significantly,O
improved,O
with,O
the,O
combined,O
expression,O
of,O
lactate,B-GP
dehydrogenase,I-GP
and,O
the,O
lactate,B-GP
transporter20,I-GP
.,O
Although,O
many,O
studies,O
have,O
described,O
the,O
mechanisms,O
of,O
action,O
and,O
regulation,O
for,O
carboxylate,O
transport,O
in,O
yeast2021,O
",",O
Y,B-OG
.,I-OG
lipolytica,I-OG
orthologous,O
gene,O
of,O
the,O
carboxylate,B-GP
transporter,I-GP
have,O
not,O
yet,O
been,O
identified,O
.,O
In,O
this,O
study,O
",",O
a,O
number,O
of,O
carboxylate,B-GP
transporters,I-GP
were,O
identified,O
from,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
",",O
which,O
exhibits,O
flexibility,O
in,O
substrate,O
specificity,O
.,O
The,O
duplication,O
of,O
endogenous,O
transporters,B-GP
might,O
provide,O
a,O
powerful,O
tool,O
to,O
ensure,O
efficient,O
carboxylate,O
synthesis,O
and,O
maintain,O
homeostasis,O
of,O
the,O
intracellular,O
environment,O
.,O
In,O
this,O
study,O
",",O
we,O
observed,O
that,O
a,O
competitive,O
dual,O
effect,O
—,O
a,O
significant,O
increase,O
in,O
α,O
-,O
KG,O
production,O
with,O
a,O
sharp,O
decrease,O
in,O
pyruvate,O
(,O
PA,O
),O
accumulation,O
resulted,O
from,O
overexpression,O
of,O
YALI0B19470g,B-GP
.,O
This,O
result,O
suggests,O
a,O
new,O
and,O
promising,O
strategy,O
for,O
gene,O
manipulation,O
that,O
can,O
efficiently,O
address,O
α,O
-,O
KG,O
accumulation,O
.,O
The,O
identification,O
of,O
these,O
transporters,B-GP
also,O
have,O
uncovered,O
the,O
mechanisms,O
of,O
extracellular,O
accumulation,O
of,O
diverse,O
organic,O
acids,O
in,O
genome,O
level,O
",",O
and,O
provides,O
new,O
clues,O
to,O
orchestrate,O
competition,O
of,O
extracellular,O
accumulation,O
between,O
target,O
and,O
non,O
-,O
target,O
carboxylates,O
in,O
yeast,B-OG
and,O
other,O
eukaryotic,O
microorganisms,B-OG
.,O
Results,O
Bioinformatics,O
analysis,O
of,O
potential,O
carboxylate,B-GP
transporters,I-GP
in,O
Y,B-OG
.,I-OG
lipolytica,I-OG
To,O
screen,O
putative,O
carboxylate,B-GP
transporters,I-GP
",",O
6611,O
proteins,O
encoded,O
by,O
Y,B-OG
.,I-OG
lipolytica,I-OG
CLIB122,I-OG
genome,O
were,O
obtained,O
from,O
the,O
UniProt,O
database,O
.,O
Of,O
these,O
",",O
1104,O
proteins,O
(,O
Supplementary,O
S1,O
),O
were,O
predicted,O
as,O
transmembrane,B-GP
proteins,I-GP
by,O
TMHMM,O
v,O
.,O
2,O
.,O
0,O
(,O
Fig,O
.,O
1A,O
).,O
Subsequently,O
",",O
117,O
proteins,O
were,O
excluded,O
from,O
this,O
set,O
",",O
due,O
to,O
the,O
presence,O
of,O
a,O
possible,O
signal,O
peptide,O
at,O
the,O
N,O
terminus,O
",",O
as,O
predicted,O
by,O
SignalP,O
4,O
.,O
1,O
.,O
A,O
sequence,O
search,O
using,O
a,O
conserved,O
carboxylate,B-GP
transporter,I-GP
signature,O
of,O
JEN,B-GP
family,O
",",O
NXXS,O
/,O
THXS,O
/,O
TQDXXXT,O
",",O
identified,O
six,O
putative,O
proteins,O
encoded,O
by,O
the,O
YALI0B19470g,B-GP
",",O
YALI0C15488g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
YALI0D20108g,B-GP
",",O
and,O
YALI0E32901g,B-GP
genes,O
",",O
which,O
exhibited,O
high,O
similarity,O
to,O
the,O
signature,O
sequence,O
.,O
A,O
multiple,O
sequence,O
alignment,O
of,O
these,O
sequences,O
using,O
homologous,O
carboxylate,B-GP
transporter,I-GP
sequences,O
from,O
other,O
fungi,O
confirmed,O
the,O
presence,O
of,O
the,O
conserved,O
sequence,O
(,O
Fig,O
.,O
1B,O
).,O
In,O
addition,O
",",O
a,O
high,O
level,O
of,O
sequence,O
similarity,O
among,O
these,O
putative,O
transporters,B-GP
and,O
the,O
characterized,O
carboxylate,B-GP
transporters,I-GP
was,O
illustrated,O
by,O
two,O
BLAST,O
(,O
http,O
://,O
blast,O
.,O
ncbi,O
.,O
nlm,O
.,O
nih,O
.,O
gov,O
/),O
protocols,O
",",O
in,O
which,O
ScJen1p,B-GP
and,O
KlJen2p,B-GP
were,O
used,O
as,O
query,O
sequences222324,O
.,O
In,O
these,O
cases,O
",",O
the,O
identity,O
to,O
ScJen1p,B-GP
and,O
to,O
KlJen2p,B-GP
were,O
prospected,O
",",O
respectively,O
(,O
Fig,O
.,O
2,O
).,O
In,O
silico,O
analysis,O
of,O
these,O
protein,O
sequences,O
using,O
the,O
TMRPres2D,O
tool,O
revealed,O
that,O
the,O
conserved,O
sequence,O
was,O
located,O
in,O
the,O
predicted,O
transmembrane,O
helices,O
(,O
Fig,O
.,O
3,O
).,O
Hence,O
",",O
these,O
transmembrane,B-GP
proteins,I-GP
were,O
suspected,O
to,O
be,O
potential,O
carboxylate,B-GP
transporters,I-GP
.,O
Exogenous,O
keto,O
acid,O
treatment,O
To,O
uncover,O
the,O
response,O
of,O
carboxylate,B-GP
transporter,I-GP
candidates,O
for,O
uptake,O
of,O
exogenous,O
keto,O
acids,O
",",O
glucose,O
-,O
grown,O
(,O
repression,O
condition,O
),O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
cells,O
were,O
transferred,O
at,O
the,O
exponential,O
phase,O
to,O
YPK,O
or,O
YPP,O
medium,O
(,O
A,O
large,O
amount,O
exogenous,O
organic,O
acids,O
were,O
accumulated,O
in,O
yeast,B-OG
cells,O
",",O
Supplementary,O
S2,O
).,O
Initially,O
",",O
neither,O
α,O
-,O
KG,O
nor,O
PA,O
was,O
detected,O
in,O
these,O
cultures,O
.,O
During,O
the,O
first,O
hour,O
",",O
the,O
intracellular,O
concentration,O
of,O
both,O
carboxylates,O
increased,O
quickly,O
to,O
maximums,O
of,O
3,O
.,O
90,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
for,O
α,O
-,O
KG,O
and,O
1,O
.,O
67,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
for,O
PA,O
in,O
α,O
-,O
KG,O
-,O
and,O
PA,O
-,O
treated,O
cells,O
",",O
respectively,O
.,O
After,O
incubation,O
in,O
YPK,O
or,O
YPP,O
medium,O
for,O
1,O
h,O
",",O
the,O
concentration,O
of,O
α,O
-,O
KG,O
gradually,O
decreased,O
1,O
h,O
to,O
3,O
h,O
",",O
until,O
the,O
minimum,O
of,O
0,O
.,O
85,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
was,O
reached,O
.,O
During,O
this,O
period,O
",",O
the,O
content,O
of,O
PA,O
also,O
decreased,O
to,O
0,O
.,O
23,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
(,O
Fig,O
.,O
4A,O
).,O
To,O
assay,O
the,O
effects,O
of,O
exogenous,O
carboxylates,O
on,O
the,O
expression,O
profiles,O
of,O
these,O
potential,O
transporters,B-GP
",",O
the,O
expression,O
of,O
these,O
genes,O
were,O
examined,O
by,O
qRT,O
-,O
PCR,O
",",O
using,O
RNA,O
extracted,O
at,O
0,O
h,O
as,O
the,O
control,O
.,O
When,O
intracellular,O
α,O
-,O
KG,O
levels,O
increased,O
",",O
the,O
expression,O
of,O
YALI0D20108g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
and,O
YALI0E32901g,B-GP
decreased,O
by,O
3,O
.,O
72,O
±,O
0,O
.,O
91,O
-,O
fold,O
",",O
3,O
.,O
88,O
±,O
0,O
.,O
34,O
-,O
fold,O
",",O
2,O
.,O
47,O
±,O
0,O
.,O
52,O
-,O
fold,O
",",O
and,O
1,O
.,O
60,O
±,O
0,O
.,O
18,O
-,O
fold,O
",",O
respectively,O
",",O
whereas,O
the,O
expression,O
of,O
YALI0B19470g,B-GP
and,O
YALI0C15488g,B-GP
increased,O
by,O
9,O
.,O
39,O
±,O
0,O
.,O
82,O
-,O
fold,O
and,O
4,O
.,O
32,O
±,O
0,O
.,O
83,O
-,O
fold,O
",",O
respectively,O
.,O
Exogenous,O
PA,O
had,O
a,O
similar,O
effect,O
on,O
expression,O
",",O
albeit,O
to,O
different,O
levels,O
.,O
When,O
incubated,O
with,O
PA,O
",",O
expression,O
of,O
YALI0D20108g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
and,O
YALI0E32901g,B-GP
decreased,O
by,O
5,O
.,O
83,O
±,O
0,O
.,O
81,O
-,O
fold,O
",",O
4,O
.,O
04,O
±,O
1,O
.,O
04,O
-,O
fold,O
",",O
6,O
.,O
44,O
±,O
0,O
.,O
98,O
-,O
fold,O
",",O
and,O
15,O
.,O
88,O
±,O
1,O
.,O
94,O
-,O
fold,O
",",O
respectively,O
",",O
whereas,O
expression,O
of,O
YALI0B19470g,B-GP
and,O
YALI0C15488g,B-GP
increased,O
by,O
2,O
.,O
83,O
±,O
0,O
.,O
21,O
-,O
fold,O
and,O
9,O
.,O
72,O
±,O
0,O
.,O
22,O
-,O
fold,O
",",O
respectively,O
(,O
Fig,O
.,O
4B,O
).,O
Hence,O
",",O
we,O
concluded,O
that,O
transport,O
of,O
both,O
keto,O
acids,O
should,O
be,O
predominantly,O
mediated,O
by,O
YALI0B19470p,B-GP
and,O
YALI0C15488p,B-GP
.,O
Assessment,O
of,O
putative,O
genes,O
using,O
heterologous,O
expression,O
in,O
S,B-OG
.,I-OG
cerevisiae,I-OG
To,O
assess,O
their,O
possible,O
roles,O
in,O
carboxylate,O
transport,O
",",O
,O
mutants,O
of,O
endogenous,O
transporters,B-GP
were,O
constructed,O
by,O
gene,O
disruption,O
in,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
.,O
The,O
ScJEN1,B-GP
deletion,O
mutant,O
displayed,O
reduced,O
growth,O
on,O
lactate,O
",",O
acetate,O
",",O
PA,O
",",O
malate,O
",",O
and,O
α,O
-,O
KG,O
compared,O
to,O
the,O
parental,O
strain,O
.,O
To,O
completely,O
abolish,O
the,O
uptake,O
by,O
endogenous,O
transporters,B-GP
",",O
the,O
Ady2p,B-GP
was,O
also,O
disrupted,O
in,O
W1,O
strain,O
.,O
In,O
contrast,O
",",O
the,O
W2,O
strain,O
",",O
in,O
which,O
both,O
ScJEN1,B-GP
and,O
ScADY2,B-GP
were,O
disrupted,O
",",O
cannot,O
grow,O
on,O
lactate,O
",",O
acetate,O
",",O
PA,O
",",O
malate,O
",",O
and,O
α,O
-,O
KG,O
containing,O
media,O
.,O
Moreover,O
",",O
the,O
parental,O
strain,O
as,O
well,O
as,O
the,O
W1,O
and,O
W2,O
strains,O
did,O
not,O
grow,O
on,O
citrate,O
(,O
Fig,O
.,O
5,O
).,O
All,O
putative,O
transporter,B-GP
genes,O
were,O
introduced,O
into,O
the,O
W2,O
strain,O
by,O
genetic,O
transformation,O
based,O
on,O
Δhis3,O
complementation,O
.,O
The,O
resulting,O
strains,O
grew,O
well,O
on,O
all,O
sources,O
including,O
citrate,O
",",O
supporting,O
the,O
conclusion,O
that,O
these,O
genes,O
encode,O
carboxylate,B-GP
transporters,I-GP
(,O
Fig,O
.,O
5,O
).,O
Substrate,O
specificity,O
assay,O
To,O
investigate,O
the,O
substrate,O
specificity,O
of,O
these,O
proteins,O
",",O
glucose,O
-,O
grown,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
and,O
mutants,O
were,O
incubated,O
in,O
YPA,O
",",O
YPL,O
",",O
YPP,O
",",O
YPM,O
",",O
YPK,O
",",O
and,O
YPC,O
medium,O
for,O
2,O
h,O
after,O
exhaustion,O
of,O
the,O
endogenous,O
carbon,O
source,O
in,O
saline,O
water,O
.,O
The,O
intracellular,O
carboxylate,O
content,O
in,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
cells,O
was,O
measured,O
(,O
Table,O
1,O
"),",O
revealing,O
that,O
2,O
.,O
22,O
±,O
0,O
.,O
21,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
lactate,O
",",O
0,O
.,O
94,O
±,O
0,O
.,O
14,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
PA,O
",",O
3,O
.,O
14,O
±,O
0,O
.,O
24,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
malate,O
",",O
and,O
1,O
.,O
29,O
±,O
0,O
.,O
12,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
α,O
-,O
KG,O
were,O
present,O
.,O
In,O
addition,O
",",O
acetate,O
and,O
citrate,O
were,O
not,O
detected,O
in,O
cells,O
incubated,O
in,O
the,O
corresponding,O
carboxylate,O
-,O
containing,O
medium,O
.,O
As,O
no,O
carboxylates,O
were,O
detected,O
in,O
the,O
double,O
deletion,O
cells,O
",",O
we,O
concluded,O
that,O
ScJen1p,B-GP
and,O
ScAdy2p,B-GP
deletions,O
influenced,O
the,O
transport,O
of,O
PA,O
",",O
malate,O
",",O
and,O
α,O
-,O
KG,O
.,O
The,O
transport,O
of,O
α,O
-,O
KG,O
was,O
restored,O
in,O
all,O
heterogeneous,O
transporter,B-GP
-,O
containing,O
strains,O
",",O
with,O
the,O
highest,O
accumulation,O
(,O
1,O
.,O
41,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
),O
occurring,O
in,O
the,O
W4,O
strain,O
.,O
Among,O
the,O
set,O
",",O
only,O
the,O
W4,O
could,O
accumulate,O
PA,O
intracellularly,O
(,O
0,O
.,O
17,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
).,O
Based,O
on,O
these,O
observations,O
",",O
we,O
conclude,O
that,O
YALI0B19470g,B-GP
and,O
YALI0D24607g,B-GP
encode,O
proteins,O
that,O
transport,O
dicarboxylates,O
and,O
tricarboxylates,O
.,O
In,O
addition,O
to,O
PA,O
",",O
W4,O
cells,O
(,O
containing,O
YALI0C15488p,B-GP
),O
also,O
accumulated,O
acetate,O
",",O
malate,O
",",O
α,O
-,O
KG,O
",",O
and,O
citrate,O
",",O
indicating,O
the,O
corresponding,O
protein,O
also,O
transported,O
these,O
carboxylates,O
.,O
In,O
a,O
similar,O
manner,O
",",O
we,O
conclude,O
the,O
proteins,O
encoded,O
by,O
the,O
corresponding,O
genes,O
transport,O
the,O
following,O
carboxylates,O
:,O
YALI0C21406p,B-GP
for,O
lactate,O
",",O
malate,O
",",O
α,O
-,O
KG,O
",",O
and,O
citrate,O
;,O
YALI0D20108p,B-GP
for,O
lactate,O
",",O
α,O
-,O
KG,O
and,O
citrate,O
",",O
and,O
YALI0E32901p,B-GP
for,O
acetate,O
",",O
malate,O
",",O
and,O
citrate,O
.,O
Copy,O
number,O
analysis,O
of,O
putative,O
transporter,B-GP
genes,O
in,O
recombinant,O
strains,O
In,O
order,O
to,O
estimate,O
copy,O
number,O
of,O
each,O
expression,O
cassette,O
that,O
integrated,O
in,O
genome,O
of,O
recombinant,O
strains,O
",",O
quantitative,O
-,O
PCR,O
(,O
qPCR,O
),O
analysis,O
was,O
carried,O
out,O
.,O
ACT1,B-GP
was,O
utilized,O
as,O
an,O
endogenous,O
control26,O
.,O
With,O
comparison,O
to,O
ACT1,B-GP
",",O
no,O
obvious,O
relative,O
changes,O
of,O
these,O
transporters,B-GP
were,O
observed,O
(,O
Fig,O
.,O
6,O
).,O
This,O
indicated,O
that,O
these,O
transporter,B-GP
genes,O
were,O
presented,O
in,O
a,O
single,O
copy,O
in,O
parental,O
strain,O
",",O
respectively,O
.,O
After,O
individual,O
transportation,O
of,O
each,O
endogenous,O
transporters,B-GP
gene,O
into,O
cells,O
of,O
parental,O
strain,O
",",O
relative,O
changes,O
of,O
2,O
.,O
54,O
±,O
0,O
.,O
22,O
-,O
fold,O
for,O
YALI0B19470g,B-GP
",",O
2,O
.,O
33,O
±,O
0,O
.,O
27,O
-,O
fold,O
for,O
YALI0C15488g,B-GP
",",O
2,O
.,O
62,O
±,O
0,O
.,O
33,O
-,O
fold,O
for,O
YALI0C21406g,B-GP
",",O
2,O
.,O
28,O
±,O
0,O
.,O
19,O
-,O
fold,O
for,O
YALI0D24607g,B-GP
",",O
2,O
.,O
39,O
±,O
0,O
.,O
26,O
-,O
fold,O
for,O
YALI0D20108g,B-GP
and,O
2,O
.,O
55,O
±,O
0,O
.,O
32,O
-,O
fold,O
for,O
YALI0E32901g,B-GP
were,O
observed,O
",",O
which,O
indicated,O
one,O
more,O
copy,O
of,O
each,O
transporter,B-GP
gene,O
existed,O
per,O
genome,O
in,O
corresponding,O
recombinant,O
strain,O
(,O
Fig,O
.,O
6,O
).,O
The,O
effects,O
of,O
transporter,B-GP
genes,O
on,O
carboxylate,O
accumulation,O
in,O
Y,B-OG
.,I-OG
lipolytica,I-OG
As,O
previously,O
reported,O
carboxylate,B-GP
transporter,I-GP
possess,O
bi,O
-,O
functions,O
for,O
carboxylate,O
influx,O
and,O
efflux25,O
.,O
To,O
clarify,O
the,O
roles,O
of,O
these,O
transporters,B-GP
on,O
carboxylate,O
extracellular,O
accumulation,O
",",O
they,O
were,O
overexpressed,O
in,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
.,O
The,O
hp4d,O
promoter,O
was,O
used,O
to,O
increase,O
the,O
transcription,O
of,O
these,O
genes,O
",",O
and,O
YALI0B19470g,B-GP
",",O
YALI0C15488g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
YALI0D20108g,B-GP
and,O
YALI0E32901g,B-GP
expression,O
was,O
improved,O
by,O
23,O
.,O
34,O
±,O
2,O
.,O
67,O
-,O
fold,O
",",O
8,O
.,O
53,O
±,O
0,O
.,O
90,O
-,O
fold,O
",",O
9,O
.,O
32,O
±,O
0,O
.,O
82,O
-,O
fold,O
",",O
11,O
.,O
79,O
±,O
1,O
.,O
32,O
-,O
fold,O
",",O
3,O
.,O
37,O
±,O
0,O
.,O
49,O
-,O
fold,O
and,O
10,O
.,O
50,O
±,O
0,O
.,O
97,O
-,O
fold,O
",",O
respectively,O
(,O
Fig,O
.,O
7,O
).,O
Due,O
to,O
the,O
flexible,O
substrate,O
specificity,O
of,O
these,O
transporters,B-GP
",",O
the,O
accumulation,O
of,O
PA,O
and,O
α,O
-,O
KG,O
increased,O
in,O
T5,O
cells,O
",",O
and,O
the,O
ratio,O
of,O
extracellular,O
α,O
-,O
KG,O
/,O
PA,O
decreased,O
from,O
2,O
.,O
06,O
to,O
1,O
.,O
87,O
compared,O
to,O
the,O
wild,O
-,O
type,O
strain,O
.,O
This,O
ratio,O
also,O
decreased,O
in,O
YALI0C15488g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
and,O
YALI0E32901g,B-GP
overexpressing,O
strains,O
",",O
as,O
only,O
extracellular,O
PA,O
increased,O
for,O
T2,O
",",O
T3,O
",",O
T4,O
",",O
and,O
T6,O
.,O
A,O
competitive,O
dual,O
effect,O
was,O
observed,O
for,O
strain,O
T1,O
:,O
the,O
transport,O
of,O
α,O
-,O
KG,O
increased,O
dramatically,O
",",O
whereas,O
the,O
concentration,O
of,O
PA,O
dropped,O
by,O
30,O
.,O
6,O
"%,",O
resulting,O
in,O
an,O
increase,O
in,O
the,O
ratio,O
of,O
extracellular,O
α,O
-,O
KG,O
/,O
PA,O
from,O
2,O
.,O
06,O
to,O
3,O
.,O
79,O
(,O
Fig,O
.,O
8,O
).,O
The,O
intracellular,O
carboxylate,O
content,O
",",O
Cin,O
(,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
"),",O
was,O
also,O
determined,O
(,O
Table,O
2,O
).,O
The,O
intracellular,O
accumulation,O
of,O
α,O
-,O
KG,O
decreased,O
from,O
0,O
.,O
026,O
±,O
0,O
.,O
005,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
to,O
0,O
.,O
014,O
±,O
0,O
.,O
002,O
",",O
0,O
.,O
023,O
±,O
0,O
.,O
003,O
",",O
0,O
.,O
014,O
±,O
0,O
.,O
002,O
and,O
0,O
.,O
020,O
±,O
0,O
.,O
002,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
for,O
strains,O
T1,O
",",O
T4,O
",",O
T5,O
and,O
T6,O
.,O
The,O
intracellular,O
accumulation,O
of,O
PA,O
decreased,O
from,O
0,O
.,O
034,O
±,O
0,O
.,O
006,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
to,O
0,O
.,O
009,O
±,O
0,O
.,O
002,O
",",O
0,O
.,O
029,O
±,O
0,O
.,O
003,O
",",O
0,O
.,O
017,O
±,O
0,O
.,O
002,O
and,O
0,O
.,O
025,O
±,O
0,O
.,O
002,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
in,O
strains,O
T1,O
",",O
T4,O
",",O
T5,O
and,O
T6,O
respectively,O
.,O
Compared,O
to,O
the,O
wild,O
-,O
type,O
strain,O
",",O
the,O
growth,O
yield,O
decreased,O
from,O
11,O
.,O
17,O
±,O
1,O
.,O
08,O
g,O
·,O
L,O
−,O
1,O
to,O
8,O
.,O
45,O
±,O
0,O
.,O
72,O
",",O
8,O
.,O
27,O
±,O
0,O
.,O
89,O
",",O
8,O
.,O
34,O
±,O
0,O
.,O
76,O
",",O
8,O
.,O
47,O
±,O
0,O
.,O
61,O
",",O
8,O
.,O
36,O
±,O
0,O
.,O
88,O
and,O
7,O
.,O
40,O
±,O
0,O
.,O
71,O
g,O
·,O
L,O
−,O
1,O
for,O
strains,O
T1,O
",",O
T2,O
",",O
T3,O
",",O
T4,O
",",O
T5,O
and,O
T6,O
",",O
respectively,O
",",O
suggesting,O
that,O
enhanced,O
carboxylate,O
transportation,O
caused,O
the,O
shift,O
in,O
carbon,O
flux,O
from,O
cellular,O
growth,O
to,O
carboxylate,O
accumulation,O
.,O
The,O
combination,O
of,O
increased,O
carboxylate,O
accumulation,O
with,O
decreased,O
cell,O
growth,O
lead,O
to,O
a,O
sharp,O
increase,O
in,O
the,O
yield,O
of,O
α,O
-,O
KG,O
and,O
PA,O
",",O
Yα,O
-,O
KG,O
/,O
DCW,O
and,O
YPA,O
/,O
DCW,O
.,O
Finally,O
",",O
the,O
ratio,O
of,O
extracellular,O
carboxylate,O
to,O
intracellular,O
carboxylate,O
increased,O
",",O
and,O
maximum,O
values,O
of,O
2399,O
.,O
71,O
±,O
241,O
.,O
63,O
for,O
α,O
-,O
KG,O
and,O
1685,O
.,O
20,O
±,O
208,O
.,O
56,O
for,O
PA,O
were,O
observed,O
for,O
the,O
T1,O
strain,O
.,O
Based,O
on,O
these,O
observations,O
",",O
overexpression,O
of,O
YALI0A9470g,B-GP
was,O
considered,O
the,O
best,O
strategy,O
to,O
enhance,O
α,O
-,O
KG,O
transport,O
and,O
reduce,O
PA,O
accumulation,O
.,O
Discussion,O
The,O
object,O
of,O
the,O
current,O
work,O
was,O
to,O
screen,O
and,O
identify,O
carboxylate,B-GP
transporters,I-GP
",",O
then,O
determine,O
whether,O
the,O
identified,O
proteins,O
regulate,O
accumulation,O
of,O
non,O
-,O
target,O
carboxylates,O
.,O
The,O
duplication,O
of,O
transporters,B-GP
and,O
the,O
flexible,O
substrate,O
specificity,O
demonstrated,O
by,O
the,O
identified,O
carboxylate,B-GP
transporters,I-GP
facilitated,O
extracellular,O
accumulation,O
of,O
carboxylates,O
.,O
Moreover,O
",",O
knowledge,O
of,O
the,O
examined,O
carboxylate,O
transport,O
mechanism,O
is,O
a,O
prerequisite,O
for,O
improving,O
carboxylate,O
synthesis,O
through,O
metabolic,O
engineering,O
.,O
The,O
results,O
provide,O
new,O
insights,O
for,O
regulating,O
extracellular,O
carboxylate,O
accumulation,O
in,O
similar,O
eukaryotic,O
microorganisms,B-OG
.,O
To,O
circumvent,O
the,O
issue,O
of,O
PA,O
accumulation,O
",",O
previous,O
studies,O
have,O
focused,O
mainly,O
on,O
the,O
regulation,O
of,O
intrinsic,O
forces,O
that,O
redistribute,O
carbon,O
flux,O
from,O
other,O
intermediates,O
to,O
α,O
-,O
KG,O
production,O
.,O
Expression,O
of,O
PA,B-GP
carboxylase10,I-GP
",",O
malate,B-GP
dehydrogenase,I-GP
",",O
and,O
fumarase3,O
dramatically,O
decreased,O
the,O
accumulation,O
of,O
PA,O
.,O
A,O
strategy,O
to,O
regulate,O
co,O
-,O
factor,O
regeneration,O
resulted,O
in,O
remarkable,O
reduction,O
of,O
extracellular,O
PA15,O
.,O
However,O
",",O
as,O
PA,O
has,O
a,O
pivotal,O
role,O
in,O
the,O
regulation,O
of,O
carbon,O
metabolism20,O
",",O
these,O
modifications,O
could,O
not,O
entirely,O
overcome,O
PA,O
accumulation,O
.,O
As,O
accumulation,O
of,O
carboxylate,O
is,O
believed,O
to,O
be,O
a,O
yeast,B-OG
defense,O
response,O
to,O
severe,O
environmental,O
conditions27,O
",",O
regulation,O
of,O
carboxylate,O
transportation,O
process,O
might,O
be,O
another,O
potent,O
route,O
for,O
enhancement,O
of,O
α,O
-,O
KG,O
production,O
.,O
The,O
carboxylate,O
transport,O
process,O
of,O
yeast,B-OG
is,O
an,O
intensively,O
investigated,O
field20,O
.,O
The,O
S,B-OG
.,I-OG
cerevisiae,I-OG
ScJEN1,B-GP
and,O
ScADY2,B-GP
genes,O
were,O
identified,O
as,O
key,O
carboxylate,O
transporters2829,O
.,O
The,O
duplication,O
of,O
transporters,B-GP
has,O
been,O
strongly,O
implicated,O
in,O
the,O
utilization,O
of,O
organic,O
acids,O
as,O
a,O
carbon,O
source24,O
.,O
In,O
Kluyveromyces,B-OG
lactis,I-OG
",",O
the,O
presence,O
of,O
two,O
carboxylate,B-GP
transporters,I-GP
",",O
Jen1p,B-GP
and,O
Jen2p,B-GP
",",O
guaranteed,O
efficient,O
uptake,O
of,O
lactic,O
acid,O
as,O
a,O
substrate,O
from,O
a,O
lactic,O
-,O
acid,O
-,O
producing,O
habitat30,O
.,O
As,O
the,O
cells,O
of,O
Y,B-OG
.,I-OG
lipolytica,I-OG
harbored,O
a,O
powerful,O
potential,O
to,O
use,O
a,O
wide,O
range,O
of,O
substrates,O
as,O
a,O
sources,O
of,O
carbon,O
and,O
energy31,O
",",O
these,O
results,O
indicated,O
that,O
powerful,O
carboxylate,B-GP
transporters,I-GP
that,O
maintain,O
intracellular,O
environment,O
homeostasis,O
.,O
A,O
previous,O
study,O
reported,O
that,O
reduction,O
of,O
by,O
-,O
product,O
resulted,O
in,O
enhanced,O
synthesis,O
of,O
target,O
carboxylate,O
by,O
de,O
-,O
repression,O
of,O
the,O
feedback,O
inhibition3,O
.,O
It,O
was,O
speculated,O
that,O
the,O
enhanced,O
synthesis,O
of,O
α,O
-,O
KG,O
could,O
be,O
achieved,O
through,O
de,O
-,O
repression,O
of,O
the,O
feedback,O
inhibition,O
by,O
efflux,O
of,O
intermediates,O
.,O
In,O
Y,B-OG
.,I-OG
lipolytica,I-OG
",",O
efficient,O
carboxylate,O
transport,O
was,O
achieved,O
by,O
the,O
duplication,O
of,O
iso,O
-,O
functional,O
transporters,B-GP
.,O
Evolution,O
analysis,O
and,O
motif,O
identification,O
confirmed,O
that,O
a,O
precursor,O
form,O
of,O
Jen1p,B-GP
",",O
preJen1p,B-GP
",",O
arose,O
from,O
the,O
duplication,O
of,O
an,O
ancestral,O
Jen2p32,O
.,O
In,O
S,B-OG
.,I-OG
cerevisiae,I-OG
",",O
the,O
transport,O
capacity,O
and,O
substrate,O
affinity,O
of,O
Jen1p,B-GP
were,O
determined,O
by,O
the,O
conserved,O
NXXS,O
/,O
THXS,O
/,O
TQDXXXT,O
sequence33,O
.,O
Presence,O
of,O
this,O
signature,O
sequence,O
also,O
determined,O
the,O
flexibility,O
of,O
substrate,O
specificity,O
for,O
these,O
transporters,B-GP
.,O
Previously,O
",",O
Jen1p,B-GP
was,O
induced,O
by,O
lactate,O
",",O
PA,O
",",O
and,O
propionate,O
",",O
whereas,O
Ady2p,B-GP
and,O
Jen2p,B-GP
were,O
induced,O
by,O
acetate2930,O
.,O
Expression,O
of,O
transporters,B-GP
from,O
Y,B-OG
.,I-OG
lipolytica,I-OG
displayed,O
different,O
responses,O
to,O
exogenous,O
carbon,O
source,O
",",O
and,O
single,O
carboxylate,O
induced,O
multiple,O
transporters,B-GP
.,O
The,O
roles,O
of,O
these,O
carboxylate,B-GP
transporters,I-GP
were,O
assayed,O
via,O
double,O
their,O
copy,O
numbers,O
in,O
the,O
genomic,O
DNA,O
of,O
α,O
-,O
KG,O
producer,O
.,O
One,O
more,O
copy,O
of,O
each,O
endogenous,O
carboxylate,B-GP
transporter,I-GP
was,O
observed,O
(,O
Fig,O
.,O
6,O
).,O
Our,O
observation,O
that,O
overexpression,O
of,O
carboxylate,B-GP
transporters,I-GP
resulted,O
in,O
enhanced,O
accumulation,O
of,O
extracellular,O
carboxylates,O
(,O
Fig,O
.,O
7,O
).,O
Previously,O
",",O
uncovered,O
the,O
mechanism,O
for,O
malate,O
efflux,O
was,O
mediated,O
by,O
monoanionic,O
malate,O
concentration,O
gradient,O
",",O
in,O
which,O
the,O
proton,O
symport,O
was,O
major,O
force25,O
.,O
Similar,O
to,O
the,O
observations,O
that,O
production,O
of,O
carboxylate,O
was,O
benefited,O
from,O
overexpression,O
of,O
carboxylate,O
transporter1334,O
",",O
the,O
efflux,O
of,O
carboxylate,O
accompanied,O
by,O
symport,O
of,O
proton,O
was,O
speculated25,O
.,O
Based,O
on,O
measurement,O
of,O
total,O
content,O
of,O
mixture,O
of,O
monoanionic,O
",",O
dianionic,O
and,O
undissociated,O
form,O
of,O
the,O
carboxylates,O
",",O
the,O
intracellular,O
content,O
of,O
carboxylates,O
was,O
not,O
correlated,O
with,O
extracellular,O
carboxylate,O
content,O
.,O
While,O
",",O
the,O
reported,O
carboxylate,B-GP
transporter,I-GP
was,O
specific,O
for,O
monoanionic,O
form,O
of,O
carboxylate,O
for,O
efflux,O
",",O
the,O
efflux,O
specificity,O
of,O
this,O
series,O
of,O
transporter,B-GP
would,O
be,O
the,O
key,O
to,O
the,O
contradictory,O
observation,O
in,O
future,O
studies,O
.,O
Methods,O
Strains,O
and,O
plasmids,O
All,O
strains,O
used,O
in,O
this,O
study,O
were,O
summarized,O
in,O
Table,O
3,O
.,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
",",O
an,O
α,O
-,O
KG,O
producing,O
wild,O
-,O
type,O
strain,O
",",O
was,O
previously,O
screened,O
by,O
our,O
lab35,O
.,O
The,O
plasmid,O
p0,O
(,O
hph,B-GP
),O
was,O
previously,O
constructed,O
based,O
on,O
plasmid,O
p0,O
.,O
The,O
p0,O
could,O
integrate,O
a,O
single,O
copy,O
of,O
exogenous,O
sequence,O
via,O
recombinant,O
at,O
the,O
locus,O
of,O
XRP2,B-GP
in,O
the,O
genome,O
of,O
Y,O
.,O
lipolytica10,O
.,O
The,O
hygromycin,B-GP
phosphotransferase,I-GP
encoded,O
by,O
hph,B-GP
was,O
amplified,O
from,O
plasmid,O
pUB4,O
-,O
CRE,B-GP
and,O
was,O
used,O
to,O
replace,O
the,O
URA3,B-GP
sequence,O
in,O
plasmid,O
p01536,O
.,O
Plasmids,O
were,O
propagated,O
in,O
Escherichia,B-OG
.,I-OG
coli,I-OG
JM109,I-OG
.,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
(,O
MATα,B-GP
",",O
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
),O
from,O
EUROSARF,O
(,O
Frankfurt,O
",",O
Germany,O
),O
and,O
the,O
pY13,O
-,O
TEF1,B-GP
plasmid,O
was,O
used,O
for,O
heterologous,O
expression,O
of,O
potential,O
transporters,B-GP
.,O
Media,O
and,O
culture,O
conditions,O
E,B-OG
.,I-OG
coli,I-OG
was,O
cultured,O
in,O
Luria,O
broth,O
(,O
LB,O
),O
medium,O
(,O
5,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
extract,O
",",O
10,O
g,O
·,O
L,O
−,O
1,O
peptone,O
",",O
10,O
g,O
·,O
L,O
−,O
1,O
NaCl,O
),O
supplemented,O
100,O
mg,O
·,O
L,O
−,O
1,O
ampicillin,O
when,O
necessary,O
.,O
Yeast,B-OG
strains,O
were,O
cultured,O
in,O
YPD,O
medium,O
(,O
10,O
g,O
·,O
L,O
−,O
1yeast,O
extract,O
",",O
20,O
g,O
·,O
L,O
−,O
1,O
peptone,O
",",O
and,O
20,O
g,O
·,O
L,O
−,O
1,O
dextrose,O
),O
or,O
YNB,O
medium,O
(,O
20,O
g,O
·,O
L,O
−,O
1,O
glucose,O
",",O
1,O
.,O
7,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
nitrogen,O
base,O
without,O
amino,O
acids,O
",",O
5,O
g,O
·,O
L,O
−,O
1,O
(,O
NH4,O
),O
2SO4,O
),O
supplemented,O
with,O
50,O
μg,O
·,O
mL,O
−,O
1,O
uracil,O
",",O
leucine,O
",",O
tryptophan,O
and,O
histidine,O
when,O
necessary,O
.,O
The,O
following,O
media,O
were,O
used,O
for,O
carboxylate,O
treatment,O
:,O
YPA,O
(,O
1,O
.,O
7,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
nitrogen,O
base,O
without,O
amino,O
acids,O
",",O
5,O
g,O
·,O
L,O
−,O
1,O
(,O
NH4,O
),O
2SO4,O
",",O
50,O
g,O
·,O
L,O
−,O
1,O
acetate,O
",",O
pH,O
7,O
.,O
0,O
"),",O
YPL,O
(,O
1,O
.,O
7,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
nitrogen,O
base,O
without,O
amino,O
acids,O
",",O
5,O
g,O
·,O
L,O
−,O
1,O
(,O
NH4,O
),O
2SO4,O
",",O
50,O
g,O
·,O
L,O
−,O
1,O
lactate,O
",",O
pH,O
7,O
.,O
0,O
"),",O
YPP,O
(,O
1,O
.,O
7,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
nitrogen,O
base,O
without,O
amino,O
acids,O
",",O
5,O
g,O
·,O
L,O
−,O
1,O
(,O
NH4,O
),O
2SO4,O
",",O
and,O
50,O
g,O
·,O
L,O
−,O
1,O
PA,O
",",O
pH,O
7,O
.,O
0,O
"),",O
YPM,O
(,O
1,O
.,O
7,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
nitrogen,O
base,O
without,O
amino,O
acids,O
",",O
5,O
g,O
·,O
L,O
−,O
1,O
(,O
NH4,O
),O
2SO4,O
",",O
50,O
g,O
·,O
L,O
−,O
1,O
malate,O
",",O
pH,O
7,O
.,O
0,O
"),",O
YPK,O
(,O
10,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
extract,O
without,O
amino,O
acids,O
",",O
5,O
g,O
·,O
L,O
−,O
1,O
(,O
NH4,O
),O
2SO4,O
",",O
and,O
100,O
g,O
·,O
L,O
−,O
1,O
α,O
-,O
KG,O
",",O
pH,O
7,O
.,O
0,O
"),",O
YPC,O
(,O
1,O
.,O
7,O
g,O
·,O
L,O
−,O
1,O
yeast,B-OG
nitrogen,O
base,O
without,O
amino,O
acids,O
",",O
5,O
g,O
·,O
L,O
−,O
1,O
(,O
NH4,O
),O
2SO4,O
",",O
50,O
g,O
·,O
L,O
−,O
1,O
citrate,O
",",O
pH,O
7,O
.,O
0,O
).,O
The,O
seed,O
-,O
culture,O
media,O
(,O
dextrose,O
",",O
20,O
g,O
·,O
L,O
−,O
1,O
;,O
peptone,O
",",O
10,O
g,O
·,O
L,O
−,O
1,O
;,O
KH2PO4,O
",",O
1,O
g,O
·,O
L,O
−,O
1,O
;,O
and,O
MgSO4,O
·,O
7H2O,O
",",O
0,O
.,O
5,O
g,O
·,O
L,O
−,O
1,O
",",O
pH,O
5,O
.,O
5,O
),O
and,O
fermentation,O
media,O
(,O
glycerol,O
",",O
100,O
g,O
·,O
L,O
−,O
1,O
;,O
(,O
NH4,O
),O
2SO4,O
",",O
3,O
g,O
·,O
L,O
−,O
1,O
;,O
KH2PO4,O
",",O
3,O
g,O
·,O
L,O
−,O
1,O
;,O
MgSO4,O
·,O
7H2O,O
",",O
1,O
.,O
2,O
g,O
·,O
L,O
−,O
1,O
;,O
NaCl,O
",",O
0,O
.,O
5,O
g,O
·,O
L,O
−,O
1,O
;,O
K2HPO4,O
",",O
0,O
.,O
1,O
g,O
·,O
L,O
−,O
1,O
;,O
and,O
thiamine,O
-,O
HCl,O
4,O
×,O
10,O
−,O
7,O
g,O
·,O
L,O
−,O
1,O
",",O
pH,O
4,O
.,O
5,O
),O
were,O
described,O
previously37,O
.,O
Bioinformatic,O
analysis,O
and,O
genome,O
-,O
wide,O
prediction,O
of,O
transmembrane,B-GP
proteins,I-GP
The,O
6611,O
putative,O
proteins,O
encoded,O
by,O
Y,B-OG
.,I-OG
lipolytica,I-OG
CLIB122,I-OG
genomic,O
DNA,O
were,O
obtained,O
from,O
UniProt,O
(,O
http,O
://,O
www,O
.,O
uniprot,O
.,O
org,O
/).,O
A,O
genome,O
-,O
wide,O
analysis,O
using,O
a,O
transmembrane,O
-,O
helix,O
sequence,O
was,O
performed,O
following,O
a,O
method,O
described,O
previously3839,O
.,O
For,O
each,O
protein,O
",",O
the,O
transmembrane,B-GP
protein,I-GP
topology,O
was,O
predicted,O
using,O
TMHMM,O
(,O
http,O
://,O
www,O
.,O
cbs,O
.,O
dtu,O
.,O
dk,O
/,O
services,O
/,O
TMHMM,O
/).,O
The,O
predicted,O
result,O
was,O
visualized,O
using,O
the,O
TMRPres2D,O
tool40,O
.,O
The,O
following,O
values,O
were,O
used,O
to,O
discriminate,O
helical,O
proteins,O
from,O
other,O
proteins41,O
:,O
(,O
i,O
),O
the,O
number,O
of,O
predicted,O
transmembrane,O
helices,O
;,O
(,O
ii,O
),O
the,O
expected,O
number,O
of,O
residues,O
in,O
the,O
transmembrane,O
helices,O
;,O
and,O
(,O
iii,O
),O
the,O
expected,O
number,O
of,O
transmembrane,O
helices,O
.,O
To,O
avoid,O
false,O
prediction,O
",",O
we,O
also,O
analyzed,O
all,O
proteins,O
with,O
putative,O
transmembrane,O
helices,O
at,O
the,O
N,O
terminus,O
with,O
SignalP,O
(,O
http,O
://,O
www,O
.,O
cbs,O
.,O
dtu,O
.,O
dk,O
/,O
services,O
/,O
SignalP,O
/),O
to,O
predict,O
whether,O
the,O
sequence,O
encoded,O
a,O
signal,O
peptide42,O
.,O
All,O
screened,O
transmembrane,B-GP
proteins,I-GP
were,O
used,O
for,O
sequence,O
-,O
similarity,O
searches,O
using,O
BLAST,O
(,O
http,O
://,O
blast,O
.,O
ncbi,O
.,O
nlm,O
.,O
nih,O
.,O
gov,O
/),O
to,O
identify,O
orthologs,O
that,O
have,O
been,O
characterized,O
as,O
carboxylate,B-GP
transporters,I-GP
.,O
Keto,O
acid,O
treatment,O
The,O
cells,O
of,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
were,O
streaked,O
onto,O
YPD,O
slants,O
from,O
glycerol,O
stocks,O
.,O
Cells,O
grown,O
in,O
glucose,O
were,O
harvested,O
at,O
the,O
exponential,O
phase,O
.,O
After,O
a,O
2,O
h,O
treatment,O
in,O
saline,O
water,O
",",O
cells,O
were,O
transferred,O
to,O
100,O
mL,O
YPK,O
or,O
100,O
mL,O
YPP,O
and,O
incubated,O
at,O
28,O
°,O
C,O
.,O
PA,O
-,O
or,O
α,O
-,O
KG,O
-,O
treated,O
cells,O
were,O
collected,O
at,O
regular,O
time,O
intervals,O
for,O
quantitative,O
real,O
-,O
time,O
PCR,O
(,O
qRT,O
-,O
PCR,O
),O
analysis,O
and,O
determination,O
of,O
intracellular,O
carboxylate,O
content,O
.,O
YPA,O
",",O
YPL,O
",",O
YPP,O
",",O
YPM,O
",",O
YPK,O
",",O
and,O
YPC,O
media,O
",",O
supplemented,O
as,O
necessary,O
with,O
50,O
μg,O
·,O
mL,O
−,O
1,O
uracil,O
",",O
leucine,O
",",O
tryptophan,O
",",O
and,O
histidine,O
",",O
were,O
used,O
to,O
assay,O
carboxylate,O
transportation,O
of,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
cells,O
and,O
derivatives,O
.,O
Yeast,B-OG
cells,O
were,O
harvested,O
by,O
centrifugation,O
at,O
10,O
",",O
000,O
×,O
g,O
for,O
10,O
min,O
",",O
and,O
washed,O
twice,O
with,O
cold,O
distilled,O
water,O
.,O
The,O
dry,O
cell,O
weight,O
was,O
determined,O
according,O
to,O
protocol,O
described,O
previously37,O
.,O
The,O
intracellular,O
carboxylate,O
content,O
was,O
determined,O
according,O
to,O
the,O
method,O
previously,O
",",O
with,O
little,O
modification43,O
.,O
Harvested,O
cells,O
were,O
stored,O
in,O
liquid,O
nitrogen,O
until,O
extraction,O
of,O
intracellular,O
organic,O
acid,O
which,O
was,O
followed,O
by,O
cell,O
disruption,O
of,O
according,O
to,O
a,O
protocol,O
described,O
previously44,O
.,O
Supernatants,O
were,O
used,O
for,O
determination,O
of,O
intracellular,O
carboxylate,O
concentrations,O
by,O
high,O
-,O
performance,O
liquid,O
chromatography,O
(,O
HPLC,O
).,O
The,O
intracellular,O
concentration,O
of,O
carboxylate,O
was,O
expressed,O
in,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
.,O
Quantitative,O
real,O
-,O
time,O
PCR,O
analysis,O
The,O
cells,O
of,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
were,O
harvested,O
",",O
centrifuged,O
at,O
10,O
",",O
000,O
×,O
g,O
for,O
10,O
min,O
",",O
and,O
immediately,O
frozen,O
in,O
liquid,O
nitrogen,O
until,O
RNA,O
extraction,O
.,O
Total,O
RNA,O
was,O
extracted,O
using,O
Trizol,O
reagent,O
(,O
Life,O
Technologies,O
",",O
Carlsbad,O
",",O
CA,O
"),",O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
cDNA,O
was,O
synthesized,O
from,O
5,O
μg,O
total,O
RNA,O
using,O
the,O
PrimeScript,O
RT,O
Reagent,O
Kit,O
Perfect,O
Real,O
Time,O
(,O
Takara,O
",",O
Dalian,O
",",O
China,O
).,O
qRT,O
-,O
PCR,O
was,O
performed,O
with,O
the,O
synthesized,O
cDNA,O
and,O
primers,O
listed,O
in,O
Table,O
4,O
using,O
the,O
SYBR,O
Premix,O
Ex,O
TaqTM,O
Kit,O
(,O
Taraka,O
",",O
Dalian,O
",",O
China,O
),O
and,O
a,O
LightCycler,O
480,O
II,O
Real,O
-,O
time,O
PCR,O
instrument,O
(,O
Roche,O
Applied,O
Science,O
",",O
Mannheim,O
",",O
Germany,O
).,O
All,O
experiments,O
were,O
performed,O
in,O
triplicate,O
and,O
mean,O
values,O
were,O
used,O
for,O
further,O
calculations,O
.,O
Fold,O
changes,O
were,O
determined,O
by,O
the,O
2,O
-,O
ΔΔCT,O
method,O
and,O
normalized,O
to,O
the,O
ACT1,B-GP
gene45,O
.,O
Disruption,O
of,O
the,O
ScJEN1,B-GP
and,O
ScADY2,B-GP
genes,O
in,O
S,B-OG
.,I-OG
cerevisiae,I-OG
To,O
disrupt,O
the,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
JEN1,B-GP
and,O
ADY2,B-GP
genes,O
",",O
two,O
disruption,O
cassettes,O
were,O
constructed,O
using,O
a,O
protocol,O
described,O
previously46,O
.,O
The,O
loxP,O
-,O
URA3,B-GP
-,O
loxP,O
and,O
loxP,O
-,O
LEU2,B-GP
-,O
loxP,O
modules,O
were,O
amplified,O
from,O
plasmids,O
pUG72,O
and,O
pUG73,O
",",O
respectively,O
",",O
with,O
oligonucleotides,O
JEN,B-GP
-,O
MF,O
/,O
JEN,B-GP
-,O
MR,O
",",O
ADY,B-GP
-,O
MF,O
/,O
ADY,B-GP
-,O
MR,O
",",O
respectively,O
(,O
Table,O
5,O
).,O
Two,O
fragments,O
of,O
ScJEN1,B-GP
were,O
amplified,O
from,O
S,B-OG
.,I-OG
cerevisiae,I-OG
genomic,O
DNA,O
and,O
were,O
subsequently,O
flanked,O
by,O
the,O
loxP,O
-,O
URA3,B-GP
-,O
loxP,O
module,O
to,O
generate,O
the,O
JEN1,B-GP
disruption,O
cassette,O
.,O
ScADY2,B-GP
fragments,O
",",O
PCR,O
-,O
amplified,O
from,O
S,B-OG
.,I-OG
cerevisiae,I-OG
genomic,O
DNA,O
",",O
were,O
flanked,O
with,O
the,O
loxP,O
-,O
LEU2,B-GP
-,O
loxP,O
module,O
to,O
generate,O
the,O
ADY2,B-GP
disruption,O
cassette,O
.,O
The,O
disruption,O
cassettes,O
were,O
introduced,O
into,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
with,O
a,O
previously,O
described,O
protocol46,O
",",O
and,O
the,O
resulting,O
line,O
",",O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1,O
",",O
is,O
referred,O
to,O
as,O
W1,O
.,O
The,O
ADY2,B-GP
disruption,O
cassette,O
was,O
introduced,O
into,O
this,O
W1,O
strain,O
",",O
and,O
the,O
resulting,O
double,O
deletion,O
strain,O
is,O
referred,O
to,O
as,O
W2,O
.,O
Heterologous,O
expression,O
of,O
putative,O
transporter,B-GP
genes,O
in,O
S,B-OG
.,I-OG
cerevisiae,I-OG
W2,I-OG
Six,O
putative,O
transporter,B-GP
genes,O
",",O
YALI0B19470g,B-GP
",",O
YALI0C15488g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
YALI0D20108g,B-GP
",",O
and,O
YALI0E32901g,B-GP
",",O
were,O
amplified,O
from,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
genomic,O
DNA,O
with,O
the,O
primers,O
listed,O
in,O
Table,O
6,O
.,O
The,O
amplified,O
fragments,O
were,O
introduced,O
into,O
BamHI,B-GP
–,O
EcoRI,B-GP
sites,O
of,O
the,O
pY13,O
-,O
TEF1,B-GP
expression,O
vector,O
",",O
resulting,O
in,O
the,O
pY13,O
-,O
TEF1,B-GP
-,O
470,O
",",O
pY13,O
-,O
TEF1,B-GP
-,O
488,O
",",O
pY13,O
-,O
TEF1,B-GP
-,O
406,O
",",O
pY13,O
-,O
TEF1,B-GP
-,O
607,O
",",O
pY13,O
-,O
TEF1,B-GP
-,O
108,O
",",O
and,O
pY13,O
-,O
TEF1,B-GP
-,O
901,O
plasmids,O
",",O
respectively,O
.,O
These,O
vectors,O
were,O
introduced,O
into,O
S,B-OG
.,I-OG
cerevisiae,I-OG
W2,I-OG
using,O
a,O
previously,O
described,O
protocol,O
",",O
and,O
the,O
resulting,O
lines,O
are,O
referred,O
to,O
as,O
W3,O
",",O
W4,O
",",O
W5,O
",",O
W6,O
",",O
W7,O
",",O
and,O
W8,O
",",O
respectively,O
.,O
Overexpression,O
of,O
putative,O
transporter,B-GP
genes,O
in,O
Y,B-OG
.,I-OG
lipolytica,I-OG
The,O
YALI0B19470g,B-GP
",",O
YALI0C15488g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
YALI0D20108g,B-GP
",",O
and,O
YALI0E32901g,B-GP
open,O
reading,O
frames,O
were,O
PCR,O
-,O
amplified,O
from,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
genomic,O
DNA,O
with,O
the,O
oligonucleotides,O
listed,O
in,O
Table,O
7,O
.,O
The,O
amplified,O
fragments,O
were,O
digested,O
with,O
Eco,B-GP
RI,I-GP
and,O
Bam,B-GP
HI,I-GP
or,O
Not,B-GP
I,I-GP
and,O
were,O
subsequently,O
inserted,O
into,O
the,O
integrative,O
expression,O
vector,O
p0,O
(,O
hph,B-GP
"),",O
resulting,O
in,O
p0,O
(,O
hph,B-GP
)-,O
470,O
",",O
p0,O
(,O
hph,B-GP
)-,O
488,O
",",O
p0,O
(,O
hph,B-GP
)-,O
406,O
",",O
p0,O
(,O
hph,B-GP
)-,O
607,O
",",O
p0,O
(,O
hph,B-GP
)-,O
108,O
",",O
and,O
p0,O
(,O
hph,B-GP
)-,O
901,O
",",O
respectively,O
.,O
These,O
vectors,O
were,O
digested,O
with,O
AvrII,B-GP
",",O
purified,O
",",O
and,O
transformed,O
into,O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
using,O
a,O
previously,O
described,O
protocol47,O
.,O
The,O
resulting,O
transformants,O
",",O
Y,B-OG
.,I-OG
lipolytica,I-OG
T1,O
",",O
T2,O
",",O
T3,O
",",O
T4,O
",",O
T5,O
",",O
and,O
T6,O
",",O
respectively,O
",",O
were,O
screened,O
on,O
YPD,O
plates,O
containing,O
400,O
mg,O
·,O
L,O
−,O
1,O
hygromycin,O
B,O
and,O
verified,O
with,O
the,O
oligonucleotides,O
listed,O
in,O
Table,O
7,O
.,O
Copy,O
number,O
analysis,O
In,O
order,O
to,O
determine,O
the,O
copy,O
number,O
of,O
the,O
integrative,O
expression,O
cassettes,O
in,O
the,O
recombinant,O
strains,O
",",O
a,O
qPCR,O
analysis,O
was,O
performed,O
on,O
the,O
genomic,O
DNA,O
template,O
using,O
ACT1,B-GP
as,O
the,O
internal,O
control26,O
.,O
Genomic,O
DNA,O
from,O
parental,O
strain,O
(,O
WSH,O
-,O
Z06,O
),O
and,O
six,O
recombinant,O
strains,O
(,O
T1,O
",",O
T2,O
",",O
T3,O
",",O
T4,O
",",O
T5,O
and,O
T6,O
),O
were,O
isolated,O
after,O
disruption,O
of,O
yeast,B-OG
cells,O
with,O
glass,O
beads,O
(,O
Sigma,O
-,O
Aldrich,O
",",O
St,O
.,O
Louis,O
",",O
MI,O
),O
by,O
FastPrep,O
24,O
(,O
MP,O
Biomedicals,O
",",O
Santa,O
Ana,O
",",O
CA,O
).,O
qPCR,O
was,O
performed,O
with,O
the,O
5,O
ng,O
genomic,O
DNA,O
and,O
primers,O
listed,O
in,O
Table,O
4,O
using,O
the,O
SYBR,O
Premix,O
Ex,O
TaqTM,O
Kit,O
(,O
Taraka,O
",",O
Dalian,O
",",O
China,O
),O
and,O
a,O
LightCycler,O
480,O
II,O
Real,O
-,O
time,O
PCR,O
instrument,O
(,O
Roche,O
Applied,O
Science,O
",",O
Mannheim,O
",",O
Germany,O
).,O
All,O
experiments,O
were,O
performed,O
in,O
triplicate,O
and,O
mean,O
values,O
were,O
used,O
for,O
further,O
calculations,O
.,O
Fold,O
changes,O
were,O
determined,O
by,O
the,O
2,O
−,O
ΔΔCT,O
method,O
and,O
normalized,O
to,O
the,O
ACT1,B-GP
gene45,O
.,O
Shake,O
flask,O
culture,O
Shake,O
flask,O
culture,O
was,O
performed,O
in,O
500,O
mL,O
flasks,O
containing,O
50,O
mL,O
fermentation,O
medium,O
following,O
the,O
protocol,O
stated,O
previously35,O
.,O
A,O
yeast,B-OG
seed,O
culture,O
was,O
inoculated,O
from,O
an,O
agar,O
slant,O
and,O
incubated,O
in,O
a,O
500,O
mL,O
flask,O
containing,O
50,O
mL,O
medium,O
for,O
18,O
h,O
on,O
a,O
rotary,O
shaker,O
at,O
28,O
°,O
C,O
.,O
The,O
culture,O
was,O
used,O
to,O
inoculate,O
500,O
mL,O
flasks,O
containing,O
50,O
mL,O
fermentation,O
medium,O
.,O
An,O
inoculum,O
volume,O
of,O
10,O
%,O
(,O
v,O
/,O
v,O
),O
was,O
used,O
for,O
α,O
-,O
KG,O
accumulation,O
assay,O
.,O
Flask,O
cultures,O
were,O
incubated,O
in,O
a,O
shaker,O
at,O
200,O
r,O
·,O
min,O
−,O
1,O
for,O
144,O
h,O
at,O
28,O
°,O
C,O
.,O
HPLC,O
analysis,O
Samples,O
taken,O
from,O
shake,O
flask,O
culture,O
were,O
centrifuged,O
at,O
10,O
",",O
000,O
×,O
g,O
for,O
10,O
min,O
.,O
The,O
supernatant,O
was,O
diluted,O
50,O
times,O
and,O
filtered,O
through,O
a,O
membrane,O
(,O
pore,O
size,O
=,O
0,O
.,O
22,O
μm,O
).,O
α,O
-,O
KG,O
",",O
pyruvic,O
acid,O
",",O
acetate,O
",",O
lactate,O
",",O
malate,O
",",O
and,O
citrate,O
present,O
in,O
the,O
supernatant,O
were,O
simultaneously,O
determined,O
by,O
HPLC,O
(,O
Agilent,O
1200,O
series,O
",",O
Santa,O
Clara,O
",",O
CA,O
",",O
USA,O
),O
with,O
an,O
Aminex,O
HPX,O
-,O
87H,O
column,O
(,O
300,O
mm,O
×,O
7,O
.,O
8,O
mm,O
;,O
Bio,O
-,O
Rad,O
Laboratories,O
Inc,O
".,",O
Hercules,O
",",O
CA,O
",",O
USA,O
).,O
The,O
mobile,O
phase,O
was,O
5,O
mmol,O
L,O
−,O
1,O
sulfuric,O
acid,O
in,O
distilled,O
",",O
de,O
-,O
ionized,O
water,O
filtered,O
to,O
0,O
.,O
22,O
μm,O
.,O
The,O
mobile,O
phase,O
flow,O
rate,O
was,O
0,O
.,O
6,O
mL,O
min,O
−,O
1,O
.,O
The,O
column,O
temperature,O
was,O
maintained,O
at,O
35,O
°,O
C,O
",",O
and,O
the,O
injection,O
volume,O
was,O
10,O
μL,O
.,O
α,O
-,O
KG,O
",",O
pyruvic,O
acid,O
",",O
acetate,O
",",O
lactate,O
",",O
malate,O
",",O
and,O
citrate,O
were,O
detected,O
with,O
a,O
UV,O
detector,O
(,O
wavelength,O
at,O
210,O
nm,O
),O
37,O
.,O
To,O
determine,O
the,O
intracellular,O
carboxylates,O
",",O
cells,O
taken,O
from,O
shake,O
flask,O
culture,O
were,O
disrupted,O
and,O
lysates,O
were,O
centrifuged,O
at,O
10,O
",",O
000,O
×,O
g,O
for,O
10,O
min,O
.,O
The,O
carboxylate,O
content,O
in,O
supernatant,O
was,O
determined,O
by,O
HPLC,O
followed,O
the,O
protocol,O
above,O
.,O
Author,O
Contributions,O
G,O
.,O
H,O
.,O
W,O
.,O
and,O
Z,O
.,O
J,O
.,O
W,O
.,O
designed,O
the,O
experiments,O
and,O
wrote,O
the,O
paper,O
.,O
G,O
.,O
H,O
.,O
W,O
.,O
and,O
L,O
.,O
P,O
.,O
R,O
.,O
performed,O
the,O
experiments,O
.,O
G,O
.,O
C,O
.,O
D,O
.,O
and,O
J,O
.,O
C,O
.,O
conceived,O
the,O
project,O
",",O
analyzed,O
the,O
data,O
and,O
wrote,O
the,O
paper,O
.,O
C,O
.,O
M,O
.,O
analyzed,O
the,O
data,O
.,O
Supplementary,O
Material,O
Supplementary,O
Information,O
(,O
A,O
),O
Number,O
of,O
predicted,O
transmembrane,O
helices,O
in,O
identified,O
putative,O
membrane,B-GP
proteins,I-GP
.,O
(,O
B,O
),O
Multiple,O
sequence,O
alignment,O
of,O
amino,O
acids,O
sequences,O
from,O
available,O
yeast,B-OG
carboxylate,B-GP
transporter,I-GP
sequences,O
.,O
The,O
results,O
showed,O
that,O
28,O
orthologs,O
of,O
the,O
JEN,B-GP
family,O
from,O
Aspergillus,B-OG
oryzae,I-OG
",",O
Aspergillus,B-OG
fumigatus,I-OG
",",O
Aspergillus,B-OG
nidulans,I-OG
",",O
Y,B-OG
.,I-OG
lipolytica,I-OG
",",O
Kluyveromyces,B-OG
lactis,I-OG
",",O
Candida,B-OG
albicans,I-OG
",",O
Kluyveromyces,B-OG
thermotolerans,I-OG
",",O
S,B-OG
.,I-OG
cerevisiae,I-OG
",",O
Debaryomyces,B-OG
hansenii,I-OG
and,O
Neurospora,B-OG
crassa,I-OG
had,O
highly,O
conserved,O
sequences,O
.,O
The,O
name,O
of,O
these,O
orthologs,O
was,O
based,O
on,O
protein,O
ID,O
in,O
NCBI,O
database,O
",",O
as,O
one,O
potential,O
JEN1,B-GP
from,O
N,B-OG
.,I-OG
crassa,I-OG
could,O
not,O
find,O
in,O
the,O
database,O
",",O
it,O
was,O
named,O
as,O
Q9P732,O
based,O
on,O
protein,O
ID,O
from,O
Uniprot,O
.,O
The,O
phylogenetic,O
tree,O
of,O
carboxylate,O
proteins,O
was,O
constructed,O
using,O
the,O
neighbor,O
-,O
joining,O
method,O
.,O
Bootstrap,O
values,O
>,O
50,O
%,O
are,O
shown,O
at,O
the,O
branch,O
points,O
.,O
One,O
thousand,O
bootstrap,O
replications,O
were,O
performed,O
using,O
the,O
MEGA,O
5,O
.,O
0,O
software48,O
.,O
(,O
A,O
),O
YALI0B19470p,B-GP
",",O
(,O
B,O
),O
YALI0C15488p,B-GP
",",O
(,O
C,O
),O
YALI0C21406p,B-GP
",",O
(,O
D,O
),O
YALI0D24607p,B-GP
",",O
(,O
E,O
),O
YALI0D20108p,B-GP
",",O
(,O
F,O
),O
YALI0E32901p,B-GP
.,O
The,O
conserved,O
signature,O
sequence,O
was,O
illustrated,O
in,O
red,O
in,O
every,O
putative,O
carboxylate,B-GP
transporter,I-GP
.,O
(,O
A,O
),O
Open,O
square,O
:,O
α,O
-,O
KG,O
",",O
open,O
circle,O
:,O
PA,O
.,O
The,O
change,O
of,O
concentration,O
of,O
α,O
-,O
KG,O
and,O
PA,O
exhibited,O
the,O
same,O
trend,O
during,O
throughout,O
the,O
treatment,O
.,O
(,O
B,O
),O
Expression,O
profile,O
of,O
putative,O
transporter,B-GP
genes,O
at,O
1,O
h,O
",",O
at,O
which,O
time,O
the,O
intracellular,O
contents,O
of,O
α,O
-,O
KG,O
and,O
PA,O
were,O
greatest,O
.,O
White,O
:,O
PA,O
treatment,O
;,O
black,O
:,O
α,O
-,O
KG,O
treatment,O
.,O
WT,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
;,O
W1,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1,O
;,O
W2,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
;,O
W3,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
470,O
);,O
W4,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
488,O
);,O
W5,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
406,O
);,O
W6,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
607,O
);,O
W7,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
108,O
);,O
W8,O
:,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
901,O
).,O
(,O
A,O
),O
YPD,O
",",O
(,O
B,O
),O
YPA,O
",",O
(,O
C,O
),O
YPL,O
",",O
(,O
D,O
),O
YPP,O
",",O
(,O
E,O
),O
YPM,O
",",O
(,O
F,O
),O
YPK,O
",",O
(,O
G,O
),O
YPC,O
.,O
Copy,O
number,O
of,O
YALI0B19470g,B-GP
in,O
T1,O
",",O
YALI0C15488g,B-GP
in,O
T2,O
",",O
YALI0C21406g,B-GP
in,O
T3,O
",",O
YALI0D24607g,B-GP
in,O
T4,O
",",O
YALI0D20108g,B-GP
in,O
T5,O
and,O
YALI0E32901g,B-GP
in,O
T6,O
were,O
determined,O
through,O
qPCR,O
analysis,O
.,O
As,O
ACT1,B-GP
existed,O
in,O
one,O
copy,O
per,O
Y,B-OG
.,I-OG
lipolytica,I-OG
genome,O
",",O
copy,O
number,O
of,O
putative,O
transporter,B-GP
genes,O
in,O
wild,O
-,O
type,O
strain,O
(,O
white,O
),O
and,O
recombinants,O
(,O
grey,O
),O
was,O
expressed,O
as,O
relative,O
change,O
.,O
With,O
comparison,O
to,O
ACT1,B-GP
",",O
one,O
more,O
copy,O
of,O
each,O
transporter,B-GP
gene,O
was,O
determined,O
in,O
corresponding,O
recombinants,O
.,O
RNA,O
extracted,O
from,O
glucose,O
-,O
grown,O
cells,O
of,O
the,O
T1,O
",",O
T2,O
",",O
T3,O
",",O
T4,O
",",O
T5,O
",",O
and,O
T6,O
strains,O
was,O
subjected,O
to,O
qRT,O
-,O
PCR,O
.,O
The,O
strains,O
T1,O
-,O
T6,O
were,O
mutant,O
variants,O
in,O
which,O
plasmid,O
p0,O
(,O
hph,B-GP
)-,O
470,O
",",O
p0,O
(,O
hph,B-GP
)-,O
488,O
",",O
p0,O
(,O
hph,B-GP
)-,O
406,O
p0,O
(,O
hph,B-GP
)-,O
607,O
",",O
p0,O
(,O
hph,B-GP
)-,O
108,O
and,O
p0,O
(,O
hph,B-GP
)-,O
901,O
were,O
individually,O
expressed,O
in,O
the,O
wild,O
-,O
type,O
strain,O
.,O
The,O
transcription,O
of,O
YALI0B19470g,B-GP
",",O
YALI0C15488g,B-GP
",",O
YALI0C21406g,B-GP
",",O
YALI0D24607g,B-GP
",",O
YALI0D20108g,B-GP
",",O
and,O
YALI0E32901g,B-GP
increased,O
by,O
23,O
.,O
34,O
±,O
2,O
.,O
67,O
-,O
fold,O
",",O
8,O
.,O
53,O
±,O
0,O
.,O
90,O
-,O
fold,O
",",O
9,O
.,O
32,O
±,O
0,O
.,O
82,O
-,O
fold,O
",",O
11,O
.,O
79,O
±,O
1,O
.,O
32,O
-,O
fold,O
",",O
3,O
.,O
37,O
±,O
0,O
.,O
49,O
-,O
fold,O
and,O
10,O
.,O
50,O
±,O
0,O
.,O
97,O
-,O
fold,O
",",O
respectively,O
.,O
White,O
:,O
α,O
-,O
KG,O
;,O
black,O
:,O
PA,O
.,O
The,O
strains,O
T1,O
–,O
T6,O
were,O
mutant,O
variants,O
in,O
which,O
plasmid,O
p0,O
(,O
hph,B-GP
)-,O
470,O
",",O
p0,O
(,O
hph,B-GP
)-,O
488,O
",",O
p0,O
(,O
hph,B-GP
)-,O
406,O
p0,O
(,O
hph,B-GP
)-,O
607,O
",",O
p0,O
(,O
hph,B-GP
)-,O
108,O
and,O
p0,O
(,O
hph,B-GP
)-,O
901,O
were,O
individually,O
expressed,O
in,O
the,O
wild,O
-,O
type,O
strain,O
.,O
The,O
transport,O
of,O
PA,O
was,O
enhanced,O
in,O
all,O
mutants,O
except,O
the,O
T1,O
strain,O
.,O
Extracellular,O
PA,O
concentration,O
increased,O
from,O
17,O
.,O
77,O
±,O
0,O
.,O
72,O
g,O
·,O
L,O
−,O
1,O
to,O
20,O
.,O
22,O
±,O
0,O
.,O
98,O
",",O
20,O
.,O
95,O
±,O
0,O
.,O
62,O
",",O
21,O
.,O
06,O
±,O
1,O
.,O
03,O
",",O
23,O
.,O
53,O
±,O
0,O
.,O
98,O
",",O
and,O
21,O
.,O
79,O
±,O
1,O
.,O
0,O
0,O
g,O
·,O
L,O
−,O
1,O
in,O
cells,O
of,O
the,O
T2,O
",",O
T3,O
",",O
T4,O
",",O
T5,O
",",O
and,O
T6,O
strains,O
",",O
respectively,O
",",O
and,O
decreased,O
by,O
30,O
.,O
6,O
%,O
to,O
the,O
concentration,O
of,O
12,O
.,O
32,O
±,O
1,O
.,O
31,O
g,O
·,O
L,O
−,O
1,O
for,O
T1,O
strain,O
.,O
The,O
content,O
of,O
α,O
-,O
KG,O
varied,O
slightly,O
in,O
strain,O
T2,O
",",O
T3,O
",",O
T4,O
and,O
T6,O
",",O
while,O
the,O
content,O
of,O
the,O
dicarboxylate,O
increased,O
to,O
46,O
.,O
66,O
±,O
2,O
.,O
59,O
-,O
and,O
44,O
.,O
02,O
±,O
1,O
.,O
87,O
g,O
·,O
L,O
−,O
1,O
in,O
strain,O
T1,O
and,O
T5,O
.,O
Strain,O
Genotype,O
Acetate,O
Lactate,O
PA,O
Malate,O
α,O
-,O
KG,O
Citrate,O
WT,O
S,B-OG
.,I-OG
cerevisiae,I-OG
",",I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
/*,O
2,O
.,O
22,O
±,O
0,O
.,O
21,O
0,O
.,O
94,O
±,O
0,O
.,O
12,O
3,O
.,O
14,O
±,O
0,O
.,O
24,O
1,O
.,O
29,O
±,O
0,O
.,O
12,O
/,O
W1,O
S,B-OG
.,I-OG
cerevisiae,I-OG
",",I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1,O
/,O
/,O
/,O
0,O
.,O
05,O
±,O
0,O
.,O
01,O
0,O
.,O
86,O
±,O
0,O
.,O
08,O
/,O
W2,O
S,B-OG
.,I-OG
cerevisiae,I-OG
",",I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
Δjen1Δady2,O
/,O
/,O
/,O
/,O
/,O
/,O
W3,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
",",O
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
470,O
),O
/,O
/,O
/,O
0,O
.,O
15,O
±,O
0,O
.,O
01,O
0,O
.,O
09,O
±,O
0,O
.,O
01,O
0,O
.,O
04,O
±,O
0,O
.,O
01,O
W4,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
",",O
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
488,O
),O
0,O
.,O
81,O
±,O
0,O
.,O
07,O
/,O
0,O
.,O
17,O
±,O
0,O
.,O
03,O
0,O
.,O
11,O
±,O
0,O
.,O
01,O
1,O
.,O
41,O
±,O
0,O
.,O
19,O
0,O
.,O
08,O
±,O
0,O
.,O
01,O
W5,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
",",O
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
406,O
),O
/,O
0,O
.,O
53,O
±,O
0,O
.,O
04,O
/,O
0,O
.,O
09,O
±,O
0,O
.,O
01,O
0,O
.,O
77,O
±,O
0,O
.,O
06,O
0,O
.,O
04,O
±,O
0,O
.,O
01,O
W6,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
",",O
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
607,O
),O
/,O
/,O
/,O
0,O
.,O
09,O
±,O
0,O
.,O
01,O
0,O
.,O
56,O
±,O
0,O
.,O
06,O
0,O
.,O
05,O
±,O
0,O
.,O
01,O
W7,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
",",O
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
108,O
),O
/,O
0,O
.,O
67,O
±,O
0,O
.,O
09,O
/,O
/,O
0,O
.,O
38,O
±,O
0,O
.,O
04,O
0,O
.,O
09,O
±,O
0,O
.,O
01,O
W8,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
",",O
Δjen1Δady2,O
(,O
pY13,O
-,O
TEF1,B-GP
-,O
901,O
),O
0,O
.,O
66,O
±,O
0,O
.,O
04,O
/,O
/,O
0,O
.,O
11,O
±,O
0,O
.,O
01,O
0,O
.,O
39,O
±,O
0,O
.,O
03,O
0,O
.,O
03,O
±,O
0,O
.,O
01,O
Cin,O
(,O
μmol,O
·(,O
mg,O
·,O
DCW,O
)−,O
1,O
),O
Ratioex,O
/,O
in,O
Strain,O
DCW,O
(,O
g,O
·,O
L,O
−,O
1,O
),O
α,O
-,O
KG,O
PA,O
Yα,O
-,O
KG,O
/,O
DCW,O
(,O
g,O
·,O
g,O
−,O
1,O
),O
YPA,O
/,O
DCW,O
(,O
g,O
·,O
g,O
−,O
1,O
),O
α,O
-,O
KG,O
PA,O
WSH,O
-,O
Z06,O
11,O
.,O
17,O
±,O
1,O
.,O
08,O
0,O
.,O
026,O
±,O
0,O
.,O
005,O
0,O
.,O
034,O
±,O
0,O
.,O
006,O
3,O
.,O
28,O
±,O
0,O
.,O
32,O
0,O
.,O
23,O
±,O
0,O
.,O
03,O
860,O
.,O
35,O
±,O
78,O
.,O
45,O
531,O
.,O
45,O
±,O
48,O
.,O
97,O
T1,O
8,O
.,O
45,O
±,O
0,O
.,O
72,O
0,O
.,O
014,O
±,O
0,O
.,O
002,O
0,O
.,O
009,O
±,O
0,O
.,O
002,O
4,O
.,O
94,O
±,O
0,O
.,O
52,O
0,O
.,O
30,O
±,O
0,O
.,O
04,O
2399,O
.,O
71,O
±,O
241,O
.,O
63,O
1685,O
.,O
20,O
±,O
208,O
.,O
56,O
T2,O
8,O
.,O
27,O
±,O
0,O
.,O
89,O
0,O
.,O
027,O
±,O
0,O
.,O
003,O
0,O
.,O
032,O
±,O
0,O
.,O
004,O
3,O
.,O
90,O
±,O
0,O
.,O
42,O
0,O
.,O
25,O
±,O
0,O
.,O
03,O
975,O
.,O
27,O
±,O
109,O
.,O
21,O
769,O
.,O
61,O
±,O
84,O
.,O
21,O
T3,O
8,O
.,O
34,O
±,O
0,O
.,O
76,O
0,O
.,O
030,O
±,O
0,O
.,O
005,O
0,O
.,O
033,O
±,O
0,O
.,O
005,O
4,O
.,O
13,O
±,O
0,O
.,O
44,O
0,O
.,O
24,O
±,O
0,O
.,O
02,O
938,O
.,O
78,O
±,O
96,O
.,O
32,O
779,O
.,O
42,O
±,O
94,O
.,O
38,O
T4,O
8,O
.,O
47,O
±,O
0,O
.,O
61,O
0,O
.,O
023,O
±,O
0,O
.,O
003,O
0,O
.,O
029,O
±,O
0,O
.,O
003,O
3,O
.,O
91,O
±,O
0,O
.,O
38,O
0,O
.,O
31,O
±,O
0,O
.,O
04,O
1161,O
.,O
29,O
±,O
125,O
.,O
76,O
865,O
.,O
52,O
±,O
90,O
.,O
76,O
T5,O
8,O
.,O
36,O
±,O
0,O
.,O
88,O
0,O
.,O
013,O
±,O
0,O
.,O
002,O
0,O
.,O
017,O
±,O
0,O
.,O
002,O
4,O
.,O
71,O
±,O
0,O
.,O
46,O
0,O
.,O
59,O
±,O
0,O
.,O
06,O
2358,O
.,O
20,O
±,O
359,O
.,O
79,O
1641,O
.,O
53,O
±,O
178,O
/,O
94,O
T6,O
7,O
.,O
40,O
±,O
0,O
.,O
71,O
0,O
.,O
020,O
±,O
0,O
.,O
002,O
0,O
.,O
025,O
±,O
0,O
.,O
002,O
5,O
.,O
27,O
±,O
0,O
.,O
61,O
0,O
.,O
36,O
±,O
0,O
.,O
04,O
1756,O
.,O
27,O
±,O
193,O
.,O
1,O
1343,O
.,O
41,O
±,O
147,O
.,O
89,O
Strain,O
Genotype,O
and,O
remarks,O
S,B-OG
.,I-OG
cerevisiae,I-OG
CEN,I-OG
.,I-OG
PK2,I-OG
-,I-OG
1D,I-OG
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
W1,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
W2,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
;,O
Δady2,O
::,O
LEU2,B-GP
W3,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
;,O
Δady2,O
::,O
LEU2,B-GP
(,O
pY13,O
-,O
TEF1,B-GP
-,O
470,O
),O
W4,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
;,O
Δady2,O
::,O
LEU2,B-GP
(,O
pY13,O
-,O
TEF1,B-GP
-,O
488,O
),O
W5,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
;,O
Δady2,O
::,O
LEU2,B-GP
(,O
pY13,O
-,O
TEF1,B-GP
-,O
406,O
),O
W6,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
;,O
Δady2,O
::,O
LEU2,B-GP
(,O
pY13,O
-,O
TEF1,B-GP
-,O
607,O
),O
W7,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
;,O
Δady2,O
::,O
LEU2,B-GP
(,O
pY13,O
-,O
TEF1,B-GP
-,O
108,O
),O
W8,O
MATα,B-GP
Δura3,O
-,O
52,O
;,O
Δtrp1,B-GP
-,O
289,O
;,O
Δleu2,O
-,O
3,O
",",O
112,O
;,O
Δhis3,O
-,O
1,O
;,O
MAL2,B-GP
-,O
8C,O
;,O
SUC2,B-GP
;,O
Δjen1,O
::,O
URA3,B-GP
;,O
Δady2,O
::,O
LEU2,B-GP
(,O
pY13,O
-,O
TEF1,B-GP
-,O
901,O
),O
Y,B-OG
.,I-OG
lipolytica,I-OG
WSH,I-OG
-,I-OG
Z06,I-OG
Wild,O
-,O
type,O
T1,O
Wild,O
-,O
type,O
(,O
p0,O
(,O
hph,B-GP
)-,O
470,O
),O
T2,O
Wild,O
-,O
type,O
(,O
p0,O
(,O
hph,B-GP
)-,O
488,O
),O
T3,O
Wild,O
-,O
type,O
(,O
p0,O
(,O
hph,B-GP
)-,O
406,O
),O
T4,O
Wild,O
-,O
type,O
(,O
p0,O
(,O
hph,B-GP
)-,O
607,O
),O
T5,O
wild,O
-,O
type,O
(,O
p0,O
(,O
hph,B-GP
)-,O
108,O
),O
T6,O
Wild,O
-,O
type,O
(,O
p0,O
(,O
hph,B-GP
)-,O
901,O
),O
Gene,O
Primers,O
Sequence,O
(,O
5,O
'-,O
3,O
'),O
Product,O
size,O
(,O
bp,O
),O
YALI0B19470g,B-GP
YALIOB19470,O
-,O
F,O
CAACAAGGAAGACAACAG,O
153,O
YALIOB19470,O
-,O
R,O
AGGTAGGTGAACATAAGC,O
YALI0C15488g,B-GP
YALIOC15488,O
-,O
F,O
GCAACCATCTCAGCCATTC,O
199,O
YALIOC15488,O
-,O
R,O
GTAACCTCGCATCTTCAGC,O
YALI0C21406g,B-GP
YALIOC21406,O
-,O
F,O
GCAGACCTACCAGCAGTTC,O
171,O
YALIOC21406,O
-,O
R,O
ACGACACAGAGCAAGTATCC,O
YALI0D20108g,B-GP
YALIOD20108,O
-,O
F,O
TGCTACAGGAAGGCTATGC,O
135,O
YALIOD20108,O
-,O
R,O
GGAAGATGATGATGAGAACAGG,O
YALI0D24607g,B-GP
YALIOD24607,O
-,O
F,O
CTGCTTGTAGGTGGTGAC,O
104,O
YALIOD24607,O
-,O
R,O
GAGTGCTGAGTGATAAATACG,O
YALI0E32901g,B-GP
YALIOE32901,O
-,O
F,O
TCTATGATTACGGTAAGGTTATG,O
188,O
YALIOE32901,O
-,O
R,O
GACTCGCTCAAGGTTCTC,O
ACT1,B-GP
ACT1,B-GP
-,O
F,O
AAGTCCAACCGAGAGAAGATG,O
132,O
ACT1,B-GP
-,O
R,O
ACCAGAGTCAAGAACGATACC,O
Primers,O
Sequence,O
(,O
5,O
'-,O
3,O
'),O
Description,O
JEN,B-GP
-,O
L,O
-,O
F,O
GGATCCATGTCGTCGTCAATTACAGATG,O
BamHI,B-GP
JEN,B-GP
-,O
L,O
-,O
R,O
ATGTGCAGTAAGGACGTAAATC,O
JEN,B-GP
-,O
R,O
-,O
F,O
AAAGGCTATATTAGGTGCCG,O
JEN,B-GP
-,O
R,O
-,O
R,O
GAATTCTTGTTCAACAATGTCACTAATCG,O
EcoRI,B-GP
JEN,B-GP
-,O
M,O
-,O
F,O
GATTTACGTCCTTACTGCACATGTGAAAACCTCTGACACATGC,O
JEN,B-GP
-,O
M,O
-,O
R,O
CGGCACCTAATATAGCCTTTGCCTTTGAGTGAGCTGATACC,O
ADY,B-GP
-,O
L,O
-,O
F,O
GGATCCATGTCTGACAAGGAACAAACGAG,O
BamHI,B-GP
ADY,B-GP
-,O
L,O
-,O
R,O
CCACCATAAAACATAGCACAACC,O
ADY,B-GP
-,O
R,O
-,O
F,O
GATTGCTGGTATTTGGGAGATAG,O
ADY,B-GP
-,O
R,O
-,O
R,O
CCTAGGCCCTTTCAGTAGATGGTAATGGG,O
AvrII,B-GP
ADY,B-GP
-,O
M,O
-,O
F,O
GGTTGTGCTATGTTTTATGGTGGGCATAGGCCACTAGTGGATCTG,O
ADY,B-GP
-,O
M,O
-,O
R,O
CTATCTCCCAAATACCAGCAATCCAGCTGAAGCTTCGTACGC,O
Primers,O
Sequence,O
(,O
5,O
'-,O
3,O
'),O
Description,O
YALI0D20108g,B-GP
-,O
F2,O
CGGGATCCATGAATTTTGACAACTTCCCAGC,O
BamHI,B-GP
YALI0D20108g,B-GP
-,O
R2,O
GGAATTCTTATCGAGTATCGCTCGAAGAAC,O
EcoRI,B-GP
YALI0C21406g,O
-,O
F2,O
GGACTAGTATGGATCTCGACAACTACCCTCC,O
BamHI,O
YALI0C21406g,O
-,O
R2,O
GGAATTCTCACTTTTGGGATCCGGGG,O
EcoRI,O
YALI0B19470g,O
-,O
F2,O
CGGGATCCATGCCCATCACAGTTTCACAAG,O
BamHI,O
YALI0B19470g,O
-,O
R2,O
GGAATTCTTAACGAGTGAGATTGGTGTCG,O
EcoRI,O
YALI0C15488g,O
-,O
F2,O
CGGGATCCATGGATTTGGACAACCTCCC,O
BamHI,O
YALI0C15488g,O
-,O
R2,O
GGAATTCCTACTTAGTAGCATTGGTGTCAACTC,O
EcoRI,O
YALI0D24607g,O
-,O
F2,O
CGGGATCCATGACCCAGTCGTACGAAGTC,O
BamHI,O
YALI0D24607g,O
-,O
R2,O
GGAATTCCTAATGAACACTTCCAACAGTGG,O
EcoRI,O
YALI0E32901g,O
-,O
F2,O
CGGGATCCATGGAAGCTCCTAATCTCTCG,O
BamHI,O
YALI0E32901g,O
-,O
R2,O
GGAATTCTACTTGGACTCGTAGGGGGA,O
EcoRI,O
Primers,O
Sequence,O
(,O
5,O
'-,O
3,O
'),O
Description,O
YALI0D20108g,O
-,O
F1,O
CGGGATCCATGAATTTTGACAACTTCCCAG,O
BamHI,O
YALI0D20108g,O
-,O
R1,O
GGAATTCTTATCGAGTATCGCTCGAAGAAC,O
EcoRI,O
YALI0C21406g,O
-,O
F1,O
GGAATTCATGGATCTCGACAACTACCCTC,O
EcoRI,O
YALI0C21406g,O
-,O
R1,O
TTGCGGCCGCTCACTTTTGGGATCCGGG,O
NotI,O
YALI0B19470g,O
-,O
F1,O
CGGGATCCATGCCCATCACAGTTTCACAAG,O
BamHI,O
YALI0B19470g,O
-,O
R1,O
GGAATTCTTAACGAGTGAGATTGGTGTCG,O
EcoRI,O
YALI0C15488g,O
-,O
F1,O
CGGGATCCATGGATTTGGACAACCTCCC,O
BamHI,O
YALI0C15488g,O
-,O
R1,O
GGAATTCCTACTTAGTAGCATTGGTGTCAACTC,O
EcoRI,O
YALI0D24607g,O
-,O
F1,O
CGGGATCCATGACCCAGTCGTACGAAGTC,O
BamHI,O
YALI0D24607g,O
-,O
R1,O
GGAATTCCTAATGAACACTTCCAACAGTGG,O
EocRI,O
YALI0E32901g,O
-,O
F1,O
CGGGATCCATGGAAGCTCCTAATCTCTCGC,O
BamHI,O
YALI0E32901g,O
-,O
R1,O
GGAATTCTTACTTGGACTCGTAGGGGGA,O
EcoRI,O
VB,O
-,O
F,O
CGTTTGCCAGCCACAGATT,O
V,O
-,O
YALI0D20108g,O
-,O
R,O
GCGTTTGCCAGCCACAGAT,O
V,O
-,O
YALI0C21406g,O
-,O
R,O
GTAGATGCAGGCAGCACCG,O
V,O
-,O
YALI0B19470g,O
-,O
R,O
AAGACAGAGGCGTTGATACCG,O
V,O
-,O
YALI0C15488g,O
-,O
R,O
TGCGAGGTTACCAAGCTGAT,O
V,O
-,O
YALI0D24607g,O
-,O
R,O
GACAAACGCCCAGGGATAG,O
V,O
-,O
YALI0E32901g,O
-,O
R,O
TGTCCATCTGCTTGCCCTC,O
Neurotoxic,O
kynurenine,O
metabolism,O
is,O
increased,O
in,O
the,O
dorsal,O
hippocampus,O
and,O
drives,O
distinct,O
depressive,O
behaviors,O
during,O
inflammation,O
The,O
kynurenine,O
pathway,O
of,O
tryptophan,O
metabolism,O
has,O
an,O
important,O
role,O
in,O
mediating,O
the,O
behavioral,O
effects,O
of,O
inflammation,O
",",O
which,O
has,O
implications,O
in,O
understanding,O
neuropsychiatric,O
comorbidity,O
and,O
for,O
the,O
development,O
of,O
novel,O
therapies,O
.,O
Inhibition,O
of,O
the,O
rate,O
-,O
limiting,O
enzyme,O
",",O
indoleamine,B-GP
2,I-GP
",",I-GP
3,I-GP
-,I-GP
dioxygenase,I-GP
(,O
IDO,B-GP
"),",O
prevents,O
the,O
development,O
of,O
many,O
of,O
these,O
inflammation,O
-,O
induced,O
preclinical,O
behaviors,O
.,O
However,O
",",O
dysregulation,O
in,O
the,O
balance,O
of,O
downstream,O
metabolism,O
",",O
where,O
neuroactive,O
kynurenines,O
are,O
generated,O
",",O
is,O
hypothesized,O
to,O
be,O
a,O
functionally,O
important,O
pathogenic,O
feature,O
of,O
inflammation,O
-,O
induced,O
depression,B-DS
.,O
Here,O
we,O
utilized,O
two,O
novel,O
transgenic,O
mouse,B-OG
strains,O
to,O
directly,O
test,O
the,O
hypothesis,O
that,O
neurotoxic,O
kynurenine,O
metabolism,O
causes,O
depressive,O
-,O
like,O
behavior,O
following,O
peripheral,O
immune,O
activation,O
.,O
Wild,O
-,O
type,O
(,O
WT,O
),O
or,O
kynurenine,B-GP
3,I-GP
-,I-GP
monooxygenase,I-GP
(,O
KMO,B-GP
)-,O
deficient,O
(,O
KMO,B-GP
−/−),O
mice,B-OG
were,O
administered,O
either,O
lipopolysaccharide,O
(,O
LPS,O
",",O
0,O
.,O
5,O
mg,O
kg,O
−,O
1,O
),O
or,O
saline,O
intraperitoneally,O
.,O
Depressive,O
-,O
like,O
behavior,O
was,O
measured,O
across,O
multiple,O
domains,O
24,O
h,O
after,O
immune,O
challenge,O
.,O
LPS,O
precipitated,O
a,O
robust,O
depressive,O
-,O
like,O
phenotype,O
",",O
but,O
KMO,B-GP
−/−,O
mice,B-OG
were,O
specifically,O
protected,O
from,O
LPS,O
-,O
induced,O
immobility,O
in,O
the,O
tail,O
suspension,O
test,O
(,O
TST,O
),O
and,O
reduced,O
spontaneous,O
alternations,O
in,O
the,O
Y,O
-,O
maze,O
.,O
Direct,O
administration,O
of,O
3,O
-,O
hydroxykynurenine,O
",",O
the,O
metabolic,O
product,O
of,O
KMO,B-GP
",",O
caused,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
depressive,O
-,O
like,O
behaviors,O
.,O
Mice,B-OG
with,O
targeted,O
deletion,O
of,O
3,B-GP
-,I-GP
hydroxyanthranilic,I-GP
acid,I-GP
dioxygenase,I-GP
(,O
HAAO,B-GP
"),",O
the,O
enzyme,O
that,O
generates,O
quinolinic,O
acid,O
",",O
were,O
similarly,O
challenged,O
with,O
LPS,O
.,O
Similar,O
to,O
KMO,B-GP
−/−,O
mice,B-OG
",",O
LPS,O
failed,O
to,O
increase,O
immobility,O
during,O
the,O
TST,O
.,O
Whereas,O
kynurenine,O
metabolism,O
was,O
generally,O
increased,O
in,O
behaviorally,O
salient,O
brain,O
regions,O
",",O
a,O
distinct,O
shift,O
toward,O
KMO,B-GP
-,O
dependent,O
kynurenine,O
metabolism,O
occurred,O
in,O
the,O
dorsal,O
hippocampus,O
in,O
response,O
to,O
LPS,O
.,O
Together,O
",",O
these,O
results,O
demonstrate,O
that,O
KMO,B-GP
is,O
a,O
pivotal,O
mediator,O
of,O
hippocampal,O
-,O
dependent,O
depressive,O
-,O
like,O
behaviors,O
induced,O
by,O
peripheral,O
LPS,O
challenge,O
.,O
Introduction,O
Although,O
it,O
remains,O
a,O
major,O
health,O
burden,O
worldwide,O
",",O
the,O
etiology,O
of,O
depression,B-DS
remains,O
unclear,O
.,O
Recent,O
studies,O
indicate,O
that,O
pro,B-GP
-,I-GP
inflammatory,I-GP
cytokines,I-GP
may,O
contribute,O
to,O
the,O
development,O
of,O
depression,B-DS
",",O
1,O
particularly,O
as,O
a,O
comorbidity,O
.,O
Patients,O
undergoing,O
cytokine,B-GP
immunotherapy2,O
or,O
healthy,O
volunteers,O
who,O
receive,O
immune,O
activating,O
agents,O
",",O
such,O
as,O
endotoxin3,O
",",O
4,O
or,O
vaccines5,O
",",O
6,O
in,O
an,O
experimental,O
setting,O
",",O
report,O
developing,O
depression,B-DS
symptoms,O
spanning,O
multiple,O
dimensions,O
(,O
for,O
example,O
",",O
mood,O
",",O
anhedonia,B-DS
",",O
cognition,O
",",O
neurovegetative,O
and,O
anxiety,B-DS
).,O
The,O
time,O
course,O
and,O
severity,O
of,O
these,O
symptoms,O
are,O
positively,O
correlated,O
with,O
pro,O
-,O
inflammatory,O
cytokine,B-GP
levels,O
.,O
4,O
",",O
5,O
Consistent,O
with,O
these,O
clinical,O
observations,O
",",O
peripheral,O
immune,O
activation,O
in,O
rodent,B-OG
models,O
precipitates,O
pro,O
-,O
inflammatory,O
cytokine,B-GP
-,O
dependent7,O
",",O
8,O
",",O
9,O
depressive,O
-,O
and,O
anxiety,B-DS
-,O
like,O
behaviors,O
.,O
Peripheral,O
pro,B-GP
-,I-GP
inflammatory,I-GP
cytokines,I-GP
signal,O
to,O
the,O
brain,O
via,O
multiple,O
routes10,O
and,O
activate,O
the,O
resident,O
immune,O
cells,O
of,O
the,O
brain,O
",",O
microglia,O
.,O
Activated,O
microglia,O
",",O
in,O
turn,O
",",O
secrete,O
cytokines,B-GP
and,O
chemokines,B-GP
",",O
generate,O
oxidative,O
stress,O
molecules,O
and,O
alter,O
local,O
metabolic,O
processes,O
.,O
11,O
Disruption,O
in,O
the,O
balance,O
of,O
tryptophan,O
metabolism,O
along,O
the,O
kynurenine,O
pathway,O
is,O
a,O
putative,O
mechanism,O
linking,O
inflammation,O
",",O
microglia,O
and,O
depression,B-DS
.,O
The,O
rate,O
-,O
limiting,O
enzyme,O
that,O
metabolizes,O
tryptophan,O
to,O
kynurenine,O
",",O
indoleamine,B-GP
2,I-GP
",",I-GP
3,I-GP
-,I-GP
dioxygenase,I-GP
(,O
IDO,B-GP
",",O
Figure,O
1,O
"),",O
is,O
potently,O
upregulated,O
by,O
pro,B-GP
-,I-GP
inflammatory,I-GP
cytokines,I-GP
.,O
12,O
Inflammation,O
-,O
associated,O
depression,B-DS
scores,O
in,O
human,B-OG
patients,O
are,O
associated,O
with,O
an,O
elevated,O
kynurenine,O
/,O
tryptophan,O
ratio,O
",",O
an,O
indicator,O
of,O
IDO,B-GP
activity,O
",",O
13,O
and,O
numerous,O
preclinical,O
mouse,B-OG
models,O
have,O
established,O
IDO,B-GP
-,O
dependent,O
kynurenine,O
metabolism,O
as,O
an,O
important,O
mediator,O
of,O
inflammation,O
-,O
induced,O
depressive,O
-,O
like,O
behaviors,O
.,O
14,O
",",O
15,O
",",O
16,O
",",O
17,O
",",O
18,O
Interestingly,O
",",O
microglia,O
are,O
the,O
predominant,O
cells,O
expressing,O
the,O
enzyme,O
(,O
kynurenine,B-GP
3,I-GP
-,I-GP
monooxygenase,I-GP
",",O
KMO,B-GP
",",O
Figure,O
1,O
),O
for,O
the,O
generation,O
of,O
neurotoxic,O
kynurenine,O
metabolites,O
",",O
and,O
reports,O
in,O
both,O
human19,B-OG
and,O
in,O
mice20,O
have,O
implicated,O
microglial,O
-,O
derived21,O
",",O
22,O
downstream,O
neurotoxic,O
kynurenine,O
metabolites,O
in,O
the,O
pathogenesis,O
of,O
inflammation,O
-,O
associated,O
depression,B-DS
;,O
however,O
",",O
mechanistic,O
studies,O
are,O
yet,O
to,O
be,O
performed,O
.,O
Kynurenine,O
metabolism,O
in,O
the,O
brain,O
results,O
in,O
accumulation,O
of,O
two,O
major,O
neuroactive,O
end,O
products,O
",",O
kynurenic,O
acid,O
(,O
KA,O
),O
and,O
quinolinic,O
acid,O
(,O
QA,O
;,O
Figure,O
1,O
).,O
Under,O
basal,O
conditions,O
",",O
most,O
kynurenine,O
is,O
metabolized,O
by,O
astrocytes,O
to,O
KA,O
",",O
an,O
N,O
-,O
methyl,O
-,O
D,O
-,O
aspartate,O
(,O
NMDA,O
),O
and,O
α7,B-GP
-,I-GP
nicotinic,I-GP
acetylcholine,I-GP
receptor,I-GP
antagonist,O
.,O
23,O
",",O
24,O
However,O
",",O
inflammation,O
and,O
subsequent,O
microglial,O
activation,O
is,O
reported,O
to,O
shift,O
kynurenine,O
metabolism,O
toward,O
KMO,B-GP
-,O
dependent,O
production,O
of,O
QA,O
.,O
20,O
",",O
25,O
QA,O
",",O
an,O
NMDAR,B-GP
agonist,O
",",O
can,O
be,O
particularly,O
disruptive,O
to,O
the,O
neuronal,O
environment,O
at,O
higher,O
concentrations,O
",",O
not,O
only,O
by,O
elevating,O
the,O
potential,O
for,O
glutamate,O
excitotoxicty,O
but,O
also,O
by,O
precipitating,O
oxidative,O
damage26,O
and,O
potentiating,O
pro,O
-,O
inflammation,O
.,O
A,O
neurotoxic,O
shift,O
in,O
kynurenine,O
metabolism,O
favoring,O
the,O
production,O
of,O
KMO,B-GP
-,O
dependent,O
metabolites,O
is,O
hypothesized,O
to,O
mediate,O
inflammation,O
-,O
associated,O
behavior,O
changes,O
.,O
27,O
Increased,O
levels,O
of,O
cerebrospinal,O
fluid,O
(,O
CSF,O
),O
QA,O
in,O
patients,O
undergoing,O
interferon,B-GP
-,I-GP
α,I-GP
immunotherapy,O
were,O
positively,O
correlated,O
to,O
more,O
severe,B-DS
depression,I-DS
scores,O
.,O
19,O
A,O
similar,O
elevation,O
in,O
central,O
QA,O
and,O
its,O
neurotoxic,O
precursor,O
",",O
3,O
-,O
hydroxykynurenine,O
(,O
3,O
-,O
HK,O
"),",O
was,O
measured,O
in,O
mice,B-OG
injected,O
peripherally,O
with,O
lipopolysaccharide,O
(,O
LPS,O
).,O
Importantly,O
",",O
LPS,O
-,O
challenged,O
mice,B-OG
also,O
exhibit,O
depressive,O
-,O
and,O
anxiety,B-DS
-,O
like,O
behaviors,O
concomitant,O
with,O
the,O
elevations,O
in,O
neurotoxic,O
metabolites,O
.,O
20,O
Whereas,O
evidence,O
implicates,O
KMO,B-GP
-,O
dependent,O
kynurenine,O
metabolism,O
as,O
a,O
likely,O
pathogenic,O
mechanism,O
underlying,O
inflammation,O
-,O
induced,O
depression,B-DS
",",O
28,O
until,O
recently,O
",",O
no,O
preclinical,O
genetic,O
models,O
were,O
available,O
to,O
directly,O
test,O
this,O
hypothesis,O
and,O
brain,O
-,O
penetrant,O
KMO,B-GP
inhibitors,O
are,O
not,O
commercially,O
available,O
.,O
In,O
order,O
to,O
determine,O
whether,O
KMO,B-GP
-,O
dependent,O
neurotoxic,O
kynurenine,O
metabolism,O
mediates,O
the,O
depressive,O
-,O
like,O
behavioral,O
changes,O
following,O
peripheral,O
immune,O
challenge,O
",",O
two,O
novel,O
transgenic,O
mouse,B-OG
strains,O
were,O
generated,O
with,O
targeted,O
deletion,O
of,O
either,O
the,O
KMO,B-GP
or,O
3,B-GP
-,I-GP
hydroxyanthranilic,I-GP
acid,I-GP
dioxygenase,I-GP
(,O
HAAO,B-GP
),O
gene,O
.,O
Inflammation,O
-,O
induced,O
depressive,O
behaviors,O
were,O
precipitated,O
in,O
control,O
or,O
transgenic,O
mice,B-OG
using,O
the,O
well,O
-,O
established,O
peripheral,O
LPS,O
challenge,O
model,O
.,O
29,O
",",O
30,O
3,O
-,O
HK,O
",",O
the,O
initial,O
substrate,O
for,O
neurotoxic,O
kynurenine,O
pathway,O
metabolism,O
",",O
was,O
directly,O
administered,O
to,O
naive,O
mice,B-OG
to,O
determine,O
the,O
behavioral,O
consequences,O
of,O
increased,O
KMO,B-GP
-,O
dependent,O
kynurenine,O
metabolites,O
.,O
Because,O
it,O
had,O
previously,O
only,O
been,O
investigated,O
at,O
the,O
whole,O
-,O
brain,O
level,O
",",O
changes,O
in,O
downstream,O
neuroactive,O
kynurenine,O
metabolism,O
in,O
behaviorally,O
salient,O
discrete,O
brain,O
regions,O
were,O
characterized,O
in,O
wild,O
-,O
type,O
(,O
WT,O
),O
mice,B-OG
following,O
LPS,O
challenge,O
.,O
These,O
novel,O
data,O
have,O
important,O
ramifications,O
for,O
not,O
only,O
our,O
understanding,O
of,O
neuropsychiatric,O
pathology,O
during,O
inflammation,O
",",O
but,O
also,O
for,O
identification,O
of,O
novel,O
therapeutic,O
targets,O
.,O
Materials,O
and,O
methods,O
Animals,B-OG
All,O
animal,B-OG
care,O
and,O
use,O
was,O
carried,O
out,O
in,O
accord,O
with,O
the,O
Guide,O
for,O
the,O
Care,O
and,O
Use,O
of,O
Laboratory,O
Animals,B-OG
",",O
8th,O
edition,O
(,O
NRC,O
),O
and,O
approved,O
by,O
the,O
Institutional,O
Animal,O
Care,O
and,O
Use,O
Committee,O
at,O
The,O
University,O
of,O
Texas,O
Health,O
Science,O
Center,O
at,O
San,O
Antonio,O
.,O
General,O
health,O
of,O
the,O
mice,B-OG
was,O
monitored,O
daily,O
.,O
Knockout,O
first,O
",",O
conditional,O
ready,O
KMO,B-GP
and,O
HAAO,B-GP
transgenic,O
mice,B-OG
(,O
Kmotm1a,O
(,O
KOMP,O
),O
Wtsi,O
and,O
Haaotm1a,B-GP
(,O
KOMP,O
),O
Wtsi,O
),O
on,O
a,O
C57BL,O
/,O
6N,O
background,O
were,O
designed,O
and,O
generated,O
by,O
the,O
Mouse,B-OG
Biology,O
Program,O
(,O
MBP,O
",",O
www,O
.,O
mousebiology,O
.,O
org,O
),O
at,O
the,O
University,O
of,O
California,O
Davis,O
(,O
UC,O
Davis,O
).,O
The,O
MBP,O
was,O
supported,O
by,O
the,O
Knock,O
-,O
Out,O
Mouse,B-OG
Project,O
(,O
KOMP,O
"),",O
a,O
trans,O
-,O
NIH,O
initiative,O
",",O
and,O
the,O
CSD,O
Consortium,O
",",O
composed,O
of,O
the,O
Children,O
',O
s,O
Hospital,O
Oakland,O
Research,O
Institute,O
(,O
CHORI,O
"),",O
the,O
Wellcome,O
Trust,O
Sanger,O
Institute,O
and,O
UC,O
Davis,O
.,O
Vectors,O
",",O
embryonic,O
stem,O
cells,O
and,O
gene,O
information,O
related,O
to,O
these,O
mouse,B-OG
strains,O
are,O
available,O
at,O
the,O
KOMP,O
Repository,O
(,O
www,O
.,O
komp,O
.,O
org,O
),O
maintained,O
by,O
UC,O
Davis,O
and,O
CHORI,O
.,O
Briefly,O
",",O
C57BL,O
/,O
6N,O
mouse,B-OG
embryonic,O
stem,O
cells,O
were,O
injected,O
with,O
a,O
vector,O
containing,O
a,O
transgenic,O
cassette,O
directed,O
for,O
the,O
target,O
gene,O
(,O
Figures,O
2a,O
and,O
c,O
).,O
Stem,O
cells,O
were,O
selected,O
for,O
site,O
-,O
specific,O
integration,O
of,O
the,O
transgene,O
",",O
microinjected,O
into,O
C57BL,O
/,O
6N,O
mouse,B-OG
blastocysts,O
and,O
implanted,O
into,O
C57BL,O
/,O
6N,O
female,O
mice,B-OG
.,O
31,O
During,O
transcription,O
",",O
the,O
proper,O
incorporation,O
of,O
the,O
transgene,O
into,O
the,O
target,O
gene,O
results,O
in,O
gene,O
-,O
trapping,O
between,O
the,O
reporter,O
gene,O
(,O
lacZ,B-GP
),O
from,O
the,O
cassette,O
and,O
the,O
endogenous,O
gene,O
.,O
32,O
When,O
these,O
transcripts,O
become,O
spliced,O
together,O
",",O
an,O
insertion,O
mutation,O
is,O
created,O
resulting,O
in,O
a,O
non,O
-,O
functional,O
target,O
protein,O
.,O
The,O
presence,O
of,O
the,O
Kmo,B-GP
transgene,O
was,O
confirmed,O
by,O
RT,O
-,O
PCR,O
of,O
genomic,O
DNA,O
using,O
the,O
following,O
primers,O
:,O
5,O
′-,O
ACCAGTCAGCAGGTCCTTGTTT,O
-,O
3,O
′,O
(,O
WT,O
forward,O
primer,O
"),",O
5,O
′-,O
CGCGTCGAGAAGTTCCTATTCC,O
-,O
3,O
′,O
(,O
Kmo,B-GP
transgene,O
forward,O
primer,O
),O
and,O
5,O
′-,O
AACCCATGTTACCGTCACACAC,O
-,O
3,O
′,O
(,O
common,O
reverse,O
primer,O
;,O
Figure,O
2b,O
).,O
The,O
Haao,B-GP
transgene,O
was,O
confirmed,O
in,O
the,O
same,O
manner,O
using,O
the,O
following,O
primers,O
:,O
5,O
′-,O
GATAAGGGATTGGGGGTGTG,O
-,O
3,O
′,O
(,O
WT,O
forward,O
primer,O
"),",O
5,O
′-,O
GAAAGTATAGGAACTTCGTCGAGAT,O
-,O
3,O
′,O
(,O
Haao,B-GP
transgene,O
forward,O
primer,O
),O
and,O
5,O
′-,O
GCCAAGGTCCTTACAGTGGA,O
-,O
3,O
′,O
(,O
common,O
reverse,O
primer,O
;,O
Figure,O
2d,O
).,O
Functional,O
deletion,O
of,O
the,O
target,O
gene,O
was,O
confirmed,O
using,O
validated,O
Taqman,O
Gene,O
Expression,O
assays,O
(,O
Mm01321343_m1,O
(,O
Kmo,B-GP
),O
and,O
Mm00517945_m1,O
(,O
Haao,B-GP
);,O
Life,O
Technologies,O
",",O
Grand,O
Island,O
",",O
NY,O
",",O
USA,O
),O
for,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
amplification,O
of,O
steady,O
-,O
state,O
mRNA,O
(,O
data,O
not,O
shown,O
).,O
Upon,O
confirmation,O
of,O
a,O
knockout,O
genotype,O
",",O
mice,B-OG
were,O
back,O
-,O
crossed,O
with,O
C57BL,O
/,O
6J,O
mice,B-OG
(,O
Jackson,O
Laboratory,O
",",O
Bar,O
Harbor,O
",",O
ME,O
",",O
USA,O
;,O
stock,O
#,O
000664,O
),O
for,O
five,O
generations,O
to,O
maintain,O
the,O
in,O
-,O
house,O
breeding,O
colonies,O
.,O
C57BL,O
/,O
6J,O
mice,B-OG
were,O
used,O
to,O
supplement,O
the,O
WT,O
littermate,O
control,O
group,O
when,O
needed,O
",",O
after,O
confirming,O
that,O
there,O
was,O
not,O
a,O
significant,O
difference,O
in,O
the,O
phenotypic,O
or,O
metabolic,O
responses,O
to,O
LPS,O
(,O
data,O
not,O
shown,O
).,O
Three,O
to,O
five,O
-,O
month,O
-,O
old,O
male,O
mice,B-OG
were,O
used,O
for,O
all,O
experiments,O
.,O
Ad,O
libitum,O
food,O
and,O
water,O
access,O
was,O
provided,O
at,O
all,O
times,O
.,O
Two,O
weeks,O
before,O
testing,O
",",O
mice,B-OG
were,O
individually,O
housed,O
in,O
a,O
modified,O
reverse,O
light,O
cycle,O
(,O
lights,O
on,O
2300,O
–,O
1100,O
hours,O
"),",O
gently,O
handled,O
and,O
weighed,O
each,O
day,O
.,O
Treatments,O
LPS,O
(,O
Escherichia,B-OG
coli,I-OG
",",O
serotype,O
0127,O
:,O
B8,O
",",O
Sigma,O
-,O
Aldrich,O
",",O
St,O
Louis,O
",",O
MO,O
",",O
USA,O
),O
was,O
prepared,O
in,O
endotoxin,O
-,O
free,O
saline,O
on,O
the,O
morning,O
of,O
injections,O
.,O
LPS,O
(,O
0,O
.,O
5,O
mg,O
kg,O
−,O
1,O
),O
or,O
saline,O
was,O
injected,O
intraperitoneally,O
(,O
i,O
.,O
p,O
.),O
24,O
h,O
before,O
behavioral,O
assessments,O
and,O
tissue,O
collection,O
.,O
3,O
-,O
HK,O
(,O
Sigma,O
-,O
Aldrich,O
),O
was,O
dissolved,O
in,O
0,O
.,O
5,O
N,O
HCl,O
at,O
a,O
concentration,O
of,O
4,O
"×,",O
diluted,O
to,O
2,O
×,O
with,O
0,O
.,O
5,O
N,O
NaOH,O
and,O
to,O
1,O
×,O
with,O
0,O
.,O
2M,O
(,O
2,O
×),O
phosphate,O
-,O
buffered,O
saline,O
.,O
3,O
-,O
HK,O
was,O
administered,O
subcutaneously,O
at,O
0,O
.,O
0,O
",",O
3,O
.,O
33,O
or,O
10,O
mg,O
kg,O
−,O
1,O
30,O
min,O
before,O
behavioral,O
testing,O
or,O
tissue,O
collection,O
",",O
which,O
was,O
previously,O
established,O
as,O
the,O
time,O
of,O
peak,O
brain,O
concentrations,O
following,O
peripheral,O
kynurenine,O
administration,O
.,O
33,O
Treatment,O
groups,O
:,O
WT,O
and,O
KMO,B-GP
−/−,O
mice,B-OG
were,O
treated,O
(,O
i,O
.,O
p,O
.),O
with,O
either,O
saline,O
(,O
WT,O
n,O
=,O
36,O
;,O
KMO,B-GP
−/−,O
n,O
=,O
24,O
),O
or,O
LPS,O
(,O
WT,O
n,O
=,O
37,O
;,O
KMO,B-GP
−/−,O
n,O
=,O
24,O
"),",O
followed,O
by,O
behavioral,O
testing,O
(,O
Figure,O
3,O
),O
and,O
tissue,O
collection,O
(,O
Table,O
1,O
),O
at,O
24,O
h,O
.,O
WT,O
mice,B-OG
were,O
injected,O
peripherally,O
(,O
subcutaneously,O
),O
with,O
0,O
.,O
0,O
mg,O
kg,O
−,O
1,O
(,O
n,O
=,O
27,O
"),",O
3,O
.,O
33,O
mg,O
kg,O
−,O
1,O
(,O
n,O
=,O
17,O
),O
or,O
10,O
mg,O
kg,O
−,O
1,O
(,O
n,O
=,O
20,O
),O
3,O
-,O
HK,O
",",O
followed,O
by,O
either,O
behavior,O
or,O
tissue,O
collection,O
(,O
Figure,O
4,O
).,O
WT,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
were,O
also,O
treated,O
(,O
i,O
.,O
p,O
.),O
with,O
either,O
saline,O
(,O
WT,O
n,O
=,O
26,O
;,O
HAAO,B-GP
−/−,O
n,O
=,O
29,O
),O
or,O
LPS,O
(,O
WT,O
n,O
=,O
29,O
;,O
HAAO,B-GP
−/−,O
n,O
=,O
31,O
"),",O
followed,O
by,O
behavioral,O
assessment,O
(,O
Figure,O
5,O
),O
and,O
tissue,O
collection,O
(,O
Table,O
1,O
),O
at,O
24,O
h,O
.,O
Finally,O
",",O
WT,O
mice,B-OG
were,O
treated,O
(,O
i,O
.,O
p,O
.),O
with,O
either,O
saline,O
(,O
n,O
=,O
12,O
),O
or,O
LPS,O
(,O
n,O
=,O
12,O
),O
and,O
brain,O
regions,O
were,O
microdissected,O
(,O
Tables,O
2,O
and,O
3,O
),O
at,O
24,O
h,O
.,O
Animals,B-OG
were,O
randomly,O
assigned,O
to,O
treatment,O
groups,O
within,O
the,O
appropriate,O
genotype,O
",",O
and,O
data,O
were,O
collected,O
and,O
analyzed,O
by,O
a,O
treatment,O
-,O
blind,O
observer,O
.,O
Previous,O
studies,O
conducted,O
by,O
our,O
laboratory,O
using,O
similar,O
treatments,O
and,O
behaviors,O
were,O
used,O
to,O
determine,O
group,O
sample,O
size,O
",",O
which,O
provide,O
adequate,O
effect,O
size,O
.,O
16,O
",",O
33,O
",",O
34,O
Behavioral,O
testing,O
Locomotor,O
activity,O
and,O
open,O
field,O
test,O
Exploratory,O
locomotor,O
activity,O
and,O
anxiety,B-DS
-,O
like,O
behavior,O
were,O
assessed,O
24,O
h,O
post,O
-,O
LPS,O
by,O
placing,O
mice,B-OG
in,O
a,O
dimly,O
lit,O
(~,O
5,O
lux,O
),O
40,O
×,O
40,O
cm,O
open,O
field,O
(,O
OF,O
),O
chamber,O
for,O
5,O
min,O
.,O
Activity,O
in,O
the,O
OF,O
was,O
video,O
-,O
recorded,O
and,O
assessed,O
for,O
total,O
horizontal,O
distance,O
traveled,O
and,O
time,O
spent,O
in,O
the,O
central,O
or,O
outer,O
areas,O
using,O
Ethovision,O
XT,O
7,O
.,O
1,O
analysis,O
software,O
(,O
Noldus,O
",",O
Leesburg,O
",",O
VA,O
",",O
USA,O
),O
as,O
previously,O
described,O
.,O
16,O
The,O
chamber,O
was,O
cleaned,O
with,O
70,O
%,O
ethanol,O
after,O
each,O
individual,O
test,O
.,O
Sucrose,O
preference,O
Three,O
days,O
before,O
LPS,O
treatment,O
",",O
mice,B-OG
were,O
trained,O
using,O
a,O
two,O
-,O
bottle,O
(,O
water,O
and,O
1,O
%,O
sucrose,O
),O
testing,O
paradigm,O
.,O
Following,O
LPS,O
injections,O
",",O
sucrose,O
preference,O
(,O
SP,O
),O
was,O
assessed,O
as,O
an,O
index,O
of,O
anhedonia,B-DS
-,O
like,O
behavior,O
as,O
previously,O
described,O
and,O
calculated,O
as,O
(,O
sucrose,O
intake,O
)/(,O
water,O
+,O
sucrose,O
intake,O
),O
×,O
100,O
.,O
16,O
To,O
control,O
for,O
potential,O
place,O
preference,O
",",O
bottles,O
were,O
placed,O
on,O
the,O
outside,O
edge,O
of,O
the,O
wire,O
food,O
hopper,O
and,O
their,O
relative,O
location,O
was,O
alternated,O
daily,O
.,O
Tail,O
suspension,O
test,O
Immediately,O
after,O
the,O
OF,O
test,O
",",O
behavioral,O
despair,O
was,O
measured,O
in,O
the,O
tail,O
suspension,O
test,O
(,O
TST,O
"),",O
as,O
previously,O
described,O
.,O
14,O
Immobility,O
during,O
the,O
6,O
min,O
test,O
was,O
scored,O
by,O
a,O
trained,O
treatment,O
-,O
blinded,O
observer,O
.,O
Any,O
mice,B-OG
that,O
climbed,O
their,O
tail,O
",",O
which,O
occurred,O
in,O
fewer,O
than,O
5,O
%,O
of,O
experimental,O
mice,B-OG
",",O
were,O
excluded,O
from,O
subsequent,O
data,O
analysis,O
.,O
Y,O
-,O
Maze,O
Mice,B-OG
were,O
placed,O
in,O
the,O
maze,O
and,O
allowed,O
to,O
freely,O
explore,O
for,O
8,O
min,O
.,O
The,O
movement,O
and,O
location,O
of,O
the,O
mouse,B-OG
was,O
recorded,O
from,O
an,O
overhead,O
camera,O
",",O
and,O
the,O
distance,O
traveled,O
and,O
sequence,O
of,O
arm,O
entries,O
were,O
scored,O
from,O
the,O
video,O
archive,O
.,O
An,O
entry,O
was,O
scored,O
only,O
when,O
the,O
mouse,B-OG
',O
s,O
full,O
body,O
(,O
minus,O
tail,O
),O
had,O
entered,O
2,O
-,O
cm,O
deep,O
into,O
the,O
arm,O
.,O
A,O
spontaneous,O
alternation,O
occurred,O
when,O
the,O
mouse,B-OG
entered,O
each,O
of,O
the,O
three,O
different,O
arms,O
sequentially,O
before,O
making,O
a,O
return,O
entry,O
to,O
an,O
already,O
visited,O
arm,O
.,O
Behavioral,O
timeline,O
Before,O
treatment,O
(,O
saline,O
or,O
LPS,O
i,O
.,O
p,O
".),",O
mice,B-OG
were,O
trained,O
on,O
the,O
two,O
-,O
bottle,O
SP,O
testing,O
paradigm,O
",",O
and,O
then,O
SP,O
data,O
were,O
collected,O
during,O
the,O
24,O
h,O
following,O
treatment,O
and,O
before,O
behavioral,O
testing,O
.,O
At,O
24,O
h,O
following,O
treatment,O
",",O
mice,B-OG
underwent,O
testing,O
in,O
the,O
OF,O
and,O
TST,O
or,O
the,O
Y,O
-,O
maze,O
immediately,O
followed,O
by,O
tissue,O
collection,O
(,O
as,O
described,O
below,O
).,O
For,O
peripheral,O
3,O
-,O
HK,O
experiments,O
",",O
mice,B-OG
were,O
injected,O
subcutaneously,O
30,O
min,O
before,O
either,O
the,O
TST,O
",",O
OF,O
",",O
Y,O
-,O
maze,O
",",O
a,O
shortened,O
2,O
h,O
SP,O
test,O
or,O
tissue,O
collection,O
.,O
Liquid,O
chromatography,O
/,O
mass,O
spectrometry,O
Either,O
following,O
behavior,O
at,O
~,O
25,O
h,O
post,O
-,O
LPS,O
treatment,O
or,O
30,O
min,O
following,O
subcutaneous,O
3,O
-,O
HK,O
administration,O
",",O
tissues,O
were,O
collected,O
for,O
analysis,O
.,O
Mice,B-OG
were,O
killed,O
by,O
carbon,O
dioxide,O
asphyxiation,O
and,O
venous,O
blood,O
was,O
collected,O
into,O
heparinized,O
tubes,O
for,O
separation,O
of,O
plasma,O
.,O
Then,O
",",O
mice,B-OG
were,O
immediately,O
perfused,O
with,O
ice,O
-,O
cold,O
heparinized,O
sterile,O
saline,O
before,O
collection,O
of,O
whole,O
-,O
brain,O
or,O
microdissection,O
of,O
dorsal,O
hippocampus,O
",",O
ventral,O
hippocampus,O
",",O
central,O
amygdala,O
and,O
nucleus,O
accumbens,O
.,O
Microdissections,O
were,O
conducted,O
using,O
a,O
brain,O
matrix,O
(,O
Stoelting,O
",",O
Wood,O
Dale,O
",",O
IL,O
",",O
USA,O
),O
and,O
serial,O
1,O
-,O
mm,O
coronal,O
brain,O
sections,O
(,O
based,O
on,O
stereological,O
coordinates,O
in,O
a,O
mouse,B-OG
brain,O
atlas35,O
).,O
All,O
tissue,O
samples,O
were,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
use,O
.,O
Samples,O
were,O
prepared,O
for,O
liquid,O
chromatography,O
/,O
mass,O
spectrometry,O
(,O
LC,O
/,O
MS,O
),O
and,O
analyzed,O
for,O
kynurenine,O
metabolites,O
as,O
previously,O
described,O
.,O
20,O
Briefly,O
",",O
thawed,O
plasma,O
samples,O
were,O
diluted,O
with,O
5,O
×,O
0,O
.,O
2,O
%,O
acetic,O
acid,O
and,O
1,O
mM,O
internal,O
standards,O
",",O
transferred,O
to,O
Amicon,O
Ultra,O
filters,O
(,O
Millipore,O
",",O
Billerica,O
",",O
MA,O
",",O
USA,O
),O
and,O
centrifuged,O
at,O
13,O
500,O
g,O
for,O
1,O
hour,O
at,O
4,O
°,O
C,O
.,O
Frozen,O
brain,O
tissue,O
was,O
diluted,O
with,O
3,O
×,O
0,O
.,O
2,O
%,O
acetic,O
acid,O
and,O
1,O
mM,O
internal,O
standards,O
and,O
then,O
homogenized,O
at,O
4,O
°,O
C,O
using,O
an,O
Omni,O
International,O
Bead,O
Ruptor,O
24,O
Homogenizer,O
(,O
Kennesaw,O
",",O
GA,O
",",O
USA,O
),O
with,O
1,O
.,O
4,O
mm,O
zirconium,O
ceramic,O
oxide,O
beads,O
(,O
Omni,O
International,O
),O
and,O
settings,O
of,O
(,O
pulse,O
duration,O
:,O
45,O
s,O
",",O
pulse,O
number,O
:,O
2,O
",",O
rest,O
interval,O
:,O
15,O
s,O
).,O
The,O
brain,O
homogenate,O
was,O
filtered,O
as,O
the,O
plasma,O
.,O
LC,O
/,O
MS,O
was,O
performed,O
on,O
a,O
Thermo,O
Fisher,O
Scientific,O
Q,O
Exactive,O
mass,O
spectrometer,O
(,O
Waltham,O
",",O
MA,O
",",O
USA,O
),O
with,O
online,O
separation,O
by,O
a,O
Thermo,O
Fisher,O
Scientific,O
Dionex,O
UltiMate,O
3000,O
HPLC,O
and,O
the,O
resulting,O
data,O
were,O
analyzed,O
using,O
Xcalibur,O
2,O
.,O
2,O
(,O
Thermo,O
Fisher,O
Scientific,O
),O
in,O
the,O
Mass,O
Spectrometry,O
Core,O
Facility,O
at,O
the,O
University,O
of,O
Texas,O
Health,O
Science,O
Center,O
at,O
San,O
Antonio,O
.,O
QA,O
and,O
3,O
-,O
HAA,O
were,O
not,O
reliably,O
measured,O
in,O
microdissected,O
brain,O
region,O
samples,O
because,O
of,O
small,O
sample,O
size,O
",",O
nor,O
was,O
QA,O
reliably,O
detected,O
in,O
whole,O
-,O
brain,O
samples,O
.,O
Statistical,O
analysis,O
All,O
statistical,O
analyses,O
were,O
performed,O
using,O
SigmaPlot,O
12,O
.,O
0,O
(,O
Systat,O
Software,O
",",O
San,O
Jose,O
",",O
CA,O
",",O
USA,O
),O
and,O
data,O
represent,O
group,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
Behavioral,O
data,O
are,O
presented,O
as,O
%,O
Saline,O
(,O
saline,O
or,O
LPS,O
i,O
.,O
p,O
.),O
or,O
%,O
Vehicle,O
(,O
3,O
-,O
HK,O
subcutaneous,O
),O
and,O
were,O
calculated,O
based,O
on,O
saline,O
within,O
the,O
individual,O
genotype,O
or,O
on,O
vehicle,O
.,O
Spurious,O
data,O
were,O
identified,O
as,O
previously,O
described33,O
and,O
analyzed,O
with,O
either,O
a,O
one,O
-,O
tailed,O
t,O
-,O
test,O
",",O
a,O
one,O
-,O
or,O
two,O
-,O
way,O
analysis,O
of,O
variance,O
.,O
When,O
a,O
significant,O
interaction,O
was,O
identified,O
",",O
post,O
hoc,O
analyses,O
were,O
completed,O
using,O
the,O
Holm,O
–,O
Sidak,O
method,O
for,O
pairwise,O
multiple,O
comparisons,O
to,O
identify,O
significant,O
differences,O
between,O
groups,O
.,O
Significant,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
within,O
-,O
group,O
differences,O
are,O
denoted,O
as,O
such,O
"(*),",O
whereas,O
significant,O
same,O
treatment,O
between,O
-,O
group,O
differences,O
are,O
denoted,O
as,O
such,O
(+).,O
Results,O
KMO,B-GP
mediates,O
distinct,O
inflammation,O
-,O
induced,O
depressive,O
-,O
like,O
behaviors,O
Mice,B-OG
were,O
tested,O
in,O
the,O
TST,O
(,O
Figure,O
3a,O
),O
24,O
h,O
after,O
i,O
.,O
p,O
.,O
LPS,O
or,O
saline,O
",",O
and,O
a,O
significant,O
genotype,O
×,O
treatment,O
interaction,O
(,O
P,O
=,O
0,O
.,O
009,O
),O
was,O
identified,O
.,O
WT,O
mice,B-OG
exhibited,O
a,O
significant,O
increase,O
in,O
duration,O
spent,O
immobile,O
following,O
LPS,O
injections,O
(,O
P,O
=,O
0,O
.,O
029,O
versus,O
saline,O
"),",O
similar,O
to,O
previously,O
observed,O
LPS,O
effects,O
in,O
the,O
TST,O
.,O
14,O
However,O
",",O
LPS,O
failed,O
to,O
cause,O
an,O
increase,O
in,O
the,O
duration,O
of,O
immobility,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
LPS,O
caused,O
a,O
significant,O
reduction,O
in,O
SP,O
(,O
Figure,O
3b,O
",",O
P,O
<,O
0,O
.,O
001,O
),O
that,O
was,O
not,O
different,O
between,O
genotypes,O
",",O
and,O
similarly,O
the,O
duration,O
of,O
time,O
spent,O
in,O
the,O
central,O
area,O
of,O
an,O
OF,O
was,O
significantly,O
reduced,O
by,O
LPS,O
-,O
independent,O
of,O
genotype,O
(,O
Figure,O
2c,O
",",O
P,O
<,O
0,O
.,O
001,O
).,O
Thigmotaxis,O
(,O
Figure,O
3d,O
"),",O
wall,O
-,O
hugging,O
behavior,O
",",O
was,O
increased,O
after,O
LPS,O
in,O
both,O
WT,O
(,O
P,O
=,O
0,O
.,O
012,O
),O
and,O
KMO,B-GP
−/−,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
mice,B-OG
",",O
but,O
to,O
a,O
greater,O
extent,O
in,O
the,O
KMO,B-GP
-,O
deficient,O
mice,B-OG
(,O
P,O
<,O
0,O
.,O
001,O
).,O
Overall,O
distance,O
traveled,O
in,O
the,O
OF,O
was,O
reduced,O
modestly,O
",",O
but,O
significantly,O
",",O
by,O
LPS,O
treatment,O
(,O
Supplementary,O
Figure,O
1A,O
",",O
P,O
<,O
0,O
.,O
001,O
),O
independent,O
of,O
genotype,O
",",O
as,O
was,O
LPS,O
-,O
induced,O
reduction,O
in,O
body,O
weight,O
(,O
Supplementary,O
Figure,O
1B,O
",",O
P,O
<,O
0,O
.,O
001,O
).,O
A,O
significant,O
genotype,O
×,O
treatment,O
interaction,O
(,O
F1,O
",",O
23,O
=,O
5,O
.,O
10,O
",",O
P,O
=,O
0,O
.,O
034,O
),O
was,O
apparent,O
for,O
spontaneous,O
alternations,O
during,O
the,O
Y,O
-,O
maze,O
test,O
(,O
Figure,O
3e,O
"),",O
where,O
LPS,O
reduced,O
alternations,O
in,O
WT,O
(,O
P,O
=,O
0,O
.,O
046,O
"),",O
but,O
not,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
3,O
-,O
HK,O
dose,O
-,O
dependently,O
induces,O
a,O
depressive,O
-,O
like,O
behavioral,O
phenotype,O
3,O
-,O
HK,O
was,O
administered,O
subcutaneously,O
30,O
min,O
before,O
behavioral,O
testing,O
at,O
the,O
indicated,O
doses,O
.,O
3,O
-,O
HK,O
induced,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
duration,O
of,O
immobility,O
during,O
the,O
TST,O
(,O
Figure,O
4a,O
",",O
P,O
=,O
0,O
.,O
012,O
).,O
SP,O
",",O
measured,O
during,O
a,O
2,O
-,O
h,O
probe,O
beginning,O
30,O
min,O
post,O
injection,O
",",O
was,O
unaffected,O
by,O
3,O
-,O
HK,O
administration,O
(,O
Figure,O
4b,O
).,O
The,O
duration,O
of,O
time,O
spent,O
in,O
the,O
central,O
area,O
of,O
an,O
OF,O
was,O
significantly,O
increased,O
by,O
3,O
-,O
HK,O
administration,O
(,O
Figure,O
4c,O
",",O
P,O
=,O
0,O
.,O
013,O
);,O
however,O
",",O
thigmotaxis,O
behavior,O
failed,O
to,O
reach,O
significance,O
(,O
Figure,O
4c,O
).,O
Importantly,O
",",O
general,O
locomotor,O
activity,O
in,O
the,O
OF,O
",",O
as,O
evaluated,O
by,O
distance,O
traveled,O
",",O
was,O
not,O
significantly,O
affected,O
by,O
3,O
-,O
HK,O
administration,O
(,O
data,O
not,O
shown,O
).,O
Similar,O
to,O
TST,O
immobility,O
",",O
exogenous,O
3,O
-,O
HK,O
administration,O
significantly,O
reduced,O
spontaneous,O
alternations,O
during,O
the,O
Y,O
-,O
maze,O
test,O
(,O
Figure,O
4e,O
",",O
P,O
=,O
0,O
.,O
007,O
),O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
Peripheral,O
3,O
-,O
HK,O
administration,O
dose,O
-,O
dependently,O
increased,O
3,O
-,O
HK,O
concentration,O
in,O
the,O
plasma,O
(,O
Figure,O
4f,O
",",O
P,O
<,O
0,O
.,O
001,O
),O
in,O
line,O
with,O
behavioral,O
changes,O
observed,O
.,O
Similarly,O
",",O
central,O
concentrations,O
of,O
3,O
-,O
HK,O
(,O
Figure,O
4g,O
),O
were,O
dose,O
-,O
dependently,O
elevated,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
in,O
response,O
to,O
peripheral,O
3,O
-,O
HK,O
injections,O
.,O
HAAO,B-GP
,O
mice,B-OG
are,O
protected,O
from,O
peripheral,O
LPS,O
-,O
induced,O
behavioral,O
despair,O
Twenty,O
-,O
four,O
hours,O
after,O
LPS,O
or,O
saline,O
treatment,O
",",O
depressive,O
-,O
like,O
behaviors,O
were,O
assessed,O
in,O
HAAO,B-GP
−/−,O
or,O
WT,O
.,O
LPS,O
administration,O
caused,O
a,O
40,O
%,O
increase,O
in,O
the,O
duration,O
of,O
immobility,O
in,O
WT,O
mice,B-OG
in,O
the,O
TST,O
;,O
however,O
",",O
HAAO,B-GP
−/−,O
mice,B-OG
were,O
entirely,O
protected,O
from,O
this,O
effect,O
(,O
Figure,O
5a,O
",",O
P,O
=,O
0,O
.,O
013,O
).,O
HAAO,B-GP
−/−,O
mice,B-OG
had,O
similar,O
LPS,O
treatment,O
responses,O
as,O
WT,O
mice,B-OG
when,O
assessed,O
for,O
anhedonia,B-DS
and,O
anxiety,B-DS
-,O
like,O
behavior,O
.,O
Following,O
LPS,O
treatment,O
",",O
there,O
was,O
a,O
significant,O
decrease,O
in,O
SP,O
caused,O
by,O
LPS,O
(,O
Figure,O
5b,O
),O
in,O
both,O
HAAO,B-GP
−/−,O
and,O
WT,O
mice,B-OG
(,O
P,O
<,O
0,O
.,O
001,O
"),",O
and,O
although,O
no,O
interaction,O
was,O
present,O
",",O
a,O
modest,O
but,O
significant,O
overall,O
reduction,O
in,O
SP,O
was,O
apparent,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
(,O
P,O
<,O
0,O
.,O
001,O
).,O
In,O
the,O
OF,O
test,O
",",O
LPS,O
caused,O
a,O
reduction,O
in,O
the,O
duration,O
of,O
time,O
spent,O
in,O
the,O
central,O
area,O
(,O
Figure,O
5c,O
",",O
P,O
<,O
0,O
.,O
001,O
),O
and,O
an,O
increase,O
in,O
thigmotaxis,O
behavior,O
(,O
Figure,O
5d,O
",",O
P,O
<,O
0,O
.,O
001,O
);,O
however,O
",",O
there,O
was,O
no,O
significant,O
effect,O
of,O
genotype,O
.,O
Similar,O
to,O
KMO,B-GP
−/−,O
mice,B-OG
",",O
distance,O
traveled,O
during,O
the,O
OF,O
(,O
Supplementary,O
Figure,O
1C,O
),O
was,O
reduced,O
24,O
h,O
following,O
LPS,O
treatment,O
independent,O
of,O
genotype,O
(,O
P,O
<,O
0,O
.,O
001,O
"),",O
and,O
LPS,O
precipitated,O
a,O
reduction,O
in,O
body,O
weight,O
that,O
was,O
not,O
different,O
between,O
genotypes,O
(,O
Supplementary,O
Figure,O
1D,O
",",O
P,O
<,O
0,O
.,O
001,O
).,O
In,O
addition,O
",",O
there,O
was,O
a,O
significant,O
genotype,O
×,O
treatment,O
interaction,O
in,O
spontaneous,O
alternations,O
assessed,O
in,O
the,O
Y,O
-,O
maze,O
(,O
Figure,O
5e,O
",",O
P,O
=,O
0,O
.,O
011,O
"),",O
in,O
which,O
LPS,O
treatment,O
induced,O
a,O
reduction,O
in,O
WT,O
mice,B-OG
(,O
P,O
=,O
0,O
.,O
041,O
),O
and,O
not,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
Characterization,O
of,O
brain,O
and,O
plasma,O
kynurenine,O
metabolism,O
in,O
KMO,B-GP
and,O
HAAO,B-GP
knockout,O
mice,B-OG
Full,O
statistical,O
analysis,O
is,O
indicated,O
in,O
the,O
table,O
",",O
and,O
",",O
for,O
the,O
sake,O
of,O
clarity,O
",",O
parsimonious,O
reporting,O
of,O
significant,O
effects,O
are,O
reported,O
here,O
.,O
To,O
determine,O
the,O
consequence,O
of,O
targeted,O
deletions,O
of,O
Kmo,B-GP
and,O
Haao,B-GP
genes,O
on,O
central,O
kynurenine,O
pathway,O
metabolism,O
(,O
Figure,O
1,O
"),",O
cerebral,O
levels,O
of,O
tryptophan,O
and,O
kynurenine,O
metabolites,O
were,O
measured,O
in,O
WT,O
",",O
KMO,B-GP
−/−,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
24,O
h,O
after,O
LPS,O
or,O
saline,O
administration,O
(,O
Table,O
1,O
).,O
There,O
was,O
a,O
significant,O
main,O
effect,O
of,O
both,O
treatment,O
and,O
genotype,O
on,O
the,O
concentration,O
of,O
central,O
tryptophan,O
(,O
μM,O
",",O
Row,O
1,O
).,O
Consistent,O
with,O
previous,O
findings,O
",",O
20,O
LPS,O
treatment,O
resulted,O
in,O
an,O
elevation,O
in,O
central,O
kynurenine,O
levels,O
(,O
μM,O
",",O
Row,O
2,O
),O
in,O
WT,O
",",O
KMO,B-GP
−/−,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
However,O
",",O
there,O
was,O
a,O
significant,O
interaction,O
between,O
genotype,O
and,O
treatment,O
as,O
KMO,B-GP
−/−,O
mice,B-OG
had,O
substantially,O
higher,O
brain,O
kynurenine,O
levels,O
.,O
3,O
-,O
HK,O
(,O
μM,O
",",O
Row,O
3,O
),O
was,O
not,O
detected,O
in,O
the,O
brain,O
of,O
KMO,B-GP
−/−,O
mice,B-OG
",",O
and,O
was,O
higher,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
relative,O
to,O
WT,O
mice,B-OG
.,O
However,O
",",O
there,O
was,O
a,O
significant,O
LPS,O
-,O
induced,O
increase,O
in,O
3,O
-,O
HK,O
in,O
WT,O
mice,B-OG
",",O
whereas,O
there,O
was,O
no,O
treatment,O
effect,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
Downstream,O
of,O
3,O
-,O
HK,O
",",O
there,O
was,O
a,O
significant,O
interaction,O
between,O
genotype,O
and,O
treatment,O
on,O
the,O
concentration,O
of,O
central,O
3,O
-,O
HAA,O
(,O
μM,O
",",O
Row,O
4,O
).,O
This,O
effect,O
is,O
largely,O
driven,O
by,O
the,O
elevation,O
of,O
central,O
3,O
-,O
HAA,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
QA,O
was,O
not,O
reliably,O
detected,O
in,O
any,O
of,O
the,O
brain,O
samples,O
in,O
our,O
study,O
.,O
KA,O
(,O
μM,O
",",O
Row,O
6,O
),O
was,O
markedly,O
elevated,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
and,O
decreased,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
",",O
with,O
no,O
significant,O
effect,O
of,O
LPS,O
.,O
Plasma,O
tryptophan,O
levels,O
(,O
μM,O
",",O
Row,O
7,O
),O
varied,O
between,O
genotype,O
",",O
but,O
were,O
significantly,O
reduced,O
by,O
LPS,O
in,O
WT,O
",",O
KMO,B-GP
−/−,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
Kynurenine,O
levels,O
(,O
μM,O
",",O
Row,O
8,O
),O
were,O
substantially,O
higher,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
overall,O
.,O
3,O
-,O
HK,O
(,O
μM,O
",",O
Row,O
9,O
),O
was,O
detected,O
in,O
plasma,O
of,O
all,O
mice,B-OG
",",O
although,O
near,O
the,O
lower,O
limit,O
of,O
detection,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
LPS,O
increased,O
3,O
-,O
HK,O
levels,O
in,O
both,O
WT,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
",",O
but,O
not,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
Plasma,O
3,O
-,O
HAA,O
(,O
μM,O
",",O
Row,O
10,O
),O
was,O
not,O
detected,O
in,O
WT,O
or,O
KMO,B-GP
−/−,O
mice,B-OG
",",O
and,O
there,O
was,O
no,O
LPS,O
treatment,O
effect,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
QA,O
levels,O
(,O
μM,O
",",O
Row,O
11,O
),O
varied,O
by,O
genotype,O
with,O
no,O
effect,O
of,O
treatment,O
.,O
Finally,O
",",O
there,O
was,O
a,O
significant,O
genotype,O
×,O
treatment,O
interaction,O
in,O
the,O
concentration,O
of,O
plasma,O
KA,O
(,O
μM,O
",",O
Row,O
12,O
).,O
This,O
effect,O
was,O
driven,O
by,O
a,O
25,O
–,O
30,O
-,O
fold,O
increase,O
in,O
KA,O
levels,O
in,O
the,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
Overall,O
",",O
LPS,O
reduced,O
plasma,O
KA,O
levels,O
.,O
Kynurenine,O
metabolism,O
within,O
discrete,O
",",O
behaviorally,O
relevant,O
",",O
brain,O
regions,O
following,O
peripheral,O
immune,O
challenge,O
with,O
LPS,O
Full,O
statistical,O
analysis,O
is,O
indicated,O
in,O
the,O
table,O
",",O
and,O
",",O
for,O
the,O
sake,O
of,O
clarity,O
",",O
parsimonious,O
reporting,O
of,O
significant,O
effects,O
are,O
reported,O
here,O
.,O
To,O
determine,O
whether,O
region,O
-,O
specific,O
differences,O
in,O
kynurenine,O
metabolism,O
underlie,O
the,O
distinct,O
neurotoxic,O
metabolism,O
-,O
dependent,O
behavioral,O
profile,O
",",O
brain,O
region,O
metabolite,O
concentrations,O
were,O
determined,O
24,O
h,O
post,O
-,O
saline,O
or,O
LPS,O
treatment,O
(,O
Table,O
2,O
).,O
In,O
the,O
dorsal,O
hippocampus,O
",",O
both,O
tryptophan,O
and,O
kynurenine,O
concentrations,O
(,O
μM,O
),O
increased,O
following,O
LPS,O
treatment,O
.,O
Neuroactive,O
kynurenine,O
metabolism,O
also,O
increased,O
with,O
elevations,O
in,O
3,O
-,O
HK,O
(,O
μM,O
"),",O
3,O
-,O
HAA,O
(,O
μM,O
),O
and,O
XA,O
(,O
μM,O
"),",O
whereas,O
KA,O
(,O
μM,O
),O
remained,O
unchanged,O
.,O
XA,O
has,O
been,O
reported,O
to,O
influence,O
synaptic,O
transmission,O
as,O
a,O
metabotropic,B-GP
glutamate,I-GP
receptor,I-GP
group,I-GP
II,I-GP
ligand,O
and,O
a,O
vesicular,B-GP
glutamate,I-GP
transporter,I-GP
inhibitor,O
.,O
36,O
",",O
37,O
In,O
the,O
ventral,O
hippocampus,O
",",O
LPS,O
treatment,O
also,O
increased,O
kynurenine,O
and,O
XA,O
.,O
However,O
",",O
no,O
other,O
metabolites,O
were,O
altered,O
by,O
LPS,O
.,O
In,O
the,O
central,O
amygdala,O
",",O
tryptophan,O
and,O
kynurenine,O
concentrations,O
increased,O
in,O
response,O
to,O
LPS,O
treatment,O
.,O
3,O
-,O
HK,O
",",O
XA,O
and,O
KA,O
were,O
also,O
significantly,O
elevated,O
following,O
LPS,O
treatment,O
.,O
In,O
the,O
nucleus,O
accumbens,O
",",O
tryptophan,O
and,O
all,O
kynurenine,O
metabolites,O
were,O
increased,O
following,O
LPS,O
treatment,O
as,O
in,O
the,O
central,O
amygdala,O
.,O
3,O
-,O
HAA,O
was,O
not,O
detected,O
in,O
either,O
the,O
central,O
amygdala,O
or,O
the,O
nucleus,O
accumbens,O
.,O
To,O
compare,O
the,O
relative,O
LPS,O
effect,O
between,O
brain,O
regions,O
",",O
metabolite,O
changes,O
were,O
normalized,O
as,O
%,O
saline,O
and,O
analyzed,O
(,O
Table,O
3,O
).,O
There,O
was,O
a,O
main,O
effect,O
of,O
region,O
on,O
tryptophan,O
concentration,O
change,O
following,O
LPS,O
treatment,O
",",O
whereby,O
tryptophan,O
was,O
significantly,O
higher,O
in,O
the,O
central,O
amygdala,O
than,O
the,O
ventral,O
or,O
dorsal,O
hippocampus,O
.,O
LPS,O
-,O
induced,O
increases,O
in,O
kynurenine,O
",",O
3,O
-,O
HK,O
and,O
XA,O
were,O
comparable,O
across,O
the,O
different,O
brain,O
regions,O
.,O
Although,O
3,O
-,O
HAA,O
was,O
not,O
detected,O
in,O
the,O
central,O
amygdala,O
or,O
nucleus,O
accumbens,O
",",O
it,O
was,O
increased,O
to,O
a,O
greater,O
extent,O
in,O
dorsal,O
compared,O
with,O
ventral,O
hippocampus,O
.,O
There,O
was,O
also,O
a,O
significant,O
effect,O
of,O
region,O
on,O
LPS,O
-,O
induced,O
KA,O
.,O
This,O
effect,O
was,O
driven,O
by,O
significantly,O
greater,O
LPS,O
-,O
induced,O
increase,O
in,O
nucleus,O
accumbens,O
and,O
central,O
amygdala,O
compared,O
with,O
hippocampal,O
subregions,O
.,O
Discussion,O
The,O
kynurenine,O
pathway,O
of,O
tryptophan,O
metabolism,O
has,O
been,O
heavily,O
implicated,O
as,O
a,O
pathogenic,O
factor,O
in,O
the,O
development,O
of,O
depression,B-DS
",",O
particularly,O
within,O
the,O
context,O
of,O
inflammation,O
-,O
associated,O
depression,B-DS
.,O
We,O
and,O
others,O
have,O
demonstrated,O
that,O
IDO,B-GP
",",O
the,O
rate,O
-,O
limiting,O
step,O
of,O
kynurenine,O
metabolism,O
(,O
Figure,O
1,O
"),",O
directly,O
mediates,O
the,O
induction,O
of,O
depressive,O
-,O
like,O
behaviors,O
in,O
response,O
to,O
peripheral,O
immune,O
challenge,O
in,O
preclinical,O
models,O
.,O
14,O
",",O
16,O
",",O
33,O
However,O
",",O
the,O
generation,O
of,O
neuroactive,O
kynurenine,O
metabolites,O
occurs,O
downstream,O
of,O
IDO,B-GP
.,O
20,O
Whereas,O
emergent,O
clinical,O
and,O
preclinical,O
data,O
suggest,O
that,O
shifting,O
the,O
balance,O
of,O
downstream,O
kynurenine,O
metabolism,O
to,O
favor,O
production,O
of,O
neurotoxic,O
kynurenines,O
drives,O
depressive,O
symptoms,O
",",O
19,O
",",O
20,O
no,O
mechanistic,O
studies,O
have,O
been,O
performed,O
to,O
directly,O
test,O
this,O
hypothesis,O
.,O
Here,O
",",O
we,O
utilized,O
two,O
novel,O
transgenic,O
mouse,B-OG
strains,O
with,O
targeted,O
deletion,O
of,O
either,O
KMO,B-GP
or,O
HAAO,B-GP
(,O
Figure,O
1,O
),O
to,O
determine,O
whether,O
neurotoxic,O
kynurenine,O
metabolism,O
causes,O
the,O
development,O
of,O
depressive,O
behaviors,O
following,O
peripheral,O
immune,O
activation,O
with,O
LPS,O
(,O
bacterial,O
endotoxin,O
).,O
KMO,B-GP
−/−,O
mice,B-OG
do,O
not,O
generate,O
detectible,O
3,O
-,O
HK,O
in,O
the,O
brain,O
before,O
or,O
after,O
LPS,O
challenge,O
(,O
Table,O
1,O
).,O
In,O
contrast,O
to,O
inhibition,O
of,O
IDO,B-GP
",",O
targeted,O
deletion,O
of,O
KMO,B-GP
inhibited,O
only,O
a,O
specific,O
subset,O
of,O
LPS,O
-,O
induced,O
depressive,O
-,O
like,O
behaviors,O
(,O
Figure,O
3,O
).,O
Direct,O
administration,O
of,O
3,O
-,O
HK,O
",",O
the,O
metabolic,O
product,O
of,O
KMO,B-GP
",",O
induced,O
the,O
development,O
of,O
depressive,O
-,O
like,O
behaviors,O
that,O
were,O
attenuated,O
in,O
the,O
KMO,B-GP
−/−,O
mice,B-OG
(,O
Figure,O
4,O
).,O
Although,O
QA,O
was,O
not,O
reliably,O
detected,O
in,O
brain,O
tissue,O
(,O
Table,O
1,O
"),",O
a,O
reduction,O
in,O
neurotoxic,O
metabolism,O
would,O
presumably,O
result,O
in,O
the,O
generation,O
of,O
less,O
QA,O
.,O
Therefore,O
",",O
LPS,O
-,O
induced,O
depressive,O
behavior,O
was,O
measured,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
",",O
and,O
these,O
mice,B-OG
were,O
also,O
protected,O
from,O
the,O
development,O
of,O
the,O
same,O
specific,O
depressive,O
-,O
like,O
behaviors,O
(,O
Figure,O
5,O
).,O
Together,O
",",O
these,O
data,O
confirm,O
that,O
KMO,B-GP
-,O
and,O
HAAO,B-GP
-,O
dependent,O
neurotoxic,O
kynurenine,O
metabolism,O
directly,O
mediates,O
the,O
development,O
of,O
inflammation,O
-,O
induced,O
behavior,O
despair,O
and,O
working,O
memory,B-DS
deficits,I-DS
;,O
behaviors,O
regulated,O
by,O
hippocampal,O
-,O
dependent,O
neurocircuitry,O
.,O
Previous,O
research,O
in,O
this,O
area,O
has,O
suffered,O
from,O
an,O
overall,O
lack,O
of,O
functional,O
precision,O
",",O
as,O
studies,O
that,O
measured,O
kynurenine,O
metabolism,O
downstream,O
of,O
IDO,B-GP
have,O
evaluated,O
only,O
CSF,O
in,O
patients,O
or,O
whole,O
-,O
brain,O
tissue,O
in,O
rodents,B-OG
.,O
19,O
",",O
20,O
For,O
example,O
",",O
Raison,O
et,O
al,O
.,O
19,O
showed,O
that,O
the,O
concentration,O
of,O
QA,O
in,O
the,O
CSF,O
was,O
positively,O
correlated,O
with,O
depression,B-DS
scores,O
of,O
controls,O
and,O
subjects,O
receiving,O
interferon,B-GP
immunotherapy,O
.,O
19,O
In,O
addition,O
",",O
the,O
first,O
preclinical,O
study,O
to,O
investigate,O
the,O
role,O
of,O
QA,O
in,O
driving,O
depressive,O
symptoms,O
showed,O
that,O
LPS,O
-,O
induced,O
depressive,O
behaviors,O
could,O
be,O
mitigated,O
in,O
inbred,O
C57BL,O
/,O
6,O
mice,B-OG
by,O
the,O
NMDAR,B-GP
",",O
ketamine,O
",",O
suggesting,O
a,O
pathogenic,O
role,O
for,O
QA,O
.,O
20,O
Metabolic,O
analysis,O
in,O
the,O
study,O
by,O
Walker,O
et,O
al,O
.,O
20,O
indicated,O
that,O
LPS,O
caused,O
a,O
shift,O
toward,O
neurotoxic,O
metabolism,O
in,O
whole,O
-,O
brain,O
tissue,O
of,O
a,O
separate,O
group,O
of,O
CD,O
-,O
1,O
outbred,O
mice,B-OG
.,O
20,O
Here,O
",",O
we,O
report,O
",",O
for,O
we,O
believe,O
the,O
first,O
time,O
",",O
direct,O
evidence,O
that,O
directly,O
implicates,O
KMO,B-GP
-,O
dependent,O
kynurenine,O
metabolism,O
in,O
LPS,O
-,O
induced,O
depression,B-DS
.,O
Further,O
",",O
as,O
only,O
specific,O
behaviors,O
were,O
mitigated,O
by,O
genetic,O
inhibition,O
of,O
neurotoxic,O
kynurenine,O
metabolism,O
",",O
the,O
data,O
suggested,O
that,O
kynurenine,O
metabolism,O
might,O
differ,O
between,O
discrete,O
brain,O
regions,O
.,O
Indeed,O
",",O
Frenois,O
et,O
al,O
.,O
38,O
demonstrated,O
that,O
neuronal,O
activation,O
following,O
peripheral,O
LPS,O
challenge,O
of,O
C57BL6,O
/,O
J,O
mice,B-OG
(,O
measured,O
by,O
FosB,B-GP
/,O
Δ,O
FosB,B-GP
immunohistochemistry,O
),O
was,O
not,O
uniformly,O
increased,O
.,O
38,O
Rather,O
",",O
discrete,O
regions,O
with,O
known,O
relevance,O
to,O
depressive,O
behavioral,O
domains,O
were,O
more,O
strongly,O
increased,O
",",O
including,O
hippocampus,O
",",O
nucleus,O
accumbens,O
and,O
central,O
amygdala,O
.,O
38,O
Whereas,O
a,O
previous,O
report,O
by,O
Giorgini,O
et,O
al,O
.,O
39,O
characterized,O
the,O
metabolic,O
changes,O
that,O
occur,O
in,O
response,O
to,O
a,O
KMO,B-GP
deficiency,O
in,O
a,O
separate,O
strain,O
of,O
mice,B-OG
",",O
39,O
the,O
data,O
in,O
Figure,O
3,O
are,O
the,O
first,O
to,O
demonstrate,O
the,O
significance,O
of,O
a,O
KMO,B-GP
genetic,O
deletion,O
on,O
the,O
behavioral,O
consequences,O
of,O
peripheral,O
LPS,O
administration,O
.,O
KMO,B-GP
−/−,O
mice,B-OG
have,O
disrupted,O
central,O
and,O
peripheral,O
kynurenine,O
metabolism,O
(,O
Table,O
1,O
),O
in,O
a,O
similar,O
pattern,O
to,O
this,O
previous,O
study,O
.,O
39,O
Interestingly,O
",",O
baseline,O
kynurenine,O
levels,O
are,O
significantly,O
elevated,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
without,O
any,O
apparent,O
changes,O
to,O
baseline,O
depressive,O
-,O
like,O
phenotype,O
.,O
This,O
is,O
seemingly,O
in,O
contrast,O
to,O
previous,O
data,O
from,O
our,O
laboratory,O
",",O
and,O
others,O
demonstrating,O
that,O
direct,O
administration,O
of,O
kynurenine,O
can,O
induce,O
deficits,O
in,O
novel,O
object,O
recognition,O
and,O
spatial,O
working,O
memory,O
alter,O
fear,O
conditioning,O
and,O
induce,O
anhedonia,B-DS
.,O
16,O
",",O
33,O
",",O
40,O
",",O
41,O
",",O
42,O
It,O
is,O
possible,O
that,O
the,O
accumulation,O
of,O
kynurenine,O
over,O
time,O
through,O
development,O
allows,O
the,O
system,O
to,O
adjust,O
preventing,O
any,O
potential,O
behavioral,O
changes,O
.,O
Peripheral,O
LPS,O
treatment,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
precipitates,O
an,O
increase,O
in,O
central,O
kynurenine,O
without,O
any,O
changes,O
in,O
central,O
3,O
-,O
HK,O
.,O
The,O
metabolite,O
analyses,O
from,O
HAAO,B-GP
−/−,O
mice,B-OG
(,O
Table,O
1,O
),O
are,O
the,O
first,O
from,O
a,O
genetic,O
mutant,O
model,O
targeted,O
at,O
this,O
enzyme,O
that,O
metabolizes,O
3,O
-,O
HAA,O
to,O
QA,O
.,O
Although,O
QA,O
was,O
not,O
reliably,O
detected,O
in,O
any,O
brain,O
tissue,O
sample,O
",",O
both,O
central,O
3,O
-,O
HK,O
and,O
3,O
-,O
HAA,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
were,O
increased,O
over,O
WT,O
levels,O
",",O
as,O
would,O
be,O
predicted,O
in,O
mice,B-OG
lacking,O
the,O
enzyme,O
to,O
metabolize,O
3,O
-,O
HAA,O
to,O
QA,O
.,O
In,O
the,O
plasma,O
",",O
3,O
-,O
HK,O
and,O
3,O
-,O
HAA,O
were,O
similarly,O
elevated,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
;,O
however,O
",",O
QA,O
was,O
still,O
detectable,O
",",O
indicating,O
the,O
potential,O
for,O
an,O
alternate,O
metabolic,O
source,O
of,O
QA,O
.,O
Although,O
surprising,O
",",O
this,O
peripheral,O
QA,O
is,O
unable,O
to,O
cross,O
the,O
blood,O
–,O
brain,O
barrier,O
and,O
therefore,O
has,O
no,O
direct,O
impact,O
on,O
central,O
QA,O
concentrations,O
and,O
does,O
not,O
contribute,O
to,O
the,O
behavioral,O
phenotype,O
of,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
It,O
is,O
well,O
accepted,O
that,O
depressive,O
symptoms,O
occur,O
across,O
multiple,O
behavioral,O
domains,O
",",O
and,O
that,O
distinct,O
regions,O
of,O
the,O
brain,O
are,O
critical,O
to,O
each,O
of,O
the,O
various,O
domains,O
of,O
depressive,O
-,O
like,O
behavior,O
.,O
In,O
fact,O
",",O
this,O
is,O
the,O
basic,O
tenet,O
of,O
the,O
National,O
Institute,O
of,O
Mental,O
Health,O
',O
s,O
(,O
NIMH,O
),O
Research,O
Domain,O
Criteria,O
(,O
RDoC,O
",",O
http,O
://,O
www,O
.,O
nimh,O
.,O
nih,O
.,O
gov,O
/,O
research,O
-,O
priorities,O
/,O
rdoc,O
/,O
index,O
.,O
shtml,O
),O
framework,O
to,O
guide,O
mental,O
health,O
research,O
.,O
43,O
",",O
44,O
Preclinical,O
neuropsychiatric,O
research,O
necessarily,O
employs,O
an,O
RDoC,O
framework,O
that,O
deconstructs,O
a,O
behavioral,O
phenotype,O
(,O
neuropsychiatric,B-DS
disorders,I-DS
being,O
modeled,O
),O
into,O
core,O
behaviors,O
(,O
analogous,O
to,O
symptoms,O
),O
that,O
are,O
functionally,O
controlled,O
by,O
primary,O
neurocircuits,O
in,O
discrete,O
brain,O
regions,O
.,O
To,O
determine,O
whether,O
increased,O
neurotoxic,O
kynurenine,O
metabolism,O
generates,O
the,O
metabolic,O
substrates,O
to,O
cause,O
the,O
distinct,O
depressive,O
-,O
like,O
behaviors,O
observed,O
in,O
Figures,O
3,O
and,O
5,O
",",O
kynurenine,O
metabolites,O
were,O
measured,O
in,O
the,O
dorsal,O
hippocampus,O
",",O
ventral,O
hippocampus,O
",",O
central,O
amygdala,O
and,O
nucleus,O
accumbens,O
of,O
C57BL6,O
/,O
J,O
mice,B-OG
(,O
Table,O
2,O
"),",O
the,O
same,O
background,O
strain,O
of,O
the,O
KMO,B-GP
−/−,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
",",O
at,O
24,O
h,O
post,O
treatment,O
.,O
These,O
regions,O
were,O
chosen,O
for,O
their,O
relevance,O
to,O
depression,B-DS
in,O
humans,B-OG
as,O
well,O
as,O
the,O
individual,O
behaviors,O
analyzed,O
in,O
this,O
study,O
following,O
peripheral,O
inflammation,O
.,O
45,O
",",O
46,O
",",O
47,O
",",O
48,O
Immobility,O
during,O
the,O
TST,O
and,O
spontaneous,O
alternations,O
in,O
Y,O
-,O
maze,O
are,O
behaviors,O
known,O
to,O
require,O
hippocampal,O
function,O
",",O
and,O
their,O
analogous,O
depressive,O
symptoms,O
are,O
behavioral,O
despair,O
and,O
working,O
memory,O
.,O
49,O
",",O
50,O
",",O
51,O
However,O
",",O
SP,O
requires,O
reward,O
circuitry,O
of,O
the,O
nucleus,O
accumbens,O
",",O
and,O
reduced,O
preference,O
reflects,O
an,O
anhedonia,B-DS
-,O
like,O
phenotype,O
.,O
46,O
Behavior,O
in,O
the,O
OF,O
reflects,O
anxiety,B-DS
-,O
like,O
states,O
that,O
involve,O
amygdala,O
activity,O
.,O
52,O
",",O
53,O
Consistent,O
with,O
previous,O
studies,O
",",O
LPS,O
caused,O
a,O
reduction,O
in,O
circulating,O
tryptophan,O
levels,O
and,O
a,O
robust,O
increase,O
in,O
the,O
concentration,O
of,O
kynurenine,O
in,O
both,O
the,O
periphery,O
and,O
in,O
each,O
brain,O
region,O
analyzed,O
(,O
Tables,O
1,O
and,O
2,O
).,O
However,O
",",O
an,O
interesting,O
pattern,O
was,O
noted,O
in,O
the,O
metabolic,O
profile,O
downstream,O
of,O
kynurenine,O
.,O
Neurotoxic,O
metabolites,O
were,O
generally,O
increased,O
across,O
each,O
brain,O
region,O
",",O
but,O
KA,O
was,O
also,O
significantly,O
increased,O
in,O
central,O
amygdala,O
and,O
nucleus,O
accumbens,O
.,O
Only,O
the,O
dorsal,O
hippocampus,O
reflected,O
a,O
clear,O
shift,O
toward,O
neurotoxic,O
and,O
neuromodulatory,O
(,O
KMO,B-GP
-,O
dependent,O
),O
metabolism,O
without,O
a,O
parallel,O
increase,O
in,O
the,O
opposing,O
KAT,B-GP
-,O
dependent,O
metabolic,O
branch,O
.,O
The,O
specific,O
behaviors,O
known,O
to,O
involve,O
hippocampal,O
activity,O
were,O
mitigated,O
by,O
genetic,O
inhibition,O
of,O
neurotoxic,O
kynurenine,O
metabolism,O
(,O
in,O
KMO,B-GP
−/−,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
),O
and,O
precipitated,O
by,O
direct,O
administration,O
of,O
3,O
-,O
HK,O
.,O
The,O
hippocampus,O
was,O
the,O
only,O
discrete,O
brain,O
region,O
where,O
LPS,O
treatment,O
resulted,O
in,O
a,O
clear,O
and,O
unbalanced,O
shift,O
toward,O
the,O
generation,O
of,O
KMO,B-GP
-,O
dependent,O
metabolites,O
.,O
These,O
findings,O
are,O
consistent,O
with,O
the,O
contemporary,O
hypothesis,O
that,O
disrupting,O
the,O
metabolic,O
balance,O
of,O
the,O
kynurenine,O
pathway,O
",",O
rather,O
than,O
simply,O
increasing,O
overall,O
kynurenine,O
metabolism,O
",",O
defines,O
the,O
functional,O
pathogenic,O
context,O
by,O
which,O
kynurenine,O
metabolism,O
mediates,O
the,O
behavioral,O
effects,O
of,O
inflammation,O
.,O
27,O
",",O
28,O
Further,O
",",O
these,O
data,O
support,O
recent,O
findings,O
from,O
our,O
laboratory,O
",",O
demonstrating,O
that,O
peripheral,O
LPS,O
induces,O
brain,O
region,O
-,O
dependent,O
changes,O
in,O
the,O
balance,O
of,O
kynurenine,O
metabolites,O
",",O
specifically,O
favoring,O
neurotoxic,O
metabolite,O
production,O
in,O
the,O
hippocampus,O
.,O
34,O
Recent,O
data,O
characterizing,O
the,O
regional,O
characteristics,O
of,O
microglia,O
throughout,O
the,O
brain,O
demonstrated,O
that,O
not,O
all,O
microglia,O
express,O
the,O
same,O
functional,O
expression,O
markers,O
.,O
54,O
Specifically,O
",",O
it,O
was,O
noted,O
that,O
microglia,O
in,O
the,O
hippocampus,O
were,O
more,O
responsive,O
to,O
pro,O
-,O
inflammatory,O
stimuli,O
",",O
earning,O
them,O
the,O
label,O
‘,O
immunovigilant,O
'.,O
54,O
This,O
hyper,O
-,O
responsive,O
state,O
of,O
hippocampal,O
microglia,O
could,O
underlie,O
the,O
region,O
-,O
specific,O
elevation,O
in,O
neurotoxic,O
kynurenine,O
metabolism,O
described,O
in,O
Table,O
2,O
.,O
Recent,O
clinical,O
data,O
demonstrated,O
that,O
",",O
following,O
a,O
suicide,O
attempt,O
in,O
depressed,O
patients,O
",",O
CSF,O
QA,O
remains,O
elevated,O
while,O
CSF,O
KA,O
stayed,O
decreased,O
.,O
55,O
In,O
patients,O
with,O
mastocytosis,B-DS
",",O
associated,O
with,O
comorbid,O
depression,B-DS
and,O
inflammation,O
",",O
plasma,O
QA,O
and,O
plasma,O
KA,O
were,O
found,O
to,O
be,O
elevated,O
.,O
56,O
More,O
specifically,O
",",O
in,O
depressed,O
patients,O
",",O
the,O
serum,O
KA,O
/,O
QA,O
ratio,O
(,O
neuroprotective,O
ratio,O
),O
was,O
positively,O
correlated,O
with,O
increasing,O
volumes,O
of,O
the,O
hippocampus,O
and,O
amygdala,O
.,O
57,O
Previous,O
data,O
in,O
mice,B-OG
with,O
either,O
genetic,O
or,O
systemic,O
inhibition,O
of,O
IDO,B-GP
clearly,O
indicate,O
a,O
pivotal,O
role,O
for,O
kynurenine,O
metabolism,O
in,O
mediating,O
depressive,O
-,O
like,O
behaviors,O
in,O
response,O
to,O
peripheral,O
immune,O
challenge,O
.,O
The,O
general,O
increase,O
in,O
kynurenine,O
metabolism,O
across,O
each,O
brain,O
region,O
(,O
Table,O
2,O
),O
that,O
was,O
identified,O
in,O
this,O
study,O
supports,O
the,O
conclusions,O
of,O
a,O
broad,O
importance,O
of,O
IDO,B-GP
in,O
mediating,O
the,O
effects,O
of,O
LPS,O
.,O
However,O
",",O
targeting,O
IDO,B-GP
does,O
not,O
provide,O
any,O
indication,O
of,O
which,O
neuroactive,O
downstream,O
metabolites,O
are,O
responsible,O
for,O
driving,O
inflammation,O
-,O
induced,O
behavioral,O
phenotypes,O
.,O
Whereas,O
the,O
previous,O
study,O
by,O
Walker,O
et,O
al,O
.,O
20,O
found,O
that,O
both,O
LPS,O
-,O
induced,O
increases,O
in,O
immobility,O
and,O
reduction,O
in,O
SP,O
could,O
be,O
mitigated,O
by,O
the,O
NMDAR,B-GP
antagonist,O
",",O
ketamine,O
",",O
a,O
direct,O
pathogenic,O
role,O
for,O
QA,O
action,O
on,O
NMDARs,B-GP
can,O
only,O
be,O
speculated,O
.,O
20,O
Here,O
",",O
we,O
provide,O
the,O
first,O
direct,O
evidence,O
that,O
a,O
shift,O
toward,O
neurotoxic,O
metabolism,O
in,O
the,O
hippocampus,O
mediates,O
the,O
behavioral,O
deficits,O
following,O
peripheral,O
LPS,O
.,O
In,O
contrast,O
to,O
the,O
data,O
from,O
Walker,O
et,O
al,O
".,",O
20,O
we,O
found,O
that,O
LPS,O
-,O
induced,O
reductions,O
in,O
SP,O
were,O
not,O
KMO,B-GP
-,O
or,O
HAAO,B-GP
-,O
dependent,O
",",O
as,O
their,O
data,O
suggested,O
.,O
This,O
discrepancy,O
could,O
be,O
the,O
result,O
of,O
strain,O
-,O
related,O
differences,O
in,O
LPS,O
-,O
induced,O
metabolism,O
of,O
CD,O
-,O
1,O
versus,O
C57BL6,O
/,O
J,O
mice,B-OG
",",O
or,O
more,O
likely,O
other,O
neuroactive,O
kynurenines,O
are,O
responsible,O
for,O
driving,O
the,O
LPS,O
-,O
induced,O
anhedonia,B-DS
phenotype,O
",",O
such,O
as,O
XA,O
or,O
KA,O
.,O
It,O
is,O
also,O
possible,O
that,O
the,O
chronic,O
alterations,O
in,O
kynurenine,O
metabolites,O
that,O
exist,O
in,O
the,O
conventional,O
KMO,B-GP
and,O
HAAO,B-GP
,O
mice,B-OG
results,O
in,O
a,O
compensatory,O
recalibration,O
of,O
the,O
reward,O
system,O
",",O
as,O
the,O
effects,O
of,O
acute,O
and,O
subchronic,O
elevations,O
in,O
KA,O
on,O
the,O
dopaminergic,O
system,O
are,O
well,O
established,O
.,O
58,O
",",O
59,O
Although,O
no,O
baseline,O
differences,O
in,O
SP,O
were,O
observed,O
",",O
it,O
is,O
of,O
interest,O
to,O
note,O
that,O
the,O
LPS,O
-,O
stimulated,O
increase,O
in,O
nucleus,O
accumbens,O
KA,O
could,O
locally,O
decrease,O
extracellular,O
dopamine,O
",",O
similar,O
to,O
a,O
previously,O
demonstrated,O
effect,O
of,O
exogenous,O
KA,O
application,O
to,O
the,O
striatum,O
.,O
60,O
This,O
local,O
reduction,O
in,O
extracellular,O
DA,O
could,O
contribute,O
to,O
the,O
development,O
of,O
anhedonia,B-DS
behavior,O
following,O
LPS,O
treatment,O
.,O
Direct,O
administration,O
of,O
exogenous,O
kynurenine,O
has,O
been,O
utilized,O
in,O
a,O
number,O
of,O
contexts,O
that,O
result,O
in,O
behavioral,O
changes,O
.,O
40,O
",",O
41,O
",",O
59,O
Our,O
previous,O
work,O
demonstrated,O
that,O
exogenous,O
kynurenine,O
acutely,O
precipitates,O
a,O
depressive,O
-,O
like,O
phenotype,O
similar,O
to,O
LPS,O
.,O
16,O
Chronic,O
administration,O
of,O
kynurenine,O
during,O
early,O
development,O
or,O
to,O
adult,O
mice,B-OG
has,O
also,O
been,O
used,O
to,O
elevate,O
KA,O
levels,O
in,O
the,O
brain,O
",",O
resulting,O
in,O
deficits,O
in,O
sensorimotor,O
gating,O
",",O
attentional,O
processing,O
of,O
environmental,O
stimuli,O
",",O
spatial,O
working,O
memory,O
and,O
contextual,O
learning,O
memory,O
.,O
40,O
",",O
41,O
",",O
61,O
The,O
data,O
here,O
are,O
the,O
first,O
to,O
demonstrate,O
that,O
exogenously,O
administered,O
peripheral,O
3,O
-,O
HK,O
is,O
able,O
to,O
precipitate,O
the,O
development,O
of,O
behavioral,O
despair,O
in,O
the,O
TST,O
",",O
impair,O
working,O
memory,O
in,O
the,O
Y,O
-,O
maze,O
and,O
induce,O
anxiety,B-DS
-,O
like,O
behavior,O
assessed,O
in,O
the,O
OF,O
.,O
Of,O
note,O
",",O
general,O
locomotor,O
activity,O
in,O
the,O
OF,O
(,O
Supplementary,O
Figure,O
1A,O
",",O
1C,O
"),",O
although,O
confirmatory,O
of,O
a,O
positive,O
effect,O
of,O
LPS,O
",",O
was,O
not,O
correlated,O
to,O
depressive,O
-,O
like,O
behaviors,O
in,O
any,O
of,O
the,O
testing,O
paradigms,O
.,O
This,O
effect,O
of,O
LPS,O
in,O
the,O
OF,O
is,O
similar,O
to,O
previously,O
published,O
data,O
from,O
our,O
laboratory,O
",",O
demonstrating,O
that,O
duration,O
in,O
the,O
central,O
area,O
(,O
anxiety,B-DS
-,O
like,O
behavior,O
),O
does,O
not,O
depend,O
on,O
locomotor,O
activity,O
.,O
16,O
Although,O
the,O
open,O
was,O
conducted,O
under,O
low,O
-,O
light,O
conditions,O
and,O
more,O
light,O
might,O
provide,O
a,O
greater,O
ethological,O
conflict,O
for,O
assessing,O
anxiety,B-DS
-,O
like,O
behavior,O
",",O
the,O
primary,O
purpose,O
of,O
this,O
assessment,O
was,O
to,O
determine,O
the,O
impact,O
of,O
treatment,O
on,O
locomotor,O
activity,O
.,O
Together,O
",",O
these,O
data,O
significantly,O
enhance,O
our,O
understanding,O
of,O
the,O
metabolic,O
substrates,O
that,O
mediate,O
inflammation,O
-,O
induced,O
depressive,O
-,O
like,O
behavior,O
.,O
Whereas,O
a,O
majority,O
of,O
brain,O
kynurenine,O
is,O
supplied,O
by,O
the,O
circulation,O
",",O
62,O
these,O
data,O
indicate,O
that,O
downstream,O
metabolism,O
is,O
a,O
regionally,O
regulated,O
process,O
with,O
implications,O
for,O
behavioral,O
pathology,O
.,O
Our,O
data,O
indicate,O
that,O
hippocampal,O
-,O
dependent,O
behaviors,O
may,O
be,O
particularly,O
vulnerable,O
to,O
neurotoxic,O
dysregulation,O
of,O
kynurenine,O
metabolism,O
",",O
which,O
could,O
also,O
have,O
larger,O
implications,O
in,O
the,O
context,O
of,O
neurodegenerative,B-DS
disease,I-DS
and,O
chronic,B-DS
inflammatory,I-DS
conditions,I-DS
.,O
Therapeutic,O
manipulation,O
of,O
the,O
kynurenine,O
metabolic,O
pathway,O
remains,O
a,O
potentially,O
valuable,O
strategy,O
for,O
alleviating,O
depressive,O
symptoms,O
",",O
particularly,O
in,O
the,O
context,O
of,O
inflammation,O
and,O
comorbidity,O
.,O
Supplementary,O
Information,O
accompanies,O
the,O
paper,O
on,O
the,O
Translational,O
Psychiatry,O
website,O
(,O
http,O
://,O
www,O
.,O
nature,O
.,O
com,O
/,O
tp,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
The,O
kynurenine,O
pathway,O
of,O
tryptophan,O
metabolism,O
.,O
In,O
the,O
kynurenine,O
pathway,O
",",O
tryptophan,O
is,O
metabolized,O
to,O
kynurenine,O
by,O
indoleamine,B-GP
2,I-GP
",",I-GP
3,I-GP
-,I-GP
dioxygenase,I-GP
(,O
IDO,B-GP
"),",O
an,O
enzyme,O
that,O
is,O
upregulated,O
by,O
pro,B-GP
-,I-GP
inflammatory,I-GP
cytokines,I-GP
.,O
Kynurenine,O
is,O
then,O
either,O
metabolized,O
to,O
kynurenic,O
acid,O
(,O
KA,O
),O
by,O
kynurenine,B-GP
aminotransferases,I-GP
(,O
KATs,B-GP
"),",O
or,O
to,O
3,O
-,O
hydroxykynurenine,O
(,O
3,O
-,O
HK,O
",",O
red,O
),O
by,O
kynurenine,B-GP
-,I-GP
3,I-GP
-,I-GP
monooxygenase,I-GP
(,O
KMO,B-GP
",",O
purple,O
).,O
Under,O
basal,O
conditions,O
",",O
most,O
of,O
kynurenine,O
in,O
the,O
brain,O
is,O
metabolized,O
to,O
KA,O
",",O
a,O
N,O
-,O
methyl,O
-,O
D,O
-,O
aspartate,O
(,O
NMDA,O
),O
and,O
α7,B-GP
-,I-GP
nicotinic,I-GP
acetylcholine,I-GP
(,I-GP
α7nACh,I-GP
),I-GP
receptor,I-GP
antagonist,O
.,O
However,O
",",O
neuroinflammation,O
and,O
pro,B-GP
-,I-GP
inflammatory,I-GP
cytokines,I-GP
will,O
shift,O
kynurenine,O
metabolism,O
through,O
KMO,B-GP
to,O
3,O
-,O
HK,O
.,O
Then,O
",",O
further,O
metabolism,O
occurs,O
to,O
3,O
-,O
hydroxyanthranilic,O
acid,O
(,O
3,O
-,O
HAA,O
),O
by,O
kynureninase,B-GP
(,O
KYNU,B-GP
"),",O
and,O
then,O
3,O
-,O
HAA,O
is,O
metabolized,O
to,O
quinolinic,O
acid,O
(,O
QA,O
",",O
red,O
),O
by,O
3,B-GP
-,I-GP
hydroxyanthranilic,I-GP
acid,I-GP
dioxygenase,I-GP
(,O
HAAO,B-GP
",",O
purple,O
).,O
During,O
neuroinflammation,O
",",O
QA,O
is,O
the,O
major,O
end,O
product,O
of,O
the,O
kynurenine,O
pathway,O
",",O
a,O
metabolite,O
that,O
is,O
a,O
NMDA,B-GP
receptor,I-GP
agonist,O
and,O
an,O
oxidative,O
stressor,O
.,O
3,O
-,O
HK,O
can,O
also,O
be,O
metabolized,O
to,O
xanthurenic,O
acid,O
(,O
XA,O
),O
by,O
KATs,B-GP
when,O
substrate,O
levels,O
are,O
high,O
enough,O
.,O
This,O
branch,O
of,O
metabolites,O
(,O
3,O
-,O
HK,O
",",O
3,O
-,O
HAA,O
",",O
QA,O
",",O
XA,O
),O
is,O
considered,O
to,O
be,O
neurotoxic,O
(,O
orange,O
box,O
),O
as,O
they,O
can,O
contribute,O
to,O
oxidative,O
stress,O
and,O
glutamate,O
excitotoxicity,O
.,O
In,O
the,O
studies,O
described,O
",",O
two,O
genetic,O
mouse,B-OG
models,O
were,O
used,O
(,O
KMO,B-GP
and,O
HAAO,B-GP
knockouts,O
),O
to,O
target,O
neurotoxic,O
kynurenine,O
metabolism,O
(,O
indicated,O
by,O
purple,O
‘,O
no,O
',O
symbol,O
).,O
Kynurenine,B-GP
3,I-GP
-,I-GP
monooxygenase,I-GP
(,O
KMO,B-GP
),O
and,O
3,B-GP
-,I-GP
hydroxyanthranilic,I-GP
acid,I-GP
dioxygenase,I-GP
(,O
HAAO,B-GP
),O
transgene,O
construct,O
.,O
(,O
a,O
),O
The,O
KMO,B-GP
transgene,O
vector,O
was,O
designed,O
with,O
a,O
neomycin,O
(,O
neo,O
),O
selection,O
cassette,O
to,O
test,O
for,O
site,O
-,O
specific,O
integration,O
of,O
the,O
transgene,O
.,O
Proper,O
incorporation,O
of,O
the,O
transgene,O
results,O
in,O
gene,O
-,O
trapping,O
between,O
the,O
reporter,O
gene,O
(,O
lacZ,B-GP
),O
from,O
the,O
cassette,O
and,O
the,O
Kmo,B-GP
gene,O
during,O
transcription,O
.,O
When,O
these,O
transcripts,O
become,O
spliced,O
together,O
",",O
an,O
insertion,O
mutation,O
is,O
created,O
resulting,O
in,O
a,O
non,O
-,O
functional,O
KMO,B-GP
protein,O
and,O
a,O
KMO,B-GP
−/−,O
mouse,B-OG
.,O
The,O
vector,O
also,O
includes,O
recombination,O
sites,O
(,O
Flp,O
recombination,O
target,O
(,O
FRT,O
"),",O
loxP,O
),O
that,O
can,O
be,O
used,O
to,O
create,O
a,O
conditional,O
-,O
ready,O
mouse,B-OG
targeted,O
for,O
the,O
gene,O
of,O
interest,O
(,O
that,O
is,O
",",O
KMO,B-GP
-,O
floxed,O
).,O
(,O
b,O
),O
The,O
presence,O
of,O
the,O
transgene,O
in,O
KMO,B-GP
transgenic,O
mice,B-OG
were,O
confirmed,O
using,O
RT,O
-,O
PCR,O
for,O
either,O
the,O
wild,O
-,O
type,O
allele,O
(,O
476,O
-,O
bp,O
band,O
),O
or,O
the,O
transgenic,O
allele,O
(,O
592,O
-,O
bp,O
band,O
"),",O
as,O
indicated,O
in,O
a,O
.,O
(,O
c,O
),O
The,O
HAAO,B-GP
transgene,O
vector,O
was,O
designed,O
identical,O
to,O
the,O
KMO,B-GP
transgene,O
(,O
a,O
"),",O
targeting,O
the,O
HAAO,B-GP
genetic,O
sequence,O
.,O
(,O
d,O
),O
The,O
presence,O
of,O
the,O
HAAO,B-GP
transgene,O
was,O
confirmed,O
in,O
the,O
same,O
manner,O
as,O
the,O
KMO,B-GP
transgene,O
using,O
a,O
RT,O
-,O
PCR,O
reaction,O
for,O
the,O
wild,O
-,O
type,O
allele,O
(,O
516,O
bp,O
),O
and,O
for,O
the,O
transgenic,O
allele,O
(,O
594,O
bp,O
).,O
Kynurenine,B-GP
3,I-GP
-,I-GP
monooxygenase,I-GP
(,O
KMO,B-GP
),O
knockout,O
mice,B-OG
are,O
protected,O
from,O
distinct,O
inflammation,O
-,O
induced,O
depressive,O
-,O
like,O
behaviors,O
.,O
(,O
a,O
),O
Twenty,O
-,O
four,O
hours,O
following,O
injection,O
with,O
either,O
lipopolysaccharide,O
(,O
LPS,O
),O
or,O
saline,O
",",O
wild,O
type,O
(,O
WT,O
),O
and,O
KMO,B-GP
−/−,O
mice,B-OG
were,O
tested,O
in,O
the,O
tail,O
suspension,O
test,O
(,O
TST,O
),O
to,O
assess,O
behavioral,O
despair,O
.,O
LPS,O
increases,O
duration,O
spent,O
immobile,O
(,O
seconds,O
",",O
represented,O
as,O
%,O
Saline,O
),O
in,O
WT,O
mice,B-OG
but,O
not,O
in,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
(,O
b,O
),O
Sucrose,O
and,O
water,O
intake,O
were,O
recorded,O
for,O
the,O
24h,O
following,O
LPS,O
or,O
saline,O
injections,O
and,O
were,O
used,O
to,O
calculate,O
sucrose,O
preference,O
(,O
SP,O
),O
to,O
assess,O
anhedonia,B-DS
-,O
like,O
behavior,O
.,O
LPS,O
treatment,O
resulted,O
in,O
a,O
characteristic,O
reduction,O
in,O
SP,O
in,O
both,O
WT,O
and,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
(,O
c,O
),O
Similarly,O
",",O
at,O
24,O
h,O
post,O
treatment,O
",",O
duration,O
(,O
seconds,O
",",O
represented,O
as,O
%,O
Saline,O
),O
in,O
the,O
center,O
of,O
the,O
open,O
field,O
(,O
OF,O
),O
was,O
recorded,O
as,O
an,O
index,O
of,O
anxiety,B-DS
-,O
like,O
behavior,O
.,O
(,O
d,O
),O
Duration,O
spent,O
near,O
the,O
walls,O
of,O
the,O
OF,O
or,O
thigmotaxis,O
behavior,O
(,O
seconds,O
",",O
represented,O
as,O
%,O
Saline,O
),O
was,O
also,O
recorded,O
to,O
asses,O
anxiety,B-DS
-,O
like,O
behavior,O
.,O
In,O
both,O
OF,O
assessments,O
(,O
c,O
",",O
d,O
"),",O
LPS,O
treatment,O
resulted,O
in,O
similar,O
elevations,O
in,O
anxiety,B-DS
-,O
like,O
behavior,O
in,O
WT,O
and,O
KMO,B-GP
−/−,O
mice,B-OG
.,O
(,O
e,O
),O
Spontaneous,O
alterations,O
(,O
represented,O
as,O
%,O
Saline,O
),O
between,O
the,O
three,O
arms,O
of,O
a,O
Y,O
-,O
maze,O
were,O
recorded,O
as,O
an,O
index,O
of,O
working,O
memory,O
.,O
LPS,O
treatment,O
resulted,O
in,O
a,O
significant,O
deficit,O
in,O
spontaneous,O
alterations,O
in,O
WT,O
mice,B-OG
but,O
KMO,B-GP
−/−,O
mice,B-OG
were,O
unaffected,O
.,O
Data,O
represent,O
sample,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
n,O
=,O
13,O
–,O
29,O
mice,B-OG
per,O
group,O
.,O
*,O
Main,O
effect,O
or,O
post,O
hoc,O
comparison,O
between,O
saline,O
and,O
LPS,O
within,O
the,O
same,O
genotype,O
.,O
+,O
Post,O
hoc,O
comparison,O
to,O
WT,O
with,O
the,O
same,O
intraperitoneal,O
(,O
i,O
.,O
p,O
.),O
treatment,O
.,O
"*,+",O
P,O
<,O
0,O
.,O
05,O
–,O
0,O
.,O
01,O
;,O
"**,++",O
P,O
<,O
0,O
.,O
01,O
–,O
0,O
.,O
001,O
;,O
"***,+++",O
P,O
<,O
0,O
.,O
001,O
.,O
3,O
-,O
Hydroxykynurenine,O
(,O
3,O
-,O
HK,O
),O
administration,O
induces,O
behavioral,O
despair,O
and,O
working,O
memory,B-DS
deficits,I-DS
.,O
(,O
a,O
),O
The,O
metabolite,O
produced,O
by,O
kynurenine,B-GP
3,I-GP
-,I-GP
monooxygenase,I-GP
(,O
KMO,B-GP
"),",O
3,O
-,O
HK,O
",",O
was,O
injected,O
subcutaneously,O
30,O
min,O
before,O
assessing,O
behavioral,O
despair,O
in,O
the,O
tail,O
suspension,O
test,O
(,O
TST,O
).,O
3,O
-,O
HK,O
was,O
administered,O
at,O
doses,O
of,O
0,O
.,O
0,O
mg,O
kg,O
−,O
1,O
(,O
vehicle,O
"),",O
3,O
.,O
33,O
and,O
10,O
mg,O
kg,O
−,O
1,O
and,O
resulted,O
in,O
an,O
increased,O
immobile,O
duration,O
(,O
seconds,O
",",O
represented,O
as,O
%,O
Vehicle,O
).,O
(,O
b,O
),O
Sucrose,O
preference,O
(,O
SP,O
),O
was,O
measured,O
2,O
h,O
beginning,O
30,O
min,O
post,O
-,O
subcutaneous,O
3,O
-,O
HK,O
administration,O
(,O
0,O
.,O
0,O
mg,O
kg,O
−,O
1,O
(,O
vehicle,O
"),",O
3,O
.,O
33,O
and,O
10,O
mg,O
kg,O
−,O
1,O
"),",O
and,O
anhedonia,B-DS
-,O
like,O
behavior,O
was,O
unaffected,O
by,O
peripheral,O
3,O
-,O
HK,O
.,O
Thirty,O
minutes,O
following,O
3,O
-,O
HK,O
subcutaneous,O
administration,O
(,O
0,O
.,O
0,O
mg,O
kg,O
−,O
1,O
(,O
vehicle,O
"),",O
3,O
.,O
33,O
and,O
10,O
mg,O
kg,O
−,O
1,O
"),",O
activity,O
was,O
recorded,O
in,O
the,O
open,O
field,O
(,O
OF,O
),O
to,O
determine,O
anxiety,B-DS
-,O
like,O
behavior,O
.,O
3,O
-,O
HK,O
decreased,O
the,O
duration,O
(,O
seconds,O
",",O
represented,O
as,O
%,O
Vehicle,O
;,O
(,O
c,O
),O
in,O
the,O
center,O
of,O
the,O
OF,O
while,O
there,O
was,O
no,O
impact,O
of,O
3,O
-,O
HK,O
on,O
(,O
d,O
),O
thigmotoxis,O
behavior,O
.,O
Working,O
memory,O
was,O
also,O
assessed,O
in,O
the,O
Y,O
-,O
maze,O
30,O
min,O
following,O
subcutaneous,O
administration,O
(,O
0,O
.,O
0,O
mg,O
kg,O
−,O
1,O
(,O
vehicle,O
"),",O
3,O
.,O
33,O
and,O
10,O
mg,O
kg,O
−,O
1,O
),O
of,O
3,O
-,O
HK,O
.,O
(,O
e,O
),O
Spontaneous,O
alterations,O
(%,O
Vehicle,O
),O
decreased,O
following,O
treatment,O
with,O
3,O
-,O
HK,O
.,O
(,O
f,O
),O
Plasma,O
3,O
-,O
HK,O
concentrations,O
(,O
μM,O
),O
increased,O
following,O
administration,O
of,O
3,O
-,O
HK,O
.,O
(,O
g,O
),O
Similarly,O
",",O
3,O
-,O
HK,O
(,O
μM,O
),O
assessed,O
in,O
brain,O
tissue,O
was,O
elevated,O
by,O
peripheral,O
3,O
-,O
HK,O
treatment,O
.,O
Data,O
represent,O
sample,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
n,O
=,O
5,O
-,O
16,O
mice,B-OG
per,O
group,O
.,O
*,O
Main,O
effect,O
or,O
post,O
hoc,O
comparison,O
to,O
saline,O
or,O
vehicle,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
–,O
0,O
.,O
01,O
;,O
**,O
P,O
<,O
0,O
.,O
01,O
–,O
0,O
.,O
001,O
;,O
***,O
P,O
<,O
0,O
.,O
001,O
.,O
3,B-GP
-,I-GP
Hydroxyanthranilic,I-GP
acid,I-GP
dioxygenase,I-GP
(,O
HAAO,B-GP
),O
transgenic,O
mice,B-OG
are,O
shielded,O
from,O
inflammation,O
-,O
induced,O
behavioral,O
despair,O
.,O
(,O
a,O
),O
HAAO,B-GP
−/−,O
or,O
wild,O
-,O
type,O
(,O
WT,O
),O
mice,B-OG
were,O
assessed,O
for,O
duration,O
spent,O
immobile,O
(,O
s,O
),O
in,O
the,O
TST,O
24,O
h,O
following,O
lipopolysaccharide,O
(,O
LPS,O
),O
or,O
saline,O
injections,O
.,O
Whereas,O
LPS,O
treatment,O
increased,O
immobile,O
duration,O
(,O
represented,O
as,O
%,O
Saline,O
),O
in,O
WT,O
mice,B-OG
",",O
HAAO,B-GP
−/−,O
mice,B-OG
were,O
protected,O
from,O
this,O
LPS,O
-,O
induced,O
change,O
in,O
behavior,O
.,O
(,O
b,O
),O
Following,O
LPS,O
treatment,O
",",O
both,O
WT,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
had,O
a,O
reduction,O
in,O
sucrose,O
preference,O
(,O
SP,O
),O
representing,O
anhedonia,B-DS
-,O
like,O
behavior,O
.,O
(,O
c,O
),O
In,O
addition,O
",",O
behavior,O
in,O
the,O
open,O
field,O
(,O
OF,O
),O
was,O
analyzed,O
for,O
the,O
effect,O
of,O
LPS,O
treatment,O
on,O
duration,O
spent,O
in,O
the,O
center,O
of,O
the,O
arena,O
(,O
represented,O
as,O
%,O
Saline,O
"),",O
an,O
index,O
of,O
anxiety,B-DS
-,O
like,O
behavior,O
.,O
LPS,O
reduced,O
time,O
spent,O
in,O
the,O
central,O
area,O
similarly,O
in,O
both,O
genotypes,O
.,O
(,O
d,O
),O
Further,O
",",O
thigmotaxis,O
(,O
duration,O
),O
was,O
extracted,O
from,O
the,O
OF,O
behavior,O
(,O
represented,O
as,O
%,O
Saline,O
"),",O
which,O
was,O
increased,O
by,O
LPS,O
treatment,O
both,O
in,O
WT,O
and,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
(,O
e,O
),O
Spontaneous,O
alternations,O
(,O
represented,O
as,O
%,O
Saline,O
),O
in,O
a,O
Y,O
-,O
maze,O
",",O
an,O
assessment,O
of,O
working,O
memory,O
",",O
were,O
reduced,O
by,O
LPS,O
treatment,O
only,O
in,O
WT,O
mice,B-OG
and,O
not,O
in,O
HAAO,B-GP
−/−,O
mice,B-OG
.,O
Data,O
represent,O
sample,O
means,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
and,O
were,O
analyzed,O
using,O
a,O
two,O
-,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
"),",O
followed,O
by,O
the,O
Holm,O
–,O
Sidak,O
method,O
for,O
pairwise,O
multiple,O
comparisons,O
.,O
n,O
=,O
11,O
–,O
22,O
mice,B-OG
per,O
group,O
.,O
*,O
Main,O
effect,O
or,O
post,O
hoc,O
comparison,O
between,O
saline,O
and,O
LPS,O
within,O
the,O
same,O
genotype,O
.,O
+,O
Post,O
hoc,O
comparison,O
to,O
WT,O
with,O
the,O
same,O
intraperitoneal,O
(,O
i,O
.,O
p,O
.),O
treatment,O
.,O
"*,+",O
P,O
<,O
0,O
.,O
05,O
–,O
0,O
.,O
01,O
;,O
"**,++",O
P,O
<,O
0,O
.,O
01,O
–,O
0,O
.,O
001,O
;,O
"***,+++",O
P,O
<,O
0,O
.,O
001,O
.,O
Genotype,O
Main,O
effects,O
Interaction,O
WT,O
KMO,B-GP
−/−,O
HAAO,B-GP
−/−,O
Treatment,O
P,O
-,O
value,O
Genotype,O
P,O
-,O
value,O
Treatment,O
×,O
genotype,O
Saline,O
LPS,O
Saline,O
LPS,O
Saline,O
LPS,O
Brain,O
metabolites,O
(,O
μM,O
),O
Tryptophan,O
31,O
.,O
20,O
(,O
2,O
.,O
1,O
),O
34,O
.,O
44,O
(,O
2,O
.,O
9,O
),O
37,O
.,O
54,O
(,O
8,O
.,O
0,O
),O
45,O
.,O
25,O
(,O
8,O
.,O
0,O
),O
55,O
.,O
49,O
(,O
3,O
.,O
3,O
),O
67,O
.,O
96,O
(,O
0,O
.,O
9,O
),O
P,O
<,O
0,O
.,O
05,O
P,O
<,O
0,O
.,O
001,O
n,O
.,O
s,O
.,O
Kynurenine,O
0,O
.,O
17,O
(,O
0,O
.,O
01,O
),O
0,O
.,O
59,O
(,O
0,O
.,O
06,O
)**,O
2,O
.,O
95,O
(,O
0,O
.,O
2,O
)+++,O
3,O
.,O
82,O
(,O
0,O
.,O
3,O
")***,+++",O
0,O
.,O
32,O
(,O
0,O
.,O
05,O
),O
2,O
.,O
02,O
(,O
0,O
.,O
1,O
")***,+++",O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
3,O
-,O
HK,O
0,O
.,O
044,O
(,O
0,O
.,O
007,O
),O
0,O
.,O
17,O
(,O
0,O
.,O
03,O
)***,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
0,O
.,O
54,O
(,O
0,O
.,O
2,O
),O
0,O
.,O
51,O
(,O
0,O
.,O
08,O
),O
n,O
/,O
a,O
n,O
/,O
a,O
n,O
/,O
a,O
3,O
-,O
HAA,O
0,O
.,O
29,O
(,O
0,O
.,O
06,O
),O
0,O
.,O
25,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
26,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
12,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
99,O
(,O
0,O
.,O
07,O
)+++,O
0,O
.,O
44,O
(,O
0,O
.,O
05,O
")***,++",O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
QA,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
/,O
a,O
n,O
/,O
a,O
n,O
/,O
a,O
KA,O
0,O
.,O
12,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
10,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
37,O
(,O
0,O
.,O
08,O
),O
0,O
.,O
31,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
021,O
(,O
0,O
.,O
002,O
),O
0,O
.,O
038,O
(,O
0,O
.,O
001,O
),O
n,O
.,O
s,O
.,O
P,O
<,O
0,O
.,O
001,O
n,O
.,O
s,O
.,O
Plasma,O
metabolites,O
(,O
μM,O
),O
Tryptophan,O
96,O
.,O
00,O
(,O
4,O
.,O
7,O
),O
78,O
.,O
36,O
(,O
7,O
.,O
4,O
),O
65,O
.,O
72,O
(,O
3,O
.,O
9,O
),O
49,O
.,O
39,O
(,O
2,O
.,O
6,O
),O
120,O
.,O
62,O
(,O
9,O
.,O
5,O
),O
98,O
.,O
23,O
(,O
3,O
.,O
0,O
),O
P,O
<,O
0,O
.,O
05,O
P,O
<,O
0,O
.,O
001,O
n,O
.,O
s,O
.,O
Kynurenine,O
0,O
.,O
80,O
(,O
0,O
.,O
06,O
),O
2,O
.,O
41,O
(,O
0,O
.,O
1,O
),O
11,O
.,O
13,O
(,O
2,O
.,O
0,O
),O
9,O
.,O
86,O
(,O
0,O
.,O
3,O
),O
0,O
.,O
88,O
(,O
0,O
.,O
08,O
),O
3,O
.,O
19,O
(,O
0,O
.,O
4,O
),O
n,O
.,O
s,O
.,O
P,O
<,O
0,O
.,O
001,O
n,O
.,O
s,O
.,O
3,O
-,O
HK,O
0,O
.,O
083,O
(,O
0,O
.,O
01,O
),O
0,O
.,O
45,O
(,O
0,O
.,O
03,O
)***,O
0,O
.,O
0098,O
(,O
0,O
.,O
002,O
),O
0,O
.,O
017,O
(,O
0,O
.,O
006,O
)+++,O
0,O
.,O
13,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
87,O
(,O
0,O
.,O
08,O
")***,+++",O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
3,O
-,O
HAA,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
2,O
.,O
17,O
(,O
0,O
.,O
27,O
),O
3,O
.,O
16,O
(,O
1,O
.,O
0,O
),O
n,O
/,O
a,O
n,O
/,O
a,O
n,O
/,O
a,O
QA,O
0,O
.,O
39,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
48,O
(,O
0,O
.,O
08,O
),O
0,O
.,O
24,O
(,O
0,O
.,O
008,O
),O
0,O
.,O
30,O
(,O
0,O
.,O
004,O
),O
0,O
.,O
64,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
58,O
(,O
0,O
.,O
02,O
),O
n,O
.,O
s,O
.,O
P,O
<,O
0,O
.,O
001,O
n,O
.,O
s,O
.,O
KA,O
0,O
.,O
94,O
(,O
0,O
.,O
1,O
),O
0,O
.,O
59,O
(,O
0,O
.,O
07,O
),O
31,O
.,O
45,O
(,O
5,O
.,O
3,O
)+++,O
15,O
.,O
78,O
(,O
0,O
.,O
8,O
")***,+++",O
0,O
.,O
24,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
21,O
(,O
0,O
.,O
02,O
),O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
P,O
<,O
0,O
.,O
001,O
Brain,O
region,O
Metabolite,O
(,O
μM,O
),O
Treatment,O
(,O
i,O
.,O
p,O
.),O
t,O
-,O
Test,O
",",O
P,O
-,O
value,O
Saline,O
LPS,O
Dorsal,O
hippocampus,O
Tryptophan,O
102,O
.,O
93,O
(,O
5,O
.,O
1,O
),O
129,O
.,O
83,O
(,O
4,O
.,O
1,O
)***,O
P,O
<,O
0,O
.,O
001,O
Kynurenine,O
0,O
.,O
39,O
(,O
0,O
.,O
03,O
),O
1,O
.,O
02,O
(,O
0,O
.,O
1,O
)***,O
P,O
<,O
0,O
.,O
001,O
3,O
-,O
HK,O
0,O
.,O
13,O
(,O
0,O
.,O
01,O
),O
0,O
.,O
19,O
(,O
0,O
.,O
02,O
)*,O
P,O
<,O
0,O
.,O
05,O
3,O
-,O
HAA,O
1,O
.,O
35,O
(,O
0,O
.,O
06,O
),O
1,O
.,O
86,O
(,O
0,O
.,O
1,O
)**,O
P,O
<,O
0,O
.,O
01,O
KA,O
0,O
.,O
095,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
13,O
(,O
0,O
.,O
02,O
),O
n,O
.,O
s,O
.,O
XA,O
0,O
.,O
0085,O
(,O
0,O
.,O
001,O
),O
0,O
.,O
023,O
(,O
0,O
.,O
003,O
)**,O
P,O
<,O
0,O
.,O
01,O
Ventral,O
hippocampus,O
Tryptophan,O
95,O
.,O
38,O
(,O
4,O
.,O
5,O
),O
122,O
.,O
83,O
(,O
9,O
.,O
2,O
),O
n,O
.,O
s,O
.,O
Kynurenine,O
0,O
.,O
33,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
85,O
(,O
0,O
.,O
04,O
)***,O
P,O
<,O
0,O
.,O
001,O
3,O
-,O
HK,O
0,O
.,O
12,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
15,O
(,O
0,O
.,O
02,O
),O
n,O
.,O
s,O
.,O
3,O
-,O
HAA,O
1,O
.,O
62,O
(,O
0,O
.,O
08,O
),O
1,O
.,O
60,O
(,O
0,O
.,O
2,O
),O
n,O
.,O
s,O
.,O
KA,O
0,O
.,O
12,O
(,O
0,O
.,O
01,O
),O
0,O
.,O
14,O
(,O
0,O
.,O
03,O
),O
n,O
.,O
s,O
.,O
XA,O
0,O
.,O
012,O
(,O
0,O
.,O
001,O
),O
0,O
.,O
024,O
(,O
0,O
.,O
003,O
)*,O
P,O
<,O
0,O
.,O
05,O
Central,O
amygdala,O
Tryptophan,O
119,O
.,O
34,O
(,O
5,O
.,O
7,O
),O
218,O
.,O
78,O
(,O
17,O
.,O
0,O
)***,O
P,O
<,O
0,O
.,O
001,O
Kynurenine,O
0,O
.,O
46,O
(,O
0,O
.,O
04,O
),O
1,O
.,O
60,O
(,O
0,O
.,O
1,O
)***,O
P,O
<,O
0,O
.,O
001,O
3,O
-,O
HK,O
0,O
.,O
11,O
(,O
0,O
.,O
01,O
),O
0,O
.,O
19,O
(,O
0,O
.,O
03,O
)*,O
P,O
<,O
0,O
.,O
05,O
3,O
-,O
HAA,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
/,O
a,O
KA,O
0,O
.,O
12,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
40,O
(,O
0,O
.,O
1,O
)*,O
P,O
<,O
0,O
.,O
05,O
XA,O
0,O
.,O
0076,O
(,O
0,O
.,O
002,O
),O
0,O
.,O
015,O
(,O
0,O
.,O
002,O
)**,O
P,O
<,O
0,O
.,O
01,O
Nucleus,O
accumbens,O
Tryptophan,O
112,O
.,O
82,O
(,O
9,O
.,O
8,O
),O
167,O
.,O
35,O
(,O
19,O
.,O
3,O
)*,O
P,O
<,O
0,O
.,O
05,O
Kynurenine,O
0,O
.,O
45,O
(,O
0,O
.,O
07,O
),O
1,O
.,O
59,O
(,O
0,O
.,O
3,O
)**,O
P,O
<,O
0,O
.,O
01,O
3,O
-,O
HK,O
0,O
.,O
14,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
24,O
(,O
0,O
.,O
02,O
)**,O
P,O
<,O
0,O
.,O
01,O
3,O
-,O
HAA,O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
n,O
/,O
a,O
KA,O
0,O
.,O
20,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
78,O
(,O
0,O
.,O
2,O
)**,O
P,O
<,O
0,O
.,O
01,O
XA,O
0,O
.,O
0073,O
(,O
0,O
.,O
002,O
),O
0,O
.,O
016,O
(,O
0,O
.,O
002,O
)*,O
P,O
<,O
0,O
.,O
05,O
Metabolite,O
(%,O
saline,O
),O
Brain,O
region,O
ANOVA,O
",",O
P,O
-,O
value,O
Dorsal,O
hippocampus,O
Ventral,O
hippocampus,O
Central,O
amygdala,O
Nucleus,O
accumbens,O
Tryptophan,O
126,O
.,O
14,O
(,O
4,O
.,O
2,O
),O
128,O
.,O
78,O
(,O
10,O
.,O
1,O
),O
183,O
.,O
33,O
(,O
15,O
.,O
1,O
),O
148,O
.,O
33,O
(,O
18,O
.,O
0,O
),O
P,O
<,O
0,O
.,O
01,O
Kynurenine,O
259,O
.,O
03,O
(,O
19,O
.,O
8,O
),O
254,O
.,O
37,O
(,O
14,O
.,O
6,O
),O
344,O
.,O
91,O
(,O
26,O
.,O
7,O
),O
356,O
.,O
87,O
(,O
70,O
.,O
5,O
),O
n,O
.,O
s,O
.,O
3,O
-,O
HK,O
146,O
.,O
92,O
(,O
16,O
.,O
5,O
),O
127,O
.,O
98,O
(,O
14,O
.,O
7,O
),O
170,O
.,O
49,O
(,O
25,O
.,O
2,O
),O
169,O
.,O
22,O
(,O
15,O
.,O
0,O
),O
n,O
.,O
s,O
.,O
3,O
-,O
HAA,O
137,O
.,O
72,O
(,O
11,O
.,O
1,O
),O
99,O
.,O
30,O
(,O
12,O
.,O
6,O
),O
n,O
.,O
d,O
.,O
n,O
.,O
d,O
.,O
P,O
<,O
0,O
.,O
05,O
KA,O
133,O
.,O
54,O
(,O
20,O
.,O
1,O
),O
109,O
.,O
07,O
(,O
25,O
.,O
9,O
),O
323,O
.,O
49,O
(,O
110,O
.,O
3,O
),O
391,O
.,O
40,O
(,O
93,O
.,O
6,O
),O
P,O
<,O
0,O
.,O
01,O
XA,O
268,O
.,O
78,O
(,O
37,O
.,O
2,O
),O
201,O
.,O
84,O
(,O
28,O
.,O
4,O
),O
200,O
.,O
66,O
(,O
29,O
.,O
0,O
),O
224,O
.,O
32,O
(,O
38,O
.,O
5,O
),O
n,O
.,O
s,O
.,O
CD4,B-GP
+,O
T,O
Cells,O
Expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
Contribute,O
to,O
HIV,B-OG
Persistence,O
during,O
ART,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
RF,O
SGD,O
SRL,O
RPS,O
NC,O
.,O
Performed,O
the,O
experiments,O
:,O
RF,O
WB,O
MBL,O
GK,O
SD,O
MK,O
.,O
Analyzed,O
the,O
data,O
:,O
RF,O
WH,O
PB,O
MK,O
LE,O
RH,O
ES,O
FMH,O
.,O
Wrote,O
the,O
paper,O
:,O
RF,O
PB,O
SGD,O
SRL,O
RPS,O
NC,O
.,O
Exhaustion,O
of,O
Activated,O
CD8,B-GP
T,O
cells,O
Predicts,O
Disease,O
Progression,O
in,O
Primary,O
HIV,B-DS
-,I-DS
1,I-DS
Infection,I-DS
HIV,B-OG
persists,O
in,O
a,O
small,O
pool,O
of,O
latently,O
infected,O
cells,O
despite,O
antiretroviral,O
therapy,O
(,O
ART,O
).,O
Identifying,O
cellular,O
markers,O
expressed,O
at,O
the,O
surface,O
of,O
these,O
cells,O
may,O
lead,O
to,O
novel,O
therapeutic,O
strategies,O
to,O
reduce,O
the,O
size,O
of,O
the,O
HIV,B-OG
reservoir,O
.,O
We,O
hypothesized,O
that,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
immune,B-GP
checkpoint,I-GP
molecules,I-GP
would,O
be,O
enriched,O
in,O
HIV,B-OG
-,O
infected,O
cells,O
in,O
individuals,O
receiving,O
suppressive,O
ART,O
.,O
Expression,O
levels,O
of,O
7,O
immune,B-GP
checkpoint,I-GP
molecules,I-GP
(,O
PD,B-GP
-,I-GP
1,I-GP
",",O
CTLA,B-GP
-,I-GP
4,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
",",O
TIGIT,B-GP
",",O
TIM,B-GP
-,I-GP
3,I-GP
",",O
CD160,B-GP
and,O
2B4,B-GP
),O
as,O
well,O
as,O
4,O
markers,O
of,O
HIV,B-OG
persistence,O
(,O
integrated,O
and,O
total,O
HIV,B-OG
DNA,O
",",O
2,O
-,O
LTR,O
circles,O
and,O
cell,O
-,O
associated,O
unspliced,O
HIV,B-OG
RNA,O
),O
were,O
measured,O
in,O
PBMCs,O
from,O
48,O
virally,O
suppressed,O
individuals,O
.,O
Using,O
negative,O
binomial,O
regression,O
models,O
",",O
we,O
identified,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
as,O
immune,B-GP
checkpoint,I-GP
molecules,I-GP
positively,O
associated,O
with,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
.,O
The,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
independently,O
predicted,O
the,O
frequency,O
of,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
.,O
Quantification,O
of,O
HIV,B-OG
genomes,O
in,O
highly,O
purified,O
cell,O
subsets,O
from,O
blood,O
further,O
revealed,O
that,O
expressions,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
were,O
associated,O
with,O
HIV,B-OG
-,O
infected,O
cells,O
in,O
distinct,O
memory,O
CD4,B-GP
+,O
T,O
cell,O
subsets,O
.,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
the,O
three,O
markers,O
were,O
highly,O
enriched,O
for,O
integrated,O
viral,O
genomes,O
(,O
median,O
of,O
8,O
.,O
2,O
fold,O
compared,O
to,O
total,O
CD4,B-GP
+,O
T,O
cells,O
).,O
Importantly,O
",",O
most,O
cells,O
carrying,O
inducible,O
HIV,B-OG
genomes,O
expressed,O
at,O
least,O
one,O
of,O
these,O
markers,O
(,O
median,O
contribution,O
of,O
cells,O
expressing,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
PD,B-GP
-,I-GP
1,I-GP
or,O
TIGIT,B-GP
to,O
the,O
inducible,O
reservoir,O
=,O
76,O
%).,O
Our,O
data,O
provide,O
evidence,O
that,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
alone,O
or,O
in,O
combination,O
are,O
enriched,O
for,O
persistent,O
HIV,B-OG
during,O
ART,O
and,O
suggest,O
that,O
immune,O
checkpoint,O
blockers,O
directed,O
against,O
these,O
receptors,O
may,O
represent,O
valuable,O
tools,O
to,O
target,O
latently,O
infected,O
cells,O
in,O
virally,O
suppressed,O
individuals,O
.,O
Author,O
Summary,O
The,O
persistence,O
of,O
HIV,B-OG
in,O
a,O
small,O
pool,O
of,O
long,O
-,O
lived,O
latently,O
infected,O
resting,O
CD4,B-GP
+,O
T,O
cells,O
is,O
a,O
major,O
barrier,O
to,O
viral,O
eradication,O
.,O
Identifying,O
cellular,O
markers,O
that,O
are,O
preferentially,O
expressed,O
at,O
the,O
surface,O
of,O
latently,O
infected,O
cells,O
may,O
lead,O
to,O
novel,O
therapeutic,O
strategies,O
to,O
cure,O
HIV,B-DS
infection,I-DS
.,O
We,O
identified,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
as,O
markers,O
preferentially,O
expressed,O
at,O
the,O
surface,O
of,O
infected,O
cells,O
in,O
individuals,O
receiving,O
ART,O
.,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
these,O
markers,O
were,O
highly,O
enriched,O
for,O
cells,O
carrying,O
HIV,B-OG
.,O
Our,O
results,O
suggest,O
that,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
may,O
represent,O
new,O
molecular,O
targets,O
to,O
interfere,O
with,O
HIV,B-OG
persistence,O
during,O
ART,O
.,O
Introduction,O
Although,O
antiretroviral,O
therapy,O
(,O
ART,O
),O
is,O
highly,O
effective,O
at,O
suppressing,O
HIV,B-OG
replication,O
",",O
viral,O
reservoirs,O
persist,O
despite,O
treatment,O
and,O
lead,O
to,O
rapid,O
viral,O
rebound,O
when,O
ART,O
is,O
interrupted,O
[,O
1,O
–,O
4,O
].,O
A,O
major,O
step,O
to,O
achieve,O
natural,O
control,O
of,O
HIV,B-OG
replication,O
after,O
ART,O
cessation,O
would,O
be,O
to,O
eliminate,O
",",O
or,O
at,O
least,O
reduce,O
",",O
the,O
number,O
of,O
long,O
-,O
lived,O
infected,O
cells,O
from,O
which,O
HIV,B-OG
reignite,O
infection,B-DS
.,O
The,O
characterization,O
of,O
cell,O
surface,O
markers,O
that,O
could,O
identify,O
HIV,B-OG
-,O
infected,O
cells,O
persisting,O
during,O
ART,O
is,O
a,O
research,O
priority,O
towards,O
an,O
HIV,B-OG
cure,O
[,O
5,O
],O
as,O
it,O
could,O
lead,O
to,O
the,O
development,O
of,O
novel,O
eradication,O
strategies,O
.,O
Several,O
subsets,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harbor,O
replication,O
-,O
competent,O
HIV,B-OG
during,O
ART,O
.,O
These,O
CD4,B-GP
+,O
T,O
cells,O
are,O
usually,O
defined,O
on,O
the,O
basis,O
of,O
their,O
differentiation,O
stage,O
[,O
6,O
–,O
8,O
"],",O
functionality,O
or,O
homing,O
potential,O
[,O
9,O
",",O
10,O
].,O
Central,O
memory,O
(,O
TCM,O
),O
and,O
transitional,O
memory,O
(,O
TTM,O
),O
CD4,B-GP
+,O
T,O
cells,O
were,O
identified,O
as,O
the,O
major,O
cellular,O
reservoirs,O
for,O
HIV,B-OG
during,O
ART,O
[,O
6,O
].,O
More,O
recently,O
",",O
a,O
less,O
differentiated,O
subset,O
of,O
long,O
-,O
lived,O
cells,O
with,O
high,O
self,O
-,O
renewal,O
capacity,O
",",O
the,O
stem,O
-,O
cell,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
(,O
TSCM,O
"),",O
has,O
been,O
identified,O
as,O
a,O
main,O
contributor,O
to,O
long,O
-,O
term,O
HIV,B-OG
persistence,O
[,O
7,O
",",O
8,O
].,O
The,O
functional,O
and,O
homing,O
capacities,O
of,O
CD4,B-GP
+,O
T,O
cells,O
also,O
dictate,O
their,O
capacity,O
to,O
serve,O
as,O
persistent,O
reservoirs,O
for,O
HIV,B-OG
:,O
Th17,O
and,O
Th1,O
/,O
Th17,O
CD4,B-GP
+,O
T,O
cells,O
as,O
well,O
as,O
cells,O
expressing,O
CCR6,B-GP
and,O
CXCR3,B-GP
show,O
increasing,O
contribution,O
to,O
the,O
viral,O
reservoir,O
with,O
duration,O
of,O
ART,O
[,O
11,O
",",O
12,O
].,O
Immune,B-GP
checkpoint,I-GP
molecules,I-GP
(,O
ICs,B-GP
),O
are,O
co,B-GP
-,I-GP
inhibitory,I-GP
receptors,I-GP
which,O
down,O
-,O
modulate,O
immune,O
responses,O
to,O
prevent,O
hyper,O
-,O
immune,O
activation,O
",",O
minimize,O
collateral,O
damage,O
",",O
and,O
maintain,O
peripheral,O
self,O
-,O
tolerance,O
[,O
13,O
].,O
ICs,B-GP
are,O
up,O
regulated,O
upon,O
T,O
-,O
cell,O
activation,O
and,O
constrain,O
the,O
effector,O
response,O
through,O
feedback,O
inhibition,O
.,O
Overexpression,O
of,O
these,O
molecules,O
is,O
associated,O
with,O
T,O
-,O
cell,O
exhaustion,O
and,O
dysfunction,O
in,O
cancer,B-DS
and,O
chronic,B-DS
viral,I-DS
infections,I-DS
",",O
including,O
HIV,B-OG
[,O
14,O
–,O
17,O
].,O
We,O
hypothesized,O
that,O
ICs,B-GP
",",O
through,O
their,O
ability,O
to,O
inhibit,O
T,O
-,O
cell,O
activation,O
",",O
will,O
favour,O
HIV,B-OG
latency,O
during,O
ART,O
",",O
and,O
that,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
ICs,B-GP
would,O
be,O
enriched,O
for,O
persistent,O
HIV,B-OG
in,O
individuals,O
receiving,O
ART,O
.,O
We,O
focused,O
our,O
analysis,O
on,O
7,O
ICs,B-GP
",",O
namely,O
PD,B-GP
-,I-GP
1,I-GP
(,O
programmed,B-GP
cell,I-GP
death,I-GP
-,I-GP
1,I-GP
"),",O
CTLA,B-GP
-,I-GP
4,I-GP
(,O
cytotoxic,B-GP
T,I-GP
-,I-GP
lymphocyte,I-GP
-,I-GP
associated,I-GP
protein,I-GP
4,I-GP
"),",O
LAG,B-GP
-,I-GP
3,I-GP
(,O
lymphocyte,B-GP
activation,I-GP
gene,I-GP
3,I-GP
"),",O
TIGIT,B-GP
(,O
T,B-GP
-,I-GP
cell,I-GP
immunoglobulin,I-GP
and,I-GP
ITIM,I-GP
domain,I-GP
"),",O
TIM,B-GP
-,I-GP
3,I-GP
(,O
T,B-GP
cell,I-GP
immunoglobulin,I-GP
and,I-GP
mucin,I-GP
3,I-GP
"),",O
CD160,B-GP
and,O
2B4,B-GP
(,O
CD244,B-GP
).,O
PD,B-GP
-,I-GP
1,I-GP
",",O
a,O
member,O
of,O
the,O
B7,B-GP
-,O
CD28,B-GP
superfamily,O
",",O
enforces,O
an,O
inhibitory,O
program,O
that,O
blocks,O
further,O
TCR,B-GP
-,O
induced,O
T,O
-,O
cell,O
proliferation,O
and,O
cytokine,B-GP
production,O
[,O
18,O
",",O
19,O
].,O
In,O
HIV,B-DS
infection,I-DS
",",O
high,O
levels,O
of,O
PD,B-GP
-,I-GP
1,I-GP
are,O
associated,O
with,O
T,O
cell,O
exhaustion,O
[,O
14,O
–,O
16,O
",",O
20,O
],O
and,O
incomplete,O
immunological,O
response,O
to,O
ART,O
[,O
21,O
].,O
CTLA,B-GP
-,I-GP
4,I-GP
",",O
a,O
CD28,B-GP
homolog,I-GP
",",O
regulates,O
the,O
amplitude,O
of,O
T,O
-,O
cell,O
activation,O
by,O
both,O
outcompeting,O
CD28,B-GP
in,O
binding,O
CD80,B-GP
and,O
CD86,B-GP
",",O
as,O
well,O
as,O
actively,O
delivering,O
inhibitory,O
signals,O
to,O
T,O
cells,O
[,O
13,O
].,O
TIGIT,B-GP
",",O
which,O
also,O
belongs,O
to,O
the,O
B7,B-GP
/,O
CD28,B-GP
superfamily,O
",",O
acts,O
as,O
a,O
co,O
-,O
inhibitory,O
molecule,O
by,O
directly,O
down,O
regulating,O
proliferation,O
of,O
human,B-OG
T,O
cells,O
[,O
22,O
"],",O
but,O
also,O
by,O
modulating,O
cytokine,B-GP
secretion,O
of,O
DCs,O
",",O
decreasing,O
IL,B-GP
-,I-GP
12,I-GP
and,O
enhancing,O
IL,B-GP
-,I-GP
10,I-GP
productions,O
[,O
23,O
].,O
TIGIT,B-GP
has,O
been,O
recently,O
associated,O
with,O
CD8,B-GP
+,O
T,O
-,O
cell,O
dysfunction,O
during,O
HIV,B-DS
infection,I-DS
[,O
24,O
].,O
The,O
expression,O
of,O
2B4,B-GP
(,O
CD244,B-GP
"),",O
a,O
member,O
of,O
the,O
signalling,B-GP
lymphocyte,I-GP
activation,I-GP
molecule,I-GP
(,O
SLAM,B-GP
),O
is,O
also,O
modulated,O
on,O
T,O
cells,O
during,O
HIV,B-DS
infection,I-DS
[,O
17,O
",",O
25,O
].,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
a,O
member,O
of,O
the,O
immunoglobulin,B-GP
superfamily,O
",",O
is,O
structurally,O
highly,O
homologous,O
to,O
the,O
CD4,B-GP
receptor,I-GP
and,O
share,O
MHC,B-GP
-,I-GP
II,I-GP
as,O
a,O
ligand,O
[,O
26,O
].,O
Its,O
expression,O
on,O
T,O
regulatory,O
cells,O
plays,O
a,O
role,O
in,O
the,O
modulation,O
of,O
T,O
cell,O
homeostasis,O
and,O
effector,O
T,O
cell,O
responses,O
[,O
27,O
",",O
28,O
].,O
TIM,B-GP
-,I-GP
3,I-GP
is,O
also,O
an,O
immunoglobulin,B-GP
superfamily,O
member,O
and,O
its,O
expression,O
is,O
increased,O
on,O
HIV,B-OG
-,O
specific,O
CD8,B-GP
+,O
and,O
CD4,B-GP
+,O
T,O
cells,O
[,O
29,O
",",O
30,O
].,O
Finally,O
",",O
CD160,B-GP
",",O
through,O
its,O
binding,O
to,O
its,O
ligand,O
Herpes,B-GP
Virus,I-GP
Entry,I-GP
Mediator,I-GP
(,O
HVEM,B-GP
"),",O
an,O
atypical,O
member,O
of,O
TNF,B-GP
-,I-GP
receptor,I-GP
superfamily,O
",",O
delivers,O
a,O
co,O
-,O
inhibitory,O
signalling,O
to,O
CD4,B-GP
+,O
T,O
cells,O
or,O
CD8,B-GP
+,O
T,O
cells,O
dampening,O
their,O
activation,O
in,O
HIV,B-OG
-,O
infected,O
individuals,O
[,O
31,O
",",O
32,O
].,O
To,O
assess,O
the,O
relationship,O
between,O
the,O
expression,O
of,O
these,O
ICs,B-GP
and,O
HIV,B-OG
persistence,O
",",O
we,O
analysed,O
the,O
association,O
between,O
their,O
levels,O
of,O
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
and,O
the,O
size,O
of,O
the,O
HIV,B-OG
reservoir,O
in,O
individuals,O
receiving,O
ART,O
for,O
at,O
least,O
3,O
years,O
.,O
Materials,O
and,O
Methods,O
Study,O
participants,O
Forty,O
-,O
eight,O
HIV,B-OG
-,O
infected,O
participants,O
receiving,O
suppressive,O
ART,O
were,O
recruited,O
at,O
the,O
University,O
of,O
California,O
San,O
Francisco,O
(,O
UCSF,O
),O
for,O
this,O
cross,O
-,O
sectional,O
study,O
.,O
Participants,O
were,O
receiving,O
ART,O
for,O
>,O
3,O
years,O
",",O
had,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
>,O
350,O
cells,O
/,O
μl,O
and,O
HIV,B-OG
RNA,O
<,O
40,O
copies,O
/,O
mL,O
as,O
measured,O
by,O
the,O
Abbott,O
real,O
time,O
HIV,B-OG
-,I-OG
1,I-OG
PCR,O
for,O
at,O
least,O
3,O
years,O
.,O
Whole,O
blood,O
(,O
50mL,O
),O
was,O
collected,O
by,O
regular,O
blood,O
draw,O
.,O
For,O
cell,O
sorting,O
experiments,O
",",O
27,O
HIV,B-OG
-,O
infected,O
individuals,O
were,O
enrolled,O
at,O
UCSF,O
and,O
at,O
VGTIFL,O
and,O
underwent,O
leukapheresis,O
.,O
Ethics,O
statement,O
All,O
subjects,O
signed,O
informed,O
consent,O
forms,O
approved,O
by,O
the,O
UCSF,O
and,O
Martin,O
Memorial,O
Health,O
Systems,O
review,O
boards,O
(,O
IRB,O
#,O
10,O
–,O
1320,O
",",O
Ref,O
#,O
068192,O
and,O
FWA,O
#,O
00004139,O
",",O
respectively,O
).,O
Immunophenotyping,O
PBMCs,O
were,O
isolated,O
from,O
peripheral,O
blood,O
and,O
leukapheresis,O
using,O
previously,O
described,O
methods,O
[,O
6,O
",",O
33,O
].,O
Cryopreserved,O
PBMCs,O
were,O
thawed,O
",",O
washed,O
and,O
stained,O
for,O
phenotyping,O
or,O
cell,O
sorting,O
.,O
Two,O
antibody,B-GP
panels,O
were,O
used,O
to,O
measure,O
the,O
expression,O
of,O
IC,O
in,O
subsets,O
of,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
.,O
The,O
same,O
antibody,B-GP
backbone,O
was,O
used,O
in,O
the,O
two,O
panels,O
:,O
CD3,B-GP
-,O
Alexa700,O
(,O
clone,O
UCHT1,O
",",O
BD,O
#,O
557943,O
"),",O
CD4,B-GP
-,O
QDot605,O
(,O
clone,O
S3,O
.,O
5,O
",",O
Invitrogen,O
#,O
Q10008,O
"),",O
CD8,B-GP
-,O
PB,O
(,O
clone,O
RPA,O
-,O
T8,O
",",O
BD,O
#,O
558207,O
"),",O
CD14,B-GP
-,O
V500,O
(,O
clone,O
M5E2,O
",",O
BD,O
#,O
561391,O
"),",O
CD19,B-GP
-,O
AmCyan,O
(,O
clone,O
SJ25C1,O
",",O
BD,O
#,O
339190,O
"),",O
LIVE,O
/,O
DEAD,O
Aqua,O
marker,O
(,O
Invitrogen,O
#,O
L34957,O
"),",O
CD45RA,B-GP
-,O
APC,O
-,O
H7,O
(,O
clone,O
HI100,O
",",O
BD,O
#,O
560674,O
"),",O
CD27,B-GP
-,O
BV650,O
(,O
clone,O
O323,O
",",O
Biolegend,O
#,O
302828,O
),O
and,O
CCR7,B-GP
-,O
PE,B-GP
-,O
Cy7,O
(,O
clone,O
3D12,O
",",O
BD,O
#,O
557648,O
).,O
The,O
following,O
antibodies,B-GP
were,O
added,O
to,O
this,O
backbone,O
:,O
PD,B-GP
-,I-GP
1,I-GP
-,O
AF647,O
(,O
clone,O
EH12,O
.,O
1,O
",",O
BD,O
#,O
560838,O
"),",O
CTLA,B-GP
-,I-GP
4,I-GP
-,O
PE,B-GP
(,O
clone,O
BNI3,O
",",O
BD,O
#,O
555853,O
"),",O
LAG,B-GP
-,I-GP
3,I-GP
-,O
FITC,O
(,O
R,O
&,O
D,O
#,O
FAB2319F,O
"),",O
TIGIT,B-GP
-,O
PerCP,O
-,O
eF710,O
(,O
clone,O
MBSA43,O
",",O
eBioscience,O
#,O
46,O
-,O
9500,O
-,O
41,O
"),",O
TIM,B-GP
-,I-GP
3,I-GP
-,O
PE,B-GP
(,O
clone,O
F38,O
-,O
2E2,O
",",O
Biolegend,O
#,O
345006,O
"),",O
CD160,B-GP
-,O
AF488,O
(,O
clone,O
By55,O
",",O
eBioscience,O
#,O
53,O
–,O
1609,O
"),",O
2B4,B-GP
-,O
PerCP,O
-,O
Cy5,O
.,O
5,O
(,O
clone,O
C1,O
.,O
7,O
",",O
Biolegend,O
#,O
329515,O
).,O
For,O
expression,O
of,O
all,O
ICs,B-GP
",",O
gates,O
were,O
defined,O
using,O
fluorescence,O
minus,O
one,O
controls,O
.,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
were,O
identified,O
by,O
CD27,B-GP
",",O
CD45RA,B-GP
",",O
and,O
CCR7,B-GP
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
after,O
exclusion,O
of,O
dump,O
positive,O
cells,O
(,O
LIVE,O
/,O
DEAD,O
",",O
CD14,B-GP
and,O
CD19,B-GP
).,O
ICs,B-GP
were,O
measured,O
in,O
gated,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
including,O
naïve,O
CD4,B-GP
+,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD8,B-GP
-,O
CD4,B-GP
+,O
CD45RA,B-GP
+,O
CCR7,B-GP
+,O
CD27,B-GP
"+),",O
central,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD8,B-GP
-,O
CD4,B-GP
+,O
CD45RA,B-GP
-,O
CCR7,B-GP
+,O
CD27,B-GP
"+),",O
transitional,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD8,B-GP
-,O
CD4,B-GP
+,O
CD45RA,B-GP
-,O
CCR7,B-GP
-,O
CD27,B-GP
"+),",O
effector,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD8,B-GP
-,O
CD4,B-GP
+,O
CD45RA,B-GP
-,O
CCR7,B-GP
-,O
CD27,B-GP
-),O
and,O
terminally,O
differentiated,O
CD4,B-GP
+,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD8,B-GP
-,O
CD4,B-GP
+,O
CD45RA,B-GP
+,O
CCR7,B-GP
-,O
CD27,B-GP
-).,O
Data,O
was,O
acquired,O
on,O
a,O
BD,O
LSR,O
II,O
flow,O
cytometer,O
using,O
the,O
FACSDiva,O
software,O
(,O
Becton,O
Dickinson,O
),O
and,O
analysed,O
using,O
Flow,O
Jo,O
version,O
9,O
(,O
Treestar,O
).,O
Cell,O
sorting,O
Central,O
",",O
transitional,O
and,O
effector,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
were,O
sorted,O
based,O
on,O
their,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
.,O
The,O
antibodies,B-GP
used,O
for,O
sorting,O
were,O
similar,O
than,O
those,O
used,O
for,O
phenotyping,O
with,O
the,O
exception,O
of,O
CD27,B-GP
-,O
QDot655,O
(,O
clone,O
CLB,O
-,O
27,O
/,O
1,O
",",O
Invitrogen,O
#,O
Q10066,O
).,O
In,O
a,O
second,O
set,O
of,O
experiments,O
",",O
total,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD4,B-GP
+,O
CD45RA,B-GP
-),O
were,O
sorted,O
based,O
on,O
their,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
.,O
Sorted,O
cells,O
were,O
collected,O
using,O
an,O
ARIA,O
FACS,O
sorter,O
(,O
Becton,O
Dickinson,O
).,O
Isolation,O
of,O
total,O
CD4,B-GP
+,O
T,O
cells,O
Total,O
CD4,B-GP
+,O
T,O
cells,O
were,O
isolated,O
from,O
cryopreserved,O
PBMCs,O
using,O
magnetic,O
depletion,O
as,O
per,O
the,O
manufacturer,O
’,O
s,O
protocol,O
(,O
Stem,O
Cell,O
Technologies,O
",",O
Vancouver,O
",",O
Canada,O
).,O
Quantification,O
of,O
integrated,O
",",O
total,O
and,O
2,O
-,O
LTR,O
circles,O
HIV,B-OG
DNA,O
",",O
cell,O
associated,O
unspliced,O
HIV,B-OG
RNA,O
and,O
Tat,O
/,O
rev,O
inducible,O
multiply,O
spliced,O
HIV,B-OG
RNA,O
Total,O
CD4,B-GP
+,O
T,O
cells,O
or,O
sorted,O
CD4,B-GP
+,O
T,O
cell,O
subsets,O
were,O
used,O
to,O
measure,O
the,O
frequency,O
of,O
cells,O
harboring,O
HIV,B-OG
DNA,O
(,O
total,O
",",O
integrated,O
and,O
2,O
-,O
LTR,O
circles,O
),O
by,O
real,O
time,O
nested,O
PCR,O
as,O
previously,O
described,O
[,O
34,O
],O
(,O
S1A,O
Text,O
).,O
The,O
CA,O
-,O
US,O
RNA,O
was,O
measured,O
by,O
real,O
time,O
nested,O
PCR,O
as,O
previously,O
described,O
[,O
35,O
].,O
The,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
with,O
inducible,O
multiply,O
spliced,O
HIV,B-OG
RNA,O
was,O
determined,O
using,O
Tat,O
/,O
rev,O
inducible,O
limiting,O
dilution,O
assay,O
(,O
TILDA,O
),O
[,O
36,O
].,O
Statistical,O
analysis,O
Data,O
distributions,O
were,O
assessed,O
through,O
descriptive,O
statistics,O
and,O
scatter,O
plots,O
.,O
Negative,O
binomial,O
regression,O
models,O
were,O
run,O
for,O
each,O
set,O
of,O
comparisons,O
with,O
the,O
percentage,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
ICs,B-GP
being,O
the,O
predictor,O
and,O
the,O
measure,O
of,O
HIV,B-OG
persistence,O
the,O
outcome,O
.,O
We,O
chose,O
this,O
approach,O
for,O
reasons,O
described,O
previously,O
[,O
12,O
",",O
35,O
"],",O
and,O
for,O
consistency,O
with,O
those,O
previous,O
publications,O
(,O
S1B,O
Text,O
).,O
The,O
approach,O
allowed,O
us,O
to,O
fit,O
models,O
adjusting,O
for,O
the,O
effects,O
of,O
absolute,O
current,O
or,O
nadir,O
CD4,B-GP
+,O
T,O
-,O
cell,O
",",O
which,O
were,O
examined,O
for,O
all,O
combinations,O
of,O
IC,O
predictors,O
and,O
HIV,B-OG
persistence,O
outcome,O
measures,O
.,O
In,O
addition,O
",",O
the,O
negative,O
binomial,O
regression,O
models,O
take,O
into,O
account,O
that,O
copies,O
/,O
input,O
is,O
measured,O
with,O
less,O
precision,O
when,O
the,O
number,O
of,O
copies,O
is,O
lower,O
and,O
when,O
the,O
amount,O
of,O
input,O
is,O
lower,O
.,O
The,O
methods,O
also,O
permit,O
proper,O
quantitative,O
use,O
of,O
instances,O
where,O
zero,O
copies,O
were,O
present,O
in,O
the,O
specimen,O
assayed,O
",",O
without,O
a,O
need,O
for,O
ad,O
hoc,O
modifications,O
to,O
permit,O
taking,O
logarithms,O
.,O
We,O
did,O
not,O
evaluate,O
the,O
results,O
of,O
alternative,O
analysis,O
methods,O
and,O
did,O
not,O
choose,O
the,O
methods,O
post,O
-,O
hoc,O
based,O
on,O
the,O
results,O
that,O
they,O
produced,O
.,O
Analyses,O
were,O
run,O
in,O
Stata,O
version,O
13,O
.,O
1,O
(,O
Stata,O
Corp,O
",",O
College,O
Station,O
",",O
TX,O
).,O
For,O
TILDA,O
results,O
analysis,O
",",O
we,O
estimated,O
the,O
within,O
-,O
person,O
fold,O
difference,O
in,O
TILDA,O
between,O
the,O
2,O
cell,O
subsets,O
analyzed,O
(,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
any,O
versus,O
none,O
of,O
the,O
ICs,B-GP
),O
by,O
fitting,O
a,O
maximum,O
likelihood,O
model,O
to,O
the,O
raw,O
data,O
on,O
numbers,O
of,O
positive,O
and,O
negative,O
wells,O
at,O
each,O
dilution,O
(,O
S1C,O
Text,O
).,O
Results,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
are,O
associated,O
with,O
markers,O
of,O
HIV,B-OG
persistence,O
during,O
ART,O
To,O
determine,O
the,O
relationship,O
between,O
ICs,B-GP
and,O
HIV,B-OG
persistence,O
",",O
48,O
HIV,B-OG
-,O
infected,O
participants,O
on,O
suppressive,O
ART,O
for,O
a,O
median,O
time,O
(,O
IQR,O
),O
of,O
8,O
.,O
5,O
years,O
(,O
5,O
.,O
0,O
–,O
12,O
.,O
4,O
),O
and,O
a,O
median,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
(,O
IQR,O
),O
of,O
684,O
cells,O
/,O
μL,O
(,O
533,O
–,O
858,O
),O
were,O
recruited,O
(,O
Table,O
1,O
).,O
The,O
expressions,O
of,O
7,O
ICs,B-GP
on,O
CD4,B-GP
+,O
T,O
cells,O
(,O
PD,B-GP
-,I-GP
1,I-GP
",",O
CTLA,B-GP
-,I-GP
4,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
",",O
TIGIT,B-GP
",",O
TIM,B-GP
-,I-GP
3,I-GP
",",O
CD160,B-GP
and,O
2B4,B-GP
),O
were,O
measured,O
by,O
multiparametric,O
flow,O
cytometry,O
(,O
S1,O
Fig,O
).,O
The,O
frequencies,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
these,O
ICs,B-GP
were,O
variable,O
(,O
median,O
(,O
IQR,O
),O
of,O
16,O
.,O
7,O
%,O
(,O
13,O
.,O
2,O
–,O
22,O
.,O
7,O
"),",O
12,O
.,O
2,O
%,O
(,O
8,O
.,O
8,O
–,O
16,O
.,O
4,O
"),",O
12,O
.,O
0,O
%,O
(,O
8,O
.,O
9,O
–,O
16,O
.,O
1,O
"),",O
9,O
.,O
5,O
%,O
(,O
3,O
.,O
5,O
–,O
18,O
.,O
5,O
"),",O
1,O
.,O
1,O
%,O
(,O
0,O
.,O
8,O
–,O
2,O
.,O
5,O
"),",O
0,O
.,O
8,O
%,O
(,O
0,O
.,O
6,O
–,O
1,O
.,O
5,O
),O
and,O
0,O
.,O
7,O
%,O
(,O
0,O
.,O
6,O
–,O
1,O
.,O
0,O
),O
for,O
TIGIT,B-GP
",",O
PD,B-GP
-,I-GP
1,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
",",O
2B4,B-GP
",",O
CD160,B-GP
",",O
TIM,B-GP
-,I-GP
3,I-GP
and,O
CTLA,B-GP
-,I-GP
4,I-GP
respectively,O
),O
(,O
Fig,O
1A,O
).,O
Clinical,O
demographics,O
of,O
the,O
cohorts,O
.,O
Characteristics,O
Cohort,O
1,O
(,O
N,O
=,O
48,O
),O
Cohort,O
2,O
(,O
N,O
=,O
31,O
),O
Gender,O
",",O
n,O
(%),O
Male,O
46,O
(,O
96,O
%),O
29,O
(,O
94,O
%),O
Female,O
1,O
(,O
2,O
%),O
2,O
(,O
6,O
%),O
Transgender,O
1,O
(,O
2,O
%),O
0,O
(,O
0,O
%),O
Age,O
",",O
years,O
median,O
(,O
IQR,O
),O
57,O
(,O
50,O
–,O
62,O
),O
50,O
(,O
50,O
–,O
62,O
),O
Viral,O
load,O
",",O
cop,O
/,O
mL,O
<,O
50,O
<,O
50,O
Nadir,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
",",O
cells,O
/,O
μl,O
median,O
(,O
IQR,O
),O
197,O
(,O
110,O
–,O
285,O
),O
a,O
42,O
(,O
14,O
–,O
179,O
),O
b,O
Current,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
",",O
cells,O
/,O
μl,O
median,O
(,O
IQR,O
),O
684,O
(,O
530,O
–,O
862,O
),O
526,O
(,O
420,O
–,O
702,O
),O
Current,O
CD8,B-GP
+,O
T,O
-,O
cell,O
count,O
",",O
cells,O
/,O
μl,O
median,O
(,O
IQR,O
),O
914,O
(,O
639,O
–,O
1091,O
),O
830,O
(,O
617,O
–,O
1135,O
),O
CD4,B-GP
/,O
CD8,B-GP
ratio,O
median,O
(,O
IQR,O
),O
0,O
.,O
77,O
(,O
0,O
.,O
57,O
–,O
1,O
.,O
17,O
),O
0,O
.,O
64,O
(,O
0,O
.,O
40,O
–,O
0,O
.,O
91,O
),O
ART,O
",",O
years,O
median,O
(,O
IQR,O
),O
8,O
.,O
5,O
(,O
5,O
.,O
0,O
–,O
12,O
.,O
4,O
),O
8,O
.,O
8,O
(,O
6,O
.,O
2,O
–,O
12,O
.,O
6,O
),O
c,O
Data,O
only,O
available,O
for,O
(,O
a,O
),O
N,O
=,O
45,O
",",O
(,O
b,O
),O
N,O
=,O
27,O
",",O
(,O
c,O
),O
N,O
=,O
24,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
are,O
associated,O
with,O
virological,O
markers,O
of,O
HIV,B-OG
persistence,O
during,O
ART,O
.,O
(,O
A,O
),O
Expression,O
of,O
7,O
ICs,B-GP
on,O
CD4,B-GP
+,O
T,O
cells,O
in,O
individuals,O
receiving,O
suppressive,O
ART,O
(,O
n,O
=,O
48,O
).,O
Data,O
is,O
represented,O
as,O
percentage,O
of,O
CD4,B-GP
+,O
T,O
cells,O
and,O
horizontal,O
bars,O
indicate,O
median,O
values,O
with,O
interquartile,O
ranges,O
.,O
(,O
B,O
),O
Size,O
of,O
the,O
HIV,B-OG
reservoir,O
measured,O
by,O
integrated,O
HIV,B-OG
DNA,O
",",O
total,O
HIV,B-OG
DNA,O
",",O
2,O
-,O
LTR,O
circles,O
represented,O
as,O
copies,O
per,O
million,O
CD4,B-GP
+,O
T,O
cells,O
and,O
cell,O
-,O
associated,O
US,O
HIV,B-OG
RNA,O
represented,O
as,O
copies,O
per,O
million,O
copies,O
of,O
18S,O
.,O
Horizontal,O
bars,O
indicate,O
median,O
values,O
with,O
interquartile,O
ranges,O
and,O
open,O
circles,O
represent,O
the,O
limit,O
of,O
detection,O
in,O
the,O
negative,O
samples,O
(,O
based,O
on,O
cell,O
input,O
).,O
(,O
C,O
"),",O
(,O
D,O
"),",O
(,O
E,O
),O
Associations,O
between,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
and,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
respectively,O
.,O
P,O
values,O
were,O
obtained,O
from,O
negative,O
binomial,O
regression,O
analysis,O
.,O
Effect,O
sizes,O
for,O
the,O
associations,O
are,O
as,O
follows,O
:,O
(,O
C,O
),O
A,O
2,O
-,O
fold,O
increase,O
in,O
the,O
percentage,O
of,O
PD,B-GP
-,I-GP
1,I-GP
+,O
CD4,B-GP
+,O
T,O
cell,O
was,O
associated,O
with,O
1,O
.,O
43,O
-,O
fold,O
increase,O
in,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cell,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
",",O
(,O
D,O
),O
a,O
2,O
-,O
fold,O
higher,O
percentage,O
of,O
TIGIT,B-GP
+,O
CD4,B-GP
+,O
T,O
cell,O
was,O
associated,O
with,O
1,O
.,O
91,O
-,O
fold,O
higher,O
integrated,O
HIV,B-OG
DNA,O
and,O
(,O
E,O
),O
a,O
2,O
-,O
fold,O
higher,O
percentage,O
of,O
LAG,B-GP
-,I-GP
3,I-GP
+,O
CD4,B-GP
+,O
T,O
cell,O
was,O
associated,O
with,O
1,O
.,O
62,O
-,O
fold,O
higher,O
integrated,O
HIV,B-OG
DNA,O
.,O
Open,O
circles,O
represent,O
the,O
limit,O
of,O
detection,O
in,O
the,O
negative,O
samples,O
(,O
based,O
on,O
cell,O
input,O
).,O
The,O
size,O
of,O
the,O
HIV,B-OG
reservoir,O
was,O
determined,O
by,O
measuring,O
the,O
frequencies,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
",",O
total,O
HIV,B-OG
DNA,O
and,O
2,O
-,O
LTR,O
circles,O
as,O
well,O
as,O
cell,O
-,O
associated,O
unspliced,O
(,O
CA,O
-,O
US,O
),O
HIV,B-OG
RNA,O
(,O
Fig,O
1B,O
and,O
S1,O
Table,O
).,O
Total,O
HIV,B-OG
DNA,O
and,O
cell,O
-,O
associated,O
US,O
HIV,B-OG
RNA,O
were,O
detected,O
in,O
all,O
samples,O
tested,O
",",O
whereas,O
integrated,O
HIV,B-OG
DNA,O
and,O
2,O
-,O
LTR,O
circles,O
were,O
detected,O
in,O
98,O
"%,",O
and,O
80,O
%,O
of,O
the,O
samples,O
",",O
respectively,O
.,O
We,O
evaluated,O
the,O
association,O
between,O
markers,O
of,O
HIV,B-OG
persistence,O
and,O
the,O
frequencies,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
ICs,B-GP
using,O
a,O
negative,O
binomial,O
regression,O
model,O
that,O
was,O
adjusted,O
for,O
current,O
and,O
nadir,O
CD4,B-GP
+,O
T,O
-,O
cell,O
counts,O
when,O
indicated,O
(,O
Table,O
2,O
and,O
S2,O
–,O
S4,O
Tables,O
).,O
Using,O
these,O
tailored,O
analytical,O
methods,O
for,O
HIV,B-OG
reservoir,O
measurements,O
",",O
we,O
identified,O
3,O
ICs,B-GP
for,O
which,O
the,O
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
was,O
statistically,O
significantly,O
associated,O
with,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
",",O
namely,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
Fig,O
1C,O
–,O
1E,O
and,O
Table,O
2,O
).,O
These,O
correlations,O
persisted,O
after,O
adjusting,O
for,O
nadir,O
CD4,B-GP
+,O
T,O
-,O
cell,O
counts,O
but,O
were,O
no,O
longer,O
significant,O
after,O
adjusting,O
for,O
current,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
",",O
a,O
clinical,O
parameter,O
strongly,O
associated,O
with,O
the,O
size,O
of,O
the,O
reservoir,O
during,O
ART,O
[,O
6,O
",",O
37,O
",",O
38,O
].,O
Negative,O
binomial,O
regression,O
models,O
to,O
assess,O
the,O
relationship,O
between,O
integrated,O
HIV,B-OG
DNA,O
and,O
IC,O
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
.,O
Outcome,O
Predictor,O
a,O
Unadjusted,O
Adjusted,O
for,O
Current,O
CD4,B-GP
Adjusted,O
for,O
Nadir,O
CD4,B-GP
Result,O
(,O
95,O
%,O
CI,O
),O
c,O
",",O
d,O
p,O
-,O
value,O
e,O
Result,O
(,O
95,O
%,O
CI,O
),O
p,O
-,O
value,O
Result,O
(,O
95,O
%,O
CI,O
),O
p,O
-,O
value,O
Integrated,O
HIV,B-OG
DNA,O
b,O
PD1,O
+,O
1,O
.,O
43,O
(,O
1,O
.,O
08,O
to,O
1,O
.,O
90,O
),O
0,O
.,O
012,O
1,O
.,O
17,O
(,O
0,O
.,O
91,O
to,O
1,O
.,O
50,O
),O
0,O
.,O
220,O
1,O
.,O
39,O
(,O
1,O
.,O
05,O
to,O
1,O
.,O
82,O
),O
0,O
.,O
020,O
CTLA,B-GP
-,I-GP
4,I-GP
+,O
1,O
.,O
50,O
(,O
0,O
.,O
90,O
to,O
2,O
.,O
51,O
),O
0,O
.,O
120,O
1,O
.,O
18,O
(,O
0,O
.,O
73,O
to,O
1,O
.,O
91,O
),O
0,O
.,O
500,O
1,O
.,O
43,O
(,O
0,O
.,O
88,O
to,O
2,O
.,O
35,O
),O
0,O
.,O
150,O
LAG,B-GP
-,I-GP
3,I-GP
+,O
1,O
.,O
62,O
(,O
1,O
.,O
07,O
to,O
2,O
.,O
45,O
),O
0,O
.,O
022,O
1,O
.,O
07,O
(,O
0,O
.,O
69,O
to,O
1,O
.,O
65,O
),O
0,O
.,O
760,O
1,O
.,O
58,O
(,O
1,O
.,O
07,O
to,O
2,O
.,O
35,O
),O
0,O
.,O
023,O
TIGIT,B-GP
+,O
1,O
.,O
91,O
(,O
1,O
.,O
11,O
to,O
3,O
.,O
28,O
),O
0,O
.,O
020,O
1,O
.,O
54,O
(,O
0,O
.,O
91,O
to,O
2,O
.,O
60,O
),O
0,O
.,O
110,O
1,O
.,O
87,O
(,O
1,O
.,O
10,O
to,O
3,O
.,O
16,O
),O
0,O
.,O
020,O
TIM,B-GP
-,I-GP
3,I-GP
+,O
1,O
.,O
28,O
(,O
0,O
.,O
83,O
to,O
1,O
.,O
97,O
),O
0,O
.,O
260,O
1,O
.,O
24,O
(,O
0,O
.,O
85,O
to,O
1,O
.,O
80,O
),O
0,O
.,O
260,O
1,O
.,O
38,O
(,O
0,O
.,O
89,O
to,O
2,O
.,O
14,O
),O
0,O
.,O
160,O
CD160,B-GP
+,O
1,O
.,O
07,O
(,O
0,O
.,O
82,O
to,O
1,O
.,O
39,O
),O
0,O
.,O
620,O
0,O
.,O
90,O
(,O
0,O
.,O
69,O
to,O
1,O
.,O
17,O
),O
0,O
.,O
420,O
1,O
.,O
13,O
(,O
0,O
.,O
86,O
to,O
1,O
.,O
48,O
),O
0,O
.,O
370,O
2B4,B-GP
+,O
1,O
.,O
06,O
(,O
0,O
.,O
83,O
to,O
1,O
.,O
36,O
),O
0,O
.,O
630,O
0,O
.,O
92,O
(,O
0,O
.,O
71,O
to,O
1,O
.,O
18,O
),O
0,O
.,O
500,O
1,O
.,O
10,O
(,O
0,O
.,O
87,O
to,O
1,O
.,O
39,O
),O
0,O
.,O
440,O
a,O
Percentage,O
CD4,B-GP
+,O
T,O
cells,O
that,O
express,O
Immune,B-GP
Checkpoint,I-GP
Molecules,I-GP
b,O
Integrated,O
HIV,B-OG
DNA,O
units,O
(,O
copies,O
/,O
million,O
CD4,B-GP
+,O
T,O
cells,O
),O
c,O
95,O
%,O
CI,O
=,O
95,O
%,O
confidence,O
interval,O
d,O
Result,O
interpretation,O
:,O
fold,O
-,O
change,O
in,O
the,O
outcome,O
(,O
marker,O
of,O
HIV,B-OG
persistence,O
),O
for,O
each,O
unit,O
change,O
of,O
the,O
predictor,O
(,O
Immune,B-GP
Checkpoint,I-GP
Molecules,I-GP
).,O
All,O
predictors,O
were,O
log2,O
transformed,O
",",O
so,O
results,O
here,O
are,O
interpreted,O
as,O
the,O
change,O
in,O
the,O
outcome,O
for,O
each,O
doubling,O
of,O
the,O
predictor,O
e,O
Statistically,O
significant,O
p,O
values,O
are,O
<,O
0,O
.,O
05,O
and,O
are,O
bold,O
The,O
frequency,O
of,O
PD,B-GP
-,I-GP
1,I-GP
expressing,O
CD4,B-GP
+,O
T,O
cells,O
was,O
also,O
associated,O
with,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
total,O
HIV,B-OG
DNA,O
(,O
S3,O
Table,O
"),",O
but,O
only,O
marginally,O
(,O
1,O
.,O
23,O
-,O
fold,O
effect,O
",",O
p,O
=,O
0,O
.,O
07,O
),O
when,O
the,O
model,O
was,O
adjusted,O
for,O
current,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
.,O
CA,O
-,O
US,O
HIV,B-OG
RNA,O
and,O
2,O
-,O
LTR,O
circles,O
did,O
not,O
show,O
statistically,O
significant,O
correlation,O
with,O
any,O
IC,O
expression,O
levels,O
",",O
with,O
the,O
exception,O
of,O
a,O
negative,O
association,O
between,O
the,O
frequency,O
of,O
CD160,B-GP
+,O
CD4,B-GP
+,O
T,O
cells,O
and,O
2,O
-,O
LTR,O
circles,O
that,O
remained,O
statistically,O
significant,O
after,O
adjusting,O
for,O
current,O
and,O
nadir,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
(,O
S3,O
and,O
S4,O
Tables,O
).,O
Co,O
-,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
is,O
a,O
marker,O
of,O
HIV,B-OG
persistence,O
during,O
ART,O
ICs,B-GP
are,O
co,O
-,O
expressed,O
on,O
exhausted,O
CD4,B-GP
+,O
and,O
CD8,B-GP
+,O
T,O
cells,O
during,O
untreated,O
HIV,B-DS
infection,I-DS
[,O
39,O
].,O
Using,O
a,O
Boolean,O
gating,O
strategy,O
",",O
we,O
determined,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
and,O
/,O
or,O
TIGIT,B-GP
and,O
/,O
or,O
LAG,B-GP
-,I-GP
3,I-GP
in,O
our,O
cohort,O
of,O
48,O
HIV,B-OG
-,O
infected,O
participants,O
receiving,O
suppressive,O
ART,O
(,O
Fig,O
2A,O
and,O
2B,O
).,O
The,O
majority,O
of,O
CD4,B-GP
+,O
T,O
cells,O
did,O
not,O
express,O
any,O
of,O
these,O
markers,O
(,O
median,O
(,O
IQR,O
),O
of,O
65,O
.,O
8,O
%,O
(,O
59,O
.,O
0,O
–,O
72,O
.,O
4,O
)),O
(,O
S6,O
Table,O
).,O
Less,O
than,O
10,O
%,O
(,O
8,O
.,O
5,O
%),O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressed,O
more,O
than,O
one,O
of,O
these,O
markers,O
and,O
0,O
.,O
9,O
%,O
simultaneously,O
expressed,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
.,O
We,O
further,O
assessed,O
if,O
the,O
frequency,O
of,O
these,O
discrete,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
was,O
associated,O
with,O
markers,O
of,O
HIV,B-OG
persistence,O
.,O
Using,O
the,O
negative,O
binomial,O
regression,O
model,O
",",O
we,O
found,O
that,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
not,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
was,O
strongly,O
and,O
negatively,O
correlated,O
to,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
(,O
p,O
=,O
0,O
.,O
002,O
",",O
Table,O
3,O
and,O
Fig,O
2C,O
).,O
Conversely,O
",",O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cell,O
co,O
-,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
was,O
strongly,O
and,O
positively,O
associated,O
with,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
(,O
p,O
=,O
0,O
.,O
001,O
",",O
Table,O
3,O
and,O
Fig,O
2F,O
).,O
Interestingly,O
",",O
the,O
frequencies,O
of,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
TIGIT,B-GP
with,O
either,O
PD,B-GP
-,I-GP
1,I-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
were,O
also,O
positively,O
associated,O
with,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
(,O
p,O
=,O
0,O
.,O
002,O
and,O
p,O
=,O
0,O
.,O
029,O
respectively,O
",",O
Table,O
3,O
and,O
Fig,O
2D,O
and,O
2E,O
).,O
Although,O
several,O
of,O
these,O
associations,O
were,O
less,O
or,O
no,O
longer,O
statistically,O
significant,O
when,O
the,O
model,O
was,O
adjusted,O
for,O
the,O
current,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
",",O
the,O
association,O
between,O
the,O
size,O
of,O
the,O
HIV,B-OG
reservoir,O
and,O
the,O
frequency,O
of,O
triple,O
positive,O
cells,O
(,O
PD,B-GP
-,I-GP
1,I-GP
"+,",O
LAG,B-GP
-,I-GP
3,I-GP
+,O
and,O
TIGIT,B-GP
+),O
remained,O
statistically,O
significant,O
after,O
adjustment,O
(,O
p,O
=,O
0,O
.,O
038,O
).,O
Adjusting,O
for,O
duration,O
of,O
ART,O
did,O
not,O
produce,O
any,O
substantial,O
changes,O
to,O
the,O
results,O
from,O
the,O
unadjusted,O
analysis,O
(,O
all,O
fold,O
-,O
effects,O
adjusted,O
for,O
ART,O
duration,O
within,O
7,O
%,O
of,O
those,O
unadjusted,O
).,O
All,O
together,O
",",O
these,O
results,O
indicate,O
that,O
the,O
co,O
-,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
identifies,O
a,O
unique,O
subset,O
of,O
CD4,B-GP
+,O
T,O
cells,O
that,O
strongly,O
predicts,O
the,O
frequency,O
of,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
during,O
ART,O
.,O
Co,O
-,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
is,O
a,O
marker,O
of,O
HIV,B-OG
persistence,O
during,O
ART,O
.,O
(,O
A,O
),O
Frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
and,O
/,O
or,O
TIGIT,B-GP
and,O
/,O
or,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
–(,O
P,O
-,O
T,O
-,O
L,O
"-),",O
PD,B-GP
-,I-GP
1,I-GP
single,O
+,O
(,O
P,O
"+),",O
TIGIT,B-GP
single,O
+,O
(,O
T,O
"+),",O
LAG,B-GP
-,I-GP
3,I-GP
single,O
+,O
(,O
L,O
"+),",O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
+,O
(,O
P,O
+,O
T,O
"+),",O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
(,O
T,O
+,O
L,O
"+),",O
PD,B-GP
-,I-GP
1,I-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
(,O
P,O
+,O
L,O
+),O
and,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
+,O
(,O
P,O
+,O
T,O
+,O
L,O
+)),O
determined,O
by,O
Boolean,O
gating,O
in,O
cohort,O
1,O
(,O
n,O
=,O
48,O
).,O
Horizontal,O
bars,O
indicate,O
median,O
values,O
with,O
interquartile,O
ranges,O
.,O
(,O
B,O
),O
Venn,O
diagram,O
showing,O
the,O
pattern,O
of,O
co,O
-,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
.,O
(,O
C,O
"),",O
(,O
D,O
"),",O
(,O
E,O
"),",O
(,O
F,O
),O
Associations,O
between,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
and,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
none,O
of,O
these,O
markers,O
(,O
triple,O
"–),",O
PD,B-GP
-,I-GP
1,I-GP
and,O
TIGIT,B-GP
(,O
double,O
"+),",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
double,O
+),O
and,O
PD,B-GP
-,I-GP
1,I-GP
and,O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
triple,O
"+),",O
respectively,O
.,O
P,O
values,O
were,O
obtained,O
from,O
negative,O
binomial,O
regression,O
analysis,O
.,O
Effect,O
sizes,O
for,O
the,O
associations,O
are,O
as,O
follows,O
:,O
(,O
C,O
),O
0,O
.,O
69,O
-,O
fold,O
-,O
change,O
in,O
integrated,O
HIV,B-OG
DNA,O
for,O
1,O
point,O
increase,O
in,O
percentage,O
of,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
—,O
CD4,B-GP
+,O
T,O
cells,O
",",O
(,O
D,O
),O
1,O
.,O
18,O
-,O
fold,O
-,O
change,O
in,O
integrated,O
HIV,B-OG
DNA,O
for,O
1,O
point,O
increase,O
in,O
percentage,O
of,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
+,O
CD4,B-GP
+,O
T,O
cells,O
",",O
(,O
E,O
),O
1,O
.,O
30,O
-,O
fold,O
-,O
change,O
in,O
integrated,O
HIV,B-OG
DNA,O
for,O
1,O
point,O
increase,O
in,O
percentage,O
of,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
CD4,B-GP
+,O
T,O
cells,O
and,O
(,O
F,O
),O
1,O
.,O
94,O
-,O
fold,O
-,O
change,O
in,O
integrated,O
HIV,B-OG
DNA,O
for,O
1,O
point,O
increase,O
in,O
percentage,O
of,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
+,O
CD4,B-GP
+,O
T,O
cells,O
.,O
Open,O
circles,O
represent,O
the,O
limit,O
of,O
detection,O
in,O
the,O
negative,O
samples,O
(,O
based,O
on,O
cell,O
input,O
).,O
Negative,O
binomial,O
regression,O
models,O
to,O
assess,O
the,O
relationship,O
between,O
Integrated,O
HIV,B-OG
DNA,O
and,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
and,O
/,O
or,O
TIGIT,B-GP
and,O
/,O
or,O
LAG,B-GP
-,I-GP
3,I-GP
.,O
Outcome,O
Predictor,O
a,O
Unadjusted,O
Adjusted,O
for,O
Current,O
CD4,B-GP
Adjusted,O
for,O
Nadir,O
CD4,B-GP
Adjusted,O
for,O
ART,O
duration,O
Result,O
(,O
95,O
%,O
CI,O
),O
c,O
",",O
d,O
p,O
-,O
value,O
e,O
Result,O
(,O
95,O
%,O
CI,O
),O
p,O
-,O
value,O
Result,O
(,O
95,O
%,O
CI,O
),O
p,O
-,O
value,O
Result,O
(,O
95,O
%,O
CI,O
),O
p,O
-,O
value,O
Integrated,O
HIV,B-OG
DNA,O
b,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
–,O
f,O
0,O
.,O
69,O
(,O
0,O
.,O
54,O
to,O
0,O
.,O
87,O
),O
0,O
.,O
002,O
0,O
.,O
82,O
(,O
0,O
.,O
65,O
to,O
1,O
.,O
03,O
),O
0,O
.,O
084,O
0,O
.,O
70,O
(,O
0,O
.,O
56,O
to,O
0,O
.,O
86,O
),O
0,O
.,O
001,O
0,O
.,O
68,O
(,O
0,O
.,O
54,O
–,O
0,O
.,O
85,O
),O
0,O
.,O
001,O
PD,B-GP
-,I-GP
1,I-GP
single,O
+,O
f,O
1,O
.,O
24,O
(,O
0,O
.,O
90,O
to,O
1,O
.,O
70,O
),O
0,O
.,O
187,O
1,O
.,O
09,O
(,O
0,O
.,O
80,O
to,O
1,O
.,O
48,O
),O
0,O
.,O
578,O
1,O
.,O
28,O
(,O
0,O
.,O
94,O
to,O
1,O
.,O
75,O
),O
0,O
.,O
118,O
1,O
.,O
32,O
(,O
0,O
.,O
93,O
–,O
1,O
.,O
88,O
),O
0,O
.,O
12,O
TIGIT,B-GP
single,O
+,O
1,O
.,O
06,O
(,O
0,O
.,O
99,O
to,O
1,O
.,O
14,O
),O
0,O
.,O
106,O
1,O
.,O
05,O
(,O
0,O
.,O
98,O
to,O
1,O
.,O
12,O
),O
0,O
.,O
210,O
1,O
.,O
06,O
(,O
0,O
.,O
99,O
to,O
1,O
.,O
13,O
),O
0,O
.,O
111,O
1,O
.,O
06,O
(,O
0,O
.,O
98,O
–,O
1,O
.,O
14,O
),O
0,O
.,O
13,O
LAG,B-GP
-,I-GP
3,I-GP
single,O
+,O
1,O
.,O
00,O
(,O
0,O
.,O
95,O
to,O
1,O
.,O
05,O
),O
0,O
.,O
963,O
0,O
.,O
97,O
(,O
0,O
.,O
92,O
to,O
1,O
.,O
02,O
),O
0,O
.,O
176,O
1,O
.,O
00,O
(,O
0,O
.,O
94,O
to,O
1,O
.,O
05,O
),O
0,O
.,O
848,O
1,O
.,O
00,O
(,O
0,O
.,O
95,O
–,O
1,O
.,O
05,O
),O
0,O
.,O
86,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
+,O
1,O
.,O
18,O
(,O
1,O
.,O
07,O
to,O
1,O
.,O
31,O
),O
0,O
.,O
002,O
1,O
.,O
13,O
(,O
1,O
.,O
00,O
to,O
1,O
.,O
26,O
),O
0,O
.,O
042,O
1,O
.,O
17,O
(,O
1,O
.,O
06,O
to,O
1,O
.,O
30,O
),O
0,O
.,O
003,O
1,O
.,O
19,O
(,O
1,O
.,O
07,O
–,O
1,O
.,O
32,O
),O
0,O
.,O
001,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
1,O
.,O
30,O
(,O
1,O
.,O
03,O
to,O
1,O
.,O
64,O
),O
0,O
.,O
029,O
1,O
.,O
16,O
(,O
0,O
.,O
97,O
to,O
1,O
.,O
38,O
),O
0,O
.,O
100,O
1,O
.,O
27,O
(,O
1,O
.,O
04,O
to,O
1,O
.,O
55,O
),O
0,O
.,O
018,O
1,O
.,O
29,O
(,O
1,O
.,O
02,O
–,O
1,O
.,O
65,O
),O
0,O
.,O
037,O
LAG,B-GP
-,I-GP
3,I-GP
/,O
PD,B-GP
-,I-GP
1,I-GP
double,O
+,O
1,O
.,O
08,O
(,O
0,O
.,O
96,O
to,O
1,O
.,O
23,O
),O
0,O
.,O
206,O
1,O
.,O
01,O
(,O
0,O
.,O
88,O
to,O
1,O
.,O
16,O
),O
0,O
.,O
910,O
1,O
.,O
09,O
(,O
0,O
.,O
96,O
to,O
1,O
.,O
25,O
),O
0,O
.,O
175,O
1,O
.,O
11,O
(,O
0,O
.,O
96,O
–,O
1,O
.,O
23,O
),O
0,O
.,O
15,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
+,O
1,O
.,O
94,O
(,O
1,O
.,O
33,O
to,O
2,O
.,O
83,O
),O
0,O
.,O
001,O
1,O
.,O
45,O
(,O
1,O
.,O
02,O
to,O
2,O
.,O
05,O
),O
0,O
.,O
038,O
1,O
.,O
86,O
(,O
1,O
.,O
26,O
to,O
2,O
.,O
72,O
),O
0,O
.,O
002,O
1,O
.,O
92,O
(,O
1,O
.,O
31,O
–,O
2,O
.,O
81,O
),O
0,O
.,O
001,O
a,O
Percentage,O
CD4,B-GP
+,O
T,O
cells,O
that,O
express,O
Immune,B-GP
Checkpoint,I-GP
Molecules,I-GP
b,O
Integrated,O
HIV,B-OG
DNA,O
units,O
(,O
copies,O
/,O
million,O
CD4,B-GP
+,O
T,O
cells,O
),O
c,O
95,O
%,O
CI,O
=,O
95,O
%,O
confidence,O
interval,O
d,O
Result,O
interpretation,O
:,O
fold,O
-,O
change,O
in,O
the,O
outcome,O
(,O
marker,O
of,O
HIV,B-OG
persistence,O
),O
for,O
each,O
one,O
point,O
increase,O
in,O
the,O
percent,O
of,O
cells,O
expressing,O
the,O
predictor,O
(,O
PD,B-GP
-,I-GP
1,I-GP
and,O
/,O
or,O
TIGIT,B-GP
and,O
/,O
or,O
LAG,B-GP
-,I-GP
3,I-GP
),O
e,O
Statistically,O
significant,O
p,O
values,O
are,O
<,O
0,O
.,O
05,O
and,O
are,O
bold,O
f,O
These,O
predictors,O
vary,O
more,O
than,O
others,O
",",O
so,O
results,O
are,O
scaled,O
to,O
be,O
per,O
10,O
point,O
increase,O
in,O
percent,O
of,O
cells,O
",",O
rather,O
than,O
per,O
one,O
point,O
increase,O
When,O
the,O
negative,O
binomial,O
regression,O
model,O
was,O
used,O
to,O
assess,O
the,O
relationship,O
between,O
Total,O
HIV,B-OG
DNA,O
",",O
2,O
-,O
LTR,O
circles,O
",",O
CA,O
-,O
US,O
RNA,O
and,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
and,O
/,O
or,O
TIGIT,B-GP
and,O
/,O
or,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
no,O
association,O
show,O
statistically,O
significant,O
",",O
with,O
the,O
exception,O
of,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
total,O
HIV,B-OG
DNA,O
and,O
the,O
frequency,O
of,O
PD,B-GP
-,I-GP
1,I-GP
single,O
+,O
(,O
p,O
=,O
0,O
.,O
005,O
",",O
1,O
.,O
10,O
-,O
fold,O
-,O
change,O
in,O
total,O
HIV,B-OG
DNA,O
for,O
1,O
point,O
increase,O
in,O
percentage,O
of,O
PD,B-GP
-,I-GP
1,I-GP
single,O
+,O
CD4,B-GP
+,O
T,O
cells,O
),O
and,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
+,O
CD4,B-GP
+,O
T,O
cells,O
(,O
p,O
=,O
0,O
.,O
017,O
",",O
1,O
.,O
40,O
-,O
fold,O
-,O
change,O
in,O
total,O
HIV,B-OG
DNA,O
for,O
1,O
point,O
increase,O
in,O
percentage,O
of,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
+,O
CD4,B-GP
+,O
T,O
cells,O
).,O
Expressions,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
are,O
associated,O
with,O
HIV,B-OG
-,O
infected,O
cells,O
in,O
distinct,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
during,O
ART,O
HIV,B-OG
persists,O
preferentially,O
in,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
[,O
6,O
–,O
8,O
].,O
To,O
determine,O
the,O
role,O
played,O
by,O
ICs,B-GP
in,O
each,O
individual,O
CD4,B-GP
+,O
T,O
-,O
cell,O
memory,O
subset,O
",",O
we,O
first,O
analyzed,O
the,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
the,O
3,O
ICs,B-GP
we,O
identified,O
to,O
be,O
associated,O
with,O
HIV,B-OG
persistence,O
",",O
on,O
naïve,O
(,O
TN,O
"),",O
central,O
memory,O
(,O
TCM,O
"),",O
transitional,O
memory,O
(,O
TTM,O
"),",O
effector,O
memory,O
(,O
TEM,O
),O
and,O
terminally,O
differentiated,O
(,O
TTD,O
),O
cells,O
in,O
48,O
HIV,B-OG
-,O
infected,O
participants,O
(,O
Cohort,O
1,O
:,O
clinical,O
characteristics,O
in,O
Table,O
1,O
),O
(,O
Fig,O
3A,O
",",O
3B,O
and,O
3C,O
respectively,O
).,O
As,O
expected,O
",",O
TN,O
cells,O
expressed,O
low,O
levels,O
of,O
these,O
ICs,B-GP
.,O
The,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
increased,O
with,O
differentiation,O
",",O
with,O
TEM,O
cells,O
displaying,O
the,O
highest,O
levels,O
of,O
expression,O
of,O
these,O
markers,O
.,O
The,O
highest,O
frequency,O
of,O
TIGIT,B-GP
+,O
cells,O
was,O
found,O
within,O
the,O
TTM,O
subset,O
.,O
These,O
results,O
demonstrated,O
that,O
the,O
subsets,O
of,O
memory,O
cells,O
that,O
were,O
previously,O
shown,O
to,O
harbor,O
persistent,O
HIV,B-OG
during,O
ART,O
express,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
.,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
identify,O
HIV,B-OG
-,O
infected,O
cells,O
in,O
distinct,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
during,O
ART,O
.,O
(,O
A,O
"),",O
(,O
B,O
"),",O
(,O
C,O
),O
Frequencies,O
of,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
(,O
naïve,O
(,O
TN,O
"),",O
central,O
memory,O
(,O
TCM,O
"),",O
transitional,O
memory,O
(,O
TTM,O
"),",O
effector,O
memory,O
(,O
TEM,O
),O
and,O
terminally,O
differentiated,O
(,O
TD,O
)),O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
respectively,O
.,O
Horizontal,O
bars,O
indicate,O
median,O
values,O
with,O
interquartile,O
ranges,O
.,O
(,O
D,O
"),",O
(,O
E,O
"),",O
(,O
F,O
),O
Frequencies,O
of,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
in,O
TCM,O
",",O
TTM,O
and,O
TEM,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
sorted,O
based,O
on,O
their,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
(,O
n,O
=,O
12,O
"),",O
TIGIT,B-GP
(,O
n,O
=,O
9,O
),O
or,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
n,O
=,O
7,O
"),",O
respectively,O
.,O
Results,O
are,O
expressed,O
as,O
the,O
HIV,B-OG
copy,O
number,O
in,O
million,O
cells,O
of,O
a,O
given,O
subset,O
.,O
P,O
values,O
were,O
obtained,O
from,O
negative,O
binomial,O
regression,O
analysis,O
.,O
Significant,O
differences,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
are,O
designated,O
by,O
a,O
p,O
value,O
in,O
bold,O
.,O
Open,O
circles,O
represent,O
the,O
limit,O
of,O
detection,O
in,O
the,O
negative,O
samples,O
(,O
based,O
on,O
cell,O
input,O
).,O
To,O
determine,O
whether,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
identify,O
cells,O
more,O
likely,O
to,O
carry,O
persistent,O
HIV,B-OG
in,O
virally,O
suppressed,O
participants,O
",",O
individual,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
were,O
sorted,O
based,O
on,O
their,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
in,O
a,O
subset,O
of,O
subjects,O
who,O
underwent,O
leukapheresis,O
(,O
Cohort,O
2,O
:,O
clinical,O
characteristics,O
in,O
Table,O
1,O
),O
and,O
the,O
results,O
were,O
analyzed,O
by,O
negative,O
binomial,O
regression,O
model,O
(,O
S5,O
Table,O
).,O
The,O
frequency,O
of,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
was,O
moderately,O
higher,O
in,O
PD,B-GP
-,I-GP
1,I-GP
expressing,O
TTM,O
when,O
compared,O
to,O
their,O
PD,B-GP
-,I-GP
1,I-GP
negative,O
counterparts,O
(,O
p,O
=,O
0,O
.,O
053,O
",",O
fold,O
-,O
difference,O
=,O
1,O
.,O
5,O
),O
(,O
Fig,O
3D,O
).,O
TEM,O
cells,O
expressing,O
TIGIT,B-GP
were,O
enriched,O
for,O
integrated,O
genomes,O
when,O
compared,O
to,O
their,O
TIGIT,B-GP
-,O
counterparts,O
(,O
p,O
=,O
0,O
.,O
001,O
",",O
fold,O
-,O
difference,O
=,O
2,O
.,O
7,O
),O
(,O
Fig,O
3E,O
).,O
Finally,O
",",O
all,O
the,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
(,O
TCM,O
",",O
TTM,O
and,O
TEM,O
cells,O
),O
expressing,O
LAG,B-GP
-,I-GP
3,I-GP
were,O
enriched,O
for,O
integrated,O
HIV,B-OG
DNA,O
when,O
compared,O
to,O
their,O
negative,O
counterparts,O
(,O
p,O
<,O
0,O
.,O
0001,O
",",O
fold,O
-,O
difference,O
=,O
1,O
.,O
9,O
",",O
p,O
=,O
0,O
.,O
003,O
",",O
fold,O
-,O
difference,O
=,O
1,O
.,O
8,O
and,O
p,O
=,O
0,O
.,O
030,O
",",O
fold,O
-,O
difference,O
=,O
2,O
.,O
5,O
respectively,O
),O
(,O
Fig,O
3F,O
).,O
All,O
together,O
these,O
results,O
indicate,O
that,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
enrich,O
for,O
infected,O
cells,O
in,O
distinct,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cell,O
subsets,O
in,O
individuals,O
on,O
ART,O
.,O
We,O
calculated,O
the,O
contribution,O
of,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
to,O
the,O
total,O
reservoir,O
by,O
taking,O
into,O
account,O
the,O
frequency,O
of,O
these,O
subsets,O
within,O
the,O
CD4,B-GP
compartment,O
and,O
their,O
relative,O
infection,B-DS
frequencies,O
.,O
The,O
mean,O
contributions,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
were,O
29,O
"%,",O
34,O
%,O
and,O
31,O
"%,",O
respectively,O
(,O
S2,O
Fig,O
).,O
As,O
a,O
comparator,O
",",O
TCM,O
",",O
TTM,O
and,O
TEM,O
cells,O
contributed,O
43,O
"%,",O
27,O
%,O
and,O
24,O
%,O
to,O
the,O
pool,O
of,O
infected,O
cells,O
in,O
these,O
same,O
virally,O
suppressed,O
individuals,O
.,O
These,O
data,O
indicate,O
that,O
a,O
third,O
of,O
the,O
reservoir,O
is,O
encompassed,O
in,O
cells,O
expressing,O
each,O
individual,O
marker,O
.,O
Co,O
-,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
highly,O
enriches,O
in,O
HIV,B-OG
-,O
infected,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
during,O
ART,O
We,O
then,O
determined,O
if,O
the,O
combination,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
would,O
further,O
enrich,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
for,O
HIV,B-OG
-,O
infected,O
cells,O
during,O
ART,O
.,O
The,O
average,O
frequency,O
of,O
cells,O
expressing,O
0,O
",",O
1,O
",",O
2,O
or,O
3,O
of,O
these,O
markers,O
in,O
the,O
memory,O
CD4,B-GP
+,O
T,O
compartment,O
(,O
CD45RA,B-GP
-),O
from,O
our,O
cohort,O
of,O
48,O
individuals,O
(,O
Table,O
1,O
),O
indicated,O
that,O
an,O
average,O
of,O
33,O
%,O
of,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressed,O
one,O
of,O
the,O
3,O
IC,O
only,O
",",O
12,O
%,O
expressed,O
2,O
and,O
2,O
%,O
expressed,O
the,O
3,O
markers,O
simultaneously,O
.,O
Large,O
numbers,O
of,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
were,O
sorted,O
based,O
on,O
their,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
from,O
5,O
individuals,O
.,O
The,O
combination,O
of,O
these,O
3,O
markers,O
allowed,O
us,O
to,O
sort,O
eight,O
subsets,O
of,O
cells,O
to,O
high,O
purity,O
",",O
namely,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
"-,",O
PD,B-GP
-,I-GP
1,I-GP
single,O
"+,",O
TIGIT,B-GP
single,O
"+,",O
LAG,B-GP
-,I-GP
3,I-GP
single,O
"+,",O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
"+,",O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
"+,",O
PD,B-GP
-,I-GP
1,I-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
and,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
+,O
cells,O
.,O
The,O
frequency,O
of,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
was,O
measured,O
by,O
qPCR,O
in,O
each,O
sorted,O
subset,O
(,O
S3,O
Fig,O
),O
and,O
the,O
mean,O
frequency,O
for,O
each,O
category,O
was,O
calculated,O
relative,O
to,O
total,O
CD4,B-GP
+,O
T,O
cells,O
(,O
Fig,O
4B,O
).,O
Memory,O
CD4,B-GP
+,O
T,O
cells,O
showed,O
a,O
gradual,O
enrichment,O
in,O
HIV,B-OG
-,O
infected,O
cells,O
when,O
expressing,O
an,O
increasing,O
number,O
of,O
ICs,B-GP
.,O
Memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
simultaneously,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
were,O
enriched,O
for,O
HIV,B-OG
-,O
infected,O
cells,O
up,O
to,O
10,O
times,O
more,O
when,O
compared,O
to,O
total,O
CD4,B-GP
+,O
T,O
cells,O
",",O
with,O
a,O
median,O
fold,O
increase,O
(,O
IQR,O
),O
of,O
8,O
.,O
15,O
(,O
4,O
.,O
92,O
–,O
9,O
.,O
59,O
).,O
These,O
results,O
demonstrated,O
that,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
a,O
combination,O
of,O
ICs,B-GP
were,O
highly,O
enriched,O
for,O
integrated,O
HIV,B-OG
DNA,O
during,O
ART,O
.,O
Co,O
-,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
identifies,O
HIV,B-OG
-,O
infected,O
cells,O
during,O
ART,O
.,O
(,O
A,O
),O
Pie,O
chart,O
representing,O
the,O
frequencies,O
of,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
and,O
/,O
or,O
TIGIT,B-GP
and,O
/,O
or,O
LAG,B-GP
-,I-GP
3,I-GP
in,O
cohort,O
1,O
(,O
n,O
=,O
48,O
).,O
Coloured,O
bars,O
on,O
the,O
right,O
side,O
designate,O
categories,O
of,O
ICs,B-GP
expressing,O
cells,O
:,O
Triple,O
-:,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
—,O
in,O
blue,O
;,O
single,O
+:,O
PD,B-GP
-,I-GP
1,I-GP
single,O
"+,",O
TIGIT,B-GP
single,O
"+,",O
LAG,B-GP
-,I-GP
3,I-GP
single,O
+,O
in,O
green,O
;,O
double,O
+:,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
"+,",O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
"+,",O
PD,B-GP
-,I-GP
1,I-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
in,O
orange,O
and,O
triple,O
+:,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
+,O
in,O
red,O
.,O
(,O
B,O
),O
Frequency,O
of,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
represented,O
as,O
a,O
fold,O
change,O
over,O
frequency,O
in,O
total,O
CD4,B-GP
+,O
T,O
cells,O
.,O
Mean,O
values,O
and,O
standard,O
deviations,O
from,O
5,O
independent,O
donors,O
are,O
represented,O
(,O
n,O
=,O
5,O
).,O
(,O
C,O
),O
Frequency,O
of,O
cells,O
harboring,O
inducible,O
msRNA,O
measured,O
by,O
TILDA,O
in,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
any,O
(,O
i,O
.,O
e,O
.,O
at,O
least,O
one,O
),O
versus,O
none,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
mLPT,O
+,O
and,O
mLPT,O
-,O
respectively,O
).,O
P,O
value,O
and,O
fold,O
-,O
difference,O
were,O
obtained,O
from,O
a,O
maximum,O
likelihood,O
model,O
.,O
As,O
the,O
majority,O
of,O
HIV,B-OG
genomes,O
",",O
even,O
when,O
integrated,O
",",O
are,O
defective,O
[,O
40,O
"],",O
we,O
assessed,O
if,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
identify,O
cells,O
in,O
which,O
HIV,B-OG
production,O
can,O
be,O
induced,O
.,O
As,O
the,O
frequency,O
of,O
triple,O
positive,O
cells,O
was,O
too,O
low,O
to,O
perform,O
this,O
experiment,O
",",O
we,O
sorted,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
(,O
CD45RA,B-GP
-),O
expressing,O
any,O
(,O
i,O
.,O
e,O
.,O
at,O
least,O
one,O
),O
versus,O
none,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
or,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
mLPT,O
+,O
and,O
mLPT,O
-,O
respectively,O
).,O
We,O
measured,O
the,O
frequency,O
of,O
cells,O
in,O
each,O
population,O
that,O
transcribe,O
multiply,O
spliced,O
HIV,B-OG
RNA,O
molecules,O
upon,O
induction,O
with,O
PMA,O
/,O
ionomycin,O
using,O
the,O
Tat,O
/,O
rev,O
induced,O
limiting,O
dilution,O
assay,O
(,O
TILDA,O
),O
[,O
36,O
].,O
Tat,O
/,O
rev,O
transcripts,O
were,O
detectable,O
by,O
TILDA,O
in,O
both,O
cell,O
subsets,O
from,O
all,O
of,O
the,O
8,O
individuals,O
tested,O
.,O
The,O
rate,O
of,O
inducible,O
virus,B-OG
per,O
million,O
cells,O
was,O
estimated,O
in,O
our,O
maximum,O
likelihood,O
model,O
to,O
average,O
3,O
.,O
0,O
-,O
fold,O
higher,O
in,O
mLPT,O
+,O
cells,O
than,O
in,O
mLPT,O
-,O
cells,O
from,O
the,O
same,O
participant,O
(,O
95,O
%,O
CI,O
1,O
.,O
0,O
to,O
9,O
.,O
0,O
",",O
p,O
=,O
0,O
.,O
049,O
",",O
S1C,O
Text,O
),O
(,O
Fig,O
4C,O
).,O
Taking,O
into,O
account,O
the,O
frequency,O
of,O
these,O
cell,O
subsets,O
",",O
the,O
contribution,O
of,O
cells,O
expressing,O
at,O
least,O
one,O
of,O
these,O
markers,O
to,O
the,O
total,O
pool,O
of,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
infected,O
with,O
inducible,O
HIV,B-OG
genomes,O
was,O
calculated,O
.,O
This,O
contribution,O
ranged,O
from,O
30,O
to,O
98,O
%,O
(,O
median,O
of,O
76,O
"%),",O
indicating,O
that,O
the,O
majority,O
of,O
inducible,O
HIV,B-OG
genomes,O
were,O
found,O
in,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
at,O
least,O
one,O
of,O
these,O
markers,O
.,O
These,O
experiments,O
provide,O
evidence,O
that,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
/,O
or,O
LAG,B-GP
-,I-GP
3,I-GP
are,O
enriched,O
for,O
HIV,B-OG
-,O
infected,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
inducible,O
proviruses,B-OG
during,O
ART,O
.,O
Discussion,O
In,O
this,O
study,O
",",O
we,O
identified,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
as,O
novel,O
markers,O
of,O
cells,O
that,O
are,O
more,O
frequently,O
infected,O
in,O
HIV,B-OG
-,O
infected,O
individuals,O
receiving,O
suppressive,O
ART,O
.,O
Co,O
-,O
expression,O
of,O
the,O
3,O
ICs,B-GP
identified,O
a,O
unique,O
subset,O
of,O
CD4,B-GP
+,O
T,O
cells,O
that,O
was,O
strongly,O
associated,O
with,O
the,O
size,O
of,O
the,O
HIV,B-OG
reservoir,O
and,O
that,O
was,O
highly,O
enriched,O
for,O
integrated,O
HIV,B-OG
DNA,O
.,O
Finally,O
",",O
our,O
results,O
provide,O
evidence,O
that,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
at,O
least,O
one,O
of,O
these,O
markers,O
are,O
the,O
major,O
contributors,O
to,O
the,O
pool,O
of,O
inducible,O
HIV,B-OG
genomes,O
during,O
ART,O
.,O
The,O
frequencies,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
CTLA,B-GP
-,I-GP
4,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
and,O
TIM,B-GP
-,I-GP
3,I-GP
were,O
similar,O
to,O
those,O
reported,O
by,O
other,O
groups,O
[,O
41,O
–,O
44,O
"],",O
indicating,O
that,O
the,O
cohort,O
of,O
participants,O
used,O
for,O
this,O
study,O
is,O
likely,O
to,O
be,O
representative,O
of,O
the,O
HIV,B-OG
population,O
receiving,O
suppressive,O
ART,O
.,O
In,O
addition,O
",",O
the,O
association,O
between,O
PD,B-GP
-,I-GP
1,I-GP
and,O
TIGIT,B-GP
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
and,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
carrying,O
HIV,B-OG
proviruses,B-OG
was,O
in,O
agreement,O
with,O
previously,O
reported,O
findings,O
[,O
6,O
",",O
24,O
",",O
41,O
].,O
We,O
found,O
positive,O
associations,O
between,O
the,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
and,O
TIGIT,B-GP
in,O
CD4,B-GP
+,O
T,O
cells,O
and,O
the,O
frequency,O
of,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
.,O
Of,O
note,O
",",O
these,O
three,O
markers,O
showed,O
the,O
strongest,O
inverse,O
associations,O
with,O
CD4,B-GP
+,O
T,O
cell,O
counts,O
among,O
the,O
7,O
markers,O
we,O
examined,O
",",O
suggesting,O
a,O
link,O
between,O
T,O
cell,O
homeostasis,O
and,O
HIV,B-OG
persistence,O
(,O
S4A,O
",",O
S4B,O
and,O
S4C,O
Fig,O
).,O
The,O
associations,O
between,O
individual,O
IC,O
expression,O
and,O
HIV,B-OG
persistence,O
marker,O
were,O
substantially,O
smaller,O
and,O
no,O
longer,O
statistically,O
significant,O
after,O
adjusting,O
for,O
current,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
.,O
These,O
findings,O
from,O
the,O
negative,O
binomial,O
regression,O
models,O
suggest,O
that,O
the,O
current,O
CD4,B-GP
+,O
T,O
-,O
cell,O
count,O
is,O
an,O
important,O
predictor,O
of,O
the,O
size,O
of,O
the,O
HIV,B-OG
reservoir,O
when,O
measured,O
as,O
the,O
frequency,O
of,O
cells,O
harboring,O
proviral,O
genomes,O
[,O
6,O
",",O
37,O
].,O
Importantly,O
",",O
and,O
in,O
contrast,O
to,O
cells,O
expressing,O
a,O
single,O
marker,O
",",O
the,O
frequency,O
of,O
cells,O
co,O
-,O
expressing,O
simultaneously,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
was,O
strongly,O
associated,O
with,O
the,O
size,O
of,O
the,O
reservoir,O
and,O
remained,O
after,O
adjusting,O
for,O
nadir,O
and,O
current,O
CD4,B-GP
+,O
T,O
-,O
cell,O
counts,O
.,O
This,O
result,O
reinforces,O
the,O
possibility,O
of,O
a,O
direct,O
—,O
and,O
maybe,O
synergistic,O
—,O
role,O
for,O
these,O
molecules,O
in,O
HIV,B-OG
persistence,O
during,O
ART,O
.,O
In,O
addition,O
",",O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
simultaneously,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
positively,O
correlated,O
with,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
HLADR,B-GP
/,O
CD38,B-GP
(,O
p,O
=,O
0,O
.,O
003,O
",",O
r,O
=,O
0,O
.,O
42,O
),O
and,O
Ki67,B-GP
(,O
p,O
=,O
0,O
.,O
022,O
",",O
r,O
=,O
0,O
.,O
33,O
),O
(,O
S1D,O
and,O
S1E,O
Text,O
and,O
S4D,O
and,O
S4E,O
Fig,O
).,O
These,O
associations,O
suggest,O
that,O
the,O
persistence,O
of,O
the,O
small,O
pool,O
of,O
cells,O
expressing,O
the,O
3,O
markers,O
is,O
associated,O
with,O
T,O
cell,O
activation,O
and,O
proliferation,O
.,O
Interestingly,O
",",O
we,O
observed,O
a,O
strong,O
negative,O
association,O
between,O
CD160,B-GP
expression,O
and,O
2,O
-,O
LTR,O
circles,O
.,O
Notably,O
",",O
this,O
correlation,O
remained,O
after,O
adjusting,O
for,O
current,O
and,O
nadir,O
CD4,B-GP
+,O
T,O
cell,O
counts,O
.,O
A,O
possible,O
explanation,O
for,O
these,O
findings,O
is,O
that,O
CD160,B-GP
+,O
cells,O
may,O
be,O
preferential,O
targets,O
for,O
infection,B-DS
and,O
depletion,O
during,O
ART,O
",",O
which,O
would,O
explain,O
the,O
strong,O
negative,O
association,O
between,O
the,O
frequency,O
of,O
CD160,B-GP
+,O
CD4,B-GP
+,O
T,O
cells,O
and,O
a,O
putative,O
marker,O
of,O
persistent,O
viral,O
replication,O
.,O
By,O
sorting,O
TCM,O
",",O
TTM,O
and,O
TEM,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
we,O
observed,O
that,O
cells,O
expressing,O
these,O
markers,O
were,O
enriched,O
for,O
HIV,B-OG
-,O
infected,O
cells,O
in,O
different,O
memory,O
CD4,B-GP
+,O
T,O
-,O
cells,O
subsets,O
during,O
ART,O
.,O
While,O
LAG,B-GP
-,I-GP
3,I-GP
enriched,O
for,O
integrated,O
HIV,B-OG
DNA,O
in,O
all,O
memory,O
subsets,O
(,O
TCM,O
",",O
TTM,O
",",O
and,O
TEM,O
"),",O
PD,B-GP
-,I-GP
1,I-GP
and,O
TIGIT,B-GP
enriched,O
for,O
HIV,B-OG
genomes,O
exclusively,O
in,O
TTM,O
and,O
TEM,O
cells,O
",",O
respectively,O
.,O
These,O
observations,O
suggest,O
that,O
ICs,B-GP
may,O
exert,O
different,O
pro,O
-,O
latency,O
effects,O
in,O
subsets,O
endowed,O
with,O
distinct,O
proliferative,O
and,O
activation,O
status,O
.,O
One,O
may,O
hypothesize,O
that,O
different,O
ICs,B-GP
provide,O
infected,O
cells,O
with,O
different,O
selective,O
advantage,O
to,O
persist,O
by,O
counteracting,O
distinct,O
stimuli,O
specific,O
to,O
an,O
individual,O
memory,O
cell,O
subset,O
.,O
Further,O
investigations,O
will,O
be,O
needed,O
to,O
characterize,O
the,O
mechanisms,O
by,O
which,O
these,O
ICs,B-GP
may,O
specifically,O
contribute,O
to,O
HIV,B-OG
persistence,O
within,O
these,O
distinct,O
subsets,O
.,O
Overall,O
",",O
the,O
majority,O
of,O
inducible,O
HIV,B-OG
genomes,O
were,O
found,O
in,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
at,O
least,O
one,O
of,O
these,O
markers,O
(,O
median,O
of,O
76,O
%).,O
Although,O
triple,O
negative,O
cells,O
also,O
contain,O
inducible,O
HIV,B-OG
genomes,O
",",O
our,O
data,O
provide,O
evidence,O
that,O
there,O
is,O
an,O
enrichment,O
for,O
inducible,O
viral,O
genomes,O
in,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
these,O
markers,O
.,O
Importantly,O
",",O
we,O
found,O
a,O
gradual,O
enrichment,O
in,O
integrated,O
HIV,B-OG
DNA,O
in,O
cells,O
that,O
express,O
multiple,O
ICs,B-GP
simultaneously,O
.,O
This,O
observation,O
mirrors,O
the,O
synergistic,O
mechanisms,O
of,O
action,O
of,O
these,O
receptors,O
to,O
dampen,O
T,O
cell,O
functions,O
.,O
Indeed,O
",",O
LAG,B-GP
-,I-GP
3,I-GP
and,O
PD,B-GP
-,I-GP
1,I-GP
are,O
commonly,O
co,O
-,O
expressed,O
on,O
exhausted,O
or,O
dysfunctional,O
T,O
cells,O
in,O
models,O
of,O
chronic,B-DS
infections,I-DS
[,O
45,O
"],",O
autoimmune,B-DS
diseases,I-DS
[,O
46,O
"],",O
and,O
cancers,B-DS
[,O
47,O
",",O
48,O
].,O
Potential,O
synergistic,O
functions,O
were,O
highlighted,O
in,O
murine,O
models,O
of,O
autoimmune,B-DS
diseases,I-DS
[,O
49,O
].,O
Anti,O
-,O
LAG,B-GP
-,I-GP
3,I-GP
blocking,O
mAb,O
has,O
recently,O
entered,O
clinical,O
testing,O
in,O
cancer,B-DS
in,O
monotherapy,O
or,O
in,O
combination,O
therapy,O
with,O
anti,O
-,O
PD,B-GP
-,I-GP
1,I-GP
(,O
NCT01968109,O
).,O
Additionally,O
",",O
TIGIT,B-GP
is,O
co,O
-,O
expressed,O
with,O
PD,B-GP
-,I-GP
1,I-GP
on,O
activated,O
CD8,B-GP
+,O
tumor,B-DS
-,O
infiltrating,O
lymphocytes,O
from,O
patients,O
with,O
melanoma,B-DS
[,O
50,O
].,O
Blockages,O
of,O
TIGIT,B-GP
and,O
PD,B-GP
-,I-GP
1,I-GP
synergize,O
to,O
improve,O
T,O
cell,O
proliferation,O
",",O
cytokines,B-GP
production,O
and,O
degranulation,O
in,O
vivo,O
in,O
melanoma,B-DS
treatment,O
and,O
in,O
vitro,O
in,O
HIV,B-DS
infection,I-DS
[,O
24,O
",",O
50,O
].,O
All,O
together,O
",",O
these,O
studies,O
indicate,O
that,O
ICs,B-GP
can,O
synergize,O
to,O
repress,O
T,O
cell,O
functions,O
and,O
suggest,O
that,O
these,O
synergies,O
may,O
also,O
play,O
a,O
role,O
in,O
HIV,B-OG
persistence,O
during,O
ART,O
.,O
The,O
expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
and,O
TIM,B-GP
-,I-GP
3,I-GP
on,O
CD4,B-GP
+,O
and,O
CD8,B-GP
+,O
T,O
cells,O
prior,O
to,O
ART,O
was,O
recently,O
identified,O
as,O
a,O
strong,O
predictor,O
of,O
time,O
to,O
viral,O
rebound,O
after,O
treatment,O
interruption,O
in,O
the,O
SPARTAC,O
study,O
[,O
43,O
].,O
It,O
is,O
possible,O
that,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
these,O
markers,O
before,O
ART,O
represent,O
a,O
preferential,O
niche,O
for,O
the,O
establishment,O
of,O
a,O
stable,O
reservoir,O
for,O
HIV,B-OG
and,O
that,O
latently,O
infected,O
cells,O
expressing,O
these,O
markers,O
preferentially,O
persist,O
during,O
ART,O
",",O
as,O
suggested,O
by,O
our,O
observations,O
.,O
In,O
our,O
study,O
",",O
we,O
identified,O
a,O
discrete,O
subset,O
of,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
as,O
an,O
important,O
predictor,O
of,O
the,O
frequency,O
of,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
during,O
ART,O
.,O
Of,O
note,O
",",O
the,O
expression,O
of,O
TIGIT,B-GP
before,O
ART,O
initiation,O
was,O
not,O
measured,O
in,O
the,O
SPARTAC,O
study,O
and,O
further,O
studies,O
will,O
be,O
needed,O
to,O
determine,O
if,O
this,O
IC,O
could,O
also,O
represent,O
a,O
pre,O
-,O
ART,O
predictor,O
of,O
viral,O
rebound,O
.,O
Our,O
data,O
provide,O
a,O
rationale,O
for,O
the,O
use,O
of,O
immune,O
checkpoint,O
blockers,O
(,O
ICBs,O
),O
to,O
target,O
latently,O
infected,O
cells,O
during,O
ART,O
.,O
Targeting,O
ICs,B-GP
by,O
ICBs,O
",",O
a,O
novel,O
class,O
of,O
molecules,O
in,O
development,O
in,O
oncology,O
",",O
may,O
have,O
a,O
double,O
benefit,O
in,O
the,O
context,O
of,O
HIV,B-OG
remission,O
by,O
both,O
targeting,O
latently,O
infected,O
cells,O
and,O
restoring,O
HIV,B-OG
-,O
specific,O
T,O
cell,O
immunity,O
.,O
By,O
enhancing,O
T,O
cell,O
activation,O
and,O
increasing,O
viral,O
transcription,O
",",O
ICBs,O
may,O
facilitate,O
HIV,B-OG
reactivation,O
in,O
latently,O
infected,O
cells,O
when,O
used,O
alone,O
or,O
in,O
combination,O
with,O
latency,O
reversing,O
agents,O
.,O
The,O
anti,O
-,O
CTLA,B-GP
-,I-GP
4,I-GP
antibody,B-GP
iplimumab,O
was,O
recently,O
shown,O
to,O
significantly,O
increase,O
CA,O
-,O
US,O
HIV,B-OG
RNA,O
in,O
an,O
HIV,B-OG
-,O
infected,O
individual,O
on,O
ART,O
",",O
consistent,O
with,O
latency,O
reversal,O
[,O
51,O
].,O
An,O
alternative,O
mechanism,O
of,O
action,O
of,O
some,O
ICBs,O
would,O
be,O
to,O
directly,O
deplete,O
cells,O
expressing,O
these,O
markers,O
",",O
as,O
observed,O
with,O
the,O
anti,O
-,O
CTLA,B-GP
-,I-GP
4,I-GP
ipilumimab,O
",",O
which,O
induces,O
direct,O
elimination,O
of,O
CTLA,B-GP
-,I-GP
4,I-GP
+,O
regulatory,O
T,O
cells,O
in,O
tumor,B-DS
tissue,O
in,O
patients,O
with,O
melanoma,B-DS
[,O
52,O
].,O
Our,O
results,O
suggest,O
that,O
the,O
administration,O
of,O
antibodies,B-GP
with,O
effector,O
functions,O
targeting,O
PD,B-GP
-,I-GP
1,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
and,O
TIGIT,B-GP
may,O
significantly,O
reduce,O
the,O
size,O
of,O
the,O
latent,O
HIV,B-OG
reservoir,O
during,O
ART,O
by,O
targeting,O
cells,O
in,O
which,O
HIV,B-OG
persists,O
.,O
Several,O
limitations,O
are,O
associated,O
with,O
our,O
study,O
.,O
We,O
have,O
not,O
adjusted,O
p,O
-,O
values,O
for,O
multiple,O
comparisons,O
",",O
because,O
such,O
adjustment,O
would,O
neglect,O
the,O
biological,O
relationships,O
among,O
our,O
positive,O
results,O
and,O
would,O
require,O
that,O
each,O
analysis,O
detract,O
from,O
the,O
others,O
",",O
rather,O
than,O
reinforcing,O
one,O
another,O
when,O
there,O
is,O
biological,O
coherence,O
[,O
53,O
],O
(,O
S1F,O
Text,O
).,O
Nevertheless,O
",",O
our,O
evidence,O
may,O
be,O
weaker,O
than,O
if,O
it,O
had,O
arisen,O
from,O
a,O
narrower,O
set,O
of,O
analyses,O
",",O
and,O
",",O
in,O
any,O
case,O
",",O
additional,O
studies,O
will,O
be,O
needed,O
to,O
confirm,O
the,O
hypotheses,O
supported,O
by,O
our,O
results,O
.,O
Most,O
of,O
our,O
analyses,O
were,O
performed,O
using,O
integrated,O
HIV,B-OG
DNA,O
as,O
a,O
marker,O
of,O
HIV,B-OG
persistence,O
.,O
We,O
chose,O
this,O
readout,O
as,O
it,O
was,O
applicable,O
to,O
small,O
subsets,O
of,O
CD4,B-GP
+,O
T,O
cells,O
on,O
which,O
measures,O
of,O
replication,O
competent,O
HIV,B-OG
cannot,O
be,O
performed,O
.,O
The,O
majority,O
of,O
viral,O
genomes,O
persisting,O
during,O
ART,O
are,O
known,O
to,O
be,O
defective,O
[,O
40,O
",",O
54,O
"],",O
and,O
although,O
our,O
experiments,O
indicate,O
that,O
cells,O
that,O
express,O
ICs,B-GP
can,O
produce,O
multiply,O
spliced,O
RNA,O
upon,O
activation,O
(,O
TILDA,O
"),",O
they,O
do,O
not,O
demonstrate,O
that,O
replication,O
competent,O
virus,B-OG
persists,O
in,O
these,O
cells,O
.,O
In,O
addition,O
",",O
our,O
results,O
are,O
limited,O
to,O
circulating,O
T,O
cells,O
.,O
It,O
is,O
possible,O
and,O
indeed,O
likely,O
that,O
the,O
biology,O
of,O
ICs,B-GP
expression,O
and,O
HIV,B-OG
persistence,O
will,O
differ,O
in,O
tissues,O
",",O
particularly,O
in,O
secondary,O
lymphoid,O
tissues,O
where,O
many,O
of,O
the,O
ligands,O
for,O
these,O
receptors,O
are,O
likely,O
to,O
be,O
expressed,O
.,O
A,O
better,O
understanding,O
of,O
the,O
nature,O
of,O
the,O
cells,O
that,O
encompass,O
the,O
latent,O
HIV,B-OG
reservoir,O
is,O
a,O
prerequisite,O
to,O
the,O
development,O
of,O
novel,O
curative,O
strategies,O
.,O
Despite,O
similarities,O
in,O
their,O
mechanisms,O
of,O
action,O
",",O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
are,O
likely,O
to,O
be,O
non,O
-,O
redundant,O
in,O
their,O
functions,O
.,O
Blocking,O
these,O
pathways,O
simultaneously,O
may,O
show,O
synergies,O
in,O
latency,O
reversal,O
",",O
as,O
suggested,O
by,O
their,O
synergistic,O
activities,O
in,O
the,O
restoration,O
of,O
T,O
cell,O
immunity,O
.,O
Supporting,O
Information,O
Materials,O
&,O
Methods,O
supporting,O
information,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Gating,O
strategy,O
of,O
7,O
ICs,B-GP
on,O
CD4,B-GP
+,O
T,O
cells,O
.,O
Expression,O
of,O
PD,B-GP
-,I-GP
1,I-GP
",",O
CTLA,B-GP
-,I-GP
4,I-GP
",",O
LAG,B-GP
-,I-GP
3,I-GP
",",O
TIGIT,B-GP
",",O
TIM,B-GP
-,I-GP
3,I-GP
",",O
CD160,B-GP
and,O
2B4,B-GP
on,O
CD4,B-GP
+,O
T,O
cells,O
in,O
individuals,O
receiving,O
suppressive,O
ART,O
(,O
n,O
=,O
48,O
).,O
Representative,O
dot,O
plots,O
from,O
one,O
participant,O
.,O
(,O
EPS,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Contribution,O
of,O
ICs,B-GP
expressing,O
cells,O
to,O
the,O
HIV,B-OG
reservoir,O
pool,O
.,O
The,O
contribution,O
of,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
(,O
A,O
"),",O
TIGIT,B-GP
(,O
B,O
),O
or,O
LAG,B-GP
-,I-GP
3,I-GP
(,O
C,O
),O
to,O
the,O
total,O
HIV,B-OG
reservoir,O
by,O
taking,O
into,O
account,O
the,O
frequency,O
of,O
these,O
subsets,O
within,O
the,O
CD4,B-GP
compartment,O
and,O
their,O
relative,O
infection,B-DS
frequencies,O
(,O
n,O
=,O
12,O
",",O
n,O
=,O
9,O
and,O
n,O
=,O
7,O
",",O
respectively,O
).,O
Horizontal,O
bars,O
indicate,O
median,O
values,O
.,O
(,O
EPS,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Frequency,O
of,O
memory,O
CD4,B-GP
+,O
T,O
cells,O
harboring,O
integrated,O
HIV,B-OG
DNA,O
in,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
–(,O
LPT,O
"-),",O
PD,B-GP
-,I-GP
1,I-GP
single,O
+,O
(,O
P,O
"),",O
TIGIT,B-GP
single,O
+,O
(,O
T,O
"),",O
LAG,B-GP
-,I-GP
3,I-GP
single,O
+,O
(,O
L,O
"),",O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
double,O
+,O
(,O
PT,O
"),",O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
(,O
LT,O
"),",O
PD,B-GP
-,I-GP
1,I-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
double,O
+,O
(,O
LP,O
),O
and,O
PD,B-GP
-,I-GP
1,I-GP
/,O
TIGIT,B-GP
/,O
LAG,B-GP
-,I-GP
3,I-GP
triple,O
+,O
(,O
LPT,O
+),O
cells,O
.,O
Raw,O
data,O
from,O
the,O
5,O
subjects,O
presented,O
in,O
Fig,O
4B,O
.,O
(,O
EPS,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
are,O
associated,O
with,O
markers,O
of,O
activation,O
/,O
proliferation,O
.,O
(,O
A,O
"),",O
(,O
B,O
"),",O
(,O
C,O
),O
Associations,O
between,O
the,O
current,O
CD4,B-GP
+,O
T,O
cell,O
counts,O
and,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
",",O
respectively,O
.,O
P,O
",",O
r,O
values,O
were,O
obtained,O
from,O
Spearman,O
’,O
s,O
ranked,O
analysis,O
.,O
(,O
D,O
"),",O
(,O
E,O
),O
Associations,O
between,O
the,O
frequency,O
of,O
CD4,B-GP
+,O
T,O
cells,O
co,O
-,O
expressing,O
PD,B-GP
-,I-GP
1,I-GP
",",O
TIGIT,B-GP
and,O
LAG,B-GP
-,I-GP
3,I-GP
and,O
the,O
frequencies,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expression,O
HLA,B-GP
-,I-GP
DR,I-GP
/,O
CD38,B-GP
and,O
Ki67,B-GP
respectively,O
.,O
P,O
",",O
r,O
values,O
were,O
obtained,O
from,O
Spearman,O
’,O
s,O
ranked,O
analysis,O
.,O
(,O
EPS,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Virological,O
markers,O
of,O
HIV,B-OG
persistence,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Negative,O
binomial,O
regression,O
models,O
to,O
assess,O
the,O
relationship,O
between,O
Total,O
HIV,B-OG
DNA,O
and,O
Immune,O
Checkpoints,O
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Negative,O
binomial,O
regression,O
models,O
to,O
assess,O
the,O
relationship,O
between,O
2,O
-,O
LTR,O
circles,O
and,O
Immune,O
Checkpoints,O
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Negative,O
binomial,O
regression,O
models,O
to,O
assess,O
the,O
relationship,O
between,O
cell,O
-,O
associated,O
US,O
HIV,B-OG
RNA,O
and,O
Immune,O
Checkpoints,O
expression,O
on,O
CD4,B-GP
+,O
T,O
cells,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Negative,O
binomial,O
regression,O
models,O
to,O
compare,O
integrated,O
HIV,B-OG
DNA,O
in,O
cells,O
expressing,O
the,O
Immune,B-GP
Checkpoint,I-GP
Molecule,I-GP
with,O
integrated,O
HIV,B-OG
DNA,O
in,O
cells,O
not,O
expressing,O
the,O
Immune,B-GP
Checkpoint,I-GP
Molecule,I-GP
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Frequencies,O
of,O
ICs,B-GP
on,O
CD4,B-GP
+,O
T,O
cells,O
in,O
cohort,O
1,O
(,O
n,O
=,O
48,O
).,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Phosphoproteomic,O
analysis,O
of,O
anaplastic,B-GP
lymphoma,I-GP
kinase,I-GP
(,O
ALK,B-GP
),O
downstream,O
signaling,O
pathways,O
identifies,O
signal,B-GP
transducer,I-GP
and,I-GP
activator,I-GP
of,I-GP
transcription,I-GP
3,I-GP
as,O
a,O
functional,O
target,O
of,O
activated,O
ALK,B-GP
in,O
neuroblastoma,B-DS
cells,O
Activation,O
of,O
the,O
anaplastic,B-GP
lymphoma,I-GP
kinase,I-GP
(,O
ALK,B-GP
),O
receptor,B-GP
tyrosine,I-GP
kinase,I-GP
is,O
a,O
key,O
oncogenic,O
mechanism,O
in,O
a,O
growing,O
number,O
of,O
tumor,B-DS
types,O
.,O
In,O
the,O
majority,O
of,O
cases,O
",",O
ALK,B-GP
is,O
activated,O
by,O
fusion,O
with,O
a,O
dimerizing,O
partner,O
protein,O
as,O
a,O
result,O
of,O
chromosomal,O
translocation,O
events,O
",",O
most,O
studied,O
in,O
the,O
case,O
of,O
the,O
nucleophosmin,B-GP
–,O
ALK,B-GP
and,O
echinoderm,B-GP
microtubule,I-GP
-,I-GP
associated,I-GP
protein,I-GP
-,I-GP
like,I-GP
4,I-GP
–,O
ALK,B-GP
oncoproteins,I-GP
.,O
It,O
is,O
now,O
also,O
appreciated,O
that,O
the,O
full,O
-,O
length,O
ALK,B-GP
receptor,I-GP
can,O
be,O
activated,O
by,O
point,O
mutations,O
and,O
by,O
deletions,O
within,O
the,O
extracellular,O
domain,O
",",O
such,O
as,O
those,O
observed,O
in,O
neuroblastoma,B-DS
.,O
Several,O
studies,O
have,O
employed,O
phosphoproteomics,O
approaches,O
to,O
find,O
substrates,O
of,O
ALK,B-GP
fusion,O
proteins,O
.,O
In,O
this,O
study,O
",",O
we,O
used,O
MS,O
-,O
based,O
phosphotyrosine,O
profiling,O
to,O
characterize,O
phosphotyrosine,O
signaling,O
events,O
associated,O
with,O
the,O
full,O
-,O
length,O
ALK,B-GP
receptor,I-GP
.,O
A,O
number,O
of,O
previously,O
identified,O
and,O
novel,O
targets,O
were,O
identified,O
.,O
One,O
of,O
these,O
",",O
signal,B-GP
transducer,I-GP
and,I-GP
activator,I-GP
of,I-GP
transcription,I-GP
3,I-GP
(,O
STAT3,B-GP
"),",O
has,O
previously,O
been,O
observed,O
to,O
be,O
activated,O
in,O
response,O
to,O
oncogenic,O
ALK,B-GP
signaling,O
",",O
but,O
the,O
significance,O
of,O
this,O
in,O
signaling,O
from,O
the,O
full,O
-,O
length,O
ALK,B-GP
receptor,I-GP
has,O
not,O
been,O
explored,O
further,O
.,O
We,O
show,O
here,O
that,O
activated,O
ALK,B-GP
robustly,O
activates,O
STAT3,B-GP
on,O
Tyr705,O
in,O
a,O
number,O
of,O
independent,O
neuroblastoma,B-DS
cell,O
lines,O
.,O
Furthermore,O
",",O
knockdown,O
of,O
STAT3,B-GP
by,O
RNA,O
interference,O
resulted,O
in,O
a,O
reduction,O
in,O
myelocytomatosis,O
neuroblastom,O
(,O
MYCN,B-GP
),O
protein,O
levels,O
downstream,O
of,O
ALK,B-GP
signaling,O
.,O
These,O
observations,O
",",O
together,O
with,O
a,O
decreased,O
level,O
of,O
MYCN,B-GP
and,O
inhibition,O
of,O
neuroblastoma,B-DS
cell,O
growth,O
in,O
the,O
presence,O
of,O
STAT3,B-GP
inhibitors,O
",",O
suggest,O
that,O
activation,O
of,O
STAT3,B-GP
is,O
important,O
for,O
ALK,B-GP
signaling,O
activity,O
in,O
neuroblastoma,B-DS
.,O
Introduction,O
Many,O
of,O
the,O
tyrosine,B-GP
kinases,I-GP
in,O
the,O
human,B-OG
kinome,O
are,O
implicated,O
in,O
human,B-OG
cancers,B-DS
1,O
",",O
and,O
provide,O
important,O
targets,O
for,O
cancer,B-DS
treatment,O
",",O
as,O
well,O
as,O
biomarkers,O
for,O
patient,O
stratification,O
.,O
Recently,O
",",O
tyrosine,B-GP
kinase,I-GP
inhibitors,O
targeting,O
anaplastic,B-GP
lymphoma,I-GP
kinase,I-GP
(,O
ALK,B-GP
),O
have,O
been,O
approved,O
for,O
the,O
treatment,O
of,O
ALK,B-GP
-,O
positive,O
non,B-DS
-,I-DS
small,I-DS
-,I-DS
cell,I-DS
-,I-DS
lung,I-DS
-,I-DS
cancer,I-DS
(,O
NSCLC,B-DS
),O
2,O
.,O
In,O
NSCLC,B-DS
",",O
ALK,B-GP
activation,O
occurs,O
via,O
chromosomal,O
translocation,O
",",O
leading,O
to,O
activation,O
of,O
the,O
kinase,B-GP
domain,O
.,O
However,O
",",O
ALK,B-GP
is,O
also,O
known,O
to,O
be,O
mutated,O
in,O
the,O
context,O
of,O
the,O
full,O
-,O
length,O
receptor,B-GP
tyrosine,I-GP
kinase,I-GP
(,O
RTK,B-GP
"),",O
this,O
being,O
most,O
clearly,O
understood,O
in,O
neuroblastoma,B-DS
.,O
Neuroblastoma,B-DS
is,O
a,O
childhood,B-DS
cancer,I-DS
that,O
stems,O
from,O
the,O
sympathetic,O
nervous,O
system,O
3,O
",",O
most,O
commonly,O
originating,O
in,O
the,O
adrenal,O
glands,O
",",O
but,O
also,O
developing,O
at,O
additional,O
sites,O
in,O
the,O
neck,O
",",O
chest,O
",",O
and,O
abdomen,O
.,O
It,O
is,O
considered,O
to,O
be,O
a,O
disease,O
of,O
developing,O
tissue,O
",",O
as,O
it,O
originates,O
from,O
precursor,O
cells,O
of,O
neural,O
crest,O
tissue,O
that,O
are,O
active,O
during,O
embryonic,O
development,O
4,O
.,O
ALK,B-GP
gain,O
-,O
of,O
-,O
function,O
mutations,O
have,O
been,O
described,O
in,O
both,O
familial,O
5,O
–,O
6,O
and,O
sporadic,O
6,O
–,O
10,O
neuroblastoma,B-DS
.,O
Although,O
there,O
is,O
currently,O
no,O
clinically,O
approved,O
specific,O
treatment,O
for,O
ALK,B-GP
mutations,O
in,O
neuroblastoma,B-DS
",",O
ongoing,O
clinical,O
trials,O
are,O
being,O
conducted,O
to,O
determine,O
the,O
potential,O
usefulness,O
of,O
ALK,B-GP
-,O
targeted,O
therapies,O
for,O
use,O
in,O
future,O
treatment,O
approaches,O
11,O
.,O
Today,O
",",O
crizotinib,O
(,O
PF,O
-,O
02341066,O
),O
is,O
in,O
use,O
as,O
a,O
Food,O
and,O
Drug,O
Administration,O
-,O
approved,O
drug,O
for,O
the,O
treatment,O
of,O
ALK,B-GP
-,O
positive,O
NSCLC,B-DS
12,O
.,O
Clinical,O
studies,O
today,O
suggest,O
that,O
anti,O
-,O
ALK,B-GP
inhibitor,O
therapy,O
offers,O
promise,O
in,O
the,O
treatment,O
of,O
ALK,B-GP
-,O
mediated,O
tumors,B-DS
2,O
",",O
11,O
.,O
One,O
consistent,O
problem,O
with,O
kinase,B-GP
inhibitors,O
and,O
their,O
use,O
in,O
a,O
more,O
personalized,O
therapy,O
approach,O
is,O
the,O
drug,O
-,O
resistant,O
mutations,O
that,O
arise,O
in,O
response,O
to,O
treatment,O
",",O
most,O
commonly,O
within,O
the,O
ATP,O
-,O
binding,O
site,O
of,O
the,O
kinase,B-GP
in,O
question,O
.,O
Originally,O
described,O
in,O
the,O
epidermal,B-GP
growth,I-GP
factor,I-GP
receptor,I-GP
and,O
breakpoint,O
cluster,O
region,O
–,O
c,O
-,O
abl,B-GP
kinase,I-GP
domains,O
14,O
–,O
18,O
",",O
this,O
has,O
now,O
also,O
been,O
described,O
for,O
echinoderm,O
microtubule,O
-,O
associated,O
protein,O
-,O
like,O
4,O
(,O
EML4,B-GP
)–,O
ALK,B-GP
by,O
Choi,O
et,O
al,O
".,",O
and,O
others,O
who,O
have,O
described,O
the,O
appearance,O
of,O
such,O
mutations,O
in,O
the,O
fusion,O
EML4,B-GP
–,O
ALK,B-GP
protein,O
that,O
confers,O
resistance,O
to,O
crizotinib,O
19,O
–,O
22,O
.,O
Phase,O
I,O
/,O
II,O
studies,O
of,O
crizotinib,O
in,O
children,O
with,O
relapsed,O
/,O
refractory,O
tumors,B-DS
involving,O
ALK,B-GP
",",O
including,O
neuroblastoma,B-DS
patients,O
",",O
have,O
been,O
initiated,O
(,O
ClinicalTrials,O
.,O
gov,O
",",O
NCT01182896,O
),O
23,O
.,O
Given,O
the,O
increasing,O
clinical,O
importance,O
of,O
ALK,B-GP
activity,O
",",O
we,O
chose,O
to,O
characterize,O
ALK,B-GP
-,O
mediated,O
tyrosine,B-GP
kinase,I-GP
signaling,O
networks,O
by,O
MS,O
-,O
based,O
phosphoproteomics,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
conducted,O
a,O
comprehensive,O
profiling,O
of,O
endogenous,O
proteins,O
that,O
are,O
tyrosine,O
-,O
phosphorylated,O
upon,O
expression,O
and,O
activation,O
of,O
wild,O
-,O
type,O
ALK,B-GP
in,O
PC12,O
cells,O
",",O
a,O
cell,O
line,O
originally,O
from,O
the,O
rat,B-OG
neural,O
crest,O
.,O
This,O
list,O
",",O
which,O
reflects,O
both,O
direct,O
and,O
indirect,O
tyrosine,O
phosphorylation,O
targets,O
as,O
a,O
result,O
of,O
ALK,B-GP
activity,O
within,O
the,O
cell,O
",",O
verifies,O
several,O
recently,O
published,O
results,O
such,O
as,O
fibroblast,B-GP
growth,I-GP
factor,I-GP
receptor,I-GP
substrate,I-GP
2,I-GP
(,O
FRS2,B-GP
),O
23,O
.,O
One,O
of,O
the,O
proteins,O
that,O
was,O
most,O
significantly,O
tyrosine,O
-,O
phosphorylated,O
in,O
response,O
to,O
ALK,B-GP
activation,O
in,O
our,O
analysis,O
was,O
signal,B-GP
transducer,I-GP
and,I-GP
activator,I-GP
of,I-GP
transcription,I-GP
3,I-GP
(,O
STAT3,B-GP
"),",O
which,O
has,O
previously,O
been,O
reported,O
to,O
be,O
phosphorylated,O
by,O
both,O
the,O
full,O
-,O
length,O
ALK,B-GP
and,O
ALK,B-GP
fusion,O
proteins,O
24,O
–,O
27,O
.,O
Here,O
",",O
we,O
investigated,O
this,O
further,O
",",O
and,O
clarified,O
the,O
importance,O
of,O
STAT3,B-GP
as,O
a,O
mediator,O
in,O
the,O
initiation,O
of,O
transcription,O
of,O
MYCN,B-GP
.,O
Results,O
Phosphotyrosine,O
profiling,O
of,O
PC12,O
cells,O
expressing,O
ALK,B-GP
To,O
identify,O
sites,O
with,O
altered,O
phosphorylation,O
associated,O
with,O
ALK,B-GP
RTK,B-GP
activity,O
",",O
we,O
utilized,O
an,O
immunoaffinity,O
-,O
coupled,O
LC,O
-,O
MS,O
/,O
MS,O
approach,O
on,O
PC12,O
Tet,O
-,O
on,O
-,O
inducible,O
cell,O
lines,O
.,O
After,O
induction,O
",",O
ALK,B-GP
was,O
activated,O
by,O
addition,O
of,O
agonist,O
mAbs,O
that,O
have,O
previously,O
been,O
reported,O
to,O
initiate,O
ALK,B-GP
signaling,O
pathways,O
10,O
–,O
28,O
.,O
Comparison,O
with,O
controls,O
expressing,O
unstimulated,O
ALK,B-GP
allowed,O
quantification,O
of,O
336,O
phosphorylation,O
sites,O
(,O
207,O
phosphotyrosine,O
",",O
78,O
phosphoserine,O
",",O
and,O
51,O
phosphothreonine,O
),O
derived,O
from,O
189,O
different,O
proteins,O
(,O
Table,O
S1,O
).,O
Label,O
-,O
free,O
quantification,O
of,O
ALK,B-GP
-,O
activated,O
versus,O
control,O
cells,O
revealed,O
101,O
phosphorylation,O
sites,O
(,O
73,O
phosphotyrosine,O
",",O
13,O
phosphoserine,O
",",O
and,O
15,O
phosphothreonine,O
),O
in,O
72,O
proteins,O
",",O
with,O
a,O
more,O
than,O
five,O
-,O
fold,O
increase,O
in,O
corresponding,O
phosphopeptide,O
intensities,O
.,O
In,O
contrast,O
",",O
only,O
19,O
phosphorylation,O
sites,O
in,O
12,O
proteins,O
were,O
found,O
with,O
decreased,O
phosphorylation,O
following,O
ALK,B-GP
induction,O
.,O
Within,O
the,O
list,O
of,O
mapped,O
phosphorylation,O
sites,O
",",O
we,O
identified,O
11,O
phosphotyrosine,O
sites,O
that,O
belong,O
to,O
ALK,B-GP
(,O
Fig,O
.,O
1A,O
).,O
As,O
expected,O
",",O
all,O
of,O
them,O
showed,O
a,O
significant,O
increase,O
in,O
the,O
level,O
of,O
phosphorylation,O
on,O
activation,O
of,O
ALK,B-GP
with,O
mAb,O
as,O
compared,O
with,O
control,O
cells,O
(,O
Table,O
S1,O
).,O
The,O
identified,O
tyrosine,O
phosphorylation,O
sites,O
in,O
full,O
-,O
length,O
ALK,B-GP
overlap,O
with,O
the,O
predicted,O
ones,O
(,O
PhosphoMotif,O
",",O
Human,B-OG
Protein,O
Reference,O
Database,O
",",O
http,O
://,O
www,O
.,O
hprd,O
.,O
org,O
/,O
PhosphoMotif_finder,O
"),",O
and,O
cover,O
",",O
with,O
only,O
one,O
exception,O
",",O
the,O
entire,O
set,O
of,O
mapped,O
phosphotyrosine,O
sites,O
from,O
earlier,O
investigations,O
of,O
EML4,B-GP
–,O
ALK,B-GP
and,O
nucleophosmin,B-GP
(,O
NPM,B-GP
)–,O
ALK,B-GP
29,O
",",O
30,O
.,O
(,O
A,O
),O
Tyrosine,O
residues,O
phosphorylated,O
in,O
the,O
kinase,B-GP
domain,O
of,O
ALK,B-GP
.,O
The,O
intracellular,O
domain,O
of,O
ALK,B-GP
containing,O
the,O
protein,O
kinase,B-GP
domain,O
(,O
PKD,O
),O
(,O
red,O
),O
and,O
potential,O
autophosphorylation,O
sites,O
were,O
searched,O
with,O
phosphomotif,O
(,O
http,O
://,O
www,O
.,O
hprd,O
.,O
org,O
/,O
PhosphoMotif_finder,O
),O
as,O
indicated,O
.,O
Presented,O
and,O
compared,O
side,O
-,O
by,O
-,O
side,O
with,O
our,O
phosphotyrosine,O
mapping,O
of,O
activated,O
full,O
-,O
length,O
ALK,B-GP
are,O
the,O
global,O
surveys,O
of,O
phosphotyrosine,O
peptides,O
identified,O
in,O
EML4,B-GP
–,O
ALK,B-GP
and,O
NPM,B-GP
–,O
ALK,B-GP
29,O
",",O
30,O
.,O
The,O
critical,O
tyrosines,O
in,O
the,O
activation,O
loop,O
of,O
the,O
kinase,B-GP
domain,O
of,O
ALK,B-GP
are,O
boxed,O
45,O
.,O
(,O
B,O
),O
Protein,O
–,O
protein,O
interactions,O
of,O
human,B-OG
orthologs,O
of,O
the,O
phosphoproteins,B-GP
identified,O
in,O
ALK,B-GP
-,O
expressing,O
PC12,O
cells,O
.,O
In,O
the,O
network,O
",",O
proteins,O
with,O
upregulated,O
phosphorylation,O
sites,O
in,O
activated,O
ALK,B-GP
-,O
expressing,O
PC12,O
cells,O
as,O
compared,O
with,O
control,O
cells,O
are,O
in,O
red,O
",",O
and,O
proteins,O
with,O
downregulated,O
phosphorylation,O
sites,O
are,O
in,O
green,O
.,O
Blue,O
edges,O
indicate,O
protein,O
–,O
protein,O
interactions,O
",",O
and,O
orange,O
edges,O
indicate,O
kinase,B-GP
–,O
substrate,O
relationships,O
.,O
Only,O
the,O
network,O
including,O
ALK,B-GP
is,O
shown,O
.,O
The,O
pale,O
blue,O
balls,O
indicate,O
(,O
human,B-OG
orthologs,O
of,O
),O
PC12,O
proteins,O
with,O
identified,O
/,O
mapped,O
phosphotyrosines,O
that,O
were,O
not,O
found,O
to,O
be,O
significantly,O
regulated,O
.,O
To,O
highlight,O
potential,O
direct,O
downstream,O
substrates,O
of,O
full,O
-,O
length,O
ALK,B-GP
",",O
a,O
network,O
analysis,O
using,O
known,O
protein,O
–,O
protein,O
interactions,O
and,O
experimentally,O
verified,O
kinase,B-GP
–,O
substrate,O
relationships,O
of,O
the,O
human,B-OG
orthologs,O
of,O
the,O
identified,O
phosphoproteins,B-GP
was,O
performed,O
(,O
Fig,O
.,O
1B,O
).,O
The,O
network,O
model,O
illustrated,O
two,O
of,O
the,O
identified,O
phosphoproteins,B-GP
with,O
increased,O
phosphorylation,O
as,O
potential,O
direct,O
targets,O
of,O
ALK,B-GP
following,O
ALK,B-GP
induction,O
",",O
namely,O
PTPN11,B-GP
(,O
SHP,B-GP
-,I-GP
2,I-GP
),O
and,O
STAT3,B-GP
.,O
Neither,O
of,O
these,O
has,O
previously,O
been,O
shown,O
to,O
interact,O
with,O
full,O
-,O
length,O
ALK,B-GP
.,O
In,O
agreement,O
with,O
a,O
role,O
for,O
these,O
proteins,O
downstream,O
of,O
ALK,B-GP
",",O
we,O
detected,O
approximately,O
10,O
-,O
fold,O
higher,O
phosphorylation,O
at,O
Tyr546,O
and,O
Tyr584,O
in,O
SHP,B-GP
-,I-GP
2,I-GP
as,O
well,O
as,O
Tyr705,O
in,O
STAT3,B-GP
under,O
ALK,B-GP
-,O
activating,O
conditions,O
in,O
our,O
model,O
.,O
Furthermore,O
",",O
identified,O
downstream,O
targets,O
of,O
ALK,B-GP
detected,O
in,O
this,O
phosphoprofiling,O
",",O
such,O
as,O
mitogen,B-GP
-,I-GP
activated,I-GP
protein,I-GP
kinase,I-GP
(,B-GP
MAPK,I-GP
),I-GP
1,I-GP
",",O
MAPK3,B-GP
[,O
extracellular,B-GP
signal,I-GP
-,I-GP
related,I-GP
kinase,I-GP
(,I-GP
ERK,I-GP
),I-GP
2,I-GP
/,I-GP
1,I-GP
"],",O
glycogen,B-GP
synthase,I-GP
kinase,I-GP
-,I-GP
3α,I-GP
",",O
STAT3,B-GP
",",O
FAK,B-GP
",",O
and,O
CRKL,B-GP
(,O
Table,O
S1,O
"),",O
showed,O
decreased,O
phosphorylation,O
upon,O
abrogation,O
of,O
ALK,B-GP
activity,O
in,O
several,O
neuroblastoma,B-DS
cell,O
lines,O
(,O
Fig,O
.,O
S1,O
).,O
ALK,B-GP
activates,O
STAT3,B-GP
in,O
PC12,O
cells,O
We,O
subsequently,O
decided,O
to,O
focus,O
in,O
more,O
detail,O
on,O
one,O
of,O
the,O
most,O
prominent,O
hits,O
from,O
the,O
phosphotyrosine,O
proteomics,O
screen,O
",",O
namely,O
STAT3,B-GP
.,O
As,O
observed,O
in,O
the,O
screen,O
",",O
activation,O
of,O
ALK,B-GP
resulted,O
in,O
clear,O
phosphorylation,O
of,O
STAT3,B-GP
at,O
Tyr705,O
.,O
PC12,O
cells,O
expressing,O
either,O
doxycycline,O
-,O
inducible,O
wild,O
-,O
type,O
ALK,B-GP
or,O
the,O
ALKF1174S,O
mutant,O
were,O
employed,O
to,O
examine,O
STAT3,B-GP
activation,O
.,O
As,O
ALK,B-GP
is,O
still,O
regarded,O
as,O
an,O
orphan,O
receptor,O
",",O
the,O
ALK,B-GP
receptor,I-GP
was,O
stimulated,O
with,O
an,O
agonist,O
mAb,O
that,O
has,O
been,O
previously,O
reported,O
to,O
bind,O
and,O
activate,O
ALK,B-GP
in,O
a,O
cell,O
culture,O
model,O
28,O
",",O
32,O
.,O
Interestingly,O
",",O
whereas,O
long,O
-,O
term,O
stimulation,O
of,O
the,O
wild,O
-,O
type,O
ALK,B-GP
receptor,I-GP
did,O
lead,O
to,O
visible,O
tyrosine,O
phosphorylation,O
of,O
STAT3,B-GP
",",O
this,O
was,O
not,O
prominently,O
observed,O
after,O
30,O
min,O
of,O
stimulation,O
",",O
a,O
time,O
point,O
when,O
ALK,B-GP
and,O
ERK1,B-GP
/,O
2,O
were,O
highly,O
phosphorylated,O
(,O
Fig,O
.,O
2A,O
",",O
compare,O
lanes,O
3,O
and,O
4,O
).,O
This,O
is,O
in,O
contrast,O
to,O
the,O
robust,O
activation,O
of,O
STAT3,B-GP
observed,O
upon,O
induction,O
of,O
expression,O
of,O
the,O
ALKF1174S,O
mutant,O
(,O
Fig,O
.,O
2A,O
",",O
compare,O
lanes,O
3,O
and,O
7,O
).,O
In,O
both,O
cases,O
",",O
tyrosine,O
phosphorylation,O
of,O
STAT3,B-GP
was,O
abrogated,O
by,O
the,O
addition,O
of,O
the,O
ALK,B-GP
inhibitor,O
crizotinib,O
(,O
Fig,O
.,O
2A,O
",",O
compare,O
lanes,O
4,O
and,O
7,O
with,O
lanes,O
5,O
and,O
8,O
).,O
STAT3,B-GP
phosphorylation,O
and,O
interaction,O
with,O
ALK,B-GP
on,O
ALK,B-GP
activation,O
.,O
(,O
A,O
),O
Tet,O
-,O
on,O
-,O
inducible,O
PC12,O
cell,O
clones,O
expressing,O
either,O
wild,O
-,O
type,O
ALK,B-GP
or,O
the,O
ALKF1174S,O
mutant,O
receptor,O
were,O
employed,O
.,O
Protein,O
expression,O
was,O
induced,O
with,O
1,O
μg,O
·,O
mL,O
−,O
1,O
doxycycline,O
",",O
and,O
cells,O
were,O
serum,O
-,O
starved,O
for,O
24,O
h,O
prior,O
to,O
stimulation,O
with,O
1,O
μg,O
·,O
mL,O
−,O
1,O
ALK,B-GP
-,O
activating,O
mAb,O
(,O
mAb31,O
),O
for,O
30,O
min,O
or,O
24,O
h,O
.,O
Whole,O
cell,O
lysates,O
were,O
analyzed,O
by,O
SDS,O
/,O
PAGE,O
",",O
and,O
this,O
was,O
followed,O
by,O
immunoblotting,O
with,O
antibodies,O
against,O
p,O
-,O
ALKY1278,O
",",O
ALK,B-GP
",",O
p,O
-,O
STAT3Y705,O
",",O
and,O
p,O
-,O
ERK,B-GP
.,O
Pan,O
-,O
ERK,B-GP
and,O
pan,O
-,O
STAT3,B-GP
antibodies,O
were,O
employed,O
as,O
loading,O
controls,O
.,O
(,O
B,O
",",O
C,O
),O
PC12,O
cells,O
were,O
transfected,O
with,O
either,O
wild,O
-,O
type,O
ALK,B-GP
or,O
the,O
ALKF1174S,O
mutant,O
together,O
with,O
FLAG,B-GP
-,O
tagged,O
STAT3,B-GP
prior,O
to,O
stimulation,O
with,O
1,O
μg,O
·,O
mL,O
−,O
1,O
ALK,B-GP
-,O
activating,O
mAb,O
(,O
mAb46,O
),O
for,O
24,O
h,O
",",O
in,O
the,O
presence,O
or,O
absence,O
of,O
250,O
nm,O
crizotinib,O
",",O
as,O
indicated,O
.,O
Lysates,O
were,O
immunoprecipitated,O
(,O
IP,O
),O
with,O
either,O
antibody,O
against,O
FLAG,B-GP
(,O
M2,O
),O
(,O
B,O
),O
or,O
with,O
antibody,O
against,O
ALK,B-GP
(,O
mAb31,O
),O
(,O
C,O
"),",O
and,O
this,O
was,O
followed,O
by,O
immunoblotting,O
for,O
ALK,B-GP
",",O
FLAG,B-GP
",",O
and,O
STAT3,B-GP
",",O
as,O
indicated,O
.,O
WCL,O
",",O
whole,O
cell,O
lysate,O
.,O
To,O
investigate,O
the,O
activation,O
process,O
further,O
",",O
we,O
examined,O
whether,O
an,O
interaction,O
between,O
ALK,B-GP
and,O
STAT3,B-GP
could,O
occur,O
.,O
We,O
were,O
unable,O
to,O
observe,O
an,O
interaction,O
between,O
doxycycline,O
-,O
induced,O
ALK,B-GP
and,O
endogenous,O
STAT3,B-GP
in,O
PC12,O
cells,O
(,O
data,O
not,O
shown,O
).,O
However,O
",",O
an,O
interaction,O
between,O
STAT3,B-GP
and,O
ALK,B-GP
was,O
observed,O
on,O
immmunoprecipitation,O
of,O
tagged,O
STAT3,B-GP
",",O
when,O
wild,O
-,O
type,O
ALK,B-GP
was,O
transiently,O
cotransfected,O
with,O
FLAG,B-GP
-,O
tagged,O
STAT3,B-GP
(,O
Fig,O
.,O
2B,O
).,O
Upon,O
stimulation,O
of,O
ALK,B-GP
",",O
increased,O
interaction,O
between,O
ALK,B-GP
and,O
STAT3,B-GP
was,O
observed,O
(,O
Fig,O
.,O
2B,O
",",O
lane,O
3,O
).,O
This,O
interaction,O
was,O
abrogated,O
by,O
addition,O
of,O
the,O
ALK,B-GP
inhibitor,O
crizotinib,O
(,O
Fig,O
.,O
2B,O
",",O
lane,O
4,O
).,O
Similarly,O
",",O
on,O
cotransfection,O
of,O
activated,O
ALKF1174S,O
with,O
FLAG,B-GP
-,O
tagged,O
STAT3,B-GP
",",O
an,O
interaction,O
was,O
observed,O
that,O
was,O
blocked,O
upon,O
addition,O
of,O
crizotinib,O
prior,O
to,O
immunoprecipitation,O
(,O
Fig,O
.,O
2B,O
",",O
compare,O
lanes,O
5,O
and,O
6,O
).,O
Similarly,O
",",O
we,O
were,O
able,O
to,O
observe,O
STAT3,B-GP
in,O
both,O
wild,O
-,O
type,O
and,O
gain,O
-,O
of,O
-,O
function,O
ALK,B-GP
immunoprecipitates,O
from,O
PC12,O
cells,O
transiently,O
expressing,O
ALK,B-GP
and,O
STAT3,B-GP
(,O
Fig,O
.,O
2C,O
).,O
In,O
agreement,O
with,O
our,O
previous,O
observations,O
",",O
the,O
STAT3,B-GP
–,O
ALK,B-GP
interaction,O
was,O
crizotinib,O
-,O
sensitive,O
(,O
Fig,O
.,O
2C,O
",",O
compare,O
lanes,O
3,O
and,O
5,O
with,O
lanes,O
4,O
and,O
6,O
).,O
Quantification,O
of,O
independent,O
blots,O
showed,O
clear,O
six,O
-,O
fold,O
to,O
10,O
-,O
fold,O
increased,O
binding,O
of,O
STAT3,B-GP
to,O
ALK,B-GP
upon,O
stimulation,O
or,O
when,O
a,O
gain,O
-,O
of,O
-,O
function,O
ALK,B-GP
variant,O
was,O
employed,O
(,O
Fig,O
.,O
S2,O
).,O
These,O
data,O
suggest,O
that,O
",",O
upon,O
activation,O
",",O
STAT3,B-GP
may,O
be,O
recruited,O
to,O
ALK,B-GP
signaling,O
complexes,O
.,O
However,O
",",O
it,O
is,O
important,O
to,O
note,O
that,O
our,O
attempts,O
to,O
verify,O
this,O
interaction,O
at,O
the,O
level,O
of,O
endogenous,O
proteins,O
in,O
neuroblastoma,B-DS
cell,O
lines,O
have,O
not,O
been,O
successful,O
.,O
STAT3,B-GP
is,O
important,O
for,O
MYCN,B-GP
expression,O
in,O
response,O
to,O
ALK,B-GP
activation,O
Given,O
recent,O
observations,O
that,O
ALK,B-GP
regulates,O
MYCN,B-GP
transcription,O
in,O
neuroblastoma,B-DS
cells,O
and,O
collaborates,O
with,O
MYCN,B-GP
in,O
neuroblastoma,B-DS
pathogenesis,O
34,O
–,O
37,O
",",O
we,O
decided,O
to,O
investigate,O
a,O
role,O
for,O
STAT3,B-GP
in,O
this,O
process,O
.,O
Initially,O
",",O
we,O
employed,O
small,O
interfering,O
RNA,O
(,O
siRNA,O
),O
targeting,O
STAT3,B-GP
in,O
a,O
number,O
of,O
neuroblastoma,B-DS
cell,O
lines,O
",",O
including,O
CBL,O
-,O
GE,O
",",O
CBL,O
-,O
BAR,O
",",O
CBL,O
-,O
GA,O
and,O
Kelly,O
cells,O
.,O
These,O
neuroblastoma,B-DS
cell,O
lines,O
are,O
all,O
ALK,B-GP
gain,O
-,O
of,O
-,O
function,O
in,O
nature,O
",",O
containing,O
either,O
an,O
activated,O
ALK,B-GP
mutation,O
(,O
ALKR1275Q,O
",",O
CBL,O
-,O
GA,O
;,O
ALKF1174V,O
",",O
CLB,O
-,O
GE,O
;,O
ALKF1174L,O
",",O
Kelly,O
),O
or,O
overexpressing,O
an,O
ALK,B-GP
receptor,I-GP
with,O
an,O
extracellular,O
domain,O
deletion,O
(,O
CLB,O
-,O
BARΔexon,O
4,O
–,O
12,O
"),",O
and,O
express,O
different,O
levels,O
of,O
MYCN,B-GP
(,O
Fig,O
.,O
S3,O
),O
38,O
",",O
39,O
.,O
Cell,O
lines,O
were,O
transfected,O
with,O
either,O
scrambled,O
siRNA,O
",",O
two,O
independent,O
siRNAs,O
targeting,O
STAT3,B-GP
",",O
or,O
a,O
mock,O
control,O
.,O
In,O
each,O
cell,O
line,O
tested,O
",",O
the,O
scrambled,O
siRNA,O
transfection,O
did,O
not,O
reduce,O
STAT3,B-GP
levels,O
",",O
which,O
were,O
comparable,O
to,O
those,O
in,O
cells,O
with,O
control,O
transfection,O
without,O
siRNA,O
.,O
However,O
",",O
upon,O
transfection,O
with,O
specific,O
STAT3,B-GP
siRNA,O
",",O
all,O
cell,O
lines,O
tested,O
showed,O
reduced,O
levels,O
of,O
STAT3,B-GP
as,O
compared,O
with,O
the,O
scrambled,O
transfection,O
controls,O
(,O
Fig,O
.,O
3A,O
–,O
D,O
",",O
top,O
panels,O
",",O
compare,O
lanes,O
3,O
and,O
4,O
with,O
lane,O
2,O
).,O
Furthermore,O
",",O
a,O
clear,O
reduction,O
in,O
MYCN,B-GP
levels,O
in,O
CLB,O
-,O
BAR,O
",",O
CLB,O
-,O
GA,O
and,O
Kelly,O
cells,O
was,O
observed,O
upon,O
treatment,O
with,O
siRNA,O
targeting,O
STAT3,B-GP
(,O
Fig,O
.,O
3A,O
–,O
D,O
",",O
middle,O
panels,O
",",O
compare,O
lanes,O
3,O
and,O
4,O
with,O
lane,O
2,O
).,O
Loss,O
of,O
STAT3,B-GP
results,O
in,O
reduced,O
MYCN,B-GP
levels,O
.,O
Two,O
independent,O
STAT3,B-GP
siRNAs,O
(#,O
1,O
or,O
#,O
2,O
),O
were,O
employed,O
to,O
downregulate,O
STAT3,B-GP
levels,O
in,O
CLB,O
-,O
GE,O
(,O
A,O
"),",O
CLB,O
-,O
BAR,O
(,O
B,O
"),",O
Kelly,O
(,O
C,O
),O
and,O
CLB,O
-,O
GA,O
(,O
D,O
),O
neuroblastoma,B-DS
cell,O
lines,O
.,O
Cells,O
were,O
transfected,O
with,O
either,O
control,O
scrambled,O
siRNA,O
",",O
STAT3,B-GP
siRNA,O
#,O
1,O
or,O
STAT3,B-GP
siRNA,O
#,O
2,O
prior,O
to,O
cell,O
lysis,O
48,O
h,O
post,O
-,O
transfection,O
.,O
Whole,O
cell,O
lysates,O
were,O
subsequently,O
immunoblotted,O
for,O
STAT3,B-GP
",",O
MYCN,B-GP
",",O
and,O
pan,O
-,O
ERK,B-GP
(,O
as,O
loading,O
control,O
"),",O
as,O
indicated,O
.,O
Lfm,O
",",O
lipofectamine,O
;,O
scC,O
",",O
scramble,O
control,O
.,O
To,O
further,O
validate,O
these,O
results,O
",",O
we,O
employed,O
a,O
number,O
of,O
STAT3,B-GP
inhibitors,O
",",O
including,O
FLLL32,O
and,O
STATTIC,O
",",O
which,O
have,O
previously,O
been,O
shown,O
to,O
inhibit,O
STAT3,B-GP
activation,O
41,O
",",O
42,O
.,O
We,O
investigated,O
ALK,B-GP
",",O
STAT3,B-GP
and,O
MYCN,B-GP
levels,O
in,O
CLB,O
-,O
GE,O
",",O
CLB,O
-,O
BAR,O
",",O
Kelly,O
and,O
CLB,O
-,O
GA,O
neuroblastoma,B-DS
cell,O
lines,O
upon,O
treatment,O
with,O
STAT3,B-GP
inhibitors,O
(,O
Fig,O
.,O
4A,O
–,O
D,O
).,O
Treatment,O
with,O
either,O
FLLL32,O
or,O
STATTIC,O
efficiently,O
abrogated,O
the,O
phosphorylation,O
of,O
STAT3,B-GP
without,O
affecting,O
general,O
STAT3,B-GP
levels,O
.,O
Importantly,O
",",O
whereas,O
these,O
inhibitors,O
blocked,O
STAT3,B-GP
activity,O
",",O
they,O
did,O
not,O
affect,O
the,O
phosphorylation,O
status,O
of,O
ERK,B-GP
or,O
ALK,B-GP
itself,O
(,O
Fig,O
.,O
4A,O
–,O
D,O
",",O
compare,O
lanes,O
3,O
and,O
4,O
with,O
lane,O
1,O
).,O
In,O
keeping,O
with,O
the,O
results,O
obtained,O
with,O
STAT3,B-GP
siRNA,O
treatment,O
",",O
both,O
inhibitors,O
reduced,O
MYCN,B-GP
levels,O
(,O
Fig,O
.,O
4A,O
–,O
D,O
",",O
compare,O
lanes,O
3,O
and,O
4,O
with,O
lane,O
1,O
"),",O
suggesting,O
that,O
STAT3,B-GP
may,O
act,O
between,O
the,O
ALK,B-GP
receptor,I-GP
and,O
expression,O
of,O
MYCN,B-GP
.,O
The,O
ALK,B-GP
inhibitor,O
crizotinib,O
was,O
employed,O
as,O
a,O
control,O
",",O
leading,O
to,O
a,O
reduction,O
in,O
the,O
phosphorylation,O
of,O
STAT3,B-GP
and,O
ALK,B-GP
",",O
expression,O
of,O
MYCN,B-GP
and,O
phosphorylation,O
of,O
ERK,B-GP
(,O
Fig,O
.,O
4A,O
–,O
D,O
",",O
compare,O
lane,O
2,O
with,O
lanes,O
1,O
",",O
3,O
and,O
4,O
).,O
STAT3,B-GP
activity,O
is,O
required,O
for,O
regulation,O
of,O
MYCN,B-GP
expression,O
by,O
ALK,B-GP
.,O
Neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
GE,O
(,O
A,O
"),",O
CLB,O
-,O
BAR,O
(,O
B,O
"),",O
Kelly,O
(,O
C,O
),O
and,O
CLB,O
-,O
GA,O
(,O
D,O
),O
were,O
starved,O
and,O
treated,O
with,O
either,O
250,O
nm,O
crizotinib,O
(,O
24,O
h,O
"),",O
5,O
μm,O
FLLL32,O
(,O
8,O
h,O
"),",O
5,O
μm,O
STATTIC,O
(,O
8,O
h,O
"),",O
or,O
control,O
",",O
as,O
indicated,O
.,O
After,O
cell,O
lysis,O
",",O
samples,O
were,O
immunoblotted,O
with,O
antibodies,O
against,O
p,O
-,O
ALKY1278,O
",",O
MYCN,B-GP
",",O
p,O
-,O
STAT3Y705,O
",",O
and,O
p,O
-,O
ERK,B-GP
.,O
Pan,O
-,O
ERK,B-GP
",",O
ALK,B-GP
and,O
STAT3,B-GP
antibodies,O
were,O
employed,O
as,O
loading,O
controls,O
.,O
Three,O
independent,O
experiments,O
with,O
similar,O
results,O
were,O
performed,O
",",O
and,O
representative,O
blots,O
are,O
shown,O
.,O
To,O
investigate,O
further,O
whether,O
STAT3,B-GP
is,O
involved,O
in,O
ALK,B-GP
-,O
activated,O
initiation,O
of,O
MYCN,B-GP
transcription,O
",",O
we,O
employed,O
an,O
MYCNP,O
–,O
luciferase,B-GP
assay,O
in,O
two,O
independent,O
neuroblastoma,B-DS
cell,O
lines,O
36,O
.,O
Cells,O
were,O
transfected,O
with,O
MYCNP,O
–,O
luciferase,B-GP
reporter,O
or,O
control,O
",",O
and,O
treated,O
with,O
either,O
STATTIC,O
or,O
FLLL32,O
.,O
Upon,O
treatment,O
with,O
STAT3,B-GP
inhibitors,O
",",O
both,O
cell,O
lines,O
showed,O
reduced,O
luciferase,B-GP
activity,O
as,O
compared,O
with,O
untreated,O
cells,O
(,O
Fig,O
.,O
5A,O
).,O
Additionally,O
",",O
we,O
employed,O
quantitative,O
RT,O
-,O
PCR,O
(,O
qRT,O
-,O
PCR,O
),O
to,O
confirm,O
a,O
role,O
for,O
STAT3,B-GP
in,O
ALK,B-GP
regulation,O
of,O
MYCN,B-GP
transcription,O
.,O
As,O
controls,O
",",O
we,O
employed,O
primers,O
amplifying,O
part,O
of,O
the,O
coding,O
sequence,O
of,O
ribosomal,B-GP
protein,I-GP
29,I-GP
(,O
RPL29,B-GP
),O
or,O
ribosomal,B-GP
protein,I-GP
19,I-GP
(,O
RPL19,B-GP
),O
(,O
Fig,O
.,O
5B,O
",",O
data,O
not,O
shown,O
).,O
Neuroblastoma,B-DS
cell,O
lines,O
treated,O
with,O
STATTIC,O
or,O
FLLL32,O
for,O
24,O
h,O
showed,O
a,O
significant,O
reduction,O
in,O
MYCN,B-GP
mRNA,O
levels,O
in,O
comparison,O
with,O
untreated,O
cells,O
(,O
Fig,O
.,O
5B,O
).,O
Thus,O
",",O
pharmacological,O
inhibition,O
of,O
STAT3,B-GP
activity,O
in,O
neuroblastoma,B-DS
cell,O
lines,O
harboring,O
ALK,B-GP
gain,O
-,O
of,O
-,O
function,O
mutations,O
results,O
in,O
reduced,O
transcription,O
of,O
MYCN,B-GP
mRNA,O
.,O
Inhibition,O
of,O
STAT3,B-GP
reduces,O
MYCN,B-GP
transcription,O
.,O
(,O
A,O
),O
Luciferase,B-GP
assay,O
of,O
neuroblastoma,B-DS
cell,O
lines,O
transfected,O
with,O
MYCNP,O
–,O
luciferase,B-GP
or,O
empty,O
pGL2,O
vector,O
as,O
a,O
control,O
(,O
ctrl,O
).,O
The,O
neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
GE,O
and,O
CLB,O
-,O
BAR,O
were,O
transfected,O
with,O
empty,O
pGL2,O
(,O
ctrl,O
),O
or,O
MYCNP,O
–,O
luciferase,B-GP
.,O
Cells,O
were,O
then,O
serum,O
-,O
starved,O
",",O
and,O
STAT3,B-GP
was,O
inhibited,O
with,O
2,O
.,O
5,O
μm,O
FLLL32,O
or,O
STATTIC,O
for,O
12,O
h,O
.,O
White,O
bars,O
:,O
untreated,O
neuroblastoma,B-DS
cells,O
.,O
Gray,O
bars,O
:,O
cells,O
treated,O
with,O
FLLL32,O
.,O
Black,O
bars,O
:,O
cells,O
treated,O
with,O
STATTIC,O
.,O
Results,O
are,O
presented,O
as,O
relative,O
luciferase,B-GP
activity,O
",",O
where,O
untreated,O
samples,O
transfected,O
with,O
empty,O
pGL2,O
vector,O
were,O
set,O
to,O
1,O
.,O
(,O
B,O
),O
qRT,O
-,O
PCR,O
of,O
MYCN,B-GP
mRNA,O
in,O
neuroblastoma,B-DS
cell,O
lines,O
.,O
The,O
neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
GE,O
and,O
CLB,O
-,O
BAR,O
were,O
starved,O
and,O
treated,O
with,O
2,O
.,O
5,O
μm,O
FLLL32,O
or,O
STATTIC,O
for,O
12,O
h,O
.,O
Primers,O
amplifying,O
part,O
of,O
the,O
coding,O
sequence,O
of,O
RPL19,B-GP
(,O
B,O
),O
or,O
RPL29,B-GP
(,O
data,O
not,O
shown,O
),O
were,O
used,O
to,O
control,O
for,O
differences,O
in,O
cDNA,O
input,O
.,O
Relative,O
expression,O
was,O
calculated,O
according,O
to,O
the,O
ΔΔCt,O
relative,O
quantification,O
method,O
.,O
Each,O
sample,O
within,O
an,O
experiment,O
was,O
analyzed,O
in,O
duplicate,O
",",O
and,O
the,O
experiment,O
was,O
carried,O
out,O
at,O
least,O
three,O
times,O
.,O
White,O
bars,O
:,O
untreated,O
cells,O
.,O
Gray,O
bars,O
:,O
cells,O
treated,O
with,O
FLLL32,O
.,O
Black,O
bars,O
:,O
cells,O
treated,O
with,O
STATTIC,O
.,O
STAT3,B-GP
activity,O
is,O
required,O
for,O
growth,O
and,O
viability,O
of,O
neuroblastoma,B-DS
cells,O
We,O
then,O
investigated,O
whether,O
STAT3,B-GP
is,O
not,O
only,O
important,O
for,O
initiation,O
of,O
MYCN,B-GP
transcription,O
but,O
also,O
might,O
influence,O
the,O
proliferation,O
of,O
our,O
neuroblastoma,B-DS
cell,O
lines,O
.,O
In,O
this,O
analysis,O
",",O
we,O
employed,O
CLB,O
-,O
GE,O
",",O
CLB,O
-,O
BAR,O
",",O
Kelly,O
and,O
CLB,O
-,O
GA,O
neuroblastoma,B-DS
cell,O
lines,O
",",O
measuring,O
their,O
growth,O
in,O
response,O
to,O
treatment,O
with,O
the,O
STAT3,B-GP
inhibitor,O
FLLL32,O
or,O
STAT3,B-GP
siRNA,O
.,O
In,O
all,O
cell,O
lines,O
examined,O
",",O
reduction,O
of,O
endogenous,O
STAT3,B-GP
expression,O
levels,O
by,O
siRNA,O
or,O
treatment,O
with,O
the,O
STAT3,B-GP
inhibitor,O
FLLL32,O
resulted,O
in,O
a,O
decrease,O
in,O
cell,O
growth,O
as,O
compared,O
with,O
untreated,O
cells,O
(,O
Fig,O
.,O
6B,O
",",O
D,O
–,O
G,O
),O
in,O
a,O
similar,O
manner,O
as,O
crizotinib,O
decreased,O
cell,O
growth,O
(,O
Fig,O
.,O
6A,O
).,O
Furthermore,O
",",O
it,O
was,O
clear,O
that,O
treatment,O
of,O
neuroblastoma,B-DS
cell,O
lines,O
with,O
either,O
FLLL32,O
or,O
crizotinib,O
reduced,O
the,O
phosphorylation,O
status,O
of,O
STAT3,B-GP
to,O
a,O
similar,O
degree,O
",",O
without,O
increasing,O
cleavage,O
of,O
poly,B-GP
(,I-GP
ADP,I-GP
-,I-GP
ribose,I-GP
),I-GP
polymerase,I-GP
(,O
PARP,B-GP
"),",O
which,O
was,O
used,O
as,O
a,O
measure,O
of,O
apoptosis,O
(,O
Fig,O
.,O
6C,O
).,O
Loss,O
of,O
STAT3,B-GP
function,O
decreases,O
neuroblastoma,B-DS
cell,O
proliferation,O
.,O
(,O
A,O
",",O
B,O
),O
Neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
GE,O
"(▪),",O
CLB,O
-,O
BAR,O
"(▴),",O
Kelly,O
(‐),O
and,O
CLB,O
-,O
GA,O
(•),O
were,O
treated,O
with,O
250,O
nm,O
crizotinib,O
(,O
A,O
),O
and,O
1,O
.,O
5,O
μm,O
FLLL32,O
(,O
B,O
),O
for,O
5,O
days,O
.,O
Proliferation,O
was,O
analyzed,O
with,O
the,O
resazurin,O
cell,O
proliferation,O
assay,O
.,O
Values,O
are,O
reported,O
as,O
fold,O
relative,O
fluorescence,O
from,O
FLLL32,O
-,O
treated,O
cells,O
versus,O
relative,O
fluorescence,O
from,O
untreated,O
cells,O
(♦).,O
Results,O
are,O
from,O
three,O
representative,O
experiments,O
",",O
with,O
each,O
experiment,O
performed,O
in,O
triplicate,O
.,O
(,O
C,O
),O
Neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
BAR,O
",",O
CLB,O
-,O
GE,O
",",O
CLB,O
-,O
GA,O
and,O
Kelly,O
were,O
grown,O
on,O
six,O
-,O
well,O
plates,O
with,O
complete,O
growth,O
medium,O
",",O
starved,O
",",O
and,O
treated,O
with,O
250,O
nm,O
crizotinib,O
and,O
1,O
.,O
5,O
μm,O
FLLL32,O
for,O
6,O
h,O
.,O
Cell,O
lysates,O
were,O
immunoblotted,O
with,O
antibodies,O
against,O
p,O
-,O
STAT3,B-GP
and,O
PARP,B-GP
.,O
Tubulin,B-GP
was,O
used,O
as,O
a,O
loading,O
control,O
.,O
(,O
D,O
–,O
G,O
),O
CLB,O
-,O
BAR,O
(,O
D,O
"),",O
CLB,O
-,O
GA,O
(,O
E,O
),O
CLB,O
-,O
GE,O
(,O
F,O
),O
and,O
Kelly,O
(,O
G,O
),O
cell,O
lines,O
were,O
transfected,O
with,O
scrambled,O
siRNA,O
(,O
SiC,O
),O
"(▪),",O
STAT3,B-GP
siRNA,O
#,O
1,O
(,O
Si1,O
),O
(▴),O
or,O
STAT3,B-GP
siRNA,O
#,O
2,O
(,O
Si2,O
),O
(▴),O
at,O
0,O
and,O
24,O
h,O
.,O
Cell,O
viability,O
was,O
assessed,O
at,O
0,O
",",O
3,O
",",O
4,O
and,O
5,O
days,O
post,O
-,O
transfection,O
",",O
with,O
the,O
resazurin,O
assay,O
.,O
Values,O
are,O
reported,O
as,O
fold,O
relative,O
fluorescence,O
from,O
siRNA,O
-,O
transfected,O
cells,O
versus,O
relative,O
fluorescence,O
from,O
control,O
mock,O
-,O
transfected,O
cells,O
.,O
Results,O
are,O
from,O
one,O
of,O
three,O
representative,O
experiments,O
",",O
with,O
each,O
experiment,O
performed,O
in,O
triplicate,O
.,O
Discussion,O
It,O
is,O
interesting,O
to,O
compare,O
the,O
results,O
of,O
this,O
study,O
with,O
earlier,O
phosphoproteomics,O
analysis,O
on,O
oncogenic,O
ALK,B-GP
fusion,O
proteins,O
",",O
such,O
as,O
EML4,B-GP
–,O
ALK,B-GP
and,O
NPM,B-GP
–,O
ALK,B-GP
29,O
",",O
30,O
.,O
In,O
terms,O
of,O
phosphorylation,O
of,O
ALK,B-GP
itself,O
",",O
these,O
studies,O
identified,O
overlapping,O
but,O
not,O
identical,O
sites,O
in,O
the,O
ALK,B-GP
intracellular,O
domain,O
.,O
Activation,O
of,O
full,O
-,O
length,O
ALK,B-GP
results,O
in,O
phosphorylation,O
of,O
Tyr1278,O
",",O
Tyr1282,O
",",O
and,O
Tyr1283,O
",",O
which,O
lie,O
in,O
the,O
Y,O
′,O
RAS,O
′,O
YY,O
autophosphorylation,O
motif,O
in,O
the,O
activation,O
loop,O
.,O
Although,O
our,O
data,O
do,O
not,O
allow,O
us,O
to,O
comment,O
on,O
the,O
order,O
of,O
phosphorylation,O
within,O
the,O
Y,O
′,O
RAS,O
′,O
YY,O
motif,O
",",O
they,O
are,O
in,O
agreement,O
with,O
previous,O
studies,O
elucidating,O
the,O
mechanism,O
of,O
phosphorylation,O
44,O
",",O
45,O
",",O
and,O
further,O
support,O
the,O
use,O
of,O
antibodies,O
against,O
pTyr1278,O
as,O
an,O
indicator,O
of,O
ALK,B-GP
activation,O
.,O
Another,O
site,O
commonly,O
used,O
to,O
denote,O
activation,O
of,O
the,O
ALK,B-GP
receptor,I-GP
is,O
Tyr1604,O
",",O
which,O
is,O
situated,O
at,O
the,O
C,O
-,O
terminal,O
tail,O
of,O
the,O
receptor,O
",",O
and,O
has,O
been,O
reported,O
to,O
be,O
important,O
for,O
transformation,O
activity,O
and,O
docking,O
of,O
phospholipase,B-GP
Cγ,I-GP
in,O
studies,O
on,O
NPM,B-GP
–,O
ALK,B-GP
47,O
.,O
Although,O
antibodies,O
against,O
pTyr1604,O
are,O
commonly,O
used,O
to,O
assay,O
ALK,B-GP
activity,O
",",O
the,O
importance,O
of,O
Tyr1604,O
in,O
the,O
interaction,O
of,O
phospholipase,B-GP
Cγ,I-GP
with,O
full,O
-,O
length,O
ALK,B-GP
has,O
not,O
been,O
confirmed,O
.,O
The,O
identification,O
in,O
this,O
study,O
reinforces,O
the,O
potential,O
importance,O
of,O
this,O
tyrosine,O
in,O
ALK,B-GP
activation,O
.,O
Of,O
the,O
phosphorylated,O
tyrosines,O
identified,O
outside,O
of,O
the,O
activation,O
loop,O
",",O
Tyr1507,O
of,O
ALK,B-GP
lies,O
within,O
a,O
consensus,O
Shc,B-GP
-,O
binding,O
site,O
(,O
NPTpY,O
"),",O
and,O
has,O
been,O
shown,O
to,O
be,O
critical,O
for,O
interaction,O
of,O
full,O
-,O
length,O
ALK,B-GP
with,O
Shc,B-GP
23,O
.,O
These,O
results,O
are,O
consistent,O
with,O
earlier,O
work,O
on,O
NPM,B-GP
–,O
ALK,B-GP
48,O
.,O
The,O
remaining,O
tyrosines,O
that,O
are,O
phosphorylated,O
in,O
response,O
to,O
ALK,B-GP
activation,O
identified,O
in,O
this,O
study,O
",",O
namely,O
Tyr1078,O
",",O
Tyr1092,O
",",O
Tyr1096,O
",",O
Tyr1131,O
",",O
Tyr1584,O
",",O
and,O
Tyr1586,O
",",O
have,O
been,O
poorly,O
characterized,O
in,O
the,O
context,O
of,O
the,O
full,O
-,O
length,O
ALK,B-GP
RTK,B-GP
",",O
and,O
determination,O
of,O
their,O
significance,O
requires,O
further,O
analysis,O
.,O
However,O
",",O
work,O
on,O
the,O
oncogenic,O
ALK,B-GP
fusion,O
proteins,O
implicates,O
these,O
residues,O
in,O
binding,O
of,O
IRS,B-GP
-,I-GP
1,I-GP
(,O
Tyr1096,O
),O
48,O
",",O
and,O
SNT,B-GP
(,O
FRS2,B-GP
),O
(,O
Tyr1096,O
and,O
Tyr1507,O
),O
49,O
.,O
As,O
well,O
as,O
identifying,O
tyrosine,O
phosphorylation,O
sites,O
in,O
ALK,B-GP
",",O
we,O
observed,O
phosphorylation,O
of,O
Ser1086,O
",",O
Ser1281,O
and,O
Thr1597,O
on,O
ALK,B-GP
.,O
Although,O
this,O
finding,O
is,O
intriguing,O
",",O
the,O
significance,O
of,O
these,O
phosphorylation,O
events,O
is,O
unclear,O
.,O
Although,O
the,O
phosphorylation,O
of,O
RTKs,B-GP
on,O
serine,O
and,O
threonine,O
is,O
well,O
recognized,O
",",O
its,O
role,O
is,O
much,O
less,O
understood,O
than,O
that,O
of,O
tyrosine,O
phosphorylation,O
.,O
However,O
",",O
serine,O
/,O
threonine,O
phosphorylation,O
is,O
known,O
to,O
have,O
important,O
regulatory,O
functions,O
for,O
",",O
for,O
example,O
",",O
fibroblast,B-GP
growth,I-GP
factor,I-GP
receptor,I-GP
",",O
epidermal,B-GP
growth,I-GP
factor,I-GP
receptor,I-GP
50,O
–,O
51,O
",",O
and,O
Kit,B-GP
52,O
",",O
to,O
name,O
but,O
a,O
few,O
.,O
Although,O
information,O
on,O
the,O
phosphorylation,O
of,O
ALK,B-GP
itself,O
in,O
response,O
to,O
activation,O
represented,O
an,O
important,O
part,O
of,O
the,O
information,O
obtained,O
with,O
this,O
phosphoproteomics,O
approach,O
",",O
the,O
identification,O
of,O
candidate,O
molecules,O
phosphorylated,O
in,O
response,O
to,O
ALK,B-GP
activation,O
was,O
the,O
primary,O
aim,O
of,O
this,O
investigation,O
.,O
The,O
list,O
of,O
phosphoproteins,B-GP
contains,O
both,O
known,O
and,O
novel,O
ALK,B-GP
signaling,O
components,O
",",O
some,O
of,O
which,O
have,O
been,O
characterized,O
",",O
but,O
the,O
majority,O
of,O
which,O
remain,O
to,O
be,O
investigated,O
for,O
their,O
relevance,O
in,O
both,O
physiological,O
and,O
pathological,O
ALK,B-GP
signaling,O
.,O
Of,O
those,O
known,O
candidates,O
",",O
several,O
examples,O
can,O
be,O
briefly,O
mentioned,O
.,O
One,O
molecule,O
identified,O
in,O
our,O
screen,O
was,O
FRS2,B-GP
",",O
which,O
was,O
phosphorylated,O
on,O
Tyr349,O
in,O
response,O
to,O
ALK,B-GP
activation,O
.,O
FRS2,B-GP
has,O
previously,O
been,O
reported,O
to,O
bind,O
full,O
-,O
length,O
ALK,B-GP
",",O
although,O
the,O
binding,O
site,O
is,O
unclear,O
23,O
.,O
Similarly,O
",",O
MAPK1,B-GP
–,O
which,O
was,O
phosphorylated,O
on,O
Thr183,O
in,O
this,O
study,O
–,O
has,O
been,O
shown,O
by,O
several,O
groups,O
to,O
be,O
phosphorylated,O
upon,O
stimulation,O
of,O
the,O
ALK,B-GP
receptor,I-GP
53,O
.,O
One,O
of,O
the,O
major,O
tyrosine,O
-,O
phosphorylated,O
proteins,O
identified,O
in,O
this,O
study,O
was,O
STAT3,B-GP
",",O
which,O
was,O
phosphorylated,O
on,O
Tyr705,O
in,O
response,O
to,O
ALK,B-GP
activation,O
.,O
STAT3,B-GP
has,O
been,O
reported,O
to,O
be,O
phosphorylated,O
downstream,O
of,O
several,O
of,O
the,O
oncogenic,O
ALK,B-GP
fusion,O
proteins,O
25,O
",",O
27,O
.,O
To,O
date,O
",",O
although,O
several,O
articles,O
have,O
reported,O
STAT3,B-GP
phosphorylation,O
downstream,O
of,O
full,O
-,O
length,O
ALK,B-GP
",",O
the,O
significance,O
of,O
this,O
is,O
unclear,O
8,O
–,O
56,O
.,O
One,O
study,O
of,O
NPM,B-GP
–,O
ALK,B-GP
has,O
suggested,O
that,O
oncogenic,O
ALK,B-GP
binds,O
and,O
activates,O
STAT3,B-GP
directly,O
via,O
the,O
first,O
tyrosine,O
(,O
Tyr1278,O
),O
in,O
the,O
Y,O
′,O
RAS,O
′,O
YY,O
motif,O
of,O
ALK,B-GP
45,O
.,O
The,O
crystal,O
structures,O
of,O
ALK,B-GP
show,O
that,O
unphosphorylated,O
Tyr1278,O
interacts,O
with,O
Cys1097,O
in,O
the,O
N,O
-,O
lobe,O
of,O
the,O
kinase,B-GP
",",O
implying,O
that,O
phosphorylation,O
of,O
Tyr1278,O
should,O
make,O
a,O
binding,O
site,O
for,O
STAT3,B-GP
available,O
",",O
consistent,O
with,O
this,O
hypothesis,O
.,O
In,O
this,O
study,O
",",O
we,O
saw,O
clear,O
phosphorylation,O
of,O
STAT3,B-GP
on,O
Tyr705,O
",",O
which,O
is,O
particularly,O
robust,O
in,O
response,O
to,O
oncogenic,O
forms,O
of,O
the,O
full,O
-,O
length,O
ALK,B-GP
receptor,I-GP
",",O
such,O
as,O
ALKF1174S,O
",",O
ALKΔexon,O
2,O
–,O
3,O
",",O
and,O
ALKΔexon,O
4,O
–,O
1239,O
",",O
55,O
.,O
Although,O
it,O
was,O
not,O
investigated,O
in,O
this,O
study,O
",",O
it,O
would,O
be,O
of,O
interest,O
to,O
examine,O
the,O
importance,O
of,O
STAT3,B-GP
phosphorylation,O
in,O
neuroblastoma,B-DS
cells,O
harboring,O
a,O
wild,O
-,O
type,O
nonactive,O
ALK,B-GP
receptor,I-GP
.,O
This,O
hypothesis,O
is,O
supported,O
by,O
inhibition,O
of,O
the,O
NB1,O
neuroblastoma,B-DS
cells,O
lines,O
with,O
crizotinib,O
",",O
which,O
resulted,O
in,O
a,O
loss,O
of,O
pSTAT3Y705,O
",",O
although,O
the,O
significance,O
of,O
STAT3,B-GP
for,O
cell,O
growth,O
was,O
not,O
discussed,O
54,O
.,O
In,O
light,O
of,O
the,O
activation,O
of,O
STAT3,B-GP
by,O
ALK,B-GP
",",O
we,O
also,O
investigated,O
the,O
interaction,O
of,O
ALK,B-GP
with,O
STAT3,B-GP
.,O
Indeed,O
",",O
we,O
observed,O
an,O
interaction,O
of,O
STAT3,B-GP
with,O
full,O
-,O
length,O
ALK,B-GP
when,O
overexpressed,O
;,O
however,O
",",O
this,O
was,O
not,O
detectable,O
at,O
the,O
level,O
of,O
endogenous,O
proteins,O
",",O
suggesting,O
that,O
care,O
should,O
be,O
taken,O
when,O
interpreting,O
these,O
results,O
.,O
It,O
is,O
unclear,O
whether,O
this,O
is,O
because,O
of,O
limitations,O
of,O
the,O
antibodies,O
employed,O
here,O
",",O
or,O
a,O
masking,O
of,O
the,O
epitope,O
by,O
the,O
interaction,O
",",O
or,O
simply,O
a,O
low,O
level,O
of,O
endogenous,O
interaction,O
.,O
Although,O
the,O
precise,O
molecular,O
mechanisms,O
underlying,O
ALK,B-GP
activation,O
of,O
STAT3,B-GP
are,O
unknown,O
",",O
it,O
is,O
clear,O
from,O
these,O
studies,O
that,O
loss,O
of,O
STAT3,B-GP
activity,O
",",O
either,O
by,O
RNA,O
interference,O
-,O
mediated,O
knockdown,O
of,O
STAT3,B-GP
or,O
by,O
addition,O
of,O
STAT3,B-GP
inhibitors,O
41,O
",",O
42,O
",",O
reduces,O
the,O
growth,O
and,O
viability,O
of,O
four,O
neuroblastoma,B-DS
lines,O
.,O
One,O
key,O
component,O
examined,O
here,O
was,O
the,O
effect,O
of,O
STAT3,B-GP
activity,O
on,O
MYCN,B-GP
levels,O
.,O
Recent,O
work,O
has,O
highlighted,O
the,O
cooperative,O
roles,O
of,O
ALK,B-GP
and,O
MYCN,B-GP
in,O
neuroblastoma,B-DS
",",O
with,O
ALK,B-GP
impacting,O
on,O
both,O
the,O
level,O
of,O
MYCN,B-GP
transcription,O
and,O
the,O
stability,O
of,O
the,O
MYCN,B-GP
protein,O
itself,O
34,O
–,O
37,O
.,O
Given,O
these,O
reports,O
",",O
our,O
finding,O
here,O
that,O
STAT3,B-GP
is,O
important,O
for,O
changes,O
in,O
MYCN,B-GP
levels,O
in,O
response,O
to,O
ALK,B-GP
signaling,O
is,O
significant,O
.,O
Indeed,O
",",O
inhibition,O
of,O
STAT3,B-GP
by,O
addition,O
of,O
inhibitors,O
",",O
or,O
by,O
RNA,O
interference,O
",",O
reduced,O
MYCN,B-GP
levels,O
even,O
in,O
the,O
presence,O
of,O
activated,O
ALK,B-GP
.,O
In,O
conclusion,O
",",O
our,O
phosphoproteomic,O
analysis,O
identifies,O
a,O
number,O
of,O
phosphorylation,O
sites,O
targeted,O
by,O
activation,O
of,O
the,O
ALK,B-GP
RTK,B-GP
.,O
One,O
prominent,O
target,O
identified,O
in,O
this,O
analysis,O
was,O
STAT3,B-GP
",",O
which,O
we,O
show,O
here,O
is,O
important,O
for,O
the,O
regulation,O
of,O
MYCN,B-GP
downstream,O
of,O
activated,O
ALK,B-GP
.,O
From,O
our,O
investigations,O
",",O
it,O
is,O
also,O
clear,O
that,O
there,O
is,O
a,O
difference,O
between,O
the,O
ability,O
of,O
wild,O
-,O
type,O
ALK,B-GP
to,O
activate,O
STAT3,B-GP
and,O
that,O
of,O
oncogenically,O
activated,O
forms,O
of,O
ALK,B-GP
.,O
The,O
molecular,O
mechanisms,O
underlying,O
this,O
difference,O
are,O
not,O
known,O
",",O
and,O
further,O
work,O
is,O
required,O
to,O
understand,O
this,O
.,O
This,O
work,O
suggests,O
that,O
STAT3,B-GP
inhibition,O
may,O
be,O
a,O
viable,O
approach,O
in,O
the,O
regulation,O
of,O
MYCN,B-GP
activity,O
in,O
neuroblastoma,B-DS
cells,O
",",O
and,O
may,O
have,O
potential,O
therapeutic,O
value,O
in,O
the,O
future,O
.,O
Experimental,O
procedures,O
Phosphotyrosine,O
profiling,O
Tyrosine,O
phosphorylation,O
profiling,O
of,O
PC12,O
cells,O
expressing,O
human,B-OG
ALK,B-GP
with,O
and,O
without,O
activation,O
of,O
ALK,B-GP
was,O
undertaken,O
by,O
immunoaffinity,O
purification,O
with,O
P,O
-,O
Tyr,O
-,O
100,O
(,O
Cell,O
Signaling,O
Technology,O
",",O
Danvers,O
",",O
MA,O
",",O
USA,O
"),",O
followed,O
by,O
LC,O
-,O
MS,O
/,O
MS,O
.,O
This,O
was,O
performed,O
as,O
previously,O
described,O
29,O
–,O
57,O
",",O
except,O
that,O
20,O
and,O
0,O
.,O
8,O
pmol,O
of,O
the,O
stable,O
isotope,O
-,O
labeled,O
phosphotyrosine,O
peptides,O
EH,O
[,O
13C3,O
",",O
15N1,O
-,O
A,O
],O
LLApYTLGVK,O
and,O
HTDDEMTGpYV,O
[,O
13C3,O
",",O
15N1,O
-,O
A,O
],O
TR,O
",",O
respectively,O
",",O
were,O
spiked,O
into,O
each,O
cell,O
lysate,O
prior,O
to,O
phosphopeptide,O
purification,O
.,O
Mass,O
spectra,O
of,O
two,O
technical,O
replicates,O
were,O
searched,O
against,O
a,O
rat,B-OG
protein,O
database,O
supplemented,O
with,O
the,O
sequence,O
for,O
human,B-OG
ALK,B-GP
(,O
extracted,O
from,O
UniProtKB,O
/,O
TrEMBL,O
ver,O
.,O
2013_01,O
;,O
41,O
749,O
reviewed,O
and,O
unreviewed,O
sequences,O
),O
with,O
maxquant,O
version,O
1,O
.,O
3,O
.,O
0,O
.,O
5,O
.,O
Standard,O
settings,O
were,O
used,O
in,O
maxquant,O
(,O
false,O
discovery,O
rate,O
of,O
<,O
1,O
%,O
at,O
the,O
protein,O
",",O
peptide,O
and,O
modification,O
site,O
levels,O
"),",O
except,O
that,O
the,O
‘,O
match,O
between,O
runs,O
’,O
function,O
was,O
enabled,O
.,O
A,O
list,O
with,O
high,O
-,O
confidence,O
phosphorylation,O
site,O
identifications,O
was,O
generated,O
by,O
filtering,O
the,O
‘,O
Phospho,O
(,O
STY,O
),O
sites,O
’,O
output,O
table,O
for,O
Localization,O
probability,O
>,O
75,O
%,O
and,O
Score,O
difference,O
>,O
5,O
.,O
Intensity,O
values,O
for,O
phosphorylation,O
sites,O
were,O
normalized,O
between,O
samples,O
by,O
using,O
correction,O
factors,O
based,O
on,O
the,O
intensity,O
values,O
of,O
the,O
phosphotyrosine,O
sites,O
of,O
the,O
heavily,O
labeled,O
peptide,O
standards,O
.,O
Changes,O
in,O
intensity,O
ratios,O
between,O
cells,O
with,O
activated,O
ALK,B-GP
and,O
control,O
cells,O
of,O
≥,O
5,O
were,O
considered,O
to,O
be,O
significantly,O
altered,O
.,O
Network,O
analysis,O
Rat,B-OG
–,O
human,B-OG
orthologs,O
were,O
extracted,O
from,O
ensembl,O
.,O
The,O
protein,O
–,O
protein,O
interactions,O
among,O
proteins,O
of,O
interest,O
were,O
retrieved,O
from,O
the,O
Protein,O
Interaction,O
Network,O
Analysis,O
platform,O
58,O
",",O
and,O
substrate,O
–,O
kinase,B-GP
relationships,O
were,O
downloaded,O
from,O
the,O
PhosphoSitePlus,O
database,O
59,O
.,O
cytoscape,O
60,O
was,O
used,O
for,O
visualization,O
of,O
networks,O
.,O
Cell,O
culture,O
Stable,O
PC12,O
Tet,O
-,O
on,O
clones,O
expressing,O
human,B-OG
pTTP,O
-,O
ALK,B-GP
(,O
wild,O
type,O
),O
have,O
been,O
described,O
previously,O
33,O
–,O
56,O
.,O
Stable,O
clones,O
were,O
selected,O
in,O
DMEM,O
containing,O
10,O
%,O
horse,B-OG
serum,O
(,O
MP,O
Biomedicals,O
",",O
France,O
"),",O
5,O
%,O
tetracycline,O
-,O
screened,O
fetal,O
bovine,B-OG
serum,O
(,O
Thermo,O
Scientific,O
“,O
HyClone,O
"”,",O
Belgium,O
"),",O
penicillin,O
",",O
streptomycin,O
",",O
l,O
-,O
glutamine,O
",",O
100,O
mg,O
·,O
mL,O
−,O
1,O
G418,O
",",O
and,O
2,O
mg,O
·,O
mL,O
−,O
1,O
puromycin,O
",",O
at,O
37,O
°,O
C,O
and,O
5,O
%,O
CO2,O
.,O
The,O
neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
GA,O
(,O
1p,O
deletion,O
",",O
11q,O
deletion,O
",",O
17q,O
gain,O
",",O
ALKR1275Q,O
mutation,O
"),",O
CLB,O
-,O
GE,O
(,O
MYCN,B-GP
/,O
ALK,B-GP
-,O
amplified,O
",",O
ALKF1174V,O
mutation,O
",",O
1p,O
deletion,O
",",O
17q,O
gain,O
"),",O
CLB,O
-,O
BAR,O
(,O
amplified,O
MYCN,B-GP
/,O
ALKΔexon,O
4,O
–,O
12,O
",",O
1p,O
deletion,O
",",O
17q,O
gain,O
),O
and,O
Kelly,O
(,O
MYCN,B-GP
-,O
amplified,O
",",O
ALKF1174L,O
mutation,O
),O
were,O
maintained,O
in,O
RPMI,O
-,O
1640,O
medium,O
supplemented,O
with,O
10,O
%,O
fetal,O
bovine,B-OG
serum,O
(,O
Sigma,O
",",O
Stockholm,O
",",O
Sweden,O
"),",O
100,O
U,O
·,O
mL,O
−,O
1,O
penicillin,O
",",O
and,O
100,O
μg,O
·,O
mL,O
−,O
1,O
streptomycin,O
",",O
at,O
37,O
°,O
C,O
in,O
humidified,O
air,O
with,O
5,O
%,O
CO2,O
38,O
–,O
40,O
.,O
Cell,O
proliferation,O
CLB,O
-,O
GA,O
(,O
0,O
.,O
035,O
×,O
106,O
per,O
well,O
"),",O
CLB,O
-,O
GE,O
(,O
0,O
.,O
025,O
×,O
106,O
per,O
well,O
"),",O
CLB,O
-,O
BAR,O
(,O
0,O
.,O
05,O
×,O
106,O
per,O
well,O
),O
and,O
Kelly,O
(,O
0,O
.,O
035,O
×,O
106,O
per,O
well,O
),O
cells,O
were,O
seeded,O
in,O
collagen,O
-,O
coated,O
48,O
-,O
well,O
plates,O
overnight,O
",",O
and,O
",",O
starting,O
on,O
the,O
following,O
day,O
",",O
treated,O
with,O
FLLL32,O
(,O
1,O
.,O
5,O
μm,O
),O
for,O
0,O
–,O
5,O
days,O
.,O
Cell,O
viability,O
was,O
determined,O
at,O
0,O
–,O
5,O
days,O
after,O
drug,O
treatment,O
",",O
with,O
55,O
μm,O
resazurin,O
(,O
Sigma,O
",",O
Stockholm,O
",",O
Sweden,O
),O
61,O
.,O
After,O
2,O
h,O
at,O
37,O
°,O
C,O
",",O
the,O
amount,O
of,O
metabolized,O
resazurin,O
was,O
analyzed,O
as,O
relative,O
fluorescence,O
with,O
an,O
Infinit200,O
plate,O
reader,O
(,O
TEKAN,O
",",O
Männedorf,O
",",O
Switzerland,O
).,O
Results,O
are,O
from,O
one,O
of,O
three,O
representative,O
experiments,O
",",O
with,O
each,O
experiment,O
being,O
performed,O
in,O
triplicate,O
.,O
Results,O
are,O
presented,O
as,O
fold,O
relative,O
fluorescence,O
from,O
FLLL32,O
-,O
treated,O
cells,O
versus,O
relative,O
fluorescence,O
from,O
control,O
untreated,O
cells,O
.,O
Cell,O
lysis,O
and,O
immunoblotting,O
Cells,O
were,O
harvested,O
and,O
lysed,O
as,O
described,O
previously,O
33,O
–,O
36,O
.,O
Samples,O
were,O
boiled,O
in,O
SDS,O
/,O
PAGE,O
sample,O
buffer,O
",",O
and,O
analyzed,O
on,O
SDS,O
/,O
PAGE,O
gel,O
.,O
The,O
antibodies,O
used,O
were,O
anti,O
-,O
STAT3,B-GP
(#,O
9132,O
"),",O
anti,O
-,O
p,O
-,O
STAT3,B-GP
(,O
Tyr705,O
),O
(#,O
9145,O
"),",O
anti,O
-,O
p,O
-,O
ALK,B-GP
(,O
Tyr1278,O
),O
(#,O
6941,O
"),",O
anti,O
-,O
p,O
-,O
ERK,B-GP
(,O
phospho,O
-,O
p44,B-GP
/,O
42,O
),O
(#,O
9101,O
"),",O
anti,O
-,O
N,B-GP
-,I-GP
MYC,I-GP
(#,O
9405,O
),O
(,O
all,O
Cell,O
Signaling,O
Technology,O
",",O
MA,O
",",O
USA,O
"),",O
anti,O
-,O
FLAG,B-GP
(,O
clone,O
M2,O
",",O
#,O
F3165,O
;,O
Sigma,O
",",O
Stockholm,O
",",O
Sweden,O
"),",O
anti,O
-,O
ERK,B-GP
(,O
610123,O
;,O
BD,O
Transduction,O
",",O
Stockholm,O
",",O
Sweden,O
"),",O
and,O
anti,O
-,O
ALK,B-GP
(,O
mAb135,O
and,O
mAb31,O
),O
10,O
.,O
STAT3,B-GP
siRNA,O
transfection,O
Cells,O
were,O
transfected,O
with,O
siRNA,O
duplexes,O
STAT3VHS40491,O
(,O
siRNA,O
#,O
1,O
:,O
sense,O
",",O
5,O
′-,O
GCAGUUUCUUCAGAGCAGGUAUCUU,O
-,O
3,O
′;,O
antisense,O
",",O
5,O
′-,O
AAGAUACCUGCUCUGAAGAAACUGC,O
-,O
3,O
′),O
and,O
STAT3VHS40497,O
(,O
siRNA,O
#,O
2,O
:,O
sense,O
",",O
5,O
′-,O
CCUGCAAGAGUCGAAUGAAUGUUCUCUAU,O
-,O
3,O
′;,O
antisense,O
",",O
5,O
′-,O
AUAGAGAACAUUCGACUCUUGCAGG,O
-,O
3,O
′),O
with,O
Lipofectamine,O
2000,O
",",O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
(,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
",",O
USA,O
).,O
After,O
6,O
h,O
",",O
the,O
medium,O
was,O
changed,O
to,O
complete,O
medium,O
without,O
antibiotic,O
",",O
and,O
allowed,O
to,O
grow,O
for,O
24,O
or,O
48,O
h,O
.,O
Cells,O
were,O
collected,O
and,O
processed,O
for,O
immunoblotting,O
as,O
described,O
above,O
to,O
determine,O
the,O
levels,O
of,O
STAT3,B-GP
",",O
MYCN,B-GP
and,O
pan,O
-,O
ERK,B-GP
for,O
a,O
loading,O
control,O
.,O
Immunoprecipitation,O
PC12,O
cells,O
were,O
transfected,O
with,O
pcDNA3,O
–,O
hALK,O
or,O
pcDNA3,O
–,O
hALKF1174S,O
(,O
0,O
.,O
6,O
μg,O
per,O
2,O
×,O
106,O
cells,O
),O
together,O
with,O
STAT3,B-GP
–,O
FLAG,B-GP
(,O
0,O
.,O
6,O
μg,O
per,O
2,O
×,O
106,O
cells,O
),O
or,O
pcDNA3,O
(,O
1,O
.,O
2,O
μg,O
per,O
2,O
×,O
106,O
cells,O
"),",O
with,O
the,O
Amaxa,O
Biosystems,O
(,O
Cologne,O
",",O
Germany,O
),O
electroporation,O
procedure,O
.,O
Cells,O
were,O
harvested,O
",",O
and,O
cell,O
lysates,O
were,O
pretreated,O
with,O
protein,O
G,B-GP
–,I-GP
Sepharose,I-GP
(,O
Sigma,O
"),",O
before,O
being,O
incubated,O
with,O
the,O
anti,O
-,O
FLAG,B-GP
M2,O
-,O
coupled,O
protein,O
G,B-GP
–,I-GP
Sepharose,I-GP
beads,O
overnight,O
at,O
4,O
°,O
C,O
",",O
washed,O
five,O
times,O
with,O
NaCl,O
/,O
Tris,O
",",O
boiled,O
in,O
sample,O
loading,O
buffer,O
",",O
run,O
on,O
an,O
SDS,O
/,O
PAGE,O
gel,O
",",O
transferred,O
to,O
poly,O
(,O
vinylidene,O
difluoride,O
),O
membranes,O
",",O
and,O
probed,O
with,O
antibodies,O
as,O
indicated,O
.,O
Luciferase,B-GP
assay,O
Cells,O
(,O
2,O
×,O
105,O
),O
of,O
the,O
neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
GE,O
and,O
CLB,O
-,O
BAR,O
were,O
transfected,O
with,O
empty,O
pGL2,O
(,O
control,O
),O
or,O
MYCNP,O
–,O
luciferase,B-GP
",",O
by,O
the,O
use,O
of,O
Lipofectamine,O
2000,O
(,O
Invitrogen,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
protocol,O
.,O
Cells,O
were,O
then,O
serum,O
-,O
starved,O
",",O
and,O
STAT3,B-GP
was,O
inhibited,O
by,O
employing,O
2,O
.,O
5,O
μm,O
FLLL32,O
(,O
generated,O
in,O
the,O
laboratory,O
of,O
P,O
.-,O
K,O
.,O
Li,O
),O
or,O
STATTIC,O
(,O
Sigma,O
",",O
St,O
Louis,O
",",O
MO,O
",",O
USA,O
),O
for,O
12,O
h,O
.,O
Each,O
sample,O
within,O
an,O
experiment,O
was,O
analyzed,O
in,O
triplicate,O
",",O
and,O
the,O
experiment,O
was,O
carried,O
out,O
three,O
times,O
.,O
Results,O
are,O
presented,O
as,O
relative,O
luciferase,B-GP
activity,O
",",O
where,O
untreated,O
samples,O
transfected,O
with,O
empty,O
pGL2,O
vector,O
were,O
set,O
to,O
1,O
.,O
qRT,O
-,O
PCR,O
The,O
neuroblastoma,B-DS
cell,O
lines,O
CLB,O
-,O
GE,O
and,O
CLB,O
-,O
BAR,O
were,O
starved,O
and,O
treated,O
with,O
2,O
.,O
5,O
μm,O
FLLL32,O
or,O
STATTIC,O
for,O
12,O
h,O
.,O
RNA,O
was,O
isolated,O
with,O
the,O
NucleoSpin,O
RNA,O
II,O
Kit,O
(,O
Macherey,O
-,O
Nagel,O
",",O
Duren,O
",",O
Germany,O
).,O
One,O
microgram,O
of,O
total,O
RNA,O
was,O
reverse,O
-,O
transcribed,O
with,O
the,O
iScript,O
cDNA,O
Synthesis,O
Kit,O
(,O
Bio,O
-,O
Rad,O
",",O
Sundbyberg,O
",",O
Sweden,O
).,O
For,O
the,O
PCR,O
amplification,O
in,O
an,O
iCycler,O
iQ5,O
(,O
Bio,O
-,O
Rad,O
"),",O
25,O
ng,O
of,O
cDNA,O
was,O
used,O
in,O
a,O
total,O
reaction,O
mixture,O
of,O
20,O
μL,O
containing,O
10,O
μL,O
of,O
Quantimix,O
Easy,O
SYG,O
Kit,O
(,O
Biotools,O
",",O
Madrid,O
",",O
Spain,O
"),",O
250,O
nm,O
forward,O
and,O
reverse,O
primers,O
",",O
and,O
0,O
.,O
08,O
μL,O
of,O
fluorescein,O
(,O
USB,O
;,O
Affimetrix,O
",",O
Santa,O
Clara,O
",",O
CA,O
",",O
USA,O
).,O
Primers,O
amplifying,O
part,O
of,O
the,O
coding,O
sequence,O
of,O
RPL29,B-GP
were,O
used,O
to,O
control,O
for,O
differences,O
in,O
cDNA,O
input,O
.,O
The,O
following,O
primers,O
were,O
used,O
:,O
human,B-OG
MYCN,B-GP
(,O
forward,O
",",O
5,O
′-,O
ACCACAAGGCCCTCAGTACC,O
-,O
3,O
′;,O
reverse,O
",",O
5,O
′-,O
TCTCCACAGTGACCACGTCGATTT,O
-,O
3,O
′);,O
human,B-OG
RPL19,B-GP
(,O
forward,O
",",O
5,O
′-,O
AACACATCCACAAGCTGAAGGCAG,O
-,O
3,O
′;,O
reverse,O
",",O
5,O
′-,O
TCTTCACGGCGCTTGCGT,O
-,O
3,O
′);,O
and,O
human,B-OG
RPL29,B-GP
(,O
forward,O
",",O
5,O
′-,O
ATGGCCAAGTCCAAGAACCACA,O
-,O
3,O
′;,O
reverse,O
",",O
5,O
′-,O
TTGGCATTGTTGGCCTGCAT,O
-,O
3,O
′).,O
Relative,O
expression,O
was,O
calculated,O
according,O
to,O
the,O
ΔΔCt,O
relative,O
quantification,O
method,O
.,O
Each,O
sample,O
within,O
an,O
experiment,O
was,O
analyzed,O
in,O
duplicate,O
",",O
and,O
the,O
experiment,O
was,O
carried,O
out,O
at,O
least,O
three,O
times,O
.,O
Results,O
are,O
presented,O
as,O
relative,O
MYCN,B-GP
mRNA,O
expression,O
where,O
untreated,O
samples,O
were,O
set,O
to,O
1,O
.,O
Socioeconomic,O
and,O
Geographic,O
Patterning,O
of,O
Smoking,O
Behaviour,O
in,O
Canada,O
:,O
A,O
Cross,O
-,O
Sectional,O
Multilevel,O
Analysis,O
Competing,O
Interests,O
:,O
All,O
authors,O
declare,O
no,O
conflicts,O
of,O
interest,O
or,O
competing,O
interests,O
.,O
Participated,O
in,O
critical,O
revisions,O
of,O
the,O
manuscript,O
:,O
DJC,O
SL,O
CC,O
SVS,O
MB,O
KT,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
DJC,O
SVS,O
CC,O
SL,O
MB,O
KT,O
.,O
Performed,O
the,O
experiments,O
:,O
DJC,O
.,O
Analyzed,O
the,O
data,O
:,O
DJC,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
DJC,O
SVS,O
CC,O
MB,O
SL,O
KT,O
.,O
Wrote,O
the,O
paper,O
:,O
DJC,O
.,O
Objective,O
To,O
describe,O
the,O
socioeconomic,O
and,O
geographic,O
distribution,O
of,O
smoking,O
behaviour,O
in,O
Canada,O
among,O
19,O
",",O
383,O
individuals,O
(,O
51,O
%,O
women,B-OG
),O
aged,O
15,O
–,O
85,O
years,O
.,O
Methods,O
Current,O
smoking,O
and,O
quitting,O
were,O
modeled,O
using,O
standard,O
and,O
multilevel,O
logistic,O
regression,O
.,O
Markers,O
of,O
socioeconomic,O
status,O
(,O
SES,O
),O
were,O
education,O
and,O
occupation,O
.,O
Geography,O
was,O
defined,O
by,O
Canadian,O
Provinces,O
.,O
Results,O
The,O
adjusted,O
prevalence,O
of,O
current,O
smoking,O
was,O
20,O
.,O
2,O
%,O
(,O
95,O
%,O
confidence,O
interval,O
[,O
CI,O
]:,O
18,O
.,O
8,O
–,O
21,O
.,O
7,O
),O
and,O
63,O
.,O
7,O
%,O
(,O
95,O
%,O
CI,O
:,O
61,O
.,O
1,O
–,O
66,O
.,O
3,O
),O
of,O
ever,O
smokers,O
had,O
quit,O
.,O
Current,O
smoking,O
decreased,O
and,O
quitting,O
increased,O
with,O
increasing,O
SES,O
.,O
The,O
adjusted,O
prevalence,O
of,O
current,O
smoking,O
was,O
32,O
.,O
8,O
%,O
(,O
95,O
%,O
CI,O
:,O
28,O
.,O
4,O
–,O
37,O
.,O
5,O
),O
among,O
the,O
least,O
educated,O
compared,O
to,O
11,O
.,O
0,O
%,O
(,O
95,O
%,O
CI,O
:,O
8,O
.,O
9,O
–,O
13,O
.,O
4,O
),O
for,O
the,O
highest,O
educated,O
.,O
Among,O
the,O
least,O
educated,O
",",O
53,O
.,O
0,O
%,O
(,O
95,O
%,O
CI,O
:,O
46,O
.,O
8,O
–,O
59,O
.,O
2,O
),O
had,O
quit,O
",",O
rising,O
to,O
68,O
.,O
7,O
%,O
(,O
95,O
%,O
CI,O
:,O
62,O
.,O
7,O
–,O
74,O
.,O
1,O
),O
for,O
the,O
most,O
educated,O
.,O
There,O
was,O
substantial,O
variation,O
in,O
current,O
smoking,O
and,O
quitting,O
at,O
the,O
provincial,O
level,O
;,O
current,O
smoking,O
varied,O
from,O
17,O
.,O
9,O
%,O
in,O
British,O
Columbia,O
to,O
26,O
.,O
1,O
%,O
in,O
Nova,O
Scotia,O
",",O
and,O
quitting,O
varied,O
from,O
57,O
.,O
4,O
%,O
in,O
Nova,O
Scotia,O
to,O
67,O
.,O
8,O
%,O
in,O
Prince,O
Edward,O
Island,O
.,O
Nationally,O
",",O
increasing,O
education,O
and,O
occupation,O
level,O
were,O
inversely,O
associated,O
with,O
current,O
smoking,O
(,O
odds,O
ratio,O
[,O
OR,O
],O
0,O
.,O
64,O
",",O
95,O
%,O
CI,O
:,O
0,O
.,O
60,O
–,O
0,O
.,O
68,O
for,O
education,O
;,O
OR,O
0,O
.,O
82,O
",",O
95,O
%,O
CI,O
:,O
0,O
.,O
77,O
–,O
0,O
.,O
87,O
for,O
occupation,O
),O
and,O
positively,O
associated,O
with,O
quitting,O
(,O
OR,O
1,O
.,O
27,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
16,O
–,O
1,O
.,O
40,O
for,O
education,O
;,O
OR,O
1,O
.,O
20,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
12,O
–,O
1,O
.,O
27,O
for,O
occupation,O
).,O
These,O
associations,O
were,O
consistent,O
in,O
direction,O
across,O
provinces,O
although,O
with,O
some,O
variability,O
in,O
magnitude,O
.,O
Conclusion,O
Our,O
findings,O
indicate,O
that,O
socioeconomic,O
inequalities,O
in,O
smoking,O
have,O
persisted,O
in,O
Canada,O
;,O
current,O
smoking,O
was,O
less,O
likely,O
and,O
quitting,O
was,O
more,O
likely,O
among,O
the,O
better,O
off,O
groups,O
and,O
in,O
certain,O
provinces,O
.,O
Current,O
prevention,O
and,O
cessation,O
policies,O
have,O
not,O
been,O
successful,O
in,O
improving,O
the,O
situation,O
for,O
all,O
areas,O
and,O
groups,O
.,O
Future,O
efforts,O
to,O
reduce,O
smoking,O
uptake,O
and,O
increase,O
cessation,O
in,O
Canada,O
will,O
need,O
consideration,O
of,O
socioeconomic,O
and,O
geographic,O
factors,O
to,O
be,O
successful,O
.,O
Introduction,O
Smoking,O
is,O
the,O
leading,O
cause,O
of,O
death,O
in,O
high,O
income,O
countries,O
such,O
as,O
Canada,O
[,O
1,O
],O
and,O
is,O
a,O
major,O
risk,O
factor,O
for,O
cardiovascular,B-DS
disease,I-DS
and,O
cancer,B-DS
.,O
[,O
2,O
"],",O
[,O
3,O
],O
In,O
Canada,O
",",O
approximately,O
20,O
%,O
of,O
all,O
deaths,O
are,O
attributable,O
smoking,O
according,O
to,O
2005,O
estimates,O
.,O
[,O
4,O
],O
The,O
majority,O
of,O
these,O
deaths,O
are,O
due,O
to,O
the,O
following,O
causes,O
:,O
lung,B-DS
cancer,I-DS
",",O
chronic,B-DS
obstructive,I-DS
pulmonary,I-DS
disease,I-DS
and,O
ischemic,B-DS
heart,I-DS
disease,I-DS
.,O
[,O
5,O
],O
About,O
50,O
%,O
of,O
smokers,O
die,O
of,O
smoking,O
-,O
related,O
diseases,O
and,O
smokers,O
who,O
die,O
between,O
the,O
ages,O
of,O
35,O
and,O
69,O
in,O
Canada,O
lose,O
on,O
average,O
more,O
than,O
20,O
years,O
of,O
life,O
.[,O
6,O
]–[,O
8,O
],O
Importantly,O
",",O
however,O
",",O
smoking,O
cessation,O
can,O
reverse,O
the,O
risk,O
for,O
mortality,O
;,O
quitting,O
by,O
age,O
50,O
can,O
halve,O
the,O
lifetime,O
risk,O
",",O
while,O
quitting,O
by,O
age,O
30,O
can,O
reduce,O
the,O
risk,O
close,O
to,O
that,O
of,O
never,O
smokers,O
.,O
[,O
9,O
"],",O
[,O
10,O
].,O
In,O
2010,O
",",O
the,O
Canadian,O
Tobacco,O
Use,O
Monitoring,O
Survey,O
(,O
CTUMS,O
),O
reported,O
an,O
overall,O
smoking,O
prevalence,O
of,O
17,O
%,O
in,O
the,O
Canadian,O
population,O
(,O
aged,O
15,O
years,O
and,O
older,O
"),",O
down,O
from,O
25,O
%,O
and,O
the,O
lowest,O
since,O
the,O
surveys,O
began,O
in,O
1999,O
[,O
11,O
];,O
however,O
the,O
rate,O
of,O
decline,O
appears,O
to,O
have,O
slowed,O
in,O
recent,O
years,O
.,O
[,O
12,O
],O
Although,O
declines,O
in,O
the,O
rates,O
of,O
smoking,O
are,O
good,O
news,O
",",O
the,O
overall,O
trends,O
may,O
hide,O
important,O
socioeconomic,O
and,O
/,O
or,O
geographic,O
variation,O
.,O
Uncovering,O
such,O
variation,O
is,O
key,O
to,O
informing,O
tobacco,O
control,O
policies,O
and,O
identifying,O
areas,O
where,O
more,O
or,O
differing,O
strategies,O
are,O
required,O
to,O
increase,O
smoking,O
cessation,O
and,O
decrease,O
smoking,O
uptake,O
.,O
Previous,O
studies,O
have,O
indicated,O
that,O
the,O
distribution,O
of,O
smoking,O
is,O
not,O
uniform,O
across,O
the,O
Canadian,O
population,O
.,O
Geographically,O
",",O
rates,O
of,O
smoking,O
vary,O
considerably,O
",",O
with,O
a,O
higher,O
prevalence,O
of,O
current,O
smoking,O
generally,O
found,O
in,O
the,O
Eastern,O
and,O
Atlantic,O
provinces,O
compared,O
to,O
Ontario,O
and,O
British,O
Columbia,O
.,O
[,O
12,O
],O
In,O
addition,O
",",O
smoking,O
has,O
consistently,O
been,O
found,O
to,O
be,O
concentrated,O
among,O
individuals,O
of,O
lower,O
socioeconomic,O
status,O
(,O
SES,O
),O
in,O
Canada,O
[,O
13,O
],O
and,O
other,O
high,O
income,O
countries,O
[,O
14,O
]–[,O
16,O
];,O
while,O
higher,O
SES,O
has,O
been,O
related,O
to,O
increased,O
smoking,O
cessation,O
.[,O
17,O
]–[,O
20,O
],O
For,O
example,O
",",O
evidence,O
from,O
the,O
National,O
Population,O
Health,O
Survey,O
in,O
Canada,O
indicated,O
that,O
high,O
levels,O
of,O
education,O
and,O
household,O
income,O
were,O
associated,O
with,O
quitting,O
over,O
a,O
two,O
year,O
period,O
in,O
men,B-OG
and,O
women,B-OG
.,O
[,O
21,O
],O
Despite,O
these,O
important,O
findings,O
",",O
many,O
questions,O
remain,O
including,O
:,O
to,O
what,O
extent,O
are,O
socioeconomic,O
differences,O
a,O
source,O
of,O
variation,O
in,O
current,O
smoking,O
and,O
quitting,O
across,O
provinces,O
?,O
And,O
is,O
the,O
between,O
-,O
provincial,O
variation,O
consistent,O
for,O
all,O
SES,O
groups,O
?,O
Identifying,O
geographic,O
variation,O
that,O
is,O
independent,O
of,O
individual,O
characteristics,O
and,O
the,O
consistency,O
of,O
this,O
variation,O
across,O
SES,O
groups,O
will,O
be,O
an,O
important,O
step,O
in,O
tailoring,O
future,O
tobacco,O
control,O
priorities,O
and,O
/,O
or,O
priorities,O
for,O
resource,O
allocations,O
to,O
programs,O
aimed,O
at,O
tobacco,O
use,O
prevention,O
and,O
/,O
or,O
cessation,O
.,O
Further,O
",",O
it,O
has,O
not,O
previously,O
been,O
shown,O
whether,O
the,O
SES,O
-,O
smoking,O
and,O
SES,O
-,O
quitting,O
relationships,O
are,O
qualitatively,O
similar,O
in,O
both,O
direction,O
and,O
magnitude,O
across,O
Canadian,O
provinces,O
.,O
Identifying,O
provinces,O
where,O
the,O
gradients,O
are,O
shallower,O
may,O
be,O
indicative,O
of,O
the,O
success,O
of,O
certain,O
programs,O
aimed,O
at,O
tobacco,O
use,O
prevention,O
and,O
/,O
or,O
cessation,O
in,O
reaching,O
all,O
SES,O
groups,O
or,O
suggestive,O
of,O
other,O
social,O
programs,O
which,O
aim,O
to,O
reduce,O
overall,O
inequalities,O
in,O
the,O
provinces,O
.,O
In,O
this,O
study,O
",",O
we,O
examine,O
the,O
socioeconomic,O
and,O
geographic,O
patterning,O
of,O
current,O
smoking,O
and,O
quitting,O
in,O
Canada,O
using,O
the,O
most,O
recent,O
and,O
nationally,O
representative,O
survey,O
on,O
smoking,O
.,O
In,O
addition,O
",",O
we,O
assess,O
the,O
consistency,O
of,O
the,O
SES,O
-,O
smoking,O
and,O
SES,O
-,O
quitting,O
associations,O
across,O
Canadian,O
provinces,O
using,O
education,O
and,O
occupation,O
as,O
markers,O
of,O
SES,O
.,O
Methods,O
Data,O
The,O
data,O
are,O
from,O
the,O
Canadian,O
Tobacco,O
Use,O
Monitoring,O
Survey,O
(,O
CTUMS,O
"),",O
conducted,O
in,O
two,O
cycles,O
in,O
the,O
ten,O
Canadian,O
provinces,O
from,O
February,O
to,O
June,O
and,O
from,O
July,O
to,O
December,O
2010,O
.,O
CTUMS,O
was,O
conducted,O
by,O
Statistics,O
Canada,O
on,O
behalf,O
of,O
Health,O
Canada,O
to,O
provide,O
nationally,O
representative,O
data,O
on,O
tobacco,O
use,O
and,O
related,O
issues,O
in,O
Canada,O
.,O
[,O
22,O
],O
CTUMS,O
covered,O
all,O
persons,O
in,O
Canada,O
aged,O
15,O
and,O
older,O
except,O
for,O
residents,O
of,O
the,O
Yukon,O
",",O
Northwest,O
Territories,O
",",O
Nunavut,O
",",O
and,O
those,O
living,O
in,O
long,O
-,O
term,O
care,O
institutions,O
or,O
Canadian,O
Forces,O
bases,O
.,O
The,O
sampling,O
frame,O
only,O
included,O
land,O
line,O
telephone,O
numbers,O
",",O
thus,O
excluding,O
people,O
without,O
telephone,O
land,O
lines,O
(,O
about,O
16,O
%,O
of,O
the,O
target,O
population,O
).,O
[,O
22,O
],O
The,O
sampling,O
weights,O
provided,O
with,O
CTUMS,O
have,O
been,O
adjusted,O
to,O
account,O
for,O
these,O
individuals,O
.,O
Survey,O
Design,O
A,O
stratified,O
two,O
-,O
stage,O
sampling,O
strategy,O
was,O
used,O
in,O
the,O
CTUMS,O
.,O
[,O
22,O
],O
In,O
each,O
of,O
the,O
ten,O
provinces,O
",",O
geographic,O
strata,O
were,O
defined,O
according,O
to,O
a,O
census,O
metropolitan,O
area,O
(,O
CMA,O
),O
stratum,O
and,O
a,O
non,O
-,O
CMA,O
stratum,O
.,O
CMAs,O
are,O
census,O
defined,O
areas,O
corresponding,O
to,O
cities,O
and,O
urban,O
areas,O
with,O
populations,O
of,O
100,O
",",O
000,O
or,O
more,O
.,O
In,O
Prince,O
Edward,O
Island,O
",",O
only,O
1,O
geographic,O
stratum,O
was,O
defined,O
",",O
and,O
in,O
Ontario,O
and,O
Quebec,O
",",O
a,O
third,O
stratum,O
was,O
defined,O
for,O
Toronto,O
and,O
Montreal,O
",",O
respectively,O
.,O
The,O
CTUMS,O
sampling,O
frame,O
was,O
a,O
list,O
of,O
in,O
-,O
service,O
telephone,O
prefixes,O
(,O
3,O
digit,O
area,O
code,O
+,O
next,O
5,O
digits,O
),O
compiled,O
from,O
telephone,O
company,O
files,O
within,O
each,O
of,O
the,O
province,O
-,O
stratum,O
combinations,O
.,O
In,O
the,O
first,O
stage,O
",",O
telephone,O
prefixes,O
were,O
systematically,O
sampled,O
within,O
each,O
stratum,O
and,O
a,O
random,O
2,O
-,O
digit,O
number,O
was,O
appended,O
to,O
the,O
prefix,O
to,O
form,O
a,O
complete,O
telephone,O
number,O
.,O
Known,O
business,O
and,O
not,O
-,O
in,O
-,O
service,O
telephone,O
numbers,O
were,O
then,O
screened,O
and,O
removed,O
from,O
the,O
sample,O
prior,O
to,O
dialing,O
.,O
In,O
the,O
second,O
stage,O
",",O
and,O
in,O
order,O
to,O
increase,O
the,O
number,O
of,O
respondents,O
in,O
the,O
15,O
to,O
19,O
and,O
20,O
to,O
24,O
age,O
groups,O
",",O
one,O
or,O
two,O
individuals,O
(,O
or,O
none,O
),O
were,O
selected,O
to,O
participate,O
in,O
the,O
survey,O
based,O
on,O
the,O
age,O
composition,O
of,O
the,O
household,O
.,O
Sampling,O
weights,O
were,O
provided,O
with,O
the,O
CTUMS,O
in,O
order,O
to,O
adjust,O
estimates,O
for,O
non,O
-,O
response,O
",",O
household,O
composition,O
",",O
and,O
an,O
external,O
adjustment,O
to,O
national,O
population,O
estimates,O
from,O
the,O
Canadian,O
census,O
.,O
[,O
22,O
],O
The,O
household,O
response,O
rate,O
(,O
defined,O
as,O
the,O
proportion,O
of,O
households,O
who,O
were,O
reached,O
and,O
provided,O
ages,O
of,O
all,O
household,O
members,O
),O
was,O
73,O
.,O
8,O
%,O
for,O
both,O
cycles,O
of,O
the,O
CTUMS,O
from,O
February,O
to,O
December,O
2010,O
",",O
and,O
the,O
individual,O
response,O
rate,O
was,O
84,O
.,O
2,O
%.,O
[,O
23,O
].,O
Interviews,O
for,O
CTUMS,O
were,O
conducted,O
using,O
a,O
computer,O
-,O
assisted,O
telephone,O
interviewing,O
(,O
CATI,O
),O
application,O
.,O
The,O
CATI,O
application,O
was,O
employed,O
in,O
conjunction,O
with,O
extensive,O
interviewer,O
training,O
in,O
order,O
to,O
minimize,O
data,O
collection,O
errors,O
.,O
[,O
23,O
],O
In,O
total,O
CTUMS,O
collected,O
information,O
from,O
19,O
",",O
822,O
respondents,O
aged,O
15,O
–,O
85,O
years,O
in,O
ten,O
Canadian,O
provinces,O
.,O
All,O
respondents,O
had,O
complete,O
information,O
on,O
current,O
smoking,O
status,O
",",O
age,O
",",O
gender,O
",",O
and,O
province,O
of,O
residence,O
.,O
Respondents,O
with,O
incomplete,O
information,O
for,O
any,O
of,O
the,O
other,O
independent,O
variables,O
(,O
marital,O
status,O
",",O
occupation,O
",",O
or,O
education,O
),O
were,O
excluded,O
(,O
n,O
=,O
439,O
",",O
2,O
.,O
2,O
%).,O
An,O
examination,O
of,O
the,O
basic,O
demographic,O
characteristics,O
between,O
complete,O
and,O
partial,O
respondents,O
did,O
not,O
reveal,O
any,O
substantive,O
differences,O
.,O
The,O
final,O
sample,O
for,O
analysis,O
was,O
19,O
",",O
383,O
.,O
Outcome,O
Categories,O
of,O
smoking,O
behaviour,O
at,O
the,O
time,O
of,O
survey,O
were,O
defined,O
as,O
follows,O
:,O
current,O
cigarette,O
smokers,O
were,O
individuals,O
who,O
had,O
smoked,O
100,O
or,O
more,O
cigarettes,O
in,O
their,O
lifetime,O
and,O
reported,O
smoking,O
daily,O
or,O
occasionally,O
during,O
the,O
past,O
30,O
days,O
.,O
Former,O
smokers,O
had,O
smoked,O
100,O
cigarettes,O
in,O
their,O
lifetime,O
and,O
reported,O
having,O
quit,O
and,O
did,O
not,O
smoke,O
any,O
cigarettes,O
in,O
the,O
30,O
days,O
prior,O
to,O
the,O
survey,O
.,O
Never,O
smokers,O
were,O
lifelong,O
never,O
smokers,O
(<,O
100,O
cigarettes,O
smoked,O
in,O
their,O
lifetime,O
).,O
For,O
these,O
analyses,O
",",O
quitting,O
was,O
defined,O
as,O
the,O
proportion,O
of,O
former,O
smokers,O
relative,O
to,O
ever,O
smokers,O
(,O
current,O
and,O
former,O
smokers,O
).,O
[,O
24,O
],O
Overall,O
in,O
the,O
CTUMS,O
sample,O
",",O
the,O
weighted,O
prevalence,O
of,O
current,O
smoking,O
was,O
16,O
.,O
57,O
%;,O
26,O
.,O
6,O
%,O
were,O
former,O
smokers,O
",",O
and,O
56,O
.,O
8,O
%,O
were,O
never,O
smokers,O
.,O
Descriptive,O
characteristics,O
of,O
the,O
sample,O
population,O
by,O
sex,O
and,O
categories,O
of,O
smoking,O
behaviour,O
have,O
been,O
tabulated,O
in,O
Table,O
1,O
.,O
Sample,O
sizes,O
and,O
weighted,O
estimates,O
(%),O
of,O
current,O
smoking,O
",",O
former,O
smoking,O
",",O
never,O
smoking,O
",",O
and,O
quitting,O
for,O
men,B-OG
and,O
women,B-OG
across,O
demographic,O
and,O
socioeconomic,O
characteristics,O
and,O
province,O
of,O
residence,O
.,O
Men,B-OG
Women,B-OG
Variables,O
Current,O
smoker,O
Former,O
smoker,O
Never,O
smoker,O
Quit,O
Total,O
Current,O
smoker,O
Former,O
smoker,O
Never,O
smoker,O
Quit,O
Total,O
n,O
%,O
n,O
%,O
n,O
%,O
%,O
n,O
n,O
%,O
n,O
%,O
n,O
%,O
%,O
n,O
Total,O
1762,O
19,O
.,O
7,O
1886,O
29,O
.,O
3,O
5198,O
51,O
.,O
0,O
59,O
.,O
9,O
8846,O
1710,O
13,O
.,O
6,O
1990,O
24,O
.,O
0,O
6837,O
62,O
.,O
5,O
63,O
.,O
9,O
10537,O
Age,O
15,O
–,O
19,O
yrs,O
375,O
13,O
.,O
1,O
51,O
2,O
.,O
0,O
2085,O
84,O
.,O
9,O
13,O
.,O
3,O
2511,O
284,O
10,O
.,O
6,O
39,O
1,O
.,O
4,O
2160,O
88,O
.,O
0,O
11,O
.,O
8,O
2483,O
20,O
–,O
24,O
yrs,O
468,O
23,O
.,O
9,O
140,O
8,O
.,O
8,O
1176,O
67,O
.,O
4,O
26,O
.,O
9,O
1784,O
447,O
20,O
.,O
0,O
164,O
8,O
.,O
2,O
1377,O
71,O
.,O
8,O
29,O
.,O
0,O
1988,O
25,O
–,O
44,O
yrs,O
388,O
24,O
.,O
5,O
275,O
18,O
.,O
2,O
803,O
57,O
.,O
3,O
42,O
.,O
6,O
1466,O
403,O
15,O
.,O
4,O
367,O
19,O
.,O
3,O
1169,O
65,O
.,O
3,O
55,O
.,O
5,O
1939,O
45,O
–,O
64,O
yrs,O
439,O
20,O
.,O
3,O
833,O
38,O
.,O
3,O
833,O
41,O
.,O
4,O
65,O
.,O
4,O
2105,O
459,O
13,O
.,O
7,O
927,O
33,O
.,O
7,O
1280,O
52,O
.,O
6,O
71,O
.,O
1,O
2666,O
65,O
+,O
yrs,O
92,O
7,O
.,O
7,O
587,O
62,O
.,O
5,O
301,O
29,O
.,O
9,O
89,O
.,O
1,O
980,O
117,O
7,O
.,O
8,O
493,O
31,O
.,O
4,O
851,O
60,O
.,O
8,O
80,O
.,O
1,O
1461,O
Marital,O
status,O
Common,O
-,O
law,O
/,O
Married,O
625,O
17,O
.,O
3,O
1282,O
35,O
.,O
8,O
1498,O
46,O
.,O
9,O
67,O
.,O
4,O
3405,O
593,O
11,O
.,O
3,O
1150,O
27,O
.,O
8,O
2287,O
61,O
.,O
0,O
71,O
.,O
2,O
4030,O
Widowed,O
/,O
Divorced,O
/,O
Separated,O
155,O
24,O
.,O
5,O
254,O
39,O
.,O
8,O
202,O
35,O
.,O
6,O
61,O
.,O
9,O
611,O
306,O
15,O
.,O
8,O
512,O
30,O
.,O
1,O
842,O
54,O
.,O
1,O
65,O
.,O
5,O
1660,O
Single,O
982,O
23,O
.,O
8,O
350,O
12,O
.,O
2,O
3498,O
64,O
.,O
0,O
33,O
.,O
8,O
4830,O
811,O
17,O
.,O
8,O
328,O
11,O
.,O
3,O
3708,O
71,O
.,O
0,O
38,O
.,O
8,O
4847,O
Education,O
Completed,O
university,O
173,O
12,O
.,O
7,O
401,O
26,O
.,O
2,O
900,O
61,O
.,O
1,O
67,O
.,O
5,O
1474,O
174,O
7,O
.,O
3,O
426,O
20,O
.,O
2,O
1339,O
72,O
.,O
5,O
73,O
.,O
4,O
1939,O
Completed,O
college,O
358,O
18,O
.,O
1,O
385,O
25,O
.,O
9,O
1158,O
56,O
.,O
0,O
59,O
.,O
0,O
1901,O
447,O
13,O
.,O
5,O
571,O
27,O
.,O
1,O
1779,O
59,O
.,O
4,O
66,O
.,O
8,O
2797,O
Completed,O
secondary,O
700,O
25,O
.,O
5,O
588,O
32,O
.,O
5,O
1445,O
42,O
.,O
0,O
56,O
.,O
0,O
2733,O
615,O
17,O
.,O
4,O
673,O
27,O
.,O
3,O
1831,O
55,O
.,O
3,O
61,O
.,O
1,O
3119,O
Less,O
than,O
secondary,O
531,O
23,O
.,O
1,O
512,O
33,O
.,O
7,O
1695,O
43,O
.,O
3,O
59,O
.,O
4,O
2738,O
474,O
17,O
.,O
0,O
320,O
18,O
.,O
1,O
1888,O
64,O
.,O
9,O
51,O
.,O
6,O
2682,O
Occupation,O
Professional,O
specialty,O
145,O
13,O
.,O
1,O
244,O
23,O
.,O
9,O
815,O
63,O
.,O
1,O
64,O
.,O
6,O
1204,O
236,O
8,O
.,O
4,O
367,O
22,O
.,O
7,O
1315,O
69,O
.,O
0,O
73,O
.,O
0,O
1918,O
Not,O
working,O
298,O
13,O
.,O
8,O
696,O
46,O
.,O
2,O
1151,O
40,O
.,O
0,O
77,O
.,O
0,O
2145,O
512,O
12,O
.,O
2,O
776,O
25,O
.,O
6,O
2054,O
62,O
.,O
3,O
67,O
.,O
8,O
3342,O
Not,O
reported,O
28,O
17,O
.,O
4,O
35,O
33,O
.,O
3,O
91,O
49,O
.,O
3,O
65,O
.,O
7,O
154,O
17,O
9,O
.,O
1,O
23,O
32,O
.,O
2,O
76,O
58,O
.,O
7,O
78,O
.,O
0,O
116,O
Executive,O
",",O
managerial,O
168,O
17,O
.,O
9,O
218,O
28,O
.,O
8,O
565,O
53,O
.,O
3,O
61,O
.,O
7,O
951,O
297,O
15,O
.,O
6,O
409,O
27,O
.,O
5,O
1066,O
57,O
.,O
0,O
63,O
.,O
8,O
1772,O
Sales,O
or,O
Service,O
388,O
20,O
.,O
8,O
214,O
17,O
.,O
1,O
1281,O
62,O
.,O
1,O
45,O
.,O
2,O
1883,O
566,O
19,O
.,O
6,O
352,O
18,O
.,O
2,O
2085,O
62,O
.,O
2,O
48,O
.,O
0,O
3003,O
Manual,O
735,O
30,O
.,O
0,O
479,O
25,O
.,O
5,O
1295,O
44,O
.,O
5,O
45,O
.,O
9,O
2509,O
82,O
18,O
.,O
9,O
63,O
22,O
.,O
1,O
241,O
59,O
.,O
0,O
53,O
.,O
8,O
386,O
Province,O
British,O
Columbia,O
121,O
14,O
.,O
9,O
172,O
27,O
.,O
7,O
523,O
57,O
.,O
4,O
65,O
.,O
0,O
816,O
126,O
14,O
.,O
6,O
175,O
25,O
.,O
8,O
614,O
59,O
.,O
6,O
63,O
.,O
9,O
915,O
Ontario,O
143,O
18,O
.,O
7,O
164,O
29,O
.,O
3,O
553,O
52,O
.,O
1,O
61,O
.,O
1,O
860,O
123,O
11,O
.,O
1,O
157,O
22,O
.,O
2,O
746,O
66,O
.,O
7,O
66,O
.,O
8,O
1026,O
Prince,O
Edward,O
Island,O
153,O
18,O
.,O
8,O
226,O
35,O
.,O
0,O
476,O
46,O
.,O
2,O
65,O
.,O
1,O
855,O
135,O
13,O
.,O
0,O
223,O
27,O
.,O
3,O
685,O
59,O
.,O
7,O
67,O
.,O
8,O
1043,O
Newfoundland,O
160,O
20,O
.,O
8,O
184,O
35,O
.,O
5,O
396,O
43,O
.,O
8,O
63,O
.,O
0,O
740,O
191,O
19,O
.,O
0,O
220,O
28,O
.,O
1,O
609,O
52,O
.,O
9,O
53,O
.,O
5,O
1020,O
Quebec,O
189,O
21,O
.,O
0,O
211,O
32,O
.,O
5,O
499,O
46,O
.,O
5,O
60,O
.,O
7,O
899,O
162,O
13,O
.,O
7,O
203,O
27,O
.,O
4,O
679,O
59,O
.,O
0,O
66,O
.,O
7,O
1044,O
Alberta,O
194,O
21,O
.,O
9,O
181,O
24,O
.,O
9,O
604,O
53,O
.,O
2,O
53,O
.,O
1,O
979,O
182,O
16,O
.,O
3,O
164,O
19,O
.,O
6,O
736,O
64,O
.,O
1,O
54,O
.,O
6,O
1082,O
New,O
Brunswick,O
178,O
22,O
.,O
0,O
180,O
33,O
.,O
3,O
444,O
44,O
.,O
8,O
60,O
.,O
2,O
802,O
170,O
15,O
.,O
6,O
199,O
25,O
.,O
2,O
640,O
59,O
.,O
2,O
61,O
.,O
8,O
1009,O
Nova,O
Scotia,O
193,O
22,O
.,O
7,O
208,O
30,O
.,O
9,O
531,O
46,O
.,O
4,O
57,O
.,O
7,O
932,O
194,O
18,O
.,O
8,O
196,O
22,O
.,O
9,O
673,O
58,O
.,O
3,O
55,O
.,O
0,O
1063,O
Manitoba,O
219,O
24,O
.,O
2,O
171,O
23,O
.,O
8,O
640,O
52,O
.,O
0,O
62,O
.,O
0,O
1030,O
217,O
17,O
.,O
5,O
232,O
23,O
.,O
4,O
758,O
59,O
.,O
1,O
57,O
.,O
2,O
1207,O
Saskatchewan,O
212,O
24,O
.,O
8,O
189,O
26,O
.,O
8,O
532,O
48,O
.,O
4,O
59,O
.,O
8,O
933,O
210,O
17,O
.,O
4,O
221,O
25,O
.,O
2,O
697,O
57,O
.,O
5,O
59,O
.,O
2,O
1128,O
Canadian,O
Tobacco,O
Use,O
Monitoring,O
Survey,O
2010,O
.,O
Independent,O
Variables,O
We,O
considered,O
age,O
",",O
sex,O
",",O
and,O
marital,O
status,O
as,O
demographic,O
characteristics,O
.,O
Age,O
was,O
grouped,O
into,O
the,O
following,O
categories,O
:,O
15,O
–,O
19,O
",",O
20,O
–,O
24,O
",",O
25,O
–,O
44,O
",",O
45,O
–,O
64,O
",",O
65,O
+,O
years,O
for,O
descriptive,O
analyses,O
",",O
and,O
centred,O
about,O
its,O
weighted,O
mean,O
(,O
45,O
years,O
),O
and,O
treated,O
as,O
a,O
continuous,O
measure,O
in,O
regression,O
models,O
.,O
In,O
addition,O
",",O
polynomial,O
terms,O
were,O
included,O
for,O
age,O
to,O
allow,O
for,O
the,O
assessment,O
of,O
non,O
-,O
linearity,O
.,O
Sex,O
was,O
based,O
on,O
self,O
-,O
report,O
.,O
Marital,O
status,O
was,O
categorized,O
as,O
common,O
-,O
law,O
/,O
married,O
",",O
single,O
",",O
or,O
widowed,O
/,O
divorced,O
/,O
separated,O
(,O
reference,O
:,O
married,O
).,O
Socioeconomic,O
status,O
was,O
measured,O
by,O
education,O
and,O
occupation,O
.,O
Education,O
was,O
grouped,O
into,O
four,O
categories,O
based,O
on,O
the,O
highest,O
level,O
completed,O
:,O
less,O
than,O
secondary,O
school,O
",",O
completed,O
secondary,O
",",O
completed,O
post,O
-,O
secondary,O
/,O
college,O
",",O
and,O
completed,O
university,O
(,O
reference,O
:,O
completed,O
university,O
).,O
Occupational,O
categories,O
were,O
adapted,O
from,O
the,O
2006,O
National,O
Occupational,O
Classification,O
for,O
Statistics,O
(,O
NOC,O
-,O
S,O
),O
[,O
25,O
"],",O
and,O
included,O
professional,O
specialties,O
",",O
executive,O
or,O
managerial,O
positions,O
",",O
sales,O
/,O
service,O
positions,O
",",O
and,O
manual,O
occupations,O
(,O
including,O
trades,O
",",O
transport,O
",",O
industry,O
",",O
manufacturing,O
",",O
and,O
utilities,O
).,O
Additional,O
categories,O
were,O
specified,O
for,O
individuals,O
not,O
currently,O
working,O
and,O
for,O
respondents,O
who,O
did,O
not,O
report,O
their,O
occupation,O
and,O
professionals,O
were,O
taken,O
as,O
the,O
reference,O
category,O
.,O
Geographic,O
location,O
was,O
defined,O
as,O
province,O
of,O
residence,O
at,O
the,O
time,O
of,O
survey,O
and,O
verified,O
by,O
telephone,O
company,O
administrative,O
files,O
.,O
Statistical,O
Analysis,O
We,O
used,O
logistic,O
regression,O
to,O
model,O
current,O
smoking,O
(,O
current,O
smokers,O
vs,O
never,O
smokers,O
),O
and,O
quitting,O
(,O
former,O
smokers,O
vs,O
current,O
smokers,O
),O
conditional,O
on,O
age,O
",",O
sex,O
",",O
marital,O
status,O
",",O
education,O
",",O
occupation,O
",",O
and,O
province,O
.,O
Province,O
of,O
residence,O
was,O
‘,O
dummy,O
’,O
coded,O
and,O
treated,O
as,O
a,O
fixed,O
classification,O
in,O
these,O
models,O
.,O
To,O
examine,O
potential,O
differences,O
in,O
smoking,O
patterns,O
between,O
men,B-OG
and,O
women,B-OG
",",O
interaction,O
effects,O
were,O
considered,O
between,O
sex,O
and,O
age,O
",",O
sex,O
and,O
education,O
",",O
and,O
sex,O
and,O
occupation,O
.,O
Adjusted,O
prevalence,O
estimates,O
were,O
calculated,O
for,O
each,O
independent,O
variable,O
separately,O
while,O
keeping,O
the,O
remaining,O
independent,O
variables,O
at,O
their,O
mean,O
values,O
and,O
expressed,O
as,O
a,O
percent,O
from,O
0,O
.,O
0,O
to,O
100,O
.,O
0,O
.,O
Next,O
",",O
models,O
were,O
extended,O
by,O
including,O
a,O
random,O
effect,O
for,O
province,O
and,O
specifying,O
two,O
-,O
level,O
multilevel,O
models,O
.,O
The,O
multilevel,O
modeling,O
strategy,O
is,O
described,O
below,O
",",O
using,O
the,O
example,O
of,O
current,O
smoking,O
.,O
Two,O
-,O
level,O
models,O
were,O
specified,O
with,O
a,O
binary,O
response,O
(,O
y,O
",",O
current,O
smoking,O
vs,O
never,O
smoking,O
),O
for,O
individual,O
i,O
in,O
province,O
j,O
.,O
Current,O
smoking,O
Pr,O
(,O
yij,O
=,O
1,O
"),",O
was,O
assumed,O
to,O
be,O
binomially,O
distributed,O
with,O
probability,O
related,O
to,O
the,O
set,O
of,O
independent,O
variables,O
and,O
a,O
random,O
effect,O
for,O
each,O
level,O
by,O
a,O
logit,O
link,O
function,O
:(,O
1,O
),O
The,O
right,O
hand,O
side,O
of,O
Equation,O
2,O
consists,O
of,O
the,O
fixed,O
part,O
linear,O
predictor,O
(),O
and,O
random,O
intercepts,O
for,O
provinces,O
().,O
The,O
intercept,O
and,O
the,O
-,O
coefficients,O
are,O
interpreted,O
as,O
before,O
in,O
Equation,O
1,O
.,O
The,O
set,O
of,O
independent,O
variables,O
remained,O
consistent,O
between,O
models,O
although,O
the,O
indicator,O
variables,O
for,O
provinces,O
were,O
included,O
in,O
the,O
random,O
part,O
of,O
Equation,O
2,O
().,O
In,O
this,O
model,O
",",O
the,O
random,O
intercepts,O
for,O
provinces,O
were,O
assumed,O
to,O
be,O
independently,O
and,O
identically,O
distributed,O
with,O
variance,O
.,O
[,O
26,O
],O
The,O
variance,O
parameter,O
quantifies,O
heterogeneity,O
in,O
the,O
log,O
odds,O
of,O
smoking,O
between,O
provinces,O
.,O
We,O
expressed,O
the,O
provincial,O
-,O
level,O
variance,O
as,O
a,O
percentage,O
of,O
the,O
total,O
variance,O
from,O
an,O
initial,O
model,O
without,O
covariates,O
and,O
from,O
a,O
final,O
model,O
accounting,O
for,O
all,O
covariates,O
.,O
In,O
order,O
to,O
examine,O
the,O
consistency,O
of,O
provincial,O
variation,O
in,O
current,O
smoking,O
and,O
quitting,O
by,O
SES,O
(,O
defined,O
by,O
education,O
and,O
occupation,O
),O
and,O
to,O
determine,O
whether,O
the,O
SES,O
-,O
smoking,O
and,O
SES,O
-,O
quitting,O
associations,O
varied,O
across,O
provinces,O
in,O
terms,O
of,O
strength,O
or,O
direction,O
",",O
we,O
expanded,O
Equation,O
1,O
to,O
allow,O
the,O
slope,O
for,O
SES,O
to,O
vary,O
across,O
provinces,O
:(,O
2,O
),O
The,O
key,O
feature,O
of,O
Equation,O
2,O
is,O
that,O
the,O
effect,O
of,O
education,O
on,O
smoking,O
in,O
province,O
j,O
consists,O
of,O
the,O
overall,O
average,O
effect,O
across,O
all,O
provinces,O
"(),",O
plus,O
a,O
province,O
-,O
specific,O
(),O
differential,O
in,O
this,O
effect,O
.,O
We,O
summarized,O
this,O
model,O
by,O
presenting,O
the,O
odds,O
ratio,O
for,O
current,O
smoking,O
and,O
quitting,O
overall,O
in,O
Canada,O
and,O
for,O
each,O
province,O
given,O
a,O
1,O
-,O
category,O
increase,O
in,O
education,O
and,O
occupation,O
.,O
The,O
sampling,O
weights,O
provided,O
with,O
the,O
CTUMS,O
were,O
used,O
in,O
all,O
analyses,O
.,O
Logistic,O
regression,O
models,O
were,O
estimated,O
with,O
Stata,O
(,O
version,O
12,O
.,O
1,O
),O
[,O
27,O
"],",O
[,O
28,O
],O
and,O
multilevel,O
models,O
were,O
estimated,O
with,O
MLwiN,O
(,O
version,O
2,O
.,O
26,O
),O
using,O
the,O
second,O
order,O
penalized,O
quasi,O
likelihood,O
(,O
PQL,O
),O
procedure,O
.,O
[,O
29,O
].,O
Results,O
In,O
the,O
2010,O
CTUMS,O
",",O
the,O
prevalence,O
(,O
adjusted,O
for,O
age,O
",",O
sex,O
",",O
marital,O
status,O
",",O
occupation,O
",",O
education,O
",",O
and,O
province,O
),O
for,O
current,O
smoking,O
among,O
Canadians,O
15,O
years,O
of,O
age,O
and,O
older,O
was,O
20,O
.,O
2,O
%,O
(,O
95,O
%,O
confidence,O
interval,O
[,O
CI,O
]:,O
18,O
.,O
8,O
–,O
21,O
.,O
7,O
),O
and,O
63,O
.,O
7,O
%,O
(,O
95,O
%,O
CI,O
:,O
61,O
.,O
1,O
–,O
66,O
.,O
3,O
),O
for,O
quitting,O
.,O
At,O
the,O
provincial,O
level,O
",",O
current,O
smoking,O
varied,O
from,O
17,O
.,O
9,O
%,O
in,O
British,O
Columbia,O
to,O
26,O
.,O
1,O
%,O
in,O
Nova,O
Scotia,O
(,O
Figure,O
1,O
"),",O
and,O
quitting,O
varied,O
from,O
57,O
.,O
4,O
%,O
in,O
Nova,O
Scotia,O
to,O
67,O
.,O
8,O
%,O
in,O
Prince,O
Edward,O
Island,O
(,O
Figure,O
2,O
).,O
Odds,O
ratios,O
and,O
95,O
%,O
confidence,O
intervals,O
for,O
current,O
smoking,O
and,O
quitting,O
from,O
the,O
mutually,O
adjusted,O
logistic,O
regression,O
models,O
are,O
presented,O
in,O
Table,O
2,O
.,O
The,O
relationship,O
between,O
current,O
regular,O
smoking,O
and,O
age,O
was,O
strongly,O
non,O
-,O
linear,O
and,O
this,O
was,O
emphasized,O
by,O
the,O
statistical,O
significance,O
of,O
the,O
quadratic,O
and,O
cubic,O
terms,O
(,O
P,O
<,O
0,O
.,O
001,O
).,O
This,O
relationship,O
had,O
an,O
inverse,O
-,O
U,O
shape,O
with,O
a,O
peak,O
smoking,O
prevalence,O
found,O
between,O
the,O
ages,O
of,O
35,O
and,O
40,O
years,O
.,O
The,O
prevalence,O
increased,O
rapidly,O
at,O
younger,O
ages,O
;,O
it,O
was,O
8,O
.,O
6,O
%,O
at,O
age,O
15,O
and,O
27,O
.,O
8,O
%,O
at,O
age,O
30,O
",",O
equivalent,O
to,O
a,O
3,O
.,O
3,O
-,O
fold,O
increase,O
(,O
95,O
%,O
CI,O
:,O
2,O
.,O
0,O
–,O
5,O
.,O
5,O
).,O
Adjusted,O
prevalence,O
of,O
current,O
smoking,O
in,O
Canadian,O
provinces,O
for,O
men,B-OG
(,O
left,O
),O
and,O
women,B-OG
(,O
right,O
),O
aged,O
15,O
years,O
and,O
above,O
",",O
Canadian,O
Tobacco,O
Use,O
Monitoring,O
Survey,O
2010,O
.,O
Darker,O
colours,O
indicate,O
higher,O
prevalence,O
.,O
Estimates,O
adjusted,O
for,O
age,O
",",O
sex,O
",",O
marital,O
status,O
",",O
occupation,O
",",O
education,O
.,O
Province,O
name,O
abbreviations,O
:,O
Alta,O
.,O
Alberta,O
;,O
B,O
.,O
C,O
.,O
British,O
Columbia,O
;,O
Man,O
.,O
Manitoba,O
;,O
N,O
.,O
B,O
.,O
New,O
Brunswick,O
;,O
N,O
.,O
L,O
.,O
Newfoundland,O
;,O
N,O
.,O
S,O
.,O
Nova,O
Scotia,O
;,O
O,O
.,O
N,O
.,O
Ontario,O
;,O
P,O
.,O
E,O
.,O
I,O
.,O
Prince,O
Edward,O
Island,O
;,O
Que,O
.,O
Quebec,O
;,O
Sask,O
.,O
Saskatchewan,O
;,O
data,O
not,O
available,O
for,O
Yukon,O
Territory,O
(,O
Y,O
.,O
T,O
".),",O
Northwest,O
Territories,O
(,O
N,O
.,O
W,O
.,O
T,O
"),",O
or,O
Nunavut,O
(,O
Nvt,O
.).,O
Adjusted,O
prevalence,O
of,O
quitting,O
in,O
Canadian,O
provinces,O
for,O
men,B-OG
(,O
left,O
),O
and,O
women,B-OG
(,O
right,O
),O
aged,O
15,O
years,O
and,O
above,O
",",O
Canadian,O
Tobacco,O
Use,O
Monitoring,O
Survey,O
2010,O
.,O
Darker,O
colours,O
indicate,O
higher,O
prevalence,O
.,O
Estimates,O
adjusted,O
for,O
age,O
",",O
sex,O
",",O
marital,O
status,O
",",O
occupation,O
",",O
education,O
.,O
Province,O
name,O
abbreviations,O
:,O
Alta,O
.,O
Alberta,O
;,O
B,O
.,O
C,O
.,O
British,O
Columbia,O
;,O
Man,O
.,O
Manitoba,O
;,O
N,O
.,O
B,O
.,O
New,O
Brunswick,O
;,O
N,O
.,O
L,O
.,O
Newfoundland,O
;,O
N,O
.,O
S,O
.,O
Nova,O
Scotia,O
;,O
O,O
.,O
N,O
.,O
Ontario,O
;,O
P,O
.,O
E,O
.,O
I,O
.,O
Prince,O
Edward,O
Island,O
;,O
Que,O
.,O
Quebec,O
;,O
Sask,O
.,O
Saskatchewan,O
;,O
data,O
not,O
available,O
for,O
Yukon,O
Territory,O
(,O
Y,O
.,O
T,O
".),",O
Northwest,O
Territories,O
(,O
N,O
.,O
W,O
.,O
T,O
"),",O
or,O
Nunavut,O
(,O
Nvt,O
.).,O
Mutually,O
adjusted,O
odds,O
ratios,O
and,O
95,O
%,O
confidence,O
intervals,O
from,O
logistic,O
regressions,O
of,O
current,O
smoking,O
and,O
quitting,O
on,O
demographic,O
and,O
socioeconomic,O
characteristics,O
and,O
province,O
of,O
residence,O
.,O
Current,O
smoking,O
Quitting,O
Variable,O
Odds,O
ratio,O
95,O
%,O
CI,O
Odds,O
ratio,O
95,O
%,O
CI,O
Age,O
10,O
year,O
change,O
0,O
.,O
92,O
(,O
0,O
.,O
82,O
–,O
1,O
.,O
04,O
),O
1,O
.,O
58,O
(,O
1,O
.,O
37,O
–,O
1,O
.,O
82,O
),O
Squared,O
0,O
.,O
82,O
(,O
0,O
.,O
79,O
–,O
0,O
.,O
85,O
),O
1,O
.,O
04,O
(,O
1,O
.,O
00,O
–,O
1,O
.,O
10,O
),O
Sex,O
Female,O
1,O
.,O
00,O
1,O
.,O
19,O
(,O
0,O
.,O
95,O
–,O
1,O
.,O
49,O
),O
Male,O
1,O
.,O
62,O
(,O
1,O
.,O
35,O
–,O
1,O
.,O
94,O
),O
1,O
.,O
00,O
Martial,O
status,O
Common,O
-,O
law,O
/,O
Married,O
1,O
.,O
00,O
2,O
.,O
01,O
(,O
1,O
.,O
48,O
–,O
2,O
.,O
74,O
),O
Widowed,O
/,O
Divorced,O
/,O
Separated,O
1,O
.,O
85,O
(,O
1,O
.,O
42,O
–,O
2,O
.,O
43,O
),O
0,O
.,O
97,O
(,O
0,O
.,O
67,O
–,O
1,O
.,O
41,O
),O
Single,O
1,O
.,O
86,O
(,O
1,O
.,O
44,O
–,O
2,O
.,O
41,O
),O
1,O
.,O
00,O
Education,O
Completed,O
university,O
1,O
.,O
00,O
1,O
.,O
82,O
(,O
1,O
.,O
24,O
–,O
2,O
.,O
68,O
),O
Completed,O
college,O
1,O
.,O
78,O
(,O
1,O
.,O
34,O
–,O
2,O
.,O
36,O
),O
1,O
.,O
82,O
(,O
1,O
.,O
28,O
–,O
2,O
.,O
58,O
),O
Completed,O
secondary,O
2,O
.,O
95,O
(,O
2,O
.,O
23,O
–,O
3,O
.,O
91,O
),O
1,O
.,O
36,O
(,O
1,O
.,O
00,O
–,O
1,O
.,O
86,O
),O
Less,O
than,O
secondary,O
3,O
.,O
92,O
(,O
2,O
.,O
78,O
–,O
5,O
.,O
52,O
),O
1,O
.,O
00,O
Occupation,O
Professional,O
specialty,O
1,O
.,O
00,O
1,O
.,O
93,O
(,O
1,O
.,O
30,O
–,O
2,O
.,O
87,O
),O
Not,O
reported,O
1,O
.,O
17,O
(,O
0,O
.,O
57,O
–,O
2,O
.,O
42,O
),O
1,O
.,O
86,O
(,O
0,O
.,O
89,O
–,O
3,O
.,O
90,O
),O
Not,O
working,O
1,O
.,O
39,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
85,O
),O
1,O
.,O
12,O
(,O
0,O
.,O
78,O
–,O
1,O
.,O
61,O
),O
Executive,O
",",O
managerial,O
1,O
.,O
54,O
(,O
1,O
.,O
14,O
–,O
2,O
.,O
10,O
),O
1,O
.,O
40,O
(,O
0,O
.,O
94,O
–,O
2,O
.,O
08,O
),O
Sales,O
or,O
Service,O
1,O
.,O
68,O
(,O
1,O
.,O
25,O
–,O
2,O
.,O
25,O
),O
0,O
.,O
98,O
(,O
0,O
.,O
67,O
–,O
1,O
.,O
45,O
),O
Manual,O
2,O
.,O
05,O
(,O
1,O
.,O
49,O
–,O
2,O
.,O
83,O
),O
1,O
.,O
00,O
Province,O
Ontario,O
1,O
.,O
00,O
1,O
.,O
43,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
94,O
),O
British,O
Columbia,O
0,O
.,O
96,O
(,O
0,O
.,O
74,O
–,O
1,O
.,O
26,O
),O
1,O
.,O
42,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
92,O
),O
Prince,O
Edward,O
Island,O
1,O
.,O
12,O
(,O
0,O
.,O
87,O
–,O
1,O
.,O
45,O
),O
1,O
.,O
58,O
(,O
1,O
.,O
20,O
–,O
2,O
.,O
09,O
),O
Alberta,O
1,O
.,O
27,O
(,O
0,O
.,O
99,O
–,O
1,O
.,O
62,O
),O
1,O
.,O
31,O
(,O
1,O
.,O
00,O
–,O
1,O
.,O
71,O
),O
Quebec,O
1,O
.,O
27,O
(,O
0,O
.,O
99,O
–,O
1,O
.,O
64,O
),O
1,O
.,O
03,O
(,O
0,O
.,O
78,O
–,O
1,O
.,O
35,O
),O
Manitoba,O
1,O
.,O
32,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
67,O
),O
1,O
.,O
05,O
(,O
0,O
.,O
80,O
–,O
1,O
.,O
38,O
),O
New,O
Brunswick,O
1,O
.,O
35,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
72,O
),O
1,O
.,O
37,O
(,O
1,O
.,O
04,O
–,O
1,O
.,O
80,O
),O
Newfoundland,O
1,O
.,O
42,O
(,O
1,O
.,O
11,O
–,O
1,O
.,O
81,O
),O
1,O
.,O
08,O
(,O
0,O
.,O
83,O
–,O
1,O
.,O
41,O
),O
Saskatchewan,O
1,O
.,O
42,O
(,O
1,O
.,O
12,O
–,O
1,O
.,O
80,O
),O
1,O
.,O
40,O
(,O
1,O
.,O
07,O
–,O
1,O
.,O
84,O
),O
Nova,O
Scotia,O
1,O
.,O
58,O
(,O
1,O
.,O
24,O
–,O
2,O
.,O
01,O
),O
1,O
.,O
00,O
Canadian,O
Tobacco,O
Use,O
Monitoring,O
Survey,O
2010,O
.,O
Men,B-OG
were,O
more,O
likely,O
to,O
smoke,O
than,O
women,B-OG
and,O
had,O
an,O
odds,O
ratio,O
(,O
OR,O
),O
of,O
1,O
.,O
62,O
(,O
95,O
%,O
CI,O
:,O
1,O
.,O
35,O
–,O
1,O
.,O
94,O
),O
for,O
current,O
smoking,O
.,O
In,O
addition,O
",",O
those,O
who,O
were,O
widowed,O
",",O
divorced,O
",",O
or,O
separated,O
(,O
OR,O
1,O
.,O
85,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
42,O
–,O
2,O
.,O
43,O
),O
and,O
singles,O
(,O
OR,O
1,O
.,O
86,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
44,O
–,O
2,O
.,O
41,O
),O
smoked,O
more,O
than,O
married,O
individuals,O
.,O
Quitters,O
were,O
more,O
likely,O
to,O
be,O
married,O
(,O
OR,O
2,O
.,O
01,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
48,O
–,O
2,O
.,O
74,O
),O
and,O
women,B-OG
(,O
OR,O
1,O
.,O
18,O
;,O
95,O
%,O
CI,O
:,O
0,O
.,O
95,O
–,O
1,O
.,O
49,O
"),",O
although,O
the,O
OR,O
for,O
sex,O
was,O
not,O
statistically,O
significant,O
at,O
the,O
conventional,O
5,O
%,O
level,O
.,O
Age,O
was,O
strongly,O
associated,O
with,O
quitting,O
;,O
a,O
10,O
year,O
change,O
in,O
age,O
was,O
associated,O
with,O
an,O
increase,O
of,O
1,O
.,O
58,O
in,O
the,O
odds,O
of,O
quitting,O
and,O
the,O
non,O
-,O
linear,O
terms,O
were,O
non,O
-,O
significant,O
indicating,O
that,O
quitting,O
generally,O
increased,O
with,O
age,O
in,O
a,O
linear,O
fashion,O
among,O
surviving,O
ever,O
smokers,O
.,O
Socioeconomic,O
Variation,O
in,O
Current,O
Smoking,O
and,O
Quitting,O
A,O
strong,O
and,O
graded,O
association,O
was,O
observed,O
between,O
education,O
and,O
current,O
smoking,O
",",O
with,O
the,O
odds,O
of,O
smoking,O
being,O
3,O
.,O
92,O
(,O
95,O
%,O
CI,O
:,O
2,O
.,O
78,O
–,O
5,O
.,O
52,O
),O
times,O
higher,O
among,O
those,O
who,O
had,O
not,O
completed,O
secondary,O
school,O
compared,O
to,O
those,O
who,O
had,O
completed,O
university,O
(,O
Table,O
2,O
).,O
There,O
was,O
no,O
evidence,O
of,O
an,O
interaction,O
in,O
this,O
association,O
by,O
sex,O
(,O
P,O
=,O
0,O
.,O
24,O
).,O
Current,O
smoking,O
was,O
higher,O
among,O
those,O
working,O
manual,O
occupations,O
(,O
OR,O
2,O
.,O
05,O
;,O
95,O
%,O
CI,O
:,O
1,O
.,O
49,O
–,O
2,O
.,O
83,O
),O
and,O
in,O
sales,O
or,O
service,O
occupations,O
(,O
OR,O
1,O
.,O
68,O
;,O
95,O
%,O
CI,O
:,O
1,O
.,O
25,O
–,O
2,O
.,O
25,O
),O
compared,O
to,O
those,O
in,O
professional,O
specialties,O
with,O
no,O
indication,O
of,O
interaction,O
by,O
sex,O
(,O
P,O
=,O
0,O
.,O
43,O
).,O
The,O
adjusted,O
prevalence,O
of,O
current,O
smoking,O
across,O
all,O
of,O
the,O
study,O
variables,O
and,O
for,O
men,B-OG
and,O
women,B-OG
is,O
presented,O
in,O
Figure,O
3A,O
.,O
We,O
observed,O
substantial,O
variation,O
in,O
prevalence,O
according,O
to,O
education,O
;,O
overall,O
the,O
prevalence,O
varied,O
from,O
11,O
.,O
0,O
%,O
among,O
individuals,O
who,O
had,O
completed,O
university,O
to,O
32,O
.,O
8,O
%,O
among,O
those,O
with,O
less,O
than,O
high,O
school,O
education,O
",",O
corresponding,O
to,O
a,O
difference,O
of,O
21,O
.,O
8,O
%,O
(,O
95,O
%,O
CI,O
:,O
16,O
.,O
4,O
–,O
27,O
.,O
3,O
).,O
Large,O
variation,O
in,O
the,O
prevalence,O
of,O
current,O
smoking,O
was,O
also,O
observed,O
by,O
occupation,O
group,O
with,O
a,O
difference,O
of,O
10,O
.,O
1,O
%,O
(,O
95,O
%,O
CI,O
:,O
4,O
.,O
2,O
–,O
16,O
.,O
3,O
),O
between,O
those,O
in,O
professional,O
specialties,O
(,O
14,O
.,O
6,O
%),O
and,O
those,O
in,O
manual,O
occupations,O
(,O
24,O
.,O
7,O
%).,O
Adjusted,O
prevalence,O
of,O
current,O
smoking,O
and,O
quitting,O
in,O
Canada,O
by,O
demographic,O
and,O
socioeconomic,O
characteristics,O
and,O
province,O
.,O
BC,O
British,O
Columbia,O
;,O
PEI,O
Prince,O
Edward,O
Island,O
.,O
Similarly,O
",",O
we,O
observed,O
strong,O
SES,O
-,O
quitting,O
associations,O
for,O
education,O
and,O
occupation,O
",",O
with,O
quitting,O
being,O
more,O
likely,O
among,O
those,O
with,O
university,O
education,O
(,O
OR,O
1,O
.,O
82,O
),O
and,O
in,O
higher,O
status,O
occupations,O
(,O
OR,O
1,O
.,O
93,O
for,O
professionals,O
"),",O
although,O
the,O
overall,O
educational,O
gradient,O
was,O
not,O
as,O
pronounced,O
as,O
compared,O
to,O
current,O
smoking,O
(,O
Table,O
2,O
).,O
In,O
addition,O
",",O
there,O
was,O
indication,O
of,O
an,O
interaction,O
in,O
the,O
education,O
-,O
quitting,O
association,O
by,O
sex,O
",",O
with,O
the,O
gradient,O
being,O
sharper,O
for,O
women,B-OG
compared,O
to,O
men,B-OG
(,O
P,O
=,O
0,O
.,O
02,O
"),",O
although,O
there,O
was,O
no,O
indication,O
of,O
an,O
interaction,O
by,O
sex,O
in,O
the,O
occupation,O
-,O
quitting,O
association,O
(,O
P,O
=,O
0,O
.,O
20,O
).,O
Conditional,O
on,O
all,O
covariates,O
",",O
a,O
15,O
.,O
7,O
%,O
(,O
95,O
%,O
CI,O
:,O
6,O
.,O
7,O
–,O
24,O
.,O
3,O
),O
difference,O
was,O
observed,O
in,O
the,O
rate,O
of,O
quitting,O
between,O
those,O
in,O
highest,O
and,O
lowest,O
educated,O
groups,O
overall,O
",",O
although,O
this,O
difference,O
was,O
27,O
.,O
3,O
%,O
among,O
women,B-OG
compared,O
to,O
6,O
.,O
0,O
%,O
among,O
men,B-OG
(,O
Figure,O
3B,O
).,O
Overal,O
a,O
14,O
.,O
7,O
%,O
difference,O
was,O
observed,O
in,O
the,O
prevalence,O
of,O
quitting,O
between,O
those,O
in,O
professional,O
(,O
72,O
.,O
6,O
%),O
and,O
manual,O
occupations,O
(,O
57,O
.,O
9,O
%).,O
Geographic,O
Variation,O
in,O
Current,O
Smoking,O
and,O
Quitting,O
A,O
statistically,O
significant,O
difference,O
in,O
current,O
smoking,O
was,O
observed,O
between,O
provinces,O
in,O
the,O
logistic,O
regression,O
model,O
treating,O
provinces,O
as,O
a,O
fixed,O
effect,O
(,O
p,O
=,O
0,O
.,O
0009,O
).,O
In,O
this,O
model,O
",",O
the,O
odds,O
of,O
current,O
smoking,O
were,O
greatest,O
in,O
Nova,O
Scotia,O
(,O
OR,O
1,O
.,O
58,O
;,O
95,O
%,O
CI,O
:,O
1,O
.,O
24,O
–,O
2,O
.,O
01,O
),O
and,O
lowest,O
in,O
B,O
.,O
C,O
.,O
(,O
OR,O
0,O
.,O
96,O
;,O
95,O
%,O
CI,O
:,O
0,O
.,O
74,O
–,O
1,O
.,O
26,O
),O
compared,O
to,O
Ontario,O
.,O
Based,O
on,O
this,O
model,O
",",O
the,O
adjusted,O
prevalence,O
of,O
current,O
smoking,O
varied,O
from,O
17,O
.,O
9,O
%,O
in,O
British,O
Columbia,O
and,O
Ontario,O
to,O
26,O
.,O
1,O
%,O
in,O
Nova,O
Scotia,O
",",O
equivalent,O
to,O
a,O
difference,O
of,O
8,O
.,O
2,O
%,O
(,O
95,O
%,O
CI,O
:,O
4,O
.,O
0,O
–,O
12,O
.,O
2,O
).,O
In,O
addition,O
",",O
the,O
prevalence,O
of,O
current,O
smoking,O
was,O
lower,O
in,O
British,O
Columbia,O
and,O
Ontario,O
compared,O
to,O
the,O
national,O
average,O
(,O
Figure,O
3A,O
).,O
The,O
adjusted,O
prevalence,O
of,O
quitting,O
across,O
provinces,O
was,O
also,O
calculated,O
from,O
a,O
logistic,O
regression,O
model,O
treating,O
province,O
as,O
a,O
fixed,O
effect,O
.,O
From,O
this,O
model,O
",",O
a,O
10,O
.,O
4,O
%,O
(,O
95,O
%,O
CI,O
:,O
3,O
.,O
9,O
–,O
16,O
.,O
8,O
),O
difference,O
was,O
observed,O
in,O
quit,O
rates,O
between,O
the,O
provinces,O
with,O
the,O
highest,O
rate,O
(,O
Prince,O
Edward,O
Island,O
",",O
67,O
.,O
8,O
%),O
and,O
lowest,O
rate,O
(,O
Nova,O
Scotia,O
",",O
57,O
.,O
4,O
%).,O
Nova,O
Scotia,O
",",O
along,O
with,O
the,O
western,O
and,O
prairie,O
provinces,O
(,O
Manitoba,O
",",O
Alberta,O
",",O
and,O
Saskatchewan,O
),O
had,O
quitter,O
percentages,O
lower,O
than,O
the,O
Canadian,O
average,O
of,O
63,O
.,O
7,O
%.,O
We,O
examined,O
geographic,O
variation,O
in,O
current,O
smoking,O
and,O
quitting,O
between,O
provinces,O
using,O
a,O
multilevel,O
modeling,O
approach,O
.,O
In,O
this,O
approach,O
",",O
provinces,O
were,O
treated,O
as,O
a,O
random,O
sample,O
and,O
between,O
provincial,O
differences,O
in,O
current,O
smoking,O
and,O
quitting,O
were,O
assumed,O
to,O
come,O
from,O
a,O
distribution,O
estimated,O
in,O
the,O
model,O
.,O
Compared,O
to,O
treating,O
provinces,O
as,O
a,O
fixed,O
classification,O
",",O
the,O
multilevel,O
model,O
yielded,O
similar,O
provincial,O
-,O
level,O
estimates,O
although,O
the,O
differences,O
between,O
provinces,O
were,O
found,O
to,O
be,O
2,O
.,O
2,O
%,O
narrower,O
(,O
6,O
.,O
0,O
%,O
vs,O
8,O
.,O
2,O
%),O
for,O
current,O
smoking,O
and,O
3,O
.,O
2,O
%,O
narrower,O
(,O
7,O
.,O
2,O
%,O
vs,O
10,O
.,O
4,O
%),O
for,O
quitting,O
.,O
The,O
fixed,O
effects,O
estimates,O
for,O
each,O
province,O
",",O
compared,O
to,O
the,O
multilevel,O
model,O
estimates,O
are,O
shown,O
for,O
current,O
smoking,O
in,O
Figure,O
4A,O
and,O
quitting,O
in,O
Figure,O
4B,O
.,O
The,O
ordering,O
of,O
provinces,O
was,O
generally,O
consistent,O
in,O
the,O
two,O
approaches,O
.,O
For,O
current,O
smoking,O
",",O
the,O
provinces,O
with,O
lower,O
than,O
average,O
rates,O
of,O
smoking,O
(,O
British,O
Columbia,O
",",O
Ontario,O
",",O
and,O
Prince,O
Edward,O
Island,O
),O
in,O
the,O
fixed,O
effects,O
model,O
also,O
emerged,O
as,O
lower,O
than,O
average,O
in,O
the,O
multilevel,O
model,O
",",O
indicating,O
the,O
reliability,O
of,O
these,O
estimates,O
.,O
The,O
multilevel,O
model,O
tends,O
to,O
‘,O
shrink,O
’,O
less,O
reliable,O
provincial,O
estimates,O
towards,O
the,O
national,O
average,O
;,O
this,O
is,O
apparent,O
in,O
the,O
quit,O
rate,O
model,O
where,O
a,O
smaller,O
range,O
in,O
the,O
multilevel,O
estimates,O
for,O
quitting,O
was,O
observed,O
compared,O
to,O
the,O
fixed,O
effects,O
approach,O
(,O
Figure,O
4B,O
).,O
Comparison,O
of,O
adjusted,O
prevalence,O
estimates,O
for,O
current,O
smoking,O
and,O
quitting,O
for,O
Canadian,O
provinces,O
based,O
on,O
mutually,O
adjusted,O
fixed,O
effects,O
and,O
multilevel,O
logistic,O
regression,O
models,O
.,O
Province,O
name,O
abbreviations,O
:,O
AB,O
Alberta,O
;,O
BC,O
British,O
Columbia,O
;,O
MB,O
Manitoba,O
;,O
NB,O
New,O
Brunswick,O
;,O
NL,O
Newfoundland,O
;,O
NS,O
Nova,O
Scotia,O
;,O
ON,O
Ontario,O
;,O
PE,O
Prince,O
Edward,O
Island,O
;,O
QC,O
Quebec,O
;,O
SK,O
Saskatchewan,O
.,O
In,O
addition,O
to,O
providing,O
estimates,O
of,O
the,O
between,O
provincial,O
differences,O
in,O
current,O
smoking,O
and,O
quitting,O
",",O
the,O
multilevel,O
modeling,O
approach,O
allows,O
for,O
a,O
more,O
detailed,O
examination,O
of,O
several,O
research,O
questions,O
that,O
are,O
of,O
substantive,O
interest,O
.,O
These,O
analyses,O
revealed,O
the,O
amount,O
of,O
between,O
-,O
provincial,O
variation,O
in,O
current,O
smoking,O
and,O
quitting,O
before,O
and,O
after,O
accounting,O
for,O
individual,O
characteristics,O
(,O
Table,O
3,O
).,O
In,O
an,O
initial,O
random,O
intercepts,O
,O
model,O
",",O
provinces,O
accounted,O
for,O
0,O
.,O
9,O
%,O
and,O
1,O
.,O
1,O
%,O
of,O
the,O
total,O
variation,O
in,O
current,O
smoking,O
and,O
quitting,O
",",O
respectively,O
.,O
The,O
addition,O
of,O
demographic,O
and,O
socioeconomic,O
characteristics,O
to,O
the,O
model,O
reduced,O
the,O
variance,O
in,O
current,O
smoking,O
by,O
26,O
.,O
7,O
%,O
and,O
in,O
quitting,O
by,O
25,O
.,O
7,O
%.,O
Variance,O
in,O
current,O
smoking,O
and,O
quitting,O
between,O
provinces,O
in,O
Canada,O
;,O
expressed,O
as,O
percentage,O
of,O
the,O
contribution,O
to,O
the,O
total,O
variance,O
.,O
Null,O
model,O
*,O
Fully,O
adjusted,O
model,O
**,O
Response,O
Variance,O
SE,O
%,O
Variance,O
SE,O
%,O
Current,O
smoking,O
0,O
.,O
030,O
0,O
.,O
014,O
0,O
.,O
9,O
0,O
.,O
022,O
0,O
.,O
010,O
0,O
.,O
7,O
Quitting,O
0,O
.,O
035,O
0,O
.,O
016,O
1,O
.,O
1,O
0,O
.,O
026,O
0,O
.,O
005,O
0,O
.,O
8,O
Notes,O
:,O
Multilevel,O
,O
model,O
with,O
random,O
intercepts,O
for,O
province,O
adjusted,O
.,O
Multilevel,O
model,O
with,O
random,O
intercepts,O
for,O
province,O
and,O
adjusted,O
for,O
age,O
",",O
sex,O
",",O
marital,O
status,O
",",O
occupation,O
",",O
and,O
education,O
.,O
In,O
order,O
to,O
assess,O
consistency,O
in,O
the,O
SES,O
-,O
current,O
smoking,O
and,O
SES,O
-,O
quitting,O
relationships,O
across,O
provinces,O
",",O
we,O
estimated,O
random,O
-,O
intercept,O
",",O
random,O
slope,O
multilevel,O
models,O
(,O
Equation,O
2,O
).,O
In,O
these,O
models,O
",",O
the,O
SES,O
-,O
current,O
smoking,O
and,O
SES,O
-,O
quitting,O
relationships,O
were,O
allowed,O
to,O
vary,O
across,O
provinces,O
for,O
education,O
and,O
occupation,O
.,O
The,O
overall,O
odds,O
ratio,O
for,O
current,O
smoking,O
in,O
Canada,O
for,O
a,O
one,O
-,O
category,O
increase,O
in,O
education,O
was,O
0,O
.,O
64,O
(,O
95,O
%,O
CI,O
:,O
0,O
.,O
60,O
–,O
0,O
.,O
68,O
),O
(,O
Figure,O
5A,O
),O
and,O
0,O
.,O
82,O
(,O
95,O
%,O
CI,O
:,O
0,O
.,O
77,O
–,O
0,O
.,O
87,O
),O
for,O
a,O
one,O
-,O
category,O
increase,O
in,O
occupation,O
(,O
Figure,O
5B,O
).,O
The,O
direction,O
of,O
these,O
relationships,O
were,O
consistent,O
and,O
statistically,O
significant,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
in,O
all,O
provinces,O
for,O
both,O
education,O
and,O
occupation,O
.,O
The,O
magnitude,O
of,O
the,O
association,O
was,O
greater,O
than,O
the,O
national,O
average,O
in,O
the,O
provinces,O
of,O
British,O
Columbia,O
",",O
Alberta,O
",",O
and,O
Saskatchewan,O
for,O
the,O
education,O
relationship,O
and,O
in,O
the,O
provinces,O
of,O
Nova,O
Scotia,O
",",O
British,O
Columbia,O
",",O
Alberta,O
",",O
Newfoundland,O
",",O
and,O
Ontario,O
for,O
the,O
occupation,O
relationship,O
.,O
In,O
general,O
",",O
the,O
magnitude,O
of,O
the,O
SES,O
-,O
current,O
smoking,O
relationship,O
was,O
stronger,O
for,O
education,O
compared,O
to,O
occupation,O
.,O
The,O
associations,O
between,O
education,O
and,O
quitting,O
and,O
occupation,O
and,O
quitting,O
were,O
positive,O
across,O
all,O
provinces,O
",",O
and,O
statistically,O
significant,O
in,O
8,O
/,O
10,O
provinces,O
for,O
education,O
(,O
Figure,O
6A,O
),O
and,O
9,O
/,O
10,O
provinces,O
for,O
occupation,O
(,O
Figure,O
6B,O
).,O
The,O
overall,O
odds,O
ratio,O
for,O
quitting,O
with,O
each,O
successive,O
increase,O
in,O
the,O
level,O
of,O
education,O
was,O
1,O
.,O
27,O
(,O
95,O
%,O
CI,O
:,O
1,O
.,O
16,O
–,O
1,O
.,O
40,O
),O
and,O
1,O
.,O
20,O
(,O
95,O
%,O
CI,O
:,O
1,O
.,O
12,O
–,O
1,O
.,O
27,O
),O
for,O
each,O
successive,O
increase,O
in,O
level,O
of,O
occupation,O
.,O
The,O
education,O
-,O
quitting,O
relationship,O
was,O
stronger,O
than,O
the,O
national,O
average,O
in,O
Saskatchewan,O
",",O
Alberta,O
",",O
Newfoundland,O
",",O
and,O
was,O
highest,O
in,O
British,O
Columbia,O
(,O
OR,O
1,O
.,O
56,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
29,O
–,O
1,O
.,O
88,O
).,O
The,O
occupation,O
-,O
quitting,O
relationship,O
was,O
stronger,O
than,O
the,O
national,O
average,O
in,O
Ontario,O
",",O
British,O
Columbia,O
",",O
and,O
Prince,O
Edward,O
Island,O
.,O
Associations,O
were,O
shallower,O
than,O
the,O
national,O
average,O
in,O
Quebec,O
",",O
Nova,O
Scotia,O
",",O
Manitoba,O
",",O
and,O
New,O
Brunswick,O
for,O
both,O
education,O
and,O
occupation,O
;,O
in,O
Ontario,O
and,O
Prince,O
Edward,O
Island,O
for,O
education,O
;,O
and,O
in,O
Alberta,O
for,O
occupation,O
.,O
Odds,O
ratios,O
for,O
current,O
smoking,O
for,O
a,O
one,O
-,O
category,O
increase,O
in,O
the,O
level,O
of,O
education,O
and,O
occupation,O
across,O
Canadian,O
provinces,O
.,O
BC,O
British,O
Columbia,O
;,O
PEI,O
Prince,O
Edward,O
Island,O
.,O
Odds,O
ratios,O
for,O
quitting,O
for,O
a,O
one,O
-,O
category,O
increase,O
in,O
the,O
level,O
of,O
education,O
and,O
occupation,O
across,O
Canadian,O
provinces,O
.,O
BC,O
British,O
Columbia,O
;,O
PEI,O
Prince,O
Edward,O
Island,O
.,O
Discussion,O
This,O
paper,O
has,O
four,O
principal,O
findings,O
.,O
First,O
",",O
current,O
smoking,O
in,O
Canada,O
was,O
strongly,O
influenced,O
by,O
socioeconomic,O
status,O
;,O
people,O
who,O
had,O
not,O
completed,O
secondary,O
level,O
education,O
were,O
more,O
than,O
three,O
times,O
as,O
likely,O
to,O
smoke,O
compared,O
to,O
those,O
who,O
had,O
completed,O
university,O
.,O
Second,O
",",O
geographic,O
analyses,O
revealed,O
that,O
the,O
adjusted,O
prevalence,O
of,O
current,O
smoking,O
was,O
statistically,O
significantly,O
lower,O
than,O
the,O
Canadian,O
average,O
in,O
three,O
provinces,O
:,O
British,O
Columbia,O
",",O
Ontario,O
",",O
and,O
to,O
a,O
lesser,O
extent,O
",",O
Prince,O
Edward,O
Island,O
.,O
This,O
finding,O
was,O
consistent,O
when,O
provinces,O
were,O
treated,O
as,O
a,O
fixed,O
classification,O
and,O
as,O
a,O
random,O
classification,O
in,O
a,O
multilevel,O
model,O
.,O
In,O
addition,O
",",O
the,O
relationships,O
between,O
education,O
and,O
current,O
smoking,O
and,O
between,O
occupation,O
and,O
current,O
smoking,O
were,O
consistent,O
",",O
negative,O
",",O
and,O
statistically,O
significant,O
across,O
all,O
provinces,O
in,O
Canada,O
.,O
Third,O
",",O
although,O
roughly,O
six,O
out,O
of,O
ten,O
Canadians,O
who,O
had,O
ever,O
smoked,O
had,O
quit,O
",",O
quitting,O
was,O
more,O
likely,O
to,O
occur,O
among,O
those,O
of,O
higher,O
socioeconomic,O
status,O
.,O
Geographically,O
",",O
large,O
differences,O
in,O
quit,O
rates,O
were,O
found,O
between,O
provinces,O
",",O
although,O
the,O
magnitude,O
of,O
difference,O
was,O
attenuated,O
when,O
province,O
was,O
treated,O
as,O
a,O
random,O
classification,O
using,O
a,O
multilevel,O
model,O
.,O
Forth,O
",",O
although,O
the,O
associations,O
between,O
education,O
and,O
quitting,O
and,O
between,O
occupation,O
and,O
quitting,O
were,O
positive,O
in,O
all,O
provinces,O
",",O
some,O
heterogeneity,O
in,O
the,O
magnitude,O
was,O
found,O
",",O
especially,O
in,O
the,O
education,O
-,O
quitting,O
relationship,O
which,O
was,O
noticeably,O
steeper,O
in,O
British,O
Columbia,O
and,O
shallower,O
in,O
Nova,O
Scotia,O
compared,O
to,O
the,O
national,O
average,O
.,O
There,O
are,O
some,O
limitations,O
in,O
this,O
work,O
.,O
First,O
",",O
the,O
CTUMS,O
data,O
are,O
cross,O
-,O
sectional,O
therefore,O
causal,O
inferences,O
from,O
our,O
findings,O
must,O
be,O
interpreted,O
cautiously,O
.,O
The,O
primary,O
motivation,O
for,O
this,O
study,O
",",O
however,O
",",O
was,O
to,O
investigate,O
variability,O
in,O
smoking,O
behaviour,O
across,O
socioeconomic,O
and,O
geographic,O
dimensions,O
and,O
such,O
a,O
design,O
is,O
appropriate,O
.,O
Second,O
",",O
the,O
data,O
are,O
from,O
a,O
telephone,O
survey,O
",",O
which,O
as,O
a,O
design,O
has,O
several,O
inherent,O
potential,O
sources,O
of,O
bias,O
in,O
terms,O
of,O
population,O
coverage,O
.,O
For,O
example,O
",",O
one,O
limitation,O
of,O
telephone,O
sampling,O
is,O
that,O
some,O
individuals,O
either,O
do,O
not,O
have,O
telephones,O
or,O
have,O
only,O
a,O
mobile,O
phone,O
",",O
which,O
were,O
not,O
part,O
of,O
the,O
random,O
telephone,O
prefix,O
sampling,O
frames,O
in,O
the,O
CTUMS,O
.,O
Estimates,O
from,O
the,O
2010,O
Residential,O
Telephone,O
Service,O
Survey,O
suggest,O
that,O
14,O
–,O
16,O
%,O
of,O
the,O
Canadian,O
population,O
do,O
not,O
have,O
a,O
landline,O
and,O
that,O
these,O
individuals,O
are,O
concentrated,O
among,O
those,O
of,O
18,O
–,O
34,O
years,O
of,O
age,O
and,O
with,O
below,O
-,O
average,O
income,O
.,O
[,O
30,O
],O
Although,O
efforts,O
were,O
made,O
to,O
weight,O
the,O
CTUMS,O
survey,O
data,O
for,O
individuals,O
without,O
land,O
lines,O
",",O
it,O
is,O
conceivable,O
that,O
some,O
of,O
the,O
prevalence,O
estimates,O
may,O
be,O
biased,O
downwards,O
given,O
that,O
our,O
findings,O
suggest,O
smoking,O
to,O
be,O
higher,O
among,O
these,O
ages,O
and,O
lower,O
SES,O
groups,O
.,O
In,O
addition,O
",",O
telephone,O
surveys,O
can,O
produce,O
a,O
potential,O
reporting,O
bias,O
among,O
younger,O
respondents,O
who,O
may,O
be,O
prone,O
to,O
give,O
socially,O
desirable,O
answers,O
about,O
their,O
smoking,O
habits,O
in,O
the,O
presence,O
of,O
their,O
parents,O
or,O
family,O
.,O
Estimates,O
of,O
youth,O
smoking,O
among,O
15,O
–,O
19,O
year,O
olds,O
in,O
the,O
CTUMS,O
were,O
lower,O
than,O
what,O
has,O
been,O
reported,O
among,O
16,O
–,O
19,O
year,O
olds,O
the,O
UK,O
(,O
12,O
%,O
vs,O
24,O
%),O
[,O
31,O
"],",O
although,O
the,O
CTUMS,O
data,O
for,O
youth,O
smoking,O
have,O
demonstrated,O
good,O
concordance,O
with,O
other,O
prevalence,O
estimates,O
in,O
Canada,O
from,O
general,O
health,O
surveys,O
such,O
as,O
the,O
Canadian,O
Community,O
Heath,O
Survey,O
",",O
which,O
uses,O
a,O
combination,O
of,O
in,O
-,O
person,O
and,O
telephone,O
-,O
based,O
interviews,O
.[,O
32,O
]–[,O
34,O
],O
Second,O
",",O
we,O
only,O
considered,O
cigarette,O
smoking,O
in,O
the,O
present,O
study,O
.,O
Socioeconomic,O
and,O
geographic,O
differences,O
for,O
the,O
use,O
of,O
cigars,O
",",O
or,O
smokeless,O
(,O
chewing,O
),O
tobacco,O
were,O
not,O
considered,O
these,O
analyses,O
although,O
these,O
forms,O
of,O
tobacco,O
use,O
may,O
be,O
important,O
to,O
consider,O
among,O
certain,O
population,O
groups,O
in,O
Canada,O
.,O
These,O
forms,O
of,O
tobacco,O
are,O
",",O
however,O
",",O
used,O
less,O
frequently,O
and,O
only,O
in,O
a,O
minority,O
of,O
the,O
Canadian,O
population,O
.,O
[,O
12,O
],O
Further,O
research,O
on,O
the,O
patterning,O
of,O
occasional,O
smoking,O
in,O
Canada,O
",",O
the,O
use,O
of,O
other,O
forms,O
of,O
tobacco,O
",",O
and,O
potentially,O
related,O
factors,O
such,O
as,O
alcohol,O
use,O
is,O
needed,O
.,O
The,O
overall,O
relationship,O
observed,O
between,O
socioeconomic,O
status,O
markers,O
and,O
smoking,O
in,O
this,O
study,O
was,O
similar,O
to,O
what,O
has,O
been,O
reported,O
previously,O
in,O
Canada,O
.,O
[,O
13,O
"],",O
[,O
35,O
"],",O
[,O
36,O
],O
We,O
noted,O
strong,O
gradients,O
in,O
current,O
smoking,O
by,O
level,O
of,O
education,O
and,O
occupation,O
",",O
which,O
were,O
minimally,O
changed,O
after,O
adjustment,O
for,O
potentially,O
confounding,O
variables,O
.,O
Differences,O
remained,O
in,O
rates,O
of,O
current,O
smoking,O
between,O
provinces,O
after,O
accounting,O
for,O
demographic,O
and,O
socioeconomic,O
characteristics,O
in,O
both,O
the,O
fixed,O
and,O
random,O
effects,O
models,O
",",O
although,O
the,O
estimated,O
prevalence,O
for,O
several,O
provinces,O
(,O
for,O
example,O
Nova,O
Scotia,O
and,O
Manitoba,O
),O
were,O
‘,O
shrunk,O
’,O
towards,O
the,O
national,O
mean,O
in,O
the,O
multilevel,O
model,O
.,O
Due,O
to,O
the,O
treatment,O
of,O
higher,O
level,O
units,O
as,O
part,O
of,O
a,O
distribution,O
",",O
the,O
multilevel,O
approach,O
is,O
typically,O
more,O
conservative,O
in,O
estimating,O
between,O
group,O
-,O
differences,O
.,O
[,O
26,O
],O
The,O
between,O
provincial,O
differences,O
in,O
quit,O
rates,O
were,O
approximately,O
a,O
third,O
narrower,O
in,O
the,O
multilevel,O
modeling,O
approach,O
",",O
and,O
the,O
most,O
obvious,O
pattern,O
of,O
attenuation,O
compared,O
to,O
the,O
fixed,O
effects,O
model,O
was,O
found,O
for,O
provinces,O
with,O
quit,O
rates,O
lower,O
than,O
the,O
national,O
average,O
.,O
In,O
this,O
way,O
",",O
the,O
random,O
effects,O
approach,O
is,O
favoured,O
because,O
it,O
protects,O
against,O
the,O
over,O
interpretation,O
of,O
extreme,O
group,O
-,O
level,O
differences,O
which,O
are,O
potentially,O
less,O
reliable,O
.,O
Conditional,O
on,O
socioeconomic,O
and,O
demographic,O
characteristics,O
",",O
province,O
of,O
residence,O
was,O
associated,O
with,O
<,O
1,O
%,O
of,O
the,O
total,O
variability,O
in,O
current,O
smoking,O
and,O
quitting,O
in,O
the,O
fully,O
adjusted,O
multilevel,O
models,O
.,O
Although,O
the,O
magnitude,O
of,O
this,O
variability,O
was,O
not,O
large,O
",",O
adjustment,O
for,O
individual,O
characteristics,O
explained,O
about,O
one,O
quarter,O
of,O
the,O
provincial,O
-,O
level,O
variation,O
in,O
current,O
smoking,O
and,O
quitting,O
",",O
indirectly,O
suggesting,O
the,O
potential,O
relevance,O
of,O
geographic,O
context,O
in,O
influencing,O
smoking,O
behaviour,O
in,O
Canada,O
.,O
[,O
37,O
"],",O
[,O
38,O
],O
Province,O
was,O
the,O
only,O
higher,O
-,O
level,O
geographic,O
unit,O
that,O
was,O
available,O
in,O
the,O
CTUMS,O
;,O
thus,O
potentially,O
important,O
geographic,O
variability,O
in,O
smoking,O
behaviour,O
at,O
lower,O
levels,O
of,O
aggregation,O
(,O
for,O
example,O
health,O
regions,O
",",O
or,O
communities,O
),O
may,O
have,O
been,O
masked,O
in,O
these,O
analyses,O
.,O
[,O
39,O
].,O
Our,O
study,O
documents,O
that,O
current,O
smoking,O
in,O
Canada,O
follows,O
an,O
inverse,O
gradient,O
by,O
SES,O
which,O
was,O
consistent,O
in,O
direction,O
across,O
all,O
provinces,O
.,O
Similarly,O
",",O
a,O
consistent,O
and,O
positive,O
gradient,O
was,O
observed,O
with,O
quitting,O
for,O
increasing,O
SES,O
.,O
Interestingly,O
",",O
there,O
was,O
some,O
variability,O
in,O
the,O
magnitude,O
of,O
these,O
associations,O
",",O
with,O
larger,O
variability,O
observed,O
for,O
quitting,O
.,O
The,O
education,O
and,O
occupation,O
gradients,O
appear,O
to,O
be,O
stronger,O
in,O
British,O
Columbia,O
",",O
a,O
province,O
with,O
the,O
lowest,O
prevalence,O
of,O
current,O
smoking,O
and,O
second,O
highest,O
quit,O
rate,O
.,O
In,O
comparison,O
",",O
the,O
education,O
gradients,O
were,O
considerably,O
shallower,O
in,O
Manitoba,O
",",O
New,O
Brunswick,O
",",O
and,O
Ontario,O
.,O
This,O
may,O
indicate,O
that,O
programs,O
aimed,O
at,O
tobacco,O
use,O
prevention,O
and,O
/,O
or,O
cessation,O
or,O
other,O
social,O
assistance,O
programs,O
have,O
been,O
better,O
able,O
to,O
reach,O
all,O
SES,O
groups,O
in,O
certain,O
provinces,O
compared,O
to,O
others,O
.,O
Further,O
comparative,O
analyses,O
of,O
provincial,O
policies,O
are,O
required,O
to,O
understand,O
why,O
SES,O
gradients,O
vary,O
across,O
provinces,O
.,O
Our,O
findings,O
related,O
to,O
the,O
socioeconomic,O
differentials,O
in,O
quitting,O
are,O
of,O
public,O
health,O
importance,O
.,O
On,O
average,O
",",O
individuals,O
who,O
where,O
married,O
",",O
highly,O
educated,O
",",O
and,O
working,O
in,O
higher,O
status,O
occupations,O
had,O
the,O
highest,O
likelihood,O
of,O
quitting,O
.,O
While,O
a,O
positive,O
SES,O
-,O
quitting,O
relationship,O
has,O
been,O
previously,O
reported,O
[,O
17,O
]–[,O
20,O
"],",O
the,O
implications,O
of,O
these,O
findings,O
have,O
been,O
given,O
less,O
attention,O
in,O
recent,O
years,O
.,O
Indeed,O
",",O
it,O
has,O
been,O
suggested,O
that,O
policies,O
aimed,O
at,O
reducing,O
tobacco,O
consumption,O
may,O
be,O
responsible,O
for,O
widening,O
the,O
socioeconomic,O
differentials,O
in,O
smoking,O
",",O
at,O
least,O
in,O
the,O
short,O
-,O
term,O
.,O
[,O
15,O
],O
Individuals,O
with,O
greater,O
education,O
and,O
/,O
or,O
material,O
resources,O
may,O
be,O
more,O
responsive,O
to,O
accessing,O
health,O
services,O
in,O
general,O
[,O
40,O
],O
and,O
this,O
may,O
extend,O
to,O
primary,O
care,O
and,O
other,O
sources,O
of,O
cessation,O
support,O
including,O
telephone,O
quitlines,O
[,O
41,O
"],",O
medication,O
",",O
nicotine,O
replacement,O
",",O
or,O
counselling,O
.,O
Interventions,O
carried,O
out,O
at,O
a,O
population,O
level,O
including,O
taxation,O
",",O
dissemination,O
of,O
health,O
information,O
and,O
pictorial,O
warnings,O
on,O
tobacco,O
products,O
",",O
restrictions,O
on,O
use,O
",",O
advertisements,O
",",O
and,O
sale,O
of,O
cigarettes,O
have,O
been,O
effective,O
at,O
reducing,O
average,O
consumption,O
[,O
42,O
"],",O
[,O
43,O
"],",O
although,O
it,O
is,O
less,O
clear,O
whether,O
these,O
interventions,O
are,O
reaching,O
all,O
segments,O
of,O
the,O
population,O
.,O
Indeed,O
",",O
there,O
is,O
evidence,O
that,O
taxation,O
policies,O
are,O
being,O
circumvented,O
among,O
some,O
population,O
groups,O
and,O
in,O
some,O
geographic,O
areas,O
.,O
For,O
example,O
",",O
a,O
quarter,O
of,O
respondents,O
in,O
the,O
Ontario,O
Tobacco,O
Survey,O
reported,O
recent,O
purchasing,O
of,O
contraband,O
cigarettes,O
from,O
First,O
Nations,O
reserves,O
without,O
paying,O
applicable,O
federal,O
or,O
provincial,O
taxes,O
.,O
[,O
44,O
],O
In,O
addition,O
",",O
the,O
usual,O
purchasing,O
of,O
contraband,O
or,O
low,O
-,O
tax,O
cigarettes,O
was,O
more,O
common,O
among,O
lower,O
educated,O
groups,O
",",O
heavy,O
smokers,O
",",O
and,O
those,O
who,O
do,O
not,O
intend,O
to,O
quit,O
.,O
[,O
44,O
].,O
In,O
Canada,O
",",O
all,O
provinces,O
and,O
territories,O
have,O
legislation,O
restricting,O
smoking,O
in,O
workplaces,O
and,O
public,O
places,O
including,O
restaurants,O
",",O
bars,O
",",O
and,O
public,O
transportation,O
.,O
[,O
45,O
],O
Although,O
such,O
contextual,O
factors,O
were,O
not,O
explicitly,O
considered,O
in,O
the,O
present,O
study,O
",",O
evidence,O
from,O
New,O
Zealand,O
suggests,O
that,O
such,O
workplace,O
restrictions,O
may,O
have,O
been,O
more,O
effective,O
in,O
reducing,O
rates,O
of,O
smoking,O
and,O
exposure,O
to,O
environmental,O
tobacco,O
smoke,O
among,O
those,O
in,O
professional,O
occupations,O
.,O
[,O
46,O
],O
In,O
addition,O
",",O
previous,O
research,O
in,O
Canada,O
has,O
revealed,O
the,O
importance,O
of,O
social,O
factors,O
such,O
as,O
family,O
norms,O
discouraging,O
smoking,O
in,O
explaining,O
between,O
-,O
area,O
differences,O
in,O
prevalence,O
.,O
[,O
39,O
],O
Successful,O
efforts,O
to,O
increase,O
smoking,O
prevention,O
and,O
cessation,O
across,O
the,O
entire,O
Canadian,O
population,O
will,O
therefore,O
need,O
explicit,O
consideration,O
of,O
lower,O
socioeconomic,O
",",O
Aboriginal,O
",",O
other,O
disadvantaged,O
groups,O
along,O
with,O
contextual,O
factors,O
at,O
the,O
local,O
and,O
provincial,O
levels,O
.,O
Policies,O
such,O
as,O
tax,O
increases,O
and,O
smoking,O
restrictions,O
may,O
not,O
be,O
effective,O
in,O
increasing,O
cessation,O
among,O
the,O
poor,O
or,O
less,O
educated,O
without,O
additional,O
support,O
or,O
assistance,O
in,O
reducing,O
tobacco,O
dependence,O
in,O
these,O
groups,O
.,O
In,O
addition,O
",",O
further,O
research,O
is,O
needed,O
to,O
understand,O
the,O
underlying,O
causes,O
of,O
geographic,O
variability,O
in,O
smoking,O
behaviour,O
in,O
Canada,O
.,O
Such,O
variation,O
may,O
be,O
a,O
result,O
of,O
different,O
legislation,O
or,O
taxation,O
but,O
may,O
also,O
be,O
influenced,O
by,O
different,O
social,O
or,O
cultural,O
norms,O
across,O
provinces,O
.,O
[,O
47,O
].,O
The,O
persistence,O
of,O
high,O
rates,O
of,O
current,O
smoking,O
and,O
low,O
quit,O
rates,O
in,O
certain,O
geographical,O
areas,O
and,O
among,O
certain,O
socioeconomic,O
groups,O
in,O
Canada,O
indicates,O
the,O
failure,O
of,O
current,O
smoking,O
cessation,O
policies,O
to,O
be,O
effective,O
in,O
improving,O
the,O
situation,O
for,O
these,O
areas,O
and,O
groups,O
.,O
Identifying,O
these,O
areas,O
and,O
groups,O
is,O
one,O
step,O
to,O
examining,O
the,O
barriers,O
to,O
decreasing,O
smoking,O
in,O
the,O
population,O
;,O
further,O
study,O
is,O
required,O
to,O
identify,O
what,O
barriers,O
exist,O
in,O
these,O
areas,O
and,O
what,O
interventions,O
may,O
improve,O
the,O
situation,O
.,O
The,O
Puf,B-GP
-,O
Family,O
RNA,B-GP
-,I-GP
Binding,I-GP
Protein,I-GP
Puf2,B-GP
Controls,O
Sporozoite,O
Conversion,O
to,O
Liver,O
Stages,O
in,O
the,O
Malaria,B-DS
Parasite,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
K,O
.,O
Müller,O
K,O
.,O
Matuschewski,O
OS,O
.,O
Performed,O
the,O
experiments,O
:,O
K,O
.,O
Müller,O
OS,O
.,O
Analyzed,O
the,O
data,O
:,O
K,O
.,O
Müller,O
K,O
.,O
Matuschewski,O
OS,O
.,O
Wrote,O
the,O
paper,O
:,O
K,O
.,O
Matuschewski,O
OS,O
.,O
Current,O
address,O
:,O
INSERM,O
UMR_S,O
945,O
"""",O
Immunity,O
and,O
infection,B-DS
""",",O
Centre,O
Hospitalier,O
Universitaire,O
Pitié,O
-,O
Salpêtrière,O
",",O
Faculté,O
de,O
Médecine,O
et,O
Université,O
Pierre,O
et,O
Marie,O
Curie,O
",",O
Paris,O
",",O
France,O
Malaria,B-DS
is,O
a,O
vector,B-DS
-,I-DS
borne,I-DS
infectious,I-DS
disease,I-DS
caused,O
by,O
unicellular,O
",",O
obligate,O
intracellular,O
parasites,O
of,O
the,O
genus,O
Plasmodium,B-OG
.,O
During,O
host,O
switch,O
the,O
malaria,B-DS
parasite,O
employs,O
specialized,O
latent,O
stages,O
that,O
colonize,O
the,O
new,O
host,O
environment,O
.,O
Previous,O
work,O
has,O
established,O
that,O
gametocytes,O
",",O
sexually,O
differentiated,O
stages,O
that,O
are,O
taken,O
up,O
by,O
the,O
mosquito,B-OG
vector,O
",",O
control,O
expression,O
of,O
genes,O
required,O
for,O
mosquito,B-OG
colonization,O
by,O
translational,O
repression,O
.,O
Sexual,O
parasite,O
development,O
is,O
controlled,O
by,O
a,O
DEAD,B-GP
-,I-GP
box,I-GP
RNA,I-GP
helicase,I-GP
of,O
the,O
DDX6,B-GP
family,O
",",O
termed,O
DOZI,B-GP
.,O
Latency,O
of,O
sporozoites,O
",",O
the,O
transmission,O
stage,O
injected,O
during,O
an,O
infectious,O
blood,O
meal,O
",",O
is,O
controlled,O
by,O
the,O
eIF2alpha,B-GP
kinase,I-GP
IK2,B-GP
",",O
a,O
general,O
inhibitor,O
of,O
protein,O
synthesis,O
.,O
Whether,O
RNA,B-GP
-,I-GP
binding,I-GP
proteins,I-GP
participate,O
in,O
translational,O
regulation,O
in,O
sporozoites,O
remains,O
to,O
be,O
studied,O
.,O
Here,O
",",O
we,O
investigated,O
the,O
roles,O
of,O
two,O
RNA,B-GP
-,I-GP
binding,I-GP
proteins,I-GP
of,O
the,O
Puf,B-GP
-,O
family,O
",",O
Plasmodium,B-OG
Puf1,B-GP
and,O
Puf2,B-GP
",",O
during,O
sporozoite,O
stage,O
conversion,O
.,O
Our,O
data,O
reveal,O
that,O
",",O
in,O
the,O
rodent,B-OG
malaria,B-DS
parasite,O
P,B-OG
.,I-OG
berghei,I-OG
",",O
Puf2,B-GP
participates,O
in,O
the,O
regulation,O
of,O
IK2,B-GP
and,O
inhibits,O
premature,O
sporozoite,O
transformation,O
.,O
Inside,O
mosquito,B-OG
salivary,O
glands,O
puf2,B-GP
(-),O
sporozoites,O
transform,O
over,O
time,O
to,O
round,O
forms,O
resembling,O
early,O
intra,O
-,O
hepatic,O
stages,O
.,O
As,O
a,O
result,O
",",O
mutant,O
parasites,O
display,O
strong,O
defects,O
in,O
initiating,O
a,O
malaria,B-DS
infection,B-DS
.,O
In,O
contrast,O
",",O
Puf1,B-GP
is,O
dispensable,O
in,O
vivo,O
throughout,O
the,O
entire,O
Plasmodium,B-OG
life,O
cycle,O
.,O
Our,O
findings,O
support,O
the,O
notion,O
of,O
a,O
central,O
role,O
for,O
Puf2,B-GP
in,O
parasite,O
latency,O
during,O
switch,O
between,O
the,O
insect,B-OG
and,O
mammalian,O
hosts,O
.,O
Introduction,O
Plasmodium,B-OG
parasites,O
",",O
the,O
causative,O
agents,O
of,O
malaria,B-DS
",",O
are,O
transmitted,O
by,O
female,O
Anopheles,B-OG
mosquitoes,B-OG
.,O
During,O
the,O
probing,O
phase,O
prior,O
to,O
the,O
blood,O
meal,O
",",O
sporozoites,O
are,O
injected,O
into,O
the,O
skin,O
of,O
the,O
mammalian,O
host,O
[,O
1,O
].,O
The,O
motile,O
sporozoites,O
actively,O
migrate,O
in,O
the,O
skin,O
",",O
enter,O
the,O
peripheral,O
blood,O
circulation,O
",",O
and,O
then,O
rapidly,O
reach,O
the,O
liver,O
.,O
Sporozoites,O
invade,O
hepatocytes,O
by,O
forming,O
a,O
parasitophorous,O
vacuole,O
(,O
PV,O
),O
[,O
2,O
"],",O
where,O
they,O
transform,O
into,O
replicative,O
exo,O
-,O
erythrocytic,O
forms,O
(,O
EEFs,O
).,O
After,O
intense,O
multiplication,O
during,O
2,O
–,O
6,O
days,O
",",O
depending,O
on,O
the,O
Plasmodium,B-OG
species,O
",",O
mature,O
EEFs,O
release,O
thousands,O
of,O
merozoites,O
",",O
which,O
invade,O
erythrocytes,O
and,O
initiate,O
the,O
pathogenic,O
blood,O
stage,O
cycle,O
[,O
3,O
].,O
Plasmodium,B-OG
sporozoites,O
are,O
formed,O
inside,O
oocysts,O
in,O
the,O
mosquito,B-OG
midgut,O
",",O
but,O
become,O
fully,O
infective,O
only,O
after,O
colonization,O
of,O
the,O
insect,B-OG
salivary,O
glands,O
.,O
This,O
maturation,O
process,O
is,O
associated,O
with,O
the,O
up,O
-,O
regulation,O
of,O
a,O
specific,O
subset,O
of,O
genes,O
",",O
referred,O
to,O
as,O
Up,B-GP
-,I-GP
regulated,I-GP
in,I-GP
Infective,I-GP
Sporozoites,I-GP
(,O
UIS,B-GP
),O
genes,O
[,O
4,O
].,O
Regulation,O
of,O
gene,O
expression,O
in,O
Plasmodium,B-OG
remains,O
poorly,O
understood,O
.,O
Genome,O
sequencing,O
data,O
initially,O
revealed,O
a,O
paucity,O
of,O
specific,O
transcription,B-GP
factors,I-GP
in,O
Plasmodium,B-OG
[,O
5,O
].,O
Recently,O
however,O
",",O
a,O
family,O
of,O
genes,O
related,O
to,O
the,O
plant,B-OG
Apetala,B-GP
-,I-GP
2,I-GP
(,O
AP2,B-GP
),O
transcription,B-GP
factors,I-GP
has,O
been,O
identified,O
in,O
Plasmodium,B-OG
and,O
related,O
apicomplexan,O
parasites,O
[,O
6,O
"],",O
[,O
7,O
"],",O
and,O
proposed,O
to,O
play,O
a,O
central,O
role,O
during,O
life,O
cycle,O
progression,O
.,O
Molecular,O
genetic,O
studies,O
have,O
demonstrated,O
vital,O
roles,O
of,O
two,O
stage,O
-,O
specific,O
AP2,B-GP
factors,O
in,O
Plasmodium,B-OG
berghei,I-OG
",",O
a,O
rodent,B-OG
malaria,B-DS
parasite,O
widely,O
used,O
as,O
a,O
model,O
[,O
8,O
"],",O
[,O
9,O
].,O
One,O
of,O
these,O
factors,O
",",O
the,O
AP2,B-GP
-,O
Sp,B-GP
transcription,B-GP
factor,I-GP
",",O
is,O
required,O
during,O
sporozoite,O
differentiation,O
and,O
binds,O
to,O
a,O
specific,O
DNA,O
sequence,O
found,O
in,O
the,O
promoter,O
region,O
of,O
many,O
genes,O
expressed,O
in,O
sporozoites,O
",",O
including,O
",",O
but,O
not,O
restricted,O
to,O
",",O
UIS,B-GP
genes,O
[,O
8,O
].,O
Intriguingly,O
",",O
genes,O
containing,O
AP2,B-GP
-,O
Sp,B-GP
binding,O
sites,O
are,O
associated,O
with,O
a,O
wide,O
range,O
of,O
biological,O
processes,O
",",O
such,O
as,O
sporozoite,O
formation,O
",",O
host,O
cell,O
invasion,O
or,O
liver,O
stage,O
development,O
.,O
This,O
observation,O
strongly,O
suggests,O
that,O
additional,O
mechanisms,O
participate,O
in,O
the,O
fine,O
-,O
tuning,O
of,O
gene,O
expression,O
during,O
sporozoite,O
development,O
and,O
stage,O
conversion,O
.,O
Another,O
factor,O
",",O
called,O
SLARP,B-GP
or,O
SAP1,B-GP
",",O
controls,O
the,O
expression,O
of,O
a,O
subset,O
of,O
genes,O
in,O
sporozoites,O
",",O
and,O
plays,O
a,O
critical,O
role,O
during,O
intrahepatic,O
development,O
of,O
the,O
parasite,O
[,O
10,O
"],",O
[,O
11,O
].,O
It,O
is,O
still,O
unclear,O
whether,O
SLARP,B-GP
/,O
SAP1,B-GP
acts,O
on,O
a,O
transcriptional,O
or,O
a,O
post,O
-,O
transcriptional,O
level,O
.,O
The,O
cellular,O
localization,O
of,O
SLARP,B-GP
/,O
SAP1,B-GP
remains,O
controversial,O
[,O
10,O
"],",O
[,O
11,O
"],",O
and,O
the,O
absence,O
of,O
any,O
domain,O
known,O
to,O
bind,O
nucleic,O
acids,O
suggests,O
an,O
indirect,O
role,O
.,O
More,O
recently,O
",",O
Zhang,O
and,O
colleagues,O
reported,O
that,O
the,O
protein,B-GP
kinase,I-GP
IK2,B-GP
",",O
initially,O
termed,O
UIS1,B-GP
[,O
4,O
"],",O
controls,O
global,O
gene,O
expression,O
in,O
sporozoites,O
at,O
a,O
post,O
-,O
transcriptional,O
level,O
[,O
12,O
].,O
IK2,B-GP
phosphorylates,O
the,O
translation,B-GP
initiation,I-GP
factor,I-GP
eIF2alpha,B-GP
and,O
down,O
-,O
regulates,O
protein,O
synthesis,O
[,O
12,O
"],",O
[,O
13,O
].,O
P,B-OG
.,I-OG
berghei,I-OG
lacking,O
UIS1,B-GP
/,O
IK2,B-GP
display,O
a,O
partial,O
loss,O
of,O
infectivity,O
associated,O
with,O
premature,O
transformation,O
of,O
sporozoites,O
in,O
the,O
mosquito,B-OG
salivary,O
glands,O
[,O
12,O
].,O
The,O
contribution,O
of,O
RNA,B-GP
-,I-GP
binding,I-GP
prxoteins,I-GP
in,O
translational,O
regulation,O
has,O
not,O
been,O
studied,O
in,O
sporozoites,O
yet,O
",",O
but,O
has,O
been,O
well,O
characterized,O
in,O
Plasmodium,B-OG
sexual,O
stages,O
.,O
In,O
female,O
gametocytes,O
",",O
many,O
transcripts,O
encoding,O
ookinete,B-GP
proteins,I-GP
are,O
translationally,O
repressed,O
by,O
a,O
DEAD,B-GP
-,I-GP
box,I-GP
RNA,I-GP
helicase,I-GP
called,O
DOZI,B-GP
",",O
which,O
binds,O
to,O
the,O
3,O
′,O
untranslated,O
region,O
(,O
UTR,O
),O
of,O
target,O
mRNAs,O
such,O
as,O
P28,B-GP
and,O
blocks,O
their,O
translation,O
until,O
occurrence,O
of,O
gamete,O
fertilization,O
and,O
differentiation,O
into,O
a,O
zygote,O
and,O
ookinete,O
[,O
14,O
"],",O
[,O
15,O
].,O
Whether,O
DOZI,B-GP
plays,O
a,O
role,O
in,O
sporozoites,O
is,O
not,O
known,O
",",O
but,O
other,O
RNA,B-GP
-,I-GP
binding,I-GP
proteins,I-GP
may,O
participate,O
in,O
translational,O
regulation,O
in,O
sporozoites,O
",",O
including,O
members,O
of,O
the,O
Puf,B-GP
-,O
family,O
.,O
Puf,B-GP
proteins,O
are,O
evolutionary,O
conserved,O
in,O
eukaryotes,B-OG
and,O
are,O
characterized,O
by,O
the,O
presence,O
of,O
a,O
RNA,O
-,O
binding,O
Puf,B-GP
domain,O
",",O
named,O
after,O
the,O
Drosophila,B-OG
melanogaster,I-OG
protein,O
Pumilio,B-GP
and,O
the,O
Caenorhabditis,B-OG
elegans,I-OG
protein,O
fem,B-GP
-,I-GP
3,I-GP
binding,I-GP
factor,I-GP
(,O
FBF,B-GP
"),",O
and,O
consisting,O
of,O
eight,O
imperfect,O
repeats,O
of,O
36,O
amino,O
acids,O
(,O
PFAM,O
:,O
PF00806,O
),O
[,O
16,O
"],",O
[,O
17,O
].,O
Puf,B-GP
proteins,O
typically,O
bind,O
to,O
the,O
3,O
′,O
UTR,O
of,O
target,O
mRNAs,O
and,O
repress,O
their,O
translation,O
or,O
induce,O
their,O
degradation,O
(,O
reviewed,O
in,O
[,O
18,O
],O
and,O
[,O
19,O
]).,O
Plasmodium,B-OG
parasites,O
possess,O
two,O
genes,O
encoding,O
proteins,O
with,O
Puf,B-GP
domains,O
",",O
Puf1,B-GP
and,O
Puf2,B-GP
[,O
20,O
].,O
In,O
P,B-OG
.,I-OG
falciparum,I-OG
",",O
both,O
Puf1,B-GP
(,O
PFE0935c,O
),O
and,O
Puf2,B-GP
(,O
PFD0825c,O
),O
are,O
differentially,O
expressed,O
in,O
gametocytes,O
[,O
20,O
"],",O
[,O
21,O
].,O
Targeted,O
gene,O
disruption,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
recently,O
revealed,O
a,O
role,O
of,O
PfPuf2,B-GP
in,O
repressing,O
gametocytogenesis,O
and,O
male,O
gametocyte,O
differentiation,O
in,O
the,O
human,B-OG
malaria,B-DS
parasite,O
[,O
22,O
].,O
Whether,O
the,O
Puf2,B-GP
protein,O
plays,O
additional,O
",",O
perhaps,O
vital,O
",",O
roles,O
in,O
subsequent,O
life,O
cycle,O
stages,O
remains,O
to,O
be,O
shown,O
.,O
Interestingly,O
",",O
microarray,O
data,O
indicate,O
that,O
Puf2,B-GP
is,O
most,O
highly,O
expressed,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
sporozoites,O
[,O
23,O
"],",O
and,O
in,O
P,B-OG
.,I-OG
berghei,I-OG
",",O
expression,O
of,O
both,O
Puf1,B-GP
(,O
PBANKA_123350,O
),O
and,O
Puf2,B-GP
(,O
PBANKA_071920,O
),O
has,O
been,O
reported,O
in,O
sporozoites,O
",",O
where,O
Puf1,B-GP
was,O
initially,O
identified,O
as,O
UIS9,B-GP
[,O
4,O
"],",O
[,O
24,O
].,O
In,O
this,O
study,O
",",O
we,O
used,O
a,O
reverse,O
genetic,O
approach,O
to,O
investigate,O
the,O
roles,O
of,O
Puf1,B-GP
and,O
Puf2,B-GP
in,O
P,B-OG
.,I-OG
berghei,I-OG
",",O
with,O
the,O
aim,O
to,O
identify,O
potential,O
mRNA,O
binding,O
proteins,O
that,O
play,O
critical,O
roles,O
in,O
sporozoite,O
stage,O
conversion,O
.,O
Results,O
Targeted,O
gene,O
deletion,O
of,O
P,B-OG
.,I-OG
berghei,I-OG
Puf1,B-GP
and,O
Puf2,B-GP
We,O
first,O
assessed,O
the,O
expression,O
of,O
Puf1,B-GP
and,O
Puf2,B-GP
during,O
P,B-OG
.,I-OG
berghei,I-OG
development,O
in,O
the,O
insect,B-OG
vector,O
",",O
in,O
comparison,O
to,O
DOZI,B-GP
and,O
UIS1,B-GP
/,O
IK2,B-GP
",",O
using,O
quantitative,O
RT,O
-,O
PCR,O
(,O
Figure,O
1,O
).,O
Similarly,O
to,O
UIS1,B-GP
/,O
IK2,B-GP
[,O
12,O
"],",O
we,O
found,O
that,O
Puf1,B-GP
and,O
Puf2,B-GP
are,O
upregulated,O
in,O
P,B-OG
.,I-OG
berghei,I-OG
salivary,O
gland,O
sporozoites,O
(,O
Figure,O
1,O
).,O
This,O
was,O
expected,O
for,O
Puf1,B-GP
",",O
which,O
was,O
initially,O
described,O
as,O
UIS9,B-GP
[,O
4,O
"],",O
[,O
24,O
].,O
Furthermore,O
",",O
Puf1,B-GP
was,O
also,O
upregulated,O
in,O
gametocytes,O
and,O
ookinetes,O
",",O
similarly,O
to,O
IK2,B-GP
and,O
DOZI,B-GP
.,O
In,O
good,O
agreement,O
with,O
published,O
microarray,O
data,O
[,O
24,O
"],",O
only,O
low,O
levels,O
of,O
DOZI,B-GP
mRNA,O
were,O
detected,O
in,O
P,B-OG
.,I-OG
berghei,I-OG
sporozoites,O
(,O
Figure,O
1,O
).,O
In,O
contrast,O
to,O
Puf1,B-GP
and,O
Puf2,B-GP
",",O
DOZI,B-GP
steady,O
state,O
mRNA,O
levels,O
were,O
down,O
-,O
regulated,O
in,O
infectious,O
salivary,O
gland,O
-,O
associated,O
sporozoites,O
resulting,O
in,O
∼,O
100,O
fold,O
lower,O
levels,O
in,O
the,O
latent,O
transmission,O
stage,O
.,O
Together,O
",",O
the,O
expression,O
profiling,O
indicated,O
that,O
both,O
Puf,B-GP
members,O
could,O
play,O
a,O
role,O
in,O
sporozoite,O
stage,O
conversion,O
",",O
as,O
has,O
been,O
described,O
previously,O
for,O
the,O
eIF2alpha,B-GP
kinase,I-GP
UIS1,B-GP
/,O
IK2,B-GP
[,O
12,O
].,O
Puf1,B-GP
and,O
Puf2,B-GP
are,O
upregulated,O
in,O
P,B-OG
.,I-OG
berghei,I-OG
sporozoites,O
.,O
Shown,O
is,O
an,O
expression,O
profiling,O
of,O
selected,O
transcripts,O
of,O
RNA,O
regulatory,B-GP
proteins,I-GP
",",O
the,O
DDX6,B-GP
-,O
family,O
DEAD,B-GP
-,I-GP
box,I-GP
helicase,I-GP
DOZI,B-GP
[,O
15,O
"],",O
the,O
Puf,B-GP
proteins,O
Puf1,B-GP
and,O
Puf2,B-GP
[,O
20,O
"],",O
and,O
of,O
the,O
eIF2alpha,B-GP
kinase,I-GP
UIS1,B-GP
/,O
IK2,B-GP
that,O
controls,O
sporozoite,O
latency,O
[,O
12,O
].,O
P,B-OG
.,I-OG
berghei,I-OG
purified,O
gametocytes,O
",",O
ookinetes,O
",",O
oocysts,O
and,O
salivary,O
gland,O
sporozoites,O
were,O
analyzed,O
by,O
RT,O
-,O
qPCR,O
using,O
primers,O
specific,O
for,O
DOZI,B-GP
",",O
UIS1,B-GP
/,O
IK2,B-GP
",",O
Puf1,B-GP
and,O
Puf2,B-GP
.,O
Expression,O
data,O
from,O
two,O
independent,O
experiments,O
are,O
shown,O
and,O
were,O
normalized,O
to,O
the,O
level,O
of,O
GFP,B-GP
transcripts,O
",",O
which,O
are,O
expressed,O
under,O
the,O
control,O
of,O
the,O
EF1alpha,B-GP
promoter,O
[,O
26,O
].,O
In,O
order,O
to,O
investigate,O
the,O
functional,O
importance,O
of,O
Puf1,B-GP
/,O
UIS9,B-GP
and,O
Puf2,B-GP
in,O
P,B-OG
.,I-OG
berghei,I-OG
",",O
we,O
generated,O
loss,O
-,O
of,O
-,O
function,O
mutants,O
(,O
Figure,O
2,O
).,O
We,O
used,O
a,O
replacement,O
strategy,O
to,O
disrupt,O
the,O
endogenous,O
Puf1,B-GP
(,O
Figure,O
2A,O
),O
or,O
Puf2,B-GP
(,O
Figure,O
2B,O
),O
gene,O
copy,O
by,O
double,O
crossover,O
homologous,O
recombination,O
[,O
25,O
].,O
Targeting,O
constructs,O
containing,O
5,O
′,O
and,O
3,O
′,O
fragments,O
of,O
either,O
Puf1,B-GP
or,O
Puf2,B-GP
flanking,O
a,O
pyrimethamine,O
-,O
resistance,O
cassette,O
were,O
used,O
to,O
transfect,O
P,B-OG
.,I-OG
berghei,I-OG
parasites,O
that,O
constitutively,O
express,O
GFP,B-GP
(,O
ANKA,O
cl507,O
),O
[,O
26,O
].,O
Recombinant,O
parasites,O
were,O
selected,O
with,O
pyrimethamine,O
in,O
the,O
mouse,B-OG
drinking,O
water,O
",",O
and,O
cloned,O
by,O
limiting,O
dilutions,O
.,O
For,O
both,O
genes,O
we,O
were,O
successful,O
in,O
generating,O
clonal,O
knockout,O
parasite,O
populations,O
",",O
as,O
demonstrated,O
by,O
PCR,O
and,O
Southern,O
blot,O
analysis,O
of,O
genomic,O
DNA,O
(,O
Figures,O
2C,O
–,O
F,O
).,O
For,O
Puf2,B-GP
we,O
also,O
generated,O
a,O
second,O
independent,O
knockout,O
clone,O
",",O
which,O
was,O
phenotypically,O
identical,O
to,O
the,O
first,O
puf2,B-GP
(-),O
clonal,O
parasite,O
line,O
(,O
unpublished,O
data,O
).,O
This,O
indicates,O
that,O
Puf1,B-GP
and,O
Puf2,B-GP
do,O
not,O
play,O
any,O
vital,O
role,O
during,O
P,B-OG
.,I-OG
berghei,I-OG
erythrocytic,O
stages,O
",",O
in,O
good,O
agreement,O
with,O
successful,O
generation,O
of,O
Pfpuf2,B-GP
(-),O
parasites,O
[,O
22,O
].,O
Targeted,O
gene,O
deletion,O
of,O
Puf1,B-GP
/,O
UIS9,B-GP
and,O
Puf2,B-GP
in,O
P,B-OG
.,I-OG
berghei,I-OG
.,O
(,O
A,O
–,O
B,O
),O
Replacement,O
strategy,O
to,O
generate,O
the,O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
parasites,O
.,O
P,B-OG
.,I-OG
berghei,I-OG
PUF1,B-GP
gene,O
(,O
A,O
),O
consists,O
of,O
five,O
exons,O
encoding,O
an,O
1183,O
amino,O
-,O
acid,O
protein,O
(,O
PBANKA_123350,O
"),",O
whereas,O
PUF2,B-GP
(,O
B,O
),O
consists,O
of,O
four,O
exons,O
encoding,O
a,O
477,O
amino,O
-,O
acid,O
protein,O
(,O
PBANKA_071920,O
).,O
The,O
PUF,B-GP
domains,O
are,O
shown,O
in,O
blue,O
.,O
For,O
each,O
gene,O
",",O
the,O
wild,O
-,O
type,O
(,O
WT,O
),O
genomic,O
locus,O
was,O
targeted,O
with,O
a,O
replacement,O
plasmid,O
containing,O
5,O
′,O
and,O
3,O
′,O
regions,O
of,O
PUF1,B-GP
or,O
PUF2,B-GP
and,O
a,O
positive,O
selectable,O
marker,O
",",O
Toxoplasma,B-OG
gondii,I-OG
dhfr,B-GP
/,O
ts,B-GP
or,O
human,B-OG
DHFR,B-GP
",",O
respectively,O
.,O
Upon,O
a,O
double,O
crossover,O
event,O
",",O
the,O
PUF1,B-GP
or,O
PUF2,B-GP
gene,O
is,O
replaced,O
by,O
the,O
selectable,O
marker,O
.,O
Replacement,O
-,O
and,O
wild,O
type,O
-,O
specific,O
test,O
primer,O
combinations,O
and,O
expected,O
PCR,O
fragments,O
(,O
WT,O
",",O
5,O
′,O
integration,O
and,O
3,O
′,O
integration,O
),O
are,O
indicated,O
by,O
arrows,O
and,O
lines,O
",",O
respectively,O
.,O
Restriction,O
sites,O
",",O
Southern,O
probes,O
and,O
expected,O
restriction,O
fragments,O
are,O
also,O
shown,O
.,O
S,O
",",O
SpeI,B-GP
;,O
X,O
",",O
XhoI,B-GP
;,O
A,O
",",O
AfeI,B-GP
;,O
E,O
",",O
EcoRV,B-GP
.,O
(,O
C,O
),O
Puf1,B-GP
replacement,O
-,O
specific,O
PCR,O
analysis,O
.,O
Confirmation,O
of,O
the,O
predicted,O
gene,O
targeting,O
is,O
achieved,O
by,O
specific,O
primer,O
combinations,O
(,O
5,O
′,O
and,O
3,O
′,O
integration,O
"),",O
which,O
can,O
only,O
amplify,O
a,O
signal,O
from,O
the,O
recombinant,O
locus,O
.,O
A,O
wild,O
type,O
-,O
specific,O
PCR,O
reaction,O
confirms,O
the,O
absence,O
of,O
residual,O
wild,O
-,O
type,O
parasites,O
in,O
the,O
clonal,O
puf1,B-GP
(-),O
population,O
.,O
(,O
D,O
),O
Southern,O
blot,O
analysis,O
of,O
genomic,O
DNA,O
isolated,O
from,O
WT,O
",",O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
parasites,O
",",O
using,O
digoxigenin,O
-,O
labelled,O
probes,O
specific,O
for,O
Puf1,B-GP
.,O
After,O
digest,O
with,O
SpeI,B-GP
and,O
XhoI,B-GP
",",O
the,O
Puf1,B-GP
probe,O
hybridizes,O
to,O
a,O
8,O
.,O
3,O
or,O
a,O
6,O
.,O
9,O
kb,O
fragment,O
in,O
WT,O
and,O
puf1,B-GP
(-),O
parasites,O
",",O
respectively,O
.,O
(,O
E,O
),O
Puf2,B-GP
replacement,O
-,O
specific,O
PCR,O
analysis,O
.,O
Confirmation,O
of,O
the,O
predicted,O
gene,O
targeting,O
is,O
achieved,O
by,O
specific,O
primer,O
combinations,O
(,O
5,O
′,O
and,O
3,O
′,O
integration,O
"),",O
which,O
can,O
only,O
amplify,O
a,O
signal,O
from,O
the,O
recombinant,O
locus,O
.,O
A,O
wild,O
type,O
-,O
specific,O
PCR,O
reaction,O
confirms,O
the,O
absence,O
of,O
residual,O
wild,O
-,O
type,O
parasites,O
in,O
the,O
clonal,O
puf2,B-GP
(-),O
population,O
.,O
(,O
F,O
),O
Southern,O
blot,O
analysis,O
of,O
genomic,O
DNA,O
isolated,O
from,O
WT,O
",",O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
parasites,O
",",O
using,O
digoxigenin,O
-,O
labelled,O
probes,O
specific,O
for,O
Puf2,B-GP
.,O
After,O
digest,O
with,O
AfeI,B-GP
and,O
EcoRV,B-GP
",",O
the,O
Puf2,B-GP
probe,O
hybridizes,O
to,O
a,O
8,O
.,O
4,O
kb,O
fragment,O
in,O
WT,O
and,O
a,O
4,O
.,O
0,O
kb,O
fragment,O
in,O
puf2,B-GP
(-),O
parasites,O
.,O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
parasites,O
produce,O
gametocytes,O
that,O
develop,O
to,O
sporozoites,O
in,O
mosquitoes,B-OG
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
parasites,O
were,O
indistinguishable,O
from,O
WT,O
parasites,O
in,O
development,O
and,O
growth,O
of,O
asexual,O
blood,O
stages,O
and,O
produced,O
gametocytes,O
.,O
Because,O
PfPuf2,B-GP
has,O
been,O
shown,O
to,O
control,O
gametocytogenesis,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
[,O
22,O
"],",O
we,O
analyzed,O
in,O
more,O
detail,O
the,O
sexual,O
development,O
of,O
P,B-OG
.,I-OG
berghei,I-OG
puf2,B-GP
(-),O
parasites,O
.,O
After,O
injection,O
of,O
107,O
infected,O
erythrocytes,O
intravenously,O
into,O
groups,O
of,O
five,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
",",O
parasitemia,B-DS
at,O
day,O
4,O
were,O
similar,O
in,O
mice,B-OG
infected,O
with,O
WT,O
or,O
puf2,B-GP
(-),O
(,O
Figure,O
3A,O
).,O
However,O
",",O
the,O
proportion,O
of,O
gametocytes,O
among,O
all,O
parasite,O
stages,O
was,O
significantly,O
higher,O
in,O
puf2,B-GP
(-),O
than,O
in,O
WT,O
parasites,O
(,O
Figure,O
3B,O
).,O
We,O
then,O
examined,O
the,O
ability,O
of,O
mature,O
male,O
gametocytes,O
to,O
exflagellate,O
in,O
puf2,B-GP
(-),O
parasites,O
.,O
The,O
number,O
of,O
exflagellation,O
centers,O
in,O
mouse,B-OG
blood,O
was,O
significantly,O
higher,O
for,O
puf2,B-GP
(-),O
parasites,O
than,O
for,O
WT,O
parasites,O
(,O
Figure,O
3C,O
"),",O
suggesting,O
that,O
male,O
gametocytes,O
contribute,O
to,O
the,O
increased,O
gametocytogenesis,O
in,O
Pbpuf2,B-GP
(-),O
parasites,O
",",O
in,O
full,O
support,O
of,O
the,O
data,O
reported,O
for,O
P,B-OG
.,I-OG
falciparum,I-OG
Puf2,B-GP
-,O
deficient,O
parasites,O
[,O
22,O
].,O
Gametocytogenesis,O
is,O
increased,O
in,O
puf2,B-GP
(-),O
parasites,O
.,O
Groups,O
of,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
(,O
n,O
=,O
5,O
),O
were,O
injected,O
intravenously,O
with,O
107,O
WT,O
or,O
puf2,B-GP
(-),O
infected,O
erythrocytes,O
.,O
Blood,O
was,O
collected,O
from,O
the,O
mice,B-OG
4,O
days,O
later,O
to,O
determine,O
the,O
parasitemia,B-DS
(,O
A,O
"),",O
the,O
proportion,O
of,O
gametocytes,O
among,O
parasites,O
(,O
B,O
"),",O
and,O
the,O
number,O
of,O
exflagellation,O
centers,O
per,O
µl,O
of,O
blood,O
(,O
C,O
).,O
Results,O
are,O
expressed,O
as,O
mean,O
+/−,O
SEM,O
.,O
"**,",O
p,O
<,O
0,O
.,O
01,O
(,O
Mann,O
-,O
Whitney,O
test,O
).,O
After,O
transmission,O
to,O
Anopheles,B-OG
stephensi,I-OG
mosquitoes,B-OG
",",O
both,O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
parasite,O
lines,O
produced,O
oocysts,O
and,O
high,O
numbers,O
of,O
sporozoites,O
(,O
Table,O
1,O
).,O
The,O
number,O
of,O
puf2,B-GP
(-),O
oocysts,O
was,O
significantly,O
higher,O
than,O
for,O
WT,O
",",O
consistent,O
with,O
the,O
higher,O
gametocyte,O
rates,O
.,O
Intriguingly,O
",",O
we,O
found,O
lower,O
numbers,O
of,O
oocysts,O
and,O
salivary,O
gland,O
sporozoites,O
in,O
puf1,B-GP
(-)-,O
infected,O
mosquitoes,B-OG
",",O
as,O
compared,O
to,O
WT,O
parasites,O
(,O
Table,O
1,O
).,O
Although,O
the,O
differences,O
were,O
not,O
statistically,O
significant,O
",",O
we,O
cannot,O
exclude,O
an,O
effect,O
of,O
puf1,B-GP
depletion,O
on,O
oocyst,O
development,O
and,O
sporogony,O
.,O
Loss,O
of,O
infectivity,O
of,O
puf2,B-GP
(-),O
sporozoites,O
in,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
.,O
Parasites,O
Number,O
of,O
oocysts,O
/,O
mosquitoa,O
(,O
mean,O
±,O
SD,O
),O
Number,O
of,O
salivary,O
gland,O
sporozoites,O
/,O
mosquitoa,O
(,O
mean,O
±,O
SD,O
),O
Route,O
of,O
injectionb,O
Number,O
of,O
infected,O
/,O
Number,O
of,O
injected,O
Prepatency,O
period,O
(,O
days,O
),O
c,O
WT,O
182,O
(±,O
164,O
),O
31,O
",",O
600,O
(±,O
18,O
",",O
600,O
),O
bites,O
(,O
d,O
21,O
),O
3,O
/,O
3,O
3,O
i,O
.,O
v,O
.,O
(,O
d,O
18,O
),O
2,O
/,O
2,O
3,O
i,O
.,O
v,O
.,O
(,O
d,O
21,O
),O
6,O
/,O
6,O
3,O
.,O
5,O
i,O
.,O
v,O
.,O
(,O
d,O
25,O
),O
4,O
/,O
4,O
3,O
puf1,B-GP
(-),O
137,O
(±,O
100,O
),O
11,O
",",O
400,O
(±,O
4,O
",",O
700,O
),O
bites,O
(,O
d,O
17,O
),O
3,O
/,O
3,O
3,O
i,O
.,O
v,O
.,O
(,O
d,O
21,O
),O
6,O
/,O
6,O
3,O
.,O
5,O
puf2,B-GP
(-),O
320,O
(±,O
234,O
),O
d,O
25,O
",",O
000,O
(±,O
18,O
",",O
800,O
),O
bites,O
(,O
d,O
21,O
),O
3,O
/,O
4,O
(,O
5,O
),O
i,O
.,O
v,O
.,O
(,O
d,O
18,O
),O
2,O
/,O
4,O
(,O
5,O
),O
i,O
.,O
v,O
.,O
(,O
d,O
25,O
),O
0,O
/,O
4,O
,O
The,O
number,O
of,O
midgut,O
oocysts,O
and,O
salivary,O
gland,O
sporozoites,O
was,O
determined,O
at,O
d10,O
–,O
14,O
and,O
d18,O
–,O
25,O
",",O
respectively,O
",",O
after,O
the,O
infectious,O
blood,O
meal,O
",",O
from,O
at,O
least,O
three,O
independent,O
feeding,O
experiments,O
.,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
were,O
exposed,O
to,O
the,O
bites,O
of,O
10,O
infected,O
mosquitoes,B-OG
or,O
injected,O
intravenously,O
(,O
i,O
.,O
v,O
.),O
with,O
1,O
",",O
000,O
sporozoites,O
",",O
18,O
–,O
25,O
days,O
after,O
mosquito,B-OG
infection,B-DS
.,O
The,O
prepatent,O
period,O
is,O
defined,O
as,O
the,O
number,O
of,O
days,O
after,O
sporozoite,O
inoculation,O
until,O
detection,O
of,O
infected,O
erythrocytes,O
by,O
microscopic,O
blood,O
smear,O
examination,O
.,O
Brackets,O
indicate,O
that,O
not,O
all,O
animals,B-OG
became,O
infected,O
.,O
,O
",",O
not,O
applicable,O
.,O
p,O
<,O
0,O
.,O
05,O
in,O
comparison,O
to,O
WT,O
",",O
as,O
determined,O
by,O
Kruskal,O
-,O
Wallis,O
followed,O
by,O
Dunn,O
',O
s,O
test,O
.,O
Liver,B-DS
infection,I-DS
is,O
impaired,O
in,O
Puf2,B-GP
-,O
deficient,O
parasites,O
We,O
then,O
analysed,O
the,O
infectivity,O
of,O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
sporozoites,O
to,O
susceptible,O
mice,B-OG
.,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
were,O
injected,O
intravenously,O
with,O
1,O
",",O
000,O
WT,O
",",O
puf1,B-GP
(-),O
or,O
puf2,B-GP
(-),O
P,B-OG
.,I-OG
berghei,I-OG
sporozoites,O
",",O
or,O
exposed,O
to,O
the,O
bites,O
of,O
10,O
infected,O
mosquitoes,B-OG
",",O
the,O
natural,O
transmission,O
route,O
(,O
Table,O
1,O
).,O
Emergence,O
of,O
erythrocytic,O
stages,O
",",O
resulting,O
from,O
complete,O
liver,O
stage,O
development,O
",",O
was,O
monitored,O
by,O
microscopic,O
examination,O
of,O
daily,O
blood,O
smears,O
.,O
With,O
both,O
inoculation,O
routes,O
",",O
all,O
mice,B-OG
injected,O
with,O
puf1,B-GP
(-),O
sporozoites,O
developed,O
a,O
parasitemia,B-DS
",",O
with,O
no,O
delay,O
as,O
compared,O
to,O
WT,O
parasites,O
(,O
Table,O
1,O
).,O
In,O
contrast,O
",",O
only,O
a,O
fraction,O
of,O
the,O
mice,B-OG
injected,O
with,O
puf2,B-GP
(-),O
sporozoites,O
developed,O
a,O
parasitemia,B-DS
",",O
with,O
a,O
two,O
-,O
day,O
delay,O
as,O
compared,O
to,O
WT,O
",",O
indicative,O
of,O
at,O
least,O
100,O
-,O
fold,O
reduction,O
of,O
infectivity,O
(,O
Table,O
1,O
).,O
Moreover,O
",",O
puf2,B-GP
(-),O
sporozoites,O
isolated,O
late,O
after,O
mosquito,B-OG
infection,B-DS
(,O
at,O
day,O
25,O
),O
were,O
not,O
capable,O
of,O
inducing,O
a,O
blood,O
stage,O
infection,B-DS
in,O
mice,B-OG
.,O
We,O
next,O
injected,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
intravenously,O
with,O
WT,O
",",O
puf1,B-GP
(-),O
or,O
puf2,B-GP
(-),O
sporozoites,O
isolated,O
on,O
day,O
18,O
from,O
mosquito,B-OG
salivary,O
glands,O
.,O
Forty,O
-,O
two,O
hours,O
after,O
infection,B-DS
",",O
livers,O
were,O
removed,O
and,O
the,O
parasite,O
loads,O
were,O
quantified,O
by,O
RT,O
-,O
qPCR,O
.,O
As,O
shown,O
in,O
Figure,O
4,O
",",O
the,O
puf2,B-GP
(-),O
liver,O
loads,O
were,O
extremely,O
reduced,O
(∼,O
500,O
fold,O
),O
as,O
compared,O
to,O
WT,O
",",O
confirming,O
that,O
infectivity,O
of,O
puf2,B-GP
(-),O
sporozoites,O
to,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
is,O
severely,O
impaired,O
.,O
The,O
reduction,O
of,O
parasite,O
liver,O
loads,O
as,O
measured,O
by,O
RT,O
-,O
qPCR,O
is,O
consistent,O
with,O
the,O
delay,O
or,O
absence,O
of,O
parasitemia,B-DS
in,O
mice,B-OG
injected,O
with,O
puf2,B-GP
(-),O
sporozoites,O
(,O
Table,O
1,O
"),",O
therefore,O
we,O
assume,O
that,O
the,O
absence,O
of,O
Puf2,B-GP
did,O
not,O
interfere,O
with,O
18S,O
rRNA,O
quantification,O
.,O
Interestingly,O
",",O
we,O
also,O
observed,O
a,O
significant,O
",",O
although,O
less,O
pronounced,O
(∼,O
4,O
fold,O
"),",O
reduction,O
of,O
puf1,B-GP
(-),O
parasite,O
liver,O
loads,O
(,O
Figure,O
4,O
).,O
Our,O
findings,O
demonstrate,O
that,O
PbPuf2,B-GP
plays,O
an,O
important,O
in,O
vivo,O
role,O
only,O
in,O
the,O
pre,O
-,O
erythrocytic,O
phase,O
of,O
the,O
Plasmodium,B-OG
life,O
cycle,O
.,O
In,O
contrast,O
",",O
Puf1,B-GP
/,O
UIS9,B-GP
appears,O
to,O
be,O
dispensable,O
for,O
parasite,O
life,O
cycle,O
progression,O
",",O
at,O
least,O
under,O
the,O
conditions,O
tested,O
.,O
Liver,B-DS
infection,I-DS
is,O
severely,O
impaired,O
in,O
puf2,B-GP
(-),O
parasites,O
.,O
Parasite,O
loads,O
were,O
determined,O
by,O
RT,O
-,O
qPCR,O
analysis,O
of,O
mouse,B-OG
livers,O
(,O
n,O
=,O
4,O
or,O
5,O
per,O
group,O
),O
harvested,O
42,O
hours,O
after,O
intravenous,O
injection,O
of,O
10,O
",",O
000,O
WT,O
",",O
puf1,B-GP
(-),O
or,O
puf2,B-GP
(-),O
sporozoites,O
.,O
Results,O
are,O
expressed,O
as,O
the,O
relative,O
expression,O
of,O
Pb18S,O
normalized,O
to,O
mouse,B-OG
GAPDH,B-GP
.,O
The,O
means,O
+/−,O
SEM,O
are,O
indicated,O
by,O
lines,O
"**,",O
p,O
<,O
0,O
.,O
01,O
(,O
Mann,O
-,O
Whitney,O
test,O
).,O
We,O
also,O
determined,O
the,O
In,O
vitro,O
infectivity,O
of,O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
sporozoites,O
isolated,O
on,O
day,O
22,O
from,O
mosquito,B-OG
salivary,O
glands,O
",",O
in,O
cultured,O
HepG2,O
hepatoma,B-DS
cells,O
(,O
Figure,O
5,O
).,O
Both,O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
sporozoites,O
entered,O
hepatoma,B-DS
cells,O
as,O
efficiently,O
as,O
WT,O
",",O
as,O
evidenced,O
by,O
similar,O
numbers,O
of,O
infected,O
cells,O
at,O
early,O
time,O
points,O
(,O
4,O
–,O
6,O
hours,O
),O
(,O
Figure,O
5A,O
).,O
While,O
the,O
number,O
of,O
EEFs,O
at,O
later,O
time,O
points,O
(,O
24,O
–,O
48,O
hours,O
),O
was,O
similar,O
in,O
WT,O
-,O
and,O
puf1,B-GP
(-)-,O
infected,O
cultures,O
(,O
Figure,O
5A,O
"),",O
it,O
was,O
reduced,O
in,O
the,O
case,O
of,O
puf2,B-GP
(-),O
parasites,O
(,O
Figure,O
5B,O
).,O
Whereas,O
early,O
after,O
infection,B-DS
a,O
vast,O
majority,O
(,O
81,O
%,O
±,O
3,O
%;,O
n,O
=,O
122,O
),O
of,O
intracellular,O
WT,O
sporozoites,O
expressed,O
UIS4,B-GP
",",O
a,O
transmembrane,B-GP
protein,I-GP
that,O
localizes,O
to,O
the,O
membrane,O
of,O
the,O
PV,O
[,O
27,O
"],",O
only,O
half,O
of,O
puf2,B-GP
(-),O
parasites,O
were,O
stained,O
with,O
UIS4,B-GP
antibodies,B-GP
(,O
53,O
%,O
±,O
9,O
%;,O
n,O
=,O
127,O
).,O
This,O
indicates,O
that,O
a,O
substantial,O
fraction,O
of,O
puf2,B-GP
(-),O
sporozoites,O
failed,O
to,O
form,O
and,O
/,O
or,O
remodel,O
the,O
PV,O
in,O
vitro,O
",",O
which,O
probably,O
explains,O
the,O
reduced,O
EEF,O
numbers,O
quantified,O
at,O
later,O
time,O
points,O
.,O
In,O
addition,O
",",O
we,O
cannot,O
exclude,O
a,O
moderate,O
impairment,O
during,O
liver,O
stage,O
development,O
in,O
puf2,B-GP
(-),O
parasites,O
",",O
as,O
suggested,O
by,O
the,O
reduction,O
of,O
EEF,O
numbers,O
observed,O
between,O
24,O
and,O
48,O
hours,O
post,O
-,O
infection,B-DS
in,O
vitro,O
.,O
Nevertheless,O
",",O
most,O
puf2,B-GP
(-),O
sporozoites,O
that,O
formed,O
a,O
PV,O
and,O
expressed,O
UIS4,B-GP
were,O
capable,O
of,O
developing,O
into,O
EEFs,O
like,O
WT,O
and,O
puf1,B-GP
(-),O
parasites,O
(,O
Figure,O
5C,O
).,O
Taken,O
together,O
",",O
our,O
data,O
indicate,O
that,O
Puf2,B-GP
plays,O
a,O
critical,O
role,O
during,O
transmission,O
of,O
P,B-OG
.,I-OG
berghei,I-OG
sporozoites,O
to,O
the,O
mammalian,O
host,O
",",O
but,O
is,O
not,O
required,O
for,O
liver,O
stage,O
development,O
per,O
se,O
.,O
puf2,B-GP
(-),O
sporozoites,O
are,O
infective,O
in,O
vitro,O
.,O
(,O
A,O
),O
HepG2,O
cells,O
were,O
infected,O
with,O
WT,O
or,O
puf1,B-GP
(-),O
sporozoites,O
and,O
the,O
numbers,O
of,O
infected,O
cells,O
were,O
determined,O
at,O
6,O
",",O
24,O
and,O
48,O
h,O
post,O
-,O
infection,B-DS
(,O
p,O
.,O
i,O
.).,O
Results,O
are,O
expressed,O
as,O
the,O
mean,O
number,O
of,O
infected,O
cells,O
in,O
triplicate,O
wells,O
+/−,O
SD,O
.,O
(,O
B,O
),O
HepG2,O
cells,O
were,O
infected,O
with,O
WT,O
or,O
puf2,B-GP
(-),O
sporozoites,O
and,O
the,O
numbers,O
of,O
infected,O
cells,O
were,O
determined,O
at,O
4,O
",",O
24,O
and,O
48,O
h,O
post,O
-,O
infection,B-DS
(,O
p,O
.,O
i,O
.).,O
Results,O
are,O
expressed,O
as,O
the,O
mean,O
number,O
of,O
infected,O
cells,O
in,O
triplicate,O
wells,O
+/−,O
SD,O
.,O
(,O
C,O
),O
Confocal,O
microscopy,O
analysis,O
of,O
HepG2,O
cells,O
cultured,O
for,O
5,O
and,O
24,O
hours,O
post,O
-,O
infection,B-DS
(,O
p,O
.,O
i,O
.),O
with,O
WT,O
",",O
puf1,B-GP
(-),O
or,O
puf2,B-GP
(-),O
sporozoites,O
",",O
using,O
antibodies,B-GP
against,O
UIS4,B-GP
(,O
red,O
"),",O
CSP,B-GP
(,O
5,O
h,O
p,O
.,O
i,O
".,",O
green,O
),O
or,O
HSP70,B-GP
(,O
24,O
h,O
p,O
.,O
i,O
".,",O
green,O
).,O
Nuclei,O
were,O
stained,O
with,O
DRAQ5,O
(,O
blue,O
).,O
Bars,O
",",O
10,O
µm,O
.,O
puf2,B-GP
(-),O
sporozoites,O
transform,O
prematurely,O
in,O
the,O
mosquito,B-OG
In,O
vivo,O
data,O
suggested,O
that,O
",",O
over,O
time,O
",",O
Puf2,B-GP
-,O
knockout,O
sporozoites,O
rapidly,O
loose,O
infectivity,O
in,O
the,O
mosquito,B-OG
(,O
Table,O
1,O
).,O
To,O
better,O
characterize,O
this,O
phenomenon,O
",",O
we,O
carefully,O
analyzed,O
puf2,B-GP
(-),O
sporozoite,O
development,O
in,O
the,O
mosquito,B-OG
(,O
Figure,O
6,O
).,O
Strikingly,O
",",O
we,O
observed,O
that,O
a,O
major,O
proportion,O
of,O
puf2,B-GP
(-),O
sporozoites,O
showed,O
signs,O
of,O
premature,O
transformation,O
",",O
characterized,O
by,O
a,O
bulb,O
-,O
like,O
aspect,O
or,O
even,O
complete,O
rounding,O
-,O
up,O
(,O
Figure,O
6A,O
).,O
In,O
WT,O
parasites,O
",",O
transformation,O
of,O
sporozoites,O
is,O
typically,O
observed,O
at,O
37,O
°,O
C,O
in,O
culture,O
medium,O
",",O
irrespective,O
of,O
the,O
presence,O
of,O
host,O
cells,O
[,O
28,O
].,O
In,O
puf2,B-GP
(-)-,O
infected,O
mosquitoes,B-OG
",",O
however,O
",",O
the,O
proportion,O
of,O
transformed,O
sporozoites,O
increased,O
over,O
time,O
during,O
the,O
course,O
of,O
infection,B-DS
in,O
the,O
mosquitoes,B-OG
",",O
which,O
are,O
kept,O
at,O
20,O
°,O
C,O
(,O
Figure,O
6B,O
).,O
Quantification,O
of,O
partial,O
and,O
complete,O
transformation,O
in,O
all,O
three,O
parasite,O
populations,O
revealed,O
that,O
at,O
day,O
29,O
almost,O
all,O
puf2,B-GP
(-),O
sporozoites,O
had,O
transformed,O
",",O
whereas,O
only,O
a,O
minor,O
fraction,O
of,O
WT,O
and,O
puf1,B-GP
(-),O
sporozoites,O
exhibited,O
signs,O
of,O
premature,O
transformation,O
(,O
Figure,O
6B,O
).,O
Interestingly,O
",",O
we,O
did,O
not,O
observe,O
expression,O
of,O
the,O
liver,O
stage,O
marker,O
UIS4,B-GP
or,O
nuclear,O
divisions,O
",",O
as,O
seen,O
in,O
EEFs,O
(,O
Figure,O
5C,O
"),",O
in,O
the,O
transformed,O
puf2,B-GP
(-),O
sporozoites,O
(,O
Figure,O
6A,O
).,O
Premature,O
transformation,O
of,O
puf2,B-GP
(-),O
sporozoites,O
in,O
the,O
mosquito,B-OG
.,O
(,O
A,O
),O
Fluorescence,O
microscopy,O
of,O
WT,O
and,O
puf2,B-GP
(-),O
sporozoites,O
isolated,O
from,O
mosquito,B-OG
salivary,O
glands,O
25,O
days,O
after,O
infection,B-DS
",",O
and,O
labelled,O
with,O
anti,O
-,O
UIS4,B-GP
(,O
red,O
),O
and,O
anti,O
-,O
CSP,B-GP
(,O
green,O
),O
antibodies,B-GP
.,O
Nuclei,O
were,O
stained,O
with,O
DRAQ5,O
(,O
blue,O
).,O
Bars,O
",",O
10,O
µm,O
.,O
(,O
B,O
),O
The,O
proportion,O
of,O
non,O
-,O
transformed,O
",",O
partially,O
transformed,O
and,O
fully,O
transformed,O
sporozoites,O
was,O
determined,O
by,O
microscopic,O
examination,O
of,O
sporozoites,O
isolated,O
from,O
mosquito,B-OG
salivary,O
glands,O
18,O
",",O
21,O
",",O
25,O
or,O
29,O
days,O
after,O
infection,B-DS
with,O
WT,O
",",O
puf1,B-GP
(-),O
or,O
puf2,B-GP
(-),O
parasites,O
.,O
puf2,B-GP
(-),O
sporozoites,O
have,O
reduced,O
levels,O
of,O
Puf1,B-GP
and,O
UIS1,B-GP
/,O
IK2,B-GP
mRNA,O
The,O
phenotype,O
of,O
puf2,B-GP
(-),O
parasites,O
is,O
essentially,O
identical,O
to,O
that,O
of,O
parasites,O
that,O
contain,O
a,O
targeted,O
deletion,O
of,O
the,O
kinase,B-GP
UIS1,B-GP
/,O
IK2,B-GP
[,O
12,O
].,O
Similarly,O
to,O
puf2,B-GP
(-),O
parasites,O
",",O
ik2,B-GP
(-),O
sporozoites,O
transform,O
prematurely,O
in,O
the,O
mosquito,B-OG
salivary,O
glands,O
and,O
have,O
a,O
decreased,O
infectivity,O
in,O
vivo,O
but,O
not,O
in,O
vitro,O
[,O
12,O
].,O
Therefore,O
",",O
we,O
sought,O
to,O
test,O
expression,O
of,O
IK2,B-GP
in,O
puf2,B-GP
(-),O
sporozoites,O
",",O
in,O
comparison,O
to,O
WT,O
and,O
puf1,B-GP
(-),O
sporozoites,O
",",O
using,O
RT,O
-,O
qPCR,O
.,O
As,O
expected,O
from,O
gene,O
deletion,O
",",O
no,O
Puf1,B-GP
and,O
Puf2,B-GP
mRNA,O
were,O
detected,O
in,O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
sporozoites,O
",",O
respectively,O
(,O
Figure,O
7,O
).,O
Whereas,O
expression,O
of,O
UIS1,B-GP
/,O
IK2,B-GP
was,O
not,O
modified,O
in,O
puf1,B-GP
(-),O
sporozoites,O
",",O
we,O
observed,O
a,O
∼,O
14,O
fold,O
reduction,O
of,O
UIS1,B-GP
/,O
IK2,B-GP
mRNA,O
in,O
Puf2,B-GP
-,O
deficient,O
sporozoites,O
as,O
compared,O
to,O
WT,O
(,O
Figure,O
7,O
).,O
Additionally,O
",",O
we,O
found,O
a,O
∼,O
17,O
fold,O
reduction,O
of,O
Puf1,B-GP
transcript,O
levels,O
in,O
puf2,B-GP
(-),O
parasites,O
.,O
Conversely,O
",",O
Puf2,B-GP
transcript,O
levels,O
were,O
not,O
affected,O
in,O
the,O
absence,O
of,O
Puf1,B-GP
(,O
Figure,O
7,O
).,O
As,O
controls,O
",",O
UIS4,B-GP
and,O
HSP70,B-GP
mRNA,O
levels,O
were,O
similar,O
in,O
the,O
mutant,O
and,O
WT,O
sporozoites,O
.,O
Altogether,O
",",O
these,O
data,O
indicate,O
that,O
Puf2,B-GP
regulates,O
a,O
subset,O
of,O
genes,O
in,O
P,B-OG
.,I-OG
berghei,I-OG
sporozoites,O
",",O
including,O
Puf1,B-GP
and,O
the,O
kinase,B-GP
UIS1,B-GP
/,O
IK2,B-GP
.,O
The,O
latter,O
probably,O
explains,O
",",O
at,O
least,O
in,O
part,O
",",O
why,O
the,O
phenotype,O
of,O
puf2,B-GP
(-),O
sporozoites,O
recapitulates,O
that,O
of,O
IK2,B-GP
-,O
knockout,O
parasites,O
.,O
puf2,B-GP
(-),O
sporozoites,O
have,O
reduced,O
levels,O
of,O
Puf1,B-GP
and,O
UIS1,B-GP
/,O
IK2,B-GP
mRNA,O
.,O
Shown,O
is,O
an,O
expression,O
profiling,O
by,O
RT,O
-,O
qPCR,O
analysis,O
of,O
Puf1,B-GP
",",O
Puf2,B-GP
",",O
UIS1,B-GP
/,O
IK2,B-GP
",",O
UIS4,B-GP
and,O
HSP70,B-GP
mRNA,O
levels,O
in,O
WT,O
",",O
puf1,B-GP
(-),O
and,O
puf2,B-GP
(-),O
P,B-OG
.,I-OG
berghei,I-OG
sporozoites,O
.,O
Expression,O
data,O
from,O
three,O
independent,O
experiments,O
are,O
shown,O
and,O
were,O
normalized,O
to,O
the,O
level,O
of,O
GFP,B-GP
transcripts,O
",",O
which,O
are,O
expressed,O
under,O
the,O
control,O
of,O
the,O
EF1alpha,B-GP
promoter,O
[,O
26,O
].,O
no,O
amplif,O
".,",O
no,O
amplification,O
.,O
Discussion,O
Plasmodium,B-OG
sporozoites,O
must,O
persist,O
and,O
remain,O
infectious,O
within,O
the,O
salivary,O
glands,O
of,O
the,O
mosquito,B-OG
for,O
many,O
days,O
until,O
they,O
are,O
eventually,O
transmitted,O
to,O
a,O
mammalian,O
host,O
.,O
Inside,O
the,O
warm,O
-,O
blooded,O
host,O
they,O
need,O
to,O
quickly,O
leave,O
the,O
site,O
of,O
deposition,O
in,O
order,O
to,O
travel,O
to,O
the,O
liver,O
",",O
invade,O
hepatocytes,O
and,O
differentiate,O
into,O
liver,O
stages,O
[,O
29,O
].,O
The,O
transient,O
developmental,O
arrest,O
of,O
sporozoites,O
inside,O
mosquito,B-OG
salivary,O
glands,O
",",O
termed,O
latency,O
[,O
12,O
"],",O
implies,O
efficient,O
control,O
mechanisms,O
to,O
prevent,O
premature,O
transformation,O
before,O
transmission,O
and,O
during,O
transmigration,O
before,O
reaching,O
a,O
suitable,O
host,O
cell,O
.,O
In,O
this,O
study,O
",",O
we,O
identified,O
a,O
factor,O
controlling,O
sporozoite,O
latency,O
in,O
P,B-OG
.,I-OG
berghei,I-OG
",",O
the,O
RNA,B-GP
-,I-GP
binding,I-GP
protein,I-GP
Puf2,B-GP
.,O
In,O
the,O
absence,O
of,O
Puf2,B-GP
",",O
sporozoites,O
transform,O
prematurely,O
in,O
the,O
mosquito,B-OG
",",O
resulting,O
in,O
a,O
severe,O
loss,O
of,O
infectivity,O
.,O
Sporozoite,O
conversion,O
into,O
liver,O
stages,O
requires,O
initial,O
remodelling,O
of,O
the,O
parasite,O
pellicle,O
",",O
with,O
disassembly,O
of,O
the,O
inner,O
membrane,O
complex,O
(,O
IMC,O
),O
and,O
appearance,O
of,O
a,O
bulb,O
that,O
progressively,O
enlarges,O
until,O
the,O
initially,O
elongated,O
sporozoite,O
has,O
transformed,O
into,O
a,O
round,O
form,O
[,O
28,O
"],",O
[,O
30,O
].,O
Previous,O
work,O
has,O
shown,O
that,O
transformation,O
of,O
salivary,O
gland,O
sporozoites,O
is,O
induced,O
at,O
37,O
°,O
C,O
in,O
culture,O
medium,O
",",O
irrespective,O
of,O
the,O
presence,O
of,O
host,O
cells,O
[,O
28,O
].,O
It,O
should,O
be,O
noted,O
that,O
differentiation,O
into,O
EEFs,O
involves,O
additional,O
events,O
",",O
including,O
expression,O
of,O
liver,O
stage,O
specific,O
proteins,O
",",O
onset,O
of,O
nuclear,O
divisions,O
and,O
parasite,O
growth,O
.,O
,O
of,O
these,O
events,O
are,O
observed,O
in,O
axenic,O
culture,O
conditions,O
[,O
28,O
"],",O
where,O
instead,O
extracellular,O
sporozoites,O
die,O
rapidly,O
after,O
transformation,O
[,O
31,O
].,O
We,O
show,O
that,O
puf2,B-GP
(-),O
sporozoites,O
transform,O
prematurely,O
in,O
the,O
mosquito,B-OG
salivary,O
glands,O
",",O
as,O
evidenced,O
by,O
the,O
characteristic,O
bulb,O
-,O
like,O
structures,O
and,O
rounding,O
-,O
up,O
of,O
the,O
parasites,O
.,O
Premature,O
transformation,O
probably,O
impairs,O
the,O
sporozoite,O
functions,O
that,O
depend,O
on,O
IMC,O
integrity,O
",",O
such,O
as,O
parasite,O
motility,O
",",O
cell,O
traversal,O
and,O
invasion,O
",",O
thus,O
resulting,O
in,O
a,O
loss,O
of,O
infectivity,O
.,O
In,O
the,O
absence,O
of,O
Puf2,B-GP
",",O
the,O
proportion,O
of,O
transformed,O
salivary,O
gland,O
sporozoites,O
increases,O
over,O
time,O
",",O
which,O
correlates,O
with,O
a,O
progressive,O
loss,O
of,O
infectivity,O
to,O
mice,B-OG
.,O
Interestingly,O
",",O
although,O
most,O
puf2,B-GP
(-),O
sporozoites,O
eventually,O
transform,O
into,O
completely,O
round,O
forms,O
",",O
these,O
forms,O
do,O
not,O
progress,O
to,O
EEF,O
differentiation,O
",",O
as,O
shown,O
by,O
minimal,O
expression,O
of,O
the,O
liver,O
stage,O
marker,O
UIS4,B-GP
and,O
absence,O
of,O
nuclear,O
division,O
or,O
growth,O
.,O
In,O
contrast,O
",",O
normal,O
differentiation,O
of,O
puf2,B-GP
(-),O
parasites,O
is,O
observed,O
once,O
sporozoites,O
invade,O
cultured,O
hepatoma,B-DS
cells,O
.,O
Collectively,O
",",O
these,O
data,O
strongly,O
suggest,O
that,O
Puf2,B-GP
plays,O
a,O
major,O
role,O
in,O
preventing,O
premature,O
remodelling,O
of,O
the,O
sporozoites,O
prior,O
to,O
liver,B-DS
infection,I-DS
",",O
but,O
is,O
not,O
required,O
for,O
EEF,O
differentiation,O
.,O
The,O
defects,O
observed,O
in,O
puf2,B-GP
(-),O
parasites,O
are,O
reminiscent,O
of,O
those,O
described,O
in,O
IK2,B-GP
-,O
knockout,O
parasites,O
[,O
12,O
].,O
Both,O
puf2,B-GP
(-),O
and,O
ik2,B-GP
(-),O
sporozoites,O
transform,O
prematurely,O
in,O
the,O
mosquito,B-OG
and,O
display,O
greatly,O
reduced,O
infectivity,O
to,O
mice,B-OG
.,O
However,O
",",O
both,O
loss,O
-,O
of,O
-,O
function,O
mutants,O
are,O
able,O
to,O
invade,O
and,O
differentiate,O
into,O
EEFs,O
in,O
cultured,O
cells,O
in,O
vitro,O
",",O
indicating,O
that,O
they,O
do,O
not,O
play,O
any,O
essential,O
role,O
after,O
host,O
cell,O
infection,B-DS
.,O
These,O
observations,O
",",O
combined,O
with,O
a,O
major,O
down,O
-,O
regulation,O
of,O
IK2,B-GP
expression,O
in,O
puf2,B-GP
(-),O
sporozoites,O
",",O
suggest,O
that,O
the,O
phenotype,O
of,O
Puf2,B-GP
-,O
deficient,O
parasites,O
can,O
be,O
explained,O
",",O
to,O
a,O
large,O
extent,O
",",O
by,O
IK2,B-GP
depletion,O
.,O
How,O
IK2,B-GP
prevents,O
sporozoite,O
transformation,O
has,O
yet,O
to,O
be,O
determined,O
.,O
Phosphorylation,O
of,O
the,O
alpha,O
subunit,O
of,O
eIF2,B-GP
by,O
distinct,O
kinases,B-GP
",",O
such,O
as,O
Plasmodium,B-OG
IK2,B-GP
",",O
is,O
a,O
central,O
mechanism,O
in,O
stress,O
-,O
induced,O
translational,O
regulation,O
[,O
32,O
"],",O
including,O
in,O
protozoans,O
.,O
For,O
example,O
",",O
the,O
eIF2alpha,B-GP
kinase,I-GP
IK1,B-GP
regulates,O
responses,O
to,O
starvation,O
stress,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
blood,O
stages,O
[,O
13,O
"],",O
and,O
in,O
Toxoplasma,B-OG
gondii,I-OG
",",O
phosphorylation,O
of,O
eIF2alpha,B-GP
promotes,O
survival,O
of,O
extracellular,O
tachyzoites,O
[,O
33,O
].,O
Our,O
data,O
corroborate,O
the,O
findings,O
of,O
Zhang,O
et,O
al,O
.,O
[,O
12,O
"],",O
which,O
together,O
suggest,O
that,O
a,O
similar,O
stress,O
response,O
operates,O
in,O
sporozoites,O
to,O
maintain,O
them,O
in,O
a,O
quiescent,O
stage,O
.,O
The,O
founding,O
member,O
of,O
the,O
Puf,B-GP
family,O
",",O
Drosophila,B-OG
melanogaster,I-OG
Pumilio,B-GP
(,O
DmPUM,B-GP
"),",O
regulates,O
",",O
amongst,O
other,O
functions,O
",",O
abdominal,O
development,O
in,O
the,O
fly,B-OG
via,O
translational,O
repression,O
of,O
the,O
maternally,O
inherited,O
hunchback,B-GP
(,O
hb,B-GP
),O
mRNA,O
[,O
34,O
].,O
The,O
Puf,B-GP
domain,O
of,O
DmPUM,B-GP
binds,O
to,O
a,O
nanos,O
response,O
element,O
(,O
NRE,O
),O
sequence,O
located,O
in,O
the,O
3,O
′,O
UTR,O
of,O
hb,B-GP
mRNA,O
.,O
Biochemical,O
data,O
",",O
such,O
as,O
in,O
vitro,O
binding,O
assays,O
using,O
recombinant,O
Puf,B-GP
domains,O
expressed,O
in,O
bacteria,B-OG
and,O
heterologous,O
in,O
vivo,O
studies,O
using,O
the,O
yeast,B-OG
three,O
-,O
hybrid,O
system,O
",",O
have,O
demonstrated,O
intrinsic,O
binding,O
activity,O
of,O
the,O
P,B-OG
.,I-OG
falciparum,I-OG
PfPuf1,B-GP
and,O
PfPuf2,B-GP
to,O
the,O
NRE,O
sequence,O
[,O
20,O
"],",O
[,O
21,O
].,O
Signature,O
RNA,O
sequences,O
that,O
are,O
recognized,O
by,O
the,O
Puf,B-GP
domain,O
vary,O
between,O
species,O
and,O
members,O
of,O
the,O
Puf,B-GP
family,O
",",O
but,O
typically,O
contain,O
a,O
UGUR,O
motif,O
[,O
35,O
"],",O
[,O
36,O
"],",O
[,O
37,O
"],",O
[,O
38,O
].,O
A,O
large,O
number,O
of,O
Plasmodium,B-OG
genes,O
contain,O
UGUR,O
motifs,O
in,O
their,O
3,O
′,O
UTR,O
",",O
but,O
their,O
functional,O
significance,O
remains,O
uncertain,O
",",O
especially,O
in,O
the,O
context,O
of,O
the,O
exceptional,O
AT,O
-,O
richness,O
of,O
the,O
Plasmodium,B-OG
genome,O
.,O
Therefore,O
",",O
endogenous,O
targets,O
of,O
Plasmodium,B-OG
Puf,B-GP
proteins,O
still,O
remain,O
elusive,O
.,O
The,O
P,B-OG
.,I-OG
falciparum,I-OG
[,O
22,O
],O
and,O
P,B-OG
.,I-OG
berghei,I-OG
(,O
this,O
study,O
),O
mutants,O
now,O
constitute,O
potential,O
tools,O
to,O
identify,O
Puf2,B-GP
target,O
genes,O
in,O
Plasmodium,B-OG
.,O
In,O
sporozoites,O
",",O
Puf2,B-GP
regulates,O
at,O
least,O
two,O
other,O
genes,O
in,O
addition,O
to,O
IK2,B-GP
and,O
Puf1,B-GP
.,O
Indeed,O
",",O
using,O
RT,O
-,O
qPCR,O
",",O
we,O
found,O
a,O
4,O
-,O
fold,O
reduction,O
of,O
Spect,B-GP
and,O
Spect2,B-GP
mRNA,O
levels,O
in,O
puf2,B-GP
(-),O
sporozoites,O
",",O
whereas,O
actin,B-GP
and,O
AMA1,B-GP
were,O
not,O
affected,O
(,O
unpublished,O
data,O
).,O
Reduced,O
expression,O
of,O
Spect,B-GP
and,O
Spect2,B-GP
genes,O
",",O
which,O
are,O
both,O
essential,O
for,O
sporozoite,O
cell,O
traversal,O
and,O
migration,O
to,O
the,O
liver,O
[,O
29,O
"],",O
[,O
39,O
"],",O
[,O
40,O
"],",O
may,O
also,O
contribute,O
to,O
the,O
loss,O
of,O
infectivity,O
of,O
puf2,B-GP
(-),O
parasites,O
in,O
vivo,O
.,O
Whereas,O
Puf,B-GP
proteins,O
typically,O
modulate,O
target,O
mRNA,O
expression,O
by,O
either,O
promoting,O
mRNA,O
turnover,O
or,O
translational,O
repression,O
",",O
they,O
can,O
also,O
activate,O
gene,O
expression,O
or,O
control,O
mRNA,O
subcellular,O
localization,O
(,O
reviewed,O
in,O
[,O
18,O
],O
and,O
[,O
19,O
]).,O
Our,O
results,O
are,O
not,O
compatible,O
with,O
a,O
role,O
of,O
Puf2,B-GP
in,O
repressing,O
IK2,B-GP
",",O
because,O
puf2,B-GP
(-),O
and,O
ik2,B-GP
(-),O
share,O
a,O
similar,O
phenotype,O
.,O
Puf2,B-GP
may,O
instead,O
participate,O
in,O
stabilization,O
of,O
IK2,B-GP
transcripts,O
.,O
Alternatively,O
",",O
depletion,O
of,O
IK2,B-GP
mRNA,O
in,O
puf2,B-GP
(-),O
could,O
be,O
an,O
indirect,O
effect,O
due,O
to,O
activation,O
of,O
an,O
upstream,O
factor,O
that,O
regulates,O
IK2,B-GP
.,O
Whereas,O
Drosophila,B-OG
encodes,O
only,O
DmPUM,B-GP
",",O
many,O
organisms,O
",",O
including,O
C,B-OG
.,I-OG
elegans,I-OG
",",O
contain,O
two,O
or,O
more,O
genes,O
encoding,O
Puf,B-GP
proteins,O
",",O
which,O
can,O
fulfil,O
partly,O
redundant,O
functions,O
[,O
41,O
].,O
Therefore,O
",",O
presence,O
of,O
two,O
Puf,B-GP
genes,O
in,O
the,O
Plasmodium,B-OG
genome,O
might,O
be,O
explained,O
by,O
overlapping,O
or,O
distinct,O
roles,O
.,O
However,O
",",O
our,O
molecular,O
genetics,O
data,O
clearly,O
exclude,O
a,O
vital,O
role,O
for,O
Puf1,B-GP
under,O
normal,O
conditions,O
throughout,O
the,O
P,B-OG
.,I-OG
berghei,I-OG
life,O
cycle,O
.,O
Puf1,B-GP
may,O
be,O
critical,O
under,O
specific,O
conditions,O
",",O
similarly,O
to,O
the,O
role,O
of,O
IK1,B-GP
in,O
P,B-OG
.,I-OG
falciparum,I-OG
during,O
starvation,O
-,O
induced,O
stress,O
[,O
13,O
].,O
Puf2,B-GP
might,O
compensate,O
for,O
the,O
absence,O
of,O
Puf1,B-GP
in,O
puf1,B-GP
(-),O
parasites,O
",",O
but,O
not,O
vice,O
versa,O
.,O
While,O
Puf1,B-GP
in,O
principle,O
might,O
be,O
able,O
to,O
functionally,O
complement,O
for,O
Puf2,B-GP
function,O
",",O
depletion,O
of,O
Puf1,B-GP
at,O
the,O
mRNA,O
level,O
precludes,O
a,O
hypothetical,O
functional,O
overlap,O
in,O
vivo,O
.,O
In,O
this,O
regard,O
",",O
it,O
should,O
be,O
noted,O
that,O
P,B-OG
.,I-OG
berghei,I-OG
Puf1,B-GP
and,O
Puf2,B-GP
proteins,O
are,O
very,O
different,O
in,O
size,O
(,O
1183,O
versus,O
477,O
amino,O
acids,O
",",O
respectively,O
"),",O
and,O
share,O
only,O
little,O
homology,O
(∼,O
27,O
%,O
identity,O
),O
restricted,O
to,O
the,O
Puf,B-GP
domains,O
.,O
P,B-OG
.,I-OG
falciparum,I-OG
parasites,O
that,O
lack,O
Puf2,B-GP
show,O
increased,O
gametocyte,O
rates,O
and,O
a,O
bias,O
towards,O
male,O
gametocytes,O
[,O
22,O
].,O
These,O
observations,O
fit,O
with,O
the,O
proposed,O
unifying,O
",",O
and,O
perhaps,O
ancestral,O
",",O
role,O
of,O
Pufs,B-GP
in,O
promoting,O
cell,O
proliferation,O
and,O
repressing,O
differentiation,O
[,O
18,O
].,O
Our,O
findings,O
that,O
Puf2,B-GP
inhibits,O
sporozoite,O
transformation,O
further,O
support,O
the,O
notion,O
of,O
a,O
central,O
role,O
in,O
suppression,O
of,O
cellular,O
differentiation,O
.,O
Because,O
of,O
the,O
published,O
data,O
from,O
P,B-OG
.,I-OG
falciparum,I-OG
puf2,B-GP
(-),O
parasites,O
we,O
did,O
not,O
investigate,O
sexual,O
development,O
and,O
differentiation,O
of,O
Pbpuf2,B-GP
(-),O
parasites,O
in,O
great,O
detail,O
other,O
than,O
to,O
confirm,O
the,O
previous,O
findings,O
",",O
i,O
.,O
e,O
.,O
an,O
increase,O
in,O
gametocytogenesis,O
in,O
puf2,B-GP
(-),O
parasites,O
",",O
partly,O
due,O
to,O
increased,O
male,O
gametocyte,O
differentiation,O
.,O
In,O
the,O
previous,O
study,O
",",O
life,O
cycle,O
progression,O
of,O
Pfpuf2,B-GP
(-),O
parasites,O
beyond,O
gametocytogenesis,O
was,O
not,O
analyzed,O
[,O
22,O
].,O
Based,O
on,O
our,O
results,O
in,O
the,O
rodent,B-OG
malaria,B-DS
model,O
system,O
",",O
we,O
predict,O
that,O
P,B-OG
.,I-OG
falciparum,I-OG
sporozoites,O
lacking,O
Puf2,B-GP
will,O
present,O
a,O
similar,O
phenotype,O
",",O
that,O
is,O
premature,O
sporozoite,O
transformation,O
in,O
the,O
mosquito,B-OG
and,O
decreased,O
infectivity,O
.,O
Therefore,O
",",O
our,O
findings,O
might,O
be,O
of,O
considerable,O
interest,O
in,O
the,O
context,O
of,O
development,O
of,O
genetically,O
attenuated,O
parasites,O
for,O
vaccination,O
[,O
42,O
].,O
In,O
conclusion,O
",",O
we,O
show,O
here,O
that,O
Puf2,B-GP
plays,O
a,O
major,O
role,O
in,O
controlling,O
sporozoite,O
latency,O
during,O
host,O
switch,O
",",O
possibly,O
through,O
the,O
regulation,O
of,O
IK2,B-GP
.,O
Our,O
results,O
also,O
highlight,O
the,O
functional,O
importance,O
of,O
post,O
-,O
transcriptional,O
regulation,O
of,O
gene,O
expression,O
during,O
transmission,O
of,O
the,O
malaria,B-DS
parasite,O
between,O
hosts,O
.,O
Materials,O
and,O
Methods,O
Ethics,O
statement,O
All,O
animal,B-OG
work,O
was,O
conducted,O
in,O
accordance,O
with,O
the,O
German,O
‘,O
Tierschutzgesetz,O
in,O
der,O
Fassung,O
vom,O
18,O
.,O
Mai,O
2006,O
(,O
BGBl,O
.,O
I,O
S,O
.,O
1207,O
")',",O
which,O
implements,O
the,O
directive,O
86,O
/,O
609,O
/,O
EEC,O
from,O
the,O
European,O
Union,O
and,O
the,O
European,O
Convention,O
for,O
the,O
protection,O
of,O
vertebrate,B-OG
animals,B-OG
used,O
for,O
experimental,O
and,O
other,O
scientific,O
purposes,O
.,O
The,O
protocol,O
was,O
approved,O
by,O
the,O
ethics,O
committee,O
of,O
MPI,O
-,O
IB,O
and,O
the,O
Berlin,O
state,O
authorities,O
(,O
LAGeSo,O
Reg,O
#,O
G0469,O
/,O
09,O
).,O
Experimental,O
animals,B-OG
",",O
parasites,O
and,O
cell,O
lines,O
Female,O
NMRI,O
and,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
were,O
from,O
Charles,O
River,O
Laboratories,O
.,O
We,O
used,O
P,B-OG
.,I-OG
berghei,I-OG
ANKA,I-OG
clone,I-OG
507,I-OG
parasites,O
",",O
which,O
constitutively,O
express,O
the,O
green,B-GP
fluorescent,I-GP
protein,I-GP
(,O
GFP,B-GP
),O
[,O
26,O
].,O
HepG2,O
cells,O
(,O
ATCC,O
HB,B-GP
-,O
8065,O
),O
were,O
cultured,O
as,O
described,O
[,O
43,O
].,O
P,B-OG
.,I-OG
berghei,I-OG
Puf1,B-GP
and,O
Puf2,B-GP
gene,O
deletion,O
A,O
targeting,O
construct,O
for,O
Puf1,B-GP
gene,O
knockout,O
was,O
generated,O
by,O
inserting,O
a,O
503,O
-,O
bp,O
5,O
′,O
fragment,O
and,O
a,O
575,O
-,O
bp,O
3,O
′,O
fragment,O
on,O
either,O
side,O
of,O
a,O
T,B-OG
.,I-OG
gondii,I-OG
DHFR,B-GP
/,O
TS,B-GP
expression,O
cassette,O
.,O
A,O
construct,O
for,O
Puf2,B-GP
gene,O
knockout,O
was,O
generated,O
by,O
inserting,O
a,O
1001,O
-,O
bp,O
5,O
′,O
fragment,O
and,O
a,O
945,O
-,O
bp,O
3,O
′,O
fragment,O
on,O
either,O
side,O
of,O
a,O
human,B-OG
DHFR,B-GP
expression,O
cassette,O
.,O
Oligonucleotide,O
sequences,O
are,O
indicated,O
in,O
Table,O
S1,O
.,O
P,B-OG
.,I-OG
berghei,I-OG
parasites,O
were,O
transfected,O
with,O
linearized,O
plasmids,O
",",O
using,O
the,O
Nucleofector,O
®,O
device,O
(,O
Amaxa,O
GmbH,O
),O
as,O
described,O
[,O
44,O
"],",O
injected,O
intravenously,O
into,O
naïve,O
NMRI,B-OG
mice,I-OG
",",O
and,O
selected,O
by,O
pyrimethamine,O
treatment,O
in,O
the,O
drinking,O
water,O
.,O
Clonal,O
parasite,O
populations,O
were,O
obtained,O
by,O
limiting,O
dilution,O
series,O
and,O
intravenous,O
injection,O
of,O
one,O
parasite,O
in,O
10,O
recipient,O
NMRI,B-OG
mice,I-OG
.,O
One,O
puf1,B-GP
(-),O
and,O
two,O
puf2,B-GP
(-),O
clonal,O
parasite,O
lines,O
were,O
established,O
and,O
phenotypically,O
characterized,O
.,O
Genotyping,O
of,O
WT,O
and,O
recombinant,O
parasites,O
was,O
performed,O
by,O
PCR,O
and,O
Southern,O
blot,O
analysis,O
of,O
genomic,O
DNA,O
.,O
Standard,O
Southern,O
blot,O
analysis,O
was,O
performed,O
using,O
the,O
PCR,O
DIG,O
Probe,O
synthesis,O
kit,O
and,O
the,O
DIG,O
Luminescent,O
Detection,O
kit,O
(,O
Roche,O
"),",O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
Real,O
time,O
quantitative,O
RT,O
-,O
PCR,O
Parasite,O
total,O
RNA,O
was,O
extracted,O
with,O
the,O
RNeasy,O
kit,O
(,O
Qiagen,O
),O
and,O
reverse,O
transcribed,O
with,O
the,O
RETROScript,O
kit,O
(,O
Ambion,O
).,O
Real,O
time,O
PCR,O
was,O
performed,O
on,O
cDNA,O
preparations,O
as,O
described,O
[,O
11,O
"],",O
using,O
the,O
StepOnePlus,O
™,O
Real,O
-,O
Time,O
PCR,O
System,O
and,O
Power,O
SYBR,O
®,O
Green,O
PCR,O
Master,O
Mix,O
(,O
Applied,O
Biosystems,O
"),",O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
Expression,O
data,O
were,O
normalized,O
using,O
the,O
constitutively,O
expressed,O
GFP,B-GP
gene,O
.,O
Immunofluorescence,O
Parasites,O
were,O
fixed,O
in,O
4,O
%,O
paraformaldehyde,O
(,O
PFA,O
),O
and,O
permeabilized,O
with,O
1,O
%,O
Triton,O
X,O
-,O
100,O
.,O
Immunofluorescence,O
was,O
then,O
carried,O
out,O
using,O
previously,O
described,O
monoclonal,O
antibodies,B-GP
against,O
P,B-OG
.,I-OG
berghei,I-OG
CSP,B-GP
[,O
45,O
],O
and,O
HSP70,B-GP
[,O
46,O
].,O
Polyclonal,O
anti,O
-,O
UIS4,B-GP
antibodies,B-GP
were,O
raised,O
in,O
rabbits,B-OG
immunized,O
with,O
two,O
synthetic,O
peptides,O
from,O
P,B-OG
.,I-OG
berghei,I-OG
UIS4,B-GP
(,O
CLFTDEHKDEINDNIV,O
and,O
CNNVYNMENKSFGPYI,O
),O
(,O
Eurogentec,O
).,O
DRAQ5,O
(,O
Biostatus,O
),O
was,O
used,O
to,O
stain,O
nuclei,O
.,O
Confocal,O
pictures,O
were,O
obtained,O
with,O
a,O
Leica,O
TCS,O
-,O
SP,B-GP
microscope,O
equipped,O
with,O
appropriate,O
filters,O
",",O
and,O
processed,O
with,O
Photoshop,O
software,O
(,O
Adobe,O
Inc,O
.).,O
Parasite,O
growth,O
and,O
sexual,O
development,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
(,O
n,O
=,O
5,O
),O
were,O
injected,O
intravenously,O
with,O
107,O
infected,O
erythrocytes,O
.,O
Four,O
days,O
later,O
",",O
the,O
parasitemia,B-DS
was,O
determined,O
by,O
microscopic,O
examination,O
of,O
Giemsa,O
-,O
stained,O
blood,O
smears,O
.,O
To,O
analyse,O
exflagellation,O
of,O
male,O
gametocytes,O
",",O
five,O
microliters,O
of,O
tail,O
blood,O
were,O
diluted,O
1,O
∶,O
25,O
in,O
RPMI,O
1640,O
containing,O
10,O
%,O
FCS,O
and,O
50,O
µM,O
xanthurenic,O
acid,O
",",O
and,O
adjusted,O
to,O
pH,O
8,O
.,O
0,O
.,O
After,O
12,O
min,O
incubation,O
at,O
room,O
temperature,O
",",O
exflagellation,O
centers,O
were,O
counted,O
in,O
a,O
Neubauer,O
chamber,O
.,O
Mean,O
parasitemia,B-DS
and,O
gametocyte,O
rates,O
were,O
compared,O
using,O
the,O
Mann,O
-,O
Whitney,O
non,O
-,O
parametric,O
test,O
.,O
After,O
parasite,O
transmission,O
to,O
Anopheles,B-OG
stephensi,I-OG
mosquitoes,B-OG
",",O
the,O
numbers,O
of,O
midgut,O
oocysts,O
and,O
salivary,O
gland,O
sporozoites,O
were,O
determined,O
at,O
day,O
10,O
–,O
14,O
and,O
day,O
18,O
–,O
25,O
",",O
respectively,O
",",O
and,O
compared,O
using,O
the,O
Kruskal,O
-,O
Wallis,O
followed,O
by,O
Dunn,O
',O
s,O
multiple,O
comparison,O
tests,O
.,O
Analysis,O
of,O
sporozoite,O
in,O
vivo,O
infectivity,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
were,O
injected,O
intravenously,O
with,O
1,O
",",O
000,O
WT,O
or,O
mutant,O
sporozoites,O
isolated,O
from,O
the,O
salivary,O
glands,O
of,O
infected,O
mosquitoes,B-OG
",",O
or,O
exposed,O
to,O
10,O
infected,O
mosquito,B-OG
bites,O
",",O
as,O
indicated,O
.,O
Infection,B-DS
was,O
then,O
monitored,O
daily,O
by,O
examination,O
of,O
Giemsa,O
-,O
stained,O
blood,O
smears,O
.,O
The,O
delay,O
of,O
patency,O
was,O
defined,O
as,O
the,O
time,O
before,O
detection,O
of,O
at,O
least,O
one,O
erythrocytic,O
stage,O
in,O
the,O
smears,O
.,O
For,O
quantification,O
of,O
parasite,O
liver,O
loads,O
by,O
real,O
time,O
RT,O
-,O
PCR,O
",",O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
were,O
infected,O
intravenously,O
with,O
10,O
",",O
000,O
sporozoites,O
.,O
At,O
42,O
hours,O
post,O
-,O
infection,B-DS
",",O
livers,O
were,O
harvested,O
",",O
total,O
RNA,O
was,O
extracted,O
with,O
the,O
RNeasy,O
kit,O
(,O
Qiagen,O
),O
and,O
cDNA,O
synthesized,O
with,O
the,O
RETROScript,O
kit,O
(,O
Ambion,O
).,O
Real,O
-,O
time,O
PCR,O
was,O
then,O
performed,O
with,O
the,O
StepOnePlus,O
™,O
Real,O
-,O
Time,O
PCR,O
System,O
and,O
Power,O
SYBR,O
®,O
Green,O
PCR,O
Master,O
Mix,O
(,O
Applied,O
Biosystems,O
"),",O
using,O
primers,O
specific,O
for,O
P,B-OG
.,I-OG
berghei,I-OG
18S,O
rRNA,O
and,O
mouse,B-OG
GAPDH,B-GP
",",O
as,O
described,O
[,O
47,O
].,O
Liver,O
parasite,O
loads,O
were,O
compared,O
using,O
the,O
Mann,O
-,O
Whitney,O
non,O
-,O
parametric,O
test,O
.,O
Supporting,O
Information,O
List,O
of,O
oligonucleotides,O
used,O
in,O
this,O
study,O
.,O
(,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Method,O
for,O
Reading,O
Sensors,O
and,O
Controlling,O
Actuators,O
Using,O
Audio,O
Interfaces,O
of,O
Mobile,O
Devices,O
This,O
article,O
presents,O
a,O
novel,O
closed,O
loop,O
control,O
architecture,O
based,O
on,O
audio,O
channels,O
of,O
several,O
types,O
of,O
computing,O
devices,O
",",O
such,O
as,O
mobile,O
phones,O
and,O
tablet,O
computers,O
",",O
but,O
not,O
restricted,O
to,O
them,O
.,O
The,O
communication,O
is,O
based,O
on,O
an,O
audio,O
interface,O
that,O
relies,O
on,O
the,O
exchange,O
of,O
audio,O
tones,O
",",O
allowing,O
sensors,O
to,O
be,O
read,O
and,O
actuators,O
to,O
be,O
controlled,O
.,O
As,O
an,O
application,O
example,O
",",O
the,O
presented,O
technique,O
is,O
used,O
to,O
build,O
a,O
low,O
cost,O
mobile,O
robot,O
",",O
but,O
the,O
system,O
can,O
also,O
be,O
used,O
in,O
a,O
variety,O
of,O
mechatronics,O
applications,O
and,O
sensor,O
networks,O
",",O
where,O
smartphones,O
are,O
the,O
basic,O
building,O
blocks,O
.,O
Introduction,O
and,O
Motivation,O
Most,O
robots,O
and,O
automation,O
systems,O
rely,O
on,O
processing,O
units,O
to,O
control,O
their,O
behavior,O
.,O
Such,O
processing,O
units,O
can,O
be,O
embedded,O
processors,O
(,O
such,O
as,O
microcontrollers,O
),O
or,O
general,O
purpose,O
computers,O
(,O
such,O
as,O
PCs,O
),O
with,O
specialized,O
Input,O
/,O
Output,O
(,O
I,O
/,O
O,O
),O
accessories,O
.,O
One,O
common,O
practice,O
is,O
the,O
use,O
of,O
USB,O
devices,O
with,O
several,O
I,O
/,O
O,O
options,O
connected,O
to,O
a,O
PC,O
.,O
Another,O
approach,O
consists,O
of,O
using,O
a,O
microcontroller,O
unit,O
that,O
runs,O
a,O
software,O
algorithm,O
to,O
control,O
the,O
system,O
.,O
Frequently,O
this,O
microcontroller,O
is,O
connected,O
to,O
a,O
computer,O
to,O
monitor,O
and,O
set,O
parameters,O
of,O
the,O
running,O
system,O
.,O
Although,O
consolidated,O
",",O
these,O
approaches,O
require,O
specific,O
device,O
drivers,O
on,O
the,O
host,O
computer,O
and,O
special,O
configurations,O
.,O
Moreover,O
",",O
if,O
the,O
control,O
algorithm,O
has,O
to,O
be,O
changed,O
",",O
the,O
user,O
must,O
reprogram,O
the,O
microcontroller,O
",",O
which,O
in,O
some,O
cases,O
requires,O
special,O
hardware,O
tools,O
such,O
as,O
in,O
-,O
circuit,O
programmers,O
and,O
debuggers,O
.,O
Mobile,O
devices,O
such,O
as,O
cell,O
phones,O
",",O
tablets,O
and,O
netbooks,O
are,O
widespread,O
and,O
getting,O
cheaper,O
due,O
to,O
their,O
large,O
production,O
",",O
making,O
them,O
an,O
interesting,O
option,O
to,O
control,O
mechatronics,O
systems,O
.,O
These,O
devices,O
also,O
include,O
several,O
sensors,O
that,O
can,O
be,O
used,O
in,O
a,O
mechatronic,O
system,O
.,O
Examples,O
of,O
sensors,O
available,O
in,O
modern,O
cell,O
phones,O
are,O
the,O
global,O
positioning,O
system,O
receiver,O
(,O
GPS,O
"),",O
3,O
-,O
axis,O
accelerometer,O
",",O
compass,O
",",O
liquid,O
crystal,O
display,O
(,O
LCD,O
),O
with,O
touchscreen,O
",",O
Internet,O
access,O
via,O
WiFi,O
or,O
GPRS,O
/,O
3G,O
services,O
",",O
camera,O
",",O
speakers,O
",",O
microphone,O
",",O
bluetooth,O
module,O
",",O
light,O
sensor,O
and,O
battery,O
(,O
some,O
have,O
even,O
gyroscope,O
",",O
barometer,O
and,O
stereo,O
camera,O
).,O
If,O
all,O
those,O
accessories,O
would,O
be,O
bought,O
separately,O
and,O
installed,O
in,O
a,O
device,O
",",O
the,O
costs,O
would,O
be,O
more,O
expensive,O
than,O
a,O
device,O
with,O
all,O
these,O
features,O
already,O
included,O
.,O
To,O
use,O
a,O
mobile,O
device,O
as,O
a,O
mechatronics,O
system,O
main,O
processing,O
unit,O
",",O
a,O
communication,O
link,O
must,O
established,O
between,O
the,O
control,O
unit,O
and,O
the,O
system,O
under,O
control,O
.,O
Some,O
works,O
[,O
1,O
–,O
3,O
],O
use,O
the,O
mobile,O
’,O
s,O
device,O
RS,O
-,O
232,O
serial,O
port,O
signals,O
while,O
others,O
use,O
bluetooth,O
[,O
1,O
",",O
4,O
].,O
In,O
all,O
these,O
works,O
",",O
a,O
microcontroller,O
still,O
needs,O
to,O
be,O
used,O
to,O
communicate,O
with,O
the,O
mobile,O
device,O
",",O
to,O
read,O
sensors,O
and,O
to,O
control,O
actuators,O
.,O
The,O
problem,O
is,O
that,O
not,O
all,O
mobile,O
devices,O
have,O
a,O
serial,O
port,O
",",O
or,O
bluetooth,O
communication,O
interface,O
.,O
Analyzing,O
modern,O
mobile,O
devices,O
it,O
is,O
possible,O
to,O
note,O
that,O
most,O
of,O
them,O
have,O
an,O
universal,O
communication,O
interface,O
:,O
audio,O
channels,O
",",O
that,O
usually,O
can,O
be,O
accessed,O
through,O
standard,O
3,O
.,O
5,O
mm,O
P2,O
connectors,O
.,O
If,O
there,O
are,O
no,O
connectors,O
for,O
external,O
audio,O
",",O
this,O
article,O
also,O
offers,O
a,O
solution,O
using,O
suction,O
cups,O
to,O
use,O
the,O
proposed,O
system,O
in,O
mobile,O
devices,O
where,O
the,O
speakers,O
or,O
microphones,O
are,O
built,O
-,O
in,O
.,O
Details,O
of,O
such,O
solution,O
are,O
discussed,O
in,O
Section,O
5,O
.,O
1,O
.,O
In,O
this,O
article,O
",",O
a,O
system,O
that,O
allows,O
closed,O
loop,O
control,O
using,O
any,O
mobile,O
device,O
that,O
can,O
produce,O
and,O
receive,O
sounds,O
was,O
designed,O
and,O
built,O
.,O
In,O
such,O
system,O
",",O
audio,O
tones,O
are,O
used,O
to,O
encode,O
actuators,O
control,O
commands,O
and,O
sensors,O
states,O
.,O
The,O
system,O
cost,O
is,O
low,O
because,O
only,O
a,O
few,O
parts,O
are,O
needed,O
(,O
these,O
parts,O
are,O
widely,O
used,O
in,O
the,O
telephony,O
industry,O
",",O
making,O
them,O
also,O
easy,O
to,O
find,O
on,O
the,O
market,O
).,O
Moreover,O
the,O
system,O
does,O
not,O
need,O
any,O
intermediate,O
processing,O
unit,O
",",O
making,O
it,O
flexible,O
to,O
easily,O
update,O
the,O
running,O
algorithm,O
",",O
avoiding,O
the,O
need,O
of,O
reprogramming,O
microcontrollers,O
.,O
Robots,O
and,O
Smartphones,O
As,O
mentioned,O
",",O
mobile,O
devices,O
have,O
several,O
features,O
that,O
can,O
be,O
used,O
in,O
robotics,O
.,O
Some,O
possibilities,O
of,O
using,O
these,O
features,O
are,O
briefly,O
discussed,O
in,O
the,O
following,O
text,O
.,O
These,O
possibilities,O
are,O
",",O
for,O
sure,O
",",O
non,O
-,O
exhaustive,O
.,O
CPU,O
:,O
Modern,O
smartphones,O
already,O
have,O
processors,O
with,O
clock,O
rates,O
of,O
1,O
GHz,O
or,O
more,O
.,O
Some,O
models,O
also,O
have,O
multi,O
-,O
core,O
processors,O
.,O
These,O
processing,O
units,O
are,O
capable,O
of,O
doing,O
many,O
complex,O
and,O
computationally,O
intensive,O
operations,O
for,O
autonomous,O
robots,O
navigation,O
.,O
Santos,O
et,O
al,O
.,O
[,O
4,O
"],",O
for,O
example,O
",",O
showed,O
that,O
it,O
is,O
feasible,O
to,O
execute,O
complex,O
robotics,O
navigation,O
algorithms,O
in,O
processors,O
of,O
older,O
smartphones,O
with,O
300,O
MHz,O
clock,O
speed,O
;,O
Camera,O
:,O
can,O
be,O
used,O
with,O
a,O
variety,O
of,O
algorithms,O
for,O
visual,O
odometry,O
",",O
object,O
recognition,O
",",O
robot,O
attention,O
(,O
the,O
ability,O
to,O
select,O
a,O
topic,O
of,O
interest,O
[,O
5,O
"]),",O
obstacle,O
detection,O
and,O
avoidance,O
",",O
object,O
tracking,O
",",O
and,O
others,O
;,O
Compass,O
:,O
can,O
be,O
used,O
to,O
sense,O
the,O
robot,O
’,O
s,O
direction,O
of,O
movement,O
.,O
The,O
system,O
can,O
work,O
with,O
one,O
or,O
two,O
encoders,O
.,O
If,O
only,O
one,O
encoder,O
is,O
used,O
",",O
the,O
compass,O
is,O
used,O
to,O
guarantee,O
that,O
the,O
robot,O
is,O
going,O
in,O
the,O
expected,O
direction,O
and,O
to,O
control,O
the,O
desired,O
curves,O
angles,O
;,O
GPS,O
:,O
can,O
be,O
used,O
to,O
obtain,O
the,O
robot,O
position,O
in,O
outdoor,O
environments,O
",",O
altitude,O
and,O
speed,O
;,O
Accelerometer,O
:,O
can,O
be,O
used,O
to,O
detect,O
speed,O
changes,O
and,O
consequently,O
if,O
the,O
robot,O
has,O
hit,O
an,O
object,O
in,O
any,O
direction,O
(,O
a,O
virtual,O
bumper,O
).,O
It,O
can,O
also,O
detect,O
the,O
robot,O
’,O
s,O
orientation,O
.,O
It,O
is,O
also,O
possible,O
to,O
use,O
Kalman,O
filtering,O
to,O
do,O
sensor,O
fusion,O
of,O
the,O
camera,O
",",O
encoders,O
and,O
accelerometer,O
to,O
get,O
more,O
accurate,O
positioning,O
;,O
Internet,O
:,O
WiFi,O
or,O
other,O
Internet,O
connection,O
can,O
be,O
used,O
to,O
remotely,O
monitor,O
the,O
robot,O
and,O
send,O
commands,O
to,O
it,O
.,O
The,O
robot,O
can,O
also,O
access,O
a,O
cloud,O
system,O
to,O
aid,O
some,O
decision,O
making,O
process,O
and,O
communicate,O
with,O
other,O
robots,O
;,O
Bluetooth,O
:,O
can,O
be,O
used,O
to,O
exchange,O
information,O
with,O
nearby,O
robots,O
and,O
for,O
robot,O
localization,O
;,O
Bluetooth,O
audio,O
:,O
As,O
the,O
standard,O
audio,O
input,O
and,O
output,O
are,O
used,O
for,O
the,O
control,O
system,O
",",O
a,O
bluetooth,O
headset,O
can,O
be,O
paired,O
with,O
the,O
mobile,O
device,O
",",O
allowing,O
the,O
robot,O
to,O
receive,O
voice,O
commands,O
and,O
give,O
synthesized,O
voice,O
feedback,O
to,O
the,O
user,O
.,O
The,O
Android,O
voice,O
recognizer,O
worked,O
well,O
for,O
both,O
English,O
and,O
Portuguese,O
.,O
The,O
user,O
can,O
press,O
a,O
button,O
in,O
the,O
bluetooth,O
headset,O
and,O
say,O
a,O
complex,O
command,O
such,O
as,O
a,O
phrase,O
.,O
The,O
Android,O
system,O
will,O
then,O
return,O
a,O
vector,O
with,O
most,O
probable,O
phrases,O
that,O
the,O
user,O
has,O
said,O
;,O
ROS,O
:,O
The,O
Robot,O
Operating,O
System,O
(,O
ROS,O
),O
[,O
6,O
],O
from,O
Willow,O
Garage,O
is,O
already,O
supported,O
in,O
mobile,O
devices,O
running,O
Android,O
using,O
the,O
ros,O
-,O
java,O
branch,O
.,O
Using,O
ROS,O
and,O
the,O
system,O
described,O
in,O
this,O
article,O
",",O
a,O
low,O
cost,O
robot,O
can,O
be,O
built,O
with,O
all,O
the,O
advantages,O
and,O
features,O
of,O
ROS,O
.,O
Contributions,O
The,O
main,O
contributions,O
of,O
this,O
work,O
are,O
:,O
A,O
novel,O
system,O
for,O
controlling,O
actuators,O
using,O
audio,O
channelsA,O
novel,O
system,O
for,O
reading,O
sensors,O
information,O
using,O
audio,O
channelsA,O
closed,O
loop,O
control,O
architecture,O
using,O
the,O
above,O
-,O
mentioned,O
itemsApplication,O
of,O
a,O
camera,O
and,O
laser,O
based,O
distance,O
measurement,O
system,O
for,O
roboticsA,O
low,O
cost,O
mobile,O
robot,O
controlled,O
by,O
smartphones,O
and,O
mobile,O
devices,O
using,O
the,O
techniques,O
introduced,O
in,O
this,O
work,O
Organization,O
This,O
paper,O
is,O
structured,O
as,O
follows,O
:,O
Section,O
2,O
describes,O
previous,O
architectures,O
for,O
mechatronics,O
systems,O
control,O
.,O
Section,O
3,O
introduces,O
the,O
new,O
technique,O
.,O
Section,O
4,O
presents,O
the,O
experimental,O
results,O
of,O
the,O
proposed,O
system,O
.,O
Section,O
5,O
describes,O
a,O
case,O
study,O
with,O
an,O
application,O
of,O
the,O
system,O
to,O
build,O
a,O
low,O
cost,O
mobile,O
robot,O
and,O
in,O
Section,O
6,O
are,O
the,O
final,O
considerations,O
.,O
Related,O
Work,O
This,O
section,O
reviews,O
some,O
of,O
the,O
most,O
relevant,O
related,O
works,O
that,O
uses,O
mobile,O
devices,O
to,O
control,O
robots,O
and,O
their,O
communication,O
interfaces,O
.,O
Digital,O
Data,O
Interfaces,O
Santos,O
et,O
al,O
.,O
[,O
4,O
],O
analyze,O
the,O
feasibility,O
of,O
using,O
smartphones,O
to,O
execute,O
robot,O
’,O
s,O
autonomous,O
navigation,O
and,O
localization,O
algorithms,O
.,O
In,O
the,O
proposed,O
system,O
",",O
the,O
robot,O
control,O
algorithm,O
is,O
executed,O
in,O
the,O
mobile,O
phone,O
and,O
the,O
motion,O
commands,O
are,O
sent,O
to,O
the,O
robot,O
using,O
bluetooth,O
.,O
Their,O
experiments,O
are,O
made,O
with,O
mobile,O
phones,O
with,O
processor,O
clocks,O
of,O
220,O
MHz,O
and,O
330,O
MHz,O
and,O
they,O
conclude,O
that,O
it,O
is,O
possible,O
and,O
robust,O
to,O
execute,O
complex,O
navigation,O
in,O
these,O
devices,O
even,O
with,O
soft,O
real,O
-,O
time,O
requirements,O
.,O
The,O
tested,O
algorithms,O
are,O
well,O
-,O
known,O
:,O
potential,O
fields,O
",",O
particle,O
filter,O
and,O
extended,O
Kalman,O
filter,O
.,O
Another,O
example,O
of,O
the,O
use,O
of,O
smartphones,O
to,O
control,O
robots,O
is,O
the,O
open,O
source,O
project,O
Cellbots,O
[,O
1,O
],O
which,O
uses,O
Android,O
based,O
phones,O
to,O
control,O
mobile,O
robots,O
.,O
The,O
project,O
requires,O
a,O
microcontroller,O
that,O
communicates,O
with,O
the,O
phone,O
via,O
bluetooth,O
or,O
serial,O
port,O
and,O
sends,O
the,O
electrical,O
control,O
signals,O
to,O
the,O
motors,O
.,O
The,O
problem,O
is,O
that,O
not,O
all,O
mobile,O
devices,O
have,O
bluetooth,O
or,O
serial,O
ports,O
.,O
Moreover,O
",",O
in,O
some,O
cases,O
the,O
device,O
has,O
the,O
serial,O
port,O
available,O
only,O
internally,O
",",O
requiring,O
disassembly,O
of,O
the,O
device,O
to,O
access,O
the,O
serial,O
port,O
signals,O
.,O
When,O
using,O
bluetooth,O
",",O
the,O
costs,O
are,O
higher,O
because,O
an,O
additional,O
bluetooth,O
module,O
must,O
be,O
installed,O
and,O
connected,O
to,O
the,O
microcontroller,O
.,O
The,O
work,O
of,O
Hess,O
and,O
Rohrig,O
[,O
7,O
],O
consists,O
of,O
using,O
mobile,O
phones,O
to,O
remotely,O
control,O
a,O
robot,O
.,O
Their,O
system,O
can,O
connect,O
to,O
the,O
robot,O
using,O
TCP,O
/,O
IP,O
interfaces,O
or,O
bluetooth,O
.,O
In,O
the,O
case,O
of,O
the,O
TCP,O
/,O
IP,O
sockets,O
",",O
the,O
connection,O
to,O
the,O
robot,O
is,O
made,O
using,O
an,O
already,O
existing,O
wireless,O
LAN,O
(,O
WiFi,O
),O
infrastructure,O
.,O
Park,O
et,O
al,O
.,O
[,O
8,O
],O
describe,O
user,O
interface,O
techniques,O
for,O
using,O
PDAs,O
or,O
smartphones,O
to,O
remotely,O
control,O
robots,O
.,O
Again,O
",",O
the,O
original,O
robot,O
controller,O
is,O
maintained,O
and,O
the,O
mobile,O
device,O
is,O
used,O
simply,O
as,O
a,O
remote,O
control,O
device,O
.,O
Their,O
system,O
commands,O
are,O
exchanged,O
using,O
WiFi,O
wireless,O
networks,O
.,O
Analog,O
Audio,O
Interfaces,O
One,O
interesting,O
alternative,O
is,O
using,O
a,O
dedicated,O
circuit,O
to,O
transform,O
the,O
audio,O
output,O
of,O
the,O
mobile,O
device,O
in,O
a,O
serial,O
port,O
signal,O
[,O
9,O
"],",O
but,O
the,O
problem,O
with,O
such,O
approach,O
is,O
that,O
only,O
unidirectional,O
communication,O
is,O
possible,O
",",O
and,O
still,O
",",O
as,O
in,O
the,O
other,O
cases,O
",",O
a,O
microcontroller,O
is,O
needed,O
to,O
decode,O
the,O
serial,O
signal,O
and,O
execute,O
some,O
action,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
telecommunications,O
industry,O
frequently,O
uses,O
the,O
Dial,O
Tone,O
Multi,O
Frequency,O
(,O
DTMF,O
),O
system,O
to,O
exchange,O
remote,O
control,O
commands,O
between,O
equipments,O
.,O
Section,O
3,O
.,O
1,O
contains,O
a,O
description,O
of,O
the,O
DTMF,O
system,O
.,O
The,O
system,O
is,O
more,O
known,O
in,O
telephony,O
for,O
sending,O
the,O
digits,O
that,O
a,O
caller,O
wants,O
to,O
dial,O
to,O
a,O
switching,O
office,O
.,O
DTMF,O
usage,O
to,O
control,O
robots,O
is,O
not,O
new,O
.,O
There,O
are,O
some,O
recent,O
projects,O
that,O
use,O
DTMF,O
digits,O
exchange,O
to,O
remotely,O
control,O
robots,O
:,O
Patil,O
and,O
Henry,O
[,O
10,O
],O
used,O
a,O
remote,O
mobile,O
phone,O
to,O
telecommand,O
a,O
robot,O
.,O
DTMF,O
tones,O
are,O
sent,O
from,O
the,O
mobile,O
phone,O
to,O
the,O
remote,O
robot,O
’,O
s,O
phone,O
and,O
decoded,O
by,O
a,O
specific,O
integrated,O
circuit,O
and,O
the,O
binary,O
output,O
is,O
connected,O
to,O
a,O
FPGA,O
that,O
controls,O
the,O
robot,O
.,O
Manikandan,O
et,O
al,O
.,O
[,O
11,O
],O
proposed,O
and,O
built,O
a,O
robot,O
that,O
uses,O
two,O
cell,O
phones,O
.,O
One,O
phone,O
is,O
placed,O
in,O
the,O
robot,O
and,O
another,O
acts,O
as,O
a,O
remote,O
control,O
.,O
The,O
DTMF,O
audio,O
produced,O
by,O
the,O
keys,O
pressed,O
in,O
the,O
remote,O
control,O
phone,O
is,O
sent,O
to,O
the,O
phone,O
installed,O
in,O
the,O
robot,O
",",O
and,O
the,O
audio,O
output,O
of,O
this,O
phone,O
is,O
connected,O
to,O
a,O
DTMF,O
decoder,O
via,O
the,O
earphone,O
output,O
of,O
the,O
cell,O
phone,O
.,O
The,O
4,O
-,O
bit,O
DTMF,O
output,O
is,O
then,O
connected,O
to,O
a,O
microcontroller,O
that,O
interprets,O
the,O
codes,O
and,O
executes,O
the,O
movements,O
related,O
to,O
the,O
keys,O
pressed,O
in,O
the,O
remote,O
control,O
phone,O
.,O
Sai,O
and,O
Sivaramakrishnan,O
[,O
12,O
],O
used,O
the,O
same,O
setup,O
",",O
where,O
two,O
mobile,O
phones,O
are,O
used,O
",",O
one,O
located,O
at,O
the,O
robot,O
and,O
another,O
used,O
as,O
a,O
remote,O
control,O
.,O
The,O
difference,O
is,O
that,O
the,O
system,O
is,O
applied,O
to,O
different,O
type,O
of,O
robot,O
(,O
mechanically,O
).,O
Naskar,O
et,O
al,O
.,O
[,O
13,O
],O
presented,O
a,O
work,O
where,O
a,O
remote,O
DTMF,O
keypad,O
is,O
used,O
to,O
control,O
a,O
military,O
robot,O
.,O
Some,O
DTMF,O
digits,O
are,O
even,O
used,O
to,O
fire,O
real,O
guns,O
.,O
The,O
main,O
difference,O
is,O
that,O
instead,O
of,O
transmitting,O
the,O
DTMF,O
tones,O
using,O
a,O
phone,O
call,O
",",O
the,O
tones,O
are,O
transmitted,O
using,O
a,O
radio,O
frequency,O
link,O
.,O
Still,O
about,O
DTMF,O
based,O
control,O
",",O
Ladwa,O
et,O
al,O
.,O
[,O
14,O
],O
proposed,O
a,O
system,O
that,O
can,O
remotely,O
control,O
home,O
appliances,O
or,O
robots,O
via,O
DTMF,O
tones,O
over,O
telephone,O
calls,O
.,O
The,O
tones,O
are,O
generated,O
by,O
keys,O
pressed,O
in,O
a,O
remote,O
phone,O
keypad,O
",",O
received,O
by,O
a,O
phone,O
installed,O
in,O
the,O
system,O
under,O
control,O
and,O
decoded,O
by,O
a,O
DTMF,O
decoder,O
circuit,O
.,O
A,O
microcontroller,O
then,O
executes,O
some,O
pre,O
-,O
programmed,O
action,O
.,O
A,O
similar,O
work,O
is,O
presented,O
by,O
Cho,O
and,O
Jeon,O
[,O
15,O
],O
where,O
key,O
presses,O
in,O
a,O
remote,O
phone,O
are,O
sent,O
through,O
a,O
telephone,O
call,O
to,O
a,O
receiver,O
cell,O
phone,O
modem,O
.,O
Its,O
audio,O
output,O
is,O
connected,O
to,O
a,O
DTMF,O
decoder,O
chip,O
which,O
is,O
then,O
connected,O
to,O
a,O
robot,O
control,O
board,O
.,O
As,O
the,O
user,O
presses,O
keys,O
in,O
the,O
remote,O
phone,O
",",O
the,O
robot,O
goes,O
forward,O
",",O
backwards,O
or,O
do,O
curves,O
according,O
with,O
the,O
pressed,O
key,O
(,O
a,O
numerical,O
digit,O
that,O
is,O
represented,O
by,O
a,O
DTMF,O
code,O
).,O
Recently,O
",",O
a,O
startup,O
company,O
created,O
a,O
mobile,O
robot,O
that,O
can,O
be,O
controlled,O
by,O
audio,O
tones,O
from,O
mobile,O
phones,O
[,O
16,O
].,O
The,O
system,O
is,O
limited,O
to,O
controlling,O
two,O
motors,O
and,O
does,O
not,O
have,O
any,O
feedback,O
or,O
sensor,O
reading,O
capability,O
.,O
The,O
alternative,O
is,O
using,O
camera,O
algorithms,O
such,O
as,O
optical,O
flow,O
to,O
implement,O
visual,O
odometry,O
",",O
but,O
even,O
if,O
so,O
",",O
such,O
limitations,O
make,O
it,O
difficult,O
to,O
build,O
a,O
complete,O
mobile,O
robot,O
because,O
of,O
the,O
lack,O
of,O
important,O
sensory,O
information,O
such,O
as,O
bumpers,O
and,O
distance,O
to,O
objects,O
.,O
Also,O
",",O
the,O
information,O
provided,O
in,O
the,O
company,O
website,O
does,O
not,O
make,O
it,O
clear,O
if,O
the,O
wheel,O
speed,O
can,O
be,O
controlled,O
and,O
which,O
audio,O
frequencies,O
are,O
used,O
.,O
With,O
the,O
exception,O
of,O
the,O
example,O
in,O
the,O
last,O
paragraph,O
",",O
all,O
other,O
mentioned,O
examples,O
and,O
projects,O
use,O
DTMF,O
tones,O
to,O
remotely,O
control,O
a,O
distant,O
robot,O
over,O
radio,O
or,O
telephone,O
lines,O
.,O
This,O
system,O
",",O
in,O
contrast,O
",",O
uses,O
DTMF,O
tones,O
to,O
control,O
actuators,O
and,O
read,O
sensors,O
in,O
a,O
scheme,O
where,O
the,O
control,O
unit,O
is,O
physically,O
attached,O
to,O
the,O
robot,O
",",O
or,O
near,O
the,O
robot,O
(,O
connected,O
by,O
an,O
audio,O
cable,O
).,O
The,O
advantage,O
is,O
that,O
DTMF,O
tones,O
are,O
very,O
robust,O
to,O
interference,O
and,O
widely,O
adopted,O
",",O
making,O
it,O
easy,O
to,O
find,O
electrical,O
components,O
and,O
software,O
support,O
for,O
dealing,O
with,O
such,O
system,O
.,O
System,O
Architecture,O
This,O
section,O
describes,O
the,O
proposed,O
system,O
architecture,O
.,O
Its,O
main,O
advantage,O
is,O
to,O
provide,O
a,O
universal,O
connection,O
system,O
to,O
read,O
sensors,O
and,O
control,O
actuators,O
of,O
mechatronics,O
systems,O
.,O
The,O
data,O
is,O
exchanged,O
using,O
audio,O
tones,O
",",O
allowing,O
the,O
technique,O
to,O
be,O
used,O
with,O
any,O
device,O
that,O
has,O
audio,O
input,O
/,O
output,O
interfaces,O
.,O
Theoretical,O
Background,O
The,O
DTMF,O
system,O
was,O
created,O
in,O
the,O
decade,O
of,O
1950,O
as,O
a,O
faster,O
option,O
to,O
the,O
(,O
now,O
obsolete,O
),O
pulse,O
dialing,O
system,O
.,O
Its,O
main,O
purpose,O
at,O
that,O
time,O
was,O
to,O
send,O
the,O
digits,O
that,O
a,O
caller,O
wants,O
to,O
dial,O
to,O
the,O
switching,O
system,O
of,O
the,O
telephone,O
company,O
.,O
Although,O
almost,O
60,O
years,O
old,O
",",O
DTMF,O
is,O
still,O
widely,O
used,O
in,O
telecommunication,O
systems,O
and,O
is,O
still,O
used,O
in,O
most,O
new,O
telephone,O
designs,O
[,O
17,O
].,O
DTMF,O
tones,O
can,O
be,O
easily,O
heard,O
by,O
pressing,O
the,O
keys,O
on,O
a,O
phone,O
during,O
a,O
telephone,O
call,O
.,O
The,O
system,O
is,O
composed,O
of,O
16,O
different,O
audio,O
frequencies,O
organized,O
in,O
a,O
4,O
×,O
4,O
matrix,O
.,O
Table,O
1,O
shows,O
these,O
frequencies,O
and,O
the,O
corresponding,O
keys,O
/,O
digits,O
.,O
A,O
valid,O
digit,O
is,O
always,O
composed,O
by,O
a,O
pair,O
of,O
frequencies,O
(,O
one,O
from,O
the,O
table,O
columns,O
and,O
one,O
from,O
the,O
table,O
rows,O
),O
transmitted,O
simultaneously,O
.,O
For,O
example,O
",",O
to,O
transmit,O
the,O
digit,O
9,O
",",O
an,O
audio,O
signal,O
containing,O
the,O
frequencies,O
852,O
Hz,O
and,O
1,O
",",O
477,O
Hz,O
would,O
have,O
to,O
be,O
generated,O
.,O
As,O
DTMF,O
was,O
designed,O
to,O
exchange,O
data,O
via,O
telephone,O
lines,O
that,O
can,O
be,O
noisy,O
",",O
the,O
use,O
of,O
2,O
frequencies,O
to,O
uniquely,O
identify,O
a,O
digit,O
makes,O
the,O
system,O
efficient,O
and,O
very,O
robust,O
to,O
noise,O
and,O
other,O
sounds,O
that,O
do,O
not,O
characterize,O
a,O
valid,O
DTMF,O
digit,O
.,O
In,O
fact,O
",",O
when,O
the,O
DTMF,O
system,O
was,O
designed,O
",",O
the,O
frequencies,O
were,O
chosen,O
to,O
minimize,O
tone,O
pairs,O
from,O
natural,O
sounds,O
[,O
18,O
].,O
The,O
described,O
robustness,O
of,O
DTMF,O
led,O
its,O
use,O
in,O
a,O
variety,O
of,O
current,O
remote,O
automation,O
systems,O
such,O
as,O
residential,O
alarm,O
monitoring,O
",",O
vehicle,O
tracking,O
systems,O
and,O
interactive,O
voice,O
response,O
systems,O
such,O
as,O
bank,O
’,O
s,O
automatic,O
answering,O
machines,O
menus,O
that,O
allows,O
the,O
user,O
to,O
execute,O
interactive,O
operations,O
like,O
“,O
Press,O
1,O
to,O
check,O
your,O
account,O
balance,O
;,O
Press,O
2,O
to,O
block,O
your,O
credit,O
card,O
”.,O
The,O
wide,O
adoption,O
and,O
reliability,O
of,O
the,O
DTMF,O
system,O
led,O
the,O
semiconductor,O
industry,O
to,O
develop,O
low,O
cost,O
integrated,O
circuits,O
(,O
ICs,O
),O
that,O
can,O
encode,O
and,O
decode,O
DTMF,O
signals,O
from,O
and,O
to,O
digital,O
binary,O
digits,O
.,O
The,O
system,O
proposed,O
in,O
this,O
article,O
uses,O
such,O
ICs,O
to,O
transmit,O
and,O
receive,O
information,O
.,O
Both,O
actuators,O
control,O
and,O
sensors,O
data,O
are,O
encoded,O
using,O
DTMF,O
tones,O
.,O
The,O
following,O
sections,O
describe,O
the,O
system,O
design,O
.,O
Device,O
Control,O
To,O
control,O
actuators,O
",",O
a,O
mobile,O
device,O
generates,O
a,O
DTMF,O
tone,O
.,O
The,O
tone,O
is,O
decoded,O
by,O
a,O
commercial,O
DTMF,O
decoder,O
chip,O
(,O
such,O
as,O
the,O
MT8870,O
"),",O
converting,O
the,O
tone,O
to,O
a,O
4,O
-,O
bit,O
binary,O
word,O
equivalent,O
to,O
the,O
DTMF,O
input,O
.,O
The,O
decoded,O
output,O
remains,O
present,O
while,O
the,O
DTMF,O
tone,O
is,O
present,O
at,O
the,O
input,O
.,O
The,O
resulting,O
bits,O
can,O
feed,O
a,O
power,O
circuit,O
to,O
control,O
up,O
to,O
four,O
independent,O
binary,O
(,O
on,O
/,O
off,O
),O
devices,O
such,O
as,O
robots,O
brakes,O
",",O
lights,O
or,O
a,O
pneumatic,O
gripper,O
.,O
Figure,O
1,O
shows,O
the,O
basic,O
concept,O
of,O
the,O
system,O
.,O
The,O
audio,O
output,O
from,O
the,O
mobile,O
device,O
can,O
be,O
directly,O
connected,O
to,O
the,O
input,O
of,O
the,O
DTMF,O
decoder,O
",",O
but,O
in,O
some,O
specific,O
cases,O
an,O
audio,O
preamplifier,O
should,O
be,O
used,O
to,O
enhance,O
the,O
audio,O
amplitude,O
.,O
Figure,O
2,O
shows,O
a,O
direct,O
current,O
(,O
DC,O
),O
motor,O
control,O
application,O
where,O
the,O
4,O
-,O
bit,O
output,O
of,O
the,O
decoder,O
is,O
connected,O
to,O
a,O
motor,O
control,O
circuit,O
(,O
an,O
H,O
-,O
bridge,O
",",O
for,O
example,O
",",O
using,O
the,O
L298,O
commercial,O
dual,O
H,O
-,O
bridge,O
IC,O
).,O
As,O
2,O
bits,O
are,O
required,O
to,O
control,O
each,O
motor,O
",",O
the,O
system,O
can,O
control,O
2,O
DC,O
motors,O
independently,O
.,O
Table,O
2,O
shows,O
the,O
DTMF,O
digits,O
and,O
corresponding,O
motor,O
states,O
.,O
Note,O
that,O
these,O
states,O
can,O
be,O
different,O
according,O
to,O
the,O
pin,O
connections,O
between,O
the,O
DTMF,O
decoder,O
and,O
the,O
H,O
-,O
bridge,O
.,O
In,O
order,O
to,O
control,O
the,O
DC,O
motor,O
’,O
s,O
speed,O
",",O
the,O
mobile,O
device,O
turns,O
the,O
DTMF,O
signals,O
on,O
and,O
off,O
in,O
a,O
fixed,O
frequency,O
",",O
mimicking,O
a,O
pulse,O
width,O
modulation,O
(,O
PWM,O
),O
signal,O
.,O
To,O
control,O
more,O
devices,O
it,O
is,O
possible,O
to,O
take,O
advantage,O
of,O
the,O
fact,O
that,O
most,O
audio,O
outputs,O
of,O
mobile,O
devices,O
are,O
stereo,O
.,O
Thus,O
",",O
generating,O
different,O
audio,O
tones,O
in,O
the,O
left,O
and,O
right,O
channels,O
doubles,O
the,O
number,O
of,O
controlled,O
devices,O
(,O
8,O
different,O
on,O
/,O
off,O
devices,O
or,O
4,O
DC,O
motors,O
).,O
One,O
interesting,O
option,O
",",O
possible,O
only,O
in,O
devices,O
with,O
USB,O
Host,O
feature,O
",",O
such,O
as,O
netbooks,O
and,O
desktop,O
computers,O
",",O
is,O
to,O
add,O
low,O
cost,O
USB,O
multimedia,O
sound,O
devices,O
",",O
increasing,O
the,O
number,O
of,O
audio,O
ports,O
in,O
the,O
system,O
.,O
Another,O
possibility,O
consists,O
in,O
directly,O
connecting,O
servo,O
-,O
motors,O
(,O
the,O
ones,O
used,O
in,O
model,O
airplanes,O
),O
control,O
signals,O
to,O
the,O
output,O
of,O
the,O
DTMF,O
decoder,O
.,O
As,O
each,O
servo,O
needs,O
only,O
one,O
PWM,O
input,O
signal,O
",",O
each,O
stereo,O
audio,O
channel,O
can,O
drive,O
up,O
to,O
eight,O
servo,O
-,O
motors,O
.,O
Sensor,O
Reading,O
Most,O
mechatronics,O
systems,O
and,O
sensor,O
networks,O
need,O
sensors,O
to,O
sense,O
the,O
surrounding,O
environment,O
and,O
their,O
own,O
state,O
in,O
order,O
to,O
decide,O
what,O
to,O
do,O
next,O
.,O
To,O
accomplish,O
this,O
task,O
in,O
this,O
system,O
",",O
sensors,O
are,O
connected,O
to,O
the,O
input,O
of,O
a,O
DTMF,O
encoder,O
chip,O
(,O
such,O
as,O
the,O
TCM5087,O
).,O
Each,O
time,O
a,O
sensor,O
state,O
changes,O
",",O
the,O
encoder,O
generates,O
a,O
DTMF,O
tone,O
that,O
is,O
captured,O
and,O
analyzed,O
by,O
the,O
mobile,O
device,O
.,O
According,O
to,O
the,O
digits,O
received,O
it,O
is,O
possible,O
to,O
know,O
which,O
sensor,O
generated,O
the,O
tone,O
.,O
More,O
details,O
on,O
how,O
to,O
identify,O
which,O
sensor,O
and,O
its,O
value,O
are,O
provided,O
in,O
Section,O
5,O
.,O
1,O
.,O
As,O
shown,O
in,O
Figure,O
3,O
",",O
up,O
to,O
four,O
sensors,O
can,O
be,O
connected,O
to,O
a,O
DTMF,O
encoder,O
that,O
generates,O
tones,O
according,O
to,O
the,O
sensors,O
states,O
.,O
The,O
generator,O
’,O
s,O
output,O
itself,O
is,O
connected,O
to,O
the,O
audio,O
input,O
of,O
the,O
mobile,O
device,O
which,O
continuously,O
samples,O
the,O
audio,O
input,O
checking,O
if,O
the,O
frequency,O
pair,O
that,O
characterizes,O
a,O
DTMF,O
digit,O
is,O
present,O
in,O
the,O
signal,O
.,O
To,O
accomplish,O
this,O
task,O
",",O
the,O
discrete,O
Fourier,O
transform,O
(,O
DFT,O
),O
is,O
used,O
",",O
according,O
to,O
Equation,O
(,O
1,O
).,O
(,O
1,O
),O
X,O
(,O
m,O
)=∑,O
n,O
=,O
0N,O
−,O
1x,O
(,O
n,O
),O
e,O
−,O
j2πnm,O
/,O
Nwhere,O
X,O
(,O
m,O
),O
is,O
the,O
frequency,O
magnitude,O
of,O
the,O
signal,O
under,O
analysis,O
at,O
index,O
m,O
",",O
x,O
(,O
n,O
),O
is,O
the,O
input,O
sequence,O
in,O
time,O
(,O
representing,O
the,O
signal,O
),O
with,O
n,O
index,O
and,O
N,O
is,O
the,O
DFT,O
number,O
of,O
points,O
.,O
N,O
determines,O
the,O
resolution,O
of,O
the,O
DFT,O
and,O
the,O
number,O
of,O
samples,O
to,O
be,O
analyzed,O
.,O
For,O
performance,O
reasons,O
",",O
a,O
Fast,O
Fourier,O
Transform,O
(,O
FFT,O
),O
[,O
19,O
],O
is,O
used,O
to,O
identify,O
the,O
frequency,O
components,O
of,O
the,O
input,O
signal,O
and,O
consequently,O
detect,O
the,O
DTMF,O
digit,O
generated,O
by,O
the,O
DTMF,O
generator,O
that,O
encodes,O
sensor,O
data,O
.,O
For,O
clear,O
and,O
detailed,O
information,O
about,O
these,O
digital,O
signal,O
processing,O
concepts,O
",",O
please,O
refer,O
to,O
Lyons,O
’,O
book,O
[,O
20,O
],O
on,O
Digital,O
Signal,O
Processing,O
.,O
To,O
optimize,O
the,O
FFT,O
computation,O
it,O
is,O
necessary,O
to,O
specify,O
adequate,O
values,O
for,O
N,O
and,O
Fs,O
(,O
the,O
sample,O
rate,O
of,O
the,O
input,O
signal,O
).,O
From,O
Table,O
1,O
",",O
the,O
highest,O
frequency,O
present,O
in,O
a,O
DTMF,O
tone,O
is,O
1,O
",",O
633,O
Hz,O
.,O
Applying,O
the,O
fundamental,O
sampling,O
theorem,O
results,O
in,O
Fs,O
=,O
3,O
",",O
266,O
Hz,O
(,O
the,O
theorem,O
states,O
that,O
the,O
sample,O
rate,O
should,O
be,O
at,O
least,O
twice,O
the,O
highest,O
signal,O
to,O
be,O
captured,O
).,O
For,O
implementation,O
convenience,O
and,O
better,O
compatibility,O
",",O
a,O
8,O
KHz,O
sample,O
rate,O
is,O
used,O
",",O
which,O
most,O
mobile,O
devices,O
can,O
perform,O
.,O
The,O
lower,O
the,O
number,O
of,O
points,O
in,O
the,O
FFT,O
",",O
the,O
faster,O
the,O
FFT,O
is,O
computed,O
",",O
and,O
more,O
digits,O
per,O
second,O
can,O
be,O
recognized,O
",",O
leading,O
to,O
a,O
better,O
sensor,O
reading,O
frequency,O
.,O
To,O
compute,O
the,O
smallest,O
adequate,O
number,O
of,O
points,O
for,O
the,O
FFT,O
",",O
Equation,O
(,O
2,O
),O
is,O
used,O
.,O
(,O
2,O
),O
f,O
(,O
m,O
)=,O
mFsN,O
In,O
Equation,O
(,O
2,O
"),",O
f,O
(,O
m,O
),O
is,O
each,O
frequency,O
under,O
analysis,O
",",O
Fs,O
is,O
the,O
sampling,O
frequency,O
(,O
8,O
KHz,O
),O
and,O
N,O
the,O
FFT,O
’,O
s,O
number,O
of,O
points,O
to,O
be,O
minimized,O
.,O
Using,O
N,O
=,O
256,O
",",O
results,O
in,O
an,O
analysis,O
resolution,O
of,O
about,O
30,O
Hz,O
",",O
that,O
is,O
enough,O
to,O
differ,O
from,O
one,O
DTMF,O
frequency,O
component,O
to,O
another,O
.,O
This,O
is,O
consistent,O
with,O
the,O
DFT,O
parameters,O
used,O
by,O
Chitode,O
to,O
detect,O
DTMF,O
digits,O
[,O
21,O
].,O
The,O
work,O
developed,O
by,O
Khan,O
also,O
uses,O
N,O
=,O
256,O
and,O
Fs,O
=,O
8,O
KHz,O
to,O
detect,O
DTMF,O
tones,O
[,O
22,O
].,O
Later,O
in,O
this,O
text,O
",",O
Section,O
5,O
.,O
1,O
and,O
Table,O
3,O
explains,O
the,O
use,O
and,O
application,O
of,O
this,O
technique,O
to,O
read,O
four,O
digital,O
(,O
on,O
/,O
off,O
),O
sensors,O
simultaneously,O
.,O
One,O
of,O
the,O
limitations,O
of,O
the,O
described,O
method,O
is,O
that,O
it,O
is,O
restricted,O
to,O
binary,O
(,O
on,O
/,O
off,O
),O
sensors,O
.,O
As,O
it,O
is,O
shown,O
is,O
Section,O
5,O
.,O
1,O
",",O
this,O
is,O
enough,O
for,O
many,O
applications,O
",",O
including,O
measuring,O
angles,O
and,O
speeds,O
using,O
incremental,O
optical,O
encoders,O
.,O
In,O
any,O
case,O
",",O
additional,O
electronics,O
could,O
be,O
used,O
to,O
encode,O
analog,O
signals,O
and,O
transmit,O
these,O
signals,O
using,O
the,O
audio,O
interface,O
.,O
As,O
each,O
DTMF,O
digit,O
encodes,O
4,O
bits,O
",",O
the,O
transmission,O
of,O
an,O
analog,O
value,O
converted,O
with,O
a,O
12,O
-,O
bit,O
analog,O
-,O
digital,O
converter,O
would,O
take,O
3,O
transmission,O
cycles,O
.,O
It,O
would,O
also,O
be,O
possible,O
to,O
use,O
digital,O
signal,O
multiplexing,O
hardware,O
to,O
encode,O
more,O
information,O
in,O
the,O
same,O
system,O
(,O
with,O
worse,O
performance,O
).,O
The,O
demultiplexing,O
would,O
be,O
done,O
in,O
the,O
mobile,O
device,O
by,O
software,O
.,O
Experimental,O
Results,O
In,O
order,O
to,O
evaluate,O
the,O
proposed,O
system,O
",",O
an,O
Android,O
application,O
was,O
developed,O
using,O
the,O
Android,O
development,O
kit,O
",",O
which,O
is,O
available,O
for,O
free,O
.,O
Experiments,O
were,O
executed,O
in,O
several,O
mobile,O
devices,O
and,O
desktop,O
computers,O
.,O
For,O
the,O
actuator,O
control,O
subsystem,O
",",O
experiments,O
showed,O
that,O
generating,O
PWM,O
signals,O
by,O
software,O
is,O
possible,O
",",O
but,O
the,O
resulting,O
signal,O
shows,O
variations,O
(,O
a,O
software,O
generated,O
PWM,O
with,O
1,O
ms,O
ON,O
time,O
and,O
1,O
ms,O
OFF,O
time,O
produces,O
a,O
real,O
signal,O
with,O
50,O
ms,O
ON,O
time,O
and,O
50,O
ms,O
OFF,O
time,O
).,O
A,O
better,O
option,O
is,O
to,O
use,O
pre,O
-,O
recorded,O
PWM,O
DTMF,O
tones,O
resulting,O
in,O
high,O
reliability,O
PWM,O
of,O
DTMF,O
tones,O
with,O
frequencies,O
greater,O
than,O
1,O
KHz,O
.,O
As,O
mobile,O
devices,O
have,O
mature,O
software,O
support,O
for,O
playing,O
pre,O
-,O
recorded,O
audio,O
",",O
the,O
PWM,O
plays,O
smoothly,O
with,O
low,O
processor,O
usage,O
.,O
In,O
these,O
experiments,O
it,O
was,O
also,O
observed,O
that,O
another,O
practical,O
way,O
of,O
doing,O
fine,O
speed,O
adjustments,O
consists,O
in,O
controlling,O
the,O
audio,O
output,O
volume,O
",",O
resulting,O
in,O
proportional,O
speed,O
changes,O
in,O
the,O
motor,O
(,O
s,O
).,O
Experiments,O
of,O
the,O
sensor,O
reading,O
subsystem,O
are,O
based,O
on,O
the,O
FFT,O
.,O
The,O
experiments,O
showed,O
that,O
in,O
the,O
worst,O
case,O
",",O
the,O
FFT,O
computation,O
time,O
is,O
17,O
ms,O
",",O
leading,O
to,O
a,O
theoretical,O
limit,O
of,O
executing,O
up,O
to,O
58,O
.,O
8,O
FFTs,O
per,O
second,O
.,O
Figure,O
4,O
shows,O
experimental,O
results,O
of,O
the,O
system,O
running,O
on,O
3,O
different,O
devices,O
.,O
The,O
tested,O
devices,O
were,O
an,O
early,O
Android,O
based,O
phone,O
",",O
the,O
HTC,O
G1,O
with,O
a,O
528,O
MHz,O
ARM,O
processor,O
",",O
an,O
Android,O
based,O
tablet,O
computer,O
with,O
a,O
dual,O
core,O
1,O
GHz,O
ARM,O
processor,O
and,O
a,O
1,O
GHz,O
PC,O
netbook,O
with,O
an,O
Intel,O
Celeron,O
processor,O
(,O
in,O
this,O
case,O
a,O
version,O
of,O
the,O
Android,O
operating,O
system,O
for,O
the,O
x86,O
architecture,O
was,O
used,O
).,O
The,O
FFT,O
was,O
implemented,O
using,O
Java,O
and,O
executed,O
in,O
the,O
virtual,O
machine,O
(,O
dalvik,O
),O
of,O
the,O
Android,O
system,O
.,O
Using,O
the,O
native,O
development,O
system,O
for,O
Android,O
",",O
thus,O
bypassing,O
the,O
virtual,O
machine,O
",",O
would,O
enhance,O
these,O
results,O
.,O
Another,O
performance,O
improvement,O
can,O
be,O
reached,O
using,O
the,O
Goertzel,O
algorithm,O
[,O
23,O
",",O
24,O
].,O
From,O
Figure,O
4,O
it,O
is,O
possible,O
to,O
note,O
that,O
even,O
the,O
device,O
with,O
less,O
processing,O
power,O
is,O
able,O
to,O
handle,O
about,O
40,O
DTMF,O
digits,O
per,O
second,O
with,O
zero,O
packet,O
loss,O
.,O
There,O
are,O
several,O
causes,O
for,O
the,O
increasing,O
packet,O
loss,O
that,O
starts,O
at,O
40,O
Hz,O
in,O
the,O
plot,O
.,O
One,O
of,O
the,O
causes,O
are,O
the,O
different,O
audio,O
input,O
timings,O
[,O
25,O
],O
caused,O
by,O
the,O
different,O
audio,O
hardware,O
of,O
each,O
device,O
.,O
Another,O
cause,O
is,O
related,O
to,O
the,O
task,O
scheduler,O
of,O
the,O
Android,O
operating,O
system,O
(,O
and,O
the,O
underlying,O
Linux,O
kernel,O
),O
that,O
can,O
be,O
indeterministic,O
when,O
the,O
CPU,O
load,O
is,O
high,O
.,O
As,O
a,O
reference,O
for,O
comparison,O
",",O
some,O
performance,O
tests,O
were,O
made,O
in,O
a,O
Lego,O
Mindstorms,O
(,O
TM,O
),O
robotics,O
kit,O
that,O
is,O
commonly,O
used,O
in,O
educational,O
robotics,O
and,O
some,O
scientific,O
researches,O
.,O
When,O
connected,O
to,O
a,O
computer,O
or,O
smartphone,O
via,O
a,O
bluetooth,O
wireless,O
link,O
",",O
the,O
maximum,O
sensor,O
reading,O
rate,O
of,O
the,O
Lego,O
-,O
NXT,O
brick,O
is,O
20,O
Hz,O
.,O
If,O
several,O
sensors,O
are,O
used,O
",",O
the,O
bandwidth,O
is,O
divided,O
.,O
For,O
example,O
",",O
using,O
2,O
encoders,O
and,O
2,O
touch,O
sensors,O
reduces,O
the,O
sensor,O
reading,O
rate,O
to,O
5,O
Hz,O
per,O
sensor,O
or,O
less,O
.,O
If,O
the,O
NXT,O
brick,O
is,O
connected,O
to,O
a,O
computer,O
using,O
the,O
USB,O
port,O
",",O
then,O
the,O
maximum,O
sensor,O
reading,O
frequency,O
rises,O
to,O
166,O
Hz,O
.,O
If,O
two,O
encoders,O
and,O
two,O
touch,O
sensors,O
(,O
bumpers,O
),O
are,O
used,O
",",O
then,O
each,O
sensor,O
will,O
be,O
read,O
at,O
a,O
rate,O
of,O
41,O
.,O
5,O
Hz,O
.,O
The,O
performance,O
of,O
the,O
system,O
proposed,O
in,O
this,O
article,O
is,O
comparable,O
to,O
this,O
commercial,O
product,O
as,O
a,O
40,O
Hz,O
rate,O
can,O
be,O
sustained,O
for,O
each,O
sensor,O
in,O
a,O
system,O
with,O
4,O
sensors,O
.,O
Case,O
Study,O
Application,O
The,O
system,O
described,O
in,O
Section,O
3,O
can,O
be,O
applied,O
to,O
several,O
situations,O
where,O
a,O
computing,O
device,O
needs,O
to,O
control,O
actuators,O
and,O
read,O
sensors,O
",",O
such,O
as,O
laboratory,O
experiments,O
",",O
machine,O
control,O
and,O
robotics,O
.,O
In,O
this,O
section,O
",",O
a,O
mobile,O
robot,O
case,O
study,O
is,O
described,O
.,O
Low,O
Cost,O
Mobile,O
Robot,O
As,O
an,O
application,O
example,O
",",O
the,O
presented,O
technique,O
was,O
used,O
to,O
build,O
a,O
low,O
cost,O
educational,O
mobile,O
robot,O
.,O
For,O
the,O
Robot,O
’,O
s,O
frame,O
",",O
wheels,O
",",O
gears,O
and,O
two,O
motors,O
24,O
US,O
dollars,O
were,O
spent,O
.,O
For,O
electronics,O
parts,O
more,O
6,O
US,O
dollars,O
were,O
spent,O
summing,O
up,O
a,O
total,O
of,O
30,O
US,O
dollars,O
to,O
build,O
the,O
robot,O
.,O
As,O
most,O
people,O
own,O
a,O
mobile,O
phone,O
or,O
a,O
smartphone,O
",",O
there,O
is,O
the,O
assumption,O
that,O
the,O
control,O
device,O
will,O
not,O
have,O
to,O
be,O
bought,O
because,O
a,O
mobile,O
device,O
that,O
the,O
user,O
already,O
has,O
will,O
be,O
used,O
.,O
Even,O
if,O
the,O
control,O
device,O
needed,O
to,O
be,O
purchased,O
",",O
the,O
option,O
of,O
using,O
a,O
smartphone,O
would,O
still,O
be,O
good,O
because,O
single,O
board,O
computers,O
",",O
typically,O
used,O
in,O
robots,O
or,O
other,O
robot,O
computers,O
",",O
are,O
more,O
expensive,O
than,O
smartphones,O
.,O
Furthermore,O
",",O
smartphones,O
include,O
camera,O
",",O
battery,O
",",O
Internet,O
connection,O
and,O
a,O
variety,O
of,O
sensors,O
that,O
would,O
have,O
to,O
be,O
bought,O
separately,O
and,O
connected,O
to,O
the,O
robot,O
’,O
s,O
computer,O
.,O
With,O
multi,O
-,O
core,O
smartphones,O
running,O
with,O
clock,O
speeds,O
faster,O
than,O
1,O
GHz,O
and,O
with,O
512,O
MB,O
or,O
1,O
GB,O
of,O
RAM,O
memory,O
",",O
they,O
are,O
a,O
good,O
alternative,O
to,O
traditional,O
robots,O
computers,O
.,O
Important,O
sensors,O
in,O
such,O
kind,O
of,O
robot,O
are,O
the,O
bumpers,O
to,O
detect,O
collisions,O
and,O
encoders,O
to,O
compute,O
odometry,O
.,O
Figure,O
5,O
shows,O
a,O
block,O
diagram,O
connecting,O
bumpers,O
and,O
2,O
wheel,O
encoders,O
to,O
the,O
DTMF,O
generator,O
.,O
Table,O
3,O
shows,O
a,O
truth,O
table,O
with,O
the,O
possible,O
states,O
of,O
each,O
sensor,O
and,O
the,O
corresponding,O
DTMF,O
digits,O
.,O
Instead,O
of,O
using,O
commercial,O
encoders,O
discs,O
",",O
several,O
encoders,O
were,O
designed,O
and,O
printed,O
with,O
a,O
conventional,O
laser,O
printer,O
.,O
The,O
discs,O
were,O
glued,O
to,O
the,O
robot,O
’,O
s,O
wheels,O
and,O
a,O
standard,O
CNY70,O
light,O
reflection,O
sensor,O
was,O
mounted,O
in,O
front,O
of,O
each,O
disc,O
.,O
As,O
can,O
be,O
seen,O
in,O
Table,O
3,O
",",O
there,O
is,O
a,O
unique,O
DTMF,O
digit,O
that,O
corresponds,O
to,O
each,O
possible,O
sensor,O
state,O
.,O
Using,O
basic,O
binary,O
arithmetic,O
it,O
is,O
possible,O
to,O
obtain,O
the,O
individual,O
state,O
of,O
each,O
sensor,O
.,O
For,O
example,O
",",O
from,O
Table,O
3,O
it,O
is,O
known,O
that,O
the,O
bumpers,O
are,O
the,O
bits,O
0,O
and,O
1,O
.,O
Using,O
a,O
bitwise,O
AND,O
operation,O
with,O
the,O
binary,O
mask,O
0001,O
will,O
filter,O
all,O
other,O
sensor,O
states,O
and,O
the,O
result,O
will,O
be,O
either,O
0,O
or,O
1,O
",",O
indicating,O
the,O
left,O
bumper,O
state,O
.,O
For,O
the,O
right,O
bumper,O
",",O
the,O
same,O
AND,O
operation,O
can,O
be,O
applied,O
with,O
the,O
binary,O
mask,O
0010,O
.,O
Furthermore,O
",",O
using,O
the,O
binary,O
0011,O
mask,O
and,O
the,O
AND,O
operation,O
will,O
only,O
return,O
a,O
value,O
different,O
than,O
zero,O
if,O
both,O
bumpers,O
are,O
activate,O
at,O
the,O
same,O
time,O
.,O
Using,O
these,O
types,O
of,O
comparisons,O
it,O
is,O
then,O
possible,O
to,O
know,O
the,O
state,O
of,O
each,O
sensor,O
.,O
In,O
the,O
case,O
of,O
the,O
optical,O
encoders,O
",",O
the,O
system,O
’,O
s,O
software,O
monitors,O
for,O
state,O
transitions,O
and,O
add,O
a,O
unit,O
for,O
each,O
transition,O
to,O
a,O
counter,O
that,O
keeps,O
how,O
many,O
pulses,O
each,O
encoder,O
generated,O
.,O
As,O
seen,O
in,O
the,O
Figure,O
5,O
",",O
up,O
to,O
four,O
sensors,O
can,O
be,O
connected,O
to,O
each,O
mono,O
audio,O
channel,O
",",O
allowing,O
closed,O
loop,O
control,O
of,O
up,O
to,O
4,O
motors,O
if,O
4,O
encoders,O
are,O
used,O
.,O
Using,O
the,O
number,O
of,O
pulses,O
accounted,O
for,O
each,O
encoder,O
it,O
is,O
possible,O
to,O
compute,O
displacement,O
and,O
speed,O
for,O
each,O
wheel,O
as,O
it,O
is,O
done,O
with,O
other,O
incremental,O
encoders,O
.,O
This,O
information,O
can,O
be,O
used,O
in,O
classical,O
odometry,O
and,O
localization,O
systems,O
to,O
obtain,O
the,O
robot,O
’,O
s,O
position,O
in,O
a,O
Cartesian,O
space,O
[,O
26,O
",",O
27,O
].,O
To,O
properly,O
design,O
a,O
robot,O
with,O
the,O
presented,O
technique,O
",",O
a,O
relation,O
between,O
wheel,O
dimensions,O
and,O
the,O
maximum,O
linear,O
speed,O
that,O
can,O
be,O
measured,O
is,O
introduced,O
here,O
.,O
In,O
Equation,O
(,O
3,O
"),",O
VMax,O
is,O
the,O
maximum,O
linear,O
speed,O
of,O
the,O
robot,O
that,O
can,O
be,O
measured,O
",",O
r,O
is,O
radius,O
of,O
the,O
wheel,O
",",O
c,O
is,O
the,O
maximum,O
digits,O
per,O
second,O
detection,O
capacity,O
of,O
the,O
mobile,O
device,O
and,O
s,O
is,O
the,O
encoder,O
disc,O
resolution,O
(,O
number,O
of,O
DTMF,O
digits,O
generated,O
at,O
each,O
complete,O
wheel,O
revolution,O
).,O
(,O
3,O
),O
VMax,O
=,O
2πrcs,O
Table,O
4,O
shows,O
the,O
distance,O
measurement,O
resolution,O
and,O
maximum,O
speed,O
that,O
can,O
be,O
measured,O
according,O
to,O
the,O
given,O
equation,O
considering,O
several,O
encoder,O
resolutions,O
.,O
Figure,O
6,O
shows,O
odometry,O
experimental,O
results,O
for,O
this,O
low,O
cost,O
robot,O
.,O
The,O
error,O
bars,O
are,O
the,O
standard,O
deviation,O
of,O
the,O
real,O
displacement,O
that,O
occurred,O
.,O
The,O
blue,O
line,O
shows,O
the,O
real,O
traveled,O
distance,O
and,O
the,O
red,O
line,O
shows,O
the,O
distance,O
measured,O
by,O
the,O
mobile,O
phone,O
using,O
the,O
proposed,O
technique,O
.,O
Each,O
point,O
in,O
the,O
graph,O
is,O
the,O
average,O
value,O
of,O
ten,O
samples,O
.,O
According,O
to,O
McComb,O
and,O
Predko,O
",",O
odometry,O
errors,O
are,O
unavoidable,O
due,O
to,O
several,O
factors,O
such,O
as,O
wheels,O
’,O
slip,O
and,O
small,O
measurement,O
errors,O
in,O
the,O
wheel,O
radius,O
that,O
accumulate,O
over,O
time,O
.,O
They,O
say,O
that,O
a,O
displacements,O
of,O
6,O
to,O
9,O
meters,O
leads,O
to,O
15,O
centimeters,O
odometer,O
error,O
[,O
28,O
],O
or,O
more,O
",",O
which,O
is,O
a,O
percentual,O
error,O
of,O
1,O
.,O
6,O
%–,O
2,O
.,O
5,O
%.,O
The,O
greatest,O
odometry,O
error,O
of,O
the,O
system,O
was,O
3,O
.,O
7,O
%,O
for,O
74,O
cm,O
range,O
.,O
But,O
for,O
130,O
cm,O
displacements,O
the,O
error,O
was,O
1,O
centimeter,O
(,O
0,O
.,O
76,O
%).,O
These,O
values,O
show,O
that,O
the,O
proposed,O
system,O
performance,O
is,O
consistent,O
with,O
classical,O
odometry,O
errors,O
described,O
in,O
the,O
literature,O
.,O
To,O
close,O
the,O
control,O
loop,O
",",O
the,O
computed,O
odometry,O
information,O
is,O
sent,O
to,O
a,O
classical,O
PI,O
(,O
Proportional,O
-,O
Integral,O
),O
controller,O
that,O
has,O
as,O
set,O
-,O
points,O
(,O
or,O
goals,O
),O
the,O
desired,O
distance,O
to,O
be,O
displaced,O
by,O
the,O
robot,O
.,O
The,O
encoders,O
are,O
read,O
at,O
a,O
40,O
Hz,O
rate,O
",",O
the,O
position,O
is,O
computed,O
and,O
sent,O
to,O
the,O
controller,O
to,O
decide,O
if,O
the,O
robot,O
has,O
to,O
go,O
faster,O
",",O
stop,O
or,O
walk,O
.,O
If,O
any,O
of,O
the,O
bumpers,O
are,O
activated,O
in,O
the,O
meantime,O
",",O
the,O
control,O
loop,O
is,O
interrupted,O
and,O
the,O
robot,O
immediately,O
stops,O
.,O
Although,O
most,O
mobile,O
devices,O
have,O
the,O
possibility,O
of,O
recording,O
and,O
reproducing,O
sounds,O
",",O
not,O
all,O
of,O
them,O
have,O
physical,O
connectors,O
for,O
both,O
the,O
audio,O
input,O
and,O
output,O
.,O
To,O
solve,O
this,O
problem,O
in,O
one,O
of,O
the,O
tested,O
devices,O
that,O
does,O
not,O
have,O
an,O
audio,O
input,O
connector,O
",",O
an,O
earphone,O
is,O
attached,O
near,O
the,O
built,O
-,O
in,O
microphone,O
of,O
the,O
device,O
using,O
a,O
suction,O
cup,O
.,O
In,O
this,O
particular,O
case,O
",",O
an,O
audio,O
preamplifier,O
must,O
be,O
used,O
to,O
generate,O
tones,O
with,O
sufficient,O
amplitude,O
to,O
be,O
detected,O
.,O
The,O
DTMF,O
tones,O
encoding,O
sensors,O
data,O
is,O
generated,O
",",O
amplified,O
and,O
sent,O
to,O
the,O
earphone,O
fixed,O
very,O
near,O
the,O
built,O
-,O
in,O
microphone,O
of,O
the,O
mobile,O
device,O
.,O
It,O
is,O
worth,O
mentioning,O
that,O
this,O
scheme,O
works,O
reliably,O
because,O
DTMF,O
system,O
was,O
designed,O
to,O
avoid,O
interference,O
from,O
natural,O
sounds,O
such,O
as,O
music,O
and,O
people,O
’,O
s,O
voices,O
[,O
18,O
].,O
Human,B-OG
Machine,O
Interface,O
Users,O
can,O
control,O
this,O
robot,O
from,O
the,O
web,O
or,O
using,O
voice,O
commands,O
.,O
Both,O
a,O
web,O
server,O
and,O
a,O
voice,O
recognition,O
system,O
were,O
implemented,O
.,O
The,O
web,O
-,O
server,O
is,O
embedded,O
into,O
the,O
application,O
",",O
therefore,O
no,O
intermediate,O
computers,O
or,O
servers,O
are,O
needed,O
.,O
Any,O
Internet,O
enabled,O
device,O
can,O
access,O
the,O
web,O
-,O
page,O
and,O
issue,O
several,O
commands,O
to,O
move,O
the,O
robot,O
forward,O
",",O
back,O
",",O
or,O
do,O
curves,O
.,O
For,O
debugging,O
purposes,O
the,O
web,O
-,O
server,O
also,O
shows,O
variable,O
values,O
such,O
as,O
distance,O
",",O
encoder,O
pulses,O
and,O
recognized,O
DTMF,O
pulses,O
from,O
sensors,O
.,O
The,O
voice,O
recognizer,O
system,O
is,O
straightforward,O
to,O
implement,O
thanks,O
to,O
the,O
Android,O
API,O
.,O
When,O
the,O
user,O
issues,O
a,O
voice,O
command,O
",",O
the,O
operating,O
systems,O
understands,O
it,O
(,O
in,O
several,O
languages,O
),O
and,O
passes,O
a,O
vector,O
of,O
strings,O
to,O
the,O
robot,O
’,O
s,O
control,O
application,O
with,O
the,O
most,O
probable,O
phrases,O
said,O
.,O
The,O
application,O
just,O
has,O
to,O
select,O
the,O
one,O
that,O
better,O
fits,O
the,O
expected,O
command,O
.,O
Example,O
voice,O
commands,O
are,O
“,O
Walk,O
30,O
centimeters,O
”,O
or,O
“,O
Forward,O
1,O
meter,O
”.,O
The,O
numbers,O
said,O
by,O
the,O
user,O
are,O
automatically,O
converted,O
to,O
numeric,O
values,O
by,O
the,O
Android,O
API,O
",",O
making,O
it,O
easy,O
to,O
implement,O
softwares,O
that,O
makes,O
the,O
robot,O
move,O
for,O
some,O
distance,O
using,O
closed,O
loop,O
control,O
.,O
Distance,O
Measurement,O
An,O
important,O
sensor,O
to,O
aid,O
the,O
navigation,O
of,O
autonomous,O
mobile,O
robots,O
is,O
the,O
distance,O
measurement,O
from,O
the,O
robot,O
to,O
obstacles,O
in,O
front,O
of,O
it,O
.,O
This,O
task,O
is,O
typically,O
performed,O
by,O
ultrasound,O
or,O
laser,O
sensors,O
.,O
Another,O
approach,O
is,O
based,O
on,O
stereo,O
vision,O
",",O
but,O
the,O
computational,O
costs,O
are,O
high,O
.,O
To,O
support,O
distance,O
measurement,O
in,O
this,O
low,O
cost,O
robot,O
",",O
a,O
laser,O
module,O
(,O
laser,O
pointer,O
),O
is,O
used,O
to,O
project,O
a,O
brilliant,O
red,O
dot,O
in,O
the,O
object,O
in,O
front,O
of,O
the,O
robot,O
.,O
The,O
camera,O
then,O
captures,O
a,O
frame,O
and,O
uses,O
the,O
projected,O
dot,O
position,O
on,O
its,O
image,O
plane,O
to,O
compute,O
the,O
distance,O
to,O
the,O
obstacle,O
based,O
on,O
simple,O
trigonometry,O
.,O
This,O
method,O
is,O
described,O
by,O
Danko,O
[,O
29,O
],O
and,O
better,O
explained,O
by,O
Portugal,O
-,O
Zambrano,O
and,O
Mena,O
-,O
Chalco,O
[,O
30,O
].,O
The,O
algorithm,O
assumes,O
that,O
the,O
brightest,O
pixels,O
on,O
the,O
captured,O
image,O
are,O
on,O
the,O
laser,O
projected,O
dot,O
.,O
Figure,O
7,O
depicts,O
how,O
the,O
system,O
works,O
.,O
A,O
laser,O
pointer,O
parallel,O
to,O
the,O
camera,O
emits,O
a,O
focused,O
red,O
dot,O
that,O
is,O
projected,O
in,O
an,O
object,O
at,O
distance,O
D,O
from,O
the,O
robot,O
.,O
This,O
red,O
dot,O
is,O
reflected,O
and,O
projected,O
in,O
the,O
camera,O
’,O
s,O
image,O
plane,O
.,O
The,O
distance,O
pfc,O
(,O
pixels,O
from,O
center,O
),O
between,O
the,O
center,O
of,O
the,O
image,O
plane,O
(,O
in,O
the,O
optical,O
axis,O
),O
and,O
the,O
red,O
dot,O
in,O
the,O
image,O
plane,O
is,O
proportional,O
to,O
the,O
distance,O
D,O
.,O
Equation,O
(,O
4,O
),O
shows,O
how,O
to,O
compute,O
the,O
distance,O
using,O
described,O
system,O
.,O
The,O
distance,O
between,O
the,O
camera,O
and,O
the,O
laser,O
(,O
H,O
),O
is,O
known,O
previously,O
",",O
the,O
number,O
of,O
pixels,O
from,O
the,O
image,O
center,O
to,O
the,O
red,O
laser,O
dot,O
(,O
pfc,O
),O
is,O
obtained,O
from,O
the,O
image,O
.,O
The,O
radians,O
per,O
pixels,O
(,O
rpc,O
),O
and,O
the,O
radian,O
offset,O
(,O
ro,O
),O
are,O
obtained,O
calibrating,O
the,O
system,O
",",O
which,O
consists,O
of,O
taking,O
several,O
measurements,O
of,O
objects,O
at,O
known,O
distances,O
and,O
their,O
pixels,O
distance,O
from,O
center,O
(,O
pfc,O
).,O
Then,O
a,O
linear,O
regression,O
algorithm,O
finds,O
the,O
best,O
ro,O
and,O
rpc,O
.,O
Details,O
on,O
this,O
calibration,O
can,O
be,O
found,O
on,O
the,O
work,O
of,O
Portugal,O
-,O
Zambrano,O
and,O
Mena,O
-,O
Chalco,O
[,O
30,O
].,O
(,O
4,O
),O
D,O
=,O
Htan,O
(,O
pfc,O
*,O
rpc,O
+,O
ro,O
As,O
can,O
be,O
seem,O
in,O
Equation,O
(,O
4,O
"),",O
the,O
measurement,O
range,O
depends,O
mainly,O
on,O
the,O
baseline,O
H,O
given,O
by,O
the,O
distance,O
between,O
the,O
laser,O
and,O
the,O
camera,O
and,O
the,O
number,O
of,O
pixels,O
from,O
the,O
image,O
center,O
",",O
pfc,O
",",O
that,O
has,O
a,O
limit,O
given,O
by,O
the,O
camera,O
resolution,O
.,O
This,O
equation,O
can,O
be,O
used,O
to,O
determine,O
the,O
measurement,O
range,O
.,O
As,O
the,O
object,O
gets,O
farther,O
away,O
",",O
its,O
pfc,O
tends,O
to,O
zero,O
.,O
Assuming,O
pfc,O
to,O
be,O
zero,O
it,O
is,O
possible,O
to,O
simplify,O
Equation,O
(,O
4,O
),O
to,O
Equation,O
(,O
5,O
),O
which,O
gives,O
the,O
maximum,O
distance,O
that,O
can,O
be,O
measured,O
.,O
In,O
the,O
same,O
way,O
",",O
the,O
minimum,O
distance,O
is,O
given,O
by,O
half,O
the,O
camera,O
resolution,O
(,O
because,O
the,O
measurement,O
is,O
made,O
from,O
the,O
point,O
to,O
the,O
center,O
of,O
image,O
).,O
Equation,O
(,O
6,O
),O
specifies,O
the,O
minimum,O
measurement,O
distance,O
.,O
Table,O
5,O
shows,O
some,O
possible,O
range,O
values,O
computed,O
using,O
these,O
equations,O
.,O
(,O
5,O
),O
Dmax,O
=,O
Htan,O
(,O
ro,O
),O
(,O
6,O
),O
Dmin,O
=,O
Htan,O
(,O
r2,O
*,O
rpc,O
+,O
ro,O
),O
Block,O
Diagram,O
Figure,O
8,O
shows,O
a,O
block,O
diagram,O
of,O
the,O
system,O
.,O
Each,O
task,O
is,O
executed,O
in,O
a,O
separated,O
thread,O
",",O
thereby,O
reading,O
sensors,O
and,O
controlling,O
motors,O
do,O
not,O
interfere,O
with,O
each,O
other,O
.,O
A,O
task,O
planner,O
module,O
allows,O
the,O
system,O
to,O
integrate,O
the,O
distance,O
measurement,O
",",O
voice,O
commands,O
and,O
web,O
interface,O
.,O
The,O
system,O
running,O
with,O
all,O
these,O
subsystems,O
used,O
between,O
10,O
%,O
and,O
45,O
%,O
of,O
the,O
processor,O
in,O
all,O
devices,O
",",O
leaving,O
room,O
to,O
also,O
execute,O
complex,O
algorithms,O
embedded,O
on,O
the,O
robot,O
.,O
Experimental,O
Results,O
The,O
algorithm,O
implementation,O
is,O
straightforward,O
:,O
the,O
system,O
has,O
to,O
scan,O
a,O
region,O
of,O
the,O
image,O
for,O
a,O
group,O
of,O
pixels,O
with,O
the,O
greatest,O
values,O
(,O
255,O
),O
in,O
the,O
red,O
channel,O
.,O
The,O
current,O
implementation,O
searches,O
for,O
a,O
pattern,O
of,O
5,O
pixels,O
in,O
a,O
cross,O
shape,O
.,O
The,O
center,O
of,O
this,O
cross,O
is,O
the,O
pfc,O
value,O
.,O
Figure,O
9,O
shows,O
the,O
results,O
for,O
3,O
different,O
distances,O
.,O
The,O
red,O
dot,O
found,O
by,O
the,O
algorithm,O
is,O
shown,O
by,O
a,O
green,O
circle,O
",",O
and,O
the,O
green,O
line,O
shows,O
the,O
distance,O
from,O
the,O
laser,O
dot,O
to,O
the,O
image,O
center,O
.,O
The,O
baseline,O
used,O
is,O
4,O
.,O
5,O
centimeters,O
and,O
after,O
executing,O
a,O
linear,O
regression,O
with,O
a,O
spreadsheet,O
",",O
the,O
calibration,O
values,O
found,O
are,O
ro,O
=,O
0,O
.,O
074,O
and,O
rpc,O
=,O
0,O
.,O
008579,O
.,O
Table,O
6,O
shows,O
experimental,O
results,O
of,O
the,O
system,O
.,O
The,O
average,O
error,O
is,O
2,O
.,O
55,O
%,O
and,O
the,O
maximum,O
observed,O
error,O
is,O
8,O
.,O
5,O
"%,",O
which,O
happened,O
at,O
the,O
limit,O
of,O
the,O
measurement,O
range,O
.,O
The,O
range,O
of,O
operation,O
goes,O
from,O
15,O
cm,O
to,O
60,O
cm,O
",",O
but,O
that,O
can,O
be,O
changed,O
modifying,O
the,O
H,O
distance,O
.,O
The,O
advantage,O
of,O
such,O
system,O
is,O
that,O
the,O
processing,O
needed,O
is,O
very,O
low,O
:,O
the,O
system,O
has,O
to,O
find,O
the,O
brightest,O
red,O
dot,O
on,O
a,O
small,O
limited,O
region,O
of,O
interest,O
in,O
the,O
image,O
",",O
and,O
then,O
compute,O
the,O
distance,O
using,O
simple,O
trigonometric,O
relations,O
.,O
The,O
implementation,O
computes,O
distance,O
at,O
a,O
rate,O
of,O
9,O
frames,O
per,O
second,O
in,O
the,O
mobile,O
device,O
while,O
running,O
the,O
FFTs,O
and,O
closed,O
loop,O
control,O
system,O
described,O
.,O
This,O
makes,O
this,O
approach,O
an,O
interesting,O
solution,O
to,O
distance,O
measurement,O
in,O
robotics,O
systems,O
.,O
Figures,O
10,O
",",O
11,O
and,O
12,O
show,O
photos,O
of,O
the,O
robot,O
under,O
the,O
control,O
of,O
different,O
devices,O
.,O
Thanks,O
to,O
the,O
portability,O
of,O
the,O
Android,O
system,O
",",O
the,O
same,O
software,O
can,O
be,O
used,O
in,O
PC,O
computers,O
and,O
mobile,O
devices,O
using,O
ARM,O
processors,O
.,O
Although,O
a,O
proof,O
of,O
concept,O
was,O
developed,O
using,O
the,O
Android,O
operating,O
system,O
",",O
the,O
proposed,O
architecture,O
can,O
be,O
used,O
with,O
any,O
system,O
or,O
programming,O
language,O
that,O
can,O
produce,O
and,O
record,O
sounds,O
.,O
One,O
should,O
note,O
that,O
the,O
main,O
contribution,O
of,O
this,O
work,O
is,O
the,O
communication,O
scheme,O
",",O
so,O
these,O
photos,O
show,O
a,O
provisional,O
robot,O
’,O
s,O
assembly,O
setup,O
used,O
to,O
validate,O
the,O
proposed,O
architecture,O
for,O
robotics,O
.,O
Conclusions,O
This,O
paper,O
introduces,O
a,O
simple,O
but,O
universal,O
control,O
architecture,O
that,O
enables,O
a,O
wide,O
variety,O
of,O
devices,O
to,O
implement,O
control,O
of,O
mechatronics,O
and,O
automation,O
systems,O
.,O
The,O
method,O
can,O
be,O
used,O
to,O
implement,O
closed,O
loop,O
control,O
systems,O
in,O
mechatronics,O
systems,O
using,O
audio,O
channels,O
of,O
computing,O
devices,O
",",O
allowing,O
the,O
processing,O
unit,O
to,O
be,O
easily,O
replaced,O
without,O
the,O
need,O
of,O
pairing,O
or,O
special,O
configurations,O
.,O
Several,O
obsolete,O
and,O
current,O
devices,O
can,O
be,O
used,O
to,O
control,O
robots,O
such,O
as,O
PDAs,O
",",O
phones,O
and,O
computers,O
.,O
Even,O
an,O
MP3,O
player,O
could,O
be,O
used,O
if,O
control,O
without,O
feedback,O
is,O
needed,O
.,O
The,O
sound,O
produced,O
by,O
the,O
player,O
would,O
drive,O
the,O
motors,O
.,O
As,O
an,O
application,O
example,O
",",O
the,O
presented,O
method,O
is,O
used,O
to,O
build,O
a,O
mobile,O
robot,O
with,O
differential,O
drive,O
.,O
The,O
robot,O
’,O
s,O
complete,O
costs,O
",",O
including,O
frame,O
",",O
motors,O
",",O
sensors,O
and,O
electronics,O
is,O
less,O
than,O
30,O
US,O
dollars,O
(,O
in,O
small,O
quantities,O
"),",O
and,O
the,O
parts,O
can,O
be,O
easily,O
found,O
in,O
stores,O
or,O
on,O
the,O
Internet,O
.,O
The,O
mentioned,O
price,O
does,O
not,O
include,O
the,O
mobile,O
device,O
.,O
The,O
method,O
can,O
be,O
used,O
for,O
several,O
applications,O
such,O
as,O
educational,O
robotics,O
",",O
low,O
cost,O
robotics,O
research,O
platforms,O
",",O
telepresence,O
robots,O
",",O
autonomous,O
and,O
remotely,O
controlled,O
robots,O
.,O
In,O
engineering,O
courses,O
it,O
is,O
also,O
a,O
motivation,O
for,O
students,O
to,O
learn,O
digital,O
signal,O
processing,O
theory,O
",",O
and,O
all,O
the,O
other,O
multidisciplinary,O
fields,O
involved,O
in,O
robotics,O
.,O
Another,O
interesting,O
application,O
of,O
this,O
system,O
is,O
to,O
build,O
sensor,O
networks,O
composed,O
of,O
smartphones,O
that,O
can,O
gather,O
data,O
from,O
their,O
internal,O
sensors,O
and,O
poll,O
external,O
sensors,O
via,O
audio,O
tones,O
",",O
allowing,O
sensor,O
networks,O
to,O
be,O
easily,O
built,O
and,O
scaled,O
using,O
commercial,O
off,O
-,O
the,O
-,O
shelf,O
mobile,O
devices,O
instead,O
of,O
specific,O
boards,O
and,O
development,O
kits,O
.,O
DTMF,O
decoder,O
with,O
four,O
independent,O
outputs,O
controlled,O
by,O
audio,O
from,O
a,O
mobile,O
device,O
.,O
Dual,O
motor,O
control,O
using,O
one,O
mono,O
audio,O
channel,O
.,O
Sensors,O
input,O
using,O
a,O
DTMF,O
generator,O
.,O
DTMF,O
digit,O
recognition,O
performance,O
in,O
different,O
devices,O
.,O
Sensors,O
connection,O
in,O
a,O
mobile,O
robot,O
with,O
differential,O
drive,O
.,O
Experimental,O
odometry,O
results,O
.,O
X,O
axis,O
is,O
the,O
real,O
traveled,O
distance,O
manually,O
measured,O
with,O
a,O
tape,O
measure,O
.,O
Y,O
axis,O
is,O
the,O
distance,O
computed,O
by,O
the,O
mobile,O
device,O
using,O
the,O
proposed,O
system,O
with,O
data,O
from,O
the,O
encoders,O
.,O
Distance,O
measurement,O
system,O
using,O
a,O
camera,O
and,O
a,O
laser,O
pointer,O
.,O
H,O
is,O
the,O
distance,O
between,O
the,O
camera,O
optical,O
axis,O
and,O
the,O
laser,O
pointer,O
",",O
D,O
the,O
distance,O
between,O
the,O
camera,O
and,O
the,O
object,O
",",O
theta,O
is,O
the,O
angle,O
between,O
the,O
camera,O
’,O
s,O
optical,O
axis,O
and,O
the,O
laser,O
reflected,O
by,O
the,O
object,O
.,O
pfc,O
(,O
pixels,O
from,O
center,O
),O
is,O
the,O
distance,O
in,O
pixels,O
from,O
the,O
center,O
of,O
the,O
image,O
and,O
the,O
red,O
dot,O
.,O
Figure,O
adapted,O
from,O
Danko,O
and,O
Portugal,O
-,O
Zambrano,O
[,O
29,O
",",O
30,O
].,O
Block,O
diagram,O
of,O
the,O
robot,O
’,O
s,O
software,O
.,O
Image,O
seen,O
by,O
the,O
robot,O
’,O
s,O
camera,O
of,O
the,O
same,O
object,O
at,O
different,O
distances,O
.,O
Note,O
the,O
distance,O
of,O
the,O
laser,O
dot,O
to,O
the,O
image,O
center,O
(,O
shown,O
by,O
the,O
green,O
line,O
),O
when,O
the,O
object,O
is,O
at,O
different,O
distances,O
.,O
Robot,O
under,O
the,O
control,O
of,O
a,O
mobile,O
phone,O
.,O
The,O
audio,O
input,O
and,O
output,O
channels,O
are,O
connected,O
in,O
a,O
single,O
connector,O
below,O
the,O
phone,O
.,O
Robot,O
under,O
the,O
control,O
of,O
a,O
tablet,O
computer,O
.,O
The,O
audio,O
output,O
is,O
driven,O
from,O
a,O
P2,O
connector,O
attached,O
to,O
the,O
earphone,O
jack,O
and,O
the,O
audio,O
input,O
is,O
captured,O
by,O
the,O
built,O
-,O
in,O
microphone,O
of,O
the,O
device,O
.,O
Note,O
the,O
suction,O
cup,O
holding,O
an,O
earphone,O
near,O
the,O
microphone,O
.,O
Robot,O
under,O
the,O
control,O
of,O
a,O
netbook,O
computer,O
.,O
Audio,O
input,O
and,O
output,O
channels,O
are,O
connected,O
with,O
independent,O
P2,O
connectors,O
.,O
This,O
is,O
the,O
most,O
common,O
case,O
for,O
computers,O
.,O
DTMF,O
frequencies,O
pairs,O
and,O
corresponding,O
digits,O
.,O
Adapted,O
from,O
the,O
Audio,O
Engineer,O
’,O
s,O
Reference,O
Book,O
[,O
17,O
].,O
1,O
",",O
209,O
Hz,O
1,O
",",O
336,O
Hz,O
1,O
",",O
477,O
Hz,O
1,O
",",O
633,O
Hz,O
697,O
Hz,O
1,O
2,O
3,O
A,O
770,O
Hz,O
4,O
5,O
6,O
B,O
852,O
Hz,O
7,O
8,O
9,O
C,O
941,O
Hz,O
*,O
0,O
#,O
D,O
DTMF,O
digits,O
and,O
corresponding,O
motors,O
states,O
.,O
DTMF,O
digit,O
Binary,O
word,O
Motor,O
state,O
Motor,O
A,O
Motor,O
B,O
,O
00,O
00,O
Stopped,O
Stopped,O
D,O
00,O
00,O
Stopped,O
Stopped,O
1,O
00,O
01,O
Stopped,O
Left,O
spin,O
2,O
00,O
10,O
Stopped,O
Right,O
spin,O
3,O
00,O
11,O
Stopped,O
Invalid,O
4,O
01,O
00,O
Left,O
spin,O
Stopped,O
5,O
01,O
01,O
Left,O
spin,O
Left,O
spin,O
6,O
01,O
10,O
Left,O
spin,O
Right,O
spin,O
7,O
01,O
11,O
Left,O
spin,O
Invalid,O
8,O
10,O
00,O
Right,O
spin,O
Stopped,O
9,O
10,O
01,O
Right,O
spin,O
Left,O
spin,O
0,O
10,O
10,O
Right,O
spin,O
Right,O
spin,O
*,O
10,O
11,O
Right,O
spin,O
Invalid,O
#,O
11,O
00,O
Invalid,O
Stopped,O
A,O
11,O
01,O
Invalid,O
Left,O
spin,O
B,O
11,O
10,O
Invalid,O
Right,O
spin,O
C,O
11,O
11,O
Invalid,O
Invalid,O
Truth,O
table,O
used,O
with,O
4,O
sensors,O
input,O
used,O
in,O
the,O
case,O
study,O
robot,O
.,O
Left,O
Encoder,O
(,O
bit,O
3,O
),O
Right,O
encoder,O
(,O
bit,O
2,O
),O
Right,O
bumper,O
(,O
bit,O
1,O
),O
Left,O
bumper,O
(,O
bit,O
0,O
),O
DTMF,O
Digit,O
0,O
0,O
0,O
0,O
0,O
0,O
0,O
0,O
1,O
1,O
0,O
0,O
1,O
0,O
2,O
0,O
0,O
1,O
1,O
3,O
0,O
1,O
0,O
0,O
4,O
0,O
1,O
0,O
1,O
5,O
0,O
1,O
1,O
0,O
6,O
0,O
1,O
1,O
1,O
7,O
1,O
0,O
0,O
0,O
8,O
1,O
0,O
0,O
1,O
9,O
1,O
0,O
1,O
0,O
A,O
1,O
0,O
1,O
1,O
B,O
1,O
1,O
0,O
0,O
C,O
1,O
1,O
0,O
1,O
D,O
1,O
1,O
1,O
0,O
*,O
1,O
1,O
1,O
1,O
#,O
Encoder,O
resolution,O
",",O
displacement,O
measurement,O
resolution,O
and,O
maximum,O
speed,O
that,O
can,O
be,O
measured,O
(,O
considering,O
r,O
=,O
25,O
mm,O
and,O
s,O
=,O
40,O
DTMF,O
digits,O
per,O
second,O
).,O
Encoder,O
resolution,O
(,O
digits,O
per,O
revolution,O
),O
Displacement,O
resolution,O
Maximum,O
speed,O
1,O
157,O
mm,O
6,O
",",O
283,O
mm,O
/,O
s,O
6,O
26,O
mm,O
1,O
",",O
047,O
mm,O
/,O
s,O
12,O
13,O
mm,O
571,O
mm,O
/,O
s,O
24,O
6,O
.,O
5,O
mm,O
261,O
mm,O
/,O
s,O
40,O
3,O
.,O
92,O
mm,O
157,O
mm,O
/,O
s,O
Measurement,O
range,O
for,O
a,O
VGA,O
camera,O
(,O
640,O
×,O
480,O
).,O
All,O
values,O
in,O
centimeters,O
.,O
H,O
Measurement,O
Range,O
Minimum,O
Maximum,O
0,O
.,O
5,O
1,O
.,O
74,O
6,O
.,O
74,O
1,O
3,O
.,O
48,O
13,O
.,O
48,O
4,O
.,O
5,O
15,O
.,O
65,O
60,O
.,O
68,O
10,O
34,O
.,O
79,O
134,O
.,O
86,O
Distance,O
measurement,O
results,O
using,O
a,O
mobile,O
phone,O
camera,O
.,O
Real,O
distance,O
(,O
cm,O
),O
Measured,O
distance,O
(,O
cm,O
),O
Error,O
(%),O
16,O
16,O
.,O
02,O
0,O
.,O
12,O
20,O
20,O
.,O
30,O
1,O
.,O
50,O
25,O
25,O
.,O
29,O
1,O
.,O
16,O
30,O
29,O
.,O
70,O
1,O
.,O
00,O
35,O
35,O
.,O
43,O
1,O
.,O
22,O
40,O
39,O
.,O
79,O
0,O
.,O
50,O
45,O
43,O
.,O
80,O
2,O
.,O
66,O
50,O
47,O
.,O
80,O
4,O
.,O
40,O
55,O
52,O
.,O
57,O
4,O
.,O
41,O
60,O
54,O
.,O
90,O
8,O
.,O
50,O
Ammonia,O
-,O
lowering,O
activities,O
and,O
carbamoyl,B-GP
phosphate,I-GP
synthetase,I-GP
1,I-GP
(,O
Cps1,B-GP
),O
induction,O
mechanism,O
of,O
a,O
natural,O
flavonoid,O
Objective,O
Ammonia,O
detoxification,O
is,O
essential,O
for,O
physiological,O
well,O
-,O
being,O
",",O
and,O
the,O
urea,O
cycle,O
in,O
liver,O
plays,O
a,O
predominant,O
role,O
in,O
ammonia,O
disposal,O
.,O
Nobiletin,O
(,O
NOB,O
"),",O
a,O
natural,O
dietary,O
flavonoid,O
",",O
is,O
known,O
to,O
exhibit,O
various,O
physiological,O
efficacies,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
investigated,O
a,O
potential,O
role,O
of,O
NOB,O
in,O
ammonia,O
control,O
and,O
the,O
underlying,O
cellular,O
mechanism,O
.,O
Materials,O
/,O
methods,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
were,O
fed,O
with,O
regular,O
chow,O
(,O
RC,O
"),",O
high,O
-,O
fat,O
(,O
HFD,O
),O
or,O
high,O
-,O
protein,O
diet,O
(,O
HPD,O
),O
and,O
treated,O
with,O
either,O
vehicle,O
or,O
NOB,O
.,O
Serum,O
and,O
/,O
or,O
urine,O
levels,O
of,O
ammonia,O
and,O
urea,O
were,O
measured,O
.,O
Liver,O
expression,O
of,O
genes,O
encoding,O
urea,O
cycle,O
enzymes,O
and,O
C,B-GP
/,I-GP
EBP,I-GP
transcription,B-GP
factors,I-GP
was,O
determined,O
over,O
the,O
circadian,O
cycle,O
.,O
Luciferase,B-GP
reporter,O
assays,O
were,O
carried,O
out,O
to,O
investigate,O
function,O
of,O
CCAAT,O
consensus,O
elements,O
on,O
the,O
carbamoyl,B-GP
phosphate,I-GP
synthetase,I-GP
(,O
Cps1,B-GP
),O
gene,O
promoter,O
.,O
A,O
circadian,O
clock,B-GP
-,O
deficient,O
mouse,B-OG
mutant,O
",",O
ClockΔ19,O
/,O
Δ19,O
",",O
was,O
utilized,O
to,O
examine,O
a,O
requisite,O
role,O
of,O
the,O
circadian,O
clock,B-GP
in,O
mediating,O
NOB,O
induction,O
of,O
Cps1,B-GP
.,O
Results,O
NOB,O
was,O
able,O
to,O
lower,O
serum,O
ammonia,O
levels,O
in,O
mice,B-OG
fed,O
with,O
RC,O
",",O
HFD,O
or,O
HPD,O
.,O
Compared,O
with,O
RC,O
",",O
HFD,O
repressed,O
the,O
mRNA,O
and,O
protein,O
expression,O
of,O
Cps1,B-GP
",",O
encoding,O
the,O
rate,O
-,O
limiting,O
enzyme,O
of,O
the,O
urea,O
cycle,O
.,O
Interestingly,O
",",O
NOB,O
rescued,O
CPS1,B-GP
protein,O
levels,O
under,O
the,O
HFD,O
condition,O
via,O
induction,O
of,O
the,O
transcription,B-GP
factors,I-GP
C,B-GP
/,I-GP
EBPα,I-GP
and,O
C,B-GP
/,I-GP
EBPβ,I-GP
.,O
Expression,O
of,O
other,O
urea,O
cycle,O
genes,O
was,O
also,O
decreased,O
by,O
HFD,O
relative,O
to,O
RC,O
and,O
again,O
restored,O
by,O
NOB,O
to,O
varying,O
degrees,O
",",O
which,O
",",O
in,O
conjunction,O
with,O
Cps1,B-GP
promoter,O
reporter,O
analysis,O
",",O
suggested,O
a,O
C,B-GP
/,I-GP
EBP,I-GP
-,O
dependent,O
mechanism,O
for,O
the,O
co,O
-,O
induction,O
of,O
urea,O
cycle,O
genes,O
by,O
NOB,O
.,O
In,O
comparison,O
",",O
HPD,O
markedly,O
increased,O
CPS1,B-GP
levels,O
relative,O
to,O
RC,O
",",O
yet,O
NOB,O
did,O
not,O
further,O
enrich,O
CPS1,B-GP
to,O
a,O
significant,O
extent,O
.,O
Using,O
the,O
circadian,O
mouse,B-OG
mutant,O
ClockΔ19,O
/,O
Δ19,O
",",O
we,O
also,O
showed,O
that,O
a,O
functional,O
circadian,O
clock,B-GP
",",O
known,O
to,O
modulate,O
C,B-GP
/,I-GP
EBP,I-GP
and,O
CPS1,B-GP
expression,O
",",O
was,O
required,O
for,O
NOB,O
induction,O
of,O
CPS1,B-GP
under,O
the,O
HFD,O
condition,O
.,O
Conclusion,O
NOB,O
",",O
a,O
dietary,O
flavonoid,O
",",O
exhibits,O
a,O
broad,O
activity,O
in,O
ammonia,O
control,O
across,O
varying,O
diets,O
",",O
and,O
regulates,O
urea,O
cycle,O
function,O
via,O
C,B-GP
/,I-GP
EBP,I-GP
-,O
and,O
clock,B-GP
-,O
dependent,O
regulatory,O
mechanisms,O
.,O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
doi,O
:,O
10,O
.,O
1186,O
/,O
s12986,O
-,O
015,O
-,O
0020,O
-,O
7,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Introduction,O
Ammonia,O
detoxification,O
is,O
an,O
essential,O
bodily,O
function,O
required,O
for,O
nitrogen,O
homeostasis,O
and,O
physiological,O
well,O
-,O
being,O
[,O
1,O
–,O
3,O
].,O
Ammonia,O
molecules,O
are,O
produced,O
mainly,O
through,O
catabolism,O
of,O
amino,O
acid,O
and,O
other,O
nitrogenous,O
metabolites,O
in,O
tissues,O
",",O
and,O
also,O
via,O
amino,O
acid,O
deamination,O
and,O
urea,O
salvage,O
by,O
gut,O
bacteria,B-OG
[,O
1,O
",",O
4,O
].,O
Whereas,O
a,O
small,O
portion,O
of,O
ammonia,O
is,O
removed,O
via,O
direct,O
renal,O
excretion,O
",",O
the,O
urea,O
cycle,O
in,O
the,O
liver,O
plays,O
a,O
predominant,O
role,O
in,O
ammonia,O
disposal,O
",",O
converting,O
ammonia,O
to,O
the,O
relatively,O
harmless,O
urea,O
for,O
excretion,O
[,O
5,O
",",O
6,O
].,O
The,O
urea,O
cycle,O
consists,O
of,O
five,O
enzymatic,O
reactions,O
sequentially,O
taking,O
place,O
in,O
the,O
mitochondrial,O
matrix,O
and,O
the,O
cytoplasm,O
of,O
periportal,O
hepatocytes,O
[,O
7,O
",",O
8,O
].,O
Carbamoyl,B-GP
phosphate,I-GP
synthetase,I-GP
1,I-GP
(,O
CPS1,B-GP
),O
catalyzes,O
the,O
first,O
reaction,O
wherein,O
ammonia,O
and,O
bicarbonate,O
combine,O
to,O
form,O
carbamoyl,O
phosphate,O
",",O
and,O
mice,B-OG
deficient,O
in,O
Cps1,B-GP
suffered,O
pronounced,O
hyperammonemia,B-DS
and,O
neonatal,O
lethality,O
[,O
9,O
].,O
As,O
a,O
strikingly,O
abundant,O
protein,O
comprising,O
as,O
much,O
as,O
20,O
%,O
of,O
total,O
mitochondrial,B-GP
matrix,I-GP
protein,I-GP
mass,O
[,O
10,O
"],",O
CPS1,B-GP
is,O
also,O
subjected,O
to,O
diverse,O
molecular,O
and,O
cellular,O
regulation,O
.,O
Besides,O
the,O
classically,O
known,O
allosteric,O
activator,O
N,O
-,O
acetylglutamate,O
(,O
NAG,O
"),",O
CPS1,B-GP
level,O
and,O
activity,O
are,O
also,O
regulated,O
by,O
complex,O
molecular,O
and,O
physiological,O
mechanisms,O
[,O
7,O
",",O
11,O
–,O
16,O
].,O
Furthermore,O
",",O
coordinate,O
induction,O
of,O
urea,O
cycle,O
components,O
has,O
also,O
been,O
reported,O
at,O
transcriptional,O
and,O
post,O
-,O
transcriptional,O
levels,O
[,O
7,O
",",O
17,O
].,O
An,O
emerging,O
cellular,O
mechanism,O
for,O
nitrogen,O
homeostasis,O
is,O
our,O
intrinsic,O
biological,O
timer,O
",",O
the,O
circadian,O
clock,B-GP
[,O
18,O
",",O
19,O
].,O
In,O
mammals,B-OG
",",O
core,O
clock,B-GP
genes,O
form,O
interlocked,O
feedback,O
loops,O
",",O
driving,O
gene,O
expression,O
to,O
regulate,O
various,O
metabolic,O
pathways,O
[,O
20,O
–,O
22,O
].,O
Several,O
earlier,O
studies,O
have,O
implicated,O
a,O
role,O
of,O
the,O
clock,B-GP
in,O
protein,O
or,O
nitrogen,O
metabolism,O
[,O
23,O
–,O
25,O
].,O
More,O
recently,O
",",O
it,O
was,O
shown,O
that,O
the,O
transcription,B-GP
factor,I-GP
Klf15,B-GP
is,O
encoded,O
by,O
a,O
clock,B-GP
-,O
controlled,O
gene,O
",",O
and,O
that,O
Klf15,B-GP
maintains,O
nitrogen,O
balance,O
via,O
regulation,O
of,O
the,O
second,O
urea,O
cycle,O
gene,O
Otc,B-GP
[,O
19,O
].,O
Furthermore,O
",",O
genomic,O
and,O
proteomic,O
studies,O
have,O
also,O
demonstrated,O
circadian,O
variation,O
of,O
Cps1,B-GP
mRNA,O
and,O
protein,O
expression,O
in,O
mouse,B-OG
liver,O
",",O
although,O
discrepancies,O
remain,O
concerning,O
mRNA,O
oscillation,O
and,O
protein,O
peaks,O
[,O
26,O
–,O
29,O
].,O
Apart,O
from,O
the,O
clock,B-GP
being,O
an,O
intrinsic,O
regulator,O
",",O
diet,O
is,O
an,O
external,O
factor,O
that,O
profoundly,O
influences,O
nitrogen,O
homeostasis,O
and,O
ammonia,O
metabolism,O
.,O
Dietary,O
management,O
for,O
genetic,O
hyperammonemia,B-DS
",",O
mainly,O
including,O
protein,O
restriction,O
and,O
supplementation,O
of,O
urea,O
cycle,O
substrate,O
",",O
serves,O
to,O
attenuate,O
ammonia,O
generation,O
and,O
/,O
or,O
bolster,O
ammonia,O
disposal,O
[,O
3,O
",",O
30,O
–,O
32,O
].,O
On,O
the,O
other,O
hand,O
",",O
dietary,O
challenges,O
also,O
strongly,O
influence,O
ammonia,O
metabolism,O
and,O
detoxification,O
.,O
For,O
example,O
",",O
the,O
ureagenic,O
capacity,O
of,O
the,O
urea,O
cycle,O
",",O
while,O
far,O
exceeding,O
demand,O
under,O
normal,O
conditions,O
[,O
14,O
"],",O
has,O
been,O
shown,O
to,O
be,O
up,O
-,O
regulated,O
in,O
response,O
to,O
greater,O
metabolic,O
challenge,O
[,O
7,O
",",O
33,O
].,O
However,O
",",O
ammonia,O
control,O
under,O
varying,O
diet,O
conditions,O
is,O
not,O
well,O
characterized,O
",",O
and,O
little,O
is,O
known,O
regarding,O
functional,O
dietary,O
components,O
for,O
ammonia,O
control,O
besides,O
metabolic,O
substrates,O
[,O
30,O
",",O
34,O
].,O
Here,O
",",O
we,O
report,O
novel,O
ammonia,O
-,O
lowering,O
activities,O
and,O
clock,B-GP
-,O
dependent,O
mechanism,O
for,O
urea,O
cycle,O
regulation,O
of,O
a,O
natural,O
polyphenolic,O
flavonoid,O
",",O
Nobiletin,O
(,O
NOB,O
).,O
Materials,O
and,O
methods,O
Animals,B-OG
All,O
animal,B-OG
husbandry,O
and,O
experimental,O
procedures,O
were,O
carried,O
out,O
in,O
accordance,O
with,O
approved,O
IACUC,O
guidelines,O
and,O
animal,B-OG
protocols,O
by,O
the,O
University,O
of,O
Texas,O
Health,O
Science,O
Center,O
at,O
Houston,O
(,O
UTHealth,O
).,O
All,O
mice,B-OG
",",O
male,O
and,O
on,O
the,O
C57BL,O
/,O
6,O
background,O
",",O
were,O
group,O
-,O
housed,O
with,O
2,O
–,O
4,O
animals,B-OG
/,O
cage,O
under,O
12,O
:,O
12,O
light,O
/,O
dark,O
(,O
12,O
:,O
12,O
LD,O
),O
cycles,O
or,O
constant,O
darkness,O
(,O
DD,O
),O
when,O
indicated,O
.,O
The,O
point,O
of,O
light,O
-,O
on,O
is,O
considered,O
as,O
Zeitgeber,O
Time,O
(,O
ZT,O
),O
0,O
",",O
whereas,O
the,O
onset,O
of,O
subjective,O
day,O
during,O
DD,O
is,O
considered,O
as,O
Circadian,O
Time,O
(,O
CT,O
),O
0,O
.,O
Animals,B-OG
were,O
ad,O
libitum,O
fed,O
with,O
regular,O
chow,O
(,O
RC,O
;,O
LabDiet,O
5001,O
"),",O
high,O
-,O
fat,O
diet,O
(,O
HFD,O
;,O
Research,O
Diets,O
D12492,O
),O
or,O
high,O
-,O
protein,O
diet,O
(,O
HPD,O
;,O
Research,O
Diets,O
D04080301,O
).,O
Nobiletin,O
was,O
obtained,O
from,O
commercial,O
sources,O
including,O
Sigma,O
and,O
Selleck,O
",",O
and,O
administered,O
via,O
oral,O
gavage,O
(,O
200,O
mg,O
/,O
kg,O
in,O
0,O
.,O
5,O
%,O
Sodium,O
carboxymethyl,O
cellulose,O
),O
every,O
other,O
day,O
.,O
Ammonia,O
and,O
urea,O
assays,O
Blood,O
and,O
urine,O
samples,O
were,O
collected,O
at,O
ZT6,O
and,O
ZT18,O
.,O
For,O
determination,O
of,O
serum,O
ammonia,O
and,O
urea,O
concentrations,O
",",O
we,O
employed,O
assay,O
kits,O
(,O
Sigma,O
",",O
AA0100,O
and,O
MAK006,O
",",O
respectively,O
),O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
protocols,O
.,O
Plasmids,O
The,O
proximal,O
Cps1,B-GP
enhancer,O
[,O
16,O
],O
was,O
cloned,O
into,O
pGL3,O
Basic,O
(,O
Promega,O
),O
using,O
C57BL6,B-OG
/,I-OG
J,I-OG
mouse,I-OG
genomic,O
DNA,O
as,O
PCR,O
template,O
with,O
pF,O
and,O
pR,O
primers,O
(,O
Additional,O
file,O
1,O
:,O
Table,O
S1,O
).,O
Site,O
-,O
directed,O
PCR,O
mutagenesis,O
was,O
performed,O
to,O
introduce,O
mutations,O
on,O
the,O
C,B-GP
/,I-GP
EBP,I-GP
binding,O
site,O
using,O
P,O
-,O
C,O
/,O
EBPmutF,O
and,O
P,O
-,O
C,O
/,O
EBPmutR,O
primers,O
(,O
Additional,O
file,O
1,O
:,O
Table,O
S1,O
).,O
Likewise,O
",",O
the,O
distal,O
enhancer,O
[,O
35,O
],O
was,O
cloned,O
into,O
pGL3,O
Basic,O
using,O
dF,O
and,O
dR,O
primers,O
.,O
Three,O
C,B-GP
/,I-GP
EBP,I-GP
binding,O
sites,O
in,O
the,O
distal,O
enhancer,O
region,O
were,O
incorporated,O
by,O
DNA,O
synthesis,O
(,O
GeneScript,O
).,O
C,B-GP
/,I-GP
EBPα,I-GP
expression,O
vector,O
was,O
purchased,O
from,O
Addgene,O
(,O
ID12550,O
).,O
Luciferase,B-GP
reporter,O
assays,O
For,O
the,O
luminescence,O
assay,O
",",O
Hepa1,O
-,O
6,O
cells,O
(,O
ATCC,O
",",O
CRL,O
-,O
1830,O
),O
were,O
plated,O
the,O
day,O
before,O
transfection,O
at,O
2,O
×,O
104,O
cells,O
per,O
well,O
in,O
96,O
-,O
well,O
plates,O
.,O
Cells,O
were,O
transfected,O
with,O
the,O
indicated,O
vectors,O
with,O
Renilla,B-OG
luciferase,B-GP
vector,O
for,O
internal,O
control,O
.,O
Twenty,O
four,O
hours,O
after,O
transfection,O
",",O
media,O
was,O
changed,O
to,O
recording,O
media,O
as,O
previously,O
described,O
[,O
36,O
],O
and,O
treated,O
with,O
different,O
concentrations,O
of,O
Nobiletin,O
.,O
Sealed,O
cultures,O
were,O
placed,O
in,O
an,O
EnVision,O
microplate,O
reader,O
(,O
Perkin,O
Elmer,O
),O
and,O
bioluminescence,O
from,O
the,O
tissue,O
was,O
recorded,O
.,O
Real,O
-,O
time,O
qPCR,O
and,O
Western,O
blot,O
analyses,O
Total,O
RNAs,O
purified,O
by,O
using,O
Trizol,O
were,O
used,O
for,O
cDNA,O
synthesis,O
and,O
real,O
-,O
time,O
qPCR,O
was,O
performed,O
with,O
an,O
Agilent,O
MaxPro3000,O
Thermocycler,O
using,O
SyBR,O
green,O
reaction,O
mix,O
(,O
GenDEPOT,O
).,O
The,O
qPCR,O
primers,O
used,O
are,O
listed,O
in,O
Additional,O
file,O
1,O
:,O
Table,O
S2,O
.,O
Tissue,O
collection,O
and,O
Western,O
blotting,O
was,O
performed,O
as,O
described,O
previously,O
[,O
37,O
",",O
38,O
].,O
Briefly,O
",",O
liver,O
tissue,O
samples,O
were,O
dissected,O
from,O
the,O
same,O
lobular,O
regions,O
in,O
different,O
animals,B-OG
to,O
ensure,O
experimental,O
consistency,O
.,O
The,O
samples,O
were,O
immediately,O
frozen,O
in,O
liquid,O
nitrogen,O
and,O
stored,O
at,O
−,O
80,O
°,O
C,O
prior,O
to,O
use,O
.,O
The,O
harvested,O
liver,O
tissues,O
were,O
homogenized,O
in,O
extraction,O
buffer,O
containing,O
0,O
.,O
1,O
%,O
TritonX,O
-,O
100,O
.,O
Protein,O
samples,O
were,O
separated,O
by,O
12,O
or,O
6,O
%,O
SDS,O
-,O
polyacrylamide,O
gel,O
then,O
transferred,O
to,O
a,O
nitrocellulose,O
membrane,O
.,O
Anti,O
-,O
CPS1,B-GP
(,O
Abcam,O
"),",O
anti,O
-,O
C,B-GP
/,I-GP
EBPα,I-GP
(,O
Cell,O
Signaling,O
"),",O
anti,O
-,O
C,B-GP
/,I-GP
EBPβ,I-GP
(,O
Abcam,O
),O
antibodies,B-GP
were,O
used,O
.,O
Quantitation,O
of,O
Western,O
blot,O
results,O
was,O
carried,O
out,O
by,O
using,O
ImageJ,O
software,O
(,O
NIH,O
).,O
Immunohistochemistry,O
Liver,O
tissues,O
(,O
right,O
lateral,O
lobe,O
),O
were,O
collected,O
at,O
the,O
indicated,O
times,O
and,O
immediately,O
fixed,O
in,O
10,O
%,O
buffered,O
formalin,O
.,O
For,O
immunohistochemistry,O
",",O
20,O
-,O
μm,O
sections,O
were,O
collected,O
using,O
a,O
VibroSlice,O
microtome,O
(,O
World,O
Precision,O
Instruments,O
),O
and,O
processed,O
free,O
floating,O
.,O
Sections,O
were,O
incubated,O
with,O
rabbit,B-OG
anti,O
-,O
CPS1,B-GP
(,O
1,O
:,O
10,O
",",O
000,O
;,O
Abcam,O
"),",O
followed,O
by,O
Alexa,O
Fluor,O
546,O
rabbit,B-OG
secondary,O
antibody,B-GP
(,O
1,O
:,O
1000,O
;,O
Invitrogen,O
).,O
After,O
30,O
min,O
of,O
DAPI,O
staining,O
(,O
5,O
μM,O
"),",O
Vectashield,O
mounting,O
media,O
(,O
Vector,O
Labs,O
),O
was,O
used,O
to,O
mount,O
the,O
liver,O
slices,O
.,O
Section,O
images,O
were,O
acquired,O
and,O
analyzed,O
by,O
using,O
a,O
Nikon,O
A1R,O
confocal,O
microscope,O
.,O
SDS,O
-,O
PAGE,O
and,O
mass,O
spectrometry,O
Liver,O
extracts,O
were,O
separated,O
on,O
SDS,O
-,O
PAGE,O
gels,O
and,O
minimally,O
stained,O
with,O
Coomassie,O
blue,O
.,O
The,O
MW,O
164KD,O
band,O
was,O
excised,O
and,O
digested,O
with,O
trypsin,B-GP
.,O
The,O
sample,O
was,O
subjected,O
to,O
mass,O
spectrometry,O
protein,O
ID,O
at,O
the,O
BCM,O
Proteome,O
Core,O
Facility,O
using,O
a,O
Velos,O
-,O
Orbitrap,O
mass,O
spectrometer,O
.,O
Spectral,O
data,O
were,O
then,O
identified,O
by,O
using,O
Proteome,O
Discoverer,O
Suites,O
with,O
Mascot,O
(,O
Orbitrap,O
data,O
),O
software,O
[,O
39,O
].,O
Statistical,O
analysis,O
Unless,O
otherwise,O
stated,O
",",O
results,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
Data,O
were,O
analyzed,O
using,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
one,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
-,O
hoc,O
analysis,O
using,O
Dunnett,O
’,O
s,O
multiple,O
comparison,O
tests,O
or,O
two,O
-,O
way,O
ANOVA,O
followed,O
by,O
post,O
-,O
hoc,O
analysis,O
using,O
Bonferroni,O
test,O
as,O
appropriate,O
.,O
A,O
value,O
of,O
p,O
<,O
0,O
.,O
05,O
was,O
considered,O
statistically,O
significant,O
.,O
Results,O
NOB,O
improves,O
ammonium,O
detoxification,O
Among,O
a,O
growing,O
number,O
of,O
bioactive,O
polyphenols,O
",",O
Nobiletin,O
(,O
NOB,O
),O
is,O
a,O
citrus,O
-,O
derived,O
dietary,O
flavonoid,O
with,O
diverse,O
physiological,O
functions,O
[,O
40,O
–,O
43,O
].,O
More,O
recently,O
",",O
NOB,O
has,O
been,O
shown,O
to,O
display,O
a,O
protective,O
role,O
against,O
high,O
-,O
fat,O
diet,O
(,O
HFD,O
)-,O
induced,O
obesity,B-DS
and,O
other,O
metabolic,O
dysfunctions,O
[,O
44,O
–,O
46,O
].,O
To,O
investigate,O
a,O
potential,O
role,O
of,O
NOB,O
in,O
nitrogen,O
homeostasis,O
",",O
we,O
examined,O
serum,O
ammonium,O
levels,O
in,O
wild,O
-,O
type,O
(,O
WT,O
),O
mice,B-OG
under,O
different,O
diets,O
.,O
Under,O
RC,O
",",O
NOB,O
did,O
not,O
significantly,O
affect,O
body,O
weight,O
(,O
Fig,O
.,O
1a,O
).,O
Consistent,O
with,O
previous,O
findings,O
[,O
44,O
",",O
45,O
"],",O
NOB,O
ameliorated,O
body,O
weight,O
gain,O
under,O
HFD,O
(,O
Fig,O
.,O
1a,O
).,O
Importantly,O
however,O
",",O
under,O
both,O
diets,O
",",O
NOB,O
markedly,O
reduced,O
serum,O
ammonium,O
levels,O
(,O
Fig,O
.,O
1b,O
).,O
At,O
Zeitgeber,O
Time,O
(,O
ZT,O
),O
6,O
corresponding,O
to,O
mid,O
-,O
day,O
(,O
inactive,O
phase,O
"),",O
NOB,O
led,O
to,O
a,O
more,O
pronounced,O
reduction,O
for,O
HFD,O
than,O
RC,O
(,O
27,O
.,O
5,O
%,O
vs,O
14,O
.,O
4,O
%),O
(,O
Fig,O
.,O
1b,O
",",O
left,O
).,O
Ammonia,O
-,O
lowering,O
activities,O
of,O
NOB,O
were,O
also,O
observed,O
at,O
ZT18,O
corresponding,O
to,O
mid,O
-,O
night,O
when,O
mice,B-OG
were,O
active,O
(,O
Fig,O
.,O
1b,O
",",O
right,O
).,O
Whereas,O
attenuated,O
serum,O
ammonia,O
levels,O
were,O
observed,O
in,O
HFD,O
.,O
Veh,O
than,O
RC,O
.,O
Veh,O
",",O
likely,O
due,O
to,O
lower,O
protein,O
content,O
in,O
HFD,O
than,O
RC,O
(,O
20,O
%,O
vs,O
.,O
29,O
%,O
in,O
calories,O
"),",O
NOB,O
treatment,O
diminished,O
the,O
ammonia,O
levels,O
in,O
both,O
diets,O
by,O
similar,O
degrees,O
.,O
Fig,O
.,O
1Nobiletin,O
(,O
NOB,O
),O
lowers,O
serum,O
ammonia,O
levels,O
.,O
a,O
Body,O
weight,O
change,O
of,O
wild,O
-,O
type,O
(,O
WT,O
),O
mice,B-OG
fed,O
with,O
regular,O
chow,O
(,O
RC,O
),O
or,O
high,O
-,O
fat,O
diet,O
(,O
HFD,O
),O
and,O
treated,O
with,O
either,O
vehicle,O
(,O
Veh,O
),O
or,O
Nobiletin,O
(,O
NOB,O
),O
for,O
10,O
weeks,O
(,O
n,O
=,O
11,O
–,O
12,O
).,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
b,O
Serum,O
ammonia,O
levels,O
at,O
Zeitgeber,O
Time,O
(,O
ZT,O
),O
6,O
and,O
18,O
in,O
the,O
mice,B-OG
described,O
in,O
(,O
a,O
).,O
ZT0,O
corresponds,O
to,O
the,O
onset,O
of,O
light,O
phase,O
.,O
c,O
Body,O
weight,O
change,O
of,O
WT,O
mice,B-OG
fed,O
with,O
RC,O
or,O
high,O
-,O
protein,O
diet,O
(,O
HPD,O
),O
and,O
treated,O
with,O
either,O
Veh,O
or,O
NOB,O
for,O
4,O
weeks,O
(,O
n,O
=,O
6,O
–,O
7,O
).,O
d,O
Serum,O
ammonia,O
levels,O
at,O
ZT6,O
and,O
ZT18,O
in,O
the,O
mice,B-OG
described,O
in,O
(,O
c,O
).,O
Data,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
For,O
panels,O
b,O
and,O
d,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
:,O
Veh,O
vs,O
.,O
NOB,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
",",O
***,O
p,O
<,O
0,O
.,O
001,O
;,O
RC,O
vs,O
.,O
HFD,O
or,O
HPD,O
",",O
††,O
p,O
<,O
0,O
.,O
01,O
We,O
next,O
investigated,O
effects,O
of,O
NOB,O
under,O
high,O
-,O
protein,O
diet,O
(,O
HPD,O
"),",O
corresponding,O
to,O
enhanced,O
protein,O
metabolism,O
and,O
ammonia,O
flux,O
[,O
19,O
].,O
NOB,O
did,O
not,O
significantly,O
affect,O
body,O
weight,O
in,O
these,O
mice,B-OG
(,O
Fig,O
.,O
1c,O
).,O
At,O
ZT6,O
",",O
serum,O
ammonia,O
levels,O
were,O
similar,O
between,O
RC,O
and,O
HPD,O
",",O
and,O
NOB,O
showed,O
a,O
modest,O
trend,O
of,O
reducing,O
serum,O
ammonia,O
levels,O
(,O
Fig,O
.,O
1d,O
",",O
left,O
).,O
Importantly,O
",",O
during,O
the,O
active,O
phase,O
at,O
ZT18,O
when,O
serum,O
ammonia,O
levels,O
were,O
significantly,O
elevated,O
in,O
HPD,O
",",O
NOB,O
robustly,O
reduced,O
serum,O
ammonia,O
to,O
RC,O
levels,O
(,O
Fig,O
.,O
1d,O
",",O
right,O
).,O
Together,O
",",O
these,O
results,O
indicated,O
a,O
broad,O
role,O
of,O
NOB,O
in,O
reducing,O
serum,O
ammonia,O
content,O
at,O
both,O
active,O
and,O
inactive,O
circadian,O
phases,O
under,O
RC,O
",",O
HFD,O
and,O
HPD,O
conditions,O
.,O
Furthermore,O
",",O
NOB,O
more,O
strongly,O
reduced,O
serum,O
ammonia,O
levels,O
under,O
HFD,O
and,O
HPD,O
at,O
ZT6,O
and,O
ZT18,O
respectively,O
",",O
serving,O
to,O
normalize,O
the,O
exaggerated,O
circadian,O
variation,O
between,O
active,O
and,O
inactive,O
phases,O
in,O
these,O
diets,O
compared,O
with,O
RC,O
.,O
Diet,O
-,O
specific,O
effects,O
of,O
NOB,O
on,O
CPS1,B-GP
expression,O
Carbamoyl,B-GP
phosphate,I-GP
synthetase,I-GP
I,I-GP
(,O
CPS1,B-GP
),O
has,O
been,O
shown,O
to,O
accumulate,O
in,O
a,O
circadian,O
manner,O
;,O
however,O
",",O
CPS1,B-GP
proteins,O
are,O
exceedingly,O
abundant,O
and,O
discrepancy,O
in,O
circadian,O
pattern,O
exists,O
[,O
26,O
",",O
27,O
].,O
We,O
therefore,O
conducted,O
Western,O
blotting,O
to,O
examine,O
CPS1,B-GP
protein,O
levels,O
in,O
mouse,B-OG
liver,O
over,O
circadian,O
time,O
course,O
.,O
While,O
largely,O
unchanged,O
between,O
Veh,O
and,O
NOB,O
treatment,O
under,O
RC,O
conditions,O
based,O
on,O
2,O
-,O
way,O
ANOVA,O
",",O
CPS1,B-GP
levels,O
were,O
significantly,O
reduced,O
in,O
HFD,O
.,O
Veh,O
compared,O
with,O
RC,O
(,O
Fig,O
.,O
2a,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S1A,O
),O
[,O
47,O
].,O
Strikingly,O
",",O
NOB,O
restored,O
CPS1,B-GP
in,O
HFD,O
to,O
RC,O
levels,O
(,O
Fig,O
.,O
2a,O
).,O
We,O
also,O
confirmed,O
the,O
above,O
results,O
using,O
Coomassie,O
staining,O
followed,O
by,O
mass,O
spectrometry,O
(,O
Additional,O
file,O
1,O
:,O
Figure,O
S1B,O
and,O
Table,O
S3,O
).,O
Furthermore,O
",",O
confocal,O
microscopy,O
using,O
anti,O
-,O
CPS1,B-GP
antibody,B-GP
also,O
clearly,O
showed,O
recovered,O
CPS1,B-GP
in,O
livers,O
from,O
HFD,O
.,O
NOB,O
mice,B-OG
relative,O
to,O
HFD,O
.,O
Veh,O
(,O
Fig,O
.,O
2b,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S1C,O
).,O
Real,O
-,O
time,O
qPCR,O
analysis,O
further,O
revealed,O
strong,O
repression,O
of,O
Cps1,B-GP
messenger,O
levels,O
by,O
HFD,O
relative,O
to,O
RC,O
(,O
Fig,O
.,O
2c,O
"),",O
consistent,O
with,O
its,O
effect,O
on,O
CPS1,B-GP
proteins,O
.,O
Importantly,O
",",O
NOB,O
restored,O
Cps1,B-GP
mRNA,O
expression,O
",",O
mirroring,O
the,O
changes,O
in,O
CPS1,B-GP
protein,O
.,O
Fig,O
.,O
2NOB,O
modulates,O
Cps1,B-GP
mRNA,O
and,O
protein,O
expression,O
.,O
a,O
Total,O
protein,O
extracts,O
were,O
prepared,O
from,O
liver,O
samples,O
collected,O
from,O
the,O
four,O
diet,O
/,O
treatment,O
groups,O
of,O
wild,O
-,O
type,O
mice,B-OG
at,O
the,O
indicated,O
circadian,O
time,O
points,O
(,O
n,O
=,O
3,O
).,O
Western,O
blotting,O
analysis,O
was,O
performed,O
using,O
anti,O
-,O
CPS1,B-GP
antibody,B-GP
.,O
RC,O
regular,O
chow,O
",",O
HFD,O
high,O
-,O
fat,O
diet,O
",",O
Veh,O
vehicle,O
",",O
NOB,O
Nobiletin,O
.,O
The,O
results,O
shown,O
are,O
representative,O
of,O
three,O
independent,O
experiments,O
.,O
See,O
Additional,O
file,O
1,O
:,O
Figure,O
S1A,O
for,O
quantitative,O
analysis,O
.,O
b,O
Immunohistochemical,O
staining,O
of,O
CPS1,B-GP
in,O
liver,O
sections,O
from,O
mice,B-OG
with,O
the,O
indicated,O
diet,O
and,O
treatment,O
at,O
ZT2,O
.,O
c,O
Real,O
-,O
time,O
RT,O
-,O
PCR,O
analysis,O
of,O
Cps1,B-GP
in,O
liver,O
samples,O
collected,O
as,O
in,O
(,O
a,O
).,O
Data,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
(,O
n,O
=,O
3,O
).,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
statistical,O
differences,O
between,O
HFD,O
.,O
Veh,O
and,O
other,O
three,O
groups,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
d,O
Western,O
blotting,O
analysis,O
of,O
protein,O
lysates,O
of,O
liver,O
samples,O
collected,O
at,O
ZT,O
6,O
and,O
18,O
from,O
mice,B-OG
with,O
the,O
indicated,O
diet,O
and,O
treatment,O
(,O
n,O
=,O
3,O
).,O
HPD,O
indicates,O
high,O
-,O
protein,O
diet,O
.,O
The,O
images,O
shown,O
to,O
the,O
left,O
are,O
representative,O
of,O
three,O
independent,O
experiments,O
.,O
Quantitation,O
of,O
Western,O
blots,O
was,O
carried,O
out,O
and,O
the,O
results,O
",",O
presented,O
as,O
mean,O
±,O
SEM,O
",",O
are,O
shown,O
in,O
the,O
lower,O
panel,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
",",O
RC,O
vs,O
.,O
HPD,O
",",O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
e,O
Real,O
-,O
time,O
qPCR,O
analysis,O
was,O
carried,O
out,O
using,O
total,O
RNAs,O
extracted,O
from,O
the,O
liver,O
samples,O
described,O
in,O
(,O
d,O
).,O
The,O
results,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
",",O
RC,O
vs,O
.,O
HPD,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
We,O
also,O
examined,O
effects,O
of,O
HPD,O
on,O
CPS1,B-GP
levels,O
.,O
HPD,O
enhanced,O
the,O
abundance,O
of,O
CPS1,B-GP
by,O
approximately,O
20,O
%,O
(,O
Fig,O
.,O
2d,O
"),",O
suggesting,O
a,O
role,O
of,O
CPS1,B-GP
induction,O
to,O
cope,O
with,O
increased,O
dietary,O
protein,O
intake,O
.,O
HPD,O
feeding,O
exerted,O
similar,O
modest,O
inducing,O
effects,O
on,O
Cps1,B-GP
mRNA,O
compared,O
with,O
RC,O
(,O
Fig,O
.,O
2e,O
).,O
NOB,O
treatment,O
",",O
on,O
the,O
other,O
hand,O
",",O
did,O
not,O
further,O
increase,O
CPS1,B-GP
protein,O
level,O
under,O
HPD,O
(,O
Fig,O
.,O
2d,O
"),",O
yet,O
seemed,O
to,O
alter,O
the,O
mRNA,O
expression,O
with,O
a,O
slight,O
increase,O
at,O
ZT18,O
(,O
Fig,O
.,O
2e,O
).,O
These,O
results,O
indicated,O
opposing,O
effects,O
of,O
HFD,O
and,O
HPD,O
on,O
Cps1,B-GP
expression,O
",",O
suggesting,O
that,O
ammonia,O
-,O
lowering,O
activities,O
of,O
NOB,O
entail,O
diet,O
-,O
specific,O
CPS1,B-GP
regulatory,O
mechanisms,O
.,O
NOB,O
restored,O
levels,O
of,O
C,B-GP
/,I-GP
EBP,I-GP
transcription,B-GP
factors,I-GP
repressed,O
under,O
HFD,O
We,O
next,O
focused,O
on,O
HFD,O
where,O
the,O
above,O
results,O
indicated,O
NOB,O
-,O
mediated,O
transcriptional,O
induction,O
of,O
Cps1,B-GP
.,O
The,O
transcription,B-GP
factors,I-GP
C,B-GP
/,I-GP
EBPα,I-GP
and,O
C,B-GP
/,I-GP
EBPβ,I-GP
are,O
known,O
to,O
play,O
important,O
roles,O
in,O
energy,O
homeostasis,O
and,O
urea,O
cycle,O
expression,O
[,O
7,O
",",O
48,O
",",O
49,O
].,O
Consistent,O
with,O
previous,O
results,O
[,O
50,O
"],",O
liver,O
expression,O
of,O
both,O
Cebp,B-GP
genes,O
exhibited,O
clear,O
circadian,O
oscillation,O
in,O
RC,O
;,O
somewhat,O
surprisingly,O
",",O
NOB,O
moderately,O
elevated,O
Cebpa,B-GP
expression,O
",",O
yet,O
strongly,O
repressed,O
Cebpb,B-GP
(,O
Fig,O
.,O
3a,O
).,O
HFD,O
significantly,O
dampened,O
levels,O
and,O
circadian,O
amplitude,O
(,O
peak,O
/,O
trough,O
difference,O
),O
of,O
both,O
Cebp,B-GP
mRNA,O
expression,O
",",O
and,O
interestingly,O
also,O
reversed,O
their,O
circadian,O
phase,O
.,O
NOB,O
treatment,O
largely,O
restored,O
Cebpa,B-GP
mRNA,O
expression,O
(,O
ZT14,O
),O
and,O
circadian,O
phase,O
relative,O
to,O
RC,O
(,O
Fig,O
.,O
3a,O
).,O
Fig,O
.,O
3NOB,O
rescued,O
Cebpa,B-GP
and,O
Cebpb,B-GP
mRNA,O
and,O
protein,O
circadian,O
expression,O
in,O
the,O
liver,O
from,O
HFD,O
fed,O
mice,B-OG
.,O
a,O
Real,O
-,O
time,O
RT,O
-,O
PCR,O
analysis,O
of,O
Cebpa,B-GP
and,O
Cebpb,B-GP
in,O
livers,O
collected,O
at,O
the,O
indicated,O
circadian,O
times,O
from,O
mice,B-OG
with,O
the,O
indicated,O
diet,O
and,O
treatment,O
as,O
in,O
Fig,O
.,O
2a,O
.,O
Student,O
’,O
s,O
t,O
-,O
test,O
:,O
RC,O
.,O
Veh,O
vs,O
.,O
HFD,O
.,O
Veh,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
;,O
HFD,O
.,O
Veh,O
vs,O
.,O
HFD,O
.,O
NOB,O
",",O
†,O
p,O
<,O
0,O
.,O
05,O
.,O
b,O
Western,O
blotting,O
was,O
performed,O
using,O
total,O
liver,O
protein,O
lysates,O
with,O
the,O
indicated,O
antibodies,B-GP
.,O
The,O
results,O
are,O
representative,O
of,O
three,O
independent,O
experiments,O
.,O
See,O
Additional,O
file,O
1,O
:,O
Figure,O
S2,O
for,O
quantitative,O
analysis,O
HFD,O
also,O
significantly,O
down,O
-,O
regulated,O
protein,O
levels,O
of,O
C,B-GP
/,I-GP
EBPα,I-GP
p42,B-GP
",",O
the,O
active,O
form,O
[,O
51,O
"],",O
across,O
the,O
circadian,O
cycle,O
(,O
HFD,O
.,O
Veh,O
vs,O
.,O
RC,O
.,O
Veh,O
;,O
Fig,O
.,O
3b,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S2A,O
).,O
In,O
comparison,O
",",O
the,O
amount,O
of,O
p30,B-GP
",",O
the,O
truncated,O
form,O
lacking,O
the,O
N,O
-,O
terminal,O
transactivation,O
domain,O
",",O
was,O
also,O
reduced,O
",",O
albeit,O
to,O
a,O
lesser,O
degree,O
(,O
Fig,O
.,O
3b,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S2B,O
).,O
Compared,O
with,O
Veh,O
",",O
NOB,O
did,O
not,O
show,O
significant,O
effects,O
on,O
p42,B-GP
/,O
p30,B-GP
levels,O
in,O
RC,O
",",O
yet,O
appeared,O
to,O
reverse,O
their,O
reduction,O
by,O
HFD,O
to,O
RC,O
levels,O
(,O
Fig,O
.,O
3b,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S2A,O
).,O
HFD,O
was,O
previously,O
reported,O
to,O
increase,O
C,B-GP
/,I-GP
EBPβ,I-GP
(,O
LAP,B-GP
and,O
LIP,B-GP
),O
levels,O
in,O
mouse,B-OG
liver,O
[,O
52,O
].,O
In,O
comparison,O
",",O
our,O
circadian,O
analysis,O
revealed,O
a,O
C,B-GP
/,I-GP
EBPβ,I-GP
(,O
LAP,B-GP
),O
phase,O
shift,O
in,O
HFD,O
(,O
Fig,O
.,O
3b,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S2C,O
).,O
Whereas,O
both,O
RC,O
.,O
Veh,O
and,O
RC,O
.,O
NOB,O
showed,O
peak,O
C,B-GP
/,I-GP
EBPβ,I-GP
expression,O
at,O
ZT20,O
",",O
HFD,O
shifted,O
the,O
peak,O
to,O
ZT14,O
",",O
with,O
HFD,O
.,O
NOB,O
displaying,O
a,O
slight,O
increase,O
over,O
HFD,O
.,O
Veh,O
(,O
Fig,O
.,O
3b,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S2C,O
).,O
These,O
results,O
illustrated,O
circadian,O
-,O
and,O
diet,O
-,O
dependent,O
expression,O
patterns,O
of,O
C,B-GP
/,I-GP
EBPs,I-GP
and,O
a,O
novel,O
function,O
of,O
NOB,O
in,O
restoring,O
C,B-GP
/,I-GP
EBP,I-GP
levels,O
repressed,O
by,O
HFD,O
.,O
C,B-GP
/,I-GP
EBP,I-GP
site,O
mutations,O
on,O
the,O
Cps1,B-GP
promoter,O
abolished,O
NOB,O
effects,O
Previous,O
studies,O
have,O
identified,O
both,O
proximal,O
and,O
distal,O
C,B-GP
/,I-GP
EBP,I-GP
sites,O
in,O
the,O
Cps1,B-GP
promoter,O
[,O
16,O
",",O
35,O
",",O
53,O
].,O
We,O
next,O
generated,O
reporter,O
constructs,O
containing,O
either,O
the,O
intact,O
Cps1,B-GP
promoter,O
or,O
mutant,O
promoters,O
respectively,O
deficient,O
in,O
either,O
C,B-GP
/,I-GP
EBP,I-GP
sites,O
(,O
Fig,O
.,O
4a,O
).,O
NOB,O
was,O
found,O
to,O
dose,O
-,O
dependently,O
activate,O
reporter,O
expression,O
from,O
the,O
WT,O
construct,O
with,O
an,O
intact,O
promoter,O
(,O
Fig,O
.,O
4b,O
and,O
c,O
).,O
Distal,O
mutations,O
markedly,O
repressed,O
the,O
reporter,O
expression,O
",",O
yet,O
seemed,O
to,O
at,O
least,O
partially,O
retain,O
NOB,O
response,O
as,O
NOB,O
increased,O
mutant,O
reporter,O
expression,O
relative,O
to,O
DMSO,O
(,O
Fig,O
.,O
4b,O
).,O
In,O
comparison,O
",",O
while,O
not,O
significantly,O
affecting,O
the,O
baseline,O
expression,O
level,O
",",O
proximal,O
mutations,O
abolished,O
NOB,O
dose,O
-,O
dependent,O
induction,O
seen,O
in,O
the,O
WT,O
construct,O
(,O
Fig,O
.,O
4c,O
).,O
C,B-GP
/,I-GP
EBPα,I-GP
co,O
-,O
transfection,O
activated,O
both,O
proximal,O
and,O
distal,O
WT,O
reporter,O
expression,O
",",O
but,O
showed,O
no,O
effects,O
on,O
mutant,O
constructs,O
in,O
the,O
absence,O
of,O
NOB,O
.,O
These,O
results,O
suggested,O
that,O
the,O
proximal,O
C,B-GP
/,I-GP
EBP,I-GP
consensus,O
site,O
plays,O
a,O
major,O
role,O
in,O
mediating,O
the,O
NOB,O
induction,O
of,O
Cps1,B-GP
.,O
Fig,O
.,O
4C,O
/,O
EBP,O
binding,O
site,O
mutations,O
in,O
proximal,O
and,O
distal,O
Cps1,B-GP
enhancer,O
regions,O
impaired,O
NOB,O
-,O
mediated,O
reporter,O
activation,O
.,O
a,O
Diagram,O
of,O
distal,O
and,O
proximal,O
C,B-GP
/,I-GP
EBP,I-GP
sites,O
on,O
the,O
Cps1,B-GP
promoter,O
region,O
.,O
b,O
and,O
c,O
Hepa1,O
-,O
6,O
cells,O
were,O
transfected,O
with,O
reporter,O
constructs,O
containing,O
wild,O
-,O
type,O
(,O
WT,O
;,O
white,O
bars,O
),O
and,O
C,B-GP
/,I-GP
EBP,I-GP
binding,O
site,O
mutated,O
(,O
black,O
bars,O
),O
enhancer,O
regions,O
",",O
and,O
treated,O
with,O
NOB,O
at,O
the,O
indicated,O
doses,O
.,O
Co,O
-,O
transfection,O
of,O
C,B-GP
/,I-GP
EBPα,I-GP
expression,O
construct,O
was,O
also,O
carried,O
out,O
in,O
parallel,O
.,O
Each,O
value,O
represented,O
mean,O
±,O
SEM,O
of,O
three,O
replicates,O
from,O
a,O
single,O
assay,O
.,O
The,O
results,O
are,O
representative,O
of,O
at,O
least,O
three,O
independent,O
experiments,O
.,O
b,O
and,O
c,O
show,O
results,O
from,O
reporter,O
constructs,O
containing,O
distal,O
and,O
proximal,O
WT,O
and,O
mutant,O
enhancers,O
respectively,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
:,O
significant,O
main,O
effects,O
of,O
plasmid,O
construct,O
",",O
(,O
b,O
),O
F,O
=,O
81,O
.,O
43,O
",",O
p,O
<,O
0,O
.,O
001,O
",",O
(,O
c,O
),O
F,O
=,O
254,O
.,O
97,O
",",O
p,O
<,O
0,O
.,O
0001,O
;,O
NOB,O
concentration,O
effect,O
",",O
(,O
b,O
),O
F,O
=,O
47,O
.,O
39,O
",",O
p,O
<,O
0,O
.,O
0001,O
",",O
(,O
c,O
),O
F,O
=,O
42,O
.,O
01,O
",",O
p,O
<,O
0,O
.,O
0001,O
;,O
and,O
a,O
significant,O
interaction,O
between,O
constructs,O
and,O
NOB,O
concentration,O
",",O
(,O
b,O
),O
F,O
=,O
23,O
",",O
p,O
<,O
0,O
.,O
0001,O
",",O
(,O
c,O
),O
F,O
=,O
24,O
.,O
37,O
",",O
p,O
<,O
0,O
.,O
0001,O
Transcriptional,O
regulation,O
of,O
other,O
urea,O
cycle,O
genes,O
by,O
NOB,O
under,O
HFD,O
A,O
number,O
of,O
pioneering,O
studies,O
have,O
provided,O
strong,O
evidence,O
for,O
co,O
-,O
regulation,O
of,O
urea,O
cycle,O
genes,O
by,O
diets,O
",",O
hormones,O
",",O
cAMP,O
and,O
other,O
factors,O
",",O
likely,O
as,O
an,O
evolutionary,O
strategy,O
to,O
efficiently,O
perform,O
ureagenesis,O
in,O
response,O
to,O
various,O
internal,O
and,O
external,O
cues,O
[,O
8,O
",",O
20,O
",",O
35,O
",",O
54,O
–,O
56,O
].,O
In,O
particular,O
",",O
C,B-GP
/,I-GP
EBP,I-GP
sites,O
are,O
found,O
on,O
several,O
urea,O
cycle,O
genes,O
(,O
Fig,O
.,O
5a,O
),O
[,O
7,O
",",O
8,O
].,O
Under,O
RC,O
",",O
NOB,O
treatment,O
showed,O
only,O
modest,O
effects,O
on,O
expression,O
of,O
the,O
four,O
other,O
urea,O
cycle,O
genes,O
(,O
Otc,B-GP
",",O
Ass1,B-GP
",",O
Asl,B-GP
",",O
Arg1,B-GP
),O
relative,O
to,O
Veh,O
controls,O
(,O
Fig,O
.,O
5b,O
-,O
e,O
).,O
Strikingly,O
",",O
whereas,O
HFD,O
generally,O
repressed,O
their,O
mRNA,O
levels,O
and,O
also,O
elicited,O
strong,O
phase,O
shifts,O
(,O
Fig,O
.,O
5,O
"),",O
NOB,O
enhanced,O
their,O
expression,O
and,O
/,O
or,O
amplitude,O
",",O
and,O
interestingly,O
also,O
correct,O
circadian,O
phases,O
.,O
Note,O
that,O
a,O
putative,O
C,B-GP
/,I-GP
EBP,I-GP
site,O
on,O
the,O
Ass1,B-GP
promoter,O
has,O
not,O
been,O
reported,O
",",O
suggesting,O
a,O
secondary,O
effect,O
by,O
C,B-GP
/,I-GP
EBP,I-GP
or,O
other,O
transcriptional,O
mechanisms,O
[,O
35,O
].,O
Since,O
C,B-GP
/,I-GP
EBPs,I-GP
are,O
master,O
regulators,O
of,O
overall,O
hepatic,O
metabolic,O
circuits,O
including,O
glucose,O
and,O
lipid,O
metabolism,O
",",O
coordinate,O
regulation,O
of,O
urea,O
cycle,O
genes,O
by,O
C,B-GP
/,I-GP
EBPs,I-GP
may,O
enable,O
metabolic,O
cross,O
-,O
talk,O
between,O
nitrogen,O
homeostasis,O
and,O
energy,O
metabolism,O
[,O
55,O
",",O
57,O
].,O
Fig,O
.,O
5NOB,O
coordinately,O
enhanced,O
urea,O
cycle,O
gene,O
expression,O
.,O
a,O
Diagram,O
of,O
C,B-GP
/,I-GP
EBP,I-GP
sites,O
on,O
the,O
genomic,O
regions,O
for,O
urea,O
cycle,O
genes,O
including,O
Otc,B-GP
",",O
Ass1,B-GP
",",O
Asl,B-GP
",",O
and,O
Arg1,B-GP
.,O
b,O
-,O
e,O
Liver,O
samples,O
were,O
collected,O
from,O
the,O
four,O
diet,O
/,O
treatment,O
groups,O
of,O
wild,O
-,O
type,O
mice,B-OG
at,O
the,O
indicated,O
circadian,O
time,O
points,O
.,O
Total,O
RNAs,O
were,O
purified,O
for,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
analysis,O
using,O
primers,O
for,O
the,O
four,O
urea,O
cycle,O
genes,O
",",O
including,O
Otc,B-GP
(,O
b,O
"),",O
Ass1c,B-GP
",",O
Asl,B-GP
d,O
and,O
Arg1,B-GP
e,O
.,O
RC,O
regular,O
chow,O
",",O
HFD,O
high,O
-,O
fat,O
diet,O
",",O
Veh,O
vehicle,O
",",O
NOB,O
Nobiletin,O
.,O
Data,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
(,O
n,O
=,O
3,O
).,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
",",O
RC,O
.,O
Veh,O
vs,O
.,O
HFD,O
.,O
Veh,O
",",O
a,O
p,O
<,O
0,O
.,O
0001,O
",",O
b,O
p,O
<,O
0,O
.,O
01,O
",",O
c,O
p,O
<,O
0,O
.,O
05,O
",",O
d,O
p,O
<,O
0,O
.,O
01,O
.,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
HFD,O
.,O
Veh,O
vs,O
.,O
HFD,O
.,O
NOB,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
Circadian,O
ClockΔ19,O
/,O
Δ19,O
mutant,O
mice,B-OG
displayed,O
attenuated,O
CPS1,B-GP
and,O
C,B-GP
/,I-GP
EBP,I-GP
levels,O
Consistent,O
with,O
previous,O
studies,O
[,O
27,O
",",O
50,O
",",O
58,O
"],",O
our,O
data,O
thus,O
far,O
indicated,O
that,O
both,O
Cps1,B-GP
and,O
Cebp,B-GP
genes,O
are,O
subjected,O
to,O
circadian,O
control,O
and,O
display,O
rhythmic,O
patterns,O
of,O
expression,O
.,O
To,O
directly,O
examine,O
whether,O
the,O
circadian,O
clock,B-GP
plays,O
an,O
essential,O
role,O
in,O
Cps1,B-GP
regulation,O
",",O
we,O
employed,O
ClockΔ19,O
/,O
Δ19,O
mutant,O
mice,B-OG
(,O
Clk,O
),O
which,O
express,O
a,O
dominant,O
negative,O
version,O
of,O
CLOCK,B-GP
proteins,O
and,O
thus,O
are,O
severely,O
impaired,O
in,O
circadian,O
rhythms,O
[,O
59,O
",",O
60,O
].,O
Compared,O
with,O
WT,O
",",O
CPS1,B-GP
",",O
C,B-GP
/,I-GP
EBPα,I-GP
p30,B-GP
and,O
C,B-GP
/,I-GP
EBPβ,I-GP
protein,O
levels,O
were,O
markedly,O
reduced,O
and,O
became,O
largely,O
arrhythmic,O
in,O
Clk,O
under,O
RC,O
feeding,O
and,O
constant,O
darkness,O
(,O
DD,O
),O
conditions,O
(,O
Fig,O
.,O
6a,O
and,O
see,O
also,O
quantification,O
in,O
Additional,O
file,O
1,O
:,O
Figure,O
S3,O
).,O
In,O
comparison,O
",",O
p42,B-GP
expression,O
and,O
oscillation,O
were,O
maintained,O
in,O
Clk,O
mice,B-OG
",",O
yet,O
interestingly,O
displayed,O
a,O
reversed,O
circadian,O
phase,O
pattern,O
(,O
Fig,O
.,O
6a,O
and,O
Additional,O
file,O
1,O
:,O
Figure,O
S3B,O
).,O
These,O
observations,O
illustrated,O
gene,O
-,O
or,O
isoform,O
-,O
specific,O
circadian,O
expression,O
regulation,O
.,O
Furthermore,O
",",O
pronounced,O
expression,O
changes,O
in,O
C,B-GP
/,I-GP
EBP,I-GP
subunits,O
were,O
observed,O
in,O
the,O
mutant,O
mice,B-OG
",",O
including,O
both,O
phase,O
shifts,O
and,O
reduced,O
levels,O
(,O
p30,B-GP
and,O
C,B-GP
/,I-GP
EBPβ,I-GP
).,O
Cps1,B-GP
and,O
Cebpa,B-GP
mRNA,O
expression,O
was,O
also,O
compromised,O
in,O
the,O
mutant,O
mice,B-OG
",",O
showing,O
strongly,O
reduced,O
levels,O
and,O
dampened,O
circadian,O
amplitude,O
(,O
Fig,O
.,O
6b,O
).,O
In,O
comparison,O
",",O
Cebpb,B-GP
mRNA,O
expression,O
exhibited,O
a,O
marked,O
phase,O
shift,O
in,O
the,O
mutant,O
compared,O
with,O
WT,O
(,O
Fig,O
.,O
6b,O
",",O
bottom,O
"),",O
while,O
maintaining,O
a,O
normal,O
amplitude,O
.,O
Whereas,O
CPS1,B-GP
levels,O
were,O
lower,O
in,O
Clk,O
than,O
WT,O
",",O
neither,O
HFD,O
nor,O
NOB,O
in,O
mutant,O
mice,B-OG
conferred,O
significant,O
changes,O
(,O
Fig,O
.,O
6c,O
;,O
lower,O
panel,O
:,O
quantification,O
).,O
These,O
results,O
together,O
indicated,O
a,O
critical,O
role,O
of,O
a,O
functional,O
clock,B-GP
to,O
mediate,O
NOB,O
induction,O
of,O
CPS1,B-GP
.,O
Fig,O
.,O
6NOB,O
restored,O
Cps1,B-GP
and,O
Cebp,B-GP
mRNA,O
and,O
protein,O
levels,O
in,O
a,O
clock,B-GP
-,O
dependent,O
manner,O
.,O
a,O
Liver,O
samples,O
were,O
collected,O
at,O
the,O
indicated,O
Circadian,O
Times,O
(,O
CT,O
),O
from,O
regular,O
chow,O
-,O
fed,O
WT,O
and,O
Clock,B-GP
Δ19,O
/,O
Δ19,O
mutant,O
(,O
Clk,O
),O
mice,B-OG
(,O
n,O
=,O
3,O
),O
in,O
constant,O
darkness,O
(,O
DD,O
),O
when,O
the,O
circadian,O
clock,B-GP
free,O
runs,O
devoid,O
of,O
light,O
cue,O
.,O
CT0,O
corresponds,O
to,O
the,O
onset,O
of,O
subjective,O
day,O
.,O
Western,O
blotting,O
was,O
performed,O
using,O
total,O
protein,O
extracts,O
from,O
the,O
liver,O
samples,O
with,O
the,O
indicated,O
antibodies,B-GP
.,O
See,O
Additional,O
file,O
1,O
:,O
Figure,O
S3,O
for,O
quantitative,O
analysis,O
.,O
b,O
Real,O
-,O
time,O
RT,O
-,O
PCR,O
analysis,O
of,O
Cps1,B-GP
",",O
Cebpa,B-GP
and,O
Cebpb,B-GP
was,O
carried,O
out,O
using,O
total,O
RNAs,O
extracted,O
from,O
the,O
liver,O
samples,O
described,O
in,O
(,O
a,O
).,O
Data,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
",",O
WT,O
vs,O
.,O
Clk,O
",",O
Cps1,B-GP
",",O
Cebpb,B-GP
p,O
<,O
0,O
.,O
01,O
;,O
Cebpa,B-GP
p,O
<,O
0,O
.,O
05,O
.,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
WT,O
vs,O
.,O
Clk,O
",",O
Cps1,B-GP
:,O
CT4,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
;,O
Cebpa,B-GP
:,O
CT8,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
;,O
Cebpb,B-GP
:,O
CT8,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
.,O
c,O
Western,O
blot,O
analysis,O
of,O
CPS1,B-GP
protein,O
levels,O
in,O
liver,O
samples,O
collected,O
at,O
ZT8,O
and,O
ZT20,O
from,O
WT,O
and,O
Clk,O
mice,B-OG
subjected,O
to,O
the,O
indicated,O
diet,O
and,O
treatment,O
.,O
RC,O
regular,O
chow,O
",",O
HFD,O
high,O
-,O
fat,O
diet,O
",",O
Veh,O
vehicle,O
",",O
NOB,O
Nobiletin,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
",",O
WT,O
vs,O
.,O
individual,O
Clk,O
groups,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
NOB,O
modulated,O
serum,O
and,O
urine,O
urea,O
content,O
Finally,O
",",O
to,O
further,O
elucidate,O
a,O
modulatory,O
role,O
of,O
NOB,O
in,O
nitrogen,O
homeostasis,O
",",O
we,O
measured,O
urea,O
content,O
in,O
serum,O
and,O
urine,O
at,O
both,O
day,O
-,O
and,O
night,O
-,O
time,O
.,O
In,O
RC,O
",",O
serum,O
urea,O
levels,O
were,O
mildly,O
reduced,O
in,O
the,O
NOB,O
group,O
at,O
both,O
day,O
-,O
and,O
night,O
-,O
time,O
(,O
ZT6,O
and,O
18,O
),O
(,O
Fig,O
.,O
7a,O
"),",O
whereas,O
the,O
urine,O
urea,O
levels,O
showed,O
the,O
opposite,O
trend,O
",",O
suggesting,O
increased,O
urine,O
urea,O
excretion,O
by,O
NOB,O
(,O
Fig,O
.,O
7b,O
).,O
In,O
comparison,O
",",O
HFD,O
feeding,O
led,O
to,O
lower,O
serum,O
urea,O
levels,O
than,O
RC,O
(,O
Fig,O
.,O
7a,O
).,O
More,O
importantly,O
",",O
HFD,O
showed,O
a,O
reverse,O
NOB,O
response,O
;,O
specifically,O
",",O
NOB,O
increased,O
serum,O
urea,O
and,O
concomitantly,O
reduced,O
renal,O
urea,O
excretion,O
",",O
particularly,O
at,O
ZT18,O
(,O
Fig,O
.,O
7b,O
).,O
These,O
results,O
further,O
illustrated,O
a,O
modulatory,O
role,O
of,O
NOB,O
in,O
nitrogen,O
homeostasis,O
.,O
Fig,O
.,O
7Effects,O
of,O
NOB,O
on,O
urea,O
production,O
.,O
a,O
and,O
b,O
Serum,O
(,O
a,O
),O
and,O
urine,O
(,O
b,O
),O
urea,O
levels,O
at,O
ZT6,O
and,O
ZT18,O
in,O
WT,O
mice,B-OG
treated,O
with,O
Veh,O
or,O
NOB,O
under,O
RC,O
(,O
n,O
=,O
7,O
),O
or,O
HFD,O
(,O
n,O
=,O
4,O
).,O
Data,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
Veh,O
vs,O
.,O
NOB,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
;,O
RC,O
vs,O
.,O
HFD,O
",",O
†,O
p,O
<,O
0,O
.,O
05,O
",",O
††,O
p,O
<,O
0,O
.,O
01,O
Discussion,O
In,O
the,O
current,O
study,O
",",O
we,O
demonstrated,O
a,O
broad,O
effect,O
of,O
the,O
natural,O
flavonoid,O
NOB,O
in,O
reducing,O
serum,O
ammonia,O
levels,O
under,O
varying,O
diet,O
conditions,O
.,O
NOB,O
and,O
other,O
related,O
polymethoxylated,O
flavonoids,O
are,O
dietary,O
components,O
generally,O
showing,O
favorable,O
pharmacokinetic,O
profiles,O
[,O
61,O
",",O
62,O
"],",O
and,O
mouse,B-OG
and,O
human,B-OG
studies,O
revealed,O
promising,O
efficacy,O
of,O
NOB,O
against,O
the,O
metabolic,B-DS
syndrome,I-DS
without,O
significant,O
toxicity,O
[,O
40,O
",",O
44,O
",",O
45,O
",",O
63,O
].,O
The,O
current,O
work,O
illustrated,O
a,O
novel,O
function,O
of,O
NOB,O
in,O
ammonia,O
disposal,O
",",O
extending,O
the,O
long,O
list,O
of,O
physiological,O
benefits,O
associated,O
with,O
NOB,O
and,O
other,O
natural,O
flavonoids,O
[,O
63,O
",",O
64,O
].,O
In,O
light,O
of,O
these,O
beneficial,O
attributes,O
",",O
it,O
warrants,O
further,O
investigation,O
whether,O
NOB,O
can,O
be,O
incorporated,O
into,O
dietary,O
management,O
for,O
congenital,O
and,O
injury,O
-,O
induced,O
hyperammonemia,B-DS
.,O
Our,O
study,O
revealed,O
broad,O
ammonia,O
-,O
lowering,O
activities,O
of,O
NOB,O
in,O
mice,B-OG
fed,O
with,O
RC,O
",",O
HFD,O
or,O
HPD,O
",",O
ostensibly,O
utilizing,O
distinct,O
",",O
diet,O
-,O
specific,O
mechanisms,O
.,O
Whereas,O
transcriptional,O
activation,O
of,O
CPS1,B-GP
via,O
C,B-GP
/,I-GP
EBP,I-GP
induction,O
seems,O
to,O
operate,O
under,O
HFD,O
",",O
NOB,O
treatment,O
in,O
conjunction,O
with,O
RC,O
and,O
HPD,O
feeding,O
appeared,O
not,O
to,O
elicit,O
significant,O
CPS1,B-GP
induction,O
.,O
Moreover,O
",",O
in,O
contrast,O
to,O
RC,O
where,O
NOB,O
similarly,O
reduced,O
serum,O
ammonia,O
at,O
both,O
ZT6,O
and,O
ZT18,O
",",O
in,O
HFD,O
and,O
HPD,O
NOB,O
more,O
strongly,O
diminished,O
the,O
relative,O
high,O
ammonia,O
levels,O
in,O
respective,O
diets,O
(,O
ZT6,O
for,O
HFD,O
and,O
ZT18,O
for,O
HPD,O
).,O
As,O
a,O
result,O
",",O
NOB,O
functions,O
to,O
reverse,O
the,O
exaggerated,O
ammonia,O
variation,O
between,O
the,O
active,O
and,O
inactive,O
phases,O
",",O
essentially,O
normalizing,O
circadian,O
ammonia,O
rhythm,O
in,O
HFD,O
and,O
HPD,O
to,O
RC,O
levels,O
.,O
Given,O
the,O
remarkably,O
diverse,O
cellular,O
pathways,O
known,O
to,O
be,O
modulated,O
by,O
NOB,O
and,O
other,O
flavonoids,O
",",O
various,O
molecular,O
and,O
cellular,O
mechanisms,O
may,O
underlie,O
such,O
mechanistic,O
and,O
functional,O
plasticity,O
[,O
63,O
–,O
67,O
].,O
Besides,O
transcriptional,O
regulation,O
(,O
C,B-GP
/,I-GP
EBP,I-GP
",",O
glucocorticoid,B-GP
receptor,I-GP
",",O
CREB,B-GP
and,O
HNF3,B-GP
),O
and,O
the,O
allosteric,O
cofactor,O
NAG,O
[,O
7,O
",",O
17,O
"],",O
recent,O
mechanistic,O
studies,O
have,O
also,O
underscored,O
the,O
importance,O
of,O
post,O
-,O
translational,O
modifications,O
(,O
PTMs,O
),O
for,O
CPS1,B-GP
protein,O
activity,O
[,O
11,O
–,O
13,O
",",O
47,O
].,O
Other,O
urea,O
cycle,O
genes,O
may,O
also,O
serve,O
as,O
the,O
primary,O
target,O
;,O
one,O
such,O
candidate,O
is,O
Otc,B-GP
",",O
especially,O
given,O
its,O
functional,O
connection,O
with,O
the,O
circadian,O
clock,B-GP
[,O
19,O
].,O
Finally,O
",",O
NOB,O
may,O
also,O
attenuate,O
HPD,O
-,O
induced,O
bacterial,O
production,O
of,O
ammonia,O
by,O
amino,O
acid,O
deamination,O
and,O
urea,O
hydrolysis,O
[,O
4,O
].,O
Our,O
analysis,O
revealed,O
differential,O
responses,O
of,O
serum,O
and,O
urine,O
urea,O
levels,O
to,O
NOB,O
treatment,O
in,O
HFD,O
.,O
Urea,O
represents,O
the,O
most,O
predominant,O
circulating,O
nitrogen,O
reservoir,O
",",O
and,O
blood,O
urea,O
nitrogen,O
(,O
BUN,O
),O
level,O
is,O
known,O
to,O
be,O
regulated,O
by,O
multiple,O
factors,O
including,O
protein,O
intake,O
",",O
protein,O
metabolism,O
and,O
renal,O
function,O
[,O
1,O
",",O
5,O
].,O
HFD,O
contains,O
lower,O
protein,O
content,O
than,O
RC,O
(,O
20,O
%,O
vs,O
.,O
29,O
%,O
in,O
calories,O
"),",O
and,O
NOB,O
acts,O
to,O
attenuate,O
ammonia,O
levels,O
by,O
activating,O
urea,O
cycle,O
gene,O
expression,O
.,O
Thus,O
",",O
urea,O
may,O
be,O
salvaged,O
to,O
maintain,O
nitrogen,O
balance,O
in,O
the,O
HFD,O
.,O
NOB,O
condition,O
.,O
For,O
example,O
",",O
urine,O
excretion,O
rate,O
/,O
volume,O
and,O
renal,O
reabsorption,O
of,O
water,O
/,O
mineral,O
/,O
urea,O
are,O
tightly,O
coupled,O
to,O
regulate,O
osmotic,O
pressure,O
",",O
which,O
may,O
in,O
turn,O
modulate,O
serum,O
and,O
urine,O
urea,O
levels,O
.,O
However,O
",",O
a,O
direct,O
role,O
of,O
NOB,O
in,O
renal,O
function,O
remains,O
to,O
be,O
elucidated,O
.,O
Amino,O
acid,O
levels,O
in,O
human,B-OG
blood,O
have,O
been,O
shown,O
to,O
exhibit,O
robust,O
circadian,O
oscillation,O
",",O
concordant,O
with,O
results,O
from,O
a,O
yeast,B-OG
metabolic,O
cycle,O
resembling,O
mammalian,O
circadian,O
rhythm,O
[,O
68,O
–,O
70,O
].,O
In,O
parallel,O
with,O
fluctuating,O
amino,O
acid,O
levels,O
over,O
the,O
daily,O
cycle,O
",",O
CPS1,B-GP
and,O
several,O
other,O
urea,O
cycle,O
components,O
exhibited,O
circadian,O
mRNA,O
and,O
protein,O
expression,O
patterns,O
[,O
27,O
].,O
However,O
",",O
much,O
conflictory,O
evidence,O
has,O
also,O
been,O
reported,O
with,O
regard,O
to,O
Cps1,B-GP
circadian,O
expression,O
[,O
26,O
",",O
28,O
",",O
29,O
].,O
Our,O
experiments,O
",",O
using,O
specific,O
primers,O
and,O
antibodies,B-GP
",",O
revealed,O
weak,O
oscillation,O
of,O
Cps1,B-GP
mRNA,O
and,O
protein,O
.,O
Interestingly,O
",",O
NOB,O
appeared,O
to,O
augment,O
CPS1,B-GP
protein,O
oscillation,O
under,O
RC,O
",",O
and,O
also,O
enhanced,O
CPS1,B-GP
levels,O
under,O
HFD,O
in,O
a,O
circadian,O
clock,B-GP
-,O
dependent,O
manner,O
.,O
One,O
possible,O
mechanism,O
of,O
circadian,O
regulation,O
may,O
depend,O
on,O
C,B-GP
/,I-GP
EBPs,I-GP
as,O
their,O
expression,O
is,O
subjected,O
to,O
clock,B-GP
control,O
[,O
50,O
"],",O
although,O
other,O
mechanisms,O
likely,O
exist,O
[,O
19,O
].,O
Of,O
note,O
",",O
we,O
observed,O
distinct,O
circadian,O
changes,O
of,O
C,B-GP
/,I-GP
EBPα,I-GP
p42,B-GP
and,O
p30,B-GP
isoforms,O
in,O
ClockΔ19,O
/,O
Δ19,O
mutant,O
mice,B-OG
relative,O
to,O
WT,O
",",O
suggesting,O
a,O
possible,O
circadian,O
regulation,O
of,O
alternative,O
translation,O
.,O
Currently,O
",",O
work,O
in,O
our,O
lab,O
aims,O
to,O
further,O
understand,O
the,O
detailed,O
mechanism,O
underlying,O
the,O
interaction,O
between,O
the,O
clock,B-GP
",",O
diet,O
and,O
NOB,O
in,O
nitrogen,O
homeostasis,O
.,O
Conclusion,O
In,O
this,O
current,O
study,O
",",O
we,O
present,O
physiological,O
evidence,O
indicating,O
that,O
NOB,O
exhibits,O
a,O
broad,O
activity,O
in,O
ammonia,O
control,O
in,O
mice,B-OG
fed,O
with,O
varying,O
diets,O
.,O
Molecular,O
experiments,O
further,O
revealed,O
that,O
NOB,O
regulates,O
urea,O
cycle,O
function,O
via,O
C,B-GP
/,I-GP
EBP,I-GP
-,O
and,O
circadian,O
clock,B-GP
-,O
dependent,O
regulatory,O
mechanisms,O
.,O
These,O
observations,O
together,O
demonstrate,O
a,O
novel,O
physiological,O
function,O
and,O
cellular,O
mechanism,O
of,O
a,O
natural,O
dietary,O
flavonoid,O
in,O
nitrogen,O
homeostasis,O
.,O
Primers,O
for,O
construction,O
of,O
reporter,O
constructs,O
.,O
Table,O
S2,O
.,O
Primers,O
for,O
real,O
-,O
time,O
qPCR,O
analysis,O
.,O
Table,O
S3,O
.,O
Mass,O
spectrometry,O
data,O
table,O
for,O
the,O
164KD,O
band,O
shown,O
in,O
the,O
Additional,O
file,O
1,O
:,O
Figure,O
S1B,O
.,O
Figure,O
S1,O
.,O
NOB,O
modulates,O
CPS1,B-GP
expression,O
.,O
(,O
A,O
),O
Quantification,O
of,O
CPS1,B-GP
protein,O
levels,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
2a,O
.,O
RC,O
",",O
regular,O
chow,O
;,O
HFD,O
",",O
high,O
-,O
fat,O
diet,O
;,O
Veh,O
",",O
vehicle,O
;,O
NOB,O
",",O
Nobiletin,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
statistical,O
differences,O
between,O
HFD,O
.,O
Veh,O
and,O
other,O
three,O
groups,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
Furthermore,O
",",O
one,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
tests,O
shows,O
significant,O
difference,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
between,O
ZT,O
time,O
points,O
in,O
RC,O
.,O
Veh,O
but,O
not,O
in,O
other,O
groups,O
.,O
(,O
B,O
),O
Coomassie,O
blue,O
staining,O
of,O
CPS1,B-GP
.,O
Mouse,B-OG
liver,O
protein,O
lysates,O
were,O
separated,O
on,O
SDS,O
-,O
PAGE,O
gel,O
and,O
stained,O
with,O
Coomassie,O
blue,O
.,O
The,O
predominant,O
164KD,O
band,O
was,O
validated,O
by,O
mass,O
spectrometry,O
as,O
CPS1,B-GP
(,O
Table,O
S3,O
).,O
(,O
C,O
),O
Control,O
microscopy,O
images,O
for,O
Fig,O
.,O
2b,O
using,O
rabbit,B-OG
IgG,O
.,O
Figure,O
S2,O
.,O
NOB,O
rescued,O
C,B-GP
/,I-GP
EBP,I-GP
protein,O
circadian,O
expression,O
in,O
the,O
liver,O
from,O
HFD,O
fed,O
mice,B-OG
.,O
(,O
A,O
),O
Quantification,O
of,O
C,B-GP
/,I-GP
EBPα,I-GP
p42,B-GP
protein,O
levels,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
3b,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
difference,O
between,O
RC,O
.,O
Veh,O
and,O
HFD,O
.,O
Veh,O
(,O
p,O
<,O
0,O
.,O
05,O
"),",O
indicating,O
diet,O
effect,O
on,O
the,O
C,B-GP
/,I-GP
EBPα,I-GP
p42,B-GP
expression,O
level,O
.,O
Importantly,O
",",O
RC,O
.,O
NOB,O
was,O
not,O
significantly,O
different,O
from,O
HFD,O
.,O
NOB,O
",",O
suggesting,O
NOB,O
reversed,O
the,O
reducing,O
effect,O
of,O
HFD,O
on,O
the,O
C,B-GP
/,I-GP
EBPα,I-GP
p42,B-GP
expression,O
.,O
(,O
B,O
),O
Quantification,O
of,O
C,B-GP
/,I-GP
EBPα,I-GP
p30,B-GP
protein,I-GP
levels,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
3b,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
difference,O
between,O
RC,O
.,O
Veh,O
and,O
HFD,O
.,O
Veh,O
(,O
p,O
<,O
0,O
.,O
01,O
"),",O
but,O
RC,O
.,O
NOB,O
and,O
HFD,O
.,O
NOB,O
was,O
not,O
significantly,O
different,O
",",O
again,O
suggesting,O
NOB,O
reversed,O
the,O
reducing,O
effect,O
of,O
HFD,O
on,O
the,O
p30,B-GP
expression,O
.,O
(,O
C,O
),O
Quantification,O
of,O
C,B-GP
/,I-GP
EBPβ,I-GP
protein,O
levels,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
3b,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
difference,O
between,O
RC,O
.,O
Veh,O
and,O
HFD,O
.,O
Veh,O
(,O
p,O
<,O
0,O
.,O
0001,O
"),",O
but,O
RC,O
.,O
NOB,O
and,O
HFD,O
.,O
NOB,O
was,O
not,O
significantly,O
different,O
.,O
Figure,O
S3,O
.,O
NOB,O
restored,O
CPS1,B-GP
and,O
C,B-GP
/,I-GP
EBP,I-GP
protein,O
levels,O
in,O
a,O
clock,B-GP
-,O
dependent,O
manner,O
.,O
(,O
A,O
),O
Quantification,O
of,O
CPS1,B-GP
protein,O
levels,O
under,O
constant,O
darkness,O
(,O
DD,O
),O
conditions,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
6a,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
statistical,O
difference,O
between,O
WT,O
and,O
Clk,O
(,O
Clock,B-GP
Δ19,O
/,O
Δ19,O
),O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
(,O
B,O
),O
Quantification,O
of,O
C,B-GP
/,I-GP
EBPα,I-GP
p42,B-GP
protein,O
levels,O
under,O
constant,O
darkness,O
(,O
DD,O
),O
conditions,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
6a,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
statistical,O
differences,O
between,O
WT,O
and,O
Clk,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
(,O
C,O
),O
Quantification,O
of,O
C,B-GP
/,I-GP
EBPα,I-GP
p30,B-GP
protein,I-GP
levels,O
under,O
constant,O
darkness,O
(,O
DD,O
),O
conditions,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
6a,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
statistical,O
difference,O
between,O
WT,O
and,O
Clk,O
(,O
p,O
<,O
0,O
.,O
01,O
).,O
(,O
D,O
),O
Quantification,O
of,O
C,B-GP
/,I-GP
EBPβ,I-GP
protein,O
levels,O
under,O
constant,O
darkness,O
(,O
DD,O
),O
conditions,O
from,O
three,O
independent,O
experiments,O
including,O
the,O
blot,O
shown,O
in,O
Fig,O
.,O
6a,O
.,O
Two,O
-,O
way,O
ANOVA,O
with,O
Bonferroni,O
post,O
-,O
hoc,O
tests,O
shows,O
significant,O
statistical,O
difference,O
between,O
WT,O
and,O
Clk,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
Kazunari,O
Nohara,O
and,O
Youngmin,O
Shin,O
contributed,O
equally,O
to,O
this,O
work,O
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
no,O
competing,O
interests,O
.,O
Authors,O
’,O
contributions,O
KN,O
and,O
BH,O
carried,O
out,O
the,O
physiological,O
assays,O
.,O
YS,O
",",O
NP,O
and,O
KJ,O
carried,O
out,O
the,O
molecular,O
studies,O
.,O
NK,O
analyzed,O
promoter,O
sequences,O
and,O
gene,O
expression,O
.,O
KN,O
",",O
NP,O
and,O
SY,O
performed,O
the,O
statistical,O
analysis,O
.,O
SY,O
and,O
ZC,O
conceived,O
of,O
the,O
study,O
",",O
and,O
participated,O
in,O
its,O
design,O
and,O
coordination,O
and,O
drafted,O
the,O
manuscript,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Childhood,O
traumas,O
as,O
a,O
risk,O
factor,O
for,O
HIV,B-OG
-,O
risk,O
behaviours,O
amongst,O
young,O
women,B-OG
and,O
men,B-OG
living,O
in,O
urban,O
informal,O
settlements,O
in,O
South,O
Africa,O
:,O
A,O
cross,O
-,O
sectional,O
study,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Childhood,O
traumas,O
",",O
in,O
the,O
form,O
of,O
physical,O
",",O
sexual,O
",",O
and,O
emotional,B-DS
abuse,I-DS
and,O
neglect,O
",",O
are,O
globally,O
widespread,O
and,O
highly,O
prevalent,O
",",O
and,O
associated,O
with,O
a,O
range,O
of,O
subsequent,O
poor,O
health,O
outcomes,O
.,O
This,O
study,O
sought,O
to,O
understand,O
the,O
relationship,O
between,O
physical,O
",",O
sexual,O
and,O
emotional,O
childhood,O
abuse,O
and,O
subsequent,O
HIV,B-OG
-,O
risk,O
behaviours,O
amongst,O
young,O
people,O
(,O
18,O
–,O
30,O
),O
living,O
in,O
urban,O
informal,O
settlements,O
in,O
Durban,O
",",O
South,O
Africa,O
.,O
Data,O
came,O
from,O
self,O
-,O
completed,O
questionnaires,O
amongst,O
680,O
women,B-OG
and,O
677,O
men,B-OG
comprising,O
the,O
baseline,O
of,O
the,O
Stepping,O
Stones,O
and,O
Creating,O
Futures,O
intervention,O
trial,O
.,O
Men,B-OG
and,O
women,B-OG
were,O
analysed,O
separately,O
.,O
Logistic,O
regression,O
models,O
assessed,O
the,O
relationship,O
between,O
six,O
HIV,B-OG
-,O
risk,O
behaviours,O
and,O
four,O
measures,O
of,O
trauma,O
:,O
the,O
form,O
of,O
trauma,O
",",O
the,O
severity,O
of,O
each,O
trauma,O
",",O
the,O
range,O
of,O
traumas,O
",",O
and,O
overall,O
severity,O
of,O
childhood,O
trauma,O
.,O
Childhood,O
traumas,O
were,O
incredibly,O
prevalent,O
in,O
this,O
population,O
.,O
All,O
childhood,O
traumas,O
were,O
associated,O
with,O
a,O
range,O
of,O
HIV,B-OG
-,O
risk,O
behaviours,O
.,O
This,O
was,O
for,O
the,O
ever,O
/,O
never,O
trauma,O
",",O
as,O
well,O
as,O
the,O
severity,O
of,O
each,O
type,O
of,O
trauma,O
",",O
the,O
range,O
of,O
trauma,O
",",O
and,O
overall,O
severity,O
of,O
childhood,O
trauma,O
.,O
Despite,O
the,O
wider,O
harsh,O
contexts,O
of,O
urban,O
informal,O
settlements,O
",",O
childhood,O
traumas,O
still,O
play,O
a,O
significant,O
role,O
in,O
shaping,O
subsequent,O
HIV,B-OG
-,O
risk,O
behaviours,O
amongst,O
young,O
people,O
.,O
Interventions,O
to,O
reduce,O
childhood,O
traumas,O
for,O
populations,O
in,O
informal,O
settlements,O
need,O
to,O
be,O
developed,O
.,O
In,O
addition,O
",",O
trauma,O
focused,O
therapies,O
need,O
to,O
be,O
considered,O
as,O
part,O
of,O
wider,O
HIV,B-OG
-,O
prevention,O
interventions,O
for,O
young,O
adults,O
.,O
Trial,O
registration,O
:,O
ClinicalTrials,O
.,O
gov,O
NCT03022370,O
Introduction,O
Childhood,O
traumas,O
",",O
in,O
the,O
form,O
of,O
physical,O
",",O
sexual,O
",",O
and,O
emotional,B-DS
abuse,I-DS
and,O
neglect,O
",",O
are,O
globally,O
widespread,O
and,O
highly,O
prevalent,O
[,O
1,O
",",O
2,O
].,O
A,O
systematic,O
review,O
of,O
population,O
-,O
based,O
studies,O
estimated,O
that,O
amongst,O
2,O
–,O
17,O
year,O
olds,O
",",O
the,O
minimum,O
prevalence,O
of,O
past,O
-,O
year,O
physical,O
abuse,O
was,O
at,O
least,O
50,O
%,O
for,O
Africa,O
",",O
Asia,O
",",O
and,O
Northern,O
America,O
and,O
over,O
30,O
%,O
for,O
Latin,O
America,O
[,O
1,O
].,O
For,O
youth,O
aged,O
2,O
to,O
14,O
",",O
estimated,O
prevalence,O
of,O
past,O
-,O
year,O
violence,O
was,O
up,O
to,O
80,O
%,O
in,O
Africa,O
[,O
1,O
].,O
In,O
South,O
Africa,O
",",O
a,O
multi,O
-,O
community,O
sample,O
of,O
children,O
aged,O
10,O
–,O
17,O
",",O
found,O
prevalence,O
of,O
lifetime,O
physical,O
abuse,O
was,O
56,O
.,O
3,O
"%,",O
emotional,B-DS
abuse,I-DS
35,O
.,O
5,O
%,O
and,O
sexual,O
abuse,O
9,O
%,O
[,O
3,O
].,O
Overall,O
",",O
in,O
the,O
South,O
African,O
multi,O
-,O
community,O
sample,O
of,O
children,O
just,O
over,O
two,O
-,O
thirds,O
(,O
68,O
.,O
9,O
%),O
reported,O
any,O
lifetime,O
abuse,O
and,O
a,O
quarter,O
(,O
27,O
.,O
1,O
%),O
reported,O
experiencing,O
multiple,O
forms,O
of,O
abuse,O
[,O
3,O
].,O
In,O
a,O
young,O
adult,O
rural,O
population,O
(,O
15,O
–,O
26,O
),O
in,O
South,O
Africa,O
",",O
39,O
.,O
1,O
%,O
of,O
women,B-OG
and,O
16,O
.,O
7,O
%,O
of,O
men,B-OG
had,O
experienced,O
sexual,O
abuse,O
",",O
while,O
89,O
.,O
3,O
%,O
of,O
women,B-OG
and,O
94,O
.,O
4,O
%,O
of,O
men,B-OG
had,O
experienced,O
physical,O
punishment,O
as,O
children,O
[,O
4,O
].,O
As,O
well,O
as,O
being,O
a,O
human,B-OG
rights,O
violation,O
",",O
experiences,O
of,O
childhood,O
traumas,O
have,O
short,O
and,O
long,O
-,O
term,O
impacts,O
on,O
people,O
’,O
s,O
health,O
.,O
Women,B-OG
and,O
men,B-OG
who,O
have,O
experienced,O
childhood,O
traumas,O
are,O
more,O
likely,O
to,O
report,O
a,O
range,O
of,O
sexual,O
risk,O
behaviours,O
[,O
5,O
"],",O
including,O
more,O
likely,O
to,O
trade,O
sex,O
for,O
cash,O
[,O
6,O
"],",O
experience,O
or,O
perpetrate,O
intimate,O
partner,O
violence,O
(,O
IPV,O
),O
[,O
7,O
",",O
8,O
"],",O
engage,O
in,O
risky,O
alcohol,O
use,O
",",O
and,O
drug,O
use,O
[,O
4,O
",",O
5,O
"],",O
and,O
have,O
more,O
sex,O
partners,O
[,O
6,O
].,O
In,O
South,O
Africa,O
",",O
a,O
longitudinal,O
study,O
showed,O
those,O
who,O
experienced,O
childhood,O
traumas,O
were,O
also,O
more,O
likely,O
to,O
acquire,O
HIV,B-OG
[,O
4,O
].,O
Globally,O
",",O
urban,O
informal,O
settlements,O
are,O
rapidly,O
growing,O
as,O
the,O
global,O
population,O
urbanises,O
[,O
9,O
].,O
Urban,O
informal,O
settlements,O
",",O
while,O
providing,O
substantial,O
opportunities,O
associated,O
with,O
urban,O
economies,O
",",O
are,O
also,O
settings,O
with,O
significant,O
health,O
challenges,O
.,O
Studies,O
suggest,O
that,O
HIV,B-OG
prevalence,O
and,O
violence,O
against,O
women,B-OG
in,O
informal,O
settlements,O
are,O
higher,O
than,O
in,O
formal,O
settlements,O
[,O
10,O
–,O
12,O
].,O
There,O
is,O
some,O
suggestion,O
that,O
urban,O
residency,O
may,O
also,O
increase,O
experiences,O
of,O
childhood,O
traumas,O
[,O
13,O
].,O
Despite,O
this,O
",",O
there,O
is,O
little,O
evidence,O
about,O
the,O
relationship,O
between,O
childhood,O
traumas,O
and,O
current,O
HIV,B-OG
-,O
risk,O
behaviours,O
amongst,O
residents,O
of,O
informal,O
settlements,O
.,O
In,O
this,O
paper,O
",",O
we,O
seek,O
to,O
describe,O
the,O
associations,O
between,O
sexual,O
",",O
physical,O
",",O
and,O
emotional,O
childhood,O
traumas,O
amongst,O
women,B-OG
and,O
men,B-OG
resident,O
in,O
informal,O
settlements,O
in,O
eThekwini,O
",",O
South,O
Africa,O
and,O
their,O
subsequent,O
HIV,B-OG
-,O
risk,O
behaviours,O
.,O
We,O
draw,O
on,O
data,O
from,O
the,O
baseline,O
of,O
the,O
Stepping,O
Stones,O
and,O
Creating,O
Futures,O
trial,O
",",O
a,O
cluster,O
randomized,O
control,O
trial,O
(,O
RCT,O
),O
assessing,O
the,O
impact,O
of,O
this,O
gender,O
transformative,O
and,O
livelihood,O
strengthening,O
intervention,O
on,O
women,B-OG
’,O
s,O
experience,O
",",O
and,O
men,B-OG
’,O
s,O
perpetration,O
",",O
of,O
IPV,O
[,O
14,O
].,O
We,O
assess,O
whether,O
experience,O
of,O
each,O
type,O
of,O
childhood,O
trauma,O
is,O
independently,O
associated,O
with,O
HIV,B-OG
-,O
risk,O
;,O
whether,O
there,O
is,O
a,O
dose,O
response,O
for,O
each,O
type,O
of,O
childhood,O
trauma,O
and,O
HIV,B-OG
-,O
risk,O
;,O
whether,O
the,O
range,O
of,O
childhood,O
traumas,O
experienced,O
is,O
independently,O
associated,O
with,O
HIV,B-OG
-,O
risk,O
;,O
and,O
whether,O
the,O
overall,O
severity,O
of,O
childhood,O
trauma,O
is,O
independently,O
associated,O
with,O
HIV,B-OG
-,O
risk,O
.,O
Methods,O
Data,O
are,O
drawn,O
from,O
N,O
=,O
680,O
women,B-OG
and,O
N,O
=,O
677,O
men,B-OG
who,O
participated,O
in,O
the,O
baseline,O
assessment,O
for,O
the,O
Stepping,O
Stones,O
and,O
Creating,O
Futures,O
RCT,O
",",O
carried,O
out,O
in,O
urban,O
informal,O
settlements,O
near,O
Durban,O
",",O
South,O
Africa,O
between,O
September,O
2015,O
and,O
September,O
2016,O
.,O
Women,B-OG
and,O
men,B-OG
between,O
18,O
and,O
30,O
",",O
who,O
were,O
out,O
of,O
school,O
",",O
not,O
in,O
formal,O
work,O
and,O
resident,O
in,O
an,O
informal,O
settlement,O
",",O
were,O
eligible,O
to,O
participate,O
.,O
We,O
worked,O
with,O
Project,O
Empower,O
",",O
a,O
local,O
implementing,O
agency,O
",",O
experienced,O
in,O
informal,O
settlement,O
interventions,O
",",O
to,O
identify,O
potential,O
participants,O
through,O
community,O
meetings,O
and,O
snow,O
-,O
ball,O
sampling,O
.,O
The,O
study,O
comprised,O
34,O
clusters,O
with,O
19,O
–,O
21,O
women,B-OG
and,O
16,O
–,O
22,O
men,B-OG
per,O
cluster,O
[,O
14,O
].,O
At,O
recruitment,O
",",O
participants,O
were,O
not,O
blinded,O
to,O
study,O
arm,O
.,O
Those,O
in,O
the,O
intervention,O
arm,O
received,O
R100,O
(~,O
US,O
$,O
7,O
),O
and,O
those,O
in,O
the,O
control,O
arm,O
received,O
R300,O
(~,O
US,O
$,O
21,O
),O
for,O
completion,O
of,O
the,O
baseline,O
survey,O
instrument,O
.,O
Ethical,O
approval,O
for,O
the,O
study,O
was,O
received,O
from,O
the,O
University,O
of,O
KwaZulu,O
-,O
Natal,O
and,O
the,O
South,O
African,O
Medical,O
Research,O
Council,O
.,O
Further,O
information,O
on,O
procedures,O
is,O
described,O
elsewhere,O
[,O
14,O
].,O
Data,O
collection,O
Once,O
enrolled,O
into,O
the,O
study,O
",",O
participants,O
self,O
-,O
completed,O
structured,O
questionnaires,O
.,O
Questionnaires,O
were,O
on,O
study,O
provided,O
cellphones,O
",",O
and,O
available,O
in,O
isiZulu,O
",",O
Xhosa,O
",",O
and,O
English,O
and,O
had,O
built,O
in,O
logic,O
and,O
skip,O
patterns,O
.,O
Questionnaires,O
had,O
been,O
tested,O
prior,O
to,O
roll,O
-,O
out,O
with,O
young,O
people,O
from,O
informal,O
settlements,O
",",O
and,O
young,O
people,O
were,O
confident,O
in,O
using,O
cellphones,O
and,O
this,O
approach,O
to,O
data,O
collection,O
.,O
If,O
literacy,O
was,O
an,O
issue,O
",",O
same,O
sex,O
trained,O
fieldworkers,O
were,O
able,O
to,O
support,O
questionnaire,O
completion,O
",",O
through,O
face,O
-,O
to,O
-,O
face,O
interviews,O
with,O
participants,O
entering,O
the,O
data,O
",",O
and,O
interviewers,O
reading,O
out,O
questions,O
.,O
Few,O
participants,O
(<,O
5,O
%),O
required,O
this,O
support,O
",",O
and,O
as,O
such,O
",",O
it,O
was,O
unlikely,O
to,O
influence,O
responses,O
given,O
the,O
small,O
number,O
of,O
cases,O
.,O
Measures,O
Six,O
variables,O
",",O
which,O
have,O
been,O
associated,O
with,O
HIV,B-OG
-,O
risk,O
in,O
a,O
range,O
of,O
studies,O
from,O
across,O
Africa,O
",",O
were,O
identified,O
as,O
outcome,O
variables,O
for,O
the,O
analysis,O
.,O
Transactional,O
sex,O
in,O
the,O
past,O
year,O
with,O
a,O
casual,O
or,O
once,O
-,O
off,O
sexual,O
partner,O
.,O
Five,O
questions,O
asked,O
about,O
whether,O
a,O
woman,B-OG
had,O
sex,O
with,O
a,O
man,B-OG
because,O
she,O
expected,O
to,O
receive,O
",",O
or,O
did,O
receive,O
a,O
range,O
of,O
items,O
",",O
including,O
cash,O
",",O
a,O
place,O
to,O
stay,O
",",O
drugs,O
",",O
school,O
fees,O
",",O
airtime,O
",",O
or,O
anything,O
else,O
she,O
could,O
not,O
afford,O
[,O
15,O
].,O
One,O
",",O
or,O
more,O
",",O
positive,O
responses,O
to,O
any,O
of,O
the,O
five,O
questions,O
was,O
coded,O
as,O
engaging,O
in,O
transactional,O
sex,O
.,O
Men,B-OG
were,O
asked,O
whether,O
they,O
thought,O
a,O
woman,B-OG
had,O
sex,O
with,O
them,O
because,O
she,O
expected,O
to,O
receive,O
items,O
[,O
16,O
].,O
Sexual,O
partners,O
in,O
past,O
year,O
.,O
We,O
asked,O
three,O
questions,O
about,O
sexual,O
partners,O
in,O
the,O
past,O
year,O
.,O
We,O
asked,O
about,O
the,O
number,O
of,O
main,O
sexual,O
partners,O
",",O
casual,O
sexual,O
partners,O
or,O
khwapheni,O
",",O
and,O
once,O
-,O
off,O
sexual,O
partners,O
.,O
In,O
each,O
instance,O
",",O
a,O
cutoff,O
score,O
of,O
4,O
or,O
more,O
was,O
used,O
in,O
the,O
logistic,O
regression,O
and,O
analysis,O
kept,O
each,O
type,O
of,O
sex,O
partner,O
separate,O
.,O
Condom,O
use,O
at,O
last,O
sex,O
.,O
A,O
single,O
question,O
asked,O
about,O
condom,O
use,O
in,O
last,O
sex,O
act,O
.,O
Responses,O
were,O
either,O
yes,O
or,O
no,O
.,O
Physical,O
and,O
/,O
or,O
sexual,O
IPV,O
perpetration,O
(,O
men,B-OG
),O
and,O
experience,O
(,O
women,B-OG
),O
in,O
the,O
past,O
year,O
.,O
Eight,O
items,O
",",O
five,O
physical,O
IPV,O
and,O
three,O
sexual,O
IPV,O
",",O
were,O
asked,O
.,O
Men,B-OG
were,O
asked,O
about,O
perpetration,O
and,O
women,B-OG
about,O
experience,O
of,O
IPV,O
.,O
Questions,O
were,O
based,O
on,O
the,O
WHO,O
multi,O
-,O
country,O
survey,O
on,O
violence,O
against,O
women,B-OG
[,O
17,O
],O
and,O
adapted,O
and,O
extensively,O
tested,O
in,O
South,O
Africa,O
[,O
18,O
].,O
Responses,O
for,O
each,O
item,O
were,O
never,O
",",O
once,O
",",O
few,O
",",O
and,O
many,O
.,O
A,O
positive,O
response,O
to,O
any,O
of,O
the,O
eight,O
items,O
led,O
to,O
a,O
person,O
being,O
coded,O
as,O
having,O
perpetrated,O
IPV,O
(,O
men,B-OG
),O
and,O
experienced,O
IPV,O
(,O
women,B-OG
),O
in,O
the,O
past,O
year,O
.,O
Non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
perpetration,O
(,O
men,B-OG
),O
and,O
experience,O
(,O
women,B-OG
),O
in,O
the,O
past,O
year,O
.,O
Six,O
items,O
asked,O
about,O
women,B-OG
’,O
s,O
experience,O
and,O
men,B-OG
’,O
s,O
perpetration,O
of,O
non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
",",O
including,O
gang,O
rape,O
.,O
Scales,O
had,O
been,O
developed,O
and,O
extensively,O
tested,O
in,O
South,O
Africa,O
[,O
19,O
].,O
Responses,O
were,O
never,O
",",O
once,O
",",O
few,O
and,O
many,O
.,O
Harmful,O
alcohol,O
use,O
.,O
Alcohol,O
use,O
was,O
assessed,O
using,O
the,O
Alcohol,O
Use,O
Disorder,O
Identification,O
Test,O
(,O
AUDIT,O
),O
scale,O
.,O
Ten,O
items,O
asked,O
about,O
past,O
year,O
alcohol,O
use,O
",",O
with,O
scores,O
summed,O
.,O
A,O
cut,O
-,O
off,O
score,O
of,O
8,O
or,O
more,O
indicated,O
potential,O
harmful,O
alcohol,O
use,O
[,O
20,O
"],",O
and,O
the,O
same,O
cut,O
-,O
off,O
score,O
was,O
used,O
for,O
women,B-OG
and,O
men,B-OG
.,O
Childhood,O
traumas,O
were,O
the,O
exposure,O
variable,O
.,O
Eleven,O
items,O
asked,O
about,O
childhood,O
traumas,O
and,O
were,O
based,O
on,O
the,O
on,O
the,O
short,O
form,O
of,O
the,O
Childhood,O
Trauma,O
Questionnaire,O
[,O
21,O
],O
and,O
modifications,O
already,O
undertaken,O
in,O
South,O
Africa,O
[,O
4,O
].,O
As,O
all,O
participants,O
were,O
18,O
or,O
older,O
",",O
participants,O
were,O
asked,O
",",O
“,O
before,O
I,O
reached,O
18,O
I,O
…”,O
Five,O
items,O
asked,O
about,O
emotional,B-DS
abuse,I-DS
and,O
neglect,O
.,O
Three,O
items,O
asked,O
about,O
physical,O
abuse,O
and,O
witnessing,O
of,O
violence,O
.,O
Three,O
items,O
asked,O
about,O
experiencing,O
sexual,O
abuse,O
.,O
Responses,O
were,O
on,O
a,O
four,O
-,O
point,O
Likert,O
scale,O
",",O
never,O
",",O
sometimes,O
",",O
often,O
",",O
very,O
often,O
.,O
Childhood,O
traumas,O
were,O
summarized,O
in,O
four,O
ways,O
.,O
First,O
",",O
each,O
type,O
of,O
trauma,O
(,O
emotional,O
",",O
physical,O
",",O
sexual,O
),O
was,O
dichotomized,O
into,O
a,O
never,O
/,O
ever,O
binary,O
.,O
Second,O
",",O
a,O
straight,O
score,O
of,O
severity,O
for,O
each,O
type,O
of,O
trauma,O
was,O
created,O
through,O
simple,O
summation,O
of,O
scores,O
for,O
individual,O
items,O
.,O
Third,O
",",O
the,O
range,O
of,O
traumas,O
was,O
assessed,O
by,O
classifying,O
participants,O
into,O
those,O
who,O
had,O
experienced,O
no,O
trauma,O
",",O
only,O
one,O
type,O
",",O
two,O
types,O
",",O
or,O
all,O
three,O
types,O
.,O
Finally,O
",",O
a,O
direct,O
summation,O
of,O
all,O
items,O
provided,O
an,O
overall,O
childhood,O
trauma,O
severity,O
score,O
.,O
Socio,O
-,O
demographic,O
measures,O
includes,O
age,O
",",O
educational,O
level,O
including,O
whether,O
a,O
person,O
had,O
passed,O
matric,O
(,O
high,O
school,O
leaving,O
"),",O
and,O
household,O
food,O
insecurity,O
.,O
Depression,B-DS
was,O
assessed,O
using,O
The,O
Centre,O
for,O
Epidemiologic,O
Studies,O
Depression,B-DS
Scale,O
(,O
CES,O
-,O
D,O
),O
scale,O
[,O
22,O
],O
and,O
had,O
been,O
used,O
in,O
South,O
Africa,O
previously,O
[,O
23,O
",",O
24,O
].,O
Twenty,O
items,O
asked,O
about,O
depressive,O
symptoms,O
in,O
the,O
past,O
week,O
",",O
with,O
responses,O
ranging,O
from,O
never,O
to,O
everyday,O
(,O
α,O
=,O
0,O
.,O
88,O
).,O
Analysis,O
Men,B-OG
and,O
women,B-OG
were,O
analysed,O
separately,O
",",O
and,O
analyses,O
included,O
adjustment,O
for,O
cluster,O
sampling,O
.,O
Descriptive,O
statistics,O
for,O
the,O
socio,O
-,O
demographic,O
measures,O
and,O
each,O
HIV,B-OG
-,O
risk,O
behaviour,O
were,O
first,O
constructed,O
.,O
We,O
then,O
compiled,O
descriptive,O
statistics,O
of,O
the,O
different,O
forms,O
of,O
childhood,O
traumas,O
",",O
including,O
summaries,O
for,O
each,O
type,O
and,O
the,O
range,O
of,O
traumas,O
.,O
For,O
analysis,O
",",O
Gaussian,O
regression,O
models,O
",",O
reporting,O
odds,O
ratios,O
and,O
adjusting,O
for,O
clustering,O
",",O
age,O
education,O
",",O
current,O
food,O
security,O
",",O
earnings,O
",",O
depressive,O
symptoms,O
",",O
length,O
of,O
time,O
living,O
in,O
community,O
and,O
study,O
arm,O
",",O
were,O
constructed,O
for,O
each,O
HIV,B-OG
-,O
risk,O
behaviour,O
.,O
Model,O
1,O
examined,O
whether,O
a,O
person,O
had,O
experienced,O
childhood,O
trauma,O
(,O
emotional,O
",",O
physical,O
",",O
sexual,O
),O
at,O
all,O
and,O
whether,O
it,O
was,O
significantly,O
associated,O
with,O
each,O
HIV,B-OG
-,O
risk,O
variable,O
.,O
In,O
model,O
2,O
",",O
each,O
childhood,O
trauma,O
was,O
treated,O
as,O
a,O
score,O
to,O
indicate,O
the,O
severity,O
of,O
the,O
trauma,O
and,O
assessment,O
was,O
made,O
as,O
to,O
whether,O
this,O
independently,O
predicted,O
each,O
HIV,B-OG
-,O
risk,O
behaviour,O
.,O
Model,O
3,O
assessed,O
whether,O
the,O
range,O
of,O
traumas,O
experienced,O
was,O
independently,O
associated,O
with,O
each,O
HIV,B-OG
-,O
risk,O
behaviour,O
.,O
Model,O
4,O
looked,O
at,O
overall,O
severity,O
of,O
childhood,O
trauma,O
and,O
its,O
relationship,O
to,O
each,O
HIV,B-OG
-,O
risk,O
behaviour,O
.,O
Results,O
In,O
total,O
680,O
women,B-OG
and,O
677,O
men,B-OG
were,O
recruited,O
into,O
the,O
study,O
.,O
There,O
were,O
few,O
differences,O
between,O
women,B-OG
and,O
men,B-OG
in,O
terms,O
of,O
age,O
and,O
education,O
level,O
(,O
Table,O
1,O
).,O
More,O
men,B-OG
than,O
women,B-OG
reported,O
HIV,B-OG
-,O
risk,O
behaviours,O
",",O
particularly,O
transactional,O
sex,O
with,O
a,O
causal,O
or,O
once,O
-,O
off,O
partner,O
",",O
and,O
the,O
number,O
of,O
all,O
sexual,O
partners,O
in,O
the,O
past,O
year,O
.,O
Condom,O
use,O
in,O
the,O
last,O
year,O
was,O
similar,O
",",O
as,O
was,O
IPV,O
experience,O
/,O
perpetration,O
and,O
non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
experience,O
/,O
perpetration,O
.,O
Men,B-OG
reported,O
higher,O
levels,O
of,O
harmful,O
alcohol,O
use,O
than,O
women,B-OG
(,O
43,O
.,O
3,O
%,O
and,O
23,O
.,O
1,O
%,O
respectively,O
).,O
Mean,O
AUDIT,O
scores,O
for,O
men,B-OG
were,O
7,O
.,O
8,O
(,O
min,O
-,O
max,O
scores,O
0,O
–,O
40,O
"),",O
and,O
for,O
women,B-OG
4,O
.,O
3,O
(,O
min,O
-,O
max,O
scores,O
0,O
–,O
38,O
).,O
Distribution,O
of,O
socio,O
-,O
demographic,O
characteristics,O
and,O
HIV,B-OG
-,O
risk,O
behaviours,O
amongst,O
women,B-OG
and,O
men,B-OG
.,O
Women,B-OG
(,O
n,O
=,O
680,O
),O
Men,B-OG
(,O
n,O
=,O
677,O
),O
Socio,O
-,O
demographics,O
n,O
(%),O
n,O
(%),O
Age,O
:,O
18,O
–,O
19,O
84,O
(,O
12,O
.,O
4,O
),O
70,O
(,O
10,O
.,O
3,O
),O
20,O
–,O
24,O
325,O
(,O
47,O
.,O
8,O
),O
355,O
(,O
52,O
.,O
4,O
),O
25,O
–,O
30,O
271,O
(,O
39,O
.,O
9,O
),O
252,O
(,O
37,O
.,O
2,O
),O
Education,O
Primary,O
only,O
55,O
(,O
8,O
.,O
1,O
),O
77,O
(,O
11,O
.,O
4,O
),O
Secondary,O
(,O
no,O
matric,O
),O
419,O
(,O
61,O
.,O
6,O
),O
393,O
(,O
58,O
.,O
1,O
),O
Matric,O
or,O
beyond,O
206,O
(,O
30,O
.,O
3,O
),O
207,O
(,O
30,O
.,O
6,O
),O
HIV,B-OG
-,O
risk,O
behaviours,O
Transactional,O
sex,O
past,O
12m,O
275,O
(,O
42,O
.,O
6,O
),O
338,O
(,O
50,O
.,O
7,O
),O
4,O
or,O
more,O
main,O
sexual,O
partners,O
past,O
12m,O
61,O
(,O
9,O
.,O
5,O
),O
156,O
(,O
23,O
.,O
4,O
),O
4,O
or,O
more,O
causal,O
sexual,O
partners,O
past,O
12m,O
19,O
(,O
3,O
.,O
0,O
),O
122,O
(,O
18,O
.,O
3,O
),O
4,O
or,O
more,O
once,O
off,O
sexual,O
partner,O
past,O
12m,O
13,O
(,O
2,O
.,O
0,O
),O
129,O
(,O
19,O
.,O
3,O
),O
Condom,O
use,O
at,O
last,O
sex,O
320,O
(,O
54,O
.,O
1,O
),O
395,O
(,O
60,O
.,O
3,O
),O
IPV,O
experience,O
/,O
perpetration,O
past,O
12m,O
443,O
(,O
65,O
.,O
2,O
),O
384,O
(,O
56,O
.,O
9,O
),O
Non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
experience,O
/,O
perpetration,O
past,O
12m,O
224,O
(,O
32,O
.,O
9,O
),O
262,O
(,O
38,O
.,O
8,O
),O
Harmful,O
alcohol,O
use,O
157,O
(,O
23,O
.,O
1,O
),O
294,O
(,O
43,O
.,O
4,O
),O
Mean,O
alcohol,O
use,O
scores,O
(,O
range,O
),O
4,O
.,O
3,O
(,O
0,O
–,O
38,O
),O
7,O
.,O
8,O
(,O
0,O
–,O
40,O
),O
Overall,O
prevalence,O
of,O
childhood,O
traumas,O
were,O
high,O
.,O
Table,O
2,O
shows,O
the,O
distribution,O
of,O
different,O
forms,O
of,O
childhood,O
abuse,O
.,O
Emotional,B-DS
abuse,I-DS
was,O
very,O
common,O
with,O
almost,O
three,O
-,O
quarters,O
of,O
women,B-OG
(,O
72,O
.,O
4,O
%),O
and,O
just,O
over,O
three,O
-,O
quarters,O
of,O
men,B-OG
(,O
77,O
.,O
9,O
%),O
reporting,O
emotional,B-DS
abuse,I-DS
or,O
neglect,O
growing,O
up,O
.,O
All,O
types,O
of,O
emotional,B-DS
abuse,I-DS
were,O
common,O
",",O
with,O
the,O
exception,O
of,O
parents,O
being,O
“,O
too,O
drunk,O
or,O
drugged,O
to,O
look,O
after,O
me,O
"”,",O
where,O
only,O
around,O
one,O
quarter,O
of,O
women,B-OG
and,O
men,B-OG
reported,O
this,O
.,O
Physical,O
abuse,O
and,O
witnessing,O
of,O
violence,O
in,O
the,O
home,O
was,O
common,O
and,O
reported,O
by,O
about,O
three,O
quarters,O
of,O
participants,O
.,O
The,O
most,O
common,O
form,O
of,O
physical,O
abuse,O
was,O
being,O
beaten,O
with,O
a,O
belt,O
",",O
stick,O
",",O
or,O
something,O
hard,O
",",O
with,O
about,O
two,O
-,O
thirds,O
of,O
women,B-OG
and,O
men,B-OG
reporting,O
having,O
experienced,O
this,O
at,O
least,O
once,O
.,O
Sexual,O
abuse,O
was,O
the,O
least,O
form,O
of,O
childhood,O
trauma,O
",",O
although,O
still,O
very,O
high,O
.,O
One,O
third,O
of,O
women,B-OG
(,O
36,O
.,O
0,O
%),O
and,O
almost,O
a,O
half,O
of,O
men,B-OG
(,O
47,O
.,O
9,O
%),O
reported,O
at,O
least,O
one,O
type,O
of,O
sexual,O
abuse,O
.,O
Experiencing,O
more,O
than,O
one,O
form,O
of,O
childhood,O
abuse,O
was,O
also,O
common,O
.,O
For,O
women,B-OG
",",O
39,O
.,O
1,O
%,O
reported,O
two,O
forms,O
of,O
childhood,O
abuse,O
",",O
and,O
27,O
.,O
7,O
%,O
three,O
types,O
of,O
childhood,O
abuse,O
",",O
while,O
for,O
men,B-OG
31,O
.,O
6,O
%,O
reported,O
two,O
forms,O
",",O
and,O
40,O
.,O
2,O
%,O
all,O
three,O
forms,O
of,O
childhood,O
abuse,O
.,O
Frequency,O
and,O
range,O
of,O
childhood,O
traumas,O
amongst,O
women,B-OG
and,O
men,B-OG
.,O
Women,B-OG
Men,B-OG
Emotional,B-DS
abuse,I-DS
/,O
neglect,O
Never,O
",",O
n,O
(%),O
Sometimes,O
",",O
n,O
(%),O
Often,O
",",O
n,O
(%),O
Very,O
often,O
",",O
n,O
(%),O
Never,O
",",O
n,O
(%),O
Sometimes,O
",",O
n,O
(%),O
Often,O
",",O
n,O
(%),O
Very,O
often,O
",",O
n,O
(%),O
I,O
lived,O
in,O
different,O
households,O
at,O
different,O
times,O
406,O
(,O
59,O
.,O
7,O
),O
169,O
(,O
24,O
.,O
9,O
),O
63,O
(,O
9,O
.,O
3,O
),O
42,O
(,O
6,O
.,O
2,O
),O
355,O
(,O
52,O
.,O
6,O
),O
203,O
(,O
30,O
.,O
1,O
),O
67,O
(,O
9,O
.,O
9,O
),O
50,O
(,O
7,O
.,O
4,O
),O
I,O
was,O
told,O
I,O
was,O
lazy,O
or,O
stupid,O
or,O
weak,O
by,O
someone,O
in,O
my,O
family,O
384,O
(,O
56,O
.,O
5,O
),O
180,O
(,O
26,O
.,O
5,O
),O
72,O
(,O
10,O
.,O
6,O
),O
44,O
(,O
6,O
.,O
5,O
),O
360,O
(,O
53,O
.,O
3,O
),O
220,O
(,O
32,O
.,O
6,O
),O
49,O
(,O
7,O
.,O
3,O
),O
46,O
(,O
6,O
.,O
8,O
),O
I,O
was,O
insulted,O
or,O
humiliated,O
by,O
someone,O
in,O
my,O
family,O
in,O
front,O
of,O
other,O
people,O
398,O
(,O
58,O
.,O
5,O
),O
185,O
(,O
27,O
.,O
2,O
),O
51,O
(,O
7,O
.,O
5,O
),O
46,O
(,O
6,O
.,O
8,O
),O
382,O
(,O
56,O
.,O
6,O
),O
197,O
(,O
29,O
.,O
2,O
),O
51,O
(,O
7,O
.,O
6,O
),O
45,O
(,O
6,O
.,O
7,O
),O
one,O
or,O
both,O
of,O
my,O
parents,O
were,O
too,O
drunk,O
or,O
drugged,O
to,O
take,O
care,O
of,O
me,O
552,O
(,O
81,O
.,O
2,O
),O
69,O
(,O
10,O
.,O
2,O
),O
28,O
(,O
4,O
.,O
1,O
),O
31,O
(,O
4,O
.,O
6,O
),O
497,O
(,O
73,O
.,O
6,O
),O
101,O
(,O
15,O
.,O
0,O
),O
45,O
(,O
6,O
.,O
7,O
),O
32,O
(,O
4,O
.,O
7,O
),O
I,O
spent,O
time,O
outside,O
the,O
home,O
and,O
none,O
of,O
the,O
adults,O
at,O
home,O
knew,O
where,O
I,O
was,O
487,O
(,O
71,O
.,O
6,O
),O
139,O
(,O
20,O
.,O
4,O
),O
38,O
(,O
5,O
.,O
6,O
),O
16,O
(,O
2,O
.,O
4,O
),O
383,O
(,O
56,O
.,O
7,O
),O
213,O
(,O
31,O
.,O
6,O
),O
47,O
(,O
7,O
.,O
0,O
),O
32,O
(,O
4,O
.,O
7,O
),O
Physical,O
abuse,O
/,O
witnessing,O
I,O
saw,O
or,O
heard,O
my,O
mother,O
being,O
beaten,O
by,O
her,O
husband,O
or,O
boyfriend,O
476,O
(,O
70,O
.,O
0,O
),O
128,O
(,O
18,O
.,O
8,O
),O
39,O
(,O
5,O
.,O
7,O
),O
37,O
(,O
5,O
.,O
4,O
),O
439,O
(,O
65,O
.,O
0,O
),O
143,O
(,O
21,O
.,O
2,O
),O
54,O
(,O
8,O
.,O
0,O
),O
39,O
(,O
5,O
.,O
8,O
),O
I,O
was,O
beaten,O
at,O
home,O
with,O
a,O
belt,O
or,O
stick,O
or,O
whip,O
or,O
something,O
else,O
which,O
was,O
hard,O
262,O
(,O
38,O
.,O
5,O
),O
275,O
(,O
40,O
.,O
4,O
),O
72,O
(,O
10,O
.,O
6,O
),O
71,O
(,O
10,O
.,O
4,O
),O
223,O
(,O
33,O
.,O
0,O
),O
289,O
(,O
42,O
.,O
8,O
),O
88,O
(,O
13,O
.,O
0,O
),O
75,O
(,O
11,O
.,O
1,O
),O
I,O
was,O
beaten,O
so,O
hard,O
at,O
home,O
that,O
it,O
left,O
a,O
mark,O
or,O
bruise,O
428,O
(,O
62,O
.,O
9,O
),O
154,O
(,O
22,O
.,O
7,O
),O
55,O
(,O
8,O
.,O
1,O
),O
43,O
(,O
6,O
.,O
3,O
),O
412,O
(,O
61,O
.,O
0,O
),O
177,O
(,O
26,O
.,O
2,O
),O
44,O
(,O
6,O
.,O
5,O
),O
42,O
(,O
6,O
.,O
2,O
),O
Sexual,O
abuse,O
someone,O
touched,O
my,O
buttocks,O
or,O
genitals,O
or,O
made,O
me,O
touch,O
them,O
when,O
I,O
did,O
not,O
want,O
to,O
545,O
(,O
80,O
.,O
2,O
),O
102,O
(,O
15,O
.,O
0,O
),O
21,O
(,O
3,O
.,O
1,O
),O
12,O
(,O
1,O
.,O
8,O
),O
474,O
(,O
70,O
.,O
2,O
),O
139,O
(,O
20,O
.,O
6,O
),O
38,O
(,O
5,O
.,O
6,O
),O
24,O
(,O
3,O
.,O
6,O
),O
I,O
had,O
sex,O
with,O
a,O
wo,B-OG
(,I-OG
man,I-OG
),I-OG
who,O
was,O
more,O
than,O
5,O
years,O
older,O
than,O
me,O
533,O
(,O
78,O
.,O
4,O
),O
77,O
(,O
11,O
.,O
3,O
),O
46,O
(,O
6,O
.,O
8,O
),O
24,O
(,O
3,O
.,O
5,O
),O
460,O
(,O
68,O
.,O
2,O
),O
153,O
(,O
22,O
.,O
7,O
),O
44,O
(,O
6,O
.,O
5,O
),O
18,O
(,O
2,O
.,O
7,O
),O
I,O
had,O
sex,O
with,O
someone,O
because,O
I,O
was,O
threatened,O
or,O
frightened,O
or,O
forced,O
567,O
(,O
83,O
.,O
4,O
),O
65,O
(,O
9,O
.,O
6,O
),O
31,O
(,O
4,O
.,O
6,O
),O
17,O
(,O
2,O
.,O
5,O
),O
554,O
(,O
82,O
.,O
1,O
),O
82,O
(,O
12,O
.,O
2,O
),O
26,O
(,O
3,O
.,O
9,O
),O
13,O
(,O
1,O
.,O
9,O
),O
Never,O
",",O
n,O
(%),O
Ever,O
",",O
(,O
n,O
%),O
Never,O
",",O
n,O
(%),O
Ever,O
",",O
(,O
n,O
%),O
Emotional,B-DS
abuse,I-DS
ever,O
188,O
(,O
27,O
.,O
7,O
),O
492,O
(,O
72,O
.,O
4,O
),O
154,O
(,O
22,O
.,O
8,O
),O
521,O
(,O
77,O
.,O
9,O
),O
Physical,O
abuse,O
ever,O
197,O
(,O
29,O
.,O
0,O
),O
483,O
(,O
71,O
.,O
0,O
),O
167,O
(,O
24,O
.,O
7,O
),O
508,O
(,O
75,O
.,O
3,O
),O
Sexual,O
abuse,O
ever,O
435,O
(,O
64,O
.,O
0,O
),O
245,O
(,O
36,O
.,O
0,O
),O
352,O
(,O
52,O
.,O
2,O
),O
323,O
(,O
47,O
.,O
9,O
),O
Range,O
of,O
Abuse,O
,O
n,O
(%),O
One,O
Form,O
",",O
n,O
(%),O
Two,O
Forms,O
",",O
n,O
(%),O
Three,O
Forms,O
",",O
n,O
(%),O
,O
n,O
(%),O
One,O
Form,O
",",O
n,O
(%),O
Two,O
Forms,O
",",O
n,O
(%),O
Three,O
Forms,O
",",O
n,O
(%),O
102,O
(,O
15,O
.,O
0,O
),O
124,O
(,O
18,O
.,O
2,O
),O
266,O
(,O
39,O
.,O
1,O
),O
188,O
(,O
27,O
.,O
7,O
),O
78,O
(,O
11,O
.,O
6,O
),O
113,O
(,O
16,O
.,O
7,O
),O
213,O
(,O
31,O
.,O
6,O
),O
271,O
(,O
40,O
.,O
2,O
),O
For,O
women,B-OG
",",O
transactional,O
sex,O
in,O
the,O
past,O
year,O
was,O
associated,O
with,O
ever,O
experiencing,O
emotional,B-DS
abuse,I-DS
",",O
severity,O
of,O
emotional,B-DS
abuse,I-DS
",",O
ever,O
experiencing,O
sexual,O
abuse,O
",",O
and,O
severity,O
of,O
sexual,O
abuse,O
(,O
Table,O
3,O
).,O
Having,O
four,O
or,O
more,O
main,O
sexual,O
partners,O
in,O
the,O
past,O
year,O
",",O
and,O
having,O
four,O
or,O
more,O
casual,O
sexual,O
partners,O
in,O
the,O
past,O
year,O
were,O
both,O
associated,O
with,O
any,O
sexual,O
abuse,O
",",O
and,O
severity,O
of,O
sexual,O
abuse,O
for,O
women,B-OG
.,O
Women,B-OG
reporting,O
more,O
than,O
four,O
once,O
-,O
off,O
sexual,O
partners,O
in,O
the,O
past,O
year,O
were,O
more,O
likely,O
to,O
report,O
ever,O
being,O
sexually,O
abused,O
.,O
Non,O
-,O
condom,O
use,O
was,O
associated,O
with,O
ever,O
experiencing,O
emotional,B-DS
abuse,I-DS
",",O
and,O
ever,O
experiencing,O
physical,O
abuse,O
.,O
Past,O
year,O
IPV,O
experience,O
was,O
associated,O
with,O
any,O
emotional,B-DS
abuse,I-DS
",",O
ever,O
physical,O
abuse,O
",",O
severity,O
of,O
physical,O
abuse,O
",",O
any,O
sexual,O
abuse,O
and,O
severity,O
of,O
sexual,O
abuse,O
in,O
childhood,O
.,O
Experience,O
of,O
non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
and,O
harmful,O
alcohol,O
use,O
were,O
both,O
associated,O
with,O
any,O
emotional,B-DS
abuse,I-DS
",",O
severity,O
of,O
emotional,B-DS
abuse,I-DS
",",O
any,O
physical,O
abuse,O
and,O
severity,O
of,O
physical,O
abuse,O
",",O
and,O
any,O
sexual,O
abuse,O
and,O
severity,O
of,O
sexual,O
abuse,O
.,O
Adjusted,O
odds,O
ratios,O
for,O
women,B-OG
and,O
men,B-OG
for,O
each,O
HIV,B-OG
-,O
risk,O
behaviour,O
and,O
form,O
of,O
childhood,O
trauma,O
.,O
Emotional,B-DS
abuse,I-DS
ever,O
(,O
model,O
1,O
),O
Emotional,B-DS
abuse,I-DS
score,O
(,O
model,O
2,O
),O
Physical,O
abuse,O
ever,O
(,O
model,O
1,O
),O
Physical,O
abuse,O
score,O
(,O
model,O
2,O
),O
Sexual,O
abuse,O
ever,O
(,O
model,O
1,O
),O
Sexual,O
abuse,O
score,O
(,O
model,O
2,O
),O
Range,O
of,O
abuse,O
(,O
none,O
-,O
three,O
",",O
model,O
3,O
),O
Childhood,O
trauma,O
score,O
(,O
model,O
4,O
),O
Women,B-OG
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
Transactional,O
sex,O
1,O
.,O
85,O
(,O
1,O
.,O
25,O
–,O
2,O
.,O
75,O
)**,O
1,O
.,O
14,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
22,O
)***,O
1,O
.,O
17,O
(,O
0,O
.,O
80,O
–,O
1,O
.,O
69,O
),O
1,O
.,O
06,O
(,O
0,O
.,O
97,O
–,O
1,O
.,O
16,O
),O
1,O
.,O
52,O
(,O
1,O
.,O
07,O
–,O
2,O
.,O
16,O
)*,O
1,O
.,O
23,O
(,O
1,O
.,O
09,O
–,O
1,O
.,O
39,O
)**,O
1,O
.,O
30,O
(,O
1,O
.,O
09,O
–,O
1,O
.,O
55,O
)**,O
1,O
.,O
07,O
(,O
1,O
.,O
03,O
–,O
1,O
.,O
11,O
)***,O
Main,O
partners,O
past12m,O
1,O
.,O
16,O
(,O
0,O
.,O
60,O
–,O
2,O
.,O
24,O
),O
1,O
.,O
06,O
(,O
0,O
.,O
96,O
–,O
1,O
.,O
17,O
),O
1,O
.,O
09,O
(,O
0,O
.,O
58,O
–,O
2,O
.,O
05,O
),O
1,O
.,O
04,O
(,O
0,O
.,O
91,O
–,O
1,O
.,O
20,O
),O
2,O
.,O
44,O
(,O
1,O
.,O
38,O
–,O
4,O
.,O
29,O
)**,O
1,O
.,O
19,O
(,O
1,O
.,O
03,O
–,O
1,O
.,O
38,O
)*,O
1,O
.,O
35,O
(,O
0,O
.,O
99,O
–,O
1,O
.,O
84,O
),O
1,O
.,O
04,O
(,O
0,O
.,O
99,O
–,O
1,O
.,O
10,O
),O
Casual,O
partners,O
past12m,O
1,O
.,O
87,O
(,O
0,O
.,O
50,O
–,O
7,O
.,O
00,O
),O
1,O
.,O
16,O
(,O
0,O
.,O
98,O
–,O
1,O
.,O
38,O
),O
0,O
.,O
99,O
(,O
0,O
.,O
33,O
–,O
2,O
.,O
98,O
),O
1,O
.,O
12,O
(,O
0,O
.,O
90,O
–,O
1,O
.,O
40,O
),O
6,O
.,O
17,O
(,O
2,O
.,O
05,O
–,O
18,O
.,O
51,O
)**,O
1,O
.,O
25,O
(,O
1,O
.,O
00,O
–,O
1,O
.,O
56,O
)*,O
2,O
.,O
00,O
(,O
1,O
.,O
08,O
–,O
3,O
.,O
71,O
)*,O
1,O
.,O
09,O
(,O
1,O
.,O
00,O
–,O
1,O
.,O
18,O
),O
Once,O
off,O
sexual,O
partners,O
past12m,O
1,O
.,O
85,O
(,O
0,O
.,O
38,O
–,O
9,O
.,O
08,O
),O
1,O
.,O
11,O
(,O
0,O
.,O
90,O
–,O
1,O
.,O
37,O
),O
1,O
.,O
10,O
(,O
0,O
.,O
28,O
–,O
4,O
.,O
33,O
),O
1,O
.,O
03,O
(,O
0,O
.,O
77,O
–,O
1,O
.,O
38,O
),O
4,O
.,O
74,O
(,O
1,O
.,O
34,O
–,O
16,O
.,O
78,O
)*,O
1,O
.,O
13,O
(,O
0,O
.,O
83,O
–,O
1,O
.,O
53,O
),O
1,O
.,O
89,O
(,O
0,O
.,O
90,O
–,O
3,O
.,O
96,O
),O
1,O
.,O
05,O
(,O
0,O
.,O
94,O
–,O
1,O
.,O
17,O
),O
Condom,O
use,O
at,O
last,O
sex,O
0,O
.,O
68,O
(,O
0,O
.,O
46,O
–,O
1,O
.,O
01,O
)*,O
0,O
.,O
97,O
(,O
0,O
.,O
91,O
–,O
1,O
.,O
04,O
),O
0,O
.,O
60,O
(,O
0,O
.,O
41,O
–,O
0,O
.,O
88,O
)**,O
0,O
.,O
97,O
(,O
0,O
.,O
89,O
–,O
1,O
.,O
06,O
),O
1,O
.,O
07,O
(,O
0,O
.,O
75,O
–,O
1,O
.,O
52,O
),O
0,O
.,O
98,O
(,O
0,O
.,O
88,O
–,O
1,O
.,O
10,O
),O
0,O
.,O
84,O
(,O
0,O
.,O
71,O
–,O
1,O
.,O
00,O
),O
0,O
.,O
99,O
(,O
0,O
.,O
95,O
–,O
1,O
.,O
02,O
),O
IPV,O
(,O
experience,O
),O
1,O
.,O
76,O
(,O
1,O
.,O
21,O
–,O
2,O
.,O
56,O
)**,O
1,O
.,O
06,O
(,O
0,O
.,O
99,O
–,O
1,O
.,O
14,O
),O
2,O
.,O
16,O
(,O
1,O
.,O
51,O
–,O
3,O
.,O
10,O
)***,O
1,O
.,O
13,O
(,O
1,O
.,O
02,O
–,O
1,O
.,O
25,O
)**,O
1,O
.,O
44,O
(,O
1,O
.,O
00,O
–,O
2,O
.,O
08,O
)*,O
1,O
.,O
17,O
(,O
1,O
.,O
02,O
–,O
1,O
.,O
34,O
)*,O
1,O
.,O
46,O
(,O
1,O
.,O
23,O
–,O
1,O
.,O
74,O
)***,O
1,O
.,O
05,O
(,O
1,O
.,O
01,O
–,O
1,O
.,O
10,O
)**,O
Non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
(,O
experience,O
),O
2,O
.,O
67,O
(,O
1,O
.,O
69,O
–,O
4,O
.,O
21,O
)***,O
1,O
.,O
22,O
(,O
1,O
.,O
14,O
–,O
1,O
.,O
31,O
)***,O
1,O
.,O
66,O
(,O
1,O
.,O
11,O
–,O
2,O
.,O
48,O
)**,O
1,O
.,O
15,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
26,O
)**,O
2,O
.,O
71,O
(,O
1,O
.,O
90,O
–,O
3,O
.,O
88,O
)***,O
1,O
.,O
33,O
(,O
1,O
.,O
18,O
–,O
1,O
.,O
50,O
)***,O
1,O
.,O
81,O
(,O
1,O
.,O
48,O
–,O
2,O
.,O
21,O
)***,O
1,O
.,O
11,O
(,O
1,O
.,O
07,O
–,O
1,O
.,O
15,O
)***,O
Harmful,O
alcohol,O
use,O
2,O
.,O
74,O
(,O
1,O
.,O
61,O
–,O
4,O
.,O
68,O
)***,O
1,O
.,O
19,O
(,O
1,O
.,O
11,O
–,O
1,O
.,O
29,O
)***,O
1,O
.,O
96,O
(,O
1,O
.,O
21,O
–,O
3,O
.,O
19,O
)**,O
1,O
.,O
14,O
(,O
1,O
.,O
04,O
–,O
1,O
.,O
26,O
)**,O
2,O
.,O
26,O
(,O
1,O
.,O
51,O
–,O
3,O
.,O
39,O
)***,O
1,O
.,O
30,O
(,O
1,O
.,O
15,O
–,O
1,O
.,O
46,O
)***,O
1,O
.,O
80,O
(,O
1,O
.,O
42,O
–,O
2,O
.,O
28,O
)***,O
1,O
.,O
10,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
14,O
)***,O
Emotional,B-DS
abuse,I-DS
ever,O
(,O
model,O
1,O
),O
Emotional,B-DS
abuse,I-DS
score,O
(,O
model,O
2,O
),O
Physical,O
abuse,O
ever,O
(,O
model,O
1,O
),O
Physical,O
abuse,O
score,O
(,O
model,O
2,O
),O
Sexual,O
abuse,O
ever,O
(,O
model,O
1,O
),O
Sexual,O
abuse,O
score,O
(,O
model,O
2,O
),O
Range,O
of,O
abuse,O
(,O
none,O
-,O
three,O
",",O
model,O
3,O
),O
Childhood,O
trauma,O
score,O
(,O
model,O
4,O
),O
Men,B-OG
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
aOR,O
(,O
95,O
%,O
CI,O
),O
Transactional,O
sex,O
1,O
.,O
72,O
(,O
1,O
.,O
15,O
–,O
2,O
.,O
58,O
)**,O
1,O
.,O
18,O
(,O
1,O
.,O
10,O
–,O
1,O
.,O
26,O
)***,O
1,O
.,O
36,O
(,O
0,O
.,O
93,O
–,O
1,O
.,O
98,O
),O
1,O
.,O
09,O
(,O
1,O
.,O
00,O
–,O
1,O
.,O
19,O
)*,O
2,O
.,O
90,O
(,O
2,O
.,O
07,O
–,O
4,O
.,O
05,O
)***,O
1,O
.,O
52,O
(,O
1,O
.,O
32,O
–,O
1,O
.,O
74,O
)***,O
1,O
.,O
54,O
(,O
1,O
.,O
30,O
–,O
1,O
.,O
84,O
)***,O
1,O
.,O
09,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
13,O
)***,O
Main,O
partners,O
past12m,O
1,O
.,O
24,O
(,O
0,O
.,O
77,O
–,O
1,O
.,O
99,O
),O
1,O
.,O
11,O
(,O
1,O
.,O
03,O
–,O
1,O
.,O
19,O
)**,O
1,O
.,O
19,O
(,O
0,O
.,O
76,O
–,O
1,O
.,O
85,O
),O
1,O
.,O
11,O
(,O
1,O
.,O
01,O
–,O
1,O
.,O
22,O
)*,O
2,O
.,O
63,O
(,O
1,O
.,O
76,O
–,O
3,O
.,O
91,O
)***,O
1,O
.,O
29,O
(,O
1,O
.,O
15,O
–,O
1,O
.,O
46,O
)***,O
1,O
.,O
39,O
(,O
1,O
.,O
13,O
–,O
1,O
.,O
71,O
)**,O
1,O
.,O
07,O
(,O
1,O
.,O
03,O
–,O
1,O
.,O
11,O
)**,O
Casual,O
partners,O
past12m,O
1,O
.,O
79,O
(,O
1,O
.,O
01,O
–,O
3,O
.,O
17,O
)*,O
1,O
.,O
14,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
23,O
)**,O
1,O
.,O
59,O
(,O
0,O
.,O
95,O
–,O
2,O
.,O
69,O
),O
1,O
.,O
13,O
(,O
1,O
.,O
02,O
–,O
1,O
.,O
25,O
)*,O
2,O
.,O
57,O
(,O
1,O
.,O
65,O
–,O
4,O
.,O
00,O
)***,O
1,O
.,O
31,O
(,O
1,O
.,O
15,O
–,O
1,O
.,O
48,O
)***,O
1,O
.,O
57,O
(,O
1,O
.,O
23,O
–,O
2,O
.,O
01,O
)***,O
1,O
.,O
08,O
(,O
1,O
.,O
04,O
–,O
1,O
.,O
12,O
)***,O
Once,O
off,O
sexual,O
partners,O
past12m,O
2,O
.,O
04,O
(,O
1,O
.,O
14,O
–,O
3,O
.,O
66,O
)*,O
1,O
.,O
10,O
(,O
1,O
.,O
02,O
–,O
1,O
.,O
19,O
)*,O
1,O
.,O
65,O
(,O
0,O
.,O
98,O
–,O
2,O
.,O
77,O
),O
1,O
.,O
10,O
(,O
0,O
.,O
99,O
–,O
1,O
.,O
21,O
),O
2,O
.,O
82,O
(,O
1,O
.,O
81,O
–,O
4,O
.,O
40,O
)***,O
1,O
.,O
32,O
(,O
1,O
.,O
16,O
–,O
1,O
.,O
50,O
)***,O
1,O
.,O
67,O
(,O
1,O
.,O
31,O
–,O
2,O
.,O
14,O
)***,O
1,O
.,O
06,O
(,O
1,O
.,O
02,O
–,O
1,O
.,O
11,O
)**,O
Condom,O
use,O
at,O
last,O
sex,O
0,O
.,O
85,O
(,O
0,O
.,O
56,O
–,O
1,O
.,O
28,O
),O
0,O
.,O
95,O
(,O
0,O
.,O
89,O
–,O
1,O
.,O
01,O
),O
0,O
.,O
58,O
(,O
0,O
.,O
39,O
–,O
0,O
.,O
86,O
)**,O
0,O
.,O
95,O
(,O
0,O
.,O
87,O
–,O
1,O
.,O
03,O
),O
0,O
.,O
87,O
(,O
0,O
.,O
63,O
–,O
1,O
.,O
21,O
),O
0,O
.,O
99,O
(,O
0,O
.,O
89,O
–,O
1,O
.,O
10,O
),O
0,O
.,O
84,O
(,O
0,O
.,O
71,O
–,O
1,O
.,O
00,O
)*,O
0,O
.,O
98,O
(,O
0,O
.,O
95,O
–,O
1,O
.,O
01,O
),O
IPV,O
(,O
perpetration,O
),O
2,O
.,O
02,O
(,O
1,O
.,O
36,O
–,O
2,O
.,O
99,O
)***,O
1,O
.,O
14,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
22,O
)***,O
1,O
.,O
91,O
(,O
1,O
.,O
32,O
–,O
2,O
.,O
77,O
)**,O
1,O
.,O
16,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
27,O
)**,O
2,O
.,O
32,O
(,O
1,O
.,O
67,O
–,O
3,O
.,O
22,O
)***,O
1,O
.,O
39,O
(,O
1,O
.,O
21,O
–,O
1,O
.,O
58,O
)***,O
1,O
.,O
60,O
(,O
1,O
.,O
35,O
–,O
1,O
.,O
89,O
)***,O
1,O
.,O
09,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
13,O
)***,O
Non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
(,O
perpetration,O
),O
2,O
.,O
21,O
(,O
1,O
.,O
42,O
–,O
3,O
.,O
45,O
)***,O
1,O
.,O
17,O
(,O
1,O
.,O
10,O
–,O
1,O
.,O
25,O
)***,O
1,O
.,O
85,O
(,O
1,O
.,O
23,O
–,O
2,O
.,O
77,O
)**,O
1,O
.,O
15,O
(,O
1,O
.,O
05,O
–,O
1,O
.,O
25,O
)**,O
3,O
.,O
98,O
(,O
2,O
.,O
80,O
–,O
5,O
.,O
67,O
)***,O
1,O
.,O
68,O
(,O
1,O
.,O
47,O
–,O
1,O
.,O
92,O
)***,O
1,O
.,O
92,O
(,O
1,O
.,O
58,O
–,O
2,O
.,O
34,O
)***,O
1,O
.,O
11,O
(,O
1,O
.,O
07,O
–,O
1,O
.,O
15,O
)***,O
Harmful,O
alcohol,O
use,O
1,O
.,O
97,O
(,O
1,O
.,O
29,O
–,O
3,O
.,O
00,O
)***,O
1,O
.,O
23,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
20,O
)***,O
2,O
.,O
11,O
(,O
1,O
.,O
42,O
–,O
3,O
.,O
15,O
)***,O
1,O
.,O
15,O
(,O
1,O
.,O
06,O
–,O
1,O
.,O
26,O
)**,O
1,O
.,O
74,O
(,O
1,O
.,O
25,O
–,O
2,O
.,O
43,O
)**,O
1,O
.,O
10,O
(,O
0,O
.,O
99,O
–,O
1,O
.,O
22,O
),O
1,O
.,O
50,O
(,O
1,O
.,O
26,O
–,O
1,O
.,O
79,O
)***,O
1,O
.,O
06,O
(,O
1,O
.,O
03,O
–,O
1,O
.,O
10,O
)***,O
All,O
models,O
control,O
for,O
:,O
age,O
",",O
education,O
",",O
food,O
security,O
",",O
earnings,O
",",O
depression,B-DS
",",O
intervention,O
arm,O
",",O
length,O
of,O
time,O
living,O
in,O
community,O
Levels,O
of,O
significance,O
:,O
*,O
p,O
<,O
0,O
.,O
05,O
;,O
**,O
p,O
<,O
0,O
.,O
01,O
;,O
***,O
p,O
<,O
0,O
.,O
0001,O
For,O
men,B-OG
",",O
transactional,O
sex,O
in,O
the,O
past,O
year,O
was,O
associated,O
with,O
ever,O
experiencing,O
emotional,B-DS
abuse,I-DS
and,O
severity,O
of,O
emotional,B-DS
abuse,I-DS
",",O
severity,O
of,O
physical,O
abuse,O
",",O
and,O
any,O
sexual,O
abuse,O
",",O
and,O
severity,O
of,O
sexual,O
abuse,O
.,O
Four,O
or,O
more,O
main,O
sexual,O
partners,O
in,O
the,O
past,O
year,O
was,O
associated,O
with,O
severity,O
of,O
emotional,B-DS
abuse,I-DS
",",O
any,O
physical,O
abuse,O
",",O
severity,O
of,O
physical,O
abuse,O
",",O
any,O
sexual,O
abuse,O
and,O
severity,O
of,O
sexual,O
abuse,O
.,O
Four,O
or,O
more,O
casual,O
sexual,O
partners,O
in,O
the,O
past,O
year,O
was,O
associated,O
with,O
any,O
emotional,O
violence,O
and,O
severity,O
of,O
emotional,O
violence,O
",",O
severity,O
of,O
physical,O
violence,O
",",O
and,O
any,O
sexual,O
abuse,O
",",O
and,O
severity,O
of,O
sexual,O
abuse,O
.,O
Four,O
or,O
more,O
once,O
-,O
off,O
sexual,O
partners,O
was,O
associated,O
with,O
any,O
emotional,B-DS
abuse,I-DS
",",O
severity,O
of,O
emotional,B-DS
abuse,I-DS
",",O
any,O
physical,O
abuse,O
",",O
and,O
any,O
sexual,O
abuse,O
",",O
and,O
severity,O
of,O
sexual,O
abuse,O
.,O
Not,O
using,O
a,O
condom,O
at,O
last,O
sex,O
was,O
associated,O
with,O
any,O
experience,O
of,O
physical,O
abuse,O
.,O
Perpetration,O
of,O
IPV,O
and,O
non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
and,O
harmful,O
alcohol,O
use,O
were,O
all,O
associated,O
with,O
ever,O
experiencing,O
emotional,B-DS
abuse,I-DS
",",O
severity,O
of,O
emotional,B-DS
abuse,I-DS
",",O
ever,O
physical,O
abuse,O
",",O
severity,O
of,O
physical,O
abuse,O
",",O
and,O
ever,O
sexual,O
abuse,O
.,O
IPV,O
perpetration,O
",",O
and,O
non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
perpetration,O
was,O
also,O
associated,O
with,O
severity,O
of,O
sexual,O
abuse,O
.,O
For,O
women,B-OG
the,O
range,O
of,O
childhood,O
abuse,O
experienced,O
was,O
significantly,O
associated,O
with,O
transactional,O
sex,O
",",O
four,O
or,O
more,O
main,O
sexual,O
partners,O
",",O
four,O
or,O
more,O
causal,O
sexual,O
partners,O
",",O
experiencing,O
IPV,O
",",O
non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
",",O
not,O
using,O
a,O
condom,O
use,O
at,O
last,O
sex,O
and,O
harmful,O
alcohol,O
use,O
.,O
The,O
overall,O
severity,O
of,O
childhood,O
trauma,O
for,O
women,B-OG
was,O
associated,O
with,O
transactional,O
sex,O
",",O
four,O
or,O
more,O
casual,O
partners,O
in,O
the,O
past,O
year,O
",",O
past,O
year,O
experience,O
of,O
IPV,O
",",O
non,O
-,O
partner,O
sexual,B-DS
violence,I-DS
",",O
and,O
harmful,O
alcohol,O
use,O
.,O
For,O
men,B-OG
",",O
the,O
range,O
of,O
childhood,O
abuse,O
experienced,O
and,O
overall,O
childhood,O
trauma,O
scores,O
had,O
similar,O
associations,O
.,O
They,O
were,O
both,O
independently,O
associated,O
with,O
transactional,O
sex,O
",",O
four,O
or,O
more,O
main,O
partners,O
",",O
casual,O
partners,O
or,O
once,O
off,O
partners,O
",",O
and,O
IPV,O
and,O
non,O
-,O
partner,O
violence,O
perpetration,O
",",O
and,O
harmful,O
alcohol,O
use,O
.,O
The,O
range,O
of,O
childhood,O
abuse,O
experienced,O
for,O
men,B-OG
was,O
also,O
independently,O
associated,O
with,O
not,O
using,O
a,O
condom,O
at,O
last,O
sex,O
.,O
Discussion,O
The,O
experience,O
of,O
violence,O
and,O
abuse,O
during,O
childhood,O
for,O
this,O
vulnerable,O
",",O
and,O
relatively,O
young,O
population,O
",",O
was,O
exceedingly,O
high,O
:,O
75,O
.,O
0,O
%,O
of,O
women,B-OG
and,O
88,O
.,O
4,O
%,O
of,O
men,B-OG
reported,O
experiencing,O
any,O
childhood,O
trauma,O
.,O
All,O
forms,O
of,O
childhood,O
trauma,O
were,O
associated,O
with,O
a,O
range,O
of,O
current,O
HIV,B-OG
-,O
risk,O
behaviours,O
",",O
and,O
this,O
was,O
true,O
for,O
ever,O
experiencing,O
a,O
variety,O
of,O
types,O
of,O
trauma,O
",",O
the,O
severity,O
of,O
trauma,O
",",O
the,O
range,O
of,O
traumas,O
experienced,O
",",O
and,O
overall,O
severity,O
of,O
childhood,O
trauma,O
.,O
The,O
high,O
prevalence,O
of,O
childhood,O
trauma,O
observed,O
here,O
is,O
somewhat,O
higher,O
than,O
other,O
studies,O
in,O
South,O
Africa,O
",",O
suggesting,O
that,O
childhood,O
abuse,O
remains,O
a,O
major,O
challenge,O
that,O
needs,O
tackling,O
in,O
South,O
Africa,O
.,O
It,O
also,O
reinforces,O
the,O
growing,O
evidence,O
suggesting,O
informal,O
settlements,O
are,O
particular,O
sites,O
of,O
vulnerability,O
for,O
childhood,O
trauma,O
[,O
13,O
],O
as,O
well,O
as,O
sites,O
of,O
poor,O
health,O
more,O
widely,O
[,O
11,O
"],",O
and,O
yet,O
under,O
-,O
resourced,O
in,O
terms,O
of,O
access,O
to,O
services,O
and,O
less,O
focused,O
on,O
by,O
interventions,O
[,O
10,O
",",O
12,O
",",O
25,O
].,O
The,O
models,O
adjusted,O
for,O
length,O
of,O
residency,O
in,O
the,O
community,O
",",O
but,O
did,O
not,O
specifically,O
assess,O
where,O
participants,O
had,O
grown,O
up,O
",",O
nor,O
where,O
they,O
had,O
experienced,O
the,O
childhood,O
traumas,O
they,O
reported,O
.,O
For,O
men,B-OG
",",O
there,O
was,O
a,O
much,O
higher,O
prevalence,O
of,O
sexual,O
abuse,O
in,O
childhood,O
than,O
in,O
many,O
other,O
studies,O
in,O
South,O
Africa,O
.,O
In,O
this,O
study,O
",",O
47,O
.,O
9,O
%,O
of,O
men,B-OG
reported,O
any,O
form,O
of,O
childhood,O
sexual,O
abuse,O
.,O
This,O
is,O
much,O
higher,O
than,O
a,O
younger,O
",",O
rural,O
cohort,O
",",O
where,O
16,O
.,O
7,O
%,O
reported,O
any,O
sexual,O
abuse,O
[,O
4,O
"],",O
and,O
9,O
%,O
in,O
a,O
much,O
younger,O
(,O
10,O
–,O
17,O
),O
probability,O
sample,O
[,O
3,O
].,O
While,O
in,O
a,O
representative,O
household,O
sample,O
of,O
men,B-OG
in,O
South,O
Africa,O
",",O
9,O
.,O
6,O
%,O
reported,O
any,O
sexual,O
victimisation,O
(,O
rape,O
),O
by,O
a,O
man,B-OG
[,O
26,O
].,O
However,O
",",O
the,O
rate,O
of,O
sexual,O
abuse,O
seen,O
is,O
only,O
slightly,O
higher,O
than,O
a,O
school,O
-,O
based,O
survey,O
where,O
36,O
.,O
8,O
%,O
of,O
male,O
students,O
reported,O
any,O
form,O
of,O
sexual,O
abuse,O
[,O
27,O
].,O
The,O
high,O
levels,O
of,O
reported,O
sexual,O
abuse,O
was,O
not,O
driven,O
by,O
any,O
single,O
item,O
;,O
29,O
.,O
8,O
%,O
reported,O
being,O
touched,O
against,O
their,O
will,O
",",O
31,O
.,O
9,O
%,O
reported,O
sex,O
with,O
woman,B-OG
5,O
years,O
older,O
",",O
and,O
17,O
.,O
9,O
%,O
reported,O
being,O
raped,O
and,O
coerced,O
into,O
sex,O
",",O
suggesting,O
that,O
it,O
was,O
not,O
an,O
issue,O
with,O
translation,O
or,O
comprehension,O
of,O
questions,O
.,O
The,O
analysis,O
suggests,O
that,O
broadly,O
for,O
women,B-OG
and,O
men,B-OG
",",O
all,O
forms,O
of,O
childhood,O
traumas,O
are,O
associated,O
with,O
current,O
HIV,B-OG
-,O
risk,O
behaviours,O
.,O
This,O
relationship,O
holds,O
true,O
whether,O
the,O
analysis,O
is,O
looking,O
at,O
ever,O
experience,O
of,O
different,O
forms,O
of,O
childhood,O
trauma,O
",",O
or,O
the,O
severity,O
of,O
childhood,O
traumas,O
experienced,O
.,O
This,O
reflects,O
a,O
growing,O
body,O
of,O
global,O
research,O
that,O
also,O
outlines,O
the,O
close,O
relationship,O
between,O
childhood,O
trauma,O
and,O
HIV,B-OG
-,O
vulnerability,O
for,O
women,B-OG
and,O
men,B-OG
[,O
4,O
–,O
6,O
",",O
28,O
].,O
There,O
was,O
some,O
variation,O
in,O
the,O
relationships,O
across,O
women,B-OG
and,O
men,B-OG
however,O
.,O
For,O
women,B-OG
and,O
men,B-OG
sexual,O
abuse,O
was,O
independently,O
associated,O
with,O
all,O
HIV,B-OG
-,O
risk,O
behaviours,O
(,O
apart,O
from,O
condom,O
use,O
"),",O
reflecting,O
the,O
fact,O
that,O
sexual,O
abuse,O
seems,O
to,O
be,O
a,O
major,O
driver,O
of,O
long,O
-,O
term,O
health,O
impact,O
.,O
For,O
women,B-OG
",",O
the,O
number,O
of,O
past,O
year,O
sex,O
partners,O
tended,O
not,O
to,O
be,O
as,O
strongly,O
associated,O
with,O
physical,O
or,O
emotional,B-DS
abuse,I-DS
",",O
or,O
the,O
range,O
or,O
overall,O
severity,O
of,O
childhood,O
trauma,O
",",O
but,O
this,O
was,O
not,O
the,O
case,O
with,O
men,B-OG
.,O
This,O
may,O
reflect,O
different,O
approaches,O
to,O
internalizing,O
and,O
externalizing,O
of,O
behaviours,O
",",O
whereby,O
there,O
is,O
a,O
tendency,O
for,O
men,B-OG
to,O
externalize,O
traumatic,O
behaviours,O
",",O
while,O
women,B-OG
internalize,O
following,O
traumatic,O
experiences,O
[,O
28,O
].,O
It,O
was,O
also,O
evident,O
from,O
the,O
analysis,O
that,O
the,O
range,O
of,O
childhood,O
trauma,O
(,O
model,O
3,O
),O
and,O
the,O
cumulative,O
severity,O
of,O
childhood,O
trauma,O
(,O
model,O
4,O
),O
were,O
both,O
independently,O
associated,O
with,O
HIV,B-OG
-,O
risk,O
.,O
In,O
other,O
populations,O
",",O
including,O
those,O
experiencing,O
significant,O
trauma,O
during,O
adulthood,O
",",O
a,O
similar,O
relationship,O
is,O
seen,O
[,O
28,O
–,O
30,O
"],",O
suggesting,O
that,O
the,O
impact,O
of,O
childhood,O
traumas,O
continues,O
to,O
shape,O
people,O
’,O
s,O
lives,O
over,O
and,O
above,O
any,O
subsequent,O
traumatic,O
experiences,O
.,O
Furthermore,O
",",O
approximately,O
two,O
-,O
thirds,O
of,O
women,B-OG
and,O
men,B-OG
experienced,O
two,O
or,O
more,O
types,O
of,O
trauma,O
",",O
highlighting,O
the,O
close,O
overlap,O
between,O
different,O
trauma,O
types,O
and,O
that,O
there,O
is,O
likely,O
to,O
be,O
a,O
cumulative,O
impact,O
.,O
The,O
analysis,O
also,O
highlighted,O
how,O
women,B-OG
and,O
men,B-OG
who,O
experienced,O
physical,O
abuse,O
or,O
witnessed,O
violence,O
in,O
their,O
home,O
were,O
more,O
likely,O
to,O
perpetrate,O
IPV,O
(,O
men,B-OG
),O
or,O
experience,O
it,O
(,O
women,B-OG
),O
later,O
in,O
life,O
.,O
This,O
co,O
-,O
occurrence,O
of,O
physical,O
abuse,O
and,O
witnessing,O
violence,O
in,O
childhood,O
is,O
increasingly,O
recognized,O
as,O
a,O
key,O
driver,O
of,O
IPV,O
[,O
31,O
],O
and,O
has,O
been,O
seen,O
in,O
multiple,O
settings,O
globally,O
[,O
8,O
",",O
31,O
].,O
The,O
data,O
suggested,O
that,O
there,O
were,O
weaker,O
relationships,O
between,O
childhood,O
traumas,O
and,O
condom,O
use,O
at,O
last,O
sex,O
for,O
women,B-OG
and,O
men,B-OG
.,O
For,O
women,B-OG
not,O
using,O
a,O
condom,O
at,O
last,O
sex,O
was,O
only,O
associated,O
with,O
ever,O
emotional,B-DS
abuse,I-DS
",",O
ever,O
physical,O
abuse,O
",",O
and,O
the,O
range,O
of,O
abuse,O
experienced,O
.,O
While,O
for,O
men,B-OG
",",O
it,O
was,O
only,O
associated,O
with,O
ever,O
physical,O
abuse,O
and,O
the,O
range,O
of,O
abuse,O
experienced,O
.,O
There,O
are,O
a,O
number,O
of,O
possible,O
explanations,O
for,O
the,O
relatively,O
weak,O
associations,O
compared,O
to,O
other,O
HIV,B-OG
-,O
risk,O
behaviours,O
examined,O
.,O
First,O
",",O
we,O
did,O
not,O
control,O
for,O
type,O
of,O
partner,O
that,O
people,O
reported,O
last,O
having,O
sex,O
with,O
.,O
Condom,O
use,O
amongst,O
couples,O
trying,O
to,O
get,O
pregnant,O
",",O
in,O
long,O
-,O
term,O
relationships,O
",",O
or,O
women,B-OG
on,O
long,O
-,O
term,O
contraceptives,O
will,O
decrease,O
[,O
32,O
",",O
33,O
].,O
Second,O
",",O
condom,O
use,O
is,O
often,O
poorly,O
reported,O
in,O
surveys,O
",",O
and,O
as,O
such,O
these,O
relationships,O
are,O
poorly,O
understood,O
.,O
The,O
exceedingly,O
high,O
levels,O
of,O
sexual,O
abuse,O
amongst,O
this,O
sample,O
",",O
alongside,O
the,O
particularly,O
consistent,O
and,O
strong,O
relationship,O
between,O
sexual,O
abuse,O
and,O
HIV,B-OG
-,O
risk,O
behaviours,O
in,O
this,O
population,O
",",O
as,O
well,O
in,O
other,O
studies,O
",",O
highlights,O
sexual,O
abuse,O
in,O
childhood,O
as,O
a,O
key,O
driver,O
of,O
poor,O
health,O
[,O
6,O
",",O
34,O
],O
and,O
suggests,O
there,O
is,O
need,O
for,O
further,O
research,O
on,O
this,O
topic,O
.,O
At,O
a,O
very,O
basic,O
level,O
",",O
understanding,O
why,O
the,O
levels,O
of,O
sexual,O
abuse,O
in,O
the,O
population,O
are,O
so,O
high,O
is,O
critical,O
.,O
In,O
addition,O
",",O
this,O
study,O
did,O
not,O
ask,O
about,O
the,O
sex,O
of,O
perpetrators,O
of,O
sexual,O
abuse,O
(,O
apart,O
from,O
in,O
one,O
item,O
).,O
There,O
is,O
research,O
in,O
South,O
Africa,O
showing,O
that,O
boys,O
and,O
young,O
men,B-OG
experience,O
sexual,O
abuse,O
by,O
women,B-OG
as,O
well,O
as,O
men,B-OG
[,O
26,O
",",O
35,O
].,O
There,O
may,O
be,O
important,O
differences,O
by,O
sex,O
of,O
perpetrator,O
in,O
terms,O
of,O
prevalence,O
",",O
and,O
long,O
-,O
term,O
impacts,O
.,O
Understanding,O
the,O
prevalence,O
",",O
forms,O
and,O
impacts,O
of,O
childhood,O
sexual,O
abuse,O
amongst,O
young,O
men,B-OG
and,O
boys,O
remains,O
a,O
key,O
research,O
challenge,O
to,O
enable,O
a,O
meaningful,O
response,O
to,O
be,O
constructed,O
.,O
There,O
are,O
a,O
number,O
of,O
limitations,O
to,O
the,O
study,O
.,O
Data,O
are,O
cross,O
-,O
sectional,O
and,O
as,O
such,O
relationships,O
may,O
be,O
bi,O
-,O
directional,O
",",O
and,O
longitudinal,O
studies,O
are,O
required,O
to,O
establish,O
the,O
temporality,O
of,O
associations,O
.,O
The,O
retrospective,O
nature,O
of,O
questions,O
may,O
mean,O
reporting,O
of,O
childhood,O
experiences,O
is,O
weaker,O
",",O
and,O
there,O
may,O
be,O
some,O
level,O
of,O
confusion,O
around,O
when,O
specific,O
acts,O
occurred,O
i,O
.,O
e,O
.,O
before,O
or,O
after,O
the,O
age,O
of,O
18,O
for,O
some,O
participants,O
.,O
Studies,O
suggest,O
that,O
recall,O
bias,O
may,O
lead,O
to,O
an,O
under,O
-,O
reporting,O
of,O
events,O
in,O
childhood,O
[,O
36,O
"],",O
as,O
such,O
",",O
the,O
impact,O
of,O
retrospective,O
reporting,O
of,O
childhood,O
traumas,O
on,O
the,O
analysis,O
is,O
unclear,O
",",O
again,O
suggesting,O
the,O
need,O
for,O
prospective,O
studies,O
.,O
Finally,O
",",O
the,O
sample,O
were,O
self,O
-,O
selecting,O
into,O
an,O
intervention,O
evaluation,O
and,O
are,O
therefore,O
not,O
representative,O
of,O
the,O
population,O
of,O
young,O
people,O
living,O
in,O
urban,O
informal,O
settlements,O
.,O
Inclusion,O
criteria,O
mean,O
those,O
in,O
formal,O
employment,O
or,O
school,O
were,O
not,O
included,O
in,O
the,O
study,O
.,O
The,O
analysis,O
highlights,O
the,O
importance,O
of,O
reducing,O
all,O
forms,O
of,O
childhood,O
traumas,O
as,O
a,O
way,O
to,O
reduce,O
subsequent,O
HIV,B-OG
-,O
risk,O
amongst,O
young,O
women,B-OG
and,O
men,B-OG
.,O
An,O
increasing,O
number,O
of,O
interventions,O
have,O
shown,O
the,O
potential,O
to,O
reduce,O
harsh,O
parenting,O
across,O
the,O
global,O
south,O
[,O
37,O
],O
and,O
modifying,O
and,O
implementing,O
these,O
in,O
informal,O
settlements,O
remains,O
a,O
critical,O
challenge,O
.,O
Another,O
response,O
to,O
this,O
analysis,O
is,O
to,O
consider,O
how,O
the,O
range,O
of,O
current,O
HIV,B-OG
and,O
IPV,O
-,O
prevention,O
interventions,O
already,O
being,O
implemented,O
can,O
include,O
components,O
on,O
reducing,O
the,O
traumatic,O
effects,O
of,O
childhood,O
trauma,O
as,O
part,O
of,O
their,O
wider,O
intervention,O
.,O
A,O
range,O
of,O
trauma,O
-,O
focused,O
cognitive,O
behavioural,O
interventions,O
[,O
38,O
",",O
39,O
],O
may,O
have,O
an,O
important,O
role,O
to,O
play,O
in,O
achieving,O
this,O
.,O
Conclusion,O
Despite,O
the,O
huge,O
challenges,O
for,O
people,O
living,O
in,O
informal,O
settlements,O
such,O
as,O
poverty,O
",",O
gender,O
inequalities,O
",",O
and,O
lack,O
of,O
access,O
to,O
services,O
",",O
which,O
independently,O
shape,O
HIV,B-OG
-,O
risk,O
behaviours,O
",",O
this,O
study,O
highlights,O
that,O
childhood,O
traumas,O
remained,O
a,O
salient,O
driver,O
of,O
HIV,B-OG
-,O
risk,O
behaviours,O
amongst,O
young,O
people,O
.,O
As,O
the,O
analysis,O
showed,O
",",O
young,O
people,O
’,O
s,O
experiences,O
of,O
all,O
forms,O
of,O
childhood,O
trauma,O
",",O
specifically,O
emotional,B-DS
abuse,I-DS
and,O
neglect,O
",",O
physical,O
abuse,O
",",O
and,O
sexual,O
abuse,O
were,O
exceedingly,O
high,O
in,O
this,O
population,O
.,O
Additionally,O
",",O
there,O
were,O
incredibly,O
consistent,O
findings,O
across,O
women,B-OG
and,O
men,B-OG
",",O
whereby,O
childhood,O
traumas,O
",",O
assessed,O
in,O
a,O
wide,O
variety,O
of,O
ways,O
were,O
consistently,O
associated,O
with,O
a,O
range,O
of,O
HIV,B-OG
-,O
risk,O
behaviours,O
.,O
As,O
such,O
",",O
despite,O
the,O
immediacy,O
of,O
many,O
of,O
the,O
problems,O
of,O
young,O
people,O
living,O
in,O
informal,O
settlements,O
",",O
there,O
remains,O
a,O
pressing,O
need,O
to,O
reduce,O
the,O
experiences,O
of,O
childhood,O
traumas,O
and,O
their,O
long,O
-,O
term,O
effects,O
.,O
Supporting,O
information,O
Dataset,O
for,O
analysis,O
of,O
women,B-OG
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Dataset,O
for,O
analysis,O
of,O
men,B-OG
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Accounting,O
for,O
Genotype,O
-,O
by,O
-,O
Environment,O
Interactions,O
and,O
Residual,O
Genetic,O
Variation,O
in,O
Genomic,O
Selection,O
for,O
Water,O
-,O
Soluble,O
Carbohydrate,O
Concentration,O
in,O
Wheat,B-OG
Present,O
address,O
:,O
The,O
University,O
of,O
Queensland,O
",",O
School,O
of,O
Agriculture,O
and,O
Food,O
Sciences,O
",",O
Brisbane,O
QLD,O
4072,O
",",O
Australia,O
Abiotic,O
stress,O
tolerance,O
traits,O
are,O
often,O
complex,O
and,O
recalcitrant,O
targets,O
for,O
conventional,O
breeding,O
improvement,O
in,O
many,O
crop,O
species,O
.,O
This,O
study,O
evaluated,O
the,O
potential,O
of,O
genomic,O
selection,O
to,O
predict,O
water,O
-,O
soluble,O
carbohydrate,O
concentration,O
(,O
WSCC,O
"),",O
an,O
important,O
drought,O
tolerance,O
trait,O
",",O
in,O
wheat,B-OG
under,O
field,O
conditions,O
.,O
A,O
panel,O
of,O
358,O
varieties,O
and,O
breeding,O
lines,O
constrained,O
for,O
maturity,O
was,O
evaluated,O
under,O
rainfed,O
and,O
irrigated,O
treatments,O
across,O
two,O
locations,O
and,O
two,O
years,O
.,O
Whole,O
-,O
genome,O
marker,O
profiles,O
and,O
factor,O
analytic,O
mixed,O
models,O
were,O
used,O
to,O
generate,O
genomic,O
estimated,O
breeding,O
values,O
(,O
GEBVs,O
),O
for,O
specific,O
environments,O
and,O
environment,O
groups,O
.,O
Additive,O
genetic,O
variance,O
was,O
smaller,O
than,O
residual,O
genetic,O
variance,O
for,O
WSCC,O
",",O
such,O
that,O
genotypic,O
values,O
were,O
dominated,O
by,O
residual,O
genetic,O
effects,O
rather,O
than,O
additive,O
breeding,O
values,O
.,O
As,O
a,O
result,O
",",O
GEBVs,O
were,O
not,O
accurate,O
predictors,O
of,O
genotypic,O
values,O
of,O
the,O
extant,O
lines,O
",",O
but,O
GEBVs,O
should,O
be,O
reliable,O
selection,O
criteria,O
to,O
choose,O
parents,O
for,O
intermating,O
to,O
produce,O
new,O
populations,O
.,O
The,O
accuracy,O
of,O
GEBVs,O
for,O
untested,O
lines,O
was,O
sufficient,O
to,O
increase,O
predicted,O
genetic,O
gain,O
from,O
genomic,O
selection,O
per,O
unit,O
time,O
compared,O
to,O
phenotypic,O
selection,O
if,O
the,O
breeding,O
cycle,O
is,O
reduced,O
by,O
half,O
by,O
the,O
use,O
of,O
GEBVs,O
in,O
off,O
-,O
season,O
generations,O
.,O
Further,O
",",O
genomic,O
prediction,O
accuracy,O
depended,O
on,O
having,O
phenotypic,O
data,O
from,O
environments,O
with,O
strong,O
correlations,O
with,O
target,O
production,O
environments,O
to,O
build,O
prediction,O
models,O
.,O
By,O
combining,O
high,O
-,O
density,O
marker,O
genotypes,O
",",O
stress,O
-,O
managed,O
field,O
evaluations,O
",",O
and,O
mixed,O
models,O
that,O
model,O
simultaneously,O
covariances,O
among,O
genotypes,O
and,O
covariances,O
of,O
complex,O
trait,O
performance,O
between,O
pairs,O
of,O
environments,O
",",O
we,O
were,O
able,O
to,O
train,O
models,O
with,O
good,O
accuracy,O
to,O
facilitate,O
genetic,O
gain,O
from,O
genomic,O
selection,O
.,O
Abiotic,O
stresses,O
such,O
as,O
water,O
deficit,O
during,O
the,O
growing,O
season,O
are,O
a,O
major,O
limitation,O
to,O
crop,O
production,O
worldwide,O
(,O
Fischer,O
et,O
al,O
.,O
2014,O
;,O
Ray,O
et,O
al,O
.,O
2015,O
;,O
Foulkes,O
and,O
Reynolds,O
2015,O
).,O
However,O
",",O
the,O
incidence,O
and,O
severity,O
",",O
as,O
well,O
as,O
the,O
timing,O
of,O
water,O
deficit,O
can,O
differ,O
markedly,O
between,O
sites,O
and,O
years,O
",",O
contributing,O
to,O
the,O
historically,O
low,O
rates,O
of,O
genetic,O
gain,O
for,O
yield,O
in,O
water,O
deficit,O
environments,O
compared,O
to,O
well,O
-,O
watered,O
environments,O
(,O
Richards,O
et,O
al,O
.,O
2010,O
;,O
Araus,O
et,O
al,O
.,O
2002,O
).,O
An,O
alternative,O
to,O
selection,O
for,O
grain,O
yield,O
directly,O
is,O
to,O
identify,O
useful,O
traits,O
that,O
confer,O
physiological,O
adaptation,O
to,O
water,O
deficit,O
conditions,O
(,O
Rebetzke,O
et,O
al,O
.,O
2009,O
;,O
Bernier,O
et,O
al,O
.,O
2008,O
;,O
Reynolds,O
et,O
al,O
.,O
2016,O
;,O
Lopes,O
et,O
al,O
.,O
2011,O
).,O
For,O
example,O
",",O
selection,O
for,O
major,O
genes,O
for,O
reduced,O
height,O
and,O
photoperiod,O
insensitivity,O
has,O
been,O
used,O
to,O
alter,O
plant,B-OG
architecture,O
and,O
provide,O
drought,O
escape,O
potential,O
in,O
wheat,B-OG
(,O
Passioura,O
1996,O
;,O
Bennett,O
et,O
al,O
.,O
2012,O
;,O
Kamran,O
et,O
al,O
.,O
2014,O
).,O
Water,O
soluble,O
carbohydrate,O
(,O
WSC,O
),O
accumulation,O
and,O
remobilization,O
can,O
contribute,O
to,O
performance,O
under,O
water,O
deficit,O
as,O
a,O
source,O
of,O
assimilate,O
for,O
grain,O
filling,O
in,O
many,O
crop,O
species,O
(,O
Slewinski,O
2012,O
).,O
Carbohydrate,O
accumulation,O
occurs,O
when,O
the,O
crop,O
synthesizes,O
assimilate,O
at,O
a,O
rate,O
greater,O
than,O
needed,O
by,O
the,O
various,O
sinks,O
(,O
for,O
example,O
",",O
developing,O
florets,O
",",O
elongating,O
shoots,O
and,O
roots,O
).,O
For,O
wheat,B-OG
",",O
the,O
excess,O
carbohydrate,O
is,O
stored,O
mainly,O
in,O
the,O
lower,O
parts,O
of,O
stems,O
and,O
culms,O
(,O
Gebbing,O
2003,O
"),",O
where,O
the,O
quantity,O
of,O
WSC,O
can,O
reach,O
as,O
much,O
as,O
40,O
%,O
of,O
total,O
stem,O
weight,O
(,O
Schnyder,O
1993,O
).,O
The,O
main,O
sink,O
for,O
remobilization,O
of,O
WSC,O
is,O
the,O
developing,O
grain,O
(,O
Schnyder,O
1993,O
;,O
Takahashi,O
et,O
al,O
.,O
2001,O
;,O
van,O
Herwaarden,O
et,O
al,O
.,O
1998,O
).,O
Remobilized,O
WSC,O
can,O
contribute,O
as,O
much,O
as,O
30,O
–,O
50,O
%,O
of,O
grain,O
yield,O
under,O
terminal,O
drought,O
conditions,O
",",O
and,O
around,O
10,O
–,O
20,O
%,O
under,O
well,O
-,O
watered,O
conditions,O
(,O
Bidinger,O
et,O
al,O
.,O
1977,O
;,O
Schnyder,O
1993,O
;,O
Pheloung,O
and,O
Siddique,O
1991,O
;,O
Gebbing,O
and,O
Schnyder,O
1999,O
).,O
Selection,O
for,O
increased,O
WSC,O
in,O
cereal,O
breeding,O
programs,O
has,O
been,O
advocated,O
for,O
some,O
time,O
(,O
Blum,O
1998,O
"),",O
and,O
may,O
be,O
an,O
alternative,O
to,O
direct,O
selection,O
for,O
grain,O
yield,O
under,O
water,O
deficit,O
conditions,O
(,O
Asseng,O
and,O
van,O
Herwaarden,O
2003,O
).,O
Previous,O
studies,O
indicate,O
higher,O
broad,O
-,O
sense,O
heritability,O
for,O
WSC,O
concentration,O
(,O
WSCC,O
),O
compared,O
to,O
grain,O
yield,O
",",O
and,O
more,O
stable,O
genotype,O
rankings,O
within,O
a,O
target,O
population,O
of,O
environments,O
(,O
Ruuska,O
et,O
al,O
.,O
2006,O
;,O
Dreccer,O
et,O
al,O
.,O
2013,O
;,O
Piaskowski,O
et,O
al,O
.,O
2016,O
).,O
Indirect,O
selection,O
for,O
WSCC,O
by,O
breeders,O
has,O
already,O
occurred,O
in,O
some,O
environments,O
.,O
For,O
example,O
",",O
Rebetzke,O
et,O
al,O
.,O
(,O
2009,O
),O
reviewed,O
the,O
trend,O
for,O
increasing,O
WSCC,O
with,O
year,O
of,O
variety,O
release,O
observed,O
for,O
Western,O
Australian,O
and,O
the,O
International,O
Maize,O
and,O
Wheat,B-OG
Improvement,O
Center,O
(,O
CIMMYT,O
),O
wheat,B-OG
breeding,O
programs,O
.,O
Shearman,O
et,O
al,O
.,O
(,O
2005,O
),O
also,O
reported,O
that,O
UK,O
wheat,B-OG
cultivars,O
showed,O
increased,O
WSCC,O
with,O
progressive,O
year,O
of,O
release,O
.,O
However,O
",",O
WSCC,O
is,O
not,O
predicted,O
to,O
be,O
a,O
useful,O
indirect,O
selection,O
criterion,O
for,O
yield,O
improvement,O
in,O
some,O
cases,O
(,O
Ovenden,O
et,O
al,O
.,O
2017,O
);,O
furthermore,O
",",O
phenotyping,O
for,O
abiotic,O
stress,O
characteristics,O
such,O
as,O
WSCC,O
is,O
resource,O
intensive,O
and,O
phenotypic,O
selection,O
may,O
not,O
always,O
be,O
feasible,O
in,O
a,O
breeding,O
program,O
.,O
The,O
practical,O
utility,O
of,O
WSCC,O
for,O
breeding,O
appears,O
to,O
be,O
context,O
-,O
dependent,O
and,O
requires,O
empirical,O
investigation,O
for,O
specific,O
populations,O
and,O
environments,O
.,O
New,O
genomic,O
approaches,O
may,O
be,O
more,O
efficient,O
to,O
select,O
for,O
abiotic,O
stress,O
traits,O
than,O
conventional,O
phenotypic,O
selection,O
",",O
as,O
genomic,O
selection,O
can,O
leverage,O
the,O
information,O
obtained,O
from,O
difficult,O
and,O
expensive,O
phenotyping,O
(,O
Lin,O
et,O
al,O
.,O
2014,O
;,O
Cooper,O
et,O
al,O
.,O
2014,O
;,O
Leplat,O
et,O
al,O
.,O
2016,O
"),",O
to,O
enable,O
more,O
rapid,O
and,O
inexpensive,O
selection,O
for,O
many,O
loci,O
that,O
may,O
be,O
involved,O
in,O
the,O
inheritance,O
of,O
these,O
complex,O
traits,O
(,O
Vivek,O
et,O
al,O
.,O
2016,O
;,O
de,O
los,O
Campos,O
et,O
al,O
.,O
2013,O
).,O
Comprehensive,O
phenotyping,O
is,O
still,O
an,O
important,O
part,O
of,O
the,O
breeding,O
process,O
when,O
genomic,O
selection,O
is,O
applied,O
",",O
as,O
it,O
is,O
essential,O
to,O
build,O
accurate,O
prediction,O
models,O
.,O
However,O
",",O
early,O
generation,O
nursery,O
screens,O
can,O
be,O
replaced,O
with,O
genomic,O
screens,O
(,O
Sallam,O
et,O
al,O
.,O
2015,O
"),",O
and,O
expensive,O
field,O
trials,O
can,O
be,O
augmented,O
by,O
genetic,O
material,O
‘,O
enriched,O
’,O
through,O
genomic,O
selection,O
(,O
Heffner,O
et,O
al,O
.,O
2009,O
).,O
Genomic,O
selection,O
methods,O
use,O
marker,O
-,O
based,O
measures,O
of,O
realized,O
relatedness,O
from,O
whole,O
-,O
genome,O
marker,O
profiles,O
to,O
predict,O
genomic,O
estimated,O
breeding,O
values,O
(,O
GEBVs,O
),O
of,O
progeny,O
(,O
Habier,O
et,O
al,O
.,O
2013,O
;,O
Meuwissen,O
et,O
al,O
.,O
2001,O
;,O
de,O
los,O
Campos,O
et,O
al,O
.,O
2013,O
).,O
For,O
lines,O
that,O
have,O
both,O
genotype,O
and,O
phenotype,O
data,O
",",O
GEBVs,O
can,O
be,O
combined,O
with,O
the,O
residual,O
line,O
effect,O
estimates,O
to,O
produce,O
Genomic,O
Best,O
Linear,O
Unbiased,O
Predictors,O
(,O
G,O
-,O
BLUPs,O
),O
for,O
the,O
total,O
genotypic,O
value,O
",",O
hereafter,O
referred,O
to,O
as,O
the,O
genotypic,O
value,O
(,O
GV,O
),O
as,O
described,O
in,O
Oakey,O
et,O
al,O
.,O
(,O
2016,O
).,O
As,O
reviewed,O
by,O
Hill,O
(,O
2012,O
);,O
Nakaya,O
and,O
Isobe,O
(,O
2012,O
),O
and,O
de,O
los,O
Campos,O
et,O
al,O
.,O
(,O
2013,O
"),",O
a,O
key,O
difference,O
between,O
genomic,O
and,O
phenotypic,O
selection,O
is,O
the,O
potential,O
reduction,O
in,O
breeding,O
cycle,O
time,O
.,O
Although,O
genomic,O
predictions,O
of,O
untested,O
individuals,O
are,O
typically,O
less,O
accurate,O
than,O
well,O
-,O
replicated,O
phenotypic,O
evaluations,O
",",O
genomic,O
selection,O
may,O
be,O
more,O
effective,O
over,O
time,O
because,O
of,O
the,O
opportunity,O
to,O
implement,O
selection,O
in,O
additional,O
generations,O
per,O
unit,O
of,O
time,O
.,O
If,O
breeding,O
cycles,O
can,O
be,O
shortened,O
",",O
then,O
relative,O
accuracy,O
can,O
also,O
decrease,O
while,O
still,O
achieving,O
greater,O
genetic,O
gain,O
than,O
phenotypic,O
selection,O
(,O
Desta,O
and,O
Ortiz,O
2014,O
).,O
Developing,O
suitable,O
genomic,O
selection,O
models,O
for,O
abiotic,O
stress,O
tolerance,O
characteristics,O
requires,O
the,O
consideration,O
of,O
complex,O
genotype,O
×,O
environment,O
interactions,O
(,O
hereafter,O
G,O
×,O
E,O
interactions,O
),O
within,O
and,O
across,O
a,O
target,O
population,O
of,O
environments,O
because,O
expression,O
of,O
these,O
traits,O
is,O
often,O
environmentally,O
-,O
dependent,O
.,O
Complex,O
patterns,O
of,O
G,O
×,O
E,O
interactions,O
can,O
be,O
incorporated,O
into,O
genomic,O
prediction,O
models,O
",",O
and,O
although,O
G,O
×,O
E,O
interactions,O
will,O
necessarily,O
limit,O
gains,O
from,O
selection,O
for,O
wide,O
adaptation,O
",",O
models,O
that,O
incorporate,O
G,O
×,O
E,O
effects,O
can,O
help,O
breeders,O
select,O
sets,O
of,O
lines,O
optimally,O
adapted,O
to,O
different,O
subsets,O
of,O
environments,O
.,O
One,O
such,O
approach,O
is,O
to,O
use,O
parsimonious,O
mixed,O
models,O
",",O
such,O
as,O
factor,O
analytic,O
(,O
FA,O
),O
models,O
",",O
that,O
attempt,O
to,O
capture,O
most,O
of,O
the,O
G,O
×,O
E,O
signal,O
with,O
a,O
reduced,O
number,O
of,O
parameters,O
compared,O
to,O
a,O
full,O
unstructured,O
covariance,O
model,O
(,O
Guo,O
et,O
al,O
.,O
2013,O
;,O
Burgueño,O
et,O
al,O
.,O
2012,O
;,O
Oakey,O
et,O
al,O
.,O
2016,O
).,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
ability,O
of,O
genomic,O
selection,O
models,O
to,O
predict,O
a,O
complex,O
physiological,O
trait,O
(,O
WSCC,O
),O
in,O
both,O
untested,O
lines,O
and,O
in,O
new,O
environments,O
using,O
a,O
mixed,O
-,O
model,O
that,O
accounts,O
for,O
variation,O
in,O
the,O
pairwise,O
correlations,O
of,O
performance,O
in,O
different,O
pairs,O
of,O
environments,O
.,O
Materials,O
and,O
Methods,O
Genotypes,O
The,O
set,O
of,O
358,O
lines,O
used,O
in,O
this,O
study,O
was,O
selected,O
from,O
a,O
multi,O
-,O
site,O
",",O
multi,O
-,O
year,O
irrigated,O
winter,O
cereals,O
evaluation,O
trial,O
with,O
a,O
total,O
of,O
1,O
",",O
314,O
genotypes,O
.,O
The,O
genetic,O
entries,O
included,O
both,O
elite,O
breeding,O
lines,O
and,O
contemporary,O
commercial,O
varieties,O
from,O
Australian,O
wheat,B-OG
breeding,O
companies,O
and,O
CIMMYT,O
representing,O
a,O
range,O
of,O
maturity,O
types,O
.,O
As,O
WSC,O
accumulation,O
varies,O
according,O
to,O
development,O
stage,O
(,O
Ehdaie,O
et,O
al,O
.,O
2008,O
"),",O
this,O
study,O
aimed,O
to,O
assess,O
genotypes,O
as,O
close,O
as,O
practicable,O
to,O
a,O
common,O
anthesis,O
date,O
.,O
At,O
the,O
Yanco,O
irrigated,O
experiment,O
in,O
2009,O
",",O
a,O
total,O
of,O
358,O
breeding,O
lines,O
and,O
varieties,O
out,O
of,O
the,O
990,O
grown,O
in,O
the,O
experiment,O
were,O
selected,O
based,O
on,O
common,O
Zadoks,O
’,O
development,O
score,O
(,O
Zadoks,O
et,O
al,O
.,O
1974,O
),O
taken,O
at,O
approximately,O
mid,O
-,O
anthesis,O
.,O
Lines,O
selected,O
were,O
between,O
Z49,O
(,O
early,O
head,O
emergence,O
),O
and,O
Z56,O
(,O
60,O
%,O
heading,O
),O
which,O
corresponds,O
to,O
a,O
range,O
of,O
approximately,O
3,O
-,O
5,O
days,O
difference,O
in,O
anthesis,O
date,O
in,O
south,O
-,O
eastern,O
Australia,O
.,O
For,O
the,O
second,O
year,O
of,O
this,O
study,O
in,O
2010,O
",",O
the,O
same,O
breeding,O
lines,O
were,O
selected,O
for,O
WSCC,O
measurement,O
except,O
for,O
11,O
breeding,O
lines,O
that,O
were,O
excluded,O
from,O
the,O
overall,O
experiment,O
in,O
that,O
year,O
.,O
Lines,O
were,O
genotyped,O
using,O
the,O
Illumina,O
9k,O
Infinium,O
iSelect,O
beadchip,O
array,O
(,O
Cavanagh,O
et,O
al,O
.,O
2013,O
),O
resulting,O
in,O
4,O
",",O
883,O
polymorphic,O
SNPs,O
across,O
the,O
population,O
(,O
File,O
S1,O
).,O
Missing,O
values,O
were,O
imputed,O
using,O
Beagle,O
(,O
Browning,O
and,O
Browning,O
2009,O
),O
implemented,O
in,O
the,O
R,O
package,O
Synbreed,O
(,O
Wimmer,O
et,O
al,O
.,O
2012,O
).,O
The,O
resulting,O
4,O
",",O
162,O
SNP,O
markers,O
(,O
excluding,O
markers,O
that,O
were,O
duplicated,O
",",O
monomorphic,O
",",O
and,O
those,O
with,O
minor,O
allele,O
frequency,O
of,O
less,O
than,O
5,O
%),O
were,O
used,O
to,O
compute,O
a,O
scaled,O
identity,O
by,O
descent,O
relationship,O
matrix,O
(,O
K,O
),O
after,O
Endelman,O
and,O
Jannink,O
(,O
2012,O
),O
(,O
File,O
S2,O
).,O
There,O
was,O
little,O
evidence,O
of,O
population,O
structure,O
in,O
the,O
set,O
of,O
lines,O
used,O
in,O
this,O
study,O
",",O
with,O
the,O
first,O
two,O
eigenvectors,O
of,O
the,O
K,O
matrix,O
accounting,O
for,O
approximately,O
15,O
%,O
of,O
the,O
observed,O
variation,O
in,O
genomic,O
relationships,O
.,O
A,O
principal,O
components,O
plot,O
of,O
these,O
eigenvectors,O
showed,O
no,O
obvious,O
clustering,O
of,O
lines,O
(,O
File,O
S3,O
).,O
Experimental,O
design,O
Experiments,O
in,O
this,O
study,O
were,O
grown,O
in,O
south,O
-,O
eastern,O
Australia,O
at,O
Coleambally,O
and,O
Yanco,O
in,O
2009,O
and,O
2010,O
.,O
A,O
split,O
-,O
plot,O
design,O
was,O
used,O
",",O
in,O
which,O
the,O
main,O
-,O
plot,O
factor,O
was,O
irrigation,O
treatment,O
(,O
irrigated,O
or,O
rainfed,O
"),",O
and,O
the,O
990,O
genotype,O
entries,O
(,O
including,O
the,O
subset,O
of,O
genotypes,O
for,O
WSCC,O
phenotyping,O
),O
were,O
the,O
sub,O
-,O
plot,O
factor,O
.,O
There,O
were,O
two,O
replicates,O
of,O
each,O
treatment,O
at,O
each,O
site,O
.,O
The,O
placement,O
of,O
genotypes,O
within,O
field,O
experiment,O
layouts,O
was,O
optimized,O
with,O
the,O
spatial,O
design,O
package,O
DiGGer,O
(,O
Coombes,O
2002,O
).,O
For,O
the,O
laboratory,O
phase,O
measuring,O
WSCC,O
using,O
near,O
-,O
infrared,O
spectroscopy,O
(,O
NIRS,O
"),",O
an,O
experimental,O
design,O
structured,O
by,O
day,O
of,O
measurement,O
and,O
NIRS,O
instrument,O
carousel,O
and,O
well,O
was,O
implemented,O
to,O
account,O
for,O
laboratory,O
as,O
well,O
as,O
field,O
sources,O
of,O
experimental,O
error,O
.,O
Samples,O
from,O
both,O
field,O
sites,O
were,O
pooled,O
into,O
one,O
experimental,O
design,O
for,O
each,O
year,O
",",O
and,O
the,O
placement,O
of,O
genotypes,O
within,O
the,O
laboratory,O
experimental,O
phase,O
was,O
also,O
optimized,O
with,O
DiGGer,O
(,O
Coombes,O
2002,O
"),",O
with,O
partial,O
replication,O
of,O
20,O
%,O
of,O
experiment,O
field,O
plots,O
sampled,O
(,O
i,O
.,O
e,O
".,",O
a,O
replication,O
level,O
of,O
1,O
.,O
20,O
"),",O
following,O
the,O
methods,O
in,O
Cullis,O
et,O
al,O
.,O
(,O
2006,O
),O
and,O
Smith,O
et,O
al,O
.,O
(,O
2006,O
).,O
Experiments,O
were,O
sown,O
on,O
a,O
full,O
profile,O
of,O
moisture,O
",",O
achieved,O
by,O
flood,O
irrigating,O
each,O
site,O
four,O
to,O
six,O
weeks,O
before,O
sowing,O
",",O
so,O
that,O
the,O
focus,O
on,O
water,O
deficit,O
conditions,O
would,O
be,O
in,O
the,O
later,O
stages,O
of,O
crop,O
growth,O
.,O
Sowing,O
dates,O
were,O
targeted,O
for,O
the,O
first,O
two,O
weeks,O
of,O
May,O
.,O
Pre,O
-,O
sowing,O
nitrogen,O
was,O
targeted,O
to,O
be,O
approximately,O
120,O
kg,O
N,O
ha,O
-,O
1,O
.,O
Irrigated,O
experiments,O
were,O
fertilized,O
further,O
to,O
a,O
total,O
of,O
approximately,O
300,O
kg,O
N,O
ha,O
-,O
1,O
",",O
consistent,O
with,O
the,O
estimated,O
nitrogen,O
demand,O
by,O
the,O
crops,O
.,O
Experiments,O
were,O
subject,O
to,O
a,O
strict,O
weed,O
",",O
pest,O
and,O
disease,O
control,O
regime,O
to,O
maximize,O
yield,O
potential,O
.,O
Irrigation,O
scheduling,O
for,O
the,O
irrigated,O
treatments,O
was,O
intended,O
to,O
maintain,O
soil,O
water,O
potentials,O
above,O
-,O
100,O
kPa,O
during,O
the,O
growing,O
season,O
",",O
with,O
irrigations,O
commencing,O
as,O
soil,O
water,O
potential,O
fell,O
below,O
-,O
75,O
kPa,O
.,O
Water,O
-,O
soluble,O
carbohydrate,O
measurement,O
Tissue,O
for,O
WSCC,O
analysis,O
was,O
sampled,O
from,O
a,O
50,O
cm,O
long,O
section,O
of,O
row,O
(,O
0,O
.,O
09,O
m2,O
),O
in,O
each,O
plot,O
when,O
the,O
irrigated,O
treatments,O
at,O
each,O
site,O
were,O
approximately,O
180,O
°,O
d,O
post,O
-,O
anthesis,O
",",O
following,O
the,O
methods,O
of,O
Rebetzke,O
et,O
al,O
.,O
(,O
2008,O
).,O
Approximately,O
5,O
-,O
10,O
stalks,O
(,O
including,O
leaves,O
",",O
leaf,O
sheaths,O
and,O
heads,O
",",O
but,O
not,O
senesced,O
plant,B-OG
material,O
),O
from,O
each,O
sample,O
were,O
ground,O
to,O
pass,O
through,O
a,O
2,O
mm,O
sieve,O
.,O
Ground,O
biomass,O
samples,O
were,O
homogenized,O
and,O
subsampled,O
for,O
scanning,O
by,O
NIRS,O
with,O
a,O
Bruker,O
Multi,O
-,O
purpose,O
Analyzer,O
(,O
Bruker,O
Optik,O
GmbH,O
",",O
Ettlingen,O
",",O
Germany,O
),O
and,O
OPUS,O
software,O
(,O
version,O
5,O
.,O
1,O
"),",O
and,O
WSCC,O
for,O
the,O
NIRS,O
calibration,O
samples,O
(,O
10,O
%,O
of,O
the,O
full,O
set,O
),O
was,O
determined,O
using,O
the,O
alkaline,O
ferricyanide,O
method,O
(,O
Piltz,O
and,O
Law,O
2007,O
).,O
For,O
the,O
2009,O
experiment,O
",",O
the,O
coefficient,O
of,O
determination,O
for,O
the,O
calibration,O
linear,O
model,O
was,O
r2,O
=,O
0,O
.,O
92,O
and,O
the,O
root,O
-,O
mean,O
-,O
square,O
error,O
of,O
cross,O
-,O
validation,O
(,O
RMSECV,O
),O
was,O
15,O
.,O
4,O
.,O
For,O
the,O
2010,O
experiment,O
",",O
the,O
calibration,O
linear,O
model,O
r2,O
=,O
0,O
.,O
92,O
and,O
the,O
RMSECV,O
=,O
16,O
.,O
0,O
.,O
The,O
WSCC,O
phenotype,O
data,O
are,O
provided,O
in,O
File,O
S4,O
.,O
Statistical,O
methods,O
A,O
single,O
-,O
stage,O
",",O
multiplicative,O
linear,O
mixed,O
model,O
was,O
used,O
to,O
analyze,O
the,O
multi,O
-,O
experiment,O
data,O
with,O
the,O
molecular,O
marker,O
data,O
following,O
the,O
approaches,O
of,O
Beeck,O
et,O
al,O
.,O
(,O
2010,O
),O
and,O
Oakey,O
et,O
al,O
.,O
(,O
2016,O
).,O
The,O
linear,O
mixed,O
model,O
was,O
:,O
y,O
=,O
Xτ,O
+,O
Zgua,O
+,O
Zgua,O
¯+,O
Zuu,O
+,O
ηwhere,O
y,O
is,O
the,O
n,O
×,O
1,O
data,O
vector,O
of,O
the,O
response,O
variable,O
across,O
p,O
experiments,O
with,O
Nj,O
plots,O
per,O
experiment,O
j,O
.,O
Each,O
combination,O
of,O
year,O
(,O
2009,O
",",O
2010,O
"),",O
site,O
(,O
YANA,O
",",O
COLE,O
),O
and,O
irrigation,O
treatment,O
(,O
IRR,O
",",O
RFD,O
),O
was,O
treated,O
as,O
a,O
separate,O
experiment,O
so,O
that,O
p,O
=,O
8,O
.,O
τ,O
is,O
a,O
t,O
×,O
1,O
vector,O
of,O
fixed,O
effects,O
for,O
the,O
corresponding,O
n,O
×,O
t,O
design,O
matrix,O
(,O
X,O
"),",O
including,O
experiment,O
main,O
and,O
design,O
-,O
based,O
effects,O
.,O
The,O
term,O
u,O
is,O
a,O
random,O
component,O
with,O
associated,O
design,O
matrix,O
Zu,O
and,O
contains,O
experiment,O
-,O
specific,O
terms,O
used,O
to,O
capture,O
extraneous,O
variation,O
(,O
after,O
Gilmour,O
et,O
al,O
.,O
1997,O
"),",O
including,O
the,O
blocking,O
structure,O
of,O
the,O
field,O
(,O
row,O
",",O
range,O
",",O
replicate,O
and,O
irrigation,O
bay,O
"),",O
and,O
laboratory,O
(,O
day,O
of,O
measurement,O
",",O
instrument,O
carousel,O
and,O
carousel,O
well,O
),O
phases,O
of,O
the,O
design,O
.,O
The,O
n,O
×,O
1,O
residual,O
vector,O
η,O
was,O
modeled,O
within,O
each,O
year,O
of,O
the,O
laboratory,O
phase,O
design,O
.,O
The,O
m,O
×,O
1,O
vector,O
of,O
genetic,O
line,O
within,O
environment,O
effects,O
g,O
",",O
with,O
corresponding,O
design,O
matrix,O
Zg,O
",",O
is,O
partitioned,O
into,O
a,O
vector,O
of,O
additive,O
line,O
within,O
environment,O
effects,O
ua,O
and,O
residual,O
line,O
within,O
environment,O
effects,O
ua,O
¯,O
such,O
that,O
g,O
=,O
ua,O
+,O
ua,O
"¯,",O
following,O
the,O
approach,O
of,O
Oakey,O
et,O
al,O
.,O
(,O
2006,O
).,O
The,O
difference,O
between,O
the,O
‘,O
additive,O
’,O
and,O
‘,O
residual,O
’,O
genetic,O
effects,O
is,O
that,O
the,O
additive,O
effects,O
have,O
a,O
covariance,O
structure,O
proportional,O
to,O
the,O
realized,O
additive,O
genetic,O
relationship,O
matrix,O
",",O
whereas,O
the,O
residual,O
genetic,O
effects,O
are,O
independent,O
among,O
lines,O
.,O
When,O
we,O
arrange,O
the,O
vectors,O
of,O
additive,O
and,O
residual,O
genetic,O
-,O
within,O
-,O
environment,O
effects,O
ordered,O
as,O
m,O
genotypes,O
within,O
each,O
of,O
p,O
environments,O
matrices,O
",",O
their,O
covariance,O
structures,O
are,O
:,O
var,O
(,O
ua,O
)=,O
Gea,O
⊗,O
Kvar,O
(,O
ua,O
¯)=,O
Gea,O
¯,O
⊗,O
Imwhere,O
K,O
is,O
the,O
m,O
×,O
m,O
realized,O
genomic,O
relationship,O
matrix,O
estimated,O
from,O
the,O
marker,O
data,O
described,O
above,O
and,O
Im,O
is,O
an,O
m,O
×,O
m,O
identity,O
matrix,O
.,O
For,O
each,O
variance,O
model,O
above,O
",",O
Gea,O
and,O
Gea,O
¯,O
are,O
the,O
p,O
×,O
p,O
matrices,O
of,O
variances,O
and,O
covariances,O
of,O
additive,O
and,O
residual,O
genetic,O
effects,O
across,O
environments,O
",",O
respectively,O
.,O
Factor,O
analytic,O
models,O
of,O
different,O
orders,O
(,O
different,O
k,O
),O
can,O
be,O
used,O
to,O
model,O
the,O
two,O
genetic,O
components,O
(,O
Smith,O
et,O
al,O
.,O
2001,O
).,O
For,O
a,O
factor,O
analytic,O
model,O
",",O
these,O
matrices,O
are,O
decomposed,O
asGea,O
=(,O
Λeap,O
×,O
kaΛea,O
’,O
+,O
ψea,O
),O
Gea,O
¯=(,O
Λea,O
¯,O
p,O
×,O
ka,O
¯,O
Λea,O
¯’,O
+,O
ψea,O
¯).,O
Here,O
",",O
Λ,O
is,O
a,O
p,O
×,O
k,O
matrix,O
of,O
p,O
environment,O
loadings,O
for,O
k,O
factors,O
retained,O
in,O
the,O
factor,O
analytic,O
model,O
",",O
and,O
ψ,O
is,O
a,O
diagonal,O
matrix,O
of,O
the,O
p,O
environment,O
specific,O
variances,O
.,O
A,O
series,O
of,O
mixed,O
models,O
of,O
increasing,O
complexity,O
of,O
the,O
Gea,O
and,O
Gea,O
¯,O
terms,O
were,O
fitted,O
to,O
the,O
data,O
.,O
First,O
",",O
we,O
fitted,O
diagonal,O
covariance,O
structures,O
",",O
in,O
which,O
the,O
genetic,O
variance,O
was,O
allowed,O
to,O
vary,O
among,O
experiments,O
",",O
but,O
genetic,O
effects,O
were,O
uncorrelated,O
between,O
experiments,O
.,O
Then,O
a,O
sequence,O
of,O
factor,O
analytic,O
models,O
in,O
which,O
the,O
covariances,O
of,O
genotype,O
effects,O
were,O
allowed,O
to,O
vary,O
within,O
and,O
among,O
experiments,O
were,O
fitted,O
to,O
the,O
data,O
.,O
Factor,O
analytic,O
models,O
for,O
each,O
combination,O
of,O
k,O
=,O
1,O
or,O
2,O
factors,O
for,O
each,O
of,O
the,O
two,O
genetic,O
effects,O
were,O
used,O
(,O
Table,O
1,O
).,O
Selection,O
of,O
the,O
final,O
model,O
was,O
performed,O
on,O
the,O
basis,O
of,O
Akaike,O
’,O
s,O
Information,O
Criterion,O
(,O
AIC,O
);,O
(,O
Akaike,O
1974,O
"),",O
and,O
log,O
likelihood,O
ratio,O
tests,O
comparing,O
the,O
nested,O
FA,O
models,O
(,O
Stram,O
and,O
Lee,O
1994,O
).,O
All,O
data,O
were,O
analyzed,O
using,O
the,O
software,O
package,O
ASReml,O
-,O
R,O
(,O
Butler,O
et,O
al,O
.,O
2009,O
"),",O
in,O
the,O
R,O
environment,O
(,O
R,O
Development,O
Core,O
Team,O
2012,O
).,O
Factor,O
analytic,O
models,O
fitted,O
to,O
the,O
dataset,O
for,O
genomic,O
prediction,O
.,O
Increasing,O
order,O
factor,O
models,O
were,O
assessed,O
using,O
AIC,O
and,O
log,O
likelihood,O
ratio,O
tests,O
comparing,O
nested,O
models,O
.,O
The,O
model,O
with,O
additive,O
:,O
FA2,O
and,O
residual,O
genetic,O
:,O
FA2,O
covariance,O
structure,O
shows,O
a,O
significant,O
improvement,O
in,O
fit,O
from,O
both,O
additive,O
:,O
FA1,O
/,O
residual,O
genetic,O
:,O
FA1,O
and,O
additive,O
:,O
FA1,O
/,O
residual,O
genetic,O
:,O
FA2,O
models,O
and,O
is,O
referred,O
to,O
as,O
the,O
final,O
model,O
.,O
Higher,O
order,O
models,O
were,O
not,O
possible,O
to,O
fit,O
with,O
the,O
computing,O
resources,O
available,O
Covariance,O
structure,O
-,O
Additive,O
Covariance,O
structure,O
-,O
Residual,O
genetic,O
REML,O
Log,O
Likelihood,O
AIC,O
Parameters,O
Full,O
/,O
reduced,O
model,O
parameters,O
difference,O
Log,O
likelihood,O
ratio,O
test,O
model,O
comparison,O
:,O
Critical,O
value,O
P,O
value,O
DIAG,O
DIAG,O
4037,O
.,O
480,O
−,O
8042,O
.,O
956,O
16,O
—,O
—,O
—,O
—,O
FA1,O
FA1,O
4405,O
.,O
638,O
−,O
8747,O
.,O
276,O
32,O
16,O
to,O
DIAG,O
/,O
DIAG,O
736,O
.,O
32,O
2,O
.,O
389,O
×,O
10,O
−,O
146,O
FA1,O
FA2,O
4465,O
.,O
921,O
−,O
8853,O
.,O
842,O
39,O
7,O
to,O
FA1,O
/,O
FA1,O
120,O
.,O
57,O
5,O
.,O
840,O
×,O
10,O
−,O
23,O
FA2,O
FA1,O
4453,O
.,O
568,O
−,O
8829,O
.,O
136,O
39,O
7,O
to,O
FA1,O
/,O
FA1,O
95,O
.,O
86,O
7,O
.,O
708,O
×,O
10,O
−,O
18,O
FA2,O
FA2,O
4473,O
.,O
418,O
−,O
8854,O
.,O
836,O
46,O
7,O
to,O
FA1,O
/,O
FA2,O
14,O
.,O
99,O
0,O
.,O
0361,O
Experiment,O
-,O
specific,O
GVs,O
incorporating,O
both,O
additive,O
and,O
residual,O
genetic,O
effects,O
were,O
obtained,O
from,O
the,O
final,O
model,O
for,O
each,O
line,O
following,O
Beeck,O
et,O
al,O
.,O
(,O
2010,O
).,O
The,O
GV,O
for,O
line,O
i,O
at,O
environment,O
j,O
was,O
estimated,O
from,O
the,O
random,O
effect,O
solutions,O
in,O
the,O
final,O
model,O
as,O
:,O
GVij,O
=,O
u,O
^,O
aij,O
+,O
u,O
^,O
a,O
¯,O
ij,O
(,O
1,O
),O
These,O
GVs,O
were,O
used,O
later,O
in,O
cross,O
-,O
validation,O
analyses,O
as,O
the,O
best,O
estimates,O
of,O
‘,O
true,O
’,O
genotypic,O
values,O
at,O
each,O
experiment,O
.,O
Additive,O
genomic,O
estimated,O
breeding,O
values,O
(,O
GEBVs,O
),O
were,O
also,O
obtained,O
using,O
the,O
same,O
methods,O
but,O
based,O
only,O
on,O
the,O
additive,O
genetic,O
component,O
of,O
the,O
model,O
.,O
The,O
GEBV,O
for,O
line,O
i,O
at,O
environment,O
j,O
was,O
estimated,O
from,O
the,O
random,O
effect,O
solutions,O
in,O
the,O
final,O
model,O
as,O
:,O
GEBVij,O
=,O
u,O
^,O
aij,O
(,O
2,O
),O
Experiments,O
were,O
clustered,O
based,O
on,O
the,O
matrix,O
of,O
genetic,O
correlations,O
among,O
experiments,O
",",O
using,O
the,O
agglomerative,O
hierarchical,O
clustering,O
method,O
given,O
in,O
Cullis,O
et,O
al,O
.,O
(,O
2010,O
).,O
Broad,O
and,O
narrow,O
-,O
sense,O
heritability,O
estimates,O
were,O
calculated,O
from,O
the,O
final,O
FA,O
model,O
(,O
Table,O
1,O
).,O
Broad,O
-,O
sense,O
heritability,O
(,O
H,O
),O
for,O
each,O
trait,O
at,O
each,O
experiment,O
j,O
was,O
calculated,O
following,O
the,O
generalized,O
formula,O
for,O
unbalanced,O
data,O
in,O
Cullis,O
et,O
al,O
.,O
(,O
2006,O
):,O
Hj,O
=,O
1,O
−,O
APPEVGVj2σaj2,O
+,O
2σa,O
¯,O
j2where,O
APPEVGTj,O
is,O
the,O
average,O
pairwise,O
prediction,O
error,O
variance,O
of,O
GVs,O
at,O
experiment,O
j,O
(,O
the,O
variance,O
of,O
pairwise,O
GV,O
differences,O
"),",O
and,O
σaj2,O
and,O
σa,O
¯,O
j2,O
are,O
the,O
additive,O
and,O
residual,O
genetic,O
variance,O
components,O
for,O
experiment,O
j,O
",",O
respectively,O
.,O
Narrow,O
-,O
sense,O
heritability,O
was,O
calculated,O
for,O
each,O
trait,O
at,O
each,O
experiment,O
using,O
:,O
hj2,O
=,O
1,O
−,O
APPEVGEBVj2σaj2where,O
APPEVGEBVj,O
is,O
the,O
average,O
variance,O
of,O
comparisons,O
between,O
GEBVs,O
at,O
experiment,O
j,O
",",O
and,O
σaj2,O
is,O
the,O
additive,O
genetic,O
variance,O
component,O
at,O
experiment,O
j,O
.,O
The,O
broad,O
-,O
sense,O
heritabilities,O
for,O
total,O
genotypic,O
values,O
of,O
lines,O
across,O
all,O
experiments,O
and,O
for,O
genotypic,O
values,O
across,O
experiments,O
within,O
each,O
of,O
the,O
water,O
deficit,O
and,O
well,O
-,O
watered,O
environment,O
clusters,O
were,O
also,O
calculated,O
using,O
similar,O
formulae,O
.,O
In,O
these,O
cases,O
",",O
however,O
",",O
we,O
estimated,O
the,O
additive,O
and,O
residual,O
genetic,O
variances,O
across,O
experiments,O
from,O
the,O
average,O
of,O
the,O
additive,O
and,O
residual,O
pairwise,O
covariance,O
estimates,O
respectively,O
between,O
experiments,O
for,O
the,O
experiments,O
within,O
each,O
environment,O
cluster,O
(,O
Zila,O
et,O
al,O
.,O
2013,O
;,O
Isik,O
et,O
al,O
.,O
2017,O
).,O
Cross,O
validation,O
of,O
genomic,O
estimated,O
breeding,O
values,O
Fivefold,O
cross,O
-,O
validation,O
(,O
Ogut,O
et,O
al,O
.,O
2015,O
;,O
Crossa,O
et,O
al,O
.,O
2014,O
;,O
Burgueño,O
et,O
al,O
.,O
2012,O
;,O
Lorenz,O
et,O
al,O
.,O
2011,O
),O
was,O
used,O
to,O
measure,O
accuracy,O
of,O
breeding,O
value,O
predictions,O
across,O
environments,O
.,O
Lines,O
were,O
randomly,O
assigned,O
to,O
five,O
subsets,O
for,O
a,O
‘,O
fivefold,O
’,O
cross,O
validation,O
scheme,O
across,O
separate,O
experiments,O
in,O
the,O
model,O
.,O
The,O
final,O
FA,O
model,O
(,O
Table,O
1,O
),O
was,O
fitted,O
to,O
four,O
of,O
the,O
five,O
∼,O
80,O
%,O
subsets,O
(‘,O
training,O
set,O
’),O
to,O
estimate,O
model,O
parameters,O
and,O
to,O
predict,O
GEBVs,O
for,O
the,O
remaining,O
subset,O
(‘,O
validation,O
set,O
’),O
(,O
Equation,O
2,O
).,O
This,O
procedure,O
was,O
repeated,O
",",O
holding,O
out,O
a,O
different,O
subset,O
as,O
the,O
validation,O
set,O
each,O
time,O
.,O
The,O
entire,O
process,O
of,O
allocating,O
lines,O
to,O
folds,O
",",O
estimating,O
model,O
parameters,O
",",O
and,O
predicting,O
GEBVs,O
was,O
replicated,O
ten,O
times,O
.,O
The,O
GVs,O
from,O
the,O
full,O
model,O
including,O
all,O
the,O
data,O
(,O
Equation,O
1,O
),O
were,O
considered,O
the,O
best,O
estimates,O
of,O
the,O
true,O
values,O
of,O
total,O
genotypic,O
value,O
for,O
each,O
line,O
-,O
experiment,O
combination,O
.,O
The,O
correlation,O
between,O
the,O
GVs,O
within,O
an,O
experiment,O
and,O
the,O
GEBVs,O
for,O
each,O
validation,O
set,O
was,O
estimated,O
.,O
We,O
refer,O
to,O
these,O
as,O
within,O
-,O
experiment,O
prediction,O
accuracies,O
.,O
In,O
addition,O
",",O
the,O
ability,O
of,O
experiment,O
-,O
specific,O
GEBVs,O
to,O
predict,O
genotypic,O
values,O
at,O
other,O
experiments,O
was,O
estimated,O
for,O
each,O
validation,O
set,O
as,O
the,O
correlation,O
between,O
the,O
GEBVs,O
for,O
experiment,O
i,O
and,O
the,O
GVs,O
from,O
the,O
full,O
model,O
at,O
experiment,O
j,O
.,O
We,O
refer,O
to,O
these,O
as,O
across,O
-,O
experiment,O
prediction,O
accuracies,O
.,O
Relative,O
accuracy,O
of,O
phenotypic,O
value,O
prediction,O
(,O
RAPV,O
),O
at,O
experiment,O
j,O
measures,O
the,O
relative,O
accuracy,O
of,O
GEBVs,O
for,O
untested,O
lines,O
compared,O
to,O
the,O
best,O
estimates,O
of,O
their,O
total,O
genetic,O
value,O
within,O
each,O
experiment,O
using,O
both,O
genomic,O
and,O
phenotypic,O
data,O
:,O
RAPVj,O
=,O
corr,O
(,O
GEBVij,O
",",O
GVij,O
),O
HjIn,O
this,O
case,O
",",O
the,O
correlation,O
value,O
is,O
divided,O
by,O
the,O
square,O
root,O
of,O
the,O
broad,O
-,O
sense,O
heritability,O
estimate,O
to,O
estimate,O
the,O
accuracy,O
of,O
GEBVs,O
relative,O
to,O
total,O
genotypic,O
value,O
estimation,O
with,O
complete,O
phenotypic,O
data,O
(,O
Legarra,O
et,O
al,O
.,O
2008,O
).,O
We,O
also,O
estimated,O
relative,O
accuracy,O
of,O
breeding,O
value,O
prediction,O
at,O
experiment,O
j,O
(,O
RABV,O
):,O
RABVj,O
=,O
corr,O
(,O
GEBVij,O
",",O
GVij,O
),O
h2The,O
RABV,O
compares,O
the,O
accuracy,O
of,O
GEBVs,O
for,O
untested,O
lines,O
relative,O
to,O
GEBVs,O
based,O
on,O
complete,O
data,O
.,O
The,O
GEBVs,O
are,O
more,O
informative,O
to,O
predict,O
gain,O
from,O
selection,O
after,O
intermating,O
selected,O
lines,O
to,O
generate,O
a,O
new,O
population,O
of,O
breeding,O
lines,O
.,O
Data,O
and,O
reagent,O
availability,O
The,O
supplementary,O
files,O
contain,O
the,O
data,O
used,O
in,O
this,O
study,O
.,O
File,O
S1,O
contains,O
the,O
SNP,O
genotype,O
information,O
",",O
File,O
S2,O
contains,O
the,O
relationship,O
matrix,O
and,O
File,O
S3,O
contains,O
a,O
PCA,O
plot,O
of,O
the,O
first,O
two,O
eigenvectors,O
of,O
the,O
relationship,O
matrix,O
.,O
File,O
S4,O
contains,O
the,O
phenotype,O
dataset,O
for,O
WSCC,O
.,O
File,O
S5,O
is,O
script,O
for,O
the,O
models,O
used,O
for,O
genomic,O
selection,O
and,O
cross,O
-,O
validation,O
and,O
File,O
S6,O
contains,O
the,O
cross,O
-,O
validation,O
sets,O
.,O
Supplemental,O
material,O
available,O
at,O
Figshare,O
:,O
https,O
://,O
doi,O
.,O
org,O
/,O
10,O
.,O
25387,O
/,O
g3,O
.,O
6143243,O
.,O
Results,O
Model,O
selection,O
and,O
genotype,O
×,O
environment,O
interactions,O
The,O
2,O
-,O
factor,O
FA,O
model,O
for,O
both,O
additive,O
and,O
residual,O
variance,O
matrices,O
was,O
selected,O
as,O
the,O
best,O
model,O
using,O
the,O
AIC,O
(,O
Table,O
1,O
),O
and,O
used,O
for,O
genomic,O
prediction,O
.,O
The,O
proportion,O
of,O
within,O
-,O
experiment,O
total,O
genotypic,O
variance,O
that,O
was,O
due,O
to,O
additive,O
polygenic,O
variance,O
in,O
this,O
model,O
ranged,O
from,O
15,O
to,O
50,O
%,O
across,O
experiments,O
(,O
Table,O
2,O
).,O
In,O
the,O
selected,O
model,O
",",O
environments,O
clustered,O
into,O
two,O
distinct,O
environmental,O
groups,O
based,O
on,O
the,O
correlations,O
between,O
total,O
genetic,O
effects,O
(,O
GV,O
),O
across,O
experiments,O
(,O
Figure,O
1,O
).,O
The,O
groups,O
consisted,O
of,O
a,O
well,O
-,O
watered,O
environment,O
cluster,O
",",O
including,O
the,O
2009,O
irrigated,O
experiments,O
and,O
all,O
2010,O
experiments,O
",",O
and,O
a,O
water,O
deficit,O
environment,O
represented,O
by,O
the,O
two,O
2009,O
rainfed,O
experiments,O
.,O
This,O
corresponded,O
with,O
environmental,O
conditions,O
encountered,O
in,O
this,O
study,O
.,O
In,O
2009,O
",",O
both,O
sites,O
experienced,O
below,O
average,O
rainfall,O
",",O
and,O
warmer,O
air,O
temperatures,O
",",O
particularly,O
during,O
the,O
later,O
stages,O
of,O
grain,O
-,O
filling,O
.,O
Weather,O
conditions,O
throughout,O
2010,O
were,O
cooler,O
than,O
average,O
",",O
with,O
substantially,O
above,O
average,O
rainfall,O
during,O
late,O
spring,O
(,O
coinciding,O
with,O
the,O
crop,O
grain,O
-,O
filling,O
period,O
).,O
Thus,O
the,O
non,O
-,O
irrigated,O
experiments,O
in,O
2010,O
did,O
not,O
suffer,O
water,O
deficit,O
.,O
Genetic,O
variances,O
",",O
heritability,O
",",O
predictive,O
ability,O
and,O
relative,O
accuracy,O
by,O
experiment,O
and,O
environment,O
cluster,O
",",O
with,O
standard,O
deviations,O
given,O
in,O
parentheses,O
.,O
Experiment,O
codes,O
are,O
given,O
as,O
year,O
-,O
site,O
-,O
irrigation,O
treatment,O
.,O
The,O
experiments,O
09YANA_RFD,O
and,O
09COLE_RFD,O
constitute,O
the,O
water,O
deficit,O
experiment,O
cluster,O
;,O
all,O
other,O
experiments,O
are,O
included,O
in,O
the,O
well,O
-,O
watered,O
experiment,O
cluster,O
.,O
The,O
predictive,O
ability,O
of,O
the,O
GEBVs,O
model,O
at,O
each,O
experiment,O
and,O
environment,O
cluster,O
was,O
divided,O
by,O
the,O
broad,O
-,O
sense,O
heritability,O
to,O
provide,O
measures,O
of,O
accuracy,O
relative,O
to,O
phenotypic,O
selection,O
(,O
RAPV,O
"),",O
and,O
by,O
the,O
narrow,O
-,O
sense,O
heritability,O
to,O
provide,O
relative,O
accuracy,O
to,O
total,O
estimated,O
breeding,O
values,O
(,O
RABV,O
),O
Experiment,O
or,O
experiment,O
cluster,O
Additive,O
genetic,O
variance,O
Residual,O
geneticvariance,O
Proportion,O
of,O
genetic,O
variance,O
that,O
is,O
additive,O
Broad,O
-,O
sense,O
heritability,O
(,O
H,O
),O
Narrow,O
-,O
sense,O
heritability,O
(,O
h2,O
),O
Predictive,O
ability,O
Relative,O
accuracy,O
against,O
H,O
(,O
RAPV,O
),O
Relative,O
accuracy,O
against,O
h2,O
(,O
RABV,O
),O
All,O
experiments,O
0,O
.,O
00824,O
0,O
.,O
01537,O
34,O
.,O
90,O
%,O
0,O
.,O
778,O
0,O
.,O
363,O
0,O
.,O
480,O
(,O
0,O
.,O
206,O
),O
0,O
.,O
544,O
(,O
0,O
.,O
234,O
),O
0,O
.,O
797,O
(,O
0,O
.,O
343,O
),O
Well,O
-,O
watered,O
0,O
.,O
01297,O
0,O
.,O
02299,O
36,O
.,O
07,O
%,O
0,O
.,O
788,O
0,O
.,O
413,O
0,O
.,O
502,O
(,O
0,O
.,O
192,O
),O
0,O
.,O
565,O
(,O
0,O
.,O
220,O
),O
0,O
.,O
781,O
(,O
0,O
.,O
304,O
),O
Water,O
deficit,O
0,O
.,O
00914,O
0,O
.,O
03028,O
23,O
.,O
19,O
%,O
0,O
.,O
810,O
0,O
.,O
181,O
0,O
.,O
455,O
(,O
0,O
.,O
177,O
),O
0,O
.,O
506,O
(,O
0,O
.,O
197,O
),O
1,O
.,O
070,O
(,O
0,O
.,O
417,O
),O
09COLE_IRR,O
0,O
.,O
012713,O
0,O
.,O
043910,O
22,O
.,O
45,O
%,O
0,O
.,O
853,O
0,O
.,O
345,O
0,O
.,O
503,O
(,O
0,O
.,O
188,O
),O
0,O
.,O
545,O
(,O
0,O
.,O
203,O
),O
0,O
.,O
857,O
(,O
0,O
.,O
320,O
),O
09COLE_RFD,O
0,O
.,O
014623,O
0,O
.,O
031643,O
31,O
.,O
61,O
%,O
0,O
.,O
760,O
0,O
.,O
242,O
0,O
.,O
471,O
(,O
0,O
.,O
169,O
),O
0,O
.,O
540,O
(,O
0,O
.,O
194,O
),O
0,O
.,O
958,O
(,O
0,O
.,O
344,O
),O
09YANA_IRR,O
0,O
.,O
013688,O
0,O
.,O
023822,O
36,O
.,O
49,O
%,O
0,O
.,O
791,O
0,O
.,O
427,O
0,O
.,O
535,O
(,O
0,O
.,O
182,O
),O
0,O
.,O
602,O
(,O
0,O
.,O
205,O
),O
0,O
.,O
819,O
(,O
0,O
.,O
279,O
),O
09YANA_RFD,O
0,O
.,O
006774,O
0,O
.,O
039412,O
14,O
.,O
67,O
%,O
0,O
.,O
891,O
0,O
.,O
260,O
0,O
.,O
445,O
(,O
0,O
.,O
185,O
),O
0,O
.,O
471,O
(,O
0,O
.,O
196,O
),O
0,O
.,O
873,O
(,O
0,O
.,O
363,O
),O
10COLE_IRR,O
0,O
.,O
018323,O
0,O
.,O
021732,O
45,O
.,O
74,O
%,O
0,O
.,O
722,O
0,O
.,O
392,O
0,O
.,O
474,O
(,O
0,O
.,O
192,O
),O
0,O
.,O
558,O
(,O
0,O
.,O
226,O
),O
0,O
.,O
757,O
(,O
0,O
.,O
306,O
),O
10COLE_RFD,O
0,O
.,O
014472,O
0,O
.,O
014562,O
49,O
.,O
84,O
%,O
0,O
.,O
777,O
0,O
.,O
552,O
0,O
.,O
466,O
(,O
0,O
.,O
179,O
),O
0,O
.,O
529,O
(,O
0,O
.,O
204,O
),O
0,O
.,O
627,O
(,O
0,O
.,O
241,O
),O
10YANA_IRR,O
0,O
.,O
012508,O
0,O
.,O
042923,O
22,O
.,O
57,O
%,O
0,O
.,O
862,O
0,O
.,O
388,O
0,O
.,O
520,O
(,O
0,O
.,O
196,O
),O
0,O
.,O
560,O
(,O
0,O
.,O
211,O
),O
0,O
.,O
835,O
(,O
0,O
.,O
315,O
),O
10YANA_RFD,O
0,O
.,O
009967,O
0,O
.,O
020868,O
32,O
.,O
32,O
%,O
0,O
.,O
806,O
0,O
.,O
400,O
0,O
.,O
481,O
(,O
0,O
.,O
196,O
),O
0,O
.,O
536,O
(,O
0,O
.,O
218,O
),O
0,O
.,O
760,O
(,O
0,O
.,O
310,O
),O
Correlations,O
between,O
total,O
additive,O
and,O
residual,O
genetic,O
GV,O
values,O
in,O
different,O
experiments,O
based,O
on,O
the,O
full,O
data,O
set,O
(,O
above,O
the,O
diagonal,O
),O
and,O
correlations,O
between,O
additive,O
GEBVs,O
in,O
different,O
experiments,O
",",O
based,O
on,O
the,O
full,O
data,O
set,O
(,O
below,O
the,O
diagonal,O
).,O
Experiment,O
codes,O
are,O
given,O
as,O
year,O
-,O
site,O
-,O
irrigation,O
treatment,O
.,O
Averaged,O
across,O
experiments,O
in,O
each,O
environment,O
cluster,O
",",O
the,O
proportion,O
of,O
total,O
genetic,O
variance,O
that,O
was,O
additive,O
was,O
36,O
%,O
for,O
the,O
well,O
-,O
watered,O
environment,O
cluster,O
",",O
and,O
23,O
%,O
for,O
the,O
water,O
deficit,O
environment,O
cluster,O
(,O
Table,O
2,O
).,O
Very,O
similar,O
patterns,O
of,O
relationships,O
and,O
clustering,O
among,O
environments,O
were,O
observed,O
based,O
on,O
the,O
correlations,O
of,O
additive,O
-,O
only,O
genetic,O
effects,O
between,O
environments,O
(,O
Figure,O
1,O
"),",O
although,O
the,O
09YANA_RFD,O
experiment,O
was,O
less,O
distinct,O
from,O
the,O
well,O
-,O
watered,O
cluster,O
in,O
this,O
case,O
than,O
when,O
the,O
total,O
genotypic,O
correlations,O
were,O
considered,O
.,O
Correlations,O
between,O
the,O
residual,O
genetic,O
effects,O
of,O
different,O
environments,O
also,O
revealed,O
a,O
similar,O
pattern,O
",",O
but,O
with,O
a,O
slightly,O
weaker,O
correlation,O
between,O
09COLE_IRR,O
and,O
the,O
other,O
well,O
-,O
watered,O
environment,O
experiments,O
(,O
Figure,O
1,O
).,O
The,O
09COLE_IRR,O
experiment,O
was,O
the,O
only,O
experiment,O
to,O
be,O
grown,O
on,O
raised,O
beds,O
with,O
all,O
other,O
irrigated,O
experiments,O
utilizing,O
a,O
flat,O
field,O
layout,O
.,O
Cross,O
-,O
validation,O
of,O
genomic,O
estimated,O
breeding,O
values,O
The,O
predictive,O
ability,O
(,O
Sallam,O
et,O
al,O
.,O
2015,O
),O
of,O
experiment,O
-,O
specific,O
GEBVs,O
was,O
measured,O
as,O
the,O
average,O
correlation,O
between,O
experiment,O
-,O
specific,O
GEBVs,O
in,O
the,O
test,O
sets,O
and,O
experiment,O
-,O
specific,O
GVs,O
estimated,O
for,O
the,O
same,O
lines,O
when,O
all,O
trait,O
data,O
are,O
used,O
.,O
Within,O
-,O
experiment,O
prediction,O
abilities,O
ranged,O
from,O
r,O
=,O
0,O
.,O
474,O
to,O
0,O
.,O
535,O
for,O
the,O
well,O
-,O
watered,O
experiments,O
and,O
from,O
r,O
=,O
0,O
.,O
445,O
to,O
r,O
=,O
0,O
.,O
481,O
for,O
the,O
water,O
deficit,O
experiments,O
(,O
Table,O
2,O
and,O
diagonal,O
elements,O
in,O
Figure,O
2,O
).,O
The,O
predictive,O
ability,O
across,O
experiments,O
within,O
the,O
well,O
-,O
watered,O
environment,O
cluster,O
averaged,O
r,O
=,O
0,O
.,O
502,O
",",O
and,O
across,O
experiments,O
within,O
the,O
water,O
deficit,O
cluster,O
was,O
r,O
=,O
0,O
.,O
455,O
(,O
Table,O
2,O
and,O
diagonal,O
elements,O
of,O
Figure,O
2,O
).,O
In,O
contrast,O
",",O
GEBVs,O
specific,O
to,O
an,O
experiment,O
within,O
one,O
cluster,O
had,O
much,O
poorer,O
predictive,O
ability,O
of,O
GVs,O
in,O
the,O
other,O
cluster,O
.,O
We,O
also,O
estimated,O
the,O
ability,O
of,O
test,O
set,O
GEBVs,O
specific,O
to,O
one,O
experiment,O
or,O
cluster,O
to,O
predict,O
GVs,O
based,O
on,O
complete,O
phenotype,O
data,O
in,O
a,O
different,O
experiment,O
or,O
cluster,O
(,O
the,O
off,O
-,O
diagonal,O
elements,O
of,O
Figure,O
2,O
).,O
GEBVs,O
for,O
water,O
-,O
deficit,O
experiments,O
had,O
only,O
a,O
weak,O
correlation,O
with,O
the,O
GVs,O
in,O
the,O
well,O
-,O
watered,O
environments,O
(,O
average,O
r,O
=,O
0,O
.,O
196,O
).,O
Similarly,O
",",O
GEBVs,O
for,O
the,O
well,O
-,O
watered,O
environments,O
had,O
an,O
average,O
correlation,O
of,O
r,O
=,O
0,O
.,O
211,O
with,O
GVs,O
in,O
the,O
water,O
deficit,O
environments,O
.,O
Average,O
GEBVs,O
across,O
all,O
experiments,O
also,O
had,O
low,O
correlation,O
with,O
GVs,O
within,O
the,O
water,O
deficit,O
environments,O
(,O
r,O
=,O
0,O
.,O
287,O
).,O
Within,O
each,O
environment,O
cluster,O
",",O
the,O
GEBVs,O
for,O
individual,O
experiments,O
had,O
moderate,O
correlations,O
with,O
GVs,O
at,O
other,O
experiments,O
(,O
r,O
=,O
0,O
.,O
442,O
to,O
r,O
=,O
0,O
.,O
536,O
for,O
the,O
well,O
-,O
watered,O
experiments,O
",",O
and,O
r,O
=,O
0,O
.,O
400,O
to,O
r,O
=,O
0,O
.,O
447,O
for,O
the,O
water,O
deficit,O
experiments,O
).,O
Predictive,O
ability,O
of,O
GEBVs,O
average,O
across,O
all,O
experiments,O
",",O
averaged,O
across,O
experiments,O
within,O
each,O
environment,O
cluster,O
(,O
well,O
-,O
watered,O
or,O
water,O
-,O
deficit,O
"),",O
or,O
predicted,O
for,O
each,O
specific,O
experiment,O
.,O
The,O
training,O
set,O
of,O
environments,O
is,O
given,O
by,O
the,O
X,O
axis,O
",",O
and,O
the,O
validation,O
set,O
of,O
environments,O
is,O
given,O
by,O
the,O
Y,O
axis,O
.,O
Experiment,O
codes,O
are,O
given,O
as,O
year,O
-,O
site,O
-,O
irrigation,O
treatment,O
.,O
Diagonal,O
values,O
represent,O
ability,O
of,O
GEBVs,O
within,O
a,O
given,O
environment,O
to,O
predict,O
GVs,O
in,O
the,O
same,O
environment,O
.,O
Off,O
-,O
diagonal,O
values,O
represent,O
the,O
ability,O
of,O
GEBVs,O
in,O
a,O
given,O
environment,O
to,O
predict,O
GVs,O
in,O
a,O
different,O
environment,O
.,O
The,O
relative,O
accuracy,O
statistics,O
were,O
computed,O
with,O
both,O
broad,O
-,O
sense,O
and,O
narrow,O
-,O
sense,O
heritabilities,O
as,O
RAPV,O
and,O
RABV,O
",",O
respectively,O
",",O
so,O
that,O
a,O
measure,O
of,O
accuracy,O
relative,O
to,O
phenotypic,O
selection,O
can,O
be,O
compared,O
to,O
the,O
accuracy,O
relative,O
to,O
breeding,O
value,O
prediction,O
(,O
Table,O
2,O
).,O
As,O
the,O
broad,O
-,O
sense,O
heritability,O
estimates,O
were,O
much,O
higher,O
than,O
narrow,O
-,O
sense,O
",",O
the,O
relative,O
accuracy,O
statistics,O
indicate,O
that,O
the,O
efficiency,O
of,O
genotype,O
value,O
prediction,O
was,O
poor,O
(,O
RAPV,O
ranged,O
from,O
0,O
.,O
471,O
to,O
0,O
.,O
602,O
at,O
individual,O
experiments,O
",",O
with,O
a,O
mean,O
of,O
0,O
.,O
544,O
",",O
Table,O
2,O
"),",O
whereas,O
the,O
relative,O
accuracy,O
of,O
breeding,O
value,O
prediction,O
with,O
marker,O
information,O
only,O
compared,O
to,O
complete,O
phenotype,O
data,O
were,O
much,O
higher,O
(,O
RABV,O
ranged,O
from,O
0,O
.,O
627,O
to,O
0,O
.,O
958,O
at,O
individual,O
experiments,O
",",O
with,O
a,O
mean,O
of,O
0,O
.,O
797,O
",",O
Table,O
2,O
).,O
The,O
RABV,O
for,O
the,O
water,O
deficit,O
experiment,O
cluster,O
was,O
1,O
.,O
07,O
",",O
a,O
surprising,O
but,O
valid,O
result,O
analogous,O
to,O
relative,O
efficiency,O
of,O
selection,O
on,O
a,O
correlated,O
trait,O
",",O
which,O
can,O
be,O
>,O
1,O
relative,O
to,O
direct,O
selection,O
.,O
Discussion,O
Integration,O
of,O
genomic,O
selection,O
with,O
genotype,O
×,O
environment,O
effects,O
Our,O
approach,O
in,O
this,O
study,O
combines,O
the,O
concept,O
of,O
a,O
Target,O
Population,O
of,O
Environments,O
(,O
TPE,O
),O
in,O
regard,O
to,O
selection,O
(,O
Comstock,O
1977,O
;,O
Cooper,O
et,O
al,O
.,O
1997,O
;,O
Basford,O
and,O
Cooper,O
1998,O
),O
with,O
genomic,O
prediction,O
methods,O
",",O
and,O
extends,O
the,O
work,O
of,O
Oakey,O
et,O
al,O
.,O
(,O
2016,O
),O
to,O
a,O
large,O
field,O
-,O
based,O
multi,O
-,O
environment,O
trial,O
.,O
The,O
TPE,O
concept,O
applies,O
equally,O
to,O
genomic,O
selection,O
as,O
phenotypic,O
selection,O
in,O
the,O
face,O
of,O
genotype,O
-,O
by,O
-,O
environment,O
interactions,O
.,O
Our,O
results,O
show,O
that,O
predictive,O
ability,O
depends,O
on,O
the,O
extent,O
and,O
nature,O
of,O
the,O
genetic,O
correlation,O
between,O
the,O
training,O
and,O
the,O
validation,O
populations,O
.,O
Heslot,O
et,O
al,O
.,O
(,O
2013,O
),O
also,O
demonstrated,O
empirically,O
in,O
wheat,B-OG
that,O
G,O
×,O
E,O
patterns,O
impact,O
genomic,O
selection,O
in,O
the,O
same,O
way,O
that,O
they,O
impact,O
phenotypic,O
selection,O
.,O
Heslot,O
et,O
al,O
.,O
(,O
2013,O
),O
also,O
observed,O
that,O
the,O
main,O
driver,O
of,O
prediction,O
accuracy,O
between,O
environments,O
were,O
G,O
×,O
E,O
effects,O
and,O
that,O
genomic,O
predictions,O
are,O
specific,O
to,O
the,O
TPE,O
they,O
are,O
predicted,O
for,O
–,O
conclusions,O
also,O
supported,O
by,O
Lado,O
et,O
al,O
.,O
(,O
2013,O
),O
and,O
Oakey,O
et,O
al,O
.,O
(,O
2016,O
"),",O
who,O
also,O
showed,O
that,O
multi,O
-,O
year,O
models,O
could,O
give,O
better,O
prediction,O
accuracy,O
when,O
environmental,O
influence,O
is,O
large,O
.,O
Genomic,O
prediction,O
models,O
based,O
on,O
multi,O
-,O
environment,O
trials,O
may,O
involve,O
considerable,O
complexity,O
to,O
allow,O
heterogeneity,O
of,O
genetic,O
correlations,O
and,O
genetic,O
variances,O
among,O
environments,O
",",O
variable,O
sources,O
of,O
extraneous,O
non,O
-,O
genetic,O
variation,O
among,O
environments,O
",",O
in,O
addition,O
to,O
the,O
high,O
dimensionality,O
of,O
marker,O
data,O
.,O
Researchers,O
are,O
faced,O
with,O
making,O
choices,O
about,O
modeling,O
greater,O
complexity,O
in,O
the,O
patterns,O
of,O
genetic,O
correlations,O
among,O
environments,O
vs,O
.,O
greater,O
complexity,O
in,O
the,O
genetic,O
architecture,O
modeled,O
by,O
marker,O
data,O
",",O
based,O
on,O
tradeoffs,O
between,O
capturing,O
more,O
signal,O
vs,O
.,O
overfitting,O
and,O
increasing,O
computational,O
demands,O
as,O
model,O
complexity,O
increases,O
.,O
A,O
variety,O
of,O
modeling,O
approaches,O
have,O
been,O
proposed,O
",",O
reflecting,O
different,O
choices,O
about,O
which,O
aspects,O
of,O
model,O
complexity,O
to,O
emphasize,O
.,O
For,O
example,O
",",O
Sallam,O
et,O
al,O
.,O
(,O
2015,O
),O
utilized,O
an,O
across,O
-,O
experiments,O
model,O
for,O
TPE,O
identified,O
as,O
having,O
low,O
G,O
×,O
E,O
so,O
the,O
term,O
in,O
the,O
model,O
was,O
minimized,O
",",O
whereas,O
Crossa,O
et,O
al,O
.,O
(,O
2010,O
),O
modeled,O
genetic,O
effects,O
within,O
each,O
environment,O
separately,O
.,O
Lopez,O
-,O
Cruz,O
et,O
al,O
.,O
(,O
2015,O
),O
introduced,O
a,O
model,O
with,O
common,O
G,O
×,O
E,O
variance,O
for,O
all,O
sets,O
",",O
but,O
allowed,O
variable,O
marker,O
effects,O
through,O
a,O
Bayesian,O
model,O
.,O
Heslot,O
et,O
al,O
.,O
(,O
2014,O
),O
and,O
Jarquín,O
et,O
al,O
.,O
(,O
2014,O
),O
introduced,O
models,O
that,O
accounted,O
for,O
marker,O
interactions,O
with,O
specific,O
climate,O
variables,O
",",O
adding,O
another,O
layer,O
of,O
complexity,O
to,O
the,O
modeling,O
of,O
G,O
×,O
E,O
patterns,O
.,O
Our,O
focus,O
in,O
this,O
study,O
was,O
to,O
emphasize,O
the,O
modeling,O
of,O
complex,O
patterns,O
of,O
heterogeneity,O
in,O
the,O
genetic,O
variation,O
expressed,O
within,O
environments,O
and,O
the,O
pairwise,O
genetic,O
correlations,O
between,O
environments,O
",",O
along,O
with,O
extraneous,O
non,O
-,O
genetic,O
effects,O
.,O
We,O
chose,O
a,O
FA,O
model,O
(,O
Cullis,O
et,O
al,O
.,O
2010,O
;,O
Smith,O
et,O
al,O
.,O
2001,O
),O
that,O
can,O
capture,O
such,O
heterogeneity,O
more,O
parsimoniously,O
than,O
fully,O
unstructured,O
models,O
.,O
The,O
patterns,O
of,O
genetic,O
correlations,O
between,O
environments,O
observed,O
in,O
training,O
data,O
sets,O
and,O
patterns,O
of,O
the,O
accuracy,O
of,O
GEBVs,O
for,O
one,O
site,O
to,O
predict,O
genetic,O
values,O
at,O
other,O
sites,O
in,O
test,O
sets,O
from,O
the,O
FA,O
model,O
provide,O
a,O
way,O
of,O
characterizing,O
target,O
environments,O
",",O
still,O
following,O
the,O
ideas,O
on,O
exploiting,O
G,O
×,O
E,O
to,O
make,O
genetic,O
gains,O
outlined,O
by,O
Byth,O
(,O
1981,O
).,O
The,O
environment,O
clusters,O
in,O
this,O
study,O
show,O
that,O
year,O
effects,O
are,O
more,O
important,O
than,O
location,O
for,O
WSCC,O
(,O
Figure,O
1,O
"),",O
and,O
this,O
observation,O
is,O
borne,O
out,O
by,O
other,O
G,O
×,O
E,O
studies,O
with,O
similar,O
findings,O
",",O
particularly,O
for,O
traits,O
where,O
expression,O
is,O
significantly,O
affected,O
by,O
seasonal,O
conditions,O
(,O
Smith,O
et,O
al,O
.,O
2015,O
;,O
Chenu,O
et,O
al,O
.,O
2011,O
;,O
Milgate,O
et,O
al,O
.,O
2015,O
).,O
Using,O
factor,O
analytic,O
models,O
for,O
genomic,O
predictions,O
Heslot,O
et,O
al,O
.,O
(,O
2014,O
),O
demonstrate,O
a,O
method,O
to,O
predict,O
genotype,O
performance,O
in,O
untested,O
environments,O
based,O
on,O
climatic,O
variables,O
.,O
In,O
contrast,O
",",O
the,O
FA,O
model,O
approach,O
helps,O
breeders,O
to,O
understand,O
the,O
groupings,O
of,O
environments,O
within,O
the,O
TPE,O
based,O
on,O
their,O
genetic,O
correlations,O
",",O
and,O
breeders,O
can,O
predict,O
average,O
performance,O
in,O
subsets,O
of,O
these,O
environments,O
.,O
Both,O
Burgueño,O
et,O
al,O
.,O
(,O
2012,O
),O
and,O
Rutkoski,O
et,O
al,O
.,O
(,O
2015,O
),O
utilized,O
similar,O
FA,O
models,O
for,O
genomic,O
prediction,O
",",O
however,O
this,O
study,O
shows,O
that,O
the,O
power,O
of,O
an,O
FA,O
model,O
lies,O
in,O
the,O
ability,O
to,O
identify,O
environment,O
subsets,O
based,O
on,O
the,O
loadings,O
and,O
predict,O
genotype,O
performance,O
more,O
accurately,O
within,O
those,O
TPE,O
rather,O
than,O
the,O
across,O
-,O
experiments,O
average,O
.,O
Since,O
we,O
predicted,O
values,O
for,O
untested,O
lines,O
within,O
tested,O
environments,O
",",O
our,O
estimated,O
prediction,O
abilities,O
are,O
biased,O
upward,O
compared,O
to,O
prediction,O
of,O
untested,O
lines,O
within,O
untested,O
environments,O
.,O
Our,O
results,O
",",O
which,O
reflect,O
upper,O
bounds,O
on,O
prediction,O
abilities,O
across,O
environments,O
",",O
demonstrate,O
that,O
GEBVs,O
have,O
reasonable,O
accuracy,O
only,O
within,O
a,O
clearly,O
defined,O
cluster,O
of,O
environments,O
",",O
and,O
have,O
substantially,O
worse,O
prediction,O
accuracy,O
of,O
performance,O
in,O
environments,O
outside,O
of,O
the,O
group,O
of,O
related,O
environments,O
for,O
which,O
they,O
were,O
predicted,O
.,O
The,O
FA,O
model,O
permits,O
prediction,O
of,O
genetic,O
values,O
for,O
untested,O
lines,O
within,O
each,O
site,O
based,O
on,O
the,O
genomic,O
relationships,O
between,O
the,O
untested,O
and,O
tested,O
lines,O
and,O
also,O
based,O
on,O
the,O
genetic,O
correlations,O
observed,O
among,O
the,O
tested,O
set,O
of,O
environments,O
.,O
The,O
FA,O
model,O
can,O
improve,O
prediction,O
accuracy,O
within,O
a,O
single,O
site,O
over,O
what,O
is,O
possible,O
from,O
a,O
single,O
-,O
environment,O
analysis,O
by,O
information,O
sharing,O
among,O
environments,O
with,O
high,O
genetic,O
correlations,O
(,O
Guo,O
et,O
al,O
.,O
2013,O
;,O
Cullis,O
et,O
al,O
.,O
2010,O
;,O
Kelly,O
et,O
al,O
.,O
2007,O
).,O
In,O
this,O
study,O
",",O
GEBVs,O
averaged,O
across,O
all,O
environments,O
were,O
less,O
accurate,O
for,O
environment,O
-,O
specific,O
prediction,O
than,O
GEBVs,O
averaged,O
across,O
subsets,O
of,O
sites,O
within,O
the,O
same,O
environmental,O
cluster,O
(,O
Figure,O
2,O
).,O
A,O
drawback,O
to,O
the,O
FA,O
model,O
is,O
that,O
the,O
emphasis,O
on,O
including,O
more,O
complexity,O
in,O
the,O
modeling,O
of,O
extraneous,O
genetic,O
variation,O
and,O
the,O
heterogeneity,O
of,O
genetic,O
covariation,O
among,O
environments,O
may,O
limit,O
the,O
complexity,O
of,O
genetic,O
architecture,O
models,O
that,O
can,O
be,O
tested,O
.,O
The,O
total,O
genotypic,O
value,O
of,O
each,O
line,O
was,O
modeled,O
as,O
the,O
sum,O
of,O
a,O
polygenic,O
additive,O
effect,O
and,O
a,O
residual,O
genetic,O
effect,O
(,O
after,O
Oakey,O
et,O
al,O
.,O
2016,O
).,O
Our,O
results,O
demonstrated,O
that,O
the,O
residual,O
genetic,O
effects,O
were,O
more,O
important,O
than,O
the,O
additive,O
effects,O
in,O
this,O
case,O
",",O
which,O
greatly,O
limits,O
the,O
effectiveness,O
of,O
prediction,O
of,O
untested,O
varieties,O
",",O
as,O
those,O
predictions,O
depend,O
only,O
on,O
the,O
additive,O
effects,O
.,O
The,O
residual,O
genetic,O
effects,O
were,O
modeled,O
as,O
independent,O
among,O
varieties,O
",",O
such,O
that,O
they,O
cannot,O
contribute,O
to,O
prediction,O
of,O
untested,O
varieties,O
.,O
Alternative,O
strategies,O
include,O
explicitly,O
modeling,O
epistatic,O
genomic,O
relationships,O
;,O
we,O
attempted,O
this,O
but,O
could,O
not,O
achieve,O
model,O
convergence,O
.,O
Oakey,O
et,O
al,O
.,O
(,O
2016,O
),O
discuss,O
the,O
implications,O
of,O
including,O
additional,O
relationship,O
matrices,O
to,O
account,O
for,O
a,O
proportion,O
of,O
non,O
-,O
additive,O
genetic,O
effects,O
",",O
however,O
they,O
also,O
note,O
the,O
difficulty,O
of,O
fitting,O
several,O
relationship,O
matrices,O
to,O
a,O
MET,O
.,O
Bayesian,O
models,O
could,O
be,O
fitted,O
to,O
the,O
genomic,O
relationships,O
",",O
to,O
capture,O
residual,O
genetic,O
relationships,O
and,O
variation,O
among,O
marker,O
effects,O
",",O
but,O
this,O
approach,O
would,O
be,O
even,O
more,O
computationally,O
difficult,O
;,O
future,O
research,O
could,O
focus,O
on,O
integrating,O
heterogeneity,O
of,O
genetic,O
covariances,O
among,O
sites,O
into,O
such,O
models,O
.,O
Practical,O
application,O
of,O
genomic,O
selection,O
for,O
water,O
soluble,O
carbohydrate,O
improvement,O
Breeders,O
focusing,O
on,O
varietal,O
development,O
for,O
target,O
populations,O
of,O
environments,O
that,O
may,O
experience,O
abiotic,O
stresses,O
often,O
seek,O
to,O
incorporate,O
resistance,O
to,O
abiotic,O
stresses,O
",",O
sometimes,O
to,O
contribute,O
to,O
grain,O
yield,O
per,O
se,O
",",O
but,O
also,O
to,O
select,O
for,O
stable,O
grain,O
yield,O
performance,O
in,O
the,O
presence,O
of,O
variable,O
levels,O
of,O
abiotic,O
stress,O
.,O
Thus,O
",",O
abiotic,O
stress,O
resistance,O
traits,O
can,O
be,O
a,O
selection,O
target,O
in,O
their,O
own,O
right,O
",",O
especially,O
in,O
situations,O
where,O
G,O
×,O
E,O
variation,O
is,O
driven,O
by,O
abiotic,O
stresses,O
and,O
resistance,O
to,O
these,O
stresses,O
can,O
ensure,O
grain,O
yield,O
stability,O
across,O
years,O
.,O
Genomic,O
selection,O
may,O
be,O
a,O
good,O
way,O
to,O
select,O
for,O
abiotic,O
stress,O
traits,O
such,O
as,O
WSCC,O
",",O
especially,O
as,O
a,O
substitute,O
for,O
resource,O
-,O
intensive,O
phenotypic,O
selection,O
.,O
Levels,O
of,O
WSCC,O
increase,O
and,O
decrease,O
with,O
crop,O
development,O
and,O
growing,O
conditions,O
",",O
meaning,O
that,O
full,O
expression,O
of,O
the,O
phenotype,O
is,O
not,O
easily,O
captured,O
",",O
and,O
both,O
wet,O
chemistry,O
and,O
NIRS,O
methods,O
for,O
measuring,O
water,O
soluble,O
carbohydrates,O
are,O
time,O
consuming,O
and,O
expensive,O
(,O
Gebbing,O
and,O
Schnyder,O
1999,O
;,O
Ruuska,O
et,O
al,O
.,O
2006,O
).,O
We,O
estimated,O
that,O
most,O
of,O
the,O
genotypic,O
variance,O
for,O
WSCC,O
did,O
not,O
fit,O
a,O
polygenic,O
additive,O
polygenic,O
model,O
",",O
a,O
surprising,O
result,O
considering,O
numerous,O
results,O
showing,O
that,O
wheat,B-OG
grain,O
yield,O
is,O
often,O
adequately,O
described,O
with,O
an,O
additive,O
genetic,O
model,O
(,O
Heslot,O
et,O
al,O
.,O
2012,O
;,O
Pérez,O
-,O
Rodríguez,O
et,O
al,O
.,O
2012,O
;,O
Burgueño,O
et,O
al,O
.,O
2012,O
).,O
However,O
",",O
other,O
studies,O
of,O
wheat,B-OG
yield,O
across,O
diverse,O
environments,O
indicate,O
that,O
residual,O
genetic,O
variation,O
may,O
explain,O
substantial,O
fraction,O
of,O
the,O
total,O
genetic,O
variation,O
(,O
Cuevas,O
et,O
al,O
.,O
2017,O
).,O
Because,O
of,O
the,O
prevalence,O
of,O
residual,O
genetic,O
variance,O
",",O
the,O
GEBVs,O
for,O
WSCC,O
were,O
not,O
very,O
accurate,O
estimates,O
of,O
total,O
genotypic,O
value,O
",",O
regardless,O
of,O
the,O
information,O
used,O
to,O
compute,O
them,O
(,O
markers,O
",",O
phenotype,O
records,O
",",O
or,O
both,O
).,O
In,O
this,O
study,O
",",O
residual,O
genetic,O
effects,O
were,O
modeled,O
by,O
fitting,O
a,O
separate,O
independent,O
random,O
term,O
for,O
residual,O
genetic,O
effects,O
in,O
addition,O
to,O
the,O
additive,O
effects,O
whose,O
covariance,O
is,O
proportional,O
to,O
the,O
additive,O
realized,O
relationship,O
matrix,O
(,O
after,O
Oakey,O
et,O
al,O
.,O
2016,O
).,O
Total,O
genotypic,O
prediction,O
",",O
which,O
includes,O
additive,O
and,O
residual,O
genetic,O
effects,O
",",O
is,O
optimal,O
for,O
identifying,O
the,O
best,O
available,O
lines,O
in,O
a,O
population,O
",",O
but,O
this,O
requires,O
phenotypic,O
records,O
on,O
each,O
line,O
to,O
be,O
predicted,O
.,O
Potentially,O
",",O
predictions,O
can,O
be,O
improved,O
by,O
explicit,O
modeling,O
of,O
non,O
-,O
additive,O
as,O
well,O
as,O
additive,O
genetic,O
relationships,O
",",O
with,O
either,O
parametric,O
models,O
including,O
dominance,O
and,O
epistasis,O
(,O
Muñoz,O
et,O
al,O
.,O
2014,O
;,O
Su,O
et,O
al,O
.,O
2012,O
;,O
Da,O
et,O
al,O
.,O
2014,O
),O
or,O
non,O
-,O
linear,O
kernel,O
methods,O
(,O
Gianola,O
and,O
van,O
Kaam,O
2008,O
).,O
These,O
models,O
would,O
allow,O
total,O
genotypic,O
values,O
to,O
be,O
predicted,O
on,O
lines,O
in,O
the,O
absence,O
of,O
any,O
phenotypic,O
records,O
.,O
If,O
the,O
total,O
genotypic,O
values,O
are,O
not,O
closely,O
correlated,O
with,O
the,O
true,O
breeding,O
values,O
",",O
they,O
will,O
not,O
be,O
the,O
best,O
predictions,O
to,O
use,O
for,O
parental,O
selection,O
to,O
generate,O
a,O
new,O
population,O
from,O
intermating,O
",",O
as,O
dominance,O
",",O
epistatic,O
",",O
and,O
most,O
other,O
non,O
-,O
additive,O
effects,O
that,O
may,O
contribute,O
to,O
the,O
residual,O
genetic,O
effects,O
do,O
not,O
contribute,O
to,O
long,O
-,O
term,O
genetic,O
gain,O
over,O
meiotic,O
outcrossing,O
generations,O
(,O
Hill,O
et,O
al,O
.,O
2008,O
;,O
Holland,O
2001,O
;,O
Oakey,O
et,O
al,O
.,O
2016,O
;,O
Cockerham,O
1983,O
;,O
Cockerham,O
and,O
Matzinger,O
1985,O
).,O
GEBVs,O
",",O
on,O
the,O
other,O
hand,O
",",O
while,O
they,O
may,O
not,O
be,O
optimal,O
for,O
predicting,O
the,O
best,O
existing,O
lines,O
",",O
should,O
be,O
better,O
estimators,O
of,O
the,O
utility,O
of,O
lines,O
as,O
parents,O
of,O
new,O
breeding,O
populations,O
.,O
To,O
distinguish,O
the,O
different,O
uses,O
of,O
GEBVs,O
in,O
a,O
breeding,O
program,O
",",O
we,O
computed,O
two,O
relative,O
accuracy,O
statistics,O
that,O
refer,O
to,O
the,O
use,O
of,O
GEBVs,O
to,O
identify,O
optimal,O
extant,O
lines,O
or,O
to,O
identify,O
lines,O
with,O
better,O
breeding,O
values,O
for,O
use,O
as,O
parents,O
for,O
intermating,O
to,O
create,O
a,O
new,O
breeding,O
population,O
.,O
Compared,O
to,O
phenotypic,O
selection,O
the,O
RAPV,O
for,O
the,O
well,O
-,O
watered,O
environment,O
cluster,O
was,O
57,O
"%,",O
and,O
51,O
%,O
for,O
the,O
water,O
deficit,O
environment,O
cluster,O
",",O
indicating,O
our,O
GEBVs,O
are,O
marginal,O
at,O
predicting,O
phenotypic,O
performance,O
in,O
these,O
environments,O
for,O
new,O
genotypes,O
(,O
Table,O
2,O
"),",O
and,O
that,O
genomic,O
selection,O
is,O
unlikely,O
to,O
be,O
a,O
substitute,O
for,O
phenotypic,O
selection,O
of,O
the,O
best,O
performing,O
lines,O
.,O
In,O
contrast,O
",",O
when,O
compared,O
with,O
true,O
breeding,O
values,O
for,O
the,O
purpose,O
of,O
selecting,O
new,O
parents,O
and,O
maximizing,O
genetic,O
gain,O
over,O
time,O
",",O
the,O
relative,O
accuracy,O
(,O
RABV,O
),O
was,O
higher,O
.,O
The,O
RABV,O
measures,O
can,O
be,O
coupled,O
with,O
the,O
assumptions,O
of,O
Desta,O
and,O
Ortiz,O
(,O
2014,O
);,O
Heffner,O
et,O
al,O
.,O
(,O
2010,O
);,O
and,O
Lorenz,O
et,O
al,O
.,O
(,O
2011,O
),O
suggesting,O
genomic,O
selection,O
is,O
predicted,O
to,O
facilitate,O
a,O
reduction,O
in,O
the,O
breeding,O
cycle,O
time,O
of,O
the,O
average,O
wheat,B-OG
breeding,O
program,O
of,O
at,O
least,O
half,O
due,O
to,O
the,O
ability,O
to,O
select,O
at,O
earlier,O
generations,O
and,O
also,O
in,O
off,O
-,O
season,O
generations,O
.,O
Therefore,O
",",O
relative,O
to,O
selection,O
using,O
the,O
true,O
breeding,O
values,O
",",O
and,O
making,O
the,O
assumption,O
of,O
a,O
decrease,O
in,O
the,O
breeding,O
cycle,O
time,O
of,O
50,O
"%,",O
genetic,O
gain,O
per,O
unit,O
of,O
time,O
from,O
genomic,O
selection,O
in,O
this,O
study,O
is,O
estimated,O
to,O
be,O
2,O
×,O
78,O
%=,O
158,O
%,O
for,O
the,O
well,O
-,O
watered,O
environment,O
cluster,O
and,O
2,O
×,O
107,O
%=,O
214,O
%,O
for,O
the,O
water,O
deficit,O
environment,O
cluster,O
.,O
This,O
indicates,O
that,O
genomic,O
selection,O
methods,O
can,O
increase,O
the,O
rate,O
of,O
genetic,O
gain,O
for,O
WSCC,O
.,O
The,O
challenge,O
in,O
practical,O
terms,O
",",O
as,O
noted,O
by,O
Cooper,O
et,O
al,O
.,O
(,O
2014,O
"),",O
may,O
be,O
in,O
implementing,O
the,O
enabling,O
technologies,O
needed,O
to,O
make,O
genomic,O
selection,O
work,O
and,O
readily,O
integrated,O
into,O
a,O
commercial,O
breeding,O
program,O
.,O
Finally,O
",",O
if,O
the,O
ultimate,O
goal,O
of,O
selection,O
is,O
to,O
improve,O
yield,O
performance,O
within,O
or,O
across,O
abiotic,O
stress,O
environments,O
",",O
the,O
genotypic,O
and,O
additive,O
genetic,O
correlations,O
of,O
WSCC,O
with,O
yield,O
and,O
other,O
agronomic,O
traits,O
must,O
be,O
considered,O
.,O
Ovenden,O
et,O
al,O
.,O
(,O
2017,O
),O
previously,O
demonstrated,O
significant,O
but,O
relatively,O
low,O
genotypic,O
correlations,O
between,O
WSCC,O
and,O
yield,O
in,O
this,O
germplasm,O
sample,O
",",O
suggesting,O
that,O
its,O
utility,O
as,O
an,O
indirect,O
selection,O
criterion,O
needs,O
to,O
be,O
assessed,O
on,O
a,O
case,O
by,O
case,O
basis,O
.,O
Conclusions,O
This,O
study,O
provides,O
empirical,O
evidence,O
that,O
genomic,O
selection,O
methods,O
could,O
improve,O
the,O
rate,O
of,O
genetic,O
gain,O
for,O
carbohydrate,O
accumulation,O
",",O
provided,O
that,O
the,O
TPE,O
are,O
carefully,O
characterized,O
and,O
understood,O
",",O
and,O
predictions,O
are,O
restricted,O
to,O
environment,O
subsets,O
of,O
interest,O
.,O
With,O
additive,O
variance,O
being,O
low,O
in,O
the,O
models,O
under,O
study,O
",",O
the,O
importance,O
of,O
relative,O
accuracy,O
for,O
different,O
genomic,O
selection,O
strategies,O
becomes,O
apparent,O
.,O
Compared,O
to,O
phenotypic,O
selection,O
",",O
the,O
relative,O
accuracy,O
of,O
the,O
GEBVs,O
modeled,O
here,O
is,O
low,O
",",O
however,O
the,O
GEBVs,O
more,O
accurately,O
model,O
the,O
true,O
breeding,O
values,O
.,O
Therefore,O
",",O
genomic,O
selection,O
could,O
well,O
result,O
in,O
higher,O
genetic,O
gain,O
per,O
unit,O
of,O
time,O
through,O
the,O
ability,O
to,O
better,O
select,O
parents,O
for,O
intermating,O
",",O
and,O
genomic,O
selection,O
may,O
be,O
a,O
useful,O
tool,O
for,O
making,O
genetic,O
gains,O
in,O
complex,O
abiotic,O
stress,O
characteristics,O
.,O
Supplemental,O
material,O
available,O
at,O
Figshare,O
:,O
https,O
://,O
doi,O
.,O
org,O
/,O
10,O
.,O
25387,O
/,O
g3,O
.,O
6143243,O
.,O
Communicating,O
editor,O
:,O
E,O
.,O
Akhunov,O
Real,O
-,O
time,O
analysis,O
of,O
gut,B-OG
flora,I-OG
in,O
Entamoeba,B-OG
histolytica,I-OG
infected,O
patients,O
of,O
Northern,O
India,O
Background,O
Amebic,B-DS
dysentery,I-DS
is,O
caused,O
by,O
the,O
protozoan,O
parasite,O
Entamoeba,B-OG
histolytica,I-OG
and,O
the,O
ingestion,O
of,O
quadrinucleate,O
cyst,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
from,O
fecally,O
contaminated,O
food,O
or,O
water,O
initiates,O
infection,B-DS
.,O
Excystation,O
occurs,O
in,O
the,O
lumen,O
of,O
small,O
intestine,O
",",O
where,O
motile,O
and,O
potentially,O
invasive,O
trophozoites,O
germinate,O
from,O
cysts,O
.,O
The,O
ability,O
of,O
trophozoites,O
to,O
interact,O
and,O
digest,O
gut,O
bacteria,B-OG
is,O
apparently,O
important,O
for,O
multiplication,O
of,O
the,O
parasite,O
and,O
its,O
pathogenicity,O
;,O
however,O
the,O
contribution,O
of,O
resident,O
bacterial,O
flora,O
is,O
not,O
well,O
understood,O
.,O
We,O
quantified,O
the,O
population,O
of,O
Bacteroides,B-OG
",",O
Bifidobacterium,B-OG
",",O
Ruminococcus,B-OG
",",O
Lactobacillus,B-OG
",",O
Clostridium,B-OG
leptum,I-OG
subgroup,O
",",O
Clostridium,B-OG
coccoides,I-OG
subgroup,O
",",O
Eubacterium,B-OG
",",O
Campylobacter,B-OG
",",O
Methanobrevibacter,B-OG
smithii,I-OG
and,O
Sulphur,B-OG
reducing,I-OG
bacteria,I-OG
using,O
genus,O
specific,O
primers,O
in,O
healthy,O
(,O
N,O
=,O
22,O
),O
vs,O
amebic,O
patients,O
(,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
",",O
N,O
=,O
17,O
),O
stool,O
samples,O
by,O
Real,O
-,O
time,O
PCR,O
.,O
Results,O
Absolute,O
quantification,O
of,O
Bacteroides,B-OG
(,O
p,O
=,O
.,O
001,O
"),",O
Closrtridium,B-OG
coccoides,I-OG
subgroup,O
(,O
p,O
=,O
0,O
.,O
002,O
"),",O
Clostridium,B-OG
leptum,I-OG
subgroup,O
(,O
p,O
=,O
0,O
.,O
0001,O
"),",O
Lactobacillus,B-OG
(,O
p,O
=,O
0,O
.,O
037,O
"),",O
Campylobacter,B-OG
(,O
p,O
=,O
0,O
.,O
0014,O
),O
and,O
Eubacterium,B-OG
(,O
p,O
=,O
0,O
.,O
038,O
),O
show,O
significant,O
drop,O
in,O
their,O
population,O
however,O
",",O
significant,O
increase,O
in,O
Bifdobacterium,B-OG
(,O
p,O
=,O
0,O
.,O
009,O
),O
was,O
observed,O
where,O
as,O
the,O
population,O
of,O
Ruminococcus,B-OG
(,O
p,O
=,O
0,O
.,O
33,O
),O
remained,O
unaltered,O
in,O
healthy,O
vs,O
amebic,O
patients,O
(,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
).,O
We,O
also,O
report,O
high,O
prevalence,O
of,O
nimE,B-GP
gene,O
in,O
stool,O
samples,O
of,O
both,O
healthy,O
volunteers,O
and,O
amebic,O
patients,O
.,O
No,O
significant,O
decrease,O
in,O
nimE,B-GP
gene,O
copy,O
number,O
was,O
observed,O
before,O
and,O
after,O
the,O
treatment,O
with,O
antiamebic,O
drug,O
.,O
Conclusions,O
Our,O
results,O
show,O
significant,O
alteration,O
in,O
predominant,O
gut,O
bacteria,B-OG
in,O
E,B-OG
.,I-OG
histolytica,I-OG
infected,O
individuals,O
.,O
The,O
frequent,O
episodes,O
of,O
intestinal,O
amoebic,B-DS
dysentery,I-DS
thus,O
result,O
in,O
depletion,O
of,O
few,O
predominant,O
genera,O
in,O
gut,O
that,O
may,O
lead,O
to,O
poor,O
digestion,O
and,O
absorption,O
of,O
food,O
in,O
intestine,O
.,O
It,O
further,O
disturbs,O
the,O
homeostasis,O
between,O
gut,O
epithelium,O
and,O
bacterial,O
flora,O
.,O
The,O
decrease,O
in,O
beneficial,O
bacterial,O
population,O
gives,O
way,O
to,O
dysbiosis,O
of,O
gut,O
bacteria,B-OG
which,O
may,O
contribute,O
to,O
final,O
outcome,O
of,O
the,O
disease,O
.,O
Increase,O
in,O
the,O
copy,O
number,O
of,O
nimE,B-GP
gene,O
harboring,O
bacteria,B-OG
in,O
our,O
population,O
reflects,O
possible,O
decrease,O
in,O
the,O
availability,O
of,O
metronidazole,O
drug,O
during,O
treatment,O
of,O
amoebiasis,B-DS
.,O
Background,O
Entamoeba,B-OG
histolytica,I-OG
",",O
a,O
micro,O
-,O
aerophilic,O
intestinal,O
protozoan,O
parasite,O
and,O
the,O
causative,O
agent,O
of,O
invasive,O
amoebiasis,B-DS
(,O
colitis,B-DS
and,O
amoebic,B-DS
liver,I-DS
abscess,I-DS
"),",O
remains,O
a,O
significant,O
cause,O
of,O
morbidity,O
and,O
mortality,O
in,O
developing,O
countries,O
[,O
1,O
].,O
It,O
is,O
well,O
known,O
that,O
the,O
parasite,O
is,O
constantly,O
interacting,O
with,O
the,O
intestinal,O
gut,B-OG
flora,I-OG
however,O
the,O
contribution,O
of,O
the,O
flora,O
in,O
the,O
manifestation,O
of,O
the,O
disease,O
is,O
poorly,O
understood,O
.,O
The,O
human,B-OG
gastrointestinal,O
(,O
GI,O
),O
tract,O
is,O
nutrient,O
-,O
rich,O
environment,O
packed,O
with,O
a,O
complex,O
and,O
dynamic,O
consortia,O
of,O
trillions,O
of,O
microbes,B-OG
[,O
2,O
].,O
The,O
vast,O
majority,O
reside,O
in,O
our,O
colon,O
where,O
densities,O
approach,O
1011,O
-,O
1012,O
cells,O
/,O
ml,O
",",O
the,O
highest,O
density,O
recorded,O
for,O
any,O
microbial,O
habitat,O
[,O
3,O
].,O
About,O
500,O
–,O
1000,O
bacterial,O
species,O
colonize,O
the,O
adult,O
intestine,O
",",O
with,O
30,O
–,O
40,O
species,O
comprising,O
up,O
to,O
97,O
%,O
of,O
the,O
total,O
population,O
[,O
4,O
",",O
5,O
].,O
Bacteroides,B-OG
",",O
Bifidobacterium,B-OG
",",O
Eubacterium,B-OG
",",O
Clostridium,B-OG
",",O
Peptococcus,B-OG
",",O
Peptostreptococcus,B-OG
",",O
Lactobacillus,B-OG
and,O
Ruminococcus,B-OG
are,O
considered,O
to,O
be,O
predominant,O
genera,O
whereas,O
Enterococcus,B-OG
",",O
Methanobrevibacter,B-OG
and,O
sulphur,B-OG
reducing,I-OG
bacteria,I-OG
(,O
SRB,B-OG
),O
remain,O
as,O
the,O
subdominant,O
genera,O
[,O
6,O
].,O
The,O
entire,O
system,O
of,O
the,O
human,B-OG
gut,O
microbiota,B-OG
functions,O
as,O
a,O
‘,O
microbial,O
organ,O
’,O
within,O
the,O
intestine,O
",",O
which,O
contributes,O
to,O
diverse,O
mammalian,O
processes,O
including,O
protective,O
functions,O
against,O
pathogens,O
and,O
immune,O
-,O
system,O
modulation,O
",",O
the,O
metabolic,O
function,O
of,O
fermenting,O
non,O
-,O
digestible,O
dietary,O
fiber,O
",",O
anaerobic,O
metabolism,O
of,O
peptides,O
and,O
proteins,O
that,O
results,O
in,O
the,O
recovery,O
of,O
metabolic,O
energy,O
for,O
the,O
host,O
[,O
7,O
].,O
The,O
microbial,O
diversity,O
of,O
the,O
human,B-OG
gut,O
is,O
the,O
result,O
of,O
co,O
-,O
evolution,O
between,O
microbial,O
communities,O
and,O
their,O
hosts,O
.,O
Microbial,O
community,O
structure,O
is,O
a,O
very,O
important,O
factor,O
that,O
can,O
influence,O
predisposition,O
to,O
specific,O
diseases,O
in,O
certain,O
host,O
contexts,O
[,O
8,O
].,O
Ingestion,O
of,O
the,O
cyst,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
through,O
fecally,O
contaminated,O
food,O
or,O
water,O
initiates,O
infection,B-DS
.,O
Excystation,O
in,O
the,O
intestinal,O
lumen,O
produces,O
trophozoites,O
and,O
colitis,B-DS
results,O
when,O
the,O
trophozoites,O
penetrate,O
the,O
mucus,O
layer,O
and,O
damages,O
intestinal,O
tissues,O
[,O
9,O
].,O
The,O
trophozoites,O
proliferate,O
in,O
lumen,O
and,O
phagocytose,O
resident,O
flora,O
.,O
E,B-OG
.,I-OG
histolytica,I-OG
trophozoites,O
are,O
quite,O
selective,O
in,O
respect,O
to,O
their,O
interactions,O
with,O
different,O
bacterial,O
species,O
and,O
only,O
those,O
bacteria,B-OG
which,O
have,O
the,O
appropriate,O
recognition,O
molecules,O
get,O
attached,O
and,O
ingested,O
[,O
10,O
].,O
It,O
has,O
been,O
observed,O
that,O
the,O
nuclear,O
DNA,O
content,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
trophozoites,O
growing,O
in,O
axenic,O
cultures,O
is,O
at,O
least,O
10,O
fold,O
higher,O
than,O
in,O
xenic,O
cultures,O
and,O
re,O
-,O
association,O
of,O
axenic,O
cultures,O
with,O
their,O
bacterial,O
flora,O
led,O
to,O
a,O
reduction,O
of,O
DNA,O
content,O
attaining,O
the,O
original,O
xenic,O
values,O
indicating,O
a,O
flexible,O
nature,O
of,O
the,O
parasite,O
genome,O
[,O
11,O
].,O
Fluctuations,O
in,O
gut,B-OG
flora,I-OG
have,O
been,O
reported,O
both,O
in,O
acute,B-DS
diarrhea,I-DS
and,O
antibiotic,B-DS
associated,I-DS
diarrhea,I-DS
[,O
12,O
"],",O
but,O
very,O
few,O
reports,O
are,O
available,O
on,O
status,O
of,O
gut,B-OG
flora,I-OG
in,O
E,B-OG
.,I-OG
histolytica,I-OG
infected,O
individuals,O
.,O
Earlier,O
studies,O
in,O
our,O
laboratory,O
[,O
1,O
],O
have,O
recorded,O
fluctuations,O
in,O
the,O
gut,B-OG
flora,I-OG
by,O
a,O
qualitative,O
method,O
during,O
disease,O
conditions,O
.,O
5,O
-,O
Nitroimidazole,O
drugs,O
are,O
still,O
used,O
as,O
first,O
line,O
of,O
defense,O
against,O
amoebic,O
and,O
other,O
infections,B-DS
caused,O
by,O
anaerobes,O
.,O
These,O
drugs,O
are,O
administered,O
as,O
pro,O
drugs,O
and,O
one,O
electron,O
reduction,O
of,O
nitro,O
group,O
converts,O
the,O
pro,O
drug,O
into,O
an,O
active,O
drug,O
[,O
13,O
].,O
Enzymatic,O
modification,O
mediated,O
by,O
nim,B-GP
-,O
class,O
of,O
genes,O
is,O
a,O
well,O
characterized,O
resistance,O
mechanism,O
.,O
Certain,O
Bacteroides,B-OG
species,O
which,O
are,O
members,O
of,O
the,O
normal,O
colonic,O
human,B-OG
microflora,B-OG
harbor,O
nim,B-GP
genes,O
[,O
14,O
].,O
Our,O
study,O
is,O
based,O
on,O
the,O
hypothesis,O
that,O
the,O
Entamoeba,B-OG
histolytica,I-OG
(,O
but,O
not,O
E,B-OG
.,I-OG
dispar,I-OG
),O
is,O
an,O
invasive,O
organism,O
and,O
invades,O
the,O
mucus,O
layer,O
and,O
subsequently,O
the,O
intestinal,O
epithelium,O
for,O
colonization,O
using,O
the,O
pathogenic,O
factors,O
.,O
In,O
this,O
context,O
we,O
attempted,O
to,O
study,O
the,O
fluctuations,O
in,O
the,O
gut,O
microbiota,B-OG
that,O
contributes,O
to,O
substantial,O
metabolic,O
changes,O
in,O
E,B-OG
.,I-OG
histolytica,I-OG
infected,O
individuals,O
compared,O
to,O
healthy,O
individuals,O
.,O
In,O
the,O
present,O
study,O
we,O
used,O
Real,O
Time,O
PCR,O
for,O
absolute,O
quantification,O
of,O
predominant,O
gut,O
bacterial,O
population,O
in,O
E,B-OG
.,I-OG
histolytica,I-OG
patients,O
suffering,O
from,O
dysentery,B-DS
for,O
5,O
–,O
7,O
days,O
.,O
We,O
also,O
quantified,O
the,O
copy,O
number,O
of,O
nim,B-GP
gene,O
in,O
stool,O
sample,O
of,O
healthy,O
vs,O
E,B-OG
.,I-OG
histolytica,I-OG
patients,O
.,O
Methods,O
Study,O
subjects,O
&,O
fecal,O
sample,O
collection,O
Stool,O
samples,O
of,O
healthy,O
person,O
(,O
without,O
any,O
enteric,O
disease,O
),O
were,O
collected,O
as,O
controls,O
from,O
volunteers,O
of,O
a,O
community,O
in,O
Delhi,O
.,O
Initial,O
survey,O
involved,O
discussion,O
with,O
the,O
focus,O
group,O
and,O
informed,O
consent,O
was,O
taken,O
from,O
participating,O
volunteers,O
for,O
the,O
study,O
.,O
Volunteers,O
in,O
age,O
group,O
of,O
21,O
–,O
40,O
year,O
(,O
mean,O
age,O
31,O
year,O
),O
were,O
randomly,O
recruited,O
.,O
Subjects,O
who,O
have,O
taken,O
any,O
antibiotic,O
/,O
antiamoebic,O
drug,O
or,O
suffered,O
from,O
any,O
gastrointestinal,B-DS
disorder,I-DS
in,O
past,O
one,O
month,O
before,O
sample,O
collection,O
were,O
not,O
included,O
in,O
the,O
study,O
.,O
Twenty,O
two,O
stool,O
samples,O
were,O
collected,O
from,O
healthy,O
volunteers,O
.,O
Clinical,O
diagnosis,O
of,O
amoebic,B-DS
colitis,I-DS
was,O
based,O
on,O
standard,O
criteria,O
:,O
patients,O
experiencing,O
days,O
to,O
weeks,O
of,O
dysentery,B-DS
(,O
stool,O
with,O
blood,O
and,O
mucus,O
),O
or,O
diarrhea,O
with,O
cramps,O
followed,O
by,O
abdominal,O
pain,O
and,O
/,O
or,O
weight,O
loss,O
.,O
The,O
sub,O
acute,O
onset,O
of,O
the,O
disease,O
was,O
a,O
helpful,O
clue,O
in,O
the,O
differential,O
diagnosis,O
because,O
bacillary,B-DS
dysentery,I-DS
caused,O
by,O
Shigella,B-OG
",",O
Salmonella,B-OG
",",O
Campylobacter,B-OG
and,O
EHEC,B-OG
E,I-OG
.,I-OG
coli,I-OG
mostly,O
lead,O
to,O
a,O
abrupt,O
onset,O
of,O
the,O
disease,O
[,O
15,O
].,O
Since,O
we,O
did,O
not,O
take,O
samples,O
from,O
individuals,O
administered,O
with,O
any,O
antibiotic,O
",",O
therefore,O
cases,O
of,O
antibiotic,B-DS
associated,I-DS
diarrhea,I-DS
were,O
excluded,O
.,O
Stool,O
samples,O
of,O
chronic,O
/,O
acute,B-DS
diarrhea,I-DS
as,O
diagnosed,O
by,O
Gastroenterologist,O
were,O
collected,O
from,O
Gastroenterology,O
department,O
of,O
All,O
India,O
Institute,O
of,O
Medical,O
Sciences,O
&,O
Safdarjung,O
hospitals,O
",",O
New,O
Delhi,O
.,O
The,O
samples,O
were,O
transported,O
to,O
the,O
laboratory,O
at,O
4,O
°,O
C,O
within,O
2,O
hrs,O
and,O
stored,O
at,O
-,O
20,O
°,O
C,O
until,O
processed,O
.,O
The,O
study,O
was,O
approved,O
by,O
the,O
research,O
ethics,O
board,O
of,O
respective,O
institutes,O
.,O
The,O
samples,O
(,O
n,O
=,O
550,O
),O
were,O
collected,O
with,O
the,O
informed,O
consent,O
of,O
the,O
patients,O
.,O
Enrichment,O
of,O
entamoeba,B-OG
cysts,O
Cysts,O
were,O
enriched,O
following,O
the,O
protocol,O
of,O
Knight,O
et,O
al,O
".,",O
1976,O
[,O
16,O
],O
with,O
slight,O
modifications,O
.,O
Briefly,O
",",O
fecal,O
samples,O
(,O
1gm,O
),O
were,O
homogenized,O
in,O
10,O
ml,O
of,O
autoclaved,O
distilled,O
water,O
",",O
strained,O
through,O
cheesecloth,O
in,O
50,O
ml,O
falcon,O
tube,O
.,O
This,O
suspension,O
was,O
centrifuged,O
at,O
2000,O
rpm,O
for,O
5,O
min,O
and,O
pellet,O
was,O
re,O
-,O
dissolved,O
in,O
10,O
ml,O
of,O
10,O
%,O
formaldehyde,O
.,O
3,O
ml,O
of,O
diethyl,O
ether,O
was,O
added,O
to,O
the,O
tube,O
and,O
this,O
mixture,O
was,O
vortexed,O
and,O
incubated,O
at,O
RT,O
for,O
30,O
min,O
.,O
The,O
mixture,O
was,O
subjected,O
to,O
centrifugation,O
at,O
2000,O
rpm,O
for,O
5,O
min,O
",",O
supernatant,O
was,O
removed,O
and,O
pellet,O
was,O
washed,O
with,O
double,O
distilled,O
water,O
.,O
The,O
Pellet,O
containing,O
concentrated,O
cyst,O
was,O
re,O
-,O
dissolved,O
in,O
400,O
μl,O
T10E1,O
buffer,O
.,O
Cysts,O
in,O
T10E1,O
buffer,O
was,O
subjected,O
to,O
freeze,O
-,O
thaw,O
cycle,O
and,O
thereafter,O
to,O
sonication,O
in,O
order,O
to,O
obtain,O
crude,O
DNA,O
for,O
Dot,O
-,O
blot,O
hybridization,O
experiment,O
.,O
Screening,O
of,O
samples,O
by,O
dot,O
blot,O
hybridization,O
The,O
crude,O
cyst,O
DNA,O
was,O
denatured,O
by,O
addition,O
of,O
NaOH,O
to,O
final,O
concentration,O
of,O
0,O
.,O
25,O
N,O
in,O
a,O
total,O
volume,O
of,O
300,O
μl,O
.,O
The,O
DNA,O
was,O
kept,O
at,O
room,O
temperature,O
for,O
30,O
minutes,O
and,O
then,O
transferred,O
on,O
to,O
ice,O
.,O
The,O
GS,O
+,O
nylon,O
membrane,O
of,O
required,O
size,O
was,O
cut,O
and,O
saturated,O
in,O
0,O
.,O
4,O
M,O
Tris,O
-,O
Cl,O
",",O
pH,O
7,O
.,O
5,O
for,O
15,O
min,O
and,O
the,O
DNA,O
were,O
spotted,O
on,O
to,O
the,O
membrane,O
with,O
the,O
help,O
of,O
mini,O
-,O
fold,O
apparatus,O
from,O
Whatman,O
",",O
Germany,O
.,O
The,O
blots,O
were,O
air,O
dried,O
and,O
UV,O
cross,O
linked,O
before,O
hybridization,O
.,O
We,O
used,O
4,O
.,O
5,O
kb,O
rDNA,O
fragment,O
(,O
EcoRI,B-GP
to,O
Hind,B-GP
III,I-GP
site,O
),O
from,O
HMe,O
region,O
of,O
EhR1,O
(,O
rDNA,O
plasmid,O
in,O
HM1,O
:,O
IMSS,O
strain,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
),O
as,O
probe,O
for,O
detection,O
of,O
Entamoeba,B-OG
positive,O
samples,O
that,O
include,O
both,O
E,B-OG
.,I-OG
histolytica,I-OG
and,O
E,B-OG
.,I-OG
dispar,I-OG
(,O
Figure,O
1A,O
),O
[,O
17,O
].,O
Screening,O
of,O
stool,O
samples,O
by,O
Dot,O
-,O
Blot,O
method,O
.,O
(,O
A,O
),O
Linear,O
map,O
of,O
EhRI,O
episome,O
(,O
24,O
.,O
5,O
kb,O
),O
showing,O
the,O
position,O
of,O
HMe,O
probe,O
(,O
4,O
.,O
5,O
kb,O
in,O
size,O
),O
common,O
for,O
both,O
E,B-OG
.,I-OG
histolytica,I-OG
and,O
E,B-OG
.,I-OG
dispar,I-OG
"),",O
E,O
-,O
EcoR1,B-GP
site,O
and,O
H,O
-,O
Hind,B-GP
III,I-GP
site,O
;,O
rDNA,O
I,O
and,O
rDNA,O
II,O
represent,O
two,O
inverted,O
repeats,O
of,O
transcription,O
units,O
with,O
various,O
restriction,O
sites,O
and,O
repeats,O
(,O
B,O
),O
Representative,O
figure,O
of,O
Dot,O
-,O
blot,O
analysis,O
of,O
stool,O
sample,O
using,O
HMe,O
probe,O
.,O
Rows,O
1,O
to,O
6,O
(,O
column,O
A,O
-,O
D,O
),O
represent,O
spots,O
of,O
DNA,O
from,O
stool,O
samples,O
.,O
About,O
20,O
ng,O
of,O
DNA,O
was,O
loaded,O
on,O
each,O
spot,O
in,O
triplicate,O
on,O
nylon,O
membrane,O
.,O
Row,O
7,O
was,O
blank,O
.,O
Row,O
8,O
(,O
column,O
A,O
),O
E,B-OG
.,I-OG
histolytica,I-OG
HM1,I-OG
:,I-OG
IMSS,I-OG
genomic,O
DNA,O
as,O
positive,O
control,O
;,O
(,O
column,O
B,O
),O
E,B-OG
.,I-OG
dispar,I-OG
SAW760,I-OG
genomic,O
DNA,O
as,O
positive,O
control,O
;,O
(,O
column,O
C,O
),O
E,B-OG
.,I-OG
Coli,I-OG
DH5α,I-OG
as,O
negative,O
control,O
;,O
(,O
column,O
D,O
),O
Plasmid,O
with,O
cloned,O
HMe,O
as,O
positive,O
control,O
.,O
All,O
samples,O
were,O
loaded,O
in,O
triplicate,O
.,O
Experimental,O
details,O
are,O
provided,O
in,O
material,O
and,O
methods,O
.,O
Genomic,O
DNA,O
extraction,O
DNA,O
was,O
extracted,O
from,O
the,O
Dot,O
blot,O
positive,O
samples,O
.,O
An,O
aliquot,O
of,O
200,O
mg,O
stool,O
sample,O
was,O
used,O
for,O
isolation,O
using,O
QIAamp,O
mini,O
stool,O
kit,O
(,O
QIAGEN,O
",",O
Germany,O
),O
as,O
per,O
manufacturer,O
’,O
s,O
guidelines,O
.,O
While,O
isolating,O
DNA,O
from,O
the,O
stool,O
samples,O
through,O
the,O
above,O
kit,O
",",O
pGEMT,O
-,O
easy,O
plasmid,O
containg,O
240,O
bp,O
fragment,O
of,O
glycoprotein,B-GP
B,I-GP
(,O
gB,B-GP
),O
gene,O
of,O
phocine,B-OG
virus,I-OG
(,O
20,O
ng,O
/,O
200,O
μl,O
of,O
ASL,O
buffer,O
),O
was,O
added,O
in,O
ASL,O
buffer,O
as,O
internal,O
control,O
during,O
the,O
isolation,O
of,O
genomic,O
DNA,O
[,O
18,O
].,O
PCR,O
analysis,O
of,O
Dot,O
blot,O
positive,O
samples,O
To,O
differentiate,O
Dot,O
-,O
blot,O
positive,O
samples,O
into,O
E,B-OG
.,I-OG
histolytica,I-OG
and,O
E,B-OG
.,I-OG
dispar,I-OG
",",O
primers,O
were,O
designed,O
from,O
EhSINE2,O
for,O
E,B-OG
.,I-OG
histolytica,I-OG
and,O
from,O
18,O
S,O
and,O
ITS2,O
region,O
of,O
rDNA,O
circle,O
for,O
E,B-OG
.,I-OG
dispar,I-OG
respectively,O
(,O
Figure,O
2A,O
&,O
B,O
).,O
Primer,O
sequences,O
were,O
as,O
follows,O
;,O
Eh,O
-,O
F,O
5,O
’-,O
GTCAGAGACACCACATGAA,O
-,O
3,O
"’,",O
Eh,O
-,O
R,O
5,O
’-,O
GAGACCCCTTAAAGAAAC,O
-,O
CC,O
-,O
3,O
’,O
and,O
Ed,O
-,O
F,O
5,O
’-,O
GAAGAAACATTGTTTCTAAATCCAA,O
-,O
3,O
’,O
&,O
Ed,O
-,O
R,O
5,O
’-,O
TTTATTAA,O
CTC,O
ACTTATA,O
-,O
3,O
’,O
[,O
19,O
].,O
Screening,O
of,O
Stool,O
samples,O
by,O
PCR,O
.,O
(,O
A,O
),O
Schematic,O
representation,O
of,O
location,O
of,O
Entamoeba,B-OG
histolytica,I-OG
specific,O
primer,O
.,O
BH16197,O
is,O
Genbank,O
accession,O
number,O
of,O
Entamoeba,B-OG
histolytica,I-OG
SINE,O
-,O
2,O
(,O
EhSINE2,O
),O
element,O
;,O
(,O
B,O
),O
Schematic,O
representation,O
of,O
location,O
of,O
Entamoeba,B-OG
dispar,I-OG
specific,O
primer,O
from,O
rDNA,O
molecule,O
.,O
18,O
S,O
",",O
5,O
.,O
8,O
S,O
and,O
28,O
S,O
are,O
corresponding,O
ribosomal,O
gene,O
sequences,O
and,O
ITS,O
-,O
1,O
and,O
ITS,O
-,O
2,O
refers,O
to,O
internal,O
transcribed,O
spacer,O
1,O
and,O
2,O
;,O
(,O
C,O
),O
Detection,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
in,O
stool,O
DNA,O
sample,O
using,O
E,B-OG
.,I-OG
histolytica,I-OG
specific,O
primers,O
",",O
Lane,O
1,O
=,O
Marker,O
100,O
bp,O
",",O
Lane,O
2,O
=,O
EhHM1,O
genomic,O
DNA,O
as,O
positive,O
control,O
",",O
Lane,O
3,O
&,O
4,O
stool,O
sample,O
DNA,O
",",O
Lane,O
5,O
=,O
Genomic,O
DNA,O
of,O
E,B-OG
.,I-OG
dispar,I-OG
SAW760,I-OG
as,O
negative,O
control,O
.,O
Sample,O
in,O
lane,O
4,O
is,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
;,O
(,O
D,O
),O
Detection,O
of,O
E,B-OG
.,I-OG
dispar,I-OG
in,O
Stool,O
sample,O
using,O
E,B-OG
.,I-OG
dispar,I-OG
specific,O
primers,O
.,O
Lane,O
1,O
=,O
Marker,O
1,O
kb,O
",",O
Lane,O
2,O
",",O
3,O
",",O
4,O
and,O
5,O
stool,O
sample,O
DNA,O
",",O
Lane,O
6,O
=,O
Genomic,O
DNA,O
of,O
E,B-OG
.,I-OG
dispar,I-OG
as,O
positive,O
control,O
.,O
Sample,O
in,O
Lane,O
3,O
and,O
5,O
are,O
E,B-OG
.,I-OG
dispar,I-OG
positive,O
.,O
Lane,O
4,O
stool,O
sample,O
is,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
and,O
was,O
used,O
as,O
negative,O
control,O
.,O
Primer,O
designing,O
for,O
detection,O
of,O
predominant,O
genera,O
of,O
gut,B-OG
flora,I-OG
Primer,O
sets,O
were,O
designed,O
to,O
differentiate,O
and,O
quantitate,O
the,O
following,O
major,O
anaerobic,O
genera,O
–,O
Bacteroides,B-OG
",",O
Clostridium,B-OG
",",O
Campylobacter,B-OG
",",O
Bifidobacterium,B-OG
",",O
Ruminococcus,B-OG
",",O
Eubacterium,B-OG
",",O
Lactobacillus,B-OG
",",O
Methanobrevibacter,B-OG
and,O
Sulfate,B-OG
-,I-OG
reducing,I-OG
bacteria,I-OG
(,O
SRB,B-OG
).,O
16S,O
rRNA,O
gene,O
was,O
targeted,O
for,O
designing,O
primers,O
except,O
for,O
SRB,B-OG
(,O
Table,O
1,O
).,O
Sulphate,O
reducing,O
gene,O
was,O
targeted,O
for,O
quantifying,O
members,O
of,O
SRB,B-OG
.,O
Primers,O
were,O
commercially,O
obtained,O
from,O
Sigma,O
-,O
aldrich,O
",",O
USA,O
.,O
Genus,O
specific,O
16S,O
rRNA,O
targeted,O
bacterial,O
primers,O
used,O
in,O
this,O
study,O
Sr,O
no,O
.,O
Genus,O
Primer,O
sequence,O
PCR,O
Product,O
(,O
bp,O
),O
Tm,O
(,O
ºC,O
),O
References,O
1,O
.,O
Methanobrevibactr,B-OG
F,O
5,O
’-,O
CGATGCGGACTTGGTGTTG,O
-,O
3,O
’,O
184,O
59,O
.,O
7,O
[,O
21,O
],O
R,O
5,O
’-,O
TGTCGCCTCTGGTGAGATGTC,O
-,O
3,O
’,O
59,O
.,O
8,O
2,O
.,O
Peptostreptococcus,B-OG
F,O
5,O
’-,O
AACTCCGGTGGTATCAGATG,O
-,O
3,O
’,O
270,O
55,O
.,O
4,O
[,O
1,O
],O
R,O
5,O
’-,O
GGGGCTTCTGAGTCAGGTA,O
-,O
3,O
’,O
56,O
.,O
4,O
3,O
.,O
Ruminococcus,B-OG
F,O
5,O
’-,O
GAAAGCGTGGGGAGCAAACAGG,O
-,O
3,O
’,O
302,O
65,O
.,O
8,O
[,O
21,O
],O
R,O
5,O
’-,O
GACGACAACCATGCACCACCTG,O
-,O
3,O
’,O
64,O
.,O
4,O
4,O
.,O
Eubacterium,B-OG
F,O
5,O
’-,O
GTAGTCCACGCCGTAAACGATG,O
-,O
3,O
’,O
278,O
60,O
.,O
4,O
[,O
21,O
],O
R,O
5,O
’-,O
ACACGAGCTGACGACAACCATG,O
-,O
3,O
’,O
62,O
.,O
4,O
5,O
.,O
Bacteroides,B-OG
F,O
5,O
’-,O
GGGGTTCTGAGAGGAAG,O
-,O
3,O
’,O
115,O
54,O
.,O
0,O
[,O
21,O
],O
R,O
5,O
’-,O
GCTACTTGGCTGGTTCAG,O
-,O
3,O
’,O
56,O
.,O
0,O
6,O
.,O
Lactobacillus,B-OG
F,O
5,O
’-,O
GCAGCAGTAGGGAATCTTCCA,O
-,O
3,O
’,O
340,O
64,O
.,O
0,O
[,O
25,O
],O
R,O
5,O
’-,O
GCATTYCACCGCTACACATG,O
-,O
3,O
’,O
58,O
.,O
0,O
7,O
.,O
Clostridium,B-OG
leptum,I-OG
subgroup,O
F,O
5,O
’-,O
CGTCAGCTCGTGTCGTGAGAT,O
-,O
3,O
’,O
125,O
60,O
.,O
0,O
[,O
21,O
],O
R,O
5,O
’-,O
CGTCATCCCCACCTTCCTCC,O
-,O
3,O
’,O
62,O
.,O
5,O
8,O
.,O
Clostridium,B-OG
coccoides,I-OG
subgroup,O
F,O
5,O
’-,O
GCCACATTGGGACTGAGA,O
-,O
3,O
’,O
170,O
56,O
.,O
0,O
This,O
study,O
R,O
5,O
’-,O
GCTTCTTAGTCAGGTACCG,O
-,O
3,O
’,O
58,O
.,O
0,O
9,O
.,O
Campylobacter,B-OG
F,O
5,O
’-,O
AGGGAATATTGCGCAATGGGGGAAA,O
-,O
3,O
’,O
180,O
58,O
.,O
0,O
[,O
21,O
],O
R,O
5,O
’-,O
GATTCCGAGTAACGCTTGCACCCT,O
-,O
3,O
’,O
59,O
.,O
0,O
10,O
.,O
Bifidobacterium,B-OG
F,O
5,O
’-,O
GATTCTGGCTCAGGATGAACGC,O
-,O
3,O
’,O
231,O
61,O
.,O
9,O
[,O
21,O
],O
R,O
5,O
’-,O
CTGATAGGACGCGACCCCAT,O
-,O
3,O
’,O
60,O
.,O
8,O
11,O
.,O
Sulfate,B-OG
-,I-OG
reducing,I-OG
bacteria,I-OG
(,O
APS,B-GP
reductase,I-GP
subunit,I-GP
A,I-GP
gene,I-GP
),O
F,O
5,O
’-,O
TGGCAGATMATGATYMACGG,O
-,O
3,O
’,O
396,O
54,O
.,O
This,O
study,O
R,O
5,O
’-,O
GGCCGTAACCGTCCTTGAA,O
-,O
3,O
’,O
54,O
.,O
0,O
Primers,O
for,O
detection,O
and,O
quantification,O
of,O
nim,B-GP
gene,O
Primers,O
were,O
designed,O
from,O
nim,B-GP
gene,O
after,O
Stephanie,O
Trinh,O
et,O
al,O
.,O
[,O
14,O
].,O
Primer,O
sequences,O
were,O
as,O
follows,O
;,O
NIM,B-GP
-,O
F,O
(,O
5,O
’-,O
ATGTTCAGAGAAATGCGGCGTAAGCG,O
-,O
3,O
’),O
and,O
NIM,B-GP
-,O
R,O
(,O
5,O
’-,O
GCTTCCTTGCCTGTCAT,O
GTGCTC,O
-,O
3,O
’).,O
Primers,O
Nim,B-GP
-,O
F,O
and,O
Nim,B-GP
-,O
R,O
designed,O
by,O
us,O
amplify,O
all,O
the,O
members,O
of,O
nim,B-GP
gene,O
family,O
viz,O
.,O
nimA,B-GP
",",O
nimB,B-GP
",",O
nimC,B-GP
",",O
nimD,B-GP
and,O
nimE,B-GP
.,O
Primers,O
were,O
commercially,O
synthesized,O
from,O
Sigma,O
-,O
Aldrich,O
",",O
USA,O
.,O
Primers,O
NIM,B-GP
-,O
F,O
&,O
R,O
did,O
not,O
amplify,O
genomic,O
DNA,O
derived,O
from,O
axenic,O
culture,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
HM1,I-OG
-,I-OG
IMSS,I-OG
[,O
1,O
],O
and,O
blast,O
result,O
of,O
the,O
selected,O
primers,O
did,O
not,O
show,O
any,O
homology,O
with,O
E,B-OG
.,I-OG
histolytica,I-OG
genome,O
.,O
NIM,B-GP
-,O
F,O
&,O
R,O
primers,O
amplified,O
458,O
bp,O
fragment,O
of,O
nim,B-GP
gene,O
from,O
stool,O
sample,O
DNA,O
.,O
This,O
amplified,O
fragment,O
of,O
458,O
bp,O
was,O
cloned,O
in,O
pGEMT,O
-,O
easy,O
vector,O
and,O
sequenced,O
to,O
ensure,O
the,O
amplification,O
of,O
correct,O
gene,O
.,O
The,O
clone,O
was,O
subsequently,O
used,O
as,O
a,O
standard,O
for,O
quantification,O
of,O
nim,B-GP
gene,O
by,O
Real,O
Time,O
-,O
PCR,O
.,O
PCR,O
-,O
RFLP,O
of,O
nim,B-GP
gene,O
Primers,O
NIM,B-GP
-,O
F,O
and,O
NIM,B-GP
-,O
R,O
were,O
used,O
to,O
amplify,O
all,O
the,O
members,O
of,O
nim,B-GP
gene,O
family,O
from,O
stool,O
sample,O
DNA,O
.,O
Members,O
of,O
nim,B-GP
gene,O
family,O
were,O
differentiated,O
by,O
digesting,O
the,O
PCR,O
product,O
with,O
restriction,B-GP
enzymes,I-GP
HpaII,B-GP
and,O
TaqI,B-GP
.,O
HpaII,B-GP
digests,O
nimA,B-GP
",",O
nimC,B-GP
",",O
nimD,B-GP
at,O
different,O
loci,O
but,O
not,O
nimB,B-GP
and,O
nimE,B-GP
where,O
as,O
TaqI,B-GP
digests,O
nimA,B-GP
",",O
nimB,B-GP
",",O
nimE,B-GP
at,O
different,O
loci,O
but,O
not,O
nimC,B-GP
and,O
nimD,B-GP
[,O
19,O
].,O
Reference,O
strains,O
Genus,O
specific,O
primers,O
were,O
used,O
to,O
amplify,O
respected,O
genera,O
from,O
DNA,O
of,O
stool,O
sample,O
of,O
healthy,O
individual,O
.,O
The,O
amplified,O
product,O
was,O
cloned,O
and,O
sequenced,O
and,O
sequences,O
were,O
deposited,O
in,O
EMBL,O
database,O
to,O
obtain,O
the,O
accession,O
numbers,O
(,O
Table,O
2,O
).,O
These,O
16S,O
rRNA,O
gene,O
fragment,O
containing,O
plasmids,O
were,O
used,O
as,O
reference,O
strains,O
.,O
Accession,O
number,O
of,O
reference,O
strain,O
used,O
in,O
the,O
study,O
Bacteria,B-OG
Source,O
Accession,O
no,O
.,O
Bacteroides,B-OG
Stool,O
of,O
healthy,O
individual,O
AM117604,O
Methanobrevibacter,B-OG
Stool,O
of,O
healthy,O
individual,O
FN813615,O
Eubacterium,B-OG
Stool,O
of,O
healthy,O
individual,O
FN813614,O
Lactobacillus,B-OG
Stool,O
of,O
healthy,O
individual,O
AM042701,O
Bifidobacterium,B-OG
Stool,O
of,O
healthy,O
individual,O
AM042698,O
Clostridium,B-OG
Stool,O
of,O
healthy,O
individual,O
AM042697,O
Campylobacter,B-OG
Stool,O
of,O
healthy,O
individual,O
AM042699,O
Ruminococcus,B-OG
Stool,O
of,O
healthy,O
individual,O
FN823053,O
Sulfate,B-OG
-,I-OG
reducing,I-OG
bacteria,I-OG
Stool,O
of,O
healthy,O
individual,O
FN995351,O
Real,O
time,O
PCR,O
analysis,O
of,O
bacterial,O
population,O
Quantification,O
was,O
done,O
using,O
ABI,O
-,O
7500,O
machine,O
and,O
power,O
syber,O
green,O
PCR,O
master,O
mix,O
kit,O
from,O
Applied,O
Biosystems,O
",",O
USA,O
.,O
Standard,O
curve,O
was,O
the,O
method,O
of,O
choice,O
for,O
absolute,O
quantification,O
of,O
bacteria,B-OG
.,O
Standard,O
curve,O
was,O
made,O
using,O
serial,O
dilutions,O
of,O
plasmid,O
(,O
containing,O
16S,O
rRNA,O
gene,O
fragment,O
),O
of,O
known,O
concentrations,O
on,O
tenfold,O
basis,O
.,O
With,O
the,O
molecular,O
weight,O
of,O
the,O
plasmid,O
and,O
insert,O
known,O
",",O
it,O
is,O
possible,O
to,O
calculate,O
the,O
copy,O
number,O
as,O
follows,O
:,O
Step,O
1,O
:,O
Determining,O
molecular,O
weight,O
(,O
mw,O
),O
Weight,O
in,O
Daltons,O
(,O
g,O
/,O
mol,O
),O
=,O
(,O
bp,O
size,O
of,O
double,O
stranded,O
product,O
)(,O
330,O
Da,O
x,O
2nt,O
/,O
bp,O
),O
Step,O
2,O
:,O
Molecular,O
weight,O
to,O
copy,O
number,O
X,O
g,O
/,O
mol,O
/,O
Avogadro,O
’,O
s,O
number,O
(,O
6,O
.,O
023,O
×,O
1023,O
molecules,O
/,O
mole,O
),O
=,O
X,O
g,O
/,O
molecule,O
Where,O
X,O
=,O
the,O
weight,O
of,O
one,O
molecule,O
or,O
copy,O
Where,O
bp,O
=,O
base,O
pairs,O
",",O
nt,O
=,O
nucleotides,O
[,O
20,O
],O
Real,O
time,O
PCR,O
runs,O
were,O
performed,O
in,O
96,O
well,O
optical,O
plates,O
(,O
each,O
containing,O
1x,O
PCR,O
master,O
mix,O
",",O
4,O
pm,O
/,O
μl,O
forward,O
and,O
reverse,O
primer,O
(,O
optimized,O
concentration,O
),O
and,O
1μl,O
plasmid,O
DNA,O
of,O
tenfold,O
dilutions,O
or,O
1μl,O
DNA,O
from,O
samples,O
in,O
20μl,O
reaction,O
),O
for,O
40,O
cycles,O
using,O
an,O
ABI,O
7500,O
sequence,O
detector,O
(,O
Applied,O
biosystems,O
).,O
Default,O
7500,O
cycle,O
conditions,O
were,O
used,O
with,O
only,O
change,O
in,O
the,O
annealing,O
temperature,O
.,O
A,O
standard,O
curve,O
was,O
drawn,O
by,O
plotting,O
the,O
natural,O
log,O
of,O
the,O
threshold,O
cycle,O
(,O
Ct,O
),O
against,O
the,O
natural,O
log,O
of,O
the,O
number,O
of,O
molecules,O
.,O
Melting,O
curves,O
were,O
obtained,O
from,O
55,O
°,O
C,O
to,O
90,O
°,O
C,O
",",O
with,O
fluorescence,O
measurements,O
taken,O
at,O
every,O
1,O
°,O
C,O
increase,O
in,O
temperature,O
.,O
All,O
reactions,O
were,O
carried,O
out,O
in,O
triplicate,O
along,O
with,O
a,O
non,O
-,O
template,O
control,O
.,O
Ct,O
values,O
were,O
calculated,O
under,O
default,O
settings,O
for,O
the,O
absolute,O
quantification,O
using,O
the,O
software,O
provided,O
with,O
the,O
instrument,O
.,O
The,O
equation,O
drawn,O
from,O
the,O
graph,O
was,O
used,O
to,O
calculate,O
the,O
precise,O
number,O
of,O
target,O
molecule,O
(,O
plasmid,O
copy,O
no,O
.,O
or,O
number,O
of,O
bacteria,B-OG
),O
tested,O
in,O
same,O
reaction,O
plate,O
as,O
standard,O
as,O
well,O
as,O
in,O
sample,O
.,O
Statistical,O
analysis,O
Graph,O
of,O
respective,O
bacterial,O
population,O
is,O
plotted,O
as,O
mean,O
value,O
with,O
standard,O
error,O
.,O
Each,O
sample,O
was,O
analyzed,O
in,O
triplicate,O
for,O
calculation,O
of,O
significant,O
differences,O
in,O
bacterial,O
population,O
by,O
the,O
Man,O
-,O
Whitney,O
test,O
.,O
P,O
values,O
of,O
0,O
.,O
05,O
or,O
below,O
considered,O
as,O
significant,O
.,O
Paired,O
samples,O
collected,O
from,O
healthy,O
volunteers,O
before,O
and,O
after,O
satronidazole,O
treatment,O
were,O
analyzed,O
by,O
Wilcoxon,O
matched,O
-,O
pairs,O
signed,O
rank,O
test,O
(,O
two,O
tailed,O
).,O
Analysis,O
was,O
done,O
using,O
GraphPad,O
Prism,O
-,O
5,O
software,O
.,O
Results,O
Screening,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
samples,O
DNA,O
from,O
concentrated,O
cyst,O
was,O
subjected,O
to,O
Dot,O
-,O
blot,O
hybridization,O
.,O
Dot,O
blot,O
analysis,O
of,O
550,O
samples,O
yielded,O
39,O
samples,O
(,O
7,O
%),O
that,O
were,O
positive,O
for,O
Entamoeba,B-OG
(,O
Figure,O
1B,O
).,O
The,O
DNA,O
from,O
Entamoeba,B-OG
positive,O
samples,O
were,O
subjected,O
to,O
PCR,O
using,O
species,O
specific,O
primers,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
and,O
E,B-OG
.,I-OG
dispar,I-OG
(,O
Figure,O
2C,O
&,O
D,O
).,O
Out,O
of,O
39,O
samples,O
",",O
17,O
samples,O
(,O
43,O
%),O
were,O
positive,O
for,O
E,B-OG
.,I-OG
histolytica,I-OG
.,O
,O
of,O
the,O
samples,O
in,O
our,O
study,O
population,O
were,O
found,O
positive,O
for,O
both,O
the,O
species,O
of,O
the,O
parasite,O
.,O
Quantification,O
of,O
predominant,O
flora,O
High,O
quality,O
DNA,O
isolated,O
from,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
stool,O
sample,O
was,O
subjected,O
to,O
Real,O
Time,O
analysis,O
to,O
assess,O
the,O
predominant,O
gut,B-OG
flora,I-OG
that,O
included,O
Bacteroides,B-OG
",",O
Bifidobacterium,B-OG
",",O
Eubacterium,B-OG
",",O
Clostridium,B-OG
leptum,I-OG
subgroup,O
",",O
Clostridium,B-OG
coccoides,I-OG
subgroup,O
",",O
Lactobacillus,B-OG
and,O
Ruminococcus,B-OG
.,O
Two,O
subdominant,O
genera,O
Methanobrevibacter,B-OG
smithii,I-OG
and,O
Sulphur,B-OG
reducing,I-OG
bacteria,I-OG
(,O
SRB,B-OG
),O
were,O
also,O
quantified,O
.,O
Validation,O
of,O
primers,O
designed,O
by,O
us,O
for,O
the,O
above,O
genera,O
have,O
already,O
been,O
reported,O
[,O
21,O
].,O
In,O
addition,O
to,O
the,O
above,O
primers,O
",",O
here,O
we,O
report,O
a,O
Real,O
time,O
analysis,O
of,O
nim,B-GP
gene,O
copy,O
number,O
for,O
which,O
a,O
standard,O
curve,O
and,O
amplification,O
curve,O
have,O
been,O
drawn,O
that,O
shows,O
specific,O
and,O
efficient,O
quantification,O
with,O
slope,O
=,O
−,O
3,O
.,O
6,O
and,O
R2,O
=,O
0,O
.,O
998,O
(,O
Figure,O
3A,O
&,O
B,O
).,O
Real,O
-,O
time,O
analysis,O
for,O
quantification,O
of,O
different,O
bacterial,O
genera,O
in,O
Healthy,O
vs,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
(,O
Eh,O
+,O
ve,O
),O
samples,O
.,O
(,O
A,O
),O
Bacteroides,B-OG
(,O
B,O
),O
Clostridium,B-OG
coccoides,I-OG
subgroup,O
(,O
C,O
),O
Clostridium,B-OG
leptum,I-OG
subgroup,O
(,O
D,O
),O
Lactobacillus,B-OG
(,O
E,O
),O
Campylobacter,B-OG
(,O
F,O
),O
Eubacterium,B-OG
.,O
P,O
value,O
=,O
.,O
05,O
or,O
below,O
was,O
considered,O
significant,O
.,O
CI,O
stands,O
for,O
confidence,O
interval,O
.,O
Our,O
analysis,O
reveals,O
that,O
during,O
healthy,O
conditions,O
",",O
the,O
members,O
of,O
Bacteroides,B-OG
were,O
the,O
most,O
abundant,O
in,O
number,O
among,O
the,O
predominant,O
targeted,O
genera,O
.,O
However,O
",",O
a,O
significant,O
decrease,O
was,O
observed,O
in,O
population,O
of,O
Bacteroides,B-OG
(,O
p,O
=,O
.,O
001,O
),O
in,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
samples,O
when,O
compared,O
to,O
that,O
of,O
Healthy,O
control,O
samples,O
(,O
Figure,O
4A,O
).,O
Simultaneously,O
",",O
we,O
also,O
observed,O
a,O
significant,O
decrease,O
in,O
the,O
population,O
of,O
Closrtridium,B-OG
coccoides,I-OG
subgroup,O
(,O
p,O
=,O
0,O
.,O
002,O
"),",O
Clostridium,B-OG
leptum,I-OG
subgroup,O
(,O
p,O
=,O
0,O
.,O
0001,O
"),",O
Lactobacillus,B-OG
(,O
p,O
=,O
0,O
.,O
037,O
"),",O
Campylobacter,B-OG
(,O
p,O
=,O
0,O
.,O
0014,O
),O
and,O
Eubacterium,B-OG
(,O
p,O
=,O
0,O
.,O
038,O
),O
in,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
samples,O
in,O
comparison,O
to,O
control,O
(,O
Figure,O
4B,O
",",O
C,O
",",O
D,O
",",O
E,O
and,O
F,O
respectively,O
).,O
Surprisingly,O
",",O
we,O
observed,O
a,O
significant,O
rise,O
in,O
the,O
population,O
of,O
Bifidobacterium,B-OG
(,O
p,O
=,O
0,O
.,O
009,O
),O
in,O
amebic,O
samples,O
when,O
compared,O
with,O
healthy,O
control,O
samples,O
(,O
Figure,O
5B,O
).,O
No,O
significant,O
changes,O
were,O
observed,O
in,O
population,O
of,O
Rumminococcus,B-OG
(,O
p,O
=,O
0,O
.,O
33,O
),O
(,O
Figure,O
5A,O
).,O
Though,O
we,O
did,O
not,O
observe,O
any,O
significant,O
change,O
in,O
the,O
population,O
of,O
Methanobrevibacter,B-OG
(,O
p,O
=,O
0,O
.,O
96,O
),O
and,O
Sulphur,B-OG
reducing,I-OG
bacteria,I-OG
(,O
p,O
=,O
0,O
.,O
88,O
),O
in,O
amoebic,O
samples,O
but,O
the,O
prevalence,O
rate,O
was,O
reduced,O
(,O
Additional,O
file,O
1,O
:,O
Figure,O
S1A,O
&,O
B,O
).,O
Real,O
-,O
time,O
analysis,O
of,O
population,O
of,O
(,O
A,O
),O
Rumminococcus,B-OG
in,O
Healthy,O
vs,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
(,O
Eh,O
+,O
ve,O
),O
samples,O
(,O
B,O
),O
Bifidobacterium,B-OG
in,O
Healthy,O
vs,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
(,O
Eh,O
+,O
ve,O
),O
samples,O
.,O
P,O
value,O
=,O
.,O
05,O
or,O
below,O
was,O
considered,O
significant,O
.,O
CI,O
stands,O
for,O
confidence,O
interval,O
.,O
Detection,O
and,O
identification,O
of,O
nim,B-GP
gene,O
in,O
stool,O
samples,O
.,O
(,O
A,O
),O
Detection,O
of,O
nim,B-GP
gene,O
using,O
nim,B-GP
gene,O
specific,O
primers,O
.,O
Lane,O
1,O
=,O
Marker,O
100,O
bp,O
",",O
Lane,O
2,O
=,O
clone,O
of,O
nim,B-GP
gene,O
as,O
positive,O
control,O
",",O
Lane,O
3,O
–,O
5,O
=,O
DNA,O
from,O
stool,O
samples,O
from,O
healthy,O
volunteer,O
",",O
Lane,O
6,O
–,O
8,O
=,O
DNA,O
from,O
stool,O
samples,O
from,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
patients,O
and,O
Lane,O
9,O
=,O
No,O
template,O
control,O
PCR,O
(,O
B,O
),O
Restriction,O
map,O
of,O
TaqI,B-GP
restriction,O
sites,O
in,O
458,O
bp,O
nimE,B-GP
gene,O
fragment,O
.,O
(,O
C,O
),O
HpaII,B-GP
does,O
not,O
digest,O
nimE,B-GP
",",O
where,O
as,O
digestion,O
of,O
nimE,B-GP
by,O
TaqI,B-GP
generates,O
four,O
fragment,O
of,O
274,O
bp,O
",",O
155,O
bp,O
",",O
6,O
bp,O
and,O
25,O
bp,O
.,O
Lane,O
1,O
=,O
Marker,O
100,O
bp,O
",",O
Lane,O
H1,O
",",O
H2,O
",",O
E1,O
and,O
E2,O
show,O
RFLP,O
profile,O
of,O
PCR,O
product,O
digested,O
with,O
HpaII,B-GP
;,O
Lane,O
H3,O
",",O
H4,O
",",O
E3,O
and,O
E4,O
show,O
RFLP,O
profile,O
of,O
PCR,O
product,O
digested,O
with,O
TaqI,B-GP
.,O
H1,O
-,O
H4,O
",",O
DNA,O
from,O
stool,O
samples,O
of,O
Healthy,O
volunteers,O
and,O
E1,O
-,O
E4,O
are,O
DNA,O
from,O
stool,O
samples,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
patients,O
.,O
Copy,O
no,O
.,O
of,O
nim,B-GP
gene,O
We,O
found,O
the,O
presence,O
of,O
nim,B-GP
genes,O
in,O
72,O
.,O
7,O
%,O
of,O
control,O
stool,O
samples,O
(,O
n,O
=,O
22,O
),O
and,O
in,O
41,O
%,O
of,O
Entamoeba,B-OG
histolytica,I-OG
infected,O
patients,O
(,O
n,O
=,O
17,O
),O
by,O
PCR,O
(,O
Figure,O
6A,O
).,O
Further,O
the,O
amplified,O
product,O
was,O
cloned,O
and,O
sequenced,O
.,O
BLAST,O
analysis,O
revealed,O
99,O
%,O
sequence,O
homology,O
with,O
nimE,B-GP
gene,O
(,O
Accession,O
no,O
.,O
AM117602,O
.,O
1,O
"),",O
a,O
member,O
of,O
nim,B-GP
gene,O
family,O
[,O
22,O
].,O
Subsequently,O
",",O
the,O
PCR,O
products,O
from,O
all,O
the,O
samples,O
of,O
healthy,O
and,O
amebic,O
individuals,O
were,O
subjected,O
to,O
RFLP,O
analysis,O
using,O
HpaII,B-GP
and,O
TaqI,B-GP
restriction,B-GP
enzymes,I-GP
.,O
PCR,O
-,O
RFLP,O
pattern,O
confirmed,O
the,O
presence,O
of,O
only,O
nimE,B-GP
gene,O
in,O
all,O
the,O
samples,O
analyzed,O
(,O
Figure,O
6B,O
&,O
C,O
).,O
Real,O
time,O
analysis,O
of,O
nim,B-GP
gene,O
in,O
the,O
stool,O
samples,O
exhibited,O
sample,O
to,O
sample,O
variation,O
(,O
4,O
×,O
102,O
to,O
4,O
×,O
105,O
copies,O
),O
in,O
the,O
both,O
category,O
of,O
samples,O
.,O
We,O
observed,O
a,O
significant,O
increase,O
in,O
copy,O
no,O
.,O
of,O
nim,B-GP
gene,O
in,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
samples,O
vs,O
samples,O
from,O
healthy,O
persons,O
(,O
p,O
=,O
0,O
.,O
025,O
),O
(,O
Figure,O
3C,O
).,O
Detemination,O
of,O
copy,O
number,O
of,O
nimE,B-GP
gene,O
by,O
Real,O
-,O
time,O
PCR,O
.,O
(,O
A,O
),O
Standard,O
curve,O
",",O
slope,O
=,O
−,O
3,O
.,O
6,O
and,O
R2,O
=,O
0,O
.,O
998,O
showing,O
good,O
efficiency,O
.,O
(,O
B,O
),O
Dissociation,O
curve,O
showing,O
specific,O
amplification,O
of,O
target,O
(,O
nimE,B-GP
gene,O
),O
and,O
NTC,O
=,O
No,O
template,O
control,O
.,O
(,O
C,O
),O
Absolute,O
quantification,O
of,O
copy,O
no,O
.,O
of,O
nimE,B-GP
gene,O
in,O
Healthy,O
vs,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
samples,O
.,O
(,O
D,O
),O
Absolute,O
quantification,O
of,O
copy,O
no,O
.,O
of,O
nimE,B-GP
gene,O
in,O
stool,O
sample,O
DNA,O
of,O
Healthy,O
volunteers,O
before,O
and,O
after,O
satronidazole,O
treatment,O
.,O
P,O
value,O
=,O
.,O
05,O
or,O
below,O
was,O
considered,O
significant,O
.,O
CI,O
stands,O
for,O
confidence,O
interval,O
.,O
To,O
see,O
the,O
effect,O
of,O
antiamoebic,O
drug,O
Satronidazole,O
(,O
Alchem,O
pharmaceuticals,O
),O
on,O
nim,B-GP
gene,O
copy,O
number,O
",",O
healthy,O
volunteers,O
(,O
n,O
=,O
5,O
),O
were,O
advised,O
to,O
take,O
the,O
drug,O
(,O
300,O
mg,O
tablets,O
),O
twice,O
daily,O
after,O
meals,O
for,O
4,O
days,O
and,O
copy,O
of,O
nim,B-GP
gene,O
was,O
quantified,O
before,O
and,O
after,O
the,O
treatment,O
using,O
the,O
primers,O
described,O
here,O
.,O
Wilcoxon,O
matched,O
-,O
pairs,O
signed,O
rank,O
test,O
(,O
two,O
tailed,O
),O
analysis,O
of,O
copy,O
no,O
.,O
of,O
nim,B-GP
gene,O
shows,O
no,O
significant,O
change,O
(,O
p,O
=,O
0,O
.,O
125,O
),O
in,O
stool,O
samples,O
collected,O
before,O
and,O
after,O
treatment,O
(,O
Figure,O
3D,O
).,O
Discussion,O
Infection,B-DS
by,O
E,B-OG
.,I-OG
histolytica,I-OG
is,O
normally,O
initiated,O
by,O
the,O
ingestion,O
of,O
fecally,O
contaminated,O
water,O
or,O
food,O
containing,O
E,B-OG
.,I-OG
histolytica,I-OG
cysts,O
.,O
Phagocytosis,O
of,O
colonic,O
bacteria,B-OG
has,O
been,O
considered,O
as,O
a,O
possible,O
stimulus,O
to,O
induce,O
the,O
invasive,O
behavior,O
by,O
the,O
parasite,O
[,O
23,O
].,O
Adult,O
gut,O
microbiota,B-OG
are,O
quite,O
stable,O
in,O
individuals,O
and,O
can,O
even,O
be,O
restored,O
after,O
perturbation,O
[,O
24,O
",",O
25,O
].,O
Our,O
earlier,O
results,O
have,O
shown,O
significant,O
changes,O
in,O
expression,O
of,O
EhCaBP,B-GP
and,O
LPG,B-GP
only,O
after,O
the,O
axenic,O
E,B-OG
.,I-OG
histolytica,I-OG
had,O
been,O
adapted,O
to,O
grow,O
with,O
bacterial,O
flora,O
for,O
a,O
number,O
of,O
generatiom,O
",",O
and,O
not,O
in,O
short,O
term,O
culture,O
[,O
26,O
].,O
In,O
the,O
present,O
study,O
we,O
tried,O
to,O
evaluate,O
perturbations,O
in,O
commensal,O
gut,B-OG
flora,I-OG
caused,O
as,O
result,O
of,O
E,B-DS
.,I-DS
histolytica,I-DS
infection,I-DS
using,O
Real,O
Time,O
PCR,O
.,O
qPCR,O
methodology,O
is,O
less,O
expensive,O
",",O
more,O
quantitative,O
and,O
is,O
more,O
efficient,O
in,O
terms,O
of,O
time,O
and,O
operation,O
[,O
27,O
].,O
The,O
absolute,O
proportions,O
of,O
eight,O
predominant,O
commensal,O
and,O
two,O
subdominant,O
genera,O
were,O
quantified,O
successfully,O
in,O
our,O
samples,O
.,O
Bacteroides,B-OG
species,O
are,O
a,O
pleomorphic,O
group,O
of,O
non,O
-,O
spore,O
forming,O
gram,B-OG
-,I-OG
negative,I-OG
anaerobic,I-OG
bacteria,I-OG
.,O
Bacteroides,B-OG
are,O
the,O
most,O
dominant,O
part,O
of,O
the,O
normal,O
indigenous,O
flora,O
in,O
the,O
human,B-OG
gut,O
.,O
Bacteroides,B-OG
are,O
mostly,O
represented,O
by,O
Bacteroides,B-OG
ovatus,I-OG
",",O
Bacteroides,B-OG
uniformis,I-OG
Bacteroides,B-OG
vulgatus,I-OG
",",O
Bacteroides,B-OG
thetaiotaomicron,I-OG
",",O
Bacteroides,B-OG
distasonis,I-OG
",",O
and,O
less,O
frequently,O
by,O
Bacteroides,B-OG
eggerthii,I-OG
and,O
Bacteroides,B-OG
fragilis,I-OG
.,O
These,O
bacteria,B-OG
are,O
significant,O
contributors,O
to,O
the,O
carbohydrate,O
metabolism,O
",",O
nutrition,O
and,O
health,O
of,O
humans,B-OG
and,O
animals,B-OG
.,O
In,O
1999,O
Hooper,O
et,O
al,O
.,O
demonstrated,O
that,O
B,B-OG
.,I-OG
thetaiotaomicron,I-OG
can,O
modify,O
intestinal,O
fucosylation,O
in,O
a,O
complex,O
interaction,O
mediated,O
by,O
fucose,B-GP
repressor,I-GP
gene,I-GP
and,O
a,O
signaling,O
system,O
[,O
28,O
].,O
The,O
significant,O
decrease,O
in,O
population,O
of,O
Bacteroides,B-OG
during,O
disease,O
condition,O
dampens,O
the,O
beneficial,O
effects,O
of,O
this,O
genera,O
to,O
host,O
.,O
In,O
the,O
human,B-OG
intestinal,O
tract,O
",",O
Eubacterium,B-OG
is,O
the,O
second,O
most,O
common,O
genus,O
after,O
the,O
genus,O
Bacteroides,B-OG
.,O
The,O
genus,O
Eubacterium,B-OG
comprises,O
a,O
nutritionally,O
diverse,O
group,O
of,O
organisms,O
.,O
The,O
members,O
of,O
genus,O
Eubacterium,B-OG
are,O
known,O
to,O
produce,O
butyrate,O
[,O
29,O
"],",O
degrade,O
flavonoids,O
(,O
from,O
vegetables,O
",",O
fruits,O
",",O
nuts,O
",",O
and,O
tea,O
),O
[,O
30,O
],O
and,O
are,O
implicated,O
in,O
steroid,O
and,O
bile,O
transformation,O
in,O
intestine,O
[,O
31,O
].,O
The,O
decrease,O
in,O
population,O
of,O
Eubacterium,B-OG
sp,O
.,O
observed,O
in,O
our,O
study,O
may,O
reduce,O
the,O
butyrate,O
production,O
and,O
may,O
also,O
affect,O
the,O
capacity,O
of,O
the,O
host,O
in,O
proper,O
digestion,O
of,O
the,O
above,O
ingredients,O
of,O
food,O
.,O
Bifidobacterium,B-OG
species,O
are,O
common,O
inhabitants,O
of,O
the,O
gastrointestinal,O
tract,O
",",O
and,O
they,O
have,O
received,O
special,O
attention,O
because,O
of,O
their,O
health,O
-,O
promoting,O
effects,O
in,O
humans,B-OG
.,O
Members,O
of,O
Bifidobacteria,B-OG
produce,O
enough,O
acetate,O
(,O
SCFA,O
),O
in,O
proximal,O
and,O
distal,O
colon,O
by,O
fermentation,O
of,O
glucose,O
and,O
fructose,O
[,O
32,O
].,O
Members,O
of,O
both,O
Bifidobacteria,B-OG
and,O
Ruminococcus,B-OG
-,O
Ruminococcus,B-OG
torques,I-OG
and,O
Bifidobacterium,B-OG
bifidum,I-OG
are,O
thought,O
to,O
ferment,O
mucin,B-GP
and,O
compete,O
to,O
colonise,O
this,O
substrate,O
for,O
their,O
energy,O
source,O
[,O
33,O
].,O
Our,O
result,O
shows,O
a,O
significant,O
increase,O
in,O
population,O
of,O
Bifidobacterium,B-OG
but,O
no,O
change,O
in,O
population,O
of,O
Rumminococcous,B-OG
despite,O
decrease,O
in,O
population,O
of,O
several,O
other,O
targeted,O
genera,O
.,O
It,O
is,O
quite,O
well,O
known,O
that,O
mucus,O
secretion,O
is,O
increased,O
in,O
E,B-DS
.,I-DS
histolytica,I-DS
infection,I-DS
especially,O
during,O
dysentery,B-DS
which,O
is,O
probably,O
result,O
of,O
a,O
mechanism,O
exerted,O
by,O
intestinal,O
epithelial,O
cells,O
to,O
counter,O
the,O
adherence,O
of,O
E,B-OG
.,I-OG
histolytica,I-OG
trophozoites,O
to,O
intestinal,O
epithelial,O
surface,O
.,O
The,O
protozoan,O
parasite,O
Entamoeba,B-OG
histolytica,I-OG
cleaves,O
Mucin,B-GP
2,I-GP
(,O
MUC2,B-GP
),O
in,O
the,O
non,O
-,O
glycosylated,O
oligomerization,O
domains,O
by,O
cysteine,B-GP
protease,I-GP
",",O
thus,O
breaking,O
down,O
the,O
macromolecular,O
structure,O
and,O
reducing,O
mucus,O
viscosity,O
[,O
34,O
].,O
Perhaps,O
under,O
this,O
condition,O
",",O
a,O
cross,O
-,O
talk,O
between,O
the,O
mucosal,O
layer,O
",",O
bacteria,B-OG
and,O
the,O
parasite,O
initiates,O
.,O
As,O
a,O
result,O
",",O
the,O
intestinal,O
epithelial,O
cells,O
tend,O
to,O
produce,O
more,O
of,O
mucin,B-GP
for,O
protection,O
that,O
promotes,O
colonization,O
of,O
Bifidobacteria,B-OG
in,O
one,O
hand,O
and,O
on,O
the,O
other,O
hand,O
the,O
parasite,O
competes,O
to,O
more,O
release,O
of,O
mucin,B-GP
for,O
its,O
adhesion,O
to,O
epithelial,O
layer,O
.,O
Bifidobacteria,B-OG
longum,I-OG
are,O
known,O
to,O
protect,O
the,O
gut,O
from,O
enteropathogenic,O
infection,B-DS
through,O
production,O
of,O
acetate,O
[,O
32,O
],O
and,O
acetate,O
is,O
major,O
energy,O
source,O
for,O
colonocytes,O
but,O
a,O
fine,O
balance,O
in,O
population,O
of,O
different,O
bacterial,O
genera,O
of,O
gut,O
is,O
needed,O
for,O
healthy,O
colon,O
.,O
The,O
C,B-OG
.,I-OG
leptum,I-OG
subgroup,O
and,O
C,B-OG
.,I-OG
coccoides,I-OG
subgroup,O
are,O
one,O
of,O
the,O
most,O
predominant,O
populations,O
of,O
human,B-OG
fecal,O
microflora,O
which,O
contains,O
a,O
large,O
number,O
of,O
butyrate,O
-,O
producing,O
bacteria,B-OG
[,O
35,O
",",O
36,O
].,O
Butyrate,O
is,O
a,O
SCFA,O
(,O
Short,O
chain,O
fatty,O
acids,O
),O
having,O
a,O
strong,O
effect,O
on,O
the,O
cell,O
cycle,O
and,O
acts,O
as,O
anti,O
-,O
inflammatory,O
molecule,O
in,O
the,O
gut,O
.,O
Effects,O
on,O
mucosal,O
defense,O
include,O
improved,O
tight,O
junction,O
assembly,O
",",O
antimicrobial,O
secretion,O
and,O
mucin,B-GP
expression,O
[,O
37,O
].,O
The,O
decrease,O
in,O
population,O
of,O
members,O
of,O
C,B-OG
.,I-OG
leptum,I-OG
subgroup,O
and,O
C,B-OG
.,I-OG
coccoides,I-OG
subgroup,O
observed,O
here,O
leads,O
to,O
decrease,O
in,O
the,O
production,O
of,O
SCFA,O
and,O
hence,O
renders,O
the,O
host,O
more,O
susceptible,O
for,O
future,O
infections,B-DS
.,O
The,O
genus,O
Lactobacillus,B-OG
comprises,O
a,O
large,O
heterogenous,O
group,O
of,O
low,O
G,O
+,O
C,O
gram,O
positive,O
",",O
non,O
sporulating,O
",",O
anaerobic,O
bacteria,B-OG
belonging,O
to,O
phylum,O
Firmicutes,B-OG
.,O
Lactobacilli,B-OG
are,O
known,O
to,O
fortify,O
epithelial,O
barrier,O
by,O
various,O
mechanism,O
such,O
as,O
induction,O
of,O
mucin,B-GP
secretion,O
",",O
enhancement,O
of,O
tight,O
-,O
junction,O
functioning,O
",",O
upregulation,O
of,O
cytoprotective,O
heat,B-GP
shock,I-GP
proteins,I-GP
and,O
prevention,O
of,O
apoptosis,O
of,O
epithelial,O
cells,O
[,O
38,O
].,O
Probiotic,O
strains,O
of,O
Lactobacillus,B-OG
are,O
known,O
to,O
prevent,O
infectious,B-DS
diarrhea,I-DS
",",O
antibiotic,B-DS
associated,I-DS
diarrhea,I-DS
and,O
diarrhea,O
in,O
children,O
who,O
are,O
unusually,O
more,O
susceptible,O
as,O
a,O
result,O
of,O
poor,O
nutrition,O
",",O
impaired,O
immune,O
status,O
or,O
frequent,O
exposure,O
to,O
pathogens,O
[,O
39,O
].,O
We,O
observed,O
significant,O
decrease,O
in,O
population,O
of,O
Lactobacillus,B-OG
in,O
gut,B-OG
flora,I-OG
of,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
patients,O
as,O
compared,O
to,O
that,O
of,O
healthy,O
individuals,O
that,O
support,O
our,O
earlier,O
observation,O
made,O
by,O
semi,O
quantitative,O
method,O
[,O
1,O
].,O
Methanobrevibacter,B-OG
smithii,I-OG
is,O
the,O
dominant,O
archaeon,O
in,O
human,B-OG
gut,O
that,O
affects,O
the,O
specificity,O
and,O
efficiency,O
of,O
bacterial,O
digestion,O
of,O
dietary,O
polysaccharides,O
",",O
thereby,O
influencing,O
host,O
calorie,O
harvest,O
and,O
adiposity,O
[,O
40,O
].,O
It,O
has,O
been,O
suggested,O
that,O
the,O
low,O
and,O
variable,O
prevalence,O
of,O
Methanobrevibacter,B-OG
smithii,I-OG
and,O
Methanosphaera,B-OG
stadtmanae,I-OG
DNA,O
in,O
human,B-OG
stool,O
contrasts,O
with,O
the,O
paramount,O
role,O
of,O
these,O
methanogenic,B-OG
archaea,I-OG
in,O
digestion,O
processes,O
and,O
hypothesized,O
that,O
this,O
contrast,O
is,O
a,O
consequence,O
of,O
the,O
inefficiencies,O
of,O
current,O
protocols,O
for,O
archaea,B-OG
DNA,O
extraction,O
[,O
41,O
].,O
In,O
our,O
samples,O
prevalence,O
of,O
M,B-OG
.,I-OG
smithii,I-OG
in,O
healthy,O
individuals,O
stool,O
samples,O
was,O
27,O
.,O
27,O
%,O
and,O
that,O
was,O
further,O
reduced,O
to,O
11,O
.,O
7,O
%,O
in,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
samples,O
.,O
Real,O
-,O
time,O
analysis,O
shows,O
no,O
significant,O
alteration,O
in,O
population,O
of,O
M,B-OG
.,I-OG
smithii,I-OG
.,O
Variation,O
in,O
the,O
loads,O
of,O
M,B-OG
.,I-OG
smithii,I-OG
under,O
different,O
pathophysiological,O
condition,O
such,O
as,O
during,O
amebiasis,B-DS
has,O
not,O
been,O
reported,O
so,O
far,O
.,O
Suphate,B-OG
reducing,I-OG
bacteria,I-OG
(,O
SRB,B-OG
),O
are,O
a,O
group,O
of,O
non,O
spore,O
forming,O
",",O
gram,O
negative,O
",",O
dissimilatory,O
sulphate,O
reducing,O
",",O
anaerobic,O
bacteria,B-OG
.,O
SRB,B-OG
can,O
be,O
isolated,O
from,O
the,O
intestinal,O
tract,O
of,O
humans,B-OG
and,O
various,O
environmental,O
sources,O
.,O
Intestinal,O
SRB,B-OG
’,O
s,O
growth,O
and,O
resultant,O
hydrogen,O
sulfide,O
production,O
have,O
been,O
implicated,O
to,O
damage,O
the,O
gastrointestinal,O
tract,O
and,O
thereby,O
contribute,O
to,O
chronic,O
intestinal,B-DS
disorders,I-DS
[,O
42,O
].,O
Desulfovibrio,B-OG
fairfieldensis,I-OG
and,O
D,B-OG
.,I-OG
desulfuricans,I-OG
have,O
been,O
associated,O
with,O
incidence,O
of,O
bacteremia,B-DS
and,O
D,B-OG
.,I-OG
vulgaris,I-OG
has,O
been,O
associated,O
with,O
intra,B-DS
-,I-DS
abdominal,I-DS
infections,I-DS
[,O
43,O
].,O
The,O
prevalence,O
of,O
Sulphate,B-OG
reducing,I-OG
bacteria,I-OG
was,O
36,O
.,O
36,O
%,O
in,O
healthy,O
and,O
11,O
.,O
7,O
%,O
in,O
amoebic,O
individuals,O
stool,O
samples,O
.,O
However,O
",",O
the,O
change,O
was,O
not,O
statistically,O
significant,O
.,O
The,O
genus,O
Campylobacter,B-OG
is,O
notorious,O
for,O
causing,O
gastroenritis,B-DS
by,O
C,B-OG
.,I-OG
jejuni,I-OG
but,O
uncultured,O
Campylobacter,B-OG
species,O
e,O
.,O
g,O
.,O
Campylobacter,B-OG
hominis,I-OG
whose,O
role,O
is,O
not,O
clear,O
yet,O
",",O
do,O
exist,O
in,O
lower,O
gastrointestinal,O
tract,O
of,O
healthy,O
humans,B-OG
[,O
44,O
].,O
We,O
observed,O
significant,O
decrease,O
in,O
population,O
of,O
Campylobacter,B-OG
in,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
individual,O
as,O
compared,O
to,O
healthy,O
individuals,O
.,O
As,O
our,O
primers,O
were,O
genus,O
specific,O
",",O
so,O
decrease,O
in,O
Campylobacter,B-OG
was,O
genera,O
specific,O
and,O
not,O
species,O
specific,O
.,O
Significant,O
increase,O
in,O
the,O
population,O
of,O
Campylobacter,B-OG
has,O
been,O
observed,O
in,O
IBD,B-DS
[,O
21,O
],O
but,O
we,O
did,O
not,O
find,O
the,O
same,O
trend,O
in,O
amoebic,O
patients,O
.,O
Several,O
species,O
of,O
Bacteroides,B-OG
are,O
known,O
to,O
harbor,O
nim,B-GP
genes,O
e,O
.,O
g,O
.,O
B,B-OG
.,I-OG
fragilis,I-OG
",",O
B,B-OG
.,I-OG
distasonis,I-OG
",",O
B,B-OG
.,I-OG
thetaiotaomicron,I-OG
",",O
B,B-OG
.,I-OG
vulgatus,I-OG
",",O
B,B-OG
.,I-OG
ovatus,I-OG
but,O
wide,O
differences,O
in,O
MIC,O
values,O
of,O
metronidazole,O
are,O
observed,O
",",O
ranging,O
from,O
1,O
.,O
5,O
to,O
>,O
256,O
mg,O
/,O
L,O
and,O
some,O
are,O
also,O
found,O
above,O
the,O
therapeutic,O
breakpoint,O
of,O
16,O
mg,O
/,O
L,O
[,O
45,O
].,O
Though,O
the,O
population,O
of,O
Bacteroides,B-OG
is,O
decreased,O
significantly,O
in,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
patients,O
however,O
we,O
have,O
observed,O
high,O
copy,O
no,O
.,O
of,O
nimE,B-GP
gene,O
in,O
the,O
same,O
.,O
We,O
attribute,O
this,O
increase,O
to,O
the,O
presence,O
of,O
plasmid,O
coded,O
nimE,B-GP
gene,O
as,O
has,O
been,O
observed,O
earlier,O
in,O
Veillonella,B-OG
sp,I-OG
.,O
[,O
46,O
].,O
Future,O
analyses,O
that,O
target,O
specific,O
members,O
of,O
the,O
Bacteroides,B-OG
group,O
will,O
shed,O
further,O
light,O
on,O
the,O
species,O
involved,O
in,O
the,O
expansion,O
of,O
nimE,B-GP
gene,O
.,O
In,O
2006,O
",",O
Rani,O
et,O
al,O
.,O
reported,O
presence,O
of,O
nim,B-GP
gene,O
in,O
stool,O
samples,O
of,O
amebic,O
individuals,O
but,O
not,O
in,O
healthy,O
individuals,O
[,O
1,O
],O
but,O
our,O
result,O
show,O
high,O
prevalence,O
rate,O
of,O
nim,B-GP
gene,O
even,O
in,O
healthy,O
individuals,O
irrespective,O
of,O
the,O
disease,O
.,O
However,O
in,O
a,O
hospital,O
based,O
study,O
carried,O
out,O
in,O
Greece,O
revealed,O
low,O
level,O
of,O
prevalence,O
of,O
nim,B-GP
gene,O
in,O
isolates,O
of,O
different,O
anaerobic,O
bacterial,O
species,O
from,O
hospitalized,O
patients,O
[,O
47,O
].,O
Though,O
the,O
presence,O
of,O
nim,B-GP
gene,O
in,O
gut,O
of,O
healthy,O
north,O
Indian,O
population,O
is,O
shocking,O
but,O
this,O
may,O
be,O
explained,O
due,O
to,O
easy,O
over,O
the,O
counter,O
drug,O
availability,O
in,O
India,O
.,O
Results,O
on,O
healthy,O
individuals,O
undergoing,O
Satronidazole,O
treatment,O
indicate,O
that,O
nimE,B-GP
gene,O
copy,O
number,O
does,O
not,O
show,O
significant,O
reduction,O
.,O
It,O
can,O
therefore,O
be,O
assumed,O
that,O
nimE,B-GP
gene,O
harboring,O
Bacteroides,B-OG
probably,O
cause,O
inactivation,O
of,O
nitroimidazole,O
drug,O
and,O
thereby,O
reduce,O
the,O
bioavailability,O
of,O
drug,O
to,O
the,O
parasite,O
and,O
hence,O
may,O
help,O
in,O
sustaining,O
the,O
infection,B-DS
.,O
Conclusion,O
The,O
metabolic,O
activities,O
of,O
the,O
predominant,O
gut,B-OG
flora,I-OG
have,O
a,O
significant,O
effect,O
on,O
the,O
health,O
of,O
the,O
human,B-OG
colon,O
.,O
The,O
current,O
findings,O
of,O
depleted,O
populations,O
of,O
metabolically,O
important,O
bacteria,B-OG
like,O
Bacteroides,B-OG
",",O
C,B-OG
.,I-OG
leptum,I-OG
and,O
C,B-OG
.,I-OG
coccoides,I-OG
sub,O
groups,O
",",O
Lactobacillus,B-OG
sp,I-OG
".,",O
Eubacterium,B-OG
sp,O
".,",O
and,O
Campylobacter,B-OG
sp,I-OG
.,I-OG
add,O
to,O
our,O
knowledge,O
of,O
the,O
changes,O
in,O
the,O
GI,O
tracts,O
of,O
amebic,O
patients,O
.,O
Such,O
changes,O
in,O
bacterial,O
population,O
in,O
the,O
normal,O
microbiota,B-OG
could,O
have,O
considerable,O
consequences,O
in,O
terms,O
of,O
functional,O
potential,O
of,O
gut,B-OG
flora,I-OG
and,O
could,O
result,O
in,O
metabolic,O
conditions,O
favorable,O
for,O
the,O
establishment,O
of,O
opportunistic,O
pathogens,O
(,O
e,O
.,O
g,O
.,O
Clostridium,B-OG
difficile,I-OG
).,O
However,O
",",O
our,O
study,O
cannot,O
conclude,O
that,O
observed,O
changes,O
in,O
the,O
gut,B-OG
flora,I-OG
is,O
the,O
cause,O
or,O
effect,O
of,O
the,O
infection,B-DS
or,O
the,O
effect,O
of,O
dysenteric,O
mechanism,O
per,O
se,O
by,O
the,O
parasite,O
.,O
Our,O
findings,O
could,O
potentially,O
guide,O
implementation,O
of,O
dietary,O
/,O
probiotic,O
interventions,O
that,O
impact,O
the,O
gut,O
microbiota,B-OG
and,O
improve,O
GI,O
health,O
in,O
individuals,O
infected,O
with,O
Entamoeba,B-OG
histolytica,I-OG
.,O
Abbreviations,O
SRB,B-OG
:,O
Sulphur,B-OG
reducing,I-OG
bacteria,I-OG
;,O
RFLP,O
:,O
Restriction,O
fragment,O
length,O
polymorphism,O
;,O
MUC2,B-GP
:,O
Mucin,B-GP
2,I-GP
;,O
SCFA,O
:,O
Short,O
-,O
chain,O
.,O
Competing,O
interests,O
We,O
declare,O
that,O
no,O
competing,O
interests,O
exist,O
among,O
the,O
authors,O
Authors,O
’,O
contributions,O
JP,O
conceived,O
and,O
coordinated,O
the,O
study,O
.,O
AKV,O
carried,O
out,O
the,O
bacterial,O
quantification,O
experiments,O
.,O
AKV,O
and,O
RV,O
conducted,O
the,O
copy,O
number,O
calculation,O
experiments,O
.,O
JP,O
and,O
AKV,O
drafted,O
the,O
manuscript,O
and,O
conducted,O
the,O
statistical,O
analysis,O
.,O
VA,O
made,O
the,O
diagnosis,O
of,O
the,O
patients,O
",",O
interpretation,O
of,O
data,O
and,O
collaborated,O
in,O
collection,O
of,O
the,O
samples,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Supplementary,O
Material,O
Additional,O
file,O
1,O
Real,O
time,O
analysis,O
of,O
population,O
of,O
(,O
A,O
),O
Methanobrevibacter,B-OG
in,O
Healthy,O
vs,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
samples,O
(,O
B,O
),O
Sulphur,B-OG
reducing,I-OG
bacteria,I-OG
in,O
Healthy,O
vs,O
E,B-OG
.,I-OG
histolytica,I-OG
positive,O
sample,O
.,O
P,O
value,O
=,O
.,O
05,O
or,O
below,O
was,O
considered,O
significant,O
.,O
Cl,O
stands,O
for,O
confidence,O
interval,O
.,O
Click,O
here,O
for,O
file,O
Secondary,O
damage,O
in,O
left,O
-,O
sided,O
frontal,O
white,O
matter,O
detected,O
by,O
diffusion,O
tensor,O
imaging,O
is,O
correlated,O
with,O
executive,B-DS
dysfunction,I-DS
in,O
patients,O
with,O
acute,B-DS
infarction,I-DS
at,O
the,O
ipsilateral,O
posterior,O
corona,O
radiata,O
Background,O
Executive,B-DS
dysfunction,I-DS
has,O
been,O
observed,O
in,O
patients,O
with,O
left,O
-,O
sided,O
anterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
.,O
However,O
",",O
whether,O
left,O
-,O
sided,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
could,O
cause,O
executive,B-DS
dysfunction,I-DS
is,O
unclear,O
.,O
Also,O
",",O
whether,O
secondary,O
damage,O
in,O
the,O
left,O
frontal,O
white,O
matter,O
following,O
ipsilateral,O
posterior,O
corona,B-DS
radiata,I-DS
infarct,I-DS
is,O
causal,O
or,O
not,O
and,O
contributes,O
to,O
the,O
occurrence,O
and,O
development,O
of,O
executive,B-DS
dysfunction,I-DS
",",O
is,O
still,O
uncertain,O
.,O
Methods,O
Twelve,O
patients,O
with,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
underwent,O
diffusion,O
tensor,O
imaging,O
(,O
DTI,O
),O
and,O
an,O
executive,O
functional,O
assessment,O
at,O
week,O
1,O
(,O
W1,O
"),",O
week,O
4,O
(,O
W4,O
"),",O
and,O
week,O
12,O
(,O
W12,O
),O
after,O
onset,O
.,O
Color,O
duplex,O
sonography,O
and,O
Transcranial,O
Duplex,O
Scanning,O
(,O
TCD,O
),O
were,O
performed,O
at,O
W1,O
and,O
W12,O
.,O
Twelve,O
healthy,O
volunteers,O
of,O
similar,O
ages,O
and,O
educational,O
histories,O
were,O
examined,O
as,O
controls,O
and,O
assessed,O
once,O
.,O
Results,O
In,O
the,O
patients,O
",",O
we,O
observed,O
an,O
increased,O
mean,O
diffusivity,O
(,O
MD,O
),O
and,O
a,O
decreased,O
fractional,O
anisotropy,O
(,O
FA,O
),O
in,O
the,O
left,O
frontal,O
white,O
matter,O
from,O
W1,O
to,O
W12,O
.,O
There,O
were,O
no,O
significant,O
changes,O
in,O
cerebral,O
blood,O
flow,O
in,O
patients,O
between,O
W1,O
and,O
W12,O
according,O
to,O
the,O
result,O
of,O
Color,O
duplex,O
sonography,O
and,O
TCD,O
.,O
Patients,O
showed,O
progressively,O
impaired,O
executive,O
function,O
during,O
12,O
weeks,O
.,O
Significant,O
correlations,O
were,O
found,O
between,O
increased,O
MD,O
and,O
decreased,O
FA,O
in,O
the,O
left,O
frontal,O
white,O
matter,O
with,O
impaired,O
degree,O
of,O
executive,O
function,O
.,O
Conclusions,O
This,O
study,O
demonstrates,O
that,O
DTI,O
detected,O
secondary,O
damage,O
in,O
left,O
-,O
sided,O
frontal,O
white,O
matter,O
in,O
patients,O
with,O
acute,B-DS
infarction,I-DS
at,O
the,O
ipsilateral,O
posterior,O
corona,O
radiata,O
.,O
This,O
change,O
may,O
be,O
correlated,O
with,O
executive,O
functional,O
changes,O
in,O
these,O
patients,O
.,O
Background,O
The,O
term,O
‘,O
executive,O
functions,O
’,O
is,O
used,O
to,O
describe,O
high,O
-,O
order,O
cognitive,O
processes,O
which,O
include,O
control,O
",",O
integration,O
",",O
organization,O
and,O
maintenance,O
of,O
other,O
cognitive,O
abilities,O
[,O
1,O
].,O
Executive,B-DS
dysfunction,I-DS
might,O
predict,O
poor,O
functional,O
outcome,O
of,O
patients,O
with,O
stroke,B-DS
[,O
2,O
].,O
The,O
frontal,O
lobes,O
have,O
extensive,O
connections,O
with,O
portions,O
of,O
the,O
limbic,O
system,O
",",O
the,O
basal,O
ganglia,O
",",O
and,O
the,O
thalamus,O
.,O
The,O
frontal,O
-,O
subcortical,O
white,O
matter,O
connections,O
as,O
well,O
as,O
the,O
frontal,O
lobe,O
are,O
well,O
known,O
to,O
be,O
functionally,O
critical,O
in,O
the,O
control,O
of,O
executive,O
function,O
[,O
3,O
].,O
Lesions,O
of,O
not,O
only,O
the,O
prefrontal,O
cortex,O
but,O
subcortical,O
areas,O
result,O
in,O
executive,B-DS
dysfunction,I-DS
[,O
4,O
"],[",O
5,O
].,O
In,O
particular,O
",",O
damage,O
of,O
frontal,O
white,O
matter,O
",",O
which,O
is,O
an,O
important,O
region,O
in,O
frontal,O
-,O
subcortical,O
circuitry,O
",",O
results,O
in,O
this,O
executive,B-DS
dysfunction,I-DS
[,O
6,O
].,O
Recently,O
",",O
accumulating,O
studies,O
have,O
shown,O
histopathological,O
and,O
radiological,O
changes,O
occurring,O
in,O
nonischemic,O
remote,O
brain,O
regions,O
that,O
have,O
synaptic,O
connections,O
with,O
the,O
primary,O
lesion,O
site,O
.,O
For,O
example,O
",",O
after,O
cerebral,B-DS
infarction,I-DS
in,O
the,O
middle,O
cerebral,O
artery,O
(,O
MCA,O
),O
territory,O
",",O
neuronal,O
and,O
/,O
or,O
axonal,O
degeneration,O
",",O
loss,O
",",O
dysfunction,O
and,O
gliosis,O
have,O
been,O
found,O
in,O
the,O
ipsilateral,O
thalamus,O
",",O
substantia,O
nigra,O
",",O
and,O
distal,O
pyramidal,O
tract,O
",",O
all,O
of,O
which,O
were,O
remote,O
from,O
the,O
MCA,O
territory,O
[,O
7,O
]–[,O
12,O
].,O
The,O
corona,O
radiata,O
is,O
the,O
core,O
of,O
the,O
hemispheric,O
white,O
matter,O
",",O
and,O
its,O
infarction,O
may,O
compromise,O
the,O
integrity,O
of,O
the,O
frontal,O
-,O
subcortical,O
white,O
matter,O
connections,O
.,O
A,O
study,O
of,O
patients,O
with,O
stroke,B-DS
scanned,O
by,O
traditional,O
magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
showed,O
that,O
ischemic,O
infarctive,O
lesions,O
affecting,O
the,O
left,O
-,O
sided,O
anterior,O
corona,O
radiata,O
caused,O
executive,B-DS
dysfunction,I-DS
[,O
4,O
].,O
The,O
disruption,O
of,O
frontal,O
-,O
subcortical,O
circuitry,O
was,O
considered,O
to,O
be,O
responsible,O
for,O
this,O
executive,B-DS
dysfunction,I-DS
.,O
However,O
",",O
whether,O
the,O
left,O
-,O
sided,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
could,O
cause,O
executive,B-DS
dysfunction,I-DS
is,O
unclear,O
.,O
Moreover,O
",",O
the,O
underlying,O
pathogenesis,O
",",O
especially,O
whether,O
secondary,O
damage,O
in,O
other,O
areas,O
",",O
such,O
as,O
frontal,O
white,O
matter,O
in,O
frontal,O
-,O
subcortical,O
circuitry,O
",",O
due,O
to,O
anterograde,O
and,O
/,O
or,O
retrograde,O
degeneration,O
following,O
focal,O
corona,B-DS
radiata,I-DS
infarction,I-DS
",",O
is,O
a,O
causal,O
phenomenon,O
and,O
is,O
involved,O
in,O
the,O
dysfunction,O
",",O
is,O
still,O
uncertain,O
.,O
The,O
recent,O
development,O
of,O
diffusion,O
tensor,O
imaging,O
(,O
DTI,O
"),",O
an,O
MRI,O
technique,O
",",O
has,O
shown,O
promise,O
for,O
detecting,O
microstructural,O
changes,O
which,O
are,O
not,O
identified,O
by,O
traditional,O
MRI,O
.,O
For,O
example,O
",",O
progressive,O
decreased,O
fractional,O
anisotropy,O
(,O
FA,O
),O
values,O
in,O
the,O
pyramidal,O
tract,O
",",O
proximal,O
and,O
distal,O
to,O
a,O
subcortical,O
cerebral,B-DS
infarct,I-DS
or,O
pontine,O
infarct,O
over,O
1,O
to,O
12,O
weeks,O
",",O
were,O
found,O
;,O
this,O
means,O
important,O
loss,O
of,O
structural,O
components,O
in,O
the,O
pyramidal,O
tract,O
above,O
and,O
below,O
the,O
primary,O
infarcts,O
[,O
11,O
"],[",O
12,O
].,O
In,O
patients,O
with,O
ischemic,O
leukoaraiosis,O
(,O
ILA,O
"),",O
increased,O
mean,O
diffusivity,O
(,O
MD,O
),O
and,O
decreased,O
FA,O
were,O
observed,O
in,O
the,O
frontal,O
and,O
occipital,O
white,O
matter,O
which,O
illustrated,O
axonal,O
loss,O
in,O
the,O
regions,O
[,O
6,O
].,O
These,O
studies,O
suggest,O
potential,O
secondary,O
damage,O
in,O
white,O
matter,O
might,O
be,O
observed,O
by,O
DTI,O
after,O
corona,B-DS
radiata,I-DS
infarction,I-DS
.,O
In,O
this,O
study,O
we,O
tested,O
the,O
hypothesis,O
that,O
there,O
is,O
axonal,O
loss,O
in,O
the,O
left,O
-,O
sided,O
frontal,O
white,O
matter,O
in,O
patients,O
following,O
acute,O
ipsilateral,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
as,O
revealed,O
by,O
DTI,O
.,O
We,O
also,O
examined,O
correlations,O
of,O
the,O
DTI,O
parameters,O
with,O
executive,O
function,O
in,O
these,O
patients,O
.,O
Methods,O
Participants,O
The,O
research,O
protocol,O
was,O
approved,O
by,O
the,O
Medical,O
Ethical,O
Committee,O
of,O
the,O
First,O
Affiliated,O
Hospital,O
",",O
Sun,O
Yat,O
-,O
Sen,O
University,O
",",O
and,O
informed,O
consent,O
was,O
obtained,O
from,O
all,O
participants,O
.,O
We,O
selected,O
12,O
consecutive,O
patients,O
(,O
7,O
male,O
",",O
5,O
female,O
),O
between,O
October,O
2008,O
and,O
May,O
2013,O
in,O
the,O
Department,O
of,O
Neurology,O
and,O
Stroke,B-DS
Center,O
",",O
the,O
First,O
Affiliated,O
Hospital,O
",",O
Sun,O
Yat,O
-,O
Sen,O
University,O
",",O
within,O
7,O
days,O
of,O
a,O
focal,O
infarct,O
in,O
the,O
left,O
posterior,O
corona,O
radiata,O
",",O
without,O
any,O
other,O
signal,O
abnormalities,O
on,O
T1,O
-,O
weighted,O
fluid,O
attenuated,O
inversion,O
recovery,O
(,O
T1,O
-,O
FLAIR,O
),O
and,O
T2,O
-,O
weighted,O
images,O
.,O
Patients,O
with,O
ILA,O
",",O
significant,O
cerebral,B-DS
atrophy,I-DS
",",O
unstable,O
vital,O
signs,O
or,O
a,O
history,O
of,O
central,B-DS
nervous,I-DS
system,I-DS
disorders,I-DS
were,O
excluded,O
.,O
Demographic,O
characteristics,O
and,O
vascular,O
risk,O
factors,O
were,O
recorded,O
in,O
each,O
patient,O
.,O
All,O
patients,O
were,O
investigated,O
with,O
conventional,O
MRI,O
",",O
DTI,O
and,O
executive,O
functional,O
assessments,O
at,O
1,O
week,O
(,O
6,O
.,O
3,O
±,O
1,O
.,O
1,O
days,O
",",O
W1,O
"),",O
4,O
weeks,O
(,O
30,O
.,O
1,O
±,O
2,O
.,O
8,O
days,O
",",O
W4,O
"),",O
and,O
12,O
weeks,O
(,O
92,O
.,O
8,O
±,O
5,O
.,O
8,O
days,O
",",O
W12,O
),O
following,O
a,O
pre,O
-,O
defined,O
protocol,O
.,O
Infarct,O
volume,O
was,O
estimated,O
from,O
the,O
T2,O
-,O
weighted,O
FLAIR,O
images,O
at,O
W12,O
.,O
For,O
every,O
patient,O
",",O
we,O
looked,O
for,O
a,O
control,O
of,O
the,O
similar,O
age,O
(±,O
3,O
years,O
),O
and,O
educational,O
history,O
(±,O
2,O
years,O
),O
with,O
no,O
current,O
or,O
previous,O
neurological,O
or,O
psychiatric,B-DS
disease,I-DS
.,O
Twelve,O
controls,O
were,O
recruited,O
over,O
the,O
same,O
period,O
and,O
examined,O
once,O
by,O
DTI,O
and,O
an,O
executive,O
functional,O
assessment,O
.,O
MRI,O
protocol,O
MRIs,O
were,O
performed,O
using,O
a,O
1,O
.,O
5,O
-,O
tesla,O
MRI,O
system,O
(,O
Signa,O
General,O
Electric,O
Medical,O
Systems,O
",",O
Milwaukee,O
",",O
WI,O
",",O
USA,O
),O
equipped,O
with,O
gradient,O
hardware,O
allowing,O
up,O
to,O
23,O
mT,O
/,O
m,O
.,O
T1,O
-,O
FLAIR,O
",",O
fast,O
spin,O
echo,O
T2,O
-,O
weighted,O
imaging,O
",",O
traditional,O
FLAIR,O
and,O
DTI,O
were,O
performed,O
.,O
Typical,O
acquisition,O
parameters,O
of,O
conventional,O
MRI,O
were,O
:,O
T1,O
-,O
FLAIR,O
(,O
6,O
mm,O
thick,O
",",O
2,O
mm,O
gap,O
",",O
TR,O
1,O
",",O
475,O
ms,O
/,O
TE,O
21,O
.,O
3,O
ms,O
/,O
TI,O
750,O
.,O
0,O
ms,O
"),",O
T2,O
-,O
FLAIR,O
(,O
3,O
mm,O
thick,O
",",O
0,O
mm,O
gap,O
",",O
TR,O
8,O
",",O
000,O
ms,O
/,O
TE,O
120,O
.,O
0,O
ms,O
/,O
TI,O
2,O
",",O
200,O
ms,O
).,O
DTI,O
was,O
obtained,O
with,O
an,O
echo,O
planar,O
imaging,O
(,O
EPI,O
),O
sequence,O
(,O
3,O
mm,O
thick,O
",",O
0,O
mm,O
gap,O
",",O
TR,O
10,O
",",O
000,O
/,O
TE,O
100,O
ms,O
",",O
NEX,O
=,O
1,O
",",O
matrix,O
128,O
×,O
128,O
",",O
field,O
of,O
view,O
24,O
×,O
24,O
cm,O
).,O
DTI,O
was,O
acquired,O
with,O
a,O
b,O
factor,O
of,O
1,O
",",O
000,O
s,O
/,O
mm2,O
and,O
diffusion,O
-,O
sensitive,O
gradients,O
were,O
applied,O
along,O
15,O
gradient,O
directions,O
.,O
In,O
addition,O
",",O
a,O
reference,O
image,O
without,O
diffusion,O
weighting,O
(,O
b,O
=,O
0,O
s,O
/,O
mm2,O
),O
was,O
acquired,O
.,O
Fifteen,O
repeats,O
were,O
acquired,O
and,O
averaged,O
to,O
improve,O
signal,O
to,O
noise,O
ratio,O
.,O
The,O
scanning,O
baseline,O
was,O
parallel,O
to,O
the,O
antero,O
-,O
posterior,O
commissural,O
(,O
AC,O
-,O
PC,O
),O
line,O
.,O
Axial,O
slices,O
were,O
obtained,O
using,O
a,O
fast,O
spin,O
echo,O
T2,O
(,O
3,O
mm,O
thick,O
",",O
0,O
mm,O
gap,O
",",O
TR,O
5,O
",",O
660,O
ms,O
/,O
TE,O
107,O
.,O
7,O
ms,O
).,O
Image,O
post,O
-,O
processing,O
An,O
experienced,O
radiographer,O
carried,O
out,O
image,O
post,O
-,O
processing,O
without,O
knowing,O
the,O
purpose,O
of,O
the,O
study,O
.,O
The,O
DTI,O
data,O
were,O
transferred,O
to,O
a,O
workstation,O
and,O
spatially,O
filtered,O
using,O
a,O
median,O
3,O
×,O
3,O
filter,O
.,O
Acquiring,O
the,O
DTI,O
data,O
with,O
the,O
dual,O
-,O
echo,O
EPI,O
sequence,O
and,O
ramp,O
sampling,O
considerably,O
reduced,O
",",O
but,O
did,O
not,O
eliminate,O
",",O
the,O
geometric,O
distortions,O
.,O
We,O
corrected,O
the,O
residual,O
distortions,O
by,O
registering,O
the,O
diffusion,O
-,O
weighted,O
imaging,O
with,O
the,O
reference,O
image,O
using,O
the,O
two,O
-,O
dimensional,O
module,O
of,O
the,O
automated,O
image,O
registration,O
package,O
(,O
eight,O
-,O
parameter,O
with,O
perspective,O
),O
[,O
13,O
].,O
With,O
this,O
correction,O
",",O
the,O
DTI,O
parameters,O
were,O
calculated,O
on,O
a,O
pixel,O
-,O
by,O
-,O
pixel,O
basis,O
.,O
Using,O
ADW4,O
.,O
2,O
Software,O
(,O
Signa,O
General,O
Electric,O
Medical,O
Systems,O
",",O
Milwaukee,O
",",O
WI,O
",",O
USA,O
"),",O
regions,O
of,O
interest,O
(,O
ROIs,O
),O
were,O
manually,O
delineated,O
in,O
the,O
left,O
and,O
right,O
frontal,O
white,O
matter,O
(,O
an,O
area,O
of,O
150,O
mm2,O
),O
defined,O
as,O
quasi,O
-,O
circular,O
",",O
the,O
white,O
matter,O
around,O
the,O
posterior,O
horn,O
(,O
an,O
area,O
of,O
224,O
mm2,O
),O
defined,O
as,O
quasi,O
-,O
circular,O
",",O
the,O
centrum,O
semiovale,O
defined,O
as,O
ellipse,O
(,O
an,O
area,O
of,O
780,O
mm2,O
),O
on,O
a,O
slice,O
from,O
the,O
FLAIR,O
images,O
and,O
then,O
transferred,O
to,O
the,O
DTI,O
image,O
on,O
the,O
same,O
slice,O
(,O
Figure,O
1,O
).,O
The,O
thalami,O
were,O
also,O
observed,O
at,O
the,O
same,O
times,O
.,O
According,O
to,O
the,O
methods,O
used,O
by,O
Hervé,O
et,O
al,O
".,",O
the,O
medial,O
boundaries,O
of,O
the,O
thalami,O
were,O
verified,O
by,O
the,O
limits,O
of,O
cerebrospinal,O
fluid,O
-,O
containing,O
ventricle,O
on,O
T2,O
-,O
FLAIR,O
",",O
and,O
the,O
lateral,O
limits,O
were,O
defined,O
by,O
the,O
internal,O
capsule,O
on,O
FA,O
maps,O
[,O
14,O
].,O
DTI,O
maps,O
were,O
calculated,O
at,O
W1,O
and,O
on,O
follow,O
-,O
up,O
scans,O
.,O
The,O
quantitative,O
MD,O
(,O
derived,O
from,O
the,O
trace,O
of,O
the,O
diffusion,O
tensor,O
",",O
MD,O
=,O
trace,O
(,O
D,O
)/,O
3,O
),O
and,O
FA,O
data,O
in,O
frontal,O
white,O
matter,O
obtained,O
at,O
different,O
time,O
points,O
were,O
analyzed,O
.,O
Ischemic,O
lesion,O
and,O
regions,O
of,O
interest,O
(,O
ROIs,O
),O
are,O
shown,O
in,O
the,O
traditional,O
magnetic,O
resonance,O
and,O
diffusion,O
tensor,O
magnetic,O
resonance,O
images,O
from,O
a,O
patient,O
with,O
acute,B-DS
infarction,I-DS
at,O
the,O
left,O
posterior,O
corona,O
radiata,O
.,O
(,O
A,O
),O
T1,O
-,O
FLAIR,O
obtained,O
at,O
week,O
1,O
(,O
W1,O
),O
after,O
stroke,B-DS
show,O
a,O
hypointense,O
area,O
at,O
the,O
left,O
posterior,O
corona,O
radiata,O
.,O
(,O
B,O
),O
T2,O
-,O
weighted,O
image,O
and,O
(,O
C,O
),O
T2,O
-,O
FLAIR,O
images,O
obtained,O
at,O
W1,O
show,O
a,O
hyperintense,O
area,O
at,O
the,O
left,O
posterior,O
corona,O
radiata,O
.,O
(,O
D,O
"),",O
(,O
E,O
),O
and,O
(,O
F,O
),O
show,O
the,O
lesion,O
at,O
W12,O
.,O
(,O
G,O
"),",O
(,O
I,O
),O
and,O
(,O
K,O
),O
mean,O
diffusivity,O
images,O
and,O
(,O
H,O
"),",O
(,O
J,O
),O
and,O
(,O
L,O
),O
fractional,O
anisotropy,O
images,O
show,O
ROIs,O
in,O
the,O
left,O
and,O
right,O
frontal,O
white,O
matter,O
",",O
posterior,O
periventricular,O
white,O
matter,O
and,O
centrum,O
semiovale,O
.,O
Color,O
duplex,O
sonography,O
and,O
transcranial,O
duplex,O
scanning,O
(,O
TCD,O
),O
The,O
examinations,O
with,O
Color,O
duplex,O
sonography,O
of,O
the,O
extracranial,O
carotid,O
arteries,O
were,O
performed,O
with,O
the,O
patients,O
at,O
W1,O
and,O
W12,O
and,O
controls,O
at,O
recruitment,O
.,O
All,O
measurements,O
were,O
performed,O
by,O
the,O
angiologist,O
who,O
was,O
blinded,O
for,O
the,O
clinical,O
status,O
of,O
the,O
study,O
patients,O
and,O
controls,O
.,O
The,O
internal,O
carotid,O
artery,O
(,O
ICA,O
),O
was,O
explored,O
using,O
a,O
10,O
-,O
MHz,O
linear,O
-,O
array,O
transducer,O
(,O
GE,O
LOGIQ5,O
ultrasound,O
system,O
",",O
Milwaukee,O
",",O
WI,O
",",O
USA,O
).,O
The,O
subjects,O
were,O
in,O
the,O
supine,O
position,O
with,O
their,O
heads,O
slightly,O
elevated,O
and,O
turned,O
25,O
°,O
to,O
40,O
°,O
to,O
the,O
contralateral,O
side,O
for,O
the,O
ICA,O
measurements,O
.,O
Peak,O
systolic,O
velocity,O
(,O
PSV,O
),O
and,O
end,O
diastolic,O
velocity,O
(,O
EDV,O
),O
were,O
measured,O
1,O
to,O
2,O
cm,O
above,O
the,O
carotid,O
bulb,O
in,O
the,O
ICAs,O
.,O
Intima,O
-,O
media,O
thickness,O
(,O
IMT,O
),O
and,O
luminal,O
diameter,O
(,O
DIA,O
),O
of,O
the,O
ICAs,O
were,O
measured,O
on,O
magnified,O
B,O
-,O
mode,O
.,O
The,O
distance,O
between,O
the,O
leading,O
edge,O
of,O
the,O
luminal,O
echo,O
and,O
the,O
leading,O
edge,O
of,O
the,O
media,O
/,O
adventitia,O
echo,O
was,O
measured,O
as,O
the,O
IMT,O
.,O
The,O
patients,O
underwent,O
TCD,O
scanning,O
at,O
W1,O
and,O
W12,O
and,O
controls,O
were,O
scanned,O
at,O
recruitment,O
.,O
Bilateral,O
mean,O
flow,O
velocity,O
was,O
continuously,O
and,O
simultaneously,O
monitored,O
by,O
a,O
2,O
-,O
MHz,O
phased,O
array,O
transducer,O
(,O
Philips,O
SONOS,O
5500,O
",",O
Eindhoven,O
",",O
the,O
Netherlands,O
),O
by,O
the,O
angiologist,O
who,O
was,O
not,O
familiar,O
with,O
the,O
clinical,O
status,O
of,O
the,O
study,O
patients,O
and,O
controls,O
.,O
The,O
highest,O
signal,O
was,O
sought,O
at,O
a,O
depth,O
ranging,O
(,O
anterior,O
cerebral,O
artery,O
:,O
61,O
to,O
75,O
mm,O
;,O
middle,O
cerebral,O
artery,O
:,O
46,O
to,O
55,O
mm,O
",",O
posterior,O
cerebral,O
artery,O
:,O
56,O
to,O
70,O
mm,O
),O
through,O
the,O
temporal,O
bone,O
window,O
.,O
Mean,O
flow,O
velocity,O
was,O
calculated,O
and,O
recorded,O
automatically,O
when,O
the,O
‘,O
record,O
’,O
function,O
of,O
the,O
Doppler,O
instrument,O
was,O
activated,O
.,O
Assessment,O
of,O
executive,B-DS
dysfunction,I-DS
A,O
‘,O
brief,O
executive,O
assessment,O
’,O
was,O
also,O
conducted,O
which,O
include,O
four,O
tests,O
often,O
used,O
clinically,O
:,O
the,O
Trail,O
making,O
B,O
-,O
A,O
test,O
",",O
the,O
Verbal,O
fluency,O
assessment,O
",",O
the,O
Digit,O
span,O
backwards,O
test,O
and,O
the,O
Digit,O
symbol,O
test,O
.,O
This,O
has,O
been,O
considered,O
to,O
be,O
a,O
sensitive,O
tool,O
for,O
detecting,O
deficits,O
in,O
patients,O
and,O
distinguishing,O
these,O
deficits,O
from,O
the,O
cognitive,O
effects,O
of,O
healthy,O
aging,O
[,O
6,O
"],[",O
15,O
].,O
Because,O
elderly,O
Chinese,O
patients,O
are,O
unfamiliar,O
with,O
the,O
English,O
language,O
",",O
the,O
Trail,O
making,O
B,O
-,O
A,O
test,O
(,O
Chinese,O
version,O
),O
and,O
Verbal,O
fluency,O
test,O
(,O
Chinese,O
version,O
),O
were,O
applied,O
[,O
6,O
"],[",O
16,O
"],[",O
17,O
].,O
The,O
Mini,O
-,O
Mental,O
State,O
Examination,O
(,O
MMSE,O
),O
was,O
also,O
applied,O
because,O
it,O
is,O
often,O
used,O
clinically,O
as,O
a,O
standard,O
measure,O
of,O
dementia,B-DS
severity,O
.,O
Statistical,O
analysis,O
MD,O
and,O
FA,O
values,O
obtained,O
at,O
W1,O
",",O
W4,O
",",O
and,O
W12,O
in,O
patients,O
were,O
first,O
compared,O
with,O
those,O
of,O
controls,O
with,O
a,O
two,O
-,O
tailed,O
Student,O
’,O
s,O
t,O
-,O
test,O
.,O
Executive,O
assessments,O
were,O
compared,O
between,O
the,O
patient,O
and,O
the,O
control,O
groups,O
using,O
a,O
Student,O
’,O
s,O
t,O
-,O
test,O
.,O
These,O
parameters,O
and,O
clinical,O
scores,O
then,O
were,O
analyzed,O
using,O
Fisher,O
’,O
s,O
Least,O
Significant,O
Difference,O
(,O
LSD,O
),O
test,O
for,O
multiple,O
testing,O
.,O
The,O
Color,O
duplex,O
sonography,O
and,O
TCD,O
parameters,O
obtained,O
at,O
W1,O
and,O
W12,O
were,O
compared,O
with,O
a,O
two,O
-,O
tailed,O
Student,O
’,O
s,O
t,O
-,O
test,O
.,O
Spearman,O
rank,O
correlation,O
analysis,O
was,O
used,O
to,O
determine,O
associations,O
between,O
changes,O
in,O
brief,O
executive,O
assessment,O
scores,O
and,O
the,O
DTI,O
parameter,O
changes,O
in,O
left,O
frontal,O
white,O
matter,O
and,O
thalamus,O
.,O
The,O
changes,O
in,O
executive,O
function,O
scores,O
over,O
time,O
and,O
the,O
DTI,O
parameter,O
changes,O
were,O
defined,O
as,O
follows,O
:,O
ΔExecutive,O
scores,O
or,O
DTI,O
Parameter,O
values,O
=,O
Value,O
measured,O
at,O
W12,O
−,O
value,O
measured,O
at,O
W1,O
Results,O
Participants,O
Twelve,O
patients,O
(,O
seven,O
male,O
and,O
five,O
female,O
),O
and,O
twelve,O
controls,O
(,O
seven,O
male,O
and,O
five,O
female,O
),O
were,O
recruited,O
in,O
the,O
study,O
.,O
All,O
patients,O
and,O
controls,O
were,O
right,O
-,O
handed,O
.,O
Each,O
patient,O
had,O
one,O
or,O
more,O
vascular,O
risk,O
factor,O
(,O
Table,O
1,O
).,O
Patient,O
demographics,O
and,O
clinical,O
data,O
Number,O
Age,O
(,O
years,O
),O
Gender,O
Educational,O
history,O
(,O
years,O
),O
Vascular,O
factors,O
Volume,O
of,O
lesion,O
(,O
mm3,O
),O
1,O
59,O
M,O
8,O
Hypertension,B-DS
11,O
",",O
160,O
2,O
67,O
F,O
6,O
Hypertension,B-DS
",",O
hypercholesterolemia,B-DS
",",O
diabetes,B-DS
mellitus,I-DS
14,O
",",O
000,O
3,O
66,O
M,O
18,O
Hypertension,B-DS
",",O
tobacco,O
use,O
",",O
overweight,O
13,O
",",O
300,O
4,O
57,O
F,O
7,O
Hypertension,B-DS
",",O
diabetes,B-DS
mellitus,I-DS
9,O
",",O
690,O
5,O
66,O
M,O
8,O
Hypertension,B-DS
",",O
diabetes,B-DS
mellitus,I-DS
6,O
",",O
790,O
6,O
65,O
M,O
6,O
Tobacco,O
use,O
8,O
",",O
450,O
7,O
46,O
F,O
11,O
Hypercholesterolemia,B-DS
7,O
",",O
370,O
8,O
69,O
F,O
6,O
Hypertension,B-DS
10,O
",",O
810,O
9,O
63,O
M,O
8,O
Hypertension,B-DS
",",O
tobacco,O
use,O
16,O
",",O
200,O
10,O
48,O
F,O
8,O
Hypertension,B-DS
9,O
",",O
660,O
11,O
65,O
M,O
12,O
Hypertension,B-DS
",",O
diabetes,B-DS
mellitus,I-DS
",",O
tobacco,O
use,O
",",O
overweight,O
12,O
",",O
150,O
12,O
50,O
M,O
5,O
Hypertension,B-DS
",",O
diabetes,B-DS
mellitus,I-DS
8,O
",",O
810,O
F,O
:,O
female,O
;,O
M,O
:,O
male,O
;,O
FLAIR,O
:,O
fluid,O
attenuated,O
inversion,O
recovery,O
.,O
The,O
volume,O
of,O
the,O
infarcted,O
lesion,O
was,O
calculated,O
on,O
T2,O
-,O
FLAIR,O
images,O
at,O
week,O
12,O
(,O
W12,O
).,O
Controls,O
were,O
matched,O
for,O
age,O
and,O
educational,O
history,O
.,O
MRI,O
data,O
Participants,O
completed,O
all,O
traditional,O
MRI,O
and,O
DTI,O
examinations,O
.,O
Within,O
the,O
first,O
week,O
from,O
stroke,B-DS
onset,O
",",O
T2,O
-,O
weighted,O
and,O
T2,O
-,O
FLAIR,O
images,O
showed,O
focal,O
hyperintensity,O
confined,O
to,O
the,O
left,O
-,O
sided,O
posterior,O
corona,O
radiata,O
in,O
each,O
patient,O
(,O
Figure,O
1B,O
and,O
C,O
"),",O
and,O
there,O
was,O
no,O
abnormal,O
signal,O
in,O
other,O
regions,O
.,O
At,O
W12,O
",",O
no,O
signal,O
abnormality,O
was,O
detected,O
on,O
T1,O
",",O
T2,O
-,O
weighted,O
",",O
and,O
T2,O
-,O
FLAIR,O
images,O
outside,O
the,O
territory,O
of,O
the,O
left,O
posterior,O
corona,O
radiata,O
(,O
Figure,O
1D,O
",",O
E,O
and,O
F,O
).,O
The,O
infarct,O
volume,O
varied,O
from,O
6,O
",",O
790,O
to,O
16,O
",",O
200,O
mm3,O
(,O
10,O
",",O
699,O
±,O
2,O
",",O
818,O
mm3,O
),O
on,O
T2,O
images,O
at,O
W12,O
.,O
No,O
definite,O
abnormal,O
signals,O
were,O
observed,O
in,O
controls,O
.,O
In,O
controls,O
",",O
in,O
the,O
absence,O
of,O
any,O
significant,O
difference,O
between,O
the,O
left,O
and,O
right,O
regions,O
for,O
MD,O
(,O
mean,O
values,O
:,O
frontal,O
white,O
matter,O
0,O
.,O
804,O
±,O
0,O
.,O
109,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
and,O
0,O
.,O
809,O
±,O
0,O
.,O
108,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
;,O
posterior,O
periventricular,O
white,O
matter,O
0,O
.,O
824,O
±,O
0,O
.,O
099,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
and,O
0,O
.,O
816,O
±,O
0,O
.,O
088,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
;,O
centrum,O
semiovale,O
0,O
.,O
764,O
±,O
0,O
.,O
093,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
and,O
0,O
.,O
771,O
±,O
0,O
.,O
095,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
;,O
thalamus,O
0,O
.,O
836,O
±,O
0,O
.,O
069,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
and,O
0,O
.,O
840,O
±,O
0,O
.,O
075,O
×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
",",O
respectively,O
",",O
all,O
P,O
>,O
0,O
.,O
05,O
),O
and,O
FA,O
(,O
mean,O
values,O
:,O
frontal,O
white,O
matter,O
0,O
.,O
421,O
±,O
0,O
.,O
057,O
and,O
0,O
.,O
433,O
±,O
0,O
.,O
102,O
;,O
posterior,O
periventricular,O
white,O
matter,O
0,O
.,O
451,O
±,O
0,O
.,O
057,O
and,O
0,O
.,O
449,O
±,O
0,O
.,O
056,O
;,O
centrum,O
semiovale,O
0,O
.,O
392,O
±,O
0,O
.,O
063,O
and,O
0,O
.,O
397,O
±,O
0,O
.,O
065,O
;,O
thalamus,O
0,O
.,O
345,O
±,O
0,O
.,O
051,O
and,O
0,O
.,O
343,O
±,O
0,O
.,O
049,O
",",O
respectively,O
",",O
all,O
P,O
>,O
0,O
.,O
05,O
"),",O
the,O
data,O
obtained,O
in,O
the,O
left,O
regions,O
in,O
controls,O
were,O
selected,O
to,O
compare,O
those,O
values,O
in,O
patients,O
.,O
MD,O
and,O
FA,O
values,O
at,O
W1,O
in,O
the,O
left,O
and,O
right,O
regions,O
(,O
frontal,O
white,O
matter,O
",",O
posterior,O
periventricular,O
white,O
matter,O
",",O
centrum,O
semiovale,O
and,O
thalamus,O
),O
were,O
not,O
significantly,O
different,O
compared,O
with,O
those,O
of,O
controls,O
(,O
P,O
>,O
0,O
.,O
05,O
).,O
There,O
was,O
a,O
significant,O
increase,O
of,O
MD,O
and,O
decrease,O
of,O
FA,O
in,O
the,O
left,O
frontal,O
white,O
matter,O
from,O
W1,O
to,O
W12,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
No,O
obvious,O
MD,O
or,O
FA,O
value,O
changes,O
were,O
found,O
in,O
the,O
right,O
frontal,O
white,O
matter,O
(,O
P,O
>,O
0,O
.,O
05,O
).,O
There,O
were,O
no,O
significant,O
differences,O
of,O
MD,O
and,O
FA,O
in,O
the,O
left,O
and,O
right,O
posterior,O
periventricular,O
white,O
matter,O
and,O
centrum,O
semiovale,O
from,O
W1,O
to,O
W12,O
(,O
P,O
>,O
0,O
.,O
05,O
).,O
In,O
the,O
thalamus,O
",",O
a,O
significant,O
increase,O
of,O
MD,O
in,O
the,O
left,O
thalamus,O
was,O
found,O
between,O
W1,O
and,O
W12,O
(,O
P,O
<,O
0,O
.,O
05,O
"),",O
and,O
no,O
obvious,O
MD,O
value,O
changes,O
were,O
found,O
in,O
right,O
thalamus,O
(,O
P,O
>,O
0,O
.,O
05,O
).,O
There,O
was,O
no,O
significant,O
difference,O
of,O
the,O
FA,O
values,O
in,O
left,O
and,O
right,O
thalami,O
between,O
W1,O
and,O
W12,O
.,O
No,O
significant,O
differences,O
of,O
MD,O
and,O
FA,O
in,O
the,O
posterior,O
periventricular,O
white,O
matter,O
or,O
centrum,O
semiovale,O
were,O
detected,O
from,O
W1,O
to,O
W12,O
(,O
P,O
>,O
0,O
.,O
05,O
),O
(,O
Table,O
2,O
).,O
Magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
parameter,O
values,O
in,O
frontal,O
white,O
matter,O
",",O
posterior,O
periventricular,O
white,O
matter,O
",",O
centrum,O
semiovale,O
and,O
thalamus,O
in,O
patients,O
and,O
controls,O
(,O
mean,O
±,O
SD,O
),O
Region,O
MD,O
(×,O
10,O
−,O
3,O
mm2,O
/,O
s,O
),O
FA,O
W1,O
W4,O
W12,O
W1,O
W4,O
W12,O
Patients,O
LFWM,O
0,O
.,O
824,O
±,O
0,O
.,O
095a,O
0,O
.,O
815,O
±,O
0,O
.,O
080,O
0,O
.,O
904,O
±,O
0,O
.,O
107bc,O
0,O
.,O
388,O
±,O
0,O
.,O
056a,O
0,O
.,O
374,O
±,O
0,O
.,O
062,O
0,O
.,O
313,O
±,O
0,O
.,O
054bc,O
RFWM,O
0,O
.,O
825,O
±,O
0,O
.,O
089,O
0,O
.,O
821,O
±,O
0,O
.,O
088,O
0,O
.,O
831,O
±,O
0,O
.,O
084,O
0,O
.,O
387,O
±,O
0,O
.,O
062,O
0,O
.,O
385,O
±,O
0,O
.,O
063,O
0,O
.,O
395,O
±,O
0,O
.,O
063,O
LPPWM,O
0,O
.,O
837,O
±,O
0,O
.,O
102,O
0,O
.,O
836,O
±,O
0,O
.,O
096,O
0,O
.,O
839,O
±,O
0,O
.,O
087,O
0,O
.,O
452,O
±,O
0,O
.,O
062,O
0,O
.,O
447,O
±,O
0,O
.,O
061,O
0,O
.,O
431,O
±,O
0,O
.,O
063,O
RPPWM,O
0,O
.,O
853,O
±,O
0,O
.,O
114,O
0,O
.,O
835,O
±,O
0,O
.,O
094,O
0,O
.,O
822,O
±,O
0,O
.,O
085,O
0,O
.,O
444,O
±,O
0,O
.,O
053,O
0,O
.,O
451,O
±,O
0,O
.,O
059,O
0,O
.,O
447,O
±,O
0,O
.,O
053,O
LCS,O
0,O
.,O
766,O
±,O
0,O
.,O
112,O
0,O
.,O
754,O
±,O
0,O
.,O
087,O
0,O
.,O
729,O
±,O
0,O
.,O
104,O
0,O
.,O
387,O
±,O
0,O
.,O
058,O
0,O
.,O
381,O
±,O
0,O
.,O
060,O
0,O
.,O
362,O
±,O
0,O
.,O
055,O
RCS,O
0,O
.,O
772,O
±,O
0,O
.,O
110,O
0,O
.,O
765,O
±,O
0,O
.,O
098,O
0,O
.,O
783,O
±,O
0,O
.,O
105,O
0,O
.,O
383,O
±,O
0,O
.,O
059,O
0,O
.,O
391,O
±,O
0,O
.,O
062,O
0,O
.,O
393,O
±,O
0,O
.,O
064,O
L,O
thalamus,O
0,O
.,O
846,O
±,O
0,O
.,O
080a,O
0,O
.,O
830,O
±,O
0,O
.,O
097,O
0,O
.,O
949,O
±,O
0,O
.,O
065bc,O
0,O
.,O
338,O
±,O
0,O
.,O
038,O
0,O
.,O
334,O
±,O
0,O
.,O
037,O
0,O
.,O
323,O
±,O
0,O
.,O
032,O
R,O
thalamus,O
0,O
.,O
839,O
±,O
0,O
.,O
788,O
0,O
.,O
840,O
±,O
0,O
.,O
081,O
0,O
.,O
841,O
±,O
0,O
.,O
083,O
0,O
.,O
344,O
±,O
0,O
.,O
042,O
0,O
.,O
344,O
±,O
0,O
.,O
043,O
0,O
.,O
342,O
±,O
0,O
.,O
040,O
Controls,O
LFWM,O
0,O
.,O
804,O
±,O
0,O
.,O
109,O
0,O
.,O
421,O
±,O
0,O
.,O
057,O
LPPWM,O
0,O
.,O
824,O
±,O
0,O
.,O
099,O
0,O
.,O
451,O
±,O
0,O
.,O
057,O
LCS,O
0,O
.,O
764,O
±,O
0,O
.,O
093,O
0,O
.,O
392,O
±,O
0,O
.,O
063,O
L,O
thalamus,O
0,O
.,O
836,O
±,O
0,O
.,O
069,O
0,O
.,O
345,O
±,O
0,O
.,O
051,O
Abbreviations,O
:,O
FA,O
",",O
fractional,O
anisotropy,O
;,O
LCS,O
",",O
left,O
centrum,O
semiovale,O
;,O
LFWM,O
",",O
left,O
frontal,O
white,O
matter,O
;,O
LPPWM,O
",",O
left,O
posterior,O
periventricular,O
white,O
matter,O
;,O
LCS,O
",",O
left,O
centrum,O
semiovale,O
;,O
L,O
thalamus,O
",",O
left,O
thalamus,O
;,O
MD,O
",",O
mean,O
diffusivity,O
;,O
R,O
thalamus,O
",",O
right,O
thalamus,O
;,O
RCS,O
",",O
right,O
centrum,O
semiovale,O
;,O
RFWM,O
",",O
right,O
frontal,O
white,O
matter,O
;,O
RPPWM,O
",",O
right,O
posterior,O
periventricular,O
white,O
matter,O
;,O
W1,O
",",O
the,O
first,O
week,O
;,O
W4,O
",",O
the,O
fourth,O
week,O
;,O
W12,O
",",O
the,O
12th,O
week,O
.,O
aP,O
<,O
0,O
.,O
05,O
",",O
LSD,O
test,O
",",O
comparison,O
between,O
W1,O
and,O
W12,O
;,O
bP,O
<,O
0,O
.,O
05,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
comparison,O
between,O
the,O
control,O
and,O
patient,O
groups,O
;,O
cP,O
<,O
0,O
.,O
05,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
comparison,O
in,O
the,O
left,O
and,O
right,O
region,O
of,O
patients,O
at,O
W12,O
.,O
The,O
controls,O
were,O
examined,O
only,O
once,O
when,O
they,O
were,O
recruited,O
.,O
Color,O
duplex,O
sonography,O
and,O
TCD,O
data,O
The,O
Color,O
duplex,O
examination,O
of,O
luminal,O
diameter,O
and,O
IMT,O
measurements,O
were,O
performed,O
in,O
all,O
the,O
ICAs,O
of,O
the,O
subjects,O
.,O
The,O
mean,O
values,O
of,O
all,O
data,O
were,O
given,O
in,O
Table,O
3,O
.,O
We,O
did,O
not,O
find,O
any,O
differences,O
of,O
IMT,O
",",O
DIA,O
",",O
PSV,O
and,O
EDV,O
detected,O
at,O
W1,O
and,O
W12,O
in,O
patients,O
(,O
all,O
P,O
>,O
0,O
.,O
05,O
).,O
Ultrasound,O
parameters,O
of,O
the,O
left,O
and,O
right,O
internal,O
carotid,O
artery,O
(,O
mean,O
±,O
SD,O
),O
Group,O
Left,O
IMT,O
(,O
mm,O
),O
Right,O
IMT,O
(,O
mm,O
),O
Left,O
DIA,O
(,O
mm,O
),O
Right,O
DIA,O
(,O
mm,O
),O
Left,O
SPV,O
(,O
cm,O
/,O
s,O
),O
Right,O
SPV,O
(,O
cm,O
/,O
s,O
),O
Left,O
EDV,O
(,O
cm,O
/,O
s,O
),O
Right,O
EDV,O
(,O
cm,O
/,O
s,O
),O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
Patients,O
1,O
.,O
21,O
±,O
0,O
.,O
13,O
1,O
.,O
22,O
±,O
0,O
.,O
14,O
1,O
.,O
18,O
±,O
0,O
.,O
09,O
1,O
.,O
18,O
±,O
0,O
.,O
10,O
4,O
.,O
86,O
±,O
0,O
.,O
63,O
4,O
.,O
84,O
±,O
0,O
.,O
61,O
4,O
.,O
97,O
±,O
0,O
.,O
55,O
5,O
.,O
02,O
±,O
0,O
.,O
58,O
61,O
±,O
9,O
.,O
8,O
65,O
±,O
11,O
.,O
1,O
58,O
±,O
8,O
.,O
7,O
60,O
±,O
9,O
.,O
4,O
24,O
.,O
3,O
±,O
3,O
.,O
8,O
24,O
.,O
5,O
±,O
3,O
.,O
7,O
23,O
.,O
9,O
±,O
3,O
.,O
7,O
24,O
.,O
1,O
±,O
3,O
.,O
8,O
Controls,O
1,O
.,O
02,O
±,O
0,O
.,O
19,O
1,O
.,O
04,O
±,O
0,O
.,O
22,O
5,O
.,O
20,O
±,O
0,O
.,O
68,O
5,O
.,O
37,O
±,O
0,O
.,O
73,O
52,O
±,O
8,O
.,O
5,O
53,O
±,O
8,O
.,O
3,O
23,O
.,O
5,O
±,O
5,O
.,O
6,O
24,O
.,O
0,O
±,O
6,O
.,O
1,O
Abbreviations,O
:,O
DIA,O
",",O
luminal,O
diameter,O
;,O
EDV,O
",",O
end,O
diastolic,O
velocity,O
;,O
IMT,O
",",O
intima,O
-,O
media,O
thickness,O
;,O
PSV,O
",",O
peak,O
systolic,O
velocity,O
;,O
W1,O
",",O
the,O
first,O
week,O
",",O
W12,O
",",O
the,O
12th,O
week,O
.,O
The,O
controls,O
were,O
examined,O
only,O
once,O
when,O
they,O
were,O
recruited,O
.,O
All,O
subjects,O
had,O
accessible,O
cranial,O
window,O
for,O
TCD,O
and,O
underwent,O
0,O
.,O
5,O
to,O
1,O
hour,O
of,O
TCD,O
monitoring,O
.,O
Mean,O
flow,O
velocity,O
values,O
(,O
MFV,O
),O
were,O
shown,O
in,O
Table,O
4,O
.,O
There,O
were,O
no,O
statistically,O
significant,O
differences,O
of,O
MFV,O
detected,O
in,O
anterior,O
cerebral,O
artery,O
(,O
ACA,O
"),",O
MCA,O
and,O
posterior,O
cerebral,O
artery,O
(,O
PCA,O
),O
at,O
W1,O
and,O
W12,O
in,O
patients,O
(,O
all,O
P,O
>,O
0,O
.,O
05,O
).,O
Values,O
of,O
the,O
mean,O
flow,O
velocity,O
(,O
cm,O
/,O
s,O
),O
in,O
the,O
left,O
and,O
right,O
anterior,O
cerebral,O
artery,O
(,O
ACA,O
"),",O
middle,O
cerebral,O
artery,O
(,O
MCA,O
),O
and,O
posterior,O
cerebral,O
artery,O
(,O
PCA,O
),O
(,O
mean,O
±,O
SD,O
),O
Group,O
Left,O
ACA,O
Right,O
ACA,O
Left,O
MCA,O
Right,O
MCA,O
Left,O
PCA,O
Right,O
PCA,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
W1,O
W12,O
Patients,O
55,O
.,O
17,O
±,O
9,O
.,O
53,O
53,O
.,O
85,O
±,O
9,O
.,O
94,O
49,O
.,O
74,O
±,O
9,O
.,O
13,O
50,O
.,O
65,O
±,O
8,O
.,O
06,O
58,O
.,O
94,O
±,O
15,O
.,O
42,O
60,O
.,O
07,O
±,O
11,O
.,O
26,O
63,O
.,O
12,O
±,O
13,O
.,O
63,O
63,O
.,O
26,O
±,O
12,O
.,O
65,O
38,O
.,O
8,O
±,O
10,O
.,O
76,O
37,O
.,O
21,O
±,O
8,O
.,O
10,O
38,O
.,O
17,O
±,O
12,O
.,O
40,O
38,O
.,O
99,O
±,O
13,O
.,O
02,O
Controls,O
46,O
.,O
62,O
±,O
7,O
.,O
05,O
47,O
.,O
81,O
±,O
8,O
.,O
89,O
64,O
.,O
95,O
±,O
9,O
.,O
35,O
62,O
.,O
88,O
±,O
5,O
.,O
40,O
37,O
.,O
20,O
±,O
5,O
.,O
65,O
36,O
.,O
97,O
±,O
6,O
.,O
13,O
Abbreviations,O
:,O
W1,O
",",O
the,O
first,O
week,O
;,O
W12,O
",",O
the,O
12th,O
week,O
.,O
The,O
controls,O
were,O
examined,O
only,O
once,O
when,O
they,O
were,O
recruited,O
.,O
Cognitive,B-DS
deficit,I-DS
There,O
were,O
no,O
significant,O
differences,O
in,O
MMSE,O
",",O
Verbal,O
fluency,O
assessment,O
and,O
Digit,O
span,O
backwards,O
test,O
between,O
patients,O
and,O
controls,O
at,O
W1,O
.,O
The,O
significant,O
difference,O
of,O
Trail,O
making,O
B,O
-,O
A,O
and,O
Digit,O
symbol,O
tests,O
were,O
found,O
between,O
patients,O
and,O
controls,O
at,O
W1,O
.,O
Mean,O
scores,O
on,O
the,O
Trail,O
making,O
B,O
-,O
A,O
test,O
",",O
Verbal,O
fluency,O
assessment,O
",",O
Digit,O
span,O
backwards,O
and,O
Digit,O
symbol,O
tests,O
for,O
patients,O
were,O
significantly,O
changed,O
between,O
W1,O
and,O
W12,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
There,O
was,O
statistical,O
difference,O
in,O
the,O
presence,O
of,O
Trail,O
making,O
B,O
-,O
A,O
",",O
Verbal,O
fluency,O
assessment,O
and,O
Digit,O
symbol,O
tests,O
between,O
patients,O
and,O
controls,O
at,O
W4,O
and,O
W12,O
",",O
and,O
Digit,O
span,O
backwards,O
test,O
at,O
W12,O
(,O
Table,O
5,O
).,O
Cognitive,O
functional,O
scores,O
of,O
patients,O
and,O
controls,O
(,O
mean,O
±,O
SD,O
),O
Patients,O
Controls,O
W1,O
W4,O
W12,O
MMSE,O
26,O
.,O
8,O
±,O
1,O
.,O
6,O
25,O
.,O
4,O
±,O
2,O
.,O
3,O
25,O
.,O
0,O
±,O
1,O
.,O
7,O
29,O
.,O
3,O
±,O
1,O
.,O
5,O
Trail,O
making,O
B,O
-,O
A,O
test,O
160,O
.,O
3,O
±,O
54,O
.,O
7ab,O
181,O
.,O
8,O
±,O
52,O
.,O
1b,O
224,O
.,O
1,O
±,O
55,O
.,O
1b,O
77,O
.,O
2,O
±,O
33,O
.,O
3,O
Verbal,O
fluency,O
assessment,O
40,O
.,O
8,O
±,O
10,O
.,O
3a,O
33,O
.,O
9,O
±,O
11,O
.,O
0b,O
26,O
.,O
9,O
±,O
11,O
.,O
0b,O
42,O
.,O
4,O
±,O
8,O
.,O
1,O
Digit,O
span,O
backwards,O
test,O
7,O
.,O
3,O
±,O
1,O
.,O
5a,O
6,O
.,O
3,O
±,O
1,O
.,O
4,O
5,O
.,O
7,O
±,O
1,O
.,O
3b,O
7,O
.,O
0,O
±,O
1,O
.,O
7,O
Digit,O
symbol,O
test,O
32,O
.,O
6,O
±,O
6,O
.,O
5ab,O
26,O
.,O
6,O
±,O
6,O
.,O
5b,O
22,O
.,O
3,O
±,O
4,O
.,O
9b,O
45,O
.,O
6,O
±,O
9,O
.,O
2,O
Abbreviations,O
:,O
MMSE,O
",",O
Mini,O
-,O
Mental,O
State,O
Examination,O
;,O
W1,O
",",O
within,O
the,O
first,O
week,O
;,O
W4,O
",",O
the,O
fourth,O
week,O
;,O
W12,O
",",O
the,O
12th,O
week,O
.,O
aP,O
<,O
0,O
.,O
05,O
",",O
LSD,O
test,O
",",O
comparison,O
between,O
W1,O
and,O
W12,O
in,O
patients,O
;,O
bP,O
<,O
0,O
.,O
05,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
comparison,O
between,O
the,O
control,O
and,O
patient,O
groups,O
.,O
Correlations,O
between,O
DTI,O
and,O
executive,O
function,O
in,O
patients,O
As,O
illustrated,O
in,O
Figure,O
2,O
",",O
the,O
Spearman,O
rank,O
correlational,O
analyses,O
showed,O
that,O
the,O
MD,O
and,O
FA,O
changes,O
in,O
the,O
left,O
frontal,O
white,O
matter,O
correlated,O
with,O
the,O
executive,O
function,O
changes,O
in,O
patients,O
.,O
There,O
were,O
only,O
weak,O
correlations,O
between,O
the,O
MD,O
changes,O
in,O
the,O
left,O
thalamus,O
and,O
Trail,O
making,O
B,O
-,O
A,O
test,O
(,O
Spearman,O
coefficient,O
of,O
rank,O
correlation,O
rs,O
=,O
0,O
.,O
488,O
",",O
P,O
=,O
0,O
.,O
098,O
),O
and,O
Digit,O
symbol,O
test,O
(,O
Spearman,O
coefficient,O
of,O
rank,O
correlation,O
rs,O
=,O
−,O
0,O
.,O
552,O
",",O
P,O
=,O
0,O
.,O
063,O
).,O
Scatter,O
plot,O
with,O
lines,O
of,O
best,O
fit,O
showing,O
the,O
relationship,O
between,O
the,O
change,O
values,O
of,O
diffusivity,O
(,O
mean,O
diffusivity,O
and,O
fractional,O
anisotropy,O
),O
in,O
the,O
left,O
frontal,O
white,O
matter,O
and,O
the,O
change,O
values,O
of,O
executive,O
function,O
(,O
trail,O
making,O
B,O
-,O
A,O
",",O
verbal,O
fluency,O
assessment,O
",",O
digit,O
span,O
backwards,O
and,O
digit,O
symbol,O
tests,O
),O
in,O
patients,O
from,O
W1,O
to,O
W12,O
.,O
A,O
-,O
H,O
show,O
the,O
relationship,O
between,O
Δmean,O
diffusivity,O
and,O
Δtrail,O
making,O
B,O
-,O
A,O
(,O
A,O
"),",O
Δverbal,O
fluency,O
(,O
B,O
"),",O
Δdigit,O
span,O
backwards,O
(,O
C,O
"),",O
Δdigit,O
symbol,O
(,O
D,O
"),",O
and,O
between,O
Δfractional,O
anisotropy,O
and,O
Δtrail,O
making,O
B,O
-,O
A,O
(,O
E,O
"),",O
Δverbal,O
fluency,O
(,O
F,O
"),",O
Δdigit,O
span,O
backwards,O
(,O
G,O
"),",O
Δdigit,O
symbol,O
(,O
H,O
).,O
Discussion,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
prospective,O
study,O
using,O
DTI,O
to,O
observe,O
secondary,O
changes,O
in,O
the,O
left,O
frontal,O
white,O
matter,O
remote,O
from,O
the,O
ipsilateral,O
posterior,O
corona,O
radiata,O
.,O
Previous,O
studies,O
have,O
shown,O
that,O
focal,O
cerebral,B-DS
infarcts,I-DS
can,O
lead,O
to,O
remote,O
tissue,O
alterations,O
within,O
connected,O
regions,O
related,O
to,O
Wallerian,O
degeneration,O
[,O
8,O
"],[",O
10,O
"],[",O
18,O
]–[,O
21,O
].,O
Because,O
computed,O
tomography,O
(,O
CT,O
),O
and,O
traditional,O
MRI,O
are,O
insufficiently,O
sensitive,O
and,O
difficult,O
to,O
quantify,O
the,O
microstructural,O
changes,O
",",O
DTI,O
was,O
used,O
in,O
this,O
study,O
.,O
DTI,O
is,O
able,O
to,O
characterize,O
brain,O
tissue,O
structure,O
by,O
measurement,O
of,O
water,O
diffusion,O
",",O
expressed,O
as,O
two,O
indices,O
",",O
MD,O
and,O
FA,O
.,O
MD,O
is,O
a,O
parameter,O
of,O
magnitude,O
of,O
average,O
molecular,O
motion,O
considered,O
in,O
all,O
directions,O
.,O
FA,O
is,O
a,O
quantitative,O
measure,O
of,O
directional,O
bias,O
in,O
the,O
diffusion,O
profile,O
.,O
A,O
significant,O
increase,O
of,O
MD,O
and,O
decrease,O
of,O
FA,O
in,O
the,O
left,O
frontal,O
white,O
matter,O
was,O
found,O
between,O
W1,O
and,O
W12,O
",",O
but,O
there,O
were,O
no,O
significant,O
changes,O
between,O
W1,O
and,O
W4,O
",",O
and,O
between,O
W4,O
and,O
W12,O
.,O
The,O
abnormal,O
diffusion,O
observed,O
suggest,O
that,O
the,O
secondary,O
damage,O
is,O
cumulative,O
from,O
W1,O
to,O
W12,O
.,O
Such,O
changes,O
in,O
MD,O
and,O
FA,O
in,O
the,O
frontal,O
white,O
matter,O
have,O
also,O
been,O
described,O
in,O
patients,O
with,O
ILA,O
",",O
which,O
is,O
suggestive,O
of,O
axonal,O
structural,O
loss,O
in,O
the,O
regions,O
[,O
6,O
].,O
Also,O
",",O
the,O
increased,O
MD,O
and,O
decrease,O
of,O
FA,O
may,O
be,O
correlated,O
with,O
executive,O
functional,O
changes,O
.,O
Frontal,O
-,O
subcortical,O
circuit,O
was,O
defined,O
as,O
including,O
the,O
frontal,O
cortex,O
",",O
caudate,O
",",O
pallidum,O
",",O
thalamus,O
",",O
genu,O
of,O
internal,O
capsule,O
",",O
anterior,O
internal,O
capsule,O
",",O
anterior,O
corona,O
radiata,O
",",O
and,O
anterior,O
centrum,O
semiovale,O
[,O
3,O
].,O
In,O
this,O
study,O
",",O
executive,B-DS
dysfunction,I-DS
was,O
found,O
in,O
the,O
patients,O
with,O
left,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
.,O
A,O
possible,O
explanation,O
for,O
this,O
is,O
that,O
the,O
region,O
itself,O
is,O
a,O
structure,O
in,O
the,O
executive,O
functional,O
circuit,O
.,O
Another,O
more,O
possible,O
mechanism,O
of,O
the,O
executive,O
changes,O
in,O
the,O
patients,O
is,O
secondary,O
degeneration,O
due,O
to,O
the,O
disruption,O
of,O
axons,O
in,O
the,O
frontal,O
white,O
matter,O
that,O
links,O
the,O
frontal,O
cortex,O
to,O
other,O
structures,O
in,O
the,O
executive,O
functional,O
circuit,O
.,O
The,O
correlation,O
of,O
MD,O
and,O
FA,O
alteration,O
in,O
the,O
left,O
posterior,O
white,O
matter,O
with,O
executive,O
performance,O
supports,O
this,O
hypothesis,O
.,O
Our,O
previous,O
study,O
has,O
shown,O
that,O
gray,O
matter,O
volumes,O
decreased,O
significantly,O
in,O
the,O
ipsilateral,O
supplementary,O
motor,O
area,O
and,O
contralateral,O
insula,O
from,O
W1,O
to,O
W12,O
in,O
patients,O
with,O
undergoing,O
acute,O
subcortical,B-DS
infarction,I-DS
.,O
The,O
changes,O
of,O
gray,O
matter,O
volumes,O
in,O
the,O
ipsilesional,O
supplementary,O
motor,O
area,O
correlated,O
with,O
the,O
changes,O
of,O
motor,O
function,O
and,O
activities,O
of,O
daily,O
living,O
[,O
22,O
].,O
In,O
the,O
present,O
study,O
",",O
a,O
significant,O
increase,O
of,O
MD,O
in,O
the,O
left,O
thalamus,O
was,O
found,O
over,O
time,O
",",O
which,O
is,O
suggestive,O
of,O
an,O
important,O
loss,O
of,O
thalamic,O
structural,O
components,O
.,O
Within,O
the,O
thalamus,O
",",O
secondary,O
damage,O
has,O
been,O
also,O
reported,O
by,O
Hervé,O
et,O
al,O
.,O
and,O
our,O
team,O
in,O
patients,O
after,O
an,O
acute,O
isolated,O
MCA,O
territory,O
infarction,O
[,O
8,O
"],[",O
14,O
].,O
A,O
weak,O
correlation,O
between,O
the,O
MD,O
changes,O
in,O
the,O
left,O
thalamus,O
and,O
executive,O
function,O
was,O
found,O
in,O
this,O
study,O
",",O
which,O
means,O
secondary,O
damage,O
of,O
the,O
left,O
thalamus,O
is,O
possibly,O
involved,O
in,O
inhibiting,O
executive,O
function,O
.,O
The,O
lack,O
of,O
FA,O
changes,O
may,O
be,O
related,O
to,O
the,O
absence,O
of,O
isolated,O
bundles,O
of,O
parallel,O
fibers,O
within,O
the,O
thalamus,O
[,O
14,O
].,O
We,O
failed,O
to,O
find,O
significant,O
diffusion,O
changes,O
in,O
the,O
posterior,O
periventricular,O
white,O
matter,O
or,O
centrum,O
semiovale,O
.,O
It,O
is,O
possible,O
that,O
only,O
the,O
most,O
significant,O
diffusion,O
changes,O
were,O
detected,O
by,O
our,O
method,O
and,O
more,O
widespread,O
secondary,O
damages,O
occur,O
in,O
other,O
areas,O
.,O
Longer,O
follow,O
-,O
up,O
and,O
more,O
sophisticated,O
image,O
analysis,O
techniques,O
may,O
be,O
required,O
for,O
determining,O
secondary,O
damage,O
in,O
other,O
regions,O
remote,O
to,O
an,O
infarction,O
.,O
In,O
our,O
patients,O
",",O
there,O
was,O
no,O
abnormal,O
signal,O
in,O
the,O
frontal,O
area,O
at,O
W1,O
and,O
W12,O
",",O
which,O
means,O
no,O
new,O
ischemic,O
lesions,O
exist,O
in,O
the,O
frontal,O
area,O
between,O
W1,O
and,O
W12,O
.,O
There,O
was,O
also,O
no,O
significant,O
change,O
of,O
blood,O
flow,O
in,O
the,O
frontal,O
area,O
between,O
W1,O
and,O
W12,O
in,O
patients,O
as,O
measured,O
by,O
the,O
evaluation,O
of,O
carotid,B-DS
artery,I-DS
stenosis,I-DS
and,O
hemodynamics,O
of,O
ACA,O
",",O
MCA,O
and,O
PCA,O
performed,O
with,O
Color,O
duplex,O
sonography,O
and,O
TCD,O
",",O
suggesting,O
that,O
frontal,O
dysfunction,O
would,O
not,O
be,O
attributed,O
to,O
potential,O
hemodynamic,O
changes,O
.,O
Vataja,O
et,O
al,O
.,O
reported,O
significant,O
executive,B-DS
dysfunction,I-DS
in,O
patients,O
with,O
anterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
",",O
but,O
failed,O
to,O
find,O
executive,O
change,O
in,O
patients,O
with,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
[,O
4,O
].,O
In,O
this,O
study,O
",",O
however,O
",",O
we,O
observed,O
a,O
poor,O
executive,O
performance,O
in,O
patients,O
with,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
.,O
The,O
difference,O
between,O
our,O
study,O
and,O
that,O
of,O
Vataja,O
et,O
al,O
.,O
was,O
that,O
our,O
study,O
included,O
patients,O
without,O
white,O
matter,O
lesions,O
(,O
WMLs,O
),O
and,O
cerebral,B-DS
atrophy,I-DS
.,O
WMLs,O
were,O
described,O
radiologically,O
as,O
LKA,O
in,O
periventricular,O
white,O
matter,O
",",O
and,O
subcortical,O
",",O
deep,O
",",O
watershed,O
areas,O
.,O
Executive,B-DS
dysfunction,I-DS
has,O
been,O
found,O
to,O
associate,O
with,O
the,O
degree,O
of,O
WMLs,O
assessed,O
by,O
MRI,O
",",O
DTI,O
or,O
MR,O
spectroscopy,O
[,O
6,O
"],[",O
23,O
]–[,O
26,O
].,O
Cerebral,B-DS
atrophy,I-DS
was,O
also,O
related,O
to,O
executive,B-DS
dysfunction,I-DS
[,O
26,O
"],[",O
27,O
].,O
In,O
this,O
study,O
",",O
executive,O
change,O
might,O
be,O
observed,O
more,O
easily,O
owing,O
to,O
posterior,O
corona,O
radiata,O
while,O
effects,O
of,O
WMLs,O
and,O
cerebral,B-DS
atrophy,I-DS
were,O
removed,O
.,O
In,O
addition,O
",",O
executive,O
function,O
assessment,O
was,O
different,O
in,O
the,O
two,O
studies,O
.,O
Digit,O
span,O
backwards,O
and,O
Digit,O
symbol,O
tests,O
were,O
applied,O
in,O
this,O
study,O
.,O
The,O
former,O
reflects,O
working,O
memory,O
performance,O
;,O
the,O
latter,O
requires,O
multiple,O
cognitive,O
abilities,O
including,O
attention,O
",",O
psychomotor,O
speed,O
",",O
complex,O
scanning,O
",",O
visual,O
tracking,O
",",O
and,O
immediate,O
memory,O
[,O
15,O
"],[",O
28,O
"],[",O
29,O
].,O
The,O
scores,O
of,O
Digit,O
span,O
backwards,O
and,O
Digit,O
symbol,O
tests,O
were,O
decreased,O
significantly,O
",",O
which,O
means,O
above,O
-,O
mentioned,O
components,O
of,O
executive,B-DS
dysfunction,I-DS
exist,O
in,O
the,O
patients,O
with,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
.,O
Besides,O
",",O
increased,O
Trail,O
making,O
B,O
-,O
A,O
and,O
decreased,O
Verbal,O
fluency,O
assessment,O
scores,O
were,O
found,O
",",O
which,O
implies,O
dysfunction,O
of,O
cognitive,O
set,O
shifting,O
",",O
mental,O
flexibility,O
and,O
strategies,O
for,O
word,O
retrieval,O
in,O
these,O
patients,O
.,O
Conclusion,O
Executive,B-DS
dysfunction,I-DS
was,O
observed,O
in,O
the,O
patients,O
with,O
left,O
posterior,O
corona,B-DS
radiata,I-DS
infarction,I-DS
.,O
The,O
axonal,O
loss,O
in,O
the,O
left,O
frontal,O
white,O
matter,O
after,O
stroke,B-DS
was,O
detected,O
by,O
DTI,O
.,O
The,O
abnormalities,O
of,O
MD,O
and,O
FA,O
in,O
the,O
region,O
may,O
be,O
correlated,O
with,O
executive,O
function,O
changes,O
in,O
the,O
patients,O
.,O
Abbreviations,O
ACA,O
:,O
anterior,O
cerebral,O
artery,O
CT,O
:,O
computed,O
tomography,O
DIA,O
:,O
luminal,O
diameter,O
DTI,O
:,O
diffusion,O
tensor,O
imaging,O
EDV,O
:,O
end,O
diastolic,O
velocity,O
EPI,O
:,O
echo,O
planar,O
imaging,O
FA,O
:,O
fractional,O
anisotropy,O
ICA,O
:,O
iInternal,O
carotid,O
artery,O
ILA,O
:,O
ischemic,O
leukoaraiosis,O
IMT,O
:,O
Intima,O
-,O
media,O
thickness,O
LSD,O
:,O
Least,O
Significant,O
Difference,O
MCA,O
:,O
middle,O
cerebral,O
artery,O
MD,O
:,O
mean,O
diffusivity,O
MFV,O
:,O
Mean,O
flow,O
velocity,O
values,O
MMSE,O
:,O
Mini,O
-,O
Mental,O
State,O
Examination,O
MRI,O
:,O
magnetic,O
resonance,O
imaging,O
PCA,O
:,O
posterior,O
cerebral,O
artery,O
PSV,O
:,O
peak,O
systolic,O
velocity,O
TCD,O
:,O
Transcranial,O
Duplex,O
Scanning,O
T1,O
-,O
FLAIR,O
:,O
T1,O
-,O
weighted,O
fluid,O
attenuatedion,O
inversion,O
recovery,O
WMLs,O
:,O
white,O
matter,O
lesions,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
’,O
contributions,O
CL,O
designed,O
the,O
study,O
",",O
collected,O
the,O
data,O
and,O
wrote,O
the,O
manuscript,O
",",O
CD,O
carried,O
out,O
image,O
post,O
-,O
processing,O
",",O
GL,O
conducted,O
the,O
MR,O
images,O
analysis,O
",",O
LC,O
and,O
JZ,O
assisted,O
with,O
the,O
data,O
collection,O
",",O
JL,O
assisted,O
with,O
the,O
statistical,O
analysis,O
",",O
ZO,O
assisted,O
with,O
the,O
data,O
collection,O
",",O
YZ,O
participated,O
in,O
the,O
design,O
of,O
the,O
study,O
",",O
AX,O
interpreted,O
the,O
results,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Neural,O
",",O
biomechanical,O
",",O
and,O
physiological,O
factors,O
involved,O
in,O
sex,O
-,O
related,O
differences,O
in,O
the,O
maximal,O
rate,O
of,O
isometric,O
torque,O
development,O
Communicated,O
by,O
Toshio,O
Moritani,O
.,O
Objective,O
Recent,O
research,O
has,O
reported,O
that,O
lower,O
maximal,O
rate,O
of,O
torque,O
development,O
(,O
dτ,O
/,O
dt,O
max,O
),O
exhibited,O
by,O
females,O
",",O
relative,O
to,O
males,O
",",O
during,O
knee,O
extension,O
can,O
be,O
accounted,O
for,O
by,O
normalization,O
to,O
a,O
maximal,O
voluntary,O
contraction,O
(,O
MVC,O
);,O
however,O
",",O
this,O
was,O
not,O
seen,O
in,O
the,O
upper,O
limb,O
.,O
Purpose,O
The,O
aim,O
of,O
the,O
current,O
work,O
was,O
to,O
examine,O
the,O
contribution,O
of,O
maximum,O
strength,O
(,O
τmax,O
"),",O
twitch,O
contraction,O
time,O
(,O
CT,O
"),",O
muscle,O
fiber,O
condition,O
velocity,O
(,O
MFCV,O
"),",O
and,O
rate,O
of,O
muscle,O
activation,O
(,O
Q30,O
),O
to,O
sex,O
-,O
differences,O
in,O
the,O
dτ,O
/,O
dt,O
max,O
during,O
maximal,O
isometric,O
dorsiflexion,O
.,O
Methods,O
Thirty,O
-,O
eight,O
participants,O
(,O
20,O
males,O
;,O
18,O
females,O
),O
performed,O
both,O
maximal,O
voluntary,O
and,O
evoked,O
isometric,O
contractions,O
of,O
the,O
tibialis,O
anterior,O
across,O
3,O
days,O
.,O
Ten,O
maximal,O
compound,O
muscle,O
action,O
potentials,O
were,O
elicited,O
and,O
subsequently,O
followed,O
by,O
three,O
",",O
5,O
-,O
s,O
contractions,O
.,O
From,O
the,O
recordings,O
",",O
MFCV,O
",",O
dτ,O
/,O
dt,O
max,O
",",O
τmax,O
",",O
CT,O
",",O
electromechanical,O
delay,O
(,O
EMD,O
"),",O
root,O
-,O
mean,O
squared,O
(,O
RMS,O
),O
amplitude,O
",",O
peak,O
-,O
to,O
-,O
peak,O
voltage,O
(,O
Vpp,O
"),",O
and,O
Q30,O
were,O
calculated,O
.,O
Results,O
An,O
ANCOVA,O
showed,O
that,O
τmax,O
accounted,O
for,O
all,O
the,O
sex,O
-,O
differences,O
in,O
dτ,O
/,O
dt,O
max,O
(,O
p,O
=,O
0,O
.,O
96,O
).,O
There,O
were,O
no,O
significant,O
differences,O
between,O
groups,O
with,O
respect,O
to,O
MFCV,O
",",O
RMS,O
amplitude,O
",",O
Vpp,O
amplitude,O
",",O
or,O
CT,O
.,O
However,O
",",O
there,O
was,O
a,O
significant,O
sex,O
-,O
difference,O
in,O
dτ,O
/,O
dt,O
max,O
",",O
τmax,O
",",O
and,O
Q30,O
.,O
Females,O
had,O
longer,O
evoked,O
EMD,O
times,O
compared,O
with,O
males,O
(,O
15,O
.,O
69,O
±,O
10,O
.,O
57,O
ms,O
versus,O
9,O
.,O
95,O
±,O
3,O
.,O
46,O
ms,O
;,O
p,O
=,O
0,O
.,O
01,O
"),",O
but,O
the,O
voluntary,O
EMD,O
times,O
were,O
not,O
different,O
.,O
Conclusion,O
The,O
current,O
research,O
supports,O
the,O
work,O
by,O
Hannah,O
et,O
al,O
.,O
Exp,O
Physiol,O
97,O
:,O
618,O
–,O
629,O
",",O
(,O
2012,O
),O
that,O
normalization,O
to,O
MVC,O
in,O
the,O
quadriceps,O
is,O
able,O
to,O
account,O
for,O
all,O
sex,O
-,O
differences,O
in,O
rate,O
of,O
toque,O
development,O
in,O
the,O
lower,O
limb,O
.,O
Introduction,O
The,O
rate,O
of,O
tension,O
development,O
has,O
received,O
increased,O
attention,O
as,O
a,O
critical,O
aspect,O
of,O
dynamic,O
muscle,O
performance,O
during,O
activities,O
of,O
daily,O
living,O
(,O
e,O
.,O
g,O
".,",O
balance,O
maintenance,O
),O
and,O
sport,O
performance,O
(,O
Aagaard,O
et,O
al,O
.,O
2002,O
;,O
LaRoche,O
et,O
al,O
.,O
2010,O
;,O
Paasuke,O
et,O
al,O
.,O
2001,O
;,O
Pijnapples,O
et,O
al,O
.,O
2008,O
;,O
Schultz,O
et,O
al,O
.,O
1997,O
;,O
Tillin,O
et,O
al,O
.,O
2013,O
).,O
A,O
number,O
of,O
studies,O
have,O
shown,O
that,O
there,O
is,O
an,O
inextricable,O
link,O
between,O
the,O
ultimate,O
strength,O
of,O
the,O
muscle,O
and,O
its,O
rate,O
of,O
tension,O
development,O
(,O
Andersen,O
and,O
Aagaard,O
2006,O
;,O
Holtermann,O
et,O
al,O
.,O
2007,O
).,O
However,O
",",O
neural,O
factors,O
can,O
also,O
play,O
an,O
important,O
role,O
",",O
as,O
training,O
-,O
related,O
increases,O
in,O
the,O
maximal,O
rate,O
of,O
tension,O
development,O
are,O
associated,O
with,O
an,O
increase,O
in,O
muscle,O
activation,O
at,O
the,O
onset,O
of,O
contraction,O
(,O
Van,O
Cutsem,O
et,O
al,O
.,O
1998,O
;,O
Van,O
Cutsem,O
and,O
Duchateau,O
2005,O
).,O
Inglis,O
et,O
al,O
.,O
(,O
2013,O
),O
recently,O
showed,O
that,O
neural,O
factors,O
also,O
play,O
a,O
role,O
in,O
sex,O
-,O
differences,O
in,O
the,O
maximal,O
rate,O
of,O
tension,O
development,O
in,O
the,O
upper,O
limb,O
.,O
Maximum,O
strength,O
was,O
used,O
as,O
a,O
covariate,O
and,O
was,O
only,O
able,O
to,O
account,O
for,O
a,O
portion,O
of,O
the,O
sex,O
-,O
differences,O
.,O
The,O
addition,O
of,O
a,O
second,O
variable,O
",",O
the,O
maximum,O
rate,O
of,O
electromyographic,O
(,O
EMG,O
),O
activity,O
at,O
the,O
onset,O
of,O
contraction,O
(,O
Q30,O
"),",O
was,O
able,O
to,O
eliminate,O
statistically,O
significant,O
sex,O
-,O
differences,O
.,O
Given,O
the,O
inherent,O
relationship,O
between,O
muscle,O
strength,O
and,O
the,O
maximum,O
rate,O
of,O
tension,O
development,O
",",O
few,O
studies,O
have,O
explored,O
additional,O
mechanisms,O
that,O
would,O
explain,O
sex,O
-,O
differences,O
in,O
the,O
maximal,O
rate,O
of,O
tension,O
development,O
(,O
Aagaard,O
et,O
al,O
.,O
2002,O
;,O
Andersen,O
and,O
Aagaard,O
2006,O
;,O
Folland,O
et,O
al,O
.,O
2014,O
;,O
Van,O
Cutsem,O
et,O
al,O
.,O
1998,O
).,O
However,O
",",O
sex,O
-,O
differences,O
in,O
lower,O
extremity,O
musculoskeletal,O
injury,O
rates,O
(,O
DiStefano,O
et,O
al,O
.,O
2015,O
),O
and,O
falls,O
incidences,O
(,O
Hess,O
and,O
Woollacott,O
2005,O
;,O
Stevens,O
and,O
Sogolow,O
2005,O
),O
may,O
be,O
linked,O
back,O
to,O
this,O
critical,O
aspect,O
of,O
muscle,O
contraction,O
(,O
Bento,O
et,O
al,O
.,O
2010,O
).,O
Hannah,O
et,O
al,O
.,O
(,O
2012,O
),O
explored,O
potential,O
neural,O
and,O
biomechanical,O
factors,O
involved,O
in,O
sex,O
-,O
differences,O
in,O
the,O
maximal,O
rate,O
of,O
tension,O
development,O
in,O
the,O
quadriceps,O
",",O
in,O
addition,O
to,O
maximum,O
strength,O
.,O
Twitch,O
properties,O
",",O
electromechanical,O
delay,O
",",O
and,O
muscle,O
activation,O
using,O
surface,O
EMG,O
(,O
sEMG,O
),O
were,O
also,O
assessed,O
.,O
Consistent,O
with,O
the,O
more,O
general,O
findings,O
for,O
the,O
relationship,O
between,O
maximum,O
strength,O
and,O
the,O
rate,O
of,O
tension,O
development,O
",",O
when,O
the,O
peak,O
rate,O
of,O
tension,O
development,O
was,O
normalized,O
with,O
respect,O
to,O
maximum,O
isometric,O
strength,O
of,O
the,O
muscle,O
",",O
the,O
sex,O
-,O
differences,O
were,O
completely,O
eliminated,O
.,O
The,O
results,O
by,O
Hannah,O
et,O
al,O
.,O
(,O
2012,O
),O
in,O
the,O
lower,O
limb,O
are,O
contrary,O
to,O
the,O
finding,O
of,O
Inglis,O
et,O
al,O
.,O
(,O
2013,O
),O
who,O
showed,O
a,O
role,O
for,O
neural,O
factors,O
in,O
the,O
upper,O
limb,O
.,O
It,O
may,O
be,O
hypothesized,O
that,O
since,O
males,O
and,O
females,O
were,O
more,O
comparable,O
in,O
absolute,O
strength,O
in,O
the,O
quadriceps,O
(,O
Δ33,O
%),O
than,O
the,O
biceps,O
(,O
Δ55,O
.,O
5,O
%;,O
Inglis,O
et,O
al,O
.,O
2013,O
"),",O
strength,O
may,O
entirely,O
explain,O
sex,O
-,O
differences,O
in,O
the,O
rate,O
of,O
tension,O
development,O
in,O
the,O
lower,O
limb,O
.,O
In,O
contrast,O
",",O
the,O
difference,O
in,O
maximum,O
strength,O
between,O
males,O
and,O
females,O
in,O
the,O
upper,O
limb,O
observed,O
by,O
Inglis,O
et,O
al,O
.,O
(,O
2013,O
),O
was,O
much,O
greater,O
(,O
Δ55,O
.,O
5,O
"%),",O
possibly,O
allowing,O
for,O
additional,O
factors,O
",",O
such,O
as,O
the,O
rate,O
of,O
muscle,O
activation,O
",",O
to,O
play,O
a,O
role,O
.,O
Inglis,O
et,O
al,O
.,O
(,O
2013,O
),O
explored,O
the,O
possibility,O
that,O
the,O
interpretation,O
of,O
the,O
results,O
may,O
differ,O
based,O
on,O
normalization,O
to,O
maximum,O
voluntary,O
strength,O
versus,O
the,O
use,O
of,O
a,O
covariate,O
approach,O
.,O
It,O
was,O
found,O
that,O
normalization,O
to,O
maximum,O
voluntary,O
strength,O
also,O
failed,O
to,O
account,O
for,O
all,O
sex,O
-,O
differences,O
in,O
the,O
maximal,O
rate,O
of,O
tension,O
development,O
.,O
Since,O
there,O
is,O
a,O
strong,O
relationship,O
between,O
maximum,O
strength,O
and,O
the,O
rate,O
of,O
tension,O
development,O
",",O
sex,O
-,O
differences,O
may,O
be,O
accounted,O
for,O
by,O
maximum,O
strength,O
only,O
when,O
the,O
two,O
groups,O
are,O
‘,O
more,O
’,O
comparable,O
with,O
respect,O
to,O
maximal,O
strength,O
as,O
exists,O
in,O
the,O
lower,O
limb,O
compared,O
with,O
the,O
upper,O
limb,O
.,O
For,O
example,O
",",O
it,O
has,O
been,O
shown,O
that,O
males,O
and,O
females,O
are,O
more,O
comparable,O
in,O
maximal,O
isometric,O
dorsiflexion,O
strength,O
(,O
Δ28,O
.,O
9,O
%),O
and,O
identical,O
with,O
respect,O
to,O
root,O
-,O
mean,O
-,O
square,O
(,O
RMS,O
),O
sEMG,O
magnitude,O
(,O
Heyward,O
et,O
al,O
.,O
1986,O
;,O
Hoffman,O
et,O
al,O
.,O
1979,O
;,O
Lenhardt,O
et,O
al,O
.,O
2009,O
).,O
Unfortunately,O
",",O
Lenhardt,O
et,O
al,O
.,O
2009,O
did,O
not,O
assess,O
the,O
maximum,O
rate,O
of,O
torque,O
development,O
.,O
The,O
28,O
.,O
9,O
%,O
strength,O
difference,O
between,O
the,O
sexes,O
is,O
consistent,O
with,O
Holmbäck,O
et,O
al,O
.,O
(,O
2003,O
),O
who,O
concluded,O
that,O
muscle,O
cross,O
-,O
sectional,O
area,O
was,O
the,O
principal,O
determinant,O
of,O
dorsiflexion,O
strength,O
.,O
In,O
general,O
",",O
the,O
muscle,O
cross,O
-,O
sectional,O
area,O
of,O
the,O
TA,O
in,O
males,O
is,O
only,O
20,O
%,O
larger,O
than,O
that,O
for,O
females,O
(,O
Holmbäck,O
et,O
al,O
.,O
2003,O
;,O
Jaworowski,O
et,O
al,O
.,O
2002,O
).,O
The,O
purpose,O
of,O
this,O
paper,O
was,O
to,O
determine,O
if,O
sex,O
-,O
differences,O
in,O
the,O
maximum,O
rate,O
of,O
isometric,O
dorsiflexion,O
torque,O
development,O
are,O
determined,O
by,O
maximum,O
isometric,O
dorsiflexion,O
torque,O
alone,O
or,O
other,O
factors,O
as,O
observed,O
for,O
the,O
upper,O
limb,O
where,O
the,O
strength,O
differences,O
are,O
more,O
pronounced,O
.,O
Based,O
on,O
the,O
work,O
of,O
Hannah,O
et,O
al,O
.,O
(,O
2012,O
"),",O
it,O
was,O
hypothesized,O
that,O
maximum,O
isometric,O
strength,O
would,O
account,O
for,O
sex,O
-,O
differences,O
in,O
the,O
maximum,O
rate,O
of,O
torque,O
development,O
in,O
the,O
TA,O
",",O
because,O
males,O
and,O
females,O
are,O
more,O
comparable,O
in,O
maximum,O
isometric,O
strength,O
in,O
the,O
lower,O
limb,O
.,O
Studying,O
mechanisms,O
behind,O
sex,O
-,O
differences,O
in,O
distal,O
muscles,O
that,O
are,O
responsible,O
for,O
balance,O
and,O
explosive,O
activity,O
can,O
guide,O
specific,O
training,O
interventions,O
or,O
rehabilitation,O
techniques,O
.,O
Methods,O
Participants,O
A,O
power,O
analysis,O
was,O
performed,O
prior,O
to,O
data,O
collection,O
based,O
on,O
research,O
by,O
Lenhardt,O
et,O
al,O
.,O
(,O
2009,O
"),",O
showing,O
that,O
a,O
subject,O
pool,O
of,O
18,O
males,O
and,O
females,O
was,O
sufficient,O
to,O
show,O
differences,O
in,O
the,O
rate,O
of,O
muscle,O
activation,O
(,O
Q30,O
).,O
However,O
",",O
to,O
protect,O
against,O
subject,O
drop,O
out,O
",",O
40,O
subjects,O
(,O
males,O
and,O
females,O
),O
were,O
recruited,O
.,O
Pre,O
-,O
tension,O
on,O
the,O
load,O
cell,O
was,O
observed,O
in,O
two,O
female,O
subjects,O
",",O
so,O
their,O
data,O
was,O
removed,O
from,O
the,O
analysis,O
.,O
Thus,O
",",O
38,O
healthy,O
Brock,O
University,O
Kinesiology,O
students,O
(,O
20,O
males,O
and,O
18,O
females,O
),O
were,O
analyzed,O
in,O
this,O
study,O
.,O
The,O
participants,O
were,O
free,O
of,O
any,O
orthopedic,O
or,O
neuromuscular,B-DS
disorders,I-DS
",",O
right,O
leg,O
dominant,O
",",O
and,O
provided,O
written,O
informed,O
consent,O
prior,O
to,O
study,O
participation,O
in,O
accordance,O
with,O
the,O
Brock,O
University,O
Research,O
Ethics,O
Board,O
guidelines,O
(,O
REB,O
-,O
02,O
-,O
284,O
).,O
Each,O
participant,O
was,O
familiarized,O
with,O
the,O
Electromyographic,O
Kinesiology,O
Laboratory,O
prior,O
to,O
the,O
first,O
testing,O
session,O
.,O
Prior,O
to,O
testing,O
",",O
participants,O
were,O
asked,O
about,O
their,O
history,O
of,O
physical,O
activity,O
and,O
weight,O
training,O
(,O
years,O
of,O
experience,O
),O
as,O
well,O
as,O
the,O
duration,O
(,O
hours,O
per,O
week,O
and,O
per,O
day,O
),O
and,O
the,O
percentage,O
of,O
weight,O
training,O
focusing,O
on,O
the,O
upper,O
body,O
or,O
lower,O
body,O
.,O
Experimental,O
setup,O
and,O
scheduling,O
All,O
testing,O
was,O
performed,O
as,O
the,O
participant,O
sat,O
in,O
a,O
custom,O
built,O
testing,O
chair,O
designed,O
to,O
isolate,O
the,O
dorsiflexors,O
during,O
maximal,O
isometric,O
contractions,O
.,O
Participants,O
sat,O
with,O
their,O
hip,O
and,O
knee,O
joints,O
secured,O
at,O
90,O
°,O
of,O
flexion,O
and,O
the,O
ankle,O
joint,O
secured,O
at,O
110,O
°,O
of,O
plantar,O
flexion,O
(,O
Inglis,O
et,O
al,O
.,O
2011,O
).,O
Slight,O
plantar,O
flexion,O
was,O
chosen,O
as,O
previous,O
research,O
has,O
shown,O
that,O
a,O
certain,O
degree,O
of,O
plantar,O
flexion,O
produces,O
a,O
maximal,O
torque,O
and,O
110,O
°,O
may,O
place,O
the,O
TA,O
closer,O
to,O
optimal,O
length,O
for,O
both,O
maximal,O
evoked,O
and,O
voluntary,O
dorsiflexion,O
torque,O
production,O
",",O
which,O
considers,O
the,O
lever,O
arm,O
length,O
(,O
Marsh,O
et,O
al,O
.,O
1981,O
).,O
A,O
load,O
cell,O
(,O
JR3,O
",",O
Woodland,O
",",O
CA,O
",",O
USA,O
),O
was,O
secured,O
under,O
the,O
foot,O
plate,O
of,O
which,O
the,O
foot,O
was,O
restrained,O
by,O
a,O
minimally,O
padded,O
steel,O
bar,O
located,O
proximal,O
to,O
the,O
metatarsals,O
for,O
all,O
torque,O
recordings,O
(,O
Christie,O
et,O
al,O
.,O
2009,O
).,O
There,O
were,O
3,O
days,O
of,O
testing,O
to,O
assess,O
the,O
reliability,O
of,O
the,O
measures,O
as,O
participants,O
can,O
exhibit,O
a,O
learning,O
effect,O
during,O
maximal,O
strength,O
assessment,O
(,O
Green,O
et,O
al,O
.,O
2014,O
).,O
On,O
each,O
day,O
",",O
participants,O
were,O
asked,O
to,O
perform,O
the,O
same,O
tasks,O
.,O
These,O
tasks,O
included,O
both,O
voluntary,O
isometric,O
maximal,O
dorsiflexion,O
contractions,O
and,O
maximal,O
evoked,O
isometric,O
torque,O
.,O
Each,O
of,O
the,O
three,O
testing,O
days,O
was,O
separated,O
by,O
at,O
least,O
48,O
h,O
to,O
avoid,O
any,O
complications,O
",",O
which,O
may,O
arise,O
as,O
a,O
result,O
of,O
fatigue,O
.,O
sEMG,O
recordings,O
Participants,O
lay,O
supine,O
on,O
a,O
gurney,O
",",O
so,O
that,O
the,O
most,O
prominent,O
TA,O
motor,O
point,O
may,O
be,O
electrically,O
identified,O
using,O
a,O
metallic,O
probe,O
over,O
the,O
skin,O
surface,O
(,O
Christie,O
et,O
al,O
.,O
2005,O
).,O
The,O
lowest,O
possible,O
current,O
that,O
produced,O
a,O
minimally,O
visible,O
twitch,O
was,O
taken,O
as,O
the,O
motor,O
point,O
(,O
Calder,O
and,O
Gabriel,O
2007,O
).,O
Following,O
motor,O
point,O
identification,O
",",O
the,O
recording,O
areas,O
were,O
shaved,O
",",O
mildly,O
abraded,O
(,O
NuPrep,O
;,O
Weaver,O
and,O
Co,O
".,",O
Aurora,O
",",O
CO,O
"),",O
and,O
finally,O
cleansed,O
with,O
alcohol,O
to,O
minimize,O
skin,O
–,O
electrode,O
input,O
impedance,O
.,O
The,O
sEMG,O
recording,O
electrode,O
had,O
three,O
parallel,O
stainless,O
steel,O
bars,O
which,O
resulted,O
in,O
two,O
bipolar,O
signals,O
.,O
Each,O
stainless,O
steel,O
bar,O
was,O
1,O
mm,O
in,O
diameter,O
",",O
10,O
mm,O
long,O
",",O
and,O
was,O
mounted,O
with,O
an,O
interbar,O
distance,O
of,O
5,O
mm,O
.,O
The,O
recording,O
electrode,O
was,O
prepared,O
with,O
double,O
-,O
sided,O
adhesive,O
tape,O
",",O
electrolyte,O
gel,O
(,O
Signal,O
Gel,O
;,O
Parker,O
Laboratories,O
",",O
Inc,O
".,",O
Fairfield,O
",",O
New,O
Jersey,O
"),",O
and,O
placed,O
in,O
line,O
with,O
the,O
muscle,O
fibers,O
",",O
1,O
cm,O
distal,O
to,O
the,O
motor,O
point,O
.,O
Alignment,O
and,O
final,O
placement,O
of,O
the,O
electrodes,O
for,O
recording,O
MFCV,O
followed,O
the,O
procedures,O
outlined,O
in,O
McIntosh,O
and,O
Gabriel,O
(,O
2012,O
).,O
Finally,O
",",O
a,O
ground,O
electrode,O
(,O
CF5000,O
;,O
Axelgaard,O
),O
was,O
placed,O
on,O
the,O
lateral,O
malleolus,O
(,O
McIntosh,O
and,O
Gabriel,O
2012,O
).,O
Electrode,O
–,O
skin,O
input,O
impedance,O
(,O
Grass,O
EZM5,O
",",O
Astro,O
-,O
Med,O
Inc,O
".,",O
West,O
Warwick,O
",",O
RI,O
),O
was,O
assessed,O
before,O
and,O
after,O
the,O
experiment,O
to,O
ensure,O
it,O
remained,O
below,O
10,O
kΩ,O
.,O
Skin,O
temperature,O
(,O
Electrotherm,O
TM99A,O
;,O
Cooper,O
Instrument,O
Corp,O
".,",O
Middlefield,O
",",O
Connecticut,O
),O
was,O
also,O
monitored,O
before,O
and,O
after,O
the,O
experiment,O
to,O
verify,O
that,O
there,O
was,O
no,O
change,O
",",O
which,O
could,O
affect,O
the,O
stability,O
of,O
the,O
myoelectric,O
signal,O
.,O
sEMG,O
was,O
band,O
-,O
pass,O
filtered,O
(,O
between,O
10,O
and,O
1000,O
Hz,O
),O
and,O
amplified,O
(,O
Grass,O
P511,O
;,O
Astro,O
-,O
Med,O
),O
to,O
maximize,O
the,O
resolution,O
on,O
a,O
16,O
-,O
bit,O
analog,O
-,O
to,O
-,O
digital,O
converter,O
(,O
MI,O
PCI,O
-,O
6052E,O
;,O
National,O
Instruments,O
",",O
Austin,O
",",O
TX,O
).,O
All,O
signals,O
were,O
collected,O
at,O
5000,O
Hz,O
and,O
acquired,O
on,O
a,O
computer,O
-,O
based,O
data,O
acquisition,O
system,O
(,O
DASYLab,O
;,O
DASYTEC,O
National,O
Instruments,O
",",O
Amherst,O
",",O
New,O
Hampshire,O
).,O
The,O
data,O
were,O
stored,O
on,O
a,O
PC,O
(,O
Celeron,O
;,O
Dell,O
",",O
Round,O
Rock,O
",",O
Texas,O
),O
for,O
offline,O
analysis,O
.,O
The,O
data,O
window,O
for,O
the,O
sEMG,O
analysis,O
of,O
the,O
maximal,O
voluntary,O
contraction,O
was,O
500,O
ms,O
",",O
terminating,O
before,O
the,O
middle,O
of,O
the,O
contraction,O
(,O
Inglis,O
et,O
al,O
.,O
2013,O
).,O
The,O
sEMG,O
signals,O
were,O
up,O
-,O
sampled,O
to,O
25,O
kHz,O
prior,O
to,O
calculating,O
the,O
cross,O
-,O
correlation,O
coefficient,O
to,O
increase,O
the,O
time,O
resolution,O
of,O
the,O
action,O
potential,O
propagation,O
(,O
Farina,O
and,O
Merletti,O
2004,O
).,O
Muscle,O
fiber,O
conduction,O
velocity,O
calculation,O
was,O
based,O
on,O
the,O
time,O
delay,O
identified,O
by,O
the,O
peak,O
of,O
the,O
cross,O
-,O
correlation,O
function,O
and,O
the,O
known,O
interbar,O
distance,O
of,O
5,O
mm,O
.,O
The,O
root,O
-,O
mean,O
-,O
square,O
(,O
RMS,O
),O
amplitude,O
of,O
sEMG,O
activity,O
was,O
also,O
calculated,O
.,O
The,O
rate,O
of,O
muscle,O
activation,O
was,O
calculated,O
by,O
first,O
rectifying,O
the,O
sEMG,O
data,O
and,O
then,O
numerically,O
integrating,O
the,O
first,O
30,O
ms,O
starting,O
from,O
the,O
sEMG,O
onset,O
(,O
Q30,O
),O
that,O
represents,O
the,O
rate,O
of,O
increase,O
in,O
the,O
sEMG,O
over,O
the,O
first,O
30,O
ms,O
of,O
muscle,O
activity,O
(,O
Gottlieb,O
et,O
al,O
.,O
1989,O
).,O
Electromechanical,O
delay,O
(,O
EMD,O
),O
comprises,O
an,O
important,O
portion,O
of,O
the,O
rate,O
of,O
tension,O
development,O
phase,O
of,O
the,O
contraction,O
(,O
Gabriel,O
et,O
al,O
.,O
2001,O
"),",O
where,O
changes,O
in,O
motor,O
unit,O
activity,O
patterns,O
have,O
been,O
demonstrated,O
to,O
play,O
a,O
critical,O
role,O
in,O
the,O
maximal,O
rate,O
of,O
torque,O
development,O
(,O
Van,O
Cutsem,O
et,O
al,O
.,O
1998,O
).,O
Electromechanical,O
delay,O
was,O
determined,O
from,O
the,O
time,O
lag,O
between,O
the,O
onset,O
of,O
dorsiflexion,O
torque,O
and,O
sEMG,O
.,O
sEMG,O
onset,O
threshold,O
was,O
identified,O
as,O
the,O
first,O
point,O
of,O
the,O
sEMG,O
signal,O
to,O
rise,O
above,O
the,O
95,O
%,O
confidence,O
interval,O
for,O
baseline,O
noise,O
and,O
to,O
remain,O
above,O
the,O
95,O
%,O
confidence,O
interval,O
for,O
20,O
ms,O
(,O
Di,O
Fabio,O
1987,O
).,O
Visual,O
inspection,O
was,O
utilized,O
to,O
ensure,O
the,O
accuracy,O
of,O
the,O
established,O
threshold,O
’,O
s,O
ability,O
to,O
detect,O
either,O
torque,O
or,O
sEMG,O
onset,O
(,O
Inglis,O
et,O
al,O
.,O
2013,O
).,O
Evoked,O
isometric,O
compound,O
muscle,O
action,O
potentials,O
Compound,O
muscle,O
action,O
potentials,O
were,O
evoked,O
through,O
a,O
cathode,O
stimulating,O
electrode,O
placed,O
over,O
the,O
fibular,O
nerve,O
along,O
with,O
an,O
anode,O
placed,O
on,O
the,O
medial,O
condyle,O
of,O
the,O
fibula,O
to,O
evoke,O
an,O
isometric,O
dorsiflexion,O
twitch,O
contraction,O
.,O
The,O
evoked,O
potentials,O
were,O
monitored,O
on,O
an,O
oscilloscope,O
(,O
VC,O
-,O
6525,O
;,O
Hitachi,O
),O
to,O
ensure,O
that,O
a,O
consistent,O
maximal,O
response,O
had,O
been,O
achieved,O
for,O
ten,O
stimulations,O
.,O
The,O
peak,O
-,O
to,O
-,O
peak,O
voltage,O
(,O
Vpp,O
),O
was,O
extracted,O
from,O
the,O
CMAP,O
",",O
while,O
contraction,O
time,O
(,O
CT,O
),O
was,O
obtained,O
from,O
the,O
torque,O
-,O
time,O
curve,O
.,O
Evoked,O
contraction,O
time,O
(,O
CT,O
),O
was,O
calculated,O
from,O
the,O
time,O
difference,O
between,O
the,O
CMAP,O
onset,O
to,O
its,O
time,O
to,O
peak,O
tension,O
(,O
Dahmane,O
et,O
al,O
.,O
2005,O
).,O
Contraction,O
time,O
is,O
used,O
in,O
this,O
paper,O
to,O
separate,O
differences,O
in,O
the,O
rate,O
of,O
torque,O
development,O
associated,O
with,O
voluntary,O
control,O
versus,O
muscle,O
fibers,O
properties,O
.,O
Ultimately,O
",",O
it,O
was,O
important,O
to,O
determine,O
if,O
potential,O
sex,O
-,O
difference,O
in,O
Q30,O
could,O
be,O
due,O
to,O
the,O
initial,O
differences,O
in,O
peripheral,O
factors,O
(,O
MFCV,O
",",O
Vpp,O
",",O
or,O
CT,O
),O
or,O
overall,O
voluntary,O
activation,O
(,O
RMS,O
).,O
Maximal,O
voluntary,O
isometric,O
dorsiflexion,O
contractions,O
After,O
the,O
evoked,O
contractions,O
",",O
a,O
15,O
-,O
min,O
rest,O
period,O
was,O
given,O
.,O
Participants,O
then,O
performed,O
three,O
voluntary,O
maximal,O
effort,O
isometric,O
dorsiflexion,O
contractions,O
by,O
pulling,O
with,O
the,O
top,O
of,O
their,O
foot,O
against,O
a,O
padded,O
metal,O
plate,O
while,O
minimizing,O
toe,O
extension,O
.,O
During,O
the,O
MVC,O
’,O
s,O
",",O
each,O
participant,O
was,O
asked,O
to,O
contract,O
“,O
as,O
hard,O
and,O
as,O
fast,O
as,O
possible,O
”,O
with,O
an,O
emphasis,O
on,O
the,O
“,O
hard,O
”,O
(,O
Sahaly,O
et,O
al,O
.,O
2001,O
).,O
Each,O
contraction,O
lasted,O
approximately,O
5,O
s,O
in,O
duration,O
and,O
was,O
separated,O
by,O
a,O
5,O
-,O
min,O
rest,O
period,O
.,O
The,O
force,O
data,O
were,O
converted,O
to,O
torque,O
values,O
using,O
the,O
lever,O
arm,O
length,O
",",O
measured,O
from,O
the,O
ankle,O
joint,O
to,O
the,O
metatarsals,O
",",O
where,O
the,O
load,O
cell,O
was,O
located,O
.,O
A,O
target,O
line,O
was,O
given,O
which,O
represented,O
110,O
%,O
of,O
the,O
previously,O
determined,O
maximal,O
effort,O
",",O
which,O
was,O
identified,O
in,O
real,O
time,O
on,O
an,O
oscilloscope,O
.,O
Furthermore,O
",",O
during,O
each,O
voluntary,O
contraction,O
",",O
the,O
participants,O
were,O
verbally,O
encouraged,O
to,O
surpass,O
the,O
target,O
line,O
.,O
Figure,O
1,O
shows,O
a,O
representative,O
torque,O
trace,O
",",O
rate,O
of,O
change,O
in,O
torque,O
",",O
and,O
surface,O
electromyographic,O
activity,O
of,O
the,O
tibialis,O
anterior,O
during,O
a,O
maximal,O
effort,O
dorsiflexion,O
contraction,O
.,O
The,O
manner,O
in,O
which,O
the,O
signals,O
were,O
collected,O
is,O
described,O
below,O
.,O
Fig,O
.,O
1Torque,O
(,O
τ,O
),O
(,O
dark,O
grey,O
"),",O
surface,O
electromyographic,O
activity,O
(,O
light,O
grey,O
"),",O
and,O
the,O
rate,O
of,O
torque,O
development,O
(,O
black,O
),O
over,O
the,O
first,O
second,O
of,O
a,O
trial,O
for,O
a,O
male,O
representative,O
subject,O
.,O
The,O
first,O
vertical,O
line,O
(,O
black,O
),O
represents,O
the,O
EMG,O
onset,O
;,O
the,O
second,O
vertical,O
line,O
(,O
grey,O
),O
represents,O
the,O
torque,O
onset,O
Maximum,O
rate,O
of,O
torque,O
development,O
was,O
calculated,O
from,O
the,O
equation,O
provided,O
by,O
Andersen,O
and,O
Aagaard,O
(,O
2006,O
).,O
The,O
calculation,O
involves,O
determining,O
the,O
slope,O
(,O
Δτ,O
/,O
Δt,O
),O
over,O
non,O
-,O
overlapping,O
",",O
successive,O
20,O
ms,O
intervals,O
",",O
starting,O
from,O
the,O
onset,O
of,O
the,O
torque,O
-,O
time,O
curve,O
.,O
The,O
onset,O
was,O
determined,O
as,O
the,O
point,O
in,O
the,O
signal,O
where,O
the,O
rate,O
of,O
change,O
surpassed,O
1,O
%,O
of,O
the,O
maximal,O
rate,O
of,O
torque,O
development,O
(,O
dτ,O
/,O
dt,O
max,O
).,O
The,O
dτ,O
/,O
dt,O
max,O
was,O
then,O
the,O
maximum,O
slope,O
",",O
which,O
is,O
synonymous,O
with,O
the,O
‘,O
peak,O
’,O
of,O
the,O
dτ,O
/,O
dt,O
curve,O
(,O
Gabriel,O
et,O
al,O
.,O
2001,O
).,O
Statistical,O
analysis,O
Statistical,O
analysis,O
was,O
conducted,O
in,O
two,O
stages,O
:,O
first,O
",",O
to,O
evaluate,O
the,O
reliability,O
of,O
the,O
criterion,O
measures,O
using,O
the,O
intraclass,O
correlational,O
analysis,O
of,O
variance,O
technique,O
for,O
males,O
and,O
females,O
",",O
separately,O
;,O
second,O
",",O
significant,O
differences,O
between,O
males,O
and,O
females,O
(,O
Sex,O
),O
in,O
the,O
magnitude,O
of,O
the,O
means,O
",",O
and,O
changes,O
in,O
the,O
means,O
across,O
test,O
sessions,O
(,O
Days,O
"),",O
and,O
the,O
interaction,O
(,O
Sex,O
×,O
Days,O
),O
was,O
evaluated,O
using,O
a,O
repeated,O
-,O
measures,O
analysis,O
of,O
covariance,O
to,O
determine,O
the,O
impact,O
of,O
potential,O
variables,O
that,O
may,O
underlie,O
sex,O
-,O
differences,O
in,O
the,O
rate,O
of,O
torque,O
development,O
.,O
Intraclass,O
correlation,O
Intraclass,O
correlational,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
was,O
performed,O
to,O
evaluate,O
the,O
reliability,O
of,O
the,O
criterion,O
measures,O
for,O
each,O
group,O
",",O
which,O
requires,O
the,O
consideration,O
of,O
both,O
the,O
stability,O
of,O
means,O
and,O
the,O
consistency,O
of,O
scores,O
.,O
A,O
one,O
-,O
way,O
repeated,O
-,O
measures,O
ANOVA,O
was,O
used,O
to,O
assess,O
the,O
stability,O
of,O
means,O
across,O
the,O
three,O
test,O
sessions,O
",",O
while,O
the,O
intraclass,O
correlation,O
coefficient,O
(,O
model,O
2,O
",",O
k,O
),O
was,O
used,O
to,O
evaluate,O
the,O
consistency,O
of,O
scores,O
within,O
subjects,O
.,O
We,O
adopted,O
the,O
convention,O
delineated,O
by,O
Fleiss,O
(,O
1986,O
),O
where,O
an,O
intraclass,O
correlation,O
coefficient,O
(,O
R,O
),O
below,O
0,O
.,O
40,O
indicates,O
poor,O
reliability,O
",",O
between,O
0,O
.,O
40,O
and,O
0,O
.,O
75,O
is,O
fair,O
reliability,O
",",O
while,O
values,O
greater,O
than,O
0,O
.,O
75,O
represent,O
excellent,O
reliability,O
.,O
The,O
magnitude,O
of,O
the,O
intraclass,O
correlation,O
coefficient,O
was,O
further,O
evaluated,O
using,O
the,O
standard,O
error,O
of,O
measurement,O
(,O
SEM,O
),O
within,O
an,O
individual,O
(,O
Green,O
et,O
al,O
.,O
2015,O
).,O
The,O
SEM,O
was,O
calculated,O
as,O
the,O
square,O
of,O
the,O
mean,O
square,O
error,O
for,O
the,O
ANOVA,O
table,O
using,O
the,O
variables,O
‘,O
Sex,O
’,O
and,O
‘,O
Day,O
’,O
(,O
Weir,O
and,O
Cockerham,O
1984,O
).,O
The,O
intrasubject,O
coefficient,O
of,O
variation,O
was,O
the,O
grand,O
mean,O
across,O
the,O
three,O
test,O
sessions,O
divided,O
by,O
the,O
SEM,O
.,O
Analysis,O
of,O
covariance,O
(,O
ANCOVA,O
),O
A,O
repeated,O
-,O
measures,O
analysis,O
of,O
covariance,O
(,O
ANCOVA,O
),O
was,O
then,O
used,O
to,O
determine,O
the,O
impact,O
of,O
a,O
covariate,O
on,O
significant,O
differences,O
between,O
males,O
and,O
females,O
with,O
respect,O
to,O
the,O
dτ,O
/,O
dt,O
max,O
development,O
.,O
Maximal,O
torque,O
and,O
Q30,O
were,O
the,O
primary,O
variables,O
of,O
interest,O
.,O
However,O
",",O
EMD,O
",",O
MFCV,O
",",O
and,O
twitch,O
contraction,O
time,O
(,O
CT,O
),O
were,O
also,O
explored,O
.,O
All,O
statistical,O
procedures,O
were,O
performed,O
using,O
SAS,O
statistical,O
software,O
(,O
SAS,O
Institute,O
Inc,O
".,",O
Cary,O
",",O
NC,O
),O
with,O
alpha,O
set,O
at,O
the,O
0,O
.,O
05,O
probability,O
level,O
.,O
The,O
means,O
±,O
standard,O
deviations,O
(,O
SD,O
),O
for,O
each,O
measure,O
are,O
reported,O
below,O
.,O
Results,O
Participant,O
characteristics,O
The,O
means,O
and,O
standard,O
deviations,O
for,O
the,O
participant,O
’,O
s,O
characteristics,O
are,O
given,O
in,O
Table,O
1,O
.,O
Significant,O
differences,O
were,O
seen,O
in,O
all,O
anthropometric,O
measurements,O
between,O
males,O
and,O
females,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
However,O
",",O
there,O
were,O
no,O
significant,O
differences,O
in,O
hours,O
per,O
week,O
engaged,O
in,O
physical,O
activity,O
or,O
weight,O
lifting,O
(,O
p,O
>,O
0,O
.,O
05,O
).,O
The,O
grand,O
means,O
and,O
standard,O
deviations,O
for,O
the,O
criterion,O
measures,O
across,O
the,O
three,O
test,O
sessions,O
for,O
males,O
and,O
females,O
are,O
presented,O
in,O
tables,O
for,O
the,O
voluntary,O
and,O
evoked,O
contractions,O
(,O
see,O
Tables,O
2,O
",",O
3,O
).,O
Table,O
1Demographic,O
characteristics,O
of,O
the,O
study,O
participantsMeasureFemales,O
(,O
N,O
=,O
18,O
),O
M,O
±,O
SDMales,O
(,O
N,O
=,O
20,O
),O
M,O
±,O
SDDifference,O
%,O
Age,O
(,O
years,O
),O
24,O
±,O
3,O
.,O
324,O
±,O
2,O
.,O
40Height,O
(,O
m,O
),O
1,O
.,O
6,O
±,O
0,O
.,O
11,O
.,O
8,O
±,O
0,O
.,O
111,O
.,O
1,O
*,O
Mass,O
(,O
kg,O
),O
56,O
.,O
5,O
±,O
8,O
.,O
579,O
.,O
7,O
±,O
3,O
.,O
929,O
.,O
1,O
*,O
Body,O
mass,O
index,O
(,O
kg,O
/,O
m2,O
),O
21,O
.,O
4,O
±,O
2,O
.,O
224,O
.,O
4,O
±,O
0,O
.,O
812,O
.,O
3,O
*,O
Foot,O
length,O
(,O
cm,O
),O
23,O
.,O
7,O
±,O
0,O
.,O
728,O
.,O
5,O
±,O
1,O
.,O
516,O
.,O
8,O
*,O
Leg,O
length,O
(,O
cm,O
),O
39,O
.,O
2,O
±,O
1,O
.,O
847,O
.,O
3,O
±,O
2,O
.,O
317,O
.,O
1,O
*,O
Leg,O
girth,O
(,O
cm,O
),O
37,O
.,O
0,O
±,O
1,O
.,O
740,O
.,O
4,O
±,O
1,O
.,O
98,O
.,O
4,O
*,O
Physical,O
activity,O
(,O
hours,O
/,O
week,O
),O
7,O
.,O
5,O
±,O
3,O
.,O
49,O
.,O
3,O
±,O
2,O
.,O
219,O
.,O
4Weight,O
-,O
lifting,O
(,O
hours,O
/,O
week,O
),O
4,O
.,O
4,O
±,O
3,O
.,O
75,O
.,O
5,O
±,O
2,O
.,O
820,O
.,O
0Significant,O
differences,O
were,O
set,O
at,O
a,O
p,O
<,O
0,O
.,O
05,O
level,O
and,O
are,O
indicated,O
with,O
*,O
Table,O
2Data,O
under,O
the,O
voluntary,O
condition,O
Female,O
vMFCV,O
(,O
m,O
/,O
s,O
),O
vEMD,O
(,O
ms,O
),O
vRTDpk,O
(,O
Nm,O
/,O
s,O
),O
vTorque,O
(,O
Nm,O
),O
Q30,O
(,O
mV,O
x,O
s,O
),O
RMS,O
(,O
mV,O
),O
Test,O
Day,O
(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
),O
15,O
.,O
16,O
±,O
1,O
.,O
6137,O
.,O
19,O
±,O
11,O
.,O
0681,O
.,O
15,O
±,O
33,O
.,O
6529,O
.,O
10,O
±,O
7,O
.,O
967,O
.,O
90,O
±,O
5,O
.,O
270,O
.,O
21,O
±,O
0,O
.,O
1025,O
.,O
28,O
±,O
1,O
.,O
4033,O
.,O
86,O
±,O
10,O
.,O
0782,O
.,O
74,O
±,O
36,O
.,O
0229,O
.,O
17,O
±,O
7,O
.,O
788,O
.,O
26,O
±,O
6,O
.,O
970,O
.,O
21,O
±,O
0,O
.,O
1335,O
.,O
33,O
±,O
1,O
.,O
6927,O
.,O
09,O
±,O
5,O
.,O
3091,O
.,O
43,O
±,O
34,O
.,O
8827,O
.,O
10,O
±,O
6,O
.,O
618,O
.,O
20,O
±,O
6,O
.,O
740,O
.,O
17,O
±,O
0,O
.,O
11Grand5,O
.,O
26,O
±,O
1,O
.,O
5532,O
.,O
71,O
±,O
9,O
.,O
94,O
*,O
85,O
.,O
11,O
±,O
34,O
.,O
5128,O
.,O
46,O
±,O
7,O
.,O
398,O
.,O
12,O
±,O
6,O
.,O
260,O
.,O
20,O
±,O
0,O
.,O
11,O
SEM,O
0,O
.,O
678,O
.,O
0210,O
.,O
352,O
.,O
763,O
.,O
060,O
.,O
03,O
R,O
0,O
.,O
810,O
.,O
350,O
.,O
910,O
.,O
860,O
.,O
760,O
.,O
92,O
Male,O
Test,O
Day14,O
.,O
92,O
±,O
0,O
.,O
9932,O
.,O
92,O
±,O
12,O
.,O
48160,O
.,O
03,O
±,O
70,O
.,O
2957,O
.,O
31,O
±,O
17,O
.,O
125,O
.,O
80,O
±,O
2,O
.,O
910,O
.,O
18,O
±,O
0,O
.,O
1125,O
.,O
13,O
±,O
1,O
.,O
2532,O
.,O
52,O
±,O
12,O
.,O
08157,O
.,O
04,O
±,O
70,O
.,O
0058,O
.,O
52,O
±,O
21,O
.,O
694,O
.,O
83,O
±,O
3,O
.,O
210,O
.,O
18,O
±,O
0,O
.,O
1334,O
.,O
70,O
±,O
1,O
.,O
0933,O
.,O
08,O
±,O
13,O
.,O
74142,O
.,O
01,O
±,O
82,O
.,O
0156,O
.,O
97,O
±,O
20,O
.,O
545,O
.,O
26,O
±,O
2,O
.,O
730,O
.,O
17,O
±,O
0,O
.,O
08Grand4,O
.,O
92,O
±,O
1,O
.,O
1132,O
.,O
84,O
±,O
12,O
.,O
57153,O
.,O
03,O
±,O
73,O
.,O
4757,O
.,O
60,O
±,O
19,O
.,O
555,O
.,O
30,O
±,O
3,O
.,O
010,O
.,O
18,O
±,O
0,O
.,O
11,O
SEM,O
0,O
.,O
556,O
.,O
1230,O
.,O
298,O
.,O
061,O
.,O
880,O
.,O
06,O
R,O
0,O
.,O
760,O
.,O
700,O
.,O
830,O
.,O
830,O
.,O
610,O
.,O
72,O
Percent,O
Difference,O
6,O
.,O
50,O
.,O
444,O
.,O
4,O
*,O
50,O
.,O
6,O
*,O
34,O
.,O
7,O
*,O
10Means,O
(,O
M,O
),O
and,O
standard,O
deviations,O
(,O
SD,O
),O
for,O
voluntary,O
muscle,O
fiber,O
conduction,O
velocity,O
(,O
vMFCV,O
"),",O
voluntary,O
electromechanical,O
delay,O
(,O
vEMD,O
"),",O
voluntary,O
peak,O
rate,O
of,O
torque,O
development,O
(,O
vRTDpk,O
"),",O
voluntary,O
maximum,O
torque,O
(,O
vTorque,O
"),",O
voluntary,O
rate,O
of,O
EMG,O
increase,O
over,O
the,O
first,O
30,O
ms,O
(,O
Q30,O
"),",O
and,O
voluntary,O
root,O
-,O
mean,O
squared,O
amplitude,O
(,O
RMS,O
).,O
Significant,O
differences,O
were,O
set,O
at,O
a,O
p,O
<,O
0,O
.,O
05,O
level,O
and,O
are,O
indicated,O
with,O
*,O
Table,O
3Data,O
under,O
the,O
evoked,O
condition,O
Female,O
eMFCV,O
(,O
m,O
/,O
s,O
),O
eEMD,O
(,O
ms,O
),O
eRTDpk,O
(,O
Nm,O
/,O
s,O
),O
eTorque,O
(,O
Nm,O
),O
Vpp,O
(,O
mV,O
),O
CT,O
(,O
ms,O
),O
Test,O
Day,O
(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
)(,O
M,O
±,O
SD,O
),O
14,O
.,O
22,O
±,O
1,O
.,O
7616,O
.,O
71,O
±,O
11,O
.,O
2146,O
.,O
07,O
±,O
18,O
.,O
412,O
.,O
59,O
±,O
1,O
.,O
432,O
.,O
17,O
±,O
0,O
.,O
9277,O
.,O
20,O
±,O
17,O
.,O
6324,O
.,O
11,O
±,O
0,O
.,O
9915,O
.,O
38,O
±,O
10,O
.,O
9846,O
.,O
75,O
±,O
18,O
.,O
432,O
.,O
69,O
±,O
1,O
.,O
282,O
.,O
22,O
±,O
0,O
.,O
9180,O
.,O
74,O
±,O
12,O
.,O
1834,O
.,O
34,O
±,O
1,O
.,O
5114,O
.,O
97,O
±,O
10,O
.,O
0246,O
.,O
25,O
±,O
14,O
.,O
432,O
.,O
68,O
±,O
1,O
.,O
102,O
.,O
07,O
±,O
0,O
.,O
9869,O
.,O
21,O
±,O
22,O
.,O
78Grand4,O
.,O
22,O
±,O
1,O
.,O
4315,O
.,O
69,O
±,O
10,O
.,O
5746,O
.,O
36,O
±,O
16,O
.,O
872,O
.,O
66,O
±,O
1,O
.,O
252,O
.,O
16,O
±,O
0,O
.,O
9275,O
.,O
72,O
±,O
18,O
.,O
37,O
SEM,O
0,O
.,O
504,O
.,O
254,O
.,O
130,O
.,O
280,O
.,O
364,O
.,O
41,O
R,O
0,O
.,O
880,O
.,O
840,O
.,O
940,O
.,O
950,O
.,O
850,O
.,O
91,O
Male,O
Test,O
Day14,O
.,O
33,O
±,O
1,O
.,O
5010,O
.,O
57,O
±,O
3,O
.,O
30106,O
.,O
48,O
±,O
39,O
.,O
665,O
.,O
89,O
±,O
2,O
.,O
332,O
.,O
59,O
±,O
1,O
.,O
1468,O
.,O
65,O
±,O
7,O
.,O
4724,O
.,O
71,O
±,O
1,O
.,O
6610,O
.,O
17,O
±,O
4,O
.,O
56101,O
.,O
01,O
±,O
41,O
.,O
675,O
.,O
54,O
±,O
2,O
.,O
482,O
.,O
51,O
±,O
1,O
.,O
1379,O
.,O
55,O
±,O
11,O
.,O
9834,O
.,O
17,O
±,O
0,O
.,O
999,O
.,O
12,O
±,O
2,O
.,O
06104,O
.,O
50,O
±,O
35,O
.,O
125,O
.,O
86,O
±,O
1,O
.,O
992,O
.,O
73,O
±,O
1,O
.,O
0176,O
.,O
60,O
±,O
8,O
.,O
09Grand4,O
.,O
40,O
±,O
1,O
.,O
409,O
.,O
95,O
±,O
3,O
.,O
46104,O
.,O
00,O
±,O
38,O
.,O
315,O
.,O
77,O
±,O
2,O
.,O
242,O
.,O
61,O
±,O
1,O
.,O
0874,O
.,O
93,O
±,O
10,O
.,O
33,O
SEM,O
0,O
.,O
762,O
.,O
278,O
.,O
570,O
.,O
450,O
.,O
402,O
.,O
32,O
R,O
0,O
.,O
710,O
.,O
570,O
.,O
950,O
.,O
960,O
.,O
870,O
.,O
64,O
Percent,O
Differences,O
4,O
.,O
136,O
.,O
6,O
*,O
55,O
.,O
4,O
*,O
53,O
.,O
9,O
*,O
17,O
.,O
20,O
.,O
01Means,O
(,O
M,O
),O
and,O
standard,O
deviations,O
(,O
SD,O
),O
for,O
evoked,O
muscle,O
fiber,O
conduction,O
velocity,O
(,O
eMFCV,O
"),",O
evoked,O
electromechanical,O
delay,O
(,O
eEMD,O
"),",O
evoked,O
peak,O
rate,O
of,O
torque,O
development,O
(,O
eRTDpk,O
"),",O
evoked,O
maximum,O
torque,O
(,O
eTorque,O
"),",O
evoked,O
peak,O
-,O
peak,O
voltage,O
(,O
Vpp,O
"),",O
and,O
the,O
evoked,O
contraction,O
time,O
(,O
CT,O
).,O
Significant,O
differences,O
were,O
set,O
at,O
a,O
p,O
<,O
0,O
.,O
05,O
level,O
and,O
are,O
indicated,O
with,O
*,O
Reliability,O
analysis,O
Table,O
2,O
shows,O
that,O
the,O
consistency,O
of,O
scores,O
within,O
subjects,O
for,O
the,O
criterion,O
measures,O
obtained,O
during,O
the,O
voluntary,O
contractions,O
for,O
females,O
was,O
excellent,O
(,O
R,O
=,O
0,O
.,O
76,O
–,O
92,O
),O
except,O
for,O
EMD,O
which,O
had,O
an,O
intraclass,O
correlation,O
coefficient,O
of,O
R,O
=,O
0,O
.,O
35,O
(,O
see,O
Table,O
2,O
).,O
Female,O
participants,O
exhibited,O
a,O
27,O
.,O
2,O
%,O
reduction,O
in,O
EMD,O
from,O
session,O
1,O
to,O
session,O
3,O
(,O
F,O
[,O
2,O
",",O
51,O
],O
=,O
5,O
.,O
83,O
",",O
p,O
=,O
0,O
.,O
0045,O
).,O
The,O
lack,O
of,O
stability,O
",",O
as,O
assess,O
by,O
the,O
repeated,O
-,O
measures,O
ANOVA,O
",",O
resulted,O
in,O
a,O
reduced,O
intraclass,O
correlation,O
coefficient,O
.,O
However,O
",",O
the,O
intrasubject,O
coefficient,O
of,O
variation,O
(,O
Grand,O
Mean,O
/,O
SEM,O
),O
was,O
24,O
.,O
5,O
"%,",O
which,O
was,O
deemed,O
acceptable,O
for,O
further,O
analyses,O
(,O
Green,O
et,O
al,O
.,O
2015,O
).,O
The,O
means,O
of,O
the,O
criterion,O
measures,O
generated,O
during,O
voluntary,O
contractions,O
as,O
shown,O
in,O
Table,O
2,O
were,O
highly,O
stable,O
across,O
test,O
sessions,O
in,O
males,O
",",O
while,O
the,O
consistency,O
of,O
scores,O
within,O
subjects,O
ranged,O
from,O
fair,O
to,O
excellent,O
(,O
R,O
=,O
0,O
.,O
61,O
–,O
83,O
).,O
The,O
higher,O
intrasubject,O
variation,O
(,O
56,O
.,O
8,O
%),O
for,O
males,O
Q30,O
resulted,O
in,O
a,O
lower,O
intraclass,O
correlation,O
coefficient,O
(,O
R,O
=,O
0,O
.,O
61,O
"),",O
but,O
was,O
still,O
acceptable,O
.,O
The,O
same,O
was,O
true,O
for,O
the,O
criterion,O
measures,O
generated,O
during,O
evoked,O
contractions,O
(,O
R,O
=,O
0,O
.,O
85,O
–,O
95,O
),O
and,O
Table,O
3,O
shows,O
that,O
consistency,O
of,O
scores,O
within,O
subjects,O
for,O
the,O
criterion,O
measures,O
obtained,O
during,O
the,O
evoked,O
contractions,O
in,O
males,O
ranged,O
from,O
fair,O
to,O
excellent,O
(,O
R,O
=,O
0,O
.,O
57,O
–,O
96,O
).,O
The,O
lowest,O
intraclass,O
correlation,O
coefficient,O
was,O
for,O
EMD,O
",",O
but,O
it,O
had,O
an,O
intrasubject,O
coefficient,O
of,O
variation,O
of,O
only,O
22,O
.,O
8,O
%.,O
While,O
there,O
was,O
a,O
slight,O
decrease,O
in,O
the,O
means,O
across,O
sessions,O
",",O
a,O
limited,O
range,O
of,O
scores,O
contributed,O
to,O
a,O
decreased,O
intraclass,O
correlation,O
coefficient,O
.,O
Thus,O
",",O
the,O
measure,O
was,O
still,O
deemed,O
acceptable,O
for,O
further,O
analyses,O
.,O
Between,O
groups,O
analyses,O
A,O
repeated,O
-,O
measures,O
ANOVA,O
revealed,O
a,O
significant,O
difference,O
between,O
groups,O
and,O
across,O
days,O
for,O
voluntary,O
maximal,O
dorsiflexion,O
isometric,O
torque,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
45,O
.,O
97,O
",",O
p,O
=,O
0,O
.,O
001,O
).,O
Males,O
had,O
on,O
average,O
a,O
50,O
.,O
6,O
%,O
greater,O
torque,O
output,O
than,O
females,O
.,O
The,O
difference,O
between,O
males,O
and,O
females,O
with,O
respect,O
to,O
the,O
maximum,O
rate,O
of,O
torque,O
development,O
was,O
similar,O
in,O
magnitude,O
.,O
The,O
maximum,O
rate,O
of,O
torque,O
development,O
was,O
44,O
.,O
6,O
%,O
greater,O
in,O
males,O
than,O
for,O
females,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
16,O
.,O
46,O
",",O
p,O
=,O
0,O
.,O
0003,O
).,O
In,O
contrast,O
",",O
females,O
had,O
a,O
34,O
.,O
7,O
%,O
greater,O
rate,O
of,O
increase,O
in,O
muscle,O
activation,O
as,O
assessed,O
by,O
Q30,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
4,O
.,O
30,O
",",O
p,O
=,O
0,O
.,O
0454,O
).,O
There,O
were,O
no,O
significant,O
differences,O
between,O
males,O
and,O
females,O
with,O
respect,O
to,O
EMD,O
",",O
RMS,O
amplitude,O
",",O
or,O
MFCV,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
0,O
.,O
00,O
",",O
p,O
=,O
0,O
.,O
9635,O
;,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
0,O
.,O
31,O
",",O
p,O
=,O
0,O
.,O
5834,O
;,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
0,O
.,O
86,O
",",O
p,O
=,O
0,O
.,O
3598,O
",",O
respectively,O
).,O
Similar,O
to,O
the,O
voluntary,O
contractions,O
",",O
maximal,O
evoked,O
dorsiflexion,O
torque,O
was,O
53,O
.,O
9,O
%,O
greater,O
for,O
males,O
than,O
for,O
females,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
28,O
.,O
52,O
",",O
p,O
=,O
0,O
.,O
001,O
"),",O
and,O
males,O
also,O
had,O
a,O
comparably,O
greater,O
maximum,O
rate,O
of,O
torque,O
development,O
of,O
55,O
.,O
4,O
%,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
13,O
.,O
99,O
",",O
p,O
=,O
0,O
.,O
0006,O
).,O
The,O
EMD,O
was,O
36,O
.,O
6,O
%,O
shorter,O
for,O
males,O
than,O
for,O
females,O
during,O
the,O
evoked,O
contractions,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
7,O
.,O
02,O
",",O
p,O
=,O
0,O
.,O
0119,O
).,O
In,O
contrast,O
",",O
MFCV,O
",",O
evoked,O
CT,O
",",O
and,O
Vpp,O
of,O
the,O
CMAP,O
were,O
not,O
significantly,O
different,O
between,O
groups,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
0,O
.,O
22,O
",",O
p,O
=,O
0,O
.,O
6451,O
;,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
0,O
.,O
03,O
",",O
p,O
=,O
0,O
.,O
8589,O
;,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
2,O
.,O
42,O
",",O
p,O
=,O
0,O
.,O
1288,O
",",O
respectively,O
).,O
Analysis,O
of,O
covariance,O
When,O
maximal,O
torque,O
was,O
used,O
as,O
the,O
covariate,O
in,O
the,O
repeated,O
-,O
measures,O
ANCOVA,O
for,O
the,O
maximum,O
rate,O
of,O
torque,O
development,O
",",O
the,O
difference,O
between,O
means,O
decreased,O
to,O
1,O
.,O
2,O
%,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
0,O
.,O
01,O
",",O
p,O
=,O
0,O
.,O
9264,O
).,O
The,O
rate,O
of,O
increase,O
in,O
muscle,O
activation,O
(,O
Q30,O
),O
was,O
not,O
assessed,O
as,O
a,O
covariate,O
",",O
because,O
females,O
were,O
actually,O
greater,O
than,O
males,O
.,O
The,O
only,O
other,O
significant,O
difference,O
between,O
males,O
and,O
females,O
was,O
EMD,O
during,O
evoked,O
contractions,O
.,O
However,O
",",O
evoked,O
EMD,O
had,O
little,O
impact,O
as,O
a,O
covariate,O
.,O
Sex,O
-,O
related,O
differences,O
in,O
the,O
maximum,O
rate,O
of,O
torque,O
development,O
were,O
reduced,O
to,O
33,O
.,O
8,O
"%,",O
which,O
were,O
still,O
significant,O
(,O
F,O
[,O
1,O
",",O
36,O
],O
=,O
8,O
.,O
27,O
",",O
p,O
=,O
0,O
.,O
0067,O
).,O
Discussion,O
The,O
main,O
finding,O
of,O
the,O
current,O
work,O
was,O
that,O
maximum,O
torque,O
was,O
able,O
to,O
account,O
for,O
almost,O
all,O
of,O
the,O
sex,O
-,O
related,O
differences,O
in,O
the,O
maximum,O
rate,O
of,O
torque,O
development,O
",",O
as,O
the,O
percent,O
difference,O
in,O
least,O
-,O
square,O
means,O
was,O
reduced,O
to,O
1,O
.,O
2,O
%,O
when,O
using,O
maximum,O
torque,O
as,O
a,O
covariate,O
.,O
There,O
also,O
were,O
no,O
significant,O
differences,O
between,O
males,O
and,O
females,O
in,O
sEMG,O
RMS,O
amplitude,O
magnitude,O
as,O
observed,O
by,O
Lenhardt,O
et,O
al,O
.,O
(,O
2009,O
).,O
The,O
absence,O
of,O
sex,O
-,O
differences,O
in,O
the,O
sEMG,O
signal,O
amplitude,O
",",O
Vpp,O
",",O
and,O
CT,O
may,O
reflect,O
a,O
comparable,O
number,O
of,O
hours,O
per,O
week,O
of,O
training,O
for,O
the,O
two,O
groups,O
(,O
Aagaard,O
et,O
al,O
.,O
2002,O
).,O
Contraction,O
time,O
was,O
used,O
in,O
the,O
study,O
to,O
determine,O
if,O
differences,O
in,O
the,O
maximal,O
rate,O
of,O
torque,O
development,O
were,O
associated,O
with,O
either,O
descending,O
voluntary,O
control,O
or,O
peripheral,O
factors,O
associated,O
with,O
muscle,O
composition,O
(,O
Close,O
1972,O
).,O
Based,O
on,O
the,O
fact,O
",",O
no,O
sex,O
-,O
related,O
differences,O
in,O
the,O
CT,O
(,O
0,O
.,O
01,O
%),O
were,O
found,O
suggests,O
that,O
the,O
two,O
groups,O
were,O
also,O
similar,O
with,O
respect,O
to,O
muscle,O
fiber,O
composition,O
",",O
which,O
is,O
consistent,O
with,O
other,O
research,O
(,O
Hicks,O
and,O
McCartney,O
1996,O
).,O
Based,O
on,O
the,O
work,O
of,O
Lenhardt,O
et,O
al,O
.,O
(,O
2009,O
"),",O
it,O
was,O
expected,O
that,O
males,O
and,O
females,O
would,O
be,O
more,O
comparable,O
in,O
maximum,O
strength,O
in,O
the,O
lower,O
limb,O
than,O
the,O
upper,O
limb,O
",",O
which,O
is,O
consistent,O
with,O
other,O
studies,O
on,O
sex,O
-,O
differences,O
in,O
maximum,O
strength,O
(,O
Heyward,O
et,O
al,O
.,O
1986,O
;,O
Hoffman,O
et,O
al,O
.,O
1979,O
).,O
Instead,O
",",O
a,O
50,O
.,O
6,O
%,O
difference,O
was,O
observed,O
",",O
which,O
was,O
the,O
same,O
order,O
of,O
magnitude,O
as,O
previously,O
observed,O
for,O
the,O
upper,O
limb,O
(,O
Inglis,O
et,O
al,O
.,O
2013,O
).,O
One,O
reason,O
may,O
be,O
related,O
to,O
differences,O
in,O
the,O
cross,O
-,O
sectional,O
area,O
(,O
CSA,O
),O
of,O
the,O
TA,O
in,O
the,O
present,O
sample,O
versus,O
that,O
of,O
Lenhardt,O
et,O
al,O
.,O
(,O
2009,O
).,O
Although,O
CSA,O
was,O
not,O
directly,O
measured,O
",",O
the,O
males,O
and,O
females,O
in,O
this,O
study,O
had,O
a,O
larger,O
difference,O
in,O
lower,O
leg,O
girth,O
(,O
8,O
.,O
4,O
%),O
than,O
the,O
5,O
.,O
2,O
%,O
observed,O
by,O
Lenhardt,O
et,O
al,O
.,O
(,O
2009,O
"),",O
which,O
may,O
suggest,O
a,O
larger,O
difference,O
in,O
TA,O
CSA,O
.,O
The,O
large,O
difference,O
in,O
maximum,O
strength,O
between,O
males,O
and,O
females,O
was,O
associated,O
with,O
a,O
comparably,O
large,O
difference,O
in,O
the,O
maximum,O
rate,O
of,O
isometric,O
dorsiflexion,O
torque,O
development,O
(,O
44,O
.,O
6,O
%).,O
Greater,O
co,O
-,O
activation,O
of,O
the,O
antagonist,O
muscle,O
group,O
in,O
females,O
could,O
contribute,O
to,O
both,O
lower,O
maximum,O
strength,O
and,O
rate,O
of,O
torque,O
development,O
.,O
Macaluso,O
et,O
al,O
.,O
(,O
2002,O
),O
showed,O
that,O
females,O
may,O
use,O
greater,O
antagonist,O
co,O
-,O
activation,O
to,O
stabilize,O
the,O
joint,O
due,O
to,O
greater,O
joint,O
laxity,O
",",O
smaller,O
agonist,O
musculature,O
",",O
and,O
potentially,O
lower,O
quality,O
muscle,O
mass,O
(,O
torque,O
/,O
CSA,O
"),",O
as,O
has,O
been,O
seen,O
in,O
older,O
versus,O
younger,O
adults,O
(,O
Solomonow,O
et,O
al,O
.,O
1988,O
;,O
Thelen,O
et,O
al,O
.,O
1996,O
).,O
However,O
",",O
antagonist,O
co,O
-,O
activation,O
was,O
not,O
measured,O
in,O
this,O
study,O
as,O
it,O
is,O
markedly,O
lower,O
during,O
isometric,O
contractions,O
compared,O
with,O
dynamic,O
contractions,O
and,O
particularly,O
lower,O
when,O
the,O
muscle,O
is,O
placed,O
in,O
a,O
shortened,O
position,O
as,O
in,O
this,O
study,O
(,O
Pasquet,O
et,O
al,O
.,O
2006,O
).,O
There,O
were,O
several,O
novel,O
findings,O
in,O
this,O
study,O
.,O
First,O
",",O
there,O
were,O
no,O
significant,O
differences,O
between,O
males,O
and,O
females,O
with,O
respect,O
to,O
MFCV,O
.,O
This,O
result,O
may,O
be,O
due,O
to,O
comparable,O
muscle,O
fiber,O
diameters,O
between,O
the,O
sexes,O
",",O
which,O
is,O
a,O
large,O
determinant,O
of,O
MFCV,O
(,O
Lange,O
et,O
al,O
.,O
2002,O
;,O
Lindstrom,O
and,O
Magnusson,O
1977,O
;,O
Merletti,O
et,O
al,O
.,O
1995,O
;,O
Nishihara,O
et,O
al,O
.,O
2005,O
;,O
Zwarts,O
1989,O
).,O
It,O
has,O
been,O
shown,O
that,O
type,O
I,O
(,O
slow,O
twitch,O
),O
fibers,O
are,O
situated,O
predominately,O
in,O
the,O
anterior,O
portion,O
of,O
the,O
TA,O
(,O
Henriksson,O
-,O
Larsén,O
et,O
al,O
.,O
1983,O
).,O
Moreover,O
",",O
it,O
is,O
a,O
general,O
result,O
that,O
",",O
while,O
males,O
have,O
larger,O
fiber,O
diameters,O
than,O
females,O
",",O
the,O
type,O
I,O
muscle,O
fiber,O
diameters,O
in,O
females,O
are,O
larger,O
than,O
their,O
type,O
II,O
muscle,O
fibers,O
.,O
The,O
small,O
interelectrode,O
distance,O
(,O
5,O
mm,O
),O
will,O
record,O
from,O
a,O
small,O
pick,O
-,O
up,O
volume,O
that,O
encapsulates,O
these,O
superficial,O
type,O
I,O
fibers,O
of,O
the,O
TA,O
",",O
which,O
are,O
comparable,O
in,O
muscle,O
fiber,O
diameter,O
between,O
the,O
sexes,O
.,O
A,O
second,O
novel,O
finding,O
is,O
that,O
there,O
were,O
pronounced,O
sex,O
-,O
differences,O
in,O
Q30,O
that,O
were,O
not,O
evident,O
in,O
either,O
the,O
voluntary,O
(,O
RMS,O
),O
or,O
evoked,O
(,O
Vpp,O
),O
sEMG,O
magnitude,O
.,O
Females,O
were,O
significantly,O
greater,O
than,O
males,O
with,O
respect,O
to,O
the,O
rate,O
of,O
muscle,O
activation,O
as,O
assessed,O
by,O
Q30,O
.,O
The,O
difference,O
increased,O
further,O
(,O
4,O
%),O
with,O
repeated,O
testing,O
.,O
This,O
change,O
was,O
also,O
associated,O
with,O
a,O
significant,O
training,O
-,O
related,O
reduction,O
in,O
voluntary,O
EMD,O
associated,O
with,O
repeated,O
testing,O
.,O
This,O
reduction,O
in,O
voluntary,O
EMG,O
but,O
“,O
not,O
”,O
evoked,O
EMG,O
",",O
and,O
highlights,O
the,O
change,O
in,O
neural,O
control,O
(,O
Gabriel,O
and,O
Boucher,O
1998,O
).,O
We,O
suggest,O
that,O
the,O
greater,O
Q30,O
and,O
reduction,O
in,O
voluntary,O
EMD,O
for,O
females,O
were,O
associated,O
with,O
a,O
different,O
motor,O
unit,O
activity,O
pattern,O
at,O
the,O
onset,O
of,O
muscle,O
contraction,O
.,O
However,O
",",O
it,O
is,O
not,O
possible,O
to,O
distinguish,O
exact,O
motor,O
unit,O
behavior,O
that,O
may,O
be,O
responsible,O
for,O
the,O
sex,O
-,O
related,O
differences,O
in,O
the,O
rate,O
of,O
increase,O
in,O
surface,O
EMG,O
.,O
Van,O
Cutsem,O
et,O
al,O
.,O
(,O
1998,O
),O
established,O
a,O
link,O
between,O
the,O
maximum,O
rate,O
of,O
isometric,O
dorsiflexion,O
torque,O
",",O
the,O
rate,O
of,O
increase,O
in,O
sEMG,O
",",O
and,O
the,O
incidence,O
of,O
doublets,O
associated,O
with,O
progressive,O
resistive,O
training,O
.,O
Similarly,O
",",O
Gabriel,O
et,O
al,O
.,O
(,O
2001,O
),O
found,O
that,O
only,O
three,O
training,O
sessions,O
were,O
sufficient,O
to,O
produce,O
an,O
increase,O
in,O
the,O
maximum,O
rate,O
of,O
isometric,O
elbow,O
extension,O
torque,O
development,O
and,O
mean,O
spike,O
frequency,O
of,O
the,O
sEMG,O
signal,O
during,O
the,O
torque,O
development,O
phase,O
of,O
the,O
contraction,O
in,O
female,O
participants,O
.,O
Bojsen,O
-,O
Moller,O
et,O
al,O
.,O
(,O
2005,O
),O
reported,O
a,O
positive,O
correlation,O
between,O
the,O
rate,O
of,O
torque,O
development,O
and,O
tendon,O
structure,O
stiffness,O
",",O
indicating,O
that,O
30,O
%,O
of,O
the,O
variation,O
in,O
torque,O
development,O
can,O
be,O
accounted,O
for,O
by,O
the,O
tendons,O
mechanical,O
properties,O
.,O
Winter,O
and,O
Brookes,O
(,O
1991,O
),O
further,O
hypothesized,O
that,O
joint,O
laxity,O
might,O
also,O
play,O
a,O
role,O
in,O
the,O
tension,O
development,O
phase,O
of,O
the,O
contraction,O
as,O
reflected,O
in,O
the,O
EMD,O
.,O
We,O
believe,O
that,O
the,O
greater,O
rate,O
of,O
increase,O
in,O
sEMG,O
activation,O
for,O
females,O
reflects,O
a,O
compensatory,O
mechanism,O
to,O
transmit,O
force,O
to,O
the,O
tendon,O
more,O
effectively,O
",",O
as,O
evident,O
in,O
the,O
observed,O
decrease,O
in,O
voluntary,O
EMD,O
(,O
Kubo,O
et,O
al,O
.,O
2003,O
;,O
Wilkerson,O
and,O
Mason,O
2000,O
;,O
Winter,O
and,O
Brookes,O
1991,O
).,O
In,O
support,O
of,O
this,O
idea,O
",",O
Rozzi,O
et,O
al,O
.,O
(,O
1999,O
),O
have,O
shown,O
that,O
females,O
exhibited,O
greater,O
integrated,O
sEMG,O
activity,O
upon,O
landing,O
from,O
a,O
jump,O
as,O
a,O
compensatory,O
mechanism,O
for,O
greater,O
knee,O
joint,O
laxity,O
",",O
which,O
includes,O
both,O
the,O
musculotendinous,O
unit,O
and,O
ligamentous,O
restraint,O
.,O
Limitations,O
sEMG,O
can,O
only,O
provide,O
an,O
indirect,O
measurement,O
of,O
differences,O
and,O
underlying,O
changes,O
in,O
motor,O
unit,O
activity,O
patterns,O
.,O
Similarly,O
",",O
the,O
use,O
of,O
CT,O
to,O
look,O
at,O
fiber,O
composition,O
differences,O
only,O
allows,O
the,O
association,O
of,O
either,O
similarities,O
or,O
differences,O
.,O
Although,O
the,O
possible,O
influence,O
of,O
different,O
muscle,O
structures,O
and,O
sizes,O
in,O
males,O
versus,O
females,O
was,O
discussed,O
in,O
the,O
paper,O
",",O
not,O
directly,O
measuring,O
it,O
with,O
ultrasound,O
is,O
a,O
limitation,O
.,O
It,O
was,O
also,O
assumed,O
that,O
there,O
were,O
differences,O
in,O
TA,O
tendon,O
stiffness,O
without,O
having,O
actually,O
measured,O
it,O
.,O
Moreover,O
",",O
caution,O
must,O
be,O
applied,O
when,O
extrapolating,O
the,O
results,O
to,O
older,O
adults,O
.,O
The,O
use,O
of,O
a,O
healthy,O
college,O
aged,O
population,O
may,O
not,O
account,O
for,O
differences,O
between,O
the,O
sexes,O
with,O
aging,O
",",O
such,O
as,O
the,O
loss,O
of,O
type,O
II,O
fibers,O
",",O
which,O
may,O
render,O
the,O
sexes,O
more,O
similar,O
in,O
the,O
6th,O
and,O
7th,O
decades,O
.,O
Conclusion,O
The,O
results,O
support,O
the,O
work,O
of,O
Hannah,O
et,O
al,O
.,O
(,O
2012,O
),O
as,O
maximal,O
strength,O
of,O
the,O
TA,O
as,O
a,O
covariate,O
accounted,O
for,O
nearly,O
all,O
of,O
the,O
sex,O
-,O
differences,O
in,O
the,O
maximum,O
rate,O
of,O
torque,O
development,O
.,O
This,O
was,O
true,O
",",O
even,O
though,O
the,O
difference,O
in,O
maximal,O
strength,O
was,O
quite,O
pronounced,O
(,O
50,O
.,O
6,O
%).,O
Thus,O
",",O
the,O
hypothesis,O
that,O
maximum,O
strength,O
accounts,O
for,O
sex,O
-,O
differences,O
in,O
the,O
maximum,O
rate,O
of,O
tension,O
development,O
in,O
the,O
lower,O
limb,O
due,O
solely,O
to,O
the,O
fact,O
that,O
males,O
and,O
females,O
are,O
more,O
comparable,O
in,O
maximum,O
strength,O
than,O
in,O
the,O
upper,O
limb,O
was,O
not,O
supported,O
.,O
Rather,O
",",O
the,O
maximum,O
strength,O
accounted,O
for,O
sex,O
-,O
difference,O
in,O
the,O
maximum,O
rate,O
of,O
tension,O
development,O
despite,O
a,O
large,O
discrepancy,O
in,O
strength,O
between,O
males,O
and,O
females,O
.,O
Furthermore,O
",",O
females,O
had,O
a,O
greater,O
rate,O
of,O
increase,O
in,O
sEMG,O
activation,O
",",O
and,O
exhibited,O
a,O
significant,O
reduction,O
in,O
EMD,O
with,O
repeated,O
testing,O
",",O
suggesting,O
that,O
they,O
might,O
utilize,O
a,O
different,O
motor,O
unit,O
activity,O
pattern,O
at,O
the,O
onset,O
of,O
contraction,O
.,O
Future,O
research,O
may,O
focus,O
on,O
training,O
modalities,O
and,O
rehabilitation,O
techniques,O
that,O
could,O
optimize,O
RTD,O
rather,O
than,O
only,O
focusing,O
on,O
maximum,O
strength,O
to,O
assist,O
an,O
older,O
population,O
in,O
balance,O
maintenance,O
and,O
recovery,O
from,O
imbalance,O
.,O
Deletion,O
of,O
JMJD2B,B-GP
in,O
neurons,O
leads,O
to,O
defective,O
spine,O
maturation,O
",",O
hyperactive,O
behavior,O
and,O
memory,O
deficits,O
in,O
mouse,B-OG
JMJD2B,B-GP
is,O
a,O
histone,B-GP
demethylase,I-GP
enzyme,O
that,O
regulates,O
gene,O
expression,O
through,O
demethylation,O
of,O
H3K9me3,O
.,O
Although,O
mutations,O
of,O
JMJD2B,B-GP
have,O
been,O
suggested,O
to,O
be,O
responsible,O
for,O
neurodevelopmental,B-DS
disorders,I-DS
",",O
the,O
function,O
of,O
JMJD2B,B-GP
in,O
the,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
remains,O
to,O
be,O
elucidated,O
.,O
Here,O
we,O
show,O
that,O
JMJD2B,B-GP
has,O
a,O
critical,O
role,O
in,O
the,O
development,O
of,O
the,O
CNS,O
.,O
We,O
observed,O
JMJD2B,B-GP
expression,O
",",O
which,O
was,O
especially,O
strong,O
in,O
the,O
hippocampus,O
",",O
throughout,O
the,O
CNS,O
from,O
embryonic,O
periods,O
through,O
adulthood,O
.,O
We,O
generated,O
neuron,O
-,O
specific,O
JMJD2B,B-GP
-,O
deficient,O
mice,B-OG
using,O
the,O
cre,B-GP
-,O
loxP,O
system,O
.,O
We,O
found,O
an,O
increase,O
in,O
total,O
spine,O
number,O
",",O
but,O
a,O
decrease,O
in,O
mature,O
spines,O
",",O
in,O
the,O
CA1,O
region,O
of,O
the,O
hippocampus,O
.,O
JMJD2B,B-GP
-,O
deficient,O
mice,B-OG
exhibited,O
hyperactive,O
behavior,O
",",O
sustained,O
hyperactivity,O
in,O
a,O
novel,O
environment,O
",",O
deficits,O
in,O
working,O
memory,O
and,O
spontaneous,O
epileptic,B-DS
-,I-DS
like,I-DS
seizures,I-DS
.,O
Together,O
these,O
observations,O
indicate,O
that,O
JMJD2B,B-GP
mutant,O
mice,B-OG
display,O
symptoms,O
reminiscent,O
of,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
Our,O
findings,O
provide,O
evidence,O
for,O
the,O
involvement,O
of,O
histone,B-GP
demethylation,O
in,O
the,O
formation,O
of,O
functional,O
neural,O
networks,O
during,O
development,O
.,O
Introduction,O
Neurodevelopmental,B-DS
disorders,I-DS
are,O
an,O
essential,O
and,O
poorly,O
understood,O
clinical,O
challenge,O
.,O
The,O
complications,O
they,O
cause,O
such,O
as,O
learning,O
disorders,O
",",O
memory,O
-,O
formation,O
deficits,O
and,O
epilepsy,B-DS
",",O
have,O
profound,O
effects,O
on,O
patients,O
',O
daily,O
life,O
.,O
1,O
",",O
2,O
Numerous,O
gene,O
mutations,O
are,O
involved,O
in,O
these,O
pathologies,O
",",O
including,O
genes,O
associated,O
with,O
postsynaptic,O
components,O
.,O
3,O
",",O
4,O
Moreover,O
",",O
recent,O
studies,O
provide,O
increasing,O
evidence,O
of,O
the,O
importance,O
of,O
epigenetic,O
mechanisms,O
in,O
the,O
underlying,O
pathobiology,O
",",O
5,O
and,O
mutations,O
of,O
genes,O
involved,O
in,O
epigenetic,O
regulation,O
are,O
found,O
in,O
patients,O
with,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
6,O
",",O
7,O
In,O
addition,O
",",O
recent,O
report,O
suggests,O
that,O
several,O
histone,B-GP
-,O
modification,O
genes,O
",",O
including,O
both,O
histone,B-GP
methyltransferases,I-GP
and,O
demethylases,B-GP
",",O
are,O
causative,O
risk,O
genes,O
for,O
such,O
disorders,O
.,O
8,O
Nevertheless,O
",",O
our,O
knowledge,O
of,O
the,O
involvement,O
of,O
histone,B-GP
modifications,O
in,O
neurodevelopmental,B-DS
disorders,I-DS
is,O
limited,O
.,O
Histone,B-GP
modification,O
is,O
an,O
epigenetic,O
process,O
that,O
regulates,O
gene,O
expression,O
through,O
the,O
modulation,O
of,O
chromatin,O
structure,O
.,O
An,O
important,O
histone,B-GP
-,O
modification,O
process,O
is,O
histone,B-GP
methylation,O
and,O
demethylation,O
.,O
Among,O
the,O
best,O
understood,O
and,O
most,O
essential,O
classes,O
of,O
histone,B-GP
demethylases,I-GP
is,O
the,O
Jumonji,B-GP
family,O
",",O
first,O
cloned,O
by,O
Takeuchi,O
et,O
al,O
.,O
9,O
in,O
1995,O
",",O
which,O
was,O
followed,O
by,O
the,O
identification,O
of,O
the,O
Jmjd2,B-GP
family,O
",",O
a,O
Jumonji,B-GP
family,O
subgroup,O
.,O
The,O
JMJD2,B-GP
family,O
consists,O
of,O
6,O
subtypes,O
(,O
JMJD2A,B-GP
-,O
JMJD2F,B-GP
);,O
JMJD2B,B-GP
acts,O
as,O
a,O
transcriptional,B-GP
activator,I-GP
of,O
targeted,O
genes,O
through,O
demethylation,O
of,O
specific,O
lysine,O
residues,O
on,O
H3K9me3,O
.,O
10,O
",",O
11,O
JMJD2B,B-GP
is,O
located,O
in,O
the,O
nucleus,O
in,O
dividing,O
cells,O
and,O
has,O
demethylase,B-GP
activity,O
to,O
H3K9me3,O
.,O
12,O
Previous,O
research,O
has,O
mainly,O
focused,O
on,O
the,O
oncogenic,O
potential,O
of,O
JMJD2B,B-GP
.,O
In,O
particular,O
",",O
overexpression,O
of,O
JMJD2B,B-GP
exhibits,O
oncogenic,O
activity,O
in,O
various,O
human,B-OG
cancers,B-DS
",",O
including,O
prostate,O
",",O
breast,O
",",O
colon,O
and,O
gastric,B-DS
cancers,I-DS
.,O
13,O
",",O
14,O
",",O
15,O
",",O
16,O
",",O
17,O
In,O
addition,O
",",O
JMJD2B,B-GP
was,O
found,O
to,O
be,O
necessary,O
for,O
self,O
-,O
renewal,O
of,O
embryonic,O
stem,O
cells,O
and,O
induced,O
pluripotent,O
stem,O
cell,O
generation,O
.,O
18,O
The,O
Jumonji,B-GP
family,O
appears,O
to,O
also,O
play,O
important,O
roles,O
in,O
the,O
brain,O
.,O
Two,O
mutations,O
of,O
JMJD2B,B-GP
have,O
been,O
found,O
in,O
individuals,O
with,O
autism,B-DS
spectrum,I-DS
disorder,I-DS
(,O
ASD,B-DS
),O
along,O
with,O
other,O
histone,B-GP
demethylase,I-GP
enzymes,O
",",O
including,O
JMJD1A,B-GP
and,O
",",O
JARID1B,B-GP
.,O
8,O
In,O
addition,O
to,O
these,O
enzymes,O
",",O
mutations,O
of,O
other,O
histone,B-GP
demethylase,I-GP
genes,O
including,O
KDM6A,B-GP
",",O
which,O
is,O
implicated,O
in,O
Kabuki,B-DS
syndrome,I-DS
",",O
19,O
and,O
JARID1C,B-GP
",",O
which,O
is,O
implicated,O
in,O
X,B-DS
-,I-DS
linked,I-DS
mental,I-DS
retardation,I-DS
syndrome,I-DS
",",O
20,O
are,O
found,O
in,O
individuals,O
with,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
Therefore,O
",",O
histone,B-GP
demethylation,O
appears,O
to,O
be,O
critically,O
associated,O
with,O
neurodevelopmental,B-DS
disorders,I-DS
;,O
however,O
",",O
the,O
function,O
of,O
the,O
Jumonji,B-GP
family,O
in,O
the,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
remains,O
largely,O
unknown,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
investigated,O
the,O
function,O
of,O
JMJD2B,B-GP
in,O
the,O
CNS,O
by,O
generating,O
neuron,O
-,O
specific,O
",",O
JMJD2B,B-GP
-,O
deficient,O
mice,B-OG
.,O
These,O
mice,B-OG
exhibited,O
various,O
symptoms,O
reminiscent,O
of,O
neurodevelopmental,B-DS
disorders,I-DS
",",O
and,O
impaired,O
synaptic,O
maturation,O
in,O
the,O
hippocampus,O
.,O
These,O
observations,O
indicate,O
that,O
JMJD2B,B-GP
is,O
required,O
for,O
neuronal,O
circuit,O
formation,O
",",O
and,O
its,O
deficiency,O
leads,O
to,O
behavioral,O
and,O
physiologic,O
abnormalities,O
observed,O
in,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
Materials,O
and,O
methods,O
Mice,B-OG
For,O
all,O
experiments,O
",",O
the,O
mice,B-OG
were,O
of,O
the,O
C57B6,O
/,O
J,O
strain,O
.,O
Jmjd2b,B-GP
floxed,O
mice,B-OG
",",O
in,O
which,O
exon,O
5,O
of,O
the,O
Jmjd2b,B-GP
allele,O
was,O
flanked,O
by,O
loxP,O
sequences,O
bilaterally,O
",",O
13,O
were,O
crossed,O
with,O
mice,B-OG
expressing,O
Cre,B-GP
recombinase,I-GP
under,O
the,O
control,O
of,O
the,O
Tau,B-GP
promoter,O
",",O
21,O
resulting,O
in,O
the,O
specific,O
deletion,O
of,O
JMJD2B,B-GP
in,O
neurons,O
.,O
Both,O
genders,O
were,O
used,O
in,O
all,O
experiments,O
except,O
for,O
behavioral,O
analysis,O
(,O
male,O
mice,B-OG
).,O
In,O
all,O
cases,O
",",O
pups,O
were,O
weaned,O
on,O
postnatal,O
day,O
(,O
P,O
),O
28,O
",",O
and,O
housed,O
in,O
sex,O
-,O
matched,O
groups,O
in,O
standard,O
mouse,B-OG
cages,O
under,O
a,O
12,O
-,O
h,O
light,O
/,O
dark,O
cycle,O
according,O
to,O
the,O
protocols,O
approved,O
by,O
Institutional,O
animal,B-OG
care,O
and,O
Use,O
Committee,O
of,O
Osaka,O
University,O
.,O
In,O
situ,O
hybridization,O
Mice,B-OG
were,O
harvested,O
for,O
in,O
situ,O
hybridization,O
analysis,O
at,O
embryonic,O
days,O
(,O
E,O
),O
13,O
",",O
15,O
and,O
17,O
",",O
and,O
P1,O
",",O
3,O
",",O
5,O
",",O
7,O
",",O
14,O
and,O
56,O
(,O
8,O
weeks,O
;,O
n,O
=,O
1,O
per,O
age,O
).,O
All,O
mice,B-OG
were,O
decapitated,O
under,O
deep,O
anesthesia,O
and,O
brains,O
were,O
quickly,O
put,O
into,O
dry,O
ice,O
powder,O
as,O
fresh,O
frozen,O
samples,O
.,O
P0,O
mice,B-OG
were,O
used,O
for,O
expression,O
analysis,O
and,O
the,O
whole,O
body,O
was,O
quickly,O
put,O
into,O
dry,O
ice,O
powder,O
as,O
fresh,O
frozen,O
samples,O
.,O
The,O
whole,O
brain,O
and,O
whole,O
body,O
were,O
cut,O
into,O
14,O
-,O
μm,O
-,O
thick,O
sagittal,O
sections,O
using,O
a,O
cryostat,O
and,O
mounted,O
on,O
APS,O
-,O
coated,O
glass,O
slides,O
(,O
Matsunami,O
",",O
Osaka,O
",",O
Japan,O
).,O
Probes,O
for,O
JMJD2B,B-GP
were,O
generated,O
from,O
complementary,O
DNA,O
(,O
cDNA,O
),O
fragments,O
of,O
mouse,B-OG
DNA,O
by,O
reverse,O
transcription,O
–,O
PCR,O
.,O
We,O
prepared,O
two,O
probes,O
to,O
confirm,O
the,O
specificity,O
.,O
The,O
primer,O
sequences,O
for,O
each,O
probe,O
were,O
as,O
follows,O
:,O
Probe1,O
—,O
forward,O
",",O
5,O
′-,O
ACGGCAGACGTATGATGACA,O
-,O
3,O
′;,O
reverse,O
",",O
5,O
′-,O
AAGGGGATGCCGTACTTCTT,O
-,O
3,O
′:,O
Probe2,O
—,O
forward,O
",",O
5,O
′-,O
TGGTGACTCACAGGGAACAA,O
-,O
3,O
′;,O
reverse,O
",",O
5,O
′-,O
AACATGTCCAGCCCTCTTTG,O
-,O
3,O
′.,O
Using,O
these,O
primers,O
",",O
we,O
amplified,O
the,O
target,O
probe,O
sequences,O
by,O
PCR,O
and,O
subsequently,O
integrated,O
the,O
PCR,O
products,O
into,O
the,O
pGEM,O
-,O
T,O
easy,O
vector,O
(,O
Promega,O
",",O
Tokyo,O
",",O
Japan,O
).,O
DNA,O
templates,O
were,O
linearized,O
by,O
restriction,B-GP
enzymes,I-GP
(,O
NdeI,B-GP
and,O
NcoI,B-GP
),O
by,O
incubation,O
at,O
37,O
°,O
C,O
for,O
16,O
h,O
.,O
Complete,O
digestion,O
of,O
the,O
vector,O
was,O
confirmed,O
by,O
agarose,O
electrophoresis,O
.,O
Then,O
",",O
we,O
prepared,O
solution,O
containing,O
1,O
μg,O
template,O
DNA,O
",",O
1,O
×,O
concentration,O
DIG,O
RNA,O
labeling,O
mix,O
2,O
μl,O
",",O
5,O
×,O
transcription,O
buffer,O
",",O
100,O
mm,O
DTT,O
and,O
the,O
appropriate,O
RNA,B-GP
polymerase,I-GP
(,O
T7,B-GP
or,O
SP6,B-GP
).,O
RNA,O
was,O
synthesized,O
by,O
incubation,O
at,O
37,O
°,O
C,O
for,O
2,O
h,O
.,O
Then,O
",",O
DNase,B-GP
was,O
added,O
and,O
samples,O
were,O
incubated,O
at,O
37,O
°,O
C,O
for,O
10,O
min,O
followed,O
by,O
RNA,O
probe,O
extraction,O
by,O
ethanol,O
precipitation,O
.,O
Before,O
beginning,O
hybridization,O
",",O
the,O
sections,O
were,O
air,O
-,O
dried,O
for,O
1,O
h,O
and,O
immediately,O
put,O
into,O
4,O
%,O
paraformaldehyde,O
for,O
30,O
min,O
",",O
followed,O
by,O
washing,O
in,O
0,O
.,O
1,O
%,O
activated,O
DEPC,O
water,O
(,O
not,O
autoclaved,O
),O
twice,O
for,O
15,O
min,O
.,O
Then,O
samples,O
were,O
equilibrated,O
in,O
5,O
×,O
SCC,O
for,O
15,O
min,O
.,O
Next,O
",",O
the,O
sections,O
were,O
pre,O
-,O
hybridized,O
at,O
58,O
°,O
C,O
for,O
1,O
h,O
in,O
hybridization,O
buffer,O
(,O
5,O
×,O
SCC,O
400,O
μg,O
ml,O
−,O
1,O
",",O
heat,O
-,O
denatured,O
salmon,O
sperm,O
DNA,O
and,O
50,O
%,O
formamide,O
),O
and,O
subsequently,O
hybridized,O
at,O
58,O
°,O
C,O
for,O
another,O
40,O
h,O
in,O
the,O
same,O
solution,O
",",O
but,O
with,O
400,O
ng,O
ml,O
−,O
1,O
RNA,O
probe,O
added,O
.,O
Then,O
",",O
sections,O
were,O
rinsed,O
in,O
2,O
×,O
SSC,O
at,O
room,O
temperature,O
for,O
30,O
min,O
",",O
followed,O
by,O
a,O
wash,O
in,O
2,O
×,O
SSC,O
for,O
1,O
h,O
at,O
65,O
°,O
C,O
",",O
and,O
then,O
in,O
0,O
.,O
1,O
×,O
SSC,O
at,O
65,O
°,O
C,O
for,O
another,O
hour,O
.,O
Next,O
",",O
sections,O
were,O
washed,O
in,O
buffer,O
A,O
(,O
100,O
mm,O
Tris,O
-,O
HCl,O
pH,O
7,O
.,O
5,O
",",O
150,O
mm,O
NaCl,O
),O
at,O
room,O
temperature,O
for,O
5,O
min,O
.,O
Sections,O
were,O
reacted,O
with,O
AP,B-GP
-,O
conjugated,O
anti,O
-,O
Dig,O
Fab,O
antibody,O
(,O
Roche,O
",",O
Mannheim,O
",",O
Germany,O
;,O
dilution,O
1,O
:,O
5000,O
in,O
wash,O
buffer,O
A,O
),O
at,O
room,O
temperature,O
for,O
2,O
h,O
.,O
After,O
washing,O
the,O
sections,O
with,O
buffer,O
A,O
twice,O
for,O
15,O
min,O
each,O
",",O
the,O
sections,O
were,O
washed,O
with,O
buffer,O
B,O
(,O
100,O
mm,O
Tris,O
-,O
HCl,O
pH,O
9,O
.,O
5,O
",",O
150,O
mm,O
NaCl,O
",",O
100,O
mm,O
MgCl2,O
),O
for,O
5,O
min,O
.,O
Next,O
",",O
these,O
sections,O
were,O
incubated,O
with,O
color,O
reagent,O
(,O
NBT,O
45,O
μl,O
",",O
BCIP,O
35,O
μl,O
",",O
each,O
in,O
10,O
ml,O
buffer,O
B,O
),O
at,O
room,O
temperature,O
for,O
48,O
h,O
.,O
After,O
that,O
",",O
sections,O
were,O
washed,O
with,O
buffer,O
B,O
and,O
the,O
reactions,O
were,O
stopped,O
by,O
applying,O
TE,O
buffer,O
(,O
10,O
mm,O
Tris,O
-,O
HCl,O
pH,O
8,O
.,O
0,O
",",O
1,O
mm,O
EDTA,O
).,O
Finally,O
",",O
sections,O
were,O
dehydrated,O
in,O
an,O
ethanol,O
gradient,O
(,O
70,O
",",O
80,O
",",O
95,O
and,O
100,O
%),O
and,O
mounted,O
with,O
EUKITT,O
(,O
O,O
.,O
Kindler,O
",",O
Freiburg,O
",",O
Germany,O
).,O
Immunohistochemistry,O
followed,O
by,O
in,O
situ,O
hybridization,O
Immunostaining,O
with,O
DAB,O
as,O
the,O
substrate,O
for,O
horseradish,B-OG
peroxidase,B-GP
followed,O
by,O
in,O
situ,O
hybridization,O
was,O
performed,O
according,O
to,O
a,O
previously,O
described,O
method,O
(,O
n,O
=,O
1,O
).,O
22,O
After,O
in,O
situ,O
hybridization,O
by,O
using,O
fresh,O
frozen,O
sections,O
was,O
complete,O
",",O
sections,O
were,O
washed,O
with,O
buffer,O
B,O
as,O
described,O
above,O
.,O
Then,O
",",O
sections,O
were,O
washed,O
with,O
PBS,O
three,O
times,O
for,O
5,O
min,O
each,O
.,O
Next,O
",",O
sections,O
were,O
incubated,O
with,O
NeuN,B-GP
(,O
anti,O
-,O
mouse,B-OG
NeuN,B-GP
1,O
:,O
100,O
MAB377,O
",",O
Millipore,O
",",O
Darmstadt,O
",",O
Germany,O
),O
or,O
GFAP,B-GP
(,O
anti,O
-,O
mouse,B-OG
GFAP,B-GP
1,O
:,O
500,O
",",O
sc58766,O
",",O
Santa,O
Cruz,O
Biotechnology,O
",",O
Dallas,O
",",O
TX,O
",",O
USA,O
),O
antibodies,O
diluted,O
in,O
PBS,O
overnight,O
at,O
4,O
°,O
C,O
followed,O
by,O
washing,O
with,O
PBS,O
three,O
times,O
at,O
room,O
temperature,O
.,O
Then,O
",",O
sections,O
were,O
incubated,O
with,O
biotin,O
-,O
conjugated,O
anti,O
-,O
mouse,B-OG
-,O
IgG,B-GP
antibody,O
for,O
30,O
min,O
in,O
a,O
moisture,O
chamber,O
followed,O
by,O
washing,O
with,O
PBS,O
twice,O
at,O
room,O
temperature,O
.,O
Next,O
",",O
sections,O
were,O
reacted,O
to,O
Avidin,B-GP
–,O
biotin,O
complex,O
using,O
an,O
ABC,O
kit,O
(,O
Vector,O
Laboratories,O
",",O
San,O
Francisco,O
",",O
CA,O
",",O
USA,O
),O
for,O
30,O
min,O
at,O
room,O
temperature,O
in,O
a,O
moist,O
box,O
followed,O
by,O
washing,O
with,O
PBS,O
twice,O
at,O
room,O
temperature,O
.,O
Then,O
",",O
sections,O
were,O
transferred,O
to,O
50,O
mm,O
TBS,O
(,O
pH,O
7,O
.,O
4,O
),O
for,O
5,O
min,O
and,O
reacted,O
in,O
50,O
mm,O
Tris,O
buffer,O
(,O
pH,O
7,O
.,O
6,O
),O
containing,O
0,O
.,O
02,O
%,O
diaminobenzidine,O
tetrahydrochloride,O
(,O
Sigma,O
",",O
Tokyo,O
",",O
Japan,O
),O
and,O
0,O
.,O
01,O
%,O
hydrogen,O
peroxide,O
for,O
several,O
minutes,O
until,O
the,O
signal,O
was,O
detected,O
.,O
Reactions,O
were,O
stopped,O
by,O
transferring,O
the,O
sections,O
to,O
50,O
mm,O
TBS,O
at,O
room,O
temperature,O
for,O
5,O
min,O
.,O
Finally,O
sections,O
were,O
dehydrated,O
in,O
an,O
ethanol,O
gradient,O
as,O
described,O
for,O
the,O
in,O
situ,O
hybridization,O
method,O
(,O
70,O
",",O
85,O
",",O
95,O
and,O
100,O
%),O
and,O
mounted,O
with,O
EUKITT,O
.,O
Genotyping,O
Genomic,O
DNA,O
was,O
prepared,O
from,O
a,O
tail,O
biopsy,O
of,O
each,O
mouse,B-OG
.,O
Tail,O
biopsies,O
were,O
incubated,O
at,O
55,O
°,O
C,O
for,O
several,O
hours,O
with,O
500,O
μl,O
genotyping,O
lysis,O
buffer,O
containing,O
0,O
.,O
01,O
m,O
Tris,O
-,O
HCl,O
(,O
pH,O
8,O
.,O
0,O
"),",O
0,O
.,O
05,O
m,O
EDTA,O
(,O
pH,O
8,O
.,O
0,O
"),",O
0,O
.,O
1,O
m,O
NaCl,O
",",O
0,O
.,O
5,O
%,O
SDS,O
and,O
0,O
.,O
1,O
mg,O
ml,O
−,O
1,O
proteinase,B-GP
K,I-GP
(,O
Roche,O
",",O
Tokyo,O
",",O
Japan,O
),O
for,O
several,O
hours,O
and,O
crushed,O
by,O
vortex,O
with,O
410,O
μl,O
of,O
3,O
.,O
75,O
m,O
NaCl,O
.,O
Then,O
samples,O
were,O
put,O
into,O
box,O
with,O
crushed,O
ice,O
for,O
10,O
minutes,O
followed,O
by,O
centrifugation,O
for,O
10,O
min,O
at,O
15,O
000,O
r,O
.,O
p,O
.,O
m,O
.,O
Then,O
",",O
500,O
μl,O
of,O
supernatant,O
were,O
collected,O
and,O
mixed,O
with,O
1000,O
μl,O
of,O
99,O
.,O
5,O
%,O
ethanol,O
(,O
Wako,O
",",O
Osaka,O
",",O
Japan,O
),O
followed,O
by,O
centrifugation,O
at,O
15,O
000,O
r,O
.,O
p,O
.,O
m,O
.,O
for,O
15,O
min,O
.,O
The,O
supernatant,O
was,O
discarded,O
",",O
70,O
%,O
ethanol,O
was,O
added,O
to,O
the,O
DNA,O
pellet,O
",",O
and,O
samples,O
were,O
centrifuged,O
for,O
5,O
min,O
at,O
15,O
000,O
r,O
.,O
p,O
.,O
m,O
.,O
This,O
supernatant,O
was,O
discarded,O
and,O
the,O
pellet,O
was,O
dehydrated,O
by,O
evaporation,O
at,O
room,O
temperature,O
.,O
Finally,O
",",O
the,O
dry,O
pellet,O
was,O
dissolved,O
in,O
RNase,B-GP
free,O
water,O
(,O
Ambion,O
",",O
Foster,O
",",O
CA,O
",",O
USA,O
).,O
PCR,O
was,O
performed,O
using,O
KOD,O
FX,O
Neo,O
(,O
TOYOBO,O
",",O
Osaka,O
",",O
Japan,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
protocol,O
.,O
PCR,O
protocol,O
was,O
as,O
follows,O
;,O
jmjd2b,B-GP
;,O
98,O
°,O
C,O
2,O
min,O
:,O
1,O
cycle,O
;,O
98,O
°,O
C,O
",",O
10,O
s,O
",",O
57,O
°,O
C,O
",",O
15,O
s,O
",",O
68,O
°,O
C,O
",",O
1,O
min,O
:,O
repeat,O
for,O
30,O
cycles,O
;,O
72,O
°,O
C,O
10,O
min,O
:,O
1,O
cycle,O
.,O
Tau,B-GP
-,O
cre,B-GP
;,O
96,O
°,O
C,O
",",O
5,O
min,O
:,O
1,O
cycle,O
;,O
96,O
°,O
C,O
",",O
45,O
s,O
",",O
60,O
°,O
C,O
",",O
30,O
s,O
",",O
72,O
°,O
C,O
30,O
s,O
:,O
repeat,O
for,O
30,O
cycles,O
;,O
72,O
°,O
C,O
",",O
30,O
s,O
:,O
1,O
cycle,O
.,O
The,O
primer,O
sequences,O
were,O
as,O
follows,O
:,O
jmjd2b,B-GP
forward,O
:,O
5,O
′-,O
AAGAAGGGTGGGGTGGCGAA,O
-,O
3,O
′;,O
jmjd2b,B-GP
reverse,O
:,O
5,O
′-,O
CGCCACGTCCTATGGACAATG,O
-,O
3,O
′;,O
Cre,B-GP
forward,O
:,O
5,O
′-,O
AGGTTCGTTCTCTCATGGA,O
-,O
3,O
′;,O
Cre,B-GP
reverse,O
:,O
5,O
′-,O
TCGACCAGTTTAGTTACCC,O
-,O
3,O
′;,O
mTau,B-GP
forward,O
:,O
5,O
′-,O
TATGGCTGACCCTCGCCAGGAGTTT,O
-,O
3,O
′;,O
mTau,B-GP
reverse,O
:,O
5,O
′-,O
GTCCACCCCACTGACCTTTTAAGCC,O
-,O
3,O
′.,O
Real,O
-,O
time,O
PCR,O
The,O
hippocampi,O
of,O
P0,O
mice,B-OG
and,O
adult,O
mice,B-OG
(,O
12,O
weeks,O
),O
from,O
each,O
genotype,O
(,O
wild,O
type,O
(,O
WT,O
):,O
n,O
=,O
3,O
knock,O
out,O
(,O
KO,O
):,O
n,O
=,O
3,O
),O
were,O
dissected,O
and,O
crushed,O
with,O
an,O
electric,O
mixer,O
in,O
1,O
ml,O
TRIZOL,O
reagent,O
(,O
Ambion,O
),O
followed,O
by,O
centrifugation,O
at,O
15,O
000,O
r,O
.,O
p,O
.,O
m,O
.,O
for,O
10,O
min,O
.,O
Then,O
",",O
100,O
μl,O
of,O
chloroform,O
were,O
added,O
to,O
the,O
500,O
μl,O
of,O
supernatant,O
.,O
The,O
mixture,O
was,O
vortexed,O
for,O
15,O
s,O
and,O
left,O
at,O
room,O
temperature,O
for,O
15,O
min,O
.,O
Samples,O
were,O
centrifuged,O
at,O
4,O
°,O
C,O
for,O
15,O
min,O
and,O
subsequently,O
100,O
μl,O
of,O
upper,O
water,O
phase,O
were,O
extracted,O
and,O
mixed,O
with,O
80,O
μl,O
isopropanol,O
.,O
Samples,O
were,O
left,O
at,O
room,O
temperature,O
for,O
10,O
min,O
and,O
centrifuged,O
at,O
4,O
°,O
C,O
for,O
10,O
min,O
.,O
Supernatant,O
was,O
removed,O
and,O
70,O
%,O
ethanol,O
was,O
added,O
",",O
followed,O
by,O
centrifugation,O
at,O
4,O
°,O
C,O
for,O
3,O
min,O
.,O
Finally,O
",",O
the,O
supernatant,O
was,O
removed,O
and,O
the,O
RNA,O
pellet,O
was,O
dried,O
by,O
evaporation,O
and,O
dissolved,O
in,O
50,O
μl,O
of,O
RNase,B-GP
free,O
water,O
.,O
We,O
then,O
performed,O
reverse,O
transcription,O
(,O
High,O
Capacity,O
cDNA,O
Reverse,O
Transcription,O
Kit,O
;,O
Applied,O
Biosystems,O
",",O
Foster,O
",",O
CA,O
",",O
USA,O
),O
on,O
the,O
RNA,O
samples,O
to,O
obtain,O
cDNA,O
fragments,O
.,O
Gene,O
expression,O
levels,O
were,O
measured,O
by,O
real,O
-,O
time,O
PCR,O
(,O
Quant,O
Studio,O
7Flex,O
",",O
Applied,O
Biosystems,O
),O
using,O
Taqman,O
probes,O
.,O
Golgi,O
staining,O
Eight,O
-,O
week,O
-,O
old,O
mice,B-OG
of,O
both,O
genotypes,O
were,O
used,O
for,O
Golgi,O
analysis,O
.,O
All,O
mice,B-OG
were,O
decapitated,O
under,O
deep,O
anesthesia,O
and,O
brains,O
were,O
quickly,O
put,O
into,O
dry,O
ice,O
powder,O
as,O
fresh,O
frozen,O
samples,O
.,O
Tissue,O
was,O
stained,O
with,O
the,O
FD,O
Rapid,O
Golgistain,O
Kit,O
(,O
Cat,O
#:,O
PK401,O
",",O
FD,O
Neurotechnologies,O
",",O
Colombia,O
",",O
MD,O
",",O
USA,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
protocol,O
.,O
Briefly,O
",",O
tissues,O
were,O
immersed,O
in,O
impregnant,O
solution,O
(,O
solution,O
A,O
+,O
solution,O
B,O
),O
for,O
14,O
days,O
in,O
dark,O
box,O
at,O
room,O
temperature,O
with,O
solution,O
exchange,O
after,O
1,O
h,O
and,O
24,O
h,O
",",O
respectively,O
.,O
Then,O
tissues,O
were,O
transferred,O
to,O
solution,O
C,O
for,O
5,O
days,O
with,O
solution,O
exchange,O
after,O
the,O
first,O
24,O
h,O
.,O
Tissues,O
were,O
immediately,O
moved,O
into,O
dry,O
ice,O
powder,O
and,O
cut,O
into,O
200,O
-,O
μm,O
-,O
thick,O
coronal,O
sections,O
using,O
a,O
cryostat,O
.,O
The,O
cut,O
sections,O
were,O
floated,O
in,O
PBS,O
and,O
placed,O
on,O
double,O
gelatin,O
-,O
coated,O
glass,O
slides,O
.,O
Sections,O
were,O
allowed,O
to,O
dry,O
by,O
evaporation,O
at,O
room,O
temperature,O
for,O
24,O
h,O
and,O
then,O
moved,O
into,O
a,O
mixture,O
solution,O
containing,O
one,O
part,O
solution,O
D,O
",",O
one,O
part,O
solution,O
E,O
and,O
two,O
parts,O
of,O
MilliQ,O
-,O
water,O
for,O
7,O
–,O
10,O
min,O
.,O
Then,O
sections,O
were,O
washed,O
in,O
MilliQ,O
-,O
water,O
(,O
Millipore,O
),O
(,O
four,O
washes,O
of,O
5,O
min,O
each,O
"),",O
dehydrated,O
by,O
immersing,O
the,O
section,O
in,O
Histoclear,O
(,O
National,O
Diagnostics,O
",",O
Atlanta,O
",",O
GA,O
",",O
USA,O
),O
three,O
times,O
(,O
10,O
min,O
each,O
time,O
),O
and,O
coverslipped,O
.,O
Analysis,O
was,O
performed,O
using,O
a,O
Neurolucida,O
system,O
(,O
MBF,O
Bioscience,O
",",O
Chiba,O
",",O
Japan,O
).,O
Dendrites,O
of,O
pyramidal,O
neurons,O
located,O
120,O
–,O
300,O
μm,O
from,O
the,O
soma,O
were,O
selected,O
.,O
We,O
counted,O
spine,O
numbers,O
and,O
classified,O
spine,O
class,O
along,O
the,O
first,O
20,O
μm,O
of,O
each,O
dendrite,O
.,O
We,O
defined,O
mature,O
spines,O
as,O
mushroom,O
-,O
like,O
spines,O
in,O
which,O
the,O
head,O
diameter,O
was,O
wider,O
than,O
the,O
neck,O
diameter,O
.,O
We,O
used,O
five,O
mutant,O
mice,B-OG
and,O
six,O
WT,O
littermates,O
and,O
analyzed,O
four,O
to,O
seven,O
dendrites,O
per,O
animal,B-OG
",",O
mainly,O
in,O
the,O
dorsal,O
CA1,O
region,O
.,O
We,O
selected,O
secondary,O
dendrites,O
located,O
120,O
–,O
300,O
μm,O
from,O
the,O
somas,O
of,O
the,O
pyramidal,O
neurons,O
in,O
CA1,O
",",O
which,O
corresponds,O
to,O
the,O
area,O
of,O
CA1,O
that,O
receives,O
inputs,O
from,O
Schaffer,O
collaterals,O
from,O
CA3,O
.,O
23,O
We,O
used,O
3,O
mutant,O
mice,B-OG
and,O
3,O
WT,O
littermates,O
and,O
analyzed,O
6,O
–,O
10,O
apical,O
dendrites,O
of,O
pyramidal,O
neurons,O
per,O
animal,B-OG
in,O
layer,O
2,O
/,O
3,O
of,O
somatosensory,O
cortex,O
.,O
Hippocampal,O
neuron,O
culture,O
and,O
analysis,O
of,O
neuron,O
morphology,O
The,O
hippocampus,O
was,O
isolated,O
from,O
P1,O
mice,B-OG
(,O
n,O
=,O
4,O
:,O
each,O
genotype,O
).,O
Neurons,O
were,O
cultured,O
in,O
DMEM,O
/,O
F12,O
medium,O
supplemented,O
with,O
10,O
%,O
FBS,O
for,O
1day,O
",",O
and,O
subsequently,O
DMEM,O
/,O
F12,O
supplemented,O
with,O
B27,O
(,O
Invitrogen,O
",",O
Foster,O
",",O
CA,O
",",O
USA,O
),O
for,O
another,O
6,O
days,O
in,O
a,O
37,O
°,O
C,O
incubator,O
containing,O
5,O
.,O
0,O
%,O
CO2,O
.,O
The,O
neuron,O
density,O
was,O
4,O
.,O
0,O
×,O
10,O
cells,O
per,O
3,O
.,O
5,O
-,O
cm,O
dish,O
.,O
After,O
7,O
days,O
of,O
incubation,O
",",O
samples,O
were,O
fixed,O
by,O
4,O
%,O
paraformaldehyde,O
for,O
30,O
min,O
followed,O
by,O
incubation,O
in,O
5,O
%,O
BSA,O
containing,O
0,O
.,O
3,O
%,O
Triton,O
X,O
-,O
100,O
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
Samples,O
were,O
stained,O
with,O
anti,O
MAP2,B-GP
antibody,O
(,O
anti,O
-,O
rabbit,B-OG
MAP2,B-GP
1,O
:,O
1000,O
",",O
45425,O
",",O
Cell,O
Signaling,O
",",O
Danvers,O
",",O
MA,O
",",O
USA,O
),O
for,O
16,O
h,O
at,O
4,O
°,O
C,O
.,O
And,O
then,O
samples,O
were,O
washed,O
in,O
PBS,O
with,O
Tween,O
20,O
three,O
times,O
followed,O
by,O
incubation,O
with,O
a,O
fluorescence,O
-,O
conjugated,O
secondary,O
antibody,O
(,O
anti,O
-,O
rabbit,B-OG
IgG,B-GP
",",O
1,O
:,O
1000,O
",",O
Alexa,O
",",O
Invitrogen,O
),O
for,O
1,O
h,O
at,O
room,O
temperature,O
in,O
a,O
dark,O
box,O
.,O
Neuron,O
morphology,O
was,O
traced,O
by,O
Neurolucida,O
.,O
We,O
selected,O
labeled,O
neurons,O
with,O
little,O
or,O
no,O
adjacent,O
stained,O
glia,O
for,O
analysis,O
.,O
Timm,O
staining,O
Mice,B-OG
(,O
3,O
–,O
5,O
months,O
old,O
),O
of,O
both,O
genotypes,O
were,O
deeply,O
anesthetized,O
and,O
transcardially,O
perfused,O
with,O
PBS,O
followed,O
by,O
4,O
%,O
paraformaldehyde,O
in,O
PBS,O
(,O
WT,O
:,O
n,O
=,O
3,O
KO,O
:,O
n,O
=,O
3,O
).,O
Following,O
perfusion,O
",",O
fixed,O
samples,O
were,O
post,O
-,O
fixed,O
in,O
the,O
same,O
fixative,O
solution,O
at,O
4,O
°,O
C,O
for,O
16,O
h,O
and,O
immersed,O
in,O
30,O
%,O
sucrose,O
in,O
PBS,O
at,O
4,O
°,O
C,O
until,O
the,O
tissue,O
sank,O
.,O
Tissues,O
were,O
cut,O
into,O
40,O
-,O
μm,O
-,O
thick,O
coronal,O
sections,O
using,O
a,O
cryostat,O
and,O
placed,O
on,O
MAS,O
-,O
coated,O
glass,O
slides,O
.,O
Cut,O
sections,O
were,O
dried,O
by,O
evaporation,O
and,O
immersed,O
in,O
1,O
%,O
sodium,O
sulfide,O
solution,O
(,O
Wako,O
),O
for,O
10,O
min,O
.,O
Then,O
",",O
the,O
sections,O
were,O
fixed,O
again,O
in,O
4,O
%,O
paraformaldehyde,O
followed,O
by,O
washing,O
in,O
PBS,O
twice,O
.,O
The,O
sections,O
were,O
dried,O
by,O
evaporation,O
and,O
reacted,O
with,O
Timm,O
staining,O
solution,O
containing,O
30,O
%,O
gum,O
Arabic,O
solution,O
(,O
Wako,O
"),",O
1,O
.,O
7,O
%,O
hydroquinone,O
solution,O
(,O
Wako,O
"),",O
0,O
.,O
08,O
%,O
caustic,O
silver,O
solution,O
(,O
Wako,O
),O
and,O
0,O
.,O
2,O
m,O
citrate,O
buffer,O
solution,O
(,O
pH,O
4,O
.,O
2,O
;,O
Wako,O
),O
at,O
room,O
temperature,O
for,O
2,O
h,O
in,O
a,O
dark,O
box,O
.,O
The,O
reaction,O
was,O
terminated,O
by,O
immersion,O
in,O
tap,O
water,O
for,O
5,O
min,O
.,O
The,O
sections,O
were,O
counterstained,O
with,O
cresyl,O
violet,O
solution,O
for,O
7,O
min,O
at,O
room,O
temperature,O
.,O
Finally,O
",",O
sections,O
were,O
dehydrated,O
by,O
ethanol,O
(,O
70,O
",",O
80,O
",",O
95,O
",",O
and,O
100,O
%),O
and,O
mounted,O
with,O
EUKITT,O
.,O
Nissl,O
staining,O
P0,O
mouse,B-OG
brains,O
of,O
both,O
genotypes,O
(,O
WT,O
:,O
n,O
=,O
3,O
;,O
KO,O
:,O
n,O
=,O
3,O
),O
were,O
fixed,O
in,O
paraformaldehyde,O
at,O
4,O
°,O
C,O
for,O
16,O
h,O
and,O
impregnated,O
with,O
30,O
%,O
sucrose,O
until,O
the,O
tissue,O
sank,O
.,O
Then,O
",",O
fixed,O
samples,O
were,O
immediately,O
moved,O
into,O
dry,O
ice,O
powder,O
and,O
cut,O
into,O
30,O
-,O
μm,O
-,O
thick,O
saggital,O
sections,O
using,O
a,O
cryostat,O
and,O
placed,O
on,O
MAS,O
-,O
coated,O
glass,O
slides,O
.,O
Cut,O
sections,O
were,O
impregnated,O
with,O
Cresyl,O
violet,O
acetate,O
(,O
C5042,O
-,O
10G,O
",",O
Sigma,O
),O
at,O
room,O
temperature,O
for,O
10,O
min,O
and,O
dehydrated,O
in,O
100,O
%,O
ethanol,O
for,O
5,O
min,O
.,O
Western,O
blotting,O
Hippocampal,O
brain,O
lysates,O
of,O
both,O
genotypes,O
of,O
3,O
or,O
4,O
-,O
month,O
-,O
old,O
mice,B-OG
(,O
WT,O
:,O
n,O
=,O
3,O
KO,O
:,O
n,O
=,O
3,O
),O
were,O
boiled,O
in,O
sample,O
buffer,O
for,O
5,O
min,O
.,O
The,O
proteins,O
were,O
separated,O
by,O
SDS,O
–,O
PAGE,O
and,O
transferred,O
onto,O
polyvinylidene,O
difluoride,O
membranes,O
(,O
Millipore,O
).,O
The,O
membrane,O
was,O
blocked,O
with,O
5,O
%,O
not,O
-,O
fat,O
dry,O
milk,O
in,O
PBS,O
containing,O
0,O
.,O
05,O
%,O
tween,O
-,O
20,O
(,O
PBS,O
-,O
T,O
),O
and,O
incubated,O
for,O
1,O
h,O
at,O
room,O
temperature,O
or,O
overnight,O
at,O
4,O
°,O
C,O
",",O
with,O
PSD95,B-GP
antibody,O
(,O
anti,O
-,O
mouse,B-OG
PSD95,B-GP
1,O
:,O
500,O
",",O
MA1,O
-,O
046,O
",",O
Thermo,O
Scientific,O
",",O
Waltham,O
",",O
MA,O
",",O
USA,O
),O
or,O
GAPDH,B-GP
antibody,O
(,O
anti,O
-,O
rabbit,B-OG
GAPDH,B-GP
1,O
:,O
1000,O
",",O
sc,O
-,O
25778,O
",",O
Santa,O
Cruz,O
Biotechnology,O
),O
diluted,O
in,O
PBS,O
-,O
T,O
containing,O
1,O
%,O
non,O
-,O
fat,O
dry,O
milk,O
.,O
After,O
washing,O
in,O
PBS,O
-,O
T,O
",",O
the,O
membrane,O
was,O
incubated,O
with,O
a,O
horseradish,B-OG
peroxidase,B-GP
-,O
conjugated,O
anti,O
-,O
mouse,B-OG
IgG,B-GP
or,O
anti,O
-,O
rabbit,B-OG
IgG,B-GP
antibody,O
(,O
1,O
:,O
5000,O
",",O
Cell,O
Signaling,O
Technology,O
).,O
For,O
detection,O
",",O
an,O
ECL,O
chemiluminescence,O
system,O
(,O
GE,O
Healthcare,O
),O
was,O
used,O
.,O
Signals,O
were,O
detected,O
and,O
quantified,O
using,O
the,O
LAS,O
-,O
3000,O
Amersham,O
Imager,O
600,O
(,O
GE,O
Healthcare,O
).,O
Behavioral,O
analysis,O
Adult,O
(,O
8,O
weeks,O
),O
WT,O
and,O
JMJD2B,B-GP
mutant,O
male,O
mice,B-OG
were,O
subjected,O
to,O
a,O
battery,O
of,O
behavioral,O
tests,O
.,O
For,O
each,O
test,O
",",O
n,O
=,O
8,O
–,O
13,O
mice,B-OG
per,O
genotype,O
were,O
tested,O
.,O
In,O
each,O
behavior,O
test,O
",",O
we,O
analyzed,O
the,O
mice,B-OG
that,O
were,O
able,O
to,O
complete,O
each,O
behavioral,O
task,O
.,O
SHIRPA,O
1st,O
screening,O
Initial,O
behavioral,O
and,O
physical,O
screening,O
was,O
performed,O
using,O
SHIRPA,O
(,O
SmithKline,O
Beecham,O
",",O
Harwell,O
",",O
Imperial,O
College,O
Royal,O
London,O
Hospital,O
",",O
Phenotype,O
Assessment,O
"),",O
as,O
previously,O
described,O
.,O
24,O
Locomotor,O
activity,O
Locomotor,O
activity,O
in,O
an,O
open,O
field,O
was,O
evaluated,O
according,O
to,O
a,O
previously,O
reported,O
method,O
.,O
25,O
Briefly,O
",",O
each,O
mouse,B-OG
was,O
placed,O
in,O
the,O
center,O
of,O
an,O
open,O
",",O
transparent,O
",",O
acrylic,O
cubic,O
box,O
with,O
a,O
black,O
",",O
plexiglass,O
floor,O
(,O
45,O
×,O
45,O
×,O
30,O
cm,O
"),",O
and,O
allowed,O
to,O
freely,O
explore,O
the,O
environment,O
for,O
60,O
min,O
under,O
dim,O
light,O
(,O
3,O
lux,O
).,O
The,O
distance,O
moved,O
in,O
the,O
first,O
10,O
min,O
was,O
defined,O
as,O
100,O
%,O
in,O
each,O
genotype,O
",",O
and,O
the,O
ratio,O
of,O
the,O
distance,O
moved,O
(%),O
was,O
assessed,O
.,O
The,O
ambulation,O
of,O
mice,B-OG
was,O
monitored,O
using,O
the,O
Panlab,O
Infrared,O
Actimeter,O
System,O
(,O
LE8815,O
),O
with,O
acquisition,O
software,O
Acti,O
-,O
Track,O
2,O
.,O
65,O
for,O
Windows,O
(,O
Panlab,O
",",O
Barcelona,O
",",O
Spain,O
).,O
Locomotion,O
in,O
the,O
home,O
cage,O
was,O
monitored,O
for,O
5,O
days,O
",",O
using,O
a,O
digital,O
counter,O
system,O
with,O
an,O
infrared,O
sensor,O
(,O
Supermex,O
;,O
Muromachi,O
Kikai,O
",",O
Kyoto,O
",",O
Japan,O
),O
as,O
described,O
previously,O
.,O
25,O
Y,O
-,O
maze,O
test,O
The,O
Y,O
-,O
maze,O
test,O
with,O
spontaneous,O
alternation,O
performance,O
was,O
performed,O
as,O
described,O
previously,O
.,O
26,O
Each,O
arm,O
(,O
33,O
×,O
13,O
×,O
30,O
cm,O
),O
converged,O
in,O
an,O
equilateral,O
triangular,O
central,O
area,O
.,O
Each,O
mouse,B-OG
",",O
naive,O
to,O
the,O
maze,O
",",O
was,O
placed,O
at,O
the,O
end,O
of,O
one,O
arm,O
and,O
allowed,O
to,O
move,O
freely,O
through,O
the,O
maze,O
during,O
an,O
8,O
-,O
min,O
session,O
.,O
The,O
series,O
of,O
arm,O
entries,O
was,O
recorded,O
.,O
Events,O
were,O
counted,O
as,O
entry,O
when,O
the,O
hind,O
paws,O
of,O
the,O
mouse,B-OG
had,O
completely,O
entered,O
the,O
arm,O
.,O
Alternation,O
was,O
defined,O
as,O
successive,O
entries,O
into,O
the,O
three,O
different,O
arms,O
on,O
overlapping,O
triplet,O
sets,O
.,O
The,O
percentage,O
of,O
spontaneous,O
alternations,O
was,O
calculated,O
as,O
the,O
ratio,O
of,O
actual,O
to,O
possible,O
alternations,O
(,O
defined,O
as,O
the,O
total,O
number,O
of,O
arm,O
entries,O
−,O
2,O
),O
multiplied,O
by,O
100,O
",",O
as,O
shown,O
in,O
the,O
following,O
equation,O
:,O
alternation,O
(%)=,O
number,O
of,O
alternations,O
/(,O
total,O
arm,O
entries,O
−,O
2,O
),O
×,O
100,O
.,O
Elevated,O
plus,O
-,O
maze,O
test,O
The,O
elevated,O
plus,O
-,O
maze,O
test,O
was,O
carried,O
out,O
according,O
to,O
a,O
previously,O
reported,O
method,O
.,O
27,O
The,O
apparatus,O
consisted,O
of,O
four,O
arms,O
(,O
30,O
×,O
5,O
cm,O
each,O
),O
extending,O
from,O
a,O
central,O
platform,O
(,O
5,O
×,O
5,O
cm,O
).,O
Each,O
set,O
of,O
arms,O
opposed,O
one,O
another,O
and,O
were,O
enclosed,O
by,O
a,O
20,O
-,O
cm,O
-,O
high,O
wall,O
.,O
The,O
maze,O
was,O
elevated,O
40,O
cm,O
above,O
the,O
ground,O
.,O
Each,O
mouse,B-OG
was,O
placed,O
on,O
the,O
central,O
platform,O
with,O
its,O
head,O
facing,O
an,O
open,O
arm,O
and,O
was,O
allowed,O
to,O
move,O
freely,O
for,O
5,O
min,O
under,O
dim,O
light,O
conditions,O
(,O
15,O
lux,O
).,O
The,O
performance,O
of,O
the,O
mouse,B-OG
for,O
5,O
min,O
was,O
videotaped,O
using,O
a,O
digital,O
camera,O
",",O
and,O
then,O
the,O
following,O
parameters,O
were,O
recorded,O
and,O
calculated,O
:,O
(,O
i,O
),O
time,O
spent,O
in,O
various,O
sections,O
of,O
the,O
maze,O
(,O
open,O
and,O
closed,O
arms,O
",",O
central,O
platform,O
);,O
(,O
ii,O
),O
number,O
of,O
open,O
and,O
closed,O
arm,O
entries,O
(,O
arm,O
entry,O
defined,O
as,O
all,O
four,O
paws,O
into,O
an,O
arm,O
);,O
(,O
iii,O
),O
ratio,O
of,O
open,O
arm,O
entries,O
(,O
open,O
arm,O
entries,O
/,O
total,O
entries,O
).,O
Novel,O
object,O
recognition,O
test,O
The,O
object,O
recognition,O
test,O
was,O
performed,O
according,O
to,O
a,O
previous,O
study,O
.,O
28,O
The,O
task,O
consisted,O
of,O
three,O
sessions,O
:,O
habituation,O
",",O
training,O
and,O
retention,O
.,O
Each,O
mouse,B-OG
was,O
individually,O
habituated,O
to,O
the,O
cage,O
(,O
30,O
×,O
30,O
×,O
30,O
cm,O
),O
with,O
10,O
min,O
of,O
exploration,O
in,O
the,O
absence,O
of,O
objects,O
for,O
3,O
days,O
.,O
Two,O
wooden,O
block,O
objects,O
were,O
placed,O
in,O
the,O
middle,O
of,O
the,O
cage,O
during,O
each,O
training,O
session,O
",",O
and,O
the,O
mouse,B-OG
was,O
allowed,O
to,O
explore,O
the,O
cage,O
for,O
10,O
min,O
.,O
In,O
the,O
retention,O
session,O
",",O
the,O
mouse,B-OG
was,O
placed,O
back,O
into,O
the,O
same,O
cage,O
with,O
a,O
novel,O
wooden,O
ball,O
object,O
together,O
with,O
a,O
familiar,O
wooden,O
block,O
object,O
6,O
h,O
after,O
the,O
training,O
session,O
.,O
The,O
animal,B-OG
was,O
then,O
allowed,O
to,O
explore,O
freely,O
for,O
10,O
min,O
and,O
the,O
time,O
spent,O
exploring,O
each,O
object,O
was,O
recorded,O
.,O
Exploratory,O
behavior,O
was,O
defined,O
as,O
directing,O
the,O
nose,O
to,O
the,O
object,O
at,O
a,O
distance,O
of,O
<,O
2,O
cm,O
and,O
/,O
or,O
touching,O
it,O
with,O
the,O
nose,O
.,O
Preference,O
index,O
",",O
a,O
ratio,O
of,O
the,O
amount,O
of,O
time,O
spent,O
exploring,O
a,O
novel,O
object,O
over,O
the,O
total,O
time,O
spent,O
exploring,O
both,O
objects,O
in,O
the,O
retention,O
session,O
",",O
was,O
used,O
to,O
measure,O
cognitive,O
function,O
.,O
Social,O
interaction,O
test,O
The,O
social,O
interaction,O
test,O
was,O
performed,O
as,O
previously,O
described,O
.,O
29,O
Each,O
mouse,B-OG
was,O
placed,O
in,O
the,O
observation,O
cage,O
and,O
allowed,O
15,O
min,O
of,O
habituation,O
under,O
dim,O
light,O
(,O
15,O
lux,O
).,O
After,O
habituation,O
",",O
a,O
juvenile,O
(,O
3,O
or,O
4,O
-,O
week,O
-,O
old,O
),O
male,O
C57BL,B-OG
/,I-OG
6,I-OG
mouse,I-OG
(,O
Shimizu,O
Laboratory,O
Supplies,O
",",O
Kyoto,O
",",O
Japan,O
),O
was,O
placed,O
in,O
the,O
center,O
of,O
the,O
cage,O
",",O
and,O
the,O
behavior,O
of,O
the,O
mouse,B-OG
was,O
recorded,O
for,O
5,O
min,O
.,O
Total,O
duration,O
of,O
social,O
interactions,O
(,O
for,O
example,O
",",O
sniffing,O
",",O
licking,O
),O
was,O
measured,O
from,O
recordings,O
by,O
a,O
trained,O
and,O
blinded,O
observer,O
.,O
Forced,O
swim,O
test,O
The,O
forced,O
swim,O
test,O
was,O
performed,O
as,O
previously,O
described,O
.,O
25,O
The,O
mice,B-OG
were,O
immersed,O
in,O
a,O
glass,O
cylinder,O
containing,O
25,O
°,O
C,O
water,O
for,O
6,O
min,O
.,O
Immobility,O
was,O
defined,O
as,O
no,O
additional,O
movements,O
by,O
the,O
mouse,B-OG
beyond,O
those,O
that,O
were,O
required,O
to,O
keep,O
the,O
head,O
above,O
the,O
water,O
.,O
The,O
duration,O
of,O
immobility,O
was,O
measured,O
from,O
video,O
recordings,O
.,O
After,O
the,O
test,O
",",O
the,O
mice,B-OG
were,O
dried,O
thoroughly,O
with,O
a,O
towel,O
and,O
returned,O
to,O
their,O
home,O
cage,O
.,O
PPI,O
test,O
Acoustic,O
startle,O
responses,O
in,O
the,O
pre,O
-,O
pulse,O
inhibition,O
(,O
PPI,O
),O
experiments,O
were,O
measured,O
in,O
a,O
startle,O
chamber,O
(,O
SR,O
-,O
LAB,O
;,O
San,O
Diego,O
Instruments,O
",",O
San,O
Diego,O
",",O
CA,O
",",O
USA,O
),O
using,O
standard,O
methods,O
described,O
previously,O
.,O
30,O
The,O
testing,O
session,O
started,O
with,O
5,O
min,O
of,O
habituation,O
to,O
the,O
startle,O
chamber,O
in,O
the,O
presence,O
of,O
65,O
dB,O
background,O
white,O
noise,O
.,O
Testing,O
was,O
composed,O
of,O
a,O
single,O
pulse,O
of,O
120,O
dB,O
preceded,O
five,O
prepulses,O
(,O
40,O
ms,O
),O
of,O
69,O
",",O
73,O
",",O
77,O
or,O
85,O
dB,O
.,O
Pulses,O
were,O
randomly,O
presented,O
with,O
an,O
average,O
of,O
16,O
s,O
between,O
pulses,O
.,O
Ten,O
no,O
-,O
stimulus,O
trials,O
were,O
included,O
to,O
assess,O
spontaneous,O
activity,O
during,O
testing,O
.,O
PPI,O
was,O
calculated,O
as,O
a,O
percentage,O
score,O
:,O
PPI,O
(%)=(,O
1,O
−[(,O
startle,O
response,O
for,O
pulse,O
with,O
pre,O
-,O
pulse,O
)/(,O
startle,O
response,O
for,O
pulse,O
alone,O
)]),O
×,O
100,O
.,O
Statistical,O
analysis,O
Adequate,O
sample,O
size,O
was,O
determined,O
according,O
to,O
the,O
previous,O
studies,O
that,O
performed,O
analogous,O
experiments,O
.,O
The,O
variances,O
between,O
the,O
groups,O
that,O
are,O
being,O
statistically,O
compared,O
were,O
similar,O
.,O
For,O
animal,B-OG
studies,O
",",O
no,O
randomization,O
and,O
blinding,O
were,O
used,O
.,O
Data,O
are,O
expressed,O
throughout,O
the,O
manuscript,O
as,O
mean,O
±,O
s,O
.,O
e,O
.,O
m,O
.,O
Statistical,O
analysis,O
was,O
performed,O
using,O
Statcel3,O
(,O
OMS,O
",",O
Saitama,O
",",O
Japan,O
),O
and,O
JMP,O
10,O
pro,O
(,O
SAS,O
Institute,O
of,O
Japan,O
",",O
Tokyo,O
",",O
Japan,O
).,O
Unpaired,O
t,O
-,O
tests,O
were,O
applied,O
to,O
compare,O
:,O
expression,O
levels,O
of,O
JMJD2B,B-GP
",",O
JMJD2C,B-GP
",",O
PSD95,B-GP
(,O
Supplementary,O
Figure,O
3,O
"),",O
Homer2,B-GP
",",O
Rhob,B-GP
and,O
Rhog,B-GP
(,O
Supplementary,O
Figure,O
6,O
),O
in,O
the,O
hippocampus,O
;,O
spine,O
number,O
(,O
Supplementary,O
Figure,O
4b,O
"),",O
structure,O
(,O
Supplementary,O
Figure,O
4a,O
"),",O
dendrite,O
number,O
and,O
length,O
in,O
the,O
hippocampus,O
and,O
somatosensory,O
cortex,O
.,O
A,O
two,O
-,O
sided,O
test,O
was,O
applied,O
",",O
except,O
for,O
the,O
analysis,O
of,O
spine,O
number,O
(,O
one,O
-,O
sided,O
test,O
).,O
The,O
raw,O
data,O
applying,O
t,O
-,O
test,O
was,O
normally,O
distributed,O
.,O
The,O
variance,O
was,O
similar,O
between,O
the,O
groups,O
that,O
are,O
being,O
statistically,O
compared,O
.,O
Two,O
-,O
way,O
analysis,O
of,O
variance,O
analysis,O
and,O
post,O
hoc,O
tests,O
were,O
applied,O
to,O
compare,O
:,O
Sholl,O
analysis,O
of,O
dendrites,O
of,O
cultured,O
hippocampal,O
neuron,O
total,O
distance,O
moved,O
activity,O
and,O
rearing,O
number,O
.,O
Mann,O
–,O
Whitney,O
tests,O
were,O
applied,O
to,O
compare,O
:,O
decrease,O
ratio,O
of,O
moved,O
distance,O
between,O
the,O
first,O
10,O
min,O
and,O
last,O
10,O
min,O
of,O
the,O
open,O
-,O
field,O
test,O
",",O
social,O
interaction,O
test,O
",",O
novel,O
object,O
cognition,O
test,O
",",O
Y,O
-,O
maze,O
test,O
",",O
elevated,O
-,O
plus,O
-,O
maze,O
test,O
(,O
Supplementary,O
Figure,O
5a,O
"),",O
PPI,O
(,O
Supplementary,O
Figure,O
5b,O
"),",O
forced,O
swim,O
test,O
(,O
Supplementary,O
Figure,O
5c,O
"),",O
rhythm,O
test,O
(,O
Supplementary,O
Figure,O
5d,O
),O
and,O
SHIRPA,O
test,O
(,O
Supplementary,O
Table,O
2,O
).,O
Results,O
JMJD2B,B-GP
expression,O
in,O
the,O
central,O
nervous,O
system,O
We,O
first,O
carried,O
out,O
in,O
situ,O
hybridization,O
to,O
characterize,O
the,O
expression,O
of,O
Jmjd2b,B-GP
mRNA,O
in,O
P0,O
WT,O
mouse,B-OG
brain,O
.,O
Strong,O
expression,O
was,O
observed,O
in,O
the,O
brain,O
and,O
retina,O
along,O
with,O
weaker,O
expression,O
in,O
other,O
organs,O
(,O
Figure,O
1a,O
).,O
We,O
then,O
analyzed,O
expression,O
of,O
Jmjd2b,B-GP
mRNA,O
in,O
the,O
brain,O
at,O
a,O
series,O
of,O
developmental,O
stages,O
.,O
From,O
E15,O
to,O
P14,O
",",O
Jmjd2b,B-GP
was,O
rather,O
diffusely,O
expressed,O
throughout,O
the,O
brain,O
.,O
Expression,O
was,O
especially,O
strong,O
in,O
the,O
cerebral,O
cortex,O
",",O
hippocampus,O
",",O
basal,O
ganglia,O
",",O
olfactory,O
bulb,O
and,O
cerebellum,O
.,O
In,O
8,O
-,O
week,O
-,O
old,O
mice,B-OG
",",O
the,O
expression,O
level,O
declined,O
",",O
but,O
prominent,O
signal,O
could,O
be,O
observed,O
in,O
hippocampus,O
and,O
cerebellum,O
.,O
The,O
time,O
course,O
of,O
the,O
expression,O
of,O
Jmjd2b,B-GP
mRNA,O
throughout,O
the,O
brain,O
is,O
detailed,O
in,O
Figure,O
1b,O
.,O
In,O
the,O
adult,O
hippocampus,O
",",O
JMJD2B,B-GP
mRNA,O
was,O
expressed,O
in,O
the,O
CA1,O
",",O
CA3,O
and,O
dentate,O
gyrus,O
.,O
To,O
assess,O
the,O
cell,O
types,O
expressing,O
JMJD2B,B-GP
in,O
the,O
hippocampus,O
",",O
we,O
performed,O
immunostaining,O
with,O
DAB,O
as,O
the,O
substrate,O
for,O
horseradish,B-OG
peroxidase,B-GP
using,O
NeuN,B-GP
",",O
GFAP,B-GP
and,O
GAD67,B-GP
primary,O
antibody,O
followed,O
by,O
in,O
situ,O
hybridization,O
.,O
The,O
signal,O
for,O
JMJD2B,B-GP
mRNA,O
was,O
observed,O
exclusively,O
in,O
NeuN,B-GP
-,O
positive,O
cells,O
",",O
but,O
not,O
in,O
NeuN,B-GP
-,O
negative,O
cells,O
(,O
Figure,O
1c,O
",",O
left,O
"),",O
and,O
could,O
not,O
be,O
detected,O
in,O
GFAP,B-GP
-,O
positive,O
astrocytes,O
.,O
These,O
results,O
demonstrate,O
that,O
Jmjd2b,B-GP
mRNA,O
is,O
predominantly,O
expressed,O
in,O
neurons,O
in,O
the,O
adult,O
mouse,B-OG
hippocampus,O
.,O
Moreover,O
the,O
signal,O
for,O
JMJD2B,B-GP
mRNA,O
was,O
observed,O
also,O
in,O
GAD67,B-GP
-,O
positive,O
cells,O
(,O
Supplementary,O
Figure,O
1a,O
).,O
The,O
signal,O
for,O
JMJD2B,B-GP
mRNA,O
was,O
observed,O
in,O
ganglionic,O
eminence,O
",",O
where,O
the,O
interneurons,O
are,O
originated,O
",",O
in,O
the,O
brain,O
on,O
E13,O
(,O
Supplementary,O
Figure,O
1b,O
).,O
These,O
results,O
suggest,O
that,O
Jmjd2b,B-GP
mRNA,O
is,O
also,O
expressed,O
in,O
GABAergic,O
neuron,O
.,O
Generation,O
of,O
mice,B-OG
lacking,O
JMJD2B,B-GP
in,O
neurons,O
We,O
next,O
explored,O
the,O
function,O
of,O
JMJD2B,B-GP
in,O
neurons,O
in,O
vivo,O
by,O
generating,O
mice,B-OG
lacking,O
JMJD2B,B-GP
specifically,O
in,O
neurons,O
.,O
We,O
crossed,O
mice,B-OG
in,O
which,O
exon,O
5,O
of,O
Jmjd2b,B-GP
was,O
flanked,O
by,O
LoxP,O
sequences,O
biallelically,O
(,O
Jmj2b,B-GP
flox,O
/,O
flox,O
),O
13,O
with,O
mice,B-OG
expressing,O
Cre,B-GP
recombinase,I-GP
under,O
the,O
tau,B-GP
promoter,O
(,O
tau,B-GP
-,O
Cre,B-GP
mice,B-OG
"),",O
21,O
resulting,O
in,O
the,O
deletion,O
of,O
coding,O
regions,O
necessary,O
for,O
demethylase,B-GP
activity,O
of,O
Jmjd2b,B-GP
specifically,O
in,O
the,O
neurons,O
of,O
these,O
compound,O
mutant,O
mice,B-OG
(,O
tau,B-GP
-,O
Cre,B-GP
;,O
Jmj2b,B-GP
flox,O
/,O
flox,O
).,O
JMJD2B,B-GP
gene,O
expression,O
was,O
barely,O
detectable,O
in,O
the,O
brains,O
of,O
tau,B-GP
-,O
Cre,B-GP
;,O
Jmj2b,B-GP
flox,O
/,O
flox,O
mice,B-OG
as,O
determined,O
by,O
reverse,O
transcription,O
–,O
PCR,O
(,O
P,O
=,O
0,O
.,O
009,O
;,O
Figure,O
2a,O
",",O
left,O
).,O
However,O
",",O
the,O
expression,O
level,O
of,O
Jmjd2c,B-GP
",",O
a,O
histone,B-GP
demethylase,I-GP
enzyme,O
closely,O
related,O
to,O
JMJD2B,B-GP
",",O
was,O
not,O
changed,O
in,O
these,O
mice,B-OG
(,O
Figure,O
2a,O
right,O
).,O
In,O
situ,O
hybridization,O
for,O
Jmjd2b,B-GP
confirmed,O
deletion,O
of,O
this,O
gene,O
in,O
these,O
mice,B-OG
(,O
Figure,O
2b,O
).,O
No,O
obvious,O
morphological,O
differences,O
were,O
observed,O
between,O
the,O
two,O
genotypes,O
including,O
in,O
the,O
hippocampus,O
(,O
Figure,O
2c,O
).,O
For,O
the,O
remainder,O
of,O
the,O
paper,O
",",O
we,O
refer,O
to,O
mice,B-OG
lacking,O
JMJD2B,B-GP
in,O
neurons,O
as,O
JMJD2B,B-GP
mutant,O
mice,B-OG
and,O
exon,O
5,O
-,O
biallelic,O
flanked,O
mice,B-OG
as,O
WT,O
mice,B-OG
.,O
JMJD2B,B-GP
regulates,O
spine,O
maturation,O
in,O
the,O
hippocampus,O
Next,O
",",O
we,O
investigated,O
structures,O
of,O
the,O
hippocampus,O
in,O
which,O
JMJD2B,B-GP
was,O
strongly,O
expressed,O
from,O
embryonic,O
stages,O
through,O
adulthood,O
in,O
detail,O
.,O
A,O
previous,O
report,O
revealed,O
that,O
HDAC2,B-GP
",",O
a,O
histone,B-GP
modifier,O
gene,O
",",O
affected,O
spine,O
number,O
in,O
hippocampus,O
and,O
regulated,O
the,O
formation,O
of,O
neural,O
circuits,O
.,O
31,O
These,O
findings,O
prompted,O
us,O
to,O
hypothesize,O
that,O
JMJD2B,B-GP
was,O
associated,O
with,O
synaptic,O
development,O
.,O
To,O
assess,O
this,O
possibility,O
",",O
we,O
examined,O
the,O
spine,O
structure,O
of,O
hippocampal,O
CA1,O
pyramidal,O
neurons,O
using,O
the,O
Golgi,O
staining,O
method,O
.,O
Dendritic,O
spines,O
of,O
pyramidal,O
neurons,O
in,O
the,O
CA1,O
region,O
receive,O
direct,O
and,O
indirect,O
excitatory,O
inputs,O
from,O
various,O
anatomical,O
regions,O
.,O
Schaffer,O
collaterals,O
from,O
CA3,O
are,O
one,O
of,O
the,O
major,O
inputs,O
to,O
CA1,O
and,O
they,O
terminate,O
in,O
the,O
distal,O
two,O
-,O
thirds,O
of,O
the,O
stratum,O
radiatum,O
of,O
the,O
CA1,O
region,O
.,O
32,O
Therefore,O
",",O
we,O
analyzed,O
the,O
spine,O
morphology,O
and,O
density,O
on,O
secondary,O
dendrites,O
of,O
the,O
pyramidal,O
neurons,O
in,O
this,O
area,O
.,O
We,O
first,O
counted,O
the,O
total,O
number,O
of,O
spines,O
per,O
20,O
μm,O
dendrite,O
and,O
found,O
a,O
significant,O
increase,O
in,O
the,O
spine,O
numbers,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
(,O
P,O
=,O
0,O
.,O
041,O
;,O
Figures,O
3a,O
–,O
d,O
).,O
We,O
then,O
performed,O
structural,O
analysis,O
of,O
spines,O
",",O
classifying,O
them,O
into,O
mature,O
spines,O
(,O
mushroom,O
type,O
),O
and,O
immature,O
spines,O
(,O
thin,O
type,O
",",O
filopodia,O
type,O
and,O
stubby,O
type,O
).,O
We,O
found,O
that,O
the,O
number,O
of,O
mature,O
mushroom,O
type,O
spines,O
was,O
significantly,O
reduced,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
(,O
P,O
=,O
0,O
.,O
006,O
"),",O
and,O
that,O
the,O
number,O
of,O
immature,O
filopodia,O
type,O
was,O
increased,O
(,O
filopodia,O
type,O
;,O
P,O
=,O
0,O
.,O
08,O
;,O
Figures,O
3a,O
–,O
c,O
and,O
e,O
).,O
However,O
the,O
expression,O
level,O
of,O
PSD95,B-GP
in,O
hippocampus,O
was,O
not,O
significantly,O
different,O
between,O
the,O
genotypes,O
(,O
Supplementary,O
Figure,O
2,O
).,O
As,O
JMJD2B,B-GP
is,O
expressed,O
also,O
in,O
somatosensory,O
cortex,O
from,O
late,O
prenatal,O
to,O
early,O
postnatal,O
mouse,B-OG
",",O
we,O
analyzed,O
the,O
number,O
and,O
structure,O
of,O
spines,O
in,O
apical,O
dendrite,O
of,O
layer,O
2,O
/,O
3,O
pyramidal,O
neuron,O
in,O
somatosensory,O
cortex,O
.,O
Notably,O
",",O
MeCP2,B-GP
mutant,O
mice,B-OG
",",O
which,O
display,O
neurodevelopmental,O
delay,O
and,O
spontaneous,O
epileptiform,O
activity,O
",",O
reveal,O
increased,O
number,O
of,O
spines,O
in,O
somatosensory,O
cortex,O
.,O
33,O
However,O
",",O
we,O
found,O
no,O
difference,O
between,O
the,O
genotypes,O
in,O
either,O
spine,O
number,O
or,O
structure,O
in,O
somatosensory,O
cortex,O
(,O
Supplementary,O
Figure,O
3,O
).,O
We,O
next,O
attempted,O
to,O
investigate,O
the,O
formation,O
of,O
dendrites,O
in,O
vivo,O
.,O
However,O
",",O
it,O
was,O
difficult,O
to,O
assess,O
the,O
length,O
and,O
elaboration,O
of,O
specific,O
neurons,O
",",O
as,O
the,O
dendrites,O
of,O
Golgi,O
-,O
stained,O
neurons,O
overlapped,O
with,O
each,O
other,O
in,O
the,O
CA1,O
region,O
.,O
Therefore,O
",",O
we,O
cultured,O
hippocampal,O
neurons,O
derived,O
from,O
P1,O
JMJD2B,B-GP
mutant,O
mice,B-OG
and,O
WT,O
mice,B-OG
for,O
7,O
days,O
",",O
and,O
assessed,O
the,O
formation,O
of,O
dendrites,O
in,O
vitro,O
.,O
We,O
found,O
no,O
significant,O
differences,O
in,O
dendrite,O
number,O
",",O
length,O
or,O
elaboration,O
between,O
the,O
two,O
genotypes,O
(,O
Figures,O
3f,O
and,O
i,O
).,O
We,O
further,O
examined,O
whether,O
abnormal,O
mossy,O
fiber,O
sprouting,O
was,O
present,O
in,O
mutant,O
mice,B-OG
using,O
Timm,O
staining,O
and,O
found,O
no,O
differences,O
between,O
genotypes,O
(,O
Supplementary,O
Figure,O
4,O
).,O
Our,O
findings,O
therefore,O
indicate,O
that,O
JMJD2B,B-GP
is,O
required,O
for,O
normal,O
spine,O
formation,O
in,O
the,O
hippocampal,O
CA1,O
region,O
",",O
and,O
disruption,O
of,O
JMJD2B,B-GP
gene,O
leads,O
to,O
impaired,O
dendritic,O
spine,O
maturation,O
.,O
JMJD2B,B-GP
mutant,O
mice,B-OG
show,O
hyperactive,O
behavior,O
Defective,O
histone,B-GP
demethylase,I-GP
function,O
is,O
associated,O
with,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
As,O
our,O
observations,O
of,O
impaired,O
dendritic,O
spine,O
formation,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
suggested,O
that,O
JMJD2B,B-GP
has,O
an,O
important,O
role,O
in,O
the,O
formation,O
of,O
neural,O
networks,O
in,O
the,O
CNS,O
",",O
we,O
hypothesized,O
that,O
JMJD2B,B-GP
mutant,O
mice,B-OG
might,O
display,O
abnormal,O
behavior,O
reminiscent,O
of,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
We,O
therefore,O
subjected,O
JMJD2B,B-GP
mutant,O
mice,B-OG
and,O
their,O
WT,O
littermates,O
to,O
a,O
comprehensive,O
battery,O
of,O
behavioral,O
tests,O
(,O
Supplementary,O
Table,O
1,O
).,O
Mutant,O
mice,B-OG
showed,O
no,O
obvious,O
differences,O
in,O
their,O
physical,O
characteristics,O
.,O
On,O
the,O
other,O
hand,O
",",O
JMJD2B,B-GP
mutant,O
mice,B-OG
displayed,O
significantly,O
increased,O
vocalization,O
",",O
which,O
was,O
the,O
index,O
of,O
the,O
excitability,O
of,O
mice34,O
(,O
SHIRPA,O
test,O
;,O
Supplementary,O
Table,O
2,O
).,O
Spontaneous,O
locomotor,O
activity,O
was,O
assessed,O
by,O
the,O
open,O
-,O
field,O
test,O
.,O
There,O
were,O
significant,O
differences,O
between,O
genotypes,O
in,O
the,O
total,O
distance,O
traveled,O
(,O
between,O
genotypes,O
;,O
P,O
<,O
0,O
.,O
0001,O
",",O
30,O
–,O
40,O
min,O
;,O
P,O
=,O
0,O
.,O
0045,O
",",O
40,O
–,O
50,O
min,O
;,O
P,O
=,O
0,O
.,O
0015,O
;,O
Figure,O
4a,O
"),",O
rearing,O
number,O
(,O
between,O
genotypes,O
;,O
P,O
=,O
0,O
.,O
0027,O
;,O
Figure,O
4b,O
),O
and,O
activity,O
(,O
between,O
genotypes,O
;,O
P,O
<,O
0,O
.,O
0001,O
",",O
30,O
–,O
40,O
min,O
;,O
P,O
=,O
0,O
.,O
0048,O
",",O
40,O
–,O
50,O
min,O
;,O
P,O
=,O
0,O
.,O
0012,O
;,O
Figure,O
4d,O
).,O
We,O
then,O
tested,O
their,O
response,O
to,O
a,O
novel,O
environment,O
",",O
a,O
test,O
of,O
anxiety,B-DS
and,O
exploratory,O
behavior,O
.,O
When,O
WT,O
mice,B-OG
were,O
placed,O
in,O
a,O
novel,O
environment,O
",",O
they,O
initially,O
became,O
hyperactive,O
in,O
response,O
to,O
the,O
unfamiliar,O
surroundings,O
.,O
They,O
then,O
became,O
accustomed,O
to,O
the,O
new,O
environment,O
and,O
their,O
enhanced,O
activity,O
gradually,O
declined,O
.,O
However,O
",",O
JMJD2B,B-GP
mutant,O
mice,B-OG
remained,O
hyperactive,O
even,O
during,O
the,O
last,O
10,O
min,O
of,O
the,O
test,O
.,O
Figure,O
4c,O
shows,O
the,O
ratio,O
of,O
the,O
distance,O
moved,O
in,O
the,O
last,O
10,O
min,O
to,O
the,O
distance,O
moved,O
in,O
the,O
first,O
10,O
min,O
(,O
P,O
=,O
0,O
.,O
024,O
).,O
Mice,B-OG
were,O
also,O
subjected,O
to,O
the,O
elevated,O
-,O
plus,O
-,O
maze,O
test,O
",",O
PPI,O
test,O
",",O
forced,O
swim,O
test,O
and,O
sleep,O
–,O
wake,O
rhythm,O
test,O
(,O
Supplementary,O
Figures,O
5a,O
–,O
d,O
).,O
There,O
were,O
no,O
significant,O
differences,O
between,O
genotypes,O
except,O
for,O
a,O
decrease,O
of,O
immobile,O
time,O
in,O
mutant,O
mice,B-OG
in,O
the,O
forced,O
swim,O
test,O
(,O
P,O
=,O
0,O
.,O
026,O
).,O
Although,O
the,O
forced,O
swim,O
test,O
is,O
used,O
as,O
an,O
index,O
of,O
depressive,O
-,O
like,O
behavior,O
in,O
mice,B-OG
",",O
this,O
result,O
does,O
not,O
necessarily,O
mean,O
that,O
the,O
mutant,O
mice,B-OG
show,O
an,O
anti,O
-,O
depressive,O
tendency,O
",",O
as,O
these,O
mice,B-OG
show,O
hyperactivity,O
at,O
baseline,O
.,O
JMJD2B,B-GP
mutant,O
mice,B-OG
show,O
deficits,O
in,O
working,O
memory,O
As,O
two,O
mutations,O
of,O
JMJD2B,B-GP
are,O
found,O
in,O
individuals,O
of,O
ASD,B-DS
",",O
we,O
performed,O
a,O
series,O
of,O
experiments,O
to,O
assess,O
autistic,O
-,O
like,O
traits,O
in,O
these,O
mice,B-OG
.,O
First,O
",",O
an,O
interest,O
in,O
novelties,O
was,O
tested,O
in,O
the,O
novel,O
object,O
recognition,O
test,O
using,O
a,O
novel,O
wooden,O
ball,O
object,O
.,O
There,O
were,O
no,O
differences,O
between,O
genotypes,O
in,O
the,O
exploration,O
rate,O
to,O
a,O
novel,O
object,O
(,O
Figure,O
5a,O
).,O
Next,O
",",O
sociability,O
was,O
tested,O
in,O
social,O
interaction,O
test,O
with,O
a,O
juvenile,O
WT,O
male,O
mouse,B-OG
as,O
a,O
social,O
partner,O
.,O
There,O
were,O
no,O
differences,O
between,O
genotypes,O
in,O
the,O
interaction,O
time,O
spent,O
with,O
a,O
social,O
partner,O
(,O
Figure,O
5b,O
).,O
Previous,O
reports,O
have,O
revealed,O
that,O
neurodevelopmental,B-DS
disorders,I-DS
are,O
sometimes,O
correlated,O
with,O
intellectual,O
disability,O
.,O
2,O
Therefore,O
",",O
we,O
examined,O
whether,O
working,O
memory,O
was,O
impaired,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
as,O
assessed,O
by,O
spontaneous,O
alteration,O
behavior,O
in,O
the,O
Y,O
-,O
maze,O
task,O
.,O
Mice,B-OG
of,O
each,O
genotype,O
were,O
put,O
into,O
the,O
box,O
with,O
a,O
Y,O
shape,O
and,O
the,O
percentage,O
of,O
correct,O
entry,O
numbers,O
per,O
total,O
entry,O
numbers,O
(,O
alteration,O
rates,O
),O
was,O
evaluated,O
.,O
WT,O
mice,B-OG
exhibited,O
alteration,O
rates,O
of,O
approximately,O
60,O
%.,O
In,O
contrast,O
",",O
JMJD2B,B-GP
mutant,O
mice,B-OG
showed,O
significantly,O
reduced,O
alteration,O
rates,O
compared,O
with,O
WT,O
littermates,O
(,O
P,O
=,O
0,O
.,O
0074,O
;,O
Figure,O
5c,O
).,O
The,O
total,O
number,O
of,O
entries,O
differed,O
between,O
genotypes,O
",",O
reflecting,O
the,O
hyperactivity,O
of,O
the,O
mutant,O
mice,B-OG
observed,O
at,O
baseline,O
(,O
P,O
=,O
0,O
.,O
0015,O
;,O
Figure,O
5d,O
).,O
These,O
results,O
suggest,O
that,O
working,O
memory,O
is,O
impaired,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
.,O
These,O
results,O
are,O
in,O
keeping,O
with,O
the,O
aberrant,O
neuronal,O
morphology,O
observed,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
",",O
as,O
accumulating,O
evidences,O
indicate,O
an,O
association,O
of,O
memory,O
function,O
with,O
alterations,O
in,O
dendritic,O
spine,O
morphology,O
.,O
35,O
Therefore,O
",",O
impaired,O
hippocampal,O
spine,O
maturation,O
may,O
cause,O
working,O
memory,O
deficits,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
.,O
Moreover,O
",",O
some,O
JMJD2B,B-GP
mutant,O
mice,B-OG
showed,O
spontaneous,O
epileptiform,O
-,O
like,O
activity,O
(,O
data,O
not,O
shown,O
"),",O
which,O
is,O
another,O
important,O
symptom,O
of,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
1,O
It,O
occurred,O
following,O
stressful,O
events,O
such,O
as,O
cage,O
opening,O
",",O
handling,O
or,O
placement,O
in,O
a,O
novel,O
environment,O
.,O
Seizures,O
generally,O
began,O
at,O
about,O
5,O
s,O
after,O
these,O
events,O
beginning,O
with,O
behavioral,O
arrest,O
and,O
rigid,O
motionless,O
posture,O
",",O
followed,O
by,O
head,O
and,O
neck,O
jerks,O
",",O
and,O
clonus,O
of,O
forelimb,O
and,O
hindlimb,O
.,O
We,O
observed,O
such,O
epileptiform,O
-,O
like,O
activity,O
in,O
3,O
mice,B-OG
out,O
of,O
153,O
mutant,O
mice,B-OG
in,O
our,O
experiment,O
(~,O
2,O
"%),",O
though,O
WT,O
mice,B-OG
never,O
displayed,O
such,O
activity,O
.,O
These,O
mice,B-OG
that,O
suffered,O
from,O
such,O
epileptiform,O
-,O
like,O
activity,O
were,O
all,O
older,O
than,O
8,O
weeks,O
.,O
In,O
summary,O
",",O
the,O
JMJD2B,B-GP
mutant,O
mice,B-OG
characterized,O
in,O
this,O
study,O
display,O
several,O
symptoms,O
reminiscent,O
of,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
Discussion,O
In,O
the,O
present,O
study,O
",",O
we,O
analyzed,O
the,O
phenotype,O
of,O
JMJD2B,B-GP
mutant,O
mice,B-OG
in,O
brain,O
development,O
.,O
We,O
found,O
a,O
decreased,O
number,O
of,O
mature,O
spines,O
and,O
increased,O
number,O
of,O
immature,O
spines,O
",",O
resulting,O
in,O
increased,O
total,O
number,O
of,O
spines,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
.,O
Pyramidal,O
neurons,O
in,O
the,O
CA3,O
region,O
partly,O
transmit,O
electrical,O
signals,O
to,O
distal,O
radial,O
stratum,O
of,O
CA1,O
region,O
through,O
Schaffer,O
collaterals,O
.,O
Therefore,O
",",O
it,O
is,O
intriguing,O
to,O
hypothesize,O
that,O
the,O
abnormalities,O
in,O
spine,O
number,O
and,O
structure,O
in,O
the,O
CA1,O
region,O
induce,O
defective,O
signal,O
transmission,O
from,O
CA3,O
to,O
CA1,O
.,O
The,O
expression,O
level,O
of,O
PSD95,B-GP
in,O
hippocampus,O
was,O
not,O
changed,O
.,O
This,O
is,O
presumably,O
because,O
the,O
change,O
in,O
the,O
PSD95,B-GP
expression,O
in,O
the,O
hippocampal,O
spines,O
was,O
region,O
-,O
specific,O
or,O
the,O
minute,O
change,O
could,O
not,O
be,O
detected,O
by,O
using,O
the,O
western,O
blot,O
test,O
.,O
JMJD2B,B-GP
mutant,O
mice,B-OG
displayed,O
spontaneous,O
epileptiform,O
-,O
like,O
activity,O
.,O
Although,O
it,O
is,O
possible,O
that,O
seizure,O
recurrence,O
can,O
alter,O
synapse,O
connectivity,O
leading,O
to,O
change,O
in,O
spine,O
number,O
and,O
structure,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
",",O
this,O
would,O
not,O
be,O
the,O
case,O
considering,O
the,O
rare,O
incidence,O
rate,O
and,O
age,O
of,O
onset,O
of,O
seizures,O
(,O
we,O
used,O
8,O
-,O
week,O
-,O
old,O
mice,B-OG
for,O
analysis,O
).,O
A,O
previous,O
report,O
suggests,O
that,O
JMJD2B,B-GP
is,O
a,O
causative,O
risk,O
gene,O
for,O
neurodevelopmental,B-DS
disorders,I-DS
",",O
8,O
while,O
accumulating,O
evidence,O
indicates,O
that,O
hippocampal,O
spines,O
in,O
various,O
mouse,B-OG
models,O
of,O
neurodevelopmental,B-DS
disorder,I-DS
are,O
structurally,O
and,O
functionally,O
abnormal,O
.,O
36,O
",",O
37,O
",",O
38,O
",",O
39,O
For,O
example,O
",",O
mice,B-OG
with,O
a,O
mutation,O
in,O
SHANK2,B-GP
",",O
a,O
risk,O
gene,O
for,O
ASD,B-DS
",",O
display,O
an,O
increased,O
number,O
of,O
hippocampal,O
spines,O
and,O
abnormal,O
synaptic,O
transmission,O
in,O
the,O
hippocampus,O
.,O
37,O
Furthermore,O
",",O
high,O
-,O
density,O
and,O
spindle,O
-,O
shaped,O
dendritic,O
spines,O
are,O
also,O
observed,O
in,O
the,O
brains,O
of,O
individuals,O
with,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
40,O
We,O
also,O
observed,O
behavioral,O
alterations,O
in,O
JMJD2B,B-GP
-,O
deficient,O
mice,B-OG
.,O
Recently,O
",",O
mutations,O
of,O
a,O
number,O
of,O
genes,O
involved,O
in,O
epigenetic,O
modification,O
",",O
including,O
DNA,O
methylation,O
",",O
histone,B-GP
acetylation,O
or,O
deacetylation,O
",",O
and,O
histone,B-GP
methylation,O
and,O
demethylation,O
",",O
have,O
been,O
identified,O
in,O
individuals,O
with,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
Indeed,O
",",O
two,O
mutations,O
of,O
JMJD2B,B-GP
were,O
identified,O
in,O
ASD,B-DS
patients,O
.,O
The,O
results,O
of,O
open,O
-,O
field,O
test,O
suggest,O
that,O
JMJD2B,B-GP
-,O
deficient,O
mice,B-OG
are,O
hyperactive,O
at,O
baseline,O
and,O
have,O
trouble,O
in,O
becoming,O
accustomed,O
to,O
a,O
novel,O
environment,O
.,O
Neurodevelopmental,B-DS
disorders,I-DS
sometimes,O
correlate,O
with,O
intellectual,O
disability,O
.,O
2,O
JMJD2B,B-GP
-,O
deficient,O
mice,B-OG
did,O
in,O
fact,O
display,O
working,O
memory,O
deficits,O
as,O
determined,O
by,O
assessment,O
of,O
correct,O
entry,O
number,O
in,O
the,O
Y,O
-,O
maze,O
test,O
(,O
Figure,O
5c,O
).,O
Moreover,O
",",O
these,O
mice,B-OG
sometimes,O
displayed,O
epileptiform,O
-,O
like,O
seizures,O
",",O
which,O
are,O
frequently,O
observed,O
in,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
3,O
These,O
mice,B-OG
also,O
displayed,O
anti,O
-,O
depressive,O
-,O
like,O
behavior,O
in,O
the,O
forced,O
swim,O
test,O
.,O
However,O
",",O
we,O
should,O
be,O
careful,O
in,O
the,O
interpretation,O
of,O
this,O
data,O
",",O
as,O
this,O
tendency,O
may,O
just,O
reflect,O
the,O
heightened,O
baseline,O
hyperactivity,O
of,O
these,O
mice,B-OG
.,O
On,O
the,O
other,O
hand,O
",",O
these,O
mice,B-OG
did,O
not,O
display,O
excessive,O
anxiety,B-DS
-,O
like,O
or,O
ASD,B-DS
-,O
like,O
behaviors,O
",",O
such,O
as,O
social,O
interaction,O
deficits,O
or,O
indifference,O
to,O
novel,O
objects,O
",",O
or,O
other,O
abnormalities,O
(,O
PPI,O
and,O
rhythm,O
tests,O
).,O
Taken,O
together,O
these,O
behavioral,O
data,O
indicate,O
that,O
JMJD2B,B-GP
mutant,O
mice,B-OG
display,O
attention,B-DS
deficit,I-DS
hyperactivity,I-DS
disorder,I-DS
-,O
like,O
behavior,O
with,O
memory,O
deficits,O
and,O
epilepsy,B-DS
.,O
However,O
",",O
JMJD2B,B-GP
is,O
suspected,O
to,O
be,O
a,O
risk,O
gene,O
for,O
ASD,B-DS
.,O
One,O
possible,O
reason,O
for,O
this,O
discrepancy,O
is,O
that,O
our,O
behavioral,O
tests,O
may,O
not,O
be,O
appropriate,O
for,O
the,O
detection,O
of,O
ASD,B-DS
-,O
like,O
symptoms,O
in,O
this,O
mouse,B-OG
.,O
For,O
example,O
",",O
several,O
mouse,B-OG
models,O
with,O
mutated,O
risk,O
genes,O
for,O
ASD,B-DS
display,O
abnormalities,O
in,O
ultrasonic,O
vocalization,O
",",O
and,O
this,O
important,O
behavioral,O
characteristic,O
in,O
ASD,B-DS
-,O
model,O
mice,B-OG
was,O
not,O
tested,O
in,O
our,O
study,O
.,O
41,O
",",O
42,O
Although,O
rearing,O
behavior,O
in,O
mice,B-OG
is,O
generally,O
described,O
as,O
an,O
index,O
of,O
exploratory,O
behavior,O
",",O
increases,O
in,O
the,O
frequency,O
of,O
rearing,O
number,O
observed,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
may,O
replicate,O
repetitive,O
behavior,O
in,O
ASD,B-DS
.,O
In,O
fact,O
",",O
recent,O
reports,O
have,O
revealed,O
that,O
Shank3,B-GP
mutant,O
mice,B-OG
",",O
a,O
model,O
of,O
ASD,B-DS
",",O
display,O
enhanced,O
rearing,O
.,O
43,O
JMJD2B,B-GP
is,O
a,O
histone,B-GP
lysine,I-GP
demethylase,I-GP
that,O
acts,O
as,O
a,O
transcriptional,B-GP
activator,I-GP
through,O
demethylation,O
of,O
H3K9me3,O
.,O
Therefore,O
",",O
the,O
transcription,O
of,O
target,O
genes,O
is,O
suppressed,O
when,O
JMJD2B,B-GP
is,O
depleted,O
.,O
Hippocampal,O
spine,O
formation,O
",",O
elimination,O
and,O
maturation,O
are,O
dynamic,O
processes,O
that,O
maintain,O
the,O
synaptic,O
network,O
of,O
the,O
brain,O
.,O
Actin,B-GP
-,I-GP
binding,I-GP
proteins,I-GP
",",O
postsynaptic,O
scaffolding,B-GP
proteins,I-GP
and,O
low,O
-,O
molecular,O
-,O
GTP,B-GP
-,I-GP
binding,I-GP
proteins,I-GP
have,O
been,O
reported,O
to,O
be,O
important,O
factors,O
involved,O
in,O
these,O
processes,O
.,O
44,O
Transcriptional,O
silencing,O
of,O
such,O
factors,O
by,O
JMJD2B,B-GP
depletion,O
may,O
alter,O
their,O
expression,O
level,O
",",O
which,O
may,O
in,O
turn,O
underlie,O
the,O
increase,O
in,O
total,O
spine,O
number,O
with,O
a,O
decrease,O
in,O
mature,O
spines,O
that,O
we,O
observed,O
in,O
the,O
hippocampal,O
CA1,O
region,O
of,O
JMJD2B,B-GP
mutant,O
mice,B-OG
.,O
A,O
previous,O
report,O
demonstrated,O
that,O
G9a,B-GP
histone,B-GP
methyltransferase,I-GP
elevates,O
the,O
density,O
of,O
dendritic,O
spines,O
in,O
nucleus,O
accumbens,O
neurons,O
by,O
reducing,O
H3K9me2,O
levels,O
on,O
exposure,O
to,O
cocaine,O
.,O
45,O
In,O
addition,O
",",O
mutation,O
of,O
MeCP2,B-GP
",",O
the,O
causative,O
gene,O
of,O
Rett,B-DS
syndrome,I-DS
and,O
an,O
epigenetic,O
regulator,O
that,O
acts,O
by,O
binding,O
to,O
methylated,O
DNA,O
",",O
also,O
causes,O
a,O
decrease,O
in,O
the,O
number,O
of,O
dendritic,O
spines,O
.,O
46,O
Thus,O
",",O
there,O
is,O
increasing,O
evidence,O
that,O
epigenetic,O
mechanisms,O
affect,O
the,O
development,O
and,O
plasticity,O
of,O
dendritic,O
spines,O
.,O
A,O
differential,O
genome,O
-,O
wide,O
expression,O
study,O
for,O
JMJD2B,B-GP
-,O
deficient,O
ES,O
cells,O
reported,O
that,O
gene,O
expression,O
of,O
several,O
genes,O
involved,O
in,O
synaptic,O
function,O
such,O
as,O
Homer2,B-GP
",",O
Rhob,B-GP
and,O
Rhog,B-GP
was,O
changed,O
.,O
47,O
",",O
48,O
",",O
49,O
However,O
",",O
the,O
expression,O
level,O
of,O
these,O
genes,O
was,O
not,O
changed,O
in,O
hippocampus,O
of,O
JMJD2B,B-GP
mutant,O
mice,B-OG
in,O
our,O
experimental,O
paradigm,O
(,O
Supplementary,O
Figure,O
6,O
).,O
Further,O
studies,O
are,O
needed,O
to,O
identify,O
the,O
target,O
genes,O
of,O
JMJD2B,B-GP
.,O
However,O
",",O
it,O
should,O
be,O
noted,O
that,O
the,O
genes,O
involved,O
in,O
the,O
regulation,O
of,O
spine,O
structure,O
might,O
not,O
be,O
direct,O
targets,O
of,O
JMJD2B,B-GP
.,O
It,O
has,O
been,O
shown,O
that,O
various,O
regions,O
in,O
the,O
brain,O
are,O
affected,O
in,O
the,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
For,O
example,O
",",O
pathological,O
findings,O
are,O
observed,O
in,O
cerebral,O
cortex,O
",",O
amygdala,O
",",O
basal,O
ganglia,O
",",O
and,O
cerebellum,O
and,O
hippocampus,O
in,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
50,O
",",O
51,O
Most,O
notably,O
",",O
abnormal,O
neurogenesis,O
in,O
the,O
cerebral,O
cortex,O
is,O
associated,O
with,O
ASD,B-DS
-,O
like,O
behavior,O
.,O
52,O
Indeed,O
",",O
disorganization,O
of,O
the,O
cerebral,O
cortex,O
is,O
observed,O
in,O
children,O
with,O
ASD,B-DS
.,O
53,O
JMJD2B,B-GP
",",O
which,O
is,O
strongly,O
expressed,O
in,O
the,O
cerebral,O
cortex,O
at,O
perinatal,O
stages,O
",",O
might,O
also,O
play,O
a,O
role,O
in,O
cortical,O
neurogenesis,O
.,O
It,O
is,O
possible,O
that,O
the,O
deficiency,O
of,O
JMJD2B,B-GP
causes,O
abnormal,O
cerebral,O
neurogenesis,O
resulting,O
in,O
abnormal,O
behavior,O
.,O
Further,O
research,O
is,O
needed,O
to,O
examine,O
whether,O
the,O
hippocampus,O
is,O
the,O
region,O
responsible,O
for,O
abnormal,O
behavior,O
in,O
JMJD2B,B-GP
mutant,O
mice,B-OG
.,O
In,O
conclusion,O
",",O
our,O
study,O
elucidates,O
the,O
function,O
of,O
JMJD2B,B-GP
in,O
the,O
dendritic,O
spine,O
regulation,O
and,O
behavior,O
",",O
and,O
provides,O
a,O
new,O
mouse,B-OG
model,O
for,O
neurodevelopmental,B-DS
disorders,I-DS
.,O
Supplementary,O
Information,O
accompanies,O
the,O
paper,O
on,O
the,O
Translational,O
Psychiatry,O
website,O
(,O
http,O
://,O
www,O
.,O
nature,O
.,O
com,O
/,O
tp,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Expression,O
of,O
Jmjd2b,O
in,O
mouse,O
.,O
(,O
a,O
),O
In,O
situ,O
hybridization,O
revealing,O
expression,O
of,O
Jmjd2b,O
mRNA,O
in,O
E17,O
mouse,O
(,O
left,O
:,O
antisense,O
",",O
right,O
:,O
sense,O
;,O
n,O
=,O
1,O
).,O
(,O
b,O
),O
In,O
situ,O
hybridization,O
for,O
the,O
detection,O
of,O
Jmjd2b,O
mRNA,O
in,O
the,O
brain,O
at,O
the,O
indicated,O
stages,O
(,O
n,O
=,O
1,O
per,O
age,O
).,O
(,O
c,O
),O
In,O
situ,O
hybridization,O
for,O
Jmjd2b,O
mRNA,O
",",O
followed,O
by,O
immunostaining,O
with,O
NeuN,O
(,O
left,O
),O
and,O
GFAP,O
(,O
right,O
;,O
n,O
=,O
1,O
).,O
Scale,O
bars,O
:,O
(,O
a,O
),O
2,O
mm,O
",",O
(,O
b,O
),O
1,O
mm,O
",",O
(,O
c,O
),O
200,O
μm,O
.,O
Generation,O
of,O
neuron,O
-,O
specific,O
Jmjd2b,O
mutant,O
mice,O
.,O
(,O
a,O
),O
Relative,O
expression,O
level,O
of,O
Jmjd2b,O
and,O
Jmjd2c,O
.,O
The,O
expression,O
level,O
was,O
normalized,O
to,O
Gapdh,O
.,O
**,O
P,O
<,O
0,O
.,O
01,O
;,O
NS,O
",",O
not,O
significant,O
.,O
(,O
WT,O
",",O
KO,O
:,O
n,O
=,O
3,O
),O
Error,O
bars,O
represent,O
s,O
.,O
e,O
.,O
m,O
.,O
(,O
b,O
),O
Expression,O
of,O
Jmjd2b,O
mRNA,O
in,O
WT,O
and,O
KO,O
mice,O
.,O
P0,O
mice,O
were,O
used,O
for,O
in,O
situ,O
hybridization,O
.,O
(,O
WT,O
",",O
KO,O
:,O
n,O
=,O
1,O
).,O
(,O
c,O
),O
Nissl,O
staining,O
showing,O
the,O
gross,O
morphology,O
of,O
the,O
brain,O
in,O
the,O
two,O
genotypes,O
.,O
(,O
WT,O
",",O
KO,O
:,O
n,O
=,O
3,O
).,O
KO,O
",",O
JMJD2B,O
mutant,O
mice,O
;,O
WT,O
",",O
wild,O
-,O
type,O
mice,O
.,O
Scale,O
bars,O
:,O
(,O
b,O
),O
1,O
mm,O
",",O
(,O
c,O
),O
50,O
μm,O
.,O
Structural,O
analysis,O
of,O
dendrites,O
and,O
spines,O
of,O
hippocampal,O
CA1,O
of,O
JMJD2B,O
mutant,O
mice,O
.(,O
a,O
),O
Representative,O
Golgi,O
staining,O
image,O
in,O
the,O
hippocampal,O
CA1,O
region,O
.,O
(,O
b,O
and,O
c,O
),O
Representative,O
Golgi,O
staining,O
images,O
of,O
dendritic,O
spines,O
in,O
the,O
hippocampal,O
CA1,O
region,O
in,O
each,O
genotype,O
.,O
(,O
b,O
′,O
and,O
c,O
′),O
Magnified,O
images,O
of,O
b,O
and,O
c,O
.,O
(,O
d,O
),O
The,O
total,O
spine,O
numbers,O
in,O
the,O
CA1,O
region,O
of,O
the,O
two,O
genotypes,O
.,O
(,O
e,O
),O
The,O
percentage,O
of,O
mature,O
mushroom,O
",",O
filopodia,O
",",O
thin,O
and,O
stubby,O
-,O
type,O
spines,O
of,O
CA1,O
pyramidal,O
neurons,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
;,O
**,O
P,O
<,O
0,O
.,O
01,O
.,O
WT,O
:,O
n,O
=,O
6,O
",",O
KO,O
:,O
n,O
=,O
5,O
(,O
a,O
–,O
e,O
).,O
Error,O
bars,O
represent,O
s,O
.,O
e,O
.,O
m,O
.,O
(,O
f,O
;,O
left,O
),O
Representative,O
images,O
of,O
hippocampal,O
neurons,O
cultured,O
for,O
7,O
days,O
",",O
and,O
stained,O
with,O
MAP2,O
.,O
(,O
g,O
),O
Sholl,O
analysis,O
of,O
hippocampal,O
neurons,O
of,O
each,O
genotype,O
.,O
A,O
concentric,O
circle,O
was,O
drawn,O
every,O
10,O
μm,O
from,O
a,O
central,O
focus,O
on,O
the,O
neuronal,O
soma,O
and,O
the,O
number,O
of,O
intersections,O
were,O
counted,O
.,O
NS,O
",",O
not,O
significant,O
.,O
(,O
WT,O
",",O
KO,O
:,O
n,O
=,O
4,O
).,O
(,O
h,O
),O
The,O
number,O
of,O
dendrites,O
extending,O
from,O
the,O
soma,O
.,O
(,O
WT,O
",",O
KO,O
:,O
n,O
=,O
3,O
).,O
(,O
i,O
),O
Total,O
dendritic,O
length,O
measured,O
from,O
the,O
soma,O
of,O
cultured,O
hippocampal,O
neurons,O
.,O
Total,O
dendritic,O
length,O
measured,O
from,O
the,O
soma,O
of,O
cultured,O
hippocampal,O
neurons,O
.,O
(,O
WT,O
",",O
KO,O
:,O
n,O
=,O
4,O
).,O
WT,O
",",O
wild,O
-,O
type,O
mice,O
;,O
KO,O
",",O
JMJD2B,O
mutant,O
mice,O
.,O
Scale,O
bars,O
:,O
(,O
a,O
),O
10,O
μm,O
",",O
(,O
b,O
and,O
c,O
),O
10,O
μm,O
",",O
(,O
b,O
',O
and,O
c,O
'),O
1,O
μm,O
",",O
(,O
f,O
),O
20,O
μm,O
.,O
Error,O
bars,O
represent,O
s,O
.,O
e,O
.,O
m,O
.,O
(,O
d,O
",",O
e,O
",",O
h,O
",",O
i,O
).,O
JMJD2B,O
mutant,O
mice,O
reveal,O
hyperactivity,O
in,O
the,O
open,O
-,O
field,O
test,O
.(,O
a,O
),O
The,O
graph,O
shows,O
the,O
distance,O
moved,O
during,O
the,O
indicated,O
time,O
period,O
.,O
(,O
b,O
),O
The,O
graph,O
shows,O
the,O
temporal,O
change,O
in,O
the,O
rate,O
of,O
activity,O
(,O
speed,O
).,O
(,O
c,O
),O
The,O
graph,O
shows,O
the,O
distance,O
moved,O
in,O
the,O
first,O
10,O
min,O
versus,O
the,O
last,O
10,O
min,O
(,O
50,O
to,O
60,O
min,O
),O
of,O
assessment,O
.,O
(,O
d,O
),O
The,O
graph,O
shows,O
temporal,O
changes,O
in,O
rearing,O
number,O
.,O
(,O
WT,O
:,O
n,O
=,O
12,O
",",O
KO,O
:,O
n,O
=,O
10,O
).,O
WT,O
",",O
wild,O
-,O
type,O
mice,O
;,O
KO,O
",",O
JMJD2B,O
mutant,O
mice,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
;,O
**,O
P,O
<,O
0,O
.,O
01,O
.,O
Error,O
bars,O
represent,O
s,O
.,O
e,O
.,O
m,O
.,O
JMJD2B,O
mutant,O
mice,O
show,O
deficits,O
in,O
short,O
-,O
term,O
memory,O
.,O
(,O
a,O
),O
The,O
result,O
of,O
the,O
social,O
interaction,O
test,O
examining,O
the,O
social,O
affinity,O
to,O
another,O
mouse,O
.,O
The,O
graph,O
shows,O
the,O
relative,O
time,O
of,O
exploration,O
of,O
the,O
novel,O
object,O
.,O
(,O
WT,O
:,O
n,O
=,O
13,O
KO,O
:,O
n,O
=,O
11,O
).,O
(,O
b,O
),O
Novel,O
object,O
recognition,O
test,O
to,O
examine,O
the,O
interest,O
in,O
unknown,O
object,O
.,O
(,O
WT,O
:,O
n,O
=,O
13,O
KO,O
:,O
n,O
=,O
11,O
).,O
(,O
c,O
and,O
d,O
),O
Y,O
-,O
maze,O
test,O
results,O
examining,O
short,O
-,O
term,O
memory,O
in,O
the,O
two,O
genotypes,O
.,O
(,O
WT,O
:,O
n,O
=,O
10,O
;,O
KO,O
:,O
n,O
=,O
11,O
).,O
(,O
c,O
),O
The,O
graph,O
shows,O
the,O
percentage,O
of,O
correct,O
entries,O
.,O
(,O
d,O
),O
The,O
graph,O
shows,O
the,O
number,O
of,O
total,O
entries,O
.,O
KO,O
",",O
JMJD2B,O
mutant,O
mice,O
;,O
NS,O
",",O
not,O
significant,O
;,O
WT,O
",",O
wild,O
-,O
type,O
mice,O
.,O
Error,O
bars,O
represent,O
s,O
.,O
e,O
.,O
m,O
.,O
**,O
P,O
<,O
0,O
.,O
01,O
.,O
Phylogenetic,O
analysis,O
of,O
the,O
diacylglycerol,B-GP
kinase,I-GP
family,O
of,O
proteins,O
and,O
identification,O
of,O
multiple,O
highly,O
-,O
specific,O
conserved,O
inserts,O
and,O
deletions,O
within,O
the,O
catalytic,O
domain,O
that,O
are,O
distinctive,O
characteristics,O
of,O
different,O
classes,O
of,O
DGK,B-GP
homologs,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Diacylglycerol,B-GP
kinase,I-GP
(,O
DGK,B-GP
),O
family,O
of,O
proteins,O
",",O
which,O
phosphorylates,O
diacylglycerol,O
into,O
phosphatidic,O
acid,O
",",O
play,O
important,O
role,O
in,O
controlling,O
diverse,O
cellular,O
processes,O
in,O
eukaryotic,O
organisms,O
.,O
Most,O
vertebrate,B-OG
species,O
contain,O
10,O
different,O
DGK,B-GP
isozymes,O
",",O
which,O
are,O
grouped,O
into,O
5,O
different,O
classes,O
based,O
on,O
the,O
presence,O
or,O
absence,O
of,O
specific,O
functional,O
domains,O
.,O
However,O
",",O
the,O
relationships,O
among,O
different,O
DGK,B-GP
isozymes,O
or,O
how,O
they,O
have,O
evolved,O
from,O
a,O
common,O
ancestor,O
is,O
unclear,O
.,O
The,O
catalytic,O
domain,O
constitutes,O
the,O
single,O
largest,O
sequence,O
element,O
within,O
the,O
DGK,B-GP
proteins,O
that,O
is,O
commonly,O
and,O
uniquely,O
shared,O
by,O
all,O
family,O
members,O
",",O
but,O
there,O
is,O
limited,O
understanding,O
of,O
the,O
overall,O
function,O
of,O
this,O
domain,O
.,O
In,O
this,O
work,O
",",O
we,O
have,O
used,O
the,O
catalytic,O
domain,O
sequences,O
to,O
construct,O
a,O
phylogenetic,O
tree,O
for,O
the,O
DGK,B-GP
family,O
members,O
from,O
representatives,O
of,O
the,O
main,O
vertebrate,B-OG
classes,O
and,O
have,O
also,O
examined,O
the,O
distributions,O
of,O
various,O
DGK,B-GP
isozymes,O
in,O
eukaryotic,O
phyla,O
.,O
In,O
a,O
tree,O
based,O
on,O
catalytic,O
domain,O
sequences,O
",",O
the,O
DGK,B-GP
homologs,O
belonging,O
to,O
different,O
classes,O
formed,O
strongly,O
supported,O
clusters,O
which,O
were,O
separated,O
by,O
long,O
branches,O
",",O
and,O
the,O
different,O
isozymes,O
within,O
each,O
class,O
also,O
generally,O
formed,O
monophyletic,O
groupings,O
.,O
Further,O
",",O
our,O
analysis,O
of,O
the,O
sequence,O
alignments,O
of,O
catalytic,O
domains,O
has,O
identified,O
>,O
10,O
novel,O
sequence,O
signatures,O
consisting,O
of,O
conserved,O
signature,O
indels,O
(,O
inserts,O
or,O
deletions,O
",",O
CSIs,O
),O
that,O
are,O
distinctive,O
characteristics,O
of,O
either,O
particular,O
classes,O
of,O
DGK,B-GP
isozymes,O
",",O
or,O
are,O
commonly,O
shared,O
by,O
members,O
of,O
two,O
or,O
more,O
classes,O
of,O
DGK,B-GP
isozymes,O
.,O
The,O
conserved,O
indels,O
in,O
protein,O
sequences,O
are,O
known,O
to,O
play,O
important,O
functional,O
roles,O
in,O
the,O
proteins,O
/,O
organisms,O
where,O
they,O
are,O
found,O
.,O
Thus,O
",",O
our,O
identification,O
of,O
multiple,O
highly,O
specific,O
CSIs,O
that,O
are,O
distinguishing,O
characteristics,O
of,O
different,O
classes,O
of,O
DGK,B-GP
homologs,O
points,O
to,O
the,O
existence,O
of,O
important,O
differences,O
in,O
the,O
catalytic,O
domain,O
function,O
among,O
the,O
DGK,B-GP
isozymes,O
.,O
The,O
identified,O
CSIs,O
in,O
conjunction,O
with,O
the,O
results,O
of,O
blast,O
searches,O
on,O
species,O
distribution,O
of,O
DGK,B-GP
isozymes,O
also,O
provide,O
useful,O
insights,O
into,O
the,O
evolutionary,O
relationships,O
among,O
the,O
DGK,B-GP
family,O
of,O
proteins,O
.,O
Introduction,O
Diacylglycerol,O
(,O
DAG,O
),O
and,O
phosphatidic,O
acid,O
(,O
PA,O
),O
are,O
two,O
main,O
signalling,O
molecules,O
within,O
eukaryotic,O
cells,O
which,O
",",O
through,O
their,O
interactions,O
with,O
different,O
effector,O
proteins,O
",",O
play,O
central,O
roles,O
in,O
regulating,O
diverse,O
cellular,O
processes,O
[,O
1,O
–,O
6,O
].,O
The,O
main,O
source,O
of,O
DAG,O
in,O
cells,O
is,O
via,O
the,O
hydrolysis,O
of,O
phosphoinositides,O
by,O
the,O
enzyme,O
phospholipase,B-GP
C,I-GP
in,O
response,O
to,O
a,O
variety,O
of,O
extracellular,O
stimuli,O
including,O
growth,O
factors,O
and,O
hormones,O
.,O
The,O
DAG,O
produced,O
serves,O
as,O
a,O
substrate,O
for,O
the,O
enzyme,O
DAG,B-GP
kinase,I-GP
(,O
DGK,B-GP
"),",O
which,O
phosphorylates,O
it,O
into,O
PA,O
.,O
Due,O
to,O
the,O
ability,O
of,O
DGK,B-GP
to,O
convert,O
one,O
important,O
signalling,O
molecule,O
(,O
DAG,O
),O
into,O
another,O
(,O
PA,O
"),",O
the,O
activity,O
of,O
DGK,B-GP
in,O
different,O
cells,O
is,O
tightly,O
controlled,O
for,O
maintenance,O
of,O
normal,O
physiological,O
conditions,O
[,O
1,O
–,O
6,O
].,O
Because,O
DGK,B-GP
plays,O
an,O
important,O
role,O
in,O
controlling,O
diverse,O
cellular,O
processes,O
including,O
development,O
",",O
cell,O
division,O
and,O
proliferation,O
",",O
neuronal,O
and,O
immune,O
responses,O
",",O
vascular,O
traffic,O
",",O
apoptosis,O
",",O
cytoskeletal,O
reorganization,O
",",O
etc,O
.,O
multiples,O
forms,O
of,O
DGK,B-GP
are,O
generally,O
found,O
in,O
most,O
eukaryotic,O
organisms,O
[,O
1,O
–,O
10,O
].,O
In,O
mammalian,O
species,O
",",O
where,O
the,O
DGK,B-GP
family,O
of,O
proteins,O
has,O
been,O
best,O
studied,O
",",O
10,O
different,O
isozymes,O
of,O
DGK,B-GP
",",O
designated,O
as,O
α,O
",",O
β,O
",",O
γ,O
",",O
δ,O
",",O
ε,O
",",O
ζ,O
",",O
η,O
",",O
θ,O
",",O
ι,O
and,O
κ,O
",",O
differing,O
in,O
their,O
biochemical,O
properties,O
",",O
tissue,O
distributions,O
",",O
as,O
well,O
as,O
their,O
lengths,O
(,O
ranging,O
from,O
567,O
aa,O
to,O
>,O
1150,O
aa,O
),O
have,O
been,O
identified,O
[,O
1,O
–,O
6,O
",",O
11,O
].,O
Based,O
on,O
sequence,O
similarities,O
between,O
these,O
isozymes,O
and,O
the,O
presence,O
or,O
absence,O
of,O
specific,O
functional,O
domains,O
",",O
the,O
known,O
DGK,B-GP
members,O
have,O
been,O
grouped,O
into,O
5,O
different,O
classes,O
or,O
Types,O
(,O
Fig,O
1,O
),O
[,O
1,O
–,O
6,O
",",O
11,O
",",O
12,O
].,O
All,O
of,O
these,O
isozymes,O
share,O
in,O
common,O
a,O
large,O
catalytic,O
domain,O
",",O
which,O
is,O
sometimes,O
divided,O
into,O
two,O
parts,O
–,O
catalytic,O
and,O
accessory,O
domains,O
",",O
and,O
2,O
or,O
3,O
cysteine,O
-,O
rich,O
domains,O
",",O
referred,O
to,O
as,O
the,O
C1,O
domains,O
[,O
reviewed,O
in,O
[,O
1,O
–,O
6,O
",",O
12,O
",",O
13,O
]].,O
The,O
simplest,O
and,O
shortest,O
(,O
567,O
aa,O
),O
of,O
these,O
isozymes,O
is,O
DGK,B-GP
-,I-GP
ε,I-GP
",",O
sole,O
member,O
of,O
the,O
class,B-GP
III,I-GP
DGK,I-GP
",",O
which,O
contains,O
only,O
the,O
commonly,O
shared,O
catalytic,O
domain,O
and,O
the,O
two,O
C1,O
domains,O
.,O
In,O
addition,O
",",O
DGK,B-GP
-,I-GP
ε,I-GP
also,O
contains,O
a,O
conserved,O
helical,O
segment,O
near,O
its,O
N,O
-,O
terminal,O
end,O
that,O
is,O
indicated,O
to,O
play,O
an,O
important,O
role,O
in,O
its,O
membrane,O
interaction,O
[,O
12,O
",",O
13,O
].,O
The,O
class,B-GP
I,I-GP
DGKs,I-GP
(,O
α,O
",",O
β,O
and,O
γ,O
isozymes,O
"),",O
in,O
addition,O
to,O
containing,O
the,O
commonly,O
shared,O
domains,O
",",O
are,O
characterized,O
by,O
the,O
presence,O
of,O
two,O
EF,O
-,O
hand,O
motifs,O
and,O
a,O
conserved,O
domain,O
of,O
unknown,O
function,O
near,O
the,O
N,O
-,O
terminal,O
end,O
[,O
1,O
–,O
6,O
",",O
11,O
",",O
12,O
].,O
Novel,O
characteristics,O
of,O
the,O
class,B-GP
II,I-GP
DGK,I-GP
isozymes,O
(,O
δ,O
",",O
η,O
and,O
κ,O
isoforms,O
),O
include,O
the,O
presence,O
of,O
a,O
plecstrin,O
homology,O
(,O
PH,O
),O
domain,O
",",O
a,O
sterile,O
α,O
motif,O
(,O
SAM,O
),O
domain,O
and,O
a,O
large,O
insert,O
within,O
the,O
catalytic,O
domain,O
separating,O
it,O
into,O
two,O
parts,O
.,O
The,O
class,B-GP
IV,I-GP
DGKs,I-GP
(,O
ζ,O
and,O
ι,O
isoforms,O
),O
are,O
distinguished,O
from,O
the,O
others,O
due,O
to,O
their,O
containing,O
a,O
sequence,O
homologous,O
to,O
the,O
MARCKS,B-GP
phosphorylation,O
site,O
domain,O
and,O
four,O
ankyrin,B-GP
repeats,O
near,O
the,O
C,O
-,O
terminal,O
end,O
.,O
Lastly,O
",",O
DGK,B-GP
-,I-GP
θ,I-GP
is,O
the,O
sole,O
member,O
of,O
the,O
class,B-GP
V,I-GP
DGK,I-GP
and,O
it,O
contains,O
three,O
C1,O
domains,O
",",O
a,O
Gly,O
-,O
Pro,O
rich,O
domain,O
and,O
a,O
PH,O
-,O
domain,O
-,O
like,O
region,O
with,O
overlapping,O
RAS,B-GP
-,O
associating,O
domain,O
[,O
1,O
–,O
6,O
",",O
11,O
].,O
The,O
unique,O
domains,O
present,O
in,O
DGK,B-GP
isozymes,O
",",O
through,O
their,O
interactions,O
with,O
various,O
regulatory,B-GP
proteins,I-GP
and,O
other,O
molecules,O
present,O
in,O
different,O
cells,O
and,O
tissues,O
",",O
play,O
key,O
roles,O
in,O
the,O
diverse,O
physiological,O
functions,O
exhibited,O
by,O
different,O
DGK,B-GP
isozymes,O
[,O
1,O
–,O
6,O
].,O
Sequence,O
characteristics,O
of,O
different,O
forms,O
of,O
DGK,B-GP
isozymes,O
that,O
are,O
found,O
in,O
mammalian,O
/,O
vertebrate,B-OG
species,O
.,O
The,O
ten,O
known,O
isozymes,O
are,O
grouped,O
into,O
five,O
Classes,O
(,O
or,O
Types,O
),O
and,O
a,O
schematic,O
of,O
the,O
known,O
main,O
functional,O
domains,O
in,O
these,O
isozymes,O
is,O
shown,O
.,O
Abbreviations,O
;,O
PH,O
",",O
plecstrin,O
homology,O
;,O
MARCKS,B-GP
",",O
sequence,O
similar,O
to,O
the,O
MARCKS,B-GP
phosphorylation,O
site,O
;,O
SAM,O
",",O
sterile,O
α,O
motif,O
.,O
The,O
information,O
for,O
the,O
presence,O
of,O
different,O
domains,O
in,O
the,O
DGK,B-GP
isozymesis,O
based,O
on,O
the,O
following,O
reviews,O
[,O
1,O
–,O
6,O
",",O
11,O
",",O
12,O
].,O
Although,O
the,O
differences,O
in,O
the,O
structural,O
characteristics,O
of,O
DGK,B-GP
isozymes,O
and,O
their,O
involvement,O
in,O
diverse,O
cellular,O
functions,O
are,O
widely,O
known,O
[,O
1,O
–,O
6,O
"],",O
there,O
is,O
limited,O
(,O
or,O
no,O
),O
information,O
available,O
at,O
present,O
as,O
to,O
how,O
different,O
DGK,B-GP
isozymes,O
",",O
or,O
the,O
different,O
classes,O
of,O
DGKs,B-GP
",",O
are,O
related,O
to,O
each,O
other,O
",",O
and,O
have,O
possibly,O
evolved,O
from,O
a,O
common,O
ancestor,O
.,O
There,O
is,O
also,O
limited,O
understanding,O
of,O
the,O
distributions,O
of,O
DGK,B-GP
isozymes,O
in,O
eukaryotic,O
organisms,O
other,O
than,O
mammals,B-OG
[,O
3,O
",",O
10,O
",",O
14,O
–,O
16,O
].,O
Knowledge,O
of,O
the,O
species,O
distribution,O
and,O
evolutionary,O
relationships,O
among,O
DGK,B-GP
isozymes,O
can,O
provide,O
useful,O
insights,O
into,O
their,O
physiological,O
functions,O
.,O
Within,O
the,O
DGK,B-GP
family,O
of,O
proteins,O
",",O
the,O
catalytic,O
domain,O
constitutes,O
the,O
single,O
largest,O
sequence,O
element,O
that,O
is,O
commonly,O
and,O
uniquely,O
shared,O
by,O
all,O
of,O
the,O
family,O
members,O
[,O
1,O
–,O
6,O
",",O
11,O
].,O
In,O
the,O
present,O
work,O
",",O
we,O
have,O
used,O
the,O
catalytic,O
domain,O
sequences,O
to,O
construct,O
a,O
phylogenetic,O
tree,O
for,O
the,O
DGK,B-GP
family,O
members,O
.,O
Additionally,O
",",O
and,O
more,O
importantly,O
",",O
our,O
analysis,O
of,O
the,O
sequence,O
alignment,O
of,O
the,O
catalytic,O
domain,O
has,O
identified,O
large,O
numbers,O
of,O
novel,O
sequence,O
signatures,O
in,O
the,O
forms,O
of,O
conserved,O
inserts,O
and,O
deletions,O
(,O
indels,O
),O
that,O
are,O
distinctive,O
of,O
either,O
particular,O
classes,O
of,O
DGK,B-GP
isozymes,O
",",O
or,O
are,O
commonly,O
shared,O
by,O
members,O
of,O
two,O
or,O
more,O
classes,O
of,O
DGK,B-GP
isozymes,O
.,O
These,O
results,O
point,O
to,O
the,O
existence,O
of,O
important,O
differences,O
in,O
the,O
function,O
of,O
catalytic,O
domain,O
for,O
different,O
classes,O
of,O
DGK,B-GP
isozymes,O
and,O
are,O
also,O
useful,O
in,O
understanding,O
the,O
evolutionary,O
relationships,O
among,O
the,O
DGK,B-GP
family,O
of,O
proteins,O
.,O
Methods,O
Phylogenetic,O
tree,O
construction,O
and,O
identification,O
of,O
conserved,O
indels,O
in,O
the,O
catalytic,O
domain,O
sequences,O
The,O
protein,O
sequences,O
of,O
all,O
ten,O
DGK,B-GP
isozymes,O
from,O
representatives,O
of,O
the,O
main,O
vertebrate,B-OG
groups,O
were,O
retrieved,O
from,O
the,O
NCBI,O
nr,O
database,O
.,O
In,O
most,O
cases,O
",",O
sequences,O
were,O
obtained,O
from,O
the,O
following,O
species,O
covering,O
the,O
diversity,O
of,O
the,O
vertebrate,B-OG
phylum,O
:,O
Mammals,B-OG
(,O
Homo,B-OG
sapiens,I-OG
",",O
Rattus,B-OG
novergicus,I-OG
"),",O
Birds,B-OG
(,O
Serinus,B-OG
canaria,I-OG
",",O
Sturnus,B-OG
vulgaris,I-OG
"),",O
Reptiles,B-OG
(,O
Protobothrops,B-OG
mucrosquamatus,I-OG
",",O
Python,B-OG
bivittatus,I-OG
"),",O
Amphibia,B-OG
(,O
Xenopus,B-OG
tropicalis,I-OG
),O
and,O
Fishes,B-OG
(,O
Pundamilia,B-OG
nyererei,I-OG
",",O
Maylandia,B-OG
zebra,I-OG
).,O
The,O
information,O
for,O
accession,O
numbers,O
and,O
sequence,O
lengths,O
of,O
different,O
DGK,B-GP
homologs,O
that,O
were,O
used,O
for,O
phylogenetic,O
studies,O
is,O
provided,O
in,O
the,O
S1,O
Table,O
.,O
Multiple,O
sequence,O
alignments,O
of,O
different,O
DGK,B-GP
isozymes,O
were,O
created,O
using,O
the,O
Clustal,O
X,O
ver,O
.,O
2,O
.,O
0,O
program,O
[,O
17,O
"],",O
and,O
based,O
on,O
these,O
alignments,O
",",O
sequences,O
corresponding,O
to,O
the,O
commonly,O
shared,O
catalytic,O
domain,O
were,O
identified,O
.,O
The,O
large,O
insert,O
present,O
within,O
the,O
catalytic,O
domain,O
(,O
CD,O
),O
of,O
Type,B-GP
II,I-GP
DGK,I-GP
homologs,O
was,O
excluded,O
from,O
these,O
alignments,O
.,O
The,O
resulting,O
sequences,O
for,O
the,O
DGK,B-GP
CDs,O
were,O
then,O
realigned,O
and,O
",",O
based,O
on,O
these,O
alignments,O
",",O
a,O
segment,O
of,O
364,O
aa,O
was,O
identified,O
that,O
showed,O
good,O
conservation,O
amongst,O
different,O
DGK,B-GP
classes,O
.,O
This,O
sequence,O
alignment,O
",",O
which,O
was,O
used,O
for,O
phylogenetic,O
analysis,O
",",O
is,O
provided,O
in,O
S1,O
Fig,O
.,O
All,O
of,O
the,O
columns,O
with,O
sequence,O
gaps,O
were,O
not,O
considered,O
during,O
tree,O
construction,O
leaving,O
a,O
total,O
of,O
260,O
aligned,O
positions,O
that,O
were,O
used,O
for,O
phylogenetic,O
analysis,O
.,O
The,O
evolutionary,O
history,O
based,O
on,O
this,O
sequence,O
alignment,O
was,O
inferred,O
using,O
the,O
Maximum,O
likelihood,O
(,O
ML,O
),O
method,O
",",O
with,O
100,O
bootstrap,O
replication,O
",",O
using,O
the,O
MEGA,O
6,O
[,O
18,O
],O
based,O
on,O
the,O
Jones,O
–,O
Taylor,O
–,O
Thornton,O
(,O
JTT,O
),O
model,O
[,O
19,O
].,O
The,O
tree,O
with,O
the,O
highest,O
log,O
likelihood,O
(-,O
7845,O
.,O
5131,O
),O
is,O
shown,O
.,O
The,O
numbers,O
shown,O
on,O
the,O
branches,O
identifies,O
clades,O
in,O
which,O
the,O
associated,O
taxa,O
clustered,O
together,O
>,O
50,O
%,O
time,O
in,O
bootstrap,O
replicates,O
.,O
Sequence,O
alignments,O
of,O
the,O
DGK,B-GP
homologs,O
were,O
also,O
examined,O
for,O
the,O
presence,O
of,O
conserved,O
indels,O
(,O
insertions,O
or,O
deletions,O
),O
which,O
were,O
flanked,O
on,O
both,O
sides,O
by,O
at,O
least,O
5,O
–,O
6,O
conserved,O
residues,O
in,O
the,O
neighboring,O
30,O
–,O
40,O
amino,O
acids,O
and,O
which,O
appeared,O
to,O
be,O
specifically,O
present,O
in,O
either,O
a,O
particular,O
class,O
of,O
DGK,B-GP
isozymes,O
",",O
or,O
which,O
were,O
shared,O
by,O
the,O
DGK,B-GP
homologs,O
from,O
more,O
one,O
than,O
classes,O
[,O
20,O
–,O
22,O
].,O
For,O
conserved,O
indels,O
meeting,O
these,O
criteria,O
",",O
additional,O
Blastp,O
searches,O
were,O
carried,O
out,O
using,O
the,O
NCBI,O
NR,O
(,O
non,O
-,O
redundant,O
),O
database,O
to,O
determine,O
the,O
specificity,O
of,O
the,O
indels,O
for,O
the,O
DGK,B-GP
classes,O
of,O
isozymes,O
.,O
These,O
blast,O
results,O
were,O
examined,O
for,O
the,O
presence,O
/,O
absence,O
of,O
the,O
identified,O
CSIs,O
in,O
top,O
500,O
blast,O
hits,O
.,O
SIG_CREATE,O
and,O
SIG_STYLE,O
programs,O
(,O
available,O
on,O
Gleans,O
.,O
net,O
),O
were,O
used,O
to,O
format,O
and,O
create,O
the,O
signature,O
CSIs,O
files,O
shown,O
here,O
[,O
22,O
",",O
23,O
].,O
Due,O
to,O
space,O
limitations,O
",",O
sequence,O
information,O
for,O
only,O
1,O
–,O
2,O
representative,O
species,O
from,O
each,O
vertebrate,B-OG
group,O
(,O
viz,O
.,O
generally,O
the,O
same,O
as,O
those,O
employed,O
for,O
phylogenetic,O
studies,O
for,O
mammals,B-OG
",",O
birds,B-OG
",",O
fishes,B-OG
",",O
reptiles,B-OG
and,O
amphibians,B-OG
),O
for,O
different,O
DGK,B-GP
isozymes,O
is,O
shown,O
in,O
the,O
alignment,O
files,O
.,O
However,O
",",O
unless,O
otherwise,O
noted,O
",",O
all,O
of,O
the,O
described,O
CSIs,O
are,O
specifically,O
present,O
in,O
the,O
indicated,O
groups,O
/,O
classes,O
of,O
DGK,B-GP
isozymes,O
",",O
in,O
different,O
vertebrate,B-OG
species,O
",",O
where,O
the,O
distribution,O
of,O
these,O
CSIs,O
was,O
studied,O
in,O
detail,O
.,O
The,O
presence,O
or,O
absence,O
of,O
different,O
DGK,B-GP
isozymes,O
in,O
members,O
from,O
different,O
kingdoms,O
and,O
main,O
phyla,O
of,O
eukaryotes,B-OG
was,O
assessed,O
by,O
carrying,O
out,O
Blastp,O
searches,O
on,O
sequences,O
of,O
different,O
DGK,B-GP
isozymes,O
from,O
human,B-OG
and,O
mouse,B-OG
species,O
against,O
annotated,O
members,O
of,O
specific,O
kingdoms,O
or,O
phyla,O
present,O
in,O
the,O
NCBI,O
nr,O
database,O
.,O
These,O
searches,O
were,O
carried,O
out,O
using,O
the,O
entire,O
sequences,O
of,O
the,O
DGK,B-GP
isozymes,O
as,O
well,O
as,O
utilizing,O
sequences,O
fonly,O
the,O
catalytic,O
domain,O
sequence,O
.,O
Based,O
on,O
significant,O
hits,O
observed,O
in,O
these,O
Blast,O
searches,O
",",O
and,O
to,O
which,O
DGK,B-GP
isozymes,O
the,O
observed,O
hits,O
exhibited,O
maximal,O
similarity,O
",",O
tentative,O
inferences,O
regarding,O
the,O
presence,O
or,O
absence,O
of,O
specific,O
DGK,B-GP
isozymes,O
in,O
deeper,O
branching,O
eukaryotic,O
taxa,O
were,O
made,O
.,O
Results,O
Phylogenetic,O
analysis,O
of,O
the,O
DGK,B-GP
isozymes,O
based,O
on,O
catalytic,O
domain,O
sequences,O
The,O
DGK,B-GP
isozymes,O
differ,O
considerably,O
from,O
each,O
other,O
in,O
their,O
sequence,O
lengths,O
and,O
different,O
domains,O
present,O
in,O
them,O
(,O
see,O
introduction,O
and,O
Fig,O
1,O
).,O
Pairwise,O
sequence,O
comparison,O
studies,O
(,O
unpublished,O
),O
indicate,O
that,O
the,O
overall,O
sequence,O
similarity,O
between,O
members,O
of,O
different,O
classes,O
is,O
in,O
the,O
range,O
of,O
15,O
–,O
30,O
%,O
and,O
much,O
of,O
the,O
observed,O
similarity,O
is,O
seen,O
within,O
the,O
commonly,O
shared,O
catalytic,O
domain,O
.,O
Based,O
on,O
sequence,O
alignments,O
of,O
DGK,B-GP
homologs,O
from,O
representatives,O
of,O
different,O
groups,O
of,O
vertebrates,B-OG
",",O
conserved,O
regions,O
from,O
the,O
catalytic,O
domain,O
which,O
could,O
be,O
properly,O
aligned,O
amongst,O
different,O
DGK,B-GP
classes,O
were,O
identified,O
and,O
these,O
were,O
subjected,O
to,O
phylogenetic,O
analyses,O
.,O
A,O
maximum,O
-,O
likelihood,O
tree,O
based,O
on,O
100,O
bootstrap,O
samples,O
of,O
this,O
sequence,O
region,O
was,O
constructed,O
using,O
the,O
JTT,O
model,O
(,O
see,O
Methods,O
),O
to,O
infer,O
the,O
evolutionary,O
relationships,O
amongst,O
different,O
DGK,B-GP
homologs,O
.,O
The,O
tree,O
shown,O
in,O
Fig,O
2,O
is,O
based,O
on,O
260,O
aligned,O
positions,O
that,O
were,O
left,O
after,O
removal,O
of,O
all,O
insertions,O
and,O
deletions,O
.,O
In,O
this,O
phylogenetic,O
tree,O
(,O
Fig,O
2,O
"),",O
DGK,B-GP
homologs,O
belonging,O
to,O
all,O
five,O
classes,O
or,O
Types,O
formed,O
strongly,O
supported,O
clusters,O
.,O
These,O
clusters,O
were,O
separated,O
by,O
long,O
branches,O
indicating,O
that,O
the,O
DGK,B-GP
sequences,O
for,O
different,O
classes,O
have,O
diverged,O
considerably,O
from,O
each,O
other,O
even,O
within,O
the,O
conserved,O
catalytic,O
domain,O
.,O
Within,O
each,O
DGK,B-GP
class,O
",",O
homologs,O
belonging,O
to,O
different,O
DGK,B-GP
isozymes,O
also,O
generally,O
formed,O
separate,O
clusters,O
",",O
except,O
for,O
the,O
homologs,O
of,O
kappa,O
and,O
zeta,O
isozymes,O
which,O
exhibited,O
polyphyletic,O
branching,O
and,O
were,O
separated,O
into,O
two,O
clusters,O
.,O
The,O
branches,O
separating,O
different,O
DGK,B-GP
isozymes,O
within,O
any,O
given,O
class,O
were,O
generally,O
short,O
indicating,O
that,O
the,O
isozymes,O
within,O
different,O
classes,O
are,O
very,O
similar,O
to,O
each,O
other,O
.,O
Based,O
on,O
the,O
phylogenetic,O
tree,O
",",O
some,O
information,O
regarding,O
relationships,O
among,O
different,O
isozymes,O
within,O
different,O
classes,O
can,O
also,O
be,O
gleaned,O
.,O
In,O
this,O
tree,O
",",O
DGK,B-GP
homologs,O
belonging,O
to,O
the,O
classes,O
I,O
and,O
IV,O
grouped,O
together,O
but,O
there,O
was,O
only,O
weak,O
support,O
(,O
clustered,O
together,O
in,O
51,O
%,O
of,O
bootstrap,O
samples,O
),O
for,O
this,O
grouping,O
.,O
Within,O
the,O
class,O
I,O
isozymes,O
",",O
the,O
DGK,B-GP
-,I-GP
α,I-GP
homologs,O
formed,O
outgroups,O
relative,O
to,O
a,O
cluster,O
consisting,O
of,O
the,O
DGK,B-GP
-,I-GP
β,I-GP
and,O
DGK,B-GP
-,I-GP
γ,I-GP
homologs,O
",",O
indicating,O
that,O
the,O
sequences,O
from,O
the,O
latter,O
two,O
groups,O
are,O
more,O
closely,O
related,O
.,O
Similarly,O
",",O
within,O
the,O
class,O
II,O
isozymes,O
",",O
a,O
grouping,O
of,O
DGK,B-GP
-,I-GP
δ,I-GP
and,O
DGK,B-GP
-,I-GP
η,I-GP
homologs,O
was,O
supported,O
by,O
the,O
observed,O
bootstrap,O
score,O
",",O
with,O
the,O
DGK,B-GP
-,I-GP
κ,I-GP
sequences,O
forming,O
an,O
outgroup,O
of,O
this,O
cluster,O
.,O
Lastly,O
",",O
in,O
the,O
tree,O
shown,O
in,O
Fig,O
2,O
",",O
which,O
was,O
rooted,O
at,O
midpoint,O
",",O
the,O
DGK,B-GP
-,I-GP
ε,I-GP
and,O
DGK,B-GP
-,I-GP
θ,I-GP
homologs,O
formed,O
the,O
most,O
outlying,O
clades,O
.,O
A,O
maximum,O
-,O
likelihood,O
tree,O
for,O
the,O
DGK,B-GP
isozymes,O
from,O
representative,O
vertebrate,B-OG
species,O
based,O
on,O
the,O
conserved,O
regions,O
in,O
catalytic,O
domain,O
.,O
The,O
accession,O
numbers,O
of,O
different,O
sequences,O
which,O
were,O
used,O
for,O
tree,O
construction,O
are,O
shown,O
after,O
the,O
species,O
names,O
.,O
The,O
tree,O
was,O
constructed,O
as,O
described,O
in,O
the,O
Methods,O
section,O
and,O
the,O
branches,O
which,O
were,O
supported,O
by,O
>,O
50,O
%,O
bootstrap,O
scores,O
are,O
marked,O
.,O
The,O
tree,O
shown,O
was,O
rooted,O
at,O
midpoint,O
and,O
drawn,O
to,O
scale,O
",",O
with,O
branch,O
lengths,O
measured,O
in,O
the,O
number,O
of,O
substitutions,O
per,O
site,O
.,O
Different,O
DGK,B-GP
isozymes,O
as,O
well,O
as,O
the,O
five,O
main,O
classes,O
are,O
marked,O
.,O
Conserved,O
signatures,O
indels,O
in,O
the,O
catalytic,O
domain,O
shared,O
by,O
different,O
classes,O
of,O
DGK,B-GP
isozymes,O
In,O
the,O
tree,O
shown,O
in,O
Fig,O
2,O
",",O
while,O
the,O
distinction,O
between,O
different,O
DGK,B-GP
classes,O
was,O
strongly,O
supported,O
",",O
the,O
nodes,O
connecting,O
these,O
classes,O
had,O
low,O
bootstrap,O
scores,O
indicating,O
that,O
the,O
evolutionary,O
relationships,O
among,O
different,O
DGK,B-GP
classes,O
were,O
not,O
reliably,O
resolved,O
.,O
Thus,O
",",O
other,O
molecular,O
sequence,O
based,O
approaches,O
which,O
can,O
provide,O
insights,O
are,O
needed,O
.,O
Conserved,O
signature,O
indels,O
(,O
CSIs,O
),O
represent,O
an,O
important,O
class,O
of,O
molecular,O
markers,O
that,O
have,O
been,O
used,O
in,O
the,O
past,O
to,O
resolve,O
a,O
number,O
of,O
important,O
evolutionary,O
questions,O
[,O
21,O
",",O
24,O
–,O
27,O
].,O
The,O
CSIs,O
that,O
are,O
useful,O
for,O
evolutionary,O
studies,O
are,O
generally,O
of,O
fixed,O
lengths,O
",",O
present,O
at,O
specific,O
positions,O
iparticular,O
genes,O
/,O
proteins,O
",",O
and,O
they,O
are,O
flanked,O
on,O
both,O
sides,O
by,O
conserved,O
regions,O
to,O
ensure,O
that,O
they,O
constitute,O
reliable,O
characteristics,O
[,O
21,O
",",O
25,O
",",O
27,O
",",O
28,O
].,O
The,O
CSIs,O
in,O
genes,O
/,O
proteins,O
sequences,O
generally,O
result,O
from,O
rare,O
genetic,O
changes,O
and,O
the,O
most,O
parsimonious,O
explanation,O
to,O
account,O
for,O
their,O
shared,O
presence,O
in,O
a,O
given,O
gene,O
or,O
protein,O
from,O
a,O
specific,O
group,O
of,O
species,O
is,O
that,O
the,O
genetic,O
change,O
giving,O
rise,O
to,O
the,O
CSI,O
occurred,O
in,O
a,O
common,O
ancestor,O
of,O
the,O
indicated,O
group,O
and,O
then,O
it,O
was,O
vertically,O
inherited,O
by,O
the,O
other,O
group,O
members,O
[,O
21,O
",",O
22,O
",",O
25,O
",",O
29,O
].,O
Due,O
to,O
the,O
discrete,O
natures,O
of,O
the,O
CSIs,O
and,O
the,O
fact,O
that,O
they,O
are,O
located,O
within,O
conserved,O
regions,O
",",O
their,O
presence,O
or,O
absence,O
in,O
different,O
lineages,O
or,O
proteins,O
is,O
generally,O
not,O
affected,O
by,O
factors,O
such,O
as,O
differences,O
in,O
evolutionary,O
rates,O
among,O
different,O
species,O
",",O
or,O
proteins,O
",",O
and,O
long,O
-,O
branch,O
attraction,O
artefacts,O
[,O
21,O
",",O
24,O
–,O
26,O
].,O
We,O
have,O
examined,O
the,O
sequence,O
alignment,O
of,O
catalytic,O
domains,O
from,O
DGK,B-GP
homologs,O
for,O
the,O
presence,O
of,O
CSIs,O
and,O
these,O
analyses,O
have,O
identified,O
a,O
number,O
of,O
useful,O
CSIs,O
that,O
are,O
specifically,O
shared,O
by,O
particular,O
groups,O
of,O
DGK,B-GP
isozymes,O
.,O
When,O
a,O
conserved,O
indel,O
is,O
present,O
in,O
a,O
given,O
protein,O
",",O
to,O
infer,O
whether,O
the,O
observed,O
indel,O
is,O
an,O
insert,O
or,O
a,O
deletion,O
",",O
information,O
for,O
the,O
presence,O
or,O
absence,O
of,O
the,O
indel,O
in,O
the,O
ancestral,O
state,O
of,O
the,O
protein,O
is,O
needed,O
[,O
22,O
].,O
In,O
most,O
cases,O
",",O
such,O
information,O
could,O
be,O
obtained,O
by,O
determining,O
the,O
presence,O
or,O
absence,O
of,O
the,O
indel,O
in,O
species,O
which,O
are,O
ancestral,O
to,O
those,O
containing,O
the,O
indel,O
[,O
25,O
",",O
27,O
",",O
28,O
",",O
30,O
].,O
In,O
some,O
instances,O
",",O
if,O
two,O
proteins,O
have,O
evolved,O
by,O
an,O
ancient,O
gene,O
duplication,O
event,O
",",O
then,O
the,O
presence,O
or,O
absence,O
of,O
the,O
indel,O
in,O
the,O
other,O
protein,O
has,O
also,O
proven,O
useful,O
to,O
infer,O
whether,O
the,O
observed,O
indel,O
is,O
an,O
insert,O
or,O
a,O
deletion,O
[,O
25,O
",",O
30,O
].,O
However,O
",",O
due,O
to,O
the,O
uniqueness,O
of,O
the,O
DGK,B-GP
catalytic,O
domain,O
sequence,O
for,O
the,O
eukaryotic,O
homologs,O
",",O
no,O
suitable,O
outgroup,O
is,O
available,O
for,O
determining,O
the,O
ancestral,O
state,O
of,O
the,O
protein,O
or,O
reliably,O
inferring,O
whether,O
a,O
given,O
CSI,O
represents,O
an,O
insertion,O
within,O
a,O
certain,O
class,O
of,O
DGK,B-GP
homologs,O
or,O
a,O
deletion,O
in,O
the,O
rest,O
of,O
the,O
DGK,B-GP
homologs,O
.,O
Hence,O
",",O
our,O
use,O
of,O
the,O
term,O
insert,O
(,O
s,O
),O
or,O
deletion,O
(,O
s,O
),O
to,O
describe,O
the,O
identified,O
CSIs,O
is,O
only,O
in,O
reference,O
to,O
the,O
presence,O
or,O
absence,O
of,O
the,O
same,O
or,O
similar,O
sequence,O
characteristics,O
in,O
other,O
classes,O
of,O
DGK,B-GP
homologs,O
.,O
Additionally,O
",",O
it,O
should,O
also,O
be,O
acknowledged,O
that,O
while,O
the,O
presence,O
or,O
absence,O
of,O
a,O
CSI,O
within,O
a,O
given,O
conserved,O
region,O
can,O
be,O
reliably,O
identified,O
(,O
due,O
to,O
the,O
sequence,O
conservation,O
of,O
flanking,O
regions,O
"),",O
it,O
is,O
often,O
difficult,O
to,O
specify,O
the,O
exact,O
location,O
of,O
the,O
CSI,O
within,O
a,O
conserved,O
region,O
.,O
This,O
is,O
especially,O
true,O
when,O
the,O
sequences,O
of,O
different,O
taxa,O
or,O
homologs,O
that,O
are,O
being,O
compared,O
differ,O
considerably,O
from,O
each,O
other,O
and,O
there,O
is,O
no,O
structural,O
information,O
available,O
for,O
the,O
proteins,O
to,O
guide,O
the,O
sequence,O
alignments,O
for,O
correct,O
placement,O
of,O
the,O
CSI,O
.,O
Due,O
to,O
this,O
limitation,O
",",O
the,O
positions,O
of,O
various,O
CSIs,O
in,O
the,O
sequence,O
alignment,O
shown,O
here,O
represent,O
their,O
most,O
likely,O
positions,O
based,O
on,O
our,O
judgement,O
of,O
the,O
sequence,O
conservation,O
of,O
the,O
flanking,O
regions,O
.,O
However,O
",",O
we,O
cannot,O
exclude,O
the,O
possibility,O
that,O
in,O
the,O
optimal,O
alignment,O
that,O
could,O
be,O
supported,O
by,O
other,O
data,O
the,O
actual,O
positions,O
of,O
some,O
of,O
these,O
CSIs,O
might,O
be,O
shifted,O
by,O
a,O
few,O
residues,O
either,O
to,O
the,O
left,O
or,O
on,O
the,O
right,O
.,O
Information,O
regarding,O
the,O
characteristics,O
of,O
various,O
CSIs,O
that,O
have,O
been,O
identified,O
by,O
our,O
analysis,O
is,O
provided,O
below,O
.,O
The,O
first,O
of,O
the,O
identified,O
CSIs,O
within,O
the,O
catalytic,O
domain,O
is,O
a,O
16,O
–,O
24,O
aa,O
insert,O
(,O
marked,O
signature,O
❶,O
in,O
Fig,O
3,O
),O
that,O
is,O
uniquely,O
found,O
in,O
all,O
of,O
the,O
Class,B-GP
I,I-GP
DGK,I-GP
homologs,O
from,O
different,O
species,O
.,O
The,O
observed,O
CSI,O
is,O
present,O
in,O
a,O
conserved,O
region,O
near,O
the,O
C,O
-,O
terminal,O
end,O
of,O
the,O
catalytic,O
domain,O
and,O
its,O
shared,O
presence,O
by,O
all,O
DGK,B-GP
-,O
α,O
",",O
-,O
β,O
and,O
-,O
γ,O
homologs,O
provides,O
further,O
evidence,O
of,O
the,O
close,O
and,O
specific,O
relationship,O
among,O
these,O
isozymes,O
belonging,O
to,O
class,B-GP
I,I-GP
DGKs,I-GP
.,O
For,O
DGK,B-GP
-,I-GP
α,I-GP
and,O
DGK,B-GP
-,I-GP
γ,I-GP
",",O
interesting,O
differences,O
are,O
also,O
seen,O
in,O
the,O
length,O
of,O
this,O
CSI,O
amongst,O
the,O
vertebrate,B-OG
species,O
.,O
For,O
DGK,B-GP
-,I-GP
α,I-GP
",",O
in,O
contrast,O
to,O
the,O
fishes,B-OG
(,O
e,O
.,O
g,O
.,O
Pundamila,B-OG
nyererei,I-OG
and,O
Maylinda,B-OG
zebra,I-OG
"),",O
homologs,O
found,O
in,O
mammals,B-OG
(,O
e,O
.,O
g,O
.,O
humans,B-OG
",",O
Rattus,B-OG
novergicus,I-OG
"),",O
birds,B-OG
(,O
Serinus,B-OG
canaria,I-OG
),O
and,O
amphibians,B-OG
(,O
Xenopus,B-OG
tropocalis,I-OG
),O
are,O
6,O
aa,O
longer,O
",",O
suggesting,O
that,O
an,O
additional,O
insert,O
within,O
the,O
DGK,B-GP
-,I-GP
α,I-GP
likely,O
occurred,O
in,O
a,O
common,O
ancestor,O
of,O
the,O
latter,O
groups,O
of,O
vertebrate,B-OG
species,O
.,O
Similarly,O
",",O
for,O
DGK,B-GP
-,I-GP
γ,I-GP
",",O
the,O
birds,B-OG
and,O
reptiles,B-OG
harbor,O
a,O
longer,O
insert,O
in,O
contrast,O
to,O
that,O
present,O
in,O
mammals,B-OG
.,O
Interestingly,O
",",O
the,O
homologs,O
for,O
DGK,B-GP
-,I-GP
γ,I-GP
were,O
not,O
detected,O
in,O
fishes,B-OG
and,O
amphibian,B-OG
species,O
.,O
In,O
addition,O
to,O
the,O
CSI,O
shown,O
in,O
Fig,O
3,O
",",O
DGK,B-GP
homologs,O
contain,O
one,O
additional,O
2,O
aa,O
conserved,O
insert,O
(,O
marked,O
Sig,O
❷A,O
in,O
Fig,O
4,O
"),",O
which,O
is,O
also,O
commonly,O
shared,O
by,O
the,O
class,B-GP
I,I-GP
DGK,I-GP
homologs,O
.,O
In,O
the,O
same,O
position,O
",",O
where,O
this,O
2,O
aa,O
CSI,O
is,O
found,O
in,O
class,O
I,O
homologs,O
",",O
a,O
4,O
aa,O
insert,O
(,O
marked,O
as,O
Sig,O
❷B,O
),O
is,O
present,O
in,O
the,O
DGK,B-GP
-,I-GP
ί,I-GP
and,O
DGK,B-GP
-,I-GP
ζ,I-GP
homologs,O
(,O
class,O
IV,O
isozymes,O
).,O
These,O
signatures,O
serve,O
to,O
distinguish,O
the,O
Class,O
I,O
and,O
Class,B-GP
IV,I-GP
DGK,I-GP
homologs,O
from,O
all,O
others,O
and,O
the,O
presence,O
of,O
the,O
inserts,O
in,O
the,O
same,O
position,O
only,O
in,O
these,O
two,O
classes,O
of,O
homologs,O
suggests,O
that,O
they,O
may,O
be,O
more,O
closely,O
related,O
to,O
each,O
other,O
than,O
to,O
the,O
other,O
DGK,B-GP
classes,O
.,O
In,O
close,O
proximity,O
of,O
signatures,O
❷A,O
",",O
B,O
",",O
another,O
CSI,O
consisting,O
of,O
2,O
aa,O
deletion,O
(,O
denoted,O
by,O
❸,O
and,O
highlighted,O
in,O
light,O
blue,O
color,O
),O
is,O
uniquely,O
present,O
in,O
the,O
DGK,B-GP
-,I-GP
θ,I-GP
homologs,O
.,O
Excerpts,O
from,O
the,O
sequence,O
alignment,O
of,O
DGK,B-GP
isozymes,O
showing,O
a,O
conserved,O
insert,O
(,O
marked,O
as,O
Sig,O
❶,O
),O
within,O
the,O
catalytic,O
domain,O
that,O
is,O
a,O
unique,O
characteristic,O
of,O
the,O
Class,B-GP
I,I-GP
DGK,I-GP
homologs,O
.,O
The,O
insert,O
shown,O
is,O
present,O
in,O
a,O
conserved,O
region,O
as,O
the,O
dashes,O
(-),O
in,O
the,O
alignment,O
denote,O
identity,O
with,O
the,O
amino,O
acid,O
shown,O
on,O
the,O
top,O
line,O
.,O
Sequence,O
information,O
is,O
shown,O
for,O
only,O
1,O
–,O
2,O
representative,O
species,O
from,O
different,O
main,O
groups,O
within,O
the,O
vertebrates,B-OG
.,O
However,O
",",O
this,O
insert,O
is,O
specific,O
for,O
the,O
Class,B-GP
I,I-GP
DGK,I-GP
homologs,O
from,O
all,O
other,O
vertebrates,B-OG
species,O
examined,O
.,O
The,O
second,O
column,O
shows,O
the,O
Genbank,O
ID,O
numbers,O
of,O
different,O
sequences,O
.,O
The,O
numbers,O
on,O
top,O
of,O
the,O
alignment,O
show,O
the,O
location,O
of,O
the,O
depicted,O
sequence,O
in,O
two,O
reference,O
DGK,B-GP
sequences,O
.,O
The,O
first,O
number,O
outside,O
of,O
the,O
parenthesis,O
indicates,O
the,O
sequence,O
position,O
in,O
the,O
human,B-OG
DGK,B-GP
-,I-GP
γ,I-GP
homolog,O
(,O
accession,O
number,O
NP_001337,O
.,O
2,O
),O
shown,O
on,O
the,O
first,O
line,O
of,O
the,O
alignment,O
",",O
whereas,O
the,O
numbers,O
within,O
the,O
parenthesis,O
correspond,O
to,O
the,O
location,O
of,O
this,O
sequence,O
in,O
athe,O
reference,O
human,B-OG
DGK,B-GP
-,I-GP
ε,I-GP
homolog,O
(,O
accession,O
number,O
NP_003638,O
).,O
The,O
vertebrate,B-OG
species,O
for,O
which,O
the,O
sequences,O
are,O
shown,O
include,O
the,O
following,O
groups,O
:,O
Mammals,B-OG
—,O
Homo,B-OG
sapiens,I-OG
and,O
Rattus,B-OG
novergicus,I-OG
;,O
Birds,B-OG
—,O
Serinus,B-OG
canaria,I-OG
and,O
Sturnus,B-OG
vulgaris,I-OG
;,O
Reptiles,B-OG
—,O
Protobothrops,B-OG
mucrosquamatus,I-OG
and,O
Python,B-OG
bivittatus,I-OG
;,O
Amphibians,B-OG
—,O
Xenopus,B-OG
tropicalis,I-OG
and,O
Fish,B-OG
—,O
Pundamilia,B-OG
nyererei,I-OG
and,O
Maylandia,B-OG
zebra,I-OG
.,O
Partial,O
sequence,O
alignment,O
of,O
the,O
DGK,B-GP
catalytic,O
domain,O
showing,O
a,O
number,O
of,O
signatures,O
that,O
are,O
specific,O
for,O
different,O
DGK,B-GP
isozymes,O
.,O
In,O
the,O
position,O
marked,O
Sig❷A,O
",",O
B,O
",",O
a,O
2,O
aa,O
insert,O
is,O
specifically,O
present,O
in,O
all,O
class,B-GP
I,I-GP
DGK,I-GP
homologs,O
",",O
whereas,O
in,O
the,O
same,O
position,O
a,O
4,O
aa,O
insert,O
is,O
found,O
in,O
the,O
class,B-GP
II,I-GP
DGK,I-GP
isozymes,O
.,O
Another,O
signature,O
marked,O
❸,O
consists,O
of,O
a,O
2,O
aa,O
deletion,O
that,O
is,O
uniquely,O
present,O
in,O
the,O
DGK,B-GP
-,I-GP
θ,I-GP
homologs,O
.,O
The,O
signatures,O
shown,O
are,O
specific,O
for,O
the,O
indicated,O
DGK,B-GP
isoforms,O
in,O
sequenced,O
vertebrate,B-OG
species,O
.,O
The,O
dashes,O
(-),O
in,O
the,O
alignment,O
denote,O
identity,O
with,O
the,O
amino,O
acid,O
on,O
the,O
top,O
and,O
the,O
Genbank,O
ID,O
numbers,O
for,O
these,O
sequences,O
are,O
provided,O
in,O
Fig,O
3,O
.,O
Our,O
analysis,O
has,O
also,O
identified,O
another,O
CSI,O
consisting,O
of,O
a,O
1,O
aa,O
deletion,O
in,O
a,O
highly,O
conserved,O
region,O
(,O
denoted,O
as,O
Sig,O
❹,O
in,O
Fig,O
5,O
"),",O
which,O
is,O
commonly,O
shared,O
by,O
all,O
of,O
the,O
Class,O
I,O
and,O
Class,B-GP
IV,I-GP
DGK,I-GP
homologs,O
.,O
This,O
CSI,O
",",O
in,O
conjunction,O
with,O
the,O
signatures,O
❷A,O
",",O
B,O
(,O
Fig,O
4,O
),O
and,O
the,O
grouping,O
together,O
of,O
the,O
members,O
of,O
these,O
two,O
classes,O
in,O
the,O
phylogenetic,O
tree,O
(,O
Fig,O
2,O
"),",O
provides,O
evidence,O
that,O
the,O
homologs,O
from,O
these,O
two,O
classes,O
are,O
specifically,O
related,O
to,O
each,O
other,O
.,O
In,O
the,O
proximity,O
of,O
Sig,O
❹,O
",",O
DGK,B-GP
-,I-GP
θ,I-GP
homologs,O
also,O
contain,O
a,O
1,O
aa,O
deletion,O
(,O
marked,O
as,O
Sig,O
❺,O
",",O
shown,O
in,O
light,O
green,O
color,O
).,O
Although,O
",",O
the,O
CSIs,O
❹,O
and,O
❺,O
are,O
placed,O
in,O
different,O
positions,O
in,O
Fig,O
5,O
",",O
due,O
to,O
limited,O
sequence,O
similarity,O
observed,O
for,O
the,O
DGK,B-GP
-,I-GP
θ,I-GP
homologs,O
in,O
the,O
vicinity,O
of,O
this,O
indel,O
",",O
it,O
is,O
possible,O
that,O
the,O
indel,O
in,O
DGK,B-GP
-,I-GP
θ,I-GP
(,O
marked,O
as,O
Sig,O
❺,O
),O
also,O
occurred,O
in,O
the,O
same,O
position,O
as,O
in,O
the,O
Class,O
I,O
and,O
Class,B-GP
IV,I-GP
DGK,I-GP
isozymes,O
.,O
In,O
that,O
case,O
",",O
the,O
indel,O
marked,O
as,O
❹,O
would,O
be,O
a,O
shared,O
characteristic,O
of,O
the,O
Class,O
I,O
",",O
Class,O
IV,O
and,O
Class,B-GP
V,I-GP
DGK,I-GP
isozymes,O
.,O
Excerpts,O
from,O
the,O
multiple,O
sequence,O
alignment,O
of,O
catalytic,O
domain,O
from,O
DGK,B-GP
isozymes,O
showing,O
a,O
1,O
aa,O
conserved,O
indel,O
(,O
deletion,O
),O
(,O
marked,O
❹,O
),O
that,O
is,O
commonly,O
shared,O
by,O
the,O
class,O
I,O
and,O
class,O
IV,O
isozymes,O
.,O
In,O
the,O
proximity,O
of,O
Sig,O
❹,O
",",O
a,O
1,O
aa,O
deletion,O
is,O
also,O
present,O
in,O
the,O
DGK,B-GP
-,I-GP
θ,I-GP
homologs,O
(,O
marked,O
as,O
signature,O
❺,O
).,O
Although,O
these,O
two,O
indels,O
are,O
placed,O
in,O
different,O
positions,O
",",O
the,O
possibility,O
that,O
they,O
have,O
occurred,O
in,O
the,O
same,O
position,O
as,O
❹,O
cannot,O
be,O
excluded,O
.,O
The,O
class,B-GP
II,I-GP
DGK,I-GP
homologs,O
are,O
known,O
to,O
contain,O
a,O
large,O
insert,O
in,O
the,O
middle,O
of,O
the,O
catalytic,O
domain,O
.,O
In,O
the,O
same,O
location,O
",",O
where,O
this,O
large,O
insert,O
is,O
present,O
in,O
the,O
class,O
II,O
homologs,O
",",O
the,O
DGK,B-GP
homologs,O
belonging,O
to,O
other,O
classes,O
are,O
also,O
found,O
to,O
contain,O
smaller,O
CSIs,O
of,O
specific,O
lengths,O
that,O
serve,O
to,O
distinguish,O
them,O
from,O
each,O
other,O
(,O
Fig,O
6,O
).,O
The,O
Class,B-GP
I,I-GP
DGK,I-GP
homologs,O
contain,O
two,O
different,O
CSIs,O
(,O
a,O
5,O
aa,O
deletion,O
and,O
a,O
2,O
aa,O
deletion,O
",",O
denoted,O
as,O
Sig,O
❻,O
),O
in,O
this,O
region,O
whereas,O
the,O
DGK,B-GP
-,I-GP
ε,I-GP
homologs,O
(,O
class,O
III,O
),O
all,O
have,O
an,O
8,O
aa,O
deletion,O
in,O
this,O
position,O
(,O
marked,O
as,O
Sig,O
❽,O
).,O
The,O
location,O
of,O
the,O
large,O
insert,O
in,O
the,O
Class,B-GP
II,I-GP
DGK,I-GP
homologs,O
is,O
marked,O
by,O
Sig,O
❼,O
.,O
In,O
addition,O
",",O
the,O
DGK,B-GP
-,I-GP
θ,I-GP
and,O
DGK,B-GP
-,I-GP
ί,I-GP
isozymes,O
can,O
also,O
be,O
distinguished,O
from,O
others,O
by,O
the,O
presence,O
of,O
1,O
aa,O
CSIs,O
(,O
deletions,O
),O
that,O
appear,O
specific,O
for,O
these,O
isoforms,O
.,O
Lastly,O
",",O
two,O
additional,O
CSIs,O
are,O
present,O
in,O
the,O
catalytic,O
domain,O
in,O
the,O
proximity,O
of,O
the,O
predicted,O
ATP,O
-,O
binding,O
site,O
[,O
2,O
",",O
31,O
",",O
32,O
],O
shown,O
in,O
the,O
sequence,O
alignment,O
in,O
Fig,O
7,O
.,O
One,O
of,O
these,O
CSIs,O
",",O
a,O
2,O
aa,O
insert,O
",",O
is,O
specific,O
for,O
the,O
DGK,B-GP
-,I-GP
ε,I-GP
homologs,O
(,O
marked,O
as,O
Sig,O
❾,O
"),",O
whereas,O
in,O
a,O
nearby,O
region,O
",",O
both,O
DGK,B-GP
-,I-GP
θ,I-GP
as,O
well,O
as,O
DGK,B-GP
-,I-GP
ε,I-GP
are,O
found,O
to,O
contain,O
CSIs,O
of,O
different,O
lengths,O
in,O
the,O
same,O
position,O
(,O
marked,O
as,O
Sig,O
❿A,O
",",O
B,O
).,O
However,O
",",O
the,O
sequence,O
of,O
the,O
ATP,O
binding,O
motif,O
(,O
G,O
-,O
X,O
-,O
G,O
-,O
X,O
-,O
X,O
-,O
G,O
),O
is,O
nearly,O
perfectly,O
conserved,O
in,O
all,O
DGK,B-GP
-,O
isozymes,O
in,O
vertebrates,B-OG
",",O
with,O
the,O
exception,O
of,O
DGK,B-GP
-,I-GP
κ,I-GP
isoform,O
",",O
where,O
a,O
Ser,O
is,O
present,O
in,O
place,O
of,O
the,O
last,O
Gly,O
residue,O
in,O
the,O
mammalian,O
homologs,O
.,O
A,O
number,O
of,O
other,O
residues,O
flanking,O
the,O
ATP,O
-,O
binding,O
motif,O
are,O
also,O
either,O
completely,O
or,O
highly,O
conserved,O
in,O
all,O
DGK,B-GP
isozymes,O
.,O
Partial,O
sequence,O
alignment,O
of,O
DGK,B-GP
isozymes,O
showing,O
a,O
region,O
of,O
the,O
catalytic,O
domain,O
where,O
indels,O
of,O
different,O
lengths,O
are,O
present,O
in,O
different,O
DGK,B-GP
isozymes,O
.,O
Signatures,O
marked,O
❻,O
are,O
specific,O
for,O
class,B-GP
I,I-GP
DGKs,I-GP
",",O
the,O
large,O
deletion,O
marked,O
❼,O
is,O
a,O
shared,O
characteristic,O
of,O
class,B-GP
II,I-GP
DGKs,I-GP
and,O
the,O
CSI,O
marked,O
as,O
❽,O
is,O
present,O
in,O
different,O
DGK,B-GP
-,I-GP
θ,I-GP
homologs,O
.,O
Excerpts,O
from,O
the,O
sequence,O
alignment,O
of,O
DGK,B-GP
isozymes,O
showing,O
a,O
number,O
of,O
CSIs,O
that,O
are,O
specific,O
for,O
the,O
DGK,B-GP
-,I-GP
θ,I-GP
and,O
DGK,B-GP
-,I-GP
ε,I-GP
isozymes,O
.,O
The,O
2,O
aa,O
insert,O
marked,O
as,O
Sig❾,O
is,O
only,O
found,O
in,O
DGK,B-GP
-,I-GP
ε,I-GP
homologs,O
",",O
whereas,O
in,O
a,O
nearby,O
region,O
",",O
both,O
DGK,B-GP
-,I-GP
θ,I-GP
as,O
well,O
as,O
DGK,B-GP
-,I-GP
ε,I-GP
are,O
found,O
to,O
contain,O
CSIs,O
of,O
different,O
lengths,O
in,O
the,O
same,O
position,O
(,O
marked,O
as,O
Sig,O
❿A,O
",",O
B,O
).,O
These,O
CSIs,O
are,O
located,O
in,O
the,O
proximity,O
of,O
ATP,O
-,O
binding,O
motif,O
(,O
shown,O
in,O
red,O
"),",O
which,O
is,O
conserved,O
in,O
all,O
isozymes,O
.,O
Distribution,O
of,O
DGK,B-GP
isozymes,O
within,O
the,O
domain,O
Eukarya,B-OG
Much,O
of,O
the,O
work,O
on,O
DGK,B-GP
isozymes,O
has,O
been,O
carried,O
out,O
in,O
mammalian,O
systems,O
and,O
is,O
limited,O
to,O
humans,B-OG
and,O
rodent,B-OG
species,O
.,O
In,O
addition,O
",",O
somework,O
has,O
been,O
carried,O
out,O
on,O
documenting,O
and,O
studying,O
the,O
functions,O
of,O
DGK,B-GP
isozymes,O
in,O
other,O
eukaryotic,O
organisms,O
such,O
as,O
Drosophila,B-OG
",",O
nematodes,B-OG
",",O
slime,B-OG
molds,I-OG
and,O
plants,B-OG
[,O
3,O
",",O
6,O
",",O
10,O
",",O
14,O
–,O
16,O
",",O
33,O
–,O
35,O
].,O
However,O
",",O
it,O
is,O
unclear,O
whether,O
all,O
of,O
the,O
different,O
DGK,B-GP
isozymes,O
are,O
present,O
in,O
different,O
vertebrate,B-OG
classes,O
and,O
other,O
deeper,O
branching,O
eukaryotic,O
phyla,O
.,O
To,O
gain,O
insights,O
in,O
these,O
regards,O
",",O
we,O
have,O
examined,O
the,O
species,O
distributions,O
of,O
various,O
DGK,B-GP
isozymes,O
in,O
different,O
eukaryotic,O
kingdoms,O
and,O
phyla,O
.,O
These,O
studies,O
were,O
carried,O
out,O
as,O
described,O
in,O
the,O
Methods,O
section,O
and,O
their,O
results,O
are,O
summarized,O
in,O
Table,O
1,O
.,O
The,O
subphylum,O
vertebrata,O
",",O
which,O
encompasses,O
all,O
of,O
the,O
large,O
animal,B-OG
species,O
",",O
contains,O
five,O
main,O
groups,O
:,O
fishes,B-OG
",",O
amphibians,B-OG
",",O
birds,B-OG
",",O
reptiles,B-OG
and,O
mammals,B-OG
.,O
Of,O
the,O
known,O
DGK,B-GP
isozymes,O
",",O
homologs,O
of,O
DGK,B-GP
-,I-GP
α,I-GP
",",O
-,O
β,O
",",O
-,O
δ,O
",",O
-,O
η,O
",",O
-,O
ζ,O
",",O
-,O
θ,O
and,O
-,O
ε,O
were,O
broadly,O
distributed,O
in,O
all,O
major,O
groups,O
within,O
the,O
vertebrates,B-OG
.,O
While,O
homologs,O
of,O
DGK,B-GP
-,I-GP
κ,I-GP
were,O
mainly,O
found,O
in,O
mammals,B-OG
",",O
birds,B-OG
and,O
some,O
fishes,B-OG
and,O
reptiles,B-OG
",",O
homologs,O
of,O
DGK,B-GP
-,I-GP
γ,I-GP
were,O
not,O
detected,O
in,O
fishes,B-OG
and,O
amphibians,B-OG
.,O
In,O
the,O
invertebrate,B-OG
phyla,O
that,O
were,O
examined,O
(,O
viz,O
.,O
Arthropoda,B-OG
",",O
Nematoda,B-OG
",",O
Mollusca,B-OG
and,O
Cnidarians,B-OG
"),",O
homologs,O
that,O
were,O
most,O
similar,O
to,O
DGK,B-GP
-,I-GP
ε,I-GP
",",O
DGK,B-GP
-,I-GP
θ,I-GP
",",O
DGK,B-GP
-,I-GP
ζ,I-GP
",",O
DGK,B-GP
-,I-GP
β,I-GP
and,O
DGK,B-GP
-,I-GP
δ,I-GP
were,O
detected,O
in,O
either,O
all,O
or,O
most,O
species,O
from,O
phyla,O
",",O
whereas,O
homologs,O
for,O
the,O
other,O
DGK,B-GP
isozymes,O
were,O
generally,O
not,O
detected,O
or,O
their,O
presence,O
could,O
not,O
be,O
reliably,O
ascertained,O
.,O
In,O
accordance,O
with,O
earlier,O
studies,O
",",O
homologs,O
showing,O
significant,O
similarity,O
to,O
the,O
DGK,B-GP
isozymes,O
were,O
not,O
detected,O
in,O
Fungi,B-OG
[,O
3,O
",",O
4,O
",",O
6,O
"],",O
but,O
in,O
plants,B-OG
",",O
homologs,O
that,O
were,O
most,O
similar,O
to,O
the,O
β,O
-,O
and,O
γ,O
-,O
isozymes,O
were,O
detected,O
[,O
3,O
",",O
10,O
].,O
Blast,O
searches,O
were,O
also,O
carried,O
out,O
against,O
members,O
of,O
a,O
number,O
of,O
protists,B-OG
phyla,O
(,O
viz,O
.,O
Plasmodium,B-OG
",",O
Euglenezoa,B-OG
",",O
Amoebozoa,B-OG
"),",O
which,O
form,O
the,O
deepest,O
branching,O
lineages,O
within,O
the,O
eukaryotes,B-OG
.,O
Except,O
for,O
an,O
isolated,O
hit,O
showing,O
limited,O
similarity,O
to,O
these,O
proteins,O
",",O
the,O
presence,O
of,O
DGK,B-GP
-,O
isozymes,O
in,O
these,O
species,O
could,O
not,O
be,O
reliably,O
ascertained,O
.,O
Distribution,O
of,O
different,O
DGK,B-GP
isozymes,O
in,O
the,O
main,O
phyla,O
of,O
vertebrates,B-OG
and,O
other,O
eukaryotes,B-OG
.,O
Eukaryotic,O
Groups,O
DAG,B-GP
kinase,I-GP
isoforms,O
α,O
β,O
γ,O
δ,O
η,O
κ,O
ι,O
ζ,O
ε,O
θ,O
Mammals,B-OG
(,O
144,O
),O
+,O
+,O
+,O
+,O
+,O
+,O
+,O
+,O
+,O
+,O
Amphibians,B-OG
(,O
1,O
),O
+,O
+,O
-,O
+,O
+,O
-,O
+,O
+,O
+,O
+,O
Birds,B-OG
(,O
61,O
),O
-,O
3,O
+,O
+,O
+,O
+,O
+,O
+,O
+,O
+,O
+,O
Reptiles,B-OG
(,O
11,O
),O
+,O
+,O
+,O
+,O
+/-,O
-,O
3,O
+/-,O
+,O
+,O
+,O
Teleost,O
Fishes,B-OG
(,O
35,O
),O
+,O
+,O
-,O
+,O
+,O
+/-,O
+,O
+,O
+,O
+,O
Plants,B-OG
(,O
81,O
),O
-,O
1,O
+,O
+,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
Fungi,O
(,O
704,O
),O
-,O
-,O
3,O
-,O
3,O
-,O
-,O
-,O
-,O
-,O
-,O
-,O
Plasmodium,O
(,O
45,O
),O
-,O
1,O
-,O
+/-,O
2,O
+/-,O
2,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
Amoebozoa,O
(,O
16,O
),O
-,O
1,O
-,O
+/-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
+/-,O
1,O
-,O
1,O
Nematoda,O
(,O
47,O
),O
-,O
+,O
-,O
+/-,O
2,O
-,O
1,O
-,O
1,O
+/-,O
2,O
+/-,O
2,O
+,O
+,O
Mollusca,O
(,O
5,O
),O
-,O
+,O
-,O
+,O
-,O
-,O
-,O
+,O
+,O
+,O
Cnidarians,O
(,O
5,O
),O
-,O
-,O
-,O
3,O
-,O
3,O
+/-,O
-,O
-,O
+,O
+,O
+,O
Arthropoda,O
(,O
107,O
),O
-,O
1,O
+/-,O
2,O
-,O
1,O
-,O
+,O
-,O
+/-,O
1,O
+/-,O
2,O
+,O
+,O
Platyhelminthes,O
(,O
7,O
),O
-,O
-,O
-,O
-,O
-,O
-,O
+,O
+/-,O
-,O
+,O
Euglenozoa,O
(,O
47,O
),O
+/-,O
2,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
-,O
1,O
+/-,O
1,O
-,O
1,O
The,O
presence,O
or,O
absence,O
of,O
different,O
DGK,B-GP
isoforms,O
in,O
the,O
indicated,O
groups,O
was,O
determined,O
based,O
on,O
blastp,O
searches,O
on,O
the,O
annotated,O
genomes,O
in,O
the,O
NCBI,O
nr,O
database,O
as,O
described,O
in,O
the,O
Methods,O
section,O
.,O
The,O
numbers,O
in,O
parenthesis,O
after,O
the,O
group,O
names,O
indicatedthe,O
numbers,O
of,O
annotated,O
genomes,O
that,O
were,O
present,O
in,O
the,O
NCBI,O
nr,O
database,O
from,O
the,O
given,O
group,O
.,O
(+/-),O
indicates,O
that,O
only,O
some,O
species,O
may,O
contain,O
the,O
isoform,O
.,O
1No,O
isoform,O
was,O
specified,O
however,O
the,O
top,O
5,O
hits,O
show,O
limited,O
similarity,O
to,O
the,O
indicated,O
isoform,O
.,O
2No,O
isoform,O
was,O
specified,O
however,O
the,O
top,O
5,O
hits,O
are,O
most,O
similar,O
to,O
the,O
indicated,O
isoform,O
.,O
3Limited,O
similarity,O
(,O
less,O
than,O
3,O
hits,O
for,O
the,O
isoform,O
of,O
interest,O
).,O
Discussion,O
Most,O
vertebrate,B-OG
species,O
contain,O
10,O
different,O
DGK,B-GP
isozymes,O
which,O
are,O
grouped,O
into,O
5,O
different,O
classes,O
or,O
types,O
(,O
Fig,O
1,O
).,O
The,O
DGKs,B-GP
from,O
different,O
classes,O
are,O
distinguished,O
from,O
each,O
other,O
by,O
the,O
presence,O
or,O
absence,O
of,O
specific,O
functional,O
domains,O
;,O
however,O
",",O
all,O
of,O
them,O
share,O
a,O
large,O
catalytic,O
domain,O
(,O
CD,O
"),",O
as,O
well,O
as,O
two,O
cysteine,O
-,O
rich,O
domains,O
.,O
In,O
the,O
simplest,O
of,O
the,O
DGK,B-GP
isozymes,O
",",O
DGK,B-GP
-,I-GP
ε,I-GP
(,O
sole,O
member,O
of,O
class,B-GP
III,I-GP
DGK,I-GP
"),",O
the,O
catalytic,O
domain,O
(>,O
300,O
aa,O
),O
makes,O
up,O
nearly,O
60,O
%,O
of,O
the,O
entire,O
protein,O
and,O
thus,O
it,O
comprises,O
the,O
single,O
largest,O
sequence,O
element,O
specific,O
for,O
the,O
DGK,B-GP
family,O
of,O
proteins,O
.,O
In,O
contrast,O
",",O
the,O
cysteine,O
-,O
rich,O
C1,O
domains,O
are,O
of,O
short,O
lengths,O
(~,O
50,O
aa,O
"),",O
show,O
considerable,O
sequence,O
variation,O
",",O
and,O
they,O
are,O
also,O
present,O
in,O
numerous,O
other,O
proteins,O
including,O
the,O
protein,B-GP
kinase,I-GP
C,I-GP
family,O
of,O
proteins,O
[,O
2,O
–,O
4,O
",",O
12,O
",",O
36,O
].,O
Due,O
to,O
the,O
prominence,O
and,O
uniqueness,O
of,O
the,O
catalytic,O
domain,O
for,O
the,O
DGK,B-GP
family,O
of,O
proteins,O
",",O
analysis,O
of,O
its,O
sequence,O
provides,O
an,O
important,O
resource,O
for,O
gaining,O
an,O
understanding,O
of,O
the,O
evolution,O
of,O
this,O
protein,O
family,O
as,O
well,O
as,O
functional,O
differences,O
among,O
its,O
members,O
.,O
Our,O
analyses,O
of,O
the,O
catalytic,O
domain,O
sequences,O
presented,O
here,O
have,O
identified,O
many,O
novel,O
sequence,O
features,O
that,O
are,O
specific,O
for,O
different,O
types,O
of,O
DGKs,B-GP
and,O
provide,O
useful,O
insights,O
into,O
the,O
evolution,O
of,O
this,O
protein,O
family,O
.,O
In,O
a,O
phylogenetic,O
tree,O
based,O
on,O
CD,O
sequences,O
",",O
DGK,B-GP
homologs,O
belonging,O
to,O
different,O
classes,O
formed,O
strongly,O
supported,O
clusters,O
",",O
which,O
were,O
separated,O
by,O
long,O
branches,O
.,O
The,O
observed,O
results,O
indicate,O
strongly,O
that,O
apart,O
from,O
the,O
other,O
known,O
differences,O
in,O
different,O
types,O
of,O
DGK,B-GP
homologs,O
(,O
see,O
[,O
1,O
–,O
6,O
]),O
their,O
catalytic,O
domain,O
sequences,O
have,O
also,O
diverged,O
considerably,O
from,O
each,O
other,O
and,O
provide,O
clear,O
distinction,O
among,O
different,O
types,O
of,O
DGK,B-GP
homologs,O
.,O
In,O
contrast,O
",",O
the,O
DGK,B-GP
isozymes,O
within,O
each,O
DGK,B-GP
class,O
were,O
tightly,O
clustered,O
in,O
the,O
phylogenetic,O
tree,O
indicating,O
that,O
their,O
catalytic,O
domain,O
sequences,O
are,O
very,O
similar,O
.,O
A,O
major,O
focus,O
of,O
the,O
present,O
work,O
was,O
on,O
identifying,O
novel,O
sequence,O
features,O
within,O
the,O
CD,O
",",O
which,O
are,O
specific,O
for,O
either,O
a,O
particular,O
type,O
of,O
DGK,B-GP
homologs,O
or,O
which,O
are,O
commonly,O
shared,O
by,O
members,O
of,O
different,O
DGK,B-GP
classes,O
.,O
A,O
large,O
number,O
of,O
sequence,O
motifs,O
or,O
signatures,O
",",O
in,O
the,O
forms,O
of,O
CSIs,O
",",O
have,O
been,O
identified,O
in,O
the,O
present,O
work,O
and,O
a,O
summary,O
of,O
the,O
identified,O
CSIs,O
",",O
their,O
DGK,B-GP
class,O
specificity,O
and,O
location,O
within,O
the,O
catalytic,O
domain,O
is,O
provided,O
in,O
Fig,O
8,O
.,O
Locations,O
of,O
the,O
different,O
CSIs,O
in,O
the,O
CD,O
are,O
indicated,O
using,O
the,O
sequence,O
of,O
the,O
human,B-OG
DGK,B-GP
-,I-GP
ε,I-GP
isoform,O
as,O
reference,O
(,O
accession,O
number,O
NP_003638,O
).,O
A,O
summary,O
diagram,O
indicating,O
the,O
locations,O
of,O
the,O
CSIs,O
within,O
the,O
catalytic,O
domain,O
that,O
are,O
specific,O
for,O
different,O
DGK,B-GP
classes,O
.,O
The,O
locations,O
of,O
the,O
CSIs,O
are,O
marked,O
using,O
the,O
catalytic,O
domain,O
sequence,O
for,O
the,O
human,B-OG
DGK,B-GP
-,I-GP
ε,I-GP
isoform,O
(,O
accession,O
number,O
NP_003638,O
),O
as,O
reference,O
.,O
As,O
seen,O
from,O
Fig,O
8,O
",",O
DGK,B-GP
homologs,O
of,O
all,O
five,O
classes,O
can,O
be,O
clearly,O
distinguished,O
from,O
each,O
other,O
by,O
the,O
presence,O
of,O
specific,O
CSIs,O
that,O
are,O
uniquely,O
found,O
in,O
them,O
.,O
For,O
class,O
I,O
",",O
class,O
III,O
",",O
class,O
IV,O
and,O
class,B-GP
V,I-GP
DGK,I-GP
homologs,O
",",O
multiple,O
CSIs,O
specific,O
for,O
these,O
groups,O
were,O
identified,O
.,O
The,O
described,O
signatures,O
are,O
uniquely,O
present,O
in,O
all,O
members,O
of,O
the,O
indicated,O
classes,O
from,O
vertebrate,B-OG
species,O
(,O
the,O
main,O
focus,O
of,O
the,O
present,O
work,O
),O
indicating,O
that,O
the,O
genetic,O
changes,O
responsible,O
for,O
these,O
CSIs,O
first,O
occurred,O
in,O
the,O
ancestors,O
of,O
specific,O
DGK,B-GP
isoforms,O
",",O
and,O
they,O
were,O
then,O
retained,O
in,O
the,O
descendent,O
species,O
.,O
Further,O
",",O
according,O
to,O
the,O
definition,O
of,O
the,O
CSI,O
(,O
s,O
),O
used,O
in,O
our,O
work,O
",",O
the,O
large,O
insert,O
(>,O
300,O
aa,O
),O
within,O
the,O
class,B-GP
II,I-GP
DGK,I-GP
members,O
[,O
2,O
–,O
6,O
",",O
12,O
"],",O
also,O
represents,O
a,O
CSI,O
(,O
marked,O
as,O
Sig,O
❼,O
),O
specific,O
for,O
the,O
class,B-GP
II,I-GP
DGK,I-GP
homologs,O
.,O
The,O
sequence,O
region,O
in,O
the,O
CD,O
where,O
this,O
large,O
CSI,O
is,O
found,O
in,O
class,O
II,O
homologs,O
",",O
it,O
is,O
flanked,O
on,O
both,O
sides,O
by,O
several,O
residues,O
that,O
are,O
conserved,O
in,O
all,O
DGK,B-GP
homologs,O
.,O
Within,O
this,O
conserved,O
region,O
",",O
CSIs,O
of,O
specific,O
lengths,O
(,O
Sig,O
❻,O
",",O
❽,O
and,O
❽A,O
),O
which,O
are,O
distinctive,O
characteristics,O
of,O
the,O
other,O
classes,O
of,O
DGK,B-GP
homologs,O
are,O
also,O
found,O
.,O
Based,O
on,O
the,O
differences,O
in,O
the,O
lengths,O
of,O
the,O
CSIs,O
in,O
different,O
classes,O
of,O
DGK,B-GP
homologs,O
",",O
this,O
region,O
is,O
predicted,O
to,O
specify,O
important,O
functional,O
differences,O
in,O
the,O
properties,O
of,O
different,O
classes,O
of,O
DGK,B-GP
homologs,O
.,O
Another,O
noteworthy,O
CSI,O
within,O
the,O
CD,O
is,O
a,O
16,O
–,O
24,O
aa,O
insert,O
(,O
Sig,O
❶,O
in,O
Fig,O
3,O
),O
that,O
is,O
uniquely,O
found,O
in,O
all,O
of,O
the,O
Class,B-GP
I,I-GP
DGK,I-GP
homologs,O
.,O
Some,O
of,O
the,O
identified,O
CSIs,O
were,O
also,O
commonly,O
shared,O
by,O
members,O
from,O
two,O
different,O
DGK,B-GP
types,O
.,O
For,O
example,O
",",O
the,O
CSI,O
in,O
Sig,O
❹,O
(,O
Fig,O
5,O
),O
is,O
commonly,O
shared,O
by,O
class,O
I,O
and,O
IV,O
",",O
and,O
also,O
possibly,O
class,O
V,O
(,O
Sig,O
❺,O
"),",O
DGK,B-GP
homologs,O
.,O
A,O
closer,O
relationship,O
between,O
class,O
I,O
and,O
IV,O
homologs,O
is,O
also,O
suggested,O
by,O
Sig❷A,O
",",O
B,O
",",O
where,O
inserts,O
that,O
are,O
either,O
2,O
aa,O
or,O
4,O
aa,O
long,O
are,O
specifically,O
present,O
in,O
these,O
two,O
classes,O
of,O
DGK,B-GP
homologs,O
and,O
by,O
the,O
observed,O
branching,O
pattern,O
of,O
these,O
homologs,O
in,O
the,O
phylogenetic,O
tree,O
.,O
In,O
another,O
instance,O
(,O
Sig❿A,O
",",O
B,O
"),",O
CSIs,O
of,O
different,O
lengths,O
(,O
3,O
aa,O
and,O
4,O
aa,O
),O
in,O
the,O
same,O
position,O
are,O
a,O
uniquely,O
present,O
in,O
theε,O
-,O
and,O
θ,O
-,O
classes,O
of,O
DGK,B-GP
-,O
homologs,O
.,O
Different,O
lengths,O
of,O
CSIs,O
in,O
the,O
same,O
position,O
in,O
specific,O
classes,O
of,O
DGK,B-GP
homologs,O
can,O
results,O
from,O
several,O
possibilities,O
.,O
First,O
",",O
it,O
is,O
possible,O
that,O
independent,O
genetic,O
changes,O
have,O
occurred,O
in,O
the,O
ancestor,O
(,O
s,O
),O
of,O
specific,O
DGK,B-GP
classes,O
",",O
giving,O
rise,O
to,O
CSIs,O
of,O
different,O
lengths,O
.,O
However,O
",",O
in,O
some,O
cases,O
such,O
as,O
Sig❷A,O
",",O
B,O
(,O
and,O
also,O
Sig❿A,O
",",O
B,O
"),",O
it,O
is,O
also,O
possible,O
that,O
initially,O
a,O
genetic,O
change,O
leading,O
to,O
either,O
2,O
aa,O
or,O
4,O
aa,O
insert,O
occurred,O
in,O
a,O
common,O
ancestor,O
of,O
the,O
class,O
I,O
and,O
IV,O
DGK,B-GP
homologs,O
",",O
and,O
then,O
another,O
insertion,O
or,O
deletion,O
event,O
occurred,O
in,O
the,O
same,O
position,O
in,O
the,O
ancestor,O
of,O
one,O
of,O
these,O
two,O
groups,O
leading,O
to,O
the,O
observed,O
differences,O
in,O
the,O
lengths,O
of,O
the,O
CSIs,O
in,O
these,O
two,O
classes,O
.,O
Although,O
it,O
is,O
difficult,O
to,O
distinguish,O
between,O
these,O
two,O
possibilities,O
",",O
the,O
fact,O
that,O
the,O
class,O
I,O
and,O
class,B-GP
IV,I-GP
DGK,I-GP
homologs,O
also,O
contain,O
another,O
uniquely,O
shared,O
CSI,O
(,O
viz,O
.,O
Sig❹,O
),O
and,O
they,O
branch,O
together,O
in,O
the,O
phylogenetic,O
tree,O
corroborate,O
the,O
view,O
that,O
the,O
homologs,O
from,O
these,O
two,O
classes,O
are,O
closely,O
related,O
and,O
that,O
the,O
CSI,O
❷A,O
",",O
B,O
initially,O
occurred,O
in,O
a,O
common,O
ancestor,O
of,O
these,O
two,O
classes,O
.,O
There,O
is,O
limited,O
understanding,O
at,O
present,O
concerning,O
the,O
overall,O
function,O
of,O
the,O
catalytic,O
domain,O
for,O
eukaryotic,O
DGKs,B-GP
[,O
1,O
–,O
5,O
",",O
31,O
].,O
Some,O
differences,O
have,O
been,O
recently,O
reported,O
in,O
the,O
activities,O
of,O
different,O
classes,O
of,O
DGKs,B-GP
towards,O
1,O
-,O
monoacylglycerol,O
and,O
2,O
-,O
monoacylglycerol,O
[,O
11,O
].,O
The,O
catalytic,O
domain,O
contains,O
a,O
highly,O
-,O
conserved,O
sequence,O
motif,O
(,O
G,O
-,O
X,O
-,O
G,O
-,O
X,O
-,O
X,O
-,O
G,O
),O
similar,O
to,O
that,O
present,O
in,O
the,O
ATP,O
-,O
binding,O
sites,O
of,O
other,O
protein,B-GP
kinases,I-GP
[,O
2,O
",",O
31,O
",",O
32,O
].,O
The,O
importance,O
of,O
this,O
motif,O
for,O
the,O
functioning,O
of,O
DGKs,B-GP
has,O
been,O
established,O
by,O
mutational,O
studies,O
[,O
2,O
",",O
31,O
",",O
37,O
].,O
The,O
CDs,O
from,O
DGK,B-GP
-,I-GP
ε,I-GP
",",O
-,O
ζ,O
",",O
and,O
-,O
θ,O
proteins,O
exhibit,O
very,O
little,O
DGK,B-GP
activity,O
when,O
expressed,O
as,O
isolated,O
subunits,O
[,O
2,O
].,O
This,O
and,O
other,O
observations,O
have,O
led,O
to,O
the,O
suggestion,O
that,O
the,O
proper,O
functioning,O
of,O
the,O
CD,O
for,O
mammalian,O
DGKs,B-GP
requires,O
interactions,O
with,O
other,O
motifs,O
(,O
proteins,O
),O
[,O
1,O
–,O
5,O
",",O
31,O
].,O
However,O
",",O
our,O
knowledge,O
of,O
the,O
sequence,O
motifs,O
in,O
the,O
CD,O
that,O
may,O
facilitate,O
its,O
interactions,O
with,O
other,O
proteins,O
/,O
effectors,O
molecules,O
",",O
and,O
how,O
different,O
DGK,B-GP
isozymes,O
",",O
or,O
classes,O
of,O
isozymes,O
",",O
differ,O
in,O
this,O
regard,O
is,O
very,O
limited,O
.,O
The,O
lack,O
of,O
structural,O
information,O
for,O
the,O
CD,O
for,O
eukaryotic,O
DGKs,B-GP
is,O
also,O
a,O
major,O
hindrance,O
in,O
understanding,O
its,O
function,O
.,O
In,O
this,O
context,O
",",O
our,O
identification,O
of,O
multiples,O
CSIs,O
within,O
the,O
CD,O
that,O
are,O
specific,O
for,O
different,O
classes,O
of,O
DGK,B-GP
homologs,O
is,O
of,O
much,O
interest,O
and,O
significance,O
.,O
Based,O
on,O
earlier,O
work,O
",",O
the,O
CSIs,O
in,O
protein,O
sequences,O
are,O
known,O
to,O
play,O
important,O
functional,O
roles,O
in,O
the,O
organisms,O
in,O
which,O
they,O
are,O
found,O
[,O
38,O
–,O
42,O
].,O
The,O
mutational,O
changes,O
in,O
the,O
CSIs,O
affect,O
proper,O
functioning,O
of,O
the,O
proteins,O
as,O
well,O
as,O
cell,O
growth,O
",",O
and,O
both,O
large,O
and,O
small,O
CSIs,O
are,O
indicated,O
to,O
be,O
significant,O
in,O
this,O
regard,O
[,O
38,O
].,O
Further,O
",",O
extensive,O
work,O
on,O
CSIs,O
show,O
that,O
they,O
are,O
generally,O
located,O
in,O
protein,O
structures,O
in,O
surface,O
loops,O
[,O
39,O
",",O
42,O
–,O
45,O
"],",O
which,O
are,O
indicated,O
to,O
play,O
important,O
roles,O
in,O
mediating,O
protein,O
-,O
protein,O
interactions,O
[,O
39,O
",",O
44,O
",",O
46,O
–,O
49,O
].,O
Based,O
on,O
these,O
observations,O
",",O
it,O
can,O
be,O
hypothesized,O
(,O
predicted,O
),O
that,O
the,O
CSIs,O
in,O
the,O
CD,O
that,O
are,O
specific,O
for,O
different,O
classes,O
of,O
DGK,B-GP
homologs,O
should,O
also,O
be,O
playing,O
important,O
roles,O
in,O
the,O
interactions,O
of,O
different,O
DGK,B-GP
isozymes,O
with,O
specific,O
proteins,O
(,O
or,O
other,O
target,O
molecules,O
),O
that,O
may,O
be,O
responsible,O
for,O
the,O
differences,O
in,O
the,O
cellular,O
functions,O
of,O
the,O
different,O
DGK,B-GP
isozymes,O
.,O
Thus,O
",",O
further,O
studies,O
on,O
understanding,O
the,O
cellular,O
functions,O
of,O
the,O
identified,O
CSIs,O
",",O
and,O
the,O
specific,O
interactions,O
that,O
they,O
may,O
be,O
involved,O
in,O
",",O
could,O
provide,O
important,O
insights,O
regarding,O
the,O
biochemical,O
basis,O
of,O
the,O
differences,O
in,O
the,O
functions,O
of,O
different,O
DGK,B-GP
isozymes,O
.,O
It,O
should,O
also,O
be,O
noted,O
that,O
apart,O
from,O
the,O
CSIs,O
that,O
are,O
specific,O
for,O
different,O
classes,O
of,O
DGKs,B-GP
",",O
sequence,O
alignments,O
shown,O
in,O
Figs,O
2,O
–,O
7,O
and,O
S1,O
Fig,O
also,O
contain,O
large,O
numbers,O
of,O
specific,O
amino,O
acid,O
substitutions,O
(,O
or,O
polymorphisms,O
),O
that,O
are,O
specific,O
for,O
particular,O
classes,O
of,O
DGK,B-GP
homologs,O
.,O
These,O
sequence,O
polymorphisms,O
constitute,O
another,O
type,O
of,O
molecular,O
signature,O
",",O
which,O
are,O
also,O
expected,O
to,O
be,O
of,O
functional,O
significance,O
[,O
12,O
",",O
38,O
].,O
The,O
DGK,B-GP
family,O
of,O
proteins,O
",",O
due,O
to,O
their,O
key,O
roles,O
in,O
controlling,O
the,O
cellular,O
concentrations,O
of,O
two,O
important,O
signalling,O
molecules,O
and,O
thereby,O
controlling,O
diverse,O
cellular,O
processes,O
",",O
are,O
targets,O
for,O
development,O
of,O
novel,O
therapeutics,O
for,O
treatment,O
of,O
cancer,B-DS
",",O
neuronal,O
",",O
metabolic,O
and,O
inflammatory,B-DS
diseases,I-DS
[,O
9,O
",",O
50,O
–,O
57,O
].,O
In,O
this,O
context,O
",",O
the,O
CSIs,O
identified,O
in,O
the,O
present,O
work,O
",",O
which,O
are,O
specific,O
for,O
different,O
classes,O
of,O
DGK,B-GP
homologs,O
and,O
predicted,O
to,O
play,O
important,O
roles,O
in,O
the,O
cellular,O
functions,O
of,O
these,O
isoforms,O
",",O
thus,O
provide,O
potentially,O
useful,O
drug,O
targets,O
[,O
58,O
].,O
The,O
DGK,B-GP
isozymes,O
are,O
primarily,O
found,O
in,O
eukaryotic,O
organisms,O
.,O
Although,O
a,O
protein,O
exhibiting,O
DGK,B-GP
activity,O
is,O
present,O
in,O
many,O
bacteria,B-OG
[,O
4,O
",",O
5,O
",",O
59,O
",",O
60,O
"],",O
it,O
shows,O
minimal,O
similarity,O
(,O
15,O
–,O
18,O
%),O
over,O
a,O
short,O
length,O
",",O
and,O
with,O
multiple,O
intervening,O
gaps,O
",",O
to,O
the,O
eukaryotic,O
DGKs,B-GP
[,O
13,O
],O
[,O
61,O
].,O
The,O
bacterial,O
DGK,B-GP
homologs,O
are,O
short,O
in,O
comparison,O
to,O
the,O
eukaryotic,O
proteins,O
and,O
they,O
do,O
not,O
contain,O
any,O
of,O
the,O
canonical,O
sequence,O
features,O
(,O
viz,O
.,O
catalytic,O
domain,O
and,O
cysteine,O
-,O
rich,O
C1,O
domains,O
"),",O
which,O
are,O
shared,O
characteristics,O
of,O
all,O
eukaryotic,O
DGK,B-GP
homologs,O
[,O
2,O
",",O
4,O
",",O
5,O
",",O
12,O
",",O
59,O
].,O
These,O
observations,O
strongly,O
suggest,O
that,O
the,O
bacterial,O
DGK,B-GP
homologs,O
are,O
evolutionarily,O
unrelated,O
to,O
the,O
eukaryotic,O
counterparts,O
",",O
and,O
that,O
the,O
proteins,O
exhibiting,O
DGK,B-GP
activity,O
have,O
evolved,O
independently,O
in,O
bacteria,B-OG
.,O
In,O
view,O
of,O
the,O
importance,O
of,O
DGK,B-GP
isozymes,O
in,O
cellular,O
signalling,O
processes,O
and,O
their,O
involvement,O
in,O
a,O
wide,O
variety,O
of,O
cellular,O
functions,O
",",O
it,O
is,O
of,O
much,O
interest,O
to,O
know,O
how,O
this,O
large,O
family,O
of,O
proteins,O
has,O
evolved,O
.,O
The,O
phylogenetic,O
approach,O
employed,O
in,O
this,O
work,O
was,O
able,O
to,O
clearly,O
distinguish,O
the,O
five,O
different,O
classes,O
of,O
DGKs,B-GP
;,O
however,O
",",O
as,O
the,O
canonical,O
DGK,B-GP
homologs,O
are,O
only,O
found,O
in,O
eukaryotic,O
organisms,O
",",O
it,O
was,O
difficult,O
to,O
root,O
the,O
tree,O
and,O
determine,O
how,O
members,O
of,O
different,O
DGK,B-GP
classes,O
are,O
related,O
to,O
each,O
other,O
and,O
which,O
of,O
these,O
DGK,B-GP
isozymes,O
is,O
ancestral,O
.,O
The,O
CSIs,O
in,O
protein,O
sequences,O
provide,O
another,O
useful,O
means,O
for,O
understanding,O
the,O
evolutionary,O
relationships,O
among,O
distantly,O
related,O
species,O
;,O
however,O
",",O
in,O
the,O
present,O
instance,O
",",O
due,O
to,O
the,O
absence,O
of,O
a,O
suitable,O
outgroup,O
",",O
it,O
was,O
difficult,O
to,O
establish,O
the,O
ancestral,O
state,O
of,O
the,O
DGK,B-GP
protein,O
sequence,O
and,O
reliably,O
infer,O
whether,O
the,O
observed,O
CSIs,O
are,O
insertions,O
or,O
deletions,O
in,O
the,O
indicated,O
classes,O
of,O
DGK,B-GP
homologs,O
.,O
Although,O
the,O
present,O
work,O
does,O
not,O
resolve,O
how,O
different,O
classes,O
of,O
DGK,B-GP
proteins,O
have,O
originated,O
from,O
a,O
common,O
ancestor,O
and,O
which,O
of,O
these,O
isoforms,O
is,O
most,O
ancestral,O
",",O
the,O
results,O
presented,O
here,O
show,O
that,O
of,O
the,O
different,O
classes,O
of,O
DGKs,B-GP
",",O
the,O
DGK,B-GP
-,I-GP
ε,I-GP
",",O
-,O
θ,O
and,O
-,O
ζ,O
isoforms,O
are,O
most,O
widely,O
distributed,O
in,O
eukaryotic,O
organisms,O
.,O
In,O
addition,O
to,O
their,O
nearly,O
ubiquitous,O
presence,O
in,O
vertebrate,B-OG
species,O
",",O
the,O
homologs,O
for,O
these,O
isoforms,O
are,O
also,O
indicated,O
to,O
be,O
present,O
in,O
most,O
invertebrate,B-OG
species,O
.,O
In,O
contrast,O
",",O
homologs,O
for,O
the,O
other,O
DGK,B-GP
isozymes,O
were,O
not,O
detected,O
in,O
a,O
number,O
of,O
invertebrate,B-OG
phyla,O
(,O
Table,O
1,O
).,O
Although,O
more,O
detailed,O
studies,O
are,O
needed,O
to,O
establish,O
with,O
certainty,O
the,O
identity,O
of,O
the,O
DGK,B-GP
isoforms,O
that,O
are,O
present,O
in,O
deep,O
branching,O
eukaryotic,O
phyla,O
",",O
the,O
observed,O
broader,O
distribution,O
of,O
the,O
DGK,B-GP
-,I-GP
ε,I-GP
",",O
DGK,B-GP
-,I-GP
θ,I-GP
and,O
DGK,B-GP
-,I-GP
ζ,I-GP
isoforms,O
within,O
eukaryotic,O
organisms,O
suggests,O
that,O
one,O
of,O
these,O
isoforms,O
likely,O
represent,O
the,O
ancestral,O
form,O
of,O
the,O
protein,O
.,O
Of,O
these,O
isoforms,O
",",O
DGK,B-GP
-,I-GP
ε,I-GP
represents,O
the,O
most,O
rudimentary,O
form,O
of,O
the,O
protein,O
containing,O
all,O
of,O
the,O
main,O
sequence,O
features,O
that,O
are,O
commonly,O
shared,O
by,O
all,O
other,O
DGK,B-GP
family,O
members,O
.,O
Further,O
",",O
DGK,B-GP
-,I-GP
ε,I-GP
is,O
the,O
only,O
isoform,O
which,O
shows,O
specificity,O
for,O
a,O
particular,O
substrate,O
i,O
.,O
e,O
.,O
arachidonoyl,O
-,O
containing,O
diacylglycerol,O
[,O
2,O
",",O
3,O
",",O
6,O
",",O
12,O
",",O
62,O
].,O
Thus,O
",",O
it,O
is,O
possible,O
that,O
the,O
DGK,B-GP
-,I-GP
ε,I-GP
originated,O
first,O
",",O
and,O
all,O
other,O
DGK,B-GP
isoforms,O
originated,O
from,O
it,O
by,O
acquisition,O
of,O
different,O
domains,O
and,O
other,O
identified,O
signatures,O
.,O
However,O
",",O
the,O
present,O
study,O
is,O
based,O
only,O
on,O
the,O
analyses,O
of,O
the,O
catalytic,O
domain,O
sequences,O
and,O
further,O
work,O
on,O
the,O
analyses,O
of,O
other,O
sequence,O
regions,O
of,O
the,O
DGK,B-GP
protein,O
family,O
could,O
provide,O
additional,O
useful,O
information,O
to,O
clarify,O
the,O
relationships,O
among,O
different,O
DGK,B-GP
isoforms,O
.,O
Supporting,O
information,O
Edited,O
multiple,O
sequence,O
alignment,O
of,O
the,O
catalytic,O
domain,O
for,O
different,O
DGK,B-GP
isozymes,O
that,O
was,O
used,O
for,O
phylogenetic,O
tree,O
construction,O
.,O
(,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Sequence,O
information,O
for,O
different,O
DGK,B-GP
homologs,O
used,O
in,O
phylogenetic,O
studies,O
.,O
(,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Antimicrobial,O
activities,O
of,O
a,O
promising,O
glycolipid,O
biosurfactant,O
from,O
a,O
novel,O
marine,O
Staphylococcussaprophyticus,B-OG
SBPS,I-OG
15,I-OG
Biosurfactants,O
have,O
gained,O
a,O
renewed,O
interest,O
in,O
the,O
recent,O
years,O
for,O
their,O
commercial,O
application,O
in,O
diverse,O
research,O
areas,O
.,O
Recent,O
evidences,O
suggest,O
that,O
the,O
antimicrobial,O
activities,O
exhibited,O
by,O
biosurfactants,O
make,O
them,O
promising,O
molecules,O
for,O
the,O
application,O
in,O
the,O
field,O
of,O
therapeutics,O
.,O
Marine,O
microbes,B-OG
are,O
well,O
known,O
for,O
their,O
unique,O
metabolic,O
and,O
functional,O
properties,O
;,O
however,O
",",O
few,O
reports,O
are,O
available,O
till,O
date,O
regarding,O
their,O
biosurfactant,O
production,O
and,O
antimicrobial,O
potential,O
.,O
In,O
an,O
ongoing,O
survey,O
for,O
bioactive,O
microbial,O
metabolites,O
from,O
microbes,B-OG
isolated,O
from,O
diverse,O
ecological,O
niches,O
",",O
a,O
marine,O
Staphylococcus,B-OG
saprophyticus,I-OG
SBPS,I-OG
15,I-OG
isolated,O
from,O
the,O
petroleum,O
hydrocarbon,O
contaminated,O
coastal,O
site,O
",",O
Puducherry,O
",",O
India,O
",",O
was,O
identified,O
as,O
a,O
promising,O
biosurfactant,O
producer,O
based,O
on,O
multiple,O
screening,O
methods,O
.,O
This,O
bacterium,B-OG
exhibited,O
growth,O
-,O
dependent,O
biosurfactant,O
production,O
and,O
the,O
recorded,O
yield,O
was,O
1,O
.,O
345,O
±,O
0,O
.,O
056,O
g,O
/,O
L,O
(,O
on,O
dry,O
weight,O
basis,O
).,O
The,O
biosurfactant,O
was,O
purified,O
and,O
chemically,O
characterized,O
as,O
a,O
glycolipid,O
with,O
a,O
molecular,O
mass,O
of,O
606,O
.,O
7,O
Da,O
",",O
based,O
on,O
TLC,O
",",O
biochemical,O
estimation,O
methods,O
",",O
FT,O
-,O
IR,O
spectrum,O
and,O
MALDI,O
-,O
TOF,O
–,O
MS,O
analysis,O
.,O
Further,O
",",O
the,O
estimated,O
molecular,O
mass,O
was,O
different,O
from,O
the,O
earlier,O
reports,O
on,O
biosurfactants,O
.,O
This,O
new,O
glycolipid,O
biosurfactant,O
exhibited,O
a,O
board,O
range,O
of,O
pH,O
and,O
temperature,O
stability,O
.,O
Furthermore,O
",",O
it,O
revealed,O
a,O
promising,O
antimicrobial,O
activity,O
against,O
many,O
tested,O
human,B-OG
pathogenic,O
bacterial,O
and,O
fungal,O
clinical,O
isolates,O
.,O
Based,O
on,O
these,O
observations,O
",",O
the,O
isolated,O
biosurfactant,O
from,O
the,O
marine,O
S,B-OG
.,I-OG
saprophyticus,I-OG
revealed,O
board,O
physicochemical,O
stabilities,O
and,O
possess,O
excellent,O
antimicrobial,O
activities,O
which,O
proves,O
its,O
significance,O
for,O
possible,O
use,O
in,O
various,O
therapeutic,O
and,O
biomedical,O
applications,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
report,O
of,O
a,O
biosurfactant,O
from,O
the,O
bacterium,B-OG
",",O
S,B-OG
.,I-OG
saprophyticus,I-OG
.,O
Introduction,O
Biosurfactants,O
possess,O
both,O
hydrophilic,O
and,O
hydrophobic,O
moieties,O
that,O
tend,O
to,O
interact,O
with,O
the,O
phase,O
boundary,O
between,O
two,O
distinct,O
phases,O
in,O
a,O
heterogeneous,O
system,O
to,O
solubilize,O
them,O
(,O
Ron,O
and,O
Rosenberg,O
2002,O
).,O
Biosurfactants,O
has,O
several,O
advantages,O
over,O
their,O
synthetic,O
counterparts,O
such,O
as,O
higher,O
biodegradability,O
;,O
lower,O
toxicity,O
;,O
good,O
biocompatibility,O
;,O
stable,O
at,O
different,O
physico,O
-,O
chemical,O
conditions,O
;,O
synthesis,O
under,O
user,O
-,O
friendly,O
conditions,O
",",O
e,O
.,O
g,O
".,",O
low,O
temperatures,O
and,O
pressures,O
(,O
Zhang,O
et,O
al,O
.,O
2004,O
;,O
Ruggeri,O
et,O
al,O
.,O
2009,O
).,O
They,O
exhibit,O
diverse,O
functional,O
properties,O
such,O
as,O
emulsification,O
",",O
wetting,O
",",O
foaming,O
",",O
cleansing,O
",",O
phase,O
separation,O
",",O
surface,O
activity,O
and,O
reduction,O
in,O
viscosity,O
of,O
crude,O
oil,O
",",O
which,O
makes,O
them,O
amenable,O
for,O
the,O
application,O
in,O
diverse,O
niche,O
areas,O
such,O
as,O
agriculture,O
",",O
pharmaceuticals,O
",",O
cosmetics,O
",",O
food,O
industries,O
",",O
oil,O
recovery,O
and,O
environmental,O
remediation,O
(,O
Mulligan,O
2005,O
;,O
Campos,O
et,O
al,O
.,O
2013,O
;,O
Sachdev,O
and,O
Cameotra,O
2013,O
;,O
Gudina,O
et,O
al,O
.,O
2016,O
).,O
In,O
addition,O
to,O
these,O
",",O
recent,O
studies,O
evidenced,O
that,O
biosurfactants,O
exhibited,O
anti,O
-,O
bacterial,O
",",O
anti,O
-,O
fungal,O
and,O
anti,O
-,O
viral,O
activities,O
which,O
makes,O
them,O
potential,O
sources,O
for,O
biomedical,O
applications,O
(,O
Singh,O
and,O
Cameotra,O
2004,O
).,O
Many,O
of,O
the,O
known,O
biosurfactants,O
having,O
bioactive,O
potential,O
have,O
been,O
reported,O
from,O
terrestrial,O
habitats,O
",",O
the,O
well,O
known,O
biosurfactants,O
are,O
surfactin,O
",",O
fengycin,O
",",O
bacillomycins,O
and,O
iturin,O
produced,O
by,O
Bacillus,B-OG
subtilis,I-OG
(,O
Ahimou,O
et,O
al,O
.,O
2000,O
"),",O
sophorolipids,O
(,O
Cavalero,O
and,O
Cooper,O
2003,O
"),",O
rhamnolipids,O
from,O
Pseudomonas,B-OG
aeruginosa,I-OG
(,O
Benincasa,O
et,O
al,O
.,O
2004,O
),O
and,O
mannosylerythritol,O
lipids,O
from,O
Candida,B-OG
antarctica,I-OG
(,O
Arutchelvi,O
et,O
al,O
.,O
2008,O
).,O
Despite,O
the,O
fact,O
that,O
marine,O
environment,O
forms,O
>,O
70,O
%,O
of,O
the,O
Earth,O
’,O
s,O
biosphere,O
comprising,O
of,O
diverse,O
group,O
of,O
microorganisms,B-OG
with,O
unique,O
metabolic,O
",",O
structural,O
and,O
functional,O
properties,O
(,O
Fenical,O
1993,O
;,O
Proksch,O
et,O
al,O
.,O
2003,O
);,O
they,O
were,O
less,O
studied,O
till,O
date,O
.,O
The,O
first,O
antimicrobial,O
marine,O
biosurfactant,O
was,O
reported,O
from,O
Bacillus,B-OG
circulans,I-OG
isolated,O
from,O
the,O
Andaman,O
and,O
Nicobar,O
Islands,O
",",O
India,O
",",O
which,O
exhibited,O
antimicrobial,O
potential,O
against,O
several,O
multidrug,O
resistant,O
human,B-OG
pathogens,O
with,O
non,O
-,O
hemolytic,O
property,O
(,O
Das,O
et,O
al,O
.,O
2008,O
).,O
Thereafter,O
",",O
some,O
researchers,O
explored,O
the,O
antimicrobial,O
activities,O
of,O
biosurfactants,O
from,O
marine,O
microbes,B-OG
(,O
Khopade,O
et,O
al,O
.,O
2012,O
;,O
Dusane,O
et,O
al,O
.,O
2011,O
;,O
Kiran,O
et,O
al,O
.,O
2010,O
).,O
However,O
",",O
when,O
compared,O
to,O
biosurfactants,O
from,O
terrestrial,O
isolates,O
",",O
few,O
marine,O
biosurfactants,O
have,O
been,O
explored,O
for,O
its,O
antimicrobial,O
potential,O
",",O
hence,O
warrants,O
this,O
investigation,O
.,O
Staphylococcus,B-OG
is,O
a,O
well,O
known,O
genus,O
for,O
its,O
human,B-OG
and,O
animal,B-OG
infections,B-DS
",",O
but,O
some,O
species,O
have,O
been,O
recognized,O
as,O
common,O
commensals,O
.,O
Recent,O
studies,O
have,O
reported,O
that,O
some,O
secondary,O
metabolites,O
produced,O
by,O
Staphylococcus,B-OG
species,O
isolated,O
from,O
natural,O
environments,O
exhibited,O
biotechnological,O
and,O
biomedical,O
significance,O
(,O
Popowicz,O
et,O
al,O
.,O
2006,O
).,O
Staphylococcus,B-OG
saprophyticus,I-OG
isolated,O
from,O
the,O
seawater,O
in,O
Jiangsu,O
",",O
China,O
showed,O
appreciable,O
production,O
of,O
lipase,B-GP
having,O
excellent,O
organic,O
solvent,O
tolerance,O
(,O
Fang,O
et,O
al,O
.,O
2006,O
).,O
Moreover,O
",",O
previous,O
studies,O
showed,O
the,O
possibilities,O
of,O
biosurfactant,O
production,O
in,O
the,O
genus,O
Staphylococcus,B-OG
species,O
(,O
Eddouaouda,O
et,O
al,O
.,O
2012,O
).,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
no,O
studies,O
have,O
been,O
reported,O
on,O
Staphylococcus,B-OG
saprophyticus,O
for,O
biosurfactant,O
production,O
.,O
Hence,O
",",O
the,O
present,O
study,O
was,O
undertaken,O
with,O
regard,O
to,O
the,O
isolation,O
of,O
potential,O
biosurfactant,O
strains,O
using,O
multiple,O
screening,O
methods,O
",",O
followed,O
by,O
the,O
production,O
and,O
purification,O
of,O
the,O
biosurfactant,O
from,O
a,O
promising,O
strain,O
of,O
Staphylococcus,B-OG
saprophyticus,O
",",O
and,O
its,O
biochemical,O
characterization,O
",",O
pH,O
and,O
temperature,O
stability,O
studies,O
and,O
evaluation,O
of,O
the,O
antimicrobial,O
potential,O
of,O
the,O
biosurfactant,O
against,O
different,O
human,B-OG
pathogenic,O
clinical,O
isolates,O
.,O
Materials,O
and,O
methods,O
Sample,O
collection,O
Sediment,O
samples,O
were,O
collected,O
using,O
Petersen,O
grab,O
sampler,O
from,O
four,O
different,O
locations,O
of,O
the,O
petroleum,O
hydrocarbon,O
contaminated,O
coastal,O
sites,O
of,O
Puducherry,O
",",O
India,O
.,O
Possible,O
aseptic,O
techniques,O
were,O
applied,O
while,O
sampling,O
to,O
avoid,O
contamination,O
and,O
the,O
collected,O
samples,O
were,O
transferred,O
to,O
pre,O
-,O
sterilized,O
bottle,O
containers,O
which,O
was,O
kept,O
in,O
an,O
icebox,O
maintained,O
at,O
4,O
°,O
C,O
till,O
further,O
processing,O
.,O
The,O
collected,O
samples,O
after,O
reaching,O
the,O
laboratory,O
were,O
processed,O
immediately,O
.,O
Screening,O
of,O
potential,O
biosurfactant,O
producing,O
bacteria,B-OG
All,O
the,O
collected,O
four,O
samples,O
were,O
processed,O
individually,O
",",O
in,O
which,O
1,O
g,O
of,O
central,O
portions,O
of,O
the,O
samples,O
was,O
serially,O
diluted,O
using,O
sterilized,O
natural,O
seawater,O
(,O
34,O
ppt,O
),O
and,O
spread,O
plated,O
on,O
Bushnell,O
Haas,O
agar,O
plates,O
prepared,O
in,O
sea,O
water,O
and,O
supplemented,O
with,O
1,O
%,O
crude,O
oil,O
.,O
After,O
5,O
days,O
of,O
incubation,O
at,O
37,O
°,O
C,O
",",O
individual,O
colonies,O
with,O
distinct,O
morphologies,O
were,O
isolated,O
and,O
further,O
sub,O
-,O
cultured,O
on,O
Zobell,O
marine,O
agar,O
plates,O
to,O
obtain,O
pure,O
cultures,O
",",O
which,O
were,O
maintained,O
in,O
lyophilized,O
form,O
for,O
further,O
studies,O
.,O
All,O
the,O
axenic,O
cultures,O
were,O
individually,O
cultured,O
in,O
Zobell,O
marine,O
broth,O
2216,O
for,O
48,O
h,O
and,O
the,O
cell,O
free,O
supernatant,O
was,O
used,O
for,O
screening,O
the,O
most,O
promising,O
biosurfactant,O
producers,O
using,O
multiple,O
screening,O
methods,O
",",O
viz,O
".,",O
surface,O
activity,O
(,O
Tadros,O
2005,O
"),",O
emulsification,O
activity,O
(,O
Cooper,O
and,O
Goldenberg,O
1987,O
"),",O
lipase,B-GP
activity,O
(,O
Kiran,O
et,O
al,O
.,O
2010,O
),O
and,O
oil,O
displacement,O
test,O
(,O
Youssef,O
et,O
al,O
.,O
2004,O
).,O
Molecular,O
identification,O
Molecular,O
identification,O
of,O
the,O
most,O
potential,O
strain,O
was,O
performed,O
based,O
on,O
16S,O
rRNA,O
gene,O
sequence,O
analysis,O
using,O
the,O
bacterial,O
universal,O
primer,O
set,O
of,O
Eubac,O
27F,O
(,O
5,O
′-,O
AGAG,O
TTTG,O
ATCM,O
TGGC,O
TCAG,O
-,O
3,O
′),O
and,O
1492R,O
(,O
5,O
′-,O
GGTT,O
ACCT,O
TGTT,O
ACGA,O
CTT,O
-,O
3,O
′).,O
The,O
PCR,O
product,O
was,O
purified,O
using,O
the,O
Qiagen,O
PCR,O
purification,O
kit,O
and,O
then,O
sequenced,O
on,O
an,O
ABI,O
Prism,O
377,O
automatic,O
sequencer,O
(,O
Applied,O
Biosystems,O
",",O
CA,O
",",O
USA,O
).,O
The,O
16S,O
rRNA,O
gene,O
sequence,O
from,O
this,O
promising,O
strain,O
was,O
compared,O
with,O
the,O
available,O
bacterial,O
sequences,O
using,O
NCBI,O
BLAST,O
(,O
http,O
://,O
blast,O
.,O
ncbi,O
.,O
nlm,O
.,O
nih,O
.,O
gov,O
/,O
Blast,O
.,O
cgi,O
),O
for,O
their,O
pair,O
-,O
wise,O
identities,O
.,O
Neighbor,O
-,O
joining,O
phylogenetic,O
tree,O
was,O
plotted,O
using,O
the,O
UPGMA,O
statistical,O
method,O
based,O
on,O
the,O
Maximum,O
-,O
Composite,O
-,O
Likelihood,O
model,O
using,O
MEGA,O
6,O
.,O
0,O
software,O
(,O
www,O
.,O
megasoftware,O
.,O
net,O
).,O
Growth,O
kinetics,O
profile,O
as,O
a,O
function,O
of,O
time,O
on,O
biosurfactant,O
production,O
The,O
identified,O
potential,O
strain,O
was,O
standardized,O
for,O
its,O
peak,O
time,O
of,O
biosurfactant,O
production,O
with,O
reference,O
to,O
its,O
cell,O
growth,O
.,O
The,O
production,O
process,O
was,O
carried,O
out,O
in,O
a,O
3,O
L,O
laboratory,O
fermentor,O
(,O
Scigenics,O
",",O
India,O
),O
with,O
2,O
.,O
1,O
L,O
working,O
volume,O
using,O
sea,O
water,O
prepared,O
glucose,O
mineral,O
salt,O
medium,O
as,O
the,O
production,O
medium,O
under,O
the,O
culture,O
conditions,O
of,O
pH,O
8,O
.,O
0,O
",",O
temperature,O
of,O
37,O
°,O
C,O
",",O
34,O
ppt,O
salinity,O
",",O
agitation,O
at,O
150,O
rpm,O
and,O
aeration,O
at,O
1,O
.,O
0,O
vvm,O
.,O
The,O
inoculum,O
was,O
prepared,O
using,O
the,O
exponential,O
phase,O
culture,O
of,O
this,O
promising,O
strain,O
in,O
the,O
same,O
production,O
medium,O
",",O
where,O
the,O
optical,O
density,O
(,O
OD,O
620,O
nm,O
),O
of,O
the,O
inoculum,O
culture,O
was,O
adjusted,O
to,O
0,O
.,O
1,O
based,O
on,O
McFarland,O
turbidity,O
0,O
.,O
5,O
standards,O
which,O
was,O
equivalent,O
to,O
the,O
bacterial,O
concentration,O
of,O
1,O
×,O
108,O
cfu,O
/,O
mL,O
.,O
The,O
biosurfactant,O
production,O
was,O
monitored,O
based,O
on,O
the,O
24,O
h,O
emulsification,O
index,O
(,O
E,O
24,O
),O
(,O
Cooper,O
and,O
Goldenberg,O
1987,O
),O
and,O
the,O
bacterial,O
growth,O
was,O
monitored,O
based,O
on,O
the,O
dry,O
weight,O
of,O
cell,O
biomass,O
.,O
The,O
fermentation,O
process,O
was,O
monitored,O
for,O
96,O
h,O
and,O
the,O
samples,O
were,O
withdrawn,O
on,O
periodic,O
intervals,O
of,O
6,O
h,O
starting,O
from,O
the,O
lag,O
phase,O
to,O
stationary,O
phase,O
under,O
batch,O
culture,O
conditions,O
.,O
The,O
values,O
are,O
represented,O
as,O
mean,O
±,O
standard,O
deviation,O
of,O
triplicate,O
experiments,O
.,O
Purification,O
of,O
biosurfactant,O
At,O
the,O
standardized,O
incubation,O
time,O
",",O
the,O
cell,O
free,O
supernatant,O
was,O
subjected,O
to,O
acid,O
precipitation,O
using,O
6,O
N,O
HCl,O
until,O
pH,O
2,O
was,O
attained,O
(,O
Nitschke,O
and,O
Pastore,O
2006,O
).,O
After,O
overnight,O
incubation,O
at,O
4,O
°,O
C,O
",",O
the,O
precipitated,O
crude,O
biosurfactant,O
was,O
collected,O
by,O
centrifugation,O
at,O
5000,O
rpm,O
for,O
15,O
minutes,O
.,O
The,O
obtained,O
crude,O
biosurfactant,O
was,O
neutralized,O
using,O
phosphate,O
buffer,O
(,O
pH,O
7,O
),O
and,O
the,O
resultant,O
biosurfactant,O
was,O
extracted,O
with,O
an,O
equal,O
volume,O
of,O
chloroform,O
.,O
The,O
organic,O
phase,O
was,O
separated,O
",",O
concentrated,O
and,O
rotary,O
vacuum,O
evaporated,O
(,O
Lablinks,O
PBU,O
-,O
6,O
",",O
India,O
),O
which,O
was,O
further,O
purified,O
on,O
normal,O
phase,O
silica,O
gel,O
(,O
60,O
–,O
120,O
mesh,O
",",O
HiMedia,O
Laboratories,O
Pvt,O
.,O
Ltd,O
".,",O
Mumbai,O
",",O
India,O
),O
column,O
chromatography,O
using,O
stepwise,O
elution,O
with,O
methanol,O
and,O
chloroform,O
ranging,O
from,O
1,O
:,O
20,O
to,O
1,O
:,O
1,O
(,O
v,O
/,O
v,O
).,O
Twenty,O
fractions,O
were,O
collected,O
and,O
every,O
fraction,O
was,O
screened,O
for,O
the,O
emulsification,O
index,O
(,O
E,O
24,O
),O
and,O
the,O
purity,O
of,O
biosurfactant,O
was,O
checked,O
by,O
thin,O
layer,O
chromatography,O
.,O
The,O
fraction,O
(,O
s,O
),O
showing,O
maximum,O
activity,O
were,O
pooled,O
",",O
rotary,O
evaporated,O
and,O
lyophilized,O
for,O
further,O
studies,O
.,O
Biochemical,O
characterization,O
The,O
purified,O
biosurfactant,O
was,O
analyzed,O
on,O
silica,O
gel,O
60,O
TLC,O
plate,O
(,O
F254,O
",",O
Merck,O
),O
which,O
was,O
separated,O
using,O
CH3Cl,O
:,O
CH3OH,O
:,O
H2O,O
(,O
65,O
/,O
15,O
/,O
2,O
",",O
v,O
/,O
v,O
/,O
v,O
),O
as,O
developing,O
system,O
.,O
Visualizing,O
reagents,O
used,O
were,O
ninhydrin,O
reagent,O
(,O
0,O
.,O
2,O
g,O
ninhydrin,O
in,O
100,O
mL,O
ethanol,O
),O
to,O
detect,O
peptides,O
",",O
anthrone,O
reagent,O
(,O
1,O
g,O
anthrone,O
in,O
5,O
mL,O
sulfuric,O
acid,O
mixed,O
with,O
95,O
mL,O
ethanol,O
),O
to,O
examine,O
sugars,O
and,O
lipid,O
portion,O
was,O
evidenced,O
using,O
rhodamine,O
B,O
reagent,O
(,O
0,O
.,O
25,O
g,O
in,O
100,O
mL,O
ethanol,O
).,O
Following,O
this,O
",",O
the,O
total,O
content,O
of,O
protein,O
",",O
carbohydrate,O
and,O
lipid,O
was,O
estimated,O
using,O
Lowry,O
’,O
s,O
method,O
(,O
Lowry,O
et,O
al,O
.,O
1951,O
"),",O
phenol,O
sulphuric,O
acid,O
method,O
(,O
Dubois,O
et,O
al,O
.,O
1956,O
),O
and,O
total,O
free,O
fatty,O
acids,O
(,O
Folch,O
et,O
al,O
.,O
1957,O
"),",O
respectively,O
.,O
Further,O
",",O
the,O
FT,O
-,O
IR,O
spectrum,O
was,O
used,O
to,O
elucidate,O
the,O
functional,O
groups,O
present,O
in,O
the,O
purified,O
unknown,O
biosurfactant,O
.,O
One,O
milligram,O
of,O
freeze,O
-,O
dried,O
biosurfactant,O
was,O
grounded,O
with,O
100,O
mg,O
of,O
KBr,O
.,O
Infrared,O
absorption,O
spectrum,O
were,O
recorded,O
on,O
a,O
Thermo,O
Nicolet,O
",",O
AVATAR,O
330,O
FTIR,O
system,O
with,O
a,O
spectral,O
resolution,O
of,O
cm,O
−,O
1,O
with,O
an,O
average,O
of,O
10,O
scans,O
in,O
the,O
wave,O
number,O
range,O
of,O
400,O
–,O
4000,O
cm,O
−,O
1,O
",",O
and,O
KBr,O
pellet,O
was,O
used,O
as,O
the,O
background,O
reference,O
.,O
Molecular,O
mass,O
determination,O
MALDI,O
-,O
TOF,O
MS,O
was,O
used,O
to,O
examine,O
the,O
molecular,O
mass,O
of,O
the,O
purified,O
biosurfactant,O
.,O
MS,O
was,O
carried,O
out,O
using,O
a,O
Voyager,O
DE,O
-,O
Pro,O
MALDI,O
-,O
TOF,O
spectrometer,O
(,O
Applied,O
Biosystems,O
",",O
Inc,O
",",O
CA,O
",",O
USA,O
),O
in,O
reflector,O
mode,O
with,O
an,O
accelerating,O
voltage,O
of,O
20,O
kV,O
.,O
Equal,O
volume,O
(,O
2,O
µL,O
),O
of,O
the,O
purified,O
fraction,O
was,O
mixed,O
with,O
an,O
equal,O
volume,O
of,O
matrix,O
solution,O
",",O
i,O
.,O
e,O
.,O
0,O
.,O
1,O
%,O
α,O
-,O
cyano,O
-,O
4,O
-,O
hydroxycinnamic,O
acid,O
in,O
acetonitrile,O
–,O
water,O
–,O
TFA,O
(,O
50,O
:,O
50,O
:,O
0,O
.,O
01,O
",",O
v,O
/,O
v,O
/,O
v,O
).,O
After,O
mixing,O
",",O
the,O
sample,O
was,O
spotted,O
on,O
the,O
target,O
plate,O
",",O
dried,O
",",O
placed,O
inside,O
the,O
sample,O
cabinet,O
and,O
the,O
molecules,O
were,O
separated,O
based,O
on,O
their,O
molecular,O
weight,O
.,O
Stability,O
studies,O
Stability,O
of,O
the,O
biosurfactant,O
was,O
evaluated,O
using,O
24,O
h,O
emulsification,O
index,O
(,O
E,O
24,O
),O
(,O
Sheppard,O
and,O
Mulligan,O
1987,O
).,O
The,O
emulsification,O
activity,O
was,O
estimated,O
using,O
crude,O
oil,O
as,O
the,O
solvent,O
and,O
the,O
estimations,O
were,O
carried,O
out,O
after,O
exposure,O
for,O
an,O
hour,O
under,O
the,O
specified,O
test,O
conditions,O
.,O
The,O
purified,O
biosurfactant,O
at,O
4,O
mg,O
/,O
mL,O
concentration,O
in,O
distilled,O
water,O
was,O
tested,O
for,O
the,O
effect,O
of,O
different,O
temperatures,O
ranging,O
between,O
30,O
and,O
120,O
°,O
C,O
(,O
Cooper,O
and,O
Goldenberg,O
1987,O
),O
and,O
the,O
influence,O
of,O
pH,O
was,O
estimated,O
by,O
adjusting,O
the,O
initial,O
pH,O
of,O
the,O
medium,O
from,O
2,O
to,O
10,O
(,O
Nitschke,O
and,O
Pastore,O
2006,O
).,O
Antimicrobial,O
activity,O
The,O
antimicrobial,O
activity,O
of,O
the,O
purified,O
biosurfactant,O
was,O
studied,O
on,O
Muller,O
-,O
Hinton,O
agar,O
(,O
MHA,O
),O
plates,O
against,O
a,O
panel,O
of,O
different,O
human,B-OG
pathogens,O
using,O
antimicrobial,O
disk,O
susceptibility,O
tests,O
as,O
per,O
the,O
Clinical,O
and,O
Laboratory,O
Standards,O
Institute,O
(,O
2015,O
),O
recommendations,O
.,O
The,O
human,B-OG
bacterial,O
pathogens,O
used,O
were,O
Escherichia,B-OG
coli,I-OG
",",O
Salmonella,B-OG
typhi,I-OG
",",O
S,B-OG
.,I-OG
paratyphi,I-OG
",",O
Klebsiella,B-OG
pneumoniae,I-OG
",",O
K,B-OG
.,I-OG
oxytoca,I-OG
",",O
Vibrio,B-OG
parahemolyticus,I-OG
",",O
V,B-OG
.,I-OG
cholerae,I-OG
",",O
Proteus,B-OG
mirabilis,I-OG
",",O
Streptococcus,B-OG
pneumoniae,I-OG
",",O
Bacillus,B-OG
subtilis,I-OG
",",O
B,B-OG
.,I-OG
cereus,I-OG
and,O
Staphylococcus,B-OG
aureus,I-OG
and,O
human,B-OG
fungal,O
pathogens,O
used,O
were,O
Aspergillus,B-OG
niger,I-OG
",",O
A,B-OG
.,I-OG
flavus,I-OG
",",O
Candida,B-OG
albicans,I-OG
",",O
Cryptococcus,B-OG
neoformans,I-OG
and,O
C,B-OG
.,I-OG
gattii,I-OG
",",O
which,O
were,O
kindly,O
provided,O
by,O
Rajah,O
Muthiah,O
Medical,O
College,O
Hospital,O
",",O
Annamalai,O
University,O
",",O
Tamilnadu,O
",",O
India,O
.,O
These,O
strains,O
were,O
cultured,O
on,O
nutrient,O
broth,O
at,O
37,O
°,O
C,O
and,O
the,O
OD,O
of,O
these,O
broth,O
cultures,O
were,O
adjusted,O
to,O
0,O
.,O
1,O
equivalent,O
to,O
an,O
inoculum,O
concentration,O
of,O
108,O
cfu,O
mL,O
−,O
1,O
(,O
according,O
to,O
McFarland,O
turbidity,O
standard,O
).,O
MHA,O
plates,O
were,O
swab,O
cultured,O
with,O
100,O
µL,O
of,O
individual,O
pathogenic,O
strains,O
and,O
the,O
wells,O
were,O
impregnated,O
with,O
50,O
µL,O
of,O
purified,O
biosurfactant,O
dissolved,O
in,O
phosphate,O
buffer,O
(,O
pH,O
7,O
),O
at,O
different,O
concentrations,O
(,O
1,O
–,O
128,O
µg,O
/,O
mL,O
),O
to,O
obtain,O
the,O
minimum,O
inhibitory,O
concentration,O
(,O
MIC,O
),O
whereas,O
phosphate,O
buffer,O
solution,O
was,O
used,O
as,O
control,O
.,O
After,O
incubation,O
for,O
24,O
h,O
at,O
37,O
°,O
C,O
",",O
the,O
plates,O
were,O
examined,O
for,O
zone,O
diameter,O
of,O
inhibition,O
using,O
an,O
antibiotic,O
zone,O
scale,O
.,O
Results,O
and,O
discussion,O
Isolation,O
and,O
screening,O
of,O
most,O
promising,O
biosurfactant,O
producing,O
bacterium,B-OG
After,O
the,O
specified,O
incubation,O
period,O
",",O
the,O
Bushnell,O
Haas,O
agar,O
plates,O
were,O
examined,O
for,O
distinct,O
morphological,O
colonies,O
which,O
were,O
isolated,O
and,O
pure,O
cultured,O
on,O
Zobell,O
marine,O
agar,O
plates,O
.,O
A,O
total,O
of,O
51,O
axenic,O
strains,O
were,O
isolated,O
and,O
named,O
as,O
SBPS,O
1,O
–,O
51,O
.,O
These,O
isolates,O
were,O
screened,O
to,O
identify,O
the,O
most,O
promising,O
biosurfactant,O
producer,O
(,O
s,O
),O
using,O
multiple,O
screening,O
tests,O
.,O
Only,O
11,O
–,O
30,O
%,O
of,O
the,O
isolates,O
showed,O
potent,O
activity,O
with,O
respect,O
to,O
surface,O
tension,O
reduction,O
(,O
13,O
"%),",O
emulsification,O
activity,O
(,O
11,O
"%),",O
lipase,B-GP
activity,O
(,O
20,O
%),O
and,O
oil,O
displacement,O
test,O
(,O
30,O
%).,O
Among,O
these,O
isolates,O
",",O
only,O
one,O
strain,O
SBPS,O
15,O
showed,O
promising,O
activity,O
with,O
respect,O
to,O
all,O
the,O
screening,O
tests,O
",",O
viz,O
".,",O
surface,O
tension,O
reduction,O
(,O
32,O
mN,O
/,O
m,O
"),",O
emulsification,O
activity,O
(,O
77,O
.,O
5,O
"%),",O
lipase,B-GP
activity,O
(,O
66,O
U,O
/,O
mL,O
),O
and,O
oil,O
displacement,O
(,O
3,O
.,O
3,O
cm,O
"),",O
while,O
the,O
rest,O
of,O
the,O
strains,O
showed,O
highly,O
variable,O
results,O
against,O
the,O
different,O
screening,O
methods,O
.,O
In,O
accordance,O
to,O
the,O
present,O
investigation,O
",",O
Bodour,O
and,O
Maier,O
(,O
2000,O
),O
earlier,O
reported,O
the,O
significance,O
of,O
petroleum,O
contaminated,O
sites,O
as,O
the,O
best,O
sources,O
for,O
the,O
isolation,O
of,O
promising,O
biosurfactant,O
producers,O
.,O
Many,O
researchers,O
have,O
also,O
previously,O
reported,O
the,O
significance,O
of,O
multiple,O
screening,O
tests,O
for,O
isolation,O
of,O
potential,O
biosurfactant,O
producers,O
and,O
some,O
methods,O
were,O
chosen,O
as,O
standard,O
techniques,O
for,O
the,O
effective,O
isolation,O
of,O
biosurfactant,O
producers,O
(,O
Khopade,O
et,O
al,O
.,O
2012,O
;,O
Kiran,O
et,O
al,O
.,O
2010,O
).,O
Based,O
on,O
the,O
multiple,O
screening,O
methods,O
adopted,O
in,O
the,O
present,O
study,O
",",O
strain,O
SBPS,O
15,O
was,O
identified,O
as,O
a,O
promising,O
biosurfactant,O
producer,O
.,O
The,O
cell,O
morphology,O
based,O
on,O
Gram,O
staining,O
and,O
microscopic,O
observation,O
revealed,O
the,O
strain,O
SBPS,O
15,O
to,O
be,O
Gram,B-OG
-,I-OG
positive,I-OG
cocci,I-OG
.,O
The,O
molecular,O
identification,O
was,O
performed,O
by,O
amplifying,O
the,O
16S,O
rRNA,O
region,O
and,O
the,O
sequence,O
homology,O
was,O
examined,O
based,O
on,O
BLASTn,O
analysis,O
.,O
The,O
total,O
length,O
of,O
the,O
amplified,O
sequence,O
was,O
1441,O
bp,O
.,O
The,O
BLASTn,O
homology,O
comparison,O
of,O
the,O
16S,O
rRNA,O
gene,O
sequence,O
of,O
the,O
strain,O
SBPS,O
15,O
against,O
the,O
nucleotide,O
sequence,O
collection,O
of,O
the,O
NCBI,O
GenBank,O
sequence,O
database,O
showed,O
100,O
%,O
sequence,O
similarity,O
with,O
Staphylococcus,B-OG
saprophyticus,O
A6,O
(,O
accession,O
number,O
KX262676,O
.,O
1,O
).,O
Based,O
on,O
these,O
comparisons,O
",",O
the,O
strain,O
SBPS,O
15,O
was,O
identified,O
as,O
Staphylococcus,B-OG
saprophyticus,O
and,O
the,O
16S,O
rRNA,O
sequence,O
was,O
deposited,O
in,O
NCBI,O
GenBank,O
with,O
the,O
accession,O
number,O
KX352162,O
.,O
The,O
genus,O
Staphylococcus,B-OG
belongs,O
to,O
the,O
family,O
Staphylococcaceae,B-OG
and,O
the,O
phylum,O
Firmicutes,B-OG
.,O
The,O
phylogenetic,O
tree,O
of,O
Staphylococcus,B-OG
saprophyticus,I-OG
SBPS,I-OG
15,I-OG
plotted,O
with,O
respect,O
to,O
their,O
homology,O
with,O
NCBI,O
strains,O
is,O
shown,O
in,O
Fig,O
.,O
1,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
Staphylococcus,B-OG
saprophyticus,O
was,O
unexplored,O
for,O
the,O
production,O
and,O
characterization,O
of,O
biosurfactant,O
",",O
hence,O
further,O
studies,O
were,O
undertaken,O
to,O
this,O
regard,O
.,O
Fig,O
.,O
1Phylogenetic,O
tree,O
of,O
the,O
most,O
potential,O
marine,O
Staphylococcus,B-OG
saprophyticus,I-OG
SBPS,I-OG
15,I-OG
and,O
their,O
homology,O
with,O
NCBI,O
strains,O
based,O
on,O
16S,O
rRNA,O
gene,O
sequences,O
.,O
Bootstrap,O
values,O
were,O
calculated,O
from,O
1000,O
resamplings,O
using,O
UPGMA,O
statistical,O
model,O
are,O
shown,O
at,O
the,O
respective,O
nodes,O
Growth,O
kinetics,O
profile,O
of,O
biosurfactant,O
production,O
The,O
kinetic,O
profile,O
of,O
biosurfactant,O
production,O
by,O
strain,O
SBPS,O
15,O
as,O
a,O
function,O
of,O
time,O
evidenced,O
that,O
the,O
biosurfactant,O
secretion,O
was,O
observed,O
from,O
the,O
early,O
logarithmic,O
phase,O
of,O
bacterial,O
growth,O
and,O
the,O
peak,O
emulsification,O
index,O
(,O
E,O
24,O
),O
was,O
measured,O
during,O
the,O
initiation,O
of,O
the,O
stationary,O
growth,O
phase,O
of,O
the,O
bacterium,B-OG
(,O
66th,O
hour,O
).,O
Further,O
",",O
the,O
maximum,O
emulsification,O
activity,O
(,O
E,O
24,O
),O
of,O
77,O
.,O
8,O
±,O
2,O
.,O
3,O
%,O
was,O
maintained,O
throughout,O
the,O
stationary,O
phase,O
of,O
the,O
bacterium,B-OG
with,O
cell,O
biomass,O
concentration,O
of,O
8,O
.,O
13,O
±,O
0,O
.,O
35,O
g,O
/,O
L,O
(,O
Fig,O
.,O
2,O
).,O
The,O
results,O
revealed,O
that,O
the,O
biosurfactant,O
production,O
with,O
reference,O
to,O
its,O
biomass,O
concentration,O
indicated,O
that,O
they,O
are,O
predominantly,O
produced,O
during,O
the,O
exponential,O
phase,O
and,O
they,O
function,O
as,O
primary,O
metabolites,O
for,O
the,O
normal,O
growth,O
and,O
nutrient,O
uptake,O
",",O
while,O
in,O
the,O
other,O
case,O
they,O
function,O
as,O
secondary,O
metabolite,O
having,O
an,O
ecological,O
role,O
rather,O
than,O
growth,O
",",O
similar,O
to,O
that,O
of,O
antibiotics,O
and,O
pigments,O
(,O
Mulligan,O
et,O
al,O
.,O
2014,O
).,O
A,O
previous,O
study,O
also,O
reported,O
a,O
similar,O
growth,O
-,O
dependent,O
pattern,O
of,O
biosurfactant,O
production,O
in,O
marine,O
Streptomyces,B-OG
species,I-OG
B3,I-OG
(,O
Khopade,O
et,O
al,O
.,O
2012,O
).,O
Fig,O
.,O
2Growth,O
kinetics,O
profile,O
as,O
a,O
function,O
of,O
time,O
on,O
biosurfactant,O
production,O
from,O
a,O
marine,O
Staphylococcus,B-OG
saprophyticus,I-OG
SBPS,I-OG
15,I-OG
Purification,O
and,O
characterization,O
of,O
the,O
biosurfactant,O
From,O
the,O
cell,O
free,O
supernatant,O
",",O
the,O
crude,O
biosurfactant,O
was,O
recovered,O
by,O
acid,O
precipitation,O
",",O
extracted,O
and,O
further,O
purified,O
using,O
silica,O
gel,O
column,O
chromatography,O
.,O
The,O
maximum,O
emulsification,O
activity,O
quantified,O
in,O
methanol,O
:,O
chloroform,O
(,O
1,O
:,O
11,O
),O
eluted,O
fraction,O
was,O
1,O
.,O
345,O
±,O
0,O
.,O
056,O
g,O
/,O
L,O
on,O
dry,O
weight,O
basis,O
.,O
The,O
silica,O
gel,O
TLC,O
plate,O
analysis,O
of,O
the,O
purified,O
biosurfactant,O
revealed,O
the,O
presence,O
of,O
two,O
spots,O
corresponding,O
to,O
lipid,O
and,O
carbohydrate,O
with,O
Rf,O
values,O
of,O
0,O
.,O
73,O
and,O
0,O
.,O
45,O
.,O
The,O
carbohydrate,O
and,O
lipid,O
contents,O
estimated,O
were,O
738,O
mg,O
/,O
g,O
(,O
nearly,O
74,O
%,O
of,O
carbohydrates,O
),O
and,O
262,O
mg,O
/,O
g,O
(,O
nearly,O
26,O
%,O
of,O
lipid,O
),O
in,O
the,O
biosurfactant,O
based,O
on,O
biochemical,O
estimation,O
methods,O
and,O
protein,O
was,O
not,O
detected,O
.,O
The,O
purified,O
biosurfactant,O
was,O
further,O
analyzed,O
for,O
its,O
functional,O
groups,O
based,O
on,O
FT,O
-,O
IR,O
spectrum,O
(,O
Fig,O
.,O
3a,O
).,O
The,O
presence,O
of,O
characteristic,O
adsorption,O
bands,O
at,O
864,O
",",O
1386,O
",",O
2862,O
and,O
2926,O
cm,O
−,O
1,O
revealed,O
the,O
presence,O
of,O
aliphatic,O
long,O
fatty,O
acid,O
chain,O
(,O
Guo,O
et,O
al,O
.,O
2009,O
;,O
Rahman,O
et,O
al,O
.,O
2010,O
).,O
The,O
important,O
functional,O
groups,O
",",O
viz,O
".,",O
OH,O
bond,O
(,O
3421,O
cm,O
−,O
1,O
"),",O
alkene,O
(,O
C,O
=,O
C,O
),O
(,O
1643,O
cm,O
−,O
1,O
),O
and,O
carbonyl,O
group,O
(,O
C,O
–,O
O,O
),O
(,O
1182,O
cm,O
−,O
1,O
),O
were,O
the,O
characteristic,O
groups,O
present,O
in,O
the,O
biosurfactants,O
(,O
Pornsunthorntawee,O
et,O
al,O
.,O
2008,O
;,O
Rahman,O
et,O
al,O
.,O
2010,O
).,O
The,O
presence,O
of,O
the,O
more,O
important,O
band,O
at,O
1724,O
cm,O
−,O
1,O
deduced,O
the,O
presence,O
of,O
carboxyl,O
group,O
",",O
which,O
represented,O
the,O
linkage,O
group,O
between,O
the,O
sugar,O
and,O
fatty,O
acid,O
(,O
Rodrigues,O
et,O
al,O
.,O
2006,O
),O
and,O
vibration,O
at,O
1105,O
cm,O
−,O
1,O
was,O
reported,O
as,O
corresponded,O
to,O
the,O
C,O
–,O
O,O
–,O
C,O
stretching,O
",",O
which,O
predicts,O
the,O
presence,O
of,O
sugar,O
moiety,O
(,O
Pornsunthorntawee,O
et,O
al,O
.,O
2008,O
).,O
These,O
results,O
suggest,O
that,O
the,O
isolated,O
biosurfactant,O
belongs,O
to,O
the,O
family,O
of,O
glycolipids,O
.,O
Fig,O
.,O
3FT,O
-,O
IR,O
spectrum,O
(,O
a,O
),O
and,O
MALDI,O
-,O
TOF,O
–,O
MS,O
analysis,O
(,O
b,O
),O
of,O
purified,O
glycolipid,O
biosurfactant,O
from,O
a,O
marine,O
Staphylococcus,B-OG
saprophyticus,I-OG
SBPS,I-OG
15,I-OG
In,O
support,O
to,O
the,O
current,O
prediction,O
",",O
prior,O
studies,O
have,O
reported,O
that,O
microbial,O
strains,O
from,O
the,O
same,O
species,O
isolated,O
from,O
different,O
ecological,O
niches,O
produce,O
different,O
types,O
of,O
biosurfactant,O
",",O
for,O
example,O
",",O
Serratia,B-OG
marcescens,I-OG
isolated,O
from,O
terrestrial,O
habitats,O
produced,O
Serrawettin,O
",",O
an,O
exolipid,O
biosurfactant,O
(,O
Li,O
et,O
al,O
.,O
2005,O
);,O
however,O
",",O
Dusane,O
et,O
al,O
.,O
(,O
2011,O
),O
reported,O
a,O
glycolipid,O
biosurfactant,O
produced,O
by,O
S,B-OG
.,I-OG
marcescens,I-OG
isolated,O
from,O
marine,O
habitats,O
.,O
Likewise,O
",",O
Pseudomonas,B-OG
aeruginosa,I-OG
is,O
mostly,O
reported,O
to,O
produce,O
rhamnolipids,O
",",O
a,O
glycolipid,O
biosurfactant,O
(,O
Pornsunthorntawee,O
et,O
al,O
.,O
2008,O
);,O
however,O
",",O
a,O
lipopeptide,O
biosurfactant,O
was,O
produced,O
by,O
P,O
.,O
aeruginosa,O
isolated,O
from,O
sea,O
water,O
of,O
Tuticorin,O
Harbor,O
",",O
India,O
(,O
Thavasi,O
et,O
al,O
.,O
2011,O
).,O
Further,O
",",O
in,O
the,O
present,O
investigation,O
",",O
the,O
isolated,O
biosurfactant,O
from,O
the,O
marine,O
bacterium,B-OG
S,B-OG
.,I-OG
saprophyticus,I-OG
revealed,O
an,O
interesting,O
observation,O
in,O
its,O
biochemical,O
diversity,O
",",O
producing,O
a,O
glycolipid,O
biosurfactant,O
which,O
was,O
unique,O
as,O
compared,O
to,O
an,O
earlier,O
report,O
of,O
Staphylococcus,B-OG
sp,I-OG
.,I-OG
strain,I-OG
1E,I-OG
isolated,O
from,O
terrestrial,O
hydrocarbon,O
contaminated,O
soil,O
of,O
Algeria,O
which,O
produced,O
a,O
lipopeptide,O
biosurfactant,O
(,O
Eddouaouda,O
et,O
al,O
.,O
2012,O
).,O
In,O
addition,O
",",O
many,O
researches,O
have,O
earlier,O
evidenced,O
that,O
marine,O
microbes,B-OG
represent,O
a,O
distinctive,O
group,O
owing,O
to,O
their,O
immense,O
genetic,O
(,O
Sogin,O
et,O
al,O
.,O
2006,O
),O
and,O
biochemical,O
diversity,O
(,O
Rusch,O
et,O
al,O
.,O
2007,O
"),",O
and,O
a,O
rich,O
resource,O
for,O
a,O
wide,O
range,O
of,O
bioactive,O
compounds,O
(,O
Debbab,O
et,O
al,O
.,O
2010,O
).,O
The,O
molecular,O
weight,O
of,O
the,O
purified,O
glycolipid,O
biosurfactant,O
from,O
strain,O
SBPS,O
15,O
was,O
examined,O
using,O
MALDI,O
-,O
TOF,O
–,O
MS,O
analysis,O
.,O
The,O
spectral,O
analysis,O
revealed,O
the,O
presence,O
of,O
a,O
cluster,O
of,O
three,O
molecules,O
at,O
m,O
/,O
z,O
607,O
.,O
7,O
",",O
629,O
.,O
7,O
and,O
645,O
.,O
7,O
which,O
were,O
attributed,O
to,O
the,O
molecules,O
of,O
protonated,O
ion,O
and,O
to,O
the,O
adducts,O
of,O
sodium,O
and,O
potassium,O
ions,O
(,O
Fig,O
.,O
3b,O
).,O
Based,O
on,O
the,O
above,O
observations,O
",",O
the,O
molecular,O
mass,O
of,O
this,O
glycolipid,O
biosurfactant,O
is,O
606,O
.,O
7,O
Da,O
and,O
its,O
molecular,O
weight,O
was,O
found,O
to,O
be,O
different,O
from,O
the,O
earlier,O
reported,O
glycolipid,O
biosurfactants,O
and,O
a,O
new,O
addition,O
to,O
the,O
existing,O
list,O
of,O
glycolipid,O
biosurfactants,O
.,O
This,O
result,O
showed,O
good,O
arguments,O
with,O
Abdel,O
-,O
Mawgoud,O
et,O
al,O
.,O
(,O
2010,O
),O
who,O
suggested,O
that,O
the,O
molecular,O
mass,O
of,O
most,O
reported,O
glycolipid,O
biosurfactants,O
are,O
present,O
within,O
the,O
molecular,O
mass,O
range,O
of,O
302,O
–,O
803,O
Da,O
.,O
Stability,O
studies,O
Emulsification,O
index,O
(,O
E,O
24,O
),O
was,O
used,O
for,O
measuring,O
the,O
biosurfactant,O
stability,O
.,O
The,O
purified,O
glycolipid,O
biosurfactant,O
from,O
strain,O
SBPS,O
15,O
showed,O
increased,O
emulsification,O
(,O
E,O
24,O
of,O
82,O
%),O
in,O
its,O
pure,O
form,O
as,O
compared,O
to,O
the,O
crude,O
form,O
observed,O
during,O
screening,O
(,O
E,O
24,O
of,O
77,O
.,O
5,O
%).,O
It,O
showed,O
good,O
stability,O
over,O
a,O
wide,O
range,O
of,O
pH,O
3,O
–,O
9,O
with,O
E,O
24,O
of,O
72,O
–,O
80,O
%,O
and,O
significantly,O
reduced,O
its,O
activity,O
beyond,O
pH,O
9,O
and,O
above,O
pH,O
3,O
(,O
Fig,O
.,O
4a,O
).,O
Similar,O
results,O
were,O
observed,O
in,O
case,O
of,O
an,O
emulsifier,O
produced,O
by,O
the,O
yeast,B-OG
Yarrowia,B-OG
lipolytica,I-OG
NCIM,O
3589,O
cultivated,O
in,O
n,O
-,O
hexadecane,O
(,O
Sobrinho,O
et,O
al,O
.,O
2008,O
).,O
In,O
terms,O
of,O
temperature,O
stability,O
",",O
the,O
glycolipid,O
biosurfactant,O
from,O
strain,O
SBPS,O
15,O
showed,O
no,O
considerable,O
loss,O
of,O
activity,O
up,O
to,O
80,O
°,O
C,O
(,O
E,O
24,O
of,O
72,O
–,O
80,O
%);,O
however,O
",",O
beyond,O
this,O
temperature,O
",",O
it,O
started,O
to,O
denature,O
and,O
showed,O
no,O
emulsification,O
activity,O
at,O
100,O
°,O
C,O
(,O
Fig,O
.,O
4b,O
).,O
On,O
the,O
other,O
hand,O
",",O
Makkar,O
and,O
Cameotra,O
(,O
2002,O
),O
reported,O
that,O
the,O
biosurfactant,O
produced,O
by,O
the,O
bacterial,O
isolates,O
were,O
stable,O
at,O
higher,O
temperature,O
up,O
to,O
120,O
°,O
C,O
.,O
The,O
broad,O
stability,O
range,O
observed,O
for,O
this,O
biosurfactant,O
makes,O
it,O
a,O
suitable,O
candidate,O
for,O
many,O
desired,O
applications,O
which,O
mandates,O
a,O
stable,O
emulsion,O
at,O
different,O
physico,O
-,O
chemical,O
conditions,O
.,O
Fig,O
.,O
4Effect,O
of,O
different,O
pH,O
(,O
a,O
),O
and,O
temperature,O
(,O
b,O
),O
on,O
stability,O
of,O
biosurfactant,O
produced,O
by,O
a,O
marine,O
Staphylococcus,B-OG
saprophyticus,I-OG
SBPS,I-OG
15,I-OG
Antimicrobial,O
activity,O
Among,O
the,O
twelve,O
tested,O
bacterial,O
human,B-OG
pathogens,O
",",O
the,O
purified,O
biosurfactant,O
from,O
strain,O
SBPS,O
15,O
showed,O
antimicrobial,O
activity,O
against,O
seven,O
strains,O
.,O
The,O
maximum,O
zone,O
of,O
inhibition,O
and,O
the,O
respective,O
minimum,O
inhibitory,O
concentration,O
(,O
MIC,O
),O
values,O
recorded,O
were,O
Klebsiella,B-OG
pneumoniae,I-OG
(,O
23,O
mm,O
",",O
4,O
µg,O
/,O
mL,O
),O
followed,O
by,O
Escherichia,B-OG
coli,I-OG
(,O
20,O
mm,O
",",O
12,O
µg,O
/,O
mL,O
"),",O
Pseudomonas,B-OG
aeruginosa,I-OG
(,O
20,O
mm,O
",",O
32,O
µg,O
/,O
mL,O
"),",O
Vibrio,B-OG
cholerae,I-OG
(,O
18,O
mm,O
",",O
64,O
µg,O
/,O
mL,O
"),",O
Bacillus,B-OG
subtilis,I-OG
(,O
15,O
mm,O
",",O
48,O
µg,O
/,O
mL,O
"),",O
Salmonella,B-OG
paratyphi,I-OG
(,O
13,O
mm,O
",",O
32,O
µg,O
/,O
mL,O
),O
and,O
Staphylococcus,B-OG
aureus,I-OG
(,O
11,O
mm,O
",",O
12,O
µg,O
/,O
mL,O
),O
(,O
Table,O
1,O
).,O
Among,O
the,O
tested,O
pathogens,O
",",O
the,O
inhibitory,O
activity,O
was,O
observed,O
in,O
case,O
of,O
both,O
Gram,O
-,O
positive,O
as,O
well,O
as,O
Gram,O
-,O
negative,O
strains,O
with,O
minimal,O
MIC,O
values,O
which,O
show,O
its,O
promising,O
and,O
diverse,O
antimicrobial,O
potential,O
.,O
Table,O
1Antimicrobial,O
activity,O
of,O
a,O
purified,O
glycolipid,O
biosurfactant,O
from,O
a,O
marine,O
Staphylococcus,B-OG
saprophyticus,I-OG
SBPS,I-OG
15,I-OG
against,O
different,O
human,B-OG
pathogenic,O
clinical,O
isolatesS,O
.,O
No,O
.,O
Bacterial,O
pathogensZone,O
of,O
inhibition,O
(,O
mm,O
),O
Minimum,O
inhibitory,O
concentration,O
(,O
MIC,O
",",O
µg,O
/,O
mL,O
),O
1,O
Escherichia,B-OG
coli,I-OG
20122,O
Salmonella,B-OG
typhi,I-OG
–,O
a,O
–,O
3,O
Salmonella,B-OG
paratyphi,I-OG
13324,O
Klebsiella,B-OG
pneumoniae,I-OG
2345,O
Klebsiella,O
oxytoca,O
––,O
6,O
Vibrio,O
cholerae,O
18647,O
Vibrio,B-OG
parahemolyticus,I-OG
––,O
8,O
Proteus,B-OG
mirabilis,I-OG
––,O
9,O
Pseudomonas,B-OG
aeruginosa,I-OG
203210,O
Bacillus,B-OG
subtilis,I-OG
154811,O
Bacillus,O
cereus,O
––,O
12,O
Staphylococcus,B-OG
aureus,I-OG
1112Fungal,O
pathogens13,O
Aspergillus,B-OG
niger,I-OG
151614,O
Aspergillus,O
flavus,O
––,O
15,O
Candida,B-OG
albicans,I-OG
213216,O
Cryptococcus,B-OG
neoformans,I-OG
223217,O
Cryptococcus,O
gattii,O
–––,O
a,O
No,O
activity,O
Regarding,O
the,O
antifungal,O
activity,O
against,O
the,O
tested,O
five,O
different,O
fungal,O
human,B-OG
pathogens,O
",",O
the,O
biosurfactant,O
from,O
strain,O
SBPS,O
15,O
showed,O
activity,O
against,O
three,O
strains,O
with,O
maximum,O
zone,O
of,O
inhibition,O
and,O
the,O
respective,O
MIC,O
values,O
recorded,O
were,O
Cryptococcus,B-OG
neoformans,I-OG
(,O
22,O
mm,O
",",O
32,O
µg,O
/,O
mL,O
),O
followed,O
by,O
Candida,B-OG
albicans,I-OG
(,O
21,O
mm,O
",",O
32,O
µg,O
/,O
mL,O
),O
and,O
Aspergillus,B-OG
niger,I-OG
(,O
15,O
mm,O
",",O
16,O
µg,O
/,O
mL,O
),O
(,O
Table,O
1,O
).,O
Based,O
on,O
these,O
studies,O
",",O
it,O
was,O
observed,O
that,O
the,O
isolated,O
biosurfactant,O
showed,O
a,O
board,O
range,O
of,O
potential,O
antimicrobial,O
activity,O
against,O
both,O
the,O
bacterial,O
and,O
fungal,O
pathogenic,O
strains,O
.,O
According,O
to,O
Das,O
et,O
al,O
.,O
(,O
2008,O
"),",O
lipopeptide,O
surfactants,O
are,O
largely,O
reported,O
for,O
wide,O
antimicrobial,O
activities,O
and,O
relatively,O
less,O
number,O
of,O
reports,O
exists,O
on,O
glycolipid,O
biosurfactants,O
exhibiting,O
effective,O
antimicrobial,O
activity,O
.,O
Similar,O
to,O
the,O
present,O
investigation,O
",",O
the,O
glycolipid,O
biosurfactant,O
produced,O
from,O
marine,O
Streptomyces,B-OG
species,I-OG
B3,I-OG
isolated,O
from,O
west,O
coastal,O
sediment,O
of,O
India,O
showed,O
antimicrobial,O
activities,O
towards,O
different,O
human,B-OG
pathogens,O
(,O
Khopade,O
et,O
al,O
.,O
2012,O
).,O
Conclusions,O
In,O
the,O
present,O
study,O
",",O
the,O
isolated,O
biosurfactant,O
from,O
the,O
marine,O
S,B-OG
.,I-OG
saprophyticus,I-OG
SBPS,O
15,O
showed,O
significant,O
surface,O
active,O
properties,O
such,O
as,O
surface,O
tension,O
reduction,O
",",O
emulsification,O
",",O
lipase,B-GP
and,O
oil,O
displacement,O
activities,O
.,O
The,O
purified,O
biosurfactant,O
showed,O
a,O
different,O
molecular,O
mass,O
as,O
compared,O
to,O
the,O
earlier,O
reports,O
which,O
can,O
be,O
designated,O
as,O
a,O
new,O
glycolipid,O
biosurfactant,O
.,O
Further,O
",",O
the,O
purified,O
glycolipid,O
biosurfactant,O
revealed,O
a,O
board,O
range,O
of,O
pH,O
and,O
temperature,O
stability,O
which,O
suggests,O
its,O
significance,O
for,O
possible,O
application,O
in,O
diverse,O
niche,O
areas,O
.,O
Moreover,O
",",O
the,O
excellent,O
antibacterial,O
and,O
antifungal,O
activities,O
of,O
this,O
biosurfactant,O
against,O
a,O
board,O
spectrum,O
of,O
clinical,O
human,B-OG
pathogens,O
evidenced,O
its,O
importance,O
in,O
the,O
field,O
of,O
therapeutics,O
.,O
Taking,O
all,O
together,O
",",O
the,O
isolated,O
new,O
glycolipid,O
biosurfactant,O
from,O
this,O
marine,O
strain,O
exhibited,O
dual,O
functions,O
as,O
a,O
surface,O
-,O
active,O
and,O
antimicrobial,O
agent,O
which,O
qualifies,O
it,O
as,O
a,O
promising,O
candidate,O
for,O
possible,O
use,O
in,O
biomedical,O
applications,O
.,O
The,O
use,O
of,O
reproductive,O
healthcare,O
at,O
commune,O
health,O
stations,O
in,O
a,O
changing,O
health,O
system,O
in,O
Vietnam,O
Background,O
With,O
health,O
sector,O
reform,O
in,O
Vietnam,O
moving,O
towards,O
greater,O
pluralism,O
",",O
commune,O
health,O
stations,O
(,O
CHSs,O
),O
have,O
been,O
subject,O
to,O
growing,O
competition,O
from,O
private,O
health,O
services,O
and,O
increasing,O
numbers,O
of,O
patients,O
bypassing,O
CHSs,O
for,O
higher,O
-,O
level,O
health,O
facilities,O
.,O
This,O
study,O
describes,O
the,O
pattern,O
of,O
reproductive,O
health,O
(,O
RH,O
),O
and,O
family,O
planning,O
(,O
FP,O
),O
service,O
utilization,O
among,O
women,O
at,O
CHSs,O
and,O
other,O
health,O
facilities,O
",",O
and,O
explores,O
socio,O
-,O
demographic,O
determinants,O
of,O
RH,O
service,O
utilization,O
at,O
the,O
CHS,O
level,O
.,O
Methods,O
This,O
study,O
was,O
based,O
on,O
a,O
cross,O
-,O
sectional,O
survey,O
conducted,O
in,O
Thua,O
Thien,O
Hue,O
and,O
Vinh,O
Long,O
provinces,O
",",O
using,O
a,O
multi,O
-,O
stage,O
cluster,O
sampling,O
technique,O
.,O
Questionnaire,O
-,O
based,O
interviews,O
with,O
978,O
ever,O
-,O
married,O
women,O
at,O
reproductive,O
age,O
provided,O
data,O
on,O
socio,O
-,O
demographic,O
characteristics,O
",",O
current,O
use,O
of,O
FP,O
methods,O
",",O
history,O
of,O
RH,O
service,O
use,O
",",O
and,O
the,O
health,O
facility,O
attended,O
for,O
their,O
most,O
recent,O
services,O
.,O
Multiple,O
logistic,O
regression,O
analyses,O
were,O
used,O
to,O
identify,O
socio,O
-,O
demographic,O
determinants,O
of,O
their,O
use,O
of,O
CHS,O
RH,O
services,O
.,O
Results,O
Eighty,O
nine,O
percent,O
of,O
ever,O
-,O
married,O
women,O
reported,O
current,O
use,O
of,O
birth,O
control,O
with,O
49,O
%,O
choosing,O
intra,O
-,O
uterine,O
device,O
(,O
IUD,O
).,O
Eighty,O
nine,O
percent,O
of,O
pregnant,O
women,O
attended,O
facility,O
-,O
based,O
antenatal,O
care,O
(,O
ANC,O
),O
with,O
62,O
%,O
having,O
at,O
least,O
3,O
check,O
-,O
ups,O
during,O
their,O
latest,O
pregnancy,O
.,O
Ninety,O
one,O
percent,O
of,O
mothers,O
had,O
their,O
last,O
delivery,O
in,O
a,O
health,O
facility,O
.,O
Seventy,O
-,O
one,O
percent,O
of,O
respondents,O
used,O
CHS,O
for,O
IUD,O
insertion,O
",",O
55,O
%,O
for,O
antenatal,O
check,O
-,O
ups,O
",",O
and,O
77,O
%,O
gynecological,O
examination,O
.,O
District,O
and,O
provincial,O
/,O
central,O
hospitals,O
dominated,O
the,O
provision,O
of,O
delivery,O
service,O
",",O
used,O
by,O
57,O
%,O
of,O
mothers,O
for,O
their,O
latest,O
delivery,O
.,O
The,O
percentage,O
of,O
women,O
opting,O
for,O
private,O
ANC,O
services,O
was,O
reported,O
at,O
35,O
"%,",O
though,O
the,O
use,O
of,O
private,O
delivery,O
services,O
was,O
low,O
(,O
11,O
%).,O
Women,O
who,O
were,O
farmers,O
",",O
earning,O
a,O
lower,O
income,O
",",O
having,O
more,O
than,O
2,O
children,O
",",O
and,O
living,O
in,O
a,O
rural,O
area,O
were,O
more,O
likely,O
than,O
others,O
to,O
use,O
ANC,O
",",O
delivery,O
",",O
and,O
/,O
or,O
gynecological,O
check,O
-,O
up,O
services,O
at,O
the,O
CHS,O
.,O
Conclusions,O
Women,O
choice,O
of,O
providers,O
for,O
FP,O
and,O
RH,O
services,O
that,O
help,O
them,O
plan,O
and,O
protect,O
their,O
pregnancies,O
is,O
driven,O
by,O
socio,O
-,O
economic,O
factors,O
.,O
While,O
the,O
CHS,O
retains,O
significant,O
utilization,O
rates,O
",",O
it,O
is,O
under,O
challenge,O
by,O
preferences,O
for,O
hospital,O
-,O
based,O
delivery,O
and,O
the,O
growing,O
use,O
of,O
private,O
ANC,O
services,O
.,O
Background,O
With,O
the,O
introduction,O
of,O
its,O
"""",O
Doi,O
Moi,O
"""",O
or,O
',O
renovation,O
',O
policy,O
in,O
1986,O
",",O
Vietnam,O
has,O
shifted,O
from,O
a,O
centrally,O
planned,O
towards,O
a,O
market,O
-,O
oriented,O
economy,O
.,O
Health,O
sector,O
reform,O
has,O
introduced,O
user,O
fees,O
in,O
public,O
hospitals,O
and,O
legalized,O
private,O
practice,O
.,O
In,O
urban,O
centers,O
in,O
particular,O
",",O
the,O
private,O
health,O
sector,O
has,O
been,O
growing,O
rapidly,O
",",O
and,O
increasingly,O
is,O
in,O
competition,O
with,O
the,O
public,O
sector,O
in,O
providing,O
health,O
services,O
.,O
These,O
changes,O
have,O
produced,O
profound,O
effects,O
on,O
the,O
use,O
of,O
health,O
services,O
at,O
state,O
health,O
facilities,O
",",O
including,O
RH,O
care,O
at,O
the,O
local,O
CHS,O
-,O
the,O
basic,O
unit,O
of,O
the,O
primary,O
healthcare,O
system,O
in,O
Vietnam,O
[,O
1,O
",",O
2,O
].,O
To,O
date,O
",",O
no,O
study,O
has,O
examined,O
the,O
use,O
of,O
FP,O
and,O
primary,O
RH,O
services,O
in,O
the,O
context,O
of,O
the,O
current,O
healthcare,O
system,O
in,O
Vietnam,O
",",O
as,O
it,O
shifts,O
from,O
a,O
state,O
monopoly,O
to,O
a,O
more,O
pluralist,O
system,O
.,O
To,O
address,O
this,O
shortcoming,O
",",O
this,O
study,O
aims,O
to,O
describe,O
the,O
pattern,O
of,O
FP,O
and,O
RH,O
service,O
utilization,O
among,O
women,O
at,O
the,O
CHS,O
and,O
other,O
state,O
and,O
private,O
facilities,O
",",O
and,O
to,O
explore,O
socio,O
-,O
demographic,O
determinants,O
of,O
RH,O
service,O
utilization,O
at,O
the,O
CHS,O
level,O
.,O
It,O
is,O
intended,O
to,O
inform,O
policy,O
and,O
program,O
reviews,O
that,O
will,O
strengthen,O
the,O
CHS,O
primary,O
RH,O
network,O
in,O
the,O
changing,O
health,O
system,O
of,O
Vietnam,O
.,O
The,O
state,O
health,O
system,O
in,O
Vietnam,O
consists,O
of,O
4,O
levels,O
:,O
the,O
national,O
level,O
with,O
the,O
Ministry,O
of,O
Health,O
and,O
central,O
hospitals,O
;,O
the,O
provincial,O
level,O
with,O
the,O
Provincial,O
Department,O
of,O
Health,O
and,O
provincial,O
hospitals,O
;,O
the,O
district,O
level,O
with,O
district,O
health,O
centers,O
and,O
district,O
hospitals,O
;,O
and,O
the,O
communal,O
level,O
with,O
CHSs,O
.,O
RH,O
and,O
FP,O
services,O
are,O
available,O
at,O
all,O
-,O
level,O
state,O
health,O
facilities,O
:,O
central,O
",",O
provincial,O
",",O
district,O
hospitals,O
and,O
CHSs,O
.,O
Despite,O
the,O
changes,O
in,O
the,O
health,O
sector,O
",",O
the,O
CHS,O
retains,O
its,O
responsibilities,O
as,O
the,O
primary,O
access,O
point,O
to,O
primary,O
RH,O
and,O
FP,O
services,O
subsidized,O
by,O
the,O
state,O
budget,O
",",O
and,O
is,O
required,O
to,O
meet,O
government,O
numerical,O
targets,O
on,O
basic,O
RH,O
and,O
FP,O
service,O
use,O
indicators,O
.,O
Every,O
CHS,O
is,O
staffed,O
by,O
at,O
least,O
one,O
midwife,O
who,O
acts,O
as,O
the,O
focal,O
point,O
for,O
RH,O
services,O
",",O
including,O
antenatal,O
and,O
post,O
-,O
natal,O
care,O
",",O
delivery,O
",",O
gynecological,O
examination,O
and,O
treatment,O
",",O
and,O
FP,O
services,O
such,O
as,O
IUD,O
",",O
oral,O
contraceptives,O
",",O
and,O
condoms,O
.,O
Some,O
CHSs,O
located,O
close,O
to,O
a,O
hospital,O
are,O
restricted,O
from,O
providing,O
delivery,O
services,O
.,O
Local,O
residents,O
are,O
entitled,O
to,O
free,O
services,O
at,O
their,O
local,O
CHS,O
but,O
not,O
at,O
the,O
CHS,O
in,O
other,O
communes,O
.,O
In,O
addition,O
to,O
everyday,O
RH,O
services,O
",",O
CHSs,O
are,O
entrusted,O
with,O
responsibilities,O
to,O
register,O
and,O
manage,O
all,O
pregnant,O
women,O
in,O
the,O
commune,O
",",O
conducting,O
1,O
-,O
day,O
monthly,O
antenatal,O
check,O
-,O
ups,O
.,O
There,O
are,O
also,O
3,O
-,O
day,O
semi,O
-,O
annual,O
RH,O
campaigns,O
based,O
at,O
the,O
CHS,O
with,O
assistance,O
of,O
midwifes,O
or,O
doctors,O
from,O
the,O
district,O
hospital,O
.,O
The,O
primary,O
purpose,O
of,O
these,O
campaigns,O
is,O
early,O
detection,O
and,O
treatment,O
of,O
reproductive,B-DS
tract,I-DS
infections,I-DS
(,O
RTIs,B-DS
),O
including,O
sexually,B-DS
transmitted,I-DS
infections,I-DS
",",O
based,O
on,O
clinical,O
examination,O
[,O
3,O
].,O
Since,O
the,O
restructuring,O
of,O
the,O
national,O
population,O
program,O
",",O
there,O
is,O
a,O
network,O
of,O
population,O
collaborators,O
affiliated,O
with,O
the,O
local,O
CHS,O
",",O
who,O
have,O
basic,O
training,O
in,O
RH,O
health,O
education,O
and,O
services,O
.,O
Population,O
collaborators,O
conduct,O
regular,O
outreach,O
communication,O
activities,O
",",O
providing,O
RH,O
counseling,O
and,O
contraceptives,O
(,O
e,O
.,O
g,O
.,O
condoms,O
",",O
pills,O
"),",O
and,O
referring,O
couples,O
to,O
the,O
CHS,O
for,O
further,O
FP,O
and,O
RH,O
services,O
such,O
as,O
IUD,O
insertion,O
",",O
gynecological,O
and,O
antenatal,O
check,O
-,O
ups,O
[,O
4,O
].,O
Private,O
healthcare,O
services,O
in,O
Vietnam,O
comprise,O
three,O
differing,O
service,O
structures,O
[,O
5,O
",",O
6,O
].,O
Private,O
hospital,O
care,O
is,O
principally,O
located,O
in,O
major,O
cities,O
.,O
Compared,O
to,O
state,O
hospitals,O
",",O
they,O
have,O
a,O
reputation,O
for,O
their,O
access,O
to,O
more,O
advanced,O
diagnostic,O
and,O
therapeutic,O
technology,O
",",O
and,O
their,O
capacity,O
to,O
provide,O
technically,O
demanding,O
services,O
.,O
Private,O
outpatient,O
clinics,O
are,O
operated,O
by,O
individuals,O
or,O
groups,O
of,O
full,O
-,O
or,O
part,O
-,O
time,O
physicians,O
in,O
urban,O
",",O
sub,O
-,O
urban,O
and,O
rural,O
areas,O
",",O
under,O
a,O
license,O
from,O
provincial,O
health,O
authorities,O
.,O
They,O
largely,O
provide,O
general,O
or,O
specialized,O
health,O
services,O
for,O
middle,O
income,O
patients,O
.,O
Third,O
",",O
"""",O
mobile,O
"""",O
private,O
practitioners,O
--,O
who,O
can,O
be,O
nurses,O
",",O
assistant,O
doctors,O
",",O
or,O
retired,O
doctors,O
--,O
are,O
commonly,O
present,O
in,O
rural,O
areas,O
",",O
providing,O
health,O
services,O
from,O
their,O
own,O
homes,O
without,O
a,O
license,O
.,O
These,O
health,O
practitioners,O
are,O
not,O
included,O
as,O
part,O
of,O
the,O
formal,O
health,O
system,O
",",O
although,O
they,O
play,O
an,O
important,O
role,O
in,O
providing,O
basic,O
health,O
services,O
[,O
6,O
].,O
For,O
RH,O
services,O
at,O
the,O
commune,O
level,O
",",O
private,O
providers,O
include,O
doctors,O
or,O
practitioners,O
(,O
e,O
.,O
g,O
.,O
midwives,O
",",O
assistant,O
doctors,O
"),",O
and,O
traditional,O
birth,O
attendants,O
",",O
who,O
provide,O
home,O
-,O
based,O
delivery,O
services,O
[,O
7,O
",",O
8,O
].,O
In,O
addition,O
",",O
local,O
pharmacies,O
can,O
offer,O
the,O
commercial,O
sale,O
of,O
birth,O
control,O
commodities,O
such,O
as,O
oral,O
contraceptives,O
",",O
without,O
prescription,O
.,O
With,O
the,O
reduction,O
in,O
government,O
subsidies,O
for,O
CHS,O
facilities,O
",",O
equipment,O
",",O
and,O
human,B-OG
resources,O
development,O
",",O
the,O
quality,O
of,O
health,O
services,O
at,O
CHSs,O
has,O
been,O
perceived,O
as,O
deteriorating,O
and,O
is,O
associated,O
with,O
less,O
-,O
qualified,O
health,O
staff,O
",",O
outdated,O
equipment,O
",",O
limited,O
drugs,O
and,O
supplies,O
[,O
2,O
].,O
At,O
the,O
same,O
time,O
",",O
the,O
private,O
sector,O
has,O
been,O
increasingly,O
popular,O
and,O
is,O
associated,O
with,O
convenient,O
opening,O
hours,O
",",O
more,O
competent,O
staff,O
",",O
better,O
equipment,O
",",O
and,O
effective,O
drug,O
prescriptions,O
[,O
9,O
].,O
Reports,O
suggest,O
that,O
increasingly,O
",",O
patients,O
are,O
seeking,O
care,O
at,O
private,O
clinics,O
or,O
bypassing,O
their,O
local,O
CHS,O
for,O
higher,O
level,O
health,O
facilities,O
",",O
willing,O
to,O
pay,O
higher,O
fees,O
based,O
on,O
their,O
perceptions,O
of,O
better,O
quality,O
and,O
enhanced,O
technology,O
[,O
1,O
",",O
2,O
",",O
10,O
",",O
11,O
].,O
The,O
Study,O
Sites,O
This,O
study,O
is,O
part,O
of,O
the,O
baseline,O
assessment,O
of,O
a,O
project,O
supported,O
by,O
Marie,O
Stopes,O
International,O
Vietnam,O
",",O
that,O
aims,O
to,O
create,O
public,O
-,O
private,O
partnerships,O
to,O
improve,O
access,O
to,O
services,O
and,O
the,O
quality,O
of,O
primary,O
RH,O
care,O
",",O
in,O
two,O
provinces,O
",",O
Thua,O
Thien,O
Hue,O
and,O
Vinh,O
Long,O
",",O
in,O
Vietnam,O
.,O
Thua,O
Thien,O
Hue,O
is,O
located,O
in,O
the,O
center,O
of,O
Viet,O
Nam,O
with,O
a,O
total,O
population,O
of,O
1,O
",",O
143,O
",",O
500,O
",",O
of,O
which,O
284,O
",",O
149,O
women,O
are,O
at,O
reproductive,O
age,O
(,O
15,O
-,O
49,O
).,O
The,O
province,O
has,O
1,O
central,O
hospital,O
",",O
9,O
district,O
hospitals,O
",",O
and,O
152,O
CHSs,O
located,O
in,O
urban,O
",",O
semi,O
-,O
urban,O
",",O
rural,O
",",O
and,O
mountainous,O
areas,O
.,O
Based,O
in,O
the,O
Mekong,O
delta,O
region,O
",",O
Vinh,O
Long,O
province,O
has,O
a,O
population,O
of,O
1,O
",",O
057,O
",",O
000,O
.,O
The,O
state,O
health,O
care,O
network,O
consists,O
of,O
107,O
CHSs,O
",",O
8,O
district,O
hospitals,O
",",O
and,O
1,O
provincial,O
hospital,O
.,O
People,O
in,O
districts,O
bordering,O
with,O
Can,O
Tho,O
city,O
may,O
seek,O
RH,O
services,O
at,O
the,O
Can,O
Tho,O
central,O
hospital,O
.,O
Almost,O
all,O
CHSs,O
in,O
the,O
2,O
provinces,O
are,O
staffed,O
by,O
a,O
doctor,O
[,O
4,O
].,O
Studies,O
sites,O
included,O
1,O
urban,O
district,O
(,O
Hue,O
city,O
"),",O
2,O
rural,O
districts,O
of,O
Thua,O
Thien,O
Hue,O
",",O
and,O
3,O
rural,O
districts,O
of,O
Vinh,O
Long,O
.,O
As,O
these,O
districts,O
received,O
no,O
external,O
support,O
for,O
primary,O
RH,O
care,O
",",O
they,O
can,O
be,O
considered,O
to,O
represent,O
the,O
baseline,O
for,O
state,O
provided,O
RH,O
services,O
.,O
In,O
each,O
of,O
these,O
districts,O
",",O
the,O
state,O
primary,O
healthcare,O
network,O
was,O
well,O
-,O
established,O
",",O
with,O
each,O
commune,O
having,O
a,O
CHS,O
and,O
a,O
team,O
of,O
population,O
collaborators,O
.,O
In,O
contrast,O
",",O
RH,O
private,O
clinics,O
were,O
mostly,O
concentrated,O
in,O
urban,O
areas,O
",",O
and,O
were,O
often,O
run,O
by,O
a,O
gynecologist,O
working,O
in,O
a,O
major,O
hospital,O
.,O
Only,O
3,O
out,O
of,O
5,O
rural,O
districts,O
had,O
a,O
gynecologist,O
working,O
in,O
the,O
district,O
hospital,O
and,O
2,O
rural,O
districts,O
in,O
Vinh,O
Long,O
had,O
an,O
accredited,O
private,O
RH,O
clinic,O
(,O
i,O
.,O
e,O
.,O
with,O
a,O
license,O
from,O
provincial,O
health,O
authorities,O
),O
operated,O
by,O
this,O
specialist,O
[,O
12,O
].,O
Methods,O
The,O
study,O
was,O
a,O
cross,O
-,O
sectional,O
survey,O
",",O
using,O
a,O
multi,O
-,O
stage,O
cluster,O
sampling,O
design,O
to,O
recruit,O
participants,O
.,O
The,O
first,O
stage,O
selected,O
5,O
communes,O
from,O
each,O
of,O
the,O
selected,O
districts,O
",",O
using,O
proportional,O
to,O
population,O
size,O
techniques,O
",",O
totaling,O
30,O
communes,O
in,O
the,O
2,O
provinces,O
.,O
The,O
second,O
stage,O
involved,O
the,O
random,O
selection,O
of,O
1,O
village,O
or,O
residential,O
group,O
in,O
each,O
commune,O
where,O
30,O
households,O
were,O
randomly,O
drawn,O
for,O
interviews,O
of,O
all,O
women,O
at,O
reproductive,O
age,O
(,O
15,O
-,O
49,O
).,O
In,O
total,O
",",O
900,O
households,O
with,O
1,O
417,O
women,O
were,O
included,O
in,O
this,O
study,O
.,O
Data,O
was,O
collected,O
using,O
questionnaire,O
-,O
based,O
interviews,O
",",O
consisting,O
of,O
mutiple,O
-,O
choice,O
questions,O
on,O
respondents,O
',O
socio,O
-,O
demographic,O
characteristics,O
(,O
e,O
.,O
g,O
.,O
age,O
",",O
marital,O
status,O
",",O
occupation,O
",",O
education,O
",",O
number,O
of,O
living,O
children,O
",",O
income,O
"),",O
their,O
RH,O
and,O
FP,O
service,O
use,O
(,O
see,O
Additional,O
File,O
1,O
).,O
Women,O
were,O
also,O
asked,O
about,O
the,O
health,O
facility,O
where,O
they,O
attended,O
antenatal,O
care,O
during,O
their,O
last,O
pregnancy,O
or,O
received,O
their,O
most,O
recent,O
gynecological,O
examination,O
",",O
and,O
the,O
place,O
where,O
they,O
had,O
their,O
latest,O
delivery,O
.,O
These,O
three,O
RH,O
services,O
were,O
considered,O
to,O
constitute,O
basic,O
RH,O
healthcare,O
provided,O
at,O
the,O
local,O
CHS,O
or,O
other,O
state,O
health,O
facilities,O
in,O
Vietnam,O
.,O
Women,O
were,O
interviewed,O
at,O
home,O
by,O
a,O
trained,O
interviewer,O
who,O
was,O
a,O
member,O
of,O
the,O
commune,O
Women,O
',O
s,O
Union,O
.,O
Data,O
collection,O
was,O
completed,O
from,O
April,O
to,O
May,O
",",O
2010,O
.,O
As,O
mentioned,O
earlier,O
",",O
the,O
research,O
was,O
undertaken,O
as,O
a,O
baseline,O
survey,O
",",O
commissioned,O
by,O
Marie,O
Stopes,O
International,O
Vietnam,O
for,O
planning,O
an,O
intervention,O
in,O
the,O
2,O
selected,O
provinces,O
.,O
Ethical,O
approval,O
was,O
given,O
by,O
the,O
Ethic,O
Committee,O
of,O
the,O
Thua,O
Thien,O
Hue,O
and,O
Vinh,O
Long,O
Provincial,O
Departments,O
of,O
Health,O
.,O
Data,O
were,O
entered,O
into,O
Epi,O
Info,O
",",O
then,O
transferred,O
to,O
STATA,O
version,O
9,O
.,O
0,O
for,O
processing,O
and,O
analyses,O
.,O
Ten,O
percent,O
of,O
questionnaires,O
were,O
double,O
entered,O
to,O
check,O
consistency,O
.,O
Data,O
analyses,O
consisted,O
of,O
two,O
sequential,O
steps,O
.,O
First,O
",",O
descriptive,O
analysis,O
was,O
performed,O
of,O
the,O
socio,O
-,O
demographic,O
characteristics,O
of,O
all,O
study,O
participants,O
and,O
the,O
frequency,O
distributions,O
of,O
variables,O
of,O
interest,O
",",O
including,O
the,O
current,O
use,O
of,O
FP,O
method,O
(,O
s,O
"),",O
history,O
of,O
ANC,O
",",O
delivery,O
",",O
and,O
gynecological,O
check,O
-,O
up,O
service,O
use,O
",",O
and,O
the,O
health,O
facility,O
where,O
women,O
attended,O
for,O
their,O
most,O
recent,O
service,O
.,O
Second,O
",",O
logistic,O
regression,O
analyses,O
were,O
performed,O
of,O
factors,O
related,O
to,O
the,O
use,O
of,O
the,O
following,O
services,O
in,O
the,O
local,O
CHS,O
:,O
(,O
i,O
),O
antenatal,O
check,O
ups,O
during,O
the,O
last,O
pregnancy,O
",",O
(,O
ii,O
),O
their,O
latest,O
delivery,O
",",O
and,O
(,O
iii,O
),O
their,O
most,O
recent,O
gynecological,O
examination,O
.,O
The,O
dependent,O
variable,O
was,O
based,O
on,O
whether,O
or,O
not,O
women,O
who,O
visited,O
a,O
health,O
facility,O
for,O
these,O
services,O
reported,O
selecting,O
their,O
local,O
CHS,O
.,O
Independent,O
variables,O
of,O
interests,O
included,O
:,O
women,O
',O
s,O
age,O
(,O
above,O
vs,O
.,O
below,O
the,O
median,O
"),",O
number,O
of,O
living,O
children,O
(,O
having,O
2,O
children,O
or,O
less,O
vs,O
.,O
3,O
children,O
or,O
more,O
"),",O
religion,O
(,O
Buddhist,O
",",O
Catholic,O
",",O
other,O
",",O
and,O
none,O
"),",O
ethnicity,O
(,O
majority,O
vs,O
.,O
minority,O
"),",O
occupation,O
(,O
farming,O
vs,O
.,O
other,O
"),",O
education,O
(,O
secondary,O
school,O
or,O
less,O
vs,O
.,O
high,O
school,O
or,O
more,O
"),",O
income,O
(,O
4,O
quartile,O
groups,O
"),",O
current,O
living,O
location,O
(,O
urban,O
vs,O
.,O
rural,O
"),",O
and,O
study,O
province,O
(,O
Vinh,O
Long,O
vs,O
.,O
Thua,O
Thien,O
Hue,O
).,O
The,O
statistical,O
model,O
for,O
the,O
use,O
of,O
CHS,O
delivery,O
services,O
excluded,O
those,O
who,O
required,O
a,O
cesarean,O
section,O
and,O
those,O
who,O
reported,O
that,O
delivery,O
service,O
was,O
unavailable,O
at,O
their,O
local,O
CHS,O
at,O
the,O
time,O
the,O
women,O
gave,O
birth,O
.,O
Each,O
socio,O
-,O
demographic,O
variable,O
was,O
analyzed,O
first,O
as,O
a,O
univariate,O
predictor,O
to,O
obtain,O
a,O
crude,O
odds,O
ratio,O
(,O
OR,O
),O
and,O
95,O
%,O
confidence,O
intervals,O
(,O
CI,O
).,O
Significantly,O
related,O
variables,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
were,O
subsequently,O
included,O
in,O
a,O
multivariate,O
analysis,O
to,O
obtain,O
an,O
adjusted,O
OR,O
and,O
95,O
%,O
CI,O
.,O
Only,O
factors,O
that,O
were,O
significantly,O
associated,O
with,O
the,O
outcome,O
variable,O
in,O
the,O
multi,O
-,O
variate,O
analytical,O
model,O
were,O
retained,O
in,O
the,O
final,O
reduced,O
model,O
.,O
Results,O
The,O
sample,O
consisted,O
of,O
678,O
women,O
(,O
48,O
%),O
in,O
Vinh,O
Long,O
and,O
739,O
women,O
(,O
52,O
%),O
in,O
Thua,O
Thien,O
Hue,O
.,O
Median,O
age,O
was,O
31,O
.,O
Sixty,O
-,O
six,O
percent,O
of,O
respondents,O
were,O
married,O
;,O
31,O
%,O
were,O
single,O
",",O
and,O
3,O
%,O
were,O
widowed,O
or,O
divorced,O
.,O
The,O
demographic,O
characteristics,O
of,O
respondents,O
are,O
presented,O
in,O
Table,O
1,O
.,O
Socio,O
-,O
demographic,O
characteristics,O
of,O
surveyed,O
respondents,O
(,O
n,O
=,O
1417,O
),O
Variable,O
n,O
%,O
Variable,O
n,O
%,O
Province,O
Vinh,O
Long,O
678,O
48,O
Religion,O
Thua,O
Thien,O
Hue,O
739,O
52,O
Buddhist,O
556,O
39,O
Age,O
Catholic,O
75,O
5,O
<,O
=,O
31,O
740,O
52,O
Other,O
58,O
4,O
>,O
31,O
677,O
48,O
,O
728,O
52,O
Marital,O
status,O
Occupation,O
Single,O
439,O
31,O
Farmer,O
570,O
40,O
Ever,O
-,O
married,O
978,O
69,O
Non,O
-,O
farming,O
job,O
847,O
60,O
Number,O
of,O
children,O
Location,O
of,O
living,O
,O
435,O
33,O
Urban,O
213,O
15,O
1,O
or,O
2,O
635,O
45,O
Rural,O
1204,O
85,O
>,O
2,O
307,O
32,O
Income,O
Education,O
1st,O
quartile,O
356,O
25,O
Secondary,O
school,O
or,O
less,O
960,O
68,O
2nd,O
quartile,O
416,O
29,O
High,O
school,O
or,O
more,O
457,O
32,O
3rd,O
quartile,O
296,O
21,O
4th,O
quartile,O
349,O
25,O
FP,O
service,O
use,O
Among,O
439,O
single,O
women,O
",",O
only,O
13,O
(,O
3,O
%),O
reported,O
having,O
a,O
current,O
sexual,O
partner,O
",",O
and,O
9,O
reported,O
current,O
use,O
of,O
a,O
birth,O
control,O
method,O
.,O
Given,O
these,O
small,O
numbers,O
",",O
analyses,O
of,O
FP,O
service,O
use,O
were,O
limited,O
to,O
ever,O
-,O
married,O
participants,O
(,O
n,O
=,O
978,O
).,O
The,O
rate,O
of,O
FP,O
service,O
use,O
among,O
ever,O
-,O
married,O
women,O
was,O
88,O
.,O
5,O
%,O
after,O
excluding,O
those,O
who,O
reported,O
not,O
using,O
a,O
birth,O
control,O
due,O
to,O
one,O
of,O
the,O
following,O
reasons,O
:,O
being,O
pregnant,O
",",O
having,O
just,O
given,O
birth,O
",",O
or,O
being,O
menopausal,O
.,O
IUD,O
appears,O
to,O
be,O
the,O
most,O
common,O
method,O
",",O
utilized,O
by,O
49,O
%,O
of,O
women,O
",",O
followed,O
by,O
condoms,O
(,O
16,O
"%),",O
oral,O
contraceptives,O
(,O
15,O
"%),",O
and,O
the,O
rhythm,O
method,O
(,O
14,O
%).,O
Male,O
or,O
female,O
sterilization,O
was,O
used,O
by,O
5,O
.,O
5,O
"%,",O
and,O
injected,O
contraceptives,O
by,O
3,O
.,O
8,O
%,O
of,O
married,O
women,O
.,O
The,O
sum,O
of,O
these,O
percentages,O
was,O
104,O
%,O
as,O
a,O
few,O
women,O
reported,O
concurrent,O
use,O
of,O
condoms,O
and,O
the,O
rhythm,O
method,O
.,O
Regarding,O
the,O
source,O
of,O
FP,O
services,O
",",O
71,O
%,O
of,O
the,O
464,O
women,O
using,O
IUDs,O
reported,O
visiting,O
the,O
local,O
CHS,O
",",O
with,O
19,O
%,O
selecting,O
district,O
hospitals,O
",",O
8,O
%,O
private,O
clinics,O
",",O
and,O
2,O
%,O
other,O
facilities,O
for,O
their,O
last,O
IUD,O
insertion,O
.,O
For,O
condoms,O
and,O
other,O
contraceptives,O
(,O
e,O
.,O
g,O
.,O
oral,O
",",O
injections,O
"),",O
the,O
CHS,O
appears,O
to,O
be,O
the,O
major,O
source,O
",",O
reported,O
by,O
61,O
%,O
women,O
",",O
followed,O
by,O
population,O
collaborators,O
(,O
37,O
"%),",O
and,O
then,O
pharmacies,O
(,O
18,O
%).,O
Only,O
5,O
%,O
of,O
women,O
had,O
obtained,O
these,O
birth,O
control,O
supplies,O
from,O
a,O
hospital,O
",",O
with,O
2,O
%,O
using,O
a,O
private,O
clinic,O
(,O
Table,O
2,O
).,O
The,O
total,O
percentage,O
of,O
123,O
%,O
reflects,O
the,O
availability,O
of,O
contraceptives,O
from,O
multiple,O
sources,O
.,O
Sources,O
of,O
FP,O
services,O
Health,O
facility,O
Last,O
IUD,O
insertion,O
(,O
n,O
=,O
464,O
),O
Condoms,O
/,O
other,O
contraceptives,O
n,O
%,O
n,O
%,O
CHS,O
329,O
71,O
.,O
0,O
345,O
60,O
.,O
8,O
Pop,O
.,O
Collaborators,O
,O
,O
208,O
36,O
.,O
7,O
Pharmacy,O
,O
,O
102,O
18,O
.,O
0,O
Dist,O
.,O
Hospital,O
86,O
18,O
.,O
5,O
24,O
4,O
.,O
2,O
Provincial,O
/,O
central,O
hospital,O
hospital,O
8,O
1,O
.,O
7,O
5,O
0,O
.,O
9,O
Private,O
clinics,O
37,O
8,O
.,O
0,O
11,O
1,O
.,O
9,O
Other,O
4,O
0,O
.,O
9,O
11,O
1,O
.,O
9,O
,O
:,O
Not,O
applicable,O
Antenatal,O
care,O
service,O
use,O
Of,O
964,O
women,O
who,O
had,O
ever,O
experienced,O
a,O
pregnancy,O
",",O
857,O
(,O
89,O
%),O
reported,O
having,O
facility,O
-,O
based,O
antenatal,O
care,O
with,O
62,O
%,O
having,O
at,O
least,O
3,O
check,O
-,O
ups,O
during,O
their,O
last,O
pregnancy,O
.,O
Among,O
these,O
857,O
women,O
",",O
more,O
than,O
half,O
(,O
55,O
%),O
used,O
the,O
CHS,O
",",O
35,O
%,O
private,O
clinics,O
",",O
and,O
31,O
%,O
the,O
district,O
hospital,O
.,O
Approximately,O
10,O
%,O
of,O
women,O
went,O
to,O
the,O
provincial,O
or,O
central,O
hospital,O
for,O
this,O
service,O
.,O
The,O
total,O
percentage,O
was,O
greater,O
than,O
100,O
"%,",O
as,O
women,O
may,O
visit,O
multiple,O
health,O
facilities,O
during,O
the,O
gestational,O
period,O
(,O
Table,O
3,O
).,O
The,O
use,O
of,O
antenatal,O
check,O
-,O
up,O
and,O
delivery,O
service,O
by,O
health,O
facility,O
Health,O
Facility,O
Antenatal,O
check,O
-,O
up,O
(,O
n,O
=,O
857,O
),O
Delivery,O
(,O
n,O
=,O
942,O
),O
Gyn,O
.,O
examination,O
(,O
n,O
=,O
759,O
),O
n,O
%,O
n,O
%,O
n,O
%,O
CHS,O
473,O
55,O
.,O
2,O
181,O
19,O
.,O
2,O
585,O
77,O
.,O
1,O
Dist,O
.,O
hospital,O
269,O
31,O
.,O
4,O
351,O
37,O
.,O
3,O
62,O
8,O
.,O
2,O
Prov,O
./,O
Cent,O
.,O
hospital,O
84,O
9,O
.,O
8,O
188,O
20,O
.,O
0,O
24,O
3,O
.,O
2,O
Private,O
clinic,O
303,O
35,O
.,O
4,O
106,O
11,O
.,O
3,O
80,O
10,O
.,O
5,O
Home,O
,O
,O
66,O
7,O
.,O
0,O
,O
,O
Self,O
-,O
delivery,O
,O
,O
22,O
2,O
.,O
2,O
,O
,O
Other,O
6,O
0,O
.,O
7,O
28,O
3,O
.,O
0,O
8,O
1,O
.,O
0,O
,O
:,O
Not,O
applicable,O
Analyses,O
of,O
data,O
by,O
provinces,O
found,O
that,O
in,O
Thua,O
Thien,O
Hue,O
",",O
the,O
local,O
CHS,O
was,O
the,O
most,O
favorable,O
service,O
provider,O
in,O
rural,O
districts,O
",",O
attracting,O
76,O
%,O
of,O
women,O
",",O
compared,O
to,O
district,O
hospitals,O
(,O
34,O
"%),",O
and,O
private,O
clinics,O
(,O
15,O
%).,O
In,O
the,O
city,O
",",O
private,O
clinics,O
ranked,O
first,O
",",O
visited,O
by,O
50,O
%,O
of,O
women,O
",",O
with,O
the,O
local,O
CHS,O
and,O
district,O
hospital,O
each,O
reporting,O
access,O
by,O
32,O
%,O
of,O
women,O
.,O
In,O
both,O
settings,O
",",O
around,O
5,O
%,O
of,O
women,O
reported,O
visiting,O
Hue,O
central,O
hospital,O
for,O
ANC,O
services,O
during,O
their,O
last,O
pregnancy,O
(,O
Figure,O
1,O
).,O
In,O
Vinh,O
Long,O
where,O
the,O
survey,O
only,O
included,O
rural,O
communes,O
",",O
an,O
almost,O
equal,O
proportion,O
of,O
women,O
(,O
47,O
%,O
and,O
46,O
%),O
reported,O
using,O
CHSs,O
and,O
private,O
clinics,O
",",O
with,O
29,O
%,O
visiting,O
the,O
district,O
hospital,O
",",O
and,O
15,O
%,O
going,O
to,O
the,O
provincial,O
or,O
central,O
hospital,O
for,O
ANC,O
services,O
(,O
Figure,O
2,O
).,O
Health,O
facility,O
visited,O
for,O
antenatal,O
check,O
-,O
ups,O
at,O
the,O
latest,O
pregnancy,O
in,O
Thua,O
Thien,O
Hue,O
(,O
n,O
=,O
402,O
).,O
Health,O
facility,O
visited,O
for,O
antenatal,O
check,O
-,O
ups,O
at,O
the,O
latest,O
pregnancy,O
in,O
Vinh,O
Long,O
(,O
n,O
=,O
455,O
).,O
Delivery,O
service,O
use,O
Of,O
942,O
women,O
who,O
reported,O
a,O
delivery,O
",",O
854,O
(,O
91,O
%),O
had,O
their,O
latest,O
delivery,O
in,O
a,O
health,O
facility,O
.,O
The,O
district,O
hospital,O
was,O
selected,O
by,O
the,O
highest,O
proportion,O
of,O
women,O
(,O
37,O
"%),",O
followed,O
by,O
provincial,O
or,O
central,O
hospitals,O
(,O
20,O
"%),",O
then,O
CHS,O
(,O
19,O
"%),",O
and,O
private,O
providers,O
(,O
11,O
%).,O
Only,O
7,O
%,O
of,O
women,O
had,O
home,O
-,O
based,O
delivery,O
with,O
a,O
birth,O
attendant,O
and,O
2,O
%,O
practised,O
self,O
-,O
delivery,O
(,O
Table,O
3,O
).,O
Gynecological,O
check,O
-,O
up,O
service,O
use,O
Sixty,O
four,O
percent,O
of,O
surveyed,O
women,O
(,O
n,O
=,O
759,O
),O
reported,O
having,O
undertaken,O
gynecological,O
check,O
-,O
ups,O
.,O
During,O
the,O
most,O
recent,O
check,O
-,O
up,O
",",O
the,O
highest,O
percentage,O
(,O
77,O
%),O
visited,O
the,O
local,O
CHS,O
",",O
11,O
%,O
opted,O
for,O
private,O
clinics,O
",",O
8,O
%,O
went,O
to,O
the,O
district,O
hospital,O
.,O
Only,O
3,O
%,O
went,O
to,O
the,O
provincial,O
/,O
central,O
hospital,O
for,O
this,O
service,O
(,O
Table,O
3,O
).,O
Socio,O
-,O
demographic,O
determinants,O
of,O
RH,O
service,O
use,O
at,O
the,O
local,O
CHS,O
Table,O
4,O
presents,O
the,O
results,O
of,O
the,O
logistic,O
regression,O
analyses,O
.,O
The,O
analyses,O
found,O
that,O
the,O
CHS,O
antenatal,O
check,O
-,O
up,O
and,O
gynecological,O
examination,O
services,O
were,O
both,O
strongly,O
related,O
to,O
number,O
of,O
children,O
(<,O
=,O
2,O
vs,O
.,O
>,O
2,O
"),",O
religion,O
(,O
Buddhist,O
vs,O
.,O
each,O
of,O
other,O
groups,O
:,O
Catholic,O
",",O
non,O
-,O
Buddhist,O
and,O
non,O
-,O
Catholic,O
",",O
and,O
non,O
-,O
religious,O
affiliation,O
"),",O
occupation,O
(,O
farmers,O
vs,O
.,O
other,O
groups,O
:,O
government,O
cadres,O
",",O
factory,O
workers,O
",",O
small,O
traders,O
",",O
and,O
students,O
"),",O
and,O
self,O
-,O
reported,O
income,O
(,O
first,O
quartile,O
vs,O
.,O
each,O
of,O
other,O
3,O
quartiles,O
).,O
Women,O
with,O
more,O
than,O
2,O
children,O
",",O
having,O
a,O
non,O
-,O
Buddhist,O
/,O
non,O
-,O
religious,O
affiliation,O
",",O
or,O
living,O
in,O
Thua,O
Thien,O
Hue,O
(,O
compared,O
to,O
Vinh,O
Long,O
),O
were,O
more,O
likely,O
than,O
others,O
to,O
attend,O
antenatal,O
check,O
-,O
ups,O
during,O
their,O
latest,O
pregnancy,O
",",O
or,O
to,O
have,O
their,O
most,O
recent,O
gynecological,O
examination,O
at,O
their,O
local,O
CHS,O
.,O
Women,O
with,O
a,O
non,O
-,O
farming,O
occupation,O
or,O
earning,O
a,O
higher,O
income,O
were,O
less,O
likely,O
than,O
others,O
to,O
visit,O
their,O
local,O
CHS,O
for,O
these,O
two,O
services,O
.,O
Regarding,O
delivery,O
service,O
use,O
",",O
mothers,O
of,O
minority,O
ethnic,O
groups,O
were,O
more,O
likely,O
than,O
those,O
of,O
the,O
majority,O
ethnic,O
group,O
to,O
have,O
their,O
latest,O
delivery,O
at,O
the,O
local,O
CHS,O
",",O
which,O
was,O
also,O
true,O
for,O
non,O
-,O
Buddhist,O
/,O
non,O
-,O
religious,O
mothers,O
compared,O
with,O
Buddhist,O
mothers,O
.,O
Women,O
from,O
non,O
-,O
farming,O
occupations,O
",",O
or,O
earning,O
a,O
higher,O
income,O
",",O
were,O
less,O
likely,O
to,O
choose,O
CHS,O
-,O
based,O
delivery,O
.,O
It,O
is,O
noted,O
that,O
the,O
use,O
of,O
CHS,O
antenatal,O
check,O
-,O
up,O
service,O
was,O
significantly,O
related,O
to,O
living,O
location,O
",",O
with,O
rural,O
women,O
more,O
likely,O
than,O
their,O
urban,O
counterparts,O
to,O
use,O
this,O
CHS,O
service,O
.,O
,O
of,O
women,O
in,O
the,O
city,O
reported,O
having,O
their,O
latest,O
delivery,O
at,O
the,O
CHS,O
.,O
Factors,O
related,O
to,O
the,O
use,O
of,O
RH,O
services,O
available,O
at,O
the,O
local,O
CHS,O
(,O
Reduced,O
logistic,O
regression,O
model,O
),O
Factors,O
Category,O
OR,O
(,O
95,O
%,O
CI,O
),O
Antenatal,O
check,O
-,O
up,O
(,O
n,O
=,O
835,O
),O
Delivery,O
(,O
n,O
=,O
577,O
),O
Gynecological,O
check,O
-,O
up,O
(,O
n,O
=,O
718,O
),O
Children,O
<,O
=,O
2,O
Ref,O
Ref,O
Ref,O
>,O
2,O
1,O
.,O
61,O
(,O
1,O
.,O
13,O
-,O
2,O
.,O
31,O
),O
NS,O
1,O
.,O
62,O
(,O
1,O
.,O
01,O
-,O
2,O
.,O
06,O
),O
Religion,O
Buddhist,O
Ref,O
Ref,O
Ref,O
Catholic,O
2,O
.,O
91,O
(,O
1,O
.,O
36,O
-,O
6,O
.,O
25,O
),O
3,O
.,O
05,O
(,O
1,O
.,O
49,O
-,O
6,O
.,O
26,O
),O
3,O
.,O
19,O
(,O
1,O
.,O
04,O
-,O
9,O
.,O
85,O
),O
Other,O
3,O
.,O
10,O
(,O
1,O
.,O
39,O
-,O
6,O
.,O
90,O
),O
2,O
.,O
85,O
(,O
1,O
.,O
16,O
-,O
7,O
.,O
01,O
),O
7,O
.,O
91,O
(,O
2,O
.,O
24,O
-,O
27,O
.,O
97,O
),O
,O
2,O
.,O
01,O
(,O
1,O
.,O
38,O
-,O
2,O
.,O
92,O
),O
2,O
.,O
17,O
(,O
1,O
.,O
39,O
-,O
3,O
.,O
38,O
),O
3,O
.,O
60,O
(,O
2,O
.,O
36,O
-,O
5,O
.,O
49,O
),O
Ethnicity,O
Majority,O
Ref,O
Ref,O
Ref,O
Minority,O
NS,O
2,O
.,O
20,O
(,O
1,O
.,O
32,O
-,O
3,O
.,O
69,O
),O
NS,O
Occupation,O
Farming,O
Ref,O
Ref,O
Ref,O
Non,O
-,O
farming,O
0,O
.,O
64,O
(,O
0,O
.,O
45,O
-,O
0,O
.,O
90,O
),O
0,O
.,O
22,O
(,O
0,O
.,O
15,O
-,O
033,O
),O
0,O
.,O
72,O
(,O
0,O
.,O
57,O
-,O
0,O
.,O
91,O
),O
Living,O
location,O
Urban,O
Ref,O
Ref,O
Ref,O
Rural,O
2,O
.,O
79,O
(,O
1,O
.,O
59,O
-,O
4,O
.,O
91,O
),O
ND,O
NS,O
Province,O
Vinh,O
Long,O
Ref,O
Ref,O
Ref,O
Thua,O
Thien,O
Hue,O
2,O
.,O
83,O
(,O
1,O
.,O
88,O
-,O
4,O
.,O
26,O
),O
NS,O
3,O
.,O
33,O
(,O
2,O
.,O
11,O
-,O
5,O
.,O
26,O
),O
Income,O
1st,O
quartile,O
Ref,O
Ref,O
Ref,O
2nd,O
quartile,O
0,O
.,O
79,O
(,O
0,O
.,O
53,O
-,O
1,O
.,O
17,O
),O
0,O
.,O
73,O
(,O
0,O
.,O
47,O
-,O
1,O
.,O
13,O
),O
0,O
.,O
41,O
(,O
0,O
.,O
24,O
-,O
0,O
.,O
71,O
),O
3rd,O
quartile,O
0,O
.,O
52,O
(,O
0,O
.,O
33,O
-,O
0,O
.,O
83,O
),O
0,O
.,O
57,O
(,O
0,O
.,O
34,O
-,O
0,O
.,O
97,O
),O
0,O
.,O
40,O
(,O
0,O
.,O
22,O
-,O
0,O
.,O
75,O
),O
4th,O
quartile,O
0,O
.,O
42,O
(,O
0,O
.,O
26,O
-,O
0,O
.,O
67,O
),O
0,O
.,O
33,O
(,O
0,O
.,O
18,O
-,O
0,O
.,O
61,O
),O
0,O
.,O
34,O
(,O
0,O
.,O
18,O
-,O
0,O
.,O
63,O
),O
NS,O
:,O
not,O
statistically,O
significant,O
so,O
not,O
included,O
in,O
the,O
model,O
;,O
ND,O
:,O
the,O
variable,O
is,O
excluded,O
because,O
none,O
of,O
the,O
urban,O
women,O
reported,O
delivery,O
at,O
CHSs,O
Discussion,O
This,O
study,O
is,O
among,O
the,O
first,O
examining,O
the,O
pattern,O
of,O
RH,O
and,O
FP,O
service,O
utilization,O
at,O
the,O
CHS,O
and,O
in,O
other,O
health,O
facilities,O
in,O
the,O
context,O
of,O
change,O
in,O
the,O
healthcare,O
system,O
in,O
Vietnam,O
.,O
With,O
basic,O
RH,O
services,O
available,O
from,O
a,O
range,O
of,O
health,O
facilities,O
",",O
women,O
in,O
Vietnam,O
",",O
especially,O
those,O
in,O
urbanized,O
areas,O
",",O
have,O
been,O
given,O
a,O
range,O
of,O
alternatives,O
.,O
However,O
",",O
state,O
services,O
continue,O
to,O
dominate,O
",",O
though,O
private,O
services,O
are,O
playing,O
a,O
significant,O
role,O
.,O
In,O
general,O
",",O
the,O
local,O
CHS,O
appears,O
to,O
be,O
the,O
most,O
frequently,O
used,O
health,O
facility,O
for,O
FP,O
",",O
ANC,O
",",O
and,O
gynecological,O
examination,O
services,O
",",O
all,O
free,O
or,O
heavily,O
subsidized,O
.,O
Hospitals,O
dominate,O
the,O
provision,O
of,O
delivery,O
services,O
.,O
There,O
were,O
marked,O
differentials,O
in,O
women,O
',O
s,O
selection,O
of,O
service,O
providers,O
for,O
ANC,O
and,O
delivery,O
services,O
between,O
rural,O
and,O
urban,O
areas,O
.,O
Data,O
on,O
behavioral,O
RH,O
care,O
indicators,O
in,O
the,O
selected,O
districts,O
were,O
impressive,O
with,O
a,O
very,O
high,O
proportion,O
of,O
married,O
women,O
currently,O
using,O
a,O
birth,O
control,O
method,O
",",O
high,O
rates,O
of,O
pregnant,O
women,O
having,O
sufficient,O
ANC,O
and,O
giving,O
birth,O
at,O
a,O
health,O
facility,O
.,O
These,O
data,O
were,O
comparable,O
with,O
the,O
national,O
-,O
level,O
statistics,O
over,O
the,O
past,O
5,O
years,O
[,O
13,O
],O
that,O
reported,O
high,O
national,O
rates,O
of,O
contraceptive,O
use,O
(,O
80,O
%-,O
90,O
"%),",O
at,O
least,O
3,O
antenatal,O
visits,O
in,O
pregnant,O
women,O
(,O
87,O
"%),",O
and,O
deliveries,O
attended,O
by,O
trained,O
health,O
personnel,O
(,O
95,O
%,O
or,O
higher,O
),O
[,O
14,O
",",O
15,O
].,O
The,O
pattern,O
of,O
birth,O
control,O
methods,O
currently,O
used,O
was,O
also,O
keeping,O
with,O
the,O
national,O
data,O
that,O
reported,O
IUD,O
to,O
be,O
the,O
most,O
popular,O
method,O
applied,O
by,O
around,O
56,O
%,O
of,O
married,O
couples,O
[,O
14,O
].,O
The,O
high,O
levels,O
of,O
contraceptive,O
use,O
",",O
with,O
the,O
local,O
CHS,O
as,O
the,O
major,O
supplier,O
",",O
indicates,O
that,O
the,O
model,O
of,O
providing,O
FP,O
services,O
in,O
Vietnam,O
is,O
effective,O
",",O
and,O
able,O
to,O
meet,O
local,O
needs,O
.,O
Historically,O
",",O
the,O
CHS,O
has,O
been,O
serving,O
as,O
the,O
primary,O
access,O
point,O
for,O
FP,O
services,O
under,O
the,O
national,O
population,O
and,O
family,O
planning,O
program,O
since,O
early,O
1960s,O
.,O
Over,O
time,O
",",O
the,O
CHS,O
has,O
gained,O
a,O
reputation,O
for,O
its,O
provision,O
of,O
subsidized,O
FP,O
services,O
",",O
with,O
delivery,O
of,O
FP,O
services,O
strengthened,O
by,O
the,O
population,O
collaborator,O
network,O
",",O
providing,O
women,O
with,O
easy,O
access,O
to,O
low,O
-,O
cost,O
",",O
community,O
-,O
based,O
services,O
.,O
The,O
contribution,O
of,O
the,O
local,O
pharmacy,O
is,O
also,O
significant,O
",",O
diversifying,O
the,O
provision,O
of,O
condoms,O
or,O
other,O
contraceptive,O
commodities,O
at,O
the,O
commune,O
level,O
.,O
The,O
hospital,O
and,O
private,O
providers,O
appear,O
to,O
have,O
a,O
little,O
role,O
in,O
the,O
provision,O
of,O
IUD,O
services,O
and,O
other,O
FP,O
commodities,O
(,O
i,O
.,O
e,O
.,O
condoms,O
or,O
pills,O
).,O
The,O
CHS,O
also,O
appears,O
to,O
be,O
a,O
major,O
provider,O
for,O
antenatal,O
check,O
-,O
ups,O
",",O
particularly,O
in,O
the,O
rural,O
area,O
",",O
although,O
the,O
number,O
of,O
private,O
antenatal,O
service,O
users,O
was,O
significant,O
.,O
This,O
finding,O
counters,O
previous,O
studies,O
that,O
reported,O
lower,O
use,O
of,O
primary,O
healthcare,O
and,O
outpatient,O
treatment,O
services,O
at,O
CHSs,O
compared,O
to,O
private,O
clinics,O
or,O
hospitals,O
[,O
1,O
",",O
16,O
].,O
Antenatal,O
care,O
check,O
-,O
ups,O
at,O
the,O
CHS,O
are,O
subsidized,O
and,O
accompanied,O
by,O
free,O
pre,O
-,O
natal,O
tetanus,B-DS
vaccination,O
",",O
and,O
the,O
CHS,O
is,O
proactive,O
in,O
inviting,O
mothers,O
to,O
register,O
for,O
the,O
monthly,O
antenatal,O
clinic,O
when,O
their,O
pregnancy,O
is,O
confirmed,O
.,O
However,O
",",O
while,O
CHSs,O
continue,O
to,O
dominate,O
the,O
provision,O
of,O
ANC,O
services,O
",",O
a,O
preference,O
for,O
delivery,O
in,O
hospitals,O
was,O
clear,O
in,O
these,O
districts,O
",",O
a,O
finding,O
consistent,O
with,O
rising,O
economic,O
status,O
and,O
increasing,O
patient,O
expectations,O
of,O
the,O
health,O
system,O
in,O
Vietnam,O
[,O
2,O
",",O
8,O
",",O
17,O
].,O
Living,O
location,O
affects,O
the,O
selection,O
of,O
ANC,O
service,O
providers,O
",",O
with,O
rural,O
women,O
more,O
likely,O
than,O
their,O
urban,O
counterparts,O
to,O
use,O
the,O
CHS,O
.,O
The,O
same,O
differential,O
was,O
not,O
seen,O
in,O
the,O
choice,O
of,O
services,O
relating,O
to,O
delivery,O
",",O
with,O
women,O
living,O
in,O
rural,O
areas,O
as,O
likely,O
to,O
choose,O
a,O
hospital,O
as,O
those,O
in,O
the,O
city,O
.,O
In,O
both,O
settings,O
",",O
district,O
hospitals,O
have,O
become,O
the,O
most,O
popular,O
provider,O
for,O
this,O
service,O
",",O
while,O
the,O
role,O
of,O
the,O
local,O
CHS,O
has,O
tended,O
to,O
diminish,O
.,O
Our,O
data,O
support,O
earlier,O
studies,O
that,O
found,O
a,O
low,O
use,O
of,O
CHS,O
delivery,O
services,O
",",O
with,O
most,O
women,O
preferring,O
district,O
hospital,O
-,O
based,O
delivery,O
because,O
of,O
the,O
perceived,O
better,O
quality,O
of,O
services,O
for,O
both,O
mothers,O
and,O
newborn,O
[,O
7,O
",",O
8,O
].,O
The,O
data,O
also,O
support,O
the,O
qualitative,O
study,O
in,O
these,O
provinces,O
that,O
noted,O
the,O
2,O
-,O
child,O
population,O
control,O
policy,O
has,O
made,O
couples,O
more,O
cautious,O
about,O
outcomes,O
for,O
their,O
baby,O
",",O
choosing,O
hospital,O
-,O
based,O
delivery,O
where,O
they,O
are,O
more,O
confident,O
in,O
provider,O
',O
s,O
expertise,O
and,O
equipment,O
",",O
and,O
life,O
saving,O
emergency,O
care,O
is,O
readily,O
available,O
[,O
4,O
].,O
The,O
high,O
use,O
of,O
gynecological,O
check,O
-,O
up,O
services,O
at,O
the,O
local,O
CHS,O
was,O
attributed,O
in,O
part,O
to,O
the,O
national,O
RH,O
semi,O
-,O
annual,O
campaign,O
.,O
Although,O
this,O
national,O
campaign,O
is,O
aimed,O
at,O
early,O
detection,O
and,O
treatment,O
of,O
RTIs,B-DS
",",O
population,O
-,O
based,O
studies,O
conducted,O
within,O
the,O
last,O
10,O
years,O
",",O
including,O
one,O
study,O
in,O
Thua,O
Thien,O
Hue,O
",",O
reported,O
a,O
prevalence,O
of,O
RTIs,B-DS
ranging,O
from,O
21,O
%,O
to,O
39,O
%,O
among,O
women,O
of,O
reproductive,O
age,O
[,O
18,O
-,O
20,O
].,O
The,O
RTIs,B-DS
prevalence,O
was,O
found,O
to,O
be,O
even,O
higher,O
in,O
hospital,O
-,O
or,O
clinic,O
-,O
based,O
studies,O
",",O
though,O
these,O
were,O
subject,O
to,O
selection,O
bias,O
[,O
21,O
",",O
22,O
].,O
While,O
RTIs,B-DS
can,O
change,O
overtime,O
and,O
vary,O
by,O
provinces,O
",",O
such,O
high,O
prevalence,O
raises,O
questions,O
around,O
the,O
strategic,O
use,O
of,O
CHS,O
-,O
based,O
free,O
gynecological,O
check,O
-,O
ups,O
during,O
the,O
national,O
semi,O
-,O
annual,O
RH,O
campaign,O
",",O
with,O
questions,O
over,O
the,O
quality,O
and,O
efficacy,O
of,O
this,O
service,O
as,O
an,O
intervention,O
strategy,O
.,O
Private,O
physicians,O
were,O
important,O
providers,O
for,O
ANC,O
services,O
in,O
both,O
rural,O
and,O
urban,O
areas,O
",",O
despite,O
their,O
uneven,O
geographical,O
distribution,O
.,O
With,O
RH,O
private,O
clinics,O
mostly,O
concentrated,O
in,O
urban,O
areas,O
",",O
using,O
private,O
services,O
not,O
only,O
incurred,O
higher,O
fees,O
",",O
but,O
also,O
travel,O
expenses,O
for,O
rural,O
women,O
.,O
Yet,O
",",O
a,O
significant,O
proportion,O
of,O
rural,O
women,O
used,O
private,O
clinics,O
during,O
their,O
latest,O
pregnancy,O
.,O
Previous,O
studies,O
report,O
criticism,O
of,O
state,O
facilities,O
and,O
a,O
preference,O
for,O
reproductive,O
healthcare,O
provided,O
at,O
private,O
clinics,O
",",O
though,O
",",O
paradoxically,O
",",O
these,O
private,O
clinics,O
are,O
serviced,O
by,O
physicians,O
who,O
routinely,O
work,O
in,O
state,O
health,O
facilities,O
[,O
23,O
].,O
In,O
the,O
private,O
clinics,O
",",O
clients,O
may,O
be,O
entitled,O
to,O
direct,O
access,O
to,O
more,O
senior,O
clinicians,O
",",O
and,O
find,O
staff,O
more,O
responsive,O
",",O
compared,O
to,O
their,O
reception,O
in,O
state,O
services,O
[,O
23,O
].,O
While,O
CHSs,O
maintained,O
dominance,O
in,O
provision,O
of,O
ANC,O
services,O
",",O
there,O
was,O
a,O
clear,O
upwards,O
trend,O
for,O
the,O
use,O
of,O
private,O
antenatal,O
services,O
",",O
consistent,O
with,O
trends,O
for,O
other,O
health,O
service,O
use,O
in,O
Vietnam,O
[,O
1,O
",",O
2,O
].,O
In,O
essence,O
",",O
the,O
patterns,O
of,O
RH,O
service,O
provider,O
choice,O
were,O
driven,O
by,O
socio,O
-,O
economic,O
and,O
geographic,O
factors,O
.,O
Women,O
of,O
lower,O
socio,O
-,O
economic,O
status,O
",",O
who,O
were,O
farmers,O
",",O
earning,O
a,O
lower,O
income,O
",",O
having,O
more,O
than,O
2,O
children,O
",",O
and,O
living,O
in,O
a,O
rural,O
area,O
were,O
more,O
likely,O
to,O
use,O
antenatal,O
",",O
delivery,O
",",O
and,O
/,O
or,O
gynecological,O
check,O
-,O
up,O
services,O
at,O
the,O
local,O
CHS,O
.,O
This,O
finding,O
is,O
consistent,O
with,O
previous,O
studies,O
that,O
found,O
the,O
poor,O
tend,O
to,O
use,O
the,O
CHS,O
more,O
frequently,O
than,O
the,O
rich,O
[,O
1,O
",",O
24,O
].,O
Among,O
the,O
2,O
provinces,O
",",O
a,O
higher,O
percentage,O
of,O
women,O
in,O
Thua,O
Thien,O
Hue,O
reported,O
visiting,O
their,O
local,O
CHS,O
for,O
ANC,O
and,O
gynecological,O
check,O
up,O
services,O
.,O
This,O
difference,O
can,O
be,O
explained,O
by,O
the,O
higher,O
number,O
of,O
CHSs,O
in,O
sampled,O
communes,O
in,O
Thua,O
Thien,O
Hue,O
staffed,O
by,O
a,O
doctor,O
(,O
13,O
"),",O
compared,O
to,O
those,O
in,O
Vinh,O
Long,O
(,O
10,O
),O
[,O
25,O
].,O
In,O
Vinh,O
Long,O
",",O
2,O
of,O
3,O
districts,O
included,O
in,O
the,O
survey,O
had,O
an,O
accredited,O
private,O
RH,O
clinic,O
",",O
while,O
there,O
were,O
none,O
in,O
rural,O
districts,O
of,O
Thua,O
Thien,O
Hue,O
.,O
This,O
was,O
reflected,O
in,O
the,O
findings,O
that,O
more,O
rural,O
women,O
in,O
Vinh,O
Long,O
used,O
antenatal,O
check,O
-,O
ups,O
at,O
private,O
clinics,O
and,O
fewer,O
of,O
them,O
used,O
this,O
service,O
at,O
the,O
CHS,O
compared,O
to,O
their,O
counterparts,O
in,O
Thua,O
Thien,O
Hue,O
",",O
though,O
in,O
both,O
provinces,O
",",O
there,O
were,O
low,O
levels,O
of,O
delivery,O
in,O
private,O
facilities,O
.,O
This,O
difference,O
also,O
indicates,O
a,O
shift,O
from,O
CHSs,O
to,O
private,O
doctors,O
for,O
ANC,O
services,O
where,O
they,O
are,O
locally,O
accessible,O
",",O
reducing,O
the,O
use,O
for,O
services,O
delivered,O
through,O
the,O
CHS,O
system,O
.,O
The,O
study,O
findings,O
should,O
be,O
considered,O
in,O
conjunction,O
with,O
the,O
limitations,O
of,O
the,O
research,O
.,O
The,O
sample,O
was,O
drawn,O
from,O
districts,O
purposively,O
selected,O
for,O
the,O
intervention,O
project,O
",",O
and,O
thus,O
not,O
representative,O
for,O
the,O
whole,O
province,O
.,O
Although,O
the,O
percentage,O
of,O
women,O
who,O
have,O
a,O
current,O
sexual,O
partner,O
(,O
3,O
%),O
was,O
consistent,O
with,O
national,O
data,O
on,O
prevalence,O
of,O
premarital,O
sex,O
among,O
young,O
women,O
(,O
5,O
.,O
2,O
"%),",O
[,O
26,O
],O
the,O
sample,O
of,O
unmarried,O
women,O
was,O
too,O
small,O
for,O
meaningful,O
statistical,O
analyses,O
.,O
Data,O
were,O
self,O
-,O
reported,O
",",O
and,O
may,O
incur,O
recall,O
bias,O
with,O
regards,O
to,O
the,O
history,O
of,O
RH,O
service,O
use,O
",",O
particularly,O
with,O
ANC,O
and,O
delivery,O
services,O
.,O
Conclusions,O
Although,O
the,O
CHS,O
in,O
this,O
study,O
retains,O
significant,O
utilization,O
rates,O
and,O
constitutes,O
an,O
important,O
provider,O
of,O
primary,O
RH,O
services,O
",",O
it,O
is,O
under,O
challenge,O
on,O
three,O
fronts,O
.,O
The,O
first,O
challenge,O
is,O
from,O
the,O
significant,O
use,O
of,O
private,O
practice,O
for,O
ANC,O
",",O
where,O
clients,O
have,O
direct,O
access,O
to,O
higher,O
grades,O
of,O
health,O
care,O
providers,O
",",O
and,O
are,O
willing,O
to,O
pay,O
higher,O
fees,O
for,O
their,O
perceptions,O
of,O
better,O
quality,O
of,O
care,O
.,O
Secondly,O
",",O
although,O
the,O
semi,O
-,O
annual,O
gynecological,O
screening,O
continues,O
to,O
attract,O
significant,O
numbers,O
of,O
women,O
with,O
its,O
subsidized,O
service,O
",",O
its,O
effectiveness,O
as,O
a,O
population,O
strategy,O
is,O
questionable,O
",",O
and,O
the,O
quality,O
of,O
services,O
needs,O
evaluation,O
.,O
Thirdly,O
",",O
the,O
preference,O
for,O
delivery,O
in,O
district,O
hospitals,O
over,O
CHS,O
is,O
marked,O
",",O
and,O
arguably,O
",",O
government,O
services,O
would,O
do,O
well,O
to,O
move,O
towards,O
strengthened,O
referral,O
services,O
and,O
shared,O
care,O
with,O
the,O
CHS,O
",",O
rather,O
than,O
invest,O
in,O
duplication,O
of,O
these,O
functions,O
at,O
both,O
levels,O
.,O
To,O
address,O
these,O
challenges,O
",",O
the,O
CHS,O
system,O
needs,O
to,O
be,O
responsive,O
to,O
specific,O
local,O
needs,O
.,O
In,O
areas,O
with,O
accessible,O
alternative,O
health,O
services,O
reducing,O
the,O
need,O
for,O
CHS,O
services,O
",",O
rationalizing,O
of,O
services,O
is,O
needed,O
.,O
Those,O
CHSs,O
that,O
attempt,O
to,O
function,O
in,O
the,O
shadow,O
of,O
hospital,O
facilities,O
need,O
to,O
be,O
protected,O
by,O
referral,O
practices,O
and,O
clear,O
differentiation,O
of,O
services,O
to,O
avoid,O
unnecessary,O
provision,O
of,O
routine,O
RH,O
care,O
by,O
more,O
costly,O
staff,O
",",O
in,O
higher,O
cost,O
level,O
facilities,O
.,O
At,O
the,O
same,O
time,O
",",O
efforts,O
should,O
be,O
made,O
to,O
improve,O
service,O
quality,O
at,O
the,O
local,O
CHS,O
as,O
the,O
economy,O
improves,O
and,O
clients,O
demonstrate,O
growing,O
demand,O
for,O
higher,O
quality,O
services,O
.,O
With,O
the,O
reduction,O
in,O
government,O
subsidies,O
",",O
a,O
responsive,O
payment,O
scheme,O
must,O
be,O
developed,O
at,O
the,O
CHS,O
level,O
that,O
generates,O
income,O
for,O
the,O
sustainable,O
provision,O
of,O
quality,O
services,O
",",O
but,O
retains,O
subsidized,O
services,O
for,O
the,O
poor,O
who,O
continue,O
to,O
rely,O
on,O
their,O
local,O
CHS,O
for,O
basic,O
reproductive,O
healthcare,O
.,O
Abbreviations,O
ANC,O
:,O
Antenatal,O
care,O
;,O
CHS,O
:,O
Commune,O
Health,O
Station,O
;,O
CI,O
:,O
Confidence,O
Interval,O
;,O
FP,O
:,O
Family,O
Planning,O
;,O
IUD,O
:,O
Intra,O
uterine,O
device,O
;,O
RH,O
:,O
Reproductive,O
Health,O
;,O
OR,O
:,O
Odd,O
Ratios,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
',O
contributions,O
AN,O
conceived,O
research,O
ideas,O
",",O
developed,O
research,O
protocol,O
and,O
data,O
collection,O
tools,O
",",O
and,O
conducted,O
data,O
collection,O
and,O
data,O
entry,O
.,O
AN,O
performed,O
data,O
analysis,O
and,O
drafted,O
the,O
manuscript,O
with,O
input,O
from,O
PH,O
.,O
PH,O
made,O
a,O
substantial,O
contribution,O
in,O
revising,O
the,O
manuscript,O
for,O
intellectual,O
content,O
.,O
All,O
authors,O
reviewed,O
and,O
approved,O
the,O
final,O
version,O
.,O
Pre,O
-,O
publication,O
history,O
The,O
pre,O
-,O
publication,O
history,O
for,O
this,O
paper,O
can,O
be,O
accessed,O
here,O
:,O
http,O
://,O
www,O
.,O
biomedcentral,O
.,O
com,O
/,O
1472,O
-,O
6963,O
/,O
11,O
/,O
237,O
/,O
prepub,O
Supplementary,O
Material,O
Additional,O
file,O
1,O
Study,O
questionnaire,O
.,O
Click,O
here,O
for,O
file,O
Overexpression,O
of,O
Rice,B-OG
Black,I-OG
-,I-OG
Streaked,I-OG
Dwarf,I-OG
Virus,I-OG
P7,B-GP
-,I-GP
1,I-GP
in,O
Arabidopsis,B-OG
Results,O
in,O
Male,O
Sterility,O
Due,O
to,O
Non,O
-,O
Dehiscent,O
Anthers,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
FS,O
QX,O
TX,O
YZ,O
.,O
Performed,O
the,O
experiments,O
:,O
FS,O
XY,O
.,O
Analyzed,O
the,O
data,O
:,O
FS,O
QX,O
YF,O
YX,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
TZ,O
YF,O
.,O
Wrote,O
the,O
paper,O
:,O
FS,O
YZ,O
.,O
Rice,B-OG
black,I-OG
-,I-OG
streaked,I-OG
dwarf,I-OG
virus,I-OG
(,O
RBSDV,B-OG
"),",O
a,O
member,O
of,O
the,O
genus,O
Fijivirus,B-OG
in,O
the,O
family,O
Reoviridae,B-OG
",",O
is,O
propagatively,O
transmitted,O
by,O
the,O
small,B-OG
brown,I-OG
planthopper,I-OG
(,O
Laodelphax,B-OG
striatellus,I-OG
Fallén,O
).,O
RBSDV,B-OG
causes,O
rice,B-DS
black,I-DS
-,I-DS
streaked,I-DS
dwarf,I-DS
and,O
maize,B-DS
rough,I-DS
dwarf,I-DS
diseases,I-DS
",",O
which,O
lead,O
to,O
severe,O
yield,O
losses,O
in,O
crops,O
in,O
China,O
.,O
Although,O
several,O
RBSDV,B-OG
proteins,O
have,O
been,O
studied,O
in,O
detail,O
",",O
the,O
functions,O
of,O
the,O
nonstructural,O
protein,B-GP
P7,I-GP
-,I-GP
1,I-GP
are,O
still,O
largely,O
unknown,O
.,O
To,O
investigate,O
the,O
role,O
of,O
the,O
P7,B-GP
-,I-GP
1,I-GP
protein,O
in,O
virus,B-OG
pathogenicity,O
",",O
transgenic,O
Arabidopsis,B-OG
thaliana,I-OG
plants,B-OG
were,O
generated,O
in,O
which,O
the,O
P7,B-GP
-,I-GP
1,I-GP
gene,O
was,O
expressed,O
under,O
the,O
control,O
of,O
the,O
35S,O
promoter,O
.,O
The,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
-,O
transgenic,O
Arabidopsis,B-OG
plants,B-OG
(,O
named,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
were,O
male,O
sterility,O
.,O
Flowers,O
and,O
pollen,O
from,O
P7,B-GP
-,I-GP
1,I-GP
-,O
transgenic,O
plants,B-OG
were,O
of,O
normal,O
size,O
and,O
shape,O
",",O
and,O
anthers,O
developed,O
to,O
the,O
normal,O
size,O
but,O
failed,O
to,O
dehisce,O
.,O
The,O
non,O
-,O
dehiscent,O
anthers,O
observed,O
in,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
were,O
attributed,O
to,O
decreased,O
lignin,O
content,O
in,O
the,O
anthers,O
.,O
Furthermore,O
",",O
the,O
reactive,O
oxygen,O
species,O
levels,O
were,O
quite,O
low,O
in,O
the,O
transgenic,O
plants,B-OG
compared,O
with,O
the,O
wild,O
type,O
.,O
These,O
results,O
indicate,O
that,O
ectopic,O
expression,O
of,O
the,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
protein,O
in,O
A,B-OG
.,I-OG
thaliana,I-OG
causes,O
male,O
sterility,O
",",O
possibly,O
through,O
the,O
disruption,O
of,O
the,O
lignin,O
biosynthesis,O
and,O
H2O2,O
-,O
dependent,O
polymerization,O
pathways,O
.,O
Introduction,O
Rice,B-OG
black,I-OG
-,I-OG
streaked,I-OG
dwarf,I-OG
virus,I-OG
(,O
RBSDV,B-OG
"),",O
a,O
member,O
of,O
the,O
genus,O
Fijivirus,B-OG
in,O
the,O
family,O
Reoviridae,B-OG
",",O
causes,O
rice,B-DS
black,I-DS
-,I-DS
streaked,I-DS
dwarf,I-DS
and,O
maize,B-DS
rough,I-DS
dwarf,I-DS
diseases,I-DS
",",O
which,O
lead,O
to,O
severe,O
yield,O
losses,O
in,O
crops,O
in,O
China,O
",",O
Japan,O
",",O
Korea,O
",",O
and,O
other,O
Asian,O
countries,O
[,O
1,O
"],",O
[,O
2,O
"],",O
[,O
3,O
].,O
The,O
virus,B-OG
is,O
propagatively,O
transmitted,O
by,O
the,O
small,B-OG
brown,I-OG
planthopper,I-OG
(,O
SBPH,B-OG
:,O
Laodelphax,B-OG
striatellus,I-OG
Fallén,O
),O
in,O
a,O
persistent,O
circulative,O
manner,O
[,O
1,O
"],",O
[,O
3,O
]–[,O
5,O
].,O
Plants,B-OG
infected,O
with,O
RBSDV,B-OG
typically,O
exhibit,O
symptoms,O
such,O
as,O
stunting,O
",",O
darkening,O
of,O
leaves,O
",",O
and,O
white,O
waxy,O
or,O
black,O
-,O
streaked,O
swellings,O
along,O
the,O
veins,O
on,O
the,O
backs,O
of,O
the,O
leaf,O
blades,O
and,O
sheaths,O
[,O
1,O
"],",O
[,O
3,O
]–[,O
5,O
].,O
The,O
RBSDV,B-OG
virion,B-OG
is,O
composed,O
of,O
icosahedral,O
",",O
two,O
-,O
layered,O
particles,O
approximately,O
75,O
–,O
80,O
nm,O
in,O
diameter,O
and,O
10,O
segments,O
of,O
double,O
-,O
stranded,O
genomic,O
RNA,O
(,O
dsRNA,O
"),",O
which,O
are,O
designed,O
S1,O
to,O
S10,O
with,O
increasing,O
order,O
of,O
electrophoretic,O
mobility,O
in,O
polyacrylamide,O
gel,O
electrophoresis,O
(,O
PAGE,O
),O
[,O
6,O
"],",O
[,O
7,O
].,O
S1,O
encodes,O
a,O
putative,O
169,O
-,O
kDa,O
RNA,B-GP
-,I-GP
dependent,I-GP
RNA,I-GP
polymerase,I-GP
",",O
while,O
S2,O
and,O
S4,O
encode,O
a,O
major,O
core,O
structural,B-GP
protein,I-GP
and,O
the,O
outer,B-GP
shell,I-GP
B,I-GP
-,I-GP
spike,I-GP
protein,I-GP
",",O
respectively,O
[,O
6,O
"],",O
[,O
7,O
"],",O
[,O
8,O
].,O
The,O
protein,O
encoded,O
by,O
S3,O
contains,O
a,O
conserved,O
motif,O
and,O
is,O
a,O
putative,O
guanylyltransferase,B-GP
[,O
9,O
].,O
Western,O
blotting,O
analysis,O
of,O
viral,O
particles,O
has,O
suggested,O
that,O
the,O
minor,B-GP
core,I-GP
capsid,I-GP
protein,I-GP
and,O
major,B-GP
outer,I-GP
capsid,I-GP
protein,I-GP
are,O
encoded,O
by,O
S8,O
and,O
S10,O
",",O
respectively,O
[,O
8,O
"],",O
[,O
10,O
"],",O
[,O
11,O
].,O
Immunoelectron,O
microscopy,O
has,O
revealed,O
that,O
S9,O
ORF1,B-GP
P9,B-GP
-,I-GP
1,I-GP
is,O
a,O
nonstructural,O
protein,O
that,O
accumulates,O
in,O
the,O
intracellular,O
viroplasms,O
in,O
infected,O
plants,B-OG
and,O
insects,B-OG
[,O
8,O
].,O
P9,B-GP
-,I-GP
1,I-GP
",",O
a,O
thermostable,O
",",O
α,O
-,O
helical,O
protein,O
",",O
self,O
-,O
interacts,O
to,O
form,O
dimers,O
and,O
is,O
the,O
minimal,O
viral,O
component,O
required,O
for,O
viroplasm,O
formation,O
[,O
12,O
].,O
The,O
protein,O
encoded,O
by,O
S6,O
is,O
a,O
viral,O
RNA,B-GP
silencing,I-GP
suppressor,I-GP
and,O
has,O
an,O
intrinsic,O
ability,O
to,O
interact,O
with,O
P9,B-GP
-,I-GP
1,I-GP
[,O
13,O
]–[,O
15,O
].,O
P7,B-GP
-,I-GP
1,I-GP
is,O
a,O
nonstructural,O
protein,O
containing,O
363,O
amino,O
acids,O
(,O
with,O
a,O
molecular,O
mass,O
of,O
41,O
.,O
0,O
kDa,O
),O
that,O
is,O
translated,O
from,O
S7,O
ORF1,B-GP
.,O
P7,B-GP
-,I-GP
1,I-GP
accumulates,O
in,O
tubule,O
-,O
like,O
structures,O
in,O
infected,O
plant,B-OG
and,O
planthopper,B-OG
cells,O
",",O
suggesting,O
that,O
P7,B-GP
-,I-GP
1,I-GP
is,O
one,O
of,O
the,O
constituents,O
of,O
these,O
structures,O
[,O
8,O
].,O
Recent,O
studies,O
demonstrate,O
that,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
forms,O
punctuate,O
points,O
at,O
plasmodesmata,O
in,O
Nicotiana,B-OG
benthamiana,I-OG
leaves,O
[,O
16,O
].,O
Tubule,O
-,O
forming,O
and,O
plasmodesmatal,O
localization,O
of,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
are,O
usually,O
thought,O
to,O
be,O
involved,O
in,O
cell,O
-,O
to,O
-,O
cell,O
movement,O
of,O
the,O
virus,B-OG
in,O
plant,B-OG
and,O
insect,B-OG
cells,O
.,O
However,O
",",O
little,O
else,O
is,O
known,O
about,O
the,O
characteristics,O
and,O
functions,O
of,O
P7,B-GP
-,I-GP
1,I-GP
.,O
In,O
this,O
study,O
",",O
we,O
determined,O
that,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
is,O
a,O
pathogenicity,O
determinant,O
and,O
that,O
this,O
protein,O
affects,O
normal,O
plant,B-OG
development,O
when,O
expressed,O
as,O
transgenes,O
in,O
Arabidopsis,B-OG
.,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
Arabidopsis,B-OG
plants,B-OG
exhibited,O
male,O
sterility,O
phenotype,O
caused,O
by,O
a,O
defect,O
of,O
secondary,O
wall,O
lignification,O
in,O
the,O
anther,O
endothecium,O
and,O
failure,O
of,O
anther,O
dehiscence,O
.,O
Furthermore,O
",",O
non,O
-,O
dehiscent,O
anthers,O
observed,O
in,O
transgenic,O
plants,B-OG
were,O
accompanied,O
by,O
decreased,O
levels,O
reactive,O
oxygen,O
species,O
(,O
ROS,O
).,O
These,O
results,O
suggest,O
that,O
impairment,O
in,O
lignin,O
biosynthesis,O
and,O
the,O
H2O2,O
-,O
dependent,O
polymerization,O
in,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
over,O
-,O
expressing,O
Arabidopsis,B-OG
plants,B-OG
cause,O
male,O
sterility,O
.,O
Materials,O
and,O
Methods,O
Virus,B-OG
Isolates,O
",",O
Vectors,O
",",O
and,O
Plant,B-OG
Materials,O
Rice,B-OG
plants,I-OG
infected,O
with,O
RBSDV,B-OG
were,O
collected,O
from,O
Jiangsu,O
Province,O
in,O
China,O
under,O
the,O
permission,O
of,O
Plant,B-OG
Protection,O
Station,O
of,O
Jiangsu,O
Province,O
",",O
China,O
.,O
Young,O
instar,O
nymphs,O
of,O
SBPHs,B-OG
(,O
small,B-OG
brown,I-OG
planthopper,I-OG
",",O
L,B-OG
.,I-OG
striatellus,I-OG
),O
were,O
fed,O
RBSDV,B-OG
-,O
infected,O
rice,B-OG
plants,I-OG
for,O
2,O
days,O
to,O
acquire,O
the,O
virus,B-OG
.,O
A,O
dot,O
immunobinding,O
assay,O
(,O
DIBA,O
),O
[,O
3,O
],O
showed,O
that,O
20,O
–,O
30,O
%,O
of,O
adult,O
insects,B-OG
were,O
viruliferous,O
.,O
A,O
virus,B-OG
-,O
free,O
planthopper,B-OG
population,O
was,O
generated,O
using,O
a,O
pair,O
of,O
recently,O
hatched,O
nymphs,O
",",O
and,O
nonvirulence,O
was,O
confirmed,O
using,O
reverse,O
transcription,O
-,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
-,O
PCR,O
).,O
Viruliferous,O
or,O
virus,B-OG
-,O
free,O
SBPHs,B-OG
were,O
reared,O
on,O
healthy,O
rice,B-OG
seedlings,O
(,O
Oryza,O
sativa,O
L,O
.,O
japonica,O
.,O
cv,O
.,O
Wuyujing,O
No,O
.,O
3,O
),O
in,O
glass,O
vessels,O
at,O
22,O
°,O
C,O
under,O
alternating,O
photoperiods,O
of,O
14,O
h,O
of,O
light,O
and,O
10,O
h,O
of,O
dark,O
.,O
Arabidopsis,B-OG
(,I-OG
Col,I-OG
-,I-OG
0,I-OG
),I-OG
seeds,O
were,O
donated,O
by,O
Prof,O
.,O
Hansong,O
Dong,O
(,O
College,O
of,O
Plant,B-OG
Protection,O
",",O
Nanjing,O
Agricultural,O
University,O
",",O
Nanjing,O
",",O
China,O
).,O
Plants,B-OG
were,O
grown,O
in,O
potting,O
soil,O
in,O
a,O
growth,O
chamber,O
at,O
24,O
°,O
C,O
under,O
200,O
µE,O
·,O
m,O
−,O
2,O
·,O
s,O
−,O
1,O
illumination,O
and,O
16,O
-,O
h,O
light,O
/,O
8,O
-,O
h,O
dark,O
cycle,O
conditions,O
.,O
RBSDV,B-OG
Inoculation,O
Assay,O
Rice,B-OG
plants,I-OG
(,O
Oryza,O
sativa,O
L,O
.,O
japonica,O
.,O
cv,O
.,O
Nipponbare,O
),O
were,O
inoculated,O
with,O
10,O
viruliferous,O
(,O
RBSDV,B-OG
),O
or,O
virus,B-OG
-,O
free,O
(,O
mock,O
),O
nymphs,O
per,O
plant,B-OG
(,O
4,O
or,O
5,O
leaves,O
),O
and,O
were,O
kept,O
in,O
a,O
growth,O
chamber,O
containing,O
30,O
plants,B-OG
.,O
After,O
incubation,O
at,O
22,O
°,O
C,O
for,O
4,O
days,O
under,O
artificial,O
light,O
",",O
planthoppers,B-OG
were,O
removed,O
.,O
Plants,B-OG
were,O
maintained,O
in,O
field,O
conditions,O
for,O
symptom,O
development,O
.,O
Construction,O
of,O
Overexpression,O
Vector,O
and,O
Arabidopsis,B-OG
Transformation,O
To,O
generate,O
the,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
overexpression,O
plasmid,O
",",O
the,O
coding,O
region,O
of,O
the,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
gene,O
(,O
from,O
+,O
1,O
to,O
+,O
1,O
",",O
089,O
bp,O
),O
was,O
amplified,O
with,O
primers,O
containing,O
the,O
SacI,B-GP
and,O
BamHI,B-GP
sites,O
(,O
Table,O
S1,O
).,O
The,O
resulting,O
PCR,O
product,O
was,O
digested,O
with,O
SacI,B-GP
and,O
BamHI,B-GP
and,O
ligated,O
into,O
the,O
SacI,B-GP
-,O
BamHI,B-GP
-,O
cleaved,O
pCHF3,O
vector,O
.,O
After,O
DNA,O
sequencing,O
",",O
the,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
overexpression,O
plasmid,O
was,O
introduced,O
into,O
Agrobacterium,B-OG
tumefaciens,I-OG
(,I-OG
strain,I-OG
EHA105,I-OG
"),",I-OG
and,O
the,O
transformation,O
of,O
Arabidopsis,B-OG
thaliana,I-OG
Col,I-OG
-,I-OG
0,I-OG
ecotype,O
was,O
performed,O
by,O
the,O
floral,O
-,O
dip,O
method,O
[,O
17,O
].,O
Homozygous,O
T3,O
generation,O
plants,B-OG
were,O
screened,O
for,O
kanamycin,O
resistance,O
and,O
identified,O
with,O
genome,O
PCR,O
.,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
gene,O
sequence,O
has,O
been,O
deposited,O
in,O
NCBI,O
Genbank,O
(,O
http,O
://,O
www,O
.,O
ncbi,O
.,O
nlm,O
.,O
nih,O
.,O
gov,O
),O
under,O
the,O
accession,O
number,O
of,O
KF532967,O
.,O
Qenome,O
DNA,O
PCR,O
Arabidopsis,B-OG
genome,O
DNA,O
was,O
isolated,O
from,O
leaves,O
using,O
SQ,O
Plant,B-OG
DNA,O
Kit,O
(,O
Omega,O
Bioservices,O
;,O
Norcross,O
",",O
GA,O
",",O
USA,O
),O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
instructions,O
.,O
PCR,O
reaction,O
was,O
performed,O
using,O
10,O
µl,O
Premix,O
Taq,O
(,O
TAKARA,O
;,O
Dalian,O
",",O
China,O
"),",O
0,O
.,O
2,O
µM,O
RBSDV,B-OG
S7,O
-,O
1,O
specific,O
forward,O
and,O
reverse,O
primers,O
(,O
Table,O
S1,O
"),",O
and,O
1,O
µl,O
DNA,O
in,O
a,O
total,O
volume,O
of,O
20,O
µl,O
.,O
All,O
samples,O
were,O
subjected,O
to,O
denaturation,O
for,O
5,O
min,O
at,O
95,O
°,O
C,O
",",O
followed,O
by,O
30,O
cycles,O
of,O
95,O
°,O
C,O
for,O
30,O
s,O
",",O
58,O
°,O
C,O
for,O
30,O
s,O
and,O
72,O
°,O
C,O
for,O
1,O
min,O
.,O
PCR,O
products,O
were,O
detected,O
using,O
agarose,O
gel,O
electrophoresis,O
",",O
and,O
images,O
were,O
obtained,O
using,O
the,O
Bio,O
-,O
Rad,O
Molecular,O
Imager,O
Gel,O
Doc,O
XR,O
System,O
(,O
Bio,O
-,O
Rad,O
;,O
Hercules,O
;,O
CA,O
",",O
USA,O
),O
after,O
staining,O
with,O
ethidium,O
bromide,O
.,O
Quantitative,O
Real,O
-,O
time,O
PCR,O
Quantitative,O
real,O
-,O
time,O
PCR,O
(,O
qRT,O
-,O
PCR,O
),O
was,O
performed,O
using,O
SsoFast,O
EvaGreen,O
Supermix,O
(,O
Bio,O
-,O
Rad,O
;,O
Hercules,O
;,O
CA,O
",",O
USA,O
),O
in,O
a,O
Bio,O
-,O
Rad,O
iQ5,O
Real,O
-,O
Time,O
PCR,O
system,O
.,O
Total,O
RNA,O
was,O
isolated,O
from,O
leaves,O
using,O
the,O
RNAiso,O
Plus,O
reagent,O
(,O
TAKARA,O
;,O
Dalian,O
",",O
China,O
),O
and,O
reverse,O
transcribed,O
using,O
M,B-OG
-,I-OG
MLV,I-OG
Reverse,B-GP
Transcriptase,I-GP
(,O
Promega,O
;,O
Fitchburg,O
;,O
WI,O
",",O
USA,O
"),",O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
instructions,O
.,O
The,O
EF1α,B-GP
gene,O
",",O
which,O
is,O
highly,O
conserved,O
and,O
constitutively,O
expressed,O
in,O
eukaryotes,B-OG
[,O
18,O
"],",O
was,O
used,O
as,O
a,O
reference,O
control,O
.,O
Each,O
quantitative,O
PCR,O
reaction,O
was,O
performed,O
using,O
10,O
µl,O
SsoFast,O
EvaGreen,O
Supermix,O
",",O
0,O
.,O
2,O
µM,O
forward,O
and,O
reverse,O
primers,O
",",O
and,O
1,O
µl,O
cDNA,O
in,O
a,O
total,O
volume,O
of,O
20,O
µl,O
.,O
All,O
samples,O
were,O
subjected,O
to,O
denaturation,O
for,O
3,O
min,O
at,O
95,O
°,O
C,O
",",O
followed,O
by,O
40,O
cycles,O
of,O
95,O
°,O
C,O
for,O
10,O
s,O
and,O
58,O
°,O
C,O
for,O
20,O
s,O
.,O
SYBR,O
Green,O
absorbance,O
was,O
detected,O
at,O
58,O
°,O
C,O
.,O
All,O
reactions,O
were,O
conducted,O
in,O
triplicate,O
.,O
Amplicon,O
dissociation,O
curves,O
",",O
i,O
.,O
e,O
".,",O
melting,O
curves,O
",",O
were,O
recorded,O
after,O
cycle,O
40,O
by,O
heating,O
from,O
60,O
°,O
C,O
to,O
95,O
°,O
C,O
at,O
a,O
ramp,O
speed,O
of,O
1,O
.,O
9,O
°,O
C,O
·,O
min,O
−,O
1,O
.,O
Data,O
were,O
analyzed,O
using,O
iQ5,O
software,O
(,O
Bio,O
-,O
Rad,O
;,O
Hercules,O
;,O
CA,O
",",O
USA,O
).,O
Table,O
S1,O
shows,O
information,O
regarding,O
additional,O
genes,O
and,O
primers,O
employed,O
in,O
this,O
study,O
.,O
Observation,O
of,O
Lignified,O
Secondary,O
Wall,O
Thickening,O
For,O
ethidium,O
bromide,O
staining,O
",",O
fresh,O
anthers,O
were,O
washed,O
in,O
10,O
mM,O
PBS,O
and,O
2,O
%,O
(,O
v,O
/,O
v,O
),O
Tween20,O
for,O
10,O
min,O
and,O
10,O
mM,O
PBS,O
for,O
10,O
min,O
",",O
followed,O
by,O
staining,O
with,O
0,O
.,O
05,O
%,O
(,O
w,O
/,O
v,O
),O
ethidium,O
bromide,O
(,O
1,O
h,O
",",O
room,O
temperature,O
).,O
The,O
anthers,O
were,O
then,O
washed,O
(,O
10,O
mM,O
PBS,O
",",O
10,O
min,O
"),",O
and,O
the,O
stained,O
tissues,O
were,O
mounted,O
on,O
a,O
glass,O
slide,O
and,O
examined,O
using,O
Zeiss,O
LSM710,O
confocal,O
microscopy,O
(,O
Carl,O
Zeiss,O
Microscopy,O
GmbH,O
;,O
Jena,O
",",O
Germany,O
),O
under,O
red,O
fluorescence,O
at,O
543,O
nm,O
excitation,O
[,O
19,O
].,O
To,O
study,O
lignin,O
autofluorescence,O
",",O
the,O
anthers,O
were,O
cleared,O
in,O
70,O
%,O
(,O
v,O
/,O
v,O
),O
lactic,O
acid,O
for,O
3,O
days,O
at,O
60,O
°,O
C,O
",",O
and,O
the,O
cleared,O
tissues,O
were,O
examined,O
using,O
Zeiss,O
LSM710,O
confocal,O
microscopy,O
(,O
Carl,O
Zeiss,O
Microscopy,O
GmbH,O
;,O
Jena,O
",",O
Germany,O
),O
under,O
UV,O
light,O
excitation,O
.,O
For,O
phloroglucinol,O
–,O
HCl,O
staining,O
",",O
flowers,O
were,O
fixed,O
in,O
FAA,O
solution,O
overnight,O
and,O
decolorized,O
with,O
an,O
ethanol,O
series,O
.,O
The,O
flowers,O
were,O
then,O
stained,O
with,O
2,O
%,O
(,O
w,O
/,O
v,O
),O
phloroglucinol,O
in,O
92,O
%,O
ethanol,O
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
Subsequently,O
",",O
the,O
tissues,O
were,O
mounted,O
with,O
18,O
.,O
5,O
%,O
(,O
v,O
/,O
v,O
),O
HCl,O
",",O
and,O
red,O
staining,O
was,O
immediately,O
monitored,O
using,O
Leica,O
M125,O
microscopy,O
(,O
Leica,O
Microsystems,O
;,O
Bannockburn,O
;,O
IL,O
",",O
USA,O
).,O
Histochemical,O
Detection,O
of,O
ROS,O
",",O
H2O2,O
",",O
and,O
O2,O
−,O
Radical,O
The,O
accumulation,O
of,O
ROS,O
was,O
visualized,O
by,O
a,O
fluoluminescence,O
assay,O
with,O
2,O
",",O
7,O
-,O
dichlorofluorescein,O
diacetate,O
(,O
DCFH,O
-,O
DA,O
"),",O
which,O
emits,O
green,O
fluorescence,O
when,O
oxidized,O
by,O
ROS,O
.,O
In,O
this,O
assay,O
",",O
anthers,O
were,O
infiltrated,O
with,O
a,O
100,O
µM,O
/,O
ml,O
aquatic,O
solution,O
of,O
DCFH,O
-,O
DA,O
(,O
Sigma,O
;,O
St,O
.,O
Louis,O
;,O
MO,O
",",O
USA,O
),O
and,O
subsequently,O
observed,O
with,O
Zeiss,O
LSM710,O
confocal,O
microscopy,O
(,O
Carl,O
Zeiss,O
Microscopy,O
GmbH,O
;,O
Jena,O
",",O
Germany,O
),O
under,O
GFP,B-GP
fluorescent,O
light,O
.,O
The,O
H2O2,O
and,O
O2,O
−,O
levels,O
were,O
measured,O
by,O
3,O
",",O
3,O
′-,O
diaminobenzidine,O
(,O
DAB,O
),O
and,O
nitroblue,O
tetrazolium,O
(,O
NBT,O
),O
(,O
Sigma,O
;,O
St,O
.,O
Louis,O
;,O
MO,O
",",O
USA,O
),O
staining,O
",",O
respectively,O
[,O
20,O
].,O
Anthers,O
were,O
infiltrated,O
in,O
DAB,O
solution,O
(,O
0,O
.,O
1,O
%,O
w,O
/,O
v,O
",",O
pH,O
3,O
.,O
8,O
),O
and,O
incubated,O
overnight,O
in,O
darkness,O
at,O
22,O
°,O
C,O
.,O
Alternatively,O
",",O
the,O
anthers,O
were,O
infiltrated,O
in,O
NBT,O
solution,O
(,O
0,O
.,O
1,O
%,O
w,O
/,O
v,O
),O
in,O
10,O
mM,O
PBS,O
(,O
pH,O
7,O
.,O
8,O
),O
containing,O
10,O
mM,O
NaN3,O
and,O
then,O
incubated,O
in,O
darkness,O
at,O
22,O
°,O
C,O
for,O
1,O
h,O
.,O
After,O
incubation,O
",",O
the,O
stained,O
tissues,O
were,O
decolorized,O
with,O
acetic,O
acid,O
:,O
glycerol,O
:,O
ethanol,O
(,O
1,O
∶,O
1,O
∶,O
3,O
",",O
v,O
/,O
v,O
/,O
v,O
),O
solution,O
at,O
95,O
°,O
C,O
for,O
10,O
min,O
and,O
then,O
photographed,O
using,O
Leica,O
M125,O
microscopy,O
(,O
Leica,O
Microsystems,O
;,O
Bannockburn,O
;,O
IL,O
",",O
USA,O
).,O
Scanning,O
Electron,O
Microscopy,O
Tissue,O
samples,O
of,O
wild,O
-,O
type,O
and,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
flower,O
bud,O
clusters,O
were,O
fixed,O
overnight,O
in,O
50,O
mM,O
phosphate,O
-,O
buffered,O
saline,O
(,O
PBS,O
",",O
pH,O
6,O
.,O
8,O
),O
containing,O
1,O
%,O
(,O
v,O
/,O
v,O
),O
glutaraldehyde,O
and,O
2,O
%,O
(,O
v,O
/,O
v,O
),O
paraformaldehyde,O
at,O
4,O
°,O
C,O
.,O
The,O
fixed,O
tissues,O
were,O
rinsed,O
twice,O
(,O
15,O
min,O
each,O
),O
with,O
100,O
mM,O
PBS,O
at,O
RT,O
.,O
The,O
tissues,O
were,O
dehydrated,O
in,O
a,O
graded,O
ethanol,O
series,O
.,O
Then,O
",",O
the,O
samples,O
were,O
coated,O
with,O
gold,O
and,O
examined,O
in,O
an,O
S,O
-,O
3000N,O
Scanning,O
Electron,O
Microscope,O
(,O
Hitachi,O
;,O
Tokyo,O
",",O
Japan,O
),O
at,O
an,O
accelerating,O
voltage,O
of,O
10,O
kV,O
.,O
Results,O
Reproductive,O
Development,O
Symptoms,O
Caused,O
by,O
RBSDV,B-DS
Infection,I-DS
in,O
Rice,B-OG
Plants,I-OG
The,O
growth,O
and,O
development,O
of,O
rice,B-OG
plants,I-OG
were,O
affected,O
by,O
RBSDV,B-DS
infection,I-DS
.,O
The,O
typical,O
symptoms,O
of,O
RBSDV,B-OG
-,O
infected,O
rice,B-OG
plants,I-OG
include,O
severe,O
stunting,O
and,O
darkening,O
of,O
leaves,O
[,O
3,O
]–[,O
5,O
].,O
However,O
",",O
reproductive,O
development,O
in,O
rice,B-OG
plants,I-OG
infected,O
by,O
RBSDV,B-OG
has,O
not,O
previously,O
been,O
studied,O
in,O
detail,O
.,O
Here,O
",",O
we,O
characterized,O
the,O
reproductive,O
development,O
phenotype,O
of,O
RBSDV,B-OG
-,O
infected,O
rice,B-OG
plants,I-OG
",",O
which,O
were,O
inoculated,O
by,O
viruliferous,O
planthoppers,B-OG
",",O
and,O
we,O
allowed,O
disease,O
symptoms,O
to,O
develop,O
under,O
field,O
conditions,O
.,O
Two,O
month,O
after,O
inoculation,O
",",O
the,O
infected,O
rice,B-OG
plants,I-OG
showed,O
significantly,O
stunted,O
growth,O
(,O
Figure,O
1A,O
),O
and,O
produced,O
poor,O
spikelets,O
(,O
Figure,O
1D,O
).,O
At,O
flowering,O
stage,O
",",O
the,O
spikelets,O
of,O
infected,O
rice,B-OG
plants,I-OG
had,O
viable,O
pollen,O
grains,O
(,O
Figure,O
1C,O
"),",O
but,O
the,O
anthers,O
failed,O
to,O
dehisce,O
(,O
Figure,O
1B,O
),O
compared,O
with,O
mock,O
rice,B-OG
plants,I-OG
which,O
were,O
inoculated,O
by,O
virus,B-OG
-,O
free,O
planthoppers,B-OG
.,O
As,O
a,O
result,O
",",O
at,O
grain,O
filling,O
stage,O
the,O
infected,O
rice,B-OG
plant,I-OG
showed,O
partial,O
to,O
complete,O
spikelet,O
sterility,O
(,O
Figure,O
1E,O
).,O
Symptoms,O
of,O
rice,B-OG
plants,I-OG
infected,O
with,O
Rice,B-OG
black,I-OG
-,I-OG
streaked,I-OG
dwarf,I-OG
virus,I-OG
(,O
RBSDV,B-OG
).,O
(,O
A,O
),O
The,O
stunted,O
symptom,O
of,O
rice,B-OG
caused,O
by,O
RBSDV,B-DS
infection,I-DS
.,O
(,O
B,O
–,O
C,O
),O
RBSDV,B-OG
-,O
infected,O
rice,B-OG
plants,I-OG
showing,O
non,O
-,O
dehiscent,O
anthers,O
(,O
B,O
),O
but,O
normal,O
viable,O
pollen,O
stained,O
with,O
I2,O
(,O
C,O
).,O
(,O
D,O
–,O
E,O
),O
The,O
spikelets,O
of,O
RBSDV,B-OG
-,O
infected,O
rice,B-OG
plants,I-OG
at,O
flowering,O
(,O
D,O
),O
and,O
at,O
the,O
grain,O
filling,O
period,O
(,O
E,O
).,O
Rice,B-OG
plants,I-OG
were,O
inoculated,O
with,O
viruliferous,O
(,O
RBSDV,B-OG
),O
or,O
virus,B-OG
-,O
free,O
SBPHs,B-OG
(,O
mock,O
).,O
Expression,O
of,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
Protein,O
Cause,O
Male,O
Sterility,O
due,O
to,O
Non,O
-,O
dehiscent,O
Anthers,O
in,O
Arabidopsis,B-OG
To,O
determine,O
whether,O
proteins,O
encoded,O
by,O
RBSDV,B-OG
contributed,O
to,O
the,O
variation,O
in,O
anther,O
dehiscence,O
and,O
spikelet,O
fertility,O
of,O
virus,B-OG
-,O
infected,O
rice,B-OG
plants,I-OG
",",O
we,O
investigated,O
the,O
effects,O
of,O
P7,B-GP
-,I-GP
1,I-GP
on,O
Arabidopsis,B-OG
plants,B-OG
.,O
Specifically,O
",",O
we,O
expressed,O
the,O
full,O
-,O
length,O
P7,B-GP
-,I-GP
1,I-GP
cDNA,O
",",O
under,O
the,O
control,O
of,O
the,O
35S,O
-,O
CaMV,B-OG
promoter,O
",",O
in,O
transgenic,O
Arabidopsis,B-OG
plants,B-OG
.,O
The,O
transgenic,O
plants,B-OG
that,O
constitutively,O
expressed,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
were,O
selected,O
using,O
kanamycin,O
medium,O
(,O
Figure,O
S1A,O
),O
and,O
confirmed,O
by,O
genomic,O
PCR,O
(,O
Figure,O
S1B,O
),O
and,O
quantitative,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
analysis,O
(,O
Figure,O
S1C,O
).,O
T3,O
generation,O
plants,B-OG
from,O
transgenic,O
lines,O
exhibiting,O
high,O
levels,O
of,O
overexpression,O
of,O
P7,B-GP
-,I-GP
1,I-GP
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
#,O
1,O
",",O
#,O
2,O
",",O
and,O
#,O
5,O
),O
were,O
selected,O
for,O
further,O
study,O
.,O
During,O
the,O
vegetative,O
growth,O
stage,O
",",O
the,O
growth,O
and,O
development,O
of,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
#,O
1,O
",",O
#,O
2,O
",",O
#,O
5,O
",",O
and,O
wild,O
-,O
type,O
Arabidopsis,B-OG
seedlings,O
were,O
indistinguishable,O
(,O
Figure,O
2A,O
).,O
However,O
",",O
all,O
transgenic,O
lines,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
#,O
1,O
",",O
#,O
2,O
",",O
and,O
#,O
5,O
),O
showed,O
significant,O
abnormalities,O
during,O
reproductive,O
growth,O
.,O
Following,O
fertilization,O
",",O
siliques,O
of,O
wild,O
-,O
type,O
plants,B-OG
elongated,O
and,O
set,O
seeds,O
.,O
But,O
in,O
transgenic,O
plants,B-OG
",",O
siliques,O
remained,O
small,O
",",O
producing,O
no,O
seeds,O
",",O
indicating,O
the,O
high,O
degree,O
of,O
sterility,O
of,O
Arabidopsis,B-OG
plants,B-OG
ectopically,O
expressing,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
(,O
Figure,O
2B,O
and,O
2C,O
).,O
Ectopic,O
expression,O
of,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
causes,O
male,O
sterility,O
in,O
Arabidopsis,B-OG
.,O
(,O
A,O
),O
Phenotypes,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
plants,B-OG
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
during,O
vegetative,O
growth,O
.,O
(,O
B,O
),O
Phenotypes,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
lines,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
during,O
reproductive,O
development,O
.,O
(,O
C,O
),O
Silique,O
phenotypes,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
lines,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
.,O
(,O
D,O
),O
Developmental,O
series,O
of,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
and,O
wild,O
-,O
type,O
flowers,O
during,O
anther,O
stages,O
12,O
to,O
14,O
.,O
To,O
investigate,O
the,O
cause,O
of,O
the,O
sterile,O
phenotype,O
in,O
transgenic,O
plants,B-OG
overexpressing,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
",",O
we,O
examined,O
the,O
flowers,O
under,O
a,O
microscope,O
.,O
These,O
observations,O
revealed,O
that,O
in,O
wild,O
-,O
type,O
flowers,O
",",O
the,O
anthers,O
started,O
to,O
dehisce,O
at,O
stage,O
13,O
[,O
21,O
"],",O
and,O
pollen,O
grains,O
were,O
released,O
to,O
the,O
stigmatic,O
papilla,O
(,O
Figure,O
2D,O
).,O
However,O
",",O
at,O
stage,O
13,O
",",O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
transgenic,O
anthers,O
did,O
not,O
dehisce,O
normally,O
",",O
resulting,O
in,O
the,O
failure,O
to,O
release,O
pollen,O
grains,O
to,O
the,O
stigmatic,O
papilla,O
(,O
Figure,O
2D,O
).,O
Even,O
at,O
late,O
stage,O
14,O
",",O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
remained,O
closed,O
",",O
and,O
no,O
pollen,O
grains,O
were,O
released,O
(,O
Figure,O
2D,O
",",O
Figure,O
S2A,O
).,O
Analysis,O
of,O
anther,O
morphology,O
by,O
scanning,O
electron,O
microscopy,O
showed,O
that,O
at,O
late,O
stage,O
13,O
",",O
wild,O
-,O
type,O
anthers,O
spilt,O
open,O
along,O
the,O
stomium,O
and,O
released,O
pollen,O
grains,O
",",O
whereas,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
remained,O
intact,O
",",O
and,O
no,O
pollen,O
grains,O
were,O
observed,O
(,O
Figure,O
3A,O
).,O
Scanning,O
electron,O
microscopy,O
and,O
Alexander,O
staining,O
revealed,O
that,O
the,O
pollen,O
grains,O
within,O
the,O
indehisced,O
anthers,O
of,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
plants,B-OG
were,O
morphologically,O
normal,O
(,O
Figure,O
3B,O
),O
and,O
viable,O
(,O
Figure,O
S2B,O
and,O
S2C,O
).,O
In,O
addition,O
",",O
when,O
used,O
for,O
hand,O
pollination,O
",",O
the,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
pollen,O
grains,O
could,O
fertilize,O
egg,O
cells,O
(,O
Figure,O
S3,O
).,O
These,O
observations,O
indicate,O
that,O
the,O
sterility,O
of,O
the,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
lines,O
is,O
caused,O
solely,O
by,O
defective,O
anther,O
dehiscence,O
.,O
Scanning,O
electron,O
micrographs,O
of,O
anthers,O
(,O
A,O
),O
and,O
pollen,O
grains,O
(,O
B,O
),O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
.,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
Anthers,O
have,O
Reduced,O
Endothecium,O
Secondary,O
Wall,O
Lignification,O
Secondary,O
wall,O
lignification,O
",",O
which,O
mainly,O
occurs,O
around,O
the,O
endothecial,O
cells,O
",",O
is,O
thought,O
to,O
be,O
critical,O
for,O
generating,O
the,O
forces,O
required,O
for,O
anther,O
dehiscence,O
[,O
22,O
].,O
In,O
wild,O
-,O
type,O
plants,B-OG
",",O
when,O
the,O
anthers,O
were,O
stained,O
with,O
ethidium,O
bromide,O
and,O
visualized,O
by,O
confocal,O
microscopy,O
",",O
lignified,O
secondary,O
walls,O
could,O
be,O
observed,O
in,O
the,O
endothecium,O
as,O
bands,O
of,O
striated,O
spring,O
-,O
like,O
thickenings,O
at,O
stages,O
12,O
and,O
13,O
(,O
Figure,O
4A,O
bottom,O
).,O
By,O
contrast,O
",",O
this,O
thickening,O
was,O
absent,O
in,O
the,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
plants,B-OG
(,O
Figure,O
4A,O
top,O
).,O
To,O
confirm,O
the,O
anther,O
wall,O
structure,O
",",O
lactic,O
acid,O
was,O
used,O
to,O
clear,O
the,O
anthers,O
.,O
Under,O
UV,O
-,O
illumination,O
",",O
a,O
net,O
-,O
like,O
structure,O
of,O
autofluorescent,O
material,O
could,O
be,O
seen,O
at,O
stage,O
12,O
or,O
13,O
in,O
wild,O
-,O
type,O
plants,B-OG
",",O
indicating,O
that,O
there,O
was,O
lignification,O
of,O
the,O
anther,O
wall,O
(,O
Figure,O
4B,O
",",O
bottom,O
).,O
However,O
",",O
these,O
structures,O
were,O
not,O
found,O
in,O
the,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
plants,B-OG
(,O
Figure,O
4B,O
",",O
top,O
).,O
Furthermore,O
",",O
we,O
investigated,O
the,O
lignification,O
patterns,O
in,O
both,O
wild,O
-,O
type,O
and,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
using,O
phloroglucinol,O
staining,O
",",O
which,O
is,O
a,O
histochemical,O
stain,O
commonly,O
used,O
for,O
specifically,O
staining,O
lignin,O
[,O
23,O
].,O
Phloroglucinol,O
-,O
stained,O
substances,O
accumulated,O
to,O
a,O
high,O
degree,O
in,O
wild,O
-,O
type,O
anthers,O
during,O
their,O
development,O
",",O
both,O
at,O
stage,O
13,O
and,O
after,O
flowering,O
(,O
Figure,O
5A,O
and,O
5B,O
).,O
By,O
contrast,O
",",O
phloroglucinol,O
staining,O
was,O
not,O
observed,O
in,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
during,O
flower,O
development,O
(,O
Figure,O
5A,O
and,O
5B,O
).,O
Moreover,O
",",O
the,O
expression,O
levels,O
of,O
the,O
lignin,O
biosynthesis,O
genes,O
4CL,B-GP
(,O
4,B-GP
-,I-GP
coumarate,I-GP
:,I-GP
CoAligase,I-GP
"),",O
CCoAOMT,B-GP
(,O
caffeoyl,B-GP
CoA,I-GP
O,I-GP
-,I-GP
methyltransferase,I-GP
"),",O
and,O
C3H,B-GP
(,O
cinnamic,B-GP
acid,I-GP
3,I-GP
-,I-GP
hydroxylase,I-GP
),O
were,O
low,O
in,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
flowers,O
",",O
especially,O
at,O
stage,O
13,O
or,O
later,O
",",O
compared,O
with,O
wild,O
-,O
type,O
flowers,O
(,O
Figure,O
5C,O
).,O
For,O
example,O
",",O
at,O
flowers,O
development,O
13,O
stage,O
",",O
the,O
relative,O
expression,O
level,O
of,O
4CL,B-GP
",",O
CCoAOMT,B-GP
were,O
0,O
.,O
8,O
",",O
0,O
.,O
3,O
in,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
plants,B-OG
but,O
1,O
.,O
3,O
",",O
0,O
.,O
7,O
in,O
wild,O
-,O
type,O
plants,B-OG
.,O
Endothecial,O
secondary,O
wall,O
thickening,O
in,O
anthers,O
from,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
plants,B-OG
.,O
(,O
A,O
),O
Anthers,O
were,O
stained,O
with,O
ethidium,O
bromide,O
and,O
visualized,O
by,O
confocal,O
microscopy,O
.,O
Secondary,O
thickening,O
occurs,O
in,O
the,O
endothecium,O
(,O
indicated,O
by,O
an,O
arrow,O
).,O
Thickening,O
is,O
clearly,O
observed,O
in,O
WT,O
but,O
is,O
reduced,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
endothecium,O
.,O
(,O
B,O
),O
Lactic,O
acid,O
-,O
cleared,O
anthers,O
visualized,O
by,O
confocal,O
microscopy,O
.,O
The,O
secondary,O
thickening,O
network,O
is,O
clearly,O
observed,O
in,O
WT,O
plants,B-OG
",",O
but,O
not,O
in,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
plants,B-OG
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
).,O
Histochemical,O
staining,O
of,O
lignin,O
components,O
in,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
and,O
WT,O
Arabidopsis,B-OG
.,O
(,O
A,O
),O
Phloroglucinol,O
staining,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
flowers,O
.,O
Phloroglucinol,O
-,O
stained,O
material,O
was,O
highly,O
accumulated,O
in,O
WT,O
anthers,O
but,O
not,O
in,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
during,O
flower,O
development,O
.,O
(,O
B,O
),O
Magnified,O
views,O
of,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
and,O
WT,O
anthers,O
stained,O
with,O
phloroglucinol,O
.,O
(,O
C,O
),O
The,O
expression,O
levels,O
of,O
4CL,B-GP
(,O
4,B-GP
-,I-GP
coumarate,I-GP
:,I-GP
CoAligase,I-GP
"),",O
CCoAOMT,B-GP
(,O
caffeoyl,B-GP
CoA,I-GP
O,I-GP
-,I-GP
methyltransferase,I-GP
"),",O
and,O
C3H,B-GP
(,O
cinnamic,B-GP
acid,I-GP
3,I-GP
-,I-GP
hydroxylase,I-GP
),O
were,O
detected,O
in,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
flowers,O
using,O
quantitative,O
real,O
-,O
time,O
polymerase,O
chain,O
reaction,O
(,O
qRT,O
-,O
PCR,O
),O
with,O
the,O
EF1a,B-GP
gene,O
as,O
an,O
internal,O
standard,O
.,O
Results,O
were,O
presented,O
as,O
means,O
±,O
SE,O
from,O
three,O
replications,O
.,O
Anthers,O
of,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
Plants,B-OG
have,O
Reduced,O
ROS,O
Level,O
To,O
assess,O
whether,O
the,O
sterility,O
of,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
flowers,O
was,O
related,O
to,O
plant,B-OG
signaling,O
molecules,O
",",O
we,O
measured,O
the,O
ROS,O
and,O
NO,O
(,O
nitric,O
oxide,O
),O
levels,O
in,O
both,O
transgenic,O
and,O
wild,O
-,O
type,O
anthers,O
using,O
florescence,O
staining,O
.,O
Our,O
results,O
clearly,O
demonstrated,O
that,O
there,O
was,O
no,O
difference,O
in,O
NO,O
content,O
between,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
and,O
wild,O
-,O
type,O
anthers,O
(,O
Figure,O
S4,O
).,O
However,O
",",O
the,O
transgenic,O
anthers,O
accumulated,O
significantly,O
lower,O
levels,O
of,O
ROS,O
than,O
wild,O
-,O
type,O
plants,B-OG
(,O
Figure,O
6A,O
).,O
We,O
further,O
investigated,O
ROS,O
production,O
in,O
anthers,O
during,O
development,O
by,O
histochemical,O
staining,O
.,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
produced,O
low,O
levels,O
of,O
H2O2,O
(,O
Figure,O
6B,O
",",O
DAB,O
staining,O
),O
but,O
equivalent,O
amounts,O
of,O
O2,O
−,O
(,O
Figure,O
S5,O
",",O
NBT,O
staining,O
),O
compared,O
with,O
wild,O
-,O
type,O
plants,B-OG
.,O
To,O
gain,O
further,O
insight,O
into,O
the,O
low,O
ROS,O
levels,O
in,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
",",O
we,O
analyzed,O
the,O
expression,O
levels,O
of,O
genes,O
in,O
the,O
ROS,O
network,O
.,O
The,O
expression,O
levels,O
of,O
some,O
genes,O
that,O
encode,O
ROS,O
-,O
scavenging,O
enzymes,O
",",O
e,O
.,O
g,O
".,",O
cytosolic,B-GP
ascorbate,I-GP
peroxidase1,I-GP
(,O
cAPX1,B-GP
"),",O
ascorbate,B-GP
peroxidase2,I-GP
(,O
APX2,B-GP
"),",O
and,O
Fe,B-GP
superoxide,I-GP
dismutase,I-GP
(,O
FSD1,B-GP
"),",O
increased,O
in,O
the,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
anthers,O
about,O
2,O
-,O
fold,O
higher,O
than,O
in,O
wild,O
-,O
type,O
",",O
but,O
the,O
levels,O
of,O
ROS,O
-,O
producing,O
related,O
genes,O
",",O
e,O
.,O
g,O
".,",O
respiratory,B-GP
burst,I-GP
oxidase,I-GP
homolog,I-GP
A,I-GP
(,O
RBOHA,B-GP
),O
and,O
respiratory,B-GP
burst,I-GP
oxidase,I-GP
homolog,I-GP
B,I-GP
(,O
RBOHB,B-GP
"),",O
were,O
reduced,O
in,O
the,O
transgenic,O
anthers,O
compared,O
with,O
the,O
wild,O
type,O
(,O
Figure,O
6C,O
).,O
These,O
results,O
show,O
that,O
the,O
accumulation,O
of,O
ROS,O
in,O
anthers,O
prior,O
to,O
dehiscence,O
is,O
nearly,O
absent,O
when,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
is,O
ectopically,O
expressed,O
.,O
Anthers,O
from,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
plants,B-OG
exhibit,O
low,O
ROS,O
and,O
H2O2,O
contents,O
compared,O
with,O
WT,O
plants,B-OG
.,O
(,O
A,O
),O
ROS,O
was,O
detected,O
by,O
staining,O
with,O
DCFH,O
-,O
DA,O
and,O
visualized,O
by,O
confocal,O
microscopy,O
.,O
(,O
B,O
),O
H2O2,O
was,O
detected,O
by,O
staining,O
with,O
DAB,O
.,O
(,O
C,O
),O
The,O
expression,O
levels,O
of,O
cytosolic,B-GP
ascorbate,I-GP
peroxidase1,I-GP
(,O
cAPX1,B-GP
"),",O
ascorbate,B-GP
peroxidase2,I-GP
(,O
APX2,B-GP
"),",O
Fe,B-GP
superoxide,I-GP
dismutase,I-GP
(,O
FSD1,B-GP
"),",O
respiratory,B-GP
burst,I-GP
oxidase,I-GP
homolog,I-GP
A,I-GP
(,O
RBOHA,B-GP
"),",O
and,O
respiratory,B-GP
burst,I-GP
oxidase,I-GP
homolog,I-GP
B,I-GP
(,O
RBOHB,B-GP
),O
were,O
detected,O
in,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
flowers,O
using,O
qRT,O
-,O
PCR,O
with,O
the,O
EF1a,B-GP
gene,O
as,O
an,O
internal,O
standard,O
.,O
Results,O
were,O
presented,O
as,O
means,O
±,O
SE,O
from,O
three,O
replications,O
.,O
Discussion,O
Rice,B-DS
black,I-DS
-,I-DS
streaked,I-DS
dwarf,I-DS
and,O
maize,B-DS
rough,I-DS
dwarf,I-DS
diseases,I-DS
",",O
which,O
are,O
caused,O
by,O
RBSDV,B-OG
",",O
lead,O
to,O
severe,O
yield,O
losses,O
in,O
crops,O
in,O
southeast,O
Asian,O
countries,O
",",O
especially,O
China,O
[,O
3,O
"],",O
[,O
4,O
].,O
Although,O
a,O
great,O
deal,O
of,O
effort,O
has,O
been,O
made,O
to,O
elucidate,O
the,O
interactions,O
between,O
the,O
virus,B-OG
",",O
insect,B-OG
vectors,O
",",O
and,O
host,O
and,O
environmental,O
conditions,O
",",O
few,O
RBSDV,B-OG
proteins,O
involved,O
in,O
pathogenesis,O
have,O
been,O
identified,O
",",O
and,O
the,O
biochemical,O
basis,O
of,O
disease,O
symptom,O
development,O
remains,O
largely,O
unknown,O
.,O
In,O
this,O
study,O
",",O
our,O
results,O
suggest,O
that,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
is,O
a,O
novel,O
determinant,O
of,O
disease,O
symptom,O
development,O
.,O
First,O
",",O
RBSDV,B-DS
infection,I-DS
caused,O
alterations,O
in,O
anther,O
development,O
in,O
rice,B-OG
plants,I-OG
",",O
resulting,O
in,O
partial,O
sterility,O
due,O
to,O
non,O
-,O
dehiscent,O
anthers,O
(,O
Figure,O
1,O
).,O
Furthermore,O
",",O
overexpressing,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
in,O
Arabidopsis,B-OG
produced,O
plants,B-OG
with,O
male,O
sterility,O
resulting,O
from,O
non,O
-,O
dehiscent,O
anthers,O
(,O
Figure,O
2,O
"),",O
which,O
approximately,O
mimicked,O
the,O
disease,O
symptoms,O
observed,O
in,O
rice,B-OG
anthers,O
.,O
The,O
non,O
-,O
dehiscent,O
anther,O
phenotype,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
plants,B-OG
was,O
correlated,O
with,O
reduced,O
secondary,O
wall,O
lignification,O
in,O
the,O
endothecium,O
and,O
decreased,O
ROS,O
levels,O
in,O
the,O
anthers,O
(,O
Figure,O
5,O
and,O
6,O
).,O
Taken,O
together,O
",",O
these,O
results,O
suggest,O
that,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
is,O
likely,O
to,O
be,O
a,O
pivotal,O
determinant,O
of,O
plant,B-OG
sterility,O
symptoms,O
caused,O
by,O
RBSDV,B-OG
.,O
Previous,O
studies,O
using,O
immunoelectron,O
analysis,O
have,O
revealed,O
that,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
accumulates,O
in,O
tubular,O
structures,O
in,O
virus,B-OG
-,O
infected,O
maize,B-OG
plants,B-OG
and,O
in,O
insects,B-OG
[,O
8,O
].,O
Furthermore,O
",",O
P7,B-GP
-,I-GP
1,I-GP
of,O
SRBSDV,B-OG
(,O
southern,B-OG
rice,I-OG
black,I-OG
-,I-OG
streaked,I-OG
dwarf,I-OG
virus,I-OG
"),",O
which,O
is,O
most,O
closely,O
related,O
to,O
RBSDV,B-OG
",",O
has,O
the,O
intrinsic,O
ability,O
to,O
form,O
tubules,O
growing,O
from,O
the,O
non,O
-,O
host,O
insect,B-OG
cell,O
surface,O
in,O
the,O
absence,O
of,O
other,O
virus,B-OG
proteins,O
[,O
24,O
].,O
Recent,O
researches,O
using,O
live,O
-,O
cell,O
imaging,O
in,O
Nicotiana,B-OG
benthamiana,I-OG
leaves,O
also,O
demonstrate,O
that,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
protein,O
forms,O
punctuate,O
points,O
at,O
plasmodesmata,O
[,O
16,O
].,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
characteristics,O
of,O
tubule,O
-,O
forming,O
and,O
plasmodesmata,O
localization,O
suggest,O
that,O
this,O
protein,O
might,O
be,O
involved,O
in,O
virus,B-OG
intercellular,O
movement,O
",",O
in,O
infected,O
insect,B-OG
and,O
plant,B-OG
cells,O
.,O
The,O
pathogenesis,O
of,O
tubular,B-GP
proteins,I-GP
during,O
viral,O
morphogenesis,O
has,O
been,O
reported,O
in,O
studies,O
of,O
other,O
members,O
of,O
the,O
family,O
Reoviridae,B-OG
.,O
For,O
example,O
",",O
BTV,B-OG
(,O
bluetongue,B-OG
virus,I-OG
),O
nonstructural,B-GP
tubular,I-GP
protein,I-GP
NS1,I-GP
plays,O
a,O
direct,O
role,O
in,O
cellular,O
pathogenesis,O
[,O
25,O
].,O
RDV,B-OG
(,O
rice,B-OG
dwarf,I-OG
virus,I-OG
),O
nonstructural,O
tubular,O
protein,B-GP
Pns10,I-GP
functions,O
as,O
a,O
viral,O
suppressor,O
of,O
RNA,O
silencing,O
and,O
plays,O
important,O
roles,O
in,O
enhancing,O
viral,O
replication,O
",",O
systemic,O
movement,O
",",O
and,O
invasion,O
of,O
new,O
tissues,O
[,O
26,O
].,O
Therefore,O
",",O
the,O
tubular,B-GP
proteins,I-GP
of,O
reoviruses,B-OG
have,O
multiple,O
functions,O
in,O
viral,O
morphogenesis,O
",",O
viral,B-DS
infection,I-DS
",",O
and,O
virulence,O
.,O
In,O
support,O
of,O
this,O
notion,O
",",O
our,O
data,O
show,O
that,O
overexpression,O
of,O
RBSDV,B-OG
tubular,B-GP
protein,I-GP
P7,I-GP
-,I-GP
1,I-GP
in,O
Arabidopsis,B-OG
causes,O
male,O
sterility,O
",",O
which,O
mimics,O
the,O
phenotype,O
observed,O
in,O
rice,B-OG
flowers,O
infected,O
with,O
the,O
virus,B-OG
.,O
It,O
will,O
be,O
interesting,O
to,O
examine,O
whether,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
",",O
like,O
RDV,B-OG
Pns10,B-GP
",",O
can,O
function,O
as,O
a,O
viral,O
suppressor,O
of,O
RNA,O
silencing,O
.,O
In,O
this,O
study,O
",",O
we,O
determined,O
that,O
the,O
male,O
sterility,O
of,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
transgenic,O
plants,B-OG
was,O
due,O
to,O
the,O
failure,O
of,O
anther,O
dehiscence,O
and,O
pollen,O
release,O
",",O
which,O
may,O
have,O
been,O
caused,O
by,O
the,O
lack,O
of,O
lignification,O
in,O
the,O
anther,O
endothecium,O
(,O
Figure,O
4,O
and,O
5,O
).,O
Actually,O
",",O
secondary,O
lignified,O
thickening,O
in,O
the,O
endothecium,O
is,O
critical,O
for,O
providing,O
the,O
mechanical,O
force,O
required,O
for,O
anther,O
dehiscence,O
[,O
22,O
"],",O
[,O
27,O
"],",O
[,O
28,O
].,O
This,O
mechanism,O
has,O
been,O
demonstrated,O
experimentally,O
by,O
analyzing,O
Arabidopsis,B-OG
mutants,O
such,O
as,O
myb26,B-GP
[,O
29,O
]–[,O
31,O
"],",O
NST1,B-GP
(,O
SECONDARYWALL,O
THICKENING,O
PROMOTING,O
FACTOR1,O
"),",O
and,O
NST2,B-GP
[,O
32,O
].,O
In,O
these,O
mutants,O
",",O
reduced,O
lignification,O
of,O
anther,O
endothecium,O
results,O
in,O
anther,O
indehiscent,O
and,O
male,O
sterility,O
.,O
Furthermore,O
",",O
the,O
triple,O
ccc,O
mutant,O
",",O
which,O
carries,O
mutations,O
in,O
monolignol,O
biosynthesis,O
genes,O
",",O
including,O
CCR1,B-GP
(,O
cinnamoyl,B-GP
CoA,I-GP
reductase1,I-GP
"),",O
CAD,B-GP
c,I-GP
(,O
cinnamyl,B-GP
alcohol,I-GP
dehydrogenase,I-GP
c,I-GP
"),",O
and,O
CAD,B-GP
d,I-GP
",",O
displays,O
severe,O
male,O
sterility,O
due,O
to,O
the,O
lack,O
of,O
lignification,O
in,O
the,O
anther,O
endothecium,O
[,O
19,O
].,O
Here,O
",",O
we,O
showed,O
that,O
the,O
transcriptional,O
levels,O
of,O
the,O
lignin,O
biosynthesis,O
genes,O
4CL,B-GP
",",O
CCoAOMT,B-GP
",",O
and,O
C3H,B-GP
were,O
reduced,O
in,O
the,O
flowers,O
of,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
plants,B-OG
compared,O
with,O
the,O
flowers,O
of,O
wild,O
-,O
type,O
plants,B-OG
(,O
Figure,O
5,O
"),",O
although,O
the,O
expression,O
levels,O
of,O
CCR1,B-GP
",",O
CAD,B-GP
c,I-GP
",",O
and,O
CAD,B-GP
d,I-GP
were,O
unchanged,O
in,O
the,O
transgenic,O
plants,B-OG
(,O
data,O
not,O
shown,O
).,O
Thus,O
",",O
the,O
reduced,O
lignification,O
of,O
anthers,O
is,O
responsible,O
for,O
male,O
sterility,O
in,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
transgenic,O
plants,B-OG
.,O
It,O
is,O
well,O
-,O
established,O
that,O
secondary,O
lignification,O
in,O
cell,O
walls,O
is,O
dependent,O
on,O
the,O
oxidative,O
coupling,O
of,O
monolignol,O
to,O
form,O
the,O
polymer,O
lignin,O
",",O
which,O
is,O
catalyzed,O
by,O
H2O2,O
-,O
dependent,O
peroxidases,B-GP
and,O
O2,O
-,O
dependent,O
laccase,B-GP
[,O
33,O
"],",O
[,O
34,O
].,O
In,O
the,O
endodermal,O
cells,O
of,O
roots,O
",",O
subcellular,O
precision,O
of,O
lignin,O
polymerization,O
is,O
achieved,O
by,O
restricted,O
",",O
localized,O
peroxidase,B-GP
activity,O
and,O
the,O
production,O
of,O
ROS,O
substrate,O
[,O
35,O
].,O
In,O
the,O
secondary,O
thickening,O
that,O
occurs,O
in,O
anthers,O
",",O
lignin,O
polymerization,O
is,O
dependent,O
on,O
the,O
H2O2,O
contents,O
.,O
For,O
example,O
",",O
Arabidopsis,B-OG
plants,B-OG
ectopically,O
expressing,O
gamma,B-GP
carbonic,I-GP
anhydrase,I-GP
2,I-GP
(,O
CA2,B-GP
),O
have,O
significantly,O
lower,O
ROS,O
contents,O
than,O
wild,O
type,O
",",O
which,O
results,O
in,O
a,O
reduction,O
in,O
the,O
H2O2,O
-,O
dependent,O
polymerization,O
pathway,O
for,O
lignin,O
formation,O
during,O
anther,O
development,O
and,O
accordingly,O
",",O
causes,O
male,O
sterility,O
[,O
36,O
].,O
Our,O
data,O
also,O
show,O
that,O
ectopic,O
expression,O
of,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
in,O
Arabidopsis,B-OG
causes,O
male,O
sterility,O
in,O
conjunction,O
with,O
low,O
ROS,O
contents,O
in,O
anthers,O
compared,O
with,O
wild,O
-,O
type,O
plants,B-OG
(,O
Figure,O
6,O
).,O
Thus,O
",",O
it,O
is,O
reasonable,O
to,O
speculate,O
that,O
the,O
male,O
sterility,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
plants,B-OG
is,O
primarily,O
achieved,O
by,O
the,O
combinatorial,O
action,O
of,O
reduced,O
monolignol,O
and,O
ROS,O
contents,O
.,O
In,O
the,O
future,O
",",O
it,O
will,O
be,O
important,O
to,O
untangle,O
the,O
relationship,O
between,O
reduced,O
production,O
of,O
ROS,O
or,O
lignin,O
and,O
RBSDV,B-OG
tubular,B-GP
protein,I-GP
P7,I-GP
-,I-GP
1,I-GP
.,O
Such,O
information,O
would,O
significantly,O
deepen,O
our,O
mechanistic,O
understanding,O
of,O
the,O
role,O
of,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
in,O
viral,O
virulence,O
.,O
Supporting,O
Information,O
Molecular,O
identity,O
of,O
RBSDV,B-OG
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
Arabidopsis,B-OG
plants,B-OG
.,O
(,O
A,O
),O
Selection,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
lines,O
on,O
MS,O
medium,O
with,O
kanamycin,O
or,O
without,O
kanamycin,O
(,O
MS,O
).,O
(,O
B,O
),O
Genome,O
DNA,O
PCR,O
showing,O
that,O
P7,B-GP
-,I-GP
1,I-GP
was,O
integrated,O
as,O
a,O
unit,O
in,O
the,O
transgenic,O
lines,O
.,O
EF1α,B-GP
was,O
used,O
to,O
control,O
for,O
DNA,O
loading,O
.,O
(,O
C,O
),O
qRT,O
-,O
PCR,O
analysis,O
showing,O
the,O
expression,O
of,O
P7,B-GP
-,I-GP
1,I-GP
in,O
wild,O
-,O
type,O
and,O
three,O
independent,O
transgenic,O
lines,O
using,O
the,O
EF1a,B-GP
gene,O
as,O
an,O
internal,O
standard,O
.,O
Results,O
were,O
presented,O
as,O
means,O
±,O
SE,O
from,O
three,O
replications,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Alexander,O
staining,O
of,O
pollen,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
and,O
wild,O
-,O
type,O
Arabidopsis,B-OG
plants,B-OG
.,O
(,O
A,O
),O
Cytological,O
comparisons,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
lines,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
anthers,O
during,O
development,O
.,O
(,O
B,O
",",O
C,O
),O
Alexander,O
staining,O
pollen,O
of,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Hand,O
-,O
pollinated,O
pollen,O
grains,O
from,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
plants,B-OG
could,O
fertilize,O
egg,O
cells,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
NO,O
detected,O
by,O
staining,O
with,O
DAF,O
-,O
FM,O
DA,O
in,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
anthers,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
O2,O
−,O
detected,O
by,O
staining,O
with,O
NBT,O
in,O
P7,B-GP
-,I-GP
1,I-GP
transgenic,O
(,O
P7,B-GP
-,I-GP
1,I-GP
-,O
OE,O
),O
and,O
wild,O
-,O
type,O
(,O
WT,O
),O
Arabidopsis,B-OG
anthers,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
List,O
of,O
primers,O
used,O
in,O
this,O
study,O
.,O
(,O
DOC,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Higher,O
Dimensional,O
Meta,O
-,O
State,O
Analysis,O
Reveals,O
Reduced,O
Resting,O
fMRI,O
Connectivity,O
Dynamism,O
in,O
Schizophrenia,B-DS
Patients,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
RLM,O
MY,O
VDC,O
.,O
Performed,O
the,O
experiments,O
:,O
RLM,O
.,O
Analyzed,O
the,O
data,O
:,O
RLM,O
.,O
Wrote,O
the,O
paper,O
:,O
RLM,O
MY,O
VDC,O
JAT,O
DM,O
AP,O
GP,O
TA,O
.,O
Contributed,O
data,O
:,O
JAT,O
DM,O
AP,O
GP,O
.,O
Resting,O
-,O
state,O
functional,O
brain,O
imaging,O
studies,O
of,O
network,O
connectivity,O
have,O
long,O
assumed,O
that,O
functional,O
connections,O
are,O
stationary,O
on,O
the,O
timescale,O
of,O
a,O
typical,O
scan,O
.,O
Interest,O
in,O
moving,O
beyond,O
this,O
simplifying,O
assumption,O
has,O
emerged,O
only,O
recently,O
.,O
The,O
great,O
hope,O
is,O
that,O
training,O
the,O
right,O
lens,O
on,O
time,O
-,O
varying,O
properties,O
of,O
whole,O
-,O
brain,O
network,O
connectivity,O
will,O
shed,O
additional,O
light,O
on,O
previously,O
concealed,O
brain,O
activation,O
patterns,O
characteristic,O
of,O
serious,O
neurological,O
or,O
psychiatric,B-DS
disorders,I-DS
.,O
We,O
present,O
evidence,O
that,O
multiple,O
explicitly,O
dynamical,O
properties,O
of,O
time,O
-,O
varying,O
whole,O
-,O
brain,O
network,O
connectivity,O
are,O
strongly,O
associated,O
with,O
schizophrenia,B-DS
",",O
a,O
complex,O
mental,B-DS
illness,I-DS
whose,O
symptomatic,O
presentation,O
can,O
vary,O
enormously,O
across,O
subjects,O
.,O
As,O
with,O
so,O
much,O
brain,O
-,O
imaging,O
research,O
",",O
a,O
central,O
challenge,O
for,O
dynamic,O
network,O
connectivity,O
lies,O
in,O
determining,O
transformations,O
of,O
the,O
data,O
that,O
both,O
reduce,O
its,O
dimensionality,O
and,O
expose,O
features,O
that,O
are,O
strongly,O
predictive,O
of,O
important,O
population,O
characteristics,O
.,O
Our,O
paper,O
introduces,O
an,O
elegant,O
",",O
simple,O
method,O
of,O
reducing,O
and,O
organizing,O
data,O
around,O
which,O
a,O
large,O
constellation,O
of,O
mutually,O
informative,O
and,O
intuitive,O
dynamical,O
analyses,O
can,O
be,O
performed,O
.,O
This,O
framework,O
combines,O
a,O
discrete,O
multidimensional,O
data,O
-,O
driven,O
representation,O
of,O
connectivity,O
space,O
with,O
four,O
core,O
dynamism,O
measures,O
computed,O
from,O
large,O
-,O
scale,O
properties,O
of,O
each,O
subject,O
’,O
s,O
trajectory,O
",",O
ie,O
".,",O
properties,O
not,O
identifiable,O
with,O
any,O
specific,O
moment,O
in,O
time,O
and,O
therefore,O
reasonable,O
to,O
employ,O
in,O
settings,O
lacking,O
inter,O
-,O
subject,O
time,O
-,O
alignment,O
",",O
such,O
as,O
resting,O
-,O
state,O
functional,O
imaging,O
studies,O
.,O
Our,O
analysis,O
exposes,O
pronounced,O
differences,O
between,O
schizophrenia,B-DS
patients,O
(,O
Nsz,O
=,O
151,O
),O
and,O
healthy,O
controls,O
(,O
Nhc,O
=,O
163,O
).,O
Time,O
-,O
varying,O
whole,O
-,O
brain,O
network,O
connectivity,O
patterns,O
are,O
found,O
to,O
be,O
markedly,O
less,O
dynamically,O
active,O
in,O
schizophrenia,B-DS
patients,O
",",O
an,O
effect,O
that,O
is,O
even,O
more,O
pronounced,O
in,O
patients,O
with,O
high,O
levels,O
of,O
hallucinatory,B-DS
behavior,I-DS
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
this,O
is,O
the,O
first,O
demonstration,O
that,O
high,O
-,O
level,O
dynamic,O
properties,O
of,O
whole,O
-,O
brain,O
connectivity,O
",",O
generic,O
enough,O
to,O
be,O
commensurable,O
under,O
many,O
decompositions,O
of,O
time,O
-,O
varying,O
connectivity,O
data,O
",",O
exhibit,O
robust,O
and,O
systematic,O
differences,O
between,O
schizophrenia,B-DS
patients,O
and,O
healthy,O
controls,O
.,O
Introduction,O
Many,O
neurological,O
",",O
cognitive,O
and,O
psychiatric,B-DS
disorders,I-DS
have,O
been,O
shown,O
to,O
affect,O
connectivity,O
between,O
functional,O
brain,O
networks,O
[,O
1,O
–,O
24,O
],O
even,O
in,O
so,O
-,O
called,O
"""",O
resting,O
"""",O
conditions,O
where,O
subjects,O
are,O
not,O
engaged,O
in,O
a,O
task,O
.,O
Network,O
connectivity,O
is,O
typically,O
assessed,O
as,O
a,O
stationary,O
feature,O
of,O
the,O
data,O
",",O
inferred,O
from,O
the,O
correlation,O
or,O
mutual,O
information,O
between,O
pairs,O
of,O
network,O
activation,O
timecourses,O
that,O
extend,O
through,O
the,O
duration,O
of,O
the,O
scan,O
.,O
Although,O
a,O
useful,O
simplification,O
",",O
there,O
is,O
no,O
a,O
priori,O
reason,O
to,O
believe,O
that,O
network,O
correlations,O
are,O
stationary,O
",",O
especially,O
in,O
the,O
resting,O
brain,O
.,O
In,O
fact,O
",",O
one,O
might,O
expect,O
cross,O
-,O
network,O
connections,O
to,O
vary,O
and,O
evolve,O
as,O
subjects,O
experience,O
different,O
thoughts,O
",",O
degrees,O
of,O
drowsiness,O
",",O
memories,O
and,O
emotional,O
states,O
.,O
Far,O
from,O
being,O
canonical,O
",",O
scan,O
duration,O
is,O
simply,O
one,O
of,O
the,O
unavoidably,O
fixed,O
features,O
of,O
any,O
functional,O
imaging,O
study,O
.,O
Thus,O
",",O
averaging,O
evidence,O
of,O
connectivity,O
over,O
an,O
entire,O
resting,O
fMRI,O
scan,O
puts,O
researchers,O
at,O
risk,O
of,O
obscuring,O
distinct,O
",",O
meaningful,O
connectivity,O
regimes,O
that,O
subjects,O
are,O
passing,O
through,O
(,O
Fig,O
1A,O
and,O
1B,O
).,O
Recent,O
investigations,O
of,O
dynamic,O
connectivity,O
have,O
in,O
fact,O
shown,O
not,O
only,O
that,O
connections,O
are,O
varying,O
through,O
time,O
[,O
25,O
–,O
36,O
"],",O
but,O
that,O
this,O
variation,O
takes,O
different,O
forms,O
in,O
different,O
demographic,O
[,O
35,O
],O
and,O
diagnostic,O
[,O
16,O
",",O
26,O
",",O
30,O
",",O
32,O
",",O
33,O
",",O
37,O
–,O
39,O
],O
groups,O
Dynamic,O
Connectivity,O
",",O
Single,O
and,O
Higher,O
Dimensional,O
Representations,O
(,O
A,O
),O
Example,O
of,O
two,O
network,O
timecourses,O
whose,O
correlation,O
evaluated,O
over,O
their,O
entire,O
duration,O
is,O
0,O
.,O
4,O
;,O
(,O
B,O
),O
One,O
of,O
the,O
many,O
different,O
ways,O
that,O
a,O
pair,O
of,O
long,O
timecourses,O
can,O
have,O
correlation,O
coefficient,O
of,O
0,O
.,O
4,O
is,O
to,O
pass,O
through,O
the,O
two,O
distinct,O
",",O
identifiable,O
connectivity,O
regimes,O
shown,O
here,O
.,O
The,O
existence,O
of,O
the,O
two,O
connectivity,O
regimes,O
and,O
the,O
transitions,O
between,O
them,O
are,O
completely,O
obscured,O
by,O
looking,O
at,O
correlation,O
on,O
a,O
longer,O
timescale,O
;,O
(,O
C,O
and,O
D,O
),O
Too,O
crude,O
a,O
dimensionality,O
-,O
reduction,O
of,O
the,O
state,O
space,O
can,O
create,O
serious,O
distortions,O
of,O
the,O
dynamics,O
being,O
analyzed,O
.,O
Dynamically,O
active,O
and,O
mobile,O
trajectories,O
(,O
C,O
),O
can,O
appear,O
constant,O
under,O
the,O
reduction,O
",",O
while,O
those,O
barely,O
moving,O
from,O
their,O
starting,O
position,O
(,O
D,O
),O
can,O
seem,O
highly,O
dynamic,O
;,O
(,O
E,O
),O
Shifting,O
up,O
one,O
dimension,O
and,O
characterizing,O
the,O
same,O
trajectories,O
by,O
vectors,O
reflecting,O
their,O
position,O
In,O
a,O
discrete,O
2,O
-,O
dimensional,O
state,O
space,O
yields,O
much,O
better,O
qualitative,O
agreement,O
between,O
the,O
geometric,O
trajectories,O
and,O
their,O
symbolic,O
representations,O
.,O
Most,O
work,O
on,O
dynamic,O
functional,O
network,O
connectivity,O
(,O
dFNC,O
),O
to,O
date,O
has,O
been,O
focused,O
on,O
computing,O
and,O
statistically,O
summarizing,O
cross,O
-,O
network,O
correlations,O
evaluated,O
separately,O
on,O
successive,O
sliding,O
windows,O
through,O
the,O
original,O
scan,O
-,O
length,O
network,O
timecourses,O
[,O
16,O
",",O
25,O
",",O
26,O
",",O
30,O
",",O
32,O
",",O
33,O
",",O
35,O
",",O
37,O
",",O
38,O
",",O
40,O
",",O
41,O
].,O
The,O
resulting,O
window,O
-,O
indexed,O
correlation,O
matrices,O
",",O
called,O
windowed,O
functional,O
network,O
connectivity,O
matrices,O
(,O
wFNC,O
"),",O
record,O
snapshots,O
of,O
network,O
connectivity,O
evolving,O
in,O
time,O
.,O
The,O
collection,O
of,O
wFNCs,O
for,O
a,O
given,O
subject,O
yields,O
N,O
(,O
N,O
−,O
1,O
),O
2,O
length,O
-,O
T,O
timeseries,O
",",O
one,O
for,O
each,O
of,O
network,O
-,O
pair,O
correlation,O
",",O
where,O
T,O
is,O
the,O
number,O
of,O
windows,O
and,O
N,O
the,O
number,O
of,O
networks,O
.,O
The,O
very,O
first,O
investigations,O
[,O
25,O
",",O
26,O
],O
of,O
dynamic,O
FNC,O
used,O
clustering,O
as,O
a,O
dimensionality,O
reduction,O
tool,O
",",O
collapsing,O
a,O
d,O
=,O
N,O
(,O
N,O
−,O
1,O
),O
N,O
>,O
1000,O
dimensional,O
connectivity,O
space,O
to,O
just,O
one,O
dimension,O
(,O
ie,O
".,",O
replacing,O
an,O
over,O
1000,O
-,O
dimensional,O
object,O
with,O
the,O
index,O
i,O
∈,O
{,O
1,O
",",O
2,O
",…,",O
k,O
},O
of,O
the,O
cluster,O
to,O
which,O
it,O
belongs,O
).,O
Although,O
some,O
interesting,O
results,O
have,O
emerged,O
from,O
this,O
initial,O
work,O
",",O
collapsing,O
connectivity,O
space,O
onto,O
a,O
single,O
dimension,O
is,O
the,O
crudest,O
possible,O
dimension,O
-,O
reduction,O
.,O
A,O
reduction,O
of,O
this,O
magnitude,O
inevitably,O
obscures,O
and,O
distorts,O
important,O
features,O
of,O
dynamical,O
network,O
-,O
coupling,O
behavior,O
(,O
Fig,O
1C,O
",",O
1D,O
and,O
1E,O
),O
that,O
might,O
characterize,O
clinically,O
or,O
demographically,O
defined,O
groups,O
Our,O
approach,O
models,O
windowed,O
FNCs,O
as,O
weighted,O
sums,O
of,O
maximally,O
independent,O
connectivity,O
patterns,O
(,O
CPs,O
),O
(,O
Fig,O
2C,O
and,O
2D,O
"),",O
Fig,O
3A,O
and,O
3B,O
).,O
Each,O
wFNC,O
is,O
recast,O
as,O
a,O
discretized,O
vector,O
of,O
CP,O
weights,O
",",O
called,O
a,O
meta,O
-,O
state,O
(,O
Fig,O
2,O
(,O
A,O
"),",O
Fig,O
3,O
(,O
C,O
)).,O
This,O
specific,O
approach,O
was,O
motivated,O
by,O
a,O
desire,O
to,O
understand,O
network,O
connectivity,O
dynamics,O
in,O
terms,O
of,O
(,O
not,O
necessarily,O
observable,O
),O
patterns,O
of,O
signed,O
network,O
pair,O
correlations,O
that,O
“,O
pipe,O
in,O
”,O
and,O
fade,O
out,O
of,O
observed,O
wFNCs,O
in,O
a,O
relatively,O
independent,O
manner,O
.,O
We,O
introduce,O
a,O
set,O
of,O
simple,O
dynamism,O
measures,O
easily,O
calculated,O
from,O
subject,O
trajectories,O
through,O
the,O
induced,O
discrete,O
five,O
-,O
dimensional,O
state,O
-,O
space,O
",",O
finding,O
consistent,O
",",O
significant,O
and,O
replicable,O
differences,O
in,O
connectivity,O
dynamics,O
between,O
schizophrenia,B-DS
patients,O
and,O
healthy,O
controls,O
(,O
Fig,O
2B,O
and,O
2D,O
).,O
While,O
the,O
temporal,O
behavior,O
of,O
specific,O
network,O
-,O
pair,O
correlations,O
might,O
be,O
of,O
interest,O
in,O
certain,O
narrowly,O
tailored,O
questions,O
",",O
it,O
seems,O
natural,O
to,O
address,O
complex,O
brain,B-DS
diseases,I-DS
that,O
encompass,O
diverse,O
categories,O
and,O
combinations,O
of,O
symptoms,O
at,O
a,O
more,O
aggregated,O
level,O
",",O
examining,O
how,O
patterns,O
or,O
aggregates,O
of,O
network,O
-,O
pair,O
correlations,O
evolve,O
en,O
masse,O
in,O
afflicted,O
populations,O
.,O
Schizophrenia,B-DS
is,O
such,O
a,O
disease,O
",",O
and,O
at,O
the,O
whole,O
-,O
brain,O
level,O
",",O
we,O
find,O
very,O
robust,O
evidence,O
of,O
reduced,O
dynamic,O
fluidity,O
and,O
range,O
in,O
network,O
correlation,O
structure,O
for,O
patients,O
suffering,O
from,O
this,O
varied,O
and,O
complex,O
disorder,O
.,O
The,O
simultaneous,O
weighted,O
contributions,O
",",O
called,O
meta,O
-,O
states,O
",",O
of,O
whole,O
-,O
brain,O
patterns,O
of,O
connectivity,O
to,O
subject,O
wFNCs,O
change,O
less,O
often,O
",",O
and,O
shift,O
between,O
a,O
smaller,O
number,O
of,O
more,O
similar,O
meta,O
-,O
states,O
in,O
schizophrenia,B-DS
patients,O
than,O
in,O
healthy,O
controls,O
(,O
Fig,O
2,O
(,O
D,O
)).,O
Supporting,O
a,O
meta,O
-,O
state,O
approach,O
is,O
the,O
fact,O
that,O
this,O
finding,O
holds,O
for,O
sets,O
of,O
whole,O
-,O
brain,O
network,O
connectivity,O
patterns,O
",",O
generally,O
quite,O
different,O
from,O
each,O
other,O
",",O
derived,O
using,O
various,O
data,O
-,O
driven,O
approaches,O
",",O
including,O
temporal,O
independent,O
component,O
analysis,O
(,O
ICA,O
"),",O
spatial,O
ICA,O
",",O
principal,O
component,O
analysis,O
(,O
PCA,O
),O
and,O
k,O
-,O
means,O
.,O
Meta,O
-,O
State,O
Dynamic,O
FNC,O
:,O
High,O
Level,O
Schematics,O
(,O
A,O
),O
Schematic,O
showing,O
connectivity,O
decomposed,O
into,O
",",O
for,O
simplicity,O
",",O
binary,O
weighted,O
sums,O
of,O
connectivity,O
patterns,O
",",O
yielding,O
meta,O
-,O
states,O
in,O
{,O
0,O
",",O
1,O
},O
s4,O
;,O
(,O
B,O
),O
Histograms,O
of,O
maximal,O
uninterrupted,O
periods,O
spent,O
in,O
any,O
fixed,O
meta,O
-,O
state,O
for,O
patients,O
(,O
red,O
),O
and,O
controls,O
(,O
blue,O
),O
(,O
C,O
),O
A,O
connectivity,O
pattern,O
in,O
which,O
network,O
-,O
pair,O
connections,O
are,O
signed,O
and,O
non,O
-,O
binary,O
(,O
for,O
example,O
",",O
given,O
by,O
correlations,O
),O
and,O
in,O
graph,O
(,O
right,O
),O
and,O
matrix,O
(,O
left,O
),O
forms,O
;,O
(,O
D,O
),O
Schematic,O
illustration,O
of,O
differences,O
in,O
dynamical,O
patterns,O
of,O
network,O
connectivity,O
between,O
schizophrenia,B-DS
patients,O
and,O
healthy,O
controls,O
.,O
Controls,O
exhibit,O
more,O
",",O
and,O
more,O
diverse,O
",",O
connectivity,O
states,O
changing,O
from,O
one,O
connectivity,O
pattern,O
to,O
another,O
more,O
often,O
than,O
patients,O
.,O
Temporal,O
ICA,O
Schematic,O
with,O
Examples,O
of,O
Single,O
Window,O
Weighted,O
CPs,O
and,O
Discretized,O
Time,O
-,O
Varying,O
CP,O
Weights,O
(,O
A,O
),O
Schematic,O
displaying,O
stages,O
involved,O
in,O
producing,O
CPs,O
;,O
top,O
row,O
illustrates,O
the,O
initial,O
decomposition,O
of,O
fMRI,O
data,O
into,O
network,O
spatial,O
maps,O
and,O
corresponding,O
timecourses,O
using,O
group,O
spatial,O
ICA,O
(,O
GICA,O
);,O
bottom,O
row,O
shows,O
decomposition,O
of,O
window,O
-,O
indexed,O
correlation,O
matrices,O
computed,O
on,O
sliding,O
windows,O
through,O
the,O
network,O
timecourses,O
(,O
left,O
-,O
hand,O
side,O
of,O
equation,O
),O
produced,O
by,O
spatial,O
ICA,O
on,O
fMRI,O
data,O
summarized,O
in,O
the,O
top,O
row,O
into,O
temporally,O
independent,O
CPs,O
(,O
matrix,O
W,O
on,O
right,O
hand,O
side,O
of,O
equation,O
),O
using,O
temporal,O
ICA,O
;,O
(,O
B,O
),O
Example,O
of,O
an,O
observed,O
wFNC,O
expressed,O
as,O
weighted,O
sum,O
of,O
the,O
five,O
displayed,O
tICA,O
CPs,O
;,O
(,O
C,O
),O
One,O
subject,O
',O
s,O
CP,O
timecourses,O
(,O
top,O
left,O
),O
transformed,O
into,O
the,O
signed,O
quartile,O
discretization,O
(,O
top,O
right,O
),O
with,O
times,O
at,O
which,O
each,O
discretized,O
timecourse,O
changes,O
from,O
one,O
level,O
to,O
another,O
(,O
bottom,O
and,O
example,O
of,O
one,O
time,O
-,O
indexed,O
5,O
-,O
vector,O
of,O
timecourse,O
values,O
converted,O
into,O
a,O
meta,O
-,O
state,O
of,O
signed,O
quartile,O
values,O
(,O
bottom,O
right,O
).,O
Methods,O
and,O
Materials,O
Sample,O
and,O
Data,O
Acquisition,O
Resting,O
state,O
functional,O
magnetic,O
resonance,O
imaging,O
data,O
(,O
162,O
volumes,O
of,O
echo,O
planar,O
imaging,O
BOLD,O
fMRI,O
",",O
TR,O
=,O
2,O
sec,O
.),O
[,O
26,O
",",O
37,O
],O
was,O
collected,O
from,O
163,O
healthy,O
controls,O
(,O
117,O
males,O
",",O
46,O
females,O
;,O
mean,O
age,O
36,O
.,O
9,O
),O
and,O
151,O
age,O
and,O
gender,O
matched,O
patients,O
with,O
schizophrenia,B-DS
(,O
114,O
males,O
",",O
37,O
females,O
;,O
mean,O
age,O
37,O
.,O
8,O
),O
during,O
eyes,O
closed,O
condition,O
at,O
7,O
different,O
sites,O
across,O
the,O
United,O
States,O
(,O
Table,O
1,O
).,O
Inclusion,O
criteria,O
for,O
the,O
patients,O
were,O
a,O
schizophrenia,B-DS
diagnosis,O
based,O
on,O
the,O
structured,O
clinical,O
interview,O
for,O
DSM,O
-,O
IV,O
-,O
TR,O
axis,B-DS
I,I-DS
disorders,I-DS
(,O
SCID,O
-,O
I,O
/,O
P,O
),O
[,O
42,O
].,O
All,O
patients,O
were,O
clinically,O
stable,O
on,O
antipsychotic,O
medication,O
for,O
at,O
least,O
2,O
months,O
",",O
and,O
had,O
an,O
illness,O
duration,O
of,O
minimally,O
one,O
year,O
.,O
Clinical,O
assessments,O
for,O
the,O
patients,O
included,O
the,O
positive,O
and,O
negative,O
syndrome,O
scale,O
(,O
PANSS,O
),O
[,O
43,O
].,O
Written,O
informed,O
consent,O
was,O
obtained,O
from,O
all,O
study,O
participants,O
",",O
including,O
permission,O
to,O
share,O
de,O
-,O
identified,O
data,O
between,O
the,O
centers,O
and,O
with,O
the,O
wider,O
research,O
community,O
.,O
This,O
analysis,O
of,O
existing,O
data,O
was,O
approved,O
by,O
the,O
institutional,O
review,O
board,O
at,O
the,O
University,O
of,O
New,O
Mexico,O
.,O
Demographic,O
Information,O
.,O
Subject,O
Demographic,O
Information,O
Schizophrenia,B-DS
Patient,O
(,O
SZ,B-DS
),O
151,O
Healthy,O
Control,O
(,O
HC,O
),O
162,O
Male,O
231,O
(,O
SZ,B-DS
=,O
114,O
),O
Female,O
83,O
(,O
SZ,B-DS
=,O
37,O
),O
Ages,O
18,O
–,O
30,O
108,O
(,O
SZ,B-DS
=,O
52,O
),O
Ages,O
31,O
–,O
60,O
206,O
(,O
SZ,B-DS
=,O
99,O
),O
Data,O
Preprocessing,O
A,O
combination,O
of,O
toolboxes,O
(,O
AFNI1,O
",",O
SPM2,O
",",O
GIFT3,O
),O
and,O
custom,O
code,O
written,O
in,O
Matlab,O
were,O
employed,O
in,O
the,O
pre,O
-,O
processing,O
pipeline,O
.,O
Rigid,O
body,O
motion,O
correction,O
was,O
performed,O
with,O
the,O
INRIAlign,O
[,O
44,O
],O
toolbox,O
in,O
SPM,O
to,O
correct,O
for,O
subject,O
head,O
motion,O
",",O
followed,O
by,O
slice,O
-,O
timing,O
correction,O
to,O
account,O
for,O
timing,O
differences,O
in,O
slice,O
acquisition,O
.,O
Data,O
was,O
then,O
despiked,O
using,O
AFNI3s,O
3dDespike,O
algorithm,O
to,O
mitigate,O
the,O
impact,O
of,O
outliers,O
and,O
despiked,O
fMRI,O
data,O
was,O
subsequently,O
warped,O
to,O
a,O
Montreal,O
Neurological,O
Institute,O
(,O
MNI,O
),O
template,O
",",O
then,O
resampled,O
to,O
3,O
mm3,O
isotropic,O
voxels,O
.,O
Instead,O
of,O
Gaussian,O
smoothing,O
",",O
we,O
smoothed,O
the,O
data,O
to,O
6,O
mm,O
full,O
width,O
at,O
half,O
maximum,O
(,O
FWHM,O
),O
using,O
AFNI3s,O
BlurToFWHM,O
algorithm,O
which,O
performs,O
smoothing,O
by,O
a,O
conservative,O
finite,O
difference,O
approximation,O
to,O
the,O
diffusion,O
equation,O
.,O
This,O
approach,O
has,O
been,O
shown,O
to,O
reduce,O
scanner,O
specific,O
variability,O
in,O
smoothness,O
providing,O
“,O
smoothness,O
equivalence,O
”,O
to,O
data,O
across,O
sites,O
[,O
45,O
].,O
Finally,O
",",O
prior,O
to,O
performing,O
group,O
independent,O
component,O
analysis,O
",",O
each,O
voxel,O
time,O
course,O
was,O
variance,O
normalized,O
as,O
this,O
approach,O
has,O
been,O
shown,O
to,O
yield,O
better,O
decompositions,O
of,O
subcortical,O
and,O
cortical,O
sources,O
.,O
Decomposition,O
into,O
Functional,O
Networks,O
After,O
preprocessing,O
",",O
the,O
functional,O
imaging,O
data,O
from,O
all,O
subjects,O
was,O
decomposed,O
into,O
a,O
set,O
of,O
100,O
statistically,O
independent,O
spatial,O
regions,O
with,O
common,O
time,O
course,O
profile,O
using,O
group,O
independent,O
component,O
analysis,O
(,O
GICA,O
"),",O
implemented,O
by,O
the,O
GIFT,O
toolbox,O
(,O
http,O
://,O
mialab,O
.,O
mrn,O
.,O
org,O
/,O
software,O
/,O
gift,O
).,O
Of,O
these,O
100,O
components,O
",",O
47,O
were,O
identified,O
as,O
intrinsic,O
connectivity,O
networks,O
(,O
ICNs,O
),O
using,O
the,O
procedures,O
described,O
in,O
our,O
earlier,O
work,O
[,O
26,O
",",O
37,O
].,O
Subject,O
-,O
specific,O
spatial,O
maps,O
and,O
time,O
courses,O
were,O
obtained,O
using,O
spatio,O
-,O
temporal,O
regression,O
.,O
The,O
subject,O
ICN,O
time,O
courses,O
were,O
detrended,O
",",O
orthogonalized,O
with,O
respect,O
to,O
motion,O
parameters,O
",",O
despiked,O
by,O
replacing,O
outlier,O
time,O
points,O
with,O
3rd,O
order,O
spline,O
fit,O
to,O
cleaner,O
neighboring,O
points,O
",",O
and,O
filtered,O
using,O
a,O
5th,O
order,O
Butterworth,O
filter,O
with,O
a,O
passband,O
of,O
0,O
.,O
01,O
to,O
0,O
.,O
15,O
Hz,O
.,O
Windowed,O
Functional,O
Network,O
Connectivity,O
Matrices,O
(,O
wFNCs,O
),O
Windowed,O
functional,O
network,O
connectivity,O
(,O
wFNC,O
),O
is,O
evaluated,O
by,O
computing,O
pairwise,O
correlations,O
between,O
windowed,O
segments,O
of,O
ICN,O
timecourses,O
using,O
a,O
tapered,O
rectangular,O
window,O
of,O
length,O
of,O
22,O
TRs,O
(,O
44,O
seconds,O
"),",O
advancing,O
1,O
TR,O
at,O
each,O
step,O
.,O
To,O
improve,O
correlation,O
estimates,O
on,O
timecourses,O
of,O
shorter,O
length,O
",",O
we,O
impose,O
an,O
L1,O
constraint,O
on,O
the,O
inverse,O
covariance,O
matrix,O
using,O
the,O
G,O
-,O
LASSO,O
framework,O
[,O
45,O
"],",O
with,O
regularization,O
parameter,O
optimized,O
subject,O
-,O
wise,O
by,O
evaluating,O
the,O
log,O
-,O
likelihood,O
of,O
each,O
subject,O
’,O
s,O
unseen,O
data,O
in,O
a,O
cross,O
-,O
validation,O
framework,O
.,O
Basis,O
Correlation,O
Patterns,O
(,O
CPs,O
),O
Recent,O
work,O
[,O
16,O
",",O
25,O
",",O
26,O
",",O
37,O
",",O
46,O
],O
on,O
functional,O
network,O
connectivity,O
dynamics,O
has,O
used,O
clustering,O
algorithms,O
to,O
identify,O
a,O
small,O
set,O
of,O
prototype,O
connectivity,O
“,O
states,O
”.,O
Observed,O
wFNCs,O
are,O
replaced,O
by,O
the,O
prototype,O
states,O
they,O
most,O
resemble,O
",",O
allowing,O
connectivity,O
dynamics,O
to,O
be,O
described,O
as,O
a,O
process,O
of,O
moving,O
from,O
one,O
to,O
another,O
of,O
these,O
summary,O
states,O
.,O
In,O
this,O
work,O
",",O
we,O
present,O
a,O
flexible,O
",",O
intuitive,O
framework,O
for,O
studying,O
network,O
connectivity,O
dynamics,O
.,O
The,O
model,O
order,O
of,O
five,O
",",O
used,O
in,O
all,O
decompositions,O
presented,O
here,O
",",O
was,O
chosen,O
in,O
an,O
effort,O
to,O
balance,O
tractability,O
of,O
complex,O
linearly,O
additive,O
effects,O
with,O
a,O
desire,O
for,O
richly,O
featured,O
basis,O
correlation,O
pattern,O
sets,O
.,O
To,O
assess,O
the,O
sensitivity,O
of,O
our,O
results,O
to,O
perturbation,O
of,O
this,O
parameter,O
",",O
we,O
also,O
performed,O
our,O
analysis,O
on,O
model,O
orders,O
ranging,O
from,O
three,O
to,O
seven,O
",",O
and,O
found,O
overall,O
results,O
to,O
be,O
consistent,O
with,O
the,O
model,O
order,O
chosen,O
as,O
the,O
focus,O
of,O
this,O
paper,O
",",O
providing,O
additional,O
confidence,O
in,O
the,O
robustness,O
of,O
the,O
framework,O
and,O
the,O
main,O
dynamical,O
metrics,O
presented,O
here,O
.,O
Temporally,O
Independent,O
Connectivity,O
Patterns,O
Our,O
objective,O
is,O
to,O
express,O
time,O
-,O
varying,O
wFNCs,O
as,O
weighted,O
sums,O
of,O
correlation,O
patterns,O
whose,O
contributions,O
change,O
independently,O
of,O
each,O
other,O
in,O
time,O
(,O
see,O
Fig,O
3,O
(,O
A,O
),O
and,O
3,O
(,O
B,O
")),",O
allowing,O
us,O
to,O
develop,O
a,O
richer,O
picture,O
of,O
the,O
interplay,O
between,O
connectivity,O
patterns,O
that,O
are,O
strongly,O
present,O
in,O
the,O
data,O
.,O
This,O
objective,O
explicitly,O
permits,O
collections,O
of,O
basis,O
connectivity,O
patterns,O
featuring,O
:,O
Two,O
or,O
more,O
patterns,O
in,O
which,O
some,O
subset,O
of,O
network,O
-,O
pairs,O
share,O
the,O
same,O
correlation,O
strength,O
.,O
Individual,O
patterns,O
that,O
do,O
not,O
strongly,O
resemble,O
empirically,O
observed,O
wFNCs,O
.,O
To,O
achieve,O
this,O
goal,O
we,O
apply,O
group,O
temporal,O
independent,O
component,O
analysis,O
(,O
tICA,O
),O
(,O
Fig,O
3,O
(,O
A,O
)),O
[,O
30,O
],O
to,O
wFNC,O
matrices,O
concatenated,O
along,O
the,O
subject,O
×,O
time,O
dimension,O
",",O
decomposing,O
this,O
concatenated,O
1081,O
network,O
-,O
pair,O
correlations,O
×,O
136,O
time,O
windows,O
×,O
314,O
subject,O
structure,O
into,O
five,O
maximally,O
mutually,O
independent,O
timecourses,O
(,O
because,O
we,O
are,O
performing,O
this,O
analysis,O
at,O
the,O
group,O
level,O
",",O
these,O
are,O
in,O
fact,O
length,O
136,O
∙,O
314,O
=,O
42,O
",",O
704,O
subject,O
×,O
time,O
“,O
courses,O
"”),",O
each,O
with,O
an,O
associated,O
47,O
×,O
47,O
connectivity,O
pattern,O
(,O
a,O
modular,O
component,O
of,O
the,O
mixing,O
matrix,O
),O
that,O
is,O
shared,O
across,O
subjects,O
(,O
Fig,O
3,O
(,O
A,O
)).,O
In,O
the,O
text,O
above,O
",",O
for,O
convenience,O
",",O
we,O
will,O
refer,O
to,O
the,O
connectivity,O
patterns,O
as,O
components,O
",",O
even,O
though,O
it,O
is,O
the,O
subject,O
×,O
timecourses,O
that,O
are,O
being,O
estimated,O
by,O
tICA,O
.,O
In,O
this,O
decomposition,O
",",O
individual,O
wFNCs,O
are,O
specified,O
as,O
weighted,O
sums,O
of,O
the,O
five,O
CPs,O
",",O
yielding,O
a,O
5,O
-,O
dimensional,O
characterization,O
of,O
each,O
subject,O
’,O
s,O
1081,O
-,O
dimensional,O
connectivity,O
structure,O
in,O
each,O
time,O
window,O
.,O
The,O
dynamical,O
object,O
of,O
investigation,O
is,O
now,O
a,O
set,O
of,O
136,O
time,O
-,O
indexed,O
five,O
-,O
vectors,O
per,O
subject,O
that,O
representing,O
the,O
contributions,O
of,O
five,O
1081,O
-,O
dimensional,O
CPs,O
to,O
the,O
observed,O
wFNCs,O
.,O
The,O
tICA,O
decomposition,O
of,O
wFNC,O
data,O
produces,O
CPs,O
whose,O
weights,O
in,O
each,O
time,O
-,O
indexed,O
five,O
-,O
vector,O
are,O
maximally,O
mutually,O
independent,O
[,O
28,O
–,O
30,O
].,O
These,O
tICA,O
CPs,O
are,O
thus,O
patterns,O
whose,O
additive,O
contributions,O
to,O
observed,O
wFNCs,O
“,O
pipe,O
in,O
”,O
and,O
fade,O
out,O
in,O
a,O
relatively,O
independent,O
manner,O
.,O
Although,O
the,O
window,O
-,O
wise,O
CP,O
weights,O
in,O
the,O
tICA,O
decomposition,O
are,O
as,O
independent,O
as,O
possible,O
",",O
intrinsic,O
dependencies,O
within,O
the,O
data,O
ensure,O
that,O
the,O
weights,O
are,O
not,O
formally,O
independent,O
",",O
i,O
.,O
e,O
.,O
P,O
(,O
a1,O
≤,O
w1,O
≤,O
b1,O
",…,",O
a5,O
≤,O
w5,O
≤,O
b5,O
)≠∏,O
k,O
=,O
15P,O
(,O
ak,O
≤,O
wk,O
≤,O
bk,O
).,O
The,O
five,O
-,O
vectors,O
thus,O
hold,O
information,O
not,O
available,O
by,O
analyzing,O
elements,O
separately,O
",",O
but,O
maximizing,O
temporal,O
independence,O
keeps,O
the,O
state,O
-,O
space,O
from,O
collapsing,O
onto,O
a,O
lower,O
-,O
dimensional,O
space,O
",",O
ie,O
.,O
if,O
CP,O
#,O
1,O
and,O
CP,O
#,O
2,O
are,O
systematically,O
mutually,O
dependent,O
then,O
only,O
one,O
is,O
necessary,O
and,O
the,O
state,O
space,O
becomes,O
four,O
-,O
dimensional,O
.,O
Reducing,O
the,O
systematic,O
dependencies,O
between,O
CPs,O
ensures,O
we,O
are,O
taking,O
maximal,O
advantage,O
of,O
the,O
dimensionality,O
in,O
which,O
the,O
dynamics,O
have,O
been,O
defined,O
.,O
Although,O
we,O
have,O
chosen,O
to,O
focus,O
on,O
maximally,O
temporally,O
independent,O
correlation,O
patterns,O
produced,O
by,O
applying,O
temporal,O
ICA,O
to,O
the,O
windowed,O
FNCs,O
(,O
Fig,O
3,O
(,O
A,O
")),",O
we,O
were,O
interested,O
in,O
understanding,O
how,O
sensitive,O
the,O
results,O
obtained,O
might,O
be,O
to,O
our,O
choice,O
of,O
method,O
for,O
extracting,O
correlation,O
patterns,O
from,O
the,O
windowed,O
FNCs,O
.,O
Thus,O
we,O
performed,O
the,O
same,O
analysis,O
on,O
correlation,O
patterns,O
obtained,O
from,O
three,O
other,O
commonly,O
utilized,O
data,O
-,O
driven,O
methods,O
:,O
spatial,O
independent,O
component,O
analysis,O
(,O
sICA,O
"),",O
principal,O
component,O
analysis,O
(,O
PCA,O
),O
and,O
kmeans,O
clustering,O
.,O
We,O
also,O
explored,O
the,O
role,O
of,O
model,O
order,O
within,O
the,O
temporal,O
ICA,O
framework,O
by,O
repeating,O
our,O
analysis,O
for,O
temporal,O
ICAs,O
producing,O
2,O
",",O
3,O
",",O
6,O
and,O
7,O
(,O
small,O
perturbations,O
of,O
the,O
featured,O
5,O
correlation,O
pattern,O
case,O
).,O
Alternative,O
Decompositions,O
into,O
CPs,O
:,O
Spatial,O
ICA,O
",",O
Principal,O
Components,O
and,O
K,O
-,O
means,O
Cluster,O
Centroids,O
We,O
perform,O
a,O
group,O
(,O
spatial,O
),O
independent,O
component,O
analysis,O
(,O
GICA,O
),O
on,O
the,O
wFNC,O
data,O
using,O
protocols,O
directly,O
analogous,O
those,O
employed,O
for,O
higher,O
-,O
dimensional,O
fMRI,O
data,O
[,O
39,O
",",O
43,O
].,O
The,O
basis,O
correlation,O
patterns,O
obtained,O
by,O
group,O
sICA,O
are,O
maximally,O
spatially,O
(,O
cell,O
-,O
wise,O
),O
independent,O
",",O
but,O
neither,O
mutually,O
orthogonal,O
nor,O
informative,O
about,O
the,O
way,O
dFNC,O
variance,O
is,O
organized,O
(,O
Fig,O
4,O
(,O
A,O
",",O
Row,O
2,O
)).,O
For,O
a,O
set,O
of,O
mutually,O
orthogonal,O
basis,O
patterns,O
whose,O
structure,O
explicitly,O
reflects,O
dominant,O
directions,O
of,O
data,O
variance,O
",",O
we,O
use,O
the,O
first,O
five,O
components,O
of,O
a,O
PCA,O
along,O
the,O
subject,O
×,O
time,O
dimension,O
of,O
the,O
concatenated,O
wFNC,O
data,O
(,O
Fig,O
4,O
(,O
A,O
",",O
Row,O
3,O
)).,O
The,O
timecourses,O
for,O
sICA,O
(,O
resp,O
.,O
PCA,O
),O
correlation,O
patterns,O
are,O
obtained,O
by,O
regressing,O
each,O
subject,O
',O
s,O
wFNC,O
data,O
at,O
each,O
time,O
window,O
on,O
the,O
set,O
of,O
sICA,O
(,O
resp,O
.,O
PCA,O
),O
correlation,O
patterns,O
.,O
Correlation,O
Patterns,O
Produced,O
by,O
Different,O
Algorithms,O
and,O
by,O
Temporal,O
ICA,O
at,O
Different,O
Model,O
Orders,O
(,O
A,O
),O
Different,O
data,O
-,O
driven,O
decompositions,O
of,O
the,O
wFNCs,O
yield,O
different,O
sets,O
of,O
correlation,O
patterns,O
;,O
correlation,O
patterns,O
produced,O
",",O
from,O
top,O
to,O
bottom,O
",",O
by,O
tICA,O
",",O
sICA,O
",",O
PCA,O
",",O
K,O
-,O
means,O
",",O
all,O
with,O
model,O
order,O
five,O
;,O
(,O
B,O
),O
Different,O
model,O
-,O
orders,O
of,O
tICA,O
applied,O
to,O
the,O
wFNCs,O
yield,O
growing,O
collections,O
of,O
correlation,O
patters,O
with,O
two,O
recurring,O
patterns,O
(,O
Row,O
1,O
",",O
Columnss,O
1,O
and,O
3,O
);,O
tICA,O
correlation,O
patterns,O
",",O
from,O
top,O
to,O
bottom,O
",",O
for,O
model,O
orders,O
three,O
through,O
seven,O
.,O
In,O
addition,O
to,O
ICA,O
and,O
PCA,O
techniques,O
",",O
we,O
also,O
apply,O
k,O
-,O
means,O
clustering,O
to,O
the,O
windowed,O
FNCs,O
.,O
Using,O
Matlab,O
’,O
s,O
implementation,O
of,O
k,O
-,O
means,O
clustering,O
with,O
the,O
squared,O
Euclidean,O
distance,O
",",O
500,O
iterates,O
and,O
150,O
replicates,O
",",O
we,O
partition,O
the,O
set,O
of,O
wFNCs,O
into,O
five,O
clusters,O
whose,O
centroids,O
are,O
treated,O
as,O
basis,O
correlation,O
patterns,O
(,O
Fig,O
4,O
(,O
A,O
",",O
Row,O
4,O
)).,O
We,O
investigate,O
the,O
time,O
-,O
varying,O
joint,O
contributions,O
of,O
these,O
CPs,O
using,O
two,O
forms,O
of,O
weighted,O
k,O
-,O
means,O
timecourses,O
.,O
The,O
first,O
",",O
directly,O
analogous,O
to,O
the,O
sICA,O
and,O
PCA,O
timecourses,O
",",O
is,O
a,O
linearly,O
additive,O
weighting,O
obtained,O
by,O
regressing,O
wFNC,O
data,O
on,O
the,O
kmeans,O
CPs,O
.,O
The,O
second,O
characterizes,O
each,O
wFNC,O
by,O
a,O
five,O
-,O
vector,O
with,O
weights,O
based,O
on,O
the,O
L2,O
distances,O
of,O
the,O
wFNCs,O
from,O
each,O
kmeans,O
CP,O
.,O
Specifically,O
",",O
for,O
subject,O
k,O
',O
s,O
time,O
t,O
wFNC,O
",",O
F,O
(,O
k,O
)(,O
t,O
"),",O
we,O
have,O
the,O
five,O
vector,O
w,O
(,O
k,O
)(,O
t,O
)=(,O
w1,O
(,O
k,O
)(,O
t,O
"),",O
w2,O
(,O
k,O
)(,O
t,O
"),",O
w3,O
(,O
k,O
)(,O
t,O
"),",O
w4,O
(,O
k,O
)(,O
t,O
"),",O
w5,O
(,O
k,O
)(,O
t,O
)),O
whose,O
ith,O
element,O
wi,O
(,O
k,O
)=,O
1,O
−‖,O
F,O
(,O
k,O
)(,O
t,O
)−,O
Ci,O
‖,O
2,O
∑,O
j,O
=,O
15,O
‖,O
F,O
(,O
k,O
)(,O
t,O
)−,O
Cj,O
‖,O
2,O
",",O
where,O
Cj,O
is,O
the,O
jth,O
kmeans,O
CP,O
.,O
For,O
consistency,O
with,O
the,O
other,O
decompositions,O
we,O
report,O
the,O
results,O
from,O
regressing,O
wFNC,O
data,O
on,O
k,O
-,O
means,O
CPs,O
",",O
but,O
results,O
using,O
the,O
alternative,O
weighting,O
system,O
presented,O
the,O
same,O
directionality,O
and,O
significance,O
.,O
Timecourse,O
Discretization,O
We,O
convert,O
the,O
original,O
real,O
-,O
valued,O
weight,O
vectors,O
to,O
discrete,O
meta,O
-,O
states,O
(,O
Fig,O
3,O
(,O
C,O
)),O
by,O
replacing,O
each,O
CP,O
weight,O
with,O
a,O
value,O
in,O
±{,O
1,O
",",O
2,O
",",O
3,O
",",O
4,O
},O
according,O
to,O
its,O
signed,O
quartile,O
:,O
the,O
vector,O
w,O
(,O
k,O
)(,O
t,O
)=(,O
w1,O
(,O
k,O
)(,O
t,O
"),",O
w2,O
(,O
k,O
)(,O
t,O
"),",O
w3,O
(,O
k,O
)(,O
t,O
"),",O
w4,O
(,O
k,O
)(,O
t,O
"),",O
w5,O
(,O
k,O
)(,O
t,O
)),O
of,O
subject,O
k,O
',O
s,O
time,O
t,O
component,O
weights,O
is,O
converted,O
to,O
λ,O
(,O
k,O
)(,O
t,O
)=(,O
λ1,O
(,O
k,O
)(,O
t,O
"),",O
λ2,O
(,O
k,O
)(,O
t,O
"),",O
λ3,O
(,O
k,O
)(,O
t,O
"),",O
λ4,O
(,O
k,O
)(,O
t,O
"),",O
λ5,O
(,O
k,O
)(,O
t,O
)),O
where,O
λi,O
(,O
k,O
)∈{±,O
1,O
",±",O
2,O
",±",O
3,O
",±",O
4,O
},O
indicating,O
the,O
quartile,O
of,O
the,O
(,O
same,O
-,O
sign,O
),O
weights,O
each,O
wi,O
(,O
k,O
),O
falls,O
into,O
.,O
When,O
λi,O
(,O
k,O
)=,O
l,O
∈{±,O
1,O
",±",O
2,O
",±",O
3,O
",±",O
4,O
"},",O
component,O
i,O
is,O
said,O
to,O
be,O
occupied,O
at,O
level,O
l,O
.,O
The,O
length,O
-,O
five,O
vectors,O
(,O
λ1,O
(,O
k,O
)(,O
t,O
"),",O
λ2,O
(,O
k,O
)(,O
t,O
"),",O
λ3,O
(,O
k,O
)(,O
t,O
"),",O
λ4,O
(,O
k,O
)(,O
t,O
"),",O
λ5,O
(,O
k,O
)(,O
t,O
)),O
are,O
referred,O
to,O
as,O
meta,O
-,O
states,O
.,O
Discretization,O
of,O
sICA,O
",",O
principal,O
component,O
and,O
weighted,O
k,O
-,O
means,O
timecourses,O
follows,O
the,O
tICA,O
procedure,O
exactly,O
.,O
2,O
.,O
9,O
Diagnosis,O
Effects,O
We,O
employ,O
a,O
linear,O
model,O
",",O
y,O
=,O
β0,O
+,O
βageXage,O
+,O
βgenderXgender,O
+,O
βdiagnosisXdiagnosis,O
+,O
ε,O
to,O
estimate,O
the,O
effect,O
of,O
diagnosis,O
on,O
the,O
various,O
measures,O
investigated,O
here,O
.,O
The,O
diagnosis,O
variable,O
is,O
binary,O
",",O
with,O
SZ,B-DS
coded,O
as,O
',O
1,O
',O
and,O
HC,O
as,O
',O
0,O
"',",O
so,O
βdiagnosis,O
>,O
0,O
indicates,O
a,O
positive,O
correlation,O
with,O
SZ,B-DS
and,O
βdiagnosis,O
<,O
0,O
shows,O
a,O
negative,O
correlation,O
with,O
SZ,B-DS
.,O
We,O
generally,O
report,O
or,O
display,O
the,O
value,O
of,O
βdiagnosis,O
when,O
its,O
false,O
discovery,O
rate,O
(,O
FDR,O
),O
corrected,O
p,O
-,O
value,O
is,O
less,O
than,O
0,O
.,O
05,O
.,O
Results,O
Our,O
meta,O
-,O
state,O
dynamical,O
framework,O
exposes,O
important,O
features,O
of,O
whole,O
-,O
brain,O
connectivity,O
dynamics,O
that,O
seem,O
to,O
emerge,O
specifically,O
at,O
this,O
level,O
of,O
analysis,O
;,O
network,O
timecourses,O
[,O
1,O
"],",O
windowed,O
network,O
timecourses,O
",",O
and,O
even,O
individual,O
network,O
-,O
pair,O
wFNC,O
values,O
",",O
for,O
example,O
",",O
exhibit,O
more,O
high,O
-,O
frequency,O
power,O
in,O
schizophrenia,B-DS
patients,O
than,O
in,O
controls,O
",",O
a,O
phenomenon,O
that,O
dissolves,O
the,O
whole,O
brain,O
meta,O
-,O
state,O
level,O
(,O
see,O
Discussion,O
section,O
).,O
The,O
persistence,O
of,O
our,O
findings,O
across,O
a,O
variety,O
of,O
approaches,O
to,O
identifying,O
individual,O
states,O
from,O
the,O
data,O
suggests,O
we,O
are,O
observing,O
robust,O
phenomena,O
at,O
this,O
particular,O
scale,O
of,O
analysis,O
.,O
To,O
gauge,O
the,O
robustness,O
of,O
our,O
findings,O
",",O
we,O
applied,O
the,O
meta,O
-,O
state,O
analytical,O
framework,O
to,O
tICA,O
decompositions,O
with,O
smaller,O
(,O
model,O
orders,O
=,O
3,O
",",O
4,O
),O
and,O
larger,O
(,O
model,O
orders,O
=,O
6,O
",",O
7,O
),O
sets,O
of,O
CPs,O
",",O
and,O
also,O
to,O
collections,O
of,O
five,O
CPs,O
produced,O
using,O
group,O
spatial,O
ICA,O
(,O
GICA,O
"),",O
PCA,O
and,O
k,O
-,O
means,O
clustering,O
(,O
Fig,O
4,O
(,O
A,O
)).,O
Broad,O
Reduction,O
of,O
Dynamic,O
Fluidity,O
and,O
Range,O
in,O
Schizophrenia,B-DS
Patients,O
The,O
state,O
space,O
X,O
induced,O
by,O
our,O
discretized,O
five,O
-,O
dimensional,O
characterization,O
of,O
connectivity,O
is,O
a,O
five,O
-,O
dimensional,O
lattice,O
with,O
a,O
set,O
of,O
five,O
mutually,O
orthogonal,O
co,O
-,O
dimension,O
one,O
hyperplanes,O
through,O
the,O
origin,O
removed,O
(,O
Fig,O
5,O
).,O
Planar,O
projection,O
of,O
the,O
discrete,O
five,O
-,O
dimensional,O
state,O
space,O
.,O
Each,O
removed,O
hyperplane,O
is,O
the,O
zero,O
set,O
of,O
one,O
of,O
the,O
dimensions,O
(,O
these,O
hyperplanes,O
are,O
not,O
part,O
of,O
X,O
because,O
the,O
range,O
of,O
our,O
signed,O
-,O
quartile,O
discretization,O
is,O
{±,O
1,O
",",O
2,O
",",O
3,O
",",O
4,O
}.,O
The,O
space,O
contains,O
C,O
≡,O
85,O
=,O
32,O
",",O
768,O
distinct,O
points,O
(,O
meta,O
-,O
states,O
"),",O
of,O
which,O
cR,O
=,O
14,O
",",O
025,O
are,O
realized,O
at,O
some,O
point,O
in,O
time,O
by,O
some,O
subject,O
.,O
Individual,O
subjects,O
can,O
visit,O
at,O
most,O
T,O
=,O
136,O
meta,O
-,O
states,O
",",O
and,O
our,O
sample,O
of,O
N,O
=,O
314,O
subjects,O
allows,O
for,O
entire,O
sample,O
to,O
visit,O
at,O
most,O
NT,O
=,O
42,O
",",O
704,O
meta,O
-,O
states,O
.,O
Although,O
the,O
entire,O
study,O
includes,O
more,O
state,O
visits,O
(,O
42,O
",",O
704,O
),O
than,O
points,O
in,O
the,O
X,O
",",O
more,O
than,O
half,O
(,O
C,O
-,O
cR,O
=,O
18,O
",",O
743,O
or,O
57,O
.,O
2,O
%),O
of,O
the,O
points,O
in,O
X,O
are,O
never,O
visited,O
.,O
The,O
combinatorics,O
make,O
a,O
full,O
exploration,O
of,O
ways,O
unvisited,O
states,O
distribute,O
in,O
X,O
prohibitive,O
",",O
but,O
some,O
high,O
-,O
level,O
facts,O
about,O
how,O
individual,O
subjects,O
sample,O
the,O
state,O
space,O
are,O
readily,O
established,O
.,O
Our,O
analysis,O
focuses,O
on,O
four,O
global,O
metrics,O
of,O
connectivity,O
dynamism,O
:,O
The,O
number,O
of,O
times,O
that,O
subjects,O
switch,O
from,O
one,O
meta,O
-,O
state,O
to,O
another,O
(,O
denoted,O
by,O
s,O
),O
The,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
subjects,O
occupy,O
during,O
their,O
scans,O
(,O
denoted,O
by,O
n,O
),O
The,O
range,O
of,O
meta,O
-,O
states,O
subjects,O
occupy,O
",",O
ie,O
".,",O
the,O
largest,O
L1,O
distance,O
between,O
occupied,O
meta,O
-,O
states,O
(,O
denoted,O
by,O
r,O
),O
The,O
overall,O
distance,O
traveled,O
by,O
each,O
subject,O
through,O
the,O
state,O
space,O
(,O
the,O
sum,O
of,O
the,O
L1,O
distances,O
between,O
successive,O
meta,O
-,O
states,O
",",O
denoted,O
by,O
d,O
),O
The,O
first,O
measure,O
captures,O
how,O
often,O
a,O
subject,O
switches,O
between,O
meta,O
-,O
states,O
",",O
without,O
accounting,O
for,O
how,O
many,O
or,O
how,O
divergent,O
the,O
meta,O
-,O
states,O
are,O
(,O
one,O
could,O
switch,O
between,O
two,O
very,O
similar,O
states,O
in,O
rapid,O
succession,O
).,O
The,O
second,O
records,O
the,O
number,O
distinct,O
meta,O
-,O
states,O
are,O
passed,O
through,O
.,O
Since,O
there,O
are,O
32,O
",",O
768,O
distinct,O
meta,O
-,O
states,O
available,O
",",O
a,O
very,O
high,O
ratio,O
of,O
n,O
to,O
the,O
number,O
of,O
time,O
points,O
implies,O
high,O
s,O
;,O
a,O
very,O
high,O
ratio,O
of,O
n,O
to,O
the,O
number,O
of,O
possible,O
meta,O
-,O
states,O
implies,O
high,O
r,O
.,O
The,O
third,O
measure,O
indicates,O
how,O
divergent,O
the,O
meta,O
-,O
states,O
occupied,O
are,O
.,O
The,O
value,O
of,O
r,O
",",O
except,O
when,O
identically,O
zero,O
",",O
need,O
not,O
imply,O
anything,O
about,O
s,O
or,O
n,O
.,O
It,O
is,O
a,O
lower,O
bound,O
for,O
d,O
.,O
The,O
final,O
measure,O
",",O
d,O
",",O
incorporates,O
information,O
from,O
the,O
other,O
three,O
without,O
being,O
fully,O
determined,O
by,O
them,O
.,O
It,O
is,O
maximized,O
when,O
a,O
subject,O
switches,O
frequently,O
between,O
two,O
meta,O
-,O
states,O
at,O
distal,O
boundaries,O
of,O
the,O
state,O
space,O
.,O
We,O
find,O
consistent,O
and,O
pervasive,O
evidence,O
(,O
Table,O
2,O
),O
of,O
reduced,O
FNC,O
dynamism,O
among,O
schizophrenia,B-DS
patients,O
with,O
respect,O
to,O
each,O
of,O
the,O
four,O
metrics,O
above,O
",",O
and,O
across,O
all,O
four,O
data,O
-,O
driven,O
decompositions,O
of,O
observed,O
wFNCs,O
into,O
collections,O
of,O
basis,O
CPs,O
:,O
SZ,B-DS
exhibit,O
diminished,O
dynamic,O
fluidity,O
:,O
Schizophrenia,B-DS
patients,O
occupy,O
fewer,O
meta,O
-,O
states,O
than,O
healthy,O
controls,O
(,O
mean,O
HC,O
=,O
73,O
.,O
2,O
meta,O
-,O
states,O
",",O
mean,O
SZ,B-DS
=,O
67,O
.,O
4,O
meta,O
-,O
states,O
;,O
diagnosis,O
effect,O
in,O
regression,O
=,O
-,O
5,O
.,O
65,O
",",O
P,O
-,O
value,O
=,O
3,O
.,O
93,O
e,O
-,O
006,O
).,O
(,O
Fig,O
6,O
(,O
A,O
"),",O
Table,O
2,O
",",O
Table,O
3,O
),O
Schizophrenia,B-DS
patients,O
change,O
from,O
one,O
meta,O
-,O
state,O
to,O
another,O
less,O
often,O
than,O
healthy,O
controls,O
(,O
mean,O
HC,O
=,O
74,O
.,O
04,O
changes,O
",",O
mean,O
SZ,B-DS
=,O
68,O
.,O
58,O
changes,O
;,O
diagnosis,O
effect,O
in,O
regression,O
=,O
-,O
5,O
.,O
32,O
",",O
P,O
-,O
value,O
=,O
1,O
.,O
72,O
e,O
-,O
006,O
).,O
(,O
Fig,O
6,O
(,O
B,O
"),",O
Table,O
2,O
",",O
Table,O
3,O
),O
SZ,B-DS
operate,O
over,O
a,O
restricted,O
dynamic,O
range,O
:,O
Schizophrenia,B-DS
patients,O
remain,O
trapped,O
in,O
a,O
smaller,O
radius,O
hypercube,O
of,O
the,O
state,O
space,O
than,O
do,O
healthy,O
controls,O
",",O
as,O
measured,O
by,O
the,O
maximal,O
L1,O
-,O
distance,O
between,O
occupied,O
meta,O
-,O
states,O
(,O
mean,O
HC,O
=,O
16,O
.,O
77,O
diameter,O
",",O
mean,O
SZ,B-DS
=,O
14,O
.,O
77,O
diameter,O
;,O
diagnosis,O
effect,O
in,O
regression,O
=,O
-,O
2,O
.,O
20,O
",",O
P,O
-,O
value,O
=,O
6,O
.,O
62,O
e,O
-,O
008,O
).,O
(,O
Fig,O
7,O
(,O
A,O
"),",O
Table,O
2,O
",",O
Table,O
3,O
),O
Schizophrenia,B-DS
patients,O
traverse,O
less,O
overall,O
distance,O
",",O
evaluated,O
by,O
summed,O
L1,O
distance,O
between,O
successive,O
meta,O
-,O
states,O
",",O
through,O
the,O
state,O
space,O
than,O
do,O
healthy,O
controls,O
(,O
mean,O
HC,O
=,O
91,O
.,O
55,O
overall,O
distance,O
",",O
mean,O
SZ,B-DS
=,O
83,O
.,O
80,O
overall,O
distance,O
;,O
diagnosis,O
effect,O
in,O
regression,O
=,O
-,O
9,O
.,O
69,O
",",O
P,O
-,O
value,O
=,O
1,O
.,O
89,O
e,O
-,O
006,O
).,O
(,O
Fig,O
7,O
(,O
B,O
"),",O
Table,O
2,O
",",O
Table,O
3,O
).,O
Effect,O
of,O
Schizophrenia,B-DS
on,O
Dynamic,O
Fluidity,O
Measures,O
(,O
A,O
),O
Number,O
of,O
meta,O
-,O
states,O
realized,O
;,O
(,O
middle,O
column,O
),O
boxplot,O
showing,O
median,O
",",O
quartiles,O
and,O
outliers,O
plus,O
mean,O
for,O
each,O
group,O
",",O
and,O
diagnosis,O
effect,O
from,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
with,O
associated,O
p,O
-,O
value,O
;,O
(,O
leftmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
healthy,O
subject,O
",",O
with,O
the,O
88,O
distinct,O
meta,O
-,O
states,O
shown,O
underneath,O
;,O
(,O
rightmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
schizophrenia,B-DS
patient,O
",",O
with,O
the,O
23,O
distinct,O
meta,O
-,O
states,O
shown,O
underneath,O
;,O
(,O
B,O
),O
Number,O
of,O
timepoints,O
at,O
which,O
subjects,O
change,O
between,O
meta,O
-,O
states,O
;,O
(,O
middle,O
column,O
),O
boxplot,O
showing,O
median,O
",",O
quartiles,O
and,O
outliers,O
plus,O
mean,O
for,O
each,O
group,O
",",O
and,O
diagnosis,O
effect,O
from,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
with,O
associated,O
p,O
-,O
value,O
;,O
(,O
leftmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
healthy,O
subject,O
",",O
with,O
the,O
87,O
timepoints,O
at,O
which,O
meta,O
-,O
state,O
changes,O
shown,O
above,O
;,O
(,O
rightmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
schizophrenia,B-DS
patient,O
",",O
with,O
the,O
33,O
timepoints,O
at,O
which,O
meta,O
-,O
state,O
changes,O
shown,O
above,O
.,O
Effect,O
of,O
Schizophrenia,B-DS
on,O
Dynamic,O
Range,O
Measures,O
(,O
A,O
),O
Maximally,O
different,O
(,O
in,O
the,O
L1,O
sense,O
),O
meta,O
-,O
states,O
that,O
subjects,O
realize,O
;,O
(,O
middle,O
column,O
),O
boxplot,O
showing,O
median,O
",",O
quartiles,O
and,O
outliers,O
plus,O
mean,O
for,O
each,O
group,O
",",O
and,O
diagnosis,O
effect,O
from,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
with,O
associated,O
p,O
-,O
value,O
;,O
(,O
leftmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
healthy,O
subject,O
",",O
with,O
the,O
two,O
most,O
divergent,O
realized,O
meta,O
-,O
states,O
(,O
L1,O
distance,O
=,O
21,O
),O
shown,O
underneath,O
;,O
(,O
rightmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
schizophrenia,B-DS
patient,O
",",O
with,O
the,O
two,O
most,O
divergent,O
realized,O
meta,O
-,O
states,O
(,O
L1,O
distance,O
=,O
8,O
),O
shown,O
underneath,O
;,O
(,O
B,O
),O
Total,O
distance,O
traveled,O
(,O
summed,O
L1,O
distance,O
between,O
successive,O
meta,O
-,O
states,O
),O
in,O
the,O
state,O
space,O
;,O
(,O
middle,O
column,O
),O
boxplot,O
showing,O
median,O
",",O
quartiles,O
and,O
outliers,O
plus,O
mean,O
for,O
each,O
group,O
",",O
and,O
diagnosis,O
effect,O
from,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
with,O
associated,O
p,O
-,O
value,O
;,O
(,O
leftmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
healthy,O
subject,O
",",O
with,O
the,O
timeseries,O
of,O
cumulative,O
distance,O
traveled,O
(,O
increasing,O
to,O
117,O
at,O
final,O
timepoint,O
),O
shown,O
above,O
;,O
(,O
rightmost,O
column,O
),O
The,O
time,O
-,O
indexed,O
meta,O
-,O
states,O
of,O
a,O
sample,O
schizophrenia,B-DS
patient,O
",",O
with,O
timeseries,O
of,O
cumulative,O
distance,O
traveled,O
(,O
increasing,O
to,O
37,O
at,O
final,O
timepoint,O
),O
shown,O
above,O
.,O
Age,O
and,O
gender,O
-,O
corrected,O
effects,O
of,O
SZ,B-DS
on,O
four,O
general,O
dynamism,O
measures,O
(,O
rows,O
),O
under,O
four,O
different,O
decompositions,O
of,O
the,O
wFNC,O
data,O
into,O
sets,O
of,O
five,O
correlation,O
patterns,O
(,O
columns,O
).,O
Method,O
of,O
Decomposing,O
wFNCs,O
into,O
CPs,O
tICA,O
sICA,O
PCA,O
K,O
-,O
means,O
Number,O
of,O
Distinct,O
Meta,O
-,O
States,O
-,O
5,O
.,O
65,O
-,O
2,O
.,O
63,O
-,O
5,O
.,O
78,O
-,O
6,O
.,O
52,O
p,O
=,O
3,O
.,O
93e,O
-,O
006,O
),O
(,O
p,O
=,O
0,O
.,O
007,O
),O
(,O
p,O
=,O
6,O
.,O
03e,O
-,O
008,O
),O
(,O
p,O
=,O
1,O
.,O
52e,O
-,O
007,O
),O
Number,O
of,O
Meta,O
-,O
State,O
Changes,O
-,O
5,O
.,O
32,O
-,O
2,O
.,O
59,O
-,O
4,O
.,O
80,O
-,O
5,O
.,O
57,O
(,O
p,O
=,O
1,O
.,O
41e,O
-,O
008,O
),O
(,O
p,O
=,O
0,O
.,O
003,O
),O
(,O
p,O
=,O
5,O
.,O
88e,O
-,O
007,O
),O
(,O
p,O
=,O
8,O
.,O
23e,O
-,O
007,O
),O
L1,O
Span,O
of,O
Realized,O
Meta,O
-,O
States,O
-,O
2,O
.,O
20,O
-,O
1,O
.,O
29,O
-,O
2,O
.,O
22,O
-,O
2,O
.,O
71,O
(,O
p,O
=,O
6,O
.,O
62e,O
-,O
008,O
),O
(,O
p,O
=,O
2,O
.,O
71e,O
-,O
006,O
),O
(,O
p,O
=,O
2,O
.,O
09e,O
-,O
010,O
),O
(,O
p,O
=,O
1,O
.,O
52e,O
-,O
009,O
),O
Total,O
Distance,O
Traveled,O
in,O
State,O
Space,O
-,O
9,O
.,O
69,O
-,O
4,O
.,O
29,O
-,O
6,O
.,O
78,O
-,O
10,O
.,O
04,O
(,O
p,O
=,O
1,O
.,O
89e,O
-,O
006,O
),O
(,O
p,O
=,O
0,O
.,O
0009,O
),O
(,O
p,O
=,O
1,O
.,O
76e,O
-,O
006,O
),O
(,O
p,O
=,O
5,O
.,O
31e,O
-,O
007,O
),O
Displayed,O
effects,O
and,O
p,O
-,O
values,O
are,O
from,O
the,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
.,O
Age,O
and,O
gender,O
-,O
corrected,O
effects,O
of,O
SZ,B-DS
on,O
four,O
general,O
dynamism,O
measures,O
(,O
rows,O
),O
computed,O
over,O
tICA,O
decompositions,O
of,O
different,O
model,O
orders,O
(,O
columns,O
).,O
Displayed,O
effects,O
and,O
p,O
-,O
values,O
are,O
from,O
the,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
.,O
Number,O
of,O
tICA,O
CPs,O
3,O
4,O
5,O
6,O
7,O
Number,O
of,O
Distinct,O
-,O
5,O
.,O
36,O
-,O
6,O
.,O
28,O
-,O
5,O
.,O
65,O
-,O
5,O
.,O
45,O
-,O
5,O
.,O
80,O
Meta,O
-,O
States,O
(,O
p,O
=,O
4,O
.,O
26e,O
-,O
006,O
),O
(,O
p,O
=,O
1,O
.,O
86e,O
-,O
007,O
),O
(,O
p,O
=,O
4,O
.,O
11e,O
-,O
006,O
),O
(,O
p,O
=,O
5,O
.,O
64e,O
-,O
007,O
),O
(,O
p,O
=,O
2,O
.,O
37e,O
-,O
009,O
),O
Number,O
of,O
Meta,O
-,O
State,O
-,O
3,O
.,O
93,O
-,O
5,O
.,O
06,O
-,O
2,O
.,O
20,O
-,O
5,O
.,O
15,O
-,O
5,O
.,O
48,O
Changes,O
(,O
p,O
=,O
9,O
.,O
64e,O
-,O
005,O
),O
(,O
p,O
=,O
3,O
.,O
09e,O
-,O
006,O
),O
(,O
p,O
=,O
6,O
.,O
62e,O
-,O
008,O
),O
(,O
p,O
=,O
4,O
.,O
98e,O
-,O
007,O
),O
(,O
p,O
=,O
6,O
.,O
22e,O
-,O
009,O
),O
L1,O
Span,O
of,O
Realized,O
-,O
1,O
.,O
24,O
-,O
1,O
.,O
93,O
-,O
1,O
.,O
94,O
-,O
2,O
.,O
64,O
-,O
3,O
.,O
07,O
Meta,O
-,O
States,O
(,O
p,O
=,O
7,O
.,O
33e,O
-,O
005,O
),O
(,O
p,O
=,O
1,O
.,O
52e,O
-,O
007,O
),O
(,O
p,O
=,O
3,O
.,O
11e,O
-,O
005,O
),O
(,O
p,O
=,O
2,O
.,O
62e,O
-,O
008,O
),O
(,O
p,O
=,O
1,O
.,O
65e,O
-,O
009,O
),O
Total,O
Distance,O
Travel,O
-,O
-,O
5,O
.,O
02,O
-,O
7,O
.,O
50,O
-,O
7,O
.,O
53,O
-,O
11,O
.,O
04,O
-,O
14,O
.,O
60,O
ed,O
in,O
State,O
Space,O
(,O
p,O
=,O
2,O
.,O
68e,O
-,O
004,O
),O
(,O
p,O
=,O
8,O
.,O
47e,O
-,O
006,O
),O
(,O
p,O
=,O
1,O
.,O
01e,O
-,O
005,O
),O
(,O
p,O
=,O
1,O
.,O
06e,O
-,O
006,O
),O
(,O
p,O
=,O
1,O
.,O
37e,O
-,O
006,O
),O
Although,O
schizophrenia,B-DS
patients,O
exhibit,O
diverse,O
symptoms,O
[,O
43,O
],O
ranging,O
from,O
blunted,O
affect,O
and,O
withdrawal,O
to,O
grandiosity,B-DS
",",O
the,O
hallmark,O
psychotic,O
symptoms,O
of,O
the,O
disease,O
",",O
delusions,B-DS
and,O
hallucinations,B-DS
",",O
are,O
of,O
special,O
interest,O
.,O
Initial,O
investigations,O
of,O
connectivity,O
dynamism,O
at,O
the,O
symptom,O
level,O
show,O
mixed,O
effects,O
of,O
the,O
main,O
psychotic,O
underpinnings,O
of,O
schizophrenia,B-DS
with,O
delusions,B-DS
having,O
weakly,O
dynamism,O
-,O
amplifying,O
effects,O
and,O
hallucinations,B-DS
presenting,O
significant,O
and,O
pervasive,O
dynamism,O
-,O
suppressing,O
effects,O
(,O
Fig,O
8,O
).,O
Effect,O
of,O
Main,O
Psychotic,O
Symptoms,O
of,O
Schizophrenia,B-DS
on,O
Connectivity,O
Dynamism,O
Measures,O
Significant,O
(,O
α,O
<,O
0,O
.,O
05,O
),O
effects,O
of,O
hallmark,O
psychotic,O
symptoms,O
of,O
SZ,B-DS
on,O
each,O
of,O
the,O
four,O
dynamism,O
measures,O
from,O
regression,O
on,O
all,O
thirty,O
symptom,O
scores,O
from,O
the,O
PANSS,O
scale,O
along,O
with,O
gender,O
and,O
age,O
as,O
covariates,O
.,O
The,O
effect,O
of,O
delusions,B-DS
on,O
L1,O
Span,O
of,O
Realized,O
Meta,O
-,O
States,O
has,O
p,O
-,O
value,O
=,O
0,O
.,O
023,O
.,O
The,O
p,O
-,O
values,O
associated,O
to,O
the,O
effects,O
of,O
hallucinatory,B-DS
behavior,I-DS
on,O
each,O
of,O
the,O
four,O
measures,O
given,O
along,O
the,O
x,O
-,O
axis,O
are,O
",",O
from,O
left,O
to,O
right,O
:,O
0,O
.,O
005,O
",",O
0,O
.,O
003,O
",",O
0,O
.,O
003,O
",",O
and,O
0,O
.,O
010,O
.,O
Schizophrenia,B-DS
Patients,O
have,O
more,O
Hub,O
States,O
than,O
Controls,O
Although,O
healthy,O
subjects,O
on,O
average,O
pass,O
through,O
a,O
significantly,O
larger,O
number,O
of,O
distinct,O
connective,O
meta,O
-,O
states,O
during,O
their,O
resting,O
fMRI,O
scans,O
(,O
Fig,O
6,O
(,O
A,O
")),",O
it,O
is,O
patients,O
that,O
include,O
a,O
larger,O
set,O
of,O
distinct,O
meta,O
-,O
states,O
among,O
those,O
they,O
visit,O
more,O
than,O
three,O
times,O
.,O
More,O
concretely,O
",",O
healthy,O
subjects,O
visit,O
a,O
significantly,O
larger,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
at,O
least,O
once,O
",",O
while,O
patients,O
visit,O
a,O
significantly,O
larger,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
at,O
least,O
four,O
times,O
(,O
Fig,O
9,O
",",O
Fig,O
10A,O
",",O
10B,O
and,O
10C,O
)).,O
The,O
overall,O
dominance,O
of,O
healthy,O
controls,O
is,O
taking,O
place,O
entirely,O
via,O
the,O
number,O
of,O
different,O
"""",O
filler,O
"""",O
meta,O
-,O
states,O
they,O
touch,O
on,O
briefly,O
while,O
passing,O
between,O
meta,O
-,O
states,O
they,O
visit,O
more,O
often,O
.,O
Basic,O
Results,O
on,O
Hub,O
Meta,O
-,O
States,O
and,O
Schizophrenia,B-DS
(,O
A,O
),O
Bar,O
plots,O
for,O
HC,O
and,O
SZ,B-DS
of,O
number,O
of,O
subjects,O
(,O
y,O
-,O
axis,O
),O
with,O
hubs,O
of,O
exactly,O
the,O
indicated,O
levels,O
(,O
x,O
-,O
axis,O
);,O
(,O
B,O
),O
Bar,O
plots,O
for,O
HC,O
and,O
SZ,B-DS
of,O
number,O
of,O
subjects,O
(,O
y,O
-,O
axis,O
),O
with,O
hubs,O
of,O
at,O
least,O
the,O
indicated,O
level,O
(,O
x,O
-,O
axis,O
).,O
Results,O
of,O
Comprehensive,O
Investigation,O
of,O
Hub,O
Meta,O
-,O
States,O
and,O
Schizophrenia,B-DS
(,O
A,O
),O
Histograms,O
of,O
within,O
-,O
subject,O
mean,O
meta,O
-,O
state,O
recurrence,O
rate,O
(,O
average,O
number,O
of,O
re,O
-,O
visitations,O
made,O
to,O
the,O
meta,O
-,O
states,O
realized,O
),O
and,O
SZ,B-DS
regression,O
effect,O
on,O
this,O
quantity,O
(,O
SZ,B-DS
effect,O
=,O
0,O
.,O
86,O
",",O
p,O
-,O
value,O
=,O
0,O
.,O
0001,O
);,O
(,O
B,O
),O
SZ,B-DS
effect,O
on,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
with,O
indicated,O
within,O
-,O
subject,O
recurrence,O
rate,O
(,O
inset,O
zooms,O
on,O
rates,O
3,O
–,O
18,O
),O
along,O
with,O
SZ,B-DS
effect,O
on,O
the,O
largest,O
number,O
of,O
visits,O
to,O
the,O
same,O
state,O
(,O
SZ,B-DS
effect,O
=,O
1,O
.,O
42,O
",",O
p,O
-,O
value,O
=,O
4,O
.,O
96e,O
-,O
005,O
(,O
also,O
see,O
(,O
C,O
),O
for,O
distribution,O
));,O
(,O
C,O
),O
Number,O
of,O
subjects,O
whose,O
most,O
visited,O
meta,O
-,O
state,O
had,O
indicated,O
recurrence,O
rate,O
;,O
(,O
D,O
),O
Mean,O
longest,O
uninterrupted,O
period,O
of,O
hub,O
state,O
occupancy,O
(,O
recall,O
that,O
level,O
k,O
hubs,O
are,O
occupied,O
k,O
times,O
",",O
not,O
necessarily,O
in,O
uninterrupted,O
stretches,O
),O
and,O
SZ,B-DS
regression,O
effect,O
(,O
SZ,B-DS
effect,O
=,O
1,O
.,O
18,O
",",O
p,O
-,O
value,O
=,O
4,O
.,O
60e,O
-,O
005,O
);,O
(,O
E,O
),O
Effect,O
of,O
SZ,B-DS
on,O
hub,O
saturation,O
",",O
evaluated,O
separately,O
for,O
hubs,O
of,O
each,O
level,O
k,O
",",O
k,O
=,O
4,O
",",O
5,O
",…,",O
36,O
.,O
Saturation,O
positively,O
correlated,O
with,O
SZ,B-DS
in,O
red,O
(,O
dark,O
red,O
indicates,O
effects,O
significant,O
0,O
.,O
05,O
level,O
after,O
FDR,O
correction,O
"),",O
negatively,O
correlated,O
with,O
saturation,O
in,O
blue,O
.,O
(,O
F,O
),O
Boxplot,O
of,O
saturation,O
index,O
over,O
all,O
hubs,O
for,O
HC,O
and,O
SZ,B-DS
with,O
group,O
means,O
(,O
μSZ,O
=,O
5,O
.,O
2,O
",",O
μHC,O
=,O
5,O
.,O
6,O
),O
and,O
SZ,B-DS
regression,O
effect,O
on,O
this,O
quantity,O
(,O
SZ,B-DS
effect,O
=,O
0,O
.,O
34,O
",",O
p,O
-,O
value,O
=,O
4,O
.,O
88e,O
-,O
005,O
);,O
All,O
SZ,B-DS
effects,O
and,O
associated,O
p,O
-,O
values,O
are,O
from,O
the,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
.,O
The,O
reported,O
regressions,O
include,O
the,O
patient,O
with,O
an,O
order,O
-,O
36,O
hub,O
(,O
ie,O
",",O
they,O
are,O
for,O
the,O
displayed,O
data,O
",",O
and,O
we,O
did,O
want,O
to,O
provide,O
evidence,O
that,O
hubs,O
of,O
higher,O
order,O
are,O
achievable,O
).,O
In,O
regressions,O
omitting,O
this,O
extreme,O
observation,O
",",O
both,O
the,O
direction,O
and,O
significance,O
level,O
of,O
displayed,O
effects,O
were,O
preserved,O
(,O
p,O
-,O
values,O
were,O
on,O
order,O
e,O
-,O
005,O
or,O
e,O
-,O
006,O
).,O
The,O
meta,O
-,O
states,O
that,O
a,O
subject,O
returns,O
to,O
four,O
or,O
more,O
times,O
are,O
the,O
subject,O
',O
s,O
hub,O
states,O
;,O
those,O
that,O
the,O
subject,O
visits,O
at,O
least,O
once,O
but,O
no,O
more,O
than,O
three,O
times,O
are,O
the,O
subject,O
',O
s,O
transient,O
states,O
.,O
A,O
state,O
that,O
is,O
visited,O
k,O
≥,O
4,O
times,O
is,O
called,O
a,O
level,O
-,O
k,O
hub,O
.,O
In,O
our,O
data,O
",",O
the,O
complete,O
set,O
of,O
level,O
-,O
k,O
hubs,O
for,O
k,O
≥,O
4,O
consists,O
of,O
2117,O
meta,O
-,O
states,O
",",O
accounting,O
for,O
approximately,O
6,O
%,O
of,O
whole,O
state,O
space,O
(,O
C,O
=,O
32,O
",",O
768,O
),O
space,O
and,O
15,O
%,O
of,O
the,O
points,O
that,O
are,O
ever,O
visited,O
at,O
least,O
once,O
by,O
some,O
subject,O
(,O
cR,O
=,O
14,O
",",O
025,O
),O
(,O
Fig,O
11,O
).,O
Every,O
subject,O
in,O
this,O
study,O
has,O
a,O
level,O
-,O
k,O
hub,O
for,O
k,O
=,O
4,O
(,O
Fig,O
9,O
(,O
A,O
)),O
and,O
only,O
one,O
subject,O
has,O
a,O
level,O
-,O
k,O
hub,O
for,O
k,O
>,O
18,O
(,O
Fig,O
9,O
(,O
B,O
)).,O
Not,O
only,O
do,O
patients,O
exhibit,O
a,O
larger,O
number,O
of,O
distinct,O
hub,O
meta,O
-,O
states,O
during,O
their,O
scans,O
(,O
Fig,O
10A,O
and,O
10B,O
"),",O
Fig,O
11,O
"),",O
they,O
tend,O
to,O
spend,O
longer,O
uninterrupted,O
periods,O
than,O
controls,O
occupying,O
these,O
meta,O
-,O
states,O
(,O
Fig,O
10C,O
",",O
10D,O
and,O
10E,O
)).,O
A,O
patient,O
",",O
for,O
example,O
",",O
with,O
some,O
level,O
-,O
20,O
hub,O
is,O
more,O
likely,O
to,O
spend,O
three,O
uninterrupted,O
time,O
intervals,O
of,O
lengths,O
5,O
",",O
7,O
and,O
8,O
in,O
that,O
meta,O
-,O
state,O
",",O
while,O
a,O
healthy,O
subject,O
is,O
more,O
likely,O
to,O
spend,O
eight,O
uninterrupted,O
intervals,O
of,O
lengths,O
2,O
",",O
1,O
",",O
4,O
",",O
1,O
",",O
2,O
",",O
1,O
",",O
6,O
and,O
3,O
in,O
one,O
of,O
its,O
level,O
-,O
20,O
hub,O
states,O
.,O
A,O
subject,O
whose,O
longest,O
uninterrupted,O
occupancy,O
of,O
a,O
level,O
-,O
k,O
hub,O
is,O
a,O
large,O
relative,O
to,O
k,O
is,O
said,O
to,O
saturate,O
that,O
hub,O
;,O
level,O
-,O
k,O
hubs,O
whose,O
longest,O
uninterrupted,O
periods,O
of,O
occupancy,O
are,O
large,O
relative,O
to,O
k,O
are,O
absorbing,O
hubs,O
.,O
The,O
level,O
-,O
k,O
hubs,O
that,O
subjects,O
land,O
on,O
k,O
times,O
but,O
always,O
move,O
on,O
from,O
quickly,O
are,O
transitory,O
hubs,O
.,O
Patients,O
have,O
more,O
hubs,O
than,O
controls,O
",",O
and,O
these,O
hubs,O
are,O
more,O
absorbing,O
(,O
Fig,O
10D,O
",",O
10E,O
and,O
10F,O
)).,O
Number,O
of,O
Distinct,O
Meta,O
-,O
States,O
Occupied,O
Multiple,O
Times,O
by,O
any,O
Subject,O
(,O
A,O
),O
Bar,O
plot,O
of,O
number,O
of,O
meta,O
-,O
states,O
with,O
indicated,O
within,O
-,O
subject,O
recurrence,O
rates,O
for,O
full,O
population,O
with,O
fitted,O
power,O
law,O
(,O
α,O
=,O
-,O
323,O
);,O
(,O
B,O
),O
Power,O
laws,O
fitted,O
separately,O
for,O
HC,O
(,O
α,O
=,O
-,O
3,O
.,O
36,O
),O
and,O
SZ,B-DS
(,O
α,O
=,O
-,O
2,O
.,O
30,O
),O
to,O
number,O
of,O
meta,O
-,O
states,O
with,O
given,O
within,O
-,O
subject,O
recurrence,O
rates,O
.,O
Although,O
there,O
are,O
multiple,O
supportable,O
ways,O
to,O
quantify,O
the,O
degree,O
to,O
which,O
level,O
-,O
k,O
hubs,O
are,O
absorbing,O
or,O
saturated,O
",",O
we,O
have,O
chosen,O
to,O
employ,O
the,O
following,O
within,O
-,O
subject,O
measure,O
of,O
level,O
-,O
k,O
saturation,O
:,O
ψk,O
(,O
s,O
)=(,O
longestuninterruptedoccupancyofalevelkhub,O
)(#,O
oftimesthemaximallevelkoccupancyoccurs,O
),O
max,O
(,O
1,O
",(#",O
oflevelkhubs,O
)),O
ψk,O
(,O
s,O
)=,O
kdmax,O
(,O
1,O
",",O
d,O
)=,O
k,O
when,O
subject,O
s,O
has,O
d,O
level,O
-,O
k,O
hubs,O
",",O
each,O
of,O
which,O
the,O
subject,O
spends,O
k,O
consecutive,O
time,O
points,O
in,O
.,O
Otherwise,O
",",O
ψk,O
(,O
s,O
)=,O
k,O
′,O
d,O
′,O
max,O
(,O
1,O
",",O
d,O
)≤,O
k,O
",",O
where,O
k,O
'≤,O
k,O
is,O
the,O
maximal,O
uninterrupted,O
occupancy,O
of,O
one,O
of,O
the,O
subject,O
',O
s,O
d,O
level,O
-,O
k,O
hubs,O
and,O
d,O
'≤,O
d,O
is,O
the,O
number,O
level,O
-,O
k,O
hubs,O
that,O
the,O
subject,O
occupies,O
for,O
an,O
uninterrupted,O
period,O
of,O
length,O
k,O
'.,O
The,O
idea,O
is,O
to,O
capture,O
",",O
in,O
a,O
way,O
that,O
gives,O
more,O
"""",O
credit,O
"""",O
for,O
saturations,O
of,O
higher,O
-,O
level,O
hubs,O
",",O
the,O
extent,O
to,O
which,O
a,O
subject,O
utilizes,O
the,O
available,O
visits,O
to,O
his,O
or,O
her,O
level,O
-,O
k,O
hubs,O
in,O
uninterrupted,O
occupation,O
.,O
The,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
visited,O
exactly,O
n,O
times,O
by,O
some,O
subject,O
decays,O
exponentially,O
with,O
recurrence,O
rate,O
(,O
Fig,O
11,O
).,O
The,O
rate,O
of,O
decay,O
is,O
slower,O
for,O
patients,O
than,O
controls,O
(,O
Fig,O
11,O
(,O
B,O
)).,O
The,O
number,O
of,O
subjects,O
returning,O
to,O
any,O
meta,O
-,O
state,O
at,O
least,O
m,O
times,O
",",O
follows,O
a,O
roughly,O
right,O
-,O
skewed,O
normal,O
distribution,O
with,O
respect,O
to,O
the,O
maximum,O
return,O
rate,O
m,O
(,O
Fig,O
10,O
(,O
C,O
)).,O
Every,O
subject,O
has,O
at,O
least,O
one,O
hub,O
",",O
ie,O
.,O
they,O
visit,O
some,O
meta,O
-,O
state,O
four,O
or,O
more,O
times,O
.,O
Only,O
eleven,O
subjects,O
(,O
3,O
%,O
of,O
the,O
total,O
"),",O
however,O
",",O
visit,O
no,O
state,O
more,O
than,O
four,O
times,O
(,O
Fig,O
10,O
(,O
C,O
)).,O
The,O
average,O
maximum,O
return,O
rate,O
is,O
8,O
.,O
4,O
for,O
patients,O
and,O
7,O
.,O
2,O
for,O
controls,O
.,O
Fewer,O
than,O
10,O
%,O
of,O
subjects,O
return,O
to,O
any,O
state,O
more,O
than,O
eleven,O
times,O
(,O
Fig,O
10,O
(,O
C,O
)).,O
And,O
in,O
terms,O
of,O
the,O
state,O
space,O
",",O
just,O
over,O
0,O
.,O
1,O
%,O
of,O
states,O
are,O
visited,O
more,O
than,O
eleven,O
times,O
by,O
some,O
subject,O
(,O
Fig,O
10,O
(,O
B,O
"),",O
Fig,O
11,O
).,O
It,O
is,O
also,O
the,O
case,O
that,O
patients,O
move,O
significantly,O
more,O
smoothly,O
through,O
the,O
state,O
space,O
than,O
do,O
healthy,O
controls,O
",",O
ie,O
.,O
the,O
average,O
L1,O
distance,O
between,O
successive,O
meta,O
-,O
states,O
is,O
smaller,O
in,O
the,O
patient,O
population,O
(,O
SZ,B-DS
Effect,O
=,O
-,O
0,O
.,O
08,O
",",O
P,O
-,O
value,O
=,O
3,O
.,O
04,O
e,O
-,O
008,O
).,O
Trajectories,O
of,O
Groups,O
of,O
Schizophrenia,B-DS
Patients,O
More,O
Likely,O
to,O
Intersect,O
at,O
Common,O
Meta,O
-,O
Sates,O
than,O
are,O
Trajectories,O
of,O
Healthy,O
Controls,O
As,O
noted,O
above,O
",",O
the,O
discrete,O
5,O
-,O
dimensional,O
state,O
space,O
in,O
which,O
we,O
are,O
studying,O
dynamics,O
is,O
large,O
relative,O
to,O
the,O
length,O
of,O
the,O
trajectories,O
(,O
the,O
state,O
space,O
X,O
contains,O
32,O
",",O
768,O
points,O
while,O
trajectories,O
consist,O
of,O
only,O
136,O
observed,O
timepoints,O
).,O
Absence,O
of,O
inter,O
-,O
subject,O
temporal,O
alignment,O
in,O
resting,O
fMRI,O
means,O
that,O
most,O
subjects,O
start,O
at,O
some,O
arbitrary,O
point,O
in,O
the,O
state,O
space,O
",",O
move,O
around,O
for,O
136,O
timepoints,O
in,O
a,O
manner,O
at,O
least,O
moderately,O
constrained,O
by,O
their,O
arbitrary,O
“,O
initial,O
condition,O
"”,",O
and,O
need,O
not,O
intersect,O
any,O
other,O
subject,O
trajectories,O
at,O
all,O
.,O
For,O
schizophrenia,B-DS
patients,O
this,O
problem,O
is,O
more,O
pronounced,O
since,O
they,O
realize,O
fewer,O
meta,O
-,O
states,O
",",O
change,O
meta,O
-,O
state,O
less,O
often,O
and,O
remain,O
trapped,O
in,O
a,O
smaller,O
radial,O
neighborhood,O
of,O
their,O
arbitrary,O
starting,O
point,O
.,O
This,O
makes,O
it,O
all,O
the,O
more,O
interesting,O
to,O
note,O
that,O
pairs,O
of,O
schizophrenia,B-DS
patients,O
are,O
significantly,O
more,O
likely,O
to,O
have,O
trajectories,O
that,O
intersect,O
than,O
are,O
healthy,O
controls,O
.,O
They,O
are,O
in,O
fact,O
more,O
likely,O
than,O
pairs,O
of,O
controls,O
to,O
have,O
trajectories,O
that,O
intersect,O
up,O
to,O
ten,O
times,O
(,O
Fig,O
12,O
(,O
B,O
)).,O
The,O
odds,O
that,O
the,O
trajectory,O
of,O
a,O
patient,O
and,O
that,O
of,O
a,O
control,O
intersect,O
are,O
lower,O
still,O
(,O
Fig,O
12,O
(,O
B,O
)).,O
It,O
is,O
also,O
the,O
case,O
that,O
the,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
(,O
points,O
in,O
X,O
),O
realized,O
by,O
more,O
than,O
a,O
handful,O
of,O
subjects,O
",",O
i,O
.,O
e,O
".,",O
for,O
which,O
there,O
exist,O
three,O
or,O
more,O
subjects,O
whose,O
trajectories,O
intersect,O
at,O
that,O
point,O
is,O
very,O
small,O
(,O
1751,O
",",O
or,O
about,O
½,O
of,O
1,O
%,O
of,O
the,O
points,O
in,O
X,O
).,O
Although,O
individual,O
schizophrenia,B-DS
patients,O
realize,O
fewer,O
meta,O
-,O
states,O
than,O
do,O
healthy,O
controls,O
",",O
it,O
is,O
also,O
the,O
case,O
that,O
a,O
significantly,O
larger,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
are,O
realized,O
by,O
collections,O
of,O
three,O
or,O
more,O
schizophrenia,B-DS
patients,O
than,O
by,O
groups,O
of,O
healthy,O
controls,O
(,O
Fig,O
12,O
(,O
A,O
)).,O
Meta,O
-,O
States,O
Realized,O
at,O
Least,O
Once,O
by,O
Multiple,O
Subjects,O
(,O
A,O
),O
Bar,O
plot,O
of,O
number,O
of,O
meta,O
-,O
states,O
realized,O
by,O
two,O
or,O
more,O
subjects,O
(,O
number,O
of,O
subjects,O
in,O
the,O
collection,O
jointly,O
realizing,O
some,O
meta,O
-,O
state,O
on,O
the,O
x,O
-,O
axis,O
"),",O
shown,O
separately,O
for,O
patients,O
and,O
healthy,O
controls,O
.,O
No,O
meta,O
-,O
state,O
whatsoever,O
is,O
realized,O
by,O
more,O
than,O
7,O
different,O
healthy,O
subjects,O
.,O
Fewer,O
than,O
50,O
(,O
of,O
32,O
",",O
768,O
),O
meta,O
-,O
states,O
are,O
realized,O
by,O
more,O
than,O
6,O
patients,O
.,O
A,O
two,O
-,O
sample,O
T,O
-,O
test,O
shows,O
that,O
the,O
number,O
NSZ,O
of,O
patients,O
jointly,O
realizing,O
some,O
meta,O
-,O
state,O
is,O
significantly,O
larger,O
than,O
the,O
number,O
NHC,O
of,O
controls,O
respectively,O
jointly,O
realizing,O
some,O
meta,O
-,O
state,O
;,O
(,O
B,O
),O
Bar,O
plot,O
of,O
the,O
number,O
of,O
subject,O
-,O
pairs,O
that,O
jointly,O
realize,O
indicated,O
(,O
x,O
-,O
axis,O
),O
number,O
of,O
meta,O
-,O
states,O
",",O
shown,O
separately,O
for,O
pairs,O
of,O
controls,O
",",O
pairs,O
of,O
patients,O
and,O
mixed,O
pairs,O
consisting,O
of,O
one,O
patient,O
and,O
one,O
control,O
.,O
A,O
two,O
-,O
sample,O
T,O
-,O
text,O
shows,O
that,O
the,O
average,O
number,O
of,O
intersection,O
points,O
(,O
jointly,O
realized,O
meta,O
-,O
states,O
),O
for,O
SZ,B-DS
subject,O
pairs,O
is,O
significantly,O
larger,O
than,O
the,O
average,O
number,O
of,O
intersection,O
points,O
for,O
HC,O
subject,O
pairs,O
.,O
Discussion,O
We,O
have,O
introduced,O
a,O
flexible,O
",",O
robust,O
framework,O
for,O
analyzing,O
dynamic,O
network,O
connectivity,O
in,O
terms,O
of,O
a,O
small,O
set,O
of,O
whole,O
-,O
brain,O
correlation,O
patterns,O
that,O
combine,O
additively,O
to,O
form,O
(,O
or,O
approximate,O
),O
observed,O
time,O
-,O
varying,O
windowed,O
FNCs,O
",",O
and,O
whose,O
simultaneous,O
contributions,O
",",O
in,O
magnitude,O
and,O
direction,O
",",O
are,O
maximally,O
mutually,O
independent,O
.,O
We,O
investigate,O
the,O
temporally,O
-,O
indexed,O
sequence,O
of,O
length,O
-,O
five,O
CP,O
weight,O
vectors,O
",",O
or,O
meta,O
-,O
states,O
.,O
At,O
this,O
level,O
",",O
we,O
find,O
very,O
strong,O
statistical,O
evidence,O
that,O
:,O
SZ,B-DS
exhibit,O
diminished,O
dynamic,O
fluidity,O
:,O
SZ,B-DS
switch,O
less,O
frequently,O
between,O
five,O
-,O
dimensional,O
meta,O
-,O
states,O
(,O
Fig,O
6,O
",",O
Table,O
2,O
",",O
Table,O
3,O
),O
SZ,B-DS
occupy,O
a,O
smaller,O
number,O
of,O
distinct,O
meta,O
-,O
states,O
during,O
their,O
scans,O
(,O
Fig,O
6,O
",",O
Table,O
2,O
",",O
Table,O
3,O
),O
SZ,B-DS
operate,O
over,O
a,O
restricted,O
in,O
dynamic,O
range,O
:,O
SZ,B-DS
remain,O
trapped,O
in,O
a,O
smaller,O
radius,O
hypercube,O
of,O
the,O
state,O
space,O
(,O
Fig,O
7,O
",",O
Table,O
2,O
",",O
Table,O
3,O
),O
SZs,O
cover,O
less,O
distance,O
as,O
they,O
move,O
through,O
the,O
state,O
space,O
(,O
Fig,O
7,O
",",O
Table,O
2,O
",",O
Table,O
3,O
),O
Simultaneously,O
considering,O
these,O
results,O
and,O
combining,O
their,O
implications,O
",",O
what,O
emerges,O
is,O
a,O
picture,O
of,O
generally,O
more,O
cautious,O
",",O
sluggish,O
patient,O
trajectories,O
through,O
constrained,O
regions,O
of,O
connectivity,O
space,O
",",O
contrasted,O
with,O
the,O
relatively,O
quick,O
",",O
fluid,O
",",O
more,O
sprawling,O
trajectories,O
of,O
healthy,O
subjects,O
.,O
Deeper,O
investigations,O
of,O
meta,O
-,O
state,O
occupancy,O
",",O
recurrence,O
",",O
span,O
and,O
change,O
patterns,O
however,O
reveal,O
a,O
richer,O
and,O
more,O
nuanced,O
perspective,O
on,O
the,O
distinctive,O
ways,O
patients,O
and,O
controls,O
move,O
dynamically,O
through,O
connectivity,O
space,O
.,O
Schizophrenia,B-DS
patients,O
",",O
for,O
example,O
",",O
tend,O
to,O
have,O
a,O
larger,O
number,O
of,O
relatively,O
more,O
absorbing,O
hub,O
states,O
than,O
controls,O
.,O
Patients,O
travel,O
less,O
distance,O
through,O
the,O
state,O
space,O
from,O
one,O
time,O
point,O
to,O
the,O
next,O
on,O
average,O
",",O
and,O
the,O
largest,O
k,O
≥,O
4,O
for,O
which,O
patients,O
have,O
a,O
level,O
-,O
k,O
hub,O
tends,O
to,O
exceed,O
that,O
for,O
healthy,O
controls,O
.,O
Although,O
not,O
statistically,O
significant,O
",",O
it,O
is,O
also,O
the,O
case,O
that,O
the,O
directional,O
effect,O
of,O
schizophrenia,B-DS
diagnosis,O
on,O
the,O
number,O
and,O
span,O
of,O
states,O
that,O
are,O
the,O
outgoing,O
targets,O
of,O
hubs,O
is,O
positive,O
(,O
Fig,O
13,O
).,O
Locally,O
",",O
in,O
the,O
immediate,O
neighborhood,O
of,O
hubs,O
",",O
the,O
schizophrenia,B-DS
patients,O
seem,O
slightly,O
more,O
dynamic,O
than,O
controls,O
",",O
while,O
globally,O
they,O
are,O
significantly,O
less,O
so,O
.,O
Dynamism,O
measures,O
restricted,O
to,O
immediate,O
neighborhoods,O
of,O
higher,O
-,O
level,O
hubs,O
.,O
We,O
examine,O
the,O
number,O
and,O
the,O
span,O
of,O
incoming,O
and,O
outgoing,O
meta,O
-,O
states,O
connected,O
to,O
each,O
hub,O
of,O
level,O
8,O
and,O
over,O
.,O
The,O
interval,O
was,O
selected,O
so,O
that,O
more,O
than,O
a,O
third,O
of,O
HCs,O
and,O
of,O
SZs,O
have,O
level,O
-,O
k,O
hubs,O
for,O
k,O
≥,O
the,O
lower,O
bound,O
of,O
the,O
interval,O
.,O
The,O
values,O
are,O
not,O
integers,O
because,O
we,O
average,O
over,O
each,O
segment,O
during,O
which,O
a,O
given,O
hub,O
is,O
occupied,O
for,O
a,O
subject,O
",",O
ie,O
.,O
the,O
subject,O
first,O
visits,O
some,O
level,O
k,O
hub,O
for,O
3,O
consecutive,O
timepoints,O
and,O
then,O
later,O
visits,O
the,O
same,O
hub,O
again,O
for,O
k,O
-,O
3,O
consecutive,O
timepoints,O
.,O
Each,O
separate,O
occupancy,O
has,O
its,O
own,O
outgoing,O
target,O
",",O
which,O
might,O
or,O
might,O
not,O
be,O
identical,O
.,O
Since,O
the,O
number,O
of,O
distinct,O
segments,O
of,O
occupancy,O
of,O
a,O
given,O
hub,O
affect,O
the,O
overall,O
number,O
and,O
range,O
of,O
the,O
targets,O
of,O
that,O
hub,O
",",O
we,O
rescale,O
by,O
1numberofsegments,O
resulting,O
in,O
non,O
-,O
integer,O
valued,O
measures,O
.,O
(,O
A,O
),O
The,O
number,O
(,O
rescaled,O
as,O
indicated,O
),O
of,O
distinct,O
target,O
meta,O
-,O
states,O
of,O
fixed,O
hubs,O
;,O
(,O
B,O
),O
The,O
span,O
(,O
maximal,O
L1,O
distance,O
between,O
",",O
also,O
rescaled,O
as,O
indicated,O
above,O
),O
of,O
target,O
meta,O
-,O
states,O
of,O
fixed,O
hubs,O
.,O
Although,O
both,O
groups,O
have,O
hub,O
states,O
that,O
they,O
return,O
to,O
relatively,O
often,O
",",O
any,O
routing,O
role,O
these,O
hubs,O
play,O
is,O
significantly,O
less,O
efficient,O
in,O
patients,O
than,O
controls,O
and,O
also,O
somewhat,O
more,O
erratic,O
:,O
patients,O
have,O
more,O
hubs,O
of,O
each,O
level,O
",",O
their,O
hubs,O
hold,O
incoming,O
trajectories,O
longer,O
",",O
and,O
ultimately,O
release,O
trajectories,O
to,O
a,O
slightly,O
wider,O
range,O
of,O
targets,O
.,O
We,O
see,O
an,O
analogous,O
scaling,O
phenomenon,O
when,O
we,O
make,O
an,O
upward,O
adjustment,O
to,O
the,O
number,O
of,O
visits,O
to,O
a,O
state,O
required,O
for,O
it,O
to,O
qualify,O
as,O
having,O
been,O
occupied,O
.,O
If,O
the,O
threshold,O
is,O
one,O
visit,O
",",O
then,O
controls,O
visit,O
significantly,O
more,O
states,O
.,O
When,O
the,O
threshold,O
is,O
shifted,O
upward,O
to,O
four,O
or,O
more,O
visits,O
",",O
then,O
it,O
is,O
patients,O
that,O
are,O
sampling,O
a,O
larger,O
number,O
of,O
states,O
(,O
Fig,O
10,O
).,O
Finally,O
",",O
although,O
patients,O
are,O
individually,O
occupying,O
fewer,O
states,O
and,O
moving,O
smaller,O
distances,O
in,O
the,O
state,O
space,O
",",O
their,O
trajectories,O
are,O
nonetheless,O
more,O
likely,O
to,O
intersect,O
at,O
some,O
meta,O
-,O
state,O
than,O
are,O
trajectories,O
of,O
healthy,O
subjects,O
(,O
Fig,O
12,O
(,O
B,O
)),O
and,O
the,O
set,O
of,O
distinct,O
meta,O
-,O
states,O
that,O
are,O
in,O
the,O
joint,O
intersection,O
of,O
some,O
collection,O
of,O
patients,O
is,O
almost,O
always,O
(,O
except,O
in,O
the,O
case,O
of,O
pairs,O
of,O
subjects,O
),O
larger,O
than,O
the,O
set,O
of,O
points,O
that,O
sit,O
in,O
the,O
joint,O
intersection,O
of,O
a,O
similarly,O
sized,O
collection,O
of,O
controls,O
(,O
Fig,O
12,O
(,O
A,O
)).,O
Our,O
findings,O
demonstrate,O
the,O
flexibility,O
",",O
sensitivity,O
",",O
and,O
robustness,O
of,O
the,O
meta,O
-,O
state,O
framework,O
for,O
dynamical,O
analysis,O
proposed,O
here,O
.,O
Schizophrenia,B-DS
is,O
a,O
complex,O
illness,O
that,O
presents,O
with,O
enormous,O
variation,O
of,O
symptom,O
combinations,O
and,O
intensities,O
",",O
and,O
its,O
effects,O
on,O
resting,O
fMRI,O
are,O
commensurately,O
complex,O
.,O
Most,O
studies,O
to,O
date,O
have,O
taken,O
a,O
static,O
point,O
of,O
view,O
",",O
assuming,O
the,O
characteristic,O
of,O
interest,O
to,O
be,O
stationary,O
on,O
the,O
timescale,O
of,O
the,O
scan,O
.,O
Such,O
studies,O
have,O
yielded,O
consistent,O
evidence,O
that,O
at,O
both,O
voxel,O
and,O
network,O
levels,O
that,O
the,O
signals,O
of,O
schizophrenia,B-DS
patients,O
contain,O
more,O
high,O
frequency,O
content,O
than,O
healthy,O
controls,O
[,O
1,O
",",O
47,O
].,O
Supporting,O
the,O
so,O
-,O
called,O
dysconnectivity,O
hypothesis,O
[,O
48,O
],O
about,O
schizophrenia,B-DS
",",O
static,O
functional,O
network,O
connectivity,O
analyses,O
have,O
consistently,O
revealed,O
diminished,O
network,O
connectivity,O
strengths,O
in,O
schizophrenia,B-DS
patients,O
[,O
7,O
",",O
49,O
–,O
53,O
"],",O
and,O
more,O
specifically,O
altered,O
connectivity,O
between,O
auditory,O
",",O
visual,O
and,O
somatosensory,O
networks,O
(,O
AVSNs,O
),O
and,O
also,O
between,O
subcortical,O
(,O
SC,O
),O
networks,O
and,O
AVSNs,O
[,O
26,O
",",O
37,O
].,O
Many,O
of,O
these,O
findings,O
appear,O
to,O
hold,O
even,O
when,O
the,O
stationarity,O
assumption,O
is,O
lifted,O
as,O
evidenced,O
by,O
significantly,O
more,O
negative,O
SZ,B-DS
timecourse,O
values,O
(,O
Fig,O
14,O
),O
for,O
CPs,O
that,O
feature,O
strong,O
positive,O
intra,O
-,O
AVSN,O
correlations,O
and,O
strong,O
negative,O
SC,O
-,O
to,O
-,O
AVSN,O
connections,O
(,O
Fig,O
4,O
(,O
A,O
"),",O
Top,O
row,O
).,O
Effect,O
of,O
Schizophrenia,B-DS
on,O
Dynamic,O
Roles,O
of,O
Individual,O
tICA,O
Correlation,O
Patterns,O
(,O
Fig,O
4,O
(,O
A,O
"),",O
Row,O
1,O
).,O
Red,O
(,O
or,O
bars,O
pointing,O
upward,O
),O
indicate,O
positive,O
correlation,O
with,O
SZ,B-DS
.,O
Only,O
effects,O
significant,O
at,O
the,O
0,O
.,O
05,O
level,O
following,O
FDR,O
-,O
correction,O
are,O
displayed,O
.,O
(,O
A,O
),O
SZ,B-DS
effects,O
on,O
the,O
number,O
of,O
times,O
each,O
discretized,O
CP,O
timecourse,O
(,O
y,O
-,O
axis,O
"),",O
assumes,O
values,O
indicated,O
on,O
the,O
x,O
-,O
axis,O
;,O
(,O
B,O
),O
SZ,B-DS
effects,O
on,O
binned,O
counts,O
(,O
x,O
-,O
axis,O
),O
of,O
the,O
number,O
of,O
timepoints,O
each,O
discretized,O
CP,O
timecourse,O
spends,O
consecutively,O
the,O
most,O
negative,O
level,O
",",O
-,O
4,O
;,O
(,O
C,O
),O
SZ,B-DS
effect,O
on,O
the,O
number,O
of,O
correlation,O
patterns,O
simultaneously,O
contributing,O
in,O
their,O
anti,O
-,O
state,O
form,O
",",O
ie,O
.,O
on,O
the,O
number,O
of,O
timepoints,O
at,O
which,O
a,O
subject,O
',O
s,O
meta,O
-,O
state,O
contains,O
the,O
indicated,O
number,O
(,O
x,O
-,O
axis,O
),O
of,O
negative,O
values,O
;,O
(,O
D,O
),O
SZ,B-DS
effects,O
",",O
component,O
-,O
wise,O
for,O
CPs,O
that,O
exhibit,O
strong,O
positive,O
AVSN,O
correlations,O
",",O
on,O
the,O
number,O
of,O
transitions,O
between,O
levels,O
indicated,O
on,O
x,O
-,O
axis,O
and,O
y,O
-,O
axis,O
;,O
All,O
diagnosis,O
effects,O
and,O
p,O
-,O
values,O
are,O
from,O
the,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
.,O
For,O
example,O
",",O
the,O
window,O
-,O
wise,O
spectrum,O
of,O
windowed,O
network,O
timecourses,O
in,O
schizophrenia,B-DS
patients,O
have,O
more,O
high,O
frequency,O
content,O
than,O
those,O
of,O
healthy,O
controls,O
(,O
Fig,O
15,O
).,O
In,O
the,O
timecourses,O
of,O
individual,O
wFNC,O
network,O
-,O
pair,O
correlations,O
",",O
schizophrenia,B-DS
patients,O
also,O
exhibit,O
greater,O
high,O
frequency,O
power,O
",",O
though,O
the,O
effect,O
is,O
weaker,O
statistically,O
than,O
for,O
network,O
and,O
voxel,O
timecourses,O
(,O
Fig,O
15,O
",",O
first,O
three,O
columns,O
).,O
Shen,O
et,O
al,O
[,O
54,O
],O
have,O
reported,O
mixed,O
effects,O
of,O
SZ,B-DS
on,O
low,O
-,O
frequency,O
power,O
in,O
windowed,O
network,O
-,O
pair,O
correlation,O
timeseries,O
",",O
with,O
patients,O
exhibiting,O
less,O
low,O
frequency,O
power,O
than,O
controls,O
in,O
DMN,O
-,O
to,O
-,O
sensorimotor,O
and,O
DMN,O
-,O
to,O
-,O
cerebellum,O
connections,O
.,O
EEG,O
microstate,O
studies,O
[,O
55,O
–,O
58,O
],O
that,O
identify,O
common,O
patterns,O
of,O
millisecond,O
-,O
scale,O
activation,O
from,O
spatially,O
segmented,O
brain,O
regions,O
also,O
indicate,O
a,O
higher,O
rate,O
of,O
pattern,O
-,O
shifting,O
among,O
schizophrenia,B-DS
patients,O
.,O
In,O
contrast,O
",",O
our,O
investigation,O
of,O
whole,O
-,O
brain,O
ensembles,O
of,O
network,O
-,O
pair,O
correlations,O
has,O
yielded,O
highly,O
robust,O
findings,O
of,O
diminished,O
connectivity,O
dynamism,O
for,O
schizophrenia,B-DS
patients,O
.,O
These,O
findings,O
are,O
consistent,O
with,O
recent,O
results,O
on,O
dynamic,O
graph,O
metrics,O
",",O
which,O
inherently,O
involve,O
ensembles,O
of,O
nodal,O
connections,O
[,O
59,O
],O
and,O
with,O
the,O
disappearance,O
of,O
positive,O
high,O
-,O
frequency,O
spectral,O
SZ,B-DS
effects,O
on,O
ensemble,O
-,O
scale,O
timeseries,O
(,O
Fig,O
15,O
",",O
last,O
two,O
columns,O
).,O
The,O
results,O
we,O
present,O
are,O
fundamentally,O
different,O
in,O
kind,O
from,O
those,O
obtained,O
in,O
static,O
settings,O
.,O
Our,O
work,O
concerns,O
the,O
adaptive,O
fluidity,O
and,O
range,O
of,O
functional,O
brain,O
connectivity,O
at,O
a,O
broad,O
multi,O
-,O
network,O
scale,O
–,O
both,O
intrinsically,O
dynamic,O
phenomena,O
that,O
do,O
not,O
have,O
static,O
analogues,O
.,O
In,O
future,O
work,O
however,O
we,O
plan,O
to,O
investigate,O
connections,O
between,O
these,O
high,O
-,O
level,O
dynamic,O
features,O
that,O
suggest,O
group,O
differences,O
in,O
connectonomic,O
adaptivity,O
and,O
the,O
underlying,O
strength,O
",",O
modularity,O
and,O
other,O
key,O
characteristics,O
of,O
static,O
and,O
structural,O
connectomes,O
.,O
It,O
seems,O
possible,O
",",O
for,O
example,O
that,O
the,O
consistent,O
findings,O
[,O
1,O
",",O
7,O
",",O
48,O
–,O
53,O
],O
of,O
diminished,O
connectivity,O
strength,O
and,O
weakened,O
connectome,O
-,O
wide,O
modularity,O
among,O
schizophrenia,B-DS
patients,O
reflect,O
a,O
degradation,O
of,O
communication,O
pathways,O
that,O
enable,O
rapid,O
and,O
widespread,O
reorganization,O
of,O
network,O
relationships,O
.,O
Effect,O
of,O
Schizophrenia,B-DS
on,O
Spectral,O
Power,O
as,O
Data,O
is,O
Transformed,O
from,O
Voxels,O
to,O
Networks,O
to,O
Meta,O
-,O
States,O
SZ,B-DS
effects,O
on,O
the,O
spectral,O
power,O
for,O
inputs,O
(,O
Columns,O
1,O
–,O
4,O
),O
to,O
the,O
meta,O
-,O
state,O
dynamic,O
connectivity,O
framework,O
and,O
its,O
output,O
(,O
Column,O
5,O
),O
(,O
red,O
indicates,O
positive,O
correlation,O
with,O
SZ,B-DS
);,O
(,O
Column,O
1,O
),O
(,O
A,O
),O
SZ,B-DS
effects,O
on,O
network,O
TC,O
spectra,O
;,O
(,O
F,O
),O
Effects,O
from,O
(,O
A,O
),O
that,O
survive,O
FDR,O
correction,O
at,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
J,O
),O
SZ,B-DS
effect,O
on,O
average,O
spectral,O
power,O
over,O
all,O
network,O
TCs,O
;,O
(,O
O,O
),O
Effects,O
from,O
(,O
J,O
),O
that,O
survive,O
FDR,O
-,O
correction,O
at,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
Column,O
2,O
),O
(,O
B,O
),O
SZ,B-DS
effect,O
on,O
windowed,O
network,O
TC,O
spectra,O
;,O
(,O
G,O
),O
Effects,O
from,O
(,O
B,O
),O
that,O
survive,O
FDR,O
-,O
correction,O
at,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
K,O
),O
SZ,B-DS
effect,O
on,O
the,O
average,O
spectral,O
power,O
over,O
all,O
windowed,O
network,O
TCs,O
;,O
(,O
P,O
),O
Effects,O
from,O
(,O
K,O
),O
that,O
survive,O
FDR,O
correction,O
at,O
the,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
Column,O
3,O
),O
(,O
C,O
),O
SZ,B-DS
effects,O
on,O
wFNC,O
network,O
-,O
pair,O
correlation,O
spectra,O
;,O
(,O
H,O
),O
Effects,O
from,O
(,O
C,O
),O
that,O
survive,O
FDR,O
-,O
correction,O
at,O
the,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
L,O
),O
SZ,B-DS
effect,O
on,O
average,O
spectral,O
power,O
over,O
all,O
wFNC,O
network,O
-,O
pair,O
correlations,O
;,O
(,O
Q,O
),O
Effects,O
from,O
(,O
L,O
),O
that,O
survive,O
FDR,O
-,O
correction,O
at,O
the,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
D,O
),O
SZ,B-DS
effects,O
on,O
tICA,O
correlation,O
pattern,O
TCs,O
;,O
(,O
I,O
),O
Effects,O
from,O
(,O
D,O
),O
that,O
survive,O
FDR,O
-,O
correction,O
at,O
the,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
M,O
),O
SZ,B-DS
effect,O
on,O
average,O
spectral,O
power,O
over,O
all,O
tICA,O
correlation,O
pattern,O
TCs,O
;,O
(,O
R,O
),O
Effects,O
from,O
(,O
M,O
),O
that,O
survive,O
FDR,O
-,O
correction,O
at,O
the,O
0,O
.,O
05,O
significance,O
level,O
;,O
(,O
E,O
),O
SZ,B-DS
effect,O
on,O
spectral,O
power,O
of,O
the,O
timeseries,O
that,O
is,O
',O
1,O
',O
when,O
a,O
five,O
-,O
dimensional,O
meta,O
-,O
state,O
changes,O
to,O
a,O
different,O
meta,O
-,O
state,O
and,O
',O
0,O
',O
otherwise,O
;,O
(,O
N,O
),O
Effects,O
from,O
(,O
E,O
),O
that,O
survive,O
FDR,O
-,O
correction,O
at,O
the,O
0,O
.,O
05,O
significance,O
level,O
;,O
All,O
diagnosis,O
effects,O
and,O
p,O
-,O
values,O
are,O
from,O
the,O
regression,O
model,O
specified,O
in,O
the,O
Methods,O
section,O
.,O
The,O
work,O
we,O
present,O
adds,O
an,O
important,O
new,O
layer,O
to,O
the,O
growing,O
constellation,O
of,O
robust,O
findings,O
specific,O
to,O
certain,O
scales,O
or,O
forms,O
of,O
analysis,O
that,O
may,O
",",O
eventually,O
combine,O
to,O
produce,O
powerful,O
predictive,O
fMRI,O
signatures,O
for,O
this,O
highly,O
complex,O
disease,O
.,O
Psychometric,O
properties,O
of,O
the,O
Dresden,O
Body,O
Image,O
Questionnaire,O
:,O
A,O
multiple,O
-,O
group,O
confirmatory,O
factor,O
analysis,O
across,O
sex,O
and,O
age,O
in,O
a,O
Dutch,O
non,O
-,O
clinical,O
sample,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
Background,O
Body,O
image,O
has,O
implications,O
for,O
psychosocial,O
functioning,O
and,O
quality,O
of,O
life,O
and,O
its,O
disturbance,O
is,O
reported,O
in,O
a,O
broad,O
range,O
of,O
psychiatric,B-DS
disorders,I-DS
.,O
In,O
view,O
of,O
the,O
lack,O
of,O
instruments,O
in,O
Dutch,O
measuring,O
body,O
image,O
as,O
a,O
broad,O
concept,O
",",O
we,O
set,O
out,O
to,O
make,O
an,O
instrument,O
available,O
that,O
reflects,O
the,O
multidimensional,O
character,O
of,O
this,O
construct,O
by,O
including,O
more,O
dimensions,O
than,O
physical,O
appearance,O
.,O
The,O
Dresden,O
Körperbildfragebogen,O
(,O
DBIQ,O
",",O
Dresden,O
Body,O
Image,O
Questionnaire,O
),O
particularly,O
served,O
this,O
purpose,O
.,O
The,O
DBIQ,O
consists,O
of,O
35,O
items,O
and,O
five,O
subscales,O
:,O
body,O
acceptance,O
",",O
sexual,O
fulfillment,O
",",O
physical,O
contact,O
",",O
vitality,O
",",O
and,O
self,O
-,O
aggrandizement,O
.,O
The,O
main,O
objective,O
of,O
the,O
present,O
study,O
was,O
to,O
evaluate,O
the,O
psychometric,O
properties,O
of,O
the,O
Dutch,O
translation,O
of,O
the,O
Dresden,O
Body,O
Image,O
Questionnaire,O
(,O
DBIQ,O
-,O
NL,O
),O
in,O
a,O
non,O
-,O
clinical,O
sample,O
.,O
Methods,O
The,O
psychometric,O
properties,O
of,O
the,O
DBIQ,O
-,O
NL,O
were,O
examined,O
in,O
a,O
non,O
-,O
clinical,O
sample,O
of,O
988,O
respondents,O
aged,O
between,O
18,O
and,O
65,O
.,O
We,O
investigated,O
the,O
subscales,O
',O
internal,O
consistency,O
and,O
test,O
-,O
retest,O
reliability,O
.,O
In,O
order,O
to,O
establish,O
construct,O
validity,O
we,O
evaluated,O
the,O
association,O
with,O
a,O
related,O
construct,O
",",O
body,O
cathexis,O
",",O
and,O
with,O
indices,O
of,O
self,O
-,O
esteem,O
and,O
psychological,O
wellbeing,O
.,O
The,O
factor,O
structure,O
of,O
the,O
DBIQ,O
-,O
NL,O
was,O
examined,O
via,O
confirmatory,O
factor,O
analysis,O
(,O
CFA,O
).,O
The,O
equivalence,O
of,O
the,O
measurement,O
model,O
across,O
sex,O
and,O
age,O
was,O
evaluated,O
by,O
multiplegroup,O
confirmatory,O
factor,O
analyses,O
.,O
Results,O
Confirmatory,O
factor,O
analyses,O
showed,O
a,O
structure,O
in,O
accordance,O
with,O
the,O
original,O
scale,O
",",O
where,O
model,O
fit,O
was,O
improved,O
significantly,O
by,O
moving,O
one,O
item,O
to,O
another,O
subscale,O
.,O
Multiple,O
group,O
confirmatory,O
factor,O
analysis,O
across,O
sex,O
and,O
age,O
demonstrated,O
partial,O
strong,O
invariance,O
.,O
Internal,O
consistency,O
was,O
good,O
with,O
little,O
overlap,O
between,O
the,O
subscales,O
.,O
Temporal,O
reliability,O
and,O
construct,O
validity,O
were,O
satisfactory,O
.,O
Conclusion,O
Results,O
indicate,O
that,O
the,O
DBIQ,O
-,O
NL,O
is,O
a,O
reliable,O
and,O
valid,O
instrument,O
for,O
non,O
-,O
clinical,O
subjects,O
.,O
This,O
provides,O
a,O
sound,O
basis,O
for,O
further,O
investigation,O
of,O
the,O
DBIQ,O
-,O
NL,O
in,O
a,O
clinical,O
sample,O
.,O
Introduction,O
The,O
term,O
‘,O
body,O
image,O
’,O
has,O
been,O
used,O
to,O
describe,O
a,O
variety,O
of,O
body,O
-,O
related,O
phenomena,O
",",O
including,O
perceptions,O
",",O
cognitions,O
",",O
affects,O
",",O
and,O
awareness,O
with,O
regard,O
to,O
the,O
body,O
[,O
1,O
",",O
2,O
].,O
Unlike,O
the,O
term,O
seems,O
to,O
suggest,O
",",O
not,O
only,O
the,O
way,O
we,O
evaluate,O
our,O
appearance,O
is,O
part,O
of,O
our,O
body,O
image,O
",",O
but,O
also,O
our,O
attitude,O
towards,O
bodily,O
experiences,O
in,O
interaction,O
with,O
others,O
",",O
sense,O
of,O
body,O
ownership,O
[,O
3,O
],O
and,O
our,O
evaluation,O
of,O
our,O
body,O
in,O
terms,O
of,O
functionality,O
and,O
vitality,O
[,O
4,O
].,O
Aspects,O
of,O
body,O
image,O
have,O
impact,O
on,O
psychosocial,O
functioning,O
[,O
5,O
",",O
6,O
],O
and,O
its,O
disturbances,O
are,O
associated,O
with,O
poorer,O
psychological,O
adjustment,O
in,O
non,O
-,O
clinical,O
samples,O
[,O
7,O
–,O
10,O
].,O
Negative,O
or,O
disturbed,B-DS
body,I-DS
image,I-DS
has,O
also,O
been,O
reported,O
in,O
a,O
broad,O
range,O
of,O
psychiatric,B-DS
disorders,I-DS
[,O
11,O
",",O
12,O
].,O
Disturbed,B-DS
body,I-DS
image,I-DS
in,O
eating,O
disordered,O
female,O
patients,O
has,O
been,O
extensively,O
researched,O
and,O
documented,O
[,O
13,O
–,O
15,O
].,O
There,O
is,O
emerging,O
evidence,O
that,O
mood,B-DS
disorders,I-DS
[,O
16,O
"],",O
anxiety,B-DS
disorders,I-DS
[,O
17,O
"],",O
trauma,B-DS
-,I-DS
related,I-DS
disorders,I-DS
[,O
18,O
–,O
20,O
"],",O
sexual,B-DS
disorders,I-DS
[,O
21,O
",",O
22,O
],O
and,O
schizophrenia,B-DS
[,O
23,O
],O
are,O
also,O
associated,O
with,O
negative,O
or,O
disturbed,B-DS
body,I-DS
image,I-DS
.,O
The,O
overall,O
impression,O
is,O
that,O
body,O
image,O
is,O
affected,O
in,O
a,O
diverse,O
range,O
of,O
mental,O
health,O
problems,O
.,O
However,O
",",O
despite,O
the,O
increasing,O
awareness,O
and,O
recognition,O
in,O
clinical,O
practice,O
of,O
body,O
image,O
problems,O
in,O
other,O
than,O
appearance,O
-,O
related,O
psychopathologies,O
",",O
sound,O
measurement,O
of,O
body,O
image,O
providing,O
evidence,O
of,O
this,O
phenomenon,O
is,O
still,O
scarce,O
in,O
most,O
psychiatric,B-DS
disorders,I-DS
.,O
To,O
date,O
",",O
the,O
Body,O
Attitude,O
Test,O
is,O
the,O
sole,O
well,O
-,O
researched,O
self,O
-,O
report,O
instrument,O
measuring,O
body,O
image,O
available,O
in,O
Dutch,O
[,O
24,O
",",O
25,O
].,O
However,O
",",O
this,O
instrument,O
is,O
specifically,O
developed,O
for,O
measuring,O
body,O
attitude,O
in,O
anorexic,O
women,B-OG
.,O
In,O
view,O
of,O
the,O
lack,O
of,O
multi,O
-,O
purpose,O
instruments,O
in,O
Dutch,O
",",O
we,O
set,O
out,O
to,O
make,O
an,O
instrument,O
available,O
that,O
reflects,O
the,O
multidimensional,O
character,O
of,O
this,O
construct,O
by,O
including,O
more,O
dimensions,O
than,O
physical,O
appearance,O
.,O
As,O
our,O
aim,O
was,O
to,O
gain,O
insight,O
in,O
the,O
way,O
psychopathology,O
and,O
body,O
image,O
are,O
associated,O
",",O
this,O
instrument,O
needed,O
to,O
be,O
suitable,O
for,O
both,O
a,O
broad,O
-,O
ranged,O
clinical,O
population,O
as,O
well,O
as,O
for,O
a,O
non,O
-,O
clinical,O
population,O
so,O
as,O
to,O
facilitate,O
comparisons,O
.,O
The,O
Dresdner,O
Körperbildfragebogen,O
(,O
DBIQ,O
",",O
Dresden,O
Body,O
Image,O
Questionnaire,O
),O
[,O
26,O
",",O
27,O
],O
particularly,O
serves,O
this,O
purpose,O
.,O
The,O
DBIQ,O
",",O
consisting,O
of,O
35,O
items,O
",",O
does,O
not,O
cover,O
all,O
aspects,O
that,O
form,O
part,O
of,O
the,O
umbrella,O
term,O
body,O
image,O
",",O
but,O
focuses,O
on,O
thoughts,O
",",O
beliefs,O
",",O
and,O
conceptual,O
aspects,O
of,O
patient,O
’,O
s,O
body,O
experiences,O
in,O
five,O
different,O
domains,O
:,O
body,O
acceptance,O
",",O
sexual,O
fulfillment,O
",",O
the,O
evaluation,O
of,O
physical,O
contact,O
",",O
experienced,O
vitality,O
",",O
and,O
self,O
-,O
aggrandizement,O
",",O
a,O
measure,O
of,O
how,O
the,O
body,O
is,O
actively,O
used,O
in,O
social,O
interactions,O
to,O
enhance,O
self,O
-,O
esteem,O
.,O
The,O
importance,O
of,O
the,O
dimensions,O
physical,O
contact,O
and,O
sexuality,O
is,O
largely,O
unknown,O
",",O
although,O
they,O
are,O
often,O
mentioned,O
by,O
patients,O
as,O
problematic,O
[,O
28,O
",",O
29,O
].,O
Furthermore,O
",",O
in,O
a,O
factor,O
analytic,O
evaluation,O
of,O
a,O
preliminary,O
version,O
of,O
the,O
DBIQ,O
",",O
body,O
contact,O
as,O
well,O
as,O
sexuality,O
emerged,O
as,O
separate,O
factors,O
[,O
26,O
].,O
Clinical,O
relevance,O
together,O
with,O
the,O
psychometric,O
indication,O
of,O
the,O
importance,O
of,O
these,O
aspects,O
",",O
make,O
its,O
inclusion,O
worthwhile,O
.,O
The,O
first,O
evaluation,O
of,O
the,O
psychometric,O
qualities,O
of,O
the,O
original,O
DBIQ,O
in,O
a,O
clinical,O
sample,O
was,O
promising,O
[,O
26,O
].,O
The,O
main,O
objective,O
of,O
the,O
present,O
study,O
was,O
to,O
evaluate,O
the,O
psychometric,O
properties,O
of,O
the,O
Dutch,O
translation,O
of,O
the,O
DBIQ,O
(,O
DBIQ,O
-,O
NL,O
),O
in,O
a,O
non,O
-,O
clinical,O
sample,O
.,O
First,O
",",O
we,O
investigated,O
the,O
subscales,O
’,O
internal,O
consistency,O
and,O
test,O
-,O
retest,O
reliability,O
.,O
In,O
order,O
to,O
establish,O
construct,O
validity,O
of,O
the,O
DBIQ,O
-,O
NL,O
we,O
evaluated,O
the,O
association,O
with,O
specific,O
related,O
constructs,O
",",O
namely,O
body,O
satisfaction,O
",",O
comfort,O
with,O
touch,O
and,O
fatigue,O
",",O
expecting,O
high,O
correlations,O
for,O
the,O
DBIQ,O
-,O
NL,O
with,O
these,O
measures,O
.,O
Furthermore,O
",",O
we,O
evaluated,O
associations,O
with,O
general,O
indices,O
of,O
psychosocial,O
wellbeing,O
and,O
self,O
-,O
esteem,O
",",O
expecting,O
moderate,O
to,O
high,O
correlations,O
with,O
these,O
measures,O
.,O
The,O
factor,O
structure,O
of,O
the,O
DBIQ,O
-,O
NL,O
was,O
examined,O
via,O
confirmatory,O
factor,O
analysis,O
(,O
CFA,O
).,O
Exploration,O
of,O
differences,O
regarding,O
gender,O
and,O
age,O
formed,O
the,O
second,O
objective,O
of,O
our,O
study,O
",",O
since,O
both,O
factors,O
are,O
known,O
to,O
affect,O
body,O
image,O
.,O
Gender,O
differences,O
in,O
body,O
image,O
have,O
received,O
considerable,O
attention,O
[,O
30,O
–,O
32,O
].,O
Research,O
shows,O
that,O
women,B-OG
are,O
generally,O
more,O
preoccupied,O
and,O
dissatisfied,O
with,O
their,O
bodies,O
than,O
men,B-OG
[,O
33,O
].,O
Gender,O
differences,O
with,O
respect,O
to,O
specific,O
issues,O
such,O
as,O
physical,O
contact,O
and,O
sexual,O
fulfillment,O
",",O
represented,O
by,O
separate,O
subscales,O
in,O
the,O
DBIQ,O
",",O
also,O
were,O
deemed,O
worth,O
investigating,O
.,O
Based,O
on,O
results,O
from,O
a,O
Flemish,O
version,O
of,O
the,O
DBIQ,O
in,O
a,O
students,O
’,O
sample,O
[,O
34,O
"],",O
it,O
might,O
be,O
hypothesized,O
that,O
no,O
gender,O
differences,O
exist,O
with,O
regard,O
to,O
physical,O
contact,O
.,O
With,O
regard,O
to,O
gender,O
differences,O
in,O
reported,O
sexual,O
fulfillment,O
it,O
might,O
be,O
hypothesized,O
",",O
based,O
on,O
results,O
from,O
Dutch,O
population,O
surveys,O
[,O
35,O
"],",O
that,O
sexual,O
fulfillment,O
is,O
higher,O
in,O
men,B-OG
than,O
in,O
women,B-OG
.,O
Contrary,O
to,O
gender,O
differences,O
",",O
age,O
effects,O
on,O
body,O
image,O
are,O
still,O
poorly,O
researched,O
[,O
31,O
",",O
36,O
].,O
Since,O
younger,O
aged,O
samples,O
are,O
overrepresented,O
in,O
body,O
image,O
research,O
",",O
comparisons,O
of,O
different,O
age,O
groups,O
are,O
scarce,O
.,O
Krauss,O
et,O
al,O
.,O
[,O
37,O
],O
have,O
noted,O
a,O
clear,O
need,O
for,O
research,O
on,O
body,O
image,O
in,O
middle,O
-,O
aged,O
and,O
older,O
adults,O
.,O
The,O
non,O
-,O
clinical,O
sample,O
enables,O
further,O
investigation,O
of,O
specific,O
aspects,O
of,O
body,O
image,O
in,O
middle,O
-,O
aged,O
adults,O
and,O
comparison,O
with,O
a,O
younger,O
group,O
.,O
Group,O
comparisons,O
of,O
scale,O
scores,O
are,O
only,O
meaningful,O
in,O
case,O
of,O
measurement,O
invariance,O
across,O
groups,O
.,O
Therefore,O
",",O
the,O
equivalence,O
of,O
the,O
measurement,O
model,O
across,O
sex,O
and,O
age,O
using,O
Multiple,O
-,O
Group,O
Confirmatory,O
Factor,O
Analyses,O
(,O
MG,O
-,O
CFA,O
),O
was,O
evaluated,O
in,O
this,O
study,O
as,O
well,O
",",O
extending,O
the,O
work,O
by,O
Pöhlmann,O
et,O
al,O
.,O
[,O
26,O
",",O
27,O
].,O
Method,O
Participants,O
Data,O
were,O
obtained,O
from,O
two,O
samples,O
with,O
a,O
total,O
of,O
988,O
(,O
sample,O
1,O
",",O
n,O
=,O
761,O
;,O
sample,O
2,O
",",O
n,O
=,O
227,O
),O
respondents,O
between,O
18,O
and,O
65,O
years,O
old,O
",",O
consisting,O
of,O
583,O
(,O
433,O
;,O
150,O
),O
women,B-OG
and,O
403,O
(,O
326,O
;,O
77,O
),O
men,B-OG
(,O
sex,O
was,O
unknown,O
for,O
two,O
respondents,O
).,O
In,O
both,O
samples,O
age,O
showed,O
a,O
bimodal,O
distribution,O
and,O
was,O
therefore,O
divided,O
in,O
two,O
categories,O
",",O
younger,O
than,O
38,O
years,O
",",O
and,O
38,O
years,O
and,O
older,O
",",O
based,O
on,O
visual,O
inspection,O
(,O
sample,O
1,O
:,O
<,O
38,O
",",O
n,O
=,O
540,O
;,O
≥,O
38,O
:,O
n,O
=,O
221,O
;,O
sample,O
2,O
:,O
<,O
38,O
",",O
n,O
=,O
151,O
;,O
≥,O
38,O
:,O
n,O
=,O
76,O
;,O
see,O
S1,O
Fig,O
.,O
for,O
more,O
information,O
on,O
distribution,O
of,O
age,O
in,O
the,O
two,O
samples,O
).,O
Women,B-OG
and,O
men,B-OG
were,O
equally,O
distributed,O
across,O
the,O
two,O
categories,O
.,O
Mage,O
of,O
sample,O
1,O
was,O
30,O
.,O
90,O
(,O
SDage,O
=,O
13,O
.,O
62,O
"),",O
of,O
sample,O
2,O
33,O
.,O
28,O
(,O
SDage,O
=,O
13,O
.,O
22,O
).,O
The,O
distinction,O
between,O
the,O
two,O
samples,O
was,O
made,O
based,O
on,O
the,O
moment,O
of,O
recruitment,O
(,O
see,O
procedure,O
).,O
Sample,O
2,O
was,O
offered,O
a,O
partly,O
different,O
set,O
of,O
extra,O
instruments,O
compared,O
to,O
sample,O
1,O
.,O
Measures,O
Dresden,O
Body,O
Image,O
Questionnaire,O
The,O
Dresden,O
Body,O
Image,O
Questionnaire,O
(,O
DBIQ,O
),O
[,O
26,O
",",O
27,O
],O
is,O
a,O
35,O
-,O
item,O
scale,O
(,O
see,O
Table,O
1,O
),O
with,O
positively,O
and,O
negatively,O
worded,O
items,O
(,O
reversely,O
coded,O
),O
that,O
consists,O
of,O
five,O
subscales,O
:,O
body,O
acceptance,O
(,O
e,O
.,O
g,O
".,",O
“,O
I,O
wish,O
I,O
had,O
a,O
different,O
body,O
"”),",O
vitality,O
(,O
e,O
.,O
g,O
".,",O
“,O
I,O
am,O
physically,O
fit,O
"”),",O
physical,O
contact,O
(,O
e,O
.,O
g,O
".,",O
“,O
I,O
do,O
not,O
like,O
people,O
touching,O
me,O
"”),",O
sexual,O
fulfillment,O
(,O
e,O
.,O
g,O
".,",O
“,O
I,O
am,O
very,O
satisfied,O
with,O
my,O
sexual,O
experiences,O
"“),",O
and,O
self,O
-,O
aggrandizement,O
(,O
e,O
.,O
g,O
".,",O
“,O
I,O
use,O
my,O
body,O
to,O
attract,O
attention,O
”).,O
Level,O
of,O
agreement,O
is,O
scored,O
on,O
a,O
5,O
-,O
point,O
Likert,O
scale,O
ranging,O
from,O
1,O
=,O
not,O
at,O
all,O
to,O
5,O
=,O
fully,O
.,O
Higher,O
scores,O
indicate,O
a,O
more,O
positive,O
body,O
image,O
.,O
Dresden,O
Body,O
Image,O
Questionnaire,O
(,O
DBIQ,O
"),",O
English,O
versiona,O
.,O
1,O
.,O
a,O
I,O
move,O
gracefully,O
.,O
2,O
.,O
v,O
I,O
often,O
feel,O
physically,O
run,O
down,O
.,O
(,O
R,O
),O
3,O
.,O
v,O
I,O
lack,O
energy,O
and,O
motivation,O
.,O
(,O
R,O
),O
4,O
.,O
s,O
I,O
experience,O
intense,O
and,O
pleasurable,O
feelings,O
during,O
sex,O
.,O
5,O
.,O
p,O
Physical,O
contact,O
is,O
important,O
for,O
me,O
to,O
express,O
closeness,O
.,O
6,O
.,O
v,O
I,O
often,O
feel,O
physically,O
exhausted,O
.,O
(,O
R,O
),O
7,O
.,O
a,O
There,O
are,O
lots,O
of,O
situations,O
in,O
which,O
I,O
feel,O
happy,O
about,O
my,O
body,O
.,O
8,O
.,O
v,O
I,O
am,O
physically,O
fit,O
.,O
9,O
.,O
s,O
I,O
am,O
very,O
satisfied,O
with,O
my,O
sexual,O
experiences,O
.,O
10,O
.,O
a,O
Other,O
people,O
find,O
me,O
attractive,O
.,O
11,O
.,O
p,O
I,O
look,O
for,O
physical,O
intimacy,O
and,O
affection,O
12,O
.,O
a,O
I,O
like,O
my,O
body,O
.,O
13,O
.,O
a,O
I,O
find,O
it,O
pleasant,O
and,O
exhilarating,O
when,O
someone,O
looks,O
at,O
me,O
attentively,O
.,O
14,O
.,O
v,O
I,O
have,O
lots,O
of,O
energy,O
.,O
15,O
.,O
a,O
I,O
choose,O
clothing,O
that,O
hides,O
the,O
shape,O
of,O
my,O
body,O
.,O
(,O
R,O
),O
16,O
.,O
s,O
I,O
think,O
sex,O
is,O
an,O
important,O
part,O
of,O
life,O
.,O
17,O
.,O
v,O
I,O
am,O
in,O
good,O
physical,O
condition,O
.,O
18,O
.,O
a,O
I,O
often,O
feel,O
uncomfortable,O
about,O
my,O
body,O
.,O
(,O
R,O
),O
19,O
.,O
p,O
I,O
do,O
not,O
like,O
people,O
touching,O
me,O
.,O
(,O
R,O
),O
20,O
.,O
a,O
I,O
feel,O
more,O
valued,O
when,O
someone,O
pays,O
attention,O
to,O
my,O
body,O
.,O
21,O
.,O
s,O
I,O
am,O
able,O
to,O
lay,O
aside,O
my,O
inhibitions,O
in,O
sexual,O
situations,O
.,O
22,O
.,O
p,O
I,O
like,O
it,O
when,O
people,O
put,O
their,O
arms,O
around,O
me,O
.,O
23,O
.,O
a,O
I,O
wish,O
I,O
had,O
a,O
different,O
body,O
.,O
(,O
R,O
),O
24,O
.,O
p,O
I,O
consciously,O
avoid,O
touching,O
other,O
people,O
.,O
(,O
R,O
),O
25,O
.,O
a,O
I,O
am,O
satisfied,O
with,O
my,O
appearance,O
.,O
26,O
.,O
v,O
I,O
quickly,O
reach,O
my,O
physical,O
limits,O
.,O
(,O
R,O
),O
27,O
.,O
s,O
I,O
am,O
able,O
to,O
enjoy,O
my,O
sexuality,O
.,O
28,O
.,O
a,O
If,O
I,O
could,O
change,O
something,O
about,O
my,O
body,O
",",O
I,O
would,O
do,O
it,O
.,O
(,O
R,O
),O
29,O
.,O
a,O
My,O
body,O
is,O
expressive,O
.,O
30,O
.,O
p,O
I,O
only,O
allow,O
a,O
few,O
people,O
to,O
touch,O
me,O
.,O
(,O
R,O
),O
31,O
.,O
a,O
I,O
use,O
my,O
body,O
to,O
attract,O
attention,O
.,O
32,O
.,O
v,O
I,O
am,O
physically,O
strong,O
and,O
resilient,O
.,O
33,O
.,O
a,O
I,O
like,O
showing,O
my,O
body,O
.,O
34,O
.,O
a,O
I,O
like,O
to,O
be,O
the,O
centre,O
of,O
attention,O
.,O
35,O
.,O
s,O
My,O
sexual,O
experiences,O
are,O
satisfying,O
.,O
Note,O
:,O
R,O
=,O
scored,O
in,O
the,O
reversed,O
direction,O
.,O
a,O
=,O
subscale,O
self,O
-,O
aggrandizement,O
;,O
b,O
=,O
subscale,O
body,O
acceptance,O
;,O
p,O
=,O
subscale,O
physical,O
contact,O
;,O
s,O
=,O
subscale,O
sexual,O
fulfillment,O
;,O
v,O
=,O
subscale,O
vitality,O
.,O
a,O
.,O
Dresdner,O
Körperbildfragebogen,O
(,O
DKB,O
-,O
35,O
"),",O
original,O
version,O
in,O
German,O
;,O
for,O
Dutch,O
version,O
",",O
see,O
S1,O
Table,O
.,O
The,O
development,O
of,O
the,O
DBIQ,O
was,O
based,O
on,O
factor,O
analytic,O
evaluation,O
of,O
three,O
German,O
questionnaires,O
measuring,O
body,O
image,O
[,O
38,O
"],",O
namely,O
the,O
“,O
Fragebogen,O
zum,O
Körperbild,O
”,O
(,O
FKB,O
-,O
20,O
),O
[,O
39,O
"],",O
the,O
“,O
Fragebogen,O
zur,O
Bewertung,O
des,O
eigenen,O
Körpers,O
”,O
(,O
FBeK,O
),O
[,O
40,O
",",O
41,O
],O
and,O
the,O
“,O
Frankfurter,O
Körper,O
Konzept,O
Skalen,O
”,O
(,O
FKKS,O
),O
[,O
42,O
].,O
In,O
a,O
German,O
non,O
-,O
clinical,O
sample,O
[,O
27,O
],O
(,O
n,O
=,O
418,O
"),",O
Cronbach,O
’,O
s,O
α,O
for,O
the,O
subscales,O
were,O
:,O
body,O
acceptance,O
.,O
93,O
",",O
vitality,O
.,O
94,O
",",O
physical,O
contact,O
.,O
83,O
",",O
sexual,O
fulfillment,O
.,O
91,O
",",O
and,O
self,O
-,O
aggrandizement,O
.,O
81,O
.,O
Correlations,O
between,O
the,O
subscales,O
varied,O
between,O
r,O
=,O
.,O
37,O
(,O
sexual,O
fulfillment,O
and,O
self,O
-,O
aggrandizement,O
),O
and,O
r,O
=,O
.,O
65,O
(,O
body,O
acceptance,O
and,O
vitality,O
"),",O
indicating,O
the,O
overlap,O
between,O
the,O
subscales,O
to,O
be,O
small,O
to,O
medium,O
.,O
A,O
confirmatory,O
factor,O
analysis,O
was,O
conducted,O
[,O
26,O
],O
in,O
a,O
sample,O
of,O
560,O
German,O
patients,O
with,O
psychosomatic,B-DS
disorders,I-DS
(,O
CFI,O
=,O
.,O
90,O
;,O
RMSEA,O
=,O
.,O
06,O
",",O
other,O
fit,O
indices,O
not,O
available,O
).,O
A,O
study,O
on,O
505,O
students,O
(,O
M,O
=,O
21,O
.,O
64,O
",",O
SD,O
=,O
2,O
.,O
14,O
),O
using,O
a,O
Flemish,O
Dutch,O
translation,O
[,O
34,O
"],",O
somewhat,O
different,O
from,O
the,O
translation,O
presently,O
used,O
",",O
reported,O
Cronbach,O
’,O
s,O
α,O
for,O
the,O
subscales,O
between,O
.,O
77,O
and,O
.,O
90,O
.,O
Correlations,O
between,O
the,O
subscales,O
varied,O
between,O
r,O
=,O
.,O
13,O
and,O
r,O
=,O
.,O
59,O
.,O
In,O
the,O
present,O
Dutch,O
sample,O
Cronbach,O
’,O
s,O
α,O
for,O
the,O
subscales,O
varied,O
from,O
α,O
=,O
.,O
83,O
for,O
self,O
-,O
aggrandizement,O
to,O
α,O
=,O
.,O
92,O
for,O
sexual,O
fulfillment,O
.,O
Correlations,O
between,O
the,O
subscales,O
varied,O
between,O
r,O
=,O
.,O
31,O
(,O
vitality,O
and,O
physical,O
contact,O
),O
to,O
r,O
=,O
.,O
65,O
(,O
physical,O
contact,O
and,O
sexual,O
fulfillment,O
).,O
The,O
Dutch,O
translation,O
of,O
the,O
DBIQ,O
(,O
DBIQ,O
-,O
NL,O
",",O
see,O
S1,O
Table,O
),O
was,O
performed,O
by,O
using,O
the,O
parallel,O
blind,O
technique,O
[,O
43,O
].,O
First,O
",",O
three,O
bilingual,O
translators,O
separately,O
performed,O
a,O
translation,O
.,O
The,O
translations,O
were,O
then,O
compared,O
and,O
differences,O
were,O
discussed,O
until,O
agreement,O
was,O
reached,O
.,O
Body,O
Cathexis,O
Scale,O
The,O
Body,O
Cathexis,O
Scale,O
(,O
BCS,O
"),",O
here,O
used,O
to,O
establish,O
the,O
association,O
between,O
the,O
total,O
score,O
of,O
the,O
DBIQ,O
with,O
body,O
satisfaction,O
",",O
was,O
originally,O
developed,O
by,O
Secord,O
and,O
Jourard,O
[,O
44,O
],O
to,O
assess,O
the,O
degree,O
of,O
satisfaction,O
with,O
parts,O
and,O
processes,O
of,O
the,O
body,O
.,O
The,O
original,O
scale,O
has,O
46,O
items,O
",",O
but,O
most,O
recent,O
studies,O
utilize,O
a,O
40,O
-,O
item,O
version,O
[,O
45,O
].,O
Subjects,O
evaluate,O
body,O
characteristics,O
according,O
to,O
a,O
5,O
-,O
point,O
Likert,O
scale,O
",",O
ranging,O
from,O
strongly,O
negative,O
to,O
strongly,O
positive,O
",",O
with,O
higher,O
scores,O
reflecting,O
greater,O
body,O
satisfaction,O
.,O
Although,O
some,O
authors,O
[,O
46,O
],O
objected,O
to,O
the,O
use,O
of,O
anatomical,O
as,O
well,O
as,O
physiological,O
aspects,O
in,O
the,O
BCS,O
",",O
we,O
follow,O
Orlandi,O
et,O
al,O
.,O
[,O
47,O
"],",O
who,O
state,O
that,O
the,O
BCS,O
is,O
a,O
useful,O
instrument,O
to,O
address,O
satisfaction,O
with,O
the,O
body,O
and,O
judge,O
the,O
emphasis,O
on,O
bodily,O
functions,O
next,O
to,O
body,O
parts,O
to,O
be,O
an,O
advantage,O
.,O
This,O
is,O
in,O
line,O
with,O
recent,O
studies,O
[,O
48,O
",",O
49,O
],O
stressing,O
the,O
importance,O
of,O
describing,O
the,O
body,O
in,O
functional,O
terms,O
.,O
The,O
validity,O
and,O
reliability,O
of,O
the,O
Dutch,O
version,O
[,O
50,O
],O
are,O
satisfactory,O
.,O
Cronbach,O
’,O
s,O
α,O
for,O
the,O
present,O
sample,O
was,O
.,O
95,O
.,O
Comfort,O
in,O
touch,O
(,O
subscale,O
of,O
the,O
Body,O
Investment,O
Scale,O
),O
Since,O
no,O
reference,O
is,O
made,O
in,O
the,O
BCS,O
to,O
physical,O
contact,O
",",O
a,O
subscale,O
of,O
the,O
Body,O
Investment,O
Scale,O
(,O
BIS,O
),O
[,O
51,O
],O
was,O
used,O
to,O
establish,O
the,O
association,O
with,O
the,O
subscale,O
‘,O
physical,O
contact,O
’,O
of,O
the,O
DBIQ,O
.,O
The,O
BIS,O
was,O
developed,O
to,O
assess,O
emotional,O
investment,O
in,O
the,O
body,O
and,O
consists,O
of,O
24,O
items,O
scored,O
on,O
a,O
5,O
-,O
point,O
Likert,O
scale,O
ranging,O
from,O
strongly,O
disagree,O
to,O
strongly,O
agree,O
with,O
higher,O
scores,O
for,O
more,O
emotional,O
investment,O
.,O
The,O
subscale,O
physical,O
contact,O
of,O
the,O
BIS,O
comprises,O
of,O
six,O
items,O
with,O
statements,O
like,O
“,O
I,O
enjoy,O
physical,O
contact,O
with,O
other,O
people,O
”.,O
The,O
BIS,O
has,O
adequate,O
psychometric,O
characteristics,O
[,O
51,O
",",O
52,O
].,O
In,O
the,O
present,O
study,O
a,O
Cronbach,O
’,O
s,O
α,O
of,O
.,O
78,O
was,O
found,O
for,O
the,O
subscale,O
‘,O
comfort,O
in,O
touch,O
’.,O
Checklist,O
Individual,O
Strength,O
As,O
the,O
BCS,O
does,O
not,O
include,O
items,O
on,O
vitality,O
the,O
Checklist,O
Individual,O
Strength,O
(,O
CIS,O
),O
[,O
53,O
],O
was,O
used,O
to,O
establish,O
the,O
construct,O
validity,O
of,O
this,O
subscale,O
of,O
the,O
DBIQ,O
.,O
The,O
CIS,O
is,O
an,O
originally,O
Dutch,O
language,O
20,O
-,O
item,O
self,O
-,O
report,O
questionnaire,O
capturing,O
fatigue,O
in,O
four,O
dimensions,O
:,O
subjective,O
experience,O
of,O
fatigue,O
(“,O
I,O
feel,O
tired,O
"”),",O
reduction,O
in,O
motivation,O
(“,O
I,O
feel,O
no,O
desire,O
to,O
do,O
anything,O
"”),",O
reduction,O
in,O
activity,O
(“,O
I,O
don,O
’,O
t,O
do,O
much,O
during,O
the,O
day,O
”),O
and,O
reduction,O
in,O
concentration,O
(“,O
My,O
thoughts,O
easily,O
wander,O
”),O
and,O
has,O
been,O
used,O
in,O
a,O
broad,O
range,O
of,O
groups,O
:,O
healthy,O
subjects,O
",",O
diverse,O
groups,O
of,O
working,O
adults,O
",",O
people,O
with,O
chronic,O
fatigue,O
as,O
well,O
as,O
people,O
with,O
multiple,B-DS
sclerosis,I-DS
[,O
54,O
].,O
By,O
adding,O
the,O
four,O
dimensions,O
a,O
CIS,O
total,O
score,O
can,O
be,O
calculated,O
.,O
Respondents,O
rate,O
the,O
extent,O
to,O
which,O
each,O
statement,O
is,O
true,O
for,O
them,O
on,O
a,O
7,O
-,O
point,O
Likert,O
scale,O
ranging,O
from,O
Yes,O
",",O
that,O
is,O
true,O
to,O
No,O
",",O
that,O
is,O
not,O
true,O
.,O
A,O
higher,O
score,O
indicates,O
more,O
fatigue,O
.,O
Fatigue,O
as,O
measured,O
with,O
the,O
CIS,O
may,O
be,O
regarded,O
as,O
the,O
opposite,O
of,O
vitality,O
.,O
In,O
their,O
description,O
and,O
evaluation,O
of,O
measures,O
of,O
fatigue,O
",",O
Hewlett,O
et,O
al,O
.,O
[,O
55,O
],O
evaluated,O
the,O
CIS,O
as,O
a,O
useful,O
generic,O
scale,O
and,O
research,O
tool,O
",",O
with,O
no,O
significant,O
respondent,O
or,O
administrative,O
burden,O
.,O
The,O
CIS,O
has,O
demonstrated,O
satisfactory,O
psychometric,O
properties,O
[,O
54,O
",",O
56,O
].,O
For,O
the,O
present,O
study,O
",",O
Cronbach,O
’,O
s,O
α,O
was,O
.,O
94,O
.,O
Rosenberg,O
Self,O
-,O
esteem,O
Scale,O
The,O
Rosenberg,O
Self,O
-,O
Esteem,O
Scale,O
(,O
RSES,O
),O
[,O
57,O
"],",O
Dutch,O
version,O
[,O
58,O
"],",O
is,O
a,O
brief,O
10,O
-,O
item,O
measure,O
of,O
global,O
self,O
-,O
esteem,O
that,O
evaluates,O
one,O
’,O
s,O
overall,O
feelings,O
of,O
self,O
-,O
worth,O
using,O
a,O
4,O
-,O
point,O
scale,O
(,O
1,O
=,O
strongly,O
disagree,O
",",O
4,O
=,O
strongly,O
agree,O
).,O
Scores,O
range,O
from,O
10,O
to,O
40,O
",",O
with,O
higher,O
scores,O
reflecting,O
higher,O
self,O
-,O
esteem,O
.,O
The,O
validity,O
and,O
reliability,O
of,O
the,O
Dutch,O
version,O
are,O
satisfactory,O
[,O
59,O
].,O
The,O
internal,O
consistency,O
in,O
the,O
present,O
study,O
was,O
.,O
87,O
.,O
Outcome,O
Questionnaire,O
The,O
Outcome,O
Questionnaire,O
(,O
OQ,O
-,O
45,O
),O
[,O
60,O
],O
is,O
a,O
45,O
-,O
item,O
scale,O
measuring,O
three,O
domains,O
of,O
psychological,O
well,O
-,O
being,O
:,O
subjective,O
discomfort,O
(“,O
I,O
feel,O
no,O
interest,O
in,O
things,O
"”),",O
interpersonal,O
relations,O
(“,O
I,O
am,O
satisfied,O
with,O
my,O
relationships,O
with,O
others,O
"”),",O
and,O
social,O
role,O
performance,O
(“,O
I,O
feel,O
that,O
I,O
am,O
doing,O
well,O
at,O
work,O
/,O
school,O
”).,O
The,O
OQ,O
-,O
45,O
is,O
rated,O
on,O
a,O
5,O
-,O
point,O
Likert,O
scale,O
ranging,O
from,O
never,O
to,O
almost,O
always,O
with,O
higher,O
scores,O
for,O
more,O
distress,O
.,O
In,O
a,O
non,O
-,O
clinical,O
group,O
",",O
Cronbach,O
’,O
s,O
α,O
was,O
.,O
93,O
for,O
the,O
original,O
total,O
scale,O
[,O
60,O
],O
and,O
.,O
92,O
in,O
the,O
Dutch,O
version,O
[,O
61,O
].,O
Cronbach,O
’,O
s,O
α,O
in,O
the,O
present,O
study,O
was,O
.,O
90,O
.,O
Procedure,O
The,O
research,O
was,O
conducted,O
in,O
agreement,O
with,O
the,O
VU,O
University,O
Amsterdam,O
guideline,O
for,O
research,O
for,O
educational,O
purposes,O
",",O
allowing,O
students,O
to,O
collect,O
data,O
with,O
the,O
use,O
of,O
questionnaires,O
in,O
healthy,O
groups,O
of,O
respondents,O
when,O
participation,O
is,O
voluntary,O
and,O
data,O
are,O
analysed,O
anonymously,O
.,O
We,O
consulted,O
the,O
Medical,O
Ethics,O
Review,O
Committee,O
of,O
VU,O
University,O
about,O
the,O
study,O
",",O
and,O
the,O
committee,O
waived,O
the,O
requirement,O
for,O
ethical,O
approval,O
.,O
Data,O
collection,O
was,O
done,O
during,O
an,O
undergraduate,O
course,O
in,O
measurement,O
and,O
statistics,O
at,O
the,O
Faculty,O
of,O
Human,O
Movement,O
Sciences,O
",",O
VU,O
University,O
Amsterdam,O
",",O
resulting,O
in,O
a,O
convenience,O
sample,O
.,O
Students,O
in,O
two,O
successive,O
courses,O
were,O
encouraged,O
to,O
forward,O
an,O
e,O
-,O
mail,O
with,O
a,O
link,O
to,O
the,O
questionnaires,O
to,O
individuals,O
in,O
their,O
personal,O
network,O
.,O
No,O
participatory,O
incentives,O
were,O
offered,O
.,O
Participants,O
completed,O
all,O
questionnaires,O
without,O
personal,O
details,O
through,O
a,O
secured,O
online,O
system,O
and,O
with,O
all,O
materials,O
removed,O
from,O
this,O
system,O
after,O
completing,O
the,O
data,O
collection,O
;,O
data,O
analysis,O
was,O
done,O
anonymously,O
.,O
Information,O
about,O
the,O
aim,O
of,O
the,O
study,O
and,O
the,O
voluntary,O
and,O
anonymous,O
nature,O
of,O
participation,O
was,O
given,O
before,O
participants,O
entered,O
the,O
study,O
.,O
In,O
this,O
way,O
consent,O
was,O
secured,O
when,O
participants,O
completed,O
the,O
questionnaire,O
and,O
no,O
formal,O
informed,O
consent,O
was,O
necessary,O
.,O
Of,O
the,O
respondents,O
all,O
were,O
given,O
the,O
DBIQ,O
-,O
NL,O
to,O
fill,O
out,O
.,O
Of,O
the,O
respondents,O
included,O
via,O
students,O
in,O
the,O
first,O
course,O
(,O
sample,O
1,O
in,O
Table,O
2,O
),O
361,O
(,O
sample,O
1a,O
),O
were,O
asked,O
to,O
also,O
complete,O
the,O
Body,O
Cathexis,O
Scale,O
(,O
BCS,O
),O
[,O
44,O
"],",O
and,O
356,O
others,O
(,O
sample,O
1b,O
),O
to,O
complete,O
the,O
Rosenberg,O
Self,O
-,O
Esteem,O
Scale,O
(,O
RSES,O
),O
[,O
57,O
"],",O
the,O
Checklist,O
Individual,O
Strength,O
(,O
CIS,O
),O
[,O
53,O
],O
and,O
the,O
subscale,O
‘,O
comfort,O
in,O
touch,O
’,O
of,O
the,O
Body,O
Investment,O
Scale,O
(,O
BIS,O
),O
[,O
51,O
].,O
Respondents,O
(,O
n,O
=,O
227,O
),O
recruited,O
by,O
the,O
students,O
in,O
the,O
second,O
course,O
(,O
sample,O
2,O
),O
also,O
completed,O
the,O
Outcome,O
Questionnaire,O
(,O
OQ,O
-,O
45,O
),O
[,O
60,O
],O
and,O
the,O
Rosenberg,O
Self,O
-,O
esteem,O
Scale,O
.,O
To,O
assess,O
temporal,O
reliability,O
",",O
56,O
respondents,O
of,O
sample,O
2,O
completed,O
the,O
DBIQ,O
-,O
NL,O
a,O
second,O
time,O
after,O
14,O
days,O
.,O
44,O
respondents,O
only,O
completed,O
the,O
DBIQ,O
-,O
NL,O
and,O
did,O
not,O
fill,O
in,O
any,O
additional,O
questionnaires,O
.,O
Mean,O
scores,O
and,O
mean,O
differences,O
sex,O
and,O
age,O
DBIQ,O
-,O
NL,O
samples,O
and,O
validation,O
measures,O
.,O
full,O
sample,O
women,B-OG
men,B-OG
age,O
<,O
38,O
age,O
≥,O
38,O
Sample,O
(,O
sub,O
),O
scale,O
n,O
Mean,O
SD,O
n,O
Mean,O
SD,O
n,O
Mean,O
SD,O
d,O
n,O
Mean,O
SD,O
n,O
Mean,O
SD,O
d,O
1,O
DBIQ,O
-,O
NL,O
755,O
*,O
3,O
.,O
66,O
0,O
.,O
45,O
430,O
3,O
.,O
56,O
0,O
.,O
44,O
323,O
3,O
.,O
79,O
0,O
.,O
43,O
0,O
.,O
53,O
537,O
3,O
.,O
71,O
0,O
.,O
44,O
218,O
3,O
.,O
53,O
0,O
.,O
45,O
0,O
.,O
40,O
1a,O
BCS,O
361,O
3,O
.,O
68,O
0,O
.,O
54,O
216,O
3,O
.,O
61,O
0,O
.,O
53,O
145,O
3,O
.,O
79,O
0,O
.,O
54,O
0,O
.,O
34,O
228,O
3,O
.,O
70,O
0,O
.,O
53,O
133,O
3,O
.,O
64,O
0,O
.,O
56,O
0,O
.,O
11,O
1b,O
RSES,O
356,O
3,O
.,O
26,O
0,O
.,O
47,O
191,O
3,O
.,O
15,O
0,O
.,O
45,O
163,O
3,O
.,O
39,O
0,O
.,O
44,O
0,O
.,O
54,O
272,O
3,O
.,O
25,O
0,O
.,O
47,O
84,O
3,O
.,O
28,O
0,O
.,O
44,O
0,O
.,O
07,O
1b,O
BIS,O
-,O
touch,O
356,O
3,O
.,O
77,O
0,O
.,O
61,O
191,O
3,O
.,O
73,O
0,O
.,O
56,O
163,O
3,O
.,O
81,O
0,O
.,O
66,O
0,O
.,O
13,O
272,O
3,O
.,O
80,O
0,O
.,O
63,O
84,O
3,O
.,O
66,O
0,O
.,O
54,O
0,O
.,O
24,O
1b,O
CIS,O
356,O
2,O
.,O
97,O
1,O
.,O
02,O
191,O
3,O
.,O
11,O
1,O
.,O
02,O
163,O
2,O
.,O
81,O
0,O
.,O
99,O
0,O
.,O
30,O
272,O
2,O
.,O
98,O
1,O
.,O
00,O
84,O
2,O
.,O
96,O
1,O
.,O
09,O
0,O
.,O
02,O
2,O
DBIQ,O
-,O
NL,O
227,O
3,O
.,O
57,O
0,O
.,O
39,O
150,O
3,O
.,O
53,O
0,O
.,O
39,O
77,O
3,O
.,O
64,O
0,O
.,O
40,O
0,O
.,O
28,O
151,O
3,O
.,O
59,O
0,O
.,O
40,O
76,O
3,O
.,O
53,O
0,O
.,O
38,O
0,O
.,O
15,O
OQ,O
-,O
45,O
227,O
1,O
.,O
96,O
0,O
.,O
38,O
150,O
1,O
.,O
98,O
0,O
.,O
31,O
77,O
1,O
.,O
93,O
0,O
.,O
45,O
0,O
.,O
13,O
151,O
1,O
.,O
96,O
0,O
.,O
40,O
76,O
1,O
.,O
94,O
0,O
.,O
36,O
0,O
.,O
05,O
RSES,O
225,O
3,O
.,O
32,O
0,O
.,O
46,O
149,O
3,O
.,O
26,O
0,O
.,O
45,O
76,O
3,O
.,O
44,O
0,O
.,O
45,O
0,O
.,O
40,O
149,O
3,O
.,O
31,O
0,O
.,O
48,O
76,O
3,O
.,O
34,O
0,O
.,O
41,O
0,O
.,O
07,O
Note,O
:,O
d,O
=,O
Cohen,O
’,O
s,O
d,O
;,O
DBIQ,O
-,O
NL,O
=,O
Dresden,O
Body,O
Image,O
Questionnaire,O
",",O
Dutch,O
translation,O
;,O
OQ,O
-,O
45,O
=,O
Outcome,O
Questionnaire,O
;,O
RSES,O
=,O
Rosenberg,O
Self,O
-,O
esteem,O
Scale,O
BCS,O
=,O
Body,O
Cathexis,O
Scale,O
;,O
BIS,O
-,O
touch,O
=,O
subscale,O
comfort,O
with,O
physical,O
touch,O
Body,O
Investment,O
Scale,O
;,O
CIS,O
=,O
Checklist,O
Individual,O
Strength,O
.,O
*,O
For,O
six,O
participants,O
",",O
no,O
total,O
scores,O
were,O
available,O
.,O
Data,O
analysis,O
SPSS,O
17,O
.,O
00,O
for,O
Windows,O
was,O
used,O
for,O
general,O
statistical,O
analyses,O
.,O
Mean,O
differences,O
between,O
subgroups,O
are,O
expressed,O
in,O
Cohen,O
’,O
s,O
d,O
and,O
considered,O
large,O
if,O
>,O
.,O
80,O
",",O
moderate,O
between,O
.,O
50,O
and,O
.,O
79,O
and,O
small,O
between,O
.,O
20,O
and,O
.,O
49,O
[,O
62,O
].,O
In,O
calculating,O
means,O
we,O
limited,O
missing,O
values,O
to,O
one,O
for,O
all,O
subscales,O
and,O
two,O
for,O
total,O
mean,O
scores,O
.,O
Test,O
-,O
retest,O
reliability,O
was,O
established,O
by,O
intraclass,O
correlation,O
(,O
ICC,O
).,O
ICC,O
>,O
.,O
75,O
was,O
considered,O
as,O
excellent,O
and,O
between,O
.,O
40,O
and,O
.,O
75,O
as,O
acceptable,O
[,O
63,O
].,O
Construct,O
validity,O
was,O
investigated,O
by,O
correlations,O
.,O
We,O
expected,O
a,O
moderate,O
correlation,O
of,O
body,O
image,O
total,O
score,O
with,O
body,O
satisfaction,O
",",O
because,O
the,O
DBIQ,O
is,O
aimed,O
to,O
measure,O
a,O
broader,O
concept,O
of,O
body,O
image,O
.,O
We,O
also,O
expected,O
moderate,O
correlations,O
of,O
body,O
image,O
total,O
score,O
with,O
self,O
-,O
esteem,O
and,O
psychological,O
well,O
-,O
being,O
.,O
Furthermore,O
",",O
high,O
correlations,O
are,O
expected,O
between,O
the,O
subscale,O
‘,O
vitality,O
’,O
of,O
the,O
DBIQ,O
-,O
NL,O
and,O
fatigue,O
as,O
measured,O
with,O
the,O
CIS,O
and,O
between,O
the,O
‘,O
physical,O
contact,O
’,O
subscale,O
of,O
the,O
DBIQ,O
-,O
NL,O
and,O
the,O
comfort,O
in,O
touch,O
subscale,O
of,O
the,O
BIS,O
.,O
The,O
factorial,O
structure,O
of,O
the,O
translated,O
version,O
was,O
tested,O
by,O
confirmatory,O
factor,O
analysis,O
(,O
CFA,O
).,O
Analyses,O
were,O
conducted,O
with,O
Mplus,O
Version,O
5,O
.,O
1,O
[,O
64,O
"],",O
using,O
the,O
robust,O
full,O
-,O
information,O
maximum,O
likelihood,O
(,O
MLR,O
),O
estimator,O
to,O
correct,O
for,O
the,O
skew,O
distribution,O
of,O
several,O
items,O
and,O
missing,O
item,O
responses,O
[,O
65,O
].,O
In,O
view,O
of,O
the,O
sufficiently,O
large,O
sample,O
size,O
and,O
focus,O
on,O
model,O
selection,O
and,O
fit,O
",",O
the,O
5,O
-,O
point,O
Likert,O
items,O
were,O
treated,O
as,O
continuous,O
measures,O
[,O
66,O
].,O
Complete,O
descriptives,O
for,O
all,O
items,O
used,O
for,O
the,O
CFA,O
are,O
provided,O
in,O
S2,O
Table,O
.,O
Because,O
a,O
five,O
factor,O
model,O
was,O
shown,O
to,O
be,O
adequate,O
for,O
the,O
German,O
questionnaire,O
",",O
we,O
investigated,O
the,O
fit,O
of,O
this,O
model,O
to,O
the,O
Dutch,O
samples,O
",",O
aiming,O
to,O
obtain,O
fit,O
measures,O
close,O
to,O
those,O
of,O
the,O
German,O
model,O
.,O
We,O
could,O
not,O
reasonably,O
expect,O
equivalent,O
fit,O
measures,O
as,O
the,O
study,O
is,O
not,O
an,O
exact,O
replication,O
study,O
.,O
The,O
three,O
essential,O
changes,O
with,O
respect,O
to,O
Pöhlmann,O
et,O
al,O
.’,O
s,O
[,O
26,O
],O
study,O
",",O
(,O
1,O
),O
translation,O
of,O
the,O
items,O
",",O
(,O
2,O
),O
non,O
-,O
clinical,O
samples,O
",",O
and,O
(,O
3,O
),O
using,O
a,O
CFA,O
model,O
without,O
correlated,O
errors,O
",",O
were,O
expected,O
to,O
lead,O
to,O
a,O
decrease,O
in,O
model,O
fit,O
[,O
67,O
",",O
68,O
].,O
Because,O
each,O
type,O
of,O
index,O
provides,O
different,O
information,O
about,O
model,O
fit,O
[,O
69,O
"],",O
we,O
chose,O
to,O
report,O
a,O
broad,O
range,O
of,O
indices,O
and,O
also,O
included,O
standardized,O
root,O
mean,O
square,O
residual,O
(,O
SRMR,O
),O
and,O
Tucker,O
Lewis,O
index,O
(,O
TLI,O
"),",O
in,O
addition,O
to,O
the,O
CFI,O
and,O
RMSEA,O
reported,O
in,O
the,O
CFA,O
on,O
the,O
German,O
items,O
[,O
26,O
].,O
The,O
RMSEA,O
(,O
Root,O
Mean,O
Square,O
Error,O
of,O
Approximation,O
),O
represents,O
the,O
fit,O
of,O
the,O
estimated,O
covariance,O
matrix,O
to,O
the,O
populations,O
covariance,O
matrix,O
[,O
70,O
].,O
It,O
is,O
regarded,O
as,O
one,O
of,O
the,O
most,O
informative,O
fit,O
indices,O
due,O
to,O
its,O
sensitivity,O
to,O
the,O
number,O
of,O
estimated,O
parameters,O
in,O
the,O
model,O
and,O
therefore,O
favouring,O
parsimonious,O
models,O
.,O
As,O
a,O
rule,O
of,O
thumb,O
",",O
RMSEA,O
values,O
less,O
than,O
.,O
08,O
suggest,O
adequate,O
model,O
fit,O
and,O
RMSEA,O
values,O
less,O
than,O
.,O
05,O
suggest,O
good,O
model,O
fit,O
[,O
71,O
].,O
The,O
SRMR,O
(,O
Standardised,O
Root,O
Mean,O
square,O
Residual,O
),O
is,O
the,O
standardized,O
square,O
root,O
of,O
the,O
difference,O
between,O
the,O
residuals,O
of,O
the,O
sample,O
covariance,O
matrix,O
and,O
the,O
hypothesised,O
covariance,O
model,O
.,O
An,O
SRMR,O
between,O
.,O
05,O
and,O
.,O
10,O
indicates,O
an,O
acceptable,O
fit,O
and,O
values,O
less,O
than,O
.,O
05,O
indicate,O
good,O
fit,O
[,O
72,O
].,O
The,O
CFI,O
(,O
Comparitive,O
Fit,O
Index,O
),O
[,O
73,O
],O
compares,O
the,O
sample,O
covariance,O
matrix,O
with,O
a,O
,O
model,O
of,O
uncorrelated,O
latent,O
variables,O
.,O
The,O
CFI,O
is,O
one,O
of,O
the,O
most,O
commonly,O
reported,O
fit,O
indices,O
due,O
to,O
being,O
one,O
of,O
the,O
measures,O
least,O
effected,O
by,O
sample,O
size,O
and,O
is,O
often,O
reported,O
together,O
with,O
the,O
TLI,O
(,O
Tucker,O
Lewis,O
Index,O
"),",O
a,O
comparative,O
fit,O
index,O
slightly,O
differing,O
from,O
the,O
CFI,O
in,O
its,O
approach,O
to,O
sample,O
size,O
and,O
handling,O
of,O
the,O
effect,O
of,O
model,O
complexity,O
[,O
69,O
].,O
CFI,O
and,O
TLI,O
values,O
in,O
the,O
range,O
between,O
.,O
90,O
and,O
.,O
95,O
may,O
be,O
regarded,O
as,O
indicative,O
of,O
acceptable,O
model,O
fit,O
[,O
69,O
].,O
Although,O
there,O
is,O
discussion,O
on,O
which,O
fit,O
-,O
indices,O
are,O
the,O
most,O
relevant,O
",",O
it,O
is,O
now,O
common,O
practice,O
to,O
test,O
the,O
fit,O
of,O
the,O
CFA,O
with,O
at,O
least,O
the,O
ones,O
used,O
here,O
.,O
Thus,O
",",O
conclusions,O
about,O
the,O
fit,O
of,O
the,O
model,O
can,O
be,O
based,O
on,O
the,O
consistency,O
between,O
fit,O
-,O
indices,O
.,O
When,O
fit,O
-,O
indices,O
fall,O
in,O
marginal,O
ranges,O
",",O
it,O
is,O
especially,O
important,O
to,O
consider,O
the,O
consistency,O
of,O
the,O
model,O
fit,O
as,O
expressed,O
by,O
the,O
various,O
types,O
of,O
fit,O
indices,O
in,O
tandem,O
with,O
the,O
particular,O
aspects,O
of,O
the,O
analytic,O
situation,O
[,O
69,O
].,O
Inadequate,O
fit,O
measures,O
are,O
an,O
indication,O
of,O
model,O
misspecification,O
.,O
Modification,O
indices,O
can,O
be,O
used,O
to,O
adjust,O
the,O
model,O
specification,O
in,O
order,O
to,O
improve,O
model,O
fit,O
.,O
First,O
",",O
the,O
five,O
-,O
factor,O
model,O
(,O
without,O
correlated,O
errors,O
),O
was,O
estimated,O
",",O
using,O
sample,O
1,O
.,O
Modification,O
indices,O
were,O
inspected,O
to,O
detect,O
possible,O
improvements,O
with,O
respect,O
to,O
dimensionality,O
.,O
We,O
refrained,O
from,O
including,O
correlated,O
errors,O
in,O
view,O
of,O
the,O
multiple,O
group,O
confirmatory,O
factor,O
analysis,O
(,O
MG,O
-,O
CFA,O
"),",O
which,O
does,O
not,O
allow,O
correlated,O
errors,O
.,O
We,O
performed,O
multiple,O
-,O
group,O
analyses,O
with,O
respect,O
to,O
gender,O
and,O
age,O
after,O
investigating,O
the,O
overall,O
five,O
-,O
factor,O
structure,O
of,O
the,O
DBIQ,O
-,O
NL,O
",",O
because,O
MG,O
-,O
CFA,O
provides,O
the,O
opportunity,O
to,O
identify,O
items,O
that,O
are,O
non,O
-,O
invariant,O
across,O
groups,O
.,O
Invariance,O
is,O
a,O
prerequisite,O
for,O
individual,O
and,O
group,O
comparisons,O
to,O
reflect,O
true,O
differences,O
[,O
69,O
",",O
74,O
"],",O
not,O
due,O
to,O
systematic,O
differences,O
in,O
interpretation,O
of,O
items,O
due,O
to,O
respondents,O
’,O
group,O
membership,O
.,O
The,O
extent,O
of,O
measurement,O
invariance,O
was,O
evaluated,O
in,O
a,O
series,O
of,O
three,O
models,O
.,O
In,O
model,O
A,O
",",O
specifying,O
‘,O
configural,O
invariance,O
"’,",O
the,O
same,O
factor,O
structure,O
is,O
imposed,O
on,O
the,O
two,O
groups,O
(,O
formed,O
by,O
either,O
sex,O
or,O
age,O
),O
In,O
the,O
next,O
model,O
(,O
B,O
"),",O
specifying,O
‘,O
weak,O
invariance,O
"’,",O
the,O
factor,O
loadings,O
are,O
constrained,O
to,O
be,O
equal,O
across,O
groups,O
.,O
In,O
Model,O
C,O
",",O
‘,O
strong,O
invariance,O
"’,",O
the,O
factor,O
loadings,O
and,O
intercepts,O
are,O
constrained,O
to,O
be,O
equal,O
across,O
groups,O
.,O
The,O
model,O
selection,O
was,O
performed,O
by,O
testing,O
invariance,O
by,O
the,O
Scaled,O
Difference,O
in,O
Chi,O
-,O
Squares,O
(,O
SDCS,O
),O
test,O
[,O
75,O
],O
for,O
nested,O
models,O
estimated,O
with,O
MLR,O
.,O
Inspection,O
of,O
size,O
and,O
consistency,O
of,O
factor,O
loadings,O
were,O
performed,O
to,O
further,O
evaluate,O
model,O
fit,O
[,O
69,O
].,O
This,O
sequential,O
model,O
estimation,O
procedure,O
to,O
study,O
measurement,O
invariance,O
is,O
used,O
since,O
lack,O
of,O
strong,O
factorial,O
invariance,O
will,O
contaminate,O
estimates,O
of,O
group,O
mean,O
differences,O
[,O
74,O
].,O
It,O
is,O
widely,O
acknowledged,O
however,O
",",O
that,O
the,O
requirement,O
of,O
strong,O
factorial,O
invariance,O
may,O
be,O
too,O
strict,O
and,O
unrealistic,O
a,O
goal,O
for,O
group,O
comparisons,O
.,O
Consequently,O
",",O
Byrne,O
et,O
al,O
.,O
[,O
76,O
],O
introduced,O
the,O
concept,O
of,O
partial,O
invariance,O
in,O
which,O
only,O
a,O
subset,O
of,O
parameters,O
in,O
each,O
subscale,O
must,O
be,O
invariant,O
whereas,O
others,O
are,O
allowed,O
to,O
vary,O
between,O
the,O
groups,O
.,O
In,O
this,O
procedure,O
",",O
fit,O
diagnostics,O
(,O
e,O
.,O
g,O
".,",O
modification,O
indices,O
),O
can,O
assist,O
the,O
researcher,O
to,O
identify,O
specific,O
items,O
that,O
are,O
non,O
-,O
invariant,O
across,O
groups,O
[,O
69,O
].,O
In,O
our,O
analysis,O
partial,O
invariance,O
was,O
investigated,O
by,O
inspecting,O
modification,O
indices,O
to,O
determine,O
which,O
cross,O
-,O
group,O
equality,O
constraint,O
most,O
significantly,O
contributed,O
to,O
lack,O
of,O
fit,O
;,O
the,O
model,O
was,O
re,O
-,O
estimated,O
after,O
freeing,O
that,O
constraint,O
and,O
this,O
process,O
was,O
reiterated,O
as,O
needed,O
[,O
77,O
].,O
Partial,O
invariance,O
of,O
certain,O
items,O
signals,O
qualitative,O
group,O
differences,O
that,O
render,O
exact,O
between,O
-,O
group,O
comparisons,O
with,O
respect,O
to,O
subscales,O
including,O
these,O
items,O
possibly,O
less,O
meaningful,O
.,O
The,O
importance,O
of,O
any,O
violation,O
of,O
factorial,O
invariance,O
should,O
be,O
judged,O
in,O
relation,O
to,O
the,O
intended,O
use,O
of,O
the,O
measure,O
in,O
practice,O
[,O
78,O
],O
and,O
may,O
also,O
be,O
dependent,O
on,O
the,O
number,O
of,O
affected,O
items,O
.,O
The,O
implications,O
of,O
the,O
findings,O
with,O
respect,O
to,O
measurement,O
invariance,O
are,O
further,O
investigated,O
by,O
comparing,O
the,O
original,O
(,O
sub,O
-),O
scale,O
scores,O
to,O
the,O
adjusted,O
(,O
sub,O
-),O
scale,O
scores,O
.,O
Moreover,O
",",O
the,O
correlations,O
between,O
the,O
full,O
and,O
reduced,O
scale,O
and,O
subscales,O
were,O
investigated,O
",",O
as,O
well,O
as,O
the,O
change,O
in,O
standardized,O
factor,O
loadings,O
.,O
Note,O
that,O
all,O
(,O
sub,O
-),O
scale,O
scores,O
are,O
calculated,O
as,O
average,O
scores,O
",",O
which,O
are,O
unweighted,O
and,O
therefore,O
not,O
affected,O
by,O
(,O
changes,O
in,O
),O
factor,O
loadings,O
.,O
Results,O
Table,O
2,O
presents,O
total,O
mean,O
scores,O
and,O
standard,O
deviations,O
in,O
both,O
DBIQ,O
-,O
NL,O
samples,O
as,O
well,O
as,O
means,O
and,O
standard,O
deviations,O
for,O
the,O
questionnaires,O
used,O
for,O
validation,O
.,O
Mean,O
group,O
differences,O
between,O
women,B-OG
and,O
men,B-OG
and,O
between,O
younger,O
and,O
older,O
participants,O
are,O
also,O
included,O
.,O
Test,O
-,O
retest,O
reliability,O
The,O
intraclass,O
correlation,O
coefficients,O
(,O
ICC,O
),O
between,O
test,O
and,O
retest,O
scores,O
on,O
the,O
DBIQ,O
-,O
NL,O
scale,O
were,O
.,O
88,O
and,O
on,O
the,O
DBIQ,O
-,O
NL,O
subscales,O
.,O
82,O
for,O
vitality,O
",",O
.,O
80,O
for,O
body,O
acceptance,O
",",O
.,O
78,O
for,O
self,O
-,O
aggrandizement,O
",",O
.,O
79,O
for,O
sexual,O
fulfillment,O
",",O
and,O
.,O
64,O
for,O
physical,O
contact,O
.,O
Test,O
and,O
retest,O
scores,O
were,O
calculated,O
using,O
the,O
original,O
composition,O
of,O
the,O
German,O
version,O
(,O
Model,O
1,O
).,O
Construct,O
validity,O
Pearson,O
’,O
s,O
r,O
between,O
the,O
DBIQ,O
-,O
NL,O
and,O
Body,O
Cathexis,O
Scale,O
(,O
BCS,O
),O
correlated,O
r,O
=,O
.,O
60,O
(,O
see,O
Table,O
3,O
).,O
The,O
subscale,O
vitality,O
of,O
the,O
DBIQ,O
-,O
NL,O
correlated,O
r,O
=,O
-.,O
70,O
with,O
the,O
Checklist,O
Individual,O
Strength,O
(,O
CIS,O
),O
and,O
the,O
subscale,O
physical,O
contact,O
of,O
the,O
DBIQ,O
-,O
NL,O
correlated,O
r,O
=,O
.,O
72,O
with,O
the,O
subscale,O
comfort,O
with,O
physical,O
touch,O
of,O
the,O
Body,O
Investment,O
Scale,O
(,O
BIS,O
).,O
Correlation,O
between,O
DBIQ,O
-,O
NL,O
and,O
the,O
Outcome,O
Questionnaire,O
(,O
OQ,O
-,O
45,O
),O
was,O
-.,O
51,O
.,O
DBIQ,O
-,O
NL,O
and,O
Rosenberg,O
Self,O
-,O
esteem,O
Scale,O
(,O
RSES,O
),O
showed,O
a,O
correlation,O
of,O
r,O
=,O
.,O
44,O
.,O
All,O
correlations,O
were,O
in,O
the,O
expected,O
direction,O
and,O
of,O
medium,O
to,O
large,O
size,O
.,O
Correlations,O
between,O
DBIQ,O
-,O
NL,O
and,O
BCS,O
were,O
notably,O
higher,O
for,O
men,B-OG
than,O
for,O
women,B-OG
.,O
Correlations,O
between,O
DBIQ,O
-,O
NL,O
and,O
OQ,O
-,O
45,O
and,O
between,O
DBIQ,O
-,O
NL,O
and,O
RSES,O
were,O
higher,O
for,O
age,O
<,O
38,O
than,O
for,O
age,O
≥,O
38,O
.,O
The,O
subscale,O
vitality,O
correlated,O
notably,O
lower,O
with,O
the,O
CIS,O
in,O
the,O
younger,O
group,O
than,O
in,O
the,O
older,O
group,O
.,O
Correlations,O
were,O
calculated,O
using,O
the,O
five,O
-,O
factor,O
model,O
identical,O
to,O
the,O
original,O
German,O
version,O
(,O
Model,O
1,O
).,O
The,O
correlations,O
between,O
the,O
measures,O
that,O
were,O
used,O
for,O
construct,O
validation,O
and,O
the,O
DBIQ,O
-,O
NL,O
were,O
recalculated,O
(,O
see,O
Table,O
3,O
),O
after,O
the,O
DBIQ,O
-,O
NL,O
was,O
revised,O
on,O
the,O
basis,O
of,O
the,O
CFA,O
",",O
as,O
reported,O
in,O
the,O
following,O
section,O
.,O
Correlations,O
in,O
Pearson,O
’,O
s,O
r,O
of,O
original,O
and,O
revised,O
DBIQ,O
scale,O
and,O
original,O
and,O
revised,O
subscale,O
‘,O
physical,O
contact,O
’,O
with,O
validation,O
instruments,O
(,O
Model,O
1,O
and,O
Model,O
2,O
).,O
DBIQ,O
-,O
NL,O
(,O
35,O
items,O
;,O
model,O
1,O
),O
DBIQ,O
-,O
NL,O
(,O
31,O
items,O
;,O
model,O
2,O
),O
Total,O
sample,O
female,O
male,O
young,O
old,O
Total,O
sample,O
female,O
male,O
young,O
old,O
BCSa,O
.,O
60,O
.,O
53,O
.,O
70,O
.,O
58,O
.,O
64,O
.,O
59,O
.,O
53,O
.,O
67,O
.,O
56,O
.,O
64,O
OQ,O
-,O
45b,O
-.,O
51,O
-.,O
49,O
-.,O
52,O
-.,O
54,O
-.,O
40,O
-.,O
50,O
-.,O
50,O
-.,O
50,O
-.,O
53,O
-.,O
43,O
RSESc,O
.,O
44,O
.,O
38,O
.,O
42,O
.,O
49,O
.,O
35,O
.,O
45,O
.,O
40,O
.,O
43,O
.,O
50,O
.,O
37,O
subscale,O
physical,O
contact,O
(,O
6,O
items,O
),O
subscale,O
physical,O
contact,O
(,O
4,O
items,O
),O
BIS,O
-,O
touchd,O
.,O
72,O
.,O
77,O
.,O
67,O
.,O
71,O
.,O
77,O
66,O
.,O
71,O
.,O
61,O
.,O
64,O
.,O
72,O
subscale,O
vitality,O
subscale,O
vitality,O
(,O
as,O
in,O
Model,O
1,O
),O
CISd,O
-.,O
70,O
-.,O
67,O
-.,O
73,O
-.,O
66,O
-.,O
83,O
-.,O
70,O
-.,O
67,O
-.,O
73,O
-.,O
66,O
-.,O
83,O
Note,O
:,O
DBIQ,O
-,O
NL,O
=,O
Dresden,O
Body,O
Image,O
Questionnaire,O
",",O
Dutch,O
translation,O
;,O
OQ,O
-,O
45,O
=,O
Outcome,O
Questionnaire,O
;,O
RSES,O
=,O
Rosenberg,O
Self,O
-,O
esteem,O
Scale,O
;,O
BCS,O
=,O
Body,O
Cathexis,O
Scale,O
;,O
BIS,O
-,O
touch,O
=,O
subscale,O
comfort,O
with,O
physical,O
touch,O
Body,O
Investment,O
Scale,O
;,O
CIS,O
=,O
Checklist,O
Individual,O
Strength,O
.,O
For,O
description,O
of,O
the,O
samples,O
1a,O
",",O
1b,O
",",O
and,O
2,O
",",O
see,O
procedure,O
and,O
Table,O
2,O
.,O
a,O
sample,O
1a,O
b,O
sample,O
2,O
c,O
samples,O
1b,O
and,O
2,O
d,O
sample,O
1b,O
Confirmatory,O
factor,O
analysis,O
and,O
measurement,O
invariance,O
on,O
sample,O
1,O
First,O
",",O
a,O
five,O
-,O
factor,O
model,O
identical,O
to,O
the,O
original,O
German,O
version,O
was,O
specified,O
(,O
Model,O
1,O
).,O
Next,O
",",O
based,O
on,O
inspection,O
of,O
the,O
modification,O
indices,O
of,O
this,O
model,O
a,O
five,O
-,O
factor,O
model,O
(,O
Model,O
2,O
),O
with,O
item,O
33,O
(“,O
I,O
like,O
showing,O
my,O
body,O
”),O
loading,O
on,O
self,O
-,O
aggrandizement,O
instead,O
of,O
body,O
acceptance,O
was,O
evaluated,O
.,O
Goodness,O
of,O
fit,O
indices,O
of,O
both,O
models,O
are,O
shown,O
in,O
Table,O
4,O
.,O
The,O
modification,O
indices,O
for,O
correlated,O
errors,O
suggested,O
partly,O
the,O
same,O
(,O
between,O
reversed,O
items,O
23,O
“,O
I,O
wish,O
I,O
had,O
a,O
different,O
body,O
”,O
and,O
28,O
“,O
If,O
I,O
could,O
change,O
something,O
about,O
my,O
body,O
",",O
I,O
would,O
do,O
it,O
"”),",O
and,O
partly,O
different,O
correlated,O
errors,O
(,O
between,O
reversed,O
items,O
24,O
“,O
I,O
consciously,O
avoid,O
touching,O
other,O
people,O
”,O
and,O
19,O
“,O
I,O
do,O
not,O
like,O
people,O
touching,O
me,O
"”),",O
as,O
reported,O
by,O
Pöhlmann,O
et,O
al,O
.,O
[,O
26,O
].,O
DBIQ,O
-,O
NL,O
:,O
Confirmatory,O
factor,O
analysis,O
",",O
goodness,O
of,O
fit,O
indices,O
of,O
Model,O
1,O
",",O
2,O
",",O
and,O
3,O
and,O
measurement,O
invariance,O
across,O
sex,O
and,O
age,O
of,O
Model,O
2,O
.,O
Model,O
χ2,O
df,O
scl,O
Δ,O
χ2,O
Δ,O
df,O
Ts,O
RMSEA,O
(,O
90,O
%,O
CI,O
),O
SRMR,O
CFI,O
TLI,O
Model,O
1,O
Original,O
35,O
Item,O
Scale,O
2169,O
550,O
1,O
.,O
265,O
.,O
062,O
(.,O
059,O
-.,O
065,O
),O
.,O
070,O
.,O
828,O
.,O
814,O
Model,O
2,O
Adapted,O
35,O
Item,O
Scale,O
a,O
1965,O
550,O
1,O
.,O
268,O
.,O
058,O
(.,O
055,O
-.,O
061,O
),O
.,O
067,O
.,O
850,O
.,O
838,O
Measurement,O
Invariance,O
Sex,O
Model,O
2sA,O
configural,O
invariance,O
2692,O
1100,O
1,O
.,O
268,O
.,O
062,O
(.,O
059,O
-.,O
065,O
),O
.,O
074,O
.,O
832,O
.,O
818,O
Model,O
2sB,O
weak,O
invariance,O
2721,O
1130,O
1,O
.,O
276,O
29,O
30,O
18,O
.,O
4,O
.,O
061,O
(.,O
058,O
-.,O
064,O
),O
.,O
077,O
.,O
832,O
.,O
823,O
Model,O
2sC,O
strong,O
invariance,O
2905,O
1160,O
1,O
.,O
322,O
184,O
30,O
60,O
.,O
2,O
**,O
.,O
063,O
(.,O
060,O
-.,O
066,O
),O
.,O
081,O
.,O
816,O
.,O
811,O
Model,O
2sC,O
-,O
1,O
partial,O
strong,O
item,O
19,O
2869,O
1158,O
1,O
.,O
317,O
148,O
28,O
49,O
.,O
8,O
*,O
.,O
062,O
(.,O
060,O
-.,O
065,O
),O
.,O
080,O
.,O
819,O
.,O
814,O
Model,O
2sC,O
-,O
2,O
partial,O
strong,O
items,O
19,O
",",O
30,O
2827,O
1156,O
1,O
.,O
315,O
106,O
26,O
35,O
.,O
2,O
*,O
.,O
062,O
(.,O
059,O
-.,O
065,O
),O
.,O
079,O
.,O
823,O
.,O
818,O
Model,O
2sC,O
-,O
3,O
partial,O
strong,O
items,O
19,O
",",O
30,O
",",O
15,O
2804,O
1154,O
1,O
.,O
313,O
83,O
24,O
27,O
.,O
1,O
.,O
061,O
(.,O
059,O
-.,O
064,O
),O
.,O
078,O
.,O
826,O
.,O
820,O
Measurement,O
Invariance,O
Age,O
Model,O
2aA,O
configural,O
invariance,O
2623,O
1100,O
1,O
.,O
253,O
.,O
060,O
(.,O
057,O
-.,O
063,O
),O
.,O
073,O
.,O
842,O
.,O
829,O
Model,O
2aB,O
weak,O
invariance,O
2645,O
1130,O
1,O
.,O
247,O
22,O
30,O
21,O
.,O
4,O
.,O
059,O
(.,O
056,O
-.,O
062,O
),O
.,O
075,O
.,O
843,O
.,O
835,O
Model,O
2aC,O
strong,O
invariance,O
2796,O
1160,O
1,O
.,O
291,O
151,O
30,O
51,O
.,O
2,O
**,O
.,O
061,O
(.,O
058,O
-.,O
064,O
),O
.,O
078,O
.,O
831,O
.,O
826,O
Model,O
2aC,O
-,O
1,O
partial,O
strong,O
item,O
15,O
2771,O
1158,O
1,O
.,O
289,O
126,O
28,O
42,O
.,O
2,O
*,O
.,O
061,O
(.,O
058,O
-.,O
063,O
),O
.,O
078,O
.,O
833,O
.,O
828,O
Model,O
2aC,O
-,O
2,O
partial,O
strong,O
items,O
15,O
",",O
28,O
2754,O
1156,O
1,O
.,O
286,O
109,O
26,O
36,O
.,O
5,O
.,O
060,O
(.,O
058,O
-.,O
064,O
),O
.,O
077,O
.,O
835,O
.,O
830,O
Model,O
3,O
Reduced,O
31,O
Item,O
Scale,O
1459,O
424,O
1,O
.,O
271,O
506,O
126,O
402,O
.,O
2,O
**,O
.,O
057,O
(.,O
053,O
-.,O
060,O
),O
.,O
063,O
.,O
877,O
.,O
865,O
Note,O
:,O
DBIQ,O
-,O
NL,O
=,O
Dresden,O
Body,O
Image,O
Questionnaire,O
",",O
Dutch,O
translation,O
;,O
χ2,O
=,O
chi,O
square,O
;,O
df,O
=,O
degrees,O
of,O
freedom,O
;,O
scl,O
=,O
scaling,O
correction,O
factor,O
;,O
Ts,O
=,O
Scaled,O
.,O
Difference,O
in,O
Chi,O
-,O
Squares,O
(,O
SDCS,O
),O
test,O
statistic,O
;,O
RMSEA,O
=,O
root,O
mean,O
square,O
error,O
of,O
approximation,O
;,O
90,O
%,O
CI,O
=,O
90,O
%,O
confidence,O
interval,O
of,O
the,O
RMSEA,O
;,O
SRMR,O
=,O
standardized,O
root,O
mean,O
square,O
residual,O
;,O
CFI,O
=,O
comparative,O
fit,O
index,O
;,O
TLI,O
=,O
Tucker,O
Lewis,O
index,O
.,O
a,O
Adapted,O
model,O
with,O
item,O
33,O
not,O
loading,O
on,O
the,O
factor,O
acceptance,O
but,O
on,O
self,O
-,O
aggrandizement,O
(,O
modification,O
index,O
item,O
33,O
=,O
184,O
.,O
979,O
).,O
*,O
p,O
<,O
.,O
01,O
.,O
**,O
p,O
<,O
.,O
001,O
.,O
The,O
best,O
fitting,O
model,O
(,O
Model,O
2,O
),O
was,O
further,O
evaluated,O
for,O
measurement,O
invariance,O
in,O
a,O
multiple,O
group,O
confirmatory,O
factor,O
analysis,O
(,O
MG,O
-,O
CFA,O
),O
with,O
sex,O
and,O
age,O
as,O
grouping,O
variables,O
.,O
Models,O
2A,O
-,O
2C,O
show,O
measurement,O
invariance,O
tests,O
for,O
sex,O
(,O
2sA,O
-,O
2sC,O
),O
and,O
age,O
(,O
2aA,O
-,O
2aC,O
),O
respectively,O
.,O
As,O
can,O
be,O
seen,O
with,O
respect,O
to,O
sex,O
as,O
grouping,O
variable,O
",",O
constraining,O
the,O
factor,O
loadings,O
to,O
be,O
equal,O
across,O
groups,O
(,O
2sB,O
),O
is,O
accompanied,O
by,O
only,O
a,O
slight,O
decrease,O
in,O
CFI,O
and,O
a,O
non,O
-,O
significant,O
increase,O
in,O
chi,O
square,O
.,O
Therefore,O
",",O
factor,O
loadings,O
can,O
be,O
considered,O
as,O
invariant,O
across,O
sex,O
.,O
In,O
model,O
2sC,O
factor,O
loadings,O
as,O
well,O
as,O
intercepts,O
are,O
constrained,O
to,O
be,O
equal,O
across,O
men,B-OG
and,O
women,B-OG
.,O
This,O
restriction,O
leads,O
to,O
a,O
considerable,O
loss,O
of,O
model,O
fit,O
",",O
which,O
may,O
indicate,O
that,O
men,B-OG
and,O
women,B-OG
interpret,O
questionnaire,O
items,O
in,O
different,O
ways,O
.,O
The,O
same,O
holds,O
true,O
for,O
the,O
model,O
fits,O
constraining,O
factor,O
loadings,O
and,O
intercepts,O
to,O
be,O
equal,O
across,O
the,O
two,O
age,O
groups,O
:,O
a,O
model,O
fit,O
with,O
only,O
factor,O
loadings,O
constrained,O
(,O
2aB,O
),O
leads,O
to,O
a,O
non,O
-,O
significant,O
increase,O
in,O
chi,O
square,O
.,O
However,O
",",O
when,O
both,O
factor,O
loadings,O
and,O
intercepts,O
are,O
constrained,O
(,O
2aC,O
),O
a,O
considerable,O
loss,O
of,O
model,O
fit,O
is,O
found,O
.,O
Based,O
on,O
inspection,O
of,O
the,O
modification,O
indices,O
",",O
the,O
following,O
items,O
were,O
identified,O
as,O
contributing,O
to,O
lack,O
of,O
strong,O
invariance,O
across,O
sex,O
:,O
item,O
19,O
(“,O
I,O
do,O
not,O
like,O
people,O
touching,O
me,O
"”),",O
item,O
30,O
(“,O
I,O
only,O
allow,O
a,O
few,O
people,O
to,O
touch,O
me,O
"”),",O
and,O
item,O
15,O
(“,O
I,O
choose,O
clothing,O
that,O
hides,O
the,O
shape,O
of,O
my,O
body,O
”).,O
In,O
model,O
2sC,O
-,O
3,O
the,O
intercepts,O
of,O
these,O
three,O
items,O
were,O
freely,O
estimated,O
for,O
men,B-OG
and,O
women,B-OG
providing,O
the,O
best,O
model,O
fit,O
for,O
partial,O
strong,O
invariance,O
across,O
sex,O
.,O
On,O
average,O
",",O
men,B-OG
score,O
higher,O
on,O
these,O
items,O
than,O
women,B-OG
(,O
Table,O
2,O
).,O
With,O
regard,O
to,O
age,O
",",O
items,O
15,O
(“,O
I,O
choose,O
clothing,O
that,O
hides,O
the,O
shape,O
of,O
my,O
body,O
”),O
and,O
28,O
(“,O
If,O
I,O
could,O
change,O
something,O
about,O
my,O
body,O
",",O
I,O
would,O
do,O
it,O
”),O
were,O
identified,O
as,O
contributing,O
to,O
lack,O
of,O
strong,O
invariance,O
.,O
For,O
item,O
15,O
",",O
the,O
younger,O
age,O
group,O
scores,O
higher,O
on,O
average,O
",",O
whereas,O
for,O
item,O
28,O
",",O
the,O
older,O
age,O
group,O
scores,O
higher,O
.,O
The,O
partial,O
strong,O
invariance,O
model,O
represented,O
in,O
model,O
2aC,O
-,O
2,O
with,O
the,O
intercepts,O
of,O
these,O
two,O
items,O
estimated,O
freely,O
represents,O
the,O
best,O
fit,O
.,O
Fit,O
of,O
the,O
revised,O
model,O
A,O
revised,O
31,O
-,O
item,O
model,O
",",O
from,O
which,O
the,O
4,O
items,O
(,O
items,O
15,O
",",O
19,O
",",O
28,O
",",O
30,O
),O
primarily,O
responsible,O
for,O
lack,O
of,O
invariance,O
across,O
sex,O
and,O
age,O
were,O
deleted,O
",",O
was,O
evaluated,O
.,O
This,O
model,O
was,O
fit,O
to,O
Sample,O
1,O
and,O
reported,O
as,O
Model,O
3,O
in,O
Table,O
4,O
.,O
Compared,O
to,O
the,O
fit,O
of,O
the,O
full,O
35,O
-,O
item,O
model,O
(,O
Model,O
2,O
"),",O
the,O
revised,O
31,O
-,O
item,O
model,O
showed,O
a,O
better,O
fit,O
in,O
all,O
fit,O
measures,O
.,O
Means,O
of,O
the,O
revised,O
subscales,O
Table,O
5,O
presents,O
scores,O
of,O
the,O
DBIQ,O
-,O
NL,O
total,O
scale,O
and,O
subscales,O
for,O
Model,O
2,O
as,O
well,O
as,O
for,O
the,O
revised,O
31,O
-,O
item,O
model,O
",",O
in,O
which,O
the,O
four,O
items,O
contributing,O
most,O
to,O
lack,O
of,O
invariance,O
across,O
sex,O
and,O
age,O
were,O
deleted,O
.,O
Scores,O
on,O
total,O
scale,O
DBIQ,O
-,O
NL,O
and,O
subscales,O
based,O
on,O
Model,O
2,O
",",O
with,O
and,O
without,O
items,O
15,O
",",O
28,O
(,O
subscale,O
body,O
acceptance,O
"),",O
19,O
",",O
and,O
30,O
(,O
subscale,O
physical,O
contact,O
).,O
Full,O
sample,O
Women,B-OG
Men,B-OG
age,O
<,O
38,O
age,O
≥,O
38,O
n,O
=,O
761,O
n,O
=,O
433,O
n,O
=,O
326,O
n,O
=,O
540,O
n,O
=,O
221,O
n,O
items,O
(,O
sub,O
),O
scale,O
(,O
items,O
),O
Mean,O
SD,O
Mean,O
SD,O
Mean,O
SD,O
d,O
Mean,O
SD,O
Mean,O
SD,O
d,O
35,O
DBIQ,O
-,O
NL,O
3,O
.,O
66,O
0,O
.,O
45,O
3,O
.,O
56,O
0,O
.,O
44,O
3,O
.,O
79,O
0,O
.,O
43,O
0,O
.,O
53,O
3,O
.,O
71,O
0,O
.,O
44,O
3,O
.,O
53,O
0,O
.,O
45,O
0,O
.,O
40,O
31,O
DBIQ,O
-,O
NL,O
3,O
.,O
65,O
0,O
.,O
45,O
3,O
.,O
56,O
0,O
.,O
44,O
3,O
.,O
77,O
0,O
.,O
44,O
0,O
.,O
48,O
3,O
.,O
71,O
0,O
.,O
44,O
3,O
.,O
51,O
0,O
.,O
46,O
0,O
.,O
44,O
8,O
Vitality,O
(,O
2,O
",",O
3,O
",",O
6,O
",",O
8,O
",",O
14,O
",",O
17,O
",",O
26,O
",",O
32,O
),O
3,O
.,O
87,O
0,O
.,O
58,O
3,O
.,O
76,O
0,O
.,O
58,O
4,O
.,O
02,O
0,O
.,O
55,O
0,O
.,O
46,O
3,O
.,O
91,O
0,O
.,O
55,O
3,O
.,O
78,O
0,O
.,O
66,O
0,O
.,O
21,O
7,O
Body,O
Acc,O
.,O
(,O
7,O
",",O
12,O
",",O
15,O
",",O
18,O
",",O
23,O
",",O
25,O
",",O
28,O
),O
3,O
.,O
83,O
0,O
.,O
67,O
3,O
.,O
70,O
0,O
.,O
69,O
4,O
.,O
00,O
0,O
.,O
60,O
0,O
.,O
46,O
3,O
.,O
85,O
0,O
.,O
67,O
3,O
.,O
79,O
0,O
.,O
68,O
0,O
.,O
09,O
5,O
Body,O
Acc,O
.,O
(,O
7,O
",",O
12,O
",",O
18,O
",",O
23,O
",",O
25,O
)*,O
3,O
.,O
87,O
0,O
.,O
69,O
3,O
.,O
74,O
0,O
.,O
71,O
4,O
.,O
03,O
0,O
.,O
62,O
0,O
.,O
44,O
3,O
.,O
89,O
0,O
.,O
68,O
3,O
.,O
82,O
0,O
.,O
69,O
0,O
.,O
10,O
8,O
Self,O
-,O
aggr,O
.,O
(,O
1,O
",",O
10,O
",",O
13,O
",",O
20,O
",",O
29,O
",",O
31,O
",",O
33,O
",",O
34,O
),O
3,O
.,O
12,O
0,O
.,O
55,O
3,O
.,O
06,O
0,O
.,O
56,O
3,O
.,O
19,O
0,O
.,O
56,O
0,O
.,O
23,O
3,O
.,O
23,O
0,O
.,O
53,O
2,O
.,O
86,O
0,O
.,O
52,O
0,O
.,O
70,O
6,O
Phys,O
.,O
Contact,O
(,O
5,O
",",O
11,O
",",O
19,O
",",O
22,O
",",O
24,O
",",O
30,O
),O
3,O
.,O
80,O
0,O
.,O
60,O
3,O
.,O
76,O
0,O
.,O
61,O
3,O
.,O
86,O
0,O
.,O
59,O
0,O
.,O
17,O
3,O
.,O
84,O
0,O
.,O
59,O
3,O
.,O
71,O
0,O
.,O
62,O
0,O
.,O
21,O
4,O
Phys,O
.,O
Contact,O
(,O
5,O
",",O
11,O
",",O
22,O
",",O
24,O
)*,O
3,O
.,O
85,O
0,O
.,O
61,O
3,O
.,O
87,O
0,O
.,O
60,O
3,O
.,O
81,O
0,O
.,O
60,O
-,O
0,O
.,O
10,O
3,O
.,O
89,O
0,O
.,O
59,O
3,O
.,O
75,O
0,O
.,O
63,O
0,O
.,O
23,O
6,O
Sexual,O
Fulfillment,O
(,O
4,O
",",O
9,O
",",O
16,O
",",O
21,O
",",O
27,O
",",O
35,O
),O
3,O
.,O
78,O
0,O
.,O
71,O
3,O
.,O
60,O
0,O
.,O
72,O
4,O
.,O
01,O
0,O
.,O
64,O
0,O
.,O
60,O
3,O
.,O
83,O
0,O
.,O
69,O
3,O
.,O
65,O
0,O
.,O
74,O
0,O
.,O
25,O
Note,O
:,O
DBIQ,O
-,O
NL,O
=,O
Dresden,O
Body,O
Image,O
Questionnaire,O
",",O
Dutch,O
translation,O
;,O
Self,O
-,O
aggr,O
.,O
=,O
Self,O
-,O
aggrandizement,O
;,O
Body,O
Acc,O
.,O
=,O
Body,O
Acceptance,O
;,O
Phys,O
.,O
Contact,O
=,O
Physical,O
Contact,O
*,O
Adapted,O
scale,O
with,O
items,O
removed,O
based,O
upon,O
MGCFA,O
outcomes,O
.,O
Total,O
mean,O
scores,O
were,O
hardly,O
influenced,O
by,O
deleting,O
items,O
15,O
",",O
19,O
",",O
28,O
",",O
and,O
30,O
with,O
changes,O
of,O
less,O
than,O
0,O
.,O
02,O
in,O
size,O
.,O
The,O
correlation,O
between,O
the,O
full,O
and,O
reduced,O
scale,O
was,O
.,O
99,O
.,O
Scores,O
on,O
the,O
subscale,O
body,O
acceptance,O
(,O
with,O
items,O
15,O
and,O
28,O
deleted,O
),O
changed,O
at,O
most,O
0,O
.,O
04,O
points,O
.,O
The,O
correlation,O
between,O
the,O
full,O
and,O
reduced,O
sub,O
-,O
scale,O
was,O
.,O
96,O
.,O
Mean,O
scores,O
for,O
the,O
subscale,O
physical,O
contact,O
increased,O
slightly,O
(.,O
05,O
),O
for,O
the,O
whole,O
group,O
when,O
items,O
19,O
and,O
30,O
were,O
deleted,O
;,O
the,O
correlation,O
between,O
the,O
original,O
and,O
adapted,O
sub,O
-,O
scale,O
was,O
.,O
92,O
;,O
Mean,O
scores,O
were,O
.,O
11,O
higher,O
for,O
women,B-OG
and,O
showed,O
a,O
decrease,O
of,O
.,O
05,O
for,O
men,B-OG
.,O
Mean,O
differences,O
on,O
the,O
subscales,O
between,O
age,O
groups,O
and,O
between,O
women,B-OG
and,O
men,B-OG
were,O
small,O
to,O
medium,O
(,O
Cohen,O
’,O
s,O
d,O
<.,O
0,O
.,O
50,O
"),",O
with,O
the,O
exception,O
of,O
medium,O
differences,O
between,O
women,B-OG
and,O
men,B-OG
on,O
the,O
subscale,O
sexual,O
fulfillment,O
(,O
d,O
=,O
0,O
.,O
60,O
),O
and,O
between,O
the,O
younger,O
and,O
older,O
age,O
group,O
on,O
the,O
subscale,O
self,O
-,O
aggrandizement,O
(,O
d,O
=,O
0,O
.,O
70,O
).,O
Differences,O
were,O
in,O
the,O
same,O
direction,O
",",O
with,O
men,B-OG
scoring,O
higher,O
than,O
women,B-OG
and,O
the,O
younger,O
age,O
group,O
scoring,O
higher,O
than,O
the,O
older,O
age,O
group,O
.,O
The,O
only,O
exception,O
were,O
men,B-OG
scoring,O
slightly,O
lower,O
than,O
women,B-OG
on,O
the,O
reduced,O
physical,O
contact,O
subscale,O
(,O
d,O
=,O
0,O
.,O
10,O
).,O
For,O
standardized,O
factor,O
loadings,O
of,O
the,O
full,O
and,O
reduced,O
item,O
sub,O
-,O
scales,O
see,O
S3,O
Table,O
.,O
Discussion,O
Structure,O
of,O
the,O
(,O
sub,O
),O
scales,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
assess,O
psychometric,O
properties,O
of,O
the,O
DBIQ,O
in,O
a,O
non,O
-,O
clinical,O
Dutch,O
sample,O
.,O
Moreover,O
",",O
the,O
work,O
done,O
by,O
the,O
developers,O
of,O
the,O
original,O
scale,O
[,O
26,O
",",O
27,O
],O
was,O
extended,O
by,O
evaluating,O
the,O
equivalence,O
of,O
the,O
measurement,O
model,O
across,O
sex,O
and,O
age,O
.,O
For,O
our,O
evaluation,O
of,O
the,O
psychometric,O
properties,O
we,O
used,O
a,O
large,O
convenience,O
sample,O
with,O
a,O
gender,O
and,O
age,O
distribution,O
deviating,O
from,O
the,O
Dutch,O
general,O
population,O
.,O
Whereas,O
the,O
investigation,O
of,O
age,O
invariance,O
of,O
the,O
DBIQ,O
was,O
in,O
fact,O
facilitated,O
by,O
the,O
bimodal,O
age,O
distribution,O
",",O
the,O
sample,O
does,O
not,O
provide,O
information,O
on,O
the,O
distribution,O
of,O
DBIQ,O
scores,O
across,O
the,O
general,O
population,O
(,O
e,O
.,O
g,O
.,O
with,O
the,O
purpose,O
of,O
computing,O
norm,O
scores,O
).,O
Confirmatory,O
Factor,O
Analysis,O
based,O
on,O
the,O
five,O
-,O
factor,O
structure,O
of,O
the,O
original,O
German,O
questionnaire,O
",",O
showed,O
adequate,O
fit,O
in,O
the,O
translated,O
version,O
for,O
RMSEA,O
and,O
SRMR,O
",",O
but,O
mediocre,O
fit,O
for,O
CFI,O
and,O
TLI,O
[,O
69,O
].,O
Adaptation,O
of,O
the,O
model,O
based,O
on,O
inspection,O
of,O
the,O
modification,O
indices,O
led,O
to,O
improvement,O
of,O
model,O
fit,O
.,O
In,O
this,O
adaptation,O
",",O
the,O
item,O
“,O
I,O
like,O
showing,O
my,O
body,O
”,O
was,O
moved,O
from,O
the,O
subscale,O
body,O
acceptance,O
to,O
the,O
subscale,O
self,O
-,O
aggrandizement,O
.,O
This,O
is,O
in,O
line,O
with,O
the,O
results,O
of,O
the,O
principal,O
component,O
analysis,O
by,O
Probst,O
et,O
al,O
.,O
[,O
34,O
"],",O
which,O
revealed,O
higher,O
loadings,O
on,O
the,O
subscale,O
self,O
-,O
aggrandizement,O
for,O
the,O
item,O
“,O
I,O
like,O
showing,O
my,O
body,O
”,O
than,O
on,O
the,O
original,O
subscale,O
.,O
Even,O
though,O
German,O
and,O
Dutch,O
are,O
closely,O
related,O
languages,O
",",O
a,O
slight,O
semantic,O
difference,O
may,O
have,O
occurred,O
",",O
suggesting,O
that,O
the,O
Dutch,O
translation,O
emphasizes,O
the,O
pleasure,O
of,O
showing,O
one,O
’,O
s,O
body,O
",",O
whereas,O
the,O
original,O
item,O
was,O
meant,O
to,O
measure,O
body,O
acceptance,O
.,O
A,O
semantic,O
explanation,O
is,O
more,O
plausible,O
than,O
a,O
cultural,O
difference,O
in,O
the,O
interpretation,O
of,O
this,O
item,O
.,O
Based,O
on,O
the,O
fit,O
indices,O
and,O
considering,O
that,O
reallocating,O
one,O
item,O
is,O
an,O
acceptable,O
model,O
change,O
when,O
an,O
instrument,O
is,O
used,O
in,O
a,O
different,O
cultural,O
setting,O
or,O
language,O
[,O
61,O
"],",O
the,O
adapted,O
model,O
was,O
used,O
for,O
further,O
evaluations,O
.,O
After,O
comparing,O
the,O
quality,O
of,O
the,O
goodness,O
of,O
fit,O
indices,O
",",O
as,O
recommended,O
by,O
[,O
79,O
"],",O
with,O
findings,O
from,O
previous,O
research,O
based,O
on,O
the,O
German,O
inventory,O
",",O
we,O
judge,O
the,O
psychometric,O
properties,O
of,O
the,O
DBIQ,O
-,O
NL,O
as,O
sufficient,O
to,O
warrant,O
further,O
research,O
on,O
the,O
scale,O
and,O
its,O
properties,O
",",O
in,O
a,O
Dutch,O
clinical,O
population,O
.,O
While,O
being,O
aware,O
of,O
new,O
developments,O
in,O
scale,O
analysis,O
by,O
Exploratory,O
Structural,O
Equation,O
Modeling,O
to,O
remedy,O
the,O
overly,O
strict,O
CFA,O
requirements,O
[,O
68,O
",",O
80,O
"],",O
we,O
refrained,O
from,O
applying,O
this,O
method,O
in,O
order,O
to,O
obtain,O
a,O
close,O
comparison,O
between,O
the,O
DBIQ,O
-,O
NL,O
and,O
the,O
original,O
DBIQ,O
by,O
following,O
a,O
similar,O
evaluation,O
procedure,O
.,O
Based,O
on,O
[,O
67,O
",",O
79,O
"],",O
it,O
was,O
to,O
be,O
expected,O
that,O
the,O
DBIQ,O
-,O
NL,O
would,O
show,O
a,O
reduced,O
goodness,O
of,O
fit,O
compared,O
to,O
the,O
original,O
scale,O
",",O
in,O
which,O
the,O
reported,O
CFI,O
only,O
just,O
met,O
the,O
often,O
used,O
threshold,O
of,O
0,O
.,O
90,O
.,O
A,O
multiple,O
-,O
group,O
confirmatory,O
factor,O
analysis,O
showed,O
configural,O
invariance,O
.,O
The,O
equal,O
item,O
intercepts,O
hypothesis,O
",",O
implying,O
factorial,O
invariance,O
",",O
however,O
",",O
was,O
not,O
supported,O
for,O
all,O
subscales,O
across,O
sex,O
and,O
age,O
.,O
When,O
testing,O
partial,O
factorial,O
invariance,O
",",O
four,O
items,O
were,O
identified,O
that,O
contributed,O
to,O
the,O
lack,O
of,O
strong,O
invariance,O
across,O
sex,O
(,O
item,O
19,O
",",O
30,O
),O
or,O
age,O
(,O
item,O
28,O
),O
or,O
across,O
both,O
groups,O
(,O
item,O
15,O
),O
indicating,O
that,O
interpretation,O
of,O
the,O
meaning,O
of,O
these,O
items,O
and,O
therefore,O
the,O
item,O
scores,O
might,O
depend,O
on,O
group,O
membership,O
.,O
Replication,O
of,O
the,O
procedure,O
by,O
fitting,O
a,O
final,O
model,O
in,O
sample,O
1,O
without,O
these,O
items,O
supported,O
the,O
best,O
",",O
although,O
moderate,O
",",O
fit,O
of,O
this,O
31,O
-,O
item,O
scale,O
.,O
Next,O
to,O
the,O
technical,O
identification,O
of,O
these,O
differing,O
items,O
",",O
there,O
are,O
arguments,O
from,O
a,O
qualitative,O
perspective,O
as,O
to,O
why,O
these,O
items,O
differ,O
across,O
groups,O
.,O
Some,O
items,O
suggest,O
interesting,O
patterns,O
.,O
In,O
items,O
19,O
and,O
30,O
",",O
differing,O
across,O
sex,O
",",O
being,O
touched,O
by,O
others,O
is,O
the,O
central,O
issue,O
.,O
These,O
items,O
may,O
be,O
interpreted,O
differently,O
by,O
men,B-OG
and,O
women,B-OG
since,O
the,O
latter,O
are,O
more,O
often,O
the,O
object,O
of,O
undesired,O
physical,O
contact,O
.,O
Invariance,O
across,O
sex,O
in,O
item,O
15,O
(“,O
I,O
choose,O
clothing,O
that,O
hides,O
the,O
shape,O
of,O
my,O
body,O
”),O
could,O
be,O
explained,O
by,O
the,O
fact,O
that,O
for,O
men,B-OG
",",O
in,O
contrast,O
to,O
women,B-OG
",",O
clothing,O
is,O
not,O
a,O
well,O
-,O
known,O
strategy,O
to,O
camouflage,O
less,O
accepted,O
parts,O
of,O
the,O
body,O
[,O
81,O
].,O
The,O
differences,O
across,O
age,O
for,O
this,O
item,O
might,O
be,O
indicative,O
for,O
age,O
-,O
or,O
cohort,O
-,O
related,O
cultural,O
differences,O
with,O
regard,O
to,O
showing,O
the,O
body,O
.,O
Item,O
28,O
(“,O
If,O
I,O
could,O
change,O
something,O
about,O
my,O
body,O
",",O
I,O
would,O
do,O
it,O
”),O
might,O
mean,O
something,O
different,O
for,O
the,O
older,O
age,O
group,O
",",O
in,O
light,O
of,O
physical,O
impairments,O
or,O
other,O
confrontations,O
with,O
unwelcome,O
bodily,O
changes,O
.,O
Millsap,O
and,O
Kwok,O
[,O
78,O
],O
describe,O
the,O
option,O
of,O
using,O
a,O
shortened,O
version,O
of,O
the,O
scale,O
that,O
omits,O
the,O
items,O
that,O
performed,O
differently,O
across,O
groups,O
",",O
at,O
the,O
same,O
time,O
warning,O
that,O
this,O
option,O
results,O
in,O
as,O
many,O
versions,O
of,O
the,O
scale,O
as,O
there,O
are,O
invariance,O
studies,O
.,O
A,O
second,O
option,O
is,O
to,O
retain,O
all,O
items,O
when,O
the,O
net,O
impact,O
of,O
the,O
differences,O
on,O
the,O
total,O
score,O
is,O
small,O
[,O
78,O
].,O
This,O
is,O
indeed,O
the,O
case,O
in,O
the,O
present,O
non,O
-,O
clinical,O
sample,O
.,O
Also,O
due,O
to,O
the,O
limited,O
number,O
of,O
affected,O
items,O
",",O
partial,O
invariance,O
only,O
slightly,O
affects,O
the,O
differences,O
between,O
sex,O
and,O
age,O
groups,O
in,O
mean,O
total,O
scores,O
on,O
the,O
DBIQ,O
-,O
NL,O
and,O
subscales,O
.,O
Therefore,O
",",O
adaptations,O
need,O
not,O
be,O
made,O
when,O
the,O
scale,O
is,O
used,O
to,O
gain,O
global,O
information,O
on,O
body,O
image,O
in,O
non,O
-,O
clinical,O
groups,O
.,O
However,O
",",O
when,O
the,O
focus,O
is,O
on,O
gathering,O
information,O
with,O
respect,O
to,O
differences,O
on,O
the,O
issue,O
of,O
physical,O
contact,O
across,O
the,O
sexes,O
or,O
on,O
the,O
theme,O
of,O
body,O
acceptance,O
among,O
different,O
age,O
groups,O
",",O
a,O
score,O
without,O
the,O
items,O
violating,O
invariance,O
could,O
be,O
relevant,O
.,O
Reliability,O
and,O
validity,O
The,O
DBIQ,O
-,O
NL,O
and,O
its,O
five,O
subscales,O
showed,O
adequate,O
internal,O
consistency,O
.,O
Test,O
-,O
retest,O
reliability,O
was,O
also,O
adequate,O
",",O
although,O
based,O
on,O
a,O
rather,O
small,O
sample,O
.,O
Good,O
construct,O
validity,O
was,O
found,O
with,O
moderate,O
associations,O
with,O
body,O
satisfaction,O
(,O
BCS,O
),O
as,O
expected,O
since,O
the,O
DBIQ,O
aims,O
to,O
measure,O
a,O
broad,O
concept,O
of,O
body,O
image,O
whereas,O
in,O
the,O
BCS,O
appearance,O
-,O
related,O
issues,O
are,O
prominent,O
.,O
The,O
higher,O
correlations,O
between,O
total,O
score,O
on,O
the,O
DBIQ,O
and,O
body,O
satisfaction,O
(,O
BCS,O
),O
for,O
men,B-OG
than,O
for,O
women,B-OG
can,O
possibly,O
be,O
explained,O
by,O
this,O
difference,O
since,O
earlier,O
studies,O
found,O
that,O
women,B-OG
are,O
likely,O
to,O
give,O
a,O
greater,O
emphasis,O
than,O
men,B-OG
to,O
appearance,O
as,O
part,O
of,O
the,O
concept,O
body,O
image,O
[,O
30,O
",",O
82,O
].,O
The,O
moderate,O
associations,O
between,O
the,O
DBIQ,O
-,O
NL,O
and,O
the,O
OQ,O
-,O
45,O
and,O
RSES,O
confirm,O
the,O
relation,O
between,O
body,O
image,O
",",O
psychosocial,O
well,O
-,O
being,O
and,O
self,O
-,O
esteem,O
and,O
its,O
importance,O
when,O
assessing,O
non,O
-,O
clinical,O
samples,O
[,O
5,O
",",O
6,O
].,O
Correlations,O
between,O
the,O
subscales,O
were,O
relatively,O
small,O
",",O
providing,O
support,O
for,O
the,O
multidimensionality,O
of,O
the,O
instrument,O
.,O
Validation,O
of,O
the,O
subscales,O
for,O
physical,O
contact,O
and,O
vitality,O
by,O
correlating,O
these,O
with,O
other,O
indices,O
showed,O
good,O
construct,O
validity,O
.,O
Implications,O
for,O
the,O
use,O
of,O
the,O
DBIQ,O
-,O
NL,O
and,O
further,O
research,O
The,O
present,O
study,O
on,O
the,O
psychometric,O
properties,O
of,O
the,O
DBIQ,O
in,O
a,O
Dutch,O
non,O
-,O
clinical,O
sample,O
shows,O
a,O
factor,O
structure,O
and,O
model,O
fit,O
that,O
are,O
satisfactory,O
and,O
motivate,O
further,O
study,O
.,O
In,O
view,O
of,O
our,O
aim,O
to,O
make,O
an,O
instrument,O
available,O
in,O
Dutch,O
language,O
measuring,O
body,O
image,O
as,O
a,O
multifaceted,O
construct,O
in,O
a,O
non,O
-,O
clinical,O
as,O
well,O
as,O
in,O
a,O
clinical,O
population,O
",",O
future,O
research,O
will,O
have,O
to,O
address,O
a,O
variety,O
of,O
clinical,O
samples,O
.,O
These,O
further,O
evaluations,O
should,O
also,O
pay,O
attention,O
to,O
measurement,O
invariance,O
across,O
sex,O
and,O
age,O
.,O
Another,O
issue,O
of,O
importance,O
in,O
clinical,O
samples,O
is,O
the,O
intimate,O
and,O
for,O
a,O
substantial,O
group,O
of,O
patients,O
possibly,O
trauma,O
related,O
nature,O
of,O
the,O
subscale,O
sexual,O
fulfillment,O
.,O
Applicability,O
of,O
this,O
subscale,O
still,O
needs,O
to,O
be,O
evaluated,O
.,O
On,O
the,O
other,O
hand,O
",",O
because,O
both,O
clinicians,O
and,O
patients,O
seem,O
to,O
be,O
reluctant,O
to,O
discuss,O
issues,O
concerning,O
sexuality,O
",",O
a,O
reluctance,O
that,O
may,O
also,O
be,O
related,O
to,O
cultural,O
or,O
religious,O
background,O
",",O
addressing,O
sexuality,O
in,O
a,O
self,O
-,O
report,O
questionnaire,O
may,O
also,O
make,O
it,O
easier,O
for,O
both,O
client,O
and,O
therapist,O
to,O
pay,O
attention,O
to,O
this,O
relevant,O
theme,O
[,O
28,O
].,O
A,O
recent,O
study,O
using,O
the,O
DBIQ,O
-,O
NL,O
in,O
a,O
broad,O
clinical,O
sample,O
including,O
mood,B-DS
disorders,I-DS
",",O
anxiety,B-DS
disorders,I-DS
",",O
adjustment,B-DS
disorder,I-DS
",",O
post,B-DS
-,I-DS
traumatic,I-DS
stress,I-DS
disorder,I-DS
",",O
eating,B-DS
disorders,I-DS
",",O
schizophrenia,B-DS
and,I-DS
other,I-DS
psychotic,I-DS
disorders,I-DS
[,O
83,O
],O
gave,O
a,O
first,O
indication,O
of,O
the,O
clinical,O
usefulness,O
of,O
the,O
scale,O
.,O
The,O
study,O
suggests,O
that,O
body,O
image,O
is,O
a,O
common,O
problem,O
occurring,O
in,O
most,O
patients,O
with,O
mental,B-DS
disorders,I-DS
.,O
Body,O
acceptance,O
and,O
sexual,O
fulfillment,O
were,O
the,O
most,O
differentiating,O
aspects,O
of,O
body,O
image,O
between,O
diagnoses,O
.,O
Surprisingly,O
",",O
vitality,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
various,O
disorders,O
.,O
It,O
may,O
be,O
concluded,O
that,O
the,O
DBIQ,O
has,O
potential,O
surplus,O
value,O
in,O
the,O
field,O
of,O
body,O
image,O
since,O
it,O
covers,O
a,O
broad,O
range,O
of,O
body,O
image,O
dimensions,O
and,O
includes,O
important,O
dimensions,O
such,O
as,O
touch,O
and,O
sexuality,O
that,O
are,O
not,O
well,O
represented,O
in,O
other,O
measures,O
of,O
body,O
image,O
.,O
Supporting,O
information,O
Distribution,O
of,O
age,O
in,O
the,O
two,O
samples,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Dresden,O
Body,O
Image,O
Questionnaire,O
(,O
DBIQ,O
"),",O
Dutch,O
version,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
DBIQ,O
-,O
NL,O
:,O
Item,O
means,O
and,O
standard,O
deviations,O
sample,O
1,O
;,O
item,O
means,O
and,O
standard,O
deviations,O
per,O
sex,O
and,O
age,O
group,O
sample,O
1,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Standardized,O
factor,O
loadings,O
full,O
and,O
reduced,O
item,O
sub,O
-,O
scales,O
.,O
(,O
DOCX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
(,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Sample,O
1,O
.,O
(,O
SAV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Sample,O
2,O
.,O
(,O
SAV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Genetics,O
of,O
longevity,O
.,O
data,O
from,O
the,O
studies,O
on,O
Sicilian,O
centenarians,O
The,O
demographic,O
and,O
social,O
changes,O
of,O
the,O
past,O
decades,O
have,O
determined,O
improvements,O
in,O
public,O
health,O
and,O
longevity,O
.,O
So,O
",",O
the,O
number,O
of,O
centenarians,O
is,O
increasing,O
as,O
a,O
worldwide,O
phenomenon,O
.,O
Scientists,O
have,O
focused,O
their,O
attention,O
on,O
centenarians,O
as,O
optimal,O
model,O
to,O
address,O
the,O
biological,O
mechanisms,O
of,O
"""",O
successful,O
and,O
unsuccessful,O
ageing,O
""".",O
They,O
are,O
equipped,O
to,O
reach,O
the,O
extreme,O
limits,O
of,O
human,B-OG
life,O
span,O
and,O
",",O
most,O
importantly,O
",",O
to,O
show,O
relatively,O
good,O
health,O
",",O
being,O
able,O
to,O
perform,O
their,O
routine,O
daily,O
life,O
and,O
to,O
escape,O
fatal,O
age,O
-,O
related,O
diseases,O
",",O
such,O
as,O
cardiovascular,B-DS
diseases,I-DS
and,O
cancer,B-DS
.,O
Thus,O
",",O
particular,O
attention,O
has,O
been,O
centered,O
on,O
their,O
genetic,O
background,O
and,O
immune,O
system,O
.,O
In,O
this,O
review,O
",",O
we,O
report,O
our,O
data,O
gathered,O
for,O
over,O
10,O
years,O
in,O
Sicilian,O
centenarians,O
.,O
Based,O
on,O
results,O
obtained,O
",",O
we,O
suggest,O
longevity,O
as,O
the,O
result,O
of,O
an,O
optimal,O
performance,O
of,O
immune,O
system,O
and,O
an,O
over,O
-,O
expression,O
of,O
anti,O
-,O
inflammatory,O
sequence,O
variants,O
of,O
immune,O
/,O
inflammatory,O
genes,O
.,O
However,O
",",O
as,O
well,O
known,O
",",O
genetic,O
",",O
epigenetic,O
",",O
stochastic,O
and,O
environmental,O
factors,O
seem,O
to,O
have,O
a,O
crucial,O
role,O
in,O
ageing,O
and,O
longevity,O
.,O
Epigenetics,O
is,O
associated,O
with,O
ageing,O
",",O
as,O
demonstrated,O
in,O
many,O
studies,O
.,O
In,O
particular,O
",",O
ageing,O
is,O
associated,O
with,O
a,O
global,O
loss,O
of,O
methylation,O
state,O
.,O
Thus,O
",",O
the,O
aim,O
of,O
future,O
studies,O
will,O
be,O
to,O
analyze,O
the,O
weight,O
of,O
epigenetic,O
changes,O
in,O
ageing,O
and,O
longevity,O
.,O
Introduction,O
Data,O
from,O
centenarian,O
offspring,O
As,O
well,O
known,O
",",O
life,O
expectancy,O
is,O
a,O
familial,O
trait,O
and,O
longevity,O
is,O
determined,O
by,O
different,O
factors,O
.,O
In,O
particular,O
",",O
the,O
environmental,O
milieu,O
and,O
genetic,O
background,O
play,O
a,O
central,O
role,O
.,O
As,O
demonstrated,O
by,O
many,O
epidemiological,O
studies,O
",",O
family,O
members,O
of,O
long,O
-,O
lived,O
subjects,O
have,O
a,O
significant,O
survival,O
advantage,O
compared,O
to,O
general,O
population,O
.,O
In,O
this,O
context,O
",",O
the,O
study,O
of,O
centenarian,O
offspring,O
(,O
CO,O
"),",O
a,O
group,O
of,O
healthy,O
elderly,O
people,O
with,O
a,O
familiar,O
history,O
of,O
longevity,O
",",O
might,O
help,O
gerontologists,O
to,O
better,O
identify,O
the,O
correlation,O
between,O
genetic,O
profile,O
and,O
hope,O
of,O
a,O
healthy,O
ageing,O
.,O
Previous,O
studies,O
have,O
reported,O
that,O
CO,O
",",O
like,O
their,O
centenarian,O
parents,O
",",O
have,O
genetic,O
and,O
immune,O
system,O
advantages,O
",",O
which,O
reflect,O
a,O
minor,O
risk,O
to,O
develop,O
major,O
age,O
-,O
related,O
diseases,O
",",O
such,O
as,O
cardiovascular,B-DS
diseases,I-DS
",",O
hypertension,B-DS
or,O
diabetes,B-DS
mellitus,I-DS
as,O
well,O
as,O
cancer,B-DS
[,O
1,O
",",O
2,O
].,O
The,O
lower,O
cardiovascular,B-DS
disease,I-DS
risk,O
in,O
CO,O
suggests,O
the,O
probability,O
that,O
CO,O
have,O
some,O
protective,O
factors,O
against,O
atherosclerosis,B-DS
",",O
such,O
as,O
a,O
good,O
lipid,O
profile,O
.,O
Male,O
CO,O
have,O
higher,O
plasma,O
HDL,O
-,O
C,O
levels,O
and,O
lower,O
plasma,O
LDL,O
-,O
C,O
levels,O
.,O
Since,O
lipid,O
profile,O
is,O
directly,O
correlated,O
to,O
atherosclerotic,B-DS
cardiovascular,I-DS
diseases,I-DS
",",O
this,O
metabolic,O
feature,O
could,O
preserve,O
CO,O
both,O
to,O
develop,O
these,O
diseases,O
and,O
",",O
as,O
consequence,O
",",O
to,O
reach,O
a,O
healthy,O
ageing,O
and,O
longer,O
survival,O
[,O
3,O
].,O
Furthermore,O
",",O
Rose,O
et,O
al,O
.,O
[,O
4,O
],O
reported,O
that,O
centenarians,O
and,O
CO,O
show,O
significantly,O
higher,O
levels,O
of,O
heteroplasmy,O
in,O
mtDNA,O
control,O
region,O
than,O
controls,O
",",O
a,O
favorable,O
condition,O
for,O
longevity,O
.,O
In,O
these,O
last,O
years,O
",",O
some,O
researchers,O
have,O
speculated,O
about,O
the,O
distinctive,O
immunological,O
profile,O
of,O
offspring,O
enriched,O
for,O
longevity,O
respect,O
to,O
the,O
immunological,O
features,O
of,O
coeval,O
elderly,O
.,O
The,O
cytomegalovirus,B-OG
(,O
CMV,B-OG
),O
is,O
one,O
of,O
the,O
most,O
common,O
viruses,B-OG
that,O
affect,O
elderly,O
people,O
.,O
Many,O
evidences,O
have,O
shown,O
that,O
CMV,B-DS
infection,I-DS
may,O
influence,O
the,O
T,O
cell,O
subset,O
distribution,O
",",O
having,O
an,O
essential,O
role,O
in,O
immunosenescence,O
[,O
5,O
-,O
7,O
].,O
CMV,B-DS
infection,I-DS
is,O
strongly,O
related,O
to,O
both,O
a,O
reduction,O
of,O
CD8,B-GP
+,O
CD45,B-GP
+,O
CCR7,B-GP
+,O
CD27,B-GP
+,O
CD28,B-GP
+,O
naïve,O
T,O
cells,O
and,O
to,O
a,O
contemporarily,O
increase,O
of,O
CD8,B-GP
+,O
CD45RA,B-GP
-,O
CCR7,B-GP
-,O
CD27,B-GP
-,O
CD28,B-GP
-,O
late,O
differentiated,O
effector,O
memory,O
and,O
CD45RA,B-GP
-,O
re,O
-,O
expressing,O
T,O
cells,O
.,O
These,O
parameters,O
are,O
considered,O
typical,O
of,O
immunosenescence,O
in,O
elderly,O
.,O
Recently,O
",",O
it,O
has,O
been,O
demonstrated,O
that,O
CMV,B-OG
-,O
seropositive,O
offspring,O
of,O
long,O
-,O
lived,O
people,O
don,O
',O
t,O
show,O
the,O
age,O
-,O
associated,O
decrease,O
of,O
naïve,O
T,O
cells,O
.,O
On,O
the,O
other,O
hand,O
",",O
memory,O
T,O
cell,O
subsets,O
above,O
described,O
do,O
not,O
increase,O
in,O
offspring,O
of,O
long,O
-,O
lived,O
families,O
",",O
differently,O
from,O
that,O
observed,O
in,O
age,O
-,O
matched,O
controls,O
[,O
8,O
].,O
It,O
has,O
been,O
also,O
demonstrated,O
that,O
CMV,B-OG
-,O
seropositive,O
offspring,O
of,O
long,O
-,O
lived,O
people,O
have,O
reduced,O
levels,O
of,O
CD8,B-GP
+,O
T,O
cells,O
expressing,O
CD57,B-GP
and,O
KLRG1,B-GP
",",O
sometimes,O
referred,O
as,O
"""",O
marker,O
of,O
senescence,O
""",",O
when,O
compared,O
to,O
their,O
CMV,B-OG
-,O
infected,O
age,O
-,O
matched,O
controls,O
.,O
The,O
reduction,O
of,O
effector,O
memory,O
T,O
cells,O
lacking,O
the,O
expression,O
of,O
CD27,B-GP
and,O
CD28,B-GP
and,O
expressing,O
CD57,B-GP
and,O
KLRG1,B-GP
",",O
observed,O
in,O
CMV,B-OG
-,O
infected,O
offspring,O
could,O
explain,O
their,O
high,O
proliferative,O
response,O
against,O
CMV,B-OG
.,O
The,O
CMV,B-OG
-,O
seropositive,O
offspring,O
have,O
also,O
shown,O
significantly,O
lower,O
CRP,B-GP
levels,O
compared,O
to,O
their,O
CMV,B-OG
-,O
seropositive,O
age,O
-,O
matched,O
controls,O
that,O
could,O
be,O
related,O
to,O
a,O
lower,O
pro,O
-,O
inflammatory,O
status,O
[,O
8,O
].,O
During,O
ageing,O
",",O
B,O
cell,O
compartment,O
also,O
shows,O
significant,O
modifications,O
in,O
numbers,O
and,O
functions,O
[,O
9,O
-,O
12,O
].,O
In,O
fact,O
",",O
advanced,O
age,O
is,O
per,O
se,O
a,O
condition,O
characterized,O
by,O
lack,O
of,O
B,O
clonotypic,O
immune,O
response,O
to,O
new,O
extracellular,O
pathogens,O
.,O
In,O
any,O
event,O
",",O
data,O
are,O
suggesting,O
that,O
the,O
loss,O
of,O
naive,O
B,O
cells,O
could,O
represent,O
a,O
hallmark,O
of,O
immunosenescence,O
[,O
13,O
].,O
On,O
the,O
other,O
hand,O
",",O
a,O
B,O
cell,O
population,O
lacking,O
of,O
both,O
IgD,B-GP
and,O
CD27,B-GP
resulted,O
increased,O
in,O
healthy,O
elderly,O
[,O
14,O
].,O
We,O
have,O
suggested,O
that,O
this,O
IgD,B-GP
-,O
CD27,B-GP
-,O
B,O
cell,O
subset,O
is,O
a,O
population,O
of,O
memory,O
B,O
cells,O
lacking,O
CD27,B-GP
",",O
a,O
typical,O
memory,O
marker,O
",",O
likely,O
considered,O
a,O
late,O
memory,O
exhausted,O
B,O
cell,O
subset,O
(,O
Table,O
1,O
),O
[,O
14,O
-,O
16,O
].,O
This,O
population,O
resulted,O
also,O
increased,O
in,O
active,O
Lupus,B-DS
patients,O
[,O
17,O
"],",O
in,O
healthy,O
subjects,O
challenged,O
with,O
respiratory,B-OG
syncitial,I-OG
virus,I-OG
[,O
18,O
"],",O
and,O
in,O
HIV,B-DS
patients,O
[,O
19,O
].,O
CO,O
don,O
',O
t,O
show,O
the,O
typical,O
naïve,O
/,O
memory,O
B,O
cell,O
shift,O
observed,O
in,O
elderly,O
.,O
Although,O
a,O
decreased,O
B,O
cell,O
count,O
was,O
observed,O
in,O
CO,O
and,O
their,O
age,O
-,O
matched,O
controls,O
",",O
it,O
has,O
been,O
demonstrated,O
that,O
naïve,O
B,O
cells,O
(,O
IgD,B-GP
+,O
CD27,B-GP
-),O
were,O
more,O
abundant,O
and,O
DN,O
B,O
cells,O
(,O
IgD,B-GP
-,O
CD27,B-GP
-),O
were,O
significantly,O
decreased,O
",",O
as,O
looked,O
similarly,O
in,O
young,O
people,O
[,O
20,O
].,O
This,O
B,O
cells,O
distribution,O
in,O
CO,O
could,O
suggest,O
that,O
antigenic,O
load,O
or,O
inflammatory,O
environment,O
play,O
a,O
central,O
role,O
in,O
exhaustion,O
of,O
the,O
B,O
cell,O
branch,O
.,O
It,O
is,O
well,O
documented,O
that,O
the,O
quality,O
and,O
the,O
size,O
of,O
the,O
humoral,O
immune,O
response,O
declines,O
with,O
age,O
[,O
15,O
",",O
21,O
-,O
26,O
].,O
This,O
change,O
is,O
characterized,O
by,O
lower,O
antibody,O
responses,O
and,O
decreased,O
production,O
of,O
high,O
affinity,O
antibodies,O
.,O
The,O
evaluation,O
of,O
IgM,B-GP
secreted,O
in,O
CO,O
serum,O
shows,O
that,O
the,O
values,O
are,O
within,O
the,O
range,O
of,O
the,O
levels,O
observed,O
in,O
young,O
subjects,O
[,O
20,O
].,O
In,O
this,O
way,O
",",O
CO,O
could,O
have,O
a,O
bigger,O
advantage,O
to,O
fight,O
against,O
new,O
infections,B-DS
and,O
appropriately,O
respond,O
to,O
vaccinations,O
",",O
giving,O
them,O
a,O
selective,O
advantage,O
for,O
longevity,O
in,O
healthiness,O
.,O
Main,O
modifications,O
of,O
B,O
cells,O
and,O
B,O
cells,O
products,O
in,O
elderly,O
human,B-OG
observed,O
in,O
our,O
laboratory,O
B,O
cells,O
or,O
B,O
cells,O
products,O
Changes,O
References,O
Total,O
B,O
cells,O
(,O
percentage,O
),O
↓,O
[,O
9,O
],O
CD19,B-GP
+,O
CD5,B-GP
+,O
B1,O
cells,O
(,O
percentage,O
and,O
absolute,O
number,O
),O
↓,O
[,O
10,O
],O
IgG,B-GP
",",O
IgA,B-GP
↑,O
[,O
11,O
],O
IgM,B-GP
",",O
IgD,B-GP
↓,O
[,O
11,O
],O
IgE,O
=,O
[,O
11,O
],O
Autoantibodies,O
↑,O
[,O
12,O
],O
Naive,O
(,O
IgD,B-GP
+,O
CD27,B-GP
-),O
↓,O
[,O
13,O
],O
DN,O
(,O
IgD,B-GP
-,O
CD27,B-GP
-),O
↑,O
[,O
14,O
-,O
16,O
],O
In,O
conclusion,O
",",O
individuals,O
genetically,O
enriched,O
for,O
longevity,O
possess,O
immune,O
different,O
signatures,O
respect,O
to,O
those,O
of,O
the,O
general,O
population,O
(,O
Table,O
2,O
).,O
This,O
suggests,O
the,O
idea,O
of,O
the,O
"""",O
familiar,O
youth,O
"""",O
of,O
the,O
immune,O
system,O
.,O
In,O
addition,O
",",O
the,O
lower,O
pro,O
-,O
inflammatory,O
status,O
in,O
CMV,B-OG
-,O
infected,O
offspring,O
of,O
long,O
-,O
lived,O
people,O
might,O
represent,O
an,O
optimal,O
advantage,O
for,O
healthy,O
longevity,O
and,O
against,O
mortality,O
associated,O
to,O
major,O
age,O
-,O
related,O
diseases,O
.,O
Cellular,O
and,O
humoral,O
immune,O
modification,O
in,O
offspring,O
from,O
longevity,O
families,O
compared,O
to,O
their,O
AM,O
controls,O
T,O
and,O
B,O
cell,O
Phenotypes,O
and,O
Products,O
Changes,O
References,O
Naïve,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD8,B-GP
+,O
CD45RA,B-GP
+,O
CCR7,B-GP
+,O
CD27,B-GP
+,O
CD28,B-GP
+),O
Increase,O
[,O
8,O
],O
Late,O
differentiated,O
effector,O
memory,O
T,O
cells,O
(,O
CD3,B-GP
+,O
CD8,B-GP
+,O
CD45RA,B-GP
-,O
CCR7,B-GP
-,O
CD27,B-GP
-,O
CD28,B-GP
-),O
Decrease,O
[,O
8,O
],O
TEMRA,O
(,O
CD3,B-GP
+,O
CD8,B-GP
+,O
CD45RA,B-GP
+,O
CCR7,B-GP
-,O
CD27,B-GP
-,O
CD28,B-GP
-),O
Decrease,O
[,O
8,O
],O
Naïve,O
B,O
cells,O
(,O
IgD,B-GP
+,O
CD27,B-GP
-),O
Increase,O
[,O
20,O
],O
Double,O
Negative,O
B,O
cells,O
(,O
IgG,B-GP
+/,O
IgA,B-GP
+,O
IgD,B-GP
-,O
CD27,B-GP
-),O
Decrease,O
[,O
20,O
],O
Serum,O
IgM,B-GP
Increase,O
[,O
20,O
],O
Gender,O
and,O
longevity,O
A,O
characteristic,O
enigma,O
of,O
longevity,O
is,O
the,O
gender,O
and,O
the,O
social,O
phenomenon,O
of,O
"""",O
feminization,O
of,O
old,O
age,O
""".",O
The,O
demographic,O
and,O
social,O
changes,O
of,O
the,O
past,O
decades,O
",",O
responsible,O
for,O
longevity,O
and,O
the,O
improvements,O
in,O
public,O
health,O
",",O
have,O
created,O
new,O
and,O
often,O
very,O
dissimilar,O
realties,O
for,O
women,O
and,O
men,O
.,O
People,O
are,O
all,O
aware,O
that,O
they,O
differ,O
in,O
their,O
anatomy,O
and,O
physiology,O
",",O
but,O
also,O
in,O
more,O
complex,O
traits,O
",",O
such,O
as,O
lifespan,O
(,O
in,O
Italy,O
",",O
78,O
.,O
8,O
years,O
for,O
men,O
and,O
84,O
.,O
1,O
years,O
for,O
women,O
",",O
respectively,O
),O
and,O
mortality,O
[,O
27,O
-,O
29,O
].,O
No,O
conclusive,O
explanation,O
for,O
these,O
new,O
differences,O
is,O
actually,O
demonstrated,O
.,O
An,O
intricate,O
interaction,O
between,O
environmental,O
",",O
social,O
structural,O
",",O
behavioural,O
(,O
i,O
.,O
e,O
.,O
the,O
complex,O
pattern,O
of,O
roles,O
and,O
values,O
that,O
define,O
what,O
is,O
thought,O
as,O
masculine,O
and,O
feminine,O
),O
and,O
genetic,O
factors,O
have,O
been,O
suggested,O
as,O
the,O
more,O
probable,O
reason,O
[,O
30,O
-,O
32,O
].,O
From,O
a,O
genetic,O
prospective,O
",",O
our,O
suggestion,O
based,O
on,O
the,O
studies,O
in,O
Sicilian,O
population,O
supports,O
a,O
female,O
-,O
specific,O
gene,O
-,O
longevity,O
association,O
",",O
by,O
emphasizing,O
the,O
paradoxical,O
role,O
of,O
socio,O
-,O
cultural,O
habits,O
in,O
female,O
longevity,O
[,O
33,O
].,O
This,O
concerns,O
the,O
HFE,B-GP
gene,O
",",O
the,O
most,O
telomeric,O
HLA,B-GP
class,I-GP
I,I-GP
gene,O
",",O
codifying,O
for,O
a,O
class,O
I,O
α,O
chain,O
",",O
the,O
HFE,B-GP
protein,O
",",O
which,O
seemingly,O
no,O
longer,O
participates,O
in,O
immunity,O
.,O
It,O
has,O
lost,O
its,O
ability,O
to,O
bind,O
peptides,O
due,O
to,O
a,O
definitive,O
closure,O
of,O
the,O
antigen,O
binding,O
cleft,O
that,O
prevents,O
peptide,O
binding,O
and,O
presentation,O
.,O
The,O
HFE,B-GP
protein,O
",",O
expressed,O
on,O
crypt,O
enterocytes,O
of,O
the,O
duodenum,O
",",O
regulates,O
the,O
iron,O
uptake,O
by,O
intestinal,O
cells,O
",",O
having,O
acquired,O
the,O
ability,O
to,O
form,O
complex,O
with,O
the,O
receptor,O
for,O
iron,O
-,O
binding,O
transferring,O
.,O
Mutations,O
in,O
HFE,B-GP
gene,O
are,O
associated,O
with,O
hereditary,B-DS
hemochromatosis,I-DS
",",O
a,O
disorder,O
caused,O
by,O
excessive,O
iron,O
uptake,O
[,O
34,O
",",O
35,O
].,O
Three,O
common,O
mutations,O
",",O
C282Y,O
",",O
H63D,O
and,O
S65C,O
",",O
have,O
been,O
identified,O
in,O
HFE,B-GP
gene,O
.,O
In,O
particular,O
",",O
the,O
C282Y,O
mutation,O
(,O
a,O
cysteine,O
-,O
to,O
-,O
tyrosine,O
mutation,O
at,O
amino,O
acid,O
282,O
),O
destroys,O
its,O
ability,O
to,O
make,O
up,O
a,O
heterodimer,O
with,O
β2,B-GP
-,I-GP
microglobulin,I-GP
.,O
The,O
defective,O
HFE,B-GP
protein,O
fails,O
to,O
associate,O
to,O
the,O
transferring,B-GP
receptor,I-GP
",",O
and,O
the,O
complex,O
cannot,O
be,O
transported,O
to,O
the,O
surface,O
of,O
the,O
duodenal,O
crypt,O
cells,O
.,O
As,O
a,O
consequence,O
",",O
in,O
homozygous,O
people,O
",",O
two,O
to,O
three,O
times,O
the,O
normal,O
amount,O
of,O
iron,O
is,O
absorbed,O
from,O
food,O
by,O
the,O
intestine,O
",",O
resulting,O
in,O
end,O
-,O
organ,O
damage,O
and,O
reducing,O
lifespan,O
.,O
Two,O
other,O
mutations,O
",",O
H63D,O
(,O
a,O
histidine,O
to,O
aspartate,O
at,O
amino,O
acid,O
63,O
),O
and,O
S65C,O
(,O
a,O
serine,O
to,O
cysteine,O
at,O
amino,O
acid,O
65,O
"),",O
are,O
associated,O
with,O
milder,O
forms,O
of,O
this,O
disease,O
[,O
34,O
",",O
35,O
].,O
An,O
association,O
between,O
C282Y,O
mutation,O
and,O
longevity,O
characterizes,O
the,O
Sicilian,O
population,O
studied,O
[,O
33,O
].,O
In,O
particular,O
",",O
women,O
carriers,O
of,O
C282Y,O
mutation,O
had,O
a,O
higher,O
frequency,O
among,O
the,O
oldest,O
old,O
compared,O
to,O
control,O
women,O
(,O
Table,O
3,O
).,O
Thus,O
",",O
the,O
C282Y,O
mutation,O
may,O
confer,O
a,O
selective,O
advantage,O
in,O
terms,O
of,O
longevity,O
in,O
Sicilian,O
women,O
.,O
Considering,O
the,O
historical,O
and,O
social,O
context,O
in,O
which,O
the,O
generation,O
of,O
women,O
under,O
study,O
lived,O
",",O
our,O
data,O
seem,O
to,O
propose,O
that,O
the,O
possession,O
of,O
iron,O
-,O
sparing,O
alleles,O
significantly,O
increases,O
the,O
possibility,O
for,O
women,O
to,O
reach,O
longevity,O
.,O
For,O
instance,O
",",O
in,O
Sicily,O
",",O
many,O
pregnancies,O
and,O
an,O
iron,O
-,O
poor,O
diet,O
",",O
consisting,O
mainly,O
in,O
grains,O
",",O
vegetables,O
",",O
and,O
fruits,O
",",O
were,O
still,O
the,O
rule,O
for,O
women,O
born,O
at,O
the,O
beginning,O
of,O
last,O
century,O
.,O
In,O
fact,O
",",O
meat,O
was,O
available,O
for,O
men,O
but,O
not,O
for,O
women,O
;,O
this,O
clearly,O
explains,O
how,O
genetic,O
background,O
also,O
interacts,O
with,O
culture,O
habits,O
[,O
30,O
",",O
31,O
",",O
33,O
].,O
Data,O
from,O
our,O
investigations,O
in,O
Sicilian,O
population,O
Gene,O
Alleles,O
of,O
genetic,O
variants,O
Centenarians,O
Young,O
controls,O
(<,O
55,O
years,O
),O
P,O
N,O
=,O
35,O
females,O
N,O
=,O
106,O
females,O
HFE,B-GP
C282,O
47,O
(,O
84,O
%),O
132,O
(,O
0,O
%),O
8,O
.,O
3,O
×,O
10,O
-,O
5,O
[,O
33,O
],O
282Y,O
9,O
(,O
16,O
%),O
0,O
(,O
0,O
%),O
Genes,O
Alleles,O
of,O
SNPs,O
or,O
genetic,O
variants,O
Centenarians,O
Young,O
controls,O
(<,O
55,O
years,O
),O
MI,O
patients,O
(<,O
55,O
years,O
),O
P,O
N,O
=,O
55,O
males,O
N,O
=,O
127,O
males,O
N,O
=,O
105,O
males,O
TLR4,B-GP
+,O
896A,O
94,O
(,O
85,O
.,O
4,O
%),O
239,O
(,O
94,O
.,O
1,O
%),O
205,O
(,O
97,O
.,O
6,O
%),O
<,O
0,O
.,O
001,O
[,O
49,O
],O
+,O
896,O
G,O
16,O
(,O
14,O
.,O
6,O
%),O
15,O
(,O
5,O
.,O
9,O
%),O
5,O
(,O
2,O
.,O
4,O
%),O
N,O
=,O
123,O
males,O
N,O
=,O
136,O
males,O
N,O
=,O
133,O
males,O
CCR5,B-GP
WT,O
221,O
(,O
89,O
.,O
8,O
%),O
252,O
(,O
92,O
.,O
6,O
%),O
263,O
(,O
98,O
.,O
8,O
%),O
0,O
.,O
00006,O
[,O
48,O
],O
Δ32,O
25,O
(,O
10,O
.,O
2,O
%),O
20,O
(,O
7,O
.,O
4,O
%),O
3,O
(,O
1,O
.,O
2,O
%),O
N,O
=,O
96,O
males,O
N,O
=,O
170,O
males,O
N,O
=,O
140,O
males,O
Cox,B-GP
-,I-GP
2,I-GP
-,O
765,O
G,O
122,O
(,O
63,O
.,O
5,O
%),O
240,O
(,O
70,O
.,O
6,O
%),O
232,O
(,O
82,O
.,O
8,O
%),O
0,O
.,O
000007,O
[,O
47,O
],O
-,O
765,O
C,O
70,O
(,O
36,O
.,O
5,O
%),O
100,O
(,O
29,O
.,O
4,O
%),O
48,O
(,O
17,O
.,O
2,O
%),O
5,B-GP
-,I-GP
Lo,I-GP
-,O
1708,O
G,O
180,O
(,O
93,O
.,O
7,O
%),O
302,O
(,O
88,O
.,O
8,O
%),O
224,O
(,O
80,O
%),O
0,O
.,O
00003,O
[,O
47,O
],O
-,O
1708A,O
12,O
(,O
6,O
.,O
3,O
%),O
38,O
(,O
11,O
.,O
2,O
%),O
56,O
(,O
20,O
%),O
0,O
.,O
001,O
21,O
C,O
176,O
(,O
91,O
.,O
7,O
%),O
299,O
(,O
88,O
%),O
225,O
(,O
80,O
.,O
4,O
%),O
21,O
T,O
16,O
(,O
8,O
.,O
3,O
%),O
41,O
(,O
12,O
%),O
55,O
(,O
19,O
.,O
6,O
%),O
Genes,O
Alleles,O
of,O
SNPs,O
or,O
genetic,O
variants,O
Centenarians,O
Young,O
controls,O
(<,O
55,O
years,O
),O
PC,B-DS
patients,O
(<,O
55,O
years,O
),O
P,O
N,O
=,O
55,O
males,O
N,O
=,O
125,O
males,O
N,O
=,O
50,O
males,O
TLR4,B-GP
+,O
896A,O
94,O
(,O
85,O
%),O
235,O
(,O
94,O
%),O
99,O
(,O
99,O
%),O
0,O
.,O
001,O
[,O
54,O
],O
+,O
896,O
G,O
16,O
(,O
15,O
%),O
15,O
(,O
6,O
%),O
1,O
(,O
1,O
%),O
Cox,B-GP
-,I-GP
2,I-GP
-,O
765,O
G,O
67,O
(,O
61,O
%),O
176,O
(,O
70,O
%),O
77,O
(,O
77,O
%),O
0,O
.,O
05,O
5,B-GP
-,I-GP
Lo,I-GP
-,O
765,O
C,O
43,O
(,O
39,O
%),O
74,O
(,O
30,O
%),O
23,O
(,O
23,O
%),O
0,O
.,O
0007,O
-,O
1708,O
G,O
104,O
(,O
95,O
%),O
223,O
(,O
89,O
%),O
77,O
(,O
77,O
%),O
-,O
1708A,O
6,O
(,O
5,O
%),O
27,O
(,O
11,O
%),O
23,O
(,O
23,O
%),O
N,O
=,O
53,O
males,O
N,O
=,O
50,O
males,O
CCR5,B-GP
WT,O
95,O
(,O
89,O
.,O
6,O
%),O
97,O
(,O
97,O
%),O
0,O
.,O
03,O
[,O
53,O
],O
Δ32,O
11,O
(,O
10,O
.,O
4,O
%),O
3,O
(,O
3,O
%),O
Gene,O
Alleles,O
of,O
SNPs,O
or,O
genetic,O
variants,O
Centenarians,O
Young,O
controls,O
(<,O
55,O
years,O
),O
BF,O
patients,O
(,O
30,O
-,O
60,O
years,O
),O
P,O
N,O
=,O
42,O
females,O
N,O
=,O
42,O
females,O
N,O
=,O
42,O
females,O
TLR4,B-GP
+,O
896A,O
81,O
(,O
96,O
.,O
4,O
%),O
78,O
(,O
92,O
.,O
9,O
%),O
76,O
(,O
90,O
.,O
4,O
%),O
0,O
.,O
003,O
[,O
55,O
],O
+,O
896,O
G,O
3,O
(,O
3,O
.,O
6,O
%),O
6,O
(,O
7,O
.,O
1,O
%),O
8,O
(,O
9,O
.,O
6,O
%),O
Our,O
data,O
",",O
showing,O
the,O
relevance,O
of,O
C282Y,O
for,O
women,O
survival,O
to,O
late,O
age,O
",",O
allow,O
adding,O
another,O
piece,O
of,O
evidence,O
to,O
the,O
complex,O
puzzle,O
of,O
genetic,O
and,O
environmental,O
factors,O
involved,O
in,O
control,O
of,O
lifespan,O
in,O
humans,B-OG
.,O
The,O
complex,O
interaction,O
of,O
environmental,O
",",O
historical,O
and,O
genetic,O
factors,O
",",O
differently,O
characterizing,O
the,O
various,O
parts,O
of,O
a,O
country,O
",",O
i,O
.,O
e,O
.,O
Italy,O
",",O
likely,O
plays,O
an,O
important,O
role,O
in,O
determining,O
the,O
gender,O
-,O
specific,O
probability,O
of,O
attaining,O
longevity,O
[,O
30,O
",",O
31,O
",",O
33,O
",",O
36,O
].,O
Role,O
of,O
innate,O
immunity,O
genes,O
in,O
longevity,O
:,O
the,O
paradigmatic,O
case,O
of,O
TLR4,B-GP
",",O
CCR5,B-GP
",",O
COX,B-GP
-,I-GP
2,I-GP
and,O
5,B-GP
-,I-GP
LO,I-GP
genes,O
According,O
to,O
evolutionary,O
ageing,O
theories,O
",",O
most,O
of,O
the,O
parameters,O
influencing,O
immunosenescence,O
appear,O
to,O
be,O
under,O
genetic,O
control,O
[,O
32,O
",",O
37,O
",",O
38,O
].,O
An,O
example,O
is,O
given,O
by,O
the,O
innate,O
immune,O
system,O
",",O
involved,O
in,O
neutralizing,O
infectious,O
agents,O
[,O
39,O
].,O
It,O
plays,O
a,O
beneficial,O
role,O
until,O
the,O
time,O
of,O
reproduction,O
and,O
parental,O
care,O
.,O
In,O
old,O
age,O
",",O
a,O
period,O
largely,O
not,O
foreseen,O
by,O
evolution,O
",",O
it,O
can,O
determine,O
an,O
opposite,O
and,O
detrimental,O
effect,O
through,O
chronic,O
inflammatory,O
responses,O
"(""",O
antagonistic,O
pleiotropy,O
""")",O
[,O
38,O
",",O
40,O
].,O
Genetic,O
pro,O
-/,O
anti,O
-,O
inflammatory,O
variations,O
in,O
innate,O
immune,O
response,O
are,O
",",O
indeed,O
",",O
thought,O
to,O
influence,O
the,O
susceptibility,O
of,O
age,O
-,O
related,O
human,B-OG
diseases,O
",",O
by,O
altering,O
host,O
response,O
to,O
environmental,O
and,O
endogenous,O
stress,O
[,O
41,O
].,O
Thus,O
",",O
they,O
are,O
able,O
to,O
determine,O
a,O
negative,O
or,O
positive,O
control,O
of,O
inflammation,O
",",O
by,O
affecting,O
both,O
interactions,O
between,O
host,O
and,O
microbes,O
and,O
survival,O
of,O
the,O
individual,O
and,O
attainment,O
of,O
longevity,O
.,O
Furthermore,O
",",O
they,O
appear,O
both,O
to,O
be,O
responsible,O
",",O
at,O
least,O
in,O
large,O
part,O
",",O
for,O
different,O
men,O
and,O
women,O
strategies,O
to,O
achieve,O
longevity,O
",",O
and,O
to,O
contribute,O
to,O
the,O
preferential,O
sex,O
dimorphism,O
of,O
the,O
age,O
-,O
related,O
diseases,O
[,O
30,O
",",O
31,O
",",O
33,O
].,O
From,O
our,O
investigations,O
in,O
Sicilian,O
population,O
",",O
TLR4,B-GP
",",O
CCR5,B-GP
",",O
Cox2,B-GP
",",O
5,B-GP
-,I-GP
Lo,I-GP
genes,O
can,O
be,O
considered,O
good,O
examples,O
.,O
They,O
provide,O
an,O
ideal,O
model,O
to,O
understand,O
the,O
different,O
implications,O
of,O
their,O
genetic,O
variants,O
in,O
the,O
risk,O
of,O
age,O
-,O
related,O
diseases,O
",",O
i,O
.,O
e,O
.,O
atherosclerosis,B-DS
and,O
prostate,B-DS
cancer,I-DS
(,O
PC,B-DS
"),",O
and,O
reciprocally,O
in,O
increased,O
chance,O
to,O
attain,O
longevity,O
.,O
TLR4,B-GP
gene,O
(,O
number,O
accession,O
of,O
GenBank,O
:,O
NM,O
-,O
138554,O
.,O
1,O
),O
codifies,O
the,O
best,O
understood,O
TLR,B-GP
member,O
involved,O
in,O
recognition,O
of,O
LPS,O
",",O
the,O
prototypic,O
TLR4,B-GP
ligand,O
",",O
and,O
other,O
exogenous,O
and,O
endogenous,O
(,O
i,O
.,O
e,O
.,O
HSPs,B-GP
",",O
hyaluronic,O
acid,O
",",O
β,B-GP
-,I-GP
defensin,I-GP
-,I-GP
2,I-GP
",",O
ox,O
-,O
LDL,O
",",O
fibronectin,B-GP
and,O
amyloid,B-GP
peptide,O
),O
ligands,O
.,O
TLR4,B-GP
activation,O
implies,O
a,O
downstream,O
signaling,O
mediated,O
by,O
several,O
intracellular,O
adaptor,O
molecules,O
and,O
the,O
consequent,O
activation,O
of,O
transcription,B-GP
factors,I-GP
",",O
such,O
as,O
NF,B-GP
-,I-GP
kB,I-GP
.,O
This,O
determines,O
the,O
production,O
of,O
different,O
pro,O
/,O
anti,O
-,O
inflammatory,O
mediators,O
.,O
These,O
lasts,O
",",O
such,O
as,O
IL,B-GP
-,I-GP
10,I-GP
",",O
are,O
produced,O
by,O
the,O
parallel,O
activation,O
of,O
anti,O
-,O
inflammatory,O
pathways,O
to,O
limit,O
the,O
potential,O
tissue,O
damage,O
from,O
excessive,O
activation,O
of,O
the,O
innate,O
immune,O
system,O
[,O
42,O
].,O
SNPs,O
seem,O
to,O
modulate,O
both,O
TLR4,B-GP
activity,O
and,O
function,O
.,O
In,O
human,B-OG
",",O
only,O
two,O
SNPs,O
",",O
+,O
896A,O
/,O
G,O
(,O
Asp299Gly,O
;,O
rs4986790,O
),O
and,O
+,O
1196,O
C,O
/,O
T,O
(,O
Thr399Ile,O
;,O
rs4986791,O
"),",O
have,O
a,O
frequency,O
>,O
5,O
%.,O
They,O
induce,O
a,O
blunted,O
response,O
to,O
LPS,O
",",O
as,O
first,O
suggested,O
by,O
Arbour,O
et,O
al,O
".,",O
and,O
are,O
phenotypically,O
associated,O
to,O
changes,O
in,O
the,O
production,O
of,O
cytokines,B-GP
",",O
principally,O
those,O
carrying,O
the,O
Asp299Gly,O
mutation,O
[,O
43,O
-,O
45,O
].,O
Accordingly,O
",",O
recent,O
literature,O
data,O
suggest,O
the,O
ability,O
of,O
this,O
SNP,O
to,O
modulate,O
the,O
risk,O
of,O
major,O
age,O
-,O
related,O
diseases,O
[,O
42,O
].,O
The,O
CCR5,B-GP
gene,O
(,O
number,O
accession,O
of,O
GenBank,O
:,O
NM,O
-,O
00579,O
),O
codifies,O
for,O
a,O
G,B-GP
protein,I-GP
-,I-GP
coupled,I-GP
chemokine,I-GP
receptor,I-GP
",",O
which,O
regulates,O
trafficking,O
and,O
effector,O
functions,O
of,O
memory,O
/,O
effector,O
Th1,O
cells,O
",",O
macrophages,O
",",O
NK,O
cells,O
and,O
immature,O
dendritic,O
cells,O
.,O
CCR5,B-GP
and,O
its,O
ligands,O
are,O
important,O
molecules,O
in,O
viral,O
pathogenesis,O
.,O
Recent,O
evidence,O
has,O
also,O
demonstrated,O
the,O
role,O
of,O
CCR5,B-GP
in,O
a,O
variety,O
of,O
human,B-OG
diseases,O
",",O
ranging,O
from,O
infectious,O
and,O
inflammatory,O
age,O
-,O
related,O
diseases,O
to,O
cancer,B-DS
.,O
A,O
notable,O
variant,O
of,O
CCR5,B-GP
gene,O
is,O
a,O
32,O
bp,O
(,O
Δ32,O
),O
deletion,O
",",O
which,O
causes,O
a,O
frame,O
shift,O
mutation,O
in,O
exon,O
4,O
(,O
CCR5Δ32,O
;,O
rs333,O
),O
and,O
determines,O
stop,O
protein,O
maturation,O
and,O
loss,O
of,O
expression,O
of,O
functional,O
CCR5,B-GP
receptor,O
[,O
46,O
].,O
Accordingly,O
",",O
it,O
seems,O
to,O
have,O
a,O
protective,O
role,O
against,O
CVD,B-DS
and,O
other,O
age,O
-,O
related,O
diseases,O
",",O
such,O
as,O
PC,B-DS
.,O
It,O
",",O
indeed,O
",",O
determines,O
a,O
slower,O
progression,O
of,O
atherogenesis,B-DS
or,O
cancerogenesis,O
as,O
a,O
consequence,O
of,O
an,O
attenuated,O
inflammatory,O
response,O
.,O
COX,B-GP
-,I-GP
2,I-GP
gene,O
maps,O
in,O
the,O
1q25,O
chromosome,O
and,O
codifies,O
for,O
the,O
Cox,B-GP
-,I-GP
2,I-GP
enzyme,O
involved,O
in,O
the,O
conversion,O
of,O
arachidonic,O
acid,O
to,O
prostaglandins,O
.,O
Polymorphisms,O
regulate,O
its,O
expression,O
and,O
hence,O
prostanoid,O
biosynthesis,O
.,O
In,O
particular,O
",",O
it,O
has,O
been,O
identified,O
a,O
guanine,O
to,O
cytosine,O
substitution,O
at,O
position,O
-,O
765,O
G,O
/,O
C,O
",",O
located,O
within,O
a,O
putative,O
binding,O
site,O
for,O
the,O
transcription,B-GP
factor,I-GP
Sp1,I-GP
",",O
associated,O
to,O
a,O
reduction,O
in,O
the,O
risk,O
of,O
clinical,O
cardiovascular,O
events,O
.,O
COX,B-GP
-,I-GP
2,I-GP
is,O
expressed,O
at,O
low,O
levels,O
in,O
most,O
tissues,O
",",O
but,O
its,O
expression,O
enhances,O
under,O
inflammatory,O
stimuli,O
and,O
in,O
inflammatory,O
age,O
-,O
related,O
processes,O
",",O
i,O
.,O
e,O
.,O
atherosclerosis,B-DS
",",O
rheumatoid,B-DS
diseases,I-DS
and,O
cancer,B-DS
[,O
47,O
].,O
The,O
5,B-GP
-,I-GP
LO,I-GP
gene,O
maps,O
in,O
the,O
chromosome,O
10q11,O
.,O
2,O
and,O
codifies,O
the,O
5,B-GP
-,I-GP
Lo,I-GP
enzyme,O
involved,O
in,O
the,O
synthesis,O
of,O
LTs,O
.,O
The,O
5,B-GP
-,I-GP
LO,I-GP
pathway,O
has,O
been,O
associated,O
to,O
atherosclerosis,B-DS
in,O
mouse,B-OG
and,O
human,B-OG
histological,O
studies,O
.,O
Several,O
SNPs,O
have,O
been,O
described,O
.,O
In,O
particular,O
",",O
the,O
-,O
1708,O
G,O
/,O
A,O
",",O
-,O
1761,O
G,O
/,O
A,O
and,O
21,O
C,O
/,O
T,O
SNPs,O
in,O
promoter,O
region,O
and,O
exon,O
-,O
1,O
of,O
5,B-GP
-,I-GP
LO,I-GP
gene,O
modify,O
the,O
gene,O
transcription,O
or,O
the,O
putative,O
protein,O
[,O
47,O
].,O
An,O
over,O
-,O
expression,O
of,O
anti,O
-,O
inflammatory,O
CCR5Δ32,O
variant,O
",",O
+,O
896,O
G,O
(,O
299Gly,O
),O
TLR4,B-GP
allele,O
",",O
-,O
765,O
C,O
Cox,B-GP
-,I-GP
2,I-GP
allele,O
",",O
-,O
1708,O
G,O
and,O
21,O
C,O
5,B-GP
-,I-GP
Lo,I-GP
alleles,O
characterizes,O
male,O
Sicilian,O
centenarians,O
(,O
Table,O
3,O
),O
[,O
47,O
-,O
49,O
].,O
So,O
",",O
male,O
centenarians,O
are,O
people,O
who,O
seem,O
genetically,O
equipped,O
for,O
defeating,O
major,O
age,O
-,O
related,O
diseases,O
.,O
They,O
present,O
SNPs,O
in,O
the,O
immune,O
system,O
genome,O
(,O
i,O
.,O
e,O
.,O
SNPs,O
or,O
other,O
genetic,O
variations,O
",",O
located,O
within,O
the,O
promoter,O
regions,O
of,O
pro,O
-,O
inflammatory,O
cytokines,B-GP
),O
which,O
",",O
regulating,O
the,O
immune,O
-,O
inflammatory,O
responses,O
",",O
seem,O
to,O
be,O
associated,O
to,O
longevity,O
[,O
30,O
-,O
32,O
].,O
Furthermore,O
",",O
centenarians,O
are,O
characterized,O
by,O
marked,O
delay,O
or,O
escape,O
from,O
age,O
-,O
associated,O
diseases,O
",",O
responsible,O
for,O
the,O
high,O
mortality,O
in,O
earlier,O
ages,O
.,O
In,O
particular,O
",",O
it,O
has,O
been,O
demonstrated,O
that,O
centenarian,O
offspring,O
have,O
an,O
increased,O
likelihood,O
of,O
surviving,O
to,O
100,O
years,O
and,O
show,O
a,O
reduced,O
prevalence,O
of,O
age,O
associated,O
diseases,O
",",O
such,O
as,O
CVD,B-DS
",",O
and,O
lower,O
prevalence,O
of,O
CVD,B-DS
risk,O
factors,O
[,O
1,O
",",O
30,O
-,O
32,O
",",O
50,O
],O
Thus,O
",",O
genes,O
involved,O
in,O
CVD,B-DS
may,O
play,O
an,O
opposite,O
role,O
in,O
human,B-OG
male,O
longevity,O
.,O
Our,O
data,O
in,O
male,O
Sicilian,O
population,O
confirm,O
this,O
suggestion,O
and,O
emphasize,O
the,O
role,O
of,O
antagonistic,O
pleiotropy,O
in,O
ageing,O
and,O
longevity,O
[,O
51,O
",",O
52,O
].,O
A,O
high,O
frequency,O
of,O
proinflammatory,O
CCR5wt,O
variant,O
",",O
+,O
896A,O
TLR4,B-GP
allele,O
",",O
-,O
765,O
G,O
Cox,B-GP
-,I-GP
2,I-GP
allele,O
",",O
1708A,O
and,O
21,O
T,O
5,B-GP
-,I-GP
Lo,I-GP
alleles,O
characterizes,O
male,O
Sicilian,O
patients,O
affected,O
by,O
MI,O
(,O
Table,O
3,O
),O
[,O
47,O
-,O
49,O
].,O
In,O
a,O
recent,O
study,O
",",O
we,O
also,O
found,O
a,O
similar,O
overexpression,O
of,O
these,O
proinflammatory,O
SNPs,O
in,O
male,O
Sicilian,O
patients,O
affected,O
by,O
PC,B-DS
(,O
Table,O
3,O
).,O
Opposite,O
data,O
were,O
obtained,O
in,O
male,O
centenarians,O
[,O
53,O
",",O
54,O
].,O
In,O
contrast,O
",",O
female,O
Sicilian,O
centenarians,O
have,O
a,O
different,O
frequency,O
of,O
the,O
alleles,O
of,O
+,O
896A,O
/,O
G,O
TLR4,B-GP
SNP,O
than,O
that,O
observed,O
in,O
male,O
Sicilian,O
centenarians,O
.,O
In,O
particular,O
",",O
female,O
Sicilian,O
centenarians,O
show,O
an,O
over,O
-,O
expression,O
of,O
the,O
pro,O
-,O
inflammatory,O
+,O
896A,O
TLR4,B-GP
allele,O
respect,O
to,O
female,O
patients,O
affected,O
by,O
Boutonneuse,B-DS
fever,I-DS
and,O
age,O
-,O
matched,O
controls,O
(,O
Table,O
3,O
),O
[,O
55,O
].,O
On,O
the,O
other,O
hand,O
",",O
pro,O
-,O
inflammatory,O
responses,O
are,O
evolutionary,O
programmed,O
to,O
resist,O
fatal,O
infections,B-DS
.,O
Thus,O
",",O
it,O
is,O
not,O
surprising,O
that,O
the,O
genetic,O
background,O
of,O
people,O
that,O
survive,O
to,O
an,O
advanced,O
age,O
may,O
be,O
protective,O
against,O
infections,B-DS
[,O
55,O
].,O
Based,O
on,O
our,O
data,O
",",O
we,O
suggest,O
that,O
Sicilian,O
men,O
and,O
women,O
may,O
follow,O
different,O
trajectories,O
to,O
reach,O
longevity,O
.,O
For,O
men,O
it,O
might,O
be,O
more,O
important,O
to,O
control,O
atherogenesis,B-DS
and,O
cancerogenesis,O
",",O
whereas,O
for,O
women,O
it,O
might,O
be,O
more,O
important,O
to,O
control,O
infectious,B-DS
diseases,I-DS
[,O
30,O
",",O
31,O
].,O
In,O
order,O
to,O
confirm,O
our,O
suggestions,O
on,O
the,O
biological,O
effects,O
of,O
+,O
896A,O
/,O
G,O
TLR4,B-GP
SNP,O
and,O
its,O
role,O
in,O
the,O
pathophysiology,O
of,O
age,O
-,O
related,O
diseases,O
studied,O
(,O
i,O
.,O
e,O
.,O
MI,O
and,O
PC,B-DS
),O
and,O
longevity,O
",",O
we,O
recently,O
assessed,O
the,O
levels,O
of,O
IL,B-GP
-,I-GP
6,I-GP
",",O
TNF,B-GP
-,I-GP
α,I-GP
",",O
IL,B-GP
-,I-GP
10,I-GP
and,O
eicosanoids,O
in,O
LPS,O
-,O
stimulated,O
whole,O
blood,O
samples,O
from,O
50,O
young,O
healthy,O
Sicilians,O
",",O
screened,O
for,O
the,O
presence,O
of,O
this,O
SNP,O
.,O
Both,O
pro,O
-,O
inflammatory,O
cytokines,B-GP
and,O
eicosanoids,O
were,O
significantly,O
lower,O
in,O
carriers,O
bearing,O
the,O
+,O
896,O
G,O
TLR4,B-GP
allele,O
",",O
whereas,O
the,O
anti,O
-,O
inflammatory,O
IL,B-GP
-,I-GP
10,I-GP
values,O
were,O
higher,O
[,O
56,O
].,O
This,O
suggests,O
the,O
ability,O
of,O
the,O
+,O
896,O
G,O
TLR4,B-GP
allele,O
to,O
mediate,O
a,O
better,O
control,O
of,O
inflammatory,O
responses,O
induced,O
by,O
chronic,O
stimuli,O
",",O
so,O
likely,O
decreasing,O
the,O
effects,O
of,O
atherogenetic,O
damage,O
and,O
prostate,O
carcinogens,O
.,O
On,O
the,O
basis,O
of,O
data,O
reported,O
herein,O
",",O
some,O
suggestions,O
can,O
be,O
drawn,O
.,O
First,O
",",O
pathogen,O
load,O
",",O
by,O
interacting,O
with,O
the,O
host,O
genotype,O
",",O
determines,O
the,O
type,O
and,O
intensity,O
of,O
inflammatory,O
responses,O
",",O
according,O
to,O
the,O
pro,O
-,O
inflammatory,O
status,O
and,O
tissue,O
injury,O
",",O
implicated,O
in,O
the,O
patho,O
-,O
physiology,O
of,O
major,O
age,O
-,O
related,O
diseases,O
.,O
Second,O
",",O
adequate,O
control,O
of,O
inflammatory,O
response,O
might,O
reduce,O
the,O
risk,O
of,O
these,O
diseases,O
",",O
and,O
",",O
reciprocally,O
",",O
might,O
increase,O
the,O
chance,O
of,O
extended,O
survival,O
in,O
an,O
environment,O
with,O
reduced,O
pathogen,O
load,O
.,O
Accordingly,O
",",O
a,O
higher,O
frequency,O
of,O
the,O
anti,O
-,O
inflammatory,O
+,O
896,O
G,O
TLR4,B-GP
allele,O
has,O
been,O
observed,O
in,O
centenarians,O
[,O
49,O
].,O
Cytokine,B-GP
profile,O
:,O
a,O
biomarker,O
for,O
successful,O
ageing,O
Cytokines,B-GP
are,O
considered,O
key,O
players,O
in,O
maintaining,O
lymphocyte,O
homeostasis,O
[,O
57,O
",",O
58,O
].,O
Their,O
function,O
is,O
not,O
limited,O
to,O
induce,O
response,O
after,O
an,O
immune,O
insult,O
",",O
but,O
they,O
can,O
modulate,O
the,O
nature,O
of,O
response,O
(,O
cytotoxic,O
",",O
humoral,O
",",O
cell,O
mediated,O
",",O
inflammatory,O
or,O
allergic,O
),O
or,O
",",O
in,O
contrast,O
",",O
they,O
may,O
cause,O
non,O
-,O
responsiveness,O
and,O
active,O
immune,O
suppression,O
[,O
58,O
].,O
Furthermore,O
",",O
sequence,O
variations,O
in,O
several,O
cytokine,B-GP
genes,O
",",O
such,O
as,O
IFN,B-GP
-,I-GP
γ,I-GP
and,O
IL,B-GP
-,I-GP
10,I-GP
genes,O
",",O
have,O
been,O
demonstrated,O
to,O
be,O
associated,O
with,O
successful,O
ageing,O
and,O
longevity,O
[,O
58,O
].,O
On,O
the,O
other,O
hand,O
",",O
individual,O
changes,O
in,O
type,O
and,O
intensity,O
of,O
immune,O
response,O
affecting,O
life,O
span,O
expectancy,O
and,O
health,O
ageing,O
seem,O
to,O
have,O
a,O
genetic,O
component,O
.,O
A,O
well,O
-,O
preserved,O
immune,O
function,O
characterizing,O
the,O
successful,O
ageing,O
has,O
been,O
found,O
in,O
centenarians,O
[,O
38,O
].,O
Recent,O
evidence,O
suggests,O
that,O
centenarians,O
seem,O
to,O
be,O
genetically,O
equipped,O
gene,O
polymorphism,O
for,O
overcame,O
the,O
major,O
age,O
-,O
related,O
diseases,O
and,O
polymorphisms,O
in,O
immune,O
system,O
genes,O
involved,O
in,O
regulation,O
of,O
immune,O
responses,O
have,O
been,O
found,O
associated,O
to,O
longevity,O
.,O
In,O
particular,O
",",O
associations,O
between,O
both,O
cytokine,B-GP
gene,O
polymorphisms,O
and,O
longevity,O
",",O
and,O
differential,O
gender,O
longevity,O
in,O
males,O
and,O
females,O
",",O
and,O
reciprocally,O
to,O
age,O
-,O
related,O
diseases,O
have,O
been,O
demonstrated,O
[,O
38,O
",",O
58,O
",",O
59,O
].,O
Our,O
data,O
in,O
Sicilian,O
population,O
confirm,O
these,O
associations,O
and,O
suggest,O
that,O
differences,O
in,O
the,O
genetic,O
regulation,O
of,O
immune,O
inflammatory,O
processes,O
might,O
explain,O
the,O
reason,O
why,O
some,O
people,O
but,O
not,O
others,O
develop,O
age,O
-,O
related,O
diseases,O
and,O
why,O
some,O
develop,O
a,O
greater,O
inflammatory,O
response,O
than,O
others,O
.,O
In,O
particular,O
",",O
this,O
suggestion,O
seems,O
to,O
be,O
suitable,O
for,O
some,O
SNPs,O
in,O
IFN,B-GP
-,I-GP
γ,I-GP
and,O
IL,B-GP
-,I-GP
10,I-GP
genes,O
(,O
Table,O
4,O
),O
[,O
60,O
-,O
63,O
].,O
Cytokine,B-GP
data,O
from,O
our,O
studies,O
in,O
Sicilian,O
population,O
Gene,O
Genotypes,O
Centenarians,O
Young,O
controls,O
(<,O
55,O
years,O
),O
P,O
N,O
=,O
31,O
males,O
N,O
=,O
161,O
males,O
IL,B-GP
-,I-GP
10,I-GP
-,O
1082GG,O
18,O
(,O
58,O
%),O
55,O
(,O
34,O
%),O
<,O
0,O
.,O
025,O
[,O
61,O
],O
-,O
1083GA,O
9,O
(,O
29,O
%),O
88,O
(,O
55,O
%),O
-,O
1082AA,O
4,O
(,O
13,O
%),O
18,O
(,O
11,O
%),O
N,O
=,O
72,O
males,O
N,O
=,O
115,O
males,O
IL,B-GP
-,I-GP
10,I-GP
-,O
1082GG,O
33,O
(,O
46,O
%),O
32,O
(,O
28,O
%),O
0,O
.,O
019,O
[,O
62,O
],O
-,O
1083GA,O
34,O
(,O
47,O
%),O
64,O
(,O
56,O
%),O
-,O
1082AA,O
5,O
(,O
7,O
%),O
19,O
(,O
16,O
%),O
Centenarians,O
Young,O
controls,O
(<,O
55,O
years,O
),O
MI,O
patients,O
(<,O
55,O
years,O
),O
P,O
N,O
=,O
52,O
males,O
N,O
=,O
110,O
males,O
N,O
=,O
90,O
males,O
IL,B-GP
-,I-GP
10,I-GP
-,O
1082GG,O
25,O
(,O
48,O
.,O
1,O
%),O
26,O
(,O
23,O
.,O
6,O
%),O
17,O
(,O
18,O
.,O
9,O
%),O
0,O
.,O
003,O
[,O
63,O
],O
-,O
1083GA,O
23,O
(,O
44,O
.,O
2,O
%),O
56,O
(,O
50,O
.,O
9,O
%),O
29,O
(,O
32,O
.,O
2,O
%),O
-,O
1082AA,O
6,O
(,O
11,O
.,O
5,O
%),O
28,O
(,O
25,O
.,O
5,O
%),O
44,O
(,O
48,O
.,O
9,O
%),O
Genes,O
Alleles,O
of,O
SNP,O
Centenarians,O
Young,O
controls,O
(<,O
55,O
years,O
),O
P,O
N,O
=,O
142,O
females,O
N,O
=,O
90,O
females,O
IFN,B-GP
-,I-GP
γ,I-GP
+,O
874,O
T,O
102,O
(,O
35,O
.,O
9,O
%),O
85,O
(,O
47,O
.,O
2,O
%),O
0,O
.,O
02,O
[,O
60,O
],O
+,O
874A,O
182,O
(,O
64,O
.,O
1,O
%),O
95,O
(,O
52,O
.,O
8,O
%),O
IFN,B-GP
-,I-GP
γ,I-GP
gene,O
codifies,O
for,O
a,O
cytokine,B-GP
involved,O
in,O
defense,O
against,O
viruses,B-OG
and,O
intracellular,O
pathogens,O
",",O
and,O
in,O
induction,O
of,O
immune,O
mediated,O
inflammatory,O
responses,O
.,O
Its,O
production,O
is,O
genetically,O
regulated,O
.,O
A,O
variable,O
length,O
CA,O
repeat,O
sequence,O
in,O
the,O
first,O
intron,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
gene,O
has,O
been,O
described,O
to,O
be,O
associated,O
with,O
high,O
IFN,B-GP
-,I-GP
γ,I-GP
production,O
.,O
Furthermore,O
",",O
a,O
SNP,O
",",O
T,O
to,O
A,O
(+,O
874,O
T,O
/,O
A,O
"),",O
at,O
59,O
end,O
of,O
the,O
CA,O
repeat,O
region,O
has,O
been,O
described,O
and,O
T,O
presence,O
has,O
been,O
related,O
to,O
high,O
-,O
producing,O
microsatellite,O
allele,O
2,O
.,O
This,O
SNP,O
coincides,O
with,O
a,O
putative,O
NF,B-GP
-,I-GP
κB,I-GP
binding,O
site,O
",",O
which,O
might,O
have,O
functional,O
consequences,O
for,O
transcription,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
gene,O
.,O
Thus,O
",",O
this,O
SNP,O
might,O
directly,O
influence,O
IFN,B-GP
-,I-GP
γ,I-GP
production,O
levels,O
associated,O
to,O
CA,O
microsatellite,O
marker,O
[,O
60,O
].,O
IL,B-GP
-,I-GP
10,I-GP
gene,O
codifies,O
for,O
IL,B-GP
-,I-GP
10,I-GP
cytokine,B-GP
.,O
IL,B-GP
-,I-GP
10,I-GP
is,O
produced,O
by,O
macrophages,O
",",O
T,O
and,O
B,O
cells,O
.,O
It,O
is,O
one,O
of,O
the,O
major,O
immune,O
-,O
regulatory,O
cytokines,B-GP
",",O
usually,O
considered,O
to,O
mediate,O
potent,O
down,O
-,O
regulation,O
of,O
inflammatory,O
responses,O
.,O
IL,B-GP
-,I-GP
10,I-GP
production,O
",",O
independently,O
on,O
interaction,O
with,O
other,O
cytokine,B-GP
gene,O
products,O
",",O
is,O
generally,O
controlled,O
by,O
several,O
polymorphic,O
elements,O
in,O
the,O
5,O
',O
flanking,O
region,O
of,O
IL,B-GP
-,I-GP
10,I-GP
gene,O
.,O
Multiple,O
SNPs,O
have,O
been,O
identified,O
in,O
human,B-OG
IL,B-GP
-,I-GP
10,I-GP
5,O
',O
flanking,O
region,O
and,O
some,O
of,O
these,O
(,O
i,O
.,O
e,O
.,O
-,O
592,O
",",O
-,O
819,O
",",O
-,O
1082,O
),O
combine,O
with,O
microsatellite,O
alleles,O
to,O
form,O
haplotype,O
associated,O
with,O
differential,O
IL,B-GP
-,I-GP
10,I-GP
production,O
.,O
These,O
three,O
SNPs,O
in,O
the,O
IL,B-GP
-,I-GP
10,I-GP
proximal,O
gene,O
region,O
(,O
considered,O
potential,O
targets,O
for,O
transcription,B-GP
regulating,I-GP
factors,I-GP
),O
might,O
be,O
involved,O
in,O
genetic,O
control,O
of,O
IL,B-GP
-,I-GP
10,I-GP
production,O
",",O
even,O
if,O
contrasting,O
literature,O
data,O
have,O
been,O
reported,O
.,O
In,O
particular,O
",",O
the,O
homozygous,O
-,O
1082GG,O
genotype,O
seems,O
to,O
be,O
associated,O
with,O
higher,O
IL,B-GP
-,I-GP
10,I-GP
production,O
respect,O
to,O
G,O
/,O
A,O
heterozygous,O
and,O
AA,O
homozygous,O
genotypes,O
.,O
Furthermore,O
",",O
this,O
SNP,O
seems,O
to,O
be,O
functionally,O
relevant,O
.,O
It,O
has,O
been,O
demonstrated,O
that,O
-,O
1082,O
A,O
carriers,O
(,O
low,O
producers,O
),O
seem,O
likely,O
develop,O
a,O
major,O
number,O
of,O
chronic,B-DS
inflammatory,I-DS
diseases,I-DS
[,O
61,O
-,O
63,O
].,O
Our,O
results,O
demonstrated,O
an,O
increase,O
of,O
subjects,O
carrying,O
the,O
-,O
1082,O
G,O
IL,B-GP
-,I-GP
10,I-GP
allele,O
in,O
centenarian,O
men,O
[,O
61,O
-,O
63,O
].,O
This,O
allele,O
is,O
associated,O
to,O
significantly,O
increased,O
IL,B-GP
-,I-GP
10,I-GP
production,O
.,O
Conversely,O
",",O
we,O
observed,O
that,O
the,O
frequency,O
of,O
-,O
1082A,O
allele,O
",",O
associated,O
to,O
low,O
IL,B-GP
-,I-GP
10,I-GP
production,O
",",O
was,O
significantly,O
higher,O
in,O
MI,O
patients,O
(,O
Table,O
4,O
),O
[,O
63,O
].,O
Thus,O
",",O
high,O
IL,B-GP
-,I-GP
10,I-GP
production,O
seems,O
to,O
be,O
protective,O
vs,O
.,O
MI,O
and,O
a,O
possible,O
biomarker,O
for,O
longevity,O
.,O
People,O
with,O
exceptional,O
longevity,O
have,O
genetic,O
factors,O
(,O
i,O
.,O
e,O
.,O
protective,O
factors,O
for,O
CVD,B-DS
),O
that,O
modulate,O
ageing,O
processes,O
[,O
63,O
].,O
This,O
supports,O
the,O
opinion,O
that,O
a,O
genetic,O
background,O
protective,O
against,O
CVD,B-DS
is,O
a,O
component,O
of,O
longevity,O
.,O
On,O
the,O
other,O
hand,O
",",O
our,O
immune,O
system,O
has,O
evolved,O
to,O
control,O
pathogens,O
and,O
pro,O
-,O
inflammatory,O
responses,O
are,O
likely,O
programmed,O
by,O
evolution,O
to,O
resist,O
fatal,O
infections,B-DS
.,O
From,O
this,O
prospective,O
",",O
low,O
IL,B-GP
-,I-GP
10,I-GP
production,O
is,O
correlated,O
with,O
increased,O
resistance,O
to,O
pathogens,O
.,O
In,O
older,O
ages,O
not,O
evolutionally,O
programmed,O
",",O
increased,O
IL,B-GP
-,I-GP
10,I-GP
levels,O
might,O
better,O
control,O
inflammatory,O
responses,O
induced,O
by,O
chronic,O
vessel,O
damage,O
and,O
reduce,O
the,O
risk,O
for,O
atherogenetic,O
complications,O
.,O
These,O
conditions,O
might,O
permit,O
to,O
achieve,O
exceptional,O
ages,O
in,O
an,O
environmental,O
with,O
a,O
reduced,O
pathogen,O
load,O
[,O
63,O
].,O
In,O
contrast,O
",",O
female,O
Sicilian,O
centenarians,O
are,O
characterized,O
by,O
an,O
over,O
-,O
expression,O
of,O
+,O
874,O
INF,B-GP
-,I-GP
γ,I-GP
allele,O
(,O
Table,O
4,O
),O
[,O
60,O
].,O
The,O
INF,B-GP
-,I-GP
γ,I-GP
production,O
is,O
also,O
influenced,O
by,O
hormonal,O
control,O
fundamentally,O
mediated,O
by,O
17β,O
extradiol,O
.,O
Hormonal,O
regulation,O
of,O
this,O
cytokine,B-GP
has,O
been,O
suggested,O
to,O
modulate,O
",",O
in,O
part,O
",",O
the,O
ability,O
of,O
estrogens,O
to,O
potentiate,O
many,O
types,O
of,O
immune,O
responses,O
and,O
to,O
influence,O
the,O
disproportionate,O
susceptibility,O
of,O
women,O
for,O
immune,B-DS
-,I-DS
inflammatory,I-DS
diseases,I-DS
.,O
Thus,O
",",O
gene,O
variants,O
representing,O
genetic,O
advantage,O
for,O
one,O
gender,O
might,O
not,O
be,O
reciprocally,O
relevant,O
for,O
the,O
other,O
gender,O
in,O
terms,O
of,O
successful,O
or,O
unsuccessful,O
ageing,O
[,O
60,O
].,O
The,O
data,O
from,O
Sicilian,O
investigation,O
add,O
another,O
piece,O
to,O
complex,O
puzzle,O
of,O
genetic,O
and,O
environmental,O
factors,O
involved,O
in,O
the,O
control,O
of,O
life,O
span,O
expectancy,O
in,O
humans,B-OG
.,O
Studies,O
on,O
cytokine,B-GP
gene,O
SNPs,O
may,O
promise,O
to,O
individuate,O
a,O
complex,O
network,O
of,O
trans,O
-,O
inactive,O
genes,O
able,O
to,O
influence,O
the,O
type,O
and,O
strength,O
of,O
immune,O
responses,O
to,O
environmental,O
stressors,O
",",O
and,O
as,O
final,O
result,O
",",O
conditioning,O
individual,O
life,O
expectancy,O
[,O
60,O
-,O
63,O
].,O
On,O
the,O
other,O
hand,O
",",O
we,O
recently,O
suggested,O
the,O
possibility,O
to,O
use,O
cytokine,B-GP
profile,O
as,O
biomarker,O
of,O
successful,O
ageing,O
",",O
by,O
evaluating,O
through,O
Lumines,O
technology,O
cytokine,B-GP
serum,O
levels,O
in,O
44,O
Sicilian,O
nonagenarians,O
and,O
79,O
control,O
subjects,O
(,O
aged,O
between,O
30,O
and,O
50,O
years,O
old,O
),O
[,O
64,O
].,O
IFN,B-GP
-,I-GP
γ,I-GP
and,O
IL,B-GP
-,I-GP
2,I-GP
levels,O
are,O
unmodified,O
",",O
suggesting,O
a,O
substantial,O
maintenance,O
of,O
relevant,O
T,O
functions,O
.,O
In,O
addition,O
",",O
a,O
significant,O
increase,O
of,O
IL,B-GP
-,I-GP
12,I-GP
serum,O
levels,O
was,O
observed,O
.,O
This,O
condition,O
might,O
be,O
associated,O
with,O
the,O
increase,O
of,O
NK,O
cell,O
function,O
with,O
ageing,O
.,O
Furthermore,O
",",O
an,O
increase,O
of,O
IL,B-GP
-,I-GP
13,I-GP
and,O
a,O
reduction,O
of,O
IL,B-GP
-,I-GP
4,I-GP
were,O
found,O
.,O
Thus,O
",",O
the,O
maintenance,O
of,O
some,O
effector,O
',O
s,O
mechanisms,O
of,O
immune,O
-,O
response,O
characterizes,O
advanced,O
ages,O
.,O
From,O
a,O
general,O
point,O
of,O
view,O
",",O
our,O
data,O
firstly,O
confirm,O
the,O
age,O
-,O
related,O
remodeling,O
of,O
cytokine,B-GP
network,O
.,O
Furthermore,O
",",O
they,O
underline,O
the,O
presence,O
of,O
unchanged,O
levels,O
of,O
some,O
crucial,O
cytokines,B-GP
useful,O
in,O
preserving,O
key,O
immune,O
function,O
in,O
long,O
-,O
living,O
persons,O
[,O
64,O
].,O
Future,O
perspectives,O
The,O
ageing,O
process,O
and,O
longevity,O
are,O
multi,O
-,O
factorial,O
events,O
.,O
Genetic,O
",",O
epigenetic,O
",",O
stochastic,O
and,O
environmental,O
factors,O
seem,O
to,O
have,O
a,O
crucial,O
role,O
in,O
ageing,O
and,O
longevity,O
.,O
Epigenetic,O
is,O
associated,O
to,O
ageing,O
",",O
as,O
shown,O
in,O
the,O
major,O
number,O
of,O
studies,O
.,O
In,O
particular,O
",",O
ageing,O
is,O
associated,O
to,O
a,O
global,O
loss,O
of,O
methylation,O
state,O
[,O
65,O
].,O
In,O
addition,O
",",O
tissue,O
-,O
dependent,O
age,O
-,O
related,O
hypermetylation,O
of,O
specific,O
DNA,O
regions,O
have,O
been,O
observed,O
.,O
Thus,O
",",O
it,O
can,O
be,O
concluded,O
that,O
epigenetic,O
age,O
-,O
related,O
modification,O
are,O
stochastic,O
and,O
no,O
linked,O
to,O
specific,O
DNA,O
region,O
",",O
while,O
epigenetic,O
changes,O
linked,O
to,O
specific,O
environmental,O
stimuli,O
are,O
limited,O
in,O
specific,O
DNA,O
region,O
[,O
66,O
",",O
67,O
].,O
These,O
observations,O
have,O
led,O
to,O
address,O
the,O
research,O
on,O
epigenomics,O
and,O
its,O
implication,O
in,O
ageing,O
and,O
longevity,O
.,O
Epigenomics,O
is,O
the,O
systematic,O
study,O
of,O
the,O
global,O
gene,O
expression,O
changes,O
due,O
to,O
epigenetic,O
processes,O
",",O
but,O
not,O
to,O
DNA,O
base,O
sequence,O
changes,O
.,O
Epigenetic,O
processes,O
consist,O
in,O
heritable,O
modification,O
that,O
result,O
in,O
a,O
selective,O
gene,O
expression,O
or,O
repression,O
and,O
consequently,O
in,O
phenotype,O
changes,O
[,O
68,O
].,O
These,O
changes,O
include,O
nucleosome,O
positioning,O
",",O
post,O
-,O
translation,O
histone,O
modifications,O
",",O
action,O
of,O
small,O
RNAs,O
",",O
DNA,O
replication,O
timing,O
",",O
heterochromatinization,O
and,O
DNA,O
methylation,O
[,O
69,O
].,O
This,O
last,O
one,O
consists,O
in,O
the,O
addition,O
of,O
a,O
methyl,O
group,O
(-,O
CH3,O
),O
in,O
the,O
carbon,O
5,O
of,O
cytosines,O
",",O
particularly,O
in,O
the,O
CpG,O
dinucleotide,O
.,O
This,O
condition,O
particularly,O
concerns,O
the,O
CpG,O
islands,O
(,O
CpGIs,O
"),",O
located,O
at,O
the,O
regulatory,O
site,O
of,O
gene,O
promoter,O
regions,O
.,O
Methylation,O
rate,O
is,O
associated,O
to,O
transcriptional,O
regulation,O
.,O
In,O
particular,O
",",O
gene,O
silencing,O
is,O
associated,O
to,O
increase,O
of,O
-,O
CH3,O
groups,O
on,O
DNA,O
",",O
conversely,O
hypometylation,O
of,O
CGIs,O
is,O
associated,O
to,O
an,O
open,O
chromatin,O
state,O
resulting,O
in,O
gene,O
expression,O
[,O
70,O
].,O
Although,O
the,O
association,O
between,O
ageing,O
and,O
epigenetic,O
is,O
a,O
real,O
evidence,O
",",O
processes,O
involved,O
are,O
not,O
clear,O
.,O
Certainly,O
",",O
the,O
nutrition,O
affects,O
epigenetic,O
modifications,O
.,O
Nutrients,O
can,O
be,O
active,O
on,O
specific,O
sites,O
.,O
For,O
example,O
",",O
vitamin,O
B12,O
",",O
vitamin,O
B6,O
",",O
riboflavin,O
",",O
methionine,O
",",O
choline,O
and,O
betaine,O
",",O
well,O
known,O
as,O
folates,O
",",O
regulate,O
levels,O
of,O
S,O
-,O
adenosylmethionine,O
and,O
S,O
-,O
adenosylhomocysteine,O
",",O
donor,O
of,O
-,O
CH3,O
group,O
and,O
methyltransferase,B-GP
inhibitor,O
respectively,O
[,O
71,O
].,O
Curcumin,O
",",O
resveratrol,O
",",O
polyphenols,O
and,O
flavonoids,O
",",O
phytoestrogen,O
",",O
and,O
lycopene,O
are,O
also,O
considered,O
key,O
nutritional,O
factors,O
both,O
for,O
regulation,O
of,O
enzyme,O
involved,O
in,O
acetylation,O
and,O
deacetylation,O
mechanism,O
and,O
for,O
one,O
-,O
carbon,O
metabolism,O
[,O
71,O
",",O
72,O
].,O
A,O
diet,O
rich,O
in,O
vegetables,O
and,O
fruit,O
",",O
such,O
as,O
Mediterranean,O
diet,O
",",O
may,O
contain,O
these,O
nutrients,O
.,O
Sicilian,O
centenarians,O
are,O
characterized,O
to,O
observe,O
this,O
kind,O
of,O
diet,O
",",O
as,O
we,O
reported,O
[,O
73,O
].,O
Since,O
genetic,O
and,O
environmental,O
factors,O
contribute,O
to,O
longevity,O
",",O
it,O
may,O
suggest,O
that,O
epigenetic,O
events,O
associated,O
to,O
the,O
modifications,O
diet,O
-,O
induced,O
are,O
very,O
important,O
for,O
successful,O
ageing,O
processes,O
.,O
Furthermore,O
",",O
several,O
literature,O
data,O
reported,O
a,O
possible,O
link,O
between,O
epigenetic,O
and,O
several,O
age,O
-,O
related,O
diseases,O
",",O
such,O
as,O
cancer,B-DS
",",O
metabolic,B-DS
syndrome,I-DS
",",O
diabetes,B-DS
and,O
neurodegenerative,B-DS
disorders,I-DS
.,O
Stable,O
propagation,O
of,O
gene,O
expression,O
from,O
cell,O
to,O
cell,O
during,O
disease,O
pathogenesis,O
is,O
regulated,O
by,O
epigenetic,O
mechanisms,O
.,O
For,O
example,O
",",O
during,O
the,O
diabetes,B-DS
onset,O
epigenetic,O
changes,O
act,O
on,O
insulin,B-GP
and,O
insulin,B-GP
metabolism,O
regulating,O
the,O
gene,O
coding,O
[,O
74,O
].,O
In,O
particular,O
",",O
a,O
recent,O
study,O
has,O
demonstrated,O
that,O
human,B-OG
insulin,B-GP
gene,O
and,O
mouse,B-OG
insulin,B-GP
2,I-GP
gene,O
expression,O
are,O
under,O
control,O
of,O
epigenetic,O
changes,O
in,O
CpGIs,O
.,O
Insulin,B-GP
non,O
expressing,O
cells,O
are,O
",",O
indeed,O
",",O
methylated,O
in,O
the,O
promoter,O
region,O
of,O
insulin,B-GP
coding,O
gene,O
",",O
while,O
insulin,B-GP
expressing,O
cells,O
are,O
completely,O
demethylated,O
in,O
the,O
same,O
site,O
resulting,O
in,O
insulin,B-GP
gene,O
expression,O
[,O
75,O
].,O
Another,O
study,O
on,O
monozygotic,O
twin,O
has,O
demonstrated,O
that,O
insulin,B-DS
resistance,I-DS
is,O
also,O
under,O
control,O
of,O
DNA,O
methylation,O
[,O
76,O
].,O
Alterations,O
in,O
insulin,B-GP
pathway,O
are,O
known,O
to,O
be,O
involved,O
in,O
metabolic,B-DS
disease,I-DS
",",O
such,O
as,O
metabolic,B-DS
syndrome,I-DS
",",O
insulin,B-DS
resistance,I-DS
and,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
Recent,O
data,O
also,O
support,O
the,O
existence,O
of,O
a,O
correlation,O
between,O
these,O
alterations,O
and,O
Alzheimer,B-DS
',I-DS
s,I-DS
disease,I-DS
.,O
In,O
the,O
light,O
of,O
these,O
observations,O
",",O
the,O
purpose,O
of,O
our,O
future,O
studies,O
will,O
be,O
to,O
evaluate,O
the,O
weight,O
of,O
epigenetic,O
changes,O
in,O
ageing,O
and,O
longevity,O
",",O
using,O
centenarians,O
as,O
super,O
-,O
controls,O
.,O
Abbreviations,O
AD,O
:,O
Alzheimer,B-DS
',I-DS
s,I-DS
disease,I-DS
;,O
BF,O
:,O
Boutonnese,O
fever,O
;,O
CCR5,B-GP
:,O
CC,O
chemokine,O
receptor,O
5,O
;,O
COX,B-GP
-,I-GP
2,I-GP
:,O
Cyclo,O
-,O
oxygenase,O
2,O
;,O
CRP,O
:,O
C,B-GP
reactive,I-GP
protein,I-GP
;,O
CVD,B-DS
:,O
Cardiovascular,B-DS
disease,I-DS
;,O
HSPs,O
:,O
Heat,O
-,O
shock,O
proteins,O
;,O
INF,B-GP
-,I-GP
γ,I-GP
:,O
Interferon,B-GP
-,I-GP
γ,I-GP
;,O
IL,B-GP
-,I-GP
6,I-GP
:,O
Interleukin,B-GP
-,I-GP
6,I-GP
;,O
IL,B-GP
-,I-GP
10,I-GP
:,O
Interleukin,B-GP
-,I-GP
10,I-GP
;,O
5,B-GP
-,I-GP
LO,I-GP
:,O
5,B-GP
-,I-GP
lipoxygenase,I-GP
;,O
LPS,O
:,O
Lipopolysaccharide,O
;,O
LTs,O
:,O
Leukotrienes,O
;,O
MI,O
:,O
Myocardial,B-DS
infarction,I-DS
;,O
ox,O
-,O
LDL,O
:,O
Oxidized,O
-,O
Low,O
Density,O
Lipoproteins,O
;,O
PC,B-DS
:,O
Prostate,B-DS
cancer,I-DS
;,O
PGs,O
:,O
Prostaglandins,O
;,O
SNPs,O
:,O
Single,O
nucleotide,O
polymorphisms,O
;,O
TLR4,B-GP
:,O
Toll,B-GP
-,I-GP
like,I-GP
-,I-GP
receptor,I-GP
-,I-GP
4,I-GP
;,O
TNF,B-GP
-,I-GP
α,I-GP
:,O
Tumor,B-GP
necrosis,I-GP
factor,I-GP
-,I-GP
α,I-GP
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
',O
contributions,O
CRB,O
",",O
GA,O
",",O
SB,O
",",O
MB,O
",",O
AM,O
and,O
GCR,O
wrote,O
the,O
first,O
draft,O
.,O
Subsequent,O
drafts,O
were,O
written,O
by,O
CRB,O
",",O
who,O
had,O
the,O
overall,O
supervision,O
of,O
the,O
review,O
processing,O
.,O
All,O
authors,O
edited,O
the,O
paper,O
and,O
approved,O
its,O
final,O
version,O
.,O
The,O
Link,O
between,O
Musculoskeletal,O
Pain,O
",",O
Lifestyle,O
Behaviors,O
",",O
Exercise,O
Self,O
-,O
Efficacy,O
",",O
and,O
Quality,O
of,O
Life,O
in,O
Overweight,O
and,O
Obese,O
Individuals,O
Objective,O
To,O
determine,O
the,O
extent,O
musculoskeletal,O
(,O
MS,O
),O
pain,O
in,O
the,O
low,O
back,O
and,O
knee,O
(,O
weight,O
-,O
bearing,O
(,O
WB,O
),O
joints,O
"),",O
shoulder,O
and,O
wrist,O
(,O
non,O
-,O
weight,O
bearing,O
joints,O
"),",O
and,O
exercise,O
self,O
-,O
efficacy,O
mediates,O
associations,O
between,O
overweight,O
and,O
obesity,B-DS
levels,O
based,O
on,O
BMI,O
(,O
4,O
levels,O
:,O
overweight,O
",",O
obese,O
class,O
I,O
",",O
II,O
",",O
or,O
III,O
"),",O
physical,O
function,O
",",O
emotional,O
role,O
",",O
social,O
interference,O
",",O
and,O
physical,O
activity,O
(,O
PA,O
),O
levels,O
.,O
Design,O
Cross,O
-,O
sectional,O
study,O
.,O
Setting,O
Four,O
long,O
-,O
term,O
nursing,O
home,O
facilities,O
in,O
the,O
Northeast,O
U,O
.,O
S,O
.,O
Participants,O
99,O
overweight,O
or,O
obese,O
(,O
BMI,O
>,O
25,O
),O
nursing,O
home,O
employees,O
.,O
Interventions,O
Self,O
-,O
reported,O
survey,O
administered,O
to,O
employees,O
who,O
met,O
inclusion,O
and,O
exclusion,O
criteria,O
.,O
Main,O
Outcome,O
Measure,O
(,O
s,O
),O
General,O
health,O
status,O
",",O
physical,O
function,O
",",O
emotional,O
role,O
",",O
Exercise,O
Self,O
-,O
Efficacy,O
Scale,O
(,O
ESE,O
"),",O
physical,O
activity,O
(,O
PA,O
"),",O
and,O
frequency,O
of,O
pain,O
at,O
each,O
joint,O
.,O
Results,O
Reported,O
pain,O
frequency,O
were,O
66,O
.,O
3,O
"%,",O
54,O
.,O
4,O
"%,",O
42,O
.,O
2,O
"%,",O
and,O
24,O
.,O
1,O
%,O
for,O
lower,O
back,O
",",O
knee,O
",",O
shoulder,O
",",O
and,O
wrist,O
",",O
respectively,O
.,O
Higher,O
obesity,B-DS
levels,O
were,O
associated,O
with,O
lower,O
physical,O
function,O
(,O
r,O
=−,O
0,O
.,O
109,O
",",O
p,O
=,O
0,O
.,O
284,O
).,O
PA,O
decreased,O
with,O
higher,O
obesity,B-DS
levels,O
(,O
r,O
=−,O
0,O
.,O
248,O
",",O
p,O
<,O
0,O
.,O
05,O
"),",O
particularly,O
in,O
moderate,O
PA,O
(,O
r,O
=−,O
0,O
.,O
293,O
",",O
p,O
<,O
0,O
.,O
05,O
).,O
Obesity,B-DS
was,O
associated,O
with,O
a,O
lower,O
ESE,O
(,O
r,O
=−,O
0,O
.,O
239,O
",",O
p,O
<,O
0,O
.,O
05,O
).,O
Wrist,O
pain,O
significantly,O
mediated,O
the,O
effect,O
of,O
obesity,B-DS
on,O
moderate,O
physical,O
function,O
",",O
emotional,O
role,O
",",O
and,O
ESE,O
.,O
ESE,O
was,O
a,O
significant,O
mediator,O
between,O
obesity,B-DS
and,O
moderate,O
and,O
vigorous,O
PA,O
.,O
Conclusions,O
Overweight,O
and,O
obese,O
nursing,O
home,O
employees,O
are,O
at,O
higher,O
risk,O
for,O
developing,O
musculoskeletal,B-DS
disorders,I-DS
due,O
to,O
high,O
demand,O
",",O
low,O
control,O
jobs,O
",",O
and,O
the,O
associated,O
biomedical,O
compromises,O
while,O
working,O
.,O
To,O
increase,O
the,O
effectiveness,O
of,O
weight,O
loss,O
interventions,O
for,O
this,O
population,O
",",O
the,O
mediating,O
effects,O
of,O
MS,O
pain,O
with,O
higher,O
levels,O
of,O
obesity,B-DS
should,O
be,O
considered,O
.,O
Introduction,O
Within,O
the,O
last,O
20,O
years,O
",",O
prevalence,O
rates,O
of,O
obesity,B-DS
have,O
dramatically,O
risen,O
from,O
10,O
%,O
to,O
more,O
than,O
30,O
%,O
in,O
the,O
United,O
States,O
[,O
1,O
].,O
In,O
the,O
year,O
2015,O
",",O
it,O
has,O
been,O
estimated,O
that,O
about,O
75,O
%,O
of,O
adults,O
will,O
be,O
overweight,O
or,O
obese,O
",",O
and,O
41,O
%,O
of,O
U,O
.,O
S,O
.,O
adults,O
will,O
be,O
obese,O
[,O
2,O
].,O
Current,O
trends,O
show,O
that,O
obesity,B-DS
is,O
associated,O
with,O
increased,O
prevalence,O
of,O
adverse,O
health,O
conditions,O
",",O
including,O
coronary,B-DS
heart,I-DS
disease,I-DS
",",O
cancers,B-DS
(,O
endometrial,O
",",O
breast,O
",",O
and,O
colon,O
"),",O
hypertension,B-DS
",",O
stroke,B-DS
",",O
dyslipidemia,B-DS
",",O
type,B-DS
2,I-DS
diabetes,I-DS
",",O
respiratory,B-DS
problems,I-DS
",",O
and,O
musculoskeletal,O
conditions,O
[,O
1,O
",",O
3,O
].,O
These,O
conditions,O
are,O
also,O
referred,O
to,O
as,O
Obesity,B-DS
-,O
related,O
Comorbidities,O
(,O
ORCs,O
"),",O
and,O
have,O
a,O
substantial,O
impact,O
on,O
morbidity,O
rates,O
[,O
4,O
].,O
In,O
the,O
U,O
.,O
S,O
".,",O
approximately,O
280,O
",",O
000,O
to,O
325,O
",",O
000,O
deaths,O
each,O
year,O
are,O
attributable,O
to,O
obesity,B-DS
[,O
5,O
",",O
6,O
].,O
Obesity,B-DS
and,O
its,O
comorbidities,O
are,O
also,O
associated,O
with,O
changes,O
in,O
health,O
-,O
related,O
quality,O
of,O
life,O
(,O
HRQOL,O
),O
in,O
overweight,O
and,O
obese,O
individuals,O
",",O
an,O
outcome,O
involving,O
substantial,O
decreases,O
in,O
physical,O
and,O
mental,O
health,O
[,O
3,O
",",O
7,O
–,O
15,O
].,O
Increased,O
adiposity,O
in,O
overweight,O
and,O
obese,O
individuals,O
are,O
associated,O
with,O
mechanical,O
and,O
structural,O
changes,O
that,O
may,O
impact,O
physical,O
health,O
and,O
induce,O
musculoskeletal,O
conditions,O
[,O
3,O
",",O
8,O
",",O
16,O
–,O
19,O
].,O
Higher,O
Body,O
Mass,O
Index,O
(,O
BMI,O
),O
may,O
lead,O
to,O
increased,O
loading,O
on,O
individual,O
joints,O
and,O
localized,O
inflammation,O
",",O
which,O
contribute,O
to,O
muscle,O
and,O
bone,B-DS
loss,I-DS
",",O
joint,O
misalignment,O
",",O
and,O
postural,O
changes,O
[,O
3,O
",",O
17,O
",",O
19,O
–,O
23,O
].,O
These,O
biomechanical,O
and,O
physiological,O
alterations,O
add,O
to,O
the,O
development,O
of,O
pain,O
",",O
musculoskeletal,O
conditions,O
and,O
joint,B-DS
disease,I-DS
[,O
3,O
",",O
8,O
",",O
24,O
].,O
Musculoskeletal,O
pain,O
in,O
various,O
body,O
sites,O
have,O
shown,O
positive,O
associations,O
with,O
increased,O
BMI,O
[,O
25,O
–,O
35,O
].,O
Understanding,O
the,O
mediating,O
effect,O
in,O
Weight,O
-,O
Bearing,O
(,O
WB,O
),O
versus,O
Non,O
-,O
Weight,O
-,O
Bearing,O
(,O
NWB,O
),O
joints,O
is,O
needed,O
to,O
expound,O
the,O
role,O
of,O
pain,O
in,O
the,O
BMI,O
-,O
HRQOL,O
relationship,O
.,O
Previous,O
research,O
has,O
shown,O
strong,O
associations,O
between,O
obesity,B-DS
and,O
self,O
-,O
efficacy,O
",",O
defined,O
as,O
an,O
individual,O
’,O
s,O
confidence,O
in,O
their,O
ability,O
to,O
perform,O
a,O
specific,O
behavior,O
to,O
achieve,O
a,O
particular,O
outcome,O
[,O
36,O
].,O
Individuals,O
with,O
a,O
high,O
BMI,O
consistently,O
report,O
a,O
lower,O
exercise,O
self,O
-,O
efficacy,O
(,O
ESE,O
"),",O
suggesting,O
less,O
confidence,O
in,O
their,O
ability,O
to,O
change,O
or,O
keep,O
up,O
with,O
an,O
exercise,O
regimen,O
.,O
Decreases,O
in,O
ESE,O
are,O
positively,O
correlated,O
with,O
decreases,O
in,O
physical,O
activity,O
(,O
PA,O
),O
levels,O
[,O
32,O
",",O
37,O
].,O
In,O
recent,O
weight,O
-,O
loss,O
interventions,O
that,O
targeted,O
ESE,O
",",O
modest,O
to,O
large,O
weight,O
reductions,O
of,O
5,O
–,O
10,O
kg,O
led,O
to,O
significant,O
increases,O
in,O
ESE,O
[,O
38,O
",",O
39,O
].,O
However,O
",",O
these,O
findings,O
need,O
to,O
be,O
further,O
elucidated,O
through,O
statistical,O
models,O
that,O
posit,O
ESE,O
as,O
a,O
mechanism,O
by,O
which,O
obesity,B-DS
affects,O
PA,O
level,O
[,O
32,O
",",O
35,O
",",O
39,O
",",O
40,O
].,O
ORCs,O
have,O
been,O
tested,O
as,O
potential,O
mediators,O
that,O
explain,O
part,O
of,O
the,O
adverse,O
effect,O
of,O
obesity,B-DS
on,O
HRQOL,O
outcomes,O
[,O
7,O
",",O
13,O
",",O
15,O
",",O
32,O
–,O
36,O
].,O
J,O
-,O
shaped,O
associations,O
between,O
obesity,B-DS
and,O
BMI,O
indicate,O
that,O
lower,O
HRQOL,O
was,O
observed,O
in,O
those,O
with,O
abnormal,O
body,O
weight,O
(,O
underweight,O
",",O
overweight,O
",",O
and,O
obese,O
individuals,O
),O
[,O
5,O
].,O
In,O
particular,O
",",O
pain,O
in,O
2,O
–,O
4,O
sites,O
partially,O
mediated,O
about,O
22,O
–,O
44,O
%,O
of,O
the,O
association,O
between,O
obesity,B-DS
and,O
HRQOL,O
",",O
suggesting,O
that,O
obesity,B-DS
’,O
s,O
adverse,O
effect,O
on,O
HRQOL,O
may,O
be,O
manifested,O
through,O
musculoskeletal,O
pain,O
[,O
13,O
].,O
Explanatory,O
models,O
that,O
estimate,O
the,O
musculoskeletal,O
pain,O
as,O
a,O
mediator,O
in,O
this,O
relationship,O
would,O
be,O
useful,O
in,O
the,O
development,O
of,O
future,O
interventions,O
for,O
the,O
overweight,O
and,O
obese,O
population,O
[,O
24,O
",",O
41,O
].,O
The,O
present,O
study,O
seeks,O
to,O
evaluate,O
the,O
prevalence,O
of,O
musculoskeletal,O
pain,O
in,O
a,O
group,O
of,O
overweight,O
and,O
obese,O
individuals,O
and,O
to,O
identify,O
the,O
mediating,O
effect,O
of,O
pain,O
and,O
ESE,O
in,O
the,O
relationship,O
between,O
obesity,B-DS
",",O
PA,O
",",O
and,O
specific,O
HRQOL,O
items,O
.,O
We,O
hypothesize,O
that,O
:,O
1,O
),O
musculoskeletal,O
pain,O
prevalence,O
will,O
be,O
high,O
in,O
both,O
WB,O
and,O
NWB,O
joints,O
;,O
2,O
),O
increased,O
obesity,B-DS
will,O
indicate,O
lower,O
HRQOL,O
;,O
3,O
),O
pain,O
will,O
partially,O
mediate,O
relationships,O
between,O
BMI,O
",",O
HRQOL,O
",",O
and,O
PA,O
;,O
and,O
4,O
),O
ESE,O
will,O
partially,O
mediate,O
the,O
BMI,O
-,O
PA,O
relationship,O
.,O
Materials,O
and,O
Methods,O
Design,O
A,O
cross,O
-,O
sectional,O
observational,O
study,O
.,O
Participants,O
The,O
study,O
sample,O
included,O
ninety,O
-,O
nine,O
overweight,O
and,O
obese,O
nursing,O
home,O
employees,O
who,O
were,O
at,O
risk,O
for,O
type,B-DS
2,I-DS
diabetes,I-DS
based,O
on,O
diabetes,B-DS
risk,O
score,O
>,O
8,O
",",O
indicating,O
that,O
risk,O
is,O
high,O
for,O
having,O
pre,B-DS
-,I-DS
diabetes,I-DS
presently,O
[,O
42,O
",",O
60,O
].,O
Participants,O
were,O
recruited,O
from,O
four,O
long,O
-,O
term,O
care,O
facilities,O
located,O
in,O
the,O
Northeast,O
United,O
States,O
",",O
and,O
were,O
required,O
to,O
sign,O
an,O
IRB,O
-,O
approved,O
consent,O
form,O
.,O
Measures,O
Body,O
Mass,O
Index,O
(,O
BMI,O
),O
Trained,O
health,O
educators,O
measured,O
height,O
(,O
nearest,O
mm,O
),O
and,O
weight,O
(,O
nearest,O
0,O
.,O
1,O
kg,O
),O
using,O
a,O
calibrated,O
Seca,O
700,O
physician,O
balance,O
beam,O
scale,O
.,O
BMI,O
was,O
calculated,O
as,O
weight,O
(,O
kg,O
),O
divided,O
by,O
height,O
(,O
m2,O
),O
and,O
categorized,O
based,O
on,O
CDC,O
recommendations,O
of,O
overweight,O
(,O
25,O
–,O
29,O
.,O
99,O
kg,O
/,O
m2,O
"),",O
obese,O
class,O
I,O
(,O
30,O
–,O
34,O
.,O
99,O
kg,O
/,O
m2,O
"),",O
obese,O
class,O
II,O
(,O
35,O
–,O
39,O
.,O
99,O
kg,O
/,O
m2,O
"),",O
and,O
(>,O
40,O
kg,O
/,O
m2,O
),O
[,O
61,O
].,O
Participant,O
questionnaire,O
A,O
standardized,O
questionnaire,O
was,O
distributed,O
to,O
all,O
participants,O
.,O
The,O
questionnaire,O
obtained,O
information,O
on,O
demographics,O
",",O
Musculoskeletal,O
Pain,O
",",O
Physical,O
Activity,O
(,O
PA,O
"),",O
Health,O
-,O
Related,O
Quality,O
of,O
Life,O
(,O
HRQOL,O
"),",O
and,O
Exercise,O
Self,O
-,O
Efficacy,O
(,O
ESE,O
).,O
Musculoskeletal,O
pain,O
was,O
defined,O
as,O
frequency,O
of,O
pain,O
in,O
the,O
WB,O
joints,O
(,O
low,O
back,O
and,O
knee,O
),O
and,O
NWB,O
joints,O
(,O
shoulder,O
and,O
wrist,O
-,O
forearm,O
),O
and,O
asked,O
how,O
often,O
on,O
hourly,O
",",O
daily,O
",",O
weekly,O
",",O
or,O
monthly,O
basis,O
the,O
participants,O
felt,O
pain,O
.,O
Physical,O
Activity,O
(,O
PA,O
),O
was,O
first,O
assessed,O
using,O
a,O
question,O
on,O
self,O
-,O
reported,O
typical,O
current,O
PA,O
not,O
specific,O
to,O
work,O
.,O
Three,O
other,O
questions,O
obtained,O
information,O
on,O
performance,O
of,O
mild,O
",",O
moderate,O
",",O
or,O
vigorous,O
PA,O
for,O
a,O
30,O
-,O
minute,O
duration,O
during,O
a,O
typical,O
7,O
-,O
day,O
week,O
.,O
Health,O
-,O
Related,O
Quality,O
of,O
Life,O
(,O
HRQOL,O
),O
was,O
evaluated,O
with,O
5,O
survey,O
items,O
from,O
the,O
Short,O
Form,O
Survey,O
(,O
SF,O
-,O
12,O
"),",O
a,O
validated,O
health,O
survey,O
.,O
General,O
Health,O
Status,O
was,O
defined,O
as,O
self,O
-,O
reported,O
general,O
health,O
using,O
the,O
first,O
SF,O
-,O
12,O
question,O
that,O
asked,O
how,O
the,O
individual,O
perceived,O
their,O
health,O
.,O
Physical,O
Function,O
was,O
assessed,O
using,O
the,O
second,O
and,O
third,O
SF,O
-,O
12,O
questions,O
",",O
and,O
asked,O
if,O
the,O
individual,O
perceived,O
their,O
health,O
to,O
limit,O
them,O
in,O
moderate,O
activities,O
(,O
moving,O
a,O
table,O
",",O
pushing,O
a,O
vacuum,O
cleaner,O
",",O
bowling,O
",",O
or,O
playing,O
golf,O
),O
and,O
vigorous,O
activities,O
(,O
climbing,O
several,O
flights,O
of,O
stairs,O
).,O
Emotional,O
Role,O
was,O
assessed,O
using,O
the,O
sixth,O
and,O
seventh,O
SF,O
-,O
12,O
question,O
and,O
asked,O
how,O
often,O
the,O
participant,O
accomplished,O
less,O
than,O
they,O
would,O
like,O
and,O
done,O
work,O
less,O
carefully,O
in,O
their,O
work,O
or,O
regular,O
daily,O
activities,O
as,O
a,O
result,O
of,O
any,O
emotional,B-DS
problems,I-DS
.,O
Social,O
Interference,O
was,O
assessed,O
using,O
the,O
last,O
SF,O
-,O
12,O
questions,O
and,O
asked,O
if,O
the,O
individual,O
perceived,O
their,O
joint,O
problem,O
to,O
interfere,O
with,O
social,O
activities,O
with,O
family,O
or,O
friends,O
.,O
Exercise,O
Self,O
-,O
Efficacy,O
(,O
ESE,O
),O
was,O
calculated,O
with,O
a,O
summary,O
score,O
comprised,O
of,O
11,O
questions,O
from,O
the,O
Sallis,O
(,O
1998,O
),O
ESE,O
Scale,O
.,O
Participants,O
were,O
given,O
questions,O
regarding,O
exercise,O
-,O
related,O
activities,O
and,O
asked,O
how,O
confident,O
they,O
were,O
that,O
they,O
could,O
keep,O
it,O
up,O
for,O
6,O
months,O
.,O
Statistical,O
Analysis,O
Expectation,O
-,O
maximization,O
imputation,O
Data,O
was,O
analyzed,O
using,O
the,O
SPSS,O
software,O
version,O
21,O
.,O
0,O
and,O
utilized,O
Preacher,O
&,O
Hayes,O
(,O
2008,O
),O
Indirect,O
Bootstrapping,O
Macro,O
.,O
Composite,O
scores,O
were,O
created,O
for,O
the,O
ESE,O
scale,O
.,O
Little,O
’,O
s,O
Missing,O
Completely,O
at,O
Random,O
(,O
MCAR,O
),O
test,O
was,O
executed,O
for,O
missing,O
data,O
(>,O
5,O
"%),",O
and,O
Expectation,O
-,O
Maximization,O
was,O
subsequently,O
performed,O
using,O
SPSS,O
Missing,O
Value,O
Analysis,O
imputation,O
to,O
create,O
maximum,O
likelihood,O
estimates,O
for,O
randomly,O
missing,O
data,O
(,O
p,O
=,O
0,O
.,O
265,O
).,O
Descriptive,O
statistics,O
and,O
associations,O
Descriptive,O
and,O
frequency,O
analysis,O
were,O
used,O
to,O
analyze,O
MS,O
pain,O
prevalence,O
.,O
Variables,O
were,O
reverse,O
coded,O
if,O
needed,O
.,O
Normality,O
was,O
assessed,O
using,O
histograms,O
and,O
frequencies,O
for,O
all,O
variables,O
and,O
outcomes,O
.,O
Total,O
exercise,O
self,O
-,O
efficacy,O
score,O
was,O
calculated,O
from,O
a,O
series,O
of,O
questions,O
.,O
Correlational,O
analyses,O
using,O
Pearson,O
’,O
s,O
Correlation,O
were,O
used,O
to,O
analyze,O
direct,O
relationships,O
between,O
levels,O
of,O
obesity,B-DS
",",O
general,O
health,O
",",O
physical,O
function,O
",",O
emotional,O
role,O
",",O
social,O
interference,O
",",O
physical,O
activity,O
levels,O
",",O
and,O
exercise,O
self,O
-,O
efficacy,O
.,O
Benferroni,O
correction,O
was,O
calculated,O
to,O
restrict,O
significance,O
to,O
a,O
more,O
conservative,O
p,O
-,O
value,O
(,O
p,O
=,O
0,O
.,O
005,O
),O
to,O
reduce,O
Type,O
I,O
error,O
.,O
Observed,O
(,O
Manifest,O
),O
variables,O
and,O
path,O
analysis,O
(,O
SEM,O
),O
Path,O
analysis,O
via,O
structural,O
equation,O
modeling,O
(,O
SEM,O
),O
and,O
bootstrapping,O
is,O
a,O
useful,O
statistical,O
approach,O
to,O
examine,O
mediation,O
between,O
observed,O
variables,O
",",O
and,O
was,O
used,O
to,O
examine,O
direct,O
and,O
indirect,O
effects,O
within,O
the,O
two,O
theoretically,O
driven,O
models,O
on,O
this,O
dataset,O
.,O
Path,O
was,O
first,O
tested,O
with,O
the,O
Obesity,B-DS
",",O
Musculoskeletal,O
Pain,O
",",O
Health,O
-,O
Related,O
Quality,O
of,O
Life,O
(,O
OMH,O
),O
with,O
musculoskeletal,O
pain,O
in,O
four,O
sites,O
as,O
mediator,O
variables,O
(,O
Figure,O
1,O
).,O
SEM,O
was,O
also,O
performed,O
for,O
the,O
Obesity,B-DS
",",O
Exercise,O
Self,O
-,O
Efficacy,O
",",O
Physical,O
activity,O
(,O
OEP,O
),O
model,O
with,O
ESE,O
as,O
the,O
mediator,O
variable,O
(,O
Figure,O
2,O
).,O
Bootstrapping,O
at,O
a,O
95,O
%,O
confidence,O
interval,O
was,O
used,O
to,O
determine,O
significance,O
of,O
indirect,O
effects,O
.,O
Proportions,O
of,O
mediation,O
were,O
calculated,O
using,O
Microsoft,O
Excel,O
via,O
algorithm,O
supported,O
by,O
Kenny,O
(,O
2014,O
).,O
As,O
indicated,O
in,O
Figure,O
1,O
",",O
the,O
Obesity,B-DS
",",O
Musculoskeletal,O
Pain,O
",",O
Health,O
-,O
Related,O
Quality,O
of,O
life,O
(,O
OMH,O
),O
model,O
identifies,O
level,O
of,O
obesity,B-DS
",",O
musculoskeletal,O
pain,O
",",O
and,O
health,O
-,O
related,O
quality,O
of,O
life,O
",",O
physical,O
activity,O
levels,O
",",O
and,O
exercise,O
self,O
-,O
efficacy,O
.,O
It,O
is,O
hypothesized,O
that,O
the,O
OMH,O
model,O
predicts,O
a,O
higher,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
),O
will,O
result,O
in,O
a,O
lower,O
self,O
-,O
reported,O
HRQOL,O
",",O
PA,O
level,O
",",O
and,O
ESE,O
",",O
and,O
that,O
higher,O
frequency,O
of,O
musculoskeletal,O
pain,O
will,O
indirectly,O
affect,O
the,O
relationship,O
",",O
resulting,O
in,O
a,O
lower,O
score,O
of,O
these,O
three,O
outcomes,O
.,O
As,O
indicated,O
in,O
Figure,O
2,O
",",O
the,O
Obesity,B-DS
",",O
Exercise,O
Self,O
-,O
Efficacy,O
",",O
Physical,O
Activity,O
(,O
OEP,O
),O
model,O
identifies,O
the,O
level,O
of,O
obesity,B-DS
",",O
exercise,O
self,O
-,O
efficacy,O
",",O
and,O
physical,O
activity,O
outcomes,O
.,O
It,O
is,O
hypothesized,O
that,O
the,O
OEP,O
model,O
predicts,O
a,O
higher,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
),O
will,O
result,O
in,O
a,O
lower,O
self,O
-,O
reported,O
PA,O
outcome,O
",",O
and,O
that,O
a,O
lower,O
ESE,O
summary,O
score,O
will,O
indirectly,O
affect,O
the,O
relationship,O
",",O
resulting,O
in,O
a,O
lower,O
self,O
-,O
reported,O
PA,O
outcome,O
.,O
Results,O
Participant,O
characteristics,O
Table,O
1,O
depicts,O
participant,O
demographics,O
and,O
body,O
weight,O
distribution,O
.,O
The,O
sample,O
reported,O
an,O
overall,O
pain,O
prevalence,O
of,O
68,O
.,O
7,O
%,O
in,O
the,O
low,O
back,O
",",O
55,O
.,O
6,O
%,O
in,O
the,O
knee,O
",",O
47,O
.,O
5,O
%,O
in,O
the,O
shoulder,O
",",O
and,O
29,O
.,O
3,O
%,O
in,O
the,O
wrist,O
/,O
forearm,O
region,O
.,O
Figure,O
3,O
indicates,O
the,O
frequency,O
of,O
WB,O
and,O
NWB,O
joint,O
pain,O
among,O
participants,O
.,O
Joint,O
pain,O
resided,O
dominantly,O
in,O
the,O
WB,O
joints,O
for,O
weekly,O
and,O
monthly,O
occurrences,O
.,O
However,O
",",O
when,O
considering,O
daily,O
frequency,O
",",O
participants,O
reported,O
that,O
the,O
dominant,O
joint,O
pain,O
sites,O
resided,O
in,O
the,O
knee,O
and,O
shoulder,O
(,O
Figure,O
3,O
).,O
Associations,O
between,O
Obesity,B-DS
",",O
HRQOL,O
",",O
PA,O
",",O
and,O
ESE,O
Table,O
2,O
shows,O
Pearson,O
’,O
s,O
correlations,O
between,O
the,O
level,O
of,O
obesity,B-DS
and,O
HRQOL,O
",",O
Physical,O
Activity,O
Levels,O
",",O
and,O
Exercise,O
Self,O
-,O
Efficacy,O
.,O
There,O
was,O
significance,O
negative,O
relationship,O
between,O
obesity,B-DS
and,O
physical,O
function,O
for,O
vigorous,O
activities,O
(,O
r,O
=−,O
0,O
.,O
308,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
suggesting,O
that,O
as,O
obesity,B-DS
increased,O
",",O
physical,O
function,O
in,O
climbing,O
stairs,O
",",O
decreased,O
(,O
Table,O
2,O
).,O
Though,O
significance,O
was,O
not,O
achieved,O
",",O
a,O
negative,O
relationship,O
with,O
moderate,O
physical,O
function,O
was,O
also,O
shown,O
(,O
r,O
=−,O
0,O
.,O
109,O
).,O
Additionally,O
",",O
associations,O
between,O
BMI,O
and,O
current,O
physical,O
activity,O
",",O
moderate,O
physical,O
activity,O
",",O
and,O
exercise,O
self,O
-,O
efficacy,O
were,O
also,O
significant,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
(,O
Table,O
2,O
).,O
Obesity,B-DS
had,O
a,O
significant,O
negative,O
relationship,O
with,O
current,O
PA,O
(,O
r,O
=−,O
0,O
.,O
248,O
",",O
p,O
=,O
0,O
.,O
013,O
"),",O
and,O
moderate,O
PA,O
(,O
r,O
=−,O
0,O
.,O
293,O
",",O
p,O
=,O
0,O
.,O
003,O
).,O
Additionally,O
",",O
the,O
relationship,O
between,O
obesity,B-DS
and,O
mild,O
PA,O
(,O
r,O
=−,O
0,O
.,O
129,O
",",O
p,O
=,O
0,O
.,O
202,O
),O
and,O
vigorous,O
PA,O
(,O
r,O
=−,O
0,O
.,O
176,O
",",O
p,O
=,O
0,O
.,O
082,O
),O
were,O
also,O
negative,O
",",O
but,O
did,O
not,O
reach,O
significance,O
.,O
Path,O
analysis,O
and,O
structural,O
equation,O
model,O
Obesity,B-DS
-,O
musculoskeletal,O
pain,O
-,O
health,O
related,O
quality,O
of,O
life,O
(,O
OMH,O
),O
Model,O
Out,O
of,O
the,O
11,O
models,O
used,O
to,O
assess,O
the,O
multiple,O
variables,O
under,O
the,O
theoretical,O
OMH,O
model,O
",",O
the,O
four,O
models,O
that,O
tested,O
wrist,O
pain,O
as,O
the,O
mediator,O
between,O
level,O
of,O
obesity,B-DS
",",O
physical,O
function,O
",",O
emotional,O
function,O
",",O
and,O
exercise,O
self,O
-,O
efficacy,O
",",O
indicated,O
significant,O
indirect,O
effects,O
and,O
are,O
presented,O
in,O
Tables,O
3,O
–,O
7,O
.,O
Table,O
3,O
depicts,O
the,O
mediation,O
results,O
between,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
"),",O
musculoskeletal,O
pain,O
frequency,O
in,O
four,O
anatomical,O
joints,O
",",O
and,O
physical,O
function,O
.,O
As,O
shown,O
in,O
Table,O
3,O
the,O
wrist,O
-,O
forearm,O
joint,O
significantly,O
mediated,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
moderate,O
physical,O
function,O
at,O
about,O
77,O
.,O
7,O
%.,O
Table,O
4,O
depicts,O
the,O
mediation,O
results,O
between,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
"),",O
musculoskeletal,O
pain,O
frequency,O
in,O
four,O
anatomical,O
joints,O
",",O
and,O
the,O
role,O
of,O
emotions,O
in,O
accomplishing,O
less,O
at,O
work,O
or,O
at,O
home,O
.,O
As,O
shown,O
in,O
Table,O
4,O
",",O
the,O
wrist,O
-,O
forearm,O
joint,O
significantly,O
mediated,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
emotional,O
role,O
in,O
regards,O
to,O
accomplishing,O
less,O
.,O
The,O
proportion,O
of,O
mediation,O
was,O
approximately,O
35,O
.,O
2,O
%.,O
Table,O
5,O
depicts,O
the,O
mediation,O
results,O
between,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
"),",O
musculoskeletal,O
pain,O
frequency,O
in,O
four,O
anatomical,O
joints,O
",",O
and,O
physical,O
function,O
in,O
a,O
moderate,O
activity,O
.,O
Table,O
5,O
depicts,O
the,O
mediation,O
results,O
between,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
"),",O
musculoskeletal,O
pain,O
frequency,O
in,O
four,O
anatomical,O
joints,O
",",O
and,O
physical,O
function,O
in,O
a,O
moderate,O
activity,O
.,O
As,O
shown,O
in,O
Table,O
5,O
",",O
the,O
wrist,O
-,O
forearm,O
joint,O
also,O
significantly,O
mediated,O
the,O
association,O
between,O
obesity,B-DS
and,O
emotional,O
role,O
regarding,O
being,O
less,O
careful,O
.,O
Table,O
6,O
depicts,O
the,O
mediation,O
results,O
between,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
"),",O
musculoskeletal,O
pain,O
frequency,O
in,O
four,O
anatomical,O
joints,O
",",O
and,O
the,O
total,O
exercise,O
self,O
-,O
efficacy,O
score,O
.,O
As,O
shown,O
in,O
Table,O
6,O
",",O
the,O
wrist,O
-,O
forearm,O
region,O
significantly,O
mediated,O
the,O
association,O
between,O
obesity,B-DS
and,O
ESE,O
of,O
about,O
17,O
.,O
7,O
%.,O
Obesity,B-DS
-,O
Exercise,O
Self,O
Efficacy,O
-,O
Physical,O
Activity,O
(,O
OEP,O
),O
Model,O
Out,O
of,O
the,O
four,O
models,O
used,O
to,O
assess,O
the,O
multiple,O
variables,O
under,O
the,O
theoretical,O
OMH,O
model,O
",",O
the,O
three,O
models,O
that,O
tested,O
exercise,O
self,O
-,O
efficacy,O
as,O
the,O
mediator,O
between,O
level,O
of,O
obesity,B-DS
",",O
current,O
physical,O
activity,O
",",O
moderate,O
physical,O
activity,O
",",O
and,O
vigorous,O
physical,O
activity,O
indicated,O
significant,O
indirect,O
effects,O
and,O
are,O
presented,O
in,O
Table,O
7,O
.,O
Table,O
7,O
depicts,O
the,O
mediation,O
results,O
between,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
BMI,O
"),",O
the,O
total,O
exercise,O
self,O
-,O
efficacy,O
score,O
",",O
and,O
levels,O
of,O
physical,O
activity,O
.,O
ESE,O
had,O
significant,O
indirect,O
effect,O
on,O
the,O
outcomes,O
of,O
current,O
PA,O
",",O
moderate,O
PA,O
",",O
and,O
vigorous,O
PA,O
.,O
For,O
current,O
physical,O
activity,O
",",O
a,O
16,O
.,O
44,O
%,O
mediating,O
effect,O
was,O
indicated,O
",",O
while,O
a,O
26,O
.,O
42,O
%,O
proportion,O
of,O
mediation,O
occurred,O
in,O
moderate,O
PA,O
.,O
Lastly,O
",",O
ESE,O
had,O
the,O
largest,O
proportion,O
of,O
mediation,O
on,O
vigorous,O
PA,O
at,O
about,O
44,O
.,O
8,O
%,O
(,O
Table,O
7,O
).,O
Discussion,O
This,O
study,O
aimed,O
to,O
understand,O
associations,O
between,O
obesity,B-DS
and,O
specific,O
health,O
-,O
related,O
quality,O
of,O
life,O
items,O
",",O
physical,O
activity,O
levels,O
",",O
and,O
exercise,O
self,O
-,O
efficacy,O
",",O
in,O
addition,O
to,O
testing,O
two,O
theoretically,O
driven,O
statistical,O
models,O
;,O
the,O
OMH,O
and,O
OEP,O
models,O
.,O
Our,O
results,O
are,O
in,O
line,O
with,O
previous,O
research,O
and,O
support,O
our,O
first,O
hypothesis,O
of,O
a,O
higher,O
prevalence,O
of,O
WB,O
and,O
NWB,O
musculoskeletal,O
pain,O
in,O
overweight,O
and,O
obese,O
nursing,O
home,O
employees,O
compared,O
to,O
general,O
nursing,O
home,O
employee,O
population,O
.,O
Comparatively,O
",",O
our,O
samples,O
’,O
prevalence,O
rates,O
are,O
higher,O
compared,O
to,O
general,O
nursing,O
home,O
employees,O
.,O
In,O
a,O
study,O
by,O
Miranda,O
et,O
al,O
".,",O
their,O
cohort,O
of,O
344,O
nursing,O
home,O
workers,O
indicated,O
the,O
prevalence,O
of,O
musculoskeletal,O
pain,O
to,O
be,O
34,O
%,O
in,O
the,O
low,O
back,O
and,O
approximately,O
25,O
%,O
each,O
in,O
the,O
knee,O
",",O
wrist,O
/,O
hands,O
and,O
shoulder,O
region,O
[,O
56,O
].,O
Another,O
survey,O
on,O
nursing,O
home,O
personnel,O
indicated,O
a,O
pain,O
prevalence,O
of,O
50,O
.,O
5,O
%,O
in,O
the,O
low,O
back,O
",",O
25,O
.,O
8,O
%,O
in,O
the,O
knee,O
",",O
27,O
.,O
9,O
%,O
in,O
the,O
shoulder,O
",",O
and,O
17,O
.,O
8,O
%,O
in,O
the,O
wrist,O
[,O
62,O
].,O
Higher,O
prevalence,O
of,O
pain,O
in,O
all,O
joints,O
may,O
be,O
explained,O
by,O
associations,O
with,O
increased,O
BMI,O
[,O
62,O
–,O
66,O
].,O
Associations,O
between,O
obesity,B-DS
and,O
HRQOL,O
outcomes,O
directionally,O
supported,O
the,O
second,O
hypothesis,O
",",O
with,O
significance,O
found,O
in,O
the,O
negative,O
relationship,O
between,O
obesity,B-DS
and,O
physical,O
function,O
for,O
vigorous,O
activities,O
",",O
suggesting,O
that,O
as,O
obesity,B-DS
increased,O
",",O
physical,O
function,O
in,O
climbing,O
stairs,O
",",O
decreased,O
.,O
Though,O
significance,O
was,O
not,O
achieved,O
",",O
a,O
negative,O
relationship,O
with,O
moderate,O
physical,O
function,O
was,O
also,O
shown,O
(,O
Table,O
2,O
).,O
These,O
results,O
are,O
in,O
line,O
with,O
previous,O
research,O
reporting,O
stronger,O
associations,O
with,O
higher,O
BMI,O
and,O
physical,O
components,O
of,O
the,O
SF,O
-,O
12,O
health,O
profile,O
[,O
5,O
",",O
14,O
",",O
15,O
",",O
62,O
–,O
67,O
].,O
In,O
particular,O
",",O
Yamakawa,O
and,O
colleagues,O
",",O
showed,O
that,O
ambulation,O
",",O
a,O
functional,O
activity,O
",",O
is,O
negatively,O
related,O
to,O
obesity,B-DS
",",O
supporting,O
our,O
results,O
.,O
In,O
addition,O
",",O
negative,O
relationships,O
were,O
expressed,O
between,O
obesity,B-DS
and,O
general,O
health,O
(,O
r,O
=−,O
0,O
.,O
191,O
).,O
The,O
findings,O
from,O
Heo,O
et,O
al,O
.,O
support,O
our,O
general,O
health,O
association,O
",",O
reporting,O
that,O
compared,O
with,O
desirable,O
weight,O
adults,O
",",O
underweight,O
",",O
overweight,O
",",O
and,O
obese,O
adults,O
were,O
significantly,O
more,O
likely,O
to,O
report,O
poor,O
to,O
fair,O
general,O
health,O
status,O
.,O
An,O
increase,O
in,O
emotional,O
role,O
limitations,O
and,O
social,O
interference,O
(,O
r,O
=,O
0,O
.,O
137,O
and,O
r,O
=,O
0,O
.,O
004,O
",",O
respectively,O
),O
were,O
shown,O
coincident,O
with,O
higher,O
BMI,O
",",O
although,O
associations,O
were,O
not,O
significant,O
.,O
These,O
results,O
are,O
supported,O
by,O
the,O
results,O
of,O
Jia,O
&,O
Lubetkin,O
that,O
show,O
HRQOL,O
scores,O
are,O
significantly,O
lower,O
for,O
overweight,O
and,O
obese,O
participants,O
.,O
Several,O
other,O
studies,O
support,O
these,O
results,O
that,O
there,O
is,O
a,O
direct,O
relationship,O
between,O
level,O
of,O
obesity,B-DS
(,O
indicated,O
using,O
increased,O
BMI,O
"),",O
and,O
greater,O
HRQOL,O
impairment,O
[,O
5,O
",",O
14,O
",",O
15,O
",",O
33,O
",",O
67,O
",",O
68,O
].,O
Similar,O
associations,O
are,O
reported,O
in,O
other,O
studies,O
between,O
obesity,B-DS
and,O
depression,B-DS
and,O
/,O
or,O
mental,B-DS
health,I-DS
impairment,I-DS
[,O
10,O
",",O
69,O
–,O
71,O
].,O
Specifically,O
",",O
Jia,O
&,O
Lubetkin,O
showed,O
that,O
mental,O
component,O
scores,O
on,O
the,O
SF,O
-,O
12,O
were,O
most,O
impaired,O
at,O
the,O
extremes,O
of,O
BMI,O
(,O
underweight,O
and,O
obese,O
class,O
III,O
"),",O
further,O
supporting,O
the,O
positive,O
association,O
within,O
our,O
data,O
.,O
Additionally,O
",",O
the,O
National,O
Obesity,B-DS
Observatory,O
(,O
NOO,O
),O
has,O
indicated,O
that,O
several,O
studies,O
posit,O
a,O
bi,O
-,O
directional,O
relationship,O
between,O
mental,O
health,O
and,O
obesity,B-DS
",",O
in,O
that,O
lower,O
mental,O
health,O
may,O
contribute,O
to,O
obesity,B-DS
",",O
and,O
higher,O
obesity,B-DS
may,O
contribute,O
to,O
lower,O
mental,O
health,O
[,O
72,O
].,O
Obesity,B-DS
had,O
a,O
significant,O
negative,O
relationship,O
with,O
current,O
PA,O
and,O
moderate,O
PA,O
(,O
Table,O
2,O
).,O
Additionally,O
",",O
the,O
relationship,O
between,O
obesity,B-DS
and,O
mild,O
PA,O
and,O
vigorous,O
PA,O
were,O
also,O
negative,O
",",O
but,O
did,O
not,O
reach,O
significance,O
(,O
Table,O
2,O
).,O
These,O
results,O
are,O
supported,O
and,O
explained,O
",",O
in,O
part,O
",",O
to,O
the,O
mechanical,O
-,O
structural,O
changes,O
that,O
have,O
been,O
proposed,O
to,O
cause,O
decrease,O
in,O
ambulation,O
and,O
change,O
in,O
gait,O
patterns,O
[,O
3,O
",",O
25,O
",",O
29,O
",",O
45,O
].,O
Hills,O
and,O
colleagues,O
reported,O
that,O
obese,O
individuals,O
had,O
changes,O
in,O
foot,O
structure,O
",",O
with,O
higher,O
plantar,O
pressure,O
under,O
their,O
longitudinal,O
arch,O
and,O
on,O
metatarsal,O
heads,O
during,O
both,O
standing,O
and,O
walking,O
",",O
making,O
it,O
more,O
likely,O
to,O
feel,O
discomfort,O
[,O
73,O
].,O
Previous,O
literature,O
have,O
also,O
reported,O
reductions,O
in,O
knee,O
range,O
of,O
motion,O
[,O
18,O
",",O
31,O
",",O
74,O
].,O
Overweight,O
and,O
obese,O
individuals,O
have,O
been,O
shown,O
to,O
walk,O
with,O
shorter,O
step,O
length,O
",",O
lower,O
cadence,O
",",O
and,O
lower,O
velocity,O
due,O
to,O
excessive,O
adipose,O
tissue,O
on,O
the,O
inside,O
of,O
the,O
thigh,O
[,O
31,O
",",O
74,O
].,O
Yamakawa,O
et,O
al,O
.,O
and,O
a,O
systematic,O
review,O
by,O
Nantel,O
support,O
that,O
walking,O
is,O
indicative,O
of,O
increasing,O
PA,O
level,O
and,O
mobility,O
.,O
Therefore,O
with,O
increased,O
weight,O
",",O
ambulation,O
becomes,O
more,O
energy,O
intensive,O
and,O
uncomfortable,O
",",O
resulting,O
in,O
further,O
sedentary,O
behavior,O
and,O
obesity,B-DS
[,O
25,O
].,O
Though,O
ambulation,O
was,O
not,O
directly,O
assessed,O
in,O
our,O
study,O
",",O
PA,O
decline,O
may,O
be,O
attributed,O
to,O
similar,O
mechanisms,O
.,O
In,O
addition,O
",",O
aerobic,O
capacity,O
in,O
obese,O
individuals,O
has,O
been,O
shown,O
to,O
be,O
lower,O
than,O
normal,O
weight,O
individuals,O
[,O
75,O
].,O
These,O
mechanisms,O
proposed,O
by,O
previous,O
researchers,O
offer,O
some,O
support,O
for,O
our,O
results,O
that,O
increases,O
in,O
obesity,B-DS
may,O
result,O
in,O
a,O
decrease,O
of,O
PA,O
level,O
.,O
ESE,O
expressed,O
a,O
significant,O
negative,O
relationship,O
with,O
obesity,B-DS
(,O
Table,O
2,O
).,O
This,O
trend,O
is,O
supported,O
by,O
current,O
as,O
literature,O
in,O
that,O
an,O
individual,O
’,O
s,O
BMI,O
increased,O
",",O
their,O
level,O
of,O
ESE,O
decreased,O
[,O
32,O
].,O
While,O
we,O
did,O
not,O
assess,O
postmenopausal,O
prevalence,O
",",O
the,O
majority,O
of,O
the,O
participant,O
population,O
was,O
30,O
–,O
49,O
years,O
old,O
.,O
This,O
suggests,O
a,O
need,O
for,O
addressing,O
exercise,O
self,O
-,O
efficacy,O
in,O
this,O
population,O
in,O
order,O
to,O
increase,O
an,O
individual,O
’,O
s,O
confidence,O
that,O
they,O
can,O
start,O
or,O
keep,O
up,O
exercise,O
and,O
lose,O
weight,O
",",O
to,O
counter,O
the,O
effects,O
of,O
being,O
overweight,O
or,O
obese,O
.,O
Trost,O
and,O
colleagues,O
found,O
significant,O
results,O
indicating,O
that,O
their,O
obese,O
participants,O
were,O
significantly,O
less,O
confident,O
in,O
their,O
ability,O
to,O
overcome,O
barriers,O
to,O
physical,O
activity,O
",",O
to,O
ask,O
parents,O
to,O
provide,O
opportunities,O
for,O
physical,O
activity,O
",",O
and,O
to,O
choose,O
physically,O
active,O
pursuits,O
over,O
sedentary,O
ones,O
[,O
32,O
].,O
In,O
our,O
third,O
hypothesis,O
",",O
the,O
mediated,O
structural,O
hypothesis,O
of,O
the,O
OMH,O
model,O
was,O
supported,O
for,O
partial,O
mediation,O
in,O
some,O
outcome,O
variables,O
.,O
Wrist,O
-,O
forearm,O
pain,O
",",O
significantly,O
mediated,O
(,O
95,O
%,O
CI,O
:,O
−,O
0,O
.,O
1050,O
",",O
−,O
0,O
.,O
0036,O
),O
about,O
29,O
.,O
7,O
%,O
of,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
moderate,O
physical,O
function,O
(,O
Table,O
3,O
).,O
This,O
suggests,O
that,O
the,O
adverse,O
effects,O
of,O
obesity,B-DS
on,O
moderate,O
physical,O
function,O
may,O
be,O
manifested,O
in,O
part,O
",",O
through,O
wrist,O
-,O
forearm,O
pain,O
.,O
Since,O
our,O
population,O
was,O
primarily,O
female,O
(,O
approximately,O
91,O
"%),",O
these,O
results,O
closely,O
align,O
with,O
findings,O
from,O
Fowler,O
-,O
Brown,O
and,O
colleagues,O
",",O
which,O
showed,O
a,O
22,O
–,O
44,O
%,O
partial,O
mediation,O
of,O
bodily,O
pain,O
with,O
physical,O
function,O
in,O
women,O
.,O
Furthermore,O
",",O
their,O
study,O
found,O
that,O
bodily,O
pain,O
was,O
significantly,O
associated,O
with,O
disability,O
",",O
performance,O
",",O
and,O
physical,O
function,O
[,O
13,O
].,O
A,O
study,O
by,O
Heo,O
et,O
al,O
.,O
found,O
that,O
attenuation,O
in,O
the,O
association,O
between,O
obesity,B-DS
and,O
functional,O
impairment,O
was,O
largely,O
explained,O
by,O
medical,O
comorbid,O
conditions,O
",",O
and,O
indicated,O
the,O
presence,O
of,O
joint,O
pain,O
and,O
mental,O
health,O
problems,O
further,O
reduced,O
the,O
odds,O
ratios,O
in,O
this,O
relationship,O
[,O
10,O
].,O
The,O
wrist,O
-,O
forearm,O
joint,O
also,O
significantly,O
mediated,O
35,O
.,O
2,O
%,O
of,O
the,O
relationship,O
between,O
the,O
role,O
of,O
emotions,O
in,O
accomplishing,O
less,O
at,O
work,O
and,O
at,O
home,O
(,O
95,O
%,O
CI,O
:,O
0,O
.,O
0010,O
",",O
0,O
.,O
1520,O
;,O
95,O
%,O
CI,O
:,O
0,O
.,O
0015,O
",",O
0,O
.,O
0985,O
),O
(,O
Table,O
4,O
).,O
Pain,O
has,O
been,O
supported,O
to,O
be,O
a,O
deterrent,O
to,O
activities,O
of,O
daily,O
living,O
(,O
ADLs,O
"),",O
and,O
has,O
been,O
supported,O
by,O
recent,O
reviews,O
[,O
3,O
",",O
8,O
",",O
9,O
].,O
Additionally,O
",",O
Heo,O
et,O
al,O
.,O
found,O
in,O
their,O
mediation,O
analysis,O
that,O
the,O
effects,O
of,O
high,O
BMI,O
on,O
HRQOL,O
were,O
significantly,O
attenuated,O
when,O
musculoskeletal,O
pain,O
and,O
obesity,B-DS
-,O
related,O
comorbidities,O
were,O
included,O
in,O
the,O
models,O
.,O
Other,O
studies,O
assessing,O
international,O
differences,O
in,O
chronic,O
widespread,O
musculoskeletal,O
pain,O
showed,O
that,O
excess,O
prevalence,O
in,O
countries,O
of,O
Eastern,O
Europe,O
were,O
associated,O
with,O
poorer,O
physical,O
health,O
and,O
psychosocial,O
factors,O
(,O
stressful,O
life,O
events,O
),O
[,O
9,O
",",O
76,O
",",O
77,O
].,O
These,O
findings,O
offer,O
some,O
support,O
for,O
our,O
results,O
that,O
wrist,O
-,O
forearm,O
pain,O
is,O
a,O
critical,O
component,O
in,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
emotional,O
role,O
in,O
accomplishing,O
less,O
at,O
work,O
or,O
at,O
home,O
.,O
In,O
assessing,O
emotional,O
role,O
of,O
being,O
less,O
careful,O
at,O
work,O
or,O
at,O
home,O
",",O
the,O
wrist,O
-,O
forearm,O
joint,O
significantly,O
expressed,O
inconsistent,O
mediation,O
(,O
95,O
%,O
CI,O
:,O
0,O
.,O
0015,O
",",O
0,O
.,O
0985,O
"),",O
with,O
the,O
indirect,O
effect,O
creating,O
a,O
larger,O
direct,O
effect,O
than,O
the,O
total,O
effect,O
(,O
Table,O
5,O
).,O
This,O
suggests,O
that,O
the,O
wrist,O
-,O
forearm,O
may,O
actually,O
decrease,O
the,O
role,O
of,O
emotions,O
in,O
being,O
less,O
careful,O
due,O
to,O
pain,O
",",O
and,O
make,O
the,O
individual,O
more,O
careful,O
.,O
One,O
potential,O
explanation,O
could,O
be,O
the,O
fear,O
-,O
avoidance,O
model,O
[,O
41,O
",",O
78,O
"],",O
which,O
postulates,O
that,O
an,O
acute,O
episode,O
of,O
pain,O
may,O
cause,O
the,O
individual,O
to,O
develop,O
pain,O
-,O
related,O
fear,O
that,O
results,O
in,O
attention,O
to,O
pain,O
and,O
guarded,O
movements,O
",",O
however,O
should,O
be,O
conditional,O
only,O
to,O
those,O
who,O
reported,O
wrist,O
-,O
forearm,O
pain,O
.,O
In,O
our,O
sample,O
",",O
an,O
acute,O
episode,O
of,O
wrist,O
-,O
forearm,O
pain,O
may,O
have,O
resulted,O
in,O
more,O
attention,O
to,O
activities,O
requiring,O
heavy,O
use,O
of,O
the,O
joint,O
",",O
and,O
contribute,O
to,O
careful,O
behavior,O
.,O
This,O
may,O
have,O
long,O
-,O
term,O
implications,O
in,O
that,O
these,O
individuals,O
may,O
develop,O
a,O
chronic,O
condition,O
due,O
to,O
the,O
adaptations,O
initiated,O
from,O
feeling,O
acute,O
pain,O
.,O
Lastly,O
",",O
the,O
pain,O
in,O
the,O
wrist,O
-,O
forearm,O
region,O
also,O
significantly,O
mediated,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
ESE,O
(,O
95,O
%,O
CI,O
:,O
−,O
0,O
.,O
1510,O
",",O
−,O
0,O
.,O
0137,O
"),",O
at,O
about,O
17,O
.,O
6,O
%,O
(,O
Table,O
6,O
).,O
This,O
suggests,O
the,O
adverse,O
effects,O
of,O
obesity,B-DS
on,O
lower,O
ESE,O
may,O
be,O
manifested,O
in,O
part,O
",",O
due,O
to,O
wrist,O
-,O
forearm,O
pain,O
.,O
Coinciding,O
with,O
previous,O
research,O
",",O
lower,O
ESE,O
has,O
consistently,O
been,O
associated,O
with,O
obesity,B-DS
",",O
and,O
is,O
also,O
associated,O
with,O
musculoskeletal,O
pain,O
[,O
40,O
].,O
In,O
particular,O
",",O
obese,O
females,O
have,O
been,O
reported,O
to,O
have,O
lower,O
self,O
-,O
efficacy,O
regarding,O
physical,O
activities,O
and,O
this,O
must,O
be,O
addressed,O
in,O
order,O
to,O
increase,O
compliance,O
with,O
exercise,O
[,O
18,O
].,O
In,O
our,O
last,O
hypothesis,O
",",O
the,O
mediated,O
structural,O
hypothesis,O
of,O
the,O
OEP,O
model,O
was,O
supported,O
for,O
partial,O
mediation,O
in,O
almost,O
all,O
variables,O
except,O
for,O
mild,O
PA,O
.,O
ESE,O
significantly,O
mediated,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
current,O
PA,O
levels,O
(,O
95,O
%,O
CI,O
:,O
−,O
0,O
.,O
1348,O
",",O
−,O
0,O
.,O
0001,O
),O
of,O
about,O
16,O
.,O
4,O
%.,O
This,O
furthers,O
previous,O
research,O
regarding,O
obese,O
adolescents,O
[,O
34,O
",",O
35,O
",",O
39,O
],O
in,O
that,O
not,O
only,O
does,O
ESE,O
at,O
baseline,O
predict,O
subsequent,O
levels,O
of,O
PA,O
",",O
but,O
is,O
an,O
explanatory,O
variable,O
in,O
the,O
relationship,O
between,O
increased,O
BMI,O
and,O
decreased,O
physical,O
activity,O
behavior,O
.,O
ESE,O
also,O
significantly,O
mediated,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
moderate,O
physical,O
activity,O
levels,O
(,O
95,O
%,O
CI,O
:,O
−,O
0,O
.,O
1595,O
",",O
−,O
0,O
.,O
0156,O
),O
with,O
about,O
26,O
.,O
4,O
"%,",O
as,O
well,O
as,O
vigorous,O
physical,O
activity,O
levels,O
(,O
95,O
%,O
CI,O
:,O
−,O
0,O
.,O
1365,O
",",O
−,O
0,O
.,O
0171,O
),O
of,O
about,O
44,O
.,O
8,O
%.,O
These,O
results,O
coincide,O
and,O
further,O
research,O
by,O
Trost,O
",",O
Kerr,O
",",O
Ward,O
",",O
and,O
Pate,O
",",O
in,O
which,O
obese,O
children,O
not,O
only,O
exhibited,O
significantly,O
lower,O
daily,O
accumulations,O
of,O
moderate,O
and,O
vigorous,O
physical,O
activity,O
",",O
but,O
also,O
significantly,O
lower,O
levels,O
of,O
physical,O
activity,O
self,O
-,O
efficacy,O
.,O
However,O
",",O
our,O
results,O
show,O
that,O
ESE,O
is,O
a,O
significant,O
partial,O
mediator,O
of,O
the,O
adverse,O
effect,O
of,O
obesity,B-DS
on,O
physical,O
activity,O
behaviors,O
in,O
this,O
sample,O
of,O
overweight,O
and,O
obesity,B-DS
.,O
Building,O
confidence,O
of,O
overweight,O
and,O
obese,O
individuals,O
",",O
who,O
intend,O
to,O
start,O
physical,O
activities,O
",",O
even,O
if,O
the,O
intensity,O
is,O
low,O
",",O
has,O
been,O
shown,O
to,O
be,O
important,O
specifically,O
for,O
females,O
",",O
who,O
report,O
lower,O
confidence,O
in,O
physical,O
activity,O
[,O
18,O
].,O
Study,O
Limitations,O
Although,O
height,O
and,O
weight,O
were,O
measured,O
by,O
trained,O
health,O
educators,O
",",O
other,O
variables,O
utilized,O
self,O
-,O
reported,O
survey,O
components,O
which,O
may,O
result,O
in,O
an,O
under,O
-,O
reporting,O
or,O
over,O
-,O
reporting,O
of,O
pain,O
symptoms,O
.,O
Our,O
sample,O
size,O
was,O
small,O
.,O
Since,O
this,O
was,O
also,O
a,O
cross,O
-,O
sectional,O
study,O
",",O
causation,O
cannot,O
be,O
determined,O
using,O
these,O
associations,O
and,O
statistical,O
models,O
.,O
The,O
reverse,O
associations,O
may,O
occur,O
in,O
that,O
musculoskeletal,O
pain,O
may,O
affect,O
obesity,B-DS
",",O
as,O
also,O
supported,O
by,O
previous,O
reviews,O
[,O
3,O
",",O
8,O
",",O
9,O
",",O
24,O
].,O
Future,O
studies,O
should,O
focus,O
on,O
testing,O
the,O
model,O
in,O
reverse,O
and,O
for,O
causality,O
",",O
as,O
well,O
as,O
obtaining,O
a,O
larger,O
population,O
for,O
more,O
pronounced,O
relationships,O
.,O
Our,O
measures,O
of,O
physical,O
activity,O
and,O
physical,O
function,O
were,O
limited,O
",",O
and,O
had,O
some,O
overlaps,O
in,O
work,O
and,O
exercise,O
allocations,O
",",O
which,O
should,O
be,O
segregated,O
in,O
future,O
questions,O
.,O
In,O
addition,O
",",O
other,O
factors,O
have,O
been,O
proposed,O
as,O
possible,O
mediators,O
in,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
HRQOL,O
outcomes,O
",",O
such,O
as,O
obesity,B-DS
-,O
related,O
comorbidities,O
",",O
and,O
should,O
be,O
tested,O
in,O
addition,O
to,O
joint,O
pain,O
in,O
future,O
models,O
.,O
Conclusion,O
Our,O
data,O
indicate,O
that,O
being,O
overweight,O
and,O
obese,O
is,O
an,O
important,O
correlate,O
of,O
impaired,O
HRQOL,O
",",O
Physical,O
Activity,O
",",O
and,O
ESE,O
.,O
In,O
addition,O
",",O
high,O
-,O
risk,O
occupations,O
such,O
as,O
the,O
nursing,O
home,O
population,O
have,O
a,O
high,O
prevalence,O
of,O
musculoskeletal,O
pain,O
in,O
WB,O
and,O
NWB,O
joints,O
.,O
The,O
results,O
from,O
the,O
empirical,O
test,O
of,O
the,O
OMH,O
and,O
OEP,O
model,O
suggest,O
that,O
experiencing,O
pain,O
may,O
be,O
a,O
mechanism,O
by,O
which,O
obesity,B-DS
affects,O
impaired,O
HRQOL,O
",",O
lower,O
PA,O
levels,O
",",O
and,O
lower,O
ESE,O
.,O
Specifically,O
",",O
the,O
WB,O
joints,O
seem,O
to,O
have,O
a,O
larger,O
influence,O
on,O
vigorous,O
physical,O
activity,O
and,O
function,O
",",O
and,O
NWB,O
joints,O
(,O
particularly,O
the,O
wrist,O
-,O
forearm,O
),O
have,O
a,O
larger,O
influence,O
on,O
moderate,O
physical,O
activities,O
and,O
function,O
.,O
Lower,O
ESE,O
is,O
also,O
a,O
significant,O
partial,O
mediator,O
in,O
the,O
relationship,O
between,O
obesity,B-DS
and,O
physical,O
activity,O
",",O
particularly,O
in,O
moderate,O
and,O
vigorous,O
physical,O
activities,O
",",O
and,O
should,O
also,O
be,O
addressed,O
in,O
weight,O
-,O
loss,O
programs,O
for,O
overweight,O
and,O
obese,O
adults,O
with,O
or,O
without,O
joint,O
pain,O
.,O
Theoretical,O
Model,O
of,O
Obesity,B-DS
",",O
Musculoskeletal,O
Pain,O
",",O
and,O
Health,O
-,O
Related,O
Quality,O
of,O
Life,O
Outcomes,O
(,O
OMH,O
).,O
Theoretical,O
Model,O
of,O
Obesity,B-DS
",",O
Exercise,O
Self,O
-,O
Efficacy,O
",",O
and,O
Physical,O
Activity,O
Outcomes,O
(,O
OEP,O
).,O
Musculoskeletal,O
Pain,O
Distribution,O
among,O
Participants,O
.,O
General,O
Demographic,O
Characteristics,O
of,O
Participants,O
(,O
n,O
=,O
99,O
).,O
Characteristic,O
N,O
n,O
%,O
Age,O
18,O
–,O
29,O
6,O
6,O
%,O
30,O
–,O
49,O
51,O
52,O
%,O
50,O
–,O
64,O
35,O
35,O
%,O
>,O
65,O
6,O
6,O
%,O
Gender,O
Male,O
9,O
9,O
%,O
Female,O
90,O
91,O
%,O
BMI,O
Overweight,O
20,O
20,O
.,O
2,O
%,O
Obese,O
Class,O
I,O
34,O
34,O
.,O
3,O
%,O
Obese,O
Class,O
II,O
23,O
23,O
.,O
2,O
%,O
Obese,O
Class,O
III,O
22,O
22,O
.,O
2,O
%,O
Education,O
Less,O
than,O
High,O
School,O
8,O
8,O
%,O
High,O
School,O
(,O
Secondary,O
),O
39,O
39,O
%,O
College,O
/,O
Professional,O
45,O
45,O
%,O
Post,O
-,O
Graduate,O
7,O
7,O
%,O
Ethnicity,O
African,O
American,O
40,O
40,O
%,O
Caucasian,O
47,O
48,O
%,O
Other,O
12,O
12,O
%,O
Job,O
Administration,O
/,O
Clerical,O
12,O
12,O
%,O
CNA,O
/,O
GNA,O
30,O
30,O
%,O
LPN,O
14,O
14,O
%,O
RN,O
13,O
13,O
%,O
Other,O
30,O
30,O
%,O
Associations,O
between,O
Level,O
of,O
Obesity,B-DS
",",O
Health,O
-,O
Related,O
Quality,O
of,O
life,O
",",O
Physical,O
Activity,O
",",O
and,O
Exercise,O
Self,O
-,O
Efficacy,O
.,O
GeneralHealth,O
PhysicalFunction,O
(,O
Moderate,O
),O
PhysicalFunction,O
(,O
Vigorous,O
),O
EmotionalRole,O
(,O
Accomplish,O
Less,O
),O
EmotionalRole,O
(,O
LessCareful,O
),O
SocialInterference,O
CurrentPhysicalActivity,O
MildPhysicalActivity,O
ModeratePhysicalActivity,O
VigorousPhysicalActivity,O
ExerciseSelf,O
-,O
Efficacy,O
BMI,O
Correlation,O
Coefficient,O
−,O
0,O
.,O
191,O
−,O
0,O
.,O
109,O
−,O
0,O
.,O
308,O
0,O
.,O
137,O
0,O
.,O
004,O
0,O
.,O
005,O
−,O
0,O
.,O
248,O
−,O
0,O
.,O
129,O
−,O
0,O
.,O
293,O
−,O
0,O
.,O
176,O
−,O
0,O
.,O
239,O
Significance,O
(,O
2,O
-,O
tailed,O
),O
0,O
.,O
059,O
0,O
.,O
284,O
0,O
.,O
002,O
0,O
.,O
178,O
0,O
.,O
969,O
0,O
.,O
961,O
0,O
.,O
013,O
0,O
.,O
202,O
0,O
.,O
003,O
0,O
.,O
082,O
0,O
.,O
017,O
Mediation,O
Results,O
on,O
Moderate,O
Physical,O
Function,O
in,O
Participants,O
(,O
n,O
=,O
99,O
).,O
Path,O
A,O
Path,O
B,O
Path,O
C,O
Direct,O
Effect,O
Indirect,O
Effect,O
Total,O
Effect,O
Proportion,O
Mediated,O
Bootstrapped,O
95,O
%,O
CI,O
(,O
Path,O
C,O
′),O
(,O
Bootstrapped,O
Path,O
A,O
*,O
B,O
),O
(,O
Path,O
C,O
),O
1,O
-,O
c,O
′/,O
c,O
(,O
Lower,O
Bound,O
",",O
Upper,O
Bound,O
),O
Mediator,O
Path,O
Coefficient,O
(,O
b,O
),O
Low,O
Back,O
0,O
.,O
1073,O
−,O
0,O
.,O
1175,O
−,O
0,O
.,O
042,O
−,O
0,O
.,O
0294,O
−,O
0,O
.,O
0117,O
−,O
0,O
.,O
0411,O
0,O
.,O
3,O
−,O
0,O
.,O
0473,O
",",O
0,O
.,O
0122,O
Knee,O
0,O
.,O
0595,O
−,O
0,O
.,O
0626,O
−,O
0,O
.,O
042,O
−,O
0,O
.,O
0383,O
−,O
0,O
.,O
0031,O
−,O
0,O
.,O
0414,O
0,O
.,O
0880952,O
−,O
0,O
.,O
0274,O
",",O
0,O
.,O
0135,O
Shoulder,O
−,O
0,O
.,O
0482,O
−,O
0,O
.,O
0865,O
−,O
0,O
.,O
042,O
−,O
0,O
.,O
0462,O
0,O
.,O
0041,O
−,O
0,O
.,O
0421,O
−,O
0,O
.,O
1,O
−,O
0,O
.,O
0211,O
",",O
0,O
.,O
0392,O
Wrist,O
-,O
forearm,O
0,O
.,O
2037,O
−,O
0,O
.,O
1598,O
−,O
0,O
.,O
042,O
−,O
0,O
.,O
0094,O
−,O
0,O
.,O
0341,O
−,O
0,O
.,O
0435,O
0,O
.,O
7761905,O
−,O
0,O
.,O
1050,O
",",O
−,O
0,O
.,O
0036,O
Mediation,O
Results,O
on,O
Emotional,O
Role,O
(,O
Accomplishing,O
Less,O
),O
in,O
Participants,O
(,O
n,O
=,O
99,O
).,O
Path,O
A,O
Path,O
B,O
Path,O
C,O
Direct,O
Effect,O
Indirect,O
Effect,O
Total,O
Effect,O
Proportion,O
Mediated,O
Bootstrapped,O
95,O
%,O
CI,O
(,O
Path,O
C,O
′),O
(,O
Bootstrapped,O
Path,O
A,O
*,O
B,O
),O
(,O
Path,O
C,O
),O
1,O
-,O
c,O
′/,O
c,O
(,O
Lower,O
Bound,O
",",O
Upper,O
Bound,O
),O
Mediator,O
Path,O
Coefficient,O
(,O
b,O
),O
Low,O
Back,O
0,O
.,O
1073,O
0,O
.,O
1966,O
0,O
.,O
1216,O
0,O
.,O
1005,O
0,O
.,O
0223,O
−,O
0,O
.,O
0182,O
0,O
.,O
1735197,O
−,O
0,O
.,O
0182,O
",",O
0,O
.,O
0881,O
Knee,O
0,O
.,O
0595,O
0,O
.,O
0911,O
0,O
.,O
1216,O
0,O
.,O
1161,O
0,O
.,O
0072,O
0,O
.,O
1233,O
0,O
.,O
0452303,O
−,O
0,O
.,O
0152,O
",",O
0,O
.,O
0623,O
Shoulder,O
−,O
0,O
.,O
0482,O
0,O
.,O
1023,O
0,O
.,O
1216,O
0,O
.,O
1265,O
−,O
0,O
.,O
0032,O
0,O
.,O
1233,O
−,O
0,O
.,O
0402961,O
−,O
0,O
.,O
0592,O
",",O
0,O
.,O
0218,O
Wrist,O
-,O
forearm,O
0,O
.,O
2037,O
0,O
.,O
2102,O
0,O
.,O
1216,O
0,O
.,O
0788,O
0,O
.,O
0434,O
0,O
.,O
1222,O
0,O
.,O
3519737,O
0,O
.,O
0010,O
",",O
0,O
.,O
1520,O
Mediation,O
Results,O
on,O
Emotional,O
Role,O
(,O
Less,O
Careful,O
),O
in,O
Participants,O
(,O
n,O
=,O
99,O
).,O
Path,O
A,O
Path,O
B,O
Path,O
C,O
Direct,O
Effect,O
Indirect,O
Effect,O
Total,O
Effect,O
Proportion,O
Mediated,O
Bootstrapped,O
95,O
%,O
CI,O
(,O
Path,O
C,O
′),O
(,O
Bootstrapped,O
Path,O
A,O
*,O
B,O
),O
(,O
Path,O
C,O
),O
1,O
-,O
c,O
′/,O
c,O
(,O
Lower,O
Bound,O
",",O
Upper,O
Bound,O
),O
Mediator,O
Path,O
Coefficient,O
(,O
b,O
),O
Low,O
Back,O
0,O
.,O
1073,O
0,O
.,O
1355,O
0,O
.,O
003,O
−,O
0,O
.,O
0115,O
0,O
.,O
0155,O
0,O
.,O
004,O
4,O
.,O
8333333,O
−,O
0,O
.,O
0117,O
",",O
0,O
.,O
0711,O
Knee,O
0,O
.,O
0595,O
0,O
.,O
095,O
0,O
.,O
003,O
−,O
0,O
.,O
0026,O
0,O
.,O
0075,O
0,O
.,O
0049,O
1,O
.,O
8666667,O
−,O
0,O
.,O
0168,O
",",O
0,O
.,O
0564,O
Shoulder,O
−,O
0,O
.,O
0482,O
0,O
.,O
0736,O
0,O
.,O
003,O
0,O
.,O
0066,O
−,O
0,O
.,O
0031,O
0,O
.,O
0035,O
−,O
1,O
.,O
2,O
−,O
0,O
.,O
0507,O
",",O
0,O
.,O
0162,O
Wrist,O
-,O
forearm,O
0,O
.,O
2037,O
0,O
.,O
1712,O
0,O
.,O
003,O
−,O
0,O
.,O
0318,O
0,O
.,O
0335,O
0,O
.,O
0017,O
11,O
.,O
6,O
0,O
.,O
0015,O
",",O
0,O
.,O
0985,O
Mediation,O
Results,O
on,O
Exercise,O
Self,O
-,O
Efficacy,O
in,O
Nursing,O
Home,O
Employees,O
(,O
n,O
=,O
99,O
).,O
Path,O
A,O
Path,O
B,O
Path,O
C,O
Direct,O
Effect,O
Indirect,O
Effect,O
Total,O
Effect,O
Proportion,O
Mediated,O
Bootstrapped,O
95,O
%,O
CI,O
(,O
Path,O
C,O
′),O
(,O
Bootstrapped,O
Path,O
A,O
*,O
B,O
),O
(,O
Path,O
C,O
),O
1,O
-,O
c,O
′/,O
c,O
(,O
Lower,O
Bound,O
",",O
Upper,O
Bound,O
),O
Mediator,O
Path,O
Coefficient,O
(,O
b,O
),O
Low,O
Back,O
0,O
.,O
1073,O
−,O
0,O
.,O
1212,O
−,O
0,O
.,O
3377,O
−,O
0,O
.,O
3247,O
−,O
0,O
.,O
0152,O
−,O
0,O
.,O
3399,O
0,O
.,O
0384957,O
−,O
0,O
.,O
0949,O
",",O
0,O
.,O
0109,O
Knee,O
0,O
.,O
0595,O
−,O
0,O
.,O
0369,O
−,O
0,O
.,O
3377,O
−,O
0,O
.,O
3355,O
−,O
0,O
.,O
0032,O
−,O
0,O
.,O
3387,O
0,O
.,O
0065147,O
−,O
0,O
.,O
0575,O
",",O
0,O
.,O
0177,O
Shoulder,O
−,O
0,O
.,O
0482,O
−,O
0,O
.,O
0262,O
−,O
0,O
.,O
3377,O
−,O
0,O
.,O
339,O
0,O
.,O
0036,O
−,O
0,O
.,O
3354,O
−,O
0,O
.,O
0038496,O
−,O
0,O
.,O
0206,O
",",O
0,O
.,O
0478,O
Wrist,O
-,O
forearm,O
0,O
.,O
2037,O
−,O
0,O
.,O
2925,O
−,O
0,O
.,O
3377,O
−,O
0,O
.,O
2781,O
−,O
0,O
.,O
0583,O
−,O
0,O
.,O
3364,O
0,O
.,O
176488,O
−,O
0,O
.,O
1510,O
",",O
−,O
0,O
.,O
0137,O
Mediation,O
Results,O
on,O
Physical,O
Activity,O
Levels,O
in,O
Nursing,O
Home,O
Employees,O
(,O
n,O
=,O
99,O
).,O
Path,O
A,O
Path,O
B,O
Path,O
C,O
Direct,O
Effect,O
Indirect,O
Effect,O
Total,O
Effect,O
Proportion,O
Mediated,O
by,O
ESE,O
Bootstrapped,O
95,O
%,O
CI,O
(,O
Path,O
C,O
′),O
(,O
Bootstrapped,O
Path,O
A,O
*,O
B,O
),O
(,O
Direct,O
Effect,O
+,O
Indirect,O
Effect,O
),O
1,O
-,O
c,O
′/,O
c,O
(,O
Lower,O
Bound,O
",",O
Upper,O
Bound,O
),O
Outcome,O
Measures,O
Path,O
Coefficient,O
(,O
b,O
),O
Current,O
Physical,O
Activity,O
−,O
0,O
.,O
3635,O
0,O
.,O
116,O
−,O
0,O
.,O
2567,O
−,O
0,O
.,O
2145,O
−,O
0,O
.,O
0428,O
−,O
0,O
.,O
2573,O
0,O
.,O
1643942,O
−,O
0,O
.,O
1348,O
",",O
−,O
0,O
.,O
0001,O
Mild,O
Physical,O
Activity,O
−,O
0,O
.,O
3635,O
0,O
.,O
0537,O
−,O
0,O
.,O
1095,O
−,O
0,O
.,O
0899,O
−,O
0,O
.,O
0205,O
−,O
0,O
.,O
1104,O
0,O
.,O
1789954,O
−,O
0,O
.,O
0986,O
",",O
0,O
.,O
0234,O
Moderate,O
Physical,O
Activity,O
(,O
PA,O
),O
−,O
0,O
.,O
3635,O
0,O
.,O
1868,O
−,O
0,O
.,O
2566,O
−,O
0,O
.,O
1888,O
−,O
0,O
.,O
0684,O
−,O
0,O
.,O
2572,O
0,O
.,O
2642245,O
−,O
0,O
.,O
1595,O
",",O
−,O
0,O
.,O
0156,O
Vigorous,O
Physical,O
Activity,O
(,O
PA,O
),O
−,O
0,O
.,O
3635,O
0,O
.,O
1743,O
−,O
0,O
.,O
1415,O
−,O
0,O
.,O
0781,O
−,O
0,O
.,O
0631,O
−,O
0,O
.,O
1412,O
0,O
.,O
4480565,O
−,O
0,O
.,O
1365,O
",",O
−,O
0,O
.,O
0171,O
Tuberculosis,B-DS
treatment,O
outcomes,O
of,O
six,O
and,O
eight,O
month,O
treatment,O
regimens,O
in,O
districts,O
of,O
Southwestern,O
Ethiopia,O
:,O
a,O
comparative,O
cross,O
-,O
sectional,O
study,O
Background,O
A,O
switch,O
of,O
continuation,O
phase,O
tuberculosis,B-DS
(,O
TB,B-DS
),O
treatment,O
regimen,O
from,O
Ethambutol,O
(,O
E,O
),O
and,O
Isoniazid,O
(,O
H,O
),O
combination,O
for,O
6,O
months,O
(,O
6EH,O
),O
to,O
Rifampicin,O
(,O
R,O
),O
and,O
Isoniazid,O
(,O
H,O
),O
combination,O
for,O
4,O
months,O
(,O
4RH,O
),O
was,O
recommended,O
.,O
However,O
",",O
the,O
effect,O
of,O
the,O
regimen,O
switch,O
in,O
Ethiopian,O
setting,O
is,O
not,O
known,O
.,O
Methods,O
A,O
comparative,O
cross,O
-,O
sectional,O
study,O
among,O
790,O
randomly,O
selected,O
new,O
cases,O
of,O
TB,B-DS
(,O
395,O
each,O
treated,O
with,O
4RH,O
and,O
6EH,O
during,O
the,O
continuation,O
phase,O
),O
was,O
conducted,O
in,O
nine,O
health,O
centers,O
and,O
one,O
hospital,O
in,O
three,O
zones,O
in,O
southwestern,O
Ethiopia,O
.,O
Data,O
were,O
abstracted,O
from,O
the,O
standard,O
unit,O
TB,B-DS
register,O
composed,O
of,O
standard,O
case,O
and,O
treatment,O
outcome,O
definitions,O
.,O
Data,O
were,O
analyzed,O
using,O
STATA,O
version,O
13,O
where,O
binary,O
logistic,O
regression,O
was,O
fitted,O
to,O
identify,O
independent,O
predictors,O
of,O
unsuccessful,O
treatment,O
outcomes,O
at,O
5,O
%,O
significance,O
level,O
.,O
Results,O
Over,O
all,O
",",O
695,O
(,O
88,O
%),O
of,O
the,O
patients,O
had,O
a,O
successful,O
treatment,O
outcome,O
with,O
statistically,O
significant,O
difference,O
(,O
85,O
.,O
3,O
%,O
vs,O
90,O
.,O
6,O
"%,",O
p,O
=,O
0,O
.,O
02,O
),O
among,O
the,O
6HE,O
and,O
4RH,O
regimens,O
",",O
respectively,O
.,O
After,O
adjusting,O
for,O
confounders,O
",",O
4RH,O
continuation,O
phase,O
treatment,O
regimen,O
adjusted,O
odds,O
ratio,O
(,O
AOR,O
),O
[(,O
95,O
%,O
confidence,O
interval,O
(,O
CI,O
)),O
0,O
.,O
55,O
(,O
0,O
.,O
34,O
",",O
0,O
.,O
89,O
")],",O
age,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
1,O
.,O
02,O
(,O
1,O
.,O
001,O
",",O
1,O
.,O
022,O
")],",O
rural,O
residence,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
),O
2,O
.,O
1,O
(,O
1,O
.,O
18,O
",",O
3,O
.,O
75,O
)],O
Human,B-OG
Immunodeficiency,I-OG
virus,I-OG
(,O
HIV,B-OG
),O
positives,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
),O
2,O
.,O
39,O
(,O
1,O
.,O
12,O
",",O
5,O
.,O
07,O
)],O
and,O
increased,O
weight,O
at,O
the,O
end,O
of,O
the,O
second,O
month,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
0,O
.,O
28,O
(,O
0,O
.,O
11,O
",",O
0,O
.,O
72,O
)],O
independently,O
predicted,O
treatment,O
outcome,O
.,O
Conclusion,O
The,O
switch,O
of,O
continuation,O
phase,O
TB,B-DS
treatment,O
regimen,O
from,O
6EH,O
to,O
4RH,O
has,O
brought,O
better,O
treatment,O
outcomes,O
which,O
imply,O
applicability,O
of,O
the,O
recommendation,O
in,O
high,O
prevalent,O
and,O
resource,O
constrained,O
settings,O
.,O
Therefore,O
",",O
it,O
should,O
be,O
maintained,O
and,O
augmented,O
through,O
further,O
studies,O
on,O
its,O
impact,O
among,O
the,O
older,O
",",O
rural,O
residents,O
and,O
HIV,B-OG
positives,O
.,O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
doi,O
:,O
10,O
.,O
1186,O
/,O
s12879,O
-,O
016,O
-,O
1917,O
-,O
0,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Background,O
In,O
the,O
history,O
of,O
tuberculosis,B-DS
(,O
TB,B-DS
),O
control,O
",",O
discovery,O
of,O
chemotherapy,O
[,O
1,O
],O
brought,O
about,O
dramatic,O
changes,O
in,O
patient,O
survival,O
.,O
Before,O
the,O
advent,O
of,O
chemotherapy,O
",",O
30,O
–,O
40,O
%,O
of,O
TB,B-DS
cases,O
used,O
to,O
die,O
within,O
a,O
year,O
and,O
50,O
–,O
70,O
%,O
within,O
5,O
–,O
7,O
years,O
after,O
the,O
onset,O
of,O
TB,B-DS
illness,O
[,O
2,O
].,O
Introduction,O
of,O
chemotherapy,O
resulted,O
in,O
cure,O
and,O
reduction,O
of,O
mortality,O
for,O
majority,O
of,O
TB,B-DS
cases,O
[,O
1,O
",",O
3,O
].,O
However,O
",",O
shortly,O
after,O
the,O
therapy,O
",",O
resistance,O
to,O
drug,O
and,O
poor,O
adherence,O
by,O
patients,O
were,O
reported,O
[,O
4,O
].,O
Consequently,O
",",O
the,O
first,O
standard,O
combination,O
therapy,O
for,O
12,O
months,O
comprised,O
of,O
Thiacetazone,O
(,O
T,O
"),",O
Isoniazid,O
(,O
H,O
),O
and,O
streptomycin,O
(,O
S,O
),O
for,O
the,O
first,O
2,O
months,O
(,O
2STH,O
),O
followed,O
by,O
T,O
and,O
H,O
for,O
10,O
months,O
(,O
10TH,O
),O
was,O
issued,O
[,O
2,O
].,O
Subsequent,O
to,O
the,O
introduction,O
of,O
rifampicin,O
(,O
R,O
"),",O
effective,O
short,O
-,O
course,O
chemotherapy,O
regimens,O
for,O
less,O
than,O
12,O
months,O
became,O
standard,O
therapy,O
[,O
2,O
",",O
5,O
–,O
7,O
].,O
The,O
short,O
-,O
course,O
regimens,O
comprised,O
of,O
an,O
initial,O
",",O
or,O
bactericidal,O
",",O
phase,O
called,O
intensive,O
that,O
aimed,O
to,O
kill,O
bacilli,B-OG
and,O
make,O
patients,O
non,O
infectious,O
and,O
a,O
continuation,O
or,O
sterilizing,O
phase,O
which,O
eliminates,O
persisting,O
mycobacteria,B-OG
to,O
prevent,O
relapse,O
[,O
1,O
",",O
8,O
].,O
Thus,O
evidence,O
based,O
combinations,O
of,O
drugs,O
for,O
different,O
categories,O
of,O
cases,O
have,O
been,O
recommended,O
for,O
the,O
two,O
phases,O
across,O
the,O
different,O
regimens,O
[,O
5,O
–,O
7,O
].,O
Introduction,O
of,O
Rifampicin,O
has,O
shortened,O
TB,B-DS
treatment,O
duration,O
[,O
1,O
",",O
9,O
].,O
In,O
1991,O
",",O
an,O
eight,O
months,O
treatment,O
regimen,O
composed,O
of,O
2,O
months,O
intensive,O
with,O
Isoniazid,O
(,O
H,O
"),",O
Rifampicin,O
(,O
R,O
"),",O
Pyrazinamide,O
(,O
Z,O
),O
and,O
Ethambutol,O
(,O
E,O
),O
(,O
2RHZE,O
/,O
S,O
),O
and,O
6,O
months,O
continuation,O
(,O
6HE,O
),O
phases,O
were,O
recommended,O
for,O
all,O
new,O
cases,O
of,O
TB,B-DS
across,O
the,O
world,O
[,O
6,O
].,O
To,O
avoid,O
resistance,O
to,O
the,O
most,O
potent,O
drugs,O
",",O
isoniazid,O
and,O
rifampcin,O
and,O
ensure,O
patient,O
adherence,O
",",O
directly,O
observed,O
treatment,O
short,O
course,O
(,O
DOTS,O
),O
strategy,O
was,O
launched,O
in,O
1994,O
[,O
10,O
].,O
Later,O
in,O
2003,O
",",O
a,O
directly,O
observed,O
intensive,O
phase,O
treatment,O
followed,O
by,O
two,O
continuation,O
phase,O
regimens,O
",",O
6,O
months,O
of,O
isoniazid,O
plus,O
ethambutol,O
(,O
6HE,O
),O
or,O
4,O
months,O
of,O
isoniazid,O
plus,O
rifampicin,O
(,O
4HR,O
),O
were,O
recommended,O
.,O
The,O
4HR,O
continuation,O
phase,O
treatment,O
regimen,O
needed,O
to,O
be,O
observed,O
throughout,O
the,O
treatment,O
period,O
whereas,O
the,O
6EH,O
regimen,O
relied,O
on,O
self,O
administered,O
treatment,O
[,O
5,O
].,O
As,O
a,O
result,O
",",O
regimens,O
without,O
rifampicin,O
had,O
been,O
considered,O
safer,O
in,O
developing,O
countries,O
owing,O
to,O
irregular,O
treatments,O
and,O
high,O
absentee,O
rates,O
[,O
1,O
",",O
5,O
].,O
However,O
",",O
the,O
latest,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
guideline,O
recommends,O
2,O
-,O
month,O
initial,O
phase,O
of,O
(,O
2RHZE,O
),O
and,O
a,O
4,O
-,O
month,O
continuation,O
phase,O
(,O
4RH,O
),O
for,O
the,O
treatment,O
of,O
virtually,O
all,O
forms,O
of,O
new,O
TB,B-DS
cases,O
across,O
the,O
globe,O
[,O
7,O
].,O
The,O
government,O
of,O
Ethiopia,O
has,O
adopted,O
the,O
switch,O
of,O
4HR,O
continuation,O
phase,O
TB,B-DS
treatment,O
for,O
all,O
new,O
cases,O
and,O
accommodated,O
in,O
the,O
latest,O
TB,B-DS
treatment,O
guideline,O
[,O
11,O
].,O
Though,O
global,O
strategies,O
are,O
relevant,O
",",O
investigation,O
of,O
the,O
applicability,O
to,O
the,O
local,O
settings,O
is,O
highly,O
required,O
.,O
A,O
continuation,O
phase,O
treatment,O
with,O
4HR,O
regimen,O
elsewhere,O
has,O
demonstrated,O
lower,O
unsuccessful,O
treatment,O
outcomes,O
and,O
costs,O
as,O
compared,O
to,O
6EH,O
continuation,O
phase,O
[,O
12,O
–,O
15,O
].,O
But,O
well,O
designed,O
studies,O
evaluating,O
effects,O
of,O
the,O
introduction,O
of,O
4RH,O
for,O
the,O
continuation,O
phase,O
TB,B-DS
treatment,O
in,O
high,O
TB,B-DS
burden,O
and,O
resource,O
limited,O
settings,O
like,O
Ethiopia,O
are,O
limited,O
.,O
Thus,O
",",O
we,O
compared,O
treatment,O
outcomes,O
of,O
TB,B-DS
cases,O
who,O
received,O
4RH,O
and,O
6EH,O
continuation,O
phase,O
regimens,O
under,O
routine,O
program,O
condition,O
in,O
high,O
burden,O
and,O
resource,O
limited,O
setting,O
.,O
Our,O
objective,O
was,O
to,O
compare,O
baseline,O
patients,O
’,O
bacteriologic,O
",",O
socio,O
-,O
demographics,O
",",O
clinical,O
characteristics,O
and,O
treatment,O
outcomes,O
among,O
those,O
TB,B-DS
patients,O
treated,O
with,O
the,O
4RH,O
and,O
6EH,O
continuation,O
phase,O
treatment,O
regimens,O
.,O
Methods,O
Study,O
setting,O
We,O
conducted,O
this,O
study,O
in,O
ten,O
health,O
facilities,O
(,O
one,O
hospital,O
and,O
nine,O
health,O
centres,O
),O
in,O
three,O
remote,O
zones,O
of,O
Southern,O
Nation,O
Nationalities,O
and,O
Peoples,O
Region,O
(,O
SNNPR,O
"),",O
one,O
of,O
the,O
nine,O
regions,O
in,O
Ethiopia,O
with,O
about,O
18million,O
population,O
[,O
16,O
].,O
Ethiopia,O
is,O
among,O
the,O
22,O
TB,B-DS
High,O
Burden,O
Countries,O
(,O
HBC,O
),O
where,O
230,O
",",O
000,O
incident,O
cases,O
of,O
which,O
147,O
",",O
592,O
(,O
64,O
%),O
were,O
notified,O
.,O
In,O
the,O
same,O
year,O
",",O
16100,O
deaths,O
and,O
90,O
%,O
treatment,O
success,O
among,O
the,O
smear,O
positives,O
cases,O
registered,O
in,O
2011,O
were,O
reported,O
[,O
17,O
",",O
18,O
].,O
The,O
country,O
has,O
adopted,O
and,O
implemented,O
the,O
DOTS,O
strategy,O
for,O
the,O
treatment,O
of,O
all,O
forms,O
of,O
TB,B-DS
.,O
Accordingly,O
new,O
cases,O
of,O
TB,B-DS
had,O
been,O
treated,O
with,O
directly,O
observed,O
RHZE,O
combinations,O
for,O
the,O
first,O
2,O
months,O
(,O
2RHZE,O
),O
followed,O
by,O
self,O
administered,O
EH,O
combinations,O
for,O
six,O
months,O
(,O
6EH,O
),O
[,O
19,O
].,O
As,O
of,O
the,O
end,O
of,O
2011,O
",",O
the,O
continuation,O
phase,O
treatment,O
was,O
switched,O
from,O
6EH,O
to,O
4RH,O
.,O
Thus,O
the,O
regimen,O
became,O
directly,O
observed,O
2RHZE,O
/,O
4RH,O
combinations,O
for,O
all,O
forms,O
of,O
new,O
TB,B-DS
cases,O
throughout,O
the,O
6,O
months,O
treatment,O
period,O
[,O
11,O
].,O
The,O
three,O
study,O
Zones,O
",",O
Bench,O
Maji,O
",",O
Kaffa,O
and,O
Sheka,O
are,O
located,O
at,O
the,O
southwestern,O
border,O
of,O
the,O
SNNPR,O
where,O
about,O
2,O
",",O
064,O
",",O
102,O
peoples,O
reside,O
[,O
16,O
].,O
The,O
zones,O
(,O
an,O
administrative,O
unit,O
that,O
liaison,O
weredas,O
with,O
the,O
region,O
),O
are,O
organized,O
in,O
to,O
four,O
town,O
administrations,O
and,O
26,O
weredas,O
(,O
lowest,O
administrative,O
unit,O
closer,O
to,O
the,O
community,O
),O
those,O
have,O
three,O
hospitals,O
and,O
65,O
health,O
centers,O
those,O
provide,O
TB,B-DS
DOTS,O
services,O
for,O
free,O
.,O
However,O
",",O
the,O
three,O
hospitals,O
and,O
only,O
27,O
health,O
centers,O
were,O
providing,O
TB,B-DS
/,O
Human,B-OG
Immunodeficeincy,I-OG
Virus,I-OG
(,O
HIV,B-OG
),O
collaborative,O
activities,O
[,O
20,O
].,O
Study,O
design,O
and,O
sampling,O
A,O
comparative,O
cross,O
-,O
sectional,O
study,O
among,O
TB,B-DS
cases,O
treated,O
with,O
2RHZE,O
/,O
6EH,O
and,O
2RHZE,O
/,O
4RH,O
regimens,O
was,O
carried,O
out,O
.,O
New,O
cases,O
registered,O
between,O
2008,O
and,O
2014,O
were,O
eligible,O
of,O
which,O
those,O
aged,O
above,O
15,O
years,O
were,O
studied,O
.,O
Sample,O
size,O
was,O
estimated,O
using,O
the,O
Stat,O
Calc,O
program,O
of,O
Epi,O
Info,O
version,O
7,O
[,O
21,O
],O
with,O
95,O
%,O
confidence,O
level,O
",",O
80,O
%,O
power,O
and,O
ratio,O
of,O
6EH,O
to,O
4RH,O
(,O
r,O
=,O
1,O
).,O
Accordingly,O
",",O
512,O
cases,O
(,O
256,O
from,O
each,O
group,O
),O
was,O
required,O
to,O
detect,O
7,O
%,O
difference,O
[,O
12,O
],O
in,O
the,O
proportion,O
of,O
unsuccessful,O
outcome,O
among,O
the,O
6EH,O
and,O
4RH,O
groups,O
.,O
Finally,O
",",O
considering,O
the,O
design,O
effect,O
of,O
1,O
.,O
5,O
and,O
10,O
%,O
missing,O
records,O
",",O
a,O
total,O
of,O
846,O
cases,O
were,O
required,O
.,O
The,O
samples,O
were,O
selected,O
through,O
proportional,O
allocation,O
to,O
the,O
three,O
zones,O
followed,O
by,O
selection,O
of,O
weredas,O
and,O
health,O
facilities,O
from,O
the,O
zone,O
using,O
probability,O
proportional,O
to,O
size,O
.,O
The,O
allocation,O
and,O
selection,O
was,O
made,O
based,O
on,O
total,O
number,O
of,O
cases,O
reported,O
from,O
the,O
weredas,O
and,O
health,O
facilities,O
during,O
2008,O
through,O
2014,O
.,O
Lastly,O
",",O
cases,O
from,O
the,O
selected,O
health,O
facilities,O
were,O
selected,O
randomly,O
using,O
SPSS,O
statistical,O
software,O
using,O
TB,B-DS
unit,O
number,O
of,O
the,O
cases,O
.,O
Data,O
were,O
extracted,O
from,O
a,O
standard,O
unit,O
TB,B-DS
register,O
recommended,O
by,O
the,O
WHO,O
[,O
11,O
",",O
19,O
",",O
22,O
],O
using,O
extraction,O
format,O
prepared,O
for,O
the,O
study,O
.,O
Thus,O
patients,O
’,O
baseline,O
attributes,O
(,O
age,O
",",O
gender,O
",",O
residence,O
",",O
sputum,O
smear,O
",",O
type,O
of,O
TB,B-DS
",",O
HIV,B-OG
status,O
),O
and,O
follow,O
-,O
up,O
measures,O
(,O
sputum,O
smear,O
",",O
weight,O
",",O
drug,O
regimen,O
and,O
treatment,O
outcomes,O
),O
were,O
extracted,O
.,O
The,O
following,O
standard,O
case,O
and,O
outcome,O
definitions,O
were,O
adopted,O
and,O
used,O
for,O
the,O
study,O
[,O
11,O
",",O
19,O
].,O
New,O
case,O
of,O
TB,B-DS
a,O
patient,O
who,O
never,O
had,O
treatment,O
for,O
TB,B-DS
",",O
or,O
had,O
been,O
on,O
anti,O
-,O
TB,B-DS
treatment,O
for,O
less,O
than,O
four,O
weeks,O
in,O
the,O
past,O
Other,O
cases,O
are,O
those,O
patients,O
who,O
do,O
not,O
fulfill,O
the,O
criteria,O
for,O
new,O
",",O
relapse,O
",",O
and,O
return,O
after,O
default,O
or,O
treatment,O
after,O
failure,O
.,O
Cured,O
:,O
a,O
patient,O
whose,O
sputum,O
smear,O
or,O
culture,O
was,O
positive,O
at,O
the,O
beginning,O
of,O
the,O
treatment,O
but,O
who,O
was,O
smear,O
or,O
culture,O
-,O
negative,O
in,O
the,O
last,O
month,O
of,O
treatment,O
and,O
on,O
at,O
least,O
one,O
previous,O
occasion,O
.,O
Treatment,O
completed,O
:,O
completed,O
treatment,O
but,O
does,O
not,O
have,O
a,O
negative,O
sputum,O
smear,O
or,O
culture,O
result,O
in,O
the,O
last,O
month,O
of,O
treatment,O
and,O
on,O
at,O
least,O
one,O
previous,O
occasion,O
.,O
Treatment,O
failure,O
:,O
a,O
patient,O
whose,O
sputum,O
smear,O
or,O
culture,O
is,O
positive,O
at,O
5,O
months,O
or,O
later,O
during,O
treatment,O
or,O
patients,O
found,O
to,O
harbor,O
Multidrug,O
Resistant,O
(,O
MDR,O
),O
TB,B-DS
strain,O
at,O
any,O
point,O
of,O
time,O
during,O
the,O
treatment,O
",",O
whether,O
they,O
are,O
smear,O
-,O
negative,O
or,O
-,O
positive,O
.,O
Died,O
:,O
a,O
patient,O
who,O
dies,O
for,O
any,O
reason,O
during,O
the,O
course,O
of,O
TB,B-DS
treatment,O
.,O
Defaulter,O
/,O
loss,O
to,O
follow,O
-,O
up,O
:,O
a,O
patient,O
who,O
has,O
been,O
on,O
treatment,O
for,O
at,O
least,O
4,O
weeks,O
and,O
interrupted,O
treatment,O
for,O
eight,O
or,O
more,O
consecutive,O
weeks,O
.,O
Successful,O
treatment,O
:,O
a,O
treatment,O
that,O
ends,O
up,O
in,O
cure,O
or,O
treatment,O
completion,O
Unsuccessful,O
treatment,O
:,O
a,O
treatment,O
that,O
end,O
up,O
in,O
treatment,O
default,O
or,O
loss,O
to,O
follow,O
up,O
",",O
treatment,O
failure,O
or,O
death,O
.,O
The,O
extracted,O
data,O
were,O
checked,O
for,O
consistency,O
and,O
completeness,O
and,O
entered,O
in,O
to,O
Epinfo,O
version,O
7,O
that,O
later,O
exported,O
to,O
STATA,O
12,O
[,O
23,O
],O
for,O
analysis,O
.,O
Data,O
were,O
described,O
separately,O
for,O
the,O
two,O
groups,O
(,O
6EH,O
and,O
4RH,O
),O
using,O
frequencies,O
",",O
mean,O
",",O
standard,O
deviations,O
and,O
tables,O
.,O
Besides,O
",",O
crude,O
comparisons,O
of,O
the,O
baseline,O
and,O
follow,O
up,O
measures,O
among,O
the,O
6EH,O
and,O
4RH,O
groups,O
were,O
made,O
using,O
chi,O
square,O
(,O
x,O
2,O
),O
or,O
t,O
-,O
tests,O
as,O
appropriate,O
.,O
Subsequently,O
",",O
bivariate,O
and,O
multiple,O
binary,O
logistic,O
regression,O
analysis,O
were,O
made,O
to,O
compute,O
crude,O
and,O
adjusted,O
odds,O
ratios,O
respectively,O
between,O
the,O
explanatory,O
and,O
outcome,O
variables,O
.,O
Multiple,O
logistic,O
regression,O
model,O
was,O
fitted,O
with,O
those,O
variables,O
having,O
p,O
≤,O
0,O
.,O
2,O
on,O
bivariate,O
analysis,O
.,O
Finally,O
",",O
statistical,O
significance,O
was,O
judged,O
at,O
p,O
<,O
0,O
.,O
05,O
and,O
/,O
or,O
95,O
%,O
confidence,O
interval,O
(,O
CI,O
),O
of,O
odds,O
ratio,O
(,O
OR,O
),O
excluding,O
one,O
.,O
Ethical,O
considerations,O
We,O
received,O
ethical,O
approval,O
from,O
the,O
institutional,O
review,O
board,O
of,O
the,O
College,O
of,O
Health,O
Sciences,O
at,O
Addis,O
Ababa,O
University,O
.,O
Accordingly,O
",",O
anonymous,O
patient,O
data,O
were,O
extracted,O
from,O
routine,O
service,O
registry,O
upon,O
permission,O
from,O
the,O
respective,O
institutions,O
.,O
Results,O
Demographic,O
and,O
baseline,O
clinical,O
characteristics,O
We,O
retrieved,O
846,O
patient,O
records,O
of,O
which,O
790,O
(,O
93,O
.,O
4,O
%),O
with,O
complete,O
outcome,O
records,O
[,O
395,O
each,O
treated,O
with,O
2RHZE,O
/,O
6HE,O
and,O
2RHZE,O
/,O
4RHregimens,O
respectively,O
],O
were,O
described,O
and,O
analyzed,O
.,O
The,O
mean,O
age,O
of,O
the,O
patients,O
was,O
30,O
.,O
8,O
(,O
31,O
.,O
5,O
vs,O
30,O
.,O
9,O
years,O
",",O
p,O
=,O
0,O
.,O
5,O
),O
respectively,O
",",O
for,O
those,O
treated,O
with,O
6HE,O
and,O
4HR,O
(,O
Table,O
1,O
).,O
More,O
than,O
half,O
",",O
56,O
.,O
6,O
%,O
and,O
55,O
.,O
7,O
%,O
of,O
the,O
patients,O
were,O
male,O
and,O
reside,O
in,O
rural,O
areas,O
",",O
respectively,O
",",O
with,O
no,O
statistically,O
significant,O
difference,O
among,O
the,O
two,O
groups,O
.,O
With,O
regard,O
to,O
the,O
patient,O
profile,O
",",O
86,O
.,O
8,O
%,O
and,O
77,O
%,O
were,O
registered,O
at,O
health,O
center,O
and,O
had,O
pulmonary,B-DS
TB,I-DS
",",O
respectively,O
.,O
Of,O
the,O
patients,O
",",O
765,O
(,O
96,O
.,O
8,O
%),O
were,O
new,O
cases,O
(,O
378,O
treated,O
with,O
6EH,O
vs387,O
with,O
4RH,O
regimen,O
),O
and,O
the,O
rest,O
((,O
25,O
(,O
3,O
.,O
2,O
%),O
(,O
17,O
from,O
6EH,O
vs,O
8,O
from,O
4RH,O
),O
were,O
transferred,O
in,O
and,O
other,O
cases,O
treated,O
with,O
new,O
case,O
regimen,O
.,O
Human,B-OG
Immunodeficiency,I-OG
virus,I-OG
(,O
HIV,B-OG
),O
test,O
result,O
was,O
available,O
for,O
612,O
(,O
77,O
.,O
5,O
%),O
with,O
statistically,O
significant,O
difference,O
among,O
the,O
two,O
groups,O
[,O
283,O
(,O
71,O
.,O
6,O
%),O
from,O
6EH,O
and,O
329,O
(,O
83,O
.,O
3,O
%),O
from,O
4RH,O
",",O
p,O
<,O
0,O
.,O
001,O
].,O
Among,O
those,O
tested,O
HIV,B-OG
positives,O
",",O
44,O
(,O
57,O
.,O
1,O
%),O
received,O
either,O
Cotrimoxazole,O
Prophylactic,O
Therapy,O
(,O
CPT,O
),O
or,O
Antiretroviral,O
Therapy,O
(,O
ART,O
),O
with,O
no,O
statistically,O
significant,O
difference,O
among,O
the,O
regimens,O
24,O
(,O
64,O
.,O
9,O
%),O
from,O
6EH,O
and,O
20,O
(,O
50,O
"%),",O
p,O
=,O
0,O
.,O
2,O
.,O
Table,O
1Demographic,O
and,O
clinical,O
characteristics,O
of,O
the,O
tuberculosis,B-DS
patients,O
registered,O
between,O
",",O
2008,O
–,O
2014,O
",",O
Southwest,O
EthiopiaVariableContinuation,O
phase,O
treatment,O
regimenTotal,O
P,O
value6EH,O
(,O
n,O
=,O
395,O
),O
n,O
(%),O
4RH,O
(,O
n,O
=,O
395,O
),O
n,O
(%),O
Age,O
(,O
years,O
),O
Mean,O
±,O
SDa,O
31,O
.,O
1,O
±,O
12,O
.,O
930,O
.,O
5,O
±,O
11,O
.,O
930,O
.,O
8,O
±,O
12,O
.,O
40,O
.,O
5GenderMale221,O
(,O
55,O
.,O
9,O
),O
226,O
(,O
57,O
.,O
2,O
),O
447,O
(,O
56,O
.,O
6,O
),O
0,O
.,O
7Female174,O
(,O
44,O
.,O
1,O
),O
169,O
(,O
42,O
.,O
8,O
),O
343,O
(,O
43,O
.,O
4,O
),O
ResidenceUrban175,O
(,O
44,O
.,O
3,O
),O
175,O
(,O
44,O
.,O
3,O
),O
350,O
(,O
44,O
.,O
3,O
),O
1Rural220,O
(,O
55,O
.,O
7,O
),O
220,O
(,O
55,O
.,O
7,O
),O
440,O
(,O
55,O
.,O
7,O
),O
ZoneKaffa106,O
(,O
26,O
.,O
8,O
),O
104,O
(,O
26,O
.,O
3,O
),O
210,O
(,O
26,O
.,O
6,O
),O
0,O
.,O
9Bench,O
Maji206,O
(,O
52,O
.,O
2,O
),O
203,O
(,O
26,O
.,O
3,O
),O
409,O
(,O
51,O
.,O
8,O
),O
Sheka83,O
(,O
21,O
.,O
0,O
),O
88,O
(,O
22,O
.,O
3,O
),O
171,O
(,O
21,O
.,O
6,O
),O
Treatment,O
centerHospital55,O
(,O
13,O
.,O
9,O
),O
49,O
(,O
12,O
.,O
4,O
),O
104,O
(,O
13,O
.,O
2,O
),O
0,O
.,O
5Health,O
center340,O
(,O
86,O
.,O
1,O
),O
346,O
(,O
87,O
.,O
6,O
),O
686,O
(,O
86,O
.,O
8,O
),O
Baseline,O
weightMean,O
±,O
SDa,O
47,O
.,O
6,O
±,O
8,O
.,O
648,O
.,O
4,O
±,O
8,O
.,O
548,O
±,O
8,O
.,O
50,O
.,O
2Baseline,O
sputum,O
smearPositive186,O
(,O
47,O
.,O
1,O
),O
173,O
(,O
43,O
.,O
8,O
),O
359,O
(,O
45,O
.,O
4,O
),O
0,O
.,O
6Negative151,O
(,O
38,O
.,O
2,O
),O
165,O
(,O
41,O
.,O
8,O
),O
316,O
(,O
40,O
),O
Unknown58,O
(,O
14,O
.,O
7,O
),O
57,O
(,O
14,O
.,O
4,O
),O
115,O
(,O
14,O
.,O
6,O
),O
Type,O
of,O
TBPulmonary303,O
(,O
76,O
.,O
7305,O
(,O
77,O
.,O
2,O
),O
608,O
(,O
77,O
.,O
0,O
),O
0,O
.,O
9Positive186,O
(,O
47,O
.,O
1,O
),O
173,O
(,O
43,O
.,O
8,O
),O
359,O
(,O
45,O
.,O
4,O
),O
Negative117,O
(,O
30,O
.,O
4,O
),O
132,O
(,O
33,O
.,O
4,O
),O
252,O
(,O
31,O
.,O
9,O
),O
Extra,O
pulmonary92,O
(,O
23,O
.,O
3,O
),O
90,O
(,O
22,O
.,O
8,O
),O
179,O
(,O
23,O
),O
HIV,B-OG
statusPositive37,O
(,O
9,O
.,O
4,O
),O
40,O
(,O
10,O
.,O
1,O
),O
77,O
(,O
9,O
.,O
7,O
)<,O
0,O
.,O
001Negative246,O
(,O
62,O
.,O
3,O
),O
289,O
(,O
73,O
.,O
2,O
),O
535,O
(,O
67,O
.,O
7,O
),O
Unknown112,O
(,O
28,O
.,O
4,O
),O
66,O
(,O
16,O
.,O
7,O
),O
178,O
(,O
22,O
.,O
5,O
),O
Received,O
CPTb,O
(,O
n,O
=,O
77,O
),O
Yes18,O
(,O
48,O
.,O
6,O
),O
17,O
(,O
42,O
.,O
5,O
),O
35,O
(,O
45,O
.,O
5,O
),O
0,O
.,O
6Received,O
CPT,O
or,O
ARTc,O
(,O
n,O
=,O
77,O
),O
Yes6,O
(,O
16,O
.,O
2,O
),O
6,O
(,O
15,O
.,O
0,O
),O
12,O
(,O
15,O
.,O
6,O
),O
0,O
.,O
8Received,O
ART,O
(,O
n,O
=,O
77,O
),O
Yes12,O
(,O
32,O
.,O
4,O
),O
9,O
(,O
22,O
.,O
5,O
),O
21,O
(,O
27,O
.,O
3,O
),O
0,O
.,O
3Baseline,O
sputum,O
smearPositive186,O
(,O
47,O
.,O
1,O
),O
173,O
(,O
43,O
.,O
8,O
),O
359,O
(,O
45,O
.,O
4,O
),O
0,O
.,O
6Negative151,O
(,O
38,O
.,O
2,O
),O
165,O
(,O
41,O
.,O
8,O
),O
316,O
(,O
40,O
),O
Unknown58,O
(,O
14,O
.,O
7,O
),O
57,O
(,O
14,O
.,O
4,O
),O
115,O
(,O
14,O
.,O
6,O
),O
aStandard,O
deviation,O
",",O
b,O
CPT,O
Cotrimoxazole,O
prophylactic,O
therapy,O
",",O
c,O
ART,O
antiretroviral,O
therapy,O
Patient,O
follow,O
-,O
ups,O
and,O
treatment,O
outcomes,O
A,O
total,O
of,O
695,O
(,O
88,O
%),O
of,O
the,O
patients,O
had,O
successful,O
treatment,O
outcomes,O
with,O
statistically,O
significant,O
difference,O
(,O
85,O
.,O
3,O
%,O
vs,O
90,O
.,O
6,O
"%,",O
p,O
=,O
0,O
.,O
02,O
),O
among,O
the,O
6HE,O
and,O
4RH,O
groups,O
",",O
respectively,O
(,O
Table,O
2,O
).,O
A,O
total,O
of,O
",",O
324,O
(,O
90,O
.,O
3,O
"%),",O
208,O
(,O
85,O
.,O
4,O
%),O
and,O
163,O
(,O
91,O
.,O
1,O
%),O
of,O
pulmonary,O
positive,O
",",O
pulmonary,O
negative,O
and,O
extra,O
pulmonary,B-DS
TB,I-DS
cases,O
respectively,O
had,O
successful,O
outcomes,O
with,O
statistically,O
significant,O
difference,O
",",O
P,O
=,O
0,O
.,O
03,O
.,O
Besides,O
",",O
statistically,O
significant,O
differences,O
in,O
successful,O
outcomes,O
",",O
64,O
(,O
83,O
.,O
1,O
"%),",O
482,O
(,O
90,O
.,O
1,O
%),O
and,O
149,O
(,O
83,O
.,O
7,O
"%,",O
p,O
=,O
0,O
.,O
005,O
were,O
also,O
found,O
among,O
HIV,B-OG
positive,O
",",O
HIV,B-OG
negatives,O
and,O
unknown,O
HIV,B-OG
status,O
TB,B-DS
cases,O
",",O
respectively,O
.,O
Table,O
2Patient,O
follow,O
-,O
up,O
measures,O
and,O
treatment,O
outcomes,O
of,O
TB,B-DS
patients,O
registered,O
during,O
2008,O
–,O
2014,O
",",O
Southwest,O
EthiopiaVariablesContinuation,O
phase,O
treatment,O
regimen6EH,O
(,O
n,O
=,O
395,O
),O
n,O
(%),O
4RH,O
(,O
n,O
=,O
395,O
),O
n,O
(%),O
Total,O
N,O
(%),O
P,O
valueWeight,O
at,O
2nd,O
monthMean,O
±,O
SD49,O
.,O
9,O
±,O
8,O
.,O
950,O
.,O
8,O
±,O
8,O
.,O
250,O
.,O
4,O
±,O
8,O
.,O
60,O
.,O
2Weight,O
at,O
5th,O
monthMean,O
±,O
SD51,O
.,O
4,O
±,O
8,O
.,O
651,O
.,O
3,O
±,O
7,O
.,O
351,O
.,O
3,O
±,O
7,O
.,O
90,O
.,O
9Weight,O
at,O
6,O
/,O
7th,O
monthMean,O
±,O
SD51,O
.,O
1,O
±,O
8,O
.,O
952,O
.,O
5,O
±,O
6,O
.,O
551,O
.,O
7,O
±,O
7,O
.,O
90,O
.,O
3Change,O
in,O
weight,O
at,O
2nd,O
monthNot,O
increased49,O
(,O
12,O
.,O
4,O
),O
61,O
(,O
15,O
.,O
4,O
),O
110,O
(,O
13,O
.,O
9,O
),O
0,O
.,O
4Increased191,O
(,O
48,O
.,O
4,O
),O
177,O
(,O
44,O
.,O
8,O
),O
368,O
(,O
46,O
.,O
6,O
),O
Unknown155,O
(,O
39,O
.,O
2,O
),O
157,O
(,O
39,O
.,O
7,O
),O
312,O
(,O
39,O
.,O
5,O
),O
Sputum,O
smear,O
end,O
of,O
2nd,O
month,O
(,O
n,O
=,O
359,O
),O
Positive4,O
(,O
2,O
.,O
2,O
),O
2,O
(,O
1,O
.,O
2,O
),O
6,O
(,O
1,O
.,O
7,O
),O
0,O
.,O
09Negative130,O
(,O
69,O
.,O
9,O
),O
138,O
(,O
79,O
.,O
8,O
),O
268,O
(,O
74,O
.,O
7,O
),O
Unknown52,O
(,O
28,O
),O
33,O
(,O
19,O
.,O
1,O
),O
85,O
(,O
23,O
.,O
7,O
),O
Sputum,O
smear,O
end,O
of,O
5th,O
month,O
(,O
n,O
=,O
359,O
),O
Positive1,O
(,O
0,O
.,O
5,O
),O
0,O
(,O
0,O
),O
1,O
(,O
0,O
.,O
3,O
),O
0,O
.,O
03Negative83,O
(,O
44,O
.,O
6,O
),O
100,O
(,O
57,O
.,O
8,O
),O
183,O
(,O
51,O
),O
Unknown102,O
(,O
54,O
.,O
8,O
),O
73,O
(,O
42,O
.,O
2,O
),O
175,O
(,O
48,O
.,O
7,O
),O
Sputum,O
smear,O
end,O
of,O
6,O
/,O
7th,O
month,O
(,O
n,O
=,O
359,O
),O
Positive0000,O
.,O
8Negative94,O
(,O
50,O
.,O
5,O
),O
85,O
(,O
49,O
.,O
1,O
),O
179,O
(,O
49,O
.,O
9,O
),O
Unknown92,O
(,O
49,O
.,O
5,O
),O
88,O
(,O
50,O
.,O
9,O
),O
180,O
(,O
50,O
.,O
1,O
),O
Sputum,O
smear,O
done,O
during,O
treatment,O
(,O
n,O
=,O
359,O
),O
No44,O
(,O
23,O
.,O
7,O
),O
33,O
(,O
19,O
.,O
1,O
),O
77,O
(,O
21,O
.,O
4,O
),O
0,O
.,O
3At,O
least,O
once142,O
(,O
76,O
.,O
3,O
),O
140,O
(,O
80,O
.,O
9,O
),O
282,O
(,O
78,O
.,O
6,O
),O
Continuation,O
phase,O
visitMean,O
±,O
SD5,O
.,O
8,O
±,O
1,O
.,O
15,O
.,O
4,O
±,O
3,O
.,O
10,O
.,O
09Treatment,O
outcomeSuccessful337,O
(,O
85,O
.,O
3,O
),O
358,O
(,O
90,O
.,O
6,O
),O
695,O
(,O
88,O
),O
0,O
.,O
02Cured77,O
(,O
19,O
.,O
5,O
),O
85,O
(,O
21,O
.,O
5,O
),O
162,O
(,O
20,O
.,O
5,O
),O
Completed260,O
(,O
65,O
.,O
8,O
),O
273,O
(,O
69,O
.,O
1,O
),O
533,O
(,O
67,O
),O
Unsuccessful58,O
(,O
14,O
.,O
7,O
),O
37,O
(,O
9,O
.,O
4,O
),O
95,O
(,O
12,O
),O
Died28,O
(,O
7,O
.,O
1,O
),O
18,O
(,O
4,O
.,O
6,O
),O
46,O
(,O
5,O
.,O
8,O
),O
Defaulted29,O
(,O
7,O
.,O
3,O
),O
19,O
(,O
4,O
.,O
8,O
),O
48,O
(,O
6,O
.,O
1,O
),O
Failure1,O
(,O
0,O
.,O
3,O
),O
01,O
(,O
0,O
.,O
1,O
),O
Measurements,O
of,O
patient,O
weight,O
at,O
the,O
end,O
of,O
second,O
",",O
fifth,O
and,O
sixth,O
/,O
seventh,O
months,O
of,O
treatment,O
were,O
available,O
for,O
504,O
(,O
63,O
.,O
8,O
"%),",O
145,O
(,O
18,O
.,O
4,O
%),O
and,O
141,O
(,O
17,O
.,O
8,O
%),O
respectively,O
.,O
Thus,O
",",O
368,O
(,O
46,O
.,O
6,O
%),O
or,O
(,O
48,O
.,O
4,O
%,O
from,O
6EH,O
and,O
44,O
.,O
8,O
%,O
from,O
4RH,O
",",O
p,O
=,O
0,O
.,O
4,O
),O
have,O
gained,O
some,O
amount,O
of,O
weight,O
at,O
the,O
end,O
of,O
second,O
month,O
of,O
treatment,O
.,O
On,O
the,O
other,O
hand,O
",",O
of,O
those,O
initially,O
smear,O
positive,O
pulmonary,B-DS
TB,I-DS
cases,O
",",O
78,O
.,O
6,O
%,O
had,O
undergone,O
sputum,O
follow,O
up,O
examination,O
at,O
least,O
once,O
after,O
the,O
diagnosis,O
(,O
76,O
.,O
3,O
%,O
among,O
6HE,O
and,O
80,O
.,O
9,O
%,O
among,O
4HR,O
",",O
p,O
=,O
0,O
.,O
3,O
).,O
Thus,O
sputum,O
smear,O
results,O
at,O
the,O
end,O
of,O
second,O
",",O
fifth,O
and,O
sixth,O
/,O
seventh,O
months,O
of,O
treatment,O
were,O
available,O
for274,O
(,O
76,O
.,O
3,O
"%),",O
184,O
(,O
51,O
.,O
3,O
%),O
and,O
179,O
(,O
49,O
.,O
9,O
%),O
cases,O
respectively,O
with,O
no,O
statistically,O
significant,O
differences,O
among,O
the,O
6EH,O
and,O
4RH,O
regimens,O
.,O
The,O
majority,O
of,O
the,O
smear,O
positives,O
(,O
69,O
.,O
9,O
%,O
vs,O
79,O
.,O
8,O
%,O
respectively,O
from,O
the,O
6EH,O
and,O
4RH,O
regimens,O
",",O
p,O
=,O
0,O
.,O
4,O
),O
converted,O
to,O
negative,O
at,O
the,O
end,O
of,O
second,O
month,O
treatment,O
.,O
Factors,O
associated,O
with,O
unsuccessful,O
treatment,O
outcomes,O
In,O
bivariate,O
analysis,O
patient,O
age,O
",",O
residence,O
",",O
zone,O
",",O
weight,O
change,O
at,O
the,O
end,O
of,O
the,O
second,O
month,O
of,O
treatment,O
",",O
sputum,O
smear,O
follow,O
-,O
up,O
and,O
continuation,O
phase,O
regimen,O
are,O
associated,O
with,O
treatment,O
success,O
at,O
p,O
<,O
0,O
.,O
05,O
.,O
But,O
",",O
in,O
multivariate,O
analysis,O
4RH,O
continuation,O
phase,O
treatment,O
regimen,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
),O
0,O
.,O
55,O
(,O
0,O
.,O
34,O
",",O
0,O
.,O
89,O
")],",O
patient,O
age,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
),O
1,O
.,O
02,O
(,O
1,O
.,O
001,O
",",O
1,O
.,O
022,O
")],",O
rural,O
residence,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
),O
2,O
.,O
1,O
(,O
1,O
.,O
18,O
",",O
3,O
.,O
75,O
")],",O
treated,O
at,O
health,O
center,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
),O
0,O
.,O
37,O
(,O
0,O
.,O
14,O
",",O
0,O
.,O
97,O
")],",O
HIV,B-OG
positives,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
2,O
.,O
38,O
(,O
1,O
.,O
12,O
",",O
5,O
.,O
07,O
")],",O
gained,O
weight,O
at,O
the,O
end,O
of,O
the,O
second,O
month,O
[,O
AOR,O
(,O
95,O
%,O
CI,O
),O
0,O
.,O
28,O
(,O
0,O
.,O
11,O
",",O
0,O
.,O
72,O
)],O
independently,O
predicted,O
unsuccessful,O
treatment,O
outcome,O
(,O
Table,O
3,O
).,O
The,O
odds,O
of,O
unsuccessful,O
outcome,O
was,O
higher,O
among,O
the,O
older,O
",",O
rural,O
residents,O
",",O
HIV,B-OG
positives,O
and,O
unknown,O
weight,O
change,O
at,O
the,O
end,O
of,O
second,O
month,O
treatment,O
.,O
The,O
odds,O
of,O
having,O
unsuccessful,O
outcome,O
increase,O
by,O
2,O
%,O
for,O
every,O
one,O
year,O
increase,O
in,O
age,O
(,O
AOR,O
=,O
1,O
.,O
02,O
).,O
On,O
the,O
other,O
hand,O
",",O
treated,O
with,O
4RH,O
continuation,O
phase,O
regimen,O
",",O
being,O
treated,O
at,O
health,O
center,O
and,O
weight,O
gain,O
at,O
the,O
end,O
of,O
second,O
month,O
have,O
lower,O
likelihood,O
of,O
unsuccessful,O
outcome,O
.,O
Patients,O
put,O
on,O
4RH,O
continuation,O
phase,O
of,O
treatment,O
regimen,O
are,O
45,O
%,O
less,O
likely,O
to,O
have,O
unsuccessful,O
outcome,O
compared,O
to,O
those,O
put,O
on,O
6EH,O
regimen,O
.,O
Patients,O
treated,O
at,O
health,O
center,O
have,O
about,O
63,O
%,O
lower,O
odds,O
of,O
unsuccessful,O
outcome,O
as,O
compared,O
to,O
those,O
treated,O
at,O
hospitals,O
.,O
HIV,B-OG
co,O
infected,O
TB,B-DS
patients,O
have,O
more,O
than,O
two,O
fold,O
higher,O
risk,O
of,O
unsuccessful,O
outcomes,O
compared,O
to,O
HIV,B-OG
negatives,O
(,O
AOR,O
=,O
2,O
.,O
38,O
).,O
Those,O
patients,O
gained,O
weight,O
at,O
the,O
end,O
of,O
the,O
second,O
month,O
of,O
treatment,O
have,O
72,O
%,O
lower,O
odds,O
of,O
unsuccessful,O
outcomes,O
compared,O
to,O
those,O
with,O
reduced,O
or,O
unchanged,O
weight,O
(,O
AOR,O
=,O
0,O
.,O
28,O
).,O
A,O
subgroup,O
analysis,O
among,O
smear,O
positive,O
pulmonary,O
cases,O
showed,O
having,O
a,O
sputum,O
checkup,O
at,O
least,O
once,O
during,O
treatment,O
independently,O
predicted,O
96,O
%,O
lower,O
odds,O
of,O
unsuccessful,O
outcomes,O
compared,O
to,O
those,O
unchecked,O
(,O
AOR,O
0,O
.,O
04,O
(,O
95,O
%,O
CI,O
",",O
0,O
.,O
01,O
–,O
0,O
.,O
12,O
"),",O
P,O
<,O
0,O
.,O
001,O
),O
(,O
Additional,O
file,O
1,O
).,O
Table,O
3Factors,O
associated,O
with,O
unsuccessful,O
treatment,O
outcomes,O
among,O
TB,B-DS
patients,O
registered,O
during,O
2008,O
–,O
2014,O
",",O
Southwestern,O
EthiopiaVariablesTreatment,O
outcomesOdds,O
ratio,O
(,O
OR,O
),O
Unsuccessful,O
n,O
(%),O
Successful,O
n,O
(%),O
Crude,O
OR95,O
%,O
CIa,O
Adjusted,O
OR95,O
%,O
CIAge,O
(,O
years,O
),O
Mean,O
(,O
SD,O
),O
33,O
.,O
5,O
(,O
14,O
),O
30,O
.,O
4,O
(,O
12,O
.,O
0,O
),O
1,O
.,O
02,O
(,O
1,O
.,O
002,O
",",O
1,O
.,O
03,O
),O
1,O
.,O
02,O
(,O
1,O
.,O
001,O
",",O
1,O
.,O
022,O
),O
GenderMale60,O
(,O
13,O
.,O
4,O
),O
387,O
(,O
86,O
.,O
6,O
),O
11Female35,O
(,O
10,O
.,O
2,O
),O
308,O
(,O
89,O
.,O
8,O
),O
0,O
.,O
73,O
(,O
0,O
.,O
47,O
.,O
1,O
.,O
14,O
),O
0,O
.,O
63,O
(,O
0,O
.,O
38,O
",",O
1,O
.,O
03,O
),O
ResidenceUrban32,O
(,O
9,O
.,O
1,O
),O
318,O
(,O
90,O
.,O
9,O
),O
11Rural63,O
(,O
14,O
.,O
3,O
),O
377,O
(,O
85,O
.,O
7,O
),O
1,O
.,O
66,O
(,O
1,O
.,O
06,O
",",O
2,O
.,O
61,O
),O
2,O
.,O
1,O
(,O
1,O
.,O
18,O
",",O
3,O
.,O
75,O
),O
ZoneKaffa34,O
(,O
16,O
.,O
2,O
),O
176,O
(,O
83,O
.,O
8,O
),O
11Bench,O
Maji50,O
(,O
12,O
.,O
2,O
),O
359,O
(,O
87,O
.,O
8,O
),O
0,O
.,O
72,O
(,O
0,O
.,O
45,O
",",O
1,O
.,O
14,O
),O
1,O
.,O
41,O
(,O
0,O
.,O
73,O
",",O
2,O
.,O
75,O
),O
Sheka11,O
(,O
6,O
.,O
4,O
),O
160,O
(,O
93,O
.,O
6,O
),O
0,O
.,O
36,O
(,O
0,O
.,O
17,O
",",O
0,O
.,O
73,O
),O
1,O
.,O
2,O
(,O
0,O
.,O
44,O
",",O
3,O
.,O
32,O
),O
Treatment,O
centerHospital17,O
(,O
16,O
.,O
3,O
),O
87,O
(,O
83,O
.,O
7,O
),O
11HC78,O
(,O
11,O
.,O
4,O
),O
608,O
(,O
88,O
.,O
6,O
),O
0,O
.,O
66,O
(,O
0,O
.,O
37,O
",",O
1,O
.,O
16,O
),O
0,O
.,O
37,O
(,O
0,O
.,O
14,O
",",O
0,O
.,O
97,O
),O
Type,O
of,O
TBPulmonary78,O
(,O
12,O
.,O
8,O
),O
530,O
(,O
87,O
.,O
2,O
),O
11EPTBb,O
17,O
(,O
9,O
.,O
3,O
),O
165,O
(,O
90,O
.,O
7,O
),O
0,O
.,O
70,O
(,O
0,O
.,O
40,O
",",O
1,O
.,O
22,O
),O
0,O
.,O
57,O
(,O
0,O
.,O
32,O
",",O
1,O
.,O
04,O
),O
HIV,B-OG
statusNegative53,O
(,O
9,O
.,O
9,O
),O
482,O
(,O
90,O
.,O
1,O
),O
11Positive13,O
(,O
16,O
.,O
9,O
),O
64,O
(,O
83,O
.,O
1,O
),O
1,O
.,O
85,O
(,O
0,O
.,O
95,O
",",O
3,O
.,O
57,O
),O
2,O
.,O
39,O
(,O
1,O
.,O
12,O
",",O
5,O
.,O
07,O
),O
Unknown29,O
(,O
16,O
.,O
3,O
),O
178,O
(,O
83,O
.,O
7,O
),O
1,O
.,O
77,O
(,O
1,O
.,O
08,O
",",O
2,O
.,O
88,O
),O
2,O
.,O
26,O
(,O
1,O
.,O
23,O
",",O
4,O
.,O
11,O
),O
Weight,O
change,O
end,O
of,O
2nd,O
monthNo,O
increase11,O
(,O
8,O
.,O
2,O
),O
357,O
(,O
91,O
.,O
8,O
),O
11Increased9,O
(,O
3,O
),O
101,O
(,O
97,O
),O
0,O
.,O
35,O
(,O
0,O
.,O
14,O
",",O
0,O
.,O
86,O
),O
0,O
.,O
28,O
(,O
0,O
.,O
11,O
",",O
0,O
.,O
72,O
),O
Unknown75,O
(,O
24,O
),O
237,O
(,O
76,O
),O
3,O
.,O
55,O
(,O
1,O
.,O
71,O
",",O
7,O
.,O
37,O
),O
3,O
.,O
48,O
(,O
1,O
.,O
60,O
",",O
7,O
.,O
54,O
),O
Continuation,O
phase,O
regimen6EH58,O
(,O
14,O
.,O
7,O
),O
337,O
(,O
85,O
.,O
3,O
),O
114RH37,O
(,O
9,O
.,O
4,O
),O
358,O
(,O
90,O
.,O
6,O
),O
0,O
.,O
60,O
(,O
0,O
.,O
39,O
",",O
0,O
.,O
93,O
),O
0,O
.,O
55,O
(,O
0,O
.,O
34,O
",",O
0,O
.,O
89,O
),O
aConfidence,O
interval,O
",",O
bExtra,O
pulmonary,B-DS
Tuberculosis,I-DS
",",O
bold,O
figures,O
indicate,O
statisticaly,O
significant,O
at,O
p,O
<,O
0,O
.,O
05,O
Discussion,O
Treatment,O
outcomes,O
among,O
TB,B-DS
patients,O
treated,O
with,O
RHZE,O
for,O
the,O
first,O
2,O
months,O
",",O
followed,O
by,O
HE,O
for,O
6,O
months,O
(,O
2RHZE,O
/,O
6EH,O
),O
and,O
RH,O
for,O
4,O
months,O
(,O
2RHZE,O
/,O
4RH,O
),O
was,O
compared,O
.,O
Both,O
groups,O
of,O
the,O
cases,O
had,O
no,O
statistically,O
significant,O
difference,O
with,O
respect,O
to,O
socio,O
-,O
demographic,O
",",O
baseline,O
clinical,O
",",O
bacteriologic,O
and,O
follow,O
up,O
measures,O
that,O
depict,O
comparability,O
of,O
the,O
groups,O
.,O
The,O
comparison,O
was,O
made,O
between,O
regimens,O
used,O
during,O
the,O
continuation,O
phase,O
treatment,O
(,O
4RH,O
vs,O
6EH,O
).,O
Thus,O
a,O
lower,O
rate,O
of,O
unsuccessful,O
outcomes,O
was,O
reported,O
among,O
those,O
treated,O
with,O
4RH,O
continuation,O
phase,O
regimen,O
.,O
A,O
statistically,O
significant,O
difference,O
in,O
treatment,O
outcomes,O
where,O
lower,O
unsuccessful,O
treatment,O
outcome,O
(,O
9,O
.,O
4,O
%,O
vs,O
14,O
.,O
7,O
%),O
was,O
observed,O
among,O
patients,O
treated,O
with,O
4RH,O
and,O
6EH,O
regimen,O
respectively,O
.,O
Similarly,O
",",O
a,O
study,O
conducted,O
in,O
Nigeria,O
[,O
14,O
],O
reported,O
higher,O
odds,O
of,O
unsuccessful,O
outcome,O
among,O
those,O
treated,O
with,O
6EH,O
.,O
This,O
could,O
be,O
due,O
to,O
the,O
differences,O
in,O
length,O
and,O
type,O
of,O
drugs,O
used,O
during,O
the,O
continuation,O
phase,O
treatment,O
those,O
influence,O
adherence,O
and,O
ultimate,O
outcome,O
.,O
Studies,O
reported,O
that,O
reduced,O
continuation,O
phase,O
(,O
from,O
6EH,O
to,O
4HR,O
),O
treatment,O
is,O
associated,O
with,O
lower,O
cost,O
and,O
expected,O
mortality,O
[,O
12,O
],O
that,O
enhance,O
successful,O
treatment,O
outcome,O
.,O
On,O
the,O
other,O
hand,O
",",O
use,O
of,O
rifampcin,O
for,O
longer,O
period,O
of,O
time,O
during,O
the,O
treatment,O
of,O
TB,B-DS
is,O
associated,O
with,O
better,O
outcomes,O
[,O
13,O
],O
that,O
might,O
be,O
related,O
with,O
efficacy,O
of,O
the,O
drug,O
.,O
The,O
finding,O
implies,O
the,O
adoption,O
[,O
11,O
],O
of,O
the,O
latest,O
WHO,O
recommendation,O
[,O
7,O
],O
in,O
high,O
prevalent,O
and,O
resource,O
constrained,O
settings,O
is,O
working,O
well,O
.,O
Apart,O
from,O
the,O
treatment,O
regimens,O
",",O
patient,O
attribute,O
like,O
age,O
and,O
residence,O
independently,O
predicted,O
treatment,O
outcomes,O
.,O
We,O
found,O
that,O
age,O
had,O
an,O
inverse,O
relation,O
with,O
unsuccessful,O
outcome,O
where,O
the,O
odds,O
of,O
unsuccessful,O
outcome,O
increase,O
with,O
age,O
.,O
Several,O
studies,O
also,O
reported,O
that,O
older,O
patients,O
were,O
more,O
likely,O
to,O
have,O
unsuccessful,O
outcomes,O
than,O
younger,O
[,O
24,O
–,O
27,O
].,O
This,O
could,O
be,O
due,O
to,O
higher,O
risk,O
of,O
age,O
related,O
co,O
morbid,O
situations,O
those,O
lead,O
to,O
poor,O
adherence,O
and,O
outcomes,O
[,O
28,O
].,O
Patients,O
residing,O
in,O
rural,O
areas,O
had,O
higher,O
risk,O
of,O
unsuccessful,O
outcomes,O
which,O
could,O
be,O
attributed,O
to,O
the,O
low,O
access,O
to,O
TB,B-DS
care,O
and,O
unfavorable,O
living,O
conditions,O
.,O
The,O
findings,O
imply,O
need,O
for,O
focused,O
intervention,O
targeted,O
to,O
those,O
older,O
age,O
groups,O
and,O
rural,O
dwellers,O
besides,O
the,O
treatment,O
regimen,O
.,O
Monitoring,O
of,O
patient,O
weight,O
and,O
sputum,O
are,O
among,O
the,O
recommended,O
follow,O
-,O
up,O
measures,O
required,O
for,O
TB,B-DS
patients,O
on,O
treatment,O
[,O
7,O
].,O
The,O
results,O
of,O
both,O
weight,O
and,O
sputum,O
monitoring,O
are,O
used,O
to,O
adjust,O
for,O
drug,O
dose,O
and,O
predict,O
outcomes,O
of,O
the,O
treatment,O
.,O
The,O
proportion,O
of,O
smear,O
positive,O
patients,O
converted,O
to,O
negative,O
at,O
the,O
end,O
of,O
the,O
intensive,O
phase,O
has,O
been,O
taken,O
among,O
indicators,O
of,O
TB,B-DS
programme,O
performance,O
[,O
7,O
].,O
However,O
",",O
only,O
small,O
proportion,O
of,O
patients,O
had,O
documented,O
results,O
of,O
the,O
weight,O
and,O
sputum,O
follow,O
-,O
ups,O
particularly,O
at,O
the,O
later,O
periods,O
of,O
treatment,O
.,O
Consistent,O
to,O
findings,O
from,O
African,O
settings,O
[,O
29,O
],O
majority,O
of,O
those,O
patients,O
undergone,O
sputum,O
checkup,O
during,O
treatment,O
converted,O
to,O
negative,O
.,O
Patients,O
gained,O
some,O
amount,O
of,O
weight,O
at,O
the,O
end,O
of,O
second,O
month,O
treatment,O
had,O
lower,O
risk,O
of,O
unsuccessful,O
outcomes,O
which,O
is,O
consistent,O
with,O
other,O
studies,O
[,O
30,O
",",O
31,O
].,O
This,O
could,O
be,O
explained,O
by,O
the,O
fact,O
that,O
weight,O
gain,O
marks,O
some,O
level,O
of,O
improvement,O
from,O
the,O
TB,B-DS
illness,O
including,O
reduced,O
appetite,O
.,O
In,O
addition,O
",",O
changes,O
in,O
weight,O
while,O
on,O
treatment,O
might,O
be,O
an,O
indication,O
of,O
appropriateness,O
of,O
the,O
drug,O
dose,O
to,O
treat,O
the,O
illness,O
.,O
On,O
the,O
other,O
hand,O
those,O
with,O
unknown,O
weight,O
change,O
at,O
the,O
end,O
of,O
first,O
two,O
months,O
treatment,O
had,O
higher,O
odds,O
of,O
unsuccessful,O
outcomes,O
.,O
This,O
might,O
have,O
occurred,O
due,O
to,O
possible,O
misclassification,O
of,O
cases,O
with,O
reduced,O
or,O
remains,O
unchanged,O
to,O
unknown,O
.,O
The,O
weight,O
change,O
might,O
be,O
unknown,O
due,O
to,O
patients,O
’,O
treatment,O
interruption,O
subsequent,O
to,O
treatment,O
default,O
or,O
death,O
those,O
constitute,O
unsuccessful,O
outcome,O
.,O
So,O
that,O
patient,O
’,O
s,O
status,O
of,O
weight,O
during,O
treatment,O
might,O
be,O
left,O
undetermined,O
.,O
Having,O
sputum,O
checkup,O
at,O
least,O
once,O
during,O
treatment,O
among,O
initially,O
smear,O
positives,O
predicted,O
lower,O
risk,O
of,O
unsuccessful,O
outcome,O
.,O
However,O
",",O
reviews,O
showed,O
low,O
sensitivity,O
and,O
modest,O
specificity,O
of,O
sputum,O
results,O
at,O
the,O
end,O
of,O
intensive,O
phase,O
to,O
predict,O
failure,O
and,O
relapse,O
[,O
32,O
].,O
On,O
the,O
other,O
hand,O
",",O
detection,O
of,O
sputum,O
positive,O
during,O
treatment,O
trigger,O
further,O
patient,O
assessment,O
that,O
influence,O
treatment,O
regimens,O
and,O
ultimate,O
outcome,O
.,O
Hence,O
",",O
the,O
routine,O
sputum,O
monitoring,O
adopted,O
by,O
the,O
country,O
[,O
11,O
],O
during,O
treatment,O
should,O
be,O
improved,O
as,O
it,O
is,O
an,O
indicator,O
of,O
program,O
performance,O
and,O
trigger,O
for,O
patient,O
assessment,O
.,O
Consistent,O
with,O
other,O
studies,O
[,O
33,O
",",O
34,O
"],",O
HIV,B-OG
positive,O
TB,B-DS
patients,O
are,O
more,O
likely,O
to,O
have,O
unsuccessful,O
outcomes,O
compared,O
to,O
those,O
negatives,O
.,O
This,O
could,O
be,O
due,O
to,O
multifaceted,O
influences,O
of,O
HIV,B-OG
on,O
TB,B-DS
diagnosis,O
and,O
response,O
to,O
TB,B-DS
treatment,O
those,O
negatively,O
affect,O
the,O
outcomes,O
of,O
TB,B-DS
treatment,O
[,O
35,O
].,O
Consequently,O
",",O
collaborative,O
services,O
have,O
been,O
recommended,O
in,O
order,O
to,O
curb,O
the,O
influence,O
of,O
HIV,B-OG
on,O
TB,B-DS
and,O
vice,O
versa,O
[,O
36,O
].,O
Evidences,O
from,O
systematic,O
review,O
in,O
African,O
context,O
supported,O
the,O
recommendation,O
and,O
reported,O
better,O
outcomes,O
among,O
concurrently,O
screened,O
and,O
managed,O
TB,B-DS
and,O
HIV,B-OG
infected,O
patients,O
[,O
37,O
].,O
Nonetheless,O
",",O
we,O
found,O
no,O
statistically,O
significant,O
difference,O
in,O
treatment,O
success,O
among,O
those,O
infected,O
TB,B-DS
patients,O
provided,O
with,O
CPT,O
and,O
/,O
or,O
ART,O
.,O
The,O
indifference,O
could,O
be,O
explained,O
by,O
the,O
low,O
uptake,O
of,O
integrated,O
TB,B-DS
/,O
HIV,B-OG
collaborative,O
services,O
among,O
the,O
studied,O
patients,O
.,O
In,O
this,O
study,O
",",O
more,O
than,O
three,O
quarter,O
of,O
the,O
patients,O
were,O
offered,O
HIV,B-OG
test,O
which,O
is,O
little,O
higher,O
than,O
the,O
national,O
average,O
of,O
65,O
%,O
[,O
18,O
],O
and,O
9,O
.,O
7,O
%,O
TB,B-DS
/,O
HIV,B-OG
co,O
infected,O
patients,O
which,O
is,O
almost,O
similar,O
to,O
the,O
national,O
average,O
of,O
10,O
%.,O
However,O
",",O
only,O
few,O
HIV,B-OG
co,O
infected,O
patients,O
(,O
45,O
%,O
on,O
CPT,O
and,O
27,O
.,O
3,O
%,O
on,O
ART,O
),O
were,O
found,O
to,O
have,O
documented,O
service,O
provision,O
.,O
[,O
18,O
].,O
The,O
discrepancies,O
could,O
be,O
due,O
to,O
differences,O
in,O
reporting,O
periods,O
where,O
the,O
national,O
average,O
is,O
a,O
single,O
year,O
attainment,O
but,O
that,O
of,O
this,O
study,O
is,O
over,O
a,O
period,O
of,O
six,O
years,O
including,O
the,O
nationally,O
reported,O
year,O
.,O
Over,O
all,O
",",O
the,O
targets,O
set,O
for,O
the,O
TB,B-DS
/,O
HIV,B-OG
service,O
collaboration,O
has,O
not,O
yet,O
met,O
which,O
calls,O
for,O
in,O
depth,O
understanding,O
and,O
focused,O
intervention,O
that,O
suit,O
local,O
settings,O
.,O
On,O
the,O
other,O
hand,O
",",O
unknown,O
HIV,B-OG
status,O
predicted,O
higher,O
odds,O
of,O
unsuccessful,O
outcomes,O
.,O
This,O
could,O
be,O
due,O
to,O
possible,O
misclassification,O
of,O
HIV,B-OG
positive,O
cases,O
those,O
predict,O
worse,O
outcome,O
in,O
to,O
unknown,O
.,O
The,O
study,O
is,O
limited,O
to,O
control,O
for,O
changes,O
in,O
medical,O
resources,O
",",O
polices,O
and,O
quality,O
of,O
care,O
across,O
the,O
study,O
periods,O
.,O
Since,O
only,O
few,O
variables,O
were,O
captured,O
on,O
the,O
register,O
",",O
we,O
could,O
not,O
control,O
for,O
possible,O
confounding,O
effect,O
of,O
socioeconomic,O
",",O
lifestyle,O
and,O
co,O
morbid,O
illness,O
.,O
Furthermore,O
resistance,O
pattern,O
of,O
the,O
treatment,O
regimens,O
could,O
not,O
be,O
evaluated,O
which,O
is,O
recommended,O
for,O
the,O
assessment,O
of,O
impact,O
of,O
treatment,O
regimens,O
.,O
On,O
the,O
other,O
hand,O
the,O
random,O
selection,O
of,O
relatively,O
large,O
sample,O
from,O
both,O
groups,O
minimized,O
risk,O
of,O
selection,O
bias,O
.,O
The,O
groups,O
treated,O
with,O
4RH,O
and,O
6EH,O
had,O
insignificant,O
differences,O
with,O
regard,O
to,O
baseline,O
and,O
follow,O
-,O
up,O
clinical,O
and,O
bacteriologic,O
attributes,O
that,O
enhanced,O
comparability,O
of,O
the,O
groups,O
.,O
Besides,O
",",O
we,O
extracted,O
data,O
from,O
a,O
standardized,O
routine,O
programme,O
register,O
that,O
reflect,O
operational,O
reality,O
.,O
In,O
general,O
",",O
our,O
study,O
is,O
valid,O
and,O
can,O
apply,O
in,O
similar,O
settings,O
given,O
the,O
limitations,O
.,O
Conclusion,O
In,O
conclusion,O
",",O
the,O
switch,O
of,O
continuation,O
phase,O
TB,B-DS
treatment,O
regimen,O
for,O
new,O
cases,O
from,O
6EH,O
to,O
4RH,O
has,O
brought,O
better,O
treatment,O
outcomes,O
.,O
The,O
findings,O
verified,O
the,O
applicability,O
of,O
latest,O
WHO,O
recommendation,O
and,O
national,O
adoption,O
to,O
the,O
high,O
prevalent,O
and,O
resource,O
constrained,O
settings,O
.,O
However,O
",",O
the,O
unsuccessful,O
outcome,O
among,O
the,O
older,O
",",O
rural,O
dwellers,O
and,O
HIV,B-OG
positives,O
is,O
higher,O
independent,O
of,O
the,O
treatment,O
regimen,O
that,O
need,O
further,O
investigation,O
and,O
focused,O
intervention,O
.,O
Therefore,O
",",O
the,O
recommended,O
switch,O
of,O
treatment,O
regimen,O
should,O
be,O
maintained,O
and,O
progressively,O
assessed,O
for,O
outcomes,O
",",O
including,O
drug,O
resistance,O
survey,O
or,O
surveillance,O
.,O
Moreover,O
",",O
further,O
studies,O
should,O
be,O
carried,O
out,O
on,O
the,O
impact,O
of,O
treatment,O
regimens,O
among,O
older,O
",",O
rural,O
residents,O
and,O
HIV,B-OG
positives,O
.,O
Table,O
4,O
:,O
Factors,O
associated,O
with,O
unsuccessful,O
treatment,O
outcome,O
among,O
smear,O
positive,O
pulmonary,B-DS
TB,I-DS
cases,O
registered,O
during,O
2008,O
-,O
2014,O
",",O
southwestern,O
Ethiopia,O
(,O
n,O
=,O
359,O
).,O
Table,O
5,O
:,O
Factors,O
associated,O
with,O
unsuccessful,O
outcome,O
among,O
clinically,O
diagnosed,O
(,O
smear,O
negative,O
10,O
.,O
1186,O
/,O
s12879,O
-,O
016,O
-,O
1917,O
-,O
0,O
pulmonary,O
and,O
extra,O
pulmonary,O
),O
TB,B-DS
cases,O
registered,O
during,O
2008,O
-,O
2014,O
",",O
Southwestern,O
Ethiopia,O
(,O
n,O
=,O
431,O
).,O
(,O
DOCX,O
17,O
kb,O
),O
Preferential,O
Enhancement,O
of,O
Sensory,O
and,O
Motor,O
Axon,O
Regeneration,O
by,O
Combining,O
Extracellular,O
Matrix,O
Components,O
with,O
Neurotrophic,B-GP
Factors,I-GP
These,O
authors,O
contributed,O
equally,O
to,O
this,O
work,O
.,O
After,O
peripheral,B-DS
nerve,I-DS
injury,I-DS
",",O
motor,O
and,O
sensory,O
axons,O
are,O
able,O
to,O
regenerate,O
but,O
inaccuracy,O
of,O
target,O
reinnervation,O
leads,O
to,O
poor,O
functional,O
recovery,O
.,O
Extracellular,O
matrix,O
(,O
ECM,O
),O
components,O
and,O
neurotrophic,B-GP
factors,I-GP
(,O
NTFs,B-GP
),O
exert,O
their,O
effect,O
on,O
different,O
neuronal,O
populations,O
creating,O
a,O
suitable,O
environment,O
to,O
promote,O
axonal,O
growth,O
.,O
Here,O
",",O
we,O
assessed,O
in,O
vitro,O
and,O
in,O
vivo,O
the,O
selective,O
effects,O
of,O
combining,O
different,O
ECM,O
components,O
with,O
NTFs,B-GP
on,O
motor,O
and,O
sensory,O
axons,O
regeneration,O
and,O
target,O
reinnervation,O
.,O
Organotypic,O
cultures,O
with,O
collagen,B-GP
",",O
laminin,B-GP
and,O
nerve,B-GP
growth,I-GP
factor,I-GP
(,O
NGF,B-GP
)/,O
neurotrophin,B-GP
-,I-GP
3,I-GP
(,O
NT3,B-GP
),O
or,O
collagen,B-GP
",",O
fibronectin,B-GP
and,O
brain,B-GP
-,I-GP
derived,I-GP
neurotrophic,I-GP
factor,I-GP
(,O
BDNF,B-GP
),O
selectively,O
enhanced,O
sensory,O
neurite,O
outgrowth,O
of,O
DRG,O
neurons,O
and,O
motor,O
neurite,O
outgrowth,O
from,O
spinal,O
cord,O
slices,O
respectively,O
.,O
For,O
in,O
vivo,O
studies,O
",",O
the,O
rat,B-OG
sciatic,O
nerve,O
was,O
transected,O
and,O
repaired,O
with,O
a,O
silicone,O
tube,O
filled,O
with,O
a,O
collagen,B-GP
and,O
laminin,B-GP
matrix,O
with,O
NGF,B-GP
/,O
NT3,B-GP
encapsulated,O
in,O
poly,O
(,O
lactic,O
-,O
co,O
-,O
glycolic,O
acid,O
),O
(,O
PLGA,O
),O
microspheres,O
(,O
MP,O
),O
(,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
"),",O
or,O
a,O
collagen,B-GP
and,O
fibronectin,B-GP
matrix,O
with,O
BDNF,B-GP
in,O
PLGA,O
MPs,O
(,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
).,O
Retrograde,O
labeling,O
and,O
functional,O
tests,O
showed,O
that,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
increased,O
the,O
number,O
of,O
regenerated,O
sensory,O
neurons,O
and,O
improved,O
sensory,O
functional,O
recovery,O
",",O
whereas,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
preferentially,O
increased,O
regenerated,O
motoneurons,O
and,O
enhanced,O
motor,O
functional,O
recovery,O
.,O
Therefore,O
",",O
combination,O
of,O
ECM,O
molecules,O
with,O
NTFs,B-GP
may,O
be,O
a,O
good,O
approach,O
to,O
selectively,O
enhance,O
motor,O
and,O
sensory,O
axons,O
regeneration,O
and,O
promote,O
appropriate,O
target,O
reinnervation,O
.,O
1,O
.,O
Introduction,O
After,O
peripheral,B-DS
nerve,I-DS
injury,I-DS
",",O
transected,O
axons,O
in,O
the,O
distal,O
stump,O
are,O
disconnected,O
from,O
the,O
neuronal,O
body,O
and,O
undergo,O
Wallerian,O
degeneration,O
",",O
thus,O
leading,O
to,O
denervation,O
of,O
peripheral,O
organs,O
[,O
1,O
].,O
Axotomized,O
neurons,O
switch,O
to,O
a,O
growth,O
state,O
",",O
and,O
non,O
-,O
neuronal,O
cells,O
in,O
the,O
distal,O
stump,O
undergo,O
activation,O
and,O
dedifferentiation,O
to,O
sustain,O
nerve,O
regeneration,O
[,O
2,O
",",O
3,O
].,O
Even,O
though,O
axons,O
are,O
able,O
to,O
regenerate,O
after,O
nerve,O
transection,O
",",O
axons,O
grow,O
randomly,O
among,O
the,O
endoneurial,O
tubules,O
in,O
the,O
distal,O
nerve,O
",",O
so,O
that,O
the,O
accuracy,O
of,O
target,O
reinnervation,O
is,O
usually,O
poor,O
",",O
resulting,O
in,O
limited,O
functional,O
recovery,O
[,O
4,O
",",O
5,O
",",O
6,O
",",O
7,O
].,O
Therefore,O
",",O
a,O
pro,O
-,O
regenerative,O
environment,O
that,O
selectively,O
guides,O
motor,O
and,O
sensory,O
axons,O
to,O
regenerate,O
into,O
different,O
branches,O
of,O
the,O
injured,O
nerve,O
may,O
be,O
useful,O
to,O
increase,O
the,O
options,O
of,O
specific,O
target,O
reinnervation,O
.,O
Selective,O
regeneration,O
of,O
different,O
axonal,O
populations,O
would,O
be,O
also,O
useful,O
in,O
the,O
field,O
of,O
neuroprosthetics,O
",",O
as,O
separating,O
motor,O
axons,O
from,O
sensory,O
axons,O
in,O
mixed,O
nerves,O
will,O
functionally,O
improve,O
selective,O
recording,O
and,O
stimulation,O
for,O
providing,O
bidirectional,O
communication,O
with,O
the,O
prosthesis,O
[,O
8,O
",",O
9,O
].,O
After,O
peripheral,B-DS
nerve,I-DS
injury,I-DS
",",O
the,O
generation,O
of,O
a,O
pro,O
-,O
regenerative,O
environment,O
involves,O
the,O
upregulation,O
and,O
secretion,O
of,O
extracellular,O
matrix,O
(,O
ECM,O
),O
components,O
",",O
such,O
as,O
collagen,B-GP
type,I-GP
IV,I-GP
",",O
laminin,B-GP
and,O
fibronectin,B-GP
",",O
and,O
the,O
secretion,O
of,O
different,O
neurotrophic,B-GP
factors,I-GP
(,O
NTFs,B-GP
"),",O
such,O
as,O
nerve,B-GP
growth,I-GP
factor,I-GP
(,O
NGF,B-GP
"),",O
brain,B-GP
-,I-GP
derived,I-GP
neurotrophic,I-GP
factor,I-GP
(,O
BDNF,B-GP
"),",O
neurotrophin,B-GP
-,I-GP
3,I-GP
(,O
NT3,B-GP
"),",O
and,O
glial,B-GP
derived,I-GP
neurotrophic,I-GP
factor,I-GP
(,O
GDNF,B-GP
"),",O
among,O
others,O
[,O
10,O
].,O
ECM,O
components,O
interact,O
with,O
integrin,B-GP
heterodimer,I-GP
receptors,I-GP
that,O
are,O
highly,O
expressed,O
in,O
growth,O
cones,O
and,O
non,O
-,O
neuronal,O
cells,O
",",O
both,O
during,O
development,O
and,O
after,O
injury,B-DS
[,O
11,O
",",O
12,O
"],",O
promoting,O
axonal,O
guidance,O
",",O
cell,O
adhesion,O
and,O
migration,O
.,O
For,O
instance,O
",",O
laminin,B-GP
substrates,O
enhance,O
elongation,O
of,O
sensory,O
neurites,O
in,O
vitro,O
when,O
compared,O
to,O
collagen,B-GP
or,O
fibronectin,B-GP
containing,O
scaffolds,O
",",O
whereas,O
fibronectin,B-GP
substrates,O
promote,O
neurite,O
elongation,O
of,O
motor,O
neurons,O
from,O
SC,O
slices,O
in,O
vitro,O
[,O
13,O
",",O
14,O
].,O
On,O
the,O
other,O
hand,O
",",O
the,O
interaction,O
between,O
NTFs,B-GP
and,O
their,O
different,O
receptors,O
",",O
such,O
as,O
Trk,B-GP
/,O
p75,B-GP
receptors,O
or,O
GDNFR,B-GP
/,O
RET,B-GP
receptors,O
",",O
promotes,O
survival,O
and,O
axonal,O
regeneration,O
of,O
different,O
neuronal,O
populations,O
.,O
For,O
example,O
",",O
we,O
found,O
that,O
NGF,B-GP
selectively,O
promotes,O
sensory,O
neurite,O
outgrowth,O
",",O
whereas,O
BDNF,B-GP
or,O
fibroblast,B-GP
growth,I-GP
factor,I-GP
(,O
FGF,B-GP
),O
preferentially,O
increase,O
motor,O
neurite,O
outgrowth,O
in,O
vitro,O
[,O
15,O
].,O
Several,O
reports,O
have,O
demonstrated,O
that,O
the,O
pattern,O
of,O
NTFs,B-GP
expressed,O
in,O
denervated,O
Schwann,O
cells,O
after,O
nerve,B-DS
injury,I-DS
is,O
different,O
between,O
motor,O
and,O
sensory,O
nerve,O
branches,O
",",O
and,O
that,O
motor,O
and,O
sensory,O
axons,O
also,O
express,O
different,O
cell,O
adhesion,O
molecules,O
that,O
may,O
promote,O
differential,O
binding,O
to,O
ECM,O
molecules,O
[,O
16,O
",",O
17,O
",",O
18,O
",",O
19,O
].,O
Manipulation,O
of,O
some,O
of,O
these,O
differential,O
biomarkers,O
may,O
play,O
a,O
role,O
in,O
promoting,O
selective,O
regeneration,O
of,O
different,O
axonal,O
populations,O
and,O
improving,O
subsequent,O
accurate,O
reinnervation,O
.,O
However,O
",",O
the,O
majority,O
of,O
the,O
studies,O
have,O
only,O
investigated,O
the,O
effect,O
of,O
these,O
molecules,O
individually,O
",",O
disregarding,O
the,O
synergistic,O
interactions,O
of,O
ECM,O
molecules,O
with,O
NTFs,B-GP
[,O
20,O
].,O
Therefore,O
",",O
in,O
this,O
study,O
",",O
we,O
tested,O
whether,O
the,O
combination,O
of,O
different,O
NTFs,B-GP
and,O
ECM,O
components,O
",",O
that,O
were,O
previously,O
shown,O
to,O
produce,O
a,O
selective,O
although,O
limited,O
stimulus,O
for,O
either,O
sensory,O
or,O
motor,O
axons,O
regeneration,O
[,O
14,O
",",O
21,O
"],",O
was,O
able,O
to,O
produce,O
a,O
synergistic,O
and,O
selective,O
pro,O
-,O
regenerative,O
effect,O
on,O
motor,O
and,O
sensory,O
neurons,O
.,O
Briefly,O
",",O
addition,O
of,O
both,O
LM,B-GP
and,O
NGF,B-GP
/,O
NT3,B-GP
or,O
FN,B-GP
and,O
BDNF,B-GP
increased,O
the,O
amount,O
of,O
sensory,O
and,O
motor,O
neurite,O
outgrowth,O
",",O
respectively,O
",",O
in,O
culture,O
models,O
.,O
Moreover,O
",",O
these,O
effects,O
were,O
maintained,O
in,O
vivo,O
in,O
adult,O
animals,B-OG
as,O
sensory,O
and,O
motor,O
axonal,O
regeneration,O
as,O
well,O
as,O
functional,O
recovery,O
was,O
enhanced,O
after,O
treating,O
nerve,B-DS
injuries,I-DS
with,O
a,O
nerve,O
conduit,O
prefilled,O
with,O
the,O
same,O
combinations,O
of,O
NTFs,B-GP
and,O
ECM,O
components,O
.,O
2,O
.,O
Results,O
2,O
.,O
1,O
.,O
In,O
Vitro,O
Effects,O
of,O
Combining,O
Neurotrophic,B-GP
Factors,I-GP
(,O
NTFs,B-GP
),O
and,O
Extracellular,O
Matrix,O
(,O
ECM,O
),O
Substrates,O
on,O
Neurite,O
Outgrowth,O
To,O
study,O
the,O
effect,O
of,O
different,O
combinations,O
of,O
NTFs,B-GP
and,O
ECM,O
components,O
on,O
motor,O
and,O
sensory,O
neurons,O
outgrowth,O
",",O
we,O
first,O
performed,O
an,O
in,O
vitro,O
screening,O
using,O
spinal,O
cord,O
(,O
SC,O
),O
slices,O
and,O
DRG,O
explants,O
.,O
In,O
cultures,O
of,O
SC,O
slices,O
(,O
Figure,O
1,O
"),",O
addition,O
of,O
FN,B-GP
to,O
the,O
matrix,O
doubled,O
the,O
maximum,O
neurite,O
length,O
whereas,O
addition,O
of,O
LM,B-GP
did,O
not,O
increase,O
it,O
compared,O
to,O
the,O
control,O
COL,B-GP
matrix,O
(,O
Figure,O
1J,O
).,O
Addition,O
of,O
BDNF,B-GP
but,O
not,O
of,O
NGF,B-GP
/,O
NT3,B-GP
to,O
the,O
different,O
substrates,O
enhanced,O
neurite,O
length,O
.,O
Furthermore,O
",",O
the,O
combination,O
of,O
FN,B-GP
+,O
BDNF,B-GP
significantly,O
enhanced,O
maximum,O
neurite,O
length,O
and,O
density,O
of,O
neurites,O
compared,O
to,O
the,O
other,O
single,O
and,O
combined,O
groups,O
.,O
Thus,O
",",O
while,O
groups,O
with,O
either,O
FN,B-GP
or,O
BDNF,B-GP
present,O
an,O
increase,O
in,O
the,O
amount,O
and,O
length,O
of,O
neurites,O
",",O
the,O
combination,O
of,O
the,O
two,O
factors,O
shows,O
a,O
synergistic,O
effect,O
with,O
significant,O
differences,O
with,O
respect,O
to,O
all,O
the,O
other,O
groups,O
.,O
On,O
the,O
other,O
hand,O
",",O
LM,B-GP
or,O
NGF,B-GP
/,O
NT3,B-GP
alone,O
or,O
combined,O
did,O
not,O
show,O
any,O
improvement,O
(,O
Figure,O
1J,O
–,O
L,O
).,O
In,O
DRG,O
explants,O
(,O
Figure,O
2,O
"),",O
addition,O
of,O
LM,B-GP
or,O
FN,B-GP
into,O
the,O
collagen,B-GP
matrix,O
similarly,O
enhanced,O
the,O
maximum,O
neurite,O
length,O
(,O
Figure,O
2J,O
),O
compared,O
to,O
collagen,B-GP
alone,O
.,O
The,O
addition,O
of,O
NGF,B-GP
/,O
NT3,B-GP
or,O
BDNF,B-GP
into,O
COL,B-GP
",",O
LM,B-GP
and,O
FN,B-GP
substrates,O
enhanced,O
maximum,O
neurite,O
length,O
compared,O
with,O
COL,B-GP
substrate,O
except,O
COL,B-GP
+,O
BDNF,B-GP
cultures,O
.,O
It,O
is,O
noteworthy,O
that,O
only,O
LM,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
group,O
showed,O
differences,O
in,O
maximum,O
neurite,O
length,O
with,O
respect,O
to,O
all,O
the,O
other,O
culture,O
conditions,O
except,O
with,O
LM,B-GP
+,O
BDNF,B-GP
.,O
The,O
addition,O
of,O
NGF,B-GP
and,O
NT3,B-GP
enhanced,O
significantly,O
the,O
density,O
of,O
neurites,O
in,O
all,O
the,O
substrates,O
",",O
being,O
LM,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
the,O
most,O
prominent,O
.,O
In,O
contrast,O
",",O
addition,O
of,O
BDNF,B-GP
only,O
promoted,O
neurite,O
growth,O
with,O
LM,B-GP
but,O
not,O
when,O
combined,O
with,O
COL,B-GP
or,O
FN,B-GP
(,O
Figure,O
2L,O
).,O
These,O
results,O
indicate,O
that,O
combination,O
of,O
FN,B-GP
+,O
BDNF,B-GP
shows,O
synergistic,O
effects,O
on,O
motor,O
neurons,O
promoting,O
neurite,O
elongation,O
and,O
arborization,O
",",O
with,O
weaker,O
effect,O
on,O
sensory,O
elongation,O
",",O
whereas,O
LM,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
is,O
the,O
only,O
condition,O
that,O
exhibits,O
a,O
synergistic,O
effects,O
on,O
sensory,O
but,O
not,O
on,O
motor,O
neurons,O
based,O
on,O
the,O
enhancement,O
observed,O
in,O
neurite,O
elongation,O
and,O
arborization,O
.,O
2,O
.,O
2,O
.,O
In,O
Vivo,O
Effects,O
of,O
Combination,O
of,O
NTF,B-GP
and,O
ECM,O
Substrates,O
on,O
Nerve,O
Regeneration,O
We,O
performed,O
first,O
an,O
in,O
vivo,O
study,O
in,O
which,O
the,O
sciatic,O
nerve,O
was,O
transected,O
and,O
repaired,O
with,O
silicone,O
tubes,O
filled,O
with,O
matrices,O
composed,O
of,O
COL,B-GP
",",O
COL,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
",",O
LM,B-GP
",",O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
",",O
COL,B-GP
+,O
MP,O
.,O
BDNF,B-GP
",",O
and,O
FN,B-GP
and,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
to,O
elucidate,O
if,O
the,O
conditions,O
with,O
a,O
more,O
relevant,O
effect,O
in,O
vitro,O
had,O
a,O
similar,O
effect,O
in,O
vivo,O
.,O
The,O
three,O
NTFs,B-GP
(,O
NGF,B-GP
",",O
NT3,B-GP
and,O
BDNF,B-GP
),O
were,O
encapsulated,O
in,O
PLGA,O
microspheres,O
to,O
allow,O
a,O
sustained,O
release,O
during,O
the,O
time,O
that,O
axons,O
regenerate,O
across,O
the,O
tube,O
[,O
21,O
].,O
All,O
rats,B-OG
showed,O
evidence,O
of,O
axonal,O
regeneration,O
",",O
as,O
judged,O
by,O
the,O
retrograde,O
labeling,O
of,O
motor,O
and,O
sensory,O
neurons,O
with,O
Fluorogold,O
(,O
FG,O
),O
(,O
Figure,O
3A,O
–,O
F,O
).,O
Regarding,O
the,O
number,O
of,O
regenerated,O
motor,O
neurons,O
",",O
all,O
groups,O
with,O
addition,O
of,O
ECM,O
and,O
NTFs,B-GP
showed,O
significant,O
differences,O
with,O
respect,O
to,O
the,O
COL,B-GP
group,O
(,O
p,O
<,O
0,O
.,O
001,O
",",O
Figure,O
3G,O
"),",O
being,O
the,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
group,O
the,O
one,O
with,O
the,O
highest,O
effect,O
",",O
that,O
was,O
also,O
significantly,O
higher,O
compared,O
to,O
all,O
other,O
groups,O
except,O
with,O
FN,B-GP
.,O
For,O
sensory,O
neurons,O
",",O
the,O
group,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
showed,O
the,O
highest,O
number,O
of,O
regenerated,O
neurons,O
",",O
and,O
all,O
other,O
groups,O
had,O
better,O
results,O
than,O
the,O
COL,B-GP
control,O
(,O
Figure,O
3H,O
).,O
We,O
then,O
tested,O
whether,O
this,O
preferential,O
effect,O
is,O
maintained,O
in,O
a,O
long,O
term,O
study,O
.,O
For,O
this,O
purpose,O
",",O
we,O
compared,O
groups,O
of,O
rats,B-OG
similar,O
to,O
the,O
short,O
term,O
study,O
but,O
leaving,O
an,O
8,O
mm,O
gap,O
between,O
stumps,O
",",O
since,O
this,O
more,O
challenging,O
gap,O
allows,O
to,O
better,O
elucidate,O
differences,O
between,O
groups,O
[,O
22,O
"],",O
and,O
applying,O
the,O
FG,O
retrotracer,O
to,O
the,O
tibial,O
nerve,O
at,O
the,O
ankle,O
at,O
75,O
dpi,O
.,O
In,O
this,O
case,O
",",O
no,O
significant,O
differences,O
in,O
the,O
number,O
of,O
regenerated,O
motor,O
neurons,O
were,O
observed,O
between,O
groups,O
(,O
Figure,O
3I,O
).,O
However,O
",",O
more,O
regenerated,O
sensory,O
neurons,O
were,O
counted,O
in,O
the,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
group,O
compared,O
to,O
the,O
other,O
four,O
groups,O
(,O
Figure,O
3J,O
).,O
Despite,O
the,O
preferential,O
effects,O
observed,O
in,O
vitro,O
appear,O
less,O
marked,O
in,O
vivo,O
",",O
these,O
results,O
indicate,O
that,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
mainly,O
favors,O
motor,O
axon,O
regeneration,O
",",O
whereas,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
is,O
more,O
effective,O
to,O
promote,O
sensory,O
axon,O
regeneration,O
.,O
2,O
.,O
3,O
.,O
Combination,O
of,O
FN,B-GP
and,O
BDNF,B-GP
Promotes,O
Motor,O
Functional,O
Recovery,O
at,O
Long,O
Term,O
We,O
tested,O
if,O
the,O
effects,O
seen,O
on,O
regeneration,O
in,O
the,O
short,O
and,O
long,O
term,O
studies,O
had,O
impact,O
on,O
muscle,O
reinnervation,O
and,O
functional,O
recovery,O
.,O
Nerve,O
conduction,O
tests,O
provided,O
first,O
evidence,O
of,O
reinnervation,O
of,O
the,O
TA,O
muscle,O
at,O
45,O
dpi,O
in,O
all,O
the,O
groups,O
(,O
Figure,O
4A,O
).,O
The,O
amplitude,O
of,O
the,O
CMAP,O
increased,O
during,O
the,O
follow,O
-,O
up,O
.,O
At,O
60,O
dpi,O
",",O
the,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
group,O
showed,O
higher,O
amplitude,O
than,O
all,O
the,O
other,O
groups,O
(,O
p,O
<,O
0,O
.,O
01,O
).,O
FN,B-GP
group,O
also,O
showed,O
significant,O
differences,O
with,O
respect,O
to,O
COL,B-GP
group,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
However,O
",",O
all,O
groups,O
reached,O
similar,O
CMAP,O
amplitude,O
at,O
75,O
dpi,O
.,O
In,O
the,O
more,O
distal,O
plantar,O
muscles,O
",",O
reinnervation,O
started,O
later,O
compared,O
to,O
TA,O
muscle,O
.,O
In,O
this,O
case,O
",",O
the,O
CMAP,O
amplitude,O
at,O
75,O
dpi,O
was,O
significantly,O
higher,O
in,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
group,O
compared,O
to,O
all,O
the,O
other,O
groups,O
(,O
p,O
<,O
0,O
.,O
001,O
",",O
Figure,O
4B,O
).,O
No,O
differences,O
in,O
the,O
CMAP,O
latency,O
were,O
observed,O
between,O
groups,O
.,O
These,O
results,O
suggest,O
that,O
an,O
intratubular,O
matrix,O
containing,O
FN,B-GP
and,O
BDNF,B-GP
promotes,O
motor,O
axon,O
regeneration,O
and,O
reinnervation,O
of,O
target,O
muscles,O
",",O
whereas,O
LM,B-GP
and,O
LM,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
groups,O
showed,O
values,O
similar,O
to,O
the,O
COL,B-GP
control,O
group,O
.,O
The,O
faster,O
muscle,O
reinnervation,O
found,O
in,O
group,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
is,O
of,O
relevance,O
considering,O
the,O
longer,O
distance,O
that,O
has,O
to,O
be,O
regenerated,O
in,O
injured,O
human,B-OG
nerves,O
.,O
2,O
.,O
4,O
.,O
Combination,O
of,O
LM,B-GP
and,O
NGF,B-GP
/,O
NT3,B-GP
Promotes,O
Sensory,O
Functional,O
Recovery,O
at,O
Long,O
Term,O
In,O
parallel,O
",",O
we,O
assessed,O
sensory,O
functional,O
recovery,O
to,O
mechanical,O
and,O
thermal,O
stimuli,O
in,O
the,O
hind,O
paw,O
.,O
For,O
the,O
pinprick,O
test,O
",",O
LM,B-GP
and,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
groups,O
presented,O
the,O
first,O
positive,O
response,O
at,O
30,O
dpi,O
",",O
whereas,O
no,O
response,O
was,O
observed,O
in,O
the,O
other,O
groups,O
at,O
this,O
time,O
point,O
.,O
At,O
later,O
time,O
points,O
",",O
all,O
groups,O
showed,O
positive,O
responses,O
",",O
being,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
the,O
only,O
group,O
with,O
significantly,O
higher,O
scores,O
compared,O
to,O
the,O
control,O
group,O
(,O
p,O
<,O
0,O
.,O
05,O
;,O
Figure,O
4C,O
).,O
Withdrawal,O
responses,O
to,O
heat,O
stimulation,O
in,O
the,O
plantar,O
test,O
showed,O
similar,O
results,O
to,O
the,O
ones,O
observed,O
for,O
the,O
pinprick,O
.,O
Denervated,O
paws,O
did,O
not,O
respond,O
to,O
the,O
hot,O
stimuli,O
on,O
the,O
lateral,O
region,O
until,O
45,O
dpi,O
and,O
at,O
this,O
time,O
point,O
group,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
showed,O
a,O
shorter,O
latency,O
compared,O
to,O
control,O
",",O
FN,B-GP
and,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
groups,O
(,O
p,O
<,O
0,O
.,O
01,O
;,O
Figure,O
4D,O
"),",O
indicating,O
that,O
more,O
sensory,O
fibers,O
arrived,O
to,O
the,O
plantar,O
skin,O
of,O
the,O
paw,O
.,O
However,O
",",O
all,O
groups,O
showed,O
similar,O
latency,O
at,O
60,O
and,O
75,O
dpi,O
.,O
To,O
further,O
corroborate,O
the,O
functional,O
results,O
",",O
skin,O
reinnervation,O
of,O
the,O
lateral,O
paw,O
pads,O
was,O
analyzed,O
by,O
immunohistochemistry,O
.,O
In,O
all,O
the,O
rats,B-OG
PGP,O
immunolabeling,O
showed,O
regenerated,O
nerve,O
fibers,O
that,O
surrounded,O
the,O
SG,O
tubules,O
",",O
reached,O
the,O
subepidermal,O
nerve,O
plexus,O
",",O
and,O
extended,O
to,O
intraepidermal,O
terminals,O
and,O
Meissner,O
corpuscles,O
at,O
the,O
papillae,O
(,O
Figure,O
4E,O
–,O
J,O
).,O
Group,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
had,O
significantly,O
higher,O
number,O
of,O
IENF,O
than,O
all,O
the,O
other,O
groups,O
(,O
Figure,O
4K,O
).,O
Similarly,O
",",O
the,O
number,O
of,O
reinnervated,O
SGs,O
was,O
highest,O
in,O
group,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
",",O
although,O
only,O
significantly,O
from,O
groups,O
COL,B-GP
and,O
LM,B-GP
(,O
Figure,O
4L,O
).,O
Taken,O
together,O
",",O
these,O
results,O
indicate,O
that,O
the,O
combination,O
of,O
LM,B-GP
and,O
NGF,B-GP
/,O
NT3,B-GP
enhances,O
sensory,O
axons,O
regeneration,O
and,O
skin,O
reinnervation,O
by,O
populations,O
of,O
sensory,O
neurons,O
that,O
contribute,O
to,O
thermal,O
and,O
mechanical,O
sensibility,O
",",O
and,O
less,O
markedly,O
of,O
sympathetic,O
fibers,O
innervating,O
the,O
SGs,O
.,O
3,O
.,O
Discussion,O
NTFs,B-GP
and,O
ECM,O
components,O
both,O
have,O
important,O
roles,O
in,O
nerve,O
regeneration,O
after,O
injury,B-DS
",",O
including,O
effects,O
on,O
Schwann,O
cell,O
migration,O
and,O
differentiation,O
",",O
neuronal,O
survival,O
",",O
cell,O
adhesion,O
and,O
axonal,O
growth,O
[,O
10,O
",",O
23,O
].,O
To,O
corroborate,O
the,O
preferential,O
effect,O
of,O
NGF,B-GP
",",O
NT,B-GP
-,I-GP
3,I-GP
and,O
LM,B-GP
on,O
sensory,O
neurons,O
and,O
BDNF,B-GP
and,O
FN,B-GP
on,O
motor,O
neurons,O
[,O
15,O
",",O
24,O
",",O
25,O
",",O
26,O
",",O
27,O
"],",O
we,O
cultured,O
DRG,O
explants,O
and,O
spinal,O
cord,O
slices,O
.,O
Organotypic,O
cultures,O
are,O
multicellular,O
in,O
vitro,O
models,O
in,O
which,O
neurons,O
and,O
growing,O
neurites,O
share,O
similar,O
differentiation,O
and,O
development,O
patterns,O
with,O
in,O
vivo,O
conditions,O
[,O
28,O
],O
while,O
they,O
are,O
still,O
in,O
contact,O
with,O
Schwann,O
cells,O
and,O
fibroblasts,O
.,O
In,O
this,O
way,O
",",O
DRG,O
explants,O
have,O
been,O
long,O
used,O
to,O
study,O
axonal,O
growth,O
and,O
regeneration,O
of,O
the,O
sensory,O
nervous,O
system,O
[,O
29,O
",",O
30,O
],O
as,O
DRG,O
contain,O
the,O
soma,O
of,O
pseudounipolar,O
sensory,O
neurons,O
that,O
project,O
growing,O
neurites,O
outside,O
the,O
ganglion,O
.,O
On,O
the,O
other,O
hand,O
",",O
neurites,O
growing,O
from,O
the,O
ventral,O
areas,O
of,O
the,O
spinal,O
cord,O
arise,O
from,O
motoneurons,O
of,O
the,O
ventral,O
horn,O
instead,O
of,O
other,O
interneurons,O
[,O
31,O
],O
making,O
this,O
3D,O
culture,O
an,O
useful,O
model,O
for,O
studying,O
regeneration,O
of,O
motor,O
neurites,O
in,O
vitro,O
[,O
32,O
].,O
Taking,O
into,O
account,O
that,O
some,O
NTFs,B-GP
show,O
an,O
attractive,O
or,O
repulsive,O
effect,O
depending,O
on,O
the,O
presence,O
of,O
different,O
ECM,O
molecules,O
[,O
33,O
"],",O
we,O
performed,O
a,O
screening,O
of,O
possible,O
combinations,O
added,O
to,O
a,O
collagen,B-GP
gel,O
substrate,O
to,O
investigate,O
if,O
the,O
preferential,O
effects,O
of,O
ECM,O
components,O
and,O
NTFs,B-GP
could,O
be,O
synergistically,O
added,O
in,O
DRG,O
and,O
SC,O
postnatal,O
cultures,O
.,O
We,O
observed,O
an,O
increased,O
effect,O
of,O
LM,B-GP
and,O
NGF,B-GP
+,O
NT3,B-GP
on,O
sensory,O
neurite,O
outgrowth,O
in,O
DRG,O
explants,O
",",O
whereas,O
this,O
combination,O
did,O
not,O
increase,O
motor,O
neurite,O
length,O
.,O
On,O
the,O
other,O
hand,O
",",O
BDNF,B-GP
combined,O
with,O
FN,B-GP
promoted,O
a,O
synergic,O
effect,O
on,O
motor,O
neurite,O
outgrowth,O
with,O
small,O
effects,O
on,O
DRG,O
explants,O
",",O
which,O
can,O
be,O
attributed,O
to,O
the,O
effect,O
on,O
regenerating,O
proprioceptive,O
neurites,O
[,O
14,O
].,O
The,O
synergistic,O
effect,O
can,O
be,O
exemplified,O
for,O
BDNF,B-GP
",",O
that,O
promotes,O
sensory,O
neurite,O
outgrowth,O
in,O
the,O
presence,O
of,O
LM,B-GP
but,O
not,O
when,O
is,O
added,O
alone,O
.,O
These,O
proregenerative,O
effects,O
may,O
be,O
mediated,O
by,O
the,O
differential,O
expression,O
of,O
integrin,O
and,O
NTF,B-GP
receptors,I-GP
in,O
regenerating,O
neurons,O
.,O
It,O
has,O
been,O
described,O
that,O
after,O
injury,B-DS
integrin,B-GP
receptors,I-GP
α7β1,I-GP
and,O
α5β1,B-GP
are,O
upregulated,O
in,O
both,O
motor,O
and,O
sensory,O
neurons,O
[,O
14,O
",",O
34,O
"],",O
whereas,O
high,O
affinity,O
TrkA,B-GP
and,O
TrkC,B-GP
receptors,O
are,O
expressed,O
in,O
sensory,O
neurons,O
and,O
TrKB,B-GP
is,O
mainly,O
expressed,O
in,O
motoneurons,O
and,O
in,O
a,O
low,O
percentage,O
of,O
sensory,O
neurons,O
[,O
35,O
].,O
It,O
can,O
be,O
hypothesized,O
that,O
the,O
partially,O
selective,O
in,O
vitro,O
effects,O
of,O
NTFs,B-GP
may,O
be,O
enhanced,O
by,O
the,O
presence,O
of,O
certain,O
ECM,O
molecules,O
in,O
the,O
substrate,O
.,O
In,O
fact,O
",",O
it,O
has,O
been,O
reported,O
that,O
the,O
pro,O
-,O
regenerative,O
effects,O
of,O
NGF,B-GP
and,O
NT3,B-GP
are,O
reduced,O
after,O
blocking,O
the,O
α7,B-GP
subunit,I-GP
of,I-GP
integrins,I-GP
in,O
sensory,O
neurons,O
[,O
36,O
"],",O
and,O
that,O
synergistic,O
actions,O
between,O
integrins,B-GP
and,O
NTF,B-GP
receptors,I-GP
may,O
be,O
attributed,O
to,O
the,O
sustained,O
activation,O
of,O
Src,B-GP
and,O
the,O
downstream,O
signaling,O
Akt,B-GP
intermediate,O
[,O
37,O
].,O
On,O
the,O
other,O
hand,O
",",O
NTFs,B-GP
may,O
also,O
modulate,O
the,O
expression,O
of,O
different,O
integrin,B-GP
receptor,I-GP
subunits,O
",",O
whose,O
upregulation,O
is,O
low,O
in,O
adult,O
compared,O
to,O
their,O
expression,O
in,O
early,O
postnatal,O
animals,B-OG
[,O
38,O
].,O
Actually,O
",",O
NGF,B-GP
contributes,O
to,O
enhance,O
ECM,O
signaling,O
by,O
promoting,O
axonal,O
transport,O
and,O
accumulation,O
of,O
β1,B-GP
integrin,I-GP
in,O
growth,O
cones,O
",",O
thus,O
enhancing,O
neurite,O
outgrowth,O
[,O
39,O
].,O
Since,O
the,O
optimal,O
developmental,O
window,O
of,O
regeneration,O
varies,O
from,O
E11,O
–,O
E15,O
in,O
the,O
chick,O
spinal,O
cord,O
to,O
P7,O
in,O
rats,B-OG
[,O
40,O
],O
and,O
the,O
effects,O
of,O
different,O
ECM,O
molecules,O
in,O
vitro,O
are,O
lost,O
when,O
switching,O
from,O
postnatal,O
P7,O
to,O
weaned,O
P21,O
rats,B-OG
[,O
14,O
"],",O
it,O
was,O
necessary,O
to,O
confirm,O
in,O
a,O
model,O
of,O
peripheral,B-DS
nerve,I-DS
injury,I-DS
and,O
regeneration,O
in,O
vivo,O
the,O
effects,O
observed,O
in,O
cultures,O
.,O
The,O
in,O
vivo,O
results,O
demonstrated,O
that,O
introduction,O
of,O
a,O
collagen,B-GP
matrix,O
enriched,O
with,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
or,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
within,O
the,O
tube,O
used,O
for,O
nerve,O
repair,O
in,O
adult,O
rats,B-OG
promoted,O
preferential,O
regeneration,O
of,O
sensory,O
and,O
motor,O
axons,O
respectively,O
.,O
The,O
NTFs,B-GP
were,O
encapsulated,O
in,O
PLGA,O
microspheres,O
as,O
they,O
have,O
been,O
approved,O
by,O
the,O
FDA,O
as,O
a,O
drug,O
delivery,O
system,O
[,O
41,O
],O
and,O
we,O
have,O
recently,O
demonstrated,O
that,O
they,O
do,O
not,O
interfere,O
with,O
axon,O
regeneration,O
and,O
their,O
slow,O
release,O
over,O
more,O
than,O
30,O
days,O
provides,O
more,O
sustained,O
support,O
for,O
nerve,O
regeneration,O
with,O
respect,O
to,O
addition,O
of,O
free,O
NTFs,B-GP
[,O
21,O
].,O
All,O
the,O
treated,O
groups,O
showed,O
an,O
increased,O
number,O
of,O
retrogradely,O
traced,O
motor,O
and,O
sensory,O
neurons,O
that,O
had,O
regenerated,O
their,O
axons,O
to,O
the,O
site,O
of,O
tracer,O
application,O
distal,O
to,O
the,O
tube,O
",",O
compared,O
to,O
the,O
control,O
COL,B-GP
group,O
.,O
This,O
is,O
a,O
positive,O
indication,O
that,O
the,O
design,O
and,O
the,O
concentrations,O
of,O
encapsulated,O
NTFs,B-GP
and,O
ECM,O
components,O
did,O
not,O
cause,O
detrimental,O
effects,O
such,O
as,O
the,O
candy,O
store,O
effect,O
[,O
42,O
],O
or,O
neuronal,O
death,O
induced,O
by,O
high,O
concentration,O
of,O
NTFs,B-GP
[,O
43,O
].,O
However,O
",",O
the,O
preferential,O
effect,O
mediated,O
by,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
and,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
treatments,O
was,O
more,O
modest,O
compared,O
to,O
the,O
in,O
vitro,O
experiments,O
.,O
This,O
comparative,O
reduction,O
may,O
be,O
explained,O
because,O
of,O
the,O
more,O
complex,O
environment,O
present,O
in,O
the,O
regenerating,O
nerve,O
.,O
After,O
nerve,B-DS
injury,I-DS
",",O
ECM,O
components,O
are,O
synthesized,O
and,O
secreted,O
by,O
non,O
-,O
neuronal,O
cells,O
such,O
as,O
Schwann,O
cells,O
and,O
fibroblasts,O
[,O
44,O
"],",O
whereas,O
NTFs,B-GP
are,O
expressed,O
by,O
both,O
neuronal,O
and,O
non,O
-,O
neuronal,O
cells,O
[,O
16,O
",",O
45,O
",",O
46,O
].,O
Furthermore,O
",",O
non,O
-,O
neuronal,O
cells,O
involved,O
in,O
Wallerian,O
degeneration,O
also,O
express,O
integrins,B-GP
and,O
NTF,B-GP
receptors,I-GP
.,O
Therefore,O
",",O
the,O
in,O
vivo,O
implant,O
of,O
a,O
matrix,O
containing,O
ECM,O
components,O
and,O
NTFs,B-GP
in,O
the,O
nerve,O
conduit,O
does,O
not,O
only,O
influence,O
the,O
injured,O
neurons,O
",",O
but,O
also,O
acts,O
on,O
the,O
migrating,O
non,O
-,O
neuronal,O
cells,O
inside,O
the,O
intratubular,O
matrix,O
.,O
Hence,O
",",O
the,O
activation,O
of,O
non,O
-,O
neuronal,O
cells,O
would,O
contribute,O
with,O
proregenerative,O
non,O
-,O
specific,O
cues,O
and,O
decrease,O
the,O
effects,O
of,O
the,O
selective,O
factors,O
introduced,O
in,O
the,O
exogenous,O
matrix,O
.,O
On,O
the,O
other,O
hand,O
",",O
although,O
we,O
still,O
found,O
in,O
vivo,O
a,O
significant,O
preferential,O
regeneration,O
of,O
sensory,O
neurons,O
in,O
animals,B-OG
treated,O
with,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
and,O
of,O
motor,O
neurons,O
in,O
animals,B-OG
treated,O
with,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
",",O
the,O
differences,O
in,O
the,O
amount,O
of,O
regenerated,O
neurons,O
were,O
reduced,O
from,O
the,O
short,O
to,O
the,O
long,O
term,O
study,O
.,O
We,O
can,O
discard,O
that,O
this,O
could,O
be,O
related,O
to,O
an,O
inefficient,O
supply,O
of,O
NTFs,B-GP
as,O
we,O
have,O
previously,O
shown,O
that,O
NTF,B-GP
encapsulation,O
in,O
MPs,O
improved,O
regeneration,O
of,O
both,O
motor,O
and,O
sensory,O
axons,O
",",O
and,O
that,O
PLGA,O
MPs,O
are,O
able,O
to,O
sustain,O
release,O
of,O
these,O
NTFs,B-GP
longer,O
than,O
a,O
month,O
[,O
21,O
].,O
The,O
most,O
plausible,O
explanation,O
for,O
the,O
reduced,O
effect,O
observed,O
would,O
be,O
that,O
most,O
axons,O
had,O
passed,O
the,O
site,O
of,O
tracer,O
application,O
at,O
75,O
dpi,O
",",O
and,O
thus,O
we,O
were,O
not,O
able,O
to,O
detect,O
differences,O
that,O
occurred,O
at,O
earlier,O
time,O
.,O
Although,O
retrolabeling,O
of,O
regenerating,O
neurons,O
is,O
a,O
useful,O
technique,O
to,O
assess,O
the,O
differential,O
effect,O
of,O
local,O
treatments,O
",",O
functional,O
restitution,O
is,O
the,O
most,O
important,O
outcome,O
after,O
nerve,B-DS
injury,I-DS
[,O
47,O
].,O
Thus,O
",",O
in,O
the,O
long,O
term,O
in,O
vivo,O
study,O
we,O
evaluated,O
functional,O
recovery,O
of,O
both,O
motor,O
and,O
sensory,O
targets,O
.,O
Electrophysiological,O
results,O
demonstrated,O
that,O
muscle,O
reinnervation,O
started,O
earlier,O
and,O
achieved,O
higher,O
levels,O
in,O
the,O
FN,B-GP
+,O
MP,O
.,O
BDNF,B-GP
group,O
than,O
in,O
all,O
the,O
other,O
groups,O
.,O
An,O
increased,O
regeneration,O
rate,O
improves,O
muscle,O
reinnervation,O
",",O
particularly,O
of,O
distal,O
muscles,O
in,O
the,O
limb,O
",",O
as,O
shown,O
in,O
the,O
foot,O
muscles,O
in,O
this,O
study,O
",",O
reducing,O
the,O
detrimental,O
consequences,O
of,O
chronic,O
denervation,O
[,O
48,O
].,O
On,O
the,O
other,O
hand,O
",",O
treatment,O
with,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
showed,O
earlier,O
sensory,O
responses,O
to,O
both,O
mechanical,O
and,O
thermal,O
stimuli,O
",",O
confirming,O
the,O
results,O
seen,O
in,O
the,O
retrotracer,O
study,O
.,O
We,O
also,O
demonstrated,O
an,O
increased,O
number,O
of,O
sensory,O
axons,O
reinnervating,O
the,O
epidermis,O
and,O
of,O
sympathetic,O
axons,O
reinnervating,O
the,O
SGs,O
in,O
the,O
skin,O
in,O
the,O
LM,B-GP
+,O
MP,O
.,O
NGF,B-GP
/,O
NT3,B-GP
group,O
.,O
This,O
parallel,O
effect,O
could,O
be,O
explained,O
by,O
the,O
proregenerative,O
role,O
of,O
NGF,B-GP
on,O
sensory,O
as,O
well,O
as,O
on,O
sympathetic,O
neurons,O
[,O
49,O
].,O
4,O
.,O
Materials,O
and,O
Methods,O
4,O
.,O
1,O
.,O
Ethics,O
Statement,O
In,O
vitro,O
(,O
procedure,O
#,O
1963M,O
),O
and,O
in,O
vivo,O
(,O
procedure,O
#,O
1162MM,O
),O
experimental,O
procedures,O
were,O
approved,O
in,O
30,O
June,O
2015,O
and,O
in,O
29,O
May,O
2015,O
respectively,O
by,O
the,O
animal,O
and,O
human,B-OG
experimentation,O
ethics,O
committee,O
(,O
CEEAH,O
),O
of,O
the,O
Universitat,O
Autonoma,O
de,O
Barcelona,O
in,O
accordance,O
with,O
the,O
European,O
Communities,O
Council,O
Directive,O
2010,O
/,O
63,O
/,O
EU,O
.,O
4,O
.,O
2,O
.,O
In,O
Vitro,O
Study,O
on,O
Organotypic,O
Cultures,O
Organotypic,O
cultures,O
were,O
prepared,O
as,O
previously,O
described,O
in,O
detail,O
[,O
32,O
].,O
Briefly,O
",",O
a,O
3,O
mg,O
/,O
mL,O
collagen,B-GP
solution,O
was,O
prepared,O
by,O
mixing,O
rat,B-OG
tail,O
collagen,B-GP
type,I-GP
I,I-GP
(#,O
354236,O
",",O
Corning,O
",",O
Wiesbaden,O
",",O
Germany,O
),O
with,O
PBS,O
(,O
D8537,O
",",O
Sigma,O
",",O
Tres,O
Cantos,O
",",O
Spain,O
),O
and,O
sodium,O
bicarbonate,O
at,O
0,O
.,O
3,O
mg,O
/,O
mL,O
",",O
and,O
diluting,O
1,O
:,O
10,O
with,O
basal,O
Eagle,O
’,O
s,O
medium,O
(,O
10,O
"×,",O
Gibco,O
",",O
Grand,O
Island,O
",",O
NY,O
",",O
USA,O
).,O
NTF,B-GP
enriched,O
substrates,O
were,O
prepared,O
by,O
adding,O
BDNF,B-GP
at,O
50,O
ng,O
/,O
mL,O
(,O
Peprotech,O
",",O
London,O
",",O
UK,O
),O
or,O
NGF,B-GP
and,O
NT3,B-GP
(,O
Peprotech,O
),O
at,O
25,O
ng,O
/,O
mL,O
each,O
",",O
and,O
fibronectin,B-GP
(,O
BD,O
Bioscences,O
",",O
Vienna,O
",",O
Austria,O
),O
or,O
laminin,B-GP
type,I-GP
I,I-GP
(,O
Sigma,O
),O
to,O
a,O
20,O
%,O
final,O
volume,O
.,O
Single,O
30,O
µL,O
drops,O
of,O
the,O
prepared,O
matrices,O
were,O
deposited,O
on,O
poly,O
-,O
d,O
-,O
lysine,O
(,O
Sigma,O
),O
coated,O
coverslips,O
",",O
which,O
were,O
placed,O
in,O
Petri,O
dishes,O
or,O
24,O
-,O
well,O
multidishes,O
(,O
Iwaki,O
",",O
Asahi,O
Technoglass,O
",",O
Chiba,O
",",O
Japan,O
"),",O
and,O
kept,O
in,O
the,O
incubator,O
at,O
37,O
°,O
C,O
and,O
5,O
%,O
CO2,O
for,O
two,O
hours,O
to,O
induce,O
collagen,B-GP
gel,O
formation,O
.,O
Collagen,B-GP
gel,O
was,O
mixed,O
with,O
PBS,O
(,O
COL,B-GP
),O
and,O
used,O
as,O
control,O
.,O
Collagen,B-GP
gels,O
were,O
also,O
combined,O
with,O
NGF,B-GP
/,O
NT3,B-GP
(,O
COL,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
),O
or,O
BDNF,B-GP
(,O
COL,B-GP
+,O
BDNF,B-GP
).,O
Similarly,O
",",O
laminin,B-GP
and,O
fibronectin,B-GP
-,O
enriched,O
gels,O
were,O
combined,O
with,O
PBS,O
(,O
LM,B-GP
and,O
FN,B-GP
",",O
respectively,O
"),",O
NGF,B-GP
+,O
NT3,B-GP
(,O
LM,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
and,O
FN,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
",",O
respectively,O
),O
or,O
BDNF,B-GP
(,O
LM,B-GP
+,O
BDNF,B-GP
and,O
FN,B-GP
+,O
BDNF,B-GP
",",O
respectively,O
),O
(,O
see,O
Table,O
1,O
).,O
The,O
lumbar,O
spinal,O
cord,O
(,O
SC,O
",",O
n,O
=,O
6,O
–,O
8,O
/,O
group,O
),O
and,O
dorsal,O
root,O
ganglia,O
(,O
DRG,O
",",O
n,O
=,O
7,O
–,O
8,O
/,O
group,O
),O
were,O
harvested,O
from,O
7,O
-,O
day,O
-,O
old,O
Sprague,O
-,O
Dawley,O
rats,B-OG
",",O
placed,O
in,O
cold,O
Gey,O
’,O
s,O
balanced,O
salt,O
solution,O
(,O
Sigma,O
),O
enriched,O
with,O
6,O
mg,O
/,O
mL,O
glucose,O
and,O
cleaned,O
.,O
SC,O
350,O
µm,O
thick,O
slices,O
and,O
DRG,O
explants,O
were,O
placed,O
on,O
gelled,O
collagen,B-GP
droplets,O
",",O
prepared,O
as,O
indicated,O
above,O
",",O
and,O
covered,O
with,O
a,O
second,O
30,O
µL,O
drop,O
.,O
The,O
embedded,O
samples,O
were,O
placed,O
in,O
the,O
incubator,O
for,O
45,O
min,O
before,O
adding,O
Neurobasal,O
medium,O
(,O
NB,O
",",O
Life,O
Technologies,O
",",O
Carlsbad,O
",",O
CA,O
",",O
USA,O
"),",O
supplemented,O
with,O
B27,O
(,O
Life,O
Technologies,O
"),",O
glutamine,O
and,O
penicillin,O
/,O
streptomycin,O
(,O
Sigma,O
).,O
SC,O
slices,O
were,O
cultured,O
for,O
4,O
days,O
",",O
and,O
DRG,O
explants,O
for,O
2,O
days,O
.,O
Then,O
",",O
cultures,O
were,O
fixed,O
with,O
4,O
%,O
paraformaldehyde,O
in,O
PBS,O
for,O
30,O
min,O
",",O
and,O
incubated,O
for,O
48,O
h,O
with,O
primary,O
antibody,O
mouse,B-OG
RT97,O
(,O
1,O
:,O
200,O
",",O
Developmental,O
Studies,O
Hybridoma,O
Bank,O
",",O
Iowa,O
City,O
",",O
IA,O
",",O
USA,O
),O
at,O
4,O
°,O
C,O
.,O
After,O
washes,O
",",O
the,O
sections,O
were,O
incubated,O
with,O
secondary,O
antibody,O
AF594,O
conjugated,O
donkey,B-OG
anti,O
-,O
mouse,B-OG
(,O
1,O
:,O
200,O
",",O
Life,O
Technologies,O
),O
overnight,O
at,O
4,O
°,O
C,O
.,O
For,O
DRG,O
and,O
SC,O
visualization,O
",",O
samples,O
were,O
mounted,O
on,O
slides,O
using,O
Mowiol,O
with,O
DAPI,O
(,O
100,O
ng,O
/,O
mL,O
",",O
Sigma,O
),O
for,O
nuclear,O
staining,O
.,O
Olympus,O
BX51,O
fluorescence,O
microscope,O
(,O
Olympus,O
",",O
Hamburg,O
",",O
Germany,O
),O
attached,O
to,O
a,O
DP73,O
camera,O
was,O
used,O
to,O
obtain,O
images,O
of,O
different,O
areas,O
using,O
cellSens,O
Entry,O
software,O
(,O
version,O
1,O
.,O
12,O
",",O
Olympus,O
"),",O
different,O
parts,O
of,O
each,O
sample,O
were,O
merged,O
using,O
Adobe,O
Photoshop,O
CS3,O
(,O
Adobe,O
System,O
",",O
San,O
Jose,O
",",O
CA,O
",",O
USA,O
).,O
To,O
analyze,O
the,O
length,O
of,O
neurites,O
",",O
ImageJ,O
software,O
(,O
NIH,O
",",O
available,O
on,O
:,O
http,O
://,O
rsb,O
.,O
info,O
.,O
nih,O
.,O
gov,O
/,O
ij,O
/),O
resolution,O
parameters,O
were,O
fixed,O
and,O
the,O
three,O
longest,O
neurites,O
were,O
followed,O
from,O
the,O
ventral,O
horn,O
(,O
spinal,O
cord,O
),O
or,O
ganglion,O
boundary,O
(,O
DRG,O
),O
to,O
their,O
ending,O
projections,O
.,O
Whole,O
culture,O
images,O
of,O
the,O
DRG,O
and,O
the,O
ventral,O
horn,O
of,O
the,O
SC,O
were,O
analyzed,O
with,O
the,O
Neurite,O
-,O
J,O
plug,O
-,O
in,O
[,O
50,O
],O
for,O
ImageJ,O
software,O
",",O
and,O
the,O
number,O
of,O
neurites,O
grown,O
at,O
different,O
distances,O
from,O
the,O
explant,O
was,O
compared,O
between,O
sets,O
of,O
cultures,O
.,O
To,O
facilitate,O
the,O
visualization,O
of,O
differences,O
between,O
groups,O
",",O
the,O
area,O
under,O
the,O
curve,O
of,O
each,O
group,O
was,O
converted,O
to,O
a,O
bar,O
plot,O
.,O
4,O
.,O
3,O
.,O
In,O
Vivo,O
Study,O
of,O
Peripheral,O
Nerve,O
Regeneration,O
Female,O
Sprague,O
-,O
Dawley,O
rats,B-OG
weighing,O
between,O
250,O
–,O
300,O
g,O
were,O
used,O
.,O
Animals,B-OG
had,O
ad,O
libitum,O
access,O
to,O
food,O
and,O
water,O
and,O
were,O
kept,O
under,O
a,O
standard,O
light,O
-,O
dark,O
cycle,O
of,O
12,O
:,O
12,O
h,O
.,O
All,O
efforts,O
were,O
made,O
to,O
minimize,O
pain,O
and,O
animal,O
distress,O
during,O
surgery,O
.,O
Rats,B-OG
were,O
anaesthetized,O
with,O
ketamine,O
/,O
xylacine,O
(,O
90,O
/,O
10,O
mg,O
/,O
kg,O
i,O
.,O
p,O
".),",O
the,O
sciatic,O
nerve,O
was,O
exposed,O
at,O
the,O
midthigh,O
and,O
sectioned,O
90,O
mm,O
from,O
the,O
tip,O
of,O
the,O
third,O
toe,O
",",O
and,O
a,O
nerve,O
portion,O
resected,O
.,O
A,O
silicone,O
tube,O
was,O
then,O
sutured,O
with,O
10,O
-,O
0,O
monofilament,O
sutures,O
to,O
each,O
nerve,O
stump,O
leaving,O
a,O
6,O
mm,O
gap,O
between,O
both,O
nerve,O
ends,O
for,O
the,O
short,O
term,O
study,O
or,O
8,O
mm,O
gap,O
for,O
the,O
long,O
term,O
study,O
.,O
Animals,B-OG
were,O
kept,O
for,O
20,O
days,O
post,O
-,O
injury,B-DS
(,O
dpi,O
),O
(,O
short,O
term,O
),O
or,O
75,O
dpi,O
(,O
long,O
term,O
),O
to,O
allow,O
axonal,O
regeneration,O
before,O
testing,O
.,O
Each,O
of,O
the,O
three,O
NTFs,B-GP
(,O
NGF,B-GP
",",O
NT3,B-GP
",",O
and,O
BDNF,B-GP
),O
were,O
encapsulated,O
in,O
microspheres,O
as,O
previously,O
described,O
[,O
51,O
],O
and,O
added,O
to,O
a,O
collagen,B-GP
solution,O
to,O
reach,O
a,O
final,O
concentration,O
of,O
2,O
µg,O
/,O
mL,O
for,O
BDNF,B-GP
and,O
1,O
µg,O
/,O
mL,O
for,O
NGF,B-GP
and,O
NT3,B-GP
respectively,O
.,O
Each,O
preparation,O
of,O
NTF,B-GP
was,O
then,O
added,O
to,O
ECM,O
solutions,O
prepared,O
as,O
for,O
the,O
cultures,O
",",O
i,O
.,O
e,O
".,",O
collagen,B-GP
at,O
3,O
mg,O
/,O
mL,O
",",O
collagen,B-GP
supplemented,O
with,O
laminin,B-GP
20,O
%,O
(,O
v,O
/,O
v,O
"),",O
and,O
collagen,B-GP
supplemented,O
with,O
fibronectin,B-GP
20,O
%,O
(,O
v,O
/,O
v,O
).,O
Silicone,O
tubes,O
8,O
or,O
10,O
mm,O
long,O
with,O
an,O
internal,O
diameter,O
of,O
2,O
mm,O
were,O
filled,O
with,O
one,O
of,O
the,O
mixtures,O
containing,O
different,O
combinations,O
of,O
ECM,O
substrates,O
and,O
encapsulated,O
NTF,B-GP
.,O
In,O
order,O
to,O
promote,O
fibril,O
alignment,O
",",O
the,O
collagen,B-GP
solution,O
was,O
left,O
to,O
gel,O
vertically,O
for,O
12,O
h,O
before,O
surgery,O
[,O
52,O
].,O
Therefore,O
",",O
there,O
were,O
7,O
experimental,O
groups,O
for,O
short,O
and,O
5,O
for,O
long,O
term,O
experiments,O
(,O
n,O
=,O
6,O
per,O
group,O
",",O
see,O
Table,O
1,O
).,O
4,O
.,O
4,O
.,O
Retrograde,O
Labeling,O
and,O
Neuronal,O
Counting,O
To,O
quantify,O
motor,O
and,O
sensory,O
regenerated,O
neurons,O
at,O
short,O
term,O
(,O
20,O
dpi,O
"),",O
rats,B-OG
were,O
anaesthetized,O
with,O
ketamine,O
/,O
xylacine,O
and,O
the,O
sciatic,O
nerve,O
was,O
exposed,O
and,O
transected,O
8,O
mm,O
distal,O
to,O
the,O
distal,O
end,O
of,O
the,O
silicone,O
tube,O
to,O
apply,O
Fluorogold,O
(,O
FG,O
;,O
5,O
%;,O
Fluorochrome,O
Inc,O
".,",O
Denver,O
",",O
CO,O
",",O
USA,O
),O
as,O
a,O
retrotracer,O
[,O
53,O
].,O
Briefly,O
",",O
5,O
µL,O
of,O
FG,O
were,O
applied,O
to,O
the,O
end,O
of,O
the,O
nerve,O
for,O
1,O
h,O
",",O
then,O
the,O
retrotracer,O
was,O
washed,O
with,O
saline,O
to,O
remove,O
any,O
residues,O
of,O
the,O
tracer,O
and,O
the,O
wound,O
sutured,O
in,O
planes,O
.,O
Similarly,O
",",O
for,O
the,O
long,O
term,O
study,O
(,O
75,O
dpi,O
),O
FG,O
was,O
also,O
applied,O
to,O
the,O
tibial,O
nerve,O
at,O
the,O
ankle,O
level,O
.,O
After,O
tracer,O
application,O
",",O
the,O
rats,B-OG
were,O
allowed,O
to,O
survive,O
for,O
7,O
days,O
",",O
then,O
",",O
they,O
were,O
deeply,O
anesthetized,O
and,O
transcardially,O
perfused,O
with,O
4,O
%,O
paraformaldehyde,O
in,O
PBS,O
.,O
The,O
lumbar,O
segment,O
(,O
L3,O
–,O
L6,O
),O
of,O
the,O
SC,O
and,O
the,O
L4,O
and,O
L5,O
DRG,O
were,O
removed,O
",",O
postfixed,O
at,O
4,O
°,O
C,O
for,O
1,O
h,O
and,O
transferred,O
to,O
30,O
%,O
sucrose,O
in,O
PBS,O
.,O
Samples,O
were,O
cut,O
in,O
a,O
cryostat,O
longitudinally,O
in,O
40,O
and,O
20,O
µm,O
thick,O
sections,O
respectively,O
",",O
mounted,O
s,O
severed,O
he,O
tube,O
on,O
slides,O
",",O
heated,O
at,O
35,O
°,O
C,O
for,O
1,O
h,O
and,O
stored,O
at,O
−,O
20,O
°,O
C,O
in,O
the,O
dark,O
.,O
DRG,O
and,O
SC,O
sections,O
were,O
observed,O
with,O
an,O
Olympus,O
BX51,O
fluorescence,O
microscope,O
and,O
the,O
fractionator,O
principle,O
[,O
54,O
],O
was,O
used,O
to,O
quantify,O
the,O
number,O
of,O
labeled,O
neurons,O
.,O
4,O
.,O
5,O
.,O
Assessment,O
of,O
Muscle,O
Reinnervation,O
Functional,O
reinnervation,O
of,O
target,O
muscles,O
was,O
assessed,O
at,O
7,O
",",O
30,O
",",O
45,O
",",O
60,O
and,O
75,O
dpi,O
by,O
means,O
of,O
nerve,O
conduction,O
tests,O
.,O
Animals,B-OG
were,O
anesthetized,O
with,O
ketamine,O
/,O
xylacine,O
and,O
the,O
sciatic,O
nerve,O
was,O
stimulated,O
by,O
transcutaneous,O
electrodes,O
placed,O
at,O
the,O
sciatic,O
notch,O
.,O
The,O
amplitudes,O
(,O
M,O
wave,O
),O
of,O
the,O
compound,O
muscle,O
action,O
potentials,O
(,O
CMAP,O
),O
of,O
tibialis,O
anterior,O
(,O
TA,O
),O
and,O
plantar,O
interossei,O
muscles,O
(,O
PL,O
),O
were,O
recorded,O
(,O
mV,O
),O
after,O
placing,O
monopolar,O
needle,O
electrodes,O
in,O
the,O
muscle,O
bellies,O
and,O
the,O
reference,O
in,O
the,O
fourth,O
toe,O
[,O
55,O
].,O
Values,O
of,O
the,O
contralateral,O
intact,O
limb,O
were,O
used,O
as,O
control,O
.,O
During,O
the,O
tests,O
",",O
the,O
rat,B-OG
body,O
temperature,O
was,O
maintained,O
by,O
means,O
of,O
a,O
thermostated,O
warming,O
flat,O
coil,O
.,O
Animals,B-OG
were,O
anesthetized,O
with,O
ketamine,O
/,O
xylacine,O
and,O
the,O
sciatic,O
nerve,O
was,O
stimulated,O
by,O
transcutaneous,O
electrodes,O
placed,O
at,O
the,O
sciatic,O
notch,O
.,O
4,O
.,O
6,O
.,O
Assessment,O
of,O
Skin,O
Nociceptive,O
Reinnervation,O
The,O
progression,O
of,O
nociceptive,O
reinnervation,O
of,O
the,O
hind,O
paw,O
was,O
assessed,O
by,O
means,O
of,O
the,O
pinprick,O
test,O
and,O
thermal,O
sensitivity,O
at,O
7,O
",",O
30,O
",",O
45,O
",",O
60,O
and,O
75,O
dpi,O
.,O
For,O
the,O
pinprick,O
test,O
",",O
animals,B-OG
were,O
gently,O
kept,O
in,O
a,O
cloth,O
with,O
the,O
sole,O
of,O
the,O
injured,O
paw,O
facing,O
upward,O
",",O
and,O
the,O
skin,O
was,O
stimulated,O
with,O
a,O
needle,O
progressively,O
from,O
proximal,O
to,O
distal,O
at,O
specific,O
sites,O
of,O
the,O
lateral,O
side,O
of,O
the,O
hind,O
paw,O
plantar,O
surface,O
[,O
56,O
].,O
Fast,O
withdrawal,O
of,O
the,O
hindpaw,O
after,O
stimulation,O
was,O
identified,O
as,O
a,O
clear,O
pain,O
reaction,O
and,O
thus,O
a,O
sign,O
of,O
functional,O
skin,O
reinnervation,O
.,O
The,O
mean,O
number,O
of,O
positive,O
responses,O
in,O
every,O
tested,O
area,O
was,O
calculated,O
per,O
group,O
at,O
each,O
day,O
of,O
testing,O
.,O
Thermal,O
sensitivity,O
was,O
evaluated,O
using,O
a,O
Plantar,O
test,O
algesimeter,O
(,O
Ugo,O
Basile,O
",",O
Comerio,O
",",O
Italy,O
),O
[,O
57,O
].,O
Rats,B-OG
were,O
individually,O
placed,O
in,O
Plexiglas,O
cubicles,O
(,O
20,O
×,O
20,O
×,O
14,O
(,O
h,O
),O
cm,O
),O
with,O
an,O
elevated,O
Plexiglas,O
floor,O
in,O
a,O
room,O
at,O
constant,O
temperature,O
(,O
24,O
±,O
0,O
.,O
5,O
°,O
C,O
).,O
The,O
beam,O
of,O
a,O
low,O
intensity,O
lamp,O
(,O
40,O
mW,O
/,O
cm2,O
),O
was,O
pointed,O
to,O
the,O
lateral,O
part,O
in,O
the,O
hind,O
paw,O
plantar,O
surface,O
with,O
a,O
heating,O
rate,O
of,O
1,O
°,O
C,O
/,O
s,O
to,O
elicit,O
activation,O
of,O
unmyelinated,O
C,O
fibers,O
.,O
A,O
cutoff,O
time,O
of,O
exposure,O
to,O
limit,O
possible,O
tissue,O
damage,O
was,O
set,O
at,O
20,O
s,O
.,O
The,O
latency,O
(,O
in,O
seconds,O
),O
of,O
hindpaw,O
withdrawal,O
from,O
the,O
thermal,O
stimulus,O
was,O
recorded,O
as,O
the,O
mean,O
of,O
3,O
tests,O
per,O
paw,O
.,O
A,O
5,O
-,O
min,O
resting,O
period,O
was,O
set,O
between,O
each,O
trial,O
.,O
4,O
.,O
7,O
.,O
Evaluation,O
of,O
Skin,O
and,O
Sweat,O
Gland,O
Reinnervation,O
For,O
assessing,O
skin,O
reinnervation,O
",",O
plantar,O
pads,O
corresponding,O
to,O
the,O
lateral,O
side,O
were,O
removed,O
at,O
the,O
end,O
of,O
the,O
functional,O
follow,O
-,O
up,O
.,O
Cryotome,O
sections,O
60,O
µm,O
thick,O
were,O
processed,O
for,O
immunolabeling,O
against,O
protein,B-GP
gene,I-GP
product,I-GP
(,I-GP
PGP,I-GP
),I-GP
9,I-GP
.,I-GP
5,I-GP
(,O
rabbit,B-OG
;,O
1,O
:,O
1000,O
;,O
UltraClone,O
",",O
Cambridge,O
",",O
UK,O
"),",O
a,O
pan,O
-,O
neuronal,O
marker,O
.,O
Secondary,O
antibodies,O
were,O
conjugated,O
to,O
Cy3,O
.,O
Sections,O
were,O
observed,O
with,O
an,O
Olympus,O
BX51,O
fluorescence,O
microscope,O
to,O
visualize,O
immunoreactive,O
nerve,O
fibers,O
that,O
had,O
reinnervated,O
the,O
epidermis,O
and,O
the,O
sweat,O
glands,O
(,O
SG,O
).,O
For,O
analysis,O
",",O
images,O
of,O
three,O
sections,O
of,O
each,O
sample,O
were,O
collected,O
with,O
an,O
Olympus,O
DP73,O
digital,O
camera,O
",",O
the,O
number,O
of,O
intraepidermal,O
nerve,O
fibers,O
(,O
IENFs,O
),O
was,O
counted,O
in,O
a,O
1,O
-,O
mm,O
-,O
long,O
segment,O
of,O
the,O
footpad,O
epidermis,O
and,O
the,O
number,O
of,O
reinnervated,O
SGs,O
in,O
the,O
whole,O
pad,O
was,O
also,O
quantified,O
[,O
58,O
].,O
4,O
.,O
8,O
.,O
Data,O
Analysis,O
Data,O
are,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
Results,O
were,O
statistically,O
analyzed,O
using,O
GraphPad,O
Prism,O
(,O
version,O
6,O
.,O
01,O
",",O
GraphPad,O
Software,O
",",O
San,O
Diego,O
",",O
CA,O
",",O
USA,O
).,O
One,O
-,O
and,O
two,O
-,O
way,O
ANOVA,O
followed,O
by,O
Bonferroni,O
’,O
s,O
post,O
hoc,O
test,O
for,O
comparison,O
between,O
groups,O
were,O
used,O
.,O
Statistical,O
significance,O
was,O
considered,O
when,O
p,O
-,O
value,O
was,O
<,O
0,O
.,O
05,O
.,O
5,O
.,O
Conclusions,O
In,O
conclusion,O
",",O
this,O
study,O
demonstrates,O
that,O
the,O
interaction,O
between,O
FN,B-GP
+,O
BDNF,B-GP
and,O
between,O
LM,B-GP
+,O
NGF,B-GP
/,O
NT3,B-GP
has,O
synergistic,O
effects,O
to,O
preferentially,O
enhance,O
motor,O
and,O
sensory,O
axon,O
regeneration,O
",",O
respectively,O
",",O
in,O
vitro,O
.,O
Furthermore,O
",",O
these,O
effects,O
are,O
maintained,O
in,O
vivo,O
in,O
adult,O
animals,B-OG
as,O
motor,O
and,O
sensory,O
axonal,O
regeneration,O
and,O
functional,O
recovery,O
was,O
enhanced,O
after,O
treating,O
nerve,B-DS
injuries,I-DS
with,O
a,O
nerve,O
conduit,O
prefilled,O
with,O
the,O
same,O
combinations,O
of,O
NTFs,B-GP
and,O
ECM,O
components,O
.,O
(,O
A,O
–,O
I,O
),O
RT97,O
stained,O
neurites,O
from,O
spinal,O
cord,O
slices,O
cultured,O
within,O
a,O
3D,O
collagen,O
matrix,O
alone,O
",",O
and,O
with,O
addition,O
of,O
NGF,O
/,O
NT3,O
or,O
brain,O
-,O
derived,O
neurotrophic,O
factor,O
(,O
BDNF,O
),O
(,O
A,O
–,O
C,O
);,O
with,O
20,O
%,O
laminin,O
",",O
plus,O
NGF,O
/,O
NT3,O
or,O
BDNF,O
(,O
D,O
–,O
F,O
);,O
and,O
with,O
20,O
%,O
fibronectin,O
",",O
plus,O
NGF,O
/,O
NT3,O
or,O
BDNF,O
(,O
G,O
–,O
I,O
);,O
plots,O
representing,O
maximum,O
neurite,O
length,O
in,O
the,O
different,O
DRG,O
culture,O
conditions,O
(,O
J,O
);,O
quantification,O
of,O
the,O
number,O
of,O
neurites,O
grown,O
at,O
increasing,O
distance,O
from,O
the,O
DRG,O
body,O
",",O
dashed,O
line,O
represents,O
the,O
values,O
for,O
COL,O
control,O
group,O
(,O
100,O
%),O
(,O
K,O
);,O
and,O
plots,O
of,O
the,O
quantified,O
area,O
under,O
each,O
curve,O
of,O
K,O
graph,O
(,O
L,O
).,O
Data,O
expressed,O
as,O
mean,O
±,O
SEM,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
and,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
(,O
A,O
–,O
I,O
),O
RT97,O
stained,O
neurites,O
from,O
DRG,O
neurons,O
cultured,O
within,O
a,O
3D,O
collagen,O
matrix,O
alone,O
",",O
and,O
with,O
addition,O
of,O
NGF,O
/,O
NT3,O
or,O
BDNF,O
(,O
A,O
–,O
C,O
);,O
with,O
20,O
%,O
laminin,O
",",O
plus,O
NGF,O
/,O
NT3,O
or,O
BDNF,O
(,O
D,O
–,O
F,O
);,O
and,O
with,O
20,O
%,O
fibronectin,O
",",O
plus,O
NGF,O
/,O
NT3,O
or,O
BDNF,O
(,O
G,O
–,O
I,O
);,O
(,O
J,O
),O
plots,O
representing,O
maximum,O
neurite,O
length,O
in,O
the,O
different,O
culture,O
conditions,O
",",O
dashed,O
line,O
represents,O
the,O
values,O
for,O
COL,O
control,O
group,O
(,O
100,O
%);,O
(,O
K,O
),O
quantification,O
of,O
the,O
number,O
of,O
neurites,O
grown,O
at,O
increasing,O
distance,O
from,O
the,O
cord,O
slice,O
;,O
and,O
(,O
L,O
),O
plots,O
of,O
the,O
quantified,O
area,O
under,O
each,O
curve,O
of,O
K,O
graph,O
.,O
Data,O
expressed,O
as,O
mean,O
±,O
SEM,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
and,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
(,O
A,O
–,O
F,O
),O
Representative,O
micrographs,O
of,O
neurons,O
retrolabeled,O
with,O
FG,O
in,O
the,O
spinal,O
cord,O
(,O
A,O
–,O
C,O
);,O
and,O
DRG,O
(,O
D,O
–,O
F,O
),O
of,O
rats,O
after,O
sciatic,O
nerve,O
section,O
and,O
repair,O
with,O
a,O
nerve,O
conduit,O
filled,O
:,O
with,O
COL,O
(,O
A,O
",",O
D,O
);,O
LM,O
+,O
MP,O
.,O
NGF,O
/,O
NT3,O
(,O
B,O
",",O
E,O
);,O
or,O
FN,O
+,O
MP,O
.,O
BDNF,O
(,O
C,O
",",O
F,O
).,O
(,O
G,O
–,O
H,O
),O
Histogram,O
of,O
the,O
number,O
of,O
regenerated,O
motor,O
neurons,O
in,O
the,O
spinal,O
cord,O
(,O
G,O
),O
and,O
sensory,O
neurons,O
in,O
the,O
DRG,O
(,O
H,O
),O
in,O
the,O
short,O
term,O
(,O
20,O
days,O
after,O
injury,O
),O
study,O
.,O
(,O
I,O
",",O
J,O
),O
Histogram,O
of,O
the,O
number,O
of,O
regenerated,O
motor,O
neurons,O
in,O
the,O
spinal,O
cord,O
(,O
I,O
),O
and,O
sensory,O
neurons,O
in,O
the,O
DRG,O
(,O
J,O
),O
after,O
application,O
of,O
FG,O
retrotracer,O
at,O
the,O
ankle,O
level,O
75,O
days,O
after,O
injury,O
.,O
Data,O
expressed,O
as,O
mean,O
±,O
SEM,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
and,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
FN,O
+,O
MP,O
.,O
BDNF,O
and,O
LM,O
+,O
MP,O
.,O
NGF,O
/,O
NT3,O
enhance,O
motor,O
and,O
sensory,O
functional,O
recovery,O
",",O
respectively,O
.,O
(,O
A,O
",",O
B,O
),O
Mean,O
amplitude,O
of,O
the,O
CMAP,O
in,O
TA,O
(,O
A,O
),O
and,O
PL,O
(,O
B,O
),O
muscles,O
during,O
follow,O
-,O
up,O
.,O
**,O
p,O
<,O
0,O
.,O
01,O
and,O
***,O
p,O
<,O
0,O
.,O
001,O
FN,O
+,O
MP,O
.,O
BDNF,O
vs,O
.,O
all,O
other,O
groups,O
referenced,O
by,O
the,O
color,O
of,O
the,O
star,O
.,O
(,O
C,O
),O
Pinprick,O
score,O
in,O
the,O
different,O
groups,O
during,O
follow,O
-,O
up,O
;,O
*,O
p,O
<,O
0,O
.,O
05,O
.,O
(,O
D,O
),O
Latency,O
of,O
withdrawal,O
response,O
to,O
thermal,O
stimuli,O
in,O
the,O
lateral,O
part,O
of,O
the,O
paw,O
during,O
follow,O
-,O
up,O
;,O
**,O
p,O
<,O
0,O
.,O
01,O
and,O
***,O
p,O
<,O
0,O
.,O
001,O
LM,O
+,O
MP,O
.,O
NGF,O
/,O
NT3,O
vs,O
.,O
all,O
other,O
groups,O
referenced,O
by,O
the,O
color,O
of,O
the,O
star,O
.,O
(,O
E,O
–,O
J,O
),O
Representative,O
images,O
of,O
plantar,O
pads,O
immunolabeled,O
against,O
PGP,O
in,O
:,O
an,O
intact,O
rat,O
(,O
E,O
);,O
COL,O
(,O
F,O
);,O
LM,O
(,O
G,O
);,O
LM,O
+,O
MP,O
.,O
NGF,O
/,O
NT3,O
(,O
H,O
);,O
FN,O
(,O
I,O
);,O
and,O
FN,O
+,O
MP,O
.,O
BDNF,O
(,O
J,O
),O
treated,O
animals,O
.,O
Insets,O
:,O
Detail,O
of,O
axons,O
stained,O
with,O
PGP,O
innervating,O
epidermis,O
and,O
SGs,O
.,O
(,O
K,O
",",O
L,O
),O
Percentage,O
of,O
reinnervated,O
IENF,O
(,O
K,O
),O
and,O
reinnervated,O
SGs,O
(,O
L,O
),O
vs,O
.,O
intact,O
values,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
and,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
Data,O
is,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
Experimental,O
conditions,O
evaluated,O
in,O
the,O
in,O
vitro,O
and,O
in,O
vivo,O
studies,O
.,O
Group,O
Abbreviation,O
N,O
Description,O
In,O
Vitro,O
Condition,O
Collagen,O
COL,O
8,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
Collagen,O
+,O
NGF,O
/,O
NT3,O
COL,O
+,O
NGF,O
/,O
NT3,O
7,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
supplemented,O
with,O
NGF,O
and,O
NT3,O
(,O
25,O
+,O
25,O
ng,O
/,O
mL,O
),O
Collagen,O
+,O
BDNF,O
COL,O
+,O
BDNF,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
supplemented,O
with,O
BDNF,O
(,O
50,O
ng,O
/,O
mL,O
),O
Laminin,O
LM,O
8,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
laminin,O
type,O
I,O
Laminin,O
+,O
NGF,O
/,O
NT3,O
LM,O
+,O
NGF,O
/,O
NT3,O
7,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
laminin,O
type,O
I,O
and,O
NGF,O
+,O
NT3,O
(,O
25,O
+,O
25,O
ng,O
/,O
mL,O
),O
Laminin,O
+,O
BDNF,O
LM,O
+,O
BDNF,O
7,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
laminin,O
type,O
I,O
and,O
BDNF,O
(,O
50,O
ng,O
/,O
mL,O
),O
Fibronectin,O
FN,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
fibronectin,O
Fibronectin,O
+,O
NGF,O
/,O
NT,O
-,O
3,O
FN,O
+,O
NGF,O
/,O
NT3,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
fibronectin,O
and,O
NGF,O
+,O
NT3,O
(,O
25,O
+,O
25,O
ng,O
/,O
mL,O
),O
Fibronectin,O
+,O
BDNF,O
FN,O
+,O
BDNF,O
7,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
fibronectin,O
and,O
BDNF,O
(,O
50,O
ng,O
/,O
mL,O
),O
In,O
Vivo,O
Condition,O
Collagen,O
COL,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
Laminin,O
LM,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
laminin,O
type,O
I,O
Collagen,O
+,O
NGF,O
/,O
NT3,O
*,O
MP,O
.,O
NGF,O
/,O
NT3,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
NGF,O
+,O
NT3,O
(,O
1,O
+,O
1,O
µg,O
/,O
mL,O
),O
encapsulated,O
in,O
PLGA,O
microspheres,O
Laminin,O
+,O
NGF,O
/,O
NT3,O
LM,O
+,O
MP,O
.,O
NGF,O
/,O
NT3,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
laminin,O
type,O
I,O
and,O
NGF,O
+,O
NT3,O
(,O
1,O
+,O
1,O
µg,O
/,O
mL,O
),O
encapsulated,O
in,O
PLGA,O
microspheres,O
Fibronectin,O
FN,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
fibronectin,O
Collagen,O
+,O
BDNF,O
*,O
MP,O
.,O
BDNF,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
2,O
µg,O
/,O
mL,O
of,O
BDNF,O
encapsulated,O
in,O
PLGA,O
microspheres,O
Fibronectin,O
+,O
BDNF,O
FN,O
+,O
MP,O
.,O
BDNF,O
6,O
Collagen,O
type,O
I,O
(,O
3,O
mg,O
/,O
mL,O
),O
gel,O
containing,O
20,O
%,O
fibronectin,O
and,O
2,O
µg,O
/,O
ml,O
of,O
BDNF,O
encapsulated,O
in,O
PLGA,O
microspheres,O
Renal,B-DS
Angiomyolipoma,I-DS
:,O
The,O
Good,O
",",O
the,O
Bad,O
",",O
and,O
the,O
Ugly,O
Angiomyolipomas,B-DS
(,O
AMLs,B-DS
),O
are,O
the,O
most,O
common,O
benign,B-DS
renal,I-DS
tumours,I-DS
.,O
Most,O
of,O
these,O
neoplasms,B-DS
are,O
found,O
incidentally,O
on,O
imaging,O
.,O
However,O
",",O
symptomatic,O
presentation,O
does,O
exist,O
.,O
Renal,B-DS
AMLs,I-DS
are,O
typically,O
composed,O
of,O
smooth,O
muscle,O
",",O
blood,O
vessels,O
",",O
and,O
adipose,O
tissue,O
.,O
Because,O
of,O
the,O
abundant,O
fat,O
tissue,O
",",O
they,O
give,O
a,O
characteristic,O
appearance,O
on,O
imaging,O
and,O
are,O
therefore,O
easily,O
diagnosed,O
.,O
However,O
",",O
sometimes,O
they,O
contain,O
too,O
little,O
fat,O
to,O
be,O
detected,O
.,O
This,O
increases,O
the,O
difficulty,O
in,O
differentiating,O
them,O
from,O
renal,B-DS
cell,I-DS
carcinoma,I-DS
(,O
RCC,B-DS
).,O
Management,O
of,O
AML,B-DS
is,O
based,O
on,O
clinical,O
presentation,O
and,O
should,O
be,O
individualized,O
for,O
every,O
patient,O
.,O
Treatment,O
modalities,O
range,O
from,O
active,O
surveillance,O
to,O
more,O
invasive,O
approaches,O
.,O
Introduction,O
Angiomyolipomas,B-DS
(,O
AMLs,B-DS
),O
are,O
the,O
most,O
frequent,O
benign,B-DS
renal,I-DS
tumour,I-DS
",",O
with,O
a,O
prevalence,O
varying,O
between,O
0,O
.,O
2,O
%,O
and,O
0,O
.,O
6,O
%,O
and,O
a,O
strong,O
female,O
predilection,O
.,O
They,O
occur,O
as,O
sporadic,O
",",O
isolated,O
entities,O
in,O
80,O
%,O
of,O
cases,O
.,O
The,O
remaining,O
20,O
%,O
of,O
AMLs,B-DS
develop,O
in,O
association,O
with,O
tuberosclerosis,B-DS
complex,I-DS
(,O
TSC,B-DS
),O
or,O
pulmonary,B-DS
lymphangioleiomyomatosis,I-DS
(,O
LAM,B-DS
),O
[,O
12,O
].,O
AMLs,B-DS
are,O
considered,O
as,O
a,O
heterogeneous,O
group,O
of,O
neoplasms,B-DS
.,O
Many,O
types,O
display,O
different,O
pathology,O
",",O
radiological,O
features,O
",",O
and,O
clinical,O
behaviour,O
",",O
although,O
they,O
all,O
consist,O
of,O
variable,O
proportions,O
of,O
the,O
same,O
three,O
elements,O
:,O
smooth,O
muscle,O
",",O
blood,O
vessels,O
",",O
and,O
adipose,O
tissue,O
[,O
23,O
].,O
Imaging,O
plays,O
a,O
central,O
role,O
in,O
the,O
diagnosis,O
and,O
management,O
of,O
renal,B-DS
AMLs,I-DS
.,O
The,O
detection,O
of,O
adipose,O
tissue,O
is,O
the,O
fundamental,O
diagnostic,O
criterion,O
of,O
a,O
classic,O
AML,B-DS
[,O
2,O
].,O
However,O
",",O
a,O
minority,O
of,O
AMLs,B-DS
lack,O
visually,O
detectable,O
fat,O
on,O
imaging,O
",",O
making,O
it,O
harder,O
to,O
distinguish,O
from,O
renal,B-DS
cell,I-DS
carcinoma,I-DS
(,O
RCC,B-DS
).,O
Therefore,O
",",O
accurate,O
preoperative,O
diagnosis,O
of,O
renal,B-DS
AMLs,I-DS
is,O
critical,O
to,O
prevent,O
unnecessary,O
nephrectomies,O
and,O
preserve,O
renal,O
functions,O
[,O
4,O
].,O
The,O
purpose,O
of,O
this,O
review,O
is,O
to,O
provide,O
a,O
radiological,O
classification,O
of,O
renal,B-DS
AML,I-DS
that,O
contributes,O
to,O
the,O
understanding,O
and,O
diagnosis,O
of,O
the,O
different,O
types,O
and,O
the,O
appropriate,O
therapeutic,O
management,O
and,O
follow,O
-,O
up,O
.,O
Classifications,O
Clinical,O
Classification,O
About,O
80,O
%,O
of,O
AMLs,B-DS
present,O
as,O
isolated,O
entities,O
",",O
most,O
commonly,O
manifesting,O
in,O
middle,O
-,O
aged,O
women,O
.,O
They,O
tend,O
to,O
be,O
single,O
and,O
small,O
and,O
rarely,O
progress,O
to,O
cause,O
significant,O
morbidity,O
[,O
35,O
].,O
In,O
the,O
remainder,O
20,O
%,O
of,O
cases,O
",",O
AMLs,B-DS
occur,O
in,O
association,O
with,O
TSC,B-DS
or,O
",",O
less,O
commonly,O
",",O
as,O
part,O
of,O
LAM,B-DS
.,O
Relative,O
to,O
the,O
sporadic,O
form,O
of,O
AML,B-DS
",",O
these,O
hereditary,O
lesions,O
affect,O
both,O
genders,O
equally,O
and,O
manifest,O
at,O
a,O
younger,O
age,O
.,O
They,O
are,O
likely,O
to,O
be,O
multiple,O
",",O
large,O
",",O
and,O
bilateral,O
",",O
and,O
are,O
prone,O
to,O
grow,O
and,O
be,O
more,O
aggressive,O
[,O
357,O
].,O
AMLs,B-DS
are,O
observed,O
in,O
approximately,O
75,O
%,O
of,O
patients,O
with,O
TSC,B-DS
.,O
TSC,B-DS
is,O
an,O
autosomal,B-DS
dominant,I-DS
multisystem,I-DS
disorder,I-DS
characterized,O
by,O
the,O
development,O
of,O
benign,B-DS
tumours,I-DS
(,O
hamartomas,B-DS
),O
in,O
multiple,O
organs,O
throughout,O
the,O
body,O
.,O
The,O
main,O
organs,O
involved,O
are,O
the,O
brain,O
",",O
skin,O
",",O
lung,O
",",O
and,O
kidney,O
[,O
8,O
].,O
TSC,B-DS
is,O
caused,O
by,O
mutations,O
in,O
one,O
of,O
two,O
genes,O
",",O
TSC1,B-GP
and,O
TSC2,B-GP
",",O
which,O
encode,O
the,O
proteins,O
hamartin,B-GP
and,O
tuberin,B-GP
",",O
respectively,O
.,O
These,O
proteins,O
interact,O
with,O
each,O
other,O
to,O
form,O
a,O
tumour,B-GP
suppressor,I-GP
complex,I-GP
",",O
which,O
inhibits,O
the,O
mammalian,B-GP
target,I-GP
of,I-GP
rapamycin,I-GP
(,O
mTOR,B-GP
),O
pathway,O
.,O
This,O
pathway,O
is,O
important,O
for,O
angiogenesis,O
",",O
protein,O
synthesis,O
",",O
and,O
cell,O
growth,O
.,O
Defective,O
or,O
deficient,O
TSC1,B-GP
or,O
TSC2,B-GP
activity,O
leads,O
to,O
unchecked,O
activation,O
of,O
mTOR,B-GP
and,O
formation,O
of,O
characteristic,O
hamartomas,B-DS
[,O
267,O
].,O
AMLs,B-DS
may,O
also,O
develop,O
in,O
patients,O
with,O
LAM,B-DS
.,O
This,O
rare,O
disorder,O
may,O
occur,O
sporadically,O
",",O
in,O
the,O
absence,O
of,O
other,O
diseases,O
",",O
but,O
is,O
common,O
in,O
patients,O
with,O
TSC,B-DS
.,O
It,O
is,O
characterized,O
by,O
diffuse,O
interstitial,O
proliferation,O
of,O
smooth,O
muscle,O
cells,O
(,O
LAM,B-DS
cells,O
),O
and,O
the,O
presence,O
of,O
thin,O
-,O
walled,O
cysts,O
distributed,O
throughout,O
the,O
lungs,O
.,O
These,O
LAM,B-DS
cells,O
have,O
mutations,O
in,O
the,O
same,O
TSC1,B-GP
and,O
TSC2,B-GP
genes,O
[,O
67,O
].,O
Histological,O
Classification,O
Renal,B-DS
AML,I-DS
can,O
be,O
classified,O
histologically,O
as,O
typical,O
(,O
triphasic,O
),O
or,O
atypical,O
(,O
monophasic,O
or,O
epithelioid,O
),O
[,O
5,O
].,O
Most,O
AMLs,B-DS
contain,O
all,O
three,O
components,O
",",O
namely,O
dilated,O
blood,O
vessels,O
(,O
angio,O
"),",O
smooth,O
muscle,O
cells,O
(,O
myo,O
"),",O
and,O
mature,O
adipocytes,O
(,O
lipo,O
"),",O
in,O
various,O
proportions,O
.,O
They,O
are,O
classified,O
as,O
triphasic,O
tumours,B-DS
.,O
However,O
",",O
some,O
tumours,B-DS
consist,O
almost,O
exclusively,O
of,O
one,O
component,O
",",O
while,O
other,O
elements,O
are,O
present,O
in,O
very,O
small,O
amounts,O
.,O
They,O
are,O
called,O
monophasic,O
.,O
At,O
last,O
",",O
the,O
epithelioid,O
variant,O
of,O
AML,B-DS
contains,O
numerous,O
epithelioid,O
muscle,O
cells,O
with,O
abundant,O
eosinophilic,O
and,O
granular,O
cytoplasm,O
and,O
few,O
or,O
no,O
fat,O
cells,O
.,O
These,O
tumours,B-DS
have,O
a,O
tendency,O
toward,O
malignant,O
transformation,O
and,O
can,O
be,O
locally,O
aggressive,O
.,O
Histologically,O
",",O
they,O
can,O
resemble,O
and,O
be,O
misdiagnosed,O
as,O
RCC,B-DS
.,O
However,O
",",O
distinction,O
of,O
epithelioid,O
AMLs,B-DS
from,O
RCC,B-DS
is,O
possible,O
by,O
the,O
presence,O
of,O
immunohistochemistry,O
markers,O
",",O
such,O
as,O
smooth,O
muscle,O
markers,O
(,O
caldesmon,B-GP
and,O
smooth,B-GP
muscle,I-GP
actin,I-GP
),O
and,O
melanocytic,O
markers,O
(,O
HMB,O
-,O
45,O
antigen,O
and,O
melan,B-GP
-,I-GP
A,I-GP
),O
[,O
2345,O
].,O
Radiological,O
Classification,O
There,O
is,O
a,O
growing,O
body,O
of,O
literature,O
describing,O
findings,O
and,O
techniques,O
that,O
may,O
be,O
used,O
to,O
distinguish,O
renal,B-DS
AMLs,I-DS
.,O
A,O
lack,O
of,O
a,O
generally,O
accepted,O
and,O
standardized,O
terminology,O
or,O
classification,O
of,O
AML,B-DS
fuels,O
the,O
persisting,O
confusion,O
.,O
In,O
this,O
review,O
",",O
a,O
radiological,O
classification,O
reported,O
by,O
two,O
groups,O
of,O
authors,O
will,O
be,O
discussed,O
.,O
A,O
recent,O
article,O
hypothesized,O
that,O
renal,B-DS
AMLs,I-DS
can,O
be,O
classified,O
according,O
to,O
CT,O
and,O
MRI,O
findings,O
using,O
quantitative,O
values,O
.,O
They,O
classified,O
these,O
tumours,B-DS
as,O
fat,O
-,O
rich,O
",",O
fat,O
-,O
poor,O
",",O
or,O
fat,O
-,O
invisible,O
",",O
based,O
on,O
the,O
amount,O
of,O
fat,O
detected,O
on,O
imaging,O
studies,O
.,O
To,O
distinguish,O
these,O
different,O
types,O
",",O
a,O
region,O
of,O
interest,O
(,O
ROI,O
),O
was,O
placed,O
in,O
the,O
most,O
hypodense,O
area,O
of,O
the,O
lesion,O
to,O
measure,O
the,O
attenuation,O
value,O
.,O
A,O
lesion,O
was,O
defined,O
as,O
fat,O
-,O
rich,O
when,O
the,O
ROI,O
measured,O
≤,O
–,O
10,O
Hounsfield,O
units,O
(,O
HU,O
),O
on,O
unenhanced,O
CT,O
(,O
UECT,O
).,O
However,O
",",O
UECT,O
could,O
not,O
differentiate,O
fat,O
-,O
poor,O
from,O
fat,O
-,O
invisible,O
AML,B-DS
.,O
Therefore,O
chemical,O
shift,O
imaging,O
(,O
CSI,O
),O
MRI,O
was,O
introduced,O
.,O
This,O
modality,O
provides,O
a,O
higher,O
sensitivity,O
for,O
fat,O
detection,O
than,O
UECT,O
.,O
As,O
in,O
UECT,O
",",O
the,O
most,O
signal,O
-,O
dropped,O
area,O
was,O
detected,O
and,O
a,O
ROI,O
was,O
placed,O
within,O
.,O
On,O
CSI,O
-,O
MRI,O
",",O
fat,O
-,O
poor,O
AML,B-DS
was,O
characterized,O
when,O
the,O
tumour,O
-,O
to,O
-,O
spleen,O
ratio,O
(,O
TSR,O
),O
was,O
<,O
0,O
.,O
71,O
or,O
the,O
signal,O
intensity,O
index,O
(,O
SII,O
),O
was,O
>,O
16,O
.,O
5,O
%.,O
Because,O
of,O
too,O
little,O
fat,O
",",O
fat,O
-,O
invisible,O
AML,B-DS
was,O
defined,O
having,O
a,O
TSR,O
≥,O
0,O
.,O
71,O
and,O
a,O
SII,O
≤,O
16,O
.,O
5,O
%,O
[,O
910,O
].,O
This,O
classification,O
showed,O
an,O
almost,O
perfect,O
inter,O
-,O
reader,O
agreement,O
",",O
which,O
means,O
it,O
is,O
feasible,O
for,O
radiologists,O
to,O
apply,O
in,O
practice,O
.,O
However,O
",",O
it,O
is,O
important,O
to,O
understand,O
that,O
detection,O
of,O
the,O
most,O
hypodense,O
area,O
on,O
CT,O
or,O
most,O
signal,O
-,O
dropped,O
area,O
on,O
MRI,O
and,O
placement,O
of,O
the,O
ROI,O
within,O
is,O
crucial,O
.,O
A,O
mislocation,O
or,O
inappropriate,O
size,O
of,O
the,O
ROI,O
may,O
change,O
the,O
type,O
of,O
AML,B-DS
",",O
with,O
misclassification,O
and,O
unwanted,O
procedures,O
as,O
a,O
result,O
.,O
Another,O
disadvantage,O
is,O
the,O
fact,O
that,O
different,O
CT,O
and,O
MR,O
scanners,O
may,O
produce,O
different,O
attenuation,O
numbers,O
and,O
signal,O
intensities,O
",",O
leading,O
to,O
a,O
wrong,O
classification,O
.,O
For,O
example,O
",",O
if,O
an,O
AML,B-DS
is,O
measured,O
–,O
9,O
HU,O
at,O
one,O
CT,O
scanner,O
",",O
it,O
will,O
be,O
classified,O
as,O
fat,O
-,O
poor,O
.,O
However,O
",",O
if,O
another,O
scanner,O
describes,O
the,O
lesion,O
as,O
–,O
11,O
HU,O
",",O
it,O
will,O
be,O
classified,O
as,O
fat,O
-,O
rich,O
.,O
Although,O
the,O
difference,O
of,O
2,O
HU,O
is,O
very,O
minimal,O
and,O
probably,O
insignificant,O
",",O
the,O
management,O
is,O
completely,O
different,O
[,O
910,O
].,O
Another,O
review,O
article,O
proposed,O
a,O
classification,O
based,O
on,O
clinical,O
",",O
histologic,O
",",O
and,O
imaging,O
features,O
.,O
First,O
",",O
the,O
authors,O
divided,O
renal,B-DS
AMLs,I-DS
into,O
sporadic,O
and,O
hereditary,O
.,O
Histologically,O
",",O
they,O
classified,O
sporadic,O
AMLs,B-DS
into,O
benign,O
triphasic,O
type,O
and,O
potentially,O
malignant,O
epithelioid,O
type,O
[,O
34,O
].,O
Benign,O
triphasic,O
type,O
was,O
further,O
divided,O
into,O
fat,O
-,O
rich,O
and,O
fat,O
-,O
poor,O
AML,B-DS
using,O
imaging,O
modalities,O
.,O
While,O
fat,O
-,O
rich,O
AML,B-DS
contained,O
enough,O
fat,O
to,O
be,O
detected,O
on,O
UECT,O
(,O
ROI,O
≤,O
–,O
10,O
HU,O
"),",O
fat,O
-,O
poor,O
AML,B-DS
did,O
not,O
.,O
Fat,O
-,O
poor,O
AML,B-DS
was,O
further,O
classified,O
into,O
three,O
subtypes,O
",",O
based,O
on,O
the,O
amount,O
and,O
distribution,O
of,O
adipocytes,O
within,O
the,O
lesion,O
and,O
other,O
imaging,O
features,O
:,O
hyperattenuating,O
AML,B-DS
",",O
isoattenuating,O
AML,B-DS
",",O
and,O
AML,B-DS
with,O
epithelial,O
cysts,O
.,O
Hyperattenuating,O
AML,B-DS
was,O
hyperattenuating,O
compared,O
to,O
renal,O
parenchyma,O
on,O
UECT,O
(>,O
45,O
HU,O
"),",O
homogeneously,O
enhancing,O
on,O
contrast,O
enhanced,O
CT,O
",",O
and,O
T2,O
-,O
hypointense,O
on,O
MRI,O
.,O
On,O
the,O
contrary,O
",",O
isoattenuating,O
AML,B-DS
was,O
characterized,O
by,O
attenuation,O
numbers,O
close,O
to,O
renal,O
parenchyma,O
on,O
UECT,O
(,O
between,O
–,O
10,O
and,O
45,O
HU,O
).,O
These,O
lower,O
attenuation,O
levels,O
were,O
caused,O
by,O
the,O
presence,O
of,O
fat,O
cells,O
",",O
sufficient,O
in,O
quantity,O
to,O
lower,O
the,O
overall,O
attenuation,O
relative,O
to,O
hyperattenuating,O
AMLs,B-DS
",",O
but,O
too,O
few,O
in,O
one,O
area,O
to,O
be,O
detected,O
on,O
regular,O
imaging,O
.,O
Finally,O
",",O
AMLs,B-DS
with,O
epithelial,O
cysts,O
could,O
be,O
distinguished,O
by,O
the,O
presence,O
of,O
epithelial,O
cysts,O
",",O
with,O
the,O
non,O
-,O
cystic,O
parts,O
appearing,O
similar,O
to,O
hyperattenuating,O
AML,B-DS
.,O
Radiological,O
features,O
of,O
this,O
rare,O
subtype,O
could,O
not,O
be,O
fully,O
described,O
",",O
due,O
to,O
the,O
lack,O
of,O
data,O
[,O
34,O
].,O
Epithelioid,O
AMLs,B-DS
",",O
that,O
can,O
be,O
potentially,O
malignant,O
and,O
metastasize,O
",",O
showed,O
hyperattenuation,O
on,O
UECT,O
",",O
heterogeneously,O
enhancement,O
on,O
contrast,O
enhanced,O
CT,O
",",O
and,O
T2,O
-,O
hypointensity,O
on,O
MRI,O
.,O
These,O
findings,O
were,O
caused,O
by,O
the,O
epithelioid,O
muscle,O
component,O
and,O
the,O
intratumoral,O
haemorrhage,O
and,O
necrosis,O
[,O
3410,O
].,O
There,O
are,O
limitations,O
associated,O
with,O
the,O
classification,O
described,O
above,O
.,O
First,O
",",O
the,O
requirement,O
of,O
clinical,O
and,O
pathological,O
information,O
makes,O
it,O
difficult,O
for,O
radiologists,O
to,O
use,O
in,O
daily,O
practice,O
.,O
Second,O
",",O
there,O
are,O
problems,O
in,O
applying,O
the,O
imaging,O
criteria,O
for,O
classifying,O
isoattenuating,O
AML,B-DS
.,O
The,O
authors,O
reported,O
isoattenuating,O
AML,B-DS
being,O
an,O
AML,B-DS
with,O
attenuation,O
values,O
between,O
–,O
10,O
and,O
45,O
HU,O
on,O
UECT,O
.,O
However,O
",",O
simple,O
renal,O
cysts,O
have,O
attenuation,O
numbers,O
ranging,O
between,O
–,O
10,O
and,O
10,O
and,O
appear,O
definitely,O
hypoattenuating,O
",",O
while,O
renal,O
masses,O
measuring,O
>,O
40,O
HU,O
frequently,O
appear,O
hyperattenuating,O
.,O
So,O
",",O
because,O
of,O
the,O
wide,O
range,O
of,O
AML,B-DS
attenuation,O
values,O
",",O
“,O
isoattenuating,O
AML,B-DS
”,O
does,O
not,O
seem,O
to,O
be,O
an,O
appropriate,O
term,O
.,O
Furthermore,O
",",O
the,O
authors,O
did,O
not,O
suggest,O
a,O
quantitative,O
threshold,O
for,O
CSI,O
-,O
MRI,O
",",O
which,O
means,O
that,O
radiologists,O
cannot,O
classify,O
AML,B-DS
using,O
TSR,O
or,O
SII,O
[,O
9,O
].,O
In,O
conclusion,O
",",O
the,O
classification,O
first,O
described,O
is,O
the,O
most,O
easily,O
applicable,O
in,O
practice,O
.,O
Radiologists,O
can,O
categorize,O
renal,B-DS
AMLs,I-DS
as,O
fat,O
-,O
rich,O
",",O
fat,O
-,O
poor,O
",",O
and,O
fat,O
-,O
invisible,O
",",O
according,O
to,O
the,O
amount,O
of,O
fat,O
detected,O
on,O
UECT,O
or,O
CSI,O
-,O
MRI,O
.,O
However,O
",",O
attention,O
should,O
be,O
paid,O
to,O
fit,O
the,O
ROI,O
within,O
the,O
right,O
area,O
of,O
the,O
fat,O
tissue,O
",",O
otherwise,O
many,O
fat,O
-,O
rich,O
or,O
fat,O
-,O
poor,O
AMLs,B-DS
may,O
be,O
misclassified,O
as,O
fat,O
-,O
poor,O
or,O
fat,O
-,O
invisible,O
.,O
Table,O
1,O
summarizes,O
the,O
features,O
of,O
this,O
classification,O
.,O
Radiological,O
classification,O
of,O
renal,B-DS
AML,I-DS
[,O
9,O
].,O
UECT,O
Region,O
of,O
interest,O
(,O
ROI,O
),O
MRI,O
-,O
CSI,O
Tumour,O
-,O
to,O
-,O
spleen,O
ratio,O
(,O
TSR,O
),O
MRI,O
-,O
CSI,O
Signal,O
intensity,O
index,O
(,O
SII,O
),O
Fat,O
-,O
rich,O
AML,B-DS
≤,O
–,O
10,O
HU,O
<,O
0,O
.,O
71,O
>,O
16,O
.,O
5,O
%,O
Fat,O
-,O
poor,O
AML,B-DS
>,O
–,O
10,O
HU,O
<,O
0,O
.,O
71,O
>,O
16,O
.,O
5,O
%,O
Fat,O
-,O
invisible,O
AML,B-DS
>,O
–,O
10,O
HU,O
≥,O
0,O
.,O
71,O
≤,O
16,O
.,O
5,O
%,O
Diagnosis,O
Clinical,O
Presentation,O
The,O
increased,O
use,O
of,O
cross,O
-,O
sectional,O
imaging,O
and,O
advances,O
in,O
imaging,O
technology,O
explain,O
that,O
the,O
majority,O
(>,O
80,O
%),O
of,O
AMLs,B-DS
are,O
now,O
incidentally,O
found,O
.,O
Most,O
patients,O
are,O
asymptomatic,O
when,O
they,O
receive,O
the,O
diagnosis,O
of,O
an,O
AML,B-DS
[,O
2,O
].,O
Symptomatic,O
presentation,O
is,O
most,O
frequently,O
related,O
to,O
spontaneous,O
retroperitoneal,O
haemorrhage,O
",",O
although,O
this,O
is,O
seen,O
in,O
less,O
than,O
15,O
%,O
of,O
cases,O
[,O
2,O
].,O
This,O
may,O
lead,O
to,O
shock,O
in,O
one,O
-,O
third,O
of,O
patients,O
.,O
Therefore,O
",",O
risk,O
of,O
a,O
life,O
-,O
threatening,O
bleeding,O
is,O
the,O
main,O
clinical,O
concern,O
in,O
a,O
patient,O
diagnosed,O
with,O
AML,B-DS
.,O
Other,O
symptoms,O
and,O
signs,O
include,O
a,O
palpable,O
mass,O
",",O
flank,O
pain,O
",",O
haematuria,O
",",O
anaemia,B-DS
",",O
urinary,B-DS
tract,I-DS
infection,I-DS
",",O
or,O
renal,B-DS
failure,I-DS
[,O
1112,O
].,O
In,O
contrast,O
to,O
the,O
benign,O
prognosis,O
of,O
classic,O
renal,B-DS
AMLs,I-DS
",",O
the,O
epithelioid,O
variant,O
may,O
undergo,O
malignant,O
transformation,O
",",O
although,O
this,O
is,O
rare,O
.,O
This,O
is,O
manifested,O
by,O
local,O
aggressiveness,O
",",O
including,O
lymphadenopathy,B-DS
",",O
and,O
distal,O
metastases,O
.,O
The,O
larger,O
the,O
tumour,O
",",O
the,O
more,O
likely,O
it,O
is,O
to,O
spread,O
[,O
311,O
].,O
In,O
TSC,B-DS
and,O
LAM,B-DS
",",O
the,O
disease,O
process,O
tends,O
to,O
be,O
more,O
aggressive,O
compared,O
to,O
the,O
sporadic,O
form,O
.,O
This,O
implicates,O
that,O
symptomatic,O
presentation,O
is,O
more,O
common,O
in,O
this,O
subgroup,O
[,O
612,O
].,O
In,O
TSC,B-DS
",",O
hamartomas,B-DS
are,O
formed,O
in,O
multiple,O
organs,O
throughout,O
the,O
body,O
",",O
leading,O
to,O
a,O
variety,O
of,O
symptoms,O
.,O
About,O
90,O
%,O
of,O
patients,O
with,O
TSC,B-DS
have,O
skin,O
manifestations,O
",",O
with,O
a,O
range,O
from,O
facial,O
angiofibromas,O
to,O
hypomelanotic,O
macules,O
.,O
Neurological,O
symptoms,O
",",O
including,O
epilepsy,B-DS
",",O
behavioural,B-DS
problems,I-DS
",",O
and,O
cognitive,B-DS
impairment,I-DS
",",O
occur,O
in,O
up,O
to,O
85,O
%,O
of,O
patients,O
.,O
Renal,B-DS
AMLs,I-DS
are,O
present,O
in,O
approximately,O
75,O
%,O
of,O
patients,O
with,O
TSC,B-DS
and,O
manifest,O
as,O
bilateral,O
and,O
multiple,O
tumours,B-DS
",",O
with,O
a,O
high,O
tendency,O
to,O
grow,O
and,O
cause,O
spontaneous,O
bleeding,O
.,O
LAM,B-DS
",",O
in,O
association,O
with,O
TSC,B-DS
or,O
in,O
the,O
sporadic,O
form,O
",",O
is,O
characterised,O
by,O
cystic,O
changes,O
within,O
the,O
lung,O
parenchyma,O
.,O
This,O
may,O
lead,O
to,O
chylous,B-DS
pleural,I-DS
effusions,I-DS
",",O
recurrent,B-DS
pneumothoraces,I-DS
",",O
and,O
cystic,B-DS
lung,I-DS
disease,I-DS
[,O
2678,O
].,O
Imaging,O
Findings,O
Typical,O
renal,B-DS
AML,I-DS
can,O
be,O
diagnosed,O
accurately,O
based,O
on,O
imaging,O
findings,O
.,O
The,O
demonstration,O
of,O
macroscopic,O
fat,O
within,O
a,O
lesion,O
is,O
the,O
hallmark,O
feature,O
on,O
all,O
modalities,O
.,O
However,O
",",O
AML,B-DS
represent,O
a,O
diagnostic,O
challenge,O
for,O
every,O
imaging,O
method,O
in,O
case,O
of,O
haemorrhage,O
",",O
calcification,O
",",O
necrosis,O
",",O
or,O
low,O
fat,O
content,O
.,O
All,O
imaging,O
features,O
of,O
renal,B-DS
AML,I-DS
are,O
summarized,O
in,O
Table,O
2,O
.,O
Imaging,O
features,O
of,O
renal,B-DS
AML,I-DS
[,O
23491011,O
].,O
US,O
UECT,O
MRI,O
-,O
T1,O
MRI,O
-,O
T2,O
MRI,O
-,O
CSI,O
Fat,O
-,O
rich,O
AML,B-DS
Markedly,O
hyperechoic,O
Hypoattenuating,O
Signal,O
loss,O
on,O
FS,O
Hyperintense,O
Decrease,O
in,O
signal,O
intensity,O
Fat,O
-,O
poor,O
AML,B-DS
Slightly,O
hyperechoic,O
Heterogeneously,O
isoattenuating,O
or,O
hyperattenuating,O
+/–,O
signal,O
loss,O
on,O
FS,O
Heterogeneously,O
or,O
homogeneosly,O
hypointense,O
Decrease,O
in,O
signal,O
intensity,O
Fat,O
-,O
invisible,O
AML,B-DS
Isoechoic,O
Homogeneously,O
hyperattenuating,O
No,O
signal,O
loss,O
on,O
FS,O
Homogeneously,O
hypointense,O
No,O
decrease,O
in,O
signal,O
intensity,O
Note,O
:,O
FS,O
=,O
fat,O
suppression,O
;,O
+/–,O
=,O
loss,O
of,O
signal,O
on,O
fat,O
-,O
suppressed,O
MRI,O
may,O
or,O
may,O
not,O
be,O
present,O
.,O
Ultrasound,O
The,O
classical,O
appearance,O
of,O
a,O
fat,O
-,O
rich,O
AML,B-DS
on,O
ultrasound,O
(,O
US,O
),O
is,O
that,O
of,O
a,O
hyperechoic,O
lesion,O
with,O
a,O
posterior,O
acoustic,O
shadow,O
(,O
Figure,O
1,O
).,O
The,O
hyperechoic,O
nature,O
of,O
a,O
classic,O
AML,B-DS
is,O
the,O
result,O
of,O
the,O
combination,O
of,O
its,O
fat,O
",",O
blood,O
vessel,O
",",O
and,O
muscle,O
contents,O
",",O
while,O
the,O
shadowing,O
is,O
due,O
to,O
the,O
multiple,O
tissue,O
interfaces,O
between,O
those,O
different,O
elements,O
[,O
11,O
].,O
The,O
echogenicity,O
of,O
the,O
mass,O
is,O
the,O
same,O
as,O
or,O
greater,O
than,O
that,O
of,O
the,O
renal,O
sinus,O
[,O
234,O
].,O
However,O
",",O
this,O
hyperechogenicity,O
is,O
not,O
a,O
constant,O
finding,O
.,O
As,O
the,O
amount,O
of,O
fat,O
deceases,O
",",O
the,O
echogenicity,O
of,O
the,O
lesion,O
decreases,O
.,O
Fat,O
-,O
poor,O
AML,B-DS
has,O
a,O
mixed,O
echotexture,O
",",O
being,O
hyperechoic,O
and,O
isoechoic,O
compared,O
with,O
renal,O
parenchyma,O
.,O
Fat,O
-,O
invisible,O
AML,B-DS
is,O
homogenously,O
isoechoic,O
with,O
respect,O
to,O
renal,O
parenchyma,O
.,O
The,O
echogenicity,O
of,O
both,O
tumours,B-DS
is,O
less,O
than,O
that,O
of,O
the,O
renal,O
sinus,O
.,O
It,O
is,O
challenging,O
to,O
differentiate,O
them,O
from,O
other,O
renal,O
lesions,O
such,O
as,O
RCC,B-DS
",",O
which,O
has,O
an,O
echogenicity,O
that,O
is,O
also,O
less,O
than,O
that,O
of,O
the,O
renal,O
sinus,O
[,O
3410,O
].,O
The,O
lack,O
of,O
sensitivity,O
of,O
US,O
at,O
defining,O
small,O
renal,O
masses,O
implicates,O
that,O
the,O
diagnostic,O
reliability,O
of,O
this,O
imaging,O
modality,O
is,O
not,O
high,O
enough,O
to,O
allow,O
it,O
to,O
be,O
used,O
for,O
diagnosing,O
renal,B-DS
AMLs,I-DS
in,O
daily,O
practice,O
[,O
211,O
].,O
Additional,O
imaging,O
studies,O
may,O
be,O
needed,O
to,O
confirm,O
the,O
diagnosis,O
",",O
i,O
.,O
e,O
.,O
the,O
presence,O
of,O
fat,O
.,O
US,O
image,O
showing,O
a,O
fat,O
-,O
rich,O
AML,B-DS
(,O
arrow,O
).,O
The,O
tumour,O
is,O
more,O
hyperechoic,O
than,O
the,O
right,O
renal,O
sinus,O
(,O
asterisk,O
),O
[,O
10,O
].,O
Computed,O
Tomography,O
The,O
imaged,O
-,O
based,O
detection,O
of,O
fat,O
generally,O
starts,O
with,O
CT,O
.,O
As,O
on,O
US,O
",",O
the,O
characteristics,O
of,O
AMLs,B-DS
on,O
UECT,O
may,O
vary,O
due,O
to,O
variable,O
quantities,O
of,O
angiogenic,O
",",O
myogenic,O
",",O
and,O
fatty,O
elements,O
.,O
The,O
presence,O
of,O
ROIs,O
containing,O
attenuations,O
of,O
–,O
10,O
HU,O
or,O
less,O
is,O
a,O
reliable,O
sign,O
of,O
an,O
area,O
of,O
adipose,O
tissue,O
[,O
34,O
].,O
Therefore,O
",",O
detecting,O
fat,O
is,O
feasible,O
in,O
most,O
fat,O
-,O
rich,O
AMLs,B-DS
(,O
Figure,O
2,O
).,O
However,O
",",O
some,O
fat,O
-,O
rich,O
AMLs,B-DS
contain,O
very,O
small,O
areas,O
of,O
fat,O
",",O
which,O
may,O
not,O
be,O
recognized,O
at,O
CT,O
.,O
Therefore,O
",",O
the,O
acquisition,O
of,O
thin,O
slice,O
sections,O
(,O
1,O
.,O
5,O
–,O
3,O
.,O
0,O
mm,O
),O
and,O
obtaining,O
attenuation,O
measurements,O
using,O
small,O
ROIs,O
or,O
even,O
pixel,O
values,O
may,O
be,O
needed,O
.,O
Several,O
authors,O
reported,O
a,O
higher,O
sensitivity,O
for,O
detecting,O
small,O
foci,O
of,O
fat,O
when,O
using,O
pixel,O
mapping,O
",",O
using,O
a,O
line,O
or,O
square,O
of,O
four,O
pixels,O
.,O
In,O
fat,O
-,O
poor,O
AMLs,B-DS
",",O
UECT,O
cannot,O
show,O
a,O
hypoattenuating,O
area,O
measuring,O
less,O
than,O
–,O
10,O
HU,O
.,O
The,O
attenuation,O
values,O
of,O
such,O
lesions,O
range,O
widely,O
",",O
according,O
to,O
the,O
size,O
or,O
location,O
of,O
a,O
ROI,O
:,O
when,O
a,O
ROI,O
is,O
placed,O
in,O
a,O
region,O
of,O
muscle,O
cells,O
and,O
vessels,O
",",O
the,O
lesion,O
attenuation,O
will,O
be,O
higher,O
than,O
when,O
a,O
ROI,O
is,O
placed,O
in,O
an,O
area,O
that,O
consists,O
mostly,O
of,O
fat,O
cells,O
.,O
For,O
this,O
reason,O
",",O
fat,O
-,O
poor,O
AMLs,B-DS
are,O
heterogeneously,O
isoattenuating,O
or,O
hyperattenuating,O
.,O
On,O
the,O
contrary,O
",",O
fat,O
-,O
invisible,O
AMLs,B-DS
appear,O
homogenously,O
hyperattenuating,O
(,O
Figure,O
3,O
).,O
Because,O
they,O
contain,O
too,O
little,O
fat,O
cells,O
",",O
UECT,O
is,O
not,O
able,O
to,O
show,O
any,O
fat,O
attenuation,O
in,O
these,O
lesions,O
.,O
So,O
wherever,O
a,O
ROI,O
is,O
placed,O
in,O
fat,O
-,O
invisible,O
AMLs,B-DS
",",O
their,O
attenuation,O
numbers,O
tend,O
to,O
be,O
higher,O
and,O
fairly,O
constant,O
compared,O
with,O
those,O
of,O
fat,O
-,O
poor,O
AMLs,B-DS
[,O
91011,O
].,O
UECT,O
showing,O
bilateral,O
and,O
multiple,O
AMLs,B-DS
in,O
a,O
patient,O
with,O
TSC,B-DS
.,O
Each,O
lesion,O
contains,O
attenuation,O
numbers,O
less,O
than,O
–,O
10,O
HU,O
",",O
consistent,O
with,O
fat,O
-,O
rich,O
AML,B-DS
[,O
3,O
].,O
UECT,O
demonstrating,O
a,O
left,O
solid,O
renal,O
lesion,O
(,O
arrow,O
).,O
It,O
appears,O
homogeneously,O
hyperdense,O
and,O
has,O
attenuation,O
values,O
as,O
high,O
as,O
44,O
HU,O
",",O
consistent,O
with,O
fat,O
-,O
invisible,O
AML,B-DS
[,O
9,O
].,O
There,O
are,O
several,O
other,O
variants,O
in,O
which,O
an,O
AML,B-DS
can,O
appear,O
on,O
UECT,O
.,O
Frequently,O
",",O
a,O
perirenal,O
or,O
intratumoural,O
haemorrhage,O
is,O
present,O
(,O
Figure,O
4,O
).,O
This,O
hyperdense,O
collection,O
may,O
obscure,O
the,O
fat,O
",",O
leading,O
to,O
misdiagnosing,O
a,O
simple,O
AML,B-DS
as,O
a,O
renal,B-DS
cancer,I-DS
[,O
2,O
].,O
Lesions,O
that,O
contain,O
fat,O
and,O
calcifications,O
also,O
represent,O
a,O
diagnostic,O
challenge,O
.,O
As,O
the,O
presence,O
of,O
adipose,O
tissue,O
is,O
highly,O
suggestive,O
of,O
AML,B-DS
",",O
the,O
presence,O
of,O
calcification,O
raises,O
the,O
possibility,O
of,O
renal,B-DS
cancer,I-DS
.,O
However,O
",",O
several,O
authors,O
reported,O
the,O
existence,O
of,O
both,O
AMLs,B-DS
with,O
calcification,O
and,O
RCCs,O
having,O
fat,O
without,O
calcification,O
[,O
111314,O
].,O
Another,O
",",O
less,O
frequent,O
appearance,O
is,O
that,O
of,O
necrosis,O
within,O
a,O
lesion,O
",",O
being,O
rather,O
typical,O
for,O
epithelioid,O
AMLs,B-DS
[,O
34,O
].,O
Contrast,O
-,O
enhanced,O
CT,O
showing,O
two,O
features,O
:,O
a,O
perirenal,O
hematoma,O
and,O
enhancing,O
lesion,O
with,O
aneurysm,B-DS
formation,O
(,O
arrowhead,O
),O
and,O
a,O
thrombus,B-DS
in,O
the,O
IVC,O
(,O
arrow,O
),O
[,O
15,O
].,O
Contrast,O
-,O
enhanced,O
CT,O
is,O
not,O
routinely,O
indicated,O
in,O
diagnosing,O
renal,B-DS
AMLs,I-DS
",",O
but,O
should,O
be,O
performed,O
in,O
selected,O
cases,O
.,O
Frequently,O
",",O
large,O
AMLs,B-DS
contain,O
dilated,O
blood,O
vessels,O
that,O
have,O
the,O
potential,O
of,O
rupturing,O
and,O
bleeding,O
.,O
Whenever,O
tumour,O
bleeding,O
is,O
suspected,O
",",O
it,O
is,O
essential,O
to,O
identify,O
the,O
tortuous,O
vessels,O
using,O
contrast,O
-,O
enhanced,O
CT,O
",",O
before,O
therapeutic,O
embolization,O
can,O
be,O
scheduled,O
[,O
1015,O
].,O
Magnetic,O
Resonance,O
Imaging,O
In,O
the,O
diagnosis,O
of,O
AML,B-DS
",",O
MRI,O
is,O
equivalent,O
in,O
accuracy,O
to,O
CT,O
.,O
Several,O
MRI,O
sequences,O
can,O
be,O
used,O
.,O
The,O
classical,O
approach,O
is,O
to,O
locate,O
fat,O
within,O
a,O
mass,O
by,O
comparing,O
T1,O
-,O
weighted,O
images,O
with,O
and,O
without,O
frequency,O
selective,O
fat,O
suppression,O
.,O
A,O
classic,O
fat,O
-,O
rich,O
AML,B-DS
appears,O
T1,O
-,O
hypointense,O
with,O
and,O
T1,O
-,O
hyperintense,O
without,O
fat,O
suppression,O
[,O
234,O
].,O
However,O
",",O
this,O
T1,O
-,O
hyperintensity,O
is,O
not,O
a,O
specific,O
characteristic,O
of,O
AML,B-DS
and,O
can,O
also,O
be,O
present,O
in,O
RCC,B-DS
and,O
haemorrhagic,O
cysts,O
.,O
Moreover,O
",",O
fat,O
-,O
invisible,O
AMLs,B-DS
contain,O
too,O
little,O
fat,O
to,O
show,O
any,O
hypointensity,O
on,O
fat,O
-,O
suppressed,O
T1,O
-,O
weighted,O
images,O
.,O
In,O
such,O
cases,O
",",O
other,O
techniques,O
may,O
help,O
in,O
differentiating,O
between,O
those,O
entities,O
[,O
1116,O
].,O
More,O
recently,O
",",O
the,O
application,O
of,O
MRI,O
artefacts,O
has,O
been,O
suggested,O
to,O
evaluate,O
fat,O
in,O
renal,B-DS
tumours,I-DS
.,O
One,O
of,O
them,O
",",O
the,O
chemical,O
shift,O
artefact,O
",",O
is,O
due,O
to,O
the,O
differences,O
between,O
resonance,O
frequencies,O
of,O
fat,O
and,O
water,O
.,O
This,O
results,O
in,O
alternating,O
high,O
and,O
low,O
signals,O
in,O
the,O
frequency,O
encoding,O
direction,O
on,O
opposed,O
-,O
phase,O
imaging,O
.,O
This,O
out,O
-,O
of,O
-,O
phase,O
cancellation,O
effect,O
between,O
fat,O
and,O
water,O
gives,O
rise,O
to,O
another,O
MRI,O
artefact,O
",",O
called,O
the,O
black,O
boundary,O
or,O
India,O
ink,O
artefact,O
.,O
This,O
artificially,O
created,O
black,O
line,O
is,O
located,O
at,O
the,O
junction,O
of,O
fat,O
(,O
present,O
in,O
AML,B-DS
cells,O
),O
and,O
water,O
(,O
present,O
in,O
renal,O
parenchyma,O
),O
and,O
results,O
in,O
a,O
sharp,O
delineation,O
of,O
the,O
muscle,O
-,O
fat,O
boundary,O
(,O
Figure,O
5,O
).,O
This,O
sign,O
is,O
indicative,O
of,O
an,O
AML,B-DS
[,O
341116,O
].,O
It,O
is,O
especially,O
useful,O
in,O
fat,O
-,O
poor,O
AMLs,B-DS
and,O
very,O
small,O
lesions,O
",",O
in,O
which,O
the,O
typical,O
T1,O
features,O
may,O
not,O
be,O
noticeable,O
[,O
2,O
].,O
However,O
",",O
fat,O
-,O
invisible,O
AMLs,B-DS
do,O
not,O
show,O
this,O
decrease,O
in,O
signal,O
intensity,O
",",O
because,O
they,O
contain,O
too,O
little,O
fat,O
cells,O
[,O
10,O
].,O
Opposed,O
-,O
phase,O
T1,O
-,O
weighted,O
MR,O
image,O
with,O
a,O
hyperintense,O
renal,O
mass,O
.,O
The,O
India,O
ink,O
artefact,O
(,O
arrow,O
),O
is,O
present,O
at,O
the,O
interface,O
of,O
the,O
lesion,O
with,O
the,O
kidney,O
[,O
16,O
].,O
T2,O
-,O
weighted,O
images,O
can,O
also,O
be,O
used,O
for,O
diagnosing,O
AML,B-DS
.,O
Fat,O
-,O
rich,O
AML,B-DS
typically,O
is,O
hyperintense,O
with,O
respect,O
to,O
renal,O
parenchyma,O
.,O
It,O
has,O
hyperintense,O
foci,O
within,O
a,O
hypointense,O
background,O
",",O
because,O
areas,O
of,O
fat,O
are,O
distributed,O
among,O
blood,O
vessels,O
and,O
muscle,O
cells,O
.,O
Fat,O
-,O
poor,O
AML,B-DS
is,O
either,O
homogeneous,O
or,O
heterogeneous,O
hypointense,O
compared,O
with,O
renal,O
tissue,O
",",O
depending,O
on,O
the,O
distribution,O
of,O
its,O
areas,O
of,O
fat,O
.,O
If,O
these,O
areas,O
are,O
small,O
but,O
diffuse,O
",",O
the,O
signal,O
intensity,O
is,O
homogeneous,O
",",O
while,O
it,O
is,O
heterogeneous,O
when,O
fat,O
cells,O
are,O
located,O
focal,O
.,O
Finally,O
",",O
fat,O
-,O
invisible,O
AML,B-DS
is,O
homogeneously,O
hypointense,O
in,O
comparison,O
to,O
renal,O
parenchyma,O
on,O
T2,O
",",O
because,O
of,O
the,O
dominance,O
of,O
the,O
muscle,O
component,O
and,O
the,O
paucity,O
of,O
adipose,O
tissue,O
[,O
23410,O
].,O
Contrast,O
-,O
enhanced,O
MRI,O
has,O
a,O
limited,O
role,O
in,O
the,O
diagnosis,O
of,O
AML,B-DS
.,O
After,O
intravenous,O
administration,O
of,O
gadolinium,O
",",O
renal,B-DS
AMLs,I-DS
show,O
hypointense,O
compared,O
to,O
renal,O
parenchyma,O
.,O
However,O
",",O
these,O
enhancement,O
characteristics,O
appear,O
to,O
be,O
similar,O
to,O
those,O
of,O
hypovascular,O
RCCs,O
[,O
1117,O
].,O
Percutaneous,O
Biopsy,O
Most,O
AMLs,B-DS
can,O
be,O
diagnosed,O
with,O
imaging,O
by,O
identifying,O
intralesional,O
fat,O
.,O
However,O
",",O
in,O
select,O
cases,O
",",O
the,O
use,O
of,O
imaging,O
alone,O
is,O
insufficient,O
and,O
percutaneous,O
renal,O
biopsy,O
may,O
be,O
necessary,O
for,O
correctly,O
diagnosing,O
the,O
renal,O
mass,O
",",O
thus,O
avoiding,O
unnecessary,O
treatment,O
.,O
Nowadays,O
",",O
percutaneous,O
biopsy,O
is,O
increasingly,O
used,O
to,O
differentiate,O
between,O
benign,O
and,O
malignant,O
renal,O
lesions,O
[,O
1819,O
].,O
Currently,O
",",O
percutaneous,O
renal,O
biopsy,O
is,O
recommended,O
only,O
for,O
differentiating,O
fat,O
-,O
invisible,O
AML,B-DS
from,O
RCC,B-DS
",",O
if,O
both,O
CT,O
and,O
MR,O
images,O
are,O
inconclusive,O
.,O
A,O
fat,O
-,O
invisible,O
AML,B-DS
typically,O
appears,O
as,O
a,O
hyperattenuating,O
mass,O
that,O
enhance,O
homogenously,O
on,O
UECT,O
.,O
Although,O
this,O
presentation,O
is,O
uncommon,O
for,O
a,O
RCC,B-DS
",",O
both,O
pathologies,O
may,O
appear,O
identical,O
on,O
imaging,O
.,O
In,O
these,O
cases,O
",",O
the,O
mass,O
should,O
be,O
evaluated,O
with,O
MRI,O
.,O
While,O
a,O
fat,O
-,O
invisible,O
AML,B-DS
is,O
homogenously,O
hypointense,O
on,O
T2,O
-,O
weighted,O
MR,O
images,O
",",O
clear,O
cell,O
RCC,B-DS
appears,O
hyperintense,O
[,O
9,O
].,O
However,O
",",O
the,O
papillary,O
subtype,O
of,O
RCC,B-DS
appears,O
also,O
hypointense,O
.,O
Therefore,O
",",O
percutaneous,O
biopsy,O
is,O
required,O
to,O
differentiate,O
fat,O
-,O
invisible,O
AML,B-DS
and,O
papillary,O
RCC,B-DS
when,O
a,O
small,O
(,O
less,O
than,O
3,O
cm,O
"),",O
T2,O
-,O
hypointense,O
renal,O
mass,O
without,O
evidence,O
of,O
intratumoural,O
fat,O
is,O
encountered,O
[,O
18,O
].,O
If,O
the,O
lesion,O
is,O
larger,O
(,O
more,O
than,O
3,O
cm,O
),O
or,O
if,O
there,O
is,O
evidence,O
of,O
haemorrhage,O
",",O
percutaneous,O
biopsy,O
may,O
be,O
skipped,O
.,O
Proceeding,O
directly,O
to,O
a,O
suitable,O
treatment,O
may,O
be,O
a,O
more,O
appropriate,O
option,O
",",O
both,O
to,O
avoid,O
further,O
bleeding,O
and,O
because,O
epithelioid,O
AML,B-DS
and,O
RCC,B-DS
are,O
more,O
presumable,O
[,O
3,O
].,O
Differential,O
Diagnosis,O
Over,O
the,O
last,O
decades,O
",",O
the,O
detection,O
of,O
small,O
renal,O
masses,O
definitely,O
increased,O
by,O
the,O
increased,O
use,O
of,O
cross,O
-,O
sectional,O
imaging,O
studies,O
.,O
A,O
lot,O
of,O
these,O
incidentally,O
found,O
renal,O
lesions,O
are,O
usually,O
presumed,O
to,O
be,O
RCC,B-DS
and,O
are,O
treated,O
as,O
such,O
.,O
However,O
",",O
a,O
recent,O
study,O
showed,O
that,O
21,O
.,O
5,O
%,O
of,O
those,O
lesions,O
turned,O
out,O
to,O
be,O
benign,O
after,O
surgery,O
.,O
AML,B-DS
accounted,O
for,O
nearly,O
half,O
of,O
this,O
group,O
of,O
benign,O
masses,O
.,O
This,O
shows,O
that,O
the,O
differentiation,O
between,O
AML,B-DS
and,O
RCC,B-DS
remains,O
difficult,O
in,O
routine,O
practice,O
[,O
202122,O
].,O
As,O
already,O
repeatedly,O
stated,O
above,O
",",O
classic,O
AML,B-DS
can,O
be,O
distinguished,O
from,O
RCC,B-DS
by,O
the,O
presence,O
of,O
macroscopic,O
fat,O
in,O
sufficient,O
quantity,O
to,O
be,O
detected,O
on,O
UECT,O
.,O
However,O
",",O
in,O
4,O
–,O
5,O
%,O
of,O
AML,B-DS
cases,O
",",O
no,O
fat,O
can,O
be,O
visualized,O
on,O
CT,O
",",O
increasing,O
the,O
difficulty,O
in,O
differentiating,O
it,O
from,O
RCC,B-DS
.,O
Correctly,O
diagnosing,O
this,O
fat,O
-,O
poor,O
and,O
fat,O
-,O
invisible,O
AML,B-DS
requires,O
sufficient,O
clinical,O
and,O
imaging,O
information,O
.,O
Clinical,O
information,O
supporting,O
a,O
diagnosis,O
of,O
AML,B-DS
includes,O
a,O
younger,O
age,O
",",O
female,O
sex,O
",",O
and,O
asymptomatic,O
presentation,O
.,O
Imaging,O
findings,O
that,O
should,O
raise,O
the,O
suspicion,O
of,O
AML,B-DS
include,O
the,O
absence,O
of,O
calcification,O
",",O
the,O
absence,O
of,O
perinephric,O
collateral,O
vessels,O
",",O
multiple,O
lesions,O
",",O
hyperattenuation,O
in,O
comparison,O
to,O
renal,O
parenchyma,O
on,O
UECT,O
",",O
and,O
hypointensity,O
on,O
T2,O
-,O
weighted,O
MRI,O
.,O
However,O
",",O
because,O
these,O
characteristic,O
features,O
are,O
not,O
present,O
in,O
every,O
AML,B-DS
and,O
exceptions,O
do,O
exist,O
",",O
no,O
single,O
finding,O
or,O
modality,O
is,O
perfectly,O
accurate,O
[,O
2021222324,O
].,O
Treatment,O
As,O
most,O
renal,B-DS
AMLs,I-DS
are,O
diagnosed,O
incidentally,O
in,O
asymptomatic,O
patients,O
",",O
therapeutic,O
interventions,O
are,O
required,O
in,O
a,O
minority,O
of,O
patients,O
.,O
Potential,O
interventions,O
include,O
selective,O
renal,O
artery,O
embolization,O
",",O
nephron,O
-,O
sparing,O
surgery,O
",",O
complete,O
nephrectomy,O
",",O
cryo,O
-,O
and,O
radiofrequency,O
ablation,O
",",O
and,O
treatment,O
with,O
mTOR,B-GP
inhibitors,O
.,O
Indications,O
Historically,O
",",O
the,O
main,O
indications,O
for,O
intervention,O
have,O
been,O
the,O
presence,O
of,O
symptoms,O
",",O
the,O
presence,O
in,O
women,O
of,O
childbearing,O
age,O
",",O
suspicion,O
of,O
malignancy,O
",",O
and,O
size,O
larger,O
than,O
4,O
cm,O
.,O
The,O
use,O
of,O
a,O
4,O
cm,O
tumour,O
size,O
as,O
a,O
criterion,O
for,O
treatment,O
comes,O
from,O
a,O
frequently,O
quoted,O
review,O
published,O
in,O
1986,O
[,O
21119,O
].,O
The,O
authors,O
of,O
this,O
review,O
reported,O
that,O
82,O
%,O
of,O
patients,O
with,O
renal,B-DS
AMLs,I-DS
larger,O
than,O
4,O
cm,O
experienced,O
symptoms,O
and,O
51,O
%,O
of,O
them,O
presented,O
with,O
active,O
retroperitoneal,O
haemorrhage,O
.,O
Other,O
early,O
series,O
showed,O
that,O
patients,O
with,O
tumours,B-DS
larger,O
than,O
4,O
cm,O
had,O
interval,O
growth,O
and,O
needed,O
treatment,O
more,O
often,O
.,O
They,O
all,O
suggested,O
4,O
cm,O
as,O
the,O
limit,O
above,O
which,O
an,O
intervention,O
should,O
be,O
considered,O
.,O
This,O
threshold,O
has,O
been,O
widely,O
adopted,O
for,O
many,O
years,O
",",O
although,O
the,O
understanding,O
of,O
the,O
biology,O
and,O
management,O
of,O
the,O
disease,O
have,O
changed,O
significantly,O
since,O
then,O
[,O
252627,O
].,O
However,O
",",O
this,O
threshold,O
has,O
recently,O
been,O
questioned,O
.,O
Recent,O
studies,O
do,O
not,O
support,O
the,O
4,O
cm,O
size,O
criterion,O
.,O
One,O
author,O
found,O
that,O
only,O
30,O
%,O
of,O
AMLs,B-DS
larger,O
than,O
4,O
cm,O
were,O
symptomatic,O
[,O
2,O
].,O
Another,O
one,O
showed,O
that,O
using,O
a,O
cut,O
-,O
off,O
of,O
4,O
cm,O
as,O
predictor,O
of,O
haemorrhage,O
has,O
a,O
lower,O
specificity,O
than,O
an,O
aneurysm,B-DS
size,O
of,O
5,O
mm,O
.,O
In,O
other,O
series,O
",",O
the,O
angiographic,O
appearance,O
of,O
AMLs,B-DS
was,O
used,O
for,O
analysing,O
them,O
.,O
They,O
found,O
that,O
lesions,O
with,O
high,O
vascularity,O
(,O
multiple,O
",",O
large,O
",",O
tortuous,O
vessels,O
),O
were,O
more,O
likely,O
to,O
require,O
intervention,O
for,O
bleeding,O
.,O
All,O
this,O
evidence,O
would,O
suggest,O
that,O
",",O
although,O
tumour,O
diameter,O
is,O
important,O
",",O
the,O
size,O
of,O
related,O
aneurysms,B-DS
and,O
the,O
vascularity,O
of,O
the,O
AML,B-DS
may,O
ultimately,O
be,O
more,O
significant,O
[,O
1127,O
].,O
As,O
most,O
AMLs,B-DS
now,O
are,O
found,O
incidentally,O
",",O
physicians,O
are,O
challenged,O
by,O
a,O
treatment,O
dilemma,O
when,O
an,O
AML,B-DS
in,O
an,O
asymptomatic,O
patient,O
reaches,O
the,O
4,O
-,O
cm,O
threshold,O
.,O
They,O
are,O
worried,O
that,O
these,O
“,O
large,O
”,O
lesions,O
may,O
rupture,O
and,O
cause,O
life,O
-,O
threatening,O
bleeding,O
.,O
Consequently,O
",",O
AMLs,B-DS
are,O
often,O
imaged,O
intensively,O
and,O
repeatedly,O
",",O
and,O
treated,O
empirically,O
once,O
they,O
attain,O
a,O
diameter,O
of,O
4,O
cm,O
[,O
26,O
].,O
The,O
current,O
guidelines,O
of,O
the,O
European,O
Association,O
of,O
Urology,O
recommend,O
intervention,O
in,O
well,O
-,O
selected,O
cases,O
",",O
including,O
symptomatic,O
tumours,B-DS
",",O
large,O
lesions,O
",",O
presence,O
in,O
women,O
of,O
childbearing,O
age,O
",",O
and,O
poor,O
access,O
to,O
follow,O
-,O
up,O
or,O
emergency,O
care,O
.,O
A,O
size,O
threshold,O
for,O
treatment,O
",",O
however,O
",",O
remains,O
controversial,O
[,O
2242526,O
].,O
Active,O
Surveillance,O
Once,O
the,O
initial,O
diagnostic,O
evaluations,O
are,O
completed,O
and,O
indications,O
for,O
treatment,O
are,O
not,O
present,O
",",O
active,O
surveillance,O
should,O
be,O
used,O
to,O
monitor,O
progression,O
of,O
known,O
tumours,B-DS
and,O
development,O
of,O
new,O
ones,O
[,O
29,O
].,O
For,O
sporadic,O
AML,B-DS
",",O
there,O
are,O
currently,O
no,O
guidelines,O
on,O
the,O
frequency,O
of,O
imaging,O
studies,O
neither,O
on,O
which,O
modality,O
should,O
be,O
used,O
.,O
These,O
decisions,O
are,O
likely,O
to,O
be,O
institution,O
dependent,O
and,O
should,O
be,O
guided,O
by,O
the,O
individual,O
clinical,O
scenario,O
[,O
2,O
].,O
Annual,O
repeat,O
of,O
imaging,O
seems,O
to,O
be,O
appropriate,O
for,O
small,O
",",O
solitary,O
lesions,O
.,O
For,O
hereditary,O
AML,B-DS
",",O
the,O
International,O
Tuberous,B-DS
Sclerosis,I-DS
Complex,O
Consensus,O
recommends,O
the,O
use,O
of,O
MRI,O
",",O
because,O
of,O
its,O
increased,O
sensitivity,O
in,O
the,O
detection,O
of,O
adipose,O
tissue,O
.,O
Annual,O
clinical,O
evaluation,O
of,O
renal,O
function,O
and,O
blood,O
pressure,O
is,O
also,O
required,O
in,O
these,O
cases,O
[,O
192830,O
].,O
Embolization,O
Historically,O
",",O
there,O
was,O
a,O
greater,O
tendency,O
towards,O
surgery,O
in,O
the,O
treatment,O
of,O
renal,B-DS
AMLs,I-DS
.,O
They,O
were,O
often,O
excised,O
because,O
malignancy,O
could,O
not,O
be,O
excluded,O
.,O
However,O
",",O
this,O
has,O
shifted,O
",",O
as,O
AMLs,B-DS
can,O
now,O
be,O
confidently,O
recognized,O
at,O
imaging,O
.,O
Selective,O
transarterial,O
embolization,O
is,O
now,O
the,O
first,O
-,O
line,O
treatment,O
option,O
",",O
especially,O
in,O
the,O
event,O
of,O
acute,O
bleeding,O
or,O
hemodynamic,O
instability,O
[,O
25,O
].,O
Many,O
clinicians,O
favour,O
embolization,O
and,O
reserve,O
surgery,O
for,O
patients,O
with,O
uncontrollable,O
symptoms,O
",",O
vascular,B-DS
malformations,I-DS
",",O
failure,O
of,O
embolization,O
",",O
and,O
rare,O
diagnostic,O
uncertainty,O
.,O
When,O
surgery,O
needs,O
to,O
be,O
performed,O
",",O
preoperative,O
embolization,O
of,O
the,O
lesion,O
may,O
be,O
taken,O
into,O
consideration,O
in,O
reducing,O
the,O
difficulty,O
and,O
complications,O
of,O
tumourectomy,O
or,O
nephrectomy,O
[,O
11192732,O
].,O
Embolization,O
is,O
associated,O
with,O
a,O
relatively,O
high,O
percentage,O
of,O
side,O
effects,O
(,O
42,O
.,O
8,O
"%),",O
although,O
most,O
of,O
these,O
are,O
post,O
-,O
embolization,O
syndromes,O
.,O
This,O
self,O
-,O
limiting,O
condition,O
is,O
characterized,O
by,O
fever,O
",",O
flank,O
pain,O
",",O
leucocytosis,B-DS
",",O
nausea,O
",",O
and,O
vomiting,O
within,O
the,O
first,O
three,O
days,O
after,O
the,O
procedure,O
",",O
and,O
it,O
is,O
managed,O
conservatively,O
with,O
standard,O
supportive,O
care,O
.,O
Routine,O
prophylaxis,O
",",O
including,O
antipyretics,O
",",O
antiemetics,O
and,O
analgesia,O
",",O
may,O
play,O
a,O
role,O
in,O
periprocedural,O
management,O
[,O
227,O
].,O
Other,O
complications,O
",",O
including,O
non,O
-,O
target,O
embolization,O
of,O
normal,O
parenchyma,O
or,O
renal,B-DS
infarction,I-DS
with,O
abscess,B-DS
forming,O
",",O
are,O
uncommon,O
[,O
111932,O
].,O
In,O
general,O
though,O
",",O
arterial,O
embolization,O
is,O
a,O
well,O
-,O
tolerated,O
procedure,O
.,O
Although,O
it,O
is,O
now,O
seen,O
as,O
the,O
first,O
-,O
line,O
treatment,O
for,O
patients,O
with,O
AMLs,B-DS
",",O
both,O
regrowth,O
and,O
repeated,O
haemorrhage,O
after,O
embolization,O
remain,O
a,O
concern,O
.,O
The,O
effect,O
of,O
embolization,O
may,O
vary,O
",",O
because,O
of,O
the,O
varying,O
amounts,O
of,O
adipose,O
",",O
vascular,O
",",O
and,O
smooth,O
muscle,O
tissue,O
in,O
the,O
lesions,O
.,O
Different,O
authors,O
showed,O
in,O
their,O
series,O
a,O
need,O
for,O
reembolization,O
varying,O
from,O
17,O
%,O
till,O
37,O
%,O
[,O
323334,O
].,O
Surgery,O
Surgical,O
excision,O
in,O
the,O
form,O
of,O
partial,O
or,O
radical,O
nephrectomy,O
is,O
the,O
only,O
treatment,O
that,O
completely,O
removes,O
the,O
renal,O
mass,O
",",O
although,O
recurrence,O
from,O
other,O
parts,O
of,O
the,O
kidney,O
may,O
occur,O
.,O
Every,O
surgery,O
should,O
rely,O
on,O
a,O
nephron,O
sparing,O
approach,O
whenever,O
possible,O
[,O
25,O
].,O
Parenchymal,O
preservation,O
is,O
even,O
more,O
important,O
in,O
patients,O
with,O
TSC,B-DS
or,O
LAM,B-DS
",",O
because,O
of,O
the,O
multifocal,O
disease,O
pattern,O
and,O
the,O
higher,O
recurrence,O
rate,O
.,O
Nephrectomy,O
is,O
indicated,O
only,O
when,O
a,O
renal,B-DS
AML,I-DS
is,O
very,O
large,O
",",O
when,O
suspicion,O
of,O
malignancy,O
is,O
high,O
",",O
and,O
when,O
other,O
treatment,O
options,O
cannot,O
be,O
performed,O
.,O
However,O
",",O
in,O
an,O
emergency,O
setting,O
",",O
a,O
nephrectomy,O
can,O
be,O
lifesaving,O
[,O
3132,O
].,O
Ablation,O
When,O
comparing,O
current,O
treatment,O
methods,O
",",O
cryoablation,O
and,O
percutaneous,O
radiofrequency,O
ablation,O
appear,O
to,O
be,O
attractive,O
alternatives,O
to,O
embolization,O
or,O
surgery,O
.,O
Different,O
series,O
demonstrate,O
good,O
efficacy,O
with,O
minimal,O
complications,O
",",O
few,O
repeat,O
treatments,O
",",O
and,O
no,O
recurrences,O
.,O
However,O
",",O
reports,O
of,O
the,O
use,O
of,O
these,O
minimal,O
invasive,O
techniques,O
are,O
confined,O
to,O
small,O
and,O
asymptomatic,O
lesions,O
[,O
19,O
].,O
Little,O
evidence,O
is,O
available,O
on,O
the,O
application,O
in,O
larger,O
or,O
symptomatic,O
tumours,B-DS
.,O
Overall,O
",",O
ablation,O
has,O
shown,O
some,O
promise,O
in,O
the,O
treatment,O
of,O
a,O
specific,O
AML,B-DS
group,O
that,O
some,O
would,O
say,O
should,O
be,O
managed,O
by,O
active,O
surveillance,O
[,O
23334,O
].,O
Drugs,O
The,O
identification,O
of,O
mutations,O
in,O
TSC1,B-GP
and,O
TSC2,B-GP
and,O
the,O
existence,O
of,O
a,O
licensed,O
drug,O
targeting,O
the,O
mTOR,B-GP
pathway,O
",",O
lead,O
to,O
rapid,O
translation,O
of,O
mTOR,B-GP
inhibitors,O
to,O
patients,O
with,O
TSC,B-DS
and,O
LAM,B-DS
.,O
These,O
medicines,O
interrupt,O
further,O
tumour,O
progression,O
and,O
promote,O
reversion,O
of,O
existing,O
lesions,O
.,O
Sirolimus,O
",",O
also,O
known,O
as,O
rapamycin,O
",",O
was,O
the,O
first,O
mTOR,B-GP
inhibitor,O
analysed,O
in,O
treating,O
hereditary,O
AML,B-DS
.,O
It,O
was,O
originally,O
developed,O
as,O
immunosuppressant,O
for,O
use,O
in,O
organ,O
transplantation,O
.,O
Overall,O
",",O
sirolimus,O
was,O
well,O
tolerated,O
in,O
these,O
early,O
studies,O
",",O
with,O
mouth,B-DS
ulcers,I-DS
",",O
skin,O
lesions,O
",",O
dyslipidaemia,B-DS
",",O
and,O
proteinuria,B-DS
as,O
most,O
commonly,O
encountered,O
side,O
effects,O
.,O
It,O
is,O
now,O
approved,O
for,O
treatment,O
of,O
LAM,B-DS
[,O
6,O
].,O
Everolimus,O
",",O
another,O
mTOR,B-GP
inhibitor,O
and,O
rapamycine,O
derivative,O
",",O
has,O
been,O
studied,O
the,O
most,O
.,O
Currently,O
",",O
the,O
Food,O
and,O
Drug,O
Administration,O
and,O
European,O
Medicines,O
Agency,O
approve,O
this,O
agent,O
for,O
treating,O
AML,B-DS
in,O
the,O
setting,O
of,O
TSC,B-DS
[,O
323536,O
].,O
The,O
position,O
of,O
mTOR,B-GP
inhibitors,O
in,O
the,O
management,O
of,O
sporadic,O
AML,B-DS
still,O
remains,O
to,O
be,O
determined,O
[,O
2,O
].,O
For,O
asymptomatic,O
AMLs,B-DS
in,O
TSC,B-DS
and,O
LAM,B-DS
that,O
are,O
enlarging,O
and,O
larger,O
than,O
3,O
cm,O
",",O
recent,O
guidelines,O
suggest,O
that,O
mTOR,B-GP
inhibition,O
currently,O
is,O
the,O
most,O
effective,O
first,O
-,O
line,O
treatment,O
.,O
The,O
demonstrated,O
tolerability,O
so,O
far,O
to,O
date,O
is,O
superior,O
to,O
the,O
renal,B-DS
impairment,I-DS
caused,O
by,O
AML,B-DS
progression,O
and,O
is,O
preferable,O
to,O
other,O
treatment,O
modalities,O
[,O
28,O
].,O
Another,O
concern,O
for,O
treating,O
physicians,O
is,O
how,O
long,O
the,O
treatment,O
with,O
those,O
drugs,O
should,O
continue,O
",",O
as,O
the,O
effect,O
of,O
mTOR,B-GP
inhibition,O
is,O
reversible,O
.,O
To,O
continue,O
the,O
treatment,O
for,O
AML,B-DS
",",O
consideration,O
should,O
be,O
given,O
to,O
long,O
-,O
term,O
complications,O
",",O
cost,O
",",O
and,O
safety,O
",",O
compared,O
with,O
other,O
treatment,O
options,O
[,O
3236,O
].,O
Conclusion,O
Renal,B-DS
AML,I-DS
is,O
the,O
most,O
prevalent,O
benign,B-DS
neoplasm,I-DS
of,I-DS
the,I-DS
kidney,I-DS
.,O
It,O
has,O
a,O
variable,O
and,O
heterogeneous,O
nature,O
",",O
with,O
the,O
potential,O
to,O
pose,O
serious,O
diagnostic,O
challenges,O
in,O
clinical,O
practice,O
.,O
The,O
characteristics,O
of,O
classic,O
AMLs,B-DS
are,O
well,O
described,O
",",O
but,O
the,O
radiological,O
distinction,O
between,O
non,O
-,O
classic,O
AMLs,B-DS
and,O
RCCs,O
continues,O
to,O
be,O
difficult,O
.,O
Knowledge,O
of,O
the,O
different,O
types,O
",",O
their,O
classification,O
",",O
and,O
their,O
radiologic,O
appearance,O
will,O
help,O
radiologists,O
in,O
making,O
a,O
correct,O
diagnosis,O
.,O
When,O
an,O
AML,B-DS
is,O
considered,O
in,O
the,O
differential,O
diagnosis,O
of,O
a,O
renal,O
lesion,O
that,O
does,O
not,O
demonstrate,O
classical,O
features,O
",",O
confirmatory,O
imaging,O
",",O
percutaneous,O
renal,O
biopsy,O
",",O
or,O
surgical,O
excision,O
should,O
be,O
performed,O
.,O
Several,O
invasive,O
",",O
non,O
-,O
invasive,O
",",O
and,O
pharmacologic,O
treatment,O
options,O
exist,O
.,O
Careful,O
surveillance,O
before,O
and,O
after,O
treatment,O
is,O
necessary,O
",",O
particularly,O
for,O
patients,O
with,O
TSC,B-DS
or,O
LAM,B-DS
.,O
Without,O
proper,O
management,O
",",O
renal,B-DS
AML,I-DS
may,O
have,O
serious,O
consequences,O
.,O
